

# **APPROVED DRUG PRODUCTS**

**WITH**

**THERAPEUTIC  
EQUIVALENCE  
EVALUATIONS**

**35<sup>th</sup> EDITION**

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER  
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH  
OFFICE OF MEDICAL PRODUCTS AND TOBACCO  
OFFICE OF GENERIC DRUGS

**2015**

# **APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS**

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2014.

## **35<sup>th</sup> EDITION**



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH  
OFFICE OF MEDICAL PRODUCTS AND TOBACCO  
OFFICE OF GENERIC DRUGS

**2015**

**FOOD AND DRUG ADMINISTRATION  
 CENTER FOR DRUG EVALUATION AND RESEARCH  
 APPROVED DRUG PRODUCTS  
 with  
 Therapeutic Equivalence Evaluations**

**CONTENTS**

	<i>PAGE</i>
PREFACE TO THIRTY FIFTH EDITION.....	iv
1 INTRODUCTION.....	vi
1.1 Content and Exclusion .....	vi
1.2 Therapeutic Equivalence-Related Terms .....	vi
1.3 Statistical Criteria for Bioequivalence .....	viii
1.4 Reference Listed Drug .....	x
1.5 General Policies and Legal Status .....	xi
1.6 Practitioner/User Responsibilities .....	xi
1.7 Therapeutic Equivalence Evaluations Codes .....	xiii
1.8 Description of Special Situations.....	xxi
1.9 Therapeutic Equivalence Code Change for a Drug Entity .....	xxiii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product .....	xxiv
1.11 Discontinued Section .....	xxiv
1.12 Changes to the Orange Book.....	xxiv
1.13 Availability of the Edition .....	xxv
2 HOW TO USE THE DRUG PRODUCTS LISTS .....	2-1
2.1 Key Sections for Using the Drug Product Lists .....	2-1
2.2 Drug Product Illustration .....	2-3
2.3 Therapeutic Equivalence Evaluations Illustration .....	2-4
<b>DRUG PRODUCT LISTS</b>	
Prescription Drug Product List .....	3-1
OTC Drug Product List .....	4-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	5-1
Discontinued Drug Product List .....	6-1
Orphan Products Designations and Approvals List .....	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	8-1
<b>APPENDICES</b>	
A. Product Name Index .....	A-1
B. Product Name Index Listed by Applicant .....	B-1
C. Uniform Terms .....	C-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM .....</b>	<b>AD1</b>
A. Patent and Exclusivity Lists .....	ADA1
B. Patent and Exclusivity Terms .....	ADB1

**FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH  
APPROVED DRUG PRODUCTS**

**with  
Therapeutic Equivalence Evaluations**

**PREFACE TO THIRTY FIFTH EDITION**

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

**Background of the Publication.** To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the List incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Legal & Regulatory Support, Office of Generic Drugs, Center for Drug and Evaluation and Research, 7620 Standish Place, Rockville, MD 20855-2773. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

# 1. INTRODUCTION

## 1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.<sup>1</sup> This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided.

An *Addendum* contains drug patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research because the main purpose of the publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the 1984 Amendments, some drug products are given tentative approvals. The Agency will not include drug products with tentative approval in the List. Tentative approval lists are available at [ANDA \(Generic\) Drug Approvals](#). When the tentative approval becomes a full approval through a subsequent action letter to the application holder, the Agency will list the drug product and the final approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

## 1.2 Therapeutic Equivalence-Related Terms

---

<sup>1</sup> Newly approved products are added to parts 1, 2, or 3, of the List, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

**Pharmaceutical Equivalents.** Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same dosage form, route of administration and are identical in strength or concentration (e.g., chlordiazepoxide hydrochloride, 5mg capsules). Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

**Pharmaceutical Alternatives.** Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Data are generally not available for FDA to make the determination of tablet to capsule bioequivalence. Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

**Therapeutic Equivalents.** Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., propoxyphene hydrochloride vs. pentazocine hydrochloride for the treatment of pain).* Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. Therapeutic equivalence determinations are not made for unapproved, off-label indications.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for

the prescribing physician to require that a particular brand be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

**Bioavailability.** This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

**Bioequivalent Drug Products.** This term describes pharmaceutical equivalent or pharmaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(8)(B) of the Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

the extent of absorption of the test drug does not show a significant difference from the extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the reference drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

Bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

### 1.3 Statistical Criteria for Bioequivalence

Under the Drug Price Competition and Patent Term Restoration Act of 1984, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the drug product is bioequivalent to the pioneer (innovator) drug product. A major premise underlying the 1984 law is that bioequivalent drug products are therapeutically equivalent, and therefore, interchangeable.

Bioavailability refers to the rate and extent to which the active ingredient or therapeutic ingredient is absorbed from a drug product and becomes available at the site of drug action (Federal Food, Drug and Cosmetic Act, section 505(j)(8)). Bioequivalence refers to equivalent release of the same drug substance from two or more drug products or formulations. This



leads to an equivalent rate and extent of absorption from these formulations. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. Methods used to define bioequivalence can be found in 21 CFR 320.24, and include (1) pharmacokinetic (PK) studies, (2) pharmacodynamic (PD) studies, (3) comparative clinical trials, and (4) in-vitro studies. The choice of study used is based on the site of action of the drug and the ability of the study design to compare drug delivered to that site by the two products.

The standard bioequivalence (PK) study is conducted using a two-treatment crossover study design in a limited number of volunteers, usually 24 to 36 adults. Alternately, a four-period, replicate design crossover study may also be used. Single doses of the test and reference drug products are administered and blood or plasma levels of the drug are measured over time. Pharmacokinetic parameters characterizing rate and extent of drug absorption are evaluated statistically. The PK parameters of interest are the resulting area under the plasma concentration-time curve (AUC), calculated to the last measured concentration ( $AUC_{(0-t)}$ ) and extrapolated to infinity ( $AUC_{(0-inf)}$ ), for extent of absorption; and the maximum or peak drug concentrations ( $C_{max}$ ), for rate of absorption. Crossover studies may not be practical in drugs with a long half-life in the body, and a parallel study design may be used instead. Alternate study methods, such as in-vitro studies or equivalence studies with clinical or pharmacodynamic endpoints, are used for drug products where plasma concentrations are not useful to determine delivery of the drug substance to the site of activity (such as inhalers, nasal sprays and topical products applied to the skin).

The statistical methodology for analyzing these bioequivalence studies is called the two one-sided test procedure. Two situations are tested with this statistical methodology. The first of the two one-sided tests determines whether a generic product (test), when substituted for a brand-name product (reference) is significantly less bioavailable. The second of the two one-sided tests determines whether a brand-name product when substituted for a generic product is significantly less bioavailable. Based on the opinions of FDA medical experts, a difference of greater than 20% for each of the above tests was determined to be significant, and therefore, undesirable for all drug products. Numerically, this is expressed as a limit of test-product average/reference-product average of 80% for the first statistical test and a limit of reference-product average/test-product average of 80% for the second statistical test. By convention, all data is expressed as a ratio of the average response (AUC and  $C_{max}$ ) for test/reference, so the limit expressed in the second statistical test is 125% (reciprocal of 80%).

For statistical reasons, all data is log-transformed prior to conducting statistical testing. In practice, these statistical tests are carried out using an analysis of variance procedure (ANOVA) and calculating a 90% confidence interval for each pharmacokinetic parameter ( $C_{max}$  and AUC). The confidence interval for both pharmacokinetic parameters, AUC and  $C_{max}$ , must be entirely within the 80% to 125% boundaries cited above. Because the mean of the study data lies in the center of the 90% confidence interval, the mean of the data is usually close to 100% (a test/reference ratio of 1). Different statistical criteria are sometimes used when bioequivalence is demonstrated through comparative clinical trials pharmacodynamic studies, or comparative in-vitro methodology.

The bioequivalence methodology and criteria described above simultaneously control for both differences in the average response between test and reference, as well as the precision with which the average response in the population is estimated. This precision depends on the within-subject

(normal volunteer or patient) variability in the pharmacokinetic parameters (AUC and Cmax) of the two products and on the number of subjects in the study. The width of the 90% confidence interval is a reflection in part of the within-subject variability of the test and reference products in the bioequivalence study. A test product with no differences in the average response when compared to the reference might still fail to pass the bioequivalence criteria if the variability of one or both products is high and the bioequivalence study has insufficient statistical power (i.e., insufficient number of subjects). Likewise, a test product with low variability may pass the bioequivalence criteria, when there are somewhat larger differences in the average response.

This system of assessing bioequivalence of generic products assures that these substitutable products do not deviate substantially in in-vivo performance from the reference product. The Office of Generic Drugs has conducted two surveys to quantify the differences between generic and brand name products. The first survey included 224 bioequivalence studies submitted in approved applications during 1985 and 1986. The observed average differences between reference and generic products for AUC was 3.5% (JAMA, Sept. 4, 1987, Vol. 258, No. 9). The second survey included 127 bioequivalence studies submitted to the agency in 273 ANDAs approved in 1997. The three measures reviewed include  $AUC_{(0-t)}$ ,  $AUC_{(0-inf)}$ , and Cmax. The observed average differences between the reference and generic products were  $\pm 3.47\%$  (SD 2.84) for  $AUC_{(0-t)}$ ,  $\pm 3.25\%$  (SD 2.97) for  $AUC_{(0-inf)}$ , and  $\pm 4.29\%$  (SD 3.72) for Cmax (JAMA, Dec. 1, 1999, Vol. 282, No. 21).

The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. The current practice of carrying out two one-sided tests at the 0.05 level of significance ensures that there is no more than a 5% chance that a generic product that is not truly equivalent to the reference will be approved.

#### 1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence (reference standard) and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when listed drugs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of a listed drug that is not designated as the reference listed drug may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second listed drug will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes products meeting necessary bioequivalence requirements* explains the (AB, AB1, AB2, AB3... coding system for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two listed drugs that have been shown to be bioequivalent to each other may both be designated as reference listed drugs. The first situation occurs when the *in vivo* determination of bioequivalence is self-evident and a waiver of the *in vivo* bioequivalence may be granted. The second situation occurs when the bioequivalence of two listed products may be determined through *in vitro* methodology. The reference listed drug is identified by the symbol "+" in the Prescription and Over-the-Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Division of Bioequivalence at this time. The Prescription and OTC Drug Product Lists identify reference drugs for oral dosage forms, Injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, Office of Generic Drugs, to confirm the appropriate reference listed drug.

## 1.5 General Policies and Legal Status

The List contains public information and advice. It does not mandate the drug products which is purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

## 1.6 Practitioner/User Responsibilities

### ***Professional care and judgment should be exercised in using the List.***

Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be better

stability of one product over another under adverse storage conditions, or allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

**Multisource and single-source drug products.** FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included on the List, but no therapeutic equivalence code is included with such products. Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

**Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product.** The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In most instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are

displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

***Every product on the List is subject at all times to regulatory action.***

From time to time, approved products may be found in violation of one or more provisions of the Act. In such circumstances, the Agency will commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product on the List. The main criterion for inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

## **1.7 Therapeutic Equivalence Evaluations Codes**

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With few exceptions, the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter as follows:

**A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:**

- (1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting

bioequivalence. These are designated **AB**.

**B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,**

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B\***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

### **"A" CODES**

**Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.**

"A" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bio-equivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied for solid oral dosage forms by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA, AN, AO, AP, or AT**, depending on the dosage form, as described below); or
- (2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable

only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency will use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note will be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts and esters of the same therapeutic moiety are regarded as pharmaceutical alternatives. For the purpose of this publication, such products are not considered to be therapeutically equivalent. There are no instances in this List where pharmaceutical alternatives are evaluated or coded with regard to therapeutic equivalence. Anhydrous and hydrated entities, as well as different polymorphs, are considered pharmaceutical equivalents and must meet the same standards and, where necessary, as in the case of ampicillin/ampicillin trihydrate, their equivalence is supported by appropriate bioavailability/bioequivalence studies.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not

affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

#### **AA Products in conventional dosage forms not presenting bioequivalence problems**

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

#### **AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements**

Multisource drug products listed under the same heading (i.e., identical active ingredient(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents*) generally will be coded **AB** if a study is submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC (Miles) and Procardia XL® (Pfizer), extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved, Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. The generic drug products bioequivalent to Adalat® CC would be assigned a rating of **AB1** and those bioequivalent to Procardia XL® would be assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the application holder's drug product if the application holder's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

#### **AN Solutions and powders for aerosolization**

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are



coded **BN**, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

### **AO Injectable oil solutions**

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

### **AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions**

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

The strength of parenteral drugs products is defined as the total drug content of the container. Until recently the strength of liquid parenteral drug products in the Orange Book have not been displayed. The concentration of the liquid parenteral drug product in the Orange Book has been shown as xmg/ml. The amount of dry powder or freeze dried powder in a container has always been identified as the strength.

With the finalization of the Waxman-Hatch amendments that characterized each strength of a drug product as a listed drug, it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end the OGD has started to display the strength of all new approvals of parenteral solutions. Previously we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/ml. If this drug product had a 20 ml and 60 ml container approved the two products would be shown as 1Gm / 20ml (50mg/ml) and 3Gm / 60ml (50mg/ml).

## **AT Topical products**

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

## **"B" CODES**

### **Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.**

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bio-equivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or
- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

## **B\* Drug products requiring further FDA investigation and review to determine therapeutic equivalence**

The code **B\*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B\*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

## **BC Extended-release dosage forms (capsules, injectables and tablets)**

Extended-release tablets are formulated in such a manner as to make the contained medicament available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because firms developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

## **BD Active ingredients and dosage forms with documented bioequivalence problems**

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

## **BE Delayed-release oral dosage forms**

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

## **BN Products in aerosol-nebulizer drug delivery systems**

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore,

the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard, such products are coded **AB**.

### **BP Active ingredients and dosage forms with potential bioequivalence problems**

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate *in vivo* bioequivalence data are submitted, such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence, such products would be coded **AB**.

### **BR Suppositories or enemas that deliver drugs for systemic absorption**

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bio-equivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

### **BS Products having drug standard deficiencies**

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

### **BT Topical products with bioequivalence issues**

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

## **BX Drug products for which the data are insufficient to determine therapeutic equivalence**

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

### **1.8 Description of Special Situations**

Certain drugs listed in the Orange Book present special situations that merit further discussion. Following is a description of those special situations:

**Amino Acid and Protein Hydrolysate Injections.** These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

**Follitropin Alfa and Beta.** Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

**Gaviscon®.** Gaviscon® is an OTC product which has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test which is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs which cite Gaviscon® tablets as the listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

**Levothyroxine Sodium.** Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid

(Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBOTT	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBOTT	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHROID	LLOYD	0.025MG	AB4	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

**Patent Certification(s) Reference Listed Drug based upon a suitability petition.** An abbreviated new drug application that refers to a Reference Listed Drug (RLD) approved pursuant to a suitability petition must demonstrate that the proposed product is bioequivalent to the RLD, and it must include appropriate patent certification(s) and an exclusivity statement with respect to the listed drug which served as the basis for the approved suitability petition. This concept also applies to an ANDA applicant that cites a RLD that was based upon an NDA that is still covered by patent (s) and/or exclusivity, e.g. a second RLD that was selected when the in vivo determination of bioequivalence of the original RLD is self evident and the waiver of the in vivo determination of bioequivalence may be granted.

**Waived exclusivity.** If a new drug application (NDA) submitted under

section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

### 1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multi-source drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7620 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submission is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies

of supporting reports published in the scientific literature or unpublished material, however, are welcome.

### **1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product**

The aforementioned procedure does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

### **1.11 Discontinued Section**

Those drug products in the Discontinued Section of the Orange Book in which a determination has already been made that the products were not withdrawn for safety or efficacy reasons have "\*\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*" following the product strength. Those drug products are only reflective of citizen petitions determinations made since 1995. The identification of these drug products in the Discontinued Section of the Orange Book should avoid the submission of multiple citizen petitions for the same drug product. FR notices no longer applicable are removed from the Annual Edition (i.e., there is a currently marketed Reference Listed Drug and no applicable patent or exclusivity). [FR Safety or Effectiveness Determinations List](#) lists products that have current and removed notices. The list is updated quarterly. Notices issued during the year are added to the [Electronic Orange Book Query](#) in the month they become effective.

Generally, approved products are added to the Discontinued Section of the Orange Book when the applicant holder notifies the Orange Book staff of the products' not marketed status. Products may also be added if annual reports indicate the product is no longer marketed or other Agency administrative action (e.g., Withdrawal of an Application). Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the Act.

### **1.12 Changes to the Orange Book**

Every effort is made to ensure the Annual Edition is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. Please inform the OBS when products are no longer marketed. Notification of the Orange Book staff to include the newly approved product in the Discontinued Drug Product List rather than parts 1, 2 or 3 of the List (as discussed in Section 1.1) must occur by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update



We can be contacted by email at [drugproducts@fda.hhs.gov](mailto:drugproducts@fda.hhs.gov). Send Changes by FAX: 301-595-1446; mail to:

FDA/CDER Orange Book Staff  
Office of Generic Drugs,  
7620 Standish Place  
Rockville, MD 20855-2773

### **1.13 Availability of the Edition**

Commencing with the 25<sup>th</sup> edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the EOB home page, [Electronic Orange Book Query](#), by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Printing Office, 866-512-1800.

## 2. HOW TO USE THE DRUG PRODUCT LISTS

### 2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

**Illustrations.** The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

**Drug Product Lists.** The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, application holders, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Section of the Orange Book.

**Product Name Index** (*Prescription and OTC Drug Product Lists*). This is an index of drug products by established or trade name. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

**Product Name Index Listed by Applicant** (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (\*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

**Uniform Terms.** To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

## 2.2 DRUG PRODUCT ILLUSTRATION

### SINGLE INGREDIENT

ACTIVE INGREDIENT	→	<u>MEPERIDINE HYDROCHLORIDE</u>					
DOSAGE FORM; ROUTE OF ADMINISTRATION	→	INJECTABLE; INJECTION					
TRADE OR GENERIC NAMES	→	<u>HEXANON</u>					
REFERENCE LISTED DRUG	→	<u>AP</u> + PAGE PHARMA	<u>25MG/ML</u>	<u>N013111</u>	<u>001</u>	AUG 22, 1983	
		<u>AP</u> +	<u>50MG/ML</u>	<u>N013111</u>	<u>002</u>	AUG 22, 1983	
		<u>AP</u> +	<u>75MG/ML</u>	<u>N013111</u>	<u>003</u>	AUG 22, 1983	
		<u>AP</u> +	<u>100MG/ML</u>	<u>N013111</u>	<u>004</u>	JAN 04, 1989	
		<u>MEPERIDINE HCL</u>					
THERAPEUTIC EQUIVALENCE (TE)		<u>AP</u> GREENBERG PHARM	<u>25MG/ML</u>	<u>A064890</u>	001	FEB 29, 1987	
CODE FOR MULTISOURCE PRODUCT	→	<u>AP</u>	<u>50MG/ML</u>	<u>A064890</u>	002	FEB 29, 1987	
		<u>AP</u>	<u>75MG/ML</u>	<u>A064890</u>	003	FEB 29, 1987	
		<u>AP</u>	<u>100MG/ML</u>	<u>A064890</u>	004	MAR 08, 1992	
SINGLE SOURCE PRODUCT (NO TE CODE)		<u>AP</u> TIMOKIM LLC	10MG/ML	A099225	001	DEC 12, 1995	
		<u>AP</u> JOHNSON MED	<u>25MG/ML</u>	<u>A099226</u>	<u>001</u>	NOV 27, 1993	
		KENDRA PHARM	150MG/ML	A079444	001	OCT 31, 1999	
APPLICANT	→						
AVAILABLE STRENGTH(S) OF A PRODUCT	→						
APPLICATION NUMBER AND PRODUCT NUMBER	→						
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY	→						
APPROVAL DATE	→						


### MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY								
ACTIVE INGREDIENT	→	<u>HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE</u>						
PRODUCT INFORMATION	→	<table border="0"> <tr> <td>TABLET; ORAL</td> <td></td> </tr> <tr> <td>HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL</td> <td></td> </tr> <tr> <td>REINWALD INC</td> <td>25MG; 15MG; 0.1MG A069808 001 JAN 18, 1982</td> </tr> </table>	TABLET; ORAL		HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL		REINWALD INC	25MG; 15MG; 0.1MG A069808 001 JAN 18, 1982
TABLET; ORAL								
HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL								
REINWALD INC	25MG; 15MG; 0.1MG A069808 001 JAN 18, 1982							

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

### 2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

## PRESCRIPTION DRUG PRODUCT LIST

ABACAVIR SULFATE

SOLUTION;ORAL

ZIAGEN

+ VIIIV HLTHCARE

EQ 20MG BASE/ML

N020978 001 Dec 17, 1998

TABLET;ORAL

ABACAVIR SULFATEAB APOTEX INCEQ 300MG BASEA201570 001 Dec 17, 2012AB AUROBINDO PHARMA LTDEQ 300MG BASEA077844 001 Dec 17, 2012AB HETERO LABS LTD IIIEQ 300MG BASEA091560 001 Sep 13, 2013AB MYLAN PHARMS INCEQ 300MG BASEA091294 001 Jun 18, 2012ZIAGENAB + VIIIV HLTHCAREEQ 300MG BASEN020977 001 Dec 17, 1998ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

+ VIIIV HLTHCARE

EQ 600MG BASE;EQ 50MG BASE;300MG

N205551 001 Aug 22, 2014

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

EPZICOM

+ VIIIV HLTHCARE

EQ 600MG BASE;300MG

N021652 001 Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINEAB LUPIN LTDEQ 300MG BASE;150MG;300MGA202912 001 Dec 05, 2013TRIZIVIRAB + VIIIV HLTHCAREEQ 300MG BASE;150MG;300MGN021205 001 Nov 14, 2000ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA

+ JANSSEN BIOTECH

250MG

N202379 001 Apr 28, 2011

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUMAB BARR LABS DIV TEVA333MGA200143 001 Nov 18, 2013AB GLENMARK GENERICS333MGA202229 001 Jul 16, 2013AB MYLAN PHARMS INC333MGA200142 001 Mar 11, 2014CAMPRALAB + FOREST LABS333MGN021431 001 Jul 29, 2004ACARBOSE

TABLET;ORAL

ACARBOSEAB EMCURE PHARMS LTD25MGA202271 001 Feb 07, 2012AB50MGA202271 002 Feb 07, 2012AB100MGA202271 003 Feb 07, 2012AB IMPAX LABS25MGA078441 001 May 14, 2009AB50MGA078441 002 May 14, 2009AB100MGA078441 003 May 14, 2009AB MYLAN25MGA091053 001 Jan 06, 2011AB50MGA091053 002 Jan 06, 2011AB100MGA091053 003 Jan 06, 2011AB ROXANE25MGA078470 001 May 07, 2008AB50MGA078470 002 May 07, 2008AB100MGA078470 003 May 07, 2008AB STRIDES PHARMA25MGA090912 001 Jul 27, 2011AB50MGA090912 002 Jul 27, 2011AB100MGA090912 003 Jul 27, 2011AB VIRTUS PHARM25MGA091343 001 Oct 17, 2013AB50MGA091343 002 Oct 17, 2013AB100MGA091343 003 Oct 17, 2013AB WATSON LABS25MGA077532 001 May 07, 2008AB50MGA077532 002 May 07, 2008AB100MGA077532 003 May 07, 2008PRECOSEAB + BAYER HLTHCARE25MGN020482 004 May 29, 1997AB50MGN020482 001 Sep 06, 1995AB100MGN020482 002 Sep 06, 1995

## PRESCRIPTION DRUG PRODUCT LIST

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

<b>AB</b>	AMNEAL PHARM	<b>EQ 200MG BASE</b>	<b>A075047 001</b>	Dec 30, 1999
<b>AB</b>		<b>EQ 400MG BASE</b>	<b>A075047 002</b>	Dec 30, 1999
<b>AB</b>	MYLAN	<b>EQ 200MG BASE</b>	<b>A074288 001</b>	Apr 24, 1995
<b>AB</b>		<b>EQ 400MG BASE</b>	<b>A074288 002</b>	Apr 24, 1995
<b>SECTRAL</b>				
<b>AB</b>	PROMIUS PHARMA	<b>EQ 200MG BASE</b>	<b>N018917 001</b>	Dec 28, 1984
<b>AB</b>	+	<b>EQ 400MG BASE</b>	<b>N018917 003</b>	Dec 28, 1984

ACETAMINOPHEN

SOLUTION; IV (INFUSION)

OFIRMEV

+	CADENCE PHARMS	1000MG/100ML (10MG/ML)	N022450 001	Nov 02, 2010
---	----------------	------------------------	-------------	--------------

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

+	NEXGEN PHARMA	300MG; 50MG	A090956 001	Aug 23, 2011
---	---------------	-------------	-------------	--------------

BUTAPAP

+	MIKART	325MG; 50MG	A089987 001	Oct 26, 1992
---	--------	-------------	-------------	--------------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	MIKART	325MG; 50MG; 40MG	A089007 001	Mar 17, 1986
---	--------	-------------------	-------------	--------------

+	NEXGEN PHARMA	300MG; 50MG; 40MG	A040885 001	Nov 16, 2009
---	---------------	-------------------	-------------	--------------

SOLUTION; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	MIKART	325MG/15ML; 50MG/15ML; 40MG/15ML	A040387 001	Jan 31, 2003
---	--------	----------------------------------	-------------	--------------

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<b>AA</b>	HIKMA PHARMS LLC	<b>325MG; 50MG; 40MG</b>	<b>A089718 001</b>	Jun 12, 1995
<b>AA</b>	LANNETT HOLDINGS INC	<b>325MG; 50MG; 40MG</b>	<b>A200243 001</b>	Sep 13, 2012
<b>AA</b>	MALLINCKRODT	<b>325MG; 50MG; 40MG</b>	<b>A087804 001</b>	Jan 24, 1985
<b>AA</b>	MIKART	<b>325MG; 50MG; 40MG</b>	<b>A089175 001</b>	Jan 21, 1987
<b>AA</b>	+	<b>VINTAGE PHARMS</b>	<b>A040511 001</b>	Aug 27, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

<b>AB</b>	HIKMA INTL PHARMS	<b>325MG; 50MG; 40MG; 30MG</b>	<b>A075618 001</b>	Mar 23, 2001
<b>AB</b>	NEXGEN PHARMA INC	<b>325MG; 50MG; 40MG; 30MG</b>	<b>A076560 001</b>	Jun 10, 2004
<b>AB</b>	VINTAGE PHARMS	<b>325MG; 50MG; 40MG; 30MG</b>	<b>A075929 001</b>	Apr 22, 2002

FIORICET W/ CODEINE

<b>AB</b>	+	<b>WATSON LABS INC</b>	<b>325MG; 50MG; 40MG; 30MG</b>	<b>N020232 001</b>	Jul 30, 1992
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE					
		NEXGEN PHARMA INC	300MG; 50MG; 40MG; 30MG	A076560 002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

TREZIX

WRASER PHARMS LLC	320.5MG; 30MG; 16MG	A204785 001	Nov 26, 2014
-------------------	---------------------	-------------	--------------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<b>AA</b>	HI TECH PHARMA	<b>120MG/5ML; 12MG/5ML</b>	<b>A040119 001</b>	Apr 26, 1996
<b>AA</b>	MIKART	<b>120MG/5ML; 12MG/5ML</b>	<b>A089450 001</b>	Oct 27, 1992
<b>AA</b>	+	<b>PHARM ASSOC</b>	<b>A087508 001</b>	
<b>AA</b>	VINTAGE PHARMS	<b>120MG/5ML; 12MG/5ML</b>	<b>A091238 001</b>	Nov 10, 2011
<b>AA</b>	WOCKHARDT	<b>120MG/5ML; 12MG/5ML</b>	<b>A087006 001</b>	

SUSPENSION; ORAL

CAPITAL AND CODEINE

+	VALEANT PHARMS LLC	120MG/5ML; 12MG/5ML	A086024 001
---	--------------------	---------------------	-------------

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<b>AA</b>	AMNEAL PHARMS NY	<b>300MG; 30MG</b>	<b>A040779 001</b>	May 29, 2008
<b>AA</b>	AUROLIFE PHARMA LLC	<b>300MG; 15MG</b>	<b>A202800 001</b>	Apr 15, 2013
<b>AA</b>		<b>300MG; 30MG</b>	<b>A202800 002</b>	Apr 15, 2013
<b>AA</b>		<b>300MG; 60MG</b>	<b>A202800 003</b>	Apr 15, 2013
<b>AA</b>	+	<b>MALLINCKRODT INC</b>	<b>A040419 001</b>	May 31, 2001
<b>AA</b>		<b>300MG; 30MG</b>	<b>A040419 002</b>	May 31, 2001
<b>AA</b>		<b>300MG; 60MG</b>	<b>A040419 003</b>	May 31, 2001

## PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	RANBAXY	<u>300MG; 30MG</u>	<u>A085868 001</u>	
<u>AA</u>		<u>300MG; 60MG</u>	<u>A087083 001</u>	
<u>AA</u>	TEVA	<u>300MG; 15MG</u>	<u>A088627 001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG; 30MG</u>	<u>A088628 001</u>	Mar 06, 1985
<u>AA</u>	+	<u>300MG; 60MG</u>	<u>A088629 001</u>	Mar 06, 1985
<u>AA</u>	VINTAGE	<u>300MG; 15MG</u>	<u>A089990 001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG; 30MG</u>	<u>A089805 001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG; 60MG</u>	<u>A089828 001</u>	Sep 30, 1988
<u>TYLENOL W/ CODEINE NO. 3</u>				
<u>AA</u>	+	JANSSEN PHARMS	<u>300MG; 30MG</u>	<u>A085055 003</u>
<u>TYLENOL W/ CODEINE NO. 4</u>				
<u>AA</u>	JANSSEN PHARMS	<u>300MG; 60MG</u>	<u>A085055 004</u>	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	+	MIKART	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A040482 001</u>	Sep 25, 2003
<u>AA</u>		PHARM ASSOC	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A040838 001</u>	May 10, 2013
<u>AA</u>		VINTAGE PHARMS	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A040894 001</u>	Jul 19, 2011
<u>AA</u>		VISTAPHARM	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A200343 001</u>	Jan 25, 2012
<u>AA</u>	+	MIKART	300MG/15ML; 10MG/15ML	A040881 001	Feb 25, 2010
<u>AA</u>	+	PHARM ASSOC	325MG/15ML; 10MG/15ML	A040834 001	Apr 18, 2008

TABLET; ORAL

ANEXSIA 5/325

<u>AA</u>	MALLINCKRODT	<u>325MG; 5MG</u>	<u>A040409 001</u>	Oct 20, 2000
-----------	--------------	-------------------	--------------------	--------------

ANEXSIA 7.5/325

<u>AA</u>	MALLINCKRODT	<u>325MG; 7.5MG</u>	<u>A040405 001</u>	Sep 08, 2000
-----------	--------------	---------------------	--------------------	--------------

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<u>A040736 001</u>	Aug 25, 2006	
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040746 001</u>	Aug 25, 2006	
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG; 5MG</u>	<u>A201013 001</u>	Apr 11, 2012	
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201013 002</u>	Apr 11, 2012	
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201013 003</u>	Apr 11, 2012	
<u>AA</u>	MALLINCKRODT	<u>325MG; 10MG</u>	<u>A040400 001</u>	Jul 26, 2000	
<u>AA</u>	+	MIKART	<u>300MG; 5MG</u>	<u>A040658 001</u>	Jan 19, 2006
<u>AA</u>	+		<u>300MG; 7.5MG</u>	<u>A040556 002</u>	Mar 24, 2006
<u>AA</u>	+		<u>300MG; 10MG</u>	<u>A040556 001</u>	Jun 23, 2004
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040432 001</u>	Jan 22, 2003	
<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 5MG</u>	<u>A090118 001</u>	Dec 23, 2008	
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090118 002</u>	Dec 23, 2008	
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090118 003</u>	Dec 23, 2008	
<u>AA</u>	TRIS PHARMA INC	<u>325MG; 5MG</u>	<u>A202214 001</u>	Mar 27, 2013	
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202214 002</u>	Mar 27, 2013	
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202214 003</u>	Mar 27, 2013	
<u>AA</u>	VINTAGE PHARMS	<u>300MG; 5MG</u>	<u>A090415 001</u>	Jan 24, 2011	
<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A090415 002</u>	Jan 24, 2011	
<u>AA</u>		<u>300MG; 10MG</u>	<u>A090415 003</u>	Jan 24, 2011	
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040655 001</u>	Jan 19, 2006	
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040656 001</u>	Jan 19, 2006	
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040355 001</u>	May 31, 2000	
<u>NORCO</u>					
<u>AA</u>	+	ACTAVIS LABS FL INC	<u>325MG; 7.5MG</u>	<u>A040148 003</u>	Sep 12, 2000
<u>AA</u>	+		<u>325MG; 10MG</u>	<u>A040148 001</u>	Feb 14, 1997
<u>AA</u>	+	WATSON LABS	<u>325MG; 5MG</u>	<u>A040099 001</u>	Jun 25, 1997
<u>HYDROCODONE BITARTRATE AND ACETAMINOPHEN</u>					
<u>AA</u>	+	MIKART	325MG; 2.5MG	A040846 001	Jun 09, 2010

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

<u>AA</u>	VINTAGE PHARMS	<u>325MG/5ML; 5MG/5ML</u>	<u>A203573 001</u>	Dec 18, 2014
-----------	----------------	---------------------------	--------------------	--------------

ROXICET

<u>AA</u>	+	ROXANE	<u>325MG/5ML; 5MG/5ML</u>	<u>A089351 001</u>	Dec 03, 1986
-----------	---	--------	---------------------------	--------------------	--------------

TABLET; ORAL

OXYCET

<u>AA</u>	MALLINCKRODT	<u>325MG; 5MG</u>	<u>A087463 001</u>	Dec 07, 1983
-----------	--------------	-------------------	--------------------	--------------

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	ACTAVIS ELIZABETH	<u>325MG; 2.5MG</u>	<u>A201447 001</u>	Apr 12, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A201447 002</u>	Apr 12, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201447 003</u>	Apr 12, 2013



## PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>		<u>325MG; 10MG</u>	<u>A201447</u>	<u>004</u>	Apr 12, 2013
<u>AA</u>	ALVOGEN INC	<u>325MG; 7.5MG</u>	<u>A202677</u>	<u>001</u>	Jul 26, 2012
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202677</u>	<u>002</u>	Jul 26, 2012
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<u>A040777</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040778</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG; 2.5MG</u>	<u>A201972</u>	<u>001</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A201972</u>	<u>002</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201972</u>	<u>003</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201972</u>	<u>004</u>	Jul 15, 2013
<u>AA</u>	COASTAL PHARMS	<u>325MG; 2.5MG</u>	<u>A090177</u>	<u>001</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090177</u>	<u>002</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090177</u>	<u>003</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090177</u>	<u>004</u>	Oct 20, 2008
<u>AA</u>	MALLINCKRODT	<u>325MG; 7.5MG</u>	<u>A040545</u>	<u>001</u>	Jun 30, 2004
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040545</u>	<u>002</u>	Jun 30, 2004
<u>AA</u>	RHODES PHARMS	<u>325MG; 5MG</u>	<u>A201278</u>	<u>001</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201278</u>	<u>002</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201278</u>	<u>003</u>	Aug 28, 2014
<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 2.5MG</u>	<u>A090535</u>	<u>001</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090535</u>	<u>002</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090535</u>	<u>003</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090535</u>	<u>004</u>	Dec 26, 2013
<u>AA</u>	VINTAGE PHARMS	<u>325MG; 2.5MG</u>	<u>A090733</u>	<u>001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040105</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090734</u>	<u>001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090734</u>	<u>002</u>	Jul 11, 2013
<u>AA</u>	WATSON LABS	<u>325MG; 5MG</u>	<u>A040171</u>	<u>001</u>	Oct 30, 1997
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040535</u>	<u>001</u>	Sep 05, 2003
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040535</u>	<u>002</u>	Sep 05, 2003

PERCOCET

<u>AA</u>	+ VINTAGE PHARMS LLC	<u>325MG; 2.5MG</u>	<u>A040330</u>	<u>001</u>	Jun 25, 1999
<u>AA</u>	+	<u>325MG; 5MG</u>	<u>A040330</u>	<u>002</u>	Jun 25, 1999
<u>AA</u>	+	<u>325MG; 7.5MG</u>	<u>A040434</u>	<u>001</u>	Nov 23, 2001
<u>AA</u>	+	<u>325MG; 10MG</u>	<u>A040434</u>	<u>002</u>	Nov 23, 2001

ROXICET

<u>AA</u>	ROXANE	<u>325MG; 5MG</u>	<u>A087003</u>	<u>001</u>	
	OXYCODONE AND ACETAMINOPHEN				
	+ MIKART	300MG; 2.5MG	A040608	001	Dec 30, 2005
	+	300MG; 5MG	A040608	002	Dec 30, 2005
	+	300MG; 7.5MG	A040608	003	Dec 30, 2005
	+	300MG; 10MG	A040608	004	Dec 30, 2005

TABLET, EXTENDED RELEASE; ORAL

XARTEMIS XR

+	MALLINCKRODT INC	325MG; 7.5MG	N204031	001	Mar 11, 2014
---	------------------	--------------	---------	-----	--------------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	325MG; 32MG	A083689	001	
-------	-------------	---------	-----	--

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

<u>AB</u>	ALLIED PHARMA INC	<u>325MG; 37.5MG</u>	<u>A202076</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>	AMNEAL PHARMS	<u>325MG; 37.5MG</u>	<u>A090485</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>	APOTEX INC	<u>325MG; 37.5MG</u>	<u>A078778</u>	<u>001</u>	Apr 07, 2014
<u>AB</u>	MICRO LABS LTD INDIA	<u>325MG; 37.5MG</u>	<u>A201952</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>	MYLAN	<u>325MG; 37.5MG</u>	<u>A077858</u>	<u>001</u>	Sep 26, 2008
<u>AB</u>	PAR PHARM	<u>325MG; 37.5MG</u>	<u>A076475</u>	<u>001</u>	Apr 21, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>325MG; 37.5MG</u>	<u>A077184</u>	<u>001</u>	Dec 16, 2005
<u>AB</u>	ZYDUS PHARMS USA INC	<u>325MG; 37.5MG</u>	<u>A090460</u>	<u>001</u>	Sep 06, 2012

ULTRACET

<u>AB</u>	+ JANSSSEN PHARMS	<u>325MG; 37.5MG</u>	<u>N021123</u>	<u>001</u>	Aug 15, 2001
-----------	-------------------	----------------------	----------------	------------	--------------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>500MG</u>	<u>A090779</u>	<u>001</u>	Jul 14, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>500MG</u>	<u>A040904</u>	<u>001</u>	Dec 10, 2008

## PRESCRIPTION DRUG PRODUCT LIST

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

DIAMOX

**AB** + DURAMED PHARMS BARR **500MG** **N012945 001**  
 TABLET; ORAL

ACETAZOLAMIDE

**AB** LANNETT **250MG** **A084840 001**  
**AB** MUTUAL PHARM **125MG** **A089752 001** Jun 22, 1988  
**AB** TARO **125MG** **A040195 001** May 28, 1997  
**AB** + **250MG** **A040195 002** May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

**AP** EUROHLTH INTL **EQ 500MG BASE/VIAL** **A040089 001** Feb 28, 1995  
**AP** SAGENT AGILA **EQ 500MG BASE/VIAL** **A200880 001** May 09, 2012  
**AP** + X GEN PHARMS **EQ 500MG BASE/VIAL** **A040784 001** Dec 10, 2008  
ACETAZOLAMIDE SODIUM  
**AP** EMCURE PHARMS LTD **EQ 500MG BASE/VIAL** **A202693 001** Dec 19, 2014

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

**AT** B BRAUN **250MG/100ML** **N018161 001**  
**AT** BAXTER HLTHCARE **250MG/100ML** **N018523 001** Feb 19, 1982  
**AT** HOSPIRA **250MG/100ML** **N017656 001**

SOLUTION/DROPS; OTIC

ACETIC ACID

**AT** TARO **2%** **A088638 001** Sep 06, 1984  
**AT** VINTAGE **2%** **A040607 001** Feb 24, 2005  
**AT** + WOCKHARDT **2%** **A040166 001** Jul 26, 1996

VOSOL

**AT** HI TECH PHARMA **2%** **N012179 001**

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

+ BAUSCH AND LOMB **2%; 0.79%** **A040063 001** Feb 25, 1994

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETASOL HC

**AT** ACTAVIS MID ATLANTIC **2%; 1%** **A087143 001** Jan 13, 1982

HYDROCORTISONE AND ACETIC ACID

**AT** TARO **2%; 1%** **A088759 001** Mar 04, 1985  
**AT** VINTAGE **2%; 1%** **A040609 001** Feb 06, 2006

VOSOL HC

**AT** + HI TECH PHARMA **2%; 1%** **N012770 001**

ACETOHYDROXAMIC ACID

TABLET; ORAL

LITHOSTAT

+ MISSION PHARMA **250MG** **N018749 001** May 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

+ BAUSCH AND LOMB **20MG/VIAL** **N020213 001** Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

**AP** + CUMBERLAND PHARMS **6GM/30ML (200MG/ML)** **N021539 001** Jan 23, 2004

ACETYLCYSTEINE

**AP** INNOPHARMA LICENSING **6GM/30ML (200MG/ML)** **A200644 001** Nov 07, 2012  
 SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

**AN** HOSPIRA **10%** **A073664 001** Aug 30, 1994  
**AN** **20%** **A074037 001** Aug 30, 1994  
**AN** INNOPHARMA LICENSING **10%** **A204674 001** Feb 11, 2014  
**AN** **20%** **A203853 001** Jun 21, 2012  
**AN** + LUITPOLD **10%** **A072489 001** Jul 28, 1995  
**AN** + **20%** **A072547 001** Jul 28, 1995

## PRESCRIPTION DRUG PRODUCT LIST

ACITRETIN

CAPSULE;ORAL

ACITRETIN

<u>AB</u>	BARR LABS INC	<u>10MG</u>	<u>A091455</u>	<u>001</u>	Apr 04, 2013
<u>AB</u>		<u>25MG</u>	<u>A091455</u>	<u>002</u>	Apr 04, 2013
<u>AB</u>	TEVA PHARMS USA	<u>17.5MG</u>	<u>A202897</u>	<u>001</u>	Apr 04, 2013
<u>AB</u>		<u>22.5MG</u>	<u>A202897</u>	<u>002</u>	Apr 04, 2013

SORIATANE

<u>AB</u>	STIEFEL LABS INC	<u>10MG</u>	<u>N019821</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		<u>17.5MG</u>	<u>N019821</u>	<u>003</u>	Aug 06, 2009
<u>AB</u>		<u>22.5MG</u>	<u>N019821</u>	<u>004</u>	Aug 06, 2009
<u>AB</u>	+	<u>25MG</u>	<u>N019821</u>	<u>002</u>	Oct 28, 1996

ACLDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

+ FOREST LABS INC 0.375MG/INH

N202450 001 Jul 23, 2012

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

+ AUXILIUM PHARMS LLC 8MG;60MG

N019806 001 Mar 25, 1994

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075677</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>	CADILA PHARMS LTD	<u>200MG</u>	<u>A201445</u>	<u>001</u>	Mar 06, 2014
<u>AB</u>	DAVA PHARMS INC	<u>200MG</u>	<u>A074833</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074727</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	RANBAXY	<u>200MG</u>	<u>A074975</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>	STASON	<u>200MG</u>	<u>A075090</u>	<u>001</u>	Jan 26, 1999
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074578</u>	<u>001</u>	Apr 22, 1997

ZOVIRAX

<u>AB</u>	+	DELCOR ASSET	<u>200MG</u>	<u>N018828</u>	<u>001</u>	Jan 25, 1985
-----------	---	--------------	--------------	----------------	------------	--------------

CREAM;TOPICAL

ZOVIRAX

	+	VALEANT BERMUDA	5%	N021478	001	Dec 30, 2002
--	---	-----------------	----	---------	-----	--------------

OINTMENT;TOPICAL

ACYCLOVIR

<u>AB</u>	AMNEAL PHARMS	<u>5%</u>	<u>A204605</u>	<u>001</u>	Jun 18, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>5%</u>	<u>A202459</u>	<u>001</u>	Apr 03, 2013

ZOVIRAX

<u>AB</u>	+	VALEANT BERMUDA	<u>5%</u>	<u>N018604</u>	<u>001</u>	Mar 29, 1982
-----------	---	-----------------	-----------	----------------	------------	--------------

SUSPENSION;ORAL

ACYCLOVIR

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>200MG/5ML</u>	<u>A074738</u>	<u>001</u>	Apr 28, 1997
<u>AB</u>	HI TECH PHARMA	<u>200MG/5ML</u>	<u>A077026</u>	<u>001</u>	Jun 07, 2005

ZOVIRAX

<u>AB</u>	+	DELCOR ASSET	<u>200MG/5ML</u>	<u>N019909</u>	<u>001</u>	Dec 22, 1989
-----------	---	--------------	------------------	----------------	------------	--------------

TABLET;BUCCAL

SITAVIG

+ INNOCUTIS HOLDINGS 50MG

N203791 001 Apr 12, 2013

TABLET;ORAL

ACYCLOVIR

<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A077309</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A077309</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	CADILA PHARMS LTD	<u>400MG</u>	<u>A202168</u>	<u>001</u>	Nov 15, 2013
<u>AB</u>		<u>800MG</u>	<u>A202168</u>	<u>002</u>	Nov 15, 2013
<u>AB</u>	CARLSBAD	<u>400MG</u>	<u>A075382</u>	<u>001</u>	Apr 30, 1999
<u>AB</u>		<u>800MG</u>	<u>A075382</u>	<u>002</u>	Apr 30, 1999
<u>AB</u>	DAVA PHARMS INC	<u>400MG</u>	<u>A074946</u>	<u>001</u>	Nov 19, 1997
<u>AB</u>		<u>800MG</u>	<u>A074946</u>	<u>002</u>	Nov 19, 1997
<u>AB</u>	HETERO LABS LTD V	<u>400MG</u>	<u>A203834</u>	<u>001</u>	Oct 29, 2013
<u>AB</u>		<u>800MG</u>	<u>A203834</u>	<u>002</u>	Oct 29, 2013
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075211</u>	<u>001</u>	Sep 28, 1998
<u>AB</u>		<u>800MG</u>	<u>A075211</u>	<u>002</u>	Sep 28, 1998
<u>AB</u>	RANBAXY	<u>400MG</u>	<u>A074980</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>		<u>800MG</u>	<u>A074980</u>	<u>002</u>	Sep 30, 1998
<u>AB</u>	TEVA	<u>400MG</u>	<u>A074556</u>	<u>002</u>	Apr 22, 1997
<u>AB</u>		<u>800MG</u>	<u>A074556</u>	<u>003</u>	Apr 22, 1997
<u>AB</u>	ZYDUS PHARMS USA INC	<u>400MG</u>	<u>A204314</u>	<u>001</u>	Aug 19, 2014
<u>AB</u>		<u>800MG</u>	<u>A204314</u>	<u>002</u>	Aug 19, 2014

## PRESCRIPTION DRUG PRODUCT LIST

ACYCLOVIR

TABLET; ORAL

ZOVIRAX

<b>AB</b>	DELCOR ASSET	<b>400MG</b>	<b>N020089 001</b>	Apr 30, 1991
<b>AB</b>	+	<b>800MG</b>	<b>N020089 002</b>	Apr 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

<b>AP</b>	AUROBINDO PHARMA LTD	<b>EQ 50MG BASE/ML</b>	<b>A203701 001</b>	Oct 11, 2013
<b>AP</b>	BEDFORD	<b>EQ 500MG BASE/VIAL</b>	<b>A074596 002</b>	Apr 22, 1997
<b>AP</b>	+	<b>EQ 50MG BASE/ML</b>	<b>A074930 001</b>	May 13, 1998
<b>AP</b>	+	<b>EQ 500MG BASE/VIAL</b>	<b>A075015 001</b>	Apr 30, 1998
	ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE			
	HIKMA MAPLE	EQ 1GM BASE/VIAL	A074885 002	Dec 19, 1997
	+	EQ 500MG BASE/VIAL	A074885 001	Dec 19, 1997
	ACYCLOVIR SODIUM			
	+	EQ 1GM BASE/VIAL	A074596 001	Apr 22, 1997

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+	VALEANT BERMUDA	5%;1%	N022436 001	Jul 31, 2009
---	-----------------	-------	-------------	--------------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

<b>AB</b>	FOUGERA PHARMS	<b>0.1%</b>	<b>A090824 001</b>	Jun 30, 2010
-----------	----------------	-------------	--------------------	--------------

DIFFERIN

<b>AB</b>	+	GALDERMA LABS LP	<b>0.1%</b>	<b>N020748 001</b>	May 26, 2000
-----------	---	------------------	-------------	--------------------	--------------

GEL; TOPICAL

ADAPALENE

<b>AB</b>	ACTAVIS MID ATLANTIC	<b>0.3%</b>	<b>A201000 001</b>	Oct 27, 2014
<b>AB</b>	GLENMARK GENERICS	<b>0.1%</b>	<b>A091314 001</b>	Jul 01, 2010
<b>AB</b>	PLIVA HRVATSKA DOO	<b>0.1%</b>	<b>A090962 001</b>	Jun 02, 2010
<b>AB</b>	TOLMAR	<b>0.3%</b>	<b>A200298 001</b>	Jun 14, 2012

DIFFERIN

<b>AB</b>	+	GALDERMA LABS LP	<b>0.1%</b>	<b>N020380 001</b>	May 31, 1996
-----------	---	------------------	-------------	--------------------	--------------

<b>AB</b>	+		<b>0.3%</b>	<b>N021753 001</b>	Jun 19, 2007
-----------	---	--	-------------	--------------------	--------------

LOTION; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010
---	------------------	------	-------------	--------------

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

EPIDUO

+	GALDERMA LABS LP	0.1%;2.5%	N022320 001	Dec 08, 2008
---	------------------	-----------	-------------	--------------

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

<b>AB</b>	SIGMAPHARM LABS LLC	<b>10MG</b>	<b>A202051 001</b>	Aug 29, 2013
-----------	---------------------	-------------	--------------------	--------------

HEPSERA

<b>AB</b>	+	GILEAD	<b>10MG</b>	<b>N021449 001</b>	Sep 20, 2002
-----------	---	--------	-------------	--------------------	--------------

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

<b>AP</b>	+	ASTELLAS	<b>3MG/ML</b>	<b>N019937 002</b>	Oct 30, 1989
-----------	---	----------	---------------	--------------------	--------------

ADENOSINE

<b>AP</b>	AGILA SPECLTS	<b>3MG/ML</b>	<b>A078640 001</b>	Mar 21, 2014
-----------	---------------	---------------	--------------------	--------------

<b>AP</b>		<b>3MG/ML</b>	<b>A078686 001</b>	May 13, 2009
-----------	--	---------------	--------------------	--------------

<b>AP</b>	AKORN	<b>3MG/ML</b>	<b>A078076 001</b>	Oct 31, 2008
-----------	-------	---------------	--------------------	--------------

<b>AP</b>	BEDFORD	<b>3MG/ML</b>	<b>A076404 001</b>	Jun 16, 2004
-----------	---------	---------------	--------------------	--------------

<b>AP</b>	FRESENIUS KABI USA	<b>3MG/ML</b>	<b>A077133 001</b>	Apr 27, 2005
-----------	--------------------	---------------	--------------------	--------------

<b>AP</b>	GLAND PHARMA LTD	<b>3MG/ML</b>	<b>A077283 001</b>	Jun 14, 2007
-----------	------------------	---------------	--------------------	--------------

<b>AP</b>	HIKMA MAPLE	<b>3MG/ML</b>	<b>A076500 001</b>	Jun 16, 2004
-----------	-------------	---------------	--------------------	--------------

<b>AP</b>	LUITPOLD	<b>3MG/ML</b>	<b>A090010 001</b>	Apr 28, 2009
-----------	----------	---------------	--------------------	--------------

<b>AP</b>	WOCKHARDT	<b>3MG/ML</b>	<b>A090220 001</b>	Jul 20, 2009
-----------	-----------	---------------	--------------------	--------------

SOLUTION; IV (INFUSION)

ADENOSCAN

<b>AP</b>	+	ASTELLAS	<b>60MG/20ML (3MG/ML)</b>	<b>N020059 001</b>	May 18, 1995
-----------	---	----------	---------------------------	--------------------	--------------

<b>AP</b>	+		<b>90MG/30ML (3MG/ML)</b>	<b>N020059 002</b>	May 18, 1995
-----------	---	--	---------------------------	--------------------	--------------

ADENOSINE

<b>AP</b>	AKORN	<b>60MG/20ML (3MG/ML)</b>	<b>A090450 001</b>	Oct 02, 2014
-----------	-------	---------------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ADENOSINE

SOLUTION;IV (INFUSION)

ADENOSINE

<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090450 002</u>	Oct 02, 2014
<u>AP</u>	EMCURE PHARMS LTD	<u>60MG/20ML (3MG/ML)</u>	<u>A202313 001</u>	Sep 15, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A202313 002</u>	Sep 15, 2014
<u>AP</u>	HOSPIRA INC	<u>60MG/20ML (3MG/ML)</u>	<u>A203883 001</u>	Mar 24, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A203883 002</u>	Mar 24, 2014
<u>AP</u>	SAGENT STRIDES	<u>60MG/20ML (3MG/ML)</u>	<u>A090212 001</u>	Mar 28, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090212 002</u>	Mar 28, 2014
<u>AP</u>	TEVA PHARMS USA	<u>60MG/20ML (3MG/ML)</u>	<u>A077425 001</u>	Aug 29, 2013
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A077425 002</u>	Aug 29, 2013

AFATINIB DIMALEATE

TABLET;ORAL

GILOTRIF

	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292 001	Jul 12, 2013
		EQ 30MG BASE	N201292 002	Jul 12, 2013
+		EQ 40MG BASE	N201292 003	Jul 12, 2013

ALBENDAZOLE

TABLET;ORAL

ALBENZA

+	AMEDRA PHARMS	200MG	N020666 001	Jun 11, 1996
---	---------------	-------	-------------	--------------

ALBUMIN HUMAN

INJECTABLE;INJECTION

OPTISON

+	GE HEALTHCARE	10MG/ML	N020899 001	Dec 31, 1997
---	---------------	---------	-------------	--------------

ALBUMIN IODINATED I-125 SERUM

INJECTABLE;INJECTION

JEANATOPE

	ISO TEX	100uCi/10ML (10uCi/ML)	N017836 003	Jun 08, 2004
		500uCi/0.5ML	N017836 001	
+		1,000uCi/ML	N017836 002	

ALBUMIN IODINATED I-131 SERUM

INJECTABLE;INJECTION

MEGATOPE

+	ISO TEX	0.5mCi/VIAL	N017837 001	
+		1mCi/VIAL	N017837 002	

ALBUTEROL SULFATE

AEROSOL, METERED;INHALATION

PROAIR HFA

BX	+ TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457 001	Oct 29, 2004
	PROVENTIL-HFA			
BX	+ 3M	EQ 0.09MG BASE/INH	N020503 001	Aug 15, 1996
	VENTOLIN HFA			
BX	+ GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983 001	Apr 19, 2001
	SOLUTION;INHALATION			

ACCUNEB

<u>AN</u>	+	MYLAN SPECLT	<u>EQ 0.021% BASE</u>	<u>N020949 002</u>	Apr 30, 2001
<u>AN</u>	+		<u>EQ 0.042% BASE</u>	<u>N020949 001</u>	Apr 30, 2001

ALBUTEROL SULFATE

<u>AN</u>	+	BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>A075050 001</u>	Jun 18, 1998
<u>AN</u>		HI TECH PHARMA	<u>EQ 0.083% BASE</u>	<u>A075063 001</u>	Feb 09, 1999
<u>AN</u>			<u>EQ 0.5% BASE</u>	<u>A074543 001</u>	Jan 15, 1998
<u>AN</u>		LANDELA PHARM	<u>EQ 0.083% BASE</u>	<u>A077569 001</u>	Apr 04, 2006
<u>AN</u>	+	MYLAN SPECLT	<u>EQ 0.083% BASE</u>	<u>A072652 001</u>	Feb 21, 1992
<u>AN</u>		NEPHRON	<u>EQ 0.021% BASE</u>	<u>A076355 002</u>	Mar 31, 2010
<u>AN</u>			<u>EQ 0.042% BASE</u>	<u>A076355 001</u>	Jun 28, 2004
<u>AN</u>			<u>EQ 0.083% BASE</u>	<u>A074880 001</u>	Sep 17, 1997
<u>AN</u>			<u>EQ 0.5% BASE</u>	<u>A075664 001</u>	Jun 26, 2001
<u>AN</u>		RITEDOSE CORP	<u>EQ 0.083% BASE</u>	<u>A077839 001</u>	Dec 16, 2008
<u>AN</u>		TEVA PHARMS	<u>EQ 0.083% BASE</u>	<u>A075343 001</u>	Nov 09, 1999
<u>AN</u>		WATSON LABS	<u>EQ 0.021% BASE</u>	<u>A077772 001</u>	Sep 25, 2007
<u>AN</u>			<u>EQ 0.042% BASE</u>	<u>A077772 002</u>	Sep 25, 2007
<u>AN</u>		WATSON LABS INC	<u>EQ 0.083% BASE</u>	<u>A076370 001</u>	Nov 24, 2003

SYRUP;ORAL

ALBUTEROL SULFATE

<u>AA</u>		ACTAVIS MID ATLANTIC	<u>EQ 2MG BASE/5ML</u>	<u>A074454 001</u>	Sep 25, 1995
<u>AA</u>		AMNEAL PHARMS	<u>EQ 2MG BASE/5ML</u>	<u>A079241 001</u>	May 12, 2010
<u>AA</u>		HI TECH PHARMA	<u>EQ 2MG BASE/5ML</u>	<u>A074749 001</u>	Jan 30, 1998

## PRESCRIPTION DRUG PRODUCT LIST

ALBUTEROL SULFATE

SYRUP; ORAL

ALBUTEROL SULFATE

<b>AA</b>	+	TEVA	<u>EQ 2MG BASE/5ML</u>	<u>A073419 001</u>	Mar 30, 1992
<b>AA</b>		VINTAGE	<u>EQ 2MG BASE/5ML</u>	<u>A078105 001</u>	Dec 27, 2006
<b>AA</b>		VISTAPHARM	<u>EQ 2MG BASE/5ML</u>	<u>A077788 001</u>	Jun 26, 2007

TABLET; ORAL

ALBUTEROL SULFATE

<b>AB</b>		MUTUAL PHARM	<u>EQ 2MG BASE</u>	<u>A072637 002</u>	Dec 05, 1989
<b>AB</b>			<u>EQ 4MG BASE</u>	<u>A072637 001</u>	Dec 05, 1989
<b>AB</b>		MYLAN	<u>EQ 2MG BASE</u>	<u>A072894 002</u>	Jan 17, 1991
<b>AB</b>	+		<u>EQ 4MG BASE</u>	<u>A072894 001</u>	Jan 17, 1991

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

<b>AB</b>		MYLAN	<u>EQ 4MG BASE</u>	<u>A078092 002</u>	Jan 29, 2007
<b>AB</b>			<u>EQ 8MG BASE</u>	<u>A078092 001</u>	Jan 29, 2007

VOSPIRE ER

<b>AB</b>		DAVA PHARMS INC	<u>EQ 4MG BASE</u>	<u>A076130 002</u>	Sep 26, 2002
<b>AB</b>	+		<u>EQ 8MG BASE</u>	<u>A076130 003</u>	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT

+	BOEHRINGER INGELHEIM	<u>EQ 0.09MG BASE/INH; 0.018MG/INH</u>	<u>N020291 001</u>	Oct 24, 1996
---	----------------------	----------------------------------------	--------------------	--------------

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

<b>AN</b>		CIPLA LTD	<u>EQ 0.083% BASE; 0.017%</u>	<u>A077559 001</u>	Dec 31, 2007
<b>AN</b>		NEPHRON	<u>EQ 0.083% BASE; 0.017%</u>	<u>A076749 001</u>	Dec 31, 2007
<b>AN</b>		RITEDOSE CORP	<u>EQ 0.083% BASE; 0.017%</u>	<u>A202496 001</u>	Oct 01, 2012
<b>AN</b>		TEVA PHARMS	<u>EQ 0.083% BASE; 0.017%</u>	<u>A076724 001</u>	Dec 31, 2007
<b>AN</b>		WATSON LABS	<u>EQ 0.083% BASE; 0.017%</u>	<u>A077063 001</u>	Dec 31, 2007

DUONEB

<b>AN</b>	+	MYLAN SPECLT	<u>EQ 0.083% BASE; 0.017%</u>	<u>N020950 001</u>	Mar 21, 2001
-----------	---	--------------	-------------------------------	--------------------	--------------

SPRAY, METERED; INHALATION

COMBIVENT RESPIMAT

+	BOEHRINGER INGELHEIM	<u>EQ 0.1MG BASE/INH; 0.02MG/INH</u>	<u>N021747 001</u>	Oct 07, 2011
---	----------------------	--------------------------------------	--------------------	--------------

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

+	ALLERGAN	0.25%	<u>N022134 001</u>	Jul 28, 2010
---	----------	-------	--------------------	--------------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

<b>AB</b>	+	FOUGERA PHARMS	<u>0.05%</u>	<u>A076973 001</u>	Jul 12, 2005
<b>AB</b>		GLENMARK GENERICS	<u>0.05%</u>	<u>A079061 001</u>	Jun 23, 2009
<b>AB</b>		TARO	<u>0.05%</u>	<u>A076587 001</u>	Sep 15, 2005

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

<b>AB</b>	+	FOUGERA PHARMS	<u>0.05%</u>	<u>A076884 001</u>	Jul 18, 2005
<b>AB</b>		GLENMARK GENERICS	<u>0.05%</u>	<u>A079227 001</u>	Jul 30, 2009
<b>AB</b>		TARO	<u>0.05%</u>	<u>A076730 001</u>	Jul 29, 2004

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% AND DEXTROSE 5%

<b>AP</b>	+	B BRAUN	<u>5ML/100ML; 5GM/100ML</u>	<u>N004589 004</u>	
		ALCOHOL 10% AND DEXTROSE 5%			
	+	B BRAUN	<u>10ML/100ML; 5GM/100ML</u>	<u>N004589 006</u>	

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

<b>AA</b>		ROXANE	<u>EQ 70MG BASE/75ML</u>	<u>A090520 001</u>	Feb 25, 2013
-----------	--	--------	--------------------------	--------------------	--------------

FOSAMAX

<b>AA</b>	+	MERCK	<u>EQ 70MG BASE/75ML</u>	<u>N021575 001</u>	Sep 17, 2003
-----------	---	-------	--------------------------	--------------------	--------------

TABLET; ORAL

ALENDRONATE SODIUM

<b>AB</b>		APOTEX	<u>EQ 5MG BASE</u>	<u>A077982 001</u>	Aug 04, 2008
<b>AB</b>			<u>EQ 10MG BASE</u>	<u>A077982 002</u>	Aug 04, 2008
<b>AB</b>			<u>EQ 35MG BASE</u>	<u>A077982 003</u>	Aug 04, 2008
<b>AB</b>			<u>EQ 70MG BASE</u>	<u>A077982 004</u>	Aug 04, 2008
<b>AB</b>		AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A090124 001</u>	Aug 04, 2008
<b>AB</b>			<u>EQ 35MG BASE</u>	<u>A090124 002</u>	Aug 04, 2008

## PRESCRIPTION DRUG PRODUCT LIST

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090124 003</u>	Aug 04, 2008
<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 5MG BASE</u>	<u>A090258 001</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090258 002</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090258 003</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090258 004</u>	Sep 24, 2009
<u>AB</u>	CADISTA PHARMS	<u>EQ 5MG BASE</u>	<u>A090557 001</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090557 002</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090557 003</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090557 004</u>	Feb 18, 2010
<u>AB</u>	CIPLA LTD	<u>EQ 5MG BASE</u>	<u>A076768 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076768 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076768 003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076768 004</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076768 005</u>	Aug 04, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 5MG BASE</u>	<u>A079109 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079109 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A079049 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A079049 002</u>	Aug 04, 2008
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076584 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076584 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076584 003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076584 004</u>	Aug 04, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A090022 001</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090022 002</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090022 003</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090022 004</u>	Sep 10, 2008
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A075710 001</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075710 002</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A075710 003</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075710 004</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A075710 005</u>	Feb 06, 2008
<u>AB</u>	WATSON LABS	<u>EQ 35MG BASE</u>	<u>A076984 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076984 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076984 003</u>	Aug 04, 2008

FOSAMAX

<u>AB</u>	+ MERCK AND CO INC	<u>EQ 70MG BASE</u>	<u>N020560 005</u>	Oct 20, 2000
	TABLET, EFFERVESCENT; ORAL			
	BINOSTO			
	+ MISSION PHARMA	EQ 70MG BASE	N202344 001	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

MERCK

+

EQ 70MG BASE; 2,800 IU

N021762 001 Apr 07, 2005

+

EQ 70MG BASE; 5,600 IU

N021762 002 Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

<u>AP</u>	+ AKORN	<u>EQ 0.5MG BASE/ML</u>	<u>N019353 001</u>	Dec 29, 1986
	<u>ALFENTANIL</u>			
<u>AP</u>	HOSPIRA	<u>EQ 0.5MG BASE/ML</u>	<u>A075221 001</u>	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A079013 001</u>	Jul 18, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079060 001</u>	Aug 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090284 001</u>	Jan 17, 2012
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A079014 001</u>	Jul 18, 2011
<u>AB</u>	SUN PHARMA GLOBAL	<u>10MG</u>	<u>A079057 001</u>	Jul 18, 2011
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A079056 001</u>	Jul 18, 2011
<u>AB</u>	TORRENT PHARMS	<u>10MG</u>	<u>A079054 001</u>	Jul 18, 2011
<u>AB</u>	WOCKHARDT LTD	<u>10MG</u>	<u>A090221 001</u>	Aug 10, 2012
	<u>UROXATRAL</u>			
<u>AB</u>	+ COVIS PHARMA SARL	<u>10MG</u>	<u>N021287 001</u>	Jun 12, 2003

## PRESCRIPTION DRUG PRODUCT LIST

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTRUNA

NOVARTIS	EQ 150MG BASE	N021985 001	Mar 05, 2007
+	EQ 300MG BASE	N021985 002	Mar 05, 2007

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL

TEKAMLO

NOVARTIS	EQ 150MG BASE; EQ 5MG BASE	N022545 001	Aug 26, 2010
	EQ 150MG BASE; EQ 10MG BASE	N022545 002	Aug 26, 2010
	EQ 300MG BASE; EQ 5MG BASE	N022545 003	Aug 26, 2010
+	EQ 300MG BASE; EQ 10MG BASE	N022545 004	Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

NOVARTIS	EQ 150MG BASE; EQ 5MG BASE; 12.5MG	N200045 001	Dec 21, 2010
	EQ 300MG BASE; EQ 5MG BASE; 12.5MG	N200045 002	Dec 21, 2010
	EQ 300MG BASE; EQ 5MG BASE; 25MG	N200045 003	Dec 21, 2010
	EQ 300MG BASE; EQ 10MG BASE; 12.5MG	N200045 004	Dec 21, 2010
+	EQ 300MG BASE; EQ 10MG BASE; 25MG	N200045 005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTRUNA HCT

NOVARTIS	EQ 150MG BASE; 12.5MG	N022107 001	Jan 18, 2008
	EQ 150MG BASE; 25MG	N022107 002	Jan 18, 2008
+	EQ 300MG BASE; 12.5MG	N022107 003	Jan 18, 2008
+	EQ 300MG BASE; 25MG	N022107 004	Jan 18, 2008

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+ EISAI INC	EQ 0.1% BASE	N020886 001	Feb 02, 1999
-------------	--------------	-------------	--------------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<u>AB</u>	ACCORD HLTHCARE	<u>100MG</u>	<u>A203154 001</u>	May 06, 2013
<u>AB</u>		<u>300MG</u>	<u>A203154 002</u>	May 06, 2013
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077353 001</u>	Sep 08, 2005
<u>AB</u>		<u>300MG</u>	<u>A077353 002</u>	Sep 08, 2005
<u>AB</u>	IPCA LABS LTD	<u>100MG</u>	<u>A090637 001</u>	Mar 16, 2011
<u>AB</u>		<u>300MG</u>	<u>A090637 002</u>	Mar 16, 2011
<u>AB</u>	MUTUAL PHARM	<u>100MG</u>	<u>A071449 001</u>	Jan 09, 1987
<u>AB</u>		<u>300MG</u>	<u>A071450 001</u>	Jan 09, 1987
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A018659 001</u>	Oct 24, 1986
<u>AB</u>		<u>300MG</u>	<u>A018659 002</u>	Oct 24, 1986
<u>AB</u>	NORTHSTAR HLTHCARE	<u>100MG</u>	<u>A078253 001</u>	Sep 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078253 002</u>	Sep 11, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>100MG</u>	<u>A078390 001</u>	Aug 30, 2007
<u>AB</u>		<u>300MG</u>	<u>A078390 002</u>	Aug 30, 2007
<u>AB</u>	VINTAGE PHARMS	<u>100MG</u>	<u>A075798 001</u>	Jun 27, 2003
<u>AB</u>		<u>300MG</u>	<u>A075798 002</u>	Jun 27, 2003
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>N018832 002</u>	Sep 28, 1984
<u>AB</u>		<u>300MG</u>	<u>N018877 001</u>	Sep 28, 1984

LOPURIN

<u>AB</u>	DR REDDYS LA	<u>100MG</u>	<u>A071586 001</u>	Apr 02, 1987
<u>AB</u>		<u>300MG</u>	<u>A071587 001</u>	Apr 02, 1987

ZYLOPRIM

<u>AB</u>	PROMETHEUS LABS	<u>100MG</u>	<u>N016084 001</u>	
<u>AB</u>	+	<u>300MG</u>	<u>N016084 002</u>	

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

<u>AP</u>	EUROHLTH INTL	<u>EQ 500MG BASE/VIAL</u>	<u>A076870 001</u>	Aug 26, 2004
-----------	---------------	---------------------------	--------------------	--------------

ALOPRIM

<u>AP</u>	+	MYLAN INSTITUTIONAL	<u>EQ 500MG BASE/VIAL</u>	<u>N020298 001</u>	May 17, 1996
-----------	---	---------------------	---------------------------	--------------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001
+	EQ 12.5MG BASE	N021001	002	May 07, 2001

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013
	EQ 12.5MG BASE	N022271	002	Jan 25, 2013
+	EQ 25MG BASE	N022271	003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;1GM	N203414	002	Jan 25, 2013
		EQ 12.5MG BASE;500MG	N203414	001	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN1

TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013
	EQ 12.5MG BASE;EQ 30MG BASE	N022426	005	Jan 25, 2013
	EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013
	EQ 25MG BASE;EQ 15MG BASE	N022426	001	Jan 25, 2013
	EQ 25MG BASE;EQ 30MG BASE	N022426	002	Jan 25, 2013
+	EQ 25MG BASE;EQ 45MG BASE	N022426	003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTROXEX

PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003
+	EQ 1MG BASE	N021107	001	Feb 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+	SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000
---	--------	-------------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+	SANDOZ	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003
---	--------	------------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

+	ROXANE	1MG/ML	A074312	001	Oct 31, 1993
---	--------	--------	---------	-----	--------------

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A074342</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074342</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>		<u>1MG</u>	<u>A074342</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>		<u>2MG</u>	<u>A074342</u>	<u>004</u>	Oct 31, 1993
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077741</u>	<u>001</u>	Jan 19, 2007
<u>AB</u>		<u>0.5MG</u>	<u>A077741</u>	<u>002</u>	Jan 19, 2007
<u>AB</u>		<u>1MG</u>	<u>A077741</u>	<u>003</u>	Jan 19, 2007
<u>AB</u>		<u>2MG</u>	<u>A077741</u>	<u>004</u>	Jan 19, 2007
<u>AB</u>	DAVA INTL INC	<u>0.25MG</u>	<u>A074174</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074174</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074174</u>	<u>003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074174</u>	<u>004</u>	Oct 19, 1993
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A074215</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>		<u>0.5MG</u>	<u>A074215</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>		<u>1MG</u>	<u>A074215</u>	<u>003</u>	Jan 27, 1994
<u>AB</u>		<u>2MG</u>	<u>A074215</u>	<u>004</u>	Jan 27, 1994
<u>AB</u>	MYLAN PHARMS INC	<u>0.25MG</u>	<u>A074046</u>	<u>001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074046</u>	<u>002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074046</u>	<u>003</u>	Oct 19, 1993

## PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>		<u>2MG</u>	<u>A074046</u>	<u>004</u>	May 07, 1997
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A074112</u>	<u>001</u>	Dec 29, 1995
<u>AB</u>		<u>0.5MG</u>	<u>A074112</u>	<u>002</u>	Dec 29, 1995
<u>AB</u>		<u>1MG</u>	<u>A074112</u>	<u>003</u>	Dec 29, 1995
<u>AB</u>		<u>2MG</u>	<u>A074909</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>	SUN PHARMA GLOBAL	<u>0.25MG</u>	<u>A090082</u>	<u>001</u>	Jun 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090082</u>	<u>002</u>	Jun 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090082</u>	<u>003</u>	Jun 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090082</u>	<u>004</u>	Jun 17, 2010
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078491</u>	<u>001</u>	Sep 25, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078491</u>	<u>002</u>	Sep 25, 2008
<u>AB</u>		<u>1MG</u>	<u>A078491</u>	<u>003</u>	Sep 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078491</u>	<u>004</u>	Dec 12, 2008
<u>AB</u>	VINTAGE PHARMS	<u>0.25MG</u>	<u>A090248</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090248</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090248</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090248</u>	<u>004</u>	Sep 17, 2010

XANAX

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.25MG</u>	<u>N018276</u>	<u>001</u>	
<u>AB</u>		<u>0.5MG</u>	<u>N018276</u>	<u>002</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N018276</u>	<u>003</u>	
<u>AB</u>		<u>2MG</u>	<u>N018276</u>	<u>004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>		<u>1MG</u>	<u>A078056</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>		<u>2MG</u>	<u>A078056</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		<u>3MG</u>	<u>A078056</u>	<u>004</u>	Feb 13, 2007
<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A077198</u>	<u>001</u>	May 13, 2010
<u>AB</u>		<u>1MG</u>	<u>A077198</u>	<u>002</u>	May 13, 2010
<u>AB</u>		<u>2MG</u>	<u>A077198</u>	<u>003</u>	May 13, 2010
<u>AB</u>		<u>3MG</u>	<u>A077198</u>	<u>004</u>	May 13, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A078387</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A078387</u>	<u>003</u>	May 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A078387</u>	<u>004</u>	May 30, 2008
<u>AB</u>	ANCHEN PHARMS	<u>0.5MG</u>	<u>A078469</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A078469</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A078469</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A078469</u>	<u>004</u>	Sep 29, 2011
<u>AB</u>	ANI PHARMS INC	<u>0.5MG</u>	<u>A077725</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>1MG</u>	<u>A077725</u>	<u>002</u>	Jul 31, 2006
<u>AB</u>		<u>2MG</u>	<u>A077725</u>	<u>004</u>	Jul 31, 2006
<u>AB</u>		<u>3MG</u>	<u>A077725</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A078449</u>	<u>001</u>	Nov 12, 2008
<u>AB</u>		<u>2MG</u>	<u>A078449</u>	<u>002</u>	Nov 12, 2008
<u>AB</u>		<u>3MG</u>	<u>A078449</u>	<u>003</u>	Nov 12, 2008
<u>AB</u>	AUROBINDO PHARMA USA	<u>0.5MG</u>	<u>A090871</u>	<u>001</u>	Jun 07, 2011
<u>AB</u>		<u>1MG</u>	<u>A090871</u>	<u>002</u>	Jun 07, 2011
<u>AB</u>		<u>2MG</u>	<u>A090871</u>	<u>003</u>	Jun 07, 2011
<u>AB</u>		<u>3MG</u>	<u>A090871</u>	<u>004</u>	Jun 07, 2011
<u>AB</u>	COREPHARMA	<u>0.5MG</u>	<u>A077996</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>1MG</u>	<u>A077996</u>	<u>002</u>	Jan 31, 2007
<u>AB</u>		<u>2MG</u>	<u>A077996</u>	<u>003</u>	Jan 31, 2007
<u>AB</u>		<u>3MG</u>	<u>A077996</u>	<u>004</u>	Jan 31, 2007
<u>AB</u>	IMPAX LABS	<u>0.5MG</u>	<u>A077968</u>	<u>004</u>	May 24, 2007
<u>AB</u>		<u>1MG</u>	<u>A077968</u>	<u>003</u>	May 24, 2007
<u>AB</u>		<u>2MG</u>	<u>A077968</u>	<u>002</u>	May 24, 2007
<u>AB</u>		<u>3MG</u>	<u>A077968</u>	<u>001</u>	May 24, 2007
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A077391</u>	<u>002</u>	Jan 26, 2006
<u>AB</u>		<u>1MG</u>	<u>A077391</u>	<u>003</u>	Jan 26, 2006
<u>AB</u>		<u>2MG</u>	<u>A077391</u>	<u>004</u>	Jan 26, 2006
<u>AB</u>		<u>3MG</u>	<u>A077391</u>	<u>001</u>	Jan 26, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A078489</u>	<u>001</u>	Oct 17, 2008
<u>AB</u>		<u>1MG</u>	<u>A078489</u>	<u>002</u>	Oct 17, 2008
<u>AB</u>		<u>2MG</u>	<u>A078489</u>	<u>003</u>	Oct 17, 2008
<u>AB</u>		<u>3MG</u>	<u>A078489</u>	<u>004</u>	Oct 17, 2008

XANAX XR

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.5MG</u>	<u>N021434</u>	<u>001</u>	Jan 17, 2003
-----------	----------------------	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

XANAX XR

<u>AB</u>		<u>1MG</u>	<u>N021434</u>	<u>002</u>	Jan 17, 2003
<u>AB</u>		<u>2MG</u>	<u>N021434</u>	<u>003</u>	Jan 17, 2003
<u>AB</u>	+	<u>3MG</u>	<u>N021434</u>	<u>004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561</u>	<u>001</u>	Mar 16, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078561</u>	<u>002</u>	Mar 16, 2010
<u>AB</u>		<u>1MG</u>	<u>A078561</u>	<u>003</u>	Mar 16, 2010
<u>AB</u>		<u>2MG</u>	<u>A078561</u>	<u>004</u>	Mar 16, 2010
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A078088</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078088</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>	+	<u>1MG</u>	<u>A078088</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>		<u>2MG</u>	<u>A078088</u>	<u>004</u>	Jan 09, 2009

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL

<u>AP</u>	EUROHLTH INTL	<u>0.5MG/ML</u>	<u>A074815</u>	<u>001</u>	Jan 20, 1998
<u>AP</u>	TEVA PHARMS USA	<u>0.5MG/ML</u>	<u>A075196</u>	<u>001</u>	Apr 30, 1999

CAVERJECT

<u>AP</u>	PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379</u>	<u>001</u>	Jul 06, 1995
<u>AP</u>	+	<u>0.02MG/VIAL</u>	<u>N020379</u>	<u>002</u>	Jul 06, 1995
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020379</u>	<u>004</u>	May 19, 1997

EDEX

<u>AP</u>	AUXILIUM PHARMS LLC	<u>0.01MG/VIAL</u>	<u>N020649</u>	<u>002</u>	Jun 12, 1997
<u>AP</u>		<u>0.02MG/VIAL</u>	<u>N020649</u>	<u>003</u>	Jun 12, 1997
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020649</u>	<u>004</u>	Jun 12, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.5MG/ML</u>	<u>N018484</u>	<u>001</u>
		CAVERJECT			
		PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003 Jun 27, 1996
		CAVERJECT IMPULSE			
		PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212	001 Jun 11, 2002
			0.02MG/VIAL	N021212	002 Jun 11, 2002
		EDEX			
		+	AUXILIUM PHARMS LLC	0.01MG/VIAL	N020649 005 Jul 30, 1998
		+		0.02MG/VIAL	N020649 006 Jul 30, 1998
		+		0.04MG/VIAL	N020649 007 Jul 30, 1998
		SUPPOSITORY; URETHRAL			
		MUSE			
		MEDA PHARMS	0.125MG	N020700	001 Nov 19, 1996
			0.25MG	N020700	002 Nov 19, 1996
			0.5MG	N020700	003 Nov 19, 1996
		+		1MG	N020700 004 Nov 19, 1996

ALTRETAMINE

CAPSULE;ORAL

HEXALEN

	+	EISAI INC	50MG	N019926	001 Dec 26, 1990
--	---	-----------	------	---------	------------------

ALVIMOPAN

CAPSULE;ORAL

ENTEREG

	+	CUBIST PHARMS	12MG	N021775	001 May 20, 2008
--	---	---------------	------	---------	------------------

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>	BANNER PHARMACAPS	<u>100MG</u>	<u>A078720</u>	<u>001</u>	May 29, 2008
<u>AB</u>	+	SANDOZ	<u>100MG</u>	<u>A071293</u>	<u>001</u> Feb 18, 1987
<u>AB</u>	USL PHARMA	<u>100MG</u>	<u>A070589</u>	<u>001</u>	Aug 05, 1986

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

<u>AA</u>	+	CAROLINA MEDCL	<u>50MG/5ML</u>	<u>A075819</u>	<u>001</u> Sep 11, 2002
<u>AA</u>	+	HI TECH PHARMA	<u>50MG/5ML</u>	<u>A074170</u>	<u>001</u> Oct 28, 1994
<u>AA</u>	+	MIKART	<u>50MG/5ML</u>	<u>A074028</u>	<u>001</u> Jun 28, 1993
<u>AA</u>	+	PHARM ASSOC	<u>50MG/5ML</u>	<u>A074509</u>	<u>001</u> Jul 17, 1995
<u>AA</u>	+	SILARX	<u>50MG/5ML</u>	<u>A076352</u>	<u>001</u> Sep 10, 2004
<u>AA</u>	+	VINTAGE	<u>50MG/5ML</u>	<u>A077992</u>	<u>001</u> Dec 12, 2006
<u>AA</u>	+	WOCKHARDT	<u>50MG/5ML</u>	<u>A075060</u>	<u>001</u> Dec 24, 1998

## PRESCRIPTION DRUG PRODUCT LIST

AMANTADINE HYDROCHLORIDE

TABLET; ORAL

AMANTADINE HYDROCHLORIDE  
+ USL PHARMA

100MG

A076186 001 Dec 16, 2002

AMBRISENTAN

TABLET; ORAL

LETAIRIS  
GILEAD  
+

5MG

N022081 001 Jun 15, 2007

10MG

N022081 002 Jun 15, 2007

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE**AB** + FOUGERA PHARMS0.1%**A076065 001** May 15, 2003**AB** TARO PHARM INDS0.1%**A076229 001** May 31, 2002

LOTION; TOPICAL

AMCINONIDE

+ FOUGERA PHARMS

0.1%

A076329 001 Nov 06, 2002

OINTMENT; TOPICAL

AMCINONIDE**AB** + FOUGERA PHARMS0.1%**A076096 001** Nov 19, 2002**AB** TARO PHARM INDS0.1%**A076367 001** Mar 19, 2003AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE**AP** SUN PHARMA GLOBAL500MG/VIAL**A077126 001** Mar 14, 2008ETHYOL**AP** + CLINIGEN HLTHCARE500MG/VIAL**N020221 001** Dec 08, 1995AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE**AP** EMCURE PHARMS LTDEQ 250MG BASE/ML**A204040 001** Dec 12, 2013**AP** + EUROHLTH INTLEQ 50MG BASE/ML**A063313 001** Apr 11, 1994**AP** +EQ 250MG BASE/ML**A063315 001** Apr 11, 1994**AP** TEVA PHARMS USAEQ 250MG BASE/ML**A064045 002** Sep 28, 1993AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE**AB** + PAR PHARM5MG**A070346 001** Jan 22, 1986**AB** SIGMAPHARM LABS LLC5MG**A079133 001** Jan 30, 2009MIDAMOR**AB** PADDOCK LLC5MG**N018200 001**AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE**AB** BARREQ 5MG ANHYDROUS; 50MG**A071111 001** May 10, 1988**AB** + MYLANEQ 5MG ANHYDROUS; 50MG**A073209 001** Oct 31, 1991AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN

15% (150GM/1000ML)

A091112 001 Apr 13, 2012

15% (300GM/2000ML)

A091112 002 Apr 13, 2012

AMINOSYN 10%

HOSPIRA

10% (10GM/100ML)

N017673 003

AMINOSYN 10% (PH6)

HOSPIRA

10% (10GM/100ML)

N017673 008 Nov 18, 1985

AMINOSYN 3.5%

HOSPIRA

3.5% (3.5GM/100ML)

N017789 004

AMINOSYN 5%

HOSPIRA

5% (5GM/100ML)

N017673 001

AMINOSYN 7%

HOSPIRA

7% (7GM/100ML)

N017673 002

AMINOSYN 7% (PH6)

HOSPIRA

7% (7GM/100ML)

N017673 006 Nov 18, 1985

AMINOSYN 8.5%

HOSPIRA

8.5% (8.5GM/100ML)

N017673 004

AMINOSYN 8.5% (PH6)

HOSPIRA

8.5% (8.5GM/100ML)

N017673 007 Nov 18, 1985

## PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS

## INJECTABLE; INJECTION

AMINOSYN II 10%			
HOSPIRA	10% (10GM/100ML)	N019438 005	Apr 03, 1986
AMINOSYN II 10% IN PLASTIC CONTAINER			
HOSPIRA	10% (10GM/100ML)	N020015 001	Dec 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER			
HOSPIRA	15% (15GM/100ML)	N020041 001	Dec 19, 1991
AMINOSYN II 7%			
HOSPIRA	7% (7GM/100ML)	N019438 003	Apr 03, 1986
AMINOSYN II 8.5%			
HOSPIRA	8.5% (8.5GM/100ML)	N019438 004	Apr 03, 1986
AMINOSYN-HBC 7%			
HOSPIRA	7% (7GM/100ML)	N019374 001	Jul 12, 1985
AMINOSYN-HF 8%			
HOSPIRA	8% (8GM/100ML)	A020345 001	Apr 04, 1996
AMINOSYN-PF 10%			
HOSPIRA	10% (10GM/100ML)	N019492 002	Oct 17, 1986
AMINOSYN-PF 7%			
HOSPIRA	7% (7GM/100ML)	N019398 001	Sep 06, 1985
AMINOSYN-RF 5.2%			
HOSPIRA	5.2% (5.2GM/100ML)	N018429 001	
BRANCHAMIN 4% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4% (4GM/100ML)	N018684 001	Sep 28, 1984
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER			
BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996
FREAMINE HBC 6.9%			
B BRAUN	6.9% (6.9GM/100ML)	N016822 006	May 17, 1983
FREAMINE III 10%			
B BRAUN	10% (10GM/100ML)	N016822 005	
FREAMINE III 8.5%			
B BRAUN	8.5% (8.5GM/100ML)	N016822 004	
HEPATAMINE 8%			
B BRAUN	8% (8GM/100ML)	N018676 001	Aug 03, 1982
NEPHRAMINE 5.4%			
B BRAUN	5.4% (5.4GM/100ML)	N017766 001	
PREMASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10GM/100ML)	A075880 002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	6% (6GM/100ML)	A075880 001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	20% (20GM/100ML)	N020849 001	Aug 26, 1998
TRAVASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10MG/100ML)	N018931 003	Aug 23, 1984
TRAVASOL 5.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931 001	Aug 23, 1984
TRAVASOL 8.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931 002	Aug 23, 1984
TROPHAMINE			
+ B BRAUN	6% (6GM/100ML)	N019018 001	Jul 20, 1984
TROPHAMINE 10%			
+ B BRAUN	10% (10GM/100ML)	N019018 003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## PROCALAMINE

B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582 001	May 08, 1982
---------	-----------------------------------------------------------------------------------	-------------	--------------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 002	Mar 26, 1997
-------------------	----------------------------------------------------------------------------	-------------	--------------

## CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 005	Mar 26, 1997
-------------------	----------------------------------------------------------------------------	-------------	--------------

## CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 001	Mar 26, 1997
-------------------	---------------------------------------------------------------------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML		N020678 009	Mar 26, 1997
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML		N020678 011	Mar 26, 1997
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML		N020678 012	Mar 26, 1997
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;2 61MG/100ML;297MG/100ML;77MG/100ML		N020678 008	Mar 26, 1997
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML		N020678 016	Mar 26, 1997
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML		N020678 017	Mar 26, 1997
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML		N020678 018	Mar 26, 1997
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML		N020678 019	Mar 26, 1997
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML		N020678 021	Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

## EMULSION; IV (INFUSION)

## KABIVEN IN PLASTIC CONTAINER

FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML		N200656 004	Aug 25, 2014
	;147MG/100ML;3.9GM/100ML (1026ML)			
	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (1540ML)		N200656 005	Aug 25, 2014
	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (2053ML)		N200656 006	Aug 25, 2014
+	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (2566ML)		N200656 007	Aug 25, 2014
PERIKABIVEN IN PLASTIC CONTAINER				
FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1440ML)		N200656 001	Aug 25, 2014
	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1920ML)		N200656 002	Aug 25, 2014
	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML		N200656 003	Aug 25, 2014
	;105MG/100ML;3.5GM/100ML (2400ML)			

AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;10GM/100ML		N020734 002	Sep 29, 1997
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML		N020734 005	Sep 29, 1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML		N020734 001	Sep 29, 1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML		N020734 008	Sep 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;20GM/100ML		N020734 010	Sep 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;25GM/100ML		N020734 011	Sep 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;5GM/100ML		N020734 007	Sep 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;10GM/100ML		N020734 014	Sep 29, 1997

**PRESCRIPTION DRUG PRODUCT LIST**AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;15GM/100ML	N020734 015	Sep 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;20GM/100ML	N020734 016	Sep 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;25GM/100ML	N020734 017	Sep 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER BAXTER HLTHCARE	5%;35GM/100ML	N020734 018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

## INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML ;440MG/100ML;690MG/100ML	N016822 007	Jul 01, 1988
----------------------------------------------	---------------------------------------------------------------------	-------------	--------------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 3.5% M HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N017789 003	
----------------------------	--------------------------------------------------------	-------------	--

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;20 0MG/100ML;120MG/100ML	N016822 003	
--------------------------------------------	------------------------------------------------------------------	-------------	--

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/100ML; 410MG/100ML	N019437 004	Apr 03, 1986
AMINOSYN II 8.5% W/ ELECTROLYTES HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG/100ML ;410MG/100ML	N019437 005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N020177 001	Oct 23, 1995
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N020173 001	Oct 27, 1995
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100M L;154MG/100ML	N020173 002	Oct 27, 1995

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789 002	
AMINOSYN 8.5% W/ ELECTROLYTES HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100M L	N017673 005	

AMINOCAPROIC ACID

## INJECTABLE; INJECTION

<b>AP</b>	<b>AMINOCAPROIC ACID</b> LUITPOLD	<b>250MG/ML</b>	<b>A071192 001</b>	Dec 01, 1987
<b>AP</b>	<b>AMINOCAPROIC ACID IN PLASTIC CONTAINER</b> + HOSPIRA	<b>250MG/ML</b>	<b>A070010 001</b>	Mar 09, 1987
	SYRUP; ORAL			
<b>AA</b>	<b>AMICAR</b> + CLOVER PHARMS	<b>1.25GM/5ML</b>	<b>N015230 002</b>	
<b>AA</b>	<b>AMINOCAPROIC ACID</b> MIKART	<b>1.25GM/5ML</b>	<b>A074759 001</b>	Sep 02, 1998
	TABLET; ORAL			
<b>AB</b>	<b>AMICAR</b> CLOVER PHARMS	<b>500MG</b>	<b>N015197 001</b>	
<b>AB</b>	<b>AMINOCAPROIC</b> MIKART	<b>500MG</b>	<b>A075602 001</b>	May 24, 2001
	AMICAR + CLOVER PHARMS	1GM	N015197 002	Jun 24, 2004

## PRESCRIPTION DRUG PRODUCT LIST

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL

LEVULAN

+ DUSA

20%

N020965 001 Dec 03, 1999

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINEAP + HOSPIRA25MG/MLA087242 001 Oct 26, 1983AP LUITPOLD25MG/MLA087600 001AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

+ JACOBUS

4GM/PACKET

A074346 001 Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDEAP + AKORN50MG/MLA076232 001 Jul 05, 2006AP + FRESENIUS KABI USA50MG/MLA075761 001 Oct 15, 2002AP + GLAND PHARMA LTD50MG/MLA077161 001 Apr 20, 2005AP HIKMA FARMACEUTICA50MG/MLA077234 001 Feb 25, 2008AP + HOSPIRA50MG/MLA075955 001 Oct 18, 2002AP HOSPIRA INC50MG/MLA203884 001 Nov 25, 2013AP50MG/MLA203885 001 Nov 25, 2013AP + MYLAN INSTITUTIONAL50MG/MLA076217 001 Oct 15, 2002AP WOCKHARDT50MG/MLA077610 001 Oct 30, 2008AP50MG/MLA077834 001 Oct 30, 2008NEXTERONEAP BAXTER HLTHCARE50MG/MLN022325 001 Dec 24, 2008

+

150MG/100ML (1.5MG/ML)

N022325 002 Nov 16, 2010

+

360MG/200ML (1.8MG/ML)

N022325 003 Nov 16, 2010

TABLET; ORAL

AMIODARONE HYDROCHLORIDEAB APOTEX CORP200MGA078578 001 Nov 06, 2008AB BARR200MGA075389 001 Jan 25, 2001AB MURTY PHARMS200MGA077069 001 Apr 08, 2005AB400MGA077069 002 Apr 08, 2005AB MYLAN200MGA075188 001 Feb 24, 1999AB SANDOZ200MGA075315 001 Dec 23, 1998AB400MGA075315 002 Jun 30, 2000AB TARO100MGA075424 002 Dec 18, 2002AB200MGA075424 001 Mar 30, 2001AB400MGA076362 001 Nov 29, 2002AB TEVA PHARMS200MGA074739 001 Nov 30, 1998AB ZYDUS PHARMS USA INC200MGA079029 001 Sep 16, 2008CORDARONEAB + WYETH PHARMS INC200MGN018972 001 Dec 24, 1985PACERONEAB UPSHER SMITH100MGA075135 002 Apr 12, 2005AB200MGA075135 001 Apr 30, 1998

AMIODARONE HYDROCHLORIDE

TARO

300MG

A076362 002 Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDEAB ACCORD HLTHCARE10MGA202446 001 Jun 04, 2014AB25MGA202446 002 Jun 04, 2014AB50MGA202446 003 Jun 04, 2014AB75MGA202446 004 Jun 04, 2014AB100MGA202446 005 Jun 04, 2014AB150MGA202446 006 Jun 04, 2014AB MUTUAL PHARM10MGA089399 002 Jul 14, 1987AB25MGA089399 001 Jul 14, 1987AB50MGA089399 003 Jul 14, 1987AB75MGA089399 004 Jul 14, 1987AB100MGA089399 005 Jul 14, 1987AB150MGA089399 006 Jul 14, 1987AB MYLAN10MGA086009 002AB25MGA086009 003AB50MGA086009 001AB75MGA086009 004



## PRESCRIPTION DRUG PRODUCT LIST

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>		<u>100MG</u>	<u>A086009</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>A086009</u>	<u>006</u>	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A085969</u>	<u>001</u>	
<u>AB</u>	+	<u>25MG</u>	<u>A085966</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A085968</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A085971</u>	<u>001</u>	
<u>AB</u>		<u>100MG</u>	<u>A085967</u>	<u>001</u>	
<u>AB</u>		<u>150MG</u>	<u>A085970</u>	<u>001</u>	
<u>AB</u>	SUN PHARM INDS INC	<u>10MG</u>	<u>A040816</u>	<u>002</u>	Jun 27, 2008
<u>AB</u>		<u>25MG</u>	<u>A040816</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>50MG</u>	<u>A040816</u>	<u>003</u>	Jun 27, 2008
<u>AB</u>		<u>75MG</u>	<u>A040816</u>	<u>004</u>	Jun 27, 2008
<u>AB</u>		<u>100MG</u>	<u>A040816</u>	<u>005</u>	Jun 27, 2008
<u>AB</u>		<u>150MG</u>	<u>A040816</u>	<u>006</u>	Jun 27, 2008
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040218</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>25MG</u>	<u>A040218</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>		<u>50MG</u>	<u>A040218</u>	<u>003</u>	Sep 11, 1997
<u>AB</u>		<u>75MG</u>	<u>A040218</u>	<u>004</u>	Sep 11, 1997
<u>AB</u>		<u>100MG</u>	<u>A040218</u>	<u>005</u>	Sep 11, 1997
<u>AB</u>		<u>150MG</u>	<u>A040218</u>	<u>006</u>	Sep 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986
	+	EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
		10MG;4MG	A071443	003	Nov 10, 1988
	+	25MG;2MG	A071443	004	Nov 10, 1988
	+	25MG;4MG	A071443	005	Nov 10, 1988
	+	50MG;4MG	A071443	001	Nov 10, 1988

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A202553</u>	<u>001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202553</u>	<u>002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202553</u>	<u>003</u>	Apr 29, 2013
<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925</u>	<u>001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925</u>	<u>002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925</u>	<u>003</u>	May 04, 2009
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 2.5MG BASE</u>	<u>A078477</u>	<u>001</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078477</u>	<u>002</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078477</u>	<u>003</u>	Jan 16, 2008
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719</u>	<u>001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719</u>	<u>002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719</u>	<u>003</u>	May 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021</u>	<u>001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021</u>	<u>002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021</u>	<u>003</u>	Jul 17, 2007
<u>AB</u>	CIPLA LTD	<u>EQ 2.5MG BASE</u>	<u>A077073</u>	<u>001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073</u>	<u>002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073</u>	<u>003</u>	Sep 26, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A076692</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2.5MG BASE</u>	<u>A078552</u>	<u>001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552</u>	<u>002</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552</u>	<u>003</u>	Apr 08, 2009
<u>AB</u>	HIKMA PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077771</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077771</u>	<u>002</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077771</u>	<u>003</u>	Apr 12, 2011
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955</u>	<u>001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955</u>	<u>002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955</u>	<u>003</u>	Aug 28, 2007
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043</u>	<u>001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043</u>	<u>002</u>	Jul 12, 2007

## PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043</u>	<u>003</u>	Jul 12, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201380</u>	<u>001</u>	Apr 13, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201380</u>	<u>002</u>	Apr 13, 2012
<u>AB</u>	MATRIX LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A078224</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078224</u>	<u>002</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078224</u>	<u>003</u>	Feb 27, 2008
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076418</u>	<u>001</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076418</u>	<u>002</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076418</u>	<u>003</u>	Oct 03, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453</u>	<u>001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453</u>	<u>002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453</u>	<u>003</u>	Jul 02, 2009
<u>AB</u>	RANBAXY	<u>EQ 2.5MG BASE</u>	<u>A077974</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	ROXANE	<u>EQ 2.5MG BASE</u>	<u>A077262</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077262</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077262</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	SECAN PHARMS	<u>EQ 5MG BASE</u>	<u>A090752</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090752</u>	<u>002</u>	Apr 15, 2011
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 2.5MG BASE</u>	<u>A078231</u>	<u>001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078231</u>	<u>002</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078231</u>	<u>003</u>	Nov 30, 2007
<u>AB</u>	TEVA	<u>EQ 2.5MG BASE</u>	<u>A076846</u>	<u>001</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076846</u>	<u>002</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076846</u>	<u>003</u>	Jun 28, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078573</u>	<u>001</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078573</u>	<u>002</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078573</u>	<u>003</u>	Sep 22, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A203245</u>	<u>001</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203245</u>	<u>002</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203245</u>	<u>003</u>	Oct 21, 2013
<u>AB</u>	UPSHER SMITH	<u>EQ 2.5MG BASE</u>	<u>A077759</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	VINTAGE	<u>EQ 2.5MG BASE</u>	<u>A078414</u>	<u>001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078414</u>	<u>002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078414</u>	<u>003</u>	Apr 07, 2010
<u>AB</u>	VIVIMED LABS	<u>EQ 2.5MG BASE</u>	<u>A077516</u>	<u>001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516</u>	<u>002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516</u>	<u>003</u>	Jul 11, 2007
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE</u>	<u>A077671</u>	<u>001</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077671</u>	<u>002</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077671</u>	<u>003</u>	Jul 19, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500</u>	<u>001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078500</u>	<u>002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500</u>	<u>003</u>	Sep 06, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226</u>	<u>003</u>	Jul 09, 2007
<u>NORVASC</u>					
<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE</u>	<u>N019787</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N019787</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N019787</u>	<u>003</u>	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A203874</u>	<u>001</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A203874</u>	<u>002</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A203874</u>	<u>003</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A203874</u>	<u>004</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A203874</u>	<u>005</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A203874</u>	<u>006</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A203874</u>	<u>007</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A203874</u>	<u>008</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A203874</u>	<u>009</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A203874</u>	<u>010</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A203874</u>	<u>011</u>	Mar 07, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A200465</u>	<u>001</u>	Nov 29, 2013

## PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A200465 002</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A200465 003</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A200465 004</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A200465 005</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A200465 006</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A200465 007</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A200465 008</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A200465 009</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A200465 010</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A200465 011</u>	Nov 29, 2013

CADUET

<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>N021540 009</u>	Jul 29, 2004
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>N021540 010</u>	Jul 29, 2004
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>N021540 011</u>	Jul 29, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>N021540 001</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>N021540 002</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>N021540 003</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>N021540 004</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>N021540 005</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>N021540 006</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>N021540 007</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>N021540 008</u>	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A091431 001</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A091431 002</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A091431 003</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A091431 004</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A091431 005</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A091431 006</u>	Dec 30, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 2.5MG BASE;10MG</u>	<u>A202239 001</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A202239 002</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A202239 003</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A202239 004</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A202239 005</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202239 006</u>	Sep 05, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A077183 001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077183 002</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077183 003</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A090149 001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077183 004</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090149 002</u>	Jul 05, 2011
<u>AB</u>	LUPIN PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A078466 001</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078466 002</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078466 003</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A078466 005</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078466 004</u>	Feb 05, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078466 006</u>	Jul 05, 2011
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE;10MG</u>	<u>A077375 001</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077375 002</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077375 003</u>	May 21, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A079047 001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077375 004</u>	May 21, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A079047 002</u>	Jul 05, 2011
<u>AB</u>	PAR PHARM	<u>EQ 2.5MG BASE;10MG</u>	<u>A078381 001</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A078381 002</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A078381 003</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A078381 005</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A078381 004</u>	Jul 29, 2010
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A078381 006</u>	Jul 29, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077179 001</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077179 002</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077179 003</u>	May 18, 2007
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A077179 005</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077179 004</u>	May 18, 2007
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A077179 006</u>	Jul 05, 2011
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077890 001</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A077890 002</u>	Oct 14, 2010

## PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<b>AB</b>		<b><u>EQ 5MG BASE;20MG</u></b>	<b><u>A077890 003</u></b>	Oct 14, 2010
<b>AB</b>		<b><u>EQ 10MG BASE;20MG</u></b>	<b><u>A077890 004</u></b>	Oct 14, 2010
<b>AB</b>	WATSON LABS INC	<b><u>EQ 5MG BASE;40MG</u></b>	<b><u>A090364 001</u></b>	Jul 05, 2011
<b>AB</b>		<b><u>EQ 10MG BASE;40MG</u></b>	<b><u>A090364 002</u></b>	Jul 05, 2011

LOTREL

<b>AB</b>	NOVARTIS	<b><u>EQ 2.5MG BASE;10MG</u></b>	<b><u>N020364 002</u></b>	Mar 03, 1995
<b>AB</b>		<b><u>EQ 5MG BASE;10MG</u></b>	<b><u>N020364 003</u></b>	Mar 03, 1995
<b>AB</b>		<b><u>EQ 5MG BASE;20MG</u></b>	<b><u>N020364 004</u></b>	Mar 03, 1995
<b>AB</b>		<b><u>EQ 5MG BASE;40MG</u></b>	<b><u>N020364 007</u></b>	Apr 11, 2006
<b>AB</b>		<b><u>EQ 10MG BASE;20MG</u></b>	<b><u>N020364 005</u></b>	Jun 20, 2002
<b>AB</b>	+	<b><u>EQ 10MG BASE;40MG</u></b>	<b><u>N020364 006</u></b>	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

TRIBENZOR

	DAIICHI SANKYO	<b><u>EQ 5MG BASE;12.5MG;20MG</u></b>	<b><u>N200175 001</u></b>	Jul 23, 2010
		<b><u>EQ 5MG BASE;12.5MG;40MG</u></b>	<b><u>N200175 002</u></b>	Jul 23, 2010
		<b><u>EQ 5MG BASE;25MG;40MG</u></b>	<b><u>N200175 003</u></b>	Jul 23, 2010
		<b><u>EQ 10MG BASE;12.5MG;40MG</u></b>	<b><u>N200175 004</u></b>	Jul 23, 2010
	+	<b><u>EQ 10MG BASE;25MG;40MG</u></b>	<b><u>N200175 005</u></b>	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

EXFORGE HCT

<b>AB</b>	NOVARTIS	<b><u>5MG;12.5MG;160MG</u></b>	<b><u>N022314 001</u></b>	Apr 30, 2009
<b>AB</b>		<b><u>5MG;25MG;160MG</u></b>	<b><u>N022314 002</u></b>	Apr 30, 2009
<b>AB</b>		<b><u>10MG;12.5MG;160MG</u></b>	<b><u>N022314 003</u></b>	Apr 30, 2009
<b>AB</b>		<b><u>10MG;25MG;160MG</u></b>	<b><u>N022314 004</u></b>	Apr 30, 2009
<b>AB</b>	+	<b><u>10MG;25MG;320MG</u></b>	<b><u>N022314 005</u></b>	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AZOR

	DAIICHI SANKYO	<b><u>EQ 5MG BASE;20MG</u></b>	<b><u>N022100 001</u></b>	Sep 26, 2007
		<b><u>EQ 5MG BASE;40MG</u></b>	<b><u>N022100 002</u></b>	Sep 26, 2007
		<b><u>EQ 10MG BASE;20MG</u></b>	<b><u>N022100 003</u></b>	Sep 26, 2007
	+	<b><u>EQ 10MG BASE;40MG</u></b>	<b><u>N022100 004</u></b>	Sep 26, 2007

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

<b>AB</b>	LUPIN LTD	<b><u>EQ 5MG BASE;40MG</u></b>	<b><u>A201586 001</u></b>	Jan 08, 2014
<b>AB</b>		<b><u>EQ 5MG BASE;80MG</u></b>	<b><u>A201586 003</u></b>	Jan 08, 2014
<b>AB</b>		<b><u>EQ 10MG BASE;40MG</u></b>	<b><u>A201586 002</u></b>	Jan 08, 2014
<b>AB</b>		<b><u>EQ 10MG BASE;80MG</u></b>	<b><u>A201586 004</u></b>	Jan 08, 2014
<b>AB</b>	MYLAN PHARMS INC	<b><u>EQ 5MG BASE;40MG</u></b>	<b><u>A202516 001</u></b>	Aug 26, 2014
<b>AB</b>		<b><u>EQ 5MG BASE;80MG</u></b>	<b><u>A202516 003</u></b>	Aug 26, 2014
<b>AB</b>		<b><u>EQ 10MG BASE;40MG</u></b>	<b><u>A202516 002</u></b>	Aug 26, 2014
<b>AB</b>		<b><u>EQ 10MG BASE;80MG</u></b>	<b><u>A202516 004</u></b>	Aug 26, 2014
<b>AB</b>	TORRENT PHARMS LTD	<b><u>EQ 5MG BASE;40MG</u></b>	<b><u>A202517 001</u></b>	Jan 08, 2014
<b>AB</b>		<b><u>EQ 5MG BASE;80MG</u></b>	<b><u>A202517 003</u></b>	Jan 08, 2014
<b>AB</b>		<b><u>EQ 10MG BASE;40MG</u></b>	<b><u>A202517 002</u></b>	Jan 08, 2014
<b>AB</b>		<b><u>EQ 10MG BASE;80MG</u></b>	<b><u>A202517 004</u></b>	Jan 08, 2014
<b><u>TWYNSTA</u></b>				
<b>AB</b>	BOEHRINGER INGELHEIM	<b><u>EQ 5MG BASE;40MG</u></b>	<b><u>N022401 001</u></b>	Oct 16, 2009
<b>AB</b>		<b><u>EQ 5MG BASE;80MG</u></b>	<b><u>N022401 003</u></b>	Oct 16, 2009
<b>AB</b>		<b><u>EQ 10MG BASE;40MG</u></b>	<b><u>N022401 002</u></b>	Oct 16, 2009
<b>AB</b>	+	<b><u>EQ 10MG BASE;80MG</u></b>	<b><u>N022401 004</u></b>	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

<b>AB</b>	PAR PHARM INC	<b><u>EQ 5MG BASE;160MG</u></b>	<b><u>A090011 001</u></b>	Mar 28, 2013
<b>AB</b>		<b><u>EQ 5MG BASE;320MG</u></b>	<b><u>A090144 001</u></b>	Mar 28, 2013
<b>AB</b>		<b><u>EQ 10MG BASE;160MG</u></b>	<b><u>A090011 002</u></b>	Mar 28, 2013
<b>AB</b>		<b><u>EQ 10MG BASE;320MG</u></b>	<b><u>A090011 004</u></b>	Mar 28, 2013
<b><u>EXFORGE</u></b>				
<b>AB</b>	NOVARTIS	<b><u>EQ 5MG BASE;160MG</u></b>	<b><u>N021990 002</u></b>	Jun 20, 2007
<b>AB</b>		<b><u>EQ 5MG BASE;320MG</u></b>	<b><u>N021990 004</u></b>	Jun 20, 2007
<b>AB</b>	+	<b><u>EQ 10MG BASE;160MG</u></b>	<b><u>N021990 003</u></b>	Jun 20, 2007
<b>AB</b>	+	<b><u>EQ 10MG BASE;320MG</u></b>	<b><u>N021990 005</u></b>	Jun 20, 2007

## PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	TEVA PHARMS	<u>5MG;12.5MG;160MG</u>	<u>A200435 001</u>	Sep 25, 2012
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A200435 002</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A200435 005</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A200435 003</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A200435 004</u>	Sep 25, 2012

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	BRIGHAM WOMENS HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203783 001</u>	Oct 30, 2014
<u>AP</u>	CARDINAL HEALTH 414	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203700 001</u>	Feb 25, 2013
<u>AP</u>	+ FEINSTEIN	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>N022119 001</u>	Aug 23, 2007
<u>AP</u>	GLOBAL ISOTOPES LLC	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204465 001</u>	Oct 23, 2014
<u>AP</u>	JOHNS HOPKINS UNIV	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204514 001</u>	Aug 19, 2014
<u>AP</u>	KREITCHMAN PET CTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203938 001</u>	Dec 09, 2013
<u>AP</u>	MCPRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203321 001</u>	Feb 25, 2013
<u>AP</u>	MIPS CRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204535 001</u>	Nov 20, 2014
<u>AP</u>	UCLA BIOMEDICAL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203812 001</u>	Jun 27, 2013
<u>AP</u>	UCSF RODIOPHARM	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204496 001</u>	Mar 28, 2014
<u>AP</u>	UNIV TX MD ANDERSON	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203933 001</u>	Jun 27, 2014
<u>AP</u>	WA UNIV SCH MED	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204506 001</u>	Feb 07, 2014
	HOUSTON CYCLOTRON	3.75-260mCi/ML	A203543 001	Dec 14, 2012
	SHERTECH LABS LLC	3.75-260mCi/ML	A204366 001	Sep 19, 2014
	WI MEDCL CYCLOTRON	3.75-260mCi/ML	A204356 001	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

	+ HOSPIRA	5MEQ/ML	A088366 001	Jun 13, 1984
--	-----------	---------	-------------	--------------

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075774 001</u>	May 01, 2002
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A075883 001</u>	Apr 10, 2003
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A076829 001</u>	Feb 07, 2006

LAC-HYDRIN

<u>AB</u>	+ RANBAXY	<u>EQ 12% BASE</u>	<u>N020508 001</u>	Aug 29, 1996
-----------	-----------	--------------------	--------------------	--------------

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075570 001</u>	Jun 23, 2004
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A076216 001</u>	May 28, 2004
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A075575 001</u>	Jun 11, 2002

LAC-HYDRIN

<u>AB</u>	+ RANBAXY	<u>EQ 12% BASE</u>	<u>N019155 001</u>	Apr 24, 1985
-----------	-----------	--------------------	--------------------	--------------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

	WATSON LABS	25MG	A072688 001	Aug 28, 1992
		50MG	A072689 001	Aug 28, 1992
		100MG	A072690 001	Aug 28, 1992
	+	150MG	A072691 001	Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>	AM ANTI BIOTICS	<u>250MG</u>	<u>A062058 001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062058 002</u>	
<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065271 001</u>	Nov 09, 2005
<u>AB</u>		<u>500MG</u>	<u>A065271 002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>250MG</u>	<u>A062884 001</u>	Feb 25, 1988
<u>AB</u>		<u>500MG</u>	<u>A062881 001</u>	Feb 25, 1988
<u>AB</u>	HIKMA PHARMS	<u>250MG</u>	<u>A065291 001</u>	Feb 05, 2007
<u>AB</u>		<u>500MG</u>	<u>A065291 002</u>	Feb 05, 2007
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065016 001</u>	Apr 08, 1999
<u>AB</u>		<u>500MG</u>	<u>A065016 002</u>	Apr 08, 1999
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A064076 001</u>	Sep 30, 1994
<u>AB</u>		<u>500MG</u>	<u>A064076 002</u>	Sep 30, 1994
<u>AB</u>	TEVA	<u>250MG</u>	<u>A061926 001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>A061926 003</u>	

## PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN

CAPSULE; ORAL

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A062216</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062216</u>	<u>004</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>200MG/5ML</u>	<u>A065334</u>	<u>001</u>	Dec 28, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065334</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>125MG/5ML</u>	<u>A204030</u>	<u>001</u>	Sep 15, 2014
<u>AB</u>		<u>250MG/5ML</u>	<u>A204030</u>	<u>002</u>	Sep 15, 2014
<u>AB</u>	DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>250MG/5ML</u>	<u>A062927</u>	<u>002</u>	Nov 25, 1988
<u>AB</u>	HIKMA	<u>125MG/5ML</u>	<u>A065322</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A065325</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065322</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065325</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065387</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A065378</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065387</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>		<u>400MG/5ML</u>	<u>A065378</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>	TEVA	<u>125MG/5ML</u>	<u>A061931</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>A065119</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	
<u>AB</u>	+	<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002
<u>AB</u>	WOCKHARDT	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

<u>AB</u>	TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982
-----------	------	----------------	----------------	------------	--------------

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>50MG/ML</u>	<u>A062226</u>	<u>005</u>	
<u>AB</u>		<u>125MG/5ML</u>	<u>A062226</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>N050760</u>	<u>001</u>	Apr 15, 1999
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>002</u>	
<u>AB</u>		<u>400MG/5ML</u>	<u>N050760</u>	<u>002</u>	Apr 15, 1999

LAROTID

<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TABLET; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>	RANBAXY	<u>500MG</u>	<u>A065059</u>	<u>001</u>	Nov 24, 2000
<u>AB</u>		<u>875MG</u>	<u>A065059</u>	<u>002</u>	Nov 24, 2000
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
<u>AB</u>	+	<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>N050754</u>	<u>002</u>	Jul 10, 1998
<u>AB</u>		<u>875MG</u>	<u>N050754</u>	<u>001</u>	Jul 10, 1998

TABLET, CHEWABLE; ORAL

AMOXICILLIN

<u>AB</u>	RANBAXY	<u>125MG</u>	<u>A065021</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		<u>250MG</u>	<u>A065021</u>	<u>002</u>	Dec 23, 1999
<u>AB</u>	TEVA	<u>125MG</u>	<u>A064013</u>	<u>002</u>	Sep 11, 1995
<u>AB</u>	+	<u>250MG</u>	<u>A064013</u>	<u>001</u>	Dec 22, 1992

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>125MG</u>	<u>N050542</u>	<u>002</u>	
<u>AB</u>		<u>250MG</u>	<u>N050542</u>	<u>001</u>	

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+	PRAGMA PHARMS LLC	775MG	N050813	001	Jan 23, 2008
---	-------------------	-------	---------	-----	--------------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

<u>AB</u>	SANDOZ	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>A202588</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>	TEVA PHARMS USA	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>A200218</u>	<u>001</u>	Aug 30, 2013

PREVPAC

<u>AB</u>	+	TAKEDA PHARMS USA	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A,</u>	<u>N050757</u>	<u>001</u>	Dec 02, 1997
-----------	---	-------------------	----------------------------------------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

PREVPAC**30MG**AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+ GASTROENTERO

500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20M  
G

N050824 001 Feb 08, 2011

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	HIKMA PHARMS	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065191 002</u>	Jan 25, 2005
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065191 001</u>	Jan 25, 2005
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065373 001</u>	Nov 09, 2007
<u>AB</u>	RANBAXY	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065132 001</u>	Mar 19, 2003
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065132 002</u>	Mar 19, 2003
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065207 002</u>	Jan 30, 2007
<u>AB</u>	SANDOZ	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065066 001</u>	Jun 05, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065066 002</u>	Jun 05, 2002
<u>AB</u>	SANDOZ INC	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065098 001</u>	Dec 16, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065098 002</u>	Dec 16, 2002
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065358 001</u>	Aug 13, 2007
<u>AB</u>	TEVA	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065089 001</u>	May 25, 2004
<u>AB</u>	+	<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065089 002</u>	May 25, 2004
<u>AB</u>	+	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065162 001</u>	Mar 12, 2004
<u>AB</u>	WOCKHARDT	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>A065431 001</u>	Nov 25, 2008
<u>AB</u>	WOCKHARDT EU OPERATN	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065420 001</u>	Dec 02, 2013

AUGMENTIN '125'

<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML;EQ 31.25MG BASE/5ML</u>	<u>N050575 001</u>	Aug 06, 1984
-----------	--------------------	--------------------------------------	--------------------	--------------

AUGMENTIN '200'

<u>AB</u>	DR REDDYS LABS INC	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>N050725 001</u>	May 31, 1996
-----------	--------------------	-------------------------------------	--------------------	--------------

AUGMENTIN '250'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>N050575 002</u>	Aug 06, 1984
-----------	---	---------------------------	-------------------------------------	--------------------	--------------

AUGMENTIN '400'

<u>AB</u>	DR REDDYS LABS INC	<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>N050725 002</u>	May 31, 1996
-----------	--------------------	-----------------------------------	--------------------	--------------

AUGMENTIN ES-600

<u>AB</u>	DR REDDYS LABS INC	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>N050755 001</u>	Jun 22, 2001
-----------	--------------------	-------------------------------------	--------------------	--------------

SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A201090 001</u>	Dec 20, 2011
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A201090 002</u>	Dec 20, 2011
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A201091 001</u>	Dec 20, 2011

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG;EQ 125MG BASE</u>	<u>A091569 001</u>	Jan 20, 2012
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A091569 002</u>	Jan 20, 2012
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A091568 001</u>	Jan 20, 2012
<u>AB</u>	RANBAXY	<u>875MG;EQ 125MG BASE</u>	<u>A065102 001</u>	Sep 17, 2002
<u>AB</u>	SANDOZ	<u>250MG;EQ 125MG BASE</u>	<u>A065189 001</u>	Aug 23, 2005
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A065064 001</u>	Mar 15, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065063 001</u>	Mar 14, 2002
<u>AB</u>	SANDOZ INC	<u>500MG;EQ 125MG BASE</u>	<u>A065117 001</u>	Nov 27, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065093 001</u>	Nov 21, 2002
<u>AB</u>	TEVA	<u>500MG;EQ 125MG BASE</u>	<u>A065101 001</u>	Oct 30, 2002
<u>AB</u>	TEVA PHARMS USA	<u>875MG;EQ 125MG BASE</u>	<u>A065096 001</u>	Oct 29, 2002

AUGMENTIN '250'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>250MG;EQ 125MG BASE</u>	<u>N050564 001</u>	Aug 06, 1984
-----------	---	---------------------------	----------------------------	--------------------	--------------

AUGMENTIN '500'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>500MG;EQ 125MG BASE</u>	<u>N050564 002</u>	Aug 06, 1984
-----------	---	---------------------------	----------------------------	--------------------	--------------

AUGMENTIN '875'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>875MG;EQ 125MG BASE</u>	<u>N050720 001</u>	Feb 13, 1996
-----------	---	---------------------------	----------------------------	--------------------	--------------

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	RANBAXY	<u>200MG;EQ 28.5MG BASE</u>	<u>A065161 001</u>	Dec 03, 2003
<u>AB</u>		<u>400MG;EQ 57MG BASE</u>	<u>A065161 002</u>	Dec 03, 2003
<u>AB</u>	SANDOZ	<u>200MG;EQ 28.5MG BASE</u>	<u>A065065 001</u>	Apr 18, 2002
<u>AB</u>		<u>400MG;EQ 57MG BASE</u>	<u>A065065 002</u>	Apr 18, 2002
<u>AB</u>	TEVA	<u>200MG;EQ 28.5MG BASE</u>	<u>A065205 001</u>	Feb 09, 2005
<u>AB</u>	+	<u>400MG;EQ 57MG BASE</u>	<u>A065205 002</u>	Feb 09, 2005

## PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, CHEWABLE; ORAL

AUGMENTIN '125'

<u>AB</u>	DR REDDYS LABS INC	<u>125MG;EQ 31.25MG BASE</u>	<u>N050597 001</u>	Jul 22, 1985
-----------	--------------------	------------------------------	--------------------	--------------

AUGMENTIN '200'

<u>AB</u>	DR REDDYS LABS INC	<u>200MG;EQ 28.5MG BASE</u>	<u>N050726 001</u>	May 31, 1996
-----------	--------------------	-----------------------------	--------------------	--------------

AUGMENTIN '250'

<u>AB</u>	DR REDDYS LABS INC	<u>250MG;EQ 62.5MG BASE</u>	<u>N050597 002</u>	Jul 22, 1985
-----------	--------------------	-----------------------------	--------------------	--------------

AUGMENTIN '400'

<u>AB</u>	DR REDDYS LABS INC	<u>400MG;EQ 57MG BASE</u>	<u>N050726 002</u>	May 31, 1996
-----------	--------------------	---------------------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	SANDOZ	<u>1GM;EQ 62.5MG BASE</u>	<u>A090227 001</u>	Apr 21, 2010
-----------	--------	---------------------------	--------------------	--------------

AUGMENTIN XR

<u>AB</u>	+ DR REDDYS LABS INC	<u>1GM;EQ 62.5MG BASE</u>	<u>N050785 001</u>	Sep 25, 2002
-----------	----------------------	---------------------------	--------------------	--------------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

<u>AB</u>	SHIRE	<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>N021303 001</u>	Oct 11, 2001
-----------	-------	--------------------------------	--------------------	--------------

ADDERALL XR 15

<u>AB</u>	SHIRE	<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>N021303 006</u>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

ADDERALL XR 20

<u>AB</u>	SHIRE	<u>5MG;5MG;5MG;5MG</u>	<u>N021303 002</u>	Oct 11, 2001
-----------	-------	------------------------	--------------------	--------------

ADDERALL XR 25

<u>AB</u>	SHIRE	<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>N021303 004</u>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

ADDERALL XR 30

<u>AB</u>	+ SHIRE	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>N021303 003</u>	Oct 11, 2001
-----------	---------	--------------------------------	--------------------	--------------

ADDERALL XR 5

<u>AB</u>	SHIRE	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>N021303 005</u>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

<u>AB</u>	TEVA	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A077488 001</u>	Apr 29, 2013
-----------	------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A077488 002</u>	Apr 29, 2013
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A077488 003</u>	Apr 29, 2013
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A077488 004</u>	Apr 29, 2013
-----------	--	------------------------	--------------------	--------------

<u>AB</u>		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A077488 005</u>	Apr 29, 2013
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A077488 006</u>	Apr 29, 2013
-----------	--	--------------------------------	--------------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A077302 001</u>	Jun 22, 2012
-----------	-------------------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A077302 002</u>	Jun 22, 2012
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A077302 003</u>	Jun 22, 2012
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A077302 004</u>	Jun 22, 2012
-----------	--	------------------------	--------------------	--------------

<u>AB</u>		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A077302 005</u>	Jun 22, 2012
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A077302 006</u>	Jun 22, 2012
-----------	--	--------------------------------	--------------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	BARR LABS INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A076536 001</u>	Feb 12, 2013
-----------	---------------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A076536 002</u>	Feb 12, 2013
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A076536 003</u>	Feb 12, 2013
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A076536 004</u>	Feb 12, 2013
-----------	--	------------------------	--------------------	--------------

<u>AB</u>		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A076536 005</u>	Feb 12, 2013
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A076536 006</u>	Feb 12, 2013
-----------	--	--------------------------------	--------------------	--------------

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040456 001</u>	May 06, 2003
-----------	-------------------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040456 002</u>	May 06, 2003
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040456 003</u>	May 06, 2003
-----------	--	------------------------	--------------------	--------------

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040456 004</u>	May 06, 2003
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>	AUROLIFE PHARMA LLC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A202424 001</u>	Nov 27, 2013
-----------	---------------------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A202424 002</u>	Nov 27, 2013
-----------	--	----------------------------------------	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A202424 003</u>	Nov 27, 2013
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A202424 004</u>	Nov 27, 2013
-----------	--	----------------------------------------	--------------------	--------------

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A202424 005</u>	Nov 27, 2013
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A202424 006</u>	Nov 27, 2013
-----------	--	------------------------	--------------------	--------------

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A202424 007</u>	Nov 27, 2013
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>	BARR	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040422 001</u>	Feb 11, 2002
-----------	------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040422 005</u>	Mar 19, 2003
-----------	--	----------------------------------------	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040422 002</u>	Feb 11, 2002
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040422 006</u>	Mar 19, 2003
-----------	--	----------------------------------------	--------------------	--------------

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040422 007</u>	Mar 19, 2003
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040422 003</u>	Feb 11, 2002
-----------	--	------------------------	--------------------	--------------

<u>AB</u>	+ COREPHARMA	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040422 004</u>	Feb 11, 2002
-----------	--------------	--------------------------------	--------------------	--------------

<u>AB</u>		<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040444 001</u>	Jun 19, 2002
-----------	--	------------------------------------	--------------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040444 002</u>	Jun 19, 2002
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040444 003</u>	Jun 19, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040444 004</u>	Jun 19, 2002
<u>AB</u>	MALLINCKRODT INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040440 001</u>	Oct 07, 2003
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040440 002</u>	Oct 07, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040440 003</u>	Oct 07, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040440 004</u>	Oct 07, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040440 005</u>	Oct 07, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040440 006</u>	Oct 07, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040440 007</u>	Oct 07, 2003
<u>AB</u>	MUTUAL PHARM	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040480 001</u>	Sep 09, 2003
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040480 002</u>	Sep 09, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040480 003</u>	Sep 09, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040480 004</u>	Sep 09, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040480 005</u>	Sep 09, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040480 006</u>	Sep 09, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040480 007</u>	Sep 09, 2003
<u>AB</u>	SANDOZ	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040439 004</u>	Sep 27, 2002
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040439 001</u>	Jun 14, 2002
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040439 002</u>	Jun 14, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040439 003</u>	Jun 14, 2002

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

ARBOR PHARMS LLC

5MG

A200166 001 Aug 09, 2012

+

10MG

A200166 002 Aug 09, 2012

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

+ X GEN PHARMS

50MG/VIAL

A063206 001 Apr 29, 1992

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+ SIGMA TAU

5MG/ML

N050724 001 Nov 20, 1995

AMPHOTEC

+ ALKOPHARMA USA

50MG/VIAL

N050729 001 Nov 22, 1996

+

100MG/VIAL

N050729 002 Nov 22, 1996

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME

+ ASTELLAS

50MG/VIAL

N050740 001 Aug 11, 1997

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>	ACS DOBFAR SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A090884 002</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090884 003</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090889 001</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090884 001</u>	Apr 03, 2013
<u>AP</u>	AGILA SPECLTS	<u>EQ 10GM BASE/VIAL</u>	<u>A202198 001</u>	Apr 07, 2014
<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE/VIAL</u>	<u>A090354 003</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090354 004</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A090354 001</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090354 002</u>	Dec 28, 2009
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A065499 004</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065499 005</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065493 001</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A065499 001</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A065499 002</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065499 003</u>	Aug 17, 2010
<u>AP</u>	HANFORD GC	<u>EQ 1GM BASE/VIAL</u>	<u>A062772 001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A063140 001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063142 001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A063145 001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063146 001</u>	Apr 15, 1993
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A062719 002</u>	May 12, 1987
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062797 002</u>	Jul 12, 1993
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201404 001</u>	Dec 20, 2013
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A062797 001</u>	Jul 12, 1993
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A062719 001</u>	May 12, 1987

## PRESCRIPTION DRUG PRODUCT LIST

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062719 003</u>	May 12, 1987
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A061395 004</u>	
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A061395 005</u>	
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A061395 006</u>	
<u>AP</u>	+	<u>EQ 125MG BASE/VIAL</u>	<u>A061395 001</u>	
<u>AP</u>	+	<u>EQ 250MG BASE/VIAL</u>	<u>A061395 002</u>	
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A061395 003</u>	
<u>AP</u>	STRIDES ARCOLAB LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A201025 003</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A201025 004</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A201025 001</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A201025 002</u>	Apr 09, 2014

POWDER; INTRAVENOUS

AMPICILLIN SODIUM

<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062738 001</u>	Feb 19, 1987
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062738 002</u>	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406 001</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406 002</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403 001</u>	Dec 23, 2009
<u>AP</u>	AGILA SPECLTS	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201024 001</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201024 002</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A202197 001</u>	Apr 07, 2014
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090340 001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349 001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090340 002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349 002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339 001</u>	Sep 20, 2010
<u>AP</u>	HANFORD GC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176 001</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176 002</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188 001</u>	Nov 25, 2005
<u>AP</u>	HIKMA MAPLE	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074 001</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074 002</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076 001</u>	Mar 19, 2002
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090375 001</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090653 001</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090375 002</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090653 002</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090646 001</u>	Dec 21, 2011
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222 001</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222 002</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314 001</u>	Nov 27, 2006
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065316 001</u>	Jun 29, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065316 002</u>	Jun 29, 2007
<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241 001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310 001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241 002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310 002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240 001</u>	Jul 25, 2006

UNASYN

<u>AP</u>	+	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A062901 002</u>	Feb 27, 1992
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901 001</u>	Nov 23, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608 002</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608 001</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608 005</u>	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

<u>AB</u>	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062883 001</u>	Feb 25, 1988
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A062882 001</u>	Feb 25, 1988
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064082 001</u>	Aug 29, 1995
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A064082 002</u>	Aug 29, 1995

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

	DAVA PHARMS INC	<u>EQ 125MG BASE/5ML</u>	<u>A062982 001</u>	Feb 10, 1989
	+	<u>EQ 250MG BASE/5ML</u>	<u>A062982 002</u>	Feb 10, 1989

## PRESCRIPTION DRUG PRODUCT LIST

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

<b>AB</b>	SHIRE LLC	<b>EQ 0.5MG BASE</b>	<b>N020333 001</b>	Mar 14, 1997
<b><u>ANAGRELIDE HYDROCHLORIDE</u></b>				
<b>AB</b>	BARR	<b>EQ 0.5MG BASE</b>	<b>A076530 001</b>	Apr 18, 2005
<b>AB</b>		<b>EQ 1MG BASE</b>	<b>A076530 002</b>	Apr 18, 2005
<b>AB</b>	IMPAX LABS	<b>EQ 0.5MG BASE</b>	<b>A076910 001</b>	Apr 18, 2005
<b>AB</b>		<b>EQ 1MG BASE</b>	<b>A076910 002</b>	Apr 18, 2005
<b>AB</b>	IVAX SUB TEVA PHARMS	<b>EQ 0.5MG BASE</b>	<b>A076468 001</b>	Apr 18, 2005
<b>AB</b>	+	<b>EQ 1MG BASE</b>	<b>A076468 002</b>	Apr 18, 2005
<b>AB</b>	MYLAN	<b>EQ 0.5MG BASE</b>	<b>A076811 001</b>	Apr 18, 2005
<b>AB</b>		<b>EQ 1MG BASE</b>	<b>A076811 002</b>	Apr 18, 2005
<b>AB</b>	MYLAN PHARMS INC	<b>EQ 0.5MG BASE</b>	<b>A077613 001</b>	Jun 27, 2006
<b>AB</b>		<b>EQ 1MG BASE</b>	<b>A077613 002</b>	Jun 27, 2006

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

<b>AB</b>	ACCORD HLTHCARE	<b>1MG</b>	<b>A090568 001</b>	Jun 28, 2010
<b>AB</b>	APOTEX INC	<b>1MG</b>	<b>A200654 001</b>	May 11, 2012
<b>AB</b>	CIPLA LTD	<b>1MG</b>	<b>A091164 001</b>	Jun 28, 2010
<b>AB</b>	DR REDDYS LABS LTD	<b>1MG</b>	<b>A090732 001</b>	Jun 28, 2010
<b>AB</b>	FRESENIUS KABI ONCOL	<b>1MG</b>	<b>A090088 001</b>	Jun 28, 2010
<b>AB</b>	MYLAN	<b>1MG</b>	<b>A091051 001</b>	Jun 28, 2010
<b>AB</b>	NATCO PHARMA LTD	<b>1MG</b>	<b>A079220 001</b>	Jun 28, 2010
<b>AB</b>	ROXANE	<b>1MG</b>	<b>A078485 001</b>	Jun 28, 2010
<b>AB</b>	SANDOZ	<b>1MG</b>	<b>A079007 001</b>	Jun 28, 2010
<b>AB</b>	SANTOS BIOTECH	<b>1MG</b>	<b>A078944 001</b>	Jun 28, 2010
<b>AB</b>	SUN PHARM INDS LTD	<b>1MG</b>	<b>A091177 001</b>	Jul 15, 2011
<b>AB</b>	TEVA PHARMS	<b>1MG</b>	<b>A078058 001</b>	Jun 28, 2010
<b>AB</b>	ZYDUS PHARMS USA INC	<b>1MG</b>	<b>A078921 001</b>	Jun 28, 2010

ARIMIDEX

<b>AB</b>	+	ASTRAZENECA	<b>1MG</b>	<b>N020541 001</b>	Dec 27, 1995
-----------	---	-------------	------------	--------------------	--------------

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+ VICURON

+

50MG/VIAL

N021632 001 Feb 17, 2006

100MG/VIAL

N021632 002 Nov 14, 2006

APIXABAN

TABLET; ORAL

ELIQUIS

BRISTOL MYERS SQUIBB

+

2.5MG

N202155 001 Dec 28, 2012

5MG

N202155 002 Dec 28, 2012

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

+ US WORLDMEDS

30MG/3ML (10MG/ML)

N021264 002 Apr 20, 2004

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE

<b>AT</b>	AKORN INC	<b>EQ 0.5% BASE</b>	<b>A077764 001</b>	Mar 12, 2009	
<b><u>IOPIDINE</u></b>					
<b>AT</b>	+	ALCON	<b>EQ 0.5% BASE</b>	<b>N020258 001</b>	Jul 30, 1993
	+		<b>EQ 1% BASE</b>	<b>N019779 001</b>	Dec 31, 1987

APREMILAST

TABLET; ORAL

OTEZLA

CELGENE CORP

+

10MG

N205437 001 Mar 21, 2014

20MG

N205437 002 Mar 21, 2014

30MG

N205437 003 Mar 21, 2014

APREPITANT

CAPSULE; ORAL

APREPITANT

<b>AB</b>	SANDOZ	<b>40MG</b>	<b>A090999 001</b>	Sep 24, 2012
<b>AB</b>		<b>80MG</b>	<b>A090999 002</b>	Sep 24, 2012
<b>AB</b>		<b>125MG</b>	<b>A090999 003</b>	Sep 24, 2012
<b><u>EMEND</u></b>				
<b>AB</b>	MERCK	<b>40MG</b>	<b>N021549 003</b>	Jun 30, 2006
<b>AB</b>		<b>80MG</b>	<b>N021549 001</b>	Mar 26, 2003

## PRESCRIPTION DRUG PRODUCT LIST

APREPITANT

CAPSULE; ORAL

EMEND**AB** + **125MG** **N021549 002** Mar 26, 2003ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

BROVANA

+ SUNOVION

EQ 0.015MG BASE/2ML

N021912 001 Oct 06, 2006

ARGATROBAN

INJECTABLE; INJECTION

ACOVA**AP** + PFIZER **250MG/2.5ML (100MG/ML)** **N020883 001** Jun 30, 2000ARGATROBAN**AP** HIKMA PHARM CO LTD **250MG/2.5ML (100MG/ML)** **N203049 001** Jan 05, 2012**AP** MYLAN INSTITUTIONAL **250MG/2.5ML (100MG/ML)** **A202626 001** Jun 30, 2014**AP** PAR STERILE PRODUCTS **250MG/2.5ML (100MG/ML)** **A091665 001** Jun 30, 2014

INJECTABLE; IV (INFUSION)

ARGATROBAN IN 0.9% SODIUM CHLORIDE

TEVA PHARMS USA

250MG/250ML (1MG/ML)

N206769 001 Dec 15, 2014

ARGATROBAN IN SODIUM CHLORIDE

+ EAGLE PHARMS

50MG/50ML (1MG/ML)

N022434 001 Jun 29, 2011

+ SANDOZ

125MG/125ML (1MG/ML)

N022485 001 May 09, 2011

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

R-GENE 10

+ PHARMACIA AND UPJOHN

10GM/100ML

N016931 001

ARIPIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

OTSUKA PHARM CO LTD

300MG/VIAL

N202971 001 Feb 28, 2013

300MG

N202971 003 Sep 29, 2014

+

400MG/VIAL

N202971 002 Feb 28, 2013

400MG

N202971 004 Sep 29, 2014

INJECTABLE; INTRAMUSCULAR

ABILIFY

+ OTSUKA

9.75MG/1.3ML (7.5MG/ML)

N021866 001 Sep 20, 2006

SOLUTION; ORAL

ABILIFY

+ OTSUKA

1MG/ML

N021713 001 Dec 10, 2004

TABLET; ORAL

ABILIFY

OTSUKA

2MG

N021436 006 Nov 15, 2002

+

5MG

N021436 005 Nov 15, 2002

+

10MG

N021436 001 Nov 15, 2002

15MG

N021436 002 Nov 15, 2002

20MG

N021436 003 Nov 15, 2002

30MG

N021436 004 Nov 15, 2002

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

+ OTSUKA

10MG

N021729 002 Jun 07, 2006

15MG

N021729 003 Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

NUVIGIL

CEPHALON

50MG

N021875 001 Jun 15, 2007

150MG

N021875 003 Jun 15, 2007

200MG

N021875 005 Mar 26, 2009

+

250MG

N021875 004 Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

TRISENOX

+ CEPHALON

1MG/ML

N021248 001 Sep 25, 2000

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

+ NOVARTIS

20MG; 120MG

N022268 001 Apr 07, 2009

## PRESCRIPTION DRUG PRODUCT LIST

ARTICAINA HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINA HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

<b>AP</b>	HOSPIRA	<b>4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)</b>	<b>A079138 001</b>	Jun 18, 2010
-----------	---------	--------------------------------------------------------	--------------------	--------------

SEPTOCAINE

<b>AP</b>	+ DEPROCO	<b>4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)</b>	<b>N020971 001</b>	Apr 03, 2000
-----------	-----------	--------------------------------------------------------	--------------------	--------------

ORABLOC

PIERREL

4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)

N022466 001 Feb 26, 2010

+

4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)

N022466 002 Feb 26, 2010

SEPTOCAINE

+ DEPROCO

4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)

N022010 001 Mar 30, 2006

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SANDOZ

80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL

N021265 001 Feb 21, 2001

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SANDOZ

80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL

N021646 001 Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ HOSPIRA

80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL

N018920 001 Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 (WITHOUT VITAMIN K)

+ HOSPIRA

20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML

N008809 006 Sep 09, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+ HOSPIRA

200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL

N021625 001 Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ HOSPIRA

200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML

N021643 001 Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

+ SALIX PHARMS

4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM

N021881 001 Aug 02, 2006

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

FOREST LABS INC

EQ 5MG BASE

N022117 001 Aug 13, 2009

+

EQ 10MG BASE

N022117 002 Aug 13, 2009

## PRESCRIPTION DRUG PRODUCT LIST

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL**AA** + WATSON LABS INC **325MG; 50MG; 40MG** **N017534 005** Apr 16, 1986LANORINAL**AA** LANNETT **325MG; 50MG; 40MG** **A086996 002** Oct 11, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE**AA** + HIKMA INTL PHARMS **325MG; 50MG; 40MG** **A086162 002** Feb 16, 1984ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE**AB** NEXGEN PHARMA INC **325MG; 50MG; 40MG; 30MG** **A075231 001** Nov 30, 2001**AB** STEVENS J **325MG; 50MG; 40MG; 30MG** **A074951 001** Aug 31, 1998FIORINAL W/CODEINE**AB** + WATSON LABS INC **325MG; 50MG; 40MG; 30MG** **N019429 003** Oct 26, 1990ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+ CARACO 356.4MG; 30MG; 16MG N011483 004 Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

NORGESIC**AB** MEDICIS **385MG; 30MG; 25MG** **N013416 003** Oct 27, 1982NORGESIC FORTE**AB** + MEDICIS **770MG; 60MG; 50MG** **N013416 004** Oct 27, 1982ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE**AB** SANDOZ **385MG; 30MG; 25MG** **A074654 001** Dec 31, 1996**AB** **770MG; 60MG; 50MG** **A074654 002** Dec 31, 1996ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN**AB** HERITAGE PHARMS INC **325MG; 200MG** **A089594 001** Mar 31, 1989**AB** MIRROR PHARMS **325MG; 200MG** **A040832 001** Jan 07, 2010**AB** PROSAM LABS **325MG; 200MG** **A040252 001** Dec 10, 1997**AB** SANDOZ **325MG; 200MG** **A040116 001** Apr 25, 1996SOMA COMPOUND**AB** + MEDA PHARMS **325MG; 200MG** **N012365 005** Jul 11, 1983ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE**AB** SANDOZ **325MG; 200MG; 16MG** **A040118 001** Apr 16, 1996SOMA COMPOUND W/ CODEINE**AB** + MEDA PHARMS **325MG; 200MG; 16MG** **N012366 002** Jul 11, 1983ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOL**AB** + BOEHRINGER INGELHEIM **25MG; 200MG** **N020884 001** Nov 22, 1999ASPIRIN AND DIPYRIDAMOLE**AB** BARR **25MG; 200MG** **A078804 001** Aug 14, 2009ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

+ STEVENS J 325MG; 400MG A081145 001 Jan 31, 1995

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN**AA** COASTAL PHARMS **325MG; 4.8355MG** **A091670 001** Mar 16, 2011**AA** WATSON LABS **325MG; 4.8355MG** **A090084 001** Mar 22, 2011PERCODAN**AA** + ENDO PHARMS **325MG; 4.8355MG** **N007337 007** Aug 05, 2005ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE**AB** TEVA PHARMS USA **EQ 150MG BASE** **A091673 002** Apr 22, 2014**AB** **EQ 200MG BASE** **A091673 003** Apr 22, 2014**AB** **EQ 300MG BASE** **A091673 004** Apr 22, 2014

## PRESCRIPTION DRUG PRODUCT LIST

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>EQ 150MG BASE</u>	<u>N021567 002</u>	Jun 20, 2003
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>N021567 003</u>	Jun 20, 2003
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N021567 004</u>	Oct 16, 2006
	ATAZANAVIR SULFATE			
	TEVA PHARMS USA	EQ 100MG BASE	A091673 001	Apr 22, 2014
	POWDER; ORAL			
	REYATAZ			
	+	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352 001 Jun 02, 2014

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078512 001</u>	Oct 31, 2007
<u>AB</u>		<u>50MG</u>	<u>A078512 002</u>	Oct 31, 2007
<u>AB</u>		<u>100MG</u>	<u>A078512 003</u>	Oct 31, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A074099 001</u>	Apr 28, 1992
<u>AB</u>		<u>50MG</u>	<u>A073542 001</u>	Dec 19, 1991
<u>AB</u>		<u>100MG</u>	<u>A073543 001</u>	Dec 19, 1991
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A077877 001</u>	Dec 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077877 002</u>	Dec 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077877 003</u>	Dec 27, 2006
<u>AB</u>	IPR	<u>25MG</u>	<u>A073646 001</u>	Jul 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A072303 001</u>	Jul 15, 1988
<u>AB</u>		<u>100MG</u>	<u>A072304 001</u>	Jul 15, 1988
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A074499 001</u>	Jul 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A073475 001</u>	Mar 30, 1993
<u>AB</u>		<u>100MG</u>	<u>A073476 001</u>	Mar 30, 1993
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A073457 002</u>	Apr 26, 1999
<u>AB</u>		<u>50MG</u>	<u>A073457 003</u>	Jan 24, 1992
<u>AB</u>		<u>100MG</u>	<u>A073457 001</u>	Jan 24, 1992
<u>AB</u>	NORTHSTAR HLTHCARE	<u>25MG</u>	<u>A078254 001</u>	Sep 25, 2009
<u>AB</u>		<u>50MG</u>	<u>A078254 002</u>	Sep 25, 2009
<u>AB</u>		<u>100MG</u>	<u>A078254 003</u>	Sep 25, 2009
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074052 001</u>	May 01, 1992
<u>AB</u>		<u>50MG</u>	<u>A073025 001</u>	Sep 17, 1991
<u>AB</u>		<u>100MG</u>	<u>A073026 001</u>	Sep 17, 1991
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A078210 001</u>	Jul 10, 2007
<u>AB</u>		<u>50MG</u>	<u>A078210 002</u>	Jul 10, 2007
<u>AB</u>		<u>100MG</u>	<u>A078210 003</u>	Jul 10, 2007
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074056 003</u>	Jul 19, 2004
<u>AB</u>		<u>50MG</u>	<u>A074056 001</u>	Jan 18, 1995
<u>AB</u>		<u>100MG</u>	<u>A074056 002</u>	Jan 18, 1995
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A077443 001</u>	Sep 13, 2006
<u>AB</u>		<u>50MG</u>	<u>A077443 002</u>	Sep 13, 2006
<u>AB</u>		<u>100MG</u>	<u>A077443 003</u>	Sep 13, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900 001</u>	Jan 28, 2005
<u>AB</u>		<u>50MG</u>	<u>A076900 002</u>	Jan 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076900 003</u>	Jan 28, 2005
	<u>TENORMIN</u>			
<u>AB</u>	ASTRAZENECA	<u>25MG</u>	<u>N018240 004</u>	Apr 09, 1990
<u>AB</u>		<u>50MG</u>	<u>N018240 001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018240 002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	IPR	<u>50MG; 25MG</u>	<u>A072301 001</u>	May 31, 1990
<u>AB</u>		<u>100MG; 25MG</u>	<u>A072302 001</u>	May 31, 1990
<u>AB</u>	MUTUAL PHARM	<u>50MG; 25MG</u>	<u>A073581 001</u>	Apr 29, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073582 001</u>	Apr 29, 1993
<u>AB</u>	MYLAN	<u>50MG; 25MG</u>	<u>A074203 001</u>	Oct 31, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A074203 002</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>50MG; 25MG</u>	<u>A073665 001</u>	Jul 02, 1992
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073665 002</u>	Jul 02, 1992
	<u>TENORETIC 100</u>			
<u>AB</u>	+	<u>100MG; 25MG</u>	<u>N018760 001</u>	Jun 08, 1984
	<u>TENORETIC 50</u>			
<u>AB</u>	ASTRAZENECA	<u>50MG; 25MG</u>	<u>N018760 002</u>	Jun 08, 1984

## PRESCRIPTION DRUG PRODUCT LIST

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATERA

LILLY

10MG

N021411 002 Nov 26, 2002

18MG

N021411 003 Nov 26, 2002

25MG

N021411 004 Nov 26, 2002

40MG

N021411 005 Nov 26, 2002

+

60MG

N021411 006 Nov 26, 2002

80MG

N021411 007 Feb 14, 2005

100MG

N021411 008 Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<b>AB</b>	APOTEX INC	<b>EQ 10MG BASE</b>	<b>A090548 001</b>	May 29, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A090548 002</b>	May 29, 2012
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A090548 003</b>	May 29, 2012
<b>AB</b>		<b>EQ 80MG BASE</b>	<b>A090548 004</b>	May 29, 2012
<b>AB</b>	DR REDDYS LABS LTD	<b>EQ 10MG BASE</b>	<b>A091650 001</b>	Jul 17, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A091650 002</b>	Jul 17, 2012
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A091650 003</b>	Jul 17, 2012
<b>AB</b>		<b>EQ 80MG BASE</b>	<b>A202357 001</b>	Jul 17, 2012
<b>AB</b>	KUDCO IRELAND	<b>EQ 10MG BASE</b>	<b>A091624 001</b>	Apr 05, 2013
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A091624 002</b>	Apr 05, 2013
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A091624 003</b>	Apr 05, 2013
<b>AB</b>		<b>EQ 80MG BASE</b>	<b>A091624 004</b>	Apr 05, 2013
<b>AB</b>	MYLAN PHARMS INC	<b>EQ 10MG BASE</b>	<b>A091226 001</b>	May 29, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A091226 002</b>	May 29, 2012
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A091226 003</b>	May 29, 2012
<b>AB</b>		<b>EQ 80MG BASE</b>	<b>A091226 004</b>	May 29, 2012
<b>AB</b>	RANBAXY LABS LTD	<b>EQ 10MG BASE</b>	<b>A076477 001</b>	Nov 30, 2011
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A076477 002</b>	Nov 30, 2011
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A076477 003</b>	Nov 30, 2011
<b>AB</b>		<b>EQ 80MG BASE</b>	<b>A076477 004</b>	Nov 30, 2011
<b>AB</b>	SANDOZ INC	<b>EQ 10MG BASE</b>	<b>A077575 001</b>	May 29, 2012
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077575 002</b>	May 29, 2012
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A077575 003</b>	May 29, 2012
<b>AB</b>		<b>EQ 80MG BASE</b>	<b>A077575 004</b>	May 29, 2012
	<b>LIPITOR</b>			
<b>AB</b>	PFIZER	<b>EQ 10MG BASE</b>	<b>N020702 001</b>	Dec 17, 1996
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>N020702 002</b>	Dec 17, 1996
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>N020702 003</b>	Dec 17, 1996
<b>AB</b>	+	<b>EQ 80MG BASE</b>	<b>N020702 004</b>	Apr 07, 2000

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

MERCK SHARP DOHME

EQ 10MG BASE;10MG

N200153 001 May 03, 2013

EQ 20MG BASE;10MG

N200153 002 May 03, 2013

EQ 40MG BASE;10MG

N200153 003 May 03, 2013

+

EQ 80MG BASE;10MG

N200153 004 May 03, 2013

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

<b>AB</b>	AMNEAL PHARMS	<b>750MG/5ML</b>	<b>A202960 001</b>	Mar 18, 2014
	<b>MEPRON</b>			
<b>AB</b>	+	<b>750MG/5ML</b>	<b>N020500 001</b>	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

<b>AB</b>	GLENMARK GENERICS	<b>250MG;100MG</b>	<b>A091211 001</b>	Jan 12, 2011
<b>AB</b>	MYLAN PHARMS INC	<b>62.5MG;25MG</b>	<b>A202362 001</b>	May 27, 2014
<b>AB</b>		<b>250MG;100MG</b>	<b>A202362 002</b>	May 27, 2014
	<b>MALARONE</b>			
<b>AB</b>	+	<b>250MG;100MG</b>	<b>N021078 001</b>	Jul 14, 2000
	<b>MALARONE PEDIATRIC</b>			
<b>AB</b>	GLAXOSMITHKLINE	<b>62.5MG;25MG</b>	<b>N021078 002</b>	Jul 14, 2000



## PRESCRIPTION DRUG PRODUCT LIST

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

<u>AP</u>	+	EUROHLTH INTL	<u>10MG/ML</u>	<u>A074901</u>	<u>001</u>	Jul 18, 1997
<u>AP</u>		HOSPIRA INC	<u>10MG/ML</u>	<u>A090761</u>	<u>001</u>	Oct 18, 2012
<u>AP</u>		SAGENT PHARMS	<u>10MG/ML</u>	<u>A091489</u>	<u>001</u>	Feb 17, 2012

ATRACURIUM BESYLATE PRESERVATIVE FREE

<u>AP</u>	+	EUROHLTH INTL	<u>10MG/ML</u>	<u>A074900</u>	<u>001</u>	Jul 18, 1997
<u>AP</u>		HOSPIRA INC	<u>10MG/ML</u>	<u>A090782</u>	<u>001</u>	Oct 18, 2012
<u>AP</u>		SAGENT PHARMS	<u>10MG/ML</u>	<u>A091488</u>	<u>001</u>	Feb 17, 2012

ATROPINE

INJECTABLE; INJECTION

ATROPEN

+	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004
+		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003
+		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003
+		EQ 2MG SULFATE/0.7ML	N017106	001	

ATROPINE SULFATE

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+	HOSPIRA	0.05MG/ML	N021146	002	Jul 09, 2001
+		0.1MG/ML	N021146	001	Jul 09, 2001

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

AKORN	1%	N206289	001	Jul 18, 2014
-------	----	---------	-----	--------------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	VALEANT	0.025MG; 1MG	N017744	002
---	---------	--------------	---------	-----

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

<u>AA</u>	+	ROXANE	<u>0.025MG/5ML; 2.5MG/5ML</u>	<u>A087708</u>	<u>001</u>	May 03, 1982
-----------	---	--------	-------------------------------	----------------	------------	--------------

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

<u>AA</u>		LANNETT	<u>0.025MG; 2.5MG</u>	<u>A085372</u>	<u>001</u>	
<u>AA</u>		MYLAN	<u>0.025MG; 2.5MG</u>	<u>A085762</u>	<u>001</u>	
<u>AA</u>		PAR PHARM	<u>0.025MG; 2.5MG</u>	<u>A040357</u>	<u>001</u>	May 02, 2000

LOMOTIL

<u>AA</u>	+	GD SEARLE LLC	<u>0.025MG; 2.5MG</u>	<u>N012462</u>	<u>001</u>	
-----------	---	---------------	-----------------------	----------------	------------	--

LONOX

<u>AA</u>		SANDOZ	<u>0.025MG; 2.5MG</u>	<u>A085311</u>	<u>002</u>	
-----------	--	--------	-----------------------	----------------	------------	--

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

+	MYLAN INSTITUTIONAL	0.14MG/ML; 10MG/ML	N019678	001	Nov 06, 1991
---	---------------------	--------------------	---------	-----	--------------

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+	MERIDIAN MEDCL	2.1MG/0.7ML; 600MG/2ML	N021983	001	Sep 28, 2006
---	----------------	------------------------	---------	-----	--------------

AURANOFIN

CAPSULE; ORAL

RIDAURA

+	PROMETHEUS LABS	3MG	N018689	001	May 24, 1985
---	-----------------	-----	---------	-----	--------------

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS	50MG	N202276	001	Apr 27, 2012
	100MG	N202276	002	Apr 27, 2012
+	200MG	N202276	003	Apr 27, 2012

AXITINIB

TABLET; ORAL

INLYTA

PFIZER	1MG	N202324	001	Jan 27, 2012
+	5MG	N202324	002	Jan 27, 2012

## PRESCRIPTION DRUG PRODUCT LIST

AZACITIDINE

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

<b>AP</b>	DR REDDYS LABS LTD	<b>100MG/VIAL</b>	<b>A201537 001</b>	Sep 16, 2013
-----------	--------------------	-------------------	--------------------	--------------

VIDAZA

<b>AP</b>	+ CELGENE	<b>100MG/VIAL</b>	<b>N050794 001</b>	May 19, 2004
-----------	-----------	-------------------	--------------------	--------------

AZATHIOPRINE

TABLET; ORAL

AZASAN

<b>AB</b>	AAIPHARMA LLC	<b>25MG</b>	<b>A075252 002</b>	Feb 03, 2003
-----------	---------------	-------------	--------------------	--------------

<b>AB</b>		<b>50MG</b>	<b>A075252 001</b>	Jun 07, 1999
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>75MG</b>	<b>A075252 003</b>	Feb 03, 2003
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>100MG</b>	<b>A075252 004</b>	Feb 03, 2003
-----------	--	--------------	--------------------	--------------

AZATHIOPRINE

<b>AB</b>	AMNEAL PHARMS LLC	<b>50MG</b>	<b>A074069 001</b>	Feb 16, 1996
-----------	-------------------	-------------	--------------------	--------------

<b>AB</b>	MYLAN	<b>50MG</b>	<b>A075568 001</b>	Dec 13, 1999
-----------	-------	-------------	--------------------	--------------

<b>AB</b>	ZYDUS PHARMS USA	<b>25MG</b>	<b>A077621 002</b>	Sep 05, 2008
-----------	------------------	-------------	--------------------	--------------

<b>AB</b>		<b>50MG</b>	<b>A077621 001</b>	Mar 15, 2007
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>75MG</b>	<b>A077621 003</b>	Sep 05, 2008
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>100MG</b>	<b>A077621 004</b>	Sep 05, 2008
-----------	--	--------------	--------------------	--------------

IMURAN

<b>AB</b>	+ PROMETHEUS LABS	<b>50MG</b>	<b>N016324 001</b>	
-----------	-------------------	-------------	--------------------	--

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+ EUROHLTH INTL

EQ 100MG BASE/VIAL

A074419 001 Mar 31, 1995

AZELAIC ACID

CREAM; TOPICAL

AZELEX

+ ALLERGAN

20%

N020428 001 Sep 13, 1995

GEL; TOPICAL

FINACEA

+ BAYER HLTHCARE

15%

N021470 001 Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

<b>AT</b>	ALCON PHARMA	<b>0.05%</b>	<b>A202305 001</b>	May 31, 2012
-----------	--------------	--------------	--------------------	--------------

<b>AT</b>	APOTEX INC	<b>0.05%</b>	<b>A078621 001</b>	Aug 03, 2009
-----------	------------	--------------	--------------------	--------------

<b>AT</b>	SUN PHARMA GLOBAL	<b>0.05%</b>	<b>A078738 001</b>	Jun 21, 2010
-----------	-------------------	--------------	--------------------	--------------

OPTIVAR

<b>AT</b>	+ MEDA PHARMS	<b>0.05%</b>	<b>N021127 001</b>	May 22, 2000
-----------	---------------	--------------	--------------------	--------------

SPRAY, METERED; NASAL

ASTELIN

<b>AB</b>	+ MEDA PHARMS	<b>EQ 0.125MG BASE/SPRAY</b>	<b>N020114 001</b>	Nov 01, 1996
-----------	---------------	------------------------------	--------------------	--------------

ASTEPRO

<b>AB</b>	+ MEDA PHARMS	<b>EQ 0.1876MG BASE/SPRAY</b>	<b>N022371 001</b>	Aug 31, 2009
-----------	---------------	-------------------------------	--------------------	--------------

AZELASTINE HYDROCHLORIDE

<b>AB</b>	APOTEX INC	<b>EQ 0.125MG BASE/SPRAY</b>	<b>A077954 001</b>	Apr 30, 2009
-----------	------------	------------------------------	--------------------	--------------

<b>AB</b>		<b>EQ 0.1876MG BASE/SPRAY</b>	<b>A201846 001</b>	Aug 31, 2012
-----------	--	-------------------------------	--------------------	--------------

<b>AB</b>	PERRIGO ISRAEL	<b>EQ 0.1876MG BASE/SPRAY</b>	<b>A202743 001</b>	May 08, 2014
-----------	----------------	-------------------------------	--------------------	--------------

<b>AB</b>	ROXANE	<b>EQ 0.125MG BASE/SPRAY</b>	<b>A091444 001</b>	Oct 24, 2014
-----------	--------	------------------------------	--------------------	--------------

<b>AB</b>	SUN PHARMA GLOBAL	<b>EQ 0.125MG BASE/SPRAY</b>	<b>A090423 001</b>	May 23, 2012
-----------	-------------------	------------------------------	--------------------	--------------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

+ MEDA PHARMS

EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY

N202236 001 May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

ARBOR PHARMS IRELAND

EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011

+

EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

ARBOR PHARMS IRELAND

EQ 40MG MEDOXOMIL; 12.5MG

N202331 001 Dec 20, 2011

+

EQ 40MG MEDOXOMIL; 25MG

N202331 002 Dec 20, 2011

## PRESCRIPTION DRUG PRODUCT LIST

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

<u>AB</u>	PLIVA	<u>EQ 100MG BASE/5ML</u>	<u>A065246 002</u>	Jul 05, 2006
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A065246 001</u>	Jul 05, 2006
<u>AB</u>	TEVA PHARMS	<u>EQ 100MG BASE/5ML</u>	<u>A065419 001</u>	Jun 24, 2008
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A065419 002</u>	Jun 24, 2008

ZITHROMAX

<u>AB</u>	PFIZER	<u>EQ 100MG BASE/5ML</u>	<u>N050710 001</u>	Oct 19, 1995
<u>AB</u>	+	<u>EQ 200MG BASE/5ML</u>	<u>N050710 002</u>	Oct 19, 1995
	+	EQ 1GM BASE/PACKET	N050693 001	Sep 28, 1994

FOR SUSPENSION, EXTENDED RELEASE; ORAL

ZMAX

+ PF PRISM CV

EQ 2GM BASE/BOT

N050797 001 Jun 10, 2005

INJECTABLE; INJECTION

AZITHROMYCIN

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A065179 001</u>	Dec 13, 2005
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065501 001</u>	Nov 09, 2009
<u>AP</u>	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A065500 001</u>	Jun 26, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065511 001</u>	Jun 26, 2009
<u>AP</u>	SAGENT STRIDES	<u>EQ 500MG BASE/VIAL</u>	<u>A065506 001</u>	Mar 24, 2009
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A090923 001</u>	Apr 02, 2013

ZITHROMAX

<u>AP</u>	+	PFIZER	<u>EQ 500MG BASE/VIAL</u>	<u>N050733 001</u>	Jan 30, 1997
-----------	---	--------	---------------------------	--------------------	--------------

SOLUTION/DROPS; OPHTHALMIC

AZASITE

+ OAK PHARMS INC

1%

N050810 001 Apr 27, 2007

TABLET; ORAL

AZITHROMYCIN

<u>AB</u>	APOTEX CORP	<u>EQ 250MG BASE</u>	<u>A065507 001</u>	Jul 13, 2011
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065509 001</u>	Jul 13, 2011
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065508 001</u>	Jul 13, 2011
<u>AB</u>	MYLAN	<u>EQ 250MG BASE</u>	<u>A065365 001</u>	May 30, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065366 001</u>	May 30, 2007
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065360 001</u>	Jan 08, 2007
<u>AB</u>	PLIVA	<u>EQ 250MG BASE</u>	<u>A065225 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065223 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065218 001</u>	Nov 14, 2005
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065211 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065212 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065209 001</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065153 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065193 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065150 001</u>	Nov 14, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A065404 001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065405 001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065302 003</u>	Feb 11, 2008

ZITHROMAX

<u>AB</u>	PFIZER	<u>EQ 250MG BASE</u>	<u>N050711 001</u>	Jul 18, 1996
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050784 001</u>	May 24, 2002
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>N050730 001</u>	Jun 12, 1996

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+ GILEAD

75MG/VIAL

N050814 001 Feb 22, 2010

INJECTABLE; INJECTION

AZACTAM

<u>AP</u>	+	BRISTOL MYERS SQUIBB	<u>1GM/VIAL</u>	<u>N050580 002</u>	Dec 31, 1986
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N050580 003</u>	Dec 31, 1986

AZTREONAM

<u>AP</u>	EUROHLTH INTL	<u>1GM/VIAL</u>	<u>A065286 001</u>	Mar 23, 2011
<u>AP</u>		<u>2GM/VIAL</u>	<u>A065286 002</u>	Mar 23, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A065439 002</u>	Jun 18, 2010
<u>AP</u>		<u>2GM/VIAL</u>	<u>A065439 003</u>	Jun 18, 2010

AZACTAM IN PLASTIC CONTAINER

+ BRISTOL MYERS SQUIBB

20MG/ML

N050632 002 May 24, 1989

+

40MG/ML

N050632 001 May 24, 1989

AZTREONAM

FRESENIUS KABI USA

500MG/VIAL

A065439 001 Jun 18, 2010

## PRESCRIPTION DRUG PRODUCT LIST

BACITRACIN

INJECTABLE; INJECTION

BACIAM

<b>AP</b>	X GEN PHARMS	<b>50,000 UNITS/VIAL</b>	<b>A064153 001</b>	May 09, 1997
-----------	--------------	--------------------------	--------------------	--------------

BACITRACIN

<b>AP</b>	FRESENIUS KABI USA	<b>50,000 UNITS/VIAL</b>	<b>A065116 001</b>	Dec 03, 2002
-----------	--------------------	--------------------------	--------------------	--------------

<b>AP</b>	+ PHARMACIA AND UPJOHN	<b>50,000 UNITS/VIAL</b>	<b>A060733 002</b>	
-----------	------------------------	--------------------------	--------------------	--

<b>AP</b>	SAGENT STRIDES	<b>50,000 UNITS/VIAL</b>	<b>A090211 001</b>	May 11, 2010
-----------	----------------	--------------------------	--------------------	--------------

<b>AP</b>	XELLIA PHARMS APS	<b>50,000 UNITS/VIAL</b>	<b>A203177 001</b>	Aug 25, 2014
-----------	-------------------	--------------------------	--------------------	--------------

	PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001
--	----------------------	-------------------	---------	-----

OINTMENT; OPHTHALMIC

BACITRACIN

	+ PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001
--	------------------------	--------------	---------	-----

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

<b>AT</b>	AKORN	<b>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</b>	<b>A065213 001</b>	Jul 25, 2012
-----------	-------	---------------------------------------------------------	--------------------	--------------

<b>AT</b>	+ BAUSCH AND LOMB	<b>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</b>	<b>A064068 001</b>	Oct 30, 1995
-----------	-------------------	---------------------------------------------------------	--------------------	--------------

OINTMENT; TOPICAL

CORTISPORIN

	+ MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984
--	------------------	-------------------------------------------------	---------	-----	--------------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

<b>AT</b>	AKORN	<b>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</b>	<b>A065088 001</b>	Feb 06, 2004
-----------	-------	------------------------------------------------------	--------------------	--------------

<b>AT</b>	+ BAUSCH AND LOMB	<b>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</b>	<b>A064064 001</b>	Oct 30, 1995
-----------	-------------------	------------------------------------------------------	--------------------	--------------

<b>AT</b>	PERRIGO CO TENNESSEE	<b>400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM</b>	<b>A060764 002</b>	
-----------	----------------------	---------------------------------------------------	--------------------	--

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

<b>AT</b>	AKORN	<b>500 UNITS/GM;10,000 UNITS/GM</b>	<b>A064028 001</b>	Jan 30, 1995
-----------	-------	-------------------------------------	--------------------	--------------

<b>AT</b>	+ BAUSCH AND LOMB	<b>500 UNITS/GM;10,000 UNITS/GM</b>	<b>A064046 001</b>	Jan 26, 1995
-----------	-------------------	-------------------------------------	--------------------	--------------

<b>AT</b>	PERRIGO CO TENNESSEE	<b>500 UNITS/GM;10,000 UNITS/GM</b>	<b>A065022 001</b>	Feb 27, 2002
-----------	----------------------	-------------------------------------	--------------------	--------------

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

<b>AT</b>	AKORN	<b>500 UNITS/GM;10,000 UNITS/GM</b>	<b>A064028 001</b>	Jan 30, 1995
-----------	-------	-------------------------------------	--------------------	--------------

<b>AT</b>	+ BAUSCH AND LOMB	<b>500 UNITS/GM;10,000 UNITS/GM</b>	<b>A064046 001</b>	Jan 26, 1995
-----------	-------------------	-------------------------------------	--------------------	--------------

<b>AT</b>	PERRIGO CO TENNESSEE	<b>500 UNITS/GM;10,000 UNITS/GM</b>	<b>A065022 001</b>	Feb 27, 2002
-----------	----------------------	-------------------------------------	--------------------	--------------

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	+ PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002
--	------------------------	--------------------------------------------------	---------	-----

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

<b>AP</b>	MALLINCKRODT INC	<b>0.05MG/ML</b>	<b>N022462 001</b>	Nov 19, 2010
-----------	------------------	------------------	--------------------	--------------

<b>AP</b>		<b>0.5MG/ML</b>	<b>N022462 002</b>	Nov 19, 2010
-----------	--	-----------------	--------------------	--------------

<b>AP</b>		<b>2MG/ML</b>	<b>N022462 003</b>	Nov 19, 2010
-----------	--	---------------	--------------------	--------------

LIORESAL

<b>AP</b>	+ MEDTRONIC NEURO	<b>0.05MG/ML</b>	<b>N020075 003</b>	Nov 07, 1996
-----------	-------------------	------------------	--------------------	--------------

<b>AP</b>	+	<b>0.5MG/ML</b>	<b>N020075 001</b>	Jun 17, 1992
-----------	---	-----------------	--------------------	--------------

<b>AP</b>	+	<b>2MG/ML</b>	<b>N020075 002</b>	Jun 17, 1992
-----------	---	---------------	--------------------	--------------

GABLOFEN

	MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012
--	------------------	--------	---------	-----	--------------

TABLET; ORAL

BACLOFEN

<b>AB</b>	CARACO	<b>10MG</b>	<b>A077984 001</b>	Aug 14, 2006
-----------	--------	-------------	--------------------	--------------

<b>AB</b>	IMPAX LABS	<b>10MG</b>	<b>A078146 001</b>	Oct 26, 2007
-----------	------------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A077971 002</b>	Oct 26, 2007
-----------	--	-------------	--------------------	--------------

<b>AB</b>	IVAX SUB TEVA PHARMS	<b>10MG</b>	<b>A072234 001</b>	Jul 21, 1988
-----------	----------------------	-------------	--------------------	--------------

<b>AB</b>	+	<b>20MG</b>	<b>A072235 001</b>	Jul 21, 1988
-----------	---	-------------	--------------------	--------------

<b>AB</b>	LANNETT	<b>10MG</b>	<b>A078220 001</b>	Jul 06, 2007
-----------	---------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A077241 001</b>	Dec 20, 2005
-----------	--	-------------	--------------------	--------------

<b>AB</b>	MYLAN	<b>10MG</b>	<b>A077181 001</b>	Jul 29, 2005
-----------	-------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A077121 002</b>	Jul 29, 2005
-----------	--	-------------	--------------------	--------------

<b>AB</b>	MYLAN PHARMS INC	<b>10MG</b>	<b>A090334 001</b>	Feb 18, 2010
-----------	------------------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A090334 002</b>	Feb 18, 2010
-----------	--	-------------	--------------------	--------------

<b>AB</b>	NORTHSTAR HLTHCARE	<b>10MG</b>	<b>A078504 001</b>	Sep 18, 2009
-----------	--------------------	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A078401 001</b>	Sep 18, 2009
-----------	--	-------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

BACLOFEN

TABLET; ORAL

BACLOFEN

<u>AB</u>	PROSAM LABS	<u>10MG</u>	<u>A077089 001</u>	Oct 31, 2007
<u>AB</u>		<u>20MG</u>	<u>A077088 001</u>	Oct 31, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>20MG</u>	<u>A077862 002</u>	Aug 14, 2006
<u>AB</u>	USL PHARMA	<u>10MG</u>	<u>A074584 001</u>	Aug 19, 1996
<u>AB</u>		<u>20MG</u>	<u>A074584 002</u>	Aug 19, 1996
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A077156 001</u>	Aug 30, 2005
<u>AB</u>		<u>20MG</u>	<u>A077068 001</u>	Aug 30, 2005
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A072824 001</u>	Sep 18, 1991
<u>AB</u>		<u>20MG</u>	<u>A072825 001</u>	Sep 18, 1991

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

<u>AB</u>	APOTEX INC	<u>750MG</u>	<u>A077883 001</u>	Dec 28, 2007
<u>AB</u>	MYLAN	<u>750MG</u>	<u>A077807 001</u>	Dec 28, 2007
<u>AB</u>	ROXANE	<u>750MG</u>	<u>A077806 001</u>	Dec 28, 2007

COLAZAL

<u>AB</u>	+ SALIX PHARMS	<u>750MG</u>	<u>N020610 001</u>	Jul 18, 2000
	TABLET; ORAL			
	GIAZO			
	+ SALIX PHARMS	1.1GM	N022205 001	Feb 03, 2012

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET; ORAL

DUAVEE

	+ WYETH PHARMS PFIZER	EQ 20MG BASE;0.45MG	N022247 001	Oct 03, 2013
--	-----------------------	---------------------	-------------	--------------

BECLMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

	+ TEVA BRANDED PHARM	0.04MG/INH	N020911 002	Sep 15, 2000
--	----------------------	------------	-------------	--------------

QVAR 80

	+ TEVA BRANDED PHARM	0.08MG/INH	N020911 001	Sep 15, 2000
--	----------------------	------------	-------------	--------------

AEROSOL, METERED; NASAL

QNASL

	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813 002	Dec 17, 2014
		0.08MG/ACTUATION	N202813 001	Mar 23, 2012

BECLMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

	+ GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389 001	Jul 27, 1987
--	-------------------	-------------------------	-------------	--------------

BEDAQUILINE FUMARATE

TABLET; ORAL

SIRTURO

	+ JANSSEN THERAP	EQ 100MG BASE	N204384 001	Dec 28, 2012
--	------------------	---------------	-------------	--------------

BELINOSTAT

POWDER; IV (INFUSION)

BELEODAQ

	+ SPECTRUM PHARMS	500MG/VIAL	N206256 001	Jul 03, 2014
--	-------------------	------------	-------------	--------------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG</u>	<u>A076267 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076267 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076267 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076267 004</u>	Feb 11, 2004
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077128 001</u>	Mar 08, 2006
<u>AB</u>		<u>10MG</u>	<u>A077128 002</u>	Mar 08, 2006
<u>AB</u>		<u>20MG</u>	<u>A077128 003</u>	Mar 08, 2006
<u>AB</u>		<u>40MG</u>	<u>A077128 004</u>	Mar 08, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>10MG</u>	<u>A078212 001</u>	May 22, 2008
<u>AB</u>		<u>20MG</u>	<u>A078212 002</u>	May 22, 2008
<u>AB</u>		<u>40MG</u>	<u>A078212 003</u>	May 22, 2008
<u>AB</u>	BIOKEY	<u>5MG</u>	<u>A076820 001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A076820 002</u>	Feb 03, 2006
<u>AB</u>		<u>20MG</u>	<u>A076820 003</u>	Feb 03, 2006
<u>AB</u>		<u>40MG</u>	<u>A076820 004</u>	Feb 03, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076333 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076333 002</u>	Feb 11, 2004

## PRESCRIPTION DRUG PRODUCT LIST

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>		<u>20MG</u>	<u>A076333 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076333 004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076430 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076430 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076430 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076430 004</u>	Feb 11, 2004
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A076118 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076118 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076118 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076118 004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076344 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076344 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076344 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076344 004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A076402 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076402 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076402 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076402 004</u>	Feb 11, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076211 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076211 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076211 003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076211 004</u>	Feb 11, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A078848 001</u>	May 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A078848 002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848 003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848 004</u>	May 23, 2008
<u>LOTENSIN</u>				
<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG</u>	<u>N019851 001</u>	Jun 25, 1991
<u>AB</u>		<u>10MG</u>	<u>N019851 002</u>	Jun 25, 1991
<u>AB</u>		<u>20MG</u>	<u>N019851 003</u>	Jun 25, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019851 004</u>	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG; 6.25MG</u>	<u>A076342 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076342 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076342 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076342 004</u>	Feb 11, 2004
<u>AB</u>	APOTEX INC	<u>5MG; 6.25MG</u>	<u>A078794 001</u>	Aug 21, 2014
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A078794 002</u>	Aug 21, 2014
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A078794 003</u>	Aug 21, 2014
<u>AB</u>		<u>20MG; 25MG</u>	<u>A078794 004</u>	Aug 21, 2014
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG; 6.25MG</u>	<u>A076348 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076348 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076348 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076348 004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG; 6.25MG</u>	<u>A076688 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076688 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076688 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076688 004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG; 6.25MG</u>	<u>A077483 001</u>	Sep 08, 2005
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A077483 002</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A077483 003</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 25MG</u>	<u>A077483 004</u>	Sep 08, 2005
<u>AB</u>	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076631 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076631 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076631 004</u>	Feb 11, 2004
<u>LOTENSIN HCT</u>				
<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG; 6.25MG</u>	<u>N020033 001</u>	May 19, 1992
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>N020033 002</u>	May 19, 1992
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>N020033 004</u>	May 19, 1992
<u>AB</u>	+	<u>20MG; 25MG</u>	<u>N020033 003</u>	May 19, 1992

## PRESCRIPTION DRUG PRODUCT LIST

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

TREANDA

+ CEPHALON

25MG/VIAL

N022249 002 May 01, 2009

+

100MG/VIAL

N022249 001 Mar 20, 2008

SOLUTION; IV (INFUSION)

TREANDA

+ CEPHALON

45MG/0.5ML (90MG/ML)

N022249 003 Sep 13, 2013

+

180MG/2ML (90MG/ML)

N022249 004 Sep 13, 2013

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDEAB KING PHARMS5MG; 40MGN018647 001 May 25, 1983AB +5MG; 80MGN018647 002 May 25, 1983NADOLOL AND BENDROFLUMETHIAZIDEAB IMPAX LABS5MG; 40MGA077833 001 Mar 30, 2007AB5MG; 80MGA077833 002 Mar 30, 2007AB MYLAN5MG; 40MGA078688 001 Feb 15, 2008AB5MG; 80MGA078688 002 Feb 15, 2008BENZONATATE

CAPSULE; ORAL

BENZONATATEAA BANNER PHARMACAPS100MGA081297 001 Jan 29, 1993AA200MGA081297 002 Oct 30, 2007AA MIKART100MGA040851 001 Nov 09, 2009AA150MGA040851 002 Nov 09, 2009AA200MGA040851 003 Nov 09, 2009AA ORIT LABS LLC100MGA040682 001 Jul 30, 2007AA200MGA040682 002 Jul 30, 2007AA SUN PHARM INDS INC100MGA040587 001 Mar 19, 2008AA200MGA040587 002 Mar 19, 2008AA + THE PHARMA NETWORK100MGA040627 001 Mar 30, 2007AA +200MGA040749 001 Jul 25, 2007AA + THEPHARMANETWORK LLC150MGA201209 001 Sep 24, 2014AA100MGA040597 001 Jun 08, 2007AA200MGA040597 002 Jun 08, 2007TESSALONAA PFIZER100MGN011210 001BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLINAB + VALEANT BERMUDA5%; EQ 1% BASEN050756 001 Dec 21, 2000CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDEAB MYLAN PHARMS INC5%; EQ 1% BASEA065443 001 Aug 11, 2009AB

PERRIGO ISRAEL

5%; 1.2%A090979 001 Jun 26, 2012DUACAB + STIEFEL5%; 1.2%N050741 001 Aug 26, 2002

ACANYA

+ DOW PHARM

2.5%; EQ 1.2% BASE

N050819 001 Oct 23, 2008

ONEXTON

DOW PHARM

3.75%; EQ 1.2% BASE

N050819 002 Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCINAB + VALEANT INTL5%; 3%N050557 001 Oct 26, 1984ERYTHROMYCIN AND BENZOYL PEROXIDEAB TOLMAR5%; 3%A065112 001 Mar 29, 2004

BENZAMYCIN PAK

+ VALEANT LUXEMBOURG

5%; 3%

N050769 001 Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDEAA EMCURE PHARMS LTD50MGA202061 001 Jan 27, 2012AA

IMPAX LABS

50MGA040845 001 Nov 18, 2008AA

KVK TECH

50MGA090968 001 Jul 20, 2010AA

MALLINCKRODT INC

50MGA040773 001 Apr 25, 2007AA

MIKART

25MGA090473 001 Sep 15, 2010AA50MGA090473 002 Sep 15, 2010AA PADDOCK50MGA040578 001 Apr 17, 2006AA

TEDOR PHARM

50MGA040747 001 Mar 30, 2007

## PRESCRIPTION DRUG PRODUCT LIST

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DIDREX

<u>AA</u>	+	PHARMACIA AND UPJOHN	<u>50MG</u>	<u>N012427</u>	<u>002</u>	
-----------	---	----------------------	-------------	----------------	------------	--

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A090233</u>	<u>001</u>	Jul 28, 2009
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A090287</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>		LUITPOLD	<u>1MG/ML</u>	<u>A091152</u>	<u>001</u>	Mar 29, 2010
<u>AP</u>		NAVINTA LLC	<u>1MG/ML</u>	<u>A091525</u>	<u>001</u>	Feb 05, 2013

COGENTIN

<u>AP</u>	+	OAK PHARMS AKORN	<u>1MG/ML</u>	<u>N012015</u>	<u>001</u>	
-----------	---	------------------	---------------	----------------	------------	--

TABLET; ORAL

BENZTROPINE MESYLATE

<u>AA</u>		COREPHARMA	<u>0.5MG</u>	<u>A072264</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>			<u>1MG</u>	<u>A072265</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>			<u>2MG</u>	<u>A072266</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>		EXCELLIUM	<u>0.5MG</u>	<u>A090168</u>	<u>001</u>	Nov 28, 2012
<u>AA</u>			<u>1MG</u>	<u>A090168</u>	<u>002</u>	Nov 28, 2012
<u>AA</u>			<u>2MG</u>	<u>A090168</u>	<u>003</u>	Nov 28, 2012
<u>AA</u>		INVAGEN PHARMS	<u>0.5MG</u>	<u>A090294</u>	<u>001</u>	Mar 29, 2010
<u>AA</u>			<u>1MG</u>	<u>A090294</u>	<u>002</u>	Mar 29, 2010
<u>AA</u>			<u>2MG</u>	<u>A090294</u>	<u>003</u>	Mar 29, 2010
<u>AA</u>		PLIVA	<u>0.5MG</u>	<u>A089058</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>			<u>1MG</u>	<u>A089059</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>			<u>2MG</u>	<u>A089060</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>	+	USL PHARMA	<u>0.5MG</u>	<u>A040103</u>	<u>001</u>	Dec 12, 1996
<u>AA</u>	+		<u>1MG</u>	<u>A040103</u>	<u>002</u>	Dec 12, 1996
<u>AA</u>	+		<u>2MG</u>	<u>A040103</u>	<u>003</u>	Dec 12, 1996
<u>AA</u>		VINTAGE	<u>0.5MG</u>	<u>A040738</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>			<u>1MG</u>	<u>A040742</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>			<u>2MG</u>	<u>A040715</u>	<u>003</u>	Aug 27, 2007

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

+ SHIONOGI INC

5%

N022129 001 Apr 09, 2009

BENZYL PENICILLOYL POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ ALLERQUEST

60UMOLAR

N050114 001

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+ BAUSCH AND LOMB INC

1.5%

N022288 001 Sep 08, 2009

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

+ ABBVIE

25MG/ML

N020032 001 Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

+ BAUSCH AND LOMB

EQ 0.6% BASE

N022308 001 May 28, 2009

BETAINE HYDROCHLORIDE

FOR SOLUTION; ORAL

CYSTADANE

+ RARE DIS THERAP

1GM/SCOOPFUL

N020576 001 Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

<u>AB</u>		LUITPOLD	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>A090747</u>	<u>001</u>	Jul 31, 2009
-----------	--	----------	------------------------------	----------------	------------	--------------

CELESTONE SOLUSPAN

<u>AB</u>	+	MERCK SHARP DOHME	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>N014602</u>	<u>001</u>	
-----------	---	-------------------	------------------------------	----------------	------------	--



## PRESCRIPTION DRUG PRODUCT LIST

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<b>EQ 0.05% BASE</b>	<b>A070885 001</b>	Feb 03, 1987
<b>AB</b>	+ FOUGERA PHARMS	<b>EQ 0.05% BASE</b>	<b>N019137 001</b>	Jun 26, 1984
<b>AB</b>	TARO	<b>EQ 0.05% BASE</b>	<b>A073552 001</b>	Apr 30, 1992

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<b>AB</b>	FOUGERA PHARMS	<b>EQ 0.05% BASE</b>	<b>A076215 001</b>	Dec 09, 2003
<b>AB</b>	GLENMARK GENERICS	<b>EQ 0.05% BASE</b>	<b>A078930 001</b>	Sep 23, 2008
<b>AB</b>	PERRIGO NEW YORK	<b>EQ 0.05% BASE</b>	<b>A076592 001</b>	Dec 09, 2003
<b>AB</b>	TARO	<b>EQ 0.05% BASE</b>	<b>A076543 001</b>	Dec 09, 2003
<b>AB</b>	TOLMAR	<b>EQ 0.05% BASE</b>	<b>A076603 001</b>	Jan 23, 2004

DIPROLENE AF

<b>AB</b>	+ MERCK SHARP DOHME	<b>EQ 0.05% BASE</b>	<b>N019555 001</b>	Apr 27, 1987
-----------	---------------------	----------------------	--------------------	--------------

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<b>AB</b>	+ FOUGERA PHARMS	<b>EQ 0.05% BASE</b>	<b>A075276 001</b>	May 13, 2003
<b>AB</b>	TARO	<b>EQ 0.05% BASE</b>	<b>A076508 001</b>	Dec 02, 2003

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<b>EQ 0.05% BASE</b>	<b>A070281 001</b>	Jul 31, 1985
<b>AB</b>	+ FOUGERA	<b>EQ 0.05% BASE</b>	<b>A070275 001</b>	Aug 12, 1985
<b>AB</b>	PERRIGO NEW YORK	<b>EQ 0.05% BASE</b>	<b>A072538 001</b>	Jan 31, 1990
<b>AB</b>	TEVA	<b>EQ 0.05% BASE</b>	<b>A071467 001</b>	Aug 10, 1987

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<b>AB</b>	FOUGERA PHARMS	<b>EQ 0.05% BASE</b>	<b>A077111 001</b>	May 21, 2007
<b>AB</b>	TARO	<b>EQ 0.05% BASE</b>	<b>A077477 001</b>	May 21, 2007

DIPROLENE

<b>AB</b>	+ MERCK SHARP DOHME	<b>EQ 0.05% BASE</b>	<b>N019716 001</b>	Aug 01, 1988
-----------	---------------------	----------------------	--------------------	--------------

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<b>EQ 0.05% BASE</b>	<b>A071012 001</b>	Feb 03, 1987
<b>AB</b>	+ FOUGERA	<b>EQ 0.05% BASE</b>	<b>N019141 001</b>	Sep 04, 1984
<b>AB</b>	TARO	<b>EQ 0.05% BASE</b>	<b>A074271 001</b>	Sep 15, 1994

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<b>EQ 0.05% BASE</b>	<b>A074304 001</b>	Aug 31, 1995
<b>AB</b>	FOUGERA PHARMS	<b>EQ 0.05% BASE</b>	<b>A075373 001</b>	Jun 22, 1999
<b>AB</b>	TARO	<b>EQ 0.05% BASE</b>	<b>A076753 001</b>	Oct 12, 2004

DIPROLENE

<b>AB</b>	+ MERCK SHARP DOHME	<b>EQ 0.05% BASE</b>	<b>N018741 001</b>	Jul 27, 1983
-----------	---------------------	----------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

<b>AB</b>	PERRIGO ISRAEL	<b>0.064%;0.005%</b>	<b>A200174 001</b>	Dec 12, 2014
<b>AB</b>	TOLMAR	<b>0.064%;0.005%</b>	<b>A201615 001</b>	Jan 14, 2013

TACLONEX

<b>AB</b>	+ LEO PHARMA AS	<b>0.064%;0.005%</b>	<b>N021852 001</b>	Jan 09, 2006
-----------	-----------------	----------------------	--------------------	--------------

SUSPENSION; TOPICAL

TACLONEX

	+ LEO PHARMA AS	<b>0.064%;0.005%</b>	<b>N022185 001</b>	May 09, 2008
--	-----------------	----------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<b>EQ 0.05% BASE;1%</b>	<b>A076002 001</b>	Aug 02, 2002
<b>AB</b>	FOUGERA PHARMS	<b>EQ 0.05% BASE;1%</b>	<b>A075502 001</b>	Jun 05, 2001
<b>AB</b>	TARO	<b>EQ 0.05% BASE;1%</b>	<b>A075673 001</b>	May 29, 2001

LOTTRISONE

<b>AB</b>	+ MERCK SHARP DOHME	<b>EQ 0.05% BASE;1%</b>	<b>N018827 001</b>	Jul 10, 1984
-----------	---------------------	-------------------------	--------------------	--------------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

<b>AB</b>	FOUGERA PHARMS	<b>EQ 0.05% BASE;1%</b>	<b>A076516 001</b>	Jun 16, 2005
<b>AB</b>	TARO	<b>EQ 0.05% BASE;1%</b>	<b>A076493 001</b>	Jul 28, 2004

LOTTRISONE

<b>AB</b>	+ MERCK SHARP DOHME	<b>EQ 0.05% BASE;1%</b>	<b>N020010 001</b>	Dec 08, 2000
-----------	---------------------	-------------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE**AB** PERRIGO **0.12%** **A078337 001** Nov 26, 2012LUXIQ**AB** + DELCOR ASSET **0.12%** **N020934 001** Feb 28, 1999  
CREAM;TOPICALBETA-VAL**AB** TEVA **EQ 0.1% BASE** **N018642 001** Mar 24, 1983BETAMETHASONE VALERATE**AB** + FOUGERA **EQ 0.1% BASE** **N018861 001** Aug 31, 1983DERMABET**AB** TARO **EQ 0.1% BASE** **A072041 001** Jan 06, 1988VALNAC**AB** ACTAVIS MID ATLANTIC **EQ 0.1% BASE** **A070050 001** Oct 10, 1984  
LOTION;TOPICALBETA-VAL**AB** TEVA **EQ 0.1% BASE** **A070072 001** Jun 27, 1985BETAMETHASONE VALERATE**AB** + FOUGERA **EQ 0.1% BASE** **N018866 001** Aug 31, 1983**AB** STI PHARMA LLC **EQ 0.1% BASE** **A070052 001** Jul 31, 1985  
OINTMENT;TOPICALBETAMETHASONE VALERATE**AB** ACTAVIS MID ATLANTIC **EQ 0.1% BASE** **A070051 001** Oct 10, 1984**AB** + FOUGERA **EQ 0.1% BASE** **N018865 001** Aug 31, 1983BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE**AT** AKORN **EQ 0.5% BASE** **A075386 001** Jun 30, 2000**AT** IGI LABS INC **EQ 0.5% BASE** **A075630 001** Apr 12, 2001**AT** WOCKHARDT **EQ 0.5% BASE** **A078694 001** Nov 16, 2009BETOPTIC**AT** + ALCON **EQ 0.5% BASE** **N019270 001** Aug 30, 1985

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC S+ ALCON **EQ 0.25% BASE** **N019845 001** Dec 29, 1989

TABLET;ORAL

BETAXOLOL HYDROCHLORIDE**AB** EPIC PHARMA **10MG** **A075541 001** Oct 22, 1999**AB** + **20MG** **A075541 002** Oct 22, 1999**AB** KVK TECH **10MG** **A078962 001** Jun 27, 2008**AB** **20MG** **A078962 002** Jun 27, 2008BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE**AA** AMNEAL PHARM **5MG** **A040855 001** Nov 21, 2007**AA** **10MG** **A040855 002** Nov 21, 2007**AA** **25MG** **A040855 003** Nov 21, 2007**AA** **50MG** **A040855 004** Nov 21, 2007**AA** EMCURE USA **5MG** **A091256 001** May 04, 2010**AA** **10MG** **A091256 002** May 04, 2010**AA** **25MG** **A091256 003** May 04, 2010**AA** **50MG** **A091256 004** May 04, 2010**AA** IMPAX LABS **5MG** **A040739 001** Nov 01, 2006**AA** **10MG** **A040741 001** Nov 01, 2006**AA** **25MG** **A040740 001** Nov 01, 2006**AA** **50MG** **A040721 004** Nov 01, 2006**AA** LANNETT **10MG** **A040704 001** Mar 27, 2008**AA** **25MG** **A040678 003** Mar 27, 2008**AA** PHARMAX **5MG** **A040725 001** Oct 26, 2007**AA** **10MG** **A040726 001** Oct 26, 2007**AA** **25MG** **A040727 001** Oct 26, 2007**AA** **50MG** **A040728 001** Oct 26, 2007**AA** SUN PHARM INDS INC **5MG** **A040897 001** Apr 22, 2009**AA** **10MG** **A040897 002** Apr 22, 2009**AA** **25MG** **A040897 003** Apr 22, 2009**AA** **50MG** **A040897 004** Apr 22, 2009**AA** UPSHER SMITH **5MG** **A040633 001** Jun 01, 2005**AA** **10MG** **A040634 001** Jun 01, 2005**AA** **25MG** **A040635 001** Jun 01, 2005**AA** **50MG** **A040636 001** Jun 01, 2005

## PRESCRIPTION DRUG PRODUCT LIST

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

<b>AA</b>	WOCKHARDT	<b>5MG</b>	<b>A040532 001</b>	Sep 29, 2003
<b>AA</b>		<b>10MG</b>	<b>A040533 001</b>	Sep 29, 2003
<b>AA</b>		<b>25MG</b>	<b>A040534 001</b>	Sep 29, 2003
<b>AA</b>		<b>50MG</b>	<b>A040518 001</b>	Sep 29, 2003

URECHOLINE

<b>AA</b>	+ ODYSSEY PHARMS	<b>5MG</b>	<b>A089095 001</b>	Dec 19, 1985
<b>AA</b>	+	<b>10MG</b>	<b>A088440 001</b>	May 29, 1984
<b>AA</b>	+	<b>25MG</b>	<b>A088441 001</b>	May 29, 1984
<b>AA</b>	+	<b>50MG</b>	<b>A089096 001</b>	Dec 19, 1985

BEXAROTENE

CAPSULE; ORAL

TARGRETIN

+ VALEANT LUXEMBOURG 75MG

N021055 001 Dec 29, 1999

GEL; TOPICAL

TARGRETIN

+ VALEANT LUXEMBOURG 1%

N021056 001 Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

<b>AB</b>	ACCORD HLTHCARE	<b>50MG</b>	<b>A078917 001</b>	Jul 06, 2009
<b>AB</b>	ACTAVIS TOTOWA	<b>50MG</b>	<b>A078634 001</b>	Aug 28, 2009
<b>AB</b>	FRESENIUS KABI ONCOL	<b>50MG</b>	<b>A079045 001</b>	May 13, 2010
<b>AB</b>	MYLAN	<b>50MG</b>	<b>A079185 001</b>	Jul 06, 2009
<b>AB</b>	SANDOZ	<b>50MG</b>	<b>A078575 001</b>	Jul 06, 2009
<b>AB</b>	SUN PHARMA GLOBAL	<b>50MG</b>	<b>A079110 001</b>	Jul 06, 2009
<b>AB</b>	TEVA	<b>50MG</b>	<b>A076932 001</b>	Jul 06, 2009
<b>AB</b>	ZYDUS PHARMS USA INC	<b>50MG</b>	<b>A079089 001</b>	Jul 06, 2009

CASODEX

<b>AB</b>	+ ASTRAZENECA	<b>50MG</b>	<b>N020498 001</b>	Oct 04, 1995
-----------	---------------	-------------	--------------------	--------------

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

LUMIGAN

+ ALLERGAN 0.01%

N022184 001 Aug 31, 2010

SOLUTION/DROPS; TOPICAL

BIMATOPROST

<b>AT</b>	APOTEX INC	<b>0.03%</b>	<b>A201894 001</b>	Dec 01, 2014
-----------	------------	--------------	--------------------	--------------

LATISSE

<b>AT</b>	+ ALLERGAN	<b>0.03%</b>	<b>N022369 001</b>	Dec 24, 2008
-----------	------------	--------------	--------------------	--------------

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL

AKINETON

+ ABBVIE 2MG

N012003 001

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

+ NOVEL LABS INC 5MG; N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM ; N/A, 5.6GM A202217 001 Aug 20, 2014

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+ FOREST LABS INC 140MG; 125MG; 125MG

N050786 001 Sep 28, 2006

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

<b>AB</b>	AUROBINDO PHARMA	<b>5MG</b>	<b>A077910 001</b>	Dec 27, 2006
<b>AB</b>		<b>10MG</b>	<b>A077910 002</b>	Dec 27, 2006
<b>AB</b>	MYLAN	<b>5MG</b>	<b>A075831 001</b>	Dec 14, 2005
<b>AB</b>		<b>10MG</b>	<b>A075831 002</b>	Dec 14, 2005
<b>AB</b>	SANDOZ	<b>5MG</b>	<b>A075643 001</b>	Nov 16, 2000
<b>AB</b>		<b>10MG</b>	<b>A075643 002</b>	Nov 16, 2000
<b>AB</b>	TEVA PHARMS	<b>5MG</b>	<b>A075644 001</b>	Jun 26, 2001
<b>AB</b>		<b>10MG</b>	<b>A075644 002</b>	Jun 26, 2001
<b>AB</b>	UNICHEM PHARMS (USA)	<b>5MG</b>	<b>A078635 001</b>	Aug 18, 2009
<b>AB</b>		<b>10MG</b>	<b>A078635 002</b>	Aug 18, 2009

ZEBETA

<b>AB</b>	TEVA WOMENS	<b>5MG</b>	<b>N019982 002</b>	Jul 31, 1992
-----------	-------------	------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

<b>AB</b>	+	<b>10MG</b>	<b>N019982 001</b>	Jul 31, 1992
-----------	---	-------------	--------------------	--------------

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

<b>AB</b>	MYLAN	<b>2.5MG; 6.25MG</b>	<b>A075768 001</b>	Sep 25, 2000
<b>AB</b>		<b>5MG; 6.25MG</b>	<b>A075768 002</b>	Sep 25, 2000
<b>AB</b>		<b>10MG; 6.25MG</b>	<b>A075768 003</b>	Sep 25, 2000
<b>AB</b>	SANDOZ	<b>2.5MG; 6.25MG</b>	<b>A075579 001</b>	Sep 25, 2000
<b>AB</b>		<b>5MG; 6.25MG</b>	<b>A075579 002</b>	Sep 25, 2000
<b>AB</b>		<b>10MG; 6.25MG</b>	<b>A075579 003</b>	Sep 25, 2000
<b>AB</b>	UNICHEM	<b>2.5MG; 6.25MG</b>	<b>A079106 001</b>	Jul 28, 2010
<b>AB</b>		<b>5MG; 6.25MG</b>	<b>A079106 002</b>	Jul 28, 2010
<b>AB</b>		<b>10MG; 6.25MG</b>	<b>A079106 003</b>	Jul 28, 2010
<b><u>ZIAC</u></b>				
<b>AB</b>	TEVA WOMENS	<b>2.5MG; 6.25MG</b>	<b>N020186 003</b>	Mar 26, 1993
<b>AB</b>		<b>5MG; 6.25MG</b>	<b>N020186 001</b>	Mar 26, 1993
<b>AB</b>	+	<b>10MG; 6.25MG</b>	<b>N020186 002</b>	Mar 26, 1993

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

+ MEDICINES CO

250MG/VIAL

N020873 001 Dec 15, 2000

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

<b>AP</b>	EUROHLTH INTL	<b>EQ 15 UNITS BASE/VIAL</b>	<b>A065042 002</b>	Oct 17, 2001	
<b>AP</b>		<b>EQ 30 UNITS BASE/VIAL</b>	<b>A065042 001</b>	Oct 17, 2001	
<b>AP</b>	+	<b>FRESENIUS KABI USA</b>	<b>EQ 15 UNITS BASE/VIAL</b>	<b>A065185 001</b>	Jan 28, 2008
<b>AP</b>	+		<b>EQ 30 UNITS BASE/VIAL</b>	<b>A065185 002</b>	Jan 28, 2008
<b>AP</b>	HOSPIRA	<b>EQ 15 UNITS BASE/VIAL</b>	<b>A065031 001</b>	Mar 10, 2000	
<b>AP</b>		<b>EQ 30 UNITS BASE/VIAL</b>	<b>A065031 002</b>	Mar 10, 2000	
<b>AP</b>	TEVA PHARMS USA	<b>EQ 15 UNITS BASE/VIAL</b>	<b>A065033 001</b>	Jun 27, 2000	
<b>AP</b>		<b>EQ 30 UNITS BASE/VIAL</b>	<b>A065033 002</b>	Jun 27, 2000	

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

+ MERCK SHARP DOHME

200MG

N202258 001 May 13, 2011

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

+ MILLENNIUM PHARMS

3.5MG/VIAL

N021602 001 May 13, 2003

ROSENTAN

TABLET; ORAL

TRACLEER

+ ACTELION PHARMS LTD

62.5MG

N021290 001 Nov 20, 2001

+

125MG

N021290 002 Nov 20, 2001

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

+ WYETH PHARMS INC

EQ 100MG BASE

N203341 001 Sep 04, 2012

+

EQ 500MG BASE

N203341 002 Sep 04, 2012

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN

100MG/100ML

N019121 001 Apr 29, 1986

+

200MG/100ML

N019121 002 Apr 29, 1986

+

400MG/100ML

N019121 003 Apr 29, 1986

BRIMONIDINE TARTRATE

GEL; TOPICAL

MIRVASO

+ GALDERMA LABS LP

EQ 0.33% BASE

N204708 001 Aug 23, 2013

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

<b>AT</b>	+	<b>ALLERGAN</b>	<b>0.15%</b>	<b>N021262 001</b>	Mar 16, 2001
-----------	---	-----------------	--------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

<b>AT</b>	AKORN	<b>0.2%</b>	<b>A076439 001</b>	Mar 14, 2006
<b>AT</b>	ALCON PHARMS LTD	<b>0.2%</b>	<b>A076254 001</b>	Sep 16, 2003
<b>AT</b>	+ BAUSCH AND LOMB	<b>0.2%</b>	<b>A076260 001</b>	May 28, 2003
<b>AT</b>	INDOCO REMEDIES	<b>0.2%</b>	<b>A091691 001</b>	Nov 18, 2014
<b>AT</b>	SANDOZ	<b>0.2%</b>	<b>A078075 001</b>	Jan 30, 2008

QOLIANA

<b>AT</b>	ALCON PHARMS LTD	<b>0.15%</b>	<b>N021764 001</b>	May 22, 2006
	ALPHAGAN P			
	+ ALLERGAN	0.1%	N021770 001	Aug 19, 2005

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

SIMBRINZA

	+ ALCON RES LTD	0.2%;1%	N204251 001	Apr 19, 2013
--	-----------------	---------	-------------	--------------

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COMBIGAN

	+ ALLERGAN	0.2%;EQ 0.5% BASE	N021398 001	Oct 30, 2007
--	------------	-------------------	-------------	--------------

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

AZOPT

	+ ALCON PHARMS LTD	1%	N020816 001	Apr 01, 1998
--	--------------------	----	-------------	--------------

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMDAY

<b>AT</b>	+ BAUSCH AND LOMB INC	<b>EQ 0.09% ACID</b>	<b>N021664 002</b>	Oct 16, 2010
-----------	-----------------------	----------------------	--------------------	--------------

BROMFENAC SODIUM

<b>AT</b>	APOTEX INC	<b>EQ 0.09% ACID</b>	<b>A202620 001</b>	Jun 23, 2014
<b>AT</b>	HI-TECH PHARMACAL	<b>EQ 0.09% ACID</b>	<b>A203395 001</b>	Jan 22, 2014
<b>AT1</b>	APOTEX INC	<b>EQ 0.09% ACID</b>	<b>A202435 001</b>	Jun 19, 2014
<b>AT1</b>	COASTAL PHARMS	<b>EQ 0.09% ACID</b>	<b>A201211 001</b>	May 11, 2011
<b>AT1</b>	LUITPOLD	<b>EQ 0.09% ACID</b>	<b>A202030 001</b>	Jan 09, 2013
	PROLENSA			
	+ BAUSCH AND LOMB	EQ 0.07% ACID	N203168 001	Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

<b>AB</b>	MYLAN	<b>EQ 5MG BASE</b>	<b>A077226 001</b>	Apr 04, 2005
<b>AB</b>	ZYDUS PHARMS USA INC	<b>EQ 5MG BASE</b>	<b>A078899 001</b>	Jul 30, 2008

PARLODEL

<b>AB</b>	+ US PHARMS HOLDINGS I	<b>EQ 5MG BASE</b>	<b>N017962 002</b>	Mar 01, 1982
-----------	------------------------	--------------------	--------------------	--------------

TABLET;ORAL

BROMOCRIPTINE MESYLATE

<b>AB</b>	LEK PHARMS	<b>EQ 2.5MG BASE</b>	<b>A074631 001</b>	Jan 13, 1998
<b>AB</b>	MYLAN	<b>EQ 2.5MG BASE</b>	<b>A076962 001</b>	Sep 24, 2004
<b>AB</b>	PADDOCK LLC	<b>EQ 2.5MG BASE</b>	<b>A077646 001</b>	Oct 01, 2008

PARLODEL

<b>AB</b>	+ US PHARMS HOLDINGS I	<b>EQ 2.5MG BASE</b>	<b>N017962 001</b>	
-----------	------------------------	----------------------	--------------------	--

CYCLOSET

	+ VEROSCIENCE	EQ 0.8MG BASE	N020866 001	May 05, 2009
--	---------------	---------------	-------------	--------------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

<b>AA</b>	+ WOCKHARDT	<b>2MG/5ML;10MG/5ML;30MG/5ML</b>	<b>A088811 001</b>	Jun 07, 1985
-----------	-------------	----------------------------------	--------------------	--------------

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

<b>AA</b>	PADDOCK LLC	<b>2MG/5ML;10MG/5ML;30MG/5ML</b>	<b>A205292 001</b>	Jul 15, 2014
<b>AA</b>	VINTAGE PHARMS	<b>2MG/5ML;10MG/5ML;30MG/5ML</b>	<b>A202940 001</b>	Jul 21, 2014

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

	+ SALIX PHARMS INC	2MG/ACTUATION	N205613 001	Oct 07, 2014
--	--------------------	---------------	-------------	--------------

CAPSULE;ORAL

BUDESONIDE

<b>AB</b>	BARR LABS DIV TEVA	<b>3MG</b>	<b>A090379 001</b>	Apr 02, 2014
<b>AB</b>	MYLAN	<b>3MG</b>	<b>A090410 001</b>	May 16, 2011

## PRESCRIPTION DRUG PRODUCT LIST

BUDESONIDE

CAPSULE; ORAL

ENTOCORT EC

<b>AB</b>	+	ASTRAZENECA	<b>3MG</b>	<b>N021324 001</b>	Oct 02, 2001
		POWDER, METERED; INHALATION			
		PULMICORT FLEXHALER			
		ASTRAZENECA	0.08MG/INH	N021949 001	Jul 12, 2006
		+	0.16MG/INH	N021949 002	Jul 12, 2006

SPRAY, METERED; NASAL

BUDESONIDE

<b>AB</b>		APOTEX INC	<b>0.032MG/INH</b>	<b>A078949 001</b>	May 12, 2014
-----------	--	------------	--------------------	--------------------	--------------

RHINOCORT

<b>AB</b>	+	ASTRAZENECA PHARMS	<b>0.032MG/INH</b>	<b>N020746 001</b>	Oct 01, 1999
-----------	---	--------------------	--------------------	--------------------	--------------

SUSPENSION; INHALATION

BUDESONIDE

<b>AN</b>		SANDOZ	<b>0.25MG/2ML</b>	<b>A201966 003</b>	Sep 27, 2013
<b>AN</b>			<b>0.5MG/2ML</b>	<b>A201966 002</b>	Sep 27, 2013
<b>AN</b>			<b>1MG/2ML</b>	<b>A201966 001</b>	Sep 27, 2013
<b>AN</b>		TEVA PHARMS	<b>0.25MG/2ML</b>	<b>A077519 001</b>	Nov 18, 2008
<b>AN</b>			<b>0.5MG/2ML</b>	<b>A077519 002</b>	Nov 18, 2008
<b>AN</b>		WATSON LABS INC	<b>0.25MG/2ML</b>	<b>A078404 001</b>	Jul 31, 2012
<b>AN</b>			<b>0.5MG/2ML</b>	<b>A078404 002</b>	Jul 31, 2012

PULMICORT RESPULES

<b>AN</b>		ASTRAZENECA PHARMS	<b>0.25MG/2ML</b>	<b>N020929 001</b>	Aug 08, 2000
<b>AN</b>			<b>0.5MG/2ML</b>	<b>N020929 002</b>	Aug 08, 2000
<b>AN</b>	+		<b>1MG/2ML</b>	<b>N020929 003</b>	Aug 08, 2000

TABLET, EXTENDED RELEASE; ORAL

UCERIS

	+	SANTARUS INC	9MG	N203634 001	Jan 14, 2013
--	---	--------------	-----	-------------	--------------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

	+	ASTRAZENECA	0.08MG/INH; 0.0045MG/INH	N021929 001	Jul 21, 2006
	+		0.16MG/INH; 0.0045MG/INH	N021929 002	Jul 21, 2006

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

<b>AP</b>	+	BEDFORD	<b>0.25MG/ML</b>	<b>A074441 001</b>	Jan 27, 1995
<b>AP</b>		HIKMA MAPLE	<b>0.25MG/ML</b>	<b>A079196 001</b>	Apr 30, 2008
<b>AP</b>		HOSPIRA	<b>0.25MG/ML</b>	<b>A074332 001</b>	Oct 31, 1994

TABLET; ORAL

BUMETANIDE

<b>AB</b>		IVAX SUB TEVA PHARMS	<b>0.5MG</b>	<b>A074225 001</b>	Apr 24, 1995
<b>AB</b>			<b>1MG</b>	<b>A074225 002</b>	Apr 24, 1995
<b>AB</b>			<b>2MG</b>	<b>A074225 003</b>	Apr 24, 1995
<b>AB</b>		SANDOZ	<b>0.5MG</b>	<b>A074700 001</b>	Nov 21, 1996
<b>AB</b>			<b>1MG</b>	<b>A074700 002</b>	Nov 21, 1996
<b>AB</b>	+		<b>2MG</b>	<b>A074700 003</b>	Nov 21, 1996

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

	+	PACIRA PHARMS INC	266MG/20ML (13.3MG/ML)	N022496 002	Oct 28, 2011
--	---	-------------------	------------------------	-------------	--------------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

<b>AP</b>		HOSPIRA	<b>0.25%</b>	<b>A070583 001</b>	Feb 17, 1987
<b>AP</b>			<b>0.25%</b>	<b>A070586 001</b>	Mar 03, 1987
<b>AP</b>			<b>0.25%</b>	<b>A070590 001</b>	Feb 17, 1987
<b>AP</b>			<b>0.25%</b>	<b>N018053 002</b>	
<b>AP</b>			<b>0.5%</b>	<b>A070584 001</b>	Feb 17, 1986
<b>AP</b>			<b>0.5%</b>	<b>A070597 001</b>	Mar 03, 1987
<b>AP</b>			<b>0.5%</b>	<b>A070609 001</b>	Mar 03, 1987
<b>AP</b>			<b>0.5%</b>	<b>N018053 001</b>	
<b>AP</b>			<b>0.75%</b>	<b>A070585 001</b>	Mar 03, 1987
<b>AP</b>			<b>0.75%</b>	<b>N018053 003</b>	
<b>AP</b>		SAGENT AGILA	<b>0.25%</b>	<b>A091503 001</b>	Oct 18, 2011
<b>AP</b>			<b>0.5%</b>	<b>A091503 002</b>	Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

<b>AP</b>		AUROBINDO PHARMA LTD	<b>0.25%</b>	<b>A203895 001</b>	Nov 05, 2013
<b>AP</b>			<b>0.5%</b>	<b>A203895 002</b>	Nov 05, 2013

## PRESCRIPTION DRUG PRODUCT LIST

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		<u>0.75%</u>	<u>A203895 003</u>	Nov 05, 2013
<u>AP</u>	SAGENT AGILA	<u>0.25%</u>	<u>A091487 002</u>	Oct 18, 2011
<u>AP</u>		<u>0.5%</u>	<u>A091487 001</u>	Oct 18, 2011
<u>AP</u>		<u>0.75%</u>	<u>A091487 003</u>	Oct 18, 2011

MARCAINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>0.25%</u>	<u>N016964 001</u>
<u>AP</u>	+		<u>0.5%</u>	<u>N016964 006</u>

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>0.25%</u>	<u>N016964 012</u>
<u>AP</u>	+		<u>0.5%</u>	<u>N016964 005</u>
<u>AP</u>	+		<u>0.75%</u>	<u>N016964 009</u>

SENSORCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>0.25%</u>	<u>A070552 001</u>	May 21, 1986
<u>AP</u>			<u>0.25%</u>	<u>N018304 001</u>	
<u>AP</u>			<u>0.5%</u>	<u>A070553 001</u>	May 21, 1986
<u>AP</u>			<u>0.5%</u>	<u>N018304 002</u>	
<u>AP</u>			<u>0.75%</u>	<u>A070554 001</u>	May 21, 1986
<u>AP</u>			<u>0.75%</u>	<u>N018304 003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>		HOSPIRA	<u>0.75%</u>	<u>A071810 001</u>	Dec 11, 1987
-----------	--	---------	--------------	--------------------	--------------

MARCAINE

<u>AP</u>	+	HOSPIRA	<u>0.75%</u>	<u>N018692 001</u>	May 04, 1984
-----------	---	---------	--------------	--------------------	--------------

SENSORCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>0.75%</u>	<u>A071202 001</u>	Apr 15, 1987
-----------	--	--------------------	--------------	--------------------	--------------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	+	HOSPIRA	<u>0.5%;0.005MG/ML</u>	<u>A071168 001</u>	Jun 16, 1988
<u>AP</u>			<u>0.5%;0.005MG/ML</u>	<u>A071170 001</u>	Jun 16, 1988
	+		0.25%;0.005MG/ML	A071165 001	Jun 16, 1988
			0.25%;0.005MG/ML	A071167 001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>		SEPTODONT	<u>0.5%;0.0091MG/ML</u>	<u>A077250 001</u>	Sep 27, 2006
-----------	--	-----------	-------------------------	--------------------	--------------

BUPIVACAINE HYDROCHLORIDE W/ EPINEPHRINE

<u>AP</u>	+	HOSPIRA	<u>0.5%;0.0091MG/ML</u>	<u>N022046 001</u>	Jul 13, 1983
-----------	---	---------	-------------------------	--------------------	--------------

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

<u>AP</u>	+	HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964 004</u>
-----------	---	---------	--------------------------	--------------------

<u>AP</u>	+		<u>0.5%;0.0091MG/ML</u>	<u>N016964 008</u>
-----------	---	--	-------------------------	--------------------

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964 013</u>
-----------	---	---------	--------------------------	--------------------

<u>AP</u>	+		<u>0.5%;0.0091MG/ML</u>	<u>N016964 007</u>
-----------	---	--	-------------------------	--------------------

<u>AP</u>	+		<u>0.75%;0.0091MG/ML</u>	<u>N016964 010</u>
-----------	---	--	--------------------------	--------------------

SENSORCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>0.25%;0.0091MG/ML</u>	<u>A070966 001</u>	Oct 13, 1987
<u>AP</u>			<u>0.25%;0.0091MG/ML</u>	<u>A070967 001</u>	Oct 13, 1987
<u>AP</u>			<u>0.5%;0.0091MG/ML</u>	<u>A070968 001</u>	Oct 13, 1987
<u>AP</u>			<u>0.5%;0.0091MG/ML</u>	<u>N018304 004</u>	Sep 02, 1983
<u>AP</u>			<u>0.75%;0.0091MG/ML</u>	<u>N018304 005</u>	Sep 02, 1983

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUTRANS

	PURDUE PHARMA LP	5MCG/HR	N021306 001	Jun 30, 2010
		7.5MCG/HR	N021306 005	Jun 30, 2014
		10MCG/HR	N021306 002	Jun 30, 2010
		15MCG/HR	N021306 004	Jul 25, 2013
	+	20MCG/HR	N021306 003	Jun 30, 2010

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENEX

<u>AP</u>	+	RECKITT BENCKISER	<u>EQ 0.3MG BASE/ML</u>	<u>N018401 001</u>
-----------	---	-------------------	-------------------------	--------------------

BUPRENORPHINE HYDROCHLORIDE

<u>AP</u>		EUROHLTH INTL	<u>EQ 0.3MG BASE/ML</u>	<u>A076931 001</u>	Mar 02, 2005
<u>AP</u>		HOSPIRA	<u>EQ 0.3MG BASE/ML</u>	<u>A074137 001</u>	Jun 03, 1996
<u>AP</u>		LUITPOLD	<u>EQ 0.3MG BASE/ML</u>	<u>A078331 001</u>	Mar 27, 2007

## PRESCRIPTION DRUG PRODUCT LIST

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 2MG BASE</u>	<u>A090360 001</u>	May 07, 2010
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090360 002</u>	May 07, 2010
<u>AB</u>	ETHYPHARM	<u>EQ 2MG BASE</u>	<u>A090622 001</u>	Sep 24, 2010
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090622 002</u>	Sep 24, 2010
<u>AB</u>	ROXANE	<u>EQ 2MG BASE</u>	<u>A078633 001</u>	Oct 08, 2009
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>A078633 002</u>	Oct 08, 2009

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL

BUNAVAIL

	BIODELIVERY SCI INTL	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637 001	Jun 06, 2014
		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637 002	Jun 06, 2014
	+	EQ 6.3MG BASE;EQ 1MG BASE	N205637 003	Jun 06, 2014

FILM;SUBLINGUAL

SUBOXONE

	RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010
		EQ 4MG BASE;EQ 1MG BASE	N022410 003	Aug 10, 2012
		EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010
	+	EQ 12MG BASE;EQ 3MG BASE	N022410 004	Aug 10, 2012

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A091422 001</u>	Feb 22, 2013
<u>AB</u>	+	<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A091422 002</u>	Feb 22, 2013
<u>AB</u>	AMNEAL PHARMS	<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A203136 002</u>	Feb 22, 2013
<u>AB</u>	ROXANE	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A203326 001</u>	Jun 27, 2014
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A203326 002</u>	Jun 27, 2014
<u>AB</u>	TEVA PHARMS USA	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A091149 001</u>	Sep 08, 2014
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A091149 002</u>	Sep 08, 2014

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A203136 001</u>	Feb 22, 2013
	ZUBSOLV			
	OREXO AB	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242 001	Jul 03, 2013
	+	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242 002	Jul 03, 2013
		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242 003	Dec 11, 2014
		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242 004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

	VALEANT BERMUDA	174MG	N022108 001	Apr 23, 2008
		348MG	N022108 002	Apr 23, 2008
	+	522MG	N022108 003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A076143 001</u>	Jan 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A076143 002</u>	Jan 17, 2006
<u>AB</u>	MYLAN	<u>75MG</u>	<u>A075491 001</u>	Apr 17, 2000
<u>AB</u>		<u>100MG</u>	<u>A075491 002</u>	Apr 17, 2000
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A075584 001</u>	Feb 07, 2000
<u>AB</u>		<u>100MG</u>	<u>A075584 002</u>	Feb 07, 2000

WELLBUTRIN

<u>AB</u>	GLAXOSMITHKLINE	<u>75MG</u>	<u>N018644 002</u>	Dec 30, 1985
<u>AB</u>	+	<u>100MG</u>	<u>N018644 003</u>	Dec 30, 1985

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>	ACTAVIS LABS FL INC	<u>100MG</u>	<u>A079095 001</u>	Mar 24, 2009
<u>AB1</u>		<u>150MG</u>	<u>A079095 002</u>	Mar 24, 2009
<u>AB1</u>		<u>200MG</u>	<u>A079095 003</u>	Mar 24, 2009
<u>AB1</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A091459 001</u>	Jun 09, 2011
<u>AB1</u>		<u>150MG</u>	<u>A091459 002</u>	Jun 09, 2011
<u>AB1</u>		<u>200MG</u>	<u>A091459 003</u>	Jun 09, 2011
<u>AB1</u>	IMPAX LABS	<u>100MG</u>	<u>A075913 001</u>	Jan 28, 2004
<u>AB1</u>		<u>150MG</u>	<u>A075913 002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A076711 001</u>	Dec 03, 2004
<u>AB1</u>	JUBILANT GENERICS	<u>100MG</u>	<u>A202774 001</u>	Oct 11, 2013
<u>AB1</u>		<u>150MG</u>	<u>A202774 002</u>	Oct 11, 2013
<u>AB1</u>		<u>200MG</u>	<u>A202774 003</u>	Oct 11, 2013
<u>AB1</u>	MYLAN	<u>100MG</u>	<u>A090325 001</u>	Apr 08, 2010
<u>AB1</u>		<u>150MG</u>	<u>A090325 002</u>	Apr 08, 2010



## PRESCRIPTION DRUG PRODUCT LIST

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>		<u>200MG</u>	<u>A090325</u>	<u>003</u>	Apr 08, 2010
<u>AB1</u>	SANDOZ	<u>100MG</u>	<u>A075932</u>	<u>001</u>	Nov 25, 2003
<u>AB1</u>		<u>150MG</u>	<u>A075932</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A075932</u>	<u>003</u>	Jun 22, 2005
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A078866</u>	<u>001</u>	Apr 06, 2010
<u>AB1</u>		<u>150MG</u>	<u>A078866</u>	<u>002</u>	Apr 06, 2010
<u>AB1</u>		<u>200MG</u>	<u>A078866</u>	<u>003</u>	Apr 06, 2010
<u>AB1</u>	TORRENT PHARMS LTD	<u>100MG</u>	<u>A203969</u>	<u>001</u>	Oct 31, 2014
<u>AB1</u>		<u>150MG</u>	<u>A203969</u>	<u>002</u>	Oct 31, 2014
<u>AB1</u>		<u>200MG</u>	<u>A203969</u>	<u>003</u>	Oct 31, 2014
<u>AB1</u>	WATSON LABS INC	<u>100MG</u>	<u>A077455</u>	<u>001</u>	Jul 19, 2010
<u>AB1</u>		<u>150MG</u>	<u>A077455</u>	<u>002</u>	Mar 12, 2008
<u>AB1</u>		<u>200MG</u>	<u>A077455</u>	<u>003</u>	Jul 19, 2010
<u>AB1</u>	WOCKHARDT LTD	<u>100MG</u>	<u>A201331</u>	<u>001</u>	Aug 30, 2012
<u>AB1</u>		<u>150MG</u>	<u>A201331</u>	<u>002</u>	Aug 30, 2012
<u>AB1</u>		<u>200MG</u>	<u>A201331</u>	<u>003</u>	Aug 30, 2012

WELLBUTRIN SR

<u>AB1</u>	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358</u>	<u>002</u>	Oct 04, 1996
<u>AB1</u>		<u>150MG</u>	<u>N020358</u>	<u>003</u>	Oct 04, 1996
<u>AB1</u>	+	<u>200MG</u>	<u>N020358</u>	<u>004</u>	Jun 14, 2002

BUPROPION HYDROCHLORIDE

<u>AB2</u>	ACTAVIS	<u>150MG</u>	<u>A077475</u>	<u>001</u>	Mar 12, 2008
<u>AB2</u>	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A079094</u>	<u>001</u>	Mar 24, 2009
<u>AB2</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A091520</u>	<u>001</u>	Jun 09, 2011
<u>AB2</u>	IMPAX LABS	<u>150MG</u>	<u>A075914</u>	<u>001</u>	May 27, 2004
<u>AB2</u>	JUBILANT GENERICS	<u>150MG</u>	<u>A202775</u>	<u>001</u>	Oct 11, 2013
<u>AB2</u>	MYLAN	<u>150MG</u>	<u>A090941</u>	<u>001</u>	May 03, 2010

ZYBAN

<u>AB2</u>	+	GLAXOSMITHKLINE	<u>150MG</u>	<u>N020711</u>	<u>003</u>	May 14, 1997
------------	---	-----------------	--------------	----------------	------------	--------------

BUPROPION HYDROCHLORIDE

<u>AB3</u>	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A077715</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A077284</u>	<u>001</u>	Dec 14, 2006
<u>AB3</u>		<u>300MG</u>	<u>A077284</u>	<u>002</u>	Dec 14, 2006
<u>AB3</u>	IMPAX LABS	<u>150MG</u>	<u>A077415</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>	MYLAN	<u>150MG</u>	<u>A090942</u>	<u>001</u>	Jul 14, 2010
<u>AB3</u>		<u>300MG</u>	<u>A090942</u>	<u>002</u>	Jul 14, 2010
<u>AB3</u>	SUN PHARMA GLOBAL	<u>150MG</u>	<u>A200695</u>	<u>001</u>	Dec 18, 2014
<u>AB3</u>	WATSON LABS INC	<u>150MG</u>	<u>A077285</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077285</u>	<u>002</u>	Aug 15, 2008
<u>AB3</u>	WOCKHARDT LTD	<u>150MG</u>	<u>A202189</u>	<u>001</u>	Nov 21, 2012
<u>AB3</u>	ZYDUS PHARMS USA INC	<u>300MG</u>	<u>A201567</u>	<u>001</u>	Jan 17, 2014

WELLBUTRIN XL

<u>AB3</u>	VALEANT INTL	<u>150MG</u>	<u>N021515</u>	<u>001</u>	Aug 28, 2003	
<u>AB3</u>	+		<u>300MG</u>	<u>N021515</u>	<u>002</u>	Aug 28, 2003
	FORFIVO XL					
	+	EDGEMONT PHARMS LLC	450MG	N022497	001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

## CONTRAVE

	+	TAKEDA PHARMS USA	90MG;8MG	N200063	001	Sep 10, 2014
--	---	-------------------	----------	---------	-----	--------------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A202557</u>	<u>001</u>	Dec 30, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202557</u>	<u>002</u>	Dec 30, 2014
<u>AB</u>		<u>10MG</u>	<u>A202557</u>	<u>003</u>	Dec 30, 2014
<u>AB</u>		<u>15MG</u>	<u>A202557</u>	<u>004</u>	Dec 30, 2014
<u>AB</u>		<u>30MG</u>	<u>A202557</u>	<u>005</u>	Dec 30, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078246</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A078246</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>15MG</u>	<u>A078246</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>		<u>30MG</u>	<u>A078246</u>	<u>004</u>	Feb 27, 2009
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075272</u>	<u>001</u>	Mar 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075467</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>7.5MG</u>	<u>A075467</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A075272</u>	<u>002</u>	Mar 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075467</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>15MG</u>	<u>A075272</u>	<u>003</u>	Mar 28, 2001

## PRESCRIPTION DRUG PRODUCT LIST

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>		<u>15MG</u>	<u>A075467</u>	<u>004</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A076008</u>	<u>001</u>	Jun 28, 2001
<u>AB</u>	PROSAM LABS	<u>30MG</u>	<u>A078302</u>	<u>001</u>	Dec 17, 2007
<u>AB</u>	STRIDES ARCOLAB LTD	<u>5MG</u>	<u>A202330</u>	<u>001</u>	Aug 25, 2014
<u>AB</u>		<u>10MG</u>	<u>A202330</u>	<u>002</u>	Aug 25, 2014
<u>AB</u>		<u>15MG</u>	<u>A202330</u>	<u>003</u>	Aug 25, 2014
<u>AB</u>		<u>30MG</u>	<u>A202330</u>	<u>004</u>	Aug 25, 2014
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022</u>	<u>002</u>	Feb 28, 2002
<u>AB</u>	+	<u>15MG</u>	<u>A075022</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022</u>	<u>004</u>	Mar 25, 2004
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074253</u>	<u>001</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A074253</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A074253</u>	<u>003</u>	Mar 13, 2002
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078888</u>	<u>001</u>	Feb 07, 2014
<u>AB</u>		<u>10MG</u>	<u>A078888</u>	<u>002</u>	Feb 07, 2014
<u>AB</u>		<u>15MG</u>	<u>A078888</u>	<u>003</u>	Feb 07, 2014
<u>AB</u>		<u>30MG</u>	<u>A078888</u>	<u>004</u>	Feb 07, 2014

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+ OTSUKA PHARM

6MG/ML

N020954 001 Feb 04, 1999

TABLET; ORAL

MYLERAN

+ ASPEN GLOBAL

2MG

N009386 001

BUTABARBITAL SODIUM

ELIXIR; ORAL

BUTISOL SODIUM

+ MEDA PHARMS

30MG/5ML

A085380 001

TABLET; ORAL

BUTISOL SODIUM

+ MEDA PHARMS

30MG

N000793 004

+

50MG

N000793 003

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+ MYLAN

1%

N020524 001 Oct 18, 1996

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

+ PERRIGO ISRAEL

2%

A200923 001 May 18, 2012

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

<u>AP</u>	BEDFORD	<u>2MG/ML</u>	<u>A075046</u>	<u>001</u>	Aug 12, 1998
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078400</u>	<u>001</u>	May 01, 2009
<u>AP</u>		<u>2MG/ML</u>	<u>A078400</u>	<u>002</u>	May 01, 2009
	<u>BUTORPHANOL TARTRATE PRESERVATIVE FREE</u>				
<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075045</u>	<u>001</u>	Aug 12, 1998
<u>AP</u>		<u>2MG/ML</u>	<u>A075045</u>	<u>002</u>	Aug 12, 1998
<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074626</u>	<u>001</u>	Jan 23, 1997
<u>AP</u>		<u>2MG/ML</u>	<u>A074626</u>	<u>002</u>	Jan 23, 1997

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

<u>AB</u>	+	MYLAN	<u>1MG/SPRAY</u>	<u>A075759</u>	<u>001</u>	Aug 08, 2001
<u>AB</u>		NOVEX	<u>1MG/SPRAY</u>	<u>A075499</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>		ROXANE	<u>1MG/SPRAY</u>	<u>A075824</u>	<u>001</u>	Mar 12, 2002

CABAZITAXEL

SOLUTION; IV (INFUSION)

JEVTANA KIT

+ SANOFI AVENTIS US

60MG/1.5ML (40MG/ML)

N201023 001 Jun 17, 2010

## PRESCRIPTION DRUG PRODUCT LIST

CABERGOLINE

TABLET; ORAL

CABERGOLINE

<b>AB</b>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A078035</u>	<u>001</u>	Apr 21, 2008
<b>AB</b>	APOTEX CORP	<u>0.5MG</u>	<u>A201503</u>	<u>001</u>	Mar 08, 2013
<b>AB</b>	IMPAX LABS INC	<u>0.5MG</u>	<u>A077843</u>	<u>001</u>	Jul 03, 2007
<b>AB</b>	IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A077750</u>	<u>001</u>	Mar 07, 2007
<b>AB</b>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A202947</u>	<u>001</u>	Dec 02, 2013
<b>AB</b>	+ PAR PHARM	<u>0.5MG</u>	<u>A076310</u>	<u>001</u>	Dec 29, 2005

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012
	+	EQ 80MG BASE	N203756	002	Nov 29, 2012

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

<b>AP</b>	+ EUROHLTH INTL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>001</u>	Sep 21, 1999
-----------	-----------------	-------------------------------------------	----------------	------------	--------------

CAFFEINE CITRATE

<b>AP</b>	EXELA PHARMA SCIENCE	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077233</u>	<u>001</u>	Sep 21, 2006
<b>AP</b>	FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077997</u>	<u>001</u>	Jul 20, 2007
<b>AP</b>	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077906</u>	<u>001</u>	May 15, 2007
<b>AP</b>	SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090827</u>	<u>001</u>	Aug 29, 2012
<b>AP</b>	SUN PHARMA GLOBAL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090077</u>	<u>001</u>	Sep 30, 2009

SOLUTION; ORAL

CAFCIT

<b>AA</b>	+ EUROHLTH INTL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>002</u>	Apr 12, 2000
-----------	-----------------	-------------------------------------------	----------------	------------	--------------

CAFFEINE CITRATE

<b>AA</b>	EXELA PHARMA SCS LLC	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077304</u>	<u>001</u>	Sep 21, 2006
<b>AA</b>	FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A078002</u>	<u>001</u>	Jan 31, 2008
<b>AA</b>	LUITPOLD	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090064</u>	<u>001</u>	Nov 20, 2009
<b>AA</b>	SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A091102</u>	<u>001</u>	Aug 29, 2012
<b>AA</b>	SUN PHARMA GLOBAL	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090357</u>	<u>001</u>	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

	+ CREALTA PHARMS LLC	100MG; 2MG	A086557	001	Oct 04, 1983
--	----------------------	------------	---------	-----	--------------

TABLET; ORAL

CAFERGOT

<b>AA</b>	+ SANDOZ	<u>100MG; 1MG</u>	<u>A084294</u>	<u>001</u>	
-----------	----------	-------------------	----------------	------------	--

ERGOTAMINE TARTRATE AND CAFFEINE

<b>AA</b>	HIKMA INTL PHARMS	<u>100MG; 1MG</u>	<u>A040510</u>	<u>001</u>	Sep 17, 2004
<b>AA</b>	MIKART	<u>100MG; 1MG</u>	<u>A040590</u>	<u>001</u>	Sep 16, 2005

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

SORILUX

	+ STIEFEL LABS INC	0.005%	N022563	001	Oct 06, 2010
--	--------------------	--------	---------	-----	--------------

CREAM; TOPICAL

CALCIPOTRIENE

<b>AB</b>	TOLMAR	<u>0.005%</u>	<u>A200935</u>	<u>001</u>	May 30, 2012
-----------	--------	---------------	----------------	------------	--------------

DOVONEX

<b>AB</b>	+ LEO PHARMA AS	<u>0.005%</u>	<u>N020554</u>	<u>001</u>	Jul 22, 1996
-----------	-----------------	---------------	----------------	------------	--------------

OINTMENT; TOPICAL

CALCIPOTRIENE

	+ GLENMARK GENERICS	0.005%	A090633	001	Mar 24, 2010
--	---------------------	--------	---------	-----	--------------

SOLUTION; TOPICAL

CALCIPOTRIENE

<b>AT</b>	FOUGERA PHARMS	<u>0.005%</u>	<u>A078305</u>	<u>001</u>	May 06, 2008
<b>AT</b>	G AND W LABS INC	<u>0.005%</u>	<u>A078468</u>	<u>001</u>	Mar 24, 2011
<b>AT</b>	HI TECH PHARMA	<u>0.005%</u>	<u>A077579</u>	<u>001</u>	Nov 19, 2009
<b>AT</b>	+ TOLMAR	<u>0.005%</u>	<u>A077029</u>	<u>001</u>	Nov 20, 2009

CALCITONIN SALMON

INJECTABLE; INJECTION

MIACALCIN

	+ SEBELA IRELAND LTD	200 IU/ML	N017808	002	Mar 29, 1991
--	----------------------	-----------	---------	-----	--------------

SPRAY, METERED; NASAL

CALCITONIN-SALMON

<b>AB</b>	APOTEX INC	<u>200 IU/SPRAY</u>	<u>A076396</u>	<u>001</u>	Nov 17, 2008
<b>AB</b>	PAR PHARM	<u>200 IU/SPRAY</u>	<u>A076979</u>	<u>001</u>	Jun 08, 2009

## PRESCRIPTION DRUG PRODUCT LIST

CALCITONIN SALMON

SPRAY, METERED;NASAL

MIACALCIN**AB** + SEBELA IRELAND LTD **200 IU/SPRAY** **N020313 002** Aug 17, 1995CALCITONIN SALMON RECOMBINANT

SPRAY, METERED;NASAL

FORTICAL

+ UPSHER SMITH

200 IU/SPRAY

N021406 001 Aug 12, 2005

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL**AB** BANNER PHARMACAPS **0.25MCG** **A091174 001** May 24, 2013**AB** **0.5MCG** **A091174 002** May 24, 2013**AB** ROXANE **0.25MCG** **A076917 001** Mar 27, 2006**AB** STRIDES ARCOLAB LTD **0.25MCG** **A091356 001** Dec 12, 2014**AB** **0.5MCG** **A091356 002** Dec 12, 2014**AB** TEVA **0.25MCG** **A075765 001** Oct 12, 2001**AB** **0.5MCG** **A075765 002** Oct 12, 2001ROCALTROL**AB** VALIDUS PHARMS **0.25MCG** **N018044 001****AB** + **0.5MCG** **N018044 002**

INJECTABLE; INJECTION

CALCIJEX**AP** + ABBVIE **0.001MG/ML** **N018874 001** Sep 25, 1986**AP** + **0.002MG/ML** **N018874 002** Sep 25, 1986CALCITRIOL**AP** AKORN **0.001MG/ML** **A078066 001** Jan 29, 2008**AP** **0.002MG/ML** **A078066 002** Jan 29, 2008**AP** FRESENIUS KABI USA **0.001MG/ML** **A075836 001** Dec 31, 2002**AP** **0.002MG/ML** **A075836 002** Dec 31, 2002**AP** FRESENIUS MEDCL **0.001MG/ML** **A075766 001** Feb 20, 2003**AP** **0.002MG/ML** **A075766 002** Feb 20, 2003**AP** LUITPOLD **0.001MG/ML** **A075746 001** Sep 26, 2003**AP** **0.002MG/ML** **A075746 002** Sep 26, 2003**AP** ROCKWELL MEDCL **0.001MG/ML** **A076206 001** Sep 17, 2003**AP** SAGENT PHARMS **0.001MG/ML** **A077102 001** Feb 08, 2006

OINTMENT; TOPICAL

VECTICAL

+ GALDERMA LABS LP

3MCG/GM

N022087 001 Jan 23, 2009

SOLUTION; ORAL

CALCITRIOL**AA** ROXANE **1MCG/ML** **A076242 001** Jul 18, 2003ROCALTROL**AA** + VALIDUS PHARMS **1MCG/ML** **N021068 001** Nov 20, 1998CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE**AB** AMNEAL PHARMS **EQ 169MG CALCIUM** **A201658 001** Oct 06, 2014**AB** INVAGEN PHARMS **EQ 169MG CALCIUM** **A203135 001** Feb 07, 2013**AB** PADDOCK LLC **EQ 169MG CALCIUM** **A091312 001** Jun 01, 2012**AB** ROXANE **EQ 169MG CALCIUM** **A077728 001** Feb 26, 2008PHOSLO GELCAPS**AB** + FRESENIUS MEDCL **EQ 169MG CALCIUM** **N021160 003** Apr 02, 2001

SOLUTION; ORAL

PHOSLYRA

+ FRESENIUS MEDCL

EQ 169MG CALCIUM/5ML

N022581 001 Apr 18, 2011

TABLET; ORAL

CALCIUM ACETATE**AB** INVAGEN PHARMS **EQ 169MG CALCIUM** **A202420 001** Feb 05, 2013**AB** PADDOCK LLC **EQ 169MG CALCIUM** **A091561 001** Apr 13, 2011ELIPHOS**AB** + CYPRESS PHARM **EQ 169MG CALCIUM** **A078502 001** Nov 25, 2008CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+ HOSPIRA

100MG/ML

N021117 001 Jan 28, 2000

## PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

**BSS PLUS**

**AT** + ALCON **0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML** **N018469 001**

**ENDOSOL EXTRA**

**AT** + AKORN **0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML** **N020079 001** Nov 27, 1991

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML N021703 010 Oct 10, 2008

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML N021703 011 Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML N021703 013 Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 006 Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 002 Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 003 Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 015 Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 004 Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 014 Oct 10, 2008

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 001 Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATHIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

## NAVSTEL

+ ALCON PHARMS LTD 0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML N022193 001 Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN 37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML N019864 001 Jun 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML N017390 001

## PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

+	B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML;9.2G M/100ML;9.6GM/100ML	N018807 001	Aug 26, 1983
---	---------	----------------------------------------------------------------	-------------	--------------

+		510MG/100ML;30GM/100ML;200MG/100ML;9.4G M/100ML;11GM/100ML	N018807 003	Aug 26, 1983
---	--	---------------------------------------------------------------	-------------	--------------

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

+	B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML;9.2G M/100ML;9.6GM/100ML	N018807 002	Aug 26, 1983
---	---------	----------------------------------------------------------------	-------------	--------------

+		510MG/100ML;50GM/100ML;200MG/100ML;9.4G M/100ML;11GM/100ML	N018807 004	Aug 26, 1983
---	--	---------------------------------------------------------------	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	<u>N018379 002</u>	
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--

<u>AT</u>		<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	<u>N018883 001</u>	Nov 30, 1984
-----------	--	---------------------------------------------------------------------------	--------------------	--------------

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	<u>N018883 004</u>	Nov 30, 1984
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	<u>N020171 001</u>	Aug 19, 1992
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	<u>N018379 003</u>	
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--

<u>AT</u>		<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	<u>N018883 002</u>	Nov 30, 1984
-----------	--	---------------------------------------------------------------------------	--------------------	--------------

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	<u>N018883 005</u>	Nov 30, 1984
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	<u>N020171 002</u>	Aug 19, 1992
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	<u>N018379 007</u>	Jun 24, 1988
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML</u>	<u>N018379 001</u>	
-----------	-----------------	----------------------------------------------------------------------------	--------------------	--

<u>AT</u>		<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML</u>	<u>N018883 003</u>	Nov 30, 1984
-----------	--	----------------------------------------------------------------------------	--------------------	--------------

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML</u>	<u>N018883 006</u>	Nov 30, 1984
-----------	-----------------	----------------------------------------------------------------------------	--------------------	--------------

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>18.4MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML</u>	<u>N020171 003</u>	Aug 19, 1992
-----------	-----------------	----------------------------------------------------------------------------	--------------------	--------------

DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	<u>N018379 004</u>	Jul 07, 1982
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	<u>N018379 005</u>	Jul 07, 1982
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	<u>N018379 008</u>	Jun 24, 1988
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<u>AT</u>	FRESENIUS MEDCL	<u>25.7MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML</u>	<u>N018379 006</u>	Jul 07, 1982
-----------	-----------------	----------------------------------------------------------------------------	--------------------	--------------

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	<u>N017512 001</u>	
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	<u>N017512 003</u>	
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML</u>	<u>N017512 002</u>	
-----------	-----------------	----------------------------------------------------------------------------	--------------------	--

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML</u>	<u>N020183 001</u>	Dec 04, 1992
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<u>AT</u>	BAXTER HLTHCARE	<u>25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML</u>	<u>N017512 007</u>	Jul 09, 1984
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<u>25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML</u>	<u>N017512 008</u>	Jul 09, 1984
-----------	-----------------	--------------------------------------------------------------------------	--------------------	--------------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<u>25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML</u>	<u>N017512 010</u>	Nov 18, 1985
-----------	-----------------	--------------------------------------------------------------------------	--------------------	--------------

DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<u>25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML</u>	<u>N017512 009</u>	Jul 09, 1984
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<u>18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	<u>N017512 004</u>	
-----------	-----------------	--------------------------------------------------------------------------	--------------------	--

<b>AT</b>		<u>25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	<u>N020163 001</u>	Dec 04, 1992
-----------	--	--------------------------------------------------------------------------	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<u>25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	<u>N017512 005</u>	
-----------	-----------------	--------------------------------------------------------------------------	--------------------	--

<b>AT</b>		<u>25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	<u>N020163 002</u>	Dec 04, 1992
-----------	--	--------------------------------------------------------------------------	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<u>25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	<u>N017512 011</u>	Nov 18, 1985
-----------	-----------------	--------------------------------------------------------------------------	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<u>25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	<u>N017512 006</u>	
-----------	-----------------	---------------------------------------------------------------------------	--------------------	--

<b>AT</b>		<u>25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	<u>N020163 003</u>	Dec 04, 1992
-----------	--	---------------------------------------------------------------------------	--------------------	--------------

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

	B BRAUN	26MG/100ML; 1.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460 007	Jan 29, 1986
--	---------	--------------------------------------------------------------	-------------	--------------

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

	B BRAUN	26MG/100ML; 2.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460 005	Nov 02, 1983
--	---------	--------------------------------------------------------------	-------------	--------------

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

	B BRAUN	26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460 009	Jan 29, 1986
--	---------	---------------------------------------------------------------	-------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183 002	Dec 04, 1992
--	-----------------	-------------------------------------------------------------------	-------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183 003	Dec 04, 1992
--	-----------------	-------------------------------------------------------------------	-------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183 004	Dec 04, 1992
--	-----------------	--------------------------------------------------------------------	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

## ELLIOTTS B SOLUTION

	+ LUKARE MEDICAL LLC	0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML	N020577 001	Sep 27, 1996
--	----------------------	----------------------------------------------------------------------	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

	+ B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	N018258 001	
--	-----------	-------------------------------------------------------------	-------------	--

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	HOSPIRA	<u>33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018254 001</u>	
-----------	---------	-------------------------------------------------------	--------------------	--

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<u>33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N020000 001</u>	Apr 17, 1992
-----------	---------	-------------------------------------------------------	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017608 001</u>	
-----------	---------	--------------------------------------------------------------------	--------------------	--

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019634 003</u>	Feb 24, 1988
-----------	---------	--------------------------------------------------------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N016679 001</b>	
-----------	-----------------	--------------------------------------------------------------------	--------------------	--

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019367 006</b>	Apr 05, 1985
-----------	-----------------	---------------------------------------------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019367 004</b>	Apr 05, 1985
-----------	-----------------	---------------------------------------------------------------------	--------------------	--------------

<b>AP</b>		<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019367 005</b>	Apr 05, 1985
-----------	--	---------------------------------------------------------------------	--------------------	--------------

<b>AP</b>	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019685 002</b>	Oct 17, 1988
-----------	---------	---------------------------------------------------------------------	--------------------	--------------

<b>AP</b>		<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019685 008</b>	Oct 17, 1988
-----------	--	---------------------------------------------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019367 007</b>	Apr 05, 1985
-----------	-----------------	---------------------------------------------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019367 008</b>	Apr 05, 1985
-----------	-----------------	---------------------------------------------------------------------	--------------------	--------------

<b>AP</b>	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019685 004</b>	Oct 17, 1988
-----------	---------	---------------------------------------------------------------------	--------------------	--------------

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	<u>10MG/100ML; 2.5GM/100ML; 15MG/100ML; 300MG/100ML; 160MG/100ML</u>	<b>N019634 001</b>	Feb 24, 1988
--	---------	----------------------------------------------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019367 002</b>	Apr 05, 1985
--	-----------------	---------------------------------------------------------------------	--------------------	--------------

		<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019367 003</b>	Apr 05, 1985
--	--	---------------------------------------------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML</u>	<b>N019367 001</b>	Apr 05, 1985
--	-----------------	---------------------------------------------------------------------	--------------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	+ HOSPIRA	<u>16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML</u>	<b>N018895 001</b>	Jul 20, 1984
--	-----------	-------------------------------------------------------------	--------------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

	+ B BRAUN	<u>35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML</u>	<b>N019718 001</b>	Sep 29, 1989
--	-----------	---------------------------------------------------------------------------------	--------------------	--------------

SOLUTION; IRRIGATION

BALANCED SALT

<b>AT</b>	AKORN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<b>A075503 001</b>	Sep 27, 2006
-----------	-------	---------------------------------------------------------------------	--------------------	--------------

<b>AT</b>	B BRAUN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<b>A091387 001</b>	Feb 03, 2010
-----------	---------	---------------------------------------------------------------------	--------------------	--------------

BSS

<b>AT</b>	+ ALCON	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<b>N020742 001</b>	Dec 10, 1997
-----------	---------	---------------------------------------------------------------------	--------------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	<u>36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML; 640MG/100ML; 496MG/100ML; 89.6MG/100ML</u>	<b>N017438 001</b>	
--	-------------------	-----------------------------------------------------------------------------------------	--------------------	--

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<b>A075323 001</b>	Apr 21, 2000
-----------	-----------------	----------------------------------------------------------------	--------------------	--------------

PLEGISOL IN PLASTIC CONTAINER

<b>AT</b>	+ HOSPIRA	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<b>N018608 001</b>	Feb 26, 1982
-----------	-----------	----------------------------------------------------------------	--------------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N020002 001</u>	Apr 17, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N016693 001</u>	
<u>AP</u>	HOSPIRA	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018251 001</u>	

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018156 001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018495 001</u>	Feb 19, 1982
<u>AT</u>	HOSPIRA	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N017635 001</u>	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019632 001</u>	Feb 29, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016682 001</u>	
<u>AP</u>	HOSPIRA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017641 001</u>	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AT</u>	+ B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018681 001</u>	Dec 27, 1982
<u>AT</u>	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018494 001</u>	Feb 19, 1982
<u>AT</u>	+	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018921 001</u>	Apr 03, 1984
<u>AT</u>	+	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019933 001</u>	Aug 29, 1989
<u>AT</u>	+ HOSPIRA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019416 001</u>	Jan 17, 1986

CALFACTANT

SUSPENSION; INTRATRACHEAL

INFASURF PRESERVATIVE FREE

+ ONY	35MG/ML	N020521 001	Jul 01, 1998
-------	---------	-------------	--------------

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

JANSSEN PHARMS	100MG	N204042 001	Mar 29, 2013
+	300MG	N204042 002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

INVOKAMET

JANSSEN PHARMS	50MG; 500MG	N204353 001	Aug 08, 2014
	50MG; 1GM	N204353 002	Aug 08, 2014
	150MG; 500MG	N204353 003	Aug 08, 2014
+	150MG; 1GM	N204353 004	Aug 08, 2014

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

<u>AB</u>	ASTRAZENECA	<u>4MG</u>	<u>N020838 001</u>	Jun 04, 1998
<u>AB</u>		<u>8MG</u>	<u>N020838 002</u>	Jun 04, 1998
<u>AB</u>		<u>16MG</u>	<u>N020838 003</u>	Jun 04, 1998
<u>AB</u>	+	<u>32MG</u>	<u>N020838 004</u>	Jun 04, 1998

CANDESARTAN CILEXETIL

<u>AB</u>	APOTEX INC	<u>4MG</u>	<u>A202079 001</u>	Jan 10, 2014
<u>AB</u>		<u>8MG</u>	<u>A202079 002</u>	Jan 10, 2014
<u>AB</u>		<u>16MG</u>	<u>A202079 003</u>	Jan 10, 2014
<u>AB</u>		<u>32MG</u>	<u>A202079 004</u>	Jan 10, 2014
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A078702 001</u>	May 03, 2013
<u>AB</u>		<u>8MG</u>	<u>A078702 002</u>	May 03, 2013
<u>AB</u>		<u>16MG</u>	<u>A078702 003</u>	May 03, 2013
<u>AB</u>		<u>32MG</u>	<u>A078702 004</u>	May 03, 2013

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

<u>AB</u>	ASTRAZENECA	<u>16MG; 12.5MG</u>	<u>N021093 001</u>	Sep 05, 2000
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>N021093 002</u>	Sep 05, 2000
<u>AB</u>	+	<u>32MG; 25MG</u>	<u>N021093 003</u>	May 16, 2008

## PRESCRIPTION DRUG PRODUCT LIST

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>16MG;12.5MG</u>	<u>A202884 001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;12.5MG</u>	<u>A202884 002</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;25MG</u>	<u>A202884 003</u>	Jun 03, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>16MG;12.5MG</u>	<u>A202965 001</u>	Jun 03, 2013
<u>AB</u>		<u>32MG;12.5MG</u>	<u>A202965 002</u>	Jun 03, 2013
<u>AB</u>		<u>32MG;25MG</u>	<u>A202965 003</u>	Jun 03, 2013
<u>AB</u>	MYLAN LABS	<u>16MG;12.5MG</u>	<u>A090704 001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;12.5MG</u>	<u>A090704 002</u>	Dec 04, 2012
<u>AB</u>		<u>32MG;25MG</u>	<u>A090704 003</u>	Dec 04, 2012

CAPECITABINE

TABLET; ORAL

CAPECITABINE

<u>AB</u>	MYLAN PHARMS INC	<u>150MG</u>	<u>A090943 001</u>	Aug 08, 2014
<u>AB</u>		<u>500MG</u>	<u>A090943 002</u>	Aug 08, 2014
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A091649 001</u>	Sep 16, 2013
<u>AB</u>		<u>500MG</u>	<u>A091649 002</u>	Sep 16, 2013

XELODA

<u>AB</u>	HOFFMANN LA ROCHE	<u>150MG</u>	<u>N020896 001</u>	Apr 30, 1998
<u>AB</u>	+	<u>500MG</u>	<u>N020896 002</u>	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

+ AKORN

EQ 1GM BASE/VIAL

N050095 001

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+ ACORDA

8%

N022395 001 Nov 16, 2009

CAPTOPRIL

TABLET; ORAL

CAPOTEN

<u>AB</u>	PAR PHARM	<u>12.5MG</u>	<u>N018343 005</u>	Jan 17, 1985
<u>AB</u>		<u>25MG</u>	<u>N018343 002</u>	
<u>AB</u>		<u>50MG</u>	<u>N018343 001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018343 003</u>	

CAPTOPRIL

<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A074737 001</u>	Oct 28, 1998
<u>AB</u>		<u>25MG</u>	<u>A074737 002</u>	Oct 28, 1998
<u>AB</u>		<u>50MG</u>	<u>A074737 003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A074737 004</u>	Oct 28, 1998
<u>AB</u>	HIKMA PHARMS LLC	<u>12.5MG</u>	<u>A074505 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074505 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074505 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074505 004</u>	Feb 13, 1996
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A074434 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074434 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074434 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074434 004</u>	Feb 13, 1996
<u>AB</u>	SANDOZ	<u>12.5MG</u>	<u>A074363 001</u>	Nov 09, 1995
<u>AB</u>		<u>25MG</u>	<u>A074363 002</u>	Nov 09, 1995
<u>AB</u>		<u>50MG</u>	<u>A074363 003</u>	Nov 09, 1995
<u>AB</u>		<u>100MG</u>	<u>A074363 004</u>	Nov 09, 1995
<u>AB</u>	STASON	<u>12.5MG</u>	<u>A074677 004</u>	May 30, 1997
<u>AB</u>		<u>25MG</u>	<u>A074677 002</u>	May 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A074677 001</u>	May 30, 1997
<u>AB</u>		<u>100MG</u>	<u>A074677 003</u>	May 30, 1997
<u>AB</u>	TEVA	<u>12.5MG</u>	<u>A074322 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074322 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074322 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074322 004</u>	Feb 13, 1996
<u>AB</u>	WATSON LABS	<u>12.5MG</u>	<u>A074386 001</u>	May 23, 1996
<u>AB</u>		<u>25MG</u>	<u>A074386 002</u>	May 23, 1996
<u>AB</u>		<u>50MG</u>	<u>A074386 003</u>	May 23, 1996
<u>AB</u>		<u>100MG</u>	<u>A074386 004</u>	May 23, 1996
<u>AB</u>	WOCKHARDT	<u>12.5MG</u>	<u>A074532 001</u>	Mar 28, 1997
<u>AB</u>		<u>25MG</u>	<u>A074532 002</u>	Mar 28, 1997
<u>AB</u>		<u>50MG</u>	<u>A074532 003</u>	Mar 28, 1997
<u>AB</u>		<u>100MG</u>	<u>A074532 004</u>	Mar 28, 1997

## PRESCRIPTION DRUG PRODUCT LIST

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN	<u>25MG;15MG</u>	<u>A074896 001</u>	Dec 29, 1997
<u>AB</u>	+	<u>25MG;25MG</u>	<u>A074896 002</u>	Dec 29, 1997
<u>AB</u>	+	<u>50MG;15MG</u>	<u>A074896 004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074896 003</u>	Dec 29, 1997
<u>AB</u>	TEVA	<u>25MG;15MG</u>	<u>A074827 001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG;25MG</u>	<u>A074827 002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;15MG</u>	<u>A074827 004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG;25MG</u>	<u>A074827 003</u>	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+ ALCON

0.01%

N016968 001

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A078986 001</u>	Nov 25, 2011
<u>AB</u>		<u>200MG</u>	<u>A078986 002</u>	Nov 25, 2011
<u>AB</u>		<u>300MG</u>	<u>A078986 003</u>	Nov 25, 2011
<u>AB</u>	NOSTRUM	<u>100MG</u>	<u>A076697 001</u>	May 20, 2011
<u>AB</u>		<u>200MG</u>	<u>A076697 002</u>	May 20, 2011
<u>AB</u>		<u>300MG</u>	<u>A076697 003</u>	May 20, 2011
<u>AB</u>	TARO	<u>100MG</u>	<u>A201106 001</u>	Jun 21, 2013
<u>AB</u>		<u>200MG</u>	<u>A201106 002</u>	Jun 21, 2013
<u>AB</u>		<u>300MG</u>	<u>A201106 003</u>	Jun 21, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A078592 001</u>	Sep 20, 2012
<u>AB</u>		<u>200MG</u>	<u>A078592 002</u>	Sep 20, 2012
<u>AB</u>		<u>300MG</u>	<u>A078592 003</u>	Sep 20, 2012

CARBATROL

<u>AB</u>	SHIRE	<u>100MG</u>	<u>N020712 003</u>	Sep 30, 1997
<u>AB</u>		<u>200MG</u>	<u>N020712 001</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020712 002</u>	Sep 30, 1997
	EQUETRO			
	VALIDUS PHARMS INC	100MG	N021710 001	Dec 10, 2004
		200MG	N021710 002	Dec 10, 2004
	+	300MG	N021710 003	Dec 10, 2004

SUSPENSION; ORAL

CARBAMAZEPINE

<u>AB</u>	WOCKHARDT	<u>100MG/5ML</u>	<u>A075714 001</u>	Jun 05, 2002
<u>AB</u>	+	<u>100MG/5ML</u>	<u>N018927 001</u>	Dec 18, 1987
<u>AB</u>	TARO	<u>100MG/5ML</u>	<u>A076729 001</u>	Sep 20, 2004

TABLET; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075948 001</u>	Feb 27, 2002
<u>AB</u>	TARO	<u>200MG</u>	<u>A074649 001</u>	Oct 03, 1996
<u>AB</u>	TORRENT PHARMS	<u>200MG</u>	<u>A077272 002</u>	Dec 07, 2005
<u>AB</u>	TEVA	<u>200MG</u>	<u>A070541 001</u>	Sep 17, 1986
<u>AB</u>	+	<u>200MG</u>	<u>N016608 001</u>	
	CARBAMAZEPINE			
	TORRENT PHARMS	100MG	A077272 001	Dec 07, 2005
		300MG	A077272 003	Dec 07, 2005
		400MG	A077272 004	Dec 07, 2005

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO PHARM INDS	<u>100MG</u>	<u>A075687 001</u>	Oct 24, 2000
<u>AB</u>	TORRENT PHARMS	<u>100MG</u>	<u>A075712 001</u>	Jul 05, 2001
<u>AB</u>	TEVA	<u>100MG</u>	<u>A073524 001</u>	Jul 29, 1992
<u>AB</u>	+	<u>100MG</u>	<u>N018281 001</u>	
	CARBAMAZEPINE			
	+	200MG	A075687 002	Jul 29, 2002
	TARO PHARM INDS			
<u>AB</u>	TARO	<u>100MG</u>	<u>A078115 001</u>	Mar 31, 2009

## PRESCRIPTION DRUG PRODUCT LIST

CARBAMAZEPINE

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

<u>AB</u>		<u>200MG</u>	<u>A078115</u>	<u>002</u>	Mar 31, 2009
<u>AB</u>		<u>400MG</u>	<u>A078115</u>	<u>003</u>	Mar 31, 2009
	<u>TEGRETOL-XR</u>				
<u>AB</u>	NOVARTIS	<u>100MG</u>	<u>N020234</u>	<u>001</u>	Mar 25, 1996
<u>AB</u>		<u>200MG</u>	<u>N020234</u>	<u>002</u>	Mar 25, 1996
<u>AB</u>	+	<u>400MG</u>	<u>N020234</u>	<u>003</u>	Mar 25, 1996

CARBIDOPA

TABLET;ORAL

CARBIDOPA

<u>AB</u>	AMERIGEN PHARMS LTD	<u>25MG</u>	<u>A203261</u>	<u>001</u>	Mar 10, 2014
	<u>LODOSYN</u>				
<u>AB</u>	+	<u>25MG</u>	<u>N017830</u>	<u>001</u>	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

<u>AB</u>	SUN PHARMA GLOBAL	<u>25MG;200MG;100MG</u>	<u>A079085</u>	<u>001</u>	May 10, 2012
<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A079085</u>	<u>002</u>	May 10, 2012
<u>AB</u>	WOCKHARDT LTD	<u>12.5MG;200MG;50MG</u>	<u>A090786</u>	<u>001</u>	Nov 20, 2012
<u>AB</u>		<u>18.75MG;200MG;75MG</u>	<u>A090833</u>	<u>001</u>	Nov 20, 2012
<u>AB</u>		<u>25MG;200MG;100MG</u>	<u>A090833</u>	<u>002</u>	Nov 20, 2012
<u>AB</u>		<u>31.25MG;200MG;125MG</u>	<u>A090833</u>	<u>003</u>	Nov 20, 2012
<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A090833</u>	<u>004</u>	Nov 20, 2012
<u>AB</u>		<u>50MG;200MG;200MG</u>	<u>A090833</u>	<u>005</u>	Nov 20, 2012
	<u>STALEVO 100</u>				
<u>AB</u>	ORION PHARMA	<u>25MG;200MG;100MG</u>	<u>N021485</u>	<u>002</u>	Jun 11, 2003
	<u>STALEVO 125</u>				
<u>AB</u>	ORION PHARMA	<u>31.25MG;200MG;125MG</u>	<u>N021485</u>	<u>006</u>	Aug 29, 2008
	<u>STALEVO 150</u>				
<u>AB</u>	ORION PHARMA	<u>37.5MG;200MG;150MG</u>	<u>N021485</u>	<u>003</u>	Jun 11, 2003
	<u>STALEVO 200</u>				
<u>AB</u>	+	<u>50MG;200MG;200MG</u>	<u>N021485</u>	<u>004</u>	Aug 02, 2007
	<u>STALEVO 50</u>				
<u>AB</u>	+	<u>12.5MG;200MG;50MG</u>	<u>N021485</u>	<u>001</u>	Jun 11, 2003
	<u>STALEVO 75</u>				
<u>AB</u>	ORION PHARMA	<u>18.75MG;200MG;75MG</u>	<u>N021485</u>	<u>005</u>	Aug 29, 2008

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG;100MG</u>	<u>A074260</u>	<u>001</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;100MG</u>	<u>A074260</u>	<u>002</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;250MG</u>	<u>A074260</u>	<u>003</u>	Sep 03, 1993
<u>AB</u>	APOTEX INC	<u>10MG;100MG</u>	<u>A077120</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A077120</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A077120</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A090324</u>	<u>001</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A090324</u>	<u>002</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A090324</u>	<u>003</u>	Sep 28, 2009
<u>AB</u>	SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078536</u>	<u>001</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078536</u>	<u>002</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A078536</u>	<u>003</u>	Oct 28, 2008
<u>AB</u>	TEVA	<u>10MG;100MG</u>	<u>A073618</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;100MG</u>	<u>A073589</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;250MG</u>	<u>A073607</u>	<u>001</u>	Aug 28, 1992
	<u>SINEMET</u>				
<u>AB</u>	MERCK SHARP DOHME	<u>10MG;100MG</u>	<u>N017555</u>	<u>001</u>	
<u>AB</u>		<u>25MG;100MG</u>	<u>N017555</u>	<u>003</u>	
<u>AB</u>	+	<u>25MG;250MG</u>	<u>N017555</u>	<u>002</u>	

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACCORD HLTHCARE	<u>25MG;100MG</u>	<u>A202323</u>	<u>001</u>	Feb 08, 2013
<u>AB</u>		<u>50MG;200MG</u>	<u>A202323</u>	<u>002</u>	Feb 08, 2013
<u>AB</u>	APOTEX	<u>25MG;100MG</u>	<u>A076212</u>	<u>001</u>	Jun 16, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076212</u>	<u>002</u>	Jun 16, 2004
<u>AB</u>	IMPAX LABS	<u>25MG;100MG</u>	<u>A076521</u>	<u>001</u>	May 14, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076521</u>	<u>002</u>	May 14, 2004
<u>AB</u>	MYLAN	<u>25MG;100MG</u>	<u>A075091</u>	<u>002</u>	Apr 21, 2000
<u>AB</u>		<u>50MG;200MG</u>	<u>A075091</u>	<u>001</u>	Sep 30, 1999
<u>AB</u>	SUN PHARM INDS	<u>25MG;100MG</u>	<u>A077828</u>	<u>001</u>	Aug 23, 2007

## PRESCRIPTION DRUG PRODUCT LIST

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>		<u>50MG;200MG</u>	<u>A077828 002</u>	Aug 23, 2007
	<u>SINEMET CR</u>			
<u>AB</u>	MERCK SHARP DOHME	<u>25MG;100MG</u>	<u>N019856 002</u>	Dec 24, 1992
<u>AB</u>	+	<u>50MG;200MG</u>	<u>N019856 001</u>	May 30, 1991

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A078893 001</u>	Sep 18, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078893 002</u>	Sep 18, 2008
<u>AB</u>	+	<u>25MG;250MG</u>	<u>A078893 003</u>	Sep 18, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>10MG;100MG</u>	<u>A078690 001</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A078690 002</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A078690 003</u>	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	CYPRESS PHARM	<u>4MG/5ML</u>	<u>A090418 001</u>	May 04, 2010
<u>AA</u>	+	<u>4MG/5ML</u>	<u>A040458 001</u>	Apr 25, 2003
<u>AA</u>	VINTAGE PHARMS	<u>4MG/5ML</u>	<u>A040814 001</u>	Feb 26, 2008

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

+ TRIS PHARMA INC 4MG/5ML

N022556 001 Mar 28, 2013

TABLET;ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	CYPRESS PHARM	<u>4MG</u>	<u>A090417 001</u>	Aug 23, 2010
<u>AA</u>	INVAGEN PHARMS	<u>4MG</u>	<u>A090435 001</u>	Apr 15, 2010
<u>AA</u>	+	<u>4MG</u>	<u>A040442 001</u>	Mar 19, 2003
<u>AA</u>	MISSION PHARMACAL CO	<u>4MG</u>	<u>A090756 001</u>	May 27, 2011
<u>AA</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040639 002</u>	May 30, 2008

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/5ML (10MG/ML)</u>	<u>A078732 001</u>	Feb 06, 2012
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078732 002</u>	Feb 06, 2012
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078732 003</u>	Feb 06, 2012
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078732 004</u>	Feb 06, 2012
<u>AP</u>	AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475 001</u>	Jul 29, 2009
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A090475 002</u>	Jul 29, 2009
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A090475 003</u>	Jul 29, 2009
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091268 002</u>	Jul 28, 2010
<u>AP</u>	CIPLA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A077861 001</u>	Jan 18, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861 002</u>	Jan 18, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861 003</u>	Jan 18, 2007
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861 004</u>	Jan 18, 2007
<u>AP</u>	EBEWE PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078280 001</u>	May 08, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078280 002</u>	May 08, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078280 003</u>	May 08, 2008
<u>AP</u>	EUROHLTH INTL	<u>50MG/5ML (10MG/ML)</u>	<u>A077244 001</u>	Oct 15, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077244 002</u>	Oct 15, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077244 003</u>	Oct 15, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077244 004</u>	Jan 20, 2006
<u>AP</u>	FRESENIUS KABI ONCOL	<u>50MG/5ML (10MG/ML)</u>	<u>A077432 001</u>	Sep 29, 2006
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077432 002</u>	Sep 29, 2006
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077432 003</u>	Sep 29, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>450MG/45ML (10MG/ML)</u>	<u>A077247 003</u>	Oct 21, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077266 003</u>	Feb 15, 2006
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077266 004</u>	Feb 15, 2006
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517 001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A076517 002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A076517 003</u>	Oct 14, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077059 001</u>	Nov 23, 2004
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077998 001</u>	Apr 24, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077998 002</u>	Apr 24, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077998 003</u>	Apr 24, 2007
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A091063 001</u>	Nov 09, 2011
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A091063 002</u>	Nov 09, 2011
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A091063 003</u>	Nov 09, 2011
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091063 004</u>	Nov 09, 2011
<u>AP</u>	+	<u>50MG/5ML (10MG/ML)</u>	<u>A077269 001</u>	Oct 14, 2004

## PRESCRIPTION DRUG PRODUCT LIST

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>	+		<u>150MG/15ML (10MG/ML)</u>	<u>A077269 002</u>	Oct 14, 2004
<u>AP</u>	+		<u>450MG/45ML (10MG/ML)</u>	<u>A077269 003</u>	Oct 14, 2004
<u>AP</u>	+		<u>600MG/60ML (10MG/ML)</u>	<u>A077269 004</u>	Dec 28, 2007
<u>AP</u>		PLIVA LACHEMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078631 001</u>	Dec 02, 2008
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A078631 002</u>	Dec 02, 2008
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A078631 003</u>	Dec 02, 2008
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A078631 004</u>	Dec 02, 2008
<u>AP</u>		SAGENT PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A077096 001</u>	Jun 14, 2005
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A077096 002</u>	Jun 14, 2005
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A077096 003</u>	Jun 14, 2005
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A077096 004</u>	Jun 03, 2013
<u>AP</u>		SUN PHARMA GLOBAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077926 001</u>	Sep 19, 2008
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A077926 002</u>	Sep 19, 2008
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A077926 003</u>	Sep 19, 2008
<u>AP</u>	+	TEVA PHARMS USA	<u>50MG/5ML (10MG/ML)</u>	<u>A077139 001</u>	Sep 21, 2005
<u>AP</u>	+		<u>150MG/15ML (10MG/ML)</u>	<u>A077139 002</u>	Sep 21, 2005
<u>AP</u>	+		<u>450MG/45ML (10MG/ML)</u>	<u>A077139 003</u>	Sep 21, 2005
<u>AP</u>	+		<u>600MG/60ML (10MG/ML)</u>	<u>A077139 004</u>	Sep 21, 2005
	+	ONCO THERAPIES LTD	1GM/100ML (10MG/ML)	A091478 001	Nov 23, 2011

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+ PHARMACIA AND UPJOHN EQ 0.25MG BASE/ML N017989 001

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+ ONYX PHARMS 60MG/VIAL N202714 001 Jul 20, 2012

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+ ORPHAN EUROPE 200MG N022562 001 Mar 18, 2010

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>		ACCELRX LABS	<u>350MG</u>	<u>A040576 001</u>	Jun 07, 2005
<u>AA</u>		AUROBINDO PHARMA	<u>350MG</u>	<u>A040792 001</u>	Aug 06, 2009
<u>AA</u>		MIRROR PHARMS	<u>350MG</u>	<u>A040823 001</u>	Oct 22, 2008
<u>AA</u>		MUTUAL PHARM	<u>350MG</u>	<u>A089346 001</u>	Oct 17, 1991
<u>AA</u>		NATCO PHARMA LTD	<u>350MG</u>	<u>A090988 001</u>	Oct 28, 2014
<u>AA</u>		ORIENT PHARMA CO LTD	<u>350MG</u>	<u>A205085 001</u>	Oct 28, 2014
<u>AA</u>		SCIEGEN PHARMS INC	<u>350MG</u>	<u>A203374 001</u>	Jan 27, 2014
<u>AA</u>		SUN PHARM INDS LTD	<u>350MG</u>	<u>A040755 001</u>	Feb 27, 2007
<u>AA</u>		VINTAGE PHARMS	<u>350MG</u>	<u>A040245 001</u>	Sep 08, 1997
<u>AA</u>		WATSON LABS	<u>350MG</u>	<u>A087499 001</u>	Apr 20, 1982
		<u>SOMA</u>			
<u>AA</u>		MEDA PHARMS	<u>350MG</u>	<u>N011792 001</u>	
	+		250MG	N011792 004	Sep 13, 2007

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+ ARBOR PHARMS LLC 7.7MG N020637 001 Sep 23, 1996

INJECTABLE; INJECTION

BICNU

+ EMCURE PHARMS LTD 100MG/VIAL N017422 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

<u>AT</u>		ALCON	<u>1%</u>	<u>A075476 001</u>	Jan 03, 2000
<u>AT</u>		BAUSCH AND LOMB	<u>1%</u>	<u>A075546 001</u>	Jan 20, 2000
		<u>OCUPRESS</u>			
<u>AT</u>	+	NOVARTIS	<u>1%</u>	<u>N019972 001</u>	May 23, 1990

## PRESCRIPTION DRUG PRODUCT LIST

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	APOTEX INC	<u>3.125MG</u>	<u>A078165 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078165 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078165 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078165 004</u>	Sep 05, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>3.125MG</u>	<u>A078332 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078332 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078332 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078332 004</u>	Sep 05, 2007
<u>AB</u>	BEXIMCO USA	<u>3.125MG</u>	<u>A078384 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078384 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078384 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078384 004</u>	Sep 05, 2007
<u>AB</u>	CIPLA LTD	<u>3.125MG</u>	<u>A077474 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077474 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077474 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077474 004</u>	Sep 05, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>3.125MG</u>	<u>A076649 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076649 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076649 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076649 004</u>	Sep 05, 2007
<u>AB</u>	GLENMARK GENERICS	<u>3.125MG</u>	<u>A078251 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078251 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078251 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078251 004</u>	Sep 05, 2007
<u>AB</u>	HIKMA	<u>3.125MG</u>	<u>A077887 001</u>	Sep 07, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077887 002</u>	Sep 07, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077887 003</u>	Sep 07, 2007
<u>AB</u>		<u>25MG</u>	<u>A077887 004</u>	Sep 07, 2007
<u>AB</u>	LUPIN	<u>3.125MG</u>	<u>A078217 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078217 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078217 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078217 004</u>	Sep 05, 2007
<u>AB</u>	MYLAN	<u>3.125MG</u>	<u>A077316 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077316 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077316 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077316 004</u>	Sep 05, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>3.125MG</u>	<u>A078240 001</u>	Oct 30, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078240 002</u>	Oct 30, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078240 003</u>	Oct 30, 2007
<u>AB</u>		<u>25MG</u>	<u>A078240 004</u>	Oct 30, 2007
<u>AB</u>	RANBAXY	<u>3.125MG</u>	<u>A076989 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076989 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076989 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076989 004</u>	Sep 05, 2007
<u>AB</u>	SANDOZ	<u>3.125MG</u>	<u>A078227 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078227 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078227 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078227 004</u>	Sep 05, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>3.125MG</u>	<u>A077346 004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077346 001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077346 002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077346 003</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780 004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373 004</u>	Sep 05, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614 004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614 001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614 002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614 003</u>	Sep 05, 2007
<u>COREG</u>				
<u>AB</u>	SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297 004</u>	May 29, 1997
<u>AB</u>		<u>6.25MG</u>	<u>N020297 003</u>	Sep 14, 1995
<u>AB</u>	+	<u>12.5MG</u>	<u>N020297 002</u>	Sep 14, 1995
<u>AB</u>		<u>25MG</u>	<u>N020297 001</u>	Sep 14, 1995

## PRESCRIPTION DRUG PRODUCT LIST

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

SB PHARCO	10MG	N022012	001	Oct 20, 2006
	20MG	N022012	002	Oct 20, 2006
+	40MG	N022012	003	Oct 20, 2006
	80MG	N022012	004	Oct 20, 2006

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

CANCIDAS

+ MERCK	50MG/VIAL	N021227	001	Jan 26, 2001
+	70MG/VIAL	N021227	002	Jan 26, 2001

CEFACTOR

CAPSULE; ORAL

CEFACTOR

<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065350</u>	<u>001</u>	Apr 03, 2007
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065350</u>	<u>002</u>	Apr 03, 2007
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146</u>	<u>001</u>	Jan 22, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065146</u>	<u>002</u>	Jan 22, 2004

FOR SUSPENSION; ORAL

CEFACTOR

<u>AB</u>	YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065412</u>	<u>001</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 187MG BASE/5ML</u>	<u>A065412</u>	<u>002</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065412</u>	<u>003</u>	Feb 17, 2012
<u>AB</u>	+	<u>EQ 375MG BASE/5ML</u>	<u>A065412</u>	<u>004</u>	Feb 17, 2012

TABLET, EXTENDED RELEASE; ORAL

CEFACTOR

TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002
+	EQ 500MG BASE	A065058	002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A065352</u>	<u>001</u>	Jan 25, 2007
<u>AB</u>	HIKMA	<u>EQ 500MG BASE</u>	<u>A065311</u>	<u>001</u>	Feb 07, 2006
<u>AB</u>	LUPIN	<u>EQ 500MG BASE</u>	<u>A065392</u>	<u>001</u>	May 29, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 500MG BASE</u>	<u>A065309</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>	SANDOZ	<u>EQ 500MG BASE</u>	<u>A062291</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065282</u>	<u>001</u>	Jan 20, 2006

FOR SUSPENSION; ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO	<u>EQ 250MG BASE/5ML</u>	<u>A065349</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065349</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	HIKMA PHARMS	<u>EQ 250MG BASE/5ML</u>	<u>A091036</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A091036</u>	<u>002</u>	Nov 28, 2012
<u>AB</u>	LUPIN	<u>EQ 250MG BASE/5ML</u>	<u>A065396</u>	<u>001</u>	Feb 21, 2008
<u>AB</u>	+	<u>EQ 500MG BASE/5ML</u>	<u>A065396</u>	<u>002</u>	Feb 21, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE/5ML</u>	<u>A065307</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065307</u>	<u>003</u>	Oct 16, 2006
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE/5ML</u>	<u>A065115</u>	<u>002</u>	Mar 26, 2003
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065115</u>	<u>003</u>	Mar 26, 2003
		EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003

TABLET; ORAL

CEFADROXIL

<u>AB</u>	HIKMA	<u>EQ 1GM BASE</u>	<u>A065260</u>	<u>001</u>	Mar 30, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1GM BASE</u>	<u>A065301</u>	<u>001</u>	Sep 18, 2006
+	TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065303</u>	<u>002</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065306</u>	<u>001</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 20GM BASE/VIAL</u>	<u>A065306</u>	<u>002</u>	Aug 18, 2014
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065303</u>	<u>001</u>	Oct 22, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1GM BASE/VIAL</u>	<u>A065047</u>	<u>002</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065143</u>	<u>001</u>	Oct 18, 2004
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065047</u>	<u>001</u>	Sep 18, 2001
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A065226</u>	<u>002</u>	Apr 21, 2005
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A065244</u>	<u>001</u>	Aug 12, 2005
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A065247</u>	<u>001</u>	Aug 12, 2005
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A065226</u>	<u>001</u>	Apr 21, 2005



## PRESCRIPTION DRUG PRODUCT LIST

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062831 002</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065345 001</u>	May 09, 2007
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A062831 003</u>	Sep 25, 1992
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062831 001</u>	Dec 09, 1988
<u>AP</u>	STERI PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A063207 001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063209 001</u>	Dec 27, 1991
<u>AP</u>	+	<u>EQ 20GM BASE/VIAL</u>	<u>A063209 002</u>	Apr 30, 1999
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063214 001</u>	Dec 27, 1991

KEFZOL

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A061773 003</u>	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A061773 004</u>	
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A061773 002</u>	
	ANCEF IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002 001	Mar 28, 1991
	+	EQ 20MG BASE/ML	A063002 002	Mar 28, 1991
	CEFAZOLIN AND DEXTROSE			
	+ B BRAUN	EQ 1GM BASE/VIAL	N050779 002	Jul 27, 2000
		EQ 2GM BASE/VIAL	N050779 003	Jan 13, 2012
	CEFAZOLIN SODIUM			
	+ SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141 001	Nov 29, 2006
	+	EQ 300GM BASE/VIAL	A065141 002	Nov 29, 2006

CEFDINIR

CAPSULE; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>300MG</u>	<u>A065434 001</u>	Jan 07, 2008
<u>AB</u>	LUPIN	<u>300MG</u>	<u>A065264 001</u>	May 19, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>300MG</u>	<u>A065418 001</u>	Jul 18, 2007
<u>AB</u>	+	<u>300MG</u>	<u>A065330 001</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>300MG</u>	<u>A065368 001</u>	May 09, 2007

FOR SUSPENSION; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065473 001</u>	Dec 14, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065473 002</u>	Dec 14, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065259 001</u>	May 31, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065259 002</u>	May 07, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065429 001</u>	Jul 18, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065429 002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337 001</u>	Apr 06, 2007
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065337 002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332 001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332 002</u>	May 04, 2007

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

	VANSEN PHARMA	200MG	N021222 001	Aug 29, 2001
	+	400MG	N021222 002	Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441 001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441 002</u>	Mar 20, 2008
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065369 002</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202268 001</u>	Jul 30, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065369 003</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202268 002</u>	Jul 30, 2012
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065369 001</u>	Jun 18, 2007

MAXIPIME

<u>AP</u>	+	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>N050679 002</u>	Jan 18, 1996
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>N050679 003</u>	Jan 18, 1996
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>N050679 001</u>	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

	B BRAUN	EQ 1GM BASE/VIAL	N050821 001	May 06, 2010
		EQ 2GM BASE/VIAL	N050821 002	May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817 001	Aug 05, 2008
	+	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817 002	Aug 05, 2008

## PRESCRIPTION DRUG PRODUCT LIST

CEFIXIME

CAPSULE; ORAL

SUPRAX

+ LUPIN LTD

400MG

N203195 001 Jun 01, 2012

FOR SUSPENSION; ORAL

SUPRAX

+ LUPIN LTD

500MG/5ML

N202091 001 Feb 20, 2013

LUPIN PHARMS

100MG/5ML

A065129 001 Feb 23, 2004

200MG/5ML

A065355 001 Apr 10, 2007

TABLET; ORAL

SUPRAX

+ LUPIN PHARMS

400MG

A065130 001 Feb 12, 2004

TABLET, CHEWABLE; ORAL

SUPRAX

LUPIN LTD

100MG

A065380 001 Oct 25, 2010

150MG

A065380 002 Oct 25, 2010

+

200MG

A065380 003 Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIMEAP HIKMAEQ 1GM BASE/VIALA065072 002 Nov 20, 2002APEQ 2GM BASE/VIALA065072 003 Nov 20, 2002APEQ 10GM BASE/VIALA065071 001 Nov 20, 2002APEQ 500MG BASE/VIALA065072 001 Nov 20, 2002AP WOCKHARDTEQ 1GM BASE/VIALA065197 001 Aug 29, 2006CEFOTAXIME SODIUMAP HOSPIRA INCEQ 1GM BASE/VIALA065290 002 Aug 11, 2006APEQ 1GM BASE/VIALA065293 001 Aug 10, 2006APEQ 2GM BASE/VIALA065290 003 Aug 11, 2006APEQ 2GM BASE/VIALA065293 002 Aug 10, 2006APEQ 10GM BASE/VIALA065292 001 Aug 10, 2006APEQ 500MG BASE/VIALA065290 001 Aug 11, 2006AP LUPINEQ 1GM BASE/VIALA065124 002 Sep 24, 2003APEQ 2GM BASE/VIALA065124 003 Sep 24, 2003APEQ 500MG BASE/VIALA065124 001 Sep 24, 2003AP WOCKHARDTEQ 2GM BASE/VIALA065197 003 Jun 20, 2008APEQ 500MG BASE/VIALA065197 002 Jun 20, 2008CLAFORANAP + SANOFI AVENTIS USEQ 1GM BASE/VIALA062659 001 Jan 13, 1987AP +EQ 1GM BASE/VIALN050547 002AP +EQ 2GM BASE/VIALA062659 002 Jan 13, 1987AP +EQ 2GM BASE/VIALN050547 003AP +EQ 10GM BASE/VIALN050547 004 Dec 29, 1983AP +EQ 500MG BASE/VIALN050547 001

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ SANOFI AVENTIS US

EQ 20MG BASE/ML

N050596 002 May 20, 1985

+

EQ 40MG BASE/ML

N050596 004 May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETANAP + FRESENIUS KABI USAEQ 1GM BASE/VIALA065374 001 Aug 09, 2007AP +EQ 2GM BASE/VIALA065374 002 Aug 09, 2007AP +EQ 10GM BASE/VIALA065375 001 Aug 09, 2007AP WEST-WARD PHARM CORPEQ 1GM BASE/VIALA091031 001 Oct 26, 2011APEQ 2GM BASE/VIALA091031 002 Oct 26, 2011APEQ 10GM BASE/VIALA091030 001 Oct 26, 2011

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

+ B BRAUN

EQ 1GM BASE/VIAL

A065430 001 Aug 09, 2007

+

EQ 2GM BASE/VIAL

A065430 002 Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITINAP + ACS DOBFAREQ 1GM BASE/VIALA065414 001 Jun 12, 2009AP +EQ 2GM BASE/VIALA065414 002 Jun 12, 2009AP +EQ 10GM BASE/VIALA065415 001 May 19, 2010AP ANTIBIOTICOS BRASILEQ 1GM BASE/VIALA065467 001 Aug 31, 2011APEQ 2GM BASE/VIALA065467 002 Aug 31, 2011APEQ 10GM BASE/VIALA065464 001 Aug 31, 2011AP HIKMA FARMACEUTICAEQ 1GM BASE/VIALA065238 001 Mar 12, 2010APEQ 2GM BASE/VIALA065238 002 Mar 12, 2010APEQ 10GM BASE/VIALA065239 001 Mar 02, 2010

## PRESCRIPTION DRUG PRODUCT LIST

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

<u>AP</u>	HIKMA MAPLE	<u>EQ 1GM BASE/VIAL</u>	<u>A065051 001</u>	Sep 11, 2000
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065051 002</u>	Sep 11, 2000
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065050 001</u>	Sep 11, 2000
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065313 001</u>	Jan 23, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065313 002</u>	Jan 23, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065312 001</u>	Feb 13, 2006

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>A065214 001</u>	Mar 10, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065214 002</u>	Mar 10, 2006
	MEFOXIN IN PLASTIC CONTAINER			
	+ MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182 001	Jan 25, 1993
	+	EQ 40MG BASE/ML	A063182 002	Jan 25, 1993

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 50MG BASE/5ML</u>	<u>A065409 001</u>	Jun 08, 2007
<u>AB</u>		<u>EQ 100MG BASE/5ML</u>	<u>A065409 002</u>	Jun 08, 2007
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE/5ML</u>	<u>A065082 001</u>	May 31, 2002
<u>AB</u>		<u>EQ 100MG BASE/5ML</u>	<u>A065082 002</u>	May 31, 2002
<u>AB</u>	SANDOZ	<u>EQ 50MG BASE/5ML</u>	<u>A090031 001</u>	Jan 14, 2009
<u>AB</u>	+	<u>EQ 100MG BASE/5ML</u>	<u>A090031 002</u>	Jan 14, 2009

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370 001</u>	Jun 11, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065370 002</u>	Jun 11, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388 001</u>	Nov 14, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065388 002</u>	Nov 14, 2007
<u>AB</u>	RANBAXY	<u>EQ 100MG BASE</u>	<u>A065083 001</u>	Aug 20, 2003
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065083 002</u>	Aug 20, 2003
<u>AB</u>	SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462 001</u>	May 28, 2008
<u>AB</u>	+	<u>EQ 200MG BASE</u>	<u>A065462 002</u>	May 28, 2008

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>125MG/5ML</u>	<u>A065351 001</u>	Feb 29, 2012
<u>AB</u>		<u>250MG/5ML</u>	<u>A065351 002</u>	Feb 29, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381 001</u>	Jan 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065381 002</u>	Jan 30, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065261 001</u>	Dec 19, 2005
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065261 002</u>	Dec 19, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284 002</u>	Dec 30, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065284 001</u>	Dec 30, 2005
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065257 001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065257 002</u>	Dec 08, 2005
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065236 001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065236 002</u>	Dec 08, 2005

TABLET; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A065327 001</u>	Mar 26, 2008
<u>AB</u>		<u>500MG</u>	<u>A065327 002</u>	Mar 26, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340 001</u>	May 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A065340 002</u>	May 24, 2007
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276 001</u>	Dec 08, 2005
<u>AB</u>	+	<u>500MG</u>	<u>A065276 002</u>	Dec 08, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A065267 001</u>	Dec 19, 2005
<u>AB</u>		<u>500MG</u>	<u>A065267 002</u>	Dec 19, 2005
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065235 001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235 002</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208 001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208 002</u>	Dec 06, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065428 001</u>	Jun 14, 2007
<u>AB</u>		<u>500MG</u>	<u>A065428 002</u>	Jun 14, 2007

## PRESCRIPTION DRUG PRODUCT LIST

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)

TEFLARO

CEREXA

400MG/VIAL

N200327 001 Oct 29, 2010

+

600MG/VIAL

N200327 002 Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIMEAP ACS DOBFAR1GM/VIALA062640 002 Nov 20, 1985AP2GM/VIALA062640 003 Nov 20, 1985AP6GM/VIALA062640 004 Feb 03, 1992AP500MG/VIALA062640 001 Nov 20, 1985AP

WOCKHARDT

1GM/VIALA065196 001 Oct 15, 2008FORTAZAP + COVIS INJECTABLES1GM/VIALN050578 002 Jul 19, 1985AP

+

2GM/VIALN050578 003 Jul 19, 1985AP

+

6GM/VIALN050578 004 Jul 19, 1985AP

+

500MG/VIALN050578 001 Jul 19, 1985TAZICEFAP HOSPIRA1GM/VIALA062662 002 Mar 06, 1986AP1GM/VIALA064032 001 Oct 31, 1993AP2GM/VIALA062662 003 Mar 06, 1986AP2GM/VIALA064032 002 Oct 31, 1993AP6GM/VIALA062662 004 Mar 06, 1986AP500MG/VIALA062662 001 Mar 06, 1986

CEFTAZIDIME IN DEXTROSE CONTAINER

B BRAUN

EQ 1GM BASE

N050823 001 Jun 13, 2011

+

EQ 2GM BASE

N050823 002 Jun 13, 2011

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

+ COVIS INJECTABLES

EQ 20MG BASE/ML

N050634 002 Apr 28, 1989

+

EQ 40MG BASE/ML

N050634 003 Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+ PERNIX THERAP

EQ 400MG BASE

N050685 002 Dec 20, 1995

FOR SUSPENSION; ORAL

CEDAX

+ PERNIX THERAP

EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995

+

EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; IV (INFUSION)

ZERBAXA

+ CUBIST PHARMS

EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL

N206829 001 Dec 19, 2014

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONEAP ACS DOBFAREQ 1GM BASE/VIALA065329 002 Jul 24, 2008APEQ 2GM BASE/VIALA065329 003 Jul 24, 2008APEQ 10GM BASE/VIALA065328 001 Jul 24, 2008APEQ 500MG BASE/VIALA065329 001 Jul 24, 2008AP

BEDFORD

EQ 10GM BASE/VIALA065475 001 Aug 18, 2008AP

HOSPIRA INC

EQ 1GM BASE/VIALA065231 001 Aug 02, 2005APEQ 1GM BASE/VIALA202563 001 Aug 20, 2012APEQ 2GM BASE/VIALA065231 002 Aug 02, 2005APEQ 2GM BASE/VIALA202563 002 Aug 20, 2012APEQ 10GM BASE/VIALA065232 001 Aug 02, 2005AP

LUPIN

EQ 10GM BASE/VIALA065263 001 Sep 12, 2006AP

+ SANDOZ

EQ 10GM BASE/VIALA065168 001 May 17, 2005AP

+ SANDOZ INC

EQ 1GM BASE/VIALA065204 001 May 03, 2005AP

+

EQ 2GM BASE/VIALA065204 002 May 03, 2005AP

STERI PHARMA

EQ 10GM BASE/VIALA065269 001 Feb 28, 2007AP

WOCKHARDT

EQ 1GM BASE/VIALA065180 001 May 12, 2006CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINERAP + B BRAUNEQ 1GM BASE/VIALN050796 001 Apr 20, 2005AP

+

EQ 2GM BASE/VIALN050796 002 Apr 20, 2005ROCEPHINAP + HOFFMANN LA ROCHEEQ 1GM BASE/VIALA063239 003 Aug 13, 1993AP

+

EQ 500MG BASE/VIALA063239 002 Aug 13, 1993

## PRESCRIPTION DRUG PRODUCT LIST

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE

SAMSON MEDCL EQ 100GM BASE/VIAL

A090057 001 Apr 25, 2014

CEFTRIAZONE IN PLASTIC CONTAINER

+ BAXTER HLTHCARE EQ 20MG BASE/ML

A065224 001 Aug 23, 2005

+ EQ 40MG BASE/ML

A065224 002 Aug 23, 2005

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

AP AKORN INC

EQ 1GM BASE/VIALA065305 003 Jan 11, 2008

AP

EQ 2GM BASE/VIALA065305 004 Jan 11, 2008

AP

EQ 250MG BASE/VIALA065305 001 Jan 11, 2008

AP

EQ 500MG BASE/VIALA065305 002 Jan 11, 2008

AP BEDFORD

EQ 1GM BASE/VIALA065465 003 Aug 18, 2008

AP

EQ 2GM BASE/VIALA065465 004 Aug 18, 2008

AP

EQ 250MG BASE/VIALA065465 001 Aug 18, 2008

AP

EQ 500MG BASE/VIALA065465 002 Aug 18, 2008

AP FRESENIUS KABI USA

EQ 250MG BASE/VIALA065245 001 Feb 15, 2006

AP HIKMA FARMACEUTICA

EQ 1GM BASE/VIALA065342 003 Jan 10, 2008

AP

EQ 2GM BASE/VIALA065342 004 Jan 10, 2008

AP

EQ 250MG BASE/VIALA065342 001 Jan 10, 2008

AP

EQ 500MG BASE/VIALA065342 002 Jan 10, 2008

AP HOSPIRA INC

EQ 1GM BASE/VIALA065230 003 Aug 02, 2005

AP

EQ 2GM BASE/VIALA065230 004 Aug 02, 2005

AP

EQ 250MG BASE/VIALA065230 001 Aug 02, 2005

AP

EQ 500MG BASE/VIALA065230 002 Aug 02, 2005

AP LUPIN

EQ 1GM BASE/VIALA065125 003 Sep 30, 2003

AP

EQ 2GM BASE/VIALA065125 004 Sep 30, 2003

AP

EQ 250MG BASE/VIALA065125 001 Sep 30, 2003

AP

EQ 500MG BASE/VIALA065125 002 Sep 30, 2003

AP + SANDOZ

EQ 1GM BASE/VIALA065169 003 May 09, 2005

AP +

EQ 2GM BASE/VIALA065169 004 May 09, 2005

AP +

EQ 250MG BASE/VIALA065169 001 May 09, 2005

AP +

EQ 500MG BASE/VIALA065169 002 May 09, 2005

AP WOCKHARDT

EQ 2GM BASE/VIALA065391 003 Apr 12, 2007

AP

EQ 250MG BASE/VIALA065391 001 Apr 12, 2007

AP

EQ 500MG BASE/VIALA065391 002 Apr 12, 2007CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

AB GLAXOSMITHKLINE

EQ 125MG BASE/5MLN050672 001 Jun 30, 1994

AB +

EQ 250MG BASE/5MLN050672 002 Apr 29, 1997CEFUROXIME AXETIL

AB RANBAXY

EQ 125MG BASE/5MLA065323 001 Feb 05, 2008

AB

EQ 250MG BASE/5MLA065323 002 Feb 05, 2008

TABLET; ORAL

CEFTIN

AB GLAXOSMITHKLINE

EQ 125MG BASEN050605 001 Dec 28, 1987

AB

EQ 250MG BASEN050605 002 Dec 28, 1987

AB +

EQ 500MG BASEN050605 003 Dec 28, 1987CEFUROXIME AXETIL

AB ALKEM LABS LTD

EQ 250MG BASEA065496 001 Jun 07, 2010

AB

EQ 500MG BASEA065496 002 Jun 07, 2010

AB APOTEX

EQ 250MG BASEA065069 001 Oct 02, 2002

AB

EQ 500MG BASEA065069 002 Oct 02, 2002

AB AUROBINDO PHARMA LTD

EQ 125MG BASEA065308 001 Mar 29, 2006

AB

EQ 250MG BASEA065308 002 Mar 29, 2006

AB

EQ 500MG BASEA065308 003 Mar 29, 2006

AB LUPIN

EQ 250MG BASEA065135 001 Jul 25, 2003

AB

EQ 500MG BASEA065135 002 Jul 25, 2003

AB ORCHID HLTHCARE

EQ 125MG BASEA065359 001 Feb 15, 2008

AB

EQ 250MG BASEA065359 002 Feb 15, 2008

AB

EQ 500MG BASEA065359 003 Feb 15, 2008

AB RANBAXY

EQ 125MG BASEA065118 001 Apr 25, 2003

AB

EQ 250MG BASEA065118 002 Apr 25, 2003

AB

EQ 500MG BASEA065118 003 Apr 25, 2003

AB TEVA

EQ 250MG BASEA065190 001 Oct 18, 2004

AB

EQ 500MG BASEA065190 002 Oct 18, 2004

AB WOCKHARDT

EQ 125MG BASEA065166 001 Jul 29, 2005

AB

EQ 250MG BASEA065166 002 Jul 29, 2005

AB

EQ 500MG BASEA065166 003 Jul 29, 2005

## PRESCRIPTION DRUG PRODUCT LIST

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+ B BRAUN	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780 002</u>	Feb 21, 2001
<u>AP</u>	+	<u>EQ 750MG BASE/VIAL</u>	<u>N050780 001</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048 002</u>	Jan 09, 2004
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046 001</u>	Jan 09, 2004
<u>AP</u>	HOSPIRA INC	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065483 002</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 1.5GM BASE/VIAL</u>	<u>A065503 001</u>	Oct 15, 2008
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065484 001</u>	Oct 15, 2008
<u>AP</u>	STERI PHARMA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125 002</u>	May 30, 1997
<u>AP</u>		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124 001</u>	May 30, 1997

ZINACEF

<u>AP</u>	+ COVIS INJECTABLES	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558 003</u>	Oct 19, 1983
<u>AP</u>	+	<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558 004</u>	Oct 23, 1986

ZINACEF IN PLASTIC CONTAINER

+ COVIS INJECTABLES EQ 30MG BASE/ML

N050643 002 Apr 28, 1989

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

<u>AB</u>	HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048 001</u>	Jan 09, 2004
<u>AB</u>	STERI PHARMA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125 001</u>	May 30, 1997

ZINACEF

<u>AB</u>	+ COVIS INJECTABLES	<u>EQ 750MG BASE/VIAL</u>	<u>N050558 002</u>	Oct 19, 1983
-----------	---------------------	---------------------------	--------------------	--------------

CEFUROXIME SODIUM

<u>AP</u>	HOSPIRA INC	<u>EQ 750MG BASE/VIAL</u>	<u>A065483 001</u>	Oct 15, 2008
-----------	-------------	---------------------------	--------------------	--------------

CELECOXIB

CAPSULE; ORAL

CELEBREX

<u>AB</u>	GD SEARLE	<u>50MG</u>	<u>N020998 004</u>	Dec 15, 2006
<u>AB</u>		<u>100MG</u>	<u>N020998 001</u>	Dec 31, 1998
<u>AB</u>		<u>200MG</u>	<u>N020998 002</u>	Dec 31, 1998
<u>AB</u>	+	<u>400MG</u>	<u>N020998 003</u>	Aug 29, 2002

CELECOXIB

<u>AB</u>	LUPIN LTD	<u>50MG</u>	<u>A202240 001</u>	Oct 29, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A078857 001</u>	May 30, 2014
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076898 001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A076898 002</u>	May 30, 2014
<u>AB</u>		<u>200MG</u>	<u>A076898 003</u>	May 30, 2014
<u>AB</u>		<u>400MG</u>	<u>A076898 004</u>	May 30, 2014

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A090836 001</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090836 002</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A090836 004</u>	Mar 29, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A065253 001</u>	Nov 16, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065253 002</u>	Nov 16, 2005
<u>AB</u>	BELCHER PHARMS	<u>EQ 250MG BASE</u>	<u>A062713 001</u>	Jul 15, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062713 002</u>	Jul 15, 1988
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065215 001</u>	Jan 24, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065215 002</u>	Jan 24, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065229 001</u>	Nov 25, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065229 002</u>	Nov 25, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A065248 001</u>	Jun 28, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065248 002</u>	Jun 28, 2005
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A065007 001</u>	Sep 16, 1999
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065007 002</u>	Sep 16, 1999
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 250MG BASE</u>	<u>A062791 001</u>	Jun 11, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062791 002</u>	Jun 11, 1987
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062702 001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062702 002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065152 001</u>	Feb 24, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065152 002</u>	Feb 24, 2005

KEFLEX

<u>AB</u>	SHIONOGI INC	<u>EQ 250MG BASE</u>	<u>N050405 002</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050405 003</u>	
<u>AB</u>	+	<u>EQ 750MG BASE</u>	<u>N050405 005</u>	May 12, 2006

CEPHALEXIN

	ALKEM LABS LTD	EQ 333MG BASE	A090836 003	Mar 29, 2013
--	----------------	---------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

<b>AB</b>	LUPIN	<b>EQ 125MG BASE/5ML</b>	<b>A065234 001</b>	Aug 17, 2005
<b>AB</b>		<b>EQ 250MG BASE/5ML</b>	<b>A065234 002</b>	Aug 17, 2005
<b>AB</b>	ORCHID HLTHCARE	<b>EQ 125MG BASE/5ML</b>	<b>A065326 001</b>	Jul 10, 2006
<b>AB</b>		<b>EQ 250MG BASE/5ML</b>	<b>A065326 002</b>	Jul 10, 2006
<b>AB</b>	TEVA	<b>EQ 125MG BASE/5ML</b>	<b>A062703 001</b>	Feb 13, 1987
<b>AB</b>	+	<b>EQ 250MG BASE/5ML</b>	<b>A062703 002</b>	Feb 13, 1987
TABLET; ORAL				
CEPHALEXIN				
	TEVA	EQ 250MG BASE	A063023 001	Jan 12, 1989
	+	EQ 500MG BASE	A063024 001	Jan 12, 1989

CERITINIB

CAPSULE; ORAL

ZYKADIA

+	NOVARTIS PHARMS CORP	150MG	N205755 001	Apr 29, 2014
---	----------------------	-------	-------------	--------------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

<b>AA</b>	AMNEAL PHARMS	<b>5MG/5ML</b>	<b>A090766 001</b>	Oct 07, 2009
<b>AA</b>	BIO PHARM INC	<b>5MG/5ML</b>	<b>A078870 001</b>	Apr 27, 2009
<b>AA</b>	BRECKENRIDGE PHARM	<b>5MG/5ML</b>	<b>A078488 001</b>	Oct 06, 2008
<b>AA</b>	PERRIGO R AND D	<b>5MG/5ML</b>	<b>A078398 001</b>	Jun 17, 2008
<b>AA</b>	SILARX	<b>5MG/5ML</b>	<b>A078876 001</b>	May 11, 2012
<b>AA</b>	SUN PHARM INDS INC	<b>5MG/5ML</b>	<b>A090191 001</b>	Nov 12, 2009
<b>AA</b>	TARO	<b>5MG/5ML</b>	<b>A076601 001</b>	Jun 20, 2008
<b>AA</b>	TEVA PHARMS	<b>5MG/5ML</b>	<b>A077279 001</b>	May 27, 2008
<b>AA</b>	VINTAGE	<b>5MG/5ML</b>	<b>A078496 001</b>	Sep 25, 2009
<b>AA</b>	WOCKHARDT	<b>5MG/5ML</b>	<b>A078757 001</b>	Aug 28, 2009
<b>ZYRTEC</b>				
<b>AA</b>	+	MCNEIL CONSUMER	<b>5MG/5ML</b>	<b>N020346 001</b> Sep 27, 1996

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

+	EMD SERONO INC	EQ 0.25MG BASE/ML	N021197 001	Aug 11, 2000
---	----------------	-------------------	-------------	--------------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE

<b>AB</b>	APOTEX INC	<b>30MG</b>	<b>A091260 001</b>	Aug 25, 2011
<b>CEVIMELINE HYDROCHLORIDE</b>				
<b>AB</b>	PACK PHARMS LLC	<b>30MG</b>	<b>A203775 001</b>	Jun 04, 2014
<b>AB</b>	ROXANE	<b>30MG</b>	<b>A091591 001</b>	Jul 08, 2013
<b>EVOXAC</b>				
<b>AB</b>	+	DAIICHI SANKYO	<b>30MG</b>	<b>N020989 002</b> Jan 11, 2000

CHENODIOL

TABLET; ORAL

CHENODIOL

+	NEXGEN PHARMA	250MG	A091019 001	Oct 22, 2009
---	---------------	-------	-------------	--------------

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+	ASPEN GLOBAL INC	2MG	N010669 002	
---	------------------	-----	-------------	--

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

+	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365 001	Aug 25, 1982
---	--------------------	------------------	-------------	--------------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

<b>AB</b>	BARR	<b>5MG</b>	<b>A084768 001</b>	
<b>AB</b>		<b>10MG</b>	<b>A083116 001</b>	
<b>AB</b>		<b>25MG</b>	<b>A084769 001</b>	
<b>AB</b>	USL PHARMA	<b>10MG</b>	<b>A084623 001</b>	
<b>LIBRIUM</b>				
<b>AB</b>	VALEANT PHARM INTL	<b>5MG</b>	<b>A085461 001</b>	
<b>AB</b>		<b>10MG</b>	<b>A085472 001</b>	
<b>AB</b>	+	<b>25MG</b>	<b>A085475 001</b>	

## PRESCRIPTION DRUG PRODUCT LIST

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

<b>AT</b>	HI TECH PHARMA	<u>0.12%</u>	<b><u>A074356</u></b>	<b><u>001</u></b>	May 07, 1996
<b>AT</b>	LYNE	<u>0.12%</u>	<b><u>A074291</u></b>	<b><u>001</u></b>	Dec 28, 1995
<b>AT</b>	TEVA	<u>0.12%</u>	<b><u>A074522</u></b>	<b><u>001</u></b>	Dec 15, 1995
<b>AT</b>	WOCKHARDT	<u>0.12%</u>	<b><u>A075006</u></b>	<b><u>001</u></b>	Mar 03, 2004
<b>AT</b>	XTTRIUM	<u>0.12%</u>	<b><u>A077789</u></b>	<b><u>001</u></b>	Jun 18, 2009

PAROEX

<b>AT</b>	SUNSTAR AMERICAS	<u>0.12%</u>	<b><u>A076434</u></b>	<b><u>001</u></b>	Nov 29, 2005
-----------	------------------	--------------	-----------------------	-------------------	--------------

PERIDEX

<b>AT</b>	+ 3M	<u>0.12%</u>	<b><u>N019028</u></b>	<b><u>001</u></b>	Aug 13, 1986
-----------	------	--------------	-----------------------	-------------------	--------------

PERIOGARD

<b>AT</b>	COLGATE	<u>0.12%</u>	<b><u>A073695</u></b>	<b><u>001</u></b>	Jan 14, 1994
-----------	---------	--------------	-----------------------	-------------------	--------------

TABLET;DENTAL

## PERIOCHIP

	+ DEXCEL PHARMA	2.5MG	N020774	001	May 15, 1998
--	-----------------	-------	---------	-----	--------------

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLOROPROCAINE HYDROCHLORIDE

<b>AP</b>	EUROHLTH INTL	<u>2%</u>	<b><u>A040273</u></b>	<b><u>001</u></b>	Sep 09, 1998
<b>AP</b>		<u>3%</u>	<b><u>A040273</u></b>	<b><u>002</u></b>	Sep 09, 1998
<b>AP</b>	HOSPIRA	<u>2%</u>	<b><u>A087447</u></b>	<b><u>001</u></b>	Apr 16, 1982
<b>AP</b>		<u>3%</u>	<b><u>A087446</u></b>	<b><u>001</u></b>	Apr 16, 1982

NESACAINE

<b>AP</b>	FRESENIUS KABI USA	<u>2%</u>	<b><u>N009435</u></b>	<b><u>002</u></b>	
-----------	--------------------	-----------	-----------------------	-------------------	--

NESACAINE-MPF

<b>AP</b>	+ FRESENIUS KABI USA	<u>2%</u>	<b><u>N009435</u></b>	<b><u>006</u></b>	May 02, 1996
-----------	----------------------	-----------	-----------------------	-------------------	--------------

<b>AP</b>	+ FRESENIUS KABI USA	<u>3%</u>	<b><u>N009435</u></b>	<b><u>007</u></b>	May 02, 1996
-----------	----------------------	-----------	-----------------------	-------------------	--------------

## NESACAINE

	+ FRESENIUS KABI USA	1%	N009435	001	
--	----------------------	----	---------	-----	--

CHLOROQUINE PHOSPHATE

TABLET;ORAL

ARALEN

<b>AA</b>	+ SANOFI AVENTIS US	<u>EQ 300MG BASE</u>	<b><u>N006002</u></b>	<b><u>001</u></b>	
-----------	---------------------	----------------------	-----------------------	-------------------	--

CHLOROQUINE PHOSPHATE

<b>AA</b>	+ HIKMA PHARMS LLC	<u>EQ 150MG BASE</u>	<b><u>A083082</u></b>	<b><u>001</u></b>	
<b>AA</b>		<u>EQ 300MG BASE</u>	<b><u>A083082</u></b>	<b><u>002</u></b>	Sep 17, 1999
<b>AA</b>	IMPAX LABS	<u>EQ 150MG BASE</u>	<b><u>A080880</u></b>	<b><u>001</u></b>	
<b>AA</b>		<u>EQ 300MG BASE</u>	<b><u>A040516</u></b>	<b><u>001</u></b>	Aug 29, 2003
<b>AA</b>	IPCA LABS LTD	<u>EQ 150MG BASE</u>	<b><u>A090610</u></b>	<b><u>001</u></b>	Dec 03, 2009
<b>AA</b>		<u>EQ 300MG BASE</u>	<b><u>A090249</u></b>	<b><u>001</u></b>	Dec 03, 2009
<b>AA</b>	NATCO PHARMA LTD	<u>EQ 150MG BASE</u>	<b><u>A091621</u></b>	<b><u>001</u></b>	Jan 21, 2011
<b>AA</b>		<u>EQ 300MG BASE</u>	<b><u>A090612</u></b>	<b><u>001</u></b>	Jan 21, 2011

CHLOROTHIAZIDE

SUSPENSION;ORAL

## DIURIL

	+ SALIX PHARMS	250MG/5ML	N011870	001	
--	----------------	-----------	---------	-----	--

TABLET;ORAL

## CHLOROTHIAZIDE

	+ MYLAN	250MG	A084388	001	
--	---------	-------	---------	-----	--

		500MG	A084217	001	
--	--	-------	---------	-----	--

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

<b>AP</b>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<b><u>A090896</u></b>	<b><u>001</u></b>	Oct 16, 2009
<b>AP</b>	LUITPOLD	<u>EQ 500MG BASE/VIAL</u>	<b><u>A202561</u></b>	<b><u>001</u></b>	Apr 22, 2013
<b>AP</b>	MYLAN INSTITUTIONAL	<u>EQ 500MG BASE/VIAL</u>	<b><u>A202493</u></b>	<b><u>001</u></b>	Jun 18, 2014
<b>AP</b>	SUN PHARMA GLOBAL	<u>EQ 500MG BASE/VIAL</u>	<b><u>A091546</u></b>	<b><u>001</u></b>	Jul 26, 2011

DIURIL

<b>AP</b>	+ OAK PHARMS AKORN	<u>EQ 500MG BASE/VIAL</u>	<b><u>N011145</u></b>	<b><u>005</u></b>	
-----------	--------------------	---------------------------	-----------------------	-------------------	--

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

## VITUZ

	+ CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013
--	-----------------	-----------------	---------	-----	--------------



## PRESCRIPTION DRUG PRODUCT LIST

<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>				
SOLUTION; ORAL				
<u>HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE</u>				
<b>AA</b>	TRIS PHARMA INC	<u>4MG/5ML; 5MG/5ML; 60MG/5ML</u>	<u>A203838 001</u>	Nov 26, 2014
<u>HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE</u>				
<b>AA</b>	PADDOCK LLC	<u>4MG/5ML; 5MG/5ML; 60MG/5ML</u>	<u>A204627 001</u>	Apr 29, 2014
<u>ZUTRIPRO</u>				
<b>AA</b>	+ CYPRESS PHARM	<u>4MG/5ML; 5MG/5ML; 60MG/5ML</u>	<u>N022439 001</u>	Jun 08, 2011
<u>CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX</u>				
CAPSULE, EXTENDED RELEASE; ORAL				
TUSSICAPS				
	ECR PHARMA	EQ 4MG MALEATE; EQ 5MG BITARTRATE	A077273 002	Sep 24, 2007
	+	EQ 8MG MALEATE; EQ 10MG BITARTRATE	A077273 001	Sep 24, 2007
SUSPENSION, EXTENDED RELEASE; ORAL				
<u>HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX</u>				
<b>AB</b>	TRIS PHARMA INC	<u>EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML</u>	<u>A091632 001</u>	Oct 01, 2010
<u>HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX</u>				
<b>AB</b>	NEOS THERAP INC	<u>EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML</u>	<u>A091671 001</u>	Jun 29, 2012
<u>TUSSIONEX PENNKINETIC</u>				
<b>AB</b>	+ UCB INC	<u>EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML</u>	<u>N019111 001</u>	Dec 31, 1987
<u>CHLORPROMAZINE HYDROCHLORIDE</u>				
INJECTABLE; INJECTION				
CHLORPROMAZINE HYDROCHLORIDE				
	+ HIKMA MAPLE	25MG/ML	A083329 001	
TABLET; ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
BP	SANDOZ	10MG	A080439 001	
BP		25MG	A080439 002	
BP		50MG	A080439 003	
BP	+	100MG	A080439 004	
BP		200MG	A080439 005	
BP	USL PHARMA	10MG	A083386 001	
BP		25MG	A084112 001	
BP		50MG	A084113 001	
BP		100MG	A084114 001	
BP		200MG	A084115 001	
<u>CHLORPROPAMIDE</u>				
TABLET; ORAL				
<u>CHLORPROPAMIDE</u>				
<b>AB</b>	ANI PHARMS INC	<u>100MG</u>	<u>A088921 001</u>	Apr 12, 1985
<b>AB</b>		<u>250MG</u>	<u>A088922 001</u>	Apr 12, 1985
<b>AB</b>	MYLAN	<u>100MG</u>	<u>A088549 002</u>	Jun 01, 1984
<b>AB</b>		<u>250MG</u>	<u>A088549 001</u>	Jun 01, 1984
<u>DIABINESE</u>				
<b>AB</b>	PFIZER	<u>100MG</u>	<u>N011641 003</u>	
<b>AB</b>	+	<u>250MG</u>	<u>N011641 006</u>	
<u>CHLORTHALIDONE</u>				
TABLET; ORAL				
CHLORTHALIDONE				
	MYLAN	25MG	A086831 002	
	+	50MG	A086831 001	
THALITONE				
	+ CITRON PHARMA LLC	15MG	N019574 001	Dec 20, 1988
<u>CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE</u>				
TABLET; ORAL				
CLORPRES				
	MYLAN	15MG; 0.1MG	A071325 003	Feb 09, 1987
		15MG; 0.2MG	A071325 002	Feb 09, 1987
	+	15MG; 0.3MG	A071325 001	Feb 09, 1987
<u>CHLORZOXAZONE</u>				
TABLET; ORAL				
<u>CHLORZOXAZONE</u>				
<b>AA</b>	BARR	<u>500MG</u>	<u>A089895 001</u>	May 04, 1988
<b>AA</b>	WATSON LABS	<u>500MG</u>	<u>A089859 001</u>	May 04, 1988
<u>PARAFON FORTE DSC</u>				
<b>AA</b>	+ JANSSEN R AND D	<u>500MG</u>	<u>N011529 002</u>	Jun 15, 1987

## PRESCRIPTION DRUG PRODUCT LIST

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

MIKART

375MG

A040861 001 Jun 01, 2010

750MG

A040861 002 Jun 01, 2010

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE**AB** PAR PHARM**EQ 4GM RESIN/PACKET****A077204 001** Aug 26, 2005**AB****EQ 4GM RESIN/SCOOPFUL****A077204 002** Aug 26, 2005**AB** + SANDOZ**EQ 4GM RESIN/PACKET****A074557 001** Aug 15, 1996**AB****EQ 4GM RESIN/SCOOPFUL****A074557 002** Aug 15, 1996CHOLESTYRAMINE LIGHT**AB** PAR PHARM**EQ 4GM RESIN/PACKET****A077203 001** Aug 26, 2005**AB****EQ 4GM RESIN/SCOOPFUL****A077203 002** Aug 26, 2005**AB** + SANDOZ**EQ 4GM RESIN/PACKET****A074558 001** Aug 15, 1996**AB****EQ 4GM RESIN/SCOOPFUL****A074558 002** Aug 15, 1996PREVALITE**AB** UPSHER SMITH**EQ 4GM RESIN/PACKET****A073263 001** Feb 22, 1996**AB****EQ 4GM RESIN/SCOOPFUL****A073263 002** Oct 30, 1997CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

+ MCPRF

4-33.1mCi/ML

N203155 001 Sep 12, 2012

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID**AB** ANCHEN PHARMS**EQ 45MG FENOFIBRIC ACID****A201573 002** Jul 18, 2013**AB****EQ 135MG FENOFIBRIC ACID****A201573 001** Jul 18, 2013**AB** LUPIN LTD**EQ 45MG FENOFIBRIC ACID****A200750 001** Dec 04, 2013**AB****EQ 135MG FENOFIBRIC ACID****A200750 002** Dec 04, 2013**AB** MYLAN PHARMS INC**EQ 45MG FENOFIBRIC ACID****A200913 001** Mar 25, 2013**AB****EQ 135MG FENOFIBRIC ACID****A200913 002** Mar 25, 2013TRILIPIX**AB** ABBVIE**EQ 45MG FENOFIBRIC ACID****N022224 001** Dec 15, 2008**AB** +**EQ 135MG FENOFIBRIC ACID****N022224 002** Dec 15, 2008CHORIOGONADOTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

OVIDREL

+ EMD SERONO

EQ 0.25MG /0.5ML

N021149 002 Oct 06, 2003

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 0.004MG CHROMIUM/ML

N018961 001 Jun 26, 1986

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+ TAKEDA GMBH

0.08MG/INH

N021658 002 Jan 10, 2008

+

0.16MG/INH

N021658 003 Jan 10, 2008

AEROSOL, METERED; NASAL

ZETONNA

+ TAKEDA GMBH

0.037MG/INH

N202129 001 Jan 20, 2012

SPRAY, METERED; NASAL

OMNARIS

+ TAKEDA GMBH

0.05MG/INH

N022004 001 Oct 20, 2006

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX**AB** FOUGERA PHARMS**0.77%****A076435 001** Dec 29, 2004**AB** G AND W LABS INC**0.77%****A078463 001** Dec 20, 2010**AB** GLENMARK PHARMS**0.77%****A090273 001** Nov 10, 2009**AB** PERRIGO**0.77%****A077364 001** Mar 03, 2006**AB** TARO**0.77%****A076790 001** Apr 12, 2005LOPROX**AB** + MEDIMETRIKS PHARMS**0.77%****N018748 001** Dec 30, 1982

GEL; TOPICAL

CICLOPIROX**AB** FOUGERA PHARMS**0.77%****A077896 001** Jun 10, 2008**AB** GLENMARK GENERICS**0.77%****A091595 001** Feb 29, 2012

## PRESCRIPTION DRUG PRODUCT LIST

CICLOPIROX

GEL; TOPICAL

CICLOPIROX**AB** PADDOCK LLC **0.77%** **A078266 001** Jan 07, 2009LOPROX**AB** + CNTY LINE PHARMS **0.77%** **N020519 001** Jul 21, 1997  
SHAMPOO; TOPICALCICLOPIROX**AT** ACTAVIS MID ATLANTIC **1%** **A090490 001** Nov 24, 2009**AT** FOUGERA PHARMS **1%** **A090146 001** May 25, 2010**AT** PERRIGO **1%** **A078594 001** Feb 16, 2010**AT** TARO **1%** **A090269 001** Feb 23, 2011LOPROX**AT** + MEDICIS **1%** **N021159 001** Feb 28, 2003  
SOLUTION; TOPICALCICLOPIROX**AT** ACTAVIS MID ATLANTIC **8%** **A078046 001** Sep 18, 2007**AT** CIPLA LTD **8%** **A078124 001** Sep 18, 2007**AT** G AND W LABS **8%** **A078233 001** Sep 18, 2007**AT** HI TECH PHARMA **8%** **A078270 001** Sep 18, 2007**AT** PERRIGO NEW YORK **8%** **A077623 001** Sep 18, 2007**AT** TARO PHARM INDS **8%** **A078144 001** Sep 18, 2007**AT** TOLMAR **8%** **A077687 001** Sep 18, 2007**AT** VERSAPHARM **8%** **A078975 001** Feb 17, 2010PENLAC**AT** + VALEANT BERMUDA **8%** **N021022 001** Dec 17, 1999  
SUSPENSION; TOPICALCICLOPIROX**AB** FOUGERA PHARMS **0.77%** **A076422 001** Aug 06, 2004**AB** PERRIGO NEW YORK **0.77%** **A077676 001** Dec 15, 2006**AB** TARO **0.77%** **A077092 001** Aug 10, 2005LOPROX**AB** + MEDIMETRIKS PHARMS **0.77%** **N019824 001** Dec 30, 1988CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR**AP** EMCURE PHARMS LTD **EQ 75MG BASE/ML** **A202501 001** Jul 26, 2012**AP** MYLAN INSTITUTIONAL **EQ 75MG BASE/ML** **A201276 001** Jun 27, 2012VISTIDE**AP** + GILEAD SCIENCES INC **EQ 75MG BASE/ML** **N020638 001** Jun 26, 1996CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAMUSCULAR

PRIMAXIN

MERCK

EQ 500MG BASE/VIAL; 500MG/VIAL

N050630 001 Dec 14, 1990

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN**AP** ACS DOBFAR **EQ 250MG BASE/VIAL; 250MG/VIAL** **A090577 001** Dec 21, 2011**AP** **EQ 500MG BASE/VIAL; 500MG/VIAL** **A090577 002** Dec 21, 2011**AP** HOSPIRA INC **EQ 250MG BASE/VIAL; 250MG/VIAL** **A090825 001** Nov 16, 2011**AP** **EQ 500MG BASE/VIAL; 500MG/VIAL** **A090825 002** Nov 16, 2011**AP** **EQ 500MG BASE/VIAL; 500MG/VIAL** **A091007 001** Nov 16, 2011PRIMAXIN**AP** + MERCK **EQ 250MG BASE/VIAL; 250MG/VIAL** **N050587 001** Nov 26, 1985**AP** + **EQ 500MG BASE/VIAL; 500MG/VIAL** **N050587 002** Nov 26, 1985CILOSTAZOL

TABLET; ORAL

CILOSTAZOL**AB** APOTEX INC **50MG** **A077030 001** Dec 10, 2004**AB** **100MG** **A077030 002** Dec 10, 2004**AB** BIOKEY **50MG** **A077722 001** Sep 24, 2012**AB** **100MG** **A077831 001** Sep 24, 2012**AB** BRECKENRIDGE PHARM **50MG** **A077708 001** Sep 28, 2009**AB** **100MG** **A077708 002** Sep 28, 2009**AB** MYLAN **50MG** **A077323 002** Apr 20, 2006**AB** **100MG** **A077323 001** Apr 20, 2006**AB** MYLAN PHARMS INC **50MG** **A077019 001** Nov 23, 2004**AB** **100MG** **A077019 002** Nov 23, 2004**AB** PLIVA HRVATSKA DOO **50MG** **A077898 001** Oct 29, 2007**AB** **100MG** **A077898 002** Oct 29, 2007**AB** ROXANE **50MG** **A077024 001** May 17, 2005**AB** **100MG** **A077024 002** May 17, 2005

## PRESCRIPTION DRUG PRODUCT LIST

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A077310</u>	<u>001</u>	Nov 08, 2005
<u>AB</u>		<u>100MG</u>	<u>A077021</u>	<u>001</u>	Nov 23, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A077027</u>	<u>001</u>	Nov 24, 2004
<u>AB</u>		<u>100MG</u>	<u>A077027</u>	<u>002</u>	Nov 24, 2004
<u>PLETAL</u>					
<u>AB</u>	+ OTSUKA	<u>50MG</u>	<u>N020863</u>	<u>001</u>	Jan 15, 1999
<u>AB</u>	+	<u>100MG</u>	<u>N020863</u>	<u>002</u>	Jan 15, 1999

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>	APOTEX	<u>200MG</u>	<u>A074890</u>	<u>001</u>	Dec 18, 1998
<u>AB</u>		<u>300MG</u>	<u>A074890</u>	<u>002</u>	Dec 18, 1998
<u>AB</u>		<u>400MG</u>	<u>A074890</u>	<u>003</u>	Dec 18, 1998
<u>AB</u>		<u>800MG</u>	<u>A074890</u>	<u>004</u>	Dec 18, 1998
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074246</u>	<u>001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074246</u>	<u>002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074246</u>	<u>003</u>	May 17, 1994
<u>AB</u>	+	<u>800MG</u>	<u>A074246</u>	<u>004</u>	May 17, 1994
<u>AB</u>	PLIVA	<u>800MG</u>	<u>A074566</u>	<u>001</u>	Feb 27, 1997
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074151</u>	<u>001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074151</u>	<u>002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074151</u>	<u>003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074463</u>	<u>001</u>	May 17, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

<u>AP</u>	DAVA PHARMS INC	<u>EQ 300MG BASE/2ML</u>	<u>A074428</u>	<u>001</u>	Apr 25, 1996
SOLUTION; ORAL					
<u>CIMETIDINE HYDROCHLORIDE</u>					
<u>AA</u>	ANI PHARMS INC	<u>EQ 300MG BASE/5ML</u>	<u>A074610</u>	<u>001</u>	Sep 26, 1996
<u>AA</u>	+ HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	<u>A074664</u>	<u>001</u>	Oct 28, 1997
<u>AA</u>	PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553</u>	<u>001</u>	Jan 27, 1997
<u>AA</u>	WOCKHARDT	<u>EQ 300MG BASE/5ML</u>	<u>A074757</u>	<u>001</u>	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

AMGEN

+

EQ 30MG BASE

N021688 001 Mar 08, 2004

EQ 60MG BASE

N021688 002 Mar 08, 2004

EQ 90MG BASE

N021688 003 Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

<u>AB</u>	BAYER HLTHCARE	<u>250MG/5ML</u>	<u>N020780</u>	<u>001</u>	Sep 26, 1997
<u>AB</u>	+	<u>500MG/5ML</u>	<u>N020780</u>	<u>002</u>	Sep 26, 1997
<u>CIPROFLOXACIN</u>					
<u>AB</u>	LUPIN LTD	<u>250MG/5ML</u>	<u>A200563</u>	<u>001</u>	Mar 05, 2014
<u>AB</u>		<u>500MG/5ML</u>	<u>A200563</u>	<u>002</u>	Mar 05, 2014

INJECTABLE; INJECTION

CIPRO

<u>AP</u>	+ BAYER HLTHCARE	<u>400MG/40ML (10MG/ML)</u>	<u>N019847</u>	<u>001</u>	Dec 26, 1990
<u>AP</u>	+	<u>200MG/20ML (10MG/ML)</u>	<u>N019847</u>	<u>002</u>	Dec 26, 1990
<u>CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ BAYER HLTHCARE	<u>200MG/100ML</u>	<u>N019857</u>	<u>001</u>	Dec 26, 1990
<u>AP</u>	+	<u>400MG/200ML</u>	<u>N019857</u>	<u>002</u>	Dec 26, 1990

CIPROFLOXACIN

<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/20ML (10MG/ML)</u>	<u>A078062</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A078062</u>	<u>002</u>	Apr 29, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A076717</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>	HOSPIRA	<u>200MG/20ML (10MG/ML)</u>	<u>A077245</u>	<u>001</u>	Aug 28, 2006
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A077245</u>	<u>002</u>	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>200MG/100ML</u>	<u>A078252</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078252</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML</u>	<u>A078024</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078024</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431</u>	<u>001</u>	Nov 18, 2009

## PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>200MG/100ML</u>	<u>A077753 001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A077753 002</u>	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

+ ALCON PHARMS LTD

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

<u>AT</u>	+ ALCON PHARMS LTD	<u>EQ 0.3% BASE</u>	<u>N020369 001</u>	Mar 30, 1998
<u>AT</u>	+ ALCON PHARMS LTD	<u>EQ 0.3% BASE</u>	<u>N019992 001</u>	Dec 31, 1990

CIPROFLOXACIN HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>EQ 0.3% BASE</u>	<u>A076555 001</u>	Dec 11, 2008
<u>AT</u>	FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568 001</u>	Jun 30, 2008
<u>AT</u>	IGI LABS INC	<u>EQ 0.3% BASE</u>	<u>A076754 001</u>	Jun 09, 2004
<u>AT</u>	NEXUS PHARMS	<u>EQ 0.3% BASE</u>	<u>A077689 001</u>	Dec 13, 2006
<u>AT</u>	PHARMAFORCE	<u>EQ 0.3% BASE</u>	<u>A078598 001</u>	Jan 16, 2008
<u>AT</u>	WATSON LABS INC	<u>EQ 0.3% BASE</u>	<u>A076673 001</u>	Jan 21, 2005

SOLUTION/DROPS; OTIC

CETRALAX

+ WRASER PHARMS

TABLET; ORAL

CIPRO

<u>AB</u>	BAYER HLTHCARE	<u>EQ 100MG BASE</u>	<u>N019537 001</u>	Apr 08, 1996
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>N019537 002</u>	Oct 22, 1987
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N019537 003</u>	Oct 22, 1987
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>N019537 004</u>	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A076896 001</u>	Nov 04, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076896 002</u>	Nov 04, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076896 003</u>	Nov 04, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859 001</u>	Apr 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077859 002</u>	Apr 26, 2007
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A077859 003</u>	Apr 26, 2007
<u>AB</u>	CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076126 003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076126 004</u>	Jun 09, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075593 003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075593 004</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075593 001</u>	Jun 09, 2004
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A076558 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076558 003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076558 004</u>	Jun 09, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076089 003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076089 004</u>	Jun 09, 2004
<u>AB</u>	MYLAN	<u>EQ 100MG BASE</u>	<u>A075817 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075685 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075817 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075685 003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075817 003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075685 001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075817 004</u>	Jun 09, 2004
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A075747 001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075747 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075747 003</u>	Jun 09, 2004
<u>AB</u>	TARO	<u>EQ 100MG BASE</u>	<u>A076912 001</u>	Feb 18, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076912 002</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076912 003</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076912 004</u>	Oct 06, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>EQ 250MG BASE</u>	<u>A076639 001</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076639 002</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076639 003</u>	Sep 10, 2004
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A076794 001</u>	Feb 10, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076794 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076794 003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076794 004</u>	Jun 09, 2004

## PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

+ ALCON PHARMS LTD EQ 0.2% BASE;1%

N020805 001 Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

<u>AB</u>	ACTAVIS LABS FL INC	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A077417 001</u>	Nov 30, 2010
<u>AB</u>		<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077809 001</u>	Nov 30, 2010
<u>AB</u>	ANCHEN PHARMS	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078166 002</u>	Nov 27, 2007
<u>AB</u>		<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078166 001</u>	Nov 27, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077701 001</u>	Mar 26, 2007
<u>AB</u>	+ MYLAN PHARMS INC	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078183 001</u>	Mar 22, 2007
<u>AB</u>	+	<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078183 002</u>	Mar 22, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

+ ALCON PHARMS LTD 0.3%;0.1%

N021537 001 Jul 18, 2003

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200159 001</u>	Feb 03, 2012
		<u>CISATRACURIUM BESYLATE PRESERVATIVE FREE</u>		
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200154 001</u>	Feb 03, 2012
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A200154 002</u>	Feb 03, 2012
		<u>NIMBEX</u>		
<u>AP</u>	+ ABBVIE	<u>EQ 2MG BASE/ML</u>	<u>N020551 001</u>	Dec 15, 1995
		<u>NIMBEX PRESERVATIVE FREE</u>		
<u>AP</u>	+ ABBVIE	<u>EQ 2MG BASE/ML</u>	<u>N020551 003</u>	Dec 15, 1995
<u>AP</u>	+	<u>EQ 10MG BASE/ML</u>	<u>N020551 002</u>	Dec 15, 1995

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

<u>AP</u>	EUROHLTH INTL	<u>1MG/ML</u>	<u>A075036 001</u>	Nov 07, 2000
<u>AP</u>	+ FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A074735 001</u>	Jul 16, 1999
<u>AP</u>	HQ SPCLT PHARMA	<u>1MG/ML</u>	<u>N018057 004</u>	Nov 08, 1988
<u>AP</u>	ONCO THERAPIES LTD	<u>1MG/ML</u>	<u>A091062 001</u>	Apr 18, 2012
<u>AP</u>	PHARMACHEMIE BV	<u>1MG/ML</u>	<u>A074656 001</u>	May 16, 2000

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

MYLAN PHARMS INC

EQ 10MG BASE

A077668 001 Feb 28, 2007

EQ 20MG BASE

A077668 002 Feb 28, 2007

+

EQ 40MG BASE

A077668 003 Feb 28, 2007

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/5ML</u>	<u>A077812 001</u>	Aug 28, 2006
<u>AA</u>	+ ROXANE	<u>EQ 10MG BASE/5ML</u>	<u>A077043 001</u>	Dec 13, 2004
<u>AA</u>	SILARX	<u>EQ 10MG BASE/5ML</u>	<u>A077629 001</u>	Jun 15, 2006

TABLET;ORAL

CELEXA

<u>AB</u>	FOREST LABS	<u>EQ 10MG BASE</u>	<u>N020822 001</u>	Apr 27, 2000
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020822 002</u>	Jul 17, 1998
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020822 003</u>	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 10MG BASE</u>	<u>A077289 001</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077289 002</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077289 003</u>	Nov 30, 2006
<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A077046 001</u>	Nov 24, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077046 002</u>	Nov 24, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077046 003</u>	Nov 24, 2004
<u>AB</u>	AUROBINDO	<u>EQ 10MG BASE</u>	<u>A077031 001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077031 002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077031 003</u>	Oct 28, 2004
<u>AB</u>	CIPLA LTD	<u>EQ 10MG BASE</u>	<u>A077044 001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077044 002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077044 003</u>	Nov 05, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A077038 001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077038 002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077038 003</u>	Oct 28, 2004

## PRESCRIPTION DRUG PRODUCT LIST

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

<b>AB</b>	EPIC PHARMA	<b>EQ 10MG BASE</b>	<b>A077045 003</b>	Apr 29, 2005
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077045 002</b>	Apr 29, 2005
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A077045 001</b>	Apr 29, 2005
<b>AB</b>	GLENMARK GENERICS	<b>EQ 10MG BASE</b>	<b>A077654 001</b>	Feb 27, 2009
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077654 002</b>	Feb 27, 2009
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A077654 003</b>	Feb 27, 2009
<b>AB</b>	INVAGEN PHARMS	<b>EQ 10MG BASE</b>	<b>A077534 001</b>	Oct 03, 2006
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077534 002</b>	Oct 03, 2006
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A077534 003</b>	Oct 03, 2006
<b>AB</b>	MYLAN	<b>EQ 10MG BASE</b>	<b>A077039 001</b>	Feb 03, 2005
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A077042 001</b>	Nov 05, 2004
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077039 002</b>	Feb 03, 2005
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077042 002</b>	Nov 05, 2004
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A077039 003</b>	Feb 03, 2005
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A077042 003</b>	Nov 05, 2004
<b>AB</b>	MYLAN PHARMS INC	<b>EQ 10MG BASE</b>	<b>A077037 001</b>	Nov 05, 2004
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077037 002</b>	Nov 05, 2004
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A077037 003</b>	Nov 05, 2004
<b>AB</b>	PLIVA	<b>EQ 10MG BASE</b>	<b>A077232 001</b>	Oct 31, 2005
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077232 002</b>	Oct 31, 2005
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A077232 003</b>	Oct 31, 2005
<b>AB</b>	SUN PHARM INDS INC	<b>EQ 10MG BASE</b>	<b>A077032 001</b>	Nov 12, 2004
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077032 002</b>	Nov 12, 2004
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A077032 003</b>	Nov 12, 2004
<b>AB</b>	TEVA PHARMS	<b>EQ 10MG BASE</b>	<b>A077048 001</b>	Nov 16, 2004
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A077048 002</b>	Nov 16, 2004
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A077048 003</b>	Nov 16, 2004
<b>AB</b>	TORRENT PHARMS	<b>EQ 10MG BASE</b>	<b>A078216 001</b>	Mar 27, 2007
<b>AB</b>		<b>EQ 20MG BASE</b>	<b>A078216 002</b>	Mar 27, 2007
<b>AB</b>		<b>EQ 40MG BASE</b>	<b>A078216 003</b>	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

RENACIDIN

+ UNITED GUARDIAN 6.602GM/100ML; 198MG/100ML; 3.177GM/100ML N019481 001 Oct 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+ FERRING PHARMS AS 12GM/PACKET; 3.5GM/PACKET; 10MG/PACKET N202535 001 Jul 16, 2012

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT:HP

+ EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

<b>AP</b>	EUROHLTH INTL	<b>1MG/ML</b>	<b>A075405 001</b>	Feb 28, 2000
<b>AP</b>	+ FRESENIUS KABI USA	<b>1MG/ML</b>	<b>A076571 001</b>	Apr 22, 2004
<b>AP</b>	ONCO THERAPIES LTD	<b>1MG/ML</b>	<b>A200510 001</b>	Oct 06, 2011

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

<b>AB</b>	ABBVIE	<b>125MG/5ML</b>	<b>N050698 001</b>	Dec 23, 1993
<b>AB</b>	+	<b>250MG/5ML</b>	<b>N050698 002</b>	Dec 23, 1993

CLARITHROMYCIN

<b>AB</b>	RANBAXY	<b>125MG/5ML</b>	<b>A065382 001</b>	Aug 30, 2007
<b>AB</b>		<b>250MG/5ML</b>	<b>A065382 002</b>	Aug 30, 2007
<b>AB</b>	SANDOZ	<b>125MG/5ML</b>	<b>A065283 002</b>	Sep 04, 2007
<b>AB</b>		<b>250MG/5ML</b>	<b>A065283 003</b>	Sep 04, 2007

TABLET; ORAL

BIAXIN

<b>AB</b>	+ ABBVIE	<b>250MG</b>	<b>N050662 001</b>	Oct 31, 1991
<b>AB</b>	+	<b>500MG</b>	<b>N050662 002</b>	Oct 31, 1991

CLARITHROMYCIN

<b>AB</b>	ALLIED PHARMA INC	<b>250MG</b>	<b>A202710 001</b>	Jun 10, 2013
<b>AB</b>		<b>500MG</b>	<b>A202710 002</b>	Jun 10, 2013
<b>AB</b>	APOTEX CORP	<b>250MG</b>	<b>A065384 001</b>	Aug 20, 2007
<b>AB</b>		<b>500MG</b>	<b>A065384 002</b>	Aug 20, 2007

## PRESCRIPTION DRUG PRODUCT LIST

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065489 001</u>	Jul 25, 2012
<u>AB</u>		<u>500MG</u>	<u>A065489 002</u>	Jul 25, 2012
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A065195 001</u>	Mar 11, 2005
<u>AB</u>		<u>500MG</u>	<u>A065195 002</u>	Mar 11, 2005
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065174 001</u>	Sep 24, 2004
<u>AB</u>		<u>500MG</u>	<u>A065174 002</u>	Sep 24, 2004
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A065178 002</u>	May 25, 2004
<u>AB</u>		<u>500MG</u>	<u>A065178 001</u>	May 25, 2004
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065144 001</u>	Oct 18, 2005
<u>AB</u>		<u>500MG</u>	<u>A065136 001</u>	Aug 25, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065155 001</u>	May 31, 2005
<u>AB</u>		<u>500MG</u>	<u>A065155 002</u>	May 31, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065266 001</u>	May 31, 2006
<u>AB</u>		<u>500MG</u>	<u>A065266 002</u>	May 31, 2006

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

<u>AB</u>	+ ABBVIE	<u>500MG</u>	<u>N050775 001</u>	Mar 03, 2000
-----------	----------	--------------	--------------------	--------------

CLARITHROMYCIN

<u>AB</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A065145 001</u>	Jun 24, 2004
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065154 001</u>	May 18, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

	+ GLAXOSMITHKLINE	EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL	N050590 003	Aug 18, 1987
		EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	A062691 001	Dec 19, 1986
	+	EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N050590 001	Apr 01, 1985
	+	EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL	N050590 002	Apr 01, 1985

TIMENTIN IN PLASTIC CONTAINER

	+ GLAXOSMITHKLINE	EQ 100MG BASE/100ML; EQ 3GM BASE/100ML	N050658 001	Dec 15, 1989
--	-------------------	----------------------------------------	-------------	--------------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

<u>AA</u>	+ TEVA	<u>EQ 0.5MG BASE/5ML</u>	<u>A073399 001</u>	Jun 30, 1994
<u>AA</u>	WOCKHARDT	<u>EQ 0.5MG BASE/5ML</u>	<u>A074863 001</u>	Mar 13, 1998

TABLET; ORAL

CLEMASTINE FUMARATE

<u>AB</u>	SANDOZ	<u>2.68MG</u>	<u>A073459 001</u>	Oct 31, 1993
<u>AB</u>	+ TEVA	<u>2.68MG</u>	<u>A073283 001</u>	Jan 31, 1992

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

	+ MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156 001	Aug 01, 2008
	+	50MG/100ML (0.5MG/ML)	N022156 002	Aug 01, 2008
	+	125MG/250ML (0.5MG/ML)	N022156 003	Nov 08, 2013

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

<u>AB</u>	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE</u>	<u>N050162 001</u>	
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>N050162 002</u>	
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N050162 003</u>	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 150MG BASE</u>	<u>A065442 001</u>	Aug 26, 2009
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065442 002</u>	Aug 26, 2009
<u>AB</u>	COREPHARMA	<u>EQ 150MG BASE</u>	<u>A065194 001</u>	Mar 22, 2004
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065194 002</u>	Mar 22, 2004
<u>AB</u>	LANNETT	<u>EQ 75MG BASE</u>	<u>A065242 001</u>	Aug 12, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065242 002</u>	Aug 12, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065243 001</u>	Aug 12, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A091225 001</u>	May 31, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091225 002</u>	May 31, 2011
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091225 003</u>	May 31, 2011
<u>AB</u>	RANBAXY	<u>EQ 150MG BASE</u>	<u>A065061 001</u>	Feb 02, 2001
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065061 002</u>	Feb 02, 2001
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A063029 001</u>	Sep 20, 1989
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063029 002</u>	Aug 05, 2005
<u>AB</u>	WATSON LABS	<u>EQ 150MG BASE</u>	<u>A063083 001</u>	Jul 31, 1991
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063083 002</u>	Mar 18, 2003



## PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 75MG BASE</u>	<u>A065217 001</u>	Jan 31, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065217 002</u>	Jan 31, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065217 003</u>	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

<u>AA</u>	+ PHARMACIA AND UPJOHN	<u>EQ 75MG BASE/5ML</u>	<u>A062644 001</u>	Apr 07, 1986
-----------	------------------------	-------------------------	--------------------	--------------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 75MG BASE/5ML</u>	<u>A203513 001</u>	Mar 13, 2014
<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 75MG BASE/5ML</u>	<u>A202409 001</u>	Apr 30, 2013
<u>AA</u>	LYNE	<u>EQ 75MG BASE/5ML</u>	<u>A201821 001</u>	Aug 28, 2012
<u>AA</u>	PADDOCK LABS	<u>EQ 75MG BASE/5ML</u>	<u>A090902 001</u>	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

<u>AT</u>	PERRIGO UK FINCO	<u>1%</u>	<u>A090785 001</u>	Mar 31, 2010
-----------	------------------	-----------	--------------------	--------------

EVOCLIN

<u>AT</u>	+ DELCOR ASSET	<u>1%</u>	<u>N050801 001</u>	Oct 22, 2004
-----------	----------------	-----------	--------------------	--------------

CREAM;VAGINAL

CLEOCIN

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 2% BASE</u>	<u>N050680 002</u>	Mar 02, 1998
-----------	------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 2% BASE</u>	<u>A065139 001</u>	Dec 27, 2004
-----------	----------------	-------------------	--------------------	--------------

CLINDESSE

+ ELAN PHARMA INTL LTD EQ 2% BASE

N050793 001 Nov 30, 2004

GEL;TOPICAL

CLEOCIN T

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050615 001</u>	Jan 07, 1987
-----------	------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A064160 001</u>	Jan 28, 2000
-----------	----------------	-------------------	--------------------	--------------

CLINDAGEL

<u>BT</u>	+ PRECISION DERMAT	<u>EQ 1% BASE</u>	<u>N050782 001</u>	Nov 27, 2000
-----------	--------------------	-------------------	--------------------	--------------

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

<u>AP</u>	PHARMACIA AND UPJOHN	<u>EQ 150MG BASE/ML</u>	<u>A062803 001</u>	Oct 16, 1987
-----------	----------------------	-------------------------	--------------------	--------------

<u>AP</u>	+	<u>EQ 150MG BASE/ML</u>	<u>N050441 001</u>	
-----------	---	-------------------------	--------------------	--

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 6MG BASE/ML</u>	<u>N050639 001</u>	Aug 30, 1989
-----------	------------------------	-----------------------	--------------------	--------------

<u>AP</u>	+	<u>EQ 12MG BASE/ML</u>	<u>N050639 002</u>	Aug 30, 1989
-----------	---	------------------------	--------------------	--------------

<u>AP</u>	+	<u>EQ 18MG BASE/ML</u>	<u>N050639 003</u>	Apr 10, 1991
-----------	---	------------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AP</u>	BEDFORD	<u>EQ 150MG BASE/ML</u>	<u>A065206 001</u>	Sep 24, 2004
-----------	---------	-------------------------	--------------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 150MG BASE/ML</u>	<u>A065346 001</u>	Mar 29, 2007
-----------	--------------------	-------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A065347 001</u>	May 09, 2007
-----------	--	-------------------------	--------------------	--------------

<u>AP</u>	HIKMA MAPLE	<u>EQ 150MG BASE/ML</u>	<u>A062889 001</u>	Apr 25, 1988
-----------	-------------	-------------------------	--------------------	--------------

<u>AP</u>	HOSPIRA	<u>EQ 150MG BASE/ML</u>	<u>A062800 001</u>	Jul 24, 1987
-----------	---------	-------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062801 001</u>	Jul 24, 1987
-----------	--	-------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062943 001</u>	Sep 29, 1988
-----------	--	-------------------------	--------------------	--------------

<u>AP</u>	SAGENT PHARMS	<u>EQ 150MG BASE/ML</u>	<u>A090108 001</u>	Sep 30, 2011
-----------	---------------	-------------------------	--------------------	--------------

<u>AP</u>	SAGENT STRIDES	<u>EQ 150MG BASE/ML</u>	<u>A090109 001</u>	Sep 30, 2011
-----------	----------------	-------------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

<u>AP</u>	AKORN INC	<u>EQ 6MG BASE/ML</u>	<u>A203048 001</u>	Apr 04, 2013
-----------	-----------	-----------------------	--------------------	--------------

<u>AP</u>		<u>EQ 12MG BASE/ML</u>	<u>A203048 002</u>	Apr 04, 2013
-----------	--	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 18MG BASE/ML</u>	<u>A203048 003</u>	Apr 04, 2013
-----------	--	------------------------	--------------------	--------------

<u>AP</u>	SANDOZ INC	<u>EQ 6MG BASE/ML</u>	<u>A201692 001</u>	May 31, 2012
-----------	------------	-----------------------	--------------------	--------------

<u>AP</u>		<u>EQ 12MG BASE/ML</u>	<u>A201692 002</u>	May 31, 2012
-----------	--	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 18MG BASE/ML</u>	<u>A201692 003</u>	May 31, 2012
-----------	--	------------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

+ ABRAXIS PHARM EQ 900MG BASE/100ML

N050635 001 Dec 22, 1989

LOTION;TOPICAL

CLEOCIN T

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050600 001</u>	May 31, 1989
-----------	------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065067 001</u>	Jan 31, 2002
-----------	----------------	-------------------	--------------------	--------------

SOLUTION;TOPICAL

CLEOCIN T

<u>AT</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537 001</u>	
-----------	------------------------	-------------------	--------------------	--

## PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDA-DERM

<b>AT</b>	PADDOCK LLC	<b>EQ 1% BASE</b>	<b>A063329 001</b>	Sep 30, 1992
-----------	-------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<b>AT</b>	FOUGERA	<b>EQ 1% BASE</b>	<b>A064159 001</b>	Jun 05, 1997
<b>AT</b>	FOUGERA PHARMS	<b>EQ 1% BASE</b>	<b>A065254 001</b>	Feb 14, 2006
<b>AT</b>	G AND W LABS INC	<b>EQ 1% BASE</b>	<b>A062811 001</b>	Sep 01, 1988
<b>AT</b>	PERRIGO NEW YORK	<b>EQ 1% BASE</b>	<b>A064050 001</b>	Nov 30, 1995
<b>AT</b>	TARO PHARM INDS	<b>EQ 1% BASE</b>	<b>A065184 001</b>	Mar 31, 2004
<b>AT</b>	WOCKHARDT	<b>EQ 1% BASE</b>	<b>A063304 001</b>	Jul 15, 1997

SUPPOSITORY; VAGINAL

CLEOCIN

+ PHARMACIA AND UPJOHN

100MG

N050767 001 Aug 13, 1999

SWAB; TOPICAL

CLEOCIN

<b>AT</b>	PHARMACIA AND UPJOHN	<b>EQ 1% BASE</b>	<b>N050537 002</b>	Feb 22, 1994
-----------	----------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<b>AT</b>	PERRIGO NEW YORK	<b>EQ 1% BASE</b>	<b>A065049 001</b>	May 25, 2000
-----------	------------------	-------------------	--------------------	--------------

<b>AT</b>	VERSAPHARM	<b>EQ 1% BASE</b>	<b>A065513 001</b>	Jun 17, 2010
-----------	------------	-------------------	--------------------	--------------

CLINDETS

<b>AT</b>	PERRIGO	<b>EQ 1% BASE</b>	<b>A064136 001</b>	Sep 30, 1996
-----------	---------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

<b>BX</b>	+ STIEFEL GSK	1.2%; 0.025%	N050803 001	Jul 16, 2010
-----------	---------------	--------------	-------------	--------------

ZIANA

<b>BX</b>	+ MEDICIS	1.2%; 0.025%	N050802 001	Nov 07, 2006
-----------	-----------	--------------	-------------	--------------

CLOBAZAM

SUSPENSION; ORAL

ONFI

+ LUNDBECK LLC

2.5MG/ML

N203993 001 Dec 14, 2012

TABLET; ORAL

ONFI

LUNDBECK LLC

10MG

N202067 002 Oct 21, 2011

+

20MG

N202067 003 Oct 21, 2011

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

<b>AB1</b>	PERRIGO ISRAEL	<b>0.05%</b>	<b>A077763 001</b>	Mar 10, 2008
------------	----------------	--------------	--------------------	--------------

OLUX

<b>AB1</b>	+ DELCOR ASSET	<b>0.05%</b>	<b>N021142 001</b>	May 26, 2000
------------	----------------	--------------	--------------------	--------------

CLOBETASOL PROPIONATE

<b>AB2</b>	PERRIGO ISRAEL	<b>0.05%</b>	<b>A201402 001</b>	Aug 14, 2012
------------	----------------	--------------	--------------------	--------------

OLUX E

<b>AB2</b>	+ DELCOR ASSET	<b>0.05%</b>	<b>N022013 001</b>	Jan 12, 2007
------------	----------------	--------------	--------------------	--------------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

<b>AB1</b>	FOUGERA	<b>0.05%</b>	<b>A074392 001</b>	Sep 30, 1996
------------	---------	--------------	--------------------	--------------

<b>AB1</b>	G AND W LABS INC	<b>0.05%</b>	<b>A074139 001</b>	Aug 03, 1994
------------	------------------	--------------	--------------------	--------------

<b>AB1</b>	TARO	<b>0.05%</b>	<b>A074249 001</b>	Jul 08, 1996
------------	------	--------------	--------------------	--------------

CORMAX

<b>AB1</b>	HI TECH PHARMA	<b>0.05%</b>	<b>A074220 001</b>	May 16, 1997
------------	----------------	--------------	--------------------	--------------

TEMOVATE

<b>AB1</b>	+ FOUGERA PHARMS	<b>0.05%</b>	<b>N019322 001</b>	Dec 27, 1985
------------	------------------	--------------	--------------------	--------------

CLOBETASOL PROPIONATE (EMOLLIENT)

<b>AB2</b>	FOUGERA PHARMS	<b>0.05%</b>	<b>A075430 001</b>	May 26, 1999
------------	----------------	--------------	--------------------	--------------

<b>AB2</b>	TARO	<b>0.05%</b>	<b>A075633 001</b>	May 17, 2000
------------	------	--------------	--------------------	--------------

EMBELINE E

<b>AB2</b>	HI TECH PHARMA	<b>0.05%</b>	<b>A075325 001</b>	Dec 24, 1998
------------	----------------	--------------	--------------------	--------------

TEMOVATE E

<b>AB2</b>	+ FOUGERA PHARMS	<b>0.05%</b>	<b>N020340 001</b>	Jun 17, 1994
------------	------------------	--------------	--------------------	--------------

GEL; TOPICAL

CLOBETASOL PROPIONATE

<b>AB</b>	FOUGERA PHARMS	<b>0.05%</b>	<b>A075368 001</b>	Feb 15, 2000
-----------	----------------	--------------	--------------------	--------------

<b>AB</b>	PERRIGO	<b>0.05%</b>	<b>A075027 001</b>	Oct 31, 1997
-----------	---------	--------------	--------------------	--------------

<b>AB</b>	TARO	<b>0.05%</b>	<b>A075279 001</b>	May 28, 1999
-----------	------	--------------	--------------------	--------------

EMBELINE

<b>AB</b>	HI TECH PHARMA	<b>0.05%</b>	<b>A076141 001</b>	Apr 12, 2002
-----------	----------------	--------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CLOBETASOL PROPIONATE

GEL; TOPICAL

TEMOVATE

**AB** + FOUGERA PHARMS **0.05%** **N020337 001** Apr 29, 1994  
 LOTION; TOPICAL

CLOBETASOL PROPIONATE

**AB** ACTAVIS MID ATLANTIC **0.05%** **A078223 001** Dec 04, 2008

**AB** TARO **0.05%** **A200302 001** Jul 02, 2012

CLOBEX

**AB** + GALDERMA LABS LP **0.05%** **N021535 001** Jul 24, 2003  
 OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

**AB** FOUGERA PHARMS **0.05%** **A074407 001** Feb 23, 1996

**AB** TARO **0.05%** **A074248 001** Jul 12, 1996

**AB** TEVA PHARMS **0.05%** **A074089 001** Feb 16, 1994

EMBELINE

**AB** HI TECH PHARMA **0.05%** **A074221 001** Mar 31, 1995

TEMOVATE

**AB** + FOUGERA PHARMS **0.05%** **N019323 001** Dec 27, 1985  
 SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

**AB** ACTAVIS MID ATLANTIC **0.05%** **A078854 001** Jun 07, 2011

**AB** PERRIGO ISRAEL **0.05%** **A090974 001** Aug 09, 2012

CLOBEX

**AB** + GALDERMA LABS **0.05%** **N021644 001** Feb 05, 2004  
 SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

**AT** FOUGERA PHARMS **0.05%** **A075391 001** Feb 08, 1999

**AT** TARO **0.05%** **A075224 001** Nov 16, 1998

**AT** **0.05%** **A075363 001** Dec 29, 2000

**AT** TOLMAR **0.05%** **A076977 001** Aug 05, 2005

**AT** WOCKHARDT **0.05%** **A075205 001** Nov 13, 1998

EMBELINE

**AT** + HI TECH PHARMA **0.05%** **A074222 001** Dec 06, 1995  
 SPRAY; TOPICAL

CLOBETASOL PROPIONATE

**AT** PADDOCK LLC **0.05%** **A090898 001** Jun 16, 2011

CLOBEX

**AT** + GALDERMA LABS LP **0.05%** **N021835 001** Oct 27, 2005

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+ PROMIUS PHARMA LLC 0.1%

N017765 001

CLOFARABINE

INJECTABLE; IV (INFUSION)

CLOLAR

+ GENZYME 20MG/20ML (1MG/ML)

N021673 001 Dec 28, 2004

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

+ NOVARTIS 50MG

N019500 002 Dec 15, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMID

**AB** + SANOFI AVENTIS US **50MG** **N016131 002**

CLOMIPHENE CITRATE

**AB** PAR PHARM **50MG** **A075528 001** Aug 30, 1999

SEROPHENE

**AB** EMD SERONO **50MG** **N018361 001** Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

**AB** MALLINCKRODT LLC **25MG** **N019906 001** Dec 29, 1989

**AB** + **50MG** **N019906 002** Dec 29, 1989

**AB** **75MG** **N019906 003** Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

**AB** MYLAN **25MG** **A074947 001** Apr 30, 1998

**AB** **50MG** **A074947 002** Apr 30, 1998

**AB** **75MG** **A074947 003** Apr 30, 1998

**AB** SANDOZ **25MG** **A074364 001** Mar 29, 1996

## PRESCRIPTION DRUG PRODUCT LIST

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A074364 002</u>	Mar 29, 1996
<u>AB</u>		<u>75MG</u>	<u>A074364 003</u>	Mar 29, 1996
<u>AB</u>	TARO	<u>25MG</u>	<u>A074694 001</u>	Dec 31, 1996
<u>AB</u>		<u>50MG</u>	<u>A074694 002</u>	Dec 31, 1996
<u>AB</u>		<u>75MG</u>	<u>A074694 003</u>	Dec 31, 1996
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074958 001</u>	Aug 26, 1997
<u>AB</u>		<u>50MG</u>	<u>A074958 002</u>	Aug 26, 1997
<u>AB</u>		<u>75MG</u>	<u>A074958 003</u>	Aug 26, 1997

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	ACCORD HLTHCARE	<u>0.5MG</u>	<u>A077147 001</u>	May 02, 2005
<u>AB</u>		<u>1MG</u>	<u>A077147 002</u>	May 02, 2005
<u>AB</u>		<u>2MG</u>	<u>A077147 003</u>	May 02, 2005
<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A074869 001</u>	Oct 31, 1996
<u>AB</u>		<u>1MG</u>	<u>A074869 002</u>	Oct 31, 1996
<u>AB</u>		<u>2MG</u>	<u>A074869 003</u>	Oct 31, 1996
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A075150 001</u>	Oct 05, 1998
<u>AB</u>		<u>1MG</u>	<u>A075150 002</u>	Oct 05, 1998
<u>AB</u>		<u>2MG</u>	<u>A075150 003</u>	Oct 05, 1998
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A074940 001</u>	Oct 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074940 002</u>	Oct 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074940 003</u>	Oct 30, 1997
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074979 001</u>	Aug 29, 1997
<u>AB</u>		<u>1MG</u>	<u>A074979 002</u>	Aug 29, 1997
<u>AB</u>		<u>2MG</u>	<u>A074979 003</u>	Aug 29, 1997
<u>AB</u>	SUN PHARM INDS INC	<u>0.5MG</u>	<u>A075423 001</u>	Apr 27, 2001
<u>AB</u>		<u>1MG</u>	<u>A075423 002</u>	Apr 27, 2001
<u>AB</u>		<u>2MG</u>	<u>A075423 003</u>	Apr 27, 2001
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A074569 001</u>	Sep 10, 1996
<u>AB</u>		<u>1MG</u>	<u>A074569 002</u>	Sep 10, 1996
<u>AB</u>		<u>2MG</u>	<u>A074569 003</u>	Sep 10, 1996
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077856 001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856 002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856 003</u>	Jun 28, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A074964 001</u>	Dec 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074964 002</u>	Dec 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074964 003</u>	Dec 30, 1997

KLONOPIN

<u>AB</u>	ROCHE	<u>0.5MG</u>	<u>N017533 001</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N017533 002</u>	
<u>AB</u>		<u>2MG</u>	<u>N017533 003</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194 001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194 002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194 003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194 004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194 005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171 001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171 002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171 003</u>	Aug 03, 2005
<u>AB</u>	+	<u>1MG</u>	<u>A077171 004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171 005</u>	Aug 03, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A078654 001</u>	Aug 27, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A078654 002</u>	Aug 27, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078654 003</u>	Aug 27, 2014
<u>AB</u>		<u>1MG</u>	<u>A078654 004</u>	Aug 27, 2014
<u>AB</u>		<u>2MG</u>	<u>A078654 005</u>	Aug 27, 2014

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891 001</u>	Oct 10, 1984
-----------	----------------------	-------------------	--------------------	--------------

CATAPRES-TTS-2

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891 002</u>	Oct 10, 1984
-----------	----------------------	-------------------	--------------------	--------------

CATAPRES-TTS-3

<u>AB</u>	+	<u>0.3MG/24HR</u>	<u>N018891 003</u>	Oct 10, 1984
-----------	---	-------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157 001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157 002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157 003</u>	Aug 18, 2009
<u>AB</u>	BARR	<u>0.1MG/24HR</u>	<u>A079090 001</u>	Aug 20, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A079090 002</u>	Aug 20, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A079090 003</u>	Aug 20, 2010
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166 001</u>	Jul 16, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076166 002</u>	Jul 16, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076166 003</u>	Jul 16, 2010
<u>AB</u>	WATSON LABS INC	<u>0.1MG/24HR</u>	<u>A090873 001</u>	May 06, 2014
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A090873 002</u>	May 06, 2014
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A090873 003</u>	May 06, 2014

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	EXELA PHARMA SCS LLC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A203167 001</u>	Oct 29, 2013
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A203167 002</u>	Oct 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200673 001</u>	Jul 08, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200673 002</u>	Jul 08, 2011
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200300 001</u>	Jan 26, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200300 002</u>	Jan 26, 2011
<u>AP</u>	LUITPOLD	<u>1MG/10ML (0.1MG/ML)</u>	<u>A091104 001</u>	Oct 08, 2009
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A091104 002</u>	Oct 08, 2009
<u>AP</u>	ZYDUS PHARMS USA INC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A202601 001</u>	Feb 20, 2014
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A202601 002</u>	Feb 20, 2014

DURACLON

<u>AP</u>	MYLAN INSTITUTIONAL	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020615 001</u>	Oct 02, 1996
<u>AP</u>	+	<u>5MG/10ML (0.5MG/ML)</u>	<u>N020615 002</u>	Apr 27, 1999

TABLET; ORAL

CATAPRES

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG</u>	<u>N017407 001</u>	
<u>AB</u>		<u>0.2MG</u>	<u>N017407 002</u>	
<u>AB</u>	+	<u>0.3MG</u>	<u>N017407 003</u>	

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974 001</u>	Dec 16, 1986
<u>AB</u>		<u>0.2MG</u>	<u>A070975 001</u>	Dec 16, 1986
<u>AB</u>		<u>0.3MG</u>	<u>A070976 001</u>	Dec 16, 1986
<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.1MG</u>	<u>A091368 001</u>	Dec 06, 2011
<u>AB</u>		<u>0.2MG</u>	<u>A091368 002</u>	Dec 06, 2011
<u>AB</u>		<u>0.3MG</u>	<u>A091368 003</u>	Dec 06, 2011
<u>AB</u>	CARLSBAD	<u>0.1MG</u>	<u>A202297 001</u>	Jun 13, 2013
<u>AB</u>		<u>0.2MG</u>	<u>A202297 002</u>	Jun 13, 2013
<u>AB</u>		<u>0.3MG</u>	<u>A202297 003</u>	Jun 13, 2013
<u>AB</u>	DAVA PHARMS INC	<u>0.1MG</u>	<u>A071783 001</u>	Apr 05, 1988
<u>AB</u>		<u>0.2MG</u>	<u>A071784 001</u>	Apr 05, 1988
<u>AB</u>		<u>0.3MG</u>	<u>A071785 001</u>	Apr 05, 1988
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099 001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099 002</u>	Aug 27, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078099 003</u>	Aug 27, 2009
<u>AB</u>	MUTUAL PHARM	<u>0.1MG</u>	<u>A070925 001</u>	Sep 04, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070924 001</u>	Sep 04, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070923 001</u>	Sep 04, 1987
<u>AB</u>	MYLAN	<u>0.1MG</u>	<u>A070317 002</u>	Jul 09, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070317 003</u>	Jun 09, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070317 001</u>	Jun 09, 1987
<u>AB</u>	SUN PHARM INDS INC	<u>0.1MG</u>	<u>A090329 001</u>	Jul 03, 2014
<u>AB</u>		<u>0.2MG</u>	<u>A090329 002</u>	Jul 03, 2014
<u>AB</u>		<u>0.3MG</u>	<u>A090329 003</u>	Jul 03, 2014
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895 001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895 002</u>	Aug 26, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078895 003</u>	Aug 26, 2009
<u>AB</u>	VINTAGE	<u>0.1MG</u>	<u>A077901 001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901 002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901 003</u>	Mar 09, 2007

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>0.1MG</u>	<u>A202983 001</u>	Apr 02, 2014
<u>AB</u>		<u>0.2MG</u>	<u>A202983 002</u>	Apr 02, 2014

## PRESCRIPTION DRUG PRODUCT LIST

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>0.1MG</u>	<u>A202984</u>	<u>001</u>	Sep 30, 2013
<u>AB</u>		<u>0.2MG</u>	<u>A202984</u>	<u>002</u>	Sep 30, 2013

KAPVAY

<u>AB</u>	+ CONCORDIA PHARMS INC	<u>0.1MG</u>	<u>N022331</u>	<u>003</u>	Sep 28, 2010
<u>AB</u>		<u>0.2MG</u>	<u>N022331</u>	<u>004</u>	Sep 28, 2010

CLOPIDOGREL

TABLET;ORAL

CLOPIDOGREL

<u>AB</u>	AMNEAL PHARMS	<u>75MG</u>	<u>A203751</u>	<u>001</u>	Apr 11, 2014
-----------	---------------	-------------	----------------	------------	--------------

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 75MG BASE</u>	<u>A202925</u>	<u>001</u>	Mar 27, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202925</u>	<u>002</u>	Mar 27, 2013
<u>AB</u>	ACTAVIS TOTOWA	<u>EQ 75MG BASE</u>	<u>A090307</u>	<u>001</u>	May 28, 2013
<u>AB</u>	APOTEX INC	<u>EQ 75MG BASE</u>	<u>A076274</u>	<u>001</u>	May 17, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076274</u>	<u>002</u>	Mar 04, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 75MG BASE</u>	<u>A090540</u>	<u>001</u>	May 17, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 75MG BASE</u>	<u>A076273</u>	<u>001</u>	Jan 14, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 300MG BASE</u>	<u>A091023</u>	<u>001</u>	May 17, 2012
<u>AB</u>	GATE PHARMS	<u>EQ 300MG BASE</u>	<u>A091216</u>	<u>001</u>	May 17, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A202928</u>	<u>001</u>	Feb 10, 2014
<u>AB</u>	MUTUAL PHARM	<u>EQ 75MG BASE</u>	<u>A078133</u>	<u>001</u>	Jun 10, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A077665</u>	<u>001</u>	May 17, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077665</u>	<u>002</u>	May 17, 2012
<u>AB</u>	ROXANE	<u>EQ 75MG BASE</u>	<u>A078004</u>	<u>001</u>	May 17, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A204165</u>	<u>001</u>	Sep 15, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204165</u>	<u>002</u>	Sep 15, 2014
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 75MG BASE</u>	<u>A090494</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TEVA	<u>EQ 75MG BASE</u>	<u>A076999</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 300MG BASE</u>	<u>A090625</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A090844</u>	<u>001</u>	May 17, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 75MG BASE</u>	<u>A202266</u>	<u>001</u>	Aug 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202266</u>	<u>002</u>	Nov 20, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 75MG BASE</u>	<u>A201686</u>	<u>001</u>	Oct 10, 2012

PLAVIX

<u>AB</u>	SANOFI AVENTIS US	<u>EQ 75MG BASE</u>	<u>N020839</u>	<u>001</u>	Nov 17, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N020839</u>	<u>002</u>	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

<u>AB</u>	MYLAN	<u>3.75MG</u>	<u>A071858</u>	<u>002</u>	Jul 17, 1987
<u>AB</u>		<u>7.5MG</u>	<u>A071858</u>	<u>003</u>	Jul 17, 1987
<u>AB</u>		<u>15MG</u>	<u>A071858</u>	<u>001</u>	Jul 17, 1987
<u>AB</u>	RANBAXY	<u>3.75MG</u>	<u>A076911</u>	<u>001</u>	Sep 29, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A076911</u>	<u>002</u>	Sep 29, 2004
<u>AB</u>		<u>15MG</u>	<u>A076911</u>	<u>003</u>	Sep 29, 2004
<u>AB</u>	TARO	<u>3.75MG</u>	<u>A075731</u>	<u>003</u>	Apr 27, 2000
<u>AB</u>		<u>7.5MG</u>	<u>A075731</u>	<u>002</u>	Apr 27, 2000
<u>AB</u>		<u>15MG</u>	<u>A075731</u>	<u>001</u>	Apr 27, 2000

GEN-XENE

<u>AB</u>	ALRA	<u>3.75MG</u>	<u>A071787</u>	<u>001</u>	Apr 26, 1988
<u>AB</u>		<u>7.5MG</u>	<u>A071788</u>	<u>001</u>	Apr 26, 1988
<u>AB</u>		<u>15MG</u>	<u>A071789</u>	<u>001</u>	Apr 26, 1988

TRANXENE

<u>AB</u>	RECORDATI RARE	<u>3.75MG</u>	<u>N017105</u>	<u>006</u>	
<u>AB</u>		<u>7.5MG</u>	<u>N017105</u>	<u>007</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017105</u>	<u>008</u>	

CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE

<u>AB</u>	FOUGERA PHARMS	<u>1%</u>	<u>A078338</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>	GLENMARK PHARMS	<u>1%</u>	<u>A090219</u>	<u>001</u>	Aug 03, 2010
<u>AB</u>	+	<u>1%</u>	<u>A072640</u>	<u>001</u>	Aug 31, 1993

SOLUTION;TOPICAL

CLOTRIMAZOLE

<u>AT</u>	+	<u>1%</u>	<u>A074580</u>	<u>001</u>	Jul 29, 1996
-----------	---	-----------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CLOTRIMAZOLE

SOLUTION; TOPICAL

CLOTRIMAZOLE

<b>AT</b>	TEVA	<b>1%</b>	<b>A073306 001</b>	Feb 28, 1995
-----------	------	-----------	--------------------	--------------

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

<b>AB</b>	PADDOCK LLC	<b>10MG</b>	<b>A076763 001</b>	Oct 28, 2005
<b>AB</b>	+ ROXANE	<b>10MG</b>	<b>A076387 001</b>	Jul 29, 2004

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

	+ JAZZ PHARMS III	50MG/ML	N203479 001	Feb 06, 2013
--	-------------------	---------	-------------	--------------

TABLET; ORAL

CLOZAPINE

<b>AB</b>	IVAX SUB TEVA PHARMS	<b>12.5MG</b>	<b>A074949 003</b>	Jul 31, 2003
<b>AB</b>		<b>25MG</b>	<b>A074949 001</b>	Nov 26, 1997
<b>AB</b>		<b>50MG</b>	<b>A074949 004</b>	Apr 25, 2005
<b>AB</b>		<b>50MG</b>	<b>A076809 003</b>	Dec 16, 2005
<b>AB</b>		<b>100MG</b>	<b>A074949 002</b>	Nov 26, 1997
<b>AB</b>		<b>100MG</b>	<b>A076809 002</b>	Dec 16, 2005
<b>AB</b>		<b>200MG</b>	<b>A076809 001</b>	Dec 16, 2005
<b>AB</b>	MYLAN	<b>12.5MG</b>	<b>A075417 003</b>	Apr 15, 2010
<b>AB</b>		<b>25MG</b>	<b>A075417 001</b>	May 27, 1999
<b>AB</b>		<b>50MG</b>	<b>A075417 004</b>	Apr 15, 2010
<b>AB</b>		<b>100MG</b>	<b>A075417 002</b>	May 27, 1999
<b>AB</b>		<b>200MG</b>	<b>A075417 005</b>	Apr 15, 2010
<b>AB</b>	SUN PHARM INDS INC	<b>25MG</b>	<b>A075713 001</b>	Nov 15, 2002
<b>AB</b>		<b>50MG</b>	<b>A075713 003</b>	Aug 19, 2005
<b>AB</b>		<b>100MG</b>	<b>A075713 002</b>	Nov 15, 2002

CLOZARIL

<b>AB</b>	NOVARTIS	<b>25MG</b>	<b>N019758 001</b>	Sep 26, 1989
<b>AB</b>	+ JAZZ PHARMS III	<b>100MG</b>	<b>N019758 002</b>	Sep 26, 1989

TABLET, ORALLY DISINTEGRATING; ORAL  
FAZACLO ODT

	JAZZ PHARMS III	12.5MG	N021590 004	May 30, 2007
		25MG	N021590 001	Feb 10, 2004
	+ JAZZ PHARMS III	100MG	N021590 002	Feb 10, 2004
		150MG	N021590 005	Jul 09, 2010
		200MG	N021590 006	Jul 09, 2010

COBICISTAT

TABLET; ORAL

TYBOST

	+ GILEAD SCIENCES INC	150MG	N203094 001	Sep 24, 2014
--	-----------------------	-------	-------------	--------------

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

	+ GILEAD SCIENCES INC	150MG; 150MG; 200MG; 300MG	N203100 001	Aug 27, 2012
--	-----------------------	----------------------------	-------------	--------------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

<b>AA</b>	VINTAGE	<b>10MG/5ML; 5MG/5ML; 6.25MG/5ML</b>	<b>A040660 001</b>	Dec 07, 2006
<b>AA</b>	+ ACTAVIS MID ATLANTIC	<b>10MG/5ML; 5MG/5ML; 6.25MG/5ML</b>	<b>A088764 001</b>	Oct 31, 1984

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

<b>AA</b>	HI-TECH PHARMA CO	<b>10MG/5ML; 5MG/5ML; 6.25MG/5ML</b>	<b>A040674 001</b>	Dec 23, 2014
-----------	-------------------	--------------------------------------	--------------------	--------------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

<b>AA</b>	+ ACTAVIS MID ATLANTIC	<b>10MG/5ML; 6.25MG/5ML</b>	<b>A088763 001</b>	Oct 31, 1984
<b>AA</b>	AMNEAL PHARMS	<b>10MG/5ML; 6.25MG/5ML</b>	<b>A200894 001</b>	Apr 24, 2013
<b>AA</b>	HI TECH PHARMA	<b>10MG/5ML; 6.25MG/5ML</b>	<b>A040151 001</b>	Aug 26, 1997
<b>AA</b>	SUN PHARM INDS INC	<b>10MG/5ML; 6.25MG/5ML</b>	<b>A090180 001</b>	Mar 17, 2010
<b>AA</b>	TRIS PHARMA INC	<b>10MG/5ML; 6.25MG/5ML</b>	<b>A200386 001</b>	Jun 29, 2012
<b>AA</b>	WOCKHARDT	<b>10MG/5ML; 6.25MG/5ML</b>	<b>A088875 001</b>	Dec 17, 1984

PROMETHAZINE WITH CODEINE

<b>AA</b>	VINTAGE	<b>10MG/5ML; 6.25MG/5ML</b>	<b>A040650 001</b>	Jan 31, 2006
-----------	---------	-----------------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

+ STI PHARMA LLC

10MG/5ML; 30MG/5ML; 1.25MG/5ML

A088704 001 Mar 22, 1985

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

+ ROXANE

30MG/5ML

N202245 001 Jun 30, 2011

TABLET; ORAL

CODEINE SULFATE**AB** LANNETT HOLDINGS INC**15MG****A203046 001** Jun 13, 2014**AB** **30MG****A203046 002** Jun 13, 2014**AB** **60MG****A203046 003** Jun 13, 2014**AB** ROXANE **15MG****N022402 001** Jul 16, 2009**AB** **30MG****N022402 002** Jul 16, 2009**AB** + **60MG****N022402 003** Jul 16, 2009COLCHICINE

CAPSULE; ORAL

MITIGARE

HIKMA PHARMS LLC

0.6MG

N204820 001 Sep 26, 2014

TABLET; ORAL

COLCRYS

+ TAKEDA PHARMS USA

0.6MG

N022352 001 Jul 29, 2009

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID**AB** + WATSON LABS**0.5MG; 500MG****A084279 001**PROBENECID AND COLCHICINE**AB** MIRROR PHARMS**0.5MG; 500MG****A040618 001** May 13, 2008COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

WELCHOL

DAIICHI SANKYO

1.875GM/PACKET

N022362 001 Oct 02, 2009

+

3.75GM/PACKET

N022362 002 Oct 02, 2009

TABLET; ORAL

WELCHOL

+ DAIICHI SANKYO

625MG

N021176 001 May 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID**AB** PHARMACIA AND UPJOHN**5GM/SCOOPFUL****N017563 003** Sep 22, 1995**AB** + **5GM/PACKET****N017563 004** Sep 22, 1995COLESTIPOL HYDROCHLORIDE**AB** IMPAX LABS**5GM/SCOOPFUL****A077277 001** May 02, 2006**AB** **5GM/PACKET****A077277 002** May 02, 2006

FLAVORED COLESTID

PHARMACIA AND UPJOHN

5GM/PACKET

N017563 001

5GM/SCOOPFUL

N017563 002

TABLET; ORAL

COLESTID**AB** + PHARMACIA AND UPJOHN**1GM****N020222 001** Jul 19, 1994COLESTIPOL HYDROCHLORIDE**AB** IMPAX LABS**1GM****A077510 001** Oct 24, 2006COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM**AP** EMCURE PHARMS LTD**EQ 150MG BASE/VIAL****A202359 001** Sep 28, 2012**AP** FRESENIUS KABI USA**EQ 150MG BASE/VIAL****A065364 001** Apr 17, 2008**AP** PADDOCK LLC**EQ 150MG BASE/VIAL****A065177 001** Mar 19, 2004**AP** SAGENT PHARMS**EQ 150MG BASE/VIAL****A201365 001** Feb 19, 2014**AP** X GEN PHARMS**EQ 150MG BASE/VIAL****A064216 001** Feb 26, 1999COLY-MYCIN M**AP** + PAR STERILE PRODUCTS**EQ 150MG BASE/VIAL****N050108 002**



## PRESCRIPTION DRUG PRODUCT LIST

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+ PAR STERILE PRODUCTS	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356 001
------------------------	--------------------------------------------------------	-------------

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+ CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697 002	Oct 08, 2008
---------------------	-----------------------	-------------	--------------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+ TEVA WOMENS	309MG/COPPER	N018680 001	Nov 15, 1984
---------------	--------------	-------------	--------------

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION

ACTHREL

+ FERRING	EQ 0.1MG BASE/VIAL	N020162 001	May 23, 1996
-----------	--------------------	-------------	--------------

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

+ QUESTCOR PHARMS	80 UNITS/ML	N008372 008
-------------------	-------------	-------------

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

+ HIKMA INTL PHARMS	25MG	A080776 002
---------------------	------	-------------

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

<b>AP</b> + AMPHASTAR PHARMS INC	<b>0.25MG/VIAL</b>	<b>N016750 001</b>
----------------------------------	--------------------	--------------------

COSYNTROPIN

<b>AP</b> MYLAN INSTITUTIONAL	<b>0.25MG/VIAL</b>	<b>A090574 001</b>	Dec 17, 2009
-------------------------------	--------------------	--------------------	--------------

<b>AP</b> SANDOZ	<b>0.25MG/VIAL</b>	<b>A202147 001</b>	Jun 29, 2012
------------------	--------------------	--------------------	--------------

CRIZOTINIB

CAPSULE; ORAL

XALKORI

PF PRISM CV	200MG	N202570 001	Aug 26, 2011
-------------	-------	-------------	--------------

+	250MG	N202570 002	Aug 26, 2011
---	-------	-------------	--------------

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

FULYZAQ

+ SALIX PHARMS	125MG	N202292 001	Dec 31, 2012
----------------	-------	-------------	--------------

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

<b>AA</b> MICRO LABS LTD INDIA	<b>100MG/5ML</b>	<b>A202745 001</b>	Apr 04, 2013
--------------------------------	------------------	--------------------	--------------

<b>AA</b> PACK PHARMS LLC	<b>100MG/5ML</b>	<b>A202583 001</b>	Oct 27, 2011
---------------------------	------------------	--------------------	--------------

GASTROCROM

<b>AA</b> + MEDA PHARMS	<b>100MG/5ML</b>	<b>N020479 001</b>	Feb 29, 1996
-------------------------	------------------	--------------------	--------------

SOLUTION; INHALATION

CROMOLYN SODIUM

<b>AN</b> BAUSCH AND LOMB	<b>10MG/ML</b>	<b>A075585 001</b>	Dec 21, 2000
---------------------------	----------------	--------------------	--------------

<b>AN</b> MYLAN SPECLT	<b>10MG/ML</b>	<b>A074209 001</b>	Apr 26, 1994
------------------------	----------------	--------------------	--------------

<b>AN</b> + TEVA PHARMS	<b>10MG/ML</b>	<b>A075271 001</b>	Jan 18, 2000
-------------------------	----------------	--------------------	--------------

<b>AN</b> WOCKHARDT	<b>10MG/ML</b>	<b>A075346 001</b>	Oct 25, 1999
---------------------	----------------	--------------------	--------------

SOLUTION/DROPS; OPHTHALMIC

CROLOM

<b>AT</b> BAUSCH AND LOMB	<b>4%</b>	<b>A074443 001</b>	Jan 30, 1995
---------------------------	-----------	--------------------	--------------

CROMOLYN SODIUM

<b>AT</b> + AKORN	<b>4%</b>	<b>A074706 001</b>	Apr 29, 1998
-------------------	-----------	--------------------	--------------

<b>AT</b> ALCON	<b>4%</b>	<b>A075282 001</b>	Jun 16, 1999
-----------------	-----------	--------------------	--------------

CROTAMITON

CREAM; TOPICAL

EURAX

+ RANBAXY	10%	N006927 001
-----------	-----	-------------

LOTION; TOPICAL

CROTAN

<b>AT</b> SUMMERS	<b>10%</b>	<b>A087204 001</b>
-------------------	------------	--------------------

## PRESCRIPTION DRUG PRODUCT LIST

CROTAMITON

LOTION; TOPICAL

EURAX**AT** + RANBAXY **10%** **N009112 003**CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 0.4MG COPPER/ML

N018960 001 Jun 26, 1986

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN**AP** + LUITPOLD **1MG/ML** **A080737 001**VIBISONE**AP** + FRESENIUS KABI USA **1MG/ML** **A080557 003**

SPRAY, METERED; NASAL

NASCOBAL

+ PAR PHARM

0.5MG/SPRAY

N021642 001 Jan 31, 2005

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX**AB** IVAX INTL **15MG** **N021777 001** Feb 01, 2007**AB** + **30MG** **N021777 002** Feb 01, 2007CYCLOBENZAPRINE HYDROCHLORIDE**AB** TWI PHARMS INC **15MG** **A091281 001** Jan 31, 2013**AB** **30MG** **A091281 002** Jan 31, 2013

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE**AB** ACTAVIS LABS FL INC **5MG** **A071611 002** Feb 03, 2006**AB** **7.5MG** **A071611 003** Feb 03, 2006**AB** **10MG** **A071611 001** May 03, 1989**AB** AUROBINDO PHARMA **5MG** **A078643 001** Sep 26, 2008**AB** **10MG** **A078643 002** Sep 26, 2008**AB** INVAGEN PHARMS **5MG** **A090478 001** Jul 23, 2010**AB** **10MG** **A090478 002** Jul 23, 2010**AB** JUBILANT CADISTA **5MG** **A077563 001** Apr 19, 2006**AB** **10MG** **A077563 002** Apr 19, 2006**AB** KVK TECH **5MG** **A078048 001** Feb 28, 2011**AB** **10MG** **A078048 002** Feb 28, 2011**AB** MUTUAL PHARM **5MG** **A073541 002** Apr 06, 2006**AB** **10MG** **A073541 001** May 23, 1995**AB** MYLAN PHARMS INC **5MG** **A073144 002** Feb 03, 2006**AB** **7.5MG** **A073144 003** Mar 25, 2013**AB** + **10MG** **A073144 001** May 30, 1991**AB** ORIT LABS LLC **10MG** **A078218 001** Apr 18, 2008**AB** PLIVA **10MG** **A074421 001** Sep 29, 1995**AB** PROSAM LABS **10MG** **A077209 001** Oct 04, 2005**AB** RANBAXY **5MG** **A078722 001** May 12, 2008**AB** **7.5MG** **A078722 002** May 12, 2008**AB** **10MG** **A078722 003** May 12, 2008**AB** VINTAGE PHARMS **5MG** **A077797 001** Feb 28, 2007**AB** **10MG** **A077797 002** Feb 28, 2007CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE**AT** AKORN **1%** **A040164 001** Jan 13, 1997CYCLOGYL**AT** + ALCON **1%** **A084110 001**PENTOLAIR**AT** BAUSCH AND LOMB **1%** **A040075 001** Apr 29, 1994CYCLOGYL

+ ALCON

0.5%

A084109 001

+ ALCON LABS INC

2%

A084108 001

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

+ ALCON

0.2%; 1%

A084300 001

## PRESCRIPTION DRUG PRODUCT LIST

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

ROXANE

25MG

N203856 001 Sep 16, 2013

+

50MG

N203856 002 Sep 16, 2013

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDEAP + BAXTER HLTHCARE1GM/VIALA040745 002 May 21, 2008AP +2GM/VIALA040745 003 May 21, 2008AP +500MG/VIALA040745 001 May 21, 2008AP JIANGSU HENGRUI MED1GM/VIALA204555 002 Oct 31, 2014AP2GM/VIALA204555 003 Oct 31, 2014AP500MG/VIALA204555 001 Oct 31, 2014CYTOXAN (LYOPHILIZED)AP + BAXTER HLTHCARE1GM/VIALN012142 004 Aug 30, 1982AP +2GM/VIALN012142 005 Aug 30, 1982AP +500MG/VIALN012142 003

TABLET; ORAL

CYCLOPHOSPHAMIDE

ROXANE

25MG

A040032 001 Aug 17, 1999

+

50MG

A040032 002 Aug 17, 1999

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

+ PURDUE GMP

250MG

A060593 001

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINEAB1 IVAX SUB TEVA PHARMS25MGA065110 003 Mar 29, 2005AB150MGA065110 001 Mar 29, 2005AB1100MGA065110 002 Mar 29, 2005AB1 SANDOZ25MGA065017 002 Jan 13, 2000AB1100MGA065017 001 Jan 13, 2000AB1 WATSON LABS INC25MGA065044 002 Dec 20, 2000AB1100MGA065044 001 Dec 20, 2000GENGRAFAB1 ABBVIE25MGA065003 001 May 12, 2000AB150MGA065003 002 May 12, 2000AB1100MGA065003 003 May 12, 2000NEORALAB1 NOVARTIS25MGN050715 001 Jul 14, 1995AB1 +100MGN050715 002 Jul 14, 1995CYCLOSPORINEAB2 APOTEX25MGA065040 001 May 09, 2002AB2100MGA065040 002 May 09, 2002SANDIMMUNEAB2 NOVARTIS25MGN050625 001 Mar 02, 1990AB2 +100MGN050625 002 Mar 02, 1990

BX

50MG

N050625 003 Nov 23, 1992

EMULSION; OPHTHALMIC

RESTASIS

+ ALLERGAN

0.05%

N050790 001 Dec 23, 2002

INJECTABLE; INJECTION

CYCLOSPORINEAP EUROHLTH INTL50MG/MLA065004 001 Oct 29, 1999AP

LUITPOLD

50MG/MLA065151 001 Oct 07, 2003SANDIMMUNEAP + NOVARTIS50MG/MLN050573 001 Nov 14, 1983

SOLUTION; ORAL

CYCLOSPORINEAB1 ABBVIE100MG/MLA065025 001 Mar 03, 2000AB1

IVAX SUB TEVA PHARMS

100MG/MLA065078 001 Mar 25, 2005AB1

WATSON LABS

100MG/MLA065054 001 Dec 18, 2001NEORALAB1 + NOVARTIS100MG/MLN050716 001 Jul 14, 1995CYCLOSPORINEAB2 WOCKHARDT100MG/MLA065133 001 Sep 17, 2004SANDIMMUNEAB2 + NOVARTIS100MG/MLN050574 001 Nov 14, 1983

## PRESCRIPTION DRUG PRODUCT LIST

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	+	LYNE	<u>2MG/5ML</u>	<u>A040668</u>	<u>001</u>	Jun 28, 2006
<u>AA</u>		PHARM ASSOC	<u>2MG/5ML</u>	<u>A091295</u>	<u>001</u>	Mar 28, 2013

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>		COREPHARMA	<u>4MG</u>	<u>A040537</u>	<u>001</u>	Sep 30, 2003
<u>AA</u>	+	IVAX SUB TEVA PHARMS	<u>4MG</u>	<u>A087056</u>	<u>001</u>	
<u>AA</u>		PAR PHARM	<u>4MG</u>	<u>A087129</u>	<u>001</u>	
<u>AA</u>		STASON PHARMS	<u>4MG</u>	<u>A040644</u>	<u>001</u>	May 30, 2006

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

		MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
	+		EQ 150MG BASE	N020392	002	Aug 15, 1994

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

		RAPTOR INC	EQ 25MG BASE	N203389	001	Apr 30, 2013
	+		EQ 75MG BASE	N203389	002	Apr 30, 2013

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYSTARAN

	+	SIGMA TAU	EQ 0.44% BASE	N200740	001	Oct 02, 2012
--	---	-----------	---------------	---------	-----	--------------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

<u>AP</u>		EUROHLTH INTL	<u>1GM/VIAL</u>	<u>A074245</u>	<u>001</u>	Aug 31, 1994
<u>AP</u>			<u>2GM/VIAL</u>	<u>A074245</u>	<u>002</u>	Aug 31, 1994
<u>AP</u>			<u>100MG/VIAL</u>	<u>A071471</u>	<u>001</u>	Aug 02, 1989
<u>AP</u>			<u>500MG/VIAL</u>	<u>A071472</u>	<u>001</u>	Aug 02, 1989
<u>AP</u>	+	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A076512</u>	<u>001</u>	Jan 15, 2004
<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>A071868</u>	<u>001</u>	Jun 04, 1990
<u>AP</u>	+		<u>20MG/ML</u>	<u>A072168</u>	<u>001</u>	Aug 31, 1990
<u>AP</u>	+		<u>20MG/ML</u>	<u>A072945</u>	<u>001</u>	Feb 28, 1994
<u>AP</u>			<u>100MG/ML</u>	<u>A075383</u>	<u>001</u>	Nov 22, 1999
<u>AP</u>		ONCO THERAPIES LTD	<u>20MG/ML</u>	<u>A200914</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>			<u>20MG/ML</u>	<u>A200915</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>			<u>20MG/ML</u>	<u>A200916</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>			<u>100MG/ML</u>	<u>A201784</u>	<u>001</u>	Jan 30, 2012

CYTOSAR-U

<u>AP</u>	+	TEVA PHARMS USA	<u>1GM/VIAL</u>	<u>A075206</u>	<u>004</u>	Dec 30, 1998
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>A075206</u>	<u>003</u>	Dec 30, 1998
<u>AP</u>			<u>100MG/VIAL</u>	<u>A075206</u>	<u>001</u>	Dec 30, 1998
<u>AP</u>	+		<u>500MG/VIAL</u>	<u>A075206</u>	<u>002</u>	Dec 30, 1998

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

	+	PACIRA PHARMS INC	10MG/ML	N021041	001	Apr 01, 1999
--	---	-------------------	---------	---------	-----	--------------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

PRADAXA

		BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010
	+		EQ 150MG BASE	N022512	002	Oct 19, 2010

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

		GLAXOSMITHKLINE	EQ 50MG BASE	N202806	001	May 29, 2013
	+		EQ 75MG BASE	N202806	002	May 29, 2013

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

<u>AP</u>		EUROHLTH INTL	<u>200MG/VIAL</u>	<u>A075812</u>	<u>001</u>	Jun 15, 2001
<u>AP</u>			<u>500MG/VIAL</u>	<u>A075812</u>	<u>002</u>	Oct 31, 2002
<u>AP</u>		FRESENIUS KABI USA	<u>100MG/VIAL</u>	<u>A075371</u>	<u>001</u>	Aug 27, 1999
<u>AP</u>			<u>200MG/VIAL</u>	<u>A075371</u>	<u>002</u>	Aug 27, 1999
<u>AP</u>		HOSPIRA	<u>200MG/VIAL</u>	<u>A075940</u>	<u>001</u>	Oct 18, 2001
<u>AP</u>		TEVA PHARMS USA	<u>200MG/VIAL</u>	<u>A075259</u>	<u>002</u>	Aug 27, 1998
<u>AP</u>	+		<u>500MG/VIAL</u>	<u>A075259</u>	<u>001</u>	Sep 22, 2000

## PRESCRIPTION DRUG PRODUCT LIST

DACARBAZINE

INJECTABLE; INJECTION

DTIC-DOME

<u>AP</u>	+	BAYER HLTHCARE	<u>100MG/VIAL</u>	<u>N017575</u>	<u>001</u>	
<u>AP</u>	+		<u>200MG/VIAL</u>	<u>N017575</u>	<u>002</u>	

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

<u>AP</u>	+	RECORDATI RARE	<u>0.5MG/VIAL</u>	<u>N050682</u>	<u>001</u>	
-----------	---	----------------	-------------------	----------------	------------	--

DACTINOMYCIN

<u>AP</u>		EUROHLTH INTL	<u>0.5MG/VIAL</u>	<u>A090304</u>	<u>001</u>	Mar 16, 2010
<u>AP</u>		LUITPOLD	<u>0.5MG/VIAL</u>	<u>A202562</u>	<u>001</u>	Aug 23, 2013

DALBAVANCIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

DALVANCE

+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014
---	---------------------	--------------------	---------	-----	--------------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

+	ACORDA	10MG	N022250	001	Jan 22, 2010
---	--------	------	---------	-----	--------------

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

+	KING PHARMS	350MG/VIAL; 150MG/VIAL	N050748	001	Sep 21, 1999
---	-------------	------------------------	---------	-----	--------------

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

	EISAI INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOL

<u>AB</u>		BARR	<u>50MG</u>	<u>A074582</u>	<u>003</u>	May 29, 1998
<u>AB</u>			<u>100MG</u>	<u>A074582</u>	<u>002</u>	May 29, 1998
<u>AB</u>	+		<u>200MG</u>	<u>A074582</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>		LANNETT	<u>50MG</u>	<u>A078214</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>			<u>100MG</u>	<u>A078214</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>			<u>200MG</u>	<u>A077246</u>	<u>001</u>	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRium

<u>AB</u>		PAR STERILE PRODUCTS	<u>25MG</u>	<u>N017443</u>	<u>001</u>	
<u>AB</u>			<u>50MG</u>	<u>N017443</u>	<u>003</u>	
<u>AB</u>	+		<u>100MG</u>	<u>N017443</u>	<u>002</u>	
		<u>DANTROLENE SODIUM</u>				
<u>AB</u>		IMPAX LABS	<u>25MG</u>	<u>A076856</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>			<u>50MG</u>	<u>A076856</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>			<u>100MG</u>	<u>A076856</u>	<u>003</u>	Mar 01, 2005
<u>AB</u>		MIKAH PHARMA	<u>25MG</u>	<u>A076686</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>			<u>50MG</u>	<u>A076686</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>			<u>100MG</u>	<u>A076686</u>	<u>003</u>	Oct 24, 2005

FOR SUSPENSION; INTRAVENOUS

RYANODEX

	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014
--	--------------	------------	---------	-----	--------------

INJECTABLE; INJECTION

DANTRium

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>20MG/VIAL</u>	<u>N018264</u>	<u>001</u>	
		<u>REVONTO</u>				
<u>AP</u>		US WORLDMEDS	<u>20MG/VIAL</u>	<u>A078378</u>	<u>001</u>	Jul 24, 2007

## PRESCRIPTION DRUG PRODUCT LIST

DAPAGLIFLOZIN

TABLET; ORAL

FARXIGA

ASTRAZENECA AB

5MG

N202293 001 Jan 08, 2014

+

10MG

N202293 002 Jan 08, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

XIGDUO XR

ASTRAZENECA AB

5MG; 1GM

N205649 002 Oct 29, 2014

5MG; 500MG

N205649 001 Oct 29, 2014

+

10MG; 1GM

N205649 004 Oct 29, 2014

10MG; 500MG

N205649 003 Oct 29, 2014

DAPSONE

GEL; TOPICAL

ACZONE

+ ALLERGAN

5%

N021794 001 Jul 07, 2005

TABLET; ORAL

DAPSONE

JACOBUS

25MG

A086841 001

+

100MG

A086842 001

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

**CUBICIN****AP + CUBIST****500MG/VIAL****N021572 002** Sep 12, 2003**DAPTOMYCIN****AP HOSPIRA INC****500MG/VIAL****A202857 001** Sep 12, 2014DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

WARNER CHILCOTT LLC

EQ 7.5MG BASE

N021513 001 Dec 22, 2004

+

EQ 15MG BASE

N021513 002 Dec 22, 2004

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+ JANSSEN PRODS

EQ 100MG BASE/ML

N202895 001 Dec 16, 2011

TABLET; ORAL

PREZISTA

JANSSEN PRODS

EQ 75MG BASE

N021976 004 Dec 18, 2008

EQ 150MG BASE

N021976 005 Dec 18, 2008

EQ 600MG BASE

N021976 002 Feb 25, 2008

+

EQ 800MG BASE

N021976 006 Nov 09, 2012

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, TABLET; ORAL

VIEKIRA PAK (COPACKAGED)

+ ABBVIE INC

EQ 250MG BASE, N/A, N/A, N/A;  
N/A, 12.5MG, 75MG, 50MG

N206619 001 Dec 19, 2014

DASATINIB

TABLET; ORAL

SPRYCEL

BRISTOL MYERS SQUIBB

20MG

N021986 001 Jun 28, 2006

50MG

N021986 002 Jun 28, 2006

70MG

N021986 003 Jun 28, 2006

80MG

N021986 005 Oct 28, 2010

100MG

N021986 004 May 30, 2008

+

140MG

N021986 006 Oct 28, 2010

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

+ GALEN (UK)

EQ 2MG BASE/ML

N050704 002 Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

**CERUBIDINE****AP + EUROHLTH INTL****EQ 20MG BASE/VIAL****A064103 001** Feb 03, 1995**DAUNORUBICIN HYDROCHLORIDE****AP + EUROHLTH INTL****EQ 5MG BASE/ML****N050731 001** Jan 30, 1998**AP FRESENIUS KABI USA****EQ 20MG BASE/VIAL****A065000 001** May 25, 1999**AP TEVA PHARMS USA****EQ 5MG BASE/ML****A065035 001** Jan 24, 2000

FRESENIUS KABI USA

EQ 5MG BASE/VIAL

A065034 001 Nov 20, 2001

## PRESCRIPTION DRUG PRODUCT LIST

DECITABINE

INJECTABLE; INTRAVENOUS

DACOGEN

<b>AP</b>	+	EISAI INC	<b>50MG/VIAL</b>	<b>N021790 001</b>	May 02, 2006
-----------	---	-----------	------------------	--------------------	--------------

DECITABINE

<b>AP</b>		DR REDDYS LABS LTD	<b>50MG/VIAL</b>	<b>A203131 001</b>	Jul 11, 2013
-----------	--	--------------------	------------------	--------------------	--------------

<b>AP</b>		SANDOZ	<b>50MG/VIAL</b>	<b>A202969 001</b>	Aug 28, 2014
-----------	--	--------	------------------	--------------------	--------------

POWDER; INTRAVENOUS

DECITABINE

	+	SUN PHARMA GLOBAL	50MG/VIAL	N205582 001	Jan 28, 2014
--	---	-------------------	-----------	-------------	--------------

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL

EXJADE

		NOVARTIS	125MG	N021882 001	Nov 02, 2005
--	--	----------	-------	-------------	--------------

			250MG	N021882 002	Nov 02, 2005
--	--	--	-------	-------------	--------------

	+		500MG	N021882 003	Nov 02, 2005
--	---	--	-------	-------------	--------------

DEFERIPRONE

TABLET; ORAL

FERRIPROX

	+	AOPHARMA INC	500MG	N021825 001	Oct 14, 2011
--	---	--------------	-------	-------------	--------------

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

<b>AP</b>		EUROHLTH INTL	<b>2GM/VIAL</b>	<b>A078086 002</b>	May 30, 2007
-----------	--	---------------	-----------------	--------------------	--------------

<b>AP</b>			<b>500MG/VIAL</b>	<b>A078086 001</b>	May 30, 2007
-----------	--	--	-------------------	--------------------	--------------

<b>AP</b>		FRESENIUS KABI USA	<b>2GM/VIAL</b>	<b>A078718 002</b>	Sep 15, 2009
-----------	--	--------------------	-----------------	--------------------	--------------

<b>AP</b>			<b>500MG/VIAL</b>	<b>A078718 001</b>	Sep 15, 2009
-----------	--	--	-------------------	--------------------	--------------

<b>AP</b>		HOSPIRA	<b>2GM/VIAL</b>	<b>A076019 002</b>	Mar 17, 2004
-----------	--	---------	-----------------	--------------------	--------------

<b>AP</b>			<b>500MG/VIAL</b>	<b>A076019 001</b>	Mar 17, 2004
-----------	--	--	-------------------	--------------------	--------------

DEFERAL

<b>AP</b>	+	NOVARTIS	<b>2GM/VIAL</b>	<b>N016267 002</b>	May 25, 2000
-----------	---	----------	-----------------	--------------------	--------------

<b>AP</b>	+		<b>500MG/VIAL</b>	<b>N016267 001</b>	
-----------	---	--	-------------------	--------------------	--

DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

FIRMAGON

		FERRING	EQ 80MG BASE/VIAL	N022201 001	Dec 24, 2008
--	--	---------	-------------------	-------------	--------------

	+		EQ 120MG BASE/VIAL	N022201 002	Dec 24, 2008
--	---	--	--------------------	-------------	--------------

DELAVIRDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

		VIIV HLTHCARE	100MG	N020705 001	Apr 04, 1997
--	--	---------------	-------	-------------	--------------

	+		200MG	N020705 002	Jul 14, 1999
--	---	--	-------	-------------	--------------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

<b>AB</b>		AMNEAL PHARM	<b>150MG</b>	<b>A065425 001</b>	Feb 27, 2008
-----------	--	--------------	--------------	--------------------	--------------

<b>AB</b>	+		<b>300MG</b>	<b>A065425 002</b>	Feb 27, 2008
-----------	---	--	--------------	--------------------	--------------

<b>AB</b>		BARR	<b>150MG</b>	<b>A065171 001</b>	Dec 13, 2004
-----------	--	------	--------------	--------------------	--------------

<b>AB</b>			<b>300MG</b>	<b>A065171 002</b>	Dec 13, 2004
-----------	--	--	--------------	--------------------	--------------

<b>AB</b>		IMPAX LABS	<b>150MG</b>	<b>A065094 001</b>	Mar 22, 2004
-----------	--	------------	--------------	--------------------	--------------

<b>AB</b>			<b>300MG</b>	<b>A065094 002</b>	Mar 22, 2004
-----------	--	--	--------------	--------------------	--------------

<b>AB</b>		VERSAPHARM	<b>150MG</b>	<b>A065389 001</b>	Dec 01, 2008
-----------	--	------------	--------------	--------------------	--------------

<b>AB</b>			<b>300MG</b>	<b>A065389 002</b>	Dec 01, 2008
-----------	--	--	--------------	--------------------	--------------

DESFLURANE

LIQUID; INHALATION

SUPRANE

	+	BAXTER HLTHCARE	99.9%	N020118 001	Sep 18, 1992
--	---	-----------------	-------	-------------	--------------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<b>AB</b>		ACTAVIS TOTOWA	<b>10MG</b>	<b>A074430 001</b>	Feb 09, 1996
-----------	--	----------------	-------------	--------------------	--------------

<b>AB</b>			<b>25MG</b>	<b>A071601 001</b>	Jun 05, 1987
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>50MG</b>	<b>A071588 001</b>	Jun 05, 1987
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>75MG</b>	<b>A071602 001</b>	Oct 05, 1987
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>100MG</b>	<b>A071766 001</b>	Oct 05, 1987
-----------	--	--	--------------	--------------------	--------------

<b>AB</b>			<b>150MG</b>	<b>A074430 002</b>	Feb 09, 1996
-----------	--	--	--------------	--------------------	--------------

<b>AB</b>		SANDOZ	<b>10MG</b>	<b>A072099 001</b>	May 24, 1988
-----------	--	--------	-------------	--------------------	--------------

<b>AB</b>			<b>25MG</b>	<b>A072100 001</b>	May 24, 1988
-----------	--	--	-------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A072101 001</u>	May 24, 1988
<u>AB</u>		<u>75MG</u>	<u>A072102 001</u>	Jun 20, 1988
<u>AB</u>		<u>100MG</u>	<u>A072103 001</u>	Jun 20, 1988
<u>AB</u>		<u>150MG</u>	<u>A072104 001</u>	Jun 20, 1988

NORPRAMIN

<u>AB</u>	SANOFI AVENTIS US	<u>10MG</u>	<u>N014399 007</u>	Feb 11, 1982
<u>AB</u>		<u>25MG</u>	<u>N014399 001</u>	
<u>AB</u>		<u>50MG</u>	<u>N014399 003</u>	
<u>AB</u>		<u>75MG</u>	<u>N014399 004</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N014399 005</u>	
<u>AB</u>		<u>150MG</u>	<u>N014399 006</u>	

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

I PRIVASK

	+ MARATHON PHARMS LLC	15MG/VIAL	N021271 001	Apr 04, 2003
--	-----------------------	-----------	-------------	--------------

DES Loratadine

SOLUTION; ORAL

CLARINEX

	+ MERCK SHARP DOHME	0.5MG/ML	N021300 001	Sep 01, 2004
--	---------------------	----------	-------------	--------------

TABLET; ORAL

CLARINEX

<u>AB</u>	+ MERCK SHARP DOHME	<u>5MG</u>	<u>N021165 001</u>	Dec 21, 2001
-----------	---------------------	------------	--------------------	--------------

DES Loratadine

<u>AB</u>	BELCHER PHARMS	<u>5MG</u>	<u>A078355 001</u>	Apr 19, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078365 001</u>	Mar 08, 2011
<u>AB</u>	LUPIN PHARMS	<u>5MG</u>	<u>A078352 001</u>	Oct 25, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A078351 001</u>	Feb 10, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A078357 001</u>	Feb 19, 2010
<u>AB</u>	PERRIGO R AND D	<u>5MG</u>	<u>A078361 001</u>	Dec 22, 2011
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A078364 001</u>	Dec 03, 2010
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A078359 001</u>	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

<u>AB</u>	MERCK SHARP DOHME	<u>2.5MG</u>	<u>N021312 002</u>	Jul 14, 2005
-----------	-------------------	--------------	--------------------	--------------

<u>AB</u>	+	<u>5MG</u>	<u>N021312 001</u>	Jun 26, 2002
-----------	---	------------	--------------------	--------------

DES Loratadine

<u>AB</u>	REDDYS	<u>2.5MG</u>	<u>A078367 001</u>	Jul 12, 2010
<u>AB</u>		<u>5MG</u>	<u>A078367 002</u>	Jul 12, 2010

DES Loratadine; Pseudoephedrine Sulfate

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

<u>AB</u>	+ MERCK SHARP DOHME	<u>5MG; 240MG</u>	<u>N021605 001</u>	Mar 03, 2005
-----------	---------------------	-------------------	--------------------	--------------

DES Loratadine AND Pseudoephedrine Sulfate 24 Hour

<u>AB</u>	DR REDDYS LABS LTD	<u>5MG; 240MG</u>	<u>A078366 001</u>	Apr 26, 2011
-----------	--------------------	-------------------	--------------------	--------------

CLARINEX-D 12 HOUR

	+ MERCK SHARP DOHME	2.5MG; 120MG	N021313 001	Feb 01, 2006
--	---------------------	--------------	-------------	--------------

DES Mopressin Acetate

INJECTABLE; INJECTION

DDAVP

<u>AP</u>	+ FERRING PHARMS INC	<u>0.004MG/ML</u>	<u>N018938 001</u>	Mar 30, 1984
-----------	----------------------	-------------------	--------------------	--------------

DES Mopressin Acetate

<u>AP</u>	HOSPIRA	<u>0.004MG/ML</u>	<u>A075220 001</u>	Aug 28, 2000
<u>AP</u>	SUN PHARM INDS LTD	<u>0.004MG/ML</u>	<u>A091280 001</u>	Jan 25, 2013
<u>AP</u>	TEVA PHARMS USA	<u>0.004MG/ML</u>	<u>A074888 001</u>	Oct 15, 1997

SOLUTION; NASAL

DDAVP

<u>AB</u>	+ FERRING PHARMS INC	<u>0.01%</u>	<u>N017922 001</u>	
-----------	----------------------	--------------	--------------------	--

DES Mopressin Acetate

<u>AB</u>	SUN PHARM INDS	<u>0.01%</u>	<u>A077212 001</u>	Apr 12, 2012
-----------	----------------	--------------	--------------------	--------------

SPRAY, METERED; NASAL

DDAVP (NEEDS NO REFRIGERATION)

<u>AB</u>	+ FERRING PHARMS INC	<u>0.01MG/SPRAY</u>	<u>N017922 003</u>	Aug 07, 1996
-----------	----------------------	---------------------	--------------------	--------------

DES Mopressin Acetate

<u>AB</u>	+ BAUSCH AND LOMB	<u>0.01MG/SPRAY</u>	<u>A074830 001</u>	Jan 25, 1999
-----------	-------------------	---------------------	--------------------	--------------

DES Mopressin Acetate (NEEDS NO REFRIGERATION)

<u>AB</u>	APOTEX INC	<u>0.01MG/SPRAY</u>	<u>A076703 001</u>	Jan 27, 2005
<u>AB</u>	SUN PHARMA GLOBAL	<u>0.01MG/SPRAY</u>	<u>A078271 001</u>	Dec 23, 2013



## PRESCRIPTION DRUG PRODUCT LIST

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL

MINIRIN

<b>AB</b>	+	FERRING	<u>0.01MG/SPRAY</u>	<u>N021333</u>	<u>001</u>	Sep 16, 2002
		STIMATE (NEEDS NO REFRIGERATION)				
		+ CSL BEHRING	1.5MG/SPRAY	N020355	002	Oct 24, 2007

TABLET;ORAL

DDAVP

<b>AB</b>		SANOFI AVENTIS US	<u>0.1MG</u>	<u>N019955</u>	<u>001</u>	Sep 06, 1995
<b>AB</b>	+		<u>0.2MG</u>	<u>N019955</u>	<u>002</u>	Sep 06, 1995

DESMOPRESSIN ACETATE

<b>AB</b>		ACTAVIS LABS FL INC	<u>0.1MG</u>	<u>A076470</u>	<u>001</u>	Jul 01, 2005
<b>AB</b>			<u>0.2MG</u>	<u>A076470</u>	<u>002</u>	Jul 01, 2005
<b>AB</b>		APOTEX INC	<u>0.1MG</u>	<u>A077414</u>	<u>001</u>	Mar 07, 2006
<b>AB</b>			<u>0.2MG</u>	<u>A077414</u>	<u>002</u>	Mar 07, 2006
<b>AB</b>		MYLAN PHARMS INC	<u>0.1MG</u>	<u>A200653</u>	<u>001</u>	Jun 27, 2014
<b>AB</b>			<u>0.2MG</u>	<u>A200653</u>	<u>002</u>	Jun 27, 2014
<b>AB</b>		TEVA PHARMS	<u>0.1MG</u>	<u>A077122</u>	<u>001</u>	Jan 25, 2006
<b>AB</b>			<u>0.2MG</u>	<u>A077122</u>	<u>002</u>	Jan 25, 2006
		FERRING	0.1MG	N021795	001	May 08, 2008
	+		0.2MG	N021795	002	May 08, 2008

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

CYCLESSA

<b>AB</b>	+	ORGANON USA INC	<u>0.125MG;0.15MG;0.1MG;0.025MG;0.025MG;0.025MG</u>	<u>N021090</u>	<u>001</u>	Dec 20, 2000
-----------	---	-----------------	-----------------------------------------------------	----------------	------------	--------------

DESOGEN

<b>AB</b>		ORGANON USA INC	<u>0.15MG;0.03MG</u>	<u>N020071</u>	<u>002</u>	Dec 10, 1992
-----------	--	-----------------	----------------------	----------------	------------	--------------

DESOGESTREL AND ETHINYL ESTRADIOL

<b>AB</b>		DURAMED PHARMS BARR	<u>0.15MG;0.03MG</u>	<u>A075256</u>	<u>002</u>	Aug 12, 1999
<b>AB</b>		FAMY CARE LTD	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A202296</u>	<u>001</u>	Aug 30, 2013
<b>AB</b>		NOVAST LABS LTD	<u>0.15MG;0.03MG</u>	<u>A091234</u>	<u>001</u>	Jul 12, 2013
<b>AB</b>		WATSON LABS	<u>0.15MG,N/A;0.02MG,0.01MG;0.02MG,0.01MG</u>	<u>A076916</u>	<u>001</u>	Dec 29, 2008
<b>AB</b>			<u>0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG</u>	<u>A077182</u>	<u>001</u>	Jan 24, 2006
<b>AB</b>			<u>0.15MG;0.03MG</u>	<u>A076915</u>	<u>001</u>	Jul 29, 2005

EMOQUETTE

<b>AB</b>		VINTAGE PHARMS LLC	<u>0.15MG;0.03MG</u>	<u>A076675</u>	<u>001</u>	Feb 25, 2011
-----------	--	--------------------	----------------------	----------------	------------	--------------

ENSKYCE

<b>AB</b>		LUPIN LTD	<u>0.15MG;0.03MG</u>	<u>A201887</u>	<u>001</u>	Mar 07, 2013
-----------	--	-----------	----------------------	----------------	------------	--------------

ORTHO-CEPT

<b>AB</b>	+	JANSSEN PHARMS	<u>0.15MG;0.03MG</u>	<u>N020301</u>	<u>002</u>	Dec 14, 1992
-----------	---	----------------	----------------------	----------------	------------	--------------

PIMTREA

<b>AB</b>		NOVAST LABS LTD	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A091247</u>	<u>001</u>	Aug 01, 2013
-----------	--	-----------------	---------------------------------	----------------	------------	--------------

VELIVET

<b>AB</b>		DURAMED PHARMS BARR	<u>0.125MG;0.15MG;0.1MG;0.025MG;0.025MG;0.025MG</u>	<u>A076455</u>	<u>001</u>	Feb 24, 2004
-----------	--	---------------------	-----------------------------------------------------	----------------	------------	--------------

VIORELE

<b>AB</b>		GLENMARK GENERICS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A091346</u>	<u>001</u>	Apr 02, 2012
		KARIVA				
	+	BARR	0.15MG,N/A;0.02MG,0.01MG;0.02MG,0.01MG	A075863	001	Apr 05, 2002

DESONIDE

AEROSOL, FOAM;TOPICAL

VERDESO

+ AQUA PHARMS

0.05%

N021978 001 Sep 19, 2006

CREAM;TOPICAL

DESONIDE

<b>AB</b>	+	PERRIGO NEW YORK	<u>0.05%</u>	<u>N017010</u>	<u>001</u>	
<b>AB</b>		TARO	<u>0.05%</u>	<u>A073548</u>	<u>001</u>	Jun 30, 1992

DESOWEN

<b>AB</b>		GALDERMA LABS LP	<u>0.05%</u>	<u>N019048</u>	<u>001</u>	Dec 14, 1984
-----------	--	------------------	--------------	----------------	------------	--------------

GEL;TOPICAL

DESONATE

+ BAYER HLTHCARE

0.05%

N021844 001 Oct 20, 2006

LOTION;TOPICAL

DESONIDE

<b>AB</b>		FOUGERA PHARMS	<u>0.05%</u>	<u>A075860</u>	<u>001</u>	Mar 19, 2002
-----------	--	----------------	--------------	----------------	------------	--------------

<b>AB</b>		TARO	<u>0.05%</u>	<u>A202161</u>	<u>001</u>	Oct 31, 2014
-----------	--	------	--------------	----------------	------------	--------------

DESOWEN

<b>AB</b>	+	GALDERMA LABS LP	<u>0.05%</u>	<u>A072354</u>	<u>001</u>	Jan 24, 1992
-----------	---	------------------	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DESONIDE

OINTMENT; TOPICAL

DESONIDE

<b>AB</b>	FOUGERA PHARMS	<u>0.05%</u>	<b><u>A075751</u></b> <b><u>001</u></b>	Mar 12, 2001
<b>AB</b>	+ PERRIGO NEW YORK	<u>0.05%</u>	<b><u>N017426</u></b> <b><u>001</u></b>	
<b>AB</b>	TARO	<u>0.05%</u>	<b><u>A074254</u></b> <b><u>001</u></b>	Aug 03, 1994

DESOWEN

<b>AB</b>	GALDERMA LABS LP	<u>0.05%</u>	<b><u>A071425</u></b> <b><u>001</u></b>	Jun 15, 1988
-----------	------------------	--------------	-----------------------------------------	--------------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

<b>AB</b>	FOUGERA PHARMS	<u>0.25%</u>	<b><u>A078369</u></b> <b><u>001</u></b>	Jun 29, 2010
<b>AB</b>	PERRIGO NEW YORK	<u>0.25%</u>	<b><u>A076510</u></b> <b><u>001</u></b>	Jul 01, 2003

TOPICORT

<b>AB</b>	+ TARO	<u>0.25%</u>	<b><u>A073193</u></b> <b><u>001</u></b>	Nov 30, 1990
	+	0.05%	A073210 001	Nov 30, 1990

GEL; TOPICAL

DESOXIMETASONE

<b>AB</b>	PERRIGO NEW YORK	<u>0.05%</u>	<b><u>A077552</u></b> <b><u>001</u></b>	Jan 09, 2006
<b>AB</b>	VERSAPHARM	<u>0.05%</u>	<b><u>A090727</u></b> <b><u>001</u></b>	Mar 10, 2011

TOPICORT

<b>AB</b>	+ TARO	<u>0.05%</u>	<b><u>A074904</u></b> <b><u>001</u></b>	Jul 14, 1998
-----------	--------	--------------	-----------------------------------------	--------------

OINTMENT; TOPICAL

DESOXIMETASONE

<b>AB</b>	FOUGERA PHARMS	<u>0.25%</u>	<b><u>A078657</u></b> <b><u>001</u></b>	Sep 28, 2012
<b>AB</b>	GLENMARK GENERICS	<u>0.25%</u>	<b><u>A202838</u></b> <b><u>001</u></b>	Sep 20, 2013
<b>AB</b>	VERSAPHARM INC	<u>0.25%</u>	<b><u>A201005</u></b> <b><u>001</u></b>	Apr 24, 2014

TOPICORT

<b>AB</b>	+ TARO	<u>0.25%</u>	<b><u>A074286</u></b> <b><u>001</u></b>	Jun 07, 1996
	+ TARO PHARMS NORTH	0.05%	N018594 001	Jan 17, 1985

SPRAY; TOPICAL

TOPICORT

	+ TARO	0.25%	N204141 001	Apr 11, 2013
--	--------	-------	-------------	--------------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

BC	+ ALEMBIC PHARMS LTD	50MG	N204150 001	Mar 04, 2013
BC	+ KHEDEZLA	100MG	N204150 002	Mar 04, 2013
BC	OSMOTICA PHARM CORP	50MG	N204683 001	Jul 10, 2013
BC		100MG	N204683 002	Jul 10, 2013

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

	+ SUN PHARMA GLOBAL	EQ 50MG BASE	N205583 001	Jan 28, 2014
	+	EQ 100MG BASE	N205583 002	Jan 28, 2014

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

PRISTIQ

	WYETH PHARMS INC	EQ 25MG BASE	N021992 003	Aug 20, 2014
	+	EQ 50MG BASE	N021992 001	Feb 29, 2008
	+	EQ 100MG BASE	N021992 002	Feb 29, 2008

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

	+ ROXANE	1MG/ML	A088252 001	Sep 01, 1983
--	----------	--------	-------------	--------------

ELIXIR; ORAL

DEXAMETHASONE

<b>AA</b>	LYNE	<u>0.5MG/5ML</u>	<b><u>A090891</u></b> <b><u>001</u></b>	Jul 12, 2011
<b>AA</b>	+ STI PHARMA LLC	<u>0.5MG/5ML</u>	<b><u>A084754</u></b> <b><u>001</u></b>	
<b>AA</b>	VINTAGE PHARMS	<u>0.5MG/5ML</u>	<b><u>A091188</u></b> <b><u>001</u></b>	May 11, 2011
<b>AA</b>	WOCKHARDT EU OPERATN	<u>0.5MG/5ML</u>	<b><u>A088254</u></b> <b><u>001</u></b>	Jul 27, 1983

IMPLANT; INTRAVITREAL

OZURDEX

	+ ALLERGAN	0.7MG	N022315 001	Jun 17, 2009
--	------------	-------	-------------	--------------

SOLUTION; ORAL

DEXAMETHASONE

	+ ROXANE	0.5MG/5ML	A088248 001	Sep 01, 1983
--	----------	-----------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DEXAMETHASONE

SUSPENSION/DROPS;OPHTHALMIC

MAXIDEX

+ ALCON 0.1% N013422 001

TABLET;ORAL

DEXAMETHASONE

<b>AB</b>	ECR	<b>1.5MG</b>	<b>A040700 001</b>	Aug 15, 2008
<b>AB</b>	ROXANE	<b>1.5MG</b>	<b>A084610 001</b>	
BP	PAR PHARM	0.5MG	A088148 001	Apr 28, 1983
BP		0.75MG	A088160 001	Apr 28, 1983
BP		1.5MG	A088237 001	Apr 28, 1983
BP		4MG	A088238 001	Apr 28, 1983
BP	+	6MG	A088481 001	Nov 28, 1983
BP	ROXANE	0.5MG	A084611 001	
BP		0.75MG	A084613 001	
BP		1MG	A088306 001	Sep 15, 1983
BP		2MG	A087916 001	Aug 26, 1982
BP		4MG	A084612 001	
BP	+	6MG	A088316 001	Sep 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

<b>AP</b>	AGILA SPECLTS	<b>EQ 4MG PHOSPHATE/ML</b>	<b>A040803 001</b>	Aug 29, 2008
<b>AP</b>		<b>EQ 10MG PHOSPHATE/ML</b>	<b>A040802 001</b>	Aug 29, 2008
<b>AP</b>	FRESENIUS KABI USA	<b>EQ 4MG PHOSPHATE/ML</b>	<b>A084916 001</b>	
<b>AP</b>	+	<b>EQ 10MG PHOSPHATE/ML</b>	<b>A040491 001</b>	Apr 11, 2003
<b>AP</b>	+	<b>EQ 10MG PHOSPHATE/ML</b>	<b>A040572 001</b>	Apr 22, 2005
<b>AP</b>	+	<b>EQ 10MG PHOSPHATE/ML</b>	<b>A087702 001</b>	Sep 07, 1982
<b>AP</b>	+	<b>EQ 4MG PHOSPHATE/ML</b>	<b>A087440 001</b>	Jul 21, 1982

SOLUTION/DROPS;OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

<b>AT</b>	+	ALCON PHARMS LTD	<b>EQ 0.1% PHOSPHATE</b>	<b>A088771 001</b>	Jan 16, 1985
<b>AT</b>		BAUSCH AND LOMB	<b>EQ 0.1% PHOSPHATE</b>	<b>A040069 001</b>	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

<b>AT</b>	+	FALCON PHARMS	<b>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</b>	<b>N050065 002</b>	
<b>NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE</b>					
<b>AT</b>		BAUSCH AND LOMB	<b>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</b>	<b>A064063 001</b>	Jul 25, 1994
<b>AT</b>		PERRIGO CO TENNESSEE	<b>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</b>	<b>A062938 001</b>	Jul 31, 1989

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

<b>AT</b>		BAUSCH AND LOMB	<b>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</b>	<b>A064135 001</b>	Sep 13, 1995
<b>MAXITROL</b>					
<b>AT</b>		ALCON	<b>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</b>	<b>A062341 001</b>	May 22, 1984
<b>AT</b>	+	FALCON PHARMS	<b>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</b>	<b>N050023 002</b>	

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

+ ALCON 0.1%;0.3% N050616 001 Sep 28, 1988

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX

<b>AB</b>	+	ALCON	<b>0.1%;0.3%</b>	<b>N050592 001</b>	Aug 18, 1988
<b>TOBRAMYCIN AND DEXAMETHASONE</b>					
<b>AB</b>		BAUSCH AND LOMB	<b>0.1%;0.3%</b>	<b>A064134 001</b>	Oct 27, 1999
TOBRADEX ST					
	+	ALCON PHARMS LTD	0.05%;0.3%	N050818 001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

+ WOCKHARDT 2MG/5ML A088251 001 Mar 23, 1984

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

TAKEDA PHARMS USA 30MG N022287 001 Jan 30, 2009

+ 60MG N022287 002 Jan 30, 2009

## PRESCRIPTION DRUG PRODUCT LIST

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202585 001</u>	Nov 24, 2014
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202881 001</u>	Aug 18, 2014
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A203972 001</u>	Aug 18, 2014
<u>PRECEDEX</u>				
<u>AP</u>	+ HOSPIRA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>N021038 001</u>	Dec 17, 1999
	+	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038 002	Mar 13, 2013
	+	EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038 003	Mar 13, 2013

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	INTELLIPHARMACEUTICS	<u>15MG</u>	<u>A078992 003</u>	Nov 18, 2013
<u>AB</u>		<u>30MG</u>	<u>A078992 004</u>	Nov 18, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>30MG</u>	<u>A202580 001</u>	Aug 28, 2013
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A078908 001</u>	Nov 19, 2013
<u>AB</u>		<u>10MG</u>	<u>A078908 002</u>	Nov 19, 2013
<u>AB</u>		<u>15MG</u>	<u>A078908 004</u>	May 19, 2014
<u>AB</u>		<u>20MG</u>	<u>A078908 003</u>	Nov 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202731 003</u>	May 19, 2014
<u>AB</u>		<u>40MG</u>	<u>A202731 002</u>	Nov 19, 2013
<u>AB</u>	WATSON LABS INC	<u>15MG</u>	<u>A079108 003</u>	May 19, 2014
<u>AB</u>		<u>30MG</u>	<u>A079108 005</u>	Nov 21, 2013
<u>FOCALIN XR</u>				
<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N021802 001</u>	May 26, 2005
<u>AB</u>		<u>10MG</u>	<u>N021802 002</u>	May 26, 2005
<u>AB</u>		<u>15MG</u>	<u>N021802 004</u>	Aug 01, 2006
<u>AB</u>		<u>20MG</u>	<u>N021802 003</u>	May 26, 2005
<u>AB</u>		<u>30MG</u>	<u>N021802 005</u>	Oct 23, 2009
<u>AB</u>	+	<u>40MG</u>	<u>N021802 006</u>	Aug 11, 2010
		25MG	N021802 008	Apr 21, 2011
		35MG	N021802 007	Apr 21, 2011

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A077107 003</u>	Jan 29, 2007
<u>AB</u>		<u>5MG</u>	<u>A077107 001</u>	Jan 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077107 002</u>	Jan 29, 2007

FOCALIN

<u>AB</u>	NOVARTIS	<u>2.5MG</u>	<u>N021278 001</u>	Nov 13, 2001
<u>AB</u>		<u>5MG</u>	<u>N021278 002</u>	Nov 13, 2001
<u>AB</u>	+	<u>10MG</u>	<u>N021278 003</u>	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL	<u>EQ 250MG BASE/VIAL</u>	<u>A076068 001</u>	Sep 28, 2004
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A076068 002</u>	Sep 28, 2004
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 250MG BASE/VIAL</u>	<u>A200752 001</u>	Oct 19, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A200752 002</u>	Oct 19, 2011
<u>ZINECARD</u>				
<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 250MG BASE/VIAL</u>	<u>N020212 001</u>	May 26, 1995
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N020212 002</u>	May 26, 1995
TOTECT				
	+ BIOCDEX INC	EQ 500MG BASE/VIAL	N022025 001	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

<u>AB</u>	AMEDRA PHARMS	<u>5MG</u>	<u>N017078 001</u>	
<u>AB</u>		<u>10MG</u>	<u>N017078 002</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017078 003</u>	

DEXTROAMPHETAMINE SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A203901 001</u>	Nov 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A203901 002</u>	Nov 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A203901 003</u>	Nov 30, 2012
<u>AB</u>	BARR	<u>5MG</u>	<u>A076137 001</u>	Jan 18, 2002
<u>AB</u>		<u>10MG</u>	<u>A076137 002</u>	Jan 18, 2002
<u>AB</u>		<u>15MG</u>	<u>A076137 003</u>	Jan 18, 2002
<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A076353 001</u>	May 06, 2003
<u>AB</u>		<u>10MG</u>	<u>A076353 002</u>	May 06, 2003
<u>AB</u>		<u>15MG</u>	<u>A076353 003</u>	May 06, 2003

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	+	OUTLOOK PHARMS	<u>5MG/5ML</u>	<u>A040776</u>	<u>001</u>	Jan 29, 2008
<u>AA</u>		TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A203644</u>	<u>001</u>	May 29, 2013

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>		AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202893</u>	<u>001</u>	Jul 31, 2013
<u>AA</u>			<u>10MG</u>	<u>A202893</u>	<u>002</u>	Jul 31, 2013
<u>AA</u>		BARR	<u>5MG</u>	<u>A040361</u>	<u>001</u>	Jan 31, 2001
<u>AA</u>	+		<u>10MG</u>	<u>A040361</u>	<u>002</u>	Jan 31, 2001
<u>AA</u>		COREPHARMA	<u>5MG</u>	<u>A090652</u>	<u>001</u>	Mar 07, 2014
<u>AA</u>			<u>10MG</u>	<u>A090652</u>	<u>002</u>	Mar 07, 2014
<u>AA</u>		MALLINCKRODT	<u>5MG</u>	<u>A040436</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>			<u>10MG</u>	<u>A040436</u>	<u>002</u>	Jan 29, 2002
<u>AA</u>		MIKART	<u>5MG</u>	<u>A090533</u>	<u>002</u>	Oct 25, 2011
<u>AA</u>			<u>10MG</u>	<u>A090533</u>	<u>004</u>	Oct 25, 2011
			2.5MG	A090533	001	Oct 25, 2011
			7.5MG	A090533	003	Oct 25, 2011
			15MG	A090533	005	Oct 25, 2011
			20MG	A090533	006	Oct 25, 2011
			30MG	A090533	007	Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

<u>AA</u>	+	VINTAGE	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040649</u>	<u>001</u>	Feb 14, 2006
<u>AA</u>		HI TECH PHARMA	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040027</u>	<u>001</u>	Jul 31, 1996
<u>AA</u>		WOCKHARDT	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088864</u>	<u>001</u>	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

NUEDEXTA

+	AVANIR PHARMS	20MG; 10MG	N021879	001	Oct 29, 2010
---	---------------	------------	---------	-----	--------------

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>10GM/100ML</u>	<u>N019626</u>	<u>004</u>	Feb 02, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N016694</u>	<u>001</u>	
<u>AP</u>	+	HOSPIRA	<u>10GM/100ML</u>	<u>N018080</u>	<u>001</u>	

DEXTROSE 20% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N017521</u>	<u>004</u>	
<u>AP</u>	+	HOSPIRA	<u>20GM/100ML</u>	<u>N018564</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 30% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>30GM/100ML</u>	<u>N017521</u>	<u>003</u>	
<u>AP</u>	+	HOSPIRA	<u>30GM/100ML</u>	<u>N019345</u>	<u>001</u>	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>40GM/100ML</u>	<u>N017521</u>	<u>002</u>	
<u>AP</u>	+	HOSPIRA	<u>40GM/100ML</u>	<u>N018562</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>5GM/100ML</u>	<u>N016730</u>	<u>001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019626</u>	<u>002</u>	Feb 02, 1988
<u>AP</u>	+		<u>50MG/ML</u>	<u>N016730</u>	<u>002</u>	
<u>AP</u>	+	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N016673</u>	<u>001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N020179</u>	<u>001</u>	Dec 07, 1992
<u>AP</u>	+		<u>50MG/ML</u>	<u>N016673</u>	<u>003</u>	Oct 30, 1985
<u>AP</u>	+		<u>50MG/ML</u>	<u>N020179</u>	<u>002</u>	Dec 07, 1992
<u>AP</u>	+	HOSPIRA	<u>5GM/100ML</u>	<u>N019466</u>	<u>001</u>	Jul 15, 1985
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019479</u>	<u>001</u>	Sep 17, 1985
<u>AP</u>	+		<u>50MG/ML</u>	<u>N016367</u>	<u>002</u>	
<u>AP</u>	+		<u>50MG/ML</u>	<u>N019222</u>	<u>001</u>	Jul 13, 1984

DEXTROSE 50% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>50GM/100ML</u>	<u>N017521</u>	<u>001</u>	
<u>AP</u>	+		<u>50GM/100ML</u>	<u>N020047</u>	<u>001</u>	Jul 02, 1991
<u>AP</u>	+	HOSPIRA	<u>50GM/100ML</u>	<u>N018563</u>	<u>001</u>	Mar 23, 1982
<u>AP</u>	+		<u>50GM/100ML</u>	<u>N019894</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>	+		<u>500MG/ML</u>	<u>N019445</u>	<u>001</u>	Jun 03, 1986

DEXTROSE 60% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>60GM/100ML</u>	<u>N017521</u>	<u>005</u>	Mar 26, 1982
-----------	---	-----------------	-------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 70% IN PLASTIC CONTAINER

<b>AP</b>	+	BAXTER HLTHCARE	<b>70GM/100ML</b>	<b>N017521 006</b>	Mar 26, 1982
<b>AP</b>	+		<b>70GM/100ML</b>	<b>N020047 003</b>	Jul 02, 1991
<b>AP</b>	+	HOSPIRA	<b>70GM/100ML</b>	<b>N018561 001</b>	Mar 23, 1982
<b>AP</b>	+		<b>70GM/100ML</b>	<b>N019893 001</b>	Dec 26, 1989
		DEXTROSE 25%			
	+	HOSPIRA	250MG/ML	N019445 002	Nov 23, 1998

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 32MG/100ML; 128MG/100ML; 234MG/100ML	N017385 001
-----------------	-------------------------------------------------	-------------

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017610 001
---------	-------------------------------------------------	-------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019873 001	Jun 10, 1993
---------	-------------------------------------------------------------	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100ML; 16MG/100ML	N019515 001	May 08, 1986
---------	---------------------------------------------------------------------------------------	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML	N017484 001
-----------------	-------------------------------------------------------------------------	-------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/100ML; 260MG/100ML; 25MG/100ML	N019513 001	May 08, 1986
---------	-------------------------------------------------------------------------	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N019844 001	Jun 10, 1993
---------	-------------------------------------------------------------	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019843 001	Aug 09, 1993
---------	--------------------------------------------------------------------------	-------------	--------------

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017609 001
---------	--------------------------------------------------------------------------	-------------

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017451 001
-----------------	--------------------------------------------------------------------------	-------------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 75MG/100ML</b>	<b>N017634 004</b>
-----------	-----------------	------------------------------	--------------------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 150MG/100ML</b>	<b>N017634 001</b>
-----------	-----------------	-------------------------------	--------------------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 224MG/100ML</b>	<b>N017634 003</b>
-----------	-----------------	-------------------------------	--------------------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>5GM/100ML; 300MG/100ML</b>	<b>N017634 002</b>
-----------	-----------------	-------------------------------	--------------------

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML	N018744 001	Nov 09, 1982
----	---------	----------------------	-------------	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;150MG/100ML	N018744 002	Nov 09, 1982
----	---------	-----------------------	-------------	--------------

AP		5GM/100ML;150MG/100ML	N019699 004	Sep 29, 1989
----	--	-----------------------	-------------	--------------

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;300MG/100ML	N018744 004	Nov 09, 1982
----	---------	-----------------------	-------------	--------------

AP		5GM/100ML;300MG/100ML	N019699 006	Sep 29, 1989
----	--	-----------------------	-------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML;224MG/100ML	N018371 003	
----	---------	-----------------------	-------------	--

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML;149MG/100ML	N018371 001	
--	---------	-----------------------	-------------	--

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML;298MG/100ML	N018371 002	
--	---------	-----------------------	-------------	--

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N019870 001	Jun 10, 1993
--	---------	----------------------------------------------------------	-------------	--------------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG/100ML;220MG/100ML	N018840 001	Jun 29, 1983
--	-----------------	-----------------------------------------------------------	-------------	--------------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;200MG/100ML	N018037 006	Apr 13, 1982
----	-----------------	----------------------------------	-------------	--------------

AP		5GM/100ML;150MG/100ML;200MG/100ML	N018037 007	Apr 13, 1982
----	--	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;200MG/100ML	N018037 004	
----	-----------------	-----------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;200MG/100ML	N018037 008	Apr 13, 1982
----	-----------------	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;200MG/100ML	N018037 001	
----	-----------------	-----------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;200MG/100ML	N018037 005	Apr 13, 1982
----	-----------------	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;200MG/100ML	N018037 009	Apr 13, 1982
----	-----------------	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;200MG/100ML	N018037 002	
----	-----------------	----------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;200MG/100ML	N018037 003	
----	-----------------	-----------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629 005	Mar 23, 1982
----	-----------------	----------------------------------	-------------	--------------

AP		5GM/100ML;150MG/100ML;330MG/100ML	N018629 002	Mar 23, 1982
----	--	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629 003	Mar 23, 1982
----	-----------------	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;330MG/100ML	N018629 004	Mar 23, 1982
----	-----------------	-----------------------------------	-------------	--------------

AP		5GM/100ML;300MG/100ML;330MG/100ML	N018629 006	Mar 23, 1982
----	--	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629 007	Mar 23, 1982
----	-----------------	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;330MG/100ML	N018629 008	Mar 23, 1982
----	-----------------	-----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629 001	Mar 23, 1982
----	-----------------	----------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 010	
----	-----------------	-----------------------------------	-------------	--

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N019630 008	Feb 17, 1988
----	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N019630 014	Feb 17, 1988
----	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N019630 020	Feb 17, 1988
----	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML;900MG/100ML	N019630 026	Feb 17, 1988
----	---------	----------------------------------	-------------	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N019630 010	Feb 17, 1988
----	---------	-----------------------------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

	<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N019630 016 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N019630 022 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;150MG/100ML;900MG/100ML	N019630 028 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N019630 012 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N019630 018 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N019630 024 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;300MG/100ML;900MG/100ML	N019630 030 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 005 Apr 28, 1982
AP		5GM/100ML;150MG/100ML;450MG/100ML	N018008 006 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 005 Mar 28, 1988
AP		5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 009 Jul 05, 1983
	<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308 004 Apr 05, 1985
AP		5GM/100ML;150MG/100ML;900MG/100ML	N019308 002 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 002 Mar 24, 1988
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691 004 Mar 24, 1988
	<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362 006 Mar 28, 1988
	<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691 006 Mar 24, 1988
	<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 007 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;149MG/100ML;450MG/100ML	N018362 010 Jul 05, 1983
AP		5GM/100ML;298MG/100ML;450MG/100ML	N018362 007 Mar 28, 1988
	<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 005 Apr 05, 1985
AP		5GM/100ML;300MG/100ML;900MG/100ML	N019308 003 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;149MG/100ML;900MG/100ML	N019691 005 Mar 24, 1988
AP		5GM/100ML;298MG/100ML;900MG/100ML	N019691 008 Mar 24, 1988
	<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008 008 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362 002
	<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML	N019308 006 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691 007 Mar 24, 1988
	<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 009 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;298MG/100ML;450MG/100ML	N018362 003
	<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML	N019308 007 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;298MG/100ML;900MG/100ML	N019691 009 Mar 24, 1988
	<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 004
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 008 Mar 28, 1988
AP		5GM/100ML;149MG/100ML;450MG/100ML	N018362 004 Mar 28, 1988
	<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 001 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 001 Mar 24, 1988
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691 003 Mar 24, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630 031 Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630 037 Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630 043 Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630 001 Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630 007 Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630 013 Feb 17, 1988



## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;37MG/100ML;450MG/100ML	N019630 019	Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;37MG/100ML;900MG/100ML	N019630 025	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;75MG/100ML;200MG/100ML	N019630 032	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;75MG/100ML;450MG/100ML	N019630 038	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;75MG/100ML;900MG/100ML	N019630 044	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;75MG/100ML;300MG/100ML	N019630 049	May 07, 1992
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;75MG/100ML;110MG/100ML	N019630 002	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;110MG/100ML;200MG/100ML	N019630 033	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;110MG/100ML;450MG/100ML	N019630 039	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;110MG/100ML;900MG/100ML	N019630 045	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;110MG/100ML;300MG/100ML	N019630 050	May 07, 1992
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;110MG/100ML	N019630 003	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;200MG/100ML	N019630 009	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;330MG/100ML	N019630 015	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;450MG/100ML	N019630 021	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;110MG/100ML;900MG/100ML	N019630 027	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;200MG/100ML	N019630 034	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;450MG/100ML	N019630 040	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;150MG/100ML;900MG/100ML	N019630 046	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;150MG/100ML;300MG/100ML	N019630 051	May 07, 1992
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;150MG/100ML;110MG/100ML	N019630 004	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;200MG/100ML	N019630 035	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;450MG/100ML	N019630 041	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;220MG/100ML;900MG/100ML	N019630 047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;220MG/100ML;300MG/100ML	N019630 052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;110MG/100ML	N019630 005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N019630 011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N019630 017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N019630 023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;220MG/100ML;900MG/100ML	N019630 029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;200MG/100ML	N019630 036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;450MG/100ML	N019630 042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	10GM/100ML;300MG/100ML;900MG/100ML	N019630 048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	3.3GM/100ML;300MG/100ML;300MG/100ML	N019630 053	May 07, 1992
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML;300MG/100ML;110MG/100ML	N019630 006	Feb 17, 1988

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;74.5MG/100ML;225MG/100ML		N018365 002	Jul 05, 1983
		5GM/100ML;149MG/100ML;225MG/100ML		N018365 006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;74.5MG/100ML;300MG/100ML		N018876 001	Jan 17, 1986
		5GM/100ML;149MG/100ML;300MG/100ML		N018876 006	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;224MG/100ML;225MG/100ML		N018365 008	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;224MG/100ML;300MG/100ML		N018876 007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;149MG/100ML;225MG/100ML		N018365 001	
		5GM/100ML;298MG/100ML;225MG/100ML		N018365 009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;298MG/100ML;300MG/100ML		N018876 008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% IN SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;149MG/100ML;300MG/100ML		N018876 002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;224MG/100ML;225MG/100ML		N018365 003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;224MG/100ML;300MG/100ML		N018876 003	Jan 17, 1986
POTASSIUM CHLORIDE 40MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;298MG/100ML;225MG/100ML		N018365 004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;298MG/100ML;300MG/100ML		N018876 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;74.5MG/100ML;225MG/100ML		N018365 005	Mar 28, 1988
		5GM/100ML;149MG/100ML;225MG/100ML		N018365 007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;74.5MG/100ML;300MG/100ML		N018876 005	Mar 28, 1988
		5GM/100ML;149MG/100ML;300MG/100ML		N018876 009	Mar 28, 1988

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>10GM/100ML;900MG/100ML</u>		<u>N019631 015</u>	Feb 24, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>10GM/100ML;900MG/100ML</u>		<u>N016696 001</u>	
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>2.5GM/100ML;450MG/100ML</u>		<u>N019631 004</u>	Feb 24, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>2.5GM/100ML;450MG/100ML</u>		<u>N016697 001</u>	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>5GM/100ML;200MG/100ML</u>		<u>N019631 007</u>	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>5GM/100ML;330MG/100ML</u>		<u>N019631 008</u>	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>5GM/100ML;450MG/100ML</u>		<u>N019631 009</u>	Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;450MG/100ML</u>		<u>N017607 001</u>	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>5GM/100ML;900MG/100ML</u>		<u>N019631 010</u>	Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;900MG/100ML</u>		<u>N017585 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;200MG/100ML</u>		<u>N016689 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;330MG/100ML</u>		<u>N016687 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;450MG/100ML</u>		<u>N016683 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;900MG/100ML</u>		<u>N016678 001</u>	
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML;110MG/100ML		N019631 011	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML;200MG/100ML		N019631 012	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML;330MG/100ML		N019631 013	Feb 24, 1988
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML;450MG/100ML		N019631 014	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER					
	B BRAUN	2.5GM/100ML;110MG/100ML		N019631 001	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER					
	B BRAUN	2.5GM/100ML;200MG/100ML		N019631 002	Feb 24, 1988

## PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER B BRAUN 2.5GM/100ML; 330MG/100ML	N019631 003	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER B BRAUN 2.5GM/100ML; 900MG/100ML	N019631 005	Feb 24, 1988
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER B BRAUN 3.3GM/100ML; 300MG/100ML	N019631 016	Jan 19, 1990
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER B BRAUN 5GM/100ML; 110MG/100ML	N019631 006	Feb 24, 1988
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER HOSPIRA 5GM/100ML; 225MG/100ML	N017606 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER HOSPIRA 5GM/100ML; 300MG/100ML	N017799 001	

DIATRIZOATE MEGLUMINE

## SOLUTION; URETHRAL

## CYSTOGRAFIN

BRACCO 30%	N010040 018	
CYSTOGRAFIN DILUTE BRACCO 18%	N010040 022	Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

## INJECTABLE; INJECTION

**MD-76R**

**AP** + MALLINCKRODT **66%;10%** **N019292 001** Sep 29, 1989

**RENOGRAFIN-76**

**AP** + BRACCO **66%;10%** **N010040 001**

## SOLUTION; ORAL, RECTAL

**GASTROGRAFIN**

**AA** + BRACCO **66%;10%** **N011245 003**

**MD-GASTROVIEW**

**AA** MALLINCKRODT **66%;10%** **A087388 001**

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

## SOLUTION; INTRAUTERINE

## SINOGRAFIN

+ BRACCO 52.7%; 26.8% N011324 002

DIAZEPAM

## CONCENTRATE; ORAL

**DIAZEPAM**

**AA** LANNETT HOLDINGS INC **5MG/ML** **A204433 001** Apr 14, 2014

**DIAZEPAM INTENSOL**

**AA** + ROXANE **5MG/ML** **A071415 001** Apr 03, 1987

## GEL; RECTAL

## DIASTAT

VALEANT PHARMS NORTH 2.5MG/0.5ML (5MG/ML) N020648 001 Jul 29, 1997

## DIASTAT ACUDIAL

VALEANT PHARMS NORTH 10MG/2ML (5MG/ML) N020648 007 Sep 15, 2005

+ 20MG/4ML (5MG/ML) N020648 006 Sep 15, 2005

## INJECTABLE; INJECTION

**DIAZEPAM**

**AP** + HOSPIRA **5MG/ML** **A071583 001** Oct 13, 1987

**AP** **5MG/ML** **A072079 001** Dec 20, 1988

## SOLUTION; ORAL

## DIAZEPAM

+ ROXANE 5MG/5ML A070928 001 Apr 03, 1987

## TABLET; ORAL

**DIAZEPAM**

**AB** BARR **2MG** **A070152 001** Nov 01, 1985

**AB** **10MG** **A070154 001** Nov 01, 1985

**AB** IVAX SUB TEVA PHARMS **2MG** **A071307 001** Dec 10, 1986

**AB** **5MG** **A071321 001** Dec 10, 1986

**AB** **10MG** **A071322 001** Dec 10, 1986

**AB** MYLAN **2MG** **A070325 002** Sep 04, 1985

**AB** **5MG** **A070325 003** Sep 04, 1985

**AB** **10MG** **A070325 001** Sep 04, 1985

**AB** VINTAGE PHARMS **2MG** **A077749 001** Mar 31, 2006

**AB** **5MG** **A077749 002** Mar 31, 2006

**AB** **10MG** **A077749 003** Mar 31, 2006

**AB** WATSON LABS **2MG** **A071134 001** Feb 03, 1987

**AB** **5MG** **A071135 001** Feb 03, 1987

**AB** **10MG** **A071136 001** Feb 03, 1987

## PRESCRIPTION DRUG PRODUCT LIST

DIAZEPAM

TABLET; ORAL

VALIUM

<b>AB</b>	ROCHE	<b>2MG</b>	<b><u>N013263</u></b>	<b><u>002</u></b>
<b>AB</b>		<b>5MG</b>	<b><u>N013263</u></b>	<b><u>004</u></b>
<b>AB</b>	+	<b>10MG</b>	<b><u>N013263</u></b>	<b><u>006</u></b>

DIAZOXIDE

SUSPENSION; ORAL

PROGLYCEM

+	TEVA BRANDED PHARM	50MG/ML	N017453	001
---	--------------------	---------	---------	-----

DICLOFENAC

CAPSULE; ORAL

ZORVOLEX

	IROKO PHARMS LLC	18MG	N204592	001	Oct 18, 2013
+		35MG	N204592	002	Oct 18, 2013

DICLOFENAC EPOLAMINE

PATCH; TOPICAL

FLECTOR

+	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007
---	--------------	------	---------	-----	--------------

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

+	DEPOMED INC	25MG	N022202	001	Jun 16, 2009
---	-------------	------	---------	-----	--------------

FOR SOLUTION; ORAL

CAMBIA

+	DEPOMED INC	50MG	N022165	001	Jun 17, 2009
---	-------------	------	---------	-----	--------------

TABLET; ORAL

CATAFLAM

<b>AB</b>	+	NOVARTIS	<b>50MG</b>	<b><u>N020142</u></b>	<b><u>002</u></b>	Nov 24, 1993
-----------	---	----------	-------------	-----------------------	-------------------	--------------

DICLOFENAC POTASSIUM

<b>AB</b>		APOTEX	<b>50MG</b>	<b><u>A076561</u></b>	<b><u>001</u></b>	Mar 18, 2004
<b>AB</b>		MYLAN	<b>50MG</b>	<b><u>A075463</u></b>	<b><u>001</u></b>	Jul 26, 1999
<b>AB</b>		SANDOZ	<b>50MG</b>	<b><u>A075229</u></b>	<b><u>001</u></b>	Nov 20, 1998
<b>AB</b>		TEVA	<b>50MG</b>	<b><u>A075219</u></b>	<b><u>001</u></b>	Aug 06, 1998

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

<b>AB</b>		TOLMAR	<b>3%</b>	<b><u>A200936</u></b>	<b><u>001</u></b>	Oct 28, 2013
-----------	--	--------	-----------	-----------------------	-------------------	--------------

SOLARAZE

<b>AB</b>	+	FOUGERA PHARMS	<b>3%</b>	<b><u>N021005</u></b>	<b><u>001</u></b>	Oct 16, 2000
-----------	---	----------------	-----------	-----------------------	-------------------	--------------

VOLTAREN

+	NOVARTIS	1%	N022122	001	Oct 17, 2007
---	----------	----	---------	-----	--------------

SOLUTION; INTRAVENOUS

DYLOJECT

+	JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)	N022396	001	Dec 23, 2014
---	--------------------	-----------------------	---------	-----	--------------

SOLUTION; TOPICAL

DICLOFENAC SODIUM

<b>AT</b>		APOTEX INC	<b>1.5%</b>	<b><u>A202027</u></b>	<b><u>001</u></b>	May 27, 2014
<b>AT</b>		PADDOCK LLC	<b>1.5%</b>	<b><u>A202393</u></b>	<b><u>001</u></b>	Nov 24, 2014
<b>AT</b>		TARO	<b>1.5%</b>	<b><u>A203818</u></b>	<b><u>001</u></b>	Nov 26, 2014
<b>AT</b>		WATSON LABS INC	<b>1.5%</b>	<b><u>A202852</u></b>	<b><u>001</u></b>	Nov 24, 2014

PENNSAID

<b>AT</b>	+	NUVO RES INC	<b>1.5%</b>	<b><u>N020947</u></b>	<b><u>001</u></b>	Nov 04, 2009
	+	HORIZON PHARMA	2%	N204623	001	Jan 16, 2014

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

<b>AT</b>		AKORN	<b>0.1%</b>	<b><u>A077845</u></b>	<b><u>001</u></b>	Apr 17, 2008
<b>AT</b>		ALCON PHARMS LTD	<b>0.1%</b>	<b><u>A078031</u></b>	<b><u>001</u></b>	Feb 06, 2008
<b>AT</b>		BAUSCH AND LOMB	<b>0.1%</b>	<b><u>A078792</u></b>	<b><u>001</u></b>	Dec 28, 2007
<b>AT</b>		NEXUS PHARMS	<b>0.1%</b>	<b><u>A078553</u></b>	<b><u>001</u></b>	Dec 28, 2007

VOLTAREN

<b>AT</b>	+	NOVARTIS	<b>0.1%</b>	<b><u>N020037</u></b>	<b><u>001</u></b>	Mar 28, 1991
-----------	---	----------	-------------	-----------------------	-------------------	--------------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

<b>AB</b>		ACTAVIS ELIZABETH	<b>50MG</b>	<b><u>A074514</u></b>	<b><u>001</u></b>	Mar 26, 1996
<b>AB</b>			<b>75MG</b>	<b><u>A074514</u></b>	<b><u>002</u></b>	Mar 26, 1996
<b>AB</b>		CARLSBAD	<b>25MG</b>	<b><u>A075185</u></b>	<b><u>002</u></b>	Nov 13, 1998
<b>AB</b>			<b>50MG</b>	<b><u>A075185</u></b>	<b><u>003</u></b>	Nov 13, 1998
<b>AB</b>			<b>75MG</b>	<b><u>A075185</u></b>	<b><u>001</u></b>	Nov 13, 1998
<b>AB</b>		MYLAN PHARMS INC	<b>50MG</b>	<b><u>A075281</u></b>	<b><u>002</u></b>	Feb 12, 2002

## PRESCRIPTION DRUG PRODUCT LIST

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

<u>AB</u>		<u>75MG</u>	<u>A075281</u>	<u>003</u>	Feb 12, 2002
<u>AB</u>	+	<u>25MG</u>	<u>A074376</u>	<u>001</u>	Sep 28, 1995
<u>AB</u>	+	<u>50MG</u>	<u>A074376</u>	<u>002</u>	Sep 28, 1995
<u>AB</u>	+	<u>75MG</u>	<u>A074394</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A090066</u>	<u>001</u>	Dec 01, 2010
<u>AB</u>		<u>50MG</u>	<u>A090066</u>	<u>002</u>	Dec 01, 2010
<u>AB</u>		<u>75MG</u>	<u>A077863</u>	<u>003</u>	Jun 08, 2007

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075910</u>	<u>001</u>	Jan 07, 2002
<u>AB</u>	DEXCEL LTD	<u>100MG</u>	<u>A076201</u>	<u>001</u>	Nov 06, 2002
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A076152</u>	<u>001</u>	Dec 13, 2001
<u>AB</u>	VALEANT INTL	<u>100MG</u>	<u>A075492</u>	<u>001</u>	Feb 11, 2000

VOLTAREN-XR

<u>AB</u>	+	<u>100MG</u>	<u>N020254</u>	<u>001</u>	Mar 08, 1996
-----------	---	--------------	----------------	------------	--------------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

ARTHROTEC

<u>AB</u>	GD SEARLE LLC	<u>50MG;0.2MG</u>	<u>N020607</u>	<u>001</u>	Dec 24, 1997
<u>AB</u>	+	<u>75MG;0.2MG</u>	<u>N020607</u>	<u>002</u>	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

<u>AB</u>	ACTAVIS LABS FL INC	<u>50MG;0.2MG</u>	<u>A201089</u>	<u>001</u>	Jul 09, 2012
<u>AB</u>		<u>75MG;0.2MG</u>	<u>A201089</u>	<u>002</u>	Jul 09, 2012
<u>AB</u>	EAGLE PHARMS	<u>50MG;0.2MG</u>	<u>A200540</u>	<u>001</u>	Mar 14, 2014
<u>AB</u>		<u>75MG;0.2MG</u>	<u>A200540</u>	<u>002</u>	Mar 14, 2014
<u>AB</u>	SANDOZ	<u>50MG;0.2MG</u>	<u>A200158</u>	<u>001</u>	May 09, 2013
<u>AB</u>		<u>75MG;0.2MG</u>	<u>A200158</u>	<u>002</u>	May 09, 2013

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A061454</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A061454</u>	<u>003</u>	
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062286</u>	<u>001</u>	Jun 03, 1982
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062286</u>	<u>002</u>	Jun 03, 1982
	SANDOZ	<u>EQ 125MG BASE</u>	<u>A061454</u>	<u>002</u>	

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

BENTYL

<u>AB</u>	+	<u>10MG</u>	<u>N007409</u>	<u>003</u>	Oct 15, 1984
-----------	---	-------------	----------------	------------	--------------

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>10MG</u>	<u>A084285</u>	<u>001</u>	
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A040319</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A085082</u>	<u>001</u>	Jun 19, 1986

INJECTABLE;INJECTION

BENTYL

<u>AP</u>	+	<u>10MG/ML</u>	<u>N008370</u>	<u>001</u>	Oct 15, 1984
-----------	---	----------------	----------------	------------	--------------

BENTYL PRESERVATIVE FREE

<u>AP</u>	+	<u>10MG/ML</u>	<u>N008370</u>	<u>002</u>	Oct 15, 1984
-----------	---	----------------	----------------	------------	--------------

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)

<u>AP</u>	EUROHLTH INTL	<u>10MG/ML</u>	<u>A040465</u>	<u>001</u>	Jun 30, 2003
-----------	---------------	----------------	----------------	------------	--------------

SYRUP;ORAL

BENTYL

<u>AA</u>	+	<u>10MG/5ML</u>	<u>N007961</u>	<u>002</u>	Oct 15, 1984
-----------	---	-----------------	----------------	------------	--------------

DICYCLOMINE HYDROCHLORIDE

<u>AA</u>	MIKART	<u>10MG/5ML</u>	<u>A040169</u>	<u>001</u>	Mar 24, 2005
-----------	--------	-----------------	----------------	------------	--------------

TABLET;ORAL

BENTYL

<u>AB</u>	+	<u>20MG</u>	<u>N007409</u>	<u>001</u>	Oct 15, 1984
-----------	---	-------------	----------------	------------	--------------

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>20MG</u>	<u>A040230</u>	<u>001</u>	Feb 26, 1999
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A040317</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A085223</u>	<u>001</u>	Jul 30, 1986

## PRESCRIPTION DRUG PRODUCT LIST

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

<u>AB</u>	AUROBINDO PHARMA	<u>125MG</u>	<u>A090094 001</u>	Sep 24, 2008
<u>AB</u>		<u>200MG</u>	<u>A090094 002</u>	Sep 24, 2008
<u>AB</u>		<u>250MG</u>	<u>A090094 003</u>	Sep 24, 2008
<u>AB</u>		<u>400MG</u>	<u>A090094 004</u>	Sep 24, 2008
<u>AB</u>	BARR	<u>200MG</u>	<u>A077167 001</u>	Dec 03, 2004
<u>AB</u>		<u>250MG</u>	<u>A077167 002</u>	Dec 03, 2004
<u>AB</u>		<u>400MG</u>	<u>A077167 003</u>	Dec 03, 2004
<u>AB</u>	MYLAN PHARMS INC	<u>125MG</u>	<u>A090788 001</u>	Apr 08, 2010
<u>AB</u>		<u>200MG</u>	<u>A090788 002</u>	Apr 08, 2010
<u>AB</u>		<u>250MG</u>	<u>A090788 003</u>	Apr 08, 2010
<u>AB</u>		<u>400MG</u>	<u>A090788 004</u>	Apr 08, 2010

VIDEX EC

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>125MG</u>	<u>N021183 001</u>	Oct 31, 2000
<u>AB</u>		<u>200MG</u>	<u>N021183 002</u>	Oct 31, 2000
<u>AB</u>		<u>250MG</u>	<u>N021183 003</u>	Oct 31, 2000
<u>AB</u>	+	<u>400MG</u>	<u>N021183 004</u>	Oct 31, 2000

FOR SOLUTION;ORAL

DIDANOSINE

<u>AA</u>	AUROBINDO PHARMA	<u>10MG/ML</u>	<u>A078112 001</u>	Mar 08, 2007
-----------	------------------	----------------	--------------------	--------------

VIDEX

<u>AA</u>	+	BRISTOL MYERS SQUIBB	<u>10MG/ML</u>	<u>N020156 001</u>	Oct 09, 1991
-----------	---	----------------------	----------------	--------------------	--------------

TABLET, FOR SUSPENSION;ORAL

DIDANOSINE

AUROBINDO 100MG A077275 001 Aug 14, 2012

150MG A077275 002 Aug 14, 2012

+ 200MG A077275 003 Aug 14, 2012

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

NATAZIA

+ BAYER HLTHCARE 2MG;3MG;N/A;1MG;2MG;2MG;3MG;N/A N022252 001 May 06, 2010

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

<u>AA</u>	AVANTHI INC	<u>25MG</u>	<u>A201212 001</u>	Dec 22, 2010
<u>AA</u>	COREPHARMA	<u>25MG</u>	<u>A040828 001</u>	Nov 05, 2008
<u>AA</u>	LANNETT HOLDINGS INC	<u>25MG</u>	<u>A200177 001</u>	Jul 18, 2011

TENUATE

<u>AA</u>	+	WATSON PHARMS	<u>25MG</u>	<u>N011722 002</u>
-----------	---	---------------	-------------	--------------------

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

<u>AB</u>	LANNETT HOLDINGS INC	<u>75MG</u>	<u>A091680 001</u>	Oct 24, 2011
-----------	----------------------	-------------	--------------------	--------------

TENUATE DOSPAN

<u>AB</u>	+	WATSON PHARMS	<u>75MG</u>	<u>N012546 001</u>
-----------	---	---------------	-------------	--------------------

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263 001	Dec 20, 2002
----	---	----------------	-------	-------------	--------------

BX	+	TARO	0.05%	A075508 001	Apr 24, 2000
----	---	------	-------	-------------	--------------

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075374 001</u>	Apr 27, 1999
-----------	----------------	--------------	--------------------	--------------

<u>AB</u>	+	TARO	<u>0.05%</u>	<u>A075331 001</u>	May 14, 1999
-----------	---	------	--------------	--------------------	--------------

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

<u>AB</u>	EMCURE PHARMS USA	<u>500MG</u>	<u>A202845 001</u>	Mar 08, 2012
-----------	-------------------	--------------	--------------------	--------------

<u>AB</u>	+	TEVA	<u>500MG</u>	<u>A073673 001</u>	Jul 31, 1992
-----------	---	------	--------------	--------------------	--------------

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DUREZOL

+ ALCON PHARMS LTD 0.05% N022212 001 Jun 23, 2008

## PRESCRIPTION DRUG PRODUCT LIST

DIGOXIN

ELIXIR; ORAL

DIGOXIN

+ ROXANE

0.05MG/ML

N021648 001 Aug 26, 2004

INJECTABLE; INJECTION

DIGOXINAP HIKMA MAPLE0.25MG/MLA083391 001AP SANDOZ0.25MG/MLA040481 001 Aug 21, 2003LANOXINAP + COVIS INJECTABLES0.25MG/MLN009330 002

LANOXIN PEDIATRIC

+ COVIS INJECTABLES

0.1MG/ML

N009330 004

TABLET; ORAL

DIGOXINAB HIKMA INTL PHARMS0.125MGA077002 002 Oct 30, 2007AB0.25MGA077002 001 Oct 30, 2007AB IMPAX LABS0.125MGA078556 001 Jul 20, 2009AB0.25MGA078556 002 Jul 20, 2009AB STEVENS J0.125MGA076268 001 Jul 26, 2002AB0.25MGA076268 002 Jul 26, 2002LANOXINAB COVIS PHARMA0.125MGN020405 002 Sep 30, 1997AB +0.25MGN020405 004 Sep 30, 1997

DIGOXIN

MYLAN PHARMS INC

0.125MG

A040282 001 Dec 23, 1999

0.25MG

A040282 002 Dec 23, 1999

LANOXIN

COVIS PHARMA

0.0625MG

N020405 001 Sep 30, 1997

0.1875MG

N020405 003 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45AP + VALEANT1MG/MLN005929 001DIHYDROERGOTAMINE MESYLATEAP BEDFORD LABS1MG/MLA040453 001 Jun 09, 2003AP PADDOCK LLC1MG/MLA040475 001 Apr 28, 2003

SPRAY, METERED; NASAL

MIGRANAL

+ VALEANT

0.5MG/INH

N020148 001 Dec 08, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILACOR XRAB2 WATSON LABS120MGN020092 001 May 29, 1992AB2180MGN020092 002 May 29, 1992AB2 +240MGN020092 003 May 29, 1992DILTIAZEM HYDROCHLORIDEAB2 ACTAVIS LABS FL INC120MGA074852 001 Oct 10, 1997AB2180MGA074852 002 Oct 10, 1997AB2240MGA074852 003 Oct 10, 1997AB2 APOTEX120MGA074943 003 Dec 19, 2000AB2180MGA074943 002 Dec 19, 2000AB2240MGA074943 001 Aug 06, 1998AB2 MYLAN120MGA075124 002 Mar 18, 1998AB2180MGA075124 003 Mar 18, 1998AB2240MGA075124 001 Mar 18, 1998CARDIZEM CDAB3 VALEANT INTL120MGN020062 001 Aug 10, 1992AB3180MGN020062 002 Dec 27, 1991AB3240MGN020062 003 Dec 27, 1991AB3300MGN020062 004 Dec 27, 1991AB3 +360MGN020062 005 Aug 24, 1999CARTIA XTAB3 ACTAVIS LABS FL INC120MGA074752 002 Jul 09, 1998AB3180MGA074752 001 Jul 09, 1998AB3240MGA074752 003 Jul 09, 1998AB3300MGA074752 004 Jul 09, 1998DILT-CDAB3 APOTEX120MGA076151 001 May 20, 2004AB3180MGA076151 002 May 20, 2004AB3240MGA076151 003 May 20, 2004AB3300MGA076151 004 May 20, 2004

## PRESCRIPTION DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>	ACTAVIS ELIZABETH	<u>360MG</u>	<u>A202463</u>	<u>001</u>	Dec 07, 2012
<u>AB3</u>	PAR PHARM	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>		<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>		<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>		<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090492</u>	<u>001</u>	Oct 28, 2011
<u>AB3</u>		<u>180MG</u>	<u>A090492</u>	<u>002</u>	Oct 28, 2011
<u>AB3</u>		<u>240MG</u>	<u>A090492</u>	<u>003</u>	Oct 28, 2011
<u>AB3</u>		<u>300MG</u>	<u>A090492</u>	<u>004</u>	Oct 28, 2011
<u>AB3</u>		<u>360MG</u>	<u>A090492</u>	<u>005</u>	Oct 28, 2011
<u>AB3</u>	VALEANT INTL	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
<u>AB3</u>		<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999
<u>AB4</u>	SANDOZ	<u>120MG</u>	<u>A091022</u>	<u>001</u>	Sep 28, 2012
<u>AB4</u>		<u>180MG</u>	<u>A091022</u>	<u>002</u>	Sep 28, 2012
<u>AB4</u>		<u>240MG</u>	<u>A091022</u>	<u>003</u>	Sep 28, 2012
<u>AB4</u>		<u>300MG</u>	<u>A091022</u>	<u>004</u>	Sep 28, 2012
<u>AB4</u>		<u>360MG</u>	<u>A091022</u>	<u>005</u>	Sep 28, 2012
<u>AB4</u>		<u>420MG</u>	<u>A091022</u>	<u>006</u>	Sep 28, 2012
<u>AB4</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090421</u>	<u>001</u>	Nov 15, 2010
<u>AB4</u>		<u>180MG</u>	<u>A090421</u>	<u>002</u>	Nov 15, 2010
<u>AB4</u>		<u>240MG</u>	<u>A090421</u>	<u>003</u>	Nov 15, 2010
<u>AB4</u>		<u>300MG</u>	<u>A090421</u>	<u>004</u>	Nov 15, 2010
<u>AB4</u>		<u>360MG</u>	<u>A090421</u>	<u>005</u>	Nov 15, 2010

DILTIZAC

<u>AB4</u>	APOTEX INC	<u>120MG</u>	<u>A076395</u>	<u>001</u>	Feb 01, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076395</u>	<u>002</u>	Feb 01, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076395</u>	<u>003</u>	Feb 01, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076395</u>	<u>004</u>	Feb 01, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076395</u>	<u>005</u>	Feb 01, 2006

TAZTIA XT

<u>AB4</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A075401</u>	<u>001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401</u>	<u>002</u>	Apr 10, 2003
<u>AB4</u>		<u>240MG</u>	<u>A075401</u>	<u>003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401</u>	<u>004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401</u>	<u>005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	VALEANT INTL	<u>120MG</u>	<u>N020401</u>	<u>001</u>	Sep 11, 1995
<u>AB4</u>		<u>180MG</u>	<u>N020401</u>	<u>002</u>	Sep 11, 1995
<u>AB4</u>		<u>240MG</u>	<u>N020401</u>	<u>003</u>	Sep 11, 1995
<u>AB4</u>		<u>300MG</u>	<u>N020401</u>	<u>004</u>	Sep 11, 1995
<u>AB4</u>		<u>360MG</u>	<u>N020401</u>	<u>005</u>	Sep 11, 1995
<u>AB4</u>	+	<u>420MG</u>	<u>N020401</u>	<u>006</u>	Oct 16, 1998

DILTIAZEM HYDROCHLORIDE

BC	+	MYLAN	120MG	A074910	003	May 02, 1997
			60MG	A074910	001	May 02, 1997
			90MG	A074910	002	May 02, 1997

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075086</u>	<u>001</u>	Apr 09, 1998	
<u>AP</u>	+	BEDFORD	<u>5MG/ML</u>	<u>A074617</u>	<u>001</u>	Feb 28, 1996
<u>AP</u>	HIKMA FARMACEUTICA	<u>5MG/ML</u>	<u>A202651</u>	<u>001</u>	Aug 09, 2012	
<u>AP</u>	HIKMA MAPLE	<u>5MG/ML</u>	<u>A078538</u>	<u>001</u>	Dec 17, 2008	
<u>AP</u>	HOSPIRA	<u>5MG/ML</u>	<u>A074941</u>	<u>001</u>	Apr 15, 1998	
<u>AP</u>	INTL MEDICATION	<u>5MG/ML</u>	<u>A075749</u>	<u>001</u>	Nov 21, 2001	
	+	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002
	+	TEVA PHARMS USA	10MG/ML	A074894	002	Apr 19, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	VALEANT INTL	<u>30MG</u>	<u>N018602</u>	<u>001</u>	Nov 05, 1982
<u>AB</u>		<u>60MG</u>	<u>N018602</u>	<u>002</u>	Nov 05, 1982
<u>AB</u>		<u>90MG</u>	<u>N018602</u>	<u>003</u>	Dec 08, 1986
<u>AB</u>	+	<u>120MG</u>	<u>N018602</u>	<u>004</u>	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>30MG</u>	<u>A072838</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A072838</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A072838</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A072838</u>	<u>001</u>	Nov 05, 1992



## PRESCRIPTION DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>		<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

<u>AB</u>	VALEANT INTL	<u>120MG</u>	<u>N021392</u>	<u>001</u>	Feb 06, 2003
<u>AB</u>		<u>180MG</u>	<u>N021392</u>	<u>002</u>	Feb 06, 2003
<u>AB</u>		<u>240MG</u>	<u>N021392</u>	<u>003</u>	Feb 06, 2003
<u>AB</u>		<u>300MG</u>	<u>N021392</u>	<u>004</u>	Feb 06, 2003
<u>AB</u>		<u>360MG</u>	<u>N021392</u>	<u>005</u>	Feb 06, 2003
<u>AB</u>	+	<u>420MG</u>	<u>N021392</u>	<u>006</u>	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A077686</u>	<u>006</u>	Mar 15, 2010
<u>AB</u>		<u>180MG</u>	<u>A077686</u>	<u>005</u>	Mar 15, 2010
<u>AB</u>		<u>240MG</u>	<u>A077686</u>	<u>004</u>	Mar 15, 2010
<u>AB</u>		<u>300MG</u>	<u>A077686</u>	<u>003</u>	Mar 15, 2010
<u>AB</u>		<u>360MG</u>	<u>A077686</u>	<u>002</u>	Mar 15, 2010
<u>AB</u>		<u>420MG</u>	<u>A077686</u>	<u>001</u>	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

+	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004
---	--------------------	---------	---------	-----	--------------

DIMERCAPROL

INJECTABLE; INJECTION

BAL

+	AKORN	10%	N005939	001	
---	-------	-----	---------	-----	--

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

	BIOGEN IDEC INC	120MG	N204063	001	Mar 27, 2013
+		240MG	N204063	002	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

<u>AT</u>	MYLAN INSTITUTIONAL	<u>50%</u>	<u>A076185</u>	<u>001</u>	Nov 29, 2002
	<u>RIMSO-50</u>				
<u>AT</u>	+	<u>50%</u>	<u>N017788</u>	<u>001</u>	

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

+	PHARMACIA AND UPJOHN	0.5MG/3GM	N019617	001	Dec 09, 1992
---	----------------------	-----------	---------	-----	--------------

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

+	FERRING CONTROLLED	10MG	N020411	001	Mar 30, 1995
---	--------------------	------	---------	-----	--------------

SUPPOSITORY; VAGINAL

PROSTIN E2

+	PHARMACIA AND UPJOHN	20MG	N017810	001	
---	----------------------	------	---------	-----	--

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	BARR	50MG	A080738	001	
---	------	------	---------	-----	--

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982
---	-------------	------------	---------	-----	--------------

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>50MG/ML</u>	<u>A040466</u>	<u>001</u>	May 28, 2002
<u>AP</u>	+	<u>50MG/ML</u>	<u>A080817</u>	<u>002</u>	
<u>AP</u>	HOSPIRA	<u>50MG/ML</u>	<u>A040140</u>	<u>001</u>	Nov 20, 1998
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/ML</u>	<u>A040498</u>	<u>001</u>	Jul 12, 2005
	<u>DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE</u>				
<u>AP</u>	BD RX	<u>50MG/ML</u>	<u>A091526</u>	<u>001</u>	Mar 26, 2013

## PRESCRIPTION DRUG PRODUCT LIST

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

<u>AP</u>	+	BEDFORD	<u>5MG/ML</u>	<u>A074939</u>	<u>001</u>	Apr 13, 1998
<u>AP</u>		FRESENIUS KABI USA	<u>5MG/ML</u>	<u>A074956</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		HIKMA MAPLE	<u>5MG/ML</u>	<u>A074521</u>	<u>001</u>	Oct 18, 1996

TABLET; ORAL

DIPYRIDAMOLE

<u>AB</u>		BARR	<u>25MG</u>	<u>A087184</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>			<u>50MG</u>	<u>A087716</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>			<u>75MG</u>	<u>A087717</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>		IMPAX LABS	<u>25MG</u>	<u>A040782</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>			<u>50MG</u>	<u>A040782</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>			<u>75MG</u>	<u>A040782</u>	<u>003</u>	Jul 18, 2007
<u>AB</u>		LANNETT	<u>25MG</u>	<u>A040898</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>			<u>50MG</u>	<u>A040898</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>			<u>75MG</u>	<u>A040898</u>	<u>003</u>	Apr 23, 2008
<u>AB</u>		MURTY PHARMS	<u>25MG</u>	<u>A040733</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>			<u>50MG</u>	<u>A040733</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>			<u>75MG</u>	<u>A040733</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		PUREPAC PHARM	<u>25MG</u>	<u>A089425</u>	<u>001</u>	Jul 12, 1990
<u>AB</u>		ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A040874</u>	<u>001</u>	Jan 28, 2008
<u>AB</u>			<u>50MG</u>	<u>A040874</u>	<u>002</u>	Jan 28, 2008
<u>AB</u>			<u>75MG</u>	<u>A040874</u>	<u>003</u>	Jan 28, 2008

PERSANTINE

<u>AB</u>		BOEHRINGER INGELHEIM	<u>25MG</u>	<u>N012836</u>	<u>003</u>	Dec 22, 1986
<u>AB</u>			<u>50MG</u>	<u>N012836</u>	<u>004</u>	Feb 06, 1987
<u>AB</u>	+		<u>75MG</u>	<u>N012836</u>	<u>005</u>	Feb 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>		TEVA	<u>EQ 100MG BASE</u>	<u>A070101</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A070102</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>		WATSON LABS	<u>EQ 100MG BASE</u>	<u>A070173</u>	<u>001</u>	May 31, 1985
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A070174</u>	<u>001</u>	May 31, 1985

NORPACE

<u>AB</u>		GD SEARLE LLC	<u>EQ 100MG BASE</u>	<u>N017447</u>	<u>001</u>	
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N017447</u>	<u>002</u>	

CAPSULE, EXTENDED RELEASE; ORAL

NORPACE CR

<u>AB</u>	+	GD SEARLE LLC	<u>EQ 150MG BASE</u>	<u>N018655</u>	<u>002</u>	Jul 20, 1982
			EQ 100MG BASE	<u>N018655</u>	<u>001</u>	Jul 20, 1982

DISULFIRAM

TABLET; ORAL

ANTABUSE

<u>AB</u>		ODYSSEY PHARMS	<u>250MG</u>	<u>A088482</u>	<u>001</u>	Dec 08, 1983
<u>AB</u>	+		<u>500MG</u>	<u>A088483</u>	<u>001</u>	Dec 08, 1983

DISULFIRAM

<u>AB</u>		ROXANE	<u>250MG</u>	<u>A202652</u>	<u>001</u>	Feb 05, 2014
<u>AB</u>			<u>500MG</u>	<u>A202652</u>	<u>002</u>	Feb 05, 2014
<u>AB</u>		SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A091619</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>			<u>500MG</u>	<u>A091619</u>	<u>002</u>	Mar 28, 2011
<u>AB</u>		VINTAGE PHARMS	<u>250MG</u>	<u>A091563</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>500MG</u>	<u>A091563</u>	<u>002</u>	Dec 31, 2012

DISULFIRAM

<u>AB</u>		ALVOGEN PINE BROOK	<u>250MG</u>	<u>A091681</u>	<u>001</u>	Aug 08, 2013
-----------	--	--------------------	--------------	----------------	------------	--------------

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

<u>AB</u>	+	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680</u>	<u>001</u>	Sep 12, 1989
-----------	---	--------	-------------------------------	----------------	------------	--------------

DIVALPROEX SODIUM

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979</u>	<u>001</u>	Jan 23, 2009
<u>AB</u>		MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090407</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919</u>	<u>001</u>	Jan 27, 2009

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

<u>AB</u>		ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723</u>	<u>003</u>	Oct 26, 1984
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>N018723</u>	<u>001</u>	Mar 10, 1983
<u>AB</u>	+		<u>EQ 500MG VALPROIC ACID</u>	<u>N018723</u>	<u>002</u>	Mar 10, 1983

## PRESCRIPTION DRUG PRODUCT LIST

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 500MG VALPROIC ACID</u>	<u>A079080 001</u>	Feb 25, 2011
<u>AB</u>	ANCHEN PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078411 001</u>	Nov 03, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A090554 001</u>	Apr 21, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090554 002</u>	Apr 21, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090554 003</u>	Apr 21, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078755 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078755 003</u>	Jul 29, 2008
<u>AB</u>	LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078790 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078790 003</u>	Jul 29, 2008
<u>AB</u>	MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090062 001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090062 002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090062 003</u>	Mar 17, 2009
<u>AB</u>	NU PHARM	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615 003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077615 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077615 001</u>	Jul 29, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853 001</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078853 002</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078853 003</u>	Nov 25, 2008
<u>AB</u>	SANDOZ	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290 003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078290 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078290 001</u>	Jul 29, 2008
<u>AB</u>	SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078597 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078597 003</u>	Jul 29, 2008
<u>AB</u>	TEVA	<u>EQ 125MG VALPROIC ACID</u>	<u>A076941 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A076941 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A076941 003</u>	Jul 29, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A079163 001</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A079163 002</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A079163 003</u>	Apr 05, 2011
<u>AB</u>	UPSHER SMITH	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078182 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078182 003</u>	Jul 29, 2008
<u>AB</u>	VINTAGE	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210 001</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090210 002</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090210 003</u>	Nov 30, 2009
<u>AB</u>	WOCKHARDT	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296 001</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077296 002</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077296 003</u>	Jul 31, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100 001</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077100 002</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077100 003</u>	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

<u>AB</u>	ABBVIE	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168 002</u>	May 31, 2002
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168 001</u>	Aug 04, 2000
<u>DIVALPROEX SODIUM</u>				
<u>AB</u>	ANCHEN PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078445 001</u>	Feb 26, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078445 002</u>	Aug 04, 2009
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A202419 001</u>	Jun 02, 2014
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A202419 002</u>	Jun 02, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A090161 001</u>	Mar 15, 2012
<u>AB</u>	IMPAX LABS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078791 001</u>	May 06, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078791 002</u>	Aug 04, 2009
<u>AB</u>	MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567 001</u>	Jan 29, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077567 002</u>	Jan 29, 2009
<u>AB</u>	REDDYS	<u>EQ 500MG VALPROIC ACID</u>	<u>A090070 001</u>	Mar 12, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705 002</u>	Feb 10, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078705 001</u>	Aug 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239 001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078239 002</u>	Aug 04, 2009

## PRESCRIPTION DRUG PRODUCT LIST

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL	<u>EQ 12.5MG BASE/ML</u>	<u>A074277 001</u>	Oct 31, 1994
<u>AP</u>	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086 001</u>	Nov 29, 1993
<u>AP</u>	+	<u>EQ 12.5MG BASE/ML</u>	<u>A074292 001</u>	Feb 16, 1995
<u>DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	+ BAXTER HLTHCARE	<u>EQ 50MG BASE/100ML</u>	<u>N020255 001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020255 003</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020255 004</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 400MG BASE/100ML</u>	<u>N020255 005</u>	Oct 19, 1993
<u>AP</u>	+ HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020201 003</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 100MG BASE/100ML</u>	<u>N020201 002</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 200MG BASE/100ML</u>	<u>N020201 001</u>	Oct 19, 1993
<u>AP</u>	+	<u>EQ 400MG BASE/100ML</u>	<u>N020201 006</u>	Jul 07, 1994

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

<u>AP</u>	ACCORD HLTHCARE	<u>20MG/ML (20MG/ML)</u>	<u>N201195 003</u>	Apr 20, 2012
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N201195 004</u>	Apr 20, 2012
<u>AP</u>	+	<u>160MG/8ML (20MG/ML)</u>	<u>N201195 005</u>	Apr 20, 2012
<u>AP</u>	ACTAVIS INC	<u>20MG/ML (20MG/ML)</u>	<u>N203551 001</u>	Apr 12, 2013
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N203551 002</u>	Apr 12, 2013
<u>AP</u>	DR REDDYS LABS LTD	<u>20MG/ML (20MG/ML)</u>	<u>A204193 001</u>	Nov 05, 2014
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A204193 002</u>	Nov 05, 2014
<u>AP</u>	+ HOSPIRA INC	<u>20MG/2ML (10MG/ML)</u>	<u>N022234 001</u>	Mar 08, 2011
<u>AP</u>	+	<u>80MG/8ML (10MG/ML)</u>	<u>N022234 002</u>	Mar 08, 2011
<u>AP</u>	+	<u>160MG/16ML (10MG/ML)</u>	<u>N022234 003</u>	Mar 08, 2011
<u>AP</u>	SANDOZ	<u>20MG/2ML (10MG/ML)</u>	<u>N201525 001</u>	Jun 29, 2011
<u>AP</u>		<u>80MG/8ML (10MG/ML)</u>	<u>N201525 002</u>	Jun 29, 2011
<u>AP</u>		<u>160MG/16ML (10MG/ML)</u>	<u>N201525 003</u>	Jun 29, 2011

TAXOTERE

<u>AP</u>	+ SANOFI AVENTIS US	<u>20MG/ML (20MG/ML)</u>	<u>N020449 003</u>	Aug 03, 2010
<u>AP</u>	+	<u>80MG/4ML (20MG/ML)</u>	<u>N020449 004</u>	Aug 02, 2010
<u>AP</u>	+	<u>160MG/8ML (20MG/ML)</u>	<u>N020449 005</u>	Apr 13, 2012

## DOCEFREZ

+	SUN PHARMA GLOBAL	20MG/VIAL	N022534 001	May 03, 2011
+		80MG/VIAL	N022534 002	May 03, 2011

## DOCETAXEL

ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011
	80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011
ACTAVIS INC	140MG/7ML (20MG/ML)	N203551 003	Apr 12, 2013
PFIZER LABS	20MG/2ML (10MG/ML)	N202356 001	Mar 13, 2014
	80MG/8ML (10MG/ML)	N202356 002	Mar 13, 2014
	130MG/13ML (10MG/ML)	N202356 003	Mar 13, 2014
	200MG/20ML (10MG/ML)	N202356 004	Mar 13, 2014

DOFETILIDE

CAPSULE; ORAL

## TIKOSYN

PFIZER	0.125MG	N020931 001	Oct 01, 1999
	0.25MG	N020931 002	Oct 01, 1999
+	0.5MG	N020931 003	Oct 01, 1999

DOLASETRON MESYLATE

INJECTABLE; INJECTION

## ANZEMET

+	SANOFI AVENTIS US	12.5MG/0.625ML (20MG/ML)	N020624 002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624 001	Sep 11, 1997
+		500MG/25ML (20MG/ML)	N020624 003	Dec 11, 2001

TABLET; ORAL

## ANZEMET

SANOFI AVENTIS US	50MG	N020623 001	Sep 11, 1997
+	100MG	N020623 002	Sep 11, 1997

DOLUTEGRAVIR SODIUM

TABLET; ORAL

## TIVICAY

+	VIIIV HLTHCARE	EQ 50MG BASE	N204790 001	Aug 12, 2013
---	----------------	--------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N020690</u>	<u>002</u>	Nov 25, 1996
<u>AB</u>	+	<u>10MG</u>	<u>N020690</u>	<u>001</u>	Nov 25, 1996
<u>AB</u>	+	<u>23MG</u>	<u>N022568</u>	<u>001</u>	Jul 23, 2010

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201724</u>	<u>001</u>	Feb 25, 2013
<u>AB</u>		<u>10MG</u>	<u>A201724</u>	<u>002</u>	Feb 25, 2013
<u>AB</u>	APOTEX	<u>5MG</u>	<u>A078841</u>	<u>001</u>	Jun 02, 2011
<u>AB</u>		<u>10MG</u>	<u>A078841</u>	<u>002</u>	Jun 02, 2011
<u>AB</u>	AUROBINDO	<u>5MG</u>	<u>A090056</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090056</u>	<u>002</u>	May 31, 2011
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077518</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A077518</u>	<u>002</u>	May 31, 2011
<u>AB</u>	CSPC OUYI PHARM CO	<u>5MG</u>	<u>A202114</u>	<u>001</u>	Jul 05, 2013
<u>AB</u>		<u>10MG</u>	<u>A202114</u>	<u>002</u>	Jul 05, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A201001</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A201001</u>	<u>002</u>	May 31, 2011
<u>AB</u>		<u>23MG</u>	<u>A202723</u>	<u>001</u>	Jul 24, 2013
<u>AB</u>	HIKMA PHARMS	<u>5MG</u>	<u>A090247</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090247</u>	<u>002</u>	May 31, 2011
<u>AB</u>	INDICUS PHARMA	<u>5MG</u>	<u>A201634</u>	<u>001</u>	Jun 13, 2012
<u>AB</u>		<u>10MG</u>	<u>A201634</u>	<u>002</u>	Jun 13, 2012
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A090768</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090768</u>	<u>002</u>	May 31, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201146</u>	<u>001</u>	Aug 17, 2012
<u>AB</u>		<u>10MG</u>	<u>A201146</u>	<u>002</u>	Aug 17, 2012
<u>AB</u>		<u>23MG</u>	<u>A202631</u>	<u>001</u>	Jan 22, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A090521</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090521</u>	<u>002</u>	May 31, 2011
<u>AB</u>	PAR PHARM	<u>23MG</u>	<u>A202542</u>	<u>001</u>	Jul 24, 2013
<u>AB</u>	PLIVA HRVATSKA DOO	<u>5MG</u>	<u>A090425</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090425</u>	<u>002</u>	May 31, 2011
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A200292</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A200292</u>	<u>002</u>	May 31, 2011
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076786</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A076786</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A078662</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A078662</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A090290</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090290</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203907</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>		<u>10MG</u>	<u>A203907</u>	<u>002</u>	Oct 29, 2014
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090493</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090493</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TEVA	<u>5MG</u>	<u>A077344</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A077344</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A090686</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090686</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TWI PHARMS INC	<u>23MG</u>	<u>A203104</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>	VIVIMED LABS	<u>5MG</u>	<u>A090551</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090551</u>	<u>002</u>	May 31, 2011
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A091267</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A091267</u>	<u>002</u>	May 31, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090100</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>		<u>10MG</u>	<u>A090100</u>	<u>002</u>	Oct 24, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N021720</u>	<u>001</u>	Oct 18, 2004
<u>AB</u>	+	<u>10MG</u>	<u>N021720</u>	<u>002</u>	Oct 18, 2004
	<u>DONEPEZIL HYDROCHLORIDE</u>				
<u>AB</u>	BARR	<u>5MG</u>	<u>A078388</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A078388</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201787</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>		<u>10MG</u>	<u>A201787</u>	<u>002</u>	Dec 14, 2012
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A091198</u>	<u>001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A091198</u>	<u>002</u>	May 10, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090175</u>	<u>001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A090175</u>	<u>002</u>	May 10, 2011

## PRESCRIPTION DRUG PRODUCT LIST

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMZARIC

FOREST LABS INC	10MG;14MG	N206439	001	Dec 23, 2014
+	10MG;28MG	N206439	002	Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>40MG/ML</u>	<u>N018132</u>	<u>001</u>	
<u>AP</u>	+		<u>80MG/100ML</u>	<u>N018132</u>	<u>002</u>	Feb 04, 1982
<u>AP</u>	+		<u>80MG/ML</u>	<u>N018132</u>	<u>004</u>	Jul 09, 1982
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018132</u>	<u>003</u>	Feb 04, 1982
<u>AP</u>	+	LUITPOLD	<u>40MG/ML</u>	<u>A070799</u>	<u>001</u>	Feb 11, 1987
<u>AP</u>	+		<u>80MG/ML</u>	<u>A070820</u>	<u>001</u>	Feb 11, 1987
<u>AP</u>	+		<u>160MG/ML</u>	<u>A070826</u>	<u>001</u>	Feb 11, 1987

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

<u>AP</u>	+	B BRAUN	<u>80MG/100ML</u>	<u>N019099</u>	<u>002</u>	Oct 15, 1986
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019099</u>	<u>004</u>	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>160MG/100ML</u>	<u>N019099</u>	<u>003</u>	Oct 15, 1986
-----------	---	---------	--------------------	----------------	------------	--------------

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>80MG/100ML</u>	<u>N019615</u>	<u>001</u>	Mar 27, 1987
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N019615</u>	<u>002</u>	Mar 27, 1987
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019615</u>	<u>003</u>	Mar 27, 1987
<u>AP</u>	+	HOSPIRA	<u>80MG/100ML</u>	<u>N018826</u>	<u>001</u>	Sep 30, 1983
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018826</u>	<u>002</u>	Sep 30, 1983
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N018826</u>	<u>003</u>	Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986
---	---------	------------	---------	-----	--------------

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	640MG/100ML	N019615	004	Mar 27, 1987
---	-----------------	-------------	---------	-----	--------------

DORIPENEM

INJECTABLE; IV (INFUSION)

DORIBAX

SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010
+	500MG/VIAL	N022106	001	Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

<u>AT</u>		ALCON PHARMS LTD	<u>EQ 2% BASE</u>	<u>A078981</u>	<u>001</u>	Apr 13, 2009
<u>AT</u>		BAUSCH AND LOMB	<u>EQ 2% BASE</u>	<u>A090143</u>	<u>001</u>	Jun 25, 2009
<u>AT</u>		HI TECH PHARMA	<u>EQ 2% BASE</u>	<u>A077846</u>	<u>001</u>	Oct 28, 2008
<u>AT</u>		LUITPOLD	<u>EQ 2% BASE</u>	<u>A079186</u>	<u>001</u>	Nov 18, 2009
<u>AT</u>		SANDOZ	<u>EQ 2% BASE</u>	<u>A078748</u>	<u>001</u>	Nov 06, 2008
<u>AT</u>		TEVA PHARMS	<u>EQ 2% BASE</u>	<u>A078756</u>	<u>001</u>	Dec 04, 2008
<u>AT</u>		WATSON LABS INC	<u>EQ 2% BASE</u>	<u>A202053</u>	<u>001</u>	Sep 11, 2014
<u>AT</u>		ZACH SYSTEMS	<u>EQ 2% BASE</u>	<u>A091034</u>	<u>001</u>	Dec 04, 2013

TRUSOPT

<u>AT</u>	+	MERCK	<u>EQ 2% BASE</u>	<u>N020408</u>	<u>001</u>	Dec 09, 1994
-----------	---	-------	-------------------	----------------	------------	--------------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

<u>AT</u>	+	OAK PHARMS INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>N020869</u>	<u>001</u>	Apr 07, 1998
-----------	---	----------------	--------------------------------	----------------	------------	--------------

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

<u>AT</u>		AKORN INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A203058</u>	<u>001</u>	Sep 22, 2014
<u>AT</u>		ALCON RES	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090604</u>	<u>001</u>	Nov 18, 2009
<u>AT</u>		BAUSCH AND LOMB	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090037</u>	<u>001</u>	Jul 14, 2009
<u>AT</u>		HI TECH PHARMA	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A077847</u>	<u>001</u>	Oct 28, 2008
<u>AT</u>		LANNETT HOLDINGS INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A201998</u>	<u>001</u>	Dec 17, 2014
<u>AT</u>		SANDOZ	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078749</u>	<u>001</u>	Nov 06, 2008
<u>AT</u>		TEVA PHARMS	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078704</u>	<u>001</u>	Sep 28, 2009
<u>AT</u>		WATSON LABS INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A202054</u>	<u>001</u>	Sep 03, 2014
<u>AT</u>		ZACH SYSTEMS	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A091180</u>	<u>001</u>	Dec 04, 2013

COSOPT PF

+	OAK PHARMS INC	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012
---	----------------	-------------------------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

<u>AP</u>	+	HIKMA MAPLE	<u>20MG/ML</u>	<u>N014879</u>	<u>001</u>	
<u>DOXAPRAM HYDROCHLORIDE</u>						
<u>AP</u>		BEDFORD	<u>20MG/ML</u>	<u>A076266</u>	<u>001</u>	Jan 10, 2003

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

<u>AB</u>	+	PFIZER	<u>EQ 1MG BASE</u>	<u>N019668</u>	<u>001</u>	Nov 02, 1990
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>N019668</u>	<u>002</u>	Nov 02, 1990
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>N019668</u>	<u>003</u>	Nov 02, 1990
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>N019668</u>	<u>004</u>	Nov 02, 1990

DOXAZOSIN MESYLATE

<u>AB</u>		ACCORD HLTHCARE	<u>EQ 1MG BASE</u>	<u>A202824</u>	<u>001</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A202824</u>	<u>002</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A202824</u>	<u>003</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A202824</u>	<u>004</u>	Jun 11, 2014
<u>AB</u>		APOTEX	<u>EQ 1MG BASE</u>	<u>A075580</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075580</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A075580</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A075580</u>	<u>004</u>	Oct 18, 2000
<u>AB</u>		DAVA PHARMS INC	<u>EQ 1MG BASE</u>	<u>A076161</u>	<u>001</u>	Jun 10, 2004
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A076161</u>	<u>002</u>	Jun 10, 2004
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A076161</u>	<u>003</u>	Jun 10, 2004
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A076161</u>	<u>004</u>	Jun 10, 2004
<u>AB</u>		MYLAN	<u>EQ 1MG BASE</u>	<u>A075509</u>	<u>001</u>	Oct 19, 2000
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075509</u>	<u>002</u>	Oct 19, 2000
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A075509</u>	<u>003</u>	Oct 19, 2000
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A075509</u>	<u>004</u>	Oct 19, 2000
<u>AB</u>		PLIVA	<u>EQ 1MG BASE</u>	<u>A075750</u>	<u>001</u>	Jun 08, 2001
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075750</u>	<u>002</u>	Jun 08, 2001
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A075750</u>	<u>003</u>	Jun 08, 2001
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A075750</u>	<u>004</u>	Jun 08, 2001
<u>AB</u>		TEVA	<u>EQ 1MG BASE</u>	<u>A075536</u>	<u>001</u>	Oct 18, 2000
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075536</u>	<u>002</u>	Oct 18, 2000
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A075536</u>	<u>003</u>	Oct 18, 2000
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A075536</u>	<u>004</u>	Oct 18, 2000

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

PFIZER

+

EQ 4MG BASE

N021269 001

Feb 22, 2005

EQ 8MG BASE

N021269 002

Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>		MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A070791</u>	<u>002</u>	May 13, 1986
<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>A070791</u>	<u>003</u>	May 13, 1986
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A070791</u>	<u>001</u>	May 13, 1986
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A070791</u>	<u>004</u>	May 13, 1986
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A070791</u>	<u>005</u>	May 13, 1986
		PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>		SILARX	<u>EQ 10MG BASE/ML</u>	<u>A074721</u>	<u>001</u>	Dec 29, 1998
<u>AA</u>	+	TEVA PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A071609</u>	<u>001</u>	Nov 09, 1987
<u>AA</u>		WOCKHARDT	<u>EQ 10MG BASE/ML</u>	<u>A071918</u>	<u>001</u>	Jul 20, 1988

CREAM; TOPICAL

ZONALON

+

FOUGERA PHARMS

5%

N020126 001

Apr 01, 1994

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 3MG BASE</u>	<u>A201951</u>	<u>001</u>	Jul 26, 2013
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A201951</u>	<u>002</u>	Jul 26, 2013

SILENOR

<u>AB</u>		PERNIX THERAPS LLC	<u>EQ 3MG BASE</u>	<u>N022036</u>	<u>001</u>	Mar 17, 2010
<u>AB</u>	+		<u>EQ 6MG BASE</u>	<u>N022036</u>	<u>002</u>	Mar 17, 2010

## PRESCRIPTION DRUG PRODUCT LIST

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

<u>AB</u>	ROXANE	<u>0.5MCG</u>	<u>A091433</u>	<u>001</u>	Sep 23, 2011
<u>AB</u>		<u>1MCG</u>	<u>A091433</u>	<u>002</u>	Jan 14, 2014
<u>AB</u>		<u>2.5MCG</u>	<u>A091433</u>	<u>003</u>	Jan 14, 2014

HECTOROL

<u>AB</u>	GENZYME CORP	<u>0.5MCG</u>	<u>N020862</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>1MCG</u>	<u>N020862</u>	<u>003</u>	Jul 13, 2009
<u>AB</u>	+	<u>2.5MCG</u>	<u>N020862</u>	<u>001</u>	Jun 09, 1999

INJECTABLE; INJECTION

DOXERCALCIFEROL

<u>AP</u>	HIKMA PHARMS LLC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091101</u>	<u>001</u>	Aug 30, 2013
<u>AP</u>	SANDOZ	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091333</u>	<u>001</u>	May 05, 2014
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A200926</u>	<u>001</u>	Feb 04, 2014

HECTOROL

<u>AP</u>	+	GENZYME CORP	<u>4MCG/2ML (2MCG/ML)</u>	<u>N021027</u>	<u>001</u>	Apr 06, 2000
			2MCG/ML (2MCG/ML)	<u>N021027</u>	<u>002</u>	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	ACTAVIS INC	<u>2MG/ML</u>	<u>A203622</u>	<u>001</u>	Jun 27, 2014	
<u>AP</u>	ALVOGEN INC	<u>2MG/ML</u>	<u>A065515</u>	<u>001</u>	Nov 08, 2012	
<u>AP</u>	+	EUROHLTH INTL	<u>2MG/ML</u>	<u>A062975</u>	<u>001</u>	Mar 17, 1989
<u>AP</u>	+		<u>10MG/VIAL</u>	<u>A062921</u>	<u>001</u>	Mar 17, 1989
<u>AP</u>	+		<u>20MG/VIAL</u>	<u>A062921</u>	<u>002</u>	Mar 17, 1989
<u>AP</u>	+		<u>50MG/VIAL</u>	<u>A062921</u>	<u>003</u>	Mar 17, 1989
<u>AP</u>	+		<u>200MG/100ML</u>	<u>A064097</u>	<u>001</u>	Sep 13, 1994
<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>A063277</u>	<u>001</u>	Oct 26, 1995	
<u>AP</u>	ONCO THERAPIES LTD	<u>2MG/ML</u>	<u>A200901</u>	<u>001</u>	Feb 14, 2012	
<u>AP</u>		<u>10MG/VIAL</u>	<u>A200170</u>	<u>001</u>	Oct 28, 2011	
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200170</u>	<u>002</u>	Oct 28, 2011	
<u>AP</u>	PHARMACHEMIE BV	<u>2MG/ML</u>	<u>A063336</u>	<u>001</u>	Feb 28, 1995	
<u>AP</u>		<u>10MG/VIAL</u>	<u>A063097</u>	<u>001</u>	May 21, 1990	
<u>AP</u>		<u>20MG/VIAL</u>	<u>A063097</u>	<u>002</u>	May 21, 1990	
<u>AP</u>		<u>50MG/VIAL</u>	<u>A063097</u>	<u>003</u>	May 21, 1990	
<u>AP</u>		<u>200MG/100ML</u>	<u>A063336</u>	<u>004</u>	Feb 28, 1995	
<u>AP</u>	SAGENT PHARMS	<u>2MG/ML</u>	<u>A091495</u>	<u>001</u>	Mar 18, 2013	
<u>AP</u>	SANDOZ INC	<u>2MG/ML</u>	<u>A200146</u>	<u>001</u>	Jul 18, 2012	
<u>AP</u>	SUN PHARM INDS	<u>2MG/ML</u>	<u>A091418</u>	<u>001</u>	Feb 15, 2012	
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A064140</u>	<u>001</u>	Jul 28, 1995	
<u>AP</u>		<u>200MG/100ML</u>	<u>A064140</u>	<u>002</u>	Jul 28, 1995	

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL (LIPOSOMAL)

<u>AB</u>	JANSSEN RES AND DEV	<u>20MG/10ML (2MG/ML)</u>	<u>N050718</u>	<u>001</u>	Nov 17, 1995
<u>AB</u>		<u>50MG/25ML (2MG/ML)</u>	<u>N050718</u>	<u>002</u>	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

<u>AB</u>	+	SUN PHARMA GLOBAL	<u>20MG/10ML (2MG/ML)</u>	<u>A203263</u>	<u>001</u>	Feb 04, 2013
<u>AB</u>	+		<u>50MG/25ML (2MG/ML)</u>	<u>A203263</u>	<u>002</u>	Feb 04, 2013

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	IMPAX LABS INC	<u>EQ 150MG BASE</u>	<u>A200065</u>	<u>001</u>	Feb 17, 2011	
<u>AB</u>	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204234</u>	<u>001</u>	Mar 05, 2014	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204234</u>	<u>002</u>	Mar 05, 2014	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204234</u>	<u>003</u>	Mar 05, 2014	
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A202778</u>	<u>001</u>	Jun 08, 2012	
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065055</u>	<u>001</u>	Dec 01, 2000	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065055</u>	<u>002</u>	Dec 01, 2000	
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>A065055</u>	<u>003</u>	Jul 15, 2005
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065053</u>	<u>001</u>	Nov 22, 2000	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065053</u>	<u>003</u>	Sep 10, 2003	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065053</u>	<u>002</u>	Nov 22, 2000	

MONODOX

<u>AB</u>	AQUA PHARMS	<u>EQ 50MG BASE</u>	<u>N050641</u>	<u>002</u>	Feb 10, 1992	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N050641</u>	<u>003</u>	Oct 18, 2006	
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N050641</u>	<u>001</u>	Dec 29, 1989
	ORACEA					
	+	GALDERMA LABS LP	40MG	<u>N050805</u>	<u>001</u>	May 26, 2006



## PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCYCLINE

<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 25MG BASE/5ML</u>	<u>A065454 001</u>	Jul 16, 2008
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE/5ML</u>	<u>A201678 001</u>	Mar 18, 2013

VIBRAMYCIN

<u>AB</u>	+ PFIZER	<u>EQ 25MG BASE/5ML</u>	<u>N050006 001</u>	
-----------	----------	-------------------------	--------------------	--

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 50MG BASE</u>	<u>A091605 001</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091605 002</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091605 003</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091605 004</u>	Dec 20, 2011
<u>AB</u>	LANNETT	<u>EQ 50MG BASE</u>	<u>A065285 001</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065285 003</u>	Jul 30, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065285 002</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065285 004</u>	Jul 30, 2008
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A065377 001</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065377 002</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065377 003</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065427 001</u>	Jun 07, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065070 001</u>	Dec 15, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065070 003</u>	Dec 30, 2002
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065070 002</u>	Dec 15, 2000
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065070 004</u>	Jul 14, 2005
<u>AB</u>	+ RANBAXY	<u>EQ 50MG BASE</u>	<u>A065356 001</u>	May 31, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065356 002</u>	May 31, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065356 003</u>	May 31, 2006

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+ PFIZER

EQ 50MG BASE/5ML

N050480 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 50MG BASE</u>	<u>A062031 002</u>	Oct 13, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062031 001</u>	
<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 50MG BASE</u>	<u>A062500 001</u>	Sep 11, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062500 002</u>	Sep 11, 1984
<u>AB</u>	HIKMA INTL PHARMS	<u>EQ 50MG BASE</u>	<u>A062396 002</u>	Nov 07, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062396 001</u>	May 07, 1984
<u>AB</u>	MUTUAL PHARM	<u>EQ 50MG BASE</u>	<u>A062675 001</u>	Jul 10, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062676 001</u>	Jul 10, 1986
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A062337 001</u>	Mar 29, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062337 002</u>	Mar 29, 1982

VIBRAMYCIN

<u>AB</u>	PFIZER	<u>EQ 50MG BASE</u>	<u>N050007 001</u>	
<u>AB</u>	+ DOXYCYCLINE HYCLATE	<u>EQ 100MG BASE</u>	<u>N050007 002</u>	

DOXYCYCLINE HYCLATE

+ HIKMA INTL PHARMS

EQ 20MG BASE

A065103 001 May 13, 2005

CAPSULE, DELAYED RELEASE; ORAL

DOXYCYCLINE HYCLATE

MEDICIS

EQ 75MG BASE

A065281 001 Dec 21, 2005

+

EQ 100MG BASE

A065281 002 Dec 21, 2005

INJECTABLE; INJECTION

DOXY 100

<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 100MG BASE/VIAL</u>	<u>A062475 001</u>	Dec 09, 1983
-----------	----------------------	---------------------------	--------------------	--------------

DOXYCYCLINE

<u>AP</u>	AGILA SPECLTS	<u>EQ 100MG BASE/VIAL</u>	<u>A091406 001</u>	Aug 21, 2012
<u>AP</u>	+ EUROHLTH INTL	<u>EQ 100MG BASE/VIAL</u>	<u>A062569 001</u>	Mar 09, 1988

DOXY 200

+ FRESENIUS KABI USA

EQ 200MG BASE/VIAL

A062475 002 Dec 09, 1983

SYSTEM, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

+ TOLMAR

50MG

N050751 001 Sep 03, 1998

TABLET; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 100MG BASE</u>	<u>A062421 001</u>	Feb 02, 1983
<u>AB</u>	BLU CARIBE INC	<u>EQ 100MG BASE</u>	<u>A062269 002</u>	Nov 08, 1982
<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 100MG BASE</u>	<u>A062505 001</u>	Sep 11, 1984
<u>AB</u>	COREPHARMA	<u>EQ 20MG BASE</u>	<u>A065182 001</u>	May 13, 2005

## PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	+	HIKMA INTL PHARMS	<u>EQ 100MG BASE</u>	<u>A065095 001</u>	Jul 02, 2003
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A065163 001</u>	May 13, 2005
<u>AB</u>	+	LANNETT	<u>EQ 20MG BASE</u>	<u>A065277 001</u>	Nov 10, 2005
<u>AB</u>		LARKEN LABS	<u>EQ 20MG BASE</u>	<u>A065287 001</u>	Feb 28, 2006
<u>AB</u>		MUTUAL PHARM	<u>EQ 100MG BASE</u>	<u>A062677 001</u>	Jul 10, 1986
<u>AB</u>		MUTUAL PHARMA	<u>EQ 20MG BASE</u>	<u>A065134 001</u>	May 13, 2005
<u>AB</u>		MYLAN	<u>EQ 100MG BASE</u>	<u>A062432 001</u>	Feb 15, 1983
<u>AB</u>		VINTAGE PHARMS	<u>EQ 100MG BASE</u>	<u>A062538 001</u>	Apr 07, 1986

ACTICLATE

AQUA PHARMS LLC

EQ 75MG BASE

N205931 001 Jul 25, 2014

+

EQ 150MG BASE

N205931 002 Jul 25, 2014

TABLET, DELAYED RELEASE; ORAL

DORYX

<u>AB</u>		MAYNE PHARMA	<u>EQ 75MG BASE</u>	<u>N050795 001</u>	May 06, 2005
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>N050795 002</u>	May 06, 2005
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>N050795 003</u>	Jun 20, 2008

DOXYCYCLINE HYCLATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 75MG BASE</u>	<u>A090134 001</u>	Dec 14, 2011
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090134 002</u>	Dec 14, 2011
<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 75MG BASE</u>	<u>A200856 001</u>	Apr 30, 2013
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A200856 002</u>	Apr 30, 2013
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A200856 003</u>	Apr 30, 2013
<u>AB</u>		IMPAX LABS INC	<u>EQ 75MG BASE</u>	<u>A090505 001</u>	Dec 28, 2010
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090505 002</u>	Dec 28, 2010
<u>AB</u>		MYLAN	<u>EQ 75MG BASE</u>	<u>A090431 001</u>	Dec 28, 2010
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090431 002</u>	Dec 28, 2010
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A091052 001</u>	Feb 08, 2012

DORYX

MAYNE PHARMA

EQ 80MG BASE

N050795 004 Apr 11, 2013

+

EQ 200MG BASE

N050795 005 Apr 11, 2013

DOXTERIC

MAYNE PHARMA

EQ 50MG BASE

N050795 006 Dec 19, 2014

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL

DICLEGIS

+ DUCHESNAY

10MG; 10MG

N021876 001 Apr 08, 2013

DRONABINOL

CAPSULE; ORAL

DRONABINOL

<u>AB</u>		AKORN INC	<u>2.5MG</u>	<u>A079217 001</u>	Jun 20, 2014
<u>AB</u>			<u>5MG</u>	<u>A079217 002</u>	Jun 20, 2014
<u>AB</u>			<u>10MG</u>	<u>A079217 003</u>	Jun 20, 2014
<u>AB</u>		INSYS THERAP	<u>2.5MG</u>	<u>A078501 001</u>	Aug 19, 2011
<u>AB</u>			<u>5MG</u>	<u>A078501 002</u>	Aug 19, 2011
<u>AB</u>			<u>10MG</u>	<u>A078501 003</u>	Aug 19, 2011
<u>AB</u>		SVC PHARMA	<u>2.5MG</u>	<u>A078292 001</u>	Jun 27, 2008
<u>AB</u>			<u>5MG</u>	<u>A078292 002</u>	Jun 27, 2008
<u>AB</u>			<u>10MG</u>	<u>A078292 003</u>	Jun 27, 2008

MARINOL

<u>AB</u>		ABBVIE	<u>2.5MG</u>	<u>N018651 001</u>	May 31, 1985
<u>AB</u>	+		<u>5MG</u>	<u>N018651 002</u>	May 31, 1985
<u>AB</u>			<u>10MG</u>	<u>N018651 003</u>	May 31, 1985

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

MULTAQ

+ SANOFI AVENTIS US

EQ 400MG BASE

N022425 001 Jul 01, 2009

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

<u>AP</u>		HOSPIRA	<u>2.5MG/ML</u>	<u>A071981 001</u>	Feb 29, 1988
<u>AP</u>		LUITPOLD	<u>2.5MG/ML</u>	<u>A072123 001</u>	Oct 24, 1988
<u>AP</u>	+	AKORN INC	<u>2.5MG/ML</u>	<u>N016796 001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

BAYER HLTHCARE	0.25MG; 0.5MG	N021355 001	Feb 29, 2012
+	0.5MG; 1MG	N021355 002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

<b>AB</b>	BARR	<b>3MG;0.02MG</b>	<b>A078515 001</b>	Mar 30, 2009
<b>AB</b>	WATSON LABS	<b>3MG;0.02MG</b>	<b>A078833 001</b>	Nov 28, 2011
<b>LORYNA</b>				
<b>AB</b>	SANDOZ	<b>3MG;0.02MG</b>	<b>A079221 001</b>	Mar 28, 2011
<b>NIKKI</b>				
<b>AB</b>	LUPIN LTD	<b>3MG;0.02MG</b>	<b>A201661 001</b>	May 27, 2014
<b>YAZ</b>				
<b>AB</b>	+ BAYER HLTHCARE	<b>3MG;0.02MG</b>	<b>N021676 001</b>	Mar 16, 2006

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

<b>AB</b>	BARR	<b>3MG;0.03MG</b>	<b>A077527 001</b>	May 09, 2008
<b>AB</b>	LUPIN LTD	<b>3MG;0.03MG</b>	<b>A201663 001</b>	Dec 18, 2012
<b>AB</b>	WATSON LABS	<b>3MG;0.03MG</b>	<b>A090081 001</b>	Sep 07, 2010
<b>SYEDA</b>				
<b>AB</b>	SANDOZ	<b>3MG;0.03MG</b>	<b>A090114 001</b>	Mar 28, 2011
<b>YAELA</b>				
<b>AB</b>	NOVAST LABS LTD	<b>3MG;0.03MG</b>	<b>A202015 001</b>	Nov 19, 2014
<b>YASMIN</b>				
<b>AB</b>	+ BAYER HLTHCARE	<b>3MG;0.03MG</b>	<b>N021098 001</b>	May 11, 2001

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

BEYAZ

BAYER HLTHCARE	3MG, N/A; 0.02MG, N/A; 0.451MG, 0.451MG	N022532 001	Sep 24, 2010
SAFYRAL			
+	BAYER HLTHCARE	3MG, N/A; 0.03MG, N/A; 0.451MG, 0.451MG	N022574 001

DROXIDOPA

CAPSULE; ORAL

NORTHERA

LUNDBECK NA LTD	100MG	N203202 001	Feb 18, 2014
	200MG	N203202 002	Feb 18, 2014
+	300MG	N203202 003	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

CYMBALTA

<b>AB</b>	LILLY	<b>EQ 20MG BASE</b>	<b>N021427 001</b>	Aug 03, 2004
<b>AB</b>		<b>EQ 30MG BASE</b>	<b>N021427 002</b>	Aug 03, 2004
<b>AB</b>	+	<b>EQ 60MG BASE</b>	<b>N021427 004</b>	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

<b>AB</b>	ACTAVIS ELIZABETH	<b>EQ 20MG BASE</b>	<b>A090776 001</b>	Dec 17, 2013
<b>AB</b>		<b>EQ 30MG BASE</b>	<b>A090776 002</b>	Dec 17, 2013
<b>AB</b>		<b>EQ 60MG BASE</b>	<b>A090776 003</b>	Dec 17, 2013
<b>AB</b>	ALEMBIC PHARMS LTD	<b>EQ 20MG BASE</b>	<b>A202949 001</b>	Jun 09, 2014
<b>AB</b>		<b>EQ 30MG BASE</b>	<b>A202949 002</b>	Jun 09, 2014
<b>AB</b>		<b>EQ 60MG BASE</b>	<b>A202949 003</b>	Jun 09, 2014
<b>AB</b>	APOTEX INC	<b>EQ 20MG BASE</b>	<b>A202045 001</b>	Jun 11, 2014
<b>AB</b>		<b>EQ 30MG BASE</b>	<b>A202045 002</b>	Jun 11, 2014
<b>AB</b>		<b>EQ 60MG BASE</b>	<b>A202045 003</b>	Jun 11, 2014
<b>AB</b>	AUROBINDO PHARMA LTD	<b>EQ 20MG BASE</b>	<b>A090778 001</b>	Dec 11, 2013
<b>AB</b>		<b>EQ 30MG BASE</b>	<b>A090778 002</b>	Dec 11, 2013
<b>AB</b>		<b>EQ 60MG BASE</b>	<b>A090778 003</b>	Dec 11, 2013
<b>AB</b>	BRECKENRIDGE PHARM	<b>EQ 20MG BASE</b>	<b>A203088 001</b>	Jun 11, 2014
<b>AB</b>		<b>EQ 30MG BASE</b>	<b>A203088 002</b>	Jun 11, 2014
<b>AB</b>		<b>EQ 60MG BASE</b>	<b>A203088 003</b>	Jun 11, 2014
<b>AB</b>	DR REDDYS LABS LTD	<b>EQ 20MG BASE</b>	<b>A090723 001</b>	Dec 11, 2013
<b>AB</b>		<b>EQ 30MG BASE</b>	<b>A090723 002</b>	Dec 11, 2013
<b>AB</b>		<b>EQ 60MG BASE</b>	<b>A090723 003</b>	Dec 11, 2013
<b>AB</b>	LUPIN LTD	<b>EQ 20MG BASE</b>	<b>A090694 001</b>	Dec 11, 2013
<b>AB</b>		<b>EQ 30MG BASE</b>	<b>A090694 002</b>	Dec 11, 2013
<b>AB</b>		<b>EQ 60MG BASE</b>	<b>A090694 004</b>	Dec 11, 2013
<b>AB</b>	SUN PHARMA GLOBAL	<b>EQ 20MG BASE</b>	<b>A090745 001</b>	Dec 11, 2013
<b>AB</b>		<b>EQ 30MG BASE</b>	<b>A090745 002</b>	Dec 11, 2013
<b>AB</b>		<b>EQ 60MG BASE</b>	<b>A090745 003</b>	Dec 11, 2013

## PRESCRIPTION DRUG PRODUCT LIST

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

<b>AB</b>	TEVA PHARMS USA	<u>EQ 20MG BASE</u>	<u>A090783 001</u>	Dec 11, 2013
<b>AB</b>		<u>EQ 30MG BASE</u>	<u>A090783 002</u>	Dec 11, 2013
<b>AB</b>		<u>EQ 60MG BASE</u>	<u>A090783 003</u>	Dec 11, 2013
<b>AB</b>	TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A090774 001</u>	Dec 11, 2013
<b>AB</b>		<u>EQ 30MG BASE</u>	<u>A090774 002</u>	Dec 11, 2013
<b>AB</b>		<u>EQ 60MG BASE</u>	<u>A090774 003</u>	Dec 11, 2013
<b>AB</b>	ZYDUS PHARMS USA INC	<u>EQ 20MG BASE</u>	<u>A090728 001</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 20MG BASE</u>	<u>A090739 001</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 30MG BASE</u>	<u>A090728 002</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 30MG BASE</u>	<u>A090739 002</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 60MG BASE</u>	<u>A090728 003</u>	Jan 08, 2014
<b>AB</b>		<u>EQ 60MG BASE</u>	<u>A090739 003</u>	Jan 08, 2014
	LUPIN LTD	EQ 40MG BASE	A090694 003	Dec 11, 2013

DUTASTERIDE

CAPSULE;ORAL

AVODART

<b>AB</b>	+ GLAXOSMITHKLINE	<u>0.5MG</u>	<u>N021319 001</u>	Nov 20, 2001
	<u>DUTASTERIDE</u>			
<b>AB</b>	BARR	<u>0.5MG</u>	<u>A090095 001</u>	Dec 21, 2010

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

<b>AB</b>	ANCHEN PHARMS	<u>0.5MG;0.4MG</u>	<u>A202509 001</u>	Feb 26, 2014
	<u>JALYN</u>			
<b>AB</b>	+ GLAXOSMITHKLINE	<u>0.5MG;0.4MG</u>	<u>N022460 001</u>	Jun 14, 2010

DYPHYLLINE

TABLET;ORAL

## LUFYLLIN

	MEDA PHARMS	200MG	A084566 001	
	+	400MG	A084566 002	

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC

## PHOSPHOLINE IODIDE

	+ WYETH PHARMS INC	0.125%	N011963 001	
--	--------------------	--------	-------------	--

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

## ECOZA

	+ VELDANA MEDICAL SA	1%	N205175 001	Oct 24, 2013
--	----------------------	----	-------------	--------------

CREAM;TOPICAL

ECONAZOLE NITRATE

<b>AB</b>	+ FOUGERA PHARMS	<u>1%</u>	<u>A076075 001</u>	Nov 26, 2002
<b>AB</b>	IGI LABS INC	<u>1%</u>	<u>A076574 001</u>	Dec 17, 2004
<b>AB</b>	PERRIGO NEW YORK	<u>1%</u>	<u>A076479 001</u>	Jun 23, 2004
<b>AB</b>	TARO	<u>1%</u>	<u>A076005 001</u>	Nov 26, 2002

EDETATE CALCIUM DISODIUM

INJECTABLE;INJECTION

## CALCIUM DISODIUM VERSENATE

	+ MEDICIS	200MG/ML	N008922 001	
--	-----------	----------	-------------	--

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON

<b>AP</b>	MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>A088873 001</u>	Aug 06, 1985
	<u>TENSILON</u>			
<b>AP</b>	+ VALEANT PHARMS	<u>10MG/ML</u>	<u>N007959 001</u>	
	<u>TENSILON PRESERVATIVE FREE</u>			
<b>AP</b>	+ VALEANT PHARMS	<u>10MG/ML</u>	<u>N007959 002</u>	

EFAVIRENZ

CAPSULE;ORAL

## SUSTIVA

	BRISTOL MYERS SQUIBB	50MG	N020972 001	Sep 17, 1998
	+	200MG	N020972 003	Sep 17, 1998

TABLET;ORAL

## SUSTIVA

	+ BRISTOL MYERS SQUIBB	600MG	N021360 002	Feb 01, 2002
--	------------------------	-------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

+ GILEAD 600MG; 200MG; 300MG N021937 001 Jul 12, 2006

EFINACONAZOLE

SOLUTION; TOPICAL

JUBLIA

+ DOW PHARM 10% N203567 001 Jun 06, 2014

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+ SKINMEDICA 13.9% N021145 001 Jul 27, 2000

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

RELPAX

PFIZER IRELAND EQ 20MG BASE N021016 001 Dec 26, 2002

+ EQ 40MG BASE N021016 002 Dec 26, 2002

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

CERDELGA

+ GENZYME CORP EQ 84MG BASE N205494 001 Aug 19, 2014

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

GLAXOSMITHKLINE EQ 12.5MG ACID N022291 004 Oct 20, 2011

EQ 25MG ACID N022291 001 Nov 20, 2008

+ EQ 50MG ACID N022291 002 Nov 20, 2008

EQ 75MG ACID N022291 003 Sep 08, 2009

EQ 100MG ACID N022291 005 Nov 16, 2012

ELVITEGRAVIR

TABLET; ORAL

VITEKTA

GILEAD SCIENCES INC 85MG N203093 001 Sep 24, 2014

+ 150MG N203093 002 Sep 24, 2014

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC

EMADINE

+ ALCON 0.05% N020706 001 Dec 29, 1997

EMPAGLIFLOZIN

TABLET; ORAL

JARDIANCE

BOEHRINGER INGELHEIM 10MG N204629 001 Aug 01, 2014

+ 25MG N204629 002 Aug 01, 2014

EMTRICITABINE

CAPSULE; ORAL

EMTRIVA

+ GILEAD 200MG N021500 001 Jul 02, 2003

SOLUTION; ORAL

EMTRIVA

+ GILEAD 10MG/ML N021896 001 Sep 28, 2005

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+ GILEAD SCIENCES INC 200MG; EQ 25MG BASE; 300MG N202123 001 Aug 10, 2011

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

+ GILEAD 200MG; 300MG N021752 001 Aug 02, 2004

ENALAPRIL MALEATE

FOR SOLUTION; ORAL

EPANED KIT

+ SILVERGATE PHARMS 1MG/ML N204308 001 Aug 13, 2013

TABLET; ORAL

ENALAPRIL MALEATEAB APOTEX 2.5MG A075178 002 Mar 23, 2001AB 5MG A075178 001 Mar 23, 2001

## PRESCRIPTION DRUG PRODUCT LIST

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

<u>AB</u>		<u>10MG</u>	<u>A075178 003</u>	Mar 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075178 004</u>	Mar 23, 2001
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A075480 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075480 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075480 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075480 004</u>	Aug 22, 2000
<u>AB</u>	TARO	<u>2.5MG</u>	<u>A075657 001</u>	Jan 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075657 002</u>	Jan 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075657 003</u>	Jan 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075657 004</u>	Jan 23, 2001
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A075479 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075479 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075479 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075479 004</u>	Aug 22, 2000
<u>AB</u>	WOCKHARDT USA	<u>2.5MG</u>	<u>A075483 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075483 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075483 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075483 004</u>	Aug 22, 2000
<u>VASOTEC</u>				
<u>AB</u>	VALEANT INTL	<u>2.5MG</u>	<u>N018998 005</u>	Jul 26, 1988
<u>AB</u>		<u>5MG</u>	<u>N018998 001</u>	Dec 24, 1985
<u>AB</u>		<u>10MG</u>	<u>N018998 002</u>	Dec 24, 1985
<u>AB</u>	+	<u>20MG</u>	<u>N018998 003</u>	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG;12.5MG</u>	<u>A076486 001</u>	Oct 27, 2004
<u>AB</u>		<u>10MG;25MG</u>	<u>A076486 002</u>	Oct 27, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG;12.5MG</u>	<u>A075909 001</u>	Oct 15, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075909 002</u>	Oct 15, 2001
<u>AB</u>	MYLAN	<u>5MG;12.5MG</u>	<u>A075624 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075624 002</u>	Sep 18, 2001
<u>AB</u>	TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075788 002</u>	Sep 18, 2001
<u>AB</u>	TEVA	<u>5MG;12.5MG</u>	<u>A075727 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075727 002</u>	Sep 18, 2001
<u>VASERETIC</u>				
<u>AB</u>	VALEANT INTL	<u>5MG;12.5MG</u>	<u>N019221 003</u>	Jul 12, 1995
<u>AB</u>	+	<u>10MG;25MG</u>	<u>N019221 001</u>	Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>	+	BEDFORD	<u>1.25MG/ML</u>	<u>A075634 001</u>	Aug 22, 2000
<u>AP</u>		HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687 001</u>	Dec 23, 2008
<u>AP</u>	+	HOSPIRA	<u>1.25MG/ML</u>	<u>A075458 001</u>	Aug 22, 2000
<u>AP</u>		TEVA PHARMS USA	<u>1.25MG/ML</u>	<u>A075578 001</u>	Aug 22, 2000

ENFLURANE

LIQUID; INHALATION

ENFLURANE

<u>AN</u>		PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074396 001</u>	Jul 29, 1994
<u>ETHRANE</u>					
<u>AN</u>	+	BAXTER HLTHCARE	<u>99.9%</u>	<u>N017087 001</u>	

ENFUVIRTIDE

INJECTABLE; SUBCUTANEOUS

## FUZEON

+ ROCHE

90MG/VIAL

N021481 001 Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

<u>AB</u>	SANDOZ INC	<u>300MG/3ML (100MG/ML)</u>	<u>A078660 001</u>	Nov 28, 2011	
<u>LOVENOX</u>					
<u>AB</u>	SANOFI AVENTIS US	<u>300MG/3ML (100MG/ML)</u>	<u>N020164 009</u>	Jan 23, 2003	
INJECTABLE; SUBCUTANEOUS					
<u>ENOXAPARIN SODIUM (PRESERVATIVE FREE)</u>					
<u>AP</u>	AMPHASTAR PHARM	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076684 001</u>	Sep 19, 2011	
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076684 002</u>	Sep 19, 2011	
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076684 003</u>	Sep 19, 2011	



## PRESCRIPTION DRUG PRODUCT LIST

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPIPEN

BX + MYLAN SPECLT 0.3MG/DELIVERY N019430 001 Dec 22, 1987

EPIPEN JR.

BX + MYLAN SPECLT 0.15MG/DELIVERY N019430 002 Dec 22, 1987

TWINJECT 0.15

BX + AMEDRA PHARMS EQ 0.15MG/DELIVERY N020800 002 May 28, 2004

TWINJECT 0.3

BX + AMEDRA PHARMS EQ 0.3MG/DELIVERY N020800 001 May 30, 2003

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

+ DEPROCO

EQ 0.02MG BASE/ML; 2%

A088389 001 Jan 22, 1985

LIGNOSPAN STANDARD

+ DEPROCO

EQ 0.01MG BASE/ML; 2%

A088390 001 Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

AP + DENTSPLY PHARM 0.005MG/ML; 4% N021383 001

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP SEPTODONT INC 0.005MG/ML; 4% A078959 001 Aug 30, 2011

EPINEPHRINE HYDROCHLORIDE

INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N204200 001 Dec 07, 2012

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML)

N204640 001 Dec 18, 2013

SOLUTION; IV (INFUSION)

EPINEPHRINE

BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N205029 001 Jul 29, 2014

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP EASTMAN KODAK 0.01MG/ML; 2% A040057 002 Feb 26, 1993

AP 0.02MG/ML; 2% A040057 001 Feb 26, 1993

AP HOSPIRA 0.005MG/ML; 0.5% A089635 001 Jun 21, 1988

AP 0.005MG/ML; 1.5% A088571 001 Sep 13, 1985

AP 0.005MG/ML; 1.5% A089645 001 Jun 21, 1988

AP 0.005MG/ML; 2% A089651 001 Jun 21, 1988

AP 0.01MG/ML; 1% A089644 001 Jun 21, 1988

AP 0.01MG/ML; 2% A078772 001 May 12, 2008

AP 0.01MG/ML; 2% A089646 001 Jun 21, 1988

AP 0.02MG/ML; 2% A078772 002 May 12, 2008

OCTOCAINE

AP + SEPTODONT 0.01MG/ML; 2% A084048 001

AP + 0.02MG/ML; 2% A084048 002

XYLOCAINE W/ EPINEPHRINE

AP + FRESENIUS KABI USA 0.005MG/ML; 0.5% N006488 012

AP + 0.005MG/ML; 1% N006488 018 Nov 13, 1986

AP + 0.005MG/ML; 1.5% N006488 017

AP + 0.005MG/ML; 2% N006488 019 Nov 13, 1986

AP + 0.01MG/ML; 1% N006488 004

AP + 0.02MG/ML; 2% N006488 005

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE

AP + PFIZER INC 200MG/100ML (2MG/ML) N050778 001 Sep 15, 1999

AP 50MG/25ML (2MG/ML) N050778 002 Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP ACTAVIS TOTOWA 10MG/5ML (2MG/ML) A065445 001 Sep 18, 2008

AP 50MG/25ML (2MG/ML) A065445 002 Sep 18, 2008

AP 200MG/100ML (2MG/ML) A065445 003 Sep 18, 2008

AP AKORN INC 50MG/25ML (2MG/ML) A090163 001 Jun 24, 2009

AP CIPLA LTD 50MG/25ML (2MG/ML) A065361 001 Oct 22, 2007

AP 200MG/100ML (2MG/ML) A065361 002 Oct 22, 2007

AP EUROHLTH INTL 50MG/25ML (2MG/ML) A065289 001 Jun 27, 2007

AP 200MG/100ML (2MG/ML) A065289 002 Jun 27, 2007

AP FRESENIUS KABI ONCOL 200MG/100ML (2MG/ML) A065411 001 Aug 20, 2007



## PRESCRIPTION DRUG PRODUCT LIST

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065411 002</u>	Aug 20, 2007
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/5ML (2MG/ML)</u>	<u>A065408 001</u>	Oct 15, 2007
<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065408 002</u>	Oct 15, 2007
<u>AP</u>		<u>150MG/75ML (2MG/ML)</u>	<u>A065408 003</u>	Oct 15, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065408 004</u>	Oct 15, 2007
<u>AP</u>	HISUN PHARM HANGZHOU	<u>50MG/25ML (2MG/ML)</u>	<u>A090075 001</u>	Mar 25, 2010
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A090075 002</u>	Mar 25, 2010
<u>AP</u>	HOSPIRA	<u>10MG/5ML (2MG/ML)</u>	<u>A065343 001</u>	Apr 19, 2007
<u>AP</u>		<u>150MG/75ML (2MG/ML)</u>	<u>A065343 003</u>	Apr 19, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065343 004</u>	Apr 19, 2007
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/25ML (2MG/ML)</u>	<u>A091599 001</u>	Mar 12, 2012
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A091599 002</u>	Mar 12, 2012
<u>AP</u>	TEVA PHARMS USA	<u>50MG/25ML (2MG/ML)</u>	<u>A065331 001</u>	Aug 09, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065331 002</u>	Aug 09, 2007

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>	APOTEX	<u>25MG</u>	<u>A078482 001</u>	Jul 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A078482 002</u>	Jul 30, 2008
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078510 001</u>	Aug 01, 2008
<u>AB</u>		<u>50MG</u>	<u>A078510 002</u>	Aug 01, 2008
<u>INSPIRA</u>				
<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N021437 001</u>	Sep 27, 2002
<u>AB</u>	+	<u>50MG</u>	<u>N021437 002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396 001</u>	Apr 23, 2008
<u>AP</u>		<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396 002</u>	Apr 23, 2008
<u>FLOLAN</u>				
<u>AP</u>	+	<u>GLAXOSMITHKLINE LLC</u>	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444 001</u>
<u>AP</u>	+		<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444 002</u>
<u>VELETRI</u>				
	ACTELION PHARMS LTD	<u>EQ 0.5MG BASE/VIAL</u>	<u>N022260 002</u>	Jun 28, 2012
	+	<u>EQ 1.5MG BASE/VIAL</u>	<u>N022260 001</u>	Jun 27, 2008

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 400MG BASE</u>	<u>A202012 001</u>	Nov 16, 2011
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A202012 002</u>	Nov 16, 2011
<u>TEVETEN</u>				
<u>AB</u>	ABBVIE	<u>EQ 400MG BASE</u>	<u>N020738 005</u>	Dec 22, 1997
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>N020738 006</u>	May 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

	ABBVIE	<u>600MG; 12.5MG</u>	<u>N021268 001</u>	Nov 01, 2001
	+	<u>600MG; 25MG</u>	<u>N021268 002</u>	Nov 01, 2001

EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

	+	SCHERING	<u>2MG/ML</u>	<u>N020718 001</u>	May 18, 1998
	+		<u>75MG/100ML</u>	<u>N020718 002</u>	May 18, 1998

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

<u>AA</u>	+	SANOFI AVENTIS US	<u>50,000 IU</u>	<u>N003444 001</u>	
<u>ERGOCALCIFEROL</u>					
<u>AA</u>		ORIT LABS LLC	<u>50,000 IU</u>	<u>A040833 001</u>	May 20, 2009
<u>AA</u>		SIGMAPHARM LABS LLC	<u>50,000 IU</u>	<u>A091004 001</u>	Jul 14, 2010
<u>AA</u>		STRIDES PHARMA	<u>50,000 IU</u>	<u>A090455 001</u>	Aug 03, 2010
<u>AA</u>		SUN PHARM INDS INC	<u>50,000 IU</u>	<u>A040865 001</u>	Dec 29, 2009
<u>VITAMIN D</u>					
<u>AA</u>		BANNER PHARMACAPS	<u>50,000 IU</u>	<u>A080704 001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES**AB** MUTUAL PHARM **1MG** **A081113 001** Oct 31, 1991HYDERGINE**AB** + NOVARTIS **1MG** **N017993 001**ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+ ROSEDALE THERAPEUTIC 2MG A087693 001 Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

HALAVEN

+ EISAI INC 1MG/2ML (0.5MG/ML) N201532 001 Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE**AB** MYLAN PHARMS INC **EQ 25MG BASE** **A091002 001** Jun 11, 2014**AB** **EQ 100MG BASE** **A091002 002** Jun 11, 2014**AB** **EQ 150MG BASE** **A091002 003** Jun 11, 2014TARCEVA**AB** OSI PHARMS **EQ 25MG BASE** **N021743 001** Nov 18, 2004**AB** **EQ 100MG BASE** **N021743 002** Nov 18, 2004**AB** + **EQ 150MG BASE** **N021743 003** Nov 18, 2004ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

INVANZ

+ MERCK SHARP DOHME EQ 1GM BASE/VIAL N021337 001 Nov 21, 2001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC**AB** + MAYNE PHARMA **250MG** **N050536 001**ERYTHROMYCIN**AB** ARBOR PHARMS LLC **250MG** **A062746 001** Dec 22, 1986

GEL; TOPICAL

ERYGEL**AT** + DELCOR ASSET CORP **2%** **N050617 001** Oct 21, 1987ERYTHROMYCIN**AT** FOUGERA PHARMS **2%** **A064184 001** Sep 30, 1997**AT** PERRIGO **2%** **A063211 001** Jan 29, 1993

OINTMENT; OPHTHALMIC

ERYTHROMYCIN**AT** AKORN **0.5%** **A064030 001** Jul 18, 1996**AT** BAUSCH AND LOMB **0.5%** **A064067 001** Jul 29, 1994**AT** + PERRIGO CO TENNESSEE **0.5%** **A062447 001** Sep 26, 1983

OINTMENT; TOPICAL

AKNE-MYCIN

+ DOW PHARM 2% N050584 001 Jan 10, 1985

SOLUTION; TOPICAL

C-SOLVE-2**AT** FOUGERA PHARMS **2%** **A062468 001** Jul 03, 1985ERYTHRA-DERM**AT** PADDOCK LLC **2%** **A062687 001** Feb 05, 1988ERYTHRO-STATIN**AT** HI TECH PHARMA **2%** **A064101 001** Oct 22, 1996ERYTHROMYCIN**AT** + FOUGERA PHARMS **2%** **A064187 001** Sep 30, 1997**AT** PERRIGO NEW YORK **2%** **A063038 001** Jan 11, 1991**AT** WOCKHARDT **2%** **A062825 001** Oct 23, 1987

SWAB; TOPICAL

ERYTHROMYCIN**AT** + PERRIGO **2%** **A064126 001** Jul 03, 1996**AT** VERSAPHARM **2%** **A090215 001** May 12, 2010

TABLET; ORAL

ERYTHROMYCIN

ARBOR PHARMS LLC 250MG A061621 001

+ 500MG A061621 002

## PRESCRIPTION DRUG PRODUCT LIST

ERYTHROMYCIN

TABLET, COATED PARTICLES;ORAL

PCE

ARBOR PHARMS LLC

333MG

N050611 001 Sep 09, 1986

+

500MG

N050611 002 Aug 22, 1990

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

ARBOR PHARMS LLC

250MG

A062298 001

333MG

A062298 003 Mar 29, 1982

+

500MG

A062298 002

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.AB ARBOR PHARMS LLCEQ 200MG BASE/5MLN050207 001ERYPEDAB ARBOR PHARMS LLCEQ 200MG BASE/5MLN050207 003 Mar 30, 1987

+

EQ 400MG BASE/5ML

N050207 002

SUSPENSION;ORAL

E.E.S. 200AB ARBOR PHARMS LLCEQ 200MG BASE/5MLA061639 001E.E.S. 400AB + ARBOR PHARMS LLCEQ 400MG BASE/5MLA061639 002PEDIAMYCINAB ARBOR PHARMS LLCEQ 200MG BASE/5MLA062304 001PEDIAMYCIN 400AB ARBOR PHARMS LLCEQ 400MG BASE/5MLA062304 002

TABLET;ORAL

E.E.S. 400

BX + ARBOR PHARMS LLC

EQ 400MG BASE

A061905 002 Aug 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE

BX + ARBOR PHARMS LLC

EQ 400MG BASE

A061904 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

+ BARR

EQ 200MG BASE/5ML;EQ 600MG BASE/5ML

A062759 001 May 20, 1988

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCINAP HOSPIRAEQ 500MG BASE/VIALA062638 001 Oct 31, 1986AP +EQ 500MG BASE/VIALN050609 001 Sep 24, 1986

+

EQ 1GM BASE/VIAL

A062638 002 Oct 31, 1986

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

+ ARBOR PHARMS LLC

EQ 250MG BASE

A060359 001

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATEAA AMNEAL PHARMSEQ 5MG BASE/5MLA202227 001 Mar 14, 2012AA AUROBINDO PHARMA LTDEQ 5MG BASE/5MLA079062 001 Apr 02, 2012AA HETERO LABS LTD IIIEQ 5MG BASE/5MLA202221 001 Jun 12, 2012AA SILARX PHARMS INCEQ 5MG BASE/5MLA090477 001 Jun 12, 2013AA TAROEQ 5MG BASE/5MLA079121 001 May 03, 2012LEXAPROAA + FOREST LABSEQ 5MG BASE/5MLN021365 001 Nov 27, 2002

TABLET;ORAL

ESCITALOPRAM OXALATEAB ACCORD HLTHCAREEQ 5MG BASEA202389 001 Sep 11, 2012ABEQ 10MG BASEA202389 002 Sep 11, 2012ABEQ 20MG BASEA202389 003 Sep 11, 2012AB APOTEX INCEQ 5MG BASEA078777 001 Sep 11, 2012ABEQ 10MG BASEA078777 002 Sep 11, 2012ABEQ 20MG BASEA078777 003 Sep 11, 2012AB AUROBINDO PHARMA LTDEQ 5MG BASEA090432 001 Sep 11, 2012ABEQ 10MG BASEA090432 002 Sep 11, 2012ABEQ 20MG BASEA090432 003 Sep 11, 2012AB HIKMA PHARMSEQ 5MG BASEA078766 001 Sep 11, 2012ABEQ 10MG BASEA078766 002 Sep 11, 2012ABEQ 20MG BASEA078766 003 Sep 11, 2012AB INVAGEN PHARMSEQ 5MG BASEA078604 001 Sep 11, 2012

## PRESCRIPTION DRUG PRODUCT LIST

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078604 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078604 003</u>	Sep 11, 2012
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A202280 001</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202280 002</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202280 003</u>	Sep 12, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 5MG BASE</u>	<u>A078169 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078169 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078169 003</u>	Sep 11, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A202210 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202210 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202210 003</u>	Sep 11, 2012
<u>AB</u>	STI PHARMA LLC	<u>EQ 5MG BASE</u>	<u>A077512 001</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077512 002</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077512 003</u>	Sep 12, 2012
<u>AB</u>	TEVA PHARMS USA	<u>EQ 5MG BASE</u>	<u>A076765 001</u>	Mar 14, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076765 002</u>	Mar 14, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076765 003</u>	Mar 14, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A090939 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090939 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090939 003</u>	Sep 11, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 5MG BASE</u>	<u>A077734 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077734 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077734 003</u>	Sep 11, 2012

LEXAPRO

<u>AB</u>	FOREST LABS	<u>EQ 5MG BASE</u>	<u>N021323 001</u>	Aug 14, 2002
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N021323 002</u>	Aug 14, 2002
<u>AB</u>	+	<u>EQ 20MG BASE</u>	<u>N021323 003</u>	Aug 14, 2002

ESLICARBAZEPINE ACETATE

TABLET; ORAL

APTIOM

	SUNOVION PHARMS INC	200MG	N022416 001	Nov 08, 2013
		400MG	N022416 002	Nov 08, 2013
		600MG	N022416 003	Nov 08, 2013
	+	800MG	N022416 004	Nov 08, 2013

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

<u>AP</u>	+	BAXTER HLTHCARE	<u>10MG/ML</u>	<u>N019386 006</u>	Feb 25, 2003
<u>AP</u>		EUROHLTH INTL	<u>10MG/ML</u>	<u>A076323 001</u>	Aug 10, 2004
<u>AP</u>		FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A076573 001</u>	May 02, 2005
<u>AP</u>		MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>A076474 001</u>	May 02, 2005
		BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER			
		+ BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003
		BREVIBLOC IN PLASTIC CONTAINER			
		+ BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

NEXIUM

	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153 001	Feb 20, 2001
	+	EQ 40MG BASE	N021153 002	Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N021957 003	Dec 15, 2011
		EQ 5MG BASE/PACKET	N021957 004	Dec 15, 2011
		EQ 10MG BASE/PACKET	N022101 001	Feb 27, 2008
		EQ 20MG BASE/PACKET	N021957 001	Oct 20, 2006
	+	EQ 40MG BASE/PACKET	N021957 002	Oct 20, 2006

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE; 375MG</u>	<u>A202461 001</u>	Sep 27, 2013
<u>AB</u>		<u>EQ 20MG BASE; 500MG</u>	<u>A202461 002</u>	Sep 27, 2013
<u>AB</u>	HORIZON PHARMA	<u>EQ 20MG BASE; 375MG</u>	<u>N022511 002</u>	Apr 30, 2010
<u>AB</u>	+	<u>EQ 20MG BASE; 500MG</u>	<u>N022511 001</u>	Apr 30, 2010

## PRESCRIPTION DRUG PRODUCT LIST

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 20MG BASE/VIAL</u>	<u>A200882 001</u>	Mar 18, 2013
<u>AP</u>		<u>EQ 40MG BASE/VIAL</u>	<u>A200882 002</u>	Mar 18, 2013

NEXIUM IV

<u>AP</u>	+ ASTRAZENECA PHARMS	<u>EQ 20MG BASE/VIAL</u>	<u>N021689 001</u>	Mar 31, 2005
<u>AP</u>	+	<u>EQ 40MG BASE/VIAL</u>	<u>N021689 002</u>	Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE STRONTIUM

	HANMI PHARM CO LTD	EQ 20MG BASE	N202342 001	Aug 06, 2013
+		EQ 40MG BASE	N202342 002	Aug 06, 2013

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

<u>AB</u>	PAR PHARM	<u>1MG</u>	<u>A074826 001</u>	Jul 03, 1997
<u>AB</u>		<u>2MG</u>	<u>A074826 002</u>	Jul 03, 1997
<u>AB</u>	TEVA	<u>1MG</u>	<u>A074921 001</u>	Jul 10, 1997
<u>AB</u>	+	<u>2MG</u>	<u>A074921 002</u>	Jul 10, 1997
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A074818 001</u>	Aug 19, 1997
<u>AB</u>		<u>2MG</u>	<u>A074818 002</u>	Aug 19, 1997

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+	WARNER CHILCOTT US	0.01%	A086069 001	Jan 31, 1984
---	--------------------	-------	-------------	--------------

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

<u>AB</u>	BAYER HLTHCARE	<u>0.0375MG/24HR</u>	<u>N020375 005</u>	May 27, 2003
<u>AB</u>		<u>0.06MG/24HR</u>	<u>N020375 006</u>	May 27, 2003

ESTRADIOL

<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.0375MG/24HR</u>	<u>A075182 004</u>	Jul 20, 2006
<u>AB</u>		<u>0.06MG/24HR</u>	<u>A075182 005</u>	Jul 20, 2006
<u>AB1</u>		<u>0.025MG/24HR</u>	<u>A201675 001</u>	Dec 19, 2014
<u>AB1</u>		<u>0.0375MG/24HR</u>	<u>A201675 002</u>	Dec 19, 2014
<u>AB1</u>		<u>0.05MG/24HR</u>	<u>A201675 003</u>	Dec 19, 2014
<u>AB1</u>		<u>0.075MG/24HR</u>	<u>A201675 004</u>	Dec 19, 2014
<u>AB1</u>		<u>0.1MG/24HR</u>	<u>A201675 005</u>	Dec 19, 2014

VIVELLE

<u>AB1</u>	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020323 002</u>	Oct 28, 1994
<u>AB1</u>		<u>0.1MG/24HR</u>	<u>N020323 004</u>	Oct 28, 1994

VIVELLE-DOT

<u>AB1</u>	NOVARTIS	<u>0.025MG/24HR</u>	<u>N020538 009</u>	May 03, 2002
<u>AB1</u>		<u>0.0375MG/24HR</u>	<u>N020538 005</u>	Jan 08, 1999
<u>AB1</u>		<u>0.05MG/24HR</u>	<u>N020538 006</u>	Jan 08, 1999
<u>AB1</u>		<u>0.075MG/24HR</u>	<u>N020538 007</u>	Jan 08, 1999
<u>AB1</u>	+	<u>0.1MG/24HR</u>	<u>N020538 008</u>	Jan 08, 1999

CLIMARA

<u>AB2</u>	BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375 004</u>	Mar 05, 1999
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>N020375 001</u>	Dec 22, 1994
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>N020375 003</u>	Mar 23, 1998
<u>AB2</u>	+	<u>0.1MG/24HR</u>	<u>N020375 002</u>	Dec 22, 1994

ESTRADIOL

<u>AB2</u>	MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182 003</u>	Jan 26, 2005
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>A075182 006</u>	Feb 24, 2000
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>A075182 002</u>	Jan 26, 2005
<u>AB2</u>		<u>0.1MG/24HR</u>	<u>A075182 001</u>	Feb 24, 2000

ALORA

BX	WATSON LABS	0.025MG/24HR	N020655 004	Apr 05, 2002
BX		0.05MG/24HR	N020655 001	Dec 20, 1996
BX		0.075MG/24HR	N020655 002	Dec 20, 1996
BX		0.1MG/24HR	N020655 003	Dec 20, 1996

ESTRADERM

BX	NOVARTIS	0.05MG/24HR	N019081 002	Sep 10, 1986
BX	+	0.1MG/24HR	N019081 003	Sep 10, 1986

MENOSTAR

+	BAYER HLTHCARE	0.014MG/24HR	N021674 001	Jun 08, 2004
---	----------------	--------------	-------------	--------------

MINIVELLE

	NOVEN	0.0375MG/24HR	N203752 001	Oct 29, 2012
		0.05MG/24HR	N203752 003	Oct 29, 2012
		0.075MG/24HR	N203752 002	Oct 29, 2012

## PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL			
MINIVELLE			
+	0.1MG/24HR	N203752 004	Oct 29, 2012
GEL;TRANSDERMAL			
DIVIGEL			
VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N022038 001	Jun 04, 2007
	0.1% (0.5GM/PACKET)	N022038 002	Jun 04, 2007
+	0.1% (1GM/PACKET)	N022038 003	Jun 04, 2007
GEL, METERED;TRANSDERMAL			
ELESTRIN			
+	MEDA PHARMS	0.06% (0.87GM/ACTIVATION)	N021813 001 Dec 15, 2006
ESTROGEL			
+	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166 002 Feb 09, 2004
INSERT, EXTENDED RELEASE;VAGINAL			
ESTRING			
+	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472 001 Apr 26, 1996
SPRAY;TRANSDERMAL			
EVAMIST			
+	ELAN PHARMA INTL LTD	1.53MG/SPRAY	N022014 001 Jul 27, 2007
TABLET;ORAL			

ESTRADIOL

<b>AB</b>	BARR LABS INC	<b>0.5MG</b>	<b>A040197 001</b>	Oct 22, 1997
<b>AB</b>		<b>1MG</b>	<b>A040197 002</b>	Oct 22, 1997
<b>AB</b>	+	<b>2MG</b>	<b>A040197 003</b>	Oct 22, 1997
<b>AB</b>	MYLAN	<b>0.5MG</b>	<b>A040326 001</b>	Apr 21, 1999
<b>AB</b>		<b>1MG</b>	<b>A040326 002</b>	Apr 21, 1999
<b>AB</b>		<b>2MG</b>	<b>A040326 003</b>	Apr 21, 1999
<b>AB</b>	USL PHARMA	<b>0.5MG</b>	<b>A040297 001</b>	Apr 17, 2002
<b>AB</b>		<b>1MG</b>	<b>A040297 002</b>	Apr 17, 2002
<b>AB</b>		<b>2MG</b>	<b>A040297 003</b>	Apr 17, 2002
<b>AB</b>	WATSON LABS	<b>0.5MG</b>	<b>A040114 003</b>	Mar 14, 1996
<b>AB</b>		<b>1MG</b>	<b>A040114 001</b>	Mar 14, 1996
<b>AB</b>		<b>2MG</b>	<b>A040114 002</b>	Mar 14, 1996
TABLET;VAGINAL				
VAGIFEM				
+	NOVO NORDISK INC	10MCG	N020908 002	Nov 25, 2009

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL				
FEMRING				
	WARNER IRELAND	EQ 0.05MG BASE/24HR	N021367 001	Mar 20, 2003
+		EQ 0.1MG BASE/24HR	N021367 002	Mar 20, 2003
TABLET;ORAL				
FEMTRACE				
	WARNER CHILCOTT LLC	0.45MG	N021633 001	Aug 20, 2004
		0.9MG	N021633 002	Aug 20, 2004
+		1.8MG	N021633 003	Aug 20, 2004

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION				
DEPO-ESTRADIOL				
+	PHARMACIA AND UPJOHN	5MG/ML	A085470 003	

ESTRADIOL HEMIHYDRATE

EMULSION;TOPICAL				
ESTRASORB				
+	MEDICIS	0.25%	N021371 001	Oct 09, 2003

ESTRADIOL VALERATE

INJECTABLE;INJECTION				
<b>DELESTROGEN</b>				
<b>AO</b>	+	PAR STERILE PRODUCTS	<b>20MG/ML</b>	<b>N009402 004</b>
<b>AO</b>	+		<b>40MG/ML</b>	<b>N009402 003</b>
<b>ESTRADIOL VALERATE</b>				
<b>AO</b>		LUITPOLD	<b>20MG/ML</b>	<b>A090920 001</b> Jan 19, 2010
<b>AO</b>			<b>40MG/ML</b>	<b>A090920 002</b> Jan 19, 2010
DELESTROGEN				
+	PAR STERILE PRODUCTS	10MG/ML	N009402 002	

## PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA PRO

+ BAYER HLTHCARE 0.045MG/24HR;0.015MG/24HR N021258 001 Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

NOVEN PHARMS INC 0.05MG/24HR;0.14MG/24HR N020870 001 Aug 07, 1998

+ 0.05MG/24HR;0.25MG/24HR N020870 002 Aug 07, 1998

TABLET;ORAL

ACTIVELLA**AB** AMNEAL PHARMS LLC **0.5MG;0.1MG** **N020907 002** Dec 28, 2006**AB** + **1MG;0.5MG** **N020907 001** Nov 18, 1998ESTRADIOL AND NORETHINDRONE ACETATE**AB** BARR **1MG;0.5MG** **A079193 001** May 11, 2010**AB** BRECKENRIDGE PHARM **0.5MG;0.1MG** **A078324 002** Jun 09, 2011**AB** **1MG;0.5MG** **A078324 001** Apr 17, 2008**AB** TEVA PHARMS USA **0.5MG;0.1MG** **A200747 001** Mar 08, 2012ESTRADIOL; NORGESTIMATE

TABLET;ORAL

ESTRADIOL AND NORGESTIMATE

+ BARR 1MG,1MG;1MG,1MG;N/A,0.09MG A076812 001 Apr 29, 2005

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE;ORAL

EMCYT

+ PHARMACIA AND UPJOHN EQ 140MG PHOSPHATE N018045 001

ESTROGENS, CONJUGATED

CREAM;TOPICAL, VAGINAL

PREMARIN

+ WYETH PHARMS INC 0.625MG/GM N020216 001

INJECTABLE;INJECTION

PREMARIN

+ WYETH PHARMS INC 25MG/VIAL N010402 001

TABLET;ORAL

PREMARIN

WYETH PHARMS INC 0.3MG N004782 003

0.45MG N004782 006 Jul 16, 2003

+ 0.625MG N004782 004

+ 0.9MG N004782 005 Jan 26, 1984

+ 1.25MG N004782 001

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL

CENESTIN

TEVA BRANDED PHARM 0.3MG N020992 001 Jun 21, 2002

0.45MG N020992 005 Feb 05, 2004

0.625MG N020992 002 Mar 24, 1999

0.9MG N020992 003 Mar 24, 1999

+ 1.25MG N020992 004 Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

ENJUWIA

TEVA WOMENS 0.3MG N021443 001 Dec 20, 2004

0.45MG N021443 002 Dec 20, 2004

0.625MG N021443 003 May 10, 2004

0.9MG N021443 005 Apr 27, 2007

+ 1.25MG N021443 004 May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28

PREMPHASE 14/14

+ WYETH PHARMS INC 0.625MG,0.625MG;0.625MG,0.625MG;N/A,5MG N020527 002 Nov 17, 1995

PREMPRO

+ WYETH PHARMS INC 0.3MG;1.5MG N020527 005 Jun 04, 2003

+ 0.45MG;1.5MG N020527 004 Mar 12, 2003

+ 0.625MG;0.625MG;2.5MG;2.5MG N020527 001 Nov 17, 1995

+ 0.625MG;0.625MG;5MG;5MG N020527 003 Jan 09, 1998

## PRESCRIPTION DRUG PRODUCT LIST

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

MONARCH PHARMS	0.3MG	A084951	001
	0.625MG	A084948	001
	1.25MG	A084950	001
+	2.5MG	A084949	001

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

<u>AB</u>	BARR	<u>0.75MG</u>	<u>A040135</u>	<u>001</u>	Nov 27, 1996
<u>AB</u>		<u>1.5MG</u>	<u>A040135</u>	<u>002</u>	Nov 27, 1996
<u>AB</u>		<u>3MG</u>	<u>A040135</u>	<u>003</u>	Nov 27, 1996
<u>AB</u>	MYLAN	<u>0.75MG</u>	<u>A040359</u>	<u>001</u>	Aug 26, 1999
<u>AB</u>		<u>1.5MG</u>	<u>A040359</u>	<u>002</u>	Aug 26, 1999
<u>AB</u>	WATSON LABS	<u>0.75MG</u>	<u>A081213</u>	<u>001</u>	Sep 23, 1993
<u>AB</u>		<u>1.5MG</u>	<u>A081214</u>	<u>001</u>	Sep 23, 1993
<u>AB</u>		<u>3MG</u>	<u>A081215</u>	<u>001</u>	Sep 23, 1993

OGEN .625

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.75MG</u>	<u>A083220</u>	<u>001</u>	
-----------	----------------------	---------------	----------------	------------	--

OGEN 1.25

<u>AB</u>	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>A083220</u>	<u>002</u>	
-----------	----------------------	--------------	----------------	------------	--

OGEN 2.5

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>3MG</u>	<u>A083220</u>	<u>003</u>	
-----------	------------------------	------------	----------------	------------	--

OGEN 5

PHARMACIA AND UPJOHN	6MG	A083220	004
----------------------	-----	---------	-----

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

<u>AB</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A091024</u>	<u>001</u>	Apr 15, 2014
<u>AB</u>		<u>2MG</u>	<u>A091024</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>		<u>3MG</u>	<u>A091024</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>	GLENMARK GENERICS	<u>1MG</u>	<u>A091166</u>	<u>001</u>	Apr 15, 2014
<u>AB</u>		<u>2MG</u>	<u>A091166</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>		<u>3MG</u>	<u>A091166</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>	LUPIN LTD	<u>1MG</u>	<u>A091124</u>	<u>001</u>	Sep 13, 2011
<u>AB</u>		<u>2MG</u>	<u>A091124</u>	<u>002</u>	Sep 13, 2011
<u>AB</u>		<u>3MG</u>	<u>A091124</u>	<u>003</u>	Sep 13, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>1MG</u>	<u>A091151</u>	<u>001</u>	Mar 26, 2013
<u>AB</u>		<u>2MG</u>	<u>A091151</u>	<u>002</u>	Mar 26, 2013
<u>AB</u>		<u>3MG</u>	<u>A091151</u>	<u>003</u>	Mar 26, 2013
<u>AB</u>	ORCHID HLTHCARE	<u>1MG</u>	<u>A091113</u>	<u>001</u>	Jun 10, 2014
<u>AB</u>		<u>2MG</u>	<u>A091113</u>	<u>002</u>	Jun 10, 2014
<u>AB</u>		<u>3MG</u>	<u>A091113</u>	<u>003</u>	Jun 10, 2014
<u>AB</u>	ROXANE	<u>1MG</u>	<u>A091153</u>	<u>001</u>	Apr 15, 2014
<u>AB</u>		<u>2MG</u>	<u>A091153</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>		<u>3MG</u>	<u>A091153</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>	SUN PHARMA GLOBAL	<u>1MG</u>	<u>A091103</u>	<u>001</u>	Apr 03, 2013
<u>AB</u>		<u>2MG</u>	<u>A091103</u>	<u>002</u>	Apr 03, 2013
<u>AB</u>		<u>3MG</u>	<u>A091103</u>	<u>003</u>	Apr 03, 2013
<u>AB</u>	TEVA	<u>1MG</u>	<u>A091169</u>	<u>001</u>	May 23, 2011
<u>AB</u>		<u>2MG</u>	<u>A091169</u>	<u>002</u>	May 23, 2011
<u>AB</u>		<u>3MG</u>	<u>A091169</u>	<u>003</u>	May 23, 2011

LUNESTA

<u>AB</u>	SUNOVION PHARMS INC	<u>1MG</u>	<u>N021476</u>	<u>001</u>	Dec 15, 2004
<u>AB</u>		<u>2MG</u>	<u>N021476</u>	<u>002</u>	Dec 15, 2004
<u>AB</u>	+	<u>3MG</u>	<u>N021476</u>	<u>003</u>	Dec 15, 2004

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECIN

+	ATON	EQ 50MG BASE/VIAL	N016093	001
---	------	-------------------	---------	-----

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

+	ATON	25MG	N016092	001
---	------	------	---------	-----



## PRESCRIPTION DRUG PRODUCT LIST

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

<b>AB</b>	BARR	<b>400MG</b>	<b>A076057 001</b>	Nov 26, 2001
<b>AB</b>	LUPIN	<b>100MG</b>	<b>A078939 001</b>	Jun 17, 2009
<b>AB</b>		<b>400MG</b>	<b>A078939 002</b>	Jun 17, 2009

MYAMBUTOL

<b>AB</b>	STI PHARMA LLC	<b>100MG</b>	<b>N016320 001</b>	
<b>AB</b>	+	<b>400MG</b>	<b>N016320 003</b>	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

+	QOL MEDCL	50MG/ML	N019357 001	Dec 22, 1988
---	-----------	---------	-------------	--------------

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

KELNOR

<b>AB</b>	BARR	<b>0.035MG;1MG</b>	<b>A076785 001</b>	May 23, 2005
	<b>ZOVIA 1/35E-28</b>			
<b>AB</b>	WATSON LABS	<b>0.035MG;1MG</b>	<b>A072721 001</b>	Dec 30, 1991
	ZOVIA 1/50E-28			
+	WATSON LABS	0.05MG;1MG	A072723 001	Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

+	ORGANON USA INC	0.015MG/24HR;0.12MG/24HR	N021187 001	Oct 03, 2001
---	-----------------	--------------------------	-------------	--------------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

DAYSEE

<b>AB</b>	LUPIN LTD	<b>0.03MG;0.01MG;0.15MG,N/A</b>	<b>A091467 001</b>	Apr 10, 2013
-----------	-----------	---------------------------------	--------------------	--------------

INTROVALE

<b>AB</b>	SANDOZ	<b>0.03MG;0.15MG</b>	<b>A079064 001</b>	Sep 27, 2010
-----------	--------	----------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

<b>AB</b>	LUPIN LTD	<b>0.02MG;0.01MG;0.1MG,N/A</b>	<b>A091674 001</b>	Oct 26, 2011
<b>AB</b>		<b>0.03MG;0.15MG</b>	<b>A091440 001</b>	Oct 23, 2012
<b>AB</b>	WATSON LABS	<b>0.02MG;0.01MG;0.1MG,N/A</b>	<b>A200407 001</b>	Oct 25, 2011

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

<b>AB</b>	WATSON LABS	<b>0.03MG;0.01MG;0.15MG,N/A</b>	<b>A078834 001</b>	May 31, 2011
-----------	-------------	---------------------------------	--------------------	--------------

LOSEASONIQUE

<b>AB</b>	TEVA BRANDED PHARM	<b>0.01MG;0.02MG;0.1MG</b>	<b>N022262 001</b>	Oct 24, 2008
-----------	--------------------	----------------------------	--------------------	--------------

OUASENSE

<b>AB</b>	WATSON LABS	<b>0.03MG;0.15MG</b>	<b>A077101 001</b>	Sep 06, 2006
-----------	-------------	----------------------	--------------------	--------------

SEASONALE

<b>AB</b>	+	TEVA BRANDED PHARM	<b>0.03MG;0.15MG</b>	<b>N021544 001</b>	Sep 05, 2003
-----------	---	--------------------	----------------------	--------------------	--------------

SEASONIQUE

<b>AB</b>	+	TEVA BRANDED PHARM	<b>0.03MG;0.01MG;0.03MG;0.01MG;0.15MG,N/A</b>	<b>N021840 001</b>	May 25, 2006
-----------	---	--------------------	-----------------------------------------------	--------------------	--------------

SETLAKIN

<b>AB</b>	NOVAST LABS LTD	<b>0.03MG;0.15MG</b>	<b>A090716 001</b>	Sep 15, 2014
-----------	-----------------	----------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

+	WATSON LABS	0.02MG;0.09MG	A079218 001	Jun 06, 2011
---	-------------	---------------	-------------	--------------

QUARTETTE

+	TEVA BRANDED PHARM	0.02MG;0.15MG	N204061 001	Mar 28, 2013
---	--------------------	---------------	-------------	--------------

TABLET; ORAL-28

ALTAVERA

<b>AB</b>	SANDOZ	<b>0.03MG;0.15MG</b>	<b>A079102 001</b>	Aug 03, 2010
-----------	--------	----------------------	--------------------	--------------

ENPRESSE-28

<b>AB</b>	DURAMED PHARMS BARR	<b>0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.125MG</b>	<b>A075809 002</b>	Jul 16, 2001
-----------	---------------------	----------------------------------------------------	--------------------	--------------

KURVELO

<b>AB</b>	LUPIN LTD	<b>0.03MG;0.15MG</b>	<b>A091408 001</b>	Oct 17, 2012
-----------	-----------	----------------------	--------------------	--------------

LEVONEST

<b>AB</b>	NOVAST LABS LTD	<b>0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.125MG</b>	<b>A090719 001</b>	Dec 29, 2010
-----------	-----------------	----------------------------------------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

<b>AB</b>	FAMY CARE LTD	<b>0.03MG;0.15MG</b>	<b>A091663 001</b>	Dec 21, 2012
-----------	---------------	----------------------	--------------------	--------------

<b>AB</b>	HAUPT PHARMA	<b>0.03MG;0.15MG</b>	<b>A201095 001</b>	Dec 08, 2014
-----------	--------------	----------------------	--------------------	--------------

LEVORA 0.15/30-28

<b>AB</b>	WATSON LABS	<b>0.03MG;0.15MG</b>	<b>A073594 001</b>	Dec 13, 1993
-----------	-------------	----------------------	--------------------	--------------

MARLISSA

<b>AB</b>	GLENMARK GENERICS	<b>0.03MG;0.15MG</b>	<b>A091452 001</b>	Feb 29, 2012
-----------	-------------------	----------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

MYZILRA

<b>AB</b>	VINTAGE PHARMS LLC	<u>0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG</u>	<u>A077502</u>	<u>001</u>	Nov 23, 2011
-----------	--------------------	---------------------------------------------------------	----------------	------------	--------------

NORDETTE-28

<b>AB</b>	+ TEVA BRANDED PHARM	<u>0.03MG; 0.15MG</u>	<u>N018782</u>	<u>001</u>	Jul 21, 1982
-----------	----------------------	-----------------------	----------------	------------	--------------

PORTIA-28

<b>AB</b>	BARR	<u>0.03MG; 0.15MG</u>	<u>A075866</u>	<u>002</u>	May 23, 2002
-----------	------	-----------------------	----------------	------------	--------------

TRIVORA-28

<b>AB</b>	+ WATSON LABS	<u>0.03MG; 0.03MG; 0.04MG; 0.05MG; 0.075MG; 0.125MG</u>	<u>A074538</u>	<u>002</u>	Dec 18, 1997
-----------	---------------	---------------------------------------------------------	----------------	------------	--------------

AVIANE-28

<b>AB1</b>	DURAMED PHARMS BARR	<u>0.02MG; 0.1MG</u>	<u>A075796</u>	<u>001</u>	Apr 30, 2001
------------	---------------------	----------------------	----------------	------------	--------------

FALMINA

<b>AB1</b>	NOVAST LABS LTD	<u>0.02MG; 0.1MG</u>	<u>A090721</u>	<u>001</u>	Mar 28, 2012
------------	-----------------	----------------------	----------------	------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

<b>AB1</b>	FAMY CARE LTD	<u>0.02MG; 0.1MG</u>	<u>A200245</u>	<u>001</u>	Oct 09, 2013
------------	---------------	----------------------	----------------	------------	--------------

<b>AB1</b>	HAUPT PHARMA	<u>0.02MG; 0.1MG</u>	<u>A201108</u>	<u>001</u>	Feb 05, 2014
------------	--------------	----------------------	----------------	------------	--------------

<b>AB1</b>	LUPIN LTD	<u>0.02MG; 0.1MG</u>	<u>A091425</u>	<u>001</u>	Jan 18, 2013
------------	-----------	----------------------	----------------	------------	--------------

<b>AB1</b>	+ WATSON LABS	<u>0.02MG; 0.1MG</u>	<u>A076625</u>	<u>001</u>	Nov 18, 2004
------------	---------------	----------------------	----------------	------------	--------------

ORSYTHIA

<b>AB1</b>	VINTAGE PHARMS LLC	<u>0.02MG; 0.1MG</u>	<u>A077099</u>	<u>001</u>	May 11, 2011
------------	--------------------	----------------------	----------------	------------	--------------

LESSINA-28

<b>AB2</b>	BARR	<u>0.02MG; 0.1MG</u>	<u>A075803</u>	<u>002</u>	Mar 20, 2002
------------	------	----------------------	----------------	------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

<b>AB2</b>	FAMY CARE LTD	<u>0.02MG; 0.1MG</u>	<u>A202247</u>	<u>001</u>	Dec 08, 2014
------------	---------------	----------------------	----------------	------------	--------------

<b>AB2</b>	+ WATSON LABS	<u>0.02MG; 0.1MG</u>	<u>A077681</u>	<u>001</u>	May 31, 2006
------------	---------------	----------------------	----------------	------------	--------------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

<b>AB</b>	+ JANSSEN PHARMS	<u>0.035MG/24HR; 0.15MG/24HR</u>	<u>N021180</u>	<u>001</u>	Nov 20, 2001
-----------	------------------	----------------------------------	----------------	------------	--------------

XULANE

<b>AB</b>	MYLAN TECHNOLOGIES	<u>0.035MG/24HR; 0.15MG/24HR</u>	<u>A200910</u>	<u>001</u>	Apr 16, 2014
-----------	--------------------	----------------------------------	----------------	------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+35 21-DAY

<b>AB</b>	WATSON LABS	<u>0.035MG; 1MG</u>	<u>N017565</u>	<u>001</u>	
-----------	-------------	---------------------	----------------	------------	--

NORTREL 1/35-21

<b>AB</b>	BARR	<u>0.035MG; 1MG</u>	<u>A072693</u>	<u>001</u>	Feb 28, 1992
-----------	------	---------------------	----------------	------------	--------------

NORTREL 7/7/7

BARR	<u>0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.75MG; 1MG</u>	<u>A075478</u>	<u>001</u>	Aug 30, 2002
------	------------------------------------------------------	----------------	------------	--------------

TABLET; ORAL-28

ALYACEN 1/35

<b>AB</b>	GLENMARK GENERICS	<u>0.035MG; 1MG</u>	<u>A091634</u>	<u>001</u>	Jan 19, 2012
-----------	-------------------	---------------------	----------------	------------	--------------

ALYACEN 7/7/7

<b>AB</b>	GLENMARK GENERICS	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	<u>A091636</u>	<u>001</u>	Jan 19, 2012
-----------	-------------------	------------------------------------------------------	----------------	------------	--------------

ARANELLE

<b>AB</b>	BARR	<u>0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.5MG; 1MG</u>	<u>A076783</u>	<u>001</u>	Sep 29, 2004
-----------	------	-----------------------------------------------------	----------------	------------	--------------

BALZIVA-28

<b>AB</b>	BARR	<u>0.035MG; 0.4MG</u>	<u>A076238</u>	<u>001</u>	Apr 22, 2004
-----------	------	-----------------------	----------------	------------	--------------

BREVICON 28-DAY

<b>AB</b>	WATSON LABS	<u>0.035MG; 0.5MG</u>	<u>N017743</u>	<u>001</u>	
-----------	-------------	-----------------------	----------------	------------	--

BRIELLYN

<b>AB</b>	GLENMARK GENERICS	<u>0.035MG; 0.4MG</u>	<u>A090538</u>	<u>001</u>	Mar 22, 2011
-----------	-------------------	-----------------------	----------------	------------	--------------

CYCLAFEM 1/35

<b>AB</b>	VINTAGE PHARMS LLC	<u>0.035MG; 1MG</u>	<u>A076337</u>	<u>001</u>	Nov 12, 2010
-----------	--------------------	---------------------	----------------	------------	--------------

CYCLAFEM 7/7/7

<b>AB</b>	VINTAGE PHARMS LLC	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	<u>A076338</u>	<u>001</u>	Nov 16, 2010
-----------	--------------------	------------------------------------------------------	----------------	------------	--------------

DASETTA 1/35

<b>AB</b>	NOVAST LABS LTD	<u>0.035MG; 1MG</u>	<u>A090948</u>	<u>001</u>	Dec 22, 2011
-----------	-----------------	---------------------	----------------	------------	--------------

DASETTA 7/7/7

<b>AB</b>	NOVAST LABS LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG</u>	<u>A090946</u>	<u>001</u>	Dec 22, 2011
-----------	-----------------	------------------------------------------------------	----------------	------------	--------------

GILDAGIA

<b>AB</b>	VINTAGE PHARMS	<u>0.035MG; 0.4MG</u>	<u>A078376</u>	<u>001</u>	Nov 06, 2012
-----------	----------------	-----------------------	----------------	------------	--------------

MODICON 28

<b>AB</b>	+ JANSSEN PHARMS	<u>0.035MG; 0.5MG</u>	<u>N017735</u>	<u>001</u>	
-----------	------------------	-----------------------	----------------	------------	--

## PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

<b>AB</b>	+	FAMY CARE LTD	<u>0.05MG;1MG</u>	<u>A203006</u>	<u>001</u>	Aug 05, 2013
<b>AB</b>		WATSON LABS	<u>0.035MG;0.4MG</u>	<u>A078323</u>	<u>001</u>	Feb 04, 2010
<b>AB</b>			<u>0.035MG;0.5MG</u>	<u>A070686</u>	<u>001</u>	Jan 29, 1987
<b>AB</b>			<u>0.035MG;1MG</u>	<u>A070687</u>	<u>001</u>	Jan 29, 1987

NORINYL 1+35 28-DAY

<b>AB</b>		WATSON LABS	<u>0.035MG;1MG</u>	<u>N017565</u>	<u>002</u>	
<b>AB</b>		<u>NORTREL 0.5/35-28</u>				
<b>AB</b>		BARR	<u>0.035MG;0.5MG</u>	<u>A072695</u>	<u>001</u>	Feb 28, 1992
<b>AB</b>		<u>NORTREL 1/35-28</u>				
<b>AB</b>		BARR	<u>0.035MG;1MG</u>	<u>A072696</u>	<u>001</u>	Feb 28, 1992
<b>AB</b>		<u>NORTREL 7/7/7</u>				
<b>AB</b>		BARR	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>A075478</u>	<u>002</u>	Aug 30, 2002

ORTHO-NOVUM 1/35-28

<b>AB</b>	+	JANSSEN PHARMS	<u>0.035MG;1MG</u>	<u>N017919</u>	<u>002</u>	
<b>AB</b>	+	JANSSEN PHARMS	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>N018985</u>	<u>002</u>	Apr 04, 1984

OVCON-35

<b>AB</b>	+	WARNER CHILCOTT LLC	<u>0.035MG;0.4MG</u>	<u>N017716</u>	<u>001</u>	
<b>AB</b>		<u>PHILITH</u>				
<b>AB</b>		NOVAST LABS LTD	<u>0.035MG;0.4MG</u>	<u>A090947</u>	<u>001</u>	Dec 22, 2011
<b>AB</b>		<u>PIRMELLA 1/35</u>				
<b>AB</b>		LUPIN LTD	<u>0.035MG;1MG</u>	<u>A201512</u>	<u>001</u>	Apr 24, 2013
<b>AB</b>		<u>PIRMELLA 7/7/7</u>				
<b>AB</b>		LUPIN LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A201510</u>	<u>001</u>	Apr 24, 2013

TRI-NORINYL 28-DAY

<b>AB</b>	+	WATSON LABS	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.5MG;1MG</u>	<u>N018977</u>	<u>002</u>	Apr 13, 1984
-----------	---	-------------	------------------------------------------------	----------------	------------	--------------

VYFEMLA

<b>AB</b>		LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A201886</u>	<u>001</u>	Sep 26, 2013
-----------	--	-----------	----------------------	----------------	------------	--------------

WERA

<b>AB</b>		NOVAST LABS LTD	<u>0.035MG;0.5MG</u>	<u>A091204</u>	<u>001</u>	Mar 27, 2012
		NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)				
		WATSON LABS	<u>0.035MG;0.035MG;0.5MG;1MG</u>	<u>A071044</u>	<u>001</u>	Apr 01, 1988

TABLET, CHEWABLE; ORAL

FEMCON FE

<b>AB</b>	+	WARNER CHILCOTT LLC	<u>0.035MG;0.4MG</u>	<u>N021490</u>	<u>001</u>	Nov 14, 2003
<b>AB</b>		<u>NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>				
<b>AB</b>		AMNEAL PHARMS	<u>0.035MG;0.4MG</u>	<u>A078892</u>	<u>001</u>	Sep 26, 2011
<b>AB</b>		BARR	<u>0.035MG;0.4MG</u>	<u>A078965</u>	<u>001</u>	Aug 05, 2010
<b>AB</b>		FAMY CARE LTD	<u>0.025MG;0.8MG</u>	<u>A203371</u>	<u>001</u>	Apr 23, 2014
<b>AB</b>	+	WARNER CHILCOTT	<u>0.025MG;0.8MG</u>	<u>N022573</u>	<u>001</u>	Dec 22, 2010

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

GILDESS 24 FE

<b>AB</b>		VINTAGE PHARMS	<u>0.02MG;1MG</u>	<u>A090293</u>	<u>001</u>	Dec 01, 2014
-----------	--	----------------	-------------------	----------------	------------	--------------

LOESTRIN 24 FE

<b>AB</b>	+	WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N021871</u>	<u>001</u>	Feb 17, 2006
-----------	---	-----------------	-------------------	----------------	------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

<b>AB</b>		AMNEAL PHARMS	<u>0.02MG;1MG</u>	<u>A078267</u>	<u>001</u>	Sep 01, 2009
<b>AB</b>		BARR LABS INC	<u>0.02MG;1MG</u>	<u>A090938</u>	<u>001</u>	Dec 01, 2014
<b>AB</b>		FAMY CARE LTD	<u>0.02MG;1MG</u>	<u>A202742</u>	<u>001</u>	Oct 30, 2014
		FEMHRT				
		WARNER CHILCOTT LLC	<u>0.0025MG;0.5MG</u>	<u>N021065</u>	<u>001</u>	Jan 14, 2005
		LO LOESTRIN FE				
		+ WARNER CHILCOTT LLC	<u>0.01MG,0.01MG;1MG,N/A</u>	<u>N022501</u>	<u>001</u>	Oct 21, 2010
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL				
		+ BARR LABS INC	<u>0.005MG;1MG</u>	<u>A076221</u>	<u>001</u>	Nov 06, 2009

TABLET; ORAL-21

GILDESS 1.5/30

<b>AB</b>		VINTAGE PHARMS LLC	<u>0.03MG;1.5MG</u>	<u>A077075</u>	<u>002</u>	Jul 24, 2012
-----------	--	--------------------	---------------------	----------------	------------	--------------

GILDESS 1/20

<b>AB</b>		VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077</u>	<u>002</u>	Jul 24, 2012
-----------	--	--------------------	-------------------	----------------	------------	--------------

JUNEL 1.5/30

<b>AB</b>		BARR	<u>0.03MG;1.5MG</u>	<u>A076381</u>	<u>001</u>	May 30, 2003
-----------	--	------	---------------------	----------------	------------	--------------

JUNEL 1/20

<b>AB</b>		BARR	<u>0.02MG;1MG</u>	<u>A076380</u>	<u>001</u>	May 30, 2003
-----------	--	------	-------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

LARIN 1.5/30

<b>AB</b>	NOVAST LABS LTD	<b>0.03MG;1.5MG</b>	<b>A202996 001</b>	Mar 20, 2014
-----------	-----------------	---------------------	--------------------	--------------

LARIN 1/20

<b>AB</b>	NOVAST LABS LTD	<b>0.02MG;1MG</b>	<b>A202995 001</b>	Dec 04, 2013
-----------	-----------------	-------------------	--------------------	--------------

LOESTRIN 21 1.5/30

<b>AB</b>	WARNER CHILCOTT LLC	<b>0.03MG;1.5MG</b>	<b>N017875 001</b>	
-----------	---------------------	---------------------	--------------------	--

LOESTRIN 21 1/20

<b>AB</b>	WARNER CHILCOTT LLC	<b>0.02MG;1MG</b>	<b>N017876 001</b>	
-----------	---------------------	-------------------	--------------------	--

MICROGESTIN 1.5/30

<b>AB</b>	WATSON LABS	<b>0.03MG;1.5MG</b>	<b>A075548 002</b>	Jul 30, 2003
-----------	-------------	---------------------	--------------------	--------------

MICROGESTIN 1/20

<b>AB</b>	WATSON LABS	<b>0.02MG;1MG</b>	<b>A075647 002</b>	Jul 30, 2003
-----------	-------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

<b>AB</b>	FAMY CARE LTD	<b>0.02MG;1MG</b>	<b>A202771 001</b>	Nov 06, 2013
-----------	---------------	-------------------	--------------------	--------------

TRI-LEGEST 21

BARR

0.02MG;0.035MG;0.03MG;1MG;1MG;1MG

A076405 001 Oct 26, 2007

TABLET; ORAL-28

ESTROSTEP FE

<b>AB</b>	+ WARNER CHILCOTT LLC	<b>0.02MG;0.035MG;0.03MG;1MG;1MG;1MG</b>	<b>N020130 002</b>	Oct 09, 1996
-----------	-----------------------	------------------------------------------	--------------------	--------------

GILDESS FE 1.5/30

<b>AB</b>	VINTAGE PHARMS LLC	<b>0.03MG;1.5MG</b>	<b>A077075 001</b>	Apr 28, 2005
-----------	--------------------	---------------------	--------------------	--------------

GILDESS FE 1/20

<b>AB</b>	VINTAGE PHARMS LLC	<b>0.02MG;1MG</b>	<b>A077077 001</b>	May 20, 2005
-----------	--------------------	-------------------	--------------------	--------------

JUNEL FE 1.5/30

<b>AB</b>	BARR	<b>0.03MG;1.5MG</b>	<b>A076064 001</b>	Sep 18, 2003
-----------	------	---------------------	--------------------	--------------

JUNEL FE 1/20

<b>AB</b>	BARR	<b>0.02MG;1MG</b>	<b>A076081 001</b>	Sep 18, 2003
-----------	------	-------------------	--------------------	--------------

LARIN FE 1.5/30

<b>AB</b>	NOVAST LABS LTD	<b>0.03MG;1.5MG</b>	<b>A091453 001</b>	Aug 23, 2013
-----------	-----------------	---------------------	--------------------	--------------

LARIN FE 1/20

<b>AB</b>	NOVAST LABS LTD	<b>0.02MG;1MG</b>	<b>A091454 001</b>	Aug 26, 2013
-----------	-----------------	-------------------	--------------------	--------------

LOESTRIN FE 1.5/30

<b>AB</b>	+ WARNER CHILCOTT LLC	<b>0.03MG;1.5MG</b>	<b>N017355 001</b>	
-----------	-----------------------	---------------------	--------------------	--

LOESTRIN FE 1/20

<b>AB</b>	WARNER CHILCOTT	<b>0.02MG;1MG</b>	<b>N017354 001</b>	
-----------	-----------------	-------------------	--------------------	--

MICROGESTIN FE 1.5/30

<b>AB</b>	WATSON LABS	<b>0.03MG;1.5MG</b>	<b>A075548 001</b>	Feb 05, 2001
-----------	-------------	---------------------	--------------------	--------------

MICROGESTIN FE 1/20

<b>AB</b>	WATSON LABS	<b>0.02MG;1MG</b>	<b>A075647 001</b>	Feb 05, 2001
-----------	-------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

<b>AB</b>	FAMY CARE LTD	<b>0.02MG;1MG</b>	<b>A202772 001</b>	Nov 14, 2013
-----------	---------------	-------------------	--------------------	--------------

<b>AB</b>	WATSON LABS	<b>0.02MG, 0.03MG, 0.035MG;1MG, 1MG, 1MG</b>	<b>A076629 001</b>	Mar 18, 2010
-----------	-------------	----------------------------------------------	--------------------	--------------

TRI-LEGEST FE

<b>AB</b>	BARR	<b>0.02MG;0.035MG;0.03MG;1MG;1MG;1MG</b>	<b>A076105 001</b>	Oct 26, 2007
-----------	------	------------------------------------------	--------------------	--------------

TABLET, CHEWABLE; ORAL

MINASTRIN 24 FE

+ WARNER CHILCOTT LLC 0.02MG;1MG

N203667 001 May 08, 2013

TABLET, CHEWABLE, TABLET; ORAL

LO MINASTRIN FE

+ WARNER CHILCOTT 0.01MG, 0.01MG, N/A; 1MG, N/A, N/A

N204654 001 Jul 24, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL

NORGESTIMATE AND ETHINYL ESTRADIOL

<b>AB</b>	GLENMARK GENERICS	<b>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</b>	<b>A200494 001</b>	Jun 17, 2011
-----------	-------------------	-----------------------------------------------------------	--------------------	--------------

TABLET; ORAL-28

ESTARYLLA

<b>AB</b>	SANDOZ	<b>0.035MG;0.25MG</b>	<b>A090794 001</b>	Jan 30, 2013
-----------	--------	-----------------------	--------------------	--------------

MONO-LINYAH

<b>AB</b>	NOVAST LABS LTD	<b>0.035MG;0.25MG</b>	<b>A090523 001</b>	May 23, 2012
-----------	-----------------	-----------------------	--------------------	--------------

NORGESTIMATE AND ETHINYL ESTRADIOL

<b>AB</b>	GLENMARK GENERICS	<b>0.035MG;0.25MG</b>	<b>A200538 001</b>	Apr 05, 2012
-----------	-------------------	-----------------------	--------------------	--------------

<b>AB</b>	LUPIN PHARMS	<b>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</b>	<b>A200541 001</b>	Jun 25, 2012
-----------	--------------	-----------------------------------------------------------	--------------------	--------------

ORTHO CYCLEN-28

<b>AB</b>	+ JANSSEN PHARMS	<b>0.035MG;0.25MG</b>	<b>N019653 002</b>	Dec 29, 1989
-----------	------------------	-----------------------	--------------------	--------------

ORTHO TRI-CYCLEN

<b>AB</b>	+ JANSSEN PHARMS	<b>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</b>	<b>N019697 001</b>	Jul 03, 1992
-----------	------------------	------------------------------------------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO TRI-CYCLEN LO

<b>AB</b>	+	JANSSEN PHARMS	<u>0.025MG;0.025MG;0.025MG;0.18MG;0.215MG;0.25MG</u>	<u>N021241 001</u>	Aug 22, 2002
-----------	---	----------------	------------------------------------------------------	--------------------	--------------

PREVIFEM

<b>AB</b>		VINTAGE PHARMS LLC	<u>0.035MG;0.25MG</u>	<u>A076334 001</u>	Jan 09, 2004
-----------	--	--------------------	-----------------------	--------------------	--------------

SPRINTEC

<b>AB</b>		BARR	<u>0.035MG;0.25MG</u>	<u>A075804 001</u>	Sep 25, 2002
-----------	--	------	-----------------------	--------------------	--------------

TRI-ESTARYLLA

<b>AB</b>		SANDOZ	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A090793 001</u>	Jan 30, 2013
-----------	--	--------	------------------------------------------------------	--------------------	--------------

TRI-LINYAH

<b>AB</b>		NOVAST LABS LTD	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A090524 001</u>	May 30, 2012
-----------	--	-----------------	------------------------------------------------------	--------------------	--------------

TRI-PREVIFEM

<b>AB</b>		VINTAGE PHARMS LLC	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	<u>A076335 001</u>	Mar 26, 2004
-----------	--	--------------------	------------------------------------------------------	--------------------	--------------

TRI-SPRINTEC

<b>AB</b>		BARR	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	<u>A075808 001</u>	Dec 29, 2003
-----------	--	------	------------------------------------------------------	--------------------	--------------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSELLE

<b>AB</b>		DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	<u>A075840 001</u>	Nov 30, 2001
-----------	--	---------------------	---------------------	--------------------	--------------

TABLET; ORAL-28

CRYSELLE

<b>AB</b>		DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	<u>A075840 002</u>	Nov 30, 2001
-----------	--	---------------------	---------------------	--------------------	--------------

ELINEST

<b>AB</b>		NOVAST LABS LTD	<u>0.03MG;0.3MG</u>	<u>A091105 001</u>	Mar 28, 2012
-----------	--	-----------------	---------------------	--------------------	--------------

LO/OVRAL-28

<b>AB</b>		WYETH PHARMS	<u>0.03MG;0.3MG</u>	<u>N017802 001</u>	
		OGESTREL 0.5/50-28			
	+	WATSON LABS	0.05MG;0.5MG	A075406 002	Dec 15, 1999

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+ GUERBET

99%

N009190 001

ETHIONAMIDE

TABLET; ORAL

TRECATOR

+ WYETH PHARMS INC

250MG

N013026 002

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

<b>AB</b>		BANNER PHARMACAPS	<u>250MG</u>	<u>A040430 001</u>	Oct 28, 2002
-----------	--	-------------------	--------------	--------------------	--------------

<b>AB</b>		VERSAPHARM	<u>250MG</u>	<u>A040686 001</u>	May 28, 2008
-----------	--	------------	--------------	--------------------	--------------

<b>AB</b>		ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A200892 001</u>	Sep 25, 2012
-----------	--	----------------------	--------------	--------------------	--------------

ZARONTIN

<b>AB</b>	+	PARKE DAVIS	<u>250MG</u>	<u>N012380 001</u>	
-----------	---	-------------	--------------	--------------------	--

SYRUP; ORAL

ETHOSUXIMIDE

<b>AA</b>		MIKART	<u>250MG/5ML</u>	<u>A040506 001</u>	Dec 22, 2003
-----------	--	--------	------------------	--------------------	--------------

<b>AA</b>		PHARM ASSOC	<u>250MG/5ML</u>	<u>A040253 001</u>	Nov 22, 2000
-----------	--	-------------	------------------	--------------------	--------------

<b>AA</b>		TEVA PHARMS	<u>250MG/5ML</u>	<u>A081306 001</u>	Jul 30, 1993
-----------	--	-------------	------------------	--------------------	--------------

ZARONTIN

<b>AA</b>	+	PARKE DAVIS	<u>250MG/5ML</u>	<u>A080258 001</u>	
-----------	---	-------------	------------------	--------------------	--

ETHOTOIN

TABLET; ORAL

PEGANONE

+ RECORDATI RARE

250MG

N010841 001

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

<b>AB</b>		PROCTER AND GAMBLE	<u>200MG</u>	<u>N017831 001</u>	
-----------	--	--------------------	--------------	--------------------	--

<b>AB</b>	+		<u>400MG</u>	<u>N017831 002</u>	
-----------	---	--	--------------	--------------------	--

ETIDRONATE DISODIUM

<b>AB</b>		MYLAN	<u>200MG</u>	<u>A075800 001</u>	Jan 24, 2003
-----------	--	-------	--------------	--------------------	--------------

<b>AB</b>			<u>400MG</u>	<u>A075800 002</u>	Jan 24, 2003
-----------	--	--	--------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ETODOLAC

CAPSULE; ORAL

ETODOLAC

<u>AB</u>	ANI PHARMS INC	<u>200MG</u>	<u>A075126 001</u>	Sep 16, 1999
<u>AB</u>		<u>300MG</u>	<u>A075126 002</u>	Sep 16, 1999
<u>AB</u>	APOTEX	<u>200MG</u>	<u>A075419 001</u>	Jul 28, 2000
<u>AB</u>		<u>300MG</u>	<u>A075419 002</u>	Jul 28, 2000
<u>AB</u>	TARO	<u>200MG</u>	<u>A075078 001</u>	Apr 30, 1998
<u>AB</u>	+	<u>300MG</u>	<u>A075078 002</u>	Apr 30, 1998

TABLET; ORAL

ETODOLAC

<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A076004 001</u>	Dec 03, 2002
<u>AB</u>		<u>500MG</u>	<u>A076004 002</u>	Dec 03, 2002
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075104 001</u>	Feb 06, 1998
<u>AB</u>		<u>500MG</u>	<u>A075104 002</u>	Nov 20, 1998
<u>AB</u>	SANDOZ	<u>400MG</u>	<u>A074903 001</u>	Apr 11, 1997
<u>AB</u>		<u>500MG</u>	<u>A074903 002</u>	Apr 19, 1999
<u>AB</u>	TARO PHARM INDS	<u>400MG</u>	<u>A075074 001</u>	Mar 11, 1998
<u>AB</u>	+	<u>500MG</u>	<u>A075074 002</u>	Apr 25, 2000
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075009 001</u>	Nov 26, 1997
<u>AB</u>		<u>500MG</u>	<u>A075009 002</u>	Dec 28, 1999

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u>	TARO	<u>400MG</u>	<u>A076174 001</u>	Mar 13, 2003
<u>AB</u>		<u>500MG</u>	<u>A076174 002</u>	Mar 13, 2003
<u>AB</u>		<u>600MG</u>	<u>A076174 003</u>	Mar 13, 2003
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075665 003</u>	Feb 05, 2001
<u>AB</u>		<u>500MG</u>	<u>A075665 002</u>	Jul 31, 2000
<u>AB</u>	+	<u>600MG</u>	<u>A075665 001</u>	Jul 31, 2000
<u>AB</u>	ZYDUS PHARMS USA INC	<u>400MG</u>	<u>A091134 001</u>	Jan 23, 2014
<u>AB</u>		<u>500MG</u>	<u>A091134 002</u>	Jan 23, 2014
<u>AB</u>		<u>600MG</u>	<u>A091134 003</u>	Jan 23, 2014

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	+	HOSPIRA	<u>2MG/ML</u>	<u>N018227 001</u>	Sep 07, 1982
-----------	---	---------	---------------	--------------------	--------------

ETOMIDATE

<u>AP</u>	AGILA SPECLTS	<u>2MG/ML</u>	<u>A078289 001</u>	Jan 02, 2009
<u>AP</u>	BEDFORD	<u>2MG/ML</u>	<u>A074593 001</u>	Nov 04, 1996
<u>AP</u>	EMCURE PHARMS LTD	<u>2MG/ML</u>	<u>A204618 001</u>	Aug 13, 2014
<u>AP</u>	LUITPOLD	<u>2MG/ML</u>	<u>A078867 001</u>	Dec 22, 2009
<u>AP</u>	PAR STERILE PRODUCTS	<u>2MG/ML</u>	<u>A091297 001</u>	Jun 20, 2012
<u>AP</u>	ZYDUS PHARMS USA INC	<u>2MG/ML</u>	<u>A202360 001</u>	Jul 18, 2014

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

	+	ORGANON USA INC	68MG/IMPLANT	N021529 001	Jul 17, 2006
--	---	-----------------	--------------	-------------	--------------

NEXPLANON

	+	ORGANON USA INC	68MG/IMPLANT	N021529 002	May 31, 2011
--	---	-----------------	--------------	-------------	--------------

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

	+	MYLAN	50MG	A075635 001	Sep 19, 2001
--	---	-------	------	-------------	--------------

INJECTABLE; INJECTION

ETOPOSIDE

<u>AP</u>	ACCORD HLTHCARE	<u>20MG/ML</u>	<u>A074513 001</u>	Mar 14, 1996	
<u>AP</u>	EUROHLTH INTL	<u>20MG/ML</u>	<u>A074290 001</u>	Jul 17, 1995	
<u>AP</u>	+	FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A074983 001</u>	Sep 30, 1998
<u>AP</u>	TEVA PHARMS USA	<u>20MG/ML</u>	<u>A074529 001</u>	Jul 24, 1996	

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPHOS PRESERVATIVE FREE

	+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N020457 001	May 17, 1996
--	---	----------------------	--------------------	-------------	--------------

ETRAVIRINE

TABLET; ORAL

INTELENCE

	JANSSEN R AND D	25MG	N022187 003	Mar 26, 2012
		100MG	N022187 001	Jan 18, 2008
	+	200MG	N022187 002	Dec 22, 2010

## PRESCRIPTION DRUG PRODUCT LIST

EVEROLIMUS

TABLET;ORAL

AFINITOR

NOVARTIS

2.5MG

N022334 003 Jul 09, 2010

5MG

N022334 001 Mar 30, 2009

7.5MG

N022334 004 Mar 30, 2012

+

10MG

N022334 002 Mar 30, 2009

ZORTRESS

NOVARTIS

0.25MG

N021560 001 Apr 20, 2010

0.5MG

N021560 002 Apr 20, 2010

+

0.75MG

N021560 003 Apr 20, 2010

TABLET, FOR SUSPENSION;ORAL

AFINITOR DISPERZ

NOVARTIS PHARM

2MG

N203985 001 Aug 29, 2012

3MG

N203985 002 Aug 29, 2012

+

5MG

N203985 003 Aug 29, 2012

EXEMESTANE

TABLET;ORAL

AROMASIN**AB** + PHARMACIA AND UPJOHN **25MG****N020753 001** Oct 21, 1999EXEMESTANE**AB** ALVOGEN INC **25MG****A200898 001** Jul 28, 2014**AB** ROXANE **25MG****A077431 001** Apr 01, 2011EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON

+ ASTRAZENECA AB

2MG/VIAL

N022200 001 Jan 27, 2012

INJECTABLE;SUBCUTANEOUS

BYETTA

+ ASTRAZENECA AB

300MCG/1.2ML (250MCG/ML)

N021773 001 Apr 28, 2005

+

600MCG/2.4ML (250MCG/ML)

N021773 002 Apr 28, 2005

EZETIMIBE

TABLET;ORAL

ZETIA

+ MSD INTL GMBH

10MG

N021445 001 Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

VYTORIN

MSD INTL

10MG;10MG

N021687 001 Jul 23, 2004

10MG;20MG

N021687 002 Jul 23, 2004

10MG;40MG

N021687 003 Jul 23, 2004

+

10MG;80MG

N021687 004 Jul 23, 2004

EZOZABINE

TABLET;ORAL

POTIGA

GLAXOSMITHKLINE

50MG

N022345 001 Jun 10, 2011

200MG

N022345 002 Jun 10, 2011

300MG

N022345 003 Jun 10, 2011

+

400MG

N022345 004 Jun 10, 2011

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR**AB** APOTEX**125MG****A091480 001** Jul 22, 2011**AB****250MG****A091480 002** Jul 22, 2011**AB****500MG****A091480 003** Jul 22, 2011**AB** AUROBINDO PHARMA LTD**125MG****A091114 001** Mar 21, 2011**AB****250MG****A091114 002** Mar 21, 2011**AB****500MG****A091114 003** Mar 21, 2011**AB** CIPLA LTD**125MG****A078278 001** Mar 21, 2011**AB****250MG****A078278 002** Mar 21, 2011**AB****500MG****A078278 003** Mar 21, 2011**AB** HETERO LABS LTD V**125MG****A202438 001** Sep 10, 2014**AB****250MG****A202438 002** Sep 10, 2014**AB****500MG****A202438 003** Sep 10, 2014**AB** MACLEODS PHARMS LTD**125MG****A201022 001** Jan 12, 2012**AB****250MG****A201022 002** Jan 12, 2012**AB****500MG****A201022 003** Jan 12, 2012**AB** MYLAN**125MG****A201333 001** Mar 24, 2011**AB****250MG****A201333 002** Mar 24, 2011

## PRESCRIPTION DRUG PRODUCT LIST

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

<u>AB</u>		<u>500MG</u>	<u>A201333</u>	<u>003</u>	Mar 24, 2011
<u>AB</u>	ROXANE	<u>125MG</u>	<u>A090128</u>	<u>001</u>	Mar 21, 2011
<u>AB</u>		<u>250MG</u>	<u>A090128</u>	<u>002</u>	Mar 21, 2011
<u>AB</u>		<u>500MG</u>	<u>A090128</u>	<u>003</u>	Mar 21, 2011
<u>AB</u>	TEVA PHARMS	<u>125MG</u>	<u>A077487</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>250MG</u>	<u>A077487</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A077487</u>	<u>003</u>	Aug 24, 2007

FAMVIR

<u>AB</u>	NOVARTIS	<u>125MG</u>	<u>N020363</u>	<u>003</u>	Dec 11, 1995
<u>AB</u>		<u>250MG</u>	<u>N020363</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>	+	<u>500MG</u>	<u>N020363</u>	<u>002</u>	Jun 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>	HI-TECH PHARMA CO	<u>40MG/5ML</u>	<u>A201995</u>	<u>001</u>	May 30, 2014
<u>AB</u>	LUPIN LTD	<u>40MG/5ML</u>	<u>A090440</u>	<u>001</u>	Jun 29, 2010
<u>AB</u>	NAVINTA LLC	<u>40MG/5ML</u>	<u>A091020</u>	<u>001</u>	May 27, 2010

PEPCID

<u>AB</u>	+	SALIX PHARMS	<u>40MG/5ML</u>	<u>N019527</u>	<u>001</u>	Feb 02, 1987
-----------	---	--------------	-----------------	----------------	------------	--------------

INJECTABLE; INJECTION

FAMOTIDINE

<u>AP</u>	AGILA SPECLTS	<u>10MG/ML</u>	<u>A078641</u>	<u>001</u>	Jun 25, 2008	
<u>AP</u>	BEDFORD	<u>10MG/ML</u>	<u>A075651</u>	<u>001</u>	Apr 16, 2001	
<u>AP</u>		<u>10MG/ML</u>	<u>A075684</u>	<u>001</u>	Apr 16, 2001	
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075709</u>	<u>001</u>	Apr 16, 2001	
<u>AP</u>	+	HIKMA MAPLE	<u>10MG/ML</u>	<u>A075488</u>	<u>001</u>	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE

<u>AP</u>	AGILA SPECLTS	<u>10MG/ML</u>	<u>A078642</u>	<u>001</u>	Jun 25, 2008	
<u>AP</u>	BEDFORD	<u>10MG/ML</u>	<u>A075622</u>	<u>001</u>	Apr 16, 2001	
<u>AP</u>	BEDFORD LABS	<u>10MG/ML</u>	<u>A075825</u>	<u>001</u>	Apr 17, 2001	
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075813</u>	<u>001</u>	Apr 16, 2001	
<u>AP</u>	+	HIKMA MAPLE	<u>10MG/ML</u>	<u>A075486</u>	<u>001</u>	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>0.4MG/ML</u>	<u>A075591</u>	<u>001</u>	May 10, 2001
-----------	---	-----------------	-----------------	----------------	------------	--------------

SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>	NOVEL LABS INC	<u>40MG/5ML</u>	<u>A201695</u>	<u>001</u>	Dec 17, 2012
-----------	----------------	-----------------	----------------	------------	--------------

TABLET; ORAL

FAMOTIDINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>20MG</u>	<u>A078916</u>	<u>001</u>	May 22, 2009
<u>AB</u>		<u>40MG</u>	<u>A078916</u>	<u>002</u>	May 22, 2009
<u>AB</u>	APOTEX	<u>20MG</u>	<u>A075611</u>	<u>001</u>	Jul 23, 2001
<u>AB</u>		<u>40MG</u>	<u>A075611</u>	<u>002</u>	Jul 23, 2001
<u>AB</u>	CARLSBAD	<u>20MG</u>	<u>A075805</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075805</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A075718</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075718</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A075511</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A075704</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075704</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	PERRIGO	<u>20MG</u>	<u>A077352</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>		<u>40MG</u>	<u>A077352</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>	TEVA	<u>20MG</u>	<u>A075311</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075311</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	WOCKHARDT	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001

PEPCID

<u>AB</u>	MARATHON PHARMS	<u>20MG</u>	<u>N019462</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>	+	<u>40MG</u>	<u>N019462</u>	<u>002</u>	Oct 15, 1986

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+	HORIZON PHARMA	<u>26.6MG; 800MG</u>	<u>N022519</u>	<u>001</u>	Apr 23, 2011
---	----------------	----------------------	----------------	------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS USA

40MG

N021856 001 Feb 13, 2009

+

80MG

N021856 002 Feb 13, 2009

FELBAMATE

SUSPENSION; ORAL

FELBAMATEAB AMNEAL PHARMS600MG/5MLA202385 001 Dec 16, 2011FELBATOLAB + MEDA PHARMS600MG/5MLN020189 003 Jul 29, 1993

TABLET; ORAL

FELBAMATEAB AMNEAL PHARMS400MGA201680 001 Sep 13, 2011AB600MGA201680 002 Sep 13, 2011FELBATOLAB MEDA PHARMS400MGN020189 001 Jul 29, 1993AB

+

600MGN020189 002 Jul 29, 1993FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINEAB AUROBINDO PHARMA LTD2.5MGA203417 001 Jan 17, 2013AB5MGA203417 002 Jan 17, 2013AB10MGA203417 003 Jan 17, 2013AB GLENMARK GENERICS2.5MGA090365 001 Dec 17, 2010AB5MGA090365 002 Dec 17, 2010AB10MGA090365 003 Dec 17, 2010AB HERITAGE PHARMS INC2.5MGA201964 001 Nov 08, 2013AB5MGA201964 002 Nov 08, 2013AB10MGA201964 003 Nov 08, 2013AB MUTUAL PHARM2.5MGA075896 001 Nov 02, 2004AB5MGA075896 002 Nov 02, 2004AB10MGA075896 003 Nov 02, 2004AB MYLAN2.5MGA078855 001 Apr 17, 2008AB5MGA078855 002 Apr 17, 2008AB

+

10MGA078855 003 Apr 17, 2008AB RANBAXY LABS LTD2.5MGA091200 001 Dec 13, 2013AB5MGA091200 002 Dec 13, 2013AB10MGA091200 003 Dec 13, 2013AB TORRENT PHARMS LTD2.5MGA202170 001 Nov 28, 2011AB5MGA202170 002 Nov 28, 2011AB10MGA202170 003 Nov 28, 2011AB VINTAGE PHARMS LLC2.5MGA200815 001 Oct 28, 2011AB5MGA200815 002 Oct 28, 2011AB10MGA200815 003 Oct 28, 2011PLENDILAB ASTRAZENECA2.5MGN019834 004 Sep 22, 1994AB5MGN019834 001 Jul 25, 1991AB10MGN019834 002 Jul 25, 1991FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)AB LUPIN ATLANTIS43MGN021695 001 Nov 30, 2004AB

+

130MGN021695 003 Nov 30, 2004FENOFIBRATEAB RANBAXY LABS LTD43MGA201748 001 Oct 31, 2014AB130MGA201748 002 Oct 31, 2014FENOFIBRATE (MICRONIZED)AB APOTEX INC43MGA202252 001 Jul 26, 2013AB130MGA202252 002 Jul 26, 2013AB DR REDDYS LABS SA43MGA090859 001 Mar 01, 2012AB130MGA090859 002 Mar 01, 2012AB IMPAX LABS67MGA075868 001 Oct 27, 2003AB134MGA075868 002 Oct 27, 2003AB200MGA075868 003 Oct 27, 2003AB MYLAN PHARMS INC43MGA202579 001 Jan 10, 2013AB67MGA202676 001 Oct 23, 2012AB130MGA202579 002 Jan 10, 2013AB134MGA202676 002 Oct 23, 2012AB200MGA202676 003 Oct 23, 2012AB TEVA67MGA075753 001 Sep 03, 2002

## PRESCRIPTION DRUG PRODUCT LIST

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

<u>AB</u>		<u>134MG</u>	<u>A075753 002</u>	Apr 09, 2002
<u>AB</u>	+	<u>200MG</u>	<u>A075753 003</u>	Apr 09, 2002
	ANTARA (MICRONIZED)			
	LUPIN ATLANTIS	30MG	N021695 004	Oct 18, 2013
		90MG	N021695 005	Oct 18, 2013
	LIPOFEN			
	CIPHER PHARMS INC	50MG	N021612 001	Jan 11, 2006
	+	150MG	N021612 003	Jan 11, 2006

TABLET; ORAL

FENOFIBRATE

<u>AB</u>	IMPAX LABS	<u>54MG</u>	<u>A076509 001</u>	Mar 26, 2008
<u>AB</u>		<u>160MG</u>	<u>A076509 002</u>	Mar 26, 2008
<u>AB</u>	LUPIN LTD	<u>48MG</u>	<u>A090856 001</u>	Dec 23, 2011
<u>AB</u>		<u>145MG</u>	<u>A090856 002</u>	Dec 23, 2011
<u>AB</u>	MYLAN	<u>54MG</u>	<u>A076520 001</u>	Oct 25, 2007
<u>AB</u>		<u>160MG</u>	<u>A076520 003</u>	Oct 25, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>48MG</u>	<u>A202856 001</u>	Dec 07, 2012
<u>AB</u>		<u>145MG</u>	<u>A202856 002</u>	Dec 07, 2012
<u>AB</u>	RANBAXY	<u>54MG</u>	<u>A076635 001</u>	Oct 31, 2005
<u>AB</u>		<u>160MG</u>	<u>A076635 003</u>	Oct 31, 2005
<u>AB</u>	TEVA	<u>54MG</u>	<u>A076433 001</u>	May 13, 2005
<u>AB</u>	+	<u>160MG</u>	<u>A076433 002</u>	May 13, 2005
<u>AB</u>	VALEANT INTL	<u>48MG</u>	<u>A090715 001</u>	Apr 05, 2012
<u>AB</u>		<u>145MG</u>	<u>A090715 002</u>	Apr 05, 2012

TRICOR

<u>AB</u>	ABBVIE	<u>48MG</u>	<u>N021656 001</u>	Nov 05, 2004
<u>AB</u>	+	<u>145MG</u>	<u>N021656 002</u>	Nov 05, 2004
	TRIGLIDE			
BX	+	160MG	N021350 002	May 07, 2005
	FENOFIBRATE			
	RANBAXY	107MG	A076635 002	Oct 31, 2005
	FENOGLIDE			
	SANTARUS INC	40MG	N022118 001	Aug 10, 2007
	+	120MG	N022118 002	Aug 10, 2007

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

	MUTUAL PHARM CO INC	35MG	N022418 001	Aug 14, 2009
	+	105MG	N022418 002	Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

<u>AP</u>	+	<u>HOSPIRA</u>	<u>EQ 10MG BASE/ML</u>	<u>N019922 001</u>	Sep 23, 1997
-----------	---	----------------	------------------------	--------------------	--------------

FENOLDOPAM MESYLATE

<u>AP</u>	EUROHLTH INTL	<u>EQ 10MG BASE/ML</u>	<u>A076582 001</u>	Oct 12, 2004
<u>AP</u>	SANDOZ	<u>EQ 10MG BASE/ML</u>	<u>A077155 001</u>	Feb 15, 2005

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

	+	XSPIRE	EQ 200MG BASE	N017604 003
			EQ 400MG BASE	N017604 004

TABLET; ORAL

FENOPROFEN CALCIUM

	+	MYLAN PHARMS INC	EQ 600MG BASE	A072267 001	Aug 17, 1988
--	---	------------------	---------------	-------------	--------------

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100

<u>AB</u>	JANSSEN PHARMS	<u>100MCG/HR</u>	<u>N019813 001</u>	Aug 07, 1990
-----------	----------------	------------------	--------------------	--------------

DURAGESIC-12

<u>AB</u>	JANSSEN PHARMS	<u>12.5MCG/HR</u>	<u>N019813 005</u>	Feb 04, 2005
-----------	----------------	-------------------	--------------------	--------------

DURAGESIC-25

<u>AB</u>	+	JANSSEN PHARMS	<u>25MCG/HR</u>	<u>N019813 004</u>	Aug 07, 1990
-----------	---	----------------	-----------------	--------------------	--------------

DURAGESIC-50

<u>AB</u>	JANSSEN PHARMS	<u>50MCG/HR</u>	<u>N019813 003</u>	Aug 07, 1990
-----------	----------------	-----------------	--------------------	--------------

DURAGESIC-75

<u>AB</u>	JANSSEN PHARMS	<u>75MCG/HR</u>	<u>N019813 002</u>	Aug 07, 1990
-----------	----------------	-----------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

<u>AB</u>	AVEVA	<u>100MCG/HR</u>	<u>A077449</u>	<u>004</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>100MCG/HR</u>	<u>A077051</u>	<u>004</u>	Aug 04, 2006
<u>AB</u>	MALLINCKRODT INC	<u>100MCG/HR</u>	<u>A077154</u>	<u>004</u>	Feb 09, 2011
<u>AB</u>	MYLAN TECHNOLOGIES	<u>100MCG/HR</u>	<u>A076258</u>	<u>004</u>	Jan 28, 2005
<u>AB</u>	PAR PHARM INC	<u>100MCG/HR</u>	<u>A077062</u>	<u>004</u>	Aug 20, 2007
<u>AB</u>	WATSON LABS	<u>100MCG/HR</u>	<u>A076709</u>	<u>004</u>	Aug 20, 2007

FENTANYL-12

<u>AB</u>	MYLAN TECHNOLOGIES	<u>12.5MCG/HR</u>	<u>A076258</u>	<u>005</u>	Jan 23, 2007
-----------	--------------------	-------------------	----------------	------------	--------------

FENTANYL-25

<u>AB</u>	AVEVA	<u>25MCG/HR</u>	<u>A077449</u>	<u>001</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>25MCG/HR</u>	<u>A077051</u>	<u>001</u>	Aug 04, 2006
<u>AB</u>	MALLINCKRODT INC	<u>25MCG/HR</u>	<u>A077154</u>	<u>001</u>	Feb 09, 2011
<u>AB</u>	MYLAN TECHNOLOGIES	<u>25MCG/HR</u>	<u>A076258</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>	PAR PHARM INC	<u>25MCG/HR</u>	<u>A077062</u>	<u>001</u>	Aug 20, 2007
<u>AB</u>	WATSON LABS	<u>25MCG/HR</u>	<u>A076709</u>	<u>001</u>	Aug 20, 2007

FENTANYL-50

<u>AB</u>	AVEVA	<u>50MCG/HR</u>	<u>A077449</u>	<u>002</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>50MCG/HR</u>	<u>A077051</u>	<u>002</u>	Aug 04, 2006
<u>AB</u>	MALLINCKRODT INC	<u>50MCG/HR</u>	<u>A077154</u>	<u>002</u>	Feb 09, 2011
<u>AB</u>	MYLAN TECHNOLOGIES	<u>50MCG/HR</u>	<u>A076258</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>	PAR PHARM INC	<u>50MCG/HR</u>	<u>A077062</u>	<u>002</u>	Aug 20, 2007
<u>AB</u>	WATSON LABS	<u>50MCG/HR</u>	<u>A076709</u>	<u>002</u>	Aug 20, 2007

FENTANYL-75

<u>AB</u>	AVEVA	<u>75MCG/HR</u>	<u>A077449</u>	<u>003</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>75MCG/HR</u>	<u>A077051</u>	<u>003</u>	Aug 04, 2006
<u>AB</u>	MALLINCKRODT INC	<u>75MCG/HR</u>	<u>A077154</u>	<u>003</u>	Feb 09, 2011
<u>AB</u>	MYLAN TECHNOLOGIES	<u>75MCG/HR</u>	<u>A076258</u>	<u>003</u>	Jan 28, 2005
<u>AB</u>	PAR PHARM INC	<u>75MCG/HR</u>	<u>A077062</u>	<u>003</u>	Aug 20, 2007
<u>AB</u>	WATSON LABS	<u>75MCG/HR</u>	<u>A076709</u>	<u>003</u>	Aug 20, 2007

## FENTANYL-37

	MYLAN TECHNOLOGIES	37.5MCG/HR	A076258	006	Dec 29, 2014
--	--------------------	------------	---------	-----	--------------

## FENTANYL-62

	MYLAN TECHNOLOGIES	62.5MCG/HR	A076258	007	Dec 29, 2014
--	--------------------	------------	---------	-----	--------------

## FENTANYL-87

	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014
--	--------------------	------------	---------	-----	--------------

SPRAY; SUBLINGUAL

SUBSYS

	INSYS THERAP	0.1MG	N202788	001	Jan 04, 2012
		0.2MG	N202788	002	Jan 04, 2012
+		0.4MG	N202788	003	Jan 04, 2012
		0.6MG	N202788	004	Jan 04, 2012
		0.8MG	N202788	005	Jan 04, 2012
		1.2MG	N202788	006	Aug 30, 2012
		1.6MG	N202788	007	Aug 30, 2012

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>N019115</u>	<u>001</u>	Jan 12, 1985
-----------	---------	--------------------------	----------------	------------	--------------

FENTANYL CITRATE PRESERVATIVE FREE

<u>AP</u>	+ HIKMA MAPLE	<u>EQ 0.05MG BASE/ML</u>	<u>N019101</u>	<u>001</u>	Jul 11, 1984
<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A072786</u>	<u>001</u>	Sep 24, 1991

SUBLIMAZE PRESERVATIVE FREE

<u>AP</u>	+ AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N016619</u>	<u>001</u>	
-----------	---------	--------------------------	----------------	------------	--

SPRAY, METERED; NASAL

LAZANDA

	DEPOMED INC	EQ 0.1MG BASE	N022569	001	Jun 30, 2011
+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011

TABLET; BUCCAL, SUBLINGUAL

FENTORA

	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006
		EQ 0.2MG BASE	N021947	002	Sep 25, 2006
+		EQ 0.4MG BASE	N021947	003	Sep 25, 2006
		EQ 0.6MG BASE	N021947	004	Sep 25, 2006
		EQ 0.8MG BASE	N021947	005	Sep 25, 2006

TABLET; SUBLINGUAL

ABSTRAL

	GALENA BIOPHARMA	EQ 0.1MG BASE	N022510	001	Jan 07, 2011
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011
		EQ 0.3MG BASE	N022510	003	Jan 07, 2011

## PRESCRIPTION DRUG PRODUCT LIST

FENTANYL CITRATE

TABLET; SUBLINGUAL

ABSTRAL

+

EQ 0.4MG BASE

N022510 004 Jan 07, 2011

EQ 0.6MG BASE

N022510 005 Jan 07, 2011

EQ 0.8MG BASE

N022510 006 Jan 07, 2011

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQAB CEPHALONEQ 0.2MG BASEN020747 001 Nov 04, 1998AB +EQ 0.4MG BASEN020747 002 Nov 04, 1998ABEQ 0.6MG BASEN020747 003 Nov 04, 1998ABEQ 0.8MG BASEN020747 004 Nov 04, 1998ABEQ 1.2MG BASEN020747 005 Nov 04, 1998ABEQ 1.6MG BASEN020747 006 Nov 04, 1998FENTANYL CITRATEAB MALLINCKRODTEQ 0.2MG BASEA078907 001 Oct 30, 2009ABEQ 0.4MG BASEA078907 002 Oct 30, 2009ABEQ 0.6MG BASEA078907 003 Oct 30, 2009ABEQ 0.8MG BASEA078907 004 Oct 30, 2009ABEQ 1.2MG BASEA078907 005 Oct 30, 2009ABEQ 1.6MG BASEA078907 006 Oct 30, 2009AB PAR PHARMEQ 0.2MG BASEA077312 001 Oct 30, 2009ABEQ 0.4MG BASEA077312 002 Oct 30, 2009ABEQ 0.6MG BASEA077312 003 Oct 30, 2009ABEQ 0.8MG BASEA077312 004 Oct 30, 2009ABEQ 1.2MG BASEA077312 005 Oct 30, 2009ABEQ 1.6MG BASEA077312 006 Oct 30, 2009FERRIC CARBOXYMALTOSE

INJECTABLE; INTRAVENOUS

INJECTAFER

+ LUITPOLD

750MG IRON/15ML (50MG IRON/ML)

N203565 001 Jul 25, 2013

FERRIC CITRATE

TABLET; ORAL

FERRIC CITRATE

+ KERYX BIOPHARMS

EQ 210MG IRON

N205874 001 Sep 05, 2014

FERRIC HEXACYANOFERRATE (II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+ HEYL CHEMISCH

500MG

N021626 001 Oct 02, 2003

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

+ AMAG PHARMS INC

EQ 510MG IRON/17ML (EQ 30MG IRON/ML)

N022180 001 Jun 30, 2009

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

TOVIAZ

PFIZER

4MG

N022030 001 Oct 31, 2008

+

8MG

N022030 002 Oct 31, 2008

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRAAB + SANOFI AVENTIS US30MG/5MLN021963 001 Oct 16, 2006FEXOFENADINE HYDROCHLORIDEAB ACTAVIS MID ATLANTIC30MG/5MLA201311 001 Jul 25, 2012

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDEAB BARR30MGA076191 001 Aug 31, 2005AB60MGA076191 002 Aug 31, 2005AB180MGA076191 003 Aug 31, 2005AB DR REDDYS LABS LTD30MGA076502 001 Apr 11, 2006AB60MGA076502 002 Apr 11, 2006AB180MGA076502 003 Apr 11, 2006AB MYLAN30MGA077081 002 Apr 11, 2008AB60MGA077081 003 Apr 11, 2008AB180MGA077081 001 Apr 16, 2007AB TEVA30MGA076447 001 Sep 01, 2005AB60MGA076447 002 Sep 01, 2005AB180MGA076447 003 Sep 01, 2005

## PRESCRIPTION DRUG PRODUCT LIST

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>60MG;120MG</u>	<u>A076236</u>	<u>001</u>	Apr 14, 2005
<u>AB</u>	IMPAX PHARMS	<u>60MG;120MG</u>	<u>A076298</u>	<u>001</u>	Nov 12, 2010

FIDAXOMICIN

TABLET;ORAL

DIFICID

	+ CUBIST PHARMS	200MG	N201699	001	May 27, 2011
--	-----------------	-------	---------	-----	--------------

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

	+ ALCON RES LTD	0.3%	N206307	001	Dec 17, 2014
--	-----------------	------	---------	-----	--------------

FINASTERIDE

TABLET;ORAL

FINASTERIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A090121</u>	<u>001</u>	Feb 23, 2010
<u>AB</u>	ACCORD HLTHCARE INC	<u>1MG</u>	<u>A091643</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>	ACTAVIS TOTOWA	<u>1MG</u>	<u>A078371</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>		<u>5MG</u>	<u>A077914</u>	<u>001</u>	Mar 28, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078341</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>1MG</u>	<u>A203687</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>	CIPLA LTD	<u>1MG</u>	<u>A077335</u>	<u>001</u>	Nov 20, 2014
<u>AB</u>	DR REDDYS LABS INC	<u>1MG</u>	<u>A076436</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076437</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>	GEDEON RICHTER USA	<u>5MG</u>	<u>A077251</u>	<u>001</u>	Dec 22, 2006
<u>AB</u>	HETERO LABS LTD III	<u>1MG</u>	<u>A090060</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>5MG</u>	<u>A090061</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077578</u>	<u>001</u>	Dec 18, 2006
<u>AB</u>	MYLAN PHARMS INC	<u>1MG</u>	<u>A078161</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>	SUN PHARMA GLOBAL	<u>1MG</u>	<u>A090508</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>5MG</u>	<u>A090507</u>	<u>001</u>	Aug 16, 2011
<u>AB</u>	TEVA	<u>1MG</u>	<u>A076905</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>		<u>5MG</u>	<u>A076511</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078900</u>	<u>001</u>	Dec 28, 2009

PROPECIA

<u>AB</u>	+ MERCK	<u>1MG</u>	<u>N020788</u>	<u>001</u>	Dec 19, 1997
-----------	---------	------------	----------------	------------	--------------

PROSCAR

<u>AB</u>	+ MERCK	<u>5MG</u>	<u>N020180</u>	<u>001</u>	Jun 19, 1992
-----------	---------	------------	----------------	------------	--------------

FINGOLIMOD

CAPSULE;ORAL

GILENYA

	+ NOVARTIS	0.5MG	N022527	001	Sep 21, 2010
--	------------	-------	---------	-----	--------------

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>100MG</u>	<u>A076835</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>	IMPAX PHARMS	<u>100MG</u>	<u>A076234</u>	<u>001</u>	Aug 28, 2003
<u>AB</u>	+ PADDOCK LLC	<u>100MG</u>	<u>A076831</u>	<u>001</u>	Dec 16, 2004

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A075442</u>	<u>001</u>	Jul 31, 2001
<u>AB</u>		<u>100MG</u>	<u>A075442</u>	<u>002</u>	Jul 31, 2001
<u>AB</u>		<u>150MG</u>	<u>A075442</u>	<u>003</u>	Jul 31, 2001
<u>AB</u>	BARR	<u>50MG</u>	<u>A075882</u>	<u>001</u>	Oct 28, 2002
<u>AB</u>		<u>100MG</u>	<u>A075882</u>	<u>002</u>	Oct 28, 2002
<u>AB</u>		<u>150MG</u>	<u>A075882</u>	<u>003</u>	Oct 28, 2002
<u>AB</u>	RANBAXY	<u>50MG</u>	<u>A076421</u>	<u>001</u>	Mar 28, 2003
<u>AB</u>		<u>100MG</u>	<u>A076421</u>	<u>002</u>	Mar 28, 2003
<u>AB</u>		<u>150MG</u>	<u>A076421</u>	<u>003</u>	Mar 28, 2003
<u>AB</u>	ROXANE	<u>50MG</u>	<u>A076278</u>	<u>001</u>	Jan 14, 2003
<u>AB</u>		<u>100MG</u>	<u>A076278</u>	<u>002</u>	Jan 14, 2003
<u>AB</u>	+	<u>150MG</u>	<u>A076278</u>	<u>003</u>	Jan 14, 2003

## PRESCRIPTION DRUG PRODUCT LIST

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+ PIRAMAL IMAGING 30ML (1.4-135mCi/ML) N204677 001 Mar 19, 2014

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+ AVID RADIOPHARMS INC 10ML (13.5-51mCi/ML) N202008 001 Apr 06, 2012

+ 10-30ML (13.5-51mCi/ML) N202008 002 Apr 06, 2012

+ 10-50ML (13.5-51mCi/ML) N202008 003 Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINEAP + EUROHLTH INTL 500MG/VIAL A075387 001 Apr 16, 2000AP FRESENIUS KABI USA 500MG/VIAL A075837 001 Feb 22, 2001FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCANAB PFIZER 50MG/5ML N020090 001 Dec 23, 1993AB + 200MG/5ML N020090 002 Dec 23, 1993FLUCONAZOLEAB AUROBINDO PHARM 50MG/5ML A079150 001 Sep 18, 2009AB 200MG/5ML A079150 002 Sep 18, 2009AB IVAX SUB TEVA PHARMS 50MG/5ML A077523 001 Sep 12, 2007AB 200MG/5ML A077523 002 Sep 12, 2007AB RANBAXY 50MG/5ML A076332 001 Jul 29, 2004AB 200MG/5ML A076332 002 Jul 29, 2004AB ROXANE 50MG/5ML A076246 001 Jul 29, 2004AB 200MG/5ML A076246 002 Jul 29, 2004

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINERAP + PFIZER 200MG/100ML (2MG/ML) N019950 003 Sep 29, 1992AP + 400MG/200ML (2MG/ML) N019950 005 Jul 08, 1994DIFLUCAN IN SODIUM CHLORIDE 0.9%AP + PFIZER 200MG/100ML (2MG/ML) N019950 001 Jan 29, 1990AP + 400MG/200ML (2MG/ML) N019950 006 Jan 29, 1990DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP + PFIZER 200MG/100ML (2MG/ML) N019950 002 Jan 29, 1990AP + 400MG/200ML (2MG/ML) N019950 004 Jan 29, 1990FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP ACS DOBFAR INFO SA 200MG/100ML (2MG/ML) A079104 001 Jul 30, 2009AP 400MG/200ML (2MG/ML) A079104 002 Jul 30, 2009FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINERAP CLARIS LIFESCIENCES 200MG/100ML (2MG/ML) A077988 001 May 26, 2010AP 400MG/200ML (2MG/ML) A077988 002 May 26, 2010AP HIKMA FARMACEUTICA 200MG/100ML (2MG/ML) A078764 001 Jan 30, 2012AP 400MG/200ML (2MG/ML) A078764 002 Jan 30, 2012AP HOSPIRA 200MG/100ML (2MG/ML) A076304 001 Jul 29, 2004AP 400MG/200ML (2MG/ML) A076304 002 Jul 29, 2004FLUCONAZOLE IN SODIUM CHLORIDE 0.9%AP BEDFORD 200MG/100ML (2MG/ML) A076087 001 Jul 29, 2004AP 400MG/200ML (2MG/ML) A076087 003 Jul 29, 2004AP CLARIS LIFESCIENCES 200MG/100ML (2MG/ML) A077947 001 May 26, 2010AP 400MG/200ML (2MG/ML) A077947 002 May 26, 2010AP FRESENIUS KABI USA 200MG/100ML (2MG/ML) A076145 001 Jul 29, 2004AP 400MG/200ML (2MG/ML) A076145 002 Jul 29, 2004AP HIKMA FARMACEUTICA 200MG/100ML (2MG/ML) A076736 001 Aug 23, 2005AP TEVA PHARMS USA 200MG/100ML (2MG/ML) A076653 001 Jul 29, 2004AP 400MG/200ML (2MG/ML) A076653 002 Jul 29, 2004FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP BAXTER HLTHCARE 200MG/100ML (2MG/ML) A076766 001 Jul 29, 2004AP 400MG/200ML (2MG/ML) A076766 002 Jul 29, 2004AP BEDFORD LABS 200MG/100ML (2MG/ML) A078107 001 Jul 30, 2008AP 400MG/200ML (2MG/ML) A078107 002 Jul 30, 2008AP CLARIS LIFESCIENCES 200MG/100ML (2MG/ML) A077909 001 May 26, 2010AP 400MG/200ML (2MG/ML) A077909 002 May 26, 2010AP HIKMA FARMACEUTICA 200MG/100ML (2MG/ML) A078698 001 Jan 30, 2012AP 400MG/200ML (2MG/ML) A078698 002 Jan 30, 2012AP HOSPIRA 200MG/100ML (2MG/ML) A076303 001 Jul 29, 2004AP 400MG/200ML (2MG/ML) A076303 002 Jul 29, 2004

## PRESCRIPTION DRUG PRODUCT LIST

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

BEDFORD

100MG/50ML (2MG/ML)

A076087 002 Sep 26, 2008

TABLET; ORAL

DIFLUCANAB PFIZER50MGN019949 001 Jan 29, 1990AB100MGN019949 002 Jan 29, 1990AB150MGN019949 004 Jun 30, 1994AB +200MGN019949 003 Jan 29, 1990FLUCONAZOLEAB APOTEX50MGA076665 001 Jul 29, 2004AB100MGA076665 002 Jul 29, 2004AB150MGA076665 003 Jul 29, 2004AB200MGA076665 004 Jul 29, 2004AB AUROBINDO PHARMA50MGA077731 001 Oct 07, 2008AB100MGA077731 002 Oct 07, 2008AB150MGA077731 003 Oct 07, 2008AB200MGA077731 004 Oct 07, 2008AB DR REDDYS LABS INC50MGA076658 001 Jul 29, 2004AB100MGA076658 002 Jul 29, 2004AB150MGA076658 003 Jul 29, 2004AB200MGA076658 004 Jul 29, 2004AB GLENMARK GENERICS50MGA077253 001 Jan 25, 2006AB100MGA077253 002 Jan 25, 2006AB150MGA077253 003 Jan 25, 2006AB200MGA077253 004 Jan 25, 2006AB IVAX SUB TEVA PHARMS50MGA076077 001 Jul 29, 2004AB100MGA076077 002 Jul 29, 2004AB150MGA076077 003 Jul 29, 2004AB200MGA076077 004 Jul 29, 2004AB MYLAN50MGA076351 001 Jul 29, 2004AB100MGA076351 002 Jul 29, 2004AB150MGA076351 003 Jul 29, 2004AB200MGA076351 004 Jul 29, 2004AB TARO50MGA076507 001 Jul 29, 2004AB100MGA076507 002 Jul 29, 2004AB150MGA076507 003 Jul 29, 2004AB200MGA076507 004 Jul 29, 2004AB TEVA50MGA074681 001 Jul 29, 2004AB100MGA074681 002 Jul 29, 2004AB150MGA074681 003 Jul 29, 2004AB200MGA074681 004 Jul 29, 2004AB UNIQUE PHARM LABS50MGA076957 001 Sep 28, 2005AB100MGA076957 002 Sep 28, 2005AB200MGA076957 003 Sep 28, 2005FLUCYDOSINE

CAPSULE; ORAL

ANCOBONAB VALEANT250MGN017001 001AB +500MGN017001 002FLUCYDOSINEAB SIGMAPHARM LABS LLC250MGA201566 001 Jun 28, 2011AB500MGA201566 002 Jun 28, 2011FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATEAP ACTAVIS TOTOWA50MG/VIALA078610 001 Feb 11, 2009AP +

FRESENIUS KABI USA

50MG/2ML (25MG/ML)A078393 001 Oct 15, 2007AP50MG/VIALA078544 001 Oct 15, 2007AP +

HOSPIRA

50MG/VIALA077790 001 Apr 06, 2007AP

MUSTAFA NEVZAT ILAC

50MG/2ML (25MG/ML)A090724 001 Sep 27, 2010AP

ONCO THERAPIES LTD

50MG/2ML (25MG/ML)A200647 001 Dec 21, 2011AP50MG/VIALA200648 001 Oct 16, 2012AP +

SANDOZ

50MG/2ML (25MG/ML)N022137 001 Sep 21, 2007AP

TEVA PHARMS USA

50MG/VIALA076349 001 Aug 28, 2003AP50MG/2ML (25MG/ML)A076661 001 Apr 28, 2004

## PRESCRIPTION DRUG PRODUCT LIST

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>	BRIGHAM WOMENS	<u>20-300mCi/ML</u>	<u>A203816</u>	<u>001</u>	Oct 30, 2014
<u>AP</u>	CHILDRENS HOSP MI	<u>20-300mCi/ML</u>	<u>A204385</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	CPDC	<u>20-300mCi/ML</u>	<u>A204525</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	ESSENTIAL ISOTOPES	<u>20-300mCi/ML</u>	<u>A203946</u>	<u>001</u>	Feb 05, 2014
<u>AP</u>	+ FEINSTEIN	<u>20-200mCi/ML</u>	<u>N021870</u>	<u>001</u>	Aug 19, 2005
<u>AP</u>	+	<u>20-400mCi/ML</u>	<u>N021870</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>	GLOBAL ISOTOPES LLC	<u>20-300mCi/ML</u>	<u>A204463</u>	<u>001</u>	Oct 21, 2014
<u>AP</u>	+ HOUSTON CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203665</u>	<u>001</u>	Feb 14, 2013
<u>AP</u>	LANTHEUS MEDICAL	<u>20-200mCi/ML</u>	<u>A203664</u>	<u>001</u>	Feb 04, 2014
<u>AP</u>	MA GENERAL HOSP	<u>20-300mCi/ML</u>	<u>A204333</u>	<u>001</u>	Sep 25, 2014
<u>AP</u>	MCPRF	<u>20-240mCi/ML</u>	<u>A203612</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	NCM USA BRONX LLC	<u>20-300mCi/ML</u>	<u>A204512</u>	<u>001</u>	Jan 07, 2015
<u>AP</u>	PETNET	<u>20-200mCi/ML</u>	<u>A079086</u>	<u>001</u>	Feb 25, 2011
<u>AP</u>	SHERTECH LABS LLC	<u>20-300mCi/ML</u>	<u>A204264</u>	<u>001</u>	Dec 18, 2014
<u>AP</u>	TRUSTEES UNIV PA	<u>20-200mCi/ML</u>	<u>A203801</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	UCSF RODIOPHARM	<u>20-300mCi/ML</u>	<u>A203902</u>	<u>001</u>	May 09, 2014
<u>AP</u>	UIHC PET IMAGING	<u>20-300mCi/ML</u>	<u>A203990</u>	<u>001</u>	Aug 06, 2014
<u>AP</u>	UNIV TX MD ANDERSON	<u>20-300mCi/ML</u>	<u>A203246</u>	<u>002</u>	Jan 13, 2014
<u>AP</u>	WI MEDCL CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203709</u>	<u>001</u>	Oct 23, 2013
<u>AP</u>	WUSM CYCLOTRON	<u>20-300mCi/ML</u>	<u>A203935</u>	<u>001</u>	Feb 05, 2014
	HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
	+ UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013
	UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	HIKMA PHARMS	<u>0.1MG</u>	<u>A091302</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>	+ IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	AGILA SPECLTS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>	+	<u>1MG/10ML (0.1MG/ML)</u>	<u>A078595</u>	<u>002</u>	May 13, 2008
<u>AP</u>	BEDFORD LABS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	HIKMA MAPLE	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	SAGENT PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A090584</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>002</u>	Aug 28, 2012
<u>AP</u>	SANDOZ	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ MEDA PHARMS INC

0.078MG/INH

N021247 001 Jan 27, 2006

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	+ BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	HI TECH PHARMA CO	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006
	+ APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	G AND W LABS	<u>0.01%</u>	<u>A089526</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		<u>0.025%</u>	<u>A089525</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982
	<u>SYNALAR</u>				
<u>AT</u>	+ MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>002</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>005</u>	



## PRESCRIPTION DRUG PRODUCT LIST

FLUOCINOLONE ACETONIDE

IMPLANT; INTRAVITREAL

ILUVIEN

+ ALIMERA SCIENCES INC 0.19MG

N201923 001 Sep 26, 2014

RETISERT

+ BAUSCH AND LOMB 0.59MG

N021737 001 Apr 08, 2005

OIL; TOPICAL

DERMA-SMOOTH/FS**AT** + HILL DERMAC **0.01%****N019452 001** Feb 03, 1988**AT** + **0.01%****N019452 002** Nov 09, 2005FLUOCINOLONE ACETONIDE**AT** IDENTI PHARMS INC **0.01%****A201759 001** Oct 17, 2011**AT** **0.01%****A201764 001** Oct 17, 2011**AT** PERRIGO ISRAEL **0.01%****A202847 001** Aug 09, 2013**AT** **0.01%****A202848 001** Aug 09, 2013

OIL/DROPS; OTIC

DERMOTIC**AT** + HILL DERMAC **0.01%****N019452 003** Nov 09, 2005FLUOCINOLONE ACETONIDE**AT** IDENTI PHARMS INC **0.01%****A091306 001** Oct 17, 2011

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE**AT** FOUGERA **0.025%****A088168 001** Dec 16, 1982**AT** G AND W LABS **0.025%****A089524 001** Jul 26, 1988**AT** TARO **0.025%****A040041 001** Sep 15, 1994SYNALAR**AT** + MEDIMETRIKS PHARMS **0.025%****N013960 001**

SHAMPOO; TOPICAL

CAPEX

+ GALDERMA LABS LP 0.01%

N020001 001 Aug 27, 1990

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE**AT** FOUGERA **0.01%****A088167 001** Dec 16, 1982**AT** TARO **0.01%****A089124 001** Sep 11, 1985SYNALAR**AT** + MEDIMETRIKS PHARMS **0.01%****N015296 001**FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

+ GALDERMA LABS LP 0.01%; 4%; 0.05%

N021112 001 Jan 18, 2002

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

+ MEDIMETRIKS PHARMS 0.025%; EQ 3.5MG BASE/GM

A060700 001

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE**AB** FOUGERA PHARMS INC **0.1%****A200735 001** Jul 14, 2014**AB** GLENMARK GENERICS **0.1%****A091282 001** Jul 14, 2014**AB** PERRIGO ISRAEL **0.1%****A090256 001** Jan 14, 2014**AB** TARO **0.1%****A200734 001** Jul 14, 2014VANOS**AB** + MEDICIS **0.1%****N021758 001** Feb 11, 2005FLUOCINONIDE**AB1** FOUGERA **0.05%****A073030 001** Oct 17, 1994**AB1** G AND W LABS INC **0.05%****A073085 001** Feb 14, 1992**AB1** + TARO **0.05%****N019117 001** Jun 26, 1984**AB1** TEVA **0.05%****A072488 001** Feb 06, 1989FLUOCINONIDE EMULSIFIED BASE**AB2** FOUGERA PHARMS **0.05%****A076586 001** Jun 23, 2004**AB2** + TARO **0.05%****A072494 001** Jan 19, 1989**AB2** TEVA **0.05%****A072490 001** Feb 07, 1989

GEL; TOPICAL

FLUOCINONIDE**AB** FOUGERA **0.05%****A072933 001** Dec 30, 1994**AB** + TARO **0.05%****A074935 001** Jul 29, 1997**AB** TEVA **0.05%****A072537 001** Feb 07, 1989

OINTMENT; TOPICAL

FLUOCINONIDE**AB** FOUGERA PHARMS **0.05%****A074905 001** Aug 26, 1997**AB** + TARO **0.05%****A075008 001** Jun 30, 1999

## PRESCRIPTION DRUG PRODUCT LIST

FLUOCINONIDE

OINTMENT; TOPICAL

FLUOCINONIDE

<b>AB</b>	TEVA	<b>0.05%</b>	<b>A073481 001</b>	Dec 27, 1991
-----------	------	--------------	--------------------	--------------

SOLUTION; TOPICAL

FLUOCINONIDE

<b>AT</b>	FOUGERA	<b>0.05%</b>	<b>A072934 001</b>	Feb 27, 1995
-----------	---------	--------------	--------------------	--------------

<b>AT</b>	G AND W LABS INC	<b>0.05%</b>	<b>A071535 001</b>	Dec 02, 1988
-----------	------------------	--------------	--------------------	--------------

<b>AT</b>	+ TARO	<b>0.05%</b>	<b>A074799 001</b>	Dec 31, 1996
-----------	--------	--------------	--------------------	--------------

<b>AT</b>	TEVA	<b>0.05%</b>	<b>A072511 001</b>	Feb 07, 1989
-----------	------	--------------	--------------------	--------------

LIDEX

<b>AT</b>	CNTY LINE PHARMS	<b>0.05%</b>	<b>N018849 001</b>	Apr 06, 1984
-----------	------------------	--------------	--------------------	--------------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

<b>AP</b>	AKORN	<b>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</b>	<b>N022186 001</b>	Aug 08, 2008
-----------	-------	---------------------------------------------	--------------------	--------------

FLUORESCITE

<b>AP</b>	+ ALCON PHARMS LTD	<b>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</b>	<b>N021980 001</b>	Mar 28, 2006
-----------	--------------------	---------------------------------------------	--------------------	--------------

AK-FLUOR 25%

	+ AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186 002	Aug 08, 2008
--	---------	--------------------------------------	-------------	--------------

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

FML

	+ ALLERGAN	0.1%	N017760 001	Sep 04, 1985
--	------------	------	-------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

FML

	+ ALLERGAN	0.1%	N016851 002	Jul 28, 1982
--	------------	------	-------------	--------------

FML FORTE

	ALLERGAN	0.25%	N019216 001	Apr 23, 1986
--	----------	-------	-------------	--------------

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

FLAREX

	+ ALCON	0.1%	N019079 001	Feb 11, 1986
--	---------	------	-------------	--------------

FLUOROURACIL

CREAM; TOPICAL

EFUDEX

<b>AB</b>	+ VALEANT PHARM INTL	<b>5%</b>	<b>N016831 003</b>	
-----------	----------------------	-----------	--------------------	--

FLUOROURACIL

<b>AB</b>	SPEAR PHARMS	<b>5%</b>	<b>A077524 001</b>	Apr 11, 2008
-----------	--------------	-----------	--------------------	--------------

<b>AB</b>	TARO	<b>5%</b>	<b>A090368 001</b>	Mar 05, 2010
-----------	------	-----------	--------------------	--------------

CARAC

	+ VALEANT BERMUDA	0.5%	N020985 001	Oct 27, 2000
--	-------------------	------	-------------	--------------

FLUOROPLEX

	+ AQUA PHARMS	1%	N016988 001	
--	---------------	----	-------------	--

INJECTABLE; INJECTION

FLUOROURACIL

<b>AP</b>	+ ACCORD HLTHCARE	<b>1GM/20ML (50MG/ML)</b>	<b>A040743 001</b>	Apr 26, 2007
-----------	-------------------	---------------------------	--------------------	--------------

<b>AP</b>		<b>2.5GM/50ML (50MG/ML)</b>	<b>A040798 002</b>	Apr 26, 2007
-----------	--	-----------------------------	--------------------	--------------

<b>AP</b>		<b>5GM/100ML (50MG/ML)</b>	<b>A040798 001</b>	Apr 26, 2007
-----------	--	----------------------------	--------------------	--------------

<b>AP</b>		<b>500MG/10ML (50MG/ML)</b>	<b>A040743 002</b>	Apr 26, 2007
-----------	--	-----------------------------	--------------------	--------------

<b>AP</b>	+ FRESENIUS KABI USA	<b>1GM/20ML (50MG/ML)</b>	<b>A040279 001</b>	Sep 30, 1998
-----------	----------------------	---------------------------	--------------------	--------------

<b>AP</b>		<b>2.5GM/50ML (50MG/ML)</b>	<b>A040278 001</b>	Sep 30, 1998
-----------	--	-----------------------------	--------------------	--------------

<b>AP</b>		<b>5GM/100ML (50MG/ML)</b>	<b>A040278 002</b>	Sep 30, 1998
-----------	--	----------------------------	--------------------	--------------

<b>AP</b>		<b>500MG/10ML (50MG/ML)</b>	<b>A040279 002</b>	Sep 30, 1998
-----------	--	-----------------------------	--------------------	--------------

<b>AP</b>	ONCO THERAPIES LTD	<b>1GM/20ML (50MG/ML)</b>	<b>A202668 002</b>	Jul 17, 2012
-----------	--------------------	---------------------------	--------------------	--------------

<b>AP</b>		<b>2.5GM/50ML (50MG/ML)</b>	<b>A202669 001</b>	Jul 17, 2012
-----------	--	-----------------------------	--------------------	--------------

<b>AP</b>		<b>5GM/100ML (50MG/ML)</b>	<b>A202669 002</b>	Jul 17, 2012
-----------	--	----------------------------	--------------------	--------------

<b>AP</b>		<b>500MG/10ML (50MG/ML)</b>	<b>A202668 001</b>	Jul 17, 2012
-----------	--	-----------------------------	--------------------	--------------

<b>AP</b>	SANDOZ	<b>2.5GM/50ML (50MG/ML)</b>	<b>A091299 001</b>	May 02, 2011
-----------	--------	-----------------------------	--------------------	--------------

<b>AP</b>		<b>5GM/100ML (50MG/ML)</b>	<b>A091299 002</b>	May 02, 2011
-----------	--	----------------------------	--------------------	--------------

<b>AP</b>	+ TEVA PHARMS USA	<b>2.5GM/50ML (50MG/ML)</b>	<b>A040334 001</b>	Feb 25, 2000
-----------	-------------------	-----------------------------	--------------------	--------------

<b>AP</b>		<b>5GM/100ML (50MG/ML)</b>	<b>A040334 002</b>	Feb 25, 2000
-----------	--	----------------------------	--------------------	--------------

<b>AP</b>		<b>500MG/10ML (50MG/ML)</b>	<b>A040333 001</b>	Jan 27, 2000
-----------	--	-----------------------------	--------------------	--------------

SOLUTION; TOPICAL

EFUDEX

<b>AT</b>	+ VALEANT PHARM INTL	<b>2%</b>	<b>N016831 001</b>	
-----------	----------------------	-----------	--------------------	--

<b>AT</b>		<b>5%</b>	<b>N016831 002</b>	
-----------	--	-----------	--------------------	--

FLUOROURACIL

<b>AT</b>	TARO	<b>2%</b>	<b>A076526 001</b>	Nov 05, 2003
-----------	------	-----------	--------------------	--------------

<b>AT</b>		<b>5%</b>	<b>A076526 002</b>	Nov 05, 2003
-----------	--	-----------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 40MG BASE</u>	<u>A090223 003</u>	Mar 19, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 40MG BASE</u>	<u>A078619 003</u>	Jan 31, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 40MG BASE</u>	<u>A075465 003</u>	Aug 02, 2001
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 40MG BASE</u>	<u>A201336 003</u>	Oct 01, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 40MG BASE</u>	<u>A075245 003</u>	Sep 28, 2004
<u>AB</u>	MYLAN	<u>EQ 40MG BASE</u>	<u>A075207 003</u>	May 25, 2007
<u>AB</u>	PAR PHARM	<u>EQ 40MG BASE</u>	<u>A076922 003</u>	Dec 16, 2004
<u>AB</u>	RANBAXY	<u>EQ 40MG BASE</u>	<u>A076990 001</u>	Dec 13, 2004
<u>AB</u>	SANDOZ	<u>EQ 40MG BASE</u>	<u>A075049 003</u>	Jan 29, 2002
<u>AB</u>	TEVA	<u>EQ 40MG BASE</u>	<u>A075452 003</u>	Jan 29, 2002

PROZAC

<u>AB</u>	+ ELI LILLY AND CO	<u>EQ 40MG BASE</u>	<u>N018936 003</u>	Jun 15, 1999
-----------	--------------------	---------------------	--------------------	--------------

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>	ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A090223 001</u>	Mar 19, 2009
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A090223 002</u>	Mar 19, 2009
<u>AB1</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078619 001</u>	Jan 31, 2008
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A078619 002</u>	Jan 31, 2008
<u>AB1</u>	BARR	<u>EQ 10MG BASE</u>	<u>A074803 002</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A074803 001</u>	Aug 02, 2001
<u>AB1</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A075465 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075465 002</u>	Jan 29, 2002
<u>AB1</u>	HERITAGE PHARMS INC	<u>EQ 10MG BASE</u>	<u>A201336 001</u>	Oct 01, 2012
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A201336 002</u>	Oct 01, 2012
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245 002</u>	Jan 31, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075245 001</u>	Jan 31, 2002
<u>AB1</u>	LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464 001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075464 002</u>	Jan 30, 2002
<u>AB1</u>	MALLINCKRODT	<u>EQ 10MG BASE</u>	<u>A075658 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075658 002</u>	Jan 29, 2002
<u>AB1</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075207 001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075207 002</u>	Jan 30, 2002
<u>AB1</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075577 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075577 002</u>	Jan 29, 2002
<u>AB1</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A075049 001</u>	Aug 02, 2001
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075049 002</u>	Jan 29, 2002
<u>AB1</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075452 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075452 002</u>	Jan 29, 2002
<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A076001 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A076001 002</u>	Jan 29, 2002

PROZAC

<u>AB1</u>	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936 006</u>	Dec 23, 1992
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>N018936 001</u>	Dec 29, 1987

FLUOXETINE HYDROCHLORIDE

<u>AB2</u>	ANI PHARMS INC	<u>EQ 10MG BASE</u>	<u>A076287 001</u>	May 20, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A076287 002</u>	May 20, 2008
<u>AB2</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078045 001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A078045 002</u>	Nov 17, 2008
<u>AB2</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A077469 001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A077469 002</u>	Nov 17, 2008

SARAFEM

<u>AB2</u>	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936 007</u>	Jul 06, 2000
<u>AB2</u>	+	<u>EQ 20MG BASE</u>	<u>N018936 008</u>	Jul 06, 2000

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 90MG BASE</u>	<u>A076237 001</u>	Mar 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 90MG BASE</u>	<u>A078572 001</u>	Mar 22, 2010

PROZAC WEEKLY

<u>AB</u>	+ LILLY	<u>EQ 90MG BASE</u>	<u>N021235 001</u>	Feb 26, 2001
-----------	---------	---------------------	--------------------	--------------

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARM	<u>EQ 20MG BASE/5ML</u>	<u>A079209 001</u>	Mar 20, 2009
<u>AA</u>	LANNETT	<u>EQ 20MG BASE/5ML</u>	<u>A076458 001</u>	May 14, 2004
<u>AA</u>	MALLINCKRODT	<u>EQ 20MG BASE/5ML</u>	<u>A075920 001</u>	Jan 29, 2002
<u>AA</u>	+ PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015 001</u>	Jan 30, 2002
<u>AA</u>	SILARX	<u>EQ 20MG BASE/5ML</u>	<u>A077849 001</u>	Feb 09, 2007
<u>AA</u>	TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506 001</u>	Aug 02, 2001
<u>AA</u>	WOCKHARDT	<u>EQ 20MG BASE/5ML</u>	<u>A075514 001</u>	Aug 29, 2002

## PRESCRIPTION DRUG PRODUCT LIST

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A076006 001</u>	Jan 30, 2002
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075755 001</u>	Aug 02, 2001
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075872 001</u>	Jan 29, 2002
<u>SARAFEM</u>				
<u>AB1</u>	WARNER CHILCOTT LLC	<u>EQ 10MG BASE</u>	<u>N021860 001</u>	May 19, 2006
<u>AB1</u>		<u>EQ 15MG BASE</u>	<u>N021860 002</u>	May 19, 2006
<u>AB1</u>	+	<u>EQ 20MG BASE</u>	<u>N021860 003</u>	May 19, 2006
<u>SELFEMRA</u>				
<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A200151 001</u>	Feb 03, 2014
<u>AB1</u>		<u>EQ 15MG BASE</u>	<u>A200151 002</u>	Feb 03, 2014
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A200151 003</u>	Feb 03, 2014
FLUOXETINE HYDROCHLORIDE				
	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133 001	Oct 06, 2011
	+	EQ 20MG BASE	A075755 002	Aug 02, 2001

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A077742 001</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077742 002</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077742 003</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077742 004</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077742 005</u>	Nov 02, 2012
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A078901 005</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A078901 001</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A078901 003</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A078901 002</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A078901 004</u>	Nov 16, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A202074 001</u>	Mar 25, 2013
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077528 001</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077528 002</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077528 003</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077528 004</u>	Jun 19, 2012
<u>SYMBYAX</u>				
<u>AB</u>	LILLY	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>N021520 001</u>	Apr 09, 2007
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>N021520 002</u>	Dec 24, 2003
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>N021520 004</u>	Dec 24, 2003
<u>AB</u>	+	<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>N021520 003</u>	Dec 24, 2003
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>N021520 005</u>	Dec 24, 2003

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

+ USL PHARMA 10MG A088342 001 Oct 21, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

<u>AO</u>	EUROHLTH INTL	<u>25MG/ML</u>	<u>A074531 001</u>	Aug 30, 1996
<u>AO</u>	+	<u>25MG/ML</u>	<u>A071413 001</u>	Jul 14, 1987
<u>AO</u>	PAR STERILE PRODUCTS	<u>25MG/ML</u>	<u>A203732 001</u>	Jul 03, 2014

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC 5MG/ML A074725 001 Sep 16, 1996

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC 2.5MG/5ML A040146 001 Aug 21, 1996

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

+ FRESENIUS KABI USA 2.5MG/ML A089556 001 Apr 16, 1987

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>1MG</u>	<u>A089740 001</u>	Aug 25, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089741 001</u>	Aug 25, 1988
<u>AB</u>		<u>5MG</u>	<u>A089742 001</u>	Aug 25, 1988
<u>AB</u>		<u>10MG</u>	<u>A089743 001</u>	Aug 25, 1988
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A089804 002</u>	Aug 12, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089804 003</u>	Aug 12, 1988
<u>AB</u>		<u>5MG</u>	<u>A089804 004</u>	Aug 12, 1988

## PRESCRIPTION DRUG PRODUCT LIST

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

<b>AB</b>	+		<b>10MG</b>	<b>A089804 001</b>	Aug 12, 1988
<b>AB</b>		SANDOZ	<b>1MG</b>	<b>A089583 001</b>	Oct 16, 1987
<b>AB</b>			<b>2.5MG</b>	<b>A089584 001</b>	Oct 16, 1987
<b>AB</b>			<b>5MG</b>	<b>A089585 001</b>	Oct 16, 1987
<b>AB</b>			<b>10MG</b>	<b>A089586 001</b>	Oct 16, 1987

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+	AQUA PHARMS	0.025%	N012806 003
+		0.05%	N012806 002

LOTION; TOPICAL

CORDRAN

+	AQUA PHARMS	0.05%	N013790 001
---	-------------	-------	-------------

TAPE; TOPICAL

CORDRAN

+	WATSON LABS INC	0.004MG/SQ CM	N016455 001
---	-----------------	---------------	-------------

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

	MYLAN PHARMS INC	15MG	A070345 002	Nov 27, 1985
+		30MG	A070345 001	Nov 27, 1985

FLURBIPROFEN

TABLET; ORAL

ANSAID

<b>AB</b>		PHARMACIA AND UPJOHN	<b>50MG</b>	<b>N018766 002</b>	Oct 31, 1988
<b>AB</b>	+		<b>100MG</b>	<b>N018766 003</b>	Oct 31, 1988
		<u>FLURBIPROFEN</u>			
<b>AB</b>		MYLAN	<b>50MG</b>	<b>A074358 001</b>	Jun 20, 1994
<b>AB</b>			<b>100MG</b>	<b>A074358 002</b>	Jun 20, 1994
<b>AB</b>		SUN PHARM INDS INC	<b>50MG</b>	<b>A075058 001</b>	Apr 27, 2001
<b>AB</b>			<b>100MG</b>	<b>A075058 002</b>	Apr 27, 2001
<b>AB</b>		TEVA	<b>100MG</b>	<b>A074431 001</b>	May 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

<b>AT</b>		BAUSCH AND LOMB	<b>0.03%</b>	<b>A074447 001</b>	Jan 04, 1995
		<u>OCUFEN</u>			
<b>AT</b>	+	ALLERGAN	<b>0.03%</b>	<b>N019404 001</b>	Dec 31, 1986

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

<b>AB</b>		ACTAVIS LABS FL INC	<b>125MG</b>	<b>A075820 001</b>	Sep 18, 2001
<b>AB</b>	+	IVAX SUB TEVA PHARMS	<b>125MG</b>	<b>A075780 001</b>	Sep 19, 2001
<b>AB</b>		MYLAN	<b>125MG</b>	<b>A076224 001</b>	May 09, 2003
<b>AB</b>		PAR PHARM	<b>125MG</b>	<b>A075298 001</b>	Sep 18, 2001

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137 001	Oct 25, 2013
+		121.5mCi/30ML (4.05mCi/ML)	N203137 002	Oct 25, 2013

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

	GLAXOSMITHKLINE	0.1MG/INH	N205625 001	Aug 20, 2014
+		0.2MG/INH	N205625 002	Aug 20, 2014

SPRAY, METERED; NASAL

VERAMYST

+	GLAXOSMITHKLINE	0.0275MG/INH	N022051 001	Apr 27, 2007
---	-----------------	--------------	-------------	--------------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREQ ELLIPTA

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275 001	May 10, 2013
---	---------------	-------------------------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

FLUTICASONE PROPIONATE

## AEROSOL, METERED; INHALATION

## FLOVENT HFA

+	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004
+		0.11MG/INH	N021433	002	May 14, 2004
+		0.22MG/INH	N021433	001	May 14, 2004

## CREAM; TOPICAL

FLUTICASONE PROPIONATE

<b>AB</b>	FOUGERA PHARMS	<u>0.05%</u>	<u>A076451</u>	<u>001</u>	May 14, 2004
<b>AB</b>	G AND W LABS	<u>0.05%</u>	<u>A077055</u>	<u>001</u>	Jun 30, 2006
<b>AB</b>	PERRIGO NEW YORK	<u>0.05%</u>	<u>A076793</u>	<u>001</u>	May 14, 2004
<b>AB</b>	TOLMAR	<u>0.05%</u>	<u>A076633</u>	<u>001</u>	May 14, 2004

## LOTION; TOPICAL

CUTIVATE

<b>AB</b>	+ FOUGERA PHARMS	<u>0.05%</u>	<u>N021152</u>	<u>001</u>	Mar 31, 2005
-----------	------------------	--------------	----------------	------------	--------------

FLUTICASONE PROPIONATE

<b>AB</b>	GLENMARK GENERICS	<u>0.05%</u>	<u>A090759</u>	<u>001</u>	May 02, 2011
<b>AB</b>	PERRIGO ISRAEL	<u>0.05%</u>	<u>A091553</u>	<u>001</u>	Jul 30, 2013

## OINTMENT; TOPICAL

CUTIVATE

<b>AB</b>	+ FOUGERA PHARMS	<u>0.005%</u>	<u>N019957</u>	<u>001</u>	Dec 14, 1990
-----------	------------------	---------------	----------------	------------	--------------

FLUTICASONE PROPIONATE

<b>AB</b>	FOUGERA PHARMS	<u>0.005%</u>	<u>A076300</u>	<u>001</u>	May 14, 2004
<b>AB</b>	G AND W LABS	<u>0.005%</u>	<u>A077168</u>	<u>001</u>	Mar 03, 2006
<b>AB</b>	PERRIGO NEW YORK	<u>0.005%</u>	<u>A076668</u>	<u>001</u>	May 14, 2004

## POWDER; INHALATION

## FLOVENT DISKUS 100

+	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000
---	---------------	-----------	---------	-----	--------------

## FLOVENT DISKUS 250

+	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000
---	---------------	------------	---------	-----	--------------

## FLOVENT DISKUS 50

+	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000
---	---------------	------------	---------	-----	--------------

## SPRAY, METERED; NASAL

FLONASE

<b>AB</b>	+ GLAXOSMITHKLINE	<u>0.05MG/SPRAY</u>	<u>N020121</u>	<u>001</u>	Oct 19, 1994
-----------	-------------------	---------------------	----------------	------------	--------------

FLUTICASONE PROPIONATE

<b>AB</b>	APOTEX INC	<u>0.05MG/SPRAY</u>	<u>A077538</u>	<u>001</u>	Sep 12, 2007
<b>AB</b>	HI TECH PHARMA	<u>0.05MG/SPRAY</u>	<u>A077570</u>	<u>001</u>	Jan 16, 2008
<b>AB</b>	ROXANE	<u>0.05MG/SPRAY</u>	<u>A076504</u>	<u>001</u>	Feb 22, 2006
<b>AB</b>	WOCKHARDT	<u>0.05MG/SPRAY</u>	<u>A078492</u>	<u>001</u>	Jan 09, 2012

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

## AEROSOL, METERED; INHALATION

## ADVAIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

## POWDER; INHALATION

## ADVAIR DISKUS 100/50

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000
---	---------------	------------------------------	---------	-----	--------------

## ADVAIR DISKUS 250/50

+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000
---	---------------	-------------------------------	---------	-----	--------------

## ADVAIR DISKUS 500/50

+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000
---	---------------	------------------------------	---------	-----	--------------

FLUVASTATIN SODIUM

## CAPSULE; ORAL

FLUVASTATIN SODIUM

<b>AB</b>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090595</u>	<u>001</u>	Apr 11, 2012
<b>AB</b>		<u>EQ 40MG BASE</u>	<u>A090595</u>	<u>002</u>	Apr 11, 2012
<b>AB</b>	TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078407</u>	<u>001</u>	Jun 12, 2012
<b>AB</b>		<u>EQ 40MG BASE</u>	<u>A078407</u>	<u>002</u>	Jun 12, 2012

LESCOL

<b>AB</b>	NOVARTIS	<u>EQ 20MG BASE</u>	<u>N020261</u>	<u>001</u>	Dec 31, 1993
<b>AB</b>	+	<u>EQ 40MG BASE</u>	<u>N020261</u>	<u>002</u>	Dec 31, 1993

## TABLET, EXTENDED RELEASE; ORAL

## LESCOL XL

+	NOVARTIS	80MG	N021192	001	Oct 06, 2000
---	----------	------	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091482</u>	<u>001</u>	Apr 23, 2013
<u>AB</u>		<u>150MG</u>	<u>A091482</u>	<u>002</u>	Nov 18, 2013
<u>AB</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A091476</u>	<u>001</u>	Mar 13, 2013
<u>AB</u>		<u>150MG</u>	<u>A091476</u>	<u>002</u>	Mar 13, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>100MG</u>	<u>A203240</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>		<u>150MG</u>	<u>A203240</u>	<u>002</u>	Oct 31, 2014

LUVOX CR

<u>AB</u>	JAZZ PHARMS	<u>100MG</u>	<u>N022033</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>	+	<u>150MG</u>	<u>N022033</u>	<u>002</u>	Feb 28, 2008

TABLET;ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	APOTEX	<u>25MG</u>	<u>A075902</u>	<u>001</u>	May 07, 2001
<u>AB</u>		<u>50MG</u>	<u>A075902</u>	<u>002</u>	May 07, 2001
<u>AB</u>		<u>100MG</u>	<u>A075902</u>	<u>003</u>	May 07, 2001
<u>AB</u>	BARR	<u>25MG</u>	<u>A075897</u>	<u>001</u>	Jan 25, 2001
<u>AB</u>		<u>50MG</u>	<u>A075897</u>	<u>002</u>	Jan 25, 2001
<u>AB</u>		<u>100MG</u>	<u>A075897</u>	<u>003</u>	Jan 25, 2001
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A075889</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075889</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>		<u>100MG</u>	<u>A075889</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A075888</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075888</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	+	<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	TEVA	<u>25MG</u>	<u>A075893</u>	<u>001</u>	Sep 10, 2002
<u>AB</u>		<u>50MG</u>	<u>A075893</u>	<u>002</u>	Sep 10, 2002
<u>AB</u>		<u>100MG</u>	<u>A075893</u>	<u>003</u>	Sep 10, 2002

LUVOX

<u>AB</u>	ANI PHARMS	<u>25MG</u>	<u>N021519</u>	<u>001</u>	Dec 20, 2007
<u>AB</u>		<u>50MG</u>	<u>N021519</u>	<u>002</u>	Dec 20, 2007
<u>AB</u>		<u>100MG</u>	<u>N021519</u>	<u>003</u>	Dec 20, 2007

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

+ FRESENIUS KABI USA

5MG/ML

A089202 001 Feb 18, 1986

TABLET;ORAL

FOLIC ACID

<u>AA</u>	+	AMNEAL PHARM	<u>1MG</u>	<u>A040625</u>	<u>001</u>	Jul 21, 2005
<u>AA</u>		BICON PHARM	<u>1MG</u>	<u>A091145</u>	<u>001</u>	Jul 12, 2013
<u>AA</u>		CADILA PHARMS LTD	<u>1 MG</u>	<u>A202437</u>	<u>001</u>	Jan 27, 2014
<u>AA</u>		CONTRACT PHARMACAL	<u>1MG</u>	<u>A085061</u>	<u>001</u>	
<u>AA</u>		EXCELLIUM	<u>1MG</u>	<u>A040796</u>	<u>001</u>	Jan 12, 2009
<u>AA</u>		HIKMA PHARMS LLC	<u>1MG</u>	<u>A080600</u>	<u>001</u>	
<u>AA</u>		INVAGEN PHARMS	<u>1MG</u>	<u>A090035</u>	<u>001</u>	Jun 09, 2009
<u>AA</u>		VINTAGE	<u>1MG</u>	<u>A040756</u>	<u>001</u>	Jun 04, 2010
<u>AA</u>	+	WATSON LABS	<u>1MG</u>	<u>A080680</u>	<u>001</u>	

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS

FOLLISTIM AQ

+ ORGANON USA INC

75 IU/0.5ML

N021273 001 Aug 26, 2005

+

150 IU/0.5ML

N021273 002 Aug 26, 2005

+

300 IU/0.36ML

N021211 001 Mar 23, 2004

+

600 IU/0.72ML

N021211 002 Mar 23, 2004

+

900 IU/1.08ML

N021211 004 Feb 11, 2005

GONAL-F

+ EMD SERONO

450 IU/VIAL

N020378 005 Mar 26, 2004

1,050 IU/VIAL

N020378 004 Feb 28, 2001

GONAL-F RFF

+ EMD SERONO

75 IU/VIAL

N021765 002 Mar 25, 2004

GONAL-F RFF REDI-JECT

+ EMD SERONO

300 IU/0.5ML

N021684 001 May 25, 2004

+

450 IU/0.75ML

N021684 002 May 25, 2004

+

900 IU/1.5ML

N021684 003 May 25, 2004

## PRESCRIPTION DRUG PRODUCT LIST

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

<b>AP</b>	<b>+</b>	<b>PALADIN LABS</b>	<b><u>1.5GM/1.5ML (1GM/ML)</u></b>	<b><u>N020696 001</u></b>	Dec 04, 1997
-----------	----------	---------------------	------------------------------------	---------------------------	--------------

FOMEPIZOLE

<b>AP</b>		<b>LUITPOLD</b>	<b><u>1.5GM/1.5ML (1GM/ML)</u></b>	<b><u>A078368 001</u></b>	Dec 14, 2007
-----------	--	-----------------	------------------------------------	---------------------------	--------------

<b>AP</b>		<b>MYLAN INSTITUTIONAL</b>	<b><u>1.5GM/1.5ML (1GM/ML)</u></b>	<b><u>A078639 001</u></b>	Mar 03, 2008
-----------	--	----------------------------	------------------------------------	---------------------------	--------------

<b>AP</b>		<b>NAVINTA LLC</b>	<b><u>1.5GM/1.5ML (1GM/ML)</u></b>	<b><u>A078537 001</u></b>	Mar 06, 2008
-----------	--	--------------------	------------------------------------	---------------------------	--------------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIKTRA

<b>AP</b>	<b>+</b>	<b>MYLAN IRELAND LTD</b>	<b><u>2.5MG/0.5ML</u></b>	<b><u>N021345 001</u></b>	Dec 07, 2001
-----------	----------	--------------------------	---------------------------	---------------------------	--------------

<b>AP</b>	<b>+</b>		<b><u>5MG/0.4ML</u></b>	<b><u>N021345 002</u></b>	May 28, 2004
-----------	----------	--	-------------------------	---------------------------	--------------

<b>AP</b>	<b>+</b>		<b><u>7.5MG/0.6ML</u></b>	<b><u>N021345 003</u></b>	May 28, 2004
-----------	----------	--	---------------------------	---------------------------	--------------

<b>AP</b>	<b>+</b>		<b><u>10MG/0.8ML</u></b>	<b><u>N021345 004</u></b>	May 28, 2004
-----------	----------	--	--------------------------	---------------------------	--------------

FONDAPARINUX SODIUM

<b>AP</b>		<b>DR REDDYS LABS LTD</b>	<b><u>2.5MG/0.5ML</u></b>	<b><u>A091316 001</u></b>	Jul 11, 2011
-----------	--	---------------------------	---------------------------	---------------------------	--------------

<b>AP</b>			<b><u>5MG/0.4ML</u></b>	<b><u>A091316 002</u></b>	Jul 11, 2011
-----------	--	--	-------------------------	---------------------------	--------------

<b>AP</b>			<b><u>7.5MG/0.6ML</u></b>	<b><u>A091316 003</u></b>	Jul 11, 2011
-----------	--	--	---------------------------	---------------------------	--------------

<b>AP</b>			<b><u>10MG/0.8ML</u></b>	<b><u>A091316 004</u></b>	Jul 11, 2011
-----------	--	--	--------------------------	---------------------------	--------------

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

<b>+</b>	<b>NOVARTIS</b>	<b>0.012MG/INH</b>	<b>N020831 001</b>	Feb 16, 2001
----------	-----------------	--------------------	--------------------	--------------

SOLUTION; INHALATION

PERFORMIST

<b>+</b>	<b>MYLAN SPECLT</b>	<b>0.02MG/2ML</b>	<b>N022007 001</b>	May 11, 2007
----------	---------------------	-------------------	--------------------	--------------

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

<b>+</b>	<b>MERCK SHARP DOHME</b>	<b>0.005MG/INH; 0.1MG/INH</b>	<b>N022518 001</b>	Jun 22, 2010
----------	--------------------------	-------------------------------	--------------------	--------------

<b>+</b>		<b>0.005MG/INH; 0.2MG/INH</b>	<b>N022518 002</b>	Jun 22, 2010
----------	--	-------------------------------	--------------------	--------------

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

<b>+</b>	<b>VIIIV HLTHCARE</b>	<b>EQ 50MG BASE/ML</b>	<b>N022116 001</b>	Jun 14, 2007
----------	-----------------------	------------------------	--------------------	--------------

TABLET; ORAL

LEXIVA

<b>+</b>	<b>VIIIV HLTHCARE</b>	<b>EQ 700MG BASE</b>	<b>N021548 001</b>	Oct 20, 2003
----------	-----------------------	----------------------	--------------------	--------------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

<b>+</b>	<b>MERCK AND CO INC</b>	<b>EQ 150MG BASE/VIAL</b>	<b>N022023 002</b>	Nov 12, 2010
----------	-------------------------	---------------------------	--------------------	--------------

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

<b>AP</b>		<b>HOSPIRA</b>	<b><u>2.4GM/100ML</u></b>	<b><u>A077174 001</u></b>	May 31, 2005
-----------	--	----------------	---------------------------	---------------------------	--------------

FOSCAVIR

<b>AP</b>	<b>+</b>	<b>CLINIGEN HLTHCARE</b>	<b><u>2.4GM/100ML</u></b>	<b><u>N020068 001</u></b>	Sep 27, 1991
-----------	----------	--------------------------	---------------------------	---------------------------	--------------

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL

<b>+</b>	<b>ZAMBON SPA</b>	<b>EQ 3GM BASE/PACKET</b>	<b>N050717 001</b>	Dec 19, 1996
----------	-------------------	---------------------------	--------------------	--------------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

<b>AB</b>		<b>ACTAVIS LABS FL INC</b>	<b><u>10MG</u></b>	<b><u>A076620 001</u></b>	Oct 15, 2004
-----------	--	----------------------------	--------------------	---------------------------	--------------

<b>AB</b>			<b><u>20MG</u></b>	<b><u>A076620 002</u></b>	Oct 15, 2004
-----------	--	--	--------------------	---------------------------	--------------

<b>AB</b>			<b><u>40MG</u></b>	<b><u>A076620 003</u></b>	Oct 15, 2004
-----------	--	--	--------------------	---------------------------	--------------

<b>AB</b>		<b>APOTEX INC</b>	<b><u>10MG</u></b>	<b><u>A076906 001</u></b>	May 17, 2005
-----------	--	-------------------	--------------------	---------------------------	--------------

<b>AB</b>			<b><u>20MG</u></b>	<b><u>A076906 002</u></b>	May 17, 2005
-----------	--	--	--------------------	---------------------------	--------------

<b>AB</b>			<b><u>40MG</u></b>	<b><u>A076906 003</u></b>	May 17, 2005
-----------	--	--	--------------------	---------------------------	--------------

<b>AB</b>		<b>AUROBINDO PHARMA LTD</b>	<b><u>10MG</u></b>	<b><u>A091163 001</u></b>	Mar 30, 2011
-----------	--	-----------------------------	--------------------	---------------------------	--------------

<b>AB</b>			<b><u>20MG</u></b>	<b><u>A091163 002</u></b>	Mar 30, 2011
-----------	--	--	--------------------	---------------------------	--------------

<b>AB</b>			<b><u>40MG</u></b>	<b><u>A091163 003</u></b>	Mar 30, 2011
-----------	--	--	--------------------	---------------------------	--------------

<b>AB</b>		<b>INVAGEN PHARMS</b>	<b><u>10MG</u></b>	<b><u>A077222 001</u></b>	Apr 20, 2005
-----------	--	-----------------------	--------------------	---------------------------	--------------

<b>AB</b>			<b><u>20MG</u></b>	<b><u>A077222 002</u></b>	Apr 20, 2005
-----------	--	--	--------------------	---------------------------	--------------

<b>AB</b>			<b><u>40MG</u></b>	<b><u>A077222 003</u></b>	Apr 20, 2005
-----------	--	--	--------------------	---------------------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A076483 001</u>	Apr 23, 2004
<u>AB</u>		<u>20MG</u>	<u>A076483 002</u>	Apr 23, 2004
<u>AB</u>		<u>40MG</u>	<u>A076483 003</u>	Apr 23, 2004
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076139 001</u>	Nov 25, 2003
<u>AB</u>		<u>20MG</u>	<u>A076139 002</u>	Nov 25, 2003
<u>AB</u>	+	<u>40MG</u>	<u>A076139 003</u>	Nov 25, 2003

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>10MG;12.5MG</u>	<u>A076608 001</u>	Dec 03, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076608 002</u>	Dec 03, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>10MG;12.5MG</u>	<u>A079245 001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A079245 002</u>	Jul 09, 2009
<u>AB</u>	EMCURE PHARMS INDIA	<u>10MG;12.5MG</u>	<u>A079025 001</u>	Sep 17, 2010
<u>AB</u>	+	<u>20MG;12.5MG</u>	<u>A079025 002</u>	Sep 17, 2010
<u>AB</u>	INVAGEN PHARMS	<u>10MG;12.5MG</u>	<u>A090228 001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A090228 002</u>	Jul 09, 2009
<u>AB</u>	RANBAXY	<u>10MG;12.5MG</u>	<u>A076739 001</u>	Dec 17, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076739 002</u>	Dec 17, 2004
<u>AB</u>	SANDOZ	<u>10MG;12.5MG</u>	<u>A076961 001</u>	Sep 28, 2005
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076961 002</u>	Sep 28, 2005

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

<u>AP</u>	PARKE DAVIS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>N020450 001</u>	Aug 05, 1996
-----------	-------------	--------------------------------	--------------------	--------------

FOSPHENYTOIN SODIUM

<u>AP</u>	AGILA SPECLTS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078736 001</u>	Jun 08, 2010
<u>AP</u>	AMNEAL PHARMS CO	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078476 001</u>	Mar 18, 2008
<u>AP</u>	BEDFORD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077481 001</u>	Aug 06, 2007
<u>AP</u>	+	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078052 001</u>	Aug 06, 2007
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078765 001</u>	Dec 02, 2009
<u>AP</u>	HIKMA MAPLE	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989 001</u>	Aug 06, 2007
<u>AP</u>	HOSPIRA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078158 001</u>	Aug 06, 2007
<u>AP</u>	LUITPOLD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078277 001</u>	Aug 06, 2007
<u>AP</u>		<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A090099 001</u>	May 13, 2010
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078417 001</u>	Mar 18, 2008
<u>AP</u>	WOCKHARDT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078137 001</u>	Aug 06, 2007

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

<u>AB</u>	+	ENDO PHARMS	<u>EQ 2.5MG BASE</u>	<u>N021006 001</u>	Nov 08, 2001
-----------	---	-------------	----------------------	--------------------	--------------

FROVATRIPTAN SUCCINATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>A202931 001</u>	Aug 28, 2014
-----------	------------------	----------------------	--------------------	--------------

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

## FASLODEX

+	ASTRAZENECA	50MG/ML	N021344 001	Apr 25, 2002
---	-------------	---------	-------------	--------------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>	CLARIS LIFESCIENCES	<u>10MG/ML</u>	<u>A202747 001</u>	Jan 27, 2014	
<u>AP</u>	EMCURE PHARMS LTD	<u>10MG/ML</u>	<u>A203428 001</u>	Aug 26, 2014	
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N018902 001</u>	May 22, 1984	
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A075241 001</u>	May 28, 1999	
<u>AP</u>		<u>10MG/ML</u>	<u>N018667 001</u>	May 28, 1982	
<u>AP</u>	+	LUITPOLD	<u>10MG/ML</u>	<u>N018579 001</u>	Nov 30, 1983
<u>AP</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A077941 001</u>	Mar 22, 2007	

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	+	ROXANE	<u>10MG/ML</u>	<u>A070434 001</u>	Apr 22, 1987
<u>AA</u>		WOCKHARDT	<u>10MG/ML</u>	<u>A070655 001</u>	Oct 02, 1987
		ROXANE	40MG/5ML	A070433 001	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	EXCELLIUM	<u>20MG</u>	<u>A077293 001</u>	Nov 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077293 002</u>	Nov 09, 2005
<u>AB</u>		<u>80MG</u>	<u>A077293 003</u>	Nov 09, 2005

## PRESCRIPTION DRUG PRODUCT LIST

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	IPCA LABS LTD	<u>20MG</u>	<u>A078010 001</u>	Sep 18, 2006
<u>AB</u>		<u>40MG</u>	<u>A078010 002</u>	Sep 18, 2006
<u>AB</u>		<u>80MG</u>	<u>A078010 003</u>	Sep 18, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>N018413 001</u>	Nov 30, 1983
<u>AB</u>		<u>40MG</u>	<u>N018413 002</u>	Nov 30, 1983
<u>AB</u>	MYLAN	<u>20MG</u>	<u>N018487 001</u>	
<u>AB</u>		<u>40MG</u>	<u>N018487 002</u>	
<u>AB</u>		<u>80MG</u>	<u>A070082 001</u>	Oct 29, 1986
<u>AB</u>	ROXANE	<u>20MG</u>	<u>N018823 001</u>	Nov 10, 1983
<u>AB</u>		<u>40MG</u>	<u>N018823 002</u>	Nov 10, 1983
<u>AB</u>		<u>80MG</u>	<u>A070086 001</u>	Jan 24, 1986
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>N018569 002</u>	
<u>AB</u>		<u>40MG</u>	<u>N018569 001</u>	
<u>AB</u>		<u>80MG</u>	<u>N018569 005</u>	Aug 14, 1984
<u>AB</u>	SUN PHARM INDS INC	<u>20MG</u>	<u>A091258 001</u>	Apr 01, 2014
<u>AB</u>		<u>40MG</u>	<u>A091258 002</u>	Apr 01, 2014
<u>AB</u>		<u>80MG</u>	<u>A091258 003</u>	Apr 01, 2014
<u>AB</u>	VINTAGE PHARMS	<u>20MG</u>	<u>A076796 001</u>	Mar 26, 2004
<u>AB</u>		<u>40MG</u>	<u>A076796 002</u>	Mar 26, 2004
<u>AB</u>		<u>80MG</u>	<u>A076796 003</u>	Mar 26, 2004

LASIX

<u>AB</u>	SANOVI AVENTIS US	<u>20MG</u>	<u>N016273 002</u>	
<u>AB</u>		<u>40MG</u>	<u>N016273 001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N016273 003</u>	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075350 001</u>	Sep 12, 2003
<u>AB</u>		<u>300MG</u>	<u>A075350 002</u>	Sep 12, 2003
<u>AB</u>		<u>400MG</u>	<u>A075350 003</u>	Sep 12, 2003
<u>AB</u>	ALKEM	<u>100MG</u>	<u>A090858 001</u>	Dec 17, 2010
<u>AB</u>		<u>300MG</u>	<u>A090858 002</u>	Dec 17, 2010
<u>AB</u>		<u>400MG</u>	<u>A090858 003</u>	Dec 17, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>100MG</u>	<u>A078428 001</u>	Jul 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078428 002</u>	Jul 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078428 003</u>	Jul 25, 2007
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A075360 001</u>	Apr 06, 2005
<u>AB</u>		<u>300MG</u>	<u>A075360 002</u>	Apr 06, 2005
<u>AB</u>		<u>400MG</u>	<u>A075360 003</u>	Apr 06, 2005
<u>AB</u>	AUROBINDO PHARM	<u>100MG</u>	<u>A078787 001</u>	Jan 31, 2008
<u>AB</u>		<u>300MG</u>	<u>A078787 002</u>	Jan 31, 2008
<u>AB</u>		<u>400MG</u>	<u>A078787 003</u>	Jan 31, 2008
<u>AB</u>	HIKMA	<u>100MG</u>	<u>A078150 001</u>	Sep 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078150 002</u>	Sep 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078150 003</u>	Sep 25, 2007
<u>AB</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A090705 001</u>	Dec 30, 2009
<u>AB</u>		<u>300MG</u>	<u>A090705 002</u>	Dec 30, 2009
<u>AB</u>		<u>400MG</u>	<u>A090705 003</u>	Dec 30, 2009
<u>AB</u>	MARKSANS PHARMA	<u>100MG</u>	<u>A090007 001</u>	Jul 21, 2011
<u>AB</u>		<u>300MG</u>	<u>A090007 002</u>	Jul 21, 2011
<u>AB</u>		<u>400MG</u>	<u>A090007 003</u>	Jul 21, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A090158 001</u>	Feb 14, 2011
<u>AB</u>		<u>300MG</u>	<u>A090158 002</u>	Feb 14, 2011
<u>AB</u>		<u>400MG</u>	<u>A090158 003</u>	Feb 14, 2011
<u>AB</u>	RANBAXY	<u>100MG</u>	<u>A076606 001</u>	Oct 07, 2005
<u>AB</u>		<u>300MG</u>	<u>A076606 002</u>	Oct 07, 2005
<u>AB</u>		<u>400MG</u>	<u>A076606 003</u>	Oct 07, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A077242 001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A077242 002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A077242 003</u>	Aug 24, 2006
<u>AB</u>	TARO	<u>100MG</u>	<u>A077261 001</u>	Aug 02, 2013
<u>AB</u>		<u>300MG</u>	<u>A077261 002</u>	Aug 02, 2013
<u>AB</u>		<u>400MG</u>	<u>A077261 003</u>	Aug 02, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A075435 001</u>	Oct 08, 2004
<u>AB</u>		<u>300MG</u>	<u>A075435 002</u>	Oct 08, 2004
<u>AB</u>		<u>400MG</u>	<u>A075435 003</u>	Oct 08, 2004

NEURONTIN

<u>AB</u>	PFIZER PHARMS	<u>100MG</u>	<u>N020235 001</u>	Dec 30, 1993
<u>AB</u>		<u>300MG</u>	<u>N020235 002</u>	Dec 30, 1993

## PRESCRIPTION DRUG PRODUCT LIST

GABAPENTIN

CAPSULE; ORAL

NEURONTIN

**AB** + **400MG** **N020235 003** Dec 30, 1993  
SOLUTION; ORAL

GABAPENTIN

**AA** ACELLA PHARMS LLC **250MG/5ML** **A076403 001** May 01, 2012  
**AA** AMNEAL PHARMS **250MG/5ML** **A202024 001** Mar 23, 2012  
**AA** HI TECH PHARMA **250MG/5ML** **A078974 001** Feb 18, 2011  
**AA** TARO **250MG/5ML** **A076672 001** Jul 03, 2013

NEURONTIN

**AA** + PARKE DAVIS **250MG/5ML** **N021129 001** Mar 02, 2000  
TABLET; ORAL

GABAPENTIN

**AB** ACI HEALTHCARE LTD **600MG** **A203244 002** Jul 12, 2013  
**AB** **800MG** **A203244 001** Jul 12, 2013  
**AB** ACTAVIS ELIZABETH **600MG** **A075694 001** Oct 21, 2004  
**AB** **800MG** **A075694 002** Oct 21, 2004  
**AB** APOTEX INC **100MG** **A077894 001** Oct 10, 2006  
**AB** **300MG** **A077894 002** Oct 10, 2006  
**AB** **400MG** **A077894 003** Oct 10, 2006  
**AB** **600MG** **A077661 004** Sep 13, 2006  
**AB** **800MG** **A077661 005** Sep 13, 2006  
**AB** AUROBINDO PHARMA LTD **600MG** **A200651 001** Oct 06, 2011  
**AB** **800MG** **A200651 002** Oct 06, 2011  
**AB** GLENMARK GENERICS **600MG** **A077662 001** Aug 18, 2006  
**AB** **800MG** **A077662 002** Aug 18, 2006  
**AB** HIKMA PHARMS **600MG** **A078782 001** Jul 21, 2011  
**AB** **800MG** **A078782 002** Jul 21, 2011  
**AB** INVAGEN PHARMS **600MG** **A202764 001** Oct 16, 2012  
**AB** **800MG** **A202764 002** Oct 16, 2012  
**AB** IVAX SUB TEVA PHARMS **100MG** **A076017 001** Apr 28, 2004  
**AB** **300MG** **A076017 002** Apr 28, 2004  
**AB** **400MG** **A076017 003** Apr 28, 2004  
**AB** **600MG** **A076017 004** Apr 29, 2005  
**AB** **800MG** **A076017 005** Apr 29, 2005  
**AB** MYLAN PHARMS INC **600MG** **A090335 001** Jun 01, 2010  
**AB** **800MG** **A090335 002** Jun 01, 2010  
**AB** SUN PHARM INDS LTD **600MG** **A077525 001** Aug 24, 2006  
**AB** **800MG** **A077525 002** Aug 24, 2006  
**AB** ZYDUS PHARMS USA INC **600MG** **A078926 001** Feb 11, 2011  
**AB** **800MG** **A078926 002** Feb 11, 2011

NEURONTIN

**AB** PFIZER PHARMS **600MG** **N020882 001** Oct 09, 1998  
**AB** + **800MG** **N020882 002** Oct 09, 1998  
GRALISE  
BX + DEPOMED INC 300MG N022544 001 Jan 28, 2011  
BX + 600MG N022544 002 Jan 28, 2011

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

XENOPORT INC 300MG N022399 002 Dec 13, 2011  
+ 600MG N022399 001 Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS

MULTIHANCE

+ BRACCO 2.645GM/5ML (529MG/ML) N021357 001 Nov 23, 2004  
+ 5.29GM/10ML (529MG/ML) N021357 002 Nov 23, 2004  
+ 7.935GM/15ML (529MG/ML) N021357 003 Nov 23, 2004  
+ 10.58GM/20ML (529MG/ML) N021357 004 Nov 23, 2004

MULTIHANCE MULTIPACK

+ BRACCO 26.45GM/50ML (529MG/ML) N021358 001 Nov 23, 2004  
+ 52.9GM/100ML (529MG/ML) N021358 002 Nov 23, 2004

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+ BAYER HLTHCARE 1.20944GM/2ML (604.72MG/ML) N201277 006 Dec 18, 2013  
+ 4.5354GM/7.5ML (604.72MG/ML) N201277 001 Mar 14, 2011  
+ 6.0472GM/10ML (604.72MG/ML) N201277 002 Mar 14, 2011  
+ 9.0708GM/15ML (604.72MG/ML) N201277 003 Mar 14, 2011  
+ 18.1416GM/30ML (604.72MG/ML) N201277 004 Mar 14, 2011

## PRESCRIPTION DRUG PRODUCT LIST

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+

39.3068GM/65ML (604.72MG/ML)

N201277 005 Mar 14, 2011

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

+ GE HEALTHCARE

28.7GM/100ML (287MG/ML)

N022066 002 Sep 05, 2007

+

287MG/ML

N020123 001 Jan 08, 1993

GADOFOSVESET TRISODIUM

SOLUTION; INTRAVENOUS

ABLAVAR

LANTHEUS MEDCL

2440MG/10ML (244MG/ML)

N021711 001 Dec 22, 2008

+

3660MG/15ML (244MG/ML)

N021711 002 Dec 22, 2008

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

MAGNEVIST

+ BAYER HLTHCARE

469.01MG/ML

N019596 001 Jun 02, 1988

+

469.01MG/ML

N021037 001 Mar 10, 2000

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+ GUERBET

3.769GM/10ML (376.9MG/ML)

N204781 002 Mar 20, 2013

+

5.6535GM/15ML (376.9MG/ML)

N204781 003 Mar 20, 2013

+

7.538GM/20ML (376.9MG/ML)

N204781 004 Mar 20, 2013

+

37.69GM/100ML (376.9MG/ML)

N204781 001 Mar 20, 2013

GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE

+ BRACCO

279.3MG/ML

N020131 001 Nov 16, 1992

PROHANCE MULTIPACK

+ BRACCO

279.3MG/ML

N021489 001 Oct 09, 2003

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+ MALLINCKRODT

16.545GM/50ML (330.9MG/ML)

N020975 001 Dec 08, 1999

+

1654.5MG/5ML (330.9MG/ML)

N020937 001 Dec 08, 1999

+

3309MG/10ML (330.9MG/ML)

N020937 002 Dec 08, 1999

+

4963.5MG/15ML (330.9MG/ML)

N020937 003 Dec 08, 1999

+

6618MG/20ML (330.9MG/ML)

N020937 004 Dec 08, 1999

OPTIMARK IN PLASTIC CONTAINER

+ MALLINCKRODT

3309MG/10ML (330.9MG/ML)

N020976 002 Dec 08, 1999

+

4963.5MG/15ML (330.9MG/ML)

N020976 003 Dec 08, 1999

+

6618MG/20ML (330.9MG/ML)

N020976 004 Dec 08, 1999

+

9927MG/30ML (330.9MG/ML)

N020976 001 Dec 08, 1999

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

+ BAYER HLTHCARE

1.8143GM/10ML (181.43MG/ML)

N022090 001 Jul 03, 2008

2.72145GM/15ML (181.43MG/ML)

N022090 002 Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE**AB** BARR**EQ 8MG BASE****A078189 001** Sep 15, 2008**AB****EQ 16MG BASE****A078189 002** Sep 15, 2008**AB****EQ 24MG BASE****A078189 003** Sep 15, 2008**AB** IMPAX LABS**EQ 8MG BASE****A078484 001** May 27, 2009**AB****EQ 16MG BASE****A078484 002** May 27, 2009**AB****EQ 24MG BASE****A078484 003** May 27, 2009**AB** MYLAN**EQ 8MG BASE****A090900 001** Jan 24, 2011**AB****EQ 16MG BASE****A090900 002** Jan 24, 2011**AB****EQ 24MG BASE****A090900 003** Jan 24, 2011**AB** SUN PHARMA GLOBAL**EQ 8MG BASE****A090178 001** Feb 02, 2011**AB****EQ 16MG BASE****A090178 002** Feb 02, 2011**AB****EQ 24MG BASE****A090178 003** Feb 02, 2011**AB** WATSON LABS**EQ 8MG BASE****A079028 001** Dec 15, 2008**AB****EQ 16MG BASE****A079028 002** Dec 15, 2008**AB****EQ 24MG BASE****A079028 003** Dec 15, 2008

## PRESCRIPTION DRUG PRODUCT LIST

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

RAZADYNE ER

<u>AB</u>	+	JANSSEN PHARMS	<u>EQ 8MG BASE</u>	<u>N021615 001</u>	Apr 01, 2005
<u>AB</u>			<u>EQ 16MG BASE</u>	<u>N021615 002</u>	Apr 01, 2005
<u>AB</u>			<u>EQ 24MG BASE</u>	<u>N021615 003</u>	Apr 01, 2005

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

<u>AA</u>		ROXANE	<u>4MG/ML</u>	<u>A078185 001</u>	Jan 30, 2009
-----------	--	--------	---------------	--------------------	--------------

RAZADYNE

<u>AA</u>	+	JANSSEN PHARMS	<u>4MG/ML</u>	<u>N021224 001</u>	Jun 22, 2001
-----------	---	----------------	---------------	--------------------	--------------

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>		APOTEX INC	<u>EQ 4MG BASE</u>	<u>A077781 001</u>	Sep 27, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077781 002</u>	Sep 27, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077781 003</u>	Sep 27, 2011
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A090957 001</u>	Mar 29, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090957 002</u>	Mar 29, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A090957 003</u>	Mar 29, 2011
<u>AB</u>		BARR	<u>EQ 4MG BASE</u>	<u>A077605 001</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077605 002</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077605 003</u>	Aug 28, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A077593 001</u>	Sep 11, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077593 002</u>	Sep 11, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077593 003</u>	Sep 11, 2008
<u>AB</u>		MYLAN	<u>EQ 4MG BASE</u>	<u>A077590 001</u>	May 29, 2009
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A077603 001</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077590 002</u>	May 29, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077603 002</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077590 003</u>	May 29, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077603 003</u>	Aug 28, 2008
<u>AB</u>		ROXANE	<u>EQ 4MG BASE</u>	<u>A077608 001</u>	Feb 11, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077608 002</u>	Feb 11, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077608 003</u>	Feb 11, 2009
<u>AB</u>		SANDOZ	<u>EQ 4MG BASE</u>	<u>A077589 001</u>	Jun 22, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077589 002</u>	Jun 22, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077589 003</u>	Jun 22, 2009
<u>AB</u>		TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A077587 001</u>	Jul 09, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077587 002</u>	Jul 09, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077587 003</u>	Jul 09, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 4MG BASE</u>	<u>A078898 001</u>	Feb 17, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A078898 002</u>	Feb 17, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A078898 003</u>	Feb 17, 2011

RAZADYNE

<u>AB</u>	+	JANSSEN PHARMS	<u>EQ 4MG BASE</u>	<u>N021169 001</u>	Feb 28, 2001
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>N021169 002</u>	Feb 28, 2001
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>N021169 003</u>	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS		LANTHEUS MEDCL	2mCi/ML	N017478 001	
BS		MALLINCKRODT	2mCi/ML	N018058 001	

GANCICLOVIR

GEL;OPHTHALMIC

ZIRGAN

+	BAUSCH AND LOMB	0.15%	N022211 001	Sep 15, 2009
---	-----------------	-------	-------------	--------------

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

CYTOVENE

<u>AP</u>	+	ROCHE PALO	<u>EQ 500MG BASE/VIAL</u>	<u>N019661 001</u>	Jun 23, 1989
-----------	---	------------	---------------------------	--------------------	--------------

GANCICLOVIR

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A090658 001</u>	Jun 21, 2010
<u>AP</u>		LUITPOLD	<u>EQ 500MG BASE/VIAL</u>	<u>A202624 001</u>	Sep 18, 2013

GANIRELIX ACETATE

INJECTABLE;INJECTION

GANIRELIX ACETATE

+	ORGANON USA INC	EQ 250MCG BASE/0.5ML	N021057 001	Jul 29, 1999
---	-----------------	----------------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

<u>AT</u>	HI-TECH PHARMA CO	<u>0.5%</u>	<u>A203189</u>	<u>001</u>	Sep 03, 2014
<u>AT</u>	LUPIN LTD	<u>0.5%</u>	<u>A202653</u>	<u>001</u>	Aug 28, 2013
<u>ZYMAXID</u>					
<u>AT</u>	+ ALLERGAN	<u>0.5%</u>	<u>N022548</u>	<u>001</u>	May 18, 2010
	ZYMAR				
	+ ALLERGAN	0.3%	N021493	001	Mar 28, 2003

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 1GM BASE/VIAL</u>	<u>A091594</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091594</u>	<u>003</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A091594</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 1GM BASE/VIAL</u>	<u>A079160</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A079160</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	CIPLA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A078759</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A078759</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091365</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202997</u>	<u>001</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A091365</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A202063</u>	<u>002</u>	Sep 11, 2012
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A202063</u>	<u>001</u>	Sep 11, 2012
<u>AP</u>	FRESENIUS KABI ONCOL	<u>EQ 1GM BASE/VIAL</u>	<u>A090799</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090799</u>	<u>003</u>	May 16, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A090799</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2GM BASE/VIAL</u>	<u>A090242</u>	<u>003</u>	May 16, 2011
<u>AP</u>	HAMELN RDS GMBH	<u>EQ 1GM BASE/VIAL</u>	<u>A090663</u>	<u>002</u>	Sep 10, 2012
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A090663</u>	<u>001</u>	Sep 10, 2012
<u>AP</u>	HOSPIRA	<u>EQ 1GM BASE/VIAL</u>	<u>A078339</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A078339</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	+ HOSPIRA INC	<u>EQ 2GM BASE/VIAL</u>	<u>A079183</u>	<u>001</u>	Nov 15, 2010
<u>AP</u>	JIANGSU HANSON PHARM	<u>EQ 1GM BASE/VIAL</u>	<u>A202485</u>	<u>002</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A202485</u>	<u>001</u>	May 07, 2013
<u>AP</u>	LUITPOLD	<u>EQ 1GM BASE/VIAL</u>	<u>A202031</u>	<u>002</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A202031</u>	<u>001</u>	May 07, 2013
<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A200145</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A200145</u>	<u>003</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A200145</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091597</u>	<u>002</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A091597</u>	<u>001</u>	May 07, 2013
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 1GM BASE/VIAL</u>	<u>A078433</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A078433</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	TEVA PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A077983</u>	<u>001</u>	Jan 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A077983</u>	<u>002</u>	Jan 25, 2011
<u>GEMZAR</u>					
<u>AP</u>	+ LILLY	<u>EQ 1GM BASE/VIAL</u>	<u>N020509</u>	<u>002</u>	May 15, 1996
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>N020509</u>	<u>001</u>	May 15, 1996
GEMCITABINE HYDROCHLORIDE					
	+ HOSPIRA INC	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011
		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011
		200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

<u>AB</u>	APOTEX	<u>600MG</u>	<u>A075034</u>	<u>001</u>	Jul 20, 1998
<u>AB</u>	BLU CARIBE	<u>600MG</u>	<u>A078012</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>	DAVA PHARMS INC	<u>600MG</u>	<u>A074270</u>	<u>001</u>	Sep 27, 1993
<u>AB</u>	HIKMA PHARMS	<u>600MG</u>	<u>A078599</u>	<u>001</u>	Aug 16, 2010
<u>AB</u>	IMPAX PHARMS	<u>600MG</u>	<u>A078207</u>	<u>001</u>	Jun 01, 2007
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A077836</u>	<u>001</u>	Jul 27, 2006
<u>AB</u>	NORTHSTAR HLTHCARE	<u>600MG</u>	<u>A079072</u>	<u>001</u>	Sep 13, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>600MG</u>	<u>A079239</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>	TEVA	<u>600MG</u>	<u>A074256</u>	<u>001</u>	Oct 31, 1993
<u>LOPID</u>					
<u>AB</u>	+ PFIZER PHARMS	<u>600MG</u>	<u>N018422</u>	<u>003</u>	Nov 20, 1986

## PRESCRIPTION DRUG PRODUCT LIST

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+ LG LIFE SCIENCES

EQ 320MG BASE

N021158 001 Apr 04, 2003

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATEAT + FOUGERAEQ 0.1% BASEA062531 001 Jul 05, 1984AT PERRIGO NEW YORKEQ 0.1% BASEA062307 001AT TAROEQ 0.1% BASEA062427 001 May 26, 1983

INJECTABLE; INJECTION

GENTAMICIN SULFATEAP FRESENIUS KABI USAEQ 10MG BASE/MLA062366 002 Feb 06, 1986AP +EQ 40MG BASE/MLA062366 001 Aug 04, 1983AP HOSPIRAEQ 10MG BASE/MLA062420 001 Aug 15, 1983APEQ 10MG BASE/MLA062612 004 Feb 20, 1986APEQ 40MG BASE/MLA062420 002 Aug 15, 1983GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP + B BRAUNEQ 0.8MG BASE/MLA062814 001 Aug 28, 1987AP +EQ 1.2MG BASE/MLA062814 002 Aug 28, 1987AP +EQ 1.4MG BASE/MLA062814 003 Aug 28, 1987AP +EQ 1.6MG BASE/MLA062814 004 Aug 28, 1987AP +EQ 1.8MG BASE/MLA062814 005 Aug 28, 1987AP +EQ 2MG BASE/MLA062814 006 Aug 28, 1987AP +EQ 2.4MG BASE/MLA062814 007 Aug 28, 1987AP +EQ 40MG BASE/100MLA062814 008 Aug 28, 1987AP +EQ 60MG BASE/100MLA062814 009 Aug 28, 1987AP +EQ 70MG BASE/100MLA062814 010 Aug 28, 1987AP +EQ 80MG BASE/100MLA062814 011 Aug 28, 1987AP +EQ 90MG BASE/100MLA062814 012 Aug 28, 1987AP +EQ 100MG BASE/100MLA062814 013 Aug 28, 1987AP +EQ 120MG BASE/100MLA062814 014 Aug 28, 1987AP HOSPIRAEQ 1.2MG BASE/MLA062414 001 Aug 15, 1983APEQ 1.4MG BASE/MLA062414 002 Aug 15, 1983APEQ 1.6MG BASE/MLA062414 003 Aug 15, 1983APEQ 1.8MG BASE/MLA062414 004 Aug 15, 1983APEQ 2MG BASE/MLA062414 005 Aug 15, 1983APEQ 60MG BASE/100MLA062414 006 Aug 15, 1983APEQ 70MG BASE/100MLA062414 007 Aug 15, 1983APEQ 80MG BASE/100MLA062414 008 Aug 15, 1983APEQ 90MG BASE/100MLA062414 009 Aug 15, 1983APEQ 100MG BASE/100MLA062414 010 Aug 15, 1983ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINERAP BAXTER HLTHCAREEQ 0.8MG BASE/MLA062373 001 Sep 07, 1982APEQ 1.2MG BASE/MLA062373 007 Sep 07, 1982APEQ 1.6MG BASE/MLA062373 008 Sep 07, 1982APEQ 2MG BASE/MLA062373 009 Sep 07, 1982APEQ 2.4MG BASE/MLA062373 010 Sep 07, 1982APEQ 40MG BASE/100MLA062373 003 Sep 07, 1982APEQ 60MG BASE/100MLA062373 004 Sep 07, 1982APEQ 80MG BASE/100MLA062373 002 Sep 07, 1982APEQ 100MG BASE/100MLA062373 005 Sep 07, 1982APEQ 120MG BASE/100MLA062373 006 Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATEAT + AKORNEQ 0.3% BASEA064093 001 Aug 31, 1995AT PERRIGO CO TENNESSEEEQ 0.3% BASEA065024 001 Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATEAT FOUGERAEQ 0.1% BASEA062533 001 Oct 05, 1984AT + PERRIGO NEW YORKEQ 0.1% BASEA062351 001 Feb 18, 1982AT TAROEQ 0.1% BASEA062477 001 Dec 23, 1983

SOLUTION/DROPS; OPHTHALMIC

GENOPTICAT ALLERGANEQ 0.3% BASEA062452 001 Oct 10, 1984GENTAKAT AKORNEQ 0.3% BASEA064163 001 Oct 12, 2001GENTAMICIN SULFATEAT AKORNEQ 0.3% BASEA062635 001 Jan 08, 1987AT ALCON RES LTDEQ 0.3% BASEA062196 001AT + BAUSCH AND LOMBEQ 0.3% BASEA064048 001 May 11, 1994AT PERRIGO CO TENNESSEEEQ 0.3% BASEA065121 001 Jan 30, 2004

## PRESCRIPTION DRUG PRODUCT LIST

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

PRED-G

+ ALLERGAN

EQ 0.3% BASE;0.6%

N050612 001 Dec 01, 1989

SUSPENSION/DROPS;OPHTHALMIC

PRED-G

+ ALLERGAN

EQ 0.3% BASE;1%

N050586 001 Jun 10, 1988

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

+ TEVA PHARMS USA

20MG/ML

N020622 002 Feb 12, 2002

+

40MG/ML

N020622 003 Jan 28, 2014

GLIMEPIRIDE

TABLET;ORAL

AMARYLAB + SANOFI AVENTIS US1MGN020496 001 Nov 30, 1995AB2MGN020496 002 Nov 30, 1995AB4MGN020496 003 Nov 30, 1995GLIMEPIRIDEAB ACCORD HLTHCARE1MGA078181 001 Aug 23, 2007AB2MGA078181 002 Aug 23, 2007AB4MGA078181 003 Aug 23, 2007AB ACTAVIS LABS FL INC1MGA076995 001 Apr 27, 2010AB2MGA076995 002 Apr 27, 2010AB4MGA076995 003 Apr 27, 2010AB AUROBINDO PHARMA LTD1MGA202759 001 Jun 29, 2012AB2MGA202759 002 Jun 29, 2012AB4MGA202759 003 Jun 29, 2012AB CARLSBAD1MGA077911 001 Sep 22, 2009AB2MGA077911 002 Sep 22, 2009AB4MGA077911 003 Sep 22, 2009AB DR REDDYS LABS LTD1MGA077091 001 Oct 06, 2005AB2MGA077091 002 Oct 06, 2005AB4MGA077091 003 Oct 06, 2005AB HIKMA PHARMS1MGA078952 001 Aug 01, 2013AB2MGA078952 002 Aug 01, 2013AB4MGA078952 003 Aug 01, 2013AB INDOCO REMEDIES1MGA202112 001 Apr 17, 2013AB2MGA202112 002 Apr 17, 2013AB4MGA202112 003 Apr 17, 2013AB INVAGEN PHARMS1MGA077295 001 Oct 06, 2005AB2MGA077295 002 Oct 06, 2005AB4MGA077295 003 Oct 06, 2005AB MICRO LABS LTD INDIA1MGA091220 001 Jun 29, 2012AB2MGA091220 002 Jun 29, 2012AB4MGA091220 004 Jun 29, 2012AB8MGA091220 006 Jun 29, 2012AB MYLAN1MGA077624 001 Nov 28, 2005AB2MGA077624 002 Nov 28, 2005AB4MGA077624 003 Nov 28, 2005AB TEVA1MGA076802 001 Oct 06, 2005AB2MGA076802 002 Oct 06, 2005AB4MGA076802 003 Oct 06, 2005AB VINTAGE1MGA077370 001 Dec 23, 2005AB2MGA077370 002 Dec 23, 2005AB4MGA077370 003 Dec 23, 2005AB8MGA077370 004 Dec 23, 2005

MICRO LABS LTD INDIA

3MG

A091220 003 Jun 29, 2012

6MG

A091220 005 Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

DUETACTAB + TAKEDA PHARMS USA2MG;30MGN021925 001 Jul 28, 2006AB4MG;30MGN021925 002 Jul 28, 2006PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDEAB SANDOZ2MG;30MGA201049 001 Jan 04, 2013AB4MG;30MGA201049 002 Jan 04, 2013



## PRESCRIPTION DRUG PRODUCT LIST

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDARYL

+ SB PHARCO

1MG; 4MG

N021700 001 Nov 23, 2005

2MG; 4MG

N021700 002 Nov 23, 2005

2MG; 8MG

N021700 004 Mar 30, 2007

4MG; 4MG

N021700 003 Nov 23, 2005

4MG; 8MG

N021700 005 Mar 30, 2007

GLIPIZIDE

TABLET; ORAL

GLIPIZIDEAB ACCORD HLTHCARE5MGA074550 001 Sep 11, 1997AB ACCORD HLTHCARE10MGA074550 002 Sep 11, 1997AB APOTEX5MGA075795 001 Jun 13, 2001AB APOTEX10MGA075795 002 Jun 13, 2001AB IVAX SUB TEVA PHARMS5MGA074497 001 Aug 31, 1995AB IVAX SUB TEVA PHARMS10MGA074497 002 Aug 31, 1995AB MYLAN5MGA074226 001 May 10, 1994AB MYLAN5MGA074438 001 Jun 20, 1995AB MYLAN10MGA074226 002 May 10, 1994AB MYLAN10MGA074438 002 Jun 20, 1995AB SANDOZ5MGA074305 001 Apr 07, 1995AB SANDOZ10MGA074305 002 Apr 07, 1995AB SUN PHARM INDS INC5MGA077820 001 Jul 11, 2006AB SUN PHARM INDS INC10MGA077820 002 Jul 11, 2006AB WATSON LABS5MGA074223 001 Feb 27, 1995AB WATSON LABS10MGA074223 002 Feb 27, 1995GLUCOTROLAB PFIZER5MGN017783 001 May 08, 1984AB +10MGN017783 002 May 08, 1984

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDEAB PAR PHARM5MGA076159 002 Sep 20, 2013AB PAR PHARM10MGA076159 001 Sep 20, 2013AB WATSON LABS2.5MGA076467 003 Mar 27, 2006AB WATSON LABS5MGA076467 001 Sep 08, 2003AB WATSON LABS10MGA076467 002 Nov 07, 2003GLUCOTROL XLAB PFIZER2.5MGN020329 003 Aug 10, 1999AB PFIZER5MGN020329 001 Apr 26, 1994AB +10MGN020329 002 Apr 26, 1994GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDEAB COREPHARMA2.5MG; 250MGA077507 001 Oct 27, 2005AB COREPHARMA2.5MG; 500MGA077507 002 Oct 27, 2005AB COREPHARMA5MG; 500MGA077507 003 Oct 27, 2005AB HERITAGE PHARMS INC2.5MG; 250MGA078728 001 Jun 23, 2010AB HERITAGE PHARMS INC2.5MG; 500MGA078728 002 Jun 23, 2010AB HERITAGE PHARMS INC5MG; 500MGA078728 003 Jun 23, 2010AB MYLAN2.5MG; 250MGA078083 001 Apr 12, 2007AB MYLAN2.5MG; 500MGA078083 002 Apr 12, 2007AB MYLAN5MG; 500MGA078083 003 Apr 12, 2007AB SUN PHARM INDS INC2.5MG; 250MGA077620 001 Jan 11, 2008AB SUN PHARM INDS INC2.5MG; 500MGA077620 002 Jan 11, 2008AB SUN PHARM INDS INC5MG; 500MGA077620 003 Jan 11, 2008AB TEVA PHARMS2.5MG; 250MGA077270 001 Oct 28, 2005AB TEVA PHARMS2.5MG; 500MGA077270 002 Oct 28, 2005AB +5MG; 500MGA077270 003 Oct 28, 2005AB ZYDUS PHARMS USA INC2.5MG; 250MGA078905 001 Jan 31, 2011AB ZYDUS PHARMS USA INC2.5MG; 500MGA078905 002 Jan 31, 2011AB ZYDUS PHARMS USA INC5MG; 500MGA078905 003 Jan 31, 2011GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION

GLUCAGEN

+ NOVO NORDISK

EQ 1MG BASE/VIAL

N020918 001 Jun 22, 1998

## PRESCRIPTION DRUG PRODUCT LIST

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION

GLUCAGON

+ LILLY

1MG/VIAL

N020928 001 Sep 11, 1998

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+ EMMAUS MEDCL

5GM/PACKET

N021667 001 Jun 10, 2004

GLYBURIDE

TABLET; ORAL

GLYBURIDE

<u>AB</u>	AUROBINDO PHARMA	<u>1.25MG</u>	<u>A077537 001</u>	Oct 18, 2007
<u>AB</u>		<u>2.5MG</u>	<u>A077537 002</u>	Oct 18, 2007
<u>AB</u>		<u>5MG</u>	<u>A077537 003</u>	Oct 18, 2007
<u>AB</u>	COREPHARMA	<u>1.25MG</u>	<u>A076257 001</u>	Jun 27, 2002
<u>AB</u>		<u>2.5MG</u>	<u>A076257 002</u>	Jun 27, 2002
<u>AB</u>		<u>5MG</u>	<u>A076257 003</u>	Jun 27, 2002
<u>AB</u>	HERITAGE PHARMS INC	<u>1.25MG</u>	<u>A090937 001</u>	Feb 28, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090937 002</u>	Feb 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A090937 003</u>	Feb 28, 2011
<u>AB</u>	TEVA	<u>1.25MG</u>	<u>A074388 001</u>	Aug 29, 1995
<u>AB</u>		<u>2.5MG</u>	<u>A074388 002</u>	Aug 29, 1995
<u>AB</u>	+	<u>5MG</u>	<u>A074388 003</u>	Aug 29, 1995

GLYBURIDE (MICRONIZED)

<u>AB</u>	DAVA PHARMS INC	<u>1.5MG</u>	<u>A074591 001</u>	Dec 22, 1997
<u>AB</u>		<u>3MG</u>	<u>A074591 002</u>	Dec 22, 1997
<u>AB</u>		<u>4.5MG</u>	<u>A074591 003</u>	Dec 22, 1997
<u>AB</u>		<u>6MG</u>	<u>A074591 004</u>	Dec 22, 1997
<u>AB</u>	HIKMA	<u>1.5MG</u>	<u>A075890 001</u>	Jul 31, 2003
<u>AB</u>		<u>3MG</u>	<u>A075890 002</u>	Jul 31, 2003
<u>AB</u>		<u>6MG</u>	<u>A075890 003</u>	Jul 31, 2003
<u>AB</u>	MYLAN	<u>1.5MG</u>	<u>A074792 001</u>	Jun 26, 1998
<u>AB</u>		<u>3MG</u>	<u>A074792 002</u>	Jun 26, 1998
<u>AB</u>		<u>6MG</u>	<u>A074792 003</u>	Aug 17, 1999
<u>AB</u>	TEVA	<u>1.5MG</u>	<u>A074686 001</u>	Apr 20, 1999
<u>AB</u>		<u>3MG</u>	<u>A074686 002</u>	Apr 20, 1999
<u>AB</u>		<u>4.5MG</u>	<u>A074686 003</u>	Apr 20, 1999
<u>AB</u>		<u>6MG</u>	<u>A074686 004</u>	Apr 20, 1999

GLYNASE

<u>AB</u>	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>N020051 001</u>	Mar 04, 1992
<u>AB</u>		<u>3MG</u>	<u>N020051 002</u>	Mar 04, 1992
<u>AB</u>	+	<u>6MG</u>	<u>N020051 004</u>	Sep 24, 1993
	DIABETA			
BX	SANOFI AVENTIS US	1.25MG	N017532 001	May 01, 1984
BX		2.5MG	N017532 002	May 01, 1984
BX	+	5MG	N017532 003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>1.25MG; 250MG</u>	<u>N021178 001</u>	Jul 31, 2000
<u>AB</u>	+	<u>2.5MG; 500MG</u>	<u>N021178 002</u>	Jul 31, 2000
<u>AB</u>		<u>5MG; 500MG</u>	<u>N021178 003</u>	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG; 250MG</u>	<u>A076716 001</u>	Jun 28, 2005
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076716 002</u>	Jun 28, 2005
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076716 003</u>	Jun 28, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>1.25MG; 250MG</u>	<u>A077870 001</u>	Nov 14, 2007
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A077870 002</u>	Nov 14, 2007
<u>AB</u>		<u>5MG; 500MG</u>	<u>A077870 003</u>	Nov 14, 2007
<u>AB</u>	COREPHARMA	<u>1.25MG; 250MG</u>	<u>A076731 001</u>	Nov 19, 2004
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076731 002</u>	Nov 19, 2004
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076731 003</u>	Nov 19, 2004
<u>AB</u>	HERITAGE PHARMS INC	<u>1.25MG; 250MG</u>	<u>A079009 001</u>	Jun 03, 2009
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A079009 002</u>	Jun 03, 2009
<u>AB</u>		<u>5MG; 500MG</u>	<u>A079009 003</u>	Jun 03, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1.25MG; 250MG</u>	<u>A076345 001</u>	Feb 18, 2004
<u>AB</u>		<u>2.5MG; 500MG</u>	<u>A076345 002</u>	Feb 18, 2004
<u>AB</u>		<u>5MG; 500MG</u>	<u>A076345 003</u>	Feb 18, 2004

## PRESCRIPTION DRUG PRODUCT LIST

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+ HYPERION THERAP INC 1.1GM/ML

N203284 001 Feb 01, 2013

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINERAT BAXTER HLTHCARE 1.5GM/100MLN017865 001GLYCINE 1.5% IN PLASTIC CONTAINERAT B BRAUN 1.5GM/100MLN016784 001AT HOSPIRA 1.5GM/100MLN018315 001GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATEAP HIKMA FARMACEUTICA 0.2MG/MLA090963 001 Sep 21, 2011AP LUITPOLD 0.2MG/MLA089335 001 Jul 23, 1986ROBINULAP + HIKMA MAPLE 0.2MG/MLN017558 001

SOLUTION; ORAL

CUVPOSA

+ MERZ PHARMS 1MG/5ML

N022571 001 Jul 28, 2010

TABLET; ORAL

GLYCOPYRROLATEAA AUROLIFE PHARMA LLC 1MGA202675 001 Apr 15, 2013AA DR REDDYS LABS LTD 1MGA040847 001 Mar 21, 2008AA 2MGA040847 002 Mar 21, 2008AA EXCELLIUM 1MGA090195 001 Sep 21, 2012AA 2MGA090195 002 Sep 21, 2012AA NEXGEN PHARMA 1.5MGA091522 001 Mar 12, 2012AA PAR PHARM 1MGA040653 001 Aug 31, 2006AA 2MGA040653 002 Aug 31, 2006AA RANBAXY 1MGA040844 001 Aug 18, 2009AA 2MGA040844 002 Aug 18, 2009AA STASON PHARMS 1MGA091182 001 Feb 03, 2014AA 2MGA091182 002 Feb 03, 2014AA VINTAGE 1MGA040821 001 Dec 29, 2008AA 2MGA040821 002 Dec 29, 2008AA VINTAGE PHARMS 1MGA090020 001 Oct 19, 2011AA 2MGA090020 002 Oct 19, 2011ROBINULAA + SHIONOGI INC 1MGN012827 001ROBINUL FORTEAA + SHIONOGI INC 2MGN012827 002GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPINAP + FERRING 10,000 UNITS/VIALN017016 007AP + FRESENIUS KABI USA 10,000 UNITS/VIALN017067 002PREGNYLAP + ORGANON USA INC 10,000 UNITS/VIALN017692 001GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

+ ASTRAZENECA EQ 3.6MG BASE

N019726 001 Dec 29, 1989

+ EQ 10.8MG BASE

N020578 001 Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDINAT + BAUSCH AND LOMB 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/MLA064047 001 Jan 31, 1996AT LUITPOLD 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/MLA065187 001 Oct 28, 2005NEOSPORINAT + MONARCH PHARMS 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/MLA060582 001

## PRESCRIPTION DRUG PRODUCT LIST

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

+ PROSTRAKAN INC

3.1MG/24HR

N022198 001 Sep 12, 2008

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A079119 001</u>	Sep 10, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078 001</u>	Sep 14, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078 002</u>	Sep 14, 2009
<u>AP</u>	BANNER PHARMACAPS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880 001</u>	Jun 30, 2008
<u>AP</u>	BEDFORD LABS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913 001</u>	Jun 26, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187 001</u>	Jun 30, 2008
<u>AP</u>	CIPLA LTD	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262 001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258 002</u>	Jun 30, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522 001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090 001</u>	Jun 30, 2008
<u>AP</u>	HIKMA MAPLE	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177 001</u>	Dec 31, 2007
<u>AP</u>	LUITPOLD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091274 001</u>	Sep 22, 2010
<u>AP</u>	SAGENT AGILA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A091137 002</u>	Apr 09, 2010
<u>AP</u>	SAGENT STRIDES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A091136 001</u>	Apr 09, 2010
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091136 002</u>	Apr 09, 2010
<u>AP</u>	SANDOZ	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534 001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531 001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531 002</u>	Apr 30, 2009
<u>AP</u>	SANDOZ INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835 002</u>	Jun 30, 2008
<u>AP</u>	+ TEVA PHARMS USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392 001</u>	Dec 31, 2007
<u>AP</u>	+	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077963 001</u>	Jan 03, 2008
<u>AP</u>	+	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297 001</u>	Jun 30, 2008
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566 001</u>	Feb 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565 001</u>	Jun 30, 2008
	<u>GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE</u>			
<u>AP</u>	BANNER PHARMACAPS	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863 002</u>	Jun 30, 2008
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096 001</u>	Jun 30, 2008
	<u>GRANISTERON HYDROCHLORIDE</u>			
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629 001</u>	Dec 23, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629 002</u>	Dec 23, 2009

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843 001</u>	Feb 27, 2008
<u>AB</u>	CIPLA LTD	<u>EQ 1MG BASE</u>	<u>A078037 001</u>	Feb 27, 2008
<u>AB</u>	COREPHARMA	<u>EQ 1MG BASE</u>	<u>A078260 001</u>	Dec 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846 001</u>	Feb 27, 2009
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A078725 001</u>	Jan 30, 2008
<u>AB</u>	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969 001</u>	Jun 22, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A078678 001</u>	Feb 13, 2008
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A077842 001</u>	Dec 31, 2007
<u>AB</u>	TARO	<u>EQ 1MG BASE</u>	<u>A090817 001</u>	May 28, 2010
<u>AB</u>	+ TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078080 001</u>	Dec 31, 2007

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISEOFULVIN

<u>AB</u>	+ ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394 001</u>	Jul 06, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>125MG/5ML</u>	<u>A065354 001</u>	Sep 10, 2007
<u>AB</u>	PERRIGO CO TENNESSEE	<u>125MG/5ML</u>	<u>A065200 001</u>	Mar 02, 2005
<u>AB</u>	VINTAGE PHARMS	<u>125MG/5ML</u>	<u>A065438 001</u>	Oct 08, 2010

TABLET; ORAL

GRIFULVIN V

<u>AB</u>	+ VALEANT LUXEMBOURG	<u>500MG</u>	<u>A062279 003</u>	
	<u>GRISEOFULVIN</u>			
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A091592 002</u>	Aug 07, 2013
<u>AB</u>	SIGMAPHARM LABS LLC	<u>500MG</u>	<u>A202482 001</u>	Oct 22, 2012
	SANDOZ	<u>250MG</u>	<u>A091592 001</u>	Aug 07, 2013

## PRESCRIPTION DRUG PRODUCT LIST

GRISEOFULVIN, ULTRAMICROSIZED

TABLET; ORAL

GRIS-PEG

<b>AB</b>	VALEANT PHARMS INC	<b>125MG</b>	<b>N050475 001</b>	
<b>AB</b>	+	<b>250MG</b>	<b>N050475 002</b>	

GRISEOFULVIN, ULTRAMICROSIZED

<b>AB</b>	RICONPHARMA LLC	<b>125MG</b>	<b>A204371 001</b>	Jan 09, 2014
<b>AB</b>		<b>250MG</b>	<b>A204371 002</b>	Jan 09, 2014

GRISEOFULVIN, ULTRAMICROSIZED

<b>AB</b>	SIGMAPHARM LABS LLC	<b>125MG</b>	<b>A202545 001</b>	Oct 22, 2012
<b>AB</b>		<b>250MG</b>	<b>A202545 002</b>	Oct 22, 2012

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

OBREDON

+	SOVEREIGN PHARMS	200MG/5ML; 2.5MG/5ML	N205474 001	Nov 14, 2014
---	------------------	----------------------	-------------	--------------

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

	ANI PHARMS INC	EQ 4MG BASE	A074149 001	Apr 07, 1995
+		EQ 8MG BASE	A074149 002	Apr 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

<b>AB</b>	AMNEAL PHARM	<b>EQ 1MG BASE</b>	<b>A075109 001</b>	Nov 25, 1998
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A075109 002</b>	Nov 25, 1998
<b>AB</b>	EPIC PHARMA LLC	<b>EQ 1MG BASE</b>	<b>A074673 001</b>	Feb 28, 1997
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A074673 002</b>	Feb 28, 1997
<b>AB</b>	MYLAN	<b>EQ 1MG BASE</b>	<b>A074796 001</b>	Jan 27, 1997
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A074796 002</b>	Jan 27, 1997
<b>AB</b>	WATSON LABS	<b>EQ 1MG BASE</b>	<b>A074145 001</b>	Oct 17, 1995
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A074145 002</b>	Oct 17, 1995

TENEX

<b>AB</b>	PROMIUS PHARMA	<b>EQ 1MG BASE</b>	<b>N019032 001</b>	Oct 27, 1986
<b>AB</b>	+	<b>EQ 2MG BASE</b>	<b>N019032 002</b>	Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

<b>AB</b>	ACTAVIS ELIZABETH	<b>EQ 1MG BASE</b>	<b>A200881 001</b>	Oct 05, 2012
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>A200881 002</b>	Oct 05, 2012
<b>AB</b>		<b>EQ 3MG BASE</b>	<b>A200881 003</b>	Oct 05, 2012
<b>AB</b>		<b>EQ 4MG BASE</b>	<b>A200881 004</b>	Oct 05, 2012

INTUNIV

<b>AB</b>	SHIRE	<b>EQ 1MG BASE</b>	<b>N022037 001</b>	Sep 02, 2009
<b>AB</b>		<b>EQ 2MG BASE</b>	<b>N022037 002</b>	Sep 02, 2009
<b>AB</b>		<b>EQ 3MG BASE</b>	<b>N022037 003</b>	Sep 02, 2009
<b>AB</b>	+	<b>EQ 4MG BASE</b>	<b>N022037 004</b>	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE

	MERCK SHARP DOHME	125MG	N001546 001	
--	-------------------	-------	-------------	--

HALCINONIDE

CREAM; TOPICAL

HALOG

+	RANBAXY	0.1%	N017556 001	
---	---------	------	-------------	--

OINTMENT; TOPICAL

HALOG

+	RANBAXY	0.1%	N017824 001	
---	---------	------	-------------	--

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

<b>AB</b>	FOUGERA PHARMS	<b>0.05%</b>	<b>A077001 001</b>	Dec 16, 2004
<b>AB</b>	G AND W LABS	<b>0.05%</b>	<b>A078162 001</b>	Apr 24, 2007
<b>AB</b>	PERRIGO ISRAEL	<b>0.05%</b>	<b>A077123 001</b>	Dec 16, 2004
<b>AB</b>	TARO	<b>0.05%</b>	<b>A077227 001</b>	Aug 04, 2005

ULTRAVATE

<b>AB</b>	+	<b>0.05%</b>	<b>N019967 001</b>	Dec 27, 1990
-----------	---	--------------	--------------------	--------------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

<b>AB</b>	G AND W LABS	<b>0.05%</b>	<b>A077721 001</b>	Sep 07, 2006
<b>AB</b>	PERRIGO	<b>0.05%</b>	<b>A076872 001</b>	Dec 16, 2004

## PRESCRIPTION DRUG PRODUCT LIST

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

<u>AB</u>	TARO	<u>0.05%</u>	<u>A076994</u>	<u>001</u>	Dec 16, 2004
<u>ULTRAVATE</u>					
<u>AB</u>	+ RANBAXY	<u>0.05%</u>	<u>N019968</u>	<u>001</u>	Dec 17, 1990

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A070278</u>	<u>006</u>	Jun 10, 1986
<u>AB</u>		<u>1MG</u>	<u>A070278</u>	<u>004</u>	Jun 10, 1986
<u>AB</u>		<u>2MG</u>	<u>A070278</u>	<u>001</u>	Jun 10, 1986
<u>AB</u>		<u>5MG</u>	<u>A070278</u>	<u>005</u>	Jun 10, 1986
<u>AB</u>		<u>10MG</u>	<u>A070278</u>	<u>002</u>	Jul 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A070278</u>	<u>003</u>	Jul 16, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071206</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>1MG</u>	<u>A071207</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>	+	<u>2MG</u>	<u>A071208</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>5MG</u>	<u>A071209</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>10MG</u>	<u>A071210</u>	<u>001</u>	Mar 11, 1988
<u>AB</u>		<u>20MG</u>	<u>A071211</u>	<u>001</u>	Mar 11, 1988
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077580</u>	<u>003</u>	Nov 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077580</u>	<u>004</u>	Nov 29, 2007
<u>AB</u>		<u>20MG</u>	<u>A077580</u>	<u>005</u>	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>AO</u>	+ JANSSEN PHARMS	<u>EQ 50MG BASE/ML</u>	<u>N018701</u>	<u>001</u>	Jan 14, 1986
<u>AO</u>	+	<u>EQ 100MG BASE/ML</u>	<u>N018701</u>	<u>002</u>	Jan 31, 1997
<u>HALOPERIDOL DECANOATE</u>					
<u>AO</u>	AGILA SPECLTS	<u>EQ 50MG BASE/ML</u>	<u>A075440</u>	<u>001</u>	Feb 28, 2000
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075440</u>	<u>002</u>	Feb 28, 2000
<u>AO</u>	EUROHLTH INTL	<u>EQ 50MG BASE/ML</u>	<u>A074811</u>	<u>001</u>	Jan 30, 1998
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075305</u>	<u>001</u>	Sep 28, 1998
<u>AO</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074893</u>	<u>001</u>	Dec 19, 1997
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A074893</u>	<u>002</u>	Dec 19, 1997
<u>AO</u>	TEVA PHARMS USA	<u>EQ 50MG BASE/ML</u>	<u>A075393</u>	<u>001</u>	May 11, 1999
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075393</u>	<u>002</u>	May 11, 1999

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>	PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037</u>	<u>001</u>	Feb 26, 1993
<u>AA</u>	SILARX	<u>EQ 2MG BASE/ML</u>	<u>A073364</u>	<u>001</u>	Sep 28, 1993
<u>AA</u>	+ TEVA PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A071617</u>	<u>001</u>	Dec 01, 1988

INJECTABLE; INJECTION

HALDOL

<u>AP</u>	+ JANSSEN PHARMS	<u>EQ 5MG BASE/ML</u>	<u>N015923</u>	<u>001</u>	
<u>HALOPERIDOL</u>					
<u>AP</u>	AGILA SPECLTS	<u>EQ 5MG BASE/ML</u>	<u>A078347</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>	EUROHLTH INTL	<u>EQ 5MG BASE/ML</u>	<u>A075858</u>	<u>001</u>	Jun 18, 2001
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A075689</u>	<u>001</u>	Mar 09, 2001
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>	SAGENT PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A091637</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A200742</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>	TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A076035</u>	<u>001</u>	Aug 29, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	+ FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>001</u>	
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017651</u>	<u>006</u>	
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>003</u>	
<u>AP</u>	+	<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>004</u>	
<u>AP</u>	+ HIKMA MAPLE	<u>1,000 UNITS/ML</u>	<u>N017037</u>	<u>001</u>	
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017037</u>	<u>002</u>	
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017037</u>	<u>003</u>	
<u>AP</u>	HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090571</u>	<u>002</u>	Aug 31, 2009
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A090571</u>	<u>003</u>	Aug 31, 2009
<u>AP</u>	SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090808</u>	<u>002</u>	Jun 30, 2010

## PRESCRIPTION DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A090808 003</u>	Jun 30, 2010
<u>AP</u>		<u>20,000 UNITS/ML</u>	<u>A090809 001</u>	Jun 30, 2010
<u>AP</u>	SANDOZ	<u>1,000 UNITS/ML</u>	<u>A091682 001</u>	Jun 08, 2011
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A091659 001</u>	Jun 08, 2011
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A091682 002</u>	Jun 08, 2011
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A201002 001</u>	Jun 08, 2011
<u>AP</u>	SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202957 001</u>	Jun 12, 2014
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A202733 001</u>	Jun 12, 2014
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A202957 002</u>	Jun 12, 2014
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A203198 001</u>	Jun 12, 2014
<u>AP</u>		<u>20,000 UNITS/ML</u>	<u>A203198 002</u>	Jun 12, 2014

HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609 001</u>	Apr 28, 1982
-----------	-----------------	------------------------	--------------------	--------------

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>200 UNITS/100ML</u>	<u>N019953 001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916 010</u>	Jun 23, 1989

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>10,000 UNITS/100ML</u>	<u>N019339 003</u>	Mar 27, 1985
-----------	---------	---------------------------	--------------------	--------------

HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609 002</u>	Apr 28, 1982
-----------	-----------------	------------------------	--------------------	--------------

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916 011</u>	Jun 23, 1989
-----------	---------	------------------------	--------------------	--------------

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>4,000 UNITS/100ML</u>	<u>N019952 001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>4,000 UNITS/100ML</u>	<u>N019805 001</u>	Jan 25, 1989

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ B BRAUN	<u>5,000 UNITS/100ML</u>	<u>N019952 004</u>	Jul 20, 1992
<u>AP</u>	+	<u>10,000 UNITS/100ML</u>	<u>N019952 005</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339 004</u>	Mar 27, 1985
<u>AP</u>		<u>5,000 UNITS/100ML</u>	<u>N019805 002</u>	Jan 25, 1989
<u>AP</u>		<u>10,000 UNITS/100ML</u>	<u>N019339 002</u>	Mar 27, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

<u>AP</u>	+ FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 013</u>	Dec 05, 1985
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017029 014</u>	Dec 05, 1985
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017029 015</u>	Dec 05, 1985
<u>AP</u>	+	<u>20,000 UNITS/ML</u>	<u>N017029 016</u>	Dec 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

<u>AP</u>	+ FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 010</u>	Apr 28, 1986
<u>AP</u>	SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090810 001</u>	Jun 30, 2010
<u>AP</u>	SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202732 001</u>	Jun 12, 2014

## HEPARIN SODIUM

+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029 020	Mar 31, 2011
+	HOSPIRA	5,000 UNITS/ML	A088100 001	Apr 28, 1983
+	PFIZER	1,000 UNITS/ML	N201370 001	Jul 21, 2011
+		5,000 UNITS/ML	N201370 002	Jul 21, 2011
+		10,000 UNITS/ML	N201370 003	Jul 21, 2011

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339 001</u>	Mar 27, 1985
--	---------	--------------------------	--------------------	--------------

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N018916 006</u>	Jan 31, 1984
--	---------	--------------------------	--------------------	--------------

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N018916 007</u>	Jan 31, 1984
		<u>10,000 UNITS/100ML</u>	<u>N018916 008</u>	Jan 31, 1984

HEPARIN SODIUM PRESERVATIVE FREE

+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029 019	Nov 22, 2010
+	HOSPIRA	10,000 UNITS/ML	A089522 001	May 04, 1987
+	PFIZER	1,000 UNITS/ML	N201370 004	Jul 21, 2011

HEXACHLOROPHENE

EMULSION; TOPICAL

## PHISOHEX

+	SANOFI AVENTIS US	3%	N006882 001
---	-------------------	----	-------------

SPONGE; TOPICAL

PRE-OP

<u>AT</u>	+ DAVIS AND GECK	<u>480MG</u>	<u>N017433 001</u>
-----------	------------------	--------------	--------------------

PRE-OP II

<u>AT</u>	DAVIS AND GECK	<u>480MG</u>	<u>N017433 002</u>
-----------	----------------	--------------	--------------------

## PRESCRIPTION DRUG PRODUCT LIST

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+ PHOTOCURE ASA 100MG/VIAL N022555 001 May 28, 2010

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+ ENDO PHARM 50MG N022058 001 May 03, 2007

VANTAS

+ ENDO PHARM 50MG N021732 001 Oct 12, 2004

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEAA ACTAVIS MID ATLANTIC 1.5MG/5ML; 5MG/5ML A088017 001 Jul 05, 1983AA + HI TECH PHARMA 1.5MG/5ML; 5MG/5ML A040613 001 Feb 08, 2008AA WOCKHARDT 1.5MG/5ML; 5MG/5ML A088008 001 Mar 03, 1983

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATEAA NOVEL LABS INC 1.5MG; 5MG A091528 001 Apr 20, 2011TUSSIGONAA + KING PHARMS 1.5MG; 5MG A088508 001 Jul 30, 1985HYALURONIDASE

INJECTABLE; INJECTION

AMPHADASE

+ AMPHASTAR PHARM 150 UNITS/ML N021665 001 Oct 26, 2004

VITRASE

+ BAUSCH AND LOMB 200 UNITS/VIAL N021640 002 Dec 02, 2004

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HYLENEX RECOMBINANT

+ HALOZYME THERAP 150 UNITS/ML N021859 001 Dec 02, 2005

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDEAP AKORN 20MG/ML A040730 001 Apr 21, 2009AP FRESENIUS KABI USA 20MG/ML A040388 001 Mar 13, 2001AP + LUITPOLD 20MG/ML A040136 001 Jun 30, 1997AP NAVINTA LLC 20MG/ML A202938 001 Mar 28, 2013

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDEAA ACTAVIS GRP PTC 10MG A091679 001 Mar 04, 2013AA 25MG A091679 002 Mar 04, 2013AA 50MG A091679 003 Mar 04, 2013AA 100MG A091679 004 Mar 04, 2013AA ALKEM LABS LTD 10MG A200737 001 Dec 07, 2012AA 25MG A200737 002 Dec 07, 2012AA 50MG A200737 003 Dec 07, 2012AA 100MG A200737 004 Dec 07, 2012AA CADILA PHARMS LTD 25MG A203845 001 Sep 18, 2014AA 50MG A203845 002 Sep 18, 2014AA 100MG A203845 003 Sep 18, 2014AA GLENMARK PHARMS LTD 10MG A090527 001 May 27, 2009AA 25MG A090527 002 May 27, 2009AA 50MG A090527 003 May 27, 2009AA 100MG A090527 004 May 27, 2009AA HERITAGE PHARMS INC 10MG A086242 001 Feb 04, 2010AA 25MG A086242 003AA 50MG A086242 002AA 100MG A086242 004 Feb 04, 2010AA HETERO LABS LTD III 10MG A040901 001 Sep 12, 2008AA 25MG A040901 002 Sep 12, 2008AA 50MG A040901 003 Sep 12, 2008AA 100MG A040901 004 Sep 12, 2008AA INVAGEN PHARMS 10MG A090255 001 Dec 15, 2008AA 25MG A090255 002 Dec 15, 2008AA 50MG A090255 003 Dec 15, 2008AA 100MG A090255 004 Dec 15, 2008AA MYLAN 10MG A090413 001 Dec 08, 2010AA 25MG A090413 002 Dec 08, 2010AA 50MG A090413 003 Dec 08, 2010



## PRESCRIPTION DRUG PRODUCT LIST

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>		<u>100MG</u>	<u>A090413</u>	<u>004</u>	Dec 08, 2010
<u>AA</u>	PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>		<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>		<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>		<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	+ PLIVA	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	+	<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	STRIDES PHARMA	<u>25MG</u>	<u>A200770</u>	<u>001</u>	May 03, 2013
<u>AA</u>		<u>50MG</u>	<u>A200770</u>	<u>002</u>	May 03, 2013
<u>AA</u>		<u>100MG</u>	<u>A200770</u>	<u>003</u>	May 03, 2013

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

	PAR PHARM	25MG; 25MG	A088957	001	Oct 21, 1985
	+	50MG; 50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

	+ ARBOR PHARMS LLC	37.5MG; 20MG	N020727	001	Jun 23, 2005
--	--------------------	--------------	---------	-----	--------------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG</u>	<u>A200645</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A078389</u>	<u>001</u>	May 16, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG</u>	<u>A078164</u>	<u>001</u>	Sep 18, 2007
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A079237</u>	<u>001</u>	Apr 02, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A077005</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>	JUBILANT CADISTA	<u>12.5MG</u>	<u>A078391</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	LANNETT HOLDINGS INC	<u>12.5MG</u>	<u>A091662</u>	<u>001</u>	Jan 27, 2012
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075640</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A090651</u>	<u>001</u>	Apr 07, 2014
<u>AB</u>	UNICHEM	<u>12.5MG</u>	<u>A090510</u>	<u>001</u>	Jan 19, 2010
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A075907</u>	<u>001</u>	Sep 17, 2002

MICROZIDE

<u>AB</u>	+ WATSON LABS	<u>12.5MG</u>	<u>N020504</u>	<u>001</u>	Dec 27, 1996
-----------	---------------	---------------	----------------	------------	--------------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ACCORD HLTHCARE	<u>12.5MG</u>	<u>A202556</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A202556</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A202556</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>	ACTAVIS ELIZABETH	<u>12.5MG</u>	<u>A040707</u>	<u>001</u>	Feb 27, 2007
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A040774</u>	<u>001</u>	Oct 03, 2007
<u>AB</u>		<u>50MG</u>	<u>A040774</u>	<u>002</u>	Oct 03, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A040780</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040780</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A087059</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A087068</u>	<u>001</u>	
<u>AB</u>	EXCELLIUM	<u>25MG</u>	<u>A040702</u>	<u>001</u>	Mar 16, 2007
<u>AB</u>		<u>50MG</u>	<u>A040702</u>	<u>002</u>	Mar 16, 2007
<u>AB</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>A085182</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085182</u>	<u>001</u>	
<u>AB</u>	HIKMA PHARMS LLC	<u>50MG</u>	<u>A084878</u>	<u>001</u>	
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A040807</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>25MG</u>	<u>A040807</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040807</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A083177</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A083177</u>	<u>002</u>	
<u>AB</u>	JUBILANT CADISTA	<u>25MG</u>	<u>A040809</u>	<u>001</u>	Sep 04, 2007
<u>AB</u>		<u>50MG</u>	<u>A040809</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>	LANNETT	<u>25MG</u>	<u>A084325</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084324</u>	<u>001</u>	
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG</u>	<u>A040770</u>	<u>001</u>	Jan 23, 2007
<u>AB</u>		<u>25MG</u>	<u>A040735</u>	<u>002</u>	Jan 23, 2007
<u>AB</u>		<u>50MG</u>	<u>A040735</u>	<u>003</u>	Jan 23, 2007
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A203018</u>	<u>001</u>	Jul 23, 2014
<u>AB</u>		<u>50MG</u>	<u>A203018</u>	<u>002</u>	Jul 23, 2014

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040857 001</u>	May 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040810 001</u>	Mar 27, 2007
<u>AB</u>		<u>50MG</u>	<u>A040810 002</u>	Mar 27, 2007
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A040907 001</u>	Aug 15, 2008
<u>AB</u>		<u>50MG</u>	<u>A040907 002</u>	Aug 15, 2008
<u>AB</u>	VINTAGE PHARMS	<u>25MG</u>	<u>A040412 001</u>	Mar 29, 2002
<u>AB</u>		<u>50MG</u>	<u>A040412 002</u>	Mar 29, 2002

ORETIC

<u>AB</u>	ABBVIE	<u>50MG</u>	<u>N011971 002</u>	
-----------	--------	-------------	--------------------	--

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

<u>AB</u>	+ SANOFI AVENTIS US	<u>12.5MG; 150MG</u>	<u>N020758 002</u>	Sep 30, 1997
<u>AB</u>	+	<u>12.5MG; 300MG</u>	<u>N020758 003</u>	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC LTD	<u>12.5MG; 150MG</u>	<u>A091370 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A091370 002</u>	Oct 15, 2012
<u>AB</u>	APOTEX INC	<u>12.5MG; 150MG</u>	<u>A201505 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A201505 002</u>	Oct 15, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>12.5MG; 150MG</u>	<u>A203630 001</u>	Feb 22, 2013
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A203630 002</u>	Feb 22, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>12.5MG; 150MG</u>	<u>A203500 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A203500 002</u>	Sep 27, 2012
<u>AB</u>	LUPIN LTD	<u>12.5MG; 150MG</u>	<u>A201524 001</u>	Feb 27, 2013
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A201524 002</u>	Feb 27, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG; 150MG</u>	<u>A202414 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A202414 002</u>	Sep 27, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG; 150MG</u>	<u>A077969 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A077969 002</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>12.5MG; 150MG</u>	<u>A203072 001</u>	May 09, 2014
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A203072 002</u>	May 09, 2014
<u>AB</u>	ROXANE	<u>12.5MG; 150MG</u>	<u>A090351 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A090351 002</u>	Oct 15, 2012
<u>AB</u>	SANDOZ	<u>12.5MG; 150MG</u>	<u>A077446 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A077446 002</u>	Sep 27, 2012
<u>AB</u>	TEVA	<u>12.5MG; 150MG</u>	<u>A077369 001</u>	Mar 30, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A077369 002</u>	Mar 30, 2012
<u>AB</u>	WATSON LABS INC	<u>12.5MG; 150MG</u>	<u>A091539 001</u>	Oct 22, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A091539 002</u>	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>12.5MG; 10MG</u>	<u>A076674 001</u>	Oct 05, 2004
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A076674 002</u>	Oct 05, 2004
<u>AB</u>		<u>25MG; 20MG</u>	<u>A076674 003</u>	Oct 05, 2004
<u>AB</u>	AUROBINDO	<u>12.5MG; 10MG</u>	<u>A077606 001</u>	Mar 14, 2006
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A077606 002</u>	Mar 14, 2006
<u>AB</u>		<u>25MG; 20MG</u>	<u>A077606 003</u>	Mar 14, 2006
<u>AB</u>	HIKMA INTL PHARMS	<u>12.5MG; 10MG</u>	<u>A076265 001</u>	Jul 08, 2002
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A076265 002</u>	Jul 08, 2002
<u>AB</u>		<u>25MG; 20MG</u>	<u>A076265 003</u>	Jul 08, 2002
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG; 10MG</u>	<u>A075776 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A075776 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG; 20MG</u>	<u>A075776 003</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>12.5MG; 10MG</u>	<u>A077912 001</u>	Sep 27, 2006
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A077912 002</u>	Sep 27, 2006
<u>AB</u>		<u>25MG; 20MG</u>	<u>A077912 003</u>	Sep 27, 2006
<u>AB</u>	MYLAN	<u>12.5MG; 10MG</u>	<u>A076113 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A076113 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG; 20MG</u>	<u>A076113 003</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>12.5MG; 10MG</u>	<u>A076230 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A076230 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG; 20MG</u>	<u>A076230 003</u>	Jul 01, 2002
<u>AB</u>	RANBAXY	<u>12.5MG; 10MG</u>	<u>A076007 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A076007 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG; 20MG</u>	<u>A076007 003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG; 10MG</u>	<u>A076262 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A076262 002</u>	Jul 01, 2002

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>		<u>25MG;20MG</u>	<u>A076262 003</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194 003</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076194 001</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076194 002</u>	Jul 01, 2002

PRINZIDE

<u>AB</u>	MERCK	<u>12.5MG;10MG</u>	<u>N019778 003</u>	Nov 18, 1993
<u>AB</u>		<u>12.5MG;20MG</u>	<u>N019778 001</u>	Feb 16, 1989

ZESTORETIC

<u>AB</u>	ASTRAZENECA	<u>12.5MG;10MG</u>	<u>N019888 003</u>	Nov 18, 1993
<u>AB</u>	+	<u>12.5MG;20MG</u>	<u>N019888 001</u>	Sep 20, 1990
<u>AB</u>	+	<u>25MG;20MG</u>	<u>N019888 002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

<u>AB</u>	MERCK SHARP DOHME	<u>12.5MG;50MG</u>	<u>N020387 001</u>	Apr 28, 1995
<u>AB</u>		<u>12.5MG;100MG</u>	<u>N020387 003</u>	Oct 20, 2005
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N020387 002</u>	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG;50MG</u>	<u>A091617 001</u>	Feb 17, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091617 002</u>	Feb 17, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A091617 003</u>	Feb 17, 2012
<u>AB</u>	APOTEX	<u>12.5MG;50MG</u>	<u>A090150 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090150 002</u>	Aug 11, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090150 003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;50MG</u>	<u>A091629 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091629 002</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091629 003</u>	Jan 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>12.5MG;50MG</u>	<u>A201845 001</u>	Sep 18, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201845 002</u>	Sep 18, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A201845 003</u>	Sep 18, 2012
<u>AB</u>	IPCA LABS LTD	<u>12.5MG;50MG</u>	<u>A201682 001</u>	Mar 01, 2013
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201682 002</u>	Mar 01, 2013
<u>AB</u>		<u>25MG;100MG</u>	<u>A201682 003</u>	Mar 01, 2013
<u>AB</u>	LUPIN LTD	<u>12.5MG;50MG</u>	<u>A078245 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A078245 002</u>	May 21, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078245 003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;50MG</u>	<u>A202289 001</u>	Aug 09, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A202289 002</u>	Aug 09, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A202289 003</u>	Aug 09, 2012
<u>AB</u>	MYLAN	<u>12.5MG;50MG</u>	<u>A091652 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091652 002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091652 003</u>	Oct 06, 2010
<u>AB</u>	ROXANE	<u>12.5MG;50MG</u>	<u>A077732 002</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077732 001</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077732 003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>12.5MG;50MG</u>	<u>A077948 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077948 003</u>	Aug 19, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077948 002</u>	Oct 06, 2010
<u>AB</u>	TEVA PHARMS	<u>12.5MG;50MG</u>	<u>A077157 001</u>	Apr 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077157 002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077157 003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>12.5MG;50MG</u>	<u>A090528 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090528 003</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090528 002</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>12.5MG;50MG</u>	<u>A078385 001</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078385 002</u>	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	MYLAN	15MG;250MG	A070265 002	Jan 23, 1986
	+	25MG;250MG	A070265 001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

	COVIS PHARMA SARL	12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006
		12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006
	+	12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

<u>AB</u>	US PHARMS HOLDINGS I	<u>25MG; 50MG</u>	<u>N018303 001</u>	Dec 31, 1984
<u>AB</u>	+	<u>25MG; 100MG</u>	<u>N018303 002</u>	Dec 31, 1984

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG; 50MG</u>	<u>A202870 001</u>	Nov 06, 2013
<u>AB</u>		<u>25MG; 100MG</u>	<u>A202870 002</u>	Nov 06, 2013
<u>AB</u>		<u>50MG; 100MG</u>	<u>A202870 003</u>	Nov 06, 2013
<u>AB</u>	MYLAN	<u>25MG; 50MG</u>	<u>A076792 001</u>	Aug 20, 2004
<u>AB</u>		<u>25MG; 100MG</u>	<u>A076792 002</u>	Aug 20, 2004
<u>AB</u>		<u>50MG; 100MG</u>	<u>A076792 003</u>	Aug 20, 2004
<u>AB</u>	SUN PHARM INDS	<u>25MG; 50MG</u>	<u>A090654 001</u>	Jan 19, 2012
<u>AB</u>		<u>25MG; 100MG</u>	<u>A090654 002</u>	Jan 19, 2012
<u>AB</u>		<u>50MG; 100MG</u>	<u>A090654 003</u>	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	GLENMARK PHARMS	<u>12.5MG; 7.5MG</u>	<u>A090718 001</u>	Mar 17, 2010
<u>AB</u>		<u>12.5MG; 15MG</u>	<u>A090718 002</u>	Mar 17, 2010
<u>AB</u>		<u>25MG; 15MG</u>	<u>A090718 003</u>	Mar 17, 2010
<u>AB</u>	TEVA	<u>12.5MG; 7.5MG</u>	<u>A076980 001</u>	Mar 07, 2007
<u>AB</u>		<u>12.5MG; 15MG</u>	<u>A076980 003</u>	Mar 07, 2007
<u>AB</u>		<u>25MG; 15MG</u>	<u>A076980 002</u>	Mar 07, 2007

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>12.5MG; 7.5MG</u>	<u>A202150 001</u>	Mar 07, 2014
<u>AB</u>		<u>12.5MG; 15MG</u>	<u>A202150 002</u>	Mar 07, 2014
<u>AB</u>		<u>25MG; 15MG</u>	<u>A202150 003</u>	Mar 07, 2014

UNIRETIC

<u>AB</u>	UCB INC	<u>12.5MG; 7.5MG</u>	<u>N020729 001</u>	Jun 27, 1997
<u>AB</u>		<u>12.5MG; 15MG</u>	<u>N020729 003</u>	Feb 14, 2002
<u>AB</u>	+	<u>25MG; 15MG</u>	<u>N020729 002</u>	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

	DAIICHI SANKYO	<u>12.5MG; 20MG</u>	<u>N021532 002</u>	Jun 05, 2003
		<u>12.5MG; 40MG</u>	<u>N021532 003</u>	Jun 05, 2003
	+	<u>25MG; 40MG</u>	<u>N021532 005</u>	Jun 05, 2003

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

<u>AB</u>	+	WYETH PHARMS INC	<u>25MG; 40MG</u>	<u>N018031 001</u>
<u>PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>		MYLAN	<u>25MG; 40MG</u>	<u>A070947 002</u>
<u>AB</u>	+		<u>25MG; 80MG</u>	<u>A070947 001</u>
<u>AB</u>		PLIVA	<u>25MG; 40MG</u>	<u>A072042 001</u>
<u>AB</u>			<u>25MG; 80MG</u>	<u>A072043 001</u>

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

<u>AB</u>	PFIZER PHARMS	<u>12.5MG; EQ 10MG BASE</u>	<u>N020125 001</u>	Dec 28, 1999
<u>AB</u>		<u>12.5MG; EQ 20MG BASE</u>	<u>N020125 002</u>	Dec 28, 1999
<u>AB</u>	+	<u>25MG; EQ 20MG BASE</u>	<u>N020125 003</u>	Dec 28, 1999
<u>QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>				
<u>AB</u>	APOTEX CORP	<u>12.5MG; EQ 10MG BASE</u>	<u>A091524 001</u>	Mar 12, 2013
<u>AB</u>		<u>12.5MG; EQ 20MG BASE</u>	<u>A091524 002</u>	Mar 12, 2013
<u>AB</u>		<u>25MG; EQ 20MG BASE</u>	<u>A091524 003</u>	Mar 12, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG; EQ 10MG BASE</u>	<u>A078450 001</u>	Aug 24, 2007
<u>AB</u>		<u>12.5MG; EQ 20MG BASE</u>	<u>A078450 002</u>	Aug 24, 2007
<u>AB</u>		<u>25MG; EQ 20MG BASE</u>	<u>A078450 003</u>	Aug 24, 2007
<u>AB</u>	INVAGEN PHARMS	<u>12.5MG; 10MG</u>	<u>A201356 001</u>	Apr 20, 2011
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A201356 002</u>	Apr 20, 2011
<u>AB</u>		<u>25MG; 20MG</u>	<u>A201356 003</u>	Apr 20, 2011
<u>AB</u>	MYLAN	<u>12.5MG; EQ 10MG BASE</u>	<u>A077093 001</u>	Mar 28, 2005
<u>AB</u>		<u>12.5MG; EQ 20MG BASE</u>	<u>A077093 002</u>	Mar 28, 2005
<u>AB</u>		<u>25MG; EQ 20MG BASE</u>	<u>A077093 003</u>	Mar 28, 2005
<u>AB</u>	RANBAXY	<u>12.5MG; EQ 10MG BASE</u>	<u>A078211 001</u>	Mar 04, 2009
<u>AB</u>		<u>12.5MG; EQ 20MG BASE</u>	<u>A078211 002</u>	Mar 04, 2009
<u>AB</u>		<u>25MG; EQ 20MG BASE</u>	<u>A078211 003</u>	Mar 04, 2009

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINARETIC

<b>AB</b>	GAVIS PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<b><u>A076374 001</u></b>	Mar 31, 2004
<b>AB</b>		<u>12.5MG;EQ 20MG BASE</u>	<b><u>A076374 002</u></b>	Mar 31, 2004
<b>AB</b>		<u>25MG;EQ 20MG BASE</u>	<b><u>A076374 003</u></b>	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

<b>AB</b>	GD SEARLE LLC	<u>25MG;25MG</u>	<b><u>N012616 004</u></b>	Dec 30, 1982
<u>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE</u>				
<b>AB</b>	MUTUAL PHARM	<u>25MG;25MG</u>	<b><u>A089534 001</u></b>	Jul 02, 1987
<b>AB</b>	MYLAN	<u>25MG;25MG</u>	<b><u>A086513 001</u></b>	
<u>ALDACTAZIDE</u>				
	+ GD SEARLE LLC	<u>50MG;50MG</u>	<b><u>N012616 005</u></b>	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

<b>AB</b>	BOEHRINGER INGELHEIM	<u>12.5MG;40MG</u>	<b><u>N021162 001</u></b>	Nov 17, 2000
<b>AB</b>		<u>12.5MG;80MG</u>	<b><u>N021162 002</u></b>	Nov 17, 2000
<b>AB</b>	+	<u>25MG;80MG</u>	<b><u>N021162 003</u></b>	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

<b>AB</b>	ALEMBIC PHARMS LTD	<u>12.5MG;40MG</u>	<b><u>A203010 001</u></b>	Feb 25, 2014
<b>AB</b>		<u>12.5MG;80MG</u>	<b><u>A203010 002</u></b>	Feb 25, 2014
<b>AB</b>		<u>25MG;80MG</u>	<b><u>A203010 003</u></b>	Feb 25, 2014
<b>AB</b>	LUPIN LTD	<u>12.5MG;40MG</u>	<b><u>A091351 001</u></b>	Aug 07, 2014
<b>AB</b>		<u>12.5MG;80MG</u>	<b><u>A091351 002</u></b>	Aug 07, 2014
<b>AB</b>		<u>25MG;80MG</u>	<b><u>A091351 003</u></b>	Aug 07, 2014
<b>AB</b>	MYLAN PHARMS INC	<u>12.5MG;40MG</u>	<b><u>A091648 001</u></b>	Feb 25, 2014
<b>AB</b>		<u>12.5MG;80MG</u>	<b><u>A091648 002</u></b>	Feb 25, 2014
<b>AB</b>		<u>25MG;80MG</u>	<b><u>A091648 003</u></b>	Feb 25, 2014
<b>AB</b>	TORRENT PHARMS LTD	<u>12.5MG;40MG</u>	<b><u>A201192 001</u></b>	Feb 25, 2014
<b>AB</b>		<u>12.5MG;80MG</u>	<b><u>A201192 002</u></b>	Feb 25, 2014
<b>AB</b>		<u>25MG;80MG</u>	<b><u>A201192 003</u></b>	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

<b>AB</b>	+	GLAXOSMITHKLINE LLC	<u>25MG;37.5MG</u>	<b><u>N016042 003</u></b>	Mar 03, 1994
<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>					
<b>AB</b>		DURAMED PHARMS BARR	<u>25MG;37.5MG</u>	<b><u>A075052 001</u></b>	Jun 18, 1999
<b>AB</b>		IVAX SUB TEVA PHARMS	<u>25MG;50MG</u>	<b><u>A074259 001</u></b>	Mar 30, 1995
<b>AB</b>		LANNETT HOLDINGS INC	<u>25MG;37.5MG</u>	<b><u>A201407 001</u></b>	Dec 09, 2011
<b>AB</b>		MYLAN	<u>25MG;37.5MG</u>	<b><u>A074701 001</u></b>	Jun 07, 1996
<b>AB</b>		SANDOZ	<u>25MG;37.5MG</u>	<b><u>A074821 001</u></b>	Jun 05, 1997
<b>AB</b>	+		<u>25MG;50MG</u>	<b><u>A073191 001</u></b>	Jul 31, 1991

TABLET; ORAL

MAXZIDE

<b>AB</b>	+	MYLAN PHARMS INC	<u>50MG;75MG</u>	<b><u>N019129 001</u></b>	Oct 22, 1984
<u>MAXZIDE-25</u>					
<b>AB</b>		MYLAN PHARMS INC	<u>25MG;37.5MG</u>	<b><u>N019129 003</u></b>	May 13, 1988
<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>					
<b>AB</b>		APOTEX INC	<u>25MG;37.5MG</u>	<b><u>A071251 002</u></b>	May 05, 1998
<b>AB</b>			<u>50MG;75MG</u>	<b><u>A071251 001</u></b>	Apr 17, 1988
<b>AB</b>		PLIVA	<u>25MG;37.5MG</u>	<b><u>A074026 001</u></b>	Apr 26, 1996
<b>AB</b>			<u>50MG;75MG</u>	<b><u>A073467 001</u></b>	Jan 31, 1996
<b>AB</b>		SANDOZ	<u>25MG;37.5MG</u>	<b><u>A073281 001</u></b>	Apr 30, 1992
<b>AB</b>			<u>50MG;75MG</u>	<b><u>A072011 001</u></b>	Jun 17, 1988
<b>AB</b>		WATSON LABS	<u>25MG;37.5MG</u>	<b><u>A073449 001</u></b>	Sep 23, 1993
<b>AB</b>			<u>50MG;75MG</u>	<b><u>A071851 001</u></b>	Nov 30, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

<b>AB</b>	NOVARTIS	<u>12.5MG;80MG</u>	<b><u>N020818 001</u></b>	Mar 06, 1998	
<b>AB</b>		<u>12.5MG;160MG</u>	<b><u>N020818 002</u></b>	Mar 06, 1998	
<b>AB</b>		<u>12.5MG;320MG</u>	<b><u>N020818 004</u></b>	Apr 28, 2006	
<b>AB</b>		<u>25MG;160MG</u>	<b><u>N020818 003</u></b>	Jan 17, 2002	
<b>AB</b>	+		<u>25MG;320MG</u>	<b><u>N020818 005</u></b>	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

<b>AB</b>	ALEMBIC LTD	<u>12.5MG;80MG</u>	<b><u>A201662 001</u></b>	Mar 21, 2013
<b>AB</b>		<u>12.5MG;160MG</u>	<b><u>A201662 002</u></b>	Mar 21, 2013

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		<u>12.5MG;320MG</u>	<u>A201662 003</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;160MG</u>	<u>A201662 004</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;320MG</u>	<u>A201662 005</u>	Mar 21, 2013
<u>AB</u>	APOTEX INC	<u>12.5MG;80MG</u>	<u>A203026 001</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A203026 002</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A203026 003</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;160MG</u>	<u>A203026 004</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;320MG</u>	<u>A203026 005</u>	Mar 21, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>12.5MG;80MG</u>	<u>A202519 001</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A202519 002</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A202519 003</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;160MG</u>	<u>A202519 004</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;320MG</u>	<u>A202519 005</u>	Mar 21, 2013
<u>AB</u>	LUPIN LTD	<u>12.5MG;80MG</u>	<u>A078946 003</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A078946 004</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A078946 001</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;160MG</u>	<u>A078946 005</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;320MG</u>	<u>A078946 002</u>	Mar 21, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;80MG</u>	<u>A203145 001</u>	Apr 19, 2013
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A203145 002</u>	Apr 19, 2013
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A203145 003</u>	Apr 19, 2013
<u>AB</u>		<u>25MG;160MG</u>	<u>A203145 004</u>	Apr 19, 2013
<u>AB</u>		<u>25MG;320MG</u>	<u>A203145 005</u>	Apr 19, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG;80MG</u>	<u>A078020 001</u>	Sep 21, 2012
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A078020 002</u>	Sep 21, 2012
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A078020 004</u>	Sep 21, 2012
<u>AB</u>		<u>25MG;160MG</u>	<u>A078020 003</u>	Sep 21, 2012
<u>AB</u>		<u>25MG;320MG</u>	<u>A078020 005</u>	Sep 21, 2012
<u>AB</u>	WATSON LABS INC	<u>12.5MG;80MG</u>	<u>A091519 001</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A091519 002</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A091519 003</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;160MG</u>	<u>A091519 004</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;320MG</u>	<u>A091519 005</u>	Mar 21, 2013

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+ ZOGENIX INC

10MG	N202880 001	Oct 25, 2013
15MG	N202880 002	Oct 25, 2013
20MG	N202880 003	Oct 25, 2013
30MG	N202880 004	Oct 25, 2013
40MG	N202880 005	Oct 25, 2013
50MG	N202880 006	Oct 25, 2013

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA

PURDUE PHARMA LP

20MG	N206627 001	Nov 20, 2014
30MG	N206627 002	Nov 20, 2014
40MG	N206627 003	Nov 20, 2014
60MG	N206627 004	Nov 20, 2014
80MG	N206627 005	Nov 20, 2014
100MG	N206627 006	Nov 20, 2014
120MG	N206627 007	Nov 20, 2014

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG;200MG</u>	<u>A077454 001</u>	Jun 23, 2010
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A076604 001</u>	Dec 31, 2003
<u>AB</u>	AMNEAL PHARMS NY	<u>5MG;200MG</u>	<u>A076642 002</u>	Mar 18, 2004
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A076642 001</u>	Oct 12, 2004
<u>AB</u>	SUN PHARM INDS INC	<u>2.5MG;200MG</u>	<u>A091633 001</u>	May 28, 2013
<u>AB</u>		<u>5MG;200MG</u>	<u>A091633 002</u>	May 28, 2013
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A091633 003</u>	May 28, 2013
<u>AB</u>		<u>10MG;200MG</u>	<u>A091633 004</u>	May 28, 2013
<u>AB</u>	TEVA	<u>7.5MG;200MG</u>	<u>A076023 001</u>	Apr 11, 2003
<u>AB</u>	VINTAGE PHARMS	<u>5MG;200MG</u>	<u>A077727 001</u>	Nov 06, 2006
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A077723 001</u>	Nov 06, 2006
<u>AB</u>		<u>10MG;200MG</u>	<u>A077723 002</u>	Nov 06, 2006

REPREXAIN

<u>AB</u>	AMNEAL PHARMS NY	<u>2.5MG;200MG</u>	<u>A076642 003</u>	Oct 19, 2007
-----------	------------------	--------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

REPREXAIN**AB** 10MG; 200MG **A076642 004** Oct 19, 2007VICOPROFEN**AB** + ABBVIE 7.5MG; 200MG **N020716 001** Sep 23, 1997HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE**AA** PADDOCK LLC 5MG/5ML; 60MG/5ML **A204658 001** Apr 29, 2014**AA** TRIS PHARMA INC 5MG/5ML; 60MG/5ML **A203839 001** Oct 28, 2014REZIRA**AA** + CYPRESS PHARM 5MG/5ML; 60MG/5ML **N022442 001** Jun 08, 2011HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT**AT** CROWN LABS 1% **A080706 006**ANUSOL HC**AT** SALIX PHARMS 2.5% **A088250 001** Jun 06, 1984HYDROCORTISONE**AT** ACTAVIS MID ATLANTIC 1% **A087795 001** May 03, 1983**AT** 2.5% **A089682 001** Mar 10, 1988**AT** + FOUGERA 1% **A080693 003****AT** + 2.5% **A089414 001** Dec 16, 1986**AT** LYNE 2.5% **A040879 001** Aug 20, 2010**AT** PERRIGO NEW YORK 2.5% **A085025 001****AT** TARO 2.5% **A088799 001** Nov 09, 1984**AT** VINTAGE PHARMS 2.5% **A040503 001** Mar 12, 2004SYNACORT**AT** MEDICIS 1% **A087458 001****AT** 2.5% **A087457 001**

ENEMA; RECTAL

COLOCORT**AB** PADDOCK LLC 100MG/60ML **A075172 001** Dec 03, 1999CORTENEMA**AB** + ANI PHARMS 100MG/60ML **N016199 001**HYDROCORTISONE**AB** TEVA PHARMS 100MG/60ML **A074171 001** May 27, 1994

LOTION; TOPICAL

HYDROCORTISONE**AT** + FOUGERA PHARMS 2.5% **A040351 001** Jul 25, 2000**AT** TARO 2.5% **A040247 001** Jul 23, 1999**AT** VINTAGE PHARMS 2.5% **A040417 001** Jul 30, 2003NUTRACORT**AT** DOW PHARM 2.5% **A087644 001** Aug 24, 1982STIE-CORT**AT** PERRIGO 2.5% **A089074 001** Nov 26, 1985ALA-SCALP

CROWN LABS 2% A083231 001

OINTMENT; TOPICAL

HYDROCORTISONE**AT** ACTAVIS MID ATLANTIC 1% **A087796 001** Oct 13, 1982**AT** + FOUGERA 2.5% **A081203 001** May 28, 1993**AT** + FOUGERA PHARMS 1% **A080692 001****AT** PERRIGO NEW YORK 2.5% **A085027 001****AT** TARO 1% **A086257 001**HYDROCORTISONE IN ABSORBASE**AT** CAROLINA MEDCL 1% **A088138 001** Sep 06, 1985

POWDER; FOR RX COMPOUNDING

HYDRO-RX

+ X GEN PHARMS 100% A085982 001

SOLUTION; TOPICAL

TEXACORT

+ MISSION PHARMA 2.5% A081271 001 Apr 17, 1992

TABLET; ORAL

CORTEF**AB** PHARMACIA AND UPJOHN 5MG **N008697 003****AB** 10MG **N008697 001****AB** + 20MG **N008697 002**HYDROCORTISONE**AB** AMEDRA PHARMS 5MG **A040646 001** Mar 30, 2007

## PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

<b>AB</b>		<b>10MG</b>	<b>A040646 002</b>	Mar 30, 2007
<b>AB</b>		<b>20MG</b>	<b>A040646 003</b>	Mar 30, 2007
<b>AB</b>	VINTAGE	<b>5MG</b>	<b>A040761 001</b>	Jul 16, 2007
<b>AB</b>		<b>10MG</b>	<b>A040761 002</b>	Jul 16, 2007
<b>AB</b>		<b>20MG</b>	<b>A040761 003</b>	Jul 16, 2007

HYDROCORTISONE ACETATEAEROSOL, METERED; RECTAL  
CORTIFOAM

+ MEDA PHARMS 10% N017351 001 Feb 10, 1982

CREAM; TOPICAL

HYDROCORTISONE ACETATE

+ FERNDALE LABS 2.5% A040259 001 Jul 29, 1999

MICORT-HC

+ SEBELA IRELAND LTD 2% A040398 001 Mar 29, 2002

2.5% A040396 001 Feb 27, 2001

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

X GEN PHARMS 100% A085981 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

+ MONARCH PHARMS 0.5%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM N050218 001 Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

EPIFOAM

BX MEDA PHARMS 1%; 1% A086457 001

PROCTOFOAM HC

BX MEDA PHARMS 1%; 1% A086195 001

CREAM; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 0.5%; 1% A083778 001

1%; 1% A085368 001

LOTION; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 1%; 1% A085980 001

2.5%; 1% A085979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

U-CORT

TARO 1%; 10% A089472 001 Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

HYDROCORTISONE BUTYRATE**AB1** TARO PHARM INDS **0.1%** **A076654 001** Aug 03, 2005LOCOID**AB1** + PRECISION DERMAT **0.1%** **N018514 001** Mar 31, 1982HYDROCORTISONE BUTYRATE**AB2** GLENMARK GENERICS **0.1%** **A202145 001** Sep 27, 2013LOCOID LIPOCREAM**AB2** + PRECISION DERMAT **0.1%** **N020769 001** Sep 08, 1997

LOTION; TOPICAL

LOCOID

+ PRECISION DERMAT 0.1% N022076 001 May 18, 2007

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATE**AB** TARO **0.1%** **A076842 001** Dec 27, 2004LOCOID**AB** + PRECISION DERMAT **0.1%** **N018652 001** Oct 29, 1982

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE**AT** TARO PHARM INDS **0.1%** **A076364 001** Jan 14, 2004LOCOID**AT** + PRECISION DERMAT **0.1%** **N019116 001** Feb 25, 1987



## PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

+ FOUGERA PHARMS 0.1%

N020453 001 Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORTAP HOSPIRAEQ 100MG BASE/VIALA040666 001 Apr 06, 2006SOLU-CORTEFAP + PHARMACIA AND UPJOHNEQ 1GM BASE/VIALN009866 004AP +EQ 100MG BASE/VIALN009866 001AP +EQ 250MG BASE/VIALN009866 002AP +EQ 500MG BASE/VIALN009866 003HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATEAB PERRIGO NEW YORK0.2%A075666 001 May 24, 2000AB + TARO0.2%A075042 001 Aug 25, 1998

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

+ TARO 0.2%

A075043 001 Aug 25, 1998

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORINAT + MONARCH PHARMS1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLN050479 001NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONEAT ALCON PHARMS LTD1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA062423 001 Aug 25, 1983AT BAUSCH AND LOMB1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA064053 001 Dec 29, 1995AT LUITPOLD1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA065216 001 Oct 31, 2005

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

+ ALCON PHARMS LTD 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062874 001 May 11, 1988

SUSPENSION/DROPS; OTIC

CORTISPORINAT + CITRON PHARMA LLC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA060613 001NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONEAT ALCON PHARMS LTD1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA062488 001 Nov 06, 1985AT LUITPOLD1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA065219 001 May 01, 2006OTICAIRAT BAUSCH AND LOMB1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA064065 001 Aug 28, 1996PEDIOTICAT MONARCH PHARMS1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA062822 001 Sep 29, 1987HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURONAB + SHIRE LLC50MGN011949 001HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDIDAP + PURDUE PHARM PRODS1MG/MLN019034 003 Apr 30, 2009AP +2MG/MLN019034 004 Apr 30, 2009AP +4MG/MLN019034 005 Apr 30, 2009DILAUDID-HPAP + PURDUE PHARM PRODS10MG/MLN019034 001 Jan 11, 1984HYDROMORPHONE HYDROCHLORIDEAP AKORN10MG/MLA078228 001 Apr 14, 2010AP10MG/MLA078261 001 Apr 14, 2010AP BARR10MG/MLA076444 001 Apr 25, 2003AP HOSPIRA10MG/MLA074598 001 Jun 19, 1997AP HOSPIRA INC1MG/MLN200403 001 Dec 01, 2011AP2MG/MLN200403 002 Dec 01, 2011AP4MG/MLN200403 003 Dec 01, 2011AP10MG/MLA078591 001 Jun 17, 2008

DILAUDID-HP

+ PURDUE PHARM PRODS 250MG/VIAL

N019034 002 Aug 04, 1994

SOLUTION; ORAL

DILAUDIDAA + PURDUE PHARM PRODS5MG/5MLN019891 001 Dec 07, 1992

## PRESCRIPTION DRUG PRODUCT LIST

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

**AA** ROXANE **5MG/5ML** **A074653 001** Jul 29, 1998  
 TABLET; ORAL

DILAUDID

**AB** PURDUE PHARM PRODS **2MG** **N019892 003** Nov 09, 2007  
**AB** **4MG** **N019892 002** Nov 09, 2007  
**AB** + **8MG** **N019892 001** Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

**AB** ELITE LABS **8MG** **A076723 001** Oct 18, 2005  
**AB** LANNETT **2MG** **A078439 001** Dec 09, 2009  
**AB** **4MG** **A078439 002** Dec 09, 2009  
**AB** **8MG** **A077471 001** Dec 09, 2009  
**AB** MALLINCKRODT **8MG** **A076855 001** Dec 23, 2004  
**AB** MALLINCKRODT INC **2MG** **A078273 001** Sep 19, 2007  
**AB** **4MG** **A078273 002** Sep 19, 2007  
**AB** ROXANE **4MG** **A074597 003** May 29, 2009  
**AB** **8MG** **A074597 001** Jul 29, 1998

TABLET, EXTENDED RELEASE; ORAL

EXALGO

**AB** MALLINCKRODT INC **8MG** **N021217 001** Mar 01, 2010  
**AB** **12MG** **N021217 002** Mar 01, 2010  
**AB** **16MG** **N021217 003** Mar 01, 2010

HYDROMORPHONE HYDROCHLORIDE

**AB** ACTAVIS LABS FL INC **8MG** **A202144 001** May 12, 2014  
**AB** **12MG** **A202144 002** May 12, 2014  
**AB** **16MG** **A202144 003** May 12, 2014

EXALGO  
 + MALLINCKRODT INC 32MG N021217 004 Aug 24, 2012

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

+ MERCK SANTE SAS 5GM/VIAL (5GM/KIT) N022041 001 Apr 08, 2011

HYDROXOCOBALAMIN

+ WATSON LABS 1MG/ML A085998 001

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+ AKORN 1%; 0.25% N019261 001 Jan 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

**AB** HIKMA PHARMS LLC **200MG** **A040760 001** Aug 15, 2007  
**AB** IPCA LABS LTD **200MG** **A040766 001** Jun 14, 2007  
**AB** MYLAN **200MG** **A040274 001** May 29, 1998  
**AB** SANDOZ **200MG** **A040104 001** Nov 30, 1995  
**AB** TEVA PHARMS **200MG** **A040081 001** Sep 30, 1994  
**AB** ZYDUS PHARMS USA INC **200MG** **A040657 001** Sep 21, 2007

PLAQUENIL

**AB** + SANOFI AVENTIS US **200MG** **N009768 001**

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+ LUMARA HEALTH INC 1250MG/5ML (250MG/ML) N021945 001 Feb 03, 2011

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+ ATON 5MG N018771 001

HYDROXYUREA

CAPSULE; ORAL

HYDREA

**AB** + BRISTOL MYERS SQUIBB **500MG** **N016295 001**

HYDROXYUREA

**AB** BARR **500MG** **A075143 001** Oct 16, 1998  
**AB** PAR PHARM **500MG** **A075340 001** Feb 24, 1999

DROXIA  
 BRISTOL MYERS SQUIBB 200MG N016295 002 Feb 25, 1998  
 300MG N016295 003 Feb 25, 1998

## PRESCRIPTION DRUG PRODUCT LIST

HYDROXYUREACAPSULE; ORAL  
DROXIA

400MG

N016295 004 Feb 25, 1998

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

AP + FRESENIUS KABI USA 25MG/ML  
AP + 50MG/ML  
AP LUITPOLD 25MG/ML  
AP 50MG/ML

A087329 001  
A087329 002  
A087408 001  
A087408 002

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA + HI TECH PHARMA 10MG/5ML  
AA SILARX PHARMS INC 10MG/5ML  
AA + VINTAGE PHARMS 10MG/5ML  
AA + WOCKHARDT 10MG/5ML

A040010 001 Oct 28, 1994  
A201674 001 Aug 21, 2013  
A040391 001 Apr 10, 2002  
A087294 001 Apr 12, 1982

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB AMNEAL PHARM 10MG A040808 001 Sep 24, 2008  
AB 25MG A040808 002 Sep 24, 2008  
AB 50MG A040808 003 Sep 24, 2008  
AB EMCURE PHARMS USA 10MG A204279 001 Aug 20, 2014  
AB 25MG A204279 002 Aug 20, 2014  
AB 50MG A204279 003 Aug 20, 2014  
AB HERITAGE PHARMS INC 10MG A040804 001 Jun 30, 2008  
AB 25MG A040804 002 Jun 30, 2008  
AB 50MG A040804 003 Jun 30, 2008  
AB HETERO LABS LTD III 10MG A040805 001 May 29, 2008  
AB 25MG A040805 002 May 29, 2008  
AB 50MG A040805 003 May 29, 2008  
AB INVAGEN PHARMS 10MG A040812 001 Mar 12, 2008  
AB 25MG A040812 002 Mar 12, 2008  
AB 50MG A040812 003 Mar 12, 2008  
AB KVK TECH 10MG A040786 001 Mar 20, 2007  
AB 25MG A040787 001 Mar 20, 2007  
AB 50MG A040788 001 Mar 20, 2007  
AB MUTUAL PHARM 10MG A089381 001 May 19, 1986  
AB 25MG A089382 001 May 19, 1986  
AB 50MG A089383 001 May 19, 1986  
AB MYLAN 10MG A091176 001 Jun 07, 2010  
AB 25MG A091176 002 Jun 07, 2010  
AB 50MG A091176 003 Jun 07, 2010  
AB NORTHSTAR HLTHCARE 10MG A040841 001 Mar 31, 2008  
AB 25MG A040842 001 Mar 31, 2008  
AB 50MG A040840 001 Mar 31, 2008  
AB + PLIVA 10MG A088617 001 Jan 10, 1986  
AB + 25MG A088618 001 Jan 10, 1986  
AB + 50MG A088619 001 Jan 10, 1986  
AB SUN PHARM INDS INC 10MG A040899 001 Jun 10, 2008  
AB 25MG A040899 002 Jun 10, 2008  
AB 50MG A040899 003 Jun 10, 2008  
AB VINTAGE PHARMS 10MG A040579 001 May 27, 2005  
AB 25MG A040574 001 May 27, 2005  
AB 50MG A040580 001 May 27, 2005  
AB WATSON LABS 10MG A088348 001 Sep 15, 1983  
AB 25MG A088349 001 Sep 15, 1983  
AB 50MG A088350 001 Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB BARR EQ 25MG HCL A088496 001 Jun 15, 1984  
AB EQ 50MG HCL A088487 001 Jun 15, 1984  
AB EMCURE PHARMS USA EQ 25MG HYDROCHLORIDE A201507 001 Jun 03, 2013  
AB EQ 50MG HYDROCHLORIDE A201507 002 Jun 03, 2013  
AB SANDOZ EQ 25MG HCL A087479 001  
AB EQ 50MG HCL A086183 001  
AB WATSON LABS EQ 25MG HCL A040156 001 Jul 15, 1996  
AB EQ 50MG HCL A040156 002 Jul 15, 1996

VISTARILAB PFIZER EQ 25MG HCLN011459 002

## PRESCRIPTION DRUG PRODUCT LIST

HYDROXYZINE PAMOATE

CAPSULE; ORAL

VISTARIL

<u>AB</u>	+		<u>EQ 50MG HCL</u>	<u>N011459</u>	<u>004</u>	
		HYDROXYZINE PAMOATE				
		BARR	EQ 100MG HCL	A088488	001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

<u>AP</u>	+	ROCHE	<u>EQ 3MG BASE/3ML</u>	<u>N021858</u>	<u>001</u>	Jan 06, 2006
-----------	---	-------	------------------------	----------------	------------	--------------

IBANDRONATE SODIUM

<u>AP</u>		AGILA SPECLTS	<u>EQ 3MG BASE/3ML</u>	<u>A202671</u>	<u>001</u>	Sep 02, 2014
<u>AP</u>		EMCURE PHARMS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A203987</u>	<u>001</u>	Sep 02, 2014
<u>AP</u>		SAGENT PHARMS	<u>EQ 3MG BASE/3ML</u>	<u>A202235</u>	<u>001</u>	Sep 02, 2014
<u>AP</u>		SUN PHARM INDS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A090853</u>	<u>001</u>	Feb 14, 2014

TABLET; ORAL

BONIVA

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>EQ 150MG BASE</u>	<u>N021455</u>	<u>002</u>	Mar 24, 2005
-----------	---	-------------------	----------------------	----------------	------------	--------------

IBANDRONATE SODIUM

<u>AB</u>		APOTEX INC	<u>EQ 150MG BASE</u>	<u>A078948</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A078997</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>		MUTUAL PHARM CO INC	<u>EQ 150MG BASE</u>	<u>A078996</u>	<u>001</u>	Aug 15, 2012
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A078995</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 150MG BASE</u>	<u>A078998</u>	<u>001</u>	Mar 19, 2012
<u>AB</u>		WATSON LABS INC	<u>EQ 150MG BASE</u>	<u>A079003</u>	<u>001</u>	Mar 20, 2012

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

	+	PHARMACYCLICS INC	140MG	N205552	001	Nov 13, 2013
--	---	-------------------	-------	---------	-----	--------------

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

	+	CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009
--	---	-------------------	----------------------	---------	-----	--------------

SUSPENSION; ORAL

IBUPROFEN

<u>AB</u>	+	ACTAVIS MID ATLANTIC	<u>100MG/5ML</u>	<u>A074978</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>		PERRIGO R AND D	<u>100MG/5ML</u>	<u>A076925</u>	<u>001</u>	Sep 23, 2004

TABLET; ORAL

IBU-TAB

<u>AB</u>		ALRA	<u>400MG</u>	<u>A071058</u>	<u>001</u>	Aug 11, 1988
<u>AB</u>			<u>600MG</u>	<u>A071059</u>	<u>001</u>	Aug 11, 1988

IBUPROFEN

<u>AB</u>		AMNEAL PHARMS NY	<u>400MG</u>	<u>A071334</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>			<u>400MG</u>	<u>A078558</u>	<u>001</u>	Jun 18, 2007
<u>AB</u>			<u>600MG</u>	<u>A071335</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>			<u>600MG</u>	<u>A078558</u>	<u>002</u>	Jun 18, 2007
<u>AB</u>			<u>800MG</u>	<u>A071935</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>			<u>800MG</u>	<u>A078558</u>	<u>003</u>	Jun 18, 2007
<u>AB</u>		CONTRACT PHARMACAL	<u>400MG</u>	<u>A071267</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>			<u>600MG</u>	<u>A071268</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>			<u>800MG</u>	<u>A072300</u>	<u>001</u>	Jul 01, 1988
<u>AB</u>		DR REDDYS LA	<u>400MG</u>	<u>A075682</u>	<u>001</u>	Nov 14, 2001
<u>AB</u>			<u>600MG</u>	<u>A075682</u>	<u>002</u>	Nov 14, 2001
<u>AB</u>	+		<u>800MG</u>	<u>A075682</u>	<u>003</u>	Nov 14, 2001
<u>AB</u>		DR REDDYS LABS INC	<u>400MG</u>	<u>A076112</u>	<u>001</u>	Oct 31, 2001
<u>AB</u>			<u>600MG</u>	<u>A076112</u>	<u>002</u>	Oct 31, 2001
<u>AB</u>			<u>800MG</u>	<u>A076112</u>	<u>003</u>	Oct 31, 2001
<u>AB</u>		MARKSANS PHARMA	<u>400MG</u>	<u>A090796</u>	<u>001</u>	Dec 21, 2010
<u>AB</u>			<u>600MG</u>	<u>A090796</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>			<u>800MG</u>	<u>A090796</u>	<u>003</u>	Dec 21, 2010
<u>AB</u>		PERRIGO R AND D	<u>400MG</u>	<u>A077114</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>			<u>600MG</u>	<u>A077114</u>	<u>002</u>	Jul 18, 2005
<u>AB</u>			<u>800MG</u>	<u>A077114</u>	<u>003</u>	Jul 18, 2005
<u>AB</u>		SHASUN USA	<u>400MG</u>	<u>A078329</u>	<u>001</u>	Feb 05, 2009
<u>AB</u>			<u>600MG</u>	<u>A078329</u>	<u>002</u>	Feb 05, 2009
<u>AB</u>			<u>800MG</u>	<u>A078329</u>	<u>003</u>	Feb 05, 2009
<u>AB</u>		VINTAGE PHARMS	<u>300MG</u>	<u>A071230</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>			<u>400MG</u>	<u>A071231</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>			<u>400MG</u>	<u>A071644</u>	<u>001</u>	Feb 01, 1988
<u>AB</u>			<u>600MG</u>	<u>A071232</u>	<u>001</u>	Oct 22, 1986
<u>AB</u>			<u>800MG</u>	<u>A072004</u>	<u>001</u>	Nov 18, 1987

## PRESCRIPTION DRUG PRODUCT LIST

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ RECORDATI RARE EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N021903 001 Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN**AB** ACTAVIS ELIZABETH **400MG; 5MG** **A078769 001** Jan 04, 2008**AB** + BARR LABS INC **400MG; 5MG** **A078316 001** Nov 29, 2007**AB** WATSON LABS **400MG; 5MG** **A078394 001** Nov 26, 2007IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT**AP** + PHARMACIA AND UPJOHN **0.1MG/ML** **N020491 001** Dec 28, 1995IBUTILIDE FUMARATE**AP** LUITPOLD **0.1MG/ML** **A090240 001** Jan 11, 2010**AP** MYLAN INSTITUTIONAL **0.1MG/ML** **A090643 001** Jan 11, 2010**AP** **0.1MG/ML** **A090924 001** Jan 11, 2010ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

+ SHIRE ORPHAN THERAP EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N022150 001 Aug 25, 2011

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

EXTRANEAL

+ BAXTER HLTHCARE 7.5GM/100ML N021321 001 Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMS 1GM N202057 001 Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFS**AP** + PHARMACIA AND UPJOHN **1MG/ML** **N050734 001** Feb 17, 1997IDARUBICIN HYDROCHLORIDE**AP** EUROHLTH INTL **1MG/ML** **A065275 001** Dec 14, 2006**AP** **1MG/ML** **A065288 001** May 15, 2007**AP** FRESENIUS KABI USA **1MG/ML** **A065440 001** Aug 04, 2009**AP** ONCO THERAPIES LTD **1MG/ML** **A200144 001** Oct 11, 2012IDARUBICIN HYDROCHLORIDE PFS**AP** TEVA PHARMS USA **1MG/ML** **A065036 001** May 01, 2002IDELALISIB

TABLET; ORAL

ZYDELIG

GILEAD SCIENCES INC 100MG N205858 001 Jul 23, 2014

+ 150MG N205858 002 Jul 23, 2014

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

DENDRID**AT** + ALCON **0.1%** **N014169 001**HERPLEX**AT** + ALLERGAN **0.1%** **N013935 002**IFOSFAMIDE

INJECTABLE; INJECTION

IFEX**AP** BAXTER HLTHCARE **1GM/VIAL** **N019763 001** Dec 30, 1988**AP** **3GM/VIAL** **N019763 002** Dec 30, 1988IFOSFAMIDE**AP** EUROHLTH INTL **1GM/20ML (50MG/ML)** **A076619 001** Jun 29, 2011**AP** **3GM/60ML (50MG/ML)** **A076619 002** Jun 29, 2011**AP** + FRESENIUS KABI USA **1GM/VIAL** **A076078 001** May 28, 2002**AP** **1GM/20ML (50MG/ML)** **A090181 001** Sep 22, 2009**AP** + **3GM/VIAL** **A076078 002** May 28, 2002**AP** **3GM/60ML (50MG/ML)** **A090181 002** Sep 22, 2009**AP** ONCO THERAPIES LTD **1GM/20ML (50MG/ML)** **A201689 001** Nov 26, 2012**AP** **3GM/60ML (50MG/ML)** **A201689 002** Nov 26, 2012**AP** + TEVA PHARMS USA **1GM/20ML (50MG/ML)** **A076657 001** Apr 04, 2007**AP** + **3GM/60ML (50MG/ML)** **A076657 002** Apr 04, 2007

## PRESCRIPTION DRUG PRODUCT LIST

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+ TEVA PHARMS USA

+

1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)

A075874 001 Feb 26, 2002

3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)

A075874 002 Feb 26, 2002

ILOPERIDONE

TABLET; ORAL

FANAPT

+ NOVARTIS

1MG

N022192 001 May 06, 2009

2MG

N022192 002 May 06, 2009

4MG

N022192 003 May 06, 2009

6MG

N022192 004 May 06, 2009

8MG

N022192 005 May 06, 2009

10MG

N022192 006 May 06, 2009

12MG

N022192 007 May 06, 2009

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+ ACTELION PHARMS LTD

10MCG/ML (10MCG/ML)

N021779 002 Dec 08, 2005

+

20MCG/ML (20MCG/ML)

N021779 003 Aug 07, 2009

IMATINIB MESYLATE

TABLET; ORAL

GLEEVEC

NOVARTIS

EQ 100MG BASE

N021588 001 Apr 18, 2003

+

EQ 400MG BASE

N021588 002 Apr 18, 2003

IMIGLUCERASE

INJECTABLE; INJECTION

CEREZYME

GENZYME

200 UNITS/VIAL

N020367 001 May 23, 1994

+

400 UNITS/VIAL

N020367 002 Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE**AB** EXCELLIUM**10MG****A040903 001** Oct 24, 2012**AB****25MG****A040903 002** Oct 24, 2012**AB****50MG****A040903 003** Oct 24, 2012**AB** LUPIN LTD**10MG****A090443 001** Mar 11, 2010**AB****25MG****A090442 001** Mar 11, 2010**AB****50MG****A090441 001** Mar 11, 2010**AB** MUTUAL PHARM**10MG****A081048 001** Jun 05, 1990**AB****25MG****A081049 001** Jun 05, 1990**AB****50MG****A081050 001** Jun 05, 1990**AB** PAR PHARM**10MG****A088292 001** Oct 21, 1983**AB****10MG****A089422 001** Jul 14, 1987**AB****25MG****A088262 001** Oct 21, 1983**AB****50MG****A088276 001** Oct 21, 1983**AB** SANDOZ**10MG****A084936 002****AB****25MG****A083745 001****AB****50MG****A084937 001**TOFRANIL**AB** MALLINCKRODT INC**10MG****A087844 001** May 22, 1984**AB****25MG****A087845 001** May 22, 1984**AB** +**50MG****A087846 001** May 22, 1984IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE**AB** LUPIN LTD**EQ 75MG HCL****A090444 001** Apr 16, 2010**AB****EQ 100MG HCL****A090444 002** Apr 16, 2010**AB****EQ 125MG HCL****A090444 003** Apr 16, 2010**AB****EQ 150MG HCL****A090444 004** Apr 16, 2010**AB** MYLAN PHARMS INC**EQ 75MG HCL****A202338 001** Jun 28, 2013**AB****EQ 100MG HCL****A202338 002** Jun 28, 2013**AB****EQ 125MG HCL****A202338 003** Jun 28, 2013**AB****EQ 150MG HCL****A202338 004** Jun 28, 2013**AB** ROXANE**EQ 75MG HCL****A091099 001** Apr 16, 2010**AB****EQ 100MG HCL****A091099 002** Apr 16, 2010**AB****EQ 125MG HCL****A091099 003** Apr 16, 2010**AB****EQ 150MG HCL****A091099 004** Apr 16, 2010

## PRESCRIPTION DRUG PRODUCT LIST

IMIPRAMINE PAMOATE

CAPSULE; ORAL

TOFRANIL-PM

<u>AB</u>	+	MALLINCKRODT INC	<u>EQ 75MG HCL</u>	<u>N017090 001</u>	
<u>AB</u>			<u>EQ 100MG HCL</u>	<u>N017090 004</u>	
<u>AB</u>			<u>EQ 125MG HCL</u>	<u>N017090 003</u>	
<u>AB</u>			<u>EQ 150MG HCL</u>	<u>N017090 002</u>	

IMIQUIMOD

CREAM; TOPICAL

ALDARA

<u>AB</u>	+	MEDICIS	<u>5%</u>	<u>N020723 001</u>	Feb 27, 1997
<u>IMIQUIMOD</u>					
<u>AB</u>		APOTEX INC	<u>5%</u>	<u>A091308 001</u>	Apr 06, 2012
<u>AB</u>		FOUGERA PHARMS	<u>5%</u>	<u>A078548 001</u>	Feb 25, 2010
<u>AB</u>		GLENMARK GENERICS	<u>5%</u>	<u>A201994 001</u>	Mar 06, 2012
<u>AB</u>		PERRIGO ISRAEL	<u>5%</u>	<u>A078837 001</u>	Sep 07, 2010
<u>AB</u>		STRIDES PHARMA	<u>5%</u>	<u>A202002 001</u>	Jun 24, 2014
<u>AB</u>		TARO	<u>5%</u>	<u>A200173 001</u>	Apr 15, 2011
<u>AB</u>		TEVA PHARMS USA	<u>5%</u>	<u>A200481 001</u>	Apr 18, 2011
<u>AB</u>		TOLMAR	<u>5%</u>	<u>A091044 001</u>	Feb 28, 2011
<u>ZYCLARA</u>					
	+	MEDICIS	2.5%	N022483 002	Jul 15, 2011
	+		3.75%	N022483 001	Mar 25, 2010

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

+	EUROHLTH INTL	EQ 5MG BASE/ML	A075513 001	May 09, 2000
---	---------------	----------------	-------------	--------------

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+	NOVARTIS	EQ 75MCG BASE	N022383 001	Jul 01, 2011
---	----------	---------------	-------------	--------------

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>1.25MG</u>	<u>A074722 001</u>	Jun 17, 1996
<u>AB</u>			<u>2.5MG</u>	<u>A074722 002</u>	Jun 17, 1996
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>1.25MG</u>	<u>A074299 002</u>	Apr 29, 1996
<u>AB</u>			<u>2.5MG</u>	<u>A074299 001</u>	Jul 27, 1995
<u>AB</u>		MYLAN	<u>1.25MG</u>	<u>A074461 002</u>	Mar 26, 1997
<u>AB</u>	+		<u>2.5MG</u>	<u>A074461 001</u>	Mar 27, 1996
<u>AB</u>		MYLAN PHARMS INC	<u>1.25MG</u>	<u>A075105 001</u>	Jul 23, 1998
<u>AB</u>			<u>2.5MG</u>	<u>A075105 002</u>	Jul 23, 1998

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

+	MERCK SHARP DOHME	EQ 200MG BASE	N020685 003	Mar 13, 1996
+		EQ 400MG BASE	N020685 001	Mar 13, 1996

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+	GE HEALTHCARE	2mCi/0.2ML	N019862 001	Dec 29, 1992
+	MALLINCKRODT	5mCi/0.5ML	N019841 001	Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN-111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044 001	Dec 24, 1985
---	---------------	---------	-------------	--------------

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+	GE HEALTHCARE	1mCi/ML	N017707 001	Feb 18, 1982
---	---------------	---------	-------------	--------------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+	MALLINCKRODT	3mCi/ML	N020314 001	Jun 02, 1994
---	--------------	---------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREENAP + AKORN 25MG/VIAL N011525 001INDOCYANINE GREENAP PULSION MEDCL 25MG/VIAL A040811 001 Nov 21, 2007INDOMETHACIN

CAPSULE; ORAL

INDOMETHACINAB GLENMARK GENERICS 25MG A091276 001 Dec 22, 2010AB 50MG A091276 002 Dec 22, 2010AB HERITAGE PHARMS INC 25MG N018851 001 May 18, 1984AB 50MG N018851 002 May 18, 1984AB HETERO LABS LTD III 25MG A091240 001 Apr 12, 2011AB 50MG A091240 002 Apr 12, 2011AB IVAX SUB TEVA PHARMS 25MG A070719 001 Feb 12, 1986AB 50MG A070756 001 Feb 12, 1986AB MYLAN 25MG N018858 001 Apr 20, 1984AB + 50MG A070624 001 Sep 04, 1985AB SANDOZ 25MG A070673 001 Apr 29, 1987AB 50MG A070674 001 Apr 29, 1987AB SUN PHARM INDS INC 25MG A091401 001 Mar 28, 2013AB 50MG A091401 002 Mar 28, 2013AB ZYDUS PHARMS USA INC 25MG A090403 001 Nov 15, 2010AB 50MG A090403 002 Nov 15, 2010

TIVORBEX

IROKO PHARMS LLC 20MG

N204768 001 Feb 24, 2014

+ 40MG

N204768 002 Feb 24, 2014

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACINAB AMNEAL PHARMS 75MG A091549 001 Dec 01, 2010AB AVANTHI INC 75MG A079175 001 Mar 06, 2009AB HETERO LABS LTD III 75MG A201807 001 Sep 28, 2012AB MYLAN PHARMS INC 75MG A202139 001 Mar 20, 2014AB PADDOCK LLC 75MG A200529 001 Nov 30, 2010AB + SANDOZ 75MG A074464 001 May 28, 1998AB WATSON LABS INC 75MG A202572 001 Dec 09, 2013

INJECTABLE; INJECTION

## INDOMETHACIN

+ FRESENIUS KABI USA EQ 1MG BASE/VIAL

N022536 001 Mar 17, 2010

SUPPOSITORY; RECTAL

## INDOMETHACIN

+ G AND W LABS 50MG

A073314 001 Aug 31, 1992

SUSPENSION; ORAL

## INDOCIN

+ IROKO PHARMS 25MG/5ML

N018332 001 Oct 10, 1985

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCINAP + RECORDATI RARE EQ 1MG BASE/VIAL N018878 001 Jan 30, 1985INDOMETHACIN SODIUMAP EUROHLTH INTL EQ 1MG BASE/VIAL A078713 001 Jul 16, 2008INGENOL MEBUTATE

GEL; TOPICAL

## PICATO

LEO PHARMA AS 0.015%

N202833 001 Jan 23, 2012

+ 0.05%

N202833 002 Jan 23, 2012

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

## NOVOLOG MIX 70/30

+ NOVO NORDISK INC 700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)

N021172 001 Nov 01, 2001

## NOVOLOG MIX 70/30 FLEXPEN

+ NOVO NORDISK INC 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 004 May 03, 2002



**PRESCRIPTION DRUG PRODUCT LIST**INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+ NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N020986 001	Jun 07, 2000
NOVOLOG FLEXPEN			
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 003	Jan 19, 2001
NOVOLOG FLEXTOUCH			
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 005	Oct 31, 2013
NOVOLOG PENFILL			
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 002	Jun 07, 2000

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR

+ NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N021536 001	Jun 16, 2005
LEVEMIR FLEXPEN			
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 002	Jun 16, 2005
LEVEMIR FLEXTOUCH			
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 005	Oct 31, 2013

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+ SANOFI AVENTIS US	100 UNITS/ML	N021081 001	Apr 20, 2000
LANTUS SOLOSTAR			
+ SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021081 002	Apr 27, 2007

INSULIN GLULISINE RECOMBINANT

INJECTABLE; IV (INFUSION), SUBCUTANEOUS

APIDRA

+ SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N021629 001	Apr 16, 2004
+ SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021629 002	Dec 20, 2005

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

SANOFI AVENTIS US	300 UNITS/3ML	N021629 003	Feb 24, 2009
-------------------	---------------	-------------	--------------

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+ LILLY	50 UNITS/ML; 50 UNITS/ML	N021018 001	Dec 22, 1999
---------	--------------------------	-------------	--------------

HUMALOG MIX 50/50 KWIKPEN

+ LILLY	50 UNITS/ML; 50 UNITS/ML	N021018 002	Sep 06, 2007
---------	--------------------------	-------------	--------------

HUMALOG MIX 75/25

+ LILLY	75 UNITS/ML; 25 UNITS/ML	N021017 001	Dec 22, 1999
---------	--------------------------	-------------	--------------

HUMALOG MIX 75/25 KWIKPEN

+ LILLY	75 UNITS/ML; 25 UNITS/ML	N021017 002	Sep 06, 2007
---------	--------------------------	-------------	--------------

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

+ LILLY	100 UNITS/ML	N020563 001	Jun 14, 1996
---------	--------------	-------------	--------------

HUMALOG KWIKPEN

+ LILLY	100 UNITS/ML	N020563 003	Sep 06, 2007
---------	--------------	-------------	--------------

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R

+ LILLY	500 UNITS/ML	N018780 004	Mar 31, 1994
---------	--------------	-------------	--------------

POWDER; INHALATION

AFREZZA

SANOFI AVENTIS	4 UNITS/INH	N022472 001	Jun 27, 2014
----------------	-------------	-------------	--------------

+ SANOFI AVENTIS	8 UNITS/INH	N022472 002	Jun 27, 2014
------------------	-------------	-------------	--------------

IOBENGUANE SULFATE I-123

SOLUTION; INTRAVENOUS

ADREVIEW

+ GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290 001	Sep 19, 2008
-----------------	---------------------	-------------	--------------

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

+ BRACCO	52%	N009321 003	
----------	-----	-------------	--

## PRESCRIPTION DRUG PRODUCT LIST

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

+ GE HEALTHCARE

55%

N020351 001 Mar 22, 1996

55%

N020808 001 Aug 29, 1997

VISIPAQUE 320

+ GE HEALTHCARE

65.2%

N020351 002 Mar 22, 1996

65.2%

N020808 002 Aug 29, 1997

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+ GE HLTHCARE INC

5mCi/2.5ML (2mCi/ML)

N022454 001 Jan 14, 2011

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 140

+ GE HEALTHCARE

30.2%

N018956 005 Nov 30, 1988

SOLUTION; INJECTION, ORAL

OMNIPAQUE 350

+ GE HEALTHCARE

75.5%

N018956 004 Dec 26, 1985

75.5%

N020608 003 Oct 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180

+ GE HEALTHCARE

38.8%

N018956 001 Dec 26, 1985

OMNIPAQUE 240

+ GE HEALTHCARE

51.8%

N018956 002 Dec 26, 1985

51.8%

N020608 001 Oct 24, 1995

OMNIPAQUE 300

+ GE HEALTHCARE

64.7%

N018956 003 Dec 26, 1985

64.7%

N020608 002 Oct 24, 1995

IOPAMIDOL

INJECTABLE; INJECTION

**IOPAMIDOL-250****AP** FRESENIUS KABI USA**51%****A074679 001** Apr 02, 1997**IOPAMIDOL-300****AP** FRESENIUS KABI USA**61%****A074679 002** Apr 02, 1997**IOPAMIDOL-370****AP** FRESENIUS KABI USA**76%****A074679 003** Apr 02, 1997**ISOVUE-200****AP** + BRACCO**41%****N018735 006** Jul 07, 1987**ISOVUE-250****AP** + BRACCO**51%****N018735 007** Jul 06, 1992**AP** +**51%****N020327 002** Oct 12, 1994**ISOVUE-300****AP** + BRACCO**61%****N018735 002** Dec 31, 1985**AP** +**61%****N020327 003** Oct 12, 1994**ISOVUE-370****AP** + BRACCO**76%****N018735 003** Dec 31, 1985**AP** +**76%****N020327 004** Oct 12, 1994**SCANLUX-300****AP** SANOCHEMIA CORP USA**61%****A090394 001** Jun 18, 2010**SCANLUX-370****AP** SANOCHEMIA CORP USA**76%****A090394 002** Jun 18, 2010

ISOVUE-M 200

+ BRACCO

41%

N018735 001 Dec 31, 1985

ISOVUE-M 300

+ BRACCO

61%

N018735 004 Dec 31, 1985

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+ BAYER HLTHCARE

49.9%

N021425 003 Mar 12, 2004

+

62.3%

N021425 001 Sep 20, 2002

+

76.9%

N021425 002 Sep 20, 2002

ULTRAVIST 150

+ BAYER HLTHCARE

31.2%

N020220 004 May 10, 1995

ULTRAVIST 240

+ BAYER HLTHCARE

49.9%

N020220 003 May 10, 1995

ULTRAVIST 300

+ BAYER HLTHCARE

62.3%

N020220 002 May 10, 1995

ULTRAVIST 300 IN PLASTIC CONTAINER

+ BAYER HLTHCARE

62.3%

N020220 005 Nov 18, 2008

## PRESCRIPTION DRUG PRODUCT LIST

IOPROMIDE

INJECTABLE; INJECTION  
 ULTRAVIST 370  
 + BAYER HLTHCARE 76.9% N020220 001 May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION  
 CONRAY  
 + MALLINCKRODT 60% N013295 001  
 CONRAY 30  
 + MALLINCKRODT 30% N016983 001  
 CONRAY 43  
 + MALLINCKRODT 43% N013295 002  
 SOLUTION; INTRAVESICAL  
 CYSTO-CONRAY II  
 MALLINCKRODT 17.2% N017057 002

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION  
 GLOFIL-125  
 ISOTEX 250-300uCi/ML N017279 001

IOVERSOL

INJECTABLE; INJECTION  
 OPTIRAY 240  
 + MALLINCKRODT 51% N019710 002 Dec 30, 1988  
 OPTIRAY 300  
 + MALLINCKRODT 64% N019710 004 Jan 22, 1992  
 + 64% N020923 004 May 13, 1999  
 OPTIRAY 320  
 + MALLINCKRODT 68% N019710 001 Dec 30, 1988  
 OPTIRAY 350  
 + MALLINCKRODT 74% N019710 005 Jan 22, 1992  
 + 74% N020923 003 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION  
 HEXABRIX  
 + GUERBET 39.3%; 19.6% N018905 002 Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION  
 OXILAN-300  
 GUERBET 62% N020316 001 Dec 21, 1995  
 OXILAN-350  
 GUERBET 73% N020316 002 Dec 21, 1995

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION  
 ATROVENT HFA  
 + BOEHRINGER INGELHEIM 0.021MG/INH N021527 001 Nov 27, 2004

IPRATROPIUM BROMIDE

**AN** BAUSCH AND LOMB **0.02%** **A075835 001** Oct 15, 2001  
**AN** LANDELA PHARM **0.02%** **A077072 001** Jul 19, 2005  
**AN** + MYLAN SPECLT **0.02%** **A074755 001** Jan 10, 1997  
**AN** NEPHRON **0.02%** **A075562 001** Sep 27, 2001  
**AN** RITEDOSE CORP **0.02%** **A075693 001** Jan 26, 2001  
**AN** WATSON LABS **0.02%** **A076291 001** May 09, 2005

## SPRAY, METERED; NASAL

ATROVENT

**AB** + BOEHRINGER INGELHEIM **0.021MG/SPRAY** **N020393 001** Oct 20, 1995  
**AB** + **0.042MG/SPRAY** **N020394 001** Oct 20, 1995

IPRATROPIUM BROMIDE

**AB** BAUSCH AND LOMB **0.021MG/SPRAY** **A076025 001** Mar 31, 2003  
**AB** **0.042MG/SPRAY** **A076103 001** Mar 31, 2003  
**AB** MYLAN SPECLT **0.021MG/SPRAY** **A075552 001** Mar 31, 2003  
**AB** **0.042MG/SPRAY** **A075553 001** Mar 31, 2003  
**AB** ROXANE **0.021MG/SPRAY** **A076664 001** Nov 05, 2003  
**AB** **0.042MG/SPRAY** **A076598 001** Nov 05, 2003

## PRESCRIPTION DRUG PRODUCT LIST

IRBESARTAN

TABLET; ORAL

AVAPRO

<u>AB</u>	SANOFI AVENTIS US	<u>75MG</u>	<u>N020757 001</u>	Sep 30, 1997
<u>AB</u>		<u>150MG</u>	<u>N020757 002</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020757 003</u>	Sep 30, 1997

IRBESARTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>75MG</u>	<u>A091236 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A091236 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A091236 003</u>	Oct 15, 2012
<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A200832 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A200832 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A200832 003</u>	Oct 15, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A203081 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203081 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203081 003</u>	Sep 27, 2012
<u>AB</u>	CIPLA LTD	<u>75MG</u>	<u>A077205 001</u>	Nov 14, 2012
<u>AB</u>		<u>150MG</u>	<u>A077205 002</u>	Nov 14, 2012
<u>AB</u>		<u>300MG</u>	<u>A077205 003</u>	Nov 14, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>75MG</u>	<u>A203161 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203161 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203161 003</u>	Sep 27, 2012
<u>AB</u>	HETERO LABS LTD V	<u>75MG</u>	<u>A202910 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A202910 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A202910 003</u>	Sep 27, 2012
<u>AB</u>	LUPIN LTD	<u>75MG</u>	<u>A201531 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A201531 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A201531 003</u>	Oct 15, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>75MG</u>	<u>A202254 001</u>	Oct 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A202254 002</u>	Oct 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A202254 003</u>	Oct 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>75MG</u>	<u>A200461 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A200461 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A200461 003</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>75MG</u>	<u>A203071 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203071 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203071 003</u>	Sep 27, 2012
<u>AB</u>	ROXANE	<u>75MG</u>	<u>A090201 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A090201 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A090201 003</u>	Oct 15, 2012
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A077466 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A077466 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A077466 003</u>	Sep 27, 2012
<u>AB</u>	TEVA PHARMS	<u>75MG</u>	<u>A077159 001</u>	Mar 30, 2012
<u>AB</u>		<u>150MG</u>	<u>A077159 002</u>	Mar 30, 2012
<u>AB</u>		<u>300MG</u>	<u>A077159 003</u>	Mar 30, 2012
<u>AB</u>	WATSON LABS INC	<u>75MG</u>	<u>A090720 001</u>	Oct 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090720 002</u>	Oct 12, 2012
<u>AB</u>		<u>300MG</u>	<u>A090720 003</u>	Oct 12, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A079213 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A079213 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A079213 003</u>	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

<u>AP</u>	+	PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571 001</u>	Jun 14, 1996
<u>AP</u>	+		<u>100MG/5ML (20MG/ML)</u>	<u>N020571 002</u>	Jun 14, 1996

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068 001</u>	Nov 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A079068 002</u>	Nov 21, 2008
<u>AP</u>	ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589 001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078589 002</u>	Feb 27, 2008
<u>AP</u>	AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726 001</u>	Sep 16, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090726 002</u>	Sep 16, 2009
<u>AP</u>	BEDFORD LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A078753 001</u>	Dec 24, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078753 002</u>	Dec 24, 2008
<u>AP</u>	CIPLA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A077219 001</u>	Feb 20, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077219 002</u>	Feb 20, 2008
<u>AP</u>	DR REDDYS LABS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A078953 001</u>	Apr 15, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078953 002</u>	Apr 15, 2010
<u>AP</u>	EBEWE PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A090137 001</u>	Nov 12, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090137 002</u>	Nov 12, 2009

## PRESCRIPTION DRUG PRODUCT LIST

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	EMCURE PHARMS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A200771 001</u>	Feb 14, 2012
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A200771 002</u>	Feb 14, 2012
<u>AP</u>	FRESENIUS KABI ONCOL	<u>40MG/2ML (20MG/ML)</u>	<u>A078188 001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078188 002</u>	Feb 27, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>40MG/2ML (20MG/ML)</u>	<u>A077776 001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077776 002</u>	Feb 27, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032 001</u>	Dec 20, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A091032 002</u>	Dec 20, 2010
<u>AP</u>	HISUN PHARM HANGZHOU	<u>40MG/2ML (20MG/ML)</u>	<u>A090016 001</u>	Jan 28, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090016 002</u>	Jan 28, 2009
<u>AP</u>	HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915 001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077915 002</u>	Feb 27, 2008
<u>AP</u>	+	<u>500MG/25ML (20MG/ML)</u>	<u>A078796 001</u>	Feb 27, 2008
<u>AP</u>	JIANGSU HENGRUI MED	<u>40MG/2ML (20MG/ML)</u>	<u>A090675 002</u>	Dec 16, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090675 001</u>	Dec 16, 2011
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>40MG/2ML (20MG/ML)</u>	<u>A090393 002</u>	May 13, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090393 003</u>	May 13, 2011
<u>AP</u>	PLIVA LACHEMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078122 001</u>	Oct 31, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078122 002</u>	Oct 31, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>40MG/2ML (20MG/ML)</u>	<u>A078805 001</u>	Apr 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078805 002</u>	Apr 21, 2008
<u>AP</u>	TEVA PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A090101 002</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090101 003</u>	Feb 27, 2008
<u>AP</u>		<u>500MG/25ML (20MG/ML)</u>	<u>A090101 001</u>	Nov 26, 2008
	CAMPTOSAR			
	+	PFIZER INC	300MG/15ML (20MG/ML)	N020571 003 Aug 05, 2010

IRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

BP	LUITPOLD	EQ 50MG IRON/ML	N040024 001	Feb 23, 1996
	INFED			
BP	+	WATSON LABS (UTAH)	EQ 50MG IRON/ML	N017441 001
	PROFERDEX			
BP	NEW RIVER	EQ 50MG IRON/ML	N017807 001	

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

+

EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135 002	Mar 20, 2005
EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135 001	Nov 06, 2000
EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135 004	Feb 09, 2007

ISOCARBOXAZID

TABLET; ORAL

MARPLAN

+

VALIDUS PHARMS INC

10MG	N011961 001	
------	-------------	--

ISOFLURANE

LIQUID; INHALATION

FORANE

<u>AN</u>	+	BAXTER HLTHCARE	<u>99.9%</u>	<u>N017624 001</u>	
		<u>ISOFLURANE</u>			
<u>AN</u>		HALOCARBON PRODS	<u>99.9%</u>	<u>A075225 001</u>	Oct 20, 1999
<u>AN</u>		HOSPIRA	<u>99.9%</u>	<u>A074097 001</u>	Jan 25, 1993
<u>AN</u>		PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074416 001</u>	Sep 30, 1994
<u>AN</u>		PIRAMAL ENT	<u>99.9%</u>	<u>A074502 001</u>	Jun 27, 1995

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

+

SANDOZ

100MG/ML	A040648 001	Jul 05, 2005
----------	-------------	--------------

SYRUP; ORAL

ISONIAZID

+

CAROLINA MEDCL

50MG/5ML	A088235 001	Nov 10, 1983
----------	-------------	--------------

TABLET; ORAL

ISONIAZID

<u>AA</u>		BARR	<u>100MG</u>	<u>A080936 001</u>	
<u>AA</u>			<u>300MG</u>	<u>A080937 002</u>	
<u>AA</u>	+	SANDOZ	<u>100MG</u>	<u>N008678 002</u>	
<u>AA</u>	+		<u>300MG</u>	<u>N008678 003</u>	
<u>AA</u>		THEPHARMANETWORK LLC	<u>100MG</u>	<u>A202610 001</u>	Oct 29, 2014

## PRESCRIPTION DRUG PRODUCT LIST

ISONIAZID

TABLET; ORAL

ISONIAZID**AA** 300MG **A202610 002** Oct 29, 2014LANIAZID**AA** LANNETT 300MG **A089776 001** Jun 13, 1988ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER

+ SANOFI AVENTIS US 50MG; 300MG; 120MG N050705 001 May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

+ SANOFI AVENTIS US 150MG; 300MG A061884 001

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISUPREL

+ HOSPIRA 0.2MG/ML N010515 001

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+ AUXILIUM PHARMS LLC 40MG N019790 001 Sep 02, 1988

TABLET; ORAL

ISORDIL**AB** VALEANT BERMUDA 5MG **N012093 007** Jul 29, 1988ISOSORBIDE DINITRATE**AB** HIKMA INTL PHARMS 5MG **A086067 001** Oct 29, 1987**AB** 10MG **A086066 001** Oct 29, 1987**AB** 20MG **A088088 001** Nov 02, 1987**AB** 30MG **A040591 001** Jan 10, 2007**AB** PAR PHARM 5MG **A086923 001** Mar 12, 1987**AB** 10MG **A086925 001** Mar 12, 1987**AB** 20MG **A087537 001** Oct 02, 1987**AB** + 30MG **A087946 001** Jan 12, 1988**AB** SANDOZ 5MG **A086221 001** Jan 07, 1988**AB** 10MG **A086223 001** Jan 07, 1988**AB** 20MG **A089367 001** Apr 07, 1988

ISORDIL

+ VALEANT BERMUDA 40MG N012093 001 Jul 29, 1988

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE**AB** COREPHARMA 40MG **A040723 001** Mar 17, 2008**AB** + SUN PHARM INDS INC 40MG **A040009 001** Dec 30, 1998ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE**AB** ACTAVIS ELIZABETH 10MG **A075037 002** Oct 30, 1998**AB** 20MG **A075037 001** Oct 30, 1998**AB** ANI PHARMS INC 20MG **A075147 001** Nov 27, 1998**AB** HIKMA PHARMS LLC 20MG **A075361 001** Oct 05, 2000MONOKET**AB** KREMERS URBAN PHARMS 10MG **N020215 002** Jun 30, 1993**AB** + 20MG **N020215 001** Jun 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE**AB** DEXCEL LTD 60MG **A075522 001** Apr 17, 2000**AB** HIKMA PHARMS 30MG **A076813 002** Mar 30, 2006**AB** 60MG **A076813 001** Jan 07, 2005**AB** KREMERS URBAN PHARMS 30MG **A075155 002** Jan 13, 2000**AB** 60MG **A075155 001** Oct 30, 1998**AB** + 120MG **A075155 003** Aug 04, 2000**AB** NESHER PHARMS 30MG **A075395 001** Mar 16, 2000**AB** 60MG **A075395 002** Mar 16, 2000**AB** 120MG **A075395 003** Mar 16, 2000**AB** TORRENT PHARMS 30MG **A200270 001** Jun 03, 2011**AB** 60MG **A200495 001** Jun 03, 2011**AB** 120MG **A200495 002** Jun 03, 2011**AB** VINTAGE PHARMS 30MG **A090598 001** Aug 11, 2010**AB** 60MG **A090598 002** Aug 11, 2010**AB** 120MG **A090598 003** Aug 11, 2010

## PRESCRIPTION DRUG PRODUCT LIST

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

+ MYLAN INSTITUTIONAL 1%

A090874 001 Jul 20, 2010

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM**AB** MYLAN PHARMS INC**10MG****A075945 001** Nov 08, 2002**AB** **20MG****A075945 002** Nov 08, 2002**AB** **40MG****A075945 003** Nov 08, 2002CLARAVIS**AB** TEVA PHARMS USA**10MG****A076356 001** Apr 11, 2003**AB** **20MG****A076135 002** Apr 11, 2003**AB** **30MG****A076135 003** May 11, 2006**AB** + **40MG****A076135 001** Apr 11, 2003MYORISAN**AB** DOUGLAS PHARMS**10MG****A076485 001** Jan 19, 2012**AB** **20MG****A076485 002** Jan 19, 2012**AB** **40MG****A076485 003** Jan 19, 2012SOTRET**AB** RANBAXY**10MG****A076041 001** Dec 24, 2002**AB** **20MG****A076041 002** Dec 24, 2002**AB** **30MG****A076503 001** Jun 20, 2003**AB** **40MG****A076041 003** Dec 24, 2002ZENATANE**AB** DR REDDYS LABS LTD**10MG****A202099 001** Mar 25, 2013**AB** **20MG****A202099 002** Mar 25, 2013**AB** **40MG****A202099 003** Mar 25, 2013

ABSORICA

BX RANBAXY

10MG

N021951 001 May 25, 2012

BX 20MG

N021951 002 May 25, 2012

BX 30MG

N021951 003 May 25, 2012

BX + 40MG

N021951 004 May 25, 2012

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE**AB** MIKAH PHARMA**2.5MG****A077169 001** Apr 24, 2006**AB** **5MG****A077169 002** Apr 24, 2006**AB** WATSON LABS**2.5MG****A077317 001** Jan 05, 2006**AB** + **5MG****A077317 002** Jan 05, 2006ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE**AB** MYLAN PHARMS INC**100MG****A200463 001** Jul 20, 2012**AB** SANDOZ**100MG****A076104 001** May 28, 2004SPORANOX**AB** + JANSSEN PHARMS**100MG****N020083 001** Sep 11, 1992

SOLUTION; ORAL

SPORANOX

+ JANSSEN PHARMS

10MG/ML

N020657 001 Feb 21, 1997

TABLET; ORAL

ONMEL

+ MERZ PHARMS

200MG

N022484 001 Apr 29, 2010

IVACAFTOR

TABLET; ORAL

KALYDECO

+ VERTEX PHARMS

150MG

N203188 001 Jan 31, 2012

IVERMECTIN

CREAM; TOPICAL

SOOLANTRA

+ GALDERMA LABS LP

1%

N206255 001 Dec 19, 2014

LOTION; TOPICAL

SKLICE

+ SANOFI PASTEUR INC

0.5%

N202736 001 Feb 07, 2012

TABLET; ORAL

IVERMECTIN**AB** EDENBRIDGE PHARMS**3MG****A204154 001** Oct 24, 2014STROMEKTOL**AB** + MERCK SHARP DOHME**3MG****N050742 002** Oct 08, 1998

## PRESCRIPTION DRUG PRODUCT LIST

IXABEPILONE

INJECTABLE; IV (INFUSION)

IXEMPRA KIT

+	BRISTOL MYERS SQUIBB	15MG/VIAL	N022065	001	Oct 16, 2007
+		45MG/VIAL	N022065	002	Oct 16, 2007

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

+	FRESENIUS KABI USA	EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002
		EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>EQ 10MG BASE/ML</u>	<u>N016812</u>	<u>001</u>
<u>AP</u>	+		<u>EQ 50MG BASE/ML</u>	<u>N016812</u>	<u>002</u>
<u>AP</u>	+		<u>EQ 100MG BASE/ML</u>	<u>N016812</u>	<u>003</u>

KETAMINE HYDROCHLORIDE

<u>AP</u>		EUROHLTH INTL	<u>EQ 50MG BASE/ML</u>	<u>A074524</u>	<u>001</u>	Mar 22, 1996
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A074524</u>	<u>002</u>	Mar 22, 1996
<u>AP</u>		HOSPIRA	<u>EQ 50MG BASE/ML</u>	<u>A074549</u>	<u>001</u>	Jun 27, 1996
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A074549</u>	<u>002</u>	Jun 27, 1996
<u>AP</u>		MYLAN INSTITUTIONAL	<u>EQ 10MG BASE/ML</u>	<u>A076092</u>	<u>001</u>	Sep 30, 2008
<u>AP</u>			<u>EQ 50MG BASE/ML</u>	<u>A076092</u>	<u>002</u>	Dec 28, 2001
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A076092</u>	<u>003</u>	Oct 25, 2002

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA

<u>AT</u>	+	DELCOR ASSET CORP	<u>2%</u>	<u>N021738</u>	<u>001</u>	Jun 12, 2007
-----------	---	-------------------	-----------	----------------	------------	--------------

KETOCONAZOLE

<u>AT</u>		PERRIGO ISRAEL	<u>2%</u>	<u>A091550</u>	<u>001</u>	Aug 25, 2011
-----------	--	----------------	-----------	----------------	------------	--------------

CREAM; TOPICAL

KETOCONAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>2%</u>	<u>A076294</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>	+	TEVA	<u>2%</u>	<u>A075581</u>	<u>001</u>	Apr 25, 2000

KETOZOLE

<u>AB</u>		TARO	<u>2%</u>	<u>A075638</u>	<u>001</u>	Dec 18, 2002
-----------	--	------	-----------	----------------	------------	--------------

GEL; TOPICAL

XOLEGEL

+	AQUA PHARMS	2%	N021946	001	Jul 28, 2006
---	-------------	----	---------	-----	--------------

SHAMPOO; TOPICAL

KETOCONAZOLE

<u>AB</u>		PERRIGO NEW YORK	<u>2%</u>	<u>A076419</u>	<u>001</u>	Jan 07, 2004
-----------	--	------------------	-----------	----------------	------------	--------------

<u>AB</u>		TOLMAR	<u>2%</u>	<u>A076942</u>	<u>001</u>	Apr 11, 2005
-----------	--	--------	-----------	----------------	------------	--------------

NIZORAL

<u>AB</u>	+	JANSSEN PHARMS	<u>2%</u>	<u>N019927</u>	<u>001</u>	Aug 31, 1990
-----------	---	----------------	-----------	----------------	------------	--------------

TABLET; ORAL

KETOCONAZOLE

<u>AB</u>		MYLAN	<u>200MG</u>	<u>A075597</u>	<u>001</u>	Dec 23, 1999
-----------	--	-------	--------------	----------------	------------	--------------

<u>AB</u>		TARO	<u>200MG</u>	<u>A075319</u>	<u>001</u>	Jun 15, 1999
-----------	--	------	--------------	----------------	------------	--------------

<u>AB</u>	+	TEVA	<u>200MG</u>	<u>A075273</u>	<u>001</u>	Jun 15, 1999
-----------	---	------	--------------	----------------	------------	--------------

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

<u>AB</u>		DORADO PHARMA	<u>50MG</u>	<u>A074014</u>	<u>002</u>	Jan 29, 1993
-----------	--	---------------	-------------	----------------	------------	--------------

<u>AB</u>			<u>75MG</u>	<u>A074014</u>	<u>003</u>	Jan 29, 1993
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>50MG</u>	<u>A074035</u>	<u>002</u>	Dec 31, 1996
-----------	--	-------	-------------	----------------	------------	--------------

<u>AB</u>			<u>75MG</u>	<u>A074035</u>	<u>003</u>	Dec 31, 1996
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		TEVA	<u>50MG</u>	<u>A073516</u>	<u>001</u>	Dec 22, 1992
-----------	--	------	-------------	----------------	------------	--------------

<u>AB</u>	+		<u>75MG</u>	<u>A073517</u>	<u>001</u>	Dec 22, 1992
-----------	---	--	-------------	----------------	------------	--------------

		DORADO PHARMA	25MG	A074014	001	Jan 29, 1993
--	--	---------------	------	---------	-----	--------------

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

<u>AB</u>		ACTAVIS LABS FL INC	<u>100MG</u>	<u>A075270</u>	<u>002</u>	Mar 24, 1999
-----------	--	---------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>150MG</u>	<u>A075270</u>	<u>003</u>	Mar 24, 1999
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>200MG</u>	<u>A075270</u>	<u>001</u>	Mar 24, 1999
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>100MG</u>	<u>A075679</u>	<u>003</u>	Feb 20, 2002
-----------	--	-------	--------------	----------------	------------	--------------

<u>AB</u>			<u>150MG</u>	<u>A075679</u>	<u>002</u>	Feb 20, 2002
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>	+		<u>200MG</u>	<u>A075679</u>	<u>001</u>	Feb 20, 2002
-----------	---	--	--------------	----------------	------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>	AGILA SPECLTS	<u>15MG/ML</u>	<u>A078299 001</u>	Jul 16, 2007
<u>AP</u>		<u>15MG/ML</u>	<u>A201155 001</u>	Aug 04, 2014
<u>AP</u>		<u>30MG/ML</u>	<u>A078299 002</u>	Jul 16, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A201155 002</u>	Aug 04, 2014
<u>AP</u>	FRESENIUS KABI USA	<u>15MG/ML</u>	<u>A075784 001</u>	Jan 11, 2002
<u>AP</u>		<u>30MG/ML</u>	<u>A075784 002</u>	Jan 11, 2002
<u>AP</u>	+ HOSPIRA	<u>15MG/ML</u>	<u>A074802 001</u>	Jun 05, 1997
<u>AP</u>		<u>15MG/ML</u>	<u>A074993 001</u>	Jan 27, 1999
<u>AP</u>	+	<u>30MG/ML</u>	<u>A074802 002</u>	Jun 05, 1997
<u>AP</u>		<u>30MG/ML</u>	<u>A074993 002</u>	Jan 27, 1999
<u>AP</u>	SAGENT PHARMS	<u>15MG/ML</u>	<u>A091065 001</u>	Nov 27, 2013
<u>AP</u>		<u>30MG/ML</u>	<u>A091065 002</u>	Nov 27, 2013
<u>AP</u>	SANDOZ	<u>30MG/ML</u>	<u>A076271 002</u>	Oct 06, 2004
<u>AP</u>	WOCKHARDT	<u>15MG/ML</u>	<u>A077942 001</u>	Mar 27, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A077942 002</u>	Mar 27, 2007

SOLUTION/DROPS; OPHTHALMIC

ACULAR

<u>AT</u>	+ ALLERGAN	<u>0.5%</u>	<u>N019700 001</u>	Nov 09, 1992
-----------	------------	-------------	--------------------	--------------

ACULAR LS

<u>AT</u>	+ ALLERGAN	<u>0.4%</u>	<u>N021528 001</u>	May 30, 2003
-----------	------------	-------------	--------------------	--------------

ACUVAIL

<u>AT</u>	+ ALLERGAN	<u>0.45%</u>	<u>N022427 001</u>	Jul 22, 2009
-----------	------------	--------------	--------------------	--------------

KETOROLAC TROMETHAMINE

<u>AT</u>	AKORN	<u>0.4%</u>	<u>A078399 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A078434 001</u>	Nov 05, 2009
<u>AT</u>	ALCON PHARMS LTD	<u>0.4%</u>	<u>A078721 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076583 001</u>	Nov 05, 2009
<u>AT</u>	APOTEX INC	<u>0.4%</u>	<u>A077308 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076109 001</u>	Nov 05, 2009
<u>AT</u>	SUN PHARMA GLOBAL	<u>0.5%</u>	<u>A090017 001</u>	Nov 05, 2009

SPRAY, METERED; NASAL

SPRIX

	+ LUITPOLD	15.75MG/SPRAY	N022382 001	May 14, 2010
--	------------	---------------	-------------	--------------

TABLET; ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	+ MYLAN	<u>10MG</u>	<u>A074761 001</u>	May 16, 1997
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A075284 001</u>	Jun 23, 1999
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074754 001</u>	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

	+ OMEROS	EQ 2.88MG BASE/ML; EQ 10.16MG BASE/ML	N205388 001	May 30, 2014
--	----------	---------------------------------------	-------------	--------------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075431 001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075524 001</u>	Nov 29, 1999
<u>AP</u>	EUROHLTH INTL	<u>5MG/ML</u>	<u>A075303 001</u>	May 28, 1999
<u>AP</u>	GLAND PHARMA LTD	<u>5MG/ML</u>	<u>A090699 001</u>	Apr 03, 2012
<u>AP</u>	+ HOSPIRA	<u>5MG/ML</u>	<u>A075239 001</u>	Nov 29, 1999
<u>AP</u>	+	<u>5MG/ML</u>	<u>A075240 001</u>	Nov 29, 1999

LABETALOL HYDROCHLORIDE

<u>AP</u>	SAGENT STRIDES	<u>5MG/ML</u>	<u>A079134 001</u>	Feb 03, 2010
-----------	----------------	---------------	--------------------	--------------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A074787 001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A074787 002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A074787 003</u>	Aug 03, 1998
<u>AB</u>	PAR FORM	<u>100MG</u>	<u>A200908 001</u>	Jul 10, 2012
<u>AB</u>		<u>200MG</u>	<u>A200908 002</u>	Jul 10, 2012
<u>AB</u>		<u>300MG</u>	<u>A200908 003</u>	Jul 10, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075113 001</u>	Aug 04, 1998
<u>AB</u>	+	<u>200MG</u>	<u>A075113 002</u>	Aug 04, 1998
<u>AB</u>		<u>300MG</u>	<u>A075113 003</u>	Aug 04, 1998
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075133 001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A075133 002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A075133 003</u>	Aug 03, 1998

## PRESCRIPTION DRUG PRODUCT LIST

LABETALOL HYDROCHLORIDE

TABLET; ORAL

TRANDATE

<u>AB</u>	CNTY LINE PHARMS	<u>100MG</u>	<u>N018716</u>	<u>001</u>	May 24, 1985
<u>AB</u>		<u>200MG</u>	<u>N018716</u>	<u>002</u>	Aug 01, 1984
<u>AB</u>		<u>300MG</u>	<u>N018716</u>	<u>003</u>	Aug 01, 1984

LACOSAMIDE

SOLUTION; INTRAVENOUS

VIMPAT

+ UCB INC

200MG/20ML (10MG/ML)

N022254 001 Oct 28, 2008

SOLUTION; ORAL

VIMPAT

+ UCB INC

10MG/ML

N022255 001 Apr 20, 2010

TABLET; ORAL

VIMPAT

UCB INC

50MG

N022253 001 Oct 28, 2008

100MG

N022253 002 Oct 28, 2008

150MG

N022253 003 Oct 28, 2008

+

200MG

N022253 004 Oct 28, 2008

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+ CUMBERLAND PHARMS

10GM/PACKET

A074712 001 Dec 10, 1997

+

20GM/PACKET

A074712 002 Dec 10, 1997

SOLUTION; ORAL

CONSTILAC

<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071054</u>	<u>001</u>	Jul 26, 1988
-----------	------	------------------	----------------	------------	--------------

CONSTULOSE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A070288</u>	<u>001</u>	Aug 15, 1988
-----------	------------------------	------------------	----------------	------------	--------------

LACTULOSE

<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A078430</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090503</u>	<u>001</u>	Jan 25, 2012
<u>AA</u>	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074076</u>	<u>001</u>	Jul 03, 1995
<u>AA</u>	MORTON GROVE	<u>10GM/15ML</u>	<u>A074602</u>	<u>001</u>	Nov 14, 1996
<u>AA</u>	PHARM ASSOC	<u>10GM/15ML</u>	<u>A074623</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	ROXANE	<u>10GM/15ML</u>	<u>A073591</u>	<u>001</u>	May 29, 1992
<u>AA</u>	VINTAGE PHARMS	<u>10GM/15ML</u>	<u>A075993</u>	<u>001</u>	Jul 26, 2001
<u>AA</u>	VISTAPHARM	<u>10GM/15ML</u>	<u>A074138</u>	<u>001</u>	Sep 30, 1992

SOLUTION; ORAL, RECTAL

CHOLAC

<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071331</u>	<u>001</u>	Jul 26, 1988
-----------	------	------------------	----------------	------------	--------------

ENULOSE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A071548</u>	<u>001</u>	Aug 15, 1988
-----------	------------------------	------------------	----------------	------------	--------------

GENERLAC

<u>AA</u>	MORTON GROVE PHARMS	<u>10GM/15ML</u>	<u>A074603</u>	<u>001</u>	Oct 31, 1996
-----------	---------------------	------------------	----------------	------------	--------------

LACTULOSE

<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A090426</u>	<u>001</u>	Nov 21, 2008
<u>AA</u>	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090502</u>	<u>001</u>	Jan 25, 2012
<u>AA</u>	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074077</u>	<u>001</u>	Jul 03, 1995

LAMIVUDINE

SOLUTION; ORAL

EPIVIR

<u>AA</u>	+ VIIV HLTHCARE	<u>10MG/ML</u>	<u>N020596</u>	<u>001</u>	Nov 17, 1995
-----------	-----------------	----------------	----------------	------------	--------------

LAMIVUDINE

<u>AA</u>	SILARX PHARMS INC	<u>10MG/ML</u>	<u>A203564</u>	<u>001</u>	Oct 31, 2014
-----------	-------------------	----------------	----------------	------------	--------------

EPIVIR-HBV

+ GLAXOSMITHKLINE

5MG/ML

N021004 001 Dec 08, 1998

TABLET; ORAL

EPIVIR

<u>AB</u>	VIIV HLTHCARE	<u>150MG</u>	<u>N020564</u>	<u>001</u>	Nov 17, 1995
-----------	---------------	--------------	----------------	------------	--------------

<u>AB</u>	+	<u>300MG</u>	<u>N020564</u>	<u>003</u>	Jun 24, 2002
-----------	---	--------------	----------------	------------	--------------

EPIVIR-HBV

<u>AB</u>	+ GLAXOSMITHKLINE	<u>100MG</u>	<u>N021003</u>	<u>001</u>	Dec 08, 1998
-----------	-------------------	--------------	----------------	------------	--------------

LAMIVUDINE

<u>AB</u>	APOTEX	<u>150MG</u>	<u>A091606</u>	<u>001</u>	Dec 02, 2011
<u>AB</u>		<u>300MG</u>	<u>A091606</u>	<u>002</u>	Dec 02, 2011
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A202941</u>	<u>001</u>	Jan 02, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>150MG</u>	<u>A202032</u>	<u>001</u>	Nov 17, 2011
<u>AB</u>		<u>300MG</u>	<u>A202032</u>	<u>002</u>	Nov 17, 2011
<u>AB</u>	HETERO LABS LTD V	<u>100MG</u>	<u>A203260</u>	<u>001</u>	Jan 02, 2014
<u>AB</u>		<u>150MG</u>	<u>A203277</u>	<u>001</u>	Jan 06, 2014

## PRESCRIPTION DRUG PRODUCT LIST

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

<u>AB</u>		<u>300MG</u>	<u>A203277</u>	<u>002</u>	Jan 06, 2014
<u>AB</u>	LUPIN LTD	<u>150MG</u>	<u>A205217</u>	<u>001</u>	Dec 18, 2014
<u>AB</u>		<u>300MG</u>	<u>A205217</u>	<u>002</u>	Dec 18, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A204002</u>	<u>001</u>	Dec 31, 2014

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

<u>AB</u>	+ VIIIV HLTHCARE	<u>150MG;300MG</u>	<u>N020857</u>	<u>001</u>	Sep 26, 1997
-----------	------------------	--------------------	----------------	------------	--------------

LAMIVUDINE AND ZIDOVUDINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>150MG;300MG</u>	<u>A202418</u>	<u>001</u>	May 15, 2012
<u>AB</u>	HETERO LABS LTD V	<u>150MG;300MG</u>	<u>A203259</u>	<u>001</u>	Feb 03, 2014
<u>AB</u>	LUPIN LTD	<u>150MG;300MG</u>	<u>A090246</u>	<u>001</u>	May 15, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>150MG;300MG</u>	<u>A204005</u>	<u>001</u>	Aug 28, 2014
<u>AB</u>	TEVA PHARMS	<u>150MG;300MG</u>	<u>A079081</u>	<u>001</u>	May 25, 2011

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N020241</u>	<u>005</u>	Dec 27, 1994
<u>AB</u>		<u>100MG</u>	<u>N020241</u>	<u>001</u>	Dec 27, 1994
<u>AB</u>		<u>150MG</u>	<u>N020241</u>	<u>002</u>	Dec 27, 1994
<u>AB</u>		<u>200MG</u>	<u>N020241</u>	<u>003</u>	Dec 27, 1994

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090607</u>	<u>001</u>	Jan 13, 2011
<u>AB</u>		<u>100MG</u>	<u>A090607</u>	<u>002</u>	Jan 13, 2011
<u>AB</u>		<u>150MG</u>	<u>A090607</u>	<u>003</u>	Jan 13, 2011
<u>AB</u>		<u>200MG</u>	<u>A090607</u>	<u>004</u>	Jan 13, 2011
<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A200694</u>	<u>001</u>	Jun 14, 2013
<u>AB</u>		<u>100MG</u>	<u>A200694</u>	<u>002</u>	Jun 14, 2013
<u>AB</u>		<u>150MG</u>	<u>A200694</u>	<u>003</u>	Jun 14, 2013
<u>AB</u>		<u>200MG</u>	<u>A200694</u>	<u>004</u>	Jun 14, 2013
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A078625</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078625</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078625</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078625</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078956</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078956</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078956</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078956</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A079132</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079132</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A079132</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079132</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A077783</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A077783</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A077783</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A077783</u>	<u>004</u>	Nov 01, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A076708</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076708</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A076708</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076708</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A090169</u>	<u>001</u>	May 12, 2012
<u>AB</u>		<u>100MG</u>	<u>A090169</u>	<u>002</u>	May 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090169</u>	<u>003</u>	May 12, 2012
<u>AB</u>		<u>200MG</u>	<u>A090169</u>	<u>004</u>	May 12, 2012
<u>AB</u>	HIKMA PHARMS	<u>25MG</u>	<u>A078134</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>100MG</u>	<u>A078134</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>150MG</u>	<u>A078134</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>		<u>200MG</u>	<u>A078134</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078691</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078691</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A078691</u>	<u>003</u>	Jun 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A078691</u>	<u>004</u>	Jun 01, 2010
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077420</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077420</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077420</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077420</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TARO PHARM INDS	<u>25MG</u>	<u>A078525</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078525</u>	<u>002</u>	Jan 27, 2009

## PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

<u>AB</u>		<u>150MG</u>	<u>A078525 003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078525 004</u>	Jan 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076388 001</u>	Aug 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A076388 002</u>	Aug 30, 2006
<u>AB</u>		<u>150MG</u>	<u>A076388 003</u>	Aug 30, 2006
<u>AB</u>		<u>200MG</u>	<u>A076388 004</u>	Aug 30, 2006
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A078947 001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078947 002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078947 003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078947 004</u>	Jan 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090170 001</u>	Oct 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A090170 002</u>	Oct 06, 2011
<u>AB</u>		<u>150MG</u>	<u>A090170 003</u>	Oct 06, 2011
<u>AB</u>		<u>200MG</u>	<u>A090170 004</u>	Oct 06, 2011
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633 001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633 003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633 004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633 005</u>	Jan 27, 2009
		50MG	A077633 002	Jan 27, 2009
		250MG	A077633 006	Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>2MG</u>	<u>N020764 004</u>	Sep 08, 2000
<u>AB</u>		<u>5MG</u>	<u>N020764 001</u>	Aug 24, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020764 002</u>	Aug 24, 1998

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201168 001</u>	Jun 12, 2014
<u>AB</u>		<u>25MG</u>	<u>A201168 002</u>	Jun 12, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401 002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401 003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701 001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076701 002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A079099 001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099 002</u>	Feb 19, 2009
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200220 001</u>	Feb 28, 2011
<u>AB</u>		<u>25MG</u>	<u>A200220 002</u>	Feb 28, 2011
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076630 001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076630 002</u>	Jan 22, 2009
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204 001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204 002</u>	Feb 04, 2009
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076420 001</u>	Jun 21, 2006
<u>AB</u>		<u>25MG</u>	<u>A076420 002</u>	Jun 21, 2006
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928 001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928 003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009 003</u>	Jan 22, 2009

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022115 001</u>	May 29, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022115 002</u>	May 29, 2009
<u>AB</u>		<u>100MG</u>	<u>N022115 003</u>	May 29, 2009
<u>AB</u>		<u>200MG</u>	<u>N022115 004</u>	May 29, 2009
<u>AB</u>		<u>250MG</u>	<u>N022115 006</u>	Jun 21, 2011
<u>AB</u>		<u>300MG</u>	<u>N022115 005</u>	Apr 14, 2010

LAMOTRIGINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A200672 003</u>	Oct 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A200672 004</u>	Oct 17, 2013
<u>AB</u>		<u>25MG</u>	<u>A200672 001</u>	Oct 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A200672 002</u>	Oct 17, 2013
<u>AB</u>		<u>250MG</u>	<u>A203733 001</u>	Nov 13, 2013
<u>AB</u>		<u>300MG</u>	<u>A200672 005</u>	Oct 17, 2013
<u>AB</u>	ANCHEN PHARMS	<u>25MG</u>	<u>A201374 001</u>	Dec 26, 2012
<u>AB</u>		<u>50MG</u>	<u>A201374 002</u>	Dec 26, 2012
<u>AB</u>		<u>100MG</u>	<u>A201374 003</u>	Dec 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A201374 004</u>	Dec 26, 2012
<u>AB</u>		<u>250MG</u>	<u>A201374 005</u>	Dec 26, 2012
<u>AB</u>		<u>300MG</u>	<u>A201374 006</u>	Dec 26, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A202383 001</u>	Jun 19, 2013

## PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

<u>AB</u>		<u>50MG</u>	<u>A202383</u>	<u>002</u>	Jun 19, 2013
<u>AB</u>		<u>100MG</u>	<u>A202383</u>	<u>003</u>	Jun 19, 2013
<u>AB</u>		<u>200MG</u>	<u>A202383</u>	<u>004</u>	Jun 19, 2013
<u>AB</u>		<u>300MG</u>	<u>A202383</u>	<u>005</u>	Jun 19, 2013
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A201791</u>	<u>001</u>	Jan 18, 2013
<u>AB</u>		<u>50MG</u>	<u>A201791</u>	<u>002</u>	Jan 18, 2013
<u>AB</u>		<u>100MG</u>	<u>A201791</u>	<u>003</u>	Jan 18, 2013
<u>AB</u>		<u>200MG</u>	<u>A201791</u>	<u>004</u>	Jan 18, 2013
<u>AB</u>		<u>250MG</u>	<u>A201791</u>	<u>005</u>	Jan 18, 2013
<u>AB</u>		<u>300MG</u>	<u>A201791</u>	<u>006</u>	Jan 18, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>25MG</u>	<u>A203370</u>	<u>001</u>	Dec 23, 2013
<u>AB</u>		<u>50MG</u>	<u>A203370</u>	<u>002</u>	Dec 23, 2013
<u>AB</u>		<u>100MG</u>	<u>A203370</u>	<u>003</u>	Dec 23, 2013
<u>AB</u>		<u>200MG</u>	<u>A203370</u>	<u>004</u>	Dec 23, 2013
<u>AB</u>	WILSHIRE PHARMS INC	<u>25MG</u>	<u>A202887</u>	<u>001</u>	Jun 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A202887</u>	<u>002</u>	Jun 17, 2013
<u>AB</u>		<u>100MG</u>	<u>A202887</u>	<u>003</u>	Jun 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A202887</u>	<u>004</u>	Jun 17, 2013
<u>AB</u>	WOCKHARDT LTD	<u>25MG</u>	<u>A202498</u>	<u>001</u>	Jan 04, 2013
<u>AB</u>		<u>50MG</u>	<u>A202498</u>	<u>002</u>	Jan 04, 2013
<u>AB</u>		<u>100MG</u>	<u>A202498</u>	<u>003</u>	Jan 04, 2013
<u>AB</u>		<u>200MG</u>	<u>A202498</u>	<u>004</u>	Jan 04, 2013
<u>AB</u>		<u>300MG</u>	<u>A202498</u>	<u>005</u>	Jan 04, 2013

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022251</u>	<u>001</u>	May 08, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022251</u>	<u>002</u>	May 08, 2009
<u>AB</u>		<u>100MG</u>	<u>N022251</u>	<u>003</u>	May 08, 2009
<u>AB</u>		<u>200MG</u>	<u>N022251</u>	<u>004</u>	May 08, 2009

LAMOTRIGINE

<u>AB</u>	IMPAX LABS INC	<u>25MG</u>	<u>A200828</u>	<u>001</u>	Jul 15, 2013
<u>AB</u>		<u>50MG</u>	<u>A200828</u>	<u>002</u>	Jul 15, 2013
<u>AB</u>		<u>100MG</u>	<u>A200828</u>	<u>003</u>	Jul 15, 2013
<u>AB</u>		<u>200MG</u>	<u>A200828</u>	<u>004</u>	Jul 15, 2013

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	<u>N022074</u>	<u>001</u>	Aug 30, 2007
+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	<u>N022074</u>	<u>002</u>	Aug 30, 2007
+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	<u>N022074</u>	<u>003</u>	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>	DR REDDYS LABS LTD	<u>15MG</u>	<u>A091269</u>	<u>001</u>	Oct 15, 2010
<u>AB</u>		<u>30MG</u>	<u>A091269</u>	<u>002</u>	Oct 15, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A090763</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090763</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	NATCO PHARMA LTD	<u>15MG</u>	<u>A201921</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>		<u>30MG</u>	<u>A201921</u>	<u>002</u>	Dec 18, 2012
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A090331</u>	<u>001</u>	Apr 23, 2010
<u>AB</u>		<u>30MG</u>	<u>A090331</u>	<u>002</u>	Apr 23, 2010
<u>AB</u>	SUN PHARMA GLOBAL	<u>15MG</u>	<u>A202637</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>		<u>30MG</u>	<u>A091509</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>	TEVA PHARMS	<u>15MG</u>	<u>A077255</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A077255</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	WOCKHARDT USA	<u>15MG</u>	<u>A202176</u>	<u>001</u>	Sep 14, 2012
<u>AB</u>		<u>30MG</u>	<u>A202176</u>	<u>002</u>	Sep 14, 2012
<u>AB</u>	ZYDUS HLTHCARE	<u>15MG</u>	<u>A202366</u>	<u>001</u>	Aug 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202366</u>	<u>002</u>	Aug 19, 2013

LANSOPRAZOLE

<u>AB</u>	KRKA TOVARNA ZDRAVIL	<u>15MG</u>	<u>A091212</u>	<u>001</u>	Sep 16, 2013
<u>AB</u>		<u>30MG</u>	<u>A091212</u>	<u>002</u>	Sep 16, 2013

PREVACID

<u>AB</u>	TAKEDA PHARMS USA	<u>15MG</u>	<u>N020406</u>	<u>001</u>	May 10, 1995
<u>AB</u>	+	<u>30MG</u>	<u>N020406</u>	<u>002</u>	May 10, 1995

## PRESCRIPTION DRUG PRODUCT LIST

LANSOPRAZOLE

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

PREVACID

TAKEDA PHARMS USA

15MG

N021428 001 Aug 30, 2002

+

30MG

N021428 002 Aug 30, 2002

LANTHANUM CARBONATE

POWDER; ORAL

FOSRENOL

+ SHIRE DEV LLC

EQ 1GM BASE

N204734 002 Sep 24, 2014

EQ 750MG BASE

N204734 001 Sep 24, 2014

TABLET, CHEWABLE; ORAL

FOSRENOL

+ SHIRE LLC

EQ 1GM BASE

N021468 004 Nov 23, 2005

EQ 500MG BASE

N021468 002 Oct 26, 2004

EQ 750MG BASE

N021468 003 Nov 23, 2005

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

+ SMITHKLINE BEECHAM

EQ 250MG BASE

N022059 001 Mar 13, 2007

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

<u>AT</u>	AKORN	<u>0.005%</u>	<u>A090887 001</u>	Jul 19, 2011
<u>AT</u>	ALCON RES	<u>0.005%</u>	<u>A091449 001</u>	Mar 22, 2011
<u>AT</u>	BAUSCH AND LOMB	<u>0.005%</u>	<u>A201006 001</u>	Mar 22, 2011
<u>AT</u>	DR REDDYS LABS LTD	<u>0.005%</u>	<u>A202077 001</u>	Feb 11, 2013
<u>AT</u>	LUITPOLD	<u>0.005%</u>	<u>A200925 001</u>	Mar 22, 2011
<u>AT</u>	MYLAN	<u>0.005%</u>	<u>A201786 001</u>	Mar 22, 2011

XALATAN

<u>AT</u>	+ PHARMACIA AND UPJOHN	<u>0.005%</u>	<u>N020597 001</u>	Jun 05, 1996
-----------	------------------------	---------------	--------------------	--------------

LEDIPASVIR; SOFOSBUVIR

TABLET; ORAL

HARVONI

+ GILEAD SCIENCES INC

90MG; 400MG

N205834 001 Oct 10, 2014

LEFLUNOMIDE

TABLET; ORAL

ARAVA

<u>AB</u>	SANOFI AVENTIS US	<u>10MG</u>	<u>N020905 001</u>	Sep 10, 1998
<u>AB</u>	+	<u>20MG</u>	<u>N020905 002</u>	Sep 10, 1998
	<u>LEFLUNOMIDE</u>			
<u>AB</u>	ALEMBIC PHARMS LTD	<u>10MG</u>	<u>A091369 001</u>	Nov 21, 2011
<u>AB</u>		<u>20MG</u>	<u>A091369 002</u>	Nov 21, 2011
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077090 001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077090 002</u>	Sep 13, 2005
<u>AB</u>	BARR	<u>10MG</u>	<u>A077083 001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077083 002</u>	Sep 13, 2005
<u>AB</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A077086 001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077086 002</u>	Sep 13, 2005
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A077084 001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077084 002</u>	Sep 13, 2005
	ARAVA			
	+ SANOFI AVENTIS US	100MG	N020905 003	Sep 10, 1998

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

CELGENE

2.5MG

N021880 005 Dec 21, 2011

5MG

N021880 001 Dec 27, 2005

10MG

N021880 002 Dec 27, 2005

15MG

N021880 003 Jun 29, 2006

20MG

N021880 006 Jun 05, 2013

+

25MG

N021880 004 Jun 29, 2006

LETROZOLE

TABLET; ORAL

FEMARA

<u>AB</u>	+ NOVARTIS PHARMS	<u>2.5MG</u>	<u>N020726 001</u>	Jul 25, 1997
	<u>LETROZOLE</u>			
<u>AB</u>	ACCORD HLTHCARE	<u>2.5MG</u>	<u>A090934 001</u>	Jun 03, 2011
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A091303 001</u>	Apr 19, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A091191 001</u>	Jun 03, 2011

## PRESCRIPTION DRUG PRODUCT LIST

LETROZOLE

TABLET; ORAL

LETROZOLE

<u>AB</u>	FRESENIUS KABI ONCOL	<u>2.5MG</u>	<u>A090491 001</u>	Jun 03, 2011
<u>AB</u>	INDICUS PHARMA	<u>2.5MG</u>	<u>A201804 001</u>	Jun 03, 2011
<u>AB</u>	JIANGSU HENGRUI MED	<u>2.5MG</u>	<u>A202716 001</u>	May 16, 2013
<u>AB</u>	KUDCO IRELAND	<u>2.5MG</u>	<u>A091098 001</u>	Jun 03, 2011
<u>AB</u>	LANNETT HOLDINGS INC	<u>2.5MG</u>	<u>A202048 001</u>	Oct 29, 2014
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A078190 001</u>	Dec 24, 2008
<u>AB</u>	NATCO PHARMA LTD	<u>2.5MG</u>	<u>A200161 001</u>	Jun 03, 2011
<u>AB</u>	ROXANE	<u>2.5MG</u>	<u>A090838 001</u>	Jun 03, 2011
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A091466 001</u>	Jun 03, 2011
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A090289 001</u>	Jun 03, 2011
<u>AB</u>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A090789 001</u>	Jun 03, 2011

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

<u>AP</u>	+	EUROHLTH INTL	<u>EQ 50MG BASE/VIAL</u>	<u>A089384 001</u>	Sep 14, 1987
<u>AP</u>	+		<u>EQ 100MG BASE/VIAL</u>	<u>A089717 001</u>	Mar 28, 1988
<u>AP</u>		TEVA PHARMS USA	<u>EQ 100MG BASE/VIAL</u>	<u>A081277 001</u>	Sep 28, 1993
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A040174 001</u>	Jun 12, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

<u>AP</u>	+	EUROHLTH INTL	<u>EQ 200MG BASE/VIAL</u>	<u>A040056 001</u>	May 23, 1995
<u>AP</u>	+		<u>EQ 350MG BASE/VIAL</u>	<u>A040335 001</u>	Apr 20, 2000
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A040258 001</u>	Feb 26, 1999
<u>AP</u>		SAGENT PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A200753 001</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 100MG BASE/VIAL</u>	<u>A200753 002</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 200MG BASE/VIAL</u>	<u>A200753 003</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A200855 001</u>	Sep 06, 2012
	+	EUROHLTH INTL	EQ 10MG BASE/ML	A040347 001	Apr 25, 2000
	+	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A040286 001	Feb 26, 1999

TABLET; ORAL

LEUCOVORIN CALCIUM

<u>AB</u>		BARR	<u>EQ 5MG BASE</u>	<u>A071198 001</u>	Sep 24, 1987
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A071199 001</u>	Sep 24, 1987
<u>AB</u>		ROXANE	<u>EQ 5MG BASE</u>	<u>A072733 001</u>	Feb 22, 1993
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A072735 001</u>	Feb 22, 1993
<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>A072736 001</u>	Feb 22, 1993
			EQ 10MG BASE	A072734 001	Feb 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

<u>AP</u>	+	SANDOZ	<u>1MG/0.2ML</u>	<u>A074728 001</u>	Aug 04, 1998
<u>AP</u>		SUN PHARMA GLOBAL	<u>1MG/0.2ML</u>	<u>A078885 001</u>	Mar 09, 2009
<u>AP</u>		TEVA PHARMS USA	<u>1MG/0.2ML</u>	<u>A075471 001</u>	Oct 25, 2000

LUPRON DEPOT

	+	ABBVIE ENDOCRINE INC	3.75MG	N020011 002	Oct 26, 1995
	+		7.5MG/VIAL	N019732 001	Jan 26, 1989
	+		11.25MG/VIAL	N020708 001	Mar 07, 1997
	+		22.5MG/VIAL	N020517 001	Dec 22, 1995
	+		30MG/VIAL	N020517 002	May 30, 1997
	+		45MG/VIAL	N020517 003	Jun 17, 2011

LUPRON DEPOT-PED

	+	ABBVIE ENDOCRINE INC	7.5MG/VIAL	N020263 002	Apr 16, 1993
	+		11.25MG/VIAL	N020263 005	Jan 21, 1994
	+		11.25MG/VIAL	N020263 007	Aug 15, 2011
	+		15MG/VIAL	N020263 006	Jan 21, 1994
	+		30MG/VIAL	N020263 008	Aug 15, 2011

INJECTABLE; SUBCUTANEOUS

ELIGARD

	+	TOLMAR THERAP	7.5MG/VIAL	N021343 001	Jan 23, 2002
	+		22.5MG/VIAL	N021379 001	Jul 24, 2002
	+		30MG/VIAL	N021488 001	Feb 13, 2003
	+		45MG/VIAL	N021731 001	Dec 14, 2004

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL

LUPANETA PACK

		ABBVIE ENDOCRINE	3.75MG/VIAL, N/A; N/A, 5MG	N203696 001	Dec 14, 2012
	+		11.25MG/VIAL, N/A; N/A, 5MG	N203696 002	Dec 14, 2012

## PRESCRIPTION DRUG PRODUCT LIST

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	CIPLA LTD	<u>EQ 0.021% BASE</u>	<u>A078171 002</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A078171 003</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.0103% BASE</u>	<u>A078171 001</u>	Dec 13, 2013
<u>AN</u>	MYLAN SPECLT	<u>EQ 0.0103% BASE</u>	<u>A077800 001</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077800 002</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077800 003</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.25% BASE</u>	<u>A078309 001</u>	Mar 20, 2009
<u>AN</u>	TEVA PARENTERAL	<u>EQ 0.25% BASE</u>	<u>A200875 001</u>	Sep 11, 2014
<u>AN</u>	TEVA PHARMS USA	<u>EQ 0.0103% BASE</u>	<u>A090297 001</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A090297 002</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A090297 003</u>	Apr 26, 2013
<u>AN</u>	WATSON LABS INC	<u>EQ 0.0103% BASE</u>	<u>A077756 003</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077756 001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756 002</u>	Apr 09, 2008

XOPENEX

<u>AN</u>	+ OAK PHARMS INC	<u>EQ 0.0103% BASE</u>	<u>N020837 003</u>	Jan 30, 2002
<u>AN</u>	+	<u>EQ 0.021% BASE</u>	<u>N020837 001</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.042% BASE</u>	<u>N020837 002</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.25% BASE</u>	<u>N020837 004</u>	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+ SUNOVION

EQ 0.045MG BASE/INH

N021730 001 Mar 11, 2005

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

KEPPRA

<u>AP</u>	+ UCB INC	<u>500MG/5ML (100MG/ML)</u>	<u>N021872 001</u>	Jul 31, 2006
-----------	-----------	-----------------------------	--------------------	--------------

LEVETIRACETAM

<u>AP</u>	FRESENIUS KABI USA	<u>500MG/5ML (100MG/ML)</u>	<u>A090813 001</u>	May 26, 2010
<u>AP</u>	HIKMA FARMACEUTICA	<u>500MG/5ML (100MG/ML)</u>	<u>A090981 001</u>	Oct 13, 2011
<u>AP</u>	HOSPIRA INC	<u>500MG/ML (100MG/ML)</u>	<u>A202869 001</u>	Apr 06, 2012
<u>AP</u>	LUITPOLD	<u>500MG/5ML (100MG/ML)</u>	<u>A202143 001</u>	Jan 31, 2012
<u>AP</u>	SAGENT PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091627 001</u>	Jun 26, 2013
<u>AP</u>	SUN PHARM INDS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A090754 001</u>	Jun 16, 2010
<u>AP</u>	X GEN PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091485 001</u>	Aug 05, 2011
	LEVETIRACETAM IN SODIUM CHLORIDE			
	+ HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543 001	Nov 09, 2011
	+	1000MG/100ML (10MG/ML)	N202543 002	Nov 09, 2011
	+	1500MG/100ML (15MG/ML)	N202543 003	Nov 09, 2011

SOLUTION; ORAL

KEPPRA

<u>AA</u>	+ UCB INC	<u>100MG/ML</u>	<u>N021505 001</u>	Jul 15, 2003
-----------	-----------	-----------------	--------------------	--------------

LEVETIRACETAM

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100MG/ML</u>	<u>A078976 001</u>	Jan 15, 2009
<u>AA</u>	AMNEAL PHARMS	<u>100MG/ML</u>	<u>A090992 001</u>	Oct 27, 2009
<u>AA</u>	AUROBINDO PHARM	<u>100MG/ML</u>	<u>A079063 001</u>	Jan 15, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>100MG/ML</u>	<u>A079120 001</u>	Jan 16, 2009
<u>AA</u>	HETERO LABS LTD III	<u>100MG/ML</u>	<u>A203052 001</u>	Feb 28, 2013
<u>AA</u>	HI-TECH PHARMACAL	<u>100MG/ML</u>	<u>A090601 001</u>	Feb 28, 2012
<u>AA</u>	LUPIN LTD	<u>100MG/ML</u>	<u>A090893 001</u>	Oct 17, 2011
<u>AA</u>	ORIT LABS LLC	<u>100MG/ML</u>	<u>A203067 001</u>	May 09, 2013
<u>AA</u>	ROXANE	<u>100MG/ML</u>	<u>A078582 001</u>	Jan 15, 2009
<u>AA</u>	SILARX	<u>100MG/ML</u>	<u>A090263 001</u>	Apr 03, 2009
<u>AA</u>	TARO	<u>100MG/ML</u>	<u>A078774 001</u>	Feb 10, 2009
<u>AA</u>	TOLMAR	<u>100MG/ML</u>	<u>A079107 001</u>	Jan 15, 2009
<u>AA</u>	TRIS PHARMA INC	<u>100MG/ML</u>	<u>A090461 001</u>	Sep 30, 2010
<u>AA</u>	VINTAGE PHARMS	<u>100MG/ML</u>	<u>A090079 001</u>	Apr 11, 2012
<u>AA</u>	WOCKHARDT	<u>100MG/ML</u>	<u>A090028 001</u>	Mar 03, 2010

TABLET; ORAL

KEPPRA

<u>AB</u>	+ UCB INC	<u>1GM</u>	<u>N021035 004</u>	Jan 06, 2006
<u>AB</u>		<u>250MG</u>	<u>N021035 001</u>	Nov 30, 1999
<u>AB</u>		<u>500MG</u>	<u>N021035 002</u>	Nov 30, 1999
<u>AB</u>		<u>750MG</u>	<u>N021035 003</u>	Nov 30, 1999

LEVETIRACETAM

<u>AB</u>	ACCORD HLTHCARE	<u>1GM</u>	<u>A090843 004</u>	Feb 14, 2011
<u>AB</u>		<u>250MG</u>	<u>A090843 001</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A090843 002</u>	Feb 14, 2011



## PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>750MG</u>	<u>A090843</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	AJANTA PHARMA	<u>1GM</u>	<u>A201293</u>	<u>004</u>	Jun 14, 2011
<u>AB</u>		<u>250MG</u>	<u>A201293</u>	<u>001</u>	Jun 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A201293</u>	<u>002</u>	Jun 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A201293</u>	<u>003</u>	Jun 14, 2011
<u>AB</u>	APOTEX INC	<u>1GM</u>	<u>A078869</u>	<u>004</u>	Mar 13, 2009
<u>AB</u>		<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>		<u>750MG</u>	<u>A078869</u>	<u>003</u>	Mar 13, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	BRECKENRIDGE PHARM	<u>1GM</u>	<u>A090511</u>	<u>004</u>	Aug 18, 2011
<u>AB</u>		<u>250MG</u>	<u>A090511</u>	<u>001</u>	Aug 18, 2011
<u>AB</u>		<u>500MG</u>	<u>A090511</u>	<u>002</u>	Aug 18, 2011
<u>AB</u>		<u>750MG</u>	<u>A090511</u>	<u>003</u>	Aug 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	HETERO LABS LTD III	<u>1GM</u>	<u>A090515</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>250MG</u>	<u>A090515</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>500MG</u>	<u>A090515</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>750MG</u>	<u>A090515</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	LOTUS PHARM CO LTD	<u>500MG</u>	<u>A090906</u>	<u>001</u>	Nov 05, 2010
<u>AB</u>	LUPIN	<u>1GM</u>	<u>A090025</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078154</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078154</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	METHAPHARM	<u>1GM</u>	<u>A090767</u>	<u>004</u>	Jul 28, 2010
<u>AB</u>		<u>250MG</u>	<u>A090767</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>		<u>500MG</u>	<u>A090767</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>		<u>750MG</u>	<u>A090767</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>	MYLAN	<u>1GM</u>	<u>A090261</u>	<u>001</u>	Dec 08, 2009
<u>AB</u>		<u>250MG</u>	<u>A076919</u>	<u>001</u>	Nov 04, 2008
<u>AB</u>		<u>500MG</u>	<u>A076919</u>	<u>002</u>	Nov 04, 2008
<u>AB</u>		<u>750MG</u>	<u>A076919</u>	<u>003</u>	Nov 04, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>1GM</u>	<u>A090484</u>	<u>001</u>	Aug 05, 2010
<u>AB</u>		<u>250MG</u>	<u>A078526</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	PRINSTON INC	<u>1GM</u>	<u>A078106</u>	<u>004</u>	Feb 10, 2009
<u>AB</u>		<u>250MG</u>	<u>A078106</u>	<u>001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106</u>	<u>003</u>	Feb 10, 2009
<u>AB</u>	ROXANE	<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	TARO	<u>1GM</u>	<u>A078960</u>	<u>001</u>	Feb 01, 2010
<u>AB</u>		<u>250MG</u>	<u>A078960</u>	<u>004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960</u>	<u>003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960</u>	<u>002</u>	Feb 01, 2010
<u>AB</u>	TEVA PHARMS	<u>1GM</u>	<u>A078101</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078101</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078101</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078101</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	TORRENT PHARMS	<u>1GM</u>	<u>A078858</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078858</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	VINTAGE PHARMS	<u>1GM</u>	<u>A091491</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>		<u>250MG</u>	<u>A077319</u>	<u>001</u>	Mar 20, 2009
<u>AB</u>		<u>250MG</u>	<u>A091491</u>	<u>001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A077319</u>	<u>002</u>	Mar 20, 2009

## PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>500MG</u>	<u>A091491</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A077319</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A091491</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>	WOCKHARDT	<u>1GM</u>	<u>A079042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A079042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1GM</u>	<u>A078918</u>	<u>002</u>	Apr 29, 2009
<u>AB</u>		<u>250MG</u>	<u>A078918</u>	<u>001</u>	Apr 29, 2009

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

<u>AB</u>	UCB INC	<u>500MG</u>	<u>N022285</u>	<u>001</u>	Sep 12, 2008
<u>AB</u>	+	<u>750MG</u>	<u>N022285</u>	<u>002</u>	Feb 12, 2009

LEVETIRACETAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A091557</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091557</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A091093</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091093</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ANCHEN PHARMS	<u>500MG</u>	<u>A091360</u>	<u>001</u>	Oct 04, 2011
<u>AB</u>		<u>750MG</u>	<u>A091360</u>	<u>002</u>	Oct 04, 2011
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A091261</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091261</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A091399</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091399</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	MUTUAL PHARM CO INC	<u>500MG</u>	<u>A091285</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091285</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200475</u>	<u>001</u>	Dec 19, 2011
<u>AB</u>		<u>750MG</u>	<u>A200475</u>	<u>002</u>	Dec 19, 2011
<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A091291</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091291</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ROUSES POINT PHARMS	<u>500MG</u>	<u>A202524</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>750MG</u>	<u>A202524</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>500MG</u>	<u>A203059</u>	<u>001</u>	Sep 09, 2013
<u>AB</u>		<u>750MG</u>	<u>A203059</u>	<u>002</u>	Sep 09, 2013
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A091430</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091430</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG</u>	<u>A091338</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>750MG</u>	<u>A091338</u>	<u>002</u>	May 29, 2012
<u>AB</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A201464</u>	<u>001</u>	May 25, 2012
<u>AB</u>		<u>750MG</u>	<u>A201464</u>	<u>002</u>	May 25, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>500MG</u>	<u>A202533</u>	<u>001</u>	Jul 20, 2012
<u>AB</u>		<u>750MG</u>	<u>A202533</u>	<u>002</u>	Jul 20, 2012

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKBETA

<u>AT</u>	AKORN	<u>0.25%</u>	<u>A074779</u>	<u>001</u>	Oct 29, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074780</u>	<u>001</u>	Oct 29, 1996

BETAGAN

<u>AT</u>	+	ALLERGAN	<u>0.25%</u>	<u>N019814</u>	<u>001</u>	Jun 28, 1989
<u>AT</u>	+		<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	ALCON RES LTD	<u>0.5%</u>	<u>A074850</u>	<u>001</u>	Oct 28, 1996
<u>AT</u>	BAUSCH AND LOMB	<u>0.25%</u>	<u>A074307</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>		<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>	FALCON PHARMS	<u>0.25%</u>	<u>A074851</u>	<u>001</u>	Oct 28, 1996

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITOR

<u>AP</u>	+	SIGMA TAU	<u>200MG/ML</u>	<u>N020182</u>	<u>001</u>	Dec 16, 1992
-----------	---	-----------	-----------------	----------------	------------	--------------

LEVOCARNITINE

<u>AP</u>	EUROHLTH INTL	<u>200MG/ML</u>	<u>A075567</u>	<u>001</u>	Mar 29, 2001
<u>AP</u>	LUITPOLD	<u>200MG/ML</u>	<u>A075861</u>	<u>001</u>	Jun 22, 2001
<u>AP</u>	TEVA PHARMS USA	<u>200MG/ML</u>	<u>A075881</u>	<u>001</u>	Mar 29, 2001

SOLUTION; ORAL

CARNITOR

<u>AA</u>	+	SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>001</u>	Apr 10, 1986
-----------	---	-----------	-----------------	----------------	------------	--------------

CARNITOR SF

<u>AA</u>	SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>002</u>	Mar 28, 2007
-----------	-----------	-----------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

LEVOCARNITINE

SOLUTION; ORAL

LEVOCARNITINE

<u>AA</u>	HI TECH PHARMA	<u>1GM/10ML</u>	<u>A077399</u>	<u>001</u>	Oct 25, 2007
<u>AA</u>	LYNE	<u>1GM/10ML</u>	<u>A076851</u>	<u>001</u>	Aug 10, 2004

TABLET; ORAL

CARNITOR

<u>AB</u>	+ SIGMA TAU	<u>330MG</u>	<u>N018948</u>	<u>001</u>	Dec 27, 1985
-----------	-------------	--------------	----------------	------------	--------------

LEVOCARNITINE

<u>AB</u>	COREPHARMA	<u>330MG</u>	<u>A076858</u>	<u>001</u>	Sep 20, 2004
-----------	------------	--------------	----------------	------------	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AA</u>	APOTEX INC	<u>2.5MG/5ML</u>	<u>A202915</u>	<u>001</u>	Aug 21, 2014
<u>AA</u>	L PERRIGO CO	<u>2.5MG/5ML</u>	<u>A091263</u>	<u>001</u>	Nov 07, 2011
<u>AA</u>	TARO PHARM INDS	<u>2.5MG/5ML</u>	<u>A202673</u>	<u>001</u>	Jul 26, 2013

XYZAL

<u>AA</u>	+ UCB INC	<u>2.5MG/5ML</u>	<u>N022157</u>	<u>001</u>	Jan 28, 2008
-----------	-----------	------------------	----------------	------------	--------------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A090392</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A090385</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A091264</u>	<u>001</u>	Jun 29, 2012
<u>AB</u>	MICRO LABS LTD INDIA	<u>5MG</u>	<u>A202046</u>	<u>001</u>	Sep 17, 2013
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203646</u>	<u>001</u>	Sep 09, 2014
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A090362</u>	<u>001</u>	Jan 31, 2013
<u>AB</u>	SYNTHON PHARMS	<u>5MG</u>	<u>A090229</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A090199</u>	<u>001</u>	Aug 22, 2011

XYZAL

<u>AB</u>	+ UCB INC	<u>5MG</u>	<u>N022064</u>	<u>001</u>	May 25, 2007
-----------	-----------	------------	----------------	------------	--------------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

<u>AP</u>	+ JANSSEN PHARMS	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>N020635</u>	<u>001</u>	Dec 20, 1996
<u>AP</u>	+	<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>N020635</u>	<u>004</u>	Dec 20, 1996
<u>LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
<u>AP</u>	+ JANSSEN PHARMS	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>002</u>	Dec 20, 1996
<u>AP</u>	+	<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>003</u>	Dec 20, 1996
<u>AP</u>	+	<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>005</u>	Dec 20, 1996

LEVOFLOXACIN

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A202328</u>	<u>001</u>	Jan 24, 2013
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A202328</u>	<u>002</u>	Jan 24, 2013
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A091436</u>	<u>001</u>	Jun 05, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A202590</u>	<u>001</u>	Jan 24, 2013
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A202590</u>	<u>002</u>	Jan 24, 2013
<u>AP</u>	SAGENT PHARMS	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A200560</u>	<u>001</u>	Jun 20, 2011
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A200560</u>	<u>002</u>	Jun 20, 2011

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>001</u>	Jul 07, 2011
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>002</u>	Jul 07, 2011
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>003</u>	Jul 07, 2011
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>001</u>	Aug 08, 2013
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>002</u>	Aug 08, 2013
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>003</u>	Aug 08, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>001</u>	Jun 19, 2013
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>002</u>	Jun 19, 2013
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>003</u>	Jun 19, 2013
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>001</u>	Sep 16, 2011
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>002</u>	Sep 16, 2011
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>003</u>	Sep 16, 2011

SOLUTION; ORAL

LEVAQUIN

<u>AA</u>	+ JANSSEN PHARMS	<u>250MG/10ML</u>	<u>N021721</u>	<u>001</u>	Oct 21, 2004
-----------	------------------	-------------------	----------------	------------	--------------

LEVOFLOXACIN

<u>AA</u>	HI TECH PHARMA	<u>250MG/10ML</u>	<u>A091678</u>	<u>001</u>	Jun 20, 2011
-----------	----------------	-------------------	----------------	------------	--------------

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A090268</u>	<u>001</u>	Dec 20, 2010
<u>AT</u>	NEXUS PHARMS	<u>0.5%</u>	<u>A077700</u>	<u>001</u>	Dec 20, 2010
<u>AT</u>	WATSON LABS INC	<u>0.5%</u>	<u>A076826</u>	<u>001</u>	Feb 10, 2011

## PRESCRIPTION DRUG PRODUCT LIST

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

QUIXIN

<u>AT</u>	+ SANTEN	<u>0.5%</u>	<u>N021199</u>	<u>001</u>	Aug 18, 2000
	TABLET;ORAL				

LEVAQUIN

<u>AB</u>	JANSSEN PHARMS	<u>250MG</u>	<u>N020634</u>	<u>001</u>	Dec 20, 1996
<u>AB</u>		<u>500MG</u>	<u>N020634</u>	<u>002</u>	Dec 20, 1996
<u>AB</u>	+	<u>750MG</u>	<u>N020634</u>	<u>003</u>	Sep 08, 2000

LEVOFLOXACIN

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A090787</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>		<u>500MG</u>	<u>A090787</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>		<u>750MG</u>	<u>A090787</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A201043</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A201043</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A201043</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	CIPLA LTD	<u>250MG</u>	<u>A076890</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A076890</u>	<u>002</u>	Mar 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A076890</u>	<u>003</u>	Mar 30, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A076710</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076710</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076710</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A200250</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A200250</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A200250</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	HETERO LABS LTD V	<u>250MG</u>	<u>A202801</u>	<u>001</u>	Jan 08, 2015
<u>AB</u>		<u>500MG</u>	<u>A202801</u>	<u>002</u>	Jan 08, 2015
<u>AB</u>		<u>750MG</u>	<u>A202801</u>	<u>003</u>	Jan 08, 2015
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078424</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A078424</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A078424</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>250MG</u>	<u>A200839</u>	<u>001</u>	Mar 22, 2012
<u>AB</u>		<u>500MG</u>	<u>A200839</u>	<u>002</u>	Mar 22, 2012
<u>AB</u>		<u>750MG</u>	<u>A200839</u>	<u>003</u>	Mar 22, 2012
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076276</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076276</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077097</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A202200</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A202200</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A202200</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077438</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A077438</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077438</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	TEVA	<u>250MG</u>	<u>A076361</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076361</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076361</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A090722</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090722</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090722</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A090367</u>	<u>001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090367</u>	<u>002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090367</u>	<u>003</u>	Jun 20, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A077652</u>	<u>001</u>	Sep 07, 2012
<u>AB</u>		<u>500MG</u>	<u>A077652</u>	<u>002</u>	Sep 07, 2012
<u>AB</u>		<u>750MG</u>	<u>A077652</u>	<u>003</u>	Sep 07, 2012

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008
---	-----------------	-------------------	---------	-----	--------------

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

	FOREST LABS INC	EQ 20MG BASE	N204168	001	Jul 25, 2013
		EQ 40MG BASE	N204168	002	Jul 25, 2013
		EQ 80MG BASE	N204168	003	Jul 25, 2013
+		EQ 120MG BASE	N204168	004	Jul 25, 2013

## PRESCRIPTION DRUG PRODUCT LIST

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST L

+ DEPROCO

0.05MG/ML;2%

A088388 001 Oct 10, 1984

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

MIRENA

+ BAYER HLTHCARE

52MG

N021225 001 Dec 06, 2000

SKYLA

+ BAYER HLTHCARE

13.5MG

N203159 001 Jan 09, 2013

TABLET; ORAL

LEVONORGESTREL**AB** NOVEL LABS INC**1.5MG****A202508 001** Feb 22, 2013**AB** PERRIGO R AND D**0.75MG****A090740 001** Dec 30, 2010**AB** + WATSON LABS**0.75MG****A078665 001** Aug 28, 2009**AB** WATSON LABS INC**1.5MG****A200670 001** Jul 12, 2012PLAN B**AB** + TEVA BRANDED PHARM**0.75MG****N021045 002** Aug 24, 2006LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

+ ROXANE

2MG

A074278 001 Mar 31, 2000

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

INST BIOCHIMIQUE

0.013MG

N022121 001 Aug 01, 2007

INSTITUT BIOCHIMIQUE

0.025MG

N021924 002 Oct 13, 2006

0.05MG

N021924 003 Oct 13, 2006

0.075MG

N021924 004 Oct 13, 2006

0.088MG

N021924 010 Oct 02, 2009

0.1MG

N021924 005 Oct 13, 2006

0.112MG

N021924 008 Oct 02, 2009

0.125MG

N021924 006 Oct 13, 2006

0.137MG

N021924 009 Oct 02, 2009

+

0.15MG

N021924 007 Oct 13, 2006

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

+ FRESENIUS KABI USA

100MCG/VIAL

N202231 001 Jun 24, 2011

+

200MCG/VIAL

N202231 002 Jun 24, 2011

+

500MCG/VIAL

N202231 003 Jun 24, 2011

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

SYNTHROID

--&gt; ABBVIE

--> **AB1, AB2****0.025MG**

N021402 001 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.05MG**

N021402 002 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.075MG**

N021402 003 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.088MG**

N021402 004 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.1MG**

N021402 005 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.112MG**

N021402 006 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.125MG**

N021402 007 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.137MG**

N021402 008 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.15MG**

N021402 009 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.175MG**

N021402 010 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.2MG**

N021402 012 Jul 24, 2002

--&gt;

--> **AB1, AB2****0.3MG**

N021402 011 Jul 24, 2002

LEVO-T

--&gt; ALARA PHARM

--> **AB1, AB2, AB3****0.025MG**

N021342 001 Mar 01, 2002

--&gt;

--> **AB1, AB2, AB3****0.05MG**

N021342 002 Mar 01, 2002

--&gt;

--> **AB1, AB2, AB3****0.075MG**

N021342 003 Mar 01, 2002

--&gt;

--> **AB1, AB2, AB3****0.088MG**

N021342 004 Mar 01, 2002

--&gt;

--> **AB1, AB2, AB3****0.1MG**

N021342 005 Mar 01, 2002

--&gt;

--> **AB1, AB2, AB3****0.112MG**

N021342 006 Mar 01, 2002

--&gt;

--> **AB1, AB2, AB3****0.125MG**

N021342 007 Mar 01, 2002

--&gt;

--> **AB1, AB2,****0.137MG**

N021342 012 Dec 08, 2003

## PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVO-T

	<u>AB3</u>	<u>0.137MG</u>			
-->	<u>--&gt; AB1,AB2,AB3</u>	<u>0.15MG</u>		N021342 008	Mar 01, 2002
-->	<u>--&gt; AB1,AB2,AB3</u>	<u>0.175MG</u>		N021342 009	Mar 01, 2002
-->	<u>--&gt; AB1,AB2,AB3</u>	<u>0.2MG</u>		N021342 010	Mar 01, 2002
--> +	<u>--&gt; AB1,AB2,AB3</u>	<u>0.3MG</u>		N021342 011	Mar 01, 2002

UNITHROID

-->	STEVENS J	<u>--&gt; AB1,AB2,AB3</u>	<u>0.025MG</u>	N021210 001	Aug 21, 2000
-->		<u>--&gt; AB1,AB2,AB3</u>	<u>0.05MG</u>	N021210 002	Aug 21, 2000
-->		<u>--&gt; AB1,AB2,AB3</u>	<u>0.075MG</u>	N021210 003	Aug 21, 2000
-->		<u>--&gt; AB1,AB2,AB3</u>	<u>0.088MG</u>	N021210 004	Aug 21, 2000
-->		<u>--&gt; AB1,AB2,AB3</u>	<u>0.1MG</u>	N021210 005	Aug 21, 2000
-->		<u>--&gt; AB1,AB2,AB3</u>	<u>0.112MG</u>	N021210 006	Aug 21, 2000
-->		<u>--&gt; AB1,AB2,AB3</u>	<u>0.125MG</u>	N021210 007	Aug 21, 2000
-->		<u>--&gt; AB1,AB2,AB3</u>	<u>0.137MG</u>	N021210 012	Feb 08, 2008
-->		<u>--&gt; AB1,AB2,AB3</u>	<u>0.15MG</u>	N021210 008	Aug 21, 2000
-->		<u>--&gt; AB1,AB2,AB3</u>	<u>0.175MG</u>	N021210 009	Aug 21, 2000
-->		<u>--&gt; AB1,AB2,AB3</u>	<u>0.2MG</u>	N021210 010	Aug 21, 2000
--> +		<u>--&gt; AB1,AB2,AB3</u>	<u>0.3MG</u>	N021210 011	Aug 21, 2000

LEVOTHYROXINE SODIUM

-->	MYLAN	<u>--&gt;</u>	<u>0.025MG</u>	A076187 001	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>	<u>0.05MG</u>	A076187 002	Jun 05, 2002
-->		<u>--&gt;</u>	<u>0.075MG</u>	A076187 003	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>	<u>0.088MG</u>	A076187 004	Jun 05, 2002
-->		<u>--&gt;</u>	<u>0.1MG</u>	A076187 005	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>	<u>0.112MG</u>	A076187 006	Jun 05, 2002
-->		<u>--&gt;</u>	<u>0.125MG</u>	A076187 007	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>	<u>0.137MG</u>	A076187 012	Dec 13, 2006
-->		<u>--&gt;</u>	<u>0.15MG</u>	A076187 008	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>	<u>0.175MG</u>	A076187 009	Jun 05, 2002
-->		<u>--&gt;</u>	<u>0.2MG</u>	A076187 010	Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>	<u>0.3MG</u>	A076187 011	Jun 05, 2002
-->		<u>--&gt;</u>			
-->		<u>AB1,AB2,AB3,AB4</u>			

LEVOXYL

-->	KING PHARMS R AND D	<u>--&gt; AB1,AB3</u>	<u>0.025MG</u>	N021301 001	May 25, 2001
-->		<u>--&gt; AB1,AB3</u>	<u>0.05MG</u>	N021301 002	May 25, 2001
-->		<u>--&gt; AB1,AB3</u>	<u>0.075MG</u>	N021301 003	May 25, 2001
-->		<u>--&gt; AB1,AB3</u>	<u>0.088MG</u>	N021301 004	May 25, 2001
-->		<u>--&gt; AB1,AB3</u>	<u>0.1MG</u>	N021301 005	May 25, 2001
-->		<u>--&gt; AB1,AB3</u>	<u>0.112MG</u>	N021301 006	May 25, 2001
-->		<u>--&gt; AB1,AB3</u>	<u>0.125MG</u>	N021301 007	May 25, 2001
-->		<u>--&gt; AB1,AB3</u>	<u>0.137MG</u>	N021301 008	May 25, 2001
-->		<u>--&gt; AB1,AB3</u>	<u>0.15MG</u>	N021301 009	May 25, 2001
-->		<u>--&gt; AB1,AB3</u>	<u>0.175MG</u>	N021301 010	May 25, 2001
--> +		<u>--&gt; AB1,AB3</u>	<u>0.2MG</u>	N021301 011	May 25, 2001

LEVOTHROID

<u>AB4</u>	LLOYD	<u>0.025MG</u>		<u>N021116 001</u>	Oct 24, 2002
<u>AB4</u>		<u>0.05MG</u>		<u>N021116 002</u>	Oct 24, 2002

## PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHROID

<u>AB4</u>		<u>0.075MG</u>	<u>N021116</u>	<u>003</u>	Oct 24, 2002
<u>AB4</u>		<u>0.088MG</u>	<u>N021116</u>	<u>010</u>	Oct 24, 2002
<u>AB4</u>		<u>0.1MG</u>	<u>N021116</u>	<u>004</u>	Oct 24, 2002
<u>AB4</u>		<u>0.112MG</u>	<u>N021116</u>	<u>011</u>	Oct 24, 2002
<u>AB4</u>		<u>0.125MG</u>	<u>N021116</u>	<u>005</u>	Oct 24, 2002
<u>AB4</u>		<u>0.137MG</u>	<u>N021116</u>	<u>012</u>	Dec 07, 2004
<u>AB4</u>		<u>0.15MG</u>	<u>N021116</u>	<u>006</u>	Oct 24, 2002
<u>AB4</u>		<u>0.175MG</u>	<u>N021116</u>	<u>007</u>	Oct 24, 2002
<u>AB4</u>		<u>0.2MG</u>	<u>N021116</u>	<u>008</u>	Oct 24, 2002
<u>AB4</u>	+	<u>0.3MG</u>	<u>N021116</u>	<u>009</u>	Oct 24, 2002

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

<u>AT</u>	+	FOUGERA	<u>5%</u>	<u>A080198</u>	<u>001</u>	
<u>AT</u>		NOVOCOL INC	<u>5%</u>	<u>A040911</u>	<u>001</u>	May 23, 2011
<u>AT</u>		TARO	<u>5%</u>	<u>A086724</u>	<u>001</u>	

PATCH; TOPICAL

LIDOCAINE

<u>AB</u>		WATSON LABS INC	<u>5%</u>	<u>A200675</u>	<u>001</u>	Aug 23, 2012
<u>AB</u>	+	TEIKOKU PHARMA USA	<u>5%</u>	<u>N020612</u>	<u>001</u>	Mar 19, 1999

LIDOCAINE HYDROCHLORIDE

GEL; OPHTHALMIC

AKTEN

+ AKORN

3.5%

N022221 001 Oct 07, 2008

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>		AGILA SPECLTS	<u>0.5%</u>	<u>A091056</u>	<u>001</u>	Dec 08, 2010
<u>AP</u>			<u>0.5%</u>	<u>A091058</u>	<u>001</u>	Sep 30, 2010
<u>AP</u>			<u>1%</u>	<u>A091056</u>	<u>002</u>	Dec 08, 2010
<u>AP</u>			<u>1%</u>	<u>A091058</u>	<u>002</u>	Sep 30, 2010
<u>AP</u>			<u>2%</u>	<u>A202242</u>	<u>001</u>	Apr 11, 2014
<u>AP</u>		HOSPIRA	<u>0.5%</u>	<u>A088328</u>	<u>001</u>	May 17, 1984
<u>AP</u>			<u>1%</u>	<u>A083158</u>	<u>001</u>	
<u>AP</u>			<u>1%</u>	<u>A088329</u>	<u>001</u>	May 17, 1984
<u>AP</u>			<u>2%</u>	<u>A040078</u>	<u>001</u>	Jun 23, 1995
<u>AP</u>			<u>2%</u>	<u>A083158</u>	<u>002</u>	
<u>AP</u>			<u>2%</u>	<u>A088294</u>	<u>001</u>	May 17, 1984
<u>AP</u>			<u>20%</u>	<u>A083158</u>	<u>003</u>	
<u>AP</u>		INTL MEDICATION	<u>1%</u>	<u>A083173</u>	<u>001</u>	
<u>AP</u>			<u>2%</u>	<u>A083173</u>	<u>002</u>	
<u>AP</u>		LUITPOLD	<u>1%</u>	<u>A080850</u>	<u>001</u>	

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>200MG/100ML</u>	<u>N019830</u>	<u>002</u>	Apr 08, 1992
<u>AP</u>		BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>400MG/100ML</u>	<u>N019830</u>	<u>003</u>	Apr 08, 1992
<u>AP</u>		BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461</u>	<u>003</u>	

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		HOSPIRA	<u>400MG/100ML</u>	<u>N018388</u>	<u>002</u>	
-----------	--	---------	--------------------	----------------	------------	--

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>800MG/100ML</u>	<u>N019830</u>	<u>004</u>	Apr 08, 1992
<u>AP</u>		BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461</u>	<u>004</u>	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		HOSPIRA	<u>800MG/100ML</u>	<u>N018388</u>	<u>003</u>	Nov 05, 1982
-----------	--	---------	--------------------	----------------	------------	--------------

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A088586</u>	<u>001</u>	Jul 24, 1985
<u>AP</u>		HOSPIRA	<u>0.5%</u>	<u>A088325</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>			<u>1%</u>	<u>A088299</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>			<u>2%</u>	<u>A088327</u>	<u>001</u>	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		AGILA SPECLTS	<u>2%</u>	<u>A090665</u>	<u>001</u>	Sep 27, 2010
<u>AP</u>		AUROBINDO PHARMA LTD	<u>1%</u>	<u>A203040</u>	<u>001</u>	Mar 14, 2013
<u>AP</u>			<u>1%</u>	<u>A203082</u>	<u>001</u>	Mar 14, 2013
<u>AP</u>			<u>2%</u>	<u>A203040</u>	<u>002</u>	Mar 14, 2013
<u>AP</u>			<u>2%</u>	<u>A203082</u>	<u>002</u>	Mar 14, 2013
<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A080404</u>	<u>002</u>	

## PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		<u>2%</u>	<u>A080404</u>	<u>003</u>	
<u>AP</u>		<u>2%</u>	<u>N017584</u>	<u>001</u>	
<u>AP</u>		<u>4%</u>	<u>N017584</u>	<u>002</u>	
<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A080408</u>	<u>001</u>	
<u>AP</u>		<u>1.5%</u>	<u>A080408</u>	<u>002</u>	
<u>AP</u>		<u>4%</u>	<u>A088295</u>	<u>001</u>	May 17, 1984
<u>AP</u>	INTL MEDICATION	<u>20%</u>	<u>N017702</u>	<u>001</u>	

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A040302</u>	<u>001</u>	Sep 28, 1998
<u>AP</u>		<u>2%</u>	<u>A040302</u>	<u>002</u>	Sep 28, 1998

XYLOCAINE

<u>AP</u>	+ FRESENIUS KABI USA	<u>0.5%</u>	<u>N006488</u>	<u>008</u>	
<u>AP</u>	+	<u>1%</u>	<u>N006488</u>	<u>007</u>	
<u>AP</u>	+	<u>1.5%</u>	<u>N006488</u>	<u>010</u>	
<u>AP</u>	+	<u>2%</u>	<u>N006488</u>	<u>002</u>	

XYLOCAINE 4% PRESERVATIVE FREE

<u>AP</u>	+ FRESENIUS KABI USA	<u>4%</u>	<u>N010417</u>	<u>001</u>	
-----------	----------------------	-----------	----------------	------------	--

XYLOCAINE PRESERVATIVE FREE

<u>AP</u>	+ FRESENIUS KABI USA	<u>1%</u>	<u>N016801</u>	<u>005</u>	Jan 19, 1988
<u>AP</u>	+	<u>2%</u>	<u>N016801</u>	<u>001</u>	
<u>AP</u>	+	<u>4%</u>	<u>N016801</u>	<u>002</u>	
<u>AP</u>	+	<u>20%</u>	<u>N016801</u>	<u>004</u>	

INJECTABLE; SPINAL

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%  
+ HOSPIRA 5%

A083914 001

JELLY; TOPICAL

GLYDO

<u>AT</u>	SAGENT PHARMS	<u>2%</u>	<u>A201094</u>	<u>001</u>	Apr 28, 2014
-----------	---------------	-----------	----------------	------------	--------------

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	AKORN	<u>2%</u>	<u>A040433</u>	<u>001</u>	Feb 12, 2003
<u>AT</u>	INTL MEDICATION	<u>2%</u>	<u>A086283</u>	<u>001</u>	
<u>AT</u>	WATSON LABS INC	<u>2%</u>	<u>A040837</u>	<u>001</u>	Mar 23, 2011

XYLOCAINE

<u>AT</u>	+ OAK PHARMS	<u>2%</u>	<u>N008816</u>	<u>001</u>	
-----------	--------------	-----------	----------------	------------	--

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>A040014</u>	<u>001</u>	Jul 10, 1995
<u>AT</u>	WOCKHARDT	<u>2%</u>	<u>A087872</u>	<u>001</u>	Nov 18, 1982

LIDOCAINE HYDROCHLORIDE VISCOUS

<u>AT</u>	VINTAGE	<u>2%</u>	<u>A040708</u>	<u>001</u>	Feb 27, 2007
-----------	---------	-----------	----------------	------------	--------------

LIDOCAINE VISCOUS

<u>AT</u>	ROXANE	<u>2%</u>	<u>A088802</u>	<u>001</u>	Apr 26, 1985
-----------	--------	-----------	----------------	------------	--------------

XYLOCAINE VISCOUS

<u>AT</u>	+ FRESENIUS KABI USA	<u>2%</u>	<u>N009470</u>	<u>001</u>	
-----------	----------------------	-----------	----------------	------------	--

SOLUTION; TOPICAL

LARYNG-O-JET KIT

<u>AT</u>	INTL MEDICATION	<u>4%</u>	<u>A086364</u>	<u>001</u>	
-----------	-----------------	-----------	----------------	------------	--

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	IGI LABS INC	<u>4%</u>	<u>A204494</u>	<u>001</u>	Mar 12, 2014
<u>AT</u>	ROXANE	<u>4%</u>	<u>A088803</u>	<u>001</u>	Apr 03, 1985
<u>AT</u>	VINTAGE	<u>4%</u>	<u>A040710</u>	<u>001</u>	Feb 27, 2007
<u>AT</u>	WOCKHARDT	<u>4%</u>	<u>A087881</u>	<u>001</u>	Nov 18, 1982

LTA II KIT

<u>AT</u>	HOSPIRA	<u>4%</u>	<u>A080409</u>	<u>001</u>	
-----------	---------	-----------	----------------	------------	--

XYLOCAINE 4% PRESERVATIVE FREE

<u>AT</u>	+ FRESENIUS KABI USA	<u>4%</u>	<u>N010417</u>	<u>002</u>	
-----------	----------------------	-----------	----------------	------------	--

SYSTEM; INTRADERMAL

ZINGO

POWDER PHARMS 0.5MG

N022114 001 Aug 16, 2007

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

<u>AB</u>	+ WATSON LABS INC	<u>2.5%;2.5%</u>	<u>N019941</u>	<u>001</u>	Dec 30, 1992
-----------	-------------------	------------------	----------------	------------	--------------

LIDOCAINE AND PRILOCAINE

<u>AB</u>	FOUGERA PHARMS	<u>2.5%;2.5%</u>	<u>A076453</u>	<u>001</u>	Aug 18, 2003
<u>AB</u>	HI TECH PHARMA	<u>2.5%;2.5%</u>	<u>A076290</u>	<u>001</u>	Sep 25, 2003
<u>AB</u>	TOLMAR	<u>2.5%;2.5%</u>	<u>A076320</u>	<u>001</u>	Aug 27, 2003



## PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE; PRILOCAINE

GEL; PERIODONTAL

ORAQIX

+ DENTSPLY PHARM

2.5%; 2.5%

N021451 001 Dec 19, 2003

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+ GALDERMA LABS LP

7%; 7%

N021717 001 Jun 29, 2006

PATCH; TOPICAL

SYNERA

+ GALEN SPECIALTY

70MG; 70MG

N021623 001 Jun 23, 2005

LINACLOTIDE

CAPSULE; ORAL

LINZESS

+ FOREST LABS INC

145MCG

N202811 001 Aug 30, 2012

+

290MCG

N202811 002 Aug 30, 2012

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

+ BOEHRINGER INGELHEIM 5MG

N201280 001 May 02, 2011

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

+ BOEHRINGER INGELHEIM

2.5MG; 1GM

N201281 003 Jan 30, 2012

2.5MG; 500MG

N201281 001 Jan 30, 2012

2.5MG; 850MG

N201281 002 Jan 30, 2012

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

+ PHARMACIA AND UPJOHN

EQ 300MG BASE/ML

N050317 001

LINDANE

LOTION; TOPICAL

**LINDANE****AT** OLTA PHARMS**1%****A087313 001****AT** + WOCKHARDT**1%****A088190 001** Aug 16, 1984

SHAMPOO; TOPICAL

**LINDANE****AT** OLTA PHARMS**1%****A087266 001****AT** + WOCKHARDT**1%****A088191 001** Sep 18, 1984LINEZOLID

FOR SUSPENSION; ORAL

ZYVOX

+ PHARMACIA AND UPJOHN

100MG/5ML

N021132 001 Apr 18, 2000

INJECTABLE; INJECTION

**LINEZOLID****AP** TEVA PHARMS**200MG/100ML****A200222 001** Jun 27, 2012**ZYVOX****AP** + PHARMACIA AND UPJOHN**200MG/100ML****N021131 001** Apr 18, 2000

TABLET; ORAL

ZYVOX

+ PHARMACIA AND UPJOHN

600MG

N021130 002 Apr 18, 2000

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

**LIOTHYRONINE SODIUM****AP** X GEN PHARMS**EQ 0.01MG BASE/ML****A076923 001** Aug 17, 2005**TRIOSTAT****AP** + PAR STERILE PRODUCTS**EQ 0.01MG BASE/ML****N020105 001** Dec 31, 1991

TABLET; ORAL

**CYTOMEL****AB** KING PHARMS R AND D**EQ 0.005MG BASE****N010379 001****AB****EQ 0.025MG BASE****N010379 002****AB** +**EQ 0.05MG BASE****N010379 003****LIOTHYRONINE SODIUM****AB** COASTAL PHARMS**EQ 0.005MG BASE****A090097 001** Mar 20, 2009**AB****EQ 0.025MG BASE****A090097 002** Mar 20, 2009**AB****EQ 0.05MG BASE****A090097 003** Mar 20, 2009**AB**

MYLAN

**EQ 0.005MG BASE****A090326 001** Jul 14, 2009**AB****EQ 0.025MG BASE****A090326 002** Jul 14, 2009

## PRESCRIPTION DRUG PRODUCT LIST

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

<b>AB</b>		<b><u>EQ 0.05MG BASE</u></b>	<b><u>A090326 003</u></b>	Jul 14, 2009
<b>AB</b>	SIGMAPHARM LABS LLC	<b><u>EQ 0.005MG BASE</u></b>	<b><u>A200295 001</u></b>	Nov 29, 2012
<b>AB</b>		<b><u>EQ 0.025MG BASE</u></b>	<b><u>A200295 002</u></b>	Nov 29, 2012
<b>AB</b>		<b><u>EQ 0.05MG BASE</u></b>	<b><u>A200295 003</u></b>	Nov 29, 2012

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25

FOREST LABS 0.0031MG;0.0125MG N016807 001

THYROLAR-0.5

FOREST LABS 0.0063MG;0.025MG N016807 005

THYROLAR-1

FOREST LABS 0.0125MG;0.05MG N016807 004

THYROLAR-2

FOREST LABS 0.025MG;0.1MG N016807 002

THYROLAR-3

+ FOREST LABS 0.0375MG;0.15MG N016807 003

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

SAXENDA

+ NOVO NORDISK INC 18MG/3ML (6MG/ML) N206321 001 Dec 23, 2014

VICTOZA

+ NOVO NORDISK INC 18MG/3ML (6MG/ML) N022341 001 Jan 25, 2010

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

SHIRE DEVELOPMENT 10MG N021977 007 Oct 30, 2014

20MG N021977 004 Dec 10, 2007

30MG N021977 001 Feb 23, 2007

40MG N021977 005 Dec 10, 2007

50MG N021977 002 Feb 23, 2007

60MG N021977 006 Dec 10, 2007

+ 70MG N021977 003 Feb 23, 2007

LISINAPRIL

TABLET; ORAL

LISINAPRIL

<b>AB</b>	ACCORD HLTHCARE	<b><u>2.5MG</u></b>	<b><u>A202554 001</u></b>	Jul 30, 2013
<b>AB</b>		<b><u>5MG</u></b>	<b><u>A202554 002</u></b>	Jul 30, 2013
<b>AB</b>		<b><u>10MG</u></b>	<b><u>A202554 003</u></b>	Jul 30, 2013
<b>AB</b>		<b><u>20MG</u></b>	<b><u>A202554 004</u></b>	Jul 30, 2013
<b>AB</b>		<b><u>30MG</u></b>	<b><u>A202554 005</u></b>	Jul 30, 2013
<b>AB</b>		<b><u>40MG</u></b>	<b><u>A202554 006</u></b>	Jul 30, 2013
<b>AB</b>	APOTEX INC	<b><u>2.5MG</u></b>	<b><u>A076102 001</u></b>	Sep 30, 2002
<b>AB</b>		<b><u>5MG</u></b>	<b><u>A076102 002</u></b>	Sep 30, 2002
<b>AB</b>		<b><u>10MG</u></b>	<b><u>A076102 003</u></b>	Sep 30, 2002
<b>AB</b>		<b><u>20MG</u></b>	<b><u>A076102 004</u></b>	Sep 30, 2002
<b>AB</b>		<b><u>30MG</u></b>	<b><u>A076102 005</u></b>	Sep 30, 2002
<b>AB</b>		<b><u>40MG</u></b>	<b><u>A076102 006</u></b>	Sep 30, 2002
<b>AB</b>	AUROBINDO	<b><u>2.5MG</u></b>	<b><u>A077622 001</u></b>	Feb 22, 2006
<b>AB</b>		<b><u>5MG</u></b>	<b><u>A077622 002</u></b>	Feb 22, 2006
<b>AB</b>		<b><u>10MG</u></b>	<b><u>A077622 003</u></b>	Feb 22, 2006
<b>AB</b>		<b><u>20MG</u></b>	<b><u>A077622 004</u></b>	Feb 22, 2006
<b>AB</b>		<b><u>30MG</u></b>	<b><u>A077622 005</u></b>	Feb 22, 2006
<b>AB</b>		<b><u>40MG</u></b>	<b><u>A077622 006</u></b>	Feb 22, 2006
<b>AB</b>	HIKMA INTL PHARMS	<b><u>2.5MG</u></b>	<b><u>A076063 001</u></b>	Jul 01, 2002
<b>AB</b>		<b><u>5MG</u></b>	<b><u>A076063 002</u></b>	Jul 01, 2002
<b>AB</b>		<b><u>10MG</u></b>	<b><u>A076063 003</u></b>	Jul 01, 2002
<b>AB</b>		<b><u>20MG</u></b>	<b><u>A076063 004</u></b>	Jul 01, 2002
<b>AB</b>		<b><u>30MG</u></b>	<b><u>A076063 006</u></b>	Jun 27, 2003
<b>AB</b>		<b><u>40MG</u></b>	<b><u>A076063 005</u></b>	Jul 01, 2002
<b>AB</b>	INVAGEN PHARMS	<b><u>2.5MG</u></b>	<b><u>A203508 001</u></b>	Oct 29, 2013
<b>AB</b>		<b><u>5MG</u></b>	<b><u>A203508 002</u></b>	Oct 29, 2013
<b>AB</b>		<b><u>10MG</u></b>	<b><u>A203508 003</u></b>	Oct 29, 2013
<b>AB</b>		<b><u>20MG</u></b>	<b><u>A203508 004</u></b>	Oct 29, 2013
<b>AB</b>		<b><u>30MG</u></b>	<b><u>A203508 005</u></b>	Oct 29, 2013
<b>AB</b>		<b><u>40MG</u></b>	<b><u>A203508 006</u></b>	Oct 29, 2013
<b>AB</b>	IVAX SUB TEVA PHARMS	<b><u>2.5MG</u></b>	<b><u>A075752 001</u></b>	Jul 01, 2002
<b>AB</b>		<b><u>5MG</u></b>	<b><u>A075752 002</u></b>	Jul 01, 2002

## PRESCRIPTION DRUG PRODUCT LIST

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>		<u>10MG</u>	<u>A075752</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075752</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075752</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075752</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>2.5MG</u>	<u>A077321</u>	<u>001</u>	Sep 09, 2005
<u>AB</u>		<u>5MG</u>	<u>A077321</u>	<u>002</u>	Sep 09, 2005
<u>AB</u>		<u>10MG</u>	<u>A077321</u>	<u>003</u>	Sep 09, 2005
<u>AB</u>		<u>20MG</u>	<u>A077321</u>	<u>004</u>	Sep 09, 2005
<u>AB</u>		<u>30MG</u>	<u>A077321</u>	<u>005</u>	Sep 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077321</u>	<u>006</u>	Sep 09, 2005
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076071</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076071</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076071</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076071</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076071</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076071</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>2.5MG</u>	<u>A076180</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076180</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076180</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076164</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076164</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076164</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	RANBAXY	<u>2.5MG</u>	<u>A075944</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075944</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075944</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075944</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075944</u>	<u>006</u>	Feb 11, 2003
<u>AB</u>		<u>40MG</u>	<u>A075944</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A075994</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075994</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075994</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075994</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	VINTAGE	<u>2.5MG</u>	<u>A075743</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076059</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076059</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WOCKHARDT	<u>2.5MG</u>	<u>A078402</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402</u>	<u>003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402</u>	<u>004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402</u>	<u>005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402</u>	<u>006</u>	Apr 19, 2007
<u>PRINIVIL</u>					
<u>AB</u>	MERCK	<u>5MG</u>	<u>N019558</u>	<u>001</u>	Dec 29, 1987
<u>AB</u>		<u>10MG</u>	<u>N019558</u>	<u>002</u>	Dec 29, 1987
<u>AB</u>		<u>20MG</u>	<u>N019558</u>	<u>003</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558</u>	<u>004</u>	Oct 25, 1988
<u>ZESTRIL</u>					
<u>AB</u>	ASTRAZENECA	<u>2.5MG</u>	<u>N019777</u>	<u>005</u>	Apr 29, 1993
<u>AB</u>		<u>5MG</u>	<u>N019777</u>	<u>001</u>	May 19, 1988
<u>AB</u>		<u>10MG</u>	<u>N019777</u>	<u>002</u>	May 19, 1988
<u>AB</u>		<u>20MG</u>	<u>N019777</u>	<u>003</u>	May 19, 1988
<u>AB</u>		<u>30MG</u>	<u>N019777</u>	<u>006</u>	Jan 20, 1999
<u>AB</u>	+	<u>40MG</u>	<u>N019777</u>	<u>004</u>	May 19, 1988

## PRESCRIPTION DRUG PRODUCT LIST

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>	ALEMBIC LTD	<u>150MG</u>	<u>A079159 001</u>	Jan 12, 2009
<u>AB</u>		<u>300MG</u>	<u>A079159 002</u>	Jan 12, 2009
<u>AB</u>		<u>600MG</u>	<u>A079159 003</u>	Jan 12, 2009
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A079139 001</u>	Feb 03, 2009
<u>AB</u>		<u>300MG</u>	<u>A079139 002</u>	Feb 03, 2009
<u>AB</u>		<u>600MG</u>	<u>A079139 003</u>	Feb 03, 2009
<u>AB</u>	HETERO LABS LTD III	<u>150MG</u>	<u>A090702 001</u>	Sep 25, 2009
<u>AB</u>		<u>300MG</u>	<u>A090702 002</u>	Sep 25, 2009
<u>AB</u>		<u>600MG</u>	<u>A090702 003</u>	Sep 25, 2009
<u>AB</u>	HIKMA INTL PHARMS	<u>150MG</u>	<u>A076243 002</u>	Feb 24, 2003
<u>AB</u>		<u>300MG</u>	<u>A076243 001</u>	Jun 27, 2002
<u>AB</u>	ROXANE	<u>150MG</u>	<u>N017812 002</u>	Jan 28, 1987
<u>AB</u>		<u>300MG</u>	<u>N017812 001</u>	
<u>AB</u>	+	<u>600MG</u>	<u>N017812 003</u>	Jan 28, 1987

TABLET; ORAL

LITHIUM CARBONATE

<u>AB</u>	+	ROXANE	<u>300MG</u>	<u>N018558 001</u>	Jan 29, 1982
<u>AB</u>		SUN PHARM INDS INC	<u>300MG</u>	<u>A091027 001</u>	Jun 24, 2010

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>	GLENMARK GENERICS	<u>300MG</u>	<u>A091544 001</u>	Dec 27, 2010
<u>AB</u>		<u>450MG</u>	<u>A091616 001</u>	Feb 14, 2011
<u>AB</u>	HIKMA INTL PHARMS	<u>450MG</u>	<u>A076490 001</u>	Jun 17, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>300MG</u>	<u>A202288 001</u>	Jun 29, 2012
<u>AB</u>		<u>450MG</u>	<u>A202219 001</u>	Aug 08, 2012
<u>AB</u>	ROXANE	<u>300MG</u>	<u>A076832 001</u>	Oct 28, 2004
<u>AB</u>	+	<u>450MG</u>	<u>A076691 001</u>	Jan 05, 2004

LITHOBID

<u>AB</u>	+	ANI PHARMS INC	<u>300MG</u>	<u>N018027 001</u>	
-----------	---	----------------	--------------	--------------------	--

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

<u>AA</u>	+	ROXANE	<u>EQ 300MG CARBONATE/5ML</u>	<u>N018421 001</u>	
<u>AA</u>		WOCKHARDT	<u>EQ 300MG CARBONATE/5ML</u>	<u>A070755 001</u>	May 21, 1986

LODOXAMIDE TROMETHAMINESOLUTION/DROPS; OPHTHALMIC  
ALOMIDE

+	ALCON	EQ 0.1% BASE	N020191 001	Sep 23, 1993
---	-------	--------------	-------------	--------------

LOMITAPIDE MESYLATE

CAPSULE; ORAL

JUXTAPID

	AEGERION	EQ 5MG BASE	N203858 001	Dec 21, 2012
		EQ 10MG BASE	N203858 002	Dec 21, 2012
+		EQ 20MG BASE	N203858 003	Dec 21, 2012

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

	CORDEN PHARMA	10MG	N017588 001	
		40MG	N017588 002	
+		100MG	N017588 003	

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

<u>AB</u>	+	MCNEIL CONS	<u>2MG</u>	<u>N017694 001</u>	
		<u>LOPERAMIDE HYDROCHLORIDE</u>			
<u>AB</u>		MYLAN	<u>2MG</u>	<u>A072741 001</u>	Sep 18, 1991
<u>AB</u>		TEVA	<u>2MG</u>	<u>A073192 001</u>	Apr 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

KALETRA

+	ABBVIE	133.3MG; 33.3MG	N021226 001	Sep 15, 2000
---	--------	-----------------	-------------	--------------

SOLUTION; ORAL

KALETRA

+	ABBVIE	80MG/ML; 20MG/ML	N021251 001	Sep 15, 2000
---	--------	------------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

LOPINAVIR; RITONAVIR

TABLET; ORAL

KALETRA

ABBVIE

100MG; 25MG

N021906 002 Nov 09, 2007

+

200MG; 50MG

N021906 001 Oct 28, 2005

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAMAA AMNEAL PHARMS2MG/MLA091383 001 Dec 23, 2009AA HI-TECH PHARMA CO2MG/MLA200169 001 Jan 30, 2012AA LUPIN LTD2MG/MLA091407 001 Feb 19, 2013AA PADDOCK LLC2MG/MLA079244 001 Apr 28, 2009AA PHARM ASSOC2MG/MLA090260 001 Jun 15, 2010LORAZEPAM INTENSOLAA + ROXANE2MG/MLA072755 001 Jun 28, 1991

INJECTABLE; INJECTION

ATIVANAP + HIKMA MAPLE2MG/MLN018140 001AP +4MG/MLN018140 002LORAZEPAMAP AKORN2MG/MLA075025 001 Jul 23, 1998AP HOSPIRA2MG/MLA074243 001 Apr 12, 1994AP2MG/MLA074282 001 May 27, 1994AP4MG/MLA074243 002 Apr 12, 1994AP4MG/MLA074282 002 May 27, 1994AP INTL MEDICATION SYS2MG/MLA076150 001 Nov 15, 2004LORAZEPAM PRESERVATIVE FREEAP BEDFORD LABS2MG/MLA077074 001 Jul 13, 2005AP4MG/MLA077074 002 Jul 13, 2005

TABLET; ORAL

ATIVANAB VALEANT INTL0.5MGN017794 001AB1MGN017794 002AB +2MGN017794 003LORAZEPAMAB AMNEAL PHARMS0.5MGA078826 001 Jun 23, 2010AB1MGA078826 002 Jun 23, 2010AB2MGA078826 003 Jun 23, 2010AB EXCELLIUM0.5MGA078203 001 Jul 30, 2007AB1MGA078203 002 Jul 30, 2007AB2MGA078203 003 Jul 30, 2007AB IVAX SUB TEVA PHARMS0.5MGA077396 001 Dec 13, 2006AB1MGA077396 002 Dec 13, 2006AB2MGA077396 003 Dec 13, 2006AB MYLAN0.5MGA071589 001 Oct 13, 1987AB0.5MGA077657 001 Mar 16, 2006AB1MGA071590 001 Oct 13, 1987AB1MGA077657 002 Mar 16, 2006AB2MGA071591 001 Oct 13, 1987AB2MGA077657 003 Mar 16, 2006AB RANBAXY0.5MGA076045 001 Aug 29, 2001AB1MGA076045 002 Aug 29, 2001AB2MGA076045 003 Aug 29, 2001AB SANDOZ0.5MGA071403 001 Apr 21, 1987AB1MGA071404 001 Apr 21, 1987AB2MGA071141 001 Apr 21, 1987AB VINTAGE PHARMS0.5MGA077754 001 May 10, 2006AB1MGA077754 002 May 10, 2006AB2MGA077754 003 May 10, 2006AB WATSON LABS0.5MGA072926 001 Oct 31, 1991AB1MGA072927 001 Oct 31, 1991AB2MGA072928 001 Oct 31, 1991LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

+ EISAI INC

10MG

N022529 001 Jun 27, 2012

## PRESCRIPTION DRUG PRODUCT LIST

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

<u>AB</u>	MERCK SHARP DOHME	<u>25MG</u>	<u>N020386 001</u>	Apr 14, 1995
<u>AB</u>		<u>50MG</u>	<u>N020386 002</u>	Apr 14, 1995
<u>AB</u>	+	<u>100MG</u>	<u>N020386 003</u>	Oct 13, 1998

LOSARTAN POTASSIUM

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090428 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090428 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090428 003</u>	Oct 06, 2010
<u>AB</u>	APOTEX CORP	<u>25MG</u>	<u>A090790 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090790 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090790 003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A090083 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090083 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090083 003</u>	Oct 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A201170 001</u>	Sep 18, 2012
<u>AB</u>		<u>50MG</u>	<u>A201170 002</u>	Sep 18, 2012
<u>AB</u>		<u>100MG</u>	<u>A201170 003</u>	Sep 18, 2012
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A200290 001</u>	Aug 30, 2013
<u>AB</u>		<u>50MG</u>	<u>A200290 002</u>	Aug 30, 2013
<u>AB</u>		<u>100MG</u>	<u>A200290 003</u>	Aug 30, 2013
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078232 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078232 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078232 003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>25MG</u>	<u>A202230 001</u>	May 30, 2012
<u>AB</u>		<u>50MG</u>	<u>A202230 002</u>	May 30, 2012
<u>AB</u>		<u>100MG</u>	<u>A202230 003</u>	May 30, 2012
<u>AB</u>	MICRO LABS LTD INDIA	<u>25MG</u>	<u>A091541 001</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A091541 002</u>	Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A091541 003</u>	Sep 24, 2012
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A091590 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091590 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091590 003</u>	Oct 06, 2010
<u>AB</u>	PRINSTON INC	<u>25MG</u>	<u>A091497 001</u>	Jun 06, 2011
<u>AB</u>		<u>50MG</u>	<u>A091497 002</u>	Jun 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A091497 003</u>	Jun 06, 2011
<u>AB</u>	ROXANE	<u>25MG</u>	<u>A077459 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077459 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077459 003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077424 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077424 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077424 003</u>	Oct 06, 2010
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076958 001</u>	Apr 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A076958 002</u>	Apr 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A076958 003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A090467 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090467 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090467 003</u>	Oct 06, 2010
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A090544 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090544 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090544 003</u>	Oct 06, 2010
<u>AB</u>	VIVIMED LABS	<u>25MG</u>	<u>A090382 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090382 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090382 003</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078243 001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078243 002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078243 003</u>	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB INC 0.5%

N202872 001 Sep 28, 2012

OINTMENT; OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB 0.5%

N200738 001 Apr 15, 2011

SUSPENSION/DROPS; OPHTHALMIC

ALREX

+ BAUSCH AND LOMB 0.2%

N020803 001 Mar 09, 1998

LOTEMAX

+ BAUSCH AND LOMB 0.5%

N020583 001 Mar 09, 1998

**PRESCRIPTION DRUG PRODUCT LIST**LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

ZYLET

+ BAUSCH AND LOMB 0.5%;0.3% N050804 001 Dec 14, 2004

LOVASTATIN

TABLET;ORAL

LOVASTATIN

<b>AB</b>	ACTAVIS ELIZABETH	<b>10MG</b>	<b>A075828 001</b>	Dec 17, 2001
<b>AB</b>		<b>20MG</b>	<b>A075828 002</b>	Dec 17, 2001
<b>AB</b>		<b>40MG</b>	<b>A075828 003</b>	Dec 17, 2001
<b>AB</b>	APOTEX INC	<b>10MG</b>	<b>A077748 001</b>	Feb 28, 2007
<b>AB</b>		<b>20MG</b>	<b>A077748 002</b>	Feb 28, 2007
<b>AB</b>		<b>40MG</b>	<b>A077748 003</b>	Feb 28, 2007
<b>AB</b>	CARLSBAD	<b>10MG</b>	<b>A075991 001</b>	Jun 05, 2002
<b>AB</b>		<b>20MG</b>	<b>A075991 002</b>	Jun 05, 2002
<b>AB</b>	+	<b>40MG</b>	<b>A075991 003</b>	Jun 05, 2002
<b>AB</b>	LUPIN	<b>10MG</b>	<b>A078296 001</b>	Mar 14, 2008
<b>AB</b>		<b>20MG</b>	<b>A078296 002</b>	Nov 01, 2007
<b>AB</b>		<b>40MG</b>	<b>A078296 003</b>	Nov 01, 2007
<b>AB</b>	MUTUAL PHARM	<b>10MG</b>	<b>A077520 001</b>	Apr 14, 2006
<b>AB</b>		<b>20MG</b>	<b>A077520 002</b>	Apr 14, 2006
<b>AB</b>		<b>40MG</b>	<b>A077520 003</b>	Apr 14, 2006
<b>AB</b>	MYLAN	<b>10MG</b>	<b>A075451 001</b>	Dec 17, 2001
<b>AB</b>		<b>10MG</b>	<b>A075935 001</b>	Dec 17, 2001
<b>AB</b>		<b>20MG</b>	<b>A075451 002</b>	Dec 17, 2001
<b>AB</b>		<b>20MG</b>	<b>A075935 002</b>	Dec 17, 2001
<b>AB</b>		<b>40MG</b>	<b>A075451 003</b>	Dec 17, 2001
<b>AB</b>		<b>40MG</b>	<b>A075935 003</b>	Dec 17, 2001
<b>AB</b>	SANDOZ	<b>10MG</b>	<b>A075300 001</b>	Dec 17, 2001
<b>AB</b>		<b>10MG</b>	<b>A075636 001</b>	Dec 17, 2001
<b>AB</b>		<b>20MG</b>	<b>A075300 002</b>	Dec 17, 2001
<b>AB</b>		<b>20MG</b>	<b>A075636 002</b>	Dec 17, 2001
<b>AB</b>		<b>40MG</b>	<b>A075300 003</b>	Dec 17, 2001
<b>AB</b>		<b>40MG</b>	<b>A075636 003</b>	Dec 17, 2001
<b>AB</b>	TEVA	<b>10MG</b>	<b>A075551 003</b>	Dec 17, 2001
<b>AB</b>		<b>20MG</b>	<b>A075551 002</b>	Dec 17, 2001
<b>AB</b>		<b>40MG</b>	<b>A075551 001</b>	Dec 17, 2001

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

	ANDRX LABS LLC	20MG	N021316 002	Jun 26, 2002
		40MG	N021316 003	Jun 26, 2002
	+	60MG	N021316 004	Jun 26, 2002

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE;ORAL

ADVICOR

+	ABBVIE	20MG;1GM	N021249 003	Dec 17, 2001
+		20MG;500MG	N021249 001	Dec 17, 2001
+		20MG;750MG	N021249 002	Dec 17, 2001
+		40MG;1GM	N021249 004	Apr 27, 2006

LOXAPINE

POWDER; INHALATION

ADASUVE

+ TEVA PHARMS USA INC 10MG N022549 001 Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

<b>AB</b>	LANNETT HOLDINGS INC	<b>EQ 5MG BASE</b>	<b>A090695 001</b>	Sep 26, 2011
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A090695 002</b>	Sep 26, 2011
<b>AB</b>		<b>EQ 25MG BASE</b>	<b>A090695 003</b>	Sep 26, 2011
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A090695 004</b>	Sep 26, 2011
<b>AB</b>	MIKAH PHARMA	<b>EQ 5MG BASE</b>	<b>A076868 001</b>	Aug 04, 2005
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A076868 002</b>	Aug 04, 2005
<b>AB</b>		<b>EQ 25MG BASE</b>	<b>A076868 003</b>	Aug 04, 2005
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A076868 004</b>	Aug 04, 2005
<b>AB</b>	MYLAN	<b>EQ 5MG BASE</b>	<b>A076762 001</b>	Nov 01, 2004
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A076762 002</b>	Nov 01, 2004
<b>AB</b>		<b>EQ 25MG BASE</b>	<b>A076762 003</b>	Nov 01, 2004
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A076762 004</b>	Nov 01, 2004
<b>AB</b>	WATSON LABS	<b>EQ 5MG BASE</b>	<b>A072204 001</b>	Jun 15, 1988
<b>AB</b>		<b>EQ 10MG BASE</b>	<b>A072205 001</b>	Jun 15, 1988

## PRESCRIPTION DRUG PRODUCT LIST

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

<b>AB</b>	+	<b>EQ 25MG BASE</b>	<b>A072206 001</b>	Jun 15, 1988
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A072062 001</b>	Jun 15, 1988

LUBIPROSTONE

CAPSULE;ORAL

AMITIZA

	SUCAMPO PHARMA LLC	8MCG	N021908 002	Apr 29, 2008
+		24MCG	N021908 001	Jan 31, 2006

LUCINACTANT

SUSPENSION;INTRATRACHEAL

SURFAXIN

+	DISCOVERY LABS	8.5ML	N021746 001	Mar 06, 2012
---	----------------	-------	-------------	--------------

LULICONAZOLE

CREAM;TOPICAL

LUZU

+	MEDICIS	1%	N204153 001	Nov 14, 2013
---	---------	----	-------------	--------------

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LATUDA

	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011
+		40MG	N200603 001	Oct 28, 2010
		60MG	N200603 005	Jul 12, 2013
		80MG	N200603 002	Oct 28, 2010
		120MG	N200603 004	Apr 26, 2012

MACITENTAN

TABLET;ORAL

OPSUMIT

+	ACTELION PHARMS LTD	10MG	N204410 001	Oct 18, 2013
---	---------------------	------	-------------	--------------

MAFENIDE ACETATE

CREAM;TOPICAL

SULFAMYLON

+	MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763 001	
---	---------------------	-----------------	-------------	--

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

<b>AT</b>	PAR FORM	<b>5%</b>	<b>A201511 001</b>	Feb 12, 2013
-----------	----------	-----------	--------------------	--------------

SULFAMYLON

<b>AT</b>	+	MYLAN INSTITUTIONAL	<b>5%</b>	<b>N019832 003</b>	Jun 05, 1998
-----------	---	---------------------	-----------	--------------------	--------------

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047 001	Jun 15, 1984
--	-----------------	------------------------------------	-------------	--------------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019696 001	Sep 29, 1989
---	---------	-----------------------------------------------------------------------------------	-------------	--------------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML</b>	<b>N017378 001</b>	
-----------	-----------------	------------------------------------------------------------------	--------------------	--

PLASMA-LYTE A IN PLASTIC CONTAINER

<b>AP</b>	BAXTER HLTHCARE	<b>30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML</b>	<b>N017378 002</b>	Nov 22, 1982
-----------	-----------------	------------------------------------------------------------------	--------------------	--------------

ISOLYTE S IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019711 001	Sep 29, 1989
--	---------	-----------------------------------------------------------	-------------	--------------

NORMOSOL-R IN PLASTIC CONTAINER

	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017586 001	
--	---------	-----------------------------------------------------------	-------------	--

SOLUTION;IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019024 001	Jun 08, 1984
--	---------	-----------------------------------------------------------	-------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N017637 002	Jul 08, 1982
---------	-------------------------------------------------------------------	-------------	--------------

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION; INJECTION

NORMOCARB HF 25

+ DIALYSIS SUPS	0.21GM/100ML; 2.8GM/100ML; 9.07GM/100ML	N021910 001	Jul 26, 2006
-----------------	-----------------------------------------	-------------	--------------

NORMOCARB HF 35

+ DIALYSIS SUPS	0.21GM/100ML; 3.97GM/100ML; 8.3GM/100ML	N021910 002	Jul 26, 2006
-----------------	-----------------------------------------	-------------	--------------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

<b>AP</b>	EXELA PHARMA SCS LLC	<b>500MG/ML</b>	<b>A206039 001</b>	Dec 18, 2014
-----------	----------------------	-----------------	--------------------	--------------

<b>AP</b>	+ FRESENIUS KABI USA	<b>500MG/ML</b>	<b>N019316 001</b>	Sep 08, 1986
-----------	----------------------	-----------------	--------------------	--------------

<b>AP</b>	+ HOSPIRA	<b>500MG/ML</b>	<b>A075151 001</b>	Apr 25, 2000
-----------	-----------	-----------------	--------------------	--------------

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ HOSPIRA	1GM/100ML	N020488 001	Jul 11, 1995
-----------	-----------	-------------	--------------

+ HOSPIRA	2GM/100ML	N020488 002	Jul 11, 1995
-----------	-----------	-------------	--------------

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA	2GM/50ML (40MG/ML)	N020309 003	Jan 26, 2007
---------	--------------------	-------------	--------------

+ HOSPIRA	4GM/100ML (40MG/ML)	N020309 001	Jun 24, 1994
-----------	---------------------	-------------	--------------

+ HOSPIRA	4GM/50ML (80MG/ML)	N020309 002	Jun 24, 1994
-----------	--------------------	-------------	--------------

+ HOSPIRA	20GM/500ML (40MG/ML)	N020309 004	Jan 18, 1995
-----------	----------------------	-------------	--------------

+ HOSPIRA	40GM/1000ML (40MG/ML)	N020309 005	Jan 18, 1995
-----------	-----------------------	-------------	--------------

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SUPREP BOWEL PREP KIT

+ BRAINTREE LABS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N022372 001	Aug 05, 2010
------------------	-----------------------------------	-------------	--------------

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

+ BRAINTREE LABS	1.6GM; 210GM; 0.74GM; 3.13GM; 2.86GM; 5.6GM; 17.5GM	N203595 001	Jan 18, 2013
------------------	-----------------------------------------------------	-------------	--------------

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOL

<b>AT</b>	BAXTER HLTHCARE	<b>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</b>	<b>N018508 001</b>	Feb 19, 1982
-----------	-----------------	------------------------------------------------------------------------	--------------------	--------------

TIS-U-SOL IN PLASTIC CONTAINER

<b>AT</b>	BAXTER HLTHCARE	<b>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</b>	<b>N018336 001</b>	
-----------	-----------------	------------------------------------------------------------------------	--------------------	--

MALATHION

LOTION; TOPICAL

MALATHION

<b>AT</b>	SUVEN LIFE	<b>0.5%</b>	<b>A091559 001</b>	May 23, 2012
-----------	------------	-------------	--------------------	--------------

OVIDE

<b>AT</b>	+ TARO PHARMS NORTH	<b>0.5%</b>	<b>N018613 001</b>	Aug 02, 1982
-----------	---------------------	-------------	--------------------	--------------

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962 001	Jun 26, 1986
---------	-----------------------	-------------	--------------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

<b>AP</b>	B BRAUN	<b>10GM/100ML</b>	<b>N016080 002</b>	
-----------	---------	-------------------	--------------------	--

MANNITOL 10% IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<b>10GM/100ML</b>	<b>N020006 002</b>	Jul 26, 1993
-----------	---------	-------------------	--------------------	--------------

<b>AP</b>	HOSPIRA	<b>10GM/100ML</b>	<b>N019603 002</b>	Jan 08, 1987
-----------	---------	-------------------	--------------------	--------------

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

<b>AP</b>	B BRAUN	<b>10GM/100ML</b>	<b>N016080 006</b>	
-----------	---------	-------------------	--------------------	--

MANNITOL 15%

<b>AP</b>	B BRAUN	<b>15GM/100ML</b>	<b>N016080 003</b>	
-----------	---------	-------------------	--------------------	--

MANNITOL 15% IN PLASTIC CONTAINER

<b>AP</b>	B BRAUN	<b>15GM/100ML</b>	<b>N020006 003</b>	Jul 26, 1993
-----------	---------	-------------------	--------------------	--------------

<b>AP</b>	HOSPIRA	<b>15GM/100ML</b>	<b>N019603 003</b>	Jan 08, 1990
-----------	---------	-------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

MANNITOL

INJECTABLE; INJECTION

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

AP	B BRAUN	15GM/100ML	N016080	005	
	<u>MANNITOL 20%</u>				
AP	B BRAUN	20GM/100ML	N016080	004	
	<u>MANNITOL 20% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	20GM/100ML	N020006	004	Jul 26, 1993
AP	HOSPIRA	20GM/100ML	N019603	004	Jan 08, 1990
	<u>MANNITOL 25%</u>				
AP	FRESENIUS KABI USA	12.5GM/50ML	A080677	001	
AP	HOSPIRA	12.5GM/50ML	N016269	006	Aug 25, 1994
AP	INTL MEDICATION	12.5GM/50ML	A083051	001	
AP	LUITPOLD	12.5GM/50ML	A087409	001	Jan 21, 1982
	<u>MANNITOL 5%</u>				
AP	B BRAUN	5GM/100ML	N016080	001	
	<u>MANNITOL 5% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	5GM/100ML	N020006	001	Jul 26, 1993
AP	HOSPIRA	5GM/100ML	N019603	001	Jan 08, 1987
	<u>MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%</u>				
AP	B BRAUN	5GM/100ML	N016080	007	
	<u>OSMITROL 10% IN WATER</u>				
AP	BAXTER HLTHCARE	10GM/100ML	N013684	002	
	<u>OSMITROL 10% IN WATER IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	10GM/100ML	N013684	006	
	<u>OSMITROL 15% IN WATER</u>				
AP	BAXTER HLTHCARE	15GM/100ML	N013684	004	
	<u>OSMITROL 15% IN WATER IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	15GM/100ML	N013684	008	
	<u>OSMITROL 20% IN WATER</u>				
AP	BAXTER HLTHCARE	20GM/100ML	N013684	003	
	<u>OSMITROL 20% IN WATER IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	20GM/100ML	N013684	007	
	<u>OSMITROL 5% IN WATER</u>				
AP	BAXTER HLTHCARE	5GM/100ML	N013684	001	
	<u>OSMITROL 5% IN WATER IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	5GM/100ML	N013684	005	

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

B BRAUN 5GM/100ML N016772 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA 540MG/100ML; 2.7GM/100ML N018316 001

MAPROTILOLINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILOLINE HYDROCHLORIDE

MYLAN 25MG A072285 002 Oct 03, 1988

+ 50MG A072285 001 Oct 03, 1988

75MG A072285 003 Oct 03, 1988

MARAVIROC

TABLET; ORAL

SELZENTRY

VIIV HLTHCARE 150MG N022128 001 Aug 06, 2007

+ 300MG N022128 002 Aug 06, 2007

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

+ AMEDRA PHARMS LLC 100MG A073580 001 Jan 04, 1995

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

NEXGEN PHARMA 2.5MG A204054 001 Mar 19, 2013

## PRESCRIPTION DRUG PRODUCT LIST

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+ IPSEN INC

40MG/4ML (10MG/ML)

N021839 001 Aug 30, 2005

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL

VALCHLOR

+ ACTELION PHARMS LTD

EQ 0.016% BASE

N202317 001 Aug 23, 2013

INJECTABLE; INJECTION

MUSTARGEN

+ RECORDATI RARE

10MG/VIAL

N006695 001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>12.5MG</u>	<u>A201451 001</u>	Feb 23, 2011
<u>AA</u>		<u>25MG</u>	<u>A201451 002</u>	Feb 23, 2011
<u>AA</u>	EPIC PHARMA LLC	<u>12.5MG</u>	<u>A200294 001</u>	Apr 13, 2012
<u>AA</u>		<u>25MG</u>	<u>A200294 002</u>	Apr 13, 2012
<u>AA</u>	JUBILANT CADISTA	<u>12.5MG</u>	<u>A040659 001</u>	Jun 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A040659 002</u>	Jun 04, 2010
<u>AA</u>	MYLAN PHARMS INC	<u>12.5MG</u>	<u>A202640 001</u>	Sep 17, 2012
<u>AA</u>		<u>25MG</u>	<u>A202640 002</u>	Sep 17, 2012
<u>AA</u>	PAR PHARM	<u>12.5MG</u>	<u>A087127 001</u>	
<u>AA</u>		<u>25MG</u>	<u>A087128 001</u>	
<u>AA</u>	SANDOZ	<u>12.5MG</u>	<u>A084843 002</u>	May 22, 1989
<u>AA</u>		<u>25MG</u>	<u>A084092 003</u>	May 22, 1989
<u>AA</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A040179 001</u>	Jan 30, 1997
<u>AA</u>		<u>25MG</u>	<u>A040179 002</u>	Jan 30, 1997

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

MYLAN

EQ 50MG BASE

A071081 002 Sep 03, 1986

+

EQ 100MG BASE

A071081 001 Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>150MG/ML</u>	<u>N020246 001</u>	Oct 29, 1992
-----------	------------------------	-----------------	--------------------	--------------

MEDROXYPROGESTERONE ACETATE

<u>AB</u>	SANDOZ	<u>150MG/ML</u>	<u>A078711 001</u>	May 20, 2009
-----------	--------	-----------------	--------------------	--------------

<u>AB</u>	TEVA PHARMS USA	<u>150MG/ML</u>	<u>A076553 001</u>	Jul 28, 2004
-----------	-----------------	-----------------	--------------------	--------------

DEPO-PROVERA

+ PHARMACIA AND UPJOHN

400MG/ML

N012541 003

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+ PHARMACIA AND UPJOHN

104MG/0.65ML

N021583 001 Dec 17, 2004

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

<u>AB</u>	BARR	<u>2.5MG</u>	<u>A040159 001</u>	Aug 09, 1996
-----------	------	--------------	--------------------	--------------

<u>AB</u>		<u>5MG</u>	<u>A040159 002</u>	Aug 09, 1996
-----------	--	------------	--------------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A040159 003</u>	Aug 09, 1996
-----------	--	-------------	--------------------	--------------

PROVERA

<u>AB</u>	PHARMACIA AND UPJOHN	<u>2.5MG</u>	<u>N011839 001</u>	
-----------	----------------------	--------------	--------------------	--

<u>AB</u>		<u>5MG</u>	<u>N011839 003</u>	
-----------	--	------------	--------------------	--

<u>AB</u>	+	<u>10MG</u>	<u>N011839 004</u>	
-----------	---	-------------	--------------------	--

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

<u>AB</u>	BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090359 001</u>	Feb 05, 2013
-----------	--------------------	--------------	--------------------	--------------

<u>AB</u>	LUPIN LTD	<u>250MG</u>	<u>A091322 001</u>	Jul 22, 2011
-----------	-----------	--------------	--------------------	--------------

<u>AB</u>	MICRO LABS LTD	<u>250MG</u>	<u>A090562 001</u>	Nov 19, 2010
-----------	----------------	--------------	--------------------	--------------

<u>AB</u>	VINTAGE PHARMS LLC	<u>250MG</u>	<u>A091608 001</u>	Jun 02, 2014
-----------	--------------------	--------------	--------------------	--------------

PONSTEL

<u>AB</u>	+ SHIONOGI INC	<u>250MG</u>	<u>N015034 003</u>	
-----------	----------------	--------------	--------------------	--

## PRESCRIPTION DRUG PRODUCT LIST

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>250MG</u>	<u>A076392</u>	<u>001</u>	Dec 29, 2003
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A076523</u>	<u>001</u>	Oct 01, 2004
<u>AB</u>	+ SANDOZ	<u>250MG</u>	<u>A076175</u>	<u>001</u>	Feb 20, 2002

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>40MG/ML</u>	<u>N020264</u>	<u>001</u>	Sep 10, 1993
-----------	------------------------	----------------	----------------	------------	--------------

MEGACE ES

<u>AB</u>	+ PAR PHARM	<u>125MG/ML</u>	<u>N021778</u>	<u>001</u>	Jul 05, 2005
-----------	-------------	-----------------	----------------	------------	--------------

MEGESTROL ACETATE

<u>AB</u>	PAR PHARM	<u>40MG/ML</u>	<u>A075671</u>	<u>001</u>	Jul 25, 2001
<u>AB</u>	ROXANE	<u>40MG/ML</u>	<u>A075997</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>	TEVA PHARMS	<u>40MG/ML</u>	<u>A075681</u>	<u>001</u>	May 05, 2003
<u>AB</u>	TWI PHARMS INC	<u>125MG/ML</u>	<u>A203139</u>	<u>001</u>	Aug 27, 2014
<u>AB</u>	WOCKHARDT	<u>40MG/ML</u>	<u>A076721</u>	<u>001</u>	Nov 01, 2004

TABLET; ORAL

MEGESTROL ACETATE

<u>AB</u>	BARR	<u>20MG</u>	<u>A074621</u>	<u>002</u>	Aug 16, 1996
<u>AB</u>		<u>40MG</u>	<u>A074621</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	PAR PHARM	<u>20MG</u>	<u>A072422</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	+	<u>40MG</u>	<u>A072423</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	ROXANE	<u>20MG</u>	<u>A074458</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>40MG</u>	<u>A074458</u>	<u>002</u>	Sep 29, 1995

MELOXICAM

SUSPENSION; ORAL

MOBIC

	+ BOEHRINGER INGELHEIM	7.5MG/5ML	N021530	001	Jun 01, 2004
--	------------------------	-----------	---------	-----	--------------

TABLET; ORAL

MELOXICAM

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>		<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>	BRECKENRIDGE PHARM	<u>7.5MG</u>	<u>A077920</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077920</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CARLSBAD	<u>7.5MG</u>	<u>A077918</u>	<u>001</u>	Dec 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A077918</u>	<u>002</u>	Dec 07, 2006
<u>AB</u>	CIPLA LTD	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>		<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A077923</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077923</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	PURACAP PHARM	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	STRIDES PHARMA	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>		<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A077937</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077937</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>	TEVA PHARMS	<u>7.5MG</u>	<u>A077936</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077936</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	UNICHEM	<u>7.5MG</u>	<u>A077927</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077927</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077921</u>	<u>002</u>	Jul 19, 2006

MOBIC

<u>AB</u>	BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938</u>	<u>001</u>	Apr 13, 2000
<u>AB</u>	+	<u>15MG</u>	<u>N020938</u>	<u>002</u>	Aug 23, 2000

## PRESCRIPTION DRUG PRODUCT LIST

MELPHALAN

TABLET; ORAL

ALKERAN

+ GLAXOSMITHKLINE 2MG N014691 002

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERANAP + GLAXOSMITHKLINE EQ 50MG BASE/VIAL N020207 001 Nov 18, 1992MELPHALAN HYDROCHLORIDEAP EUROHLTH INTL EQ 50MG BASE/VIAL A090303 001 Oct 28, 2010AP MYLAN INSTITUTIONAL EQ 50MG BASE/VIAL A090270 001 Jun 09, 2009MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

FOREST LABS 7MG N022525 001 Jun 21, 2010

14MG N022525 002 Jun 21, 2010

21MG N022525 003 Jun 21, 2010

+ 28MG N022525 004 Jun 21, 2010

SOLUTION; ORAL

NAMENDA

+ FOREST LABS 2MG/ML N021627 001 Apr 18, 2005

TABLET; ORAL

NAMENDAAB FOREST LABS 5MG N021487 001 Oct 16, 2003AB + 10MG N021487 002 Oct 16, 2003MENOTROPINS (FSH; LH)

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

+ FERRING 75 IU/VIAL; 75 IU/VIAL N021047 001 Aug 27, 1999

INJECTABLE; SUBCUTANEOUS

MENOPUR

+ FERRING 75 IU/VIAL; 75 IU/VIAL N021663 001 Oct 29, 2004

MEPENZOLATE BROMIDE

TABLET; ORAL

CANTIL

+ SANOFI AVENTIS US 25MG N010679 003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROLAP + HOSPIRA 25MG/ML N021171 001AP + 50MG/ML N021171 002AP + 75MG/ML N021171 003AP + 100MG/ML N021171 004MEPERIDINE HYDROCHLORIDEAP HIKMA MAPLE 25MG/ML A080445 001AP 25MG/ML A080455 007AP 50MG/ML A080445 002AP 50MG/ML A080455 008AP 75MG/ML A080445 003AP 75MG/ML A080455 009AP 100MG/ML A080445 004AP 100MG/ML A080455 010MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREEAP HIKMA MAPLE 10MG/ML A081002 001 Jul 30, 1993AP + HOSPIRA 10MG/ML A088432 001 Aug 16, 1984

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

+ ROXANE 50MG/5ML A088744 001 Jan 30, 1985

TABLET; ORAL

DEMEROLAA + SANOFI AVENTIS US 50MG N005010 001AA + 100MG N005010 004MEPERIDINE HYDROCHLORIDEAA BARR 50MG A088639 001 Jul 02, 1984AA 100MG A088640 001 Sep 19, 1984AA EPIC PHARMA 50MG A040331 001 May 28, 1999AA 100MG A040331 002 May 28, 1999AA MALLINCKRODT 50MG A040352 001 Jun 13, 2000AA 100MG A040352 002 Jun 13, 2000AA MIKART 50MG A040893 001 Jun 24, 2009

## PRESCRIPTION DRUG PRODUCT LIST

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

<u>AA</u>		<u>100MG</u>	<u>A040893 003</u>	Jun 24, 2009
<u>AA</u>	ROXANE	<u>50MG</u>	<u>A040110 001</u>	Mar 12, 1997
<u>AA</u>		<u>100MG</u>	<u>A040110 002</u>	Mar 12, 1997
<u>AA</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A040446 001</u>	Aug 08, 2002
<u>AA</u>		<u>100MG</u>	<u>A040446 002</u>	Aug 08, 2002
<u>AA</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040191 001</u>	Dec 17, 1998
<u>AA</u>		<u>100MG</u>	<u>A040191 002</u>	Dec 17, 1998
	MIKART	75MG	A040893 002	Jun 24, 2009
		150MG	A040893 004	Jun 24, 2009

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	+	HOSPIRA	<u>1%</u>	<u>N012250 001</u>
<u>AP</u>	+		<u>1.5%</u>	<u>N012250 005</u>
<u>AP</u>	+		<u>2%</u>	<u>N012250 002</u>

ISOCAINE HYDROCHLORIDE

<u>AP</u>	+	NOVOCOL	<u>3%</u>	<u>A080925 001</u>
-----------	---	---------	-----------	--------------------

MEPIVACAINE HYDROCHLORIDE

<u>AP</u>		HOSPIRA INC	<u>3%</u>	<u>A040806 001</u>	Apr 28, 2008
-----------	--	-------------	-----------	--------------------	--------------

POLOCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089407 001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089410 001</u>	Dec 01, 1986

POLOCAINE-MPF

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089406 001</u>	Dec 01, 1986
<u>AP</u>			<u>1.5%</u>	<u>A089408 001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089409 001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	+	DEPROCO	<u>3%</u>	<u>A088387 001</u>	Oct 10, 1984
-----------	---	---------	-----------	--------------------	--------------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>		ALEMBIC PHARMS LTD	<u>200MG</u>	<u>A090122 001</u>	Feb 18, 2009
<u>AA</u>			<u>400MG</u>	<u>A090122 002</u>	Feb 18, 2009
<u>AA</u>		INVAGEN PHARMS	<u>200MG</u>	<u>A040797 001</u>	Feb 27, 2008
<u>AA</u>			<u>400MG</u>	<u>A040797 002</u>	Feb 27, 2008
<u>AA</u>	+	WATSON LABS	<u>200MG</u>	<u>A083304 001</u>	
<u>AA</u>	+		<u>400MG</u>	<u>A083308 001</u>	

MERCAPTOPYRINE

SUSPENSION; ORAL

PURIXAN

	+	NOVA LABS LTD	20MG/ML	N205919 001	Apr 28, 2014
--	---	---------------	---------	-------------	--------------

TABLET; ORAL

MERCAPTOPYRINE

<u>AB</u>		MYLAN	<u>50MG</u>	<u>A040594 001</u>	Jul 01, 2005
<u>AB</u>		PROMETHEUS LABS	<u>50MG</u>	<u>A040461 001</u>	Feb 11, 2004
<u>AB</u>	+	ROXANE	<u>50MG</u>	<u>A040528 001</u>	Feb 13, 2004

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>		ACS DOBFAR	<u>1GM/VIAL</u>	<u>A091404 002</u>	Oct 26, 2011
<u>AP</u>			<u>500MG/VIAL</u>	<u>A091404 001</u>	Oct 26, 2011
<u>AP</u>		HOSPIRA INC	<u>1GM/VIAL</u>	<u>A090940 002</u>	Jun 22, 2010
<u>AP</u>			<u>500MG/VIAL</u>	<u>A090940 001</u>	Jun 22, 2010
<u>AP</u>		SANDOZ	<u>1GM/VIAL</u>	<u>A091201 002</u>	Mar 29, 2011
<u>AP</u>			<u>500MG/VIAL</u>	<u>A091201 001</u>	Mar 29, 2011

MERREM

<u>AP</u>	+	ASTRAZENECA	<u>1GM/VIAL</u>	<u>N050706 001</u>	Jun 21, 1996
<u>AP</u>	+		<u>500MG/VIAL</u>	<u>N050706 003</u>	Jun 21, 1996

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

	+	WARNER CHILCOTT LLC	400MG	N204412 001	Feb 01, 2013
--	---	---------------------	-------	-------------	--------------

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

	+	SALIX PHARMS	375MG	N022301 001	Oct 31, 2008
--	---	--------------	-------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

PENTASA

SHIRE

250MG

N020049 001 May 10, 1993

+

500MG

N020049 002 Jul 08, 2004

ENEMA;RECTAL

MESALAMINEAB PERRIGO ISRAEL4GM/60MLA076751 001 Sep 17, 2004AB TEVA4GM/60MLA076841 001 Sep 30, 2004ROWASAAB + MEDA PHARMS4GM/60MLN019618 001 Dec 24, 1987SFROWASAAB MEDA PHARMS4GM/60MLN019618 002 Jun 20, 2008

SUPPOSITORY;RECTAL

CANASA

+ FOREST LABS INC

1GM

N021252 002 Nov 05, 2004

TABLET, DELAYED RELEASE;ORAL

ASACOL

+ WARNER CHILCOTT LLC

400MG

N019651 001 Jan 31, 1992

ASACOL HD

+ WARNER CHILCOTT LLC

800MG

N021830 001 May 29, 2008

LIALDA

+ SHIRE

1.2GM

N022000 001 Jan 16, 2007

MESNA

INJECTABLE;INTRAVENOUS

MESNAAP AGILA SPECLTS100MG/MLA203364 001 Jul 18, 2014AP EUROHLTH INTL100MG/MLA075739 001 Jan 09, 2004AP FRESENIUS KABI USA100MG/MLA075811 001 Apr 26, 2001AP MYLAN INSTITUTIONAL100MG/MLA076488 001 Mar 08, 2012AP SAGENT PHARMS100MG/MLA090913 001 Apr 13, 2010AP TEVA PHARMS USA100MG/MLA075764 001 Apr 27, 2001MESNEXAP + BAXTER HLTHCARE100MG/MLN019884 001 Dec 30, 1988

TABLET;ORAL

MESNEX

+ BAXTER HLTHCARE

400MG

N020855 001 Mar 21, 2002

MESTRANOL; NORETHINDRONE

TABLET;ORAL-28

NORINYL 1+50 28-DAY

+ WATSON LABS

0.05MG;1MG

N016659 001

METAPROTERENOL SULFATE

SOLUTION;INHALATION

METAPROTERENOL SULFATEAN + MYLAN SPECLT0.4%A071786 001 Aug 05, 1988AN +0.6%A070804 001 Aug 17, 1987AN WOCKHARDT0.4%A075586 001 May 30, 2002AN0.6%A075586 002 May 30, 2002

SYRUP;ORAL

METAPROTERENOL SULFATE

+ SILARX

10MG/5ML

A073632 001 Jul 22, 1992

TABLET;ORAL

METAPROTERENOL SULFATE

PAR PHARM

10MG

A072024 001 Jun 28, 1988

+

20MG

A072025 001 Jun 28, 1988

METARAMINOL BITARTRATE

INJECTABLE;INJECTION

METARAMINOL BITARTRATE

+ FRESENIUS KABI USA

EQ 10MG BASE/ML

A080722 001

METAXALONE

TABLET;ORAL

METAXALONEAB AMNEAL PHARMS800MGA203399 001 Jun 21, 2013AB SANDOZ800MGA040445 001 Mar 31, 2010SKELAXINAB + KING PHARMS800MGN013217 003 Aug 30, 2002

## PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+ RANBAXY

500MG/5ML

N021591 001 Sep 11, 2003

TABLET; ORAL

GLUCOPHAGEAB + BRISTOL MYERS SQUIBB1GMN020357 005 Nov 05, 1998AB500MGN020357 001 Mar 03, 1995AB850MGN020357 002 Mar 03, 1995METFORMIN HYDROCHLORIDEAB ALKEM1GMA091184 003 Nov 01, 2010AB500MGA091184 001 Nov 01, 2010AB850MGA091184 002 Nov 01, 2010AB AMNEAL PHARMS NY1GMA077880 003 Jun 05, 2006AB500MGA077880 001 Jun 05, 2006AB850MGA077880 002 Jun 05, 2006AB APOTEX1GMA075984 003 Apr 23, 2002AB1GMA090666 003 Dec 07, 2011AB500MGA075984 001 Apr 23, 2002AB500MGA090666 001 Dec 07, 2011AB850MGA075984 002 Apr 23, 2002AB850MGA090666 002 Dec 07, 2011AB ATLAS PHARMS LLC1GMA076033 003 Jan 24, 2002AB500MGA076033 001 Jan 24, 2002AB850MGA076033 002 Jan 24, 2002AB AUROBINDO1GMA077095 003 Jan 14, 2005AB500MGA077095 001 Jan 14, 2005AB850MGA077095 002 Jan 14, 2005AB CHARTWELL LIFE SCI1GMA075972 003 Jan 24, 2002AB500MGA075972 001 Jan 24, 2002AB850MGA075972 002 Jan 24, 2002AB DR REDDYS LABS INC1GMA077787 003 Aug 23, 2006AB500MGA077787 001 Aug 23, 2006AB850MGA077787 002 Aug 23, 2006AB GLENMARK GENERICS1GMA078170 003 May 23, 2008AB500MGA078170 001 May 23, 2008AB850MGA078170 002 May 23, 2008AB GRANULES INDIA1GMA090564 003 Apr 22, 2010AB500MGA090564 001 Apr 22, 2010AB850MGA090564 002 Apr 22, 2010AB INDICUS PHARMA1GMA079148 003 Nov 25, 2008AB500MGA079148 001 Nov 25, 2008AB850MGA079148 002 Nov 25, 2008AB MARKSANS PHARMA1GMA090888 003 Mar 12, 2012AB500MGA090888 001 Mar 12, 2012AB850MGA090888 002 Mar 12, 2012AB MUTUAL PHARMA1GMA076038 003 Feb 21, 2002AB500MGA076038 001 Feb 21, 2002AB850MGA076038 002 Feb 21, 2002AB MYLAN1GMA075973 003 Jan 25, 2002AB1GMA075976 003 Jan 24, 2002AB500MGA075973 001 Jan 25, 2002AB500MGA075976 001 Jan 24, 2002AB850MGA075973 002 Jan 25, 2002AB850MGA075976 002 Jan 24, 2002AB MYLAN PHARMS INC1GMA075969 003 Jan 29, 2002AB500MGA075969 001 Jan 29, 2002AB850MGA075969 002 Jan 29, 2002AB PROVIDENT PHARM1GMA077853 003 Jul 28, 2006AB500MGA077853 001 Jul 28, 2006AB850MGA077853 002 Jul 28, 2006AB SANDOZ1GMA075965 003 Jan 25, 2002AB1GMA075985 003 Jan 25, 2002AB500MGA075965 001 Jan 25, 2002AB500MGA075985 001 Jan 25, 2002AB850MGA075965 002 Jan 25, 2002AB850MGA075985 002 Jan 25, 2002AB SCIEGEN PHARMS INC500MGA203769 001 Sep 11, 2013AB850MGA203769 002 Sep 11, 2013AB1GMA203769 003 Sep 11, 2013AB SUN PHARM INDS INC1GMA075967 003 Jan 29, 2002AB500MGA075967 001 Jan 29, 2002



## PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>850MG</u>	<u>A075967 002</u>	Jan 29, 2002
<u>AB</u>	TEVA	<u>1GM</u>	<u>A075978 003</u>	Nov 05, 2002
<u>AB</u>		<u>500MG</u>	<u>A075978 001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075978 002</u>	Jan 25, 2002
<u>AB</u>	TORRENT PHARMS	<u>1GM</u>	<u>A077711 003</u>	Jan 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A077711 001</u>	Jan 24, 2007
<u>AB</u>		<u>850MG</u>	<u>A077711 002</u>	Jan 24, 2007
<u>AB</u>	WATSON LABS FLORIDA	<u>1GM</u>	<u>A075961 003</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075961 001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075961 002</u>	Jan 25, 2002
<u>AB</u>	ZYDUS HLTHCARE	<u>1GM</u>	<u>A203686 003</u>	Aug 28, 2014
<u>AB</u>		<u>500MG</u>	<u>A203686 001</u>	Aug 28, 2014
<u>AB</u>		<u>850MG</u>	<u>A203686 002</u>	Aug 28, 2014
<u>AB</u>	ZYDUS PHARMS USA	<u>1GM</u>	<u>A077064 003</u>	Apr 18, 2005
<u>AB</u>		<u>500MG</u>	<u>A077064 001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064 002</u>	Apr 18, 2005
	CHARTWELL LIFE SCI	625MG	A075972 005	Jan 24, 2002
		750MG	A075972 004	Jan 24, 2002

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>750MG</u>	<u>N021202 004</u>	Apr 11, 2003
-----------	------------------------	--------------	--------------------	--------------

METFORMIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>750MG</u>	<u>A076869 001</u>	Apr 12, 2005
<u>AB</u>	AMNEAL PHARMS NY	<u>750MG</u>	<u>A078596 002</u>	Jan 03, 2008
<u>AB</u>	APOTEX	<u>750MG</u>	<u>A076706 002</u>	Dec 29, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A079118 002</u>	Jul 20, 2012
<u>AB</u>	BARR	<u>750MG</u>	<u>A076863 001</u>	Oct 14, 2004
<u>AB</u>	CSPC OUYI PHARM CO	<u>750MG</u>	<u>A078321 002</u>	Apr 17, 2008
<u>AB</u>	IMPAX LABS	<u>750MG</u>	<u>A076985 001</u>	Sep 13, 2005
<u>AB</u>	MYLAN	<u>750MG</u>	<u>A077113 001</u>	Sep 08, 2005
<u>AB</u>	NOSTRUM PHARMS LLC	<u>750MG</u>	<u>A076756 002</u>	Dec 12, 2011
<u>AB</u>	SUN PHARM INDS (IN)	<u>750MG</u>	<u>A077336 002</u>	Feb 09, 2006
<u>AB</u>	TEVA	<u>750MG</u>	<u>A076864 001</u>	Apr 12, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>750MG</u>	<u>A077078 001</u>	Apr 21, 2005

GLUCOPHAGE XR

<u>AB1</u>	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N021202 001</u>	Oct 13, 2000
------------	----------------------	--------------	--------------------	--------------

METFORMIN HYDROCHLORIDE

<u>AB1</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A076172 001</u>	Jun 16, 2004
<u>AB1</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596 001</u>	Jan 03, 2008
<u>AB1</u>	APOTEX	<u>500MG</u>	<u>A076706 001</u>	Dec 14, 2004
<u>AB1</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A079118 001</u>	Jul 20, 2012
<u>AB1</u>	CSPC OUYI PHARM CO	<u>500MG</u>	<u>A078321 001</u>	Apr 17, 2008
<u>AB1</u>	IMPAX LABS	<u>500MG</u>	<u>A076249 001</u>	Jul 30, 2004
<u>AB1</u>	INVENTIA HLTHCARE	<u>500MG</u>	<u>A201991 001</u>	Jan 18, 2012
<u>AB1</u>	MYLAN	<u>500MG</u>	<u>A076650 001</u>	Sep 13, 2005
<u>AB1</u>	NOSTRUM PHARMS LLC	<u>500MG</u>	<u>A076756 001</u>	Jul 26, 2006
<u>AB1</u>	SANDOZ	<u>500MG</u>	<u>A076873 001</u>	Dec 14, 2004
<u>AB1</u>	SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336 001</u>	Feb 09, 2006
<u>AB1</u>	TEVA	<u>500MG</u>	<u>A076269 001</u>	Jun 18, 2004
<u>AB1</u>	TORRENT PHARM	<u>500MG</u>	<u>A090014 001</u>	Dec 30, 2009
<u>AB1</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077060 001</u>	Apr 20, 2005

FORTAMET

<u>AB2</u>	+ ANDRX LABS LLC	<u>1GM</u>	<u>N021574 002</u>	Apr 27, 2004
<u>AB2</u>		<u>500MG</u>	<u>N021574 001</u>	Apr 27, 2004

METFORMIN HYDROCHLORIDE

<u>AB2</u>	LUPIN LTD	<u>1GM</u>	<u>A090692 002</u>	Jun 29, 2011
<u>AB2</u>		<u>500MG</u>	<u>A090692 001</u>	Jun 29, 2011
<u>AB2</u>	MYLAN PHARMS INC	<u>1GM</u>	<u>A200690 002</u>	Aug 01, 2012
<u>AB2</u>		<u>500MG</u>	<u>A200690 001</u>	Aug 01, 2012
<u>AB3</u>	LUPIN LTD	<u>1GM</u>	<u>A091664 002</u>	Jul 19, 2013
<u>AB3</u>		<u>500MG</u>	<u>A091664 001</u>	Jul 19, 2013

GLUMETZA

	+ SANTARUS INC	1GM	N021748 002	Jun 03, 2005
		500MG	N021748 001	Jun 03, 2005

## PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

<b>AB</b>	TAKEDA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>N021842 001</u>	Aug 29, 2005
<b>AB</b>	+	<u>850MG;EQ 15MG BASE</u>	<u>N021842 002</u>	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

<b>AB</b>	AUROBINDO PHARMA LTD	<u>500MG;EQ 15MG BASE</u>	<u>A200823 001</u>	Feb 13, 2013
<b>AB</b>		<u>850MG;EQ 15MG BASE</u>	<u>A200823 002</u>	Feb 13, 2013
<b>AB</b>	MYLAN	<u>500MG;EQ 15MG BASE</u>	<u>A090406 001</u>	Feb 25, 2011
<b>AB</b>		<u>850MG;EQ 15MG BASE</u>	<u>A090406 002</u>	Feb 25, 2011
<b>AB</b>	SANDOZ	<u>500MG;EQ 15MG BASE</u>	<u>A091273 001</u>	Apr 16, 2013
<b>AB</b>		<u>850MG;EQ 15MG BASE</u>	<u>A091273 002</u>	Apr 16, 2013
<b>AB</b>	TEVA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>A091155 001</u>	Mar 10, 2014
<b>AB</b>		<u>850MG;EQ 15MG BASE</u>	<u>A091155 002</u>	Mar 10, 2014
<b>AB</b>	TORRENT PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A202001 001</u>	Feb 13, 2013
<b>AB</b>		<u>850MG;EQ 15MG BASE</u>	<u>A202001 002</u>	Feb 13, 2013

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024 001	May 12, 2009
	+	1GM;EQ 30MG BASE	N022024 002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

PRANDIMET

	NOVO NORDISK INC	500MG;1MG	N022386 001	Jun 23, 2008
	+	500MG;2MG	N022386 002	Jun 23, 2008

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

<b>AB</b>	SB PHARMCO	<u>1GM;EQ 2MG BASE</u>	<u>N021410 004</u>	Aug 25, 2003
<b>AB</b>	+	<u>1GM;EQ 4MG BASE</u>	<u>N021410 005</u>	Aug 25, 2003
<b>AB</b>		<u>500MG;EQ 2MG BASE</u>	<u>N021410 002</u>	Oct 10, 2002
<b>AB</b>		<u>500MG;EQ 4MG BASE</u>	<u>N021410 003</u>	Oct 10, 2002

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

<b>AB</b>	TEVA	<u>1GM;EQ 4MG BASE</u>	<u>A077337 004</u>	May 07, 2014
<b>AB</b>		<u>1GM;EQ 2MG BASE</u>	<u>A077337 003</u>	May 07, 2014
<b>AB</b>		<u>500MG;EQ 2MG BASE</u>	<u>A077337 001</u>	May 07, 2014
<b>AB</b>		<u>500MG;EQ 4MG BASE</u>	<u>A077337 002</u>	May 07, 2014

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	ASTRAZENECA AB	1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010
	+	1GM;EQ 5MG BASE	N200678 002	Nov 05, 2010
		500MG;EQ 5MG BASE	N200678 001	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK SHARP DOHME	1GM;EQ 50MG BASE	N022044 002	Mar 30, 2007
		500MG;EQ 50MG BASE	N022044 001	Mar 30, 2007

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012
	+	1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012
		500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

	METHAPHARM	100MG/VIAL	N019193 001	Oct 31, 1986
--	------------	------------	-------------	--------------

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

<b>AA</b>	ROXANE	<u>10MG/ML</u>	<u>A040180 001</u>	Apr 30, 1998
<b>AA</b>	VISTAPHARM	<u>10MG/ML</u>	<u>A040088 001</u>	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

<b>AA</b>	ROXANE	<u>10MG/ML</u>	<u>A089897 001</u>	Sep 06, 1988
-----------	--------	----------------	--------------------	--------------

METHADOSE

<b>AA</b>	+	MALLINCKRODT	<u>10MG/ML</u>	<u>N017116 002</u>
-----------	---	--------------	----------------	--------------------

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

	+	MYLAN INSTITUTIONAL	10MG/ML	N021624 001
--	---	---------------------	---------	-------------

## PRESCRIPTION DRUG PRODUCT LIST

METHADONE HYDROCHLORIDE

POWDER; FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT

50GM/BOT

N006383 002

100GM/BOT

N006383 003

500GM/BOT

N006383 004

SOLUTION; ORAL

METHADONE HYDROCHLORIDEAA + ROXANE5MG/5MLA087393 001AA +10MG/5MLA087997 001

Aug 30, 1982

AA VISTAPHARM5MG/5MLA090707 001

Jun 30, 2010

AA10MG/5MLA090707 002

Jun 30, 2010

TABLET; ORAL

DOLOPHINE HYDROCHLORIDEAA + ROXANE5MGN006134 002AA +10MGN006134 010METHADONE HYDROCHLORIDEAA MALLINCKRODT5MGA040517 001

Apr 27, 2004

AA10MGA040517 002

Apr 27, 2004

AA SANDOZ10MGA040241 002

May 29, 1998

AA THE PHARMANETWORK10MGA090635 001

Nov 25, 2009

METHADOSEAA MALLINCKRODT5MGA040050 001

Apr 15, 1993

AA10MGA040050 002

Apr 15, 1993

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDEAA MALLINCKRODT INC40MGA077142 001

Jul 12, 2005

AA + ROXANE40MGN017058 001AA SANDOZ40MGA075082 001

Mar 25, 1998

METHADOSEAA MALLINCKRODT40MGA074184 001

Apr 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYNAA + RECORDATI RARE5MGN005378 002METHAMPHETAMINE HYDROCHLORIDEAA COASTAL PHARMS5MGA091189 001

Apr 21, 2010

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDEAB ANI PHARMS INC25MGA040001 001

Jun 30, 1993

AB50MGA040001 002

Jun 30, 1993

AB MIKART25MGA040062 001

Jan 27, 1994

AB +50MGA040062 002

Jan 27, 1994

AB SANDOZ25MGA040036 001

Jun 30, 1993

AB50MGA040036 002

Jun 30, 1993

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREXAB + SANOFI AVENTIS US1GMN017681 001METHENAMINE HIPPURATEAB COREPHARMA1GMA076411 001

Jun 20, 2003

UREXAB CNTY LINE PHARMS1GMN016151 001METHIMAZOLE

TABLET; ORAL

METHIMAZOLEAB CEDAR PHARMS5MGA040547 001

Feb 18, 2005

AB10MGA040547 002

Feb 18, 2005

AB EMCURE PHARMS USA5MGA040734 001

Dec 14, 2007

AB10MGA040734 002

Dec 14, 2007

AB MYLAN5MGA040350 001

Mar 29, 2000

AB +10MGA040350 002

Mar 29, 2000

AB SANDOZ5MGA040411 001

Mar 27, 2001

AB10MGA040411 002

Mar 27, 2001

AB SUN PHARM INDS INC5MGA040870 001

Sep 25, 2007

AB10MGA040870 002

Sep 25, 2007

AB VINTAGE PHARMS5MGA202068 001

Mar 07, 2012

AB10MGA202068 002

Mar 07, 2012

## PRESCRIPTION DRUG PRODUCT LIST

METHIMAZOLE

TABLET; ORAL

TAPAZOLE

<u>AB</u>	KING PHARMS	<u>5MG</u>	<u>A040320</u>	<u>001</u>	Mar 31, 2000
<u>AB</u>		<u>10MG</u>	<u>A040320</u>	<u>002</u>	Mar 31, 2000

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

<u>AP</u>	MYLAN INSTITUTIONAL	<u>1GM/10ML (100MG/ML)</u>	<u>A204404</u>	<u>001</u>	Dec 05, 2014
-----------	---------------------	----------------------------	----------------	------------	--------------

ROBAXIN

<u>AP</u>	+ HIKMA MAPLE	<u>1GM/10ML (100MG/ML)</u>	<u>N011790</u>	<u>001</u>	
-----------	---------------	----------------------------	----------------	------------	--

TABLET; ORAL

METHOCARBAMOL

<u>AA</u>	AUSTARPHARMA LLC	<u>500MG</u>	<u>A200958</u>	<u>001</u>	Oct 21, 2011
<u>AA</u>		<u>750MG</u>	<u>A200958</u>	<u>002</u>	Oct 21, 2011
<u>AA</u>	HETERO LABS LTD III	<u>500MG</u>	<u>A090200</u>	<u>001</u>	Nov 06, 2009
<u>AA</u>		<u>750MG</u>	<u>A090200</u>	<u>002</u>	Nov 06, 2009
<u>AA</u>	HIKMA INTL PHARMS	<u>500MG</u>	<u>A085159</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A085123</u>	<u>001</u>	
<u>AA</u>	LANNETT HOLDINGS INC	<u>500MG</u>	<u>A084756</u>	<u>002</u>	Mar 31, 2003
<u>AA</u>		<u>750MG</u>	<u>A084756</u>	<u>001</u>	
<u>AA</u>	PRINSTON INC	<u>500MG</u>	<u>A086989</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A086988</u>	<u>001</u>	
<u>AA</u>	SANDOZ	<u>500MG</u>	<u>A084616</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A084615</u>	<u>001</u>	
<u>AA</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A040489</u>	<u>001</u>	Jan 29, 2003
<u>AA</u>		<u>750MG</u>	<u>A040489</u>	<u>002</u>	Jan 29, 2003
<u>AA</u>	WATSON LABS	<u>500MG</u>	<u>A084277</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A084276</u>	<u>002</u>	

ROBAXIN

<u>AA</u>	+ AUXILIUM PHARMS LLC	<u>500MG</u>	<u>N011011</u>	<u>004</u>	
-----------	-----------------------	--------------	----------------	------------	--

ROBAXIN-750

<u>AA</u>	+ AUXILIUM PHARMS LLC	<u>750MG</u>	<u>N011011</u>	<u>006</u>	
-----------	-----------------------	--------------	----------------	------------	--

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

	+ PAR STERILE PRODUCTS	2.5GM/VIAL	N011559	002	
		200MG/VIAL	N011559	004	Dec 21, 2012
		500MG/VIAL	N011559	001	

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

	ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014
		10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013
		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013
		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013
		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013

RASUVO

	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014
		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014
		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014
		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014
		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014
		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
		27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014
		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A040266</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	PHARMACHEMIE BV	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A200171</u>	<u>001</u>	Feb 27, 2012

METHOTREXATE SODIUM

<u>AP</u>	+ EUROHLTH INTL	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A089341</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>002</u>	Feb 26, 1999
<u>AP</u>	+ HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>010</u>	Dec 15, 2004

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	+ ACCORD HLTHCARE	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716</u>	<u>001</u>	Apr 30, 2007
-----------	-------------------	-------------------------------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	+		<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767 001</u>	Apr 30, 2007
<u>AP</u>	+		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768 001</u>	Apr 30, 2007
<u>AP</u>		EBEWE PHARMA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029 001</u>	Mar 31, 2009
<u>AP</u>			<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039 001</u>	Mar 31, 2009
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039 002</u>	Mar 31, 2009
<u>AP</u>	+	EUROHLTH INTL	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340 001</u>	Sep 16, 1986
<u>AP</u>	+		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343 001</u>	Sep 16, 1986
<u>AP</u>	+	HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719 012</u>	Apr 13, 2005
<u>AP</u>		ONCO THERAPIES LTD	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A201530 001</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A201529 001</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A201529 002</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 200MG BASE/8ML (EQ 25MG BASE/ML)</u>	<u>A201529 003</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A201529 004</u>	Mar 29, 2012
<u>AP</u>		PHARMACHEMIE BV	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843 001</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040850 001</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 250MG/10ML (EQ 25MG BASE/ML)</u>	<u>A040853 001</u>	Jan 11, 2010

METHOTREXATE SODIUM

+ EUROHLTH INTL EQ 200MG BASE/8ML (EQ 25MG BASE/ML)

A089342 001 Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

+ EUROHLTH INTL EQ 1GM BASE/VIAL

A040632 001 Aug 12, 2005

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u>		BARR	<u>EQ 2.5MG BASE</u>	<u>A081099 001</u>	Oct 15, 1990
<u>AB</u>	+	DAVA PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>N008085 002</u>	
<u>AB</u>		MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235 001</u>	May 15, 1992
<u>AB</u>		ROXANE	<u>EQ 2.5MG BASE</u>	<u>A040054 001</u>	Aug 01, 1994
		TREXALL			
		BARR	EQ 5MG BASE	A040385 001	Mar 21, 2001
			EQ 7.5MG BASE	A040385 002	Mar 21, 2001
			EQ 10MG BASE	A040385 003	Mar 21, 2001
	+		EQ 15MG BASE	A040385 004	Mar 21, 2001

METHOXSALLEN

CAPSULE; ORAL

METHOXSALLEN

<u>AB</u>		STRIDES PHARMA	<u>10MG</u>	<u>A202687 001</u>	Jun 05, 2014
-----------	--	----------------	-------------	--------------------	--------------

OXSORALEN-ULTRA

<u>AB</u>	+	DOW PHARM	<u>10MG</u>	<u>N019600 001</u>	Oct 30, 1986
-----------	---	-----------	-------------	--------------------	--------------

8-MOP

+ VALEANT PHARM INTL 10MG N009048 001

INJECTABLE; INJECTION

UVADEX

+ THERAKOS 0.02MG/ML N020969 001 Feb 25, 1999

LOTION; TOPICAL

OXSORALEN

+ VALEANT PHARM INTL 1% N009048 002

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

<u>AA</u>		BAYSHORE PHARMS LLC	<u>2.5MG</u>	<u>A200602 001</u>	Sep 24, 2012
<u>AA</u>			<u>5MG</u>	<u>A200602 002</u>	Sep 24, 2012
<u>AA</u>		BRECKENRIDGE PHARM	<u>2.5MG</u>	<u>A040642 001</u>	Dec 06, 2011
<u>AA</u>			<u>5MG</u>	<u>A040642 002</u>	Dec 06, 2011
<u>AA</u>		VINTAGE PHARMS	<u>2.5MG</u>	<u>A040624 001</u>	Dec 28, 2006
<u>AA</u>			<u>5MG</u>	<u>A040624 002</u>	Dec 28, 2006

PAMINE

<u>AA</u>	+	FOUGERA PHARMS	<u>2.5MG</u>	<u>N008848 001</u>	
-----------	---	----------------	--------------	--------------------	--

PAMINE FORTE

<u>AA</u>	+	FOUGERA PHARMS	<u>5MG</u>	<u>N008848 002</u>	Mar 25, 2003
-----------	---	----------------	------------	--------------------	--------------

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

PARKE DAVIS 150MG N010596 007

+ 300MG N010596 008

## PRESCRIPTION DRUG PRODUCT LIST

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

+ MYLAN PHARMS INC

5MG

A087672 001 Aug 17, 1982

METHYLDOPA

TABLET; ORAL

METHYLDOPAAB ACCORD HLTHCARE250MGA070084 001 Oct 15, 1985AB 500MGA070085 001 Oct 15, 1985AB IVAX SUB TEVA PHARMS 250MGA070098 001 Feb 20, 1986AB 500MGA070343 001 Feb 20, 1986AB MYLAN 250MGA070076 002 Apr 18, 1985AB + 500MGA070076 001 Apr 18, 1985AB WATSON LABS 500MGA070625 001 Jun 06, 1986METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDEAP + LUITPOLD 50MG/MLA071279 001 Oct 02, 1987METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINEAP + EDISON THERAPS LLC 0.2MG/MLN006035 004METHYLERGONOVINE MALEATEAP ERGOJECT 0.2MG/MLA040889 001 Sep 13, 2010AP LUITPOLD 0.2MG/MLA090193 001 Nov 24, 2008

TABLET; ORAL

METHERGINEAB + EDISON THERAPS LLC 0.2MGN006035 003METHYLERGONOVINE MALEATEAB NOVEL LABS INC 0.2MGA091577 001 May 02, 2011METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS

8MG/0.4ML (8MG/0.4ML)

N021964 002 Sep 27, 2010

+

12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008

SOLUTION; SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS

12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

NOVEN PHARMS INC

10MG/9HR (1.1MG/HR)

N021514 001 Apr 06, 2006

15MG/9HR (1.6MG/HR)

N021514 002 Apr 06, 2006

20MG/9HR (2.2MG/HR)

N021514 003 Apr 06, 2006

+

30MG/9HR (3.3MG/HR)

N021514 004 Apr 06, 2006

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDEAB1 BARR LABS INC 10MGA079031 004 Oct 15, 2014AB1 20MGA079031 001 Jul 13, 2012AB1 30MGA079031 002 Jul 13, 2012AB1 40MGA079031 003 Jul 13, 2012AB1 WATSON LABS INC 20MGA078458 001 Dec 01, 2011AB1 30MGA078458 002 Dec 01, 2011AB1 40MGA078458 003 Dec 01, 2011RITALIN LAAB1 NOVARTIS 10MGN021284 004 Apr 10, 2004AB1 20MGN021284 001 Jun 05, 2002AB1 30MGN021284 002 Jun 05, 2002AB1 + 40MGN021284 003 Jun 05, 2002METADATE CDAB2 UCB INC 10MGN021259 003 May 27, 2003AB2 20MGN021259 001 Apr 03, 2001AB2 30MGN021259 002 Jun 19, 2003AB2 40MGN021259 004 Feb 19, 2006AB2 50MGN021259 005 Feb 19, 2006AB2 + 60MGN021259 006 Feb 19, 2006METHYLPHENIDATE HYDROCHLORIDEAB2 TEVA PHARMS 10MGA077707 001 Jul 19, 2012

## PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB2</u>		<u>20MG</u>	<u>A077707</u>	<u>002</u>	Jul 19, 2012
<u>AB2</u>		<u>30MG</u>	<u>A077707</u>	<u>003</u>	Jul 19, 2012
<u>AB2</u>		<u>40MG</u>	<u>A078873</u>	<u>001</u>	Jul 19, 2012
<u>AB2</u>		<u>50MG</u>	<u>A078873</u>	<u>002</u>	Jul 19, 2012
<u>AB2</u>		<u>60MG</u>	<u>A078873</u>	<u>003</u>	Jul 19, 2012

RITALIN LA

NOVARTIS

60MG

N021284 005 Oct 27, 2014

FOR SUSPENSION, EXTENDED RELEASE;ORAL

QUILLIVANT XR

+ NEXTWAVE PHARMS

5MG/ML

N202100 001 Sep 27, 2012

SOLUTION;ORAL

METHYLIN

<u>AA</u>	+	MALLINCKRODT	<u>5MG/5ML</u>	<u>N021419</u>	<u>001</u>	Dec 19, 2002
<u>AA</u>	+		<u>10MG/5ML</u>	<u>N021419</u>	<u>002</u>	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>		SUN PHARM INDS INC	<u>5MG/5ML</u>	<u>A201466</u>	<u>001</u>	Nov 12, 2013
<u>AA</u>			<u>10MG/5ML</u>	<u>A201466</u>	<u>002</u>	Nov 12, 2013
<u>AA</u>		TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A091601</u>	<u>001</u>	Jul 23, 2010
<u>AA</u>			<u>10MG/5ML</u>	<u>A091601</u>	<u>002</u>	Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>5MG</u>	<u>A040220</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>			<u>10MG</u>	<u>A040220</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>			<u>20MG</u>	<u>A040220</u>	<u>003</u>	Aug 29, 1997
<u>AB</u>		COREPHARMA	<u>5MG</u>	<u>A091159</u>	<u>001</u>	Mar 12, 2014
<u>AB</u>			<u>10MG</u>	<u>A091159</u>	<u>002</u>	Mar 12, 2014
<u>AB</u>			<u>20MG</u>	<u>A091159</u>	<u>003</u>	Mar 12, 2014
<u>AB</u>		MALLINCKRODT	<u>5MG</u>	<u>A040300</u>	<u>001</u>	Nov 27, 1998
<u>AB</u>			<u>10MG</u>	<u>A040300</u>	<u>002</u>	Nov 27, 1998
<u>AB</u>			<u>20MG</u>	<u>A040300</u>	<u>003</u>	Nov 27, 1998
<u>AB</u>		SUN PHARM INDS INC	<u>5MG</u>	<u>A090710</u>	<u>001</u>	Mar 15, 2012
<u>AB</u>			<u>10MG</u>	<u>A090710</u>	<u>002</u>	Mar 15, 2012
<u>AB</u>			<u>20MG</u>	<u>A090710</u>	<u>003</u>	Mar 15, 2012
<u>AB</u>		UCB INC	<u>5MG</u>	<u>A086429</u>	<u>001</u>	
<u>AB</u>			<u>10MG</u>	<u>A085799</u>	<u>001</u>	
<u>AB</u>			<u>20MG</u>	<u>A086428</u>	<u>001</u>	
<u>AB</u>		VINTAGE PHARMS	<u>5MG</u>	<u>A202892</u>	<u>001</u>	Sep 23, 2014
<u>AB</u>			<u>10MG</u>	<u>A202892</u>	<u>002</u>	Sep 23, 2014
<u>AB</u>			<u>20MG</u>	<u>A202892</u>	<u>003</u>	Sep 23, 2014

RITALIN

<u>AB</u>		NOVARTIS	<u>5MG</u>	<u>N010187</u>	<u>003</u>	
<u>AB</u>			<u>10MG</u>	<u>N010187</u>	<u>006</u>	
<u>AB</u>	+		<u>20MG</u>	<u>N010187</u>	<u>010</u>	

TABLET, CHEWABLE;ORAL

METHYLIN

MALLINCKRODT

2.5MG

N021475 001 Apr 15, 2003

5MG

N021475 002 Apr 15, 2003

+

10MG

N021475 003 Apr 15, 2003

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

<u>AB</u>	+	UCB INC	<u>20MG</u>	<u>A089601</u>	<u>001</u>	Jun 01, 1988
-----------	---	---------	-------------	----------------	------------	--------------

METHYLIN ER

<u>AB</u>		MALLINCKRODT INC	<u>20MG</u>	<u>A075629</u>	<u>002</u>	May 09, 2000
-----------	--	------------------	-------------	----------------	------------	--------------

RITALIN-SR

<u>AB</u>		NOVARTIS	<u>20MG</u>	<u>N018029</u>	<u>001</u>	Mar 30, 1982
-----------	--	----------	-------------	----------------	------------	--------------

METHYLPHENIDATE HYDROCHLORIDE

BX		KUDCO IRELAND	18MG	A091695	001	Jul 09, 2013
BX			27MG	A091695	002	Jul 09, 2013
BX			36MG	A091695	003	Sep 23, 2013
BX			54MG	A091695	004	Sep 23, 2013
BX		MALLINCKRODT INC	27MG	A202608	001	Dec 28, 2012
BX			36MG	A202608	002	Dec 28, 2012
BX			54MG	A202608	003	Dec 28, 2012

CONCERTA

JANSSEN PHARMS

18MG

N021121 001 Aug 01, 2000

27MG

N021121 004 Apr 01, 2002

36MG

N021121 002 Aug 01, 2000

+

54MG

N021121 003 Dec 08, 2000

## PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METHYLIN ER

MALLINCKRODT INC 10MG

A075629 001 May 09, 2000

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL**AB** PHARMACIA AND UPJOHN **2MG****N011153 002****AB** **4MG****N011153 001****AB** **8MG****N011153 004****AB** **16MG****N011153 003****AB** + **32MG****N011153 006**METHYLPREDNISOLONE**AB** DURAMED PHARMS BARR **4MG****A088497 001** Feb 21, 1984**AB** JUBILANT CADISTA **4MG****A040189 001** Oct 31, 1997**AB** **8MG****A040189 002** Oct 31, 1997**AB** **16MG****A040189 003** Jul 20, 2007**AB** **32MG****A040189 004** Jul 20, 2007**AB** SANDOZ **4MG****A040194 001** Oct 31, 1997**AB** VINTAGE PHARMS **4MG****A040183 001** Dec 22, 1998**AB** WATSON LABS **4MG****A040232 001** Oct 16, 1997METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL**AB** + PHARMACIA AND UPJOHN **40MG/ML****N011757 001****AB** + **80MG/ML****N011757 004**METHYLPREDNISOLONE ACETATE**AB** SANDOZ **40MG/ML****A040719 001** Jan 29, 2009**AB** **40MG/ML****A040794 001** Mar 05, 2009**AB** **80MG/ML****A040719 002** Jan 29, 2009**AB** **80MG/ML****A040794 002** Mar 05, 2009**AB** TEVA PHARMS USA **40MG/ML****A040557 001** Feb 23, 2005**AB** **40MG/ML****A040620 001** Oct 27, 2006**AB** **80MG/ML****A040557 002** Feb 23, 2005**AB** **80MG/ML****A040620 002** Oct 27, 2006

DEPO-MEDROL

+ PHARMACIA AND UPJOHN 20MG/ML

N011757 002

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED**AP** HOSPIRA **EQ 40MG BASE/VIAL****A040664 001** Dec 20, 2005**AP** **EQ 125MG BASE/VIAL****A040665 001** Dec 20, 2005**AP** HOSPIRA INC **EQ 40MG BASE/VIAL****A040793 001** Nov 25, 2008**AP** **EQ 125MG BASE/VIAL****A040827 001** Nov 25, 2008METHYLPREDNISOLONE SODIUM SUCCINATE**AP** FRESENIUS KABI USA **EQ 1GM BASE/VIAL****A040612 001** Aug 12, 2004**AP** **EQ 40MG BASE/VIAL****A040583 001** Jul 30, 2004**AP** **EQ 125MG BASE/VIAL****A040583 002** Jul 30, 2004**AP** MUSTAFA NEVSAT **EQ 1GM BASE/VIAL****A040888 004** Jul 18, 2011**AP** **EQ 2GM BASE/VIAL****A040888 005** Jul 18, 2011**AP** **EQ 40MG BASE/VIAL****A040888 001** Jul 18, 2011**AP** **EQ 125MG BASE/VIAL****A040888 002** Jul 18, 2011**AP** **EQ 500MG BASE/VIAL****A040888 003** Jul 18, 2011SOLU-MEDROL**AP** + PHARMACIA AND UPJOHN **EQ 1GM BASE/VIAL****N011856 006****AP** + **EQ 2GM BASE/VIAL****N011856 007** Feb 27, 1985**AP** + **EQ 40MG BASE/VIAL****N011856 003****AP** + **EQ 125MG BASE/VIAL****N011856 004****AP** + **EQ 500MG BASE/VIAL****N011856 005**METHYLTESTOSTERONE

CAPSULE; ORAL

TESTRED

+ VALEANT PHARM INTL 10MG

A083976 001

TABLET; ORAL

ANDROID 10

BP VALEANT PHARM INTL 10MG

A086450 001

ANDROID 25

BP VALEANT PHARM INTL 25MG

A087147 001

METHYLTESTOSTERONE

BP IMPAX LABS 10MG

A080767 002



## PRESCRIPTION DRUG PRODUCT LIST

METHYLTESTOSTERONE

TABLET; ORAL

METHYLTESTOSTERONE

BP 25MG A084310 001

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

AT ALCON RES LTD 0.3% A075720 001 Aug 06, 2001

OPTIPRANOLOL

AT + BAUSCH AND LOMB 0.3% N019907 001 Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE

AP EMCURE PHARMS LTD EQ 5MG BASE/ML A204756 001 Dec 20, 2013

METOCLOPRAMIDE HYDROCHLORIDE

AP BD RX EQ 5MG BASE/ML A091392 001 Apr 19, 2013

AP HOSPIRA EQ 5MG BASE/ML A073118 001 Jan 17, 1991

AP TEVA PHARMS USA EQ 5MG BASE/ML A073135 001 Nov 27, 1991

REGLAN

AP + BAXTER HLTHCARE CORP EQ 5MG BASE/ML N017862 001

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA ANI PHARMS EQ 5MG BASE/5ML A071402 001 Jun 25, 1993

AA PHARM ASSOC EQ 5MG BASE/5ML A072744 001 May 28, 1991

AA SILARX EQ 5MG BASE/5ML A073680 001 Oct 27, 1992

AA VISTAPHARM EQ 5MG BASE/5ML A075051 001 Jan 26, 2001

AA + WOCKHARDT EQ 5MG BASE/5ML A074703 001 Oct 31, 1997

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB IPCA LABS LTD EQ 5MG BASE A078807 001 Jun 12, 2008

AB EQ 10MG BASE A078807 002 Jun 12, 2008

AB MUTUAL PHARM EQ 5MG BASE A071536 002 Jan 16, 1997

AB NORTHSTAR HLTHCARE EQ 5MG BASE A078374 001 Nov 30, 2007

AB EQ 10MG BASE A078374 002 Nov 30, 2007

AB PAR PHARM INC EQ 10MG BASE A070581 001 Oct 17, 1985

AB TEVA EQ 5MG BASE A072801 001 Jun 15, 1993

AB EQ 10MG BASE A070184 001 Jul 29, 1985

AB VINTAGE PHARMS EQ 5MG BASE A077878 001 Aug 28, 2006

AB EQ 10MG BASE A077878 002 Aug 28, 2006

AB WATSON LABS EQ 5MG BASE A072750 001 Dec 28, 1995

AB EQ 10MG BASE A071250 001 Feb 03, 1988

REGLAN

AB ANI PHARMS EQ 5MG BASE N017854 002 May 05, 1987

AB + EQ 10MG BASE N017854 001

TABLET, ORALLY DISINTEGRATING; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB NOVEL LABS INC EQ 5MG BASE A202191 001 Aug 15, 2014

METOZOLV ODT

AB + SALIX PHARMS EQ 5MG BASE N022246 001 Sep 04, 2009

METOCLOPRAMIDE HYDROCHLORIDE

NOVEL LABS INC EQ 10MG BASE A202191 002 Aug 15, 2014

METOLAZONE

TABLET; ORAL

METOLAZONE

AB MYLAN 2.5MG A076698 001 Dec 23, 2003

AB 5MG A076698 002 Oct 19, 2004

AB 10MG A076698 003 Oct 19, 2004

AB SANDOZ 2.5MG A076732 001 Dec 19, 2003

AB 5MG A076466 001 Dec 19, 2003

AB 10MG A076466 002 Dec 19, 2003

ZAROXOLYN

AB UCB INC 2.5MG N017386 001

AB + 5MG N017386 002

AB + 10MG N017386 003

## PRESCRIPTION DRUG PRODUCT LIST

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 25MG TARTRATE</u>	<u>A077118 001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A076862 001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A077298 001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A077298 002</u>	Apr 15, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG TARTRATE</u>	<u>A090617 001</u>	Aug 01, 2012
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090617 002</u>	Aug 01, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG TARTRATE</u>	<u>A202033 001</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A202033 002</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A202033 003</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A202033 004</u>	Dec 15, 2011
<u>AB</u>	REDDYS	<u>EQ 100MG TARTRATE</u>	<u>A078889 001</u>	Aug 15, 2012
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A078889 002</u>	Aug 15, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 25MG TARTRATE</u>	<u>A090615 001</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090615 002</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A090615 003</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A090615 004</u>	Jul 22, 2010

TOPROL-XL

<u>AB</u>	ASTRAZENECA PHARMS	<u>EQ 25MG TARTRATE</u>	<u>N019962 004</u>	Feb 05, 2001
<u>AB</u>	+	<u>EQ 50MG TARTRATE</u>	<u>N019962 001</u>	Jan 10, 1992
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>N019962 002</u>	Jan 10, 1992
<u>AB</u>	+	<u>EQ 200MG TARTRATE</u>	<u>N019962 003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

<u>AP</u>	+	NOVARTIS	<u>1MG/ML</u>	<u>N018704 001</u>	Mar 30, 1984
-----------	---	----------	---------------	--------------------	--------------

METOPROLOL TARTRATE

<u>AP</u>	BEDFORD LABS	<u>1MG/ML</u>	<u>A076495 001</u>	Jul 07, 2003
<u>AP</u>	CLARIS LIFESCIENCES	<u>1MG/ML</u>	<u>A078950 001</u>	Apr 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A091045 001</u>	Oct 25, 2010
<u>AP</u>	GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A204205 001</u>	Aug 27, 2014
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761 001</u>	May 30, 2007
<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074133 001</u>	Dec 21, 1993
<u>AP</u>		<u>1MG/ML</u>	<u>A075160 001</u>	Jul 06, 1998
<u>AP</u>		<u>1MG/ML</u>	<u>A078085 001</u>	Apr 29, 2008
<u>AP</u>	LUITPOLD	<u>1MG/ML</u>	<u>A090386 001</u>	Sep 30, 2009
<u>AP</u>		<u>1MG/ML</u>	<u>A091307 001</u>	Dec 29, 2010
<u>AP</u>	SAGENT STRIDES	<u>1MG/ML</u>	<u>A090317 001</u>	Apr 19, 2010
<u>AP</u>	SANDOZ	<u>1MG/ML</u>	<u>A077360 001</u>	Oct 02, 2007

TABLET; ORAL

LOPRESSOR

<u>AB</u>	US PHARMS HOLDINGS I	<u>50MG</u>	<u>N017963 001</u>	
<u>AB</u>		<u>100MG</u>	<u>N017963 002</u>	

METOPROLOL TARTRATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A202871 001</u>	May 28, 2013
<u>AB</u>		<u>50MG</u>	<u>A202871 002</u>	May 28, 2013
<u>AB</u>		<u>100MG</u>	<u>A202871 003</u>	May 28, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A077739 001</u>	Sep 11, 2007
<u>AB</u>		<u>50MG</u>	<u>A077739 002</u>	Sep 11, 2007
<u>AB</u>		<u>100MG</u>	<u>A077739 003</u>	Sep 11, 2007
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A078459 001</u>	Jun 17, 2008
<u>AB</u>		<u>50MG</u>	<u>A078459 002</u>	Jun 17, 2008
<u>AB</u>		<u>100MG</u>	<u>A078459 003</u>	Jun 17, 2008
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A073654 002</u>	Jul 15, 2009
<u>AB</u>		<u>50MG</u>	<u>A073653 001</u>	Dec 21, 1993
<u>AB</u>		<u>100MG</u>	<u>A073654 001</u>	Dec 21, 1993
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076704 001</u>	Jan 16, 2004
<u>AB</u>		<u>50MG</u>	<u>A076704 002</u>	Jan 16, 2004
<u>AB</u>	+	<u>100MG</u>	<u>A076704 003</u>	Jan 16, 2004
<u>AB</u>	RUBICON RES PVT LTD	<u>25MG</u>	<u>A200981 001</u>	Oct 28, 2014
<u>AB</u>		<u>50MG</u>	<u>A200981 002</u>	Oct 28, 2014
<u>AB</u>		<u>100MG</u>	<u>A200981 003</u>	Oct 28, 2014
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A073288 001</u>	Mar 25, 1994
<u>AB</u>		<u>100MG</u>	<u>A073289 001</u>	Mar 25, 1994
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A076670 001</u>	Jan 15, 2004
<u>AB</u>		<u>50MG</u>	<u>A074644 001</u>	Dec 10, 1996
<u>AB</u>		<u>100MG</u>	<u>A074644 002</u>	Dec 10, 1996
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074141 001</u>	Jan 31, 1995
<u>AB</u>		<u>100MG</u>	<u>A074141 002</u>	Jan 31, 1995
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A074217 001</u>	May 27, 1994

## PRESCRIPTION DRUG PRODUCT LIST

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

<u>AB</u>		<u>100MG</u>	<u>A074217 002</u>	May 27, 1994
-----------	--	--------------	--------------------	--------------

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+	GD SEARLE LLC	<u>375MG</u>	<u>N020334 001</u>	May 03, 1995
-----------	---	---------------	--------------	--------------------	--------------

METRONIDAZOLE

<u>AB</u>		ALEMBIC LTD	<u>375MG</u>	<u>A079065 001</u>	Jun 23, 2009
-----------	--	-------------	--------------	--------------------	--------------

<u>AB</u>		PAR PHARM	<u>375MG</u>	<u>A076522 001</u>	Jan 29, 2004
-----------	--	-----------	--------------	--------------------	--------------

CREAM; TOPICAL

METROCREAM

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020531 001</u>	Sep 20, 1995
-----------	---	------------------	--------------	--------------------	--------------

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A076408 001</u>	May 28, 2004
-----------	--	----------------	--------------	--------------------	--------------

<u>AB</u>		G AND W LABS	<u>0.75%</u>	<u>A077549 001</u>	Dec 19, 2007
-----------	--	--------------	--------------	--------------------	--------------

NORITATE

	+	VALEANT BERMUDA	1%	N020743 001	Sep 26, 1997
--	---	-----------------	----	-------------	--------------

GEL; TOPICAL

METROGEL

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N019737 001</u>	Nov 22, 1988
-----------	---	------------------	--------------	--------------------	--------------

<u>AB</u>	+		<u>1%</u>	<u>N021789 001</u>	Jun 30, 2005
-----------	---	--	-----------	--------------------	--------------

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077018 001</u>	Jun 06, 2006
-----------	--	----------------	--------------	--------------------	--------------

<u>AB</u>		G AND W LABS INC	<u>0.75%</u>	<u>A078178 001</u>	Jan 19, 2011
-----------	--	------------------	--------------	--------------------	--------------

<u>AB</u>		TARO	<u>0.75%</u>	<u>A077819 001</u>	Jul 18, 2006
-----------	--	------	--------------	--------------------	--------------

<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077547 001</u>	Jul 13, 2006
-----------	--	--------	--------------	--------------------	--------------

<u>AB</u>			<u>1%</u>	<u>A090903 001</u>	Jul 22, 2011
-----------	--	--	-----------	--------------------	--------------

GEL; VAGINAL

METROGEL-VAGINAL

<u>AB</u>	+	MEDICIS	<u>0.75%</u>	<u>N020208 001</u>	Aug 17, 1992
-----------	---	---------	--------------	--------------------	--------------

METRONIDAZOLE

<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077264 001</u>	Oct 31, 2006
-----------	--	--------	--------------	--------------------	--------------

VANDAZOLE

BX		TEVA PHARMS	0.75%	N021806 001	May 20, 2005
----	--	-------------	-------	-------------	--------------

METRONIDAZOLE

	+	WATSON LABS INC	1.3%	N205223 001	Mar 24, 2014
--	---	-----------------	------	-------------	--------------

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>N018657 001</u>	
-----------	---	-----------------	--------------------	--------------------	--

<u>AP</u>	+	PFIZER	<u>500MG/100ML</u>	<u>N018353 002</u>	
-----------	---	--------	--------------------	--------------------	--

METRO I.V. IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>500MG/100ML</u>	<u>N018900 001</u>	Sep 29, 1983
-----------	---	---------	--------------------	--------------------	--------------

METRONIDAZOLE IN PLASTIC CONTAINER

<u>AP</u>		CLARIS LIFESCIENCES	<u>500MG/100ML</u>	<u>A078084 001</u>	Mar 31, 2008
-----------	--	---------------------	--------------------	--------------------	--------------

<u>AP</u>	+	HOSPIRA	<u>500MG/100ML</u>	<u>N018890 002</u>	Nov 18, 1983
-----------	---	---------	--------------------	--------------------	--------------

LOTION; TOPICAL

METROLOTION

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020901 001</u>	Nov 24, 1998
-----------	---	------------------	--------------	--------------------	--------------

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077197 001</u>	May 24, 2006
-----------	--	----------------	--------------	--------------------	--------------

TABLET; ORAL

FLAGYL

<u>AB</u>		GD SEARLE LLC	<u>250MG</u>	<u>N012623 001</u>	
-----------	--	---------------	--------------	--------------------	--

<u>AB</u>	+		<u>500MG</u>	<u>N012623 003</u>	
-----------	---	--	--------------	--------------------	--

METRONIDAZOLE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>250MG</u>	<u>A079067 001</u>	Mar 13, 2009
-----------	--	--------------------	--------------	--------------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A079067 002</u>	Mar 13, 2009
-----------	--	--	--------------	--------------------	--------------

<u>AB</u>		MUTUAL PHARM	<u>250MG</u>	<u>A070772 001</u>	Jul 16, 1986
-----------	--	--------------	--------------	--------------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A070773 001</u>	Jul 16, 1986
-----------	--	--	--------------	--------------------	--------------

<u>AB</u>		PLIVA	<u>500MG</u>	<u>A070033 001</u>	Dec 06, 1984
-----------	--	-------	--------------	--------------------	--------------

<u>AB</u>		TEVA PHARMS USA	<u>250MG</u>	<u>A070027 001</u>	Nov 06, 1984
-----------	--	-----------------	--------------	--------------------	--------------

<u>AB</u>		UNICHEM LABS LTD	<u>250MG</u>	<u>A203458 001</u>	Jan 22, 2014
-----------	--	------------------	--------------	--------------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A203458 002</u>	Jan 22, 2014
-----------	--	--	--------------	--------------------	--------------

<u>AB</u>		WATSON LABS	<u>250MG</u>	<u>A070035 001</u>	Dec 20, 1984
-----------	--	-------------	--------------	--------------------	--------------

<u>AB</u>		WATSON LABS INC	<u>500MG</u>	<u>A070044 001</u>	Feb 08, 1985
-----------	--	-----------------	--------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

<u>AB</u>	+	GD SEARLE LLC	<u>750MG</u>	<u>N020868 001</u>	Nov 26, 1997
-----------	---	---------------	--------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

METRONIDAZOLE

TABLET, EXTENDED RELEASE;ORAL

METRONIDAZOLE

<b>AB</b>	ALEMBIC LTD	<b>750MG</b>	<b>A090222</b>	<b>001</b>	May 05, 2010
-----------	-------------	--------------	----------------	------------	--------------

METYRAPONE

CAPSULE;ORAL

METOPIRONE

+ HRA PHARMA

250MG

N012911 002 Aug 09, 1996

METYROSINE

CAPSULE;ORAL

DEMSEER

+ ATON PHARMA VPNA

250MG

N017871 001

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

TEVA

150MG

A074377 001 May 16, 1995

200MG

A074377 002 May 16, 1995

+

250MG

A074377 003 May 16, 1995

MICAFUNGIN SODIUM

INJECTABLE;IV (INFUSION)

MYCAMINE

+ ASTELLAS

50MG/VIAL

N021506 002 Mar 16, 2005

+

100MG/VIAL

N021506 003 Jun 27, 2006

MICONAZOLE

TABLET;BUCCAL

ORAVIG

+ BIOALLIANCE PHARMA

50MG

N022404 001 Apr 16, 2010

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

<b>AB</b>	ACTAVIS MID ATLANTIC	<b>200MG</b>	<b>A073508</b>	<b>001</b>	Nov 19, 1993
-----------	----------------------	--------------	----------------	------------	--------------

MONISTAT 3

<b>AB</b>	+ MEDTECH PRODUCTS	<b>200MG</b>	<b>N018888</b>	<b>001</b>	Aug 15, 1984
-----------	--------------------	--------------	----------------	------------	--------------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT;TOPICAL

VUSION

+ DELCOR ASSET

0.25%;81.35%;15%

N021026 001 Feb 16, 2006

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

<b>AP</b>	AKORN INC	<b>EQ 1MG BASE/ML</b>	<b>A075494</b>	<b>001</b>	Jun 30, 2000
-----------	-----------	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A075481</b>	<b>001</b>	Jun 30, 2000
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A075494</b>	<b>002</b>	Jun 30, 2000
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>	BEDFORD	<b>EQ 1MG BASE/ML</b>	<b>A075247</b>	<b>002</b>	Jun 23, 2000
-----------	---------	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A075247</b>	<b>001</b>	Jun 23, 2000
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>	BEDFORD LABS	<b>EQ 1MG BASE/ML</b>	<b>A075421</b>	<b>002</b>	Jun 20, 2000
-----------	--------------	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A075421</b>	<b>001</b>	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>	FRESENIUS KABI USA	<b>EQ 1MG BASE/ML</b>	<b>A075154</b>	<b>002</b>	Jun 20, 2000
-----------	--------------------	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A075154</b>	<b>001</b>	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>	GLAND PHARMA LTD	<b>EQ 1MG BASE/ML</b>	<b>A090696</b>	<b>001</b>	Feb 29, 2012
-----------	------------------	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A090850</b>	<b>001</b>	Jan 25, 2012
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>	HIKMA MAPLE	<b>EQ 1MG BASE/ML</b>	<b>A075243</b>	<b>001</b>	Jun 20, 2000
-----------	-------------	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 1MG BASE/ML</b>	<b>A075324</b>	<b>001</b>	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A075243</b>	<b>002</b>	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A075324</b>	<b>002</b>	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>	+ HOSPIRA	<b>EQ 1MG BASE/ML</b>	<b>A075293</b>	<b>001</b>	Jun 20, 2000
-----------	-----------	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 1MG BASE/ML</b>	<b>A075856</b>	<b>001</b>	Jun 13, 2002
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A075293</b>	<b>002</b>	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A075856</b>	<b>002</b>	Jun 13, 2002
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>	WOCKHARDT	<b>EQ 1MG BASE/ML</b>	<b>A078141</b>	<b>001</b>	May 30, 2008
-----------	-----------	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 1MG BASE/ML</b>	<b>A078511</b>	<b>001</b>	Nov 10, 2008
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A078141</b>	<b>002</b>	May 30, 2008
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A078511</b>	<b>002</b>	Nov 10, 2008
-----------	--	-----------------------	----------------	------------	--------------

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

<b>AP</b>	BD RX	<b>EQ 1MG BASE/ML</b>	<b>A203460</b>	<b>001</b>	Aug 22, 2014
-----------	-------	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A203460</b>	<b>002</b>	Aug 22, 2014
-----------	--	-----------------------	----------------	------------	--------------

<b>AP</b>	+ HOSPIRA	<b>EQ 1MG BASE/ML</b>	<b>A075857</b>	<b>001</b>	Jul 22, 2002
-----------	-----------	-----------------------	----------------	------------	--------------

<b>AP</b>		<b>EQ 5MG BASE/ML</b>	<b>A075857</b>	<b>002</b>	Jul 22, 2002
-----------	--	-----------------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090315 001</u>	Nov 29, 2010
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090315 002</u>	Nov 29, 2010

MIDOZALAM HYDROCHLORIDE

<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090316 001</u>	May 04, 2011
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090316 002</u>	May 04, 2011

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u>	HI TECH PHARMA	<u>EQ 2MG BASE/ML</u>	<u>A075958 001</u>	Sep 04, 2003
<u>AA</u>	PADDOCK LLC	<u>EQ 2MG BASE/ML</u>	<u>A076379 001</u>	May 02, 2005
<u>AA</u>	RANBAXY	<u>EQ 2MG BASE/ML</u>	<u>A076058 001</u>	Mar 15, 2002
<u>AA</u>	+ ROXANE	<u>EQ 2MG BASE/ML</u>	<u>A075873 001</u>	Apr 30, 2002

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A077746 001</u>	Sep 12, 2006
<u>AB</u>		<u>5MG</u>	<u>A077746 002</u>	Sep 12, 2006
<u>AB</u>		<u>10MG</u>	<u>A077746 003</u>	Sep 12, 2006
<u>AB</u>	IMPAX PHARMS	<u>2.5MG</u>	<u>A076449 001</u>	May 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A076449 002</u>	May 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A076449 003</u>	Dec 16, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A076577 001</u>	Sep 10, 2003
<u>AB</u>	+	<u>5MG</u>	<u>A076577 002</u>	Sep 10, 2003
<u>AB</u>		<u>10MG</u>	<u>A076577 003</u>	Sep 10, 2003
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076514 001</u>	Sep 11, 2003
<u>AB</u>		<u>5MG</u>	<u>A076514 002</u>	Sep 11, 2003
<u>AB</u>		<u>10MG</u>	<u>A076514 003</u>	Jul 02, 2004

ORVATEN

<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076725 001</u>	Nov 03, 2004
<u>AB</u>		<u>5MG</u>	<u>A076725 002</u>	Nov 03, 2004
<u>AB</u>		<u>10MG</u>	<u>A076725 003</u>	Nov 03, 2004

MIFEPRISTONE

TABLET; ORAL

KORLYM

+ CORCEPT THERAP

300MG

N202107 001 Feb 17, 2012

MIFEPREX

+ DANCO LABS LLC

200MG

N020687 001 Sep 28, 2000

MIGLITOL

TABLET; ORAL

GLYSET

PHARMACIA AND UPJOHN

25MG

N020682 001 Dec 18, 1996

50MG

N020682 002 Dec 18, 1996

+

100MG

N020682 003 Dec 18, 1996

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

+ ACTELION PHARMS LTD

100MG

N021348 001 Jul 31, 2003

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

CYPRESS BIOSCIENCE

12.5MG

N022256 001 Jan 14, 2009

25MG

N022256 002 Jan 14, 2009

+

50MG

N022256 003 Jan 14, 2009

100MG

N022256 004 Jan 14, 2009

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

<u>AP</u>	+ BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A075660 001</u>	May 28, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075936 001</u>	May 28, 2002
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A077190 001</u>	Oct 31, 2006
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML</u>	<u>A077966 001</u>	Dec 03, 2010
<u>AP</u>	HIKMA MAPLE	<u>EQ 1MG BASE/ML</u>	<u>A075530 001</u>	May 28, 2002
<u>AP</u>	HOSPIRA INC	<u>EQ 1MG BASE/ML</u>	<u>A203280 001</u>	Sep 03, 2014
<u>AP</u>	INTL MEDICATED	<u>EQ 1MG BASE/ML</u>	<u>A076013 001</u>	Aug 02, 2002

MILRINONE LACTATE IN DEXTROSE 5%

<u>AP</u>	APOTEX INC	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A077151 002</u>	Jul 20, 2005
-----------	------------	----------------------------------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A076414 001</u>	Aug 18, 2004
<u>AP</u>	+ BAXTER HLTHCARE	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075834 001</u>	May 28, 2002
<u>AP</u>	+ BEDFORD LABS	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075834 002</u>	May 28, 2002
<u>AP</u>		<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A078113 001</u>	May 21, 2008
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A078113 002</u>	May 21, 2008
<u>AP</u>	HOSPIRA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075885 001</u>	May 28, 2002
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075885 002</u>	May 28, 2002

MILRINONE LACTATE IN PLASTIC CONTAINER

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A090038 001</u>	Jan 21, 2010
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A090038 002</u>	Jan 21, 2010

MILTEFOSINE

CAPSULE; ORAL

IMPAVIDO

+ KNIGHT THERAPS

50MG

N204684 001 Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

<u>AB</u>	CNTY LINE PHARMS	<u>EQ 75MG BASE</u>	<u>A063067 002</u>	Sep 15, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063067 001</u>	Jul 31, 1990

MINOCIN

<u>AB</u>	PRECISION DERMAT	<u>EQ 50MG BASE</u>	<u>N050649 001</u>	May 31, 1990
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050649 002</u>	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 50MG BASE</u>	<u>A065470 001</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065470 002</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065470 003</u>	Mar 11, 2008
<u>AB</u>	IMPAX LABS	<u>EQ 50MG BASE</u>	<u>A065005 001</u>	Mar 23, 1999
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065005 003</u>	Apr 18, 2001
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065005 002</u>	Mar 23, 1999
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065062 001</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065062 002</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065062 003</u>	Nov 30, 2000
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 50MG BASE</u>	<u>A090867 001</u>	May 13, 2013
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090867 002</u>	May 13, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090867 003</u>	May 13, 2013
<u>AB</u>	TEVA	<u>EQ 50MG BASE</u>	<u>A063011 001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063009 002</u>	Aug 12, 2003
<u>AB</u>	+ WATSON LABS	<u>EQ 100MG BASE</u>	<u>A063009 001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A063181 001</u>	Dec 30, 1991
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063065 002</u>	Jun 10, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063065 001</u>	Dec 30, 1991

INJECTABLE; INJECTION

MINOCIN

+ REMPEX PHARMS INC

EQ 100MG BASE/VIAL

N050444 001

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

+ ORAPHARMA

EQ 1MG BASE

N050781 001 Feb 16, 2001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 50MG BASE</u>	<u>A065436 001</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065436 002</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065436 003</u>	Dec 26, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065131 001</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065131 002</u>	Apr 16, 2003
<u>AB</u>	+ RANBAXY	<u>EQ 100MG BASE</u>	<u>A065131 003</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A065156 001</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065156 002</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065156 003</u>	Jan 06, 2004

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 45MG BASE</u>	<u>A202261 001</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A202261 003</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A202261 005</u>	Nov 19, 2012
<u>AB</u>	BARR LABS INC	<u>EQ 45MG BASE</u>	<u>A065485 001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A065485 004</u>	May 18, 2012
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A065485 002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A065485 005</u>	May 18, 2012
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A065485 003</u>	Mar 17, 2009

## PRESCRIPTION DRUG PRODUCT LIST

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	IMPAX LABS INC	<u>EQ 45MG BASE</u>	<u>A090024 001</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090024 002</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090024 003</u>	Feb 03, 2009
<u>AB</u>	LUPIN LTD	<u>EQ 45MG BASE</u>	<u>A091424 001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091424 003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091424 004</u>	Nov 30, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 45MG BASE</u>	<u>A090911 001</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A203443 002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090911 002</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A203443 003</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090911 003</u>	Jul 20, 2010
<u>AB</u>	RANBAXY LABS LTD	<u>EQ 45MG BASE</u>	<u>A091118 001</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091118 004</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091118 005</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A091118 006</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091118 008</u>	Sep 25, 2014
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422 001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422 002</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090422 003</u>	Aug 13, 2009
<u>SOLODYN</u>				
<u>AB</u>	MEDICIS	<u>EQ 65MG BASE</u>	<u>N050808 004</u>	Jul 23, 2009
<u>AB</u>	+	<u>EQ 80MG BASE</u>	<u>N050808 007</u>	Aug 27, 2010
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>N050808 006</u>	Aug 27, 2010
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>N050808 005</u>	Jul 23, 2009
	+	EQ 55MG BASE	N050808 008	Aug 27, 2010

MINOXIDIL

TABLET;ORAL

MINOXIDIL

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A072708 001</u>	Dec 14, 1995
<u>AB</u>		<u>10MG</u>	<u>A072709 001</u>	Dec 14, 1995
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A071826 001</u>	Nov 14, 1988
<u>AB</u>		<u>10MG</u>	<u>A071839 001</u>	Nov 14, 1988
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A071344 001</u>	Mar 03, 1987
<u>AB</u>	+	<u>10MG</u>	<u>A071345 001</u>	Mar 03, 1987

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS

KYNAMRO

+ GENZYME CORP

200MG/ML (200MG/ML)

N203568 001 Jan 29, 2013

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MYRBETRIQ

APGDI

25MG

N202611 001 Jun 28, 2012

+

50MG

N202611 002 Jun 28, 2012

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS LABS FL INC	<u>15MG</u>	<u>A076336 001</u>	Jun 20, 2003
<u>AB</u>		<u>30MG</u>	<u>A076336 002</u>	Jun 20, 2003
<u>AB</u>		<u>45MG</u>	<u>A076336 003</u>	Jun 20, 2003
<u>AB</u>	APOTEX INC	<u>15MG</u>	<u>A077666 001</u>	Aug 22, 2007
<u>AB</u>		<u>30MG</u>	<u>A077666 002</u>	Aug 22, 2007
<u>AB</u>		<u>45MG</u>	<u>A077666 003</u>	Aug 22, 2007
<u>AB</u>	AUROBINDO	<u>7.5MG</u>	<u>A076921 001</u>	Oct 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076921 002</u>	Oct 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076921 003</u>	Oct 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076921 004</u>	Oct 22, 2004
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A076122 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076122 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076122 003</u>	Jun 19, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A076176 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076176 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076176 003</u>	Jun 19, 2003
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A076219 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076219 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076219 003</u>	Jun 19, 2003
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A076541 004</u>	Apr 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076541 001</u>	Apr 22, 2004

## PRESCRIPTION DRUG PRODUCT LIST

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

<u>AB</u>		<u>30MG</u>	<u>A076541</u>	<u>002</u>	Apr 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076541</u>	<u>003</u>	Apr 22, 2004
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076119</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>30MG</u>	<u>A076119</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>		<u>45MG</u>	<u>A076119</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076312</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076312</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076312</u>	<u>003</u>	Jun 19, 2003

REMERON

<u>AB</u>	+ ORGANON USA INC	<u>15MG</u>	<u>N020415</u>	<u>001</u>	Jun 14, 1996
<u>AB</u>		<u>30MG</u>	<u>N020415</u>	<u>002</u>	Jun 14, 1996
<u>AB</u>		<u>45MG</u>	<u>N020415</u>	<u>003</u>	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS LABS FL INC	<u>15MG</u>	<u>A076307</u>	<u>001</u>	Dec 17, 2003
<u>AB</u>		<u>30MG</u>	<u>A076307</u>	<u>002</u>	Dec 17, 2003
<u>AB</u>		<u>45MG</u>	<u>A076307</u>	<u>003</u>	Feb 28, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>15MG</u>	<u>A077376</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077376</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>45MG</u>	<u>A077376</u>	<u>004</u>	Feb 28, 2006
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076901</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>30MG</u>	<u>A076901</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		<u>45MG</u>	<u>A076901</u>	<u>003</u>	Jun 28, 2005

REMERON SOLTAB

<u>AB</u>	+ ORGANON USA INC	<u>15MG</u>	<u>N021208</u>	<u>001</u>	Jan 12, 2001
<u>AB</u>		<u>30MG</u>	<u>N021208</u>	<u>002</u>	Jan 12, 2001
<u>AB</u>		<u>45MG</u>	<u>N021208</u>	<u>003</u>	Jan 12, 2001

MISOPROSTOL

TABLET; ORAL

CYTOTEC

<u>AB</u>	GD SEARLE LLC	<u>0.1MG</u>	<u>N019268</u>	<u>003</u>	Sep 21, 1990
<u>AB</u>	+	<u>0.2MG</u>	<u>N019268</u>	<u>001</u>	Dec 27, 1988

MISOPROSTOL

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.1MG</u>	<u>A076095</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>		<u>0.2MG</u>	<u>A076095</u>	<u>002</u>	Jul 10, 2002
<u>AB</u>	NOVEL LABS INC	<u>0.1MG</u>	<u>A091667</u>	<u>001</u>	Jul 25, 2012
<u>AB</u>		<u>0.2MG</u>	<u>A091667</u>	<u>002</u>	Jul 25, 2012

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+ MOBIUS THERAP 0.2MG/VIAL

N022572 001 Feb 07, 2012

INJECTABLE; INJECTION

MITOMYCIN

<u>AP</u>	+ ACCORD HLTHCARE	<u>5MG/VIAL</u>	<u>A064144</u>	<u>001</u>	Apr 30, 1998
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A064144</u>	<u>002</u>	Apr 30, 1998
<u>AP</u>	+	<u>40MG/VIAL</u>	<u>A064144</u>	<u>003</u>	Aug 11, 2009
<u>AP</u>	BEDFORD	<u>5MG/VIAL</u>	<u>A064117</u>	<u>001</u>	Apr 19, 1995
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064117</u>	<u>002</u>	Apr 19, 1995
<u>AP</u>	HIKMA MAPLE	<u>5MG/VIAL</u>	<u>A064180</u>	<u>001</u>	Dec 23, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064180</u>	<u>002</u>	Dec 23, 1999

MITOTANE

TABLET; ORAL

LYSODREN

+ BRISTOL MYERS SQUIBB 500MG

N016885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	+	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>	+	<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>	+	<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A078980</u>	<u>001</u>	Apr 13, 2009



## PRESCRIPTION DRUG PRODUCT LIST

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A078980 002</u>	Apr 13, 2009
<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A201014 001</u>	Dec 11, 2012
<u>AP</u>	TEVA PHARMS USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077356 001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077356 002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077356 003</u>	Apr 11, 2006

MODAFINIL

TABLET; ORAL

MODAFINIL

<u>AB</u>	ALEMBIC LTD	<u>100MG</u>	<u>A202700 001</u>	Oct 18, 2012
<u>AB</u>		<u>200MG</u>	<u>A202700 002</u>	Oct 18, 2012
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077667 001</u>	Feb 03, 2014
<u>AB</u>		<u>200MG</u>	<u>A077667 002</u>	Feb 03, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A202566 001</u>	Sep 27, 2012
<u>AB</u>		<u>200MG</u>	<u>A202566 002</u>	Sep 27, 2012
<u>AB</u>	CARLSBAD	<u>100MG</u>	<u>A076715 001</u>	Nov 01, 2012
<u>AB</u>		<u>200MG</u>	<u>A076715 002</u>	Nov 01, 2012
<u>AB</u>	HIKMA PHARMS	<u>100MG</u>	<u>A090543 001</u>	Sep 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A090543 002</u>	Sep 26, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A076594 001</u>	Jul 16, 2012
<u>AB</u>		<u>200MG</u>	<u>A076594 002</u>	Jul 16, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>100MG</u>	<u>A078963 001</u>	Sep 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A078963 002</u>	Sep 26, 2012

PROVIGIL

<u>AB</u>	CEPHALON	<u>100MG</u>	<u>N020717 001</u>	Dec 24, 1998
<u>AB</u>	+	<u>200MG</u>	<u>N020717 002</u>	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A078454 001</u>	Jun 02, 2008
<u>AB</u>		<u>15MG</u>	<u>A078454 002</u>	Jun 02, 2008
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A090416 001</u>	Mar 30, 2010
<u>AB</u>		<u>15MG</u>	<u>A090416 002</u>	Mar 30, 2010
<u>AB</u>	PADDOCK LLC	<u>7.5MG</u>	<u>A077536 001</u>	Nov 30, 2006
<u>AB</u>		<u>15MG</u>	<u>A077536 002</u>	Nov 30, 2006
<u>AB</u>	TEVA	<u>7.5MG</u>	<u>A076204 001</u>	May 08, 2003
<u>AB</u>		<u>15MG</u>	<u>A076204 002</u>	May 08, 2003

UNIVASC

<u>AB</u>	UCB INC	<u>7.5MG</u>	<u>N020312 001</u>	Apr 19, 1995
<u>AB</u>	+	<u>15MG</u>	<u>N020312 002</u>	Apr 19, 1995

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

ASMANEX HFA

MERCK SHARP DOHME

0.10MG/INH

N205641 001 Apr 25, 2014

+

0.20MG/INH

N205641 002 Apr 25, 2014

CREAM; TOPICAL

ELOCON

<u>AB</u>	+	MERCK SHARP DOHME	<u>0.1%</u>	<u>N019625 001</u>	May 06, 1987
<u>AB</u>			<u>0.1%</u>	<u>N019625 002</u>	Apr 19, 2013

MOMETASONE FUROATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A076171 001</u>	Apr 08, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077447 001</u>	May 22, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078541 001</u>	May 28, 2008
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076679 001</u>	Dec 21, 2004
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076591 001</u>	Apr 18, 2007

LOTION; TOPICAL

ELOCON

<u>AB</u>	+	MERCK SHARP DOHME	<u>0.1%</u>	<u>N019796 001</u>	Mar 30, 1989
-----------	---	-------------------	-------------	--------------------	--------------

MOMETASONE FUROATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A075919 001</u>	Nov 29, 2007
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077678 001</u>	Nov 21, 2007
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A090506 001</u>	Aug 09, 2010
<u>AB</u>	PERRIGO	<u>0.1%</u>	<u>A077180 001</u>	Apr 06, 2005
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076788 001</u>	Mar 15, 2006
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076499 001</u>	Nov 21, 2007

OINTMENT; TOPICAL

ELOCON

<u>AB</u>	+	MERCK SHARP DOHME	<u>0.1%</u>	<u>N019543 001</u>	Apr 30, 1987
-----------	---	-------------------	-------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

MOMETASONE FUROATE

OINTMENT; TOPICAL

MOMETASONE FUROATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077061</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077401</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078571</u>	<u>001</u>	May 28, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>0.1%</u>	<u>A076067</u>	<u>001</u>	Mar 18, 2002
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076481</u>	<u>001</u>	Nov 14, 2003

POWDER; INHALATION

ASMANEX TWISTHALER

	MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008
+		0.22MG/INH	N021067	001	Mar 30, 2005

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997
---	-------------------	----------------------	---------	-----	--------------

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A202906</u>	<u>001</u>	Sep 17, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE/PACKET</u>	<u>A202776</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE/PACKET</u>	<u>A090955</u>	<u>001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	+ MERCK	<u>EQ 4MG BASE/PACKET</u>	<u>N021409</u>	<u>001</u>	Jul 26, 2002
-----------	---------	---------------------------	----------------	------------	--------------

TABLET; ORAL

MONTELUKAST SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A202717</u>	<u>001</u>	Sep 21, 2012
<u>AB</u>	APOTEX CORP	<u>EQ 10MG BASE</u>	<u>A201294</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A202468</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A201582</u>	<u>001</u>	Aug 06, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A090926</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 10MG BASE</u>	<u>A202843</u>	<u>001</u>	Sep 10, 2014
<u>AB</u>	KUDCO IRELAND	<u>EQ 10MG BASE</u>	<u>A201522</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A203366</u>	<u>001</u>	Sep 11, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A079103</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	ROXANE	<u>EQ 10MG BASE</u>	<u>A090655</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A200889</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A078605</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A201515</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 10MG BASE</u>	<u>A202859</u>	<u>001</u>	Oct 30, 2014
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 10MG BASE</u>	<u>A091576</u>	<u>001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	+ MERCK	<u>EQ 10MG BASE</u>	<u>N020829</u>	<u>002</u>	Feb 20, 1998
-----------	---------	---------------------	----------------	------------	--------------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	APOTEX INC	<u>EQ 4MG BASE</u>	<u>A201508</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201508</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A202096</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202096</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A201581</u>	<u>001</u>	Aug 06, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201581</u>	<u>002</u>	Aug 06, 2012
<u>AB</u>	KUDCO IRELAND	<u>EQ 4MG BASE</u>	<u>A200405</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A200405</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE</u>	<u>A079142</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079142</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	ROXANE	<u>EQ 4MG BASE</u>	<u>A091128</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091128</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 4MG BASE</u>	<u>A091414</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091414</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A078723</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078723</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A090984</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090984</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 4MG BASE</u>	<u>A203037</u>	<u>001</u>	Oct 30, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203037</u>	<u>002</u>	Oct 30, 2014
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 4MG BASE</u>	<u>A091588</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091588</u>	<u>002</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	MERCK	<u>EQ 4MG BASE</u>	<u>N020830</u>	<u>002</u>	Mar 03, 2000
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N020830</u>	<u>001</u>	Feb 20, 1998

## PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

<u>AB1</u>	+ WATSON LABS INC	<u>10MG</u>	<u>N020616 008</u>	Apr 20, 2007
<u>AB1</u>		<u>20MG</u>	<u>N020616 001</u>	Jul 03, 1996
<u>AB1</u>		<u>30MG</u>	<u>N020616 004</u>	Mar 09, 2001
<u>AB1</u>		<u>50MG</u>	<u>N020616 002</u>	Jul 03, 1996
<u>AB1</u>		<u>60MG</u>	<u>N020616 005</u>	Mar 09, 2001
<u>AB1</u>		<u>80MG</u>	<u>N020616 006</u>	Oct 27, 2006
<u>AB1</u>	+	<u>100MG</u>	<u>N020616 003</u>	Jul 03, 1996
<u>AB1</u>	+	<u>200MG</u>	<u>N020616 007</u>	Feb 27, 2007

MORPHINE SULFATE

<u>AB1</u>	PAR PHARM INC	<u>20MG</u>	<u>A200812 001</u>	Nov 10, 2011
<u>AB1</u>		<u>30MG</u>	<u>A200812 002</u>	Nov 10, 2011
<u>AB1</u>		<u>50MG</u>	<u>A200812 003</u>	Nov 10, 2011
<u>AB1</u>		<u>60MG</u>	<u>A200812 004</u>	Nov 10, 2011
<u>AB1</u>		<u>80MG</u>	<u>A200812 005</u>	Nov 10, 2011
<u>AB1</u>		<u>100MG</u>	<u>A200812 006</u>	Nov 10, 2011
<u>AB1</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A202718 001</u>	Dec 29, 2014
<u>AB1</u>		<u>30MG</u>	<u>A202718 002</u>	Dec 29, 2014
<u>AB1</u>		<u>50MG</u>	<u>A202718 003</u>	Dec 29, 2014
<u>AB1</u>		<u>60MG</u>	<u>A202718 004</u>	Dec 29, 2014
<u>AB1</u>		<u>80MG</u>	<u>A202718 005</u>	Dec 29, 2014
<u>AB1</u>		<u>100MG</u>	<u>A202718 006</u>	Dec 29, 2014
<u>AB1</u>	UPSHER SMITH	<u>10MG</u>	<u>A202104 001</u>	Jun 03, 2013
<u>AB1</u>		<u>20MG</u>	<u>A202104 002</u>	Jun 03, 2013
<u>AB1</u>		<u>30MG</u>	<u>A202104 003</u>	Jun 03, 2013
<u>AB1</u>		<u>50MG</u>	<u>A202104 004</u>	Jun 03, 2013
<u>AB1</u>		<u>60MG</u>	<u>A202104 005</u>	Jun 03, 2013
<u>AB1</u>		<u>80MG</u>	<u>A202104 006</u>	Jun 03, 2013
<u>AB1</u>		<u>100MG</u>	<u>A202104 007</u>	Jun 03, 2013

AVINZA

<u>AB2</u>	KING PHARMS LLC	<u>30MG</u>	<u>N021260 001</u>	Mar 20, 2002
<u>AB2</u>		<u>45MG</u>	<u>N021260 005</u>	Dec 18, 2008
<u>AB2</u>		<u>60MG</u>	<u>N021260 002</u>	Mar 20, 2002
<u>AB2</u>		<u>75MG</u>	<u>N021260 006</u>	Dec 18, 2008
<u>AB2</u>		<u>90MG</u>	<u>N021260 003</u>	Mar 20, 2002
<u>AB2</u>	+	<u>120MG</u>	<u>N021260 004</u>	Mar 20, 2002

MORPHINE SULFATE

<u>AB2</u>	ACTAVIS ELIZABETH	<u>30MG</u>	<u>A079040 001</u>	Jan 16, 2013
<u>AB2</u>		<u>45MG</u>	<u>A079040 002</u>	Jan 16, 2013
<u>AB2</u>		<u>60MG</u>	<u>A079040 003</u>	Jan 16, 2013
<u>AB2</u>		<u>75MG</u>	<u>A079040 004</u>	Jan 16, 2013
<u>AB2</u>		<u>90MG</u>	<u>A079040 005</u>	Jan 16, 2013
<u>AB2</u>		<u>120MG</u>	<u>A079040 006</u>	Jan 16, 2013

KADIAN

	WATSON LABS INC	40MG	N020616 009	Jul 09, 2012
		70MG	N020616 010	Jul 09, 2012
		130MG	N020616 011	Jul 09, 2012
		150MG	N020616 012	Jul 09, 2012

INJECTABLE; INJECTION

ASTRAMORPH PF

<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/ML</u>	<u>A071050 001</u>	Oct 07, 1986
<u>AP</u>		<u>0.5MG/ML</u>	<u>A071051 001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071052 001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071053 001</u>	Oct 07, 1986

DURAMORPH PF

<u>AP</u>	+ HIKMA MAPLE	<u>0.5MG/ML</u>	<u>N018565 001</u>	Sep 18, 1984
<u>AP</u>	+	<u>1MG/ML</u>	<u>N018565 002</u>	Sep 18, 1984

MORPHINE SULFATE

<u>AP</u>	HOSPIRA	<u>0.5MG/ML</u>	<u>A071849 001</u>	May 11, 1988
<u>AP</u>		<u>0.5MG/ML</u>	<u>A073509 001</u>	Sep 30, 1992
<u>AP</u>		<u>1MG/ML</u>	<u>A071850 001</u>	May 11, 1988
<u>AP</u>		<u>1MG/ML</u>	<u>A073510 001</u>	Sep 30, 1992
<u>AP</u>	+	<u>1MG/ML</u>	<u>N019916 001</u>	Oct 30, 1992

INFUMORPH

	+ HIKMA MAPLE	10MG/ML	N018565 003	Jul 19, 1991
	+	25MG/ML	N018565 004	Jul 19, 1991

MORPHINE SULFATE

	+ HOSPIRA	5MG/ML	N019916 002	Oct 27, 2006
	+ HOSPIRA INC	2MG/ML	N202515 001	Nov 14, 2011
	+	4MG/ML	N202515 002	Nov 14, 2011

## PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

## INJECTABLE; INJECTION

## MORPHINE SULFATE

+		8MG/ML	N202515	003	Nov 14, 2011
+		10MG/ML	N202515	004	Nov 14, 2011
+		15MG/ML	N202515	005	Nov 14, 2011
+	MERIDIAN MEDCL TECHN	15MG/ML	N019999	001	Jul 12, 1990

## SOLUTION; INTRAMUSCULAR, INTRAVENOUS

## MORPHINE SULFATE

+	BD RX	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013
+		4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013
+		5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013
+		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013
+		10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013

## SOLUTION; ORAL

MORPHINE SULFATE

<u>AA</u>	MALLINCKRODT INC	<u>100MG/5ML</u>	<u>A202348</u>	<u>001</u>	Jul 15, 2011
<u>AA</u>	PADDOCK LLC	<u>100MG/5ML</u>	<u>A201574</u>	<u>001</u>	Aug 06, 2012
<u>AA</u>	ROXANE	<u>10MG/5ML</u>	<u>N022195</u>	<u>001</u>	Mar 17, 2008
<u>AA</u>		<u>20MG/5ML</u>	<u>N022195</u>	<u>002</u>	Mar 17, 2008
<u>AA</u>	+	<u>100MG/5ML</u>	<u>N022195</u>	<u>003</u>	Jan 25, 2010
<u>AA</u>	SUN PHARM INDS INC	<u>10MG/5ML</u>	<u>A201011</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>		<u>20MG/5ML</u>	<u>A201011</u>	<u>002</u>	Feb 05, 2014
<u>AA</u>	VISTAPHARM	<u>10MG/5ML</u>	<u>A201947</u>	<u>001</u>	Jan 05, 2012
<u>AA</u>		<u>20MG/5ML</u>	<u>A201947</u>	<u>002</u>	Jan 05, 2012
	LANNETT HOLDINGS INC	100MG/5ML	N201517	001	Jun 23, 2011

## TABLET; ORAL

## MORPHINE SULFATE

	ROXANE	15MG	N022207	001	Mar 17, 2008
+		30MG	N022207	002	Mar 17, 2008

## TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

<u>AB</u>	DAVA PHARMS INC	<u>15MG</u>	<u>A075407</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	MALLINCKRODT	<u>15MG</u>	<u>A076412</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>30MG</u>	<u>A076412</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>60MG</u>	<u>A076412</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>		<u>100MG</u>	<u>A076438</u>	<u>001</u>	Jul 03, 2003
<u>AB</u>		<u>200MG</u>	<u>A076438</u>	<u>002</u>	Jul 03, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A200824</u>	<u>001</u>	Oct 18, 2011
<u>AB</u>		<u>30MG</u>	<u>A200824</u>	<u>002</u>	Oct 18, 2011
<u>AB</u>		<u>60MG</u>	<u>A200824</u>	<u>003</u>	Oct 18, 2011
<u>AB</u>		<u>100MG</u>	<u>A200824</u>	<u>004</u>	Oct 18, 2011
<u>AB</u>		<u>200MG</u>	<u>A200824</u>	<u>005</u>	Oct 18, 2011
<u>AB</u>	NESHER PHARMS	<u>15MG</u>	<u>A076733</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>30MG</u>	<u>A076720</u>	<u>002</u>	Dec 23, 2005
<u>AB</u>		<u>60MG</u>	<u>A076720</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>100MG</u>	<u>A077855</u>	<u>001</u>	Sep 27, 2007
<u>AB</u>		<u>200MG</u>	<u>A077855</u>	<u>002</u>	Sep 27, 2007
<u>AB</u>	RANBAXY LABS LTD	<u>15MG</u>	<u>A078761</u>	<u>001</u>	May 11, 2012
<u>AB</u>		<u>30MG</u>	<u>A078761</u>	<u>002</u>	May 11, 2012
<u>AB</u>		<u>60MG</u>	<u>A078761</u>	<u>003</u>	May 11, 2012
<u>AB</u>		<u>100MG</u>	<u>A078761</u>	<u>004</u>	May 11, 2012
<u>AB</u>		<u>200MG</u>	<u>A078761</u>	<u>005</u>	May 11, 2012
<u>AB</u>	RHODES PHARMS	<u>15MG</u>	<u>A074862</u>	<u>001</u>	Jul 07, 1998
<u>AB</u>		<u>30MG</u>	<u>A074862</u>	<u>002</u>	Jul 07, 1998
<u>AB</u>		<u>60MG</u>	<u>A074862</u>	<u>003</u>	Jul 07, 1998
<u>AB</u>		<u>100MG</u>	<u>A074769</u>	<u>001</u>	Jul 02, 1998
<u>AB</u>		<u>200MG</u>	<u>A074769</u>	<u>002</u>	Jul 02, 1998
<u>AB</u>	VINTAGE PHARMS LLC	<u>15MG</u>	<u>A075295</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295</u>	<u>004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295</u>	<u>005</u>	Sep 15, 2000

MS CONTIN

<u>AB</u>	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516</u>	<u>003</u>	Sep 12, 1989
<u>AB</u>		<u>30MG</u>	<u>N019516</u>	<u>001</u>	May 29, 1987
<u>AB</u>		<u>60MG</u>	<u>N019516</u>	<u>002</u>	Apr 08, 1988
<u>AB</u>	+	<u>100MG</u>	<u>N019516</u>	<u>004</u>	Jan 16, 1990
<u>AB</u>		<u>200MG</u>	<u>N019516</u>	<u>005</u>	Nov 08, 1993

## PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EMBEDA

	ALPHARMA PHARMS	20MG; 0.8MG	N022321 001	Aug 13, 2009
		30MG; 1.2MG	N022321 002	Aug 13, 2009
		50MG; 2MG	N022321 003	Aug 13, 2009
+		60MG; 2.4MG	N022321 004	Aug 13, 2009
		80MG; 3.2MG	N022321 005	Aug 13, 2009
		100MG; 4MG	N022321 006	Aug 13, 2009

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+ BAYER HLTHCARE 160MG/100ML N021277 001 Nov 30, 2001

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

<b>AT</b>	LUPIN LTD	<b>EQ 0.5% BASE</b>	<b>A202867 001</b>	Sep 04, 2014
	<b>VIGAMOX</b>			
<b>AT</b>	+ ALCON PHARMS LTD	<b>EQ 0.5% BASE</b>	<b>N021598 001</b>	Apr 15, 2003
	MOXEZA			
	+ ALCON PHARMS LTD	EQ 0.5% BASE	N022428 001	Nov 19, 2010
	TABLET; ORAL			
	<b>AVELOX</b>			
<b>AB</b>	+ BAYER HLTHCARE	<b>EQ 400MG BASE</b>	<b>N021085 001</b>	Dec 10, 1999
	<b>MOXIFLOXACIN HYDROCHLORIDE</b>			
<b>AB</b>	AUROBINDO PHARMA LTD	<b>EQ 400MG BASE</b>	<b>A202632 001</b>	Mar 04, 2014
<b>AB</b>	DR REDDYS LABS LTD	<b>EQ 400MG BASE</b>	<b>A076938 001</b>	Mar 04, 2014
<b>AB</b>	TEVA PHARMS USA	<b>EQ 400MG BASE</b>	<b>A077437 001</b>	Feb 18, 2014
<b>AB</b>	TORRENT PHARMS LTD	<b>EQ 400MG BASE</b>	<b>A200160 001</b>	Apr 03, 2014

MUPIROICIN

OINTMENT; TOPICAL

BACTROBAN

<b>AB</b>	+ GLAXOSMITHKLINE	<b>2%</b>	<b>N050591 001</b>	Dec 31, 1987
	<b>MUPIROICIN</b>			
<b>AB</b>	FOUGERA PHARMS	<b>2%</b>	<b>A065192 001</b>	Nov 30, 2005
<b>AB</b>	GLENMARK PHARMS	<b>2%</b>	<b>A090480 001</b>	Jun 08, 2011
<b>AB</b>	PERRIGO NEW YORK	<b>2%</b>	<b>A065123 001</b>	Nov 07, 2003
<b>AB</b>	TARO	<b>2%</b>	<b>A065170 001</b>	Sep 23, 2005
<b>AB</b>	TEVA	<b>2%</b>	<b>A065085 001</b>	Nov 07, 2003
	CENTANY			
<b>BX</b>	PERRIGO NEW YORK	2%	N050788 001	Dec 04, 2002

MUPIROICIN CALCIUM

CREAM; TOPICAL

BACTROBAN

<b>AB</b>	+ GLAXOSMITHKLINE	<b>EQ 2% BASE</b>	<b>N050746 001</b>	Dec 11, 1997
	<b>MUPIROICIN</b>			
<b>AB</b>	GLENMARK GENERICS	<b>EQ 2% BASE</b>	<b>A201587 001</b>	Jan 24, 2013
	OINTMENT; NASAL			
	BACTROBAN			
	+ GLAXOSMITHKLINE	EQ 2% BASE	N050703 001	Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPT

<b>AB</b>	+ ROCHE PALO	<b>250MG</b>	<b>N050722 001</b>	May 03, 1995
	<b>MYCOPHENOLATE MOFETIL</b>			
<b>AB</b>	ACCORD HLTHCARE	<b>250MG</b>	<b>A090253 001</b>	May 04, 2009
<b>AB</b>	ALKEM LABS LTD	<b>250MG</b>	<b>A200197 001</b>	Jun 13, 2013
<b>AB</b>	APOTEX CORP	<b>250MG</b>	<b>A090419 001</b>	Apr 22, 2009
<b>AB</b>	CADISTA PHARMS	<b>250MG</b>	<b>A090762 001</b>	Dec 15, 2014
<b>AB</b>	DR REDDYS LABS LTD	<b>250MG</b>	<b>A091315 001</b>	Oct 27, 2011
<b>AB</b>	MYLAN	<b>250MG</b>	<b>A065520 001</b>	May 04, 2009
<b>AB</b>	ROXANE	<b>250MG</b>	<b>A065410 001</b>	Jul 29, 2008
<b>AB</b>	SANDOZ	<b>250MG</b>	<b>A065379 001</b>	Oct 15, 2008
<b>AB</b>	STRIDES PHARMA	<b>250MG</b>	<b>A090055 001</b>	Jun 10, 2010
<b>AB</b>	TEVA PHARMS	<b>250MG</b>	<b>A065491 001</b>	May 06, 2009
<b>AB</b>	VINTAGE PHARMS LLC	<b>250MG</b>	<b>A090111 001</b>	Dec 22, 2009
	SUSPENSION; ORAL			
	<b>CELLCEPT</b>			
<b>AB</b>	+ ROCHE PALO	<b>200MG/ML</b>	<b>N050759 001</b>	Oct 01, 1998
	<b>MYCOPHENOLATE MOFETIL</b>			
<b>AB</b>	ALKEM LABS LTD	<b>200MG/ML</b>	<b>A203005 001</b>	Nov 14, 2014

## PRESCRIPTION DRUG PRODUCT LIST

MYCOPHENOLATE MOFETIL

TABLET; ORAL

CELLCEPT

<b>AB</b>	+ ROCHE PALO	<b>500MG</b>	<b>N050723 001</b>	Jun 19, 1997
-----------	--------------	--------------	--------------------	--------------

MYCOPHENOLATE MOFETIL

<b>AB</b>	ACCORD HLTHCARE	<b>500MG</b>	<b>A065416 001</b>	May 04, 2009
<b>AB</b>	ALKEM LABS LTD	<b>500MG</b>	<b>A091249 001</b>	Nov 04, 2011
<b>AB</b>	APOTEX	<b>500MG</b>	<b>A090499 001</b>	Apr 22, 2009
<b>AB</b>	CADISTA PHARMS	<b>500MG</b>	<b>A090661 001</b>	Dec 15, 2014
<b>AB</b>	MYLAN	<b>500MG</b>	<b>A065521 001</b>	May 04, 2009
<b>AB</b>	ROXANE	<b>500MG</b>	<b>A065413 001</b>	Jul 29, 2008
<b>AB</b>	SANDOZ	<b>500MG</b>	<b>A065451 001</b>	Oct 15, 2008
<b>AB</b>	STRIDES PHARMA	<b>500MG</b>	<b>A090456 001</b>	Jun 10, 2010
<b>AB</b>	TEVA PHARMS	<b>500MG</b>	<b>A065457 001</b>	May 04, 2009
<b>AB</b>	VINTAGE PHARMS LLC	<b>500MG</b>	<b>A090606 001</b>	Jul 16, 2010

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

	+ ROCHE PALO	500MG/VIAL	N050758 001	Aug 12, 1998
--	--------------	------------	-------------	--------------

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

<b>AB</b>	APOTEX INC	<b>180MG</b>	<b>A091558 001</b>	Aug 21, 2012
<b>AB</b>		<b>360MG</b>	<b>A091558 002</b>	Aug 19, 2014
<b>AB</b>	MYLAN PHARMS INC	<b>180MG</b>	<b>A091248 002</b>	Jan 08, 2014
<b>AB</b>		<b>360MG</b>	<b>A091248 001</b>	Jan 08, 2014
<b>AB</b>	TEVA PHARMS USA	<b>180MG</b>	<b>A202720 001</b>	Oct 30, 2014
<b>AB</b>		<b>360MG</b>	<b>A202720 002</b>	Oct 30, 2014

MYFORTIC

<b>AB</b>	NOVARTIS	<b>180MG</b>	<b>N050791 001</b>	Feb 27, 2004
<b>AB</b>	+	<b>360MG</b>	<b>N050791 002</b>	Feb 27, 2004

NABILONE

CAPSULE; ORAL

CESAMET

	+ MEDA PHARMS	1MG	N018677 001	Dec 26, 1985
--	---------------	-----	-------------	--------------

NABUMETONE

TABLET; ORAL

NABUMETONE

<b>AB</b>	APOTEX INC	<b>500MG</b>	<b>A090427 001</b>	Dec 30, 2011
<b>AB</b>		<b>750MG</b>	<b>A090427 002</b>	Dec 30, 2011
<b>AB</b>	INVAGEN PHARMS	<b>500MG</b>	<b>A078671 001</b>	Mar 07, 2008
<b>AB</b>		<b>750MG</b>	<b>A078671 002</b>	Mar 07, 2008
<b>AB</b>	LUPIN LTD	<b>500MG</b>	<b>A090445 001</b>	Jan 12, 2011
<b>AB</b>		<b>750MG</b>	<b>A090445 002</b>	Jan 12, 2011
<b>AB</b>	MYLAN PHARMS INC	<b>500MG</b>	<b>A090516 001</b>	Jul 12, 2010
<b>AB</b>		<b>750MG</b>	<b>A090516 002</b>	Jul 12, 2010
<b>AB</b>	PAR PHARM	<b>500MG</b>	<b>A076009 001</b>	Jan 24, 2003
<b>AB</b>		<b>750MG</b>	<b>A076009 002</b>	Jan 24, 2003
<b>AB</b>	SANDOZ	<b>500MG</b>	<b>A075280 001</b>	Feb 25, 2002
<b>AB</b>		<b>750MG</b>	<b>A075280 002</b>	Feb 25, 2002
<b>AB</b>	TEVA	<b>500MG</b>	<b>A075189 001</b>	May 26, 2000
<b>AB</b>	+	<b>750MG</b>	<b>A075189 002</b>	Sep 24, 2001
<b>AB</b>	WATSON LABS	<b>500MG</b>	<b>A091083 001</b>	Jun 13, 2011
<b>AB</b>		<b>750MG</b>	<b>A091083 002</b>	Jun 13, 2011

NADOLOL

TABLET; ORAL

CORGARD

<b>AB</b>	KING PHARMS	<b>20MG</b>	<b>N018063 005</b>	Oct 28, 1986
<b>AB</b>		<b>40MG</b>	<b>N018063 001</b>	
<b>AB</b>	+	<b>80MG</b>	<b>N018063 002</b>	

NADOLOL

<b>AB</b>	IVAX SUB TEVA PHARMS	<b>20MG</b>	<b>A074229 001</b>	Aug 30, 1996
<b>AB</b>		<b>40MG</b>	<b>A074229 002</b>	Aug 30, 1996
<b>AB</b>		<b>80MG</b>	<b>A074255 001</b>	Jan 24, 1996
<b>AB</b>	MYLAN	<b>20MG</b>	<b>A074172 001</b>	Oct 31, 1993
<b>AB</b>		<b>40MG</b>	<b>A074172 002</b>	Oct 31, 1993
<b>AB</b>		<b>80MG</b>	<b>A074172 003</b>	Oct 31, 1993
<b>AB</b>	SANDOZ	<b>20MG</b>	<b>A074501 001</b>	Nov 09, 1995
<b>AB</b>		<b>40MG</b>	<b>A074501 002</b>	Nov 09, 1995
<b>AB</b>		<b>80MG</b>	<b>A074501 003</b>	Nov 09, 1995

## PRESCRIPTION DRUG PRODUCT LIST

NAFARELIN ACETATE

SPRAY, METERED;NASAL

SYNAREL

+ GD SEARLE LLC

EQ 0.2MG BASE/SPRAY

N019886 001 Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUMAP AGILA SPECLTSEQ 1GM BASE/VIALA200002 001 Apr 07, 2014APEQ 2GM BASE/VIALA200002 002 Apr 07, 2014AP ANTIBIOTICEEQ 1GM BASE/VIALA090560 001 Oct 03, 2011APEQ 2GM BASE/VIALA090560 002 Oct 03, 2011AP AUROBINDO PHARMA LTDEQ 1GM BASE/VIALA091613 001 Dec 26, 2012APEQ 2GM BASE/VIALA091613 002 Dec 26, 2012APEQ 10GM BASE/VIALA091614 001 Dec 26, 2012AP ISTITUTO BIO ITA SPAEQ 1GM BASE/VIALA090002 001 Jun 30, 2011APEQ 2GM BASE/VIALA090002 002 Jun 30, 2011APEQ 10GM BASE/VIALA090005 001 Apr 20, 2011AP SAGENT PHARMSEQ 1GM BASE/VIALA090582 001 Aug 24, 2012APEQ 2GM BASE/VIALA090582 002 Aug 24, 2012APEQ 10GM BASE/VIALA090580 001 Aug 24, 2012AP + SANDOZEQ 1GM BASE/VIALA062527 002 Aug 02, 1984AP +EQ 1GM BASE/VIALA062732 001 Dec 23, 1986AP +EQ 2GM BASE/VIALA062527 003 Aug 02, 1984AP +EQ 2GM BASE/VIALA062732 002 Dec 23, 1986AP +EQ 10GM BASE/VIALA062527 004 Aug 02, 1984

NALLPEN IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

EQ 2GM BASE/100ML

N050655 002 Oct 31, 1989

+

EQ 20MG BASE/ML

N050655 001 Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+ MERZ PHARMS

1%

N019599 001 Feb 29, 1988

+

2%

N019599 002 Jan 13, 2012

GEL; TOPICAL

NAFTIN

+ MERZ PHARMS

1%

N019356 001 Jun 18, 1990

+

2%

N204286 001 Jun 27, 2013

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDEAP + HOSPIRA10MG/MLA070914 001 Feb 03, 1989AP +10MG/MLA070915 001 Feb 03, 1989AP +20MG/MLA070916 001 Feb 03, 1989AP +20MG/MLA070918 001 Feb 03, 1989NALOXEGOL OXALATE

TABLET; ORAL

MOVANTIK

ASTRAZENECA PHARMS

EQ 12.5MG BASE

N204760 001 Sep 16, 2014

+

EQ 25MG BASE

N204760 002 Sep 16, 2014

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDEAP + HOSPIRA0.4MG/MLA070172 001 Sep 24, 1986AP +0.4MG/MLA070254 001 Jan 07, 1987AP +0.4MG/MLA070256 001 Jan 07, 1987AP +0.4MG/MLA070257 001 Jan 07, 1987AP INTL MEDICATION0.4MG/MLA070639 001 Sep 24, 1986AP +1MG/MLA072076 001 Mar 24, 1988AP MYLAN INSTITUTIONAL0.4MG/MLA204997 001 Mar 06, 2014

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

+ KALEO INC

0.4MG/0.4ML

N205787 001 Apr 03, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDEAB GAVIS PHARMSEQ 0.5MG BASE;EQ 50MG BASEA075735 001 Jul 11, 2001AB RANBAXYEQ 0.5MG BASE;EQ 50MG BASEA075523 001 Mar 17, 2000AB + WATSON LABSEQ 0.5MG BASE;EQ 50MG BASEA074736 001 Jan 21, 1997

## PRESCRIPTION DRUG PRODUCT LIST

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+ ALKERMES

380MG/VIAL

N021897 001 Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>50MG</u>	<u>A091205 001</u>	Aug 17, 2011
<u>AB</u>	BARR	<u>50MG</u>	<u>A074918 001</u>	May 08, 1998
<u>AB</u>	ELITE LABS	<u>50MG</u>	<u>A075274 001</u>	May 26, 1999
<u>AB</u>	MALLINCKRODT	<u>50MG</u>	<u>A076264 002</u>	Mar 22, 2002
<u>AB</u>	SUN PHARMA GLOBAL	<u>50MG</u>	<u>A090356 001</u>	Feb 24, 2012

REVIA

<u>AB</u>	+ TEVA WOMENS	<u>50MG</u>	<u>N018932 001</u>	Nov 20, 1984
	NALTREXONE HYDROCHLORIDE			
	MALLINCKRODT	25MG	A076264 001	Mar 22, 2002
		100MG	A076264 003	Mar 22, 2002

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

+ PHARMAFORCE

200MG/ML

A091252 001 Aug 30, 2010

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

+ AKORN INC

0.1%

A083590 001

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

<u>AB</u>	+ ROCHE PALO	<u>25MG/ML</u>	<u>N018965 001</u>	Mar 23, 1987
-----------	--------------	----------------	--------------------	--------------

NAPROXEN

<u>AB</u>	ROXANE	<u>25MG/ML</u>	<u>A074190 001</u>	Mar 30, 1994
-----------	--------	----------------	--------------------	--------------

TABLET; ORAL

NAPROSYN

<u>AB</u>	ROCHE PALO	<u>250MG</u>	<u>N017581 002</u>	
<u>AB</u>		<u>375MG</u>	<u>N017581 003</u>	
<u>AB</u>	+	<u>500MG</u>	<u>N017581 004</u>	Apr 15, 1982

NAPROXEN

<u>AB</u>	AMNEAL PHARMS NY	<u>250MG</u>	<u>A075927 001</u>	Dec 18, 2001
<u>AB</u>		<u>375MG</u>	<u>A075927 002</u>	Dec 18, 2001
<u>AB</u>		<u>500MG</u>	<u>A075927 003</u>	Dec 18, 2001
<u>AB</u>	AUROBINDO PHARMA USA	<u>250MG</u>	<u>A200429 001</u>	Nov 08, 2011
<u>AB</u>		<u>375MG</u>	<u>A200429 002</u>	Nov 08, 2011
<u>AB</u>		<u>500MG</u>	<u>A200429 003</u>	Nov 08, 2011
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A078250 001</u>	Mar 28, 2007
<u>AB</u>		<u>375MG</u>	<u>A078250 002</u>	Mar 28, 2007
<u>AB</u>		<u>500MG</u>	<u>A078250 003</u>	Mar 28, 2007
<u>AB</u>	HIKMA INTL PHARMS	<u>250MG</u>	<u>A076494 001</u>	Jan 14, 2004
<u>AB</u>		<u>375MG</u>	<u>A076494 002</u>	Jan 14, 2004
<u>AB</u>		<u>500MG</u>	<u>A076494 003</u>	Jan 14, 2004
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A091305 001</u>	Aug 24, 2011
<u>AB</u>		<u>375MG</u>	<u>A091305 002</u>	Aug 24, 2011
<u>AB</u>		<u>500MG</u>	<u>A091305 003</u>	Aug 24, 2011
<u>AB</u>	MARKSANS PHARMA	<u>250MG</u>	<u>A091416 001</u>	Feb 14, 2011
<u>AB</u>		<u>375MG</u>	<u>A091416 002</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A091416 003</u>	Feb 14, 2011
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A074121 001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074121 002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074121 003</u>	Dec 21, 1993
<u>AB</u>	PERRIGO R AND D	<u>250MG</u>	<u>A077339 001</u>	Apr 27, 2005
<u>AB</u>		<u>375MG</u>	<u>A077339 002</u>	Apr 27, 2005
<u>AB</u>		<u>500MG</u>	<u>A077339 003</u>	Apr 27, 2005
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A074140 001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074140 002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074140 003</u>	Dec 21, 1993
<u>AB</u>	TEVA	<u>250MG</u>	<u>A074201 001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074201 002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074201 003</u>	Dec 21, 1993
<u>AB</u>	ZYDUS PHARMS USA	<u>250MG</u>	<u>A078620 001</u>	Jun 07, 2007
<u>AB</u>		<u>375MG</u>	<u>A078620 002</u>	Jun 07, 2007
<u>AB</u>		<u>500MG</u>	<u>A078620 003</u>	Jun 07, 2007



## PRESCRIPTION DRUG PRODUCT LIST

NAPROXEN

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

<u>AB</u>	+	ROCHE PALO	<u>375MG</u>	<u>N020067</u>	<u>002</u>	Oct 14, 1994
<u>AB</u>	+		<u>500MG</u>	<u>N020067</u>	<u>003</u>	Oct 14, 1994

NAPROXEN

<u>AB</u>		INVAGEN PHARMS	<u>375MG</u>	<u>A091432</u>	<u>001</u>	Sep 19, 2011
<u>AB</u>			<u>500MG</u>	<u>A091432</u>	<u>002</u>	Sep 19, 2011
<u>AB</u>		MYLAN PHARMS INC	<u>375MG</u>	<u>A075390</u>	<u>001</u>	Apr 19, 2001
<u>AB</u>			<u>500MG</u>	<u>A075390</u>	<u>002</u>	Apr 19, 2001
<u>AB</u>		PLIVA	<u>375MG</u>	<u>A075337</u>	<u>001</u>	May 26, 1999
<u>AB</u>			<u>500MG</u>	<u>A075337</u>	<u>002</u>	May 26, 1999
<u>AB</u>		SANDOZ	<u>375MG</u>	<u>A075061</u>	<u>001</u>	Feb 18, 1998
<u>AB</u>			<u>500MG</u>	<u>A075061</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>		TEVA	<u>375MG</u>	<u>A075227</u>	<u>001</u>	Jun 30, 1998
<u>AB</u>			<u>500MG</u>	<u>A075227</u>	<u>002</u>	Jun 30, 1998

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

<u>AB</u>		HOFFMANN LA ROCHE	<u>EQ 250MG BASE</u>	<u>N018164</u>	<u>001</u>	
-----------	--	-------------------	----------------------	----------------	------------	--

ANAPROX DS

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>EQ 500MG BASE</u>	<u>N018164</u>	<u>003</u>	Sep 30, 1987
-----------	---	-------------------	----------------------	----------------	------------	--------------

NAPROXEN SODIUM

<u>AB</u>		AMNEAL PHARMS NY	<u>EQ 250MG BASE</u>	<u>A078432</u>	<u>001</u>	Apr 25, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078432</u>	<u>002</u>	Apr 25, 2007
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A200629</u>	<u>001</u>	Oct 31, 2011
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A200629</u>	<u>002</u>	Oct 31, 2011
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486</u>	<u>001</u>	Jul 26, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078486</u>	<u>002</u>	Jul 26, 2007
<u>AB</u>		GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078314</u>	<u>001</u>	Apr 27, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078314</u>	<u>002</u>	Apr 27, 2007
<u>AB</u>		HIKMA	<u>EQ 250MG BASE</u>	<u>A074480</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A074480</u>	<u>001</u>	May 14, 1996
<u>AB</u>		TEVA	<u>EQ 250MG BASE</u>	<u>A074198</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A074198</u>	<u>002</u>	Dec 21, 1993

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

<u>AB</u>		ALMATICA PHARMA INC	<u>EQ 375MG BASE</u>	<u>N020353</u>	<u>001</u>	Jan 05, 1996
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>N020353</u>	<u>002</u>	Jan 05, 1996

NAPROXEN SODIUM

<u>AB</u>		ACTAVIS LABS FL INC	<u>EQ 375MG BASE</u>	<u>A075416</u>	<u>002</u>	Apr 23, 2003
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075416</u>	<u>001</u>	Aug 27, 2002
		NAPRELAN				
	+	ALMATICA PHARMA INC	<u>EQ 750MG BASE</u>	<u>N020353</u>	<u>003</u>	Jan 05, 1996

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

	+	PERNIX IRELAND LTD	<u>500MG;EQ 85MG BASE</u>	<u>N021926</u>	<u>001</u>	Apr 15, 2008
--	---	--------------------	---------------------------	----------------	------------	--------------

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

AMERGE

<u>AB</u>		GLAXOSMITHKLINE LLC	<u>EQ 1MG BASE</u>	<u>N020763</u>	<u>002</u>	Feb 10, 1998
<u>AB</u>	+		<u>EQ 2.5MG BASE</u>	<u>N020763</u>	<u>001</u>	Feb 10, 1998

NARATRIPTAN

<u>AB</u>		APOTEX CORP	<u>EQ 1MG BASE</u>	<u>A091373</u>	<u>001</u>	Apr 22, 2011
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A091373</u>	<u>002</u>	Apr 22, 2011
<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 1MG BASE</u>	<u>A200502</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A200502</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 1MG BASE</u>	<u>A202431</u>	<u>001</u>	May 31, 2012
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A202431</u>	<u>002</u>	May 31, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A091441</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A091441</u>	<u>002</u>	Apr 30, 2012
<u>AB</u>		PADDOCK LLC	<u>EQ 1MG BASE</u>	<u>A091326</u>	<u>001</u>	Jul 08, 2010
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A091326</u>	<u>002</u>	Jul 08, 2010
<u>AB</u>		ROXANE	<u>EQ 1MG BASE</u>	<u>A090381</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A090381</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>		SANDOZ	<u>EQ 1MG BASE</u>	<u>A090288</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A090288</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A091552</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078751</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A078751</u>	<u>002</u>	Jul 07, 2010

## PRESCRIPTION DRUG PRODUCT LIST

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

+ ALCON

5%

N050514 001

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE**AB** DR REDDYS LABS LTD**60MG****A077461 001** Sep 09, 2009**AB** **120MG****A077461 002** Sep 09, 2009**AB** PAR PHARM**60MG****A077463 001** Sep 09, 2009**AB** **120MG****A077463 002** Sep 09, 2009**AB** WATSON LABS**60MG****A077462 001** Mar 30, 2011**AB** **120MG****A077462 002** Mar 30, 2011STARLIX**AB** NOVARTIS**60MG****N021204 001** Dec 22, 2000**AB** + **120MG****N021204 002** Dec 22, 2000NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC

FOREST LABS

EQ 2.5MG BASE

N021742 002 Dec 17, 2007

EQ 5MG BASE

N021742 003 Dec 17, 2007

EQ 10MG BASE

N021742 004 Dec 17, 2007

+

EQ 20MG BASE

N021742 005 Oct 08, 2008

NEDOCROMIL SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALOCRIIL**AT** + ALLERGAN**2%****N021009 001** Dec 08, 1999NEDOCROMIL SODIUM**AT** AKORN**2%****A090638 001** Aug 22, 2012NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE**AB** RANBAXY**50MG****A076409 001** Sep 16, 2003**AB** **100MG****A076409 002** Sep 16, 2003**AB** **150MG****A076409 003** Sep 16, 2003**AB** **200MG****A076409 004** Sep 16, 2003**AB** **250MG****A076409 005** Sep 16, 2003**AB** TEVA**50MG****A076037 001** Sep 16, 2003**AB** **100MG****A076037 002** Sep 16, 2003**AB** **150MG****A076037 003** Sep 16, 2003**AB** **200MG****A076037 004** Sep 16, 2003**AB** + **250MG****A076037 005** Sep 16, 2003

BX DR REDDYS LABS INC

50MG

A076309 001 Sep 16, 2003

BX 100MG

A076309 002 Sep 16, 2003

BX 150MG

A076309 003 Sep 16, 2003

BX 200MG

A076309 004 Sep 16, 2003

BX 250MG

A076309 005 Sep 16, 2003

NELARABINE

INJECTABLE;IV (INFUSION)

ARRANON

+ SMITHKLINE BEECHAM

250MG/50ML (5MG/ML)

N021877 001 Oct 28, 2005

NELFINAVIR MESYLATE

TABLET;ORAL

VIRACEPT

+ AGOURON

EQ 250MG BASE

N020779 001 Mar 14, 1997

+

EQ 625MG BASE

N021503 001 Apr 30, 2003

NEOMYCIN SULFATE

SOLUTION;ORAL

NEO-FRADIN

+ X GEN PHARMS

EQ 87.5MG BASE/5ML

A065010 001 May 23, 2002

TABLET;ORAL

NEOMYCIN SULFATE**AA** OMAN PHARM PRODUCTS**500MG****A065468 001** Mar 29, 2010**AA** + TEVA**500MG****A060304 001****AA** X GEN PHARMS**500MG****A065220 001** Jul 28, 2006

## PRESCRIPTION DRUG PRODUCT LIST

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

<b>AT</b>	WATSON LABS	<b>EQ 40MG BASE/ML; 200,000 UNITS/ML</b>	<b>A062664 001</b>	Apr 08, 1986
<b>AT</b>	X GEN PHARMS	<b>EQ 40MG BASE/ML; 200,000 UNITS/ML</b>	<b>A065106 001</b>	Jan 31, 2006
<b>AT</b>		<b>EQ 40MG BASE/ML; 200,000 UNITS/ML</b>	<b>A065108 001</b>	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

<b>AT</b>	+ MONARCH PHARMS	<b>EQ 40MG BASE/ML; 200,000 UNITS/ML</b>	<b>A060707 001</b>	
-----------	------------------	------------------------------------------	--------------------	--

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

	+ ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)	N204078 001	May 31, 2013
	+	10MG/10ML (1MG/ML)	N204078 002	May 31, 2013

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

	+ ALCON RES LTD	0.3%	N203491 001	Oct 16, 2012
--	-----------------	------	-------------	--------------

NEVANAC

	+ ALCON PHARMS LTD	0.1%	N021862 001	Aug 19, 2005
--	--------------------	------	-------------	--------------

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

	+ SCIOS LLC	1.5MG/VIAL	N020920 001	Aug 10, 2001
--	-------------	------------	-------------	--------------

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

AKYNZEO

	+ HELSINN HLTHCARE	300MG; EQ 0.5MG BASE	N205718 001	Oct 10, 2014
--	--------------------	----------------------	-------------	--------------

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

<b>AA</b>	AUROBINDO	<b>50MG/5ML</b>	<b>A077702 001</b>	May 22, 2012
-----------	-----------	-----------------	--------------------	--------------

VIRAMUNE

<b>AA</b>	+ BOEHRINGER INGELHEIM	<b>50MG/5ML</b>	<b>N020933 001</b>	Sep 11, 1998
-----------	------------------------	-----------------	--------------------	--------------

TABLET; ORAL

NEVIRAPINE

<b>AB</b>	APOTEX INC	<b>200MG</b>	<b>A203021 001</b>	May 22, 2012
<b>AB</b>	AUROBINDO	<b>200MG</b>	<b>A077521 001</b>	May 22, 2012
<b>AB</b>	CIPLA	<b>200MG</b>	<b>A077956 001</b>	May 22, 2012
<b>AB</b>	HETERO LABS LTD III	<b>200MG</b>	<b>A078584 001</b>	May 22, 2012
<b>AB</b>	MICRO LABS LTD	<b>200MG</b>	<b>A203080 001</b>	May 22, 2012
<b>AB</b>	MYLAN LABS	<b>200MG</b>	<b>A078864 001</b>	May 22, 2012
<b>AB</b>	MYLAN PHARMS INC	<b>200MG</b>	<b>A202523 001</b>	May 22, 2012
<b>AB</b>	PRINSTON INC	<b>200MG</b>	<b>A078644 001</b>	May 22, 2012
<b>AB</b>	SCIEGEN PHARMS INC	<b>200MG</b>	<b>A203176 001</b>	May 22, 2012
<b>AB</b>	STRIDES PHARMA	<b>200MG</b>	<b>A078195 001</b>	May 22, 2012

VIRAMUNE

<b>AB</b>	+ BOEHRINGER INGELHEIM	<b>200MG</b>	<b>N020636 001</b>	Jun 21, 1996
-----------	------------------------	--------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

<b>AB</b>	APOTEX INC	<b>400MG</b>	<b>A205258 001</b>	Apr 03, 2014
<b>AB</b>	MYLAN PHARMS INC	<b>400MG</b>	<b>A205651 001</b>	Oct 27, 2014
<b>AB</b>	SANDOZ	<b>400MG</b>	<b>A203411 001</b>	Apr 03, 2014

VIRAMUNE XR

<b>AB</b>	+ BOEHRINGER INGELHEIM	<b>400MG</b>	<b>N201152 001</b>	Mar 25, 2011
		100MG	N201152 002	Nov 08, 2012

NIACIN

TABLET; ORAL

NIACIN

<b>AA</b>	WOCKHARDT	<b>500MG</b>	<b>A081134 001</b>	Apr 28, 1992
-----------	-----------	--------------	--------------------	--------------

NIACOR

<b>AA</b>	+ UPSHER SMITH	<b>500MG</b>	<b>A040378 001</b>	May 03, 2000
-----------	----------------	--------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NIACIN

<b>AB</b>	BARR	<b>1GM</b>	<b>A076250 001</b>	Apr 14, 2005
<b>AB</b>		<b>500MG</b>	<b>A076378 001</b>	Apr 26, 2005
<b>AB</b>		<b>750MG</b>	<b>A076378 002</b>	Apr 26, 2005
<b>AB</b>	LUPIN LTD	<b>1GM</b>	<b>A090446 001</b>	Mar 20, 2014
<b>AB</b>		<b>500MG</b>	<b>A090860 001</b>	Mar 20, 2014
<b>AB</b>		<b>750MG</b>	<b>A090892 001</b>	Mar 20, 2014

## PRESCRIPTION DRUG PRODUCT LIST

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

<u>AB</u>	SUN PHARMA GLOBAL	<u>1GM</u>	<u>A200484</u>	<u>002</u>	Apr 23, 2014
<u>AB</u>		<u>500MG</u>	<u>A200484</u>	<u>001</u>	Apr 23, 2014
<u>AB</u>		<u>750MG</u>	<u>A201273</u>	<u>001</u>	Apr 23, 2014

NIASPAN

<u>AB</u>	+ ABBVIE	<u>1GM</u>	<u>N020381</u>	<u>004</u>	Jul 28, 1997
<u>AB</u>		<u>500MG</u>	<u>N020381</u>	<u>002</u>	Jul 28, 1997
<u>AB</u>	+	<u>750MG</u>	<u>N020381</u>	<u>003</u>	Jul 28, 1997

NIACIN; SIMVASTATIN

TABLET, EXTENDED RELEASE;ORAL

## SIMCOR

+	ABBVIE	1GM;20MG	N022078	003	Feb 15, 2008
+		1GM;40MG	N022078	005	Jul 28, 2010
+		500MG;20MG	N022078	001	Feb 15, 2008
+		500MG;40MG	N022078	004	Jul 28, 2010
+		750MG;20MG	N022078	002	Feb 15, 2008

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

CARDENE

<u>AB</u>	CHIESI USA INC	<u>20MG</u>	<u>N019488</u>	<u>001</u>	Dec 21, 1988
<u>AB</u>	+	<u>30MG</u>	<u>N019488</u>	<u>002</u>	Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>20MG</u>	<u>A074439</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>		<u>20MG</u>	<u>A074540</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		<u>30MG</u>	<u>A074439</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>		<u>30MG</u>	<u>A074540</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>	EPIC PHARMA	<u>20MG</u>	<u>A074928</u>	<u>001</u>	Mar 19, 1998
<u>AB</u>		<u>30MG</u>	<u>A074928</u>	<u>002</u>	Mar 19, 1998
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074642</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>		<u>30MG</u>	<u>A074642</u>	<u>002</u>	Jul 18, 1996

INJECTABLE;INJECTION

CARDENE

<u>AP</u>	+ CHIESI USA INC	<u>25MG/10ML (2.5MG/ML)</u>	<u>N019734</u>	<u>001</u>	Jan 30, 1992
-----------	------------------	-----------------------------	----------------	------------	--------------

NICARDIPINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>25MG/10ML (2.5MG/ML)</u>	<u>A078714</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>	EXELA PHARMA SCIENCE	<u>25MG/10ML (2.5MG/ML)</u>	<u>N022276</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>	LUITPOLD	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090534</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	MYLAN INSTITUTIONAL	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090664</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	NAVINTA LLC	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090125</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	SUN PHARMA GLOBAL	<u>25MG/10ML (2.5MG/ML)</u>	<u>N078405</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	WOCKHARDT	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090671</u>	<u>001</u>	Nov 17, 2009

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008
---	----------------	-----------------------	---------	-----	--------------

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008
---	----------------	-----------------------	---------	-----	--------------

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008
---	----------------	-----------------------	---------	-----	--------------

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008
---	----------------	-----------------------	---------	-----	--------------

NICOTINE

INHALANT;ORAL

## NICOTROL

+	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714	001	May 02, 1997
---	----------------------	---------------	---------	-----	--------------

SPRAY, METERED;NASAL

## NICOTROL

+	PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996
---	------------	-------------	---------	-----	--------------

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072579</u>	<u>001</u>	Jan 08, 1991
<u>AB</u>		<u>20MG</u>	<u>A072556</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	EMCURE PHARMS USA	<u>10MG</u>	<u>A202644</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202644</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	INTERGEL PHARM	<u>10MG</u>	<u>A072781</u>	<u>001</u>	Jul 30, 1993

PROCARDIA

<u>AB</u>	+	PFIZER	<u>10MG</u>	<u>N018482</u>	<u>001</u>
-----------	---	--------	-------------	----------------	------------

## PRESCRIPTION DRUG PRODUCT LIST

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

<u>AB1</u>	BAYER HLTHCARE	<u>30MG</u>	<u>N020198</u>	<u>001</u>	Apr 21, 1993
<u>AB1</u>	+	<u>60MG</u>	<u>N020198</u>	<u>002</u>	Apr 21, 1993
<u>AB1</u>	+	<u>90MG</u>	<u>N020198</u>	<u>003</u>	Apr 21, 1993

AFEDITAB CR

<u>AB1</u>	WATSON LABS	<u>30MG</u>	<u>A075128</u>	<u>001</u>	Mar 10, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075659</u>	<u>001</u>	Oct 26, 2001

NIFEDIPINE

<u>AB1</u>	MYLAN	<u>30MG</u>	<u>A201071</u>	<u>001</u>	Dec 03, 2010
<u>AB1</u>		<u>60MG</u>	<u>A201071</u>	<u>002</u>	Dec 03, 2010
<u>AB1</u>		<u>90MG</u>	<u>A201071</u>	<u>003</u>	Dec 03, 2010
<u>AB1</u>	PAR PHARM	<u>30MG</u>	<u>A077899</u>	<u>001</u>	Dec 13, 2006
<u>AB1</u>		<u>60MG</u>	<u>A077899</u>	<u>002</u>	Dec 13, 2006
<u>AB1</u>		<u>90MG</u>	<u>A077899</u>	<u>003</u>	May 25, 2012
<u>AB1</u>	VALEANT INTL	<u>30MG</u>	<u>A075269</u>	<u>001</u>	Dec 04, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075269</u>	<u>002</u>	Dec 04, 2000
<u>AB1</u>		<u>90MG</u>	<u>A076070</u>	<u>001</u>	Aug 16, 2002
<u>AB2</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A090602</u>	<u>001</u>	Sep 13, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090602</u>	<u>002</u>	Sep 13, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090602</u>	<u>003</u>	Sep 13, 2010
<u>AB2</u>	MYLAN	<u>30MG</u>	<u>A090649</u>	<u>001</u>	Jun 21, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090649</u>	<u>002</u>	Jun 21, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090649</u>	<u>003</u>	Jun 21, 2010
<u>AB2</u>	OSMOTICA PHARM	<u>30MG</u>	<u>A077127</u>	<u>001</u>	Nov 21, 2005
<u>AB2</u>		<u>60MG</u>	<u>A077127</u>	<u>002</u>	Nov 21, 2005
<u>AB2</u>		<u>90MG</u>	<u>A077410</u>	<u>001</u>	Oct 03, 2007
<u>AB2</u>	TWI PHARMS INC	<u>30MG</u>	<u>A203126</u>	<u>001</u>	Apr 03, 2014
<u>AB2</u>		<u>60MG</u>	<u>A203126</u>	<u>002</u>	Apr 03, 2014
<u>AB2</u>		<u>90MG</u>	<u>A203126</u>	<u>003</u>	Apr 03, 2014
<u>AB2</u>	VALEANT INTL	<u>30MG</u>	<u>A075289</u>	<u>002</u>	Feb 06, 2001
<u>AB2</u>		<u>60MG</u>	<u>A075289</u>	<u>001</u>	Sep 27, 2000

PROCARDIA XL

<u>AB2</u>	PFIZER	<u>30MG</u>	<u>N019684</u>	<u>001</u>	Sep 06, 1989
<u>AB2</u>		<u>60MG</u>	<u>N019684</u>	<u>002</u>	Sep 06, 1989
<u>AB2</u>	+	<u>90MG</u>	<u>N019684</u>	<u>003</u>	Sep 06, 1989

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE;ORAL

TASIGNA

	NOVARTIS	EQ 150MG BASE	N022068	002	Jun 17, 2010
	+	EQ 200MG BASE	N022068	001	Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

	+ COVIS PHARMA SARL	150MG	N020169	002	Apr 30, 1999
--	---------------------	-------	---------	-----	--------------

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

<u>AB</u>	+	BANNER PHARMACAPS	<u>30MG</u>	<u>A076740</u>	<u>001</u>	Jan 17, 2008
<u>AB</u>		BARR LABS INC	<u>30MG</u>	<u>A077811</u>	<u>001</u>	May 02, 2007
<u>AB</u>		SUN PHARM INDS INC	<u>30MG</u>	<u>A077067</u>	<u>001</u>	Apr 17, 2007
<u>AB</u>		THEPHARMANETWORK LLC	<u>30MG</u>	<u>A090103</u>	<u>001</u>	Apr 07, 2014

SOLUTION;ORAL

NYMALIZE

	+ ARBOR PHARMS LLC	60MG/20ML	N203340	001	May 10, 2013
--	--------------------	-----------	---------	-----	--------------

NINTEDANIB

CAPSULE;ORAL

OFEV

	BOEHRINGER INGELHEIM	100MG	N205832	001	Oct 15, 2014
	+	150MG	N205832	002	Oct 15, 2014

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

<u>AB</u>	MYLAN	<u>8.5MG</u>	<u>A091001</u>	<u>001</u>	Jan 26, 2011
<u>AB</u>		<u>17MG</u>	<u>A091001</u>	<u>002</u>	Jan 26, 2011
<u>AB</u>		<u>34MG</u>	<u>A091001</u>	<u>004</u>	Jan 26, 2011

SULAR

<u>AB</u>	+	SHIONOGI INC	<u>8.5MG</u>	<u>N020356</u>	<u>008</u>	Jan 02, 2008
<u>AB</u>	+		<u>17MG</u>	<u>N020356</u>	<u>007</u>	Jan 02, 2008

## PRESCRIPTION DRUG PRODUCT LIST

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

SULAR

<b>AB</b>	+	<b>34MG</b>	<b>N020356 005</b>	Jan 02, 2008
		NISOLDIPINE		
		MYLAN	A079051 001	Jul 25, 2008
		20MG	A091001 003	Jan 26, 2011
	+	30MG	A079051 002	Jul 25, 2008
	+	40MG	A079051 003	Jul 25, 2008

NITAZOXANIDE

FOR SUSPENSION;ORAL

## ALINIA

	+	ROMARK	100MG/5ML	N021498 001	Nov 22, 2002
		TABLET;ORAL			
		ALINIA			
	+	ROMARK	500MG	N021497 001	Jul 21, 2004

NITISINONE

CAPSULE;ORAL

## ORFADIN

		SWEDISH ORPHAN	2MG	N021232 001	Jan 18, 2002
			5MG	N021232 002	Jan 18, 2002
	+		10MG	N021232 003	Jan 18, 2002

NITRIC OXIDE

GAS; INHALATION

## INOMAX

		INO	100PPM	N020845 002	Dec 23, 1999
	+		800PPM	N020845 003	Dec 23, 1999

NITROFURANTOIN

SUSPENSION;ORAL

FURADANTIN

<b>AB</b>	+	SHIONOGI INC	<b>25MG/5ML</b>	<b>N009175 001</b>	
		<u>NITROFURANTOIN</u>			
<b>AB</b>		AMNEAL PHARMS	<b>25MG/5ML</b>	<b>A201679 001</b>	May 11, 2011
<b>AB</b>		NOVEL LABS INC	<b>25MG/5ML</b>	<b>A201693 001</b>	Sep 08, 2014
<b>AB</b>		SUN PHARM INDS INC	<b>25MG/5ML</b>	<b>A201355 001</b>	Aug 14, 2013

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

<b>AB</b>		ALVOGEN INC	<b>50MG</b>	<b>N016620 001</b>	
<b>AB</b>	+		<b>100MG</b>	<b>N016620 002</b>	
		<u>NITROFURANTOIN</u>			
<b>AB</b>		IVAX SUB TEVA PHARMS	<b>50MG</b>	<b>A073671 001</b>	Jan 28, 1993
<b>AB</b>			<b>100MG</b>	<b>A073652 001</b>	Jan 28, 1993
<b>AB</b>		MYLAN	<b>50MG</b>	<b>A074967 001</b>	Jul 09, 1997
<b>AB</b>			<b>100MG</b>	<b>A077025 001</b>	Aug 18, 2004
		MACRODANTIN			
		ALVOGEN INC	25MG	N016620 003	

NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACROBID

<b>AB</b>	+	ALVOGEN INC	<b>75MG;25MG</b>	<b>N020064 001</b>	Dec 24, 1991
		<u>NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)</u>			
<b>AB</b>		MYLAN	<b>75MG;25MG</b>	<b>A076648 001</b>	Mar 22, 2004
<b>AB</b>		SANDOZ	<b>75MG;25MG</b>	<b>A077066 001</b>	Apr 05, 2005

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL

## NITROMIST

	+	MIST PHARMS LLC	0.4MG/SPRAY	N021780 001	Nov 02, 2006
--	---	-----------------	-------------	-------------	--------------

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

<b>AB1</b>		MEDICIS	<b>0.2MG/HR</b>	<b>A089772 001</b>	Aug 30, 1996
<b>AB1</b>			<b>0.4MG/HR</b>	<b>A089773 001</b>	Aug 30, 1996
<b>AB1</b>		VALEANT PHARM NORTH	<b>0.1MG/HR</b>	<b>A089771 001</b>	Aug 30, 1996
<b>AB1</b>			<b>0.6MG/HR</b>	<b>A089774 001</b>	Aug 30, 1996

NITRO-DUR

<b>AB1</b>	+	MERCK SHARP DOHME	<b>0.1MG/HR</b>	<b>N020145 001</b>	Apr 04, 1995
<b>AB1</b>	+		<b>0.2MG/HR</b>	<b>N020145 002</b>	Apr 04, 1995
<b>AB1</b>	+		<b>0.4MG/HR</b>	<b>N020145 004</b>	Apr 04, 1995
<b>AB1</b>	+		<b>0.6MG/HR</b>	<b>N020145 005</b>	Apr 04, 1995

## PRESCRIPTION DRUG PRODUCT LIST

## NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

<u>AB2</u>	HERCON PHARM	<u>0.2MG/HR</u>	<u>A089884</u>	<u>001</u>	Oct 30, 1998
<u>AB2</u>		<u>0.4MG/HR</u>	<u>A089885</u>	<u>001</u>	Oct 30, 1998
<u>AB2</u>		<u>0.6MG/HR</u>	<u>A089886</u>	<u>001</u>	Oct 30, 1998
<u>AB2</u>	+ MYLAN TECHNOLOGIES	<u>0.2MG/HR</u>	<u>A074559</u>	<u>003</u>	Aug 30, 1996
<u>AB2</u>	+	<u>0.4MG/HR</u>	<u>A074559</u>	<u>002</u>	Aug 30, 1996
<u>AB2</u>	+	<u>0.6MG/HR</u>	<u>A074559</u>	<u>001</u>	Aug 30, 1996
	NITRO-DUR				
	+ MERCK SHARP DOHME	0.3MG/HR	N020145	003	Apr 04, 1995
	+	0.8MG/HR	N020145	006	Apr 04, 1995
	NITROGLYCERIN				
	+ MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%

<u>AP</u>	+	BAXTER HLTHCARE	<u>10MG/100ML</u>	<u>N019970</u>	<u>001</u>	Dec 29, 1989
<u>AP</u>	+		<u>20MG/100ML</u>	<u>N019970</u>	<u>002</u>	Dec 29, 1989
<u>AP</u>	+		<u>40MG/100ML</u>	<u>N019970</u>	<u>003</u>	Dec 29, 1989
<u>AP</u>		HOSPIRA	<u>10MG/100ML</u>	<u>A071846</u>	<u>001</u>	Aug 31, 1990
<u>AP</u>			<u>20MG/100ML</u>	<u>A071847</u>	<u>001</u>	Aug 31, 1990
<u>AP</u>			<u>40MG/100ML</u>	<u>A071848</u>	<u>001</u>	Aug 31, 1990
		NITROGLYCERIN				
		+ LUITPOLD	5MG/ML	A072034	001	May 24, 1988
		OINTMENT; INTRA-ANAL				
		RECTIV				
		+ FOREST LABS INC	0.4%	N021359	001	Jun 21, 2011
		OINTMENT; TRANSDERMAL				
		NITROGLYCERIN				
		+ FOUGERA	2%	A087355	001	Jul 08, 1988
		SPRAY, METERED; SUBLINGUAL				

NITROGLYCERIN

<u>AB</u>		PERRIGO ISRAEL	<u>0.4MG/SPRAY</u>	<u>A091496</u>	<u>001</u>	Sep 20, 2013
		<u>NITROLINGUAL PUMPSPRAY</u>				
<u>AB</u>	+	POHL BOSKAMP	<u>0.4MG/SPRAY</u>	<u>N018705</u>	<u>002</u>	Jan 10, 1997
		TABLET; SUBLINGUAL				
		NITROSTAT				
		PFIZER PHARMS	0.3MG	N021134	001	May 01, 2000
			0.4MG	N021134	002	May 01, 2000
		+	0.6MG	N021134	003	May 01, 2000

## NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

<u>AB</u>		ANI PHARMS INC	<u>150MG</u>	<u>A075668</u>	<u>001</u>	Sep 12, 2002
<u>AB</u>			<u>300MG</u>	<u>A075668</u>	<u>002</u>	Sep 12, 2002
<u>AB</u>		DR REDDYS LABS LTD	<u>150MG</u>	<u>A077314</u>	<u>001</u>	Sep 15, 2005
<u>AB</u>			<u>300MG</u>	<u>A077314</u>	<u>002</u>	Sep 15, 2005
<u>AB</u>		GLENMARK GENERICS	<u>150MG</u>	<u>A090618</u>	<u>001</u>	Jul 15, 2011
<u>AB</u>			<u>300MG</u>	<u>A090618</u>	<u>002</u>	Jul 15, 2011
<u>AB</u>		MYLAN PHARMS INC	<u>150MG</u>	<u>A075806</u>	<u>001</u>	Jul 05, 2002
<u>AB</u>	+		<u>300MG</u>	<u>A075806</u>	<u>002</u>	Jul 05, 2002
<u>AB</u>		SANDOZ	<u>150MG</u>	<u>A076178</u>	<u>001</u>	Jul 05, 2002
<u>AB</u>			<u>300MG</u>	<u>A076178</u>	<u>002</u>	Jul 05, 2002
<u>AB</u>		WATSON LABS	<u>150MG</u>	<u>A075616</u>	<u>001</u>	Jul 09, 2002
<u>AB</u>			<u>300MG</u>	<u>A075616</u>	<u>002</u>	Jul 09, 2002

SOLUTION; ORAL

AXID

<u>AA</u>	+	BRAINTREE	<u>15MG/ML</u>	<u>N021494</u>	<u>001</u>	May 25, 2004
-----------	---	-----------	----------------	----------------	------------	--------------

NIZATIDINE

<u>AA</u>		AMNEAL PHARMS	<u>15MG/ML</u>	<u>A090576</u>	<u>001</u>	Nov 18, 2009
-----------	--	---------------	----------------	----------------	------------	--------------

## NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

<u>AP</u>	+	HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>N007513</u>	<u>001</u>	
		<u>NOREPINEPHRINE BITARTRATE</u>				
<u>AP</u>		BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A040462</u>	<u>001</u>	Oct 31, 2003
<u>AP</u>		CLARIS LIFESCIENCES	<u>EQ 1MG BASE/ML</u>	<u>A040859</u>	<u>001</u>	Mar 27, 2012
<u>AP</u>		TEVA PHARMS USA	<u>EQ 1MG BASE/ML</u>	<u>A040455</u>	<u>001</u>	Mar 03, 2003

## PRESCRIPTION DRUG PRODUCT LIST

NORETHINDRONE

TABLET; ORAL-28

CAMILAAB1 BARR 0.35MG A076177 001 Oct 21, 2002HEATHERAB1 GLENMARK GENERICS 0.35MG A090454 001 Apr 23, 2010NOR-ODAB1 + WATSON LABS (UTAH) 0.35MG N017060 001NORETHINDRONEAB1 FAMY CARE LTD 0.35MG A201483 001 Jun 24, 2013AB1 HAUPT PHARMA 0.35MG A202260 001 Aug 01, 2013AB1 LUPIN LTD 0.35MG A091325 001 Sep 19, 2011AB1 NOVAST LABS LTD 0.35MG A202014 001 Sep 13, 2013ERRINAB2 BARR 0.35MG A076225 001 Oct 21, 2002JENCYCLAAB2 LUPIN LTD 0.35MG A091323 001 Mar 28, 2013MICRONORAB2 + JANSSEN PHARMS 0.35MG N016954 001NORETHINDRONEAB2 FAMY CARE LTD 0.35MG A200980 001 Jun 12, 2013AB2 GLENMARK GENERICS 0.35MG A091209 001 Jul 21, 2010AB2 NOVAST LABS 0.35MG A200961 001 Sep 13, 2013NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTINAB + DURAMED RES 5MG N018405 001 Apr 21, 1982NORETHINDRONE ACETATEAB AMNEAL PHARMS 5MG A200275 001 Jul 30, 2012AB BARR 5MG A075951 001 May 25, 2001AB GLENMARK GENERICS 5MG A091090 001 Jul 21, 2010NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDEAB MYLAN EQ 10MG BASE A074234 001 Jul 26, 1993AB EQ 25MG BASE A074234 002 Jul 26, 1993AB EQ 50MG BASE A074234 003 Jul 26, 1993AB EQ 75MG BASE A074234 004 Jul 26, 1993AB TARO EQ 10MG BASE A075520 004 May 08, 2000AB EQ 25MG BASE A075520 003 May 08, 2000AB EQ 50MG BASE A075520 001 May 08, 2000AB EQ 75MG BASE A075520 002 May 08, 2000AB TEVA EQ 10MG BASE A074132 001 Mar 27, 1995AB EQ 25MG BASE A074132 002 Mar 27, 1995AB EQ 50MG BASE A074132 003 Mar 27, 1995AB EQ 75MG BASE A074132 004 Mar 27, 1995AB WATSON LABS EQ 10MG BASE A073553 001 Mar 30, 1992AB EQ 25MG BASE A073554 001 Mar 30, 1992AB EQ 50MG BASE A073555 001 Mar 30, 1992AB EQ 75MG BASE A073556 001 Mar 30, 1992PAMELORAB MALLINCKRODT LLC EQ 10MG BASE N018013 001AB EQ 25MG BASE N018013 002AB EQ 50MG BASE N018013 004AB + EQ 75MG BASE N018013 003

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDEAA + PHARM ASSOC EQ 10MG BASE/5ML A075606 001 Aug 28, 2000AA TARO EQ 10MG BASE/5ML A077965 001 Jun 20, 2006NYSTATIN

CREAM; TOPICAL

NYSTATINAT ACTAVIS MID ATLANTIC 100,000 UNITS/GM A062949 001 Jun 13, 1988AT FOUGERA PHARMS 100,000 UNITS/GM A062129 001AT PERRIGO NEW YORK 100,000 UNITS/GM A062225 001AT + TARO 100,000 UNITS/GM A064022 001 Jan 29, 1993AT VINTAGE 100,000 UNITS/GM A065315 001 May 31, 2006

OINTMENT; TOPICAL

NYSTATINAT ACTAVIS MID ATLANTIC 100,000 UNITS/GM A062840 001 Nov 13, 1987AT + FOUGERA PHARMS 100,000 UNITS/GM A062124 002 Sep 23, 1982



## PRESCRIPTION DRUG PRODUCT LIST

NYSTATIN

OINTMENT; TOPICAL

NYSTATIN

<u>AT</u>	PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472</u>	<u>001</u>	Feb 13, 1984
-----------	------------------	-------------------------	----------------	------------	--------------

POWDER; TOPICAL

NYSTATIN

<u>AT</u>	+	COASTAL PHARMS	<u>100,000 UNITS/GM</u>	<u>A065203</u>	<u>001</u>	Jul 15, 2004
<u>AT</u>		GAVIS PHARMS	<u>100,000 UNITS/GM</u>	<u>A065138</u>	<u>001</u>	Jul 23, 2004
<u>AT</u>		UPSHER SMITH	<u>100,000 UNITS/GM</u>	<u>A065183</u>	<u>001</u>	May 03, 2005
<u>AT</u>		X GEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175</u>	<u>001</u>	Dec 17, 2004

NYSTOP

<u>AT</u>	PADDOCK LLC	<u>100,000 UNITS/GM</u>	<u>A064118</u>	<u>001</u>	Aug 16, 1996
-----------	-------------	-------------------------	----------------	------------	--------------

SUSPENSION; ORAL

NYSTATIN

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/ML</u>	<u>A062349</u>	<u>001</u>	Jul 14, 1982	
<u>AA</u>	FOUGERA	<u>100,000 UNITS/ML</u>	<u>A062517</u>	<u>001</u>	Jun 07, 1984	
<u>AA</u>	HI TECH PHARMA	<u>100,000 UNITS/ML</u>	<u>A064042</u>	<u>001</u>	Feb 28, 1994	
<u>AA</u>	TARO	<u>100,000 UNITS/ML</u>	<u>A062876</u>	<u>001</u>	Feb 29, 1988	
<u>AA</u>	VINTAGE PHARMS	<u>100,000 UNITS/ML</u>	<u>A065148</u>	<u>001</u>	Jun 28, 2005	
<u>AA</u>	VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142</u>	<u>001</u>	Jun 25, 1998	
<u>AA</u>		<u>100,000 UNITS/ML</u>	<u>A065422</u>	<u>001</u>	Mar 07, 2011	
<u>AA</u>	+	WOCKHARDT	<u>100,000 UNITS/ML</u>	<u>A062512</u>	<u>001</u>	Oct 29, 1984

TABLET; ORAL

NYSTATIN

<u>AA</u>	HERITAGE PHARMS INC	<u>500,000 UNITS</u>	<u>A062474</u>	<u>001</u>	Dec 22, 1983	
<u>AA</u>	MUTUAL PHARM	<u>500,000 UNITS</u>	<u>A062838</u>	<u>001</u>	Dec 22, 1988	
<u>AA</u>	+	TEVA	<u>500,000 UNITS</u>	<u>A062506</u>	<u>001</u>	Jan 16, 1984

TABLET; VAGINAL

NYSTATIN

+	ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985
---	----------------	---------------	---------	-----	--------------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062599</u>	<u>001</u>	Oct 08, 1985	
<u>AT</u>	+	TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062364</u>	<u>001</u>	Dec 22, 1987

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062602</u>	<u>001</u>	Oct 09, 1985	
<u>AT</u>	+	TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A063305</u>	<u>001</u>	Mar 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	+	EUROHLTH INTL	<u>EQ 0.2MG BASE/ML</u>	<u>A076330</u>	<u>001</u>	Apr 08, 2005
<u>AP</u>	+		<u>EQ 1MG BASE/ML</u>	<u>A076330</u>	<u>002</u>	Apr 08, 2005
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 0.2MG BASE/ML</u>	<u>A077450</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>			<u>EQ 1MG BASE/ML</u>	<u>A077450</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>		SAGENT PHARMS	<u>EQ 0.2MG BASE/ML</u>	<u>A091041</u>	<u>001</u>	Nov 12, 2013
<u>AP</u>			<u>EQ 1MG BASE/ML</u>	<u>A091041</u>	<u>002</u>	Nov 12, 2013
<u>AP</u>		SUN PHARM INDS	<u>EQ 0.05MG BASE/ML</u>	<u>A077329</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>			<u>EQ 0.05MG BASE/ML</u>	<u>A077372</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>			<u>EQ 0.1MG BASE/ML</u>	<u>A077329</u>	<u>002</u>	Mar 04, 2008
<u>AP</u>			<u>EQ 0.1MG BASE/ML</u>	<u>A077372</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>			<u>EQ 0.2MG BASE/ML</u>	<u>A077330</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>			<u>EQ 0.2MG BASE/ML</u>	<u>A077373</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>			<u>EQ 0.5MG BASE/ML</u>	<u>A077329</u>	<u>003</u>	Mar 04, 2008
<u>AP</u>			<u>EQ 0.5MG BASE/ML</u>	<u>A077372</u>	<u>003</u>	Aug 14, 2007
<u>AP</u>			<u>EQ 1MG BASE/ML</u>	<u>A077331</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>			<u>EQ 1MG BASE/ML</u>	<u>A077373</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>		TEVA PHARMS USA	<u>EQ 0.05MG BASE/ML</u>	<u>A075957</u>	<u>001</u>	Oct 03, 2005
<u>AP</u>			<u>EQ 0.1MG BASE/ML</u>	<u>A075957</u>	<u>002</u>	Oct 03, 2005
<u>AP</u>			<u>EQ 0.2MG BASE/ML</u>	<u>A075959</u>	<u>001</u>	Nov 21, 2005
<u>AP</u>			<u>EQ 0.5MG BASE/ML</u>	<u>A075957</u>	<u>003</u>	Oct 03, 2005
<u>AP</u>			<u>EQ 1MG BASE/ML</u>	<u>A075959</u>	<u>002</u>	Nov 21, 2005
<u>AP</u>		WOCKHARDT USA	<u>EQ 0.2MG BASE/ML</u>	<u>A090986</u>	<u>001</u>	May 11, 2011
<u>AP</u>			<u>EQ 1MG BASE/ML</u>	<u>A090986</u>	<u>002</u>	May 11, 2011

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	+	EUROHLTH INTL	<u>EQ 0.05MG BASE/ML</u>	<u>A076313</u>	<u>001</u>	Mar 28, 2005
<u>AP</u>	+		<u>EQ 0.1MG BASE/ML</u>	<u>A076313</u>	<u>003</u>	Mar 28, 2005
<u>AP</u>	+		<u>EQ 0.5MG BASE/ML</u>	<u>A076313</u>	<u>002</u>	Mar 28, 2005
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A077457</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>			<u>EQ 0.1MG BASE/ML</u>	<u>A077457</u>	<u>002</u>	Feb 10, 2006

## PRESCRIPTION DRUG PRODUCT LIST

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077457 003</u>	Feb 10, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.05MG BASE/ML</u>	<u>A079198 001</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A079198 002</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A079198 003</u>	Feb 10, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>A090834 001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090834 002</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090834 003</u>	Nov 12, 2013
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.05MG BASE/ML</u>	<u>A090985 001</u>	May 11, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090985 002</u>	May 11, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090985 003</u>	May 11, 2011

SANDOSTATIN

<u>AP</u>	+	NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667 001</u>	Oct 21, 1988
<u>AP</u>	+		<u>EQ 0.1MG BASE/ML</u>	<u>N019667 002</u>	Oct 21, 1988
<u>AP</u>	+		<u>EQ 0.2MG BASE/ML</u>	<u>N019667 004</u>	Jun 12, 1991
<u>AP</u>	+		<u>EQ 0.5MG BASE/ML</u>	<u>N019667 003</u>	Oct 21, 1988
<u>AP</u>	+		<u>EQ 1MG BASE/ML</u>	<u>N019667 005</u>	Jun 12, 1991
SANDOSTATIN LAR					
		NOVARTIS	EQ 10MG BASE/VIAL	N021008 001	Nov 25, 1998
			EQ 20MG BASE/VIAL	N021008 002	Nov 25, 1998
	+		EQ 30MG BASE/VIAL	N021008 003	Nov 25, 1998

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

<u>AT</u>	+	ALLERGAN	<u>0.3%</u>	<u>N019921 001</u>	Jul 30, 1993
-----------	---	----------	-------------	--------------------	--------------

OFLOXACIN

<u>AT</u>		AKORN	<u>0.3%</u>	<u>A076407 001</u>	Apr 15, 2008
<u>AT</u>		ALCON PHARMS LTD	<u>0.3%</u>	<u>A076231 001</u>	May 14, 2004
<u>AT</u>		ALTAIRE PHARMS INC	<u>0.3%</u>	<u>A202692 001</u>	Apr 29, 2013
<u>AT</u>		BAUSCH AND LOMB	<u>0.3%</u>	<u>A076622 001</u>	May 14, 2004
<u>AT</u>		FDC LTD	<u>0.3%</u>	<u>A078559 001</u>	Feb 25, 2009
<u>AT</u>		FERA PHARMS	<u>0.3%</u>	<u>A076830 001</u>	Aug 31, 2004
<u>AT</u>		HI TECH PHARMA	<u>0.3%</u>	<u>A076615 001</u>	May 14, 2004

SOLUTION/DROPS; OTIC

FLOXIN OTIC

<u>AT</u>	+	DAIICHI	<u>0.3%</u>	<u>N020799 001</u>	Dec 16, 1997
-----------	---	---------	-------------	--------------------	--------------

OFLOXACIN

<u>AT</u>		ALCON PHARMS LTD	<u>0.3%</u>	<u>A078222 001</u>	Mar 17, 2008
<u>AT</u>		APOTEX INC	<u>0.3%</u>	<u>A076527 001</u>	Sep 28, 2007
<u>AT</u>		BAUSCH AND LOMB	<u>0.3%</u>	<u>A076128 001</u>	Mar 17, 2008
<u>AT</u>		FERA PHARMS	<u>0.3%</u>	<u>A090395 001</u>	Aug 11, 2009
<u>AT</u>		HI TECH PHARMA	<u>0.3%</u>	<u>A076616 001</u>	Mar 17, 2008

TABLET; ORAL

OFLOXACIN

<u>AB</u>		CADILA PHARMS LTD	<u>200MG</u>	<u>A091656 001</u>	Sep 18, 2014
<u>AB</u>			<u>300MG</u>	<u>A091656 002</u>	Sep 18, 2014
<u>AB</u>			<u>400MG</u>	<u>A091656 003</u>	Sep 18, 2014
<u>AB</u>		DR REDDYS LABS LTD	<u>200MG</u>	<u>A077098 001</u>	Feb 10, 2006
<u>AB</u>			<u>300MG</u>	<u>A077098 002</u>	Feb 10, 2006
<u>AB</u>			<u>400MG</u>	<u>A077098 003</u>	Feb 10, 2006
<u>AB</u>		TEVA	<u>200MG</u>	<u>A076182 001</u>	Sep 02, 2003
<u>AB</u>			<u>300MG</u>	<u>A076182 002</u>	Sep 02, 2003
<u>AB</u>	+		<u>400MG</u>	<u>A076182 003</u>	Sep 02, 2003

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

<u>AP</u>		LUITPOLD	<u>10MG/VIAL</u>	<u>A201741 001</u>	Mar 20, 2012
<u>AP</u>		SANDOZ INC	<u>10MG/VIAL</u>	<u>A201588 001</u>	Oct 24, 2011

ZYPREXA

<u>AP</u>	+	LILLY	<u>10MG/VIAL</u>	<u>N021253 001</u>	Mar 29, 2004
-----------	---	-------	------------------	--------------------	--------------

TABLET; ORAL

OLANZAPINE

<u>AB</u>		APOTEX INC	<u>2.5MG</u>	<u>A090798 001</u>	Apr 23, 2012
<u>AB</u>			<u>5MG</u>	<u>A090798 002</u>	Apr 23, 2012
<u>AB</u>			<u>7.5MG</u>	<u>A090798 003</u>	Apr 23, 2012
<u>AB</u>			<u>10MG</u>	<u>A090798 004</u>	Apr 23, 2012
<u>AB</u>			<u>15MG</u>	<u>A090798 005</u>	Apr 23, 2012
<u>AB</u>			<u>20MG</u>	<u>A090798 006</u>	Apr 23, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A202050 001</u>	Apr 23, 2012

## PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET; ORAL

OLANZAPINE

<u>AB</u>		<u>5MG</u>	<u>A202050 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202050 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202050 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202050 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202050 006</u>	Apr 23, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A076255 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076255 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076255 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076255 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076133 001</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076133 002</u>	Oct 24, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A202862 001</u>	Aug 15, 2014
<u>AB</u>		<u>5MG</u>	<u>A202862 002</u>	Aug 15, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202862 003</u>	Aug 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A202862 004</u>	Aug 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A202862 005</u>	Aug 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A202862 006</u>	Aug 15, 2014
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076866 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076866 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076866 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076866 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076866 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076866 006</u>	Apr 23, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A202287 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202287 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202287 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202287 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202287 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202287 006</u>	Apr 23, 2012
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A091038 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091038 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091038 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091038 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091038 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091038 006</u>	Apr 23, 2012
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A076000 001</u>	Oct 24, 2011
<u>AB</u>		<u>5MG</u>	<u>A076000 002</u>	Oct 24, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A076000 003</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076000 004</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076000 005</u>	Oct 24, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A091434 001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091434 002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091434 003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091434 004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091434 005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091434 006</u>	Apr 23, 2012

ZYPREXA

<u>AB</u>	LILLY	<u>2.5MG</u>	<u>N020592 001</u>	Sep 30, 1996
<u>AB</u>	+	<u>5MG</u>	<u>N020592 002</u>	Sep 30, 1996
<u>AB</u>		<u>7.5MG</u>	<u>N020592 003</u>	Sep 30, 1996
<u>AB</u>		<u>10MG</u>	<u>N020592 004</u>	Sep 30, 1996
<u>AB</u>		<u>15MG</u>	<u>N020592 005</u>	Sep 09, 1997
<u>AB</u>		<u>20MG</u>	<u>N020592 006</u>	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A091265 001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A091265 002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A091265 003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A091265 004</u>	Oct 24, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203708 001</u>	May 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A203708 002</u>	May 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A203708 003</u>	May 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A203708 004</u>	May 15, 2014
<u>AB</u>	BARR LABS INC	<u>5MG</u>	<u>A077243 001</u>	Jan 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077243 002</u>	Jan 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A077243 003</u>	Jan 30, 2012
<u>AB</u>		<u>20MG</u>	<u>A077243 004</u>	Jan 30, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076534 001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076534 002</u>	Oct 24, 2011

## PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

<u>AB</u>		<u>15MG</u>	<u>A076534 003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A076534 004</u>	Oct 24, 2011
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200221 001</u>	Sep 12, 2012
<u>AB</u>		<u>10MG</u>	<u>A200221 002</u>	Sep 12, 2012
<u>AB</u>		<u>15MG</u>	<u>A200221 003</u>	Sep 12, 2012
<u>AB</u>		<u>20MG</u>	<u>A200221 004</u>	Sep 12, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A202285 001</u>	May 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A202285 002</u>	May 12, 2014
<u>AB</u>		<u>15MG</u>	<u>A202285 003</u>	May 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A202285 004</u>	May 12, 2014
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A078109 001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A078109 002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A078109 003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A078109 004</u>	Oct 24, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090881 001</u>	Feb 28, 2012
<u>AB</u>		<u>10MG</u>	<u>A090881 002</u>	Feb 28, 2012
<u>AB</u>		<u>15MG</u>	<u>A090881 003</u>	Feb 28, 2012
<u>AB</u>		<u>20MG</u>	<u>A090881 004</u>	Feb 28, 2012
<u>AB</u>	TORRENT PHARMS LLC	<u>5MG</u>	<u>A091415 001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A091415 002</u>	Oct 25, 2011
<u>AB</u>		<u>15MG</u>	<u>A091415 003</u>	Oct 25, 2011
<u>AB</u>		<u>20MG</u>	<u>A091415 004</u>	Oct 25, 2011
<u>ZYPREXA ZYDIS</u>				
<u>AB</u>	+ LILLY	<u>5MG</u>	<u>N021086 001</u>	Apr 06, 2000
<u>AB</u>		<u>10MG</u>	<u>N021086 002</u>	Apr 06, 2000
<u>AB</u>		<u>15MG</u>	<u>N021086 003</u>	Apr 06, 2000
<u>AB</u>		<u>20MG</u>	<u>N021086 004</u>	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

ELI LILLY CO

EQ 210MG BASE/VIAL

N022173 001 Dec 11, 2009

EQ 300MG BASE/VIAL

N022173 002 Dec 11, 2009

+

EQ 405MG BASE/VIAL

N022173 003 Dec 11, 2009

OLAPARIB

CAPSULE;ORAL

OLAPARIB

ASTRAZENECA PHARMS

50MG

N206162 001 Dec 19, 2014

OLIVE OIL; SOYBEAN OIL

INJECTABLE; INJECTION

CLINOLIPID 20%

+ BAXTER HLTHCARE

16% (160GM/1000ML); 4% (40GM/1000ML)

N204508 001 Oct 03, 2013

OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR

DAIICHI SANKYO

5MG

N021286 001 Apr 25, 2002

20MG

N021286 003 Apr 25, 2002

+

40MG

N021286 004 Apr 25, 2002

OLODATEROL HYDROCHLORIDE

SPRAY, METERED; INHALATION

STRIVERDI RESPIMAT

+ BOEHRINGER INGELHEIM

EQ 0.0025MG BASE/INH

N203108 001 Jul 31, 2014

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PATADAY

+ ALCON PHARMS LTD

EQ 0.2% BASE

N021545 001 Dec 22, 2004

PATANOL

+ ALCON

EQ 0.1% BASE

N020688 001 Dec 18, 1996

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>0.665MG/SPRAY</u>	<u>A091572 001</u>	Oct 08, 2014
<u>AB</u>	+ ALCON PHARMS LTD	<u>0.665MG/SPRAY</u>	<u>N021861 001</u>	Apr 15, 2008

## PRESCRIPTION DRUG PRODUCT LIST

OLSALAZINE SODIUM

CAPSULE;ORAL

DIPENTUM

+ MEDA PHARMS

250MG

N019715 001 Jul 31, 1990

OMACETAXINE MEPESUCCINATE

POWDER;SUBCUTANEOUS

SYNRIBO

+ IVAX INTL

3.5MG/VIAL

N203585 001 Oct 26, 2012

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZAAB + SMITHKLINE BEECHAM1GM CONTAINS AT LEAST 900MG OF THE  
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSN021654 001 Nov 10, 2004OMEGA-3-ACID ETHYL ESTERSAB APOTEX INC1GM CONTAINS AT LEAST 900MG OF THE  
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA090973 001 Sep 30, 2014AB PAR PHARM INC1GM CONTAINS AT LEAST 900MG OF THE  
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA091018 001 Jun 24, 2014AB TEVA PHARMS USA1GM CONTAINS AT LEAST 900MG OF THE  
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA091028 001 Apr 07, 2014

OMTRYG

+ TRYGG

1.2GM CONTAINS AT LEAST 900MG OF THE  
ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

N204977 001 Apr 23, 2014

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL

EPANOVA

+ ASTRAZENECA PHARMS

1GM CONTAINS AT LEAST 850MG OF  
POLYUNSATURATED FATTY ACIDS

N205060 001 May 05, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLEAB ACTAVIS LABS FL INC10MGA075347 001 May 30, 2008AB20MGA075347 002 May 30, 2008AB40MGA075347 003 May 30, 2008AB APOTEX10MGA076048 001 Oct 22, 2007AB20MGA076048 002 Oct 22, 2007AB40MGA076048 003 Jan 21, 2009AB DR REDDYS LABS LTD10MGA075576 003 Oct 22, 2007AB10MGA078490 002 Mar 16, 2009AB20MGA075576 002 Oct 22, 2007AB20MGA078490 003 Mar 16, 2009AB40MGA075576 001 Jan 21, 2009AB40MGA078490 001 Apr 17, 2009AB GLENMARK GENERICS10MGA091672 001 Oct 31, 2014AB20MGA091672 002 Oct 31, 2014AB40MGA091672 003 Oct 31, 2014AB IMPAX LABS10MGA075785 001 Oct 22, 2007AB20MGA075785 002 Oct 22, 2007AB40MGA075785 003 Jan 21, 2009AB KREMERS URBAN PHARMS10MGA075410 001 Nov 01, 2002AB20MGA075410 002 Nov 01, 2002AB40MGA075410 003 Jan 23, 2009AB MYLAN10MGA075876 001 May 29, 2003AB20MGA075876 002 May 29, 2003AB40MGA075876 003 Jan 21, 2009AB SANDOZ10MGA075757 001 Jan 28, 2003AB20MGA075757 002 Jan 28, 2003AB40MGA076515 001 Jan 21, 2009AB ZYDUS PHARMS USA INC10MGA091352 001 Nov 19, 2012AB20MGA091352 002 Nov 19, 2012AB40MGA091352 003 Nov 19, 2012PRILOSECAB ASTRAZENECA PHARMS10MGN019810 003 Oct 05, 1995AB +20MGN019810 001 Sep 14, 1989AB +40MGN019810 002 Jan 15, 1998

## PRESCRIPTION DRUG PRODUCT LIST

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PRILOSEC

ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
+	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<b>AB</b>	PAR PHARM	<b>20MG;1.1GM</b>	<b>A078966</b>	<b>001</b>	May 25, 2010
<b>AB</b>		<b>40MG;1.1GM</b>	<b>A078966</b>	<b>002</b>	May 25, 2010
<b><u>ZEGERID</u></b>					
<b>AB</b>	SANTARUS INC	<b>20MG;1.1GM</b>	<b>N021849</b>	<b>001</b>	Feb 27, 2006
<b>AB</b>	+	<b>40MG;1.1GM</b>	<b>N021849</b>	<b>002</b>	Feb 27, 2006
FOR SUSPENSION; ORAL					
ZEGERID					
	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004
+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004

ONDANSETRON

FILM; ORAL

ZUPLENZ

GALENA BIOPHARMA INC	4MG	N022524	001	Jul 02, 2010
+	8MG	N022524	002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

<b>AB</b>	AUROBINDO PHARMA	<b>4MG</b>	<b>A090469</b>	<b>001</b>	Apr 12, 2010
<b>AB</b>		<b>8MG</b>	<b>A090469</b>	<b>002</b>	Apr 12, 2010
<b>AB</b>	BARR	<b>4MG</b>	<b>A076693</b>	<b>001</b>	Jun 25, 2007
<b>AB</b>		<b>8MG</b>	<b>A076693</b>	<b>002</b>	Jun 25, 2007
<b>AB</b>	GLENMARK GENERICS	<b>4MG</b>	<b>A078152</b>	<b>001</b>	Jun 27, 2007
<b>AB</b>		<b>8MG</b>	<b>A078152</b>	<b>002</b>	Jun 27, 2007
<b>AB</b>	MYLAN	<b>4MG</b>	<b>A078139</b>	<b>001</b>	Jun 25, 2007
<b>AB</b>		<b>8MG</b>	<b>A078139</b>	<b>002</b>	Jun 25, 2007
<b>AB</b>	RANBAXY	<b>4MG</b>	<b>A078602</b>	<b>001</b>	Feb 24, 2011
<b>AB</b>		<b>8MG</b>	<b>A078602</b>	<b>002</b>	Feb 24, 2011
<b>AB</b>	SANDOZ	<b>4MG</b>	<b>A078050</b>	<b>001</b>	Aug 13, 2007
<b>AB</b>		<b>8MG</b>	<b>A078050</b>	<b>002</b>	Aug 13, 2007
<b>AB</b>	SUN PHARM INDS	<b>4MG</b>	<b>A077557</b>	<b>001</b>	Aug 02, 2007
<b>AB</b>		<b>8MG</b>	<b>A077557</b>	<b>002</b>	Aug 02, 2007
<b>AB</b>	TEVA	<b>4MG</b>	<b>A076810</b>	<b>001</b>	Jun 25, 2007
<b>AB</b>		<b>8MG</b>	<b>A076810</b>	<b>002</b>	Jun 25, 2007

ZOFRAN ODT

<b>AB</b>	GLAXOSMITHKLINE	<b>4MG</b>	<b>N020781</b>	<b>001</b>	Jan 27, 1999
<b>AB</b>	+	<b>8MG</b>	<b>N020781</b>	<b>002</b>	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

<b>AP</b>	AGILA SPECLTS	<b>EQ 2MG BASE/ML</b>	<b>A078257</b>	<b>001</b>	Apr 23, 2008
<b>AP</b>	AUROBINDO PHARMA LTD	<b>EQ 2MG BASE/ML</b>	<b>A202599</b>	<b>001</b>	Dec 21, 2012
<b>AP</b>	BEDFORD	<b>EQ 2MG BASE/ML</b>	<b>A076967</b>	<b>001</b>	Dec 26, 2006
<b>AP</b>	CLARIS LIFESCIENCES	<b>EQ 2MG BASE/ML</b>	<b>A078288</b>	<b>001</b>	Feb 22, 2013
<b>AP</b>	EMCURE PHARMS	<b>EQ 2MG BASE/ML</b>	<b>A090424</b>	<b>001</b>	Apr 16, 2010
<b>AP</b>	FRESENIUS KABI USA	<b>EQ 2MG BASE/ML</b>	<b>A076974</b>	<b>001</b>	Dec 26, 2006
<b>AP</b>	GLAND PHARMA LTD	<b>EQ 2MG BASE/ML</b>	<b>A079224</b>	<b>001</b>	Sep 25, 2009
<b>AP</b>		<b>EQ 2MG BASE/ML</b>	<b>A090648</b>	<b>001</b>	Jun 15, 2012
<b>AP</b>	HIKMA FARMACEUTICA	<b>EQ 2MG BASE/ML</b>	<b>A076781</b>	<b>001</b>	Dec 26, 2006
<b>AP</b>	HIKMA MAPLE	<b>EQ 2MG BASE/ML</b>	<b>A077365</b>	<b>001</b>	Dec 26, 2006
<b>AP</b>	HOSPIRA	<b>EQ 2MG BASE/ML</b>	<b>A077473</b>	<b>001</b>	Dec 26, 2006
<b>AP</b>		<b>EQ 2MG BASE/ML</b>	<b>A077840</b>	<b>001</b>	Jan 19, 2007
<b>AP</b>	LANNETT	<b>EQ 2MG BASE/ML</b>	<b>A090883</b>	<b>001</b>	Aug 05, 2010
<b>AP</b>	LUITPOLD	<b>EQ 2MG BASE/ML</b>	<b>A079039</b>	<b>001</b>	Nov 18, 2008
<b>AP</b>	QILU PHARM CO LTD	<b>EQ 2MG BASE/ML</b>	<b>A203711</b>	<b>001</b>	Sep 08, 2014
<b>AP</b>	SANDOZ	<b>EQ 2MG BASE/ML</b>	<b>A077430</b>	<b>001</b>	Jun 27, 2007
<b>AP</b>	SUN PHARM INDS (IN)	<b>EQ 2MG BASE/ML</b>	<b>A077172</b>	<b>001</b>	Dec 26, 2006
<b>AP</b>	TEVA	<b>EQ 2MG BASE/ML</b>	<b>A076876</b>	<b>001</b>	Nov 22, 2006
<b>AP</b>	WOCKHARDT	<b>EQ 2MG BASE/ML</b>	<b>A077577</b>	<b>001</b>	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<b>AP</b>	AGILA SPECLTS	<b>EQ 2MG BASE/ML</b>	<b>A078244</b>	<b>001</b>	Apr 23, 2008
<b>AP</b>	AUROBINDO PHARMA LTD	<b>EQ 2MG BASE/ML</b>	<b>A202600</b>	<b>001</b>	Dec 21, 2012
<b>AP</b>	BD RX	<b>EQ 2MG BASE/ML</b>	<b>A202253</b>	<b>001</b>	Jul 19, 2013
<b>AP</b>	BEDFORD LABS	<b>EQ 2MG BASE/ML</b>	<b>A077011</b>	<b>001</b>	Dec 26, 2006
<b>AP</b>	CLARIS LIFESCIENCES	<b>EQ 2MG BASE/ML</b>	<b>A078287</b>	<b>001</b>	Feb 22, 2013

## PRESCRIPTION DRUG PRODUCT LIST

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078945 001</u>	Jan 03, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076972 001</u>	Dec 26, 2006
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076780 001</u>	Dec 26, 2006
<u>AP</u>	HIKMA MAPLE	<u>EQ 2MG BASE/ML</u>	<u>A077541 001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548 001</u>	Dec 26, 2006
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079032 001</u>	Nov 18, 2008
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077551 001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A077173 001</u>	Dec 26, 2006
<u>AP</u>	TARO PHARMS IRELAND	<u>EQ 2MG BASE/ML</u>	<u>A078014 001</u>	Mar 21, 2008
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076759 001</u>	Nov 22, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716 001</u>	Dec 26, 2006

ZOFRAN

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007 001</u>	Jan 04, 1991
-----------	-------------------	-----------------------	--------------------	--------------

ZOFRAN PRESERVATIVE FREE

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007 003</u>	Dec 10, 1993
-----------	-------------------	-----------------------	--------------------	--------------

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091483 001</u>	Jan 31, 2011
<u>AA</u>	APOTEX	<u>EQ 4MG BASE/5ML</u>	<u>A078127 001</u>	Jun 25, 2007
<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776 001</u>	Nov 28, 2007
<u>AA</u>	ROXANE	<u>EQ 4MG BASE/5ML</u>	<u>A076960 001</u>	Dec 26, 2006
<u>AA</u>	SILARX	<u>EQ 4MG BASE/5ML</u>	<u>A091342 001</u>	Jan 27, 2011
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009 001</u>	Nov 30, 2007

ZOFRAN

<u>AA</u>	+ GLAXOSMITHKLINE	<u>EQ 4MG BASE/5ML</u>	<u>N020605 001</u>	Jan 24, 1997
-----------	-------------------	------------------------	--------------------	--------------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 4MG BASE</u>	<u>A077306 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077306 002</u>	Jun 25, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539 001</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539 002</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078539 003</u>	Jul 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183 003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183 002</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076183 001</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077535 003</u>	Jun 25, 2007
<u>AB</u>	IPCA LABS LTD	<u>EQ 4MG BASE</u>	<u>A203761 001</u>	Jan 23, 2014
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A203761 002</u>	Jan 23, 2014
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A076930 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076930 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076930 004</u>	Jun 25, 2007
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851 002</u>	Jun 25, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 4MG BASE</u>	<u>A077112 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077112 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077112 003</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077517 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077517 003</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050 002</u>	Jun 25, 2007
<u>AB</u>	TEVA	<u>EQ 4MG BASE</u>	<u>A076252 001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076252 002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076252 003</u>	Jun 25, 2007

ZOFRAN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 4MG BASE</u>	<u>N020103 001</u>	Dec 31, 1992
-----------	-----------------	--------------------	--------------------	--------------

<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N020103 002</u>	Dec 31, 1992
-----------	--	--------------------	--------------------	--------------

<u>AB</u>	+ ONDANSETRON HYDROCHLORIDE	<u>EQ 24MG BASE</u>	<u>N020103 003</u>	Aug 27, 1999
-----------	-----------------------------	---------------------	--------------------	--------------

DR REDDYS LABS LTD

EQ 16MG BASE	A076183 004	Dec 26, 2006
--------------	-------------	--------------

ORITAVANCIN DIPHOSPHATE

POWDER; IV (INFUSION)

ORBACTIV

+ MEDICINES CO	EQ 400MG BASE/VIAL	N206334 001	Aug 06, 2014
----------------	--------------------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ORLISTAT

CAPSULE; ORAL

XENICAL

+ HOFFMANN LA ROCHE

120MG

N020766 001 Apr 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEXAP + MEDICIS30MG/MLN013055 001ORPHENADRINE CITRATEAP AKORN30MG/MLA040484 001 May 24, 2006AP EUROHLTH INTL30MG/MLA040463 001 Mar 04, 2003AP SAGENT PHARMS30MG/MLA090585 001 Aug 30, 2011AP WATSON LABS30MG/MLA084779 001 Mar 15, 1982

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATEAB GAVIS PHARMS100MGA040284 001 Jun 19, 1998AB IMPAX PHARMS100MGA040368 001 Jun 23, 2000AB INVAGEN PHARMS100MGA091158 001 Jul 27, 2012AB + SANDOZ100MGA040327 001 Feb 15, 2000AB TEDOR PHARMA INC100MGA040249 001 Jan 29, 1999OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

TAMIFLU

ROCHE

EQ 30MG BASE

N021087 003 Jul 02, 2007

EQ 45MG BASE

N021087 002 Jul 02, 2007

+

EQ 75MG BASE

N021087 001 Oct 27, 1999

FOR SUSPENSION; ORAL

TAMIFLU

+ ROCHE

EQ 6MG BASE/ML

N021246 002 Mar 21, 2011

OSPEMIFENE

TABLET; ORAL

OSPHENA

+ SHIONOGI INC

60MG

N203505 001 Feb 26, 2013

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUMAP AGILA SPECLTSEQ 1GM BASE/VIALA091486 001 Aug 25, 2014AP +EQ 2GM BASE/VIALA091486 002 Aug 25, 2014AP AUROBINDO PHARMA LTDEQ 1GM BASE/VIALA201539 001 Jan 18, 2013AP +EQ 2GM BASE/VIALA201539 002 Jan 18, 2013AP +EQ 10GM BASE/VIALA201538 001 Jan 18, 2013AP SAGENT PHARMSEQ 1GM BASE/VIALA091246 001 Mar 30, 2012AP +EQ 2GM BASE/VIALA091246 002 Mar 30, 2012AP +EQ 10GM BASE/VIALA091245 001 Mar 30, 2012AP +EQ 1GM BASE/VIALA061490 003AP +EQ 2GM BASE/VIALA061490 004AP +EQ 10GM BASE/VIALA061490 006 May 09, 1991

BACTOCILL IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

EQ 20MG BASE/ML

N050640 001 Oct 26, 1989

+

EQ 40MG BASE/ML

N050640 002 Oct 26, 1989

POWDER; INTRAVENOUS

OXACILLIN SODIUMAP + SANDOZEQ 1GM BASE/VIALA062737 001 Dec 23, 1986AP +EQ 2GM BASE/VIALA062737 002 Dec 23, 1986OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATINAP + SANOFI AVENTIS US50MG/10ML (5MG/ML)N021759 001 Jan 31, 2005AP +100MG/20ML (5MG/ML)N021759 002 Jan 31, 2005OXALIPLATINAP ACTAVIS TOTOWA50MG/VIALA078803 001 Aug 08, 2012AP +100MG/VIALA078803 002 Aug 08, 2012AP EBEWE PHARMA50MG/10ML (5MG/ML)A078812 001 Aug 07, 2009AP +100MG/20ML (5MG/ML)A078812 002 Aug 07, 2009AP FRESENIUS KABI ONCOL50MG/10ML (5MG/ML)A078811 001 Jun 10, 2010AP +100MG/20ML (5MG/ML)A078811 002 Jun 10, 2010AP +50MG/VIALA078810 001 Aug 07, 2009AP +100MG/VIALA078810 002 Aug 07, 2009AP FRESENIUS KABI USA50MG/VIALA078819 001 Jun 02, 2010AP +100MG/VIALA078819 002 Jun 02, 2010



## PRESCRIPTION DRUG PRODUCT LIST

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

<u>AP</u>	HOSPIRA INC	<u>50MG/VIAL</u>	<u>A078815 001</u>	Sep 30, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078815 002</u>	Sep 30, 2009
<u>AP</u>	HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813 001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078813 002</u>	Aug 07, 2009
<u>AP</u>	JIANGSU HENGRUI MED	<u>50MG/10ML (5MG/ML)</u>	<u>A203869 001</u>	Jun 18, 2014
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A203869 002</u>	Jun 18, 2014
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A091358 001</u>	Aug 07, 2012
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200979 001</u>	Aug 08, 2012
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A091358 002</u>	Aug 07, 2012
<u>AP</u>		<u>100MG/VIAL</u>	<u>A200979 002</u>	Aug 08, 2012
<u>AP</u>	SANDOZ	<u>50MG/10ML (5MG/ML)</u>	<u>A078817 001</u>	Jan 24, 2011
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078817 002</u>	Jan 24, 2011
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>50MG/VIAL</u>	<u>A078818 001</u>	Aug 07, 2009
<u>AP</u>		<u>50MG/10ML (5MG/ML)</u>	<u>A202922 001</u>	Apr 08, 2014
<u>AP</u>	+	<u>100MG/VIAL</u>	<u>A078818 002</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A202922 002</u>	Apr 08, 2014
<u>AP</u>	+ TEVA PHARMS	<u>50MG/10ML (5MG/ML)</u>	<u>N022160 001</u>	Aug 07, 2009
<u>AP</u>	+	<u>100MG/20ML (5MG/ML)</u>	<u>N022160 002</u>	Aug 07, 2009
	ELOXATIN			
	+ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759 003	Nov 17, 2006

OXANDROLONE

TABLET; ORAL

OXANDRIN

<u>AB</u>	CREALTA PHARMS LLC	<u>2.5MG</u>	<u>N013718 001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N013718 002</u>	Nov 05, 2001
	<u>OXANDROLONE</u>			
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A077827 001</u>	Jun 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A077827 002</u>	Jun 22, 2007
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076761 001</u>	Dec 01, 2006
<u>AB</u>		<u>10MG</u>	<u>A078033 001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+ GD SEARLE	<u>600MG</u>	<u>N018841 004</u>	Oct 29, 1992
-----------	-------------	--------------	--------------------	--------------

OXAPROZIN

<u>AB</u>	APOTEX INC	<u>600MG</u>	<u>A075987 001</u>	Sep 02, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855 001</u>	Jan 31, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>600MG</u>	<u>A075846 001</u>	May 13, 2002
<u>AB</u>	SANDOZ	<u>600MG</u>	<u>A075845 001</u>	Jan 31, 2001
<u>AB</u>	SUN PHARM INDS INC	<u>600MG</u>	<u>A075844 001</u>	Jan 03, 2002
<u>AB</u>	TEVA	<u>600MG</u>	<u>A075849 001</u>	Jul 03, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072251 001</u>	Apr 14, 1988
<u>AB</u>		<u>15MG</u>	<u>A072252 001</u>	Apr 14, 1988
<u>AB</u>	+	<u>30MG</u>	<u>A072253 001</u>	Apr 14, 1988
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A071813 001</u>	Apr 19, 1988
<u>AB</u>		<u>15MG</u>	<u>A071756 001</u>	Apr 19, 1988
<u>AB</u>		<u>30MG</u>	<u>A071814 001</u>	Apr 19, 1988

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

<u>AB</u>	AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A202961 001</u>	Sep 17, 2012
<u>AB</u>	RANBAXY	<u>300MG/5ML</u>	<u>A078734 001</u>	Jun 26, 2009
<u>AB</u>	ROXANE	<u>300MG/5ML</u>	<u>A201193 001</u>	Oct 03, 2012

TRILEPTAL

<u>AB</u>	+ NOVARTIS	<u>300MG/5ML</u>	<u>N021285 001</u>	May 25, 2001
-----------	------------	------------------	--------------------	--------------

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>	APOTEX INC	<u>150MG</u>	<u>A077747 001</u>	Apr 09, 2008
<u>AB</u>		<u>300MG</u>	<u>A077747 002</u>	Apr 09, 2008
<u>AB</u>		<u>600MG</u>	<u>A077747 003</u>	Apr 09, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069 001</u>	Jan 11, 2008
<u>AB</u>		<u>300MG</u>	<u>A078069 002</u>	Jan 11, 2008
<u>AB</u>		<u>600MG</u>	<u>A078069 003</u>	Jan 11, 2008
<u>AB</u>	CADISTA PHARMS	<u>150MG</u>	<u>A090239 001</u>	Jan 25, 2010

## PRESCRIPTION DRUG PRODUCT LIST

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>		<u>300MG</u>	<u>A090239</u>	<u>002</u>	Jan 25, 2010
<u>AB</u>		<u>600MG</u>	<u>A090239</u>	<u>003</u>	Jan 25, 2010
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A077802</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077802</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077802</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	ROXANE	<u>150MG</u>	<u>A077795</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077795</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077795</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A077794</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077794</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077794</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	TARO	<u>150MG</u>	<u>A077801</u>	<u>001</u>	Nov 15, 2007
<u>AB</u>		<u>300MG</u>	<u>A077801</u>	<u>002</u>	Nov 15, 2007
<u>AB</u>		<u>600MG</u>	<u>A077801</u>	<u>003</u>	Nov 15, 2007

TRILEPTAL

<u>AB</u>	NOVARTIS	<u>150MG</u>	<u>N021014</u>	<u>001</u>	Jan 14, 2000
<u>AB</u>		<u>300MG</u>	<u>N021014</u>	<u>002</u>	Jan 14, 2000
<u>AB</u>	+	<u>600MG</u>	<u>N021014</u>	<u>003</u>	Jan 14, 2000
TABLET, EXTENDED RELEASE; ORAL					
OXTELLAR XR					
	SUPERMUS PHARMS	150MG	N202810	001	Oct 19, 2012
		300MG	N202810	002	Oct 19, 2012
	+	600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+ FOUGERA PHARMS

EQ 1% BASE

N019828 001 Dec 30, 1988

LOTION; TOPICAL

OXISTAT

+ FOUGERA PHARMS

EQ 1% BASE

N020209 001 Sep 30, 1992

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+ WARNER CHILCOTT LLC

400MG

A087863 001 May 24, 1983

+

600MG

A086742 001

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYBUTYNIN

<u>AB</u>	BARR LABS DIV TEVA	<u>3.9MG/24HR</u>	<u>A090526</u>	<u>001</u>	Mar 04, 2014
-----------	--------------------	-------------------	----------------	------------	--------------

OXYTROL

<u>AB</u>	+	WATSON LABS (UTAH)	<u>3.9MG/24HR</u>	<u>N021351</u>	<u>002</u>	Feb 26, 2003
-----------	---	--------------------	-------------------	----------------	------------	--------------

GEL, METERED; TRANSDERMAL

GELNIQUE 3%

+ WATSON LABS INC

3%

N202513 001 Dec 07, 2011

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+ WATSON LABS

10% (100MG/PACKET)

N022204 001 Jan 27, 2009

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A075137</u>	<u>001</u>	Dec 18, 1998	
<u>AA</u>	SILARX	<u>5MG/5ML</u>	<u>A074520</u>	<u>001</u>	Mar 29, 1996	
<u>AA</u>	VINTAGE PHARMS	<u>5MG/5ML</u>	<u>A076682</u>	<u>001</u>	Dec 28, 2004	
<u>AA</u>	+	WOCKHARDT	<u>5MG/5ML</u>	<u>A074868</u>	<u>001</u>	Feb 12, 1997

TABLET; ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A071655</u>	<u>001</u>	Nov 14, 1988	
<u>AB</u>	USL PHARMA	<u>5MG</u>	<u>A074625</u>	<u>001</u>	Jul 31, 1996	
<u>AB</u>	+	VINTAGE PHARMS	<u>5MG</u>	<u>A075079</u>	<u>001</u>	Oct 31, 1997

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

<u>AB</u>	JANSSEN PHARMS	<u>5MG</u>	<u>N020897</u>	<u>001</u>	Dec 16, 1998
<u>AB</u>		<u>10MG</u>	<u>N020897</u>	<u>002</u>	Dec 16, 1998
<u>AB</u>	+	<u>15MG</u>	<u>N020897</u>	<u>003</u>	Jun 22, 1999

OXYBUTYNIN CHLORIDE

<u>AB</u>	IMPAX PHARMS	<u>5MG</u>	<u>A076745</u>	<u>002</u>	May 09, 2007
<u>AB</u>		<u>10MG</u>	<u>A076745</u>	<u>003</u>	May 09, 2007

## PRESCRIPTION DRUG PRODUCT LIST

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>		<u>15MG</u>	<u>A076745 001</u>	Nov 09, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076702 001</u>	Nov 09, 2006
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A076644 001</u>	Nov 09, 2006
<u>AB</u>		<u>15MG</u>	<u>A076644 002</u>	May 10, 2007
<u>AB</u>	OSMOTICA PHARM	<u>5MG</u>	<u>A078503 001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503 002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503 003</u>	Feb 04, 2009

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	COASTAL PHARMS	<u>5MG</u>	<u>A203107 001</u>	Jul 26, 2012
<u>AB</u>	LANNETT HOLDINGS INC	<u>5MG</u>	<u>A203823 001</u>	Aug 01, 2014
<u>AB</u>	+ LEHIGH VALLEY	<u>5MG</u>	<u>N200534 001</u>	Oct 20, 2010

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	COASTAL PHARMS	<u>100MG/5ML</u>	<u>A204092 001</u>	Jun 05, 2014
<u>AA</u>	LANNETT HOLDINGS INC	<u>100MG/5ML</u>	<u>A204085 001</u>	Sep 09, 2014
<u>AA</u>	LEHIGH VALLEY	<u>5MG/5ML</u>	<u>N200535 002</u>	Aug 22, 2013
<u>AA</u>	+	<u>100MG/5ML</u>	<u>N200535 001</u>	Oct 20, 2010
<u>AA</u>	ROXANE	<u>5MG/5ML</u>	<u>A204037 001</u>	Jul 15, 2013
<u>AA</u>		<u>100MG/5ML</u>	<u>A203208 001</u>	Jul 12, 2013
<u>AA</u>	+ VISTAPHARM	<u>5MG/5ML</u>	<u>N201194 001</u>	Jan 12, 2012
<u>AA</u>		<u>100MG/5ML</u>	<u>A202537 001</u>	Jul 30, 2012

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A076636 001</u>	Feb 06, 2004
<u>AB</u>		<u>30MG</u>	<u>A076636 002</u>	Feb 06, 2004
<u>AB</u>	ALVOGEN INC	<u>5MG</u>	<u>A202116 001</u>	Dec 30, 2011
<u>AB</u>		<u>15MG</u>	<u>A202116 002</u>	Dec 30, 2011
<u>AB</u>		<u>30MG</u>	<u>A202116 003</u>	Dec 30, 2011
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203638 001</u>	Jun 03, 2014
<u>AB</u>		<u>10MG</u>	<u>A203638 002</u>	Jun 03, 2014
<u>AB</u>		<u>15MG</u>	<u>A203638 003</u>	Jun 03, 2014
<u>AB</u>		<u>20MG</u>	<u>A203638 004</u>	Jun 03, 2014
<u>AB</u>		<u>30MG</u>	<u>A203638 005</u>	Jun 03, 2014
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202160 001</u>	Nov 19, 2012
<u>AB</u>		<u>15MG</u>	<u>A202160 002</u>	Nov 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A202160 003</u>	Nov 19, 2012
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393 001</u>	Aug 31, 2009
<u>AB</u>		<u>10MG</u>	<u>A091393 002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393 003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393 004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393 005</u>	Aug 31, 2009
<u>AB</u>	COASTAL PHARMS	<u>5MG</u>	<u>A091313 001</u>	Feb 18, 2011
<u>AB</u>		<u>15MG</u>	<u>A091313 002</u>	Feb 18, 2011
<u>AB</u>		<u>30MG</u>	<u>A091313 003</u>	Feb 18, 2011
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A090895 001</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A090895 002</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A090895 003</u>	Aug 24, 2009
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A076758 003</u>	Mar 19, 2007
<u>AB</u>		<u>15MG</u>	<u>A076758 001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758 002</u>	Jun 30, 2004
<u>AB</u>	NESHER PHARMS	<u>5MG</u>	<u>A077290 001</u>	Dec 08, 2005
<u>AB</u>		<u>10MG</u>	<u>A077290 002</u>	Dec 08, 2005
<u>AB</u>		<u>15MG</u>	<u>A077290 003</u>	Dec 08, 2005
<u>AB</u>		<u>20MG</u>	<u>A077290 004</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077290 005</u>	Dec 08, 2005
<u>AB</u>	RHODES PHARMS	<u>5MG</u>	<u>A091490 001</u>	Mar 09, 2011
<u>AB</u>		<u>10MG</u>	<u>A091490 002</u>	Mar 09, 2011
<u>AB</u>		<u>15MG</u>	<u>A091490 003</u>	Mar 09, 2011
<u>AB</u>		<u>20MG</u>	<u>A091490 004</u>	Mar 09, 2011
<u>AB</u>		<u>30MG</u>	<u>A091490 005</u>	Mar 09, 2011
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659 001</u>	Apr 10, 2009
<u>AB</u>		<u>10MG</u>	<u>A090659 005</u>	Nov 06, 2012
<u>AB</u>		<u>15MG</u>	<u>A090659 002</u>	Apr 10, 2009
<u>AB</u>		<u>20MG</u>	<u>A090659 004</u>	Nov 06, 2012
<u>AB</u>		<u>30MG</u>	<u>A090659 003</u>	Apr 10, 2009
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077712 003</u>	Mar 02, 2009
<u>AB</u>		<u>15MG</u>	<u>A077712 001</u>	Jan 31, 2007

## PRESCRIPTION DRUG PRODUCT LIST

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<b>AB</b>		<b>30MG</b>	<b>A077712 002</b>	Jan 31, 2007
-----------	--	-------------	--------------------	--------------

ROXICODONE

<b>AB</b>	MALLINCKRODT INC	<b>5MG</b>	<b>N021011 003</b>	May 15, 2009
-----------	------------------	------------	--------------------	--------------

<b>AB</b>	+	<b>15MG</b>	<b>N021011 001</b>	Aug 31, 2000
-----------	---	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>N021011 002</b>	Aug 31, 2000
-----------	--	-------------	--------------------	--------------

OXECTA

	ACURA PHARMS INC	5MG	N202080 001	Jun 17, 2011
--	------------------	-----	-------------	--------------

		7.5MG	N202080 002	Jun 17, 2011
--	--	-------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

	PURDUE PHARMA LP	10MG	N022272 001	Apr 05, 2010
--	------------------	------	-------------	--------------

		15MG	N022272 002	Apr 05, 2010
--	--	------	-------------	--------------

		20MG	N022272 003	Apr 05, 2010
--	--	------	-------------	--------------

		30MG	N022272 004	Apr 05, 2010
--	--	------	-------------	--------------

+		40MG	N022272 005	Apr 05, 2010
---	--	------	-------------	--------------

		60MG	N022272 006	Apr 05, 2010
--	--	------	-------------	--------------

		80MG	N022272 007	Apr 05, 2010
--	--	------	-------------	--------------

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

+	MEDA PHARMS	50MG	N016848 001	
---	-------------	------	-------------	--

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

+	ENDO PHARMS	1MG/ML	N011707 002	
---	-------------	--------	-------------	--

TABLET; ORAL

OPANA

<b>AB</b>	ENDO PHARMS	<b>5MG</b>	<b>N021611 001</b>	Jun 22, 2006
-----------	-------------	------------	--------------------	--------------

<b>AB</b>	+	<b>10MG</b>	<b>N021611 002</b>	Jun 22, 2006
-----------	---	-------------	--------------------	--------------

OXYMORPHONE HYDROCHLORIDE

<b>AB</b>	AVANTHI INC	<b>5MG</b>	<b>A203601 001</b>	Jan 30, 2013
-----------	-------------	------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A203601 002</b>	Jan 30, 2013
-----------	--	-------------	--------------------	--------------

<b>AB</b>	COREPHARMA	<b>5MG</b>	<b>A201187 001</b>	Dec 15, 2014
-----------	------------	------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A201187 002</b>	Dec 15, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>	MALLINCKRODT INC	<b>5MG</b>	<b>A202321 001</b>	Apr 25, 2013
-----------	------------------	------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A202321 002</b>	Apr 25, 2013
-----------	--	-------------	--------------------	--------------

<b>AB</b>	ROXANE	<b>5MG</b>	<b>A090964 001</b>	Sep 27, 2010
-----------	--------	------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A090964 002</b>	Sep 27, 2010
-----------	--	-------------	--------------------	--------------

<b>AB</b>	TEVA	<b>5MG</b>	<b>A091443 002</b>	Feb 15, 2011
-----------	------	------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A091443 001</b>	Feb 15, 2011
-----------	--	-------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

<b>AB</b>	ACTAVIS ELIZABETH	<b>5MG</b>	<b>A079046 003</b>	Jul 11, 2013
-----------	-------------------	------------	--------------------	--------------

<b>AB</b>		<b>7.5MG</b>	<b>A079046 001</b>	Dec 13, 2010
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A079046 004</b>	Jul 11, 2013
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>15MG</b>	<b>A079046 002</b>	Dec 13, 2010
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A079046 005</b>	Jul 11, 2013
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A079046 006</b>	Jul 11, 2013
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A079046 007</b>	Jul 11, 2013
-----------	--	-------------	--------------------	--------------

<b>AB</b>	IMPAX LABS	<b>5MG</b>	<b>A079087 001</b>	Jun 14, 2010
-----------	------------	------------	--------------------	--------------

<b>AB</b>		<b>7.5MG</b>	<b>A079087 002</b>	Dec 21, 2010
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A079087 003</b>	Jun 14, 2010
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>15MG</b>	<b>A079087 004</b>	Dec 21, 2010
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A079087 005</b>	Jun 14, 2010
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A079087 006</b>	Jul 22, 2010
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A079087 007</b>	Jun 14, 2010
-----------	--	-------------	--------------------	--------------

<b>AB</b>	MALLINCKRODT INC	<b>5MG</b>	<b>A202946 001</b>	Jun 27, 2014
-----------	------------------	------------	--------------------	--------------

<b>AB</b>		<b>7.5MG</b>	<b>A202946 002</b>	Jun 27, 2014
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A202946 003</b>	Jun 27, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>15MG</b>	<b>A202946 004</b>	Jun 27, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A202946 005</b>	Jun 27, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>30MG</b>	<b>A202946 006</b>	Jun 27, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A202946 007</b>	Jun 27, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>	PAR PHARM	<b>5MG</b>	<b>A200792 001</b>	Oct 24, 2014
-----------	-----------	------------	--------------------	--------------

<b>AB</b>		<b>7.5MG</b>	<b>A200792 002</b>	Oct 24, 2014
-----------	--	--------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A200792 003</b>	Oct 24, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>15MG</b>	<b>A200792 004</b>	Oct 24, 2014
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A200792 005</b>	Oct 24, 2014
-----------	--	-------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

<u>AB</u>		<u>30MG</u>	<u>A200792 006</u>	Oct 24, 2014
<u>AB</u>		<u>40MG</u>	<u>A200792 007</u>	Oct 24, 2014
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A200822 002</u>	Jul 15, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200822 003</u>	Jul 15, 2013
<u>AB</u>		<u>10MG</u>	<u>A200822 004</u>	Jul 15, 2013
<u>AB</u>		<u>15MG</u>	<u>A200822 005</u>	Jul 15, 2013
<u>AB</u>		<u>20MG</u>	<u>A200822 006</u>	Jul 15, 2013
<u>AB</u>		<u>30MG</u>	<u>A200822 007</u>	Jul 15, 2013
<u>AB</u>		<u>40MG</u>	<u>A200822 001</u>	Jul 15, 2013
	OPANA ER			
	ENDO PHARMS	5MG	N201655 001	Dec 09, 2011
		7.5MG	N201655 002	Dec 09, 2011
		10MG	N201655 003	Dec 09, 2011
		15MG	N201655 004	Dec 09, 2011
		20MG	N201655 005	Dec 09, 2011
		30MG	N201655 006	Dec 09, 2011
	+	40MG	N201655 007	Dec 09, 2011

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

+ PFIZER EQ 5MG BASE/GM;10,000 UNITS/GM A061015 001

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

<u>AP</u>	+	FRESENIUS KABI USA	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018248 001</u>	
<u>AP</u>	+		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018248 002</u>	
<u>AP</u>		HIKMA FARMACEUTICA	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>A200219 001</u>	Feb 13, 2013
<u>AP</u>	+	HIKMA MAPLE	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018243 001</u>	
<u>AP</u>	+		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018243 002</u>	Jan 10, 2007
<u>AP</u>		SAGENT PHARMS	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>A091676 001</u>	Oct 29, 2014
<u>AP</u>			<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>A091676 002</u>	Oct 29, 2014

PITOCIN

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018261 001</u>	
<u>AP</u>			<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018261 002</u>	Jul 27, 2007
		OXYTOCIN			
	+	FRESENIUS KABI USA	300USP UNITS/30ML (10USP UNITS/ML)	N018248 003	Jul 27, 2007
		PITOCIN			
		PAR STERILE PRODUCTS	500USP UNITS/50ML (10USP UNITS/ML)	N018261 003	Sep 05, 2012

PACLITAXEL

FOR SUSPENSION;IV (INFUSION)

ABRAXANE

+ ABRAXIS BIOSCIENCE 100MG/VIAL N021660 001 Jan 07, 2005

INJECTABLE;INJECTION

PACLITAXEL

<u>AP</u>		ACTAVIS TOTOWA	<u>6MG/ML</u>	<u>A090130 001</u>	Dec 09, 2009
<u>AP</u>		EBEWE PHARMA	<u>6MG/ML</u>	<u>A078167 001</u>	Dec 26, 2007
<u>AP</u>		EUROHLTH INTL	<u>6MG/ML</u>	<u>A075190 001</u>	Jan 28, 2002
<u>AP</u>		FRESENIUS KABI ONCOL	<u>6MG/ML</u>	<u>A077574 001</u>	Nov 27, 2006
<u>AP</u>	+	HOSPIRA	<u>6MG/ML</u>	<u>A076131 001</u>	May 08, 2002
<u>AP</u>		ONCO THERAPIES LTD	<u>6MG/ML</u>	<u>A091540 001</u>	Sep 29, 2011
<u>AP</u>		TEVA PHARMS	<u>6MG/ML</u>	<u>A075184 001</u>	Jan 25, 2002

TAXOL

<u>AP</u>		HQ SPCLT PHARMA	<u>6MG/ML</u>	<u>N020262 001</u>	Dec 29, 1992
-----------	--	-----------------	---------------	--------------------	--------------

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

INVEGA

	JANSSEN PHARMS	1.5MG	N021999 006	Aug 26, 2008
		3MG	N021999 001	Dec 19, 2006
	+	6MG	N021999 002	Dec 19, 2006
		9MG	N021999 003	Dec 19, 2006

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA SUSTENNA

	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264 001	Jul 31, 2009
		78MG/0.5ML (78MG/0.5ML)	N022264 002	Jul 31, 2009
	+	117MG/0.75ML (117MG/0.75ML)	N022264 003	Jul 31, 2009
		156MG/ML (156MG/ML)	N022264 004	Jul 31, 2009

## PRESCRIPTION DRUG PRODUCT LIST

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

234MG/1.5ML (156MG/ML)

N022264 005 Jul 31, 2009

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

+ HELSINN HLTHCARE

EQ 0.075MG BASE/1.5ML (EQ 0.05MG  
BASE/ML)

N021372 002 Feb 29, 2008

+

EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

N021372 001 Jul 25, 2003

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>	AGILA SPECLTS	<u>30MG/10ML (3MG/ML)</u>	<u>A078520 001</u>	Oct 31, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078520 002</u>	Oct 31, 2008
<u>AP</u>	AREVA PHARMS	<u>30MG/VIAL</u>	<u>A077433 001</u>	Nov 26, 2008
<u>AP</u>		<u>60MG/VIAL</u>	<u>A077433 002</u>	Nov 26, 2008
<u>AP</u>		<u>90MG/VIAL</u>	<u>A077433 003</u>	Nov 26, 2008
<u>AP</u>	EUROHLTH INTL	<u>30MG/VIAL</u>	<u>A075290 001</u>	Apr 30, 2001
<u>AP</u>	+	<u>30MG/10ML (3MG/ML)</u>	<u>N021113 001</u>	Mar 04, 2002
<u>AP</u>		<u>90MG/VIAL</u>	<u>A075290 003</u>	Apr 30, 2001
<u>AP</u>	+	<u>90MG/10ML (9MG/ML)</u>	<u>N021113 002</u>	Mar 04, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>30MG/VIAL</u>	<u>A075773 001</u>	May 06, 2002
<u>AP</u>		<u>30MG/10ML (3MG/ML)</u>	<u>A076207 001</u>	May 17, 2002
<u>AP</u>		<u>90MG/VIAL</u>	<u>A075773 002</u>	May 06, 2002
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A076207 002</u>	May 17, 2002
<u>AP</u>	+	<u>30MG/10ML (3MG/ML)</u>	<u>A075841 001</u>	Jun 27, 2002
<u>AP</u>	+	<u>60MG/10ML (6MG/ML)</u>	<u>A075841 002</u>	Jun 27, 2002
<u>AP</u>	+	<u>90MG/10ML (9MG/ML)</u>	<u>A075841 003</u>	Jun 27, 2002
<u>AP</u>	LUITPOLD	<u>30MG/10ML (3MG/ML)</u>	<u>A078942 001</u>	Jul 25, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078942 002</u>	Jul 25, 2008
<u>AP</u>	MUSTAFA NEVZAT	<u>30MG/10ML (3MG/ML)</u>	<u>A078373 001</u>	Dec 23, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078373 002</u>	Dec 23, 2008
<u>AP</u>	PLIVA LACHEMA	<u>30MG/10ML (3MG/ML)</u>	<u>A078156 001</u>	Aug 19, 2008
<u>AP</u>		<u>60MG/10ML (6MG/ML)</u>	<u>A078156 002</u>	Aug 19, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078156 003</u>	Aug 19, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>30MG/VIAL</u>	<u>A077703 001</u>	Dec 24, 2008
<u>AP</u>		<u>90MG/VIAL</u>	<u>A077703 002</u>	Dec 24, 2008
<u>AP</u>	TEVA PHARMS USA	<u>30MG/10ML (3MG/ML)</u>	<u>A076153 001</u>	Mar 27, 2002
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A076153 002</u>	Mar 27, 2002

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBVIE

12,000USP UNITS\;38,000USP  
UNITS\;60,000USP UNITS\

N020725 002 Apr 30, 2009

15,000USP UNITS\;3,000USP  
UNITS\;9,500USP UNITS\

N020725 004 Jul 12, 2011

19,000USP UNITS\;30,000USP  
UNITS\;6,000USP UNITS\

N020725 001 Apr 30, 2009

114,000USP UNITS;180,000USP  
UNITS;36,000USP UNITS

N020725 005 Mar 14, 2013

+

120,000USP UNITS\;24,000USP  
UNITS\;76,000USP UNITS\

N020725 003 Apr 30, 2009

PANCREAZE

JANSSEN PHARMS

10,850USP UNITS;2,600USP UNITS;6,200USP  
UNITS

N022523 005 Mar 07, 2014

17,500USP UNITS;4,200USP  
UNITS;10,000USP UNITS

N022523 001 Apr 12, 2010

43,750USP UNITS;10,500USP  
UNITS;25,000USP UNITS

N022523 002 Apr 12, 2010

+

61,000USP UNITS;21,000USP  
UNITS;37,000USP UNITS

N022523 003 Apr 12, 2010

70,000USP UNITS;16,800USP  
UNITS;40,000USP UNITS

N022523 004 Apr 12, 2010

PERTZYE

DIGESTIVE CARE INC

30,250USP UNITS;8,000USP  
UNITS;28,750USP UNITS

N022175 001 May 17, 2012

+

60,500USP UNITS;16,000USP  
UNITS;57,500USP UNITS

N022175 002 May 17, 2012

ULTRESA

FOREST LABS INC

13,800USP UNITS;27,600USP  
UNITS;27,600USP UNITS

N022222 001 Mar 01, 2012

20,700USP UNITS;41,400USP  
UNITS;41,400USP UNITS

N022222 002 Mar 01, 2012

## PRESCRIPTION DRUG PRODUCT LIST

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

ULTRESA

+

23,000USP UNITS;46,000USP  
UNITS;46,000USP UNITS

N022222 003 Mar 01, 2012

ZENPEP

FOREST LABS INC

218,000USP UNITS; 40,00USP UNITS;  
136,000 USP UNITS

N022210 007 Mar 25, 2014

10,000USP UNITS;16,000USP  
UNITS;3,000USP UNITS

N022210 005 Jun 15, 2011

10,000USP UNITS;34,000USP  
UNITS;55,000USP UNITS

N022210 002 Aug 27, 2009

15,000USP UNITS;51,000USP  
UNITS;82,000USP UNITS

N022210 003 Aug 27, 2009

17,000USP UNITS;27,000USP  
UNITS;5,000USP UNITS

N022210 001 Aug 27, 2009

109,000USP UNITS;20,000USP  
UNITS;68,000USP UNITS

N022210 004 Aug 27, 2009

+

136,000USP UNITS;25,000USP  
UNITS;85,000USP UNITS

N022210 006 Jul 13, 2011

TABLET;ORAL

VIOKACE

FOREST LABS INC

10440USPU;39150USPU;39150USPU

N022542 001 Mar 01, 2012

+

20880USPU;78300USPU;78300USPU

N022542 002 Mar 01, 2012

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDEAP HOSPIRA1MG/MLA072320 001 Jan 19, 1989AP + TEVA PHARMS USA1MG/MLA072759 001 Jul 31, 1990AP +2MG/MLA072760 001 Jul 31, 1990PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PROTONIX

+ WYETH PHARMS INC

EQ 40MG BASE

N022020 001 Nov 14, 2007

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUMAP AKORN INCEQ 40MG BASE/VIALA079197 001 Nov 08, 2012PROTONIX IVAP + WYETH PHARMS INCEQ 40MG BASE/VIALN020988 001 Mar 22, 2001

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUMAB ACTAVIS TOTOWAEQ 20MG BASEA090797 001 Feb 07, 2011ABEQ 40MG BASEA090797 002 Feb 07, 2011AB APOTEX INCEQ 20MG BASEA090807 001 May 02, 2012ABEQ 40MG BASEA090807 002 May 02, 2012AB AUROBINDO PHARMA LTDEQ 20MG BASEA202038 001 Sep 28, 2012ABEQ 40MG BASEA202038 002 Sep 28, 2012AB DR REDDYS LABS LTDEQ 20MG BASEA077619 001 Jan 19, 2011ABEQ 40MG BASEA077619 002 Jan 19, 2011AB HETERO LABS LTD VEQ 20MG BASEA202882 001 Sep 10, 2014ABEQ 40MG BASEA202882 002 Sep 10, 2014AB JUBILANT GENERICSEQ 20MG BASEA090901 001 Aug 30, 2011ABEQ 40MG BASEA090901 002 Aug 30, 2011AB KUDCO IRELANDEQ 20MG BASEA078281 001 Jan 20, 2011ABEQ 40MG BASEA078281 002 Jan 20, 2011AB MACLEODS PHARMS LTDEQ 20MG BASEA200821 001 Feb 16, 2012ABEQ 40MG BASEA200821 002 Feb 16, 2012AB MYLAN PHARMS INCEQ 20MG BASEA090970 001 Jan 19, 2011ABEQ 40MG BASEA090970 002 Jan 19, 2011AB ORCHID HLTHCAREEQ 20MG BASEA202052 001 Dec 02, 2014ABEQ 40MG BASEA202052 002 Dec 02, 2014AB PERRIGO R AND DEQ 20MG BASEA203024 001 May 07, 2014ABEQ 20MG BASEA200794 001 May 02, 2012AB RANBAXY LABS LTDEQ 40MG BASEA200794 002 May 02, 2012ABEQ 20MG BASEA077058 001 Sep 10, 2007AB SUN PHARMA GLOBALEQ 40MG BASEA077058 002 Sep 10, 2007ABEQ 20MG BASEA077056 001 Aug 02, 2007AB TEVAEQ 40MG BASEA077056 002 Aug 02, 2007ABEQ 20MG BASEA090074 001 Jan 19, 2011AB TORRENT PHARMSEQ 40MG BASEA090074 002 Jan 19, 2011ABEQ 20MG BASEA091231 001 Jan 19, 2011AB WOCKHARDTEQ 40MG BASEA091231 002 Jan 19, 2011AB

## PRESCRIPTION DRUG PRODUCT LIST

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

PROTONIX

<u>AB</u>	WYETH PHARMS INC	<u>EQ 20MG BASE</u>	<u>N020987 002</u>	Jun 12, 2001
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020987 001</u>	Feb 02, 2000

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

<u>AB</u>	BANNER PHARMACAPS	<u>1MCG</u>	<u>A202539 001</u>	Mar 27, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202539 002</u>	Mar 27, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202539 003</u>	Mar 27, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>1MCG</u>	<u>A091412 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A091412 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A091412 003</u>	Jun 24, 2014
<u>AB</u>	RISING PHARMS INC	<u>1MCG</u>	<u>A202124 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202124 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202124 003</u>	Jun 24, 2014
<u>AB</u>	TEVA PHARMS USA	<u>1MCG</u>	<u>A090829 001</u>	Sep 27, 2013
<u>AB</u>		<u>2MCG</u>	<u>A090829 002</u>	Sep 27, 2013
<u>AB</u>		<u>4MCG</u>	<u>A090829 003</u>	Sep 27, 2013

ZEMPLAR

<u>AB</u>	ABBVIE	<u>1MCG</u>	<u>N021606 001</u>	May 26, 2005
<u>AB</u>		<u>2MCG</u>	<u>N021606 002</u>	May 26, 2005
<u>AB</u>	+	<u>4MCG</u>	<u>N021606 003</u>	May 26, 2005

SOLUTION;INTRAVENOUS

PARICALCITOL

<u>AP</u>	HIKMA PHARMS	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N205917 001</u>	Nov 18, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N205917 002</u>	Nov 18, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N205917 003</u>	Nov 18, 2014
<u>AP</u>	HOSPIRA INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N201657 001</u>	Oct 21, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N201657 002</u>	Oct 21, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N201657 003</u>	Oct 21, 2014
<u>AP</u>	SANDOZ CANADA INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A091108 001</u>	Jul 27, 2011
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A091108 002</u>	Jul 27, 2011
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A091108 003</u>	Jul 27, 2011

ZEMPLAR

<u>AP</u>	+	ABBVIE	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N020819 002</u>	Feb 01, 2000
<u>AP</u>	+		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N020819 001</u>	Apr 17, 1998
<u>AP</u>	+		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N020819 003</u>	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE;ORAL

PAROMOMYCIN SULFATE

<u>AA</u>	HERITAGE PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065173 001</u>	Dec 14, 2007	
<u>AA</u>	+	SUN PHARM INDS INC	<u>EQ 250MG BASE</u>	<u>A064171 001</u>	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAXIL

<u>AB</u>	+	APOTEX TECHNOLOGIES	<u>EQ 10MG BASE/5ML</u>	<u>N020710 001</u>	Jun 25, 1997
-----------	---	---------------------	-------------------------	--------------------	--------------

TABLET;ORAL

PAROXETINE

<u>AB</u>	PRINSTON INC	<u>EQ 10MG BASE</u>	<u>A203854 001</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A203854 002</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203854 003</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A203854 004</u>	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 10MG BASE</u>	<u>A075356 001</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075356 002</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075356 003</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075356 004</u>	Jul 30, 2003
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406 001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078406 002</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078406 003</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078406 004</u>	Jul 25, 2007
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078902 001</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078902 002</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078902 003</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078902 004</u>	Mar 13, 2008
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075716 001</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075716 002</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075716 003</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075716 004</u>	Mar 08, 2004



## PRESCRIPTION DRUG PRODUCT LIST

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	PROSAM LABS	<u>EQ 10MG BASE</u>	<u>A076968 001</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076968 002</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076968 003</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076968 004</u>	Jun 21, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 10MG BASE</u>	<u>A078194 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078194 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078194 003</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078194 004</u>	Jun 29, 2007
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076618 001</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076618 002</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076618 003</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076618 004</u>	Aug 15, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584 001</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077584 002</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077584 003</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077584 004</u>	Mar 07, 2007

PAXIL

<u>AB</u>	APOTEX TECHNOLOGIES	<u>EQ 10MG BASE</u>	<u>N020031 001</u>	Dec 29, 1992
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020031 002</u>	Dec 29, 1992
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>N020031 003</u>	Dec 29, 1992
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020031 005</u>	Dec 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE</u>	<u>A077873 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A077873 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A091427 001</u>	Apr 14, 2011

PAXIL CR

<u>AB</u>	APOTEX TECHNOLOGIES	<u>EQ 12.5MG BASE</u>	<u>N020936 001</u>	Feb 16, 1999
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N020936 002</u>	Feb 16, 1999
<u>AB</u>	+	<u>EQ 37.5MG BASE</u>	<u>N020936 003</u>	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

+ NOVEN THERAP

TABLET; ORAL

PEXEVA

NOVEN THERAP

EQ 7.5MG BASE

N204516 001 Jun 28, 2013

EQ 10MG BASE

N021299 001 Jul 03, 2003

EQ 20MG BASE

N021299 002 Jul 03, 2003

EQ 30MG BASE

N021299 003 Jul 03, 2003

EQ 40MG BASE

N021299 004 Jul 03, 2003

PASIREOTIDE DIASPARTATE

SOLUTION; SUBCUTANEOUS

SIGNIFOR

NOVARTIS

EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)

N200677 001 Dec 14, 2012

EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)

N200677 002 Dec 14, 2012

+

EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)

N200677 003 Dec 14, 2012

PASIREOTIDE PAMOATE

POWDER; INTRAMUSCULAR

SIGNIFOR LAR

NOVARTIS PHARMS CORP

EQ 20MG BASE/VIAL

N203255 001 Dec 15, 2014

EQ 40MG BASE/VIAL

N203255 002 Dec 15, 2014

+

EQ 60MG BASE/VIAL

N203255 003 Dec 15, 2014

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

+ GLAXOSMITHKLINE

EQ 200MG BASE

N022465 001 Oct 19, 2009

EQ 400MG BASE

N022465 002 Oct 19, 2009

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

+ SIGMA TAU

250 UNITS/ML

N019818 001 Mar 21, 1990

## PRESCRIPTION DRUG PRODUCT LIST

PEGAPTANIB SODIUMINJECTABLE; INTRAVITREAL  
MACUGEN

+ VALEANT PHARMS LLC EQ 0.3MG ACID/0.09ML N021756 001 Dec 17, 2004

PEGVISOMANTINJECTABLE; SUBCUTANEOUS  
SOMAVERT+ PHARMACIA AND UPJOHN 10MG/VIAL N021106 001 Mar 25, 2003  
+ 15MG/VIAL N021106 002 Mar 25, 2003  
+ 20MG/VIAL N021106 003 Mar 25, 2003  
+ 25MG/VIAL N021106 004 Jul 31, 2014  
+ 30MG/VIAL N021106 005 Jul 31, 2014PEMETREXED DISODIUMINJECTABLE; IV (INFUSION)  
ALIMTA+ LILLY EQ 100MG BASE/VIAL N021462 002 Sep 07, 2007  
+ EQ 500MG BASE/VIAL N021462 001 Feb 04, 2004PENCICLOVIR SODIUMCREAM; TOPICAL  
DENA VIR

+ DENCO ASSET 1% N020629 001 Sep 24, 1996

PENICILLAMINECAPSULE; ORAL  
CUPRIMINE

+ ATON 250MG N019853 001

TABLET; ORAL  
DEPEN

+ MEDA PHARMS 250MG N019854 001

PENICILLIN G BENZATHINEINJECTABLE; INJECTION  
BICILLIN L-A

BC + KING PHARMS 600,000 UNITS/ML N050141 001

PERMAPEN

BC PFIZER 600,000 UNITS/ML A060014 001

BICILLIN L-A

+ KING PHARMS 300,000 UNITS/ML N050141 003

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+ KING PHARMS 150,000 UNITS/ML; 150,000 UNITS/ML N050138 002

+ 300,000 UNITS/ML; 300,000 UNITS/ML N050138 001

BICILLIN C-R 900/300

+ KING PHARMS 900,000 UNITS/2ML; 300,000 UNITS/2ML N050138 003

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM**AP** HANFORD GC 5,000,000 UNITS/VIAL **A065149 002** Jul 23, 2009**AP** 20,000,000 UNITS/VIAL **A065149 003** Jul 23, 2009**AP** ISTITUTO BIO ITA SPA 5,000,000 UNITS/VIAL **A065448 001** Aug 18, 2009**AP** 20,000,000 UNITS/VIAL **A065448 002** Aug 18, 2009**AP** SANDOZ 5,000,000 UNITS/VIAL **A065079 002** Aug 30, 2002**AP** 20,000,000 UNITS/VIAL **A065079 003** Aug 30, 2002PFIZERPEN**AP** + PFIZER 5,000,000 UNITS/VIAL **A060657 002****AP** + 20,000,000 UNITS/VIAL **A060657 003**

PENICILLIN G POTASSIUM

HANFORD GC 1,000,000 UNITS/VIAL A065149 001 Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 20,000 UNITS/ML N050638 001 Jun 25, 1990

+ 40,000 UNITS/ML N050638 002 Jun 25, 1990

+ 60,000 UNITS/ML N050638 003 Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

+ KING PHARMS 300,000 UNITS/ML A060101 002

+ 600,000 UNITS/ML A060101 001

## PRESCRIPTION DRUG PRODUCT LIST

PENICILLIN G SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

+ SANDOZ

5,000,000 UNITS/VIAL

A065068 001 Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUMAA DAVA PHARMS INCEQ 125MG BASE/5MLA062981 001 Feb 10, 1989AAEQ 250MG BASE/5MLA062981 002 Feb 10, 1989PENICILLIN-VKAA TEVAEQ 125MG BASE/5MLA060456 001AA +EQ 250MG BASE/5MLA060456 002

TABLET; ORAL

PENICILLIN V POTASSIUMAB AUROBINDO PHARMAEQ 250MG BASEA065435 001 Apr 29, 2008ABEQ 500MG BASEA065435 002 Apr 29, 2008AB DAVA PHARMS INCEQ 250MG BASEA062936 001 Nov 25, 1988ABEQ 500MG BASEA062935 001 Nov 23, 1988AB HIKMA PHARMSEQ 250MG BASEA090549 001 Oct 11, 2013ABEQ 500MG BASEA090549 002 Oct 11, 2013AB SANDOZEQ 250MG BASEA064071 001 Nov 30, 1995AB +EQ 500MG BASEA064071 002 Nov 30, 1995PENICILLIN-VKAB TEVAEQ 250MG BASEA060711 002ABEQ 500MG BASEA060711 003PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

+ FRESENIUS KABI USA

300MG/VIAL

N019887 001 Jun 15, 1989

INJECTABLE; INJECTION

PENTAM

+ FRESENIUS KABI USA

300MG/VIAL

N019264 001 Oct 16, 1984

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+ HOSPIRA

EQ 30MG BASE/ML

N016194 001

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+ OAK PHARMS

50MG/ML

A083246 001

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ JANSSEN PHARMS

100MG

N020193 001 Sep 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENTAP + HOSPIRA INC10MG/VIALN020122 001 Oct 11, 1991PENTOSTATINAP EUROHLTH INTL10MG/VIALA077841 001 Aug 07, 2007AP MYLAN INSTITUTIONAL10MG/VIALA203554 001 Sep 19, 2014PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINEAB APOTEX400MGA075191 001 Jun 09, 1999AB IMPAX LABS400MGA075093 001 Aug 10, 1999AB MYLAN400MGA074425 001 Jul 08, 1997AB PLIVA400MGA074874 001 May 25, 1999AB VALEANT BERMUDA400MGA075028 001 Jul 20, 1998PENTOXILAB UPSHER SMITH400MGA074962 001 Mar 31, 1999PERAMIVIR

SOLUTION; IV (INFUSION)

RAPIVAB

+ BIOCRYST

200MG/20ML (10MG/ML)

N206426 001 Dec 19, 2014

## PRESCRIPTION DRUG PRODUCT LIST

PERAMPANEL

TABLET; ORAL

FYCOMPA

EISAI INC	2MG	N202834 001	Oct 22, 2012
	4MG	N202834 002	Oct 22, 2012
	6MG	N202834 003	Oct 22, 2012
	8MG	N202834 004	Oct 22, 2012
	10MG	N202834 005	Oct 22, 2012
+	12MG	N202834 006	Oct 22, 2012

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+ LANTHEUS MEDCL	6.52MG/ML	N021064 001	Jul 31, 2001
------------------	-----------	-------------	--------------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

<u>AB</u> SYMPLMED PHARMS LLC	<u>2MG</u>	<u>N020184 001</u>	Dec 30, 1993
<u>AB</u>	<u>4MG</u>	<u>N020184 002</u>	Dec 30, 1993
<u>AB</u> +	<u>8MG</u>	<u>N020184 003</u>	Dec 30, 1993

PERINDOPRIL ERBUMINE

<u>AB</u> ANI PHARMS INC	<u>2MG</u>	<u>A078138 001</u>	Nov 10, 2009
<u>AB</u>	<u>4MG</u>	<u>A078138 002</u>	Nov 10, 2009
<u>AB</u>	<u>8MG</u>	<u>A078138 003</u>	Nov 10, 2009
<u>AB</u> APOTEX	<u>2MG</u>	<u>A090463 001</u>	Aug 30, 2010
<u>AB</u>	<u>4MG</u>	<u>A090463 002</u>	Aug 30, 2010
<u>AB</u>	<u>8MG</u>	<u>A090463 003</u>	Aug 30, 2010
<u>AB</u> AUROBINDO PHARMA	<u>2MG</u>	<u>A079070 001</u>	Nov 10, 2009
<u>AB</u>	<u>4MG</u>	<u>A079070 002</u>	Nov 10, 2009
<u>AB</u>	<u>8MG</u>	<u>A079070 003</u>	Nov 10, 2009
<u>AB</u> LUPIN LTD	<u>2MG</u>	<u>A078263 001</u>	Jan 27, 2010
<u>AB</u>	<u>4MG</u>	<u>A078263 002</u>	Jan 27, 2010
<u>AB</u>	<u>8MG</u>	<u>A078263 003</u>	Jan 27, 2010
<u>AB</u> ROXANE	<u>2MG</u>	<u>A090072 001</u>	Nov 10, 2009
<u>AB</u>	<u>4MG</u>	<u>A090072 002</u>	Nov 10, 2009
<u>AB</u>	<u>8MG</u>	<u>A090072 003</u>	Nov 10, 2009

PERMETHRIN

CREAM; TOPICAL

ELIMITE

<u>AB</u> + RENAISSANCE PHARMA	<u>5%</u>	<u>N019855 001</u>	Aug 25, 1989
--------------------------------	-----------	--------------------	--------------

PERMETHRIN

<u>AB</u> ACTAVIS MID ATLANTIC	<u>5%</u>	<u>A074806 001</u>	Jan 23, 1998
<u>AB</u> PERRIGO NEW YORK	<u>5%</u>	<u>A076369 001</u>	Apr 21, 2003

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

<u>AB</u> SANDOZ	<u>2MG</u>	<u>A089683 001</u>	Dec 08, 1988
<u>AB</u>	<u>4MG</u>	<u>A089684 001</u>	Dec 08, 1988
<u>AB</u>	<u>8MG</u>	<u>A089685 001</u>	Dec 08, 1988
<u>AB</u> +	<u>16MG</u>	<u>A089686 001</u>	Dec 08, 1988
<u>AB</u> VINTAGE PHARMS	<u>2MG</u>	<u>A040226 001</u>	Dec 31, 1998
<u>AB</u>	<u>4MG</u>	<u>A040226 002</u>	Dec 31, 1998
<u>AB</u>	<u>8MG</u>	<u>A040226 003</u>	Dec 31, 1998
<u>AB</u>	<u>16MG</u>	<u>A040226 004</u>	Dec 31, 1998

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

BONTRIL

BC VALEANT	105MG	A088021 001	Sep 21, 1982
BC + SANDOZ	105MG	N018074 001	

TABLET; ORAL

BONTRIL PDM

<u>AA</u> + VALEANT	<u>35MG</u>	<u>A085272 001</u>	
---------------------	-------------	--------------------	--

PHENDIMETRAZINE TARTRATE

<u>AA</u> ELITE LABS INC	<u>35MG</u>	<u>A040762 001</u>	Jan 28, 2008
<u>AA</u> KVK TECH	<u>35MG</u>	<u>A091042 001</u>	Aug 31, 2010
<u>AA</u> MIKART	<u>35MG</u>	<u>A089452 001</u>	Oct 30, 1991
<u>AA</u> SANDOZ	<u>35MG</u>	<u>A085588 001</u>	

## PRESCRIPTION DRUG PRODUCT LIST

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

<u>AB</u>	+	PARKE DAVIS	<u>EQ 15MG BASE</u>	<u>N011909 002</u>	
<u>PHENELZINE SULFATE</u>					
<u>AB</u>		NOVEL LABS INC	<u>EQ 15MG BASE</u>	<u>A200181 001</u>	Dec 08, 2010

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

<u>AB</u>	+	COVIS PHARMA SARL	<u>10MG</u>	<u>N008708 001</u>	
<u>PHENOXYBENZAMINE HYDROCHLORIDE</u>					
<u>AB</u>		ROXANE	<u>10MG</u>	<u>A201050 001</u>	Jul 16, 2012

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

<u>AA</u>	+	TEVA	<u>37.5MG</u>	<u>A088023 001</u>	Aug 02, 1983
<u>PHENTERMINE HYDROCHLORIDE</u>					
<u>AA</u>		BARR	<u>15MG</u>	<u>A090591 001</u>	Mar 18, 2010
<u>AA</u>			<u>30MG</u>	<u>A090591 002</u>	Mar 18, 2010
<u>AA</u>		ELITE LABS	<u>15MG</u>	<u>A202248 001</u>	Sep 28, 2012
<u>AA</u>			<u>30MG</u>	<u>A202248 002</u>	Sep 28, 2012
<u>AA</u>		INVAGEN PHARMS	<u>15MG</u>	<u>A202858 001</u>	Feb 14, 2014
<u>AA</u>			<u>30MG</u>	<u>A202858 002</u>	Feb 14, 2014
<u>AA</u>			<u>30MG</u>	<u>A204414 001</u>	May 05, 2014
<u>AA</u>			<u>37.5MG</u>	<u>A202846 001</u>	Feb 05, 2014
<u>AA</u>		KEN LIFESCIENCE	<u>15MG</u>	<u>A205019 001</u>	Dec 05, 2014
<u>AA</u>			<u>30MG</u>	<u>A205019 002</u>	Dec 05, 2014
<u>AA</u>			<u>37.5MG</u>	<u>A205017 001</u>	Sep 25, 2014
<u>AA</u>		KVK TECH	<u>15MG</u>	<u>A040886 002</u>	Mar 31, 2008
<u>AA</u>			<u>30MG</u>	<u>A040875 001</u>	Mar 21, 2008
<u>AA</u>			<u>30MG</u>	<u>A040886 001</u>	Mar 31, 2008
<u>AA</u>			<u>37.5MG</u>	<u>A040887 001</u>	Apr 24, 2008
<u>AA</u>		LANNETT	<u>15MG</u>	<u>A087022 002</u>	Jan 20, 2012
<u>AA</u>			<u>30MG</u>	<u>A087022 001</u>	Feb 03, 1983
<u>AA</u>			<u>30MG</u>	<u>A091359 001</u>	Jul 16, 2010
<u>AA</u>		LANNETT HOLDINGS INC	<u>37.5MG</u>	<u>A201961 001</u>	Jul 20, 2011
<u>AA</u>		MUTUAL PHARM	<u>30MG</u>	<u>A040525 001</u>	Oct 23, 2003
<u>AA</u>	+	SANDOZ	<u>15MG</u>	<u>A087190 002</u>	
<u>AA</u>	+		<u>30MG</u>	<u>A086945 001</u>	Jul 20, 1983
<u>AA</u>	+		<u>30MG</u>	<u>A087190 001</u>	

TABLET; ORAL

ADIPEX-P

<u>AA</u>	+	TEVA	<u>37.5MG</u>	<u>A085128 001</u>	
<u>PHENTERMINE HYDROCHLORIDE</u>					
<u>AA</u>		AUROLIFE PHARMA LLC	<u>37.5MG</u>	<u>A203068 001</u>	Aug 06, 2014
<u>AA</u>		BARR	<u>37.5MG</u>	<u>A090470 001</u>	Aug 31, 2009
<u>AA</u>		ELITE LABS	<u>37.5MG</u>	<u>A200272 001</u>	Jan 31, 2011
<u>AA</u>		INVAGEN PHARMS	<u>37.5MG</u>	<u>A202942 001</u>	Feb 05, 2014
<u>AA</u>		KEN LIFESCIENCE	<u>37.5MG</u>	<u>A205008 001</u>	Sep 25, 2014
<u>AA</u>		KVK TECH	<u>37.5MG</u>	<u>A040876 001</u>	Mar 31, 2008
<u>AA</u>		LANNETT	<u>37.5MG</u>	<u>A040555 001</u>	Apr 15, 2005
<u>AA</u>		MIKAH PHARMA	<u>37.5MG</u>	<u>A040190 001</u>	May 30, 1997
<u>AA</u>		MIRROR PHARMS	<u>37.5MG</u>	<u>A091451 001</u>	Sep 21, 2012
<u>AA</u>		MUTUAL PHARM	<u>37.5MG</u>	<u>A040526 001</u>	Oct 23, 2003
<u>AA</u>		SUN PHARM INDS INC	<u>37.5MG</u>	<u>A040790 001</u>	Aug 21, 2007
<u>AA</u>		VINTAGE PHARMS	<u>37.5MG</u>	<u>A040377 001</u>	Jan 04, 2002

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

		CITIUS PHARMS	15MG	N202088 001	Jun 13, 2011
			30MG	N202088 002	Jun 13, 2011
	+		37.5MG	N202088 003	Mar 27, 2012

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

		VIVUS	EQ 3.75MG BASE; 23MG	N022580 001	Jul 17, 2012
			EQ 7.5MG BASE; 46MG	N022580 002	Jul 17, 2012
			EQ 11.25MG BASE; 69MG	N022580 003	Jul 17, 2012
	+		EQ 15MG BASE; 92MG	N022580 004	Jul 17, 2012

## PRESCRIPTION DRUG PRODUCT LIST

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011
+		EQ 30MG BASE	A040872	002	Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

<b>AP</b>	EUROHLTH INTL	<b>5MG/VIAL</b>	<b>A040235</b>	<b>001</b>	Mar 11, 1998
<b>AP</b>	+ NOVARTIS	<b>5MG/VIAL</b>	<b>N008278</b>	<b>003</b>	
	ORAVerse				
	+ SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

PHENYLEPHRINE HYDROCHLORIDE

+	WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012
	VAZCULEP				
	ECLAT PHARMS LLC	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014
		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014
+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013
+		10%	N203510	002	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

<b>AA</b>	HI-TECH PHARMACAL	<b>5MG/5ML; 6.25MG/5ML</b>	<b>A040675</b>	<b>001</b>	Dec 23, 2014
<b>AA</b>	VINTAGE	<b>5MG/5ML; 6.25MG/5ML</b>	<b>A040654</b>	<b>001</b>	Dec 07, 2006
	<u>PROMETH VC PLAIN</u>				
<b>AA</b>	+ ACTAVIS MID ATLANTIC	<b>5MG/5ML; 6.25MG/5ML</b>	<b>A088761</b>	<b>001</b>	Nov 08, 1984
	<u>PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE</u>				
<b>AA</b>	AMNEAL PHARMS	<b>5MG/5ML; 6.25MG/5ML</b>	<b>A040902</b>	<b>001</b>	Aug 25, 2009

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

<b>AB</b>	+ PARKE DAVIS	<b>125MG/5ML</b>	<b>N008762</b>	<b>001</b>	
	<u>PHENYTOIN</u>				
<b>AB</b>	TARO	<b>125MG/5ML</b>	<b>A040521</b>	<b>001</b>	Mar 08, 2004
<b>AB</b>	VISTAPHARM	<b>125MG/5ML</b>	<b>A040342</b>	<b>001</b>	Jan 31, 2001
<b>AB</b>		<b>125MG/5ML</b>	<b>A040610</b>	<b>001</b>	Aug 18, 2005
<b>AB</b>	WOCKHARDT	<b>125MG/5ML</b>	<b>A040420</b>	<b>001</b>	Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN

<b>AB</b>	+ PFIZER PHARMS	<b>50MG</b>	<b>A084427</b>	<b>001</b>	
	<u>PHENYTOIN</u>				
<b>AB</b>	COREPHARMA	<b>50MG</b>	<b>A040884</b>	<b>001</b>	Nov 28, 2014
<b>AB</b>	MYLAN PHARMS INC	<b>50MG</b>	<b>A200691</b>	<b>001</b>	Dec 26, 2012
<b>AB</b>	TARO	<b>50MG</b>	<b>A200565</b>	<b>001</b>	Apr 17, 2014

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

<b>AB</b>	+ PARKE DAVIS	<b>30MG EXTENDED</b>	<b>A084349</b>	<b>001</b>	
<b>AB</b>	+	<b>100MG EXTENDED</b>	<b>A084349</b>	<b>002</b>	
	<u>EXTENDED PHENYTOIN SODIUM</u>				
<b>AB</b>	AMNEAL PHARMS NY	<b>100MG EXTENDED</b>	<b>A040765</b>	<b>001</b>	Nov 12, 2008
<b>AB</b>	MYLAN	<b>100MG EXTENDED</b>	<b>A040298</b>	<b>001</b>	Dec 28, 1998
<b>AB</b>	SUN PHARM INDS	<b>200MG EXTENDED</b>	<b>A040731</b>	<b>001</b>	Jun 30, 2008
<b>AB</b>		<b>300MG EXTENDED</b>	<b>A040731</b>	<b>002</b>	Jun 30, 2008
<b>AB</b>	SUN PHARM INDS (IN)	<b>100MG EXTENDED</b>	<b>A040621</b>	<b>001</b>	Dec 11, 2006
<b>AB</b>	TARO	<b>100MG EXTENDED</b>	<b>A040684</b>	<b>001</b>	Sep 05, 2006
<b>AB</b>	WOCKHARDT	<b>30MG EXTENDED</b>	<b>A040759</b>	<b>001</b>	Dec 18, 2007
<b>AB</b>	WOCKHARDT USA	<b>100MG EXTENDED</b>	<b>A040732</b>	<b>001</b>	Jan 30, 2008
	<u>PHENYTEK</u>				
<b>AB</b>	MYLAN	<b>200MG EXTENDED</b>	<b>A040298</b>	<b>002</b>	Dec 06, 2001
<b>AB</b>	+	<b>300MG EXTENDED</b>	<b>A040298</b>	<b>003</b>	Dec 06, 2001

## PRESCRIPTION DRUG PRODUCT LIST

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

<b>AP</b>	+	HIKMA MAPLE	<b>50MG/ML</b>	<b>A084307 001</b>	
<b>AP</b>		HOSPIRA	<b>50MG/ML</b>	<b>A089521 001</b>	Mar 17, 1987
<b>AP</b>		LUITPOLD	<b>50MG/ML</b>	<b>A040781 001</b>	Dec 04, 2007
<b>AP</b>		X-GEN PHARMS	<b>50MG/ML</b>	<b>A040573 001</b>	Sep 13, 2006

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722 001	
		VITAMIN K1			
BP	+	HOSPIRA	1MG/0.5ML	A087954 001	Jul 25, 1983
	+		10MG/ML	A087955 001	Jul 25, 1983

TABLET; ORAL

MEPHYTON

	+	VALEANT PHARMS	5MG	N010104 003	
--	---	----------------	-----	-------------	--

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC

PILOPINE HS

	+	ALCON	4%	N018796 001	Oct 01, 1984
--	---	-------	----	-------------	--------------

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

		ALCON RES	1%	N200890 001	Jun 22, 2010
--	--	-----------	----	-------------	--------------

			2%	N200890 002	Jun 22, 2010
--	--	--	----	-------------	--------------

	+		4%	N200890 003	Jun 22, 2010
--	---	--	----	-------------	--------------

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

<b>AB</b>		COREPHARMA	<b>5MG</b>	<b>A076746 001</b>	Nov 16, 2004
<b>AB</b>		IMPAX LABS	<b>5MG</b>	<b>A077248 001</b>	Mar 31, 2006
<b>AB</b>			<b>7.5MG</b>	<b>A077248 002</b>	Mar 31, 2006
<b>AB</b>		LANNETT	<b>5MG</b>	<b>A077220 001</b>	Oct 14, 2005
<b>AB</b>			<b>7.5MG</b>	<b>A077220 002</b>	May 06, 2009
<b>AB</b>		ROXANE	<b>5MG</b>	<b>A076963 001</b>	Dec 22, 2004
<b>AB</b>			<b>7.5MG</b>	<b>A076963 002</b>	Feb 27, 2007

SALAGEN

<b>AB</b>		EISAI INC	<b>5MG</b>	<b>N020237 001</b>	Mar 22, 1994
<b>AB</b>	+		<b>7.5MG</b>	<b>N020237 002</b>	Apr 18, 2003

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

	+	VALEANT BERMUDA	1%	N021302 001	Dec 13, 2001
--	---	-----------------	----	-------------	--------------

PIMOZIDE

TABLET; ORAL

ORAP

		TEVA	1MG	N017473 003	Aug 27, 1997
--	--	------	-----	-------------	--------------

	+		2MG	N017473 001	Jul 31, 1984
--	---	--	-----	-------------	--------------

PINDOLOL

TABLET; ORAL

PINDOLOL

<b>AB</b>		MUTUAL PHARM	<b>5MG</b>	<b>A074063 001</b>	Jan 27, 1994
<b>AB</b>			<b>10MG</b>	<b>A074063 002</b>	Jan 27, 1994
<b>AB</b>		MYLAN PHARMS INC	<b>5MG</b>	<b>A074019 001</b>	Sep 03, 1992
<b>AB</b>	+		<b>10MG</b>	<b>A074019 002</b>	Sep 03, 1992

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

<b>AB</b>		TAKEDA PHARMS USA	<b>EQ 15MG BASE</b>	<b>N021073 001</b>	Jul 15, 1999
<b>AB</b>			<b>EQ 30MG BASE</b>	<b>N021073 002</b>	Jul 15, 1999
<b>AB</b>	+		<b>EQ 45MG BASE</b>	<b>N021073 003</b>	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

<b>AB</b>		ACCORD HLTHCARE	<b>EQ 15MG BASE</b>	<b>A200044 001</b>	Feb 13, 2013
<b>AB</b>			<b>EQ 30MG BASE</b>	<b>A200044 002</b>	Feb 13, 2013
<b>AB</b>			<b>EQ 45MG BASE</b>	<b>A200044 003</b>	Feb 13, 2013
<b>AB</b>		AUROBINDO PHARMA LTD	<b>EQ 15MG BASE</b>	<b>A200268 001</b>	Feb 13, 2013
<b>AB</b>			<b>EQ 30MG BASE</b>	<b>A200268 002</b>	Feb 13, 2013
<b>AB</b>			<b>EQ 45MG BASE</b>	<b>A200268 003</b>	Feb 13, 2013
<b>AB</b>		BRECKENRIDGE PHARM	<b>EQ 15MG BASE</b>	<b>A078472 001</b>	Feb 13, 2013
<b>AB</b>			<b>EQ 30MG BASE</b>	<b>A078472 002</b>	Feb 13, 2013





## PRESCRIPTION DRUG PRODUCT LIST

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; IV (INFUSION)

PIPERACILLIN AND TAZOBACTAM

SANDOZ

EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL

A203557 001 Oct 29, 2014

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

+ MEDICIS

EQ 0.2MG BASE/INH

N020014 001 Nov 30, 1992

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

+ INTERMUNE INC

267MG

N022535 001 Oct 15, 2014

PIROXICAM

CAPSULE; ORAL

FELDENEAB PFIZER10MGN018147 002 Apr 06, 1982AB +20MGN018147 003 Apr 06, 1982PIROXICAMAB MUTUAL PHARM10MGA073535 001 Mar 12, 1993AB MYLAN10MGA074102 001 Jul 31, 1992AB20MGA074102 002 Jul 31, 1992AB NOSTRUM LABS10MGA074116 001 Jun 15, 1993AB20MGA074118 001 Jun 15, 1993AB TEVA10MGA074131 001 Dec 11, 1992AB20MGA074131 002 Dec 11, 1992PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

KOWA CO

EQ 1MG BASE

N022363 001 Aug 03, 2009

EQ 2MG BASE

N022363 002 Aug 03, 2009

+

EQ 4MG BASE

N022363 003 Aug 03, 2009

PLERIXAFOR

SOLUTION; SUBCUTANEOUS

MOZOBIL

+ GENZYME

24MG/1.2ML (20MG/ML)

N022311 001 Dec 15, 2008

PODOFILOX

GEL; TOPICAL

CONDYLOX

+ WATSON PHARMS

0.5%

N020529 001 Mar 13, 1997

SOLUTION; TOPICAL

CONDYLOXAT + WATSON PHARMS0.5%N019795 001 Dec 13, 1990PODOFILOXAT PADDOCK LLC0.5%A075600 001 Jan 29, 2002AT PRECISION DERMAT0.5%A090184 001 Jul 21, 2010POLIDOCANOL

SOLUTION; INTRAVENOUS

ASCLERA

CHEMISCH FBRK KRSSLR

10MG/2ML (5MG/ML)

N021201 001 Mar 30, 2010

+

20MG/2ML (10MG/ML)

N021201 002 Mar 30, 2010

VARITHENA

+ PROVENSIS

180MG/18ML (10MG/ML)

N205098 001 Nov 25, 2013

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAXAA KREMERS URBAN PHARMS17GM/SCOOPFULA076652 001 Jul 02, 2004POLYETHYLENE GLYCOL 3350AA BRECKENRIDGE PHARM17GM/SCOOPFULA077736 001 May 26, 2006AA NEXGEN PHARMA INC17GM/SCOOPFULA077706 001 Sep 27, 2006AA PADDOCK LLC17GM/SCOOPFULA077893 001 May 26, 2006POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

LAX-LYTE WITH FLAVOR PACKSAA PADDOCK LLC420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOTA079232 001 Feb 25, 2010NULYTELYAA + BRAINTREE420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOTN019797 001 Apr 22, 1991

## PRESCRIPTION DRUG PRODUCT LIST

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY-FLAVORED

<u>AA</u>	+	BRAINTREE	<u>420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT</u>	<u>N019797 002</u>	Nov 18, 1994
-----------	---	-----------	------------------------------------------------------	--------------------	--------------

PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

<u>AA</u>		MYLAN	<u>420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT</u>	<u>A090409 001</u>	Apr 02, 2010
-----------	--	-------	------------------------------------------------------	--------------------	--------------

<u>AA</u>		NOVEL LABS INC	<u>420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT</u>	<u>A090019 001</u>	May 27, 2009
-----------	--	----------------	------------------------------------------------------	--------------------	--------------

TRILYTE

<u>AA</u>		MEDA PHARMS	<u>420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT</u>	<u>A076491 001</u>	Feb 05, 2004
-----------	--	-------------	------------------------------------------------------	--------------------	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

GOLYTELY

<u>AA</u>	+	BRAINTREE	<u>236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT</u>	<u>N019011 001</u>	Jul 13, 1984
-----------	---	-----------	-------------------------------------------------------------------	--------------------	--------------

PEG 3350 AND ELECTROLYTES

<u>AA</u>		MYLAN	<u>236GM; 2.97GM; 6.74GM; 5.86GM; 22.74GM</u>	<u>A090928 001</u>	Jan 28, 2010
-----------	--	-------	-----------------------------------------------	--------------------	--------------

<u>AA</u>		NOVEL LABS INC	<u>236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT</u>	<u>A090231 001</u>	Jun 01, 2009
-----------	--	----------------	-------------------------------------------------------------------	--------------------	--------------

<u>AA</u>			<u>240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT</u>	<u>A090186 001</u>	Jun 01, 2009
-----------	--	--	-------------------------------------------------------------------	--------------------	--------------

COLYTE

		MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983 010	Jan 31, 1989
--	--	-------------	-------------------------------------------------------------	-------------	--------------

COLYTE WITH FLAVOR PACKS

		MEDA PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983 012	Oct 08, 1998
--	--	-------------	------------------------------------------------------------	-------------	--------------

GOLYTELY

	+	BRAINTREE	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N019011 002	Jun 02, 1992
--	---	-----------	----------------------------------------------------------------------------	-------------	--------------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

<u>AP</u>		SAGENT STRIDES	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A090110 001</u>	Jun 29, 2011
-----------	--	----------------	-----------------------------------	--------------------	--------------

POLYMYXIN B SULFATE

<u>AP</u>	+	EUROHLTH INTL	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A060716 001</u>	
-----------	---	---------------	-----------------------------------	--------------------	--

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A065372 001</u>	Jan 10, 2008
-----------	--	--------------------	-----------------------------------	--------------------	--------------

<u>AP</u>		X GEN PHARMS	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A063000 001</u>	Sep 30, 1994
-----------	--	--------------	-----------------------------------	--------------------	--------------

<u>AP</u>		XELLIA PHARMS APS	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A202766 001</u>	Jan 15, 2014
-----------	--	-------------------	-----------------------------------	--------------------	--------------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

<u>AT</u>	+	ALLERGAN	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	<u>N050567 001</u>	Oct 20, 1988
-----------	---	----------	----------------------------------------	--------------------	--------------

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

<u>AT</u>		AKORN INC	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	<u>A065006 001</u>	Dec 17, 1998
-----------	--	-----------	----------------------------------------	--------------------	--------------

<u>AT</u>		BAUSCH AND LOMB	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	<u>A064120 001</u>	Feb 14, 1997
-----------	--	-----------------	----------------------------------------	--------------------	--------------

<u>AT</u>		FALCON PHARMS	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	<u>A064211 001</u>	Apr 13, 1998
-----------	--	---------------	----------------------------------------	--------------------	--------------

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

		CELGENE	1MG	N204026 001	Feb 08, 2013
--	--	---------	-----	-------------	--------------

			2MG	N204026 002	Feb 08, 2013
--	--	--	-----	-------------	--------------

			3MG	N204026 003	Feb 08, 2013
--	--	--	-----	-------------	--------------

	+		4MG	N204026 004	Feb 08, 2013
--	---	--	-----	-------------	--------------

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

		ARIAD	EQ 15MG BASE	N203469 001	Dec 14, 2012
--	--	-------	--------------	-------------	--------------

	+		EQ 45MG BASE	N203469 002	Dec 14, 2012
--	---	--	--------------	-------------	--------------

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF

	+	CHIESI USA INC	80MG/ML	N020744 001	Nov 18, 1999
--	---	----------------	---------	-------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

CONCORDIA LABS INC

75MG/VIAL

N020451 001 Dec 27, 1995

POSACONAZOLE

SOLUTION; IV (INFUSION)

NOXAFIL

+ MERCK SHARP DOHME

300MG/16.7ML (18MG/ML)

N205596 001 Mar 13, 2014

SUSPENSION; ORAL

NOXAFIL

+ SCHERING

40MG/ML

N022003 001 Sep 15, 2006

TABLET, DELAYED RELEASE; ORAL

NOXAFIL

+ MERCK SHARP DOHME

100MG

N205053 001 Nov 25, 2013

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

+ HOSPIRA

2MEQ/ML

N018896 001 Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-KAB NESHER PHARMS8MEQN018238 001MICRO-K 10AB NESHER PHARMS10MEQN018238 002 May 14, 1984POTASSIUM CHLORIDEAB ACTAVIS LABS FL INC8MEQA077419 001 Jun 02, 2008AB +10MEQA077419 002 Jun 02, 2008AB AMNEAL PHARMS10MEQA202128 001 Feb 22, 2013AB ANCHEN PHARMS8MEQA202886 001 Dec 26, 2013AB +10MEQA202886 002 Dec 26, 2013AB PADDOCK LLC8MEQA200185 001 May 18, 2011AB +10MEQA200185 002 May 18, 2011

INJECTABLE; INJECTION

POTASSIUM CHLORIDEAP B BRAUN2MEQ/MLA085870 001AP BAXTER HLTHCARE2MEQ/MLA085499 001AP FRESENIUS KABI USA2MEQ/MLA080225 001AP + HOSPIRA2MEQ/MLA080205 001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE14.9MG/MLN019904 001 Dec 26, 1989AP +746MG/100MLN019904 005 Dec 17, 1990AP HOSPIRA14.9MG/MLN020161 005 Nov 30, 1992AP +745MG/100MLN020161 001 Nov 30, 1992POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE1.49GM/100MLN019904 006 Dec 17, 1990AP +29.8MG/MLN019904 002 Dec 26, 1989AP HOSPIRA1.49GM/100MLN020161 002 Nov 30, 1992AP +29.8MG/MLN020161 006 Aug 11, 1998POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE2.24GM/100MLN019904 003 Dec 26, 1989AP + HOSPIRA2.24GM/100MLN020161 003 Aug 11, 1998POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE2.98GM/100MLN019904 004 Dec 26, 1989AP + HOSPIRA2.98GM/100MLN020161 004 Aug 11, 1998POTASSIUM CHLORIDE IN PLASTIC CONTAINERAP FRESENIUS KABI USA2MEQ/MLA088901 001 Jan 25, 1985AP +2MEQ/MLA088908 001 Jan 25, 1985

POTASSIUM CHLORIDE

+ FRESENIUS KABI USA

3MEQ/ML

A080225 003

SOLUTION; ORAL

POTASSIUM CHLORIDE

PHARMA-MED INC

20MEQ/15ML

N206814 001 Dec 22, 2014

+

40MEQ/15ML

N206814 002 Dec 22, 2014

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M10AB1 UPSHER SMITH LABS10MEQA074726 002 Aug 09, 2000KLOR-CON M20AB1 + UPSHER SMITH LABS20MEQA074726 001 Nov 20, 1998POTASSIUM CHLORIDEAB1 ACTAVIS LABS FL INC10MEQA075604 001 Apr 10, 2002AB1 +20MEQA075604 002 Apr 10, 2002

## PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

<b>AB1</b>	EURAND	<b>20MEQ</b>	<b>A076368 001</b>	Aug 18, 2004
	<b>KLOR-CON</b>			
<b>AB2</b>	UPSHER-SMITH LABS	<b>8MEQ</b>	<b>N019123 001</b>	Apr 17, 1986
<b>AB2</b>	+	<b>10MEQ</b>	<b>N019123 002</b>	Apr 17, 1986
	<b>POTASSIUM CHLORIDE</b>			
<b>AB2</b>	MYLAN PHARMS INC	<b>8.0MEQ</b>	<b>A204662 001</b>	Aug 21, 2014
<b>AB2</b>		<b>10.0MEQ</b>	<b>A204662 002</b>	Aug 21, 2014
	<b>K-TAB</b>			
BC	ABBVIE	8MEQ	N018279 002	Aug 01, 1988
BC		10MEQ	N018279 001	
BC	+	20MEQ	N018279 003	Nov 25, 2013
	<b>KLOR-CON M15</b>			
	UPSHER SMITH LABS	15MEQ	A074726 003	Jun 06, 2003

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<b>AP</b>	HOSPIRA	<b>149MG/100ML;450MG/100ML</b>	<b>A078446 001</b>	Sep 10, 2008
	<b>POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</b>			
<b>AP</b>	+	<b>150MG/100ML;450MG/100ML</b>	<b>N017648 005</b>	Nov 26, 2002
	<b>POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</b>			
<b>AP</b>	B BRAUN	<b>150MG/100ML;900MG/100ML</b>	<b>N019708 004</b>	Sep 29, 1989
<b>AP</b>	BAXTER HLTHCARE	<b>150MG/100ML;900MG/100ML</b>	<b>N017648 001</b>	
	<b>POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</b>			
<b>AP</b>	BAXTER HLTHCARE	<b>300MG/100ML;900MG/100ML</b>	<b>N017648 002</b>	
	<b>POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</b>			
<b>AP</b>	HOSPIRA	<b>149MG/100ML;900MG/100ML</b>	<b>N019686 001</b>	Oct 17, 1988
	<b>POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</b>			
<b>AP</b>	HOSPIRA	<b>298MG/100ML;900MG/100ML</b>	<b>N019686 002</b>	Oct 17, 1988
	<b>POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%</b>			
	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648 003	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

<b>AB</b>	COREPHARMA	<b>5MEQ</b>	<b>A077440 001</b>	Jun 09, 2006
<b>AB</b>		<b>10MEQ</b>	<b>A077440 002</b>	Jun 09, 2006
<b>AB</b>	ZYDUS PHARMS USA INC	<b>5MEQ</b>	<b>A203546 001</b>	Aug 06, 2014
<b>AB</b>		<b>10MEQ</b>	<b>A203546 002</b>	Aug 06, 2014
<b>AB</b>		<b>15MEQ</b>	<b>A203546 003</b>	Aug 06, 2014
	<b>UROKIT-K</b>			
<b>AB</b>	MISSION PHARMA	<b>5MEQ</b>	<b>N019071 001</b>	Aug 30, 1985
<b>AB</b>		<b>10MEQ</b>	<b>N019071 002</b>	Aug 31, 1992
<b>AB</b>	+	<b>15MEQ</b>	<b>N019071 003</b>	Dec 30, 2009

POVIDONE-IODINE

SOLUTION/DROPS;OPHTHALMIC

BETADINE

+	ALCON PHARMS LTD	5%	N018634 001	Dec 17, 1986
---	------------------	----	-------------	--------------

PRALATREXATE

SOLUTION; INTRAVENOUS

FOLOTYN

	ALLOS	20MG/ML (20MG/ML)	N022468 001	Sep 24, 2009
+		40MG/2ML (20MG/ML)	N022468 002	Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

+	MERIDIAN MEDCL TECHN	300MG/ML	N018986 001	Apr 26, 1983
---	----------------------	----------	-------------	--------------

PROTOPAM CHLORIDE

+	BAXTER HLTHCARE CORP	1GM/VIAL	N014134 001	
---	----------------------	----------	-------------	--

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

<b>AB</b>	BOEHRINGER INGELHEIM	<b>0.125MG</b>	<b>N020667 001</b>	Jul 01, 1997
<b>AB</b>	+	<b>0.25MG</b>	<b>N020667 002</b>	Jul 01, 1997
<b>AB</b>		<b>0.5MG</b>	<b>N020667 006</b>	Feb 12, 1998
<b>AB</b>		<b>0.75MG</b>	<b>N020667 007</b>	Jul 30, 2007
<b>AB</b>		<b>1MG</b>	<b>N020667 003</b>	Jul 01, 1997
<b>AB</b>		<b>1.5MG</b>	<b>N020667 005</b>	Jul 01, 1997

## PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ACTAVIS GRP PTC	<u>0.125MG</u>	<u>A091254 001</u>	Nov 30, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091254 002</u>	Nov 30, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091254 003</u>	Nov 30, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A091254 004</u>	Nov 30, 2010
<u>AB</u>		<u>1MG</u>	<u>A091254 005</u>	Nov 30, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091254 006</u>	Nov 30, 2010
<u>AB</u>	ALEMBIC LTD	<u>0.125MG</u>	<u>A078894 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078894 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078894 003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A078894 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078894 005</u>	Oct 08, 2010
<u>AB</u>	APOTEX INC	<u>0.125MG</u>	<u>A090151 001</u>	Apr 30, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A090151 002</u>	Apr 30, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A090151 003</u>	Apr 30, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A090151 006</u>	Apr 30, 2012
<u>AB</u>		<u>1MG</u>	<u>A090151 004</u>	Apr 30, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A090151 005</u>	Apr 30, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.125MG</u>	<u>A202633 001</u>	Oct 26, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202633 002</u>	Oct 26, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202633 003</u>	Oct 26, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A202633 004</u>	Oct 26, 2012
<u>AB</u>		<u>1MG</u>	<u>A202633 005</u>	Oct 26, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202633 006</u>	Oct 26, 2012
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077724 001</u>	Feb 19, 2008
<u>AB</u>		<u>0.25MG</u>	<u>A077724 002</u>	Feb 19, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077724 003</u>	Feb 19, 2008
<u>AB</u>		<u>1MG</u>	<u>A077724 004</u>	Feb 19, 2008
<u>AB</u>		<u>1.5MG</u>	<u>A077724 005</u>	Feb 19, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>0.125MG</u>	<u>A091450 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091450 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091450 003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A091450 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091450 005</u>	Oct 08, 2010
<u>AB</u>	GLENMARK GENERICS	<u>0.125MG</u>	<u>A090781 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090781 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090781 003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090781 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090781 005</u>	Oct 08, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.125MG</u>	<u>A202164 001</u>	Sep 20, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202164 002</u>	Sep 20, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202164 003</u>	Sep 20, 2012
<u>AB</u>		<u>1MG</u>	<u>A202164 004</u>	Sep 20, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202164 005</u>	Sep 20, 2012
<u>AB</u>	MYLAN	<u>0.125MG</u>	<u>A077854 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A077854 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A077854 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090764 001</u>	Apr 09, 2010
<u>AB</u>		<u>1MG</u>	<u>A077854 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A077854 005</u>	Oct 08, 2010
<u>AB</u>	SANDOZ	<u>0.125MG</u>	<u>A090190 001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090190 002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090190 003</u>	Jul 06, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090190 006</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090190 004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090190 005</u>	Jul 06, 2010
<u>AB</u>	SCIEGEN PHARMS INC	<u>0.125MG</u>	<u>A203855 001</u>	Oct 28, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A203855 002</u>	Oct 28, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A203855 003</u>	Oct 28, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A203855 004</u>	Oct 28, 2014
<u>AB</u>		<u>1MG</u>	<u>A203855 005</u>	Oct 28, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A203855 006</u>	Oct 28, 2014
<u>AB</u>	STRIDES PHARMA	<u>0.125MG</u>	<u>A202702 001</u>	Jun 03, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A202702 002</u>	Jun 03, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A202702 003</u>	Jun 03, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202702 004</u>	Jun 03, 2014
<u>AB</u>		<u>1MG</u>	<u>A202702 005</u>	Jun 03, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202702 006</u>	Jun 03, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A091683 001</u>	Mar 27, 2013
<u>AB</u>		<u>0.25MG</u>	<u>A091683 002</u>	Mar 27, 2013

## PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>0.5MG</u>	<u>A091683</u>	<u>003</u>	Mar 27, 2013
<u>AB</u>		<u>0.75MG</u>	<u>A091683</u>	<u>004</u>	Mar 27, 2013
<u>AB</u>		<u>1MG</u>	<u>A091683</u>	<u>005</u>	Mar 27, 2013
<u>AB</u>		<u>1.5MG</u>	<u>A091683</u>	<u>006</u>	Mar 27, 2013
<u>AB</u>	TEVA PHARMS	<u>0.125MG</u>	<u>A090241</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090241</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090241</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090241</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090241</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090241</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>	TORRENT PHARMS	<u>0.125MG</u>	<u>A090865</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090865</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090865</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090865</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090865</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090865</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.125MG</u>	<u>A078920</u>	<u>001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078920</u>	<u>002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078920</u>	<u>003</u>	Jul 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078920</u>	<u>004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078920</u>	<u>005</u>	Jul 06, 2010

TABLET, DELAYED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	SANDOZ	<u>0.375MG</u>	<u>A202353</u>	<u>001</u>	Dec 04, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202353</u>	<u>002</u>	Dec 04, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202353</u>	<u>003</u>	Dec 04, 2014
<u>AB</u>		<u>3MG</u>	<u>A202353</u>	<u>004</u>	Dec 04, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202353</u>	<u>005</u>	Dec 04, 2014

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>0.375MG</u>	<u>N022421</u>	<u>001</u>	Feb 19, 2010
<u>AB</u>		<u>0.75MG</u>	<u>N022421</u>	<u>002</u>	Feb 19, 2010
<u>AB</u>		<u>1.5MG</u>	<u>N022421</u>	<u>003</u>	Feb 19, 2010
<u>AB</u>		<u>2.25MG</u>	<u>N022421</u>	<u>006</u>	Jun 17, 2011
<u>AB</u>		<u>3MG</u>	<u>N022421</u>	<u>004</u>	Feb 19, 2010
<u>AB</u>		<u>3.75MG</u>	<u>N022421</u>	<u>007</u>	Jun 17, 2011
<u>AB</u>		<u>4.5MG</u>	<u>N022421</u>	<u>005</u>	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>0.375MG</u>	<u>A202206</u>	<u>001</u>	Feb 06, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202206</u>	<u>002</u>	Feb 06, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202206</u>	<u>003</u>	Feb 06, 2014
<u>AB</u>		<u>2.25MG</u>	<u>A202206</u>	<u>004</u>	Feb 06, 2014
<u>AB</u>		<u>3MG</u>	<u>A202206</u>	<u>005</u>	Feb 06, 2014
<u>AB</u>		<u>3.75MG</u>	<u>A202206</u>	<u>006</u>	Feb 06, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202206</u>	<u>007</u>	Feb 06, 2014

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
	+	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

EFFIENT

	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009
	+	EQ 10MG BASE	N022307	002	Jul 10, 2009

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>20MG</u>	<u>N019898</u>	<u>003</u>	Oct 31, 1991
<u>AB</u>		<u>40MG</u>	<u>N019898</u>	<u>004</u>	Mar 22, 1993
<u>AB</u>	+	<u>80MG</u>	<u>N019898</u>	<u>008</u>	Dec 18, 2001

PRAVASTATIN SODIUM

<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076341</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076341</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076341</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076341</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	CIPLA LTD	<u>10MG</u>	<u>A077904</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077904</u>	<u>002</u>	Oct 23, 2006

## PRESCRIPTION DRUG PRODUCT LIST

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>		<u>40MG</u>	<u>A077904 003</u>	Oct 23, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714 004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987 001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A077987 002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987 003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A077987 004</u>	Dec 28, 2007
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917 001</u>	Jan 08, 2008
<u>AB</u>		<u>20MG</u>	<u>A077917 002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917 003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917 004</u>	Jan 08, 2008
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A077013 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077013 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077013 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077013 004</u>	Dec 28, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A079187 001</u>	May 27, 2010
<u>AB</u>		<u>20MG</u>	<u>A079187 002</u>	May 27, 2010
<u>AB</u>		<u>40MG</u>	<u>A079187 003</u>	May 27, 2010
<u>AB</u>		<u>80MG</u>	<u>A079187 004</u>	May 27, 2010
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A076397 003</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076397 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076397 001</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077491 001</u>	Feb 11, 2008
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056 001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056 002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056 003</u>	Apr 24, 2006
<u>AB</u>	TEVA PHARMS	<u>80MG</u>	<u>A077793 001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076939 004</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939 003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939 002</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939 001</u>	Dec 28, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A077751 001</u>	Apr 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A077751 002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751 003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751 004</u>	Apr 30, 2008

PRAZIOUANTEL

TABLET; ORAL

BILTRICIDE

+ BAYER HLTHCARE

600MG

N018714 001 Dec 29, 1982

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	PFIZER	<u>EQ 1MG BASE</u>	<u>N017442 002</u>	
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N017442 003</u>	
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N017442 001</u>	

PRAZOSIN HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071994 001</u>	Sep 12, 1988
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A072575 003</u>	May 16, 1989
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A072575 002</u>	May 16, 1989
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A072575 001</u>	May 16, 1989
<u>AB</u>	TEVA PHARMS	<u>EQ 2MG BASE</u>	<u>A071995 001</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A071745 001</u>	Sep 12, 1988

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

<u>AB</u>	+	VALEANT BERMUDA	<u>0.1%</u>	<u>N020279 001</u>	Oct 29, 1993
-----------	---	-----------------	-------------	--------------------	--------------

PREDNICARBATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077287 001</u>	Sep 19, 2006
-----------	----------------	-------------	--------------------	--------------

OINTMENT; TOPICAL

DERMATOP

<u>AB</u>	+	VALEANT BERMUDA	<u>0.1%</u>	<u>N019568 001</u>	Sep 23, 1991
-----------	---	-----------------	-------------	--------------------	--------------

PREDNICARBATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077236 001</u>	Mar 09, 2007
-----------	----------------	-------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

<u>AA</u>	ALPHARMA	<u>15MG/5ML</u>	<u>A040323</u>	<u>001</u>	May 13, 1999
<u>AA</u>	+ HI TECH PHARMA CO	<u>15MG/5ML</u>	<u>A040401</u>	<u>001</u>	Feb 27, 2003
<u>AA</u>	PHARM ASSOC	<u>15MG/5ML</u>	<u>A040399</u>	<u>001</u>	Mar 05, 2003
<u>AA</u>	VINTAGE	<u>15MG/5ML</u>	<u>A040775</u>	<u>001</u>	Sep 21, 2007
<u>AA</u>	WOCKHARDT	<u>15MG/5ML</u>	<u>A040313</u>	<u>001</u>	Sep 10, 2003

PRELONE

<u>AA</u>	TEVA	<u>15MG/5ML</u>	<u>A089081</u>	<u>001</u>	Feb 04, 1986
-----------	------	-----------------	----------------	------------	--------------

TABLET; ORAL

PREDNISOLONE

+ WATSON LABS

5MG

A080354 001

PREDNISOLONE ACETATE

SUSPENSION; ORAL

FLO-PRED

+ TARO

EQ 15MG BASE/5ML

N022067 002 Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

<u>AB</u>	ALCON	<u>1%</u>	<u>N017469</u>	<u>001</u>	
-----------	-------	-----------	----------------	------------	--

PRED FORTE

<u>AB</u>	+ ALLERGAN	<u>1%</u>	<u>N017011</u>	<u>001</u>	
-----------	------------	-----------	----------------	------------	--

PRED MILD

+ ALLERGAN

0.12%

N017100 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

+ ALLERGAN

0.2%;10%

A087748 001 Dec 03, 1986

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

+ ALLERGAN

0.2%;10%

N012813 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

<u>AA</u>	+ CONCORDIA PHARMS INC	<u>EQ 15MG BASE/5ML</u>	<u>A075117</u>	<u>001</u>	Dec 14, 2000
-----------	------------------------	-------------------------	----------------	------------	--------------

PEDIAPRED

<u>AA</u>	+ SETON PHARM	<u>EQ 5MG BASE/5ML</u>	<u>N019157</u>	<u>001</u>	May 28, 1986
-----------	---------------	------------------------	----------------	------------	--------------

PREDNISOLONE SODIUM PHOSPHATE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/5ML</u>	<u>A078345</u>	<u>001</u>	Mar 10, 2009
<u>AA</u>	HI TECH PHARMA	<u>EQ 5MG BASE/5ML</u>	<u>A075183</u>	<u>001</u>	Mar 26, 2003
<u>AA</u>	PADDOCK LLC	<u>EQ 5MG BASE/5ML</u>	<u>A075988</u>	<u>001</u>	May 25, 2004
<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/5ML</u>	<u>A076913</u>	<u>001</u>	Apr 25, 2005
<u>AA</u>	VINTAGE	<u>EQ 15MG BASE/5ML</u>	<u>A079010</u>	<u>001</u>	May 26, 2009
<u>AA</u>	WOCKHARDT	<u>EQ 5MG BASE/5ML</u>	<u>A075099</u>	<u>001</u>	Jun 28, 2002
<u>AA</u>		<u>EQ 15MG BASE/5ML</u>	<u>A076895</u>	<u>001</u>	Oct 04, 2004
	+ MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010
	+ PHARM ASSOC	EQ 10MG BASE/5ML	A078465	001	Mar 07, 2008
		EQ 20MG BASE/5ML	A078988	001	Jun 09, 2008

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

+ BAUSCH AND LOMB

EQ 0.9% PHOSPHATE

A040070 001 Jul 29, 1994

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

<u>AB</u>	CONCORDIA PHARMS INC	<u>EQ 10MG BASE</u>	<u>N021959</u>	<u>001</u>	Jun 01, 2006
-----------	----------------------	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 15MG BASE</u>	<u>N021959</u>	<u>002</u>	Jun 01, 2006
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 30MG BASE</u>	<u>N021959</u>	<u>003</u>	Jun 01, 2006
-----------	--	---------------------	----------------	------------	--------------

PREDNISOLONE SODIUM PHOSPHATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A202179</u>	<u>001</u>	Apr 10, 2013
-----------	------------------	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A202179</u>	<u>002</u>	Apr 10, 2013
-----------	--	---------------------	----------------	------------	--------------

<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202179</u>	<u>003</u>	Apr 10, 2013
-----------	--	---------------------	----------------	------------	--------------

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

<u>AT</u>	ALCON PHARMS LTD	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A073630</u>	<u>001</u>	May 27, 1993
-----------	------------------	-------------------------------	----------------	------------	--------------

<u>AT</u>	+ BAUSCH AND LOMB	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A074449</u>	<u>001</u>	Dec 29, 1995
-----------	-------------------	-------------------------------	----------------	------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

PREDNISON

SOLUTION;ORAL

PREDNISON

+ ROXANE

5MG/5ML

A088703 001 Nov 08, 1984

PREDNISON INTENSOL

+ ROXANE

5MG/ML

A088810 001 Feb 20, 1985

TABLET;ORAL

PREDNISONAB CONTRACT PHARMACAL5MGA080209 001AB HIKMA PHARMS1MGA040890 001 Nov 01, 2010AB 2.5MGA040538 001 Jan 08, 2004AB 5MGA080292 001AB 10MGA088832 001 Dec 04, 1985AB 20MGA083677 001AB 50MGA088465 001 Jun 01, 1984AB JUBILANT CADISTA1MGA040611 001 Jun 06, 2005AB 5MGA040362 002 Aug 29, 2001AB 10MGA040362 001 Aug 29, 2001AB 20MGA040362 003 Jun 29, 2005AB MUTUAL PHARM5MGA089245 001 Dec 04, 1985AB 10MGA089246 001 Dec 04, 1985AB 20MGA089247 001 Dec 04, 1985AB + ROXANE1MGA087800 001 Apr 22, 1982AB + 2.5MGA087801 001 Apr 22, 1982AB + 5MGA080352 001AB + 10MGA084122 001AB + 20MGA087342 001AB + 50MGA084283 001AB VINTAGE PHARMS1MGA040584 001 Dec 21, 2004AB 2.5MGA040581 001 Dec 21, 2004AB 5MGA040256 001 Jul 12, 2002AB 10MGA040256 002 Jul 12, 2002AB 20MGA040392 001 Feb 12, 2003AB WATSON LABS5MGA080356 001AB 10MGA085162 001AB 20MGA085161 001

TABLET, DELAYED RELEASE;ORAL

RAYOS

HORIZON PHARMA

1MG

N202020 001 Jul 26, 2012

+ 2MG

N202020 002 Jul 26, 2012

+ 5MG

N202020 003 Jul 26, 2012

PREGABALIN

CAPSULE;ORAL

LYRICAAB PF PRISM CV25MGN021446 001 Dec 30, 2004AB 50MGN021446 002 Dec 30, 2004AB 75MGN021446 003 Dec 30, 2004AB 100MGN021446 004 Dec 30, 2004AB 150MGN021446 005 Dec 30, 2004AB 200MGN021446 006 Dec 30, 2004AB 225MGN021446 007 Dec 30, 2004AB + 300MGN021446 008 Dec 30, 2004PREGABALINAB LUPIN LTD25MGA091040 001 Jul 03, 2012AB 50MGA091040 002 Jul 03, 2012AB 75MGA091040 003 Jul 03, 2012AB 100MGA091040 004 Jul 03, 2012AB 150MGA091040 005 Jul 03, 2012AB 200MGA091040 006 Jul 03, 2012AB 225MGA091040 007 Jul 03, 2012AB 300MGA091040 008 Jul 03, 2012AB TEVA PHARMS25MGA091219 001 Jul 03, 2012AB 50MGA091219 002 Jul 03, 2012AB 75MGA091224 001 Jul 03, 2012AB 100MGA091224 002 Jul 03, 2012AB 150MGA091224 003 Jul 03, 2012AB 200MGA091224 004 Jul 03, 2012AB 225MGA091224 005 Jul 03, 2012AB 300MGA091224 006 Jul 03, 2012AB WATSON LABS INC25MGA091221 001 Jul 03, 2012AB 50MGA091221 002 Jul 03, 2012AB 75MGA091221 003 Jul 03, 2012

## PRESCRIPTION DRUG PRODUCT LIST

PREGABALIN

CAPSULE; ORAL

PREGABALIN

<u>AB</u>		<u>100MG</u>	<u>A091221 004</u>	Jul 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A091221 005</u>	Jul 03, 2012
<u>AB</u>		<u>200MG</u>	<u>A091221 006</u>	Jul 03, 2012
<u>AB</u>		<u>225MG</u>	<u>A091221 007</u>	Jul 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A091221 008</u>	Jul 03, 2012

SOLUTION; ORAL

LYRICA

+ PF PRISM CV

20MG/ML

N022488 001 Jan 04, 2010

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRILOCAINE HYDROCHLORIDE

+ SEPTODONT INC

4%

A079235 001 Sep 29, 2010

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

<u>AB</u>	+ SANOFI AVENTIS US	<u>EQ 15MG BASE</u>	<u>N008316 001</u>	
-----------	---------------------	---------------------	--------------------	--

PRIMAQUINE PHOSPHATE

<u>AB</u>	ALVOGEN INC	<u>EQ 15MG BASE</u>	<u>A203924 001</u>	Feb 03, 2014
<u>AB</u>	BAYSHORE PHARMS LLC	<u>EQ 15MG BASE</u>	<u>A204476 001</u>	Feb 25, 2014

PRIMIDONE

TABLET; ORAL

MYSOLINE

<u>AB</u>	+ VALEANT	<u>50MG</u>	<u>N009170 003</u>	
<u>AB</u>		<u>250MG</u>	<u>N009170 002</u>	

PRIMIDONE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A040866 001</u>	Apr 23, 2008
<u>AB</u>		<u>250MG</u>	<u>A040866 002</u>	Apr 23, 2008
<u>AB</u>	HIKMA PHARMS LLC	<u>250MG</u>	<u>A040667 002</u>	Jul 27, 2006
<u>AB</u>	IMPAX LABS	<u>50MG</u>	<u>A040717 001</u>	Feb 12, 2008
<u>AB</u>		<u>250MG</u>	<u>A040717 002</u>	Feb 12, 2008
<u>AB</u>	LANNETT	<u>50MG</u>	<u>A084903 002</u>	May 24, 2001
<u>AB</u>		<u>250MG</u>	<u>A084903 001</u>	
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A040626 001</u>	Sep 29, 2005
<u>AB</u>		<u>250MG</u>	<u>A040626 002</u>	Sep 29, 2005
<u>AB</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040586 001</u>	Feb 24, 2005
<u>AB</u>		<u>250MG</u>	<u>A040586 002</u>	Feb 24, 2005
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A083551 001</u>	

PROBENECID

TABLET; ORAL

PROBALAN

<u>AB</u>	LANNETT	<u>500MG</u>	<u>A080966 001</u>	
-----------	---------	--------------	--------------------	--

PROBENECID

<u>AB</u>	+ MYLAN	<u>500MG</u>	<u>A084211 002</u>	
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A084442 004</u>	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

+ HOSPIRA

100MG/ML

A089069 001 Feb 12, 1986

+

500MG/ML

A089070 001 Feb 12, 1986

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

+ SIGMA TAU

EQ 50MG BASE

N016785 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO

<u>AB</u>	PADDOCK LLC	<u>25MG</u>	<u>A040246 001</u>	Jun 28, 2000
-----------	-------------	-------------	--------------------	--------------

PROCHLORPERAZINE

<u>AB</u>	+ G AND W LABS	<u>25MG</u>	<u>A040058 001</u>	Nov 24, 1993
-----------	----------------	-------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

<u>AP</u>	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>A040540</u>	<u>001</u>	May 28, 2004
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 5MG BASE/ML</u>	<u>A204147</u>	<u>001</u>	Oct 15, 2013
<u>AP</u>	+ HIKMA MAPLE	<u>EQ 5MG BASE/ML</u>	<u>A089903</u>	<u>001</u>	Aug 29, 1989

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A040185</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040185</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A040101</u>	<u>001</u>	Jul 19, 1996
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>A040101</u>	<u>002</u>	Jul 19, 1996
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A040120</u>	<u>001</u>	Jul 11, 1996
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040120</u>	<u>002</u>	Jul 11, 1996
<u>PROCOMP</u>					
<u>AB</u>	JUBILANT CADISTA	<u>EQ 5MG BASE</u>	<u>A040268</u>	<u>001</u>	Feb 27, 1998
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040268</u>	<u>002</u>	Feb 27, 1998

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

<u>AB</u>	BANNER PHARMACAPS	<u>100MG</u>	<u>A200900</u>	<u>001</u>	Aug 16, 2013
<u>AB</u>		<u>200MG</u>	<u>A200900</u>	<u>002</u>	Aug 16, 2013
<u>AB</u>	SOFGEN PHARMS	<u>100MG</u>	<u>A200456</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>		<u>200MG</u>	<u>A200456</u>	<u>002</u>	Sep 28, 2012
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A202121</u>	<u>001</u>	Feb 29, 2012
<u>AB</u>		<u>200MG</u>	<u>A202121</u>	<u>002</u>	Feb 29, 2012

PROMETRIUM

<u>AB</u>	ABBVIE INC	<u>100MG</u>	<u>N019781</u>	<u>001</u>	May 14, 1998
<u>AB</u>	+	<u>200MG</u>	<u>N019781</u>	<u>002</u>	Oct 15, 1999

GEL; VAGINAL

CRINONE

WATSON LABS

4%

N020701 001 Jul 31, 1997

+

8%

N020701 002 Jul 31, 1997

INJECTABLE; INJECTION

PROGESTERONE

<u>AO</u>	FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A075906</u>	<u>001</u>	Apr 25, 2001
<u>AO</u>	HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A091033</u>	<u>001</u>	Oct 28, 2010
<u>AO</u>	LUITPOLD	<u>50MG/ML</u>	<u>A090845</u>	<u>001</u>	Jun 22, 2009
<u>AO</u>	+ WATSON LABS (UTAH)	<u>50MG/ML</u>	<u>N017362</u>	<u>002</u>	

INSERT; VAGINAL

ENDOMETRIN

+ FERRING

100MG

N022057 001 Jun 21, 2007

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	+ HIKMA MAPLE	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
<u>AP</u>	+	<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>	X-GEN PHARMS	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	G AND W LABS	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	+	<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>	PERRIGO NEW YORK	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>		<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>	TARO	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>		<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006
<u>AB</u>	WATSON LABS INC	<u>12.5MG</u>	<u>A040479</u>	<u>001</u>	Jun 24, 2003
<u>AB</u>		<u>25MG</u>	<u>A040479</u>	<u>002</u>	Jun 24, 2003

PROMETHEGAN

+ G AND W LABS

50MG

A087165 001 Aug 14, 1987

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>	HI TECH PHARMA	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>	SUN PHARM INDS INC	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>	TARO	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>	TRIS PHARMA INC	<u>6.25MG/5ML</u>	<u>A091675</u>	<u>001</u>	Jun 28, 2012
<u>AA</u>	VINTAGE	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006

## PRESCRIPTION DRUG PRODUCT LIST

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE PLAIN

**AA** + WOCKHARDT **6.25MG/5ML** **A087953 001** Nov 15, 1982  
 TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

**AB** AMNEAL PHARMS NY **12.5MG** **A091179 001** Dec 13, 2010  
**AB** **25MG** **A091179 002** Dec 13, 2010  
**AB** **50MG** **A091179 003** Dec 13, 2010  
**AB** EMCURE PHARMS USA **12.5MG** **A040673 001** Mar 05, 2008  
**AB** **25MG** **A040673 002** Mar 05, 2008  
**AB** **50MG** **A040673 003** Mar 05, 2008  
**AB** IMPAX LABS **12.5MG** **A040724 001** Feb 12, 2008  
**AB** **25MG** **A040724 002** Feb 12, 2008  
**AB** **50MG** **A040791 001** May 20, 2008  
**AB** KVK TECH **12.5MG** **A040712 002** May 04, 2007  
**AB** **25MG** **A040712 001** Jul 31, 2006  
**AB** **50MG** **A040713 001** Jul 31, 2006  
**AB** MYLAN **12.5MG** **A091054 001** Aug 30, 2011  
**AB** **25MG** **A091054 002** Aug 30, 2011  
**AB** **50MG** **A091054 003** Aug 30, 2011  
**AB** SANDOZ **25MG** **A084176 003**  
**AB** + **50MG** **A084176 001**  
**AB** SUN PHARM INDS INC **12.5MG** **A040863 001** Dec 30, 2008  
**AB** **25MG** **A040863 002** Dec 30, 2008  
**AB** **50MG** **A040863 003** Dec 30, 2008  
**AB** VINTAGE PHARMS **12.5MG** **A040622 001** Jul 18, 2006  
**AB** **25MG** **A040622 002** Jul 18, 2006  
**AB** **50MG** **A040622 003** Jul 18, 2006  
**AB** WATSON LABS **25MG** **A083426 001**  
**AB** **50MG** **A083711 001**  
**AB** ZYDUS PHARMS USA **12.5MG** **A040596 001** Nov 18, 2005  
**AB** **25MG** **A040596 002** Nov 18, 2005  
**AB** **50MG** **A040596 003** Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

**AB** PAR PHARM **225MG** **A078540 001** Oct 18, 2010  
**AB** **325MG** **A078540 002** Oct 18, 2010  
**AB** **425MG** **A078540 003** Oct 18, 2010  
RYTHMOL SR  
**AB** GLAXOSMITHKLINE LLC **225MG** **N021416 001** Sep 04, 2003  
**AB** **325MG** **N021416 002** Sep 04, 2003  
**AB** + **425MG** **N021416 003** Sep 04, 2003  
 TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

**AB** ANI PHARMS INC **150MG** **A076550 001** Apr 23, 2004  
**AB** **225MG** **A076550 002** Apr 23, 2004  
**AB** **300MG** **A076550 003** Apr 23, 2004  
**AB** MUTUAL PHARM **150MG** **A075998 001** Nov 29, 2001  
**AB** **225MG** **A075998 002** Nov 29, 2001  
**AB** **300MG** **A075998 003** Nov 29, 2001  
**AB** VINTAGE PHARMS **150MG** **A075938 001** Oct 17, 2002  
**AB** **225MG** **A075938 002** Oct 17, 2002  
**AB** **300MG** **A075938 003** Oct 17, 2002  
**AB** WATSON LABS **150MG** **A075203 001** Oct 24, 2000  
**AB** **225MG** **A075203 002** Oct 24, 2000  
RYTHMOL  
**AB** GLAXOSMITHKLINE LLC **150MG** **N019151 001** Nov 27, 1989  
**AB** **225MG** **N019151 003** Nov 20, 1992  
**AB** + **300MG** **N019151 002** Nov 27, 1989

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+ ROXANE 15MG A080927 002

## PRESCRIPTION DRUG PRODUCT LIST

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALCAINE

<b>AT</b>	+	ALCON	<u>0.5%</u>	<u>A080027</u>	<u>001</u>	
<u>PROPARACAINE HYDROCHLORIDE</u>						
<b>AT</b>		AKORN INC	<u>0.5%</u>	<u>A040277</u>	<u>001</u>	Mar 16, 2000
<b>AT</b>		BAUSCH AND LOMB	<u>0.5%</u>	<u>A040074</u>	<u>001</u>	Sep 29, 1995

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

<b>AB</b>	+	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N019627</u>	<u>002</u>	Jun 11, 1996
<u>PROPOFOL</u>						
<b>AB</b>		HOSPIRA	<u>10MG/ML</u>	<u>A077908</u>	<u>001</u>	Mar 17, 2006
<b>AB</b>		TEVA PHARMS USA	<u>10MG/ML</u>	<u>A075102</u>	<u>001</u>	Jan 04, 1999

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

PVT FORM

32MG

A083464 001

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

<b>AB</b>		CRANFORD PHARMS LLC	<u>60MG</u>	<u>N018553</u>	<u>004</u>	Mar 18, 1987
<b>AB</b>			<u>80MG</u>	<u>N018553</u>	<u>002</u>	Apr 19, 1983
<b>AB</b>			<u>120MG</u>	<u>N018553</u>	<u>003</u>	Apr 19, 1983
<b>AB</b>	+		<u>160MG</u>	<u>N018553</u>	<u>001</u>	Apr 19, 1983
<u>PROPRANOLOL HYDROCHLORIDE</u>						
<b>AB</b>		ACTAVIS ELIZABETH	<u>60MG</u>	<u>A078494</u>	<u>001</u>	Aug 10, 2007
<b>AB</b>			<u>80MG</u>	<u>A078494</u>	<u>002</u>	Aug 10, 2007
<b>AB</b>			<u>120MG</u>	<u>A078494</u>	<u>003</u>	Aug 10, 2007
<b>AB</b>			<u>160MG</u>	<u>A078494</u>	<u>004</u>	Aug 10, 2007
<b>AB</b>		APTALIS PHARMATECH	<u>60MG</u>	<u>A078703</u>	<u>001</u>	Jul 15, 2011
<b>AB</b>			<u>80MG</u>	<u>A078703</u>	<u>002</u>	Jul 15, 2011
<b>AB</b>			<u>120MG</u>	<u>A078703</u>	<u>003</u>	Jul 15, 2011
<b>AB</b>			<u>160MG</u>	<u>A078703</u>	<u>004</u>	Jul 15, 2011
<b>AB</b>		MYLAN	<u>60MG</u>	<u>A078022</u>	<u>001</u>	Feb 15, 2007
<b>AB</b>			<u>80MG</u>	<u>A078022</u>	<u>002</u>	Feb 15, 2007
<b>AB</b>			<u>120MG</u>	<u>A078022</u>	<u>003</u>	Feb 15, 2007
<b>AB</b>			<u>160MG</u>	<u>A078022</u>	<u>004</u>	Feb 15, 2007
<b>AB</b>		NORTEC DEV ASSOC	<u>60MG</u>	<u>A078065</u>	<u>001</u>	Jan 26, 2007
<b>AB</b>			<u>80MG</u>	<u>A078065</u>	<u>002</u>	Jan 26, 2007
<b>AB</b>			<u>120MG</u>	<u>A078065</u>	<u>003</u>	Jan 26, 2007
<b>AB</b>			<u>160MG</u>	<u>A078065</u>	<u>004</u>	Jan 26, 2007
<b>AB</b>		UPSHER SMITH	<u>60MG</u>	<u>A078311</u>	<u>001</u>	Mar 06, 2009
<b>AB</b>			<u>80MG</u>	<u>A078311</u>	<u>002</u>	Mar 06, 2009
<b>AB</b>			<u>120MG</u>	<u>A078311</u>	<u>003</u>	Mar 06, 2009
<b>AB</b>			<u>160MG</u>	<u>A078311</u>	<u>004</u>	Mar 06, 2009
<b>AB</b>		ZYDUS PHARMS USA INC	<u>60MG</u>	<u>A090321</u>	<u>001</u>	Mar 25, 2011
<b>AB</b>			<u>80MG</u>	<u>A090321</u>	<u>002</u>	Mar 25, 2011
<b>AB</b>			<u>120MG</u>	<u>A090321</u>	<u>003</u>	Mar 25, 2011
<b>AB</b>			<u>160MG</u>	<u>A090321</u>	<u>004</u>	Mar 25, 2011

INNOPRAN XL

BX		GLAXOSMITHKLINE LLC	80MG	N021438	001	Mar 12, 2003
BX			120MG	N021438	002	Mar 12, 2003

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

<b>AP</b>	+	BAXTER HLTHCARE CORP	<u>1MG/ML</u>	<u>N016419</u>	<u>001</u>	
<b>AP</b>		BEDFORD	<u>1MG/ML</u>	<u>A075792</u>	<u>001</u>	Aug 29, 2000
<b>AP</b>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A075826</u>	<u>001</u>	Aug 31, 2001
<b>AP</b>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077760</u>	<u>001</u>	Jan 31, 2008
<b>AP</b>		SANDOZ	<u>1MG/ML</u>	<u>A076400</u>	<u>001</u>	Feb 26, 2003

SOLUTION; ORAL

HEMANGEOL

+ PIERRE FABRE DERMA

4.28MG/ML

N205410 001 Mar 14, 2014

PROPRANOLOL HYDROCHLORIDE

+ ROXANE

20MG/5ML

A070979 001 May 15, 1987

+

40MG/5ML

A070690 001 May 15, 1987

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

<b>AB</b>		IPCA LABS LTD	<u>10MG</u>	<u>A078955</u>	<u>001</u>	Jun 02, 2008
<b>AB</b>			<u>20MG</u>	<u>A078955</u>	<u>002</u>	Jun 02, 2008
<b>AB</b>			<u>40MG</u>	<u>A078955</u>	<u>003</u>	Jun 02, 2008

## PRESCRIPTION DRUG PRODUCT LIST

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		<u>60MG</u>	<u>A078955 004</u>	Jun 02, 2008
<u>AB</u>		<u>80MG</u>	<u>A078955 005</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A070213 002</u>	Nov 19, 1985
<u>AB</u>		<u>20MG</u>	<u>A070213 003</u>	Nov 19, 1985
<u>AB</u>		<u>40MG</u>	<u>A070213 001</u>	Nov 19, 1985
<u>AB</u>		<u>60MG</u>	<u>A070213 005</u>	Apr 08, 2011
<u>AB</u>		<u>80MG</u>	<u>A070213 004</u>	Nov 19, 1985
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078213 001</u>	Jan 10, 2008
<u>AB</u>		<u>20MG</u>	<u>A078213 002</u>	Jan 10, 2008
<u>AB</u>		<u>40MG</u>	<u>A078213 003</u>	Jan 10, 2008
<u>AB</u>		<u>60MG</u>	<u>A078213 004</u>	Jan 10, 2008
<u>AB</u>		<u>80MG</u>	<u>A078213 005</u>	Jan 10, 2008
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A071972 001</u>	Apr 06, 1988
<u>AB</u>		<u>20MG</u>	<u>A071973 001</u>	Apr 06, 1988
<u>AB</u>		<u>40MG</u>	<u>A071974 001</u>	Apr 06, 1988
<u>AB</u>		<u>60MG</u>	<u>A071975 001</u>	Apr 06, 1988
<u>AB</u>	+	<u>80MG</u>	<u>A071976 001</u>	Apr 06, 1988
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A070217 001</u>	Aug 01, 1986
<u>AB</u>		<u>20MG</u>	<u>A070218 001</u>	Aug 01, 1986
<u>AB</u>		<u>40MG</u>	<u>A070219 001</u>	Aug 01, 1986
<u>AB</u>		<u>60MG</u>	<u>A070220 001</u>	Sep 24, 1986
<u>AB</u>		<u>80MG</u>	<u>A070221 001</u>	Apr 14, 1986
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A070175 001</u>	May 13, 1986
<u>AB</u>		<u>20MG</u>	<u>A070176 001</u>	May 13, 1986
<u>AB</u>		<u>40MG</u>	<u>A070177 001</u>	May 13, 1986
<u>AB</u>		<u>80MG</u>	<u>A070178 001</u>	May 13, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172 001	
BD	+	DAVA PHARMS INC	50MG	N006188 001

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

+	FRESENIUS KABI USA	10MG/ML	A089454 001	Apr 07, 1987
---	--------------------	---------	-------------	--------------

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A202220 001</u>	Nov 19, 2012
<u>AB</u>		<u>10MG</u>	<u>A202220 002</u>	Nov 19, 2012
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A078913 001</u>	Sep 16, 2008
<u>AB</u>		<u>10MG</u>	<u>A078913 002</u>	Sep 16, 2008
<u>AB</u>	SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A090462 001</u>	May 03, 2010
<u>AB</u>		<u>10MG</u>	<u>A090462 002</u>	May 03, 2010

VIVACTIL

<u>AB</u>	ODYSSEY PHARMS	<u>5MG</u>	<u>A073644 001</u>	Aug 24, 1995
<u>AB</u>	+	<u>10MG</u>	<u>A073645 001</u>	Aug 24, 1995

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

<u>AB</u>	+	DAVA PHARMS INC	<u>500MG</u>	<u>A080157 001</u>
<u>AB</u>		MIKART	<u>500MG</u>	<u>A081319 001</u> Jun 30, 1992

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

<u>AP</u>	+	VALEANT PHARM INTL	<u>5MG/ML</u>	<u>N009830 001</u>
-----------	---	--------------------	---------------	--------------------

REGONOL

<u>AP</u>		SANDOZ	<u>5MG/ML</u>	<u>N017398 001</u>
-----------	--	--------	---------------	--------------------

SYRUP; ORAL

MESTINON

+	VALEANT PHARM NORTH	60MG/5ML	N015193 001	
---	---------------------	----------	-------------	--

TABLET; ORAL

MESTINON

<u>AB</u>	+	VALEANT PHARMS LLC	<u>60MG</u>	<u>N009829 002</u>
-----------	---	--------------------	-------------	--------------------

PYRIDOSTIGMINE BROMIDE

<u>AB</u>		IMPAX LABS	<u>60MG</u>	<u>A040502 001</u> Apr 24, 2003
-----------	--	------------	-------------	---------------------------------

## PRESCRIPTION DRUG PRODUCT LIST

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

MESTINON

+ VALEANT PHARMS LLC 180MG N011665 001

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

+ FRESENIUS KABI USA 100MG/ML A080618 001

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

+ AMEDRA PHARMS 25MG N008578 001

QUAZEPAM

TABLET;ORAL

DORAL

+ SCIECURE PHARMA INC 15MG N018708 001 Dec 27, 1985

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 25MG BASE</u>	<u>A202152 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202152 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202152 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202152 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202152 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202152 006</u>	Mar 27, 2012
<u>AB</u>	ACTAVIS GRP PTC	<u>EQ 25MG BASE</u>	<u>A201762 001</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201762 002</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201762 003</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A201762 004</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201762 005</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201762 006</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201762 007</u>	Feb 27, 2013
<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A203390 001</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A203390 002</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A203390 003</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A203390 004</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A203390 005</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A203390 006</u>	Oct 28, 2014
<u>AB</u>	ALKEM LABS LTD	<u>EQ 25MG BASE</u>	<u>A201504 001</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201504 002</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201504 003</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A201504 004</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201504 005</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201504 006</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201504 007</u>	Feb 12, 2013
<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A090960 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090960 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090960 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090960 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090960 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090960 006</u>	Mar 27, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 25MG BASE</u>	<u>A091388 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A091388 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091388 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091388 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091388 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091388 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A091388 007</u>	Mar 27, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A077380 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077380 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077380 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077380 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077380 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077380 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077380 007</u>	Mar 27, 2012
<u>AB</u>	JUBILANT GENERICS	<u>EQ 25MG BASE</u>	<u>A203150 001</u>	Nov 26, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A201109 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201109 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201109 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201109 004</u>	Mar 27, 2012

## PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201109 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201109 006</u>	Mar 27, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A090323 001</u>	Mar 27, 2012
<u>AB</u>	ROXANE	<u>EQ 25MG BASE</u>	<u>A090120 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090749 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090749 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090749 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090749 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090749 005</u>	Mar 27, 2012
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A078679 001</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078679 002</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078679 003</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078679 004</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A078679 005</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078679 006</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078679 007</u>	Dec 14, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 25MG BASE</u>	<u>A201190 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201190 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201190 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201190 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201190 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201190 006</u>	Mar 27, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A077745 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077745 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077745 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077745 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077745 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077745 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077745 007</u>	Mar 27, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A200363 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200363 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200363 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A200363 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A200363 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A200363 006</u>	Mar 27, 2012
<u>SEROQUEL</u>				
<u>AB</u>	+ ASTRAZENECA	<u>EQ 25MG BASE</u>	<u>N020639 001</u>	Sep 26, 1997
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N020639 007</u>	Oct 04, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N020639 002</u>	Sep 26, 1997
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>N020639 003</u>	Sep 26, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N020639 005</u>	Jul 26, 2000
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>N020639 006</u>	Oct 04, 2005

TABLET, EXTENDED RELEASE; ORAL

SEROQUEL XR

ASTRAZENECA

	EQ 50MG BASE	N022047 001	May 17, 2007
	EQ 150MG BASE	N022047 005	Aug 11, 2008
+	EQ 200MG BASE	N022047 002	May 17, 2007
	EQ 300MG BASE	N022047 003	May 17, 2007
	EQ 400MG BASE	N022047 004	May 17, 2007

	EQ 50MG BASE	N022047 001	May 17, 2007
	EQ 150MG BASE	N022047 005	Aug 11, 2008
+	EQ 200MG BASE	N022047 002	May 17, 2007
	EQ 300MG BASE	N022047 003	May 17, 2007
	EQ 400MG BASE	N022047 004	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCUPRIL

<u>AB</u>	PFIZER PHARMS	<u>EQ 5MG BASE</u>	<u>N019885 001</u>	Nov 19, 1991
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N019885 002</u>	Nov 19, 1991
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N019885 003</u>	Nov 19, 1991
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N019885 004</u>	Nov 19, 1991
<u>QUINAPRIL HYDROCHLORIDE</u>				
<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 5MG BASE</u>	<u>A076049 001</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076049 002</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076049 003</u>	Jan 14, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076049 004</u>	Jan 14, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202725 001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202725 002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202725 003</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202725 004</u>	Apr 29, 2013
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078457 001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078457 002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078457 003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078457 004</u>	Aug 24, 2007



## PRESCRIPTION DRUG PRODUCT LIST

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

<u>AB</u>	LUPIN	<u>EQ 5MG BASE</u>	<u>A077690 001</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077690 002</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077690 003</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077690 004</u>	Jun 20, 2006
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076694 001</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076694 002</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076694 003</u>	Dec 23, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076694 004</u>	Dec 23, 2004
<u>AB</u>	RANBAXY	<u>EQ 5MG BASE</u>	<u>A076607 001</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076607 002</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076607 003</u>	Dec 15, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076607 004</u>	Dec 15, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 5MG BASE</u>	<u>A090800 001</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090800 002</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090800 003</u>	Jun 18, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090800 004</u>	Jun 18, 2009
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A075504 001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075504 002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075504 003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075504 004</u>	Aug 24, 2007

QUINIDINE GLUCONATE

INJECTABLE; INJECTION

QUINIDINE GLUCONATE

+ LILLY 80MG/ML

N007529 002 Feb 10, 1989

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX + MUTUAL PHARM 324MG

A089338 001 Feb 11, 1987

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

<u>AB</u>	MUTUAL PHARM	<u>200MG</u>	<u>A081030 001</u>	Apr 14, 1989
<u>AB</u>		<u>300MG</u>	<u>A081031 001</u>	Apr 14, 1989
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A088072 002</u>	
<u>AB</u>		<u>300MG</u>	<u>A088072 001</u>	Sep 26, 1983
<u>AB</u>	+ WATSON LABS	<u>200MG</u>	<u>A083288 001</u>	
<u>AB</u>	+	<u>300MG</u>	<u>A085583 001</u>	

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

+ TEVA PHARMS 300MG

A040045 001 Jun 30, 1994

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

<u>AB</u>	+ MUTUAL PHARM CO INC	<u>324MG</u>	<u>N021799 001</u>	Aug 12, 2005
-----------	-----------------------	--------------	--------------------	--------------

QUININE SULFATE

<u>AB</u>	MYLAN PHARMS INC	<u>324MG</u>	<u>A202581 001</u>	Dec 14, 2012
<u>AB</u>	TEVA PHARMS	<u>324MG</u>	<u>A091661 001</u>	Sep 28, 2012

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

EISAI INC 5MG

N204736 001 Mar 26, 2013

+ 10MG

N204736 002 Mar 26, 2013

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

<u>AB</u>	+ EISAI INC	<u>20MG</u>	<u>N020973 002</u>	Aug 19, 1999
-----------	-------------	-------------	--------------------	--------------

RABEPRAZOLE SODIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A076824 001</u>	Nov 08, 2013
<u>AB</u>	KREMERS URBAN DEV	<u>20MG</u>	<u>A090678 001</u>	Nov 08, 2013
<u>AB</u>	LUPIN LTD	<u>20MG</u>	<u>A078964 001</u>	Nov 08, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>20MG</u>	<u>A076885 001</u>	Nov 08, 2013
<u>AB</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A076822 001</u>	Nov 08, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>20MG</u>	<u>A202376 001</u>	Nov 08, 2013

## PRESCRIPTION DRUG PRODUCT LIST

RADIUM RA-223 DICHLORIDE

SOLUTION; INTRAVENOUS

XOFIGO

+ BAYER HLTHCARE

162mCi/6ML (27mCi/ML)

N203971 001 May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTAAB + LILLY60MGN020815 001 Dec 09, 1997RALOXIFENE HYDROCHLORIDEAB INVAGEN PHARMS60MGA090842 001 Sep 24, 2014AB TEVA PHARMS USA60MGA078193 001 Mar 04, 2014RALTEGRAVIR POTASSIUM

POWDER; ORAL

ISENTRESS

+ MERCK SHARP DOHME

EQ 100MG BASE/PACKET

N205786 001 Dec 20, 2013

TABLET; ORAL

ISENTRESS

+ MERCK SHARP DOHME

EQ 400MG BASE

N022145 001 Oct 12, 2007

TABLET, CHEWABLE; ORAL

ISENTRESS

MERCK SHARP DOHME

EQ 25MG BASE

N203045 001 Dec 21, 2011

+

EQ 100MG BASE

N203045 002 Dec 21, 2011

RAMELTEON

TABLET; ORAL

RAMELTEONAB TEVA PHARMS USA8MGA091693 001 Jul 26, 2013ROZEREMAB + TAKEDA PHARMS USA8MGN021782 001 Jul 22, 2005RAMIPRIL

CAPSULE; ORAL

ALTACEAB KING PHARMS1.25MGN019901 001 Jan 28, 1991AB2.5MGN019901 002 Jan 28, 1991AB5MGN019901 003 Jan 28, 1991AB +10MGN019901 004 Jan 28, 1991RAMIPRILAB ACCORD HLTHCARE INC1.25MGA202392 001 Apr 15, 2014AB2.5MGA202392 002 Apr 15, 2014AB5MGA202392 003 Apr 15, 2014AB10MGA202392 004 Apr 15, 2014AB APOTEX1.25MGA079116 001 Jun 20, 2008AB2.5MGA079116 002 Jun 20, 2008AB5MGA079116 003 Jun 20, 2008AB10MGA079116 004 Jun 20, 2008AB AUROBINDO PHARMA LTD1.25MGA091604 001 Jun 08, 2011AB2.5MGA091604 002 Jun 08, 2011AB5MGA091604 003 Jun 08, 2011AB10MGA091604 004 Jun 08, 2011AB DR REDDYS LABS LTD1.25MGA078191 001 Jun 18, 2008AB2.5MGA078191 002 Jun 18, 2008AB5MGA078191 003 Jun 18, 2008AB10MGA078191 004 Jun 18, 2008AB INVAGEN PHARMS1.25MGA078745 001 Jun 18, 2008AB2.5MGA078745 002 Jun 18, 2008AB5MGA078745 003 Jun 18, 2008AB10MGA078745 004 Jun 18, 2008AB LUPIN1.25MGA077626 001 Jun 09, 2008AB2.5MGA077626 002 Jun 09, 2008AB5MGA077626 003 Jun 09, 2008AB10MGA077626 004 Jun 09, 2008AB ROXANE1.25MGA077900 001 Jun 18, 2008AB2.5MGA077900 002 Jun 18, 2008AB5MGA077900 003 Jun 18, 2008AB10MGA077900 004 Jun 18, 2008AB SANDOZ1.25MGA077514 001 Jun 18, 2008AB2.5MGA077514 002 Jun 18, 2008AB5MGA077514 003 Jun 18, 2008AB10MGA077514 004 Jun 18, 2008AB TEVA PHARMS1.25MGA077470 001 Jun 18, 2008AB2.5MGA077470 002 Jun 18, 2008

## PRESCRIPTION DRUG PRODUCT LIST

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

<u>AB</u>		<u>5MG</u>	<u>A077470 003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077470 004</u>	Jun 18, 2008
<u>AB</u>	WATSON LABS	<u>1.25MG</u>	<u>A076549 001</u>	Oct 24, 2005
<u>AB</u>		<u>2.5MG</u>	<u>A076549 002</u>	Oct 24, 2005
<u>AB</u>		<u>5MG</u>	<u>A076549 003</u>	Oct 24, 2005
<u>AB</u>		<u>10MG</u>	<u>A076549 004</u>	Oct 24, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>1.25MG</u>	<u>A078832 001</u>	Sep 02, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078832 002</u>	Sep 02, 2008
<u>AB</u>		<u>5MG</u>	<u>A078832 003</u>	Sep 02, 2008
<u>AB</u>		<u>10MG</u>	<u>A078832 004</u>	Sep 02, 2008

TABLET; ORAL

RAMIPRIL

<u>AB</u>	MYLAN PHARMS INC	<u>1.25MG</u>	<u>A090650 001</u>	Jun 30, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090650 002</u>	Jun 30, 2011
<u>AB</u>		<u>5MG</u>	<u>A090650 003</u>	Jun 30, 2011
<u>AB</u>		<u>10MG</u>	<u>A090650 004</u>	Jun 30, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1.25MG</u>	<u>A090697 001</u>	Sep 24, 2009
<u>AB</u>		<u>2.5MG</u>	<u>A090697 002</u>	Sep 24, 2009
<u>AB</u>		<u>5MG</u>	<u>A090697 003</u>	Sep 24, 2009
<u>AB</u>		<u>10MG</u>	<u>A090697 004</u>	Sep 24, 2009

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742 001</u>	Nov 29, 2000
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075742 002</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655 001</u>	Oct 22, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>A074655 002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL	<u>EQ 25MG BASE/ML</u>	<u>A074777 001</u>	Mar 02, 2005
<u>AP</u>		<u>EQ 25MG BASE/ML</u>	<u>A077458 001</u>	Feb 16, 2006
<u>AP</u>	ZYDUS PHARMS USA INC	<u>25MG/ML</u>	<u>A091534 001</u>	Feb 22, 2013

ZANTAC

<u>AP</u>	+	COVIS INJECTABLES	<u>EQ 25MG BASE/ML</u>	<u>N019090 001</u>	Oct 19, 1984
-----------	---	-------------------	------------------------	--------------------	--------------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>EQ 15MG BASE/ML</u>	<u>A076124 001</u>	Feb 21, 2007
<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078312 001</u>	Sep 02, 2008
<u>AA</u>	AUROBINDO PHARM	<u>EQ 15MG BASE/ML</u>	<u>A090623 001</u>	Jul 28, 2010
<u>AA</u>	BIO PHARM INC	<u>EQ 15MG BASE/ML</u>	<u>A090102 001</u>	May 26, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>EQ 15MG BASE/ML</u>	<u>A078684 001</u>	Aug 27, 2009
<u>AA</u>	CARACO	<u>EQ 15MG BASE/ML</u>	<u>A091091 001</u>	Sep 20, 2011
<u>AA</u>	HI TECH PHARMA	<u>EQ 15MG BASE/ML</u>	<u>A091078 001</u>	Mar 22, 2011
<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405 001</u>	Sep 21, 2007
<u>AA</u>	SILARX	<u>EQ 15MG BASE/ML</u>	<u>A091288 001</u>	Dec 09, 2010
<u>AA</u>	TARO	<u>EQ 15MG BASE/ML</u>	<u>A077476 001</u>	Jan 13, 2011
<u>AA</u>	TOLMAR	<u>EQ 15MG BASE/ML</u>	<u>A090054 001</u>	Nov 15, 2010
<u>AA</u>	VINTAGE PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078890 001</u>	Jul 01, 2010
<u>AA</u>	WOCKHARDT	<u>EQ 15MG BASE/ML</u>	<u>A079211 001</u>	May 26, 2009
<u>AA</u>		<u>EQ 15MG BASE/ML</u>	<u>A079212 001</u>	Feb 23, 2009

ZANTAC

<u>AA</u>	+	GLAXO GRP LTD	<u>EQ 15MG BASE/ML</u>	<u>N019675 001</u>	Dec 30, 1988
-----------	---	---------------	------------------------	--------------------	--------------

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 150MG BASE</u>	<u>A077824 001</u>	Oct 13, 2006
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077824 002</u>	Oct 13, 2006
<u>AB</u>	APOTEX	<u>EQ 150MG BASE</u>	<u>A074680 001</u>	Sep 12, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074680 002</u>	Sep 12, 1997
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705 001</u>	Jul 27, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705 002</u>	Jul 27, 2005
<u>AB</u>	GLENMARK GENERICS	<u>EQ 150MG BASE</u>	<u>A078542 001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542 002</u>	Nov 19, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 150MG BASE</u>	<u>A075165 001</u>	Sep 30, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075165 002</u>	Sep 30, 1998
<u>AB</u>	MYLAN	<u>EQ 150MG BASE</u>	<u>A074023 001</u>	Aug 22, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074023 002</u>	Aug 22, 1997
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180 001</u>	Jan 28, 1999
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075180 002</u>	Jan 28, 1999
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467 001</u>	Aug 29, 1997

## PRESCRIPTION DRUG PRODUCT LIST

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467 002</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A074488 001</u>	Jul 31, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074488 002</u>	Jul 31, 1997
<u>AB</u>	WOCKHARDT	<u>EQ 150MG BASE</u>	<u>A075208 001</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075208 002</u>	Dec 17, 1998
	<u>ZANTAC 150</u>			
<u>AB</u>	GLAXO GRP LTD	<u>EQ 150MG BASE</u>	<u>N018703 001</u>	Jun 09, 1983
	<u>ZANTAC 300</u>			
<u>AB</u>	+ GLAXO GRP LTD	<u>EQ 300MG BASE</u>	<u>N018703 002</u>	Dec 09, 1985

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

<u>AB</u>	+ GILEAD	<u>1GM</u>	<u>N021526 001</u>	Feb 12, 2007
<u>AB</u>		<u>500MG</u>	<u>N021526 002</u>	Jan 27, 2006
	<u>RANOLAZINE</u>			
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A201046 001</u>	Jul 29, 2013
<u>AB</u>		<u>1GM</u>	<u>A201046 002</u>	Jul 29, 2013

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

<u>AB</u>	TEVA	<u>EQ 0.5MG BASE</u>	<u>N021641 001</u>	May 16, 2006
<u>AB</u>	+	<u>EQ 1MG BASE</u>	<u>N021641 002</u>	May 16, 2006
	<u>RASAGILINE MESYLATE</u>			
<u>AB</u>	APOTEX INC	<u>EQ 0.5MG BASE</u>	<u>A201950 001</u>	Sep 12, 2013
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201950 002</u>	Sep 12, 2013

REGADENOSON

SOLUTION; INTRAVENOUS

LEXISCAN

+ ASTELLAS

0.4MG/5ML (0.08MG/ML)

N022161 001 Apr 10, 2008

REGORAFENIB

TABLET; ORAL

STIVARGA

+ BAYER HLTHCARE

40MG

N203085 001 Sep 27, 2012

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

MYLAN INSTITUTIONAL

EQ 1MG BASE/VIAL

N020630 001 Jul 12, 1996

EQ 2MG BASE/VIAL

N020630 002 Jul 12, 1996

+ EQ 5MG BASE/VIAL

N020630 003 Jul 12, 1996

REPAGLINIDE

TABLET; ORAL

PRANDIN

<u>AB</u>	NOVO NORDISK INC	<u>0.5MG</u>	<u>N020741 001</u>	Dec 22, 1997
<u>AB</u>		<u>1MG</u>	<u>N020741 002</u>	Dec 22, 1997
<u>AB</u>	+	<u>2MG</u>	<u>N020741 003</u>	Dec 22, 1997
	<u>REPAGLINIDE</u>			
<u>AB</u>	ACTAVIS TOTOWA	<u>0.5MG</u>	<u>A090008 001</u>	Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A090008 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090008 003</u>	Jan 22, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A203820 001</u>	Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A203820 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A203820 003</u>	Jan 22, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A090252 001</u>	Aug 23, 2013
<u>AB</u>		<u>1MG</u>	<u>A090252 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090252 003</u>	Jan 22, 2014
<u>AB</u>	PADDOCK LLC	<u>0.5MG</u>	<u>A201189 001</u>	Jul 17, 2013
<u>AB</u>		<u>1MG</u>	<u>A201189 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A201189 003</u>	Jan 22, 2014
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078555 001</u>	Nov 22, 2013
<u>AB</u>		<u>1MG</u>	<u>A078555 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A078555 003</u>	Jan 22, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>1MG</u>	<u>A077571 002</u>	Jul 11, 2013
<u>AB</u>		<u>2MG</u>	<u>A077571 003</u>	Jul 11, 2013

## PRESCRIPTION DRUG PRODUCT LIST

RESERPINE

TABLET; ORAL

RESERPINE

BP	SANDOZ	0.1MG	N009838	001	
BP	+	0.25MG	N009838	002	

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+ GLAXO GRP LTD

1%

N022055 001 Apr 12, 2007

RIBAVIRIN

CAPSULE; ORAL

REBETOL

<b>AB</b>	<b>+</b>	<b>MERCK SHARP DOHME</b>	<b>200MG</b>	<b>N020903</b>	<b>002</b>	Jul 25, 2001
-----------	----------	--------------------------	--------------	----------------	------------	--------------

RIBASPHERE

<b>AB</b>		<b>THREE RIVERS PHARMS</b>	<b>200MG</b>	<b>A076203</b>	<b>001</b>	Apr 06, 2004
-----------	--	----------------------------	--------------	----------------	------------	--------------

RIBAVARIN

<b>AB</b>		<b>AUROBINDO PHARMA</b>	<b>200MG</b>	<b>A079117</b>	<b>001</b>	Sep 17, 2009
-----------	--	-------------------------	--------------	----------------	------------	--------------

RIBAVIRIN

<b>AB</b>		<b>SANDOZ</b>	<b>200MG</b>	<b>A076192</b>	<b>001</b>	Apr 06, 2004
-----------	--	---------------	--------------	----------------	------------	--------------

<b>AB</b>		<b>TEVA</b>	<b>200MG</b>	<b>A076277</b>	<b>001</b>	Oct 04, 2004
-----------	--	-------------	--------------	----------------	------------	--------------

<b>AB</b>		<b>ZYDUS PHARMS USA</b>	<b>200MG</b>	<b>A077224</b>	<b>001</b>	Oct 28, 2005
-----------	--	-------------------------	--------------	----------------	------------	--------------

REBETOL

+ MERCK SHARP DOHME

200MG\*\*Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy\*\*

N020903 001 Jun 03, 1998

FOR SOLUTION; INHALATION

VIRAZOLE

+ VALEANT PHARM INTL

6GM/VIAL

N018859 001 Dec 31, 1985

SOLUTION; ORAL

REBETOL

+ SCHERING

40MG/ML

N021546 001 Jul 29, 2003

TABLET; ORAL

COPEGUS

<b>AB</b>		<b>ROCHE</b>	<b>200MG</b>	<b>N021511</b>	<b>001</b>	Dec 03, 2002
-----------	--	--------------	--------------	----------------	------------	--------------

RIBAVIRIN

<b>AB</b>		<b>AUROBINDO PHARMA</b>	<b>200MG</b>	<b>A079111</b>	<b>001</b>	Sep 17, 2009
-----------	--	-------------------------	--------------	----------------	------------	--------------

<b>AB</b>		<b>SANDOZ</b>	<b>200MG</b>	<b>A077743</b>	<b>001</b>	Oct 03, 2006
-----------	--	---------------	--------------	----------------	------------	--------------

<b>AB</b>			<b>200MG</b>	<b>A202546</b>	<b>001</b>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<b>AB</b>			<b>400MG</b>	<b>A202546</b>	<b>002</b>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<b>AB</b>			<b>500MG</b>	<b>A202546</b>	<b>003</b>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<b>AB</b>			<b>600MG</b>	<b>A202546</b>	<b>004</b>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<b>AB</b>		<b>TEVA</b>	<b>200MG</b>	<b>A077053</b>	<b>001</b>	Dec 05, 2005
-----------	--	-------------	--------------	----------------	------------	--------------

<b>AB</b>		<b>THREE RIVERS PHARMS</b>	<b>200MG</b>	<b>A077456</b>	<b>001</b>	Dec 05, 2005
-----------	--	----------------------------	--------------	----------------	------------	--------------

<b>AB</b>			<b>400MG</b>	<b>A077456</b>	<b>002</b>	Dec 05, 2005
-----------	--	--	--------------	----------------	------------	--------------

<b>AB</b>	<b>+</b>		<b>600MG</b>	<b>A077456</b>	<b>003</b>	Dec 05, 2005
-----------	----------	--	--------------	----------------	------------	--------------

<b>AB</b>		<b>ZYDUS PHARMS USA</b>	<b>200MG</b>	<b>A077094</b>	<b>001</b>	Dec 05, 2005
-----------	--	-------------------------	--------------	----------------	------------	--------------

<b>AB</b>			<b>400MG</b>	<b>A077094</b>	<b>002</b>	Mar 16, 2007
-----------	--	--	--------------	----------------	------------	--------------

<b>AB</b>			<b>500MG</b>	<b>A077094</b>	<b>004</b>	Apr 18, 2008
-----------	--	--	--------------	----------------	------------	--------------

<b>AB</b>			<b>600MG</b>	<b>A077094</b>	<b>003</b>	Mar 16, 2007
-----------	--	--	--------------	----------------	------------	--------------

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN

<b>AB</b>	<b>+</b>	<b>PHARMACIA AND UPJOHN</b>	<b>150MG</b>	<b>N050689</b>	<b>001</b>	Dec 23, 1992
-----------	----------	-----------------------------	--------------	----------------	------------	--------------

RIFABUTIN

<b>AB</b>		<b>LUPIN LTD</b>	<b>150MG</b>	<b>A090033</b>	<b>001</b>	Feb 24, 2014
-----------	--	------------------	--------------	----------------	------------	--------------

RIFAMPIN

CAPSULE; ORAL

RIFADIN

<b>AB</b>		<b>SANOFI AVENTIS US</b>	<b>150MG</b>	<b>A062303</b>	<b>001</b>	
-----------	--	--------------------------	--------------	----------------	------------	--

<b>AB</b>	<b>+</b>		<b>300MG</b>	<b>N050420</b>	<b>001</b>	
-----------	----------	--	--------------	----------------	------------	--

RIFAMPIN

<b>AB</b>		<b>LANNETT</b>	<b>150MG</b>	<b>A065390</b>	<b>001</b>	Mar 28, 2008
-----------	--	----------------	--------------	----------------	------------	--------------

<b>AB</b>			<b>300MG</b>	<b>A065390</b>	<b>002</b>	Mar 28, 2008
-----------	--	--	--------------	----------------	------------	--------------

<b>AB</b>		<b>LUPIN PHARMS</b>	<b>150MG</b>	<b>A090034</b>	<b>001</b>	Aug 21, 2013
-----------	--	---------------------	--------------	----------------	------------	--------------

<b>AB</b>			<b>300MG</b>	<b>A090034</b>	<b>002</b>	Aug 21, 2013
-----------	--	--	--------------	----------------	------------	--------------

<b>AB</b>		<b>SANDOZ</b>	<b>150MG</b>	<b>A064150</b>	<b>002</b>	Jan 02, 1998
-----------	--	---------------	--------------	----------------	------------	--------------

<b>AB</b>			<b>300MG</b>	<b>A064150</b>	<b>001</b>	May 28, 1997
-----------	--	--	--------------	----------------	------------	--------------

<b>AB</b>		<b>VERSAPHARM</b>	<b>150MG</b>	<b>A065028</b>	<b>001</b>	Mar 14, 2001
-----------	--	-------------------	--------------	----------------	------------	--------------

<b>AB</b>			<b>300MG</b>	<b>A065028</b>	<b>002</b>	Mar 14, 2001
-----------	--	--	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

<b>AB</b>	PROSAM LABS	<b>300MG</b>	<b>N050429</b>	<b>001</b>	
-----------	-------------	--------------	----------------	------------	--

INJECTABLE; INJECTION

RIFADIN

<b>AP</b>	+ SANOFI AVENTIS US	<b>600MG/VIAL</b>	<b>N050627</b>	<b>001</b>	May 25, 1989
-----------	---------------------	-------------------	----------------	------------	--------------

RIFAMPIN

<b>AP</b>	AGILA SPEC LTS	<b>600MG/VIAL</b>	<b>A065421</b>	<b>001</b>	May 22, 2008
<b>AP</b>	BEDFORD	<b>600MG/VIAL</b>	<b>A064217</b>	<b>001</b>	Oct 29, 1999
<b>AP</b>	EMCURE PHARMS LTD	<b>600MG/VIAL</b>	<b>A204101</b>	<b>001</b>	Aug 18, 2014
<b>AP</b>	FRESENIUS KABI USA	<b>600MG/VIAL</b>	<b>A091181</b>	<b>001</b>	Aug 21, 2014
<b>AP</b>	VERSAPHARM INC	<b>600MG/VIAL</b>	<b>A065502</b>	<b>001</b>	Sep 21, 2010

RIFAPENTINE

TABLET; ORAL

PRIFTIN

	+ SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998
--	---------------------	-------	---------	-----	--------------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

	+ SALIX PHARMS	200MG	N021361	001	May 25, 2004
--	----------------	-------	---------	-----	--------------

	+	550MG	N022554	001	Mar 24, 2010
--	---	-------	---------	-----	--------------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

	+ JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011
--	-----------------	--------------	---------	-----	--------------

RILUZOLE

TABLET; ORAL

RILUTEK

<b>AB</b>	+ COVIS PHARMA SARL	<b>50MG</b>	<b>N020599</b>	<b>001</b>	Dec 12, 1995
-----------	---------------------	-------------	----------------	------------	--------------

RILUZOLE

<b>AB</b>	APOTEX CORP	<b>50MG</b>	<b>A091300</b>	<b>001</b>	Jun 18, 2013
<b>AB</b>	GLENMARK GENERICS	<b>50MG</b>	<b>A091394</b>	<b>001</b>	Jun 18, 2013
<b>AB</b>	IMPAX LABS	<b>50MG</b>	<b>A076173</b>	<b>001</b>	Jan 29, 2003
<b>AB</b>	MYLAN PHARMS INC	<b>50MG</b>	<b>A203042</b>	<b>001</b>	Jul 01, 2013
<b>AB</b>	SUN PHARM INDS LTD	<b>50MG</b>	<b>A091417</b>	<b>001</b>	Jun 18, 2013

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

<b>AB</b>	+ CARACO	<b>100MG</b>	<b>N019649</b>	<b>001</b>	Sep 17, 1993
-----------	----------	--------------	----------------	------------	--------------

RIMANTADINE HYDROCHLORIDE

<b>AB</b>	IMPAX LABS	<b>100MG</b>	<b>A076132</b>	<b>001</b>	Aug 30, 2002
-----------	------------	--------------	----------------	------------	--------------

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

	+ ALCON	1%	N020474	001	Dec 30, 1994
--	---------	----	---------	-----	--------------

RIOCIGUAT

TABLET; ORAL

ADEMPAS

	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013
--	----------------	-------	---------	-----	--------------

		1MG	N204819	002	Oct 08, 2013
--	--	-----	---------	-----	--------------

		1.5MG	N204819	003	Oct 08, 2013
--	--	-------	---------	-----	--------------

		2MG	N204819	004	Oct 08, 2013
--	--	-----	---------	-----	--------------

	+	2.5MG	N204819	005	Oct 08, 2013
--	---	-------	---------	-----	--------------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

<b>AB</b>	WARNER CHILCOTT LLC	<b>5MG</b>	<b>N020835</b>	<b>002</b>	Apr 14, 2000
-----------	---------------------	------------	----------------	------------	--------------

<b>AB</b>		<b>30MG</b>	<b>N020835</b>	<b>001</b>	Mar 27, 1998
-----------	--	-------------	----------------	------------	--------------

<b>AB</b>	+	<b>35MG</b>	<b>N020835</b>	<b>003</b>	May 25, 2002
-----------	---	-------------	----------------	------------	--------------

<b>AB</b>	+	<b>150MG</b>	<b>N020835</b>	<b>005</b>	Apr 22, 2008
-----------	---	--------------	----------------	------------	--------------

RISEDRONATE SODIUM

<b>AB</b>	APOTEX INC	<b>75MG</b>	<b>A090877</b>	<b>002</b>	Jun 10, 2014
-----------	------------	-------------	----------------	------------	--------------

<b>AB</b>		<b>150MG</b>	<b>A090877</b>	<b>003</b>	Jun 10, 2014
-----------	--	--------------	----------------	------------	--------------

<b>AB</b>	MYLAN PHARMS INC	<b>75MG</b>	<b>A200477</b>	<b>004</b>	Jun 10, 2014
-----------	------------------	-------------	----------------	------------	--------------

<b>AB</b>		<b>150MG</b>	<b>A200477</b>	<b>005</b>	Jun 10, 2014
-----------	--	--------------	----------------	------------	--------------

<b>AB</b>	SUN PHARMA GLOBAL	<b>75MG</b>	<b>A090886</b>	<b>004</b>	Jun 10, 2014
-----------	-------------------	-------------	----------------	------------	--------------

<b>AB</b>		<b>150MG</b>	<b>A090886</b>	<b>005</b>	Jun 10, 2014
-----------	--	--------------	----------------	------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

RISEDRONATE SODIUM

TABLET; ORAL

RISEDRONATE SODIUM

<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077132</u>	<u>001</u>	Oct 05, 2007
<u>AB</u>		<u>30MG</u>	<u>A077132</u>	<u>002</u>	Oct 05, 2007
<u>AB</u>		<u>35MG</u>	<u>A077132</u>	<u>003</u>	Oct 05, 2007
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A079215</u>	<u>001</u>	Jun 13, 2014

TABLET, DELAYED RELEASE; ORAL

ATELVIA

+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010
---	---------------------	------	---------	-----	--------------

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007
+		25MG/VIAL	N021346	001	Oct 29, 2003
		37.5MG/VIAL	N021346	002	Oct 29, 2003
		50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION; ORAL

RISPERDAL

<u>AA</u>	+	JANSSEN PHARMS	<u>1MG/ML</u>	<u>N020588</u>	<u>001</u>	Jun 10, 1996
-----------	---	----------------	---------------	----------------	------------	--------------

RISPERIDONE

<u>AA</u>	AMNEAL PHARMS	<u>1MG/ML</u>	<u>A091384</u>	<u>001</u>	May 25, 2011
<u>AA</u>	ANI PHARMS INC	<u>1MG/ML</u>	<u>A076440</u>	<u>001</u>	Jan 30, 2009
<u>AA</u>	APOTEX INC	<u>1MG/ML</u>	<u>A077719</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A078452</u>	<u>001</u>	Sep 04, 2009
<u>AA</u>	BIO PHARM INC	<u>1MG/ML</u>	<u>A078909</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>	PRECISION DOSE	<u>1MG/ML</u>	<u>A076797</u>	<u>001</u>	Jun 28, 2010
<u>AA</u>	ROXANE	<u>1MG/ML</u>	<u>A076904</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>	SILARX PHARMS INC	<u>1MG/ML</u>	<u>A202386</u>	<u>001</u>	Jan 12, 2015
<u>AA</u>	TARO	<u>1MG/ML</u>	<u>A090347</u>	<u>001</u>	Feb 07, 2011
<u>AA</u>	TRIS PHARMA INC	<u>1MG/ML</u>	<u>A079059</u>	<u>001</u>	Dec 12, 2012
<u>AA</u>	VINTAGE	<u>1MG/ML</u>	<u>A079158</u>	<u>001</u>	Dec 03, 2010
<u>AA</u>	WOCKHARDT	<u>1MG/ML</u>	<u>A078744</u>	<u>001</u>	Oct 08, 2009

TABLET; ORAL

RISPERDAL

<u>AB</u>	JANSSEN PHARMS	<u>0.25MG</u>	<u>N020272</u>	<u>008</u>	May 10, 1999
<u>AB</u>		<u>0.5MG</u>	<u>N020272</u>	<u>007</u>	Jan 27, 1999
<u>AB</u>	+	<u>1MG</u>	<u>N020272</u>	<u>001</u>	Dec 29, 1993
<u>AB</u>		<u>2MG</u>	<u>N020272</u>	<u>002</u>	Dec 29, 1993
<u>AB</u>		<u>3MG</u>	<u>N020272</u>	<u>003</u>	Dec 29, 1993
<u>AB</u>		<u>4MG</u>	<u>N020272</u>	<u>004</u>	Dec 29, 1993

RISPERIDONE

<u>AB</u>	AJANTA PHARMA LTD	<u>0.25MG</u>	<u>A201003</u>	<u>001</u>	Aug 24, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A201003</u>	<u>002</u>	Aug 24, 2011
<u>AB</u>		<u>1MG</u>	<u>A201003</u>	<u>003</u>	Aug 24, 2011
<u>AB</u>		<u>2MG</u>	<u>A201003</u>	<u>004</u>	Aug 24, 2011
<u>AB</u>		<u>3MG</u>	<u>A201003</u>	<u>005</u>	Aug 24, 2011
<u>AB</u>		<u>4MG</u>	<u>A201003</u>	<u>006</u>	Aug 24, 2011
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077953</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077953</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A077953</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A077953</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A077953</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A077953</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>0.25MG</u>	<u>A078269</u>	<u>001</u>	Oct 08, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078269</u>	<u>002</u>	Oct 08, 2008
<u>AB</u>		<u>1MG</u>	<u>A078269</u>	<u>003</u>	Oct 08, 2008
<u>AB</u>		<u>2MG</u>	<u>A078269</u>	<u>004</u>	Oct 08, 2008
<u>AB</u>		<u>3MG</u>	<u>A078269</u>	<u>005</u>	Oct 08, 2008
<u>AB</u>		<u>4MG</u>	<u>A078269</u>	<u>006</u>	Oct 08, 2008
<u>AB</u>	CIPLA	<u>0.25MG</u>	<u>A077543</u>	<u>001</u>	May 18, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077543</u>	<u>002</u>	May 18, 2011
<u>AB</u>		<u>1MG</u>	<u>A077543</u>	<u>003</u>	May 18, 2011
<u>AB</u>		<u>2MG</u>	<u>A077543</u>	<u>004</u>	May 18, 2011
<u>AB</u>		<u>3MG</u>	<u>A077543</u>	<u>005</u>	May 18, 2011
<u>AB</u>		<u>4MG</u>	<u>A077543</u>	<u>006</u>	May 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>0.25MG</u>	<u>A076879</u>	<u>001</u>	Oct 24, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076879</u>	<u>002</u>	Oct 24, 2008
<u>AB</u>		<u>1MG</u>	<u>A076879</u>	<u>003</u>	Oct 24, 2008
<u>AB</u>		<u>2MG</u>	<u>A076879</u>	<u>004</u>	Oct 24, 2008
<u>AB</u>		<u>3MG</u>	<u>A076879</u>	<u>005</u>	Oct 24, 2008
<u>AB</u>		<u>4MG</u>	<u>A076879</u>	<u>006</u>	Oct 24, 2008

## PRESCRIPTION DRUG PRODUCT LIST

## RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A076288</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076288</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A076288</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A076288</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A076288</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A076288</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.25MG</u>	<u>A077769</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077769</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A077769</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A077769</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A077769</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A077769</u>	<u>006</u>	Oct 16, 2008
<u>AB</u>	PRINSTON INC	<u>0.25MG</u>	<u>A077493</u>	<u>001</u>	Nov 29, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077493</u>	<u>002</u>	Nov 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A077493</u>	<u>003</u>	Nov 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A077493</u>	<u>004</u>	Nov 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A077493</u>	<u>005</u>	Nov 29, 2011
<u>AB</u>		<u>4MG</u>	<u>A077493</u>	<u>006</u>	Nov 29, 2011
<u>AB</u>	PROSAM LABS	<u>0.25MG</u>	<u>A078071</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078071</u>	<u>002</u>	Jun 17, 2009
<u>AB</u>		<u>1MG</u>	<u>A078071</u>	<u>003</u>	Jun 17, 2009
<u>AB</u>		<u>2MG</u>	<u>A078071</u>	<u>004</u>	Jun 17, 2009
<u>AB</u>		<u>3MG</u>	<u>A078071</u>	<u>005</u>	Jun 17, 2009
<u>AB</u>		<u>4MG</u>	<u>A078071</u>	<u>006</u>	Jun 17, 2009
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A078528</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078528</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>		<u>1MG</u>	<u>A078528</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>2MG</u>	<u>A078528</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	SUN PHARM INDS INC	<u>0.25MG</u>	<u>A078036</u>	<u>001</u>	Mar 10, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078036</u>	<u>002</u>	Mar 10, 2014
<u>AB</u>		<u>1MG</u>	<u>A078036</u>	<u>003</u>	Mar 10, 2014
<u>AB</u>		<u>2MG</u>	<u>A078036</u>	<u>004</u>	Mar 10, 2014
<u>AB</u>		<u>3MG</u>	<u>A078036</u>	<u>005</u>	Mar 10, 2014
<u>AB</u>		<u>4MG</u>	<u>A078036</u>	<u>006</u>	Mar 10, 2014
<u>AB</u>	TEVA	<u>0.25MG</u>	<u>A076228</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076228</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A076228</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A076228</u>	<u>004</u>	Jun 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A076228</u>	<u>005</u>	Jun 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A076228</u>	<u>006</u>	Jun 30, 2008
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078707</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078707</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>1MG</u>	<u>A078707</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>2MG</u>	<u>A078707</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>3MG</u>	<u>A078707</u>	<u>005</u>	Dec 29, 2008
<u>AB</u>		<u>4MG</u>	<u>A078707</u>	<u>006</u>	Dec 29, 2008
<u>AB</u>	WOCKHARDT	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

<u>AB</u>	JANSSEN PHARMS	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
-----------	----------------	--------------	----------------	------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERDAL

<u>AB</u>	+	<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A076996</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>1MG</u>	<u>A076996</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>2MG</u>	<u>A076996</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>		<u>3MG</u>	<u>A076996</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>		<u>4MG</u>	<u>A076996</u>	<u>005</u>	Apr 19, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>	JUBILANT GENERICS	<u>0.5MG</u>	<u>A090839</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>		<u>1MG</u>	<u>A090839</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		<u>2MG</u>	<u>A090839</u>	<u>003</u>	Nov 04, 2011
<u>AB</u>		<u>3MG</u>	<u>A090839</u>	<u>004</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A090839</u>	<u>005</u>	Nov 04, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>0.25MG</u>	<u>A091537</u>	<u>006</u>	Feb 12, 2013
<u>AB</u>		<u>0.5MG</u>	<u>A091537</u>	<u>001</u>	Mar 30, 2011
<u>AB</u>		<u>1MG</u>	<u>A091537</u>	<u>002</u>	Mar 30, 2011
<u>AB</u>		<u>2MG</u>	<u>A091537</u>	<u>003</u>	Mar 30, 2011
<u>AB</u>		<u>3MG</u>	<u>A091537</u>	<u>004</u>	Mar 30, 2011
<u>AB</u>		<u>4MG</u>	<u>A091537</u>	<u>005</u>	Mar 30, 2011
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A077494</u>	<u>001</u>	Apr 30, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	RANBAXY	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		<u>2MG</u>	<u>A077542</u>	<u>003</u>	Aug 06, 2010
<u>AB</u>		<u>3MG</u>	<u>A078474</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>4MG</u>	<u>A078474</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A078464</u>	<u>001</u>	Apr 08, 2013
<u>AB</u>		<u>1MG</u>	<u>A078464</u>	<u>002</u>	Apr 08, 2013
<u>AB</u>		<u>2MG</u>	<u>A078464</u>	<u>003</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078464</u>	<u>004</u>	Apr 08, 2013
<u>AB</u>		<u>4MG</u>	<u>A078464</u>	<u>005</u>	Apr 08, 2013
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A076908</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		<u>1MG</u>	<u>A076908</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>		<u>2MG</u>	<u>A076908</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516</u>	<u>001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516</u>	<u>003</u>	May 01, 2009

RITONAVIR

CAPSULE;ORAL

NORVIR

+ ABBVIE

100MG

N020945 001 Jun 29, 1999

SOLUTION;ORAL

NORVIR

+ ABBVIE

80MG/ML

N020659 001 Mar 01, 1996

TABLET;ORAL

NORVIRAB + ABBVIE100MGN022417 001 Feb 10, 2010RITONAVIRAB ROXANE100MGA202573 001 Jan 15, 2015

## PRESCRIPTION DRUG PRODUCT LIST

RIVAROXABAN

TABLET;ORAL

XARELTO

+	JANSSEN PHARMS	10MG	N022406	001	Jul 01, 2011
		15MG	N022406	002	Nov 04, 2011
+		20MG	N022406	003	Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

	NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007
+		9.5MG/24HR	N022083	002	Jul 06, 2007
		13.3MG/24HR	N022083	005	Aug 31, 2012

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

EXELON

<u>AB</u>	+	NOVARTIS	<u>EQ 1.5MG BASE</u>	<u>N020823</u>	<u>003</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>N020823</u>	<u>004</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>N020823</u>	<u>005</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>N020823</u>	<u>006</u>	Apr 21, 2000

RIVASTIGMINE TARTRATE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A091689</u>	<u>001</u>	Jun 12, 2012
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A091689</u>	<u>002</u>	Jun 12, 2012
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A091689</u>	<u>003</u>	Jun 12, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A091689</u>	<u>004</u>	Jun 12, 2012
<u>AB</u>		APOTEX INC	<u>EQ 1.5MG BASE</u>	<u>A091072</u>	<u>001</u>	May 16, 2013
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A091072</u>	<u>002</u>	May 16, 2013
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A091072</u>	<u>003</u>	May 16, 2013
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A091072</u>	<u>004</u>	May 16, 2013
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 1.5MG BASE</u>	<u>A077130</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A077130</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A077130</u>	<u>003</u>	Oct 31, 2007
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A077130</u>	<u>004</u>	Oct 31, 2007
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A203148</u>	<u>001</u>	Aug 22, 2014
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A203148</u>	<u>002</u>	Aug 22, 2014
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A203148</u>	<u>003</u>	Aug 22, 2014
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A203148</u>	<u>004</u>	Aug 22, 2014
<u>AB</u>		SUN PHARM INDS	<u>EQ 1.5MG BASE</u>	<u>A077131</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A077131</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A077131</u>	<u>003</u>	Oct 22, 2007
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A077131</u>	<u>004</u>	Oct 22, 2007
<u>AB</u>		WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>A077129</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>A077129</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A077129</u>	<u>004</u>	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

<u>AB</u>		MERCK	<u>EQ 5MG BASE</u>	<u>N020864</u>	<u>001</u>	Jun 29, 1998
<u>AB</u>	+		<u>EQ 10MG BASE</u>	<u>N020864</u>	<u>002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>		APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202244</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A202244</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202490</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A202490</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		CIPLA LTD	<u>EQ 5MG BASE</u>	<u>A077526</u>	<u>001</u>	Mar 26, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A077526</u>	<u>002</u>	Mar 26, 2013
<u>AB</u>		EMCURE PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A204090</u>	<u>001</u>	Nov 26, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A204090</u>	<u>002</u>	Nov 26, 2013
<u>AB</u>		GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201967</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A201967</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A204339</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A204339</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>		JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203252</u>	<u>001</u>	Dec 31, 2014
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203252</u>	<u>002</u>	Dec 31, 2014
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203147</u>	<u>001</u>	Feb 11, 2014
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203147</u>	<u>002</u>	Feb 11, 2014
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A201993</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A201993</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A200482</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A200482</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		SANDOZ	<u>EQ 5MG BASE</u>	<u>A079230</u>	<u>001</u>	Dec 31, 2012

## PRESCRIPTION DRUG PRODUCT LIST

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079230 002</u>	Dec 31, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A202047 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202047 002</u>	Dec 31, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A077263 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077263 002</u>	Dec 31, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

<u>AB</u>	MERCK	<u>EQ 5MG BASE</u>	<u>N020865 001</u>	Jun 29, 1998
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020865 002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202477 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202477 002</u>	Jul 01, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203062 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203062 002</u>	Jul 01, 2013
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201914 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201914 002</u>	Jul 01, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203146 001</u>	Sep 19, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203146 002</u>	Sep 19, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A078173 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078173 002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203478 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203478 002</u>	Jul 01, 2013
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A078739 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078739 002</u>	Jul 01, 2013

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A078651 001</u>	Dec 29, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078651 002</u>	Dec 29, 2008
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078519 002</u>	Nov 26, 2008
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A079199 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079199 002</u>	Nov 26, 2008
<u>AP</u>	SAGENT STRIDES	<u>50MG/5ML (10MG/ML)</u>	<u>A091458 001</u>	Jul 28, 2010
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091458 002</u>	Jul 28, 2010
<u>AP</u>	+	<u>50MG/5ML (10MG/ML)</u>	<u>A079195 001</u>	Dec 05, 2008
<u>AP</u>	+	<u>100MG/10ML (10MG/ML)</u>	<u>A079195 002</u>	Dec 05, 2008
<u>AP</u>	TAMARANG	<u>50MG/5ML (10MG/ML)</u>	<u>A091115 001</u>	Aug 27, 2012
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091115 002</u>	Aug 27, 2012
<u>AP</u>	TEVA PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A078717 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078717 002</u>	Nov 26, 2008

ROFLUMILAST

TABLET; ORAL

DALIRESP

	+	FOREST RES INST INC	500MCG	N022522 001	Feb 28, 2011
--	---	---------------------	--------	-------------	--------------

ROMIDEPSIN

POWDER; IV (INFUSION)

ISTODAX

	+	CELGENE	10MG/VIAL	N022393 001	Nov 05, 2009
--	---	---------	-----------	-------------	--------------

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>EQ 0.25MG BASE</u>	<u>N020658 001</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>N020658 002</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>N020658 003</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>N020658 004</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>N020658 006</u>	Jan 27, 1999
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>N020658 007</u>	Jan 27, 1999
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>N020658 005</u>	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ALEMBIC LTD	<u>EQ 0.25MG BASE</u>	<u>A090429 001</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090429 002</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090429 003</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090429 004</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090429 005</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090429 006</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090429 007</u>	Mar 24, 2010

## PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 0.25MG BASE</u>	<u>A079165 001</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079165 002</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079165 003</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079165 004</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079165 005</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079165 006</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079165 007</u>	Feb 07, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.25MG BASE</u>	<u>A090135 001</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090135 002</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090135 003</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090135 004</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090135 005</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090135 006</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090135 007</u>	Feb 25, 2010
<u>AB</u>	MYLAN	<u>EQ 0.25MG BASE</u>	<u>A078881 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078881 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078881 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881 007</u>	May 19, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.25MG BASE</u>	<u>A079229 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079229 002</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079229 003</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079229 004</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079229 005</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079229 006</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079229 007</u>	Nov 28, 2012
<u>AB</u>	PRINSTON INC	<u>EQ 0.25MG BASE</u>	<u>A078110 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078110 007</u>	Jul 11, 2008
<u>AB</u>	ROXANE	<u>EQ 0.25MG BASE</u>	<u>A077852 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077852 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077852 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077852 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077852 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077852 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077852 007</u>	May 19, 2008
<u>AB</u>	TEVA	<u>EQ 0.25MG BASE</u>	<u>A077460 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077460 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077460 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077460 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077460 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077460 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077460 007</u>	May 19, 2008
<u>AB</u>	WOCKHARDT	<u>EQ 0.25MG BASE</u>	<u>A079050 001</u>	May 29, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079050 002</u>	May 29, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079050 003</u>	May 29, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079050 004</u>	May 29, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079050 005</u>	May 29, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079050 006</u>	May 29, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079050 007</u>	May 29, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 0.25MG BASE</u>	<u>A090411 001</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090411 002</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090411 003</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090411 004</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090411 005</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090411 006</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090411 007</u>	Jun 01, 2009

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 2MG BASE</u>	<u>N022008 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N022008 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>N022008 006</u>	Apr 10, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N022008 004</u>	Jun 13, 2008

## PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

<u>AB</u>		<u>EQ 12MG BASE</u>	<u>N022008 005</u>	Oct 31, 2008
	<u>ROPINIROLE HYDROCHLORIDE</u>			
<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090869 001</u>	May 17, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090869 002</u>	May 17, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090869 003</u>	May 17, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090869 004</u>	May 17, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A090869 005</u>	May 17, 2012
<u>AB</u>	ALEMBIC LTD	<u>EQ 2MG BASE</u>	<u>A202786 001</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202786 002</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202786 003</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A202786 004</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A202786 005</u>	Apr 22, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2MG BASE</u>	<u>A201576 001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201576 002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201576 003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201576 004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201576 005</u>	Jun 06, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A200462 001</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200462 003</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A200462 004</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A200462 005</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200462 006</u>	Oct 15, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A201047 001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201047 003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201047 004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201047 005</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201047 006</u>	Jun 06, 2012
<u>AB</u>	WATSON LABS INC	<u>EQ 2MG BASE</u>	<u>A200431 001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200431 002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A200431 003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A200431 004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200431 005</u>	Jun 06, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 2MG BASE</u>	<u>A091395 001</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091395 002</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091395 003</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A091395 004</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A091395 005</u>	Aug 27, 2012
<u>AB</u>	MYLAN PHARMS INC	EQ 3MG BASE	A200462 002	Oct 15, 2012

ROPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NAROPIN

<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>N020533 001</u>	Sep 24, 1996
<u>AP</u>		<u>5MG/ML</u>	<u>N020533 003</u>	Sep 24, 1996
<u>AP</u>		<u>7.5MG/ML</u>	<u>N020533 004</u>	Sep 24, 1996
<u>AP</u>	+	<u>10MG/ML</u>	<u>N020533 005</u>	Sep 24, 1996
	<u>ROPIVACAINE HYDROCHLORIDE</u>			
<u>AP</u>	HOSPIRA	<u>2MG/ML</u>	<u>A090194 001</u>	Sep 23, 2014
<u>AP</u>		<u>5MG/ML</u>	<u>A090194 002</u>	Sep 23, 2014
<u>AP</u>		<u>7.5MG/ML</u>	<u>A090194 003</u>	Sep 23, 2014
<u>AP</u>		<u>10MG/ML</u>	<u>A090194 004</u>	Sep 23, 2014
<u>AP</u>	NAVINTA LLC	<u>5MG/ML</u>	<u>A078601 002</u>	Jul 17, 2014
<u>AP</u>		<u>10MG/ML</u>	<u>A078601 003</u>	Jul 17, 2014
<u>AP</u>	SAGENT STRIDES	<u>2MG/ML</u>	<u>A090318 001</u>	Sep 23, 2014
<u>AP</u>		<u>5MG/ML</u>	<u>A090318 002</u>	Sep 23, 2014
<u>AP</u>		<u>7.5MG/ML</u>	<u>A090318 003</u>	Sep 23, 2014
<u>AP</u>		<u>10MG/ML</u>	<u>A090318 004</u>	Sep 23, 2014

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

<u>AB</u>	SB PHARMCO	<u>EQ 2MG BASE</u>	<u>N021071 002</u>	May 25, 1999
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N021071 003</u>	May 25, 1999
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>N021071 004</u>	May 25, 1999
	<u>ROSIGLITAZONE MALEATE</u>			
<u>AB</u>	TEVA	<u>EQ 2MG BASE</u>	<u>A076747 001</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076747 002</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076747 003</u>	Jan 25, 2013

## PRESCRIPTION DRUG PRODUCT LIST

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

IPR

5MG

N021366 002 Aug 12, 2003

10MG

N021366 003 Aug 12, 2003

20MG

N021366 004 Aug 12, 2003

+

40MG

N021366 005 Aug 12, 2003

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

UCB INC

1MG/24HR

N021829 004 Apr 02, 2012

+

2MG/24HR

N021829 001 May 09, 2007

3MG/24HR

N021829 005 Apr 02, 2012

4MG/24HR

N021829 002 May 09, 2007

6MG/24HR

N021829 003 May 09, 2007

8MG/24HR

N021829 006 Apr 02, 2012

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82

BRACCO

N/A

N019414 001 Dec 29, 1989

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+ EISAI INC

40MG/ML

N201367 001 Mar 03, 2011

TABLET; ORAL

BANZEL

EISAI INC

200MG

N021911 002 Nov 14, 2008

+

400MG

N021911 003 Nov 14, 2008

RUXOLITINIB PHOSPHATE

TABLET; ORAL

JAKAFI

INCYTE CORP

EQ 5MG BASE

N202192 001 Nov 16, 2011

EQ 10MG BASE

N202192 002 Nov 16, 2011

EQ 15MG BASE

N202192 003 Nov 16, 2011

EQ 20MG BASE

N202192 004 Nov 16, 2011

+

EQ 25MG BASE

N202192 005 Nov 16, 2011

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+ QOL MEDCL

8,500 IU/ML

N020772 001 Apr 09, 1998

SALMETEROL XINAFOATE

POWDER; INHALATION

SEREVENT

+ GLAXOSMITHKLINE

EQ 0.05MG BASE/INH

N020692 001 Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+ LANTHEUS MEDICAL

50mCi/ML

N020570 001 Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN

+ BIOMARIN PHARM

100MG/PACKET

N205065 001 Dec 19, 2013

TABLET; ORAL

KUVAN

+ BIOMARIN PHARM

100MG

N022181 001 Dec 13, 2007

SAQUINAVIR MESYLATE

CAPSULE; ORAL

INVIRASE

+ HOFFMANN LA ROCHE

EQ 200MG BASE

N020628 001 Dec 06, 1995

TABLET; ORAL

INVIRASE

+ HOFFMAN LA ROCHE

EQ 500MG BASE

N021785 001 Dec 17, 2004

## PRESCRIPTION DRUG PRODUCT LIST

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

ASTRAZENECA AB	EQ 2.5MG BASE	N022350 001	Jul 31, 2009
+	EQ 5MG BASE	N022350 002	Jul 31, 2009

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

TRANSDERM SCOP

NOVARTIS	1MG/72HR	N017874 001	
----------	----------	-------------	--

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

MARATHON PHARMS	50MG	A086101 001	Oct 03, 1983
+	100MG	A086101 002	Oct 03, 1983

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

CHIRHOCLIN	16MCG/VIAL	N021256 001	Apr 09, 2004
	40MCG/VIAL	N021256 002	Jun 21, 2007

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

SOMERSET	6MG/24HR	N021336 001	Feb 27, 2006
	9MG/24HR	N021336 002	Feb 27, 2006
	12MG/24HR	N021336 003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYL

<b>AB</b>	+	SOMERSET	<b>5MG</b>	<b>N020647 001</b>	May 15, 1996
-----------	---	----------	------------	--------------------	--------------

SELEGILINE HYDROCHLORIDE

<b>AB</b>		APOTEX	<b>5MG</b>	<b>A075321 001</b>	Dec 04, 1998
-----------	--	--------	------------	--------------------	--------------

<b>AB</b>		DAVA PHARMS INC	<b>5MG</b>	<b>A075352 001</b>	Nov 30, 1998
-----------	--	-----------------	------------	--------------------	--------------

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

<b>AB</b>	+	APOTEX INC	<b>5MG</b>	<b>A074871 001</b>	Jun 06, 1997
-----------	---	------------	------------	--------------------	--------------

<b>AB</b>		MYLAN	<b>5MG</b>	<b>A074866 001</b>	Nov 26, 1997
-----------	--	-------	------------	--------------------	--------------

<b>AB</b>		STASON	<b>5MG</b>	<b>A074912 001</b>	Apr 30, 1998
-----------	--	--------	------------	--------------------	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

ZELAPAR

VALEANT PHARM INTL	1.25MG	N021479 001	Jun 14, 2006
--------------------	--------	-------------	--------------

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

<b>AT</b>		PERRIGO NEW YORK	<b>2.5%</b>	<b>A089996 001</b>	Jan 10, 1991
-----------	--	------------------	-------------	--------------------	--------------

<b>AT</b>		WOCKHARDT	<b>2.5%</b>	<b>A088228 001</b>	Sep 01, 1983
-----------	--	-----------	-------------	--------------------	--------------

SELSUN

<b>AT</b>	+	CHATTEM	<b>2.5%</b>	<b>N007936 001</b>	
-----------	---	---------	-------------	--------------------	--

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

VALEANT LUXEMBOURG	2%	N021385 001	Dec 10, 2003
--------------------	----	-------------	--------------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

<b>AA</b>		AUROBINDO PHARMA	<b>EQ 20MG BASE/ML</b>	<b>A078861 001</b>	Oct 31, 2008
-----------	--	------------------	------------------------	--------------------	--------------

ZOLOFT

<b>AA</b>	+	PFIZER	<b>EQ 20MG BASE/ML</b>	<b>N020990 001</b>	Dec 07, 1999
-----------	---	--------	------------------------	--------------------	--------------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<b>AB</b>		ACCORD HLTHCARE	<b>EQ 25MG BASE</b>	<b>A202825 001</b>	Nov 07, 2014
-----------	--	-----------------	---------------------	--------------------	--------------

<b>AB</b>			<b>EQ 50MG BASE</b>	<b>A202825 002</b>	Nov 07, 2014
-----------	--	--	---------------------	--------------------	--------------

<b>AB</b>			<b>EQ 100MG BASE</b>	<b>A202825 003</b>	Nov 07, 2014
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>		APOTEX INC	<b>EQ 25MG BASE</b>	<b>A076882 001</b>	Feb 06, 2007
-----------	--	------------	---------------------	--------------------	--------------

<b>AB</b>			<b>EQ 50MG BASE</b>	<b>A076882 002</b>	Feb 06, 2007
-----------	--	--	---------------------	--------------------	--------------

<b>AB</b>			<b>EQ 100MG BASE</b>	<b>A076882 003</b>	Feb 06, 2007
-----------	--	--	----------------------	--------------------	--------------

<b>AB</b>		AUROBINDO PHARMA	<b>EQ 25MG BASE</b>	<b>A077206 001</b>	Feb 06, 2007
-----------	--	------------------	---------------------	--------------------	--------------

<b>AB</b>			<b>EQ 50MG BASE</b>	<b>A077206 002</b>	Feb 06, 2007
-----------	--	--	---------------------	--------------------	--------------

<b>AB</b>			<b>EQ 100MG BASE</b>	<b>A077206 003</b>	Feb 06, 2007
-----------	--	--	----------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<b>AB</b>	AUSTARPHARMA LLC	<b>EQ 25MG BASE</b>	<b>A078677 001</b>	Mar 04, 2009
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A078677 002</b>	Mar 04, 2009
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A078677 003</b>	Mar 04, 2009
<b>AB</b>	HIKMA PHARMS	<b>EQ 25MG BASE</b>	<b>A077864 001</b>	Aug 10, 2009
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A077864 002</b>	Aug 10, 2009
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A077864 003</b>	Aug 10, 2009
<b>AB</b>	INVAGEN PHARMS	<b>EQ 25MG BASE</b>	<b>A077397 001</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A077397 002</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A077397 003</b>	Feb 06, 2007
<b>AB</b>	LUPIN	<b>EQ 25MG BASE</b>	<b>A077670 001</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A077670 002</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A077670 003</b>	Feb 06, 2007
<b>AB</b>	MYLAN	<b>EQ 25MG BASE</b>	<b>A076671 001</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A076671 002</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A076671 003</b>	Feb 06, 2007
<b>AB</b>	MYLAN PHARMS INC	<b>EQ 25MG BASE</b>	<b>A078626 001</b>	Jan 31, 2008
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A078626 002</b>	Jan 31, 2008
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A078626 003</b>	Jan 31, 2008
<b>AB</b>	PROSAM LABS	<b>EQ 25MG BASE</b>	<b>A078175 001</b>	Jul 21, 2010
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A078175 002</b>	Jul 21, 2010
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A078175 003</b>	Jul 21, 2010
<b>AB</b>	RANBAXY	<b>EQ 25MG BASE</b>	<b>A077977 001</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A077977 002</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A077977 003</b>	Feb 06, 2007
<b>AB</b>	SUN PHARM INDS (IN)	<b>EQ 25MG BASE</b>	<b>A078108 001</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A078108 002</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A078108 003</b>	Feb 06, 2007
<b>AB</b>	TEVA	<b>EQ 25MG BASE</b>	<b>A076465 001</b>	Aug 11, 2006
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A076465 002</b>	Aug 11, 2006
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A076465 003</b>	Aug 11, 2006
<b>AB</b>	TORRENT PHARMS	<b>EQ 25MG BASE</b>	<b>A077765 001</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A077765 002</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A077765 003</b>	Feb 06, 2007
<b>AB</b>	WOCKHARDT	<b>EQ 25MG BASE</b>	<b>A078403 001</b>	Jan 08, 2008
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A078403 002</b>	Jan 08, 2008
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A078403 003</b>	Jan 08, 2008
<b>AB</b>	ZYDUS PHARMS USA	<b>EQ 25MG BASE</b>	<b>A077106 001</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>A077106 002</b>	Feb 06, 2007
<b>AB</b>		<b>EQ 100MG BASE</b>	<b>A077106 003</b>	Feb 06, 2007
<b>ZOLOFT</b>				
<b>AB</b>	PFIZER	<b>EQ 25MG BASE</b>	<b>N019839 005</b>	Mar 06, 1996
<b>AB</b>		<b>EQ 50MG BASE</b>	<b>N019839 001</b>	Dec 30, 1991
<b>AB</b>	+	<b>EQ 100MG BASE</b>	<b>N019839 002</b>	Dec 30, 1991
	SERTRALINE HYDROCHLORIDE			
	RANBAXY	EQ 150MG BASE	A077977 004	Feb 06, 2007
		EQ 200MG BASE	A077977 005	Feb 06, 2007
<u>SEVELAMER CARBONATE</u>				
FOR SUSPENSION; ORAL				
RENVELA				
	+ GENZYME	2.4GM/PACKET	N022318 002	Feb 18, 2009
		800MG/PACKET	N022318 001	Aug 12, 2009
TABLET; ORAL				
RENVELA				
	+ GENZYME	800MG	N022127 001	Oct 19, 2007
<u>SEVELAMER HYDROCHLORIDE</u>				
TABLET; ORAL				
RENAGEL				
	GENZYME	400MG	N021179 001	Jul 12, 2000
	+	800MG	N021179 002	Jul 12, 2000
<u>SEVOFLURANE</u>				
LIQUID; INHALATION				
<u>SEVOFLURANE</u>				
<b>AN</b>	BAXTER HLTHCARE	<b>100%</b>	<b>A075895 001</b>	Jul 02, 2002
<b>AN</b>	HALOCARBON PRODS	<b>100%</b>	<b>A078650 001</b>	Nov 19, 2007
<u>SOJOURN</u>				
<b>AN</b>	PIRAMAL CRITICAL	<b>100%</b>	<b>A077867 001</b>	May 02, 2007



## PRESCRIPTION DRUG PRODUCT LIST

SEVOFLURANE

LIQUID; INHALATION

ULTANE

<b>AN</b>	+ ABBVIE	<b>100%</b>	<b>N020478 001</b>	Jun 07, 1995
-----------	----------	-------------	--------------------	--------------

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

+ PFIZER

EQ 10MG BASE/ML

N203109 001 Aug 30, 2012

SOLUTION; INTRAVENOUS

REVATIO

+ PFIZER

EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)

N022473 001 Nov 18, 2009

TABLET; ORAL

REVATIO

<b>AB</b>	+ PFIZER	<b>EQ 20MG BASE</b>	<b>N021845 001</b>	Jun 03, 2005
-----------	----------	---------------------	--------------------	--------------

SILDENAFIL CITRATE

<b>AB</b>	ACTAVIS GRP PTC	<b>EQ 20MG BASE</b>	<b>A200149 001</b>	Feb 25, 2013
-----------	-----------------	---------------------	--------------------	--------------

<b>AB</b>	AMNEAL PHARMS	<b>EQ 20MG BASE</b>	<b>A202025 001</b>	Feb 28, 2013
-----------	---------------	---------------------	--------------------	--------------

<b>AB</b>	APOTEX CORP	<b>EQ 20MG BASE</b>	<b>A091379 001</b>	Nov 06, 2012
-----------	-------------	---------------------	--------------------	--------------

<b>AB</b>	DR REDDYS LABS LTD	<b>EQ 20MG BASE</b>	<b>A202598 001</b>	Nov 06, 2012
-----------	--------------------	---------------------	--------------------	--------------

<b>AB</b>	HETERO LABS LTD V	<b>EQ 20MG BASE</b>	<b>A203623 001</b>	Nov 26, 2014
-----------	-------------------	---------------------	--------------------	--------------

<b>AB</b>	MACLEODS PHARMS LTD	<b>EQ 20MG BASE</b>	<b>A203814 001</b>	Dec 17, 2013
-----------	---------------------	---------------------	--------------------	--------------

<b>AB</b>	MYLAN PHARMS INC	<b>EQ 20MG BASE</b>	<b>A201150 001</b>	Nov 09, 2012
-----------	------------------	---------------------	--------------------	--------------

<b>AB</b>	TEVA PHARMS	<b>EQ 20MG BASE</b>	<b>A078380 001</b>	Jan 07, 2013
-----------	-------------	---------------------	--------------------	--------------

<b>AB</b>	TORRENT PHARMS LTD	<b>EQ 20MG BASE</b>	<b>A091479 001</b>	Nov 06, 2012
-----------	--------------------	---------------------	--------------------	--------------

<b>AB</b>	WATSON LABS INC	<b>EQ 20MG BASE</b>	<b>A202503 001</b>	Nov 06, 2012
-----------	-----------------	---------------------	--------------------	--------------

VIAGRA

PFIZER IRELAND

EQ 25MG BASE

N020895 001 Mar 27, 1998

EQ 50MG BASE

N020895 002 Mar 27, 1998

+

EQ 100MG BASE

N020895 003 Mar 27, 1998

SILODOSIN

CAPSULE; ORAL

RAPAFLO

+ WATSON LABS

4MG

N022206 001 Oct 08, 2008

8MG

N022206 002 Oct 08, 2008

SILVER SULFADIAZINE

CREAM; TOPICAL

SILVADENE

<b>AB</b>	+ KING PHARMS	<b>1%</b>	<b>N017381 001</b>	
-----------	---------------	-----------	--------------------	--

SSD

<b>AB</b>	DR REDDYS LA	<b>1%</b>	<b>N018578 001</b>	Feb 25, 1982
-----------	--------------	-----------	--------------------	--------------

THERMAZENE

<b>AB</b>	THEPHARMANETWORK LLC	<b>1%</b>	<b>N018810 001</b>	Dec 23, 1985
-----------	----------------------	-----------	--------------------	--------------

SSD AF

<b>BX</b>	DR REDDYS LA	<b>1%</b>	<b>N018578 003</b>	Jul 11, 1990
-----------	--------------	-----------	--------------------	--------------

SIMEPREVIR SODIUM

CAPSULE; ORAL

OLYSIO

+ JANSSEN PRODS

EQ 150MG BASE

N205123 001 Nov 22, 2013

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<b>AB</b>	ACCORD HLTHCARE	<b>5MG</b>	<b>A078155 005</b>	Apr 05, 2013
-----------	-----------------	------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A078155 002</b>	Feb 26, 2008
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A078155 003</b>	Feb 26, 2008
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A078155 004</b>	Feb 26, 2008
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>80MG</b>	<b>A078155 001</b>	Feb 26, 2008
-----------	--	-------------	--------------------	--------------

<b>AB</b>	AUROBINDO PHARMA	<b>5MG</b>	<b>A077691 001</b>	Dec 20, 2006
-----------	------------------	------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A077691 002</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A077691 003</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A077691 004</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>80MG</b>	<b>A077691 005</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>	BLU CARIBE	<b>5MG</b>	<b>A078034 001</b>	Dec 20, 2006
-----------	------------	------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A078034 002</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A078034 003</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A078034 004</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>80MG</b>	<b>A078034 005</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>	DR REDDYS LABS INC	<b>5MG</b>	<b>A077752 005</b>	Jan 23, 2008
-----------	--------------------	------------	--------------------	--------------

<b>AB</b>		<b>10MG</b>	<b>A077752 001</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>20MG</b>	<b>A077752 002</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

<b>AB</b>		<b>40MG</b>	<b>A077752 003</b>	Dec 20, 2006
-----------	--	-------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>		<u>80MG</u>	<u>A077752</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A200895</u>	<u>001</u>	Nov 25, 2014
<u>AB</u>		<u>10MG</u>	<u>A200895</u>	<u>002</u>	Nov 25, 2014
<u>AB</u>		<u>20MG</u>	<u>A200895</u>	<u>003</u>	Nov 25, 2014
<u>AB</u>		<u>40MG</u>	<u>A200895</u>	<u>004</u>	Nov 25, 2014
<u>AB</u>		<u>80MG</u>	<u>A200895</u>	<u>005</u>	Nov 25, 2014
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076052</u>	<u>001</u>	Jun 23, 2006
<u>AB</u>		<u>10MG</u>	<u>A076052</u>	<u>002</u>	Jun 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076052</u>	<u>003</u>	Jun 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076052</u>	<u>004</u>	Jun 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076052</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	LUPIN	<u>5MG</u>	<u>A078103</u>	<u>005</u>	Apr 14, 2009
<u>AB</u>		<u>10MG</u>	<u>A078103</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A078103</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A078103</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A078103</u>	<u>004</u>	May 11, 2007
<u>AB</u>	MICRO LABS LTD	<u>5MG</u>	<u>A090383</u>	<u>001</u>	Sep 16, 2011
<u>AB</u>		<u>10MG</u>	<u>A090383</u>	<u>002</u>	Sep 16, 2011
<u>AB</u>		<u>20MG</u>	<u>A090383</u>	<u>003</u>	Sep 16, 2011
<u>AB</u>		<u>40MG</u>	<u>A090383</u>	<u>004</u>	Sep 16, 2011
<u>AB</u>		<u>80MG</u>	<u>A090383</u>	<u>005</u>	Sep 16, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A090868</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>10MG</u>	<u>A090868</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>20MG</u>	<u>A090868</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>		<u>40MG</u>	<u>A090868</u>	<u>004</u>	Jun 08, 2010
<u>AB</u>		<u>80MG</u>	<u>A090868</u>	<u>005</u>	Jun 08, 2010
<u>AB</u>	PROSAM LABS	<u>5MG</u>	<u>A078735</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076285</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076285</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076285</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076285</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076285</u>	<u>005</u>	Jun 23, 2006
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006

ZOCOR

<u>AB</u>	MERCK	<u>5MG</u>	<u>N019766</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>		<u>10MG</u>	<u>N019766</u>	<u>002</u>	Dec 23, 1991
<u>AB</u>		<u>20MG</u>	<u>N019766</u>	<u>003</u>	Dec 23, 1991
<u>AB</u>		<u>40MG</u>	<u>N019766</u>	<u>004</u>	Dec 23, 1991
<u>AB</u>	+	<u>80MG</u>	<u>N019766</u>	<u>005</u>	Jul 10, 1998

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

+ BRACCO

0.005MG/VIAL

N017697 001

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+ MEDIGENE AG

15%

N021902 001 Oct 31, 2006

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

+ PF PRISM CV

1MG/ML

N021083 001 Sep 15, 1999

TABLET; ORAL

RAPAMUNE

<u>AB</u>	PF PRISM CV	<u>0.5MG</u>	<u>N021110</u>	<u>004</u>	Jan 25, 2010
<u>AB</u>		<u>1MG</u>	<u>N021110</u>	<u>001</u>	Aug 25, 2000

## PRESCRIPTION DRUG PRODUCT LIST

SIROLIMUS

TABLET; ORAL

RAPAMUNE

<b>AB</b>	+	<b>2MG</b>	<b>N021110 002</b>	Aug 22, 2002
<b>AB</b>		<b>1MG</b>	<b>A201578 001</b>	Oct 27, 2014
<b>AB</b>		<b>2MG</b>	<b>A201578 002</b>	Oct 27, 2014
<b>AB</b>		<b>0.5MG</b>	<b>A201676 003</b>	Jan 08, 2014

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

	MERCK SHARP DOHME	EQ 25MG BASE	N021995 001	Oct 16, 2006
		EQ 50MG BASE	N021995 002	Oct 16, 2006
+		EQ 100MG BASE	N021995 003	Oct 16, 2006

SODIUM ACETATE ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER

+	HOSPIRA	2MEQ/ML	N018893 001	May 04, 1983
---	---------	---------	-------------	--------------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)

AMMONUL

+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645 001	Feb 17, 2005
---	---------	-----------------------------	-------------	--------------

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

+	HOSPIRA	0.9MEQ/ML	A077394 001	Nov 09, 2005
+		1MEQ/ML	A077394 002	Nov 09, 2005

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<b>AP</b>	FRESENIUS KABI USA	<b>9MG/ML</b>	<b>A088911 001</b>	Feb 07, 1985
<b>AP</b>	+	<b>9MG/ML</b>	<b>N018800 001</b>	Oct 29, 1982
		<b>450MG/100ML</b>	<b>N019635 001</b>	Mar 09, 1988
<b>AP</b>	B BRAUN	<b>450MG/100ML</b>	<b>N018016 001</b>	
<b>AP</b>	BAXTER HLTHCARE	<b>450MG/100ML</b>	<b>N018090 001</b>	
<b>AP</b>	HOSPIRA	<b>450MG/100ML</b>	<b>N019759 001</b>	Jun 08, 1988
		<b>9MG/ML</b>	<b>A201850 001</b>	Jan 20, 2012
		<b>900MG/100ML</b>	<b>N017464 001</b>	
<b>AP</b>	+	<b>900MG/100ML</b>	<b>N019635 002</b>	Mar 09, 1988
<b>AP</b>	+	<b>9MG/ML</b>	<b>N016677 004</b>	Oct 30, 1985
<b>AP</b>		<b>9MG/ML</b>	<b>N020178 002</b>	Dec 07, 1992
<b>AP</b>	+	<b>900MG/100ML</b>	<b>N016677 001</b>	
<b>AP</b>	+	<b>900MG/100ML</b>	<b>N020178 001</b>	Dec 07, 1992
<b>AP</b>	+	<b>9MG/ML</b>	<b>A088912 001</b>	Jan 10, 1985
<b>AP</b>	FRESENIUS KABI USA	<b>9MG/ML</b>	<b>A078177 001</b>	Apr 12, 2007
<b>AP</b>	FRESENIUS MEDCL	<b>900MG/100ML</b>	<b>A076316 001</b>	Oct 27, 2004
<b>AP</b>	HAEMONETICS	<b>900MG/100ML</b>	<b>N018803 001</b>	Oct 29, 1982
<b>AP</b>	+	<b>9MG/ML</b>	<b>N019217 001</b>	Jul 13, 1984
<b>AP</b>	+	<b>9MG/ML</b>	<b>N019465 002</b>	Jul 15, 1985
<b>AP</b>	+	<b>900MG/100ML</b>	<b>N016366 001</b>	
<b>AP</b>	+	<b>900MG/100ML</b>	<b>N019465 001</b>	Jul 15, 1985
<b>AP</b>	+	<b>900MG/100ML</b>	<b>N019480 001</b>	Sep 17, 1985
<b>AP</b>	+	<b>9MG/ML</b>	<b>A077407 001</b>	Aug 11, 2006
		90MG/10ML (9MG/ML)	N202832 006	Jan 06, 2012
		9MG/ML	A201833 001	Sep 24, 2013
		45MG/50ML (9MG/ML)	N021569 001	Jul 27, 2006
		112.5MG/125ML (9MG/ML)	N021569 002	Jul 27, 2006
		3GM/100ML	N019022 001	Nov 01, 1983
		5GM/100ML	N019022 002	Nov 01, 1983
		2.5MEQ/ML	N018897 001	Jul 20, 1984

## PRESCRIPTION DRUG PRODUCT LIST

SODIUM CHLORIDE

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>900MG/100ML</u>	<u>N016733</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N017427</u>	<u>001</u>	
<u>AT</u>		<u>900MG/100ML</u>	<u>N017867</u>	<u>001</u>	
<u>AT</u>	HOSPIRA	<u>900MG/100ML</u>	<u>N017514</u>	<u>001</u>	
<u>AT</u>		<u>900MG/100ML</u>	<u>N018314</u>	<u>001</u>	

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

BAXTER HLTHCARE 900MG/100ML N019319 002 May 17, 1985

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

<u>AB</u>	+ SANOFI AVENTIS US	<u>62.5MG/5ML</u>	<u>N020955</u>	<u>001</u>	Feb 18, 1999
<u>AB</u>	HIKMA PHARMS	<u>62.5MG/5ML</u>	<u>A078215</u>	<u>001</u>	Mar 31, 2011

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

<u>AP</u>	BIOMEDCL RES FDN	<u>10-200mCi/ML</u>	<u>A204351</u>	<u>001</u>	Jan 09, 2015
<u>AP</u>	ESSENTIAL ISOTOPES	<u>10-200mCi/ML</u>	<u>A204541</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	GLOBAL ISOTOPES LLC	<u>10-200mCi/ML</u>	<u>A204464</u>	<u>001</u>	Oct 21, 2014
<u>AP</u>	+ HOUSTON CYCLOTRON	<u>10-200mCi/ML</u>	<u>A203544</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>	NCM USA BRONX LLC	<u>10-200mCi/ML</u>	<u>A204513</u>	<u>001</u>	Nov 28, 2014
<u>AP</u>	SHERTECH LABS LLC	<u>10-200mCi/ML</u>	<u>A204315</u>	<u>001</u>	Sep 22, 2014
<u>AP</u>	UCSF RODIOPHARM	<u>10-200mCi/ML</u>	<u>A204437</u>	<u>001</u>	Mar 13, 2014
<u>AP</u>	UNIV TX MD ANDERSON	<u>10-200mCi/ML</u>	<u>A203247</u>	<u>001</u>	Dec 23, 2013
	+ MCPRF	10-91.5mCi/ML	A203605	001	Jun 28, 2013
	THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

<u>AA</u>	+ CARDINAL HLTH 414	<u>100uCi</u>	<u>N018671</u>	<u>001</u>	May 27, 1982
<u>AA</u>	+ MALLINCKRODT	<u>200uCi</u>	<u>N018671</u>	<u>002</u>	May 27, 1982
<u>AA</u>		<u>100uCi</u>	<u>A071909</u>	<u>001</u>	Feb 28, 1989
<u>AA</u>		<u>200uCi</u>	<u>A071910</u>	<u>001</u>	Feb 28, 1989

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ MALLINCKRODT 0.8-100mCi N016517 001

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE 0.009-0.1mCi N021305 006 May 19, 2005

SOLUTION; ORAL

HICON

+ JUBILANT DRAXIMAGE 250-1000mCi N021305 007 Dec 05, 2011

SODIUM IODIDE I 131

+ MALLINCKRODT 3.5-150mCi/VIAL N016515 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>1.87GM/100ML</u>	<u>N016692</u>	<u>001</u>	
-----------	-----------------	---------------------	----------------	------------	--

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>1.87GM/100ML</u>	<u>N020004</u>	<u>001</u>	Apr 21, 1992
	SODIUM LACTATE IN PLASTIC CONTAINER				
	+ HOSPIRA	5MEQ/ML	N018947	001	Sep 05, 1984

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS 300MG/10ML (30MG/ML) N203922 001 Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODE

+ HOPE PHARMS 300MG/10ML (30MG/ML), N/A; N/A, 12.5GM/50ML (250MG/ML) N201444 001 Jan 14, 2011

## PRESCRIPTION DRUG PRODUCT LIST

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

+ HOSPIRA

25MG/ML

A071961 001 Aug 01, 1988

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ JAZZ PHARMS

500MG/ML

N021196 001 Jul 17, 2002

SODIUM PHENYL BUTYRATE

POWDER; ORAL

BUPHENYL**AB** + HYPERION THERAPS INC**3GM/TEASPOONFUL****N020573 001** Apr 30, 1996SODIUM PHENYL BUTYRATE**AB** SIGMAPHARM LABS LLC**3GM/TEASPOONFUL****A202819 001** Mar 22, 2013

TABLET; ORAL

BUPHENYL**AB** + HYPERION THERAPS INC**500MG****N020572 001** May 13, 1996SODIUM PHENYL BUTYRATE**AB** AMPOLGEN**500MG****A090910 001** Nov 18, 2011SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

+ SALIX PHARMS

0.398GM; 1.102GM

N021892 001 Mar 16, 2006

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

+ HOSPIRA

142MG/ML; 276MG/ML

N018892 001 May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE**AA** KVK TECH**454GM/BOT****A040905 001** Mar 30, 2009KAYEXALATE**AA** + COVIS PHARMA SARL**453.6GM/BOT****N011287 001**KIONEX**AA** PADDOCK LLC**454GM/BOT****A040029 001** Feb 06, 1998SODIUM POLYSTYRENE SULFONATE**AA** CAROLINA MEDCL**454GM/BOT****A089910 001** Jan 19, 1989**AA** CEDAR PHARMS**453.6GM/BOT****A090313 001** Dec 21, 2011**AA** EPIC PHARMA LLC**453.6GM/BOT****A202333 001** Mar 19, 2014**AA** NUVO PHARM INC**454GM/BOT****A204071 001** Nov 28, 2014

15GM/BOT

A204071 002 Nov 28, 2014

SUSPENSION; ORAL, RECTAL

KIONEX**AA** PADDOCK LLC**15GM/60ML****A040028 001** Sep 17, 2007SODIUM POLYSTYRENE SULFONATE**AA** PADDOCK LLC**15GM/60ML****A090590 001** May 13, 2011**AA** ROXANE**15GM/60ML****A089049 001** Nov 17, 1986SPS**AA** + CAROLINA MEDCL**15GM/60ML****A087859 001** Dec 08, 1982SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

MYLAN INSTITUTIONAL

20MG/2ML (10MG/ML)

A040541 001 Nov 12, 2004

+

60MG/2ML (30MG/ML)

A040541 002 Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS

12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012

SOFOBUVIR

TABLET; ORAL

SOVALDI

+ GILEAD SCIENCES INC

400MG

N204671 001 Dec 06, 2013

## PRESCRIPTION DRUG PRODUCT LIST

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

<b>AB</b>	TEVA PHARMS USA	<b>5MG</b>	<b>A091464 001</b>	Apr 02, 2014
<b>AB</b>		<b>10MG</b>	<b>A091464 002</b>	Apr 02, 2014
<b>VESICARE</b>				
<b>AB</b>	ASTELLAS	<b>5MG</b>	<b>N021518 001</b>	Nov 19, 2004
<b>AB</b>	+	<b>10MG</b>	<b>N021518 002</b>	Nov 19, 2004

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

## GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280 006	Aug 24, 1995
GENOTROPIN PRESERVATIVE FREE					
BX		PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280 004	Aug 24, 1995
HUMATROPE					
BX	+	LILLY	5MG/VIAL	N019640 004	Mar 08, 1987
BX			6MG/VIAL	N019640 005	Feb 04, 1999
NORDITROPIN FLEXPRO					
BX		NOVO NORDISK INC	5MG/1.5ML	N021148 008	Mar 01, 2010
BX			10MG/1.5ML	N021148 009	Mar 01, 2010
NUTROPIN					
BX		GENENTECH	5MG/VIAL	N020168 001	Nov 17, 1993
OMNITROPE					
BX		SANDOZ	1.5MG/VIAL	N021426 002	May 30, 2006
BX			5MG/1.5ML	N021426 003	Jan 16, 2008
BX			5.8MG/VIAL	N021426 001	May 30, 2006
BX			10MG/1.5ML	N021426 004	Aug 25, 2008
SAIZEN					
BX		EMD SERONO	5MG/VIAL	N019764 002	Oct 08, 1996
SEROSTIM					
BX		EMD SERONO	4MG/VIAL	N020604 003	Jul 25, 1997
BX			5MG/VIAL	N020604 002	Aug 23, 1996
BX			6MG/VIAL	N020604 001	Aug 23, 1996
TEV-TROPIN					
BX	+	FERRING	5MG/VIAL	N019774 002	Jan 04, 2002
VALTROPIN					
BX		LG LIFE	5MG/VIAL	N021905 001	Apr 19, 2007
GENOTROPIN					
	+	PHARMACIA AND UPJOHN	13.8MG/VIAL	N020280 007	Oct 23, 1996
GENOTROPIN PRESERVATIVE FREE					
		PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280 001	Jan 27, 1998
			0.4MG/VIAL	N020280 002	Jan 27, 1998
			0.6MG/VIAL	N020280 003	Jan 27, 1998
			0.8MG/VIAL	N020280 005	Jan 27, 1998
			1MG/VIAL	N020280 008	Jan 27, 1998
			1.2MG/VIAL	N020280 009	Jan 27, 1998
			1.4MG/VIAL	N020280 010	Jan 27, 1998
			1.6MG/VIAL	N020280 011	Jan 27, 1998
			1.8MG/VIAL	N020280 012	Jan 27, 1998
	+		2MG/VIAL	N020280 013	Jan 27, 1998
HUMATROPE					
	+	LILLY	12MG/VIAL	N019640 006	Feb 04, 1999
	+		24MG/VIAL	N019640 007	Feb 04, 1999
NORDITROPIN FLEXPRO					
		NOVO NORDISK INC	15MG/1.5ML	N021148 010	Mar 01, 2010
NORDITROPIN NORDIFLEX					
		NOVO NORDISK INC	30MG/3ML	N021148 007	Mar 10, 2009
NUTROPIN					
	+	GENENTECH	10MG/VIAL	N020168 002	Nov 17, 1993
NUTROPIN AQ					
	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522 003	Jan 03, 2008
	+		10MG/2ML (5MG/ML)	N020522 001	Dec 29, 1995
	+		20MG/2ML (10MG/ML)	N020522 004	Jan 03, 2008
NUTROPIN AQ PEN					
	+	GENENTECH	10MG/2ML (5MG/ML)	N020522 002	Apr 22, 2002
SAIZEN					
	+	EMD SERONO	8.8MG/VIAL	N019764 003	Aug 29, 2000
ZORBATIVE					
	+	EMD SERONO	8.8MG/VIAL	N021597 004	Dec 01, 2003

## PRESCRIPTION DRUG PRODUCT LIST

SORAFENIB TOSYLATE

TABLET;ORAL

NEXAVAR

+ BAYER HLTHCARE

EQ 200MG BASE

N021923 001 Dec 20, 2005

SORBITOL

SOLUTION;IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE 3GM/100ML

N017863 001

SORBITOL 3.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML

N016741 001

SOTALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE

+ ACADEMIC PHARMS 150MG/10ML (15MG/ML)

N022306 001 Jul 02, 2009

SOLUTION;ORAL

SOTYLIZE

+ ARBOR PHARMS LLC

5MG/ML (5MG/ML)

N205108 001 Oct 22, 2014

TABLET;ORAL

BETAPACEAB1 BAYER HLTHCARE80MGN019865 001 Oct 30, 1992AB1 BAYER HLTHCARE120MGN019865 005 Apr 20, 1994AB1 +160MGN019865 002 Oct 30, 1992AB1 BAYER HLTHCARE240MGN019865 003 Oct 30, 1992SORINEAB1 UPSHER SMITH80MGA075500 001 Apr 27, 2001AB1 UPSHER SMITH120MGA075500 004 Apr 27, 2001AB1 UPSHER SMITH160MGA075500 002 Apr 27, 2001AB1 UPSHER SMITH240MGA075500 003 Apr 27, 2001SOTALOL HYDROCHLORIDEAB1 APOTEX INC80MGA076140 001 Sep 26, 2002AB1 APOTEX INC120MGA076140 002 Sep 26, 2002AB1 APOTEX INC160MGA076140 003 Sep 26, 2002AB1 APOTEX INC240MGA076140 004 Sep 26, 2002AB1 IMPAX PHARMS80MGA075663 001 Nov 07, 2000AB1 IMPAX PHARMS120MGA075663 002 Nov 07, 2000AB1 IMPAX PHARMS160MGA075663 003 Nov 07, 2000AB1 IMPAX PHARMS240MGA075663 004 Nov 07, 2000AB1 MYLAN80MGA075237 001 May 01, 2000AB1 MYLAN80MGA075725 001 Dec 19, 2000AB1 MYLAN120MGA075237 002 May 01, 2000AB1 MYLAN120MGA075725 002 Dec 19, 2000AB1 MYLAN160MGA075237 003 May 01, 2000AB1 MYLAN160MGA075725 003 Dec 19, 2000AB1 MYLAN240MGA075237 004 May 01, 2000AB1 MYLAN240MGA075725 004 Dec 19, 2000AB1 SANDOZ80MGA075366 001 May 01, 2000AB1 SANDOZ120MGA075366 002 May 01, 2000AB1 SANDOZ160MGA075366 003 May 01, 2000AB1 SANDOZ240MGA075366 004 May 01, 2000AB1 TEVA80MGA075429 001 May 01, 2000AB1 TEVA120MGA075429 002 May 01, 2000AB1 TEVA160MGA075429 003 May 01, 2000AB1 TEVA240MGA075429 004 May 01, 2000AB1 VINTAGE PHARMS80MGA075563 001 Nov 07, 2003AB1 VINTAGE PHARMS120MGA075563 002 Nov 07, 2003AB1 VINTAGE PHARMS160MGA075563 003 Nov 07, 2003AB1 VINTAGE PHARMS240MGA075563 004 Nov 07, 2003BETAPACE AFAB2 COVIS PHARMA SARL80MGN021151 001 Feb 22, 2000AB2 COVIS PHARMA SARL120MGN021151 002 Feb 22, 2000AB2 +160MGN021151 003 Feb 22, 2000SOTALOL HYDROCHLORIDEAB2 APOTEX80MGA076214 001 Aug 27, 2003AB2 APOTEX120MGA076214 002 Aug 27, 2003AB2 APOTEX160MGA076214 003 Aug 27, 2003AB2 EPIC PHARMA INC80MGA077070 001 Nov 04, 2005AB2 EPIC PHARMA INC120MGA077070 002 Nov 04, 2005AB2 EPIC PHARMA INC160MGA077070 003 Nov 04, 2005AB2 MYLAN80MGA077616 001 Feb 07, 2007AB2 MYLAN120MGA077616 002 Feb 07, 2007AB2 MYLAN160MGA077616 003 Feb 07, 2007

## PRESCRIPTION DRUG PRODUCT LIST

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

<b>AB2</b>	TEVA	<b>80MG</b>	<b>A076883 001</b>	Jul 26, 2004
<b>AB2</b>		<b>120MG</b>	<b>A076883 002</b>	Jul 26, 2004
<b>AB2</b>		<b>160MG</b>	<b>A076883 003</b>	Jul 26, 2004

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

<b>AP</b>	+	FRESENIUS	<b>10%</b>	<b>N017643 001</b>	
-----------	---	-----------	------------	--------------------	--

INTRALIPID 20%

<b>AP</b>	+	FRESENIUS	<b>20%</b>	<b>N018449 001</b>	
-----------	---	-----------	------------	--------------------	--

<b>AP</b>	+		<b>20%</b>	<b>N020248 001</b>	Aug 07, 1996
-----------	---	--	------------	--------------------	--------------

INTRALIPID 30%

<b>AP</b>	+	FRESENIUS	<b>30%</b>	<b>N019942 001</b>	Dec 30, 1993
-----------	---	-----------	------------	--------------------	--------------

NUTRILIPID 10%

<b>AP</b>	+	B BRAUN	<b>10%</b>	<b>N019531 001</b>	May 28, 1993
-----------	---	---------	------------	--------------------	--------------

NUTRILIPID 20%

<b>AP</b>	+	B BRAUN	<b>20%</b>	<b>N019531 002</b>	May 28, 1993
-----------	---	---------	------------	--------------------	--------------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

	+	PARAPRO LLC	<b>0.9%</b>	<b>N022408 001</b>	Jan 18, 2011
--	---	-------------	-------------	--------------------	--------------

SPIRONOLACTONE

TABLET; ORAL

ALDACTONE

<b>AB</b>		GD SEARLE LLC	<b>25MG</b>	<b>N012151 009</b>	Dec 30, 1983
-----------	--	---------------	-------------	--------------------	--------------

<b>AB</b>			<b>50MG</b>	<b>N012151 008</b>	Dec 30, 1982
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>	+		<b>100MG</b>	<b>N012151 010</b>	Dec 30, 1983
-----------	---	--	--------------	--------------------	--------------

SPIRONOLACTONE

<b>AB</b>		ACTAVIS ELIZABETH	<b>25MG</b>	<b>A040353 003</b>	Mar 15, 2006
-----------	--	-------------------	-------------	--------------------	--------------

<b>AB</b>			<b>50MG</b>	<b>A040353 001</b>	Jul 29, 1999
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>100MG</b>	<b>A040353 002</b>	Jul 29, 1999
-----------	--	--	--------------	--------------------	--------------

<b>AB</b>		AMNEAL PHARMS	<b>25MG</b>	<b>A091426 001</b>	Jun 08, 2010
-----------	--	---------------	-------------	--------------------	--------------

<b>AB</b>			<b>50MG</b>	<b>A091426 002</b>	Jun 08, 2010
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>100MG</b>	<b>A091426 003</b>	Jun 08, 2010
-----------	--	--	--------------	--------------------	--------------

<b>AB</b>		JUBILANT GENERICS	<b>25MG</b>	<b>A203253 001</b>	Apr 23, 2014
-----------	--	-------------------	-------------	--------------------	--------------

<b>AB</b>			<b>50MG</b>	<b>A203253 002</b>	Apr 23, 2014
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>100MG</b>	<b>A203253 003</b>	Apr 23, 2014
-----------	--	--	--------------	--------------------	--------------

<b>AB</b>		MUTUAL PHARM	<b>25MG</b>	<b>A089424 001</b>	Jul 23, 1986
-----------	--	--------------	-------------	--------------------	--------------

<b>AB</b>			<b>50MG</b>	<b>A089424 002</b>	Aug 11, 1999
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>100MG</b>	<b>A089424 003</b>	Aug 11, 1999
-----------	--	--	--------------	--------------------	--------------

<b>AB</b>		MYLAN	<b>25MG</b>	<b>A040424 001</b>	Aug 20, 2001
-----------	--	-------	-------------	--------------------	--------------

<b>AB</b>			<b>50MG</b>	<b>A040424 002</b>	Aug 20, 2001
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>100MG</b>	<b>A040424 003</b>	Aug 20, 2001
-----------	--	--	--------------	--------------------	--------------

<b>AB</b>		ORION CORP ORION	<b>25MG</b>	<b>A202187 001</b>	Mar 06, 2014
-----------	--	------------------	-------------	--------------------	--------------

<b>AB</b>			<b>50MG</b>	<b>A202187 002</b>	Mar 06, 2014
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>100MG</b>	<b>A202187 003</b>	Mar 06, 2014
-----------	--	--	--------------	--------------------	--------------

<b>AB</b>		SANDOZ	<b>25MG</b>	<b>A086809 001</b>	
-----------	--	--------	-------------	--------------------	--

<b>AB</b>		VINTAGE	<b>25MG</b>	<b>A040750 001</b>	Aug 29, 2006
-----------	--	---------	-------------	--------------------	--------------

<b>AB</b>			<b>50MG</b>	<b>A040750 002</b>	Aug 29, 2006
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>100MG</b>	<b>A040750 003</b>	Aug 29, 2006
-----------	--	--	--------------	--------------------	--------------

STAVUDINE

CAPSULE; ORAL

STAVUDINE

<b>AB</b>		AUROBINDO PHARMA	<b>15MG</b>	<b>A077672 003</b>	Dec 29, 2008
-----------	--	------------------	-------------	--------------------	--------------

<b>AB</b>			<b>20MG</b>	<b>A077672 004</b>	Dec 29, 2008
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>30MG</b>	<b>A077672 001</b>	Dec 29, 2008
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>40MG</b>	<b>A077672 002</b>	Dec 29, 2008
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>		HETERO LABS LTD III	<b>15MG</b>	<b>A078957 001</b>	Dec 29, 2008
-----------	--	---------------------	-------------	--------------------	--------------

<b>AB</b>			<b>20MG</b>	<b>A078957 002</b>	Dec 29, 2008
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>30MG</b>	<b>A078957 003</b>	Dec 29, 2008
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>40MG</b>	<b>A078957 004</b>	Dec 29, 2008
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>		MATRIX LABS LTD	<b>30MG</b>	<b>A078775 001</b>	Jan 05, 2009
-----------	--	-----------------	-------------	--------------------	--------------

<b>AB</b>			<b>40MG</b>	<b>A078775 002</b>	Jan 05, 2009
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>		MYLAN	<b>15MG</b>	<b>A079069 001</b>	Dec 29, 2008
-----------	--	-------	-------------	--------------------	--------------

<b>AB</b>			<b>20MG</b>	<b>A079069 002</b>	Dec 29, 2008
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>30MG</b>	<b>A079069 003</b>	Dec 29, 2008
-----------	--	--	-------------	--------------------	--------------

<b>AB</b>			<b>40MG</b>	<b>A079069 004</b>	Dec 29, 2008
-----------	--	--	-------------	--------------------	--------------



## PRESCRIPTION DRUG PRODUCT LIST

STAVUDINE

CAPSULE; ORAL

ZERIT

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>15MG</u>	<u>N020412</u>	<u>002</u>	Jun 24, 1994
<u>AB</u>		<u>20MG</u>	<u>N020412</u>	<u>003</u>	Jun 24, 1994
<u>AB</u>		<u>30MG</u>	<u>N020412</u>	<u>004</u>	Jun 24, 1994
<u>AB</u>	+	<u>40MG</u>	<u>N020412</u>	<u>005</u>	Jun 24, 1994

FOR SOLUTION; ORAL

STAVUDINE

<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A077774</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>	CIPLA LTD	<u>1MG/ML</u>	<u>A078030</u>	<u>001</u>	Mar 20, 2009

ZERIT

<u>AA</u>	+	BRISTOL MYERS SQUIBB	<u>1MG/ML</u>	<u>N020413</u>	<u>001</u>	Sep 06, 1996
-----------	---	----------------------	---------------	----------------	------------	--------------

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	HOSPIRA	<u>100%</u>	<u>N018802</u>	<u>001</u>	Oct 27, 1982
-----------	---	---------	-------------	----------------	------------	--------------

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>100%</u>	<u>N019633</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>100%</u>	<u>N018632</u>	<u>001</u>	Jun 30, 1982
<u>AP</u>	+		<u>100%</u>	<u>N018632</u>	<u>002</u>	Apr 19, 1988
<u>AP</u>		FRESENIUS KABI USA	<u>100%</u>	<u>A088400</u>	<u>001</u>	Jan 16, 1984
<u>AP</u>	+	HOSPIRA	<u>100%</u>	<u>N018233</u>	<u>001</u>	
<u>AP</u>	+		<u>100%</u>	<u>N018801</u>	<u>001</u>	Oct 27, 1982
<u>AP</u>	+		<u>100%</u>	<u>N019869</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>		TARO PHARMS IRELAND	<u>100%</u>	<u>A077393</u>	<u>001</u>	Aug 11, 2006

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER

<u>AT</u>		BAXTER HLTHCARE	<u>100%</u>	<u>N017428</u>	<u>001</u>	
-----------	--	-----------------	-------------	----------------	------------	--

STERILE WATER IN PLASTIC CONTAINER

<u>AT</u>		B BRAUN	<u>100%</u>	<u>N016734</u>	<u>001</u>	
<u>AT</u>		BAXTER HLTHCARE	<u>100%</u>	<u>N017866</u>	<u>001</u>	
<u>AT</u>		HOSPIRA	<u>100%</u>	<u>N017513</u>	<u>001</u>	
<u>AT</u>			<u>100%</u>	<u>N018313</u>	<u>001</u>	

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

+ X GEN PHARMS

EQ 1GM BASE/VIAL

A064210 001 Jun 30, 1998

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

+ TEVA PHARMS USA

1GM/VIAL

N050577 001 May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE; INJECTION

METASTRON

<u>AP</u>	+	GE HEALTHCARE	<u>1mCi/ML</u>	<u>N020134</u>	<u>001</u>	Jun 18, 1993
-----------	---	---------------	----------------	----------------	------------	--------------

STRONTIUM CHLORIDE SR-89

<u>AP</u>		BIO NUCLEONICS	<u>1mCi/ML</u>	<u>A075941</u>	<u>001</u>	Jan 06, 2003
-----------	--	----------------	----------------	----------------	------------	--------------

SUCCIMER

CAPSULE; ORAL

CHEMET

+ RECORDATI RARE

100MG

N019998 002 Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

<u>AP</u>	+	SANDOZ	<u>20MG/ML</u>	<u>N008453</u>	<u>002</u>	
-----------	---	--------	----------------	----------------	------------	--

QUELICIN

<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>N008845</u>	<u>006</u>	
-----------	---	---------	----------------	----------------	------------	--

QUELICIN PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>N008845</u>	<u>001</u>	
-----------	---	---------	----------------	----------------	------------	--

+

100MG/ML

N008845 004

## PRESCRIPTION DRUG PRODUCT LIST

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+ FOREST LABS INC

1GM/10ML

N019183 001 Dec 16, 1993

TABLET; ORAL

CARAFATE**AB** + FOREST LABS INC**1GM****N018333 001**SUCRALFATE**AB** NOSTRUM LABS**1GM****A074415 001** Jun 08, 1998**AB** TEVA**1GM****A070848 001** Mar 29, 1996SUCROFERRIC OXYHYDROXIDE

TABLET, CHEWABLE; ORAL

VELPHORO

+ VIFOR FRESENIUS

500MG

N205109 001 Nov 27, 2013

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA PRESERVATIVE FREE**AP** + AKORN**EQ 0.05MG BASE/ML****N019050 001** May 04, 1984SUFENTANIL CITRATE**AP** HIKMA MAPLE**EQ 0.05MG BASE/ML****A074413 001** Dec 15, 1995**AP** HOSPIRA**EQ 0.05MG BASE/ML****A074534 001** Dec 11, 1996SULCONAZOLE NITRATE

CREAM; TOPICAL

EXELDERM

+ RANBAXY

1%

N018737 001 Feb 28, 1989

SOLUTION; TOPICAL

EXELDERM

+ RANBAXY

1%

N018738 001 Aug 30, 1985

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON**AB** + VALEANT BERMUDA**10%****N019931 001** Dec 23, 1996SULFACETAMIDE SODIUM**AB** FOUGERA PHARMS**10%****A077015 001** Nov 17, 2006**AB** PERRIGO CO TENNESSEE**10%****A078649 001** Mar 23, 2009**AB** TARO**10%****A078668 001** May 20, 2009

OINTMENT; OPHTHALMIC

CETAMIDE**AT** + ALCON**10%****A080021 001**SULFACETAMIDE SODIUM**AT** PERRIGO CO TENNESSEE**10%****A080029 001**

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10**AT** + ALLERGAN**10%****A080028 001**SULFACETAMIDE SODIUM**AT** ALCON PHARMS LTD**10%****A089560 001** Oct 18, 1988**AT** BAUSCH AND LOMB**10%****A040066 001** Dec 28, 1994SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

+ SANDOZ

500MG

A040091 001 Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

+ TEVA PHARMS USA

80MG/ML; 16MG/ML

A073303 001 Oct 31, 1991

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM**AB** AUROBINDO PHARMA**200MG/5ML; 40MG/5ML****A091348 001** Jun 08, 2010**AB** + HI TECH PHARMA**200MG/5ML; 40MG/5ML****A074650 001** Dec 29, 1997**AB** VINTAGE**200MG/5ML; 40MG/5ML****A077785 001** Jan 24, 2007SULFATRIM PEDIATRIC**AB** STI PHARMA LLC**200MG/5ML; 40MG/5ML****N018615 001** Jan 07, 1983

TABLET; ORAL

BACTRIM**AB** MUTUAL PHARM**400MG; 80MG****N017377 001**BACTRIM DS**AB** + MUTUAL PHARM**800MG; 160MG****N017377 002**SEPTRA**AB** MONARCH PHARMS**400MG; 80MG****N017376 001**

## PRESCRIPTION DRUG PRODUCT LIST

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SEPTRA DS

<b>AB</b>	MONARCH PHARMS	<b>800MG;160MG</b>	<b>N017376 002</b>	
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM</u>				
<b>AB</b>	AMNEAL PHARMS NY	<b>400MG;80MG</b>	<b>A076899 001</b>	Jan 27, 2005
<b>AB</b>		<b>800MG;160MG</b>	<b>A076899 002</b>	Jan 27, 2005
<b>AB</b>	AUROBINDO PHARMA	<b>400MG;80MG</b>	<b>A090624 001</b>	Feb 16, 2010
<b>AB</b>		<b>800MG;160MG</b>	<b>A090624 002</b>	Feb 16, 2010
<b>AB</b>	GLENMARK GENERICS	<b>400MG;80MG</b>	<b>A090828 002</b>	Dec 22, 2010
<b>AB</b>		<b>800MG;160MG</b>	<b>A090828 001</b>	Dec 22, 2010
<b>AB</b>	MUTUAL PHARM	<b>800MG;160MG</b>	<b>A071017 001</b>	Aug 25, 1986
<b>AB</b>	VINTAGE	<b>400MG;80MG</b>	<b>A078060 002</b>	Jan 25, 2007
<b>AB</b>		<b>800MG;160MG</b>	<b>A078060 001</b>	Jan 25, 2007
<b>AB</b>	VISTA PHARMS	<b>400MG;80MG</b>	<b>A076817 001</b>	Oct 07, 2005
<b>AB</b>		<b>800MG;160MG</b>	<b>A076817 002</b>	Oct 07, 2005
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH</u>				
<b>AB</b>	TEVA	<b>800MG;160MG</b>	<b>A070037 001</b>	Jun 02, 1987
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH</u>				
<b>AB</b>	TEVA PHARMS	<b>400MG;80MG</b>	<b>A070030 001</b>	Jun 02, 1987

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	MEDA PHARMS	15%	N006530 003	Jan 27, 1987
---	-------------	-----	-------------	--------------

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

+	PHARMACIA AND UPJOHN	250MG/5ML	A086983 001	
---	----------------------	-----------	-------------	--

TABLET; ORAL

AZULFIDINE

<b>AB</b>	+	PHARMACIA AND UPJOHN	<b>500MG</b>	<b>N007073 001</b>	
<u>SULFASALAZINE</u>					
<b>AB</b>	VINTAGE PHARMS	<b>500MG</b>	<b>A040349 001</b>	Jan 11, 2002	
<b>AB</b>	WATSON LABS	<b>500MG</b>	<b>A085828 001</b>		
TABLET, DELAYED RELEASE; ORAL					
<u>AZULFIDINE EN-TABS</u>					
<b>AB</b>	+	PHARMACIA AND UPJOHN	<b>500MG</b>	<b>N007073 002</b>	Apr 06, 1983
<u>SULFASALAZINE</u>					
<b>AB</b>	VINTAGE PHARMS	<b>500MG</b>	<b>A075339 001</b>	Jan 11, 2002	

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSOPHERES

FOR SUSPENSION; INTRAVENOUS

LUMASON

+	BRACCO	60.7MG/25MG	N203684 001	Oct 15, 2014
---	--------	-------------	-------------	--------------

SULINDAC

TABLET; ORAL

CLINORIL

<b>AB</b>	+	MERCK	<b>200MG</b>	<b>N017911 002</b>	
<u>SULINDAC</u>					
<b>AB</b>	EPIC PHARMA	<b>150MG</b>	<b>A072710 001</b>	Mar 25, 1991	
<b>AB</b>		<b>200MG</b>	<b>A072711 001</b>	Mar 25, 1991	
<b>AB</b>	HERITAGE PHARMS INC	<b>150MG</b>	<b>A073262 002</b>	Sep 06, 1991	
<b>AB</b>		<b>200MG</b>	<b>A073262 001</b>	Sep 06, 1991	
<b>AB</b>	MUTUAL PHARM	<b>150MG</b>	<b>A072050 001</b>	Apr 17, 1991	
<b>AB</b>		<b>200MG</b>	<b>A072051 001</b>	Apr 17, 1991	
<b>AB</b>	MYLAN	<b>150MG</b>	<b>A073039 002</b>	Jun 22, 1993	
<b>AB</b>		<b>200MG</b>	<b>A073039 001</b>	Jun 22, 1993	
<b>AB</b>	WATSON LABS	<b>150MG</b>	<b>A071891 001</b>	Apr 03, 1990	
<b>AB</b>		<b>200MG</b>	<b>A071795 001</b>	Apr 03, 1990	

SUMATRIPTAN

SPRAY; NASAL

IMITREX

+	GLAXOSMITHKLINE	5MG/SPRAY	N020626 001	Aug 26, 1997
+		20MG/SPRAY	N020626 003	Aug 26, 1997

## PRESCRIPTION DRUG PRODUCT LIST

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080 003</u>	Dec 23, 1996
-----------	-------------------	--------------------------------------------	--------------------	--------------

SUMATRIPTAN SUCCINATE

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090495 001</u>	Jan 29, 2014
-----------	--------------------	--------------------------------------------	--------------------	--------------

<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090358 001</u>	Jun 21, 2011
-----------	-------------------	--------------------------------------------	--------------------	--------------

IMITREX

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080 001</u>	Dec 28, 1992
-----------	-------------------	--------------------------------------------	--------------------	--------------

SUMATRIPTAN SUCCINATE

<u>AP</u>	AGILA SPECLTS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A203322 001</u>	Apr 14, 2014
-----------	---------------	--------------------------------------------	--------------------	--------------

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A202758 001</u>	Apr 23, 2013
-----------	----------------------	--------------------------------------------	--------------------	--------------

<u>AP</u>	BEDFORD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079123 001</u>	Feb 06, 2009
-----------	---------	--------------------------------------------	--------------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079242 001</u>	Mar 02, 2009
-----------	--------------------	--------------------------------------------	--------------------	--------------

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A200183 001</u>	Sep 16, 2013
-----------	--------------------	--------------------------------------------	--------------------	--------------

<u>AP</u>	INJECTALIA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090310 001</u>	Aug 11, 2010
-----------	------------	--------------------------------------------	--------------------	--------------

<u>AP</u>	PAR PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077332 001</u>	Oct 09, 2009
-----------	-----------	--------------------------------------------	--------------------	--------------

<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077871 001</u>	Jul 09, 2009
-----------	----------------------	--------------------------------------------	--------------------	--------------

<u>AP</u>	SAGENT AGILA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090641 001</u>	Jul 28, 2010
-----------	--------------	--------------------------------------------	--------------------	--------------

<u>AP</u>	SAGENT STRIDES	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090314 001</u>	Jun 10, 2010
-----------	----------------	--------------------------------------------	--------------------	--------------

<u>AP</u>	TEVA PHARMS USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077907 001</u>	Feb 06, 2009
-----------	-----------------	--------------------------------------------	--------------------	--------------

<u>AP</u>	WOCKHARDT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078593 001</u>	Feb 06, 2009
-----------	-----------	--------------------------------------------	--------------------	--------------

ALSUMA

BX	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010
----	----------------	-------------------------------------	-------------	--------------

IMITREX STATDOSE

BX	+ GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080 002	Feb 01, 2006
----	-------------------	------------------------------------	-------------	--------------

SUMAVEL DOSEPRO

BX	+ ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239 002	Nov 26, 2013
----	---------------------	------------------------------------	-------------	--------------

BX	+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001	Jul 15, 2009
----	---	-------------------------------------	-------------	--------------

SYSTEM; IONTOPHORESIS

ZECURITY

+ TEVA BRANDED PHARM

EQ 6.5MG BASE/4HR	N202278 001	Jan 17, 2013
-------------------	-------------	--------------

TABLET; ORAL

IMITREX

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 25MG BASE</u>	<u>N020132 002</u>	Jun 01, 1995
-----------	-----------------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N020132 003</u>	Jun 01, 1995
-----------	--	---------------------	--------------------	--------------

<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N020132 001</u>	Jun 01, 1995
-----------	---	----------------------	--------------------	--------------

SUMATRIPTAN SUCCINATE

<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A200263 001</u>	Jun 19, 2012
-----------	------------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200263 002</u>	Jun 19, 2012
-----------	--	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200263 003</u>	Jun 19, 2012
-----------	--	----------------------	--------------------	--------------

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A078327 001</u>	Aug 10, 2009
-----------	------------------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078327 002</u>	Aug 10, 2009
-----------	--	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078327 003</u>	Aug 10, 2009
-----------	--	----------------------	--------------------	--------------

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 25MG BASE</u>	<u>A076847 001</u>	Aug 10, 2009
-----------	--------------------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076847 002</u>	Aug 10, 2009
-----------	--	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076847 003</u>	Aug 10, 2009
-----------	--	----------------------	--------------------	--------------

<u>AB</u>	HIKMA PHARMS	<u>EQ 25MG BASE</u>	<u>A078298 001</u>	May 21, 2013
-----------	--------------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078298 002</u>	May 21, 2013
-----------	--	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078298 003</u>	May 21, 2013
-----------	--	----------------------	--------------------	--------------

<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077744 001</u>	Aug 10, 2009
-----------	-------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077744 002</u>	Aug 10, 2009
-----------	--	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077744 003</u>	Aug 10, 2009
-----------	--	----------------------	--------------------	--------------

<u>AB</u>	ORCHID HLTHCARE	<u>EQ 25MG BASE</u>	<u>A078284 001</u>	Aug 10, 2009
-----------	-----------------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078284 002</u>	Aug 10, 2009
-----------	--	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078284 003</u>	Aug 10, 2009
-----------	--	----------------------	--------------------	--------------

<u>AB</u>	RANBAXY	<u>EQ 25MG BASE</u>	<u>A076554 001</u>	Aug 10, 2009
-----------	---------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076554 002</u>	Aug 10, 2009
-----------	--	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076572 001</u>	Feb 09, 2009
-----------	--	----------------------	--------------------	--------------

<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A076976 001</u>	Aug 10, 2009
-----------	--------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076976 002</u>	Aug 10, 2009
-----------	--	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076976 003</u>	Aug 10, 2009
-----------	--	----------------------	--------------------	--------------

<u>AB</u>	SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295 001</u>	Aug 10, 2009
-----------	----------------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078295 002</u>	Aug 10, 2009
-----------	--	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078295 003</u>	Aug 10, 2009
-----------	--	----------------------	--------------------	--------------

<u>AB</u>	WATSON LABS	<u>EQ 25MG BASE</u>	<u>A076933 001</u>	Aug 10, 2009
-----------	-------------	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076933 002</u>	Aug 10, 2009
-----------	--	---------------------	--------------------	--------------

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076933 003</u>	Aug 10, 2009
-----------	--	----------------------	--------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

SUNITINIB MALATE

CAPSULE; ORAL

SUNITINIB MALATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 12.5MG BASE</u>	<u>A201275 001</u>	Jan 30, 2014
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A201275 002</u>	Jan 30, 2014
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A201275 003</u>	Jan 30, 2014
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201275 004</u>	Jan 30, 2014

SUTENT

<u>AB</u>	CPPI CV	<u>EQ 12.5MG BASE</u>	<u>N021938 001</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N021938 002</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>N021938 004</u>	Mar 31, 2009
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N021938 003</u>	Jan 26, 2006

SUVOREXANT

TABLET; ORAL

BELSOMRA

MERCK SHARP DOHME

+

5MG	N204569 001	Aug 13, 2014
10MG	N204569 002	Aug 13, 2014
15MG	N204569 003	Aug 13, 2014
20MG	N204569 004	Aug 13, 2014

TACROLIMUS

CAPSULE; ORAL

PROGRAF

<u>AB</u>	ASTELLAS	<u>EQ 0.5MG BASE</u>	<u>N050708 003</u>	Aug 24, 1998
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>N050708 001</u>	Apr 08, 1994
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N050708 002</u>	Apr 08, 1994

TACROLIMUS

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A091195 001</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A091195 002</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091195 003</u>	Aug 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A090509 001</u>	May 12, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090509 002</u>	May 12, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090509 003</u>	May 12, 2010
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A090596 001</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090596 002</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090596 003</u>	Sep 17, 2010
<u>AB</u>	PANACEA BIOTEC LTD	<u>EQ 0.5MG BASE</u>	<u>A090802 001</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090802 002</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090802 003</u>	Sep 28, 2012
<u>AB</u>	SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A065461 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A065461 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A065461 003</u>	Aug 10, 2009
<u>AB</u>	STRIDES PHARMA	<u>EQ 0.5MG BASE</u>	<u>A090687 001</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090687 002</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090687 003</u>	Jul 22, 2014

CAPSULE, EXTENDED RELEASE; ORAL

ASTAGRAF XL

ASTELLAS

+

INJECTABLE; INJECTION

PROGRAF

+ ASTELLAS

OINTMENT; TOPICAL

PROTOPIC

<u>AB</u>	+	ASTELLAS	<u>0.03%</u>	<u>N050777 001</u>	Dec 08, 2000
<u>AB</u>	+		<u>0.1%</u>	<u>N050777 002</u>	Dec 08, 2000

TACROLIMUS

<u>AB</u>	FOUGERA PHARMS INC	<u>0.03%</u>	<u>A200744 001</u>	Sep 09, 2014
<u>AB</u>		<u>0.1%</u>	<u>A200744 002</u>	Sep 09, 2014

TADALAFIL

TABLET; ORAL

ADCIRCA

+ ELI LILLY CO

CIALIS

LILLY

+

20MG	N022332 001	May 22, 2009
2.5MG	N021368 004	Jan 07, 2008
5MG	N021368 001	Nov 21, 2003
10MG	N021368 002	Nov 21, 2003
20MG	N021368 003	Nov 21, 2003

## PRESCRIPTION DRUG PRODUCT LIST

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

ZIOPTAN

+ OAK PHARMS INC 0.0015% N202514 001 Feb 10, 2012

TALC

AEROSOL, METERED;INTRAPLEURAL

SCLEROSOL

+ BRYAN 400MG/SPRAY N202587 001 Dec 24, 1997

POWDER;INTRAPLEURAL

TALC

+ BRYAN 5GM/BOT N2021388 001 Dec 15, 2003

TALIGLUCERASE ALFA

POWDER;IV (INFUSION)

ELELYSO

+ PFIZER 200 UNITS/VIAL N2022458 001 May 01, 2012

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

DARA BIOSCIENCES EQ 10MG BASE/5ML N2021807 001 Oct 29, 2005

TABLET;ORAL

TAMOXIFEN CITRATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 10MG BASE</u>	<u>A070929 001</u>	Feb 20, 2003
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076179 001</u>	Feb 20, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A070929 002</u>	Feb 20, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076179 002</u>	Feb 20, 2003
<u>AB</u>	APOTEX	<u>EQ 10MG BASE</u>	<u>A090878 001</u>	Sep 23, 2011
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090878 002</u>	Sep 23, 2011
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A074732 002</u>	Feb 20, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A074732 001</u>	Feb 20, 2003
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075797 001</u>	Feb 20, 2003
<u>AB</u>	+ TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A074858 001</u>	Feb 20, 2003

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

FLOMAXAB + BOEHRINGER INGELHEIM 0.4MG N202579 001 Apr 15, 1997TAMSULOSIN HYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>0.4MG</u>	<u>A202010 001</u>	Jan 04, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.4MG</u>	<u>A202433 001</u>	Apr 30, 2013
<u>AB</u>	IMPAX LABS	<u>0.4MG</u>	<u>A090377 001</u>	Mar 02, 2010
<u>AB</u>	MYLAN	<u>0.4MG</u>	<u>A090408 001</u>	Apr 27, 2010
<u>AB</u>	SANDOZ	<u>0.4MG</u>	<u>A078015 001</u>	Apr 27, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>0.4MG</u>	<u>A090931 001</u>	Jul 15, 2010
<u>AB</u>	SYNTHON PHARMS	<u>0.4MG</u>	<u>A078801 001</u>	Apr 27, 2010
<u>AB</u>	TEVA PHARMS	<u>0.4MG</u>	<u>A077630 001</u>	Apr 27, 2010
<u>AB</u>	WOCKHARDT	<u>0.4MG</u>	<u>A078938 001</u>	Apr 27, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.4MG</u>	<u>A078225 001</u>	Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

+ JANSSEN PHARMS EQ 20MG BASE/ML N203794 001 Oct 15, 2012

TABLET;ORAL

NUCYNTA

JANSSEN PHARMS EQ 50MG BASE N2022304 001 Nov 20, 2008

EQ 75MG BASE N2022304 002 Nov 20, 2008

+ EQ 100MG BASE N2022304 003 Nov 20, 2008

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

JANSSEN PHARMS EQ 50MG BASE N200533 001 Aug 25, 2011

EQ 100MG BASE N200533 002 Aug 25, 2011

EQ 150MG BASE N200533 003 Aug 25, 2011

EQ 200MG BASE N200533 004 Aug 25, 2011

+ EQ 250MG BASE N200533 005 Aug 25, 2011

TASIMELTEON

CAPSULE;ORAL

HETLIOZ

+ VANDA PHARMS INC 20MG N205677 001 Jan 31, 2014

## PRESCRIPTION DRUG PRODUCT LIST

TAVABOROLE

SOLUTION; TOPICAL

KERYDIN

+ ANACOR PHARMS INC 5%

N204427 001 Jul 07, 2014

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+ STIEFEL LABS INC 0.1%

N202428 001 May 11, 2012

CREAM; TOPICAL

AVAGE

+ ALLERGAN 0.1%

N021184 003 Sep 30, 2002

TAZORAC

+ ALLERGAN 0.05%

N021184 001 Sep 29, 2000

+ 0.1%

N021184 002 Sep 29, 2000

GEL; TOPICAL

TAZORAC

+ ALLERGAN 0.05%

N020600 001 Jun 13, 1997

+ 0.1%

N020600 002 Jun 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

PULMOLITE

BS JUBILANT DRAXIMAGE N/A

N017776 001

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS DRAXIMAGE N/A

N017881 001 Dec 30, 1987

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

LANTHEUS MEDCL N/A

N020256 001 Nov 23, 1994

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION

HEPATOLITE

PHARMALUCENCE N/A

N018467 001 Mar 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION

CERETEC

+ GE HEALTHCARE N/A

N019829 001 Dec 30, 1988

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

**CHOLETEC****AP + BRACCO N/A****N018963 001** Jan 21, 1987**TECHNETIUM TC-99M MEBROFENIN****AP PHARMALUCENCE N/A****A078242 001** Jan 29, 2008TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-25

+ JUBILANT DRAXIMAGE N/A

N018035 002 Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

**CIS-MDP****AP PHARMALUCENCE N/A****N018124 001****MDP-BRACCO****AP BRACCO N/A****N018107 001**TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNESCAN MAG3

+ MALLINCKRODT N/A

N019882 001 Jun 15, 1990

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN

+ MALLINCKRODT N/A

N018321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

**AN-DTPA****AP JUBILANT DRAXIMAGE N/A****N017714 001****DTPA****AP DRAXIMAGE N/A****N018511 001** Dec 29, 1989

## PRESCRIPTION DRUG PRODUCT LIST

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO

<b>AP</b>	PHARMALUCENCE	<b>N/A</b>	<b>N019039 001</b>	Jun 30, 1987
-----------	---------------	------------	--------------------	--------------

TECHNESCAN PYP KIT

<b>AP</b>	MALLINCKRODT	<b>N/A</b>	<b>N017538 001</b>	
-----------	--------------	------------	--------------------	--

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

MALLINCKRODT N/A

N019981 001 Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

<b>AP</b>	+ LANTHEUS MEDCL	<b>N/A</b>	<b>N019785 001</b>	Dec 21, 1990
-----------	------------------	------------	--------------------	--------------

TECHNETIUM TC 99M SESTAMIBI

<b>AP</b>	CARDINAL HEALTH 414	<b>N/A</b>	<b>A078809 001</b>	Apr 28, 2009
-----------	---------------------	------------	--------------------	--------------

<b>AP</b>	DRAXIMAGE	<b>N/A</b>	<b>A078806 001</b>	Apr 29, 2009
-----------	-----------	------------	--------------------	--------------

<b>AP</b>	PHARMALUCENCE	<b>10-30mCi</b>	<b>A079157 001</b>	Jul 10, 2009
-----------	---------------	-----------------	--------------------	--------------

TECHNETIUM TC-99M SESTAMIBI

<b>AP</b>	MALLINCKRODT	<b>N/A</b>	<b>A078098 001</b>	Sep 22, 2008
-----------	--------------	------------	--------------------	--------------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS

TECHNELITE

+ LANTHEUS MEDCL 1-20 CI/GENERATOR

N017771 002 Feb 12, 2014

ULTRA-TECHNEKOW FM

+ MALLINCKRODT 1-19 CI/GENERATOR

N017243 003 Feb 18, 2014

SOLUTION; INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

+ GE HEALTHCARE 68-2703mCi/GENERATOR

N017693 002 Dec 13, 2013

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT

GE HEALTHCARE N/A

N017944 001 May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID

+ PHARMALUCENCE N/A

N017858 001

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW

+ GE HEALTHCARE N/A

N020372 001 Feb 09, 1996

MYOVIEW 30ML

+ GE HEALTHCARE N/A

N020372 002 Jul 07, 2005

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT

+ NAVIDEA BIOPHARMS N/A

N202207 001 Mar 13, 2013

TEDIZOLID PHOSPHATE

POWDER; IV (INFUSION)

SIVEXTRO

+ CUBIST PHARMS INC 200MG/VIAL

N205436 001 Jun 20, 2014

TABLET; ORAL

SIVEXTRO

+ CUBIST PHARMS INC 200MG

N205435 001 Jun 20, 2014

TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS

GATTEX KIT

+ NPS PHARMS INC 5MG/VIAL

N203441 001 Dec 21, 2012

TELAPREVIR

TABLET; ORAL

INCIVEK

+ VERTEX PHARMS 375MG

N201917 001 May 23, 2011



## PRESCRIPTION DRUG PRODUCT LIST

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

VIBATIV

THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009
+	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009

TELBIVUDINE

TABLET; ORAL

TYZEKA

+ NOVARTIS	600MG	N022011	001	Oct 25, 2006
------------	-------	---------	-----	--------------

TELITHROMYCIN

TABLET; ORAL

KETEK

SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005
+	400MG	N021144	001	Apr 01, 2004

TELMISARTAN

TABLET; ORAL

MICARDIS

<b>AB</b>	BOEHRINGER INGELHEIM	<b>20MG</b>	<b>N020850</b>	<b>003</b>	Apr 04, 2000
<b>AB</b>		<b>40MG</b>	<b>N020850</b>	<b>001</b>	Nov 10, 1998
<b>AB</b>	+	<b>80MG</b>	<b>N020850</b>	<b>002</b>	Nov 10, 1998

TELMISARTAN

<b>AB</b>	ALEMBIC PHARMS LTD	<b>20MG</b>	<b>A202130</b>	<b>001</b>	Jul 07, 2014
<b>AB</b>		<b>40MG</b>	<b>A202130</b>	<b>002</b>	Jul 07, 2014
<b>AB</b>		<b>80MG</b>	<b>A202130</b>	<b>003</b>	Jul 07, 2014
<b>AB</b>	GLENMARK GENERICS	<b>20MG</b>	<b>A090032</b>	<b>001</b>	Jul 07, 2014
<b>AB</b>		<b>40MG</b>	<b>A090032</b>	<b>002</b>	Jul 07, 2014
<b>AB</b>		<b>80MG</b>	<b>A090032</b>	<b>003</b>	Jul 07, 2014
<b>AB</b>	MYLAN PHARMS INC	<b>20MG</b>	<b>A202397</b>	<b>001</b>	Jul 07, 2014
<b>AB</b>		<b>40MG</b>	<b>A202397</b>	<b>002</b>	Jul 07, 2014
<b>AB</b>		<b>80MG</b>	<b>A202397</b>	<b>003</b>	Jul 07, 2014
<b>AB</b>	SANDOZ	<b>20MG</b>	<b>A203867</b>	<b>001</b>	Nov 03, 2014
<b>AB</b>		<b>40MG</b>	<b>A203867</b>	<b>002</b>	Nov 03, 2014
<b>AB</b>		<b>80MG</b>	<b>A203867</b>	<b>003</b>	Nov 03, 2014
<b>AB</b>	TORRENT PHARMS LTD	<b>20MG</b>	<b>A203171</b>	<b>001</b>	Jul 07, 2014
<b>AB</b>		<b>40MG</b>	<b>A203171</b>	<b>002</b>	Jul 07, 2014
<b>AB</b>		<b>80MG</b>	<b>A203171</b>	<b>003</b>	Jul 07, 2014
<b>AB</b>	WATSON LABS	<b>20MG</b>	<b>A078710</b>	<b>001</b>	Jan 08, 2014
<b>AB</b>		<b>40MG</b>	<b>A078710</b>	<b>002</b>	Jan 08, 2014
<b>AB</b>		<b>80MG</b>	<b>A078710</b>	<b>003</b>	Jan 08, 2014
<b>AB</b>	ZYDUS PHARMS USA INC	<b>20MG</b>	<b>A203325</b>	<b>001</b>	Aug 26, 2014
<b>AB</b>		<b>40MG</b>	<b>A203325</b>	<b>002</b>	Aug 26, 2014
<b>AB</b>		<b>80MG</b>	<b>A203325</b>	<b>003</b>	Aug 26, 2014

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

<b>AB</b>	MALLINCKRODT INC	<b>7.5MG</b>	<b>N018163</b>	<b>003</b>	Oct 25, 1991
<b>AB</b>		<b>15MG</b>	<b>N018163</b>	<b>001</b>	
<b>AB</b>		<b>22.5MG</b>	<b>N018163</b>	<b>004</b>	Nov 02, 2004
<b>AB</b>	+	<b>30MG</b>	<b>N018163</b>	<b>002</b>	

TEMAZEPAM

<b>AB</b>	ACTAVIS ELIZABETH	<b>15MG</b>	<b>A071638</b>	<b>001</b>	Aug 07, 1987
<b>AB</b>		<b>30MG</b>	<b>A071620</b>	<b>001</b>	Aug 07, 1987
<b>AB</b>	MUTUAL PHARM	<b>7.5MG</b>	<b>A078581</b>	<b>001</b>	Sep 08, 2009
<b>AB</b>		<b>22.5MG</b>	<b>A071175</b>	<b>002</b>	Sep 14, 2009
<b>AB</b>	MYLAN	<b>7.5MG</b>	<b>A070920</b>	<b>002</b>	May 21, 2010
<b>AB</b>		<b>15MG</b>	<b>A070920</b>	<b>004</b>	Jul 07, 1986
<b>AB</b>		<b>22.5MG</b>	<b>A070920</b>	<b>003</b>	Jun 12, 2009
<b>AB</b>		<b>30MG</b>	<b>A070920</b>	<b>001</b>	Jul 10, 1986
<b>AB</b>	NOVEL LABS INC	<b>7.5MG</b>	<b>A071457</b>	<b>002</b>	Jun 22, 2012
<b>AB</b>		<b>15MG</b>	<b>A071456</b>	<b>001</b>	Apr 21, 1987
<b>AB</b>		<b>22.5MG</b>	<b>A071457</b>	<b>003</b>	Jun 22, 2012
<b>AB</b>		<b>30MG</b>	<b>A071457</b>	<b>001</b>	Apr 21, 1987
<b>AB</b>	SANDOZ	<b>15MG</b>	<b>A071427</b>	<b>001</b>	Jan 12, 1988
<b>AB</b>		<b>30MG</b>	<b>A071428</b>	<b>001</b>	Jan 12, 1988

## PRESCRIPTION DRUG PRODUCT LIST

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

<u>AB</u>	MERCK SHARP DOHME	<u>5MG</u>	<u>N021029 001</u>	Aug 11, 1999
<u>AB</u>		<u>20MG</u>	<u>N021029 002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>N021029 003</u>	Aug 11, 1999
<u>AB</u>		<u>140MG</u>	<u>N021029 005</u>	Oct 19, 2006
<u>AB</u>		<u>180MG</u>	<u>N021029 006</u>	Oct 19, 2006
<u>AB</u>	+	<u>250MG</u>	<u>N021029 004</u>	Aug 11, 1999

TEMOZOLOMIDE

<u>AB</u>	BARR	<u>5MG</u>	<u>A078879 001</u>	Mar 01, 2010
<u>AB</u>		<u>20MG</u>	<u>A078879 002</u>	Mar 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078879 003</u>	Mar 01, 2010
<u>AB</u>		<u>140MG</u>	<u>A078879 005</u>	Mar 01, 2010
<u>AB</u>		<u>180MG</u>	<u>A078879 006</u>	Mar 01, 2010
<u>AB</u>		<u>250MG</u>	<u>A078879 004</u>	Mar 01, 2010
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A201742 001</u>	Feb 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A201742 002</u>	Feb 12, 2014
<u>AB</u>		<u>100MG</u>	<u>A201742 003</u>	Feb 12, 2014
<u>AB</u>		<u>140MG</u>	<u>A201742 004</u>	Feb 12, 2014
<u>AB</u>		<u>180MG</u>	<u>A201742 005</u>	Feb 12, 2014
<u>AB</u>		<u>250MG</u>	<u>A201742 006</u>	Feb 12, 2014

POWDER; INTRAVENOUS

TEMODAR

+	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009
---	-------------------	------------	-------------	--------------

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TORISEL

+	PF PRISM CV	25MG/ML (25MG/ML)	N022088 001	May 30, 2007
---	-------------	-------------------	-------------	--------------

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

+	HQ SPECLT PHARMA	10MG/ML	N020119 001	Jul 14, 1992
---	------------------	---------	-------------	--------------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577 001	Jan 18, 2012
---	---------------------	---------------	-------------	--------------

TABLET; ORAL

VIREAD

	GILEAD SCIENCES INC	150MG	N021356 002	Jan 18, 2012
		200MG	N021356 003	Jan 18, 2012
		250MG	N021356 004	Jan 18, 2012
+		300MG	N021356 001	Oct 26, 2001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075498 001</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075498 002</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075498 003</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075498 004</u>	Apr 12, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A075614 002</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075614 001</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075614 003</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075614 004</u>	Jan 30, 2001
<u>AB</u>	JUBILANT CADISTA	<u>EQ 1MG BASE</u>	<u>A075317 001</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075317 002</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075317 003</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075317 004</u>	Dec 20, 2004
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075140 002</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075140 003</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075140 001</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075140 004</u>	Feb 11, 2000
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A074823 001</u>	Mar 30, 1998
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>A074823 002</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A074823 003</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A074823 004</u>	Mar 30, 1998

## PRESCRIPTION DRUG PRODUCT LIST

TERBINAFINE HYDROCHLORIDE

GRANULE; ORAL

LAMISIL

NOVARTIS

EQ 125MG BASE/PACKET

N022071 001 Sep 28, 2007

+

EQ 187.5MG BASE/PACKET

N022071 002 Sep 28, 2007

TABLET; ORAL

LAMISIL**AB** + NOVARTISEQ 250MG BASE**N020539 001** May 10, 1996TERBINAFINE HYDROCHLORIDE**AB** APOTEXEQ 250MG BASE**A078199 001** Jul 02, 2007**AB** AUROBINDO PHARMAEQ 250MG BASE**A078297 001** Jul 02, 2007**AB** BRECKENRIDGE PHARMEQ 250MG BASE**A077714 001** Jun 04, 2010**AB** CIPLA LTDEQ 250MG BASE**A077137 001** Jul 02, 2007**AB** DR REDDYS LABS INCEQ 250MG BASE**A076390 001** Jul 02, 2007**AB** GLENMARK GENERICSEQ 250MG BASE**A078157 001** Jul 02, 2007**AB** HARRIS PHARMEQ 250MG BASE**A077919 001** Jul 02, 2007**AB** INVAGEN PHARMSEQ 250MG BASE**A077533 001** Jul 02, 2007**AB** MYLANEQ 250MG BASE**A077195 001** Jul 02, 2007**AB** ORCHID HLTHCAREEQ 250MG BASE**A078163 001** Jul 02, 2007**AB** TEVAEQ 250MG BASE**A076377 001** Jul 02, 2007**AB** WOCKHARDTEQ 250MG BASE**A078229 001** Jul 02, 2007TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE**AP** AKORN1MG/ML**A078151 001** Jan 07, 2008**AP** + BEDFORD1MG/ML**A076770 001** Apr 23, 2004**AP** FRESENIUS KABI USA1MG/ML**A076887 001** May 26, 2004**AP** HIKMA FARMACEUTICA1MG/ML**A078630 001** May 20, 2009**AP** UNITED BIOMEDCL1MG/ML**A200122 001** Nov 08, 2013

TABLET; ORAL

TERBUTALINE SULFATE**AB** IMPAX LABS2.5MG**A075877 001** Jun 26, 2001**AB** +5MG**A075877 002** Jun 26, 2001**AB** LANNETT2.5MG**A077152 001** Mar 25, 2005**AB**5MG**A077152 002** Mar 25, 2005TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3**AB** + JANSSEN PHARMS0.8%**N019964 001** Feb 21, 1991TERAZOL 7**AB** + JANSSEN PHARMS0.4%**N019579 001** Dec 31, 1987TERCONAZOLE**AB** FOUGERA PHARMS0.4%**A076712 001** Feb 18, 2005**AB** TARO0.4%**A076043 001** Jan 19, 2005**AB**0.8%**A075953 001** Apr 06, 2004

BX + NYCOMED US

0.8%

N021735 001 Oct 01, 2004

SUPPOSITORY; VAGINAL

TERAZOL 3**AB** + JANSSEN PHARMS80MG**N019641 001** May 24, 1988TERCONAZOLE**AB** PERRIGO NEW YORK80MG**A077149 001** Mar 17, 2006TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

SANOFI AVENTIS US

7MG

N202992 001 Sep 12, 2012

+

14MG

N202992 002 Sep 12, 2012

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

+ LILLY

0.6MG/2.4ML (0.25MG/ML)

N021318 002 Jun 25, 2008

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

+ THERATECHNOLOGIES

EQ 1MG BASE/VIAL

N022505 001 Nov 10, 2010

## PRESCRIPTION DRUG PRODUCT LIST

TESTOSTERONE

FILM, EXTENDED RELEASE;TRANSDERMAL

ANDRODERM

+ ACTAVIS LABS UT INC

2MG/24HR

N020489 003 Oct 20, 2011

+

4MG/24HR

N020489 004 Oct 20, 2011

GEL;TRANSDERMAL

ANDROGELAB ABBVIE25MG/2.5GM PACKETN021015 001 Feb 28, 2000AB +50MG/5GM PACKETN021015 002 Feb 28, 2000TESTOSTERONEAB PERRIGO ISRAEL25MG/2.5GM PACKETN203098 002 Jan 31, 2013AB50MG/5GM PACKETN203098 003 Jan 31, 2013

TESTIM

BX + AUXILIUM PHARMS

1% (50MG/5GM PACKET)

N021454 001 Oct 31, 2002

TESTOSTERONE

BX TEVA PHARMS

25MG/2.5GM PACKET

N202763 001 Feb 14, 2012

BX

50MG/5GM PACKET

N202763 002 Feb 14, 2012

ANDROGEL

ABBVIE

1.62% (20.25MG/1.25GM PACKET)

N022309 002 Sep 07, 2012

+

1.62% (40.5MG/2.5GM PACKET)

N022309 003 Sep 07, 2012

VOGELXO

UPSHER SMITH

50MG/5GM PACKET

N204399 002 Jun 04, 2014

GEL, METERED;NASAL

NATESTO

ENDO VENTURES LTD

5.5MG/0.122GM ACTUATION

N205488 001 May 28, 2014

GEL, METERED;TRANSDERMAL

ANDROGELAB + ABBVIE12.5MG/1.25GM ACTUATIONN021015 003 Sep 26, 2003TESTOSTERONEAB PERRIGO ISRAEL12.5MG/1.25GM ACTUATIONN203098 001 Jan 31, 2013

VOGELXO

BX UPSHER SMITH

12.5MG/1.25GM ACTUATION

N204399 003 Jun 04, 2014

ANDROGEL

+ ABBVIE

1.62% (20.25MG/1.25GM ACTUATION)

N022309 001 Apr 29, 2011

FORTESTA

+ ENDO PHARMS

10MG/0.5GM ACTUATION

N021463 001 Dec 29, 2010

PELLET;IMPLANTATION

TESTOPEL

+ ACTIENT PHARMS

75MG

A080911 001

SOLUTION, METERED;TRANSDERMAL

AXIRON

+ ELI LILLY AND CO

30MG/1.5ML ACTUATION

N022504 001 Nov 23, 2010

TABLET, EXTENDED RELEASE;BUCCAL

STRIANT

+ AUXILIUM PHARMS LLC

30MG

N021543 001 Jun 19, 2003

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTOSTERONEAO + PHARMACIA AND UPJOHN100MG/MLA085635 002AO +200MG/MLA085635 003TESTOSTERONE CYPIONATEAO BEDFORD100MG/MLA090387 001 Jul 15, 2010AO200MG/MLA090387 002 Jul 15, 2010AO HIKMA FARMACEUTICA200MG/MLA091244 001 May 01, 2012AO MYLAN INSTITUTIONAL200MG/MLA040652 001 Dec 11, 2006AO PADDOCK LLC200MG/MLA040530 001 Jan 31, 2005AO SANDOZ100MG/MLA040615 001 Aug 10, 2006AO200MG/MLA040615 002 Aug 10, 2006AO SUN PHARM INDS LTD100MG/MLA201720 001 Jun 03, 2013AO200MG/MLA201720 002 Jun 03, 2013AO WATSON LABS200MG/MLA086030 001TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

DELATESTRYLAO + ENDO PHARMS200MG/MLN009165 003TESTOSTERONE ENANTHATEAO HIKMA FARMACEUTICA200MG/MLA091120 001 Sep 18, 2012AO MYLAN INSTITUTIONAL200MG/MLA040647 001 Oct 05, 2009AO PADDOCK LLC200MG/MLA040575 001 Jun 14, 2006AO WATSON LABS200MG/MLA085598 001

## PRESCRIPTION DRUG PRODUCT LIST

TESTOSTERONE UNDECANOATE

INJECTABLE; INTRAMUSCULAR

AVEED

+ ENDO PHARMS INC 750MG/3ML (250MG/ML) N022219 001 Mar 04, 2014

TETRABENAZINE

TABLET; ORAL

XENAZINE

VALEANT BERMUDA 12.5MG N021894 001 Aug 15, 2008

+ 25MG N021894 002 Aug 15, 2008

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V**AB** HERITAGE PHARMS INC **250MG** **N050278 003****AB** **500MG** **N050278 001**TETRACYCLINE HYDROCHLORIDE**AB** IMPAX LABS **250MG** **A060469 001****AB** **500MG** **A060469 003****AB** IVAX SUB TEVA PHARMS **250MG** **A060704 001****AB** + **500MG** **A060704 002****AB** WATSON LABS **250MG** **A061837 001****AB** **500MG** **A061837 002**

IMPAX LABS 100MG A060469 002

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+ FOUGERA PHARMS 0.05% A086576 002

0.1% A086576 001

SPRAY; NASAL

TYZINE

+ FOUGERA PHARMS 0.1% A086576 003

THALIDOMIDE

CAPSULE; ORAL

THALOMID

CELGENE 50MG N020785 001 Jul 16, 1998

100MG N020785 002 Jan 17, 2003

150MG N020785 004 Jan 10, 2007

+ 200MG N020785 003 Jan 17, 2003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201**AP** + GE HEALTHCARE **1mCi/ML** **N018110 002** Feb 27, 1996**AP** + LANTHEUS MEDCL **1mCi/ML** **N017806 001****AP** + MALLINCKRODT **1mCi/ML** **N018150 001**

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201**AP** + LANTHEUS MEDCL **2mCi/ML** **N017806 002** Oct 09, 1998THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

ACTIENT PHARMS 100MG A087942 001 Aug 22, 1983

200MG A087943 001 Aug 22, 1983

300MG A087944 001 Aug 22, 1983

+ 400MG A081034 001 Feb 28, 1992

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER**AP** + B BRAUN **40MG/100ML** **N019826 001** Aug 14, 1992THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER**AP** + B BRAUN **80MG/100ML** **N019826 002** Aug 14, 1992THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER**AP** + B BRAUN **160MG/100ML** **N019826 003** Aug 14, 1992THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER**AP** + B BRAUN **320MG/100ML** **N019826 006** Aug 14, 1992THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER**AP** + HOSPIRA INC **4MG/ML** **N019211 007** Dec 14, 1984**AP** + **40MG/100ML** **N019211 001** Dec 14, 1984**AP** + **160MG/100ML** **N019211 003** Dec 14, 1984**AP** + **320MG/100ML** **N019211 006** Jan 20, 1988

## PRESCRIPTION DRUG PRODUCT LIST

THEOPHYLLINE

SOLUTION; ORAL

THEOPHYLLINE

<b>AA</b>	+	SILARX	<b>80MG/15ML</b>	<b>A091156 001</b>	Apr 13, 2011
<b>AA</b>		TRIS PHARMA INC	<b>80MG/15ML</b>	<b>A091586 001</b>	Jun 15, 2012
SOLUTION, ELIXIR; ORAL					
ELIXOPHYLLIN					
	+	SUN PHARM INDS INC	80MG/15ML	A085186 001	
TABLET; ORAL					
THEOLAIR					
	+	MEDICIS	125MG	A086399 001	
	+		250MG	A086399 002	
TABLET, EXTENDED RELEASE; ORAL					

THEOCHRON

<b>AB</b>		SUN PHARM INDS INC	<b>100MG</b>	<b>A088320 001</b>	Feb 21, 1985
<b>AB</b>			<b>200MG</b>	<b>A088321 001</b>	Feb 21, 1985

THEOPHYLLINE

<b>AB</b>		ALEMBIC LTD	<b>300MG</b>	<b>A090430 001</b>	Oct 27, 2010
<b>AB</b>			<b>450MG</b>	<b>A090430 002</b>	Oct 27, 2010
<b>AB</b>		GLENMARK GENERICS	<b>400MG</b>	<b>A090355 001</b>	Jul 13, 2010
<b>AB</b>			<b>600MG</b>	<b>A090355 002</b>	Jul 13, 2010
<b>AB</b>		NOSTRUM	<b>400MG</b>	<b>A040595 001</b>	Apr 21, 2006
<b>AB</b>	+		<b>600MG</b>	<b>A040560 002</b>	Apr 21, 2006
<b>AB</b>	+	PLIVA	<b>100MG</b>	<b>A089807 001</b>	Apr 30, 1990
<b>AB</b>	+		<b>200MG</b>	<b>A089808 001</b>	Apr 30, 1990
<b>AB</b>			<b>300MG</b>	<b>A089763 001</b>	Apr 30, 1990
<b>AB</b>		RHODES PHARMS	<b>600MG</b>	<b>A040086 001</b>	Apr 15, 1996
<b>AB</b>	+	TEVA PHARMS	<b>450MG</b>	<b>A081236 001</b>	Nov 09, 1992

UNIPHYL

<b>AB</b>		RHODES PHARMS	<b>400MG</b>	<b>A087571 001</b>	Sep 01, 1982
-----------	--	---------------	--------------	--------------------	--------------

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

<b>AP</b>	+	FRESENIUS KABI USA	<b>100MG/ML</b>	<b>A080556 001</b>	
<b>AP</b>		MYLAN INSTITUTIONAL	<b>100MG/ML</b>	<b>A091623 001</b>	Jun 25, 2012

THIOGUANINE

TABLET; ORAL

THIOGUANINE

	+	ASPEN GLOBAL INC	40MG	N012429 001	
--	---	------------------	------	-------------	--

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

<b>AB</b>		MUTUAL PHARM	<b>10MG</b>	<b>A089953 004</b>	Aug 01, 1986
<b>AB</b>			<b>25MG</b>	<b>A089953 003</b>	Aug 01, 1986
<b>AB</b>			<b>50MG</b>	<b>A089953 002</b>	Aug 01, 1986
<b>AB</b>			<b>100MG</b>	<b>A089953 001</b>	Oct 07, 1988
<b>AB</b>		MYLAN	<b>10MG</b>	<b>A088004 002</b>	Mar 15, 1983
<b>AB</b>			<b>25MG</b>	<b>A088004 003</b>	Mar 15, 1983
<b>AB</b>			<b>50MG</b>	<b>A088004 004</b>	Mar 15, 1983
<b>AB</b>	+		<b>100MG</b>	<b>A088004 001</b>	Nov 18, 1983

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

		EUROHLTH INTL	15MG/VIAL	A075547 001	Apr 02, 2001
--	--	---------------	-----------	-------------	--------------

THIOTHIXENE

CAPSULE; ORAL

NAVANE

<b>AB</b>		PFIZER	<b>1MG</b>	<b>N016584 001</b>	
<b>AB</b>			<b>2MG</b>	<b>N016584 002</b>	
<b>AB</b>	+		<b>5MG</b>	<b>N016584 003</b>	
<b>AB</b>			<b>10MG</b>	<b>N016584 004</b>	

THIOTHIXENE

<b>AB</b>		MYLAN	<b>1MG</b>	<b>A071093 002</b>	Jun 23, 1987
<b>AB</b>			<b>2MG</b>	<b>A071093 003</b>	Jun 23, 1987
<b>AB</b>			<b>5MG</b>	<b>A071093 004</b>	Jun 23, 1987
<b>AB</b>			<b>10MG</b>	<b>A071093 001</b>	Jun 23, 1987
<b>AB</b>		SANDOZ	<b>1MG</b>	<b>A071610 001</b>	Jun 24, 1987
<b>AB</b>			<b>2MG</b>	<b>A071570 001</b>	Jun 24, 1987
<b>AB</b>			<b>5MG</b>	<b>A071529 001</b>	Jun 24, 1987
<b>AB</b>			<b>10MG</b>	<b>A071530 001</b>	Jun 24, 1987

## PRESCRIPTION DRUG PRODUCT LIST

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN

+ GENZYME

1.1MG/VIAL

N020898 001 Nov 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRILAB CEPHALON2MGN020646 005 Apr 16, 1999AB +4MGN020646 001 Sep 30, 1997TIAGABINE HYDROCHLORIDEAB SUN PHARM INDS2MGA077555 001 Nov 04, 2011AB4MGA077555 002 Nov 04, 2011

GABITRIL

CEPHALON

12MG

N020646 002 Sep 30, 1997

16MG

N020646 003 Sep 30, 1997

TICAGRELOR

TABLET; ORAL

BRILINTA

+ ASTRAZENECA LP

90MG

N022433 001 Jul 20, 2011

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDEAB APOTEX250MGA075089 001 Jul 01, 1999AB SUN PHARM INDS INC250MGA075526 001 Sep 26, 2002AB +

TEVA

250MGA075149 001 Aug 20, 1999TIGECYCLINE

INJECTABLE; IV (INFUSION)

TYGACIL

+ PF PRISM CV

50MG/VIAL

N021821 001 Jun 15, 2005

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

+ OAK PHARMS INC

EQ 0.25% BASE

N020439 001 Mar 31, 1995

+

EQ 0.5% BASE

N020439 002 Mar 31, 1995

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATEAB ALCON RES LTDEQ 0.25% BASEN020963 001 Oct 21, 1998ABEQ 0.5% BASEN020963 002 Oct 21, 1998TIMOPTIC-XEAB + VALEANT PHARMS LLCEQ 0.25% BASEN020330 001 Nov 04, 1993AB +EQ 0.5% BASEN020330 002 Nov 04, 1993

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATEAT AKORNEQ 0.5% BASEA074466 001 Mar 25, 1997ATEQ 0.5% BASEA074516 001 Mar 25, 1997AT ALCON RES LTDEQ 0.25% BASEA074261 001 Apr 28, 1995ATEQ 0.5% BASEA074262 001 Apr 28, 1995AT BAUSCH AND LOMBEQ 0.25% BASEA074778 001 Mar 25, 1997ATEQ 0.5% BASEA074776 001 Mar 25, 1997AT FDC LTDEQ 0.25% BASEA077259 001 Apr 30, 2008ATEQ 0.5% BASEA077259 002 Apr 30, 2008AT HI TECH PHARMAEQ 0.5% BASEA075163 001 Sep 10, 2002AT

PACIFIC PHARMA

EQ 0.25% BASEA074746 001 Mar 25, 1997AT

WOCKHARDT

EQ 0.5% BASEA074747 001 Mar 25, 1997AT

WOCKHARDT

EQ 0.25% BASEA078771 001 Sep 28, 2009AT

WOCKHARDT

EQ 0.5% BASEA078771 002 Sep 28, 2009TIMOPTICAT + ATONEQ 0.25% BASEN018086 001AT +EQ 0.5% BASEN018086 002

ISTALOL

BT + BAUSCH AND LOMB

EQ 0.5% BASE

N021516 001 Jun 04, 2004

TIMOPTIC IN OCUDOSE

+ ATON

EQ 0.25% BASE

N019463 001 Nov 05, 1986

+

EQ 0.5% BASE

N019463 002 Nov 05, 1986

TABLET; ORAL

TIMOLOL MALEATE

MYLAN

5MG

A072668 002 Jun 08, 1990

10MG

A072668 003 Jun 08, 1990

## PRESCRIPTION DRUG PRODUCT LIST

TIMOLOL MALEATE

TABLET; ORAL

TIMOLOL MALEATE

+

20MG

A072668 001 Jun 08, 1990

TINIDAZOLE

TABLET; ORAL

TINDAMAXAB MISSION PHARMA250MGN021618 001 May 17, 2004AB +500MGN021618 002 May 17, 2004TINIDAZOLEAB NOVEL LABS INC250MGA202044 001 Apr 30, 2012AB500MGA202044 002 Apr 30, 2012AB ROXANE250MGA201172 001 Apr 30, 2012AB500MGA201172 002 Apr 30, 2012AB UNIQUE PHARM LABS250MGA202489 001 Oct 09, 2013AB500MGA202489 002 Oct 09, 2013TIOPRONIN

TABLET; ORAL

THIOLA

+ MISSION PHARMA

100MG

N019569 001 Aug 11, 1988

TIOTROPIUM BROMIDE

POWDER; INHALATION

SPIRIVA

+ BOEHRINGER INGELHEIM

EQ 0.018MG BASE/INH

N021395 001 Jan 30, 2004

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

+ BOEHRINGER INGELHEIM

EQ 0.0025MG BASE/INH

N021936 001 Sep 24, 2014

TIPRANAVIR

CAPSULE; ORAL

APTIVUS

+ BOEHRINGER INGELHEIM

250MG

N021814 001 Jun 22, 2005

SOLUTION; ORAL

APTIVUS

+ BOEHRINGER INGELHEIM

100MG/ML

N022292 001 Jun 23, 2008

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

+

EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)

N020913 002 May 17, 2002

EQ 12.5MG BASE/250ML (EQ 0.05MG

N020913 003 Apr 20, 2000

BASE/ML)

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDEAB APOTEX INCEQ 2MG BASEA078868 001 Feb 03, 2012ABEQ 4MG BASEA078868 002 Feb 03, 2012ABEQ 6MG BASEA078868 003 Feb 03, 2012AB MYLAN PHARMS INCEQ 2MG BASEA091502 001 Nov 09, 2012ABEQ 4MG BASEA091502 002 Nov 09, 2012ABEQ 6MG BASEA091502 003 Nov 09, 2012ZANAFLEXAB ACORDAEQ 2MG BASEN021447 001 Aug 29, 2002ABEQ 4MG BASEN021447 002 Aug 29, 2002AB +EQ 6MG BASEN021447 003 Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDEAB APOTEXEQ 2MG BASEA076533 001 Jan 16, 2004ABEQ 4MG BASEA076533 002 Jan 16, 2004AB COREPHARMAEQ 2MG BASEA076347 001 Oct 11, 2002ABEQ 4MG BASEA076347 002 Oct 11, 2002AB DR REDDYS LABS INCEQ 2MG BASEA076286 001 Jul 03, 2002ABEQ 4MG BASEA076286 002 Jul 03, 2002AB MYLANEQ 2MG BASEA076354 001 Mar 28, 2003ABEQ 4MG BASEA076354 002 Mar 28, 2003AB PROSAM LABSEQ 2MG BASEA076281 001 Oct 20, 2003ABEQ 4MG BASEA076281 002 Oct 20, 2003AB SANDOZ INCEQ 2MG BASEA076280 001 Nov 26, 2002ABEQ 4MG BASEA076280 002 Jun 27, 2002AB SUN PHARM INDS INCEQ 2MG BASEA076416 001 Sep 29, 2003ABEQ 4MG BASEA076416 002 Sep 29, 2003AB TEVAEQ 2MG BASEA076284 001 Jul 03, 2002



## PRESCRIPTION DRUG PRODUCT LIST

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076284 002</u>	Jul 03, 2002
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A091283 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091283 002</u>	Nov 28, 2012

ZANAFLEX

<u>AB</u>	+ ACORDA	<u>EQ 4MG BASE</u>	<u>N020397 001</u>	Nov 27, 1996
-----------	----------	--------------------	--------------------	--------------

TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBREX

+ ALCON

0.3%

N050555 001

POWDER; INHALATION

TOBI PODHALER

+ NOVARTIS

28MG

N201688 001 Mar 22, 2013

SOLUTION; INHALATION

TOBI

<u>AN</u>	+ NOVARTIS PHARMS	<u>300MG/5ML</u>	<u>N050753 001</u>	Dec 22, 1997
-----------	-------------------	------------------	--------------------	--------------

TOBRAMYCIN

<u>AN</u>	AKORN INC	<u>300MG/5ML</u>	<u>A201422 001</u>	May 28, 2014
<u>AN</u>	TEVA PHARMS USA	<u>300MG/5ML</u>	<u>A091589 001</u>	Oct 10, 2013

BETHKIS

CHIESI USA INC

300MG/4ML

N201820 001 Oct 12, 2012

KITABIS PAK

+ PULMOFLOW INC

300MG/5ML

N205433 001 Dec 02, 2014

SOLUTION/DROPS; OPHTHALMIC

AKTOB

<u>AT</u>	AKORN	<u>0.3%</u>	<u>A064096 001</u>	Jan 31, 1996
-----------	-------	-------------	--------------------	--------------

TOBRAMYCIN

<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A064052 001</u>	Nov 29, 1993
-----------	-----------------	-------------	--------------------	--------------

<u>AT</u>	FERA PHARMS	<u>0.3%</u>	<u>A065026 001</u>	Sep 11, 2001
-----------	-------------	-------------	--------------------	--------------

TOBREX

<u>AT</u>	ALCON	<u>0.3%</u>	<u>A062535 001</u>	Dec 13, 1984
-----------	-------	-------------	--------------------	--------------

<u>AT</u>	+ FALCON PHARMS	<u>0.3%</u>	<u>N050541 001</u>	
-----------	-----------------	-------------	--------------------	--

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

<u>AP</u>	AGILA SPECLTS	<u>EQ 40MG BASE/ML</u>	<u>A065407 001</u>	Mar 11, 2008
-----------	---------------	------------------------	--------------------	--------------

<u>AP</u>	AKORN	<u>EQ 40MG BASE/ML</u>	<u>A205179 001</u>	Sep 16, 2014
-----------	-------	------------------------	--------------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1.2GM BASE/VIAL</u>	<u>N050789 001</u>	Jul 13, 2004
-----------	--------------------	---------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A065122 001</u>	Nov 29, 2002
-----------	--	------------------------	--------------------	--------------

<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A065122 002</u>	Nov 29, 2002
-----------	---	------------------------	--------------------	--------------

<u>AP</u>	HIKMA MAPLE	<u>EQ 40MG BASE/ML</u>	<u>A063117 001</u>	Apr 26, 1991
-----------	-------------	------------------------	--------------------	--------------

<u>AP</u>	+ HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A063112 001</u>	Apr 30, 1991
-----------	-----------	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A063111 001</u>	Apr 30, 1991
-----------	--	------------------------	--------------------	--------------

<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A063116 001</u>	May 18, 1992
-----------	---	------------------------	--------------------	--------------

<u>AP</u>	TEVA PHARMS USA	<u>EQ 40MG BASE/ML</u>	<u>A063100 001</u>	Jan 30, 1992
-----------	-----------------	------------------------	--------------------	--------------

<u>AP</u>	+ X GEN PHARMS	<u>EQ 1.2GM BASE/VIAL</u>	<u>A065013 001</u>	Aug 17, 2001
-----------	----------------	---------------------------	--------------------	--------------

<u>AP</u>	XELLIA PHARMS APS	<u>EQ 1.2GM BASE/VIAL</u>	<u>A205685 001</u>	Sep 16, 2014
-----------	-------------------	---------------------------	--------------------	--------------

TOBRAMYCIN SULFATE (PHARMACY BULK)

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 40MG BASE/ML</u>	<u>A065120 001</u>	Nov 29, 2002
-----------	--------------------	------------------------	--------------------	--------------

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA

EQ 1.2MG BASE/ML

A063081 003 Jul 31, 1990

+

EQ 1.6MG BASE/ML

A063081 006 Jun 02, 1993

+

EQ 80MG BASE/100ML

A063081 001 Jul 31, 1990

TOFACITINIB CITRATE

TABLET; ORAL

XELJANZ

+ PF PRISM CV

EQ 5MG BASE

N203214 001 Nov 06, 2012

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

MYLAN PHARMS INC

250MG

A070259 001 Jan 02, 1986

+

500MG

A070259 003 Mar 17, 1986

## PRESCRIPTION DRUG PRODUCT LIST

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+ MYLAN PHARMS INC 500MG A086445 001

TOLCAPONE

TABLET; ORAL

TASMAR

+ VALEANT PHARMS LLC 100MG N020697 001 Jan 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

**AB** MYLAN **EQ 400MG BASE** **A073393 001** May 27, 1993  
**AB** + TEVA **EQ 400MG BASE** **A073290 001** Nov 27, 1991

TABLET; ORAL

TOLMETIN SODIUM

**AB** MUTUAL PHARM **EQ 200MG BASE** **A073310 001** Nov 27, 1991  
**AB** + MYLAN **EQ 600MG BASE** **A074473 001** Aug 30, 1994

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROL LA

**AB** PHARMACIA AND UPJOHN **2MG** **N021228 001** Dec 22, 2000  
**AB** + **4MG** **N021228 002** Dec 22, 2000

TOLTERODINE TARTRATE

**AB** MYLAN PHARMS INC **2MG** **A201486 001** Oct 31, 2013  
**AB** **4MG** **A201486 002** Oct 31, 2013

TABLET; ORAL

DETROL

**AB** PHARMACIA AND UPJOHN **1MG** **N020771 001** Mar 25, 1998  
**AB** + **2MG** **N020771 002** Mar 25, 1998

TOLTERODINE TARTRATE

**AB** APOTEX CORP **1MG** **A200164 001** Sep 25, 2012  
**AB** **2MG** **A200164 002** Sep 25, 2012  
**AB** MYLAN PHARMS INC **1MG** **A202641 001** Nov 27, 2012  
**AB** **2MG** **A202641 002** Nov 27, 2012

TOLVAPTAN

TABLET; ORAL

SAMSCA

OTSUKA AMERICA PHARM 15MG N022275 001 May 19, 2009  
+ 30MG N022275 002 May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

**AB** JANSSEN PHARMS **15MG** **N020844 001** Oct 26, 1998  
**AB** + **25MG** **N020844 002** Oct 26, 1998

TOPIRAMATE

**AB** MYLAN **15MG** **A078418 001** Oct 14, 2009  
**AB** **25MG** **A078418 002** Oct 14, 2009  
**AB** TEVA **15MG** **A076575 001** Apr 17, 2009  
**AB** **25MG** **A076575 002** Apr 17, 2009  
**AB** WATSON LABS **15MG** **A077868 001** Apr 15, 2009  
**AB** **25MG** **A077868 002** Apr 15, 2009  
**AB** ZYDUS PHARMS USA INC **15MG** **A078877 001** Oct 14, 2009  
**AB** **25MG** **A078877 002** Oct 14, 2009

CAPSULE, EXTENDED RELEASE; ORAL

QUDEXY XR

UPSHER SMITH 25MG N205122 001 Mar 11, 2014  
50MG N205122 002 Mar 11, 2014  
100MG N205122 003 Mar 11, 2014  
150MG N205122 004 Mar 11, 2014  
+ 200MG N205122 005 Mar 11, 2014

TROKENDI XR

SUPERMUS PHARMS 25MG N201635 001 Aug 16, 2013  
50MG N201635 002 Aug 16, 2013  
100MG N201635 003 Aug 16, 2013  
+ 200MG N201635 004 Aug 16, 2013

TABLET; ORAL

TOPAMAX

**AB** JANSSEN PHARMS **25MG** **N020505 004** Dec 24, 1996  
**AB** **50MG** **N020505 005** Dec 24, 1996  
**AB** + **100MG** **N020505 001** Dec 24, 1996

## PRESCRIPTION DRUG PRODUCT LIST

TOPIRAMATE

TABLET; ORAL

TOPAMAX

<u>AB</u>		<u>200MG</u>	<u>N020505 002</u>	Dec 24, 1996
	<u>TOPIRAMATE</u>			
<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A076311 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076311 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076311 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076311 004</u>	Mar 27, 2009
<u>AB</u>	ACTIVIS TOTOWA LLC	<u>25MG</u>	<u>A078637 001</u>	Feb 27, 2013
<u>AB</u>		<u>50MG</u>	<u>A078637 002</u>	Feb 27, 2013
<u>AB</u>		<u>100MG</u>	<u>A078637 003</u>	Feb 27, 2013
<u>AB</u>		<u>200MG</u>	<u>A078637 004</u>	Feb 27, 2013
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077733 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077733 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077733 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077733 004</u>	Mar 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078462 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078462 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078462 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078462 004</u>	Mar 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A076343 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076343 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076343 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076343 004</u>	Mar 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077627 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077627 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077627 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077627 004</u>	Mar 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A079162 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079162 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079162 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079162 004</u>	Mar 27, 2009
<u>AB</u>	LUPIN	<u>25MG</u>	<u>A078410 001</u>	Sep 11, 2013
<u>AB</u>		<u>50MG</u>	<u>A078410 002</u>	Sep 11, 2013
<u>AB</u>		<u>100MG</u>	<u>A078410 003</u>	Sep 11, 2013
<u>AB</u>		<u>200MG</u>	<u>A078410 004</u>	Sep 11, 2013
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076314 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076314 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076314 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076314 004</u>	Mar 27, 2009
<u>AB</u>	RANBAXY	<u>25MG</u>	<u>A076327 001</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076327 002</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076327 003</u>	Mar 27, 2009
<u>AB</u>	SUN PHARMA GLOBAL	<u>25MG</u>	<u>A090278 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090278 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090278 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090278 004</u>	Mar 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317 004</u>	Mar 27, 2009
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A079153 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079153 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079153 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079153 004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090162 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090162 004</u>	Feb 19, 2013
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A078499 001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499 002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499 003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499 004</u>	Jan 07, 2010
<u>AB</u>	WOCKHARDT USA	<u>25MG</u>	<u>A090353 001</u>	Sep 01, 2010
<u>AB</u>		<u>50MG</u>	<u>A090353 002</u>	Sep 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A090353 003</u>	Sep 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A090353 004</u>	Sep 01, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235 004</u>	Mar 27, 2009

## PRESCRIPTION DRUG PRODUCT LIST

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<b>AB</b>	HIKMA PHARMS	<b>25MG</b>	<b><u>A091185 001</u></b>	Nov 25, 2013
<b>AB</b>		<b>50MG</b>	<b><u>A091185 002</u></b>	Nov 25, 2013
<b>AB</b>		<b>100MG</b>	<b><u>A091185 003</u></b>	Nov 25, 2013
<b>AB</b>		<b>200MG</b>	<b><u>A091185 004</u></b>	Nov 25, 2013

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCAMTIN

GLAXO WELLCOME

EQ 0.25MG BASE

N020981 001 Oct 11, 2007

+

EQ 1MG BASE

N020981 002 Oct 11, 2007

INJECTABLE; INJECTION

HYCAMTIN

<b>AP</b>	+ GLAXOSMITHKLINE	<b><u>EQ 4MG BASE/VIAL</u></b>	<b><u>N020671 001</u></b>	May 28, 1996
-----------	-------------------	--------------------------------	---------------------------	--------------

TOPOTECAN HYDROCHLORIDE

<b>AP</b>	ACCORD HLTHCARE	<b><u>EQ 4MG BASE/VIAL</u></b>	<b><u>A202351 001</u></b>	Jun 26, 2013
<b>AP</b>	ACTAVIS TOTOWA	<b><u>EQ 4MG BASE/VIAL</u></b>	<b><u>A090620 001</u></b>	Dec 02, 2010
<b>AP</b>	CIPLA LTD	<b><u>EQ 4MG BASE/VIAL</u></b>	<b><u>A091199 001</u></b>	Dec 01, 2010
<b>AP</b>	DR REDDYS LABS LTD	<b><u>EQ 4MG BASE/VIAL</u></b>	<b><u>A201191 001</u></b>	Mar 09, 2011
<b>AP</b>	FRESENIUS KABI USA	<b><u>EQ 4MG BASE/VIAL</u></b>	<b><u>A091089 001</u></b>	Nov 29, 2010
<b>AP</b>	INNOPHARMA LICENSING	<b><u>EQ 4MG BASE/VIAL</u></b>	<b><u>A201166 001</u></b>	Aug 08, 2012
<b>AP</b>	ONCO THERAPIES LTD	<b><u>EQ 4MG BASE/VIAL</u></b>	<b><u>A091542 001</u></b>	Aug 28, 2012
<b>AP</b>	SAGENT PHARMS	<b><u>EQ 4MG BASE/VIAL</u></b>	<b><u>A091284 001</u></b>	Jan 26, 2011
<b>AP</b>	SUN PHARM INDS LTD	<b><u>EQ 4MG BASE/VIAL</u></b>	<b><u>A202203 001</u></b>	Aug 29, 2013

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

<b>AP</b>	+ HOSPIRA INC	<b><u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u></b>	<b><u>N200582 001</u></b>	Feb 02, 2011
<b>AP</b>	TEVA PHARMS USA	<b><u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u></b>	<b><u>N022453 001</u></b>	Dec 20, 2012

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+ PROSTRAKAN INC

EQ 60MG BASE

N020497 001 May 29, 1997

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

<b>AP</b>	+ EUROHLTH INTL	<b><u>20MG/2ML (10MG/ML)</u></b>	<b><u>A078007 001</u></b>	Jun 11, 2008
<b>AP</b>	+ LUITPOLD	<b><u>50MG/5ML (10MG/ML)</u></b>	<b><u>A078007 002</u></b>	Jun 11, 2008
<b>AP</b>		<b><u>20MG/2ML (10MG/ML)</u></b>	<b><u>A090656 001</u></b>	Apr 21, 2010
<b>AP</b>		<b><u>50MG/5ML (10MG/ML)</u></b>	<b><u>A090656 002</u></b>	Apr 21, 2010

TABLET; ORAL

DEMADEX

<b>AB</b>	MEDA PHARMS	<b>5MG</b>	<b><u>N020136 001</u></b>	Aug 23, 1993
<b>AB</b>		<b>10MG</b>	<b><u>N020136 002</u></b>	Aug 23, 1993
<b>AB</b>	+	<b>20MG</b>	<b><u>N020136 003</u></b>	Aug 23, 1993
<b>AB</b>		<b>100MG</b>	<b><u>N020136 004</u></b>	Aug 23, 1993

TORSEMIDE

<b>AB</b>	APOTEX INC	<b>5MG</b>	<b><u>A076894 001</u></b>	May 31, 2005
<b>AB</b>		<b>10MG</b>	<b><u>A076894 002</u></b>	May 31, 2005
<b>AB</b>		<b>20MG</b>	<b><u>A076894 003</u></b>	May 31, 2005
<b>AB</b>		<b>100MG</b>	<b><u>A076894 004</u></b>	May 31, 2005
<b>AB</b>	AUROBINDO PHARMA	<b>5MG</b>	<b><u>A078249 001</u></b>	Oct 17, 2007
<b>AB</b>		<b>10MG</b>	<b><u>A078249 002</u></b>	Oct 17, 2007
<b>AB</b>		<b>20MG</b>	<b><u>A078249 003</u></b>	Oct 17, 2007
<b>AB</b>		<b>100MG</b>	<b><u>A078249 004</u></b>	Oct 17, 2007
<b>AB</b>	HETERO LABS LTD III	<b>5MG</b>	<b><u>A079234 001</u></b>	Jan 27, 2009
<b>AB</b>		<b>10MG</b>	<b><u>A079234 002</u></b>	Jan 27, 2009
<b>AB</b>		<b>20MG</b>	<b><u>A079234 003</u></b>	Jan 27, 2009
<b>AB</b>		<b>100MG</b>	<b><u>A079234 004</u></b>	Jan 27, 2009
<b>AB</b>	PAR PHARM	<b>5MG</b>	<b><u>A076226 001</u></b>	May 27, 2003
<b>AB</b>		<b>10MG</b>	<b><u>A076226 002</u></b>	May 27, 2003
<b>AB</b>		<b>20MG</b>	<b><u>A076226 003</u></b>	May 27, 2003
<b>AB</b>		<b>100MG</b>	<b><u>A076226 004</u></b>	May 27, 2003
<b>AB</b>	PLIVA PHARM IND	<b>5MG</b>	<b><u>A076346 001</u></b>	May 30, 2003
<b>AB</b>		<b>10MG</b>	<b><u>A076346 002</u></b>	May 30, 2003
<b>AB</b>		<b>20MG</b>	<b><u>A076346 003</u></b>	May 30, 2003
<b>AB</b>		<b>100MG</b>	<b><u>A076346 004</u></b>	Oct 19, 2004
<b>AB</b>	ROXANE	<b>5MG</b>	<b><u>A076943 001</u></b>	Mar 01, 2005
<b>AB</b>		<b>10MG</b>	<b><u>A076943 002</u></b>	Mar 01, 2005
<b>AB</b>		<b>20MG</b>	<b><u>A076943 003</u></b>	Mar 01, 2005
<b>AB</b>	SUN PHARM INDS	<b>5MG</b>	<b><u>A078478 001</u></b>	Feb 26, 2008

## PRESCRIPTION DRUG PRODUCT LIST

TORSEMIDE

TABLET; ORAL

TORSEMIDE

<u>AB</u>		<u>10MG</u>	<u>A078478</u>	<u>002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078478</u>	<u>003</u>	Feb 26, 2008
<u>AB</u>		<u>100MG</u>	<u>A078478</u>	<u>004</u>	Feb 26, 2008
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076110</u>	<u>001</u>	May 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A076110</u>	<u>002</u>	May 14, 2002
<u>AB</u>		<u>20MG</u>	<u>A076110</u>	<u>003</u>	May 14, 2002
<u>AB</u>		<u>100MG</u>	<u>A076110</u>	<u>004</u>	May 14, 2002
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A090613</u>	<u>001</u>	Mar 22, 2011
<u>AB</u>		<u>10MG</u>	<u>A090613</u>	<u>002</u>	Mar 22, 2011
<u>AB</u>		<u>20MG</u>	<u>A090613</u>	<u>003</u>	Mar 22, 2011
<u>AB</u>		<u>100MG</u>	<u>A090613</u>	<u>004</u>	Mar 22, 2011

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
		150MG	N022370	004	Aug 01, 2011
		200MG	N022370	002	May 07, 2010
		300MG	N022370	003	May 07, 2010

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE INC	<u>50MG</u>	<u>A202390</u>	<u>001</u>	May 16, 2013
<u>AB</u>	ALLIED PHARMA INC	<u>50MG</u>	<u>A202075</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A203494</u>	<u>001</u>	Mar 31, 2014
<u>AB</u>	CSPC OUYI PHARM CO	<u>50MG</u>	<u>A091498</u>	<u>001</u>	Mar 29, 2013
<u>AB</u>	IPCA LABS LTD	<u>50MG</u>	<u>A201973</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>	MALLINCKRODT	<u>50MG</u>	<u>A075983</u>	<u>001</u>	Jun 25, 2002
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A076100</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A075980</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	NORTHSTAR HLTHCARE	<u>50MG</u>	<u>A078935</u>	<u>001</u>	May 26, 2010
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A090404</u>	<u>001</u>	Jan 31, 2011

ULTRAM

<u>AB</u>	+	JANSSEN PHARMS	<u>50MG</u>	<u>N020281</u>	<u>002</u>	Mar 03, 1995
-----------	---	----------------	-------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	LUPIN LTD	<u>100MG</u>	<u>A200503</u>	<u>001</u>	Aug 29, 2011
<u>AB1</u>		<u>200MG</u>	<u>A200503</u>	<u>002</u>	Aug 29, 2011
<u>AB1</u>		<u>300MG</u>	<u>A200503</u>	<u>003</u>	Aug 29, 2011
<u>AB1</u>	PAR PHARM INC	<u>100MG</u>	<u>A078783</u>	<u>001</u>	Nov 13, 2009
<u>AB1</u>		<u>200MG</u>	<u>A078783</u>	<u>002</u>	Nov 13, 2009
<u>AB1</u>		<u>300MG</u>	<u>A078783</u>	<u>003</u>	Sep 20, 2011
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A201384</u>	<u>001</u>	Dec 07, 2011
<u>AB1</u>		<u>200MG</u>	<u>A201384</u>	<u>002</u>	Dec 07, 2011
<u>AB1</u>		<u>300MG</u>	<u>A201384</u>	<u>003</u>	Dec 07, 2011

ULTRAM ER

<u>AB1</u>	+	VALEANT INTL	<u>100MG</u>	<u>N021692</u>	<u>001</u>	Sep 08, 2005
<u>AB1</u>			<u>200MG</u>	<u>N021692</u>	<u>002</u>	Sep 08, 2005
<u>AB1</u>			<u>300MG</u>	<u>N021692</u>	<u>003</u>	Sep 08, 2005

TRAMADOL HYDROCHLORIDE

<u>AB2</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091609</u>	<u>001</u>	Jun 27, 2012	
<u>AB2</u>		<u>200MG</u>	<u>A091609</u>	<u>002</u>	Jun 27, 2012	
<u>AB2</u>		<u>300MG</u>	<u>A091609</u>	<u>003</u>	Jun 27, 2012	
<u>AB2</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A200491</u>	<u>001</u>	Jun 27, 2012	
<u>AB2</u>		<u>200MG</u>	<u>A200491</u>	<u>002</u>	Jun 27, 2012	
<u>AB2</u>		<u>300MG</u>	<u>A200491</u>	<u>003</u>	Jun 27, 2012	
<u>AB2</u>	+	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A091607</u>	<u>001</u>	Dec 30, 2011
<u>AB2</u>			<u>200MG</u>	<u>A091607</u>	<u>002</u>	Dec 30, 2011
<u>AB2</u>			<u>300MG</u>	<u>A091607</u>	<u>003</u>	Dec 30, 2011

## PRESCRIPTION DRUG PRODUCT LIST

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

GLAXOSMITHKLINE LLC	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013
	EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013
+	EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013

TRANDOLAPRIL

TABLET; ORAL

MAVIK

<u>AB</u>	ABBVIE	<u>1MG</u>	<u>N020528</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>		<u>2MG</u>	<u>N020528</u>	<u>002</u>	Apr 26, 1996
<u>AB</u>	+	<u>4MG</u>	<u>N020528</u>	<u>003</u>	Apr 26, 1996

TRANDOLAPRIL

<u>AB</u>	AUROBINDO PHARMA	<u>1MG</u>	<u>A078438</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078438</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078438</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	EPIC PHARMA	<u>1MG</u>	<u>A078508</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>2MG</u>	<u>A078508</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>4MG</u>	<u>A078508</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A078320</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078320</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078320</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	LUPIN	<u>1MG</u>	<u>A077522</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077522</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077522</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A078346</u>	<u>001</u>	Apr 28, 2008
<u>AB</u>		<u>2MG</u>	<u>A078346</u>	<u>002</u>	Apr 28, 2008
<u>AB</u>		<u>4MG</u>	<u>A078346</u>	<u>003</u>	Apr 28, 2008
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A077489</u>	<u>001</u>	Dec 12, 2006
<u>AB</u>		<u>2MG</u>	<u>A077489</u>	<u>002</u>	Dec 12, 2006
<u>AB</u>		<u>4MG</u>	<u>A077489</u>	<u>003</u>	Dec 12, 2006
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A077805</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077805</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077805</u>	<u>003</u>	Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA

<u>AB</u>	ABBVIE	<u>1MG;240MG</u>	<u>N020591</u>	<u>003</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;180MG</u>	<u>N020591</u>	<u>001</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;240MG</u>	<u>N020591</u>	<u>004</u>	Oct 22, 1996
<u>AB</u>	+	<u>4MG;240MG</u>	<u>N020591</u>	<u>002</u>	Oct 22, 1996

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>1MG;240MG</u>	<u>A079135</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>2MG;180MG</u>	<u>A079135</u>	<u>001</u>	May 26, 2010
<u>AB</u>		<u>2MG;240MG</u>	<u>A079135</u>	<u>002</u>	May 26, 2010
<u>AB</u>		<u>4MG;240MG</u>	<u>A079135</u>	<u>003</u>	May 05, 2010

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>N019281</u>	<u>001</u>	Dec 30, 1986
<u>AP</u>		ACIC FINE CHEMS	<u>100MG/ML</u>	<u>A202436</u>	<u>001</u>	Feb 11, 2014
<u>AP</u>		EMCURE PHARMS LTD	<u>100MG/ML</u>	<u>A203521</u>	<u>001</u>	Aug 12, 2014
<u>AP</u>		LUITPOLD	<u>100MG/ML</u>	<u>A201885</u>	<u>001</u>	Aug 10, 2011
<u>AP</u>		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091657</u>	<u>001</u>	Nov 03, 2011
<u>AP</u>		VERSAPHARM INC	<u>100MG/ML</u>	<u>A202373</u>	<u>001</u>	Nov 17, 2011
<u>AP</u>		X-GEN PHARMS INC	<u>100MG/ML</u>	<u>A201580</u>	<u>001</u>	Jun 14, 2013

TABLET; ORAL

LYSTEDA

<u>AB</u>	+	FERRING PHARMS AS	<u>650MG</u>	<u>N022430</u>	<u>001</u>	Nov 13, 2009
<u>AB</u>		ACTAVIS LABS FL INC	<u>650MG</u>	<u>A202093</u>	<u>001</u>	Dec 27, 2012
<u>AB</u>		APOTEX INC	<u>650MG</u>	<u>A202286</u>	<u>001</u>	Jan 27, 2014

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

<u>AB</u>	+	COVIS PHARMA	<u>EQ 10MG BASE</u>	<u>N012342</u>	<u>003</u>	Aug 16, 1985
<u>AB</u>		PAR PHARM	<u>EQ 10MG BASE</u>	<u>A040640</u>	<u>001</u>	Jun 29, 2006

## PRESCRIPTION DRUG PRODUCT LIST

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

+ ALCON LABS INC 0.003% N204822 001 May 15, 2014

TRAVATAN Z

+ ALCON PHARMS LTD 0.004% N021994 001 Sep 21, 2006

TRAVOPROST

+ PAR PHARM 0.004% A091340 001 Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

<u>AB</u>	ALVOGEN	<u>50MG</u>	<u>A071636 001</u>	Apr 18, 1988
<u>AB</u>		<u>100MG</u>	<u>A071514 001</u>	Apr 18, 1988
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A071258 001</u>	Mar 25, 1987
<u>AB</u>	+ APOTEX INC	<u>100MG</u>	<u>A071196 001</u>	Mar 25, 1987
<u>AB</u>		<u>150MG</u>	<u>A071196 002</u>	Apr 26, 1999
<u>AB</u>		<u>300MG</u>	<u>A071196 003</u>	Apr 26, 1999
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A073137 002</u>	Mar 24, 1993
<u>AB</u>		<u>100MG</u>	<u>A073137 001</u>	Mar 24, 1993
<u>AB</u>		<u>150MG</u>	<u>A073137 003</u>	Dec 22, 1995
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A090514 001</u>	Jun 02, 2009
<u>AB</u>		<u>100MG</u>	<u>A090514 002</u>	Jun 02, 2009
<u>AB</u>		<u>150MG</u>	<u>A090514 003</u>	Jun 02, 2009
<u>AB</u>		<u>300MG</u>	<u>A090514 004</u>	Jun 02, 2009
<u>AB</u>	PLIVA	<u>150MG</u>	<u>A071525 001</u>	Mar 09, 1988
<u>AB</u>	TEVA PHARMS USA	<u>50MG</u>	<u>A071523 001</u>	Dec 11, 1987
<u>AB</u>		<u>100MG</u>	<u>A071524 001</u>	Dec 11, 1987
<u>AB</u>	TORRENT PHARMS LTD	<u>50MG</u>	<u>A202180 001</u>	Nov 27, 2013
<u>AB</u>		<u>100MG</u>	<u>A202180 002</u>	Nov 27, 2013
<u>AB</u>		<u>150MG</u>	<u>A202180 003</u>	Nov 27, 2013
<u>AB</u>		<u>300MG</u>	<u>A202180 004</u>	Nov 27, 2013
<u>AB</u>	VINTAGE	<u>50MG</u>	<u>A072192 001</u>	Feb 02, 1989
<u>AB</u>		<u>100MG</u>	<u>A072193 001</u>	Feb 02, 1989

TABLET, EXTENDED RELEASE;ORAL

OLEPTRO

+ ANGELINI PHARMA 150MG N022411 001 Feb 02, 2010

300MG N022411 002 Feb 02, 2010

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

REMODULIN

UNITED THERAP 1MG/ML N021272 001 May 21, 2002

2.5MG/ML N021272 002 May 21, 2002

5MG/ML N021272 003 May 21, 2002

+ 10MG/ML N021272 004 May 21, 2002

SOLUTION;INHALATION

TYVASO

+ UNITED THERAP 0.6MG/ML N022387 001 Jul 30, 2009

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

UNITED THERAP EQ 0.125MG BASE N203496 001 Dec 20, 2013

EQ 0.25MG BASE N203496 002 Dec 20, 2013

EQ 1MG BASE N203496 003 Dec 20, 2013

+ EQ 2.5MG BASE N203496 004 Dec 20, 2013

TRETINOIN

CAPSULE;ORAL

TRETINOIN

<u>AB</u>	ANCHEN PHARMS	<u>10MG</u>	<u>A201687 001</u>	Oct 24, 2012
<u>AB</u>	+ BARR LABS INC	<u>10MG</u>	<u>A077684 001</u>	Jun 22, 2007

CREAM;TOPICAL

AVITAAB MYLAN PHARMS INC 0.025% N020404 003 Jan 14, 1997RETIN-AAB + VALEANT BERMUDA 0.025% N019049 001 Sep 16, 1988AB + 0.1% N017340 001TRETINOINAB MATAWAN PHARMS 0.025% A075264 001 Dec 24, 1998AB 0.1% A075213 001 Dec 24, 1998RETIN-AAB1 + VALEANT BERMUDA 0.05% N017522 001

## PRESCRIPTION DRUG PRODUCT LIST

TRETINOIN

CREAM; TOPICAL

TRETINOIN

<b>AB1</b>	MATAWAN PHARMS	<b>0.05%</b>	<b>A075265 001</b>	Dec 24, 1998
	<b>RENOVA</b>			
<b>AB2</b>	+ VALEANT INTL	<b>0.05%</b>	<b>N019963 001</b>	Dec 29, 1995
	<b>TRETINOIN</b>			
<b>AB2</b>	SUNEVA MEDCL	<b>0.05%</b>	<b>A076498 001</b>	Sep 15, 2005
	RENOVA			
	+ VALEANT INTL	0.02%	N021108 001	Aug 31, 2000
	TRETINOIN			
	+ WATSON LABS INC	0.0375%	A090098 001	Mar 22, 2010
		0.075%	A202209 001	Oct 11, 2012

GEL; TOPICAL

RETIN-A

<b>AB</b>	+ VALEANT INTL	<b>0.01%</b>	<b>N017955 001</b>	
<b>AB</b>	+	<b>0.025%</b>	<b>N017579 002</b>	
	<b>RETIN-A MICRO</b>			
<b>AB</b>	+ VALEANT INTL	<b>0.04%</b>	<b>N020475 002</b>	May 10, 2002
<b>AB</b>	+	<b>0.1%</b>	<b>N020475 001</b>	Feb 07, 1997

TRETINOIN

<b>AB</b>	MATAWAN PHARMS	<b>0.01%</b>	<b>A075589 001</b>	Jun 11, 2002
<b>AB</b>		<b>0.025%</b>	<b>A075529 001</b>	Feb 22, 2000
<b>AB</b>	SPEAR PHARMS INC	<b>0.04%</b>	<b>A202567 001</b>	Jul 17, 2013
<b>AB</b>		<b>0.1%</b>	<b>A202026 001</b>	Jul 17, 2013
	AVITA			
BT	MYLAN	0.025%	N020400 001	Jan 29, 1998
	ATRALIN			
	+ DOW PHARM	0.05%	N022070 001	Jul 26, 2007
	RETIN-A-MICRO			
	+ VALEANT INTL	0.08%	N020475 003	Jan 28, 2014
	SOLUTION; TOPICAL			
	RETIN-A			
	+ VALEANT INTL	0.05%	N016921 001	

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

<b>AT</b>	+ FOUGERA PHARMS	<b>0.025%</b>	<b>A085692 001</b>	
<b>AT</b>	+	<b>0.1%</b>	<b>A085692 003</b>	
<b>AT</b>	+	<b>0.5%</b>	<b>A085692 002</b>	
<b>AT</b>	PERRIGO NEW YORK	<b>0.025%</b>	<b>A086415 001</b>	
<b>AT</b>		<b>0.1%</b>	<b>A086414 001</b>	
<b>AT</b>		<b>0.5%</b>	<b>A086413 001</b>	
<b>AT</b>	TARO	<b>0.1%</b>	<b>A040039 001</b>	Nov 26, 1997
<b>AT</b>	VINTAGE	<b>0.025%</b>	<b>A040671 001</b>	Jun 09, 2006
<b>AT</b>		<b>0.1%</b>	<b>A040671 002</b>	Jun 09, 2006

TRIDERM

<b>AT</b>	CROWN LABS	<b>0.1%</b>	<b>A088042 001</b>	Mar 19, 1984
	INJECTABLE; INJECTION			
	KENALOG-10			
	APOTHECON	10MG/ML	N012041 001	
	KENALOG-40			
	+ APOTHECON	40MG/ML	N014901 001	
	INJECTABLE; INTRAVITREAL			
	TRIESENCE			
	+ ALCON	40MG/ML (40MG/ML)	N022048 001	Nov 29, 2007

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

<b>AT</b>	FOUGERA PHARMS	<b>0.025%</b>	<b>A040467 001</b>	Apr 21, 2003
<b>AT</b>		<b>0.1%</b>	<b>A040467 002</b>	Apr 21, 2003
<b>AT</b>	VERSAPHARM INC	<b>0.025%</b>	<b>A202374 001</b>	May 08, 2013
<b>AT</b>		<b>0.1%</b>	<b>A202374 002</b>	May 08, 2013
<b>AT</b>	VINTAGE	<b>0.1%</b>	<b>A040672 002</b>	Dec 13, 2006
<b>AT</b>	+ WOCKHARDT	<b>0.1%</b>	<b>A088451 001</b>	Apr 03, 1985
<b>AT</b>	+ WOCKHARDT EU OPERATN	<b>0.025%</b>	<b>A088450 001</b>	Apr 01, 1985

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

<b>AT</b>	FOUGERA PHARMS	<b>0.025%</b>	<b>A085691 001</b>	
<b>AT</b>		<b>0.1%</b>	<b>A085691 003</b>	
<b>AT</b>		<b>0.5%</b>	<b>A085691 002</b>	
<b>AT</b>	+ PERRIGO NEW YORK	<b>0.025%</b>	<b>A087356 001</b>	
<b>AT</b>	+	<b>0.1%</b>	<b>A087357 001</b>	



## PRESCRIPTION DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

<b>AT</b>	+		<b>0.5%</b>	<b>A087385 001</b>	
<b>AT</b>		TARO	<b>0.1%</b>	<b>A040037 001</b>	Sep 30, 1994
		TRIAMCINOLONE ACETONIDE IN ABSORBASE			
		+ CAROLINA MEDCL	0.05%	A089595 001	Mar 23, 1995

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

<b>AT</b>		LYNE	<b>0.1%</b>	<b>A040771 001</b>	Jul 01, 2010
<b>AT</b>	+	TARO	<b>0.1%</b>	<b>A070730 001</b>	Oct 01, 1986

SPRAY; TOPICAL

KENALOG

		+ RANBAXY	0.147MG/GM	N012104 001	
--	--	-----------	------------	-------------	--

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

		TEVA PHARMS	0.055MG/SPRAY	A078104 001	Jul 30, 2009
--	--	-------------	---------------	-------------	--------------

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

		+ SANDOZ	5MG/ML	N016466 001	
		+	20MG/ML	N016466 002	

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

		COVIS PHARMA SARL	50MG	N013174 001	
		+	100MG	N013174 002	

TRIAZOLAM

TABLET; ORAL

HALCION

<b>AB</b>		PHARMACIA AND UPJOHN	<b>0.125MG</b>	<b>N017892 003</b>	Apr 26, 1985
<b>AB</b>	+		<b>0.25MG</b>	<b>N017892 001</b>	Nov 15, 1982

TRIAZOLAM

<b>AB</b>		MYLAN PHARMS INC	<b>0.125MG</b>	<b>A074031 001</b>	Mar 25, 1994
<b>AB</b>			<b>0.25MG</b>	<b>A074031 002</b>	Mar 25, 1994
<b>AB</b>		ROXANE	<b>0.125MG</b>	<b>A074224 001</b>	Jun 01, 1994
<b>AB</b>			<b>0.25MG</b>	<b>A074224 002</b>	Jun 01, 1994

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

SYPRINE

		+ ATON	250MG	N019194 001	Nov 08, 1985
--	--	--------	-------	-------------	--------------

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

<b>AB</b>		MYLAN	<b>EQ 1MG BASE</b>	<b>A040209 001</b>	Jul 07, 1997
<b>AB</b>			<b>EQ 2MG BASE</b>	<b>A040209 002</b>	Jul 07, 1997
<b>AB</b>			<b>EQ 5MG BASE</b>	<b>A040209 003</b>	Jul 07, 1997
<b>AB</b>	+		<b>EQ 10MG BASE</b>	<b>A040209 004</b>	Jul 07, 1997
<b>AB</b>		SANDOZ	<b>EQ 1MG BASE</b>	<b>A085785 001</b>	
<b>AB</b>			<b>EQ 2MG BASE</b>	<b>A085786 001</b>	
<b>AB</b>			<b>EQ 5MG BASE</b>	<b>A085789 001</b>	
<b>AB</b>			<b>EQ 10MG BASE</b>	<b>A085788 001</b>	

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

<b>AT</b>		ALCON PHARMS LTD	<b>1%</b>	<b>A074311 001</b>	Oct 06, 1995
-----------	--	------------------	-----------	--------------------	--------------

VIROPTIC

<b>AT</b>	+	MONARCH PHARMS	<b>1%</b>	<b>N018299 001</b>	
-----------	---	----------------	-----------	--------------------	--

TRIHENXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHENXYPHENIDYL HYDROCHLORIDE

<b>AA</b>		MIKART	<b>2MG/5ML</b>	<b>A040251 001</b>	Sep 27, 1999
<b>AA</b>	+	PHARM ASSOC	<b>2MG/5ML</b>	<b>A040177 001</b>	Apr 17, 1997

TABLET; ORAL

TRIHENXYPHENIDYL HYDROCHLORIDE

<b>AA</b>		NATCO PHARMA LTD	<b>2MG</b>	<b>A091630 001</b>	Nov 17, 2010
<b>AA</b>			<b>5MG</b>	<b>A091630 002</b>	Nov 17, 2010
<b>AA</b>		VINTAGE PHARMS	<b>2MG</b>	<b>A040254 001</b>	Dec 24, 1998
<b>AA</b>			<b>5MG</b>	<b>A040254 002</b>	Dec 24, 1998

## PRESCRIPTION DRUG PRODUCT LIST

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

<b>AA</b>	+	WATSON LABS	<b>2MG</b>	<b>A084363</b>	<b>001</b>	
<b>AA</b>	+		<b>5MG</b>	<b>A084364</b>	<b>001</b>	

TRIMETHADIONE

TABLET; ORAL

TRIDIONE

+	ABBVIE	150MG		N005856	009	
---	--------	-------	--	---------	-----	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

<b>AB</b>	+	KING PHARMS	<b>300MG</b>	<b>N017531</b>	<b>006</b>	Dec 13, 2001
-----------	---	-------------	--------------	----------------	------------	--------------

TRIMETHOBENZAMIDE HYDROCHLORIDE

<b>AB</b>		GAVIS PHARMS	<b>300MG</b>	<b>A076546</b>	<b>001</b>	Aug 20, 2003
<b>AB</b>		MUTUAL PHARMA	<b>300MG</b>	<b>A076570</b>	<b>001</b>	Aug 28, 2003

INJECTABLE; INJECTION

TIGAN

<b>AP</b>	+	PAR STERILE PRODUCTS	<b>100MG/ML</b>	<b>N017530</b>	<b>001</b>	
-----------	---	----------------------	-----------------	----------------	------------	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

<b>AP</b>		LUITPOLD	<b>100MG/ML</b>	<b>A091330</b>	<b>001</b>	Mar 08, 2011
-----------	--	----------	-----------------	----------------	------------	--------------

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

<b>AP</b>		LUITPOLD	<b>100MG/ML</b>	<b>A091329</b>	<b>001</b>	Mar 08, 2011
-----------	--	----------	-----------------	----------------	------------	--------------

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

<b>AB</b>		NOVEL LABS INC	<b>100MG</b>	<b>A091437</b>	<b>001</b>	Jun 15, 2011
<b>AB</b>	+	TEVA	<b>100MG</b>	<b>N018679</b>	<b>001</b>	Jul 30, 1982
<b>AB</b>		WATSON LABS	<b>100MG</b>	<b>A070049</b>	<b>001</b>	Jun 06, 1985

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

+	FSC	EQ 50MG BASE/5ML		N074973	001	Jan 24, 2000
---	-----	------------------	--	---------	-----	--------------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

<b>AB</b>		ODYSSEY PHARMS	<b>EQ 25MG BASE</b>	<b>N016792</b>	<b>001</b>	
<b>AB</b>			<b>EQ 50MG BASE</b>	<b>N016792</b>	<b>002</b>	
<b>AB</b>	+		<b>EQ 100MG BASE</b>	<b>N016792</b>	<b>003</b>	Sep 15, 1982
<b>TRIMIPRAMINE MALEATE</b>						
<b>AB</b>		MIKAH PHARMA	<b>EQ 25MG BASE</b>	<b>A077361</b>	<b>001</b>	Aug 02, 2006
<b>AB</b>			<b>EQ 50MG BASE</b>	<b>A077361</b>	<b>002</b>	Aug 02, 2006
<b>AB</b>			<b>EQ 100MG BASE</b>	<b>A077361</b>	<b>003</b>	Aug 02, 2006

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+	WATSON LABS	EQ 3.75MG BASE/VIAL		N020715	001	Jun 15, 2000
+		EQ 11.25MG BASE/VIAL		N021288	001	Jun 29, 2001
+		EQ 22.5MG BASE/VIAL		N022437	001	Mar 10, 2010

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+	HOSPIRA	3.6GM/100ML		N013025	002	
---	---------	-------------	--	---------	-----	--

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

<b>AT</b>	+	ALCON	<b>0.5%</b>	<b>A084305</b>	<b>001</b>	
<b>AT</b>	+		<b>1%</b>	<b>A084306</b>	<b>001</b>	

TROPICACYL

<b>AT</b>		AKORN	<b>0.5%</b>	<b>A040314</b>	<b>001</b>	Sep 29, 2000
<b>AT</b>			<b>1%</b>	<b>A040315</b>	<b>001</b>	Sep 29, 2000

TROPICAMIDE

<b>AT</b>		BAUSCH AND LOMB	<b>0.5%</b>	<b>A040067</b>	<b>001</b>	Jul 27, 1994
<b>AT</b>			<b>1%</b>	<b>A040064</b>	<b>001</b>	Jul 27, 1994

## PRESCRIPTION DRUG PRODUCT LIST

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

SANCTURA XR

<b>AB</b>	+ ALLERGAN	<b>60MG</b>	<b><u>N022103</u></b>	<b><u>001</u></b>	Aug 03, 2007
-----------	------------	-------------	-----------------------	-------------------	--------------

TROSPIUM CHLORIDE

<b>AB</b>	ACTAVIS LABS FL INC	<b>60MG</b>	<b><u>A091289</u></b>	<b><u>001</u></b>	Oct 12, 2012
-----------	---------------------	-------------	-----------------------	-------------------	--------------

<b>AB</b>	PADDOCK LLC	<b>60MG</b>	<b><u>A201291</u></b>	<b><u>001</u></b>	May 24, 2013
-----------	-------------	-------------	-----------------------	-------------------	--------------

TABLET;ORAL

SANCTURA

<b>AB</b>	+ ALLERGAN	<b>20MG</b>	<b><u>N021595</u></b>	<b><u>001</u></b>	May 28, 2004
-----------	------------	-------------	-----------------------	-------------------	--------------

TROSPIUM CHLORIDE

<b>AB</b>	APOTEX	<b>20MG</b>	<b><u>A091513</u></b>	<b><u>001</u></b>	Dec 06, 2011
-----------	--------	-------------	-----------------------	-------------------	--------------

<b>AB</b>	GLENMARK GENERICS	<b>20MG</b>	<b><u>A091575</u></b>	<b><u>001</u></b>	Aug 13, 2010
-----------	-------------------	-------------	-----------------------	-------------------	--------------

<b>AB</b>	PADDOCK LLC	<b>20MG</b>	<b><u>A091573</u></b>	<b><u>001</u></b>	Nov 17, 2010
-----------	-------------	-------------	-----------------------	-------------------	--------------

TRYPAN BLUE

SOLUTION;OPHTHALMIC

MEMBRANEBLUE

+ DORC	0.15%	N022278	001	Feb 20, 2009
--------	-------	---------	-----	--------------

VISIONBLUE

+ DORC	0.06%	N021670	001	Dec 16, 2004
--------	-------	---------	-----	--------------

ULIPRISTAL ACETATE

TABLET;ORAL

ELLA

+ LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010
------------------	------	---------	-----	--------------

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+ GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382	001	Apr 30, 2014
---------------------	---------------------	---------	-----	--------------

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+ GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH;EQ 0.025MG	N203975	001	Dec 18, 2013
-------------------	---------------------------------	---------	-----	--------------

BASE/INH

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC

RESCULA

+ SUCAMPO PHARMS	0.15%	N021214	001	Aug 03, 2000
------------------	-------	---------	-----	--------------

UREA, C-14

CAPSULE;ORAL

PYTEST

+ AVENT	1uCi	N020617	001	May 09, 1997
---------	------	---------	-----	--------------

PYTEST KIT

+ AVENT	1uCi	N020617	002	May 09, 1997
---------	------	---------	-----	--------------

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

+ FERRING	75 IU/VIAL	N021289	001	May 06, 2002
-----------	------------	---------	-----	--------------

URSODIOL

CAPSULE;ORAL

ACTIGALL

<b>AB</b>	+ WATSON PHARMS	<b>300MG</b>	<b><u>N019594</u></b>	<b><u>002</u></b>	Dec 31, 1987
-----------	-----------------	--------------	-----------------------	-------------------	--------------

URSODIOL

<b>AB</b>	COREPHARMA	<b>300MG</b>	<b><u>A077895</u></b>	<b><u>001</u></b>	Jul 27, 2006
-----------	------------	--------------	-----------------------	-------------------	--------------

<b>AB</b>	EPIC PHARMA	<b>300MG</b>	<b><u>A075517</u></b>	<b><u>001</u></b>	Mar 14, 2000
-----------	-------------	--------------	-----------------------	-------------------	--------------

<b>AB</b>	LANNETT	<b>300MG</b>	<b><u>A079082</u></b>	<b><u>001</u></b>	Dec 15, 2008
-----------	---------	--------------	-----------------------	-------------------	--------------

<b>AB</b>	MYLAN	<b>300MG</b>	<b><u>A090530</u></b>	<b><u>001</u></b>	Feb 17, 2010
-----------	-------	--------------	-----------------------	-------------------	--------------

<b>AB</b>	TEVA PHARMS	<b>300MG</b>	<b><u>A075592</u></b>	<b><u>001</u></b>	May 25, 2000
-----------	-------------	--------------	-----------------------	-------------------	--------------

TABLET;ORAL

URSO 250

<b>AB</b>	FOREST LABS INC	<b>250MG</b>	<b><u>N020675</u></b>	<b><u>001</u></b>	Dec 10, 1997
-----------	-----------------	--------------	-----------------------	-------------------	--------------

URSO FORTE

<b>AB</b>	+ FOREST LABS INC	<b>500MG</b>	<b><u>N020675</u></b>	<b><u>002</u></b>	Jul 21, 2004
-----------	-------------------	--------------	-----------------------	-------------------	--------------

URSODIOL

<b>AB</b>	GLENMARK GENERICS	<b>250MG</b>	<b><u>A090801</u></b>	<b><u>001</u></b>	Jul 12, 2011
-----------	-------------------	--------------	-----------------------	-------------------	--------------

<b>AB</b>		<b>500MG</b>	<b><u>A090801</u></b>	<b><u>002</u></b>	Jul 12, 2011
-----------	--	--------------	-----------------------	-------------------	--------------

<b>AB</b>	IMPAX LABS INC	<b>250MG</b>	<b><u>A200826</u></b>	<b><u>001</u></b>	Dec 23, 2011
-----------	----------------	--------------	-----------------------	-------------------	--------------

<b>AB</b>		<b>500MG</b>	<b><u>A200826</u></b>	<b><u>002</u></b>	Dec 23, 2011
-----------	--	--------------	-----------------------	-------------------	--------------

<b>AB</b>	PAR PHARM	<b>250MG</b>	<b><u>A202540</u></b>	<b><u>001</u></b>	Feb 14, 2013
-----------	-----------	--------------	-----------------------	-------------------	--------------

<b>AB</b>		<b>500MG</b>	<b><u>A202540</u></b>	<b><u>002</u></b>	Feb 14, 2013
-----------	--	--------------	-----------------------	-------------------	--------------

## PRESCRIPTION DRUG PRODUCT LIST

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 1GM BASE</u>	<u>A090500 002</u>	Apr 04, 2014
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090500 001</u>	Apr 04, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE</u>	<u>A090682 002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090682 001</u>	May 24, 2010
<u>AB</u>	CIPLA LTD	<u>EQ 1GM BASE</u>	<u>A077135 002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077135 001</u>	May 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 1GM BASE</u>	<u>A079012 002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A079012 001</u>	May 24, 2010
<u>AB</u>	JUBILANT GENERICS	<u>EQ 1GM BASE</u>	<u>A201506 002</u>	Apr 03, 2012
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A201506 001</u>	Apr 03, 2012
<u>AB</u>	MYLAN	<u>EQ 1GM BASE</u>	<u>A078070 002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078070 001</u>	May 24, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 1GM BASE</u>	<u>A078518 002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078518 001</u>	May 24, 2010
<u>AB</u>	RANBAXY	<u>EQ 1GM BASE</u>	<u>A076588 002</u>	Jan 31, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076588 001</u>	Jan 31, 2007
<u>AB</u>	ROXANE	<u>EQ 1GM BASE</u>	<u>A078656 002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078656 001</u>	May 24, 2010
<u>AB</u>	SANDOZ	<u>EQ 1GM BASE</u>	<u>A077478 002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077478 001</u>	May 24, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 1GM BASE</u>	<u>A077655 002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077655 001</u>	May 24, 2010
<u>AB</u>	WATSON LABS INC	<u>EQ 1GM BASE</u>	<u>A090370 002</u>	Mar 16, 2011
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090370 001</u>	Mar 16, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 1GM BASE</u>	<u>A090216 002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090216 001</u>	May 24, 2010
<u>VALTREX</u>				
<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 1GM BASE</u>	<u>N020487 002</u>	Jun 23, 1995
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N020487 001</u>	Jun 23, 1995

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+ HOFFMANN LA ROCHE 50MG/ML

N022257 001 Aug 28, 2009

TABLET; ORAL

VALCYTE

<u>AB</u>	+ HOFFMANN LA ROCHE	<u>EQ 450MG BASE</u>	<u>N021304 001</u>	Mar 29, 2001
<u>VALGANCICLOVIR HYDROCHLORIDE</u>				
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 450MG BASE</u>	<u>A203511 001</u>	Nov 04, 2014
<u>AB</u>	ENDO PHARMS INC	<u>EQ 450MG BASE</u>	<u>A200790 001</u>	Nov 04, 2014

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPACON

<u>AP</u>	+ ABBVIE	<u>EQ 100MG BASE/ML</u>	<u>N020593 001</u>	Dec 30, 1996
-----------	----------	-------------------------	--------------------	--------------

VALPROATE SODIUM

<u>AP</u>	BEDFORD	<u>EQ 100MG BASE/ML</u>	<u>A076295 001</u>	Nov 14, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 100MG BASE/ML</u>	<u>A076539 001</u>	Jun 26, 2003
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523 001</u>	Feb 17, 2010

VALPROIC ACID

CAPSULE; ORAL

DEPAKENE

<u>AB</u>	+ ABBVIE	<u>250MG</u>	<u>N018081 001</u>	
-----------	----------	--------------	--------------------	--

VALPROIC ACID

<u>AB</u>	BANNER PHARMACAPS	<u>250MG</u>	<u>A073484 001</u>	Jun 29, 1993
<u>AB</u>	CATALENT	<u>250MG</u>	<u>A073229 001</u>	Oct 29, 1991
<u>AB</u>	SUN PHARM INDS LTD	<u>250MG</u>	<u>A091037 001</u>	Feb 22, 2013

SYRUP; ORAL

DEPAKENE

<u>AA</u>	+ ABBVIE	<u>250MG/5ML</u>	<u>N018082 001</u>	
-----------	----------	------------------	--------------------	--

VALPROIC ACID

<u>AA</u>	ALPHARMA	<u>250MG/5ML</u>	<u>A075782 001</u>	Dec 22, 2000
<u>AA</u>	ANI PHARMS INC	<u>250MG/5ML</u>	<u>A073178 001</u>	Aug 25, 1992
<u>AA</u>	HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060 001</u>	Jan 13, 1995
<u>AA</u>	PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379 001</u>	Dec 15, 2000
<u>AA</u>	SUN PHARM INDS INC	<u>250MG/5ML</u>	<u>A090517 001</u>	May 28, 2010
<u>AA</u>	VINTAGE	<u>250MG/5ML</u>	<u>A077960 001</u>	Oct 13, 2006
<u>AA</u>	WOCKHARDT	<u>250MG/5ML</u>	<u>A070868 001</u>	Jul 01, 1986

## PRESCRIPTION DRUG PRODUCT LIST

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

+ ENDO PHARM

40MG/ML

N020892 001 Sep 25, 1998

VALSARTAN

TABLET; ORAL

DIOVANAB NOVARTIS40MGN021283 004 Aug 14, 2002AB80MGN021283 001 Jul 18, 2001AB160MGN021283 002 Jul 18, 2001AB +320MGN021283 003 Jul 18, 2001VALSARTANAB ALEMBIC PHARMS LTD40MGA091367 001 Jan 05, 2015AB80MGA091367 002 Jan 05, 2015AB160MGA091367 003 Jan 05, 2015AB320MGA091367 004 Jan 05, 2015AB AUROBINDO PHARMA LTD40MGA202223 001 Jan 05, 2015AB80MGA202223 002 Jan 05, 2015AB160MGA202223 003 Jan 05, 2015AB320MGA202223 004 Jan 05, 2015AB HETERO LABS LTD V40MGA203311 001 Jan 05, 2015AB80MGA203311 002 Jan 05, 2015AB160MGA203311 003 Jan 05, 2015AB320MGA203311 004 Jan 05, 2015AB IVAX PHARMS40MGA077530 001 Jan 05, 2015AB80MGA077530 002 Jan 05, 2015AB160MGA077530 003 Jan 05, 2015AB320MGA077530 004 Jan 05, 2015AB JUBILANT GENERICS40MGA203536 001 Jan 05, 2015AB80MGA203536 002 Jan 05, 2015AB160MGA203536 003 Jan 05, 2015AB320MGA203536 004 Jan 05, 2015AB LUPIN LTD40MGA201677 001 Jan 05, 2015AB80MGA201677 002 Jan 05, 2015AB160MGA201677 003 Jan 05, 2015AB320MGA201677 004 Jan 05, 2015AB MYLAN LABS LTD40MGA090866 001 Jan 05, 2015AB80MGA090866 002 Jan 05, 2015AB160MGA090866 003 Jan 05, 2015AB320MGA090866 004 Jan 05, 2015AB OHM LABS INC40MGA077492 001 Jun 26, 2014AB80MGA077492 002 Jun 26, 2014AB160MGA077492 003 Jun 26, 2014AB320MGA077492 004 Jun 26, 2014AB TORRENT PHARMS LTD40MGA202728 001 Jan 05, 2015AB80MGA202728 002 Jan 05, 2015AB160MGA202728 003 Jan 05, 2015AB320MGA202728 004 Jan 05, 2015AB WATSON LABS INC40MGA090642 001 Jan 05, 2015AB80MGA090642 002 Jan 05, 2015AB160MGA090642 003 Jan 05, 2015AB320MGA090642 004 Jan 05, 2015VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOVIN HYDROCHLORIDEAB ANI PHARMS INCEQ 125MG BASEN050606 001 Apr 15, 1986AB +EQ 250MG BASEN050606 002 Apr 15, 1986VANCOMYCIN HYDROCHLORIDEAB AKORNEQ 125MG BASEA065478 001 Apr 09, 2012ABEQ 250MG BASEA065478 002 Apr 09, 2012AB FRESENIUS KABI USAEQ 125MG BASEA065453 001 Jun 18, 2012ABEQ 250MG BASEA065453 002 Jun 18, 2012AB STRIDES PHARMAEQ 125MG BASEA065490 001 Apr 09, 2012ABEQ 250MG BASEA065490 002 Apr 09, 2012AB WATSON LABSEQ 125MG BASEA065510 001 Apr 09, 2012ABEQ 250MG BASEA065510 002 Apr 09, 2012

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDEAP AGILA SPECLTSEQ 1GM BASE/VIALA065397 002 Dec 30, 2008APEQ 5GM BASE/VIALA065432 001 Dec 30, 2008APEQ 10GM BASE/VIALA091469 001 Jul 01, 2011

## PRESCRIPTION DRUG PRODUCT LIST

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091554</u>	<u>001</u>	Sep 19, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065397</u>	<u>001</u>	Dec 30, 2008
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A202275</u>	<u>002</u>	Oct 31, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A202464</u>	<u>001</u>	Oct 09, 2013
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A202274</u>	<u>001</u>	Oct 31, 2013
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A202275</u>	<u>001</u>	Oct 31, 2013
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A062663</u>	<u>002</u>	Jul 31, 1987
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A062663</u>	<u>003</u>	Jun 03, 1988
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A062663</u>	<u>004</u>	Nov 28, 1997
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062663</u>	<u>001</u>	Mar 17, 1987
<u>AP</u>	+ HOSPIRA	<u>EQ 1GM BASE/VIAL</u>	<u>A062912</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062933</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A063076</u>	<u>001</u>	Dec 21, 1990
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062911</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062931</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 750MG BASE/VIAL</u>	<u>A062912</u>	<u>002</u>	Jan 07, 2009
<u>AP</u>	+	<u>EQ 750MG BASE/VIAL</u>	<u>A062933</u>	<u>002</u>	May 27, 2009
<u>AP</u>	HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455</u>	<u>001</u>	Apr 29, 2009
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>EQ 1GM BASE/VIAL</u>	<u>A065401</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065401</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	SAGENT PHARMS	<u>EQ 5GM BASE/VIAL</u>	<u>A200837</u>	<u>001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A200837</u>	<u>002</u>	Sep 02, 2014
<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A090250</u>	<u>002</u>	Apr 27, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090250</u>	<u>001</u>	Apr 27, 2010
<u>AP</u>	SANDOZ INC	<u>EQ 5GM BASE/VIAL</u>	<u>A201048</u>	<u>001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201048</u>	<u>002</u>	Aug 10, 2012
	VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
	+	EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010

VANDETANIB

TABLET; ORAL

CAPRELSA

IPR PHARMS INC

100MG

N022405 001 Apr 06, 2011

+ 300MG

N022405 002 Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

<u>AB</u>	BAYER HLTHCARE	<u>2.5MG</u>	<u>N021400</u>	<u>003</u>	Aug 19, 2003
<u>AB</u>		<u>5MG</u>	<u>N021400</u>	<u>001</u>	Aug 19, 2003
<u>AB</u>		<u>10MG</u>	<u>N021400</u>	<u>002</u>	Aug 19, 2003
<u>AB</u>	+	<u>20MG</u>	<u>N021400</u>	<u>004</u>	Aug 19, 2003

VARDENAFIL HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A091347</u>	<u>001</u>	May 03, 2012
<u>AB</u>		<u>5MG</u>	<u>A091347</u>	<u>002</u>	May 03, 2012
<u>AB</u>		<u>10MG</u>	<u>A091347</u>	<u>003</u>	May 03, 2012
<u>AB</u>		<u>20MG</u>	<u>A091347</u>	<u>004</u>	May 03, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

+ BAYER HLTHCARE

10MG

N200179 001 Jun 17, 2010

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

PFIZER INC

EQ 0.5MG BASE

N021928 001 May 10, 2006

+ EQ 1MG BASE

N021928 002 May 10, 2006

VASOPRESSIN

SOLUTION; IV (INFUSION)

VASOSTRICT

+ PAR STERILE PRODUCTS

20UNITS/ML (20UNITS/ML)

N204485 001 Apr 17, 2014

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>	AGILA SPECLTS	<u>10MG/VIAL</u>	<u>A090243</u>	<u>001</u>	May 11, 2010
<u>AP</u>		<u>20MG/VIAL</u>	<u>A090243</u>	<u>002</u>	May 11, 2010
<u>AP</u>	BEDFORD	<u>10MG/VIAL</u>	<u>A075549</u>	<u>001</u>	Jun 13, 2000
<u>AP</u>		<u>20MG/VIAL</u>	<u>A075549</u>	<u>002</u>	Jun 13, 2000
<u>AP</u>	HOSPIRA	<u>10MG/VIAL</u>	<u>A075164</u>	<u>001</u>	Oct 21, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A075164</u>	<u>002</u>	Oct 21, 1999

## PRESCRIPTION DRUG PRODUCT LIST

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>	MUSTAFA NEVZAT	<u>10MG/VIAL</u>	<u>A078274 001</u>	Dec 29, 2008
<u>AP</u>		<u>20MG/VIAL</u>	<u>A078274 002</u>	Dec 29, 2008
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>10MG/VIAL</u>	<u>A079001 001</u>	Jun 17, 2009
<u>AP</u>	+ TEVA PHARMS USA	<u>20MG/VIAL</u>	<u>A079001 002</u>	Jun 17, 2009
<u>AP</u>		<u>10MG/VIAL</u>	<u>A074688 001</u>	Aug 25, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A074688 002</u>	Aug 25, 1999

VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)

VPRIV

	SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575 001	Feb 26, 2010
--	---------------------	----------------	-------------	--------------

VEMURAFENIB

TABLET; ORAL

ZELBORAF

	+ HOFFMANN LA ROCHE	240MG	N202429 001	Aug 17, 2011
--	---------------------	-------	-------------	--------------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

<u>AB</u>	WYETH PHARMS INC	<u>EQ 37.5MG BASE</u>	<u>N020699 001</u>	Oct 20, 1997
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N020699 002</u>	Oct 20, 1997
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N020699 004</u>	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>EQ 37.5MG BASE</u>	<u>A078087 001</u>	Mar 16, 2012
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078087 002</u>	Mar 16, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078087 003</u>	Mar 16, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 37.5MG BASE</u>	<u>A200834 001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A200834 002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A200834 003</u>	Apr 14, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 37.5MG BASE</u>	<u>A078421 001</u>	May 06, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078421 002</u>	May 06, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078421 003</u>	May 06, 2011
<u>AB</u>	MYLAN	<u>EQ 37.5MG BASE</u>	<u>A078789 001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078789 002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078789 003</u>	Jun 01, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 37.5MG BASE</u>	<u>A091123 001</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091123 002</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091123 003</u>	Jul 11, 2011
<u>AB</u>	TEVA	<u>EQ 37.5MG BASE</u>	<u>A076565 001</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076565 002</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A076565 003</u>	Jun 28, 2010
<u>AB</u>	TORRENT PHARMS LLC	<u>EQ 37.5MG BASE</u>	<u>A090899 001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090899 002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090899 003</u>	Jun 01, 2011
<u>AB</u>	VALEANT BERMUDA	<u>EQ 37.5MG BASE</u>	<u>A090071 001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090071 002</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090071 003</u>	Apr 15, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 37.5MG BASE</u>	<u>A078865 001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078865 002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078865 003</u>	Apr 14, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 37.5MG BASE</u>	<u>A090174 001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090174 002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090174 003</u>	Apr 14, 2011

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A078932 001</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078932 002</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078932 003</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078932 004</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078932 005</u>	Dec 14, 2010
<u>AB</u>	AMNEAL PHARMS	<u>EQ 25MG BASE</u>	<u>A079098 001</u>	May 11, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A079098 002</u>	May 11, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A079098 003</u>	May 11, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A079098 004</u>	May 11, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A079098 005</u>	May 11, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A090555 001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090555 002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090555 003</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090555 004</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090555 005</u>	Apr 07, 2010

## PRESCRIPTION DRUG PRODUCT LIST

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078301 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078301 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078301 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078301 005</u>	Jun 13, 2008
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078554 001</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078554 002</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078554 003</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078554 004</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078554 005</u>	Jan 09, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077166 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077166 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077166 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077166 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077166 005</u>	Jun 13, 2008
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 25MG BASE</u>	<u>A078627 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078627 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078627 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078627 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078627 005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690 001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690 002</u>	Aug 03, 2006
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>A076690 003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690 004</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690 005</u>	Aug 03, 2006
<u>AB</u>	VINTAGE	<u>EQ 25MG BASE</u>	<u>A090027 001</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090027 002</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090027 003</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090027 004</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090027 005</u>	Aug 04, 2010
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653 005</u>	Jun 13, 2008

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	OSMOTICA PHARM	<u>EQ 37.5MG BASE</u>	<u>N022104 001</u>	May 20, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N022104 002</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N022104 003</u>	May 20, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 37.5MG BASE</u>	<u>A091272 001</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091272 002</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091272 003</u>	Aug 18, 2010
	OSMOTICA PHARM	EQ 225MG BASE	N022104 004	May 20, 2008

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>100MG</u>	<u>A078306 001</u>	Aug 09, 2007
<u>AB</u>		<u>120MG</u>	<u>A075138 001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138 002</u>	Apr 20, 1999
<u>AB</u>		<u>200MG</u>	<u>A078306 002</u>	Aug 09, 2007
<u>AB</u>		<u>240MG</u>	<u>A075138 003</u>	Apr 20, 1999
<u>AB</u>		<u>300MG</u>	<u>A078306 003</u>	Aug 09, 2007
	<u>VERELAN</u>			
<u>AB</u>	ALKERMES GAINESVILLE	<u>120MG</u>	<u>N019614 001</u>	May 29, 1990
<u>AB</u>		<u>180MG</u>	<u>N019614 003</u>	Jan 09, 1992
<u>AB</u>		<u>240MG</u>	<u>N019614 002</u>	May 29, 1990
	<u>VERELAN PM</u>			
<u>AB</u>	ALKERMES GAINESVILLE	<u>100MG</u>	<u>N020943 001</u>	Nov 25, 1998
<u>AB</u>		<u>200MG</u>	<u>N020943 002</u>	Nov 25, 1998
<u>AB</u>	+	<u>300MG</u>	<u>N020943 003</u>	Nov 25, 1998
	VERELAN			
	+ ALKERMES GAINESVILLE	360MG	N019614 004	May 10, 1996

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>10MG/4ML (2.5MG/ML)</u>	<u>A070738 001</u>	May 06, 1987
<u>AP</u>	+		<u>5MG/2ML (2.5MG/ML)</u>	<u>A075136 001</u>	Oct 20, 1998
<u>AP</u>	+		<u>5MG/2ML (2.5MG/ML)</u>	<u>A070737 001</u>	May 06, 1987
<u>AP</u>	+		<u>10MG/4ML (2.5MG/ML)</u>	<u>A070737 002</u>	May 06, 1987



## PRESCRIPTION DRUG PRODUCT LIST

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

CALAN

<u>AB</u>	GD SEARLE LLC	<u>40MG</u>	<u>N018817 003</u>	Feb 23, 1988
<u>AB</u>		<u>80MG</u>	<u>N018817 001</u>	Sep 10, 1984
<u>AB</u>	+	<u>120MG</u>	<u>N018817 002</u>	Sep 10, 1984

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>80MG</u>	<u>A071880 001</u>	Apr 05, 1988
<u>AB</u>		<u>120MG</u>	<u>A071881 001</u>	Apr 05, 1988
<u>AB</u>	MYLAN	<u>80MG</u>	<u>A071483 002</u>	Feb 15, 1989
<u>AB</u>		<u>120MG</u>	<u>A071483 001</u>	Feb 15, 1989
<u>AB</u>	WATSON LABS	<u>40MG</u>	<u>A072924 001</u>	Jun 29, 1993
<u>AB</u>		<u>80MG</u>	<u>A070995 001</u>	Oct 01, 1986
<u>AB</u>		<u>120MG</u>	<u>A070994 001</u>	Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

<u>AB</u>	+	PFIZER	<u>120MG</u>	<u>N019152 003</u>	Mar 06, 1991
<u>AB</u>	+		<u>180MG</u>	<u>N019152 002</u>	Dec 15, 1989
<u>AB</u>	+		<u>240MG</u>	<u>N019152 001</u>	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	APOTEX CORP	<u>120MG</u>	<u>A200878 001</u>	Apr 20, 2012
<u>AB</u>		<u>180MG</u>	<u>A200878 002</u>	Apr 20, 2012
<u>AB</u>		<u>240MG</u>	<u>A200878 003</u>	Apr 20, 2012
<u>AB</u>	GLENMARK GENERICS	<u>120MG</u>	<u>A090700 001</u>	Aug 03, 2011
<u>AB</u>		<u>180MG</u>	<u>A090700 002</u>	Aug 03, 2011
<u>AB</u>		<u>240MG</u>	<u>A078906 001</u>	Sep 17, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>120MG</u>	<u>A073568 002</u>	Oct 10, 1997
<u>AB</u>		<u>180MG</u>	<u>A074330 001</u>	Jan 31, 1994
<u>AB</u>		<u>240MG</u>	<u>A073568 001</u>	Jul 31, 1992
<u>AB</u>	MYLAN	<u>120MG</u>	<u>A074587 002</u>	Feb 21, 1997
<u>AB</u>		<u>180MG</u>	<u>A074587 003</u>	Sep 09, 1997
<u>AB</u>		<u>240MG</u>	<u>A074587 001</u>	Mar 23, 1996
<u>AB</u>	PAR PHARM	<u>120MG</u>	<u>A075072 001</u>	May 25, 1999
<u>AB</u>		<u>240MG</u>	<u>A075072 003</u>	May 25, 1999
<u>AB</u>	SUN PHARM INDS INC	<u>120MG</u>	<u>A090529 001</u>	Dec 30, 2011
<u>AB</u>		<u>180MG</u>	<u>A090529 002</u>	Dec 30, 2011
<u>AB</u>		<u>240MG</u>	<u>A090529 003</u>	Dec 30, 2011

COVERA-HS

BC	+	GD SEARLE LLC	180MG	N020552 001	Feb 26, 1996
BC	+		240MG	N020552 002	Feb 26, 1996

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

+	VALEANT PHARMS INC	15MG/VIAL	N021119 001	Apr 12, 2000
---	--------------------	-----------	-------------	--------------

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+	LUNDBECK LLC	500MG/PACKET	N022006 001	Aug 21, 2009
---	--------------	--------------	-------------	--------------

TABLET; ORAL

SABRIL

+	LUNDBECK LLC	500MG	N020427 001	Aug 21, 2009
---	--------------	-------	-------------	--------------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011
		20MG	N022567 002	Jan 21, 2011
		40MG	N022567 003	Jan 21, 2011

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

+	EUROHLTH INTL	10MG/VIAL	A089395 001	Apr 09, 1987
+	FRESENIUS KABI USA	1MG/ML	A089515 001	Apr 29, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE PFS

<u>AP</u>	+	HOSPIRA	<u>1MG/ML</u>	<u>A071484 001</u>	Apr 19, 1988
<u>AP</u>		TEVA PHARMS USA	<u>1MG/ML</u>	<u>A075493 001</u>	Sep 01, 1999

## PRESCRIPTION DRUG PRODUCT LIST

VINCRIStINE SULFATE

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+ TALON THERAP

5MG/5ML (1MG/ML)

N202497 001 Aug 09, 2012

VINORELBINE

INJECTABLE; INJECTION

VINORELBINEAP ONCO THERAPIES LTDEQ 10MG BASE/MLA200148 001 Aug 31, 2012VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINEAP + PIERRE FABREEQ 10MG BASE/MLN020388 001 Dec 23, 1994VINORELBINE TARTRATEAP ACTAVIS TOTOWAEQ 10MG BASE/MLA078011 001 Jul 22, 2009AP BEDFORDEQ 10MG BASE/MLA076461 001 Dec 11, 2003AP DR REDDYS LABS LTDEQ 10MG BASE/MLA202017 001 Sep 12, 2013AP FRESENIUS KABI USAEQ 10MG BASE/MLA076849 001 Apr 18, 2005AP HIKMA MAPLEEQ 10MG BASE/MLA075992 001 Jun 10, 2003AP HOSPIRAEQ 10MG BASE/MLA076827 001 Jun 02, 2005AP JIANGSU HANSON PHARMEQ 10MG BASE/MLA091106 001 Sep 26, 2012AP TEVA PHARMS USAEQ 10MG BASE/MLA076028 001 Feb 03, 2003VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+ GENENTECH

150MG

N203388 001 Jan 30, 2012

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+ HOSPIRA

EQ 50,000 UNITS BASE/ML

N006823 001

VORAPAXAR SULFATE

TABLET; ORAL

ZONTIVITY

+ MERCK SHARP DOHME

EQ 2.08MG BASE

N204886 001 May 08, 2014

VORICONAZOLE

FOR SUSPENSION; ORAL

VFENDAB + PF PRISM CV200MG/5MLN021630 001 Dec 19, 2003VORICONAZOLEAB MYLAN PHARMS INC200MG/5MLA202361 001 May 28, 2013

INJECTABLE; IV (INFUSION)

VFENDAP + PF PRISM CV200MG/VIALN021267 001 May 24, 2002VORICONAZOLEAP SANDOZ INC200MG/VIALA090862 001 May 30, 2012

TABLET; ORAL

VFENDAB PF PRISM CV50MGN021266 001 May 24, 2002AB +200MGN021266 002 May 24, 2002VORICONAZOLEAB MYLAN PHARMS INC50MGA090547 001 Apr 22, 2010AB200MGA090547 002 Apr 22, 2010AB SANDOZ INC50MGA200265 001 Dec 12, 2011AB200MGA200265 002 Dec 12, 2011AB TEVA PHARMS50MGA091658 001 Apr 06, 2012AB200MGA091658 002 Apr 06, 2012VORINOSTAT

CAPSULE; ORAL

ZOLINZA

+ MERCK

100MG

N021991 001 Oct 06, 2006

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

BRINTELLIX

TAKEDA PHARMS USA

EQ 5MG BASE

N204447 001 Sep 30, 2013

EQ 10MG BASE

N204447 002 Sep 30, 2013

EQ 15MG BASE

N204447 003 Sep 30, 2013

+

EQ 20MG BASE

N204447 004 Sep 30, 2013

## PRESCRIPTION DRUG PRODUCT LIST

## WARFARIN SODIUM

TABLET; ORAL

COUMADIN

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>1MG</u>	<u>N009218 022</u>	Mar 01, 1990
<u>AB</u>		<u>2MG</u>	<u>N009218 013</u>	
<u>AB</u>		<u>2.5MG</u>	<u>N009218 018</u>	
<u>AB</u>		<u>3MG</u>	<u>N009218 025</u>	Nov 18, 1996
<u>AB</u>		<u>4MG</u>	<u>N009218 023</u>	Aug 24, 1993
<u>AB</u>		<u>5MG</u>	<u>N009218 007</u>	
<u>AB</u>		<u>6MG</u>	<u>N009218 026</u>	Nov 18, 1996
<u>AB</u>		<u>7.5MG</u>	<u>N009218 016</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N009218 005</u>	

JANTOVEN

<u>AB</u>	USL PHARMA	<u>1MG</u>	<u>A040416 001</u>	Oct 02, 2003
<u>AB</u>		<u>2MG</u>	<u>A040416 002</u>	Oct 02, 2003
<u>AB</u>		<u>2.5MG</u>	<u>A040416 003</u>	Oct 02, 2003
<u>AB</u>		<u>3MG</u>	<u>A040416 004</u>	Oct 02, 2003
<u>AB</u>		<u>4MG</u>	<u>A040416 005</u>	Oct 02, 2003
<u>AB</u>		<u>5MG</u>	<u>A040416 006</u>	Oct 02, 2003
<u>AB</u>		<u>6MG</u>	<u>A040416 007</u>	Oct 02, 2003
<u>AB</u>		<u>7.5MG</u>	<u>A040416 008</u>	Oct 02, 2003
<u>AB</u>		<u>10MG</u>	<u>A040416 009</u>	Oct 02, 2003

WARFARIN SODIUM

<u>AB</u>	AMNEAL PHARMS	<u>1MG</u>	<u>A202202 001</u>	Mar 04, 2013
<u>AB</u>		<u>2MG</u>	<u>A202202 002</u>	Mar 04, 2013
<u>AB</u>		<u>2.5MG</u>	<u>A202202 003</u>	Mar 04, 2013
<u>AB</u>		<u>3MG</u>	<u>A202202 004</u>	Mar 04, 2013
<u>AB</u>		<u>4MG</u>	<u>A202202 005</u>	Mar 04, 2013
<u>AB</u>		<u>5MG</u>	<u>A202202 006</u>	Mar 04, 2013
<u>AB</u>		<u>6MG</u>	<u>A202202 007</u>	Mar 04, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A202202 008</u>	Mar 04, 2013
<u>AB</u>		<u>10MG</u>	<u>A202202 009</u>	Mar 04, 2013
<u>AB</u>	BARR	<u>1MG</u>	<u>A040145 001</u>	Mar 26, 1997
<u>AB</u>		<u>2MG</u>	<u>A040145 002</u>	Mar 26, 1997
<u>AB</u>		<u>2.5MG</u>	<u>A040145 003</u>	Mar 26, 1997
<u>AB</u>		<u>3MG</u>	<u>A040145 008</u>	Nov 05, 1998
<u>AB</u>		<u>4MG</u>	<u>A040145 004</u>	Mar 26, 1997
<u>AB</u>		<u>5MG</u>	<u>A040145 005</u>	Mar 26, 1997
<u>AB</u>		<u>6MG</u>	<u>A040145 009</u>	Nov 05, 1998
<u>AB</u>		<u>7.5MG</u>	<u>A040145 006</u>	Mar 26, 1997
<u>AB</u>		<u>10MG</u>	<u>A040145 007</u>	Mar 26, 1997
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090935 001</u>	May 25, 2011
<u>AB</u>		<u>2MG</u>	<u>A090935 002</u>	May 25, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090935 003</u>	May 25, 2011
<u>AB</u>		<u>3MG</u>	<u>A090935 004</u>	May 25, 2011
<u>AB</u>		<u>4MG</u>	<u>A090935 005</u>	May 25, 2011
<u>AB</u>		<u>5MG</u>	<u>A090935 006</u>	May 25, 2011
<u>AB</u>		<u>6MG</u>	<u>A090935 007</u>	May 25, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A090935 008</u>	May 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A090935 009</u>	May 25, 2011
<u>AB</u>	IPCA LABS LTD	<u>1MG</u>	<u>A200104 001</u>	Jun 27, 2013
<u>AB</u>		<u>2MG</u>	<u>A200104 002</u>	Jun 27, 2013
<u>AB</u>		<u>2.5MG</u>	<u>A200104 003</u>	Jun 27, 2013
<u>AB</u>		<u>3MG</u>	<u>A200104 004</u>	Jun 27, 2013
<u>AB</u>		<u>4MG</u>	<u>A200104 005</u>	Jun 27, 2013
<u>AB</u>		<u>5MG</u>	<u>A200104 006</u>	Jun 27, 2013
<u>AB</u>		<u>6MG</u>	<u>A200104 007</u>	Jun 27, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200104 008</u>	Jun 27, 2013
<u>AB</u>		<u>10MG</u>	<u>A200104 009</u>	Jun 27, 2013
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A040415 001</u>	Sep 27, 2004
<u>AB</u>		<u>2MG</u>	<u>A040415 002</u>	Sep 27, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040415 003</u>	Sep 29, 2004
<u>AB</u>		<u>3MG</u>	<u>A040415 004</u>	Sep 27, 2004
<u>AB</u>		<u>4MG</u>	<u>A040415 005</u>	Sep 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A040415 006</u>	Sep 27, 2004
<u>AB</u>		<u>6MG</u>	<u>A040415 007</u>	Sep 27, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A040415 008</u>	Sep 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A040415 009</u>	Sep 27, 2004
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616 009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616 001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616 002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616 003</u>	Jul 05, 2006

## PRESCRIPTION DRUG PRODUCT LIST

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>		<u>4MG</u>	<u>A040616</u>	<u>004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616</u>	<u>005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616</u>	<u>006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616</u>	<u>007</u>	Jul 05, 2006
<u>AB</u>		<u>10MG</u>	<u>A040616</u>	<u>008</u>	Jul 05, 2006
<u>AB</u>	TARO	<u>1MG</u>	<u>A040301</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301</u>	<u>003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301</u>	<u>004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301</u>	<u>005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301</u>	<u>006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301</u>	<u>007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301</u>	<u>008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301</u>	<u>009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663</u>	<u>001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663</u>	<u>002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663</u>	<u>003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663</u>	<u>004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663</u>	<u>005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663</u>	<u>006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663</u>	<u>007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663</u>	<u>008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663</u>	<u>009</u>	May 30, 2006

XENON XE-133

GAS; INHALATION

XENON XE 133

<u>AA</u>	LANTHEUS MEDCL	<u>20mCi/VIAL</u>	<u>N017284</u>	<u>002</u>	
		10mCi/VIAL		N017284	001

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

<u>AB</u>	ASTRAZENECA	<u>10MG</u>	<u>N020547</u>	<u>003</u>	Sep 17, 1999
<u>AB</u>	+	<u>20MG</u>	<u>N020547</u>	<u>001</u>	Sep 26, 1996
	<u>ZAFIRLUKAST</u>				
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A090372</u>	<u>001</u>	Nov 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090372</u>	<u>002</u>	Nov 18, 2010

ZALEPLON

CAPSULE; ORAL

SONATA

<u>AB</u>	PFIZER	<u>5MG</u>	<u>N020859</u>	<u>001</u>	Aug 13, 1999
<u>AB</u>	+	<u>10MG</u>	<u>N020859</u>	<u>002</u>	Aug 13, 1999

ZALEPLON

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078829</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078829</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077505</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>		<u>10MG</u>	<u>A077505</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>	HIKMA PHARMS LLC	<u>5MG</u>	<u>A078147</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>10MG</u>	<u>A078147</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077238</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077238</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A090374</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>		<u>10MG</u>	<u>A090374</u>	<u>002</u>	Sep 17, 2009
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077237</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077237</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077239</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077239</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A078989</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078989</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UPSHER SMITH	<u>5MG</u>	<u>A078706</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078706</u>	<u>002</u>	Jun 06, 2008

ZANAMIVIR

POWDER; INHALATION

RELENZA

+	GLAXOSMITHKLINE	5MG	N021036	001	Jul 26, 1999
---	-----------------	-----	---------	-----	--------------

## PRESCRIPTION DRUG PRODUCT LIST

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004

ZIDOVDINE

CAPSULE; ORAL

RETROVIR

<b>AB</b>	+	VIIV HLTHCARE	<b>100MG</b>	<b>N019655</b>	<b>001</b>	Mar 19, 1987
-----------	---	---------------	--------------	----------------	------------	--------------

ZIDOVDINE

<b>AB</b>		AUROBINDO PHARMA LTD	<b>100MG</b>	<b>A078128</b>	<b>001</b>	Mar 27, 2006
<b>AB</b>		CIPLA LTD	<b>100MG</b>	<b>A078349</b>	<b>001</b>	May 23, 2007

INJECTABLE; INJECTION

RETROVIR

<b>AP</b>	+	VIIV HLTHCARE	<b>10MG/ML</b>	<b>N019951</b>	<b>001</b>	Feb 02, 1990
-----------	---	---------------	----------------	----------------	------------	--------------

ZIDOVDINE

<b>AP</b>		LUITPOLD	<b>10MG/ML</b>	<b>A091457</b>	<b>001</b>	May 06, 2010
-----------	--	----------	----------------	----------------	------------	--------------

SYRUP; ORAL

RETROVIR

<b>AA</b>	+	VIIV HLTHCARE	<b>50MG/5ML</b>	<b>N019910</b>	<b>001</b>	Sep 28, 1989
-----------	---	---------------	-----------------	----------------	------------	--------------

ZIDOVDINE

<b>AA</b>		AUROBINDO	<b>50MG/5ML</b>	<b>A077268</b>	<b>001</b>	Sep 19, 2005
<b>AA</b>		CIPLA LTD	<b>50MG/5ML</b>	<b>A077981</b>	<b>001</b>	Jun 26, 2008

TABLET; ORAL

ZIDOVDINE

<b>AB</b>		AUROBINDO	<b>300MG</b>	<b>A077267</b>	<b>001</b>	Sep 19, 2005
<b>AB</b>		CIPLA	<b>300MG</b>	<b>A090561</b>	<b>001</b>	Oct 27, 2010
<b>AB</b>	+	HETERO LABS LTD III	<b>300MG</b>	<b>A090092</b>	<b>001</b>	Apr 25, 2008
<b>AB</b>		MYLAN PHARMS INC	<b>300MG</b>	<b>A078922</b>	<b>001</b>	Feb 14, 2008
<b>AB</b>		ROXANE	<b>300MG</b>	<b>A076844</b>	<b>001</b>	Sep 19, 2005
<b>AB</b>		SUNSHINE LAKE	<b>300MG</b>	<b>A202058</b>	<b>001</b>	Oct 07, 2011

ZILEUTON

TABLET; ORAL

ZYFLO

+	CHIESI USA INC	600MG	N020471	003	Dec 09, 1996
---	----------------	-------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

ZYFLO CR

+	CHIESI USA INC	600MG	N022052	001	May 30, 2007
---	----------------	-------	---------	-----	--------------

ZINC ACETATE

CAPSULE; ORAL

GALZIN

	TEVA	EQ 25MG ZINC	N020458	001	Jan 28, 1997
+		EQ 50MG ZINC	N020458	002	Jan 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986
---	---------	----------------	---------	-----	--------------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

<b>AB</b>	+	PFIZER	<b>EQ 20MG BASE</b>	<b>N020825</b>	<b>001</b>	Feb 05, 2001
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>N020825</b>	<b>002</b>	Feb 05, 2001
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>N020825</b>	<b>003</b>	Feb 05, 2001
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>N020825</b>	<b>004</b>	Feb 05, 2001

ZIPRASIDONE HYDROCHLORIDE

<b>AB</b>		APOTEX CORP	<b>EQ 20MG BASE</b>	<b>A077561</b>	<b>001</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>A077561</b>	<b>002</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>A077561</b>	<b>003</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>A077561</b>	<b>004</b>	Mar 02, 2012
<b>AB</b>		DR REDDYS LABS INC	<b>EQ 20MG BASE</b>	<b>A077565</b>	<b>001</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>A077565</b>	<b>002</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>A077565</b>	<b>003</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>A077565</b>	<b>004</b>	Mar 02, 2012
<b>AB</b>		LUPIN PHARMS	<b>EQ 20MG BASE</b>	<b>A077560</b>	<b>001</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>A077560</b>	<b>002</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 60MG BASE</b>	<b>A077560</b>	<b>003</b>	Mar 02, 2012
<b>AB</b>			<b>EQ 80MG BASE</b>	<b>A077560</b>	<b>004</b>	Mar 02, 2012
<b>AB</b>		MYLAN PHARMS INC	<b>EQ 20MG BASE</b>	<b>A202395</b>	<b>001</b>	Oct 10, 2013
<b>AB</b>			<b>EQ 40MG BASE</b>	<b>A202395</b>	<b>002</b>	Oct 10, 2013

## PRESCRIPTION DRUG PRODUCT LIST

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A202395 003</u>	Oct 10, 2013
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202395 004</u>	Oct 10, 2013
<u>AB</u>	SANDOZ INC	<u>EQ 20MG BASE</u>	<u>A077562 001</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077562 002</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077562 003</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077562 004</u>	Jun 01, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 20MG BASE</u>	<u>A090348 001</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090348 002</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090348 003</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090348 004</u>	Sep 05, 2012
SUSPENSION; ORAL				
GEODON				
	+ PFIZER INC	EQ 10MG BASE/ML	N021483 001	Mar 29, 2006

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

+ PFIZER

EQ 20MG BASE/ML

N020919 001 Jun 21, 2002

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

RECLAST

<u>AP</u>	+ NOVARTIS	<u>EQ 5MG BASE/100ML</u>	<u>N021817 001</u>	Apr 16, 2007
<u>ZOLEDRONIC ACID</u>				
<u>AP</u>	ACS DOBFAR INFO SA	<u>EQ 4MG BASE/100ML</u>	<u>N203231 001</u>	Aug 02, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202828 001</u>	Sep 23, 2013
<u>AP</u>	ACTAVIS INC	<u>EQ 4MG BASE/5ML</u>	<u>A202472 001</u>	Mar 04, 2013
<u>AP</u>	AGILA SPECLTS	<u>EQ 4MG BASE/5ML</u>	<u>A202650 001</u>	Mar 04, 2013
<u>AP</u>	AKORN	<u>EQ 5MG BASE/100ML</u>	<u>A200918 001</u>	Aug 21, 2014
<u>AP</u>	AKORN INC	<u>EQ 4MG BASE/5ML</u>	<u>A202548 001</u>	May 22, 2014
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A091186 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A091363 001</u>	Mar 29, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A201783 001</u>	Mar 12, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A201801 001</u>	Mar 29, 2013
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202930 001</u>	Aug 05, 2013
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 4MG BASE/5ML</u>	<u>A202182 001</u>	Jun 03, 2013
<u>AP</u>	HOSPIRA INC	<u>EQ 5MG BASE/100ML</u>	<u>A202837 001</u>	Apr 05, 2013
<u>AP</u>	PHARMACEUTICS	<u>EQ 4MG BASE/5ML</u>	<u>A091170 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202163 001</u>	Aug 05, 2013
<u>AP</u>	PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A202571 001</u>	May 07, 2013
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091493 001</u>	Nov 24, 2014
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>EQ 4MG BASE/VIAL</u>	<u>A090018 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 4MG BASE/5ML</u>	<u>A202746 001</u>	Mar 04, 2013
<u>AP</u>	USV NORTH AMERICA	<u>EQ 4MG BASE/VIAL</u>	<u>A202923 001</u>	Sep 04, 2014
<u>ZOMETA</u>				
<u>AP</u>	+ NOVARTIS	<u>EQ 4MG BASE/5ML</u>	<u>N021223 002</u>	Mar 07, 2003
<u>AP</u>	+	<u>EQ 4MG BASE/100ML</u>	<u>N021223 003</u>	Jun 17, 2011

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

ASTRAZENECA

2.5MG/SPRAY

N021450 003 Sep 16, 2013

+

5MG/SPRAY

N021450 004 Sep 30, 2003

TABLET; ORAL

ZOLMITRIPTAN

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A202078 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202078 002</u>	May 14, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A201779 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A201779 002</u>	May 14, 2013
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A204284 001</u>	Apr 09, 2014
<u>AB</u>		<u>5MG</u>	<u>A204284 002</u>	Apr 09, 2014
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202279 001</u>	Nov 20, 2014
<u>AB</u>		<u>5MG</u>	<u>A202279 002</u>	Nov 20, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A203186 001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A203186 002</u>	May 14, 2013
<u>AB</u>	SUN PHARMA GLOBAL	<u>2.5MG</u>	<u>A203476 001</u>	Nov 13, 2014
<u>AB</u>		<u>5MG</u>	<u>A203476 002</u>	Nov 13, 2014
<u>AB</u>	TEVA PHARMS USA	<u>2.5MG</u>	<u>A090861 001</u>	Mar 04, 2014
<u>AB</u>		<u>5MG</u>	<u>A090861 002</u>	Mar 04, 2014

## PRESCRIPTION DRUG PRODUCT LIST

ZOLMITRIPTAN

TABLET; ORAL

ZOMIG

<u>AB</u>	IPR	<u>2.5MG</u>	<u>N020768</u>	<u>001</u>	Nov 25, 1997
<u>AB</u>	+	<u>5MG</u>	<u>N020768</u>	<u>002</u>	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A202476</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202476</u>	<u>002</u>	May 14, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A202560</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202560</u>	<u>002</u>	May 14, 2013
<u>AB</u>	ZYDUS PHARMS USA INC	<u>2.5MG</u>	<u>A202890</u>	<u>001</u>	May 15, 2013
<u>AB</u>		<u>5MG</u>	<u>A202890</u>	<u>002</u>	May 15, 2013

ZOMIG-ZMT

<u>AB</u>	ASTRAZENECA	<u>2.5MG</u>	<u>N021231</u>	<u>001</u>	Feb 13, 2001
<u>AB</u>	+	<u>5MG</u>	<u>N021231</u>	<u>002</u>	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED; ORAL

ZOLPIMIST

+ NOVADEL

5MG/SPRAY

N022196 001 Dec 19, 2008

TABLET; ORAL

AMBIEN

<u>AB</u>	SANOFI AVENTIS US	<u>5MG</u>	<u>N019908</u>	<u>001</u>	Dec 16, 1992
<u>AB</u>	+	<u>10MG</u>	<u>N019908</u>	<u>002</u>	Dec 16, 1992

ZOLPIDEM TARTRATE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077884</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077884</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078413</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>10MG</u>	<u>A078413</u>	<u>002</u>	May 04, 2007
<u>AB</u>	CARLSBAD	<u>5MG</u>	<u>A077990</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077990</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077388</u>	<u>001</u>	Jul 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077388</u>	<u>002</u>	Jul 30, 2012
<u>AB</u>	HIKMA	<u>5MG</u>	<u>A078129</u>	<u>001</u>	Apr 30, 2008
<u>AB</u>		<u>10MG</u>	<u>A078129</u>	<u>002</u>	Apr 30, 2008
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A078184</u>	<u>001</u>	Sep 07, 2007
<u>AB</u>		<u>10MG</u>	<u>A078184</u>	<u>002</u>	Sep 07, 2007
<u>AB</u>	LEK PHARMS DD	<u>5MG</u>	<u>A077322</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077322</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076578</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076578</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A078055</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A078055</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077214</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077214</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A077359</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077359</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076410</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076410</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A077903</u>	<u>001</u>	Aug 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A077903</u>	<u>002</u>	Aug 17, 2007
<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A078616</u>	<u>001</u>	Nov 21, 2008
<u>AB</u>		<u>10MG</u>	<u>A078616</u>	<u>002</u>	Nov 21, 2008
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A078426</u>	<u>001</u>	May 15, 2007
<u>AB</u>		<u>10MG</u>	<u>A078426</u>	<u>002</u>	May 15, 2007

TABLET; SUBLINGUAL

EDLUAR

MEDA PHARMS

5MG

N021997 001 Mar 13, 2009

+

10MG

N021997 002 Mar 13, 2009

INTERMEZZO

PURDUE PHARMA

1.75MG

N022328 001 Nov 23, 2011

+

3.5MG

N022328 002 Nov 23, 2011

TABLET, EXTENDED RELEASE; ORAL

AMBIEN CR

<u>AB</u>	SANOFI AVENTIS US	<u>6.25MG</u>	<u>N021774</u>	<u>002</u>	Sep 02, 2005
<u>AB</u>	+	<u>12.5MG</u>	<u>N021774</u>	<u>001</u>	Sep 02, 2005

ZOLPIDEM TARTRATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>6.25MG</u>	<u>A078179</u>	<u>002</u>	Oct 13, 2010
<u>AB</u>		<u>12.5MG</u>	<u>A078179</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>	ACTAVIS LABS FL INC	<u>6.25MG</u>	<u>A090153</u>	<u>001</u>	Mar 25, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A090153</u>	<u>002</u>	Mar 25, 2013
<u>AB</u>	ANCHEN PHARMS	<u>6.25MG</u>	<u>A078148</u>	<u>002</u>	Apr 14, 2011

## PRESCRIPTION DRUG PRODUCT LIST

ZOLPIDEM TARTRATE

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

<u>AB</u>		<u>12.5MG</u>	<u>A078148 001</u>	Dec 03, 2010
<u>AB</u>	APOTEX INC	<u>6.25MG</u>	<u>A200266 001</u>	Sep 10, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A200266 002</u>	Sep 10, 2013
<u>AB</u>	LUPIN LTD	<u>6.25MG</u>	<u>A078970 001</u>	Sep 11, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A078970 002</u>	Sep 11, 2013
<u>AB</u>	SANDOZ	<u>6.25MG</u>	<u>A090107 001</u>	Jul 01, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A090107 002</u>	Jul 01, 2011
<u>AB</u>	SYNTHON PHARMS	<u>6.25MG</u>	<u>A078483 001</u>	Apr 12, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A078483 002</u>	Jun 06, 2011

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

<u>AB</u>	EISAI INC	<u>25MG</u>	<u>N020789 003</u>	Aug 22, 2003
<u>AB</u>		<u>50MG</u>	<u>N020789 002</u>	Aug 22, 2003
<u>AB</u>	+	<u>100MG</u>	<u>N020789 001</u>	Mar 27, 2000

ZONISAMIDE

<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077642 001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077642 002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077642 003</u>	Dec 22, 2005
<u>AB</u>	BANNER PHARMACAPS	<u>25MG</u>	<u>A077813 001</u>	Aug 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077813 002</u>	Aug 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077813 003</u>	Aug 16, 2006
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077651 001</u>	Jan 30, 2006
<u>AB</u>		<u>50MG</u>	<u>A077651 002</u>	Jan 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A077651 003</u>	Jan 30, 2006
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A077869 001</u>	May 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A077869 002</u>	May 31, 2006
<u>AB</u>		<u>100MG</u>	<u>A077869 003</u>	May 31, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077637 001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077637 002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077637 003</u>	Dec 22, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A077647 001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077647 002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077647 003</u>	Dec 22, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634 001</u>	Mar 17, 2006
<u>AB</u>		<u>50MG</u>	<u>A077634 002</u>	Mar 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A077634 003</u>	Mar 17, 2006
<u>AB</u>	WOCKHARDT	<u>25MG</u>	<u>A077636 003</u>	Jul 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077636 002</u>	Jul 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077636 001</u>	Dec 22, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625 001</u>	Oct 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077625 002</u>	Oct 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077625 003</u>	Oct 16, 2006



## OTC DRUG PRODUCT LIST

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS

120MG

N018060 001

325MG

A072344 001 Mar 27, 1992

325MG

N018060 003 Dec 18, 1986

650MG

A072237 001 Mar 27, 1992

650MG

N018060 002

ACETAMINOPHEN

PERRIGO NEW YORK

120MG

A070607 001 Apr 06, 1987

650MG

A070608 001 Dec 01, 1986

TARO PHARMS NORTH

120MG

N018337 003 Sep 12, 1983

325MG

N018337 002

+

650MG

N018337 001

INFANTS' FEVERALL

TARO PHARMS NORTH

80MG

N018337 004 Aug 26, 1992

NEOPAP

POLYMEDICA

120MG

N016401 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

OHM LABS

650MG

A076200 001 Mar 19, 2002

PERRIGO

650MG

A075077 001 Feb 25, 2000

RANBAXY LABS LTD

650MG

A078569 001 Dec 14, 2011

TYLENOL

+ MCNEIL CONS

650MG

N019872 001 Jun 08, 1994

+

650MG

N019872 002 Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO

250MG; 250MG; 65MG

A075794 001 Nov 26, 2001

EXCEDRIN (MIGRAINE)

+ NOVARTIS

250MG; 250MG; 65MG

N020802 001 Jan 14, 1998

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

+ 3M

61%; 1%

N021074 001 Jun 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT

GUARDIAN DRUG

80MG; 20MG

A071793 001 Sep 04, 1987

GAVISCON

SANOFI AVENTIS US

80MG; 20MG

N018685 001 Dec 09, 1983

+

160MG; 40MG

N018685 002 Dec 09, 1983

ASPIRIN

CAPSULE; ORAL

ASPIRIN

+ PLX PHARMA

325MG

N203697 001 Jan 14, 2013

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL

ANTHELIOS SX

+ LOREAL USA

2%; 2%; 10%

N021502 001 Jul 21, 2006

CAPITAL SOLEIL 15

+ LOREAL USA

2%; 3%; 10%

N021501 001 Oct 02, 2006

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL

ANTHELIOS 20

+ LOREAL USA

2%; 2%; 10%; 2%

N021471 001 Oct 05, 2006

ANTHELIOS 40

+ LOREAL USA

2%; 3%; 10%; 5%

N022009 001 Mar 31, 2008

+

2%; 3%; 10%; 5%

N022009 002 Oct 29, 2009

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+ SCHERING PLOUGH

3%; 7.5%; 3%

N020045 001 Dec 07, 1992

## OTC DRUG PRODUCT LIST

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK

+ STAND HOMEOPATH 5% N020532 001 Aug 26, 1996

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

LOTRIMIN ULTRA

+ SCHERING PLOUGH 1% N021307 001 Dec 07, 2001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+ BAYER 2% N020421 001 Dec 21, 1995

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG; 10MG; 165MG A077355 001 Feb 06, 2008

PEPCID COMPLETE

+ MCNEIL CONS 800MG; 10MG; 165MG N020958 001 Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER PHARMACAPS 5MG N022429 001 Jul 23, 2009

+ 10MG N022429 004 Jul 23, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER PHARMACAPS 5MG N022429 003 Jul 23, 2009

+ 10MG N022429 002 Jul 23, 2009

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS 5MG/5ML A090765 002 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML A090750 002 Feb 02, 2010

BIO PHARM INC 5MG/5ML A090474 002 Mar 30, 2009

CYPRESS PHARM 5MG/5ML A090300 001 Oct 10, 2008

PERRIGO R AND D 5MG/5ML A204226 001 Sep 09, 2013

5MG/5ML A090254 002 Apr 09, 2008

SILARX 5MG/5ML A091130 001 Apr 22, 2011

SUN PHARM INDS INC 5MG/5ML A091327 001 Oct 17, 2011

TARO 5MG/5ML A090182 002 Apr 22, 2008

5MG/5ML A201546 001 May 20, 2011

TRIS PHARMA INC 5MG/5ML A090572 001 Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS 5MG/5ML A090765 001 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML A090750 001 Feb 02, 2010

BIO PHARM INC 5MG/5ML A090474 001 Mar 30, 2009

CYPRESS PHARM 5MG/5ML A090300 002 Oct 10, 2008

PERRIGO R AND D 5MG/5ML A090254 001 Apr 09, 2008

SILARX 5MG/5ML A091130 002 Apr 22, 2011

SUN PHARM INDS INC 5MG/5ML A091327 002 Oct 17, 2011

TARO 5MG/5ML A090182 001 Apr 22, 2008

5MG/5ML A201546 002 May 20, 2011

TRIS PHARMA INC 5MG/5ML A090572 002 Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+ MCNEIL CONSUMER 5MG/5ML N022155 002 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+ MCNEIL CONSUMER 5MG/5ML N022155 001 Nov 16, 2007

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY 5MG A078780 001 Jan 21, 2010

10MG A078780 004 Jan 21, 2010

APOTEX INC 5MG A078317 001 Dec 27, 2007

10MG A078317 002 Dec 27, 2007

CADISTA PHARMS 5MG A078933 001 Jun 15, 2010

10MG A078933 002 Jun 15, 2010

CIPLA LTD 5MG A077318 001 Jul 25, 2013

10MG A077318 002 Jul 25, 2013

CONTRACT PHARMACAL 5MG A076047 001 Dec 27, 2007

10MG A076047 002 Dec 27, 2007

DR REDDYS LABS LTD 5MG A078343 004 Jan 15, 2008

10MG A078343 003 Jan 15, 2008

IPCA LABS LTD 5MG A202277 002 Mar 11, 2014

10MG A202277 004 Mar 11, 2014

## OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

## TABLET; ORAL

## CETIRIZINE HYDROCHLORIDE ALLERGY

MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
RANBAXY	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
SANDOZ	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007
	10MG	A077499	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
	10MG	A079191	004	Apr 15, 2010
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007

## CETIRIZINE HYDROCHLORIDE HIVES

CADISTA PHARMS	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
	10MG	A202277	003	Mar 11, 2014
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
RANBAXY	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
	10MG	A077829	002	Aug 26, 2009

## CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010

## ZYRTEC ALLERGY

MCNEIL CONSUMER	5MG	N019835	003	Nov 16, 2007
+	10MG	N019835	004	Nov 16, 2007

## ZYRTEC HIVES RELIEF

MCNEIL CONSUMER	5MG	N019835	005	Nov 16, 2007
+	10MG	N019835	006	Nov 16, 2007

## TABLET, CHEWABLE; ORAL

## CETIRIZINE HYDROCHLORIDE ALLERGY

SANDOZ	5MG	A078692	001	Feb 14, 2008
+	10MG	A078692	002	Feb 14, 2008

## CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARMA GLOBAL	5MG	A090142	001	Aug 30, 2011
	10MG	A090142	002	Aug 30, 2011

## CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARMA GLOBAL	5MG	A090142	003	Aug 30, 2011
	10MG	A090142	004	Aug 30, 2011

## TABLET, ORALLY DISINTEGRATING; ORAL

## ZYRTEC ALLERGY

+	MCNEIL CONSUMER	10MG	N022578	001	Sep 03, 2010
---	-----------------	------	---------	-----	--------------

## OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
SANDOZ	5MG;120MG	A077991	001	Mar 05, 2008
SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012
ZYRTEC-D 12 HOUR				
+ MCNEIL	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL

EXIDINE

+ XTTRIUM	4%	N019127	001	Dec 24, 1984
-----------	----	---------	-----	--------------

CLOTH;TOPICAL

CHLORHEXIDINE GLUCONATE

+ SAGE PRODS	2%	N021669	001	Apr 25, 2005
--------------	----	---------	-----	--------------

SOLUTION;TOPICAL

BRIAN CARE

SOAPCO	4%	A071419	001	Dec 17, 1987
--------	----	---------	-----	--------------

CHG SCRUB

ECOLAB	4%	N019258	002	Jul 22, 1986
--------	----	---------	-----	--------------

CIDA-STAT

ECOLAB	2%	N019258	001	Jul 22, 1986
--------	----	---------	-----	--------------

DYNA-HEX

BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997
-------------------	-------	---------	-----	--------------

EXIDINE

+ XTTRIUM	2%	N019422	001	Dec 17, 1985
-----------	----	---------	-----	--------------

	4%	N019125	001	Dec 24, 1984
--	----	---------	-----	--------------

HIBICLENS

+ MOLNLYCKE HLTH	4%	N017768	001	
------------------	----	---------	-----	--

HIBISTAT

+ MOLNLYCKE HLTH	0.5%	N018300	001	
------------------	------	---------	-----	--

SPONGE;TOPICAL

BIOSCRUB

GRIFFEN	4%	N019822	001	Mar 31, 1989
---------	----	---------	-----	--------------

CHLORHEXIDINE GLUCONATE

BECTION DICKINSON	4%	A072525	001	Oct 24, 1989
-------------------	----	---------	-----	--------------

PHARMASEAL SCRUB CARE

+ CAREFUSION	4%	N019793	001	Dec 02, 1988
--------------	----	---------	-----	--------------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+ CAREFUSION	2%;70% (3ML)	N020832	001	Jul 14, 2000
--------------	--------------	---------	-----	--------------

	2%;70% (10.5ML)	N020832	004	Aug 20, 2003
--	-----------------	---------	-----	--------------

	2%;70% (26ML)	N020832	006	Nov 21, 2006
--	---------------	---------	-----	--------------

CHLORAPREP ONE-STEP FREPP

+ CAREFUSION	2%;70% (1.5ML)	N020832	003	Apr 26, 2002
--------------	----------------	---------	-----	--------------

CHLORAPREP WITH TINT

+ CAREFUSION	2%;70% (26ML)	N020832	002	May 03, 2005
--------------	---------------	---------	-----	--------------

	2%;70% (10.5ML)	N020832	005	Apr 03, 2006
--	-----------------	---------	-----	--------------

	2%;70% (3ML)	N020832	007	Oct 10, 2006
--	--------------	---------	-----	--------------

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+ CAREFUSION	2%;70% (0.67ML)	N021555	001	Oct 07, 2002
--------------	-----------------	---------	-----	--------------

CHLORAPREP SINGLE SWABSTICK

+ CAREFUSION	2%;70% (1.75ML)	N021555	002	May 10, 2005
--------------	-----------------	---------	-----	--------------

CHLORAPREP TRIPLE SWABSTICK

+ CAREFUSION	2%;70% (5.25ML)	N021555	003	Jun 10, 2009
--------------	-----------------	---------	-----	--------------

PREVANTICS MAXI SWABSTICK

+ PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005
--------------	-------------------	---------	-----	--------------

PREVANTICS SWAB

+ PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005
--------------	-----------------	---------	-----	--------------

PREVANTICS SWABSTICK

+ PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005
--------------	-------------------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+ SCHERING PLOUGH	12MG	N007638	002	
-------------------	------	---------	-----	--

CHLORPHENIRAMINE MALEATE

AVANTHI INC	12MG	A040829	001	May 13, 2009
-------------	------	---------	-----	--------------

## OTC DRUG PRODUCT LIST

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+ PFIZER 4MG;200MG;10MG

N022113 001 Dec 21, 2011

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+ PFIZER 1MG/5ML;100MG/5ML;15MG/5ML

N021587 001 Feb 24, 2004

TABLET;ORAL

ADVIL ALLERGY SINUS

+ PFIZER 2MG;200MG;30MG

N021441 001 Dec 19, 2002

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+ SCHERING PLOUGH 8MG;120MG

N018397 001

CIMETIDINE

TABLET;ORAL

CIMETIDINE

APOTEX 100MG

A074948 001 Jun 19, 1998

200MG

A074948 002 Jul 26, 2002

CONTRACT PHARMACAL 200MG

A074961 001 Jun 19, 1998

200MG

A074963 001 Jun 19, 1998

IVAX SUB TEVA PHARMS 200MG

A075345 001 Jun 16, 1999

PERRIGO 200MG

A075285 001 Oct 29, 1998

TAGAMET HB

+ MEDTECH PRODUCTS 200MG

N020238 002 Aug 21, 1996

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

PERRIGO 1.34MG

A074512 001 Nov 22, 1995

SANDOZ 1.34MG

A073458 001 Oct 31, 1993

TAVIST-1

+ NOVARTIS 1.34MG

N020925 001 Aug 21, 1992

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

ACTAVIS MID ATLANTIC 1%

A074165 001 Jul 16, 1993

TARO 1%

A072641 001 Dec 04, 1995

GYNE-LOTRIMIN

+ SCHERING PLOUGH 1%

N018052 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ SCHERING PLOUGH 2%

N020574 001 Nov 24, 1998

MYCELEX-7

BAYER HEALTHCARE LLC 1%

N018230 002 Dec 26, 1991

TRIVAGIZOLE 3

TARO 2%

N021143 001 Apr 12, 2000

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+ BAYER HEALTHCARE LLC 200MG;200MG

N020526 002 Jul 29, 1996

GYNE-LOTRIMIN COMBINATION PACK

+ SCHERING PLOUGH 100MG;100MG

N020289 002 Apr 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER HEALTHCARE LLC 1%;100MG

N020389 002 Jun 23, 1994

TABLET;VAGINAL

GYNE-LOTRIMIN

+ SCHERING PLOUGH 100MG

N017717 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 200MG

N020525 001 Jul 29, 1996

MYCELEX-7

BAYER HEALTHCARE LLC 100MG

N018182 002 Dec 26, 1991

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

+ BAUSCH AND LOMB 5.2MG/SPRAY

A075702 001 Jul 03, 2001

PERRIGO 5.2MG/SPRAY

A075427 001 Dec 12, 2001

## OTC DRUG PRODUCT LIST

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC

6MG;120MG

A078648 001 Feb 27, 2013

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFFENESIN

TABLET, EXTENDED RELEASE;ORAL

MUCINEX DM

RECKITT BENCKISER 30MG;600MG

N021620 002 Apr 29, 2004

+

60MG;1.2GM

N021620 001 Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+ RECKITT BENCKISER EQ 30MG HBR/5ML

N018658 001 Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

TRIS PHARMA INC EQ 30MG HBR/5ML

A091135 001 May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+ PFIZER

38MG;200MG

N021394 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

DR REDDYS LABS LTD 38MG;200MG

A090619 001 Jul 08, 2009

PERRIGO R AND D 38MG;200MG

A079113 001 Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+ PFIZER

25MG;EQ 200MG FREE ACID AND POTASSIUM  
SALT

N021393 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER PHARMACAPS 25MG;EQ 200MG FREE ACID AND POTASSIUM  
SALT

A090397 001 Nov 22, 2010

STRIDES PHARMA 25MG;EQ 200MG FREE ACID AND POTASSIUM  
SALT

A200888 001 Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+ BAYER HLTHCARE

25MG;220MG

N205352 001 Jan 17, 2014

DOCOSANOL

CREAM;TOPICAL

ABREVA

+ GLAXOSMITHKLINE

10%

N020941 001 Jul 25, 2000

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

LNK 25MG

A040564 001 Aug 27, 2004

PERRIGO 25MG

A040167 001 Sep 18, 1996

UNISOM

+ CHATTEM

25MG

N018066 001

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

NEXIUM 24HR

+ ASTRAZENECA LP

EQ 20MG BASE

N204655 001 Mar 28, 2014

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

DR REDDYS LABS LTD 10MG

A075758 001 Aug 17, 2001

20MG

A077367 001 Sep 25, 2006

IVAX SUB TEVA PHARMS 10MG

A075512 001 Jul 26, 2001

MYLAN 10MG

A075674 001 Dec 21, 2001

PERRIGO 10MG

A075400 001 Mar 18, 2005

20MG

A077351 001 Sep 25, 2006

RANBAXY 10MG

A090283 001 Nov 17, 2009

20MG

A090283 002 Nov 17, 2009

TEVA 10MG

A075312 001 May 31, 2001

WOCKHARDT 10MG

A077146 001 Mar 07, 2005

20MG

A090837 001 Aug 04, 2010

PEPCID AC

MCNEIL CONS 10MG

N020325 001 Apr 28, 1995

+

20MG

N020325 002 Sep 23, 2003

## OTC DRUG PRODUCT LIST

FAMOTIDINE

TABLET;ORAL

PEPCID AC

MCNEIL CONS

10MG

N020902 001 Aug 05, 1999

TABLET, CHEWABLE;ORAL

FAMOTIDINE

PERRIGO

10MG

A075715 001 Aug 22, 2003

PEPCID AC

+ MCNEIL CONS

20MG

N020801 002 Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US

30MG/5ML

N201373 001 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US

30MG/5ML

N201373 002 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC

30MG/5ML

A203330 001 Nov 18, 2014

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

ACTAVIS MID ATLANTIC

30MG/5ML

A203330 002 Nov 18, 2014

TABLET;ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US

60MG

N020872 007 Jan 24, 2011

+

180MG

N020872 010 Jan 24, 2011

ALLEGRA HIVES

SANOFI AVENTIS US

60MG

N020872 008 Jan 24, 2011

+

180MG

N020872 009 Jan 24, 2011

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US

30MG

N020872 005 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US

30MG

N020872 006 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC

30MG

A202039 001 Nov 19, 2014

DR REDDYS LABS LTD

30MG

A076502 004 Apr 12, 2011

MYLAN

30MG

A077081 004 Jul 21, 2011

SUN PHARM INDS

30MG

A091567 002 Feb 06, 2012

TEVA

30MG

A076447 004 Apr 13, 2011

WOCKHARDT LTD

30MG

A079112 002 Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD

30MG

A076502 005 Apr 12, 2011

MYLAN

30MG

A077081 005 Jul 21, 2011

SUN PHARM INDS

30MG

A091567 001 Feb 06, 2012

TEVA

30MG

A076447 005 Apr 13, 2011

WOCKHARDT LTD

30MG

A079112 001 Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC

60MG

A202039 002 Nov 19, 2014

180MG

A202039 003 Nov 19, 2014

DR REDDYS LABS LTD

60MG

A076502 006 Apr 12, 2011

180MG

A076502 008 Apr 12, 2011

MYLAN

60MG

A077081 006 Jul 21, 2011

180MG

A077081 008 Jul 21, 2011

SUN PHARM INDS

60MG

A091567 004 Feb 06, 2012

180MG

A091567 006 Feb 06, 2012

TEVA

60MG

A076447 006 Apr 13, 2011

180MG

A076447 008 Apr 13, 2011

WOCKHARDT LTD

60MG

A079112 004 Feb 08, 2012

180MG

A079112 006 Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD

60MG

A076502 007 Apr 12, 2011

180MG

A076502 009 Apr 12, 2011

MYLAN

60MG

A077081 007 Jul 21, 2011

180MG

A077081 009 Jul 21, 2011

SUN PHARM INDS

60MG

A091567 003 Feb 06, 2012

180MG

A091567 005 Feb 06, 2012

TEVA

60MG

A076447 007 Apr 13, 2011

180MG

A076447 009 Apr 13, 2011

WOCKHARDT LTD

60MG

A079112 003 Feb 08, 2012

180MG

A079112 005 Feb 08, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US

30MG

N021909 002 Jan 24, 2011

## OTC DRUG PRODUCT LIST

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG N021909 003 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD 30MG A202978 001 Jan 18, 2013

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD 30MG A202978 002 Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US 60MG;120MG N020786 002 Jan 24, 2011

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US 180MG;240MG N021704 002 Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD 60MG;120MG A076667 001 Nov 18, 2014

180MG;240MG A079043 002 Jun 22, 2011

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE CONS 0.05MG/SPRAY N205434 001 Jul 23, 2014

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

PERRIGO R AND D 600MG A078912 001 Nov 23, 2011

MUCINEX

+ RECKITT BENCKISER 1.2GM N021282 002 Dec 18, 2002

600MG N021282 001 Jul 12, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MUCINEX D

+ RECKITT BENCKISER 1.2GM;120MG N021585 002 Jun 22, 2004

600MG;60MG N021585 001 Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS

+ PFIZER EQ 200MG FREE ACID AND POTASSIUM SALT N020402 001 Apr 20, 1995

ADVIL MIGRAINE LIQUI-GELS

+ PFIZER EQ 200MG FREE ACID AND POTASSIUM SALT N020402 002 Mar 16, 2000

IBUPROFEN

AMNEAL PHARMS EQ 200MG FREE ACID AND POTASSIUM SALT A202300 001 Dec 23, 2011

BANNER PHARMACAPS EQ 200MG FREE ACID AND POTASSIUM SALT A078682 001 Mar 24, 2009

+ CONTRACT PHARMACAL 200MG A074782 001 Jul 06, 1998

MARKSANS PHARMA EQ 200MG FREE ACID AND POTASSIUM SALT A079205 001 Jun 26, 2009

P AND L DEV LLC EQ 200MG FREE ACID AND POTASSIUM SALT A077338 001 Jul 10, 2009

MIDOL LIQUID GELS

+ BANNER PHARMACAPS 200MG N021472 001 Oct 18, 2002

SUSPENSION;ORAL

CHILDREN'S ADVIL

PFIZER 100MG/5ML N020589 001 Jun 27, 1996

CHILDREN'S ADVIL-FLAVORED

PFIZER 100MG/5ML N020589 002 Nov 07, 1997

CHILDREN'S ELIXSURE

MOBERG PHARMA NORTH 100MG/5ML N021604 001 Jan 07, 2004

CHILDREN'S IBUPROFEN

PERRIGO 100MG/5ML A074937 001 Dec 22, 1998

CHILDREN'S MOTRIN

+ MCNEIL 100MG/5ML N020516 001 Jun 16, 1995

IBUPROFEN

ACTAVIS MID ATLANTIC 100MG/5ML A074916 001 Apr 30, 1999

AMNEAL PHARMS 100MG/5ML A200457 001 Aug 18, 2011

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

+ MCNEIL CONS 40MG/ML N020603 001 Jun 10, 1996

IBUPROFEN

PERRIGO 40MG/ML A075217 001 Dec 16, 1998

TRIS PHARMA INC 40MG/ML A079058 001 Aug 31, 2009

PEDIATRIC ADVIL

+ PFIZER 100MG/2.5ML N020812 001 Jan 30, 1998



## OTC DRUG PRODUCT LIST

IBUPROFEN

## TABLET; ORAL

ADVIL					
PFIZER	200MG	N018989	001	May 18, 1984	
IBU-TAB 200					
ALRA	200MG	A071057	001	Aug 11, 1988	
IBUPROFEN					
AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	
AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987	
	200MG	A072199	001	May 23, 1988	
AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003	
CONTRACT PHARMACAL	200MG	A071732	001	Sep 10, 1987	
	200MG	A071735	001	Sep 10, 1987	
	200MG	A072299	001	Jul 01, 1988	
	200MG	A074931	001	Jul 20, 1998	
DR REDDYS LA	200MG	A075661	001	Dec 12, 2001	
DR REDDYS LABS INC	100MG	A076117	001	Nov 20, 2001	
GRANULES INDIA	200MG	A079174	001	Dec 10, 2010	
LNK	100MG	A076741	001	Jun 17, 2004	
	200MG	A075010	001	Mar 01, 1999	
	200MG	A075139	001	Mar 01, 1999	
MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011	
	200MG	A091239	001	Feb 01, 2011	
MCNEIL	200MG	A073019	001	Mar 30, 1994	
MERRO PHARM	200MG	A070985	001	Oct 02, 1987	
OHM	200MG	A071163	001	Jul 15, 1986	
PAR PHARM	200MG	A070481	001	Sep 24, 1986	
PERRIGO	200MG	A072096	001	Dec 08, 1987	
	200MG	A075995	001	Mar 14, 2002	
PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005	
SVADS HOLDINGS SA	200MG	A079129	001	Mar 28, 2011	
	200MG	A091355	001	Apr 04, 2011	
VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987	
	200MG	A071639	001	Feb 02, 1988	
IBUPROHM					
OHM LABS	200MG	A071214	001	Dec 01, 1986	
JUNIOR STRENGTH ADVIL					
PFIZER	100MG	N020267	002	Dec 13, 1996	
JUNIOR STRENGTH IBUPROFEN					
PERRIGO	100MG	A075367	001	Apr 22, 1999	
JUNIOR STRENGTH MOTRIN					
MCNEIL CONS	100MG	N020602	001	Jun 10, 1996	
MOTRIN IB					
+ MCNEIL	200MG	N019012	003	Dec 17, 1990	
MOTRIN MIGRAINE PAIN					
+ MCNEIL	200MG	N019012	004	Feb 25, 2000	
PROFEN					
CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986	
TAB-PROFEN					
PERRIGO	200MG	A072095	001	Dec 08, 1987	
TABLET, CHEWABLE; ORAL					
CHILDREN'S ADVIL					
PFIZER	50MG	N020944	001	Dec 18, 1998	
CHILDREN'S MOTRIN					
MCNEIL CONS	50MG	N020601	001	Nov 15, 1996	
IBUPROFEN					
PERRIGO	50MG	A076359	001	Jan 16, 2004	
	100MG	A076359	002	Jan 16, 2004	
JUNIOR STRENGTH ADVIL					
PFIZER	100MG	N020944	002	Dec 18, 1998	
JUNIOR STRENGTH MOTRIN					
+ MCNEIL CONS	100MG	N020601	003	Nov 15, 1996	

IBUPROFEN SODIUM

## TABLET; ORAL

ADVIL					
+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012	

## OTC DRUG PRODUCT LIST

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL CONGESTION RELIEF

+ PFIZER 200MG;10MG N022565 001 May 27, 2010

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

PERRIGO R AND D 200MG;10MG A203200 001 Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+ PFIZER EQ 200MG FREE ACID AND POTASSIUM SALT;30MG N021374 001 May 30, 2002

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD

PFIZER 100MG/5ML;15MG/5ML N021373 001 Apr 18, 2002

CHILDREN'S MOTRIN COLD

+ MCNEIL CONS 100MG/5ML;15MG/5ML N021128 001 Aug 01, 2000

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO 100MG/5ML;15MG/5ML A076478 001 Nov 05, 2003

TABLET; ORAL

ADVIL COLD AND SINUS

+ PFIZER 200MG;30MG N019771 001 Sep 19, 1989

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL 200MG;30MG A075588 001 Apr 08, 2002

DR REDDYS LABS LTD 200MG;30MG A077628 001 Aug 14, 2006

IBUPROHM COLD AND SINUS

OHM LABS 200MG;30MG A074567 001 Apr 17, 2001

SINE-AID IB

MCNEIL CONS 200MG;30MG N019899 001 Dec 31, 1992

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R

+ LILLY 100 UNITS/ML N018780 001 Oct 28, 1982

HUMULIN R PEN

+ LILLY 100 UNITS/ML N018780 005 Aug 06, 1998

NOVOLIN R

+ NOVO NORDISK INC 100 UNITS/ML N019938 001 Jun 25, 1991

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 70/30

+ LILLY 30 UNITS/ML;70 UNITS/ML N019717 001 Apr 25, 1989

HUMULIN 70/30 PEN

+ LILLY 30 UNITS/ML;70 UNITS/ML N019717 002 Aug 06, 1998

NOVOLIN 70/30

+ NOVO NORDISK INC 30 UNITS/ML;70 UNITS/ML N019991 001 Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N

+ LILLY 100 UNITS/ML N018781 001 Oct 28, 1982

NOVOLIN N

+ NOVO NORDISK INC 100 UNITS/ML N019959 001 Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP

+ 3M EQ 0.7% IODINE;74% (6ML) N021586 001 Sep 29, 2006

+ EQ 0.7% IODINE;74% (26ML) N021586 002 Sep 29, 2006

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

+ JOHNSON AND JOHNSON 1% N020310 001 Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+ BAUSCH AND LOMB EQ 0.025% BASE N021996 001 Dec 01, 2006

KETOTIFEN FUMARATE

AKORN EQ 0.025% BASE A077958 001 Jul 26, 2007

ALCON PHARMS LTD EQ 0.025% BASE A077200 001 Sep 02, 2008

ZADITOR

+ ALCON PHARMA EQ 0.025% BASE N021066 002 Oct 19, 2006

## OTC DRUG PRODUCT LIST

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
PERRIGO R AND D	15MG	A202319	001	May 18, 2012
WOCKHARDT LTD	15MG	A202727	001	May 18, 2012
PREVACID 24 HR				
+ NOVARTIS	15MG	N022327	001	May 18, 2009

LEVONORGESTREL

TABLET;ORAL

FALLBACK SOLO

LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014
LEVONORGESTREL				
FAMY CARE LTD	1.5MG	A202739	001	Oct 31, 2014
NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010
	1.5MG	A202334	001	Aug 20, 2014
+ WATSON LABS	0.75MG	A078665	001	Aug 28, 2009
WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012
OPCICON ONE-STEP				
SUN PHARM INDS LTD	1.5MG	A202635	001	Sep 11, 2014
PLAN B				
+ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006
PLAN B ONE-STEP				
+ TEVA BRANDED PHARM	1.5MG	N021998	001	Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER PHARMACAPS	1MG	N021855	001	Aug 04, 2005
	2MG	N021855	002	Aug 04, 2005
SOLUTION;ORAL				
IMODIUM A-D				
+ MCNEIL CONS	1MG/5ML	N019487	001	Mar 01, 1988
LOPERAMIDE HYDROCHLORIDE				
HI TECH PHARMA	1MG/5ML	A074352	001	Nov 17, 1995
PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
ROXANE	1MG/5ML	A073079	001	Apr 30, 1992
WOCKHARDT	1MG/5ML	A074730	001	Aug 28, 1997
SUSPENSION;ORAL				
IMODIUM A-D				
+ MCNEIL CONS	1MG/7.5ML	N019487	002	Jul 08, 2004
LOPERAMIDE HYDROCHLORIDE				
PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011
TABLET;ORAL				
IMODIUM A-D				
+ MCNEIL CONS	2MG	N019860	001	Nov 22, 1989
LOPERAMIDE HYDROCHLORIDE				
CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993
LNK	2MG	A076497	001	Jun 10, 2003
OHM LABS	2MG	A074091	001	Dec 10, 1992
PERRIGO	2MG	A075232	001	Jan 06, 2000
TABLET, CHEWABLE;ORAL				
IMODIUM A-D EZ CHEWS				
+ MCNEIL	2MG	N020448	001	Jul 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

IMODIUM MULTI-SYMPOM RELIEF

+ MCNEIL CONS	2MG;125MG	N021140	001	Nov 30, 2000
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE				
RANBAXY	2MG;125MG	A077500	001	Sep 06, 2006
TABLET, CHEWABLE;ORAL				
IMODIUM MULTI-SYMPOM RELIEF				
+ MCNEIL	2MG;125MG	N020606	001	Jun 26, 1996
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE				
PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002

## OTC DRUG PRODUCT LIST

LORATADINE

CAPSULE; ORAL

CLARITIN

+ SCHERING PLOUGH 10MG N021952 001 Jun 16, 2008

SUSPENSION; ORAL

LORATADINE

+ TARO 1MG/ML N021734 001 Oct 04, 2005

SYRUP; ORAL

CLARITIN

+ SCHERING PLOUGH 1MG/ML N020641 002 Nov 27, 2002

LORATADINE

PERRIGO 1MG/ML A075728 001 Aug 20, 2004

SILARX 1MG/ML A077421 001 Jun 29, 2006

TARO 1MG/ML A076805 001 Aug 20, 2004

TEVA 1MG/ML A075505 001 Nov 07, 2003

WOCKHARDT 1MG/ML A075815 001 Aug 20, 2004

TABLET; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG N019658 002 Nov 27, 2002

CLARITIN HIVES RELIEF

+ BAYER HEALTHCARE LLC 10MG N019658 003 Nov 19, 2003

LORATADINE

APOTEX INC 10MG A076471 001 Feb 14, 2006

MYLAN 10MG A075790 001 Nov 07, 2008

10MG A076154 001 Aug 20, 2003

10MG A078447 001 Aug 12, 2011

PERRIGO 10MG A076301 001 Jun 25, 2004

RANBAXY 10MG A076134 001 Aug 18, 2003

SANDOZ 10MG A075209 001 Jan 21, 2003

TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+ SCHERING PLOUGH 5MG N021891 001 Aug 23, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

PFIZER 10MG N021375 001 Dec 19, 2002

CLARITIN HIVES RELIEF REDITAB

+ BAYER HEALTHCARE LLC 10MG N020704 003 Nov 19, 2003

CLARITIN REDITABS

+ BAYER HEALTHCARE LLC 10MG N020704 002 Nov 27, 2002

+ SCHERING PLOUGH 5MG N021993 001 Dec 12, 2006

LORATADINE

ACTAVIS LABS FL INC 10MG A075990 001 Nov 03, 2003

IMPAX LABS 10MG A076011 001 Sep 29, 2003

PFIZER 10MG A075822 001 Feb 10, 2003

LORATADINE REDIDOSE

RANBAXY 10MG A077153 001 Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+ SCHERING PLOUGH 5MG;120MG N019670 002 Nov 27, 2002

CLARITIN-D 24 HOUR

+ SCHERING PLOUGH 10MG;240MG N020470 002 Nov 27, 2002

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ACTAVIS LABS FL INC 10MG;240MG A075706 001 Feb 21, 2003

IMPAX LABS 5MG;120MG A076050 001 Jan 30, 2003

10MG;240MG A075989 001 Mar 04, 2004

RANBAXY 10MG;240MG A076557 001 Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH; TOPICAL

SALONPAS

+ HISAMITSU PHARM CO 3%;10% N022029 001 Feb 20, 2008

3%;10% N022029 002 Nov 05, 2012

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO 2%;4% A076357 001 Mar 30, 2004

MONISTAT 3 COMBINATION PACK

MEDTECH PRODUCTS 2%;4% N021261 003 Jun 17, 2003

MONISTAT 3 COMBINATION PACK (PREFILLED)

+ MEDTECH PRODUCTS 2%;4% N021261 001 Feb 02, 2001

## OTC DRUG PRODUCT LIST

MICONAZOLE NITRATE

## CREAM; VAGINAL

## MICONAZOLE 3

TARO 4% A076773 001 Mar 02, 2005

## MICONAZOLE 7

ACTAVIS MID ATLANTIC 2% A074164 001 Mar 29, 1996

## MICONAZOLE NITRATE

G AND W LABS INC 2% A074366 001 Feb 22, 1996

PERRIGO 2% A074760 001 May 15, 1997

PERRIGO R AND D 4% A091366 001 Jan 15, 2010

TARO 2% A074444 001 Jan 13, 1997

## MONISTAT 3

+ MEDTECH PRODUCTS 4% N020827 001 Mar 30, 1998

## MONISTAT 7

+ MEDTECH PRODUCTS 2% N017450 002 Feb 15, 1991

## CREAM, SUPPOSITORY; TOPICAL, VAGINAL

## M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC 2%; 200MG A074926 001 Apr 16, 1999

## MICONAZOLE 7 COMBINATION PACK

G AND W LABS 100MG; 2% A076585 001 Mar 26, 2004

## MICONAZOLE NITRATE

PERRIGO R AND D 1.2GM; 2% A079114 001 Jun 02, 2010

## MICONAZOLE NITRATE COMBINATION PACK

PERRIGO 200MG; 200MG A075329 001 Apr 20, 1999

## MONISTAT 1 COMBINATION PACK

+ MEDTECH PRODUCTS 1.2GM; 2% N021308 001 Jun 29, 2001

## MONISTAT 7 COMBINATION PACK

+ MEDTECH PRODUCTS 100MG; 2% N020288 002 Apr 26, 1993

## MONISTAT-3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%; 200MG N020670 002 Apr 16, 1996

## SUPPOSITORY; VAGINAL

## MICONAZOLE NITRATE

ACTAVIS MID ATLANTIC 100MG A073507 001 Nov 19, 1993

G AND W LABS 100MG A074414 001 Apr 30, 1997

+ PERRIGO 100MG A074395 001 Mar 20, 1997

## MONISTAT 7

+ MEDTECH PRODUCTS 100MG N018520 002 Feb 15, 1991

MINOXIDIL

## AEROSOL, FOAM; TOPICAL

## MEN'S ROGAINE

+ JOHNSON AND JOHNSON 5% N021812 001 Jan 20, 2006

## MINOXIDIL

PERRIGO ISRAEL 5% A091344 001 Apr 28, 2011

## WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON 5% N021812 002 Feb 28, 2014

## SOLUTION; TOPICAL

## MINOXIDIL (FOR MEN)

ACTAVIS MID ATLANTIC 2% A074588 001 Apr 05, 1996

HI TECH PHARMA 2% A074731 001 Dec 24, 1996

PERRIGO 2% A075357 001 Jul 30, 1999

WOCKHARDT 2% A074767 001 Feb 28, 1997

## MINOXIDIL (FOR WOMEN)

HI TECH PHARMA 2% A074731 002 May 11, 2005

PERRIGO 2% A075357 002 Jul 30, 1999

## MINOXIDIL EXTRA STRENGTH (FOR MEN)

ACTAVIS MID ATLANTIC 5% A075518 001 Nov 17, 2000

AVACOR PRODS 5% A075619 001 Nov 17, 2000

PERRIGO 5% A075598 001 Jun 13, 2001

PERRIGO NEW YORK 5% A075737 001 Mar 15, 2002

WOCKHARDT 5% A075438 001 Feb 27, 2003

## ROGAINE (FOR MEN)

+ JOHNSON AND JOHNSON 2% N019501 002 Feb 09, 1996

## ROGAINE (FOR WOMEN)

+ JOHNSON AND JOHNSON 2% N019501 003 Feb 09, 1996

## ROGAINE EXTRA STRENGTH (FOR MEN)

+ JOHNSON AND JOHNSON 5% N020834 001 Nov 14, 1997

## THEROXIDIL

EI INC 2% A078176 001 Nov 09, 2007

5% A076239 001 Aug 24, 2004

## OTC DRUG PRODUCT LIST

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC	0.025%;0.3%	A202795	001	Jan 24, 2013
ALTAIRE PHARMS INC	0.02675%;0.315%	A078208	001	Sep 27, 2010
NAPHCN-A				
+ ALCON	0.025%;0.3%	N020226	001	Jun 08, 1994
OPCON-A				
+ BAUSCH AND LOMB	0.02675%;0.315%	N020065	001	Jun 08, 1994
VISINE-A				
+ JOHNSON AND JOHNSON	0.025%;0.3%	N020485	001	Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BANNER PHARMACAPS	EQ 200MG BASE	N021920	001	Feb 17, 2006
---------------------	---------------	---------	-----	--------------

TABLET;ORAL

ALEVE

+ BAYER	EQ 200MG BASE	N020204	002	Jan 11, 1994
NAPROXEN SODIUM				
AMNEAL PHARMS NY	EQ 200MG BASE	A079096	001	Dec 16, 2008
CONTRACT PHARMACAL	EQ 200MG BASE	A074635	001	Jan 13, 1997
	EQ 200MG BASE	A074789	001	Feb 27, 1997
DR REDDYS LABS INC	EQ 200MG BASE	A075168	001	Jul 28, 1998
GRANULES INDIA	EQ 200MG BASE	A091353	001	Sep 20, 2011
MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011
PERRIGO	EQ 200MG BASE	A074661	001	Jan 13, 1997
RANBAXY LABS LTD	EQ 200MG BASE	A091183	001	May 20, 2011

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS &amp; COLD

+ BAYER	200MG;120MG	N021076	001	Nov 29, 1999
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE				
DR REDDYS LABS INC	EQ 220MG BASE;120MG	A077381	001	Sep 27, 2006
PERRIGO	EQ 200MG BASE;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+ DR REDDYS LABS INC	7MG/24HR	N020076	004	Nov 12, 1999
	14MG/24HR	N020076	005	Nov 12, 1999
	21MG/24HR	N020076	006	Nov 12, 1999

NICODERM CQ

+ SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996
	14MG/24HR	N020165	005	Aug 02, 1996
	21MG/24HR	N020165	004	Aug 02, 1996

NICOTINE

AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
	14MG/24HR	A074612	003	Oct 20, 1997
	21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE

+ GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
	EQ 2MG BASE	N018612	004	Sep 25, 2000
	EQ 4MG BASE	N020066	002	Feb 09, 1996
	EQ 4MG BASE	N020066	004	Sep 25, 2000

NICORETTE (MINT)

GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
	EQ 4MG BASE	N020066	003	Dec 23, 1998

NICOTINE POLACRILEX

ACTAVIS LABS NY INC	EQ 2MG BASE	A074507	001	Mar 15, 1999
	EQ 2MG BASE	A076569	001	Jul 29, 2004
	EQ 2MG BASE	A078699	001	Dec 29, 2008
	EQ 2MG BASE	A079216	001	Jul 08, 2009
	EQ 4MG BASE	A074707	001	Mar 19, 1999
	EQ 4MG BASE	A076568	002	Jul 29, 2004
	EQ 4MG BASE	A078697	001	Dec 29, 2008
	EQ 4MG BASE	A079038	001	Jul 08, 2009
	EQ 4MG BASE	A079219	001	Jul 08, 2009
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009
	EQ 4MG BASE	A077850	001	Feb 18, 2009

## OTC DRUG PRODUCT LIST

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

PERRIGO

EQ 2MG BASE

A076775 001 Sep 16, 2004

EQ 2MG BASE

A076776 001 Sep 16, 2004

EQ 2MG BASE

A076777 001 Sep 16, 2004

EQ 4MG BASE

A076778 001 Sep 16, 2004

EQ 4MG BASE

A076779 001 Sep 16, 2004

EQ 4MG BASE

A076789 001 Sep 16, 2004

PERRIGO R AND D

EQ 2MG BASE

A078325 001 Oct 30, 2006

EQ 2MG BASE

A078547 001 May 24, 2007

EQ 2MG BASE

A078967 001 Apr 23, 2008

EQ 2MG BASE

A091349 001 Jul 20, 2011

EQ 4MG BASE

A078326 001 Oct 30, 2006

EQ 4MG BASE

A078546 001 May 24, 2007

EQ 4MG BASE

A078968 001 Apr 23, 2008

EQ 4MG BASE

A091354 001 Jul 20, 2011

WATSON LABS

EQ 2MG BASE

A079044 001 Jul 08, 2009

THRIVE

NOVARTIS

EQ 2MG BASE

A077658 001 Jun 19, 2007

EQ 4MG BASE

A077656 001 Jun 19, 2007

TROCHE/LOZENGE;ORAL

COMMIT

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N021330 001 Oct 31, 2002

+

EQ 4MG BASE

N021330 002 Oct 31, 2002

NICORETTE

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N022360 001 May 18, 2009

+

EQ 4MG BASE

N022360 002 May 18, 2009

NICOTINE POLACRILEX

PERRIGO R AND D

EQ 2MG BASE

A077007 001 Jan 31, 2006

EQ 2MG BASE

A090711 001 Jul 10, 2009

EQ 2MG BASE

A090821 001 Jul 10, 2009

EQ 2MG BASE

A203690 001 Oct 09, 2012

EQ 4MG BASE

A077007 002 Jan 31, 2006

EQ 4MG BASE

A090711 002 Jul 10, 2009

EQ 4MG BASE

A090821 002 Jul 10, 2009

EQ 4MG BASE

A203690 002 Oct 09, 2012

NIZATIDINE

TABLET;ORAL

AXID AR

+ PFIZER

75MG

N020555 001 May 09, 1996

NONOXYNOL-9

SPONGE;VAGINAL

TODAY

+ MAYER LABS INC

1GM

N018683 001 Apr 01, 1983

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

+ DEXCEL PHARMA

20MG

N022032 001 Dec 04, 2007

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

+ DR REDDYS LABS LTD

EQ 20MG BASE

A078878 001 Jun 05, 2009

TABLET, DELAYED RELEASE;ORAL

PRILOSEC OTC

+ ASTRAZENECA PHARMS

EQ 20MG BASE

N021229 001 Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID OTC

+ MSD CONSUMER

20MG;1.1GM

N022281 001 Dec 01, 2009

FOR SUSPENSION;ORAL

ZEGERID OTC

+ MSD CONSUMER

20MG/PACKET;1.68GM/PACKET

N022283 001 Jun 17, 2013

## OTC DRUG PRODUCT LIST

ORLISTAT

CAPSULE;ORAL

ALLI

+ GLAXOSMITHKLINE CONS 60MG

N021887 001 Feb 07, 2007

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ BAYER HEALTHCARE LLC 3.9MG/24HR

N202211 001 Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OCUCLEAR

SCHERING PLOUGH 0.025%

N018471 001 May 30, 1986

VISINE L.R.

+ JOHNSON AND JOHNSON 0.025%

N019407 001 Mar 31, 1989

PERMETHRIN

LOTION;TOPICAL

NIX

+ MEDTECH PRODUCTS 1%

N019918 001 May 02, 1990

PERMETHRIN

ACTAVIS MID ATLANTIC 1%

A075014 001 Mar 28, 2000

PERRIGO NEW YORK 1%

A076090 001 Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

KREMERS URBAN PHARMS 17GM/PACKET  
17GM/SCOOPFUL

A090600 001 Oct 06, 2009

A090600 002 Oct 06, 2009

MIRALAX

+ SCHERING PLOUGH 17GM/SCOOPFUL

N022015 001 Oct 06, 2006

POLYETHYLENE GLYCOL 3350

EMCURE PHARMS USA 17GM/SCOOPFUL

A202071 001 Dec 28, 2012

MYLAN 17GM/PACKET

A078915 001 Oct 06, 2009

17GM/SCOOPFUL

A078915 002 Oct 06, 2009

NEXGEN PHARMA 17GM/SCOOPFUL

A090812 001 Oct 07, 2009

NOVEL LABS INC 17GM/SCOOPFUL

A091077 001 Oct 06, 2009

PAR PHARM 17GM/SCOOPFUL

A079214 001 Jan 31, 2013

PERRIGO R AND D 17GM/PACKET

A090685 001 Oct 06, 2009

17GM/SCOOPFUL

A090685 002 Oct 06, 2009

POTASSIUM IODIDE

SOLUTION;ORAL

THYROSHIELD

+ ARCO PHARMS LLC 65MG/ML

A077218 001 Jan 12, 2005

TABLET;ORAL

IOSAT

ANBEX 65MG

N018664 002 May 12, 2011

+ 130MG

N018664 001 Oct 14, 1982

THYROSAFE

+ RECIP 65MG

A076350 001 Sep 10, 2002

POVIDONE-IODINE

SOLUTION;TOPICAL

POVIDONE IODINE

+ ALLEGIANCE HLTHCARE 1%

N019522 001 Mar 31, 1989

SPONGE;TOPICAL

E-Z SCRUB 201

+ BECTON DICKINSON 20%

N019240 001 Nov 29, 1985

E-Z SCRUB 241

+ BECTON DICKINSON 10%

N019476 001 Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO 120MG

A075153 001 Feb 26, 1999

RANBAXY 120MG

A077442 001 Sep 28, 2005

SUDAFED 12 HOUR

+ MCNEIL CONS 120MG

A073585 001 Oct 31, 1991

SUDAFED 24 HOUR

+ MCNEIL CONS 240MG

N020021 002 Dec 15, 1992



## OTC DRUG PRODUCT LIST

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

AFRINOL

+ SCHERING PLOUGH 120MG N018191 001

PURIFIED WATER

SOLUTION;OPHTHALMIC

PUR-WASH

+ NIAGARA PHARMS 98.3% N022305 001 Sep 01, 2011

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC

EQ 150MG BASE A200172 001 May 31, 2012

CONTRACT PHARMACAL

EQ 75MG BASE A075094 001 Jun 21, 1999

DR REDDYS LABS LTD

EQ 75MG BASE A075294 001 Mar 28, 2000

EQ 150MG BASE A078192 001 Aug 31, 2007

EQ 75MG BASE A075296 001 Jan 14, 2000

EQ 75MG BASE A075497 001 Jan 14, 2000

EQ 75MG BASE A076195 001 Aug 30, 2002

EQ 150MG BASE A091429 001 May 11, 2011

EQ 150MG BASE A091429 002 May 11, 2011

EQ 75MG BASE A201745 001 Feb 29, 2012

EQ 150MG BASE A200536 001 Jun 28, 2011

EQ 75MG BASE A075167 001 May 04, 2000

EQ 75MG BASE A076760 001 Feb 24, 2006

EQ 75MG BASE A078884 001 Jul 31, 2008

ZANTAC 150

+ BOEHRINGER INGELHEIM EQ 150MG BASE N021698 001 Aug 31, 2004

EQ 150MG BASE N021698 002 Mar 13, 2007

ZANTAC 75

BOEHRINGER INGELHEIM EQ 75MG BASE N020520 001 Dec 19, 1995

SODIUM CHLORIDE

AEROSOL, METERED;INHALATION

BRONCHO SALINE

+ BLAIREX 0.9% N019912 001 Sep 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE 0.24%;0.3% N020231 001 Jul 11, 1997

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+ NOVARTIS 1% N021958 001 Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

+ NOVARTIS 1% N020980 001 Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

TARO 1% A077511 001 Jul 02, 2007

SOLUTION;TOPICAL

LAMISIL AT

+ NOVARTIS 1% N021124 001 Mar 17, 2000

SPRAY;TOPICAL

LAMISIL AT

+ NOVARTIS 1% N021124 002 Mar 17, 2000

TIOCONAZOLE

OINTMENT;VAGINAL

TIOCONAZOLE

PERRIGO 6.5% A075915 001 Nov 21, 2001

VAGISTAT-1

+ NOVARTIS 6.5% N020676 001 Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

+ SANOFI AVENTIS US 0.055MG/SPRAY N020468 002 Oct 11, 2013

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS

MANUFACTURING INC

N760305

Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC

N020037

Aug 26, 2003

ACD-A SOLUTION

TERUMO BCT INC

A010228

ANDA

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

ANDA

Feb 06, 2002

AS3 SOLUTION/ACD-A

TERUMO BCT INC

N001214

May 29, 2002

NONE

HAEMONETICS

MANUFACTURING INC

A710497

ANDA

Nov 06, 1987

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N160918

Mar 17, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

ARTERIOCYTE MEDICAL

SYSTEMS, INC

A110057

May 11, 2012

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS

MANUFACTURING INC

N800077

Nov 06, 1980

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC

N900223

Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC

N900224

Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPRODUCTIONS SAS

N040083

Nov 21, 2005

NONE

TERUMO BCT INC

A070025

Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N170401

Dec 06, 1977

N811012

Jun 28, 1983

HAEMONETICS

N800222

Aug 23, 1982

MANUFACTURING INC

TERUMO MEDICAL CORP

N781211

Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC

N811104

May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP

N880217

Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS

0.042GM/100ML;0.276GM/100ML;

N820915

Oct 19, 1984

MANUFACTURING INC

0.410GM/100ML;0.30GM/100ML;

1.10GM/100ML;0.588GM/100ML

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP

0.042GM/100ML;0.285GM/100ML;

N820915

Sep 22, 1983

0.718GM/100ML;0.017GM/100ML;

0.396GM/100ML;0.588GM/100ML

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS

N980123

Mar 03, 2000

CORPORATION

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL

LABORATORIES INC

N010409

Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N770923

Jan 20, 1978

TERUMO MEDICAL CORP

N781214

Feb 08, 1980

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB

N830715

Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC

10GM/100ML;5GM/100ML

A720563

ANDA

Oct 30, 1992

NONE

B BRAUN MEDICAL INC

10GM/100ML;5GM/100ML

N160767

Apr 06, 1970

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC

10GM/100ML;0.9GM/100ML

A720562

ANDA

Oct 30, 1992

NONE

B BRAUN MEDICAL INC

10GM/100ML;0.9GM/100ML

N160767

Apr 06, 1970

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

NONE

B BRAUN MEDICAL INC

6GM/100ML;0.9 GM/100ML

N090024

Aug 18, 1969

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC

6GM/100ML

N200952

Mar 31, 1999

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC

6GM/100ML;0.9GM/100ML

A740193

ANDA

Jan 30, 1995

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC

6GM/100ML;0.9GM/100ML

N890105

Apr 04, 1991

NONE

B BRAUN MEDICAL INC

6GM/100ML;0.9GM/100ML

A740283

ANDA

Oct 21, 1998

TEVA PARENTERAL

6GM/100ML;0.9GM/100ML

A740592

ANDA

Nov 12, 1998

MEDICINES INC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

NONE

B. BRAUN MEDICAL A110013 ANDA Jan 09, 2015

VOLUVEN

FRESENIUS KABI 6GM/100ML;0.9GM/100ML N070012 NDA Dec 27, 2007  
DEUTSCHLAND GMBH

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

INJECTABLE; INJECTION

ISOPLATE SOLUTION

HAEMONETICS CORP N90067 Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL

HAEMONETICS CORP N110059 Apr 25, 2013

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

PENTASPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 10GM/100ML;0.9GM/100ML N890104 Apr 04, 1991

RED BLOOD CELL PROCESSING SOLUTION

INJECTABLE; INJECTION

REJUVESOL

CITRA LABS LLC N950522 Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

INJECTABLE; INJECTION

INTERSOL SOLUTION

FENWAL INC. 2.26G/500ML; 2.21G/500ML; 1.59G/500ML; N080041 Dec 09, 2009  
1.53G/500ML; 0.465G/500ML

**DISCONTINUED DRUG PRODUCT LIST**ABARELIX

INJECTABLE; INTRAMUSCULAR

PLENAXIS

SPECIALITY EUROPEAN 100MG/VIAL N021320 001 Nov 25, 2003

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

WATSON LABS EQ 200MG BASE A074007 001 Oct 18, 1995

EQ 400MG BASE A074007 002 Oct 18, 1995

ACETAMINOPHEN

INJECTABLE; INJECTION

INJECTAPAP

ORTHO MCNEIL PHARM 100MG/ML N017785 001 Mar 07, 1986

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS 120MG A072218 001 Mar 27, 1992

ACETAMINOPHEN

ABLE 120MG A073106 001 Feb 27, 1995

325MG A073107 001 Feb 27, 1995

650MG A073108 001 Feb 27, 1995

ROXANE 120MG A071010 001 May 12, 1987

650MG A071011 001 May 12, 1987

TYLENOL

MCNEIL CONS 120MG N017756 002

650MG N017756 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

RANBAXY 650MG A090205 001 Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART 150MG; 180MG; 15MG A081095 001 Oct 26, 1990

150MG; 180MG; 30MG A081096 001 Oct 26, 1990

150MG; 180MG; 60MG A081097 001 Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

SCHERER LABS 150MG; 180MG; 15MG A085640 001

CODEINE, ASPIRIN, APAP FORMULA NO. 3

SCHERER LABS 150MG; 180MG; 30MG A085639 001

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS 150MG; 180MG; 60MG A085638 001

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BANCAP

FOREST PHARMS 325MG; 50MG A088889 001 Jan 16, 1986

BUCET

MALLINCKRODT 650MG; 50MG A088991 001 Jun 28, 1985

PHRENILIN FORTE

VALEANT 650MG; 50MG A088831 001 Jun 19, 1985

TENCON

MALLINCKRODT 650MG; 50MG A089405 001 May 15, 1990

TRIAPRIN

DUNHALL 325MG; 50MG A089268 001 Jul 02, 1987

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

HALSEY 325MG; 50MG A089568 001 Oct 05, 1988

WATSON LABS 325MG; 50MG A087550 001 Oct 19, 1984

BUTAPAP

MIKART 650MG; 50MG A089988 001 Oct 26, 1992

PHRENILIN

VALEANT 325MG; 50MG A087811 001 Jun 19, 1985

SEDAPAP

MAYRAND 650MG; 50MG A088944 001 Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

SHIRE 325MG; 50MG; 40MG A087628 001 Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GRAHAM DM 325MG; 50MG; 40MG A088743 001 Jul 18, 1985

325MG; 50MG; 40MG A088765 001 Mar 27, 1985

325MG; 50MG; 40MG A089067 001 Apr 19, 1985

**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; BUTALBITAL; CAFFEINE

## CAPSULE; ORAL

## BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

HIKMA PHARMS LLC	500MG; 50MG; 40MG	A040261	001	Oct 28, 1998
MALLINCKRODT	325MG; 50MG; 40MG	A088758	001	Mar 27, 1985

## BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS	325MG; 50MG; 40MG	A088825	001	Dec 05, 1984
--------------	-------------------	---------	-----	--------------

## ESGIC-PLUS

MIKART	500MG; 50MG; 40MG	A040085	001	Mar 28, 1996
--------	-------------------	---------	-----	--------------

## FEMCET

MALLINCKRODT	325MG; 50MG; 40MG	A089102	001	Jun 19, 1985
--------------	-------------------	---------	-----	--------------

## MEDIGESIC PLUS

US CHEM	325MG; 50MG; 40MG	A089115	001	Jan 14, 1986
---------	-------------------	---------	-----	--------------

## TRIAD

MALLINCKRODT	325MG; 50MG; 40MG	A089023	001	Jun 19, 1985
--------------	-------------------	---------	-----	--------------

## TABLET; ORAL

## BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE	325MG; 50MG; 40MG	A040390	001	Jul 23, 2001
------	-------------------	---------	-----	--------------

	500MG; 50MG; 40MG	A040394	001	Jul 23, 2001
--	-------------------	---------	-----	--------------

GILBERT LABS	325MG; 50MG; 40MG	A087629	001	Nov 13, 1984
--------------	-------------------	---------	-----	--------------

HIKMA PHARMS LLC	500MG; 50MG; 40MG	A040336	001	Aug 18, 1999
------------------	-------------------	---------	-----	--------------

MIKART	750MG; 50MG; 40MG	A040496	001	Dec 23, 2003
--------	-------------------	---------	-----	--------------

MIRROR PHARMS	325MG; 50MG; 40MG	A040864	001	Dec 01, 2008
---------------	-------------------	---------	-----	--------------

MIRROR PHARMS LLC	500MG; 50MG; 40MG	A040883	001	Dec 23, 2008
-------------------	-------------------	---------	-----	--------------

MUTUAL PHARM	325MG; 50MG; 40MG	A040601	001	Jul 29, 2005
--------------	-------------------	---------	-----	--------------

VINTAGE PHARMS	500MG; 50MG; 40MG	A040513	001	Aug 25, 2003
----------------	-------------------	---------	-----	--------------

WATSON LABS	325MG; 50MG; 40MG	A089536	001	Feb 16, 1988
-------------	-------------------	---------	-----	--------------

	500MG; 50MG; 40MG	A040267	001	Jul 30, 1998
--	-------------------	---------	-----	--------------

## ESGIC

FOREST PHARMS	325MG; 50MG; 40MG	A089660	001	Dec 23, 1988
---------------	-------------------	---------	-----	--------------

## ESGIC-PLUS

MIKART	500MG; 50MG; 40MG	A089451	001	May 23, 1988
--------	-------------------	---------	-----	--------------

## FIORICET

WATSON PHARMS	325MG; 50MG; 40MG	A088616	001	Nov 09, 1984
---------------	-------------------	---------	-----	--------------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

## CAPSULE; ORAL

## BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE	325MG; 50MG; 40MG; 30MG	A076528	001	Aug 21, 2003
------	-------------------------	---------	-----	--------------

## PHRENILIN WITH CAFFEINE AND CODEINE

VALEANT	325MG; 50MG; 40MG; 30MG	A074911	001	Aug 22, 2001
---------	-------------------------	---------	-----	--------------

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

## CAPSULE; ORAL

## ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

MIKART	356.4MG; 30MG; 16MG	A040109	001	Aug 26, 1997
--------	---------------------	---------	-----	--------------

WRASER PHARMS LLC	356.4MG; 30MG; 16MG	A040688	001	Apr 03, 2007
-------------------	---------------------	---------	-----	--------------

## DHC PLUS

PHARM RES ASSOC	356.4MG; 30MG; 16MG	A088584	001	Mar 04, 1986
-----------------	---------------------	---------	-----	--------------

## SYNALGOS-DC-A

LEITNER PHARMS	356.4MG; 30MG; 16MG	A089166	001	May 14, 1986
----------------	---------------------	---------	-----	--------------

## TABLET; ORAL

## ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

BOCA PHARMA LLC	712.8MG; 60MG; 32MG	A040701	001	Apr 03, 2007
-----------------	---------------------	---------	-----	--------------

MIKART	712.8MG; 60MG; 32MG	A040316	001	Apr 28, 1999
--------	---------------------	---------	-----	--------------

WEST-WARD PHARM CORP	712.8MG; 60MG; 32MG	A040637	001	Sep 22, 2006
----------------------	---------------------	---------	-----	--------------

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

## TABLET; ORAL

## TAVIST ALLERGY/SINUS/HEADACHE

NOVARTIS	500MG; EQ 0.25MG BASE; 30MG	N021082	001	Mar 01, 2001
----------	-----------------------------	---------	-----	--------------

ACETAMINOPHEN; CODEINE PHOSPHATE

## CAPSULE; ORAL

## ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA	300MG; 15MG	A088537	001	Jun 04, 1984
------	-------------	---------	-----	--------------

	300MG; 30MG	A088324	001	Dec 29, 1983
--	-------------	---------	-----	--------------

	300MG; 60MG	A088599	001	Jun 01, 1984
--	-------------	---------	-----	--------------

## PHENAPHEN W/ CODEINE NO. 2

ROBINS AH	325MG; 15MG	A084444	001	
-----------	-------------	---------	-----	--

## PHENAPHEN W/ CODEINE NO. 3

ROBINS AH	325MG; 30MG	A084445	001	
-----------	-------------	---------	-----	--

## PHENAPHEN W/ CODEINE NO. 4

ROBINS AH	325MG; 60MG	A084446	001	
-----------	-------------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; CODEINE PHOSPHATE

## CAPSULE; ORAL

## PROVAL #3

SOLVAY	325MG;30MG	A085685	001
TYLENOL W/ CODEINE NO. 3			
ORTHO MCNEIL PHARM	300MG;30MG	A087422	001
TYLENOL W/ CODEINE NO. 4			
ORTHO MCNEIL PHARM	300MG;60MG	A087421	001

## SOLUTION; ORAL

## ACETAMINOPHEN AND CODEINE PHOSPHATE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001
DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098	001 Sep 20, 1996
ROXANE	120MG/5ML;12MG/5ML	A086366	001
TYLENOL W/ CODEINE			
ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057	001

## SUSPENSION; ORAL

## CAPITAL AND CODEINE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001
----------------------	--------------------	---------	-----

## TABLET; ORAL

## ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE	300MG;30MG	A040452	001 Aug 01, 2002
	300MG;60MG	A040459	001 Aug 01, 2002
AM THERAP	300MG;15MG	A089478	001 Mar 03, 1987
	300MG;15MG	A089481	001 Mar 03, 1987
	300MG;30MG	A089479	001 Mar 03, 1987
	300MG;30MG	A089482	001 Mar 03, 1987
	300MG;60MG	A089480	001 Mar 03, 1987
	300MG;60MG	A089483	001 Mar 03, 1987
DURAMED PHARMS BARR	300MG;15MG	A040223	001 Nov 18, 1997
	300MG;15MG	A088353	001 Feb 06, 1984
	300MG;30MG	A040223	002 Nov 18, 1997
	300MG;30MG	A088354	001 Feb 06, 1984
	300MG;60MG	A040223	003 Nov 18, 1997
	300MG;60MG	A088355	001 Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217	001
HALSEY	300MG;15MG	A083871	001
	300MG;30MG	A083872	001
	300MG;60MG	A086549	001
KV PHARM	300MG;30MG	A085288	001
	300MG;60MG	A085365	001
	325MG;15MG	A085364	001
	325MG;45MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085363	001
LEDERLE	300MG;30MG	A087141	001
MIKART	300MG;30MG	A089238	001 Feb 25, 1986
	300MG;60MG	A089244	001 Feb 25, 1986
	650MG;30MG	A089231	001 Mar 03, 1986
	650MG;60MG	A089363	001 Sep 09, 1991
MUTUAL PHARM	300MG;15MG	A085795	001
	300MG;15MG	A089671	001 Feb 10, 1988
	300MG;30MG	A085794	001
	300MG;30MG	A089672	001 Feb 10, 1988
	300MG;60MG	A087653	001 Apr 13, 1982
	300MG;60MG	A089673	001 Feb 10, 1988
PURACAP PHARM	300MG;30MG	A087762	001 Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681	001
	300MG;30MG	A089080	001 Jul 17, 1986
	300MG;60MG	A086683	001
ROXANE	300MG;15MG	A084659	001
	300MG;30MG	A084656	001
	300MG;60MG	A084667	001
	500MG;15MG	A089511	001 Apr 25, 1989
	500MG;30MG	A089512	001 Apr 25, 1989
	500MG;60MG	A089513	001 Apr 25, 1989
SANDOZ	300MG;15MG	A087433	001
	300MG;30MG	A081250	001 Jul 16, 1992
	300MG;30MG	A085291	002
	300MG;30MG	A085917	001
	300MG;60MG	A081249	001 Jul 16, 1992
	300MG;60MG	A085964	001
	300MG;60MG	A087423	001



**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

## ACETAMINOPHEN AND CODEINE PHOSPHATE

SUPERPHARM	300MG;15MG	A089183 001	Oct 18, 1985
	300MG;30MG	A089184 001	Oct 18, 1985
	300MG;30MG	A089253 001	May 19, 1986
	300MG;60MG	A089185 001	Oct 18, 1985
	300MG;60MG	A089254 001	May 19, 1986
USL PHARMA	300MG;30MG	A087919 001	Jun 22, 1982
	300MG;60MG	A087920 001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896 001	
VITARINE	300MG;30MG	A085676 001	
WARNER CHILCOTT	300MG;15MG	A085992 001	
	300MG;30MG	A085218 002	
	300MG;60MG	A087306 001	
WATSON LABS	300MG;15MG	A087277 001	May 26, 1982
	300MG;15MG	A089997 001	Dec 28, 1994
	300MG;30MG	A087276 001	May 26, 1982
	300MG;30MG	A089998 001	Dec 28, 1994
	300MG;60MG	A087275 001	May 26, 1982
	300MG;60MG	A089999 001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443 001	Jan 22, 2003
	300MG;30MG	A040443 002	Jan 22, 2003
	300MG;60MG	A040443 003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360 001	
	300MG;60MG	A085607 001	
CAPITAL AND CODEINE			
CARNRICK	325MG;30MG	A083643 001	
CODRIX			
WATSON LABS FLORIDA	500MG;15MG	A040447 001	Feb 26, 2003
	500MG;30MG	A040441 001	Mar 27, 2003
	500MG;60MG	A040488 001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3			
GLAXOSMITHKLINE	300MG;30MG	A083951 001	
EMPRACET W/ CODEINE PHOSPHATE #4			
GLAXOSMITHKLINE	300MG;60MG	A083951 002	
PAPA-DEINE #3			
VANGARD	300MG;30MG	A088037 001	Mar 20, 1984
PAPA-DEINE #4			
VANGARD	300MG;60MG	A088715 001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE			
ROBINS AH	650MG;30MG	A085856 001	
TYLENOL W/ CODEINE			
ORTHO MCNEIL PHARM	325MG;7.5MG	A085056 001	
	325MG;15MG	A085056 002	
	325MG;30MG	A085056 003	
	325MG;60MG	A085056 004	
TYLENOL W/ CODEINE NO. 1			
JANSSEN PHARMS	300MG;7.5MG	A085055 001	
TYLENOL W/ CODEINE NO. 2			
JANSSEN PHARMS	300MG;15MG	A085055 002	

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

## DRIXORAL PLUS

SCHERING PLOUGH	500MG;3MG;60MG	N019453 001	May 22, 1987
-----------------	----------------	-------------	--------------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

## ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS	500MG;5MG	A088898 001	Mar 27, 1985
ALLAY			
IVAX PHARMS	500MG;5MG	A089907 001	Jan 13, 1989
BANCAP HC			
FOREST PHARMS	500MG;5MG	A087961 001	Mar 17, 1983
CO-GESIC			
CENT PHARMS	500MG;5MG	A089360 001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
MALLINCKRODT	500MG;5MG	A088956 001	Jul 19, 1985
	500MG;5MG	A089006 001	Aug 09, 1985
MIKART	500MG;5MG	A081067 001	Nov 30, 1989
	500MG;5MG	A081068 001	Nov 30, 1989
	500MG;5MG	A081069 001	Nov 30, 1989

## DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; HYDROCODONE BITARTRATE

## CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

500MG; 5MG

A081070 001 Nov 30, 1989

500MG; 5MG

A089008 001 Feb 21, 1986

## LORCET-HD

MALLINCKRODT

500MG; 5MG

A087336 001 Jul 08, 1982

## SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT

500MG/15ML; 7.5MG/15ML

A040418 001 Jun 27, 2001

MALLINCKRODT INC

500MG/15ML; 10MG/15ML

A040508 001 Aug 29, 2003

MIKART

500MG/15ML; 5MG/15ML

A081226 001 Oct 27, 1992

500MG/15ML; 5MG/15ML

A089557 001 Apr 29, 1992

500MG/15ML; 7.5MG/15ML

A081051 001 Aug 28, 1992

NESHER PHARMS

500MG/15ML; 7.5MG/15ML

A040366 001 Jan 23, 2002

PHARM ASSOC

500MG/15ML; 7.5MG/15ML

A040182 001 Mar 13, 1998

VINTAGE PHARMS

500MG/15ML; 7.5MG/15ML

A040520 001 Oct 30, 2003

## TABLET; ORAL

## ANEXSIA

MALLINCKRODT

500MG; 5MG

A089160 001 Apr 23, 1987

750MG; 10MG

A040468 001 Oct 31, 2002

## ANEXSIA 7.5/650

MALLINCKRODT

650MG; 7.5MG

A089725 001 Sep 30, 1987

## CO-GESIC

UCB INC

500MG; 5MG

A087757 001 May 03, 1982

## DURADYNE DHC

FOREST PHARMS

500MG; 5MG

A087809 001 Mar 17, 1983

## HY-PHEN

ASCHER

500MG; 5MG

A087677 001 May 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

ABLE

325MG; 5MG

A040478 001 Nov 08, 2002

325MG; 7.5MG

A040464 001 Oct 23, 2002

325MG; 10MG

A040464 002 Oct 23, 2002

500MG; 5MG

A040477 001 Nov 06, 2002

500MG; 7.5MG

A040490 001 May 21, 2003

500MG; 10MG

A040473 001 Nov 06, 2002

650MG; 7.5MG

A040474 001 Jan 02, 2003

650MG; 10MG

A040476 001 Oct 23, 2002

750MG; 7.5MG

A040469 001 Oct 25, 2002

ACTAVIS LABS FL INC

500MG; 10MG

A040148 002 Feb 14, 1997

AMNEAL PHARMS NY

500MG; 5MG

A040729 001 Aug 25, 2006

500MG; 7.5MG

A040748 001 Aug 25, 2006

500MG; 10MG

A040813 001 Feb 23, 2007

650MG; 7.5MG

A040754 001 Aug 25, 2006

650MG; 10MG

A040757 001 Aug 25, 2006

750MG; 7.5MG

A040769 001 Aug 28, 2006

BARR

500MG; 2.5MG

A040307 001 Jul 26, 2000

500MG; 5MG

A040308 001 Jul 26, 2000

500MG; 5MG

A088577 001 Dec 21, 1984

500MG; 7.5MG

A040307 002 Jul 26, 2000

500MG; 10MG

A040309 001 Jul 26, 2000

650MG; 7.5MG

A040307 003 Jul 26, 2000

650MG; 10MG

A040307 004 Jul 26, 2000

750MG; 7.5MG

A040308 002 Jul 26, 2000

CARACO

500MG; 5MG

A090265 001 Dec 23, 2008

500MG; 7.5MG

A090265 002 Dec 23, 2008

500MG; 10MG

A090265 003 Dec 23, 2008

650MG; 7.5MG

A090380 001 Dec 23, 2008

650MG; 10MG

A090380 002 Dec 23, 2008

660MG; 10MG

A090380 003 Dec 23, 2008

750MG; 7.5MG

A090380 004 Dec 23, 2008

HALSEY

500MG; 5MG

A089554 001 Jun 12, 1987

IVAX PHARMS

500MG; 5MG

A089696 001 Apr 21, 1988

MALLINCKRODT

500MG; 5MG

A040084 002 Jun 01, 1995

500MG; 7.5MG

A040201 001 Feb 27, 1998

500MG; 10MG

A040201 002 Feb 27, 1998

650MG; 10MG

A040084 004 Oct 16, 1996

660MG; 10MG

A040084 003 Jul 29, 1996

750MG; 7.5MG

A040084 001 Jun 01, 1995

MIKART

500MG; 2.5MG

A089698 001 Aug 25, 1989

500MG; 5MG

A089271 001 Jul 16, 1986

500MG; 5MG

A089697 001 Jan 28, 1992

**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	500MG; 7.5MG	A089699	001	Aug 25, 1989
	650MG; 5MG	A040849	001	Jun 09, 2010
	650MG; 7.5MG	A089689	001	Jun 29, 1988
	650MG; 10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG; 5MG	A040236	001	Sep 25, 1997
	650MG; 7.5MG	A040240	002	Nov 26, 1997
	650MG; 10MG	A040240	001	Nov 26, 1997
	750MG; 7.5MG	A040236	002	Sep 25, 1997
RANBAXY	500MG; 5MG	A040825	001	Aug 16, 2007
	500MG; 10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	325MG; 10MG	A040826	001	Aug 16, 2007
	750MG; 7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG; 5MG	A040149	001	Jan 27, 1997
	750MG; 7.5MG	A040149	002	Jan 27, 1997
UCB INC	500MG; 10MG	A040210	001	Aug 13, 1997
	650MG; 7.5MG	A040134	001	Nov 21, 1996
USL PHARMA	500MG; 5MG	A089290	001	May 29, 1987
	500MG; 5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG; 2.5MG	A040144	002	Apr 25, 1997
	500MG; 5MG	A089831	001	Sep 07, 1988
	500MG; 5MG	A089971	001	Dec 02, 1988
	500MG; 7.5MG	A040144	001	Feb 22, 1996
	500MG; 10MG	A040356	001	May 31, 2000
	650MG; 7.5MG	A040155	001	Apr 14, 1997
	650MG; 10MG	A040143	001	Feb 22, 1996
	660MG; 10MG	A040358	001	May 31, 2000
	750MG; 7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG; 5MG	A040281	001	Sep 30, 1998
	500MG; 7.5MG	A040280	001	Sep 30, 1998
	650MG; 7.5MG	A040280	002	Sep 30, 1998
	650MG; 10MG	A040280	003	Sep 30, 1998
	750MG; 7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	325MG; 7.5MG	A040248	001	Apr 28, 2000
	325MG; 10MG	A040248	002	Apr 28, 2000
	500MG; 2.5MG	A040123	003	Mar 04, 1996
	500MG; 2.5MG	A081079	001	Aug 30, 1991
	500MG; 5MG	A040122	001	Mar 04, 1996
	500MG; 5MG	A089883	001	Dec 01, 1988
	500MG; 7.5MG	A040123	004	Mar 04, 1996
	500MG; 7.5MG	A081080	001	Aug 30, 1991
	650MG; 7.5MG	A040094	001	Sep 29, 1995
	650MG; 7.5MG	A040123	001	Mar 04, 1996
	650MG; 10MG	A040094	002	Sep 29, 1995
	650MG; 10MG	A040123	002	Mar 04, 1996
	660MG; 10MG	A040094	003	Aug 08, 2000
	750MG; 7.5MG	A040122	002	Mar 04, 1996
	750MG; 7.5MG	A081083	001	Aug 30, 1991
	750MG; 10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA	500MG; 5MG	A040493	001	May 28, 2003
	660MG; 10MG	A040495	001	May 28, 2003
	750MG; 7.5MG	A040494	001	May 28, 2003
LORTAB				
UCB INC	500MG; 5MG	A087722	001	Jul 09, 1982
	500MG; 10MG	A040100	001	Jan 26, 1996
NORCET				
ABANA	500MG; 5MG	A088871	001	May 15, 1986
TYCOLET				
ORTHO MCNEIL PHARM	500MG; 5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG; 5MG	A085667	001	
ABBVIE	500MG; 5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG; 7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG; 10MG	A040117	001	Sep 23, 1996
ZYDONE				
VINTAGE PHARMS LLC	400MG; 5MG	A040288	001	Nov 27, 1998
	400MG; 7.5MG	A040288	002	Nov 27, 1998
	400MG; 10MG	A040288	003	Nov 27, 1998

**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## CAPSULE; ORAL

## OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	500MG; 5MG	A040199	001	Dec 30, 1998
BARR	500MG; 5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR	500MG; 5MG	A040289	001	Mar 16, 1999
HALSEY	500MG; 5MG	A089994	001	May 04, 1989
MALLINCKRODT	500MG; 5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM	500MG; 5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS	500MG; 5MG	A040106	001	Jul 30, 1996
VINTAGE PHARMS LLC	500MG; 5MG	A040303	001	Dec 30, 1999
WATSON LABS	500MG; 5MG	A040234	001	Oct 30, 1997

## ROXILOX

ROXANE	500MG; 5MG	A040061	001	Jul 03, 1995
--------	------------	---------	-----	--------------

## TYLOX

JANSSEN PHARMS	500MG; 5MG	A088790	001	Dec 12, 1984
----------------	------------	---------	-----	--------------

## TYLOX-325

ORTHO MCNEIL PHARM	325MG; 5MG	A088246	001	Nov 08, 1984
--------------------	------------	---------	-----	--------------

## SOLUTION; ORAL

## OXYCODONE AND ACETAMINOPHEN

MALLINCKRODT INC	325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006
------------------	--------------------	---------	-----	--------------

## TABLET; ORAL

## OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB	500MG; 2.5MG	A085910	001	
----------------------	--------------	---------	-----	--

## OXYCODONE 5/APAP 500

BRISTOL MYERS SQUIBB	500MG; 5MG	A085911	001	
----------------------	------------	---------	-----	--

## OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	325MG; 5MG	A040203	001	Mar 15, 1999
	325MG; 7.5MG	A040800	001	Apr 03, 2012
	325MG; 10MG	A040800	002	Apr 03, 2012
AMNEAL PHARMS NY	500MG; 7.5MG	A040789	001	Nov 27, 2007
	650MG; 10MG	A040789	002	Nov 27, 2007
BARR	325MG; 5MG	A087406	001	
COASTAL PHARMS	500MG; 7.5MG	A090177	005	Oct 20, 2008
	650MG; 10MG	A090177	006	Oct 20, 2008
DURAMED PHARMS BARR	325MG; 5MG	A040272	001	Jun 30, 1998
MALLINCKRODT	500MG; 7.5MG	A040550	001	Jun 30, 2004
	650MG; 10MG	A040550	002	Jun 30, 2004
MIKART	400MG; 2.5MG	A040679	001	May 16, 2006
	400MG; 5MG	A040687	001	Apr 27, 2006
	400MG; 7.5MG	A040698	001	Apr 27, 2006
	400MG; 10MG	A040692	001	Apr 27, 2006
	500MG; 10MG	A040676	001	Apr 19, 2006
WATSON LABS	500MG; 7.5MG	A040371	001	Dec 29, 2000
	650MG; 10MG	A040371	002	Dec 29, 2000

## PERCOCET

VINTAGE PHARMS LLC	325MG; 5MG	A085106	002	
	500MG; 7.5MG	A040341	001	Jul 26, 1999
	650MG; 10MG	A040341	002	Jul 26, 1999

## ROXICET 5/500

ROXANE	500MG; 5MG	A089775	001	Jan 12, 1989
--------	------------	---------	-----	--------------

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

## CAPSULE; ORAL

## TYLOX

ORTHO MCNEIL PHARM	500MG; 4.5MG; 0.38MG	A085375	001	
--------------------	----------------------	---------	-----	--

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

## TABLET; ORAL

## ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

GAVIS PHARMS	650MG; EQ 25MG BASE	A076202	001	Aug 02, 2002
WATSON LABS	650MG; EQ 25MG BASE	A074699	001	Mar 24, 2000

## TALACEN

SANOFI AVENTIS US	650MG; EQ 25MG BASE	N018458	001	Sep 23, 1982
-------------------	---------------------	---------	-----	--------------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

## TABLET; ORAL

## DARVOCET

AAIPHARMA LLC	325MG; 32.5MG	N016844	001	
---------------	---------------	---------	-----	--

## DOLENE AP-65

LEDERLE	650MG; 65MG	A085100	001	
---------	-------------	---------	-----	--

## PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	650MG; 65MG	A083978	001	
SANDOZ	650MG; 65MG	A089959	001	Jul 18, 1989

**DISCONTINUED DRUG PRODUCT LIST**ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

## TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

VINTAGE PHARMS	650MG; 65MG	A040507	001	Jul 30, 2003
WATSON LABS	650MG; 65MG	A040139	001	Dec 16, 1996
WYGESIC				
CARACO	650MG; 65MG	A084999	001	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

## TABLET; ORAL

DARVOCET A500

XANODYNE PHARM	500MG; 100MG	A076429	001	Sep 10, 2003
----------------	--------------	---------	-----	--------------

DARVOCET-N 100

XANODYNE PHARM	650MG; 100MG	N017122	002	
----------------	--------------	---------	-----	--

DARVOCET-N 50

XANODYNE PHARM	325MG; 50MG	N017122	001	
----------------	-------------	---------	-----	--

PROPACET 100

TEVA	650MG; 100MG	A070107	001	Jun 12, 1985
------	--------------	---------	-----	--------------

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

ABLE	650MG; 100MG	A075838	001	Jul 11, 2001
------	--------------	---------	-----	--------------

ACTAVIS ELIZABETH	650MG; 100MG	A070910	001	Jan 02, 1987
-------------------	--------------	---------	-----	--------------

CORNERSTONE	325MG; 100MG	A076743	001	May 07, 2004
-------------	--------------	---------	-----	--------------

	500MG; 100MG	A076750	001	Jun 28, 2004
--	--------------	---------	-----	--------------

HALSEY	325MG; 50MG	A072105	001	May 13, 1988
--------	-------------	---------	-----	--------------

	650MG; 100MG	A072106	001	May 13, 1988
--	--------------	---------	-----	--------------

IVAX SUB TEVA PHARMS	650MG; 100MG	A070146	001	Aug 02, 1985
----------------------	--------------	---------	-----	--------------

MALLINCKRODT	650MG; 100MG	A075738	001	Feb 02, 2001
--------------	--------------	---------	-----	--------------

MIRROR PHARMS	650MG; 100MG	A077821	001	Feb 11, 2008
---------------	--------------	---------	-----	--------------

MUTUAL PHARM	325MG; 50MG	A070115	001	Jun 12, 1985
--------------	-------------	---------	-----	--------------

	650MG; 100MG	A070116	001	Jun 12, 1985
--	--------------	---------	-----	--------------

	650MG; 100MG	A070615	001	Mar 21, 1986
--	--------------	---------	-----	--------------

	650MG; 100MG	A070771	001	Mar 21, 1986
--	--------------	---------	-----	--------------

	650MG; 100MG	A070775	001	Mar 21, 1986
--	--------------	---------	-----	--------------

MYLAN	650MG; 100MG	A072195	001	Feb 16, 1988
-------	--------------	---------	-----	--------------

MYLAN PHARMS INC	650MG; 100MG	A070145	001	Jun 12, 1985
------------------	--------------	---------	-----	--------------

SANDOZ	650MG; 100MG	A070443	001	Jan 23, 1986
--------	--------------	---------	-----	--------------

SUPERPHARM	650MG; 100MG	A071319	001	Jan 06, 1987
------------	--------------	---------	-----	--------------

TEVA	650MG; 100MG	A070732	001	Jan 03, 1986
------	--------------	---------	-----	--------------

	650MG; 100MG	A074119	001	Dec 19, 1994
--	--------------	---------	-----	--------------

VINTAGE PHARMS	325MG; 50MG	A074843	002	Feb 15, 2001
----------------	-------------	---------	-----	--------------

	650MG; 100MG	A074843	001	Feb 12, 1997
--	--------------	---------	-----	--------------

WATSON LABS	325MG; 50MG	A070398	001	Dec 18, 1986
-------------	-------------	---------	-----	--------------

	650MG; 100MG	A070399	001	Dec 18, 1986
--	--------------	---------	-----	--------------

WATSON LABS FLORIDA	500MG; 100MG	A077196	001	Jun 28, 2005
---------------------	--------------	---------	-----	--------------

	650MG; 100MG	A076609	001	Nov 16, 2004
--	--------------	---------	-----	--------------

WOCKHARDT LTD	325MG; 50MG	A077677	001	Mar 16, 2007
---------------	-------------	---------	-----	--------------

	650MG; 100MG	A077677	002	Mar 16, 2007
--	--------------	---------	-----	--------------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

## TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

WATSON LABS	325MG; 37.5MG	A076914	001	Jul 26, 2006
-------------	---------------	---------	-----	--------------

ACETAZOLAMIDE

## TABLET; ORAL

ACETAZOLAMIDE

ALRA	250MG	A083320	001	
------	-------	---------	-----	--

ASCOT	250MG	A087686	001	Oct 20, 1982
-------	-------	---------	-----	--------------

MUTUAL PHARM	250MG	A089753	001	Jun 22, 1988
--------------	-------	---------	-----	--------------

VANGARD	250MG	A087654	001	Feb 05, 1982
---------	-------	---------	-----	--------------

WATSON LABS	250MG	A084498	002	
-------------	-------	---------	-----	--

	250MG	A088882	001	Oct 22, 1985
--	-------	---------	-----	--------------

DIAMOX

TEVA BRANDED PHARM	125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008943	001	
--------------------	------------------------------------------------------------------------------------------------------------------------	---------	-----	--

	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008943	002	
--	------------------------------------------------------------------------------------------------------------------------	---------	-----	--

**DISCONTINUED DRUG PRODUCT LIST**ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

HOSPIRA	EQ 500MG BASE/VIAL	A040108 001	Oct 30, 1995
---------	--------------------	-------------	--------------

DIAMOX

TEVA WOMENS	EQ 500MG BASE/VIAL	N009388 001	Dec 05, 1990
-------------	--------------------	-------------	--------------

\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

ACTAVIS MID ATLANTIC	2%	A087146 001	
----------------------	----	-------------	--

ACETIC ACID

KV PHARM	2%	A085493 001	
----------	----	-------------	--

ORLEX

WARNER CHILCOTT	2%	A086845 001	
-----------------	----	-------------	--

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

BOROFAIR

PHARMAFAIR	2%;0.79%	A088606 001	Aug 21, 1985
------------	----------	-------------	--------------

DOMEBORO

BAYER PHARMS	2%;0.79%	A084476 001	
--------------	----------	-------------	--

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC

TRIDESILON

BAYER PHARMS	2%;0.05%	N017914 001	
--------------	----------	-------------	--

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETIC ACID W/ HYDROCORTISONE

KV PHARM	2%;1%	A085492 001	
----------	-------	-------------	--

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB	2%;1%	A040097 001	Oct 31, 1994
-----------------	-------	-------------	--------------

WOCKHARDT	2%;1%	A040168 001	Aug 30, 1996
-----------	-------	-------------	--------------

ORLEX HC

WARNER CHILCOTT	2%;1%	A086844 001	
-----------------	-------	-------------	--

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

BAYER PHARMS	2%;1%;EQ 0.35% BASE	N050238 001	
--------------	---------------------	-------------	--

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

BARR	250MG	A070869 001	Feb 09, 1987
------	-------	-------------	--------------

	500MG	A070870 001	Feb 09, 1987
--	-------	-------------	--------------

USL PHARMA	250MG	A070753 001	Nov 03, 1986
------------	-------	-------------	--------------

	500MG	A070754 001	Nov 03, 1986
--	-------	-------------	--------------

WATSON LABS	250MG	A071893 001	Nov 25, 1987
-------------	-------	-------------	--------------

	500MG	A071894 001	Nov 25, 1987
--	-------	-------------	--------------

DYMELOR

LILLY	250MG	N013378 002	
-------	-------	-------------	--

	500MG	N013378 001	
--	-------	-------------	--

ACETOPHENAZINE MALEATE

TABLET; ORAL

TINDAL

SCHERING	20MG	N012254 002	
----------	------	-------------	--

ACETRIZOATE SODIUM

SOLUTION; INTRAUTERINE

SALPIX

ORTHO MCNEIL PHARM	53%	N009008 001	
--------------------	-----	-------------	--

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL

NOVARTIS	20MG/VIAL	N016211 001	
----------	-----------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

HOSPIRA	10%	A071364 001	May 01, 1989
	20%	A071365 001	May 01, 1989
ROXANE	10%	A072323 001	Apr 30, 1992
	10%	A072621 001	Sep 30, 1992
	20%	A072324 001	Apr 30, 1992
	20%	A072622 001	Sep 30, 1992
MUCOMYST			
APOTHECON	10%	N013601 002	
	20%	N013601 001	
MUCOSIL-10			
DEY	10%	A070575 001	Oct 14, 1986
MUCOSIL-20			
DEY	20%	A070576 001	Oct 14, 1986

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON 10%; 0.05% N017366 001

ACETYLDIGITOXIN

TABLET; ORAL

ACYLANID

NOVARTIS 0.1MG N009436 001

ACRISORCIN

CREAM; TOPICAL

AKRINOL

SCHERING 2MG/GM N012470 001

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH	200MG	A074906 001	Aug 26, 1997
DAVA PHARMS INC	200MG	A074872 001	Apr 22, 1997
HERITAGE PHARMS INC	200MG	A074889 001	Oct 31, 1997
IVAX SUB TEVA PHARMS	200MG	A074674 001	Apr 22, 1997
LEK PHARM	200MG	A074750 001	Apr 22, 1997
MYLAN	200MG	A074977 001	Apr 13, 1998
ROXANE	200MG	A074570 002	Apr 22, 1997
TEVA	200MG	A074828 001	Apr 22, 1997
TEVA PHARMS	200MG	A074914 001	Nov 26, 1997
WATSON LABS	200MG	A075101 001	Apr 15, 1998

TABLET; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH	400MG	A074870 001	Jun 05, 1997
	800MG	A074870 002	Jun 05, 1997
DAVA PHARMS INC	400MG	A074834 001	Apr 24, 1997
	800MG	A074834 002	Apr 24, 1997
HERITAGE PHARMS INC	400MG	A074891 001	Oct 31, 1997
	800MG	A074891 002	Oct 31, 1997
IVAX SUB TEVA PHARMS	400MG	A074836 001	Apr 22, 1997
	800MG	A074836 002	Apr 22, 1997
LEK PHARM	400MG	A074658 001	Apr 22, 1997
	800MG	A074658 002	Apr 22, 1997
MYLAN	400MG	A074976 001	Apr 13, 1998
	800MG	A074976 002	Apr 13, 1998
TEVA	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A074556 001	Apr 22, 1997
TEVA PHARMS	400MG	A075021 001	Mar 18, 1998
	800MG	A075021 002	Mar 18, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBVIE EQ 50MG BASE/ML A075114 001 Jul 26, 1999

ACYCLOVIR SODIUM

APOTHECON	EQ 1GM BASE/VIAL	A074897 002	Feb 27, 1998
	EQ 500MG BASE/VIAL	A074897 001	Feb 27, 1998
HIKMA MAPLE	EQ 1GM BASE/VIAL	A074913 002	Oct 15, 1997
	EQ 500MG BASE/VIAL	A074913 001	Oct 15, 1997

## DISCONTINUED DRUG PRODUCT LIST

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

HOSPIRA

EQ 1GM BASE/VIAL

A074663 002 Apr 22, 1997

EQ 1GM BASE/VIAL

A074758 002 Apr 22, 1997

EQ 25MG BASE/ML

A074720 001 Apr 22, 1997

EQ 50MG BASE/ML

A075065 001 Feb 25, 1999

EQ 500MG BASE/VIAL

A074663 001 Apr 22, 1997

EQ 500MG BASE/VIAL

A074758 001 Apr 22, 1997

TEVA PARENTERAL

EQ 1GM BASE/VIAL

A074969 002 Aug 26, 1997

EQ 50MG BASE/ML

A075627 001 Mar 28, 2001

EQ 500MG BASE/VIAL

A074969 001 Aug 26, 1997

ZOVIRAX

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N018603 002 Jun 29, 1989

EQ 250MG BASE/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N018603 003 Aug 30, 1983

EQ 500MG BASE/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N018603 001 Oct 22, 1982

ADAPALENE

SOLUTION; TOPICAL

DIFFERIN

GALDERMA LABS LP

0.1%

N020338 001 May 31, 1996

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

HIKMA MAPLE

3MG/ML

A076501 001 Jun 16, 2004

TEVA PHARMS USA

3MG/ML

A076564 001 Jun 16, 2004

3MG/ML

A078676 001 Jul 31, 2008

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

PFIZER

EQ 200MG BASE/VIAL

N020760 001 Dec 18, 1997

EQ 300MG BASE/VIAL

N020760 002 Dec 18, 1997

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

ISO TEX

100uCi/VIAL

N017835 001

250uCi/VIAL

N017835 002

500uCi/VIAL

N017835 003

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS

2.5uCi/AMP

N017846 001

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

MALLINCKRODT

6.67uCi/ML

N017844 003

10uCi/ML

N017844 001

100uCi/ML

N017844 002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

ISO TEX

2mCi/VIAL

N017837 003

5uCi/AMP

N017837 004

20uCi/AMP

N017837 005

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS

0.09MG/INH

A072273 001 Aug 14, 1996

GENPHARM

0.09MG/INH

A073045 001 Aug 19, 1997

IVAX SUB TEVA PHARMS

0.09MG/INH

A073272 001 Dec 28, 1995

PLIVA

0.09MG/INH

A074072 001 Aug 01, 1996

PROVENTIL

SCHERING

0.09MG/INH

N017559 001



## DISCONTINUED DRUG PRODUCT LIST

ALBUTEROL

AEROSOL, METERED; INHALATION

VENTOLIN

GLAXOSMITHKLINE 0.09MG/INH N018473 001

ALBUTEROL SULFATE

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE EQ 0.2MG BASE N019489 001 May 04, 1988

SOLUTION; INHALATION

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC EQ 0.083% BASE A073533 001 Sep 26, 1995

APOTEX INC EQ 0.021% BASE A078623 001 Apr 05, 2010

EQ 0.042% BASE A078623 002 Apr 05, 2010

EQ 0.083% BASE A075717 001 Feb 02, 2007

EQ 0.5% BASE A076391 001 Apr 01, 2003

BAUSCH AND LOMB EQ 0.083% BASE A075358 001 Mar 29, 2000

COPLEY PHARM EQ 0.083% BASE A073495 001 May 28, 1993

EQ 0.5% BASE A073307 001 Nov 27, 1991

ROXANE EQ 0.083% BASE A075129 001 Feb 13, 2001

WOCKHARDT EU OPERATN EQ 0.083% BASE A075394 001 Nov 22, 1999

PROVENTIL

SCHERING EQ 0.083% BASE N019243 002 Jan 14, 1987

EQ 0.5% BASE N019243 001 Jan 14, 1987

VENTOLIN

GLAXOSMITHKLINE EQ 0.083% BASE N019773 001 Apr 23, 1992

EQ 0.5% BASE N019269 002 Jan 16, 1987

SYRUP; ORAL

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC EQ 2MG BASE/5ML A075262 001 Mar 30, 1999

MOVA EQ 2MG BASE/5ML A074302 001 Sep 30, 1994

WATSON LABS EQ 2MG BASE/5ML A073165 001 Apr 29, 1993

PROVENTIL

SCHERING EQ 2MG BASE/5ML N018062 001 Jan 19, 1983

VENTOLIN

GLAXOSMITHKLINE EQ 2MG BASE/5ML N019621 001 Jun 10, 1987

TABLET; ORAL

ALBUTEROL SULFATE

AM THERAP EQ 2MG BASE A072449 001 Dec 05, 1989

EQ 4MG BASE A072450 001 Dec 05, 1989

COPLEY PHARM EQ 2MG BASE A072966 001 Nov 22, 1991

EQ 4MG BASE A072967 001 Nov 22, 1991

DAVA PHARMS INC EQ 2MG BASE A072859 001 Dec 20, 1989

EQ 4MG BASE A072860 001 Dec 20, 1989

PLIVA EQ 2MG BASE A072316 001 Dec 05, 1989

EQ 4MG BASE A072317 001 Dec 05, 1989

SANDOZ EQ 2MG BASE A072151 001 Dec 05, 1989

EQ 4MG BASE A072152 001 Dec 05, 1989

TEVA EQ 2MG BASE A072619 001 Dec 05, 1989

EQ 2MG BASE A072779 001 Jun 25, 1993

EQ 2MG BASE A072938 001 Mar 30, 1990

EQ 4MG BASE A072620 001 Dec 05, 1989

EQ 4MG BASE A072780 001 Jun 25, 1993

EQ 4MG BASE A072939 001 Mar 30, 1990

UCB INC EQ 2MG BASE A073120 001 Sep 29, 1992

EQ 4MG BASE A073121 001 Sep 29, 1992

WARNER CHILCOTT EQ 2MG BASE A072817 001 Jan 09, 1990

EQ 4MG BASE A072818 001 Jan 09, 1990

WATSON LABS EQ 2MG BASE A072629 001 Jan 31, 1991

EQ 2MG BASE A072764 001 Aug 28, 1991

EQ 4MG BASE A072630 001 Jan 31, 1991

EQ 4MG BASE A072765 001 Aug 28, 1991

PROVENTIL

SCHERING EQ 2MG BASE N017853 001 May 07, 1982

EQ 4MG BASE N017853 002 May 07, 1982

VENTOLIN

GLAXOSMITHKLINE EQ 2MG BASE N019112 001 Jul 10, 1986

EQ 4MG BASE N019112 002 Jul 10, 1986

TABLET, EXTENDED RELEASE; ORAL

PROVENTIL

SCHERING EQ 4MG BASE N019383 001 Jul 13, 1987

## DISCONTINUED DRUG PRODUCT LIST

ALBUTEROL SULFATE

TABLET, EXTENDED RELEASE;ORAL

VOLMAX

MURO

EQ 4MG BASE

N019604 002 Dec 23, 1992

EQ 8MG BASE

N019604 001 Dec 23, 1992

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

APOTEX INC

EQ 0.083% BASE;0.017%

A077117 001 Dec 31, 2007

SANDOZ INC

EQ 0.083% BASE;0.017%

A076867 001 Dec 21, 2006

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ACLOVATE

FOUGERA PHARMS

0.05%

N018707 001 Dec 14, 1982

OINTMENT;TOPICAL

ACLOVATE

FOUGERA PHARMS

0.05%

N018702 001 Dec 14, 1982

ALCOHOL

INJECTABLE;INJECTION

ALCOHOL 5% IN DEXTROSE 5%

MILES

5ML/100ML

A083483 001

ALCOHOL; DEXTROSE

INJECTABLE;INJECTION

ALCOHOL 5% IN D5-W

HOSPIRA

5ML/100ML;5GM/100ML

A083263 001

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE

5ML/100ML;5GM/100ML

A083256 001

ALENDRONATE SODIUM

TABLET;ORAL

ALENDRONATE SODIUM

MYLAN

EQ 35MG BASE

A078638 001 Aug 04, 2008

EQ 70MG BASE

A078638 002 Aug 04, 2008

SANDOZ

EQ 5MG BASE

A075871 001 Apr 22, 2009

EQ 10MG BASE

A075871 002 Apr 22, 2009

EQ 35MG BASE

A075871 004 Apr 22, 2009

EQ 40MG BASE

A075871 003 Apr 22, 2009

EQ 70MG BASE

A075871 005 Apr 22, 2009

TEVA PHARMS

EQ 35MG BASE

A076184 002 Aug 04, 2008

EQ 70MG BASE

A076184 001 Feb 06, 2008

FOSAMAX

MERCK AND CO INC

EQ 5MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020560 003 Apr 25, 1997

EQ 10MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020560 001 Sep 29, 1995

EQ 35MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020560 004 Oct 20, 2000

EQ 40MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020560 002 Sep 29, 1995

ALGLUCERASE

INJECTABLE;INJECTION

CEREDASE

GENZYME

10 UNITS/ML

N020057 004 May 08, 1992

80 UNITS/ML

N020057 003 Apr 05, 1991

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET;ORAL

VALTURNA

NOVARTIS

EQ 150MG BASE;160MG

N022217 001 Sep 16, 2009

EQ 300MG BASE;320MG

N022217 002 Sep 16, 2009

## DISCONTINUED DRUG PRODUCT LIST

ALKAVERVIR

TABLET; ORAL

VERILOID

3M

2MG

N007336 002

3MG

3MG

N007336 003

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

MUTUAL PHARM

100MG

A070466 001 Dec 24, 1985

300MG

A070467 001 Dec 24, 1985

PURACAP PHARM

100MG

A070150 001 Dec 10, 1985

300MG

A070147 001 Dec 10, 1985

PUREPAC PHARM

100MG

A070579 001 Apr 14, 1986

300MG

A070580 001 Apr 14, 1986

SANDOZ

100MG

A070268 001 Dec 31, 1985

300MG

A070269 001 Dec 31, 1985

SUPERPHARM

100MG

A070950 001 Nov 30, 1988

300MG

A070951 001 Nov 30, 1988

WATSON LABS

100MG

N018241 001 Nov 16, 1984

100MG

N018785 001 Sep 28, 1984

300MG

N018241 002 Nov 16, 1984

300MG

N018785 002 Sep 28, 1984

LOPURIN

ABBOTT

100MG

N018297 001

300MG

N018297 002

ALPRAZOLAM

SOLUTION; ORAL

ALPRAZOLAM

ROXANE

0.5MG/5ML

A074314 001 Oct 31, 1993

TABLET; ORAL

ALPRAZOLAM

IVAX SUB TEVA PHARMS

0.25MG

A074294 001 Jul 29, 1994

0.5MG

A074294 002 Jul 29, 1994

1MG

A074294 003 Jul 29, 1994

2MG

A074294 004 Jul 29, 1994

ROXANE

0.25MG

A074199 001 Oct 19, 1993

0.5MG

A074199 002 Oct 19, 1993

1MG

A074199 003 Oct 19, 1993

TEVA

0.25MG

A074085 001 Feb 16, 1994

0.5MG

A074085 002 Feb 16, 1994

1MG

A074085 003 Feb 16, 1994

2MG

A074085 004 Feb 26, 1996

WATSON LABS

0.25MG

A074456 001 Aug 31, 1995

0.25MG

A074479 001 Jan 21, 1997

0.5MG

A074456 002 Aug 31, 1995

0.5MG

A074479 002 Jan 21, 1997

1MG

A074456 003 Aug 31, 1995

1MG

A074479 003 Jan 21, 1997

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

ANI PHARMS INC

0.5MG

A077979 001 Feb 28, 2007

1MG

A077979 002 Feb 28, 2007

2MG

A077979 003 Feb 28, 2007

3MG

A077979 004 Feb 28, 2007

SANDOZ INC

0.5MG

A077777 001 Jun 30, 2006

1MG

A077777 002 Jun 30, 2006

2MG

A077777 003 Jun 30, 2006

3MG

A077777 004 Jun 30, 2006

VINTAGE PHARMS

0.5MG

A078442 001 Oct 15, 2007

1MG

A078442 002 Oct 15, 2007

2MG

A078442 003 Oct 15, 2007

3MG

A078442 004 Oct 15, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

UCB INC

0.25MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021726 001 Jan 19, 2005

0.5MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021726 002 Jan 19, 2005

## DISCONTINUED DRUG PRODUCT LIST

ALPRAZOLAM

TABLET, ORALLY DISINTEGRATING;ORAL

NIRAVAM

1MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021726 003 Jan 19, 2005

2MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021726 004 Jan 19, 2005

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

PFIZER

0.005MG/ML

N020755 001 Oct 31, 1997

0.01MG/ML

N020755 002 Oct 01, 1997

0.02MG/ML

N020755 003 Oct 01, 1997

EDEX

AUXILIUM PHARMS LLC

0.005MG/VIAL

N020649 001 Jun 12, 1997

ALSEROXYLON

TABLET;ORAL

RAUTENSIN

NOVARTIS

2MG

N009215 001

RAUWILOID

3M

2MG

N008867 001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE

PENNEX

80MG;20MG

A089449 001 Nov 27, 1987

FOAMICON

NOVARTIS

80MG;20MG

A072687 001 Jun 28, 1989

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH

100MG

A077659 001 Feb 23, 2006

WATSON LABS

100MG

A071382 001 Jan 21, 1987

SYMADINE

SOLVAY

100MG

A071000 001 Sep 04, 1986

SYMMETREL

ENDO PHARMS

100MG

N016020 001

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

50MG/5ML

A072655 001 Oct 30, 1990

TEVA PHARMS

50MG/5ML

A073115 001 Aug 23, 1991

SYMMETREL

ENDO PHARMS

50MG/5ML

N016023 002

TABLET;ORAL

SYMMETREL

ENDO PHARMS

100MG

N018101 001

AMBENONIUM CHLORIDE

TABLET;ORAL

MYTELASE

SANOFI AVENTIS US

10MG

N010155 002

AMCINONIDE

CREAM;TOPICAL

CYCLOCORT

ASTELLAS

0.025%

N018116 001

0.1%

N018116 002

LOTION;TOPICAL

CYCLOCORT

ASTELLAS

0.1%

N019729 001 Jun 13, 1988

OINTMENT;TOPICAL

CYCLOCORT

ASTELLAS

0.1%

N018498 001

## DISCONTINUED DRUG PRODUCT LIST

AMDINOCILLIN

INJECTABLE; INJECTION

COACTIN

ROCHE

1GM/VIAL  
250MG/VIAL  
500MG/VIALN050565 003 Dec 21, 1984  
N050565 001 Dec 21, 1984  
N050565 002 Dec 21, 1984AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

CLINIGEN HLTHCARE

375MG/VIAL

N020221 002 Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

ABBOTT

EQ 250MG BASE/ML  
EQ 250MG BASE/MLA063265 001 Nov 30, 1994  
A063266 001 Oct 31, 1994

ASTRAZENECA

EQ 50MG BASE/ML

A063167 001 Dec 14, 1995

HIKMA MAPLE

EQ 250MG BASE/ML

A063169 001 Dec 14, 1995

HOSPIRA

EQ 50MG BASE/ML

A063274 001 May 18, 1992

HOSPIRA

EQ 250MG BASE/ML

A063275 001 May 18, 1992

HOSPIRA

EQ 50MG BASE/ML

A063263 001 Nov 30, 1994

HOSPIRA

EQ 50MG BASE/ML

A063350 001 Jul 30, 1993

HOSPIRA

EQ 62.5MG BASE/ML

A063283 001 Oct 31, 1994

HOSPIRA

EQ 250MG BASE/ML

A063264 001 Nov 30, 1994

HOSPIRA

EQ 250MG BASE/ML

A063350 002 Jul 30, 1993

HOSPIRA

EQ 250MG BASE/ML

A064098 001 Jun 26, 1995

HOSPIRA

EQ 250MG BASE/ML

A064099 001 Jun 20, 1995

HOSPIRA

EQ 50MG BASE/ML

A064045 001 Sep 28, 1993

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA

EQ 500MG BASE/100ML

A064146 001 Apr 02, 1997

AMIKIN

APOTHECON

EQ 50MG BASE/ML

A062311 001

APOTHECON

EQ 50MG BASE/ML

A062562 001 Sep 20, 1984

APOTHECON

EQ 50MG BASE/ML

N050495 001

APOTHECON

EQ 250MG BASE/ML

A062311 002

APOTHECON

EQ 250MG BASE/ML

A062562 002 Sep 20, 1984

APOTHECON

EQ 250MG BASE/ML

N050495 002

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

APOTHECON

EQ 5MG BASE/ML

N050618 002 Nov 30, 1987

APOTHECON

EQ 10MG BASE/ML

N050618 001 Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SANDOZ

EQ 5MG ANHYDROUS; 50MG

A073357 001 Nov 27, 1991

TEVA

EQ 5MG ANHYDROUS; 50MG

A070795 001 Apr 17, 1988

WATSON LABS

EQ 5MG ANHYDROUS; 50MG

A073334 001 Jul 19, 1991

HYDRO-RIDE

PAR PHARM

EQ 5MG ANHYDROUS; 50MG

A070347 001 Dec 25, 1990

MODURETIC 5-50

MERCK

EQ 5MG ANHYDROUS; 50MG

N018201 001

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA

5.2% (5.2GM/100ML)

N018901 001 Apr 06, 1984

AMINOSYN 3.5% IN PLASTIC CONTAINER

ABBOTT

3.5% (3.5GM/100ML)

N018804 001 May 15, 1984

ABBOTT

3.5% (3.5GM/100ML)

N018875 001 Aug 08, 1984

AMINOSYN II 3.5%

HOSPIRA

3.5% (3.5GM/100ML)

N019438 001 Apr 03, 1986

AMINOSYN II 3.5% IN PLASTIC CONTAINER

ABBOTT

3.5% (3.5GM/100ML)

N019491 001 Oct 10, 1986

AMINOSYN II 5%

HOSPIRA

5% (5GM/100ML)

N019438 002 Apr 03, 1986

AMINOSYN-HBC 7% IN PLASTIC CONTAINER

ABBOTT

7% (7GM/100ML)

N019400 001 Jul 23, 1986

BRANCHAMIN 4%

BAXTER HLTHCARE

4% (4GM/100ML)

N018678 001 Sep 28, 1984

FREAMINE 8.5%

B BRAUN

8.5% (8.5GM/100ML)

N016822 001

FREAMINE II 8.5%

B BRAUN

8.5% (8.5GM/100ML)

N016822 002

**DISCONTINUED DRUG PRODUCT LIST**AMINO ACIDS

## INJECTABLE; INJECTION

HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML)	N020107	001	Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML ;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	001	Sep 12, 1988
HOSPIRA INC	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML ;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	001	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;20GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	002	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;20GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	002	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;25GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	004	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;25GM/100ML;51MG/100M L;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	003	Nov 07, 1988
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019714	003	Sep 12, 1988
HOSPIRA INC	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019683	004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019118	001	Oct 11, 1984
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019120	001	Oct 11, 1984
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019119	001	Oct 11, 1984
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019505	002	Nov 07, 1986
HOSPIRA	3.5%;25GM/100ML	N019713	006	Sep 09, 1988
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019506	001	Nov 07, 1986
HOSPIRA	3.5%;5GM/100ML	N019713	002	Sep 09, 1988
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML	N019713	001	Sep 09, 1988
HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
ABBOTT	4.25%;20GM/100ML	N019713	004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988

**DISCONTINUED DRUG PRODUCT LIST**AMINO ACIDS; DEXTROSE

## INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019504 002	Nov 07, 1986
	4.25%;25GM/100ML	N019713 005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681 003	Nov 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%;25GM/100ML	N019565 001	Dec 17, 1986
	5%;25GM/100ML	N019713 003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681 006	Nov 01, 1988

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML	N019520 002	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML	N019520 003	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML	N019520 004	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML	N019520 005	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML	N019520 001	Sep 23, 1988
-----------------	-----------------	-------------	--------------

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML	N019520 007	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML	N019520 008	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML	N019520 009	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML	N019520 010	Sep 23, 1988
-----------------	------------------	-------------	--------------

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML	N019520 006	Sep 23, 1988
-----------------	-----------------	-------------	--------------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019712 002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019682 003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564 002	Dec 16, 1986
--------	-----------------------------------------------------------------	-------------	--------------

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564 004	Dec 16, 1986
--------	------------------------------------------------------------------	-------------	--------------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC; HEPTAHYDRATE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564 001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019712 001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 001	Nov 01, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564 003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682 002	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 002	Oct 23, 1995
-----------------	-----------------------------------------------------------------	-------------	--------------

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147 003	Oct 23, 1995
-----------------	-----------------------------------------------------------------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%; 20GM/100ML; 51MG/100ML; 261MG/100ML ; 216MG/100ML; 112MG/100ML	N020147 004	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%; 25GM/100ML; 51MG/100ML; 261MG/100ML ; 216MG/100ML; 112MG/100ML	N020147 005	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%; 5GM/100ML; 51MG/100ML; 261MG/100ML; 216MG/100ML; 112MG/100ML	N020147 001	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%; 10GM/100ML; 51MG/100ML; 261MG/100ML ; 297MG/100ML; 77MG/100ML	N020147 007	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%; 15GM/100ML; 51MG/100ML; 261MG/100ML ; 297MG/100ML; 77MG/100ML	N020147 008	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%; 20GM/100ML; 51MG/100ML; 261MG/100ML ; 297MG/100ML; 77MG/100ML	N020147 009	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%; 25GM/100ML; 51MG/100ML; 261MG/100ML ; 297MG/100ML; 77MG/100ML	N020147 010	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%; 5GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020147 006	Oct 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER ABBOTT	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	N018804 002	May 15, 1984
	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML	N018875 002	Aug 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN 3.5% M HOSPIRA	3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017789 005	
----------------------------	--------------------------------------------	-------------	--

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER ABBOTT	3.5%; 32MG/100ML; 128MG/100ML; 222MG/100ML ; 49MG/100ML	N019493 001	Oct 16, 1986
---------------------------------------------------	------------------------------------------------------------	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

## INJECTABLE; INJECTION

VEINAMINE 8% HOSPIRA INC	8%; 61MG/100ML; 211MG/100ML; 56MG/100ML; 38 8MG/100ML	N017957 001	
-----------------------------	----------------------------------------------------------	-------------	--

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

## INJECTABLE; INJECTION

AMINOSYN II 7% W/ ELECTROLYTES HOSPIRA	7%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 4 10MG/100ML	N019437 006	Apr 03, 1986
-------------------------------------------	-----------------------------------------------------------	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

## INJECTABLE; INJECTION

AMINOSYN II 3.5% M HOSPIRA	3.5%; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49MG/100ML	N019437 007	Apr 03, 1986
-------------------------------	----------------------------------------------------------	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

TRAVASOL 3.5% W/ ELECTROLYTES BAXTER HLTHCARE	3.5%; 51MG/100ML; 131MG/100ML; 218MG/100ML ; 35MG/100ML	N017493 003	
TRAVASOL 5.5% W/ ELECTROLYTES BAXTER HLTHCARE	5.5%; 102MG/100ML; 522MG/100ML; 431MG/100M L; 224MG/100ML	N017493 001	
TRAVASOL 8.5% W/ ELECTROLYTES BAXTER HLTHCARE	8.5%; 102MG/100ML; 522MG/100ML; 594MG/100M L; 154MG/100ML	N017493 002	



## DISCONTINUED DRUG PRODUCT LIST

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

CLOVER PHARMS

250MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N015229 002

AMINOCAPROIC ACID

ABRAXIS PHARM

250MG/ML

A070522 001 Jun 17, 1986

BAXTER HLTHCARE

250MG/ML

N018590 001 Oct 29, 1982

HOSPIRA

250MG/ML

A070888 001 Jun 16, 1988

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN

NOVARTIS

250MG

N018202 001

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

MERCK

20%

N005619 001

AMINOPHYLLINE

ENEMA; RECTAL

SOMOPHYLLIN

FISONS

300MG/5ML

N018232 001 Apr 02, 1982

INJECTABLE; INJECTION

AMINOPHYLLIN

GD SEARLE LLC

25MG/ML

A087243 001 May 24, 1982

25MG/ML

A087621 001 May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM

25MG/ML

A084568 001

25MG/ML

A087200 001

25MG/ML

A087250 001 Jan 06, 1982

25MG/ML

A087886 001 Aug 30, 1983

25MG/ML

A088407 001 Jan 25, 1984

ELKINS SINN

25MG/ML

A087239 001

HOSPIRA

25MG/ML

A087601 001 Jul 23, 1982

INTL MEDICATION

25MG/ML

A087209 001 Feb 01, 1982

25MG/ML

A087867 001 Nov 10, 1983

25MG/ML

A087868 001 Nov 10, 1983

KING PHARMS

25MG/ML

A086606 001

LUITPOLD

25MG/ML

A087240 001

LYPHOMED

25MG/ML

A087431 001

PHARMA SERVE NY

25MG/ML

A087387 001 Jun 03, 1983

25MG/ML

A087392 001 Dec 15, 1983

SMITH AND NEPHEW

25MG/ML

A088429 001 May 30, 1985

25MG/ML

A088749 001 May 30, 1985

TEVA PARENTERAL

25MG/ML

A081142 001 Sep 25, 1991

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

HOSPIRA

100MG/100ML

A088147 002 May 03, 1983

200MG/100ML

A088147 003 May 03, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA

100MG/100ML

N018924 001 Dec 12, 1984

200MG/100ML

N018924 002 Dec 12, 1984

400MG/100ML

N018924 003 Dec 12, 1984

500MG/100ML

N018924 004 Dec 12, 1984

SOLUTION; ORAL

AMINOPHYLLINE

MORTON GROVE

105MG/5ML

A088156 001 Dec 05, 1983

ROXANE

105MG/5ML

A088126 001 Aug 19, 1983

AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC

105MG/5ML

A087727 001 Apr 16, 1982

SOMOPHYLLIN

FISONS

105MG/5ML

A086466 001

SOMOPHYLLIN-DF

FISONS

105MG/5ML

A087045 001

SUPPOSITORY; RECTAL

TRUPHYLLINE

G AND W LABS

250MG

A085498 001 Mar 23, 1983

500MG

A085498 002 Jan 03, 1983

TABLET; ORAL

AMINOPHYLLIN

GD SEARLE LLC

100MG

N002386 002

## DISCONTINUED DRUG PRODUCT LIST

AMINOPHYLLINE

## TABLET; ORAL

## AMINOPHYLLIN

200MG N002386 003

## AMINOPHYLLINE

## ASCOT

100MG

A087522 001 Feb 12, 1982

200MG

A087523 001 Feb 12, 1982

## BARR

100MG

A088297 001 Aug 19, 1983

200MG

A088298 001 Aug 19, 1983

## DURAMED PHARMS BARR

100MG

A088182 001 Mar 31, 1983

200MG

A088183 001 Mar 31, 1983

## HALSEY

100MG

A084674 001

## HIKMA INTL PHARMS

100MG

A084540 001

200MG

A085003 001

## IMPAX LABS

100MG

A084574 001

200MG

A084576 001

## KV PHARM

100MG

A085284 001

200MG

A085289 001

## LANNETT

100MG

A084588 001

200MG

A084588 002

## PAL PAK

100MG

A084533 001

## PANRAY

100MG

A084552 001

200MG

A084552 002

## PUREPAC PHARM

100MG

A084699 001

200MG

A085333 001

## ROXANE

100MG

A087500 001 Feb 09, 1982

200MG

A087501 001 Feb 09, 1982

## SANDOZ

100MG

A085261 003

100MG

A085262 002

200MG

A085261 002

## VALEANT PHARM INTL

200MG

A084563 001

## VANGARD

100MG

A088314 001 Oct 03, 1983

200MG

A088319 001 Oct 03, 1983

## VINTAGE PHARMS

100MG

A085409 001

200MG

A085410 001

## WATSON LABS

100MG

A085567 001

200MG

A085564 001

## TABLET, DELAYED RELEASE; ORAL

## AMINOPHYLLINE

## IMPAX LABS

100MG

A084577 001

200MG

A084575 001

## TABLICAPS

100MG

A084632 002

## VALE

100MG

A084531 001

200MG

A084530 001

## TABLET, EXTENDED RELEASE; ORAL

## PHYLLOCONTIN

## PHARM RES ASSOC

225MG

A086760 001

AMINOSALICYLATE SODIUM

## POWDER; ORAL

## P.A.S. SODIUM

## CENTURY PHARMS

4GM/PACKET

A080947 001

## SODIUM AMINOSALICYLATE

## HEXCEL

100%

A080097 001

## TABLET; ORAL

## PARASAL SODIUM

## PANRAY

1GM

N006811 011

500MG

N006811 006

## SODIUM P.A.S.

## LANNETT

500MG

A080138 002

## TEEBACIN

## CONSOLIDATED MIDLAND

500MG

N007320 002

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

## TABLET; ORAL

## NEOPASALATE

## MEDPOINTE PHARM HLC

846MG;112MG

A080059 002

## DISCONTINUED DRUG PRODUCT LIST

AMINOSALICYLIC ACID

TABLET; ORAL

PARASAL

PANRAY

1GM

N006811 002

500MG

N006811 001

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL

REZIPAS

BRISTOL MYERS SQUIBB EQ 500MG BASE/GM

N009052 001

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

BEDFORD

50MG/ML

A076018 001 Oct 15, 2002

BEDFORD LABS

50MG/ML

A076299 001 Oct 24, 2002

BEN VENUE

50MG/ML

A076088 001 Oct 15, 2002

HOSPIRA

50MG/ML

A076108 001 Oct 15, 2002

INTL MEDICATION SYS

50MG/ML

N021594 001 Feb 04, 2004

PAR STERILE PRODUCTS

50MG/ML

A076394 001 Apr 25, 2003

TEVA PHARMS USA

50MG/ML

A076163 001 Sep 05, 2003

CORDARONE

WYETH PHARMS INC

50MG/ML

N020377 001 Aug 03, 1995

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

TEVA

200MG

A074895 001 Apr 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

ROCHE

40MG/ML

A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS

10MG/ML

A085594 001

ELAVIL

ASTRAZENECA

10MG/ML

N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB

10MG

A086454 001

25MG

A086454 002

50MG

A086454 003

75MG

A086454 004

100MG

A086454 005

AMITRIL

WARNER CHILCOTT

10MG

A083939 001

25MG

A083937 001

50MG

A083938 002

75MG

A084957 001

100MG

A085093 001

150MG

A086295 001

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP

25MG

A088672 001 Nov 20, 1984

50MG

A088673 001 Nov 20, 1984

75MG

A088674 001 Nov 20, 1984

100MG

A088675 001 Nov 20, 1984

COPLEY PHARM

10MG

A088421 001 Apr 30, 1984

25MG

A088422 001 Apr 30, 1984

50MG

A088423 001 Apr 30, 1984

75MG

A088424 001 Apr 30, 1984

100MG

A088425 001 Apr 30, 1984

150MG

A088426 001 Apr 30, 1984

HALSEY

10MG

A085923 001

25MG

A085922 001

50MG

A085925 001

50MG

A087557 001 Mar 05, 1982

75MG

A085926 001 May 20, 1983

100MG

A085927 001 May 20, 1983

LEDERLE

10MG

A086744 001

10MG

A087366 001 Jan 04, 1982

25MG

A086746 001

25MG

A087367 001 May 03, 1982

50MG

A086743 001

50MG

A087181 001 Jan 04, 1982

75MG

A086745 001

## DISCONTINUED DRUG PRODUCT LIST

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

## AMITRIPTYLINE HYDROCHLORIDE

	75MG	A087369 001	Jan 04, 1982
	100MG	A086747 001	
	100MG	A087368 001	May 03, 1982
	150MG	A087370 001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744 001	
	25MG	A085627 001	
	50MG	A085745 001	
	75MG	A085743 001	
	100MG	A085742 002	May 11, 1982
	150MG	A089423 001	Feb 17, 1987
PAR PHARM	10MG	A088697 001	Sep 25, 1984
	25MG	A088698 001	Sep 25, 1984
	50MG	A088699 001	Sep 25, 1984
	75MG	A088700 001	Sep 25, 1984
	100MG	A088701 001	Sep 25, 1984
	150MG	A088702 001	Sep 25, 1984
PLIVA	10MG	A088883 001	Sep 26, 1984
	25MG	A088884 001	Sep 26, 1984
	50MG	A088885 001	Sep 26, 1984
	75MG	A088886 001	Sep 26, 1984
	100MG	A088887 001	Sep 26, 1984
	150MG	A088888 001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075 001	Sep 16, 1983
	10MG	A088084 001	Jul 18, 1983
	25MG	A088076 001	May 20, 1983
	25MG	A088085 001	Jul 18, 1983
	50MG	A088077 001	Sep 16, 1983
	50MG	A088105 001	Jul 18, 1983
	75MG	A088078 001	Sep 16, 1983
	75MG	A088106 001	Jul 18, 1983
	100MG	A088079 001	Sep 16, 1983
	100MG	A088107 001	Jul 18, 1983
ROXANE	10MG	A086002 001	
	10MG	A086144 001	
	25MG	A085944 001	
	25MG	A086145 001	
	50MG	A085945 001	
	50MG	A086143 001	
	75MG	A086004 001	
	75MG	A086147 001	
	100MG	A086003 001	
	100MG	A086146 001	
	150MG	A086090 001	
	150MG	A086148 001	
SUPERPHARM	10MG	A088853 001	Nov 13, 1984
	25MG	A088854 001	Nov 13, 1984
	50MG	A088855 001	Nov 13, 1984
	75MG	A088856 001	Nov 13, 1984
	100MG	A088857 001	Nov 13, 1984
TEVA	10MG	A084910 003	
	10MG	A086610 001	
	25MG	A085031 001	
	25MG	A086859 001	
	50MG	A085032 001	
	50MG	A086857 001	
	75MG	A085030 001	
	75MG	A086860 001	
	100MG	A085836 001	
	100MG	A086854 001	
	150MG	A086853 001	
UCB INC	10MG	A085864 001	
	25MG	A085935 001	
	50MG	A085936 001	
	75MG	A086337 001	
	100MG	A086336 001	
	150MG	A086335 001	
USL PHARMA	25MG	A087775 001	Feb 10, 1982
VANGARD	10MG	A087632 001	Feb 01, 1982
	50MG	A087616 001	Feb 08, 1982

**DISCONTINUED DRUG PRODUCT LIST**AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

## AMITRIPTYLINE HYDROCHLORIDE

	75MG	A087617 001	Feb 05, 1982
	100MG	A087639 001	Feb 08, 1982
WATSON LABS	10MG	A085816 001	
	10MG	A088620 001	Mar 02, 1984
	25MG	A085817 001	
	25MG	A088621 001	Mar 02, 1984
	50MG	A085815 001	
	50MG	A088622 001	Mar 02, 1984
	75MG	A085819 001	
	75MG	A088633 001	Mar 02, 1984
	100MG	A085820 001	
	100MG	A088634 001	Mar 02, 1984
	150MG	A085821 001	
	150MG	A088635 001	Mar 02, 1984
WEST WARD	10MG	A087647 001	Mar 05, 1982
	25MG	A087278 001	
ELAVIL			
ASTRAZENECA	10MG	N012703 001	
	25MG	N012703 003	
	50MG	N012703 004	
	75MG	N012703 005	
	100MG	N012703 006	
	150MG	N012703 007	
ENDEP			
ROCHE	10MG	A083639 001	
	25MG	A083639 002	
	50MG	A083639 003	
	75MG	A083639 004	
	100MG	A083639 005	
	150MG	A085303 001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

## CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MUTUAL PHARM	EQ 12.5MG BASE;5MG	A070765 001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766 001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277 001	May 09, 1988
	EQ 25MG BASE;10MG	A072278 001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477 001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478 001	Jan 12, 1988
WATSON LABS	EQ 12.5MG BASE;5MG	A072052 001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053 001	Dec 16, 1988
LIMBITROL			
VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001	
LIMBITROL DS			
VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

## ETRAFON 2-10

SCHERING 10MG;2MG N014713 007

## ETRAFON 2-25

SCHERING 25MG;2MG N014713 004

## ETRAFON-A

SCHERING 10MG;4MG N014713 002

## ETRAFON-FORTE

SCHERING 25MG;4MG N014713 006

## PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	10MG;2MG	A070935 001	Sep 11, 1986
	10MG;4MG	A070937 001	Sep 11, 1986
	25MG;2MG	A070936 001	Sep 11, 1986
	25MG;4MG	A070938 001	Sep 11, 1986
	50MG;4MG	A070939 001	Sep 12, 1986
MUTUAL PHARM	10MG;2MG	A071077 001	Nov 12, 1986
	10MG;4MG	A071078 001	Nov 12, 1986
	25MG;2MG	A070297 001	Nov 12, 1986
	25MG;4MG	A071079 001	Nov 12, 1986
PAR PHARM	10MG;2MG	A070565 001	Sep 11, 1986
	10MG;4MG	A070620 001	Sep 11, 1986
	25MG;2MG	A070621 001	Sep 11, 1986

## DISCONTINUED DRUG PRODUCT LIST

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	25MG; 4MG	A070595	001	Sep 11, 1986
	50MG; 4MG	A070574	001	Sep 11, 1986
SANDOZ	10MG; 2MG	A071062	001	Nov 27, 1987
	10MG; 4MG	A071862	001	Dec 21, 1987
	25MG; 2MG	A071063	001	Nov 27, 1987
	25MG; 4MG	A071064	001	Nov 27, 1987
	50MG; 4MG	A071863	001	Dec 21, 1987
WATSON LABS	10MG; 2MG	A070373	001	Aug 25, 1986
	10MG; 2MG	A072539	001	Feb 15, 1989
	10MG; 2MG	A073007	001	Oct 17, 1991
	10MG; 4MG	A070375	001	Aug 25, 1986
	10MG; 4MG	A072540	001	Feb 15, 1989
	10MG; 4MG	A073009	001	Oct 17, 1991
	25MG; 2MG	A070374	001	Aug 25, 1986
	25MG; 2MG	A072541	001	Feb 15, 1989
	25MG; 2MG	A073008	001	Oct 17, 1991
	25MG; 4MG	A070376	001	Aug 25, 1986
	25MG; 4MG	A072134	001	Feb 15, 1989
	25MG; 4MG	A073010	001	Oct 17, 1991
	50MG; 4MG	A070377	001	Nov 04, 1986
	50MG; 4MG	A071558	001	Mar 02, 1987
	50MG; 4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10				
NEW RIVER	10MG; 2MG	N014715	004	
TRIAVIL 2-25				
NEW RIVER	25MG; 2MG	N014715	002	
TRIAVIL 4-10				
NEW RIVER	10MG; 4MG	N014715	003	
TRIAVIL 4-25				
NEW RIVER	25MG; 4MG	N014715	005	
TRIAVIL 4-50				
NEW RIVER	50MG; 4MG	N014715	006	

AMLEXANOX

PASTE; DENTAL

APHTHASOL

ULURU

5%

N020511 001 Dec 17, 1996

PATCH; TOPICAL

AMLEXANOX

ULURU

2MG

N021727 001 Sep 29, 2004

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

GEDEON RICHTER USA

EQ 2.5MG BASE

A077333 001 Jul 17, 2007

EQ 5MG BASE

A077333 002 Jul 17, 2007

EQ 10MG BASE

A077333 003 Jul 17, 2007

GENPHARM

EQ 2.5MG BASE

A077362 001 Jul 09, 2007

EQ 5MG BASE

A077362 002 Jul 09, 2007

EQ 10MG BASE

A077362 003 Jul 09, 2007

MUTUAL PHARMA

EQ 2.5MG BASE

A078081 001 Jan 31, 2008

EQ 5MG BASE

A078081 002 Jan 31, 2008

EQ 10MG BASE

A078081 003 Jan 31, 2008

PURACAP PHARM

EQ 2.5MG BASE

A078131 001 Sep 04, 2007

EQ 5MG BASE

A078131 002 Sep 04, 2007

EQ 10MG BASE

A078131 003 Sep 04, 2007

SANDOZ

EQ 2.5MG BASE

A076859 001 Sep 10, 2007

EQ 5MG BASE

A076859 002 Sep 10, 2007

EQ 10MG BASE

A076859 003 Sep 10, 2007

SYNTHON PHARMS

EQ 2.5MG BASE

A077080 001 Jun 27, 2007

EQ 5MG BASE

A077080 002 Jun 27, 2007

EQ 10MG BASE

A077080 003 Jun 27, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS

EQ 2.5MG BASE

N022026 001 Sep 27, 2007

EQ 5MG BASE

N022026 002 Sep 27, 2007

EQ 10MG BASE

N022026 003 Sep 27, 2007

## DISCONTINUED DRUG PRODUCT LIST

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC	2.5MG	N021435 001	Oct 31, 2003
	5MG	N021435 002	Oct 31, 2003
	10MG	N021435 003	Oct 31, 2003

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT	5MEQ/ML	A083130 001	
GD SEARLE LLC	3MEQ/ML	A086205 001	
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE			
MCGAW	900MG/100ML	N006580 001	
AMMONIUM CHLORIDE 2.14%			
B BRAUN	40MEQ/100ML	A085734 001	

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS	EQ 200MG BASE	N006441 001	
-------------	---------------	-------------	--

AMOXAPINE

TABLET; ORAL

AMOXAPINE

SANDOZ	25MG	A072943 001	Jun 28, 1991
	50MG	A072944 001	Jun 28, 1991
	100MG	A072878 001	Jun 28, 1991
	150MG	A072879 001	Jun 28, 1991
WATSON LABS	25MG	A072418 001	May 11, 1989
	50MG	A072419 001	May 11, 1989
	100MG	A072420 001	May 11, 1989
	150MG	A072421 001	May 11, 1989

ASENDIN

LEDERLE	25MG	N018021 001	
	50MG	N018021 002	
	100MG	N018021 003	
	150MG	N018021 004	

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

LABS ATRAL	250MG	A062528 001	Aug 07, 1985
	500MG	A062528 002	Aug 07, 1985
MYLAN	250MG	A062067 001	
	500MG	A062067 002	
TEVA	250MG	A062853 001	Dec 22, 1987
	250MG	A063030 001	Feb 28, 1989
	500MG	A062854 001	Dec 22, 1987
	500MG	A063031 001	Feb 28, 1989

AMOXIL

GLAXOSMITHKLINE	250MG	N050459 001	
	500MG	N050459 002	

TRIMOX

APOTHECON	250MG	A061885 001	
	250MG	A062098 001	
	250MG	A062152 001	
	250MG	A063099 001	Mar 20, 1992
	500MG	A061885 002	
	500MG	A062098 002	
	500MG	A062152 002	
	500MG	A063099 002	Mar 20, 1992

UTIMOX

PARKE DAVIS	250MG	A062107 001	
	500MG	A062107 002	

WYMOX

WYETH AYERST	250MG	A062120 001	
	500MG	A062120 002	

FOR SUSPENSION; ORAL

AMOXICILLIN

AM ANTIBIOTICS	125MG/5ML	A062059 001	
	250MG/5ML	A062059 002	
MYLAN	125MG/5ML	A062090 001	
	250MG/5ML	A062090 002	

## DISCONTINUED DRUG PRODUCT LIST

AMOXICILLIN

## FOR SUSPENSION; ORAL

AMOXICILLIN					
RANBAXY	200MG/5ML	A065113	001	Nov 29, 2002	
	400MG/5ML	A065113	002	Nov 29, 2002	
TEVA	125MG/5ML	A062946	001	Nov 01, 1988	
	250MG/5ML	A063001	001	Jan 06, 1989	
AMOXIL					
GLAXOSMITHKLINE	50MG/ML	N050460	005		
	125MG/5ML	N050460	001		
	250MG/5ML	N050460	002		
LAROTID					
GLAXOSMITHKLINE	50MG/ML	N050460	006		
POLYMOX					
APOTHECON	125MG/5ML	A061851	001		
	125MG/5ML	A062323	001		
	250MG/5ML	A061851	002		
	250MG/5ML	A062323	002		
TRIMOX					
APOTHECON	50MG/ML	A061886	001		
	125MG/5ML	A061886	002		
	125MG/5ML	A062099	001		
	125MG/5ML	A062154	001		
	125MG/5ML	A062885	001	Mar 08, 1988	
	250MG/5ML	A061886	003		
	250MG/5ML	A062099	002		
	250MG/5ML	A062154	002		
	250MG/5ML	A062885	002	Mar 08, 1988	
UTIMOX					
PARKE DAVIS	125MG/5ML	A062127	001		
	250MG/5ML	A062127	002		
WYMOX					
WYETH AYERST	125MG/5ML	A062131	001		
	250MG/5ML	A062131	002		
TABLET; ORAL					
AMOXICILLIN					
DAVA PHARMS INC	875MG	A065344	001	Jan 15, 2009	
TABLET, CHEWABLE; ORAL					
AMOXICILLIN					
APOTHECON	125MG	A064131	001	May 06, 1996	
	250MG	A064131	002	May 06, 1996	
DAVA PHARMS INC	125MG	A064139	001	Jan 29, 1996	
	250MG	A064139	002	Jan 29, 1996	
RANBAXY	200MG	A065060	001	Nov 29, 2000	
	400MG	A065060	002	Nov 29, 2000	
TEVA	125MG	A064031	001	Dec 19, 1996	
	250MG	A064031	002	Dec 19, 1996	
AMOXIL					
DR REDDYS LABS INC	200MG	N050761	001	Apr 15, 1999	
	400MG	N050761	002	Apr 15, 1999	
TABLET, FOR SUSPENSION; ORAL					
AMOXICILLIN					
AUROBINDO PHARMA LTD	200MG	A065324	001	Jan 17, 2007	
	400MG	A065324	002	Jan 17, 2007	
DISPERMOX					
RANBAXY LABS LTD	200MG	A065080	002	Aug 11, 2003	
	400MG	A065080	001	Aug 11, 2003	
	600MG	A065159	001	Dec 04, 2003	

AMOXICILLIN; CLAVULANATE POTASSIUM

## TABLET; ORAL

## AMOXICILLIN AND CLAVULANATE POTASSIUM

APOTEX INC	250MG;EQ 125MG BASE	A065333	001	Feb 24, 2009	
	500MG;EQ 125MG BASE	A065333	002	Feb 24, 2009	
	875MG;EQ 125MG BASE	A065317	003	Oct 20, 2008	
RANBAXY LABS	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	



## DISCONTINUED DRUG PRODUCT LIST

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

## CAPSULE; ORAL

## DELCOBESE

## TEVA

1.25MG;1.25MG;1.25MG;1.25MG **Federal	A083564	001	
Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**			
2.5MG;2.5MG;2.5MG;2.5MG **Federal	A083564	002	
Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**			
3.75MG;3.75MG;3.75MG;3.75MG **Federal	A083564	003	
Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**			
5MG;5MG;5MG;5MG **Federal Register	A083564	004	
determination that product was not discontinued or withdrawn for safety or efficacy reasons**			

## TABLET; ORAL

## DELCOBESE

## TEVA

1.25MG;1.25MG;1.25MG;1.25MG	A083563	004	
2.5MG;2.5MG;2.5MG;2.5MG	A083563	003	
3.75MG;3.75MG;3.75MG;3.75MG	A083563	002	
5MG;5MG;5MG;5MG	A083563	001	

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

## TABLET; ORAL

## ADDERALL 10

## TEVA WOMENS

2.5MG;2.5MG;2.5MG;2.5MG	N011522	007	Feb 13, 1996
-------------------------	---------	-----	--------------

## ADDERALL 12.5

## TEVA WOMENS

3.125MG;3.125MG;3.125MG;3.125MG	N011522	012	Aug 31, 2000
---------------------------------	---------	-----	--------------

## ADDERALL 15

## TEVA WOMENS

3.75MG;3.75MG;3.75MG;3.75MG	N011522	013	Aug 31, 2000
-----------------------------	---------	-----	--------------

## ADDERALL 20

## TEVA WOMENS

5MG;5MG;5MG;5MG	N011522	008	Feb 13, 1996
-----------------	---------	-----	--------------

## ADDERALL 30

## TEVA WOMENS

7.5MG;7.5MG;7.5MG;7.5MG	N011522	010	May 12, 1997
-------------------------	---------	-----	--------------

## ADDERALL 5

## TEVA WOMENS

1.25MG;1.25MG;1.25MG;1.25MG	N011522	009	May 12, 1997
-----------------------------	---------	-----	--------------

## ADDERALL 7.5

## TEVA WOMENS

1.875MG;1.875MG;1.875MG;1.875MG	N011522	011	Aug 31, 2000
---------------------------------	---------	-----	--------------

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

## TEVA PHARMS

1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003
2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003
5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003
7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

## CAPSULE, EXTENDED RELEASE; ORAL

## BIPHETAMINE 12.5

## UCB INC

EQ 6.25MG BASE;EQ 6.25MG BASE	N010093	007	
-------------------------------	---------	-----	--

## BIPHETAMINE 20

## UCB INC

EQ 10MG BASE;EQ 10MG BASE	N010093	003	
---------------------------	---------	-----	--

## BIPHETAMINE 7.5

## UCB INC

EQ 3.75MG BASE;EQ 3.75MG BASE	N010093	009	
-------------------------------	---------	-----	--

AMPHETAMINE SULFATE

## TABLET; ORAL

## AMPHETAMINE SULFATE

## LANNETT

5MG	A083901	001	Aug 31, 1984
10MG	A083901	002	Aug 31, 1984

AMPHOTERICIN B

## CREAM; TOPICAL

## FUNGIZONE

## APOTHECON

3%	N050314	001	
----	---------	-----	--

## INJECTABLE; INJECTION

## AMPHOTERICIN B

## ABBOTT

50MG/VIAL	A064141	001	Dec 23, 1996
-----------	---------	-----	--------------

## ABRAXIS PHARM

50MG/VIAL	A062728	001	Apr 13, 1987
-----------	---------	-----	--------------

## TEVA PARENTERAL

50MG/VIAL	A064062	001	Mar 31, 1995
-----------	---------	-----	--------------

## FUNGIZONE

## APOTHECON

50MG/VIAL	A060517	001	
-----------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

AMPHOTERICIN B

LOTION; TOPICAL

FUNGIZONE

APOTHECON

3%

A060570 001

OINTMENT; TOPICAL

FUNGIZONE

APOTHECON

3%

N050313 001

SUSPENSION; ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB

100MG/ML

N050341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

APOTHECON

EQ 1GM BASE/VIAL

A062860 004 Feb 05, 1988

EQ 2GM BASE/VIAL

A062860 005 Feb 05, 1988

EQ 125MG BASE/VIAL

A062860 001 Feb 05, 1988

EQ 250MG BASE/VIAL

A062860 002 Feb 05, 1988

EQ 500MG BASE/VIAL

A062860 003 Feb 05, 1988

CONSOLIDATED PHARM

EQ 1GM BASE/VIAL

A061936 003

EQ 2GM BASE/VIAL

A061936 004

EQ 125MG BASE/VIAL

A061936 005

EQ 250MG BASE/VIAL

A061936 001

EQ 500MG BASE/VIAL

A061936 002

HANFORD GC

EQ 1GM BASE/VIAL

A063139 001 Apr 15, 1993

EQ 2GM BASE/VIAL

A063141 001 Apr 15, 1993

EQ 125MG BASE/VIAL

A063143 001 Apr 15, 1993

EQ 500MG BASE/VIAL

A063147 001 Apr 15, 1993

HIKMA MAPLE

EQ 1GM BASE/VIAL

A062692 004 Jun 24, 1986

EQ 2GM BASE/VIAL

A062692 005 Jun 24, 1986

EQ 10GM BASE/VIAL

A062692 006 Jun 24, 1986

EQ 125MG BASE/VIAL

A062692 001 Jun 24, 1986

EQ 250MG BASE/VIAL

A062692 002 Jun 24, 1986

EQ 500MG BASE/VIAL

A062692 003 Jun 24, 1986

INTL MEDICATION

EQ 1GM BASE/VIAL

A062634 002 Jan 09, 1987

EQ 2GM BASE/VIAL

A062634 003 Jan 09, 1987

LILLY

EQ 1GM BASE/VIAL

A062565 002 Apr 04, 1985

EQ 2GM BASE/VIAL

A062565 003 Jun 24, 1986

EQ 500MG BASE/VIAL

A062565 001 Apr 04, 1985

WATSON LABS INC

EQ 1GM BASE/VIAL

A062816 004 Oct 24, 1988

EQ 2GM BASE/VIAL

A062816 005 Oct 24, 1988

EQ 10GM BASE/VIAL

A062994 001 Sep 15, 1988

EQ 125MG BASE/VIAL

A062816 001 Oct 24, 1988

EQ 250MG BASE/VIAL

A062816 002 Oct 24, 1988

EQ 500MG BASE/VIAL

A062816 003 Oct 24, 1988

OMNIPEN-N

WYETH AYERST

EQ 1GM BASE/VIAL

A060626 004

EQ 1GM BASE/VIAL

A062718 004 Dec 16, 1986

EQ 2GM BASE/VIAL

A060626 005

EQ 2GM BASE/VIAL

A062718 005 Dec 16, 1986

EQ 125MG BASE/VIAL

A060626 001

EQ 125MG BASE/VIAL

A062718 001 Dec 16, 1986

EQ 250MG BASE/VIAL

A060626 002

EQ 250MG BASE/VIAL

A062718 002 Dec 16, 1986

EQ 500MG BASE/VIAL

A060626 003

EQ 500MG BASE/VIAL

A062718 003 Dec 16, 1986

PENBRITIN-S

WYETH AYERST

EQ 1GM BASE/VIAL

N050072 004

EQ 2GM BASE/VIAL

N050072 005

EQ 4GM BASE/VIAL

N050072 006

EQ 125MG BASE/VIAL

N050072 001

EQ 250MG BASE/VIAL

N050072 002

EQ 500MG BASE/VIAL

N050072 003

POLYCILLIN-N

BRISTOL

EQ 1GM BASE/VIAL

N050309 004

EQ 2GM BASE/VIAL

N050309 005

EQ 125MG BASE/VIAL

N050309 001

EQ 250MG BASE/VIAL

N050309 002

EQ 500MG BASE/VIAL

N050309 003

TOTACILLIN-N

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A060677 004

EQ 1GM BASE/VIAL

A062727 001 Dec 19, 1986

EQ 2GM BASE/VIAL

A060677 005

**DISCONTINUED DRUG PRODUCT LIST**AMPICILLIN SODIUM

INJECTABLE; INJECTION

TOTACILLIN-N

EQ 2GM BASE/VIAL	A062727 002	Dec 19, 1986
EQ 10GM BASE/VIAL	A060677 006	
EQ 125MG BASE/VIAL	A060677 001	
EQ 250MG BASE/VIAL	A060677 002	
EQ 500MG BASE/VIAL	A060677 003	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

PFIZER	EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL	N050608 003	Dec 31, 1986
--------	----------------------------------------	-------------	--------------

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS	EQ 250MG BASE	A062041 001
	EQ 500MG BASE	A062041 002

AMPICILLIN TRIHYDRATE

AM ANTI-BIOTICS	EQ 250MG BASE	A061602 001
	EQ 500MG BASE	A061602 002
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A060765 001
	EQ 500MG BASE	A060765 002
LEDERLE	EQ 250MG BASE	A062208 001
	EQ 500MG BASE	A062208 002
MYLAN	EQ 250MG BASE	A061755 001
	EQ 500MG BASE	A061755 002
PUREPAC PHARM	EQ 250MG BASE	A061853 001
	EQ 500MG BASE	A061853 002
TEVA	EQ 250MG BASE	A061502 001
	EQ 500MG BASE	A061502 002
VITARINE	EQ 250MG BASE	A061387 001
	EQ 500MG BASE	A061387 003

OMNIPEN (AMPICILLIN)

WYETH AYERST	250MG	A060624 001
	500MG	A060624 002

PENBRITIN

WYETH AYERST	EQ 250MG BASE	A060908 001
	EQ 500MG BASE	A060908 002

PFIZERPEN-A

PFIZER	EQ 250MG BASE	A062050 001
	EQ 500MG BASE	A062050 002

POLYCILLIN

BRISTOL	EQ 250MG BASE	N050310 001
	EQ 500MG BASE	N050310 002

PRINCIPEN

APOTHECON	EQ 250MG BASE	A062888 001	Mar 04, 1988
	EQ 500MG BASE	A062888 002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392 001	
	EQ 500MG BASE	A061392 002	

PRINCIPEN '250'

APOTHECON	EQ 250MG BASE	A062157 002
	EQ 250MG BASE	N050056 001

PRINCIPEN '500'

APOTHECON	EQ 500MG BASE	A062157 001
	EQ 500MG BASE	N050056 002

TOTACILLIN

GLAXOSMITHKLINE	EQ 250MG BASE	A060060 001
	EQ 250MG BASE	A062212 001
	EQ 500MG BASE	A060060 002
	EQ 500MG BASE	A062212 002

FOR SUSPENSION; ORAL

AMCILL

PARKE DAVIS	EQ 125MG BASE/5ML	A062030 001
	EQ 250MG BASE/5ML	A062030 002

AMPICILLIN TRIHYDRATE

AM ANTI-BIOTICS	EQ 125MG BASE/5ML	A061601 001
	EQ 250MG BASE/5ML	A061601 002
MYLAN	EQ 125MG BASE/5ML	A061829 002
	EQ 250MG BASE/5ML	A061829 001
PUREPAC PHARM	EQ 125MG BASE/5ML	A061980 001
	EQ 250MG BASE/5ML	A061980 002

## DISCONTINUED DRUG PRODUCT LIST

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL

AMPICILLIN TRIHYDRATE

TEVA	EQ 125MG BASE/5ML	A061370 001
	EQ 250MG BASE/5ML	A061370 002

OMNIPEN (AMPICILLIN)

WYETH AYERST	100MG/ML	A060625 001
	125MG/5ML	A060625 002
	250MG/5ML	A060625 003
	500MG/5ML	A060625 004

PENBRITIN

WYETH AYERST	EQ 100MG BASE/ML	N050019 001
	EQ 125MG BASE/5ML	N050019 002
	EQ 250MG BASE/5ML	N050019 003

PFIZERPEN-A

PFIZER	EQ 125MG BASE/5ML	A062049 001
	EQ 250MG BASE/5ML	A062049 002

POLYCILLIN

APOTHECON	EQ 125MG BASE/5ML	A062297 001
	EQ 250MG BASE/5ML	A062297 002
BRISTOL	EQ 100MG BASE/ML	N050308 004
	EQ 125MG BASE/5ML	N050308 001
	EQ 250MG BASE/5ML	N050308 002
	EQ 500MG BASE/5ML	N050308 003

PRINCIPEN

APOTHECON	EQ 100MG BASE/ML	A061394 001
	EQ 125MG BASE/5ML	A061394 002
	EQ 250MG BASE/5ML	A061394 003

PRINCIPEN '125'

APOTHECON	EQ 125MG BASE/5ML	A060127 002
	EQ 125MG BASE/5ML	A062151 001

PRINCIPEN '250'

APOTHECON	EQ 250MG BASE/5ML	A060127 001
	EQ 250MG BASE/5ML	A062151 002

TOTACILLIN

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666 001
	EQ 125MG BASE/5ML	A062223 001
	EQ 250MG BASE/5ML	A060666 002
	EQ 250MG BASE/5ML	A062223 002

TABLET, CHEWABLE;ORAL

POLYCILLIN

BRISTOL	EQ 125MG BASE	N050093 001
---------	---------------	-------------

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL

PRINCIPEN W/ PROBENECID

APOTHECON	EQ 389MG BASE;111MG	A062150 001
	EQ 389MG BASE;111MG	N050488 001

FOR SUSPENSION;ORAL

POLYCILLIN-PRB

APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898 001
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457 001

PROBAMPACIN

TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	A061741 001
------	---------------------------	-------------

AMPRENAVIR

CAPSULE;ORAL

AGENERASE

GLAXOSMITHKLINE	50MG	N021007 001	Apr 15, 1999
	150MG	N021007 002	Apr 15, 1999

SOLUTION;ORAL

AGENERASE

GLAXOSMITHKLINE	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021039 001	Apr 15, 1999
-----------------	-----------------------------------------------------------------------------------------------------------------------------------	-------------	--------------

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

SHIRE LLC	EQ 1MG BASE	N020333 002	Mar 14, 1997
-----------	-------------	-------------	--------------

ANAGRELIDE HYDROCHLORIDE

ROXANE	EQ 0.5MG BASE	A076489 001	Apr 18, 2005
	EQ 1MG BASE	A076489 002	Apr 18, 2005

## DISCONTINUED DRUG PRODUCT LIST

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005
	EQ 1MG BASE	A076683 002	Apr 18, 2005
WATSON LABS	EQ 0.5MG BASE	A076417 001	Apr 18, 2005
	EQ 1MG BASE	A076417 002	Apr 18, 2005

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

IMPAX LABS INC	1MG	A091242 001	May 31, 2012
KUDCO IRELAND	1MG	A091331 001	Jan 05, 2011
SYNTHON PHARMS	1MG	A078322 001	Jun 28, 2010
WATSON LABS	1MG	A078984 001	Jun 28, 2010

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL

LERITINE

MERCK	EQ 25MG BASE	N010585 002	
-------	--------------	-------------	--

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE

MERCK	25MG/ML	N010520 003	
-------	---------	-------------	--

ANISINDIONE

TABLET; ORAL

MIRADON

SCHERING	50MG	N010909 003	
----------	------	-------------	--

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS	50MG	A086046 001	
VALPIN 50			
ENDO PHARMS	50MG	N013428 001	

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

NOVARTIS	0.5%; 0.05%	N018746 002	Jul 11, 1994
----------	-------------	-------------	--------------

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

US WORLDMEDS	20MG/2ML (10MG/ML)	N021264 001	Apr 20, 2004
--------------	--------------------	-------------	--------------

APROTININ

INJECTABLE; INJECTION

TRASYLOL

BAYER HLTHCARE	10,000KIU/ML	N020304 001	Dec 29, 1993
----------------	--------------	-------------	--------------

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

GENSIA AUTOMEDICS	0.05MG/ML	N020420 001	Sep 12, 1997
-------------------	-----------	-------------	--------------

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020227 002	May 23, 1997
	10,000 UNITS/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020227 001	May 23, 1997

ARGATROBAN

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

SANDOZ	125MG/125ML (1MG/ML)	N201743 001	May 09, 2011
--------	----------------------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

ARIPIPIRAZOLE

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

OTSUKA	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021729 004	Jun 07, 2006
	30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021729 005	Jun 07, 2006

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

MYLAN PHARMS INC	50MG	A200043 001	Jun 01, 2012
	150MG	A200043 002	Jun 01, 2012
	250MG	A200043 003	Jun 01, 2012
WATSON LABS INC	100MG	A200156 002	Aug 29, 2012
	200MG	A200156 004	Aug 29, 2012
NUVIGIL			
CEPHALON	100MG	N021875 002	Mar 26, 2009

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

BEROCCA PN

ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;	N006071 003	Oct 10, 1985
-------	------------------------------------------------------------------------------------	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.C. 9+3

ABRAXIS PHARM	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018440 002	Aug 08, 1985
---------------	----------------------------------------------------------------------------------	-------------	--------------

M.V.I.-12

HOSPIRA	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N008809 004	Aug 08, 1985
---------	----------------------------------------------------------------------------------	-------------	--------------

MVC PLUS

WATSON LABS	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018439 002	Aug 08, 1985
-------------	----------------------------------------------------------------------------------	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12

HOSPIRA	20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M	N008809 005	Apr 22, 2004
---------	----------------------------------------------------------------------------------	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

ASTRAZENECA	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4 MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10 MG/VIAL	N018933 002	Aug 08, 1985
-------------	--------------------------------------------------------------------------------------------------------------------------------	-------------	--------------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

VITAPED

HOSPIRA	N/A, 80MG/VIAL;N/A, 0.02MG/VIAL;N/A, 0.001 MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A, 17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A, 1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A	N020176 001	Dec 29, 1993
---------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

NOVEL LABS INC 4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM A090145 001 Jan 25, 2012

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER 500MG N021317 001 Oct 18, 2001

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER 650MG N016030 001

MEASURIN

BAYER 650MG N016030 002

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

SAVAGE LABS 650MG;50MG A088305 001 Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

MUTUAL PHARM 325MG;50MG;40MG A078149 001 Jun 13, 2007

WATSON LABS 325MG;50MG;40MG A086231 002 Feb 12, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH 325MG;50MG;40MG A086710 002 Aug 23, 1983

HALSEY 325MG;50MG;40MG A089448 001 Dec 01, 1986

IVAX PHARMS 325MG;50MG;40MG A085441 002 Oct 31, 1984

PURACAP PHARM 325MG;50MG;40MG A087048 002 Dec 09, 1983

QUANTUM PHARMICS 325MG;50MG;40MG A088972 001 Jun 18, 1985

SANDOZ 325MG;50MG;40MG A086398 002 Apr 06, 1984

WATSON LABS 325MG;50MG;40MG A086237 002 Mar 23, 1984

FIORINAL

WATSON LABS INC 325MG;50MG;40MG N017534 003 Apr 16, 1986

LANORINAL

LANNETT 325MG;50MG;40MG A086986 002 Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC 325MG;50MG;40MG;30MG A075351 001 Mar 05, 1999

WATSON LABS 325MG;50MG;40MG;30MG A074359 001 Aug 31, 1995

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

SANDOZ 385MG;30MG;25MG A074817 001 Nov 27, 1996

INVAGESIC FORTE

SANDOZ 770MG;60MG;50MG A074817 002 Nov 27, 1996

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

STEVENS J 385MG;30MG;25MG A074988 001 Apr 30, 1999

770MG;60MG;50MG A074988 002 Apr 30, 1999

ORPHENGESIC

PRINSTON INC 385MG;30MG;25MG A075141 001 May 29, 1998

ORPHENGESIC FORTE

PRINSTON INC 770MG;60MG;50MG A075141 002 May 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA 389MG;32.4MG;65MG A084553 002 Aug 17, 1983

DARVON COMPOUND

XANODYNE PHARM 389MG;32.4MG;32MG N010996 006 Mar 08, 1983

DARVON COMPOUND-65

XANODYNE PHARM 389MG;32.4MG;65MG N010996 007 Mar 08, 1983

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS 389MG;32.4MG;65MG A083077 002 Dec 07, 1984

SANDOZ 389MG;32.4MG;65MG A080044 002 Sep 16, 1983

TEVA 389MG;32.4MG;65MG A089025 001 Mar 29, 1985

PROPOXYPHENE COMPOUND-65

SANDOZ 389MG;32.4MG;65MG A083101 002 Jun 24, 1985

**DISCONTINUED DRUG PRODUCT LIST**ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE  
WATSON LABS 389MG; 32.4MG; 65MG

A085732 002 Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL COMPOUND  
WATSON LABS 325MG; 200MG

A088809 001 Oct 03, 1985

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE  
MIRROR PHARMS 325MG; 200MG; 16MG  
PROSAM LABS 325MG; 200MG; 16MG

A040860 001 Jan 07, 2010

A040283 001 Dec 29, 1998

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

SCHWARZ PHARMA 500MG; 5MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

A089420 001 Jan 25, 1988

VICOPRIN

ABBOTT 500MG; 5MG

A086333 001 Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

CARACO 325MG; 200MG

N011702 003 Dec 29, 1983

MEPRO-ASPIRIN

SANDOZ 325MG; 200MG

A089127 001 Mar 02, 1987

MEPROBAMATE AND ASPIRIN

PAR PHARM 325MG; 200MG

A089126 001 Aug 19, 1986

MICRAININ

MEDPOINTE PHARM HLC 325MG; 200MG

A084978 001

Q-GESIC

QUANTUM PHARMICS 325MG; 200MG

A088740 001 Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS 325MG; 400MG

A087211 001 Dec 22, 1982

MCNEIL 325MG; 400MG

A089193 001 Feb 12, 1986

PAR PHARM 325MG; 400MG

A089657 001 Nov 04, 1988

ROBAXISAL

ROBINS AH 325MG; 400MG

N012281 001

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY 325MG; 4.5MG; 0.38MG

A087464 001 Jul 01, 1982

OXYCODONE AND ASPIRIN

MUTUAL PHARM 325MG; 4.5MG; 0.38MG

A040260 001 Jul 17, 1998

325MG; 4.5MG; 0.38MG

A087794 001 May 26, 1982

WATSON LABS 325MG; 4.5MG; 0.38MG

A040255 001 Feb 27, 1998

OXYCODONE AND ASPIRIN (HALF-STRENGTH)

ROXANE 325MG; 2.25MG; 0.19MG

A087742 001 Jun 04, 1982

PERCODAN

ENDO PHARMS 325MG; 4.5MG; 0.38MG

N007337 006

PERCODAN-DEMI

ENDO PHARMS 325MG; 2.25MG; 0.19MG

N007337 005

ROXIPRIN

ROXANE 325MG; 4.5MG; 0.38MG

A087743 001 Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

SANOFI AVENTIS US 325MG; EQ 12.5MG BASE

N016891 001

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB 325MG, N/A; N/A, 80MG

N021387 006 Jun 24, 2003



## DISCONTINUED DRUG PRODUCT LIST

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET, TABLET; ORAL  
PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG, N/A; N/A, 20MG	N021387 001	Jun 24, 2003
	81MG, N/A; N/A, 40MG	N021387 002	Jun 24, 2003
	81MG, N/A; N/A, 80MG	N021387 003	Jun 24, 2003
	325MG, N/A; N/A, 20MG	N021387 004	Jun 24, 2003
	325MG, N/A; N/A, 40MG	N021387 005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM	325MG; 65MG	N010996 005	
----------------	-------------	-------------	--

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG; 100MG	N016829 001	
---------------	--------------	-------------	--

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG; 100MG	N016863 001	
---------------	--------------	-------------	--

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

BRISTOL MYERS SQUIBB	EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021567 001	Jun 20, 2003
----------------------	--------------------------------------------------------------------------------------------------------------------------------	-------------	--------------

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

ASTRAZENECA	0.5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019058 001	Sep 13, 1989
-------------	---------------------------------------------------------------------------------------------------------------------------	-------------	--------------

TABLET; ORAL

ATENOLOL

ABLE	25MG	A076907 001	Jul 30, 2004
	50MG	A076907 002	Jul 30, 2004
	100MG	A076907 003	Jul 30, 2004
APOTHECON	50MG	A073317 001	Mar 20, 1992
	100MG	A073318 001	Mar 20, 1992
MYLAN	25MG	A074126 003	Aug 26, 1998
	50MG	A074126 001	Mar 23, 1994
	100MG	A074126 002	Mar 23, 1994
NOSTRUM LABS	50MG	A074127 001	Feb 21, 1995
	100MG	A074127 002	Feb 21, 1995
PLIVA	25MG	A074101 001	Jul 17, 1997
	50MG	A074101 002	Jul 17, 1997
	100MG	A074101 003	Jul 17, 1997
SANDOZ	25MG	A074265 001	Feb 28, 1994
	50MG	A074265 002	Feb 28, 1994
	100MG	A074265 003	Feb 28, 1994
SCS	50MG	A073676 001	Oct 30, 1992
	100MG	A073676 002	Oct 30, 1992
TEVA	50MG	A073315 001	May 28, 1993
	100MG	A073316 001	May 28, 1993
TEVA PHARMS	50MG	A074120 001	Feb 24, 1995
	100MG	A074120 002	Feb 24, 1995
WATSON LABS	50MG	A073352 001	Dec 27, 1991
	100MG	A073353 001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS	50MG; 25MG	A074404 001	May 14, 1998
	100MG; 25MG	A074404 002	May 14, 1998
PLIVA	50MG; 25MG	A074107 001	Sep 24, 1997
	100MG; 25MG	A074107 002	Sep 24, 1997

## DISCONTINUED DRUG PRODUCT LIST

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

ZYDUS PHARMS USA INC

18MG

A079017 001 Sep 17, 2010

25MG

A079017 002 Sep 17, 2010

40MG

A079017 003 Sep 17, 2010

60MG

A079017 004 Sep 17, 2010

80MG

A079017 005 Sep 17, 2010

100MG

A079017 006 Sep 17, 2010

STRATTERA

LILLY

5MG

N021411 001 Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

TEVA PHARMS

EQ 10MG BASE

A078773 001 May 29, 2012

EQ 20MG BASE

A078773 002 May 29, 2012

EQ 40MG BASE

A078773 003 May 29, 2012

EQ 80MG BASE

A078773 004 May 29, 2012

ATOVAQUONE

TABLET; ORAL

MEPRON

GLAXOSMITHKLINE LLC

250MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N020259 001 Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE

10MG/ML

A074824 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074753 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074632 001 Dec 23, 1996

10MG/ML

A074740 001 Mar 28, 1997

TEVA PARENTERAL

10MG/ML

A074784 001 Jun 11, 1997

WATSON LABS INC

10MG/ML

A074945 001 Jul 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

BAXTER HLTHCARE

10MG/ML

A074825 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074768 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074633 001 Dec 23, 1996

10MG/ML

A074639 001 Mar 25, 1997

10MG/ML

A074741 001 Mar 28, 1997

WATSON LABS INC

10MG/ML

A074944 001 Jul 28, 1998

TRACRIUM

HOSPIRA

10MG/ML \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N018831 002 Jun 20, 1985

TRACRIUM PRESERVATIVE FREE

HOSPIRA

10MG/ML \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N018831 001 Nov 23, 1983

ATROPINE

INJECTABLE; INJECTION

ATROPINE

ABBVIE

EQ 2MG SULFATE/0.7ML

A071295 001 Jan 30, 1987

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

US ARMY

EQ 0.36MG BASE/INH

N020056 001 Sep 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

VALEANT

0.025MG; 0.5MG

N017744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

SCHERER RP

0.025MG; 2.5MG

A086440 001

SOLUTION; ORAL

COLONOID

MEDPOINTE PHARM HLC

0.025MG/5ML; 2.5MG/5ML

A085735 001

**DISCONTINUED DRUG PRODUCT LIST**ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

## SOLUTION; ORAL

## LOMANATE

ALPHARMA US PHARMS 0.025MG/5ML; 2.5MG/5ML A085746 001

## LOMOTIL

GD SEARLE LLC 0.025MG/5ML; 2.5MG/5ML N012699 001

## TABLET; ORAL

## COLONALID

MEDPOINTE PHARM HLC 0.025MG; 2.5MG A085737 001

## DI-ATRO

MD PHARM 0.025MG; 2.5MG A085266 001

## DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE 0.025MG; 2.5MG A040395 001 Nov 27, 2000

ASCOT 0.025MG; 2.5MG A087934 001 Jul 19, 1983

HEATHER 0.025MG; 2.5MG A086798 001

HIKMA PHARMS LLC 0.025MG; 2.5MG A087765 001 Mar 15, 1982

INWOOD LABS 0.025MG; 2.5MG A085509 001

IVAX PHARMS 0.025MG; 2.5MG A086727 001

KV PHARM 0.025MG; 2.5MG A085659 001

LEDERLE 0.025MG; 2.5MG A086950 001

MUTUAL PHARM 0.025MG; 2.5MG A085506 001

PARKE DAVIS 0.025MG; 2.5MG A087131 001

PVT FORM 0.025MG; 2.5MG A085766 001

R AND S PHARMA 0.025MG; 2.5MG A085035 001

ROXANE 0.025MG; 2.5MG A086057 001

SANDOZ 0.025MG; 2.5MG A086173 001

USL PHARMA 0.025MG; 2.5MG A087842 001 Mar 29, 1982

VALEANT PHARM INTL 0.025MG; 2.5MG A087195 001 Feb 16, 1982

WATSON LABS 0.025MG; 2.5MG A085876 001

## LO-TROL

VANGARD 0.025MG; 2.5MG A088009 001 Mar 25, 1983

## LOGEN

SUPERPHARM 0.025MG; 2.5MG A088962 001 May 10, 1985

## LOW-QUEL

HALSEY 0.025MG; 2.5MG A085211 001

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

## INJECTABLE; INJECTION

## ENLON-PLUS

MYLAN INSTITUTIONAL 0.14MG/ML; 10MG/ML N019677 001 Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## ATROPINE AND DEMEROL

ABBVIE 0.4MG/ML; 50MG/ML A087853 001 Nov 26, 1982

0.4MG/ML; 75MG/ML A087847 001 Nov 26, 1982

0.4MG/ML; 100MG/ML A087848 001 Nov 26, 1982

## MEPERIDINE AND ATROPINE SULFATE

WYETH AYERST 0.4MG/ML; 50MG/ML A085121 001

0.4MG/ML; 75MG/ML A085121 002

0.4MG/ML; 100MG/ML A085121 003

ATROPINE; PRALIDOXIME CHLORIDE

## INJECTABLE; INTRAMUSCULAR

## ATNAA

US ARMY 2.1MG/0.7ML; 600MG/0.7ML; 600MG/0.7ML N021175 001 Jan 17, 2002

AZATADINE MALEATE

## TABLET; ORAL

## OPTIMINE

SCHERING 1MG N017601 001

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

## TABLET, EXTENDED RELEASE; ORAL

## TRINALIN

SCHERING 1MG; 120MG N018506 001 Mar 23, 1982

AZATHIOPRINE

## TABLET; ORAL

## IMURAN

PROMETHEUS LABS 25MG N016324 002

**DISCONTINUED DRUG PRODUCT LIST**AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

PROMETHEUS LABS

EQ 100MG BASE/VIAL

N017391 001

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTEPRO

MEDA PHARMS

EQ 0.125MG BASE/SPRAY

N022203 001 Oct 15, 2008

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

PFIZER

EQ 250MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N050670 001 Nov 01, 1991

FOR SUSPENSION; ORAL

AZITHROMYCIN

SANDOZ

EQ 100MG BASE/5ML

A065297 001 Sep 18, 2006

EQ 200MG BASE/5ML

A065297 002 Sep 18, 2006

INJECTABLE; INJECTION

AZITHROMYCIN

PLIVA HRVATSKA DOO

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007

TEVA PARENTERAL

EQ 2.5GM BASE/VIAL

N050809 002 Dec 19, 2006

EQ 500MG BASE/VIAL

N050809 001 Dec 19, 2006

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER

EQ 1GM BASE, N/A; N/A, EQ 100MG BASE

N050762 001 Dec 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

BAYER PHARMS

EQ 2GM BASE/VIAL

A062388 001 Sep 08, 1982

EQ 2GM BASE/VIAL

A062417 001 Oct 12, 1982

EQ 2GM BASE/VIAL

N050562 001 Sep 03, 1982

EQ 3GM BASE/VIAL

A062388 002 Sep 08, 1982

EQ 3GM BASE/VIAL

A062417 002 Oct 12, 1982

EQ 3GM BASE/VIAL

N050562 002 Sep 03, 1982

EQ 4GM BASE/VIAL

A062388 003 Sep 08, 1982

EQ 4GM BASE/VIAL

A062417 003 Oct 12, 1982

EQ 4GM BASE/VIAL

N050562 003 Sep 03, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

BRISTOL MYERS SQUIBB

500MG/VIAL

N050580 001 Dec 31, 1986

AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB

10MG/ML

N050632 003 May 24, 1989

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

PFIZER

125MG/5ML

N050556 001 Mar 23, 1982

TABLET; ORAL

SPECTROBID

PFIZER

400MG

N050520 001

800MG

N050520 002 Sep 12, 1983

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

PFIZER

50,000 UNITS/VIAL

A060282 001

OINTMENT; OPHTHALMIC

BACIGUENT

PHARMACIA AND UPJOHN

500 UNITS/GM

A060734 001

BACITRACIN

LILLY

500 UNITS/GM

A060687 001

PHARMADERM

500 UNITS/GM

A062158 001

PHARMAFAIR

500 UNITS/GM

A062453 001 Mar 28, 1984

OINTMENT; TOPICAL

BACITRACIN

COMBE

500 UNITS/GM

A062799 001 May 14, 1987

NASKA

500 UNITS/GM

A062857 001 Nov 13, 1987

**DISCONTINUED DRUG PRODUCT LIST**BACITRACIN

POWDER;FOR RX COMPOUNDING

BACI-RX

X GEN PHARMS

5,000,000 UNITS/BOT

A061580 001

BACITRACIN

APOTHEKERNES

5,000,000 UNITS/BOT

A061699 001

PADDOCK LLC

5,000,000 UNITS/BOT

A062456 001 Jul 27, 1983

BACITRACIN ZINC

POWDER;FOR RX COMPOUNDING

ZIBA-RX

X GEN PHARMS

500,000 UNITS/BOT

A061737 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CORTISPORIN

CITRON PHARMA LLC

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050416 002

ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE &amp; HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062389 001 Jul 02, 1982

OINTMENT;TOPICAL

NEOMYCIN &amp; POLYMYXIN B SULFATES &amp; BACITRACIN ZINC &amp; HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062381 001 Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

LANABIOTIC

COMBE

400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM

A062499 001 Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR

400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062386 001 Sep 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM

400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062167 001

NEO-POLYICIN

DOW PHARM

500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A060647 001

NEOSPORIN

CITRON PHARMA LLC

400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050417 001

OINTMENT;TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

NASKA

400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062833 001 Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL

POLYSPORIN

GLAXOSMITHKLINE

10,000 UNITS/GM;2,000,000 UNITS/GM

N050167 002 Mar 01, 1985

OINTMENT;OPHTHALMIC

OCUMYCIN

PHARMAFAIR

500 UNITS/GM;10,000 UNITS/GM

A062430 001 Apr 08, 1983

POLYSPORIN

MONARCH PHARMS

500 UNITS/GM;10,000 UNITS/GM

A061229 001

OINTMENT;TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

NASKA

500 UNITS/GM;10,000 UNITS/GM

A062849 001 Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A060731 002

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MYCITRACIN

PHARMACIA AND UPJOHN

500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A061048 001

**DISCONTINUED DRUG PRODUCT LIST**BACITRACIN; POLYMYXIN B SULFATE

DISC;TOPICAL

LANABIOTIC

COMBE

500 UNITS/GM;5,000 UNITS/GM

N050598 001 Sep 22, 1986

BACLOFEN

TABLET;ORAL

BACLOFEN

TEVA

10MG

A073043 001 Feb 27, 1992

20MG

A073044 001 Feb 27, 1992

USL PHARMA

10MG

A071260 001 May 06, 1988

20MG

A071261 001 May 06, 1988

WATSON LABS

10MG

A073092 001 Jan 28, 1994

10MG

A074698 001 Aug 20, 1996

20MG

A073093 001 Jan 28, 1994

20MG

A074698 002 Aug 20, 1996

LIORESAL

NOVARTIS

10MG

N017851 001

20MG

N017851 003 Jan 20, 1982

TABLET, ORALLY DISINTEGRATING;ORAL

KEMSTRO

UCB INC

10MG

N021589 001 Oct 30, 2003

20MG

N021589 002 Oct 30, 2003

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

BECLOVENT

GLAXOSMITHKLINE

0.042MG/INH

N018153 001

VANCERIL

SCHERING

0.042MG/INH

N017573 001

VANCERIL DOUBLE STRENGTH

SCHERING

0.084MG/INH

N020486 001 Dec 24, 1996

AEROSOL, METERED;NASAL

BECONASE

GLAXOSMITHKLINE

0.042MG/INH

N018584 001

VANCENASE

SCHERING

0.042MG/INH

N018521 001

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL

VANCENASE AQ

SCHERING

EQ 0.042MG DIPROP/SPRAY

N019589 001 Dec 23, 1987

EQ 0.084MG DIPROP/SPRAY

N020469 001 Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

GENPHARM

5MG

A076476 001 Feb 11, 2004

10MG

A076476 002 Feb 11, 2004

20MG

A076476 003 Feb 11, 2004

40MG

A076476 004 Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MYLAN PHARMS INC

5MG;6.25MG

A076612 001 Feb 11, 2004

10MG;12.5MG

A076612 002 Feb 11, 2004

20MG;12.5MG

A076612 003 Feb 11, 2004

20MG;25MG

A076612 004 Feb 11, 2004

BENDROFLUMETHIAZIDE

TABLET;ORAL

NATURETIN-10

APOTHECON

10MG

N012164 003

NATURETIN-2.5

APOTHECON

2.5MG

N012164 001

NATURETIN-5

APOTHECON

5MG

N012164 002

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND

0.4%

A084149 001

## DISCONTINUED DRUG PRODUCT LIST

BENTIROMIDE

SOLUTION; ORAL

CHYMEX

SAVAGE LABS

500MG/7.5ML

N018366 001 Dec 29, 1983

BENZONATATE

CAPSULE; ORAL

BENZONATATE

NESHER PHARMS

100MG

A040795 001 Oct 31, 2007

200MG

A040795 002 Oct 31, 2007

TESSALON

PFIZER

200MG

N011210 003 Jun 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZAACLIN

VALEANT BERMUDA

5%;EQ 1% BASE

N050756 002 Apr 20, 2007

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

COREPHARMA

50MG

A040714 001 Oct 29, 2007

DIDREX

PHARMACIA AND UPJOHN

25MG

N012427 003

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

PFIZER

EQ 50MG BASE/VIAL

N016820 001

SUPPOSITORY; RECTAL

EMETE-CON

ROERIG

EQ 100MG BASE

N016818 006

BENZTHIAZIDE

TABLET; ORAL

AQUATAG

SOLVAY

25MG

N016001 001

50MG

N016001 002

BENZTHIAZIDE

PVT FORM

50MG

A083206 001

EXNA

AH ROBINS INC

50MG

N012489 001

FOVANE

PFIZER

50MG

N012128 002

URESE

PFIZER

25MG

N012128 003

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

LANNETT HOLDINGS INC

0.5MG

A088877 001 Apr 11, 1985

1MG

A088894 001 Apr 11, 1985

2MG

A088895 001 Apr 11, 1985

MUTUAL PHARM

1MG

A081264 001 Jan 23, 1992

2MG

A081265 001 Jan 23, 1992

PROSAM LABS

0.5MG

A040699 001 Feb 14, 2008

1MG

A040705 001 Feb 14, 2008

2MG

A040706 001 Feb 14, 2008

QUANTUM PHARMICS

0.5MG

A088514 001 Jan 31, 1984

1MG

A088510 001 Jan 31, 1984

2MG

A088511 001 Jan 31, 1984

USL PHARMA

0.5MG

A089211 001 Jun 14, 1988

1MG

A089212 001 Jun 14, 1988

2MG

A089213 001 Jun 14, 1988

COGENTIN

MERCK

0.5MG

N009193 004

1MG

N009193 003

2MG

N009193 002

BENZYL BENZOATE

EMULSION; TOPICAL

BENZYL BENZOATE

LANNETT

50%

A084535 001

## DISCONTINUED DRUG PRODUCT LIST

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

BEPADIN

MEDPOINTE PHARM HLC	200MG	N019001 001	Dec 28, 1990
	300MG	N019001 002	Dec 28, 1990
	400MG	N019001 003	Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON	200MG	N019002 001	Dec 28, 1990
	300MG	N019002 002	Dec 28, 1990
	400MG	N019002 003	Dec 28, 1990

BETA CAROTENE

CAPSULE; ORAL

SOLATENE

ROCHE	30MG	N017589 001	
-------	------	-------------	--

BETAMETHASONE

CREAM; TOPICAL

CELESTONE

SCHERING	0.2%	N014762 001	
----------	------	-------------	--

SYRUP; ORAL

CELESTONE

MERCK SHARP DOHME	0.6MG/5ML	N014215 002	
-------------------	-----------	-------------	--

TABLET; ORAL

CELESTONE

SCHERING	0.6MG	N012657 003	
----------	-------	-------------	--

BETAMETHASONE BENZOATE

CREAM; TOPICAL

UTICORT

PARKE DAVIS	0.025%	N016998 002	
-------------	--------	-------------	--

GEL; TOPICAL

UTICORT

PARKE DAVIS	0.025%	N017244 001	
-------------	--------	-------------	--

LOTION; TOPICAL

UTICORT

PARKE DAVIS	0.025%	N017528 001	
-------------	--------	-------------	--

OINTMENT; TOPICAL

UTICORT

PARKE DAVIS	0.025%	N018089 001	
-------------	--------	-------------	--

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

SAVAGE LABS	EQ 0.05% BASE	N019138 001	Jun 26, 1984
-------------	---------------	-------------	--------------

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK	EQ 0.05% BASE	A072536 001	Jan 31, 1990
	EQ 0.05% BASE	A074579 001	Nov 26, 1997
PHARMADERM	EQ 0.05% BASE	N019136 001	Jun 26, 1984
TARO	EQ 0.05% BASE	A071143 001	Jun 17, 1987
TEVA	EQ 0.05% BASE	A071476 001	Aug 10, 1987

DIPROSONE

SCHERING	EQ 0.05% BASE	N017536 001	
----------	---------------	-------------	--

CREAM, AUGMENTED; TOPICAL

DIPROLENE

SCHERING	EQ 0.05% BASE	N019408 001	Jan 31, 1986
----------	---------------	-------------	--------------

DISC; TOPICAL

DIPROSONE

SCHERING	EQ 0.1% BASE	N017829 001	
----------	--------------	-------------	--

GEL, AUGMENTED; TOPICAL

DIPROLENE

SCHERING	EQ 0.05% BASE	N019408 002	Nov 22, 1991
----------	---------------	-------------	--------------

LOTION; TOPICAL

ALPHATREX

SAVAGE LABS	EQ 0.05% BASE	A070273 001	Aug 12, 1985
-------------	---------------	-------------	--------------

BETAMETHASONE DIPROPIONATE

ALPHARMA US PHARMS	EQ 0.05% BASE	A071085 001	Feb 03, 1987
PHARMADERM	EQ 0.05% BASE	A070274 001	Aug 12, 1985
TARO	EQ 0.05% BASE	A072276 001	Aug 24, 1988
	EQ 0.05% BASE	A074272 001	Sep 30, 1994
TEVA PHARMS	EQ 0.05% BASE	A071882 001	Jun 06, 1988

DIPROSONE

SCHERING	EQ 0.05% BASE	N017781 001	
----------	---------------	-------------	--



## DISCONTINUED DRUG PRODUCT LIST

BETAMETHASONE DIPROPIONATE

## OINTMENT; TOPICAL

## ALPHATREX

SAVAGE LABS	EQ 0.05% BASE	N019143	001	Sep 04, 1984
-------------	---------------	---------	-----	--------------

## BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK	EQ 0.05% BASE	A072526	001	Jan 31, 1990
------------------	---------------	---------	-----	--------------

PHARMADERM	EQ 0.05% BASE	N019140	001	Sep 04, 1984
------------	---------------	---------	-----	--------------

TEVA	EQ 0.05% BASE	A071477	001	Aug 10, 1987
------	---------------	---------	-----	--------------

## DIPROSONE

SCHERING	EQ 0.05% BASE	N017691	001	
----------	---------------	---------	-----	--

BETAMETHASONE SODIUM PHOSPHATE

## INJECTABLE; INJECTION

## BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS	EQ 3MG BASE/ML	A085738	001	
-------------	----------------	---------	-----	--

## CELESTONE

SCHERING	EQ 3MG BASE/ML **Federal Register	N017561	001	
----------	-----------------------------------	---------	-----	--

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

BETAMETHASONE VALERATE

## CREAM; TOPICAL

## BETADERM

ROACO	EQ 0.1% BASE	N018839	001	Jun 30, 1983
-------	--------------	---------	-----	--------------

## BETAMETHASONE VALERATE

PERRIGO NEW YORK	EQ 0.1% BASE	A070053	001	Jun 10, 1986
------------------	--------------	---------	-----	--------------

PHARMADERM	EQ 0.1% BASE	N018860	002	Aug 31, 1983
------------	--------------	---------	-----	--------------

PHARMAFAIR	EQ 0.1% BASE	A070485	001	May 29, 1987
------------	--------------	---------	-----	--------------

TARO	EQ 0.1% BASE	A070062	001	May 14, 1985
------	--------------	---------	-----	--------------

## BETATREX

SAVAGE LABS	EQ 0.1% BASE	N018862	001	Aug 31, 1983
-------------	--------------	---------	-----	--------------

## VALISONE

SCHERING	EQ 0.01% BASE	N016322	002	
----------	---------------	---------	-----	--

	EQ 0.1% BASE	N016322	001	
--	--------------	---------	-----	--

## LOTION; TOPICAL

## BETAMETHASONE VALERATE

PHARMADERM	EQ 0.1% BASE	N018870	001	Aug 31, 1983
------------	--------------	---------	-----	--------------

PHARMAFAIR	EQ 0.1% BASE	A070484	001	May 29, 1987
------------	--------------	---------	-----	--------------

TEVA PHARMS	EQ 0.1% BASE	A071883	001	Apr 22, 1988
-------------	--------------	---------	-----	--------------

## BETATREX

SAVAGE LABS	EQ 0.1% BASE	N018867	001	Aug 31, 1983
-------------	--------------	---------	-----	--------------

## VALISONE

SCHERING	EQ 0.1% BASE	N016932	001	
----------	--------------	---------	-----	--

## OINTMENT; TOPICAL

## BETA-VAL

TEVA	EQ 0.1% BASE	A070069	001	Dec 19, 1985
------	--------------	---------	-----	--------------

## BETAMETHASONE VALERATE

PERRIGO NEW YORK	EQ 0.1% BASE	A071478	001	Dec 23, 1987
------------------	--------------	---------	-----	--------------

PHARMADERM	EQ 0.1% BASE	N018864	001	Aug 31, 1983
------------	--------------	---------	-----	--------------

PHARMAFAIR	EQ 0.1% BASE	A070486	001	May 29, 1987
------------	--------------	---------	-----	--------------

## BETATREX

SAVAGE LABS	EQ 0.1% BASE	N018863	001	Aug 31, 1983
-------------	--------------	---------	-----	--------------

## VALISONE

SCHERING	EQ 0.1% BASE	N016740	001	
----------	--------------	---------	-----	--

BETAXOLOL HYDROCHLORIDE

## SOLUTION/DROPS; OPHTHALMIC

## BETAXOLOL HYDROCHLORIDE

APOTEX INC	EQ 0.5% BASE	A075446	001	Sep 28, 2000
------------	--------------	---------	-----	--------------

## TABLET; ORAL

## KERLONE

SANOFI AVENTIS US	10MG	N019507	001	Oct 27, 1989
-------------------	------	---------	-----	--------------

	20MG	N019507	002	Oct 27, 1989
--	------	---------	-----	--------------

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

## TABLET; ORAL

## KERLEDEX

SANOFI AVENTIS US	5MG;12.5MG	N019807	001	Oct 30, 1992
-------------------	------------	---------	-----	--------------

	10MG;12.5MG	N019807	002	Oct 30, 1992
--	-------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC PILO

ALCON

EQ 0.25% BASE;1.75%

N020619 001 Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

LILLY

50MG/ML

N009344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

ODYSSEY PHARMS

5MG/ML \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N006536 001

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE

5MG

A040492 001 Jul 27, 2004

10MG

A040483 001 Jul 27, 2004

25MG

A040485 001 Jul 27, 2004

50MG

A040509 001 Jul 27, 2004

ACTAVIS ELIZABETH

5MG

A040552 001 Oct 28, 2004

10MG

A040553 001 Oct 28, 2004

25MG

A040554 001 Oct 28, 2004

50MG

A040551 001 Oct 28, 2004

ASCOT

10MG

A088288 001 Jun 08, 1983

25MG

A088289 001 Jun 08, 1983

IVAX SUB TEVA PHARMS

25MG

A084689 001

LANNETT

5MG

A084702 001

10MG

A084712 001

25MG

A084074 001

LANNETT HOLDINGS INC

5MG

A040703 001 Mar 27, 2008

50MG

A040677 001 Mar 27, 2008

SANDOZ

5MG

A084353 001

10MG

A084378 001

10MG

A084379 001

25MG

A084383 001

25MG

A084384 001

WATSON LABS

5MG

A084402 001

5MG

A085230 002

5MG

A085841 001

10MG

A084408 001

10MG

A085228 001

10MG

A085842 001

25MG

A084441 001

25MG

A085229 001

25MG

A085839 001

50MG

A087397 001

50MG

A087444 001

DUVOID

WELLSPRING PHARM

10MG

A086262 001

25MG

A086263 001

50MG

A085882 003

MYOTONACHOL

GLENWOOD

5MG

A084188 001

10MG

A084188 003

25MG

A084188 004

URECHOLINE

ODYSSEY PHARMS

5MG

N006536 003

10MG

N006536 002

25MG

N006536 004

50MG

N006536 005

BETHANIDINE SULFATE

TABLET; ORAL

TENATHAN

ROBINS AH

10MG

N017675 001

25MG

N017675 002

**DISCONTINUED DRUG PRODUCT LIST**BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

BANNER PHARMACAPS 75MG A203174 001 Aug 12, 2014

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

KUDCO IRELAND 50MG A077995 001 Jul 06, 2009

ROXANE 50MG A078285 001 Mar 24, 2011

SYNTHON PHARMS 50MG A077973 001 Jul 06, 2009

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

LUMIGAN

ALLERGAN 0.03% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\* N021275 001 Mar 16, 2001BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

ABBVIE 5MG/ML N012418 002

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

BRAINTREE 5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM  
; N/A, 5.6GM N021551 003 Jul 16, 2010BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

PROMETHEUS LABS 262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 5  
00MG N050719 001 Aug 15, 1996BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

MUTUAL PHARM 5MG A075474 001 Oct 25, 2002

10MG A075474 002 Oct 25, 2002

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH 2.5MG; 6.25MG A075672 001 Sep 25, 2000

5MG; 6.25MG A075672 002 Sep 25, 2000

10MG; 6.25MG A075672 003 Sep 25, 2000

APOTHECON 2.5MG; 6.25MG A075642 002 Dec 27, 2000

5MG; 6.25MG A075642 001 Dec 27, 2000

10MG; 6.25MG A075642 003 Dec 27, 2000

IVAX SUB TEVA PHARMS 2.5MG; 6.25MG A075632 001 Sep 27, 2000

5MG; 6.25MG A075632 002 Sep 27, 2000

10MG; 6.25MG A075632 003 Sep 27, 2000

SANDOZ 2.5MG; 6.25MG A075527 001 Sep 25, 2000

5MG; 6.25MG A075527 003 Sep 25, 2000

10MG; 6.25MG A075527 002 Sep 25, 2000

TEVA 2.5MG; 6.25MG A075686 001 Jan 19, 2001

5MG; 6.25MG A075686 002 Jan 19, 2001

10MG; 6.25MG A075686 003 Jan 19, 2001

WATSON LABS 2.5MG; 6.25MG A075469 001 Sep 25, 2000

5MG; 6.25MG A075469 002 Sep 25, 2000

10MG; 6.25MG A075469 003 Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

SANOFI AVENTIS US 0.37MG/INH N018770 001 Dec 28, 1984

SOLUTION; INHALATION

TORNALATE

SANOFI AVENTIS US 0.2% N019548 001 Feb 19, 1992

## DISCONTINUED DRUG PRODUCT LIST

BLEOMYCIN SULFATE

## INJECTABLE; INJECTION

## BLENOXANE

BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL	N050443	001	
	EQ 30 UNITS BASE/VIAL	N050443	002	Sep 07, 1995

## BLEOMYCIN SULFATE

PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007
TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084	001	Jun 01, 1996
	EQ 30 UNITS BASE/VIAL	A064084	002	Jun 01, 1996

BRETYLIUM TOSYLATE

## INJECTABLE; INJECTION

## BRETYLIUM TOSYLATE

ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
	100MG/ML	A071298	001	Feb 13, 1987
ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
	50MG/ML	A071152	001	Aug 10, 1987
	50MG/ML	A071153	001	Aug 10, 1987
HIKMA MAPLE	50MG/ML	A070545	001	May 14, 1986
	50MG/ML	A070546	001	May 14, 1986
HOSPIRA	50MG/ML	N019030	001	Apr 29, 1986
	50MG/ML	N019033	001	Apr 29, 1986
INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988

## BRETYLIUM TOSYLATE IN DEXTROSE 5%

ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
	400MG/100ML	N019005	003	Apr 29, 1986
	800MG/100ML	N019005	001	Apr 29, 1986

## BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
	400MG/100ML	N019837	001	Apr 12, 1989
HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
	400MG/100ML	N019008	003	Apr 29, 1986
	800MG/100ML	N019008	001	Apr 29, 1986

## BRETYLOL

HOSPIRA	50MG/ML	N017954	001	
---------	---------	---------	-----	--

BRIMONIDINE TARTRATE

## SOLUTION/DROPS; OPHTHALMIC

## ALPHAGAN

ALLERGAN	0.2%	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997

## BRIMONIDINE TARTRATE

TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004
-----------------	------	---------	-----	--------------

BROMFENAC SODIUM

## SOLUTION/DROPS; OPHTHALMIC

## XIBROM

BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005
---------------------	---------------	---------	-----	--------------

BROMOCRIPTINE MESYLATE

## CAPSULE; ORAL

## BROMOCRIPTINE MESYLATE

LEK PHARM	EQ 5MG BASE	A075100	001	Dec 10, 1998
-----------	-------------	---------	-----	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE

## CAPSULE; ORAL

## AMBODRYL

PARKE DAVIS	25MG	N007984	001	
-------------	------	---------	-----	--

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

## SYRUP; ORAL

## AMBENYL

FOREST LABS	12.5MG/5ML; 10MG/5ML	N009319	006	Jan 10, 1984
-------------	----------------------	---------	-----	--------------

## BROMANYL

ALPHARMA US PHARMS	12.5MG/5ML; 10MG/5ML	A088343	001	Aug 15, 1984
--------------------	----------------------	---------	-----	--------------

## BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT	12.5MG/5ML; 10MG/5ML	A088626	001	Oct 12, 1984
-----------	----------------------	---------	-----	--------------

BROMPHENIRAMINE MALEATE

## ELIXIR; ORAL

## BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS	2MG/5ML	A086936	001	
KV PHARM	2MG/5ML	A085466	001	
PHARM ASSOC	2MG/5ML	A087517	001	
USL PHARMA	2MG/5ML	A087964	001	Jan 25, 1983

**DISCONTINUED DRUG PRODUCT LIST**BROMPHENIRAMINE MALEATE

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS

10MG/ML

A083821 001

100MG/ML

A083820 001

DIMETANE-TEN

WYETH AYERST

10MG/ML

N011418 002

TABLET; ORAL

BROMPHENIRAMINE MALEATE

BARR

4MG

A084468 001

IVAX SUB TEVA PHARMS

4MG

A084351 001

NEWTRON PHARMS

4MG

A086987 001

NEXGEN PHARMA INC

4MG

A086187 001

PAR PHARM

4MG

A087009 001

PIONEER PHARMS

4MG

A088604 001 Jul 13, 1984

SANDOZ

4MG

A083215 001

VITARINE

4MG

A085850 001

WATSON LABS

4MG

A083123 001

4MG

A085769 001

DIMETANE

WYETH CONS

4MG

N010799 003

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS

8MG

N010799 010 Jun 10, 1983

12MG

N010799 011 Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

ALPHARMA US PHARMS

2MG/5ML; 10MG/5ML; 30MG/5ML

A088722 001 Mar 07, 1985

BROMFED-DM

WOCKHARDT

2MG/5ML; 10MG/5ML; 30MG/5ML

A089681 001 Dec 22, 1988

DIMETANE-DX

ROBINS AH

2MG/5ML; 10MG/5ML; 30MG/5ML

N019279 001 Aug 24, 1984

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA

16MG; 240MG

N019672 001 Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S

STUART PHARMS

50MG

N010911 006

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

ASTRAZENECA

0.032MG/INH

N020233 001 Feb 14, 1994

POWDER, METERED; INHALATION

PULMICORT

ASTRAZENECA

0.16MG/INH

N020441 002 Jun 24, 1997

0.32MG/INH

N020441 003 Jun 24, 1997

SPRAY, METERED; NASAL

RHINOCORT

ASTRAZENECA PHARMS

0.064MG/INH

N020746 002 Oct 01, 1999

SUSPENSION; INHALATION

BUDESONIDE

APOTEX INC

0.25MG/2ML

A078202 001 Mar 30, 2009

0.5MG/2ML

A078202 002 Mar 30, 2009

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

HOSPIRA

0.25MG/ML

A074160 001 Oct 30, 1997

TEVA PARENTERAL

0.25MG/ML

A074613 001 Nov 18, 1997

BUMEX

VALIDUS PHARMS INC

0.25MG/ML

N018226 001 Feb 28, 1983

TABLET; ORAL

BUMEX

VALIDUS PHARMS INC

0.5MG

N018225 002 Feb 28, 1983

1MG

N018225 001 Feb 28, 1983

2MG

N018225 003 Jun 14, 1985

**DISCONTINUED DRUG PRODUCT LIST**BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

PACIRA PHARMS INC 133MG/10ML (13.3MG/ML) N022496 001 Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

HOSPIRA 0.75% A070587 001 Mar 03, 1987

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA 0.075% N019978 001 Sep 03, 1992

0.114% N019978 002 Sep 03, 1992

0.23% N019978 003 Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED 0.25% A076012 001 Jan 09, 2002

0.5% A076012 002 Jan 09, 2002

0.75% A076012 003 Jan 09, 2002

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA 0.25%; 0.005MG/ML A071166 001 Jun 16, 1988

0.5%; 0.005MG/ML A071169 001 Jun 16, 1988

0.75%; 0.005MG/ML A071171 001 Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

AMPHASTAR PHARMS INC EQ 0.375% (37.5MG/10ML); EQ 1% N021496 001 May 23, 2003

(100MG/10ML)

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBUTEX

RECKITT BENCKISER EQ 2MG BASE N020732 002 Oct 08, 2002

EQ 8MG BASE N020732 003 Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER EQ 2MG BASE; EQ 0.5MG BASE N020733 001 Oct 08, 2002

EQ 8MG BASE; EQ 2MG BASE N020733 002 Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ 75MG A075613 002 Oct 10, 2000

100MG A075613 001 Oct 10, 2000

TEVA 75MG A075310 001 Nov 29, 1999

100MG A075310 002 Nov 29, 1999

WELLBUTRIN

GLAXOSMITHKLINE 50MG N018644 001 Dec 30, 1985

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

ACTAVIS LABS FL INC 300MG A077715 002 Jun 13, 2007

IMPAX LABS 300MG A077415 002 Dec 15, 2006

SANDOZ 100MG A076845 001 Jul 14, 2005

150MG A076834 001 Jul 14, 2005

150MG A076845 002 Jul 14, 2005

WELLBUTRIN SR

GLAXOSMITHKLINE 50MG N020358 001 Oct 04, 1996

ZYBAN

GLAXOSMITHKLINE 100MG N020711 002 May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

BRISTOL MYERS SQUIBB 5MG N021190 001 Dec 20, 2000

7.5MG N021190 002 Dec 20, 2000

10MG N021190 003 Dec 20, 2000

15MG N021190 004 Dec 20, 2000

TABLET; ORAL

BUSPAR

BRISTOL MYERS SQUIBB 5MG N018731 001 Sep 29, 1986

10MG N018731 002 Sep 29, 1986

15MG N018731 003 Apr 22, 1996

## DISCONTINUED DRUG PRODUCT LIST

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

	30MG	N018731 004	Apr 22, 1996
BUSPIRONE HYDROCHLORIDE			
APOTEX	5MG	A075521 001	Apr 05, 2002
	10MG	A075521 002	Apr 05, 2002
	15MG	A075521 003	Apr 05, 2002
EGIS	5MG	A075119 001	Mar 14, 2002
	10MG	A075119 002	Mar 14, 2002
	15MG	A075119 003	Jan 23, 2003
IVAX SUB TEVA PHARMS	5MG	A075385 001	Mar 01, 2002
	10MG	A075385 002	Mar 01, 2002
	15MG	A075385 003	Mar 01, 2002
NESHER PHARMS	5MG	A075572 001	Feb 27, 2002
	10MG	A075572 002	Feb 27, 2002
	15MG	A075572 003	Feb 27, 2002
PROSAM LABS	5MG	A075388 001	May 09, 2002
	10MG	A075388 002	May 09, 2002
	15MG	A075388 003	May 09, 2002
SANDOZ	5MG	A075413 001	Mar 19, 2002
	10MG	A075413 002	Mar 19, 2002
	15MG	A075413 003	Mar 19, 2002

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS

MEDPOINTE PHARM HLC	15MG	A085381 001	
	30MG	A085381 002	
	50MG	A085381 003	
	100MG	A085381 004	

ELIXIR; ORAL

BUTABARB

ALPHARMA US PHARMS	30MG/5ML	A085873 001	
--------------------	----------	-------------	--

BUTABARBITAL SODIUM

WOCKHARDT	30MG/5ML	A085383 001	
-----------	----------	-------------	--

BUTALAN

LANNETT	33.3MG/5ML	A085880 001	
---------	------------	-------------	--

SARISOL

HALSEY	30MG/5ML	A084723 001	
--------	----------	-------------	--

TABLET; ORAL

BUTABARBITAL

BUNDY	30MG	A085550 001	
-------	------	-------------	--

BUTABARBITAL SODIUM

SANDOZ	15MG	A084292 003	Feb 09, 1982
--------	------	-------------	--------------

	15MG	A085938 001	
--	------	-------------	--

	30MG	A084272 002	
--	------	-------------	--

	30MG	A085934 001	
--	------	-------------	--

SOLVAY	16.2MG	A083606 001	
--------	--------	-------------	--

	32.4MG	A083898 001	
--	--------	-------------	--

	48.6MG	A083897 001	
--	--------	-------------	--

	97.2MG	A083896 001	
--	--------	-------------	--

TEVA	15MG	A088632 001	May 18, 1985
------	------	-------------	--------------

	30MG	A088631 001	May 01, 1985
--	------	-------------	--------------

WATSON LABS	15MG	A085764 001	
-------------	------	-------------	--

	30MG	A085772 001	
--	------	-------------	--

WHITEWORTH TOWN PLSN	15MG	A083325 002	
----------------------	------	-------------	--

	30MG	A083337 001	
--	------	-------------	--

BUTISOL SODIUM

MEDA PHARMS	15MG	N000793 002	
-------------	------	-------------	--

	100MG	N000793 005	
--	-------	-------------	--

SARISOL NO. 1

HALSEY	15MG	A084719 001	
--------	------	-------------	--

SARISOL NO. 2

HALSEY	30MG	A084719 002	
--------	------	-------------	--

SODIUM BUTABARBITAL

HIKMA PHARMS LLC	15MG	A085418 001	
------------------	------	-------------	--

	30MG	A085432 001	
--	------	-------------	--

IVAX SUB TEVA PHARMS	15MG	A083484 001	
----------------------	------	-------------	--

	30MG	A084040 001	
--	------	-------------	--

LANNETT	15MG	A085849 001	
---------	------	-------------	--

	30MG	A085866 001	
--	------	-------------	--

	100MG	A085881 001	
--	-------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

BUTABARBITAL SODIUM

TABLET; ORAL

SODIUM BUTABARBITAL

MARSHALL PHARMA

16.2MG

A083524 001

32.4MG

A083858 001

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX-TC

MYLAN

1%

N021408 001 Oct 17, 2002

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT

ROCHE PALO

2%

N019215 001 Nov 25, 1985

GYNAZOLE-1

ELAN PHARMA INTL LTD

2%

N019881 001 Feb 07, 1997

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO

100MG

N019359 001 Nov 25, 1985

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

APOTEX INC

2MG/ML

A075697 001 Oct 23, 2001

HIKMA FARMACEUTICA

2MG/ML

A078247 001 Apr 29, 2009

HOSPIRA

1MG/ML

A075342 001 Nov 04, 1999

1MG/ML

A075559 001 Mar 20, 2000

2MG/ML

A075342 002 Nov 04, 1999

2MG/ML

A075559 002 Mar 20, 2000

BUTORPHANOL TARTRATE PRESERVATIVE FREE

APOTEX INC

1MG/ML

A075695 001 Oct 23, 2001

HOSPIRA

2MG/ML

A075695 002 Oct 23, 2001

HOSPIRA

1MG/ML

A074620 001 Jan 22, 1997

1MG/ML

A075170 001 Sep 28, 1998

2MG/ML

A074620 002 Jan 22, 1997

2MG/ML

A075170 002 Sep 28, 1998

STADOL

APOTHECON

2MG/ML

N017857 004

STADOL PRESERVATIVE FREE

APOTHECON

1MG/ML

N017857 001

2MG/ML

N017857 002

SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB

1MG/SPRAY

N019890 001 Dec 12, 1991

CABERGOLINE

TABLET; ORAL

DOSTINEX

PHARMACIA AND UPJOHN

0.5MG

N020664 001 Dec 23, 1996

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

NOVARTIS

100MG; 2MG

N009000 002

TABLET; ORAL

CAFERGOT

NOVARTIS

100MG; 1MG

N006620 001

WIGRAINE

ORGANON USA INC

100MG; 1MG

A086562 001

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

ORGANON USA INC

0.02MG

N018312 001

0.05MG

N018312 002

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

LEO PHARMA AS

0.005%

N020273 001 Dec 29, 1993

SOLUTION; TOPICAL

DOVONEX

LEO PHARM

0.005% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy

N020611 001 Mar 03, 1997



**DISCONTINUED DRUG PRODUCT LIST**CALCIPOTRIENESOLUTION; TOPICAL  
DOVONEX

reasons\*\*

CALCITONIN HUMANINJECTABLE; INJECTION  
CIBACALCIN  
NOVARTIS

0.5MG/VIAL

N018470 001 Oct 31, 1986

CALCITONIN SALMONINJECTABLE; INJECTION  
CALCIMAR

SANOFI AVENTIS US

200 IU/ML  
400 IU/VIAL

N017769 001

N017497 001

CALCITONIN-SALMON

ASTRAZENECA

200 IU/ML

A073690 001 Apr 14, 1995

MIACALCIN

SEBELA IRELAND LTD

100 IU/ML

N017808 001 Jul 03, 1986

CALCITRIOLINJECTABLE; INJECTION  
CALCITRIOL

HOSPIRA

0.001MG/ML

A075816 001 Jan 16, 2004

0.002MG/ML

A075816 002 Jan 16, 2004

TEVA PARENTERAL

0.001MG/ML

A075823 001 Mar 31, 2003

0.002MG/ML

A075823 002 Mar 31, 2003

CALCIUM ACETATECAPSULE; ORAL  
PHOSLO

FRESENIUS MEDCL

EQ 84.5MG CALCIUM

N021160 001 Apr 02, 2001

EQ 169MG CALCIUM

N021160 002 Apr 02, 2001

TABLET; ORAL

CALCIUM ACETATE

ROXANE

EQ 169MG CALCIUM

A077693 001 Jan 30, 2008

PHOSLO

FRESENIUS MEDCL

EQ 169MG CALCIUM

N019976 001 Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET; ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

WARNER CHILCOTT

EQ 500MG BASE, N/A; N/A, 35MG \*\*Federal  
Register determination that product was  
not discontinued or withdrawn for  
safety or efficacy reasons\*\*

N021823 001 Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML;  
3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML;  
7.07GM/1000ML

N021703 012 Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML;  
0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 005 Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML;  
2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML;  
6.46GM/1000ML

N021703 008 Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML;  
N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 007 Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML;  
0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 009 Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML;  
330MG/100ML; 88MG/100ML

N018271 001

**DISCONTINUED DRUG PRODUCT LIST**CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

## INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019867 001	Dec 20, 1993
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N018269 002	Jan 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER			
B BRAUN	29MG/100ML; 2.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 006	Jan 29, 1986
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER			
B BRAUN	29MG/100ML; 1.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 001	
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER			
B BRAUN	29MG/100ML; 4.25GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER			
B BRAUN	26MG/100ML; 1.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460 002	
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER			
B BRAUN	26MG/100ML; 5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460 008	Jan 29, 1986
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER			
B BRAUN	26MG/100ML; 4.25GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460 004	
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER			
FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374 001	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER			
FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374 002	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER			
FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374 003	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER			
FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374 004	Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER			
B BRAUN	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N018256 001	
BAXTER HLTHCARE	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N016695 001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER			
B BRAUN	4MG/100ML; 4GM/100ML; 6MG/100ML; 120MG/100ML; 62MG/100ML	N019634 002	Feb 24, 1988
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER			
B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017510 001	
MILES	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018499 001	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
HOSPIRA	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 005	Oct 17, 1988
HOSPIRA	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685 006	Oct 17, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
HOSPIRA	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 007	Oct 17, 1988
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
HOSPIRA	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 003	Oct 17, 1988

**DISCONTINUED DRUG PRODUCT LIST**CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 001	Oct 17, 1988
---------	--------------------------------------------------------------	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 538MG/100ML; 448MG/100ML	N019395 001	Mar 26, 1986
-----------------	-----------------------------------------------------	-------------	--------------

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 538MG/100ML; 448MG/100ML	N019395 002	Mar 26, 1986
-----------------	-----------------------------------------------------	-------------	--------------

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 538MG/100ML; 448MG/100ML	N019395 003	Mar 26, 1986
-----------------	------------------------------------------------------	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML	N019399 001	Jun 16, 1986
--------	------------------------------------------------------	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N018899 001	Oct 31, 1983
---------	--------------------------------------------------------------------------	-------------	--------------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	N018725 001	Nov 29, 1982
---------	--------------------------------------------------	-------------	--------------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML; 30MG/100ML; 860MG/100ML	N018721 001	Nov 09, 1982
---------	-------------------------------------	-------------	--------------

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

ABBOTT	33MG/100ML; 30MG/100ML; 860MG/100ML	N018462 001	
--------	-------------------------------------	-------------	--

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019485 001	Oct 24, 1985
--------	--------------------------------------------------	-------------	--------------

B BRAUN	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018023 001	
---------	--------------------------------------------------	-------------	--

MILES	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018417 001	
-------	--------------------------------------------------	-------------	--

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

ABBOTT	EQ 90MG CALCIUM/5ML	A080001 001	
--------	---------------------	-------------	--

	EQ 90MG CALCIUM/5ML	A083159 001	
--	---------------------	-------------	--

ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373 001	Apr 30, 1987
---------------	---------------------	-------------	--------------

LILLY	EQ 90MG CALCIUM/5ML	N006470 001	
-------	---------------------	-------------	--

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION

ISOPAQUE 440

GE HEALTHCARE	0.78MG/ML; 75.9MG/ML; 0.15MG/ML; 16.6MG/ML	N016847 001	
---------------	--------------------------------------------	-------------	--

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION

ISOPAQUE 280

GE HEALTHCARE	0.35MG/ML; 140.1MG/ML; 461.8MG/ML	N017506 001	
---------------	-----------------------------------	-------------	--

CANDICIDIN

OINTMENT; VAGINAL

VANOBIID

SANOFI AVENTIS US	0.6MG/GM	A061596 001	
-------------------	----------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

CANDICIDIN

TABLET;VAGINAL

VANOBI

SANOFI AVENTIS US 3MG A061613 001

CAPTOPRIL

TABLET;ORAL

CAPOTEN

PAR PHARM	37.5MG	N018343 006	Sep 17, 1986
	75MG	N018343 007	Jun 13, 1995
	150MG	N018343 004	Jun 13, 1995

CAPTOPRIL

APOTHECON	12.5MG	A074472 001	Mar 31, 1995
	25MG	A074472 002	Mar 31, 1995
	50MG	A074472 003	Mar 31, 1995
	100MG	A074472 004	Mar 31, 1995
DAVA PHARMS INC	12.5MG	A074423 001	Feb 13, 1996
	25MG	A074423 002	Feb 13, 1996
	50MG	A074423 003	Feb 13, 1996
	100MG	A074423 004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748 004	May 29, 1997
	25MG	A074748 002	May 29, 1997
	50MG	A074748 001	May 29, 1997
	100MG	A074748 003	May 29, 1997
IVAX SUB TEVA PHARMS	12.5MG	A074590 004	Aug 30, 1996
	25MG	A074590 002	Aug 30, 1996
	50MG	A074590 001	Aug 30, 1996
	100MG	A074590 003	Aug 30, 1996
PAR PHARM	12.5MG	A074493 001	Feb 13, 1996
	25MG	A074493 002	Feb 13, 1996
	50MG	A074493 003	Feb 13, 1996
	100MG	A074493 004	Feb 13, 1996
PRINSTON INC	12.5MG	A074477 001	Feb 13, 1996
	25MG	A074477 002	Feb 13, 1996
	50MG	A074477 003	Feb 13, 1996
	100MG	A074477 004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640 001	Mar 31, 1997
	25MG	A074640 002	Mar 31, 1997
	50MG	A074640 003	Mar 31, 1997
	100MG	A074640 004	Mar 31, 1997
SANDOZ	12.5MG	A074481 001	Feb 13, 1996
	12.5MG	A074519 001	Feb 13, 1996
	25MG	A074481 002	Feb 13, 1996
	25MG	A074519 002	Feb 13, 1996
	50MG	A074481 003	Feb 13, 1996
	50MG	A074519 003	Feb 13, 1996
	100MG	A074481 004	Feb 13, 1996
	100MG	A074519 004	Feb 13, 1996
TEVA	12.5MG	A074433 001	Feb 13, 1996
	12.5MG	A074483 001	Feb 13, 1996
	25MG	A074433 002	Feb 13, 1996
	25MG	A074483 002	Feb 13, 1996
	50MG	A074433 003	Feb 13, 1996
	50MG	A074483 003	Feb 13, 1996
	100MG	A074433 004	Feb 13, 1996
	100MG	A074483 004	Feb 13, 1996
TEVA PHARMS	12.5MG	A074462 001	Feb 13, 1996
	25MG	A074462 002	Feb 13, 1996
	50MG	A074462 003	Feb 13, 1996
	100MG	A074462 004	Feb 13, 1996
VINTAGE PHARMS LLC	12.5MG	A074418 001	Feb 13, 1996
	25MG	A074418 002	Feb 13, 1996
	50MG	A074418 003	Feb 13, 1996
	100MG	A074418 004	Feb 13, 1996
WATSON LABS	12.5MG	A074451 001	Feb 13, 1996
	12.5MG	A074576 001	Apr 23, 1996
	25MG	A074451 002	Feb 13, 1996
	25MG	A074576 002	Apr 23, 1996
	50MG	A074451 003	Feb 13, 1996
	50MG	A074576 003	Apr 23, 1996
	100MG	A074451 004	Feb 13, 1996
	100MG	A074576 004	Apr 23, 1996

**DISCONTINUED DRUG PRODUCT LIST**CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

APOTHECON

25MG;15MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N018709 001 Oct 12, 1984

CAPOZIDE 25/25

APOTHECON

25MG;25MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N018709 002 Oct 12, 1984

CAPOZIDE 50/15

APOTHECON

50MG;15MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N018709 004 Oct 12, 1984

CAPOZIDE 50/25

APOTHECON

50MG;25MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N018709 003 Oct 12, 1984

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS

25MG;15MG

A075055 001 Jun 18, 1998

25MG;25MG

A075055 002 Jun 18, 1998

50MG;15MG

A075055 004 Jun 18, 1998

50MG;25MG

A075055 003 Jun 18, 1998

VINTAGE PHARMS LLC

25MG;15MG

A074788 001 Dec 29, 1997

25MG;25MG

A074788 002 Dec 29, 1997

50MG;15MG

A074788 004 Dec 29, 1997

50MG;25MG

A074788 003 Dec 29, 1997

WATSON LABS

50MG;25MG

A074832 001 Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL

PHARMAFAIR

0.01%

A070292 001 May 21, 1986

CARBASTAT

NOVARTIS

0.01%

A073677 001 Apr 28, 1995

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

TARO

100MG/5ML

A075875 001 Dec 21, 2000

TABLET; ORAL

CARBAMAZEPINE

ACTAVIS ELIZABETH

200MG

A071696 001 Nov 09, 1987

INWOOD LABS

200MG

A070231 001 Aug 14, 1986

PLIVA

200MG

A071479 001 Jul 24, 1987

USL PHARMA

200MG

A070300 001 May 15, 1986

WARNER CHILCOTT

200MG

A070429 001 Jan 02, 1987

TERIL

TARO

200MG

A076525 001 Sep 26, 2003

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

JUBILANT CADISTA

100MG

A071940 001 Feb 01, 1988

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

ROERIG

EQ 1GM BASE/VIAL

N050306 001

EQ 2GM BASE/VIAL

N050306 004

EQ 5GM BASE/VIAL

N050306 002

EQ 10GM BASE/VIAL

N050306 006

EQ 30GM BASE/VIAL

N050306 007

PYOPEN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N050298 001

EQ 2GM BASE/VIAL

N050298 002

EQ 5GM BASE/VIAL

N050298 003

EQ 10GM BASE/VIAL

N050298 006

EQ 20GM BASE/VIAL

N050298 007

## DISCONTINUED DRUG PRODUCT LIST

CARBENICILLIN INDANYL SODIUM

TABLET;ORAL

GEOCILLIN

PFIZER

EQ 382MG BASE

N050435 001

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

SANDOZ

10MG;100MG

A073586 001 Jun 29, 1995

25MG;100MG

A073587 001 Jun 29, 1995

25MG;250MG

A073620 001 Jun 29, 1995

SCS

10MG;100MG

A074080 001 Mar 25, 1994

25MG;100MG

A074080 002 Mar 25, 1994

25MG;250MG

A074080 003 Mar 25, 1994

WATSON LABS

10MG;100MG

A073381 001 Sep 28, 1993

25MG;100MG

A073382 001 Sep 28, 1993

25MG;250MG

A073383 001 Sep 28, 1993

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

KV PHARM

50MG;200MG

A076663 001 Jun 24, 2004

TABLET, FOR SUSPENSION;ORAL

CARBILEV

RANBAXY

10MG;100MG

A076643 001 Jun 10, 2005

25MG;100MG

A076643 002 Jun 10, 2005

25MG;250MG

A076643 003 Jun 10, 2005

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

IMPAX LABS

10MG;100MG

A090631 001 Jun 08, 2010

25MG;100MG

A090631 002 Jun 08, 2010

25MG;250MG

A090631 003 Jun 08, 2010

PARCOPA

UCB INC

10MG;100MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

A076699 001 Aug 27, 2004

25MG;100MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

A076699 002 Aug 27, 2004

25MG;250MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

A076699 003 Aug 27, 2004

CARBINOXAMINE MALEATE

ELIXIR;ORAL

CLISTIN

MCNEIL

4MG/5ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N008955 001

TABLET;ORAL

CLISTIN

ORTHO MCNEIL PHARM

4MG

N008915 001

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

CIPLA LTD

50MG/VIAL

A077383 001 Jan 27, 2006

150MG/VIAL

A077383 002 Jan 27, 2006

450MG/VIAL

A077383 003 Jan 27, 2006

EUROHLTH INTL

50MG/VIAL

A076099 001 Oct 14, 2004

150MG/VIAL

A076099 002 Oct 14, 2004

450MG/VIAL

A076099 003 Oct 14, 2004

FRESENIUS KABI USA

50MG/VIAL

A076235 001 Oct 14, 2004

150MG/VIAL

A076235 002 Oct 14, 2004

450MG/VIAL

A076235 003 Oct 14, 2004

HOSPIRA

50MG/VIAL

A076473 001 Oct 27, 2004

150MG/VIAL

A076473 002 Oct 27, 2004

450MG/VIAL

A076473 003 Oct 27, 2004

ONCO THERAPIES LTD

50MG/VIAL

A091510 001 May 29, 2012

150MG/VIAL

A091510 002 May 29, 2012

450MG/VIAL

A091510 003 May 29, 2012

PLIVA

50MG/VIAL

A076602 001 Nov 16, 2004

150MG/VIAL

A076602 002 Nov 16, 2004

## DISCONTINUED DRUG PRODUCT LIST

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

	450MG/VIAL	A076602 003	Nov 16, 2004
SANDOZ	50MG/VIAL	A076959 001	Mar 18, 2005
	150MG/VIAL	A076959 002	Mar 18, 2005
	450MG/VIAL	A076959 003	Mar 18, 2005
WATSON LABS	50MG/VIAL	A076162 001	Oct 14, 2004
	150MG/VIAL	A076162 002	Oct 14, 2004
	450MG/VIAL	A076162 003	Oct 14, 2004
PARAPLATIN			
CORDEN PHARMA	50MG/VIAL	N019880 001	Mar 03, 1989
	150MG/VIAL	N019880 002	Mar 03, 1989
	450MG/VIAL	N019880 003	Mar 03, 1989

INJECTABLE; IV (INFUSION)

CARBOPLATIN

FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077247 001	Oct 21, 2004
	50MG/5ML (10MG/ML)	A077266 001	Feb 15, 2006
	150MG/15ML (10MG/ML)	A077247 002	Oct 21, 2004
	150MG/15ML (10MG/ML)	A077266 002	Feb 15, 2006
PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679 001	Feb 25, 2009
	150MG/15ML (10MG/ML)	A077679 002	Feb 25, 2009
	450MG/45ML (10MG/ML)	A077679 003	Feb 25, 2009
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389 001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389 002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389 003	Mar 30, 2007
PARAPLATIN			
CORDENPHARMA	50MG/5ML (10MG/ML)	N020452 001	Jul 14, 2003
	150MG/15ML (10MG/ML)	N020452 002	Jul 14, 2003
	450MG/45ML (10MG/ML)	N020452 003	Jul 14, 2003
	600MG/60ML (10MG/ML)	N020452 004	Jan 15, 2004

CARISOPRODOL

CAPSULE; ORAL

SOMA

MEDA PHARMS	250MG	N011792 003	
-------------	-------	-------------	--

TABLET; ORAL

CARISOPRODOL

ABLE	350MG	A040421 001	Jun 21, 2001
COREPHARMA	350MG	A040397 001	Sep 21, 2000
HIKMA INTL PHARMS	350MG	A040124 001	Jan 24, 1996
PIONEER PHARMS	350MG	A089390 001	Oct 13, 1988
PROSAM LABS	350MG	A040188 001	Mar 07, 1997
SANDOZ	350MG	A081025 001	Apr 13, 1989
	350MG	A089566 001	Aug 30, 1988
WATSON LABS	350MG	A040152 001	Dec 03, 1996
	350MG	A085433 001	
	350MG	A086179 001	

RELA

SCHERING	350MG	N012155 001	
----------	-------	-------------	--

CARPENAZINE MALEATE

CONCENTRATE; ORAL

PROKETAZINE

WYETH AYERST	50MG/ML	N014173 001	
--------------	---------	-------------	--

TABLET; ORAL

PROKETAZINE

WYETH AYERST	12.5MG	N012768 001	
	25MG	N012768 002	
	50MG	N012768 004	

CARPROFEN

TABLET; ORAL

RIMADYL

ROCHE	100MG	N018550 002	Dec 31, 1987
	150MG	N018550 003	Dec 31, 1987

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

APOTEX INC	1%	A076097 001	Feb 06, 2002
------------	----	-------------	--------------

TABLET; ORAL

CARTROL

ABBVIE	2.5MG	N019204 001	Dec 28, 1988
--------	-------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

CARTEOLOL HYDROCHLORIDE

TABLET;ORAL

CARTROL

5MG	N019204	002	Dec 28, 1988
10MG	N019204	003	Dec 28, 1988

CARVEDILOL

TABLET;ORAL

CARVEDILOL

WOCKHARDT LTD	3.125MG	A078786	001	Dec 22, 2009
	6.25MG	A078786	002	Dec 22, 2009
	12.5MG	A078786	003	Dec 22, 2009
	25MG	A078786	004	Dec 22, 2009

CEFACTOR

CAPSULE;ORAL

CECLOR

LILLY	EQ 250MG BASE	N050521	001
	EQ 500MG BASE	N050521	002

CEFACTOR

CEPH INTL	EQ 250MG BASE	A062205	001	
	EQ 500MG BASE	A062205	002	
DAVA PHARMS INC	EQ 250MG BASE	A064107	001	Apr 27, 1995
	EQ 500MG BASE	A064107	002	Apr 27, 1995
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A064061	001	Apr 27, 1995
	EQ 500MG BASE	A064061	002	Apr 27, 1995
RANBAXY	EQ 250MG BASE	A064156	001	Aug 28, 1997
	EQ 500MG BASE	A064156	002	Aug 28, 1997
TEVA	EQ 250MG BASE	A064081	001	Sep 16, 1996
	EQ 250MG BASE	A064145	001	Jun 24, 1996
	EQ 500MG BASE	A064081	002	Sep 16, 1996
	EQ 500MG BASE	A064145	002	Jun 24, 1996
WATSON LABS INC	EQ 250MG BASE	A064148	001	May 23, 1996
	EQ 500MG BASE	A064148	002	May 23, 1996

FOR SUSPENSION;ORAL

CECLOR

LILLY	EQ 125MG BASE/5ML	N050522	001
	EQ 250MG BASE/5ML	N050522	002

CEFACTOR

DAVA PHARMS INC	EQ 125MG BASE/5ML	A064114	001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064115	001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064116	001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064110	001	Apr 28, 1995
FACTA FARMA	EQ 125MG BASE/5ML	A062206	001	
	EQ 187MG BASE/5ML	A062206	003	Apr 20, 1988
	EQ 250MG BASE/5ML	A062206	002	
	EQ 375MG BASE/5ML	A062206	004	Apr 20, 1988
IVAX SUB TEVA PHARMS	EQ 125MG BASE/5ML	A064087	001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064086	001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064085	001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064070	001	Apr 28, 1995
RANBAXY	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997
	EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997
	EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997
	EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997
WATSON LABS INC	EQ 125MG BASE/5ML	A064204	001	Feb 18, 1998
	EQ 187MG BASE/5ML	A064205	001	Feb 18, 1998
	EQ 250MG BASE/5ML	A064206	001	Feb 18, 1998
	EQ 375MG BASE/5ML	A064207	001	Feb 18, 1998

TABLET, CHEWABLE;ORAL

RANICLOR

RANBAXY LABS LTD	EQ 125MG BASE	A065092	001	Dec 22, 2003
	EQ 187MG BASE	A065092	002	Dec 22, 2003
	EQ 250MG BASE	A065092	003	Dec 22, 2003
	EQ 375MG BASE	A065092	004	Dec 22, 2003

TABLET, EXTENDED RELEASE;ORAL

CECLOR CD

LILLY	EQ 375MG BASE	N050673	001	Jun 28, 1996
	EQ 500MG BASE	N050673	002	Jun 28, 1996

CEFACTOR

WORLD GEN	EQ 500MG BASE	A065057	001	Jan 05, 2001
-----------	---------------	---------	-----	--------------



**DISCONTINUED DRUG PRODUCT LIST**CEFADROXIL/CEFADROXIL HEMIHYDRATE

## CAPSULE; ORAL

## CEFADROXIL

IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766 001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017 001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999
TEVA	EQ 500MG BASE	A062695 001	Feb 10, 1989

## DURICEF

WARNER CHILCOTT	EQ 250MG BASE	N050512 002	
	EQ 500MG BASE	N050512 001	

## ULTRACEF

BRISTOL	EQ 500MG BASE	A062378 001	Mar 16, 1982
---------	---------------	-------------	--------------

## FOR SUSPENSION; ORAL

## CEFADROXIL

ANI PHARMS INC	EQ 125MG BASE/5ML	A062698 001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698 002	Mar 01, 1989
	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006
	EQ 500MG BASE/5ML	A062698 003	Mar 01, 1989
	EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006
APOTHECON	EQ 125MG BASE/5ML	A062334 001	
	EQ 250MG BASE/5ML	A062334 002	
	EQ 500MG BASE/5ML	A062334 003	

## DURICEF

WARNER CHILCOTT	EQ 125MG BASE/5ML	N050527 002	
	EQ 250MG BASE/5ML	N050527 003	
	EQ 500MG BASE/5ML	N050527 001	

## ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	A062376 001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376 002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376 003	Mar 16, 1982

## TABLET; ORAL

## CEFADROXIL

RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999
---------	-------------	-------------	--------------

## DURICEF

WARNER CHILCOTT	EQ 1GM BASE	N050528 001	
-----------------	-------------	-------------	--

## ULTRACEF

APOTHECON	EQ 1GM BASE	A062390 001	Jun 10, 1982
BRISTOL	EQ 1GM BASE	A062408 001	Aug 31, 1982

CEFAMANDOLE NAFATE

## INJECTABLE; INJECTION

## MANDOL

LILLY	EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	N050504 002	
	EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
	EQ 2GM BASE/VIAL	N050504 003	
	EQ 10GM BASE/VIAL	N050504 004	
	EQ 500MG BASE/VIAL	N050504 001	

CEFAZOLIN SODIUM

## INJECTABLE; INJECTION

## ANCEF

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050461 003	
	EQ 5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 004	
	EQ 10GM BASE/VIAL	N050461 005	
	EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 001	
	EQ 500MG BASE/VIAL	N050461 002	

## ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 004	Jun 08, 1983

## ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 002	Jun 08, 1983

## CEFAZOLIN AND DEXTROSE

B BRAUN	EQ 500MG BASE/VIAL	N050779 001	Jul 27, 2000
---------	--------------------	-------------	--------------

## CEFAZOLIN SODIUM

ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062688 003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688 004	Nov 17, 1986

## DISCONTINUED DRUG PRODUCT LIST

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

	EQ 20GM BASE/VIAL	A062688 005	Aug 03, 1987
	EQ 500MG BASE/VIAL	A062688 002	Nov 17, 1986
AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065395 002	Aug 08, 2008
	EQ 500MG BASE/VIAL	A065395 001	Aug 08, 2008
BEDFORD	EQ 1GM BASE/VIAL	A062894 003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894 004	Jul 21, 1988
	EQ 10GM BASE/VIAL	A062894 005	Jul 21, 1988
	EQ 250MG BASE/VIAL	A062894 001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894 002	Jul 21, 1988
CEPHAZONE PHARMA	EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009
	EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009
	EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009
	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009
FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A064169 002	Aug 14, 1998
	EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998
	EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998
	EQ 500MG BASE/VIAL	A064169 001	Aug 14, 1998
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033 001	Oct 31, 1993
HIKMA MAPLE	EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988
	EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
	EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988
	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
STERI PHARMA	EQ 1GM BASE/VIAL	A063208 001	Dec 27, 1991
	EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991
TEVA PHARMS	EQ 1GM BASE/VIAL	A063016 003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018 001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018 002	Mar 05, 1990
	EQ 250MG BASE/VIAL	A063016 001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016 002	Mar 14, 1989
WATSON LABS INC	EQ 1GM BASE/VIAL	A062988 003	Dec 29, 1989
	EQ 5GM BASE/VIAL	A062989 001	Dec 29, 1989
	EQ 10GM BASE/VIAL	A062989 002	Dec 29, 1989
	EQ 20GM BASE/VIAL	A062989 003	Dec 29, 1989
	EQ 250MG BASE/VIAL	A062988 001	Dec 29, 1989
	EQ 500MG BASE/VIAL	A062988 002	Dec 29, 1989
KEFZOL			
ACS DOBFAR	EQ 20GM BASE/VIAL	A061773 005	Sep 08, 1987
	EQ 250MG BASE/VIAL	A061773 001	
LILLY	EQ 1GM BASE/VIAL	A062557 002	Sep 10, 1985
	EQ 500MG BASE/VIAL	A062557 001	Sep 10, 1985

CEFDINIR

CAPSULE; ORAL

OMNICEF

FOR SUSPENSION; ORAL

OMNICEF

ABBVIE

300MG N050739 001 Dec 04, 1997

ABBVIE

125MG/5ML

N050749 001 Dec 04, 1997

250MG/5ML

N050749 002 Jul 29, 2004

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

SANDOZ

EQ 1GM BASE/VIAL

A090291 002 Dec 21, 2010

EQ 2GM BASE/VIAL

A090291 003 Dec 21, 2010

EQ 500MG BASE/VIAL

A090291 001 Dec 21, 2010

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

LEDERLE

100MG/5ML

N050622 001 Apr 28, 1989

TABLET; ORAL

SUPRAX

LEDERLE

200MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N050621 001 Apr 28, 1989

400MG

N050621 002 Apr 28, 1989

## DISCONTINUED DRUG PRODUCT LIST

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFMAX

TAP PHARM

EQ 1GM BASE/VIAL

N050571 002 Dec 30, 1987

EQ 2GM BASE/VIAL

N050571 003 Dec 30, 1987

EQ 500MG BASE/VIAL

N050571 001 Dec 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL

N050637 001 Dec 11, 1989

EQ 2GM BASE/VIAL

N050637 002 Dec 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

PHARMACIA AND UPJOHN

EQ 20MG BASE/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N050683 001 Dec 29, 1992

EQ 40MG BASE/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N050683 002 Dec 29, 1992

CEFONICID SODIUM

INJECTABLE; INJECTION

MONOCID

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A063295 001 Jul 26, 1993

EQ 1GM BASE/VIAL

N050579 002 May 23, 1984

EQ 2GM BASE/VIAL

N050579 003 May 23, 1984

EQ 10GM BASE/VIAL

N050579 004 May 23, 1984

EQ 500MG BASE/VIAL

N050579 001 May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

PFIZER

EQ 1GM BASE/VIAL

A063333 001 Mar 31, 1995

EQ 1GM BASE/VIAL

N050551 001 Nov 18, 1982

EQ 2GM BASE/VIAL

A063333 002 Mar 31, 1995

EQ 2GM BASE/VIAL

N050551 002 Nov 18, 1982

EQ 10GM BASE/VIAL

N050551 003 Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER

EQ 20MG BASE/ML

N050613 002 Jul 31, 1987

EQ 40MG BASE/ML

N050613 001 Jul 23, 1986

CEFORANIDE

INJECTABLE; INJECTION

PRECEF

APOTHECON

1GM/VIAL

A062579 002 Nov 26, 1984

2GM/VIAL

A062579 003 Nov 26, 1984

10GM/VIAL

A062579 004 Nov 26, 1984

20GM/VIAL

A062579 005 Nov 26, 1984

500MG/VIAL

A062579 001 Nov 26, 1984

BRISTOL

1GM/VIAL

N050554 002 May 24, 1984

2GM/VIAL

N050554 003 May 24, 1984

10GM/VIAL

N050554 004 May 24, 1984

20GM/VIAL

N050554 005 May 24, 1984

500MG/VIAL

N050554 001 May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

FRESENIUS KABI USA

EQ 1GM BASE/VIAL

A064200 002 Mar 24, 2000

EQ 2GM BASE/VIAL

A064200 003 Mar 24, 2000

EQ 10GM BASE/VIAL

A064201 001 Mar 24, 2000

EQ 20GM BASE/VIAL

A064201 002 Mar 24, 2000

EQ 500MG BASE/VIAL

A064200 001 Mar 24, 2000

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

B BRAUN

EQ 2GM BASE

N050792 001 Jul 29, 2004

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

B BRAUN

EQ 1GM BASE

N050792 002 Jul 29, 2004

CEFOTAXIME SODIUM

AUROBINDO PHARMA

EQ 1GM BASE/VIAL

A065517 002 Nov 06, 2009

EQ 2GM BASE/VIAL

A065517 003 Nov 06, 2009

EQ 500MG BASE/VIAL

A065517 001 Nov 06, 2009

AUROBINDO PHARMA LTD

EQ 10GM BASE/VIAL

A065516 001 Nov 06, 2009

CEPHAZONE PHARMA

EQ 10GM BASE/VIAL

A065348 001 Jan 25, 2010

## DISCONTINUED DRUG PRODUCT LIST

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

SANOFI AVENTIS US

EQ 20MG BASE/ML

N050596 001 May 20, 1985

EQ 40MG BASE/ML

N050596 003 May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

ASTRAZENECA

EQ 1GM BASE/VIAL

A063293 001 Apr 29, 1993

EQ 1GM BASE/VIAL

N050588 001 Dec 27, 1985

EQ 2GM BASE/VIAL

A063293 002 Apr 29, 1993

EQ 2GM BASE/VIAL

N050588 002 Dec 27, 1985

EQ 10GM BASE/VIAL

N050588 003 Apr 25, 1988

CEFOTAN IN PLASTIC CONTAINER

ASTRAZENECA

EQ 20MG BASE/ML

N050694 002 Jul 30, 1993

EQ 40MG BASE/ML

N050694 001 Jul 30, 1993

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION

CERADON

TAKEDA

EQ 1GM BASE/VIAL

N050601 001 Dec 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

FRESENIUS KABI USA

EQ 1GM BASE/VIAL

A065012 001 Jul 03, 2000

EQ 2GM BASE/VIAL

A065012 002 Jul 03, 2000

EQ 10GM BASE/VIAL

A065011 001 Jul 03, 2000

MEFOXIN

MYLAN INSTITUTIONAL

EQ 1GM BASE/VIAL

A062757 001 Jan 08, 1987

EQ 1GM BASE/VIAL

N050517 001

EQ 2GM BASE/VIAL

A062757 002 Jan 08, 1987

EQ 2GM BASE/VIAL

N050517 002

EQ 10GM BASE/VIAL

N050517 003

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

MERCCK

EQ 20MG BASE/ML

N050581 003 Sep 20, 1984

EQ 40MG BASE/ML

N050581 004 Sep 20, 1984

MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MERCCK

EQ 20MG BASE/ML

N050581 002 Sep 20, 1984

EQ 40MG BASE/ML

N050581 001 Sep 20, 1984

CEFPYRAMIDE SODIUM

INJECTABLE; INJECTION

CEFPYRAMIDE SODIUM

WYETH AYERST

EQ 1GM BASE/VIAL

N050633 002 Jan 31, 1989

EQ 2GM BASE/VIAL

N050633 003 Jan 31, 1989

EQ 10GM BASE/VIAL

N050633 005 Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO

EQ 50MG BASE/5ML

N050688 002 Aug 07, 1992

EQ 100MG BASE/5ML

N050688 001 Aug 07, 1992

VANTIN

PHARMACIA AND UPJOHN

EQ 50MG BASE/5ML

N050675 001 Aug 07, 1992

EQ 100MG BASE/5ML

N050675 002 Aug 07, 1992

TABLET; ORAL

BANAN

SANKYO

EQ 100MG BASE

N050687 001 Aug 07, 1992

EQ 200MG BASE

N050687 002 Aug 07, 1992

VANTIN

PHARMACIA AND UPJOHN

EQ 100MG BASE

N050674 001 Aug 07, 1992

EQ 200MG BASE

N050674 002 Aug 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

RANBAXY LABS LTD

125MG/5ML

A065202 001 Jun 30, 2006

250MG/5ML

A065202 002 Jun 30, 2006

CEFZIL

CORDEN PHARMA

125MG/5ML

N050665 001 Dec 23, 1991

250MG/5ML

N050665 002 Dec 23, 1991

## DISCONTINUED DRUG PRODUCT LIST

CEFPROZIL

TABLET; ORAL

CEFPROZIL

RANBAXY LABS LTD	250MG	A065198	001	Dec 13, 2006
	500MG	A065198	002	Dec 13, 2006

CEFZIL

CORDEN PHARMA	250MG	N050664	001	Dec 23, 1991
	500MG	N050664	002	Dec 23, 1991

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AUROBINDO PHARMA LTD	1GM/VIAL	A065481	002	May 28, 2010
	2GM/VIAL	A065481	003	May 28, 2010
	6GM/VIAL	A065482	001	May 28, 2010
	500MG/VIAL	A065481	001	May 28, 2010

CEPTAZ

GLAXOSMITHKLINE	1GM/VIAL	N050646	002	Sep 27, 1990
	2GM/VIAL	N050646	003	Sep 27, 1990
	10GM/VIAL	N050646	004	Sep 27, 1990
	500MG/VIAL	N050646	001	Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE	1GM/VIAL	A063322	001	Nov 07, 1995
	1GM/VIAL	A064006	001	Mar 31, 1992
	2GM/VIAL	A063322	002	Nov 07, 1995
	2GM/VIAL	A064006	002	Mar 31, 1992
	6GM/VIAL	A064008	001	Mar 31, 1992
	10GM/VIAL	A064008	002	Mar 31, 1992

TAZIDIME

LILLY	1GM/VIAL	A062655	001	Nov 20, 1985
	2GM/VIAL	A062655	002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	A062739	001	Jul 10, 1986
	2GM/VIAL	A062739	002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221	001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221	002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221	003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

COVIS INJECTABLES	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989
-------------------	-----------------	---------	-----	--------------

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS	EQ 1GM BASE/VIAL	A063294	002	Mar 31, 1994
	EQ 1GM BASE/VIAL	N050560	002	Sep 15, 1983
	EQ 2GM BASE/VIAL	A063294	003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560	003	Sep 15, 1983
	EQ 10GM BASE/VIAL	N050560	005	Mar 19, 1993
	EQ 500MG BASE/VIAL	N050560	001	Sep 15, 1983

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589	001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589	002	Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589	003	Apr 13, 1995
	EQ 40MG BASE/ML	N050589	004	Apr 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504	001	Jul 31, 2008
FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065252	001	Feb 15, 2006
TEVA	EQ 10GM BASE/VIAL	A065274	001	May 01, 2006

ROCEPHIN

HOFFMANN LA ROCHE	EQ 1GM BASE/VIAL	A062654	002	Apr 30, 1987
	EQ 2GM BASE/VIAL	A062654	003	Apr 30, 1987
	EQ 10GM BASE/VIAL	N050585	005	Dec 21, 1984
	EQ 250MG BASE/VIAL	A063239	001	Aug 13, 1993
	EQ 500MG BASE/VIAL	A062654	001	Apr 30, 1987
ROCHE	EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985

**DISCONTINUED DRUG PRODUCT LIST**CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

ROCEPHIN

	EQ 250MG BASE/VIAL	A062510 001	Mar 12, 1985
	EQ 500MG BASE/VIAL	A062510 002	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER			
HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624 001	Feb 11, 1987
	EQ 20MG BASE/ML	N050624 002	Feb 11, 1987
	EQ 40MG BASE/ML	N050624 003	Feb 11, 1987
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS			
CEFTRIAXONE			
AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A065505 003	Jul 31, 2008
	EQ 2GM BASE/VIAL	A065505 004	Jul 31, 2008
	EQ 250MG BASE/VIAL	A065505 001	Jul 31, 2008
	EQ 500MG BASE/VIAL	A065505 002	Jul 31, 2008
CEPHAZONE PHARMA	EQ 1GM BASE/VIAL	A065294 003	Mar 26, 2007
	EQ 2GM BASE/VIAL	A065294 004	Mar 26, 2007
	EQ 250MG BASE/VIAL	A065294 001	Mar 26, 2007
	EQ 500MG BASE/VIAL	A065294 002	Mar 26, 2007
FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065245 003	Feb 15, 2006
	EQ 2GM BASE/VIAL	A065245 004	Feb 15, 2006
	EQ 500MG BASE/VIAL	A065245 002	Feb 15, 2006
STERI PHARMA	EQ 1GM BASE/VIAL	A065268 001	Feb 28, 2007
	EQ 2GM BASE/VIAL	A065268 002	Feb 28, 2007
TEVA	EQ 1GM BASE/VIAL	A065262 001	Jun 29, 2006
	EQ 2GM BASE/VIAL	A065262 002	Jun 29, 2006
TEVA PHARMS USA	EQ 1GM BASE/VIAL	A065227 003	Mar 15, 2007
	EQ 2GM BASE/VIAL	A065227 004	Mar 15, 2007
	EQ 250MG BASE/VIAL	A065227 001	Mar 15, 2007
	EQ 500MG BASE/VIAL	A065227 002	Mar 15, 2007
ROCEPHIN			
HOFFMANN LA ROCHE	EQ 1GM BASE/VIAL	N050585 003	Dec 21, 1984
	EQ 2GM BASE/VIAL	N050585 004	Dec 21, 1984
	EQ 250MG BASE/VIAL	N050585 001	Dec 21, 1984
	EQ 500MG BASE/VIAL	N050585 002	Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

HOFFMANN LA ROCHE	EQ 1GM BASE/VIAL, N/A; N/A, 1%	N050585 006	May 08, 1996
	EQ 500MG BASE/VIAL, N/A; N/A, 1%	N050585 007	May 08, 1996

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002
	EQ 250MG BASE	A065043 002	Feb 15, 2002
	EQ 500MG BASE	A065043 001	Feb 15, 2002
SANDOZ	EQ 250MG BASE	A065126 001	Oct 28, 2003
	EQ 500MG BASE	A065126 002	Oct 28, 2003

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001 002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002 001	Sep 28, 1998
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035 002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036 001	Feb 26, 1993
CEFUROXIME SODIUM IN PLASTIC CONTAINER			
SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251 001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251 002	Dec 30, 2009
KEFUROX			
ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591 002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591 003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592 002	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER			
LILLY	EQ 1.5GM BASE/VIAL	A062590 002	Jan 10, 1986
ZINACEF IN PLASTIC CONTAINER			
COVIS INJECTABLES	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS			
CEFUROXIME SODIUM			
FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001 001	May 30, 2001
TEVA PHARMS	EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998

## DISCONTINUED DRUG PRODUCT LIST

CEFUROXIME SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035 001	Feb 26, 1993
KEFUROX			
ACS DOBFAR	EQ 750MG BASE/VIAL	A062591 001	Jan 10, 1986
INJECTABLE; INTRAVENOUS			
KEFUROX			
LILLY	EQ 750MG BASE/VIAL	A062592 001	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER			
LILLY	EQ 750MG BASE/VIAL	A062590 001	Jan 10, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757 002	Dec 28, 1982
	300GM/BOT	N018757 003	Oct 16, 1984

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973 001	Nov 08, 1988
	EQ 250MG BASE	A063063 001	Sep 29, 1989
	EQ 250MG BASE	A063186 001	Dec 30, 1994
	EQ 500MG BASE	A062974 001	Nov 23, 1988
	EQ 500MG BASE	A063063 002	Sep 29, 1989
	EQ 500MG BASE	A063186 002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773 001	Jun 26, 1987
	EQ 500MG BASE	A062775 001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118 001	
	EQ 500MG BASE	A062118 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969 001	
	EQ 500MG BASE	A061969 002	
PUREPAC PHARM	EQ 250MG BASE	A062809 001	Apr 22, 1987
	EQ 500MG BASE	A062809 002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870 001	Mar 17, 1988
	EQ 500MG BASE	A062869 001	Mar 17, 1988
TEVA	EQ 250MG BASE	A062760 001	Apr 24, 1987
	EQ 250MG BASE	A062821 001	Feb 05, 1988
	EQ 500MG BASE	A062761 001	Apr 24, 1987
	EQ 500MG BASE	A062823 001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872 001	Jun 20, 1988
	EQ 500MG BASE	A062871 001	Jul 05, 1988
KEFLEX			
SHIONOGI INC	EQ 333MG BASE	N050405 004	May 12, 2006
FOR SUSPENSION; ORAL			
CEPHALEXIN			
APOTHECON	EQ 125MG BASE/5ML	A062986 001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987 001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778 001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777 001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML	A062117 001	
	EQ 125MG BASE/5ML	A062117 002	
	EQ 250MG BASE/5ML	A062117 003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444 001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444 002	Aug 28, 2009
RANBAXY	EQ 125MG BASE/5ML	A065081 001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081 002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767 001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873 001	May 23, 1988
	EQ 250MG BASE/5ML	A062768 001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867 001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779 001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781 001	Dec 22, 1987
YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336 001	Jul 25, 2007
	EQ 250MG BASE/5ML	A065336 002	Jul 25, 2007
KEFLEX			
SHIONOGI INC	EQ 100MG BASE/ML	N050406 003	
	EQ 125MG BASE/5ML	N050406 001	
	EQ 250MG BASE/5ML	N050406 002	

## DISCONTINUED DRUG PRODUCT LIST

CEPHALEXIN

TABLET; ORAL

CEPHALEXIN

BARR

EQ 250MG BASE

A062826 001 Aug 17, 1987

EQ 500MG BASE

A062827 001 Aug 17, 1987

VITARINE

EQ 1GM BASE

A062863 003 Aug 11, 1988

EQ 250MG BASE

A062863 001 Aug 11, 1988

EQ 500MG BASE

A062863 002 Aug 11, 1988

KEFLET

LILLY

EQ 1GM BASE

N050440 002

EQ 250MG BASE

A062745 001 Dec 01, 1986

EQ 250MG BASE

N050440 003 Feb 26, 1987

EQ 500MG BASE

A062745 002 Dec 01, 1986

EQ 500MG BASE

N050440 001

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE

RANBAXY LABS LTD

EQ 125MG BASE

A065100 002 Sep 11, 2003

EQ 250MG BASE

A065100 001 Sep 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

LILLY

EQ 250MG BASE

N050614 001 Oct 29, 1987

EQ 333MG BASE

N050614 003 May 16, 1988

EQ 500MG BASE

N050614 002 Oct 29, 1987

CEPHALOGLYCIN

CAPSULE; ORAL

KAFOCIN

LILLY

250MG

N050219 001

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN

INTL MEDICATION

EQ 1GM BASE/VIAL

A062426 002 May 03, 1985

EQ 2GM BASE/VIAL

A062426 003 May 03, 1985

EQ 4GM BASE/VIAL

A062426 004 May 03, 1985

EQ 500MG BASE/VIAL

A062426 001 May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT

EQ 1GM BASE/VIAL

A062547 001 Sep 11, 1985

EQ 1GM BASE/VIAL

A062548 001 Sep 11, 1985

EQ 2GM BASE/VIAL

A062547 002 Sep 11, 1985

EQ 2GM BASE/VIAL

A062548 002 Sep 11, 1985

ABRAXIS PHARM

EQ 1GM BASE/VIAL

A062666 002 Jun 10, 1987

EQ 2GM BASE/VIAL

A062666 001 Jun 10, 1987

BRISTOL

EQ 1GM BASE/VIAL

A062464 001 May 07, 1984

EQ 2GM BASE/VIAL

A062464 002 May 07, 1984

EQ 4GM BASE/VIAL

A062464 003 May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 003 Jan 31, 1984

EQ 20MG BASE/ML

A062422 005 Jul 16, 1991

EQ 20MG BASE/ML

A062730 001 Mar 05, 1987

EQ 40MG BASE/ML

A062422 004 Jan 31, 1984

EQ 40MG BASE/ML

A062422 006 Jul 16, 1991

EQ 40MG BASE/ML

A062730 002 Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 001 Jan 31, 1984

EQ 40MG BASE/ML

A062422 002 Jan 31, 1984

KEFLIN

LILLY

EQ 1GM BASE/VIAL

N050482 001

EQ 2GM BASE/VIAL

N050482 002

EQ 4GM BASE/VIAL

N050482 003

EQ 20GM BASE/VIAL

N050482 007

KEFLIN IN PLASTIC CONTAINER

LILLY

EQ 1GM BASE/VIAL

A062549 001 Sep 10, 1985

EQ 2GM BASE/VIAL

A062549 002 Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A062435 001 Nov 15, 1983

EQ 2GM BASE/VIAL

A062435 002 Nov 15, 1983

EQ 10GM BASE/VIAL

A062435 003 Nov 15, 1983



## DISCONTINUED DRUG PRODUCT LIST

CEPHAPIRIN SODIUM

## INJECTABLE; INJECTION

## CEFADYL

## APOTHECON

EQ 1GM BASE/VIAL	A061769	001	
EQ 1GM BASE/VIAL	A062724	001	Dec 23, 1986
EQ 1GM BASE/VIAL	A062961	002	Sep 20, 1988
EQ 1GM BASE/VIAL	N050446	001	
EQ 2GM BASE/VIAL	A061769	002	
EQ 2GM BASE/VIAL	A062724	002	Dec 23, 1986
EQ 2GM BASE/VIAL	A062961	003	Sep 20, 1988
EQ 2GM BASE/VIAL	N050446	002	
EQ 4GM BASE/VIAL	A061769	003	
EQ 4GM BASE/VIAL	A062961	004	Sep 20, 1988
EQ 4GM BASE/VIAL	N050446	003	
EQ 20GM BASE/VIAL	N050446	004	
EQ 500MG BASE/VIAL	A062961	001	Sep 20, 1988
EQ 500MG BASE/VIAL	N050446	005	

## CEPHAPIRIN SODIUM

## ABRAXIS PHARM

EQ 1GM BASE/VIAL	A062723	002	Nov 17, 1986
EQ 2GM BASE/VIAL	A062723	003	Nov 17, 1986
EQ 4GM BASE/VIAL	A062723	004	Nov 17, 1986
EQ 20GM BASE/VIAL	A062723	005	Nov 17, 1986
EQ 500MG BASE/VIAL	A062723	001	Nov 17, 1986

## HIKMA MAPLE

EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987
EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987
EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987
EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987

CEPHRADINE

## CAPSULE; ORAL

## ANSPOR

## GLAXOSMITHKLINE

250MG	A061859	001	
500MG	A061859	002	

## CEPHRADINE

## BARR

250MG	A062850	001	Apr 22, 1988
500MG	A062851	001	Apr 22, 1988

## IVAX SUB TEVA PHARMS

250MG	A062762	001	Mar 06, 1987
500MG	A062762	002	Mar 06, 1987

## TEVA

250MG	A062683	001	Jan 09, 1987
500MG	A062683	002	Jan 09, 1987

## VITARINE

250MG	A062813	001	Feb 25, 1988
500MG	A062813	002	Feb 25, 1988

## VELOSEF

## APOTHECON

250MG	A061764	001	
500MG	A061764	002	

## VELOSEF '250'

## ERSANA

250MG	N050548	001	
-------	---------	-----	--

## VELOSEF '500'

## ERSANA

500MG	N050548	002	
-------	---------	-----	--

## FOR SUSPENSION; ORAL

## ANSPOR

## GLAXOSMITHKLINE

125MG/5ML	A061866	001	
250MG/5ML	A061866	002	

## CEPHRADINE

## BARR

125MG/5ML	A062858	001	May 19, 1988
250MG/5ML	A062859	001	May 19, 1988

## TEVA

125MG/5ML	A062693	001	Jan 09, 1987
250MG/5ML	A062693	002	Jan 09, 1987

## VELOSEF '125'

## APOTHECON

125MG/5ML	A061763	001	
-----------	---------	-----	--

## VELOSEF '250'

## APOTHECON

250MG/5ML	A061763	002	
-----------	---------	-----	--

## INJECTABLE; INJECTION

## VELOSEF

## APOTHECON

1GM/VIAL	A061976	004	
2GM/VIAL	A061976	003	
4GM/VIAL	A061976	005	
250MG/VIAL	A061976	001	
500MG/VIAL	A061976	002	

## TABLET; ORAL

## VELOSEF

## BRISTOL MYERS SQUIBB

1GM	N050530	001	
-----	---------	-----	--

**DISCONTINUED DRUG PRODUCT LIST**CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS	0.05MG	N020740 001	Jun 26, 1997
	0.1MG	N020740 002	Jun 26, 1997
	0.2MG	N020740 003	Jun 26, 1997
	0.3MG	N020740 004	Jun 26, 1997
	0.4MG	N020740 005	May 24, 1999
	0.8MG	N020740 006	Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN

PHARMACIA AND UPJOHN	0.02MG/ML	N018296 001	
----------------------	-----------	-------------	--

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	5MG/5ML	A078617 001	Feb 02, 2010
APOTEX INC	5MG/5ML	A078412 001	Jun 18, 2008
AUROBINDO PHARMA LTD	5MG/5ML	A090751 001	Dec 16, 2009
RANBAXY LABS LTD	5MG/5ML	A077472 001	Jun 18, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC	5MG/5ML	A090378 002	May 09, 2008
APOTEX INC	5MG/5ML	A090188 002	Apr 22, 2008
RANBAXY LABS LTD	5MG/5ML	A090183 002	Apr 24, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC	5MG/5ML	A090378 001	May 09, 2008
APOTEX INC	5MG/5ML	A090188 001	Apr 22, 2008
RANBAXY LABS LTD	5MG/5ML	A090183 001	Apr 24, 2008

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS ELIZABETH	5MG	A078615 003	Dec 28, 2007
	10MG	A078615 004	Dec 28, 2007

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC	5MG	A077631 004	Jan 11, 2008
	10MG	A077631 003	Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC	5MG	A077631 001	Jan 11, 2008
	10MG	A077631 002	Jan 11, 2008

CHILDREN'S ZYRTEC ALLERGY

MCNEIL CONS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621 003	Nov 16, 2007
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621 004	Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

MCNEIL CONS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621 005	Nov 16, 2007
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621 006	Nov 16, 2007

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

EMD SERONO INC	EQ 3MG BASE/ML	N021197 002	Aug 11, 2000
----------------	----------------	-------------	--------------

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE	12MG/VIAL; 108MG/VIAL; 8MG/VIAL	N020044 001	Aug 02, 1990
-----------------	---------------------------------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

CHENODIOL

TABLET; ORAL

CHENIX

SIGMA TAU

250MG

N018513 002 Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP; ORAL

ULO

3M

25MG/5ML

N012126 001

CHLORAMPHENICOL

CAPSULE; ORAL

AMPHICOL

FERRANTE

100MG

A060058 001

CHLOROMYCETIN

PARKEDALE

50MG

A060591 001

100MG

A060591 003

CREAM; TOPICAL

CHLOROMYCETIN

PARKE DAVIS

1%

N050183 001

FOR SOLUTION; OPHTHALMIC

CHLOROMYCETIN

PARKEDALE

25MG/VIAL

N050143 001

INJECTABLE; INJECTION

CHLOROMYCETIN

PARKE DAVIS

250MG/ML

N050153 001

OINTMENT; OPHTHALMIC

CHLORAMPHENICOL

ALTANA

1%

A060133 001

CHLOROFAIR

PHARMAFAIR

1%

A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE

1%

N050156 001

CHLOROPTIC S.O.P.

ALLERGAN

1%

A061187 001

ECONOCHLOR

ALCON

1%

A061648 001

SOLUTION/DROPS; OPHTHALMIC

CHLORAMPHENICOL

AKORN

0.5%

A062042 001

ALCON

0.5%

A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR

0.5%

A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN

0.5%

N050091 001

ECONOCHLOR

ALCON

0.5%

A061645 001

OPHTHOCHLOR

PARKEDALE

0.5%

A061220 001

OPTOMYCIN

OPTOPICS

0.5%

A062171 001 Mar 31, 1982

SOLUTION/DROPS; OTIC

CHLOROMYCETIN

PARKEDALE

0.5%

N050205 001

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

PARKE DAVIS

EQ 150MG BASE/5ML

A062301 001

EQ 150MG BASE/5ML

N050152 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL

ELKINS SINN

EQ 1GM BASE/VIAL

A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT

EQ 1GM BASE/VIAL

A062278 001

CHLOROMYCETIN

PARKEDALE

EQ 1GM BASE/VIAL

N050155 001

MYCHEL-S

ANGUS

EQ 1GM BASE/VIAL

A060132 001

**DISCONTINUED DRUG PRODUCT LIST**CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

PARKE DAVIS

10MG/GM; 666 UNITS/GM; 1 UNITS/GM

N050294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE

12.5MG/VIAL; 25MG/VIAL

N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

PARKEDALE

10MG/GM; 5MG/GM; 10,000 UNITS/GM

N050201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CHLOROMYCETIN

PARKE DAVIS

1%; 10,000 UNITS/GM

N050203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC

CHLOROPTIC-P S.O.P.

ALLERGAN

1%; 0.5%

A061188 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL

LIBRELEASE

VALEANT PHARM INTL

30MG

N017813 001 Sep 12, 1983

TABLET; ORAL

LIBRITABS

VALEANT PHARM INTL

5MG

A085482 001

10MG

A085481 001

25MG

A085488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

A-POXIDE

ABBOTT

5MG

A085447 001

5MG

A085517 001

10MG

A085447 002

10MG

A085518 001

25MG

A085447 003

25MG

A085513 001

CHLORDIAZACHEL

RACHELLE

5MG

A085086 001

10MG

A084639 001

25MG

A085087 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT

5MG

A087525 001 Jan 07, 1982

10MG

A087524 001 Jan 07, 1982

25MG

A087512 001 Jan 07, 1982

FERRANTE

5MG

A085118 001

10MG

A085119 001

25MG

A085120 001

HALSEY

5MG

A085340 001

10MG

A085339 001

25MG

A084685 001

HIKMA PHARMS LLC

5MG

A085014 001

10MG

A085000 001

25MG

A085294 001

IMPAX LABS

5MG

A086213 001

10MG

A085113 001

25MG

A086212 001

IVAX SUB TEVA PHARMS

5MG

A083741 001

10MG

A083742 001

25MG

A083570 001

LEDERLE

5MG

A086892 001

5MG

A087234 001

10MG

A086876 001

10MG

A087037 001

25MG

A086893 001

25MG

A087231 001

MAST MM

10MG

A086217 001

MYLAN

5MG

A084886 001

**DISCONTINUED DRUG PRODUCT LIST**CHLORDIAZEPOXIDE HYDROCHLORIDE

## CAPSULE; ORAL

## CHLORDIAZEPOXIDE HYDROCHLORIDE

	10MG	A084601	001	
	25MG	A084887	001	
PARKE DAVIS	5MG	A085163	001	
	10MG	A084598	001	
	25MG	A085164	001	
PIONEER PHARMS	10MG	A089533	001	Jul 15, 1988
	25MG	A089558	001	Jul 15, 1988
PUREPAC PHARM	5MG	A085155	001	
	10MG	A084939	002	
	25MG	A085144	001	
ROXANE	5MG	A084706	001	
	10MG	A084700	001	
	25MG	A084705	001	
SANDOZ	5MG	A084678	001	
	5MG	A084919	001	
	10MG	A084041	001	
	10MG	A084920	001	
	25MG	A084679	002	
	25MG	A084823	001	
SUPERPHARM	5MG	A088987	001	Apr 25, 1985
	10MG	A088986	001	Apr 25, 1985
	25MG	A088988	001	Apr 25, 1985
TEVA	5MG	A088705	001	Jan 18, 1985
	10MG	A088706	001	Jan 18, 1985
	25MG	A086494	001	
	25MG	A088707	001	Jan 18, 1985
USL PHARMA	5MG	A084644	001	
	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WATSON LABS	5MG	A086383	001	
	10MG	A086294	001	
	25MG	A086382	001	
LIBRIUM				
VALEANT PHARM INTL	5MG	N012249	002	
	10MG	N012249	001	
	25MG	N012249	003	
LYGEN				
ALRA	5MG	A085107	001	
	10MG	A085009	001	
	25MG	A085108	001	

## INJECTABLE; INJECTION

## LIBRIUM

VALEANT PHARMS LLC	100MG/AMP	N012301	001	
--------------------	-----------	---------	-----	--

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

## TABLET; ORAL

## MENRIUM 10-4

ROCHE	10MG; 0.4MG	N014740	006	
-------	-------------	---------	-----	--

## MENRIUM 5-2

ROCHE	5MG; 0.2MG	N014740	002	
-------	------------	---------	-----	--

## MENRIUM 5-4

ROCHE	5MG; 0.4MG	N014740	004	
-------	------------	---------	-----	--

CHLORHEXIDINE GLUCONATE

## SOLUTION; DENTAL

## CHLORHEXIDINE GLUCONATE

APOTEX INC	0.12%	A075561	001	Nov 14, 2000
------------	-------	---------	-----	--------------

## SOLUTION; TOPICAL

## EXIDINE

XTTRIUM	2.5%	N019421	001	Dec 17, 1985
---------	------	---------	-----	--------------

## MICRODERM

J AND J	4%	A072255	001	Apr 15, 1991
---------	----	---------	-----	--------------

## PREVACARE R

J AND J	0.5%	A072292	001	Jan 28, 1992
---------	------	---------	-----	--------------

## STERI-STAT

MATRIX MEDCL	4%	A070104	001	Jul 24, 1986
--------------	----	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

KENDALL IL

4%

N019490 001 Mar 27, 1987

E-Z SCRUB

BECTON DICKINSON

4%

A073416 001 Mar 14, 2000

HIBICLENS

MOLNLYCKE HLTH

4% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N018423 001

MICRODERM

J AND J

4%

A072295 001 Feb 28, 1991

CHLORMERODRIN HG-197

INJECTABLE; INJECTION

CHLORMERODRIN HG 197

BRACCO

0.6-1.4mCi/ML

N017269 001

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

SANOFI AVENTIS US

100MG

N011467 003

200MG

N011467 005

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE-MPF

FRESENIUS KABI USA

2%

N009435 003

3%

N009435 004

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HYDROCHLORIDE

SANOFI AVENTIS US

EQ 40MG BASE/ML

N006002 002

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

MD PHARM

EQ 150MG BASE

A087228 001

PUREPAC PHARM

EQ 150MG BASE

A080886 001

TEVA

EQ 150MG BASE

A087504 001

Jan 13, 1982

WATSON LABS

EQ 150MG BASE

A087979 001

Dec 21, 1982

EQ 300MG BASE

A088030 001

Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US

EQ 300MG BASE; EQ 45MG BASE

N014860 002

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

ABC HOLDING

250MG

A085569 001

HIKMA INTL PHARMS

250MG

A086028 001

Jul 14, 1982

500MG

A087736 001

Jul 14, 1982

LEDERLE

250MG

A086940 001

500MG

A086938 001

SANDOZ

250MG

A085485 001

WATSON LABS

250MG

A085165 001

250MG

A085173 001

250MG

A086795 001

Aug 15, 1983

500MG

A084026 001

Sep 01, 1982

500MG

A086796 001

Aug 15, 1983

DIURIL

OAK PHARMS AKORN

250MG

N011145 004

500MG

N011145 002

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

MERCK

150MG; 250MG

N016016 001

ALDOCLOR-250

MERCK

250MG; 250MG

N016016 002

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM

150MG; 250MG

A070783 001

Nov 06, 1987

250MG; 250MG

A070654 001

Nov 06, 1987

## DISCONTINUED DRUG PRODUCT LIST

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

HIKMA PHARMS LLC 250MG;0.125MG  
500MG;0.125MGA088557 001 Dec 22, 1983  
A088365 001 Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS 250MG;0.125MG  
500MG;0.125MGA084853 001  
A088151 001 Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN 250MG;0.125MG  
500MG;0.125MGA087744 001 May 06, 1982  
A087745 001 May 06, 1982

DIUPRES-250

MERCK 250MG;0.125MG

N011635 003 Aug 26, 1987

DIUPRES-500

MERCK 500MG;0.125MG

N011635 006 Aug 26, 1987

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS 12MG

A084652 001

TACE

SANOFI AVENTIS US 12MG  
25MG  
72MGN008102 004  
N011444 001  
N016235 001CHLOROXINE

SHAMPOO; TOPICAL

CAPITROL

WESTWOOD SQUIBB 2%

N017594 001

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

PHARMACIA AND UPJOHN 400MG

N014217 002

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

SANDOZ 12MG

A070797 001 Aug 12, 1988

TELDRIN

GLAXOSMITHKLINE 8MG  
12MGN017369 001  
N017369 002

INJECTABLE; INJECTION

CHLOR-TRIMETON

SCHERING PLOUGH 10MG/ML  
100MG/MLN008826 001  
N008794 001

CHLORPHENIRAMINE MALEATE

BEL MAR 10MG/ML  
ELKINS SINN 10MG/ML  
WATSON LABS 10MG/ML  
10MG/ML  
100MG/MLA080821 001  
A080797 001  
A083593 001  
A086096 001  
A086095 001

PYRIDAMAL 100

BEL MAR 100MG/ML

A083733 001

SYRUP; ORAL

CHLOR-TRIMETON

SCHERING 2MG/5ML

N006921 006

CHLORPHENIRAMINE MALEATE

PHARM ASSOC 2MG/5ML

A087520 001 Feb 10, 1982

TABLET; ORAL

ANTAGONATE

BAYER PHARMS 4MG

A083381 001

CHLOR-TRIMETON

SCHERING 4MG

N006921 002

CHLORPHENIRAMINE MALEATE

ANABOLIC 4MG  
BELL PHARMA 4MG  
ELKINS SINN 4MG  
IMPAX LABS 4MG  
IVAX SUB TEVA PHARMS 4MG  
KV PHARM 4MG  
LEDERLE 4MG  
MUTUAL PHARM 4MG  
NEWTRON PHARMS 4MGA083078 001  
A083062 001  
A080938 001  
A080809 001  
A080779 001  
A087164 001  
A086941 001  
A080700 001  
A086519 001

## DISCONTINUED DRUG PRODUCT LIST

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

PANRAY	4MG	A083243	001	
PHARMAVITE	4MG	A085104	001	
PHARMERAL	4MG	A083753	001	
PIONEER PHARMS	4MG	A088556	001	Jul 13, 1984
PUREPAC PHARM	4MG	A086306	001	
PVT FORM	4MG	A080786	001	
ROXANE	4MG	A080626	001	
SANDOZ	4MG	A080961	001	
VITARINE	4MG	A085837	001	
WATSON LABS	4MG	A080696	001	
	4MG	A080791	001	
	4MG	A085139	001	
	4MG	A083787	001	

WEST WARD

Kloromin

HALSEY 4MG A083629 001

PHENETRON

LANNETT 4MG A080846 001

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

SCHERING PLOUGH 8MG N007638 001

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA 16MG N019746 002 Nov 18, 1994

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV

GRAHAM DM 12MG; 75MG N018793 001 Apr 25, 1985

COLD CAPSULE V

GRAHAM DM 8MG; 75MG N018794 001 Apr 23, 1985

TABLET, EXTENDED RELEASE; ORAL

TRIAMINIC-12

NOVARTIS 12MG; 75MG N018115 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12

SCHWARZ PHARMA 12MG; 120MG N018935 001 Apr 15, 1985

ISOCOLOR

FISONS 8MG; 120MG N018747 001 Mar 06, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS 8MG; 120MG N019428 001 Aug 02, 1988

GRAHAM DM 8MG; 120MG N018844 001 Mar 20, 1985

12MG; 120MG N018843 001 Mar 18, 1985

KV PHARM 12MG; 120MG A071455 001 Mar 01, 1989

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

UCB INC EQ 4MG MALEATE/5ML; EQ 20MG BASE/5ML N021369 001 Jun 21, 2004

PENNTUSS

FISONS EQ 4MG MALEATE/5ML; EQ 10MG BASE/5ML N018928 001 Aug 14, 1985

CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PRE-SATE

PARKE DAVIS EQ 65MG BASE N014696 001

CHLORPROMAZINE

SUPPOSITORY; RECTAL

THORAZINE

GLAXOSMITHKLINE 25MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\* N009149 024

100MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\* N009149 033



## DISCONTINUED DRUG PRODUCT LIST

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

GLAXOSMITHKLINE	30MG	N011120	016
	75MG	N011120	017
	150MG	N011120	018
	200MG	N011120	019
	300MG	N011120	020

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A086863	001
PHARM ASSOC	30MG/ML	A040231	001 Dec 30, 1999
	100MG/ML	A040224	001 Jan 26, 1999
WOCKHARDT	30MG/ML	A087032	001 Jul 08, 1982
	100MG/ML	A087053	001

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

ROXANE	30MG/ML	A088157	001 Apr 27, 1983
	100MG/ML	A088158	001 Apr 27, 1983

SONAZINE

SANDOZ	30MG/ML	A080983	004
	100MG/ML	A080983	005

THORAZINE

GLAXOSMITHKLINE	30MG/ML	N009149	032
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	100MG/ML	N009149	043
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM	25MG/ML	A084911	001
MARSAM PHARMS LLC	25MG/ML	A089563	001 Apr 15, 1988
WATSON LABS	25MG/ML	A080365	001
	25MG/ML	A085591	001
WYETH AYERST	25MG/ML	A080370	001

THORAZINE

GLAXOSMITHKLINE	25MG/ML	N009149	011
-----------------	---------	---------	-----

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A086712	001
--------------------	----------	---------	-----

SONAZINE

SANDOZ	10MG/5ML	A083040	001
--------	----------	---------	-----

THORAZINE

GLAXOSMITHKLINE	10MG/5ML	N009149	022
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT	10MG	A084414	001
	25MG	A084415	001
	50MG	A084411	001
	100MG	A084412	001
	200MG	A084413	001
IVAX SUB TEVA PHARMS	10MG	A083549	001
	25MG	A083549	002
	50MG	A083549	003
	100MG	A083574	001
	200MG	A083575	001
KV PHARM	10MG	A085750	002 Jan 04, 1982
	25MG	A085751	001
	50MG	A085484	001
	100MG	A085752	001
	200MG	A085748	002 Jan 04, 1982
LEDERLE	10MG	A084803	001
	25MG	A084801	001
	50MG	A084800	001
	100MG	A084789	001
	200MG	A084802	001
PUREPAC PHARM	10MG	A080403	004
	25MG	A080403	001
	50MG	A080403	002

## DISCONTINUED DRUG PRODUCT LIST

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

## CHLORPROMAZINE HYDROCHLORIDE

	100MG	A080403 003	
	200MG	A080403 005	
PVT FORM	25MG	A080340 001	
	50MG	A080340 002	
	200MG	A080340 003	
ROXANE	10MG	A085331 001	
	25MG	A085331 002	
	50MG	A085331 003	
	100MG	A085331 004	
	200MG	A085331 005	
VANGARD	10MG	A088038 001	Aug 16, 1982
	25MG	A087645 001	
	50MG	A087646 001	
WATSON LABS	10MG	A085959 001	
	25MG	A085956 001	
	50MG	A085960 001	
	100MG	A085957 001	
	200MG	A085958 001	
WEST WARD	10MG	A087783 001	Sep 16, 1982
	25MG	A087865 001	Sep 16, 1982
	50MG	A087878 001	Sep 15, 1982
	100MG	A087884 001	Sep 15, 1982
	200MG	A087880 001	Sep 16, 1982
PROMAPAR			
PARKE DAVIS	10MG	A086886 001	
	25MG	A084423 001	
	50MG	A086887 001	
	100MG	A086888 001	
	200MG	A086885 001	
THORAZINE			
GLAXOSMITHKLINE	10MG	N009149 002	
	25MG	N009149 007	
	50MG	N009149 013	
	100MG	N009149 018	
	200MG	N009149 020	

CHLORPROPAMIDE

TABLET; ORAL

## CHLORPROPAMIDE

ANI PHARMS INC	100MG	A088768 001	Oct 11, 1984
	100MG	A088812 001	Oct 19, 1984
	100MG	A088840 001	Oct 25, 1984
	100MG	A088918 001	Oct 16, 1984
	100MG	A089446 001	Nov 17, 1986
	250MG	A088813 001	Oct 19, 1984
	250MG	A088919 001	Oct 16, 1984
	250MG	A089447 001	Nov 17, 1986
DAVA PHARMS INC	100MG	A089561 001	Sep 04, 1987
	250MG	A089562 001	Sep 04, 1987
HALSEY	100MG	A089321 001	Jan 16, 1986
	250MG	A088662 001	Jan 09, 1986
PAR PHARM	100MG	A088175 001	Feb 27, 1984
	250MG	A088176 001	Feb 27, 1984
SANDOZ	100MG	A088725 001	Aug 31, 1984
	250MG	A084669 001	
	250MG	A088726 001	Aug 31, 1984
SUPERPHARM	100MG	A088694 001	Sep 17, 1984
	250MG	A088695 001	Sep 17, 1984
TEVA PHARMS USA	250MG	A087353 001	
USL PHARMA	100MG	A088708 001	Aug 30, 1984
	250MG	A088709 001	Aug 30, 1984
WATSON LABS	100MG	A086865 001	Sep 24, 1984
	100MG	A088608 001	Apr 12, 1984
	250MG	A086866 001	
	250MG	A088568 001	Apr 12, 1984
WATSON LABS INC	100MG	A088852 001	Sep 26, 1984
	250MG	A088826 001	Sep 26, 1984
GLUCAMIDE			
TEVA PHARMS USA	250MG	A088641 001	Oct 11, 1984

## DISCONTINUED DRUG PRODUCT LIST

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE 100MG/5ML N016149 002

INJECTABLE; INJECTION

TARACTAN

ROCHE 12.5MG/ML N012487 001

TABLET; ORAL

TARACTAN

ROCHE 10MG N012486 005

25MG N012486 004

50MG N012486 003

100MG N012486 001

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

LEDERLE 1% N050404 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

ABBOTT 25MG A087364 001

50MG A087384 001

ASCOT 25MG A087698 001 Oct 20, 1982

50MG A087699 001 Oct 20, 1982

BARR LABS INC 25MG A088902 001 Sep 19, 1985

50MG A088903 001 Sep 19, 1985

DAVA PHARMS INC 25MG A087451 001

50MG A087450 001

IVAX PHARMS 25MG A087555 001

25MG A088164 001 Jan 09, 1984

50MG A087176 001

50MG A087947 001 Feb 27, 1984

KV PHARM 25MG A087311 001

50MG A087312 001

MUTUAL PHARM 25MG A087292 001

25MG A089285 001 Jul 21, 1986

25MG A089738 001 Sep 19, 1988

50MG A087293 001

50MG A089286 001 Jul 21, 1986

50MG A089739 001 Sep 19, 1988

PIONEER PHARMS 50MG A089591 001 Jul 21, 1988

PUREPAC PHARM 25MG A088139 001 Jul 16, 1986

50MG A088140 001 Aug 11, 1983

SANDOZ 25MG A087380 001

50MG A087118 001

50MG A087381 001

SUPERPHARM 25MG A087473 001 Feb 09, 1983

50MG A087247 001 Feb 09, 1983

TEVA 50MG A088651 001 May 30, 1985

USL PHARMA 25MG A089051 001 Jun 01, 1987

50MG A089052 001 Jun 01, 1987

VANGARD 25MG A088012 001 Jul 14, 1982

50MG A088073 001 Mar 25, 1983

WARNER CHILCOTT 25MG A087515 001 Jan 24, 1983

50MG A087516 001 Feb 09, 1983

WATSON LABS 25MG A087050 001

25MG A087100 001

25MG A087296 001

25MG A087706 001

50MG A087029 001

50MG A087082 001

50MG A087521 001

50MG A087689 001

HYGROTON

SANOFI AVENTIS US 25MG N012283 004

50MG N012283 003

THALITONE

CITRON PHARMA LLC 25MG N019574 002 Feb 12, 1992

MONARCH PHARMS 25MG A088051 001 Nov 12, 1982

## DISCONTINUED DRUG PRODUCT LIST

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

## TABLET; ORAL

## CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG; 0.1MG	A071179	001	Dec 16, 1987
	15MG; 0.2MG	A071178	001	Dec 16, 1987
	15MG; 0.3MG	A071142	001	Dec 16, 1987

## COMBIPRES

BOEHRINGER INGELHEIM	15MG; 0.1MG	N017503	001	
	15MG; 0.2MG	N017503	002	
	15MG; 0.3MG	N017503	003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

## CAPSULE; ORAL

## LOPRESSIDONE

NOVARTIS	25MG; 100MG	N019451	001	Dec 31, 1987
	25MG; 200MG	N019451	002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

## TABLET; ORAL

## DEMI-REGROTON

SANOFI AVENTIS US	25MG; 0.125MG	N015103	002	
-------------------	---------------	---------	-----	--

## REGROTON

SANOFI AVENTIS US	50MG; 0.25MG	N015103	001	
-------------------	--------------	---------	-----	--

CHLORZOXAZONE

## TABLET; ORAL

## CHLORZOXAZONE

ACTAVIS ELIZABETH	250MG	A088928	001	May 08, 1987
	500MG	A040113	001	Sep 29, 1995
MUTUAL PHARM	500MG	A089970	001	Sep 27, 1990
OHM LABS	250MG	A081298	001	Dec 29, 1993
	500MG	A081299	001	Dec 29, 1993
PAR PHARM	250MG	A087981	001	Sep 20, 1983
PIONEER PHARMS	250MG	A089592	001	Jan 06, 1989
	500MG	A089948	001	Jan 06, 1989
SANDOZ	250MG	A089852	001	May 04, 1988
	500MG	A089853	001	May 04, 1988
WATSON LABS	250MG	A086901	001	
	250MG	A086948	001	Aug 09, 1982
	500MG	A040137	001	Aug 09, 1996
	500MG	A081019	001	Jul 29, 1991
	500MG	A081040	001	Aug 22, 1989

## PARAFLEX

ORTHO MCNEIL PHARM	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011300	003	
--------------------	------------------------------------------------------------------------------------------------------------------------	---------	-----	--

## STRIFON FORTE DSC

FERNDALE LABS	500MG	A081008	001	Dec 23, 1988
---------------	-------	---------	-----	--------------

CHOLESTYRAMINE

## BAR, CHEWABLE; ORAL

## CHOLYBAR

PARKE DAVIS	EQ 4GM RESIN/BAR	A071621	001	May 26, 1988
	EQ 4GM RESIN/BAR	A071739	001	May 26, 1988

## POWDER; ORAL

## CHOLESTYRAMINE

IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771	001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771	002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996
	EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996

## CHOLESTYRAMINE LIGHT

TEVA	EQ 4GM RESIN/PACKET	A074348	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555	001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555	002	Sep 30, 1998

## LOCHOLEST

SANDOZ	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996

## LOCHOLEST LIGHT

SANDOZ	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996

## DISCONTINUED DRUG PRODUCT LIST

CHOLESTYRAMINE

POWDER; ORAL

QUESTRAN

BRISTOL MYERS

EQ 4GM RESIN/PACKET

N016640 001

EQ 4GM RESIN/SCOOPFUL

N016640 003

QUESTRAN LIGHT

BRISTOL MYERS

EQ 4GM RESIN/PACKET

N019669 001 Dec 05, 1988

EQ 4GM RESIN/SCOOPFUL

N019669 003 Dec 05, 1988

TABLET; ORAL

QUESTRAN

APOTHECON

EQ 1GM RESIN

A073403 001 Apr 28, 1994

EQ 800MG RESIN

A073403 002 Dec 27, 1999

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

EMD SERONO

0.25MG/VIAL

N021149 001 Sep 20, 2000

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

ABRAXIS PHARM

EQ 0.004MG CHROMIUM/ML

N019271 001 May 05, 1987

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION

PHOSPHOCOL P32

MALLINCKRODT

5mCi/ML

N017084 001

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

CHART MEDCL

4,000 UNITS/VIAL

N018663 002 Aug 21, 1984

10,000 UNITS/VIAL \*\*Federal Register

N018663 001 Nov 10, 1982

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

DISCASE

ABBOTT

12,500 UNITS/VIAL

N018625 001 Jan 18, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

ALPHA CHYMAR

SOLA BARNES HIND

750 UNITS/VIAL

N011837 001

CATARASE

CIBA

300 UNITS/VIAL

N016938 001

NOVARTIS

150 UNITS/VIAL

N018121 001

ZOLYSE

ALCON

750 UNITS/VIAL

N011903 001

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

APOTEX INC

8%

A078172 001 Sep 18, 2007

MYLAN PHARMS INC

8%

A078567 001 Sep 18, 2007

TEVA PHARMS

8%

A078079 001 Sep 18, 2007

CILASTATIN SODIUM; IMPENEM

INJECTABLE; INJECTION

PRIMAXIN

MERCK

EQ 250MG BASE/VIAL; 250MG/VIAL

A062756 001 Jan 08, 1987

EQ 500MG BASE/VIAL; 500MG/VIAL

A062756 002 Jan 08, 1987

POWDER; INTRAMUSCULAR

PRIMAXIN

MERCK

EQ 750MG BASE/VIAL; 750MG/VIAL

N050630 002 Dec 14, 1990

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

ACTAVIS ELIZABETH

100MG

A077028 002 Nov 26, 2004

COREPHARMA

50MG

A077150 001 Mar 11, 2005

100MG

A077022 001 Nov 23, 2004

IVAX SUB TEVA PHARMS

100MG

A077020 002 Mar 01, 2005

MUTUAL PHARM

50MG

A077208 002 Mar 29, 2006

100MG

A077208 001 Mar 29, 2006

## DISCONTINUED DRUG PRODUCT LIST

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200

GLAXOSMITHKLINE 200MG/20ML N020951 001 Jul 09, 1999

TABLET; ORAL

CIMETIDINE

CYCLE PHARMS LTD 300MG A074361 001 Dec 23, 1994

400MG A074361 002 Dec 23, 1994

800MG A074371 001 Dec 23, 1994

DAVA PHARMS INC 300MG A074340 001 Jun 23, 1995

400MG A074340 002 Jun 23, 1995

800MG A074339 001 Jun 23, 1995

IVAX SUB TEVA PHARMS 200MG A074401 001 May 30, 1995

200MG A074424 001 Jul 28, 1995

300MG A074401 002 May 30, 1995

300MG A074424 002 Jul 28, 1995

400MG A074401 003 May 30, 1995

400MG A074424 003 Jul 28, 1995

800MG A074402 001 May 30, 1995

800MG A074424 004 Jul 28, 1995

LEK PHARMS 100MG A075122 001 Jun 19, 1998

200MG A074250 001 Jun 29, 1995

200MG A075122 002 Jun 19, 1998

300MG A074250 002 Jun 29, 1995

400MG A074250 003 Jun 29, 1995

800MG A074250 004 Jun 29, 1995

PERRIGO 100MG A074972 001 Jun 19, 1998

PLIVA 200MG A074568 001 Feb 27, 1997

300MG A074568 002 Feb 27, 1997

400MG A074568 003 Feb 27, 1997

SANDOZ 200MG A074100 001 Jan 31, 1995

200MG A074506 001 Jan 24, 1996

300MG A074100 002 Jan 31, 1995

300MG A074506 002 Jan 24, 1996

400MG A074100 003 Jan 31, 1995

400MG A074506 003 Jan 24, 1996

800MG A074100 004 Jan 31, 1995

800MG A074506 004 Jan 24, 1996

TEVA 200MG A074365 001 Feb 28, 1995

300MG A074365 002 Feb 28, 1995

400MG A074365 003 Feb 28, 1995

800MG A074365 004 Feb 28, 1995

VINTAGE PHARMS LLC 200MG A074281 001 May 17, 1994

300MG A074281 002 May 17, 1994

400MG A074281 003 May 17, 1994

800MG A074329 001 May 17, 1994

WATSON LABS 200MG A075425 001 Jul 29, 1999

WATSON LABS INC 200MG A074349 001 Aug 30, 1996

300MG A074349 002 Aug 30, 1996

400MG A074349 003 Aug 30, 1996

800MG A074316 001 Feb 28, 1996

TAGAMET

GLAXOSMITHKLINE 200MG N017920 002

300MG N017920 003

400MG N017920 004 Dec 14, 1983

800MG N017920 005 Apr 30, 1986

TAGAMET HB

MEDTECH PRODUCTS 100MG N020238 001 Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

HOSPIRA EQ 300MG BASE/2ML A074296 001 Mar 28, 1997

EQ 300MG BASE/2ML A074344 001 Jan 31, 1995

EQ 300MG BASE/2ML A074345 001 Jan 31, 1995

EQ 300MG BASE/2ML A074412 001 Mar 28, 1997

EQ 300MG BASE/2ML A074422 001 Jan 31, 1995

LUITPOLD EQ 300MG BASE/2ML A074353 001 Dec 20, 1994

TEVA PARENTERAL EQ 300MG BASE/2ML A074252 001 Nov 26, 1997

VINTAGE PHARMS LLC EQ 300MG BASE/2ML A074005 001 Aug 31, 1994

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA EQ 6MG BASE/ML A074269 001 Dec 27, 1994

EQ 90MG BASE/100ML A074468 005 Dec 29, 1994

## DISCONTINUED DRUG PRODUCT LIST

CIMETIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

EQ 120MG BASE/100ML	A074468	006	Dec 29, 1994
EQ 180MG BASE/100ML	A074468	003	Dec 29, 1994
EQ 240MG BASE/100ML	A074468	004	Dec 29, 1994
EQ 360MG BASE/100ML	A074468	001	Dec 29, 1994
EQ 480MG BASE/100ML	A074468	002	Dec 29, 1994

## TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/2ML	N017939	002
-----------------	-------------------	---------	-----

TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 6MG BASE/ML	N019434	001	Oct 31, 1985
-----------------	----------------	---------	-----	--------------

## SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994
ANI PHARMS INC	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998
	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998
APOTEX INC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000
CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994

## TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/5ML	N017924	001
-----------------	-------------------	---------	-----

CINOXACIN

## CAPSULE; ORAL

CINOXACIN

LILLY	250MG	N018067	001
	500MG	N018067	002

CINOXACIN

TEVA	250MG	A073005	001	Feb 28, 1992
	500MG	A073006	001	Feb 28, 1992

CIPROFLOXACIN

## INJECTABLE; INJECTION

CIPRO

BAYER HLTHCARE	1200MG/120ML (10MG/ML)	N019847	003	Dec 26, 1990
----------------	------------------------	---------	-----	--------------

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS	200MG/100ML	N019858	001	Dec 26, 1990
--------------	-------------	---------	-----	--------------

CIPROFLOXACIN

BEDFORD LABS	200MG/20ML (10MG/ML)	A076992	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076992	002	Aug 28, 2006
	1200MG/120ML (10MG/ML)	A076993	001	Aug 28, 2006
FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076484	002	Aug 28, 2006
TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA	200MG/100ML	A076757	001	Apr 21, 2008
--------------------	-------------	---------	-----	--------------

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	A077888	001	Mar 18, 2008
	400MG/200ML	A077888	002	Mar 18, 2008
BEDFORD	200MG/100ML	A078114	001	Mar 18, 2008
	400MG/200ML	A078114	002	Mar 18, 2008
TEVA PHARMS	200MG/100ML	A077138	001	Mar 18, 2008
	400MG/200ML	A077138	002	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

## SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

APOTEX INC	EQ 0.3% BASE	A075928	001	Jun 09, 2004
------------	--------------	---------	-----	--------------

## TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

BARR	EQ 250MG BASE	A074124	001	Jun 09, 2004
	EQ 500MG BASE	A074124	002	Jun 09, 2004
	EQ 750MG BASE	A074124	003	Jun 09, 2004
NOSTRUM LABS	EQ 250MG BASE	A076138	001	Jun 09, 2004
	EQ 500MG BASE	A076138	002	Jun 09, 2004
	EQ 750MG BASE	A076138	003	Jun 09, 2004
PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005
	EQ 250MG BASE	A076426	002	Jun 15, 2005
	EQ 500MG BASE	A076426	003	Jun 15, 2005
	EQ 750MG BASE	A076426	004	Jun 15, 2005
SANDOZ	EQ 100MG BASE	A075939	001	Mar 03, 2005
	EQ 250MG BASE	A075939	002	Jun 09, 2004

**DISCONTINUED DRUG PRODUCT LIST**CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

	EQ 250MG BASE	A076593 002	Jun 09, 2004
	EQ 500MG BASE	A075939 003	Jun 09, 2004
	EQ 500MG BASE	A076593 003	Jun 09, 2004
	EQ 750MG BASE	A075939 004	Jun 09, 2004
	EQ 750MG BASE	A076593 004	Jun 09, 2004
TEVA	EQ 250MG BASE	A076136 001	Jun 09, 2004
	EQ 500MG BASE	A076136 002	Jun 09, 2004
	EQ 750MG BASE	A076136 003	Jun 09, 2004

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

DEPOMED INC	EQ 500MG BASE	N021744 001	May 19, 2005
-------------	---------------	-------------	--------------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE	N021473 001	Dec 13, 2002
	425.2MG;EQ 574.9MG BASE	N021473 002	Aug 28, 2003

CIPROFLOXACIN EXTENDED RELEASE

DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007
SANDOZ	212.6MG;EQ 287.5MG BASE	A078712 001	Dec 11, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL

PROPULSID

JANSSEN PHARMS	EQ 1MG BASE/ML	N020398 001	Sep 15, 1995
----------------	----------------	-------------	--------------

TABLET; ORAL

PROPULSID

JANSSEN PHARMS	EQ 10MG BASE	N020210 001	Jul 29, 1993
	EQ 20MG BASE	N020210 002	Dec 23, 1993

TABLET, ORALLY DISINTEGRATING; ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA	EQ 20MG BASE	N020767 001	Nov 07, 1997
----------------	--------------	-------------	--------------

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

BEDFORD	10MG/VIAL	A074713 001	Nov 14, 2000
	50MG/VIAL	A074713 002	Nov 14, 2000
TEVA PHARMS USA	1MG/ML	A074814 001	May 16, 2000

PLATINOL

HQ SPCLT PHARMA	10MG/VIAL	N018057 001	
	50MG/VIAL	N018057 002	

PLATINOL-AQ

HQ SPCLT PHARMA	0.5MG/ML	N018057 003	Jul 18, 1984
-----------------	----------	-------------	--------------

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CELEXA

FOREST LABS	EQ 10MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021046 001	Dec 22, 1999
-------------	-----------------------------------------------------------------------------------------------------------------------------------	-------------	--------------

CITALOPRAM HYDROBROMIDE

APOTEX INC	EQ 10MG BASE/5ML	A077601 001	Nov 15, 2005
------------	------------------	-------------	--------------

TABLET; ORAL

CELEXA

FOREST LABS	EQ 60MG BASE	N020822 004	Jul 17, 1998
-------------	--------------	-------------	--------------

CITALOPRAM HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 10MG BASE	A077033 001	Oct 28, 2004
	EQ 20MG BASE	A077033 002	Oct 28, 2004
	EQ 40MG BASE	A077033 003	Oct 28, 2004
COREPHARMA	EQ 10MG BASE	A077036 001	Oct 28, 2004
	EQ 20MG BASE	A077036 002	Oct 28, 2004
	EQ 40MG BASE	A077036 003	Oct 28, 2004
MUTUAL PHARM	EQ 10MG BASE	A077052 001	Jul 03, 2006
	EQ 20MG BASE	A077052 002	Jul 03, 2006
	EQ 40MG BASE	A077052 003	Jul 03, 2006
NATCO PHARMA LTD	EQ 20MG BASE	A077141 002	Apr 10, 2008
	EQ 40MG BASE	A077141 001	Apr 10, 2008
ROXANE	EQ 10MG BASE	A077041 001	Nov 23, 2004
	EQ 20MG BASE	A077041 002	Nov 23, 2004
	EQ 40MG BASE	A077041 003	Nov 23, 2004



## DISCONTINUED DRUG PRODUCT LIST

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

SANDOZ

EQ 10MG BASE

A077035 001 Oct 28, 2004

EQ 10MG BASE

A077040 001 Aug 17, 2005

EQ 20MG BASE

A077035 002 Oct 28, 2004

EQ 20MG BASE

A077040 002 Aug 17, 2005

EQ 40MG BASE

A077035 003 Oct 28, 2004

EQ 40MG BASE

A077040 003 Aug 17, 2005

TARO

EQ 10MG BASE

A077278 001 Mar 22, 2006

EQ 20MG BASE

A077278 002 Mar 22, 2006

EQ 40MG BASE

A077278 003 Mar 22, 2006

TEVA PHARMS

EQ 10MG BASE

A077213 001 Mar 31, 2006

EQ 20MG BASE

A077213 002 Mar 31, 2006

EQ 40MG BASE

A077213 003 Mar 31, 2006

WATSON LABS

EQ 10MG BASE

A077034 001 Jun 30, 2005

EQ 20MG BASE

A077034 002 Jun 30, 2005

EQ 40MG BASE

A077034 003 Jun 30, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL

EQ 10MG BASE

N021763 001 Dec 20, 2005

EQ 20MG BASE

N021763 002 Dec 20, 2005

EQ 40MG BASE

N021763 003 Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE

3.24GM/100ML; 380MG/100ML; 430MG/100ML

N018519 001 Jun 22, 1982

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA

3.24GM/100ML; 380MG/100ML; 430MG/100ML

N018904 001 May 27, 1983

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN

JANSSEN PHARMS

1MG/ML \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020229 001 Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

ABBVIE

187MG/5ML

N050698 003 Sep 30, 1998

TABLET; ORAL

CLARITHROMYCIN

IVAX SUB TEVA PHARMS

250MG

A065137 001 May 31, 2005

500MG

A065137 002 May 31, 2005

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

RANBAXY

1GM

A065210 001 Jan 26, 2005

SANDOZ

500MG

A065250 001 Aug 25, 2005

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

ACTAVIS MID ATLANTIC

EQ 0.5MG BASE/5ML

A074075 001 Oct 31, 1993

APOTEX INC

EQ 0.5MG BASE/5ML

A075703 001 Nov 27, 2000

SILARX

EQ 0.5MG BASE/5ML

A074884 001 Dec 17, 1997

TEVA PHARMS

EQ 0.5MG BASE/5ML

A073095 001 Apr 21, 1992

TAVIST

NOVARTIS

EQ 0.5MG BASE/5ML

N018675 001 Jun 28, 1985

TABLET; ORAL

CLEMASTINE FUMARATE

TEVA

1.34MG

A073282 001 Jan 31, 1992

1.34MG

A073282 002 Dec 03, 1992

TAVIST

NOVARTIS

2.68MG

N017661 001

TAVIST-1

NOVARTIS

1.34MG

N017661 002

NOVARTIS

1.34MG

N017661 003 Aug 21, 1992

**DISCONTINUED DRUG PRODUCT LIST**CLIDINIUM BROMIDE

CAPSULE; ORAL

QUARZAN

ROCHE

2.5MG

N010355 001

5MG

N010355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 75MG BASE

A061809 001

EQ 150MG BASE

A061809 002

CLINDAMYCIN HYDROCHLORIDE

TEVA

EQ 75MG BASE

A063027 001 Sep 20, 1989

WATSON LABS

EQ 75MG BASE

A063082 001 Jul 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 75MG BASE/5ML

A061827 001

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 2% BASE

N050680 001 Aug 11, 1992

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN

EQ 150MG BASE/ML

A061839 001

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM

EQ 150MG BASE/ML

A062747 001 Jun 03, 1988

ASTRAZENECA

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989

BEDFORD

EQ 150MG BASE/ML

A063163 001 Jun 30, 1994

BRISTOL MYERS SQUIBB

EQ 150MG BASE/ML

A062908 001 Feb 01, 1989

HIKMA MAPLE

EQ 150MG BASE/ML

A062806 001 Oct 15, 1987

EQ 150MG BASE/ML

A062953 001 Apr 21, 1988

EQ 150MG BASE/ML

A063068 001 Aug 28, 1989

LOCH

EQ 150MG BASE/ML

A062905 001 May 09, 1988

MARSAM PHARMS LLC

EQ 150MG BASE/ML

A062913 001 Oct 20, 1988

SOLOPAK

EQ 150MG BASE/ML

A062819 001 Mar 15, 1988

EQ 150MG BASE/ML

A062852 001 Mar 17, 1988

TEVA PARENTERAL

EQ 150MG BASE/ML

A063041 001 Dec 29, 1989

EQ 150MG BASE/ML

A063282 001 May 29, 1992

WATSON LABS

EQ 150MG BASE/ML

A062900 001 Jun 08, 1988

EQ 150MG BASE/ML

A063079 001 Mar 05, 1990

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM

EQ 12MG BASE/ML

N050636 001 Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE

EQ 6MG BASE/ML

A065027 001 Jun 29, 2001

EQ 12MG BASE/ML

A065027 002 Jun 29, 2001

EQ 18MG BASE/ML

A065027 003 Jun 29, 2001

BAXTER HLTHCARE

EQ 6MG BASE/ML

N050648 001 Dec 29, 1989

EQ 12MG BASE/ML

N050648 002 Dec 29, 1989

EQ 900MG BASE/100ML

N050648 003 Dec 29, 1989

SOLUTION; TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN

EQ 1% BASE

A062363 001 Feb 08, 1982

CLINDAMYCIN PHOSPHATE

COPLEY PHARM

EQ 1% BASE

A062944 001 Jan 11, 1989

RENAISSANCE PHARMA

EQ 1% BASE

A064108 001 Sep 27, 1996

VINTAGE PHARMS

EQ 1% BASE

A062930 001 Jun 28, 1989

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL

NYSTAFORM

BAYER PHARMS

10MG/GM; 100,000 UNITS/GM

N050235 001

CLOBAZAM

TABLET; ORAL

ONFI

LUNDBECK LLC

5MG

N202067 001 Oct 21, 2011

## DISCONTINUED DRUG PRODUCT LIST

CLOBETASOL PROPIONATE

## CREAM; TOPICAL

## CLOBETASOL PROPIONATE

RENAISSANCE PHARMA	0.05%	A075338	001	Feb 09, 2001
TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994

## CLOBETASOL PROPIONATE (EMOLLIENT)

RENAISSANCE PHARMA	0.05%	A075733	001	Aug 22, 2001
--------------------	-------	---------	-----	--------------

## OINTMENT; TOPICAL

## CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994
RENAISSANCE PHARMA	0.05%	A075057	001	Aug 12, 1998

## SOLUTION; TOPICAL

## CLOBETASOL PROPIONATE

G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995
------------------	-------	---------	-----	--------------

## TEMOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019966	001	Feb 22, 1990
----------------	------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------

CLOFAZIMINE

## CAPSULE; ORAL

## LAMPRENE

NOVARTIS	100MG	N019500	001	Dec 15, 1986
----------	-------	---------	-----	--------------

CLOFIBRATE

## CAPSULE; ORAL

## ATROMID-S

WYETH AYERST	500MG	N016099	002	
--------------	-------	---------	-----	--

## CLOFIBRATE

BANNER PHARMACAPS	500MG	A073396	001	Mar 20, 1992
SANDOZ	500MG	A072191	001	May 02, 1988
TEVA	500MG	A072600	001	Jul 25, 1991
USL PHARMA	500MG	A070531	001	Jun 16, 1986
WATSON LABS	500MG	A071603	001	Sep 18, 1987

CLOMIPHENE CITRATE

## TABLET; ORAL

## MILOPHENE

MILEX	50MG	A072196	001	Dec 20, 1988
-------	------	---------	-----	--------------

CLOMIPRAMINE HYDROCHLORIDE

## CAPSULE; ORAL

## CLOMIPRAMINE HYDROCHLORIDE

SANDOZ	25MG	A074953	001	Jun 25, 1997
	50MG	A074953	002	Jun 25, 1997
	75MG	A074953	003	Jun 25, 1997
TEVA	25MG	A074849	001	Apr 04, 1997
	50MG	A074849	002	Apr 04, 1997
	75MG	A074849	003	Apr 04, 1997
WATSON LABS	25MG	A074600	001	Nov 27, 1996
	25MG	A074751	001	Sep 30, 1998
	50MG	A074600	002	Nov 27, 1996
	50MG	A074751	002	Sep 30, 1998
	75MG	A074600	003	Nov 27, 1996
	75MG	A074751	003	Sep 30, 1998

CLONAZEPAM

## TABLET; ORAL

## CLONAZEPAM

APOTEX INC	0.5MG	A075468	001	Oct 06, 2000
	1MG	A075468	002	Oct 06, 2000
	2MG	A075468	003	Oct 06, 2000
SANDOZ	0.5MG	A074925	001	Sep 30, 1997
	1MG	A074925	002	Sep 30, 1997
	2MG	A074925	003	Sep 30, 1997
TEVA	0.5MG	A074920	001	Aug 04, 1998
	1MG	A074920	002	Aug 04, 1998
	2MG	A074920	003	Aug 04, 1998

## KLONOPIN

ROCHE	0.125MG	N017533	005	Apr 09, 1997
	0.25MG	N017533	006	Apr 09, 1997

## TABLET, ORALLY DISINTEGRATING; ORAL

## KLONOPIN RAPIDLY DISINTEGRATING

ROCHE	0.125MG **Federal Register	N020813	001	Dec 23, 1997
-------	----------------------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL  
 KLONOPIN RAPIDLY DISINTEGRATING

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

0.25MG \*\*Federal Register determination N020813 002 Dec 23, 1997

that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

0.5MG \*\*Federal Register determination N020813 003 Dec 23, 1997

that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

1MG \*\*Federal Register determination N020813 004 Dec 23, 1997

that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

2MG \*\*Federal Register determination N020813 005 Dec 23, 1997

that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

CLONIDINE

SUSPENSION, EXTENDED RELEASE;ORAL

CLONIDINE

TRIS PHARMA INC EQ 0.09MG BASE/ML

N022499 001 Dec 03, 2009

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE

TRIS PHARMA INC EQ 0.17MG BASE

N022500 001 Dec 03, 2009

EQ 0.26MG BASE

N022500 002 Dec 03, 2009

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP

0.1MG

A070881 001 Jul 08, 1986

0.2MG

A070882 001 Jul 08, 1986

0.3MG

A070883 001 Jul 08, 1986

DURAMED PHARMS BARR

0.1MG

A071103 001 Aug 14, 1986

0.2MG

A071102 001 Aug 14, 1986

0.3MG

A071101 001 Aug 14, 1986

INTERPHARM

0.1MG

A071252 001 Oct 01, 1986

0.2MG

A071253 001 Oct 01, 1986

0.3MG

A071254 001 Oct 01, 1986

PAR PHARM

0.1MG

A070461 001 Jul 08, 1986

0.2MG

A070460 001 Jul 08, 1986

0.3MG

A070459 001 Jul 08, 1986

SANDOZ

0.1MG

A070887 001 Aug 31, 1988

0.2MG

A070886 001 Aug 31, 1988

0.3MG

A071294 001 Aug 31, 1988

TEVA

0.1MG

A070747 001 Jul 08, 1986

0.2MG

A070702 001 Jul 08, 1986

0.3MG

A070659 001 Jul 08, 1986

WARNER CHILCOTT

0.1MG

A072138 001 Jun 13, 1988

0.2MG

A072139 001 Jun 13, 1988

0.3MG

A072140 001 Jun 13, 1988

WATSON LABS

0.1MG

A070395 001 Mar 23, 1987

0.1MG

A070965 001 Jul 08, 1986

0.2MG

A070396 001 Mar 23, 1987

0.2MG

A070964 001 Jul 08, 1986

0.3MG

A070397 001 Mar 23, 1987

0.3MG

A070963 001 Jul 08, 1986

TABLET, EXTENDED RELEASE;ORAL

JENLOGA

CONCORDIA PHARMS INC 0.1MG

N022331 001 Sep 30, 2009

0.2MG

N022331 002 May 25, 2010

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE

3.75MG

A071777 001 Jul 14, 1987

7.5MG

A071778 001 Jul 14, 1987

15MG

A071779 001 Jul 14, 1987

AM THERAP

3.75MG

A071429 001 Jun 23, 1987

7.5MG

A071430 001 Jun 23, 1987

15MG

A071431 001 Jun 23, 1987

## DISCONTINUED DRUG PRODUCT LIST

CLORAZEPATE DIPOTASSIUM

## CAPSULE; ORAL

## CLORAZEPATE DIPOTASSIUM

DAVA PHARMS INC	3.75MG	A071742	001	Dec 14, 1987
	7.5MG	A071743	001	Dec 14, 1987
	15MG	A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
	7.5MG	A071728	001	Dec 18, 1987
	15MG	A071729	001	Dec 18, 1987
MYLAN	3.75MG	A071509	001	Oct 19, 1987
	7.5MG	A071510	001	Oct 19, 1987
	15MG	A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
	7.5MG	A071925	001	Apr 25, 1988
	15MG	A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
	7.5MG	A071550	001	Sep 12, 1988
	15MG	A071522	001	Sep 12, 1988
SANDOZ	3.75MG	A072219	001	Aug 26, 1988
	7.5MG	A072220	001	Aug 26, 1988
	15MG	A072112	001	Aug 26, 1988
USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
	7.5MG	A071243	001	Jun 23, 1987
	15MG	A071244	001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
	7.5MG	A071775	001	Mar 01, 1988
	15MG	A071776	001	Mar 01, 1988
WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
	7.5MG	A071879	001	Mar 15, 1988
	15MG	A071860	001	Mar 15, 1988
TRANXENE				
RECORDATI RARE	3.75MG	N017105	001	
	7.5MG	N017105	002	
	15MG	N017105	003	

## TABLET; ORAL

## CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780	001	Jun 26, 1987
	7.5MG	A071781	001	Jun 26, 1987
	15MG	A071782	001	Jun 26, 1987
AM THERAP	3.75MG	A071747	001	Jun 23, 1987
	7.5MG	A071748	001	Jun 23, 1987
	15MG	A071749	001	Jun 23, 1987
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
SANDOZ	3.75MG	A072512	001	May 11, 1990
	7.5MG	A072513	001	May 11, 1990
	15MG	A072514	001	May 11, 1990
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988
WATSON LABS	3.75MG	A071852	001	Feb 09, 1988
	7.5MG	A071853	001	Feb 09, 1988
	15MG	A071854	001	Feb 09, 1988
TRANXENE SD				
RECORDATI RARE	11.25MG	N017105	005	
	22.5MG	N017105	004	

CLOTRIMAZOLE

## CREAM; TOPICAL

## LOTRIMIN

SCHERING PLOUGH	1%	N017619	001	
MYCELEX				
BAYER HEALTHCARE LLC	1%	N018183	001	

**DISCONTINUED DRUG PRODUCT LIST**CLOTRIMAZOLE

LOTION; TOPICAL

LOTRIMIN

SCHERING

1%

N018813 001 Feb 17, 1984

SOLUTION; TOPICAL

LOTRIMIN

SCHERING PLOUGH

1%

N017613 001

MYCELEX

BAYER HLTHCARE

1%

N018181 001

TABLET; VAGINAL

GYNIX

TEVA PHARMS

100MG

A073249 001 Feb 13, 1998

MYCELEX-G

BAYER PHARMS

500MG

N019069 001 Apr 19, 1985

TROCHE/LOZENGE; ORAL

MYCELEX

BAYER HLTHCARE

10MG

N018713 001 Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM

APOTHECON

EQ 250MG BASE

A061452 001

EQ 500MG BASE

A061452 002

TEVA

EQ 250MG BASE

A062240 001

EQ 500MG BASE

A062240 002

CLOXAPEN

GLAXOSMITHKLINE

EQ 250MG BASE

A061806 001

EQ 250MG BASE

A062233 001

EQ 500MG BASE

A061806 002

EQ 500MG BASE

A062233 002

FOR SOLUTION; ORAL

CLOXACILLIN SODIUM

TEVA

EQ 125MG BASE/5ML

A062268 001

EQ 125MG BASE/5ML

A062978 001 Apr 06, 1989

TEGOPEN

APOTHECON

EQ 125MG BASE/5ML

A061453 001

EQ 125MG BASE/5ML

N050192 001

CLOZAPINE

TABLET; ORAL

CLOZAPINE

PAR PHARM

25MG

A075162 001 Apr 26, 2005

100MG

A075162 002 Apr 26, 2005

SANDOZ

25MG

A074546 001 Aug 30, 1996

100MG

A074546 002 Aug 30, 1996

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ PHARMS III

50MG

N021590 003 Jun 03, 2005

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-57 KIT

BRACCO

N/A; N/A; N/A; N/A

N016089 001

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-60 KIT

BRACCO

N/A; N/A; N/A; N/A

N016090 001

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC W/ CODEINE

ANI PHARMS

10MG/5ML; 5MG/5ML; 6.25MG/5ML

N008306 005 Apr 02, 1984

PHERAZINE VC W/ CODEINE

HALSEY

10MG/5ML; 5MG/5ML; 6.25MG/5ML

A088870 001 Mar 02, 1987

PROMETHAZINE VC W/ CODEINE

CENCI

10MG/5ML; 5MG/5ML; 6.25MG/5ML

A088816 001 Nov 22, 1985

WOCKHARDT

10MG/5ML; 5MG/5ML; 6.25MG/5ML

A088896 001 Jan 04, 1985

**DISCONTINUED DRUG PRODUCT LIST**CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN W/ CODEINE			
ANI PHARMS	10MG/5ML;6.25MG/5ML	N008306 004	Apr 02, 1984
PHERAZINE W/ CODEINE			
HALSEY	10MG/5ML;6.25MG/5ML	A088739 001	Dec 23, 1988
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE			
PHARM ASSOC	10MG/5ML;6.25MG/5ML	A089647 001	Dec 22, 1988
PROMETHAZINE W/ CODEINE			
CENCI	10MG/5ML;6.25MG/5ML	A088814 001	Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIFED W/ CODEINE			
GLAXOSMITHKLINE	10MG/5ML;30MG/5ML;1.25MG/5ML	N012575 003	Apr 04, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE			
CENCI	10MG/5ML;30MG/5ML;1.25MG/5ML	A089018 001	Jul 23, 1986
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE			
WOCKHARDT	10MG/5ML;30MG/5ML;1.25MG/5ML	A088833 001	Nov 16, 1984

COLCHICINE; PROBENECID

TABLET;ORAL

COLBENEMID			
MERCK	0.5MG;500MG	N012383 001	
PROBEN-C			
WATSON LABS	0.5MG;500MG	A085552 001	
PROBENECID AND COLCHICINE			
BEECHAM	0.5MG;500MG	A084321 001	
IMPAX LABS	0.5MG;500MG	A083720 002	
IVAX SUB TEVA PHARMS	0.5MG;500MG	A083734 001	
SANDOZ	0.5MG;500MG	A086130 001	
PROBENECID W/ COLCHICINE			
LEDERLE	0.5MG;500MG	A086954 001	
WATSON LABS	0.5MG;500MG	A083221 001	

COLESEVELAM HYDROCHLORIDE

CAPSULE;ORAL

WELCHOL			
DAIICHI SANKYO	375MG	N021141 001	May 26, 2000

COLISTIN SULFATE

SUSPENSION;ORAL

COLY-MYCIN S			
PARKE DAVIS	EQ 25MG BASE/5ML	N050355 001	

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;IV (INFUSION)

VAPRISOL			
CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697 001	Dec 29, 2005

COPPER

INTRAUTERINE DEVICE;INTRAUTERINE

CU-7			
GD SEARLE LLC	89MG	N017408 001	
TATUM-T			
GD SEARLE LLC	120MG	N018205 001	

CORTICOTROPIN

INJECTABLE;INJECTION

ACTH			
PARKEDALE	25 UNITS/VIAL	N008317 002	
	40 UNITS/VIAL	N008317 004	
ACTHAR			
SANOVI AVENTIS US	25 UNITS/VIAL	N007504 002	
	40 UNITS/VIAL	N007504 003	
CORTICOTROPIN			
ORGANICS LAGRANGE	40 UNITS/ML	N010831 001	
	80 UNITS/ML	N010831 002	
WATSON LABS	40 UNITS/VIAL	A088772 001	Nov 21, 1984
H.P. ACTHAR GEL			
QUESTCOR PHARMS	40 UNITS/ML	N008372 006	
PURIFIED CORTROPHIN GEL			
ORGANON USA INC	40 UNITS/ML	N008975 001	
	80 UNITS/ML	N008975 002	

## DISCONTINUED DRUG PRODUCT LIST

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

ORGANON USA INC 40 UNITS/ML N009854 001

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTISONE ACETATE

PHARMACIA AND UPJOHN 25MG/ML N008126 002

WATSON LABS 25MG/ML A083147 003

25MG/ML A085677 001

50MG/ML A083147 004

50MG/ML A085677 002

CORTONE

MERCK 25MG/ML N007110 002

50MG/ML N007110 003

TABLET; ORAL

CORTISONE ACETATE

BARR 25MG A083471 001

ELKINS SINN 25MG A080836 001

EVERYLIFE 25MG A084246 001

HEATHER 25MG A085736 001

IMPAX LABS 25MG N009458 001

INWOOD LABS 25MG A080731 001

IVAX SUB TEVA PHARMS 25MG A080630 001

25MG A083536 001

LANNETT 25MG A080694 001

PANRAY 5MG N008284 002

25MG N008284 001

PHARMACIA AND UPJOHN 5MG N008126 003

10MG N008126 004

25MG N008126 001

PUREPAC PHARM 25MG A080493 001

VITARINE 25MG A080333 001

WATSON LABS 25MG A085884 001

WHITEWORTH TOWN PLSN 25MG A080341 001

CORTONE

MERCK 25MG N007750 003

COSYNTROPIN

SOLUTION; INTRAVENOUS

COSYNTROPIN

SANDOZ 0.25MG/ML (0.25MG/ML) N022028 001 Feb 21, 2008

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

KING PFIZER 0.8MG/INH N018887 001 Dec 05, 1985

CAPSULE; INHALATION

INTAL

SANOFI AVENTIS US 20MG \*\*Federal Register determination N016990 001

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

CAPSULE; ORAL

GASTROCROM

UCB INC 100MG N019188 001 Dec 22, 1989

CONCENTRATE; ORAL

CROMOLYN SODIUM

GENERA PHARMS 100MG/5ML A090954 001 Dec 18, 2009

SOLUTION; INHALATION

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC 10MG/ML A075067 001 Jul 19, 1999

APOTEX INC 10MG/ML A075333 001 Apr 30, 2002

PHARMASCIENCE INC 10MG/ML A075437 001 Apr 21, 2000

ROXANE 10MG/ML A075175 001 Sep 30, 1999

WATSON LABS 10MG/ML A076469 001 Jun 17, 2005

INTAL

KING PHARMS 10MG/ML N018596 001 May 28, 1982

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

APOTEX INC 4% A075615 001 Jan 26, 2001

CROMOPTIC

KING PHARMS 4% A075088 001 Apr 27, 1999



## DISCONTINUED DRUG PRODUCT LIST

CROMOLYN SODIUM

SOLUTION/DROPS;OPHTHALMIC

OPTICROM

ALLERGAN

4%

N018155 001 Oct 03, 1984

SPRAY, METERED;NASAL

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

5.2MG/SPRAY

A074800 001 Jul 26, 2001

HH AND P

5.2MG/SPRAY

A077976 001 Sep 07, 2007

NASALCROM

BLACKSMITH BRANDS

5.2MG/SPRAY \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020463 001 Jan 03, 1997

CRYPTENAMINE ACETATES

INJECTABLE;INJECTION

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT/ML

N008814 001

CRYPTENAMINE TANNATES

TABLET;ORAL

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT

N009217 001

CUPRIC SULFATE

INJECTABLE;INJECTION

CUPRIC SULFATE

ABRAXIS PHARM

EQ 0.4MG COPPER/ML

N019350 001 May 05, 1987

CYANOCOBALAMIN

GEL, METERED;NASAL

NASCOBAL

PAR PHARM

0.5MG/INH

N019722 001 Nov 05, 1996

INJECTABLE;INJECTION

BERUBIGEN

PHARMACIA AND UPJOHN

1MG/ML

N006798 001

BETALIN 12

LILLY

0.1MG/ML

A080855 001

1MG/ML

A080855 002

COBAVITE

WATSON LABS

0.1MG/ML

A083013 001

1MG/ML

A083064 001

CYANOCOBALAMIN

ABRAXIS PHARM

0.03MG/ML

A080510 003

0.1MG/ML

A080510 001

1MG/ML

A080510 002

AKORN

1MG/ML

A087969 001 Nov 10, 1983

DELL LABS

0.03MG/ML

A080689 001

0.1MG/ML

A080689 002

1MG/ML

A080689 003

FRESENIUS KABI USA

0.1MG/ML

A080557 002

HIKMA MAPLE

1MG/ML

A080515 002

LUITPOLD

0.03MG/ML

A080668 001

LYPHOMED

1MG/ML

A083075 001

MYLAN INSTITUTIONAL

1MG/ML

A040451 001 Sep 23, 2003

SANOFI AVENTIS US

1MG/ML

A080564 001

SOLOPAK

1MG/ML

A087551 001 Feb 29, 1984

WARNER CHILCOTT

1MG/ML

N007085 002

WATSON LABS

0.1MG/ML

A080573 002

0.1MG/ML

A083120 001

1MG/ML

A080573 001

1MG/ML

A083120 002

WYETH AYERST

0.1MG/ML

A080554 001

1MG/ML

A080554 002

REDISOL

MERCK

1MG/ML

N006668 010

RUBIVITE

BEL MAR

0.03MG/ML

N010791 004

0.05MG/ML

N010791 001

0.1MG/ML

N010791 002

0.12MG/ML

N010791 005

1MG/ML

N010791 003

RUBRAMIN PC

BRISTOL MYERS SQUIBB

0.1MG/ML

N006799 002

1MG/ML

N006799 004

## DISCONTINUED DRUG PRODUCT LIST

CYANOCOBALAMIN

INJECTABLE; INJECTION

RUBRAMIN PC

1MG/ML

N006799 010 Apr 28, 1988

RUVITE

SAVAGE LABS

1MG/ML

A080570 002

VI-TWEL

BAYER HLTHCARE

1MG/ML

N007012 002

SPRAY, METERED; NASAL

CALOMIST

PAR PHARM

25MCG/SPRAY

N022102 001 Jul 27, 2007

TABLET; ORAL

CYANOCOBALAMIN

WEST WARD

1MG

A084264 001

CYANOCOBALAMIN CO-57

CAPSULE; ORAL

RUBRATOPE-57

BRACCO

0.5-1uCi

N016089 002

CYANOCOBALAMIN CO-60

CAPSULE; ORAL

RUBRATOPE-60

BRACCO

0.5-1uCi

N016090 002

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A; N/A

DICOPAC KIT

GE HEALTHCARE

N/A; N/A; N/A

N017406 001

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

MALLINCKRODT

0.1MG; 0.5uCi; 60MG

N016635 001

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR

ARMOUR PHARM

0.5MG/ML; 2.3MG/ML; 1MG/ML

N011208 001

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W

WYETH AYERST

125MG/5ML

N050508 001

250MG/5ML

N050508 002

500MG/5ML

N050508 003

TABLET; ORAL

CYCLACILLIN

TEVA

250MG

A062895 001 Aug 04, 1988

500MG

A062895 002 Aug 04, 1988

CYCLAPEN-W

WYETH AYERST

250MG

N050509 001

500MG

N050509 002

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE

GLAXOSMITHKLINE

50MG/ML

N009495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

PROSAM LABS

5MG

A077291 001 Feb 03, 2006

SANDOZ

5MG

A072854 002 Feb 03, 2006

10MG

A072854 001 Nov 19, 1991

10MG

A073683 001 Feb 26, 1993

WATSON LABS

10MG

A073143 001 Nov 27, 1991

10MG

A074436 001 Nov 30, 1994

FLEXERIL

JANSSEN RES AND DEV

5MG

N017821 001

10MG

N017821 002

**DISCONTINUED DRUG PRODUCT LIST**CYCLOPENTOLATE HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## AK-PENTOLATE

AKORN 1% A085555 001

## AKPENTOLATE

AKORN 2% A040165 001 Jan 13, 1997

## CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD 1% A089162 001 Jan 24, 1991

SOLA BARNES HIND 1% A084150 001

1% A084863 001

## PENTOLAIR

PHARMAFAIR 0.5% A088643 001 Feb 09, 1987

1% A088150 001 Feb 25, 1983

CYCLOPHOSPHAMIDE

## INJECTABLE; INJECTION

## CYCLOPHOSPHAMIDE

BAXTER HLTHCARE 1GM/VIAL A088374 001 Sep 24, 1986

100MG/VIAL A088371 001 Jul 03, 1986

200MG/VIAL A088372 001 Jul 03, 1986

500MG/VIAL A088373 001 Jul 03, 1986

## CYTOXAN

BAXTER HLTHCARE 100MG/VIAL N012142 001

200MG/VIAL N012142 002

## CYTOXAN (LYOPHILIZED)

BAXTER HLTHCARE 1GM/VIAL N012142 010 Sep 24, 1985

2GM/VIAL N012142 009 Dec 10, 1985

500MG/VIAL N012142 008 Jan 04, 1984

## LYOPHILIZED CYTOXAN

BAXTER HLTHCARE 100MG/VIAL N012142 006 Dec 05, 1985

200MG/VIAL N012142 007 Dec 10, 1985

## NEOSAR

BEDFORD 1GM/VIAL A087442 004 Jul 08, 1983

2GM/VIAL A087442 005 Mar 30, 1989

100MG/VIAL A087442 001 Feb 16, 1982

200MG/VIAL A087442 002 Feb 16, 1982

500MG/VIAL A087442 003 Feb 16, 1982

TEVA PARENTERAL 1GM/VIAL A040015 004 Apr 29, 1993

2GM/VIAL A040015 005 Apr 29, 1993

100MG/VIAL A040015 001 Apr 29, 1993

200MG/VIAL A040015 002 Apr 29, 1993

500MG/VIAL A040015 003 Apr 29, 1993

## TABLET; ORAL

## CYTOXAN

BAXTER HLTHCARE 25MG N012141 002

50MG N012141 001

CYCLOSPORINE

## CAPSULE; ORAL

## NEORAL

NOVARTIS 50MG N050715 003 Jul 14, 1995

## SOLUTION; ORAL

## CYCLOSPORINE

APOTEX INC 100MG/ML A065167 001 Jan 05, 2005

CYCLOTHIAZIDE

## TABLET; ORAL

## ANHYDRON

LILLY 2MG N013157 002

## FLUIDIL

PHARMACIA AND UPJOHN 2MG N018173 001

CYCRIMINE HYDROCHLORIDE

## TABLET; ORAL

## PAGITANE

LILLY 1.25MG N008951 001

2.5MG N008951 002

CYPROHEPTADINE HYDROCHLORIDE

## SYRUP; ORAL

## CYPROHEPTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 2MG/5ML A086833 001

HALSEY 2MG/5ML A089199 001 Jul 03, 1986

MORTON GROVE 2MG/5ML A087001 001 Nov 04, 1982

NASKA 2MG/5ML A089021 001 Dec 21, 1987

## DISCONTINUED DRUG PRODUCT LIST

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

PERIACTIN

MERCCK

2MG/5ML

N013220 002

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP

4MG

A088798 001 Feb 15, 1985

ASCOT

4MG

A087685 001 Oct 25, 1982

DURAMED PHARMS BARR

4MG

A088232 001 Oct 25, 1983

HALSEY

4MG

A089057 001 Jul 03, 1986

KV PHARM

4MG

A086737 001

MD PHARM

4MG

A087566 001 Nov 10, 1982

MYLAN

4MG

A086678 001

PIONEER PHARMS

4MG

A087839 001 Feb 08, 1984

PLIVA

4MG

A088205 001 Jul 26, 1983

SANDOZ

4MG

A086808 001

SUPERPHARM

4MG

A087405 001

TG UNITED LABS

4MG

A088212 001 May 26, 1983

VITARINE

4MG

A087284 001

WATSON LABS

4MG

A085245 001

4MG

A086165 001

4MG

A086580 001

PERIACTIN

MERCCK

4MG

N012649 001

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

HOSPIRA

7.25% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N019523 001 Oct 22, 1986

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

TEVA PARENTERAL

1GM/VIAL

N016793 003 Dec 21, 1987

2GM/VIAL

N016793 004 Dec 21, 1987

100MG/VIAL

N016793 001

500MG/VIAL

N016793 002

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM

100MG/VIAL

A070962 001 Aug 28, 1986

200MG/VIAL

A070990 001 Aug 28, 1986

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

KING PHARMS

420MG/VIAL; 180MG/VIAL

N050748 002 Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

EISAI INC

7,500 IU/0.75ML

N020287 008 Apr 04, 2002

INJECTABLE; SUBCUTANEOUS

FRAGMIN

EISAI INC

10,000IU/0.4ML (25,000IU/ML)

N020287 002 May 01, 2007

95,000IU/9.5ML (10,000IU/ML)

N020287 007 Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

AGI

750 UNITS/0.6ML

N020430 001 Dec 24, 1996

DANAZOL

CAPSULE; ORAL

DANAZOL

AM THERAP

200MG

A071569 001 Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US

50MG

N017557 003

100MG

N017557 004

200MG

N017557 002

**DISCONTINUED DRUG PRODUCT LIST**DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

FERA PHARMS

0.5%

N019849 001 Dec 31, 1990

DAPTOMYCIN

INJECTABLE;IV (INFUSION)

CUBICIN

CUBIST

250MG/VIAL

N021572 001 Sep 12, 2003

DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZISTA

JANSSEN PRODS

EQ 300MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021976 001 Jun 23, 2006

EQ 400MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021976 003 Oct 21, 2008

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

CERUBIDINE

SANOFI AVENTIS US

EQ 20MG BASE/VIAL

A061876 001

WYETH AYERST

EQ 20MG BASE/VIAL

N050484 001

DAUNORUBICIN HYDROCHLORIDE

TEVA PARENTERAL

EQ 20MG BASE/VIAL

A064212 001 Jun 23, 1998

EQ 50MG BASE/VIAL

A064212 002 May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE;INJECTION

SYNCURINE

GLAXOSMITHKLINE

1MG/ML

N006931 002

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

WATSON LABS

2GM/VIAL

A076806 002 Mar 31, 2006

500MG/VIAL

A076806 001 Mar 31, 2006

DEMECARIUM BROMIDE

SOLUTION/DROPS;OPHTHALMIC

HUMORSOL

MERCK

0.125%

N011860 002

0.25%

N011860 001

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

DECLOMYCIN

LEDERLE

150MG

N050262 001

SYRUP;ORAL

DECLOMYCIN

LEDERLE

75MG/5ML

N050257 001

TABLET;ORAL

DECLOMYCIN

COREPHARMA

75MG

N050261 001

150MG

N050261 002

300MG

N050261 003

DESERPIDINE

TABLET;ORAL

HARMONYL

ABBVIE

0.1MG

N010796 001

0.25MG

N010796 002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ORETICYL 25

ABBVIE

0.125MG;25MG

N012148 001

ORETICYL 50

ABBVIE

0.125MG;50MG

N012148 003

ORETICYL FORTE

ABBVIE

0.25MG;25MG

N012148 002

## DISCONTINUED DRUG PRODUCT LIST

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT

0.25MG; 5MG

N012775 001

ENDURONYL FORTE

ABBOTT

0.5MG; 5MG

N012775 002

METHYCLOTHIAZIDE AND DESERPIDINE

WATSON LABS

0.25MG; 5MG

A088486 001 Aug 10, 1984

0.5MG; 5MG

A088452 001 Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US

25MG

N013621 001

50MG

N013621 002

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC

25MG

A071800 001 Dec 08, 1987

50MG

A071801 001 Dec 08, 1987

75MG

A071802 001 Dec 08, 1987

100MG

A071803 001 May 29, 1997

150MG

A071804 001 May 29, 1997

USL PHARMA

25MG

A071864 001 Sep 09, 1987

50MG

A071865 001 Sep 09, 1987

75MG

A071866 001 Sep 09, 1987

100MG

A071867 001 Sep 09, 1987

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS

0.2MG/ML

N009282 002

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

FERRING PHARMS INC

0.015MG/ML

N018938 002 Apr 25, 1995

DESMOPRESSIN ACETATE

BEDFORD

0.004MG/ML

A074575 001 Feb 18, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD

0.004MG/ML

A074574 001 Feb 18, 2000

SOLUTION; NASAL

CONCENTRAID

FERRING

0.01%

N019776 001 Dec 26, 1990

SPRAY, METERED; NASAL

DDAVP

FERRING PHARMS INC

0.01MG/SPRAY

N017922 002 Feb 06, 1989

STIMATE

CSL BEHRING

0.15MG/SPRAY

N020355 001 Mar 07, 1994

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGEN

ORGANON USA INC

0.15MG; 0.03MG

N020071 001 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR

0.15MG; 0.03MG

A075256 001 Aug 12, 1999

ORTHO-CEPT

JANSSEN PHARMS

0.15MG; 0.03MG

N020301 001 Dec 14, 1992

TABLET; ORAL-28

MIRCETTE

TEVA BRANDED PHARM

0.15MG, N/A; 0.02MG, 0.01MG; 0.02MG, 0.01MG

N020713 001 Apr 22, 1998

\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

DESONIDE

CREAM; TOPICAL

DESONIDE

TEVA PHARMS

0.05%

A074027 001 Sep 28, 1992

## DISCONTINUED DRUG PRODUCT LIST

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

TARO PHARMS NORTH	0.25% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017856 001	
-------------------	------------------------------------------------------------------------------------------------------------------------	-------------	--

TOPICORT LP

TARO PHARMS NORTH	0.05%	N018309 001	
-------------------	-------	-------------	--

GEL; TOPICAL

TOPICORT

TARO PHARMS NORTH	0.05%	N018586 001	Mar 29, 1982
-------------------	-------	-------------	--------------

OINTMENT; TOPICAL

DESOXIMETASONE

ALTANA	0.25%	A073440 001	Apr 01, 1998
--------	-------	-------------	--------------

TOPICORT

TARO PHARMS NORTH	0.25%	N018763 001	Sep 30, 1983
-------------------	-------	-------------	--------------

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION

DOCA

ORGANON USA INC	5MG/ML	N001104 001	
-----------------	--------	-------------	--

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS	125MG	N005151 001	
----------	-------	-------------	--

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION

PERCORTEN

NOVARTIS	25MG/ML	N008822 001	
----------	---------	-------------	--

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

TEVA PHARMS USA	EQ 50MG BASE	N205208 001	Oct 11, 2013
	EQ 100MG BASE	N205208 002	Oct 11, 2013

DEXAMETHASONE

AEROSOL; TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT	0.01% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083296 002	
------------------	------------------------------------------------------------------------------------------------------------------------	-------------	--

DECASPRAY

MERCK	0.04% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012731 002	
-------	------------------------------------------------------------------------------------------------------------------------	-------------	--

ELIXIR; ORAL

DECADRON

MERCK	0.5MG/5ML	N012376 002	
-------	-----------	-------------	--

DEXAMETHASONE

ALPHARMA US PHARMS	0.5MG/5ML	A088997 001	Oct 10, 1986
--------------------	-----------	-------------	--------------

HEXADROL

ORGANON USA INC	0.5MG/5ML	N012674 001	
-----------------	-----------	-------------	--

GEL; TOPICAL

DECADERM

MERCK	0.1%	N013538 001	
-------	------	-------------	--

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS	0.1%	A089170 001	May 09, 1989
-------------	------	-------------	--------------

TABLET; ORAL

DECADRON

MERCK	0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 004	
-------	-------------------------------------------------------------------------------------------------------------------------	-------------	--

	0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 001	
--	------------------------------------------------------------------------------------------------------------------------	-------------	--

	0.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 002	
--	-------------------------------------------------------------------------------------------------------------------------	-------------	--

	1.5MG	N011664 003	
--	-------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

DEXAMETHASONE

TABLET; ORAL

DECADRON

4MG	N011664 005	
6MG	N011664 006	Jul 30, 1982

DEXAMETHASONE

IMPAX LABS

0.75MG A085376 001

MUTUAL PHARM

0.25MG A084013 001

0.25MG A084764 001

0.5MG A084084 001

0.5MG A084766 001

0.75MG A084081 001

0.75MG A084765 001

1.5MG A084086 001

1.5MG A084763 001

PAR PHARM

0.25MG A088149 001 Apr 28, 1983

PHOENIX LABS NY

0.75MG A083806 001

PVT FORM

0.75MG A083420 001

ROXANE

0.25MG A084614 001

SANDOZ

0.75MG A080399 001

UPSHER SMITH

0.75MG A087534 001

1.5MG A087533 001

WATSON LABS

0.25MG A085455 001

0.5MG A085458 001

0.75MG A080968 001

0.75MG A084457 001

0.75MG A085818 001

1.5MG A085456 001

1.5MG A085840 001

WHITEWORTH TOWN PLSN

0.75MG A084327 001

DEXONE 0.5

SOLVAY

0.5MG A084991 001

DEXONE 0.75

SOLVAY

0.75MG A084993 001

DEXONE 1.5

SOLVAY

1.5MG A084990 001

DEXONE 4

SOLVAY

4MG A084992 001

HEXADROL

ORGANON USA INC

0.5MG N012675 004

0.75MG N012675 007

1.5MG N012675 009

4MG N012675 010

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

MERCCK

EQ 8MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016675 001	
------------------------------------------------------------------------------------------------------------------------------------------	-------------	--

DEXAMETHASONE ACETATE

WATSON LABS

EQ 8MG BASE/ML A084315 001

EQ 16MG BASE/ML A087711 001 May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH N014242 001

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH N013413 001

CREAM; TOPICAL

DECADRON

MERCCK

EQ 0.1% PHOSPHATE N011983 002

INJECTABLE; INJECTION

DECADRON

MERCCK

EQ 4MG PHOSPHATE/ML N012071 002

EQ 24MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012071 004	
------------------------------------------------------------------------------------------------------------------------------------------------	-------------	--

DEXACEN-4

CENT PHARMS

EQ 4MG PHOSPHATE/ML A084342 001



**DISCONTINUED DRUG PRODUCT LIST**DEXAMETHASONE SODIUM PHOSPHATE

## INJECTABLE; INJECTION

## DEXAMETHASONE

ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448	001	Jan 25, 1984
FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A088469	001	Jan 25, 1984

## DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 4MG PHOSPHATE/ML	A084493	001	
BEL MAR	EQ 4MG PHOSPHATE/ML	A084752	001	
DELL LABS	EQ 4MG PHOSPHATE/ML	A083161	001	
HIKMA MAPLE	EQ 4MG PHOSPHATE/ML	A084282	001	
INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522	001	Feb 17, 1984
LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065	001	
TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125	001	Aug 31, 1990
	EQ 10MG PHOSPHATE/ML	A081126	001	Aug 31, 1990
WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702	001	
	EQ 4MG PHOSPHATE/ML	A084355	001	
	EQ 4MG PHOSPHATE/ML	A089169	001	Apr 09, 1986
	EQ 10MG PHOSPHATE/ML	A087668	001	Jul 01, 1982
	EQ 24MG PHOSPHATE/ML	A085606	001	
WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641	001	

## HEXADROL

ORGANON USA INC	EQ 4MG PHOSPHATE/ML	N014694	002	
	EQ 10MG PHOSPHATE/ML	N014694	003	
	EQ 20MG PHOSPHATE/ML	N014694	004	

## OINTMENT; OPHTHALMIC

## DECADRON

MERCK	EQ 0.05% PHOSPHATE	N011977	001	
-------	--------------------	---------	-----	--

## DEXAIR

PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071	001	Dec 28, 1982
------------	--------------------	---------	-----	--------------

## MAXIDEX

ALCON	EQ 0.05% PHOSPHATE	A083342	001	
-------	--------------------	---------	-----	--

## SOLUTION/DROPS; OPHTHALMIC

## DEXAIR

PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433	001	Dec 15, 1983
------------	-------------------	---------	-----	--------------

## DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170	001	
	EQ 0.1% PHOSPHATE	A084173	001	

## SOLUTION/DROPS; OPHTHALMIC, OTIC

## DECADRON

MERCK	EQ 0.1% PHOSPHATE	N011984	001	
-------	-------------------	---------	-----	--

## SOLUTION/DROPS; OTIC

## DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 0.1% PHOSPHATE	A084855	001	
-------	-------------------	---------	-----	--

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## DECADRON W/ XYLOCAINE

MERCK	EQ 4MG PHOSPHATE/ML; 10MG/ML	N013334	002	
-------	------------------------------	---------	-----	--

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

## OINTMENT; OPHTHALMIC

## NEODECADRON

MERCK	EQ 0.05% PHOSPHATE; EQ 3.5MG BASE/GM	N050324	001	
-------	--------------------------------------	---------	-----	--

## SOLUTION/DROPS; OPHTHALMIC

## NEODECADRON

MERCK	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N050322	001	
-------	-------------------------------------	---------	-----	--

## NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A064055	001	Oct 30, 1995
-----------------	-------------------------------------	---------	-----	--------------

## NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

ALCON PHARMS LTD	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A062714	001	Jul 21, 1986
PHARMAFAIR	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A062539	001	Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

## OINTMENT; OPHTHALMIC

## DEXACIDIN

NOVARTIS	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062566	001	Feb 22, 1985
----------	-----------------------------------------	---------	-----	--------------

## DEXASPORIN

PHARMAFAIR	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062411	001	May 16, 1983
------------	-----------------------------------------	---------	-----	--------------

## SUSPENSION/DROPS; OPHTHALMIC

## DEXACIDIN

NOVARTIS	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062544	001	Oct 29, 1984
----------	-----------------------------------------	---------	-----	--------------

## DEXASPORIN

PHARMAFAIR	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062428	001	May 18, 1983
------------	-----------------------------------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

ALCON PHARMS LTD 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062721 001 Nov 17, 1986

DEXBROMPHENIRAMINE MALEATE

SYRUP;ORAL

DISOMER

SCHERING 2MG/5ML N011814 002

TABLET;ORAL

DISOMER

SCHERING 2MG N011814 001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET;ORAL

DISOPHROL

SCHERING 2MG;60MG N012394 002

TABLET, EXTENDED RELEASE;ORAL

BROMPHERIL

COPLEY PHARM 6MG;120MG A089116 001 Jan 22, 1987

DISOBROM

SANDOZ 6MG;120MG A070770 001 Sep 30, 1991

DISOPHROL

SCHERING PLOUGH 6MG;120MG N013483 004 Sep 13, 1982

DRIXORAL

SCHERING PLOUGH 6MG;120MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\* N013483 003 Sep 13, 1982

RESPORAL

PIONEER PHARMS 6MG;120MG A089139 001 Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

POLARAMINE

SCHERING 2MG/5ML A086837 001 Jul 19, 1982

TABLET;ORAL

DEXCHLORPHENIRAMINE MALEATE

ANI PHARMS INC 2MG A088682 001 Jan 17, 1986

POLARAMINE

SCHERING 2MG A086835 001

DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL

DEXAMPEX

TEVA 15MG A085355 001

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

ABLE 5MG A076814 001 Aug 25, 2004

10MG A076814 002 Aug 25, 2004

15MG A076814 003 Aug 25, 2004

ELIXIR;ORAL

DEXEDRINE

GLAXOSMITHKLINE 5MG/5ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\* A083902 001

TABLET;ORAL

DEXAMPEX

TEVA 5MG A083735 001

10MG A083735 002

DEXEDRINE

GLAXOSMITHKLINE 5MG A084935 001

DEXTROAMPHETAMINE SULFATE

HALSEY 10MG A083930 001

LANNETT 5MG A083903 001

10MG A083903 003

15MG A085652 001

MAST MM 5MG A086521 001

NESHER PHARMS 5MG A040365 001 Oct 31, 2002

10MG A040367 001 Oct 31, 2002

PUREPAC PHARM 5MG A084125 001

SANDOZ 5MG A085370 001

10MG A085371 001

VINTAGE PHARMS LLC 5MG A040299 001 May 13, 1999

**DISCONTINUED DRUG PRODUCT LIST**DEXTROAMPHETAMINE SULFATE

## TABLET; ORAL

## DEXTROAMPHETAMINE SULFATE

VITARINE	5MG	A084986	001
	10MG	A085892	001

## DEXTROSTAT

SHIRE	5MG	A084051	001
	10MG	A084051	002

## FERNDEX

FERNDALE LABS	5MG	A084001	001
---------------	-----	---------	-----

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

## SYRUP; ORAL

## PHERAZINE DM

HALSEY	15MG/5ML; 6.25MG/5ML	A088913	001	Mar 02, 1987
--------	----------------------	---------	-----	--------------

## PROMETH W/ DEXTROMETHORPHAN

ACTAVIS MID ATLANTIC	15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984
----------------------	----------------------	---------	-----	--------------

## PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

ANI PHARMS	15MG/5ML; 6.25MG/5ML	N011265	002	Apr 02, 1984
------------	----------------------	---------	-----	--------------

## PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011
---------------	----------------------	---------	-----	--------------

TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012
-----------------	----------------------	---------	-----	--------------

DEXTROSE

## INJECTABLE; INJECTION

## DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML	N018046	001
---------	------------	---------	-----

MILES	10GM/100ML	N018504	001
-------	------------	---------	-----

## DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML	N018358	001
---------	-------------	---------	-----

	2.5GM/100ML	N019626	001	Feb 02, 1988
--	-------------	---------	-----	--------------

## DEXTROSE 38.5% IN PLASTIC CONTAINER

ABBOTT	38.5GM/100ML	N018923	001	Sep 19, 1984
--------	--------------	---------	-----	--------------

## DEXTROSE 5% IN PLASTIC CONTAINER

DHL	5GM/100ML	N019971	001	Sep 28, 1995
-----	-----------	---------	-----	--------------

## DEXTROSE 60%

B BRAUN	60GM/100ML	N017995	002	Sep 22, 1982
---------	------------	---------	-----	--------------

## DEXTROSE 60% IN PLASTIC CONTAINER

B BRAUN	60GM/100ML	N017995	001
---------	------------	---------	-----

BAXTER HLTHCARE	60GM/100ML	N020047	002	Jul 02, 1991
-----------------	------------	---------	-----	--------------

HOSPIRA	60GM/100ML	N019346	001	Jan 25, 1985
---------	------------	---------	-----	--------------

## DEXTROSE 7.7% IN PLASTIC CONTAINER

B BRAUN	7.7GM/100ML	N019626	003	Feb 02, 1988
---------	-------------	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

## INJECTABLE; INJECTION

## ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019025	001	Dec 27, 1984
---------	-------------------------------------------------------------	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

## ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N018273	001
---------	-------------------------------------------------------------	---------	-----

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

## INJECTABLE; INJECTION

## ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N018274	001
---------	--------------------------------------------------------------------------	---------	-----

DEXTROSE; POTASSIUM CHLORIDE

## INJECTABLE; INJECTION

## POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 37MG/100ML	N019699	001	Sep 29, 1989
---------	-----------------------	---------	-----	--------------

## POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 75MG/100ML	N019699	002	Sep 29, 1989
---------	-----------------------	---------	-----	--------------

## POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 110MG/100ML	N019699	003	Sep 29, 1989
---------	------------------------	---------	-----	--------------

## POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML	N018744	003	Nov 09, 1982
---------	------------------------	---------	-----	--------------

	5GM/100ML; 220MG/100ML	N019699	005	Sep 29, 1989
--	------------------------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

## INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 111MG/100ML; 256MG/100ML; 146MG	N019514 001	May 08, 1986
	/100ML; 207MG/100ML		

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG	N018270 001	
	/100ML; 91MG/100ML		

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML; 75MG/100ML; 200MG/100ML	N018268 009	
---------	------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 200MG/100ML	N018268 004	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 200MG/100ML	N018268 005	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 200MG/100ML	N018268 006	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 75MG/100ML; 330MG/100ML	N018268 011	Jan 18, 1986
---------	------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 330MG/100ML	N018268 012	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 330MG/100ML	N018268 013	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 330MG/100ML	N018268 014	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML; 75MG/100ML; 450MG/100ML	N018268 010	
---------	------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 450MG/100ML	N018268 001	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 450MG/100ML	N018268 002	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 450MG/100ML	N018268 003	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 450MG/100ML	N018008 003	
-----------------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 450MG/100ML	N018008 001	
-----------------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 450MG/100ML	N018008 002	
-----------------	------------------------------------	-------------	--

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 200MG/100ML	N018386 001	
---------	-------------------------	-------------	--

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 450MG/100ML	N018229 001	
---------	-------------------------	-------------	--

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 900MG/100ML	N018047 001	
---------	-------------------------	-------------	--

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML; 450MG/100ML	N018030 001	
---------	--------------------------	-------------	--

HOSPIRA	2.5GM/100ML; 450MG/100ML	N018096 001	
---------	--------------------------	-------------	--

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML; 900MG/100ML	N018376 001	
---------	--------------------------	-------------	--

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	3.3GM/100ML; 300MG/100ML	N018055 001	
--------	--------------------------	-------------	--

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 110MG/100ML	N018030 005	
---------	------------------------	-------------	--

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 200MG/100ML	N018030 004	
---------	------------------------	-------------	--

MILES	5GM/100ML; 200MG/100ML	N018399 001	
-------	------------------------	-------------	--

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 225MG/100ML	N019482 001	Oct 04, 1985
--------	------------------------	-------------	--------------

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 300MG/100ML	N019486 001	Oct 04, 1985
--------	------------------------	-------------	--------------

MILES	5GM/100ML; 300MG/100ML	N018501 001	
-------	------------------------	-------------	--

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 330MG/100ML	N018030 003	
---------	------------------------	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 450MG/100ML	N019484 001	Oct 04, 1985
B BRAUN	5GM/100ML; 450MG/100ML	N018030 002	
MILES	5GM/100ML; 450MG/100ML	N018400 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 900MG/100ML	N019483 001	Oct 04, 1985
B BRAUN	5GM/100ML; 900MG/100ML	N018026 001	
MILES	5GM/100ML; 900MG/100ML	N018500 001	

DEXTROTHYROXINE SODIUM

## TABLET; ORAL

CHOLOXIN

ABBVIE	1MG	N012302 005	
	2MG	N012302 002	
	4MG	N012302 004	
	6MG	N012302 006	

DEZOCINE

## INJECTABLE; INJECTION

DALGAN

ASTRAZENECA	5MG/ML	N019082 001	Dec 29, 1989
	10MG/ML	N019082 002	Dec 29, 1989
	15MG/ML	N019082 003	Dec 29, 1989

DIATRIZOATE MEGLUMINE

## INJECTABLE; INJECTION

ANGIOVIST 282

BAYER HLTHCARE	60%	A087726 001	Sep 23, 1982
----------------	-----	-------------	--------------

CARDIOGRAFIN

BRACCO	85%	N011620 002	
--------	-----	-------------	--

DIATRIZOATE MEGLUMINE

BRACCO	76%	N010040 017	
--------	-----	-------------	--

HYPAQUE

GE HEALTHCARE	30%	N016403 002	
	60%	N016403 001	

RENO-60

BRACCO	60%	N010040 016	
--------	-----	-------------	--

RENO-DIP

BRACCO	30%	N010040 012	
--------	-----	-------------	--

UROVIST MEGLUMINE DIU/CT

BAYER HLTHCARE	30%	A087739 001	Sep 23, 1982
----------------	-----	-------------	--------------

## SOLUTION; URETERAL

RENO-30

BRACCO	30%	N010040 021	
--------	-----	-------------	--

UROVIST CYSTO

BAYER HLTHCARE	30%	A087729 001	Sep 23, 1982
----------------	-----	-------------	--------------

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE	30%	A087731 001	Sep 23, 1982
----------------	-----	-------------	--------------

## SOLUTION; URETHRAL

HYPAQUE-CYSTO

GE HEALTHCARE	30%	N016403 003	
---------------	-----	-------------	--

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

## INJECTABLE; INJECTION

ANGIOVIST 292

BAYER HLTHCARE	52%; 8%	A087724 001	Sep 23, 1982
----------------	---------	-------------	--------------

ANGIOVIST 370

BAYER HLTHCARE	66%; 10%	A087723 001	Sep 23, 1982
----------------	----------	-------------	--------------

DIATRIZOATE-60

INTL MEDICATION	52%; 8%	A088166 001	Jun 17, 1983
-----------------	---------	-------------	--------------

HYPAQUE-76

GE HEALTHCARE	66%; 10%	A086505 001	
---------------	----------	-------------	--

HYPAQUE-M, 75%

GE HEALTHCARE	50%; 25%	N010220 003	
---------------	----------	-------------	--

HYPAQUE-M, 90%

GE HEALTHCARE	60%; 30%	N010220 002	
---------------	----------	-------------	--

MD-60

MALLINCKRODT	52%; 8%	A087074 001	
--------------	---------	-------------	--

MD-76

MALLINCKRODT	66%; 10%	A087073 001	
--------------	----------	-------------	--

RENOCAL-76

BRACCO	66%; 10%	A089347 001	Jun 01, 1988
--------	----------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

## INJECTABLE; INJECTION

RENOGRAFIN-60

BRACCO 52%;8% N010040 006

RENOVIST

BRACCO 34.3%;35% N010040 020

RENOVIST II

BRACCO 28.5%;29.1% N010040 019

## SOLUTION; ORAL, RECTAL

GASTROVIST

BAYER HLTHCARE 66%;10% A087728 001 Sep 23, 1982

DIATRIZOATE SODIUM

## FOR SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 100% N011386 001

## INJECTABLE; INJECTION

HYPAQUE

GE HEALTHCARE 25% N009561 003

50% N009561 001

MD-50

MALLINCKRODT 50% A087075 001

UROVIST SODIUM 300

BAYER HLTHCARE 50% A087725 001 Sep 23, 1982

## SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 40% N011386 003

## SOLUTION; URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE 20% N009561 002

DIAZEPAM

## CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE

ROCHE 15MG N018179 001

## GEL; RECTAL

DIASTAT

VALEANT PHARMS NORTH 5MG/ML (5MG/ML) \*\*Federal Register N020648 002 Jul 29, 1997

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

10MG/2ML (5MG/ML) N020648 003 Jul 29, 1997

15MG/3ML (5MG/ML) N020648 004 Jul 29, 1997

20MG/4ML (5MG/ML) N020648 005 Jul 29, 1997

## INJECTABLE; INJECTION

DIAZEPAM

ABRAXIS PHARM 5MG/ML A070662 001 Jun 25, 1986

HIKMA MAPLE 5MG/ML A070311 001 Dec 16, 1985

5MG/ML A070312 001 Dec 16, 1985

5MG/ML A070313 001 Dec 16, 1985

5MG/ML A071308 001 Jul 17, 1987

5MG/ML A071309 001 Jul 17, 1987

5MG/ML A071310 001 Jul 17, 1987

5MG/ML A071584 001 Oct 13, 1987

MARSAM PHARMS LLC 5MG/ML A072371 001 Jan 29, 1993

PARENTA PHARMS 5MG/ML A076815 001 Apr 15, 2004

US ARMY 5MG/ML N020124 001 Dec 05, 1990

WARNER CHILCOTT 5MG/ML A071613 001 Oct 22, 1987

5MG/ML A071614 001 Oct 22, 1987

WATSON LABS 5MG/ML A070296 001 Feb 12, 1986

5MG/ML A070911 001 Aug 28, 1986

5MG/ML A070912 001 Aug 28, 1986

5MG/ML A070930 001 Dec 01, 1986

WATSON LABS INC 5MG/ML A072370 001 Jan 29, 1993

5MG/ML A072397 001 Jan 29, 1993

DIZAC

PHARMACIA AND UPJOHN 5MG/ML N019287 001 Jun 18, 1993

VALIUM

ROCHE 5MG/ML N016087 001

## TABLET; ORAL

DIAZEPAM

ACTAVIS ELIZABETH 2MG A070781 001 Mar 19, 1986

5MG A070706 001 Mar 19, 1986

10MG A070707 001 Mar 19, 1986

## DISCONTINUED DRUG PRODUCT LIST

DIAZEPAM

TABLET; ORAL

DIAZEPAM

DAVA PHARMS INC	2MG	A070226 001	Sep 26, 1985
	5MG	A070227 001	Sep 26, 1985
	10MG	A070228 001	Sep 26, 1985
DURAMED PHARMS BARR	2MG	A070894 001	Aug 27, 1986
	5MG	A070895 001	Aug 27, 1986
	10MG	A070896 001	Aug 27, 1986
FERNDALE LABS	2MG	A070903 001	Apr 01, 1987
	5MG	A070904 001	Apr 01, 1987
	10MG	A070905 001	Apr 01, 1987
HALSEY	2MG	A070987 001	Aug 15, 1986
	5MG	A070996 001	Aug 15, 1986
	10MG	A070956 001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360 001	Sep 04, 1985
	5MG	A070361 001	Sep 04, 1985
	10MG	A070362 001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402 001	Apr 25, 1989
PAR PHARM	2MG	A070462 001	Feb 25, 1986
	5MG	A070463 001	Feb 25, 1986
	10MG	A070464 001	Feb 25, 1986
PIONEER PHARMS	2MG	A070787 001	Aug 02, 1988
	5MG	A070788 001	Aug 02, 1988
	10MG	A070776 001	Aug 02, 1988
ROXANE	2MG	A070356 001	Jun 17, 1986
	5MG	A070357 001	Jun 17, 1986
	10MG	A070358 001	Jun 17, 1986
SANDOZ	2MG	A070302 001	Dec 20, 1985
	5MG	A070303 001	Dec 20, 1985
	10MG	A070304 001	Dec 20, 1985
TEVA PHARMS	5MG	A070153 001	Nov 01, 1985
WARNER CHILCOTT	2MG	A070209 001	Sep 04, 1985
	5MG	A070210 001	Sep 04, 1985
	10MG	A070222 001	Sep 04, 1985
WATSON LABS	2MG	A070456 001	Nov 01, 1985
	5MG	A070457 001	Nov 01, 1985
	10MG	A070458 001	Nov 01, 1985

Q-PAM

QUANTUM PHARMICS	2MG	A070423 001	Dec 12, 1985
	2MG	A072431 001	Apr 29, 1988
	5MG	A070424 001	Dec 12, 1985
	5MG	A072432 001	Apr 29, 1988
	10MG	A070425 001	Dec 12, 1985
	10MG	A072433 001	Apr 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

TEVA BRANDED PHARM	50MG	N017425 001
	100MG	N017425 002

INJECTABLE; INJECTION

DIAZOXIDE

ABRAXIS PHARM	15MG/ML	A071519 001	Aug 26, 1987
HYPERSTAT			
SCHERING	15MG/ML	N016996 001	

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEAVY SOLUTION NUPERCAINE

NOVARTIS	2.5MG/ML	N006203 001
----------	----------	-------------

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

TARO	50MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011366 001
------	------	------------------------------------------------------------------------------------------------------------------	-------------

## DISCONTINUED DRUG PRODUCT LIST

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

NOVARTIS

25MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020142 001 Nov 24, 1993

DICLOFENAC POTASSIUM

MUTUAL PHARM

50MG

A075470 001 Feb 21, 2002

SANDOZ

50MG

A075582 001 Feb 23, 2001

WATSON LABS

50MG

A075152 001 Nov 27, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

APOTEX INC

0.1%

A077600 001 Nov 13, 2008

FALCON PHARMS

0.1%

N020809 001 May 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

NOSTRUM LABS

50MG

A074986 001 Feb 26, 1999

75MG

A074986 002 Feb 26, 1999

PLIVA

50MG

A074432 002 Jul 29, 1999

75MG

A074432 003 Jul 29, 1999

ROXANE

25MG

A074391 001 Jun 29, 1995

50MG

A074391 002 Jun 29, 1995

75MG

A074391 003 Jun 29, 1995

TEVA

50MG

A074723 001 Mar 30, 1999

75MG

A074390 001 Aug 15, 1996

TEVA PHARMS

25MG

A074459 001 Jun 25, 1997

50MG

A074459 002 Jun 25, 1997

75MG

A074459 003 Jun 25, 1997

VOLTAREN

NOVARTIS

25MG

N019201 001 Jul 28, 1988

50MG

N019201 002 Jul 28, 1988

75MG

N019201 003 Jul 28, 1988

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DYCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A060254 002

EQ 250MG BASE

A062238 001

EQ 500MG BASE

A060254 003

EQ 500MG BASE

A062238 002

PATHOCIL

WYETH AYERST

EQ 250MG BASE

N050011 002

EQ 500MG BASE

N050011 003 Mar 28, 1983

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

APOTHECON

EQ 62.5MG BASE/5ML

A061455 001

DYNAPEN

APOTHECON

EQ 62.5MG BASE/5ML

N050337 002

PATHOCIL

WYETH AYERST

EQ 62.5MG BASE/5ML

N050092 001

DICUMAROL

CAPSULE; ORAL

DICUMAROL

LILLY

25MG

N005509 003

50MG

N005509 001

TABLET; ORAL

DICUMAROL

ABBVIE

25MG

N005545 003

50MG

N005545 004

100MG

N005545 005

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

HIKMA PHARMS LLC

10MG

A040204 001 Feb 28, 1997

MUTUAL PHARM

10MG

A084505 001 Oct 21, 1986

PIONEER PHARMS

10MG

A089361 001 Jan 10, 1989

WATSON LABS

10MG

A083179 001 Feb 12, 1986



**DISCONTINUED DRUG PRODUCT LIST**DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

WATSON LABS

10MG/ML

A080614 001 Feb 11, 1986

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS

10MG/5ML

A084479 001

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

HIKMA PHARMS LLC

20MG

A040161 001 Oct 01, 1996

MUTUAL PHARM

20MG

A084600 001 Jul 29, 1985

PIONEER PHARMS

20MG

A088585 001 Aug 20, 1986

WATSON LABS

20MG

A084361 001 Feb 06, 1986

DIDANOSINE

FOR SOLUTION; ORAL

VIDEX

BRISTOL MYERS SQUIBB

100MG/PACKET

N020155 003 Oct 09, 1991

167MG/PACKET

N020155 004 Oct 09, 1991

250MG/PACKET

N020155 005 Oct 09, 1991

375MG/PACKET

N020155 006 Oct 09, 1991

TABLET, CHEWABLE; ORAL

VIDEX

BRISTOL MYERS SQUIBB

25MG

N020154 002 Oct 09, 1991

50MG

N020154 003 Oct 09, 1991

100MG

N020154 004 Oct 09, 1991

150MG

N020154 005 Oct 09, 1991

200MG

N020154 006 Oct 28, 1999

DIENESTROL

CREAM; VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM

0.01%

N006110 005

DV

SANOFI AVENTIS US

0.01%

A083518 001

ESTRAGUARD

SOLVAY

0.01%

A084436 001

SUPPOSITORY; VAGINAL

DV

SANOFI AVENTIS US

0.7MG

A083517 001

DIETHYLCARBAMAZINE CITRATE

TABLET; ORAL

HETRAZAN

LEDERLE

50MG

N006459 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

SANDOZ

25MG

A085916 001

TEVA

25MG

A088642 001 Sep 20, 1984

TG UNITED LABS

25MG

A088267 001 Aug 25, 1983

25MG

A088268 001 Aug 25, 1983

UCB INC

25MG

A085544 001

WATSON LABS

25MG

A085741 001

TENUATE

SANOFI AVENTIS US

25MG

N017668 001

TEPANIL

3M

25MG

N011673 001

TABLET, EXTENDED RELEASE; ORAL

TENUATE

SANOFI AVENTIS US

75MG

N017669 001

TEPANIL TEN-TAB

3M

75MG

N017956 001

DIETHYLSTILBESTROL

INJECTABLE; INJECTION

STILBESTROL

BRISTOL MYERS SQUIBB

0.2MG/ML

N004056 003

0.5MG/ML

N004056 004

1MG/ML

N004056 005

5MG/ML

N004056 006

## DISCONTINUED DRUG PRODUCT LIST

DIETHYLSTILBESTROL

## SUPPOSITORY; VAGINAL

## DIETHYLSTILBESTROL

LILLY	0.1MG	N004040 001
	0.5MG	N004040 002

## STILBESTROL

BRISTOL MYERS SQUIBB	0.1MG	N004056 001
	0.5MG	N004056 002

## TABLET; ORAL

## DIETHYLSTILBESTROL

LILLY	0.1MG	N004041 002
	0.5MG	N004041 003
	1MG	N004041 004
	5MG	N004041 005

## STILBESTROL

TABLICAPS	0.5MG	A083004 001
	1MG	A083002 001
	5MG	A083006 001

## STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056 007
	0.25MG	N004056 017
	0.5MG	N004056 008
	1MG	N004056 009
	5MG	N004056 010

## TABLET, DELAYED RELEASE; ORAL

## DIETHYLSTILBESTROL

LILLY	0.1MG	N004039 002
	0.25MG	N004039 005
	0.5MG	N004039 003
	1MG	N004039 004
	5MG	N004039 006

## STILBESTROL

TABLICAPS	0.5MG	A083003 001
	1MG	A083005 001
	5MG	A083007 001

## STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056 011
	0.5MG	N004056 012
	1MG	N004056 013
	5MG	N004056 014

DIETHYLSTILBESTROL DIPHOSPHATE

## INJECTABLE; INJECTION

## STILPHOSTROL

BAYER PHARMS	250MG/5ML	N010010 001
--------------	-----------	-------------

## TABLET; ORAL

## STILPHOSTROL

BAYER PHARMS	50MG	N010010 002
--------------	------	-------------

DIFLORASONE DIACETATE

## CREAM; TOPICAL

## DIFLORASONE DIACETATE

FOUGERA PHARMS	0.05%	A075187 001	Mar 30, 1998
----------------	-------	-------------	--------------

## FLORONE

PHARMACIA AND UPJOHN	0.05%	N017741 001
----------------------	-------	-------------

## FLORONE E

PHARMACIA AND UPJOHN	0.05%	N019259 001	Aug 28, 1985
----------------------	-------	-------------	--------------

## PSORCON

TARO PHARMS NORTH	0.05%	N020205 001	Nov 20, 1992
-------------------	-------	-------------	--------------

## OINTMENT; TOPICAL

## PSORCON

PHARMACIA AND UPJOHN	0.05%	N019260 001	Aug 28, 1985
----------------------	-------	-------------	--------------

## PSORCON E

PHARMACIA AND UPJOHN	0.05%	N017994 001
----------------------	-------	-------------

DIFLUNISAL

## TABLET; ORAL

## DIFLUNISAL

PUREPAC PHARM	250MG	A074285 001	May 07, 1996
---------------	-------	-------------	--------------

	500MG	A074285 002	May 07, 1996
--	-------	-------------	--------------

ROXANE	250MG	A073562 001	Nov 27, 1992
--------	-------	-------------	--------------

	500MG	A073563 001	Nov 27, 1992
--	-------	-------------	--------------

SANDOZ	500MG	A074604 001	Jun 10, 1996
--------	-------	-------------	--------------

TEVA	250MG	A073679 001	Jul 31, 1992
------	-------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

WATSON LABS

250MG

A074400 001 Jul 17, 1997

500MG

A074400 002 Jul 17, 1997

DOLOBID

MERCCK

250MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*  
500MG

N018445 001 Apr 19, 1982

N018445 002 Apr 19, 1982

DIGITOXIN

INJECTABLE; INJECTION

CRYSTODIGIN

LILLY

0.2MG/ML

A084100 005

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

GLAXOSMITHKLINE LLC

0.05MG

N018118 002 Jul 26, 1982

0.1MG

N018118 003 Jul 26, 1982

0.15MG

N018118 004 Sep 24, 1984

0.2MG

N018118 001 Jul 26, 1982

INJECTABLE; INJECTION

DIGOXIN

ABRAXIS PHARM

0.25MG/ML

A083217 001

HOSPIRA

0.25MG/ML

A040093 001 May 16, 1996

0.25MG/ML

A040206 001 Aug 28, 1998

WYETH AYERST

0.25MG/ML

A084386 001

DIGOXIN PEDIATRIC

HOSPIRA

0.1MG/ML

A040092 001 Apr 25, 1996

TABLET; ORAL

DIGOXIN

SUN PHARM INDS INC

0.125MG

A076363 001 Jan 31, 2003

0.25MG

A076363 002 Jan 31, 2003

LANOXIN

COVIS PHARMA

0.375MG

N020405 005 Sep 30, 1997

0.5MG

N020405 006 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

EMBOLEX

NOVARTIS

0.5MG/0.5ML; 2,500  
UNITS/0.5ML; 5.33MG/0.5ML  
0.5MG/0.7ML; 5,000  
UNITS/0.7ML; 7.46MG/0.7ML

N018885 001 Nov 30, 1984

N018885 002 Nov 30, 1984

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

BIOVAIL

60MG

N019471 001 Jan 23, 1989

90MG

N019471 002 Jan 23, 1989

120MG

N019471 003 Jan 23, 1989

180MG

N019471 004 Jan 23, 1989

DILTIAZEM HYDROCHLORIDE

BIOVAIL

60MG

A074845 001 Sep 15, 1999

90MG

A074845 002 Sep 15, 1999

120MG

A074845 003 Sep 15, 1999

120MG

N020939 001 Jan 28, 2000

180MG

N020939 002 Jan 28, 2000

240MG

N020939 003 Jan 28, 2000

300MG

N020939 004 Jan 28, 2000

360MG

N020939 005 Sep 14, 2001

420MG

N020939 006 Sep 14, 2001

NESHER PHARMS

120MG

A076563 002 Sep 12, 2006

180MG

A076563 003 Sep 12, 2006

240MG

A076563 004 Sep 12, 2006

300MG

A076563 005 Sep 12, 2006

360MG

A076563 006 Sep 12, 2006

420MG

A076563 001 Sep 12, 2006

TEVA

60MG

A074079 001 Nov 30, 1993

90MG

A074079 002 Nov 30, 1993

120MG

A074079 003 Nov 30, 1993

## DISCONTINUED DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

CARDIZEM

BIOVAIL	100MG/VIAL	N020792 001	Sep 05, 1997
BIOVAIL LABS INTL	5MG/ML	N020027 001	Oct 24, 1991
	25MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020027 003	Aug 18, 1995

DILTIAZEM HYDROCHLORIDE

AGILA SPECLTS	5MG/ML	A075375 001	Sep 30, 1999
HOSPIRA	5MG/ML	A075004 001	Feb 16, 2000
	5MG/ML	A075106 001	Apr 29, 1999
TEVA PHARMS USA	5MG/ML	A074894 001	Aug 26, 1997

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON	30MG	A074051 001	Mar 31, 1993
	60MG	A074051 002	Mar 31, 1993
	90MG	A074051 003	Mar 31, 1993
	120MG	A074051 004	Mar 31, 1993
DAVA PHARMS INC	30MG	A074093 001	Nov 05, 1992
	60MG	A074093 002	Nov 05, 1992
	90MG	A074093 003	Nov 05, 1992
	120MG	A074093 004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG	A074168 001	Mar 03, 1995
	60MG	A074168 002	Mar 03, 1995
	90MG	A074168 003	Mar 03, 1995
	120MG	A074168 004	Mar 03, 1995
TEVA	30MG	A074084 001	Feb 25, 1994
	60MG	A074084 002	Feb 25, 1994
TEVA PHARMS	30MG	A074067 001	Nov 05, 1992
	60MG	A074067 002	Nov 05, 1992
	90MG	A074067 003	Nov 05, 1992
	120MG	A074067 004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

MERCK	EQ 120MG HCL	N020506 001	Oct 04, 1996
	EQ 180MG HCL	N020506 002	Oct 04, 1996
	EQ 240MG HCL	N020506 003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

BIOVAIL	EQ 180MG HCL; 5MG	N020507 001	Oct 04, 1996
---------	-------------------	-------------	--------------

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767 001	
WATSON LABS	50MG/ML	A080615 001	
	50MG/ML	A083531 001	
WYETH AYERST	50MG/ML	A084316 001	

LIQUID; ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715 001	
------	------------	-------------	--

TABLET; ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841 001	
NEXGEN PHARMA INC	50MG	A085985 001	
WATSON LABS	50MG	A085166 001	

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

IMCOR PHARMS CO	0.92MG/VIAL; 0.092MG/VIAL	N021191 001	May 31, 2002
-----------------	---------------------------	-------------	--------------

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION

PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434 001	
----------------------	----------------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

DIPHEMANIL METHYLSULFATE

TABLET; ORAL

PRANTAL

SCHERING	100MG	N008114	004
----------	-------	---------	-----

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

BENADRYL

MCNEIL CONS	25MG	N005845	007
-------------	------	---------	-----

	50MG	N005845	001
--	------	---------	-----

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA	25MG	A080519	004
------	------	---------	-----

	50MG	A080519	003
--	------	---------	-----

ANABOLIC	50MG	A083275	001
----------	------	---------	-----

ELKINS SINN	25MG	A085701	001
-------------	------	---------	-----

	50MG	A085701	002
--	------	---------	-----

HALSEY	50MG	A087914	001 Jun 04, 1984
--------	------	---------	------------------

HEATHER	25MG	A084524	001
---------	------	---------	-----

	50MG	A083953	001
--	------	---------	-----

HIKMA PHARMS LLC	50MG	A083567	001
------------------	------	---------	-----

IMPAX LABS	25MG	A080807	001
------------	------	---------	-----

	50MG	A080807	002
--	------	---------	-----

IVAX SUB TEVA PHARMS	25MG	A080762	001
----------------------	------	---------	-----

	50MG	A080762	002
--	------	---------	-----

LANNETT	25MG	A080868	001
---------	------	---------	-----

	50MG	A080868	002
--	------	---------	-----

LEDERLE	25MG	A086874	001
---------	------	---------	-----

	50MG	A086875	001
--	------	---------	-----

LNK	25MG	A087977	001 Jan 27, 1983
-----	------	---------	------------------

	50MG	A087978	001 Jan 27, 1983
--	------	---------	------------------

MK LABS	25MG	A083087	001
---------	------	---------	-----

	50MG	A083087	002
--	------	---------	-----

MUTUAL PHARM	25MG	A084506	001
--------------	------	---------	-----

	25MG	A089488	001 Jan 02, 1987
--	------	---------	------------------

	50MG	A089489	001 Jan 02, 1987
--	------	---------	------------------

NEWTRON PHARMS	25MG	A086543	001
----------------	------	---------	-----

	50MG	A086544	001
--	------	---------	-----

NEXGEN PHARMA INC	25MG	A083634	001
-------------------	------	---------	-----

PERRIGO	25MG	A083061	001
---------	------	---------	-----

	50MG	A083061	002
--	------	---------	-----

PIONEER PHARMS	25MG	A089101	001 Dec 20, 1985
----------------	------	---------	------------------

	50MG	A088880	001 Dec 20, 1985
--	------	---------	------------------

PUREPAC PHARM	25MG	A085156	001
---------------	------	---------	-----

	50MG	A085150	001
--	------	---------	-----

PVT FORM	25MG	A083027	001
----------	------	---------	-----

	50MG	A083027	002
--	------	---------	-----

ROXANE	50MG	A080635	001
--------	------	---------	-----

SANDOZ	25MG	A080832	001
--------	------	---------	-----

	25MG	A080845	002
--	------	---------	-----

	50MG	A080832	002
--	------	---------	-----

	50MG	A080845	001
--	------	---------	-----

SUPERPHARM	25MG	A089040	001 May 15, 1985
------------	------	---------	------------------

	50MG	A089041	001 May 15, 1985
--	------	---------	------------------

TEVA	25MG	A085874	001
------	------	---------	-----

	50MG	A085874	002
--	------	---------	-----

VALEANT PHARM INTL	25MG	A080596	001
--------------------	------	---------	-----

	50MG	A080592	001
--	------	---------	-----

VANGARD	25MG	A088034	001 Oct 27, 1982
---------	------	---------	------------------

	50MG	A087630	001
--	------	---------	-----

WATSON LABS	25MG	A080728	001
-------------	------	---------	-----

	25MG	A083797	001
--	------	---------	-----

	25MG	A085138	001
--	------	---------	-----

	50MG	A080727	001
--	------	---------	-----

	50MG	A083797	002
--	------	---------	-----

	50MG	A085083	001
--	------	---------	-----

WHITEWORTH TOWN PLSN	25MG	A083441	001
----------------------	------	---------	-----

	50MG	A080800	001
--	------	---------	-----

ELIXIR; ORAL

BELIX

HALSEY	12.5MG/5ML	A086586	001 Oct 03, 1983
--------	------------	---------	------------------

BENADRYL

MCNEIL CONS	12.5MG/5ML	N005845	004
-------------	------------	---------	-----

## DISCONTINUED DRUG PRODUCT LIST

DIPHENHYDRAMINE HYDROCHLORIDE

## ELIXIR; ORAL

## DIBENIL

CENCI	12.5MG/5ML	A088304 001	Dec 16, 1983
-------	------------	-------------	--------------

## DIPHEN

USL PHARMA	12.5MG/5ML	A084640 001	
------------	------------	-------------	--

## DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY	12.5MG/5ML	A083674 001	
CENCI	12.5MG/5ML	A087941 001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621 001	
LANNETT	12.5MG/5ML	A080939 002	
LEDERLE	12.5MG/5ML	A086937 001	
MK LABS	12.5MG/5ML	A083088 002	
NASKA	12.5MG/5ML	A088680 001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063 001	
PUREPAC PHARM	12.5MG/5ML	A083237 001	Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287 001	
ROXANE	12.5MG/5ML	A080643 001	

## HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A080763 002	
--------------------	------------	-------------	--

## INJECTABLE; INJECTION

## BENADRYL

MCNEIL CONS	10MG/ML	N006146 001	
	50MG/ML	N006146 002	

## BENADRYL PRESERVATIVE FREE

MCNEIL CONS	50MG/ML	N009486 001	
-------------	---------	-------------	--

## DIPHENHYDRAMINE HYDROCHLORIDE

BEL MAR	10MG/ML	A080822 001	
HIKMA MAPLE	50MG/ML	A083183 001	
LYPHOMED	10MG/ML	A087066 001	
WATSON LABS	10MG/ML	A083533 001	
WATSON LABS INC	10MG/ML	A080873 001	
	50MG/ML	A080873 002	
WYETH AYERST	50MG/ML	A080577 001	

## DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM	50MG/ML	A080586 002	
INTL MEDICATION	50MG/ML	A084094 001	
WATSON LABS INC	50MG/ML	A080873 003	

## SYRUP; ORAL

## ANTITUSSIVE

PERRIGO	12.5MG/5ML	A071292 001	Apr 10, 1987
---------	------------	-------------	--------------

## BELDIN

HALSEY	12.5MG/5ML	A089179 001	Jun 05, 1986
--------	------------	-------------	--------------

## BENYLIN

PARKE DAVIS	12.5MG/5ML	N006514 004	
-------------	------------	-------------	--

## DIPHEN

MORTON GROVE	12.5MG/5ML	A070118 001	Oct 01, 1985
--------------	------------	-------------	--------------

## DIPHENHYDRAMINE HYDROCHLORIDE

ALPHARMA US PHARMS	12.5MG/5ML	A070497 001	Apr 25, 1989
CUMBERLAND SWAN	12.5MG/5ML	A073611 001	Aug 20, 1992
HI TECH PHARMA	12.5MG/5ML	A072416 001	Sep 28, 1990

## HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A070205 001	Jan 28, 1986
--------------------	------------	-------------	--------------

## SILPHEN

SILARX	12.5MG/5ML	A072646 001	Feb 27, 1992
--------	------------	-------------	--------------

## VICKS FORMULA 44

WARNER CHILCOTT	12.5MG/5ML	A070524 001	Jan 14, 1987
-----------------	------------	-------------	--------------

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

## SOLUTION; ORAL

## BENYLIN

PARKE DAVIS	12.5MG/5ML; 30MG/5ML	N019014 001	Jun 11, 1985
-------------	----------------------	-------------	--------------

DIPHENIDOL HYDROCHLORIDE

## TABLET; ORAL

## VONTROL

GLAXOSMITHKLINE	EQ 25MG BASE	N016033 001	
-----------------	--------------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

HISPRIL

GLAXOSMITHKLINE 5MG N011945 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPRO

AKORN 0.1% A074382 001 Sep 29, 1995

DIPIVEFRIN HYDROCHLORIDE

BAUSCH AND LOMB 0.1% A074188 001 May 19, 1995

FALCON PHARMS 0.1% A073636 001 Jun 30, 1994

PROPINE

ALLERGAN 0.1% N018239 001

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AGILA SPECLTS 5MG/ML A075769 001 Nov 27, 2002

HOSPIRA 5MG/ML A074601 001 Dec 19, 1997

TEVA PHARMS USA 5MG/ML A074952 001 Nov 26, 1997

IV PERSANTINE

BOEHRINGER INGELHEIM 5MG/ML N019817 001 Dec 13, 1990

TABLET;ORAL

DIPYRIDAMOLE

GLENMARK GENERICS 25MG A088999 001 Feb 05, 1991

50MG A089000 001 Feb 05, 1991

75MG A089001 001 Feb 05, 1991

PROSAM LABS 25MG A040542 001 Apr 21, 2006

50MG A040542 002 Apr 21, 2006

75MG A040542 003 Apr 21, 2006

PUREPAC PHARM 50MG A089426 001 Jul 12, 1990

75MG A089427 001 Jul 12, 1990

SANDOZ 25MG A086944 002 Apr 16, 1991

50MG A087562 001 Feb 25, 1992

75MG A087561 001 Feb 25, 1992

WATSON LABS 50MG A087160 001 Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE;ORAL

DYNABAC

LILLY RES LABS 250MG N050678 001 Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

INTERPHARM EQ 100MG BASE A071190 001 Jan 15, 1987

EQ 150MG BASE A071191 001 Jan 15, 1987

IVAX SUB TEVA PHARMS EQ 100MG BASE A070186 001 Nov 18, 1985

EQ 150MG BASE A070187 001 Nov 18, 1985

MUTUAL PHARM EQ 100MG BASE A070351 001 Dec 17, 1985

EQ 150MG BASE A070352 001 Dec 17, 1985

MYLAN EQ 100MG BASE A070138 001 Jun 14, 1985

EQ 150MG BASE A070139 001 Jun 14, 1985

SANDOZ EQ 100MG BASE A070470 001 Dec 10, 1985

EQ 150MG BASE A070471 001 Dec 10, 1985

SUPERPHARM EQ 100MG BASE A070940 001 Feb 09, 1987

EQ 150MG BASE A070941 001 Feb 09, 1987

WATSON LABS EQ 100MG BASE A070240 001 Feb 02, 1986

EQ 150MG BASE A070241 001 Feb 02, 1986

CAPSULE, EXTENDED RELEASE;ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS EQ 150MG BASE A071200 001 Dec 15, 1987

DISULFIRAM

TABLET;ORAL

ANTABUSE

TEVA WOMENS 250MG N007883 003

500MG N007883 002

DISULFIRAM

PAR PHARM 250MG A088792 001 Aug 14, 1984

500MG A088793 001 Aug 14, 1984

WATSON LABS 250MG A086889 001

250MG A087973 001 Aug 05, 1983

500MG A086890 001

## DISCONTINUED DRUG PRODUCT LIST

DISULFIRAM

TABLET;ORAL  
DISULFIRAM

500MG A087974 001 Aug 05, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE CP  
ABBOTT

EQ 250MG BASE N019794 001 Jul 11, 1990

EQ 500MG BASE N019794 002 Jul 11, 1990

DIVALPROEX SODIUM  
MYLAN

EQ 125MG VALPROIC ACID A077254 001 Jul 29, 2008

EQ 250MG VALPROIC ACID A077254 002 Jul 29, 2008

EQ 500MG VALPROIC ACID A077254 003 Jul 29, 2008

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

TEVA PHARMS USA

EQ 500MG VALPROIC ACID A078700 001 Aug 03, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

ASTRAZENECA

EQ 12.5MG BASE/ML A074098 001 Feb 21, 1995

BAXTER HLTHCARE

EQ 12.5MG BASE/ML A074381 001 Sep 26, 1996

HOSPIRA

EQ 1.25GM BASE/100ML A074634 001 Sep 27, 1996

LUITPOLD

EQ 12.5MG BASE/ML A074545 001 Jun 25, 1998

TEVA PARENTERAL

EQ 12.5MG BASE/ML A074206 001 Oct 19, 1993

WATSON LABS

EQ 12.5MG BASE/ML A074114 001 Nov 30, 1993

WATSON LABS INC

EQ 12.5MG BASE/ML A074279 001 Feb 18, 1998

EQ 12.5MG BASE/ML A074995 001 Mar 31, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA

EQ 50MG BASE/100ML N020269 001 Oct 19, 1993

EQ 100MG BASE/100ML N020269 002 Oct 19, 1993

EQ 200MG BASE/100ML N020269 003 Oct 19, 1993

DOBUTREX

LILLY

EQ 12.5MG BASE/ML N017820 002

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

APOTEX INC

20MG/0.5ML (40MG/ML) N022312 001 Jan 11, 2012

80MG/2ML (40MG/ML) N022312 002 Jan 11, 2012

TAXOTERE

SANOFI AVENTIS US

40MG/ML \*\*Federal Register N020449 001 May 14, 1996

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

DONEPEZIL HYDROCHLORIDE

SOLUTION;ORAL

ARICEPT

EISAI INC

5MG/5ML N021719 001 Oct 18, 2004

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

ACCORD HLTHCARE

5MG A201335 001 Aug 29, 2011

10MG A201335 002 Aug 29, 2011

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

MUTUAL PHARM

5MG A077975 002 Dec 11, 2009

10MG A077975 001 Dec 11, 2009

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT

40MG/ML A070656 001 Jan 24, 1989

80MG/ML A070657 001 Jan 24, 1989

ABRAXIS PHARM

40MG/ML A070012 001 Jun 12, 1985

40MG/ML A070058 001 Mar 20, 1985

80MG/ML A070013 001 Jun 12, 1985

80MG/ML A070059 001 Mar 20, 1985

160MG/ML A070364 001 Dec 04, 1985

ASTRAZENECA

40MG/ML A070087 001 Oct 23, 1985

40MG/ML N018656 001 Jun 28, 1983

80MG/ML A070089 001 Oct 23, 1985

80MG/ML A070090 001 Oct 23, 1985

80MG/ML A070091 001 Oct 23, 1985



## DISCONTINUED DRUG PRODUCT LIST

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
BAXTER HLTHCARE	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
INTL MEDICATION	40MG/ML	N018014	001	
LYPHOMED	40MG/ML	N018549	001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%				
HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995
INTROPIN				
HOSPIRA	40MG/ML	N017395	001	
	80MG/ML	N017395	002	
	160MG/ML	N017395	003	

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

APOTEX INC	EQ 2% BASE	A078395	001	Oct 28, 2008
------------	------------	---------	-----	--------------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

APOTEX INC	EQ 2% BASE; EQ 0.5% BASE	A078201	001	Oct 28, 2008
------------	--------------------------	---------	-----	--------------

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

NUROMAX

ABBVIE	EQ 1MG BASE/ML	N019946	001	Mar 07, 1991
--------	----------------	---------	-----	--------------

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992
-------------	---------	---------	-----	--------------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000
	EQ 2MG BASE	A075574	002	Oct 18, 2000
	EQ 4MG BASE	A075574	003	Oct 18, 2000
	EQ 8MG BASE	A075574	004	Oct 18, 2000
GENPHARM	EQ 1MG BASE	A075466	001	Oct 18, 2000
	EQ 2MG BASE	A075466	002	Oct 18, 2000
	EQ 4MG BASE	A075466	003	Oct 18, 2000
	EQ 8MG BASE	A075466	004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453	001	Oct 18, 2000
	EQ 2MG BASE	A075453	002	Oct 18, 2000
	EQ 4MG BASE	A075453	003	Oct 18, 2000
	EQ 8MG BASE	A075453	004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000
	EQ 2MG BASE	A075609	002	Oct 18, 2000
	EQ 4MG BASE	A075609	003	Oct 18, 2000
	EQ 8MG BASE	A075609	004	Oct 18, 2000
SANDOZ	EQ 1MG BASE	A075432	001	Oct 18, 2000
	EQ 1MG BASE	A075646	001	Oct 18, 2000
	EQ 2MG BASE	A075432	002	Oct 18, 2000
	EQ 2MG BASE	A075646	002	Oct 18, 2000
	EQ 4MG BASE	A075432	003	Oct 18, 2000
	EQ 4MG BASE	A075646	003	Oct 18, 2000
	EQ 8MG BASE	A075432	004	Oct 18, 2000
	EQ 8MG BASE	A075646	004	Oct 18, 2000
TEVA	EQ 1MG BASE	A075353	001	Jan 12, 2001
	EQ 2MG BASE	A075353	002	Jan 12, 2001

**DISCONTINUED DRUG PRODUCT LIST**DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

	EQ 4MG BASE	A075353 003	Jan 12, 2001
	EQ 8MG BASE	A075353 004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426 001	Oct 18, 2000
	EQ 2MG BASE	A075426 002	Oct 18, 2000
	EQ 4MG BASE	A075426 003	Oct 18, 2000
	EQ 8MG BASE	A075426 004	Oct 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC	EQ 10MG BASE	A071685 001	Jan 05, 1988
	EQ 25MG BASE	A071686 001	Jan 05, 1988
	EQ 50MG BASE	A071673 001	Jan 05, 1988
	EQ 75MG BASE	A071674 001	Jan 05, 1988
	EQ 100MG BASE	A071675 001	Jan 05, 1988
	EQ 150MG BASE	A071676 001	Jan 05, 1988
MUTUAL PHARM	EQ 25MG BASE	A071502 001	Feb 18, 1988
	EQ 50MG BASE	A071653 001	Feb 18, 1988
	EQ 75MG BASE	A071654 001	Feb 18, 1988
	EQ 100MG BASE	A071521 001	Feb 18, 1988
NEW RIVER	EQ 10MG BASE	N016987 001	
	EQ 25MG BASE	N016987 002	
	EQ 50MG BASE	N016987 003	
	EQ 75MG BASE	N016987 006	
	EQ 100MG BASE	N016987 004	
	EQ 150MG BASE	N016987 007	Apr 13, 1987
PAR PHARM	EQ 10MG BASE	A071697 001	Nov 09, 1987
	EQ 25MG BASE	A071437 001	Nov 09, 1987
	EQ 50MG BASE	A071595 001	Nov 09, 1987
	EQ 75MG BASE	A071608 001	Nov 09, 1987
	EQ 100MG BASE	A071422 001	Nov 09, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054 001	Dec 28, 1990
	EQ 25MG BASE	A072109 001	Dec 28, 1990
	EQ 50MG BASE	A073055 001	Dec 28, 1990
	EQ 75MG BASE	A072386 001	Sep 08, 1988
	EQ 100MG BASE	A072110 001	Sep 08, 1988
	EQ 150MG BASE	A072387 001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972 001	Sep 29, 1987
	EQ 25MG BASE	A070973 001	Sep 29, 1987
	EQ 50MG BASE	A070931 001	Sep 29, 1987
	EQ 75MG BASE	A070932 001	Sep 29, 1987
	EQ 100MG BASE	A072375 001	Mar 15, 1989
	EQ 150MG BASE	A072376 001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487 001	Mar 02, 1987
	EQ 25MG BASE	A070827 001	May 15, 1986
	EQ 50MG BASE	A070828 001	May 15, 1986
	EQ 75MG BASE	A070825 001	May 15, 1986
	EQ 100MG BASE	A071562 001	Mar 02, 1987
WATSON LABS	EQ 10MG BASE	A070952 001	Mar 04, 1987
	EQ 10MG BASE	A071485 001	Apr 30, 1987
	EQ 10MG BASE	A072985 001	Mar 29, 1991
	EQ 25MG BASE	A070953 001	May 15, 1986
	EQ 25MG BASE	A071486 001	Apr 30, 1987
	EQ 25MG BASE	A072986 001	Mar 29, 1991
	EQ 50MG BASE	A070954 001	May 15, 1986
	EQ 50MG BASE	A071238 001	Apr 30, 1987
	EQ 50MG BASE	A072987 001	Mar 29, 1991
	EQ 75MG BASE	A071326 001	Apr 30, 1987
	EQ 75MG BASE	A071763 001	Feb 09, 1988
	EQ 100MG BASE	A070955 001	May 15, 1986
	EQ 100MG BASE	A071239 001	Apr 30, 1987
	EQ 150MG BASE	A071764 001	Feb 09, 1988

SINEQUAN

PFIZER

	EQ 10MG BASE	N016798 003	
	EQ 25MG BASE	N016798 001	
	EQ 50MG BASE	N016798 002	
	EQ 75MG BASE	N016798 006	
	EQ 100MG BASE	N016798 005	
	EQ 150MG BASE	N016798 007	

## DISCONTINUED DRUG PRODUCT LIST

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004
SINEQUAN				
PFIZER	EQ 10MG BASE/ML	N017516	001	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

PHARMACIA AND UPJOHN	2MG/ML	A063165	001	Jan 30, 1991
	2MG/ML	N050629	001	Dec 23, 1987
	200MG/100ML	A063165	002	Jan 30, 1991
	200MG/100ML	N050629	002	May 03, 1988

ADRIAMYCIN RDF

PHARMACIA AND UPJOHN	10MG/VIAL	N050467	001	
	20MG/VIAL	N050467	003	May 20, 1985
	50MG/VIAL	N050467	002	
	150MG/VIAL	N050467	004	Jul 22, 1987

RUBEX

BRISTOL MYERS SQUIBB	10MG/VIAL	A062926	001	Apr 13, 1989
	50MG/VIAL	A062926	002	Apr 13, 1989
	100MG/VIAL	A062926	003	Apr 13, 1989

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

PAR PHARM	EQ 75MG BASE	A065055	004	Apr 18, 2005
SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000
	EQ 100MG BASE	A065032	002	Jun 30, 2000
WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000
	EQ 100MG BASE	A065041	002	Apr 28, 2000

FOR SUSPENSION; ORAL

DOXYCHEL

RACHELLE	EQ 25MG BASE/5ML	A061720	001	
----------	------------------	---------	-----	--

TABLET; ORAL

DOXYCYCLINE

MUTUAL PHARM	EQ 50MG BASE	A065471	001	Apr 17, 2009
	EQ 75MG BASE	A065471	002	Apr 17, 2009
	EQ 100MG BASE	A065471	003	Apr 17, 2009
SANDOZ INC	EQ 50MG BASE	A065353	001	Nov 27, 2006
	EQ 75MG BASE	A065353	002	Nov 27, 2006
	EQ 100MG BASE	A065353	003	Nov 27, 2006

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXY-LEMMON

TEVA	EQ 50MG BASE	A062497	001	Aug 23, 1984
	EQ 100MG BASE	A062497	002	Jun 15, 1984

DOXYCYCLINE HYCLATE

HALSEY	EQ 50MG BASE	A062119	002	May 24, 1985
	EQ 100MG BASE	A062119	001	May 24, 1985
HEATHER	EQ 50MG BASE	A062463	001	Dec 07, 1983
	EQ 100MG BASE	A062463	002	Dec 07, 1983
INTERPHARM	EQ 50MG BASE	A062763	001	Sep 02, 1988
	EQ 100MG BASE	A062763	002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418	001	Jan 28, 1983
	EQ 100MG BASE	A062418	002	Jan 28, 1983
PAR PHARM	EQ 50MG BASE	A062434	001	Oct 19, 1984
	EQ 100MG BASE	A062442	001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631	001	Jul 24, 1986
	EQ 100MG BASE	A062631	002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479	001	Dec 23, 1983
	EQ 100MG BASE	A062479	002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469	001	Oct 31, 1984
	EQ 100MG BASE	A062469	002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594	001	Dec 05, 1985
	EQ 100MG BASE	A062594	002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717	001	
	EQ 50MG BASE	A062142	001	
	EQ 100MG BASE	A061717	002	
	EQ 100MG BASE	A062142	002	

## DISCONTINUED DRUG PRODUCT LIST

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

PERIOSTAT

COLLAGENEX EQ 20MG BASE N050744 001 Sep 30, 1998

CAPSULE, COATED PELLETS; ORAL

DOXYCYCLINE HYCLATE

PLIVA EQ 100MG BASE A063187 001 Jun 30, 1992

CAPSULE, DELAYED RELEASE; ORAL

DORYX

MAYNE PHARMA INTL EQ 75MG BASE N050582 002 Aug 13, 2001

EQ 100MG BASE N050582 001 Jul 22, 1985

WARNER CHILCOTT EQ 100MG BASE A062653 001 Oct 30, 1985

INJECTABLE; INJECTION

DOXYCHEL HYCLATE

RACHELLE EQ 100MG BASE/VIAL A061953 001

DOXYCYCLINE

EUROHLTH INTL EQ 200MG BASE/VIAL A062569 002 Mar 09, 1988

HIKMA MAPLE EQ 100MG BASE/VIAL A062450 001 Oct 27, 1983

EQ 200MG BASE/VIAL A062450 002 Oct 27, 1983

DOXYCYCLINE HYCLATE

HIKMA MAPLE EQ 100MG BASE/VIAL A062992 001 Feb 16, 1989

EQ 200MG BASE/VIAL A062992 002 Feb 16, 1989

VIBRAMYCIN

PFIZER EQ 100MG BASE/VIAL N050442 002

EQ 200MG BASE/VIAL N050442 001

TABLET; ORAL

DOXY-LEMMON

TEVA EQ 100MG BASE A062581 001 Mar 15, 1985

DOXYCYCLINE HYCLATE

BLU CARIBE INC EQ 50MG BASE A062269 003

HEATHER EQ 100MG BASE A062462 001 May 11, 1983

INTERPHARM EQ 100MG BASE A062764 001 Sep 02, 1988

MUTUAL PHARM EQ 100MG BASE A062391 001 Sep 30, 1982

SUPERPHARM EQ 100MG BASE A062494 001 Feb 20, 1985

WARNER CHILCOTT EQ 100MG BASE A062593 001 Aug 28, 1985

WATSON LABS EQ 50MG BASE A062392 001 Mar 31, 1983

EQ 100MG BASE A062392 002 Mar 31, 1983

PERIOSTAT

GALDERMA LABS LP EQ 20MG BASE \*\*Federal Register N050783 001 Feb 02, 2001

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

VIBRA-TABS

PFIZER EQ 100MG BASE \*\*Federal Register N050533 001

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*DOXYLAMINE SUCCINATE

CAPSULE; ORAL

UNISOM

PFIZER 25MG N019440 001 Feb 05, 1986

TABLET; ORAL

DECAPRYN

SANOFI AVENTIS US 12.5MG N006412 015

25MG N006412 014

DOXY-SLEEP-AID

PAR PHARM 25MG A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE

COPLEY PHARM 25MG A088900 002 Feb 12, 1988

QUANTUM PHARMICS 25MG A088603 001 Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BENDECTIN

SANOFI AVENTIS US 10MG;10MG \*\*Federal Register N010598 002

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

**DISCONTINUED DRUG PRODUCT LIST**DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION

DROLBAN

LILLY 50MG/ML N012936 001

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

ABRAXIS PHARM	2.5MG/ML	A070992 001	Nov 17, 1986
	2.5MG/ML	A070993 001	Nov 17, 1986
ASTRAZENECA	2.5MG/ML	A072018 001	Oct 20, 1988
	2.5MG/ML	A072019 001	Oct 19, 1988
	2.5MG/ML	A072020 001	Oct 19, 1988
	2.5MG/ML	A072021 001	Oct 19, 1988
HOSPIRA	2.5MG/ML	A071645 001	Apr 07, 1988
	2.5MG/ML	A072272 001	Aug 31, 1995
LUITPOLD	2.5MG/ML	A072335 001	Oct 24, 1988
SMITH AND NEPHEW	2.5MG/ML	A071750 001	Sep 06, 1988
SOLOPAK	2.5MG/ML	A071754 001	Sep 06, 1988
	2.5MG/ML	A071755 001	Sep 06, 1988
WATSON LABS	2.5MG/ML	A073520 001	Nov 27, 1991
	2.5MG/ML	A073521 001	Nov 27, 1991
	2.5MG/ML	A073523 001	Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	A072026 001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072027 001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072028 001	Apr 13, 1989
HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	A071982 001	May 04, 1988
INNOVAR			
AKORN MFG	2.5MG/ML;EQ 0.05MG BASE/ML	N016049 001	

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

DYCLONE

ASTRAZENECA	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009925 002	
	1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009925 001	

DYDROGESTERONE

TABLET; ORAL

GYNOREST

SOLVAY	5MG	N017388 001	
	10MG	N017388 002	

DYPHYLLINE

ELIXIR; ORAL

NEOTHYLLINE

TEVA 160MG/15ML N007794 003

INJECTABLE; INJECTION

NEOTHYLLINE

TEVA 250MG/ML N009088 001

TABLET; ORAL

DILOR

SAVAGE LABS 200MG A084514 001

DILOR-400

SAVAGE LABS 400MG A084751 001

NEOTHYLLINE

TEVA 200MG N007794 001

400MG N007794 002

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

WYETH PHARMS INC	0.03%	N011963 002	
	0.06%	N011963 004	
	0.25%	N011963 003	

## DISCONTINUED DRUG PRODUCT LIST

ECONAZOLE NITRATE

CREAM; TOPICAL

SPECTAZOLE

MERZ PHARMS LLC

1%

N018751 001 Dec 23, 1982

EDETATE CALCIUM DISODIUM

TABLET; ORAL

CALCIUM DISODIUM VERSENATE

MEDICIS

500MG

N008922 002

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

HOSPIRA

10MG/ML

A040131 001 Feb 24, 1998

WATSON LABS

10MG/ML

A040044 001 Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS

10MG/ML

A040043 001 Mar 20, 1996

REVERSOL

ORGANON USA INC

10MG/ML

A089624 001 May 13, 1988

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB

100MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N020972 002 Sep 17, 1998

TABLET; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB

300MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N021360 001 Feb 01, 2002

EFLORNITHINE HYDROCHLORIDE

INJECTABLE; INJECTION

ORNIDYL

SANOFI AVENTIS US

200MG/ML

N019879 002 Nov 28, 1990

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

APOTHECON

2.5MG

A075583 001 Aug 22, 2000

5MG

A075583 002 Aug 22, 2000

10MG

A075583 003 Aug 22, 2000

20MG

A075583 004 Aug 22, 2000

IVAX SUB TEVA PHARMS

2.5MG

A075482 001 Aug 22, 2000

5MG

A075482 002 Aug 22, 2000

10MG

A075482 003 Aug 22, 2000

20MG

A075482 004 Aug 22, 2000

KRKA DD NOVO MESTO

2.5MG

A075370 001 Aug 22, 2000

5MG

A075370 002 Aug 22, 2000

10MG

A075369 001 Aug 22, 2000

20MG

A075369 002 Aug 22, 2000

MYLAN

2.5MG

A075472 001 Aug 22, 2000

5MG

A075472 002 Aug 22, 2000

10MG

A075472 003 Aug 22, 2000

20MG

A075472 004 Aug 22, 2000

RANBAXY

2.5MG

A075556 001 Aug 22, 2000

5MG

A075556 002 Aug 22, 2000

10MG

A075556 003 Aug 22, 2000

20MG

A075556 004 Aug 22, 2000

SANDOZ

2.5MG

A075048 001 Aug 22, 2000

5MG

A075048 002 Aug 22, 2000

10MG

A075048 003 Aug 22, 2000

20MG

A075048 004 Aug 22, 2000

SANDOZ INC

2.5MG

A075496 001 Aug 22, 2000

2.5MG

A075621 001 Aug 22, 2000

5MG

A075496 002 Aug 22, 2000

5MG

A075621 002 Aug 22, 2000

10MG

A075459 001 Aug 22, 2000

10MG

A075621 003 Aug 22, 2000

20MG

A075459 002 Aug 22, 2000

20MG

A075621 004 Aug 22, 2000

WATSON LABS

2.5MG

A075501 001 Aug 22, 2000

5MG

A075501 002 Aug 22, 2000

## DISCONTINUED DRUG PRODUCT LIST

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

10MG

A075501 003 Aug 22, 2000

20MG

A075501 004 Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

ASTRAZENECA

5MG; 2.5MG

N020668 002 Oct 28, 1998

5MG; 5MG

N020668 001 Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS

5MG; 12.5MG

A075736 001 Mar 25, 2003

10MG; 25MG

A075736 002 Mar 25, 2003

SANDOZ INC

5MG; 12.5MG

A076116 001 Sep 19, 2001

10MG; 25MG

A076116 002 Sep 19, 2001

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

HOSPIRA

1.25MG/ML

A075456 001 Aug 22, 2000

1.25MG/ML

A075571 001 Aug 22, 2000

VASOTEC

BIOVAIL LABS INTL

1.25MG/ML

N019309 001 Feb 09, 1988

ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT

99.9%

A070803 001 Sep 08, 1987

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US

200MG

N019616 004 Dec 31, 1991

400MG

N019616 005 Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

SANOFI AVENTIS US

90MG/0.6ML (150MG/ML) \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N020164 006 Jun 02, 2000

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

STERLING

0.25MG/INH

N016803 001

EPINEPHRINE

ARMSTRONG PHARMS

0.2MG/INH

A087907 001 May 23, 1984

PRIMATENE MIST

WYETH CONS

0.2MG/INH

N016126 001

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

FOREST LABS

1.5MG/AMP

N007942 003 Feb 05, 1999

5MG/ML

N007942 001

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MYLAN SPEC LT

0.15MG/DELIVERY

N019430 004 Aug 03, 1995

EPIPEN E Z PEN

MYLAN SPEC LT

0.3MG/DELIVERY

N019430 003 Aug 03, 1995

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS

0.3MG/INH

N016126 002

MEDIHALER-EPI

3M

0.3MG/INH

N010374 003

**DISCONTINUED DRUG PRODUCT LIST**EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA	0.005MG/ML;1%	N017751	006
	0.005MG/ML;1.5%	N017751	007
DENTSPLY PHARM	0.005MG/ML;1.5%	N021384	001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA	0.005MG/ML;4%	N014763	008
-------------	---------------	---------	-----

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA	0.005MG/ML;0.5%	N017751	004
-------------	-----------------	---------	-----

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE	0.01MG/ML;2%	A084720	001
	0.02MG/ML;2%	A084732	001

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

GRAHAM CHEM	0.01MG/ML;2%	A080504	004	Oct 19, 1983
	0.02MG/ML;2%	A080504	005	Oct 19, 1983
HIKMA MAPLE	0.01MG/ML;1%	A080406	001	
	0.01MG/ML;2%	A080406	002	
HOSPIRA	0.005MG/ML;1%	A089649	001	Jun 21, 1988
	0.005MG/ML;1.5%	A089650	001	Jun 21, 1988

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT	0.01MG/ML;1%	A083154	001
BEL MAR	0.01MG/ML;1%	A080820	001
	0.01MG/ML;2%	A080757	001
DELL LABS	0.01MG/ML;1%	A083389	001
	0.01MG/ML;2%	A083390	001
INTL MEDICATION	0.01MG/ML;1%	A086402	001
WATSON LABS	0.01MG/ML;1%	A080377	003
	0.01MG/ML;1%	A085463	001
	0.01MG/ML;2%	A080377	004

LIDOCATON

PHARMATON	0.01MG/ML;2%	A084729	001	Aug 17, 1983
	0.02MG/ML;2%	A084728	001	Aug 17, 1983

XYLOCAINE DENTAL WITH EPINEPHRINE

DENTSPLY PHARM	0.01MG/ML;2%	N021381	001
	0.02MG/ML;2%	N021381	002

XYLOCAINE W/ EPINEPHRINE

ASTRAZENECA	0.005MG/ML;1%	N010418	006
	0.005MG/ML;1.5%	N010418	010
	0.005MG/ML;2%	N010418	008
FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

VYTERIS	1.05MG/PATCH;100MG/PATCH	N021504	001	May 06, 2004
---------	--------------------------	---------	-----	--------------

SOLUTION; IONTOPHORESIS

IONTOCAINE

IOMED	0.01MG/ML;2%	N020530	001	Dec 21, 1995
-------	--------------	---------	-----	--------------

SOLUTION; IONTOPHORESIS, TOPICAL

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EMPI	0.01MG/ML;2%	N021486	001	Oct 26, 2004
------	--------------	---------	-----	--------------

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE

BEL MAR	0.02MG/ML;1%	A080758	001
	0.02MG/ML;2%	A080759	001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009
	200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009
HOSPIRA	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007
MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011
	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011
MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007



**DISCONTINUED DRUG PRODUCT LIST**EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

200MG/100ML (2MG/ML)

A065371 002 Nov 28, 2007

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

HOSPIRA

50MG/VIAL

N050807 001 Sep 15, 2006

200MG/VIAL

N050807 002 Sep 15, 2006

EPLERENONE

TABLET; ORAL

INSPRA

GD SEARLE LLC

100MG

N021437 003 Sep 27, 2002

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

ABBVIE

EQ 300MG BASE

N020738 004 Dec 22, 1997

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN

LILLY

50,000 IU

A080884 001

VITAMIN D

CHASE CHEM

50,000 IU

A080747 001

EVERYLIFE

50,000 IU

A080956 001

IMPAX LABS

50,000 IU

A080951 001

LANNETT

50,000 IU

A080825 001

VITARINE

50,000 IU

A084053 001

WEST WARD

50,000 IU

A083102 001

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

NOVARTIS

1MG

N018706 001 Jan 18, 1983

SOLUTION; ORAL

HYDERGINE

NOVARTIS

1MG/ML

N018418 001

TABLET; ORAL

ERGOLOID MESYLATES

MUTUAL PHARM

1MG

A088891 001 Nov 01, 1985

WATSON LABS

1MG

A086433 001 May 27, 1982

1MG

A087244 001 Aug 16, 1982

GERIMAL

WATSON LABS

1MG

A088207 001 Mar 22, 1984

HYDERGINE

NOVARTIS

0.5MG

N017993 003

TABLET; SUBLINGUAL

ALKERGOT

SANDOZ

0.5MG

A085153 001

1MG

A087417 001

CIRCANOL

3M

0.5MG

A084868 001

1MG

A085809 001

DEAPRIL-ST

BRISTOL MYERS SQUIBB

1MG

A085020 002

ERGOLOID MESYLATES

KV PHARM

0.5MG

A085899 001

0.5MG

A086265 001

1MG

A085900 001

1MG

A086264 001

LEDERLE

0.5MG

A086984 001

1MG

A086985 001

MUTUAL PHARM

0.5MG

A087407 001

1MG

A087552 001

SUPERPHARM

0.5MG

A089233 001 Sep 23, 1986

1MG

A089234 001 Sep 23, 1986

VANGARD

0.5MG

A088013 001 Sep 20, 1982

1MG

A088014 001 Sep 20, 1982

WATSON LABS

0.5MG

A084930 001

0.5MG

A087233 001

1MG

A085177 001

1MG

A087183 001

## DISCONTINUED DRUG PRODUCT LIST

ERGOLOID MESYLATES

TABLET;SUBLINGUAL

GERIMAL

WATSON LABS

0.5MG

A086189 001

1MG

A086188 001

HYDERGINE

NOVARTIS

0.5MG

N009087 002

1MG

N009087 001

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMS

0.5MG

A087186 001

1MG

A087185 001

ERGOTAMINE TARTRATE

AEROSOL, METERED;INHALATION

MEDIHALER ERGOTAMINE

3M

0.36MG/INH

N012102 001

TABLET;SUBLINGUAL

ERGOSTAT

PARKE DAVIS

2MG

A088337 001

Jun 08, 1984

WIGRETTES

ORGANON USA INC

2MG

A086750 001

Jul 29, 1982

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

PARKE DAVIS

250MG

A062546 001

Jul 25, 1985

250MG

A062618 001

Sep 25, 1985

WARNER CHILCOTT LLC

250MG

A062338 001

ERYC 125

PARKE DAVIS

125MG

A062648 001

Oct 24, 1985

ERYC SPRINKLES

HOSPIRA

125MG

N050593 001

Jul 22, 1985

ERYTHROMYCIN

BARR

250MG

A063098 001

May 04, 1989

GEL;TOPICAL

E-GLADES

RENAISSANCE PHARMA

2%

A065009 001

Mar 18, 2002

EMGEL

ALTANA

2%

A063107 001

Aug 23, 1991

LOTION;TOPICAL

E-SOLVE 2

SYOSSET

2%

A062467 001

Jul 03, 1985

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

PHARMADERM

5MG/GM

A062446 001

Sep 26, 1983

PHARMAFAIR

5MG/GM

A062481 001

Apr 05, 1984

ILOTYCIN

DISTA

0.5%

N050368 001

POWDER;FOR RX COMPOUNDING

ERYTHROMYCIN

PADDOCK LLC

100%

N050610 001

Nov 07, 1986

SOLUTION;TOPICAL

A/T/S

TARO PHARMS NORTH

2%

A062405 001

Nov 18, 1982

ERYDERM

ARBOR PHARMS INC

2%

A062290 001

ERYMAX

MERZ PHARMS

2%

A062508 002

Jul 11, 1985

ERYTHROMYCIN

ALPHARMA US PHARMS

1.5%

A062328 001

Apr 19, 1982

2%

A062326 001

Apr 19, 1982

2%

A062327 001

Apr 19, 1982

2%

A062342 001

Feb 25, 1982

2%

A062957 001

Jul 21, 1988

BAUSCH AND LOMB

2%

A064039 001

Jan 27, 1994

LILLY

2%

N050532 001

PHARMAFAIR

1.5%

A062485 001

Jul 11, 1984

2%

A062616 001

Jul 25, 1985

RENAISSANCE PHARMA

2%

A064127 001

Feb 14, 1997

SANSAC

DOW PHARM

2%

A062522 001

Jan 24, 1985

STATICIN

WESTWOOD SQUIBB

1.5%

N050526 001

## DISCONTINUED DRUG PRODUCT LIST

ERYTHROMYCIN

SOLUTION; TOPICAL

T-STAT

WESTWOOD SQUIBB 2% A062436 001 Mar 09, 1983

SWAB; TOPICAL

C-SOLVE-2

IVAX SUB TEVA PHARMS 2% A062751 001 Jul 30, 1993

ERYCETTE

JOHNSON AND JOHNSON 2% N050594 001 Feb 15, 1985

ERYTHROMYCIN

FOUGERA PHARMS 2% A065320 001 Jul 25, 2006

RENAISSANCE PHARMA 2% A064128 001 Jul 03, 1996

T-STAT

WESTWOOD SQUIBB 2% A062748 001 Jul 23, 1987

TABLET, DELAYED RELEASE; ORAL

E-BASE

BARR 333MG A063028 001 May 15, 1990

333MG A063086 001 May 15, 1990

500MG A062999 001 Nov 25, 1988

E-MYCIN

ARBOR PHARMS INC 250MG A060272 001

333MG A060272 002

ILOTYCIN

DISTA 250MG A061910 001

R-P MYCIN

SOLVAY 250MG A061659 001

ROBIMYCIN

ROBINS AH 250MG A061633 001

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATE

BARR EQ 125MG BASE A062162 001

EQ 250MG BASE A062162 002

IVAX SUB TEVA PHARMS EQ 250MG BASE A062237 001

WATSON LABS EQ 250MG BASE A062087 001

ILOSONE

LILLY EQ 125MG BASE A061897 001

EQ 250MG BASE A061897 002

FOR SUSPENSION; ORAL

ILOSONE

DISTA EQ 125MG BASE/5ML A061893 001

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA US PHARMS EQ 125MG BASE/5ML A062353 001 Nov 18, 1982

EQ 250MG BASE/5ML A062409 001 Dec 16, 1982

BARR EQ 125MG BASE/5ML A062169 001 Oct 17, 1990

EQ 250MG BASE/5ML A062169 002 Oct 17, 1990

LIFE LABS EQ 250MG BASE/5ML A062362 001 Dec 17, 1982

ILOSONE

LILLY EQ 125MG BASE/5ML A061894 001

EQ 125MG BASE/5ML N050010 001

EQ 250MG BASE/5ML A061894 002

EQ 250MG BASE/5ML N050010 002

SUSPENSION/DROPS; ORAL

ILOSONE

LILLY EQ 100MG BASE/ML A061894 003

TABLET; ORAL

ILOSONE

LILLY EQ 500MG BASE A061896 001

TABLET, CHEWABLE; ORAL

ILOSONE

DISTA EQ 125MG BASE A061895 001

EQ 250MG BASE A061895 002

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION; ORAL

ILOSONE SULFA

LILLY EQ 125MG BASE/5ML; EQ 600MG BASE/5ML N050599 001 Sep 29, 1989

**DISCONTINUED DRUG PRODUCT LIST**ERYTHROMYCIN ETHYLSUCCINATE

## GRANULE; ORAL

## ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 200MG BASE/5ML A062055 001

## PEDIAMYCIN

ROSS LABS EQ 200MG BASE/5ML A062305 001

## SUSPENSION; ORAL

## E-MYCIN E

PHARMACIA AND UPJOHN EQ 200MG BASE/5ML A062198 001

EQ 400MG BASE/5ML A062198 002

## ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS EQ 200MG BASE/5ML A062200 001

EQ 400MG BASE/5ML A062200 002

DISTA EQ 200MG BASE/5ML A062177 001

EQ 400MG BASE/5ML A062177 002

NASKA EQ 400MG BASE/5ML A062674 001 Mar 10, 1987

PARKE DAVIS EQ 200MG BASE/5ML A062231 001

EQ 400MG BASE/5ML A062231 002

PHARMAFAIR EQ 200MG BASE/5ML A062559 001 Mar 15, 1985

EQ 400MG BASE/5ML A062558 001 Mar 15, 1985

## WYAMYCIN E

WYETH AYERST EQ 200MG BASE/5ML A062123 002

EQ 400MG BASE/5ML A062123 001

## SUSPENSION/DROPS; ORAL

## PEDIAMYCIN

ROSS LABS EQ 100MG BASE/2.5ML A062305 002

## TABLET; ORAL

## E.E.S. 400

ARBOR PHARMS LLC EQ 400MG BASE A061905 001

## ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 400MG BASE A062256 001

MYLAN EQ 400MG BASE A062847 001 Sep 14, 1988

## TABLET, CHEWABLE; ORAL

## E.E.S.

ARBOR PHARMS INC EQ 200MG BASE N050297 002

## ERYPED

ARBOR PHARMS INC EQ 200MG BASE N050297 003 Jul 05, 1988

## PEDIAMYCIN

ROSS LABS EQ 200MG BASE A062306 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

## GRANULE; ORAL

## ERYZOLE

ALRA EQ 200MG BASE/5ML; EQ 600MG BASE/5ML A062758 001 Jun 15, 1988

## PEDIAZOLE

ROSS LABS EQ 200MG BASE/5ML; EQ 600MG BASE/5ML N050529 001

ERYTHROMYCIN GLUCEPTATE

## INJECTABLE; INJECTION

## ILOTYCIN GLUCEPTATE

DISTA EQ 1GM BASE/VIAL N050370 003

EQ 250MG BASE/VIAL N050370 001

EQ 500MG BASE/VIAL N050370 002

ERYTHROMYCIN LACTOBIONATE

## INJECTABLE; INJECTION

## ERYTHROCIN

ABBOTT EQ 1GM BASE/VIAL A062586 002 Jan 04, 1988

EQ 500MG BASE/VIAL A062586 001 Jan 04, 1988

HOSPIRA EQ 1GM BASE/VIAL N050182 003

EQ 1GM BASE/VIAL N050609 002 Sep 24, 1986

EQ 500MG BASE/VIAL N050182 002

## ERYTHROMYCIN

ELKINS SINN EQ 1GM BASE/VIAL A062563 002 Mar 28, 1985

EQ 500MG BASE/VIAL A062563 001 Mar 28, 1985

## ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM EQ 1GM BASE/VIAL A062604 002 Nov 24, 1986

EQ 500MG BASE/VIAL A062604 001 Nov 24, 1986

BAXTER HLTHCARE EQ 1GM BASE/VIAL A062993 002 May 09, 1989

EQ 500MG BASE/VIAL A062993 001 May 09, 1989

TEVA PARENTERAL EQ 1GM BASE/VIAL A063253 002 Jul 30, 1993

EQ 500MG BASE/VIAL A063253 001 Jul 30, 1993

## DISCONTINUED DRUG PRODUCT LIST

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

BRISTOL	EQ 250MG BASE	A061304	001
	EQ 250MG BASE	A061887	001

ERYPAR

PARKE DAVIS	EQ 250MG BASE	A062032	001
	EQ 500MG BASE	A062032	002
WARNER CHILCOTT	EQ 250MG BASE	A062322	001

ERYTHROCIN STEARATE

ARBOR PHARMS LLC	EQ 125MG BASE	A060359	002
	EQ 500MG BASE	A060359	003

ERYTHROMYCIN STEARATE

ANI PHARMS INC	EQ 250MG BASE	A061461	001
	EQ 250MG BASE	A061591	001
	EQ 500MG BASE	A061461	002
	EQ 500MG BASE	A063179	001
			May 15, 1990
LEDERLE	EQ 250MG BASE	A062089	001
	EQ 500MG BASE	A062089	002
MYLAN	EQ 250MG BASE	A061505	001
	EQ 500MG BASE	A061505	002
PUREPAC PHARM	EQ 250MG BASE	A061743	001
WATSON LABS	EQ 250MG BASE	A062121	002
	EQ 500MG BASE	A062121	001

ETHRIL 250

BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605	001
----------------------	---------------	---------	-----

ETHRIL 500

BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605	002
----------------------	---------------	---------	-----

PFIZER-E

PFIZER	EQ 250MG BASE	A061791	001
	EQ 500MG BASE	A061791	002

WYAMYCIN S

WYETH AYERST	EQ 250MG BASE	A061675	001
	EQ 500MG BASE	A061675	002

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC	EQ 5MG BASE	A077660	001	Jul 31, 2007
	EQ 10MG BASE	A077660	002	Jul 31, 2007
	EQ 20MG BASE	A077660	003	Jul 31, 2007

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE	10MG/ML	N019386	003	Aug 15, 1988
	20MG/ML	N019386	007	May 28, 2003

ESTAZOLAM

TABLET; ORAL

PROSOM

ABBOTT	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019080	001	Dec 26, 1990
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019080	002	Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE	0.025MG/24HR	N020847	001	Aug 04, 1998
	0.0375MG/24HR	N020847	002	Aug 04, 1998
	0.05MG/24HR	N020847	003	Aug 04, 1998
	0.075MG/24HR	N020847	004	Aug 04, 1998
	0.1MG/24HR	N020847	005	Aug 04, 1998

ESTRADIOL

ORTHO MCNEIL PHARM	0.05MG/24HR	N021048	001	Sep 20, 1999
	0.075MG/24HR	N021048	002	Sep 20, 1999
	0.1MG/24HR	N021048	003	Sep 20, 1999

FEMPATCH

PARKE DAVIS	0.025MG/24HR	N020417	001	Dec 03, 1996
-------------	--------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

VIVELLE

NOVARTIS	0.025MG/24HR	N020323	005	Aug 16, 2000
	0.0375MG/24HR	N020323	001	Oct 28, 1994
	0.075MG/24HR	N020323	003	Oct 28, 1994

GEL; TOPICAL

ESTROGEL

ASCEND THERAPS US	0.06%	N021166	001	Feb 09, 2004
-------------------	-------	---------	-----	--------------

TABLET; ORAL

ESTRACE

BRISTOL MYERS SQUIBB	0.5MG	A081295	001	Jun 30, 1993
	1MG	A084499	001	
	2MG	A084500	001	

ESTRADIOL

HERITAGE PHARMS INC	0.5MG	A040275	001	Dec 29, 1998
	1MG	A040275	002	Dec 29, 1998
	2MG	A040275	003	Dec 29, 1998
LANNETT HOLDINGS INC	0.5MG	A040138	001	Jan 30, 1998
	1MG	A040138	002	Jan 30, 1998
	2MG	A040138	003	Jan 30, 1998

GYNODIOL

DURAMED PHARMS BARR	0.5MG	A040212	001	Dec 29, 1997
	1MG	A040212	002	Dec 29, 1997
	1.5MG	A040212	003	Dec 29, 1997
	2MG	A040212	004	Dec 29, 1997

INNOFEM

NOVO NORDISK INC	0.5MG	A040312	001	Nov 19, 1999
	1MG	A040312	002	Nov 19, 1999
	2MG	A040312	003	Nov 19, 1999

TABLET; VAGINAL

VAGIFEM

NOVO NORDISK INC	25MCG	N020908	001	Mar 26, 1999
------------------	-------	---------	-----	--------------

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

PHARMACIA AND UPJOHN	1MG/ML	A085470	001	
	3MG/ML	A085470	002	

ESTRADIOL CYPIONATE

WATSON LABS	5MG/ML	A085620	001	
-------------	--------	---------	-----	--

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

LUNELLE

PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000
----------------------	-----------------------	---------	-----	--------------

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTADIOL

PHARMACIA AND UPJOHN	2MG/ML; 50MG/ML	N017968	001	
----------------------	-----------------	---------	-----	--

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

WATSON LABS	2MG/ML; 50MG/ML	A085603	001	Mar 13, 1986
-------------	-----------------	---------	-----	--------------

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

SANDOZ	10MG/ML	A040628	001	Oct 04, 2007
	20MG/ML	A040628	002	Oct 04, 2007
	40MG/ML	A040628	003	Oct 04, 2007
WATSON LABS	10MG/ML	A083546	001	
	40MG/ML	A083714	001	
WATSON LABS INC	20MG/ML	A083547	001	

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DITATE-DS

SAVAGE LABS	8MG/ML; 180MG/ML	A086423	001	
-------------	------------------	---------	-----	--

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

WATSON LABS	4MG/ML; 90MG/ML	A085865	001	
	8MG/ML; 180MG/ML	A085860	001	

**DISCONTINUED DRUG PRODUCT LIST**ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

TEVA WOMENS

1MG, 1MG; 1MG, 1MG; N/A, 0.09MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N021040 001 Oct 22, 1999

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

WYETH PHARMS INC

2.5MG

N004782 002

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

TEVA WOMENS

0.625MG/GM

N021788 001 Nov 28, 2008

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN; CYCRIN 14/14)

WYETH PHARMS INC

0.625MG; 0.625MG; N/A, 5MG

N020303 002 Dec 30, 1994

PREMPRO (PREMARIN; CYCRIN)

WYETH PHARMS INC

0.625MG; 0.625MG; 2.5MG; 2.5MG

N020303 001 Dec 30, 1994

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

MILPREM-200

MEDPOINTE PHARM HLC

0.45MG; 200MG

N011045 002

MILPREM-400

MEDPOINTE PHARM HLC

0.45MG; 400MG

N011045 001

PMB 200

WYETH AYERST

0.45MG; 200MG

N010971 005

PMB 400

WYETH AYERST

0.45MG; 400MG

N010971 003

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN

BRISTOL MYERS SQUIBB

0.3MG

A083266 001

0.625MG

A083266 002

1.25MG

A083266 003

2.5MG

A083266 004

ESTERIFIED ESTROGENS

PVT FORM

0.625MG

A083414 001

1.25MG

A083765 001

2.5MG

A085907 001

SANDOZ

1.25MG

A085302 001

ESTRATAB

SOLVAY

0.3MG

A086715 001

0.625MG

A083209 001

1.25MG

A083856 001

2.5MG

A083857 001

EVEX

ROCHE PALO

0.625MG

A084215 001

1.25MG

A083376 002

FEMOGEN

PVT FORM

0.625MG

A085076 001

1.25MG

A085008 001

2.5MG

A085007 001

ESTRONE

INJECTABLE; INJECTION

ESTROGENIC SUBSTANCE

WYETH AYERST

2MG/ML

A083488 001

ESTRONE

WATSON LABS

2MG/ML

A083397 001

5MG/ML

A085239 001

NATURAL ESTROGENIC SUBSTANCE-ESTRONE

WATSON LABS

2MG/ML

A085237 001 Nov 23, 1982

THEELIN

PARKEDALE

1MG/ML

N003977 001

2MG/ML

N003977 002

5MG/ML

N003977 003

## DISCONTINUED DRUG PRODUCT LIST

ESTROPIPATE

CREAM; VAGINAL

OGEN

PHARMACIA AND UPJOHN 1.5MG/GM

A084710 001

TABLET; ORAL

ESTROPIPATE

DURAMED PHARMS BARR 0.75MG

A040296 001 Nov 01, 1999

1.5MG

A040296 002 Nov 01, 1999

3MG

A040296 003 Nov 01, 1999

MYLAN 3MG

A040359 003 Aug 26, 1999

WATSON LABS 6MG

A081216 001 Sep 23, 1993

ORTHO-EST

SUN PHARM INDS INC 0.75MG

A089567 001 Feb 27, 1991

1.5MG

A089582 001 Jul 17, 1991

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

WOCKHARDT LTD 1MG

A091165 001 Jul 14, 2011

2MG

A091165 002 Jul 14, 2011

3MG

A091165 003 Jul 14, 2011

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

ATON 50MG

N016092 002

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

VERSAPHARM INC 100MG

A075095 001 Nov 30, 1999

400MG

A075095 002 Nov 30, 1999

MYAMBUTOL

STI PHARMA LLC 200MG

N016320 002

500MG

N016320 004

ETHCHLORVYNOL

CAPSULE; ORAL

ETHCHLORVYNOL

BANNER PHARMACAPS 100MG

A084463 001

200MG

A084463 002

500MG

A084463 003

750MG

A084463 004

PLACIDYL

ABBVIE 100MG

N010021 004

200MG

N010021 007

500MG

N010021 002

750MG

N010021 010

ETHINAMATE

CAPSULE; ORAL

VALMID

DISTA 500MG

N009750 001

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

SCHERING 0.02MG

N005292 001

0.05MG

N005292 002

0.5MG

N005292 003

FEMINONE

PHARMACIA AND UPJOHN 0.05MG

N016649 001

LYNORAL

ORGANON USA INC 0.01MG

N005490 003

0.05MG

N005490 002

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC 0.035MG; 1MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N018168 001

DEMULEN 1/50-21

GD SEARLE LLC 0.05MG; 1MG

N016927 001



**DISCONTINUED DRUG PRODUCT LIST**ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21

ZOVIA 1/35E-21

WATSON LABS

0.035MG;1MG

A072720 001 Dec 30, 1991

ZOVIA 1/50E-21

WATSON LABS

0.05MG;1MG

A072722 001 Dec 30, 1991

TABLET;ORAL-28

DEMULEN 1/35-28

GD SEARLE LLC

0.035MG;1MG

N018160 001

DEMULEN 1/50-28

GD SEARLE LLC

0.05MG;1MG

N016936 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28

NORQUEST FE

GD SEARLE LLC

0.035MG;75MG;1MG

N018926 001 Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET;ORAL-28

NORLESTRIN FE 1/50

PARKE DAVIS

0.05MG;75MG;1MG

N016766 001

NORLESTRIN FE 2.5/50

PARKE DAVIS

0.05MG;75MG;2.5MG

N016854 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

LYBREL

WYETH PHARMS INC

0.02MG;0.09MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021864 001 May 22, 2007

PREVEN EMERGENCY CONTRACEPTIVE KIT

TEVA BRANDED PHARM

0.05MG;0.25MG

N020946 001 Sep 01, 1998

TABLET;ORAL-21

ALESSE

WYETH PHARMS

0.02MG;0.1MG \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020683 001 Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR

0.02MG;0.1MG

A075796 002 Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1  
25MG

A075809 001 Jul 16, 2001

LESSINA-21

BARR

0.02MG;0.1MG

A075803 001 Mar 20, 2002

LEVLITE

BAYER HLTHCARE

0.02MG;0.1MG

N020860 001 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR

0.02MG;0.1MG

A075862 001 Apr 29, 2003

LEVORA 0.15/30-21

WATSON LABS

0.03MG;0.15MG

A073592 001 Dec 13, 1993

NORDETTE-21

TEVA BRANDED PHARM

0.03MG;0.15MG

N018668 001 May 10, 1982

PORTIA-21

BARR

0.03MG;0.15MG

A075866 001 May 23, 2002

TRIPHASIL-21

WYETH PHARMS

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1  
25MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N019192 001 Nov 01, 1984

TRIVORA-21

WATSON LABS

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1  
25MG

A074538 001 Dec 18, 1997

TABLET;ORAL-28

ALESSE

WYETH PHARMS

0.02MG;0.1MG

N020683 002 Mar 27, 1997

LEVLITE

BAYER HLTHCARE

0.02MG;0.1MG

N020860 002 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR

0.02MG;0.1MG

A075862 002 Apr 29, 2003

TRIPHASIL-28

WYETH PHARMS INC

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1  
25MG

N019190 001 Nov 01, 1984

## DISCONTINUED DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE

## TABLET; ORAL-21

BALZIVA-21				
BARR	0.035MG;0.4MG	A076198	001	Apr 22, 2004
BREVICON 21-DAY				
WATSON LABS	0.035MG;0.5MG	N017566	001	
GENCEPT 10/11-21				
BARR	0.035MG;0.035MG;0.5MG;1MG	A072694	001	Feb 28, 1992
MODICON 21				
ORTHO MCNEIL PHARM	0.035MG;0.5MG	N017488	001	
N.E.E. 1/35 21				
LPI	0.035MG;1MG	A071541	001	Dec 14, 1987
NORCEPT-E 1/35 21				
ORTHO MCNEIL PHARM	0.035MG;1MG	A071545	001	Feb 09, 1989
NORETHIN 1/35E-21				
WATSON LABS	0.035MG;1MG	A071480	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL				
WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010
	0.035MG;0.5MG	A070684	001	Jan 29, 1987
	0.035MG;1MG	A070685	001	Jan 29, 1987
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)				
WATSON LABS	0.035MG;0.035MG;0.5MG;1MG	A071043	001	Apr 01, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)				
WATSON LABS	0.035MG;0.035MG;0.5MG;1MG	A071041	001	Sep 24, 1991
NORTREL 0.5/35-21				
BARR	0.035MG;0.5MG	A072692	001	Feb 28, 1992
ORTHO-NOVUM 1/35-21				
ORTHO MCNEIL PHARM	0.035MG;1MG	N017489	002	
ORTHO-NOVUM 10/11-21				
ORTHO MCNEIL JANSSEN	0.035MG;0.035MG;0.5MG;1MG	N018354	001	Jan 11, 1982
ORTHO-NOVUM 7/14-21				
ORTHO MCNEIL PHARM	0.035MG;0.035MG;0.5MG;1MG	N019004	001	Apr 04, 1984
ORTHO-NOVUM 7/7/7-21				
JANSSEN PHARMS	0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG	N018985	001	Apr 04, 1984
OVCON-35				
WARNER CHILCOTT	0.035MG;0.4MG	N018127	001	
OVCON-50				
WARNER CHILCOTT	0.05MG;1MG	N018128	001	
TRI-NORINYL 21-DAY				
WATSON LABS	0.035MG;0.035MG;0.035MG;0.5MG;0.5MG;1MG	N018977	001	Apr 13, 1984
TABLET; ORAL-28				
GENCEPT 10/11-28				
BARR	0.035MG;0.035MG;0.5MG;1MG	A072697	001	Feb 28, 1992
N.E.E. 1/35 28				
LPI	0.035MG;1MG	A071542	001	Dec 14, 1987
NORCEPT-E 1/35 28				
ORTHO MCNEIL PHARM	0.035MG;1MG	A071546	001	Feb 09, 1989
NORETHIN 1/35E-28				
WATSON LABS	0.035MG;1MG	A071481	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL				
WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076393	001	Feb 04, 2010
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)				
WATSON LABS	0.035MG,0.035MG;0.035MG,0.035MG;0.5MG,1MG;0.5MG,1MG	A071042	001	Sep 24, 1991
ORTHO-NOVUM 10/11-28				
ORTHO MCNEIL JANSSEN	0.035MG;0.035MG;0.5MG;1MG	N018354	002	Jan 11, 1982
ORTHO-NOVUM 7/14-28				
ORTHO MCNEIL PHARM	0.035MG;0.035MG;0.5MG;1MG	N019004	002	Apr 04, 1984
OVCON-50				
WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

## CAPSULE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE				
WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013
TABLET; ORAL				
FEMHRT				
WARNER CHILCOTT LLC	0.005MG;1MG	N021065	002	Oct 15, 1999
TABLET; ORAL-21				
ESTROSTEP 21				
WARNER CHILCOTT LLC	0.02MG;0.035MG;0.03MG;1MG;1MG;1MG	N020130	001	Oct 09, 1996

## DISCONTINUED DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21			
NORLESTRIN 21 1/50			
PARKE DAVIS	0.05MG; 1MG		N016749 001
NORLESTRIN 21 2.5/50			
PARKE DAVIS	0.05MG; 2.5MG		N016852 001
TABLET; ORAL-28			
NORLESTRIN 28 1/50			
PARKE DAVIS	0.05MG; 1MG		N016723 001

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21			
ORTHO CYCLEN-21			
JANSSEN PHARMS	0.035MG; 0.25MG		N019653 001 Dec 29, 1989
ORTHO TRI-CYCLEN			
JANSSEN PHARMS	0.035MG; 0.035MG; 0.035MG; 0.18MG; 0.215MG; 0.25MG		N019697 002 Jul 03, 1992
TABLET; ORAL-28			
NORGESTIMATE AND ETHINYL ESTRADIOL			
WATSON LABS	0.025MG; 0.025MG; 0.025MG; 0.18MG; 0.215MG; 0.25MG		A090479 001 Mar 09, 2011
	0.035MG; 0.035MG; 0.035MG; 0.18MG; 0.215MG; 0.25MG		A076626 001 Aug 17, 2006
	0.035MG; 0.25MG		A076627 001 Aug 17, 2006
TRI LO SPRINTEC			
BARR LABS INC	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG		A076784 001 Jun 29, 2009

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21			
LO/OVRAL			
WYETH PHARMS INC	0.03MG; 0.3MG		N017612 001
LOW-OGESTREL-21			
WATSON LABS	0.03MG; 0.3MG		A075288 001 Jul 28, 1999
OGESTREL 0.5/50-21			
WATSON LABS	0.05MG; 0.5MG		A075406 001 Dec 15, 1999
OVRAL			
WYETH PHARMS	0.05MG; 0.5MG		N016672 001
TABLET; ORAL-28			
LOW-OGESTREL-28			
WATSON LABS	0.03MG; 0.3MG		A075288 002 Jul 28, 1999
OVRAL-28			
WYETH PHARMS	0.05MG; 0.5MG		N016806 001

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL			
PARSIDOL			
PARKE DAVIS	10MG		N009078 003
	50MG		N009078 006
	100MG		N009078 008

ETHOTOIN

TABLET; ORAL			
PEGANONE			
RECORDATI RARE	500MG		N010841 003

ETHOXZOLAMIDE

TABLET; ORAL			
CARDRASE			
PHARMACIA AND UPJOHN	62.5MG		N011047 002
	125MG		N011047 001
ETHAMIDE			
ALLERGAN	125MG		N016144 001

ETHYLESTRENOL

ELIXIR; ORAL			
MAXIBOLIN			
ORGANON USA INC	2MG/5ML		N014006 002
TABLET; ORAL			
MAXIBOLIN			
ORGANON USA INC	2MG		N014005 002

**DISCONTINUED DRUG PRODUCT LIST**ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20

OVULEN

GD SEARLE LLC 1MG;0.1MG N016029 002

TABLET; ORAL-21

OVULEN-21

GD SEARLE LLC 1MG;0.1MG N016029 003

TABLET; ORAL-28

OVULEN-28

GD SEARLE LLC 1MG;0.1MG N016705 001

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA 0.5% N017751 003

1% N017751 005

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

MGI PHARMA INC 50MG/ML N019545 001 Apr 20, 1987

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AAIPHARMA LLC 300MG A074929 001 Jan 30, 1998

ANI PHARMS INC 200MG A074899 001 Jul 08, 1997

300MG A074899 002 Jul 08, 1997

MYLAN 200MG A074932 001 May 16, 1997

200MG A075071 001 Sep 30, 1998

300MG A074932 002 May 16, 1997

300MG A075071 002 Sep 30, 1998

SANDOZ 200MG A074840 001 Aug 29, 1997

200MG A074942 001 Sep 30, 1997

300MG A074840 002 Aug 29, 1997

300MG A074942 002 Sep 30, 1997

VINTAGE PHARMS LLC 200MG A074842 001 Jul 17, 1997

300MG A074842 002 Jul 17, 1997

WATSON LABS 200MG A074844 001 Dec 23, 1997

300MG A074844 002 Dec 23, 1997

LODINE

WYETH PHARMS INC 200MG N018922 002 Jan 31, 1991

300MG N018922 003 Jan 31, 1991

TABLET; ORAL

ETODOLAC

AAIPHARMA LLC 400MG A074927 001 Oct 30, 1997

IVAX SUB TEVA PHARMS 400MG A074883 001 Feb 28, 1997

500MG A074883 002 Nov 20, 1998

MYLAN 400MG A075012 001 Sep 30, 1998

500MG A075012 002 Sep 30, 1998

PROSAM LABS 400MG A074819 001 Feb 28, 1997

500MG A074819 002 Apr 28, 1998

RANBAXY LABS LTD 400MG A075226 001 Nov 24, 1998

500MG A075226 002 Nov 24, 1998

SANDOZ 400MG A074839 001 Jul 11, 1997

400MG A074846 001 Feb 28, 1997

TEVA 400MG A074847 001 Apr 23, 1999

500MG A074847 002 Apr 23, 1999

VINTAGE PHARMS LLC 400MG A074841 001 Jun 27, 1997

WATSON LABS 400MG A074892 001 Apr 16, 1997

400MG A075069 001 Apr 16, 1998

500MG A074892 002 Oct 29, 1998

LODINE

WYETH PHARMS INC 400MG N018922 004 Jul 29, 1993

500MG N018922 005 Jun 28, 1996

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

ACTAVIS ELIZABETH 400MG A075696 001 Jul 31, 2000

SANDOZ 400MG A075943 001 Jul 26, 2002

500MG A075943 002 Jul 26, 2002

600MG A075943 003 Jul 26, 2002

WATSON LABS FLORIDA 400MG A075829 001 Nov 30, 2001

500MG A075829 002 Nov 30, 2001

**DISCONTINUED DRUG PRODUCT LIST**ETODOLAC

TABLET, EXTENDED RELEASE;ORAL

LODINE XL

WYETH PHARMS INC	400MG	N020584 001	Oct 25, 1996
	500MG	N020584 003	Jan 20, 1998
	600MG	N020584 002	Oct 25, 1996

ETOPOSIDE

CAPSULE;ORAL

VEPESID

DAVA PHARMS INC	50MG	N019557 001	Dec 30, 1986
	100MG	N019557 002	Dec 30, 1986

INJECTABLE; INJECTION

ETOPOSIDE

HOSPIRA	20MG/ML	A074320 001	Aug 30, 1995
	20MG/ML	A074351 001	Aug 30, 1995
PHARMACHEMIE BV	20MG/ML	A074227 001	Feb 22, 1996
PIERRE FABRE	20MG/ML	A074813 001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML	A074510 001	Jun 29, 1995
TEVA PHARMS USA	20MG/ML	A074284 001	Feb 10, 1994
WATSON LABS	20MG/ML	A074228 001	Oct 15, 1996
WATSON LABS INC	20MG/ML	A074968 001	Jan 09, 1998
TOPOSAR			
TEVA PARENTERAL	20MG/ML	A074166 001	Feb 27, 1995
VEPESID			
CORDEN PHARMA	20MG/ML	N018768 001	Nov 10, 1983

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB	EQ 1GM BASE/VIAL	N020906 002	Feb 27, 1998
	EQ 500MG BASE/VIAL	N020906 001	Feb 27, 1998

ETRETINATE

CAPSULE;ORAL

TEGISON

ROCHE	10MG	N019369 001	Sep 30, 1986
	25MG	N019369 002	Sep 30, 1986

EVANS BLUE

INJECTABLE; INJECTION

EVANS BLUE

PARKE DAVIS	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008041 001	
-------------	-----------------------------------------------------------------------------------------------------------------------	-------------	--

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

APOTEX INC	10MG/ML	A075942 001	Aug 02, 2002
APOTHECON	10MG/ML	A075707 001	Apr 16, 2001
HIKMA MAPLE	10MG/ML	A075799 001	Apr 30, 2002
HOSPIRA	10MG/ML	A075705 001	Apr 16, 2001
	10MG/ML	A075870 001	Nov 23, 2001
	10MG/ML	A075905 001	Nov 23, 2001

FAMOTIDINE PRESERVATIVE FREE

APOTEX INC	10MG/ML	A076324 001	Nov 27, 2002
APOTHECON	10MG/ML	A075708 001	Apr 16, 2001
HIKMA MAPLE	10MG/ML	A075789 001	Apr 30, 2002
HOSPIRA	10MG/ML	A075669 001	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

APOTEX INC	10MG/ML	A076322 001	Nov 27, 2002
------------	---------	-------------	--------------

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBVIE	0.4MG/ML	A075729 001	Dec 17, 2001
--------	----------	-------------	--------------

PEPCID

MERCK	10MG/ML	N019510 001	Nov 04, 1986
-------	---------	-------------	--------------

PEPCID PRESERVATIVE FREE

MERCK	10MG/ML	N019510 004	Nov 04, 1986
-------	---------	-------------	--------------

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

MERCK SHARP DOHME	0.4MG/ML	N020249 001	Feb 18, 1994
-------------------	----------	-------------	--------------

TABLET;ORAL

FAMOTIDINE

ACTAVIS ELIZABETH	20MG	A075650 001	Sep 14, 2001
	40MG	A075650 002	Sep 14, 2001

## DISCONTINUED DRUG PRODUCT LIST

FAMOTIDINE

## TABLET; ORAL

## FAMOTIDINE

APOTEX	10MG	A075610 001	Mar 12, 2002
MUTUAL PHARM	20MG	A075639 002	Dec 12, 2001
	40MG	A075639 001	Dec 12, 2001
MYLAN PHARMS INC	20MG	A075457 001	Apr 18, 2001
	40MG	A075457 002	Apr 18, 2001
SANDOZ	10MG	A076101 001	Oct 21, 2002
	20MG	A075302 001	Apr 16, 2001
	20MG	A075607 001	May 10, 2001
	20MG	A075793 001	Apr 16, 2001
	40MG	A075302 002	Apr 16, 2001
	40MG	A075607 002	May 10, 2001
	40MG	A075793 002	Apr 16, 2001
WATSON LABS	10MG	A075404 001	Nov 28, 2001
	20MG	A075062 002	Apr 16, 2001
	40MG	A075062 001	Apr 16, 2001

## TABLET, CHEWABLE; ORAL

## PEPCID AC

MCNEIL CONS	10MG	N020801 001	Sep 24, 1998
-------------	------	-------------	--------------

## TABLET, ORALLY DISINTEGRATING; ORAL

## FLUXID

UCB INC	20MG	N021712 001	Sep 24, 2004
	40MG	N021712 002	Sep 24, 2004

## PEPCID RPD

MERCK	20MG	N020752 001	May 28, 1998
	40MG	N020752 002	May 28, 1998

FELODIPINE

## TABLET, EXTENDED RELEASE; ORAL

## FELODIPINE

WOCKHARDT LTD	2.5MG	A091484 001	Aug 15, 2012
	5MG	A091484 002	Aug 15, 2012
	10MG	A091484 003	Aug 15, 2012

FENOFIBRATE

## CAPSULE; ORAL

## ANTARA (MICRONIZED)

LUPIN ATLANTIS	87MG	N021695 002	Nov 30, 2004
----------------	------	-------------	--------------

## LIPIDIL

ABBVIE	100MG	N019304 001	Dec 31, 1993
--------	-------	-------------	--------------

## LIPOFEN

CIPHER PHARMS INC	100MG	N021612 002	Jan 11, 2006
-------------------	-------	-------------	--------------

## TRICOR (MICRONIZED)

ABBVIE	67MG	N019304 002	Feb 09, 1998
	134MG	N019304 003	Jun 30, 1999
	200MG	N019304 004	Jun 30, 1999

## TABLET; ORAL

## FENOFIBRATE

MYLAN	107MG	A076520 002	Dec 29, 2005
-------	-------	-------------	--------------

## TRICOR

ABBOTT	54MG	N021203 001	Sep 04, 2001
	160MG	N021203 003	Sep 04, 2001

## TRIGLIDE

SKYEPHARMA AG	50MG	N021350 001	May 07, 2005
---------------	------	-------------	--------------

FENOLDOPAM MESYLATE

## INJECTABLE; INJECTION

## FENOLDOPAM MESYLATE

LUITPOLD	EQ 10MG BASE/ML	A076656 001	Dec 01, 2003
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826 001	Mar 07, 2007

FENOPROFEN CALCIUM

## CAPSULE; ORAL

## FENOPROFEN CALCIUM

AM THERAP	EQ 200MG BASE	A072307 001	Aug 22, 1988
	EQ 300MG BASE	A072308 001	Aug 22, 1988
HALSEY	EQ 200MG BASE	A072355 001	Aug 17, 1988
	EQ 300MG BASE	A072356 001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437 001	Aug 22, 1988
	EQ 300MG BASE	A072438 001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214 001	Aug 17, 1988
	EQ 300MG BASE	A071738 001	Aug 17, 1988

## DISCONTINUED DRUG PRODUCT LIST

FENOPROFEN CALCIUM

## CAPSULE; ORAL

## FENOPROFEN CALCIUM

SANDOZ	EQ 200MG BASE	A072394 001	Oct 17, 1988
	EQ 300MG BASE	A072395 001	Oct 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	A072946 001	Apr 30, 1991
	EQ 300MG BASE	A072472 001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294 001	Aug 17, 1988
	EQ 200MG BASE	A072981 001	Aug 19, 1991
	EQ 300MG BASE	A072293 001	Aug 17, 1988
	EQ 300MG BASE	A072982 001	Aug 19, 1991

## NALFON

XSPIRE	EQ 300MG BASE	N017604 002	
--------	---------------	-------------	--

## TABLET; ORAL

## FENOPROFEN CALCIUM

ACTAVIS ELIZABETH	EQ 600MG BASE	A072274 001	May 02, 1988
AM THERAP	EQ 600MG BASE	A072309 001	Aug 17, 1988
DAVA PHARMS INC	EQ 600MG BASE	A072326 001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357 001	Aug 17, 1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557 001	Aug 29, 1988
MUTUAL PHARM	EQ 600MG BASE	A072902 001	Dec 21, 1990
PAR PHARM	EQ 600MG BASE	A072429 001	Aug 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194 001	Aug 17, 1988
SANDOZ	EQ 600MG BASE	A072396 001	Oct 17, 1988
USL PHARMA	EQ 600MG BASE	A072362 001	Aug 17, 1988
WATSON LABS	EQ 600MG BASE	A072165 001	Aug 17, 1988
	EQ 600MG BASE	A072407 001	Aug 17, 1988
	EQ 600MG BASE	A072602 001	Oct 11, 1988

## NALFON

DISTA	EQ 600MG BASE	N017710 001	
-------	---------------	-------------	--

FENTANYL

## FILM, EXTENDED RELEASE; TRANSDERMAL

## FENTANYL-100

NOVEN	100MCG/HR	A077775 004	Oct 16, 2009
-------	-----------	-------------	--------------

## FENTANYL-25

NOVEN	25MCG/HR	A077775 001	Oct 16, 2009
-------	----------	-------------	--------------

## FENTANYL-50

NOVEN	50MCG/HR	A077775 002	Oct 16, 2009
-------	----------	-------------	--------------

## FENTANYL-75

NOVEN	75MCG/HR	A077775 003	Oct 16, 2009
-------	----------	-------------	--------------

FENTANYL CITRATE

## FILM; BUCCAL

## ONSOLIS

MEDA PHARMS	EQ 0.2MG BASE	N022266 001	Jul 16, 2009
	EQ 0.4MG BASE	N022266 002	Jul 16, 2009
	EQ 0.6MG BASE	N022266 003	Jul 16, 2009
	EQ 0.8MG BASE	N022266 004	Jul 16, 2009
	EQ 1.2MG BASE	N022266 005	Jul 16, 2009

## INJECTABLE; INJECTION

## FENTANYL CITRATE

ABBOTT	EQ 0.05MG BASE/ML	A070636 001	Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637 001	Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488 001	Jun 30, 1992

## FENTANYL CITRATE PRESERVATIVE FREE

WATSON LABS INC	EQ 0.05MG BASE/ML	A074917 001	Feb 03, 1998
-----------------	-------------------	-------------	--------------

## TABLET; BUCCAL, SUBLINGUAL

## FENTANYL CITRATE

WATSON LABS	EQ 0.1MG BASE	A079075 001	Jan 07, 2011
	EQ 0.2MG BASE	A079075 002	Jan 07, 2011
	EQ 0.4MG BASE	A079075 003	Jan 07, 2011
	EQ 0.6MG BASE	A079075 004	Jan 07, 2011
	EQ 0.8MG BASE	A079075 005	Jan 07, 2011

## FENTORA

CEPHALON	EQ 0.3MG BASE	N021947 006	Mar 02, 2007
----------	---------------	-------------	--------------

## TROCHE/LOZENGE; ORAL

## FENTANYL

CEPHALON	EQ 0.1MG BASE	N020195 007	Oct 30, 1995
	EQ 0.2MG BASE	N020195 001	Oct 04, 1993
	EQ 0.3MG BASE	N020195 002	Oct 04, 1993
	EQ 0.4MG BASE	N020195 003	Oct 04, 1993

**DISCONTINUED DRUG PRODUCT LIST**FENTANYL HYDROCHLORIDESYSTEM; IONTOPHORESIS, TRANSDERMAL  
IONSYS

INCLINE THERAP 10.8MCG N021338 001 May 22, 2006

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

OTSUKA 600MG/PACKET N020292 001 Oct 14, 1997

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT 25uCi/ML N016729 001

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL

FOLVRON

LEDERLE 182MG; 0.33MG N006012 003

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

AMAG PHARMS INC EQ 11.2MG IRON/ML N020416 001 Aug 30, 1996

FERUMOXSIIL

SUSPENSION; ORAL

GASTROMARK

AMAG PHARMS INC EQ 0.175MG IRON/ML N020410 001 Dec 06, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA

SANOFI AVENTIS US 60MG N020625 001 Jul 25, 1996

FEXOFENADINE HYDROCHLORIDE

BARR 60MG A076169 001 Jul 13, 2005

FIBRINOGEN, I-125

INJECTABLE; INJECTION

IBRIN

GE HEALTHCARE 154uCi/VIAL N017879 001

RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR

ABBOTT 140uCi/ML N017787 001

FINASTERIDE

TABLET; ORAL

FINASTERIDE

IVAX SUB TEVA PHARMS 5MG A076340 001 Jun 19, 2006

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

URISPAS

ORTHO MCNEIL JANSSEN 100MG N016769 001

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

APOTEX INC 50MG A079164 001 Jul 09, 2009

100MG A079164 002 Jul 09, 2009

150MG A079164 003 Jul 09, 2009

SANDOZ 50MG A076030 001 Oct 28, 2002

100MG A076030 002 Oct 28, 2002

150MG A076030 003 Oct 28, 2002

TAMBOCOR

CNTY LINE PHARMS 50MG N018830 004 Aug 23, 1988

100MG N018830 001 Oct 31, 1985

150MG N018830 003 Jun 03, 1988

200MG N018830 002 Oct 31, 1985

FLOXURIDINE

INJECTABLE; INJECTION

FUDR

HOSPIRA 500MG/VIAL \*\*Federal Register N016929 001

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*



**DISCONTINUED DRUG PRODUCT LIST**FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

TARO PHARM INDS	50MG/5ML	A076918	001	Dec 18, 2006
	200MG/5ML	A076918	002	Dec 18, 2006

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005
HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004
TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005
	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005

TABLET; ORAL

FLUCONAZOLE

GEDEON RICHTER USA	50MG	A076432	001	Jul 29, 2004
	100MG	A076432	002	Jul 29, 2004
	150MG	A076432	003	Jul 29, 2004
	200MG	A076432	004	Jul 29, 2004
HARRIS PHARM	50MG	A078423	001	Mar 07, 2011
	100MG	A078423	002	Mar 07, 2011
	150MG	A078423	003	Mar 07, 2011
	200MG	A078423	004	Mar 07, 2011
MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004
	100MG	A076042	002	Jul 29, 2004
	150MG	A076042	003	Jul 29, 2004
	200MG	A076042	004	Jul 29, 2004
PLIVA	50MG	A076424	001	Jul 29, 2004
	100MG	A076424	002	Jul 29, 2004
	150MG	A076424	003	Jul 29, 2004
	200MG	A076424	004	Jul 29, 2004
RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004
	100MG	A076386	002	Jul 29, 2004
	150MG	A076386	003	Jul 29, 2004
	200MG	A076386	004	Jul 29, 2004
ROXANE	50MG	A076213	001	Jul 29, 2004
	100MG	A076213	002	Jul 29, 2004
	150MG	A076213	003	Jul 29, 2004
	200MG	A076213	004	Jul 29, 2004
SANDOZ	50MG	A076086	001	Jul 29, 2004
	100MG	A076086	002	Jul 29, 2004
	150MG	A076086	003	Jul 29, 2004
	200MG	A076086	004	Jul 29, 2004

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

GENZYME CORP	50MG/VIAL	N020038	001	Apr 18, 1991
--------------	-----------	---------	-----	--------------

TABLET; ORAL

OFORTA

SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008
-------------------	------	---------	-----	--------------

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F 18

DOWNSTATE CLINCL	4-40mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020306	001	Aug 19, 1994
	4-90mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020306	002	Sep 25, 2001

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

WEILL MEDCL COLL	10-100mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021768	001	Aug 05, 2004
------------------	----------------------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

CITRON PHARMA LLC

0.1MG

N010060 001

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

APOTEX INC

0.5MG/5ML (0.1MG/ML)

A076755 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076755 001 Oct 12, 2004

TEVA PHARMS USA

0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004

ROMAZICON

HOFFMANN LA ROCHE

1MG/10ML (0.1MG/ML) \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020073 001 Dec 20, 1991

0.5MG/5ML (0.1MG/ML) \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020073 002 Dec 20, 1991

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS

0.03%

N016379 001

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

ROCHE PALO

0.25MG/INH

N018340 001 Aug 17, 1984

SPRAY, METERED; NASAL

NASALIDE

IVAX RES

0.025MG/SPRAY

N018148 001

NASAREL

TEVA BRANDED PHARM

0.029MG/SPRAY

N020409 001 Mar 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCET

ALPHARMA US PHARMS

0.025%

A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS

0.01%

A088361 001 Jan 16, 1984

PERRIGO NEW YORK

0.01%

A086810 001 Mar 04, 1982

0.025%

A086811 001 Mar 04, 1982

PHARMADERM

0.01%

A088047 001 Dec 16, 1982

0.025%

A088045 001 Dec 16, 1982

PHARMAFAIR

0.01%

A088499 001 Aug 02, 1984

0.025%

A088506 001 Aug 02, 1984

TARO

0.01%

A040035 001 Oct 31, 1994

0.01%

A087102 001 Apr 27, 1982

0.025%

A040042 001 Oct 31, 1994

USL PHARMA

0.01%

A088757 001 Feb 11, 1985

0.025%

A088756 001 Mar 28, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087156 002 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.01%

A088174 001 May 06, 1983

0.025%

A088173 001 Mar 09, 1983

SYNALAR-HP

MEDIMETRIKS PHARMS

0.2%

N016161 002

GEL; TOPICAL

FLUONID

ALLERGAN HERBERT

0.025%

A087300 001 May 27, 1982

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

PHARMADERM

0.025%

A088046 001 Dec 16, 1982

PHARMAFAIR

0.025%

A088507 001 Feb 27, 1984

USL PHARMA

0.025%

A088742 001 Feb 08, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087157 001 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.025%

A088172 001 Mar 09, 1983

## DISCONTINUED DRUG PRODUCT LIST

FLUOCINOLONE ACETONIDE

## SOLUTION; TOPICAL

## FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.01%	A087159 001	Jun 16, 1982
BAUSCH AND LOMB	0.01%	A040059 001	Dec 20, 1993
MORTON GROVE	0.01%	A088312 001	Jan 27, 1984
PHARMADERM	0.01%	A088048 001	Dec 16, 1982
PHARMAFAIR	0.01%	A088449 001	Feb 08, 1984

## FLUONID

ALLERGAN HERBERT	0.01%	A087158 001	Mar 17, 1983
------------------	-------	-------------	--------------

## FLUOTREX

SAVAGE LABS	0.01%	A088171 001	Mar 09, 1983
-------------	-------	-------------	--------------

FLUOCINONIDE

## CREAM; TOPICAL

## FLUOCINONIDE

PERRIGO NEW YORK	0.05%	A071790 001	Jul 13, 1988
TARO	0.05%	A071500 001	Jun 10, 1987

## FLUOCINONIDE EMULSIFIED BASE

G AND W LABS INC	0.05%	A074204 001	Jun 13, 1995
------------------	-------	-------------	--------------

## LIDEX

CNTY LINE PHARMS	0.05%	N016908 002	
------------------	-------	-------------	--

## LIDEX-E

CNTY LINE PHARMS	0.05%	N016908 003	
------------------	-------	-------------	--

## GEL; TOPICAL

## LIDEX

CNTY LINE PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017373 001	
------------------	------------------------------------------------------------------------------------------------------------------------	-------------	--

## OINTMENT; TOPICAL

## LIDEX

CNTY LINE PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016909 002	
------------------	------------------------------------------------------------------------------------------------------------------------	-------------	--

## SOLUTION; TOPICAL

## FLUOCINONIDE

TARO	0.05%	A072857 001	Aug 02, 1989
TEVA PHARMS	0.05%	A072522 001	Sep 28, 1990

FLUORESCEIN SODIUM

## INJECTABLE; INJECTION

## FUNDUSCEIN-25

NOVARTIS	25%	N017869 001	
----------	-----	-------------	--

FLUOROMETHOLONE

## CREAM; TOPICAL

## OXYLONE

PHARMACIA AND UPJOHN	0.025%	N011748 001	
----------------------	--------	-------------	--

## SUSPENSION/DROPS; OPHTHALMIC

## FLUOR-OP

NOVARTIS	0.1%	A070185 001	Feb 27, 1986
----------	------	-------------	--------------

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

## SUSPENSION/DROPS; OPHTHALMIC

## TOBRASONE

ALCON	0.1%; 0.3%	N050628 001	Jul 21, 1989
-------	------------	-------------	--------------

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

## SUSPENSION/DROPS; OPHTHALMIC

## FML-S

ALLERGAN	0.1%; 10%	N019525 001	Sep 29, 1989
----------	-----------	-------------	--------------

FLUOROURACIL

## INJECTABLE; INJECTION

## ADRUCIL

PHARMACIA AND UPJOHN	50MG/ML	A081222 001	Jun 28, 1991
	50MG/ML	N017959 001	
TEVA PARENTERAL	50MG/ML	A040023 001	Oct 18, 1991
	50MG/ML	A081225 001	Aug 28, 1991

## FLUOROURACIL

ABIC	50MG/ML	A088929 001	Mar 04, 1986
ABRAXIS PHARM	50MG/ML	A089152 001	Mar 21, 1986
	50MG/ML	A089428 001	Jan 12, 1987
	50MG/ML	A089519 001	Mar 12, 1987

## DISCONTINUED DRUG PRODUCT LIST

FLUOROURACIL

## INJECTABLE; INJECTION

## FLUOROURACIL

BEDFORD	50MG/ML	A089508	001	Jan 26, 1988
EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772	001	Aug 11, 2008
FRESENIUS KABI USA	50MG/ML	A040291	001	Mar 24, 1999
	50MG/ML	A040379	001	Nov 15, 2000
MARCHAR	50MG/ML	A087791	001	Jan 18, 1983
SMITH AND NEPHEW	50MG/ML	A088766	001	Dec 28, 1984
	50MG/ML	A088767	001	Dec 28, 1984
	50MG/ML	A089434	001	Mar 26, 1987
SPECTRUM PHARMS	50MG/ML	A087792	001	Oct 13, 1982
VALEANT	500MG/10ML (50MG/ML)	N012209	001	

## SOLUTION; TOPICAL

## FLUOROPLEX

ELORAC	1%	N016765	001	
--------	----	---------	-----	--

FLUOXETINE HYDROCHLORIDE

## CAPSULE; ORAL

## FLUOXETINE

MUTUAL PHARMA	EQ 10MG BASE	A075787	001	Jan 29, 2002
	EQ 20MG BASE	A075787	002	Jan 29, 2002
WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
	EQ 20MG BASE	A075662	002	Jan 29, 2002

## FLUOXETINE HYDROCHLORIDE

BARR	EQ 40MG BASE	A076251	001	May 18, 2005
CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002
	EQ 20MG BASE	A076022	002	Jan 30, 2002
CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002
	EQ 20MG BASE	A076165	002	Feb 01, 2002
PAR PHARM	EQ 10MG BASE	A076922	001	Dec 16, 2004
	EQ 20MG BASE	A076922	002	Dec 16, 2004
SANDOZ	EQ 10MG BASE	A075807	001	Jan 29, 2002
	EQ 20MG BASE	A075807	002	Jan 29, 2002
WOCKHARDT LTD	EQ 10MG BASE	A078143	001	Jan 16, 2008
	EQ 20MG BASE	A078143	002	Jan 16, 2008
	EQ 40MG BASE	A078143	003	Jan 16, 2008

## PROZAC

ELI LILLY AND CO	EQ 60MG BASE	N018936	004	Jun 15, 1999
------------------	--------------	---------	-----	--------------

## SOLUTION; ORAL

## FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690	001	Jan 31, 2002
APOTEX INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002
HI TECH PHARMA	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002

## PROZAC

LILLY	EQ 20MG BASE/5ML	N020101	001	Apr 24, 1991
-------	------------------	---------	-----	--------------

## TABLET; ORAL

## FLUOXETINE HYDROCHLORIDE

BARR	EQ 10MG BASE	A075810	001	Feb 01, 2002
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865	001	Feb 28, 2002
	EQ 40MG BASE	A075865	003	Aug 30, 2004
SANDOZ	EQ 10MG BASE	A076024	001	Jan 29, 2002

## PROZAC

LILLY	EQ 10MG BASE	N020974	001	Mar 09, 1999
	EQ 20MG BASE	N020974	002	Mar 09, 1999

FLUOXYMESTERONE

## TABLET; ORAL

## ANDROID-F

VALEANT PHARM INTL	10MG	A087196	001	
--------------------	------	---------	-----	--

## FLUOXYMESTERONE

VALEANT PHARM INTL	10MG	A088221	001	May 05, 1983
WATSON LABS	2MG	A088260	001	Dec 06, 1983
	5MG	A088265	001	Dec 06, 1983
	10MG	A088309	001	Dec 06, 1983

## HALOTESTIN

PHARMACIA AND UPJOHN	2MG	N010611	002	
	5MG	N010611	006	
	10MG	N010611	010	

## ORA-TESTRYL

BRISTOL MYERS SQUIBB	2MG	N011359	001	
	5MG	N011359	002	

## DISCONTINUED DRUG PRODUCT LIST

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AGILA SPECLTS	25MG/ML	A075918	001	Aug 17, 2001
HOSPIRA	25MG/ML	A074966	001	Apr 16, 1998
TEVA PARENTERAL	25MG/ML	A074795	001	Sep 10, 1996
PROLIXIN DECANOATE				
BRISTOL MYERS SQUIBB	25MG/ML	N016727	001	

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

PROLIXIN ENANTHATE

APOTHECON	25MG/ML	N016110	001	
-----------	---------	---------	-----	--

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS	5MG/ML	A073058	001	Aug 30, 1991
PERMITIL				
SCHERING	5MG/ML	N016008	001	
PROLIXIN				
APOTHECON	5MG/ML	A070533	001	Nov 07, 1985

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993
PROLIXIN				
APOTHECON	2.5MG/5ML	N012145	003	

INJECTABLE; INJECTION

PROLIXIN

APOTHECON	2.5MG/ML	N011751	005	
-----------	----------	---------	-----	--

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

WATSON LABS	1MG	A088555	001	Dec 18, 1987
	2.5MG	A088544	001	Dec 18, 1987
	5MG	A088527	001	Dec 18, 1987
	10MG	A088550	001	Dec 18, 1987

PERMITIL

SCHERING	0.25MG	N012034	001	
	2.5MG	N012034	004	
	5MG	N012034	005	
	10MG	N012034	006	

PROLIXIN

APOTHECON	1MG	N011751	004	
	2.5MG	N011751	001	
	5MG	N011751	003	
	10MG	N011751	002	

TABLET, EXTENDED RELEASE; ORAL

PERMITIL

SCHERING	1MG	N012419	004	
----------	-----	---------	-----	--

FLUPREDNISOLONE

TABLET; ORAL

ALPHADROL

PHARMACIA AND UPJOHN	1.5MG	N012259	002	
----------------------	-------	---------	-----	--

FLURANDRENOLIDE

LOTION; TOPICAL

FLURANDRENOLIDE

ALPHARMA US PHARMS	0.05%	A087203	001	Apr 29, 1982
--------------------	-------	---------	-----	--------------

OINTMENT; TOPICAL

CORDRAN

AQUA PHARMS	0.025% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012806	004	
	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012806	001	

## DISCONTINUED DRUG PRODUCT LIST

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN-N

LILLY 0.05%;EQ 3.5MG BASE/GM N050346 001

OINTMENT; TOPICAL

CORDRAN-N

LILLY 0.05%;EQ 3.5MG BASE/GM N050345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

VALEANT PHARM INTL 15MG N016721 001

30MG N016721 002

FLURAZEPAM HYDROCHLORIDE

HALSEY

15MG A071808 001 Jan 07, 1988

30MG A071809 001 Jan 07, 1988

HIKMA PHARMS LLC

15MG A071107 001 Dec 08, 1986

30MG A071108 001 Dec 08, 1986

MUTUAL PHARM

15MG A070454 001 Aug 04, 1986

30MG A070455 001 Aug 04, 1986

PAR PHARM

15MG A070444 001 Mar 20, 1986

30MG A070445 001 Mar 20, 1986

PUREPAC PHARM

15MG A071927 001 Sep 09, 1987

30MG A071551 001 Sep 09, 1987

SANDOZ

15MG A071716 001 Jul 31, 1991

30MG A071717 001 Jul 31, 1991

SUPERPHARM

15MG A071659 001 Aug 04, 1988

30MG A071660 001 Aug 04, 1988

USL PHARMA

15MG A070562 001 Jul 09, 1987

30MG A070563 001 Jul 09, 1987

WARNER CHILCOTT

15MG A071767 001 Dec 04, 1987

30MG A071768 001 Dec 04, 1987

WATSON LABS

15MG A071205 001 Nov 25, 1986

15MG A072368 001 Mar 30, 1989

30MG A071068 001 Nov 25, 1986

30MG A072369 001 Mar 30, 1989

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

IVAX SUB TEVA PHARMS

50MG A074411 001 May 31, 1995

100MG A074411 002 May 31, 1995

PLIVA

50MG A074647 001 Apr 01, 1997

100MG A074647 002 Apr 01, 1997

SANDOZ

50MG A074448 001 Jul 28, 1995

100MG A074448 002 Jul 28, 1995

TEVA

50MG A074405 002 May 24, 1995

100MG A074405 001 May 24, 1995

THERAGEN

100MG A074560 002 May 16, 1997

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

SCHERING

125MG N018554 001 Jan 27, 1989

FLUTAMIDE

SANDOZ

125MG A075818 001 Sep 18, 2001

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH N020548 001 Mar 27, 1996

0.11MG/INH N020548 002 Mar 27, 1996

0.22MG/INH N020548 003 Mar 27, 1996

CREAM; TOPICAL

CUTIVATE

FOUGERA PHARMS

0.05% \*\*Federal Register determination

that product was not discontinued or

withdrawn for safety or efficacy

reasons\*\*

N019958 001 Dec 18, 1990

FLUTICASONE PROPIONATE

NESHER PHARMS

0.05% A076865 001 Sep 10, 2004

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

TARO PHARM INDS

0.005% A077145 001 Jun 14, 2005

## DISCONTINUED DRUG PRODUCT LIST

FLUTICASONE PROPIONATE

POWDER; INHALATION

FLOVENT

GLAXOSMITHKLINE	0.044MG/INH	N020549	001	Nov 07, 1997
	0.088MG/INH	N020549	002	Nov 07, 1997
	0.22MG/INH	N020549	003	Nov 07, 1997

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH	25MG	A075901	001	Dec 28, 2000
	50MG	A075901	002	Dec 28, 2000
	100MG	A075901	003	Dec 28, 2000
IVAX SUB TEVA PHARMS	25MG	A075898	001	Mar 12, 2001
	50MG	A075898	002	Mar 12, 2001
	100MG	A075898	003	Mar 12, 2001
MUTUAL PHARM	25MG	A076125	001	Apr 29, 2002
	50MG	A076125	002	Apr 29, 2002
	100MG	A076125	003	Apr 29, 2002
MYLAN	50MG	A075950	001	Oct 15, 2001
	100MG	A075950	002	Oct 15, 2001
SANDOZ	25MG	A075887	001	Jan 05, 2001
	50MG	A075887	002	Jan 05, 2001
	100MG	A075887	003	Jan 05, 2001
SUN PHARM INDS INC	25MG	A075900	001	Feb 23, 2006
	50MG	A075900	002	Feb 23, 2006
	100MG	A075900	003	Feb 23, 2006
SYNTHON PHARMS	25MG	A075899	001	Jan 17, 2001
	50MG	A075899	002	Jan 17, 2001
	100MG	A075899	003	Jan 17, 2001
WATSON LABS	25MG	A075894	001	Apr 18, 2001
	50MG	A075894	002	Apr 18, 2001
	100MG	A075894	003	Apr 18, 2001
LUVOX				
SOLVAY	25MG	N020243	001	Dec 05, 1994
	50MG	N020243	002	Dec 05, 1994
	100MG	N020243	003	Dec 05, 1994
	150MG	N020243	004	Dec 05, 1994

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

BEN VENUE	5MG/ML	A081066	001	Dec 29, 1993
-----------	--------	---------	-----	--------------

FOLVITE

HIKMA (MAPLE)	5MG/ML	N005897	008	
---------------	--------	---------	-----	--

TABLET; ORAL

FOLIC ACID

BARR	1MG	A089177	001	Jan 08, 1986
EVERYLIFE	1MG	A080755	001	
HALSEY	1MG	A083598	001	
IMPAX LABS	1MG	A080686	001	
IVAX SUB TEVA PHARMS	1MG	A083000	001	
JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005
LANNETT	1MG	A080816	001	
LILLY	1MG	N006135	003	
MK LABS	1MG	A083526	001	
MUTUAL PHARM	1MG	A040582	001	Jul 18, 2005
NEXGEN PHARMA INC	1MG	A084915	001	
PHARMERAL	1MG	A084158	001	
PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784	001	
SANDOZ	1MG	A084472	001	
TABLICAPS	1MG	A083133	002	
UDL	1MG	A088199	001	Mar 29, 1983
USL PHARMA	1MG	A087828	001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903	001	
VANGARD	1MG	A088730	001	Mar 23, 1984
VINTAGE PHARMS	1MG	A086296	001	
WATSON LABS	1MG	A083141	001	
	1MG	A085141	002	
WHITEWORTH TOWN PLSN	1MG	A080691	002	

FOLICET

MISSION PHARMA	1MG	A087438	001	
----------------	-----	---------	-----	--

**DISCONTINUED DRUG PRODUCT LIST**FOLIC ACID

TABLET; ORAL

FOLVITE

HIKMA (MAPLE)

1MG

N005897 004

FOLLITROPIN ALFA/BETA

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

FOLLISTIM

ORGANON USA INC

75 IU/VIAL

N020582 001 Sep 29, 1997

150 IU/VIAL

N020582 002 Sep 29, 1997

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC

150 IU/0.18ML

N021211 003 Feb 11, 2004

GONAL-F

EMD SERONO

37.5 IU/VIAL

N020378 003 May 25, 2000

37.5 IU/VIAL

N021765 001 Mar 25, 2004

75 IU/VIAL

N020378 001 Sep 29, 1997

150 IU/VIAL

N020378 002 Sep 29, 1997

150 IU/VIAL

N021765 003 Mar 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

MYLAN INSTITUTIONAL

1.5GM/1.5ML (1GM/ML)

A079033 001 Apr 07, 2009

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS

6.6MG/ML

N020961 001 Aug 26, 1998

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

NOVARTIS

0.0085MG/INH

N021592 001 Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

MERCK AND CO INC

EQ 115MG BASE/VIAL

N022023 001 Jan 25, 2008

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

RANBAXY LABS LTD

10MG

A076580 001 Apr 23, 2004

20MG

A076580 002 Apr 23, 2004

40MG

A076580 003 Apr 23, 2004

SANDOZ

10MG

A076188 001 Oct 08, 2004

20MG

A076188 002 Oct 08, 2004

40MG

A076188 003 Oct 08, 2004

WATSON LABS

10MG

A076987 001 Dec 23, 2004

10MG

A077531 001 Aug 31, 2006

20MG

A076987 002 Dec 23, 2004

20MG

A077531 002 Aug 31, 2006

40MG

A076987 003 Dec 23, 2004

40MG

A077531 003 Aug 31, 2006

MONOPRIL

BRISTOL MYERS SQUIBB

10MG

N019915 002 May 16, 1991

20MG

N019915 003 May 16, 1991

40MG

N019915 004 Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

MYLAN

10MG; 12.5MG

A077705 001 Aug 14, 2006

20MG; 12.5MG

A077705 002 Aug 14, 2006

TEVA

10MG; 12.5MG

A076945 001 Jul 05, 2006

20MG; 12.5MG

A076945 002 Jul 05, 2006

WATSON LABS

10MG; 12.5MG

A077144 001 Aug 16, 2005

20MG; 12.5MG

A077144 002 Aug 16, 2005

MONOPRIL-HCT

BRISTOL MYERS SQUIBB

10MG; 12.5MG

N020286 002 Nov 30, 1994

20MG; 12.5MG

N020286 001 Nov 30, 1994



## DISCONTINUED DRUG PRODUCT LIST

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

APOTEX INC

EQ 50MG PHENYTOIN NA/ML

A078126 001 Aug 06, 2007

TEVA PHARMS USA

EQ 50MG PHENYTOIN NA/ML

A076886 001 Aug 06, 2007

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

EISAI INC

1050MG/30ML (35MG/ML)

N022244 001 Dec 12, 2008

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

SHIRE

50MG/15ML

N011323 002

TABLET; ORAL

FUROXONE

SHIRE

100MG

N011270 002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

ABRAXIS PHARM

10MG/ML

N018507 001 Jul 30, 1982

10MG/ML

N019036 001 Aug 13, 1984

ASTRAZENECA

10MG/ML

A070014 001 Sep 09, 1985

10MG/ML

A070095 001 Sep 09, 1985

10MG/ML

A070096 001 Sep 09, 1985

HIKMA MAPLE

10MG/ML

A071439 001 Sep 14, 1990

10MG/ML

N018267 001

HOSPIRA

10MG/ML

A070578 001 Jul 08, 1987

10MG/ML

A072080 001 Aug 13, 1991

10MG/ML

A074337 001 Oct 31, 1994

10MG/ML

N018025 001

INTL MEDICATION

MARSAM PHARMS LLC

10MG/ML

A074017 001 Jun 30, 1994

ORGANON USA INC

10MG/ML

A070017 001 Dec 15, 1986

SMITH AND NEPHEW

10MG/ML

A070023 001 Feb 05, 1986

10MG/ML

A070078 001 Feb 05, 1986

WARNER CHILCOTT

10MG/ML

N018420 001 Feb 26, 1982

WATSON LABS

10MG/ML

A070019 001 Sep 22, 1986

10MG/ML

A070604 001 Jan 02, 1987

WYETH AYERST

10MG/ML

N018670 001 Jul 20, 1982

LASIX

SANOFI AVENTIS US

10MG/ML

N016363 001

SOLUTION; ORAL

LASIX

SANOFI AVENTIS US

10MG/ML

N017688 001

TABLET; ORAL

FUROSEMIDE

DAVA PHARMS INC

20MG

N018415 001 Jul 27, 1982

40MG

N018415 002 Jul 27, 1982

80MG

N018415 003 Nov 26, 1984

INTL MEDICATION

20MG

N018753 001 Feb 28, 1984

40MG

N018753 002 Feb 28, 1984

KALAPHARM

20MG

N018868 001 Jun 28, 1983

40MG

N018868 002 Jun 28, 1983

MUTUAL PHARM

20MG

A070043 001 Sep 26, 1985

40MG

N018790 001 Nov 29, 1983

80MG

A070100 001 Jan 26, 1988

SANDOZ

40MG

N018750 002 Jul 30, 1984

SUPERPHARM

20MG

N018370 002 Jun 26, 1984

40MG

N018370 001 Feb 10, 1983

WARNER CHILCOTT

20MG

N018419 001 Jan 31, 1983

40MG

N018419 002 Jan 31, 1983

80MG

N018419 003 Nov 13, 1984

WATSON LABS

20MG

A070412 001 Feb 26, 1986

20MG

A070449 001 Nov 22, 1985

20MG

A071379 001 Jan 02, 1987

20MG

N018369 001 May 14, 1982

40MG

A070413 001 Feb 26, 1986

40MG

A070450 001 Nov 22, 1985

40MG

N018369 002 May 14, 1982

80MG

A070528 001 Jan 07, 1986

80MG

A071594 001 Feb 09, 1988

## DISCONTINUED DRUG PRODUCT LIST

GABAPENTIN

## CAPSULE; ORAL

## GABAPENTIN

IVAX SUB TEVA PHARMS	100MG	A075477 001	Mar 23, 2005
	300MG	A075477 002	Mar 23, 2005
	400MG	A075477 003	Mar 23, 2005
MUTUAL PHARM	100MG	A076537 001	Jun 30, 2005
	300MG	A076537 002	Jun 30, 2005
	400MG	A076537 003	Jun 30, 2005
SANDOZ	100MG	A075428 001	Jan 24, 2006
	100MG	A075539 001	Apr 06, 2005
	300MG	A075428 002	Jan 24, 2006
	300MG	A075539 002	Apr 06, 2005
	400MG	A075428 003	Jan 24, 2006
	400MG	A075539 003	Apr 06, 2005
WATSON LABS	100MG	A075485 003	May 11, 2007
	300MG	A075485 002	May 11, 2007
	400MG	A075485 001	May 11, 2007

## TABLET; ORAL

## GABAPENTIN

RANBAXY	600MG	A076605 001	Sep 14, 2005
	800MG	A076605 002	Sep 14, 2005
SANDOZ	600MG	A076120 001	Jan 27, 2006
	600MG	A076877 001	Jul 06, 2006
	800MG	A076120 002	Jan 27, 2006
	800MG	A076877 002	Jul 06, 2006
TEVA	600MG	A075827 001	Dec 15, 2004
	800MG	A075827 002	Dec 15, 2004

GADODIAMIDE

## INJECTABLE; INJECTION

## OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066 001	Sep 05, 2007
---------------	-------------------------	-------------	--------------

GALANTAMINE HYDROBROMIDE

## TABLET; ORAL

## GALANTAMINE HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 4MG BASE	A077585 001	Sep 15, 2009
	EQ 8MG BASE	A077585 002	Sep 15, 2009
	EQ 12MG BASE	A077585 003	Sep 15, 2009
YBAO PHARM	EQ 4MG BASE	A077604 001	Feb 06, 2009
	EQ 8MG BASE	A077604 002	Feb 06, 2009
	EQ 12MG BASE	A077604 003	Feb 06, 2009

GALLAMINE TRIETHIODIDE

## INJECTABLE; INJECTION

## FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842 001	
	100MG/ML	N007842 002	

GALLIUM CITRATE GA-67

## INJECTABLE; INJECTION

## GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700 001	
NEOSCAN			
GE HEALTHCARE	2mCi/ML	N017655 001	

GALLIUM NITRATE

## INJECTABLE; INJECTION

## GANITE

CHAPTER 7 TRUSTEE	25MG/ML	N019961 002	Jan 17, 1991
-------------------	---------	-------------	--------------

GANCICLOVIR

## CAPSULE; ORAL

## CYTOVENE

ROCHE PALO	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460 001	Dec 22, 1994
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460 002	Dec 12, 1997

## GANCICLOVIR

RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003
	500MG	A076457 002	Jun 27, 2003

## DISCONTINUED DRUG PRODUCT LIST

GANCICLOVIR

IMPLANT; IMPLANTATION

VITRASERT

BAUSCH AND LOMB

4.5MG

N020569 001 Mar 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

EUROHLTH INTL

EQ 500MG BASE/VIAL

A076222 001 Jul 16, 2003

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

APOTEX INC

0.3%

A079084 001 Aug 19, 2011

GEFITINIB

TABLET; ORAL

IRESSA

ASTRAZENECA

250MG

N021399 001 May 05, 2003

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

MYLAN

300MG

A073466 001 Jan 25, 1993

PUREPAC PHARM

300MG

A072929 001 Jan 29, 1993

LOPID

PFIZER PHARMS

200MG

N018422 001

300MG

N018422 002

TABLET; ORAL

GEMFIBROZIL

MYLAN

600MG

A074452 001 Feb 16, 1995

PUREPAC PHARM

600MG

A074360 001 Aug 31, 1994

SANDOZ

600MG

A074615 001 Sep 29, 1995

WATSON LABS

600MG

A074156 001 Oct 24, 1994

600MG

A074442 001 Apr 28, 1995

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

MYLOTARG

WYETH PHARMS INC

5MG/VIAL

N021174 001 May 17, 2000

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

SCHERING

EQ 0.1% BASE

A060462 001

GENTAFAIR

PHARMAFAIR

EQ 0.1% BASE

A062458 001 Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS

EQ 0.1% BASE

A062471 001 Sep 27, 1983

G AND W LABS INC

EQ 0.1% BASE

A064056 001 Apr 29, 1994

PHARMADERM

EQ 1MG BASE/GM

A062530 001 Jul 05, 1984

INJECTABLE; INJECTION

APOGEN

KING PHARMS

EQ 10MG BASE/ML

A062289 001

EQ 40MG BASE/ML

A062289 002

BRISTAGEN

BRISTOL

EQ 40MG BASE/ML

A062288 001

GARAMYCIN

SCHERING

EQ 1MG BASE/ML

A061716 002

EQ 10MG BASE/ML

A061739 001

EQ 40MG BASE/ML

A061716 001

GENTAFAIR

PHARMAFAIR

EQ 40MG BASE/ML

A062493 001 Aug 28, 1985

GENTAMICIN

INTL MEDICATION

EQ 1MG BASE/ML

A062325 003 Jun 23, 1982

EQ 40MG BASE/ML

A062325 001

EQ 100MG BASE/100ML

A062325 004 Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT

EQ 1.2MG BASE/ML

A062413 001 Aug 11, 1983

EQ 1.4MG BASE/ML

A062413 002 Aug 11, 1983

EQ 1.6MG BASE/ML

A062413 003 Aug 11, 1983

EQ 1.8MG BASE/ML

A062413 004 Aug 11, 1983

EQ 2MG BASE/ML

A062413 005 Aug 11, 1983

EQ 60MG BASE/100ML

A062413 006 Aug 11, 1983

EQ 70MG BASE/100ML

A062413 007 Aug 11, 1983

## DISCONTINUED DRUG PRODUCT LIST

GENTAMICIN SULFATE

## INJECTABLE; INJECTION

## GENTAMICIN SULFATE

	EQ 80MG BASE/100ML	A062413 008	Aug 11, 1983
	EQ 90MG BASE/100ML	A062413 009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413 010	Aug 11, 1983
FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356 001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356 002	Mar 04, 1982
HIKMA MAPLE	EQ 10MG BASE/ML	A062251 002	
	EQ 40MG BASE/ML	A062251 001	
KALAPHARM	EQ 40MG BASE/ML	A062354 001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340 001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507 001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507 002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149 001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106 002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318 002	
	EQ 40MG BASE/ML	A062318 001	
WYETH AYERST	EQ 10MG BASE/ML	A062264 001	
	EQ 40MG BASE/ML	A062264 002	

## GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

## HOSPIRA

	EQ 1.2MG BASE/ML	A062588 001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062588 002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588 003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062588 004	Jan 06, 1986
	EQ 2MG BASE/ML	A062588 005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062588 006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062588 007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588 008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062588 009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588 010	Jan 06, 1986

## U-GENCIN

## PHARMACIA AND UPJOHN

	EQ 10MG BASE/ML	A062248 001	
	EQ 40MG BASE/ML	A062248 002	

## INJECTABLE; INTRATHECAL

## GARAMYCIN

## SCHERING

	EQ 2MG BASE/ML	N050505 001	
--	----------------	-------------	--

## OINTMENT; OPHTHALMIC

## GARAMYCIN

## SCHERING

	EQ 0.3% BASE	N050425 001	
--	--------------	-------------	--

## GENTACIDIN

## NOVARTIS

	EQ 0.3% BASE	A062501 001	Jul 26, 1984
--	--------------	-------------	--------------

## GENTAFAIR

## PHARMAFAIR

	EQ 3MG BASE/GM	A062443 001	May 26, 1983
--	----------------	-------------	--------------

## OINTMENT; TOPICAL

## GARAMYCIN

## SCHERING

	EQ 0.1% BASE	A060463 001	
--	--------------	-------------	--

## GENTAFAIR

## PHARMAFAIR

	EQ 0.1% BASE	A062444 001	May 26, 1983
--	--------------	-------------	--------------

## GENTAMICIN SULFATE

## ALPHARMA US PHARMS

	EQ 0.1% BASE	A062496 001	Mar 14, 1984
--	--------------	-------------	--------------

## G AND W LABS INC

	EQ 0.1% BASE	A064054 001	Apr 29, 1994
--	--------------	-------------	--------------

## PHARMADERM

	EQ 0.1% BASE	A062534 001	Oct 10, 1984
--	--------------	-------------	--------------

## SOLUTION/DROPS; OPHTHALMIC

## GARAMYCIN

## SCHERING

	EQ 0.3% BASE	N050039 002	
--	--------------	-------------	--

## GENTACIDIN

## NOVARTIS

	EQ 0.3% BASE	A062480 001	Mar 30, 1984
--	--------------	-------------	--------------

## GENTAFAIR

## PHARMAFAIR

	EQ 0.3% BASE	A062440 001	May 03, 1983
--	--------------	-------------	--------------

## GENTAMICIN SULFATE

## ALCON PHARMS LTD

	EQ 0.3% BASE	A062523 001	Nov 25, 1985
--	--------------	-------------	--------------

## PACO

	EQ 3MG BASE/ML	A062932 001	Nov 07, 1988
--	----------------	-------------	--------------

GENTIAN VIOLET

## SUPPOSITORY; VAGINAL

## GVS

## SAVAGE LABS

	0.4%	A083513 001	
--	------	-------------	--

## TAMPON; VAGINAL

## GENAPAX

## KEY PHARMS

	5MG	A085017 001	
--	-----	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS

COPAXONE

TEVA PHARMS USA 20MG/VIAL N020622 001 Dec 20, 1996

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

COREPHARMA	1MG	A077274 001	Oct 06, 2005
	2MG	A077274 002	Oct 06, 2005
	4MG	A077274 003	Oct 06, 2005
MYLAN	1MG	A077486 001	Feb 10, 2006
	2MG	A077486 002	Feb 10, 2006
	4MG	A077486 003	Feb 10, 2006
RANBAXY	3MG	A077366 001	Oct 06, 2005
	6MG	A077366 002	Oct 06, 2005
RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005
	2MG	A076875 002	Oct 06, 2005
	4MG	A076875 003	Oct 06, 2005
	8MG	A076875 004	Oct 06, 2005
WATSON LABS	1MG	A077280 001	Feb 03, 2006
	2MG	A077280 002	Feb 03, 2006
	4MG	A077280 003	Feb 03, 2006

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

BARR LABS INC	5MG	A074619 001	Apr 04, 1997
	10MG	A074619 002	Apr 04, 1997
SANDOZ	5MG	A074542 001	Jun 20, 1995
	10MG	A074542 002	Jun 20, 1995
TEVA	5MG	A074387 001	Mar 04, 1996
	10MG	A074387 002	Mar 04, 1996
VINTAGE PHARMS LLC	5MG	A074378 001	Nov 28, 1994
	10MG	A074378 002	Nov 28, 1994
WATSON LABS	5MG	A074370 001	Nov 22, 1994
	10MG	A074370 002	Nov 22, 1994
GLUCOTROL			
PFIZER	2.5MG	N017783 003	May 11, 1993

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

METAGLIP

BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460 001	Oct 21, 2002
	2.5MG;500MG	N021460 002	Oct 21, 2002
	5MG;500MG	N021460 003	Oct 21, 2002

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION

GLUCAGON

LILLY	EQ 1MG BASE/VIAL	N012122 001	
	EQ 10MG BASE/VIAL	N012122 002	

GLUTETHIMIDE

CAPSULE;ORAL

DORIDEN

SANOFI AVENTIS US 500MG N009519 008

TABLET;ORAL

DORIDEN

SANOFI AVENTIS US	250MG	N009519 002	
	500MG	N009519 005	

GLUTETHIMIDE

HALSEY	250MG	A089458 001	Oct 10, 1986
	500MG	A089459 001	Oct 10, 1986
LANNETT	250MG	A083475 001	
	500MG	A085571 001	
SANDOZ	500MG	A083234 002	
UCB INC	500MG	A085171 001	
VITARINE	500MG	A087297 001	
WATSON LABS	500MG	A084362 001	
	500MG	A085763 001	

## DISCONTINUED DRUG PRODUCT LIST

GLYBURIDE

## TABLET; ORAL

## GLYBURIDE

ACTAVIS ELIZABETH	1.5MG	A075947 001	Nov 14, 2002
	3MG	A075947 002	Nov 14, 2002
	6MG	A075947 003	Nov 14, 2002

## GLYBURIDE (MICRONIZED)

SANDOZ	1.5MG	A075174 001	Jun 22, 1998
	3MG	A075174 002	Jun 22, 1998
SANOFI AVENTIS US	1.5MG	N020055 001	Apr 17, 1992
	3MG	N020055 002	Apr 17, 1992
	6MG	N020055 003	Mar 08, 2000

## GLYNASE

PHARMACIA AND UPJOHN	4.5MG	N020051 003	Sep 24, 1993
----------------------	-------	-------------	--------------

## MICRONASE

PHARMACIA AND UPJOHN	1.25MG	N017498 001	May 01, 1984
	2.5MG	N017498 002	May 01, 1984
	5MG	N017498 003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

## TABLET; ORAL

## GLYBURIDE AND METFORMIN HYDROCHLORIDE

TEVA	1.25MG; 250MG	A076821 001	Jan 27, 2005
	2.5MG; 500MG	A076821 002	Jan 27, 2005
	5MG; 500MG	A076821 003	Jan 27, 2005

GLYCINE

## SOLUTION; IRRIGATION

## GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	1.5GM/100ML	N018522 001	Feb 19, 1982
HOSPIRA	1.5GM/100ML	N017633 001	

GLYCOPYRROLATE

## INJECTABLE; INJECTION

## GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475 001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393 001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169 001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947 001	Jun 24, 1983

## ROBINUL

ROBINS AH	0.2MG/ML	N014764 001	
-----------	----------	-------------	--

## TABLET; ORAL

## GLYCOPYRROLATE

COREPHARMA	1MG	A040568 001	Dec 22, 2004
	2MG	A040568 002	Dec 22, 2004
HIKMA PHARMS LLC	1MG	A040836 001	Mar 05, 2009
	2MG	A040836 002	Mar 05, 2009
WATSON LABS	1MG	A085562 001	
	1MG	A086902 001	
	2MG	A085563 001	
	2MG	A086178 001	
	2MG	A086900 001	

GONADORELIN ACETATE

## INJECTABLE; INJECTION

## LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687 001	Oct 10, 1989
	3.2MG/VIAL	N019687 002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

## INJECTABLE; INJECTION

## FACTREL

HIKMA (MAPLE)	EQ 0.1MG BASE/VIAL	N018123 001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123 002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123 003	Sep 30, 1982

GONADOTROPIN, CHORIONIC

## INJECTABLE; INJECTION

## A.P.L.

FERRING	5,000 UNITS/VIAL	N017055 001	
	10,000 UNITS/VIAL	N017055 002	
	20,000 UNITS/VIAL	N017055 003	

## CHORIONIC GONADOTROPIN

BEL MAR	5,000 UNITS/VIAL	N017054 001	
	10,000 UNITS/VIAL	N017054 002	

**DISCONTINUED DRUG PRODUCT LIST**GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

FERRING	2,000 UNITS/VIAL	N017016 009	Dec 27, 1984
	2,000 UNITS/VIAL	N017016 011	Feb 16, 1990
	5,000 UNITS/VIAL	N017016 006	
	15,000 UNITS/VIAL	N017016 010	Feb 15, 1985
	20,000 UNITS/VIAL	N017016 004	
FRESENIUS KABI USA	5,000 UNITS/VIAL	N017067 001	
	15,000 UNITS/VIAL	N017067 004	
	20,000 UNITS/VIAL	N017067 003	
FOLLUTEIN			
BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056 001	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEO-POLYCYCIN

DOW PHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060427 001	
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN			
IPHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062818 001	Oct 11, 1988
WATSON LABS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062788 001	Jun 11, 1987
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN			
PHARMAFAIR	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062383 001	Aug 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

APOTEX INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197 001	Dec 31, 2007
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008
SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808 001	Apr 29, 2008
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE			
TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007
KYTRIL			
ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020239 003	Sep 17, 2004
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N020239 004	Mar 11, 1994
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	EQ 3MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020239 001	Dec 29, 1993
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N020239 002	Mar 11, 1994
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
SOLUTION; ORAL			
GRANISOL			
PEDIATRAX	EQ 2MG BASE/10ML	A078334 001	Feb 28, 2008
KYTRIL			
ROCHE	EQ 2MG BASE/10ML	N021238 001	Jun 27, 2001
TABLET; ORAL			
GRANISETRON HYDROCHLORIDE			
BARR	EQ 1MG BASE	A078221 001	Dec 31, 2007
KYTRIL			
ROCHE	EQ 1MG BASE	N020305 001	Mar 16, 1995
	EQ 2MG BASE	N020305 002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

OTSUKA	EQ 200MG BASE	N020695 001	Nov 06, 1997
	EQ 400MG BASE	N020695 002	May 14, 1998
	EQ 600MG BASE	N020695 003	May 14, 1998

**DISCONTINUED DRUG PRODUCT LIST**GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE;ORAL

GRISACTIN

WYETH AYERST

125MG

N050051 002

250MG

N050051 001

SUSPENSION;ORAL

GRIFULVIN V

JOHNSON AND JOHNSON

125MG/5ML

N050448 001

TABLET;ORAL

FULVICIN-U/F

ELORAC

250MG

A060569 002

500MG

A060569 001

GRIFULVIN V

J AND J

125MG

A060618 001

250MG

A060618 002

500MG

A060618 003

VALEANT LUXEMBOURG

125MG

A062279 001

250MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

A062279 002

GRISACTIN

WYETH AYERST

500MG

A060212 001

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRIFULVIN V

VALEANT LUXEMBOURG

125MG/5ML

A062483 001 Jan 26, 1984

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

ELORAC

125MG

A061996 001

250MG

A061996 002

FULVICIN P/G 165

ELORAC

165MG

A061996 003 Apr 06, 1982

FULVICIN P/G 330

ELORAC

330MG

A061996 004 Apr 06, 1982

GRISACTIN ULTRA

WYETH AYERST

125MG

A062178 001

165MG

A062438 001 Nov 17, 1983

250MG

A062178 002

330MG

A062438 002 Nov 17, 1983

ULTRAGRIS-165

PLIVA

165MG

A062645 001 Jun 30, 1992

ULTRAGRIS-330

PLIVA

330MG

A062646 001 Jun 30, 1992

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

ANI PHARMS INC

EQ 4MG BASE

A074267 001 Jun 01, 1994

EQ 8MG BASE

A074267 002 Jun 01, 1994

SANDOZ

EQ 4MG BASE

A074517 001 Sep 30, 1998

EQ 8MG BASE

A074517 002 Sep 30, 1998

WATSON LABS

EQ 4MG BASE

A074025 001 Feb 28, 1994

EQ 8MG BASE

A074025 002 Feb 28, 1994

WYTENSIN

WYETH AYERST

EQ 4MG BASE

N018587 001 Sep 07, 1982

EQ 8MG BASE

N018587 002 Sep 07, 1982

EQ 16MG BASE

N018587 003 Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL

HYLOREL

PHARMACIA AND UPJOHN

10MG

N018104 001 Dec 29, 1982

25MG

N018104 002 Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET;ORAL

GUANETHIDINE MONOSULFATE

WATSON LABS

EQ 10MG SULFATE

A086113 001 Mar 26, 1985

EQ 25MG SULFATE

A086114 001 Mar 26, 1985

ISMELIN

NOVARTIS

EQ 10MG SULFATE

N012329 001



## DISCONTINUED DRUG PRODUCT LIST

GUANETHIDINE MONOSULFATE

TABLET; ORAL

ISMELIN

EQ 25MG SULFATE

N012329 002

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ESIMIL

NOVARTIS

10MG; 25MG

N013553 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

WATSON LABS

EQ 1MG BASE

A074762 001 Jun 25, 1997

EQ 2MG BASE

A074762 002 Jun 25, 1997

TENEX

PROMIUS PHARMA

EQ 3MG BASE

N019032 003 Nov 07, 1988

HALAZEPAM

TABLET; ORAL

PAXIPAM

SCHERING

20MG

N017736 003

40MG

N017736 004

HALCINONIDE

CREAM; TOPICAL

HALOG

WESTWOOD SQUIBB

0.025%

N017818 001

HALOG-E

RANBAXY

0.1%

N018234 001

OINTMENT; TOPICAL

HALOG

BRISTOL MYERS SQUIBB

0.025%

N018125 001

SOLUTION; TOPICAL

HALOG

RANBAXY

0.1%

N017823 001

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

FOUGERA PHARMS

0.05%

A076903 001 Dec 16, 2004

G AND W LABS INC

0.05%

A077109 001 Jun 14, 2005

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET; ORAL

HALDOL

ORTHO MCNEIL

0.5MG

N015921 001

1MG

N015921 002

2MG

N015921 003

5MG

N015921 004

10MG

N015921 005

20MG

N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM

1MG

N017079 001

HALOPERIDOL

DURAMED PHARMS BARR

0.5MG

A071216 001 Dec 04, 1986

1MG

A071217 001 Dec 04, 1986

2MG

A071218 001 Dec 04, 1986

5MG

A071219 001 Dec 04, 1986

10MG

A071220 001 Jul 07, 1987

20MG

A071221 001 Jul 07, 1987

LEDERLE

0.5MG

A072727 001 Sep 19, 1989

1MG

A072728 001 Sep 19, 1989

2MG

A072729 001 Sep 19, 1989

5MG

A072730 001 Sep 19, 1989

10MG

A072731 001 Sep 19, 1989

20MG

A072732 001 Sep 19, 1989

MUTUAL PHARM

0.5MG

A071156 001 Jan 02, 1987

1MG

A071157 001 Jan 02, 1987

2MG

A071172 001 Jan 02, 1987

5MG

A071212 001 Jan 07, 1988

## DISCONTINUED DRUG PRODUCT LIST

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	10MG	A071173	001	Jan 07, 1988
	20MG	A071177	001	Jan 07, 1988
PAR PHARM	20MG	A071328	001	Jul 20, 1987
PUREPAC PHARM	0.5MG	A071071	001	Nov 03, 1986
	1MG	A071072	001	Nov 03, 1986
	2MG	A071073	001	Nov 03, 1986
	5MG	A071074	001	Nov 03, 1986
	10MG	A071075	001	Aug 04, 1987
	20MG	A071076	001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
	1MG	A071269	001	Feb 17, 1987
	2MG	A071256	001	Feb 17, 1987
	5MG	A071257	001	Feb 17, 1987
ROXANE	0.5MG	A071128	001	Feb 17, 1987
	1MG	A071129	001	Feb 17, 1987
	2MG	A071130	001	Feb 17, 1987
	5MG	A071131	001	Feb 17, 1987
	10MG	A071132	001	May 12, 1987
	20MG	A071133	001	May 12, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
VINTAGE	0.5MG	A071233	001	Nov 03, 1986
	1MG	A071234	001	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071236	001	Nov 03, 1986
	10MG	A071237	001	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML	N015922	001	
HALOPERIDOL				
ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987
HALOPERIDOL INTENSOL				
ROXANE	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988

**DISCONTINUED DRUG PRODUCT LIST**HALOPERIDOL LACTATE

## INJECTABLE; INJECTION

## HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187 001	Jan 20, 1987
APOTEX INC	EQ 5MG BASE/ML	A076791 001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828 001	Aug 25, 2004
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516 001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517 001	Feb 25, 1993
SANDOZ	EQ 5MG BASE/ML	A076464 001	Sep 29, 2004
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802 001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800 001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801 001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864 001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713 001	May 17, 1988
	EQ 5MG BASE/ML	A070714 001	May 17, 1988
	EQ 5MG BASE/ML	A070744 001	May 17, 1988

## SOLUTION; ORAL

## HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536 001	Nov 02, 1995
----------------------	----------------	-------------	--------------

HALOPROGIN

## CREAM; TOPICAL

## HALOTEX

WESTWOOD SQUIBB	1%	N016942 001	
-----------------	----	-------------	--

## SOLUTION; TOPICAL

## HALOTEX

WESTWOOD SQUIBB	1%	N016943 001	
-----------------	----	-------------	--

HALOTHANE

## LIQUID; INHALATION

## FLUOTHANE

WYETH AYERST	99.99%	N011338 001	
--------------	--------	-------------	--

## HALOTHANE

BH	99.99%	A084977 001	
HALOCARBON	99.99%	A080810 001	
HOSPIRA	99.99%	A083254 001	

HEPARIN CALCIUM

## INJECTABLE; INJECTION

## CALCIPARINE

SANOFI AVENTIS US	25,000 UNITS/ML	N018237 001	
-------------------	-----------------	-------------	--

HEPARIN SODIUM

## INJECTABLE; INJECTION

## HEPARIN LOCK FLUSH

HOSPIRA	100 UNITS/ML	N005264 010	
INTL MEDICATION	10 UNITS/ML	A086357 001	
	500 UNITS/ML	A086357 002	
LUITPOLD	10 UNITS/ML	A089063 001	Oct 09, 1985
	100 UNITS/ML	A089064 001	Oct 09, 1985
PARKE DAVIS	10 UNITS/ML	N017346 006	
SMITH AND NEPHEW	10 UNITS/ML	A087904 001	Apr 20, 1983
	10 UNITS/ML	A087958 001	Apr 20, 1983
	10 UNITS/ML	A088458 001	Jul 26, 1984
	10 UNITS/ML	A088580 001	Oct 25, 1984
	100 UNITS/ML	A087906 001	Apr 20, 1983
	100 UNITS/ML	A087959 001	Apr 20, 1983
	100 UNITS/ML	A088460 001	Jul 26, 1984
	100 UNITS/ML	A088581 001	Oct 25, 1984
SOLOPAK	10 UNITS/ML	A087903 001	Apr 20, 1983
	10 UNITS/ML	A088457 001	Oct 25, 1984
	100 UNITS/ML	A087905 001	Apr 20, 1983
	100 UNITS/ML	A088459 001	Jul 26, 1984

## HEPARIN SODIUM

ABRAXIS PHARM	1,000 UNITS/ML	N017033 001	
	1,000 UNITS/ML	N017979 001	
	5,000 UNITS/ML	N017979 003	
	10,000 UNITS/ML	N017979 002	
AKORN	1,000 UNITS/ML	N017486 001	
	5,000 UNITS/ML	N017486 002	
	10,000 UNITS/ML	N017486 003	
	20,000 UNITS/ML	N017486 004	
	40,000 UNITS/ML	N017486 005	
BAXTER HLTHCARE CORP	1,000 UNITS/ML	N017007 001	

## DISCONTINUED DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	2,500 UNITS/ML	N017007	007	
	5,000 UNITS/ML	N017007	002	
	5,000 UNITS/0.5ML	N017007	010	
	7,500 UNITS/ML	N017007	003	
	10,000 UNITS/ML	N017007	004	
	15,000 UNITS/ML	N017007	005	
	20,000 UNITS/ML	N017007	006	
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130	001	
	5,000 UNITS/ML	N017130	002	
	10,000 UNITS/ML	N017130	003	
	20,000 UNITS/ML	N017130	004	
DELL LABS	1,000 UNITS/ML	N017540	001	
	5,000 UNITS/ML	N017540	002	
	10,000 UNITS/ML	N017540	003	
	20,000 UNITS/ML	N017540	004	
	40,000 UNITS/ML	N017540	005	
FRESENIUS KABI USA	1,000 UNITS/ML	N017651	005	
	5,000 UNITS/ML	N017029	002	
	10,000 UNITS/ML	N017651	003	
	20,000 UNITS/ML	N017651	008	
HIKMA MAPLE	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983
	10,000 UNITS/ML	A040095	001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521	001	
	10,000 UNITS/ML	N005521	002	
	20,000 UNITS/ML	N005521	004	
LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
ORGANON USA INC	1,000 UNITS/ML	N000552	008	
	5,000 UNITS/ML	N000552	009	
	10,000 UNITS/ML	N000552	010	
PARKE DAVIS	1,000 UNITS/ML	N017346	001	
	5,000 UNITS/ML	N017346	002	
	7,500 UNITS/ML	N017346	003	
	10,000 UNITS/ML	N017346	004	
	20,000 UNITS/ML	N017346	005	
PHARM SPEC	1,000 UNITS/ML	N017780	001	
	5,000 UNITS/ML	N017780	002	
	10,000 UNITS/ML	N017780	003	
	20,000 UNITS/ML	N017780	004	
	40,000 UNITS/ML	N017780	005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
	5,000 UNITS/ML	N004570	002	
	10,000 UNITS/ML	N004570	003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043	001	
	5,000 UNITS/ML	A087077	001	
	5,000 UNITS/0.5ML	A087395	001	
	10,000 UNITS/ML	A087107	001	
	10,000 UNITS/0.5ML	A087363	001	
WATSON LABS	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	
WATSON LABS INC	1,000 UNITS/ML	A040007	001	Jun 07, 1996
	1,000 UNITS/ML	A040008	001	Oct 10, 1995
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%				
HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985

## DISCONTINUED DRUG PRODUCT LIST

HEPARIN SODIUM

## INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS	IN SODIUM CHLORIDE 0.45%			
HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
	10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
	10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS	IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS	IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS	AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS	IN SODIUM CHLORIDE 0.45%			
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
WATSON LABS INC	1,000 UNITS/ML	A089464	001	Jun 03, 1986
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ORGANON USA INC	100 UNITS/ML	N000552	007	
LIQUAEMIN SODIUM				
ORGANON USA INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	

**DISCONTINUED DRUG PRODUCT LIST**HEPARIN SODIUM

INJECTABLE; INJECTION

LIQUAEMIN SODIUM

20,000 UNITS/ML

N000552 001

40,000 UNITS/ML

N000552 002

LIQUAEMIN SODIUM PRESERVATIVE FREE

ORGANON USA INC

1,000 UNITS/ML

N000552 011 Apr 11, 1986

5,000 UNITS/ML

N000552 012 Apr 11, 1986

10,000 UNITS/ML

N000552 013 Apr 11, 1986

PANHEPRIN

HOSPIRA

1,000 UNITS/ML

N005264 004

5,000 UNITS/ML

N005264 006

10,000 UNITS/ML

N005264 007

20,000 UNITS/ML

N005264 008

40,000 UNITS/ML

N005264 009

SODIUM HEPARIN

ABRAXIS PHARM

5,000 UNITS/ML

N017033 002

10,000 UNITS/ML

N017033 003

20,000 UNITS/ML

N017033 004

BAXTER HLTHCARE

1,000 UNITS/ML

N017036 001 Mar 04, 1988

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN

BRISTOL

EQ 112.5MG AMPICIL/ML

A061398 001

EQ 112.5MG AMPICIL/5ML

N050060 001

EQ 112.5MG AMPICIL/ML

N050060 003

EQ 225MG AMPICIL/5ML

A061398 002

HETACILLIN POTASSIUM

CAPSULE; ORAL

VERSAPEN-K

BRISTOL

EQ 225MG AMPICIL

A061396 001

EQ 450MG AMPICIL

A061396 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

SEPTISOL

VESTAL LABS

0.23%

N017424 001

TURGEX

XTTRIUM

3%

N018375 001

EMULSION; TOPICAL

HEXA-GERM

HUNTINGTON LABS

3%

N017411 001

PHISOHEX

SANOFI AVENTIS US

3%

N008402 001

SOY-DOME

BAYER PHARMS

3%

N017405 001

TURGEX

XTTRIUM

3%

N019055 001 Nov 30, 1984

SOAP; TOPICAL

GAMOPHEN

ARBROOK

2%

N006270 003

SOLUTION; TOPICAL

DIAL

DIAL

0.25%

N017421 002

GERMA-MEDICA

HUNTINGTON LABS

1%

N017412 001

GERMA-MEDICA "MG"

HUNTINGTON LABS

0.25%

N017412 002

SEPTI-SOFT

CALGON

0.25%

N017460 001

SEPTISOL

VESTAL LABS

0.25%

N017423 001

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON

450MG

N017452 001

HEXASCRUB

PROF DSPLS

3%

N018363 001

PHISO-SCRUB

SANOFI AVENTIS US

3%

N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M

330MG

N017413 001

## DISCONTINUED DRUG PRODUCT LIST

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION

MYLAXEN

MEDPOINTE PHARM HLC 20MG/ML N009789 003

HEXOCYCLIUM METHYLSULFATE

TABLET; ORAL

TRAL

ABBVIE 25MG N010599 001

HEXYLCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

CYCLAINE

MERCK 5% N008472 001

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION

HISTAMINE PHOSPHATE

LILLY

EQ 0.1MG BASE/ML N000734 003

EQ 0.2MG BASE/ML N000734 002

EQ 1MG BASE/ML N000734 001

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

SHIRE

EQ 0.2MG BASE/ML N019836 001 Dec 24, 1991

EQ 0.5MG BASE/ML N019836 002 Dec 24, 1991

EQ 1MG BASE/ML N019836 003 Dec 24, 1991

HOMATROPINE METHYLBROMIDE

TABLET; ORAL

HOMAPIN-10

MISSION PHARMA 10MG A086308 001

HOMAPIN-5

MISSION PHARMA 5MG A086309 001

TABLET, CHEWABLE; ORAL

EQUIPIN

MISSION PHARMA 3MG A086310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

ENDO PHARMS 1.5MG/5ML; 5MG/5ML N005213 002 Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS 1.5MG/5ML; 5MG/5ML A040285 001 Jul 19, 1999

HYDROPANE

HALSEY 1.5MG/5ML; 5MG/5ML A088066 001 Jun 28, 1985

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH 1.5MG; 5MG A040295 001 Dec 01, 2000

HYCODAN

ENDO PHARMS 1.5MG; 5MG N005213 001 Jul 26, 1988

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

AKORN INC 150 UNITS/ML N021716 001 Oct 25, 2005

VITRASE

BAUSCH AND LOMB 6,200 UNITS/VIAL N021640 001 May 05, 2004

WYDASE

BAXTER HLTHCARE 150 UNITS/ML N006343 002

150 UNITS/VIAL \*\*Federal Register

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons\*\*

1,500 UNITS/VIAL \*\*Federal Register

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons\*\*

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

NOVARTIS 20MG/ML N008303 003

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM 20MG/ML A089532 001 Aug 11, 1987

SMITH AND NEPHEW 20MG/ML A088518 001 Apr 20, 1984

## DISCONTINUED DRUG PRODUCT LIST

HYDRALAZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## HYDRALAZINE HYDROCHLORIDE

SOLOPAK	20MG/ML	A088517	001	Aug 22, 1985
TEVA PARENTERAL	20MG/ML	A040373	001	Feb 23, 2000

## TABLET; ORAL

## APRESOLINE

NOVARTIS	10MG	N008303	004	
	25MG	N008303	001	
	50MG	N008303	002	
	100MG	N008303	005	

## DRALZINE

TEVA	25MG	A084301	001	
------	------	---------	-----	--

## HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH	25MG	A088560	001	Oct 04, 1984
	50MG	A088649	001	Oct 18, 1984
ASCOT	25MG	A088310	001	Dec 19, 1984
	50MG	A088311	001	Dec 19, 1984
HALSEY	10MG	A089218	001	Jan 22, 1986
	25MG	A089130	001	Jan 15, 1986
	50MG	A089222	001	Jan 22, 1986
	100MG	A089178	001	Jan 15, 1986
IMPAX LABS	25MG	A084922	001	
	50MG	A084923	001	
IVAX SUB TEVA PHARMS	10MG	A084443	001	
	25MG	A084437	001	
	50MG	A084469	002	
	100MG	A084581	001	
MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
	10MG	A089359	001	Jul 25, 1986
	25MG	A084106	002	
	25MG	A089258	001	May 05, 1986
	50MG	A084107	002	
	50MG	A089259	001	May 05, 1986
	100MG	A088729	001	Apr 11, 1985
PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983
	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
SANDOZ	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
	50MG	A085088	001	
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
TG UNITED LABS	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983
ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010
	25MG	A040858	002	Feb 26, 2010
	50MG	A040858	003	Feb 26, 2010
	100MG	A040858	004	Feb 26, 2010



**DISCONTINUED DRUG PRODUCT LIST**HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

## CAPSULE; ORAL

## APRESAZIDE

NOVARTIS	25MG; 25MG	A084735	001
	50MG; 50MG	A084810	001
	100MG; 50MG	A084811	001

## HYDRA-ZIDE

PAR PHARM	100MG; 50MG	A088961	001 Oct 21, 1985
-----------	-------------	---------	------------------

## HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG; 25MG	A087608	001 Feb 08, 1982
	50MG; 50MG	A087213	001 Feb 08, 1982
	100MG; 50MG	A087609	001 Feb 08, 1982
SUPERPHARM	25MG; 25MG	A089200	001 Feb 09, 1987
	50MG; 50MG	A089201	001 Feb 09, 1987
WATSON LABS	25MG; 25MG	A085457	001 Mar 04, 1982
	50MG; 50MG	A085446	001 Mar 04, 1982
	100MG; 50MG	A085440	001 Mar 04, 1982

## HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS	100MG; 50MG	A088358	001 Apr 10, 1984
-------------	-------------	---------	------------------

## HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS	25MG; 25MG	A088356	001 Apr 10, 1984
-------------	------------	---------	------------------

## HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS	50MG; 50MG	A088357	001 Apr 10, 1984
-------------	------------	---------	------------------

## TABLET; ORAL

## APRESOLINE-ESIDRIX

NOVARTIS	25MG; 15MG	N012026	002
----------	------------	---------	-----

## HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS	25MG; 15MG	A085827	001
-------------	------------	---------	-----

## HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS	25MG; 15MG	A085373	001
-------------	------------	---------	-----

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

## TABLET; ORAL

## CAM-AP-ES

TG UNITED LABS	25MG; 15MG; 0.1MG	A084897	001
----------------	-------------------	---------	-----

## HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS	25MG; 15MG; 0.1MG	A084291	001
----------------------	-------------------	---------	-----

## HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

MYLAN	25MG; 15MG; 0.1MG	A087085	001
-------	-------------------	---------	-----

## HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

WATSON LABS	25MG; 15MG; 0.1MG	A085771	001
-------------	-------------------	---------	-----

## HYDRAP-ES

SANDOZ	25MG; 15MG; 0.1MG	A084876	001
--------	-------------------	---------	-----

## HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

WATSON LABS	25MG; 15MG; 0.1MG	A083770	001
-------------	-------------------	---------	-----

## HYDROSERPINE PLUS (R-H-H)

IVAX SUB TEVA PHARMS	25MG; 15MG; 0.1MG	A083877	001
----------------------	-------------------	---------	-----

## RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MUTUAL PHARM	25MG; 15MG; 0.1MG	A088570	001 Apr 10, 1984
--------------	-------------------	---------	------------------

SOLVAY	25MG; 15MG; 0.1MG	A088376	001 Oct 28, 1983
--------	-------------------	---------	------------------

WATSON LABS	25MG; 15MG; 0.1MG	A085549	001
-------------	-------------------	---------	-----

	25MG; 15MG; 0.1MG	A087556	001
--	-------------------	---------	-----

## RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE

LEDERLE	25MG; 15MG; 0.1MG	A087709	001 May 13, 1982
---------	-------------------	---------	------------------

## SER-A-GEN

SOLVAY	25MG; 15MG; 0.1MG	A087210	001
--------	-------------------	---------	-----

## SER-AP-ES

NOVARTIS	25MG; 15MG; 0.1MG	N012193	005
----------	-------------------	---------	-----

## UNIPRES

SOLVAY	25MG; 15MG; 0.1MG	A085893	001
--------	-------------------	---------	-----

	25MG; 15MG; 0.1MG	A086298	001
--	-------------------	---------	-----

HYDRALAZINE HYDROCHLORIDE; RESERPINE

## TABLET; ORAL

## DRALSERP

SANDOZ	25MG; 0.1MG	A084617	001
--------	-------------	---------	-----

## SERPASIL-APRESOLINE

NOVARTIS	25MG; 0.1MG	N009296	004
----------	-------------	---------	-----

	50MG; 0.2MG	N009296	002
--	-------------	---------	-----

## DISCONTINUED DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

## CAPSULE; ORAL

## HYDROCHLOROTHIAZIDE

HIKMA INTL PHARMS	12.5MG	A077885	001	Nov 26, 2007
-------------------	--------	---------	-----	--------------

## SOLUTION; ORAL

## HYDROCHLOROTHIAZIDE

MORTON GROVE	50MG/5ML	A089661	001	Jun 20, 1988
--------------	----------	---------	-----	--------------

ROXANE	50MG/5ML	A088587	001	Jul 02, 1984
--------	----------	---------	-----	--------------

## HYDROCHLOROTHIAZIDE INTENSOL

ROXANE	100MG/ML	A088588	001	Jul 02, 1984
--------	----------	---------	-----	--------------

## TABLET; ORAL

## ESIDRIX

NOVARTIS	25MG	N011793	005	
----------	------	---------	-----	--

	50MG	N011793	008	
--	------	---------	-----	--

	100MG	N011793	009	
--	-------	---------	-----	--

## HYDRO-D

HALSEY	25MG	A086504	001	
--------	------	---------	-----	--

	50MG	A083891	002	
--	------	---------	-----	--

## HYDROCHLOROTHIAZIDE

ABC HOLDING	50MG	A085672	001	
-------------	------	---------	-----	--

ACTAVIS ELIZABETH	25MG	A085054	002	
-------------------	------	---------	-----	--

	50MG	A085208	001	
--	------	---------	-----	--

ALRA	25MG	A086369	001	
------	------	---------	-----	--

	50MG	A083554	001	
--	------	---------	-----	--

ASCOT	25MG	A087539	001	Feb 03, 1982
-------	------	---------	-----	--------------

	50MG	A087540	001	Feb 03, 1982
--	------	---------	-----	--------------

BARR	50MG	A084771	001	
------	------	---------	-----	--

DAVA PHARMS INC	100MG	A087060	001	
-----------------	-------	---------	-----	--

ELKINS SINN	50MG	A085152	002	
-------------	------	---------	-----	--

HEATHER	50MG	A084135	001	
---------	------	---------	-----	--

HIKMA PHARMS LLC	25MG	A084878	002	Jul 12, 2006
------------------	------	---------	-----	--------------

IMPAX LABS	25MG	A084029	001	
------------	------	---------	-----	--

	50MG	A083607	002	
--	------	---------	-----	--

	100MG	A085098	001	
--	-------	---------	-----	--

INWOOD LABS	25MG	A084776	001	
-------------	------	---------	-----	--

	25MG	A085067	001	
--	------	---------	-----	--

	50MG	A084776	002	
--	------	---------	-----	--

IVAX SUB TEVA PHARMS	50MG	A084658	001	
----------------------	------	---------	-----	--

	100MG	A085022	001	
--	-------	---------	-----	--

MAST MM	25MG	A086192	001	
---------	------	---------	-----	--

	50MG	A086192	002	
--	------	---------	-----	--

MUTUAL PHARM	25MG	A083972	001	
--------------	------	---------	-----	--

	50MG	A083972	002	
--	------	---------	-----	--

	100MG	A083972	003	
--	-------	---------	-----	--

MYLAN	25MG	A084880	001	
-------	------	---------	-----	--

	50MG	A085112	001	
--	------	---------	-----	--

PVT FORM	50MG	A086597	001	
----------	------	---------	-----	--

ROXANE	25MG	A085004	001	
--------	------	---------	-----	--

	50MG	A084536	002	
--	------	---------	-----	--

	50MG	A085005	001	
--	------	---------	-----	--

SANDOZ	25MG	A083899	001	
--------	------	---------	-----	--

	25MG	A087565	001	Mar 09, 1982
--	------	---------	-----	--------------

	50MG	A084912	001	
--	------	---------	-----	--

	50MG	A085219	001	
--	------	---------	-----	--

SOLVAY	25MG	A085323	001	
--------	------	---------	-----	--

SUPERPHARM	25MG	A088827	001	Dec 28, 1984
------------	------	---------	-----	--------------

	50MG	A088828	001	Dec 28, 1984
--	------	---------	-----	--------------

	100MG	A088829	001	Dec 28, 1984
--	-------	---------	-----	--------------

TEVA	25MG	A088924	001	Feb 07, 1985
------	------	---------	-----	--------------

	50MG	A088923	001	Feb 07, 1985
--	------	---------	-----	--------------

TG UNITED LABS	25MG	A085683	001	
----------------	------	---------	-----	--

	50MG	A083965	001	
--	------	---------	-----	--

USL PHARMA	25MG	A087827	001	Apr 19, 1982
------------	------	---------	-----	--------------

	50MG	A087752	001	Apr 19, 1982
--	------	---------	-----	--------------

VANGARD	25MG	A087638	001	
---------	------	---------	-----	--

	50MG	A087610	001	
--	------	---------	-----	--

WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
-----------------	------	---------	-----	--------------

	50MG	A087587	001	May 03, 1982
--	------	---------	-----	--------------

WATSON LABS	25MG	A081189	001	Jan 24, 1992
-------------	------	---------	-----	--------------

	25MG	A083458	001	
--	------	---------	-----	--

	25MG	A085232	002	
--	------	---------	-----	--

	50MG	A083232	001	
--	------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	50MG	A083456 001	
	50MG	A085233 001	
	50MG	A086087 001	
	50MG	A086594 001	
	100MG	A081190 001	Jan 24, 1992
	100MG	A085099 001	
	100MG	A087002 001	
WEST WARD	25MG	A084899 001	
WHITEWORTH TOWN PLSN	25MG	A083809 002	
	50MG	A083809 001	
	100MG	A085347 001	
HYDRODIURIL			
MERCK	25MG	N011835 003	
	50MG	N011835 006	
	100MG	N011835 007	
ORETIC			
ABBVIE	25MG	N011971 001	
ZIDE			
SOLVAY	50MG	A083925 001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

SANOFI AVENTIS US	12.5MG;75MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758 001	Sep 30, 1997
	25MG;300MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758 004	Mar 15, 2005
IRBESARTAN AND HYDROCHLOROTHIAZIDE				
TEVA	25MG;300MG		A077369 003	Mar 30, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

SCHERING	25MG;100MG		N019046 001	Apr 06, 1987
	25MG;200MG		N019046 002	Apr 06, 1987
	25MG;300MG		N019046 003	Apr 06, 1987
	25MG;400MG		N019046 004	Apr 06, 1987
TRANDATE HCT				
GLAXOSMITHKLINE	25MG;100MG		N019174 001	Apr 10, 1987
	25MG;200MG		N019174 002	Apr 10, 1987
	25MG;300MG		N019174 003	Apr 10, 1987
	25MG;400MG		N019174 004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

SANDOZ	12.5MG;10MG		A075926 001	Jul 01, 2002
	12.5MG;20MG		A075926 002	Jul 01, 2002
	25MG;20MG		A075926 003	Jul 01, 2002
TEVA	12.5MG;10MG		A075869 001	Jul 01, 2002
	12.5MG;20MG		A075869 002	Jul 01, 2002
	25MG;20MG		A075869 003	Jul 01, 2002
PRINZIDE				
MERCK	25MG;20MG		N019778 002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

WATSON LABS	12.5MG;50MG		A200180 001	Jan 12, 2011
	12.5MG;100MG		A200180 002	Jan 12, 2011
	25MG;100MG		A200180 003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

MERCK	15MG;250MG		N013402 001	
ALDORIL 25				
MERCK	25MG;250MG		N013402 002	

**DISCONTINUED DRUG PRODUCT LIST**HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL D30				
MERCK	30MG; 500MG	N013402	003	
ALDORIL D50				
MERCK	50MG; 500MG	N013402	004	
<u>METHYLDOPA AND HYDROCHLOROTHIAZIDE</u>				
DAVA PHARMS INC	15MG; 250MG	A072507	001	Jun 02, 1989
	25MG; 250MG	A072508	001	Jun 02, 1989
	30MG; 500MG	A072509	001	Jun 02, 1989
	50MG; 500MG	A072510	001	Jun 02, 1989
IVAX SUB TEVA PHARMS	15MG; 250MG	A071458	001	Mar 08, 1988
	25MG; 250MG	A071459	001	Mar 08, 1988
	30MG; 500MG	A071460	001	Mar 08, 1988
	50MG; 500MG	A071461	001	Mar 08, 1988
PAR PHARM	15MG; 250MG	A070616	001	Feb 02, 1987
	25MG; 250MG	A070612	001	Feb 02, 1987
	30MG; 500MG	A070613	001	Feb 02, 1987
	50MG; 500MG	A070614	001	Feb 02, 1987
PARKE DAVIS	15MG; 250MG	A071897	001	Nov 23, 1987
	25MG; 250MG	A071898	001	Nov 23, 1987
	30MG; 500MG	A071899	001	Nov 23, 1987
	50MG; 500MG	A071900	001	Nov 23, 1987
PUREPAC PHARM	15MG; 250MG	A070853	001	Oct 08, 1986
	25MG; 250MG	A070688	001	Apr 24, 1986
	30MG; 500MG	A070854	001	Oct 08, 1986
	50MG; 500MG	A070689	001	Apr 24, 1986
SANDOZ	15MG; 250MG	A070182	001	Jan 15, 1986
	15MG; 250MG	A070829	001	Mar 09, 1987
	25MG; 250MG	A070183	001	Jan 15, 1986
	25MG; 250MG	A070830	001	Mar 09, 1987
	30MG; 500MG	A070543	001	Jan 15, 1986
	50MG; 500MG	A070544	001	Jan 15, 1986
TEVA	15MG; 250MG	A071819	001	Apr 08, 1988
	25MG; 250MG	A071820	001	Apr 08, 1988
	30MG; 500MG	A071821	001	Apr 08, 1988
	50MG; 500MG	A071822	001	Apr 08, 1988
WATSON LABS	15MG; 250MG	A070365	001	Mar 19, 1986
	15MG; 250MG	A070958	001	Feb 06, 1989
	15MG; 250MG	A071920	001	Aug 29, 1988
	25MG; 250MG	A070366	001	Apr 16, 1986
	25MG; 250MG	A070959	001	Jan 19, 1989
	25MG; 250MG	A071921	001	Aug 29, 1988
	30MG; 500MG	A070367	001	Mar 19, 1986
	30MG; 500MG	A071069	001	Jan 19, 1989
	30MG; 500MG	A071922	001	Aug 29, 1988
	50MG; 500MG	A070368	001	Apr 16, 1986
	50MG; 500MG	A070960	001	Feb 06, 1989
	50MG; 500MG	A071923	001	Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT				
US PHARMS HOLDINGS I	50MG; 100MG	N018303	003	Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

<u>MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>				
PADDOCK LLC	12.5MG; 7.5MG	A090096	001	Sep 25, 2008
	12.5MG; 15MG	A090096	002	Sep 25, 2008
	25MG; 15MG	A090096	003	Sep 25, 2008

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

<u>VISKAZIDE</u>				
NOVARTIS	25MG; 5MG	N018872	001	Jul 22, 1987
	25MG; 10MG	N018872	002	Jul 22, 1987

## DISCONTINUED DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50				
WYETH AYERST	50MG;120MG		N019059 002	Jul 03, 1985
INDERIDE LA 160/50				
WYETH AYERST	50MG;160MG		N019059 003	Jul 03, 1985
INDERIDE LA 80/50				
WYETH AYERST	50MG;80MG		N019059 001	Jul 03, 1985

## TABLET; ORAL

INDERIDE-80/25				
WYETH PHARMS INC	25MG;80MG		N018031 002	
PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE				
DURAMED PHARMS BARR	25MG;40MG		A071126 001	Mar 02, 1987
	25MG;80MG		A071127 001	Mar 02, 1987
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
ACTAVIS ELIZABETH	25MG;40MG		A070851 001	May 15, 1986
	25MG;80MG		A070852 001	May 15, 1986
BARR	25MG;40MG		A070704 001	Oct 01, 1986
	25MG;80MG		A070705 001	Oct 01, 1986
IVAX SUB TEVA PHARMS	25MG;40MG		A071552 001	Dec 01, 1988
	25MG;80MG		A071553 001	Dec 01, 1988
SANDOZ	25MG;40MG		A071060 001	Aug 26, 1987
	25MG;80MG		A071061 001	Aug 26, 1987
WARNER CHILCOTT	25MG;40MG		A071771 001	Jan 26, 1988
	25MG;80MG		A071772 001	Jan 26, 1988
WATSON LABS	25MG;40MG		A070301 001	Apr 18, 1986
	25MG;40MG		A071498 001	Dec 18, 1991
	25MG;80MG		A070305 001	Apr 18, 1986
	25MG;80MG		A071501 001	Dec 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

## TABLET; ORAL

H.R.-50				
WHITEWORTH TOWN PLSN	50MG;0.125MG		A085338 001	
HYDRO-RESERP				
ABC HOLDING	50MG;0.125MG		A084714 002	Jun 29, 1982
HYDRO-SERP "25"				
SANDOZ	25MG;0.125MG		A084827 001	
HYDRO-SERP "50"				
SANDOZ	50MG;0.125MG		A085213 001	
HYDROCHLOROTHIAZIDE W/ RESERPINE				
IVAX SUB TEVA PHARMS	25MG;0.1MG		A083572 001	
	25MG;0.125MG		A083571 001	
	50MG;0.1MG		A083568 001	
	50MG;0.125MG		A083573 001	
PHARMERAL	25MG;0.125MG		A085421 001	
	50MG;0.125MG		A085420 001	
ROXANE	50MG;0.125MG		A084603 001	
WATSON LABS	25MG;0.125MG		A084466 001	
	25MG;0.125MG		A085317 001	
	25MG;0.125MG		A086330 002	
	50MG;0.125MG		A083666 001	
	50MG;0.125MG		A084467 001	
	50MG;0.125MG		A086331 001	
HYDROPRES 25				
MERCK	25MG;0.125MG		N011958 002	
HYDROPRES 50				
MERCK	50MG;0.125MG		N011958 003	
RESERPINE AND HYDROCHLOROTHIAZIDE				
BARR	25MG;0.125MG		A084580 001	
	50MG;0.125MG		A084579 001	
SANDOZ	50MG;0.125MG		A088200 001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
WEST WARD	50MG;0.125MG		A088189 001	May 10, 1984
SERPASIL-ESIDRIX #1				
NOVARTIS	25MG;0.1MG		N011878 003	
SERPASIL-ESIDRIX #2				
NOVARTIS	50MG;0.1MG		N011878 005	

**DISCONTINUED DRUG PRODUCT LIST**HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

## TABLET; ORAL

## SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG; 25MG	A088025	001	Nov 23, 1984
MUTUAL PHARM	25MG; 25MG	A087267	001	
PUREPAC PHARM	25MG; 25MG	A087999	001	Nov 06, 1985
SANDOZ	25MG; 25MG	A086881	001	
SUPERPHARM	25MG; 25MG	A089137	001	Aug 26, 1985
WATSON LABS	25MG; 25MG	A087398	001	

## SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

IVAX PHARMS	25MG; 25MG	A087004	002	May 24, 1982
LEDERLE	25MG; 25MG	A087511	001	
PARKE DAVIS	25MG; 25MG	A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG; 25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG; 25MG	A087553	001	
USL PHARMA	25MG; 25MG	A087651	001	
VANGARD	25MG; 25MG	A087655	001	
WATSON LABS	25MG; 25MG	A085974	001	
	25MG; 25MG	A086026	001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

## TABLET; ORAL

## TIMOLIDE 10-25

MERCK	25MG; 10MG	N018061	001	
-------	------------	---------	-----	--

HYDROCHLOROTHIAZIDE; TRIAMTERENE

## CAPSULE; ORAL

## DYAZIDE

GLAXOSMITHKLINE LLC	25MG; 50MG	N016042	002	
---------------------	------------	---------	-----	--

## TRIAMTERENE AND HYDROCHLOROTHIAZIDE

BARR	25MG; 37.5MG	A074970	001	Jan 06, 1998
NOVARTIS	25MG; 37.5MG	A074857	001	Sep 09, 1997
VITARINE	25MG; 50MG	A071737	001	Feb 12, 1988

## TABLET; ORAL

## TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP	50MG; 75MG	A072022	001	Apr 17, 1988
QUANTUM PHARMICS	50MG; 75MG	A071980	001	Apr 17, 1988
WATSON LABS	50MG; 75MG	A071969	001	Apr 17, 1988

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

## SYRUP; ORAL

## CODAMINE

ALPHARMA US PHARMS	5MG/5ML; 25MG/5ML	A075103	001	Sep 29, 2000
--------------------	-------------------	---------	-----	--------------

HYDROCORTAMATE HYDROCHLORIDE

## OINTMENT; TOPICAL

## MAGNACORT

PFIZER	0.5%	N010554	001	
--------	------	---------	-----	--

HYDROCORTISONE

## AEROSOL; TOPICAL

## AEROSEB-HC

ALLERGAN HERBERT	0.5%	A085805	001	
------------------	------	---------	-----	--

## CREAM; TOPICAL

## CORT-DOME

BAYER PHARMS	0.5%	N009585	003	
	1%	N009585	001	

## DERMACORT

MONARCH PHARMS	1%	A083011	002	
----------------	----	---------	-----	--

## ELDECORT

VALEANT PHARM INTL	1%	A080459	001	
	2.5%	A084055	001	

## FLEXICORT

WESTWOOD SQUIBB	0.5%	A087136	003	Apr 08, 1982
	1%	A087136	002	Apr 08, 1982
	2.5%	A087136	001	Apr 08, 1982

## H-CORT

PHARM ASSOC	0.5%	A086823	001	
-------------	------	---------	-----	--

## HC #1

BAYER PHARMS	0.5%	A080438	001	
--------------	------	---------	-----	--

## HC #4

BAYER PHARMS	1%	A080438	002	
--------------	----	---------	-----	--

## HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080482	003	
	1%	A080482	004	

## DISCONTINUED DRUG PRODUCT LIST

HYDROCORTISONE

## CREAM; TOPICAL

HI-COR			
C AND M PHARMA	2.5%	A080483 001	
HYDROCORTISONE			
ALPHARMA US PHARMS	2.5%	A089754 001	Feb 01, 1989
ALTANA	0.5%	A080848 002	
	1%	A080848 003	
AMBIX	1%	A086080 001	
	2.5%	A086271 001	
EVERYLIFE	0.5%	A080452 001	
	1%	A080452 002	
G AND W LABS	1%	A084059 001	
INGRAM PHARM	0.5%	A080456 002	
	1%	A080456 003	
IVAX PHARMS	1%	A085733 001	
NASKA	1%	A089706 001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084970 002	
	1%	A085026 001	
PHARMADERM	1%	A088845 001	Feb 27, 1986
	2.5%	A089413 001	Dec 16, 1986
PHARMAFAIR	1%	A087838 001	Jul 28, 1982
STIEFEL	1%	A086170 001	
SYOSSET	0.5%	A085527 001	
TARO	0.5%	A086154 001	
	1%	A086155 001	
TEVA	0.5%	A080400 002	
	1%	A080400 003	
	1%	A085191 001	
	2.5%	A080400 004	
TOPIDERM	1%	A089273 001	Feb 17, 1989
USL PHARMA	1%	A088027 001	Sep 27, 1983
	2.5%	A088029 001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%	A080496 002	
HYTONE			
VALEANT INTL	1%	A080472 003	
	2.5%	A080472 004	
NOGENIC HC			
IVAX PHARMS	1%	A087427 001	Apr 04, 1988
NUTRACORT			
DOW PHARM	0.5%	A080442 002	
	1%	A080442 003	
PENECORT			
ALLERGAN HERBERT	1%	A088216 001	Jun 06, 1984
PROTCOCORT			
MONARCH PHARMS	1%	A083011 001	
SYNACORT			
MEDICIS	0.5%	A087459 001	
GEL; TOPICAL			
NUTRACORT			
HEALTHPOINT	1%	A084698 001	
PENECORT			
ALLERGAN HERBERT	1%	A088215 001	Jun 06, 1984
INJECTABLE; INJECTION			
CORTEF			
PHARMACIA AND UPJOHN	50MG/ML	N009864 001	
LOTION; TOPICAL			
ACTICORT			
BAKER NORTON	1%	A086535 001	
ALA-CORT			
CROWN LABS	1%	A083201 001	
BALNEOL-HC			
SOLVAY	1%	A088041 001	Dec 03, 1982
BETA-HC			
BETA DERMAC	1%	A089495 001	Jan 25, 1988
CETACORT			
DOW PHARM	0.5%	A080426 002	
	1%	A080426 001	
CORT-DOME			
BAYER PHARMS	0.5%	N009895 003	
	1%	N009895 001	

## DISCONTINUED DRUG PRODUCT LIST

HYDROCORTISONE

## LOTION; TOPICAL

## DERMACORT

SOLVAY

0.5%

A084573 002

1%

A086462 001

## EPICORT

BLULINE

0.5%

A083219 002

## GLYCORT

HERAN

1%

A087489 001 Oct 03, 1983

## H-CORT

PHARM ASSOC

0.5%

A086824 001

## HYDROCORTISONE

ALPHARMA US PHARMS

0.5%

A087317 001 Jun 07, 1982

1%

A087315 001 Jun 07, 1982

MERICON

0.5%

A085282 001

1%

A085282 002 Feb 26, 1987

NASKA

1%

A089705 001 Apr 25, 1988

PERRIGO NEW YORK

0.5%

A085662 001

1%

A085663 001

TARO

1%

A089024 001 Feb 12, 1986

## HYTONE

VALEANT INTL

1%

A080473 003

2.5%

A080473 004 Nov 30, 1982

## NUTRACORT

DOW PHARM

0.5%

A080443 002

1%

A080443 003

## STIE-CORT

PERRIGO CO

1%

A089066 001 Nov 25, 1985

## OINTMENT; TOPICAL

## CORTRIL

PFIZER GLOBAL

1%

N009176 001

2.5%

N009176 002

## HC (HYDROCORTISONE)

C AND M PHARMA

0.5%

A080481 001

1%

A080481 002

## HYDROCORTISONE

ALTANA

0.5%

A080489 002

1%

A080489 003

AMBIX

1%

A086079 001

2.5%

A086272 001

NASKA

1%

A089704 001 Mar 10, 1988

PERRIGO NEW YORK

0.5%

A084969 003

1%

A085028 001

PHARMADERM

1%

A088842 001 Feb 09, 1987

TARO

0.5%

A086256 001

2.5%

A040310 001 Dec 29, 2000

USL PHARMA

1%

A088061 001 Sep 27, 1983

2.5%

A088039 001 Sep 27, 1983

## HYTONE

DERMIK LABS

1%

A080474 003

2.5%

A080474 004

## PENECORT

ALLERGAN HERBERT

2.5%

A088217 001 Jun 06, 1984

## POWDER; FOR RX COMPOUNDING

## H-CORT

TORCH

100%

A087834 001 Mar 29, 1982

## HYDROCORTISONE

PADDOCK LLC

100%

A088082 001 Apr 08, 1983

## SOLUTION; TOPICAL

## PENECORT

ALLERGAN HERBERT

1%

A088214 001 Jun 06, 1984

## TEXACORT

MISSION PHARMA

1%

A080425 001

## TABLET; ORAL

## CORTRIL

PFIZER

10MG

N009127 005

20MG

N009127 003

## HYDROCORTISONE

BARR

20MG

A083999 001

ELKINS SINN

20MG

A080624 001

FERRANTE

10MG

A080568 001

20MG

A080568 002



## DISCONTINUED DRUG PRODUCT LIST

HYDROCORTISONE

## TABLET; ORAL

## HYDROCORTISONE

HIKMA INTL PHARMS	20MG	A083365	001	
IMPAX LABS	20MG	A080781	001	
INWOOD LABS	20MG	A080732	001	
LANNETT	20MG	A085070	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	
PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	
HYDROCORTONE				
MERCK	10MG	N008506	007	
	20MG	N008506	011	

## TABLET; VAGINAL

## CORTRIL

PFIPHARMECS	10MG	N009796	001	
-------------	------	---------	-----	--

HYDROCORTISONE ACETATE

## CREAM; TOPICAL

## HEMSOL-HC

ABLE	1%	A081274	001	Jun 19, 1992
------	----	---------	-----	--------------

## HYDROCORTISONE ACETATE

CENCI	1%	A080419	001	Jan 25, 1982
PARKE DAVIS	1%	A089914	001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050	001	
	1%	A086052	001	

## INJECTABLE; INJECTION

## CORTEF ACETATE

PHARMACIA AND UPJOHN	50MG/ML	N009378	002	
----------------------	---------	---------	-----	--

## CORTRIL

PFIZER	25MG/ML	N009164	001	
--------	---------	---------	-----	--

## HYDROCORTISONE ACETATE

AKORN	25MG/ML	N009637	001	
	50MG/ML	N009637	002	
BEL MAR	25MG/ML	A083739	001	
	50MG/ML	A083739	002	
WATSON LABS	25MG/ML	A083128	001	
	25MG/ML	A083759	001	
	50MG/ML	A083759	002	
	50MG/ML	A085214	001	

## HYDROCORTONE

MERCK	25MG/ML	N008228	001	
	50MG/ML	N008228	004	

## LOTION; TOPICAL

## DRICORT

INGRAM PHARM	0.5%	A086207	001	
--------------	------	---------	-----	--

## OINTMENT; OPHTHALMIC

## HYDROCORTISONE ACETATE

FERA PHARMS	0.5%	A080828	001	
-------------	------	---------	-----	--

## OINTMENT; OPHTHALMIC, OTIC

## HYDROCORTONE

MERCK	1.5%	N009018	003	
-------	------	---------	-----	--

## OINTMENT; TOPICAL

## CORTEF ACETATE

PHARMACIA AND UPJOHN	1%	N008917	002	
	2.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008917	001	

## PASTE; TOPICAL

## ORABASE HCA

COLGATE	0.5%	A083205	001	
---------	------	---------	-----	--

**DISCONTINUED DRUG PRODUCT LIST**HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049	001
	2.5%;EQ 3.5MG BASE/GM	A061049	002

OINTMENT; OPHTHALMIC

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610	001
	1.5%;EQ 3.5MG BASE/GM	A060610	002

OINTMENT; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751	001
	1%;EQ 3.5MG BASE/GM	A060751	002
	2.5%;EQ 3.5MG BASE/GM	A060751	003

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

AKORN	1.5%;EQ 3.5MG BASE/ML	A060188	001
-------	-----------------------	---------	-----

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612	002
	1.5%;EQ 3.5MG BASE/ML	A060612	001

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC

TERRA-CORTRIL

PFIZER	1.5%;EQ 5MG BASE/ML	A061016	001
--------	---------------------	---------	-----

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988
----------------	-------	---------	-----	--------------

LOTION; TOPICAL

PRAMOSONE

FERNDALE LABS	0.5%;1%	A083213	002
---------------	---------	---------	-----

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

FOUGERA PHARMS	1%;10%	A080505	001
----------------	--------	---------	-----

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N018795	001	Jan 07, 1983
------------	------	---------	-----	--------------

OINTMENT; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N019106	001	Jul 03, 1984
------------	------	---------	-----	--------------

SOLUTION; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N019819	001	Sep 15, 1988
------------	------	---------	-----	--------------

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

CORTEF

PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900	001
----------------------	------------------	---------	-----

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

MERCK	EQ 50MG BASE/ML	N012052	001
-------	-----------------	---------	-----

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

ABBOTT	EQ 1GM BASE/VIAL	A089580	001	Apr 11, 1989
--------	------------------	---------	-----	--------------

	EQ 100MG BASE/VIAL	A085928	001
--	--------------------	---------	-----

	EQ 100MG BASE/VIAL	A089577	001	Apr 11, 1989
--	--------------------	---------	-----	--------------

	EQ 250MG BASE/VIAL	A089578	001	Apr 11, 1989
--	--------------------	---------	-----	--------------

	EQ 500MG BASE/VIAL	A089579	001	Apr 11, 1989
--	--------------------	---------	-----	--------------

HOSPIRA	EQ 1GM BASE/VIAL	A085932	001
---------	------------------	---------	-----

	EQ 100MG BASE/VIAL	A085929	001
--	--------------------	---------	-----

	EQ 250MG BASE/VIAL	A085930	001
--	--------------------	---------	-----

	EQ 500MG BASE/VIAL	A085931	001
--	--------------------	---------	-----

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM	EQ 1GM BASE/VIAL	A088670	001	Jun 08, 1984
---------------	------------------	---------	-----	--------------

	EQ 100MG BASE/VIAL	A088667	001	Jun 08, 1984
--	--------------------	---------	-----	--------------

	EQ 100MG BASE/VIAL	A088712	001	Jun 08, 1984
--	--------------------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**HYDROCORTISONE SODIUM SUCCINATE

## INJECTABLE; INJECTION

## HYDROCORTISONE SODIUM SUCCINATE

	EQ 250MG BASE/VIAL	A088668	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A088669	001	Jun 08, 1984
BAXTER HLTHCARE	EQ 1GM BASE/VIAL	A087569	001	
	EQ 100MG BASE/VIAL	A086619	001	
	EQ 250MG BASE/VIAL	A087567	001	
	EQ 500MG BASE/VIAL	A087568	001	
INTL MEDICATION	EQ 100MG BASE/VIAL	A087532	001	Mar 19, 1982
WATSON LABS	EQ 1GM BASE/VIAL	A084748	001	
	EQ 100MG BASE/VIAL	A084737	002	
	EQ 100MG BASE/VIAL	A084738	001	
	EQ 250MG BASE/VIAL	A084737	001	
	EQ 500MG BASE/VIAL	A084747	001	

HYDROCORTISONE VALERATE

## CREAM; TOPICAL

## HYDROCORTISONE VALERATE

TEVA PHARMS	0.2%	A074489	001	Aug 12, 1998
WESTCORT				
RANBAXY	0.2%	N017950	001	
OINTMENT; TOPICAL				
HYDROCORTISONE VALERATE				
FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001
WESTCORT				
RANBAXY	0.2%	N018726	001	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

## CREAM; TOPICAL

## NEO-CORT-DOME

BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237	006	Jun 05, 1984
	1%;EQ 3.5MG BASE/GM	N050237	005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

## SOLUTION/DROPS; OTIC

## NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394	001	Sep 29, 1982
OTOCORT				
WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730	002	
SUSPENSION/DROPS; OPHTHALMIC				
CORTISPORIN				
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623	001	Sep 24, 1985
SUSPENSION/DROPS; OTIC				
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617	001	Sep 18, 1985
OTICAIR				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399	001	Nov 18, 1982
OTOBIONE				
SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816	001	
OTOCORT				
ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521	001	Jul 11, 1985

HYDROCORTISONE; POLYMYXIN B SULFATE

## SOLUTION/DROPS; OTIC

## OTOBiotic

SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302	001	
PYOCIDIN				
FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606	001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

## OINTMENT; OPHTHALMIC

## ACHROMYCIN

LEDERLE	1.5%;1%	N050272	001	
---------	---------	---------	-----	--

HYDROCORTISONE; UREA

## CREAM; TOPICAL

## ALPHADERM

BIOGLAN	1%;10%	A086008	001	
CALMURID HC				
PHARMACIA AND UPJOHN	1%;10%	A083947	001	

## DISCONTINUED DRUG PRODUCT LIST

HYDROFLUMETHIAZIDE

TABLET; ORAL

DIUCARDIN

WYETH AYERST

50MG

A083383 001

HYDROFLUMETHIAZIDE

PAR PHARM

50MG

A088850 001 May 31, 1985

WATSON LABS

50MG

A088031 001 Apr 06, 1983

50MG

A088528 001 Aug 15, 1984

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA

50MG; 0.125MG

A088195 001 Oct 26, 1983

WATSON LABS

25MG; 0.125MG

A088127 001 Mar 22, 1983

50MG; 0.125MG

A088110 001 Mar 22, 1983

RESERPINE AND HYDROFLUMETHIAZIDE

IVAX PHARMS

50MG; 0.125MG

A088932 001 Jan 11, 1985

PAR PHARM

50MG; 0.125MG

A088907 001 Sep 20, 1985

SALUTENSIN

SHIRE

50MG; 0.125MG

N012359 003

SALUTENSIN-DEMI

SHIRE

25MG; 0.125MG

N012359 004

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

PURDUE PHARMA LP

12MG

N021044 001 Sep 24, 2004

16MG

N021044 002 Sep 24, 2004

24MG

N021044 003 Sep 24, 2004

32MG

N021044 004 Sep 24, 2004

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

WATSON LABS

10MG/ML

A074317 001 Aug 23, 1995

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

NESHER PHARMS

2MG

A077311 001 Nov 09, 2005

4MG

A077311 002 Nov 09, 2005

8MG

A077311 003 Nov 09, 2005

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL

MERCCK

1MG/ML

A080778 001

CYANOKIT

MERCCK SANTE SAS

2.5GM/VIAL (5GM/KIT)

N022041 002 Dec 15, 2006

HYDROXOCOBALAMIN

ABRAXIS PHARM

1MG/ML

A084921 001

WATSON LABS

1MG/ML

A085528 001

HYDROXOMIN

BEL MAR

1MG/ML

A084629 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIINE

PHARMICS

1%

N000004 004

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

SANDOZ

200MG

A040150 001 Jan 27, 1996

WATSON LABS

200MG

A040133 001 Nov 30, 1995

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

BRISTOL MYERS SQUIBB

125MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N010347 004

125MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N016911 001

250MG/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or

N010347 002

## DISCONTINUED DRUG PRODUCT LIST

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

efficacy reasons\*\*

250MG/ML \*\*Federal Register

N016911 002

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons\*\*

HYDROXYPROGESTERONE CAPROATE

AKORN

125MG/ML

N018004 001

WATSON LABS

125MG/ML

N017439 001

250MG/ML

N017439 002

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US

225MG/AMP

N009166 001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR

250MG

A075143 002 Sep 21, 2000

BARR LABS INC

250MG

A075020 002 Jun 26, 2000

500MG

A075020 001 Jul 30, 1998

ROXANE

500MG

A074476 001 Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR

1GM

A075734 001 Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE

50MG/ML

A085551 002

HYDROXYZINE HYDROCHLORIDE

ALTANA

25MG/ML

A087273 001 Apr 20, 1982

50MG/ML

A087273 002 Apr 20, 1982

BAXTER HLTHCARE

25MG/ML

A085551 001

FRESENIUS KABI USA

25MG/ML

A088184 001 Mar 31, 1983

50MG/ML

A088185 001 Mar 31, 1983

HOSPIRA

25MG/ML

A087416 001

50MG/ML

A086821 001

50MG/ML

A087546 001

PHARMAFAIR

25MG/ML

A088862 001 Feb 14, 1986

25MG/ML

A089106 001 Feb 14, 1986

50MG/ML

A088881 001 Feb 14, 1986

50MG/ML

A089107 001 Feb 14, 1986

SMITH AND NEPHEW

25MG/ML

A087592 001

SOLOPAK

25MG/ML

A086822 001

25MG/ML

A087591 001

50MG/ML

A087310 001

50MG/ML

A087593 001

50MG/ML

A087595 001

50MG/ML

A087596 001

WATSON LABS

25MG/ML

A085778 001

25MG/ML

A087274 001

50MG/ML

A085779 001

50MG/ML

A087274 002

WYETH AYERST

25MG/ML

A086258 001

50MG/ML

A086258 002

ORGATRAX

ORGANON USA INC

25MG/ML

A087014 001

50MG/ML

A087014 002

VISTARIL

PFIZER

25MG/ML

N011111 001

50MG/ML

N011111 002

SYRUP; ORAL

ATARAX

ROERIG

10MG/5ML

N010485 001

HYDROXYZINE HYDROCHLORIDE

ALPHARMA US PHARMS

10MG/5ML

A088785 001 Feb 03, 1988

KV PHARM

10MG/5ML

A087730 001 Jul 01, 1982

STI PHARMA LLC

10MG/5ML

A086880 001

## DISCONTINUED DRUG PRODUCT LIST

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

ATARAX

PFIZER	10MG	N010392 001
	25MG	N010392 004
	50MG	N010392 006
	100MG	N010392 005

HYDROXYZINE HYDROCHLORIDE

ABLE	10MG	A040559 001	Jul 22, 2004
	25MG	A040562 001	Jul 22, 2004
	50MG	A040563 001	Jul 22, 2004
ACTAVIS ELIZABETH	10MG	A089071 001	Jul 22, 1986
	25MG	A089072 001	Jul 22, 1986
	50MG	A089073 001	Jul 22, 1986
HALSEY	10MG	A089366 001	May 02, 1988
	25MG	A089117 001	May 02, 1988
	50MG	A089396 001	May 02, 1988
IVAX PHARMS	10MG	A087216 001	
	25MG	A087410 001	
	50MG	A087411 001	
KV PHARM	10MG	A087819 001	Jun 23, 1982
	25MG	A087820 001	Jun 23, 1982
	50MG	A087821 001	Jun 23, 1982
	100MG	A087822 001	Jun 23, 1982
MIKAH PHARMA	10MG	A040600 001	Dec 28, 2004
	25MG	A040602 001	Dec 28, 2004
	50MG	A040604 001	Dec 28, 2004
MUTUAL PHARM	10MG	A088409 001	Nov 15, 1983
	25MG	A087857 001	Apr 18, 1983
	50MG	A087860 001	Apr 18, 1983
	100MG	A087862 001	Apr 18, 1983
PLIVA	100MG	A081054 001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120 001	Sep 25, 1984
	25MG	A088121 001	Sep 25, 1984
	50MG	A088122 001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540 001	Oct 22, 1985
	25MG	A088551 001	Oct 22, 1985
	50MG	A088529 001	Oct 22, 1985
SANDOZ	10MG	A087246 002	
	10MG	A087869 001	Dec 20, 1982
	25MG	A085247 001	
	25MG	A087870 001	Dec 20, 1982
	50MG	A087245 001	
	50MG	A087871 001	Dec 20, 1982
SUPERPHARM	10MG	A088794 001	Dec 05, 1984
	25MG	A088795 001	Dec 05, 1984
	50MG	A088796 001	Dec 05, 1984
USL PHARMA	10MG	A089121 001	Mar 20, 1986
	25MG	A089122 001	Mar 20, 1986
	50MG	A089123 001	Mar 20, 1986
VINTAGE	10MG	A087602 001	Jan 22, 1982
	25MG	A087603 001	Jan 22, 1982
	50MG	A087604 001	Jan 22, 1982
WATSON LABS	10MG	A081149 001	Mar 18, 1994
	10MG	A086827 001	
	25MG	A081150 001	Mar 18, 1994
	25MG	A086829 001	
	50MG	A081151 001	Mar 18, 1994
	50MG	A086836 001	

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM "25"

TEVA	EQ 25MG HCL	A088713 001	Mar 04, 1985
------	-------------	-------------	--------------

HYDROXYZINE PAMOATE

DURAMED PHARMS BARR	EQ 25MG HCL	A088593 001	Feb 29, 1984
	EQ 50MG HCL	A088594 001	Feb 29, 1984
	EQ 100MG HCL	A088595 001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HCL	A087761 001	Mar 05, 1982
	EQ 50MG HCL	A087760 001	Mar 05, 1982
PAR PHARM	EQ 25MG HCL	A087656 001	Jun 11, 1982
	EQ 25MG HCL	A089145 001	Mar 17, 1986
	EQ 50MG HCL	A087657 001	Jun 11, 1982

## DISCONTINUED DRUG PRODUCT LIST

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

	EQ 50MG HCL	A089146 001	Mar 17, 1986
	EQ 100MG HCL	A087658 001	Jun 11, 1982
SANDOZ	EQ 25MG HCL	A081127 001	Jun 28, 1991
	EQ 50MG HCL	A081128 001	Jun 28, 1991
	EQ 100MG HCL	A081129 001	Jun 28, 1991
SUPERPHARM	EQ 25MG HCL	A089031 001	Jan 02, 1987
	EQ 50MG HCL	A089032 001	Jan 02, 1987
	EQ 100MG HCL	A089033 001	Jan 02, 1987
VANGARD	EQ 25MG HCL	A088392 001	Sep 19, 1983
	EQ 50MG HCL	A088393 001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165 001	Jul 31, 1991
	EQ 25MG HCL	A086698 001	
	EQ 25MG HCL	A086840 001	Jul 01, 1982
	EQ 50MG HCL	A086695 001	
	EQ 50MG HCL	A086705 001	Jul 01, 1982
	EQ 50MG HCL	A087767 001	Aug 16, 1982
	EQ 100MG HCL	A086697 001	
	EQ 100MG HCL	A086728 001	Oct 05, 1982
	EQ 100MG HCL	A087790 001	Aug 16, 1982
VISTARIL			
PFIZER	EQ 100MG HCL	N011459 006	
SUSPENSION; ORAL			
VISTARIL			
PFIZER	EQ 25MG HCL/5ML	N011795 001	

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

HOFFMANN LA ROCHE

EQ 2.5MG BASE \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N021455 001 May 16, 2003

IBUPROFEN

CAPSULE; ORAL

MIDOL

BAYER

200MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

A070626 001 Sep 02, 1987

200MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

A071002 001 Sep 02, 1987

SOLUTION; INTRAVENOUS

CALDOLOR

CUMBERLAND PHARMS

400MG/4ML (100MG/ML)

N022348 001 Jun 11, 2009

SUSPENSION; ORAL

CHILDREN'S ADVIL

WYETH CONS

100MG/5ML

N019833 002 Sep 19, 1989

IBU

ABBOTT

100MG/5ML

N019784 001 Dec 18, 1989

MOTRIN

MCNEIL CONSUMER

100MG/5ML

N019842 001 Sep 19, 1989

SUSPENSION/DROPS; ORAL

MOTRIN

MCNEIL

40MG/ML

N020476 001 May 25, 1995

TABLET; ORAL

ACHES-N-PAIN

LEDERLE

200MG

A071065 001 May 28, 1987

CAP-PROFEN

PERRIGO

200MG

A072097 001 Dec 08, 1987

IBU

BASF

400MG

A070083 001 Feb 22, 1985

400MG

N018197 001

600MG

A070088 001 Feb 08, 1985

600MG

A070099 001 Mar 29, 1985

800MG

A070745 001 Jul 23, 1986

IBU-TAB

ALRA

800MG

A071965 001 Aug 11, 1988

## DISCONTINUED DRUG PRODUCT LIST

IBUPROFEN

TABLET; ORAL

IBUPRIN

PLIVA

200MG

A071773 001 Jul 16, 1987

IBUPROFEN

ABBOTT

600MG

A070556 001 Jun 14, 1985

800MG

A071264 001 Jul 25, 1986

CONTRACT PHARMACAL

200MG

A073691 001 Feb 25, 1994

HALSEY

200MG

A071027 001 Sep 29, 1987

300MG

A071028 001 Mar 23, 1987

400MG

A071029 001 Mar 23, 1987

600MG

A071030 001 Mar 23, 1987

800MG

A072137 001 Feb 05, 1988

IVAX SUB TEVA PHARMS

200MG

A071144 001 Jan 20, 1987

200MG

A071154 001 Oct 27, 1987

200MG

A072040 001 Apr 29, 1988

200MG

A072901 001 Dec 19, 1991

200MG

A072903 001 Dec 19, 1991

400MG

A071145 001 Sep 23, 1986

600MG

A071146 001 Sep 23, 1986

800MG

A071769 001 May 08, 1987

LEDERLE

400MG

A070629 001 Sep 19, 1986

600MG

A070630 001 Sep 19, 1986

LEINER

300MG

A071266 001 Oct 15, 1986

MCNEIL

400MG

A070081 001 Jun 16, 1986

600MG

A070476 001 Jun 16, 1986

MUTUAL PHARM

200MG

A070493 001 Dec 24, 1985

200MG

A070908 001 Sep 26, 1986

200MG

A071462 001 Oct 02, 1986

400MG

A070079 001 Jul 24, 1985

600MG

A070080 001 Jul 24, 1985

800MG

A071448 001 Feb 18, 1987

MYLAN

200MG

A071870 001 May 05, 1988

400MG

A070045 001 Sep 24, 1985

600MG

A070057 001 Sep 24, 1985

800MG

A071999 001 Dec 03, 1987

NORTHSTAR HLTHCARE

400MG

A078132 001 Sep 10, 2007

600MG

A078132 002 Sep 10, 2007

800MG

A078132 003 Sep 10, 2007

OHM LABS

400MG

A070818 001 Dec 26, 1985

PAR PHARM

200MG

A071575 001 May 08, 1987

300MG

A070328 001 Aug 06, 1985

400MG

A070329 001 Aug 06, 1985

600MG

A070330 001 Aug 06, 1985

800MG

A070986 001 Jul 25, 1986

PERRIGO

200MG

A072098 001 Dec 08, 1987

PLIVA

400MG

A071666 001 Jun 18, 1987

600MG

A071667 001 Jun 18, 1987

800MG

A071668 001 Jun 18, 1987

PUREPAC PHARM

200MG

A071122 001 Oct 03, 1986

200MG

A071664 001 Feb 03, 1987

300MG

A071123 001 Sep 19, 1986

400MG

A071124 001 Sep 19, 1986

600MG

A071125 001 Sep 19, 1986

800MG

A071964 001 Feb 01, 1988

SANDOZ

200MG

A070733 001 Sep 19, 1986

200MG

A071807 001 Feb 25, 1988

200MG

A074525 001 Dec 15, 1995

200MG

A074533 001 Dec 15, 1995

300MG

A070734 001 Jun 12, 1986

400MG

A070735 001 Jun 12, 1986

400MG

A072064 001 Jan 14, 1988

600MG

A070736 001 Jun 12, 1986

600MG

A072065 001 Jan 14, 1988

800MG

A071938 001 Jan 14, 1988

800MG

A072169 001 Dec 11, 1987

SUPERPHARM

600MG

A070709 001 Apr 25, 1986

TEVA

200MG

A073141 001 May 29, 1992

400MG

A073343 001 Jun 30, 1992

600MG

A073344 001 Jun 30, 1992

800MG

A073345 001 Jun 30, 1992

VINTAGE PHARMS

200MG

A072249 001 Jan 10, 1989



**DISCONTINUED DRUG PRODUCT LIST**IBUPROFEN

TABLET; ORAL

IBUPROFEN

WATSON LABS

200MG

A070435 001 Mar 05, 1986

200MG

A071765 001 Sep 04, 1987

200MG

A071905 001 Mar 08, 1988

300MG

A071338 001 Dec 01, 1986

400MG

A070038 001 Sep 06, 1985

400MG

A070436 001 Aug 21, 1985

600MG

A070041 001 Sep 06, 1985

600MG

A070437 001 Aug 21, 1985

800MG

A071547 001 Jul 02, 1987

800MG

A071911 001 Oct 13, 1987

IBUPROHM

OHM LABS

400MG

A070469 001 Aug 29, 1985

MEDIPREN

MCNEIL

200MG

A070475 001 Feb 06, 1986

200MG

A071215 001 Jun 26, 1986

MIDOL

BAYER

200MG

A070591 001 Sep 02, 1987

200MG

A071001 001 Sep 02, 1987

MOTRIN

MCNEIL CONSUMER

300MG

N017463 003

400MG

N017463 002

600MG

N017463 004

800MG

N017463 005 May 22, 1985

MCNEIL PED

100MG

N020418 001 Nov 16, 1994

NUPRIN

BRISTOL MYERS

200MG

A072035 001 Feb 16, 1988

200MG

A072036 001 Feb 16, 1988

MCNEIL

200MG

N019012 001 May 18, 1984

200MG

N019012 002 Jul 29, 1987

RUFEN

BASF

600MG

N018197 002 Mar 05, 1984

TABLET, CHEWABLE; ORAL

MOTRIN

MCNEIL PED

50MG

N020135 001 Nov 16, 1994

100MG

N020135 002 Nov 16, 1994

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

FOREST LABS

400MG; 5MG

N021378 001 Nov 26, 2004

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

PHARMACIA AND UPJOHN

5MG/VIAL

N050661 002 Sep 27, 1990

10MG/VIAL

N050661 001 Sep 27, 1990

20MG/VIAL

N050661 003 Apr 25, 1995

IDARUBICIN HYDROCHLORIDE

SANDOZ

1MG/ML

A091293 001 Mar 29, 2011

TEVA PARENTERAL

5MG/VIAL

A065037 003 May 01, 2002

10MG/VIAL

A065037 002 May 01, 2002

20MG/VIAL

A065037 001 May 01, 2002

IDOXURIDINE

OINTMENT; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE

0.5%

N015868 001

SOLUTION/DROPS; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE

0.1%

N013934 001

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

BAXTER HLTHCARE

1GM/VIAL; 100MG/ML

N019763 003 Oct 10, 1992

3GM/VIAL; 100MG/ML

N019763 004 Oct 10, 1992

## DISCONTINUED DRUG PRODUCT LIST

ILOPROST

SOLUTION; INHALATION

VENTAVIS

ACTELION PHARMS LTD 20MCG/2ML (10MCG/ML) N021779 001 Dec 29, 2004

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

NOVARTIS EQ 50MG BASE N021335 001 May 10, 2001

EQ 100MG BASE N021335 002 May 10, 2001

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS 25MG/ML A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS 12.5MG/ML N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

LEDERLE 10MG A086269 001

25MG A086267 001

50MG A086268 001

PAR PHARM 25MG A089497 001 Jul 14, 1987

PROSAM LABS 10MG A040753 001 Feb 28, 2008

25MG A040752 001 Feb 28, 2008

50MG A040751 001 Feb 28, 2008

ROXANE 10MG A083799 001

25MG A083799 002

50MG A083799 003

SANDOZ 10MG A085200 001

25MG A084869 002

50MG A085133 001

TEVA 10MG A083729 001

25MG A083729 004

50MG A083729 003

USL PHARMA 25MG A087776 001 Feb 10, 1982

VANGARD 10MG A088036 001 Nov 03, 1982

25MG A087619 001 Feb 09, 1982

50MG A087631 001 Jan 04, 1982

WATSON LABS 10MG A085220 001

10MG A085875 001

25MG A084252 002

25MG A085878 001

50MG A085221 001

50MG A085877 001

WEST WARD 25MG A088222 001 May 26, 1983

50MG A088223 001 May 26, 1983

JANIMINE

ABBOTT 10MG N017895 001

25MG N017895 002

50MG N017895 003

PRAMINE

ALRA 10MG A083827 001

25MG A083827 002

50MG A083827 003

PRESAMINE

SANOFI AVENTIS US 10MG N011836 006

25MG N011836 003

50MG N011836 007

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP EQ 5MG BASE/ML A075542 001 May 10, 2000

HOSPIRA EQ 5MG BASE/ML A074616 001 Aug 03, 1998

INOCOR

SANOFI AVENTIS US EQ 5MG BASE/ML N018700 001 Jul 31, 1984

## DISCONTINUED DRUG PRODUCT LIST

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AMERIGEN PHARMS LTD	1.25MG	A075201 001	Dec 04, 1998
	2.5MG	A075201 002	Dec 04, 1998
SANDOZ	1.25MG	A074594 001	May 23, 1996
	2.5MG	A074594 002	May 23, 1996
TEVA	1.25MG	A074498 002	Feb 12, 1998
	1.25MG	A074665 001	Apr 04, 1997
	2.5MG	A074498 001	Oct 31, 1996
	2.5MG	A074665 002	Apr 04, 1997
WATSON LABS	1.25MG	A074585 001	Sep 26, 1996
	2.5MG	A074585 002	Sep 26, 1996

LOZOL

SANOFI AVENTIS US	1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018538 002	Apr 29, 1993
	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018538 001	Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID

LILLY	EQ 50MG BASE	N019693 001	Dec 29, 1989
	EQ 75MG BASE	N019693 002	Dec 29, 1989
	EQ 100MG BASE	N019693 003	Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

MERCK SHARP DOHME	EQ 100MG BASE	N020685 006	Apr 19, 2000
	EQ 333MG BASE	N020685 005	Dec 17, 1998

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AKORN	10MG/VIAL	N011525 003	
	40MG/VIAL	N011525 004	
	50MG/VIAL	N011525 002	

INDOMETHACIN

CAPSULE; ORAL

INDO-LEMMON

TEVA	25MG	A070266 001	Nov 07, 1985
	50MG	A070267 001	Nov 07, 1985

INDOCIN

IROKO PHARMS LLC	25MG	N016059 001	
	50MG	N016059 002	

INDOMETHACIN

ABLE	25MG	A076666 001	Dec 17, 2003
	50MG	A076666 002	Dec 17, 2003
CYCLE PHARMS LTD	25MG	A070353 001	Jun 18, 1985
	50MG	A070354 001	Jun 18, 1985
DURAMED PHARMS BARR	25MG	A070326 001	Oct 18, 1985
	50MG	A070327 001	Oct 18, 1985
HALSEY	25MG	A070782 001	Jun 03, 1987
	50MG	A070635 001	Jun 03, 1987
IVAX SUB TEVA PHARMS	25MG	N018730 001	May 04, 1984
	50MG	N018730 002	May 04, 1984
MUTUAL PHARM	25MG	A070067 001	Oct 03, 1986
	25MG	A070899 001	Feb 09, 1987
	50MG	A070068 001	Oct 03, 1986
	50MG	A070900 001	Feb 09, 1987
MYLAN	50MG	N018858 002	Apr 20, 1984
PARKE DAVIS	25MG	N018806 001	Nov 23, 1984
	50MG	N018806 002	Nov 23, 1984
PIONEER PHARMS	25MG	A070813 001	Aug 11, 1986
	50MG	A070592 001	Aug 11, 1986
PLIVA	25MG	A071148 001	Mar 18, 1987
	50MG	A071149 001	Mar 18, 1987
SUPERPHARM	25MG	A070487 001	Oct 10, 1986
	50MG	A070488 001	Oct 10, 1986

**DISCONTINUED DRUG PRODUCT LIST**INDOMETHACIN

## CAPSULE; ORAL

## INDOMETHACIN

TEVA	25MG	A071342 001	Apr 18, 1988
	50MG	A071343 001	Apr 18, 1988
VINTAGE	25MG	N018829 002	Aug 06, 1984
	50MG	A070651 001	Mar 05, 1986
	50MG	N018829 001	Aug 06, 1984
WATSON LABS	25MG	A070529 001	Oct 18, 1985
	25MG	A070784 001	Aug 20, 1986
	25MG	A072996 001	Jul 31, 1991
	25MG	N018690 001	Jul 31, 1984
	50MG	A070530 001	Oct 18, 1985
	50MG	A070785 001	Aug 20, 1986
	50MG	A071635 001	May 18, 1987
	50MG	A072997 001	Jul 31, 1991
	50MG	N018690 002	Jul 31, 1984

## CAPSULE, EXTENDED RELEASE; ORAL

## INDOCIN SR

IROKO PHARMS	75MG	N018185 001	Feb 23, 1982
--------------	------	-------------	--------------

## INDOMETHACIN

ABLE	75MG	A076114 001	Feb 06, 2002
INWOOD LABS	75MG	A072410 001	Mar 15, 1989

## SUPPOSITORY; RECTAL

## INDOCIN

IROKO PHARMS	50MG	N017814 001	Aug 13, 1984
--------------	------	-------------	--------------

## SUSPENSION; ORAL

## INDOMETHACIN

CYCLE PHARMS LTD	25MG/5ML	A071412 001	Mar 18, 1987
------------------	----------	-------------	--------------

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

## INJECTABLE; SUBCUTANEOUS

## NOVOLOG MIX 50/50

NOVO NORDISK INC	50 UNITS/ML; 50 UNITS/ML	N021810 001	Aug 26, 2008
------------------	--------------------------	-------------	--------------

## NOVOLOG MIX 70/30 PENFILL

NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172 002	Nov 01, 2001
------------------	--------------------------------------------------------	-------------	--------------

	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172 003	Nov 01, 2001
--	--------------------------------------------------------	-------------	--------------

INSULIN ASPART RECOMBINANT

## INJECTABLE; SUBCUTANEOUS

## NOVOLOG INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 004	Apr 23, 2004
------------------	------------------------------	-------------	--------------

INSULIN DETEMIR RECOMBINANT

## INJECTABLE; SUBCUTANEOUS

## LEVEMIR INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 003	Jun 16, 2005
------------------	------------------------------	-------------	--------------

## LEVEMIR PENFILL

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 004	Jun 16, 2005
------------------	------------------------------	-------------	--------------

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

## INJECTABLE; INJECTION

## HUMALOG MIX 50/50 PEN

LILLY	50 UNITS/ML; 50 UNITS/ML	N021018 003	Dec 22, 1999
-------	--------------------------	-------------	--------------

## HUMALOG MIX 75/25 PEN

LILLY	75 UNITS/ML; 25 UNITS/ML	N021017 003	Dec 22, 1999
-------	--------------------------	-------------	--------------

INSULIN LISPRO RECOMBINANT

## INJECTABLE; INJECTION

## HUMALOG PEN

LILLY	100 UNITS/ML	N020563 002	Aug 06, 1998
-------	--------------	-------------	--------------

INSULIN PORK

## INJECTABLE; INJECTION

## Iletin I

LILLY	500 UNITS/ML	N017931 001	
-------	--------------	-------------	--

## INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017926 001	
------------------	-------------	-------------	--

## REGULAR INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017926 003	
------------------	--------------	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**INSULIN PURIFIED BEEF

INJECTABLE; INJECTION

REGULAR ILETIN II

LILLY

100 UNITS/ML

N018478 001

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

ILETIN II

LILLY

500 UNITS/ML

N018344 002

REGULAR ILETIN II (PORK)

LILLY

100 UNITS/ML

N018344 001

REGULAR PURIFIED PORK INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018381 001

VELOSULIN

NOVO NORDISK INC

100 UNITS/ML

N018193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)

NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N018195 001

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN BR

LILLY

100 UNITS/ML

N019529 001 Apr 28, 1986

VELOSULIN BR

NOVO NORDISK INC

100 UNITS/ML

N021028 001 Jul 19, 1999

POWDER; INHALATION

EXUBERA

PFIZER

1MG/INH

N021868 001 Jan 27, 2006

3MG/INH

N021868 002 Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

LILLY

50 UNITS/ML; 50 UNITS/ML

N020100 001 Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN R

NOVO NORDISK INC

100 UNITS/ML

N018778 001 Aug 30, 1983

VELOSULIN BR HUMAN

NOVO NORDISK INC

100 UNITS/ML

N019450 001 May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30

BAYER PHARMS

30 UNITS/ML; 70 UNITS/ML

N019585 001 Mar 11, 1988

NOVOLIN 70/30

NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N019441 001 Jul 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN

NOVO NORDISK INC

40 UNITS/ML

N017929 001

100 UNITS/ML

N017929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)

LILLY

40 UNITS/ML

N017936 001

100 UNITS/ML

N017936 002

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION

NPH ILETIN II

LILLY

100 UNITS/ML

N018479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN INSULATARD NPH NORDISK

NOVO NORDISK INC

100 UNITS/ML

N018194 001

NPH ILETIN II (PORK)

LILLY

100 UNITS/ML

N018345 001

NPH PURIFIED PORK ISOPHANE INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018623 001

**DISCONTINUED DRUG PRODUCT LIST**INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

INSULATARD NPH HUMAN

NOVO NORDISK INC 100 UNITS/ML

N019449 001 May 30, 1986

NOVOLIN N

NOVO NORDISK INC 100 UNITS/ML

N019065 001 Jan 23, 1985

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION

PROTAMINE ZINC &amp; ILETIN I (BEEF-PORK)

LILLY 40 UNITS/ML

N017932 001

100 UNITS/ML

N017932 002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II

LILLY 100 UNITS/ML

N018476 001

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB 40 UNITS/ML

N017928 001

100 UNITS/ML

N017928 003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II (PORK)

LILLY 100 UNITS/ML

N018346 001

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION

LENTE INSULIN

NOVO NORDISK INC 40 UNITS/ML

N017998 001

100 UNITS/ML

N017998 003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION

ULTRALENTE INSULIN

NOVO NORDISK INC 100 UNITS/ML

N017997 003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION

ULTRALENTE

NOVO NORDISK INC 100 UNITS/ML

N018385 001

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN U

LILLY 40 UNITS/ML

N019571 001 Jun 10, 1987

100 UNITS/ML

N019571 002 Jun 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION

SEMILENTE INSULIN

NOVO NORDISK INC 100 UNITS/ML

N017996 003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION

SEMILENTE

NOVO NORDISK INC 100 UNITS/ML

N018382 001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION

LENTE ILETIN II

LILLY 100 UNITS/ML

N018477 001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION

LENTARD

NOVO NORDISK INC 100 UNITS/ML

N018384 001

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE

NOVO NORDISK INC 100 UNITS/ML

N018383 001

LENTE ILETIN II (PORK)

LILLY 100 UNITS/ML

N018347 001

**DISCONTINUED DRUG PRODUCT LIST**INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN L

LILLY

100 UNITS/ML

N019377 002 Sep 30, 1985

NOVOLIN L

NOVO NORDISK INC

100 UNITS/ML

N019965 001 Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN L

NOVO NORDISK INC

100 UNITS/ML

N018777 001 Aug 30, 1983

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

ISO TEX

100MG/ML

N002282 001

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE

10GM/100ML

N016717 001

IOBENGUANE SULFATE I-131

INJECTABLE; INJECTION

IOBENGUANE SULFATE I 131

PHARMALUCENCE

2.3mCi/ML

N020084 001 Mar 25, 1994

IO CETAMIC ACID

TABLET; ORAL

CHOLEBRINE

MALLINCKRODT

750MG

N017129 001

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

RENOVUE-65

BRACCO

65%

N017902 001

RENOVUE-DIP

BRACCO

24%

N017903 001

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

BRACCO

10.3%

N009321 007

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

CHOLOGRAFIN SODIUM

BRACCO

20%

N009321 001

IODOHIPPURATE SODIUM I-123

INJECTABLE; INJECTION

NEPHROFLOW

GE HEALTHCARE

1mCi/ML

N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131

INJECTABLE; INJECTION

HIPURAN I 131

MALLINCKRODT

0.25mCi/ML

N016666 001

HIPPUTOPE

BRACCO

1-2mCi/VIAL

N015419 002

IODOHIPPURATE SODIUM I 131

PHARMALUCENCE

0.2mCi/ML

N017313 001

IODOXAMATE MEGLUMINE

INJECTABLE; INJECTION

CHOLOVUE

BRACCO

9.9%

N018077 001

40.3%

N018076 001

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION

SPECTAMINE

IMP

1mCi/ML

N019432 001 Dec 24, 1987

**DISCONTINUED DRUG PRODUCT LIST**IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 210

GE HEALTHCARE

45.3%

N018956 006 Jun 30, 1989

SOLUTION; URETHRAL

OMNIPAQUE 70

GE HEALTHCARE

15.1%

N018956 007 Jun 01, 1994

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

BAXTER HLTHCARE

41%

A074629 001 Nov 06, 1996

51%

A074629 004 Mar 31, 1998

61%

A074629 002 Nov 06, 1996

76%

A074629 003 Nov 06, 1996

HOSPIRA

61%

A074734 001 Dec 10, 1996

76%

A074734 002 Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING

41%

A074881 001 Jul 28, 2000

HOSPIRA

41%

A074898 001 Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA

41%

A074636 001 Dec 30, 1997

IOPAMIDOL-250

COOK IMAGING

51%

A074881 002 Jul 28, 2000

HOSPIRA

51%

A074898 002 Dec 30, 1997

51%

A075005 001 Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA

51%

A074636 002 Dec 30, 1997

IOPAMIDOL-300

ABBVIE

61%

A074638 001 Apr 30, 1997

COOK IMAGING

61%

A074881 003 Jul 28, 2000

HOSPIRA

61%

A074898 003 Dec 30, 1997

61%

A075005 002 Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA

61%

A074636 003 Dec 30, 1997

61%

A074637 001 Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING

76%

A074881 004 Jul 28, 2000

HOSPIRA

76%

A074898 004 Dec 30, 1997

76%

A075005 003 Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA

76%

A074636 004 Dec 30, 1997

ISOVUE-128

BRACCO

26%

N018735 005 Oct 21, 1986

ISOVUE-200

BRACCO

41%

N020327 001 Oct 12, 1994

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

GE HEALTHCARE

500MG

N008032 001

IOPHENDYLATE

INJECTABLE; INJECTION

PANTOPAQUE

ALCON

100%

N005319 001

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY

MALLINCKRODT

52%; 26%

N016783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

ANGIO-CONRAY

MALLINCKRODT

80%

N013319 001

CONRAY 325

MALLINCKRODT

54.3%

N017685 001

CONRAY 400

MALLINCKRODT

66.8%

N014295 001



**DISCONTINUED DRUG PRODUCT LIST**IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

BAYER HLTHCARE

40.6%

N019580 001 Dec 07, 1989

OSMOVIST 240

BAYER HLTHCARE

51.3%

N019580 002 Dec 07, 1989

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

MALLINCKRODT

34%

N019710 003 Dec 30, 1988

OPTIRAY 240

MALLINCKRODT

51%

N020923 001 May 28, 1998

OPTIRAY 320

MALLINCKRODT

68%

N020923 002 May 29, 1998

IPODATE CALCIUM

GRANULE; ORAL

ORAGRAFIN CALCIUM

BRACCO

3GM/PACKET

N012968 001

IPODATE SODIUM

CAPSULE; ORAL

BILIVIST

BAYER HLTHCARE

500MG

A087768 001 Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO

500MG

N012967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

BOEHRINGER INGELHEIM

0.018MG/INH

N019085 001 Dec 29, 1986

SOLUTION; INHALATION

ATROVENT

BOEHRINGER INGELHEIM

0.02%

N020228 001 Sep 29, 1993

IPRATROPIUM BROMIDE

ACTAVIS MID ATLANTIC

0.02%

A075111 001 Apr 22, 1999

APOTEX INC

0.02%

A075441 001 Mar 28, 2001

PHARMASCIENCE INC

0.02%

A075507 001 Jan 19, 2001

ROXANE

0.02%

A075867 001 Jul 22, 2002

TEVA PHARMS USA

0.02%

A075313 001 Feb 07, 2000

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

APOTEX INC

0.021MG/SPRAY

A076156 001 Apr 18, 2003

0.042MG/SPRAY

A076155 001 Apr 18, 2003

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

SANDOZ

40MG/2ML (20MG/ML)

A077994 001 Feb 27, 2008

100MG/5ML (20MG/ML)

A077994 002 Feb 27, 2008

IRON DEXTRAN

INJECTABLE; INJECTION

IRON DEXTRAN

SANOFI AVENTIS US

EQ 50MG IRON/ML

N010787 002

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)

N021135 005 Mar 29, 2013

EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)

N021135 003 Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON

1%

A086711 001

BRONKOSOL

SANOFI AVENTIS US

0.25%

N012339 009

1%

N012339 008

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS

1%

A087101 001

ASTRAZENECA

0.062%

A087937 001 Nov 15, 1982

0.062%

A089614 001 Jun 13, 1991

0.125%

A087938 001 Nov 15, 1982

0.125%

A089615 001 Jun 13, 1991

## DISCONTINUED DRUG PRODUCT LIST

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HYDROCHLORIDE

	0.167%	A088470 001	Mar 14, 1984
	0.167%	A089616 001	Jun 13, 1991
	0.2%	A088471 001	Mar 14, 1984
	0.2%	A089617 001	Jun 13, 1991
	0.25%	A088472 001	Mar 14, 1984
	0.25%	A089618 001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144 001	Jul 29, 1983
	0.14%	A088145 001	Mar 26, 1984
	0.25%	A088146 001	Aug 01, 1983
DEY	0.08%	A088187 001	Dec 03, 1982
	0.1%	A087389 001	
	0.17%	A087390 001	
	0.25%	A088188 001	Dec 03, 1982
	1%	A086763 001	
INTL MEDICATION	0.077%	A086651 001	
	0.08%	A086651 002	
	0.1%	A086651 003	
	0.143%	A086651 004	
	0.167%	A086651 005	
	0.2%	A086651 006	
	0.25%	A086651 007	
	1%	A086651 008	
PARKE DAVIS	0.5%	A085997 001	
	1%	A085889 001	
ROXANE	0.1%	A087396 001	
	0.125%	A087025 001	
	0.167%	A088226 001	Sep 16, 1983
	0.2%	A087324 001	
	0.25%	A088275 001	Jun 03, 1983
	1%	A086899 001	
ISOETHARINE HYDROCHLORIDE S/F			
DEY	0.08%	A089817 001	Nov 22, 1988
	0.1%	A089818 001	Nov 22, 1988
	0.17%	A089819 001	Nov 22, 1988
	0.25%	A089820 001	Nov 22, 1988
	1%	A089252 001	Sep 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

BRONKOMETER

SANOFI AVENTIS US	0.34MG/INH	N012339 007	
ISOETHARINE MESYLATE			
ALPHARMA US PHARMS	0.34MG/INH	A087858 001	Aug 21, 1984

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

WATSON LABS INC	99.9%	A074393 001	May 12, 1995
-----------------	-------	-------------	--------------

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL

MERCK	0.025%	N010656 001	
-------	--------	-------------	--

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

SANDOZ	100MG/ML	N008662 001	
--------	----------	-------------	--

RIMIFON

ROCHE	25MG/ML	N008420 002	
	100MG/ML	N008420 003	

SYRUP; ORAL

ISONIAZID

MIKART	50MG/5ML	A081118 001	Jul 21, 1997
--------	----------	-------------	--------------

LANIAZID

LANNETT	50MG/5ML	A089243 001	Feb 03, 1986
---------	----------	-------------	--------------

RIMIFON

ROCHE	50MG/5ML	N008420 001	
-------	----------	-------------	--

TABLET; ORAL

DOW-ISONIAZID

DOW PHARM	300MG	A080330 002	
-----------	-------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

ISONIAZID

TABLET; ORAL

HYZYD

MEDPOINTE PHARM HLC	100MG	A080134	003
	300MG	A080134	004

INH

NOVARTIS	300MG	A080935	001
----------	-------	---------	-----

ISONIAZID

DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
	300MG	A088119	001	Mar 17, 1983
HALSEY	50MG	A083632	001	
HIKMA INTL PHARMS	100MG	A080212	001	
	300MG	A087425	001	
IMPAX LABS	100MG	A080153	001	
IVAX SUB TEVA PHARMS	100MG	A080270	001	
	300MG	A083610	001	
LILLY	100MG	N008499	002	
	300MG	N008499	003	
MIKART	100MG	A040090	001	Jun 26, 1997
	300MG	A040090	002	Jun 26, 1997
MK LABS	100MG	A080941	001	
MUTUAL PHARM	100MG	A080136	001	
	300MG	A083633	001	
NEXGEN PHARMA INC	100MG	A084050	001	
PANRAY	50MG	N008428	001	
	100MG	N008428	002	
	300MG	N008428	003	
PERRIGO	100MG	A083060	001	
PHARMAVITE	100MG	A085091	001	
PHOENIX LABS NY	50MG	A080368	001	
	100MG	A080368	002	
PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
	100MG	A080132	004	Jul 14, 1982
WATSON LABS	50MG	A080522	001	
	100MG	A080401	001	
	100MG	A080523	001	
	100MG	A085790	001	
	300MG	A080521	001	
	300MG	A083178	001	
	300MG	A085784	001	
WHITEWORTH TOWN PLSN	100MG	A080120	002	

LANIAZID

LANNETT	50MG	A080140	001
	100MG	A080140	002

NYDRAZID

BRISTOL MYERS SQUIBB	100MG	N008392	003
----------------------	-------	---------	-----

STANOZIDE

EVERYLIFE	100MG	A080126	001
	300MG	A080126	002

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMPIN AND ISONIAZID

HIKMA INTL PHARMS	150MG; 300MG	A065221	001	Jul 29, 2005
-------------------	--------------	---------	-----	--------------

ISOPROPAMIDE IODIDE

TABLET; ORAL

DARBID

GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001
-----------------	-------------	---------	-----

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HYDROCHLORIDE

3M	0.12MG/INH	N010375	004
ALPHARMA US PHARMS	0.12MG/INH	A085904	001

ISUPREL

SANOFI AVENTIS US	0.103MG/INH	N011178	001
-------------------	-------------	---------	-----

DISC; INHALATION

NORISODRINE AEROTROL

ABBOTT	0.25%	N016814	001
--------	-------	---------	-----

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM	0.2MG/ML	A083431	001
BAXTER HLTHCARE	0.2MG/ML	A083486	001

## DISCONTINUED DRUG PRODUCT LIST

ISOPROTERENOL HYDROCHLORIDE

## INJECTABLE; INJECTION

## ISOPROTERENOL HYDROCHLORIDE

HOSPIRA	0.02MG/ML	A083283	001	
	0.2MG/ML	A083346	001	
INTL MEDICATION	0.2MG/ML	A083724	001	

## SOLUTION; INHALATION

## AEROLONE

LILLY	0.25%	N007245	001	
-------	-------	---------	-----	--

## ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM	0.031%	A087935	001	Nov 18, 1982
	0.062%	A087936	001	Nov 18, 1982
DEY	0.5%	A086764	001	Jan 04, 1982
PARKE DAVIS	0.25%	A085994	001	
	0.5%	A085540	001	

## ISUPREL

SANOFI AVENTIS US	0.5%	N006327	002	
	1%	N006327	003	

## VAPO-ISO

FISONS	0.5%	N016813	001	
--------	------	---------	-----	--

## TABLET; RECTAL, SUBLINGUAL

## ISUPREL

SANOFI AVENTIS US	10MG	N006328	001	
	15MG	N006328	002	

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

## AEROSOL, METERED; INHALATION

## DUO-MEDIHALER

3M	0.16MG/INH; 0.24MG/INH	N013296	001	
----	------------------------	---------	-----	--

ISOPROTERENOL SULFATE

## AEROSOL, METERED; INHALATION

## MEDIHALER-ISO

3M	0.08MG/INH	N010375	003	
----	------------	---------	-----	--

## POWDER; INHALATION

## NORISODRINE

ABBVIE	10%	N006905	003	
	25%	N006905	002	

ISOSORBIDE

## SOLUTION; ORAL

## ISMOTIC

ALCON	100GM/220ML	N017063	001	
-------	-------------	---------	-----	--

ISOSORBIDE DINITRATE

## CAPSULE, EXTENDED RELEASE; ORAL

## ISORDIL

WYETH AYERST	40MG	N012882	002	Jul 29, 1988
--------------	------	---------	-----	--------------

## TABLET; ORAL

## ISORDIL

VALEANT BERMUDA	10MG	N012093	002	Jul 29, 1988
	20MG	N012093	006	Jul 29, 1988
	30MG	N012093	005	Jul 29, 1988

## ISOSORBIDE DINITRATE

## MUTUAL PHARM

	5MG	A086166	002	Sep 19, 1986
	10MG	A086169	001	Sep 19, 1986
	20MG	A086167	001	Sep 19, 1986
	30MG	A087564	001	Sep 18, 1986

## SUPERPHARM

	5MG	A089190	001	Feb 17, 1987
	10MG	A089191	001	Feb 17, 1987
	20MG	A089192	001	Feb 17, 1987
WATSON LABS	5MG	A086034	001	Jan 06, 1988
	10MG	A086032	001	Jan 07, 1988

## SORBITRATE

## ASTRAZENECA

	5MG	N016192	001	Apr 01, 1996
	10MG	N016192	002	Apr 01, 1996
	20MG	A086405	002	Aug 21, 1990
	30MG	A088124	001	Aug 21, 1990
	40MG	A088125	001	Aug 21, 1990

## TABLET; SUBLINGUAL

## ISORDIL

BIOVAIL	2.5MG	N012940	004	Jul 29, 1988
	5MG	N012940	003	Jul 29, 1988
	10MG **Federal Register determination	N012940	005	Jul 29, 1988

## DISCONTINUED DRUG PRODUCT LIST

ISOSORBIDE DINITRATE

TABLET;SUBLINGUAL

ISORDIL

that product was not discontinued or  
 withdrawn for safety or efficacy  
 reasons\*\*

ISOSORBIDE DINITRATE

HIKMA INTL PHARMS

2.5MG

A086054 001 Oct 29, 1987

5MG

A086055 001 Nov 02, 1987

MUTUAL PHARM

2.5MG

A084204 001 Sep 18, 1986

5MG

A086168 001 Sep 18, 1986

10MG

A087545 001 Sep 18, 1986

SANDOZ

2.5MG

A086225 001 Feb 19, 1988

5MG

A086222 001 Feb 19, 1988

WATSON LABS

2.5MG \*\*Federal Register determination  
 that product was not discontinued or  
 withdrawn for safety or efficacy  
 reasons\*\*

A086033 001 Feb 26, 1988

5MG \*\*Federal Register determination  
 that product was not discontinued or  
 withdrawn for safety or efficacy  
 reasons\*\*

A086031 001 Sep 29, 1987

SORBITRATE

ASTRAZENECA

2.5MG

N016191 002 Apr 01, 1996

5MG

N016191 001 Apr 01, 1996

TABLET, CHEWABLE;ORAL

SORBITRATE

ASTRAZENECA

5MG

N016776 002 Apr 01, 1996

10MG

N016776 003 Apr 01, 1996

TABLET, EXTENDED RELEASE;ORAL

ISORDIL

WYETH AYERST

40MG

N012882 001 Jul 29, 1988

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISMO

PROMIUS PHARMA

20MG

N019091 001 Dec 30, 1991

TABLET, EXTENDED RELEASE;ORAL

IMDUR

SCHERING PLOUGH

30MG

N020225 001 Aug 12, 1993

60MG

N020225 002 Aug 12, 1993

120MG

N020225 003 Mar 30, 1995

ISOSORBIDE MONONITRATE

ACTAVIS ELIZABETH

30MG

A075306 001 Dec 31, 1998

60MG

A075306 002 Dec 31, 1998

ALKERMES GAINESVILLE

60MG

A075041 001 Sep 22, 1998

IVAX SUB TEVA PHARMS

30MG

A075448 002 Aug 07, 2001

60MG

A075448 001 Jun 19, 2000

120MG

A075448 003 Aug 07, 2001

SKYEPHARMA AG

60MG

A075166 001 Oct 07, 1999

ISOSULFAN BLUE

INJECTABLE;INJECTION

LYMPHAZURIN

COVIDIEN

1% \*\*Federal Register determination  
 that product was not discontinued or  
 withdrawn for safety or efficacy  
 reasons\*\*

N018310 001

ISOTRETINOIN

CAPSULE;ORAL

ACCUANE

HOFFMANN LA ROCHE

10MG

N018662 002 May 07, 1982

20MG

N018662 004 Mar 28, 1983

40MG

N018662 003 May 07, 1982

ISRADIPINE

CAPSULE;ORAL

DYNACIRC

SMITHKLINE BEECHAM

2.5MG

N019546 001 Dec 20, 1990

5MG

N019546 002 Dec 20, 1990

TABLET, EXTENDED RELEASE;ORAL

DYNACIRC CR

GLAXOSMITHKLINE LLC

5MG \*\*Federal Register determination  
 that product was not discontinued or  
 withdrawn for safety or efficacy

N020336 001 Jun 01, 1994

## DISCONTINUED DRUG PRODUCT LIST

ISRADIPINE

TABLET, EXTENDED RELEASE;ORAL  
DYNACIRC CR

reasons\*\*

10MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020336 002 Jun 01, 1994

ITRACONAZOLE

INJECTABLE; INJECTION  
SPORANOX  
JANSSEN PHARMS

10MG/ML

N020966 001 Mar 30, 1999

IVERMECTIN

TABLET; ORAL  
STROMEKTOL  
MERCK SHARP DOHME

6MG

N050742 001 Nov 22, 1996

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

APOTHECON

EQ 500MG BASE

A060516 001

EQ 500MG BASE

A061911 001

EQ 500MG BASE

A062726 001 Mar 06, 1987

INJECTABLE; INJECTION

KANAMYCIN

HIKMA MAPLE

EQ 1GM BASE/3ML

A062324 003

EQ 75MG BASE/2ML

A062324 001

EQ 500MG BASE/2ML

A062324 002

KANAMYCIN SULFATE

ABRAXIS PHARM

EQ 1GM BASE/3ML

A062504 003 Apr 05, 1984

EQ 75MG BASE/2ML

A062504 001 Apr 05, 1984

EQ 500MG BASE/2ML

A062504 002 Apr 05, 1984

INTL MEDICATION

EQ 1GM BASE/3ML

A062466 002 Sep 30, 1983

EQ 500MG BASE/2ML

A062466 001 Sep 30, 1983

LOCH

EQ 1GM BASE/3ML

A063025 001 Jul 31, 1992

EQ 75MG BASE/2ML

A063021 001 Jul 31, 1992

EQ 500MG BASE/2ML

A063022 001 Jul 31, 1992

PHARMAFAIR

EQ 1GM BASE/3ML

A062669 001 May 07, 1987

EQ 75MG BASE/2ML

A062668 001 May 07, 1987

EQ 500MG BASE/2ML

A062672 001 May 07, 1987

SOLOPAK

EQ 1GM BASE/3ML

A062605 002 Feb 26, 1986

EQ 75MG BASE/2ML

A062605 003 Feb 26, 1986

EQ 500MG BASE/2ML

A062605 001 Feb 26, 1986

WARNER CHILCOTT

EQ 1GM BASE/3ML

A063092 001 Oct 11, 1989

WATSON LABS

EQ 1GM BASE/3ML

A062520 003 May 09, 1985

KANTREX

APOTHECON

EQ 1GM BASE/3ML

A061655 002

EQ 1GM BASE/3ML

A061901 002

EQ 1GM BASE/3ML

A062564 003 Sep 21, 1984

EQ 75MG BASE/2ML

A061655 003

EQ 75MG BASE/2ML

A061901 003

EQ 75MG BASE/2ML

A062564 001 Sep 21, 1984

EQ 500MG BASE/2ML

A061655 001

EQ 500MG BASE/2ML

A061901 001

EQ 500MG BASE/2ML

A062564 002 Sep 21, 1984

KLEBCIL

KING PHARMS

EQ 1GM BASE/3ML

A062170 003

EQ 75MG BASE/2ML

A062170 001

EQ 500MG BASE/2ML

A062170 002

KETOCONAZOLE

CREAM; TOPICAL

NIZORAL

JANSSEN PHARMA

2%

N019084 001 Dec 31, 1985

SUSPENSION; ORAL

NIZORAL

JANSSEN PHARMA

100MG/5ML

A070767 001 Nov 07, 1986

TABLET; ORAL

KETOCONAZOLE

AAIPHARMA LLC

200MG

A075341 001 Jul 27, 1999

APOTEX

200MG

A075912 001 Jan 10, 2002

MUTUAL PHARMA

200MG

A075314 001 Jun 15, 1999

PLIVA

200MG

A075362 001 Jun 15, 1999

## DISCONTINUED DRUG PRODUCT LIST

KETOCONAZOLE

## TABLET; ORAL

## KETOCONAZOLE

TEVA	200MG	A074971	001	Jun 15, 1999
NIZORAL				
JANSSEN PHARMS	200MG	N018533	001	

KETOPROFEN

## CAPSULE; ORAL

## KETOPROFEN

SANDOZ	50MG	A074024	001	Dec 29, 1995
	75MG	A074024	002	Dec 29, 1995
TEVA	25MG	A073515	001	Dec 22, 1992
ORUDIS				
WYETH AYERST	25MG	N018754	001	Jul 31, 1987
	50MG	N018754	002	Jan 09, 1986
	75MG	N018754	003	Jan 09, 1986

## CAPSULE, EXTENDED RELEASE; ORAL

## KETOPROFEN

ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997
ORUVAIL				
WYETH PHARMS INC	100MG	N019816	003	Feb 08, 1995
	150MG	N019816	002	Feb 08, 1995
	200MG	N019816	001	Sep 24, 1993

## FILM; ORAL

## NEXCEDE

NOVARTIS	12.5MG	N022470	001	Nov 25, 2009
----------	--------	---------	-----	--------------

## TABLET; ORAL

## ACTRON

BAYER	12.5MG	N020499	001	Oct 06, 1995
-------	--------	---------	-----	--------------

## KETOPROFEN

PERRIGO	12.5MG	A075364	001	Feb 07, 2002
---------	--------	---------	-----	--------------

## ORUDIS KT

WYETH CONS	12.5MG	N020429	001	Oct 06, 1995
------------	--------	---------	-----	--------------

\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

KETOROLAC TROMETHAMINE

## INJECTABLE; INJECTION

## KETOROLAC TROMETHAMINE

AMPHASTAR PHARM	15MG/ML	A076209	001	Jul 21, 2004
	30MG/ML	A076209	002	Jul 21, 2004
APOTEX INC	15MG/ML	A075631	002	Jun 29, 2001
	30MG/ML	A075626	001	Jul 24, 2001
	30MG/ML	A075631	001	Jun 29, 2001
	30MG/ML	A077201	001	Oct 14, 2005
APOTHECON	15MG/ML	A075348	001	Nov 28, 2000
	30MG/ML	A075348	002	Nov 28, 2000
BEDFORD	15MG/ML	A075222	001	Apr 26, 1999
	15MG/ML			**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
	15MG/ML	A075230	002	Oct 25, 1999
	30MG/ML	A075222	002	Apr 26, 1999
	30MG/ML			**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
	30MG/ML	A075228	001	Apr 26, 1999
	30MG/ML			**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
	30MG/ML	A075230	001	Oct 25, 1999
GLAND PHARMA LTD	15MG/ML	A076722	001	Jul 27, 2004
	30MG/ML	A076722	002	Jul 27, 2004
HIKMA MAPLE	15MG/ML	A075299	001	Nov 03, 1999
	15MG/ML	A075772	001	Jul 21, 2004
	30MG/ML	A075299	002	Nov 03, 1999
	30MG/ML	A075772	002	Jul 21, 2004
HOSPIRA	15MG/ML	A074801	001	Jun 05, 1997
	30MG/ML	A074801	002	Jun 05, 1997
LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008
	30MG/ML	A078145	002	Jan 14, 2008
SANDOZ	15MG/ML	A076271	001	Oct 06, 2004
SUN PHARMA GLOBAL	15MG/ML	A078737	001	Oct 06, 2008

**DISCONTINUED DRUG PRODUCT LIST**KETOROLAC TROMETHAMINE

## INJECTABLE; INJECTION

## KETOROLAC TROMETHAMINE

	30MG/ML	A078737 002	Oct 06, 2008
WOCKHARDT	30MG/ML	A077943 001	Mar 27, 2007
TORADOL			
ROCHE PALO	15MG/ML	N019698 001	Nov 30, 1989
	30MG/ML	N019698 002	Nov 30, 1989
SOLUTION/DROPS; OPHTHALMIC			
ACULAR PRESERVATIVE FREE			
ALLERGAN	0.5%	N020811 001	Nov 03, 1997
KETOROLAC TROMETHAMINE			
AKORN	0.45%	A203376 001	Feb 10, 2014
TABLET; ORAL			
KETOROLAC TROMETHAMINE			
CYCLE PHARMS LTD	10MG	A074790 001	Jun 26, 1997
WATSON LABS	10MG	A074955 001	Sep 19, 1997
TORADOL			
ROCHE PALO	10MG	N019645 001	Dec 20, 1991

KETOTIFEN FUMARATE

## SOLUTION/DROPS; OPHTHALMIC

## KETOTIFEN FUMARATE

## APOTEX INC

EQ 0.025% BASE

A077354 001 May 09, 2006

KRYPTON, KR-81M

## GAS; INHALATION

## MPI KRYPTON 81M GENERATOR

## GE HEALTHCARE

N/A

N018088 001

LABETALOL HYDROCHLORIDE

## INJECTABLE; INJECTION

## LABETALOL HYDROCHLORIDE

APOTEX INC	5MG/ML	A076051 001	Jul 05, 2002
APOTHECON	5MG/ML	A075355 001	Nov 29, 1999
HOSPIRA	5MG/ML	A075242 001	Sep 30, 1999
NORMODYNE			
SCHERING	5MG/ML	N018686 001	Aug 01, 1984
TRANDATE			
PROMETHEUS LABS	5MG/ML	N019425 001	Dec 31, 1985
TABLET; ORAL			
LABETALOL HYDROCHLORIDE			
APOTHECON	100MG	A075223 001	Nov 20, 1998
	200MG	A075223 002	Nov 20, 1998
	300MG	A075223 003	Nov 20, 1998
MUTUAL PHARM	100MG	A075215 001	Jul 29, 1999
	200MG	A075215 002	Jul 29, 1999
	300MG	A075215 003	Jul 29, 1999
TEVA	100MG	A074989 001	Sep 30, 1998
	200MG	A074989 002	Sep 30, 1998
	300MG	A074989 003	Sep 30, 1998
NORMODYNE			
SCHERING	100MG	N018687 001	Aug 31, 1987
	200MG	N018687 002	Aug 01, 1984
	300MG	N018687 003	Aug 01, 1984
	400MG	N018687 004	Aug 01, 1984
TRANDATE			
CNTY LINE PHARMS	400MG	N018716 004	Aug 01, 1984

LACTULOSE

## SOLUTION; ORAL

## CHRONULAC

## SANOFI AVENTIS US

10GM/15ML

N017884 001

## DUPHALAC

## SOLVAY

10GM/15ML

A072372 001 Mar 22, 1989

## EVALOSE

## TEVA PHARMS

10GM/15ML

A073497 001 May 28, 1993

## LACTULOSE

## APOTEX INC

10GM/15ML

A075911 001 Feb 21, 2002

## MORTON GROVE

10GM/15ML

A071841 001 Sep 22, 1988

## PACO

10GM/15ML

A073160 001 Aug 25, 1992

## LAXILOSE

## NOSTRUM LABS

10GM/15ML

A073686 001 May 28, 1993



**DISCONTINUED DRUG PRODUCT LIST**LACTULOSE

SOLUTION;ORAL, RECTAL

ACILAC

NOSTRUM LABS

10GM/15ML

A073685 001 May 28, 1993

CEPHULAC

SANOFI AVENTIS US

10GM/15ML

N017657 001

GENERLAC

MORTON GROVE

10GM/15ML

A071842 001 Sep 27, 1988

HEPTALAC

TEVA PHARMS

10GM/15ML

A073504 001 May 28, 1993

LACTULOSE

APOTEX INC

10GM/15ML

A076645 001 Jul 28, 2003

PACO

10GM/15ML

A072029 001 Aug 25, 1992

ROXANE

10GM/15ML

A073590 001 May 29, 1992

SOLVAY

10GM/15ML

N017906 001

PORTALAC

SOLVAY

10GM/15ML

A072374 001 Mar 22, 1989

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

GLAXOSMITHKLINE LLC

50MG

N020241 006 Dec 27, 1994

250MG

N020241 004 Dec 27, 1994

LAMOTRIGINE

ACTAVIS TOTOWA

25MG

A078669 001 Apr 08, 2011

100MG

A078669 002 Apr 08, 2011

150MG

A078669 003 Apr 08, 2011

200MG

A078669 004 Apr 08, 2011

MATRIX LABS LTD

25MG

A078443 001 Feb 11, 2009

100MG

A078443 002 Feb 11, 2009

150MG

A078443 003 Feb 11, 2009

200MG

A078443 004 Feb 11, 2009

MYLAN

25MG

A077428 001 Jan 27, 2009

100MG

A077428 002 Jan 27, 2009

150MG

A077428 003 Jan 27, 2009

200MG

A077428 004 Jan 27, 2009

PHARMASCIENCE INC

25MG

A078310 001 Feb 04, 2009

100MG

A078310 002 Feb 04, 2009

150MG

A078310 003 Feb 04, 2009

200MG

A078310 004 Feb 04, 2009

ROXANE

25MG

A077392 001 Jan 27, 2009

100MG

A077392 002 Jan 27, 2009

150MG

A077392 003 Jan 27, 2009

200MG

A077392 004 Jan 27, 2009

SANDOZ

25MG

A078645 001 Jan 27, 2009

100MG

A078645 002 Jan 27, 2009

150MG

A078645 003 Jan 27, 2009

200MG

A078645 004 Jan 27, 2009

WOCKHARDT

25MG

A078982 001 Jan 27, 2009

100MG

A078982 002 Jan 27, 2009

150MG

A078982 003 Jan 27, 2009

200MG

A078982 004 Jan 27, 2009

TABLET, CHEWABLE;ORAL

LAMICTAL CD

GLAXOSMITHKLINE LLC

100MG

N020764 003 Aug 24, 1998

LAMOTRIGINE

SANDOZ

5MG

A078409 002 Jan 22, 2009

25MG

A078409 003 Jan 22, 2009

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL

PREVACID

TAKEDA PHARMS NA

15MG/PACKET

N021281 001 May 03, 2001

30MG/PACKET

N021281 002 May 03, 2001

INJECTABLE;INTRAVENOUS

PREVACID IV

TAKEDA PHARMS NA

30MG/VIAL

N021566 001 May 27, 2004

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL

LANSOPRAZOLE

ANI PHARMS INC

15MG

A078730 001 Oct 15, 2010

30MG

A078730 002 Oct 15, 2010

## DISCONTINUED DRUG PRODUCT LIST

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,250MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021507 002	Nov 14, 2003
------------------	--------------------	------------------------------------------------------------------------------------------------------------------	-------------	--------------

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,375MG		N021507 003	Nov 14, 2003
------------------	--------------------	--	-------------	--------------

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,500MG		N021507 004	Nov 14, 2003
------------------	--------------------	--	-------------	--------------

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

FOSRENOL

SHIRE LLC	EQ 250MG BASE		N021468 001	Oct 26, 2004
-----------	---------------	--	-------------	--------------

LAPYRIUM CHLORIDE; UNDECOYLUM CHLORIDE IODINE COMPLEX

SOLUTION;TOPICAL

VIRAC REX

CHESEBROUGH PONDS	0.5%;1.8%		N011914 001	
-------------------	-----------	--	-------------	--

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

APOTEX INC	0.005%		A077697 001	Mar 22, 2011
------------	--------	--	-------------	--------------

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

SANDOZ	10MG		A077085 001	Sep 13, 2005
	10MG		A077087 001	Sep 13, 2005
	20MG		A077085 002	Sep 13, 2005
	20MG		A077087 002	Sep 13, 2005

LEPIRUDIN RECOMBINANT

INJECTABLE;INJECTION

REFLUDAN

BAYER HLTHCARE	50MG/VIAL		N020807 001	Mar 06, 1998
----------------	-----------	--	-------------	--------------

LETROZOLE

TABLET;ORAL

LETROZOLE

ACTAVIS TOTOWA	2.5MG		A090292 001	Jul 13, 2011
IMPAX LABS	2.5MG		A091638 001	Jun 03, 2011
SYNTHON PHARMS	2.5MG		A090196 001	Jun 03, 2011

LEUCOVORIN CALCIUM

FOR SOLUTION;ORAL

LEUCOVORIN CALCIUM

HOSPIRA	EQ 60MG BASE/VIAL		N008107 003	Jan 30, 1987
---------	-------------------	--	-------------	--------------

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

ABIC	EQ 3MG BASE/ML		A089352 001	Jun 01, 1988
	EQ 50MG BASE/VIAL		A089353 001	Jun 01, 1988
ABRAXIS PHARM	EQ 50MG BASE/VIAL		A088939 001	Dec 01, 1986
	EQ 50MG BASE/VIAL		A070480 001	Jan 02, 1987
ELKINS SINN	EQ 100MG BASE/VIAL		A081224 001	Jun 03, 1994
	EQ 3MG BASE/ML		N008107 001	
HOSPIRA	EQ 50MG BASE/VIAL		N008107 002	
	EQ 100MG BASE/VIAL		N008107 004	May 23, 1988
	EQ 350MG BASE/VIAL		N008107 005	Apr 05, 1989
PHARMACHEMIE	EQ 350MG BASE/VIAL		A040262 001	Dec 15, 1999
	EQ 50MG BASE/VIAL		A089628 001	Apr 17, 1997
PHARMACHEMIE USA	EQ 100MG BASE/VIAL		A089915 001	Apr 17, 1997
	EQ 50MG BASE/VIAL		A081278 001	Sep 28, 1993

LEUCOVORIN CALCIUM PRESERVATIVE FREE

HOSPIRA	EQ 10MG BASE/ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A040147 001	Jun 25, 1997
---------	-----------------	------------------------------------------------------------------------------------------------------------------	-------------	--------------

LUITPOLD	EQ 50MG BASE/VIAL		A040338 001	Jan 31, 2001
----------	-------------------	--	-------------	--------------

TEVA PARENTERAL	EQ 10MG BASE/ML		A040332 001	Jun 28, 1999
-----------------	-----------------	--	-------------	--------------

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE/ML		A087439 001	Oct 19, 1982
	EQ 25MG BASE/VIAL		A089833 001	Jan 23, 1989
	EQ 50MG BASE/VIAL		A089465 001	Jan 23, 1989

## DISCONTINUED DRUG PRODUCT LIST

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

WELLCOVORIN

EQ 100MG BASE/VIAL

A089834 001 Jan 23, 1989

TABLET; ORAL

LEUCOVORIN CALCIUM

COREPHARMA

EQ 5MG BASE

A074544 001 Aug 28, 1997

EQ 25MG BASE

A074544 002 Aug 28, 1997

PAR PHARM

EQ 5MG BASE

A071600 001 Oct 14, 1987

EQ 25MG BASE

A071598 001 Oct 14, 1987

PHARMACHEMIE

EQ 5MG BASE

A073099 001 Mar 28, 1997

EQ 25MG BASE

A073101 001 Mar 28, 1997

SANDOZ

EQ 15MG BASE

A075327 001 Mar 24, 1999

XANODYNE PHARM

EQ 5MG BASE

N018459 001 Jan 30, 1986

EQ 10MG BASE

A071962 001 Nov 19, 1987

EQ 15MG BASE

A071104 001 Mar 04, 1987

WELLCOVORIN

GLAXOSMITHKLINE

EQ 5MG BASE

N018342 001 Jul 08, 1983

EQ 25MG BASE

N018342 002 Jul 08, 1983

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

ORTHO MCNEIL JANSSEN

EQ 65MG BASE

N021088 001 Mar 03, 2000

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

GENZYME

1MG/0.2ML

A075721 001 Nov 29, 2001

LUPRON

ABBVIE ENDOCRINE INC

1MG/0.2ML

N019010 001 Apr 09, 1985

LUPRON DEPOT

ABBVIE ENDOCRINE INC

3.75MG/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020011 001 Oct 22, 1990

LUPRON DEPOT-PED

ABBVIE ENDOCRINE INC

3.75MG/VIAL, 7.5MG/VIAL; 3.75MG/VIAL, 7.5M  
G/VIAL \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020263 003 Apr 16, 1993

7.5MG/VIAL, 7.5MG/VIAL; 7.5MG/VIAL, 7.5MG/  
VIAL \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020263 004 Apr 16, 1993

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION

LORFAN

ROCHE

1MG/ML

N010423 001

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

JANSSEN PHARMA

EQ 50MG BASE

N020035 001 Jun 18, 1990

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

APOTEX INC

100MG/ML

A090187 001 Aug 05, 2011

TABLET; ORAL

LEVETIRACETAM

ACTAVIS LABS FL INC

250MG

A077408 001 Mar 02, 2009

500MG

A077408 002 Mar 02, 2009

750MG

A077408 003 Mar 02, 2009

MYLAN

1GM

A078731 004 Feb 10, 2009

250MG

A078731 001 Feb 10, 2009

500MG

A078731 002 Feb 10, 2009

750MG

A078731 003 Feb 10, 2009

SANDOZ

1GM

A077324 004 Jan 15, 2009

250MG

A077324 001 Jan 15, 2009

500MG

A077324 002 Jan 15, 2009

750MG

A077324 003 Jan 15, 2009

WATSON LABS INC

1GM

A078797 001 Jan 15, 2009

250MG

A078797 002 Jan 15, 2009

500MG

A078797 003 Jan 15, 2009

## DISCONTINUED DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

750MG

A078797 004 Jan 15, 2009

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

SANDOZ

500MG

A091668 001 Nov 01, 2012

750MG

A091668 002 Nov 01, 2012

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

ALCON PHARMS LTD

EQ 0.5% BASE

N021114 001 Feb 23, 2000

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

APOTEX INC

0.25%

A075473 001 Aug 03, 2000

0.5%

A075475 001 Aug 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

PURDUE PHARMA LP

EQ 2.5MG BASE/ML

N020997 001 Aug 05, 1999

EQ 5MG BASE/ML

N020997 002 Aug 05, 1999

EQ 7.5MG BASE/ML

N020997 003 Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

NOVARTIS

EQ 0.05% BASE

N020219 001 Nov 10, 1993

LEVOCARNITINE

SOLUTION; ORAL

CARNITOR

SIGMA TAU

1GM/10ML

N018948 002 Apr 27, 1988

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

SANDOZ

5MG

A090486 001 Mar 26, 2013

LEVODOPA

CAPSULE; ORAL

BENDOPA

VALEANT PHARM INTL

100MG

N016948 003

250MG

N016948 001

500MG

N016948 002

DOPAR

SHIRE

100MG

N016913 003

250MG

N016913 001

500MG

N016913 002

LARODOPA

ROCHE

100MG

N016912 002

250MG

N016912 001

500MG

N016912 006

TABLET; ORAL

DOPAR

SHIRE

250MG

N016913 004

500MG

N016913 005

LARODOPA

ROCHE

100MG

N016912 005

250MG

N016912 003

500MG

N016912 004

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AKORN

EQ 500MG/20ML (EQ 25MG/ML)

A091644 001 Jun 20, 2011

EQ 750MG/30ML (EQ 25MG/ML)

A091644 002 Jun 20, 2011

SOLUTION/DROPS; OPHTHALMIC

IQUIX

SANTEN

1.5% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021571 001 Mar 01, 2004

## DISCONTINUED DRUG PRODUCT LIST

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

APOTEX INC

0.5%

A078282 001 Dec 20, 2010

TABLET;ORAL

LEVOFLOXACIN

WATSON LABS INC

250MG

A201484 001 Nov 22, 2013

500MG

A201484 002 Nov 22, 2013

750MG

A201484 003 Nov 22, 2013

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

FUSILEV

SPECTRUM PHARMS

EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)

N020140 002 Apr 29, 2011

\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

N020140 003 Apr 29, 2011

\*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

LEVOMEPRMAZINE

INJECTABLE;INJECTION

LEVOPROME

IMMUNEX

20MG/ML

N015865 001

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE;ORAL

ORLAAM

ROXANE

10MG/ML \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N020315 001 Jul 09, 1993

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

SOLVAY

0.05MG/ML;2%

A085010 001

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML;2%

N012125 002

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

NOVOCOL

0.05MG/ML;2%

A084697 001

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

GRAHAM CHEM

0.05MG/ML;2%

A084850 002 Oct 21, 1983

POLOCAINE W/ LEVONORDEFRIN

DENTSPLY PHARM

0.05MG/ML;2%

A089517 001 Apr 14, 1988

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML;2%;0.4%

N008592 007

LEVONORGESTREL

IMPLANT;IMPLANTATION

JADELLE

POPULATION COUNCIL

75MG/IMPLANT \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

N020544 001 Nov 01, 1996

LEVONORGESTREL

WYETH PHARMS INC

75MG/IMPLANT

N020627 001 Aug 15, 1996

NORPLANT

POPULATION COUNCIL

36MG/IMPLANT

N019897 001 Dec 10, 1990

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC

36MG/IMPLANT

N020088 001 Dec 10, 1990

TABLET;ORAL

LEVONORGESTREL

LUPIN LTD

0.75MG

A091328 001 Jan 23, 2013

WATSON LABS

0.75MG

A078666 001 Jun 24, 2009

PLAN B

TEVA BRANDED PHARM

0.75MG

N021045 001 Jul 28, 1999

**DISCONTINUED DRUG PRODUCT LIST**LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD

LILLY

EQ 50MG BASE

N012928 006

EQ 100MG BASE

N012928 004

SUSPENSION; ORAL

NOVRAD

LILLY

EQ 50MG BASE/5ML

N012928 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN

VALEANT PHARM INTL

2MG/ML

N008719 001 Dec 19, 1991

TABLET; ORAL

LEVO-DROMORAN

VALEANT PHARM INTL

2MG

N008720 001 Dec 19, 1991

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOLET

VINTAGE

0.025MG

N021137 001 Jun 06, 2003

0.05MG

N021137 002 Jun 06, 2003

0.075MG

N021137 003 Jun 06, 2003

0.088MG

N021137 004 Jun 06, 2003

0.1MG

N021137 005 Jun 06, 2003

0.112MG

N021137 006 Jun 06, 2003

0.125MG

N021137 007 Jun 06, 2003

0.137MG

N021137 008 Jun 06, 2003

0.15MG

N021137 009 Jun 06, 2003

0.175MG

N021137 010 Jun 06, 2003

0.2MG

N021137 011 Jun 06, 2003

0.3MG

N021137 012 Jun 06, 2003

LEVOTHYROXINE SODIUM

MERCK KGAA

0.025MG

A076752 001 Jun 16, 2005

0.05MG

A076752 002 Jun 16, 2005

0.075MG

A076752 003 Jun 16, 2005

0.088MG

A076752 004 Jun 16, 2005

0.1MG

A076752 005 Jun 16, 2005

0.112MG

A076752 006 Jun 16, 2005

0.125MG

A076752 007 Jun 16, 2005

0.15MG

A076752 008 Jun 16, 2005

0.175MG

A076752 009 Jun 16, 2005

0.2MG

A076752 010 Jun 16, 2005

0.3MG

A076752 011 Jun 16, 2005

LEVOXYL

KING PHARMS R AND D

0.3MG

N021301 012 May 25, 2001

NOVOthyrox

MERCK KGAA

0.025MG

N021292 001 May 31, 2002

0.05MG

N021292 002 May 31, 2002

0.075MG

N021292 003 May 31, 2002

0.088MG

N021292 004 May 31, 2002

0.1MG

N021292 005 May 31, 2002

0.112MG

N021292 006 May 31, 2002

0.125MG

N021292 007 May 31, 2002

0.137MG

N021292 008 May 31, 2002

0.15MG

N021292 009 May 31, 2002

0.175MG

N021292 010 May 31, 2002

0.2MG

N021292 011 May 31, 2002

0.3MG

N021292 012 May 31, 2002

LIDOCAINE

AEROSOL; ORAL

XYLOCAINE

ASTRAZENECA

10%

N014394 001

FILM, EXTENDED RELEASE; BUCCAL

DENTIPATCH

NOVEN

23MG/PATCH

N020575 001 May 21, 1996

OINTMENT; TOPICAL

ALPHACAINE

CARLISLE

5%

A084944 001

5%

A084946 001

5%

A084947 001

## DISCONTINUED DRUG PRODUCT LIST

LIDOCAINE

## OINTMENT; TOPICAL

## LIDOCAINE

GRAHAM CHEM

5%

A080210 001

## XYLOCAINE

ASTRAZENECA

5%

N008048 001

## PATCH; TOPICAL

## DENTIPATCH

NOVEN

46.1MG/PATCH

N020575 002 May 21, 1996

## SOLUTION; TOPICAL

## XYLOCAINE

ASTRAZENECA

5%

N014127 001

## SUPPOSITORY; RECTAL

## XYLOCAINE

ASTRAZENECA

100MG

N013077 001

LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## ALPHACAINE HYDROCHLORIDE

CARLISLE

2%

A084721 001

## LIDOCAINE HYDROCHLORIDE

ABBOTT

10%

A087980 001 Feb 02, 1983

20%

A089362 001 May 25, 1988

ABRAXIS PHARM

1%

A080420 001

1%

A086761 001

1.5%

A080420 005

2%

A080420 002

2%

A080420 004

2%

A086761 002

2%

N017508 001

4%

N017508 002

20%

N017508 004

AKORN

1%

A085037 001

2%

A085037 002

BEL MAR

1%

A080710 001

2%

A080760 001

DELL LABS

1%

A083387 001

2%

A083388 001

ELKINS SINN

0.5%

A085131 001

4%

A084626 001

GD SEARLE LLC

1%

A083135 001

2%

A083135 002

GRAHAM CHEM

2%

A080504 001

HIKMA MAPLE

1%

A080407 001

2%

A080407 002

HOSPIRA

1%

A040013 001 Jun 23, 1995

1.5%

A088330 001 May 17, 1984

2%

A088331 001 May 17, 1984

INTL MEDICATION

1%

N017701 002

1GM/VIAL

N018543 001

2%

N017701 001

2GM/VIAL

N018543 002

LUITPOLD

2%

A083198 001

LYPHOMED

1%

A080390 001

2%

A080390 002

MILES

1%

A080414 001

2%

A080414 002

WATSON LABS

1%

A080377 001

1%

A083627 001

2%

A080377 002

2%

A083627 002

WYETH AYERST

1%

A083083 001

2%

A083083 002

LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

100MG/100ML

N018461 001

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

200MG/100ML

N018967 001 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%

HOSPIRA

200MG/100ML

A083158 005

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT

200MG/100ML

N018954 001 Jul 09, 1985

HOSPIRA

200MG/100ML

N018388 001

**DISCONTINUED DRUG PRODUCT LIST**LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	400MG/100ML	N018967 002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%			
HOSPIRA	400MG/100ML	A083158 006	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	800MG/100ML	N018967 003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER			
HOSPIRA	1.5%	A088326 001	Jul 31, 1984
	10%	A088367 001	Jul 31, 1984
	20%	A088368 001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE			
HIKMA MAPLE	1%	A084625 001	
	2%	A084625 002	
INTL MEDICATION	4%	N017702 002	
LIDOCATON			
PHARMATON	2%	A084727 001	Aug 17, 1983
LIDOPEN			
MERIDIAN MEDCL TECHN	10%	N017549 001	
XYLOCAINE			
ASTRAZENECA	1%	N010418 005	
	1.5%	N010418 009	
	2%	N010418 007	
XYLOCAINE DENTAL			
DENTSPLY PHARM	2%	N021380 001	
XYLOCAINE PRESERVATIVE FREE			
FRESENIUS KABI USA	10%	N016801 003	
INJECTABLE; SPINAL			
XYLOCAINE 1.5% W/ DEXTROSE 7.5%			
FRESENIUS KABI USA	1.5%	N016297 001	
XYLOCAINE 5% W/ GLUCOSE 7.5%			
ASTRAZENECA	5%	N010496 002	Jul 07, 1982
JELLY; TOPICAL			
ANESTACON			
BANNER PHARMACAPS	2%	A080429 001	
LIDOCAINE HYDROCHLORIDE			
TEVA PHARMS USA	2%	A081318 001	Apr 29, 1993
SOLUTION; ORAL			
LIDOCAINE HYDROCHLORIDE VISCOUS			
ACTAVIS MID ATLANTIC	2%	A086578 001	
INTL MEDICATION	2%	A086389 001	Feb 02, 1982
SOLUTION; TOPICAL			
LARYNGOTRACHEAL ANESTHESIA KIT			
KENDALL IL	4%	A087931 001	Jun 10, 1983
LIDOCAINE HYDROCHLORIDE			
PACO	4%	A089688 001	Jun 30, 1989
LTA II KIT			
HOSPIRA	4%	A088542 001	Jul 31, 1984
PEDIATRIC LTA KIT			
ABBOTT	2%	A088572 001	Jul 31, 1984
HOSPIRA	2%	A085995 001	

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

## INJECTABLE; INJECTION

## TERRAMYCIN

PFIZER	2%; 50MG/ML	A060567 001	
	2%; 125MG/ML	A060567 002	

LIDOCAINE; PRILUCAINE

## DISC; TOPICAL

## EMLA

ASTRAZENECA	2.5%; 2.5%	N020962 001	Feb 04, 1998
-------------	------------	-------------	--------------

LINCOMYCIN HYDROCHLORIDE

## CAPSULE; ORAL

## LINCOCIN

PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316 001	
	EQ 500MG BASE	N050316 002	

## INJECTABLE; INJECTION

## LINCOMYCIN HYDROCHLORIDE

WATSON LABS	EQ 300MG BASE/ML	A063180 001	Apr 16, 1991
-------------	------------------	-------------	--------------



## DISCONTINUED DRUG PRODUCT LIST

LINDANE

CREAM; TOPICAL

KWELL

REED AND CARNRICK

1%

A084218 001

1%

N006309 001

LOTION; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084989 001

KWELL

REED AND CARNRICK

1%

A084218 002

1%

N006309 003

SCABENE

STIEFEL

1%

A086769 001

SHAMPOO; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084988 001

KWELL

REED AND CARNRICK

1%

A084219 001

1%

N010718 001

SCABENE

STIEFEL

1%

A087940 001 Apr 08, 1983

LINEZOLID

TABLET; ORAL

ZYVOX

PHARMACIA AND UPJOHN

400MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

WATSON LABS

EQ 0.025MG BASE

A085755 001 Jan 25, 1982

EQ 0.05MG BASE

A085753 001 Feb 03, 1982

LIOTRIX (T4;T3)

TABLET; ORAL

EUTHROID-0.5

PARKE DAVIS

0.0075MG;0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS

0.015MG;0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS

0.03MG;0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS

0.045MG;0.045MG

N016680 004

THYROLAR-5

FOREST LABS

0.0625MG;0.25MG

N016807 006

LISINAPRIL

TABLET; ORAL

LISINAPRIL

SANDOZ

2.5MG

A075903 001 Jul 01, 2002

2.5MG

A075999 001 Jul 01, 2002

5MG

A075903 002 Jul 01, 2002

5MG

A075999 002 Jul 01, 2002

10MG

A075903 003 Jul 01, 2002

10MG

A075999 003 Jul 01, 2002

20MG

A075903 004 Jul 01, 2002

20MG

A075999 004 Jul 01, 2002

30MG

A075903 005 Jul 01, 2002

30MG

A075999 005 Jul 01, 2002

40MG

A075903 006 Jul 01, 2002

40MG

A075999 006 Jul 01, 2002

TEVA

2.5MG

A075783 001 Jul 01, 2002

5MG

A075783 002 Jul 01, 2002

10MG

A075783 003 Jul 01, 2002

20MG

A075783 004 Jul 01, 2002

30MG

A075783 005 Jul 01, 2002

40MG

A075783 006 Jul 01, 2002

PRINIVIL

MERCK

2.5MG

N019558 006 Jan 28, 1994

## DISCONTINUED DRUG PRODUCT LIST

LITHIUM CARBONATE

## CAPSULE; ORAL

## ESKALITH

NOVEN THERAP

300MG

N016860 001

## LITHIUM CARBONATE

## ABLE

150MG

A076823 001 Jun 29, 2004

300MG

A076121 001 Sep 27, 2001

300MG

A076823 002 Jun 29, 2004

600MG

A076823 003 Jun 29, 2004

APOTEX INC

300MG

A076795 001 Nov 22, 2004

HIKMA PHARMS LLC

600MG

A078763 001 Apr 15, 2008

USL PHARMA

300MG

A072542 001 Feb 01, 1989

WATSON LABS

300MG

A070407 001 Mar 19, 1987

## LITHONATE

SOLVAY

300MG

N016782 001

## TABLET; ORAL

## ESKALITH

JDS PHARMS

300MG

N017971 001

## LITHANE

BAYER PHARMS

300MG

N018833 001 Jul 18, 1985

## LITHIUM CARBONATE

HIKMA INTL PHARMS

300MG

A078715 001 Dec 28, 2010

PFIZER

300MG

N016834 001

## LITHOTABS

SOLVAY

300MG

N016980 001

## TABLET, EXTENDED RELEASE; ORAL

## ESKALITH CR

JDS PHARMS

450MG

N018152 001 Mar 29, 1982

## LITHIUM CARBONATE

## ABLE

300MG

A076382 001 Apr 21, 2003

## BARR

300MG

A076170 001 Jun 10, 2002

450MG

A076366 001 Aug 21, 2003

LITHIUM CITRATE

## SYRUP; ORAL

## LITHONATE

SOLVAY

EQ 300MG CARBONATE/5ML

N017672 001

LOMEFLOXACIN HYDROCHLORIDE

## TABLET; ORAL

## MAXAQUIN

PHARMACIA

EQ 400MG BASE

N020013 001 Feb 21, 1992

LOPERAMIDE HYDROCHLORIDE

## CAPSULE; ORAL

## IMODIUM

MCNEIL PED

2MG

N017690 001

## LOPERAMIDE HYDROCHLORIDE

ROXANE

2MG

A073080 001 Nov 27, 1991

SANDOZ

2MG

A072993 001 Aug 28, 1992

TEVA

2MG

A073122 001 Aug 30, 1991

## SOLUTION; ORAL

## IMODIUM

JANSSEN PHARMS

1MG/5ML

N019037 001 Jul 31, 1984

## LOPERAMIDE HYDROCHLORIDE

ALPHARMA US PHARMS

1MG/5ML

A073187 001 Sep 15, 1992

DURAMED PHARMS BARR

1MG/5ML

A074991 001 Dec 29, 1997

TEVA

1MG/5ML

A073478 001 Jun 23, 1995

WATSON LABS

1MG/5ML

A073062 001 May 28, 1993

## TABLET; ORAL

## LOPERAMIDE HYDROCHLORIDE

## ABLE

2MG

A073528 001 Nov 30, 1993

## PERRIGO

2MG

A074194 001 Oct 30, 1992

LORACARBEF

## CAPSULE; ORAL

## LORABID

KING PHARMS

200MG

N050668 001 Dec 31, 1991

400MG

N050668 002 Apr 05, 1996

## FOR SUSPENSION; ORAL

## LORABID

KING PHARMS

100MG/5ML

N050667 001 Dec 31, 1991

200MG/5ML

N050667 002 Dec 31, 1991

## DISCONTINUED DRUG PRODUCT LIST

LORATADINE

## SYRUP; ORAL

## CLARITIN HIVES RELIEF

SCHERING PLOUGH	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020641	003	Nov 19, 2003
-----------------	-------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------

## LORATADINE

APOTEX INC	1MG/ML	A075565	001	Oct 05, 2004
------------	--------	---------	-----	--------------

RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004
------------------	--------	---------	-----	--------------

## TABLET; ORAL

## LORATADINE

PERRIGO	10MG	N021512	001	Jun 24, 2004
---------	------	---------	-----	--------------

LORATADINE; PSEUDOEPHEDRINE SULFATE

## TABLET, EXTENDED RELEASE; ORAL

## LORATADINE AND PSEUDOEPHEDRINE SULFATE

ACTAVIS LABS FL INC	5MG;120MG	A076208	001	Jan 28, 2004
---------------------	-----------	---------	-----	--------------

LORAZEPAM

## INJECTABLE; INJECTION

## LORAZEPAM

AKORN	2MG/ML	A074974	001	Jul 23, 1998
-------	--------	---------	-----	--------------

BEDFORD	2MG/ML	A077076	001	Jul 13, 2005
---------	--------	---------	-----	--------------

	4MG/ML	A077076	002	Jul 13, 2005
--	--------	---------	-----	--------------

DAVA PHARMS INC	2MG/ML	A074793	001	Mar 16, 2000
-----------------	--------	---------	-----	--------------

	4MG/ML	A074793	002	Mar 16, 2000
--	--------	---------	-----	--------------

HIKMA MAPLE	2MG/ML	A074496	001	Sep 28, 1998
-------------	--------	---------	-----	--------------

	4MG/ML	A074496	002	Sep 28, 1998
--	--------	---------	-----	--------------

HOSPIRA	2MG/ML	A074280	001	May 27, 1994
---------	--------	---------	-----	--------------

	2MG/ML	A074300	001	Apr 12, 1994
--	--------	---------	-----	--------------

	4MG/ML	A074280	002	May 27, 1994
--	--------	---------	-----	--------------

	4MG/ML	A074300	003	Mar 19, 1997
--	--------	---------	-----	--------------

WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994
-------------	--------	---------	-----	--------------

	4MG/ML	A074276	002	Apr 15, 1994
--	--------	---------	-----	--------------

WATSON LABS INC	1MG/0.5ML	A074551	003	Sep 12, 1996
-----------------	-----------	---------	-----	--------------

	2MG/ML	A074535	001	Sep 12, 1996
--	--------	---------	-----	--------------

	2MG/ML	A074551	001	Sep 12, 1996
--	--------	---------	-----	--------------

	4MG/ML	A074535	002	Sep 12, 1996
--	--------	---------	-----	--------------

	4MG/ML	A074551	002	Sep 12, 1996
--	--------	---------	-----	--------------

## SOLUTION; ORAL

## LORAZEPAM

ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997
--------	-----------	---------	-----	--------------

## TABLET; ORAL

## LORAZ

QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
------------------	-------	---------	-----	--------------

	1MG	A070201	001	Aug 09, 1985
--	-----	---------	-----	--------------

	2MG	A070202	001	Aug 09, 1985
--	-----	---------	-----	--------------

## LORAZEPAM

AM THERAP	0.5MG	A070727	001	Mar 07, 1986
-----------	-------	---------	-----	--------------

	1MG	A070728	001	Mar 07, 1986
--	-----	---------	-----	--------------

	2MG	A070729	001	Mar 07, 1986
--	-----	---------	-----	--------------

HALSEY	0.5MG	A071434	001	Sep 01, 1987
--------	-------	---------	-----	--------------

	1MG	A071435	001	Sep 01, 1987
--	-----	---------	-----	--------------

	2MG	A071436	001	Sep 01, 1987
--	-----	---------	-----	--------------

MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
--------------	-------	---------	-----	--------------

	0.5MG	A072553	001	Mar 29, 1991
--	-------	---------	-----	--------------

	1MG	A070473	001	Dec 10, 1985
--	-----	---------	-----	--------------

	1MG	A072554	001	Mar 29, 1991
--	-----	---------	-----	--------------

	2MG	A070474	001	Dec 10, 1985
--	-----	---------	-----	--------------

	2MG	A072555	001	Mar 29, 1991
--	-----	---------	-----	--------------

PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
-----------	-------	---------	-----	--------------

	1MG	A070676	001	Dec 01, 1986
--	-----	---------	-----	--------------

	2MG	A070677	001	Dec 01, 1986
--	-----	---------	-----	--------------

SANDOZ	0.5MG	A071193	001	Apr 15, 1988
--------	-------	---------	-----	--------------

	1MG	A071194	001	Apr 15, 1988
--	-----	---------	-----	--------------

	2MG	A071195	001	Apr 15, 1988
--	-----	---------	-----	--------------

SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
------------	-------	---------	-----	--------------

	1MG	A071246	001	Feb 09, 1987
--	-----	---------	-----	--------------

	2MG	A071247	001	Feb 09, 1987
--	-----	---------	-----	--------------

USL PHARMA	1MG	A070539	001	Dec 22, 1986
------------	-----	---------	-----	--------------

	2MG	A070540	001	Dec 22, 1986
--	-----	---------	-----	--------------

WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
-----------------	-----	---------	-----	--------------

	2MG	A071039	001	Jan 12, 1988
--	-----	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

LORAZEPAM

TABLET; ORAL

LORAZEPAM

WATSON LABS	0.5MG	A071086 001	Mar 23, 1987
	0.5MG	A071117 001	Jul 24, 1986
	1MG	A071087 001	Mar 23, 1987
	1MG	A071118 001	Jul 24, 1986
	2MG	A071088 001	Mar 23, 1987
	2MG	A071110 001	Jul 24, 1986

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

WATSON LABS	25MG	A091129 001	Oct 06, 2010
	50MG	A091129 002	Oct 06, 2010
	100MG	A091129 003	Oct 06, 2010

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

PHARMOS	0.5%	N020841 001	Mar 09, 1998
---------	------	-------------	--------------

LOVASTATIN

TABLET; ORAL

MEVACOR

MERCK	10MG	N019643 002	Mar 28, 1991
	20MG	N019643 003	Aug 31, 1987
	40MG	N019643 004	Dec 14, 1988

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

ANDRX LABS LLC	10MG	N021316 001	Jun 26, 2002
----------------	------	-------------	--------------

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

WATSON LABS	EQ 25MG BASE/ML	N017658 001	
-------------	-----------------	-------------	--

INJECTABLE; INJECTION

LOXITANE IM

WATSON LABS	EQ 50MG BASE/ML	N018039 001	
-------------	-----------------	-------------	--

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

WATSON LABS	EQ 5MG BASE	N017525 001	
	EQ 10MG BASE	N017525 002	
	EQ 25MG BASE	N017525 003	
	EQ 50MG BASE	N017525 004	

TABLET; ORAL

LOXITANE

WATSON LABS	EQ 10MG BASE	N017525 006	
	EQ 25MG BASE	N017525 007	
	EQ 50MG BASE	N017525 008	

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

EMD SERONO	75 IU/VIAL	N021322 001	Oct 08, 2004
------------	------------	-------------	--------------

LYPRESSIN

SOLUTION; NASAL

DIAPID

NOVARTIS	0.185MG/ML	N016755 001	
----------	------------	-------------	--

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN

	30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML	N019006 001	Apr 04, 1984
--	-----------------------------------------------------------------------------------------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG /100ML; 500MG/100ML	N018252 001	
---------	-------------------------------------------------------------------	-------------	--

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC	14MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N018406 001	
-------------	-------------------------------------------------------------------	-------------	--

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N018406 002	Jul 08, 1982
-------------	-------------------------------------------------------------------	-------------	--------------

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG /100ML; 502MG/100ML	N019326 001	Jan 25, 1985
-----------------	-------------------------------------------------------------------	-------------	--------------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS	343MG; 20MG; 750MG	N022456 001	Dec 04, 2009
	343MG; 40MG; 750MG	N022456 002	Dec 04, 2009

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS	700MG; 20MG; 600MG	N021850 001	Mar 24, 2006
	700MG; 40MG; 600MG	N021850 002	Mar 24, 2006

MALATHION

LOTION; TOPICAL

MALATHION

MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009
------------------	------	-------------	--------------

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

GE HEALTHCARE	37.9MG/ML	N020652 001	Nov 26, 1997
---------------	-----------	-------------	--------------

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

BRACCO	3.49MG/GM	N020686 001	Dec 19, 1997
--------	-----------	-------------	--------------

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML	N019228 001	May 05, 1987
---------------	-----------------------	-------------	--------------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

HOSPIRA	10GM/100ML	N016269 002	
MILES	10GM/100ML	N016472 002	

MANNITOL 15%

HOSPIRA	15GM/100ML	N016269 003	
MILES	15GM/100ML	N016472 005	

MANNITOL 20%

B BRAUN	20GM/100ML	N014738 001	
HOSPIRA	20GM/100ML	N016269 004	
MILES	20GM/100ML	N016472 004	

MANNITOL 25%

ABRAXIS PHARM	12.5GM/50ML	A086754 001	
ASTRAZENECA	12.5GM/50ML	A089239 001	May 06, 1987
	12.5GM/50ML	A089240 001	May 06, 1987
HOSPIRA	12.5GM/50ML	N016269 005	
MERCK	12.5GM/50ML	N005620 001	
WATSON LABS	12.5GM/50ML	A087460 001	Jun 27, 1983

MANNITOL 5%

HOSPIRA	5GM/100ML	N016269 001	
---------	-----------	-------------	--

POWDER; INHALATION

ARIDOL KIT

PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368 001	Oct 05, 2010
---------------	----------------------------	-------------	--------------

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN	5GM/100ML	N016704 002	
---------	-----------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

HOSPIRA 540MG/100ML; 2.7GM/100ML A080224 001

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA 540MG/100ML; 2.7GM/100ML N017636 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

NOVARTIS 25MG N017543 001

50MG N017543 002

75MG N017543 003 Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP 25MG A072129 001 Jan 14, 1988

50MG A072130 001 Jan 14, 1988

75MG A072131 001 Jan 14, 1988

WATSON LABS 25MG A071943 001 Dec 30, 1987

25MG A072162 001 Jun 01, 1988

50MG A071944 001 Dec 30, 1987

50MG A072163 001 Jun 01, 1988

75MG A071945 001 Dec 30, 1987

75MG A072164 001 Jun 01, 1988

MASOPROCOL

CREAM; TOPICAL

ACTINEX

UNIV AZ CANCER CTR 10% N019940 001 Sep 04, 1992

MAZINDOL

TABLET; ORAL

MAZANOR

WYETH AYERST 1MG N017980 002

2MG N017980 001

SANOREX

NOVARTIS 1MG \*\*Federal Register determination N017247 001

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

2MG \*\*Federal Register determination N017247 002

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*MEBENDAZOLE

TABLET, CHEWABLE; ORAL

VERMOX

JANSSEN PHARMS 100MG N017481 001

MEBUTAMATE

TABLET; ORAL

DORMATE

MEDPOINTE PHARM HLC 600MG N017374 001

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

TARGACEPT 2.5MG N010251 001

MECASERMIN RINFABATE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPLEX

INSMED 36MG/0.6ML N021884 001 Dec 12, 2005

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

CITRON PHARMA LLC 12.5MG N010721 006

25MG N010721 004

50MG N010721 001 Jan 20, 1982

MECLIZINE HYDROCHLORIDE

ABC HOLDING 12.5MG A085253 001

25MG A085252 001

AMNEAL PHARMS 50MG A201451 003 Feb 23, 2011

ANABOLIC 25MG A085891 001

BUNDY 12.5MG A084382 001

25MG A084872 001

## DISCONTINUED DRUG PRODUCT LIST

MECLIZINE HYDROCHLORIDE

## TABLET; ORAL

## MECLIZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	12.5MG	A083784	001	
	12.5MG	A084975	001	
	25MG	A084657	001	
KV PHARM	12.5MG	A085524	001	
	25MG	A085523	001	
MYLAN PHARMS INC	50MG	A202640	003	Sep 17, 2012
PAR PHARM	50MG	A089674	001	Mar 31, 1988
PLIVA	12.5MG	A088732	001	Dec 11, 1985
	25MG	A088734	001	Dec 11, 1985
SUPERPHARM	12.5MG	A089113	001	Aug 20, 1985
	25MG	A089114	001	Aug 20, 1985
UDL	12.5MG	A088256	001	Jun 13, 1983
	25MG	A088257	001	Jun 13, 1983
VANGARD	12.5MG	A087877	001	Apr 20, 1982
	25MG	A087620	001	Jan 04, 1982
WATSON LABS	12.5MG	A085195	001	
	12.5MG	A085269	001	
	25MG	A085740	001	

## TABLET, CHEWABLE; ORAL

## ANTIVERT

CITRON PHARMA LLC	25MG	N010721	005	
MECLIZINE HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	25MG	A084976	001	
NEXGEN PHARMA INC	25MG	A086392	001	
PLIVA	25MG	A088733	001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

## CREAM; TOPICAL

## MECLAN

JOHNSON AND JOHNSON	1%	N050518	001	
---------------------	----	---------	-----	--

MECLOFENAMATE SODIUM

## CAPSULE; ORAL

## MECLODIUM

QUANTUM PHARMICS	EQ 50MG BASE	A071380	001	Jul 14, 1987
	EQ 100MG BASE	A071381	001	Jul 14, 1987

## MECLOFENAMATE SODIUM

AM THERAP	EQ 50MG BASE	A071362	001	Feb 10, 1987
	EQ 100MG BASE	A071363	001	Feb 10, 1987
BARR	EQ 50MG BASE	A072848	001	Mar 20, 1989
	EQ 100MG BASE	A072809	001	Mar 20, 1989
PAR PHARM	EQ 50MG BASE	A072077	001	Mar 10, 1988
	EQ 100MG BASE	A072078	001	Mar 10, 1988
SANDOZ	EQ 50MG BASE	A072262	001	Nov 29, 1988
	EQ 100MG BASE	A072263	001	Nov 29, 1988
USL PHARMA	EQ 50MG BASE	A071007	001	Mar 25, 1988
	EQ 100MG BASE	A071008	001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710	001	Jun 15, 1988
	EQ 100MG BASE	A071684	001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400	001	Nov 25, 1986
	EQ 50MG BASE	A071468	001	Apr 15, 1987
	EQ 50MG BASE	A071640	001	Aug 11, 1987
	EQ 100MG BASE	A070401	001	Nov 25, 1986
	EQ 100MG BASE	A071469	001	Apr 15, 1987
	EQ 100MG BASE	A071641	001	Aug 11, 1987

## MECLOMEN

PARKE DAVIS	EQ 50MG BASE	N018006	001	
	EQ 100MG BASE	N018006	002	

MEDROXYPROGESTERONE ACETATE

## INJECTABLE; INJECTION

## DEPO-PROVERA

PHARMACIA AND UPJOHN	100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012541	002	
----------------------	---------------------------------------------------------------------------------------------------------------------------	---------	-----	--

## MEDROXYPROGESTERONE ACETATE

TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004
-----------------	----------	---------	-----	--------------

## TABLET; ORAL

## AMEN

AMARIN PHARMS	10MG	A083242	001	
---------------	------	---------	-----	--

**DISCONTINUED DRUG PRODUCT LIST**MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

CURRETAB

SOLVAY

10MG

A085686 001

CYCRIN

ESI

2.5MG

A081239 001 Oct 30, 1992

5MG

A081240 001 Oct 30, 1992

10MG

A089386 001 Sep 09, 1987

MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR

2.5MG

A040311 001 Dec 01, 1999

5MG

A040311 002 Dec 01, 1999

10MG

A040311 003 Dec 01, 1999

USL PHARMA

10MG

A088484 001 Jul 26, 1984

MEDRYSONE

SUSPENSION; OPHTHALMIC

HMS

ALLERGAN

1%

N016624 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

ROCHE

250MG

N019591 001 May 02, 1989

MEFLOQUINE HYDROCHLORIDE

HIKMA PHARMS LLC

250MG

A077699 001 Apr 21, 2010

US ARMY WALTER REED

250MG

N019578 001 May 02, 1989

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

APOTEX INC

40MG/ML

A077404 001 Feb 16, 2006

TABLET; ORAL

MEGACE

BRISTOL MYERS SQUIBB

20MG

N016979 001

40MG

N016979 002

MEGESTROL ACETATE

TEVA

40MG

A074745 001 Feb 27, 1998

USL PHARMA

20MG

A070646 001 Oct 02, 1987

40MG

A070647 001 Oct 02, 1987

MELOXICAM

TABLET; ORAL

MELOXICAM

COREPHARMA

7.5MG

A077930 001 Jul 19, 2006

15MG

A077930 002 Jul 19, 2006

CR DOUBLE CRANE

7.5MG

A078039 001 Dec 14, 2006

15MG

A078039 002 Dec 14, 2006

MUTUAL PHARM

7.5MG

A077935 001 Jul 19, 2006

15MG

A077935 002 Jul 19, 2006

MYLAN

7.5MG

A077934 001 Jul 20, 2006

15MG

A077934 002 Jul 20, 2006

ROXANE

7.5MG

A077925 001 Jul 19, 2006

15MG

A077925 002 Jul 19, 2006

YABAO PHARM

7.5MG

A077933 001 Jul 19, 2006

15MG

A077933 002 Jul 19, 2006

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

MYLAN INSTITUTIONAL

EQ 50MG BASE/VIAL

A090299 001 Oct 27, 2009

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE

SUN PHARMA GLOBAL

5MG

A090058 001 May 05, 2010

10MG

A090058 002 May 05, 2010

MEMANTINE HYDROCHLORIDE

DR REDDYS LABS LTD

5MG

A090048 001 Apr 14, 2010

10MG

A090048 002 Apr 14, 2010

ORCHID HLTHCARE

5MG

A090044 001 Mar 12, 2012

10MG

A090044 002 Mar 12, 2012

TEVA PHARMS

5MG

A090052 001 Oct 25, 2011

10MG

A090052 002 Oct 25, 2011



## DISCONTINUED DRUG PRODUCT LIST

MENADIOL SODIUM DIPHOSPHATE

## INJECTABLE; INJECTION

KAPPADIONE

LILLY

10MG/ML

N005725 001

SYNKAYVITE

ROCHE

5MG/ML

N003718 004

10MG/ML

N003718 006

37.5MG/ML

N003718 008

## TABLET; ORAL

SYNKAYVITE

ROCHE

5MG

N003718 010

MENADIONE

## TABLET; ORAL

MENADIONE

LILLY

5MG

N002139 003

MENOTROPINS (FSH; LH)

## INJECTABLE; INJECTION

HUMEGON

ORGANON USA INC

75 IU/VIAL; 75 IU/VIAL

N020328 001 Sep 01, 1994

150 IU/VIAL; 150 IU/VIAL

N020328 002 Sep 01, 1994

MENOTROPINS

FERRING

75 IU/VIAL; 75 IU/VIAL

A073598 001 Jan 30, 1997

150 IU/VIAL; 150 IU/VIAL

A073599 001 Jan 30, 1997

PERGONAL

SERONO

75 IU/AMP; 75 IU/AMP

N017646 001

150 IU/AMP; 150 IU/AMP

N017646 002 May 20, 1985

REPRONEX

FERRING

150 IU/VIAL; 150 IU/VIAL

N021047 002 Aug 27, 1999

MEPENZOLATE BROMIDE

## SOLUTION; ORAL

CANTIL

SANOFI AVENTIS US

25MG/5ML

N010679 004

MEPERIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

DEMEROL

SANOFI AVENTIS US

25MG/ML

N005010 007

50MG/ML

N005010 002

75MG/ML

N005010 009

100MG/ML

N005010 003

MEPERIDINE HYDROCHLORIDE

ABBOTT

25MG/ML

A080388 001

50MG/ML

A080385 001

50MG/ML

A080387 001

75MG/ML

A080389 001

100MG/ML

A080386 001

ASTRAZENECA

25MG/ML

A089781 001 Mar 31, 1989

50MG/ML

A089782 001 Mar 31, 1989

50MG/ML

A089783 001 Mar 31, 1989

50MG/ML

A089784 001 Mar 31, 1989

75MG/ML

A089785 001 Mar 31, 1989

100MG/ML

A089786 001 Mar 31, 1989

100MG/ML

A089787 001 Mar 31, 1989

100MG/ML

A089788 001 Mar 31, 1989

BAXTER HLTHCARE

25MG/ML

A088279 001 Jun 15, 1984

50MG/ML

A088280 001 Jun 15, 1984

75MG/ML

A088281 001 Jun 15, 1984

100MG/ML

A088282 001 Jun 15, 1984

INTL MEDICATION

10MG/ML

A086332 001

PARKE DAVIS

50MG/ML

A080364 002

75MG/ML

A080364 003

100MG/ML

A080364 001

WATSON LABS

50MG/ML

A073444 001 Mar 17, 1992

100MG/ML

A073445 001 Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA

10MG/ML

A040305 001 Mar 10, 1999

INTL MEDICATION

10MG/ML

A081309 001 Aug 30, 1993

MALLINCKRODT

10MG/ML

A040163 001 May 12, 1997

WATSON LABS

10MG/ML

A073443 001 Mar 17, 1992

## DISCONTINUED DRUG PRODUCT LIST

MEPERIDINE HYDROCHLORIDE

SYRUP; ORAL

DEMEROL

SANOFI AVENTIS US 50MG/5ML N005010 005

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

DURAMED PHARMS BARR 50MG A040318 001 Oct 05, 1999

100MG A040318 002 Oct 05, 1999

MUTUAL PHARM 50MG A080448 001

100MG A080448 002

WATSON LABS 50MG A040186 001 Jun 30, 1997

100MG A040186 002 Jun 30, 1997

WYETH AYERST 50MG A080454 001

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

BAXTER HLTHCARE CORP 25MG/ML; 25MG/ML N011730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP EQ 15MG BASE/ML N008248 002

EQ 30MG BASE/ML N008248 001

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

NOVARTIS 100MG \*\*Federal Register determination N006008 001

that product was not discontinued or

withdrawn for safety or efficacy

reasons\*\*

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY 3% A084777 002 Apr 18, 1982

CARBOCAINE

EASTMAN KODAK 3% N012125 003

MEPIVACAINE HYDROCHLORIDE

GRAHAM CHEM 3% A083559 001

INTL MEDICATION 1% A087509 001 Oct 05, 1982

WATSON LABS 1% A088769 001 Nov 20, 1984

2% A088770 001 Nov 20, 1984

POLOCAINE

DENTSPLY PHARM 3% A088653 001 Aug 21, 1984

MEPREDNISONE

TABLET; ORAL

BETAPAR

SCHERING 4MG N016053 002

MEPROBAMATE

CAPSULE; ORAL

EQUANIL

WYETH AYERST 400MG N012455 002

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

MEDPOINTE PHARM HLC 200MG N011284 001

400MG N011284 002

TABLET; ORAL

AMOSENE

FERNDAL LABS 400MG A084030 001

BAMATE

ALRA 200MG A080380 001

400MG A080380 002

EQUANIL

WYETH AYERST 200MG N010028 005

400MG N010028 004

MEPRIAM

TEVA 400MG N016069 001

MEPROBAMATE

BARR 600MG A084230 001

ELKINS SINN 200MG N015426 002

400MG N015426 001

HEATHER 400MG N016928 003

## DISCONTINUED DRUG PRODUCT LIST

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

	600MG	A084329 001	
IMPAX LABS	200MG	N014322 002	
	400MG	N014322 001	
IVAX SUB TEVA PHARMS	200MG	N015438 001	
	400MG	N015438 002	
	600MG	A084181 001	
IVC INDS	400MG	A084153 001	
LANNETT	200MG	N014882 002	
	400MG	N014882 001	
LEDERLE	400MG	A086299 001	
LEE KM	400MG	A089538 001	Nov 25, 1987
MALLARD	400MG	N015072 002	
MK LABS	200MG	N014368 004	
	400MG	N014368 002	
MUTUAL PHARM	200MG	A080699 001	
	400MG	A080699 002	
MYLAN	400MG	A083618 001	
NEXGEN PHARMA INC	200MG	A084220 001	
	400MG	A084589 001	
PARKE DAVIS	200MG	A084744 001	
	400MG	A084744 002	
PERRIGO	200MG	A084546 001	
	400MG	A084547 001	
PHARMAVITE	400MG	A084438 001	
PUREPAC PHARM	200MG	A084804 001	
	400MG	A084804 002	
PVT FORM	400MG	N014601 001	
ROXANE	600MG	A084332 001	
SANDOZ	200MG	N014547 002	
	400MG	A080655 001	
	400MG	N014547 001	
SCHERER LABS	400MG	A083343 001	
SOLVAY	200MG	A084435 001	
STANLABS PHARM	200MG	N014474 002	
	400MG	N014474 004	
TABLICAPS	400MG	A083494 001	
TARO	200MG	A200998 001	May 23, 2011
	400MG	A200998 002	May 23, 2011
USL PHARMA	200MG	A087825 001	Mar 18, 1982
	400MG	A087826 001	Mar 18, 1982
VALEANT PHARM INTL	200MG	N015139 006	
	400MG	N015139 005	
VANGARD	400MG	A088011 001	Jul 14, 1982
WATSON LABS	200MG	A085720 001	
	400MG	A085721 001	
	600MG	A084274 001	
	600MG	A085719 001	
WEST WARD	200MG	N015417 003	
	400MG	N015417 002	
WHITEWORTH TOWN PLSN	200MG	A083830 001	
	400MG	A083442 001	
MILTOWN			
MEDPOINTE PHARM HLC	200MG	N009698 004	
	400MG	N009698 002	
	600MG	A083919 001	
NEURAMATE			
HALSEY	200MG	N014359 002	
	400MG	N014359 001	
TRANMEP			
SOLVAY	400MG	A084369 001	
	400MG	N016249 001	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

AQUA PHARMS	2%;0.01%	N020922 001	Dec 10, 1999
-------------	----------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

MERCAPTOPYRINE

TABLET; ORAL  
PURINETHOL  
TEVA

50MG N009053 002

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION  
MERSALYL-THEOPHYLLINE  
WATSON LABS

100MG/ML; 50MG/ML A084875 001

MESALAMINE

SUPPOSITORY; RECTAL  
CANASA  
FOREST LABS INC  
ROWASA  
MEDA PHARMS

500MG N021252 001 Jan 05, 2001  
500MG N019919 001 Dec 18, 1990

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL  
SERENTIL

NOVARTIS EQ 25MG BASE/ML

N016997 001

INJECTABLE; INJECTION  
SERENTIL

NOVARTIS EQ 25MG BASE/ML

N016775 001

TABLET; ORAL

SERENTIL

NOVARTIS EQ 10MG BASE  
EQ 25MG BASE  
EQ 50MG BASE  
EQ 100MG BASE

N016774 001  
N016774 002  
N016774 003  
N016774 004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

WATSON LABS 0.1MG; 2MG

N013625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

WATSON LABS 0.05MG; 1MG

A071539 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS 0.05MG; 1MG

A070758 001 Jul 01, 1988

NORINYL 1+50 21-DAY

WATSON LABS 0.05MG; 1MG

N013625 002

NORINYL 1+80 21-DAY

GD SEARLE LLC 0.08MG; 1MG

N016724 001

ORTHO-NOVUM 1/50 21

ORTHO MCNEIL PHARM 0.05MG; 1MG

N012728 004

ORTHO-NOVUM 1/80 21

ORTHO MCNEIL PHARM 0.08MG; 1MG

N016715 001

ORTHO-NOVUM 10-21

ORTHO MCNEIL PHARM 0.06MG; 10MG

N012728 001

ORTHO-NOVUM 2-21

ORTHO MCNEIL PHARM 0.1MG; 2MG

N012728 005

TABLET; ORAL-28

NORETHIN 1/50M-28

WATSON LABS 0.05MG; 1MG

A071540 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS 0.05MG; 1MG

A070759 001 Jul 01, 1988

NORINYL 1+80 28-DAY

GD SEARLE LLC 0.08MG; 1MG

N016725 001

ORTHO-NOVUM 1/50 28

ORTHO MCNEIL JANSSEN 0.05MG; 1MG

N016709 001

ORTHO-NOVUM 1/80 28

ORTHO MCNEIL PHARM 0.08MG; 1MG

N016715 002

MESTRANOL; NORETHYNODREL

TABLET; ORAL

ENOVID

GD SEARLE LLC 0.075MG; 5MG  
0.15MG; 9.85MG

N010976 008  
N010976 005

TABLET; ORAL-20

ENOVID

GD SEARLE LLC 0.075MG; 5MG

N010976 004

ENOVID-E

GD SEARLE LLC 0.1MG; 2.5MG

N010976 006

## DISCONTINUED DRUG PRODUCT LIST

MESTRANOL; NORETHYNODREL

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC

0.1MG; 2.5MG

N010976 007

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.65MG/INH

N016402 001

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.4%

N018761 002 Oct 10, 1986

0.6%

N018761 001 Jun 30, 1983

5%

N017659 001

METAPROTERENOL SULFATE

APOTEX INC

0.4%

A075402 001 Feb 28, 2001

0.6%

A075403 001 Feb 28, 2001

ASTRAZENECA

0.4%

A071275 001 Jul 27, 1988

0.6%

A071018 001 Jul 27, 1988

DEY

0.33%

A071806 001 Aug 05, 1988

0.5%

A071805 001 Aug 05, 1988

5%

A070805 001 Aug 17, 1987

NEPHRON

0.4%

A071855 001 Jul 14, 1988

0.6%

A071726 001 Jul 14, 1988

WOCKHARDT

5%

A072190 001 Jun 07, 1988

PROMETA

MURO

5%

A073340 001 Mar 30, 1992

SYRUP; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG/5ML

N017571 001

METAPROTERENOL SULFATE

APOTEX INC

10MG/5ML

A075235 001 Jan 27, 2000

MORTON GROVE

10MG/5ML

A071656 001 Oct 13, 1987

TEVA

10MG/5ML

A072761 001 Feb 27, 1992

TEVA PHARMS

10MG/5ML

A073034 001 Aug 30, 1991

WOCKHARDT

10MG/5ML

A074702 001 Mar 24, 1997

PROMETA

MURO

10MG/5ML

A072023 001 Sep 15, 1988

TABLET; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG

N015874 002

20MG

N015874 001

METAPROTERENOL SULFATE

AM THERAP

10MG

A072054 001 Jun 23, 1988

20MG

A072055 001 Jun 23, 1988

TEVA

10MG

A072519 001 Mar 30, 1990

20MG

A072520 001 Mar 30, 1990

USL PHARMA

10MG

A071013 001 Jan 25, 1988

20MG

A071014 001 Jan 25, 1988

WATSON LABS

10MG

A073013 001 Jan 31, 1991

20MG

A072795 001 Jan 31, 1991

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

MERCK

EQ 10MG BASE/ML

N009509 002 Dec 22, 1987

METARAMINOL BITARTRATE

ABRAXIS PHARM

EQ 10MG BASE/ML

A080431 001

ELKINS SINN

EQ 10MG BASE/ML

A083363 001

GD SEARLE LLC

EQ 10MG BASE/ML

A086418 001

EQ 20MG BASE/ML

A086418 002

METAXALONE

TABLET; ORAL

SKELAXIN

KING PHARMS

400MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N013217 001

## DISCONTINUED DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

BRISTOL MYERS SQUIBB	625MG	N020357	003	Nov 05, 1998
	750MG	N020357	004	Nov 05, 1998

METFORMIN HYDROCHLORIDE

BARR	1GM	A075971	003	Jan 25, 2002
	500MG	A075971	001	Jan 25, 2002
	850MG	A075971	002	Jan 25, 2002
IPCA LABS LTD	1GM	A078422	003	Aug 06, 2007
	500MG	A078422	001	Aug 06, 2007
	850MG	A078422	002	Aug 06, 2007
IVAX SUB TEVA PHARMS	1GM	A075975	003	Jan 24, 2002
	500MG	A075975	001	Jan 24, 2002
	625MG	A075975	004	Jan 24, 2002
	750MG	A075975	005	Jan 24, 2002
	850MG	A075975	002	Jan 24, 2002
TEVA	1GM	A076328	003	Dec 16, 2002
	500MG	A076328	001	Dec 16, 2002
	850MG	A076328	002	Dec 16, 2002
WATSON LABS	1GM	A075979	003	Jan 24, 2002
	500MG	A075979	001	Jan 24, 2002
	850MG	A075979	002	Jan 24, 2002

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004
	750MG	A076878	001	Apr 13, 2005
BARR	500MG	A076496	001	Nov 25, 2005
IVAX SUB TEVA PHARMS	500MG	A076545	001	Dec 01, 2003
MUTUAL PHARM	500MG	A077124	001	Dec 21, 2005
RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004
	750MG	A077211	001	Jun 29, 2005
SANDOZ	500MG	A076223	001	Dec 14, 2004
TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010
WATSON LABS INC	500MG	A076818	001	Dec 14, 2004

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

SB PHARMCO	500MG;EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410	001	Oct 10, 2002
------------	------------------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------

METHACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641	001	
	EQ 280MG BASE	A060641	002	

SYRUP; ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641	003	
---------------------	------------------	---------	-----	--

METHADONE HYDROCHLORIDE

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

ROXANE	10MG/30ML	N006134	004	
--------	-----------	---------	-----	--

TABLET; ORAL

METHADONE HYDROCHLORIDE

ROXANE	5MG	A088108	001	Mar 08, 1983
	10MG	A088109	001	Mar 08, 1983
	40MG	A074081	001	Apr 28, 1995
SANDOZ	5MG	A040241	001	May 29, 1998

TABLET, DISPERSIBLE; ORAL

WESTADONE

SANDOZ	2.5MG	N017108	001	
--------	-------	---------	-----	--

TABLET, EFFERVESCENT; ORAL

WESTADONE

SANDOZ	5MG	N017108	002	
	10MG	N017108	003	
	40MG	N017108	004	

## DISCONTINUED DRUG PRODUCT LIST

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPEX

TEVA 10MG A083889 001

METHAMPHETAMINE HYDROCHLORIDE

ABLE 5MG A040529 001 Feb 25, 2004

REXAR 5MG A084931 001

10MG A084931 002

TEVA 5MG A086359 001

TABLET, EXTENDED RELEASE; ORAL

DESOXYN

RECORDATI RARE 5MG N005378 004

10MG N005378 003

15MG N005378 005

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

SHIRE 50MG N007390 001

METHARBITAL

TABLET; ORAL

GEMONIL

ABBVIE 100MG N008322 001

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

APPLIED ANAL 25MG A040011 001 Jul 17, 1997

50MG A040011 002 Jul 17, 1997

SANDOZ 25MG A040102 001 Aug 28, 1996

50MG A040102 002 Aug 28, 1996

NEPTAZANE

LEDERLE 25MG N011721 002 Nov 25, 1991

50MG N011721 001

METHDILAZINE

TABLET, CHEWABLE; ORAL

TACARYL

WESTWOOD SQUIBB 3.6MG N011950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS 4MG/5ML A087122 001

TACARYL

WESTWOOD SQUIBB 4MG/5ML N011950 007

TABLET; ORAL

TACARYL

WESTWOOD SQUIBB 8MG N011950 006

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHICILLIN

APOTHECON EQ 3.6GM BASE/VIAL A061449 002

EQ 3.6GM BASE/VIAL N050117 002

EQ 5.4GM BASE/VIAL A061449 003

EQ 5.4GM BASE/VIAL N050117 003

EQ 900MG BASE/VIAL A061449 001

EQ 900MG BASE/VIAL N050117 001

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

CEDAR PHARMS 15MG A040619 003 Jul 12, 2005

20MG A040547 004 Feb 18, 2005

MYLAN 20MG A040350 003 Jun 07, 2001

TAPAZOLE

KING PHARMS 5MG N007517 002

10MG N007517 004

**DISCONTINUED DRUG PRODUCT LIST**METHIXENE HYDROCHLORIDE

TABLET; ORAL

TREST

NOVARTIS 1MG N013420 001

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

MARSAM PHARMS LLC 100MG/ML A089849 001 Dec 27, 1991

WATSON LABS 100MG/ML A086459 001

TABLET; ORAL

DELAXIN

FERNDAL LABS 500MG A085454 001

FORBAXIN

FOREST LABS 750MG A085136 001

METHOCARBAMOL

ABLE 500MG A040413 001 Mar 17, 2003

750MG A040413 002 Mar 17, 2003

AM THERAP 500MG A089417 001 Feb 11, 1987

750MG A089418 001 Feb 11, 1987

ASCOT 500MG A087660 001 Oct 27, 1982

750MG A087661 001 Oct 27, 1982

CLONMEL HLTHCARE 500MG A085961 001

750MG A085963 001

HEATHER 500MG A084675 001

750MG A084924 001

IMPAX LABS 500MG A084927 001

750MG A084928 001

INWOOD LABS 500MG A085137 001

IVAX SUB TEVA PHARMS 500MG A084648 001

750MG A084649 001

KV PHARM 500MG A085660 001

750MG A085658 001

MUTUAL PHARM 500MG A084488 001

750MG A084486 001

MYLAN 500MG A084259 001

750MG A084323 001

NYLOS 750MG A085033 001

PIONEER PHARMS 500MG A088731 001 Dec 13, 1985

750MG A089082 001 Dec 13, 1985

PURACAP PHARM 500MG A084231 002

750MG A084471 001

PUREPAC PHARM 500MG A085718 001

750MG A085718 002

ROXANE 500MG A088646 001 Feb 29, 1984

750MG A088647 001 Feb 29, 1984

SANDOZ 500MG A087283 001

750MG A087282 001

SOLVAY 500MG A084448 001

750MG A084449 001

SUPERPHARM 500MG A087589 001 Jan 22, 1982

750MG A087590 001 Jan 22, 1982

TABLICAPS 500MG A084846 001

UPSHER SMITH 500MG A087453 001

750MG A087454 001

WATSON LABS 500MG A083605 001

500MG A085180 001

750MG A083605 002

750MG A085192 001

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

PAR STERILE PRODUCTS 5GM/VIAL N011559 003

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC EQ 25MG BASE/ML A089161 001 Mar 10, 1987

EQ 50MG BASE/VIAL A089354 001 Jul 17, 1987

EQ 100MG BASE/VIAL A089355 001 Jul 17, 1987

EQ 250MG BASE/VIAL A089356 001 Jul 17, 1987



## DISCONTINUED DRUG PRODUCT LIST

METHOTREXATE SODIUM

## INJECTABLE; INJECTION

## FOLEX

PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695 001	Apr 08, 1983
	EQ 50MG BASE/VIAL	A087695 002	Apr 08, 1983
	EQ 100MG BASE/VIAL	A087695 003	Apr 08, 1983
	EQ 250MG BASE/VIAL	A088954 001	Oct 24, 1985

## FOLEX PFS

PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242 001	Aug 23, 1991
	EQ 25MG BASE/ML	A089180 001	Jan 03, 1986

## METHOTREXATE LPF

HOSPIRA	EQ 25MG BASE/ML	N011719 007	Mar 31, 1982
---------	-----------------	-------------	--------------

## METHOTREXATE PRESERVATIVE FREE

FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265 001	Feb 26, 1999
HOSPIRA	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719 011	Apr 13, 2005
	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719 014	Apr 13, 2005
	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N011719 013	Apr 13, 2005
	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

## METHOTREXATE SODIUM

ABRAXIS PHARM	EQ 2.5MG BASE/ML	A089323 001	Jun 13, 1986
	EQ 20MG BASE/VIAL	A088935 001	Oct 11, 1985
	EQ 25MG BASE/ML	A089263 001	Jun 13, 1986
	EQ 25MG BASE/ML	A089322 001	Jun 13, 1986
	EQ 50MG BASE/VIAL	A088936 001	Oct 11, 1985
	EQ 100MG BASE/VIAL	A088937 001	Oct 11, 1985
HOSPIRA	EQ 2.5MG BASE/ML	N011719 004	
	EQ 20MG BASE/VIAL	N011719 001	
	EQ 25MG BASE/ML	N011719 005	
	EQ 50MG BASE/VIAL	N011719 003	
	EQ 100MG BASE/VIAL	N011719 006	
NORBROOK	EQ 25MG BASE/ML	A088648 001	May 09, 1986
PHARMACHEMIE USA	EQ 25MG BASE/ML	A089158 001	Jul 08, 1988

## METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA	EQ 1GM BASE/VIAL	N011719 009	Apr 07, 1988
---------	------------------	-------------	--------------

## MEXATE

BRISTOL	EQ 20MG BASE/VIAL	A086358 001	
	EQ 50MG BASE/VIAL	A086358 002	
	EQ 100MG BASE/VIAL	A086358 003	
	EQ 250MG BASE/VIAL	A086358 004	

## MEXATE-AQ

BRISTOL MYERS	EQ 25MG BASE/ML	A088760 001	Feb 14, 1985
---------------	-----------------	-------------	--------------

## MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	A089887 001	Apr 14, 1989
----------------------	-----------------	-------------	--------------

## TABLET; ORAL

## METHOTREXATE SODIUM

DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233 001	Jun 17, 1999
---------------------	---------------	-------------	--------------

METHOXAMINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## VASOXYL

GLAXOSMITHKLINE	10MG/ML	N006772 002	
	20MG/ML	N006772 001	

METHOXSALEN

## CAPSULE; ORAL

## METHOXSALEN

SANDOZ	10MG	A087781 001	Jun 08, 1982
--------	------	-------------	--------------

METHSCOPOLAMINE BROMIDE

## TABLET; ORAL

## METHSCOPOLAMINE BROMIDE

PVT FORM	2.5MG	A080970 001	
----------	-------	-------------	--

METHYLCLOTHIAZIDE

## TABLET; ORAL

## AQUATENSEN

MEDPOINTE PHARM HLC	5MG	N017364 001	
---------------------	-----	-------------	--

## ENDURON

ABBVIE	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012524 001	
--------	------------------------------------------------------------------------------------------------------------------------	-------------	--

**DISCONTINUED DRUG PRODUCT LIST**METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURON

	5MG	N012524	004	
METHYLCLOTHIAZIDE				
IVAX PHARMS	2.5MG	A087913	001	Jun 03, 1982
	5MG	A087786	001	May 18, 1982
MYLAN	2.5MG	A087671	001	Aug 17, 1982
PAR PHARM	2.5MG	A089135	001	Feb 12, 1986
	5MG	A089136	001	Feb 12, 1986
SANDOZ	2.5MG	A089835	001	Aug 18, 1988
	5MG	A089837	001	Aug 18, 1988
USL PHARMA	5MG	A088745	001	Mar 21, 1985
WATSON LABS	2.5MG	A085487	001	Mar 11, 1982
	2.5MG	A088750	001	Sep 06, 1984
	5MG	A085476	001	Mar 11, 1982
	5MG	A088724	001	Sep 06, 1984

METHYLCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTRON

ABBOTT	5MG; 25MG	N016047	001	
--------	-----------	---------	-----	--

METHYLCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC	2.5MG; 0.1MG	N012708	005	
---------------------	--------------	---------	-----	--

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004
------------------	---------------	---------	-----	--------------

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

MERCK	250MG/5ML	N018389	001	
-------	-----------	---------	-----	--

TABLET; ORAL

ALDOMET

MERCK	125MG	N013400	003	
	250MG	N013400	001	
	500MG	N013400	002	

METHYLDOPA

ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985
DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
	500MG	A071009	001	Dec 16, 1986
HALSEY	125MG	A071751	001	Mar 28, 1988
	250MG	A071752	001	Mar 28, 1988
	500MG	A071753	001	Mar 28, 1988
MUTUAL PHARM	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
PAR PHARM	125MG	A070535	001	Jan 02, 1987
	250MG	A070536	001	Jan 02, 1987
	500MG	A070537	001	Jan 02, 1987
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
SANDOZ	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986

## DISCONTINUED DRUG PRODUCT LIST

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	50MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

MERCK	50MG/ML	N013401	001	
METHYLDOPATE HYDROCHLORIDE				
ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE	5MG	A040404	001	Mar 29, 2001
	10MG	A040404	002	Mar 29, 2001
	20MG	A040404	003	Mar 29, 2001
ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
	10MG	A040321	002	Feb 05, 2002
	20MG	A040321	003	Feb 05, 2002

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

UCB INC	10MG	A040306	001	Oct 20, 1999
METHYLPHENIDATE HYDROCHLORIDE				
ABLE	20MG	A076032	001	May 09, 2001
ACTAVIS ELIZABETH	20MG	A075450	001	Dec 21, 2001
WATSON LABS	20MG	A040410	001	Feb 09, 2001

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

PHARMACIA AND UPJOHN	24MG	N011153	005	
METHYLPREDNISOLONE				
HEATHER	4MG	A085650	001	
PAR PHARM	16MG	A089207	001	Apr 25, 1988
	24MG	A089208	001	Apr 25, 1988
	32MG	A089209	001	Apr 25, 1988
SANDOZ	4MG	A087341	001	
WATSON LABS	4MG	A086161	001	Feb 09, 1982
	16MG	A086159	001	Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA; RECTAL

MEDROL

PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	
----------------------	----------	---------	-----	--

INJECTABLE; INJECTION

M-PREDROL

BEL MAR	40MG/ML	A086666	001	
	80MG/ML	A087135	001	

METHYLPREDNISOLONE ACETATE

AKORN	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	

**DISCONTINUED DRUG PRODUCT LIST**METHYLPREDNISOLONE ACETATE

OINTMENT; TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%	N012421	001
	1%	N012421	002

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611	002
	1%;EQ 3.5MG BASE/GM	A060611	001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

ABBOTT

EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991
EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991

HOSPIRA

EQ 1GM BASE/VIAL	A085852	001	
EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987
EQ 40MG BASE/VIAL	A085853	001	
EQ 125MG BASE/VIAL	A085855	001	
EQ 500MG BASE/VIAL	A085854	001	
EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987

METHYLPREDNISOLONE

ELKINS SINN

EQ 1GM BASE/VIAL	A086906	004	
EQ 125MG BASE/VIAL	A086906	002	
EQ 500MG BASE/VIAL	A086906	003	

ORGANON USA INC

EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982
EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984
EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986
EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986
EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986

BEDFORD LABS

EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007
EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007
EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007
EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007
EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007
EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007

ELKINS SINN

EQ 40MG BASE/VIAL A086906 001

INTL MEDICATION

EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983
EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983

TEVA PARENTERAL

EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992
EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992
EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992

WATSON LABS

EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984
EQ 40MG BASE/VIAL	A086953	001	Jul 22, 1982
EQ 125MG BASE/VIAL	A087030	001	Jul 22, 1982
EQ 500MG BASE/VIAL	A088523	001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645	001
----------------------	-----------------------	---------	-----

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER

10MG	A084967	001	
------	---------	-----	--

VIRILON

STAR PHARMS FL

10MG	A087750	001	Nov 24, 1982
------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

METHYLTESTOSTERONE

TABLET;BUCCAL

ANDROID 5

VALEANT PHARM INTL

5MG

A087222 001

ORETON

SCHERING

10MG

A080281 001

TABLET;BUCCAL, SUBLINGUAL

METANDREN

NOVARTIS

5MG

N003240 004

10MG

N003240 001

10MG

N003240 005

25MG

N003240 003

METHYLTESTOSTERONE

IMPAX LABS

10MG

A084287 001

LILLY

10MG

A080256 001

25MG

A080256 002

PUREPAC PHARM

10MG

A080308 001

10MG

A080475 001

10MG

A080475 002

25MG

A080475 003

PVT FORM

5MG

A083836 001

TABLICAPS

10MG

A085125 001

USL PHARMA

10MG

A080271 001

TABLET;ORAL

METHYLTESTOSTERONE

INWOOD LABS

10MG

A080839 001

25MG

A080973 001

KV PHARM

10MG

A084312 001

LANNETT

10MG

A087092 001

Nov 05, 1982

25MG

A087111 001

Jan 27, 1983

PARKE DAVIS

10MG

A084244 001

25MG

A084241 001

PUREPAC PHARM

10MG

A080309 001

25MG

A080310 001

PVT FORM

5MG

A080214 001

10MG

A080214 002

25MG

A080214 003

TABLICAPS

10MG

A080313 001

25MG

A085270 001

WATSON LABS

10MG

A080933 001

25MG

A080931 001

WEST WARD

10MG

A084331 001

25MG

A084331 002

25MG

A084642 001

ORETON METHYL

SCHERING

10MG

N003158 001

25MG

N003158 002

METHYPRYLON

CAPSULE;ORAL

NOLUDAR

ROCHE

300MG

N009660 008

ELIXIR;ORAL

NOLUDAR

ROCHE

50MG/5ML

N009660 007

TABLET;ORAL

NOLUDAR

ROCHE

50MG

N009660 002

ROCHE

200MG

N009660 004

METHYSERGIDE MALEATE

TABLET;ORAL

SANSERT

NOVARTIS

2MG

N012516 001

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE;ORAL

METOCLOPRAMIDE INTENSOL

ROXANE

EQ 10MG BASE/ML

A072995 001

Jan 30, 1992

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD

EQ 5MG BASE/ML

A072155 001

Mar 30, 1992

EQ 5MG BASE/ML

A072244 001

Mar 30, 1992

EQ 5MG BASE/ML

A072247 001

May 18, 1992

## DISCONTINUED DRUG PRODUCT LIST

METOCLOPRAMIDE HYDROCHLORIDE

## INJECTABLE; INJECTION

## METOCLOPRAMIDE HYDROCHLORIDE

HOSPIRA	EQ 5MG BASE/ML	A070505	001	Jun 23, 1989
	EQ 5MG BASE/ML	A070506	001	Jun 22, 1989
	EQ 5MG BASE/ML	A070847	001	Nov 07, 1988
	EQ 5MG BASE/ML	A071291	001	Mar 03, 1989
	EQ 5MG BASE/ML	A071990	001	Jan 18, 1989
	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991
	EQ 5MG BASE/ML	A074147	001	Aug 02, 1996
LYPHOMED	EQ 10MG BASE/2ML	A070293	001	Jan 24, 1986
NORBROOK	EQ 10MG BASE/2ML	A070892	001	Aug 26, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623	001	Mar 02, 1987
	EQ 10MG BASE/2ML	A070622	001	Mar 02, 1987

## REGLAN

BAXTER HLTHCARE CORP	EQ 10MG BASE/ML	N017862	004	May 28, 1987
----------------------	-----------------	---------	-----	--------------

## SOLUTION; ORAL

## METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340	001	Aug 18, 1988
MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
TEVA	EQ 5MG BASE/5ML	A070819	001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315	001	Jun 30, 1993

## REGLAN

ROBINS AH	EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018821	001	Mar 25, 1983
-----------	----------------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------

## TABLET; ORAL

## CLOPRA

QUANTUM PHARMICS	EQ 5MG BASE	A072384	001	Jun 02, 1988
	EQ 10MG BASE	A070294	001	Jul 29, 1985

## CLOPRA-"YELLOW"

QUANTUM PHARMICS	EQ 10MG BASE	A070632	001	Oct 28, 1985
------------------	--------------	---------	-----	--------------

## MAXOLON

KING PHARMS	EQ 10MG BASE	A070106	001	Mar 04, 1986
-------------	--------------	---------	-----	--------------

## METOCLOPRAMIDE HYDROCHLORIDE

CLONMEL	EQ 10MG BASE	A072639	001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906	001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213	001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660	001	Feb 10, 1987
	EQ 10MG BASE	A071536	001	Apr 28, 1993
PAR PHARM	EQ 10MG BASE	A070342	001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436	001	Jun 22, 1989
	EQ 5MG BASE	A074478	001	Oct 05, 1995
	EQ 10MG BASE	A070850	001	Feb 03, 1987
	EQ 10MG BASE	A072215	001	Jan 30, 1990
	EQ 10MG BASE	A074478	002	Oct 05, 1995
SCHERING	EQ 10MG BASE	A070598	001	Feb 02, 1987
SUPERPHARM	EQ 10MG BASE	A070926	001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339	001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363	001	Mar 02, 1987
	EQ 10MG BASE	A070453	001	Jun 06, 1986
	EQ 10MG BASE	A070511	001	Jan 22, 1986
	EQ 10MG BASE	A070645	001	May 11, 1987

## TABLET, ORALLY DISINTEGRATING; ORAL

## METOZOLV ODT

SALIX PHARMS	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022246	002	Sep 04, 2009
--------------	-------------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------

## REGLAN ODT

MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005
	EQ 10MG BASE	N021793	002	Jun 10, 2005

METOCURINE IODIDE

## INJECTABLE; INJECTION

## METUBINE IODIDE

LILLY	2MG/ML	N006632	003	
-------	--------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

METOLAZONE

TABLET; ORAL

DIULO

GD SEARLE LLC	2.5MG	N018535	001	
	5MG	N018535	002	
	10MG	N018535	003	

METOLAZONE

ROXANE	10MG	A076482	002	Apr 29, 2004
--------	------	---------	-----	--------------

TEVA	2.5MG	A076600	001	Jan 06, 2004
------	-------	---------	-----	--------------

	5MG	A076833	001	Mar 01, 2004
--	-----	---------	-----	--------------

	10MG	A075543	003	Dec 24, 2003
--	------	---------	-----	--------------

WATSON LABS	10MG	A076891	001	Jul 21, 2004
-------------	------	---------	-----	--------------

MYKROX

UCB INC	0.5MG	N019532	001	Oct 30, 1987
---------	-------	---------	-----	--------------

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL

LOPRESSOR

NOVARTIS	EQ 100MG TARTRATE	N019786	001	Dec 27, 1989
----------	-------------------	---------	-----	--------------

	EQ 200MG TARTRATE	N019786	002	Dec 27, 1989
--	-------------------	---------	-----	--------------

	EQ 300MG TARTRATE	N019786	003	Dec 27, 1989
--	-------------------	---------	-----	--------------

	EQ 400MG TARTRATE	N019786	004	Dec 27, 1989
--	-------------------	---------	-----	--------------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008
---------------	------------------	---------	-----	--------------

	EQ 50MG TARTRATE	A077176	001	May 14, 2008
--	------------------	---------	-----	--------------

	EQ 100MG TARTRATE	A076640	002	May 18, 2007
--	-------------------	---------	-----	--------------

	EQ 200MG TARTRATE	A076640	001	May 18, 2007
--	-------------------	---------	-----	--------------

SANDOZ	EQ 25MG TARTRATE	A076969	001	Jul 31, 2006
--------	------------------	---------	-----	--------------

	EQ 50MG TARTRATE	A076969	002	May 18, 2007
--	------------------	---------	-----	--------------

	EQ 100MG TARTRATE	A076969	003	Mar 20, 2008
--	-------------------	---------	-----	--------------

	EQ 200MG TARTRATE	A076969	004	Mar 20, 2008
--	-------------------	---------	-----	--------------

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993
-------------	--------	---------	-----	--------------

TABLET; ORAL

METOPROLOL TARTRATE

APOTHECON	50MG	A074258	001	Jan 27, 1994
-----------	------	---------	-----	--------------

	100MG	A074258	002	Jan 27, 1994
--	-------	---------	-----	--------------

MYLAN	50MG	A073666	001	Dec 21, 1993
-------	------	---------	-----	--------------

	100MG	A073666	002	Dec 21, 1993
--	-------	---------	-----	--------------

PRINSTON INC	50MG	A074453	001	Apr 27, 1995
--------------	------	---------	-----	--------------

	100MG	A074453	002	Apr 27, 1995
--	-------	---------	-----	--------------

PUREPAC PHARM	50MG	A074380	001	Jul 29, 1994
---------------	------	---------	-----	--------------

	100MG	A074380	002	Jul 29, 1994
--	-------	---------	-----	--------------

TEVA	50MG	A074143	001	Sep 30, 1994
------	------	---------	-----	--------------

	100MG	A074143	002	Sep 30, 1994
--	-------	---------	-----	--------------

TEVA PHARMS	50MG	A074333	001	Jan 27, 1994
-------------	------	---------	-----	--------------

	100MG	A074333	002	Jan 27, 1994
--	-------	---------	-----	--------------

METRIZAMIDE

INJECTABLE; INJECTION

AMIPAQUE

GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
---------------	------------	---------	-----	--------------

	3.75GM/VIAL	N017982	001	
--	-------------	---------	-----	--

	6.75GM/VIAL	N017982	002	
--	-------------	---------	-----	--

	13.5GM/VIAL	N017982	004	Sep 12, 1983
--	-------------	---------	-----	--------------

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

ABLE	375MG	A076505	001	Nov 13, 2003
------	-------	---------	-----	--------------

INJECTABLE; INJECTION

METRO I.V.

B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982
---------	-------------	---------	-----	--------------

METRONIDAZOLE

ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983
--------	-------------	---------	-----	--------------

ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
---------------	-------------	---------	-----	--------------

HIKMA MAPLE	500MG/100ML	N018907	001	Mar 30, 1984
-------------	-------------	---------	-----	--------------

INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
-----------------	-------------	---------	-----	--------------

WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
-------------	-------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

METRONIDAZOLE

## INJECTABLE; INJECTION

METRONIDAZOLE

500MG/100ML

A070170 001 Apr 01, 1986

## TABLET; ORAL

METROMIDOL

LABS AF

250MG

A074523 001 Oct 24, 1996

500MG

A074523 002 Oct 24, 1996

METRONIDAZOLE

ABLE

250MG

A076519 001 Jun 27, 2003

500MG

A076519 002 Jun 27, 2003

HALSEY

250MG

A070021 001 Apr 02, 1985

500MG

A070593 001 Feb 27, 1986

IVAX SUB TEVA PHARMS

250MG

N018517 001

500MG

N018517 002 May 05, 1982

LNK

250MG

N019029 001 Apr 10, 1984

MUTUAL PHARM

250MG

N018818 001 Feb 16, 1983

500MG

N018818 002 Feb 16, 1983

PAR PHARM

250MG

N018845 001 Aug 18, 1983

500MG

N018930 001 Aug 18, 1983

SANDOZ

250MG

N018620 001 Mar 04, 1982

250MG

N018740 001 Oct 22, 1982

500MG

N018620 002 Jun 02, 1983

500MG

N018740 002 Oct 22, 1982

SUPERPHARM

250MG

A070008 001 Dec 11, 1984

500MG

A070009 001 Dec 11, 1984

VIVIMED LABS

250MG

A070040 001 Jan 29, 1985

500MG

A070039 001 Jan 29, 1985

WATSON LABS

250MG

N018599 001 Sep 17, 1982

250MG

N018764 001 Sep 17, 1982

500MG

N018599 002 Feb 13, 1984

500MG

N018764 002 Dec 20, 1982

PROTOSTAT

ORTHO MCNEIL PHARM

250MG

N018871 001 Mar 02, 1983

500MG

N018871 002 Mar 02, 1983

SATRIC

SAVAGE LABS

250MG

A070029 001 Mar 19, 1985

500MG

A070731 001 Jun 08, 1987

## TABLET, EXTENDED RELEASE; ORAL

METRONIDAZOLE

ABLE

750MG

A076462 001 Jun 25, 2003

METRONIDAZOLE HYDROCHLORIDE

## INJECTABLE; INJECTION

FLAGYL I.V.

PFIZER

EQ 500MG BASE/VIAL

N018353 001

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A070295 001 Oct 15, 1985

METYRAPONE

## TABLET; ORAL

METOPIRONE

HRA PHARMA

250MG

N012911 001

MEXILETINE HYDROCHLORIDE

## CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

SANDOZ

150MG

A074450 001 May 16, 1996

200MG

A074450 002 May 16, 1996

250MG

A074450 003 May 16, 1996

WATSON LABS

150MG

A074711 001 Feb 26, 1997

150MG

A074865 001 Apr 13, 1998

200MG

A074711 002 Feb 26, 1997

200MG

A074865 002 Apr 13, 1998

250MG

A074711 003 Feb 26, 1997

250MG

A074865 003 Apr 13, 1998

MEXITIL

BOEHRINGER INGELHEIM

150MG

N018873 002 Dec 30, 1985

200MG

N018873 003 Dec 30, 1985

250MG

N018873 004 Dec 30, 1985



## DISCONTINUED DRUG PRODUCT LIST

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
	EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549	001	
	EQ 2GM BASE/VIAL	A062333	002	
	EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549	002	
	EQ 3GM BASE/VIAL	A062333	003	
	EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549	003	
	EQ 4GM BASE/VIAL	A062333	004	
	EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549	004	
	EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

JANSSEN PHARMA	10MG/ML	N018040	001	
----------------	---------	---------	-----	--

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS	2%	N017494	001	
----------------	----	---------	-----	--

CREAM; VAGINAL

MICONAZOLE NITRATE

TEVA	2%	A074136	001	Jan 04, 1995
TEVA PHARMS	2%	A074030	001	Oct 30, 1992

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC	2%, 100MG	A074586	001	Jul 17, 1997
----------------------	-----------	---------	-----	--------------

LOTION; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS	2%	N017739	001	
----------------	----	---------	-----	--

TAMPON; VAGINAL

MONISTAT 5

PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989
----------------	-------	---------	-----	--------------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

APOTEX INC	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000
	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000
APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
ASTRAZENECA	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
HOSPIRA INC	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004

VERSED

HLR	EQ 1MG BASE/ML	N018654	002	May 26, 1987
	EQ 5MG BASE/ML	N018654	001	Dec 20, 1985

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

APOTEX INC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005
------------	----------------	---------	-----	--------------

VERSED

ROCHE	EQ 2MG BASE/ML	N020942	001	Oct 15, 1998
-------	----------------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

SHIRE LLC

2.5MG

N019815 001 Sep 06, 1996

5MG

N019815 002 Sep 06, 1996

10MG

N019815 003 Mar 20, 2002

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

APOTEX INC

EQ 1MG BASE/ML

A076427 001 Sep 21, 2004

HIKMA MAPLE

EQ 1MG BASE/ML

A075852 001 May 28, 2002

HOSPIRA

EQ 1MG BASE/ML

A075830 001 May 28, 2002

EQ 1MG BASE/ML

A075884 001 May 28, 2002

MYLAN INSTITUTIONAL

EQ 1MG BASE/ML

A076428 001 Jun 16, 2003

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

APOTEX INC

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A077151 001 Jul 20, 2005

BAXTER HLTHCARE

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A076259 001 Aug 08, 2002

HIKMA MAPLE

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A075510 001 May 28, 2002

PRIMACOR

SANOFI AVENTIS US

EQ 1MG BASE/ML

N019436 001 Dec 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

SANOFI AVENTIS US

EQ 10MG BASE/100ML

N020343 001 Aug 09, 1994

EQ 15MG BASE/100ML

N020343 002 Aug 09, 1994

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

N020343 003 Aug 09, 1994

EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)

N020343 004 Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

CNTY LINE PHARMS

EQ 50MG BASE

A063066 001 Aug 14, 1990

MINOCIN

PRECISION DERMAT

EQ 75MG BASE

N050649 003 Feb 12, 2001

TRIAx PHARMS

EQ 50MG BASE

N050315 002

EQ 100MG BASE

N050315 001

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

RANBAXY LABS LTD

EQ 45MG BASE

N201922 001 Jul 11, 2012

EQ 67.5MG BASE

N201922 002 Jul 11, 2012

EQ 90MG BASE

N201922 003 Jul 11, 2012

EQ 112.5MG BASE

N201922 004 Jul 11, 2012

EQ 135MG BASE

N201922 005 Jul 11, 2012

INJECTABLE; INJECTION

MINOCIN

LEDERLE

EQ 100MG BASE/VIAL

A062139 001

SUSPENSION; ORAL

MINOCIN

PRECISION DERMAT

EQ 50MG BASE/5ML

N050445 001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

TRIAx PHARMS

EQ 50MG BASE

N050451 003 Aug 10, 1982

EQ 100MG BASE

N050451 002 Aug 10, 1982

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

LUPIN LTD

EQ 55MG BASE

A091424 002 Nov 30, 2011

SOLODYN

MEDICIS

EQ 45MG BASE

N050808 001 May 08, 2006

EQ 90MG BASE

N050808 002 May 08, 2006

EQ 135MG BASE

N050808 003 May 08, 2006

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

APOTEX INC

2%

A074924 001 Apr 29, 1998

BAUSCH AND LOMB

2%

A074643 001 Apr 09, 1996

COPLY PHARM

2%

A074500 001 May 23, 1996

SIGHT PHARMS

2%

A074743 002 Oct 18, 1996

TEVA

2%

A074589 001 Apr 05, 1996

MINOXIDIL (FOR WOMEN)

APOTEX INC

2%

A074924 002 Apr 29, 1998

SIGHT PHARMS

2%

A074743 001 Oct 18, 1996

MINOXIDIL EXTRA STRENGTH (FOR MEN)

APOTEX INC

5%

A075839 001 Oct 01, 2001

## DISCONTINUED DRUG PRODUCT LIST

MINOXIDIL

## TABLET; ORAL

## LONITEN

PHARMACIA AND UPJOHN	2.5MG	N018154	001	
	10MG	N018154	003	
MINODYL				
QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
	10MG	A071534	001	Mar 19, 1987
MINOXIDIL				
ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
	10MG	A071796	001	Nov 10, 1987
USL PHARMA	2.5MG	A071537	001	Dec 16, 1988

MIRTAZAPINE

## TABLET; ORAL

## MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003
	15MG	A076308	001	Jun 20, 2003
	30MG	A076241	002	Jun 25, 2003
	30MG	A076308	002	Jun 20, 2003
	45MG	A076241	003	Jun 25, 2003
	45MG	A076308	003	Jun 20, 2003
IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003
	30MG	A076244	002	Dec 22, 2003
	45MG	A076244	003	Dec 22, 2003
ROXANE	15MG	A076270	001	Jun 19, 2003
	30MG	A076270	002	Jun 19, 2003
	45MG	A076270	003	Jun 19, 2003
SANDOZ	15MG	A076189	001	Jun 19, 2003
	30MG	A076189	002	Jun 19, 2003
	45MG	A076189	003	Jun 19, 2003

## TABLET, ORALLY DISINTEGRATING; ORAL

## MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005
	15MG	A077959	001	Feb 14, 2011
	30MG	A076689	002	Aug 31, 2005
	30MG	A077959	002	Feb 14, 2011
	45MG	A076689	003	Aug 31, 2005
	45MG	A077959	003	Feb 14, 2011

MITOMYCIN

## INJECTABLE; INJECTION

## MITOMYCIN

HOSPIRA	20MG/VIAL	A064106	001	Nov 29, 1995
MITOZYTREX				
SUPERGEN	5MG/VIAL	N050763	001	Nov 14, 2002
MUTAMYCIN				
BRISTOL	5MG/VIAL	N050450	001	
	20MG/VIAL	N050450	002	
BRISTOL MYERS	5MG/VIAL	A062336	001	
	20MG/VIAL	A062336	002	
	40MG/VIAL	A062336	003	Mar 10, 1988

MITOXANTRONE HYDROCHLORIDE

## INJECTABLE; INJECTION

## MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008
NOVANTRONE				
EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	N019297	002	Dec 23, 1987
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N019297	003	Dec 23, 1987

MIVACURIUM CHLORIDE

## INJECTABLE; INJECTION

## MIVACRON

ABBVIE	EQ 2MG BASE/ML	N020098	001	Jan 22, 1992
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBVIE	EQ 0.5MG BASE/ML	N020098	002	Jan 22, 1992
	EQ 50MG BASE/100ML	N020098	003	Jan 22, 1992
MIVACURIUM CHLORIDE				
AGILA SPECLTS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009

## DISCONTINUED DRUG PRODUCT LIST

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

ENDO PHARMS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 001
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 002
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 003

CONCENTRATE; ORAL

MOBAN

ENDO PHARMS	20MG/ML	N017938 001
-------------	---------	-------------

TABLET; ORAL

MOBAN

ENDO PHARMS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 004
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 005
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 006
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 007
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 008

MOMETASONE FUROATE

OINTMENT; TOPICAL

MOMETASONE FUROATE

TARO

0.1%	A076624 001	Dec 03, 2004
------	-------------	--------------

MONOBENZONE

CREAM; TOPICAL

BENOQUIN

VALEANT PHARM INTL

20%	N008173 003
-----	-------------

MONOCTANOIN

LIQUID; PERFUSION, BILIARY

MOCTANIN

ETHITEK

100%	N019368 001	Oct 29, 1985
------	-------------	--------------

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

ETHMOZINE

SHIRE

200MG	N019753 001	Jun 19, 1990
250MG	N019753 002	Jun 19, 1990
300MG	N019753 003	Jun 19, 1990

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

HOSPIRA

0.5MG/ML	N019917 001	Oct 30, 1992
----------	-------------	--------------

MALLINCKRODT

1MG/ML	N020631 001	Jul 03, 1996
--------	-------------	--------------

2MG/ML	N020631 002	Jul 03, 1996
--------	-------------	--------------

WATSON LABS

0.5MG/ML	A073373 001	Sep 30, 1991
----------	-------------	--------------

0.5MG/ML	A073375 001	Sep 30, 1991
----------	-------------	--------------

1MG/ML	A073374 001	Sep 30, 1991
--------	-------------	--------------

1MG/ML	A073376 001	Sep 30, 1991
--------	-------------	--------------

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

PACIRA PHARMS INC

10MG/ML (10MG/ML)	N021671 001	May 18, 2004
-------------------	-------------	--------------

15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004
----------------------	-------------	--------------

20MG/2ML (10MG/ML)	N021671 003	May 18, 2004
--------------------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

WATSON LABS

100MG

A075656 001 Jan 30, 2001

ORAMORPH SR

XANODYNE PHARMS INC

15MG

N019977 004 Nov 23, 1994

30MG

N019977 001 Aug 15, 1991

60MG

N019977 002 Aug 15, 1991

100MG

N019977 003 Aug 15, 1991

MOXALACTAM DISODIUM

INJECTABLE; INJECTION

MOXAM

LILLY

EQ 1GM BASE/VIAL

N050550 003

EQ 2GM BASE/VIAL

N050550 004

EQ 10GM BASE/VIAL

N050550 008

EQ 250MG BASE/VIAL

N050550 001

EQ 500MG BASE/VIAL

N050550 002

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

ZYDUS PHARMS USA INC

250MG

A065433 001 May 04, 2009

TABLET; ORAL

MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD

500MG

A090464 001 Sep 13, 2010

ZYDUS PHARMS USA INC

500MG

A065477 001 May 04, 2009

NABUMETONE

TABLET; ORAL

NABUMETONE

COPLEY PHARM

750MG

A075179 001 Jun 06, 2000

DR REDDYS LABS LTD

500MG

A078420 001 Sep 24, 2008

750MG

A078420 002 Sep 24, 2008

PROSAM LABS

500MG

A079093 001 Feb 27, 2009

750MG

A079093 002 Feb 27, 2009

SANDOZ

500MG

A075590 001 Feb 25, 2002

750MG

A075590 002 Feb 25, 2002

RELAFEN

SMITHKLINE BEECHAM

500MG

N019583 001 Dec 24, 1991

750MG

N019583 002 Dec 24, 1991

NADOLOL

TABLET; ORAL

CORCARD

KING PHARMS

120MG

N018063 003

160MG

N018063 004

NADOLOL

IVAX SUB TEVA PHARMS

120MG

A074255 002 Jan 24, 1996

160MG

A074255 003 Jan 24, 1996

TEVA PHARMS

80MG

A074368 001 Aug 31, 1994

120MG

A074368 002 Aug 31, 1994

160MG

A074368 003 Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE; ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE

N050111 001

FOR SOLUTION; ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE/5ML

N050199 001

INJECTABLE; INJECTION

NAFCILLIN SODIUM

APOTHECON

EQ 1GM BASE/VIAL

A061984 002

EQ 2GM BASE/VIAL

A061984 003

EQ 4GM BASE/VIAL

A061984 005

EQ 500MG BASE/VIAL

A061984 001

SANDOZ

EQ 500MG BASE/VIAL

A062527 001 Aug 02, 1984

WATSON LABS INC

EQ 1GM BASE/VIAL

A062844 002 Oct 26, 1988

EQ 1.5GM BASE/VIAL

A062844 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062844 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062844 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A063008 001 Sep 29, 1988

EQ 500MG BASE/VIAL

A062844 001 Oct 26, 1988

## DISCONTINUED DRUG PRODUCT LIST

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NALLPEN

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A061999 002	
	EQ 1GM BASE/VIAL	A062755 001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A061999 003	
	EQ 2GM BASE/VIAL	A062755 002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A061999 004	
	EQ 500MG BASE/VIAL	A061999 001	

UNIPEN

WYETH AYERST	EQ 1GM BASE/VIAL	A062717 002	Dec 16, 1986
	EQ 2GM BASE/VIAL	A062717 004	Dec 16, 1986
	EQ 2GM BASE/VIAL	N050320 003	
	EQ 4GM BASE/VIAL	N050320 004	
	EQ 10GM BASE/VIAL	N050320 005	
	EQ 20GM BASE/VIAL	N050320 006	
	EQ 500MG BASE/VIAL	A062717 001	Dec 16, 1986
	EQ 500MG BASE/VIAL	N050320 001	

UNIPEN IN PLASTIC CONTAINER

WYETH AYERST	EQ 1GM BASE/VIAL	N050320 002	
--------------	------------------	-------------	--

TABLET; ORAL

UNIPEN

WYETH AYERST	EQ 500MG BASE	N050462 001	
--------------	---------------	-------------	--

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM	10MG/ML	A070751 001	Jul 02, 1986
	20MG/ML	A070752 001	Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT	20MG/ML	A070917 001	Feb 03, 1989
ABBVIE	1.5MG/ML	N020200 001	Mar 12, 1993
ASTRAZENECA	10MG/ML	A072070 001	Apr 10, 1989
	10MG/ML	A072071 001	Apr 10, 1989
	10MG/ML	A072072 001	Apr 10, 1989
	20MG/ML	A072073 001	Apr 10, 1989
	20MG/ML	A072074 001	Apr 10, 1989
	20MG/ML	A072075 001	Apr 10, 1989
BARR	10MG/ML	A074471 001	Mar 19, 1998
	20MG/ML	A074471 002	Mar 19, 1998

NUBAIN

ENDO PHARMS	10MG/ML	N018024 001	
	20MG/ML	N018024 002	May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGRAM

SANOFI AVENTIS US	250MG/5ML	N017430 001	
-------------------	-----------	-------------	--

TABLET; ORAL

NALIDIXIC ACID

MUTUAL PHARM	1GM	A070272 001	Jun 29, 1988
	250MG	A070270 001	Jun 29, 1988
	500MG	A070271 001	Jun 29, 1988
WATSON LABS	1GM	A071919 001	Jun 29, 1988
	250MG	A071936 001	Jun 29, 1988
	500MG	A072061 001	Jun 29, 1988

NEGRAM

SANOFI AVENTIS US	1GM	N014214 005	
	250MG	N014214 002	
	500MG	N014214 004	

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML	N020459 001	Apr 17, 1995
	EQ 1MG BASE/ML	N020459 002	Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

HIKMA MAPLE	0.4MG/ML	A070298 001	Sep 24, 1986
	0.4MG/ML	A070299 001	Sep 24, 1986
	0.4MG/ML	A070496 001	Sep 24, 1986
WYETH AYERST	0.02MG/ML	A070188 001	Sep 24, 1986

## DISCONTINUED DRUG PRODUCT LIST

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

0.02MG/ML	A070189	001	Sep 24, 1986
0.4MG/ML	A070190	001	Sep 24, 1986
0.4MG/ML	A070191	001	Sep 24, 1986

NALOXONE HYDROCHLORIDE

ABRAXIS PHARM

0.02MG/ML	A070648	001	Nov 17, 1986
0.02MG/ML	A070661	001	Nov 17, 1986
0.4MG/ML	A070649	001	Nov 17, 1986
1MG/ML	A071604	001	Dec 16, 1988

ASTRAZENECA

0.02MG/ML	A072081	001	Apr 11, 1989
0.02MG/ML	A072082	001	Apr 11, 1989
0.02MG/ML	A072083	001	Apr 11, 1989
0.02MG/ML	A072084	001	Apr 11, 1989
0.02MG/ML	A072085	001	Apr 11, 1989
0.4MG/ML	A072086	001	Apr 11, 1989
0.4MG/ML	A072087	001	Apr 11, 1989
0.4MG/ML	A072088	001	Apr 11, 1989
0.4MG/ML	A072089	001	Apr 11, 1989
0.4MG/ML	A072090	001	Apr 11, 1989
1MG/ML	A072091	001	Apr 11, 1989
1MG/ML	A072092	001	Apr 11, 1989
1MG/ML	A072093	001	Apr 11, 1989

HIKMA MAPLE

0.02MG/ML	A071272	001	May 24, 1988
1MG/ML	A071273	001	May 24, 1988
1MG/ML	A071274	001	May 24, 1988
1MG/ML	A071287	001	May 24, 1988

HOSPIRA

0.02MG/ML	A070171	001	Sep 24, 1986
0.02MG/ML	A070252	001	Jan 16, 1987
0.02MG/ML	A070253	001	Jan 16, 1987
0.4MG/ML	A070255	001	Jan 07, 1987

INTL MEDICATION

0.4MG/ML	A070417	001	Sep 24, 1986
1MG/ML	A072115	001	Apr 27, 1988

MARSAM PHARMS LLC

0.4MG/ML	A071811	001	Jul 19, 1988
----------	---------	-----	--------------

SMITH AND NEPHEW

0.02MG/ML	A071671	001	Nov 17, 1987
0.4MG/ML	A071681	001	Nov 17, 1987
0.4MG/ML	A071682	001	Nov 17, 1987

SOLOPAK

0.02MG/ML	A071672	001	Nov 17, 1987
0.4MG/ML	A071683	001	Nov 17, 1987

WATSON LABS

0.4MG/ML	A071339	001	Nov 18, 1987
----------	---------	-----	--------------

NARCAN

BRISTOL MYERS SQUIBB

0.4MG/ML	A071083	001	Jul 28, 1988
1MG/ML	A071084	001	Jul 28, 1988
1MG/ML	A071311	001	Jul 28, 1988

ENDO PHARMS

0.02MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	002	
0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	001	
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	003	Jun 14, 1982

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARGINIQ

PURDUE PHARMA LP

5MG;10MG	N205777	001	Jul 23, 2014
10MG;20MG	N205777	002	Jul 23, 2014
20MG;40MG	N205777	003	Jul 23, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN NX

SANOFI AVENTIS US

EQ 0.5MG BASE; EQ 50MG BASE	N018733	001	Dec 16, 1982
-----------------------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE  
SANDOZ

50MG

A075434 001 Mar 08, 2000

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN  
AGI50MG/ML  
100MG/ML  
200MG/MLN013132 001 Jun 12, 1986  
N013132 002 Jun 12, 1986  
N013132 003 Jun 12, 1986

NANDROLONE DECANOATE

ABRAXIS PHARM

100MG/ML  
200MG/MLA088290 001 Oct 03, 1983  
A088317 001 Oct 14, 1983

AKORN

100MG/ML

A087519 001 Sep 28, 1983

WATSON LABS

50MG/ML

A086385 001 Jan 13, 1984

50MG/ML

A087598 001 Oct 06, 1983

50MG/ML

A088554 001 Feb 10, 1986

100MG/ML

A086598 001 Jan 13, 1984

100MG/ML

A087599 001 Oct 06, 1983

200MG/ML

A088128 001 Dec 05, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN

ORGANON USA INC

25MG/ML  
50MG/MLN011891 001  
N011891 002

NANDROLONE PHENPROPIONATE

WATSON LABS

25MG/ML

A086386 001 Jun 17, 1983

50MG/ML

A087488 001 Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

ALLERGAN

0.1% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

A080248 001

NAFAZAIR

BAUSCH AND LOMB

0.1%

A040073 001 May 25, 1994

PHARMAFAIR

0.1%

A088101 001 Apr 15, 1983

NAPHCON FORTE

ALCON

0.1%

A080229 001

OPCON

BAUSCH AND LOMB

0.1%

A087506 001

VASOCON

NOVARTIS

0.1%

A080235 002 Mar 24, 1983

NAPROXEN

TABLET; ORAL

NAPROXEN

DAVA PHARMS INC

250MG

A074105 001 Dec 21, 1993

250MG

A074410 001 Apr 28, 1995

375MG

A074105 002 Dec 21, 1993

375MG

A074410 002 Apr 28, 1995

500MG

A074105 003 Dec 21, 1993

500MG

A074410 003 Apr 28, 1995

HAMILTON PHARMS

250MG

A074110 001 Oct 30, 1992

375MG

A074110 002 Oct 30, 1992

500MG

A074110 003 Oct 30, 1992

IVAX SUB TEVA PHARMS

250MG

A074111 001 Feb 28, 1995

375MG

A074111 002 Feb 28, 1995

500MG

A074111 003 Feb 28, 1995

PLIVA

250MG

A074182 001 Jun 27, 1996

375MG

A074182 002 Jun 27, 1996

500MG

A074182 003 Jun 27, 1996

PUREPAC PHARM

250MG

A074263 001 Dec 21, 1993

375MG

A074263 002 Dec 21, 1993

500MG

A074263 003 Dec 21, 1993

ROXANE

250MG

A074211 001 Feb 28, 1994

375MG

A074211 002 Feb 28, 1994

500MG

A074211 003 Feb 28, 1994

TEVA

250MG

A074129 001 Dec 21, 1993

250MG

A074216 001 Apr 11, 1996

375MG

A074129 002 Dec 21, 1993



## DISCONTINUED DRUG PRODUCT LIST

NAPROXEN

TABLET; ORAL

NAPROXEN

	375MG	A074216 002	Apr 11, 1996
	500MG	A074129 003	Dec 21, 1993
	500MG	A074216 003	Apr 11, 1996
TEVA PHARMS	250MG	A074207 001	Dec 21, 1993
	375MG	A074207 002	Dec 21, 1993
	500MG	A074207 003	Dec 21, 1993
WATSON LABS	250MG	A074163 001	Feb 10, 1995
	250MG	A074457 001	May 31, 1995
	375MG	A074163 002	Feb 10, 1995
	375MG	A074457 002	May 31, 1995
	500MG	A074163 003	Feb 10, 1995
	500MG	A074457 003	May 31, 1995

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

ACTAVIS ELIZABETH	375MG	A074936 001	Feb 24, 1998
	500MG	A074936 002	Feb 24, 1998

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544 001	Aug 22, 2003
	EQ 500MG BASE	A076544 002	Aug 22, 2003
HAMILTON PHARMS	EQ 250MG BASE	A074106 001	Aug 31, 1993
	EQ 500MG BASE	A074106 002	Aug 31, 1993
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230 001	Mar 14, 1995
	EQ 500MG BASE	A074230 002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367 001	Aug 31, 1994
	EQ 500MG BASE	A074367 002	Aug 31, 1994
PLIVA	EQ 250MG BASE	A074242 001	Jun 20, 1996
	EQ 500MG BASE	A074242 002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319 001	Mar 20, 1995
	EQ 500MG BASE	A074319 002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257 001	Dec 21, 1993
	EQ 500MG BASE	A074257 002	Dec 21, 1993
SANDOZ	EQ 200MG BASE	A074646 001	Jan 13, 1997
	EQ 250MG BASE	A074162 001	Dec 21, 1993
	EQ 250MG BASE	A074495 001	Dec 05, 1994
	EQ 500MG BASE	A074162 002	Dec 21, 1993
	EQ 500MG BASE	A074495 002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142 001	Dec 21, 1993
	EQ 500MG BASE	A074142 002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289 001	Jan 27, 1994
	EQ 500MG BASE	A074289 002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195 001	Dec 21, 1993
	EQ 250MG BASE	A074455 001	May 31, 1995
	EQ 500MG BASE	A074195 002	Dec 21, 1993
	EQ 500MG BASE	A074455 002	May 31, 1995

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

TEVA PHARMS	60MG	A077467 001	Sep 09, 2009
	120MG	A077467 002	Sep 09, 2009

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

KING PHARMS	1.75MG/INH	N019660 001	Dec 30, 1992
-------------	------------	-------------	--------------

SOLUTION; INHALATION

TILADE

SANOFI AVENTIS US	0.5%	N020750 001	Oct 01, 1997
-------------------	------	-------------	--------------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003
	100MG	A075763 002	Sep 16, 2003
	150MG	A075763 003	Sep 16, 2003
	200MG	A075763 004	Sep 16, 2003
	250MG	A075763 005	Sep 16, 2003
MYLAN	100MG	A076129 002	Sep 16, 2003

**DISCONTINUED DRUG PRODUCT LIST**NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	150MG	A076129 003	Sep 16, 2003
	200MG	A076129 004	Sep 16, 2003
	250MG	A076129 005	Sep 16, 2003
ROXANE	50MG	A076196 001	Sep 16, 2003
	100MG	A076196 002	Sep 16, 2003
	150MG	A076196 003	Sep 16, 2003
	200MG	A076196 004	Sep 16, 2003
	250MG	A076196 005	Sep 16, 2003
SANDOZ	50MG	A076072 001	Sep 16, 2003
	50MG	A076302 001	Sep 16, 2003
	100MG	A076072 002	Sep 16, 2003
	100MG	A076302 002	Sep 16, 2003
	150MG	A076072 003	Sep 16, 2003
	150MG	A076302 003	Sep 16, 2003
	200MG	A076072 004	Sep 16, 2003
	200MG	A076302 004	Sep 16, 2003
	250MG	A076072 005	Sep 16, 2003
	250MG	A076302 005	Sep 16, 2003
WATSON LABS	100MG	A076073 002	Sep 16, 2003
	150MG	A076073 003	Sep 16, 2003
	200MG	A076073 004	Sep 16, 2003
	250MG	A076073 005	Sep 16, 2003
SERZONE			
BRISTOL MYERS SQUIBB	50MG	N020152 001	Dec 22, 1994
	100MG	N020152 002	Dec 22, 1994
	150MG	N020152 003	Dec 22, 1994
	200MG	N020152 004	Dec 22, 1994
	250MG	N020152 005	Dec 22, 1994
	300MG	N020152 006	Dec 22, 1994

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

AGOURON

EQ 50MG BASE/SCOOPFUL

N020778 001 Mar 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

X GEN PHARMS

100%

A061579 001

SOLUTION; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN

EQ 87.5MG BASE/5ML

N050285 001

TABLET; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN

EQ 350MG BASE

A060520 001

NEOBIOTIC

PFIZER

EQ 350MG BASE

A060475 001

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB

500MG

A060365 001

LANNETT

500MG

A060607 001

LILLY

500MG

A060385 001

ROXANE

500MG

A062173 001

SANDOZ

500MG

A061586 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE

EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050176 002 Jan 14, 1985

OINTMENT; OPHTHALMIC

STATROL

ALCON

EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050344 002

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON

EQ 3.5MG BASE/ML; 16,250 UNITS/ML

A062339 001 Nov 30, 1984

EQ 3.5MG BASE/ML; 16,250 UNITS/ML

N050456 001

**DISCONTINUED DRUG PRODUCT LIST**NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

POLY-PRED

ALLERGAN EQ 0.35% BASE;10,000 UNITS/ML;0.5% N050081 002

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN EQ 3.5MG BASE/GM;0.25% A061039 002

EQ 3.5MG BASE/GM;0.5% A061039 001

SUSPENSION/DROPS;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN EQ 3.5MG BASE/ML;0.25% A061037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC

NEO-HYDELTRASOL

MERCK EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE N050378 001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYTRES A

SAVAGE LABS EQ 3.5MG BASE/GM;0.1% A062598 001 Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA EQ 3.5MG BASE/GM;0.1% A062600 001 Jul 21, 1986

PHARMADERM EQ 3.5MG BASE/GM;0.1% A062595 001 Jul 21, 1986

OINTMENT;TOPICAL

MYTRES A

SAVAGE LABS EQ 3.5MG BASE/GM;0.1% A062609 001 May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA EQ 3.5MG BASE/GM;0.1% A062608 001 May 23, 1986

PHARMADERM EQ 3.5MG BASE/GM;0.1% A062607 001 May 23, 1986

NETILMICIN SULFATE

INJECTABLE;INJECTION

NETROMYCIN

SCHERING EQ 10MG BASE/ML N050544 001 Feb 28, 1983

EQ 25MG BASE/ML N050544 002 Feb 28, 1983

EQ 100MG BASE/ML N050544 003 Feb 28, 1983

NIACIN

CAPSULE;ORAL

WAMPOCAP

MEDPOINTE PHARM HLC 500MG N011073 003

TABLET;ORAL

NIACIN

EVERYLIFE 500MG A083203 001

HALSEY 500MG A083453 001

HIKMA PHARMS LLC 500MG A083718 001

IMPAX LABS 500MG A083115 001

IVAX SUB TEVA PHARMS 500MG A083180 001

MK LABS 500MG A083525 001

PUREPAC PHARM 500MG A083271 001

SANDOZ 500MG A083306 001

TABLICAPS 500MG A084237 001

WATSON LABS 500MG A083136 001

500MG A083305 001

500MG A085172 001

NICOLAR

SANOFI AVENTIS US 500MG A083823 001

TABLET, EXTENDED RELEASE;ORAL

NIASPAN

ABBVIE 375MG N020381 001 Jul 28, 1997

NIASPAN TITRATION STARTER PACK

ABBVIE 375MG N020381 005 Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION;ORAL

TPN

INTL MINERALS 15MG/5ML;3.75MG/5ML;600MG/5ML N008378 003

**DISCONTINUED DRUG PRODUCT LIST**NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

WATSON LABS

20MG

A074670 001 Oct 28, 1996

30MG

A074670 002 Oct 28, 1996

CAPSULE, EXTENDED RELEASE;ORAL

CARDENE SR

CHIESI USA INC

30MG

N020005 001 Feb 21, 1992

45MG

N020005 002 Feb 21, 1992

60MG

N020005 003 Feb 21, 1992

NICLOSAMIDE

TABLET, CHEWABLE;ORAL

NICLOCIDE

BAYER PHARMS

500MG

N018669 001 May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NICOTROL

MCNEIL CONS

15MG/16HR

N020536 001 Jul 03, 1996

PROSTEP

AVEVA

11MG/24HR

N019983 003 Dec 23, 1998

22MG/24HR

N019983 004 Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

ACTAVIS LABS NY INC

EQ 2MG BASE

A076568 001 Jul 29, 2004

EQ 4MG BASE

A076569 002 Jul 29, 2004

NIFEDIPINE

CAPSULE;ORAL

ADALAT

BAYER PHARMS

10MG

N019478 001 Nov 27, 1985

20MG

N019478 002 Sep 17, 1986

NIFEDIPINE

CATALENT

10MG

A073250 001 Oct 08, 1991

20MG

A074045 001 Apr 30, 1992

CHASE LABS NJ

10MG

A072409 001 Jul 04, 1990

20MG

A073421 001 Jun 19, 1991

TEVA

10MG

A072651 001 Feb 19, 1992

PROCARDIA

PFIZER

20MG

N018482 002 Jul 24, 1986

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

MARTEC USA LLC

90MG

A075414 003 Mar 23, 2004

MYLAN

30MG

A075108 001 Dec 17, 1999

NILUTAMIDE

TABLET;ORAL

NILANDRON

COVIS PHARMA SARL

50MG

N020169 001 Sep 19, 1996

NIMODIPINE

CAPSULE;ORAL

NIMOTOP

BAYER PHARMS

30MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N018869 001 Dec 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

SULAR

SHIONOGI INC

10MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020356 001 Feb 02, 1995

20MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020356 002 Feb 02, 1995

25.5MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020356 006 Jan 02, 2008

30MG \*\*Federal Register determination  
that product was not discontinued or

N020356 003 Feb 02, 1995

## DISCONTINUED DRUG PRODUCT LIST

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL  
SULAR

withdrawn for safety or efficacy  
reasons\*\*

40MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N020356 004 Feb 02, 1995

NITROFURANTOIN

CAPSULE;ORAL

NITROFURANTOIN

WATSON LABS

50MG

A084326 001

100MG

A084326 002

TABLET;ORAL

FURADANTIN

PROCTER AND GAMBLE

50MG

N008693 001

100MG

N008693 002

FURALAN

LANNETT

50MG

A080017 001

100MG

A080017 002

NITROFURANTOIN

ELKINS SINN

50MG

A080003 001

100MG

A080003 002

IVAX SUB TEVA PHARMS

50MG

A080078 002

100MG

A080078 001

SANDOZ

50MG

A080043 001

100MG

A080043 002

WATSON LABS

50MG

A080447 001

50MG

A085797 001

100MG

A080447 002

100MG

A085796 001

WHITEWORTH TOWN PLSN

100MG

A084085 002

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION

IVADANTIN

PROCTER AND GAMBLE

EQ 180MG BASE/VIAL

N012402 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

MYLAN

100MG

A074967 002 Jul 09, 1997

SANDOZ

25MG

A074336 001 Jan 25, 1995

50MG

A074336 002 Jan 25, 1995

100MG

A074336 003 Jan 25, 1995

WATSON LABS

25MG

A073696 001 Dec 31, 1992

50MG

A073696 002 Dec 31, 1992

100MG

A073696 003 Dec 31, 1992

NITROFURANTOIN MACROCRYSTALLINE

WATSON LABS

50MG

A070248 001 Jun 24, 1988

100MG

A070249 001 Jun 24, 1988

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

RANBAXY LABS LTD

75MG;25MG

A076951 001 Mar 30, 2005

NITROFURAZONE

CREAM; TOPICAL

FURACIN

SHIRE

0.2%

A083789 001

DRESSING; TOPICAL

ACTIN-N

SHERWOOD MEDCL

0.2%

N017343 001

OINTMENT; TOPICAL

FURACIN

SHIRE

0.2%

N005795 001

NITROFURAZONE

AMBIX

0.2%

A086077 001

LANNETT

0.2%

A084393 001

PERRIGO NEW YORK

0.2%

A084968 001

TARO

0.2%

A086156 001

WENDT

0.2%

A086766 001

## DISCONTINUED DRUG PRODUCT LIST

NITROFURAZONE

POWDER; TOPICAL

FURACIN

SHIRE

0.2%

A083791 001

SOLUTION; TOPICAL

NITROFURAZONE

PERRIGO NEW YORK

0.2%

A085130 001

WENDT

0.2%

A087081 001

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

POHL BOSKAMP

0.4MG/SPRAY

N018705 001 Oct 31, 1985

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

KREMERS URBAN PHARMS

0.2MG/HR

A075115 001 Aug 10, 2004

0.4MG/HR

A075115 002 Aug 10, 2004

MYLAN TECHNOLOGIES

0.1MG/HR

A074992 004 Nov 12, 1999

0.2MG/HR

A074992 003 Nov 12, 1999

0.4MG/HR

A074992 002 Nov 12, 1999

0.6MG/HR

A074992 001 Nov 12, 1999

TRANSDERM-NITRO

NOVARTIS

0.1MG/HR

N020144 001 Feb 27, 1996

0.2MG/HR

N020144 002 Feb 27, 1996

0.4MG/HR

N020144 003 Feb 27, 1996

0.6MG/HR

N020144 004 Feb 27, 1996

0.8MG/HR

N020144 005 Feb 27, 1996

INJECTABLE; INJECTION

NITRO IV

POHL BOSKAMP

5MG/ML

N018672 002 Aug 30, 1983

NITRO-BID

SANOFI AVENTIS US

5MG/ML

N018621 001 Jan 05, 1982

10MG/ML

A071159 001 Feb 28, 1990

NITROGLYCERIN

ABRAXIS PHARM

5MG/ML

A070077 001 Dec 13, 1985

5MG/ML

A071203 001 May 08, 1987

HOSPIRA

5MG/ML

N018531 001

INTL MEDICATION

5MG/ML

A070026 001 Sep 10, 1985

LUITPOLD

5MG/ML

A071492 001 May 24, 1988

SMITH AND NEPHEW

5MG/ML

A070633 001 Jun 19, 1986

5MG/ML

A070634 001 Jun 19, 1986

NITROGLYCERIN IN DEXTROSE 5%

HOSPIRA

0.1MG/ML

A074083 001 Oct 26, 1994

NITROL

RORER

0.8MG/ML

N018774 001 Jan 19, 1983

NITRONAL

POHL BOSKAMP

1MG/ML

N018672 001 Aug 30, 1983

NITROSTAT

PARKE DAVIS

0.8MG/ML

N018588 001

5MG/ML

A070863 001 Jan 08, 1987

5MG/ML

N018588 002 Dec 23, 1983

10MG/ML

A070871 001 Jan 08, 1987

10MG/ML

A070872 001 Jan 08, 1987

TRIDIL

HOSPIRA

0.5MG/ML

N018537 002 Jun 16, 1983

5MG/ML

N018537 001

NIZATIDINE

CAPSULE; ORAL

AXID

SMITHKLINE BEECHAM

150MG

N019508 001 Apr 12, 1988

300MG

N019508 002 Apr 12, 1988

NIZATIDINE

ANI PHARMS INC

150MG

A075461 001 Jul 08, 2002

300MG

A075461 002 Jul 08, 2002

APOTEX INC

150MG

A076383 001 Jan 23, 2003

300MG

A076383 002 Jan 23, 2003

MYLAN PHARMS INC

150MG

A075934 001 Jul 09, 2002

300MG

A075934 002 Jul 09, 2002

**DISCONTINUED DRUG PRODUCT LIST**NONOXYNOL-9

AEROSOL; VAGINAL

DELFIN

PERSONAL PRODS

12.5%

N014349 002

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

METRICS PHARM

EQ 1MG BASE/ML

A040522 001 Sep 30, 2004

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

EASTMAN KODAK

EQ 0.033MG BASE/ML; 2%; 0.4%

N008592 003

NORETHINDRONE

TABLET; ORAL

NORLUTIN

PARKE DAVIS

5MG

N010895 002

NORETHINDRONE ACETATE

TABLET; ORAL

NORLUTATE

PARKE DAVIS

5MG

N012184 002

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

MERCK

0.3%

N019757 001 Jun 17, 1991

TABLET; ORAL

NOROXIN

MERCK

400MG

N019384 002 Oct 31, 1986

NORGESTREL

TABLET; ORAL

OVRETE

WYETH PHARMS

0.075MG

N017031 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HYDROCHLORIDE

LILLY

EQ 10MG BASE

N014684 001

EQ 25MG BASE

N014684 002

NORTRIPTYLINE HYDROCHLORIDE

SANDOZ

EQ 10MG BASE

A074054 001 Dec 31, 1992

EQ 10MG BASE

A074835 001 Jun 30, 1997

EQ 25MG BASE

A074054 002 Dec 31, 1992

EQ 25MG BASE

A074835 002 Jun 30, 1997

EQ 50MG BASE

A074054 003 Dec 31, 1992

EQ 50MG BASE

A074835 003 Jun 30, 1997

EQ 75MG BASE

A074054 004 Dec 31, 1992

EQ 75MG BASE

A074835 004 Jun 30, 1997

TEVA

EQ 10MG BASE

A073667 001 Apr 11, 1996

EQ 25MG BASE

A073667 002 Apr 11, 1996

EQ 50MG BASE

A073667 003 Apr 11, 1996

EQ 75MG BASE

A073667 004 Apr 11, 1996

SOLUTION; ORAL

AVENTYL

RANBAXY

EQ 10MG BASE/5ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N014685 001

PAMELOR

MALLINCKRODT INC

EQ 10MG BASE/5ML

N018012 001

NYSTATIN

CREAM; TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/GM

A061810 001

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM

A060575 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062387 001 Jul 29, 1982

NILSTAT

LEDERLE

100,000 UNITS/GM

A061445 001

**DISCONTINUED DRUG PRODUCT LIST**NYSTATIN

CREAM; TOPICAL

NYSTATIN

G AND W LABS INC	100,000 UNITS/GM	A061966 001	
TARO	100,000 UNITS/GM	A062457 001	Jul 28, 1983

LOTION; TOPICAL

CANDEX

BAYER PHARMS	100,000 UNITS/ML	N050233 001	
--------------	------------------	-------------	--

OINTMENT; TOPICAL

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/GM	A060571 001	
-------------------	------------------	-------------	--

MYKINAC

ALPHARMA US PHARMS	100,000 UNITS/GM	A062731 001	Sep 22, 1986
--------------------	------------------	-------------	--------------

NILSTAT

LEDERLE	100,000 UNITS/GM	A061444 001	
---------	------------------	-------------	--

PASTILLE; ORAL

MYCOSTATIN

BRISTOL MYERS SQUIBB	200,000 UNITS	N050619 001	Apr 09, 1987
----------------------	---------------	-------------	--------------

POWDER; ORAL

BARSTATIN 100

BARLAN	100%	A062489 001	Apr 27, 1988
--------	------	-------------	--------------

NILSTAT

DAVA PHARMS INC	100%	N050576 001	Dec 22, 1983
-----------------	------	-------------	--------------

NYSTATIN

PADDOCK LLC	100%	A062613 001	Nov 26, 1985
-------------	------	-------------	--------------

POWDER; TOPICAL

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/GM	A060578 001	
-------------------	------------------	-------------	--

NYSTATIN

NESHER PHARMS	100,000 UNITS/GM	A065321 001	Aug 18, 2006
---------------	------------------	-------------	--------------

SUPPOSITORY; VAGINAL

NYSERT

WARNER CHILCOTT	100,000 UNITS	N050478 001	
-----------------	---------------	-------------	--

SUSPENSION; ORAL

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/ML	A061533 001	
-------------------	------------------	-------------	--

NILSTAT

GLENMARK GENERICS	100,000 UNITS/ML	N050299 001	
-------------------	------------------	-------------	--

NYSTATIN

ALPHARMA US PHARMS	100,000 UNITS/ML	A062571 001	Oct 29, 1985
--------------------	------------------	-------------	--------------

MORTON GROVE	100,000 UNITS/ML	A062835 001	Nov 19, 1987
--------------	------------------	-------------	--------------

PHARMADERM	100,000 UNITS/ML	A062518 001	Jul 06, 1984
------------	------------------	-------------	--------------

PHARMAFAIR	100,000 UNITS/ML	A062541 001	Jan 16, 1985
------------	------------------	-------------	--------------

ROXANE	100,000 UNITS/ML	A062832 001	Dec 27, 1991
--------	------------------	-------------	--------------

TEVA	100,000 UNITS/ML	A062670 001	Jun 18, 1987
------	------------------	-------------	--------------

	100,000 UNITS/ML	A062776 001	Dec 17, 1987
--	------------------	-------------	--------------

NYSTEX

SAVAGE LABS	100,000 UNITS/ML	A062519 001	Jul 06, 1984
-------------	------------------	-------------	--------------

TABLET; ORAL

MYCOSTATIN

DELCOR ASSET CORP	500,000 UNITS	A060574 001	
-------------------	---------------	-------------	--

NILSTAT

LEDERLE	500,000 UNITS	A061151 001	
---------	---------------	-------------	--

NYSTATIN

QUANTUM PHARMICS	500,000 UNITS	A062525 001	Oct 29, 1984
------------------	---------------	-------------	--------------

SANDOZ	500,000 UNITS	A062065 001	
--------	---------------	-------------	--

USL PHARMA	500,000 UNITS	A062524 001	Nov 26, 1985
------------	---------------	-------------	--------------

WATSON LABS	500,000 UNITS	A062402 001	Dec 16, 1982
-------------	---------------	-------------	--------------

TABLET; VAGINAL

KOROSTATIN

HOLLAND RANTOS	100,000 UNITS	A061718 001	
----------------	---------------	-------------	--

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS	A060577 001	
-------------------	---------------	-------------	--

NILSTAT

LEDERLE	100,000 UNITS	A061325 001	
---------	---------------	-------------	--

NYSTATIN

FOUGERA	100,000 UNITS	A062459 001	Nov 09, 1983
---------	---------------	-------------	--------------

PHARMADERM	100,000 UNITS	A062460 001	Nov 09, 1983
------------	---------------	-------------	--------------

QUANTUM PHARMICS	100,000 UNITS	A062509 001	Apr 03, 1984
------------------	---------------	-------------	--------------

SANDOZ	100,000 UNITS	A061965 001	
--------	---------------	-------------	--

TEVA	100,000 UNITS	A062502 001	Dec 23, 1983
------	---------------	-------------	--------------

WATSON LABS	100,000 UNITS	A062176 001	
-------------	---------------	-------------	--



**DISCONTINUED DRUG PRODUCT LIST**NYSTATIN; TRIAMCINOLONE ACETONIDE

## CREAM; TOPICAL

MYCO-TRIA CET II					
TEVA	100,000 UNITS/GM;0.1%		A061954	002	Sep 20, 1985
MYCOLOG-II					
DELCOR ASSET CORP	100,000 UNITS/GM;0.1%		A060576	002	May 01, 1985
	100,000 UNITS/GM;0.1%		A062606	001	May 15, 1985
MYKACET					
G AND W LABS INC	100,000 UNITS/GM;0.1%		A062367	001	May 28, 1985
MYTRES F					
SAVAGE LABS	100,000 UNITS/GM;0.1%		A062597	001	Oct 08, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE					
ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%		A063010	001	Dec 20, 1988
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%		A062186	002	Jun 06, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%		A062657	001	Jul 30, 1986
TARO	100,000 UNITS/GM;0.1%		A062347	001	Mar 30, 1987
NYSTATIN-TRIAMCINOLONE ACETONIDE					
PHARMADERM	100,000 UNITS/GM;0.1%		A062596	001	Oct 08, 1985
OINTMENT; TOPICAL					
MYCO-TRIA CET II					
TEVA	100,000 UNITS/GM;0.1%		A062045	002	Nov 26, 1985
MYCOLOG-II					
DELCOR ASSET CORP	100,000 UNITS/GM;0.1%		A060572	001	Jun 28, 1985
MYKACET					
G AND W LABS INC	100,000 UNITS/GM;0.1%		A062733	001	Mar 09, 1987
MYTRES F					
SAVAGE LABS	100,000 UNITS/GM;0.1%		A062601	001	Oct 09, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE					
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%		A062280	002	Oct 10, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%		A062656	001	Jul 30, 1986
NYSTATIN-TRIAMCINOLONE ACETONIDE					
PHARMADERM	100,000 UNITS/GM;0.1%		A062603	001	Oct 09, 1985

OFLOXACIN

## INJECTABLE; INJECTION

FLOXIN					
ORTHO MCNEIL PHARM	20MG/ML		N020087	002	Mar 31, 1992
	40MG/ML		N020087	003	Mar 31, 1992
FLOXIN IN DEXTROSE 5%					
ORTHO MCNEIL PHARM	400MG/100ML		N020087	001	Mar 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
ORTHO MCNEIL PHARM	4MG/ML		N020087	004	Mar 31, 1992
	400MG/100ML		N020087	005	Mar 31, 1992
OFLOXACIN					
BEDFORD	40MG/ML		A075762	001	Jan 16, 2002
SOLUTION/DROPS; OPHTHALMIC					
OFLOXACIN					
APOTEX INC	0.3%		A076513	001	May 14, 2004
SANDOZ	0.3%		A076848	001	Nov 25, 2008
TABLET; ORAL					
FLOXIN					
JANSSEN PHARMS	200MG		N019735	001	Dec 28, 1990
	300MG		N019735	002	Dec 28, 1990
	400MG		N019735	003	Dec 28, 1990
OFLOXACIN					
LARKEN LABS	200MG		A076093	001	Sep 02, 2003
	300MG		A076093	002	Sep 02, 2003
	400MG		A076093	003	Sep 02, 2003
RANBAXY LABS LTD	200MG		A076220	001	Sep 02, 2003
	300MG		A076220	002	Sep 02, 2003
	400MG		A076220	003	Sep 02, 2003

OMEPRAZOLE; SODIUM BICARBONATE

## FOR SUSPENSION; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE					
PAR PHARM	20MG/PACKET;1.68GM/PACKET		A079182	001	Apr 19, 2013
	40MG/PACKET;1.68GM/PACKET		A079182	002	Apr 19, 2013

## DISCONTINUED DRUG PRODUCT LIST

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

NESHER PHARMS	4MG	A077717 001	Jun 25, 2007
	8MG	A077717 002	Jun 25, 2007
PAR PHARM	4MG	A076506 001	Dec 26, 2006
	8MG	A076506 002	Dec 26, 2006
	16MG	A077406 001	Dec 26, 2006
	24MG	A077406 002	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

APOTEX INC	EQ 2MG BASE/ML	A077368 001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076695 001	Dec 26, 2006
LANNETT	EQ 2MG BASE/ML	A090116 001	Apr 14, 2010
LUITPOLD	EQ 2MG BASE/ML	A077582 001	Dec 26, 2006
PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544 001	Dec 26, 2006
SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

BEDFORD LABS	EQ 0.64MG BASE/ML	A078291 001	Apr 13, 2009
CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308 001	Mar 17, 2008
HOSPIRA	EQ 0.64MG BASE/ML	A076978 001	Feb 26, 2007
	EQ 0.64MG BASE/ML	A077348 001	Feb 01, 2007
TEVA PHARMS	EQ 0.64MG BASE/ML	A077480 001	Nov 22, 2006

ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 0.64MG BASE/ML	N021915 002	Dec 27, 2006
-----------------	-------------------	-------------	--------------

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

APOTEX INC	EQ 2MG BASE/ML	A077343 001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076696 001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077387 001	Dec 26, 2006

ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 0.64MG BASE/ML	N020403 001	Jan 31, 1995
-----------------	-------------------	-------------	--------------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

HIKMA PHARMS LLC	EQ 4MG BASE	A077545 001	Sep 06, 2007
	EQ 8MG BASE	A077545 002	Sep 06, 2007
	EQ 24MG BASE	A077545 003	Sep 06, 2007
PAR PHARM	EQ 4MG BASE	A077303 001	Jun 25, 2007
	EQ 8MG BASE	A077303 002	Jun 25, 2007
	EQ 24MG BASE	A077303 004	Jun 25, 2007
TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011
	EQ 8MG BASE	A077729 002	Mar 28, 2011
	EQ 24MG BASE	A077729 003	Mar 28, 2011

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

WATSON LABS	30MG/ML	A087062 001	
-------------	---------	-------------	--

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

MEDICIS	100MG	N012157 001	
---------	-------	-------------	--

ORPHENADRINE CITRATE

ASCOT	100MG	A088067 001	Apr 06, 1983
SANDOZ	100MG	A085046 001	
WATSON LABS	100MG	A084303 001	

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

3M	50MG	N010653 001	
----	------	-------------	--

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

ROCHE	EQ 12MG BASE/ML	N021246 001	Dec 14, 2000
-------	-----------------	-------------	--------------

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A061336 001	
	EQ 250MG BASE	A062241 001	
	EQ 500MG BASE	A061336 002	
	EQ 500MG BASE	A062241 002	

## DISCONTINUED DRUG PRODUCT LIST

OXACILLIN SODIUM

CAPSULE; ORAL

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE

A061450 002

EQ 500MG BASE

A061450 001

TEVA

EQ 250MG BASE

A062222 001

EQ 500MG BASE

A062222 002

PROSTAPHLIN

APOTHECON

EQ 500MG BASE

N050118 002

FOR SOLUTION; ORAL

BACTOCILL

GLAXOSMITHKLINE

EQ 250MG BASE/5ML

A062321 001

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/5ML

A061457 001

TEVA

EQ 250MG BASE/5ML

A062252 001

PROSTAPHLIN

APOTHECON

EQ 250MG BASE/5ML

N050194 001

INJECTABLE; INJECTION

BACTOCILL

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A061334 006 Mar 26, 1982

EQ 1GM BASE/VIAL

A062736 001 Dec 19, 1986

EQ 2GM BASE/VIAL

A061334 007 Mar 26, 1982

EQ 2GM BASE/VIAL

A062736 002 Dec 19, 1986

EQ 4GM BASE/VIAL

A061334 008 Mar 26, 1982

EQ 10GM BASE/VIAL

A061334 010

EQ 500MG BASE/VIAL

A061334 009 Mar 26, 1982

OXACILLIN SODIUM

APOTHECON

EQ 1GM BASE/VIAL

N050195 003

EQ 2GM BASE/VIAL

N050195 004

EQ 4GM BASE/VIAL

N050195 005

EQ 250MG BASE/VIAL

N050195 001

EQ 500MG BASE/VIAL

N050195 002

ELKINS SINN

EQ 1GM BASE/VIAL

A062711 003 Feb 03, 1989

EQ 2GM BASE/VIAL

A062711 004 Feb 03, 1989

EQ 4GM BASE/VIAL

A062711 005 Feb 03, 1989

EQ 10GM BASE/VIAL

A062711 006 Feb 03, 1989

EQ 250MG BASE/VIAL

A062711 001 Feb 03, 1989

EQ 500MG BASE/VIAL

A062711 002 Feb 03, 1989

ISTITUTO BIO ITA SPA

EQ 1GM BASE/VIAL

A062798 001 Dec 11, 1995

EQ 2GM BASE/VIAL

A062798 002 Dec 11, 1995

EQ 125MG BASE/VIAL

A062798 003 Dec 11, 1995

EQ 250MG BASE/VIAL

A062798 004 Dec 11, 1995

EQ 500MG BASE/VIAL

A062798 005 Dec 11, 1995

SANDOZ

EQ 250MG BASE/VIAL

A061490 001

EQ 500MG BASE/VIAL

A061490 002

WATSON LABS INC

EQ 1GM BASE/VIAL

A062856 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062856 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062856 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A062984 001 Sep 29, 1988

EQ 250MG BASE/VIAL

A062856 001 Oct 26, 1988

EQ 500MG BASE/VIAL

A062856 002 Oct 26, 1988

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

SANOFI AVENTIS US

50MG/VIAL

N021492 001 Aug 09, 2002

100MG/VIAL

N021492 002 Aug 09, 2002

OXALIPLATIN

SANDOZ

50MG/VIAL

A090849 001 Apr 28, 2011

100MG/VIAL

A090849 002 Apr 28, 2011

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

PFIZER

250MG

N018069 001

OXANDROLONE

TABLET; ORAL

OXANDROLONE

ROXANE

2.5MG

A077249 001 Jul 10, 2007

10MG

A077249 002 Jul 10, 2007

SANDOZ

2.5MG

A076897 001 Dec 01, 2006

10MG

A076897 002 Dec 01, 2006

## DISCONTINUED DRUG PRODUCT LIST

OXAPROZIN

TABLET; ORAL

OXAPROZIN

ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
MYLAN	600MG	A075851	001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001
SANDOZ	600MG	A075842	001	Apr 12, 2001
	600MG	A075850	001	Apr 27, 2001
WATSON LABS	600MG	A075848	001	Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

GD SEARLE	600MG	N020776	001	Oct 17, 2002
-----------	-------	---------	-----	--------------

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987
	15MG	A070944	001	Aug 03, 1987
	30MG	A070945	001	Aug 03, 1987
MUTUAL PHARM	10MG	A071026	002	Aug 10, 1987
	15MG	A071026	003	Aug 10, 1987
	30MG	A071026	001	Aug 10, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987
WATSON LABS	10MG	A072952	001	Sep 28, 1990
	15MG	A072953	001	Sep 28, 1990
	30MG	A072954	001	Sep 28, 1990

SERAX

ALPHARMA US PHARMS	10MG	N015539	002	
	15MG	N015539	004	
	30MG	N015539	006	

ZAXOPAM

QUANTUM PHARMICS	10MG	A070650	001	Mar 01, 1988
	15MG	A070640	001	Mar 01, 1988
	30MG	A070641	001	Mar 01, 1988

TABLET; ORAL

OXAZEPAM

MUTUAL PHARM	15MG	A070683	001	Jan 16, 1987
PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987

SERAX

ALPHARMA US PHARMS	15MG	N015539	008	
--------------------	------	---------	-----	--

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007
	300MG	A078005	002	Dec 11, 2007
	600MG	A078005	003	Dec 11, 2007

OXPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL

TRASICOR

NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL

CHOLEDYL

PARKE DAVIS	100MG/5ML	N009268	012	Nov 27, 1984
-------------	-----------	---------	-----	--------------

OXTRIPHYLLINE

MORTON GROVE	100MG/5ML	A088243	001	Dec 05, 1983
--------------	-----------	---------	-----	--------------

SYRUP; ORAL

CHOLEDYL

PARKE DAVIS	50MG/5ML	N009268	011	
-------------	----------	---------	-----	--

**DISCONTINUED DRUG PRODUCT LIST**OXTRIPHYLLINE

SYRUP; ORAL

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE

50MG/5ML

A088242 001 Dec 05, 1983

TABLET, DELAYED RELEASE; ORAL

CHOLEDYL

PARKE DAVIS

100MG

N009268 003

200MG

N009268 007

OXTRIPHYLLINE

WATSON LABS

100MG

A087866 001 Aug 25, 1983

200MG

A087835 001 Aug 25, 1983

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

ORTHO MCNEIL JANSSEN

5MG/5ML

N018211 001

OXYBUTYNIN CHLORIDE

APOTEX INC

5MG/5ML

A074997 001 Oct 15, 1997

MIKART

5MG/5ML

A075039 001 Jan 29, 1999

TABLET; ORAL

DITROPAN

JANSSEN PHARMS

5MG

N017577 001

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS

5MG

A072296 001 Dec 08, 1988

USL PHARMA

5MG

A070746 001 Mar 10, 1988

WATSON LABS

5MG

A072485 001 Apr 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ROXICODONE

ROXANE

10MG

N020932 001 Oct 26, 1998

30MG

N020932 002 Oct 26, 1998

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

ENDO PHARMS

1.5MG/ML

N011707 001

SUPPOSITORY; RECTAL

NUMORPHAN

ENDO PHARMS

5MG

N011738 004

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

ENDO PHARMS

5MG

N021610 001 Jun 22, 2006

7.5MG

N021610 005 Feb 29, 2008

10MG

N021610 002 Jun 22, 2006

15MG

N021610 006 Feb 29, 2008

20MG

N021610 003 Jun 22, 2006

30MG

N021610 007 Feb 29, 2008

40MG

N021610 004 Jun 22, 2006

OXYPHENBUTAZONE

TABLET; ORAL

OXYPHENBUTAZONE

WATSON LABS

100MG

A088399 001 Sep 17, 1984

TANDEARIL

NOVARTIS

100MG

N012542 004 Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

DARICON

PFIZER

10MG

N011612 001

OXYPHENONIUM BROMIDE

TABLET; ORAL

ANTRENYL

NOVARTIS

5MG

N008492 002

OXYTETRACYCLINE

TABLET; ORAL

TERRAMYCIN

PFIZER

250MG

N050287 001

**DISCONTINUED DRUG PRODUCT LIST**OXYTETRACYCLINE CALCIUM

SYRUP; ORAL

TERRAMYCIN

PFIZER EQ 125MG BASE/5ML A060595 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

OXY-KESSO-TETRA

FERRANTE EQ 250MG BASE A060179 001

OXYTETRACYCLINE HYDROCHLORIDE

HIKMA PHARMS LLC EQ 250MG BASE A060770 001

IMPAX LABS EQ 250MG BASE A060760 001

PROTER EQ 250MG BASE A060869 001

PUREPAC PHARM EQ 250MG BASE A060634 001

TERRAMYCIN

PFIZER EQ 125MG BASE N050286 001

EQ 250MG BASE N050286 002

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER EQ 250MG BASE/VIAL A060586 001

EQ 500MG BASE/VIAL A060586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC

TERRAMYCIN W/ POLYMYXIN

PFIZER EQ 5MG BASE/GM;10,000 UNITS/GM A061841 001

TABLET; VAGINAL

TERRAMYCIN-POLYMYXIN

PFIZER EQ 100MG BASE;100,000 UNITS A061009 001

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

TEVA PHARMS USA 10USP UNITS/ML (10USP UNITS/ML) A077453 001 Jan 24, 2008

100USP UNITS/10ML (10USP UNITS/ML) A077453 002 Jan 24, 2008

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

ABBOTT 1USP UNITS/100ML N019185 004 Mar 29, 1985

2USP UNITS/100ML N019185 003 Mar 29, 1985

OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

ABBOTT 2USP UNITS/100ML N019185 002 Mar 29, 1985

OXYTOCIN 5 USP UNITS IN DEXTROSE 5%

ABBOTT 1USP UNITS/100ML N019185 001 Mar 29, 1985

SYNTOCINON

NOVARTIS 10USP UNITS/ML N018245 001

SOLUTION; NASAL

SYNTOCINON

RETROPHIN INC 40USP UNITS/ML N012285 001

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

ACCORD HLTHCARE 6MG/ML A075436 001 Nov 12, 2004

HOSPIRA 6MG/ML A076233 001 Aug 01, 2002

MYLAN 6MG/ML A075278 001 Jan 25, 2002

PLIVA LACHEMA 6MG/ML A077413 001 Mar 12, 2008

TEVA PHARMS USA 6MG/ML A075297 001 Jan 25, 2002

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

JANSSEN PHARMS 12MG \*\*Federal Register determination N021999 004 Dec 19, 2006

that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

ALOXI

HELSINN HLTHCARE EQ 0.5MG BASE \*\*Federal Register N022233 001 Aug 22, 2008

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

## DISCONTINUED DRUG PRODUCT LIST

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

ARELIA

NOVARTIS

30MG/VIAL

N020036 001 Oct 31, 1991

60MG/VIAL

N020036 003 May 06, 1993

90MG/VIAL

N020036 004 May 06, 1993

PAMIDRONATE DISODIUM

AESGEN

30MG/VIAL

A075594 001 May 06, 2002

90MG/VIAL

A075594 002 May 06, 2002

MN PHARMS

30MG/VIAL

A078300 001 Mar 10, 2009

90MG/VIAL

A078300 002 Mar 10, 2009

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE; ORAL

COTAZYM

ORGANON USA INC

30000USPU; 30000USPU; 8000USPU

N020580 001 Dec 09, 1996

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

ASTRAZENECA

1MG/ML

A072210 001 Mar 31, 1988

2MG/ML

A072211 001 Mar 31, 1988

2MG/ML

A072212 001 Mar 31, 1988

2MG/ML

A072213 001 Mar 31, 1988

ELKINS SINN

1MG/ML

A072058 001 Mar 23, 1988

2MG/ML

A072059 001 Mar 23, 1988

2MG/ML

A072060 001 Mar 23, 1988

HOSPIRA

2MG/ML

A072321 001 Jan 19, 1989

PAVULON

ORGANON USA INC

1MG/ML

N017015 002

2MG/ML

N017015 001

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

ABBVIE

150MG

N006800 003

300MG

N006800 001

SOLUTION; ORAL

PARADIONE

ABBVIE

300MG/ML

N006800 002

PARAMETHASONE ACETATE

TABLET; ORAL

HALDRONE

LILLY

1MG

N012772 005

2MG

N012772 006

PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTONYL

ABBOTT

10MG

N013448 002

25MG

N013448 003

50MG

N013448 004

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

KING PFIZER

EQ 250MG BASE

A062310 001

PARKEDALE

EQ 250MG BASE

A060521 001

SYRUP; ORAL

HUMATIN

PARKE DAVIS

EQ 125MG BASE/5ML

A060522 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

APOTEX TECHNOLOGIES

EQ 10MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020885 001 Oct 09, 1998

EQ 20MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020885 002 Oct 09, 1998

EQ 30MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or

N020885 003 Oct 09, 1998

## DISCONTINUED DRUG PRODUCT LIST

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL

PAXIL

efficacy reasons\*\*

EQ 40MG BASE \*\*Federal Register N020885 004 Oct 09, 1998  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

SUSPENSION;ORAL

PAROXETINE HYDROCHLORIDE

APOTEX INC

EQ 10MG BASE/5ML A077395 001 Dec 05, 2006

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

ROXANE

EQ 10MG BASE A078026 001 Jun 29, 2007

EQ 20MG BASE A078026 002 Jun 29, 2007

EQ 30MG BASE A078026 003 Jun 29, 2007

EQ 40MG BASE A078026 004 Jun 29, 2007

SANDOZ

EQ 10MG BASE A075566 001 Mar 08, 2004

EQ 20MG BASE A075566 002 Mar 08, 2004

EQ 30MG BASE A075566 003 Mar 08, 2004

EQ 40MG BASE A075566 004 Mar 08, 2004

TEVA PHARMS

EQ 10MG BASE A077082 001 Jun 29, 2007

EQ 20MG BASE A077082 002 Jun 29, 2007

EQ 30MG BASE A077082 003 Jun 29, 2007

EQ 40MG BASE A077082 004 Jun 29, 2007

PAXIL

APOTEX TECHNOLOGIES

EQ 50MG BASE N020031 004 Dec 29, 1992

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA

EQ 10MG BASE/ML (EQ 10MG BASE/ML) N202799 007 Mar 27, 2012

EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N202799 008 Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA

EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) N202799 001 Mar 27, 2012

EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) N202799 002 Mar 27, 2012

EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) N202799 003 Mar 27, 2012

EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) N202799 004 Mar 27, 2012

EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) N202799 005 Mar 27, 2012

EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) N202799 006 Mar 27, 2012

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC

ALAMAST

SANTEN

0.1% N021079 001 Sep 24, 1999

PEMOLINE

TABLET;ORAL

CYLERT

ABBOTT

18.75MG N016832 001

37.5MG N016832 002

75MG N016832 003

PEMOLINE

ACTAVIS ELIZABETH

18.75MG A075595 001 Feb 28, 2000

37.5MG A075595 002 Feb 28, 2000

75MG A075595 003 Feb 28, 2000

MALLINCKRODT

18.75MG A075726 003 Mar 30, 2001

37.5MG A075726 002 Mar 30, 2001

75MG A075726 001 Mar 30, 2001

SANDOZ

18.75MG A075286 001 Dec 27, 1999

37.5MG A075286 002 Jun 30, 1999

75MG A075286 003 Jun 30, 1999

TEVA PHARMS

18.75MG A075030 003 Feb 22, 2000

37.5MG A075030 001 Jan 29, 1999

75MG A075030 002 Jan 29, 1999

VINTAGE PHARMS

18.75MG A075328 001 Apr 19, 2000

37.5MG A075328 002 Apr 19, 2000

75MG A075328 003 Apr 19, 2000

WATSON LABS

18.75MG A075287 001 Jun 13, 2001

37.5MG A075287 002 Sep 18, 2000

75MG A075287 003 Sep 18, 2000

TABLET, CHEWABLE;ORAL

CYLERT

ABBOTT

37.5MG N017703 001



**DISCONTINUED DRUG PRODUCT LIST**PEMOLINE

TABLET, CHEWABLE;ORAL

PEMOLINE

ACTAVIS ELIZABETH

37.5MG

A075678 001 Jul 26, 2000

TEVA PHARMS

37.5MG

A075555 001 Feb 18, 2000

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

AUXILIUM PHARMS LLC

10MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N018976 001 Dec 30, 1987

20MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N018976 004 Jan 05, 1989

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

ATON

125MG

N019853 002

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION

BICILLIN L-A

WYETH AYERST

300,000 UNITS/ML

N050131 001

SUSPENSION;ORAL

BICILLIN

WYETH AYERST

300,000 UNITS/5ML

N050126 002

TABLET;ORAL

BICILLIN

WYETH AYERST

200,000 UNITS

N050128 001

PENICILLIN G POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN

TEVA

200,000 UNITS/5ML

A060307 002

400,000 UNITS/5ML

A060307 004

PENICILLIN G POTASSIUM

MYLAN

200,000 UNITS/5ML

A060752 003

250,000 UNITS/5ML

A060752 002

400,000 UNITS/5ML

A060752 001

PUREPAC PHARM

250,000 UNITS/5ML

A061740 001

400,000 UNITS/5ML

A061740 002

PENICILLIN-2

TEVA

250,000 UNITS/5ML

A060307 003

PENTIDS '200'

APOTHECON

200,000 UNITS/5ML

A062149 001

PENTIDS '400'

APOTHECON

400,000 UNITS/5ML

A062149 002

PFIZERPEN G

PFIZER

400,000 UNITS/5ML

A060587 001

INJECTABLE;INJECTION

PENICILLIN G POTASSIUM

APOTHECON

1,000,000 UNITS/VIAL

A060362 001

5,000,000 UNITS/VIAL

A060362 003

10,000,000 UNITS/VIAL

A060362 004

20,000,000 UNITS/VIAL

A060362 002

CONSOLIDATED PHARM

500,000 UNITS/VIAL

A060806 001

1,000,000 UNITS/VIAL

A060806 002

5,000,000 UNITS/VIAL

A060806 003

10,000,000 UNITS/VIAL

A060806 004

LILLY

200,000 UNITS/VIAL

A060384 004

500,000 UNITS/VIAL

A060384 003

1,000,000 UNITS/VIAL

A060384 002

5,000,000 UNITS/VIAL

A060384 001

20,000,000 UNITS/VIAL

A060384 005

20,000,000 UNITS/VIAL

A060601 001

PARKE DAVIS

1,000,000 UNITS/VIAL

A062003 001

5,000,000 UNITS/VIAL

A062003 002

20,000,000 UNITS/VIAL

A060074 003

PFIZER

SANDOZ

1,000,000 UNITS/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or

A065079 001 Aug 30, 2002

## DISCONTINUED DRUG PRODUCT LIST

PENICILLIN G POTASSIUM

## INJECTABLE; INJECTION

## PENICILLIN G POTASSIUM

	efficacy reasons**		
WATSON LABS INC	1,000,000 UNITS/VIAL	A062991 001	Sep 13, 1988
	5,000,000 UNITS/VIAL	A062991 002	Sep 13, 1988
	10,000,000 UNITS/VIAL	A062991 003	Sep 13, 1988
	20,000,000 UNITS/VIAL	A062991 004	Sep 13, 1988

## PFIZERPEN

PFIZER	1,000,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060657 001	
--------	---------------------------------------------------------------------------------------------------------------------------------------	-------------	--

## TABLET; ORAL

## PENICILLIN G POTASSIUM

APOTHECON	250,000 UNITS	A060392 003	
IVAX SUB TEVA PHARMS	400,000 UNITS	A060073 004	
LILLY	250,000 UNITS	A060403 001	
MYLAN	200,000 UNITS	A060781 001	
	250,000 UNITS	A060781 002	
	400,000 UNITS	A060781 003	
	500,000 UNITS	A060781 005	
	800,000 UNITS	A060781 004	
PUREPAC PHARM	200,000 UNITS	A061588 001	
	250,000 UNITS	A061588 002	
	400,000 UNITS	A061588 003	
TEVA	200,000 UNITS	A060306 001	
	250,000 UNITS	A060306 002	
	400,000 UNITS	A060306 003	
	500,000 UNITS	A060306 004	
WYETH AYERST	200,000 UNITS	A060413 001	
	250,000 UNITS	A060413 002	
	400,000 UNITS	A060413 003	

## PENTIDS '200'

APOTHECON	200,000 UNITS	A062155 001	
-----------	---------------	-------------	--

## PENTIDS '250'

APOTHECON	250,000 UNITS	A062155 002	
-----------	---------------	-------------	--

## PENTIDS '400'

APOTHECON	400,000 UNITS	A060392 004	
-----------	---------------	-------------	--

	400,000 UNITS	A062155 003	
--	---------------	-------------	--

## PENTIDS '800'

APOTHECON	800,000 UNITS	A060392 005	
-----------	---------------	-------------	--

	800,000 UNITS	A062155 004	
--	---------------	-------------	--

## PFIZERPEN G

PFIZER	50,000 UNITS	A060075 001	
	100,000 UNITS	A060075 002	
	200,000 UNITS	A060075 003	
	250,000 UNITS	A060075 004	
	400,000 UNITS	A060075 005	
	800,000 UNITS	A060075 006	

PENICILLIN G PROCAINE

## INJECTABLE; INJECTION

## DURACILLIN A.S.

LILLY	300,000 UNITS/ML	A060093 001	
-------	------------------	-------------	--

## PENICILLIN G PROCAINE

CONSOLIDATED PHARM	300,000 UNITS/ML	A060800 001	
--------------------	------------------	-------------	--

	600,000 UNITS/1.2ML	A060800 002	
--	---------------------	-------------	--

PARKE DAVIS	300,000 UNITS/ML	A062029 001	
-------------	------------------	-------------	--

PFIZER	300,000 UNITS/VIAL	A060099 001	
--------	--------------------	-------------	--

	1,500,000 UNITS/VIAL	A060099 002	
--	----------------------	-------------	--

## PFIZERPEN-AS

PFIZER	300,000 UNITS/ML	A060286 001	
--------	------------------	-------------	--

	600,000 UNITS/ML	A060286 002	
--	------------------	-------------	--

PENICILLIN G SODIUM

## INJECTABLE; INJECTION

## PENICILLIN G SODIUM

BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935 001	
----------------------	----------------------	-------------	--

COPANOS	5,000,000 UNITS/VIAL	A061051 001	
---------	----------------------	-------------	--

PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046 001	
----------------------	----------------------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

PENICILLIN G SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

WATSON LABS INC

5,000,000 UNITS/VIAL

A063014 001 Sep 13, 1988

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN

LILLY

125MG/0.6ML

A060002 001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

A062270 001

EQ 250MG BASE/5ML

A062270 002

BETAPEN-VK

APOTHECON

EQ 125MG BASE/5ML

A061149 001

EQ 250MG BASE/5ML

A061149 002

LEDERCILLIN VK

LEDERLE

EQ 125MG BASE/5ML

A060136 001

EQ 250MG BASE/5ML

A060136 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE/5ML

A060007 001

EQ 250MG BASE/5ML

A060007 002

PENAPAR-VK

PARKE DAVIS

EQ 125MG BASE/5ML

A062002 001

EQ 250MG BASE/5ML

A062002 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 125MG BASE/5ML

A061529 001

EQ 250MG BASE/5ML

A061529 002

MYLAN

EQ 125MG BASE/5ML

A061624 002

EQ 250MG BASE/5ML

A061624 001

PUREPAC PHARM

EQ 125MG BASE/5ML

A061758 001

EQ 250MG BASE/5ML

A061758 002

PFIZERPEN VK

PFIZER

EQ 125MG BASE/5ML

A061815 001

EQ 250MG BASE/5ML

A061815 002

V-CILLIN K

LILLY

EQ 125MG BASE/5ML

A060004 001

EQ 250MG BASE/5ML

A060004 002

VEETIDS

APOTHECON

EQ 125MG BASE/5ML

A061410 001

EQ 250MG BASE/5ML

A061410 002

VEETIDS '125'

APOTHECON

EQ 125MG BASE/5ML

A061206 001

EQ 125MG BASE/5ML

A062153 001

VEETIDS '250'

APOTHECON

EQ 250MG BASE/5ML

A061206 002

EQ 250MG BASE/5ML

A062153 002

TABLET; ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 250MG BASE

A062273 001

EQ 500MG BASE

A062273 002

BETAPEN-VK

BRISTOL

EQ 250MG BASE

A061150 001

EQ 500MG BASE

A061150 002

LEDERCILLIN VK

LEDERLE

EQ 250MG BASE

A060134 001

EQ 500MG BASE

A060134 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE

A060006 001

EQ 250MG BASE

A060006 002

EQ 500MG BASE

A060006 003

PENAPAR-VK

PARKE DAVIS

EQ 250MG BASE

A062001 001

EQ 500MG BASE

A062001 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 250MG BASE

A061528 001

EQ 500MG BASE

A061528 002

IVAX SUB TEVA PHARMS

EQ 125MG BASE

A060518 001

EQ 250MG BASE

A060518 002

EQ 500MG BASE

A060518 003

MYLAN

EQ 250MG BASE

A061530 001

## DISCONTINUED DRUG PRODUCT LIST

PENICILLIN V POTASSIUM

TABLET;ORAL

PENICILLIN V POTASSIUM

	EQ 500MG BASE	A061530 002	
PUREPAC PHARM	EQ 125MG BASE	A061571 001	
	EQ 250MG BASE	A061571 002	
	EQ 500MG BASE	A061571 003	
PFIZERPEN VK			
PFIZER	EQ 250MG BASE	A061836 001	
	EQ 500MG BASE	A061836 002	
UTICILLIN VK			
PHARMACIA AND UPJOHN	EQ 250MG BASE	A061651 001	
	EQ 500MG BASE	A061651 002	
V-CILLIN K			
LILLY	EQ 125MG BASE	A060003 001	
	EQ 250MG BASE	A060003 002	
	EQ 500MG BASE	A060003 003	
VEETIDS			
APOTHECON	EQ 250MG BASE	A061411 001	
	EQ 500MG BASE	A061411 002	
VEETIDS '250'			
APOTHECON	EQ 250MG BASE	A061164 001	
	EQ 250MG BASE	A062156 002	
VEETIDS '500'			
APOTHECON	EQ 500MG BASE	A061164 002	
	EQ 500MG BASE	A062156 001	

PENTAGASTRIN

INJECTABLE;INJECTION

PEPTAVLON

WYETH AYERST	0.25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017048 001	
--------------	-------------------------------------------------------------------------------------------------------------------------------------	-------------	--

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

NEBUPENT

FRESENIUS KABI USA	600MG/VIAL	N019887 002	Mar 22, 1996
INJECTABLE;INJECTION			
PENTACARINAT			
ARMOUR PHARM	300MG/VIAL	A073447 001	Apr 28, 1994
PENTAMIDINE ISETHIONATE			
BAXTER HLTHCARE	300MG/VIAL	A073617 001	Dec 18, 1995
HOSPIRA	300MG/VIAL	A073479 001	Jun 30, 1992
WATSON LABS	300MG/VIAL	A074303 001	Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

TALWIN 50

SANOFI AVENTIS US	EQ 50MG BASE	N016732 001	
-------------------	--------------	-------------	--

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021749 001	Aug 11, 2004
---------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------	--------------

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE;INJECTION

YTTERBIUM YB 169 DTPA

3M	2mCi/ML	N017518 001	
----	---------	-------------	--

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021751 001	Aug 11, 2004
---------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**PENTOBARBITAL

ELIXIR; ORAL

NEMBUTAL

OAK PHARMS 18.2MG/5ML A083244 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

OAK PHARMS 30MG A084095 001

50MG A084093 001

100MG A083245 001

PENTOBARBITAL SODIUM

LANNETT 50MG A085937 001

100MG A085915 001

VITARINE 100MG A083284 001

WHITEWORTH TOWN PLSN 100MG A083338 001

SODIUM PENTOBARBITAL

ANABOLIC 100MG A084590 001

ELKINS SINN 100MG A083368 001

EVERYLIFE 100MG A083259 001

HALSEY 100MG A084677 001

IVAX SUB TEVA PHARMS 50MG A083461 001

100MG A083461 002

PARKE DAVIS 100MG A084156 001

PERRIGO 100MG A084560 001

PUREPAC PHARM 100MG A083301 001

VALEANT PHARM INTL 100MG A083264 001

WATSON LABS 100MG A085791 001

WYETH AYERST 100MG A083239 001

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

ELKINS SINN 50MG/ML A083270 001

SODIUM PENTOBARBITAL

WYETH AYERST 50MG/ML A083261 001

SUPPOSITORY; RECTAL

NEMBUTAL

OAK PHARMS 30MG A083247 001 Jan 25, 1982

60MG A083247 002 Jan 25, 1982

120MG A083247 003 Jan 25, 1982

200MG A083247 004 Jan 25, 1982

TABLET; ORAL

PENTOBARBITAL SODIUM

VITARINE 100MG A083285 001

SODIUM PENTOBARBITAL

NEXGEN PHARMA INC 100MG A084238 001

PENTOLINIUM TARTRATE

INJECTABLE; INJECTION

ANSOLYSEN

WYETH AYERST 10MG/ML N009372 001

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

ACTAVIS ELIZABETH 400MG A074878 001 Jul 09, 1997

HERITAGE PHARMS INC 400MG A074877 001 Jul 08, 1997

TEVA 400MG A075199 001 Sep 03, 1999

WATSON LABS 400MG A075107 001 Sep 04, 1998

TRENTAL

SANOFI AVENTIS US 400MG N018631 001 Aug 30, 1984

PERFLUBRON

LIQUID; ORAL

IMAGENT

ALLIANCE PHARM 100% N020091 001 Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY 50%; 50% N021084 001 Feb 17, 2000

## DISCONTINUED DRUG PRODUCT LIST

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094 001	Sep 04, 2003
	EQ 0.25MG BASE	A076094 002	Sep 04, 2003
	EQ 1MG BASE	A076094 003	Sep 04, 2003
PAR PHARM	EQ 0.05MG BASE	A076061 001	Nov 27, 2002
	EQ 0.25MG BASE	A076061 002	Nov 27, 2002
	EQ 1MG BASE	A076061 003	Nov 27, 2002
PERMAX			
VALEANT PHARM INTL	EQ 0.05MG BASE	N019385 001	Dec 30, 1988
	EQ 0.25MG BASE	N019385 002	Dec 30, 1988
	EQ 1MG BASE	N019385 003	Dec 30, 1988

PERMETHRIN

LOTION; TOPICAL

NIX

GLAXOSMITHKLINE	1%	N019435 001	Mar 31, 1986
-----------------	----	-------------	--------------

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

PHARM ASSOC	16MG/5ML	A040360 001	May 25, 2001
-------------	----------	-------------	--------------

TRILAFON

SCHERING	16MG/5ML	N011557 001	
----------	----------	-------------	--

INJECTABLE; INJECTION

TRILAFON

SCHERING	5MG/ML	N011213 002	
----------	--------	-------------	--

SYRUP; ORAL

TRILAFON

SCHERING	2MG/5ML	N011294 002	
----------	---------	-------------	--

TABLET; ORAL

PERPHENAZINE

ANI PHARMS INC	8MG	A089456 001	Sep 10, 1987
----------------	-----	-------------	--------------

TEVA PHARMS USA	2MG	A089707 001	Sep 10, 1987
-----------------	-----	-------------	--------------

	4MG	A089708 001	Sep 10, 1987
--	-----	-------------	--------------

	16MG	A089457 001	Sep 10, 1987
--	------	-------------	--------------

TRILAFON

SCHERING	2MG	N010775 001	
----------	-----	-------------	--

	4MG	N010775 002	
--	-----	-------------	--

	8MG	N010775 003	
--	-----	-------------	--

	16MG	N010775 004	
--	------	-------------	--

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING	8MG	N011361 002	
----------	-----	-------------	--

PHENACEMIDE

TABLET; ORAL

PHENURONE

ABBVIE	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007707 001	
--------	------------------------------------------------------------------------------------------------------------------------	-------------	--

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

ROCHE	100MG; 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013294 001	Sep 10, 1987
-------	-------------------------------------------------------------------------------------------------------------------------------	-------------	--------------

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HYDROCHLORIDE

ABLE	200MG; 800MG; 160MG	N021105 001	Jun 26, 2001
------	---------------------	-------------	--------------

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

ROCHE	50MG; 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019358 001	Aug 31, 1990
-------	------------------------------------------------------------------------------------------------------------------------------	-------------	--------------

## DISCONTINUED DRUG PRODUCT LIST

PHENDIMETRAZINE TARTRATE

## CAPSULE; ORAL

PHENAZINE				
MAST MM	35MG	A086523	001	
	35MG	A086524	001	
	35MG	A086525	001	
PHENDIMETRAZINE TARTRATE				
SANDOZ	35MG	A085633	001	
	35MG	A085694	001	
	35MG	A085695	001	
	35MG	A085702	001	
VITARINE	35MG	A085634	001	
	35MG	A085645	001	
	35MG	A085670	001	
	35MG	A086403	001	
	35MG	A086408	001	
	35MG	A086410	001	
	35MG	A087424	001	
SPRX-3				
SOLVAY	35MG	A085897	001	
STATOBEX				
TEVA	35MG	A085507	001	
X-TROZINE				
SHIRE RICHWOOD	35MG	A087394	001	Sep 22, 1982
CAPSULE, EXTENDED RELEASE; ORAL				
MELFIAT-105				
NUMARK	105MG	A087487	001	Oct 13, 1982
PHENDIMETRAZINE TARTRATE				
GRAHAM DM	105MG	A087214	001	May 26, 1982
	105MG	A088020	001	Aug 16, 1982
	105MG	A088028	001	Aug 16, 1982
	105MG	A088062	001	Sep 13, 1982
	105MG	A088063	001	Sep 10, 1982
	105MG	A088111	001	Oct 18, 1982
SANDOZ	105MG	A087378	001	
SPRX-105				
NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A.				
SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982
TABLET; ORAL				
ADPHEN				
FERNDALE LABS	35MG	A083655	001	
ALPHAZINE				
SANDOZ	35MG	A085034	001	
CAM-METRAZINE				
ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
TG UNITED LABS	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	
DI-METREX				
PVT FORM	35MG	A085698	001	
MELFIAT				
NUMARK	35MG	A083790	002	
METRA				
FOREST PHARMS	35MG	A083754	001	
PHENAZINE				
MAST MM	35MG	A087305	001	
PHENAZINE-35				
ABC HOLDING	35MG	A085512	001	
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	

## DISCONTINUED DRUG PRODUCT LIST

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

	35MG	A084742 001
	35MG	A084743 001
IVAX PHARMS	35MG	A085611 001
	35MG	A085612 001
IVAX SUB TEVA PHARMS	35MG	A083682 001
KV PHARM	35MG	A084138 001
	35MG	A084141 001
	35MG	A085525 001
MFG CHEMISTS	35MG	A085914 001
NEXGEN PHARMA INC	35MG	A086020 001
NUMARK	35MG	A083790 001
PVT FORM	35MG	A085199 001
	35MG	A085697 001
SANDOZ	35MG	A085402 001
	35MG	A085497 001
	35MG	A085830 001
	35MG	A086365 001
	35MG	A086370 001
SOLVAY	35MG	A083993 001
TG UNITED LABS	35MG	A085761 001
	35MG	A085941 001
USL PHARMA	35MG	A083805 001
	35MG	A084398 001
	35MG	A084399 001
VITARINE	35MG	A085519 001
	35MG	A086005 001
	35MG	A086106 001
WATSON LABS	35MG	A085767 001
	35MG	A085768 001
	35MG	A085770 001
	35MG	A085773 001
PLEGINE		
WYETH AYERST	35MG	N012248 001
STATOBEX		
TEVA	35MG	A086013 001
STATOBEX-G		
TEVA	35MG	A085095 001
X-TROZINE		
SHIRE RICHWOOD	35MG	A086550 001
	35MG	A086551 001
	35MG	A086552 001
	35MG	A086553 001
	35MG	A086554 001

Jun 27, 1983

PHENINDIONE

TABLET; ORAL

HEDULIN

SANOFI AVENTIS US	50MG	N008767 002
-------------------	------	-------------

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL

PRELUDIN

BOEHRINGER INGELHEIM	25MG	N010460 005
----------------------	------	-------------

TABLET, EXTENDED RELEASE; ORAL

PRELUDIN

BOEHRINGER INGELHEIM	50MG	N011752 004
	75MG	N011752 003

PHENPROCOUMON

TABLET; ORAL

LIQUAMAR

ORGANON USA INC	3MG	N011228 001
-----------------	-----	-------------

PHENSUXIMIDE

CAPSULE; ORAL

MILONTIN

PARKE DAVIS	500MG	N008855 004
-------------	-------	-------------



## DISCONTINUED DRUG PRODUCT LIST

PHENTERMINE HYDROCHLORIDE

## CAPSULE; ORAL

## FASTIN

GLAXOSMITHKLINE	30MG	N017352	001	
OBESTIN-30				
FERNDALE LABS	30MG	A087144	001	
OBY-TRIM				
SHIRE RICHWOOD	30MG	A087764	001	Mar 18, 1982
ONA-MAST				
MAST MM	30MG	A086511	001	
	30MG	A086516	001	

## PHENTERMINE HYDROCHLORIDE

ABC HOLDING	30MG	A085411	001	
ABLE	15MG	A040497	001	Mar 13, 2003
	30MG	A040403	001	Aug 30, 2001
	30MG	A040427	001	Aug 30, 2001
CAMALL	15MG	A086735	001	
	30MG	A087226	001	
DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986
IVAX PHARMS	30MG	A086329	001	
MIKAH PHARMA	15MG	A040460	001	Jan 14, 2003
	30MG	A040227	001	Jun 18, 1997
	30MG	A040448	001	Jan 22, 2003
	37.5MG	A040228	001	Jun 19, 1997
MUTUAL PHARM	37.5MG	A040527	001	Oct 23, 2003
SANDOZ	30MG	A087208	001	
	30MG	A087223	001	
	37.5MG	A088414	001	Oct 19, 1983
TEVA	30MG	A086911	001	
	30MG	A087126	001	
	30MG	A087777	001	Nov 01, 1985
	30MG	A088612	001	Apr 04, 1984
	30MG	A088613	001	Apr 09, 1984
	30MG	A088614	001	Apr 09, 1984
TG UNITED INC	30MG	A040083	001	Mar 07, 1997
TG UNITED LABS	18.75MG	A088576	001	May 23, 1984
	30MG	A085417	001	
	30MG	A086732	002	
	30MG	A087215	001	
	37.5MG	A087915	001	Dec 22, 1983
	37.5MG	A087918	001	Dec 22, 1983
	37.5MG	A087930	001	Oct 14, 1983
	37.5MG	A088610	001	Jun 04, 1984
	37.5MG	A088611	001	Jun 04, 1984
	37.5MG	A088625	001	Aug 23, 1984
USL PHARMA	30MG	A084487	001	Apr 09, 1982
	30MG	A088430	001	Mar 27, 1984
	30MG	A088797	001	Dec 10, 1984
VITARINE	30MG	A087202	001	
	30MG	A087235	001	
WATSON LABS	30MG	A086740	001	Mar 21, 1985

## TABLET; ORAL

## ONA-MAST

MAST MM	8MG	A086260	001	
PHENTERMINE HYDROCHLORIDE				
ABLE	37.5MG	A040402	001	Aug 30, 2001
ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
IVAX PHARMS	8MG	A085553	001	
SANDOZ	8MG	A085671	001	
	8MG	A085689	001	
SANDOZ INC	30MG	A088605	001	Sep 28, 1987
TG UNITED LABS	8MG	A083923	001	
	8MG	A085319	001	
	37.5MG	A087805	001	Dec 06, 1982
	37.5MG	A088596	001	Apr 04, 1984
USL PHARMA	8MG	A083804	001	
	37.5MG	A088910	001	Jul 17, 1985
	37.5MG	A088917	001	Jul 17, 1985
VITARINE	8MG	A086453	001	
	8MG	A086456	001	
WATSON LABS	8MG	A085739	001	

**DISCONTINUED DRUG PRODUCT LIST**PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

TORA

SOLVAY 8MG A084035 001

WILPO

SANDOZ 8MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\* N012737 001PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN

UCB INC EQ 15MG BASE N011613 004

EQ 30MG BASE N011613 002

PHENTERMINE RESIN 30

QUANTUM PHARMICS EQ 30MG BASE A089120 001 Feb 04, 1988

PHENYL AMINOSALICYLATE

POWDER; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC 50% N011695 002

TABLET; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC 500MG N011695 003

PHENYLBUTAZONE

CAPSULE; ORAL

AZOLID

SANOFI AVENTIS US 100MG A087260 001

BUTAZOLIDIN

NOVARTIS 100MG N008319 009

PHENYLBUTAZONE

IVAX PHARMS 100MG A088218 001 Jun 24, 1983

MUTUAL PHARM 100MG A088994 001 Dec 04, 1985

SANDOZ 100MG A087774 001 Jun 16, 1982

WATSON LABS 100MG A087756 001 Dec 17, 1982

TABLET; ORAL

AZOLID

SANOFI AVENTIS US 100MG A087091 001

BUTAZOLIDIN

NOVARTIS 100MG N008319 008

PHENYLBUTAZONE

MUTUAL PHARM 100MG A088863 001 Dec 04, 1985

SANDOZ 100MG A084339 001

WATSON LABS 100MG A086151 001

100MG A087674 001 Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC

ANI PHARMS 5MG/5ML; 6.25MG/5ML N008604 003 Apr 02, 1984

PHERAZINE VC

HALSEY 5MG/5ML; 6.25MG/5ML A088868 001 Mar 02, 1987

PROMETHAZINE VC PLAIN

CENCI 5MG/5ML; 6.25MG/5ML A088815 001 Nov 22, 1985

WOCKHARDT 5MG/5ML; 6.25MG/5ML A088897 001 Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

ALLERGAN 0.12%; 0.1% N007953 001

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-30

PARKE DAVIS 30MG/5ML N008762 002

PHENYTOIN

ACTAVIS MID ATLANTIC 125MG/5ML A089892 001 Sep 25, 1992

**DISCONTINUED DRUG PRODUCT LIST**PHENYTOIN SODIUM

## CAPSULE; ORAL

## DIPHENYLAN SODIUM

LANNETT

30MG PROMPT  
100MG PROMPTA080857 001  
A080857 002

## EXTENDED PHENYTOIN SODIUM

ANI PHARMS INC

100MG EXTENDED  
100MG EXTENDEDA040435 001 Jun 20, 2003  
A089441 001 Dec 18, 1986

## PHENYTEX

WATSON LABS

100MG EXTENDED

A088711 001 Dec 21, 1984

## PHENYTOIN SODIUM

PHARMERAL

100MG PROMPT

A085435 001

WATSON LABS

100MG PROMPT

A085894 001

## PROMPT PHENYTOIN SODIUM

ANI PHARMS INC

100MG PROMPT

A080259 001

WATSON LABS

100MG PROMPT

A080905 001

## INJECTABLE; INJECTION

## DILANTIN

PARKE DAVIS

50MG/ML

N010151 001

## PHENYTOIN SODIUM

FRESENIUS KABI USA

50MG/ML

A089003 001 May 31, 1985

HOSPIRA

50MG/ML

A089744 001 Dec 18, 1987

MARSAM PHARMS LLC

50MG/ML

A089501 001 Oct 13, 1987

50MG/ML

A089779 001 Nov 27, 1992

SMITH AND NEPHEW

50MG/ML

A088519 001 Dec 19, 1984

50MG/ML

A088521 001 Dec 18, 1984

SOLOPAK

50MG/ML

A088520 001 Dec 17, 1984

WARNER CHILCOTT

50MG/ML

A089900 001 Mar 30, 1990

WATSON LABS

50MG/ML

A085434 001

PHYTONADIONE

## INJECTABLE; INJECTION

## AQUAMEPHYTON

BIOVAIL TECHNOLOGIES

1MG/0.5ML  
10MG/MLN012223 002  
N012223 001

## KONAKION

ROCHE

1MG/0.5ML  
10MG/MLN011745 001  
N011745 003

## PHYTONADIONE

GLAXOSMITHKLINE

1MG/0.5ML  
10MG/MLA084060 001  
A084060 002

## VITAMIN K1

HOSPIRA

10MG/ML

A087956 001 Jul 25, 1983

PILOCARPINE

## INSERT, EXTENDED RELEASE; OPHTHALMIC

## OCUSERT PILO-20

AKORN

5MG

N017431 001

## OCUSERT PILO-40

AKORN

11MG

N017548 001

PINACIDIL

## CAPSULE, EXTENDED RELEASE; ORAL

## PINDAC

LEO PHARM

12.5MG  
25MGN019456 001 Dec 28, 1989  
N019456 002 Dec 28, 1989PINDOLOL

## TABLET; ORAL

## PINDOLOL

IVAX SUB TEVA PHARMS

5MG

A073687 001 Feb 26, 1993

10MG

A073687 002 Feb 26, 1993

MYLAN PHARMS INC

5MG

A074013 001 Sep 24, 1992

10MG

A074018 001 Sep 24, 1992

NOSTRUM LABS

5MG

A074474 001 Oct 28, 1996

10MG

A074474 002 Oct 28, 1996

PUREPAC PHARM

5MG

A074125 001 Apr 28, 1993

10MG

A074125 002 Apr 28, 1993

SANDOZ

5MG

A073608 001 Mar 29, 1993

10MG

A073609 001 Mar 29, 1993

TEVA

5MG

A073661 001 Oct 31, 1993

5MG

A074123 001 Apr 17, 1997

10MG

A073661 002 Oct 31, 1993

10MG

A074123 002 Apr 17, 1997

**DISCONTINUED DRUG PRODUCT LIST**PINDOLOL

TABLET; ORAL

PINDOLOL

WATSON LABS

5MG

A074437 001 Feb 27, 1995

10MG

A074437 002 Feb 27, 1995

VISKEN

NOVARTIS

5MG

N018285 001 Sep 03, 1982

10MG

N018285 002 Sep 03, 1982

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

ORGANON USA INC

10MG/VIAL

N019638 001 Jun 26, 1990

PIPERACETAZINE

TABLET; ORAL

QUIDE

DOW PHARM

10MG

N013615 001

25MG

N013615 002

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

WYETH PHARMS INC

EQ 2GM BASE/VIAL

A062750 001 Oct 13, 1987

EQ 2GM BASE/VIAL

N050545 002

EQ 3GM BASE/VIAL

A062750 002 Oct 13, 1987

EQ 3GM BASE/VIAL

N050545 003

EQ 4GM BASE/VIAL

A062750 003 Oct 13, 1987

EQ 4GM BASE/VIAL

N050545 004

EQ 40GM BASE/VIAL

N050545 006 Sep 30, 1985

PIPERAZINE CITRATE

SYRUP; ORAL

ANTEPAR

GLAXOSMITHKLINE

EQ 500MG BASE/5ML

N009102 001

BRYREL

SANOFI AVENTIS US

EQ 500MG BASE/5ML

N017796 001

MULTIFUGE

BLULINE

EQ 500MG BASE/5ML

N009452 001

PIPERAZINE CITRATE

ALPHARMA US PHARMS

EQ 500MG BASE/5ML

A080774 001

LANNETT

EQ 500MG BASE/5ML

A080963 001

LUITPOLD

EQ 500MG BASE/5ML

A080671 001

VERMIDOL

SOLVAY

EQ 500MG BASE/5ML

A080992 001

TABLET; ORAL

ANTEPAR

GLAXOSMITHKLINE

EQ 500MG BASE

N009102 003

PIPERAZINE CITRATE

IMPAX LABS

EQ 250MG BASE

A080874 001

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

BAYER HEALTHCARE LLC

4%;EQ 0.33% BASE

N021043 001 Mar 07, 2000

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT

10MG

N016245 001

25MG

N016245 002

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

VALEANT PHARM NORTH

EQ 0.2MG BASE/INH

N019009 001 Dec 30, 1986

PIROXICAM

CAPSULE; ORAL

PIROXICAM

CYCLE PHARMS LTD

10MG

A073651 001 Feb 26, 1993

20MG

A073651 002 Feb 26, 1993

EGIS

10MG

A074808 001 Jul 08, 1997

20MG

A074808 002 Jul 08, 1997

IVAX SUB TEVA PHARMS

10MG

A074148 001 Jun 03, 1996

20MG

A074148 002 Jun 03, 1996

**DISCONTINUED DRUG PRODUCT LIST**PIROXICAM

CAPSULE; ORAL

PIROXICAM

MUTUAL PHARM	20MG	A073536 001	Mar 12, 1993
MYLAN	10MG	A074043 001	Sep 22, 1992
	20MG	A074043 002	Sep 22, 1992
SCS	10MG	A074036 001	May 29, 1992
	20MG	A074036 002	May 29, 1992
TEVA	10MG	A073637 001	Jan 28, 1994
	20MG	A073638 001	Jan 28, 1994
TEVA PHARMS	10MG	A074103 001	Aug 28, 1992
	20MG	A074103 002	Aug 28, 1992
WATSON LABS	10MG	A074287 001	May 16, 1996
	10MG	A074460 001	Sep 29, 1995
	20MG	A074287 002	May 16, 1996
	20MG	A074460 002	Sep 29, 1995

PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER	2.5MG/VIAL	N050109 001	
--------	------------	-------------	--

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST	40MG/AMP	N010753 001	
--------------	----------	-------------	--

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

PADDOCK LLC	17GM/SCOOPFUL	A090567 001	Oct 15, 2009
TEVA PHARMS	17GM/SCOOPFUL	A077445 001	May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

PADDOCK LLC	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A090769 001	Jun 07, 2010
-------------	------------------------------------------------------------	-------------	--------------

SOLUTION; ORAL

OCL

HOSPIRA	6GM/100ML; 75MG/100ML; 168MG/100ML; 146MG/100ML; 1.29GM/100ML	N019284 001	Apr 30, 1986
---------	---------------------------------------------------------------	-------------	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATEANHYDROUS

FOR SOLUTION; ORAL

COLYTE

MEDA PHARMS	120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET	N018983 005	Oct 26, 1984
	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N018983 004	Oct 26, 1984
	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983 007	Jun 12, 1987
	360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET	N018983 006	Oct 26, 1984

COLYTE-FLAVORED

MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983 008	Nov 14, 1991
	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983 009	Nov 14, 1991

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A090712 001	Feb 25, 2010
-------------	------------------------------------------------------------	-------------	--------------

FOR SUSPENSION; ORAL

CO-LAV

VINTAGE PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A073428 001	Jan 28, 1992
----------------	------------------------------------------------------------	-------------	--------------

COLOVAGE

DYNAPHARM	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	A071320 001	Apr 20, 1988
-----------	----------------------------------------------------------------------------	-------------	--------------

E-Z-EM PREP LYTE

E Z EM	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A071278 001	Nov 21, 1988
--------	------------------------------------------------------------	-------------	--------------

GLYCOPREP

GOLDLINE	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A072319 001	Dec 23, 1988
----------	------------------------------------------------------------	-------------	--------------

**DISCONTINUED DRUG PRODUCT LIST**POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION; ORAL

GO-EVAC

VINTAGE PHARMS	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A073433 001	Apr 28, 1992
----------------	------------------------------------------------------------	-------------	--------------

PEG-LYTE

SANDOZ	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A073098 001	Aug 31, 1993
--------	------------------------------------------------------------	-------------	--------------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

GLAXOSMITHKLINE	EQ 500,000 U BASE/VIAL	A062036 001	
-----------------	------------------------	-------------	--

POWDER; FOR RX COMPOUNDING

POLY-RX

X GEN PHARMS	100,000,000 UNITS/BOT	A061578 001	
--------------	-----------------------	-------------	--

POLYMYXIN B SULFATE

PADDOCK LLC	100,000,000 UNITS/BOT	A062455 001	Jul 27, 1983
-------------	-----------------------	-------------	--------------

POLYTHIAZIDE

TABLET; ORAL

RENESE

PFIZER	1MG	N012845 001	
	2MG	N012845 002	
	4MG	N012845 003	

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE

PFIZER	0.5MG; EQ 1MG BASE	N017986 001	
	0.5MG; EQ 2MG BASE	N017986 002	
	0.5MG; EQ 5MG BASE	N017986 003	

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

RENESE-R

PFIZER	2MG; 0.25MG	N013636 001	
--------	-------------	-------------	--

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM

GLENWOOD	500MG	N009395 004	
----------	-------	-------------	--

POWDER; ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL	100%	A080098 001	
--------	------	-------------	--

TABLET; ORAL

PASKALIUM

GLENWOOD	1GM	N009395 003	
----------	-----	-------------	--

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

SAVAGE LABS	8MEQ	A073398 001	Jan 28, 1992
	10MEQ	A072427 001	Mar 28, 1990

POTASSIUM CHLORIDE

NESHER PHARMS	10MEQ	A070980 001	Feb 17, 1987
	8MEQ	A073531 001	Apr 26, 1996
	10MEQ	A073532 001	Apr 26, 1996

FOR SUSPENSION, EXTENDED RELEASE; ORAL

MICRO-K LS

KV PHARM	20MEQ/PACKET	N019561 003	Aug 26, 1988
----------	--------------	-------------	--------------

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM	2MEQ/ML	A080204 001	
	2MEQ/ML	A084290 001	
	2MEQ/ML	A086713 001	
	2MEQ/ML	A086714 001	
	2MEQ/ML	A087787 001	Apr 20, 1982
	2MEQ/ML	A087885 001	Feb 03, 1983
	2MEQ/ML	A088286 001	Sep 05, 1985
	2MEQ/ML	A080203 001	
	2MEQ/ML	A087817 001	Oct 20, 1982
	1MEQ/ML	A086219 001	
GD SEARLE LLC	2MEQ/ML	A086219 002	
	2MEQ/ML	A086220 002	

## DISCONTINUED DRUG PRODUCT LIST

POTASSIUM CHLORIDE

## INJECTABLE; INJECTION

## POTASSIUM CHLORIDE

	3MEQ/ML	A086219	003	
	3MEQ/ML	A086220	001	
	4MEQ/ML	A086219	004	
HOSPIRA	1MEQ/ML	A080205	003	
	1MEQ/ML	A083345	003	
	1.5MEQ/ML	A083345	001	
	2MEQ/ML	A083345	002	
	2.4MEQ/ML	A080205	004	
	3.2MEQ/ML	A080205	005	
INTL MEDICATION	2MEQ/ML	A083163	001	
LILLY	2MEQ/ML	N007865	002	
LUITPOLD	2MEQ/ML	A080221	001	
	2MEQ/ML	A080736	001	
	2MEQ/ML	A087584	001	
	2MEQ/ML	A087585	001	
MILES	1MEQ/ML	A080195	002	
	2MEQ/ML	A080195	001	
	3MEQ/ML	A080195	003	
	4MEQ/ML	A080195	004	
PHARMA SERVE NY	2MEQ/ML	A086297	001	
	2MEQ/ML	A087362	001	Mar 08, 1983
WATSON LABS	2MEQ/ML	A086208	001	
	2MEQ/ML	A089163	001	Mar 10, 1988
	2MEQ/ML	A089421	001	Jan 02, 1987
	3MEQ/ML	A086210	001	
TABLET, EXTENDED RELEASE; ORAL				
K+10				
FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
K+8				
FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
KAON CL				
SAVAGE LABS	6.7MEQ	N017046	001	
KAON CL-10				
SAVAGE LABS	10MEQ	N017046	002	
KLOTRIX				
APOTHECON	10MEQ	N017850	001	
POTASSIUM CHLORIDE				
COPLBY PHARM	8MEQ	A070618	001	Sep 09, 1987
NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
SCHERING	10MEQ	N019439	002	Jun 13, 1986
	20MEQ	N019439	001	Jun 13, 1986
SLOW-K				
NOVARTIS	8MEQ	N017476	002	
TEN-K				
NOVARTIS	10MEQ	N019381	001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	37MG/100ML; 900MG/100ML	N019708	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML; 900MG/100ML	N019708	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	110MG/100ML; 900MG/100ML	N019708	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML; 900MG/100ML	N019708	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML; 900MG/100ML	N019708	006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML; 900MG/100ML	N018722	001	Nov 09, 1982
BAXTER HLTHCARE	75MG/100ML; 900MG/100ML	N017648	004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	150MG/100ML; 900MG/100ML	N018722	002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML; 900MG/100ML	N018722	003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML; 900MG/100ML	N018722	004	Nov 09, 1982

**DISCONTINUED DRUG PRODUCT LIST**POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

HOSPIRA

370MG/VIAL; 1.75GM/VIAL; 36GM/VIAL

N013025 001

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

UT SW MEDCTR

10MEQ/PACKET \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N019647 002 Oct 13, 1988

20MEQ/PACKET \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N019647 001 Oct 13, 1988

POTASSIUM IODIDE

SOLUTION; ORAL

POTASSIUM IODIDE

ROXANE

1GM/ML

N018551 001 Feb 19, 1982

TABLET; ORAL

THYRO-BLOCK

MEDPOINTE PHARM HLC

130MG

N018307 001

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

MALLINCKRODT

200MG

N017551 001

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP

CLINIPAD

10%

N019382 001 Jul 25, 1989

SPONGE; TOPICAL

E-Z PREP

CLINIPAD

5%

N019382 002 Jul 25, 1989

E-Z PREP 220

CLINIPAD

5%

N019382 003 Jul 25, 1989

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP

300MG/ML

N018799 001 Dec 13, 1982

TABLET; ORAL

PROTOPAM CHLORIDE

WYETH AYERST

500MG

N014122 002

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

BOEHRINGER INGELHEIM

1.25MG

N020667 004 Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

WATSON LABS

0.125MG

A078551 001 Oct 08, 2010

0.25MG

A078551 002 Oct 08, 2010

0.5MG

A078551 003 Oct 08, 2010

1MG

A078551 004 Oct 08, 2010

1.5MG

A078551 005 Oct 08, 2010

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

ASTRAZENECA AB

EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)

N021332 001 Mar 16, 2005

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

BRISTOL MYERS SQUIBB

10MG

N019898 002 Oct 31, 1991

PRAVASTATIN SODIUM

PLIVA HRVATSKA DOO

10MG

A077730 001 Nov 21, 2006

20MG

A077730 002 Nov 21, 2006

30MG

A077730 003 Nov 21, 2006

40MG

A077730 005 Nov 21, 2006

RANBAXY LABS LTD

10MG

A076445 001 Apr 23, 2007

20MG

A076445 002 Apr 23, 2007

40MG

A076445 003 Apr 23, 2007

80MG

A076445 004 Apr 23, 2007



## DISCONTINUED DRUG PRODUCT LIST

PRAZEPAM

## CAPSULE; ORAL

## CENTRAX

PARKE DAVIS	5MG	N018144	001	
	10MG	N018144	002	
	20MG	N018144	003	May 10, 1982

## PRAZEPAM

USL PHARMA	5MG	A070427	001	Nov 06, 1987
	10MG	A070428	001	Nov 06, 1987

## TABLET; ORAL

## CENTRAX

PARKE DAVIS	10MG	N017415	001	
-------------	------	---------	-----	--

PRAZOSIN HYDROCHLORIDE

## CAPSULE; ORAL

## PRAZOSIN HYDROCHLORIDE

AM THERAP	EQ 1MG BASE	A072782	001	May 16, 1989
	EQ 2MG BASE	A072783	001	May 16, 1989
	EQ 5MG BASE	A072784	001	May 16, 1989
DAVA PHARMS INC	EQ 1MG BASE	A072705	001	May 16, 1989
	EQ 2MG BASE	A072706	001	May 16, 1989
	EQ 5MG BASE	A072707	001	May 16, 1989
PUREPAC PHARM	EQ 1MG BASE	A072991	001	May 16, 1989
	EQ 2MG BASE	A072921	001	May 16, 1989
	EQ 5MG BASE	A072992	001	May 16, 1989
SANDOZ	EQ 1MG BASE	A072576	001	May 16, 1989
	EQ 2MG BASE	A072577	001	May 16, 1989
	EQ 5MG BASE	A072578	001	May 16, 1989
WATSON LABS	EQ 1MG BASE	A072352	001	May 16, 1989
	EQ 2MG BASE	A072333	001	May 16, 1989
	EQ 5MG BASE	A072609	001	May 16, 1989

## TABLET, EXTENDED RELEASE; ORAL

## MINIPRESS XL

PFIZER	2.5MG	N019775	001	Jan 29, 1992
	5MG	N019775	002	Jan 29, 1992

PREDNISOLONE

## CREAM; TOPICAL

## METI-DERM

SCHERING	0.5%	N010209	002	
----------	------	---------	-----	--

## SYRUP; ORAL

## PREDNISOLONE

APOTEX INC	5MG/5ML	A040570	001	Aug 25, 2005
	15MG/5ML	A040571	001	Aug 25, 2005
IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999
NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001
	15MG/5ML	A040364	001	Apr 10, 2002
TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000
WE PHARMS	15MG/5ML	A040192	001	May 28, 1998

## PRELONE

MURO	5MG/5ML	A089654	001	Jan 17, 1989
------	---------	---------	-----	--------------

## TABLET; ORAL

## CORTALONE

HALSEY	1MG	A080304	003	
	2.5MG	A080304	002	
	5MG	A080304	001	

## DELTA-CORTEF

PHARMACIA AND UPJOHN	5MG	N009987	004	
----------------------	-----	---------	-----	--

## FERNISOLONE-P

FERNDAL LABS	5MG	A083941	001	
--------------	-----	---------	-----	--

## PREDNISOLONE

BARR	5MG	A084426	002	
BUNDY	5MG	A083675	001	
ELKINS SINN	5MG	A080625	001	
EVERYLIFE	1MG	A084439	001	
	2.5MG	A084439	002	
	5MG	A084439	003	
FERRANTE	2.5MG	A080562	001	
	5MG	A080562	002	
HEATHER	5MG	A080326	001	
IMPAX LABS	5MG	A080780	001	
INWOOD LABS	5MG	A080748	001	
IVAX SUB TEVA PHARMS	5MG	A080378	001	

## DISCONTINUED DRUG PRODUCT LIST

PREDNISOLONE

## TABLET; ORAL

## PREDNISOLONE

LANNETT	5MG	A080531	002	
MARSHALL PHARMA	5MG	A080307	001	
PANRAY	1MG	A080351	001	
	5MG	A080351	002	
PERRIGO	5MG	A084542	001	
PHOENIX LABS NY	5MG	A080322	001	
PUREPAC PHARM	5MG	A080325	001	
PVT FORM	5MG	A080211	001	
ROXANE	5MG	A080327	002	
SANDOZ	5MG	A080339	001	
	5MG	A084773	001	
SPERTI	1MG	A080358	001	
	2.5MG	A080358	002	
	5MG	A080358	003	
SUPERPHARM	5MG	A088892	001	Feb 26, 1985
TABLICAPS	5MG	A085170	001	
TEVA	5MG	A080398	001	
UDL	5MG	A087987	001	Jan 18, 1983
VALEANT PHARM INTL	5MG	A080236	001	
VITARINE	5MG	A080534	001	
WATSON LABS	5MG	A085085	002	
	5MG	A085415	001	
	5MG	A085416	001	
WEST WARD	5MG	A080324	001	
WHITEWORTH TOWN PLSN	5MG	A080342	001	
STERANE				
PFIZER	5MG	N009996	001	

PREDNISOLONE ACETATE

## INJECTABLE; INJECTION

## METICORTELONE

SCHERING	25MG/ML	N010255	002	
----------	---------	---------	-----	--

## PREDNISOLONE ACETATE

AKORN	25MG/ML	A083032	001	
	50MG/ML	A084492	001	
BEL MAR	25MG/ML	A083738	001	
	50MG/ML	A083738	002	
CENT PHARMS	25MG/ML	A084717	001	
	50MG/ML	A084717	002	
WATSON LABS	25MG/ML	A083398	001	
	25MG/ML	A083654	001	
	40MG/ML	A083767	001	
	50MG/ML	A083764	001	
	50MG/ML	A085781	001	

## STERANE

PFIZER	25MG/ML	N011446	001	
--------	---------	---------	-----	--

## SUSPENSION; ORAL

## FLO-PRED

TARO	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008
------	-----------------	---------	-----	--------------

## SUSPENSION/DROPS; OPHTHALMIC

## ECONOPRED

ALCON	0.125%	N017468	001	
-------	--------	---------	-----	--

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

## OINTMENT; OPHTHALMIC

## CETAPRED

ALCON	0.25%;10%	A087771	001	Aug 06, 1993
-------	-----------	---------	-----	--------------

## METIMYD

SCHERING	0.5%;10%	N010210	002	Sep 09, 1984
----------	----------	---------	-----	--------------

## PREDSULFAIR

PHARMAFAIR	0.5%;10%	A088032	001	Apr 15, 1983
------------	----------	---------	-----	--------------

## VASOCIDIN

NOVARTIS	0.5%;10%	A088791	001	Oct 05, 1984
----------	----------	---------	-----	--------------

## SUSPENSION; OPHTHALMIC

## ISOPTO CETAPRED

ALCON	0.25%;10%	A087547	001	
-------	-----------	---------	-----	--

## SUSPENSION/DROPS; OPHTHALMIC

## METIMYD

SCHERING	0.5%;10%	N010210	001	
----------	----------	---------	-----	--

**DISCONTINUED DRUG PRODUCT LIST**PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

## SUSPENSION/DROPS;OPHTHALMIC

## PREDAMIDE

AKORN	0.5%;10%	A088059	001	Jul 29, 1983
PREDSULFAIR				
PHARMAFAIR	0.5%;10%	A088007	001	Apr 19, 1983
PREDSULFAIR II				
PHARMAFAIR	0.2%;10%	A088837	001	Dec 24, 1985
SULPHRIN				
BAUSCH AND LOMB	0.5%;10%	A088089	001	Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

## INJECTABLE; INJECTION

## HYDELTRASOL

MERCK	EQ 20MG PHOSPHATE/ML	N011583	002	
PREDNISOLONE SODIUM PHOSPHATE				
WATSON LABS	EQ 20MG PHOSPHATE/ML	A080517	001	

## OINTMENT;OPHTHALMIC, OTIC

## HYDELTRASOL

MERCK	EQ 0.25% PHOSPHATE	N011028	001	
-------	--------------------	---------	-----	--

## SOLUTION;ORAL

## PREDNISOLONE SODIUM PHOSPHATE

MEDICIS PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002
NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24, 2005
	EQ 15MG BASE/5ML	A076988	001	May 24, 2005
PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002
VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007
WE PHARMS	EQ 5MG BASE/5ML	A075181	001	Dec 23, 2002

## SOLUTION/DROPS;OPHTHALMIC

## INFLAMASE FORTE

NOVARTIS	EQ 0.9% PHOSPHATE	A080751	002	
INFLAMASE MILD				
NOVARTIS	EQ 0.11% PHOSPHATE	A080751	001	
METRETON				
SCHERING	EQ 0.5% PHOSPHATE	A083834	001	
PREDAIR				
PHARMAFAIR	EQ 0.11% PHOSPHATE	A088415	001	Feb 29, 1984
PREDAIR FORTE				
PHARMAFAIR	EQ 0.9% PHOSPHATE	A088165	001	Mar 28, 1983
PREDNISOLONE SODIUM PHOSPHATE				
AKORN	EQ 0.11% PHOSPHATE	A083358	001	
	EQ 0.9% PHOSPHATE	A083358	002	
ALCON PHARMS LTD	EQ 0.11% PHOSPHATE	A081043	001	Oct 24, 1991
	EQ 0.9% PHOSPHATE	A081044	001	Oct 24, 1991
BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994
SOLA BARNES HIND	EQ 0.11% PHOSPHATE	A084171	001	
	EQ 0.9% PHOSPHATE	A084168	001	
	EQ 0.9% PHOSPHATE	A084169	001	
	EQ 0.9% PHOSPHATE	A084172	001	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

## SOLUTION/DROPS;OPHTHALMIC

## SULSTER

AKORN	EQ 0.23% PHOSPHATE;10%	A074511	001	Jul 30, 1996
VASOCIDIN				
NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988

PREDNISOLONE TEBUTATE

## INJECTABLE; INJECTION

## HYDELTRA-TBA

MERCK	20MG/ML	N010562	001	
PREDNISOLONE TEBUTATE				
WATSON LABS	20MG/ML	A083362	001	Feb 17, 1984

PREDNISONE

## SOLUTION;ORAL

## PREDNISONE

WOCKHARDT	5MG/5ML	A089726	001	Aug 02, 1988
-----------	---------	---------	-----	--------------

## SYRUP;ORAL

## LIQUID PRED

MURO	5MG/5ML	A087611	002	Sep 07, 1982
------	---------	---------	-----	--------------

## TABLET;ORAL

## CORTAN

HALSEY	20MG	A087480	001	
--------	------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

PREDNISONE

## TABLET; ORAL

## DELTA-DOME

BAYER PHARMS	5MG	A080293	001
--------------	-----	---------	-----

## DELTASONE

PHARMACIA AND UPJOHN	2.5MG	N009986	005
	5MG	N009986	002
	10MG	N009986	006
	20MG	N009986	007
	50MG	N009986	008

## FERNISONE

FERNDALE LABS	5MG	A083364	001
---------------	-----	---------	-----

## METICORTEN

SCHERING	1MG	N009766	002
	5MG	N009766	001

## ORASONE

SOLVAY	1MG	A083009	001
	5MG	A083009	002
	10MG	A083009	003
	20MG	A083009	004
	50MG	A085999	001

## PARACORT

PARKE DAVIS	5MG	N010962	002
-------------	-----	---------	-----

## PREDNICEN-M

SCHWARZ PHARMA	5MG	A084655	001
----------------	-----	---------	-----

## PREDNISONE

AM THERAP	5MG	A089387	001	Nov 06, 1986
	10MG	A089388	001	Nov 06, 1986
	20MG	A089389	001	Nov 06, 1986
AMNEAL PHARMS NY	5MG	A089597	001	Oct 05, 1987
	10MG	A089598	001	Oct 05, 1987
	20MG	A089599	001	Oct 05, 1987
BUNDY	5MG	A083676	001	
DURAMED PHARMS BARR	5MG	A088394	001	Oct 04, 1983
	10MG	A088395	001	Oct 04, 1983
	20MG	A088396	001	Oct 04, 1983
ELKINS SINN	5MG	A080491	001	
	20MG	A085811	001	
EVERYLIFE	1MG	A084440	001	
	2.5MG	A084440	002	
	5MG	A084440	003	
FERRANTE	2.5MG	A080563	001	
	5MG	A080563	002	
HALSEY	5MG	A080300	001	
HEATHER	5MG	A080320	001	
	10MG	A084341	001	
	20MG	A084417	001	
	20MG	A085543	001	
	50MG	A086946	001	
IMPAX LABS	5MG	A080782	001	
INWOOD LABS	1MG	A080328	001	
	2.5MG	A080306	001	
	5MG	A080279	001	
IVAX SUB TEVA PHARMS	5MG	A080283	001	
	10MG	A084133	001	
	20MG	A084134	001	
KV PHARM	5MG	A084236	001	
LANNETT	5MG	A080514	001	
	20MG	A084275	001	
LEDERLE	5MG	A086968	001	
MARSHALL PHARMA	5MG	A080301	001	
MUTUAL PHARM	5MG	A080701	001	
	10MG	A086595	001	
	20MG	A084634	001	
	50MG	A086596	001	
NYLOS	5MG	A085115	001	
PANRAY	1MG	A080350	001	
	2.5MG	A080350	002	
	5MG	A080350	003	
PERRIGO	5MG	A083059	001	
PHARMAVITE	5MG	A084662	002	
PHOENIX LABS NY	5MG	A080321	001	

**DISCONTINUED DRUG PRODUCT LIST**PREDNISONE

TABLET; ORAL

PREDNISONE

	20MG	A083807	001	
PUREPAC PHARM	5MG	A080353	001	
	10MG	A086062	001	
	20MG	A086061	001	
PVT FORM	20MG	A085151	001	
REXALL	5MG	A080232	001	
ROXANE	20MG	N017109	001	
	25MG	A087833	001	May 04, 1982
SANDOZ	5MG	A080336	002	
	5MG	A084774	001	
	10MG	A089983	001	Jan 12, 1989
	20MG	A085813	001	
	50MG	A089984	001	Jan 12, 1989
SCHERER LABS	5MG	A080371	001	
SPERTI	1MG	A080359	001	
	2.5MG	A080359	002	
	5MG	A080359	003	
SUPERPHARM	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	
UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	
	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	
SERVISONE				
LEDERLE	5MG	A080223	001	

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST

ASTRAZENECA	1%	N014763	004	
	2%	N014763	005	
	3%	N014763	003	
CITANEST PLAIN				
ASTRAZENECA	4%	N014763	007	
CITANEST PLAIN DENTAL				
DENTSPLY PHARM	4%	N021382	001	

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

NURO PHARMA	250MG/5ML	N010401	001	
-------------	-----------	---------	-----	--

TABLET; ORAL

PRIMIDONE

DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008
	250MG	A040862	002	Oct 03, 2008
HIKMA PHARMS LLC	50MG	A040667	001	Jul 27, 2006
WATSON LABS	250MG	A085052	001	

**DISCONTINUED DRUG PRODUCT LIST**PROBENECID

TABLET; ORAL

BENEMID

MERCK	500MG	N007898	004	
PROBENECID				
IVAX SUB TEVA PHARMS	500MG	A083740	001	May 09, 1984
LEDERLE	500MG	A086917	001	
WATSON LABS	500MG	A086150	002	Apr 23, 1982

PROBUCOL

TABLET; ORAL

LORELCO

SANOFI AVENTIS US	250MG	N017535	001	
	500MG	N017535	002	Jul 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ASCOT	250MG	A087542	001	Jan 08, 1982
	375MG	A087697	001	Mar 01, 1983
	500MG	A087543	001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG	A084604	001	
	375MG	A084595	001	
	500MG	A084606	001	
LANNETT	250MG	A083693	001	
	500MG	A084696	001	
	375MG	A086942	001	
LEDERLE	250MG	A086952	001	
	375MG	A086943	001	
	500MG	A086943	001	
ROXANE	250MG	A088989	001	Apr 26, 1985
	500MG	A088990	001	Apr 26, 1985
SANDOZ	250MG	A089219	001	Jul 01, 1986
	375MG	A089220	001	Jul 01, 1986
	500MG	A089221	001	Jul 01, 1986
VANGARD	250MG	A087643	001	Jun 01, 1982
	500MG	A087875	001	Jun 01, 1982
WATSON LABS	250MG	A083287	001	
	250MG	A083795	001	
	250MG	A085167	001	
	375MG	A084403	001	
	375MG	A087020	001	
	500MG	A084280	001	
	500MG	A084357	001	
	500MG	A087021	001	
	500MG	A087021	001	
PROCAN				
PARKE DAVIS	250MG	A085804	001	
	375MG	A087502	001	
	500MG	A085079	001	
PROCAPAN				
PANRAY	250MG	A083553	002	
PRONESTYL				
APOTHECON	250MG	N007335	001	
	375MG	N007335	004	
	500MG	N007335	003	

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM	100MG/ML	A089415	001	Nov 17, 1986
	500MG/ML	A089416	001	Nov 17, 1986
HIKMA MAPLE	100MG/ML	A089029	001	Apr 17, 1986
	500MG/ML	A089030	001	Apr 17, 1986
HOSPIRA	500MG/ML	A089537	001	Aug 25, 1987
INTL MEDICATION	100MG/ML	A088636	001	Jul 31, 1984
	500MG/ML	A088637	001	Jul 31, 1984
PHARMAFAIR	100MG/ML	A088824	001	Nov 20, 1985
	500MG/ML	A088830	001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML	A088530	001	Mar 04, 1985
	500MG/ML	A088531	001	Mar 04, 1985
SOLOPAK	500MG/ML	A088532	001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528	001	May 03, 1988
	500MG/ML	A089529	001	May 03, 1988
WATSON LABS	100MG/ML	A087079	001	
	500MG/ML	A087080	001	

## DISCONTINUED DRUG PRODUCT LIST

PROCAINAMIDE HYDROCHLORIDE

## INJECTABLE; INJECTION

## PRONESTYL

APOTHECON	100MG/ML	N007335	002
	500MG/ML	N007335	005

## TABLET; ORAL

## PRONESTYL

APOTHECON	250MG	N017371	001
	375MG	N017371	002
	500MG	N017371	003

## TABLET, EXTENDED RELEASE; ORAL

## PROCAINAMIDE HYDROCHLORIDE

## ANI PHARMS INC

	1GM	A040111	001	Dec 13, 1996
	250MG	A088958	001	Dec 02, 1985
	500MG	A088959	001	Dec 02, 1985
	500MG	A088974	001	Jul 22, 1985
	750MG	A089438	001	Mar 23, 1987
INWOOD LABS	500MG	A089840	001	Mar 06, 1989
SANDOZ	250MG	A089369	001	Aug 14, 1987
	500MG	A089284	001	Jun 23, 1986
	500MG	A089370	001	Jan 09, 1987
	750MG	A089371	001	Aug 14, 1987
WATSON LABS	1GM	A089520	001	Jan 15, 1987
	250MG	A088533	001	Dec 03, 1984
	250MG	A089026	001	Oct 22, 1985
	500MG	A088534	001	Dec 03, 1984
	500MG	A089027	001	Oct 22, 1985
	750MG	A088535	001	Nov 03, 1984
	750MG	A089042	001	Oct 22, 1985

## PROCAN SR

## PARKE DAVIS

## PARKEDALE

	250MG	A086468	001	
	1GM	A088489	001	Jan 16, 1985
	500MG	A086065	001	
	750MG	A087510	001	Apr 01, 1982

## PROCANBID

## KING PHARMS

	1GM	N020545	002	Jan 31, 1996
	500MG	N020545	001	Jan 31, 1996

## PRONESTYL-SR

## APOTHECON

	500MG	A087361	001
--	-------	---------	-----

PROCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## NOVOCAIN

## HOSPIRA

	1%	A085362	003
	2%	A085362	004
	10%	A086797	001

## PROCAINE HYDROCHLORIDE

## ABRAXIS PHARM

	1%	A080384	002
	1%	A080421	001
	2%	A080384	003
	2%	A080421	002

## BEL MAR

	1%	A080711	001
	2%	A080756	001

## ELKINS SINN

	1%	A083315	001
	2%	A083315	002

## GD SEARLE LLC

	1%	A086202	001
	2%	A086202	002

## HOSPIRA

	1%	A080416	001
	2%	A080416	002

## MILES

	1%	A080415	001
	2%	A080415	002

## WATSON LABS

	1%	A080658	001
	1%	A083535	001
	2%	A080658	002
	2%	A083535	002

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## ACHROMYCIN

## LEDERLE

	40MG/VIAL; 100MG/VIAL	N050276	001
	40MG/VIAL; 250MG/VIAL	N050276	003

## TETRACYN

## PFIZER

	40MG/VIAL; 100MG/VIAL	A060285	002
--	-----------------------	---------	-----

**DISCONTINUED DRUG PRODUCT LIST**PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

TETRACYN

40MG/VIAL; 250MG/VIAL

A060285 003

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE

LILLY

100MG/ML; 50MG/ML

N008869 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

GLAXOSMITHKLINE

2.5MG

N011127 003

5MG

N011127 001

25MG

N011127 002

PROCHLORPERAZINE

ABLE

2.5MG

A040407 001 Jul 11, 2001

5MG

A040407 002 Jul 11, 2001

25MG

A040407 003 Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE/ML

N011276 001

PROCHLORPERAZINE

ALPHARMA US PHARMS

EQ 10MG BASE/ML

A087153 001 Jun 08, 1982

PROCHLORPERAZINE EDISYLATE

MORTON GROVE

EQ 10MG BASE/ML

A088598 001 Oct 25, 1984

INJECTABLE; INJECTION

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/ML

N010742 002

PROCHLORPERAZINE

BAXTER HLTHCARE

EQ 5MG BASE/ML

A087759 001 Oct 01, 1982

PROCHLORPERAZINE EDISYLATE

HIKMA MAPLE

EQ 5MG BASE/ML

A089523 001 May 03, 1988

HOSPIRA

EQ 5MG BASE/ML

A089703 001 Apr 07, 1988

MARSAM PHARMS LLC

EQ 5MG BASE/ML

A089675 001 Dec 05, 1988

SMITH AND NEPHEW

EQ 5MG BASE/ML

A089251 001 Dec 04, 1986

TEVA PARENTERAL

EQ 5MG BASE/ML

A040505 001 May 30, 2003

WATSON LABS

EQ 5MG BASE/ML

A089530 001 Jul 08, 1987

EQ 5MG BASE/ML

A089605 001 Jul 08, 1987

EQ 5MG BASE/ML

A089606 001 Jul 08, 1987

EQ 5MG BASE/ML

A086348 001

WYETH AYERST

SYRUP; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/5ML

N011188 001

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS

EQ 5MG BASE/5ML

A087154 001 Sep 01, 1982

MORTON GROVE

EQ 5MG BASE/5ML

A088597 001 Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE

N011000 001

EQ 10MG BASE

N021019 001 Oct 06, 1999

EQ 15MG BASE

N011000 002

EQ 15MG BASE

N021019 002 Oct 06, 1999

EQ 30MG BASE

N011000 003

EQ 75MG BASE

N011000 004

TABLET; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE

N010571 001

EQ 10MG BASE

N010571 002

EQ 25MG BASE

N010571 003

PROCHLORPERAZINE

WATSON LABS

EQ 5MG BASE

A085580 001

EQ 10MG BASE

A085178 001

EQ 25MG BASE

A085579 001

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR

EQ 5MG BASE

A040207 001 May 01, 1997

EQ 5MG BASE

A089484 001 Jan 20, 1987

EQ 10MG BASE

A040207 002 May 01, 1997

EQ 10MG BASE

A089485 001 Jan 20, 1987



## DISCONTINUED DRUG PRODUCT LIST

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

	EQ 25MG BASE	A089486 001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162 001	Jan 20, 1998
	EQ 10MG BASE	A040162 002	Jan 20, 1998
SANDOZ	EQ 25MG BASE	A040101 003	Jul 19, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS	2MG	N009818 005	
	5MG	N009818 003	

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

ABBVIE INC	300MG	N019781 003	Oct 15, 1999
------------	-------	-------------	--------------

INJECTABLE; INJECTION

PROGESTERONE

LILLY	25MG/ML	N009238 002	
	50MG/ML	N009238 001	

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA	38MG	N017553 001	
------	------	-------------	--

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST	30MG/ML	N010942 001	
	100MG/ML	N010942 004	

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS	25MG/ML	A084510 001	
	50MG/ML	A084517 001	

SPARINE

BAXTER HLTHCARE CORP	25MG/ML	N010349 008	
	50MG/ML	N010349 006	

SYRUP; ORAL

SPARINE

WYETH AYERST	10MG/5ML	N010942 003	
--------------	----------	-------------	--

TABLET; ORAL

SPARINE

WYETH AYERST	10MG	N010348 006	
	25MG	N010348 001	
	50MG	N010348 002	
	100MG	N010348 003	
	200MG	N010348 004	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

WYETH AYERST	25MG/ML	N008857 002	
	50MG/ML	N008857 003	

PROMETHAZINE HYDROCHLORIDE

ABBOTT	25MG/ML	A084223 001	
	50MG/ML	A084222 001	
AKORN	25MG/ML	A083955 002	
	50MG/ML	A083955 001	
BEDFORD LABS	25MG/ML	A040524 001	Mar 17, 2004
	50MG/ML	A040524 002	Mar 17, 2004
HOSPIRA	25MG/ML	A040372 001	Jun 08, 2000
	50MG/ML	A040372 002	Jun 08, 2000
	50MG/ML	A083838 002	
LUITPOLD	25MG/ML	A040515 001	Mar 19, 2003
MARSAM PHARMS LLC	25MG/ML	A089463 001	May 02, 1988
	50MG/ML	A089477 001	May 02, 1988
MYLAN INSTITUTIONAL	25MG/ML	A040471 001	Nov 21, 2002
SANDOZ	25MG/ML	A040593 001	Nov 08, 2006
	50MG/ML	A040593 002	Nov 08, 2006
TEVA PHARMS USA	25MG/ML	A040454 001	Aug 22, 2002
	50MG/ML	A040454 002	Aug 22, 2002
WATSON LABS	25MG/ML	A083532 001	
	25MG/ML	A084591 001	

## DISCONTINUED DRUG PRODUCT LIST

PROMETHAZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## PROMETHAZINE HYDROCHLORIDE

	50MG/ML	A080629 002	
	50MG/ML	A083532 002	
WOCKHARDT	25MG/ML	A040785 001	Sep 26, 2008
	50MG/ML	A040785 002	Sep 26, 2008

## ZIPAN-25

ALTANA	25MG/ML	A083997 001	
--------	---------	-------------	--

## ZIPAN-50

ALTANA	50MG/ML	A083997 002	
--------	---------	-------------	--

## SUPPOSITORY; RECTAL

## PHENERGAN

DELCOR ASSET CORP	50MG	N011689 001	
-------------------	------	-------------	--

SHIONOGI INC	12.5MG	N010926 002	
--------------	--------	-------------	--

	25MG	N010926 001	
--	------	-------------	--

## PROMETHACON

POLYMEDICA	25MG	A084901 001	
------------	------	-------------	--

	50MG	A084902 001	
--	------	-------------	--

## PROMETHAZINE HYDROCHLORIDE

ABLE	12.5MG	A040504 001	Apr 11, 2003
------	--------	-------------	--------------

	25MG	A040504 002	Apr 11, 2003
--	------	-------------	--------------

	50MG	A040449 001	Feb 27, 2003
--	------	-------------	--------------

## SYRUP; ORAL

## MYMETHAZINE FORTIS

USL PHARMA	25MG/5ML	A087996 001	Jan 18, 1983
------------	----------	-------------	--------------

## PROMETH FORTIS

ALPHARMA US PHARMS	25MG/5ML	A084772 001	
--------------------	----------	-------------	--

## PROMETH PLAIN

ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953 001	
----------------------	------------	-------------	--

## PROMETHAZINE

CENCI	6.25MG/5ML	A089013 001	Sep 20, 1985
-------	------------	-------------	--------------

## PROMETHAZINE HYDROCHLORIDE

KV PHARM	6.25MG/5ML	A085388 001	
----------	------------	-------------	--

	25MG/5ML	A085385 001	
--	----------	-------------	--

PHARM ASSOC	6.25MG/5ML	A087518 001	
-------------	------------	-------------	--

WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395 001	
----------------------	------------	-------------	--

## PROMETHAZINE HYDROCHLORIDE PLAIN

ANI PHARMS	6.25MG/5ML	N008381 004	Apr 18, 1984
------------	------------	-------------	--------------

	25MG/5ML **Federal Register	N008381 003	
--	-----------------------------	-------------	--

determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\*

## TABLET; ORAL

## PHENERGAN

DELCOR ASSET CORP	12.5MG	N007935 002	
-------------------	--------	-------------	--

	25MG	N007935 003	
--	------	-------------	--

	50MG	N007935 004	
--	------	-------------	--

## PROMETHAZINE HYDROCHLORIDE

ABBOTT	12.5MG	A084160 001	
--------	--------	-------------	--

	25MG	A084166 001	
--	------	-------------	--

	50MG	A084539 001	
--	------	-------------	--

ABLE	12.5MG	A040558 001	Jul 01, 2004
------	--------	-------------	--------------

	25MG	A040558 002	Jul 01, 2004
--	------	-------------	--------------

	50MG	A040558 003	Jul 01, 2004
--	------	-------------	--------------

IMPAX LABS	25MG	A084214 002	Jul 07, 1982
------------	------	-------------	--------------

IVAX SUB TEVA PHARMS	12.5MG	A083604 001	
----------------------	--------	-------------	--

	25MG	A083603 001	
--	------	-------------	--

	50MG	A083613 001	
--	------	-------------	--

LANNETT	12.5MG	A080949 001	
---------	--------	-------------	--

	25MG	A080949 002	
--	------	-------------	--

	50MG	A080949 003	
--	------	-------------	--

MUTUAL PHARM	12.5MG	A084555 001	
--------------	--------	-------------	--

	25MG	A084554 001	
--	------	-------------	--

	50MG	A084557 001	
--	------	-------------	--

PVT FORM	12.5MG	A083214 001	
----------	--------	-------------	--

	25MG	A083658 001	
--	------	-------------	--

SANDOZ	12.5MG	A084176 002	May 22, 2009
--------	--------	-------------	--------------

	12.5MG	A084233 001	
--	--------	-------------	--

	25MG	A085146 001	
--	------	-------------	--

	50MG	A085146 002	
--	------	-------------	--

TABLICAPS	12.5MG	A084080 001	
-----------	--------	-------------	--

	25MG	A084027 001	
--	------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

TEVA	25MG	A089109 001	Sep 10, 1985
WATSON LABS	12.5MG	A083401 001	
	12.5MG	A083712 001	
	12.5MG	A085986 001	
	25MG	A083204 001	
	25MG	A085684 001	
	50MG	A083403 001	
	50MG	A085664 001	
REMSSED			
BRISTOL MYERS SQUIBB	25MG	A083176 002	
	50MG	A083176 001	

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

NESHER PHARMS	150MG	A076193 001	Feb 07, 2002
	225MG	A076193 002	Feb 07, 2002
	300MG	A076193 003	Feb 07, 2002

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC	30MG/VIAL	N008843 001	
---------------	-----------	-------------	--

TABLET; ORAL

PRO-BANTHINE

SHIRE	7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008732 003	
	15MG	N008732 002	

PROPANTHELINE BROMIDE

ASCOT	15MG	A087663 001	Oct 25, 1982
HEATHER	15MG	A085780 001	
IMPAX LABS	15MG	A084541 002	
MYLAN	15MG	A083706 001	
PAR PHARM	15MG	A088377 001	Dec 08, 1983
PVT FORM	15MG	A080977 001	
ROXANE	7.5MG	A080927 001	
SANDOZ	15MG	A080928 001	
TABLICAPS	15MG	A084428 001	
WATSON LABS	15MG	A083029 002	
	15MG	A083151 001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR

PHARMAFAIR	0.5%	A088087 001	Jun 07, 1983
------------	------	-------------	--------------

OPHTHAINE

APOTHECON	0.5%	N008883 001	
-----------	------	-------------	--

OPHTHETIC

ALLERGAN	0.5%	N012583 001	
----------	------	-------------	--

PARACAINE

OPTOPICS	0.5%	A087681 001	Aug 05, 1982
----------	------	-------------	--------------

PROPARACAINE HYDROCHLORIDE

SOLA BARNES HIND	0.5%	A084144 001	
	0.5%	A084151 001	

PROPIOLACTONE

SOLUTION; IRRIGATION

BETAPRONE

FOREST LABS	N/A	N011657 001	
-------------	-----	-------------	--

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

HIKMA MAPLE	20MG/ML	N012382 002	
-------------	---------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

PROPOFOL

## INJECTABLE; INJECTION

## DIPRIVAN

FRESENIUS KABI USA 10MG/ML N019627 001 Oct 02, 1989

## PROPOFOL

EUROHLTH INTL 10MG/ML A074848 001 Apr 19, 2005

TEVA PARENTERAL 10MG/ML A075392 001 Sep 19, 2000

PROPOXYPHENE HYDROCHLORIDE

## CAPSULE; ORAL

## DARVON

XANODYNE PHARM 32MG N010997 001

65MG N010997 003

## DOLENE

HERITAGE PHARMS INC 65MG A080530 001

## KESSO-GESIC

MK LABS 65MG A083544 001

## PROPHENE 65

HALSEY 65MG A083538 002

## PROPOXYPHENE HYDROCHLORIDE

ALRA 65MG A083184 001

IMPAX LABS 65MG A083317 001

IVAX SUB TEVA PHARMS 32MG A083597 001

MUTUAL PHARM 65MG A083186 001

MYLAN 32MG A083528 001

65MG A040569 001 Dec 16, 2004

65MG A083299 001

NEXGEN PHARMA INC 65MG A083185 001

PAR PHARM 65MG A080269 001

PUREPAC PHARM 65MG A083278 001

PVT FORM 65MG A083113 001

ROXANE 32MG A083089 001

65MG A083089 002

SANDOZ 32MG A084014 001

65MG A083125 002

65MG A083688 001

65MG A083870 002

65MG A086495 001

TEVA 65MG A088615 001 Oct 22, 1984

VALEANT PHARM INTL 65MG A080783 001

VINTAGE PHARMS 65MG A040908 001 Jul 17, 2009

WATSON LABS 65MG A080908 002

65MG A085190 001

WEST WARD 65MG A083501 001

WHITEWORTH TOWN PLSN 65MG A084551 001

## PROPOXYPHENE HYDROCHLORIDE 65

WARNER CHILCOTT 65MG A083786 001

PROPOXYPHENE NAPSYLATE

## SUSPENSION; ORAL

## DARVON-N

AAIPHARMA LLC 50MG/5ML N016861 001

## TABLET; ORAL

## DARVON-N

XANODYNE PHARM 100MG N016862 002

PROPRANOLOL HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## PROPRANOLOL HYDROCHLORIDE

INWOOD LABS 60MG A072499 001 Apr 11, 1989

80MG A072500 001 Apr 11, 1989

120MG A072501 001 Apr 11, 1989

160MG A072502 001 Apr 11, 1989

## CONCENTRATE; ORAL

## PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE 80MG/ML A071388 001 May 15, 1987

## INJECTABLE; INJECTION

## PROPRANOLOL HYDROCHLORIDE

SMITH AND NEPHEW 1MG/ML A070135 001 Apr 15, 1986

1MG/ML A070137 001 Apr 15, 1986

SOLOPAK 1MG/ML A070136 001 Apr 15, 1986

## DISCONTINUED DRUG PRODUCT LIST

PROPRANOLOL HYDROCHLORIDE

## SOLUTION; ORAL

## PROPRANOLOL HYDROCHLORIDE

MORTON GROVE

20MG/5ML

A071984 001 Mar 03, 1989

40MG/5ML

A071985 001 Mar 03, 1989

## SUSPENSION; ORAL

## INDERAL

WYETH AYERST

10MG/ML

N019536 001 Dec 12, 1986

## TABLET; ORAL

## INDERAL

WYETH PHARMS INC

10MG

N016418 001

20MG

N016418 003

40MG

N016418 002

60MG

N016418 009 Oct 18, 1982

80MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N016418 004

90MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N016418 010 Oct 18, 1982

## PROPRANOLOL HYDROCHLORIDE

ANI PHARMS INC

90MG

A071977 001 Apr 06, 1988

DAVA PHARMS INC

10MG

A070125 001 Jul 30, 1985

20MG

A070126 001 Jul 30, 1985

40MG

A070127 001 Jul 30, 1985

60MG

A071495 001 Dec 31, 1987

80MG

A070128 001 Jul 30, 1985

90MG

A071496 001 Dec 31, 1987

DURAMED PHARMS BARR

10MG

A070306 001 Sep 09, 1985

20MG

A070307 001 Sep 09, 1985

40MG

A070308 001 Sep 09, 1985

60MG

A070309 001 Oct 01, 1986

80MG

A070310 001 Sep 09, 1985

90MG

A071327 001 Oct 01, 1986

INTERPHARM

10MG

A071368 001 May 05, 1987

20MG

A071369 001 May 05, 1987

40MG

A071370 001 May 05, 1987

80MG

A071371 001 May 05, 1987

IVAX SUB TEVA PHARMS

10MG

A072063 001 Jul 29, 1988

20MG

A072066 001 Jul 29, 1988

40MG

A072067 001 Jul 29, 1988

60MG

A072068 001 Jul 29, 1988

80MG

A072069 001 Jul 29, 1988

LEDERLE

10MG

A072117 001 Jun 23, 1988

20MG

A072118 001 Jun 23, 1988

40MG

A072119 001 Jun 23, 1988

80MG

A072120 001 Jun 23, 1988

MUTUAL PHARM

10MG

A070319 001 Oct 22, 1985

20MG

A070320 001 Oct 22, 1985

40MG

A070103 001 Oct 22, 1985

60MG

A070321 001 Sep 24, 1986

80MG

A070322 001 Aug 04, 1986

MYLAN

60MG

A072275 001 Jun 09, 1989

PAR PHARM

90MG

A071288 001 Oct 22, 1986

PUREPAC PHARM

10MG

A070814 001 Nov 03, 1986

20MG

A070815 001 Nov 03, 1986

40MG

A070816 001 Nov 03, 1986

60MG

A070817 001 Nov 03, 1986

80MG

A070757 001 Nov 03, 1986

ROXANE

10MG

A070516 001 Jul 07, 1986

20MG

A070517 001 Jul 07, 1986

40MG

A070518 001 Jul 07, 1986

60MG

A070519 001 Sep 24, 1986

80MG

A070520 001 Jul 07, 1986

90MG

A070521 001 Sep 24, 1986

SANDOZ

10MG

A070663 001 Jun 13, 1986

10MG

A071658 001 Jul 05, 1988

20MG

A070664 001 Jun 13, 1986

20MG

A071687 001 Jul 05, 1988

40MG

A070665 001 Jun 13, 1986

40MG

A071688 001 Jul 05, 1988

## DISCONTINUED DRUG PRODUCT LIST

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

60MG	A070666	001	Oct 10, 1986
60MG	A072197	001	Jul 05, 1988
80MG	A070667	001	Jun 13, 1986
80MG	A071689	001	Jul 05, 1988
90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001 Aug 06, 1985
	20MG	A070121	001 Aug 06, 1985
	40MG	A070122	001 Aug 06, 1985
	60MG	A070123	001 Oct 29, 1986
	80MG	A070124	001 Aug 06, 1985
SUPERPHARM	10MG	A071515	001 Jun 08, 1988
	20MG	A071516	001 Jun 08, 1988
	40MG	A071517	001 Jun 08, 1988
	80MG	A071518	001 Jun 08, 1988
TEVA	10MG	A070232	001 Oct 07, 1987
	20MG	A070233	001 Jun 23, 1986
	40MG	A070234	001 Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001 Sep 15, 1986
	20MG	A070439	001 Sep 15, 1986
	40MG	A070440	001 Sep 15, 1986
	60MG	A070441	001 Sep 24, 1986
	80MG	A070442	001 Sep 15, 1986
WATSON LABS	10MG	A070140	001 Jul 30, 1985
	10MG	A070378	001 Mar 19, 1987
	10MG	A070548	001 Jul 10, 1986
	20MG	A070141	001 Jul 30, 1985
	20MG	A070379	001 Mar 19, 1987
	20MG	A070549	001 Apr 11, 1986
	40MG	A070142	001 Jul 30, 1985
	40MG	A070380	001 Mar 19, 1987
	40MG	A070550	001 Apr 11, 1986
	60MG	A070143	001 Jan 15, 1987
	60MG	A070381	001 Mar 19, 1987
	60MG	A071098	001 Oct 06, 1986
	60MG	A071791	001 Jul 15, 1987
	80MG	A070144	001 Jul 30, 1985
	80MG	A070382	001 Mar 19, 1987
	80MG	A070551	001 Jul 10, 1986
	90MG	A071183	001 Oct 06, 1986
	90MG	A071792	001 Jul 15, 1987

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE 50% N009309 001

DIONOSIL OILY

GLAXOSMITHKLINE 60% N009309 002

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT	50MG	A084075	001
ANABOLIC	50MG	A080285	001
ANI PHARMS INC	50MG	A080215	001
HALSEY	50MG	A080015	001
HIKMA PHARMS LLC	50MG	A080154	001
IMPAX LABS	50MG	A080159	001
LANNETT	50MG	A080016	001
LILLY	50MG	N006213	001
MUTUAL PHARM	50MG	A083982	001
PERRIGO	50MG	A084543	001
TABLICAPS	50MG	A080840	001
WATSON LABS	50MG	A080932	001
	50MG	A085201	001

## DISCONTINUED DRUG PRODUCT LIST

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

HIKMA MAPLE	10MG/ML	A089474	001	Nov 05, 1986
	10MG/ML	A089475	001	Nov 05, 1986
LILLY	10MG/ML	N006460	002	
PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001	
	250MG/VIAL	N007413	002	Aug 02, 1984

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBVIE	5%	N005932	012	Jan 31, 1985
HYPROTIGEN 5%				
B BRAUN	5%	N006170	003	Jan 10, 1984

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT	0.5MG/ML	N017638	001	
THYREL TRH				
FERRING	0.5MG/ML	N018087	001	

PROTOKYLQLOL HYDROCHLORIDE

TABLET; ORAL

VENTAIRE

SANOFI AVENTIS US	2MG	A083459	001	
-------------------	-----	---------	-----	--

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

TEVA WOMENS	5MG	N016012	001	
	10MG	N016012	002	

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

SANOFI AVENTIS US	120MG	N017603	001	
-------------------	-------	---------	-----	--

SUDAFED 12 HOUR

GLAXOSMITHKLINE	120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017941	002	
-----------------	------------------------------------------------------------------------------------------------------------------------	---------	-----	--

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACTIFED

GLAXOSMITHKLINE	120MG; 5MG	N018996	001	Jun 17, 1985
-----------------	------------	---------	-----	--------------

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM	120MG; 5MG	A071798	001	Mar 16, 1989
----------	------------	---------	-----	--------------

SYRUP; ORAL

ACTAHIST

CENCI	30MG/5ML; 1.25MG/5ML	A088344	001	Feb 09, 1984
-------	----------------------	---------	-----	--------------

HISTAFED

CENCI	30MG/5ML; 1.25MG/5ML	A088283	001	Apr 20, 1984
-------	----------------------	---------	-----	--------------

MYFED

USL PHARMA	30MG/5ML; 1.25MG/5ML	A088116	001	Mar 04, 1983
------------	----------------------	---------	-----	--------------

TRILITRON

NEWTRON PHARMS	30MG/5ML; 1.25MG/5ML	A088474	001	Feb 12, 1985
----------------	----------------------	---------	-----	--------------

TABLET; ORAL

ALLERFED

PVT FORM	60MG; 2.5MG	A088860	001	Jan 31, 1985
----------	-------------	---------	-----	--------------

CORPHED

SANDOZ	60MG; 2.5MG	A088602	001	Apr 11, 1985
--------	-------------	---------	-----	--------------

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ	60MG; 2.5MG	A088193	001	May 17, 1983
--------	-------------	---------	-----	--------------

TRILITRON

NEWTRON PHARMS	60MG; 2.5MG	A088515	001	Jan 09, 1985
----------------	-------------	---------	-----	--------------

TRIPHED

TEVA	60MG; 2.5MG	A088630	001	May 17, 1984
------	-------------	---------	-----	--------------

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS	60MG; 2.5MG	A088318	002	Jan 13, 1984
-------------	-------------	---------	-----	--------------

WEST WARD	60MG; 2.5MG	A088117	001	Apr 19, 1983
-----------	-------------	---------	-----	--------------

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	60MG; 2.5MG	A085273	001	Dec 12, 1984
----------------------	-------------	---------	-----	--------------

SUPERPHARM	60MG; 2.5MG	A088578	001	Feb 21, 1985
------------	-------------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG;5MG

A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

PSEUDO-12

UCB INC

EQ 60MG HCL/5ML

N019401 001 Jun 19, 1987

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

BARR

30MG

A040512 002 Jul 20, 2005

60MG

A040512 001 Oct 08, 2003

COREPHARMA

60MG

A040457 001 Dec 26, 2002

SOLVAY

30MG

A089572 001 Nov 27, 1990

US ARMY

30MG

N020414 001 Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

HEXA-BETALIN

LILLY

100MG/ML

A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN

100MG/ML

A087967 001 Oct 01, 1982

BEL MAR

100MG/ML

A080761 001

DELL LABS

50MG/ML

A083771 001

100MG/ML

A083772 001

ELKINS SINN

100MG/ML

A080581 001

LUITPOLD

100MG/ML

A080669 001

WATSON LABS

100MG/ML

A080572 001

100MG/ML

A083760 001

PYRILAMINE MALEATE

TABLET;ORAL

PYRILAMINE MALEATE

IMPAX LABS

25MG

A080808 001

WATSON LABS

25MG

A085231 001

PYRIMETHAMINE; SULFADOXINE

TABLET;ORAL

FANSIDAR

ROCHE

25MG;500MG

N018557 001

PYRITHIONE ZINC

LOTION;TOPICAL

HEAD &amp; SHOULDERS CONDITIONER

WARNER CHILCOTT

0.3%

N019412 002 Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION;ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE/5ML

N011964 001

TABLET;ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE

N012485 002

QUAZEPAM

TABLET;ORAL

DORAL

SCIECURE PHARMA INC

7.5MG

N018708 003 Feb 26, 1987

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

ASTRAZENECA

EQ 150MG BASE

N020639 004 Dec 20, 1998

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 5MG BASE

A076459 001 Dec 22, 2004

EQ 10MG BASE

A076459 002 Dec 22, 2004

EQ 20MG BASE

A076459 003 Dec 22, 2004

EQ 40MG BASE

A076459 004 Dec 22, 2004

APOTEX INC

EQ 5MG BASE

A076240 001 Jan 26, 2006

EQ 10MG BASE

A076240 002 Jan 26, 2006

EQ 20MG BASE

A076240 003 Jan 26, 2006



## DISCONTINUED DRUG PRODUCT LIST

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	EQ 40MG BASE	A076240 004	Jan 26, 2006
MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005
	EQ 10MG BASE	A076036 002	Jan 28, 2005
	EQ 20MG BASE	A076036 003	Jan 28, 2005
	EQ 40MG BASE	A076036 004	Jan 28, 2005
SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005
	EQ 10MG BASE	A076803 002	Mar 02, 2005
	EQ 20MG BASE	A076803 003	Mar 02, 2005
	EQ 40MG BASE	A076803 004	Mar 02, 2005

QUINESTROL

TABLET; ORAL

ESTROVIS

PARKE DAVIS	0.1MG	N016768 002	
	0.2MG	N016768 003	

QUINETHAZONE

TABLET; ORAL

HYDROMOX

LEDERLE	50MG	N013264 001	
---------	------	-------------	--

QUINETHAZONE; RESERPINE

TABLET; ORAL

HYDROMOX R

LEDERLE	50MG; 0.125MG	N013927 001	
---------	---------------	-------------	--

QUINIDINE GLUCONATE

TABLET; ORAL

QUINACT

BAYER HLHCARE	266MG	A085978 001	
	400MG	A086099 001	

TABLET, EXTENDED RELEASE; ORAL

DURAQUIN

WARNER CHILCOTT	330MG	N017917 001	
-----------------	-------	-------------	--

QUINAGLUTE

BAYER HLHCARE	324MG	N016647 001	
---------------	-------	-------------	--

QUINALAN

LANNETT	324MG	A088081 001	Feb 10, 1986
---------	-------	-------------	--------------

QUINATIME

WATSON LABS	324MG	A087448 001	
-------------	-------	-------------	--

QUINIDINE GLUCONATE

ASCOT	324MG	A088582 001	Jun 17, 1985
HALSEY	324MG	A089476 001	Apr 10, 1987
ROXANE	324MG	A088431 001	Jan 06, 1984
SANDOZ	324MG	A089894 001	Dec 15, 1988
SUPERPHARM	324MG	A089164 001	Nov 21, 1985
WATSON LABS	324MG	A087785 001	Jan 24, 1983
	324MG	A087810 001	Sep 29, 1982

QUINIDINE POLYGALACTURONATE

TABLET; ORAL

CARDIOQUIN

PHARM RES ASSOC	275MG	N011642 002	
-----------------	-------	-------------	--

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY	200MG	A085296 001	
	300MG	A085297 001	

QUINIDINE SULFATE

LILLY	200MG	A085103 001	
-------	-------	-------------	--

TABLET; ORAL

CIN-QUIN

SOLVAY	100MG	A085299 001	
	200MG	A084932 001	
	300MG	A085298 001	

QUINIDINE SULFATE

BARR	200MG	A084177 001	
CONTRACT PHARMACAL	200MG	A083808 001	
DAVA PHARMS INC	200MG	A087011 001	
ELKINS SINN	200MG	A083622 001	
EVERYLIFE	200MG	A083439 001	

**DISCONTINUED DRUG PRODUCT LIST**QUINIDINE SULFATE

TABLET;ORAL

## QUINIDINE SULFATE

HALSEY	200MG	A083583	001	
HIKMA PHARMS LLC	200MG	A083862	001	
IMPAX LABS	200MG	A083347	001	
IVAX SUB TEVA PHARMS	200MG	A084549	001	
KING PHARMS	200MG	A085175	001	
KV PHARM	200MG	A085276	001	
LANNETT	200MG	A083743	001	
LEDERLE	200MG	A086176	001	
LILLY	200MG	A085038	001	
MUTUAL PHARM	100MG	A081029	001	Apr 14, 1989
PERRIGO	200MG	A085322	001	
PHARMAVITE	200MG	A084627	001	
PUREPAC PHARM	200MG	A084003	001	
ROXANE	200MG	A083640	001	
	300MG	A085632	001	
SANDOZ	200MG	A084631	001	
	200MG	A084914	001	
	300MG	A089839	001	Sep 29, 1988
SCHERER LABS	200MG	A085068	001	
SUPERPHARM	200MG	A088973	001	Apr 10, 1985
USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A085140	002	
WHITEWORTH TOWN PLSN	200MG	A085444	001	

## QUINORA

KEY PHARMS	200MG	A083576	001	
SCHERING	300MG	A085222	001	

TABLET, EXTENDED RELEASE;ORAL

## QUINIDEX

WYETH PHARMS INC	300MG	N012796	002	
------------------	-------	---------	-----	--

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

## ACIPHEX

EISAI INC	10MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020973	001	May 29, 2002
-----------	------	------------------------------------------------------------------------------------------------------------------	---------	-----	--------------

RAMIPRIL

CAPSULE;ORAL

## RAMIPRIL

ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008
	2.5MG	A077513	002	Jun 18, 2008
	5MG	A077513	003	Jun 18, 2008
	10MG	A077513	004	Jun 18, 2008
CIPLA	1.25MG	A077004	001	Aug 07, 2008
	2.5MG	A077004	002	Aug 07, 2008
	5MG	A077004	003	Aug 07, 2008
	10MG	A077004	004	Aug 07, 2008
RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009
	10MG	A078849	002	Mar 06, 2009

TABLET;ORAL

## ALTACE

KING PFIZER	1.25MG	N022021	001	Feb 27, 2007
	2.5MG	N022021	002	Feb 27, 2007
	5MG	N022021	003	Feb 27, 2007
	10MG	N022021	004	Feb 27, 2007

RANITIDINE BISMUTH CITRATE

TABLET;ORAL

## TRITEC

GLAXOSMITHKLINE	400MG	N020559	001	Aug 08, 1996
-----------------	-------	---------	-----	--------------

**DISCONTINUED DRUG PRODUCT LIST**RANITIDINE HYDROCHLORIDE

## CAPSULE; ORAL

## RANITIDINE HYDROCHLORIDE

MYLAN

EQ 150MG BASE

A075564 001 Oct 27, 2000

EQ 300MG BASE

A075564 002 Oct 27, 2000

TEVA

EQ 150MG BASE

A075557 001 Oct 31, 2003

EQ 300MG BASE

A075557 002 Oct 31, 2003

ZANTAC 150

GLAXOSMITHKLINE

EQ 150MG BASE

N020095 001 Mar 08, 1994

ZANTAC 300

GLAXOSMITHKLINE

EQ 300MG BASE

N020095 002 Mar 08, 1994

## GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE/PACKET

N020251 002 Mar 31, 1994

## INJECTABLE; INJECTION

## RANITIDINE HYDROCHLORIDE

BEDFORD

EQ 25MG BASE/ML

A074764 001 Nov 19, 2004

## ZANTAC IN PLASTIC CONTAINER

COVIS INJECTABLES

EQ 1MG BASE/ML

N019593 002 Sep 27, 1991

EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986

## SYRUP; ORAL

## RANITIDINE HYDROCHLORIDE

APOTEX INC

EQ 15MG BASE/ML

A077602 001 Sep 17, 2007

RANBAXY

EQ 15MG BASE/ML

A078448 001 Dec 13, 2007

## TABLET; ORAL

## RANITIDINE HYDROCHLORIDE

BOEHRINGER INGELHEIM

EQ 150MG BASE

A074662 001 Aug 29, 1997

EQ 300MG BASE

A074662 002 Aug 29, 1997

MYLAN

EQ 150MG BASE

A074552 001 Jul 30, 1998

EQ 300MG BASE

A074552 002 Jul 30, 1998

RANBAXY

EQ 75MG BASE

A075132 001 Jan 14, 2000

EQ 75MG BASE

A075254 001 Jan 14, 2000

EQ 150MG BASE

A075000 001 Jan 30, 1998

EQ 150MG BASE

A075439 001 Apr 19, 2000

EQ 300MG BASE

A075000 002 Jan 30, 1998

EQ 300MG BASE

A075439 002 Apr 19, 2000

SANDOZ

EQ 75MG BASE

A075519 001 Sep 26, 2002

WATSON LABS

EQ 75MG BASE

A075212 001 Jan 14, 2000

EQ 150MG BASE

A074864 001 Oct 20, 1997

EQ 300MG BASE

A074864 002 Oct 20, 1997

WATSON LABS INC

EQ 150MG BASE

A077426 001 Dec 19, 2005

EQ 300MG BASE

A077426 002 Dec 19, 2005

WOCKHARDT

EQ 150MG BASE

A078653 001 Nov 26, 2007

EQ 150MG BASE

A078701 001 Nov 12, 2009

EQ 300MG BASE

A078701 002 Dec 11, 2009

## TABLET, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE

N020251 001 Mar 31, 1994

ZANTAC 25

GLAXO GRP LTD

EQ 25MG BASE

N020251 003 Apr 01, 2004

ZANTAC 75

BOEHRINGER INGELHEIM

EQ 75MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020745 001 Feb 26, 1998

RAPACURONIUM BROMIDE

## INJECTABLE; INJECTION

## RAPLON

ORGANON USA INC

100MG/VIAL

N020984 001 Aug 18, 1999

200MG/VIAL

N020984 002 Aug 18, 1999

RASAGILINE MESYLATE

## TABLET; ORAL

## RASAGILINE MESYLATE

WATSON LABS INC

EQ 0.5MG BASE

A201823 001 Jul 01, 2013

EQ 1MG BASE

A201823 002 Jul 01, 2013

**DISCONTINUED DRUG PRODUCT LIST**RAUWOLFIA SERPENTINA ROOT

TABLET; ORAL

HIWOLFIA

BOWMAN PHARMS	50MG	N009276 003
	50MG	N009276 005
	100MG	N009276 004

HYSERPIN

PHYS PRODS VA	50MG	N010581 001
---------------	------	-------------

KONGLUCOID

PANRAY	50MG	N009278 001
	100MG	N009278 002

RAUDIXIN

APOTHECON	50MG	N008842 001
	100MG	N008842 002

RAUSERPIN

FERNDALE LABS	50MG	N009926 002
	100MG	N009926 004

RAUVAL

PAL PAK	50MG	N009108 002
	100MG	N009108 004

RAUWOLFIA SERPENTINA

BUNDY	50MG	N009477 001
	100MG	N009477 002

HALSEY	50MG	A080498 001
	100MG	A080498 002

IMPAX LABS	50MG	N009273 001
	100MG	N009273 002

IVAX SUB TEVA PHARMS	50MG	N011521 001
	100MG	N011521 002

PUREPAC PHARM	50MG	A080842 001
	100MG	A080842 002

PVT FORM	50MG	A080583 001
	100MG	A080583 002

SOLVAY	50MG	A080500 001
	100MG	A080500 002

TABLICAPS	50MG	A083867 001
	100MG	A083444 001

VALEANT PHARM INTL	50MG	N009668 001
	100MG	N009668 002

WATSON LABS	50MG	A080907 001
	100MG	A080914 001

WOLFINA

FOREST PHARMS	50MG	N009255 008
	100MG	N009255 006

RESCINNAMINE

CAPSULE; ORAL

CINNASIL

PANRAY	0.5MG	A084736 001
--------	-------	-------------

TABLET; ORAL

MODERIL

PFIZER	0.25MG	N010686 003
	0.5MG	N010686 006

RESERPINE

ELIXIR; ORAL

SERPASIL

NOVARTIS	0.2MG/4ML	N009115 005
----------	-----------	-------------

INJECTABLE; INJECTION

SANDRIL

LILLY	2.5MG/ML	N010012 001
-------	----------	-------------

SERPASIL

NOVARTIS	2.5MG/ML	N009434 002
----------	----------	-------------

TABLET; ORAL

HISERPIA

BOWMAN PHARMS	0.1MG	N009631 002
	0.25MG	N009631 004

RAU-SED

BRISTOL MYERS SQUIBB	0.1MG	N009357 001
	0.25MG	N009357 004
	0.5MG	N009357 006
	1MG	N009357 008

## DISCONTINUED DRUG PRODUCT LIST

RESERPINE

TABLET; ORAL

RESERPINE

BARR	0.25MG	A080721	002	
BELL PHARMA	0.1MG	A083058	001	
	0.25MG	A083058	002	
BUNDY	0.1MG	N009663	001	
	0.25MG	N009663	003	
CYCLE PHARMS LTD	0.1MG	N009859	001	
	0.25MG	N009859	002	
ELKINS SINN	0.1MG	A083145	001	
	0.25MG	A083145	002	
EVERYLIFE	0.1MG	N010441	001	
	0.25MG	N010441	002	
	0.5MG	N010441	003	
	1MG	N010441	004	
HALSEY	0.1MG	A080457	002	
	0.25MG	A080457	001	
	1MG	A080457	003	
HIKMA PHARMS LLC	0.1MG	A080975	001	
	0.25MG	A080975	002	
	1MG	A080975	003	
IMPAX LABS	0.1MG	N009627	001	
	0.25MG	N009627	002	
IVAX SUB TEVA PHARMS	0.1MG	N011185	001	
	0.25MG	N011185	002	
MARSHALL PHARMA	0.1MG	A080492	001	
	0.25MG	A080492	002	
MK LABS	0.1MG	A080525	002	
	0.25MG	A080525	001	
MYLAN	1MG	A084974	001	
PHARMAVITE	0.25MG	A084663	001	
PUREPAC PHARM	0.1MG	A080753	002	
	0.25MG	A080753	001	
PVT FORM	0.1MG	A086117	001	
	0.25MG	A080582	001	
	0.25MG	A085775	001	
	1MG	A080582	002	
REXALL	0.25MG	A080637	001	
SOLVAY	0.25MG	A080446	001	
TABLICAPS	0.25MG	A085207	001	
TEVA	0.1MG	A089020	001	Mar 07, 1985
	0.25MG	A089019	001	Mar 07, 1985
VALEANT PHARM INTL	0.1MG	N009667	001	
	0.25MG	N009667	002	
WATSON LABS	0.1MG	A080679	001	
	0.25MG	A080393	001	
	0.25MG	A085401	001	
	1MG	A080749	001	
WHITEWORTH TOWN PLSN	0.1MG	A080723	001	
	0.25MG	A080723	002	
	1MG	A080723	003	
SANDRIL				
LILLY	0.1MG	N009376	004	
	0.25MG	N009376	001	
SERPALAN				
LANNETT	0.1MG	N010124	001	
	0.25MG	N010124	002	
SERPANRAY				
PANRAY	0.1MG	N009391	001	
	0.25MG	N009391	002	
	1MG	N009391	004	
SERPASIL				
NOVARTIS	0.1MG	N009115	001	
	0.25MG	N009115	003	
	1MG	N009115	004	
SERPATE				
VALE	0.1MG	N009453	001	
	0.25MG	N009453	002	
SERPIVITE				
VITARINE	0.25MG	N009645	002	

**DISCONTINUED DRUG PRODUCT LIST**RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2

SANOFI AVENTIS US 0.1MG;2MG N012972 001

METATENSIN #4

SANOFI AVENTIS US 0.1MG;4MG N012972 002

NAQUIVAL

SCHERING 0.1MG;4MG N012265 003

TRICHLORMETHIAZIDE W/ RESERPINE

WATSON LABS 0.1MG;4MG A085248 001

RIBAVIRIN

TABLET; ORAL

COPEGUS

ROCHE 400MG N021511 002 Jun 21, 2005

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

FLUMADINE

FOREST LABS 50MG/5ML N019650 001 Sep 17, 1993

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH 100MG A076375 001 Jan 14, 2003

COREPHARMA 100MG A075916 001 Nov 02, 2001

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

WARNER CHILCOTT LLC 75MG \*\*Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons\*\* N020835 004 Apr 16, 2007

RISPERIDONE

TABLET; ORAL

RISPERDAL

JANSSEN PHARMS 5MG N020272 005 Dec 29, 1993

RISPERIDONE

CADISTA PHARMS 0.25MG A078828 001 Mar 23, 2009

0.5MG A078828 002 Mar 23, 2009

1MG A078828 003 Mar 23, 2009

2MG A078828 004 Mar 23, 2009

3MG A078828 005 Mar 23, 2009

4MG A078828 006 Mar 23, 2009

RATIOPHARM 0.25MG A077784 001 Jun 08, 2010

0.5MG A077784 002 Jun 08, 2010

1MG A077784 003 Jun 08, 2010

2MG A077784 004 Jun 08, 2010

3MG A077784 005 Jun 08, 2010

4MG A077784 006 Jun 08, 2010

SYNTHON PHARMS 0.25MG A078187 001 Oct 22, 2009

0.5MG A078187 002 Oct 22, 2009

1MG A078187 003 Oct 22, 2009

2MG A078187 004 Oct 22, 2009

3MG A078187 005 Oct 22, 2009

4MG A078187 006 Oct 22, 2009

WATSON LABS 0.25MG A077860 001 Dec 05, 2008

0.5MG A077860 002 Dec 05, 2008

1MG A077860 003 Dec 05, 2008

2MG A077860 004 Dec 05, 2008

3MG A077860 005 Dec 05, 2008

4MG A077860 006 Dec 05, 2008

WEST WARD PHARMS 0.25MG A078740 001 May 29, 2009

0.5MG A078740 002 May 29, 2009

1MG A078740 003 May 29, 2009

2MG A078740 004 May 29, 2009

3MG A078740 005 May 29, 2009

4MG A078740 006 May 29, 2009

**DISCONTINUED DRUG PRODUCT LIST**RITODRINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## RITODRINE HYDROCHLORIDE

ABRAXIS PHARM	10MG/ML	A071188 001	Jul 23, 1987
	15MG/ML	A071189 001	Jul 23, 1987
HOSPIRA	10MG/ML	A071618 001	Feb 28, 1991
	15MG/ML	A071619 001	Feb 28, 1991

## RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML	A071438 001	Jan 22, 1991
---------	------------	-------------	--------------

## YUTOPAR

ASTRAZENECA	10MG/ML	N018580 001	
	15MG/ML	N018580 002	

## TABLET; ORAL

## YUTOPAR

ASTRAZENECA	10MG	N018555 001	
-------------	------	-------------	--

RITONAVIR

## CAPSULE; ORAL

## NORVIR

ABBOTT	100MG	N020680 001	Mar 01, 1996
--------	-------	-------------	--------------

RIVASTIGMINE TARTRATE

## SOLUTION; ORAL

## EXELON

NOVARTIS	EQ 2MG BASE/ML	N021025 001	Apr 21, 2000
----------	----------------	-------------	--------------

ROCURONIUM BROMIDE

## INJECTABLE; INJECTION

## ZEMURON

ORGANON USA INC	50MG/5ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214 001	Mar 17, 1994
	10MG/ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214 002	Mar 17, 1994
	100MG/10ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214 003	Mar 17, 1994

ROFECOXIB

## SUSPENSION; ORAL

## VIOXX

MERCK	12.5MG/5ML	N021052 001	May 20, 1999
	25MG/5ML	N021052 002	May 20, 1999

## TABLET; ORAL

## VIOXX

MERCK	12.5MG	N021042 001	May 20, 1999
	25MG	N021042 002	May 20, 1999
	50MG	N021042 003	Feb 25, 2000

ROPINIROLE HYDROCHLORIDE

## TABLET; ORAL

## ROPINIROLE HYDROCHLORIDE

COREPHARMA	EQ 0.25MG BASE	A078230 001	May 20, 2008
	EQ 0.5MG BASE	A078230 002	May 20, 2008
	EQ 1MG BASE	A078230 003	May 20, 2008
	EQ 2MG BASE	A078230 004	May 20, 2008
	EQ 3MG BASE	A078230 005	May 20, 2008
	EQ 4MG BASE	A078230 006	May 20, 2008
	EQ 5MG BASE	A078230 007	May 20, 2008

## TABLET, EXTENDED RELEASE; ORAL

## REQUIP XL

GLAXOSMITHKLINE LLC	EQ 3MG BASE	N022008 002	Jun 13, 2008
---------------------	-------------	-------------	--------------

ROSE BENGAL SODIUM I-131

## INJECTABLE; INJECTION

## ROBENGATOPE

BRACCO	0.5mCi/VIAL	N016224 001	
	1mCi/VIAL	N016224 002	
	2mCi/VIAL	N016224 003	

## SODIUM ROSE BENGAL I 131

SORIN	0.5mCi/ML	N017318 001	
-------	-----------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

RUFINAMIDE

TABLET; ORAL

BANZEL

EISAI INC

100MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021911 001 Nov 14, 2008

SAFFLOWER OIL

INJECTABLE; INJECTION

LIPOSYN 10%

ABBOTT

10% (10GM/100ML)

N018203 001

LIPOSYN 20%

ABBOTT

20% (20GM/100ML)

N018614 001

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

HOSPIRA

5%;5% (5GM/100ML)

N018997 001 Aug 27, 1984

LIPOSYN II 20%

HOSPIRA

10%;10% (10GM/100ML)

N018991 001 Aug 27, 1984

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

SEREVENT

GLAXOSMITHKLINE

EQ 0.021MG BASE/INH

N020236 001 Feb 04, 1994

SAQUINAVIR

CAPSULE; ORAL

FORTOVASE

HOFFMANN LA ROCHE

200MG

N020828 001 Nov 07, 1997

SARALASIN ACETATE

INJECTABLE; INJECTION

SARENIN

PROCTER AND GAMBLE

EQ 0.6MG BASE/ML

N018009 001

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

ANABOLIC

100MG

A084422 001

BARR

100MG

A084225 001

EVERYLIFE

100MG

A085895 001

HALSEY

100MG

A084676 001

IVAX PHARMS

100MG

A085869 001

KV PHARM

100MG

A085285 001

LANNETT

50MG

A085909 001

100MG

100MG

A085903 001

PARKE DAVIS

100MG

A084762 001

PERRIGO

100MG

A084561 001

PUREPAC PHARM

100MG

A085867 001

VALEANT PHARM INTL

100MG

A085477 001

VITARINE

100MG

A085898 001

100MG

100MG

A086273 001

WATSON LABS

100MG

A085792 001

WEST WARD

100MG

A084926 001

WHITEWORTH TOWN PLSN

100MG

A085798 001

WYETH AYERST

100MG

A086390 001

INJECTABLE; INJECTION

SECOBARBITAL SODIUM

ELKINS SINN

100MG/VIAL

A083281 001

WYETH AYERST

50MG/ML

A083262 001

SECONAL SODIUM

LILLY

50MG/ML

N007392 002

SUPPOSITORY; RECTAL

SECONAL SODIUM

LILLY

30MG

A086530 001

60MG

A086530 002

120MG

A086530 003

200MG

A086530 004



## DISCONTINUED DRUG PRODUCT LIST

SECRETIN

INJECTABLE; INJECTION

SECRETIN-FERRING

FERRING

75CU/VIAL

N018290 001

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREFLO

CHIRHOCLIN

16MCG/VIAL

N021136 001 Apr 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

LANNETT HOLDINGS INC

5MG

A075145 001 Sep 15, 2003

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

DAVA PHARMS INC

5MG

A074641 001 Aug 02, 1996

IVAX SUB TEVA PHARMS

5MG

A074756 001 Nov 25, 1998

SIEGFRIED

5MG

A074672 001 Apr 01, 1997

SOMERSET

5MG

N019334 001 Jun 05, 1989

TEVA

5MG

A074537 001 Aug 02, 1996

5MG

A074744 001 Jan 27, 1997

VINTAGE PHARMS LLC

5MG

A074565 001 Aug 02, 1996

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

EXSEL

ALLERGAN HERBERT

2.5%

A083892 001

SELENIUM SULFIDE

ACTAVIS MID ATLANTIC

2.5%

A084394 001

G AND W LABS INC

2.5%

A086209 001

IVAX PHARMS

2.5%

A085777 001

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

GE HEALTHCARE

250uCi/ML

N017257 001

MALLINCKRODT

100uCi/ML

N017098 001

PHARMALUCENCE

500uCi/ML

N017322 001

SETHOTOPE

BRACCO

85-550uCi/ML

N017047 001

SERACTIDE ACETATE

INJECTABLE; INJECTION

ACTHAR GEL-SYNTHETIC

ARMOUR PHARM

40 UNITS/ML

N017861 001

80 UNITS/ML

N017861 002

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

EMD SERONO

EQ 0.05MG BASE/AMP \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N019863 001 Dec 28, 1990

EMD SERONO INC

EQ 0.5MG BASE/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020443 001 Sep 26, 1997

EQ 1MG BASE/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020443 002 Sep 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

RANBAXY LABS LTD

EQ 20MG BASE/ML

A078053 001 Feb 05, 2007

ROXANE

EQ 20MG BASE/ML

A076934 001 Jun 30, 2006

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 25MG BASE

A077345 001 Feb 06, 2007

EQ 50MG BASE

A077345 002 Feb 06, 2007

EQ 100MG BASE

A077345 003 Feb 06, 2007

CIPLA LTD

EQ 25MG BASE

A077162 001 Feb 06, 2007

EQ 50MG BASE

A077162 002 Feb 06, 2007

EQ 100MG BASE

A077162 003 Feb 06, 2007

**DISCONTINUED DRUG PRODUCT LIST**SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

DR REDDYS LABS LTD	EQ 25MG BASE	A076442 001	Apr 30, 2007
	EQ 50MG BASE	A076442 002	Apr 30, 2007
	EQ 100MG BASE	A076442 003	Apr 30, 2007
IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719 003	Jun 30, 2006
	EQ 50MG BASE	A075719 001	Jun 30, 2006
	EQ 100MG BASE	A075719 002	Jun 30, 2006
MUTUAL PHARM	EQ 25MG BASE	A077818 001	Feb 06, 2007
	EQ 50MG BASE	A077818 002	Feb 06, 2007
	EQ 100MG BASE	A077818 003	Feb 06, 2007
MYLAN PHARMS INC	EQ 25MG BASE	A076540 001	Mar 20, 2007
	EQ 50MG BASE	A076540 002	Mar 20, 2007
	EQ 100MG BASE	A076540 003	Mar 20, 2007
PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299 001	Feb 06, 2007
	EQ 50MG BASE	A077299 002	Feb 06, 2007
	EQ 100MG BASE	A077299 003	Feb 06, 2007
ROXANE	EQ 25MG BASE	A076881 001	Feb 06, 2007
	EQ 50MG BASE	A076881 002	Feb 06, 2007
	EQ 100MG BASE	A076881 003	Feb 06, 2007
SANDOZ	EQ 25MG BASE	A077713 001	Feb 06, 2007
	EQ 50MG BASE	A077713 002	Feb 06, 2007
	EQ 100MG BASE	A077713 003	Feb 06, 2007
WATSON LABS	EQ 25MG BASE	A077663 001	Feb 06, 2007
	EQ 50MG BASE	A077663 002	Feb 06, 2007
	EQ 100MG BASE	A077663 003	Feb 06, 2007
ZOLOFT			
PFIZER	EQ 150MG BASE	N019839 003	Dec 30, 1991
	EQ 200MG BASE	N019839 004	Dec 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

GENZYME	403MG	N020926 001	Oct 30, 1998
---------	-------	-------------	--------------

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

MERIDIA

ABBOTT	5MG	N020632 001	Nov 22, 1997
	10MG	N020632 002	Nov 22, 1997
	15MG	N020632 003	Nov 22, 1997

SILVER SULFADIAZINE

DRESSING; TOPICAL

SILDAFLO

FRANKLIN PHARMS	1%	N019608 001	Nov 30, 1989
-----------------	----	-------------	--------------

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL

SONORX

BRACCO	7.5MG/ML	N020773 001	Oct 29, 1998
--------	----------	-------------	--------------

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

SANDOZ INC	5MG	A077766 001	Dec 20, 2006
	10MG	A077766 002	Dec 20, 2006
	20MG	A077766 003	Dec 20, 2006
	40MG	A077766 004	Dec 20, 2006
	80MG	A077766 005	Dec 20, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

SIMVASTATIN

SYNTHON PHARMS	10MG	N021961 001	Oct 09, 2007
	20MG	N021961 002	Oct 09, 2007
	40MG	N021961 003	Oct 09, 2007
	80MG	N021961 004	Oct 09, 2007

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

MERCK SHARP DOHME	10MG; EQ 50MG BASE	N202343 004	Sep 18, 2012
	10MG; EQ 100MG BASE	N202343 001	Oct 07, 2011
	20MG; EQ 50MG BASE	N202343 005	Sep 18, 2012
	20MG; EQ 100MG BASE	N202343 002	Oct 07, 2011

**DISCONTINUED DRUG PRODUCT LIST**SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

40MG; EQ 50MG BASE  
40MG; EQ 100MG BASEN202343 006 Sep 18, 2012  
N202343 003 Oct 07, 2011SIROLIMUS

TABLET; ORAL

RAPAMUNE

PF PRISM CV

5MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N021110 003 Feb 23, 2004

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

B BRAUN

100MG/ML; 100MG/ML

N019530 001 Dec 23, 1987

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT

0.9MEQ/ML

N019443 001 Jun 03, 1986

1MEQ/ML

N019443 002 Jun 03, 1986

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

MALLINCKRODT INC

460MG/GM; 420MG/GM

N018509 001 Aug 07, 1985

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABRAXIS PHARM

9MG/ML

A088909 001 Feb 07, 1985

SODIUM CHLORIDE

ABBOTT

20GM/100ML

N017013 001

B BRAUN

20GM/100ML

N017038 001

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN

450MG/100ML

N018184 001

MILES

450MG/100ML

N018503 001

SODIUM CHLORIDE 0.9%

MEDEFIL INC

18MG/2ML (9MG/ML)

N202832 002 Jan 06, 2012

22.5MG/2.5ML (9MG/ML)

N202832 003 Jan 06, 2012

27MG/3ML (9MG/ML)

N202832 004 Jan 06, 2012

45MG/5ML (9MG/ML)

N202832 005 Jan 06, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT

9MG/ML

N019218 001 Jul 13, 1984

MEDEFIL INC

9MG/ML (9MG/ML)

N202832 001 Jan 06, 2012

MILES

900MG/100ML

N018502 001

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

ABRAXIS PHARM

234MG/ML

N019329 001 Apr 22, 1987

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

B BRAUN

3GM/100ML

N019635 003 Mar 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML

N019635 004 Mar 09, 1988

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

BAXTER HLTHCARE

450MG/100ML

N017864 001

450MG/100ML

N018497 001 Feb 19, 1982

HOSPIRA

450MG/100ML

N017670 001

450MG/100ML

N018380 001

SODIUM CHLORIDE IN PLASTIC CONTAINER

MILES

900MG/100ML

N018247 001

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPE SODIUM

BRACCO

2mCi/VIAL

N013993 002

200uCi/ML

N013993 001

SODIUM CHROMATE CR 51

MALLINCKRODT

100uCi/ML

N016708 001

**DISCONTINUED DRUG PRODUCT LIST**SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

GE HEALTHCARE

2mCi/ML \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N017042 001

SODIUM FLUORIDE F 18

NIH NCI DCTD

10-200mCi/ML

N022494 001 Jan 26, 2011

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

CARDINAL HLTH 414

400uCi

N018671 003 May 27, 1982

GE HEALTHCARE

100uCi

N017630 001

SOLUTION; ORAL

SODIUM IODIDE I 123

GE HEALTHCARE

2mCi/ML

N017630 002

SODIUM IODIDE I-131

CAPSULE; ORAL

IODOTOPE

BRACCO

1-130mCi

N010929 001

1-150mCi

N010929 003

SODIUM IODIDE I 131

CIS

50uCi

N017316 001

MALLINCKRODT

0.8-100mCi

N017316 002

MALLINCKRODT

15-100uCi

N016515 002

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE

2-200mCi

N021305 004 Nov 18, 2004

SOLUTION; ORAL

HICON

JUBILANT DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003

1-500mCi/0.5ML

N021305 003 Jan 24, 2003

1-1000mCi/ML

N021305 005 Apr 04, 2006

IODOTOPE

BRACCO

7-106mCi/BOT

N010929 002

SODIUM IODIDE I 131

CIS

50mCi/ML

N017315 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N018186 001

HOSPIRA

1.87GM/100ML

N018249 001

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 002 Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 001 Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE

50MG/VIAL

N017546 001

NITROPRESS

ABBOTT

50MG/VIAL

A071555 001 Nov 16, 1987

ABBVIE

50MG/VIAL

N018450 001

HOSPIRA

50MG/VIAL

A070566 001 Jun 09, 1986

SODIUM NITROPRUSSIDE

ABRAXIS PHARM

50MG/VIAL

A070031 001 Jan 17, 1985

BAXTER HLTHCARE

50MG/VIAL

N018581 001 Jul 28, 1982

TEVA PARENTERAL

25MG/ML

A073465 001 Mar 30, 1992

SODIUM PHOSPHATE P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

BRACCO

1-8mCi/VIAL

N010927 001

SODIUM PHOSPHATE P 32

MALLINCKRODT

0.67mCi/ML

N011777 001

1.5mCi/VIAL

N011777 002

**DISCONTINUED DRUG PRODUCT LIST**SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

VISICOL

SALIX PHARMS

0.398GM;1.102GM

N021097 001 Sep 21, 2000

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

NOVEL LABS INC

0.398GM;1.102GM

A079247 001 Dec 30, 2011

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

CITRUSPHRMA

454GM/BOT

A040909 001 Dec 03, 2008

WOCKHARDT

453.6GM/BOT

A088786 001 Sep 11, 1984

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

MORTON GROVE

15GM/60ML

A088717 001 Sep 11, 1984

ROXANE

15GM/60ML

A088453 001 Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

ELKINS SINN

30%

A080516 001

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

ELKINS SINN

1% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N005970 004

3% \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N005970 005

SODIUM THIOSULFATE

INJECTABLE; INJECTION

SODIUM THIOSULFATE

US ARMY

250MG/ML

N020166 001 Feb 14, 1992

SOMATREM

INJECTABLE; INJECTION

PROTROPIN

GENENTECH

5MG/VIAL

N019107 001 Oct 17, 1985

10MG/VIAL

N019107 002 Oct 24, 1989

SOMATROPIN

INJECTABLE; INJECTION

ASELLACRIN 10

SERONO

10 IU/VIAL

N017726 001

ASELLACRIN 2

SERONO

2 IU/VIAL

N017726 002 Jul 21, 1983

CRESCORMON

GENENTECH

4 IU/VIAL

N017992 001

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

ACCRETROPIN

EMERGENT

5MG/ML (5MG/ML)

N021538 001 Jan 23, 2008

BIO-TROPIN

FERRING

4.8MG/VIAL

N019774 001 May 25, 1995

HUMATROPE

LILLY

2MG/VIAL

N019640 001 Jun 23, 1987

NORDITROPIN

NOVO NORDISK INC

4MG/VIAL

N019721 001 May 08, 1995

5MG/1.5ML

N021148 001 Jun 20, 2000

8MG/VIAL

N019721 002 May 08, 1995

10MG/1.5ML

N021148 002 Jun 20, 2000

15MG/1.5ML

N021148 003 Jun 20, 2000

NORDITROPIN NORDIFLEX

NOVO NORDISK INC

5MG/1.5ML

N021148 004 Oct 01, 2004

10MG/1.5ML

N021148 005 Oct 01, 2004

15MG/1.5ML

N021148 006 Oct 01, 2004

NUTROPIN DEPOT

GENENTECH

13.5MG/VIAL

N021075 001 Dec 22, 1999

**DISCONTINUED DRUG PRODUCT LIST**SOMATROPIN RECOMBINANT

## INJECTABLE; INJECTION

## NUTROPIN DEPOT

18MG/VIAL

N021075 002 Dec 22, 1999

22.5MG/VIAL

N021075 003 Dec 22, 1999

## SAIZEN

## EMD SERONO

4MG/VIAL

N019764 005 Jan 16, 2007

6MG/VIAL

N019764 001 Oct 08, 1996

## SEROSTIM

## EMD SERONO

8.8MG/VIAL

N020604 004 Sep 06, 2001

## ZORBTIVE

## EMD SERONO

4MG/VIAL

N021597 001 Dec 01, 2003

5MG/VIAL

N021597 002 Dec 01, 2003

6MG/VIAL

N021597 003 Dec 01, 2003

## INJECTABLE; SUBCUTANEOUS

## SEROSTIM LQ

## EMD SERONO

6MG/0.5ML (6MG/0.5ML)

N020604 005 Feb 11, 2005

SORBITOL

## SOLUTION; IRRIGATION

## SORBITOL 3% IN PLASTIC CONTAINER

## BAXTER HLTHCARE

3GM/100ML

N018512 001 May 27, 1982

SOTALOL HYDROCHLORIDE

## TABLET; ORAL

## BETAPACE

## BAYER HLTHCARE

320MG

N019865 004 Oct 30, 1992

## BETAPACE AF

## COVIS PHARMA SARL

40MG

N021151 006 Apr 02, 2003

60MG

N021151 007 Apr 02, 2003

100MG

N021151 005 Mar 14, 2003

## SOTALOL HYDROCHLORIDE

## MUTUAL PHARM

80MG

A075515 001 Oct 15, 2001

80MG

A076576 001 Apr 08, 2004

120MG

A075515 004 Oct 15, 2001

120MG

A076576 002 Apr 08, 2004

160MG

A075515 002 Oct 15, 2001

160MG

A076576 003 Apr 08, 2004

240MG

A075515 003 Oct 15, 2001

## WATSON LABS

80MG

A075238 001 Jul 13, 2000

120MG

A075238 002 Jul 13, 2000

160MG

A075238 003 Jul 13, 2000

240MG

A075238 004 Jul 13, 2000

SOYBEAN OIL

## INJECTABLE; INJECTION

## LIPOSYN III 10%

## HOSPIRA

10%

N018969 001 Sep 24, 1984

## LIPOSYN III 20%

## HOSPIRA

20%

N018970 001 Sep 25, 1984

## LIPOSYN III 30%

## HOSPIRA

30%

N020181 001 Jan 13, 1998

## SOYACAL 10%

## ALPHA THERA

10%

N018465 001 Jun 29, 1983

## SOYACAL 20%

## ALPHA THERA

20%

N018786 001 Jun 29, 1983

## TRAVAMULSION 10%

## BAXTER HLTHCARE

10%

N018660 001 Feb 26, 1982

## TRAVAMULSION 20%

## BAXTER HLTHCARE

20%

N018758 001 Feb 15, 1983

SPARFLOXACIN

## TABLET; ORAL

## ZAGAM

## MYLAN

200MG

N020677 001 Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

## INJECTABLE; INJECTION

## TROBICIN

## PFIZER

EQ 2GM BASE/VIAL

N050347 001

EQ 4GM BASE/VIAL

N050347 002

## DISCONTINUED DRUG PRODUCT LIST

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING	3MG	N020240 001	Dec 29, 1994
	6MG	N020240 002	Dec 29, 1994
	12MG	N020240 003	Dec 29, 1994
	24MG	N020240 004	Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ASCOT	25MG	A087687 001	Oct 20, 1982
IVAX PHARMS	25MG	A087108 001	
LEDERLE	25MG	A087634 001	
MUTUAL PHARM	25MG	A087265 001	
MYLAN	25MG	A087086 001	
PUREPAC PHARM	25MG	A087998 001	Oct 14, 1983
	25MG	A088053 001	Aug 25, 1983
SUPERPHARM	25MG	A089364 001	Nov 07, 1986
UPSHER SMITH	25MG	A087554 001	
VANGARD	25MG	A087648 001	Feb 01, 1982
WARNER CHILCOTT	25MG	A087952 001	Nov 18, 1982
WATSON LABS	25MG	A086898 002	Mar 02, 1982
	25MG	A087078 001	

STANZOLOL

TABLET; ORAL

WINSTROL

LUNDBECK INC	2MG	N012885 001	May 14, 1984
--------------	-----	-------------	--------------

STAVUDINE

CAPSULE; ORAL

ZERIT

BRISTOL MYERS SQUIBB	5MG	N020412 001	Jun 24, 1994
----------------------	-----	-------------	--------------

CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR

BRISTOL MYERS SQUIBB	37.5MG	N021453 001	Dec 31, 2002
	50MG	N021453 002	Dec 31, 2002
	75MG	N021453 003	Dec 31, 2002
	100MG	N021453 004	Dec 31, 2002

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM	100%	A089099 001	Dec 29, 1987
	100%	A089100 001	Dec 29, 1987

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN	100%	N019077 001	Mar 02, 1984
---------	------	-------------	--------------

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES	100%	N018246 001	
-------	------	-------------	--

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

COPANOS	EQ 500MG BASE/ML	A060684 001	
LILLY	EQ 1GM BASE/VIAL	A060107 001	
	EQ 1GM BASE/2ML	A060404 001	
	EQ 5GM BASE/VIAL	A060107 002	
PFIZER	EQ 1GM BASE/VIAL	A060076 001	
	EQ 1GM BASE/2.5ML	A060111 001	
	EQ 5GM BASE/VIAL	A060076 002	

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

SANDOZ	1GM/VIAL	N008453 004	
	50MG/ML	N008453 003	
	500MG/VIAL	N008453 001	

QUELICIN PRESERVATIVE FREE

HOSPIRA	50MG/ML	N008845 002	
---------	---------	-------------	--

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION	100MG/VIAL	A085400 001	Feb 04, 1982
ORGANON USA INC	20MG/ML	A080997 001	

## DISCONTINUED DRUG PRODUCT LIST

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCOSTRIN

APOTHECON

20MG/ML

N008847 001

100MG/ML

N008847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS

EQ 0.05MG BASE/ML

A074406 001 Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN

10%

A084015 001

SODIUM SULAMYD

SCHERING

10%

N005963 002

SULFAIR 10

PHARMAFAIR

10%

A088000 001 Dec 22, 1982

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN

30%

A080028 002

ISOPTO CETAMIDE

ALCON

15%

A080020 002

OCUSULF-10

MIZA PHARMS USA

10%

A080660 001

OCUSULF-30

MIZA PHARMS USA

30%

A080660 002

SODIUM SULAMYD

SCHERING

10%

N005963 001

30%

N005963 003

SODIUM SULFACETAMIDE

AKORN

10%

A083021 001

15%

A083021 002

30%

A083021 003

SOLA BARNES HIND

10%

A084143 001

10%

A084145 001

30%

A084146 001

30%

A084147 001

SULF-10

NOVARTIS

10%

A080025 001

SULF-15

NOVARTIS

15%

A089047 001 Oct 31, 1995

SULFACEL-15

OPTOPICS

15%

A080024 001

SULFACETAMIDE SODIUM

AKORN

10%

A040215 001 May 25, 1999

30%

A040216 001 May 25, 1999

ALCON PHARMS LTD

30%

A089068 001 May 05, 1987

PHARMAFAIR

10%

A088947 001 May 17, 1985

SULFAIR 10

PHARMAFAIR

10%

A087949 001 Dec 13, 1982

SULFAIR FORTE

PHARMAFAIR

30%

A088385 001 Oct 13, 1983

SULFAIR-15

PHARMAFAIR

15%

A088186 001 May 25, 1983

SULTEN-10

BAUSCH AND LOMB

10%

A087818 001 Feb 03, 1983

SULFACYTINE

TABLET; ORAL

RENOQUID

GLENWOOD

250MG

N017569 001

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

ABBVIE

300MG

N004125 005

EVERYLIFE

500MG

A080088 001

IMPAX LABS

500MG

A080081 001

LANNETT

500MG

A080084 001

LEDERLE

500MG

N004054 001

LILLY

500MG

N004122 002



**DISCONTINUED DRUG PRODUCT LIST**SULFADIAZINE SODIUM

INJECTABLE; INJECTION  
SULFADIAZINE SODIUM  
LEDERLE

250MG/ML N004054 002

SULFADIAZINE; SULFAMERAZINE

SUSPENSION; ORAL  
SULFONAMIDES DUPLEX  
LILLY

250MG/5ML; 250MG/5ML N006317 007

SULFAMETER

TABLET; ORAL  
SULLA  
BAYER HLTHCARE

500MG N016000 002

SULFAMETHIZOLE

TABLET; ORAL  
MICROSUL  
FOREST PHARMS  
PROKLAR  
FOREST PHARMS  
THIOSULFIL  
WYETH AYERST

1GM A086012 001  
500MG A080273 001  
250MG N008565 001  
500MG N008565 004

SULFAMETHOXAZOLE

SUSPENSION; ORAL  
GANTANOL

ROCHE 500MG/5ML N013664 002

TABLET; ORAL

GANTANOL

ROCHE 500MG N012715 002

GANTANOL-DS

ROCHE 1GM N012715 003

SULFAMETHOXAZOLE

ASCOT 500MG A087662 001 Oct 20, 1982

BARR 500MG A087189 001 Jul 25, 1983

HEATHER 500MG A086163 001

SANDOZ 500MG A085844 001

WATSON LABS 1GM A086000 001

500MG A085053 001

UROBAK

SHIONOGI 500MG A087307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

MUTUAL PHARM 80MG/ML; 16MG/ML N018374 001

SEPTRA

MONARCH PHARMS 80MG/ML; 16MG/ML N018452 001

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM 80MG/ML; 16MG/ML A070223 001 Dec 29, 1987

BEDFORD 80MG/ML; 16MG/ML A072383 001 Apr 29, 1992

HIKMA MAPLE 80MG/ML; 16MG/ML A070627 001 Dec 29, 1987

80MG/ML; 16MG/ML A070628 001 Dec 29, 1987

HOSPIRA 80MG/ML; 16MG/ML A073199 001 Sep 11, 1992

WATSON LABS 80MG/ML; 16MG/ML A071556 001 Dec 29, 1987

SUSPENSION; ORAL

BACTRIM

MUTUAL PHARM 200MG/5ML; 40MG/5ML N017560 001

BACTRIM PEDIATRIC

MUTUAL PHARM 200MG/5ML; 40MG/5ML N017560 002

SEPTRA

MONARCH PHARMS 200MG/5ML; 40MG/5ML N017598 001

SEPTRA GRAPE

MONARCH PHARMS 200MG/5ML; 40MG/5ML N017598 002 Feb 12, 1986

SULFAMETHOXAZOLE AND TRIMETHOPRIM

TEVA 200MG/5ML; 40MG/5ML A070028 001 Jun 02, 1987

200MG/5ML; 40MG/5ML N018812 001 Jan 28, 1983

200MG/5ML; 40MG/5ML N018812 002 Jun 10, 1983

TEVA PHARMS 200MG/5ML; 40MG/5ML A077612 001 Nov 13, 2006

SULFATRIM

STI PHARMA LLC 200MG/5ML; 40MG/5ML N018615 002 Jan 07, 1983

## DISCONTINUED DRUG PRODUCT LIST

SULFAMETHOXAZOLE; TRIMETHOPRIM

## SUSPENSION; ORAL

## SULMEPRIM

USL PHARMA 200MG/5ML; 40MG/5ML A070063 001 Aug 01, 1986

## SULMEPRIM PEDIATRIC

USL PHARMA 200MG/5ML; 40MG/5ML A070064 001 Aug 01, 1986

## TRIMETH/SULFA

ALPHARMA US PHARMS 200MG/5ML; 40MG/5ML A072289 001 May 23, 1988

200MG/5ML; 40MG/5ML A072398 001 May 23, 1988

NASKA 200MG/5ML; 40MG/5ML A072399 001 May 23, 1988

## TABLET; ORAL

## COTRIM

TEVA 400MG; 80MG A070034 001 May 16, 1985

## COTRIM D.S.

TEVA 800MG; 160MG A070048 001 Mar 18, 1985

## SULFAMETHOPRIM

NOVEL LABS INC 400MG; 80MG A070022 001 Feb 15, 1985

## SULFAMETHOPRIM-DS

NOVEL LABS INC 800MG; 160MG A070032 001 Feb 15, 1985

## SULFAMETHOXAZOLE AND TRIMETHOPRIM

HEATHER 400MG; 80MG N018946 001 Aug 10, 1984

800MG; 160MG N018946 002 Aug 10, 1984

INTERPHARM 400MG; 80MG A071299 001 Oct 27, 1987

800MG; 160MG A071300 001 Oct 27, 1987

MARTEC USA LLC 400MG; 80MG A072408 001 Dec 07, 1988

MUTUAL PHARM 400MG; 80MG A070006 001 Nov 14, 1984

400MG; 80MG A071016 001 Aug 25, 1986

PLIVA 400MG; 80MG A070215 001 Sep 10, 1985

800MG; 160MG A070216 001 Sep 10, 1985

ROXANE 400MG; 80MG A072768 001 Aug 30, 1991

SANDOZ 400MG; 80MG A070889 001 Nov 13, 1986

400MG; 80MG N018598 003 May 19, 1982

800MG; 160MG A070890 001 Nov 13, 1986

TEVA 400MG; 80MG N018242 001

800MG; 160MG N018242 002

USL PHARMA 400MG; 80MG A070203 001 Nov 08, 1985

800MG; 160MG A070204 001 Nov 08, 1985

WATSON LABS 400MG; 80MG A070002 001 Nov 07, 1984

400MG; 80MG N018852 001 May 09, 1983

800MG; 160MG A070000 001 Nov 07, 1984

## SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

MARTEC USA LLC 800MG; 160MG A072417 001 Dec 07, 1988

MUTUAL PHARM 800MG; 160MG A070007 001 Nov 14, 1984

ROXANE 800MG; 160MG A072769 001 Aug 30, 1991

SANDOZ 800MG; 160MG N018598 004 May 19, 1982

WATSON LABS 800MG; 160MG N018854 001 May 09, 1983

## SULFATRIM-DS

SUPERPHARM 800MG; 160MG A070066 001 Jun 24, 1985

## SULFATRIM-SS

SUPERPHARM 400MG; 80MG A070065 002 Jun 24, 1985

## UROPLUS DS

SHIONOGI 800MG; 160MG A071816 001 Sep 28, 1987

## UROPLUS SS

SHIONOGI 400MG; 80MG A071815 001 Sep 28, 1987

SULFANILAMIDE

## CREAM; VAGINAL

## SULFANILAMIDE

TEVA 15% A088718 001 Sep 19, 1985

## SUPPOSITORY; VAGINAL

## AVC

MEDA PHARMS 1.05GM N006530 004 Jan 27, 1987

SULFAPHENAZOLE

## SUSPENSION; ORAL

## SULFABID

PHARM RES ASSOC 500MG/5ML N013093 001

## TABLET; ORAL

## SULFABID

PURDUE FREDERICK 500MG N013092 002

## DISCONTINUED DRUG PRODUCT LIST

SULFAPYRIDINE

TABLET; ORAL

SULFAPYRIDINE

LILLY

500MG

N000159 001

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

PHARMACIA AND UPJOHN

250MG/5ML

N018605 001

TABLET; ORAL

S.A.S.-500

SOLVAY

500MG

A083450 001

SULFASALAZINE

HERITAGE PHARMS INC

500MG

A080197 001

MUTUAL PHARM

500MG

A089590 001 Oct 19, 1987

SANDOZ

500MG

A086184 001

SUPERPHARM

500MG

A089339 001 Oct 26, 1987

WATSON LABS

500MG

A084964 001

500MG

A087197 001

TABLET, DELAYED RELEASE; ORAL

SULFASALAZINE

WATSON LABS

500MG

A088052 001 May 24, 1983

SULFINPYRAZONE

CAPSULE; ORAL

ANTURANE

NOVARTIS

200MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N011556 004

SULFINPYRAZONE

BARR

200MG

A087666 001 Sep 17, 1982

IVAX PHARMS

200MG

A087770 001 Nov 19, 1982

PAR PHARM

200MG

A088934 001 Sep 06, 1985

VANGARD

200MG

A088666 001 Feb 17, 1984

TABLET; ORAL

ANTURANE

NOVARTIS

100MG \*\*Federal Register determination  
that product was not discontinued or  
withdrawn for safety or efficacy  
reasons\*\*

N011556 003

SULFINPYRAZONE

BARR

100MG

A087665 001 Sep 17, 1982

IVAX PHARMS

100MG

A087769 001 Jun 01, 1982

PAR PHARM

100MG

A088933 001 Sep 06, 1985

WATSON LABS

100MG

A087667 001 May 26, 1982

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

ROCHE

500MG

N006525 001

SOSOL

MK LABS

500MG

A080036 001

SOXAZOLE

ALRA

500MG

A080366 001

SULFALAR

PARKE DAVIS

500MG

A084955 001

SULFISOXAZOLE

BARR

500MG

A084031 001

HEATHER

500MG

A080189 001

IMPAX LABS

500MG

A080109 001

IVAX SUB TEVA PHARMS

500MG

A080142 001

LANNETT

500MG

A080085 001

LEDERLE

500MG

A087649 001

PHARMERAL

500MG

A084385 001

PUREPAC PHARM

500MG

A080087 001

ROXANE

500MG

A080082 001

SANDOZ

500MG

A085628 001

VALEANT PHARM INTL

500MG

A080268 002

VITARINE

500MG

A087332 001

WATSON LABS

500MG

A085534 001

WEST WARD

500MG

A080379 001

SULSOXIN

SOLVAY

500MG

A080040 001

## DISCONTINUED DRUG PRODUCT LIST

SULFISOXAZOLE ACETYL

EMULSION; ORAL

LIPO GANTRISIN

ROCHE

EQ 1GM BASE/5ML

N009182 009

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

ROCHE

EQ 500MG BASE/5ML

N009182 004

SYRUP; ORAL

GANTRISIN

ROCHE

EQ 500MG BASE/5ML

N009182 002

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION

GANTRISIN

ROCHE

EQ 400MG BASE/ML

N006917 001

OINTMENT; OPHTHALMIC

GANTRISIN

ROCHE

EQ 4% BASE

N008414 002

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

ROCHE

EQ 4% BASE

N007757 002

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND

EQ 4% BASE

A084148 001

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL

DIASONE SODIUM

ABBVIE

165MG

N006044 003

SULFUR

POWDER; TOPICAL

BENSULFOID

POYTHRESS

33.32%

N002918 001

SULINDAC

TABLET; ORAL

CLINORIL

MERCK

150MG

N017911 001

SULINDAC

SANDOZ

150MG

A072712 001 Aug 30, 1991

SANDOZ

200MG

A072713 001 Aug 30, 1991

TEVA

150MG

A072972 001 Feb 28, 1992

TEVA

200MG

A072973 001 Feb 28, 1992

SUMATRIPTAN

SPRAY; NASAL

IMITREX

GLAXOSMITHKLINE

10MG/SPRAY

N020626 002 Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USA

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A079240 002 Sep 18, 2009

FRESENIUS KABI USA

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A079240 001 Sep 18, 2009

SANDOZ

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078067 002 Feb 06, 2009

SANDOZ

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078067 001 Feb 06, 2009

TEVA PARENTERAL

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078318 001 Feb 06, 2009

TEVA PARENTERAL

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078318 002 Feb 06, 2009

TABLET; ORAL

SUMATRIPTAN SUCCINATE

MYLAN

EQ 25MG BASE

A077163 001 Nov 02, 2009

MYLAN

EQ 50MG BASE

A077163 002 Nov 02, 2009

MYLAN

EQ 100MG BASE

A077163 003 Nov 02, 2009

ROXANE

EQ 25MG BASE

A078241 001 Aug 10, 2009

ROXANE

EQ 50MG BASE

A078241 002 Aug 10, 2009

ROXANE

EQ 100MG BASE

A078241 003 Aug 10, 2009

TEVA

EQ 25MG BASE

A076840 001 Feb 09, 2009

TEVA

EQ 50MG BASE

A076840 002 Feb 09, 2009

TEVA

EQ 100MG BASE

A076840 003 Feb 09, 2009

**DISCONTINUED DRUG PRODUCT LIST**SUPROFEN

SOLUTION/DROPS;OPHTHALMIC

PROFENAL

ALCON

1%

N019387 001 Dec 23, 1988

SUTILAINS

OINTMENT;TOPICAL

TRAVASE

ABBOTT

82,000 UNITS/GM \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N012828 001

TACRINE HYDROCHLORIDE

CAPSULE;ORAL

COGNEX

SHIONOGI INC

EQ 10MG BASE

N020070 001 Sep 09, 1993

EQ 20MG BASE

N020070 002 Sep 09, 1993

EQ 30MG BASE

N020070 003 Sep 09, 1993

EQ 40MG BASE

N020070 004 Sep 09, 1993

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

WATSON LABS

EQ 5MG BASE

A090402 001 Jul 01, 2010

TALBUTAL

TABLET;ORAL

LOTUSATE

SANOFI AVENTIS US

120MG

N009410 005

TAMOXIFEN CITRATE

TABLET;ORAL

NOLVADEX

ASTRAZENECA

EQ 10MG BASE

N017970 001

EQ 20MG BASE

N017970 002 Mar 21, 1994

TAMOXIFEN CITRATE

AEGIS PHARMS

EQ 10MG BASE

A076398 001 Mar 31, 2003

EQ 20MG BASE

A076398 002 Mar 31, 2003

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075740 001 Feb 20, 2003

EQ 20MG BASE

A075740 002 Feb 20, 2003

PHARMACHEMIE

EQ 10MG BASE

A074539 001 Mar 31, 2003

ROXANE

EQ 10MG BASE

A076027 001 Feb 20, 2003

EQ 20MG BASE

A076027 002 Feb 20, 2003

TEVA

EQ 10MG BASE

A074504 001 Apr 28, 2003

EQ 20MG BASE

A074504 002 Apr 28, 2003

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE;INJECTION

TC 99M-LUNGAGGREGATE

GE HEALTHCARE

5mCi/ML

N017848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE;INJECTION

A-N STANNOUS AGGREGATED ALBUMIN

SYNCOR PHARMS

N/A

N017916 001

AN-MAA

PHARMALUCENCE

N/A

N017792 001

LUNGAGGREGATE REAGENT

GE HEALTHCARE

N/A

N017838 001

MACROTEC

BRACCO

N/A

N017833 001

TECHNESCAN MAA

MALLINCKRODT

N/A

N017842 001

TECHNETIUM TC 99M MAA

GE HEALTHCARE

N/A

N017773 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE;INJECTION

MICROLITE

PHARMALUCENCE

N/A

N018263 001 Mar 25, 1983

## DISCONTINUED DRUG PRODUCT LIST

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M HSA

GE HEALTHCARE N/A

N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION

INSTANT MICROSPHERES

3M N/A

N017832 001

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

CIS BIO INTL SA N/A

N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

CIS BIO INTL SA N/A

N021012 001 Aug 03, 1999

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION

CINTICHEM TECHNETIUM 99M HEDSPA

GE HEALTHCARE N/A

N017653 001

MPI STANNOUS DIPHOSPHONATE

GE HEALTHCARE N/A

N017667 001

OSTEOSCAN

MALLINCKRODT N/A

N017454 001

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

GE HEALTHCARE N/A

N017562 001

TECHNETIUM TC-99M FERSENTETATE KIT

INJECTABLE; INJECTION

RENOTEC

BRACCO N/A

N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION

GLUCOSCAN

BRISTOL MYERS SQUIBB N/A

N017907 001

TECHNESCAN GLUCEPTATE

DRAXIMAGE N/A

N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION

TECHNESCAN HIDA

DRAXIMAGE N/A

N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

JUBILANT DRAXIMAGE N/A

N018035 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AMERSCAN MDP KIT

GE HEALTHCARE N/A

N018335 001 Aug 05, 1982

OSTEOLITE

PHARMALUCENCE N/A

N017972 001

TECHNETIUM TC 99M MPI MDP

GE HEALTHCARE N/A

N018141 001

N/A

N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

MPI DTPA KIT - CHELATE

GE HEALTHCARE N/A

N017255 001

TECHNETIUM TC-99M PENTETATE KIT

GE HEALTHCARE N/A

N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION

SODIUM POLYPHOSPHATE-TIN KIT

GE HEALTHCARE N/A

N017664 001

## DISCONTINUED DRUG PRODUCT LIST

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

PHARMALUCENCE N/A

N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

PHOSPHOTEC

BRACCO N/A

N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA N/A

N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA

LANTHEUS MEDCL N/A

N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

GE HEALTHCARE	2-100mCi/ML **Federal Register notice determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017471 001
---------------	----------------------------------------------------------------------------------------------------------------------------------------------	-------------

MALLINCKRODT	10-60mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017725 001
--------------	---------------------------------------------------------------------------------------------------------------------------------------	-------------

PHARMALUCENCE	12mCi/ML	N017321 001
---------------	----------	-------------

	24mCi/ML	N017321 002
--	----------	-------------

	48mCi/ML	N017321 003
--	----------	-------------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

MINITEC

BRACCO	0.22-2.22 CI/GENERATOR	N017339 001
--------	------------------------	-------------

SOLUTION; INTRAVENOUS

TECHNELITE

LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771 001
----------------	-------------------------	-------------

ULTRA-TECHNEKOW FM

MALLINCKRODT	0.25-3 CI/GENERATOR	N017243 002
--------------	---------------------	-------------

SOLUTION; INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

GE HEALTHCARE	830-16600mCi/GENERATOR	N017693 001
---------------	------------------------	-------------

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE	4mCi/ML	N017456 001
---------------	---------	-------------

SOLUTION; ORAL

TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT	3mCi/ML	N017724 001
--------------	---------	-------------

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

TECHNECOLL

MALLINCKRODT	N/A	N017059 001
--------------	-----	-------------

TECHNETIUM TC 99M TSC

GE HEALTHCARE	N/A	N017784 001
---------------	-----	-------------

TESULOID

BRACCO	N/A	N016923 001
--------	-----	-------------

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION

CARDIOTEC

BRACCO N/A

N019928 001 Dec 19, 1990

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

NOVARTIS EQ 2MG BASE

N021200 001 Jul 24, 2002

EQ 6MG BASE

N021200 002 Jul 24, 2002

## DISCONTINUED DRUG PRODUCT LIST

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

NOVARTIS

100MG/5ML

N022154 001 Apr 28, 2009

TEMAZEPAM

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS

15MG

A070564 001 Oct 15, 1985

30MG

A070547 001 Oct 15, 1985

TEMAZEPAM

DURAMED PHARMS BARR

15MG

A071708 001 Sep 29, 1988

30MG

A071709 001 Sep 29, 1988

MUTUAL PHARM

15MG

A071174 001 Jul 10, 1986

30MG

A071175 001 Jul 10, 1986

USL PHARMA

15MG

A070489 001 Jul 07, 1986

30MG

A070490 001 Jul 07, 1986

WATSON LABS

15MG

A070383 001 Mar 23, 1987

15MG

A071446 001 May 21, 1993

30MG

A070384 001 Mar 23, 1987

30MG

A071447 001 May 21, 1993

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

HYTRIN

ABBOTT

EQ 1MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020347 001 Dec 14, 1994

EQ 2MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020347 002 Dec 14, 1994

EQ 5MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020347 003 Dec 14, 1994

EQ 10MG BASE \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N020347 004 Dec 14, 1994

TERAZOSIN HYDROCHLORIDE

MYLAN TECHNOLOGIES

EQ 1MG BASE

A075384 001 Dec 01, 2000

EQ 2MG BASE

A075384 002 Dec 01, 2000

EQ 5MG BASE

A075384 003 Dec 01, 2000

EQ 10MG BASE

A075384 004 Dec 01, 2000

RANBAXY LABS LTD

EQ 1MG BASE

A076021 001 Aug 22, 2002

EQ 2MG BASE

A076021 002 Aug 22, 2002

EQ 5MG BASE

A076021 003 Aug 22, 2002

EQ 10MG BASE

A076021 004 Aug 22, 2002

SANDOZ

EQ 1MG BASE

A075667 001 Jul 28, 2000

EQ 2MG BASE

A075667 002 Jul 28, 2000

EQ 5MG BASE

A075667 003 Jul 28, 2000

EQ 10MG BASE

A075667 004 Jul 28, 2000

TABLET; ORAL

HYTRIN

ABBOTT

EQ 1MG BASE

N019057 001 Aug 07, 1987

EQ 2MG BASE

N019057 002 Aug 07, 1987

EQ 5MG BASE

N019057 003 Aug 07, 1987

EQ 10MG BASE

N019057 004 Aug 07, 1987

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS

EQ 1MG BASE

A074530 001 Apr 21, 2000

EQ 2MG BASE

A074530 002 Apr 21, 2000

EQ 5MG BASE

A074530 003 Apr 21, 2000

EQ 10MG BASE

A074530 004 Apr 21, 2000

SANDOZ

EQ 1MG BASE

A074315 001 Dec 31, 1998

EQ 1MG BASE

A074657 001 Apr 28, 2000

EQ 2MG BASE

A074315 002 Dec 31, 1998

EQ 2MG BASE

A074657 002 Apr 28, 2000

EQ 5MG BASE

A074315 003 Dec 31, 1998

EQ 5MG BASE

A074657 003 Apr 28, 2000

EQ 10MG BASE

A074315 004 Dec 31, 1998

EQ 10MG BASE

A074657 004 Apr 28, 2000

TEVA

EQ 1MG BASE

A074446 001 May 18, 2000

EQ 2MG BASE

A074446 002 May 18, 2000



## DISCONTINUED DRUG PRODUCT LIST

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

TERAZOSIN HYDROCHLORIDE

EQ 5MG BASE  
EQ 10MG BASEA074446 003 May 18, 2000  
A074446 004 May 18, 2000TERBINAFINE

GEL; TOPICAL

LAMISIL

NOVARTIS

1%

N020846 001 Apr 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

NOVARTIS

1%

N020192 001 Dec 30, 1992

SOLUTION; TOPICAL

LAMISIL

NOVARTIS

1%

N020749 001 Oct 17, 1997

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

GEDEON RICHTER USA

EQ 250MG BASE

A077065 001 Jul 02, 2007

MYLAN

EQ 250MG BASE

A077136 001 Jul 02, 2007

ROXANE

EQ 250MG BASE

A077223 001 Jul 02, 2007

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS

0.2MG/INH

N018762 001 Aug 17, 1984

BRICANYL

SANOFI AVENTIS US

0.2MG/INH

N018000 001 Mar 19, 1985

INJECTABLE; INJECTION

BRETHINE

AAIPHARMA LLC

1MG/ML

N018571 001

BRICANYL

SANOFI AVENTIS US

1MG/ML

N017466 001

TERBUTALINE SULFATE

TEVA PHARMS USA

1MG/ML

A076853 001 Jul 20, 2004

TABLET; ORAL

BRETHINE

LEHIGH VALLEY

2.5MG

N017849 001

5MG

N017849 002

BRICANYL

SANOFI AVENTIS US

2.5MG

N017618 001

5MG

N017618 002

TERCONAZOLE

SUPPOSITORY; VAGINAL

TERCONAZOLE

FOUGERA PHARMS

80MG

A076850 001 Jul 12, 2006

TARO

80MG

A077553 001 Mar 09, 2007

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US

200 UNITS/VIAL

N019498 001 Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY

0.75MG/3ML (0.25MG/ML)

N021318 001 Nov 26, 2002

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

THERATECHNOLOGIES

EQ 2MG BASE/VIAL

N022505 002 Nov 29, 2011

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB

100MG/ML

N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB

50MG

N016118 001

250MG

N016118 002

## DISCONTINUED DRUG PRODUCT LIST

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

ACTAVIS LABS UT INC	2.5MG/24HR	N020489 001	Sep 29, 1995
	5MG/24HR	N020489 002	May 02, 1997

TESTODERM

ALZA	4MG/24HR	N019762 001	Oct 12, 1993
	6MG/24HR	N019762 002	Oct 12, 1993

TESTODERM TTS

ALZA	5MG/24HR	N020791 001	Dec 18, 1997
------	----------	-------------	--------------

GEL; TRANSDERMAL

TESTOSTERONE

PAR PHARM	1% (2.5GM/PACKET)	A076744 001	May 23, 2007
	1% (5GM/PACKET)	A076744 002	May 23, 2007
WATSON LABS	1% (2.5GM/PACKET)	A076737 001	Jan 27, 2006
	1% (5GM/PACKET)	A076737 002	Jan 27, 2006

INJECTABLE; INJECTION

TESTOSTERONE

WATSON LABS	25MG/ML	A086420 001	May 10, 1983
	50MG/ML	A086419 001	Aug 23, 1983
	100MG/ML	A086417 001	Jul 07, 1983

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN	50MG/ML	A085635 001	
----------------------	---------	-------------	--

TESTOSTERONE CYPIONATE

WATSON LABS	100MG/ML	A084401 001	
	100MG/ML	A086029 001	
	200MG/ML	A084401 002	

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

ENDO PHARMS	200MG/ML	N009165 001	
-------------	----------	-------------	--

TESTOSTERONE ENANTHATE

WATSON LABS	100MG/ML	A083667 001	
	100MG/ML	A085599 001	
	200MG/ML	A083667 002	

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

BEL MAR	25MG/ML	A080741 001	
	50MG/ML	A080742 001	
	100MG/ML	A080743 001	
ELKINS SINN	25MG/ML	A080276 001	
LILLY	50MG/ML	A080254 002	
WATSON LABS	25MG/ML	A080188 001	
	25MG/ML	A085490 001	
	50MG/ML	A080188 002	
	50MG/ML	A085490 002	
	100MG/ML	A080188 003	
	100MG/ML	A083595 003	

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

BRISTACYCLINE

BRISTOL	250MG	A061658 001	
	250MG	A061888 001	
	500MG	A061658 002	
	500MG	A061888 002	

CYCLOPAR

WARNER CHILCOTT	250MG	A061725 001	
	250MG	A062175 001	
	250MG	A062332 001	
	500MG	A061725 002	
	500MG	A062332 002	

PANMYCIN

PHARMACIA AND UPJOHN	250MG	A060347 001	
----------------------	-------	-------------	--

RETET

SOLVAY	250MG	A061443 001	
	500MG	A061443 002	

## DISCONTINUED DRUG PRODUCT LIST

TETRACYCLINE HYDROCHLORIDE

## CAPSULE; ORAL

## ROBITET

WYETH AYERST	250MG	A061734	001
	500MG	A061734	002

## SUMYCIN

APOTHECON	100MG	A060429	002
	125MG	A060429	004
	250MG	A060429	001
	500MG	A060429	003

## TETRACHEL

ANGUS	250MG	A060343	001
	500MG	A060343	003

## TETRACYCLINE HYDROCHLORIDE

ABBOTT	250MG	A061802	001
	500MG	A061802	002
ELKINS SINN	250MG	A060059	001
FERRANTE	125MG	A060173	001
	250MG	A060173	002
HEATHER	250MG	A061148	001
	500MG	A061148	002
HIKMA PHARMS LLC	250MG	A060768	001
	500MG	A060768	002
LABS ATRAL	250MG	A062752	001
	500MG	A062752	002
MAST MM	250MG	A062085	001
MUTUAL PHARM	250MG	A060736	001
	500MG	A060736	002
MYLAN	250MG	A060783	001
	500MG	A060783	002
PUREPAC PHARM	250MG	A060290	001
	500MG	A060290	002
PVT FORM	250MG	A062686	001
	500MG	A062686	002
ROXANE	500MG	A061214	002
SANDOZ	250MG	A061471	001
SUPERPHARM	250MG	A062540	001
	500MG	A062540	002
VALEANT PHARM INTL	250MG	A060471	001
	500MG	A060471	002
WARNER CHILCOTT	250MG	A062300	001
	500MG	A062300	002
WATSON LABS	250MG	A062103	001
	250MG	A062343	001
	500MG	A062103	002
	500MG	A062343	002
WYETH AYERST	250MG	A061685	001
	500MG	A061685	002

Aug 12, 1988

Aug 12, 1988

Jul 24, 1986

Jul 24, 1986

Mar 21, 1985

Mar 21, 1985

## TETRACYN

PFIPHARMECS	250MG	A060082	003
	500MG	A060082	004

## FIBER, EXTENDED RELEASE; PERIODONTAL

## ACTISITE

SCHIFF AND CO	12.7MG/FIBER	N050653	001	Mar 25, 1994
---------------	--------------	---------	-----	--------------

## FOR SOLUTION; TOPICAL

## TOPICYCLINE

SHIRE	2.2MG/ML	N050493	001
-------	----------	---------	-----

## INJECTABLE; INJECTION

## ACHROMYCIN

LEDERLE	250MG/VIAL	N050273	002
	500MG/VIAL	N050273	003

## TETRACYN

PFIZER	250MG/VIAL	A060096	001
	500MG/VIAL	A060096	002

## OINTMENT; OPHTHALMIC

## ACHROMYCIN

STORZ	10MG/GM	N050266	001
-------	---------	---------	-----

## SUSPENSION; ORAL

## ACHROMYCIN V

LEDERLE	125MG/5ML	N050263	002
---------	-----------	---------	-----

## SUMYCIN

PAR PHARM	125MG/5ML	A060400	001
-----------	-----------	---------	-----

**DISCONTINUED DRUG PRODUCT LIST**TETRACYCLINE HYDROCHLORIDE

## SUSPENSION; ORAL

## TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS	125MG/5ML	A060633	001
FERRANTE	125MG/5ML	A060174	001
PROTER	125MG/5ML	A060446	001
PUREPAC PHARM	125MG/5ML	A060291	001

## TETRACYN

PFIPHARMECS	125MG/5ML	A060095	001
-------------	-----------	---------	-----

## TETRAMED

IVAX SUB TEVA PHARMS	125MG/5ML	A061468	001
----------------------	-----------	---------	-----

## SUSPENSION/DROPS; OPHTHALMIC

## ACHROMYCIN

STORZ	1%	N050268	001
-------	----	---------	-----

## TABLET; ORAL

## PANMYCIN

PHARMACIA AND UPJOHN	250MG	A061705	001
	500MG	A061705	002

## SUMYCIN

PAR PHARM	50MG	A061147	003
	100MG	A061147	002
	250MG	A061147	001
	500MG	A061147	004

TETRACYCLINE PHOSPHATE COMPLEX

## CAPSULE; ORAL

## TETREX

BRISTOL	EQ 100MG HCL	A061653	001
	EQ 250MG HCL	A061653	002
	EQ 250MG HCL	A061889	002
	EQ 250MG HCL	N050212	002
	EQ 500MG HCL	A061653	003
	EQ 500MG HCL	A061889	001
	EQ 500MG HCL	N050212	003

THALLOUS CHLORIDE TL-201

## INJECTABLE; INJECTION

## THALLOUS CHLORIDE TL 201

BRACCO	1mCi/ML	N018548	001	Dec 30, 1982
TRACE LIFE	1mCi/ML	A075569	001	Nov 21, 2001

## INJECTABLE; INTRAVENOUS

## THALLOUS CHLORIDE TL 201

MALLINCKRODT	2mCi/ML	A077698	001	Nov 09, 2006
--------------	---------	---------	-----	--------------

THEOPHYLLINE

## CAPSULE; ORAL

## BRONKODYL

SANOVI AVENTIS US	100MG	A085264	001
	200MG	A085264	002

## ELIXOPHYLLIN

FOREST LABS	100MG	A085545	001	Jul 31, 1984
	200MG	A083921	001	Jul 31, 1984

## SOMOPHYLLIN-T

FISONS	100MG	A087155	001	Feb 25, 1985
	200MG	A087155	002	Feb 25, 1985
	250MG	A087155	003	Feb 25, 1985

## THEOPHYLLINE

KV PHARM	100MG	A085263	001	
	200MG	A085263	002	
SCHERER RP	100MG	A084731	002	Nov 07, 1986
	200MG	A084731	001	Nov 07, 1986
	250MG	A084731	003	Nov 07, 1986

## CAPSULE, EXTENDED RELEASE; ORAL

## AEROLATE III

FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986
----------------	------	---------	-----	--------------

## AEROLATE JR

FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986
----------------	-------	---------	-----	--------------

## AEROLATE SR

FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986
----------------	-------	---------	-----	--------------

## ELIXOPHYLLIN SR

FOREST LABS	125MG	A086826	001	Jan 29, 1985
	250MG	A086826	002	Jan 29, 1985

## DISCONTINUED DRUG PRODUCT LIST

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

SLO-BID

SANOFI AVENTIS US	50MG	A088269 001	Jan 31, 1985
	75MG	A089539 001	May 10, 1989
	100MG	A087892 001	Jan 31, 1985
	125MG	A089540 001	May 10, 1989
	200MG	A087893 001	Jan 31, 1985
	300MG	A087894 001	Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US	60MG	A085206 001	May 24, 1982
	125MG	A085203 001	May 24, 1982
	250MG	A085205 001	May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM	50MG	A087763 001	Feb 27, 1985
	100MG	A087194 001	
	200MG	A088382 001	Feb 27, 1985
	250MG	A087193 001	
	300MG	A088383 001	Feb 27, 1985

THEO-DUR

SCHERING	50MG	A088022 001	Sep 10, 1985
	75MG	A088015 001	Sep 10, 1985
	125MG	A088016 001	Sep 10, 1985
	200MG	A087995 001	Sep 10, 1985

THEOBID

WHITBY	260MG	A085983 001	Mar 20, 1985
--------	-------	-------------	--------------

THEOBID JR.

WHITBY	130MG	A087854 001	Mar 20, 1985
--------	-------	-------------	--------------

THEOCLEAR L.A.-130

SCHWARZ PHARMA	130MG	A086569 001	May 27, 1982
----------------	-------	-------------	--------------

THEOCLEAR L.A.-260

SCHWARZ PHARMA	260MG	A086569 002	May 27, 1982
----------------	-------	-------------	--------------

THEOPHYL-SR

ORTHO MCNEIL PHARM	125MG	A086480 001	Feb 08, 1985
	250MG	A086471 001	Feb 08, 1985

THEOPHYLLINE

CENT PHARMS	125MG	A088654 001	Feb 12, 1985
	250MG	A088689 001	Feb 12, 1985
HOSPIRA	100MG	A089976 001	Jan 04, 1995
	200MG	A089977 001	Jan 04, 1995
	300MG	A089932 001	Jan 04, 1995
INWOOD LABS	100MG	A040052 001	Feb 14, 1994
	125MG	A040052 002	Feb 14, 1994
	200MG	A040052 003	Feb 14, 1994
	300MG	A040052 004	Feb 14, 1994
SANDOZ	260MG	A087462 001	May 11, 1982

THEOPHYLLINE-SR

SCHERER RP	300MG	A088255 001	Jun 12, 1986
------------	-------	-------------	--------------

THEOVENT

SCHERING	125MG	A087010 001	Jan 31, 1985
	250MG	A087910 001	Jan 31, 1985

ELIXIR;ORAL

ELIXOMIN

CENCI	80MG/15ML	A088303 001	Jan 25, 1984
-------	-----------	-------------	--------------

LANOPHYLLIN

LANNETT	80MG/15ML	A084578 001	
---------	-----------	-------------	--

THEOLIXIR

PANRAY	80MG/15ML	A084559 001	
--------	-----------	-------------	--

THEOPHYL-225

ORTHO MCNEIL PHARM	112.5MG/15ML	A086485 001	
--------------------	--------------	-------------	--

THEOPHYLLINE

ALPHARMA US PHARMS	80MG/15ML	A089223 001	May 27, 1988
CENCI	80MG/15ML	A087679 001	Apr 15, 1982
HALSEY	80MG/15ML	A085169 001	
PERRIGO	80MG/15ML	A085952 001	
PHARM ASSOC	80MG/15ML	A086720 001	
PRECISION DOSE	80MG/15ML	A085863 001	
ROXANE	80MG/15ML	A084739 001	
TARO	80MG/15ML	A089626 001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748 001	

## DISCONTINUED DRUG PRODUCT LIST

THEOPHYLLINE

## INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER B BRAUN	40MG/100ML	N019083 001	Nov 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER B BRAUN	80MG/100ML	N019083 002	Nov 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER B BRAUN	160MG/100ML	N019083 003	Nov 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER B BRAUN	200MG/100ML	N019212 001	Nov 07, 1984
	200MG/100ML	N019826 004	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER B BRAUN	4MG/ML	N019212 003	Nov 07, 1984
	400MG/100ML	N019212 002	Nov 07, 1984
	400MG/100ML	N019826 005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982
	40MG/100ML	N018649 001	Jul 26, 1982
	80MG/100ML	N018649 002	Jul 26, 1982
	160MG/100ML	N018649 003	Jul 26, 1982
	200MG/100ML	N018649 004	Jul 26, 1982
	320MG/100ML	N018649 006	Nov 13, 1985
	400MG/100ML	N018649 005	Jul 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA INC	80MG/100ML	N019211 002	Dec 14, 1984
	200MG/100ML	N019211 004	Dec 14, 1984
	400MG/100ML	N019211 005	Dec 14, 1984

## SOLUTION; ORAL

AEROLATE FLEMING PHARMS	150MG/15ML	A089141 001	Dec 03, 1986
THEOLAIR 3M	80MG/15ML	A086107 001	
THEOPHYLLINE ROXANE	80MG/15ML	A087449 001	Sep 15, 1983

## SUSPENSION; ORAL

ELIXICON FOREST LABS	100MG/5ML	A085502 001	
-------------------------	-----------	-------------	--

## SYRUP; ORAL

ACCUREBRON SANOFI AVENTIS US	150MG/15ML	A088746 001	Nov 22, 1985
AQUAPHYLLIN FERNDALE LABS	80MG/15ML	A087917 001	Jan 18, 1983
SLO-PHYLLIN SANOFI AVENTIS US	80MG/15ML	A085187 001	
THEOCLEAR-80 CENT PHARMS	80MG/15ML	A087095 001	Mar 01, 1982
THEOPHYLLINE ALPHARMA US PHARMS	80MG/15ML	A086001 001	
	150MG/15ML	A086545 001	

## TABLET; ORAL

QUIBRON-T MONARCH PHARMS	300MG	A088656 001	Aug 22, 1985
SLO-PHYLLIN SANOFI AVENTIS US	100MG	A085202 001	
	200MG	A085204 001	
THEOCLEAR-100 CENT PHARMS	100MG	A085353 002	
THEOCLEAR-200 CENT PHARMS	200MG	A085353 001	
THEOPHYL-225 ORTHO MCNEIL PHARM	225MG	A084726 001	

## TABLET, CHEWABLE; ORAL

THEOPHYL ORTHO MCNEIL PHARM	100MG	A086506 001	Sep 12, 1985
--------------------------------	-------	-------------	--------------

## TABLET, EXTENDED RELEASE; ORAL

DURAPHYL FOREST LABS	100MG	A088503 001	Apr 03, 1985
	200MG	A088504 001	Apr 03, 1985
	300MG	A088505 001	Apr 03, 1985

## LABID

WARNER CHILCOTT	250MG	A087225 001	
-----------------	-------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

QUIBRON-T/SR

MONARCH PHARMS

300MG

A087563 001 Jun 21, 1983

SUSTAIRE

ROERIG

100MG

A085665 001

300MG

A085665 002

T-PHYL

PHARM RES ASSOC

200MG

A088253 001 Aug 17, 1983

THEO-DUR

SCHERING

100MG

A085328 001

200MG

A086998 001

300MG

A085328 002

450MG

A089131 001 Jun 25, 1986

THEOCHRON

SUN PHARM INDS INC

300MG

A087400 002 Jan 11, 1983

THEOLAIR-SR

3M

200MG

A088369 001 Jul 16, 1987

250MG

A086363 002 Jul 16, 1987

300MG

A088364 001 Jul 16, 1987

500MG

A089132 001 Jul 16, 1987

THEOPHYLLINE

ABLE

300MG

A040548 001 Apr 30, 2004

400MG

A040543 001 Apr 27, 2004

450MG

A040546 001 Apr 30, 2004

600MG

A040539 001 Apr 27, 2004

INWOOD LABS

450MG

A040034 001 Apr 28, 1995

UNI-DUR

SCHERING

400MG

A089822 001 Jan 04, 1995

600MG

A089823 001 Jan 04, 1995

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR;ORAL

SYNOHYLATE

CENT PHARMS

EQ 165MG BASE/15ML

N006333 008

TABLET;ORAL

ASBRON

NOVARTIS

EQ 150MG BASE

A085148 001

THIABENDAZOLE

SUSPENSION;ORAL

MINTEZOL

MERCK SHARP DOHME

500MG/5ML

N016097 001

TABLET, CHEWABLE;ORAL

MINTEZOL

MERCK SHARP DOHME

500MG

N016096 001

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

BETALIN S

LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001 Oct 01, 1982

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

HIKMA MAPLE

100MG/ML

A080575 001

HOSPIRA

100MG/ML

A040079 001 May 03, 1996

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A080571 001

100MG/ML

A083534 001

200MG/ML

A080571 002

200MG/ML

A083534 002

WYETH AYERST

100MG/ML

A080553 001

THIAMYLAL SODIUM

INJECTABLE;INJECTION

SURITAL

PARKEDALE

1GM/VIAL

N007600 003

5GM/VIAL

N007600 005

10GM/VIAL

N007600 009

## DISCONTINUED DRUG PRODUCT LIST

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION

TORECAN

NOVARTIS

5MG/ML

N012754 002

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

TORECAN

NOVARTIS

10MG

N013247 001

TABLET; ORAL

TORECAN

NOVARTIS

10MG

N012753 001

THIOPENTAL SODIUM

SUSPENSION; RECTAL

PENTOTHAL

ABBOTT

400MG/GM

N011679 001

THIORIDAZINE

SUSPENSION; ORAL

MELLARIL-S

NOVARTIS

EQ 25MG HCL/5ML

N017923 001

EQ 100MG HCL/5ML

N017923 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL

NOVARTIS

30MG/ML

N011808 012

100MG/ML

N011808 018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

100MG/ML

A088229 001 Aug 23, 1983

ALPHARMA US PHARMS

30MG/ML

A087766 001 Apr 26, 1983

ANI PHARMS INC

100MG/ML

A089603 001 Nov 09, 1987

HI TECH PHARMA

30MG/ML

A040125 001 Aug 16, 1996

100MG/ML

A040126 001 Aug 16, 1996

PHARM ASSOC

30MG/ML

A040187 001 Aug 28, 1997

SANDOZ

100MG/ML

A040213 001 May 29, 1998

30MG/ML

A088307 001 Nov 23, 1983

100MG/ML

A088308 001 Nov 23, 1983

TEVA PHARMS

30MG/ML

A089602 001 Nov 09, 1987

WOCKHARDT

30MG/ML

A088258 001 Jul 25, 1983

100MG/ML

A088227 001 Jul 05, 1983

THIORIDAZINE HYDROCHLORIDE INTENSOL

ROXANE

30MG/ML

A088941 001 Dec 16, 1985

100MG/ML

A088942 001 Dec 16, 1985

TABLET; ORAL

MELLARIL

NOVARTIS

10MG

N011808 003

15MG

N011808 016

25MG

N011808 006

50MG

N011808 011

100MG

N011808 009

150MG

N011808 017

200MG

N011808 015

THIORIDAZINE HYDROCHLORIDE

ANI PHARMS INC

10MG

A088270 001 Apr 14, 1983

10MG

A088493 001 May 17, 1985

15MG

A088271 001 Apr 14, 1983

25MG

A088272 001 Apr 14, 1983

50MG

A088194 001 Apr 14, 1983

100MG

A088273 001 Oct 03, 1983

100MG

A088456 001 May 17, 1985

MUTUAL PHARM

10MG

A088375 001 Nov 18, 1983

15MG

A088461 001 Nov 18, 1983

25MG

A087264 001 Nov 18, 1983

50MG

A088370 001 Nov 18, 1983

100MG

A088379 001 Nov 16, 1983

150MG

A088737 001 Sep 26, 1984

200MG

A088738 001 Oct 16, 1984

MYLAN

10MG

A088332 001 Jun 27, 1983

25MG

A088333 001 Jun 27, 1983

50MG

A088334 001 Jun 27, 1983

100MG

A088335 001 Nov 18, 1983

PAR PHARM

10MG

A088351 001 Dec 05, 1983



**DISCONTINUED DRUG PRODUCT LIST**THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

	15MG	A088352	001	Dec 05, 1983
	25MG	A088336	001	Dec 05, 1983
	50MG	A088322	001	Dec 05, 1983
	100MG	A088480	001	Dec 29, 1983
	150MG	A089764	001	Feb 09, 1988
	200MG	A089765	001	Feb 09, 1988
ROXANE	10MG	A088663	001	Mar 15, 1984
	25MG	A088664	001	Mar 15, 1984
	50MG	A088665	001	Mar 15, 1984
	100MG	A089048	001	Feb 26, 1985
SANDOZ	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986
SUPERPHARM	10MG	A089103	001	Jul 02, 1985
	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985
WATSON LABS	10MG	A088412	001	Sep 12, 1983
	10MG	A088476	001	Nov 08, 1983
	10MG	A088561	001	May 11, 1984
	15MG	A088345	001	Jul 28, 1983
	15MG	A088477	001	Nov 08, 1983
	15MG	A088562	001	May 11, 1984
	25MG	A088296	001	Jul 28, 1983
	25MG	A088478	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	25MG	A088755	001	Jul 24, 1984
	50MG	A088323	001	Jul 28, 1983
	50MG	A088479	001	Nov 08, 1983
	50MG	A088563	001	May 11, 1984
	100MG	A088284	001	Aug 25, 1983
	100MG	A088564	001	May 11, 1984
	100MG	A088736	001	Jul 24, 1984
	150MG	A088410	001	Mar 05, 1984
	150MG	A088869	001	Jun 28, 1985
	200MG	A088381	001	Mar 14, 1984
	200MG	A088872	001	Apr 26, 1985
WEST WARD	10MG	A088658	001	Mar 26, 1984
	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

IMMUNEX	15MG/VIAL	N020058	001	Dec 22, 1994
---------	-----------	---------	-----	--------------

THIOTEPA

FRESENIUS KABI USA	15MG/VIAL	A075698	001	Sep 20, 2001
IMMUNEX	15MG/VIAL	N011683	001	
TEVA PARENTERAL	15MG/VIAL	A075730	001	Apr 20, 2001
	30MG/VIAL	A075730	002	Apr 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

PFIZER	20MG	N016584	005	
--------	------	---------	-----	--

THIOTHIXENE

AM THERAP	1MG	A071884	001	Aug 12, 1987
	2MG	A071885	001	Aug 12, 1987
	5MG	A071886	001	Aug 12, 1987
	10MG	A071887	001	Aug 12, 1987
	20MG	A072200	001	Dec 17, 1987
WATSON LABS	1MG	A070600	001	Jun 05, 1987
	2MG	A070601	001	Jun 05, 1987
	2MG	A071626	001	Jun 25, 1987
	5MG	A070602	001	Jun 05, 1987
	5MG	A071627	001	Jun 25, 1987

**DISCONTINUED DRUG PRODUCT LIST**THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

10MG	A070603	001	Jun 05, 1987
10MG	A071628	001	Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER	EQ 5MG BASE/ML	N016758	001
THIOTHIXENE HYDROCHLORIDE			
ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969	001 Oct 16, 1987
PACO	EQ 1MG BASE/ML	A071917	001 Sep 20, 1989
	EQ 5MG BASE/ML	A071939	001 Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184	001 Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554	001 Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE	INTENSOL		
CYCLE PHARMS LTD	EQ 5MG BASE/ML	A073494	001 Jun 30, 1992

INJECTABLE; INJECTION

NAVANE

PFIZER	EQ 2MG BASE/ML	N016904	001
	EQ 10MG BASE/VIAL	N016904	002

THYROGLOBULIN

TABLET; ORAL

PROLOID

PARKE DAVIS	16MG	N002245	009
	32MG	N002245	005
	65MG	N002245	002
	100MG	N002245	008
	130MG	N002245	010
	200MG	N002245	007
	325MG	N002245	004

THYROGLOBULIN

IMPAX LABS	64.8MG	A080151	001
------------	--------	---------	-----

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

SANOFI AVENTIS US	10 IU/VIAL	N008682	001
-------------------	------------	---------	-----

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON	6MG	N020646	006 Nov 29, 2005
	8MG	N020646	007 Nov 29, 2005
	10MG	N020646	008 Nov 29, 2005
	20MG	N020646	004 Sep 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497	001
	EQ 3GM BASE/VIAL	A062690	001 Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497	002
	EQ 6GM BASE/VIAL	N050497	003
	EQ 20GM BASE/VIAL	N050497	004
	EQ 30GM BASE/VIAL	N050497	005 Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO	125MG	N019979	001 Mar 24, 1993
	250MG	N019979	002 Oct 31, 1991
THIOTHIXENE HYDROCHLORIDE			
ACTAVIS ELIZABETH	250MG	A075253	001 Aug 20, 1999
MYLAN	250MG	A075161	001 Sep 13, 1999
	250MG	A075316	001 Nov 02, 1999
SANDOZ	250MG	A075318	001 Aug 20, 1999
	250MG	A075326	001 Aug 20, 1999
WATSON LABS	250MG	A075309	001 Apr 26, 2000

## DISCONTINUED DRUG PRODUCT LIST

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

SANOFI AVENTIS US	EQ 200MG BASE	N020707	001	Mar 07, 1997
-------------------	---------------	---------	-----	--------------

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AKORN	EQ 0.25% BASE	A074465	001	Mar 25, 1997
	EQ 0.25% BASE	A074515	001	Mar 25, 1997
APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000
	EQ 0.5% BASE	A075412	001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667	001	Mar 25, 1997
	EQ 0.5% BASE	A074668	001	Mar 25, 1997

TABLET; ORAL

BLOCADREN

MERCK

5MG	N018017	001
10MG	N018017	002
20MG	N018017	004

TIMOLOL MALEATE

QUANTUM PHARMICS

5MG	A072466	001	May 19, 1989
10MG	A072467	001	May 19, 1989
20MG	A072468	001	May 19, 1989

SANDOZ

5MG	A072550	001	Apr 13, 1989
10MG	A072551	001	Apr 13, 1989
20MG	A072552	001	Apr 13, 1989

TEVA

5MG	A072648	001	Jun 16, 1993
10MG	A072649	001	Jun 16, 1993
20MG	A072650	001	Jun 16, 1993

USL PHARMA

5MG	A072001	001	Apr 11, 1989
10MG	A072002	001	Apr 11, 1989
20MG	A072003	001	Apr 11, 1989

WATSON LABS

5MG	A072269	001	Apr 11, 1989
5MG	A072917	001	Jul 31, 1991
10MG	A072270	001	Apr 11, 1989
10MG	A072918	001	Jul 31, 1991
20MG	A072271	001	Apr 11, 1989
20MG	A072919	001	Jul 31, 1991

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

LEO PHARMA AS

20,000 IU/ML	N020484	001	Jul 14, 2000
--------------	---------	-----	--------------

TIOCONAZOLE

CREAM; TOPICAL

TZ-3

PFIZER

1%	N018682	001	Feb 18, 1983
----	---------	-----	--------------

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912	001	May 14, 1998
EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 2MG BASE	A076283	001	Jul 12, 2002
EQ 4MG BASE	A076283	002	Jul 12, 2002

BARR

EQ 2MG BASE	A076371	001	Apr 09, 2003
EQ 4MG BASE	A076371	002	Apr 09, 2003

IVAX SUB TEVA PHARMS

EQ 2MG BASE	A076321	001	Sep 30, 2004
EQ 4MG BASE	A076321	002	Sep 30, 2004

MYLAN PHARMS INC

EQ 2MG BASE	A076282	001	Dec 16, 2003
EQ 4MG BASE	A076282	002	Dec 16, 2003

ZANAFLEX

ACORDA

EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020397	002	Feb 04, 2000
---------------------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

TOBRAMYCIN

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

ALCON PHARMS LTD	0.3%	A063176	001	May 25, 1994
APOTEX INC	0.3%	A065087	001	Feb 25, 2002

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY	EQ 1.2GM BASE/VIAL	N050519	001	
	EQ 10MG BASE/ML	A062008	004	
	EQ 10MG BASE/ML	A062707	001	Apr 29, 1987
	EQ 10MG BASE/ML	N050477	005	
	EQ 40MG BASE/ML	A062008	001	

TOBRAMYCIN SULFATE

APOTHECON	EQ 10MG BASE/ML	A064021	001	May 31, 1994
	EQ 40MG BASE/ML	A064021	002	May 31, 1994
	EQ 40MG BASE/ML	A064026	001	May 31, 1994
ASTRAZENECA	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994
HIKMA MAPLE	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991
HOSPIRA	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161	001	May 29, 1991
WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989
	EQ 40MG BASE/ML	A062945	002	Aug 09, 1989

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA	400MG	N018257	001	Nov 09, 1984
	600MG	N018257	002	Nov 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

BARR	100MG	A070162	001	Jan 14, 1986
	250MG	A070163	001	Jan 14, 1986
	500MG	A070164	001	Jan 14, 1986
DURAMED PHARMS BARR	100MG	A070165	001	Jan 10, 1986
	250MG	A070166	001	Jan 10, 1986
	500MG	A070167	001	Jan 10, 1986
INTERPHARM	250MG	A071270	001	Sep 23, 1986
	500MG	A071271	001	Sep 23, 1986
IVAX SUB TEVA PHARMS	100MG	N018894	001	Nov 02, 1984
	250MG	N018894	002	Nov 02, 1984
	500MG	N018894	003	Nov 02, 1984
MUTUAL PHARM	100MG	A071357	001	Jul 16, 1987
	250MG	A071358	001	Jul 16, 1987
	500MG	A071359	001	Jul 16, 1987
PAR PHARM	100MG	A070159	001	Jan 06, 1986
	250MG	A070160	001	Jan 06, 1986
	500MG	A070161	001	Jan 06, 1986
SANDOZ	100MG	A071633	001	Dec 09, 1987
	250MG	A070289	001	Mar 13, 1986
	500MG	A070290	001	Mar 13, 1986
SUPERPHARM	250MG	A070763	001	Jun 16, 1986
	500MG	A070764	001	Jun 16, 1986
USL PHARMA	100MG	A071355	001	Jan 11, 1988
	250MG	A070168	001	Apr 02, 1986
	500MG	A070169	001	Apr 02, 1986
WATSON LABS	100MG	A070242	001	Aug 01, 1986
	100MG	A070513	001	Jan 09, 1986
	250MG	A070243	001	Aug 01, 1986
	250MG	A070514	001	Jan 09, 1986
	500MG	A070244	001	Aug 01, 1986
	500MG	A070515	001	Jan 09, 1986

TOLINASE

PHARMACIA AND UPJOHN	100MG **Federal Register determination that product was not discontinued or	N015500	002	
----------------------	-----------------------------------------------------------------------------	---------	-----	--

## DISCONTINUED DRUG PRODUCT LIST

TOLAZAMIDE

TABLET; ORAL

TOLINASE

withdrawn for safety or efficacy  
reasons\*\*250MG N015500 004  
500MG N015500 005TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

NOVARTIS

25MG/ML

N006403 005 Feb 22, 1985

TOLBUTAMIDE

TABLET; ORAL

ORINASE

PHARMACIA AND UPJOHN

250MG

N010670 002

500MG

N010670 001

TOLBUTAMIDE

ALRA

500MG

A086141 001

ASCOT

500MG

A087541 001 Mar 01, 1983

BARR

500MG

A087121 001

DAVA PHARMS INC

500MG

A086926 001

IVAX PHARMS

500MG

A087093 001

PARKE DAVIS

500MG

A086047 001

PUREPAC PHARM

500MG

A088950 001 Jun 17, 1985

SANDOZ

500MG

A086574 001

500MG

N012678 001

SUPERPHARM

500MG

A088893 001 Nov 19, 1984

VANGARD

500MG

A087876 001 Apr 20, 1982

WATSON LABS

250MG

A089110 001 May 29, 1987

500MG

A086109 001

500MG

A087318 001

500MG

A089111 001 May 29, 1987

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL

N012095 001

TOLCAPONE

TABLET; ORAL

TASMAR

VALEANT PHARMS LLC

200MG

N020697 002 Jan 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

TOLECTIN DS

ORTHO MCNEIL JANSSEN

EQ 400MG BASE

N018084 001

TOLMETIN SODIUM

ACTAVIS ELIZABETH

EQ 400MG BASE

A073308 001 Jan 24, 1992

IVAX SUB TEVA PHARMS

EQ 400MG BASE

A073392 001 Jan 24, 1992

MUTUAL PHARM

EQ 400MG BASE

A073311 001 Nov 27, 1991

SANDOZ

EQ 400MG BASE

A073462 001 Apr 30, 1992

TEVA

EQ 400MG BASE

A073519 001 May 29, 1992

TABLET; ORAL

TOLECTIN

ORTHO MCNEIL JANSSEN

EQ 200MG BASE

N017628 001

TOLECTIN 600

ORTHO MCNEIL JANSSEN

EQ 600MG BASE

N017628 002 Mar 08, 1989

TOLMETIN SODIUM

ACTAVIS ELIZABETH

EQ 600MG BASE

A073527 001 Jun 30, 1992

IVAX SUB TEVA PHARMS

EQ 600MG BASE

A074399 001 Mar 28, 1996

SANDOZ

EQ 200MG BASE

A073588 001 Jul 31, 1992

EQ 600MG BASE

A074002 001 Sep 27, 1993

TEVA

EQ 600MG BASE

A074729 001 Feb 27, 1997

TOLVAPTAN

TABLET; ORAL

SAMSCA

OTSUKA AMERICA PHARM

60MG

N022275 003 May 19, 2009

## DISCONTINUED DRUG PRODUCT LIST

TOPIRAMATE

## CAPSULE; ORAL

## TOPAMAX SPRINKLE

JANSSEN PHARMS

50MG

N020844 003 Oct 26, 1998

## TOPIRAMATE

BARR

15MG

A076448 001 Apr 15, 2009

25MG

A076448 002 Apr 15, 2009

SANDOZ

15MG

A079206 001 Oct 14, 2009

25MG

A079206 002 Oct 14, 2009

## TABLET; ORAL

## TOPAMAX

JANSSEN PHARMS

300MG

N020505 003 Dec 24, 1996

400MG

N020505 006 Dec 24, 1996

## TOPIRAMATE

BARR

25MG

A076315 001 Mar 27, 2009

100MG

A076315 002 Mar 27, 2009

200MG

A076315 003 Mar 27, 2009

PLIVA HRVATSKA DOO

25MG

A077905 001 Mar 30, 2009

50MG

A077905 002 Mar 30, 2009

100MG

A077905 003 Mar 30, 2009

200MG

A077905 004 Mar 30, 2009

ROXANE

25MG

A076306 001 Mar 27, 2009

50MG

A076306 002 Mar 27, 2009

100MG

A076306 003 Mar 27, 2009

200MG

A076306 004 Mar 27, 2009

WATSON LABS

25MG

A077643 001 Mar 27, 2009

50MG

A077643 002 Mar 27, 2009

100MG

A077643 003 Mar 27, 2009

200MG

A077643 004 Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

## INJECTABLE; INJECTION

## TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI ONCOL

EQ 4MG BASE/VIAL

A091376 001 Nov 29, 2010

## SOLUTION; INTRAVENOUS

## TOPOTECAN

SANDOZ INC

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N200199 001 Feb 25, 2011

EQ 3MG BASE/3ML (EQ 1MG BASE/ML)

N200199 002 Feb 25, 2011

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N200199 003 Feb 25, 2011

TORSEMIDE

## INJECTABLE; INJECTION

## DEMADEX

ROCHE

50MG/5ML (10MG/ML)

N020137 002 Aug 23, 1993

20MG/2ML (10MG/ML)

N020137 001 Aug 23, 1993

TRAMADOL HYDROCHLORIDE

## TABLET; ORAL

## TRAMADOL HYDROCHLORIDE

ACTAVIS ELIZABETH

50MG

A075960 001 Jun 19, 2002

ASTA

50MG

A075974 001 Jul 12, 2002

IVAX SUB TEVA PHARMS

50MG

A075963 001 Jul 03, 2002

SANDOZ

50MG

A075968 001 Jun 25, 2002

WATSON LABS

50MG

A075962 001 Jun 24, 2002

## ULTRAM

JANSSEN PHARMS

100MG

N020281 001 Mar 03, 1995

## TABLET, EXTENDED RELEASE; ORAL

## RYZOLT

PURDUE PHARMA

100MG

N021745 001 Dec 30, 2008

200MG

N021745 002 Dec 30, 2008

300MG

N021745 003 Dec 30, 2008

## TABLET, ORALLY DISINTEGRATING; ORAL

## RYBIX ODT

SHIONOGI INC

50MG

N021693 001 May 05, 2005

TRANDOLAPRIL

## TABLET; ORAL

## TRANDOLAPRIL

CIPLA

1MG

A077307 002 Jun 12, 2007

2MG

A077307 001 Jun 12, 2007

4MG

A077307 003 Jun 12, 2007

COREPHARMA

1MG

A077256 001 Jun 12, 2007

2MG

A077256 002 Jun 12, 2007

4MG

A077256 003 Jun 12, 2007

## DISCONTINUED DRUG PRODUCT LIST

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

DR REDDYS LABS LTD

1MG

A078493 001 Aug 25, 2008

2MG

A078493 002 Aug 25, 2008

4MG

A078493 003 Aug 25, 2008

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

FRESENIUS KABI USA

100MG/ML

A091596 001 Mar 02, 2012

TABLET; ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN

500MG

N019280 001 Dec 30, 1986

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

ALCON PHARMS LTD

0.004%

N021257 001 Mar 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

APOTHECON

50MG

N018207 001

100MG

N018207 002

150MG

N018207 003 Mar 25, 1985

300MG

N018207 004 Nov 07, 1988

TRAZODONE HYDROCHLORIDE

AM THERAP

50MG

A071139 001 Oct 29, 1986

100MG

A071140 001 Oct 29, 1986

MYLAN

50MG

A071405 001 Feb 27, 1991

100MG

A071406 001 Feb 27, 1991

QUANTUM PHARMICS

100MG

A070921 001 Dec 01, 1986

SANDOZ

50MG

A072484 001 Apr 30, 1990

100MG

A072483 001 Apr 30, 1990

TEVA

150MG

A074357 001 Apr 30, 1997

USL PHARMA

50MG

A070491 001 Apr 29, 1987

100MG

A070492 001 Apr 29, 1987

WATSON LABS

50MG

A070857 001 Oct 10, 1986

50MG

A071112 001 Nov 17, 1986

100MG

A070858 001 Oct 10, 1986

100MG

A071113 001 Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS

50MG

A070942 001 Dec 01, 1986

TRETINOIN

CAPSULE; ORAL

VESANOID

ROCHE

10MG

N020438 001 Nov 22, 1995

SOLUTION; TOPICAL

TRETINOIN

TEVA PHARMS

0.05%

A074873 001 Jun 19, 1998

WOCKHARDT

0.05%

A075260 001 Jan 25, 1999

SWAB; TOPICAL

RETIN-A

VALEANT INTL

0.05%

N016921 002

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS

1MG

N011161 009

2MG

N011161 004

4MG

N011161 007

8MG

N011161 011

16MG

N011161 010

KENACORT

DELCOR ASSET CORP

1MG

N011283 003

2MG

N011283 008

4MG

N011283 006

8MG

N011283 010

TRIAMCINOLONE

BARR

2MG

A084286 001

2MG

A084318 001

4MG

A084267 001

4MG

A084319 001

## DISCONTINUED DRUG PRODUCT LIST

TRIAMCINOLONE

TABLET; ORAL

TRIAMCINOLONE

	8MG	A084268	001
	8MG	A084320	001
IMPAX LABS	4MG	A084340	001
IVAX SUB TEVA PHARMS	4MG	A083750	001
MYLAN	2MG	A084406	001
PUREPAC PHARM	2MG	A084020	002
	4MG	A084020	003
ROXANE	2MG	A084708	001
	4MG	A084709	001
	8MG	A084707	001
SANDOZ	4MG	A085601	001
TEVA	4MG	A084775	001
WATSON LABS	4MG	A084270	001
	4MG	A085834	001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

ABBVIE	0.1MG/INH	N018117	001	Apr 23, 1982
--------	-----------	---------	-----	--------------

AEROSOL, METERED; NASAL

NASACORT

SANOFI AVENTIS US	0.055MG/INH	N019798	001	Jul 11, 1991
-------------------	-------------	---------	-----	--------------

CREAM; TOPICAL

ARISTOCORT

ASTELLAS	0.025%	A083017	003
	0.1%	A083016	004
	0.5%	A083015	002

ARISTOCORT A

ASTELLAS	0.025%	A083017	004	
	0.025%	A088818	001	Oct 16, 1984
	0.1%	A083016	005	
	0.1%	A088819	001	Oct 16, 1984
	0.5%	A083015	003	
	0.5%	A088820	001	Oct 16, 1984

FLUTEX

IVAX PHARMS	0.025%	A085539	001
	0.1%	A085539	002
	0.5%	A085539	003

KENALOG

DELCOR ASSET CORP	0.025%	N011601	003
	0.1%	N011601	006
	0.5%	A083943	001

KENALOG-H

DELCOR ASSET CORP	0.1%	A086240	001
-------------------	------	---------	-----

TRIACET

TEVA	0.025%	A084908	001
	0.1%	A084908	002
	0.5%	A084908	003

TRIACORT

SOLVAY	0.1%	A087113	001
--------	------	---------	-----

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982
ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982
AMBIX	0.025%	A087932	001	May 09, 1983
G AND W LABS	0.025%	A089797	001	May 31, 1991
	0.1%	A089798	001	May 31, 1991
MORTON GROVE	0.025%	A088094	001	Sep 01, 1983
	0.1%	A088095	001	Sep 01, 1983
	0.5%	A088096	001	Sep 01, 1983
PHARMADERM	0.025%	A087990	001	Jul 07, 1983
	0.1%	A087991	001	Jul 07, 1983
	0.5%	A087992	001	Jul 07, 1983
PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982
	0.1%	A087912	001	Aug 10, 1982
	0.5%	A087922	001	Aug 10, 1982
TARO	0.025%	A040038	001	Oct 26, 1994
	0.025%	A086277	001	
	0.1%	A086276	001	
	0.5%	A086275	001	
TOPIDERM	0.025%	A089274	001	Feb 21, 1989



## DISCONTINUED DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

## CREAM; TOPICAL

## TRIAMCINOLONE ACETONIDE

0.1%	A089275 001	Feb 21, 1989
0.5%	A089276 001	Feb 21, 1989

## TRIALEX

## IVAX PHARMS

0.025%	A087430 001	Nov 01, 1988
0.1%	A087429 001	Nov 01, 1988
0.5%	A087428 001	Nov 01, 1988

## TRYMEX

## SAVAGE LABS

0.025%	A088196 001	Mar 25, 1983
0.1%	A088197 001	Mar 25, 1983
0.5%	A088198 001	Mar 25, 1983

## GEL; TOPICAL

## ARISTOGEL

## ASTELLAS

0.1%	A083380 001	
------	-------------	--

## INJECTABLE; INJECTION

## TRIAMCINOLONE ACETONIDE

## PARNELL

3MG/ML	N019503 001	Oct 16, 1987
--------	-------------	--------------

## SANDOZ

10MG/ML	A090166 001	May 27, 2009
---------	-------------	--------------

## SANDOZ CANADA INC

40MG/ML	A090164 001	Jun 01, 2009
---------	-------------	--------------

## WATSON LABS

40MG/ML	A085825 001	
---------	-------------	--

## INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL

## TRIVARIS

## ALLERGAN

8MG/0.1ML (8MG/0.1ML)	N022220 001	Jun 16, 2008
-----------------------	-------------	--------------

## LOTION; TOPICAL

## KENALOG

## DELCOR ASSET CORP

0.025%	A084343 001	
0.025%	N011602 003	
0.1%	A084343 002	
0.1%	N011602 001	

## TRIAMCINOLONE ACETONIDE

## ALPHARMA US PHARMS

0.025%	A087191 001	Sep 08, 1982
0.1%	A087192 001	Sep 08, 1982

## G AND W LABS INC

0.1%	A089129 001	Aug 14, 1986
------	-------------	--------------

## OINTMENT; TOPICAL

## ARISTOCORT

## ASTELLAS

0.1%	A080750 004	
0.5%	A080745 002	

## ARISTOCORT A

## ASTELLAS

0.1%	A080750 003	
0.1%	A088780 001	Oct 01, 1984
0.5%	A080745 003	
0.5%	A088781 001	Oct 05, 1984

## FLUTEX

## IVAX PHARMS

0.025%	A087375 001	Nov 01, 1988
0.1%	A087377 001	Nov 01, 1988
0.5%	A087376 001	Nov 01, 1988

## KENALOG

## DELCOR ASSET CORP

0.025%	N011600 003	
0.1%	N011600 001	
0.5%	A083944 001	

## TRIAMCINOLONE ACETONIDE

## ACTAVIS MID ATLANTIC

0.1%	A087799 001	Jun 07, 1982
------	-------------	--------------

## ALPHARMA US PHARMS

0.5%	A089913 001	Dec 23, 1988
------	-------------	--------------

## G AND W LABS

0.025%	A089795 001	Dec 23, 1988
--------	-------------	--------------

0.1%	A089796 001	Dec 23, 1988
------	-------------	--------------

## MORTON GROVE

0.025%	A088090 001	Sep 01, 1983
--------	-------------	--------------

0.1%	A088091 001	Sep 01, 1983
------	-------------	--------------

0.5%	A088092 001	Sep 01, 1983
------	-------------	--------------

## PHARMADERM

0.025%	A088692 001	Aug 02, 1984
--------	-------------	--------------

0.1%	A088690 001	Aug 02, 1984
------	-------------	--------------

## TARO

0.025%	A040040 001	Sep 30, 1994
--------	-------------	--------------

0.025%	A040374 001	Jun 05, 2001
--------	-------------	--------------

0.1%	A087902 001	Dec 27, 1982
------	-------------	--------------

0.5%	A040386 001	Jun 05, 2001
------	-------------	--------------

## TRYMEX

## SAVAGE LABS

0.025%	A088693 001	Aug 02, 1984
0.1%	A088691 001	Aug 02, 1984

## PASTE; DENTAL

## KENALOG IN ORABASE

## DELCOR ASSET CORP

0.1%	N012097 001	
------	-------------	--

## DISCONTINUED DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

PASTE; DENTAL

ORALONE

TARO

0.1%

A071383 001 Jul 06, 1987

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS

0.05MG/SPRAY

N020120 001 Feb 04, 2000

NASACORT HFA

SANOFI AVENTIS US

0.055MG/SPRAY

N020784 001 Apr 07, 2004

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

SANDOZ

25MG/ML

N011685 003

40MG/ML \*\*Federal Register

N012802 001

determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

TRIAMCINOLONE DIACETATE

AKORN

25MG/ML

A085122 001

40MG/ML

A086394 001

WATSON LABS

40MG/ML

A084072 001

40MG/ML

A085529 001

SYRUP; ORAL

ARISTOCORT

ASTELLAS

2MG/5ML

N011960 004

KENACORT

DELCOR ASSET CORP

EQ 4MG BASE/5ML

N012515 001

TRIAZOLAM

TABLET; ORAL

HALCION

PHARMACIA AND UPJOHN

0.5MG

N017892 002 Nov 15, 1982

TRIAZOLAM

WATSON LABS

0.125MG

A074445 001 Oct 20, 1995

0.25MG

A074445 002 Oct 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US

2MG

N012594 001 Jun 16, 1988

4MG

N012594 002 Jun 16, 1988

NAQUA

SCHERING

2MG

N012265 001

4MG

N012265 002

TRICHLOREX

LANNETT

4MG

A083436 001

4MG

A085630 001

TRICHLORMAS

MAST MM

4MG

A086259 001

TRICHLORMETHIAZIDE

IMPAX LABS

4MG

A083967 001

PAR PHARM

2MG

A087007 001

4MG

A087005 001

SANDOZ

4MG

A086171 001

TG UNITED LABS

4MG

A085568 001

WATSON LABS

2MG

A083847 001

2MG

A086458 001

4MG

A083462 001

4MG

A083855 001

4MG

A085962 001

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

SANOFI AVENTIS US

1.5GM/15ML

N016830 001

TABLET; ORAL

TRICLOS

SANOFI AVENTIS US

750MG

N016809 002

## DISCONTINUED DRUG PRODUCT LIST

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON

LEDERLE 10MG/ML N009729 001

TABLET; ORAL

PATHILON

LEDERLE 25MG N009489 005

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

STELAZINE

GLAXOSMITHKLINE EQ 10MG BASE/ML N011552 006

TRIFLUOPERAZINE HYDROCHLORIDE

SANDOZ EQ 10MG BASE/ML A085787 001 Apr 15, 1982

WOCKHARDT EQ 10MG BASE/ML A088143 001 Jul 26, 1983

INJECTABLE; INJECTION

STELAZINE

GLAXOSMITHKLINE EQ 2MG BASE/ML N011552 005

TABLET; ORAL

STELAZINE

GLAXOSMITHKLINE EQ 1MG BASE N011552 001

EQ 2MG BASE N011552 002

EQ 5MG BASE N011552 003

EQ 10MG BASE N011552 004

TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR EQ 1MG BASE A088967 001 Apr 23, 1985

EQ 2MG BASE A088968 001 Apr 23, 1985

EQ 5MG BASE A088969 001 Apr 23, 1985

EQ 10MG BASE A088970 001 Apr 23, 1985

IVAX PHARMS EQ 1MG BASE A087612 001 Nov 19, 1982

EQ 2MG BASE A087613 001 Nov 19, 1982

EQ 5MG BASE A087328 001 Nov 19, 1982

EQ 10MG BASE A087614 001 Nov 19, 1982

SANDOZ EQ 1MG BASE A040153 001 Oct 25, 1996

EQ 2MG BASE A040153 002 Oct 25, 1996

EQ 5MG BASE A040153 003 Oct 25, 1996

EQ 10MG BASE A040153 004 Oct 25, 1996

WATSON LABS EQ 1MG BASE A085975 001 Jun 23, 1988

EQ 2MG BASE A085976 001 Jun 23, 1988

EQ 5MG BASE A085973 001 Jun 23, 1988

EQ 10MG BASE A088710 001 Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN

APOTHECON EQ 50MG HCL/5ML N011491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON 3MG/ML N011325 005

10MG/ML N011325 004

20MG/ML N011325 001

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB 10MG N011123 001

25MG N011123 002

50MG N011123 003

TRIHENXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE 5MG N006773 010

5MG N012947 001

ELIXIR; ORAL

ARTANE

LEDERLE 2MG/5ML N006773 009

TRIHENXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES 2MG/5ML A089514 001 Apr 07, 1989

TABLET; ORAL

ARTANE

LEDERLE 2MG N006773 005

5MG N006773 003

**DISCONTINUED DRUG PRODUCT LIST**TRIHXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TREMID

SCHERING	2MG	A080381	001	
	5MG	A080381	003	

TRIHXYPHENIDYL HYDROCHLORIDE

HIKMA PHARMS LLC	2MG	A040337	002	Feb 16, 2000
	5MG	A040337	001	Feb 16, 2000
NYLOS	5MG	A085622	001	
VANGARD	2MG	A088035	001	Jul 30, 1982
WATSON LABS	2MG	A040184	001	Feb 06, 1998
	2MG	A085117	001	
	5MG	A040184	002	Feb 06, 1998
	5MG	A085105	001	

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION	30MG	N018719	002	Dec 31, 1984
	60MG	N018719	001	Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 5MG BASE	N011316	004	
------------------	-------------	---------	-----	--

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N011316	003	
------------------	-------------------	---------	-----	--

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS	EQ 2.5MG BASE/5ML	A085015	001	Feb 18, 1982
MORTON GROVE	EQ 2.5MG BASE/5ML	A088285	001	Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 2.5MG BASE	N011316	001	
------------------	---------------	---------	-----	--

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBVIE	300MG	N005856	005	
--------	-------	---------	-----	--

SOLUTION; ORAL

TRIDIONE

ABBVIE	200MG/5ML	N005856	002	
--------	-----------	---------	-----	--

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE	50MG/ML	N008983	001	
-------	---------	---------	-----	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987
SMITH AND NEPHEW	100MG/ML	A088960	001	Apr 04, 1986
	100MG/ML	A089043	001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094	001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577	001	Oct 19, 1982
	100MG/ML	A087939	001	Dec 28, 1982

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS	100MG	N017943	001	
	200MG	N017943	003	Jul 14, 1982

TRIMETHOPRIM

MUTUAL PHARM	100MG	A070494	001	Jan 22, 1986
	200MG	A070495	001	Sep 24, 1986
TEVA	200MG	A071259	001	Jun 18, 1987

TRIMPEX

ROCHE	100MG	N017952	001	
-------	-------	---------	-----	--

TRIMPEX 200

ROCHE	200MG	N017952	002	Nov 09, 1982
-------	-------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

FSC

EQ 25MG BASE/5ML

A074374 001 Jun 23, 1995

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY

EQ 25MG BASE/VIAL

N020326 001 Dec 17, 1993

EQ 200MG BASE/VIAL

N020326 002 Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

USL PHARMA

EQ 25MG BASE

A071283 001 Dec 08, 1987

EQ 50MG BASE

A071284 001 Dec 08, 1987

EQ 100MG BASE

A071285 001 Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL

5MG

N012697 001

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

NOVARTIS

EQ 25MG HCL/5ML

N005914 004

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

NOVARTIS

25MG

A083149 001

50MG

N005914 002

TRIPLENNAMINE HYDROCHLORIDE

ANABOLIC

50MG

A083037 001

BARR

50MG

A080744 001

HEATHER

50MG

A083989 001

IMPAX LABS

50MG

A080785 001

LANNETT

50MG

A083557 001

NYLOS

50MG

A085412 001

PARKE DAVIS

25MG

A083625 001

50MG

A083626 001

WATSON LABS

50MG

A080713 001

50MG

A080790 001

50MG

A085188 001

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

NOVARTIS

50MG

N010533 002

100MG

N010533 001

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

G AND W LABS

2.86%; 3.42%; 3.7%

A088607 001 Jun 09, 1986

SULTRIN

ORTHO MCNEIL PHARM

2.86%; 3.42%; 3.7%

N005794 001

TRIPLE SULFA

ALPHARMA US PHARMS

2.86%; 3.42%; 3.7%

A087864 001 Sep 01, 1982

FOUGERA

2.86%; 3.42%; 3.7%

A086424 001

PERRIGO NEW YORK

2.86%; 3.42%; 3.7%

A087285 001 Nov 15, 1982

TRYSUL

SAVAGE LABS

2.86%; 3.42%; 3.7%

A087887 001 Jul 23, 1982

VAGILIA

TEVA

3.42%; 3.42%; 3.42%

A088821 001 Nov 09, 1987

TABLET; VAGINAL

SULTRIN

ORTHO MCNEIL PHARM

143.75MG; 172.5MG; 184MG

N005794 002

TRIPLE SULFA

FOUGERA

172.5MG; 172.5MG; 172.5MG

A088463 001 Jan 03, 1985

PHARMADERM

172.5MG; 172.5MG; 172.5MG

A088462 001 Jan 03, 1985

**DISCONTINUED DRUG PRODUCT LIST**TRIPROLIDINE HYDROCHLORIDE

## SYRUP; ORAL

## ACTIDIL

GLAXOSMITHKLINE 1.25MG/5ML N011496 002 Jul 01, 1983

## MYIDYL

USL PHARMA 1.25MG/5ML A087963 001 Jan 18, 1983

## TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS 1.25MG/5ML A085940 001

HALSEY 1.25MG/5ML A088735 001 Jan 17, 1985

PHARM ASSOC 1.25MG/5ML A087514 001 Feb 10, 1982

## TABLET; ORAL

## ACTIDIL

GLAXOSMITHKLINE 2.5MG N011110 002 Jul 01, 1983

## TRIPROLIDINE HYDROCHLORIDE

VITARINE 2.5MG A085610 001

WATSON LABS 2.5MG A085094 001

TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE; SULFAMETHAZINE)

## SUSPENSION; ORAL

## LANTRISUL

LANNETT 167MG/5ML; 167MG/5ML; 167MG/5ML A080123 002

## NEOTRIZINE

LILLY 167MG/5ML; 167MG/5ML; 167MG/5ML N006317 012

## SULFALOID

FOREST PHARMS 167MG/5ML; 167MG/5ML; 167MG/5ML A080100 001

## SULFOSE

WYETH AYERST 167MG/5ML; 167MG/5ML; 167MG/5ML A080013 002

## TERFONYL

BRISTOL MYERS SQUIBB 167MG/5ML; 167MG/5ML; 167MG/5ML N006904 002

## TRIPLE SULFA

ALPHARMA US PHARMS 167MG/ML; 167MG/ML; 167MG/ML A080280 001

## TRIPLE SULFAS

LEDERLE 167MG/5ML; 167MG/5ML; 167MG/5ML N006920 003

## TABLET; ORAL

## NEOTRIZINE

LILLY 167MG; 167MG; 167MG N006317 011

## SULFA-TRIPLE #2

IMPAX LABS 167MG; 167MG; 167MG A080079 001

## SULFALOID

FOREST PHARMS 167MG; 167MG; 167MG A080099 001

## SULFOSE

WYETH AYERST 167MG; 167MG; 167MG A080013 001

## TERFONYL

BRISTOL MYERS SQUIBB 167MG; 167MG; 167MG N006904 001

## TRIPLE SULFA

PUREPAC PHARM 167MG; 167MG; 167MG A080086 001

## TRIPLE SULFAS

LEDERLE 167MG; 167MG; 167MG N006920 002

## TRIPLE SULFOID

PAL PAK 167MG; 167MG; 167MG A080094 001

TROGLITAZONE

## TABLET; ORAL

## PRELAY

SANKYO 200MG N020719 001 Jan 29, 1997

300MG N020719 003 Aug 04, 1997

400MG N020719 002 Jan 29, 1997

## REZULIN

PFIZER PHARMS 200MG N020720 001 Jan 29, 1997

300MG N020720 003 Aug 04, 1997

400MG N020720 002 Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

## SOLUTION/DROPS; OTIC

## CERUMENEX

PHARM RES ASSOC 10% N011340 002

TROLEANDOMYCIN

## CAPSULE; ORAL

## TAO

PFIZER EQ 250MG BASE N050336 002

## SUSPENSION; ORAL

## TAO

PFIZER EQ 125MG BASE/5ML N050332 001

**DISCONTINUED DRUG PRODUCT LIST**TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

ALCON	0.5%	N012111	002
	1%	N012111	004

MYDRIAFAIR

PHARMAFAIR	0.5%	A088274	001 Sep 16, 1983
	1%	A088230	001 Sep 16, 1983

TROPICAMIDE

AKORN	1%	A088447	001 Aug 28, 1985
ALCON PHARMS LTD	1%	A089172	001 Dec 28, 1990
MIZA PHARMS USA	0.5%	A087636	001 Jul 30, 1982
	1%	A087637	001 Aug 09, 1982
WATSON LABS	0.5%	A089171	001 Dec 28, 1990

TROVAFLOXACIN MESYLATE

TABLET;ORAL

TROVAN

PFIZER	EQ 100MG BASE	N020759	001 Dec 18, 1997
	EQ 200MG BASE	N020759	002 Dec 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE;INJECTION

TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB	3MG/ML	N005657	001
HOSPIRA	3MG/ML	N006095	001
LILLY	3MG/ML	N006325	001

TYROPANOATE SODIUM

CAPSULE;ORAL

BILOPAQUE

GE HEALTHCARE	750MG	N013731	001
---------------	-------	---------	-----

URACIL MUSTARD

CAPSULE;ORAL

URACIL MUSTARD

SHIRE	1MG	N012892	001
-------	-----	---------	-----

UREA

INJECTABLE;INJECTION

STERILE UREA

HOSPIRA	40GM/VIAL	N017698	001
---------	-----------	---------	-----

UREAPHIL

HOSPIRA	40GM/VIAL	N012154	001
---------	-----------	---------	-----

UREA C-13

FOR SOLUTION;ORAL

BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA	EQ 75MG/POUCH	N020586	002 May 10, 2001
----------------	---------------	---------	------------------

HELICOSOL

METABOLIC SOLUTIONS	125MG/VIAL	N021092	001 Dec 17, 1999
---------------------	------------	---------	------------------

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA	125MG/VIAL	N020586	001 Sep 17, 1996
----------------	------------	---------	------------------

PYLORI-CHEK BREATH TEST

DXS DEVICES	100MG/VIAL	N020900	001 Feb 04, 1999
-------------	------------	---------	------------------

UROFOLLITROPIN

INJECTABLE;INTRAMUSCULAR

METRODIN

SERONO	75 IU/AMP	N019415	002 Sep 18, 1986
	150 IU/AMP	N019415	003 Sep 18, 1986

INJECTABLE;SUBCUTANEOUS

FERTINEX

SERONO	75 IU/AMP	N019415	005 Aug 23, 1996
	150 IU/AMP	N019415	004 Aug 23, 1996

UROKINASE

INJECTABLE;INJECTION

KINLYTIC

MICROBIX BIOSYSTEMS	5,000 IU/VIAL	N021846	003
	9,000 IU/VIAL	N021846	002
	250,000 IU/VIAL	N021846	001

## DISCONTINUED DRUG PRODUCT LIST

URSODIOL

CAPSULE; ORAL

ACTIGALL

WATSON PHARMS

150MG

N019594 001 Dec 31, 1987

TABLET; ORAL

URSODIOL

TEVA PHARMS USA

250MG

A079184 001 May 13, 2009

500MG

A079184 002 May 13, 2009

VALDECOXIB

TABLET; ORAL

BEXTRA

GD SEARLE

10MG

N021341 002 Nov 16, 2001

20MG

N021341 003 Nov 16, 2001

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

PAR PHARM

250MG

A070431 001 Feb 28, 1986

SCHERER RP

250MG

A070195 001 Jul 02, 1987

USL PHARMA

250MG

A070631 001 Jun 11, 1987

CAPSULE, DELAYED RELEASE; ORAL

STAVZOR

BANNER PHARMACAPS

125MG

N022152 001 Jul 29, 2008

250MG

N022152 002 Jul 29, 2008

500MG

N022152 003 Jul 29, 2008

SYRUP; ORAL

VALPROIC ACID

APOTEX INC

250MG/5ML

A077105 001 Jul 29, 2005

VALSARTAN

CAPSULE; ORAL

DIOVAN

NOVARTIS

80MG

N020665 001 Dec 23, 1996

160MG

N020665 002 Dec 23, 1996

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 250MG BASE/5ML

A061667 002 Jul 13, 1983

EQ 500MG BASE/6ML

A061667 001

VANCOLED

LEDERLE

EQ 250MG BASE/5ML

A063321 002 Oct 15, 1993

EQ 500MG BASE/6ML

A063321 003 Oct 15, 1993

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 1GM BASE/VIAL

A060180 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987

EQ 1GM BASE/VIAL

A062812 002 Nov 17, 1987

EQ 10GM BASE/VIAL

A062812 003 Nov 17, 1987

EQ 500MG BASE/VIAL

A060180 001

EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984

EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987

EQ 500MG BASE/VIAL

A062812 001 Nov 17, 1987

VANCOLED

HIKMA MAPLE

EQ 1GM BASE/VIAL

A062682 002 Mar 30, 1988

EQ 2GM BASE/VIAL

A062682 003 May 11, 1988

EQ 5GM BASE/VIAL

A062682 004 May 11, 1988

EQ 10GM BASE/VIAL

A062682 005 May 11, 1988

EQ 500MG BASE/VIAL

A062682 001 Jul 22, 1986

VANCOMYCIN HYDROCHLORIDE

HIKMA MAPLE

EQ 1GM BASE/VIAL

A062879 002 Aug 02, 1988

EQ 500MG BASE/VIAL

A062879 001 Aug 02, 1988

VANCOR

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL

A062956 002 Aug 01, 1988

EQ 500MG BASE/VIAL

A062956 001 Aug 01, 1988

VASOPRESSIN TANNATE

INJECTABLE; INJECTION

PITRESSIN TANNATE

PARKE DAVIS

5PRESSOR UNITS/ML

N003402 001



## DISCONTINUED DRUG PRODUCT LIST

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

ORGANON USA INC	10MG/VIAL	N018776 002	Apr 30, 1984
	20MG/VIAL	N018776 003	Jan 03, 1992

VECURONIUM BROMIDE

HIKMA MAPLE	10MG/VIAL	A075218 001	Aug 23, 1999
	20MG/VIAL	A075218 002	Aug 23, 1999
HOSPIRA	4MG/VIAL	A075558 001	Sep 11, 2001
WATSON LABS	10MG/VIAL	A074334 001	Aug 31, 1995
	20MG/VIAL	A074334 002	Aug 31, 1995

VELAGLUCERASE ALFA

POWDER; IV (INFUSION)

VPRIV

SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575 002	Feb 26, 2010
---------------------	----------------	-------------	--------------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH PHARMS INC	EQ 100MG BASE	N020699 003	Oct 20, 1997
------------------	---------------	-------------	--------------

TABLET; ORAL

EFFEXOR

WYETH PHARMS INC	EQ 12.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020151 001	Dec 28, 1993
	EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020151 002	Dec 28, 1993
	EQ 37.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020151 006	Dec 28, 1993
	EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020151 003	Dec 28, 1993
	EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020151 004	Dec 28, 1993
	EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020151 005	Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517 001	Jun 13, 2008
	EQ 37.5MG BASE	A078517 002	Jun 13, 2008
	EQ 50MG BASE	A078517 003	Jun 13, 2008
	EQ 75MG BASE	A078517 004	Jun 13, 2008
	EQ 100MG BASE	A078517 005	Jun 13, 2008
SANDOZ	EQ 25MG BASE	A077515 001	Jun 13, 2008
	EQ 37.5MG BASE	A077515 002	Jun 13, 2008
	EQ 50MG BASE	A077515 003	Jun 13, 2008
	EQ 75MG BASE	A077515 004	Jun 13, 2008
	EQ 100MG BASE	A077515 005	Jun 13, 2008

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

CALAN

GD SEARLE LLC	2.5MG/ML	N018925 001	Mar 30, 1984
	2.5MG/ML	N019038 001	Mar 30, 1984

ISOPTIN

FSC	2.5MG/ML	N018485 001	
-----	----------	-------------	--

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM	2.5MG/ML	A070348 001	May 01, 1986
BEDFORD	2.5MG/ML	A072888 001	Jul 28, 1995
HOSPIRA	2.5MG/ML	A070577 001	Feb 02, 1987
	2.5MG/ML	A070739 001	May 06, 1987
	2.5MG/ML	A070740 001	May 06, 1987
INTL MEDICATION	2.5MG/ML	A070451 001	Dec 16, 1985
LUITPOLD	2.5MG/ML	A070225 001	Nov 12, 1985
	2.5MG/ML	A070617 001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233 001	Feb 26, 1993

## DISCONTINUED DRUG PRODUCT LIST

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

	2.5MG/ML	A073485 001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696 001	Jul 31, 1987
	2.5MG/ML	A070697 001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695 001	Jul 31, 1987

TABLET; ORAL

CALAN

GD SEARLE LLC	160MG	N018817 004	Feb 23, 1988
---------------	-------	-------------	--------------

ISOPTIN

FSC	40MG	N018593 003	Nov 23, 1987
	80MG	N018593 001	Mar 08, 1982
	120MG	N018593 002	Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH	80MG	A071019 001	Sep 24, 1986
	120MG	A070468 001	Sep 24, 1986
MUTUAL PHARM	80MG	A070482 001	Sep 24, 1986
	80MG	A071489 002	Jan 13, 1988
	120MG	A070483 001	Sep 24, 1986
	120MG	A071489 001	Jan 13, 1988
PLIVA	40MG	A072751 001	Feb 23, 1996
	80MG	A072124 001	Jan 26, 1989
	120MG	A072125 001	Jan 26, 1989
SANDOZ	40MG	A073168 001	Jul 31, 1992
	80MG	A071423 001	May 24, 1988
	120MG	A071424 001	May 25, 1988
WARNER CHILCOTT	80MG	A070340 001	Sep 24, 1986
	120MG	A070341 001	Sep 24, 1986
WATSON LABS	40MG	A072799 001	Apr 28, 1989
	40MG	A072923 001	Jun 29, 1993
	80MG	A070855 001	Sep 24, 1986
	80MG	A071366 001	Oct 01, 1986
	120MG	A070856 001	Sep 24, 1986
	120MG	A071367 001	Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

PLIVA	240MG	A072922 001	Mar 01, 1996
-------	-------	-------------	--------------

VERATRUM VIRIDE ROOT

TABLET; ORAL

VERTAVIS

MEDPOINTE PHARM HLC	130CSR UNIT	N005691 002	
---------------------	-------------	-------------	--

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDALE	EQ 187.4MG BASE/ML	N050523 001	
-----------	--------------------	-------------	--

OINTMENT; OPHTHALMIC

VIRA-A

PARKEDALE	3%	N050486 001	
-----------	----	-------------	--

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

LILLY	10MG/VIAL	N012665 001	
-------	-----------	-------------	--

VINBLASTINE SULFATE

ABRAXIS PHARM	10MG/VIAL	A089011 001	Nov 18, 1985
HOSPIRA	10MG/VIAL	A089565 001	Aug 18, 1987

VINCRIStINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

LILLY	1MG/VIAL	N014103 001	
	1MG/ML	N014103 003	Mar 07, 1984
	5MG/VIAL	N014103 002	

VINCASAR PFS

TEVA PARENTERAL	1MG/ML	A071426 001	Jul 17, 1987
-----------------	--------	-------------	--------------

VINCRES

BRISTOL MYERS SQUIBB	5MG/VIAL	A070867 001	Jul 12, 1988
----------------------	----------	-------------	--------------

VINCRIStINE SULFATE

ABIC	1MG/ML	A070873 001	Feb 19, 1987
ABRAXIS PHARM	1MG/ML	A070411 001	Sep 10, 1986
FRESENIUS KABI USA	1MG/ML	A076296 001	Dec 20, 2002

## DISCONTINUED DRUG PRODUCT LIST

VINCRIStINE SULFATEINJECTABLE; INJECTION  
VINCRIStINE SULFATE

	1MG/ML	A076401 001	Oct 28, 2003
HOSPIRA	1MG/VIAL	A071559 001	Apr 11, 1988
	2MG/VIAL	A071560 001	Apr 11, 1988
	5MG/VIAL	A071561 001	Apr 11, 1988

VINORELBINE TARTRATEINJECTABLE; INJECTION  
VINORELBINE TARTRATE  
EBEWE PHARMA

EQ 10MG BASE/ML A078408 001 Feb 13, 2008

VIOMYCIN SULFATEINJECTABLE; INJECTION  
VIOCIN SULFATE

PFIZER	EQ 1GM BASE/VIAL	A061086 001	
	EQ 5GM BASE/VIAL	A061086 002	

VITAMIN ACAPSULE; ORAL  
AQUASOL A

ASTRAZENECA	25,000USP UNITS	A083080 002	
	50,000USP UNITS	A083080 001	

VITAMIN A

BANNER PHARMACAPS	50,000USP UNITS	A083973 001	
CHASE CHEM	50,000 IU	A083351 001	
EVERYLIFE	50,000 IU	A083134 001	
IMPAX LABS	50,000USP UNITS	A080952 001	
WEST WARD	50,000USP UNITS	A080985 001	

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

STERLING WINTHROP EQ 50,000 UNITS BASE A083187 001

ALPHALIN

LILLY EQ 50,000 UNITS BASE A080883 001

DEL-VI-A

DEL RAY LABS EQ 50,000 UNITS BASE A080830 001

VI-DOM-A

BAYER PHARMS EQ 50,000 UNITS BASE A080972 001

VITAMIN A

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702 001	
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860 001	
CHASE CHEM	EQ 50,000 UNITS BASE	A080746 001	
	EQ 50,000 UNITS BASE	A083207 001	
ELKINS SINN	EQ 50,000 UNITS BASE	A085479 001	
EVERYLIFE	EQ 50,000 UNITS BASE	A080943 001	
	EQ 50,000 UNITS BASE	A083114 001	
IMPAX LABS	EQ 50,000 UNITS BASE	A080953 001	
	EQ 50,000 UNITS BASE	A080955 001	
IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035 001	
	EQ 50,000 UNITS BASE	A083190 001	
MK LABS	EQ 25,000 UNITS BASE	A083457 002	
	EQ 50,000 UNITS BASE	A083457 001	
WEST WARD	EQ 50,000 UNITS BASE	A080967 001	
WHARTON LABS	EQ 50,000 UNITS BASE	A083665 001	

VITAMIN A PALMITATE

ARCUM	EQ 50,000 UNITS BASE	A083311 001	
	EQ 50,000 UNITS BASE	A083321 001	
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001	
	EQ 50,000 UNITS BASE	A083981 001	

VITAMIN A SOLUBILIZED

TEVA EQ 50,000 UNITS BASE A080921 001

INJECTABLE; INJECTION

VITAMIN A PALMITATE

BEL MAR EQ 50,000 UNITS BASE/ML A080819 001

WARFARIN POTASSIUM

TABLET; ORAL

ATHROMBIN-K

PHARM RES ASSOC	2MG	N011771 007	
	5MG	N011771 004	
	10MG	N011771 005	
	25MG	N011771 006	

**DISCONTINUED DRUG PRODUCT LIST**WARFARIN SODIUM

## INJECTABLE; INJECTION

## COUMADIN

BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995
	50MG/VIAL	N009218	020	
	75MG/VIAL	N009218	012	

## TABLET; ORAL

## ATHROMBIN

PHARM RES ASSOC	5MG	N011771	003	
	10MG	N011771	002	
	25MG	N011771	001	

## PANWARFIN

ABBOTT	2MG	N017020	001	
	2.5MG	N017020	002	
	5MG	N017020	003	
	7.5MG	N017020	004	
	10MG	N017020	005	

## WARFARIN SODIUM

## SANDOZ

	1MG	A040196	001	Sep 30, 1997
	2MG	A040196	002	Sep 30, 1997
	2.5MG	A040196	003	Sep 30, 1997
	3MG	A040196	008	Jul 26, 2000
	4MG	A040196	004	Sep 30, 1997
	5MG	A040196	005	Sep 30, 1997
	6MG	A040196	009	Jul 26, 2000
	7.5MG	A040196	006	Sep 30, 1997
	10MG	A040196	007	Sep 30, 1997

## USL PHARMA

	2MG	A088719	001	Jun 27, 1985
	2.5MG	A088720	001	Aug 06, 1985
	5MG	A088721	001	Jul 02, 1985

## WATSON LABS

	2MG	A086123	001	Aug 17, 1982
	2.5MG	A086120	001	Aug 17, 1982
	5MG	A086119	001	Aug 17, 1982
	7.5MG	A086118	001	Aug 17, 1982
	10MG	A086122	001	Aug 17, 1982

XENON XE-127

## GAS; INHALATION

## XENON XE 127

MALLINCKRODT	5mCi/VIAL	N018536	001	Oct 01, 1982
	10mCi/VIAL	N018536	002	Oct 01, 1982

XENON XE-133

## GAS; INHALATION

## XENON XE 133

GE HEALTHCARE	1 CI/AMP	N017256	002	
	10mCi/VIAL	N017687	002	
	20mCi/VIAL	N017687	003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550	001	
	0.25-5 CI/AMP	N017550	003	
MALLINCKRODT	10mCi/VIAL	N018327	001	Mar 09, 1982
	20mCi/VIAL	N018327	002	Mar 09, 1982

## XENON XE 133-V.S.S.

GE HEALTHCARE	10mCi/VIAL	N017687	001	
---------------	------------	---------	-----	--

## INJECTABLE; INJECTION

## XENON XE 133

GE HEALTHCARE	1.3-1.7 CI/AMP	N017256	001	
LANTHEUS MEDCL	6.3mCi/ML	N017283	001	

## SOLUTION; INHALATION, INJECTION

## XENEISOL

MALLINCKRODT	18-25mCi/AMP	N017262	002	
--------------	--------------	---------	-----	--

XYLOSE

## POWDER; ORAL

## XYLO-PFAN

SAVAGE LABS	25GM/BOT	N017605	001	
-------------	----------	---------	-----	--

## XYLOSE

LYNE	25GM/BOT	N018856	001	Mar 26, 1987
------	----------	---------	-----	--------------

## DISCONTINUED DRUG PRODUCT LIST

ZALCITABINE

TABLET; ORAL

HIVID

ROCHE

0.375MG

N020199 001 Jun 19, 1992

0.75MG

N020199 002 Jun 19, 1992

ZALEPLON

CAPSULE; ORAL

ZALEPLON

SANDOZ

5MG

A078095 001 Jun 06, 2008

10MG

A078095 002 Jun 06, 2008

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

JAZZ PHARMS INTL

200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

LIAONING CHENGDA

10MG/ML

A204538 001 Nov 26, 2013

TABLET; ORAL

RETROVIR

VIIV HLTHCARE

200MG

N020518 001 Dec 19, 1995

300MG

N020518 002 Oct 04, 1996

ZIDOVUDINE

AUROBINDO PHARMA

60MG

N022294 001 Jul 23, 2009

MATRIX LABS LTD

100MG

N200732 001 Feb 23, 2011

RANBAXY LABS LTD

300MG

A077327 001 Sep 19, 2005

ZILEUTON

TABLET; ORAL

ZYFLO

CHIESI USA INC

300MG

N020471 001 Dec 09, 1996

ZINC SULFATE

INJECTABLE; INJECTION

ZINC SULFATE

ABRAXIS PHARM

EQ 1MG ZINC/ML

N019229 002 May 05, 1987

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

NOVARTIS

EQ 4MG BASE/VIAL \*\*Federal Register  
determination that product was not  
discontinued or withdrawn for safety or  
efficacy reasons\*\*

N021223 001 Aug 20, 2001

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

DR REDDYS LABS LTD

5MG

A077985 001 Apr 23, 2007

10MG

A077985 002 Apr 23, 2007

MUTUAL PHARMA

5MG

A077288 001 Apr 23, 2007

10MG

A077288 002 Apr 23, 2007

MYLAN PHARMS INC

5MG

A078016 001 Apr 23, 2007

10MG

A078016 002 Apr 23, 2007

SYNTHON PHARMS

5MG

A077540 001 Apr 23, 2007

10MG

A077540 002 Apr 23, 2007

VIVIMED LABS

5MG

A076062 001 Apr 23, 2007

10MG

A076062 002 Apr 23, 2007

WATSON LABS

5MG

A077773 001 Apr 23, 2007

10MG

A077773 002 Apr 23, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

TOVALT ODT

BIOVAIL LABS INTL

5MG

N021412 001 Apr 25, 2007

10MG

N021412 002 Apr 25, 2007

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

ANI PHARMS INC

25MG

A077639 001 Dec 22, 2005

25MG

A077641 003 Dec 22, 2005

50MG

A077639 002 Dec 22, 2005

50MG

A077641 002 Dec 22, 2005

100MG

A077639 003 Dec 22, 2005

100MG

A077641 001 Dec 22, 2005

**DISCONTINUED DRUG PRODUCT LIST**ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

COREPHARMA	25MG	A077876 001	Feb 21, 2007
	50MG	A077876 002	Feb 21, 2007
	100MG	A077876 003	Feb 21, 2007
DR REDDYS LABS LTD	25MG	A077645 002	Sep 29, 2006
	50MG	A077645 003	Sep 29, 2006
	100MG	A077645 001	Dec 22, 2005
MUTUAL PHARM	25MG	A077635 001	Dec 22, 2005
	50MG	A077635 002	Dec 22, 2005
	100MG	A077635 003	Dec 22, 2005
ROXANE	25MG	A077648 001	Dec 22, 2005
	50MG	A077648 002	Dec 22, 2005
	100MG	A077648 003	Dec 22, 2005
SANDOZ	25MG	A077644 001	Dec 22, 2005
	50MG	A077644 002	Dec 22, 2005
	100MG	A077644 003	Dec 22, 2005
WATSON LABS	25MG	A077650 001	Apr 20, 2006
	50MG	A077650 002	Apr 20, 2006
	100MG	A077650 003	Apr 20, 2006

**ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST**

The list of List of Orphan Designations and Approvals is available at:  
<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN;ASPIRIN;BUTALBITAL  
CAPSULE OR TABLET; ORAL  
160-165MG;160-165MG;50MG  
325MG;325MG;50MG

ASPIRIN;CAFFEINE;CARISOPRODOL;  
CODEINE PHOSPHATE  
TABLET; ORAL  
160MG;32MG;200MG;16MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;  
CAFFEINE  
CAPSULE OR TABLET; ORAL  
160-165MG;160-165MG;50MG;40MG  
325MG;325MG;50MG;40MG

ASPIRIN;CARISOPRODOL  
TABLET; ORAL  
325MG;200MG

ACETAMINOPHEN;BUTALBITAL  
CAPSULE OR TABLET; ORAL  
325MG;50MG

ASPIRIN;CARISOPRODOL;  
CODEINE PHOSPHATE  
TABLET; ORAL  
325MG;200MG;16MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE  
CAPSULE OR TABLET; ORAL  
325MG;50MG;40MG

ASPIRIN;MEPROBAMATE  
TABLET; ORAL  
325MG;200MG

AMINOPHYLLINE  
TABLET; ORAL  
100MG;200MG

ASPIRIN;METHOCARBAMOL  
TABLET; ORAL  
325MG;400MG

ASPIRIN;BUTALBITAL  
CAPSULE OR TABLET; ORAL  
325MG;50MG  
650MG;50MG

CHLOROTHIAZIDE  
TABLET; ORAL  
250MG

ASPIRIN;BUTALBITAL;CAFFEINE  
CAPSULE OR TABLET; ORAL  
325MG;50MG;40MG  
650MG;50MG;40MG

HYDROXYZINE HYDROCHLORIDE  
TABLET; ORAL  
10MG;25MG;  
50MG;100MG

ASPIRIN;CAFFEINE;CARISOPRODOL  
TABLET; ORAL  
160MG;32MG;200MG

PREDNISONE  
TABLET; ORAL  
1MG;2.5MG;5MG;10MG;  
20MG;25MG;50MG



## APPENDIX A - PRODUCT NAME INDEX

\*\* 8 \*\*

8-MOP, METHOXSALEN

\*\* A \*\*

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE  
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE  
ABACAVIR SULFATE, ABACAVIR SULFATE  
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE  
ABELCET, AMPHOTERICIN B  
ABILIFY, ARIPIPIRAZOLE  
ABILIFY MAINTENA KIT, ARIPIPIRAZOLE  
ABLAVAR, GADOFOSVESET TRISODIUM  
ABRAXANE, PACLITAXEL  
ABREVA, DOCOSANOL (OTC)  
ABSORICA, ISOTRETINOIN  
ABSTRAL, FENTANYL CITRATE  
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM  
ACANYA, BENZOYL PEROXIDE  
ACARBOSE, ACARBOSE  
ACCOLATE, ZAFIRLUKAST  
ACCUNEB, ALBUTEROL SULFATE  
ACCUPRIL, QUINAPRIL HYDROCHLORIDE  
ACCURETIC, HYDROCHLOROTHIAZIDE  
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE  
ACEON, PERINDOPRIL ERBUMINE  
ACEPHEN, ACETAMINOPHEN (OTC)  
ACETADOTE, ACETYLCYSTEINE  
ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)  
ACETASOL HC, ACETIC ACID, GLACIAL  
ACETAZOLAMIDE, ACETAZOLAMIDE  
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
ACETIC ACID, ACETIC ACID, GLACIAL  
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL  
ACETYLCYSTEINE, ACETYLCYSTEINE  
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE  
ACIPHEX, RABEPRAZOLE SODIUM  
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM  
ACITRETIN, ACITRETIN  
ACOVA, ARGATROBAN  
ACTHREL, CORTICORELIN OVINE TRIFLUTATE  
ACTICLATE, DOXYCYCLINE HYCLATE  
ACTIGALL, URSODIOL  
ACTIQ, FENTANYL CITRATE  
ACTIVELLA, ESTRADIOL  
ACTONEL, RISEDRONATE SODIUM  
ACTOPLUS MET, METFORMIN HYDROCHLORIDE  
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE  
ACTOS, PIOGLITAZONE HYDROCHLORIDE  
ACULAR, KETOROLAC TROMETHAMINE  
ACULAR LS, KETOROLAC TROMETHAMINE  
ACUVAIL, KETOROLAC TROMETHAMINE  
ACYCLOVIR, ACYCLOVIR  
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM  
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM  
ACZONE, DAPSONE  
ADAGEN, PEGADEMASE BOVINE  
ADALAT CC, NIFEDIPINE  
ADAPALENE, ADAPALENE  
ADASUVE, LOXAPINE  
ADCIRCA, TADALAFIL  
ADDERALL XR 10, AMPHETAMINE ASPARTATE  
ADDERALL XR 15, AMPHETAMINE ASPARTATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* A \*\*

ADDERALL XR 20, AMPHETAMINE ASPARTATE  
ADDERALL XR 25, AMPHETAMINE ASPARTATE  
ADDERALL XR 30, AMPHETAMINE ASPARTATE  
ADDERALL XR 5, AMPHETAMINE ASPARTATE  
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL  
ADEMPAS, RIOCIQUAT  
ADENOCARD, ADENOSINE  
ADENOSCAN, ADENOSINE  
ADENOSINE, ADENOSINE  
ADIPEX-P, PHENTERMINE HYDROCHLORIDE  
ADRENACLICK, EPINEPHRINE  
ADRENALIN, EPINEPHRINE HYDROCHLORIDE  
ADREVIEW, IOBENGUANE SULFATE I-123  
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE  
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE  
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE  
ADVAIR HFA, FLUTICASONE PROPIONATE  
ADVICOR, LOVASTATIN  
ADVIL, IBUPROFEN (OTC)  
ADVIL, IBUPROFEN SODIUM (OTC)  
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)  
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
ADVIL COLD AND SINUS, IBUPROFEN (OTC)  
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)  
ADVIL LIQUI-GELS, IBUPROFEN (OTC)  
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)  
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)  
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
AEROSPAN HFA, FLUNISOLIDE  
AFEDITAB CR, NIFEDIPINE  
AFINITOR, EVEROLIMUS  
AFINITOR DISPERZ, EVEROLIMUS  
AFREZZA, INSULIN RECOMBINANT HUMAN  
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)  
AGGRASTAT, TIROFIBAN HYDROCHLORIDE  
AGGRENOLX, ASPIRIN  
AGRYLIN, ANAGRELIDE HYDROCHLORIDE  
AK-FLUOR 10%, FLUORESCEIN SODIUM  
AK-FLUOR 25%, FLUORESCEIN SODIUM  
AKBETA, LEVOBUNOLOL HYDROCHLORIDE  
AKINETON, BIPERIDEN HYDROCHLORIDE  
AKNE-MYCIN, ERYTHROMYCIN  
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE  
AKTEN, LIDOCAINE HYDROCHLORIDE  
AKTOB, TOBRAMYCIN  
AKYNZEO, NETUPITANT  
ALA-CORT, HYDROCORTISONE  
ALA-SCALP, HYDROCORTISONE  
ALAVERT, LORATADINE (OTC)  
ALAWAY, KETOTIFEN FUMARATE (OTC)  
ALBENZA, ALBENDAZOLE  
ALBUTEROL SULFATE, ALBUTEROL SULFATE  
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
ALCAINE, PROPARACAINE HYDROCHLORIDE  
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE  
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL  
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL  
ALDACTAZIDE, HYDROCHLOROTHIAZIDE  
ALDACTONE, SPIRONOLACTONE  
ALDARA, IMIQUIMOD  
ALENDRONATE SODIUM, ALENDRONATE SODIUM  
ALEVE, NAPROXEN SODIUM (OTC)  
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)  
ALFENTA, ALFENTANIL HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* A \*\*

ALFENTANIL, ALFENTANIL HYDROCHLORIDE  
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
ALIMTA, PEMETREXED DISODIUM  
ALINIA, NITAZOXANIDE  
ALKERAN, MELPHALAN  
ALKERAN, MELPHALAN HYDROCHLORIDE  
ALLEGRA, FEXOFENADINE HYDROCHLORIDE  
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)  
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)  
ALLI, ORLISTAT (OTC)  
ALLOPURINOL, ALLOPURINOL  
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM  
ALOCRIL, NEDOCROMIL SODIUM  
ALOMIDE, LODOXAMIDE TROMETHAMINE  
ALOPRIM, ALLOPURINOL SODIUM  
ALORA, ESTRADIOL  
ALOXI, PALONOSETRON HYDROCHLORIDE  
ALPHAGAN P, BRIMONIDINE TARTRATE  
ALPRAZOLAM, ALPRAZOLAM  
ALPROSTADIL, ALPROSTADIL  
ALREX, LOTEPIREDNOL ETABONATE  
ALSUMA, SUMATRIPTAN SUCCINATE  
ALTABAX, RETAPAMULIN  
ALTACE, RAMIPRIL  
ALTAVERA, ETHINYL ESTRADIOL  
ALTOPREV, LOVASTATIN  
ALVESCO, CICLESONIDE  
ALYACEN 1/35, ETHINYL ESTRADIOL  
ALYACEN 7/7/7, ETHINYL ESTRADIOL  
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
AMARYL, GLIMEPIRIDE  
AMBIEN, ZOLPIDEM TARTRATE  
AMBIEN CR, ZOLPIDEM TARTRATE  
AMBISOME, AMPHOTERICIN B  
AMCINONIDE, AMCINONIDE  
AMERGE, NARATRIPTAN HYDROCHLORIDE  
AMICAR, AMINOCAPROIC ACID  
AMIDATE, ETOMIDATE  
AMIFOSTINE, AMIFOSTINE  
AMIKACIN SULFATE, AMIKACIN SULFATE  
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE  
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE  
AMINO ACIDS, AMINO ACIDS  
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE  
AMINOCAPROIC, AMINOCAPROIC ACID  
AMINOCAPROIC ACID, AMINOCAPROIC ACID  
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID  
AMINOPHYLLINE, AMINOPHYLLINE  
AMINOSYN 10%, AMINO ACIDS  
AMINOSYN 10% (PH6), AMINO ACIDS  
AMINOSYN 3.5%, AMINO ACIDS  
AMINOSYN 3.5% M, AMINO ACIDS  
AMINOSYN 5%, AMINO ACIDS  
AMINOSYN 7%, AMINO ACIDS  
AMINOSYN 7% (PH6), AMINO ACIDS  
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN 8.5%, AMINO ACIDS  
AMINOSYN 8.5% (PH6), AMINO ACIDS  
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN II 10%, AMINO ACIDS  
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS  
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS

## APPENDIX A - PRODUCT NAME INDEX

\*\* A \*\*

AMINOSYN II 7%, AMINO ACIDS  
AMINOSYN II 8.5%, AMINO ACIDS  
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS  
AMINOSYN-HBC 7%, AMINO ACIDS  
AMINOSYN-HF 8%, AMINO ACIDS  
AMINOSYN-PF 10%, AMINO ACIDS  
AMINOSYN-PF 7%, AMINO ACIDS  
AMINOSYN-RF 5.2%, AMINO ACIDS  
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
AMITIZA, LUBIPROSTONE  
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE  
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE  
AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE  
AMMONIA N 13, AMMONIA N-13  
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE  
AMMONIUM LACTATE, AMMONIUM LACTATE  
AMMONUL, SODIUM BENZOATE  
AMNESTEEM, ISOTRETINOIN  
AMOXAPINE, AMOXAPINE  
AMOXICILLIN, AMOXICILLIN  
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
AMOXICILLIN PEDIATRIC, AMOXICILLIN  
AMOXIL, AMOXICILLIN  
AMPHADASE, HYALURONIDASE  
AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF, AMPHETAMINE  
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE  
AMPHOTEC, AMPHOTERICIN B  
AMPHOTERICIN B, AMPHOTERICIN B  
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
AMPICILLIN SODIUM, AMPICILLIN SODIUM  
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE  
AMPYRA, DALFAMPRIDINE  
AMRINONE LACTATE, INAMRINONE LACTATE  
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE  
AMTURNIDE, ALISKIREN HEMIFUMARATE  
AMYVID, FLORBETAPIR F-18  
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT  
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT  
ANADROL-50, OXYMETHOLONE  
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE  
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
ANAPROX, NAPROXEN SODIUM  
ANAPROX DS, NAPROXEN SODIUM  
ANASTROZOLE, ANASTROZOLE  
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM  
ANCOBON, FLUCYTOSINE  
ANDRODERM, TESTOSTERONE  
ANDROGEL, TESTOSTERONE  
ANDROID 10, METHYLTESTOSTERONE  
ANDROID 25, METHYLTESTOSTERONE  
ANECTINE, SUCCINYLCHOLINE CHLORIDE  
ANEXSIA 5/325, ACETAMINOPHEN  
ANEXSIA 7.5/325, ACETAMINOPHEN  
ANGELIQ, DROSPIRENONE  
ANGIOMAX, BIVALIRUDIN  
ANORO ELLIPTA, UMECLIDINIUM BROMIDE  
ANSAID, FLURBIPROFEN  
ANTABUSE, DISULFIRAM  
ANTARA (MICRONIZED), FENOFIBRATE  
ANTHELIOS 20, AVOBENZONE (OTC)  
ANTHELIOS 40, AVOBENZONE (OTC)  
ANTHELIOS SX, AVOBENZONE (OTC)

## APPENDIX A - PRODUCT NAME INDEX

\*\* A \*\*

ANTIZOL, FOMEPIZOLE  
ANUSOL HC, HYDROCORTISONE  
ANZEMET, DOLASETRON MESYLATE  
APIDRA, INSULIN GLULISINE RECOMBINANT  
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT  
APLENZIN, BUPROPION HYDROBROMIDE  
APOKYN, APOMORPHINE HYDROCHLORIDE  
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE  
APREPITANT, APREPITANT  
APRISO, MESALAMINE  
APTIOM, ESLICARBAZEPINE ACETATE  
APTIVUS, TIPRANAVIR  
AQUASOL A, VITAMIN A PALMITATE  
ARALEN, CHLOROQUINE PHOSPHATE  
ARANELLE, ETHINYL ESTRADIOL  
ARAVA, LEFLUNOMIDE  
ARCAPTA NEOHALER, INDACATEROL MALEATE  
ARESTIN, MINOCYCLINE HYDROCHLORIDE  
ARGATROBAN, ARGATROBAN  
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN  
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN  
ARICEPT, DONEPEZIL HYDROCHLORIDE  
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE  
ARIMIDEX, ANASTROZOLE  
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE  
ARIXTRA, FONDAPARINUX SODIUM  
ARNUITY ELLIPTA, FLUTICASONE FUROATE  
AROMASIN, EXEMESTANE  
ARRANON, NELARABINE  
ARTHROTEC, DICLOFENAC SODIUM  
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE  
ASACOL, MESALAMINE  
ASACOL HD, MESALAMINE  
ASCLERA, POLIDOCANOL  
ASMANEX HFA, MOMETASONE FUROATE  
ASMANEX TWISTHALER, MOMETASONE FUROATE  
ASPIRIN, ASPIRIN (OTC)  
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN  
ASTAGRAF XL, TACROLIMUS  
ASTELIN, AZELASTINE HYDROCHLORIDE  
ASTEPRO, AZELASTINE HYDROCHLORIDE  
ASTRAMORPH PF, MORPHINE SULFATE  
ATACAND, CANDESARTAN CILEXETIL  
ATACAND HCT, CANDESARTAN CILEXETIL  
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE  
ATELVIA, RISEDRONATE SODIUM  
ATENOLOL, ATENOLOL  
ATENOLOL AND CHLORTHALIDONE, ATENOLOL  
ATIVAN, LORAZEPAM  
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
ATOVAQUONE, ATOVAQUONE  
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE  
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE  
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE  
ATRALIN, TRETINOIN  
ATRIDOX, DOXYCYCLINE HYCLATE  
ATRIPLA, EFAVIRENZ  
ATROPEN, ATROPINE  
ATROPINE SULFATE, ATROPINE SULFATE  
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE  
ATROVENT, IPRATROPIUM BROMIDE  
ATROVENT HFA, IPRATROPIUM BROMIDE  
AUBAGIO, TERIFLUNOMIDE  
AUGMENTIN '125', AMOXICILLIN  
AUGMENTIN '200', AMOXICILLIN

## APPENDIX A - PRODUCT NAME INDEX

\*\* A \*\*

AUGMENTIN '250', AMOXICILLIN  
 AUGMENTIN '400', AMOXICILLIN  
 AUGMENTIN '500', AMOXICILLIN  
 AUGMENTIN '875', AMOXICILLIN  
 AUGMENTIN ES-600, AMOXICILLIN  
 AUGMENTIN XR, AMOXICILLIN  
 AUVI-Q, EPINEPHRINE  
 AVAGARD, ALCOHOL (OTC)  
 AVAGE, TAZAROTENE  
 AVALIDE, HYDROCHLOROTHIAZIDE  
 AVANDAMET, METFORMIN HYDROCHLORIDE  
 AVANDARYL, GLIMEPIRIDE  
 AVANDIA, ROSIGLITAZONE MALEATE  
 AVAPRO, IRBESARTAN  
 AVC, SULFANILAMIDE  
 AVEED, TESTOSTERONE UNDECANOATE  
 AVELOX, MOXIFLOXACIN HYDROCHLORIDE  
 AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE  
 AVIANE-28, ETHINYL ESTRADIOL  
 AVINZA, MORPHINE SULFATE  
 AVITA, TRETINOIN  
 AVODART, DUTASTERIDE  
 AXERT, ALMOTRIPTAN MALATE  
 AXID, NIZATIDINE  
 AXID AR, NIZATIDINE (OTC)  
 AXIRON, TESTOSTERONE  
 AYGESTIN, NORETHINDRONE ACETATE  
 AZACITIDINE, AZACITIDINE  
 AZACTAM, AZTREONAM  
 AZACTAM IN PLASTIC CONTAINER, AZTREONAM  
 AZASAN, AZATHIOPRINE  
 AZASITE, AZITHROMYCIN  
 AZATHIOPRINE, AZATHIOPRINE  
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM  
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
 AZELEX, AZELAIC ACID  
 AZILECT, RASAGILINE MESYLATE  
 AZITHROMYCIN, AZITHROMYCIN  
 AZOPT, BRINZOLAMIDE  
 AZOR, AMLODIPINE BESYLATE  
 AZTREONAM, AZTREONAM  
 AZULFIDINE, SULFASALAZINE  
 AZULFIDINE EN-TABS, SULFASALAZINE

\*\* B \*\*

BACIIM, BACITRACIN  
 BACITRACIN, BACITRACIN  
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC  
 BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN  
 BACLOFEN, BACLOFEN  
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM  
 BACTRIM, SULFAMETHOXAZOLE  
 BACTRIM DS, SULFAMETHOXAZOLE  
 BACTROBAN, MUPIROCIN  
 BACTROBAN, MUPIROCIN CALCIUM  
 BAL, DIMERCAPROL  
 BALANCED SALT, CALCIUM CHLORIDE  
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM  
 BALZIVA-28, ETHINYL ESTRADIOL  
 BANZEL, RUFINAMIDE  
 BARACLUDE, ENTECAVIR  
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE  
 BELEODAQ, BELINOSTAT

## APPENDIX A - PRODUCT NAME INDEX

\*\* B \*\*

BELSOMRA, SUVOREXANT  
BELVIQ, LORCASERIN HYDROCHLORIDE  
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
BENICAR, OLMESARTAN MEDOXOMIL  
BENICAR HCT, HYDROCHLOROTHIAZIDE  
BENTYL, DICYCLOMINE HYDROCHLORIDE  
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE  
BENZAFLIN, BENZOYL PEROXIDE  
BENZAMYCIN, BENZOYL PEROXIDE  
BENZAMYCIN PAK, BENZOYL PEROXIDE  
BENZONATATE, BENZONATATE  
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
BEPREVE, BEPOTASTINE BESILATE  
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE  
BETA-VAL, BETAMETHASONE VALERATE  
BETADINE, POVIDONE-IODINE  
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE  
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE  
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
BETAPACE, SOTALOL HYDROCHLORIDE  
BETAPACE AF, SOTALOL HYDROCHLORIDE  
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
BETHKIS, TOBRAMYCIN  
BETIMOL, TIMOLOL  
BETOPTIC, BETAXOLOL HYDROCHLORIDE  
BETOPTIC S, BETAXOLOL HYDROCHLORIDE  
BEYAZ, DROSPIRENONE  
BIAXIN, CLARITHROMYCIN  
BIAXIN XL, CLARITHROMYCIN  
BICALUTAMIDE, BICALUTAMIDE  
BICILLIN C-R, PENICILLIN G BENZATHINE  
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE  
BICILLIN L-A, PENICILLIN G BENZATHINE  
BICNU, CARMUSTINE  
BIDIL, HYDRALAZINE HYDROCHLORIDE  
BILTRICIDE, PRAZIQUANTEL  
BIMATOPROST, BIMATOPROST  
BINOSTO, ALENDRONATE SODIUM  
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)  
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE  
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE  
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE  
BLEPH-10, SULFACETAMIDE SODIUM  
BLEPHAMIDE, PREDNISOLONE ACETATE  
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE  
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE  
BONIVA, IBANDRONATE SODIUM  
BONTRIL, PHENDIMETRAZINE TARTRATE  
BONTRIL PDM, PHENDIMETRAZINE TARTRATE  
BOSULIF, BOSUTINIB MONOHYDRATE  
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS  
BRAVELLE, UROFOLLITROPIN  
BREGO ELLIPTA, FLUTICASON FUROATE  
BRETILUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETILUM TOSYLATE  
BREVIBLOC, ESMOLOL HYDROCHLORIDE  
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE  
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE  
BREVICON 28-DAY, ETHINYL ESTRADIOL  
BREVITAL SODIUM, METHOHEXITAL SODIUM  
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)  
BRIELLYN, ETHINYL ESTRADIOL

## APPENDIX A - PRODUCT NAME INDEX

\*\* B \*\*

BRILINTA, TICAGRELOR  
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
 BRINTELLIX, VORTIOXETINE HYDROBROMIDE  
 BRISDELLE, PAROXETINE MESYLATE  
 BROMDAY, BROMFENAC SODIUM  
 BROMFED-DM, BROMPHENIRAMINE MALEATE  
 BROMFENAC SODIUM, BROMFENAC SODIUM  
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE  
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,  
 BRONCHO SALINE, SODIUM CHLORIDE (OTC)  
 BROVANA, ARFORMOTEROL TARTRATE  
 BSS, CALCIUM CHLORIDE  
 BSS PLUS, CALCIUM CHLORIDE  
 BUDESONIDE, BUDESONIDE  
 BUMETANIDE, BUMETANIDE  
 BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE  
 BUPHENYL, SODIUM PHENYLBUTYRATE  
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 BUSULFEX, BUSULFAN  
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN  
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN  
 BUTAPAP, ACETAMINOPHEN  
 BUTISOL SODIUM, BUTABARBITAL SODIUM  
 BUTOCONAZOLE NITRATE, BUTOCONAZOLE NITRATE  
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE  
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE  
 BUTRANS, BUPRENORPHINE  
 BYDUREON, EXENATIDE SYNTHETIC  
 BYETTA, EXENATIDE SYNTHETIC  
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

\*\* C \*\*

C-SOLVE-2, ERYTHROMYCIN  
 CABERGOLINE, CABERGOLINE  
 CADUET, AMLODIPINE BESYLATE  
 CAFKIT, CAFFEINE CITRATE  
 CAFERGOT, CAFFEINE  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 CALAN, VERAPAMIL HYDROCHLORIDE  
 CALAN SR, VERAPAMIL HYDROCHLORIDE  
 CALCIJEX, CALCITRIOL  
 CALCIPOTRIENE, CALCIPOTRIENE  
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CALCITONIN-SALMON, CALCITONIN SALMON  
 CALCITRIOL, CALCITRIOL  
 CALCIUM ACETATE, CALCIUM ACETATE  
 CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)  
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM  
 CALDOLOR, IBUPROFEN  
 CAMBIA, DICLOFENAC POTASSIUM  
 CAMILA, NORETHINDRONE  
 CAMPRAL, ACAMPROSATE CALCIUM



## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CAMPTOSAR, IRINOTECAN HYDROCHLORIDE  
CANASA, MESALAMINE  
CANCIDAS, CASPOFUNGIN ACETATE  
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL  
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL  
CANTIL, MEPENZOLATE BROMIDE  
CAPASTAT SULFATE, CAPREOMYCIN SULFATE  
CAPECITABINE, CAPECITABINE  
CAPEX, FLUOCINOLONE ACETONIDE  
CAPITAL AND CODEINE, ACETAMINOPHEN  
CAPITAL SOLEIL 15, AVOBENZONE (OTC)  
CAPOTEN, CAPTOPRIL  
CAPRELSA, VANDETANIB  
CAPTOPRIL, CAPTOPRIL  
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL  
CARAC, FLUOROURACIL  
CARAFATE, SUCRALFATE  
CARBAGLU, CARGLUMIC ACID  
CARBAMAZEPINE, CARBAMAZEPINE  
CARBATROL, CARBAMAZEPINE  
CARBIDOPA, CARBIDOPA  
CARBIDOPA AND LEVODOPA, CARBIDOPA  
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA  
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE  
CARBOPLATIN, CARBOPLATIN  
CARDENE, NICARDIPINE HYDROCHLORIDE  
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82  
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT  
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
CARDIZEM, DILTIAZEM HYDROCHLORIDE  
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE  
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE  
CARDURA, DOXAZOSIN MESYLATE  
CARDURA XL, DOXAZOSIN MESYLATE  
CARISOPRODOL, CARISOPRODOL  
CARISOPRODOL AND ASPIRIN, ASPIRIN  
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN  
CARNITOR, LEVOCARNITINE  
CARNITOR SF, LEVOCARNITINE  
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE  
CARTIA XT, DILTIAZEM HYDROCHLORIDE  
CARVEDILOL, CARVEDILOL  
CASODEX, BICALUTAMIDE  
CATAFLAM, DICLOFENAC POTASSIUM  
CATAPRES, CLONIDINE HYDROCHLORIDE  
CATAPRES-TTS-1, CLONIDINE  
CATAPRES-TTS-2, CLONIDINE  
CATAPRES-TTS-3, CLONIDINE  
CAVERJECT, ALPROSTADIL  
CAVERJECT IMPULSE, ALPROSTADIL  
CAYSTON, AZTREONAM  
CEDAX, CEFTIBUTEN DIHYDRATE  
CEFAFLOR, CEFAFLOR  
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM  
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
CEFDINIR, CEFDINIR  
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE  
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE  
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CEFOTAXIME, CEFOTAXIME SODIUM  
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM  
 CEFOTETAN, CEFOTETAN DISODIUM  
 CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM  
 CEFOXITIN, CEFOXITIN SODIUM  
 CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM  
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
 CEFPROZIL, CEFPROZIL  
 CEFTAZIDIME, CEFTAZIDIME  
 CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME  
 CEFTIN, CEFUROXIME AXETIL  
 CEFTRIAXONE, CEFTRIAXONE SODIUM  
 CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM  
 CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM  
 CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CEFUROXIME SODIUM, CEFUROXIME SODIUM  
 CELEBREX, CELECOXIB  
 CELECOXIB, CELECOXIB  
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE  
 CELEXA, CITALOPRAM HYDROBROMIDE  
 CELLCEPT, MYCOPHENOLATE MOFETIL  
 CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE  
 CELONTIN, METHSUXIMIDE  
 CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A  
 CENTANY, MUPIROCIN  
 CEPHALEXIN, CEPHALEXIN  
 CERDELGA, ELIGLUSTAT TARTRATE  
 CEREBYX, FOSPHENYTOIN SODIUM  
 CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT  
 CEREZYME, IMIGLUCERASE  
 CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE  
 CERVIDIL, DINOPROSTONE  
 CESAMET, NABILONE  
 CETAMIDE, SULFACETAMIDE SODIUM  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE  
 CETROTIDE, CETRORELIX  
 CEVIMELINE, CEVIMELINE HYDROCHLORIDE  
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE  
 CHANTIX, VARENICLINE TARTRATE  
 CHEMET, SUCCIMER  
 CHENODIOL, CHENODIOL  
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)  
 CHILDREN'S ADVIL, IBUPROFEN (OTC)  
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)  
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)  
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CLARITIN, LORATADINE (OTC)  
 CHILDREN'S ELIXSURE, IBUPROFEN (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)  
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)  
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)  
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)

## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN  
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)  
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE  
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE  
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE  
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE  
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE  
CHLOROTHIAZIDE, CHLOROTHIAZIDE  
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM  
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)  
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE  
CHLORPROPAMIDE, CHLORPROPAMIDE  
CHLORTHALIDONE, CHLORTHALIDONE  
CHLORZOAZONE, CHLORZOAZONE  
CHOLAC, LACTULOSE  
CHOLEDYL SA, OXTRIPHYLLINE  
CHOLESTYRAMINE, CHOLESTYRAMINE  
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE  
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT  
CHOLINE C-11, CHOLINE C-11  
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE  
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC  
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE  
CIALIS, TADALAFIL  
CICLOPIROX, CICLOPIROX  
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)  
CIDOFOVIR, CIDOFOVIR  
CILOSTAZOL, CILOSTAZOL  
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE  
CIMETIDINE, CIMETIDINE (OTC)  
CIMETIDINE, CIMETIDINE  
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
CIPRO, CIPROFLOXACIN  
CIPRO, CIPROFLOXACIN HYDROCHLORIDE  
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE  
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
CIPRODEX, CIPROFLOXACIN  
CIPROFLOXACIN, CIPROFLOXACIN  
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN  
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT  
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE  
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE  
CISPLATIN, CISPLATIN  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE  
CLADRIBINE, CLADRIBINE  
CLAFORAN, CEFOTAXIME SODIUM  
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM  
CLARAVIS, ISOTRETINOIN  
CLARINEX, DESLORATADINE  
CLARINEX D 24 HOUR, DESLORATADINE  
CLARINEX-D 12 HOUR, DESLORATADINE  
CLARITHROMYCIN, CLARITHROMYCIN  
CLARITIN, LORATADINE (OTC)

## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CLARITIN HIVES RELIEF, LORATADINE (OTC)  
 CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)  
 CLARITIN REDITABS, LORATADINE (OTC)  
 CLARITIN-D, LORATADINE (OTC)  
 CLARITIN-D 24 HOUR, LORATADINE (OTC)  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE  
 CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE  
 CLEOCIN, CLINDAMYCIN PHOSPHATE  
 CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE  
 CLEOCIN T, CLINDAMYCIN PHOSPHATE  
 CLEVIPREX, CLEVIDIPINE  
 CLIMARA, ESTRADIOL  
 CLIMARA PRO, ESTRADIOL  
 CLINDA-DERM, CLINDAMYCIN PHOSPHATE  
 CLINDAGEL, CLINDAMYCIN PHOSPHATE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE  
 CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE  
 CLINDESSE, CLINDAMYCIN PHOSPHATE  
 CLINDETS, CLINDAMYCIN PHOSPHATE  
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINOLIPID 20%, OLIVE OIL  
 CLINORIL, SULINDAC  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE  
 CLOBEX, CLOBETASOL PROPIONATE  
 CLODERM, CLOCORTOLONE PIVALATE  
 CLOLAR, CLOFARABINE  
 CLOMID, CLOMIPHENE CITRATE  
 CLOMIPHENE CITRATE, CLOMIPHENE CITRATE  
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE  
 CLONAZEPAM, CLONAZEPAM  
 CLONIDINE, CLONIDINE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* C \*\*

CLOPIDOGREL, CLOPIDOGREL  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM  
CLORPRES, CHLOROTHALIDONE  
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)  
CLOTRIMAZOLE, CLOTRIMAZOLE  
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
CLOZAPINE, CLOZAPINE  
CLOZARIL, CLOZAPINE  
COARTEM, ARTEMETHER  
CODEINE SULFATE, CODEINE SULFATE  
COGENTIN, BENZTROPINE MESYLATE  
COL-PROBENECID, COLCHICINE  
COLAZAL, BALSALAZIDE DISODIUM  
COLCRYS, COLCHICINE  
COLESTID, COLESTIPOL HYDROCHLORIDE  
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE  
COLGATE TOTAL, SODIUM FLUORIDE (OTC)  
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
COLOCORT, HYDROCORTISONE  
COLY-MYCIN M, COLISTIMETHATE SODIUM  
COLY-MYCIN S, COLISTIN SULFATE  
COLYTE, POLYETHYLENE GLYCOL 3350  
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350  
COMBIGAN, BRIMONIDINE TARTRATE  
COMBIPATCH, ESTRADIOL  
COMBIVENT, ALBUTEROL SULFATE  
COMBIVENT RESPIMAT, ALBUTEROL SULFATE  
COMBIVIR, LAMIVUDINE  
COMETRIQ, CABOZANTINIB S-MALATE  
COMMIT, NICOTINE POLACRILEX (OTC)  
COMPLERA, EMTRICITABINE  
COMPRO, PROCHLORPERAZINE  
COMTAN, ENTACAPONE  
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE  
CONDYLOX, PODOFILOX  
CONRAY, IOTHALAMATE MEGLUMINE  
CONRAY 30, IOTHALAMATE MEGLUMINE  
CONRAY 43, IOTHALAMATE MEGLUMINE  
CONSTILAC, LACTULOSE  
CONSTULOSE, LACTULOSE  
CONTRAVE, BUPROPION HYDROCHLORIDE  
CONZIP, TRAMADOL HYDROCHLORIDE  
COPAXONE, GLATIRAMER ACETATE  
COPEGUS, RIBAVIRIN  
CORDARONE, AMIODARONE HYDROCHLORIDE  
CORDRAN, FLURANDRENOLIDE  
CORDRAN SP, FLURANDRENOLIDE  
COREG, CARVEDILOL  
COREG CR, CARVEDILOL PHOSPHATE  
CORGARD, NADOLOL  
CORLOPAM, FENOLDOPAM MESYLATE  
CORMAX, CLOBETASOL PROPIONATE  
CORTEF, HYDROCORTISONE  
CORTENEMA, HYDROCORTISONE  
CORTIFOAM, HYDROCORTISONE ACETATE  
CORTISONE ACETATE, CORTISONE ACETATE  
CORTISPORIN, BACITRACIN ZINC  
CORTISPORIN, HYDROCORTISONE  
CORTISPORIN, HYDROCORTISONE ACETATE  
CORTROSYN, COSYNTROPIN  
CORVERT, IBUTILIDE FUMARATE  
CORZIDE, BENDROFLUMETHIAZIDE  
COSMEGEN, DACTINOMYCIN  
COSOPT, DORZOLAMIDE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

## \*\* C \*\*

COSOPT PF, DORZOLAMIDE HYDROCHLORIDE  
 COSYNTROPIN, COSYNTROPIN  
 COUMADIN, WARFARIN SODIUM  
 COVERA-HS, VERAPAMIL HYDROCHLORIDE  
 COZAAR, LOSARTAN POTASSIUM  
 CREON, PANCRELIPASE (AMYLASE)  
 CRESTOR, ROSUVASTATIN CALCIUM  
 CRINONE, PROGESTERONE  
 CRIXIVAN, INDINAVIR SULFATE  
 CROLOM, CROMOLYN SODIUM  
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 CROTAN, CROTAMITON  
 CRYSELLE, ETHINYL ESTRADIOL  
 CUBICIN, DAPTOMYCIN  
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE  
 CUPRIMINE, PENICILLAMINE  
 CUROSURF, PORACTANT ALFA  
 CUTIVATE, FLUTICASONE PROPIONATE  
 CUVPOSA, GLYCOPYRROLATE  
 CYANOCOBALAMIN, CYANOCOBALAMIN  
 CYANOKIT, HYDROXOCOBALAMIN  
 CYCLAFEM 1/35, ETHINYL ESTRADIOL  
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL  
 CYCLESSA, DESOGESTREL  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE  
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE  
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE  
 CYCLOSET, BROMOCRIPTINE MESYLATE  
 CYCLOSPORINE, CYCLOSPORINE  
 CYKLOKAPRON, TRANEXAMIC ACID  
 CYMBALTA, DULOXETINE HYDROCHLORIDE  
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
 CYSTADANE, BETAINE HYDROCHLORIDE  
 CYSTAGON, CYSTEAMINE BITARTRATE  
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE  
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE  
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE  
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE  
 CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE  
 CYTARABINE, CYTARABINE  
 CYTOMEL, LIOTHYRONINE SODIUM  
 CYTOSAR-U, CYTARABINE  
 CYTOTEC, MISOPROSTOL  
 CYTOVENE, GANCICLOVIR SODIUM  
 CYTOXAN (LYOPHILIZED), CYCLOPHOSPHAMIDE

## \*\* D \*\*

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE  
 DACARBAZINE, DACARBAZINE  
 DACOGEN, DECITABINE  
 DACTINOMYCIN, DACTINOMYCIN  
 DALIRESP, ROFLUMILAST  
 DALVANCE, DALBAVANCIN HYDROCHLORIDE  
 DANAZOL, DANAZOL  
 DANTRIUM, DANTROLENE SODIUM  
 DANTROLENE SODIUM, DANTROLENE SODIUM  
 DAPSONE, DAPSONE  
 DAPTOMYCIN, DAPTOMYCIN  
 DARAPRIM, PYRIMETHAMINE  
 DASETTA 1/35, ETHINYL ESTRADIOL  
 DASETTA 7/7/7, ETHINYL ESTRADIOL  
 DATSCAN, IOFLUPANE I-123  
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* D \*\*

DAUNOXOME, DAUNORUBICIN CITRATE  
DAYPRO, OXAPROZIN  
DAYSEE, ETHINYL ESTRADIOL  
DAYTRANA, METHYLPHENIDATE  
DDAVP, DESMOPRESSIN ACETATE  
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
DECITABINE, DECITABINE  
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE  
DEFINITY, PERFLUTREN  
DELATESTRYL, TESTOSTERONE ENANTHATE  
DELESTROGEN, ESTRADIOL VALERATE  
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)  
DELZICOL, MESALAMINE  
DEMADEX, TORSEMIDE  
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE  
DEMEROL, MEPERIDINE HYDROCHLORIDE  
DEMSEER, METYROSINE  
DENAVIR, PENCICLOVIR SODIUM  
DENDRID, IDOXURIDINE  
DEPACON, VALPROATE SODIUM  
DEPAKENE, VALPROIC ACID  
DEPAKOTE, DIVALPROEX SODIUM  
DEPAKOTE ER, DIVALPROEX SODIUM  
DEPEN, PENICILLAMINE  
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE  
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE  
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE  
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE  
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE  
DEPOCYT, CYTARABINE  
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE  
DERMABET, BETAMETHASONE VALERATE  
DERMATOP, PREDNICARBATE  
DERMATOP E EMOLLIENT, PREDNICARBATE  
DERMOTIC, FLUOCINOLONE ACETONIDE  
DESFERAL, DEFEROXAMINE MESYLATE  
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE  
DESLORATADINE, DESLORATADINE  
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE  
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
DESOGEN, DESOGESTREL  
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL  
DESONATE, DESONIDE  
DESONIDE, DESONIDE  
DESOWEN, DESONIDE  
DESOXIMETASONE, DESOXIMETASONE  
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE  
DESVENLAFAXINE, DESVENLAFAXINE  
DESVENLAFAXINE, DESVENLAFAXINE FUMARATE  
DETROL, TOLTERODINE TARTRATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* D \*\*

DETROL LA, TOLTERODINE TARTRATE  
DEXAMETHASONE, DEXAMETHASONE  
DEXAMETHASONE INTENSOL, DEXAMETHASONE  
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
DEXASPORIN, DEXAMETHASONE  
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE (OTC)  
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE  
DEXEDRINE, DEXTROAMPHETAMINE SULFATE  
DEXFERRUM, IRON DEXTRAN  
DEXILANT, DEXLANSOPRAZOLE  
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE  
DXTROAMP SACCHARATE, AMP ASPARTATE, DXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
DXTROAMP SACCHARATE, AMP ASPARTATE, DXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
DXTROAMPHETAMINE SULFATE, DXTROAMPHETAMINE SULFATE  
DXTROMETHORPHAN POLISTIREX, DXTROMETHORPHAN POLISTIREX (OTC)  
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 25%, DEXTROSE  
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE  
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE



## APPENDIX A - PRODUCT NAME INDEX

## \*\* D \*\*

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,  
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE  
 DIABETA, GLYBURIDE  
 DIABINESE, CHLORPROPAMIDE  
 DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIAMOX, ACETAZOLAMIDE  
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIASTAT, DIAZEPAM  
 DIASTAT ACUDIAL, DIAZEPAM  
 DIAZEPAM, DIAZEPAM  
 DIAZEPAM INTENSOL, DIAZEPAM  
 DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE  
 DICLEGIS, DOXYLAMINE SUCCINATE  
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM  
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM  
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE  
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE  
 DIDANOSINE, DIDANOSINE  
 DIDREX, BENZPHETAMINE HYDROCHLORIDE  
 DIDRONEL, ETIDRONATE DISODIUM  
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE  
 DIFFERIN, ADAPALENE  
 DIFICID, FIDAXOMICIN  
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE  
 DIFLUCAN, FLUCONAZOLE  
 DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
 DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 DIFLUNISAL, DIFLUNISAL  
 DIGOXIN, DIGOXIN  
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE  
 DILACOR XR, DILTIAZEM HYDROCHLORIDE  
 DILANTIN, PHENYTOIN  
 DILANTIN, PHENYTOIN SODIUM  
 DILANTIN-125, PHENYTOIN  
 DILATRATE-SR, ISOSORBIDE DINITRATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* D \*\*

DILAUDID, HYDROMORPHONE HYDROCHLORIDE  
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE  
DILT-CD, DILTIAZEM HYDROCHLORIDE  
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
DILTZAC, DILTIAZEM HYDROCHLORIDE  
DIMENHYDRINATE, DIMENHYDRINATE  
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE  
DIOVAN, VALSARTAN  
DIOVAN HCT, HYDROCHLOROTHIAZIDE  
DIPENTUM, OLSALAZINE SODIUM  
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE  
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE  
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE  
DIPRIVAN, PROPOFOL  
DIPROLENE, BETAMETHASONE DIPROPIONATE  
DIPROLENE AF, BETAMETHASONE DIPROPIONATE  
DIPYRIDAMOLE, DIPYRIDAMOLE  
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE  
DISULFIRAM, DISULFIRAM  
DISULFIRAM, DISULFIRAM  
DITROPAN XL, OXYBUTYNYN CHLORIDE  
DIURIL, CHLOROTHIAZIDE  
DIURIL, CHLOROTHIAZIDE SODIUM  
DIVALPROEX SODIUM, DIVALPROEX SODIUM  
DIVIGEL, ESTRADIOL  
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE  
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE  
DOCEFREZ, DOCETAXEL  
DOCETAXEL, DOCETAXEL  
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE  
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE  
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
DOPRAM, DOXAPRAM HYDROCHLORIDE  
DORAL, QUAZEPAM  
DORIBAX, DORIPENEM  
DORYX, DOXYCYCLINE HYCLATE  
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
DOTAREM, GADOTERATE MEGLUMINE  
DOVONEX, CALCIPOTRIENE  
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE  
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
DOXERCALCIFEROL, DOXERCALCIFEROL  
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE  
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE  
DOXTERIC, DOXYCYCLINE HYCLATE  
DOXY 100, DOXYCYCLINE HYCLATE  
DOXY 200, DOXYCYCLINE HYCLATE  
DOXYCYCLINE, DOXYCYCLINE  
DOXYCYCLINE, DOXYCYCLINE HYCLATE  
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)  
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE  
DRISDOL, ERGOCALCIFEROL  
DRONABINOL, DRONABINOL  
DROPERIDOL, DROPERIDOL  
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE  
DROXIA, HYDROXYUREA  
DTIC-DOME, DACARBAZINE  
DTPA, TECHNETIUM TC-99M PENTETATE KIT

## APPENDIX A - PRODUCT NAME INDEX

## \*\* D \*\*

DUAC, BENZOYL PEROXIDE  
 DUAVEE, BAZEDOXIFENE ACETATE  
 DUETACT, GLIMEPIRIDE  
 DUEXIS, FAMOTIDINE  
 DULERA, FORMOTEROL FUMARATE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 DUODOTE, ATROPINE  
 DUONEB, ALBUTEROL SULFATE  
 DURACLON, CLONIDINE HYDROCHLORIDE  
 DURAGESIC-100, FENTANYL  
 DURAGESIC-12, FENTANYL  
 DURAGESIC-25, FENTANYL  
 DURAGESIC-50, FENTANYL  
 DURAGESIC-75, FENTANYL  
 DURAMORPH PF, MORPHINE SULFATE  
 DURAPREP, IODINE POVACRYLEX (OTC)  
 DUREZOL, DIFLUPREDNATE  
 DUTASTERIDE, DUTASTERIDE  
 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE  
 DUTOPROL, HYDROCHLOROTHIAZIDE  
 DYAZIDE, HYDROCHLOROTHIAZIDE  
 DYLOJECT, DICLOFENAC SODIUM  
 DYMISTA, AZELASTINE HYDROCHLORIDE  
 DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)  
 DYNACIN, MINOCYCLINE HYDROCHLORIDE  
 DYRENIUM, TRIAMTERENE

## \*\* E \*\*

E-Z SCRUB 201, POVIDONE-IODINE (OTC)  
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)  
 E.E.S., ERYTHROMYCIN ETHYLSUCCINATE  
 E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE  
 E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE  
 EC-NAPROSYN, NAPROXEN  
 ECONAZOLE NITRATE, ECONAZOLE NITRATE  
 ECOZA, ECONAZOLE NITRATE  
 EDARBI, AZILSARTAN KAMEDOXOMIL  
 EDARBYCLOR, AZILSARTAN KAMEDOXOMIL  
 EDECRIN, ETHACRYNATE SODIUM  
 EDECRIN, ETHACRYNIC ACID  
 EDEX, ALPROSTADIL  
 EDLUAR, ZOLPIDEM TARTRATE  
 EDURANT, RILPIVIRINE HYDROCHLORIDE  
 EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE  
 EFFIENT, PRASUGREL HYDROCHLORIDE  
 EFUDEX, FLUOROURACIL  
 EGRIFTA, TESAMORELIN ACETATE  
 ELDEPRYL, SELEGILINE HYDROCHLORIDE  
 ELELYSO, TALIGLUCERASE ALFA  
 ELESTAT, EPINASTINE HYDROCHLORIDE  
 ELESTRIN, ESTRADIOL  
 ELIDEL, PIMECROLIMUS  
 ELIGARD, LEUPROLIDE ACETATE  
 ELIMITE, PERMETHRIN  
 ELINEST, ETHINYL ESTRADIOL  
 ELIPHOS, CALCIUM ACETATE  
 ELIQUIS, APIXABAN  
 ELIXOPHYLLIN, THEOPHYLLINE  
 ELLA, ULIPRISTAL ACETATE  
 ELLENCE, EPIRUBICIN HYDROCHLORIDE  
 ELLIOTTS B SOLUTION, CALCIUM CHLORIDE  
 ELMIRON, PENTOSAN POLYSULFATE SODIUM  
 ELOCON, MOMETASONE FUROATE  
 ELOXATIN, OXALIPLATIN  
 EMADINE, EMEDASTINE DIFUMARATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* E \*\*

EMBEDA, MORPHINE SULFATE  
EMBELINE, CLOBETASOL PROPIONATE  
EMBELINE E, CLOBETASOL PROPIONATE  
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM  
EMEND, APREPITANT  
EMEND, FOSAPREPITANT DIMEGLUMINE  
EMLA, LIDOCAINE  
EMOQUETTE, DESOGESTREL  
EMSAM, SELEGILINE  
EMTRIVA, EMTRICITABINE  
ENABLEX, DARIFENACIN HYDROBROMIDE  
ENALAPRIL MALEATE, ENALAPRIL MALEATE  
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
ENALAPRILAT, ENALAPRILAT  
ENDOMETRIN, PROGESTERONE  
ENDOSOL EXTRA, CALCIUM CHLORIDE  
ENFLURANE, ENFLURANE  
ENJUVA, ESTROGENS, CONJUGATED SYNTHETIC B  
ENLON, EDROPHONIUM CHLORIDE  
ENLON-PLUS, ATROPINE SULFATE  
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM  
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
ENPRESSE-28, ETHINYL ESTRADIOL  
ENSKYCE, DESOGESTREL  
ENTACAPONE, ENTACAPONE  
ENTECAVIR, ENTECAVIR  
ENTEREG, ALVIMOPAN  
ENTOCORT EC, BUDESONIDE  
ENULOSE, LACTULOSE  
EOVIST, GADOXETATE DISODIUM  
EPANED KIT, ENALAPRIL MALEATE  
EPANOVA, OMEGA-3-CARBOXYLIC ACIDS  
EPIDUO, ADAPALENE  
EPIFOAM, HYDROCORTISONE ACETATE  
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE  
EPINEPHRINE, EPINEPHRINE HYDROCHLORIDE  
EPIPEN, EPINEPHRINE  
EPIPEN JR., EPINEPHRINE  
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
EPITOL, CARBAMAZEPINE  
EPIVIR, LAMIVUDINE  
EPIVIR-HBV, LAMIVUDINE  
EPLERENONE, EPLERENONE  
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM  
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE  
EPZICOM, ABACAVIR SULFATE  
EQUETRO, CARBAMAZEPINE  
ERAXIS, ANIDULAFUNGIN  
ERGOCALCIFEROL, ERGOCALCIFEROL  
ERGOLOID MESYLATES, ERGOLOID MESYLATES  
ERGOMAR, ERGOTAMINE TARTRATE  
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE  
ERIVEDGE, VISMODEGIB  
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE  
ERRIN, NORETHINDRONE  
ERTACZO, SERTACONAZOLE NITRATE  
ERY-TAB, ERYTHROMYCIN  
ERYC, ERYTHROMYCIN  
ERYGEL, ERYTHROMYCIN  
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE  
ERYTHRA-DERM, ERYTHROMYCIN  
ERYTHRO-STATIN, ERYTHROMYCIN  
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE  
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE  
ERYTHROMYCIN, ERYTHROMYCIN

## APPENDIX A - PRODUCT NAME INDEX

## \*\* E \*\*

ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE  
 ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE  
 ESBRIET, PIRFENIDONE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE  
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM  
 ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM  
 ESTARYLLA, ETHINYL ESTRADIOL  
 ESTAZOLAM, ESTAZOLAM  
 ESTRACE, ESTRADIOL  
 ESTRADERM, ESTRADIOL  
 ESTRADIOL, ESTRADIOL  
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL  
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL  
 ESTRADIOL VALERATE, ESTRADIOL VALERATE  
 ESTRASORB, ESTRADIOL HEMIHYDRATE  
 ESTRING, ESTRADIOL  
 ESTROGEL, ESTRADIOL  
 ESTROPIPATE, ESTROPIPATE  
 ESTROSTEP FE, ETHINYL ESTRADIOL  
 ESZOPICLONE, ESZOPICLONE  
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE  
 ETHAMOLIN, ETHANOLAMINE OLEATE  
 ETHOSUXIMIDE, ETHOSUXIMIDE  
 ETHRANE, ENFLURANE  
 ETHYOL, AMIFOSTINE  
 ETIDRONATE DISODIUM, ETIDRONATE DISODIUM  
 ETODOLAC, ETODOLAC  
 ETOMIDATE, ETOMIDATE  
 ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE  
 ETOPOSIDE, ETOPOSIDE  
 EURAX, CROTAMITON  
 EVAMIST, ESTRADIOL  
 EVISTA, RALOXIFENE HYDROCHLORIDE  
 EVOCLIN, CLINDAMYCIN PHOSPHATE  
 EVOXAC, CEVIMELINE HYDROCHLORIDE  
 EVZIO, NALOXONE HYDROCHLORIDE  
 EXALGO, HYDROMORPHONE HYDROCHLORIDE  
 EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)  
 EXELDERM, SULCONAZOLE NITRATE  
 EXELON, RIVASTIGMINE  
 EXELON, RIVASTIGMINE TARTRATE  
 EXEMESTANE, EXEMESTANE  
 EXFORGE, AMLODIPINE BESYLATE  
 EXFORGE HCT, AMLODIPINE BESYLATE  
 EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)  
 EXJADE, DEFERASIROX  
 EXPAREL, BUPIVACAINE  
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 EXTINA, KETOCONAZOLE  
 EXTRANEAL, ICODEXTRIN

## \*\* F \*\*

FABIOR, TAZAROTENE  
 FACTIVE, GEMIFLOXACIN MESYLATE  
 FALLBACK SOLO, LEVONORGESTREL (OTC)  
 FALMINA, ETHINYL ESTRADIOL  
 FAMCICLOVIR, FAMCICLOVIR  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 FAMOTIDINE, FAMOTIDINE  
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE  
 FAMVIR, FAMCICLOVIR  
 FANAPT, ILOPERIDONE

## APPENDIX A - PRODUCT NAME INDEX

\*\* F \*\*

FARESTON, TOREMIFENE CITRATE  
FARXIGA, DAPAGLIFLOZIN  
FASLODEX, FULVESTRANT  
FAZACLO ODT, CLOZAPINE  
FELBAMATE, FELBAMATE  
FELBATOL, FELBAMATE  
FELDENE, PIROXICAM  
FELODIPINE, FELODIPINE  
FEMARA, LETROZOLE  
FEMCON FE, ETHINYL ESTRADIOL  
FEMHRT, ETHINYL ESTRADIOL  
FEMRING, ESTRADIOL ACETATE  
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)  
FEMTRACE, ESTRADIOL ACETATE  
FENOFIBRATE, FENOFIBRATE  
FENOFIBRATE (MICRONIZED), FENOFIBRATE  
FENOFIBRIC ACID, CHOLINE FENOFIBRATE  
FENOGLIDE, FENOFIBRATE  
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE  
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM  
FENTANYL CITRATE, FENTANYL CITRATE  
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE  
FENTANYL-100, FENTANYL  
FENTANYL-12, FENTANYL  
FENTANYL-25, FENTANYL  
FENTANYL-37, FENTANYL  
FENTANYL-50, FENTANYL  
FENTANYL-62, FENTANYL  
FENTANYL-75, FENTANYL  
FENTANYL-87, FENTANYL  
FENTORA, FENTANYL CITRATE  
FERAHEME, FERUMOXYTOL  
FERRIC CITRATE, FERRIC CITRATE  
FERRIPROX, DEFERIPRONE  
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX  
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE  
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
FIBRICOR, FENOFIBRIC ACID  
FINACEA, AZELAIC ACID  
FINASTERIDE, FINASTERIDE  
FIORICET W/ CODEINE, ACETAMINOPHEN  
FIORINAL, ASPIRIN  
FIORINAL W/CODEINE, ASPIRIN  
FIRAZYR, ICATIBANT ACETATE  
FIRMAGON, DEGARELIX ACETATE  
FLAGYL, METRONIDAZOLE  
FLAGYL ER, METRONIDAZOLE  
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE  
FLAREX, FLUOROMETHOLONE ACETATE  
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE  
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE  
FLECAINIDE ACETATE, FLECAINIDE ACETATE  
FLECTOR, DICLOFENAC EPOLAMINE  
FLO-PRED, PREDNISOLONE ACETATE  
FLOLAN, EPOPROSTENOL SODIUM  
FLOMAX, TAMSULOSIN HYDROCHLORIDE  
FLONASE, FLUTICASONE PROPIONATE  
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)  
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE  
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE  
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* F \*\*

FLOVENT HFA, FLUTICASONE PROPIONATE  
FLOXIN OTIC, OFLOXACIN  
FLOXURIDINE, FLOXURIDINE  
FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
FLUCONAZOLE, FLUCONAZOLE  
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
FLUCYTOSINE, FLUCYTOSINE  
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE  
FLUMADINE, RIMANTADINE HYDROCHLORIDE  
FLUMAZENIL, FLUMAZENIL  
FLUNISOLIDE, FLUNISOLIDE  
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
FLUOCINONIDE, FLUOCINONIDE  
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE  
FLUORESCITE, FLUORESCEIN SODIUM  
FLUROPLEX, FLUOROURACIL  
FLUOROURACIL, FLUOROURACIL  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FLUOXYMESTERONE, FLUOXYMESTERONE  
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE  
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE  
FLURBIPROFEN, FLURBIPROFEN  
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM  
FLUTAMIDE, FLUTAMIDE  
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM  
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
FML, FLUOROMETHOLONE  
FML FORTE, FLUOROMETHOLONE  
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)  
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE  
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE  
FOLIC ACID, FOLIC ACID  
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA  
FOLOTYN, PRALATREXATE  
FOMEPIZOLE, FOMEPIZOLE  
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM  
FORADIL, FORMOTEROL FUMARATE  
FORANE, ISOFLURANE  
FORFIVO XL, BUPROPION HYDROCHLORIDE  
FORTAMET, METFORMIN HYDROCHLORIDE  
FORTAZ, CEFTAZIDIME  
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM  
FORTEO, TERIPARATIDE RECOMBINANT HUMAN  
FORTESTA, TESTOSTERONE  
FORTICAL, CALCITONIN SALMON RECOMBINANT  
FOSAMAX, ALENDRONATE SODIUM  
FOSAMAX PLUS D, ALENDRONATE SODIUM  
FOSCARNET SODIUM, FOSCARNET SODIUM  
FOSCAVIR, FOSCARNET SODIUM  
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
FOSRENOL, LANTHANUM CARBONATE  
FRAGMIN, DALTEPARIN SODIUM  
FREAMINE HBC 6.9%, AMINO ACIDS  
FREAMINE III 10%, AMINO ACIDS  
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS  
FREAMINE III 8.5%, AMINO ACIDS  
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS

## APPENDIX A - PRODUCT NAME INDEX

## \*\* F \*\*

FROVA, FROVATRIPTAN SUCCINATE  
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE  
 FULYZAQ, CROFELEMER  
 FURADANTIN, NITROFURANTOIN  
 FUROSEMIDE, FUROSEMIDE  
 FUSILEV, LEVOLEUCOVORIN CALCIUM  
 FUZEON, ENFUVIRTIDE  
 FYCOMPA, PERAMPANEL

## \*\* G \*\*

GABAPENTIN, GABAPENTIN  
 GABITRIL, TIAGABINE HYDROCHLORIDE  
 GABLOFEN, BACLOFEN  
 GADAVIST, GADOBUTROL  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67  
 GALZIN, ZINC ACETATE  
 GANCICLOVIR, GANCICLOVIR SODIUM  
 GANIRELIX ACETATE, GANIRELIX ACETATE  
 GASTROCROM, CROMOLYN SODIUM  
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE  
 GATIFLOXACIN, GATIFLOXACIN  
 GATTEX KIT, TEDUGLUTIDE RECOMBINANT  
 GAVISCON, ALUMINUM HYDROXIDE (OTC)  
 GELNIQUE, OXYBUTYNIN CHLORIDE  
 GELNIQUE 3%, OXYBUTYNIN  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GEMFIBROZIL, GEMFIBROZIL  
 GEMZAR, GEMCITABINE HYDROCHLORIDE  
 GEN-XENE, CLORAZEPATE DIPOTASSIUM  
 GENERLAC, LACTULOSE  
 GENGRAF, CYCLOSPORINE  
 GENOPTIC, GENTAMICIN SULFATE  
 GENOTROPIN, SOMATROPIN RECOMBINANT  
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT  
 GENTAK, GENTAMICIN SULFATE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE  
 GEODON, ZIPRASIDONE HYDROCHLORIDE  
 GEODON, ZIPRASIDONE MESYLATE  
 GIAZO, BALSALAZIDE DISODIUM  
 GILDAGIA, ETHINYL ESTRADIOL  
 GILDESS 1.5/30, ETHINYL ESTRADIOL  
 GILDESS 1/20, ETHINYL ESTRADIOL  
 GILDESS 24 FE, ETHINYL ESTRADIOL  
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL  
 GILDESS FE 1/20, ETHINYL ESTRADIOL  
 GILENYA, FINGOLIMOD  
 GILOTRIF, AFATINIB DIMALEATE  
 GLEEVEC, IMATINIB MESYLATE  
 GLEOSTINE, LOMUSTINE  
 GLIADEL, CARMUSTINE  
 GLIMEPIRIDE, GLIMEPIRIDE  
 GLIPIZIDE, GLIPIZIDE  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
 GLOFIL-125, IOTHALAMATE SODIUM I-125  
 GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT  
 GLUCAGON, GLUCAGON RECOMBINANT  
 GLUCOPHAGE, METFORMIN HYDROCHLORIDE  
 GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE  
 GLUCOTROL, GLIPIZIDE  
 GLUCOTROL XL, GLIPIZIDE  
 GLUCOVANCE, GLYBURIDE  
 GLUMETZA, METFORMIN HYDROCHLORIDE  
 GLYBURIDE, GLYBURIDE



## APPENDIX A - PRODUCT NAME INDEX

## \*\* G \*\*

GLYBURIDE (MICRONIZED), GLYBURIDE  
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE  
 GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)  
 GLYCOLAX, POLYETHYLENE GLYCOL 3350  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 GLYDO, LIDOCAINE HYDROCHLORIDE  
 GLYNASE, GLYBURIDE  
 GLYSET, MIGLITOL  
 GOLYTELY, POLYETHYLENE GLYCOL 3350  
 GONAL-F, FOLLITROPIN ALFA/BETA  
 GONAL-F RFF, FOLLITROPIN ALFA/BETA  
 GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA  
 GRALISE, GABAPENTIN  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE  
 GRANISTERON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 GRIFULVIN V, GRISEOFULVIN, MICROSIZED  
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZED  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZED  
 GRISEOFULVIN, ULTRAMICROSIZED, GRISEOFULVIN, ULTRAMICROSIZED  
 GRISEOFULVIN, ULTRAMICROSIZED, GRISEOFULVIN, ULTRAMICROSIZED  
 GUAIFENESIN, GUAIFENESIN (OTC)  
 GUANABENZ ACETATE, GUANABENZ ACETATE  
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE  
 GYNE-LOTTRIMIN, CLOTRIMAZOLE (OTC)  
 GYNE-LOTTRIMIN 3, CLOTRIMAZOLE (OTC)  
 GYNE-LOTTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 GYNE-LOTTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)

## \*\* H \*\*

H.P. ACTHAR GEL, CORTICOTROPIN  
 HABITROL, NICOTINE (OTC)  
 HALAVEN, ERIBULIN MESYLATE  
 HALCION, TRIAZOLAM  
 HALDOL, HALOPERIDOL DECANOATE  
 HALDOL, HALOPERIDOL LACTATE  
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
 HALOG, HALCINONIDE  
 HALOPERIDOL, HALOPERIDOL  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE  
 HARVONI, LEDIPASVIR  
 HEATHER, NORETHINDRONE  
 HECTOROL, DOXERCALCIFEROL  
 HEMABATE, CARBOPROST TROMETHAMINE  
 HEMANGEOL, PROPRANOLOL HYDROCHLORIDE  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPATAMINE 8%, AMINO ACIDS  
 HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT  
 HEPSERA, ADEFOVIR DIPIVOXIL  
 HERPLEX, IDOXURIDINE

## APPENDIX A - PRODUCT NAME INDEX

\*\* H \*\*

HETLIOZ, TASIMELTEON  
 HEXABRIX, IOXAGLATE MEGLUMINE  
 HEXALEN, ALTRETAMINE  
 HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)  
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)  
 HICON, SODIUM IODIDE I-131  
 HIPREX, METHENAMINE HIPPURATE  
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE  
 HORIZANT, GABAPENTIN ENACARBIL  
 HUMALOG, INSULIN LISPRO RECOMBINANT  
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT  
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMATROPE, SOMATROPIN RECOMBINANT  
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN R, INSULIN RECOMBINANT HUMAN  
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)  
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE  
 HYDERGINE, ERGOLOID MESYLATES  
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDREA, HYDROXYUREA  
 HYDRO-RX, HYDROCORTISONE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE  
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE  
 HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE  
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,  
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,  
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX  
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX  
 HYDROCORTISONE, HYDROCORTISONE  
 HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE  
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL  
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE  
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE  
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 HYDROXYUREA, HYDROXYUREA  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE  
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN  
 HYSINGLA, HYDROCODONE BITARTRATE  
 HYZAAR, HYDROCHLOROTHIAZIDE

\*\* I \*\*

IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 IBU-TAB, IBUPROFEN  
 IBU-TAB 200, IBUPROFEN (OTC)  
 IBUPROFEN, IBUPROFEN (OTC)  
 IBUPROFEN, IBUPROFEN  
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)  
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
 IBUPROHM, IBUPROFEN (OTC)  
 IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)

## APPENDIX A - PRODUCT NAME INDEX

\*\* I \*\*

IBUTILIDE FUMARATE, IBUTILIDE FUMARATE  
IC-GREEN, INDOCYANINE GREEN  
ICLUSIG, PONATINIB HYDROCHLORIDE  
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE  
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE  
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE  
IDKIT:HP, CITRIC ACID  
IFEX, IFOSFAMIDE  
IFOSFAMIDE, IFOSFAMIDE  
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE  
ILEVRO, NEPAFENAC  
ILUVIEN, FLUOCINOLONE ACETONIDE  
IMBRUVICA, IBRUTINIB  
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM  
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE  
IMIQUIMOD, IMIQUIMOD  
IMITREX, SUMATRIPTAN  
IMITREX, SUMATRIPTAN SUCCINATE  
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE  
IMODIUM, LOPERAMIDE HYDROCHLORIDE  
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)  
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)  
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)  
IMPAVIDO, MILTEFOSINE  
IMPLANON, ETNOGESTREL  
IMURAN, AZATHIOPRINE  
INAPSINE, DROPERIDOL  
INCIVEK, TELAPREVIR  
INCRELEX, MECASERMIN RECOMBINANT  
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE  
INDAPAMIDE, INDAPAMIDE  
INDERAL LA, PROPRANOLOL HYDROCHLORIDE  
INDERIDE-40/25, HYDROCHLOROTHIAZIDE  
INDICLOR, INDIUM IN-111 CHLORIDE  
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE  
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE  
INDOCIN, INDOMETHACIN  
INDOCIN, INDOMETHACIN SODIUM  
INDOCYANINE GREEN, INDOCYANINE GREEN  
INDOMETHACIN, INDOMETHACIN  
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM  
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)  
INFASURF PRESERVATIVE FREE, CALFACTANT  
INFED, IRON DEXTRAN  
INFUMORPH, MORPHINE SULFATE  
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE  
INFUVITE PEDIATRIC, ASCORBIC ACID  
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID  
INJECTAFER, FERRIC CARBOXYMALTOSE  
INLYTA, AXITINIB  
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE  
INOMAX, NITRIC OXIDE  
INSPIRA, EPLERENONE  
INTEGRILIN, EPTIFIBATIDE  
INTELENCE, ETRAVIRINE  
INTERMEZZO, ZOLPIDEM TARTRATE  
INTRALIPID 10%, SOYBEAN OIL  
INTRALIPID 20%, SOYBEAN OIL  
INTRALIPID 30%, SOYBEAN OIL  
INTROVALE, ETHINYL ESTRADIOL  
INTUNIV, GUANFACINE HYDROCHLORIDE  
INVANZ, ERTAPENEM SODIUM  
INVEGA, PALIPERIDONE  
INVEGA SUSTENNA, PALIPERIDONE PALMITATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* I \*\*

INVIRASE, SAQUINAVIR MESYLATE  
 INVOKAMET, CANAGLIFLOZIN  
 INVOKANA, CANAGLIFLOZIN  
 IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 IOPAMIDOL-250, IOPAMIDOL  
 IOPAMIDOL-300, IOPAMIDOL  
 IOPAMIDOL-370, IOPAMIDOL  
 IOPIDINE, APRACLONIDINE HYDROCHLORIDE  
 IOSAT, POTASSIUM IODIDE (OTC)  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
 IPRIVASK, DESIRUDIN RECOMBINANT  
 IRBESARTAN, IRBESARTAN  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 ISENTRESS, RALTEGRAVIR POTASSIUM  
 ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE  
 ISOFLURANE, ISOFLURANE  
 ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 ISONIAZID, ISONIAZID  
 ISOPTO CARPINE, Pilocarpine Hydrochloride  
 ISORDIL, ISOSORBIDE DINITRATE  
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
 ISOSULFAN BLUE, ISOSULFAN BLUE  
 ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE  
 ISOVUE-200, IOPAMIDOL  
 ISOVUE-250, IOPAMIDOL  
 ISOVUE-300, IOPAMIDOL  
 ISOVUE-370, IOPAMIDOL  
 ISOVUE-M 200, IOPAMIDOL  
 ISOVUE-M 300, IOPAMIDOL  
 ISRADIPINE, ISRADIPINE  
 ISTALOL, TIMOLOL MALEATE  
 ISTODAX, ROMIDEPSIN  
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE  
 ITRACONAZOLE, ITRACONAZOLE  
 IVERMECTIN, IVERMECTIN  
 IVY BLOCK, BENTOQUATAM (OTC)  
 IXEMPRA KIT, IXABEPILONE  
 IZBA, TRAVOPROST

\*\* J \*\*

JAKAFI, RUXOLITINIB PHOSPHATE  
 JALYN, DUTASTERIDE  
 JANTOVEN, WARFARIN SODIUM  
 JANUMET, METFORMIN HYDROCHLORIDE  
 JANUMET XR, METFORMIN HYDROCHLORIDE  
 JANUVIA, SITAGLIPTIN PHOSPHATE  
 JARDIANCE, EMPAGLIFLOZIN  
 JEANATOPE, ALBUMIN IODINATED I-125 SERUM  
 JENCYCLA, NORETHINDRONE  
 JENTADUETO, LINAGLIPTIN  
 JEVTANA KIT, CABAZITAXEL  
 JUBLIA, EFINAACONAZOLE  
 JUNEL 1.5/30, ETHINYL ESTRADIOL  
 JUNEL 1/20, ETHINYL ESTRADIOL  
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL

## APPENDIX A - PRODUCT NAME INDEX

## \*\* J \*\*

JUNEL FE 1/20, ETHINYL ESTRADIOL  
 JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)  
 JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)  
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)  
 JUXTAPID, LOMITAPIDE MESYLATE

## \*\* K \*\*

K-TAB, POTASSIUM CHLORIDE  
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS  
 KADIAN, MORPHINE SULFATE  
 KALETRA, LOPINAVIR  
 KALEXATE, SODIUM POLYSTYRENE SULFONATE  
 KALYDECO, IVACAFTOR  
 KANAMYCIN SULFATE, KANAMYCIN SULFATE  
 KAPVAY, CLONIDINE HYDROCHLORIDE  
 KARBINAL ER, CARBINOXAMINE MALEATE  
 KARIVA, DESOGESTREL  
 KAYEXALATE, SODIUM POLYSTYRENE SULFONATE  
 KAZANO, ALOGLIPTIN BENZOATE  
 KEFLEX, CEPHALEXIN  
 KEFZOL, CEFAZOLIN SODIUM  
 KELNOR, ETHINYL ESTRADIOL  
 KENALOG, TRIAMCINOLONE ACETONIDE  
 KENALOG-10, TRIAMCINOLONE ACETONIDE  
 KENALOG-40, TRIAMCINOLONE ACETONIDE  
 KEPPRA, LEVETIRACETAM  
 KEPPRA XR, LEVETIRACETAM  
 KERYDIN, TAVABOROLE  
 KETALAR, KETAMINE HYDROCHLORIDE  
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE  
 KETEK, TELITHROMYCIN  
 KETOCONAZOLE, KETOCONAZOLE  
 KETOPROFEN, KETOPROFEN  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)  
 KETOZOLE, KETOCONAZOLE  
 KHEDEZLA, DESVENLAFAXINE  
 KINEVAC, SINCALIDE  
 KIONEX, SODIUM POLYSTYRENE SULFONATE  
 KITABIS PAK, TOBRAMYCIN  
 KLARON, SULFACETAMIDE SODIUM  
 KLONOPIN, CLONAZEPAM  
 KLOR-CON, POTASSIUM CHLORIDE  
 KLOR-CON M10, POTASSIUM CHLORIDE  
 KLOR-CON M15, POTASSIUM CHLORIDE  
 KLOR-CON M20, POTASSIUM CHLORIDE  
 KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE  
 KORLYM, MIFEPRISTONE  
 KURVELO, ETHINYL ESTRADIOL  
 KUVAN, SAPROPTERIN DIHYDROCHLORIDE  
 KYNAMRO, MIPOMERSEN SODIUM  
 KYPROLIS, CARFILZOMIB

## \*\* L \*\*

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LAC-HYDRIN, AMMONIUM LACTATE  
 LACRISERT, HYDROXYPROPYL CELLULOSE  
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LACTULOSE, LACTULOSE  
 LAMICTAL, LAMOTRIGINE  
 LAMICTAL CD, LAMOTRIGINE  
 LAMICTAL ODT, LAMOTRIGINE  
 LAMICTAL XR, LAMOTRIGINE

## APPENDIX A - PRODUCT NAME INDEX

\*\* L \*\*

LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)  
 LAMISIL, TERBINAFINE HYDROCHLORIDE  
 LAMISIL AT, TERBINAFINE (OTC)  
 LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)  
 LAMIVUDINE, LAMIVUDINE  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LAMOTRIGINE, LAMOTRIGINE  
 LAMPRENE, CLOFAZIMINE  
 LANIAZID, ISONIAZID  
 LANORINAL, ASPIRIN  
 LANOXIN, DIGOXIN  
 LANOXIN PEDIATRIC, DIGOXIN  
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN  
 LANTUS, INSULIN GLARGINE RECOMBINANT  
 LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT  
 LARIN 1.5/30, ETHINYL ESTRADIOL  
 LARIN 1/20, ETHINYL ESTRADIOL  
 LARIN FE 1.5/30, ETHINYL ESTRADIOL  
 LARIN FE 1/20, ETHINYL ESTRADIOL  
 LAROTID, AMOXICILLIN  
 LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE  
 LASIX, FUROSEMIDE  
 LASTACAFT, ALCAFTADINE  
 LATANOPROST, LATANOPROST  
 LATISSE, BIMATOPROST  
 LATUDA, LURASIDONE HYDROCHLORIDE  
 LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350  
 LAZANDA, FENTANYL CITRATE  
 LEFLUNOMIDE, LEFLUNOMIDE  
 LESCOL, FLUVASTATIN SODIUM  
 LESCOL XL, FLUVASTATIN SODIUM  
 LESSINA-28, ETHINYL ESTRADIOL  
 LETAIRIS, AMBRISENTAN  
 LETROZOLE, LETROZOLE  
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM  
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM  
 LEUKERAN, CHLORAMBUCIL  
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE  
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE  
 LEVAQUIN, LEVOFLOXACIN  
 LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVEMIR, INSULIN DETEMIR RECOMBINANT  
 LEVEMIR FLEXPEN, INSULIN DETEMIR RECOMBINANT  
 LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM  
 LEVITRA, VARDENAFIL HYDROCHLORIDE  
 LEVO-T, LEVOTHYROXINE SODIUM \*\*  
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE  
 LEVOCARNITINE, LEVOCARNITINE  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVONEST, ETHINYL ESTRADIOL  
 LEVONORGESTREL, LEVONORGESTREL (OTC)  
 LEVONORGESTREL, LEVONORGESTREL  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVOPHED, NOREPINEPHRINE BITARTRATE  
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL  
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE  
 LEVOTHROID, LEVOTHYROXINE SODIUM \*\*

## APPENDIX A - PRODUCT NAME INDEX

## \*\* L \*\*

LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM  
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM \*\*  
 LEVOXYL, LEVOTHYROXINE SODIUM \*\*  
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE  
 LEXAPRO, ESCITALOPRAM OXALATE  
 LEXISCAN, REGADENOSON  
 LEXIVA, FOSAMPRENAVIR CALCIUM  
 LIALDA, MESALAMINE  
 LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE  
 LIDEX, FLUOCINONIDE  
 LIDOCAINE, LIDOCAINE  
 LIDOCAINE AND PRILOCAINE, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE  
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE  
 LIDODERM, LIDOCAINE  
 LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE  
 LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE  
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE  
 LINDANE, LINDANE  
 LINEZOLID, LINEZOLID  
 LINZESS, LINACLOTIDE  
 LIORESAL, BACLOFEN  
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM  
 LIPIODOL, ETHIODIZED OIL  
 LIPITOR, ATORVASTATIN CALCIUM  
 LIPOFEN, FENOFIBRATE  
 LIPTRUZET, ATORVASTATIN CALCIUM  
 LISINOPRIL, LISINOPRIL  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 LITHIUM CITRATE, LITHIUM CITRATE  
 LITHOBID, LITHIUM CARBONATE  
 LITHOSTAT, ACETOHYDROXAMIC ACID  
 LIVALO, PITAVASTATIN CALCIUM  
 LO LOESTRIN FE, ETHINYL ESTRADIOL  
 LO MINASTRIN FE, ETHINYL ESTRADIOL  
 LO/OVRAL-28, ETHINYL ESTRADIOL  
 LOCID, HYDROCORTISONE BUTYRATE  
 LOCID LIPOCREAM, HYDROCORTISONE BUTYRATE  
 LODOSYN, CARBIDOPA  
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL  
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL  
 LOESTRIN 24 FE, ETHINYL ESTRADIOL  
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL  
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL  
 LOMOTIL, ATROPINE SULFATE  
 LONOX, ATROPINE SULFATE  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE  
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 LOPID, GEMFIBROZIL  
 LOPRESSOR, METOPROLOL TARTRATE  
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE  
 LOPROX, CICLOPIROX

## APPENDIX A - PRODUCT NAME INDEX

## \*\* L \*\*

LOPURIN, ALLOPURINOL  
 LORATADINE, LORATADINE (OTC)  
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)  
 LORATADINE REDIDOSE, LORATADINE (OTC)  
 LORAZEPAM, LORAZEPAM  
 LORAZEPAM INTENSOL, LORAZEPAM  
 LORAZEPAM PRESERVATIVE FREE, LORAZEPAM  
 LORYNA, DROSPIRENONE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSEASONIQUE, ETHINYL ESTRADIOL  
 LOTEMAX, LOTEPIREDNOL ETABONATE  
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE  
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE  
 LOTREL, AMLODIPINE BESYLATE  
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)  
 LOTRISONE, BETAMETHASONE DIPROPIONATE  
 LOTRONEX, ALOSETRON HYDROCHLORIDE  
 LOVASTATIN, LOVASTATIN  
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS  
 LOVENOX, ENOXAPARIN SODIUM  
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE  
 LTA II KIT, LIDOCAINE HYDROCHLORIDE  
 LUFYLLIN, DYPHYLLINE  
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES  
 LUMIGAN, BIMATOPROST  
 LUNESTA, ESZOPICLONE  
 LUPANETA PACK, LEUPROLIDE ACETATE  
 LUPRON DEPOT, LEUPROLIDE ACETATE  
 LUPRON DEPOT-PED, LEUPROLIDE ACETATE  
 LUVOX, FLUVOXAMINE MALEATE  
 LUVOX CR, FLUVOXAMINE MALEATE  
 LUXIQ, BETAMETHASONE VALERATE  
 LUZU, LULICONAZOLE  
 LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT  
 LYRICA, PREGABALIN  
 LYSODREN, MITOTANE  
 LYSTEDA, TRANEXAMIC ACID

## \*\* M \*\*

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 M.V.I. ADULT, ASCORBIC ACID  
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID  
 M.V.I. PEDIATRIC, ASCORBIC ACID  
 M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID  
 MACROBID, NITROFURANTOIN  
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE  
 MACUGEN, PEGAPTANIB SODIUM  
 MAFENIDE ACETATE, MAFENIDE ACETATE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNEVIST, GADOPENTETATE DIMEGLUMINE  
 MAKENA, HYDROXYPROGESTERONE CAPROATE  
 MALARONE, ATOVAQUONE  
 MALARONE PEDIATRIC, ATOVAQUONE  
 MALATHION, MALATHION  
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE  
 MANNITOL 10%, MANNITOL  
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL  
 MANNITOL 15%, MANNITOL  
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL



## APPENDIX A - PRODUCT NAME INDEX

\*\* M \*\*

MANNITOL 20%, MANNITOL  
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL  
MANNITOL 25%, MANNITOL  
MANNITOL 5%, MANNITOL  
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL  
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL  
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE  
MARCAINE, BUPIVACAINE HYDROCHLORIDE  
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
MARINOL, DRONABINOL  
MARLISSA, ETHINYL ESTRADIOL  
MARPLAN, ISOCARBOXAZID  
MARQIBO KIT, VINCRISTINE SULFATE  
MATULANE, PROCARBAZINE HYDROCHLORIDE  
MAVIK, TRANDOLAPRIL  
MAXAIR, PIRBUTEROL ACETATE  
MAXALT, RIZATRIPTAN BENZOATE  
MAXALT-MLT, RIZATRIPTAN BENZOATE  
MAXIDEX, DEXAMETHASONE  
MAXIPIME, CEFEPIME HYDROCHLORIDE  
MAXITROL, DEXAMETHASONE  
MAXZIDE, HYDROCHLOROTHIAZIDE  
MAXZIDE-25, HYDROCHLOROTHIAZIDE  
MD-76R, DIATRIZOATE MEGLUMINE  
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE  
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT  
MEBENDAZOLE, MEBENDAZOLE  
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE  
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM  
MEDROL, METHYLPREDNISOLONE  
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE  
MEFENAMIC ACID, MEFENAMIC ACID  
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE  
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM  
MEGACE, MEGESTROL ACETATE  
MEGACE ES, MEGESTROL ACETATE  
MEGATOPE, ALBUMIN IODINATED I-131 SERUM  
MEGESTROL ACETATE, MEGESTROL ACETATE  
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE  
MELOXICAM, MELOXICAM  
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE  
MEMBRANEBLUE, TRYPAN BLUE  
MEN'S ROGAINE, MINOXIDIL (OTC)  
MENEST, ESTROGENS, ESTERIFIED  
MENOPUR, MENOTROPINS (FSH)  
MENOSTAR, ESTRADIOL  
MENTAX, BUTENAFINE HYDROCHLORIDE  
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE  
MEPHYTON, PHYTONADIONE  
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE  
MEPROBAMATE, MEPROBAMATE  
MEPRON, ATOVAQUONE  
MERCAPTOPYRINE, MERCAPTOPYRINE  
MEROPENEM, MEROPENEM  
MERREM, MEROPENEM  
MESALAMINE, MESALAMINE  
MESNA, MESNA  
MESNEX, MESNA  
MESTINON, PYRIDOSTIGMINE BROMIDE  
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* M \*\*

METADATE ER, METHYLPHENIDATE HYDROCHLORIDE  
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE  
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE  
METASTRON, STRONTIUM CHLORIDE SR-89  
METAXALONE, METAXALONE  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE  
METHADOSE, METHADONE HYDROCHLORIDE  
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE  
METHAZOLAMIDE, METHAZOLAMIDE  
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE  
METHERGINE, METHYLERGONOVINE MALEATE  
METHIMAZOLE, METHIMAZOLE  
METHOCARBAMOL, METHOCARBAMOL  
METHOCARBAMOL AND ASPIRIN, ASPIRIN  
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM  
METHOTREXATE SODIUM, METHOTREXATE SODIUM  
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
METHOXSALEN, METHOXSALEN  
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE  
METHYLCLOTHIAZIDE, METHYLCLOTHIAZIDE  
METHYLDOPA, METHYLDOPA  
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE  
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE  
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE  
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE  
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
METHYLPREDNISOLONE, METHYLPREDNISOLONE  
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE  
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE  
METHYLTESTOSTERONE, METHYLTESTOSTERONE  
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE  
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE  
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
METOLAZONE, METOLAZONE  
METOPIRONE, METYRAPONE  
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE  
METOPROLOL TARTRATE, METOPROLOL TARTRATE  
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE  
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE  
METROCREAM, METRONIDAZOLE  
METROGEL, METRONIDAZOLE  
METROGEL-VAGINAL, METRONIDAZOLE  
METROLOTION, METRONIDAZOLE  
METRONIDAZOLE, METRONIDAZOLE  
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE  
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE  
MIACALCIN, CALCITONIN SALMON  
MICARDIS, TELMISARTAN  
MICARDIS HCT, HYDROCHLOROTHIAZIDE  
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)  
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)  
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)  
MICONAZOLE NITRATE, MICONAZOLE NITRATE  
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MICORT-HC, HYDROCORTISONE ACETATE  
MICRO-K, POTASSIUM CHLORIDE  
MICRO-K 10, POTASSIUM CHLORIDE  
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL  
MICROGESTIN 1/20, ETHINYL ESTRADIOL

## APPENDIX A - PRODUCT NAME INDEX

\*\* M \*\*

MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL  
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL  
MICRONOR, NORETHINDRONE  
MICROZIDE, HYDROCHLOROTHIAZIDE  
MIDAMOR, AMILORIDE HYDROCHLORIDE  
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE  
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE  
MIDOL LIQUID GELS, IBUPROFEN (OTC)  
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
MIFEPREX, MIFEPRISTONE  
MIGERGOT, CAFFEINE  
MIGRANAL, DIHYDROERGOTAMINE MESYLATE  
MILRINONE LACTATE, MILRINONE LACTATE  
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE  
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE  
MINASTRIN 24 FE, ETHINYL ESTRADIOL  
MINIPRESS, PRAZOSIN HYDROCHLORIDE  
MINIRIN, DESMOPRESSIN ACETATE  
MINITRAN, NITROGLYCERIN  
MINIVELLE, ESTRADIOL  
MINOCIN, MINOCYCLINE HYDROCHLORIDE  
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
MINOXIDIL, MINOXIDIL (OTC)  
MINOXIDIL, MINOXIDIL  
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)  
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)  
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
MIOCHOL-E, ACETYLCHOLINE CHLORIDE  
MIOSTAT, CARBACHOL  
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)  
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE  
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE  
MIRENA, LEVONORGESTREL  
MIRTAZAPINE, MIRTAZAPINE  
MIRVASO, BRIMONIDINE TARTRATE  
MISOPROSTOL, MISOPROSTOL  
MITIGARE, COLCHICINE  
MITOMYCIN, MITOMYCIN  
MITOSOL, MITOMYCIN  
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
MOBIC, MELOXICAM  
MODAFINIL, MODAFINIL  
MODICON 28, ETHINYL ESTRADIOL  
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE  
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
MOMETASONE FUROATE, MOMETASONE FUROATE  
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT 3, MICONAZOLE NITRATE (OTC)  
MONISTAT 3, MICONAZOLE NITRATE  
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)  
MONISTAT 7, MICONAZOLE NITRATE (OTC)  
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MONO-LINYAH, ETHINYL ESTRADIOL  
MONODOX, DOXYCYCLINE  
MONOKET, ISOSORBIDE MONONITRATE  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
MONUROL, FOSFOMYCIN TROMETHAMINE  
MORPHINE SULFATE, MORPHINE SULFATE  
MOTOFEN, ATROPINE SULFATE  
MOTRIN IB, IBUPROFEN (OTC)

## APPENDIX A - PRODUCT NAME INDEX

## \*\* M \*\*

MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)  
 MOVANTIK, NALOXEGOL OXALATE  
 MOVIPREP, ASCORBIC ACID  
 MOXATAG, AMOXICILLIN  
 MOXEZA, MOXIFLOXACIN HYDROCHLORIDE  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 MOZOBIL, PLERIXAFOR  
 MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT  
 MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM  
 MS CONTIN, MORPHINE SULFATE  
 MUCINEX, GUAIFENESIN (OTC)  
 MUCINEX D, GUAIFENESIN (OTC)  
 MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)  
 MULTAQ, DRONEDARONE HYDROCHLORIDE  
 MULTIHANCE, GADOBENATE DIMEGLUMINE  
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE  
 MUPIROCIN, MUPIROCIN  
 MUPIROCIN, MUPIROCIN CALCIUM  
 MUSE, ALPROSTADIL  
 MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE  
 MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE  
 MYCAMINE, MICAFUNGIN SODIUM  
 MYCELEX-7, CLOTRIMAZOLE (OTC)  
 MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
 MYCOBUTIN, RIFABUTIN  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID  
 MYDRIACYL, TROPICAMIDE  
 MYFORTIC, MYCOPHENOLIC ACID  
 MYLERAN, BUSULFAN  
 MYORISAN, ISOTRETINOIN  
 MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT  
 MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT  
 MYRBETRIQ, MIRABEGRON  
 MYSOLINE, PRIMIDONE  
 MYZILRA, ETHINYL ESTRADIOL

## \*\* N \*\*

NABUMETONE, NABUMETONE  
 NADOLOL, NADOLOL  
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM  
 NAFTIN, NAFTIFINE HYDROCHLORIDE  
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE  
 NALFON, FENOPROFEN CALCIUM  
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM  
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE  
 NAMENDA, MEMANTINE HYDROCHLORIDE  
 NAMENDA XR, MEMANTINE HYDROCHLORIDE  
 NAMZARIC, DONEPEZIL HYDROCHLORIDE  
 NANDROLONE DECANOATE, NANDROLONE DECANOATE  
 NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE  
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 NAPRELAN, NAPROXEN SODIUM  
 NAPROSYN, NAPROXEN  
 NAPROXEN, NAPROXEN  
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 NARDIL, PHENELZINE SULFATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* N \*\*

NAROPIN, ROPIVACAINE HYDROCHLORIDE  
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)  
 NASCOBAL, CYANOCOBALAMIN  
 NASONEX, MOMETASONE FUROATE MONOHYDRATE  
 NATACYN, NATAMYCIN  
 NATAZIA, DIENOGEST  
 NATEGLINIDE, NATEGLINIDE  
 NATESTO, TESTOSTERONE  
 NATRECOR, NESIRITIDE RECOMBINANT  
 NATROBA, SPINOSAD  
 NAVANE, THIOTHIXENE  
 NAVELBINE, VINORELBINE TARTRATE  
 NAVSTEL, CALCIUM CHLORIDE  
 NEBUPENT, PENTAMIDINE ISETHIONATE  
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM  
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE  
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM  
 NEO-FRADIN, NEOMYCIN SULFATE  
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE  
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC  
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN  
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE  
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC  
 NEOMYCIN SULFATE, NEOMYCIN SULFATE  
 NEOPAP, ACETAMINOPHEN (OTC)  
 NEOPROFEN, IBUPROFEN LYSINE  
 NEORAL, CYCLOSPORINE  
 NEOSPORIN, GRAMICIDIN  
 NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE  
 NEPHRAMINE 5.4%, AMINO ACIDS  
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE  
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE  
 NESINA, ALOGLIPTIN BENZOATE  
 NEUPRO, ROTIGOTINE  
 NEURACEQ, FLORBETABEN F-18  
 NEUROLITE, TECHNETIUM TC-99M BICISATE KIT  
 NEURONTIN, GABAPENTIN  
 NEVANAC, NEPAFENAC  
 NEVIRAPINE, NEVIRAPINE  
 NEXAVAR, SORAFENIB TOSYLATE  
 NEXIUM, ESOMEPRAZOLE MAGNESIUM  
 NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)  
 NEXIUM IV, ESOMEPRAZOLE SODIUM  
 NEXPLANON, ETNOGESTREL  
 NEXTERONE, AMIODARONE HYDROCHLORIDE  
 NIACIN, NIACIN  
 NIACOR, NIACIN  
 NIASPAN, NIACIN  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 NICODERM CQ, NICOTINE (OTC)  
 NICORETTE, NICOTINE POLACRILEX (OTC)  
 NICORETTE (MINT), NICOTINE POLACRILEX (OTC)  
 NICOTINE, NICOTINE (OTC)  
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)  
 NICOTROL, NICOTINE  
 NIFEDIPINE, NIFEDIPINE  
 NIKKI, DROSPIRENONE  
 NILANDRON, NILUTAMIDE  
 NIMBEX, CISATRACURIUM BESYLATE  
 NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE  
 NIMODIPINE, NIMODIPINE  
 NIPENT, PENTOSTATIN  
 NISOLDIPINE, NISOLDIPINE

## APPENDIX A - PRODUCT NAME INDEX

\*\* N \*\*

NITHIODOLE, SODIUM NITRITE  
 NITRO-DUR, NITROGLYCERIN  
 NITROFURANTOIN, NITROFURANTOIN  
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE  
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN  
 NITROGLYCERIN, NITROGLYCERIN  
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN  
 NITROLINGUAL PUMPSPRAY, NITROGLYCERIN  
 NITROMIST, NITROGLYCERIN  
 NITROPRESS, SODIUM NITROPRUSSIDE  
 NITROSTAT, NITROGLYCERIN  
 NIX, PERMETHRIN (OTC)  
 NIZATIDINE, NIZATIDINE  
 NIZORAL, KETOCONAZOLE  
 NIZORAL A-D, KETOCONAZOLE (OTC)  
 NOR-QD, NORETHINDRONE  
 NORCO, ACETAMINOPHEN  
 NORDETTE-28, ETHINYL ESTRADIOL  
 NORDITROPIN FLEXPOR, SOMATROPIN RECOMBINANT  
 NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT  
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE  
 NORETHINDRONE, NORETHINDRONE  
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORFLEX, ORPHENADRINE CITRATE  
 NORGESIC, ASPIRIN  
 NORGESIC FORTE, ASPIRIN  
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL  
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL  
 NORINYL 1+50 28-DAY, MESTRANOL  
 NORITATE, METRONIDAZOLE  
 NORMOCARB HF 25, MAGNESIUM CHLORIDE  
 NORMOCARB HF 35, MAGNESIUM CHLORIDE  
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 NORPACE, DISOPYRAMIDE PHOSPHATE  
 NORPACE CR, DISOPYRAMIDE PHOSPHATE  
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE  
 NORTHERA, DROXIDOPA  
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL  
 NORTREL 1/35-21, ETHINYL ESTRADIOL  
 NORTREL 1/35-28, ETHINYL ESTRADIOL  
 NORTREL 7/7/7, ETHINYL ESTRADIOL  
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
 NORVASC, AMLODIPINE BESYLATE  
 NORVIR, RITONAVIR  
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLOG, INSULIN ASPART RECOMBINANT  
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT  
 NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT  
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT  
 NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT  
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT  
 NOXAFIL, POSACONAZOLE  
 NUCYNTA, TAPENTADOL HYDROCHLORIDE  
 NUCYNTA ER, TAPENTADOL HYDROCHLORIDE  
 NUDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* N \*\*

NULYTELY, POLYETHYLENE GLYCOL 3350  
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350  
 NUTRACORT, HYDROCORTISONE  
 NUTRESTORE, GLUTAMINE  
 NUTRILIPID 10%, SOYBEAN OIL  
 NUTRILIPID 20%, SOYBEAN OIL  
 NUTROPIN, SOMATROPIN RECOMBINANT  
 NUTROPIN AQ, SOMATROPIN RECOMBINANT  
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT  
 NUVARING, ETHINYL ESTRADIOL  
 NUVIGIL, ARMODAFINIL  
 NYMALIZE, NIMODIPINE  
 NYSTATIN, NYSTATIN  
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN  
 NYSTOP, NYSTATIN

\*\* O \*\*

OBREDON, GUAIFENESIN  
 OCTOCAINE, EPINEPHRINE  
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
 OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)  
 OCUFEN, FLURBIPROFEN SODIUM  
 OCUFLOX, OFLOXACIN  
 OCUPRESS, CARTEOLOL HYDROCHLORIDE  
 OFEV, NINTEDANIB  
 OFIRMEV, ACETAMINOPHEN  
 OFLOXACIN, OFLOXACIN  
 OGEN .625, ESTROPIPATE  
 OGEN 1.25, ESTROPIPATE  
 OGEN 2.5, ESTROPIPATE  
 OGEN 5, ESTROPIPATE  
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL  
 OLANZAPINE, OLANZAPINE  
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 OLAPARIB, OLAPARIB  
 OLEPTRO, TRAZODONE HYDROCHLORIDE  
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE  
 OLUX, CLOBETASOL PROPIONATE  
 OLUX E, CLOBETASOL PROPIONATE  
 OLYSIO, SIMEPREVIR SODIUM  
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS  
 OMEPRAZOLE, OMEPRAZOLE (OTC)  
 OMEPRAZOLE, OMEPRAZOLE  
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN  
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE  
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)  
 OMIDRIA, KETOROLAC TROMETHAMINE  
 OMNARIS, CICLESONIDE  
 OMNIPAQUE 140, IOHEXOL  
 OMNIPAQUE 180, IOHEXOL  
 OMNIPAQUE 240, IOHEXOL  
 OMNIPAQUE 300, IOHEXOL  
 OMNIPAQUE 350, IOHEXOL  
 OMNIPRED, PREDNISOLONE ACETATE  
 OMNISCAN, GADODIAMIDE  
 OMNITROPE, SOMATROPIN RECOMBINANT  
 OMTRYG, OMEGA-3-ACID ETHYL ESTERS  
 ONDANSETRON, ONDANSETRON  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONEXTON, BENZOYL PEROXIDE  
 ONFI, CLOBAZAM  
 ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* O \*\*

ONMEL, ITRACONAZOLE  
OPANA, OXYMORPHONE HYDROCHLORIDE  
OPANA ER, OXYMORPHONE HYDROCHLORIDE  
OPCICON ONE-STEP, LEVONORGESTREL (OTC)  
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
OPSUMIT, MACITENTAN  
OPTIMARK, GADOVERSETAMIDE  
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE  
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE  
OPTIRAY 240, IOVERSOL  
OPTIRAY 300, IOVERSOL  
OPTIRAY 320, IOVERSOL  
OPTIRAY 350, IOVERSOL  
OPTISON, ALBUMIN HUMAN  
OPTIVAR, AZELASTINE HYDROCHLORIDE  
ORABLOC, ARTICAINA HYDROCHLORIDE  
ORACEA, DOXYCYCLINE  
ORAP, PIMOZIDE  
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE  
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE  
ORAQIX, LIDOCAINE  
ORAVerse, PHENTOLAMINE MESYLATE  
ORAVIG, MICONAZOLE  
ORBACTIV, ORITAVANCIN DIPHOSPHATE  
ORENITRAM, TREPROSTINIL DIOLAMINE  
ORETIC, HYDROCHLOROTHIAZIDE  
ORFADIN, NITISINONE  
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN  
ORSYTHIA, ETHINYL ESTRADIOL  
ORTHO CYCLEN-28, ETHINYL ESTRADIOL  
ORTHO EVRA, ETHINYL ESTRADIOL  
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL  
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL  
ORTHO-CEPT, DESOGESTREL  
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL  
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL  
ORVATEN, MIDODRINE HYDROCHLORIDE  
OSENI, ALOGLIPTIN BENZOATE  
OSMITROL 10% IN WATER, MANNITOL  
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL  
OSMITROL 15% IN WATER, MANNITOL  
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL  
OSMITROL 20% IN WATER, MANNITOL  
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL  
OSMITROL 5% IN WATER, MANNITOL  
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL  
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS  
OSPHENA, OSPEMIFENE  
OTEZLA, APREMILAST  
OTICAIR, HYDROCORTISONE  
OTREXUP, METHOTREXATE  
OVCON-35, ETHINYL ESTRADIOL  
OVIDE, MALATHION  
OVIDREL, CHORIOGONADOTROPIN ALFA  
OXACILLIN SODIUM, OXACILLIN SODIUM  
OXALIPLATIN, OXALIPLATIN  
OXANDRIN, OXANDROLONE  
OXANDROLONE, OXANDROLONE  
OXAPROZIN, OXAPROZIN  
OXAZEPAM, OXAZEPAM  
OXCARBAZEPINE, OXCARBAZEPINE  
OJECTA, OXYCODONE HYDROCHLORIDE  
OXILAN-300, IOXILAN  
OXILAN-350, IOXILAN



**APPENDIX A - PRODUCT NAME INDEX****\*\* O \*\***

OXISTAT, OXICONAZOLE NITRATE  
 OXSORALEN, METHOXSALEN  
 OXSORALEN-ULTRA, METHOXSALEN  
 OXTELLAR XR, OXCARBAZEPINE  
 OXYBUTYNIN, OXYBUTYNIN  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
 OXYCET, ACETAMINOPHEN  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE AND ASPIRIN, ASPIRIN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN  
 OXYCONTIN, OXYCODONE HYDROCHLORIDE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 OXYTOCIN, OXYTOCIN  
 OXYTROL, OXYBUTYNIN  
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)  
 OZURDEX, DEXAMETHASONE

**\*\* P \*\***

PACERONE, AMIODARONE HYDROCHLORIDE  
 PACLITAXEL, PACLITAXEL  
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PAMINE, METHSCOPOLAMINE BROMIDE  
 PAMINE FORTE, METHSCOPOLAMINE BROMIDE  
 PANCREAZE, PANCRELIPASE (AMYLASE)  
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE  
 PANDEL, HYDROCORTISONE PROBUTATE  
 PANRETIN, ALITRETINOIN  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PARAFON FORTE DSC, CHLORZOXAZONE  
 PARAGARD T 380A, COPPER  
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE  
 PARICALCITOL, PARICALCITOL  
 PARLODEL, BROMOCRIPTINE MESYLATE  
 PARNATE, TRANYLCPROMINE SULFATE  
 PAROEX, CHLORHEXIDINE GLUCONATE  
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE  
 PAROXETINE, PAROXETINE HYDROCHLORIDE  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PASER, AMINOSALICYLIC ACID  
 PATADAY, OLOPATADINE HYDROCHLORIDE  
 PATANASE, OLOPATADINE HYDROCHLORIDE  
 PATANOL, OLOPATADINE HYDROCHLORIDE  
 PAXIL, PAROXETINE HYDROCHLORIDE  
 PAXIL CR, PAROXETINE HYDROCHLORIDE  
 PCE, ERYTHROMYCIN  
 PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE  
 PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE  
 PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE  
 PEDIATRIC ADVIL, IBUPROFEN (OTC)  
 PEDIOTIC, HYDROCORTISONE  
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350  
 PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL, BISACODYL  
 PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE, POLYETHYLENE GLYCOL 3350  
 PEGANONE, ETHOTOIN  
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM  
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM  
 PENICILLIN G PROCAINE, PENICILLIN G PROCAINE  
 PENICILLIN G SODIUM, PENICILLIN G SODIUM  
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM  
 PENICILLIN-VK, PENICILLIN V POTASSIUM  
 PENLAC, CICLOPIROX  
 PENNSAID, DICLOFENAC SODIUM

## APPENDIX A - PRODUCT NAME INDEX

\*\* P \*\*

PENTAM, PENTAMIDINE ISETHIONATE  
PENTASA, MESALAMINE  
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE  
PENTOSTATIN, PENTOSTATIN  
PENTOXIFYLLINE, PENTOXIFYLLINE  
PENTOXIL, PENTOXIFYLLINE  
PEPCID, FAMOTIDINE  
PEPCID AC, FAMOTIDINE (OTC)  
PEPCID AC, FAMOTIDINE (OTC)  
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)  
PERCOCET, ACETAMINOPHEN  
PERCODAN, ASPIRIN  
PERFOROMIST, FORMOTEROL FUMARATE  
PERIDEX, CHLORHEXIDINE GLUCONATE  
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS  
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
PERIOCHIP, CHLORHEXIDINE GLUCONATE  
PERIOGARD, CHLORHEXIDINE GLUCONATE  
PERMAPEN, PENICILLIN G BENZATHINE  
PERMETHRIN, PERMETHRIN (OTC)  
PERMETHRIN, PERMETHRIN  
PERPHENAZINE, PERPHENAZINE  
PERPHENAZINE AND AMTRIPTYLINE HYDROCHLORIDE, AMTRIPTYLINE HYDROCHLORIDE  
PERSANTINE, DIPYRIDAMOLE  
PERTZYE, PANCRELIPASE (AMYLASE)  
PEXEVA, PAROXETINE MESYLATE  
PFIZERPEN, PENICILLIN G POTASSIUM  
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)  
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE  
PHENELZINE SULFATE, PHENELZINE SULFATE  
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE  
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
PHENTERMINE RESIN COMPLEX, PHENTERMINE RESIN COMPLEX  
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE  
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE  
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE  
PHENYTEK, PHENYTOIN SODIUM  
PHENYTOIN, PHENYTOIN  
PHENYTOIN SODIUM, PHENYTOIN SODIUM  
PHILITH, ETHINYL ESTRADIOL  
PHISOHEX, HEXACHLOROPHENE  
PHOSLO GELCAPS, CALCIUM ACETATE  
PHOSLYRA, CALCIUM ACETATE  
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE  
PHOTOFRIN, PORFIMER SODIUM  
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
PHYTONADIONE, PHYTONADIONE  
PICATO, INGENOL MEBUTATE  
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE  
PILOPINE HS, PILOCARPINE HYDROCHLORIDE  
PIMTREA, DESOGESTREL  
PINDOLOL, PINDOLOL  
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE  
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
PIPERACILLIN, PIPERACILLIN SODIUM  
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
PIRMELLA 1/35, ETHINYL ESTRADIOL  
PIRMELLA 7/7/7, ETHINYL ESTRADIOL  
PIROXICAM, PIROXICAM  
PITOCIN, OXYTOCIN  
PLAN B, LEVONORGESTREL (OTC)  
PLAN B, LEVONORGESTREL  
PLAN B ONE-STEP, LEVONORGESTREL (OTC)

## APPENDIX A - PRODUCT NAME INDEX

\*\* P \*\*

PLAQUENIL, HYDROXYCHLOROQUINE SULFATE  
 PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE  
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PLAVIX, CLOPIDOGREL BISULFATE  
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PLENDIL, FELODIPINE  
 PLETAL, CILOSTAZOL  
 PLIAGLIS, LIDOCAINE  
 PODOFILOX, PODOFILOX  
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE  
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350  
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE  
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 POLYTRIM, POLYMYXIN B SULFATE  
 POMALYST, POMALIDOMIDE  
 PONSTEL, MEFENAMIC ACID  
 PORTIA-28, ETHINYL ESTRADIOL  
 POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE



## APPENDIX A - PRODUCT NAME INDEX

\*\* P \*\*

POVIDONE IODINE, POVIDONE-IODINE (OTC)  
PRADAXA, DABIGATRAN ETEXILATE MESYLATE  
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
PRAMOSONE, HYDROCORTISONE ACETATE  
PRANDIMET, METFORMIN HYDROCHLORIDE  
PRANDIN, REPAGLINIDE  
PRAVACHOL, PRAVASTATIN SODIUM  
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE  
PRE-OP, HEXACHLOROPHENE  
PRE-OP II, HEXACHLOROPHENE  
PRE-PEN, BENZYLPENICILLOYL POLYLYSINE  
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE  
PRECOSE, ACARBOSE  
PRED FORTE, PREDNISOLONE ACETATE  
PRED MILD, PREDNISOLONE ACETATE  
PRED-G, GENTAMICIN SULFATE  
PREDNICARBATE, PREDNICARBATE  
PREDNISOLONE, PREDNISOLONE  
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
PREDNISON, PREDNISON  
PREDNISON INTENSOL, PREDNISON  
PREGABALIN, PREGABALIN  
PREGNYL, GONADOTROPIN, CHORIONIC  
PRELONE, PREDNISOLONE  
PREMARIN, ESTROGENS, CONJUGATED  
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS  
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS  
PREMPHASE 14/14, ESTROGENS, CONJUGATED  
PREMPRO, ESTROGENS, CONJUGATED  
PREPIDIL, DINOPROSTONE  
PREPOPIK, CITRIC ACID  
PREVACID, LANSOPRAZOLE  
PREVACID 24 HR, LANSOPRAZOLE (OTC)  
PREVALITE, CHOLESTYRAMINE  
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)  
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
PREVIFEM, ETHINYL ESTRADIOL  
PREVPAC, AMOXICILLIN  
PREZISTA, DARUNAVIR ETHANOLATE  
PRIALT, ZICONOTIDE ACETATE  
PRIFTIN, RIFAPENTINE  
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE  
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE  
PRILOSEC, OMEPRAZOLE  
PRILOSEC, OMEPRAZOLE MAGNESIUM  
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)  
PRIMAQUINE, PRIMAQUINE PHOSPHATE  
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE  
PRIMAXIN, CILASTATIN SODIUM  
PRIMIDONE, PRIMIDONE  
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE  
PRINIVIL, LISINAPRIL  
PRINZIDE, HYDROCHLOROTHIAZIDE  
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* P \*\*

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
PRISTIQ, DESVENLAFAXINE SUCCINATE  
PROAIR HFA, ALBUTEROL SULFATE  
PROBALAN, PROBENECID  
PROBENECID, PROBENECID  
PROBENECID AND COLCHICINE, COLCHICINE  
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE  
PROCALAMINE, AMINO ACIDS  
PROCARDIA, NIFEDIPINE  
PROCARDIA XL, NIFEDIPINE  
PROCHLORPERAZINE, PROCHLORPERAZINE  
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE  
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE  
PROCOMP, PROCHLORPERAZINE MALEATE  
PROCTOFOAM HC, HYDROCORTISONE ACETATE  
PROCYSBI, CYSTEAMINE BITARTRATE  
PROFEN, IBUPROFEN (OTC)  
PROFERDEX, IRON DEXTRAN  
PROGESTERONE, PROGESTERONE  
PROGLYCEM, DIAZOXIDE  
PROGRAF, TACROLIMUS  
PROHANCE, GADOTERIDOL  
PROHANCE MULTIPACK, GADOTERIDOL  
PROLENSA, BROMFENAC SODIUM  
PROMACTA, ELTROMBOPAG OLAMINE  
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE  
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE  
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE  
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE  
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN  
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE  
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE  
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE  
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE  
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE  
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE  
PROMETRIUM, PROGESTERONE  
PROPAPENONE HYDROCHLORIDE, PROPAPENONE HYDROCHLORIDE  
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE  
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE  
PROPECIA, FINASTERIDE  
PROPOFOL, PROPOFOL  
PROPOXYPHENE HYDROCHLORIDE, PROPOXYPHENE HYDROCHLORIDE  
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
PROPYLTHIOURACIL, PROPYLTHIOURACIL  
PROSCAR, FINASTERIDE  
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS  
PROSTIN E2, DINOPROSTONE  
PROSTIN VR PEDIATRIC, ALPROSTADIL  
PROTAMINE SULFATE, PROTAMINE SULFATE  
PROTONIX, PANTOPRAZOLE SODIUM  
PROTONIX IV, PANTOPRAZOLE SODIUM  
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE  
PROTOPIC, TACROLIMUS  
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE  
PROVENTIL-HFA, ALBUTEROL SULFATE  
PROVERA, MEDROXYPROGESTERONE ACETATE  
PROVIGIL, MODAFINIL  
PROVOCHOLINE, METHACHOLINE CHLORIDE  
PROZAC, FLUOXETINE HYDROCHLORIDE  
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

## \*\* P \*\*

PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
 PULMICORT FLEXHALER, BUDESONIDE  
 PULMICORT RESPULES, BUDESONIDE  
 PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT  
 PUR-WASH, PURIFIED WATER (OTC)  
 PURIXAN, MERCAPTOPYRINE  
 PYLERA, BISMUTH SUBCITRATE POTASSIUM  
 PYRAZINAMIDE, PYRAZINAMIDE  
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE  
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE  
 PYTEST, UREA, C-14  
 PYTEST KIT, UREA, C-14

## \*\* Q \*\*

QNASL, BECLOMETHASONE DIPROPIONATE  
 QOLIANA, BRIMONIDINE TARTRATE  
 QSYMIA, PHENTERMINE HYDROCHLORIDE  
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM  
 QUALAQUIN, QUININE SULFATE  
 QUARTETTE, ETHINYL ESTRADIOL  
 QUASENSE, ETHINYL ESTRADIOL  
 QUDEXY XR, TOPIRAMATE  
 QUELICIN, SUCCINYLCHOLINE CHLORIDE  
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 QUINARETIC, HYDROCHLOROTHIAZIDE  
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE  
 QUINIDINE SULFATE, QUINIDINE SULFATE  
 QUININE SULFATE, QUININE SULFATE  
 QUIXIN, LEVOFLOXACIN  
 QUTENZA, CAPSAICIN  
 QVAR 40, BECLOMETHASONE DIPROPIONATE  
 QVAR 80, BECLOMETHASONE DIPROPIONATE

## \*\* R \*\*

R-GENE 10, ARGININE HYDROCHLORIDE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)  
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE  
 RAMELTEON, RAMELTEON  
 RAMIPRIL, RAMIPRIL  
 RANEXA, RANOLAZINE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RANOLAZINE, RANOLAZINE  
 RAPAFLO, SILODOSIN  
 RAPAMUNE, SIROLIMUS  
 RAPIVAB, PERAMIVIR  
 RASAGILINE MESYLATE, RASAGILINE MESYLATE  
 RASUVO, METHOTREXATE  
 RAVICTI, GLYCEROL PHENYL BUTYRATE  
 RAYOS, PREDNISONE  
 RAZADYNE, GALANTAMINE HYDROBROMIDE  
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE  
 REBETOL, RIBAVIRIN  
 RECLAST, ZOLEDRONIC ACID  
 RECTIV, NITROGLYCERIN  
 REGITINE, PHENTOLAMINE MESYLATE  
 REGLAN, METOCLOPRAMIDE HYDROCHLORIDE  
 REGONOL, PYRIDOSTIGMINE BROMIDE  
 RELENZA, ZANAMIVIR  
 RELISTOR, METHYLNALTREXONE BROMIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* R \*\*

RELPAX, ELETRIPTAN HYDROBROMIDE  
REMERON, MIRTAZAPINE  
REMERON SOLTAB, MIRTAZAPINE  
REMODULIN, TREPROSTINIL  
RENACIDIN, CITRIC ACID  
RENAGEL, SEVELAMER HYDROCHLORIDE  
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE  
RENOVA, TRETINOIN  
RENVELA, SEVELAMER CARBONATE  
REPAGLINIDE, REPAGLINIDE  
REPREXAIN, HYDROCODONE BITARTRATE  
REPRONEX, MENOTROPINS (FSH  
REQUIP, ROPINIROLE HYDROCHLORIDE  
REQUIP XL, ROPINIROLE HYDROCHLORIDE  
RESCRIPTOR, DELAVIRDINE MESYLATE  
RESCULA, UNOPROSTONE ISOPROPYL  
RESECTISOL IN PLASTIC CONTAINER, MANNITOL  
RESERPINE, RESERPINE  
RESTASIS, CYCLOSPORINE  
RESTORIL, TEMAZEPAM  
RETIN-A, TRETINOIN  
RETIN-A MICRO, TRETINOIN  
RETIN-A-MICRO, TRETINOIN  
RETISERT, FLUOCINOLONE ACETONIDE  
RETROVIR, ZIDOVUDINE  
REVATIO, SILDENAFIL CITRATE  
REVIA, NALTREXONE HYDROCHLORIDE  
REVLIMID, LENALIDOMIDE  
REVONTO, DANTROLENE SODIUM  
REYATAZ, ATAZANAVIR SULFATE  
REZIRA, HYDROCODONE BITARTRATE  
RHINOCORT, BUDESONIDE  
RIBASPHERE, RIBAVIRIN  
RIBAVARIN, RIBAVIRIN  
RIBAVIRIN, RIBAVIRIN  
RIDAURA, AURANOFIN  
RIFABUTIN, RIFABUTIN  
RIFADIN, RIFAMPIN  
RIFAMATE, ISONIAZID  
RIFAMPIN, RIFAMPIN  
RIFATER, ISONIAZID  
RILUTEK, RILUZOLE  
RILUZOLE, RILUZOLE  
RIMACTANE, RIFAMPIN  
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE  
RIMSO-50, DIMETHYL SULFOXIDE  
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
RIOMET, METFORMIN HYDROCHLORIDE  
RISEDRONATE SODIUM, RISEDRONATE SODIUM  
RISPERDAL, RISPERIDONE  
RISPERDAL CONSTA, RISPERIDONE  
RISPERIDONE, RISPERIDONE  
RITALIN, METHYLPHENIDATE HYDROCHLORIDE  
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE  
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE  
RITONAVIR, RITONAVIR  
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
ROBAXIN, METHOCARBAMOL  
ROBAXIN-750, METHOCARBAMOL  
ROBINUL, GLYCOPYRROLATE  
ROBINUL FORTE, GLYCOPYRROLATE  
ROCALTROL, CALCITRIOL  
ROCEPHIN, CEFTRIAXONE SODIUM  
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE



## APPENDIX A - PRODUCT NAME INDEX

## \*\* R \*\*

ROGAINE (FOR MEN), MINOXIDIL (OTC)  
 ROGAINE (FOR WOMEN), MINOXIDIL (OTC)  
 ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE  
 ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE  
 ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 ROWASA, MESALAMINE  
 ROXICET, ACETAMINOPHEN  
 ROXICODONE, OXYCODONE HYDROCHLORIDE  
 ROZEREM, RAMELTEON  
 RYANODEX, DANTROLENE SODIUM  
 RYTHMOL, PROPAFENONE HYDROCHLORIDE  
 RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

## \*\* S \*\*

SABRIL, VIGABATRIN  
 SAFYRAL, DROSPIRENONE  
 SAIZEN, SOMATROPIN RECOMBINANT  
 SALAGEN, PILOCARPINE HYDROCHLORIDE  
 SALONPAS, MENTHOL (OTC)  
 SALURON, HYDROFLUMETHIAZIDE  
 SAMSCA, TOLVAPTAN  
 SANCTURA, TROSPIUM CHLORIDE  
 SANCTURA XR, TROSPIUM CHLORIDE  
 SANCUSO, GRANISETRON  
 SANDIMMUNE, CYCLOSPORINE  
 SANDOSTATIN, OCTREOTIDE ACETATE  
 SANDOSTATIN LAR, OCTREOTIDE ACETATE  
 SAPHRIS, ASENAPINE MALEATE  
 SARAFEM, FLUOXETINE HYDROCHLORIDE  
 SAVELLA, MILNACIPRAN HYDROCHLORIDE  
 SAXENDA, LIRAGLUTIDE RECOMBINANT  
 SCANDONEST L, LEVONORDEFRIN  
 SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE  
 SCANLUX-300, IOPAMIDOL  
 SCANLUX-370, IOPAMIDOL  
 SCLEROSOL, TALC  
 SEASONALE, ETHINYL ESTRADIOL  
 SEASONIQUE, ETHINYL ESTRADIOL  
 SECONAL SODIUM, SECOBARBITAL SODIUM  
 SECTRAL, ACEBUTOLOL HYDROCHLORIDE  
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE  
 SELENIUM SULFIDE, SELENIUM SULFIDE  
 SELFEMRA, FLUOXETINE HYDROCHLORIDE  
 SELSUN, SELENIUM SULFIDE  
 SELZENTRY, MARAVIROC  
 SEMPREX-D, ACRIVASTINE  
 SENSIPAR, CINACALCET HYDROCHLORIDE  
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE  
 SEPTOCAINE, ARTICAINE HYDROCHLORIDE  
 SEPTRA, SULFAMETHOXAZOLE  
 SEPTRA DS, SULFAMETHOXAZOLE  
 SEREVENT, SALMETEROL XINAFOATE  
 SEROMYCIN, CYCLOSERINE  
 SEROPHENE, CLOMIPHENE CITRATE  
 SEROQUEL, QUETIAPINE FUMARATE  
 SEROQUEL XR, QUETIAPINE FUMARATE  
 SEROSTIM, SOMATROPIN RECOMBINANT  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SETLAKIN, ETHINYL ESTRADIOL  
 SEVOFLURANE, SEVOFLURANE  
 SFROWASA, MESALAMINE  
 SHADE UVAGUARD, AVOBENZONE (OTC)  
 SIGNIFOR, PASIREOTIDE DIASPARTATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* S \*\*

SIGNIFOR LAR, PASIREOTIDE PAMOATE  
SILDENAFIL CITRATE, SILDENAFIL CITRATE  
SILENOR, DOXEPIN HYDROCHLORIDE  
SILVADENE, SILVER SULFADIAZINE  
SIMBRINZA, BRIMONIDINE TARTRATE  
SIMCOR, NIACIN  
SIMVASTATIN, SIMVASTATIN  
SINE-AID IB, IBUPROFEN (OTC)  
SINEMET, CARBIDOPA  
SINEMET CR, CARBIDOPA  
SINGULAIR, MONTELUKAST SODIUM  
SINOGRAFIN, DIATRIZOATE MEGLUMINE  
SIROLIMUS, SIROLIMUS  
SIRTURO, BEDAQUILINE FUMARATE  
SITAVIG, ACYCLOVIR  
SIVEXTRO, TEDIZOLID PHOSPHATE  
SKELAXIN, METAXALONE  
SKLICE, IVERMECTIN  
SKYLA, LEVONORGESTREL  
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS  
SODIUM BICARBONATE, SODIUM BICARBONATE  
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE  
SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE  
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE  
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18  
SODIUM IODIDE I 123, SODIUM IODIDE I-123  
SODIUM IODIDE I 131, SODIUM IODIDE I-131  
SODIUM IODIDE I-131, SODIUM IODIDE I-131  
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE  
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE  
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE  
SODIUM NITRITE, SODIUM NITRITE  
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE  
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE  
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE  
SODIUM THIOSULFATE, SODIUM THIOSULFATE  
SOJOURN, SEVOFLURANE  
SOLARAZE, DICLOFENAC SODIUM  
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE  
SOLODYN, MINOCYCLINE HYDROCHLORIDE  
SOLTAMOX, TAMOXIFEN CITRATE  
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE  
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE  
SOMA, CARISOPRODOL  
SOMA COMPOUND, ASPIRIN  
SOMA COMPOUND W/ CODEINE, ASPIRIN  
SOMATULINE DEPOT, LANREOTIDE ACETATE  
SOMAVERT, PEGVISOMANT  
SONATA, ZALEPLON  
SOOLANTRA, IVERMECTIN  
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL  
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL  
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL  
SORIATANE, ACITRETIN  
SORILUX, CALCIPOTRIENE  
SORINE, SOTALOL HYDROCHLORIDE  
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
SOTRADECOL, SODIUM TETRADECYL SULFATE  
SOTRET, ISOTRETINOIN

## APPENDIX A - PRODUCT NAME INDEX

\*\* S \*\*

SOTYLIZE, SOTALOL HYDROCHLORIDE  
SOVALDI, SOFOSBUVIR  
SPECTRACEF, CEFDITOREN PIVOXIL  
SPIRIVA, TIOTROPIUM BROMIDE  
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE  
SPIRONOLACTONE, SPIRONOLACTONE  
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
SPORANOX, ITRACONAZOLE  
SPRINTEC, ETHINYL ESTRADIOL  
SPRIX, KETOROLAC TROMETHAMINE  
SPRYCEL, DASATINIB  
SPS, SODIUM POLYSTYRENE SULFONATE  
SSD, SILVER SULFADIAZINE  
SSD AF, SILVER SULFADIAZINE  
STALEVO 100, CARBIDOPA  
STALEVO 125, CARBIDOPA  
STALEVO 150, CARBIDOPA  
STALEVO 200, CARBIDOPA  
STALEVO 50, CARBIDOPA  
STALEVO 75, CARBIDOPA  
STARLIX, NATEGLINIDE  
STAVUDINE, STAVUDINE  
STAXYN, VARDENAFIL HYDROCHLORIDE  
STENDRA, AVANAFIL  
STERILE WATER, STERILE WATER FOR IRRIGATION  
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION  
STIE-CORT, HYDROCORTISONE  
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
STIVARGA, REGORAFENIB  
STRATTERA, ATOMOXETINE HYDROCHLORIDE  
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE  
STRIANT, TESTOSTERONE  
STRIBILD, COBICISTAT  
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE  
STROMECTOL, IVERMECTIN  
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89  
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE  
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE  
SUBSYS, FENTANYL  
SUCLEAR, MAGNESIUM SULFATE  
SUCRAID, SACROSIDASE  
SUCRALFATE, SUCRALFATE  
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE  
SUFENTANIL CITRATE, SUFENTANIL CITRATE  
SULAR, NISOLDIPINE  
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM  
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
SULFADIAZINE, SULFADIAZINE  
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE  
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE  
SULFAMYLON, MAFENIDE ACETATE  
SULFASALAZINE, SULFASALAZINE  
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE  
SULINDAC, SULINDAC  
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE  
SUNITINIB MALATE, SUNITINIB MALATE  
SUPPRELIN LA, HISTRELIN ACETATE  
SUPRANE, DESFLURANE  
SUPRAX, CEFIXIME  
SUPRENZA, PHENTERMINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* S \*\*

SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS  
 SURFAXIN, LUCINACTANT  
 SURMONTIL, TRIMIPRAMINE MALEATE  
 SURVANTA, BERACTANT  
 SUSTIVA, EFAVIRENZ  
 SUTENT, SUNITINIB MALATE  
 SYEDA, DROSPIRENONE  
 SYMBICORT, BUDESONIDE  
 SYMBYAX, FLUOXETINE HYDROCHLORIDE  
 SYMLIN, PRAMLINTIDE ACETATE  
 SYNACORT, HYDROCORTISONE  
 SYNALAR, FLUOCINOLONE ACETONIDE  
 SYNALGOS-DC, ASPIRIN  
 SYNAREL, NAFARELIN ACETATE  
 SYNERA, LIDOCAINE  
 SYNERCID, DALFOPRISTIN  
 SYNRIPO, OMACETAXINE MEPESUCCINATE  
 SYNTHROID, LEVOTHYROXINE SODIUM \*\*  
 SYPRINE, TRIENTINE HYDROCHLORIDE

\*\* T \*\*

TAB-PROFEN, IBUPROFEN (OTC)  
 TACLONEX, BETAMETHASONE DIPROPIONATE  
 TACROLIMUS, TACROLIMUS  
 TAFINLAR, DABRAFENIB MESYLATE  
 TAGAMET HB, CIMETIDINE (OTC)  
 TALC, TALC  
 TALWIN, PENTAZOCINE LACTATE  
 TAMIFLU, OSELTAMIVIR PHOSPHATE  
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TAPAZOLE, METHIMAZOLE  
 TARCEVA, ERLOTINIB HYDROCHLORIDE  
 TARGRETIN, BEXAROTENE  
 TARKA, TRANDOLAPRIL  
 TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE  
 TASMAR, TOLCAPONE  
 TAVIST-1, CLEMASTINE FUMARATE (OTC)  
 TAXOL, PACLITAXEL  
 TAXOTERE, DOCETAXEL  
 TAZICEF, CEFTAZIDIME  
 TAZORAC, TAZAROTENE  
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE  
 TECFIDERA, DIMETHYL FUMARATE  
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT  
 TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT  
 TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT  
 TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT  
 TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT  
 TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT  
 TEFLARO, CEFTAROLINE FOSAMIL  
 TEGRETOL, CARBAMAZEPINE  
 TEGRETOL-XR, CARBAMAZEPINE  
 TEKAMLO, ALISKIREN HEMIFUMARATE  
 TEKTURNA, ALISKIREN HEMIFUMARATE  
 TEKTURNA HCT, ALISKIREN HEMIFUMARATE  
 TELMISARTAN, TELMISARTAN  
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE  
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TEMAZEPAM, TEMAZEPAM  
 TEMODAR, TEMOZOLOMIDE  
 TEMOVATE, CLOBETASOL PROPIONATE

## APPENDIX A - PRODUCT NAME INDEX

\*\* T \*\*

TEMOVATE E, CLOBETASOL PROPIONATE  
TEMOZOLOMIDE, TEMOZOLOMIDE  
TENEX, GUANFACINE HYDROCHLORIDE  
TENORETIC 100, ATENOLOL  
TENORETIC 50, ATENOLOL  
TENORMIN, ATENOLOL  
TENSILON, EDROPHONIUM CHLORIDE  
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE  
TENUATE, DIETHYLPROPION HYDROCHLORIDE  
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE  
TERAZOL 3, TERCONAZOLE  
TERAZOL 7, TERCONAZOLE  
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
TERBUTALINE SULFATE, TERBUTALINE SULFATE  
TERCONAZOLE, TERCONAZOLE  
TERIL, CARBAMAZEPINE  
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE  
TESSALON, BENZONATATE  
TESTIM, TESTOSTERONE  
TESTOPEL, TESTOSTERONE  
TESTOSTERONE, TESTOSTERONE  
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE  
TESTRED, METHYLTESTOSTERONE  
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE  
TEV-TROPIN, SOMATROPIN RECOMBINANT  
TEVETEN, EPROSARTAN MESYLATE  
TEVETEN HCT, EPROSARTAN MESYLATE  
TEXACORT, HYDROCORTISONE  
THALITONE, CHLORTHALIDONE  
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201  
THALOMID, THALIDOMIDE  
THAM, TROMETHAMINE  
THEO-24, THEOPHYLLINE  
THEOCHRON, THEOPHYLLINE  
THEOLAIR, THEOPHYLLINE  
THEOPHYLLINE, THEOPHYLLINE  
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
THERMAZENE, SILVER SULFADIAZINE  
THEROXIDIL, MINOXIDIL (OTC)  
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE  
THIOGUANINE, THIOGUANINE  
THIOLA, TIOPRONIN  
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE  
THIOTEPA, THIOTEPA  
THIOTHIXENE, THIOTHIXENE  
THRIVE, NICOTINE POLACRILEX (OTC)  
THYROGEN, THYROTROPIN ALFA  
THYROLAR-0.25, LIOTRIX (T4)  
THYROLAR-0.5, LIOTRIX (T4)  
THYROLAR-1, LIOTRIX (T4)  
THYROLAR-2, LIOTRIX (T4)  
THYROLAR-3, LIOTRIX (T4)  
THYROSAFE, POTASSIUM IODIDE (OTC)  
THYROSHIELD, POTASSIUM IODIDE (OTC)  
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE  
TIAZAC, DILTIAZEM HYDROCHLORIDE  
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE  
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* T \*\*

TIKOSYN, DOFETILIDE  
TIMENTIN, CLAVULANATE POTASSIUM  
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM  
TIMOLOL MALEATE, TIMOLOL MALEATE  
TIMOPTIC, TIMOLOL MALEATE  
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE  
TIMOPTIC-XE, TIMOLOL MALEATE  
TINDAMAX, TINIDAZOLE  
TINIDAZOLE, TINIDAZOLE  
TIOCONAZOLE, TIOCONAZOLE (OTC)  
TIROSINT, LEVOTHYROXINE SODIUM  
TIS-U-SOL, MAGNESIUM SULFATE  
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
TIVICAY, DOLUTEGRAVIR SODIUM  
TIVORBEX, INDOMETHACIN  
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
TOBI, TOBRAMYCIN  
TOBI PODHALER, TOBRAMYCIN  
TOBRADEX, DEXAMETHASONE  
TOBRADEX ST, DEXAMETHASONE  
TOBRAMYCIN, TOBRAMYCIN  
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE  
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE  
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE  
TOBEX, TOBRAMYCIN  
TODAY, NONOXYNOL-9 (OTC)  
TOFRANIL, IMIPRAMINE HYDROCHLORIDE  
TOFRANIL-PM, IMIPRAMINE PAMOATE  
TOLAZAMIDE, TOLAZAMIDE  
TOLBUTAMIDE, TOLBUTAMIDE  
TOLMETIN SODIUM, TOLMETIN SODIUM  
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE  
TOPAMAX, TOPIRAMATE  
TOPICORT, DESOXIMETASONE  
TOPIRAMATE, TOPIRAMATE  
TOPIRAMATE, TOPIRAMATE  
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
TOPROL-XL, METOPROLOL SUCCINATE  
TORISEL, TEMSIROLIMUS  
TORSEMIDE, TORSEMIDE  
TOTECT, DEXRAZOXANE HYDROCHLORIDE  
TOVIAZ, FESOTERODINE FUMARATE  
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
TRACLEER, BOSENTAN  
TRADJENTA, LINAGLIPTIN  
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
TRANDATE, LABETALOL HYDROCHLORIDE  
TRANDOLAPRIL, TRANDOLAPRIL  
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL  
TRANEXAMIC ACID, TRANEXAMIC ACID  
TRANSERM SCOP, SCOPOLAMINE  
TRANXENE, CLORAZEPATE DIPOTASSIUM  
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE  
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS  
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS  
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS  
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS  
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS  
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS  
TRAVATAN Z, TRAVOPROST  
TRAVOPROST, TRAVOPROST  
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
TREATANDA, BENDAMUSTINE HYDROCHLORIDE

## APPENDIX A - PRODUCT NAME INDEX

\*\* T \*\*

TRECTOR, ETHIONAMIDE  
TRELSTAR, TRIPTORELIN PAMOATE  
TRETINOIN, TRETINOIN  
TRESALL, METHOTREXATE SODIUM  
TRESIMET, NAPROXEN SODIUM  
TRESIX, ACETAMINOPHEN  
TRI-ESTARYLLA, ETHINYL ESTRADIOL  
TRI-LEGEST 21, ETHINYL ESTRADIOL  
TRI-LEGEST FE, ETHINYL ESTRADIOL  
TRI-LINYAH, ETHINYL ESTRADIOL  
TRI-LUMA, FLUOCINOLONE ACETONIDE  
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL  
TRI-PREVIFEM, ETHINYL ESTRADIOL  
TRI-SPRINTEC, ETHINYL ESTRADIOL  
TRIAFIN-C, CODEINE PHOSPHATE  
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE  
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
TRIAZOLAM, TRIAZOLAM  
TRIBENZOR, AMLODIPINE BESYLATE  
TRICOR, FENOFIBRATE  
TRIDERM, TRIAMCINOLONE ACETONIDE  
TRIDIONE, TRIMETHADIONE  
TRIESENCE, TRIAMCINOLONE ACETONIDE  
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE  
TRIFLURIDINE, TRIFLURIDINE  
TRIGLIDE, FENOFIBRATE  
TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE  
TRILEPTAL, OXCARBAZEPINE  
TRILIPIX, CHOLINE FENOFIBRATE  
TRILYTE, POLYETHYLENE GLYCOL 3350  
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE  
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE  
TRIMETHOPRIM, TRIMETHOPRIM  
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE  
TRIOSTAT, LIOTHYRONINE SODIUM  
TRISENOX, ARSENIC TRIOXIDE  
TRIUMEQ, ABACAVIR SULFATE  
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)  
TRIVORA-28, ETHINYL ESTRADIOL  
TRIZIVIR, ABACAVIR SULFATE  
TROCENDI XR, TOPIRAMATE  
TROPAMINE, AMINO ACIDS  
TROPAMINE 10%, AMINO ACIDS  
TROPICACYL, TROPICAMIDE  
TROPICAMIDE, TROPICAMIDE  
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE  
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE  
TRUVADA, EMTRICITABINE  
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE  
TUSSICAPS, CHLORPHENIRAMINE POLYSTIREX  
TUSSIGON, HOMATROPINE METHYLBROMIDE  
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLYSTIREX  
TWINJECT 0.15, EPINEPHRINE  
TWINJECT 0.3, EPINEPHRINE  
TWINSTA, AMLODIPINE BESYLATE  
TYBOST, COBICISTAT  
TYGACIL, TIGECYCLINE  
TYKERB, LAPATINIB DITOSYLATE  
TYLENOL, ACETAMINOPHEN (OTC)  
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN  
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN  
TYVASO, TREPROSTINIL  
TYZEKA, TELBIVUDINE

## APPENDIX A - PRODUCT NAME INDEX

\*\* T \*\*

TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

\*\* U \*\*

U-CORT, HYDROCORTISONE ACETATE  
 UCERIS, BUDESONIDE  
 ULESFIA, BENZYL ALCOHOL  
 ULORIC, FEBUXOSTAT  
 ULTANE, SEVOFLURANE  
 ULTIVA, REMIFENTANIL HYDROCHLORIDE  
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 ULTRACET, ACETAMINOPHEN  
 ULTRAM, TRAMADOL HYDROCHLORIDE  
 ULTRAM ER, TRAMADOL HYDROCHLORIDE  
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT  
 ULTRAVATE, HALOBETASOL PROPIONATE  
 ULTRAVIST (PHARMACY BULK), IOPROMIDE  
 ULTRAVIST 150, IOPROMIDE  
 ULTRAVIST 240, IOPROMIDE  
 ULTRAVIST 300, IOPROMIDE  
 ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE  
 ULTRAVIST 370, IOPROMIDE  
 ULTRESA, PANCRELIPASE (AMYLASE)  
 UNASYN, AMPICILLIN SODIUM  
 UNIPHYL, THEOPHYLLINE  
 UNIRETIC, HYDROCHLOROTHIAZIDE  
 UNISOM, DOXYLAMINE SUCCINATE (OTC)  
 UNITHROID, LEVOTHYROXINE SODIUM \*\*  
 UNIVASC, MOEXIPRIL HYDROCHLORIDE  
 URECHOLINE, BETHANECHOL CHLORIDE  
 UREX, METHENAMINE HIPPURATE  
 UROCIT-K, POTASSIUM CITRATE  
 UROXATRAL, ALFUZOSIN HYDROCHLORIDE  
 URSO 250, URSODIOL  
 URSO FORTE, URSODIOL  
 URSODIOL, URSODIOL  
 UVADEX, METHOXSALLEN

\*\* V \*\*

VAGIFEM, ESTRADIOL  
 VAGISTAT-1, TIOCONAZOLE (OTC)  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE  
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE  
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE  
 VALIUM, DIAZEPAM  
 VALNAC, BETAMETHASONE VALERATE  
 VALPROATE SODIUM, VALPROATE SODIUM  
 VALPROIC ACID, VALPROIC ACID  
 VALSARTAN, VALSARTAN  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VALSTAR PRESERVATIVE FREE, VALRUBICIN  
 VALTRES, VALACYCLOVIR HYDROCHLORIDE  
 VALTROPIN, SOMATROPIN RECOMBINANT  
 VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VANDAZOLE, METRONIDAZOLE  
 VANIQA, EFLORNITHINE HYDROCHLORIDE  
 VANOS, FLUOCINONIDE  
 VANTAS, HISTRELIN ACETATE  
 VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE  
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE  
 VARITHENA, POLIDOCANOL  
 VASCEPA, ICOSAPENT ETHYL  
 VASERETIC, ENALAPRIL MALEATE



## APPENDIX A - PRODUCT NAME INDEX

\*\* v \*\*

VASOSTRICT, VASOPRESSIN  
VASOTEC, ENALAPRIL MALEATE  
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE  
VECTICAL, CALCITRIOL  
VECURONIUM BROMIDE, VECURONIUM BROMIDE  
VELCADE, BORTEZOMIB  
VELETRI, EPOPROSTENOL SODIUM  
VELIVET, DESOGESTREL  
VELPHORO, SUCROFERRIC OXYHYDROXIDE  
VELTIN, CLINDAMYCIN PHOSPHATE  
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
VENOFER, IRON SUCROSE  
VENTAVIS, ILOPROST  
VENTOLIN HFA, ALBUTEROL SULFATE  
VERAMYST, FLUTICASONE FUROATE  
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
VERDESO, DESONIDE  
VEREGEN, SINECATECHINS  
VERELAN, VERAPAMIL HYDROCHLORIDE  
VERELAN PM, VERAPAMIL HYDROCHLORIDE  
VERSACLOZ, CLOZAPINE  
VESICARE, SOLIFENACIN SUCCINATE  
VEXOL, RIMEXOLONE  
VFEND, VORICONAZOLE  
VIAGRA, SILDENAFIL CITRATE  
VIBATIV, TELAVANCIN HYDROCHLORIDE  
VIBISONE, CYANOCOBALAMIN  
VIBRAMYCIN, DOXYCYCLINE  
VIBRAMYCIN, DOXYCYCLINE CALCIUM  
VIBRAMYCIN, DOXYCYCLINE HYCLATE  
VICOPROFEN, HYDROCODONE BITARTRATE  
VICTOZA, LIRAGLUTIDE RECOMBINANT  
VICTRELIS, BOCEPREVIR  
VIDAZA, AZACITIDINE  
VIDEX, DIDANOSINE  
VIDEX EC, DIDANOSINE  
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM  
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE  
VIBRYD, VILAZODONE HYDROCHLORIDE  
VIMOVO, ESOMEPRAZOLE MAGNESIUM  
VIMPAT, LACOSAMIDE  
VINBLASTINE SULFATE, VINBLASTINE SULFATE  
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE  
VINORELBINE, VINORELBINE  
VINORELBINE TARTRATE, VINORELBINE TARTRATE  
VIOKACE, PANCRELIPASE (AMYLASE  
VIORELE, DESOGESTREL  
VIRACEPT, NELFINAVIR MESYLATE  
VIRAMUNE, NEVIRAPINE  
VIRAMUNE XR, NEVIRAPINE  
VIRAZOLE, RIBAVIRIN  
VIREAD, TENOFOVIR DISOPROXIL FUMARATE  
VIROPTIC, TRIFLURIDINE  
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)  
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
VISIONBLUE, TRYPAN BLUE  
VISIPAQUE 270, IODIXANOL  
VISIPAQUE 320, IODIXANOL  
VISTARIL, HYDROXYZINE PAMOATE  
VISTIDE, CIDOFOVIR  
VISUDYNE, VERTEPORFIN  
VITAMIN D, ERGOCALCIFEROL  
VITAMIN K1, PHYTONADIONE  
VITEKTA, ELVITEGRAVIR  
VITRASE, HYALURONIDASE

## APPENDIX A - PRODUCT NAME INDEX

\*\* V \*\*

VITUZ, CHLORPHENIRAMINE MALEATE  
 VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE  
 VIVELLE, ESTRADIOL  
 VIVELLE-DOT, ESTRADIOL  
 VIVITROL, NALTREXONE  
 VIZAMYL, FLUTEMETAMOL F-18  
 VOGELXO, TESTOSTERONE  
 VOLTAREN, DICLOFENAC SODIUM  
 VOLTAREN-XR, DICLOFENAC SODIUM  
 VORICONAZOLE, VORICONAZOLE  
 VOSOL, ACETIC ACID, GLACIAL  
 VOSOL HC, ACETIC ACID, GLACIAL  
 VOSPIRE ER, ALBUTEROL SULFATE  
 VOTRIENT, PAZOPANIB HYDROCHLORIDE  
 VPRIV, VELAGLUCERASE ALFA  
 VUMON, TENIPOSIDE  
 VUSION, MICONAZOLE NITRATE  
 VYFEMLA, ETHINYL ESTRADIOL  
 VYTORIN, EZETIMIBE  
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE

\*\* W \*\*

WARFARIN SODIUM, WARFARIN SODIUM  
 WELCHOL, COLESEVELAM HYDROCHLORIDE  
 WELLBUTRIN, BUPROPION HYDROCHLORIDE  
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE  
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE  
 WERA, ETHINYL ESTRADIOL  
 WOMEN'S ROGAINE, MINOXIDIL (OTC)

\*\* X \*\*

XALATAN, LATANOPROST  
 XALKORI, CRIZOTINIB  
 XANAX, ALPRAZOLAM  
 XANAX XR, ALPRAZOLAM  
 XARELTO, RIVAROXABAN  
 KARTEMIS XR, ACETAMINOPHEN  
 KELJANZ, TOFACITINIB CITRATE  
 XELODA, CAPECITABINE  
 XENAZINE, TETRABENAZINE  
 XENICAL, ORLISTAT  
 XENON XE 133, XENON XE-133  
 XERESE, ACYCLOVIR  
 XIFAXAN, RIFAXIMIN  
 XIGDUO XR, DAPAGLIFLOZIN  
 XOFIGO, RADIUM RA-223 DICHLORIDE  
 XOLEGEL, KETOCONAZOLE  
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE  
 XOPENEX HFA, LEVALBUTEROL TARTRATE  
 XTANDI, ENZALUTAMIDE  
 XTORO, FINAFOXACIN  
 XULANE, ETHINYL ESTRADIOL  
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE  
 XYREM, SODIUM OXYBATE  
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

\*\* Y \*\*

YAELA, DROSPIRENONE  
 YASMIN, DROSPIRENONE  
 YAZ, DROSPIRENONE

## APPENDIX A - PRODUCT NAME INDEX

\*\* Z \*\*

ZADITOR, KETOTIFEN FUMARATE (OTC)  
ZAFIRLUKAST, ZAFIRLUKAST  
ZALEPLON, ZALEPLON  
ZANAFLEX, TIZANIDINE HYDROCHLORIDE  
ZANOSAR, STREPTOZOCIN  
ZANTAC, RANITIDINE HYDROCHLORIDE  
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)  
ZANTAC 150, RANITIDINE HYDROCHLORIDE  
ZANTAC 300, RANITIDINE HYDROCHLORIDE  
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)  
ZARONTIN, ETHOSUXIMIDE  
ZAROXOLYN, METOLAZONE  
ZAVESCA, MIGLUSTAT  
ZEBETA, BISOPROLOL FUMARATE  
ZECUITY, SUMATRIPTAN SUCCINATE  
ZEGERID, OMEPRAZOLE  
ZEGERID OTC, OMEPRAZOLE (OTC)  
ZELAPAR, SELEGILINE HYDROCHLORIDE  
ZELBORAF, VEMURAFENIB  
ZEMPLAR, PARICALCITOL  
ZENATANE, ISOTRETINOIN  
ZENPEP, PANCRELIPASE (AMYLASE)  
ZERBAXA, CEFTOLOZANE SULFATE  
ZERIT, STAVUDINE  
ZESTORETIC, HYDROCHLOROTHIAZIDE  
ZESTRIL, LISINAPRIL  
ZETIA, EZETIMIBE  
ZETONNA, CICLESONIDE  
ZIAC, BISOPROLOL FUMARATE  
ZIAGEN, ABACAVIR SULFATE  
ZIANA, CLINDAMYCIN PHOSPHATE  
ZIDOVUDINE, ZIDOVUDINE  
ZINACEF, CEFUROXIME SODIUM  
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM  
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE  
ZINECARD, DEXRAZOXANE HYDROCHLORIDE  
ZINGO, LIDOCAINE HYDROCHLORIDE  
ZIOPTAN, TAFLUPROST  
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE  
ZIPSOR, DICLOFENAC POTASSIUM  
ZIRGAN, GANCICLOVIR  
ZITHROMAX, AZITHROMYCIN  
ZMAX, AZITHROMYCIN  
ZOCOR, SIMVASTATIN  
ZOFRAN, ONDANSETRON HYDROCHLORIDE  
ZOFRAN ODT, ONDANSETRON  
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
ZOHYDRO ER, HYDROCODONE BITARTRATE  
ZOLADEX, GOSERELIN ACETATE  
ZOLEDRONIC ACID, ZOLEDRONIC ACID  
ZOLINZA, VORINOSTAT  
ZOLMITRIPTAN, ZOLMITRIPTAN  
ZOLOFT, SERTRALINE HYDROCHLORIDE  
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE  
ZOLPIMIST, ZOLPIDEM TARTRATE  
ZOMETA, ZOLEDRONIC ACID  
ZOMIG, ZOLMITRIPTAN  
ZOMIG-ZMT, ZOLMITRIPTAN  
ZONALON, DOXEPIN HYDROCHLORIDE  
ZONEGRAN, ZONISAMIDE  
ZONISAMIDE, ZONISAMIDE  
ZONTIVITY, VORAPAXAR SULFATE  
ZORBTIVE, SOMATROPIN RECOMBINANT  
ZORTRESS, EVEROLIMUS  
ZORVOLEX, DICLOFENAC

**APPENDIX A - PRODUCT NAME INDEX****\*\* Z \*\***

ZOSYN, PIPERACILLIN SODIUM  
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM  
ZOVIA 1/35E-28, ETHINYL ESTRADIOL  
ZOVIA 1/50E-28, ETHINYL ESTRADIOL  
ZOVIRAX, ACYCLOVIR  
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE  
ZUPLENZ, ONDANSETRON  
ZUTRIPRO, CHLORPHENIRAMINE MALEATE  
ZYBAN, BUPROPION HYDROCHLORIDE  
ZYCLARA, IMIQUIMOD  
ZYDELIG, IDELALISIB  
ZYFLO, ZILEUTON  
ZYFLO CR, ZILEUTON  
ZYKADIA, CERITINIB  
ZYLET, LOTEHPREDNOL ETABONATE  
ZYLOPRIM, ALLOPURINOL  
ZYMAR, GATIFLOXACIN  
ZYMAXID, GATIFLOXACIN  
ZYPREXA, OLANZAPINE  
ZYPREXA RELPREVV, OLANZAPINE PAMOATE  
ZYPREXA ZYDIS, OLANZAPINE  
ZYRTEC, CETIRIZINE HYDROCHLORIDE  
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)  
ZYTIGA, ABIRATERONE ACETATE  
ZYVOX, LINEZOLID

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* 3 \*\*****3M**

- \* 3M CO  
PERIDEX, CHLORHEXIDINE GLUCONATE
- \* 3M HEALTH CARE INC  
AVAGARD, ALCOHOL (OTC)  
DURAPREP, IODINE POVACRYLEX (OTC)
- \* 3M PHARMACEUTICALS INC  
PROVENTIL-HFA, ALBUTEROL SULFATE

**\*\* A \*\*****AAIPHARMA LLC**

- \* AAIPHARMA LLC  
AZASAN, AZATHIOPRINE

**ABBVIE**

- \* ABBVIE INC  
ADVICOR, LOVASTATIN  
AKINETON, BIPERIDEN HYDROCHLORIDE  
ANDROGEL, TESTOSTERONE  
BIAXIN XL, CLARITHROMYCIN  
BIAXIN, CLARITHROMYCIN  
CALCIJEX, CALCITRIOL  
CREON, PANCRELIPASE (AMYLASE)  
CYCLOSPORINE, CYCLOSPORINE  
DEPACON, VALPROATE SODIUM  
DEPAKENE, VALPROIC ACID  
DEPAKOTE ER, DIVALPROEX SODIUM  
DEPAKOTE, DIVALPROEX SODIUM  
GENGRAF, CYCLOSPORINE  
K-TAB, POTASSIUM CHLORIDE  
KALETRA, LOPINAVIR  
MARINOL, DRONABINOL  
MAVIK, TRANDOLAPRIL  
NIASPAN, NIACIN  
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE  
NIMBEX, CISATRACURIUM BESYLATE  
NORVIR, RITONAVIR  
ORETIC, HYDROCHLOROTHIAZIDE  
SIMCOR, NIACIN  
SURVANTA, BERACTANT  
SYNTHROID, LEVOTHYROXINE SODIUM \*\*  
TARKA, TRANDOLAPRIL  
TEVETEN HCT, EPROSARTAN MESYLATE  
TEVETEN, EPROSARTAN MESYLATE  
TRICOR, FENOFIBRATE  
TRIDIONE, TRIMETHADIONE  
TRILIPIX, CHOLINE FENOFIBRATE  
ULTANE, SEVOFLURANE  
VICOPROFEN, HYDROCODONE BITARTRATE  
ZEMPLAR, PARICALCITOL

**ABBVIE ENDOCRINE**

- \* ABBVIE ENDOCRINE INC  
LUPANETA PACK, LEUPROLIDE ACETATE

**ABBVIE ENDOCRINE INC**

- \* ABBVIE ENDOCRINE INC  
LUPRON DEPOT, LEUPROLIDE ACETATE  
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

**ABBVIE INC**

- \* ABBVIE INC  
PROMETRIUM, PROGESTERONE  
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM

**ABRAXIS BIOSCIENCE**

- \* ABRAXIS BIOSCIENCE LLC  
ABRAXANE, PACLITAXEL

**ABRAXIS PHARM**

- \* ABRAXIS PHARMACEUTICAL PRODUCTS

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ABRAXIS PHARMACEUTICAL PRODUCTS  
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

**ACADEMIC PHARMS**

\* ACADEMIC PHARMACEUTICALS INC  
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

**ACCELRX LABS**

\* ACCELRX LABS LLC  
CARISOPRODOL, CARISOPRODOL

**ACCORD HLTHCARE**

\* ACCORD HEALTHCARE INC  
ALLOPURINOL, ALLOPURINOL  
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
ANASTROZOLE, ANASTROZOLE  
BICALUTAMIDE, BICALUTAMIDE  
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
CARBIDOPA AND LEVODOPA, CARBIDOPA  
CLONAZEPAM, CLONAZEPAM  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
DOCETAXEL, DOCETAXEL  
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
ETOPOSIDE, ETOPOSIDE  
FINASTERIDE, FINASTERIDE  
FLUOROURACIL, FLUOROURACIL  
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
GLIMEPIRIDE, GLIMEPIRIDE  
GLIPIZIDE, GLIPIZIDE  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
LETROZOLE, LETROZOLE  
LEVETIRACETAM, LEVETIRACETAM  
LISINAPRIL, LISINAPRIL  
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
METHYLDOPA, METHYLDOPA  
MITOMYCIN, MITOMYCIN  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE  
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
SIMVASTATIN, SIMVASTATIN  
TACROLIMUS, TACROLIMUS  
TOPIRAMATE, TOPIRAMATE  
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

**ACCORD HLTHCARE INC**

\* ACCORD HEALTHCARE INC USA  
FINASTERIDE, FINASTERIDE  
RAMIPRIL, RAMIPRIL  
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**ACELLA PHARMS LLC**

\* ACELLA PHARMACEUTICALS LLC  
GABAPENTIN, GABAPENTIN

**ACI HEALTHCARE LTD**

\* ACI HEALTHCARE LTD  
GABAPENTIN, GABAPENTIN

**ACIC FINE CHEMS**

\* ACIC FINE CHEMICALS INC  
TRANEXAMIC ACID, TRANEXAMIC ACID

**ACORDA**

\* ACORDA THERAPEUTICS INC  
AMPYRA, DALFAMPRIDINE  
QUTENZA, CAPSAICIN  
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****ACS DOBFAR**

\* ACS DOBFAR SPA  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE  
 CEFOXITIN, CEFOXITIN SODIUM  
 CEFTAZIDIME, CEFTAZIDIME  
 CEFTRIAXONE, CEFTRIAXONE SODIUM  
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM  
 KEFZOL, CEFAZOLIN SODIUM  
 MEROPENEM, MEROPENEM

**ACS DOBFAR INFO SA**

\* ACS DOBFAR INFO SA  
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
 FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**ACS DOBFAR SPA**

\* ACS DOBFAR SPA  
 AMPICILLIN SODIUM, AMPICILLIN SODIUM

**ACTAVIS**

\* ACTAVIS SOUTHATLANTIC LLC  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

**ACTAVIS ELIZABETH**

\* ACTAVIS ELIZABETH LLC  
 ALPRAZOLAM, ALPRAZOLAM  
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CLONAZEPAM, CLONAZEPAM  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 GABAPENTIN, GABAPENTIN  
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 INDAPAMIDE, INDAPAMIDE  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM  
 LOVASTATIN, LOVASTATIN  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NIFEDIPINE, NIFEDIPINE  
 OXAZEPAM, OXAZEPAM  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 PROPYLTHIOURACIL, PROPYLTHIOURACIL  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SPIRONOLACTONE, SPIRONOLACTONE  
 TEMAZEPAM, TEMAZEPAM  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**ACTAVIS GRP PTC**

\* ACTAVIS GROUP PTC EHF  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ACTAVIS GROUP PTC EHF  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE

**ACTAVIS INC**

\* ACTAVIS INC  
 DOCETAXEL, DOCETAXEL  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**ACTAVIS LABS FL INC**

\* ACTAVIS LABORATORIES FL INC  
 ALPRAZOLAM, ALPRAZOLAM  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CABERGOLINE, CABERGOLINE  
 CARTIA XT, DILTIAZEM HYDROCHLORIDE  
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 FLUTAMIDE, FLUTAMIDE  
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 GLIMEPIRIDE, GLIMEPIRIDE  
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 KETOPROFEN, KETOPROFEN  
 LEVETIRACETAM, LEVETIRACETAM  
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)  
 LORATADINE, LORATADINE (OTC)  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE  
 MIRTAZAPINE, MIRTAZAPINE  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NORCO, ACETAMINOPHEN  
 OMEPRAZOLE, OMEPRAZOLE  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE  
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**ACTAVIS LABS NY INC**

\* ACTAVIS LABORATORIES NY INC  
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

**ACTAVIS LABS UT INC**

\* ACTAVIS LABORATORIES UT INC  
 ANDRODERM, TESTOSTERONE

**ACTAVIS MID ATLANTIC**

\* ACTAVIS MID ATLANTIC LLC  
 ACETASOL HC, ACETIC ACID, GLACIAL  
 ACYCLOVIR, ACYCLOVIR  
 ADAPALENE, ADAPALENE  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ACTAVIS MID ATLANTIC LLC  
 CICLOPIROX, CICLOPIROX  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)  
 CONSTULOSE, LACTULOSE  
 ENULOSE, LACTULOSE  
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE  
 HYDROCORTISONE, HYDROCORTISONE  
 IBUPROFEN, IBUPROFEN  
 IBUPROFEN, IBUPROFEN (OTC)  
 LEVETIRACETAM, LEVETIRACETAM  
 M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MICONAZOLE 7, MICONAZOLE NITRATE (OTC)  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)  
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)  
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
 NYSTATIN, NYSTATIN  
 PERMETHRIN, PERMETHRIN  
 PERMETHRIN, PERMETHRIN (OTC)  
 PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE  
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 VALNAC, BETAMETHASONE VALERATE

**ACTAVIS TOTOWA**

\* ACTAVIS TOTOWA LLC  
 BICALUTAMIDE, BICALUTAMIDE  
 CARBOPLATIN, CARBOPLATIN  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 FINASTERIDE, FINASTERIDE  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 OXALIPLATIN, OXALIPLATIN  
 PACLITAXEL, PACLITAXEL  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 REPAGLINIDE, REPAGLINIDE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE

**ACTELION PHARMS LTD**

\* ACTELION PHARMACEUTICALS LTD  
 OPSUMIT, MACITENTAN  
 TRACLEER, BOSENTAN  
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE  
 VELETRI, EPOPROSTENOL SODIUM  
 VENTAVIS, ILOPROST  
 ZAVESCA, MIGLUSTAT

**ACTIENT PHARMS**

\* ACTIENT PHARMACEUTICALS LLC  
 TESTOPEL, TESTOSTERONE  
 THEO-24, THEOPHYLLINE

**ACTIVIS TOTOWA LLC**

\* ACTIVIS TOTOWA LLC  
 TOPIRAMATE, TOPIRAMATE

**ACURA PHARMS INC**

\* ACURA PHARMACEUTICALS INC  
 OXECTA, OXYCODONE HYDROCHLORIDE

**AEGERION**

\* AEGERION PHARMACEUTICALS INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* AEGERION PHARMACEUTICALS INC  
JUXTAPID, LOMITAPIDE MESYLATE

**AGILA SPECLTS**

\* AGILA SPECIALTIES PRIVATE LTD  
ADENOSINE, ADENOSINE  
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
AMPICILLIN SODIUM, AMPICILLIN SODIUM  
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
DOXYCYCLINE, DOXYCYCLINE HYCLATE  
ETOMIDATE, ETOMIDATE  
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
FAMOTIDINE, FAMOTIDINE  
FLUMAZENIL, FLUMAZENIL  
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE  
HALOPERIDOL, HALOPERIDOL LACTATE  
IBANDRONATE SODIUM, IBANDRONATE SODIUM  
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
MESNA, MESNA  
NAFCILLIN SODIUM, NAFCILLIN SODIUM  
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
OXACILLIN SODIUM, OXACILLIN SODIUM  
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
RIFAMPIN, RIFAMPIN  
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
VECURONIUM BROMIDE, VECURONIUM BROMIDE  
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**AGOURON**

\* AGOURON PHARMACEUTICALS INC  
VIRACEPT, NELFINAVIR MESYLATE

**AJANTA PHARMA**

\* AJANTA PHARMA LTD  
LEVETIRACETAM, LEVETIRACETAM

**AJANTA PHARMA LTD**

\* AJANTA PHARMA LTD  
RISPERIDONE, RISPERIDONE

**AKORN**

\* AKORN INC  
ADENOSINE, ADENOSINE  
AK-FLUOR 10%, FLUORESCEIN SODIUM  
AK-FLUOR 25%, FLUORESCEIN SODIUM  
AKBETA, LEVOBUNOLOL HYDROCHLORIDE  
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE  
AKTEN, LIDOCAINE HYDROCHLORIDE  
AKTOB, TOBRAMYCIN  
ALFENTA, ALFENTANIL HYDROCHLORIDE  
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
ATROPINE SULFATE, ATROPINE SULFATE  
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC  
BAL, DIMERCAPROL  
BALANCED SALT, CALCIUM CHLORIDE  
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
CALCITRIOL, CALCITRIOL  
CAPASTAT SULFATE, CAPREOMYCIN SULFATE  
CARBOPLATIN, CARBOPLATIN  
CROMOLYN SODIUM, CROMOLYN SODIUM  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
ENDOSOL EXTRA, CALCIUM CHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* AKORN INC**

ERYTHROMYCIN, ERYTHROMYCIN  
 GENTAK, GENTAMICIN SULFATE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 IC-GREEN, INDOCYANINE GREEN  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)  
 LATANOPROST, LATANOPROST  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 LORAZEPAM, LORAZEPAM  
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM  
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC  
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC  
 OFLOXACIN, OFLOXACIN  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE  
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE  
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 TROPICACYL, TROPICAMIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**AKORN INC****\* AKORN INC**

APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE  
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 DRONABINOL, DRONABINOL  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 INAPSINE, DROPERIDOL  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE  
 TOBRAMYCIN, TOBRAMYCIN  
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**ALARA PHARM**

**\* ALARA PHARMACEUTICAL CORPORATION**  
 LEVO-T, LEVOETHYRAXINE SODIUM \*\*

**ALCON****\* ALCON INC**

TRIESENCE, TRIAMCINOLONE ACETONIDE

**\* ALCON LABORATORIES INC**

ALCALINE, PROPARACAINE HYDROCHLORIDE  
 ALOMIDE, LODOXAMIDE TROMETHAMINE  
 BETOPTIC S, BETAXOLOL HYDROCHLORIDE  
 BETOPTIC, BETAXOLOL HYDROCHLORIDE  
 BSS PLUS, CALCIUM CHLORIDE  
 BSS, CALCIUM CHLORIDE  
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE  
 CETAMIDE, SULFACETAMIDE SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ALCON LABORATORIES INC  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE  
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE  
 DENDRID, IDOXURIDINE  
 EMADINE, EMEDASTINE DIFUMARATE  
 FLAREX, FLUOROMETHOLONE ACETATE  
 IOPIDINE, APRACLONIDINE HYDROCHLORIDE  
 MAXIDEX, DEXAMETHASONE  
 MAXITROL, DEXAMETHASONE  
 MIOSTAT, CARBACHOL  
 MYDRIACYL, TROPICAMIDE  
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 NATACYN, NATAMYCIN  
 OMNIPRED, PREDNISOLONE ACETATE  
 PATANOL, OLOPATADINE HYDROCHLORIDE  
 PILOPINE HS, PILOCARPINE HYDROCHLORIDE  
 TOBRADEX, DEXAMETHASONE  
 TOBEX, TOBRAMYCIN  
 VEXOL, RIMEXOLONE

**ALCON LABS INC**

\* ALCON LABORATORIES INC  
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE  
 IZBA, TRAVOPROST

**ALCON PHARMA**

\* ALCON RESEARCH LTD  
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
 ZADITOR, KETOTIFEN FUMARATE (OTC)

**ALCON PHARMS LTD**

\* ALCON PHARMACEUTICALS LTD  
 AZOPT, BRINZOLAMIDE  
 BETADINE, POVIDONE-IODINE  
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
 CILOXAN, CIPROFLOXACIN HYDROCHLORIDE  
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE  
 CIPRODEX, CIPROFLOXACIN  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 DUREZOL, DIFLUPREDNATE  
 FLUORESCITE, FLUORESCEIN SODIUM  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)  
 MOXEZA, MOXIFLOXACIN HYDROCHLORIDE  
 NAVSTEL, CALCIUM CHLORIDE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE  
 NEVANAC, NEPAFENAC  
 OFLOXACIN, OFLOXACIN  
 PATADAY, OLOPATADINE HYDROCHLORIDE  
 PATANASE, OLOPATADINE HYDROCHLORIDE  
 QOLIANA, BRIMONIDINE TARTRATE  
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM  
 TOBRADEX ST, DEXAMETHASONE  
 TRAVATAN Z, TRAVOPROST  
 TRIFLURIDINE, TRIFLURIDINE  
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE

**ALCON RES**

\* ALCON RESEARCH LTD  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE  
 LATANOPROST, LATANOPROST

**ALCON RES LTD**

\* ALCON RESEARCH LTD  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* ALCON RESEARCH LTD**

ILEVRO, NEPAFENAC  
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE  
 METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE  
 SIMBRINZA, BRIMONIDINE TARTRATE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 XTORO, FINAFLOXACIN

**ALEMBIC LTD****\* ALEMBIC LTD**

IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 METRONIDAZOLE, METRONIDAZOLE  
 MODAFINIL, MODAFINIL  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 THEOPHYLLINE, THEOPHYLLINE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**ALEMBIC PHARMS LTD****\* ALEMBIC PHARMACEUTICALS LTD**

CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 DESVENLAFAXINE, DESVENLAFAXINE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 FAMOTIDINE, FAMOTIDINE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 LAMOTRIGINE, LAMOTRIGINE  
 LEFLUNOMIDE, LEFLUNOMIDE  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 MEPROBAMATE, MEPROBAMATE  
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 METRONIDAZOLE, METRONIDAZOLE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TELMISARTAN, TELMISARTAN  
 VALSARTAN, VALSARTAN  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**ALIMERA SCIENCES INC****\* ALIMERA SCIENCES INC**

ILUVIEN, FLUOCINOLONE ACETONIDE

**ALKEM****\* ALKEM LABORATORIES LTD**

AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 GABAPENTIN, GABAPENTIN  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**ALKEM LABS LTD****\* ALKEM LABORATORIES LTD**

CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CEPHALEXIN, CEPHALEXIN  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 LAMOTRIGINE, LAMOTRIGINE  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

**ALKERMES****\* ALKERMES INC**

VIVITROL, NALTREXONE

**ALKERMES GAINESVILLE****\* ALKERMES GAINESVILLE LLC**

VERELAN PM, VERAPAMIL HYDROCHLORIDE  
 VERELAN, VERAPAMIL HYDROCHLORIDE

**ALKOPHARMA USA**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ALKOPHARMA USA INC  
AMPHOTEC, AMPHOTERICIN B

**ALLEGIANCE HLTHCARE**

\* ALLEGIANCE HEALTHCARE CORP  
POVIDONE IODINE, POVIDONE-IODINE (OTC)

**ALLERGAN**

\* ALLERGAN  
ACULAR LS, KETOROLAC TROMETHAMINE  
ALPHAGAN P, BRIMONIDINE TARTRATE  
BLEPH-10, SULFACETAMIDE SODIUM  
GENOPTIC, GENTAMICIN SULFATE  
Zymaxid, Gatifloxacin

\* ALLERGAN INC  
ACULAR, KETOROLAC TROMETHAMINE  
ACUVAIL, KETOROLAC TROMETHAMINE  
ACZONE, DAPSONE  
ALOCRIL, NEDOCROMIL SODIUM  
ALPHAGAN P, BRIMONIDINE TARTRATE  
AVAGE, TAZAROTENE  
AZELEX, AZELAIC ACID  
COMBIGAN, BRIMONIDINE TARTRATE  
ELESTAT, EPINASTINE HYDROCHLORIDE  
LASTACFT, ALCAFTADINE  
LATISSE, BIMATOPROST  
LUMIGAN, BIMATOPROST  
OCUFLOX, OFLOXACIN  
OZURDEX, DEXAMETHASONE  
POLYTRIM, POLYMYXIN B SULFATE  
RESTASIS, CYCLOSPORINE  
SANCTURA XR, TROSPIMUM CHLORIDE  
SANCTURA, TROSPIMUM CHLORIDE  
TAZORAC, TAZAROTENE  
Zymar, Gatifloxacin

\* ALLERGAN PHARMACEUTICAL  
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE  
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE  
BLEPHAMIDE, PREDNISOLONE ACETATE  
FML FORTE, FLUOROMETHOLONE  
FML, FLUOROMETHOLONE  
HERPLEX, IDOXURIDINE  
OCUFEN, FLURBIPROFEN SODIUM  
PRED FORTE, PREDNISOLONE ACETATE  
PRED MILD, PREDNISOLONE ACETATE  
PRED-G, GENTAMICIN SULFATE

**ALLERQUEST**

\* ALLERQUEST LLC  
PRE-PEN, BENZYL PENICILLOYL POLYLYSINE

**ALLIED PHARMA INC**

\* ALLIED PHARMA INC  
CLARITHROMYCIN, CLARITHROMYCIN  
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**ALLOS**

\* ALLOS THERAPEUTICS INC  
FOLOTYN, PRALATREXATE

**ALMATICA PHARMA INC**

\* ALMATICA PHARMA INC  
NAPRELAN, NAPROXEN SODIUM

**ALPHARMA**

\* ALPHARMA USPD INC  
PREDNISOLONE, PREDNISOLONE  
VALPROIC ACID, VALPROIC ACID

**ALPHARMA PHARMS**

\* ALPHARMA PHARMACEUTICALS LLC  
EMBEDA, MORPHINE SULFATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****ALRA**

- \* ALRA LABORATORIES INC  
CHOLAC, LACTULOSE  
CONSTILAC, LACTULOSE  
GEN-XENE, CLORAZEPATE DIPOTASSIUM  
IBU-TAB 200, IBUPROFEN (OTC)  
IBU-TAB, IBUPROFEN

**ALTAIRE PHARMS INC**

- \* ALTAIRE PHARMACEUTICALS INC  
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)  
OFLOXACIN, OFLOXACIN

**ALVOGEN**

- \* ALVOGEN INC  
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

**ALVOGEN INC**

- \* ALVOGEN INC  
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
EXEMESTANE, EXEMESTANE  
MACROBID, NITROFURANTOIN  
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE  
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

**ALVOGEN PINE BROOK**

- \* ALVOGEN PINE BROOK INC  
DISULFIRAM, DISULFIRAM

**AM ANTIBIOTICS**

- \* AMERICAN ANTIBIOTICS INC  
AMOXICILLIN, AMOXICILLIN

**AMAG PHARMS INC**

- \* AMAG PHARMACEUTICALS INC  
FERAHEME, FERUMOXYTOL

**AMARIN PHARMS**

- \* AMARIN PHARMACEUTICALS IRELAND LTD  
VASCEPA, ICOSAPENT ETHYL

**AMEDRA PHARMS**

- \* AMEDRA PHARMACEUTICALS LLC  
ADRENACLICK, EPINEPHRINE  
ALBENZA, ALBENDAZOLE  
DARAPRIM, PYRIMETHAMINE  
DEXEDRINE, DEXTROAMPHETAMINE SULFATE  
HYDROCORTISONE, HYDROCORTISONE  
TWINJECT 0.15, EPINEPHRINE  
TWINJECT 0.3, EPINEPHRINE

**AMEDRA PHARMS LLC**

- \* AMEDRA PHARMACEUTICALS LLC  
MEBENDAZOLE, MEBENDAZOLE

**AMERIGEN PHARMS LTD**

- \* AMERIGEN PHARMACEUTICALS LTD  
CARBIDOPA, CARBIDOPA

**AMGEN**

- \* AMGEN INC  
SENSIPAR, CINACALCET HYDROCHLORIDE

**AMNEAL PHARM**

- \* AMNEAL PHARMACEUTICAL  
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE  
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE  
FLECAINIDE ACETATE, FLECAINIDE ACETATE  
FOLIC ACID, FOLIC ACID  
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
PRIMIDONE, PRIMIDONE

**AMNEAL PHARMS**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

- \* AMNEAL PHARMACEUTICALS
  - ACYCLOVIR, ACYCLOVIR
  - ALBUTEROL SULFATE, ALBUTEROL SULFATE
  - ATOVAQUONE, ATOVAQUONE
  - BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
  - BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  - CALCIUM ACETATE, CALCIUM ACETATE
  - CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
  - CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  - CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  - CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
  - CLOPIDOGREL, CLOPIDOGREL
  - ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
  - FELBAMATE, FELBAMATE
  - GABAPENTIN, GABAPENTIN
  - IBUPROFEN, IBUPROFEN (OTC)
  - INDOMETHACIN, INDOMETHACIN
  - LEVETIRACETAM, LEVETIRACETAM
  - LORAZEPAM, LORAZEPAM
  - MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
  - METAXALONE, METAXALONE
  - NITROFURANTOIN, NITROFURANTOIN
  - NIZATIDINE, NIZATIDINE
  - NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
  - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  - OXCARBAZEPINE, OXCARBAZEPINE
  - OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  - POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  - PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
  - PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
  - PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
  - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  - RISPERIDONE, RISPERIDONE
  - SILDENAFIL CITRATE, SILDENAFIL CITRATE
  - SPIRONOLACTONE, SPIRONOLACTONE
  - TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
  - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  - WARFARIN SODIUM, WARFARIN SODIUM
- \* AMNEAL PHARMACEUTICALS LLC
  - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
- \* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
  - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
  - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
- AMNEAL PHARMS CO**
  - \* AMNEAL PHARMACEUTICALS CO GMBH
    - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
- AMNEAL PHARMS LLC**
  - \* AMNEAL PHARMACEUTICALS LLC
    - ACTIVELLA, ESTRADIOL
    - AZATHIOPRINE, AZATHIOPRINE
- AMNEAL PHARMS NY**
  - \* AMNEAL PHARMACEUTICALS NY LLC
    - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
    - ALPRAZOLAM, ALPRAZOLAM
    - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
    - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
    - CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
    - CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
    - EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
    - GABAPENTIN, GABAPENTIN
    - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
    - HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
    - IBUPROFEN, IBUPROFEN
    - IBUPROFEN, IBUPROFEN (OTC)



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

- \* AMNEAL PHARMACEUTICALS NY LLC  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 NAPROXEN, NAPROXEN  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 REPREXAIN, HYDROCODONE BITARTRATE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
- AMPHASTAR PHARM**
- \* AMPHASTAR PHARMACEUTICAL INC  
 AMPHADASE, HYALURONIDASE  
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
- AMPHASTAR PHARMS INC**
- \* AMPHASTAR PHARMACEUTICALS INC  
 CORTROSYN, COSYNTROPIN
- AMPOLGEN**
- \* AMPOLGEN PHARMACEUTICALS LLC  
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
- ANACOR PHARMS INC**
- \* ANACOR PHARMACEUTICALS INC  
 KERYDIN, TAVABOROLE
- ANBEX**
- \* ANBEX INC  
 IOSAT, POTASSIUM IODIDE (OTC)
- ANCHEN PHARMS**
- \* ANCHEN PHARMACEUTICALS INC  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE  
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE  
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRETINOIN, TRETINOIN  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- \* ANCHEN PHARMACEUTICALS TAIWAN INC  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
- \* ANCHEN PHARMACEUTICALS, INC  
 ALPRAZOLAM, ALPRAZOLAM  
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
- ANDRX LABS LLC**
- \* ANDRX LABS LLC  
 ALTOPREV, LOVASTATIN  
 FORTAMET, METFORMIN HYDROCHLORIDE
- ANGELINI PHARMA**
- \* ANGELINI PHARMA INC  
 OLEPTRO, TRAZODONE HYDROCHLORIDE
- ANI PHARMS**
- \* ANI PHARMACEUTICALS INC  
 CORTENEMA, HYDROCORTISONE  
 LACTULOSE, LACTULOSE  
 LUVOX, FLUVOXAMINE MALEATE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
- ANI PHARMS INC**
- \* ANI PHARMACEUTICALS INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* ANI PHARMACEUTICALS INC**

ALPRAZOLAM, ALPRAZOLAM  
 CHLORPROPAMIDE, CHLORPROPAMIDE  
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
 ETODOLAC, ETODOLAC  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 GUANABENZ ACETATE, GUANABENZ ACETATE  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
 LITHOBID, LITHIUM CARBONATE  
 METHAZOLAMIDE, METHAZOLAMIDE  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 NIZATIDINE, NIZATIDINE  
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE  
 VALPROIC ACID, VALPROIC ACID  
 VANCOGIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**ANTARES PHARMA INC****\* ANTARES PHARMA INC**

OTREXUP, METHOTREXATE

**ANTIBIOTICE****\* ANTIBIOTICE SA**

AMPICILLIN SODIUM, AMPICILLIN SODIUM  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM

**ANTIBIOTICOS BRASIL****\* ANTIBIOTICOS DO BRASIL LTDA**

CEFOXITIN, CEFOXITIN SODIUM

**APGDI****\* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC**

MYRBETRIQ, MIRABEGRON

**APOPHARMA INC****\* APOPHARMA INC**

FERRIPROX, DEFERIPRONE

**APOTEX****\* APOTEX CORP**

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

**\* APOTEX INC**

ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 CAPTOPRIL, CAPTOPRIL  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CIMETIDINE, CIMETIDINE  
 CIMETIDINE, CIMETIDINE (OTC)  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CYCLOSPORINE, CYCLOSPORINE  
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM  
 DILT-CD, DILTIAZEM HYDROCHLORIDE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
 ENALAPRIL MALEATE, ENALAPRIL MALEATE  
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE  
 EPLERENONE, EPLERENONE  
 ETODOLAC, ETODOLAC  
 FAMCICLOVIR, FAMCICLOVIR  
 FAMOTIDINE, FAMOTIDINE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 GEMFIBROZIL, GEMFIBROZIL  
 GLIPIZIDE, GLIPIZIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LAMIVUDINE, LAMIVUDINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* APOTEX INC**

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 OMEPRAZOLE, OMEPRAZOLE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PENTOXIFYLLINE, PENTOXIFYLLINE  
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
 RAMIPRIL, RAMIPRIL  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE  
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

**APOTEX CORP****\* APOTEX CORP**

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AZITHROMYCIN, AZITHROMYCIN  
 CABERGOLINE, CABERGOLINE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 RILUZOLE, RILUZOLE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**APOTEX INC****\* APOTEX INC**

ABACAVIR SULFATE, ABACAVIR SULFATE  
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
 ALPRAZOLAM, ALPRAZOLAM  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 ANASTROZOLE, ANASTROZOLE  
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BIMATOPROST, BIMATOPROST  
 BROMFENAC SODIUM, BROMFENAC SODIUM  
 CALCITONIN-SALMON, CALCITONIN SALMON  
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL  
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CEFPROZIL, CEFPROZIL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CEVIMELINE, CEVIMELINE HYDROCHLORIDE  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 FENOFIBRATE (MICRONIZED), FENOFIBRATE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 IMIQUIMOD, IMIQUIMOD  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* APOTEX INC  
 IRBESARTAN, IRBESARTAN  
 LAMIVUDINE, LAMIVUDINE  
 LAMOTRIGINE, LAMOTRIGINE  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LOVASTATIN, LOVASTATIN  
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE  
 MODAFINIL, MODAFINIL  
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID  
 NABUMETONE, NABUMETONE  
 NEVIRAPINE, NEVIRAPINE  
 OFLOXACIN, OFLOXACIN  
 OLANZAPINE, OLANZAPINE  
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE  
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS  
 OXCARBAZEPINE, OXCARBAZEPINE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 RASAGILINE MESYLATE, RASAGILINE MESYLATE  
 RISEDRONATE SODIUM, RISEDRONATE SODIUM  
 RISPERIDONE, RISPERIDONE  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 ZOLMITRIPTAN, ZOLMITRIPTAN  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

\* APOTEX INC ETOBICOKE SITE  
 ACYCLOVIR, ACYCLOVIR  
 ALLOPURINOL, ALLOPURINOL  
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CARVEDILOL, CARVEDILOL  
 CILOSTAZOL, CILOSTAZOL  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DILTIZAC, DILTIAZEM HYDROCHLORIDE  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
 ETODOLAC, ETODOLAC  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 GABAPENTIN, GABAPENTIN  
 LEFLUNOMIDE, LEFLUNOMIDE  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINOPRIL, LISINOPRIL  
 LORATADINE, LORATADINE (OTC)  
 MELOXICAM, MELOXICAM  
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 OXAPROZIN, OXAPROZIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

- \* APOTEX INC ETOBICOKE SITE  
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE  
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
TOPIRAMATE, TOPIRAMATE  
TORSEMIDE, TORSEMIDE  
ZONISAMIDE, ZONISAMIDE
- \* APOTEX INC RICHMOND HILL  
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
BUDESONIDE, BUDESONIDE  
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
FLUNISOLIDE, FLUNISOLIDE  
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
RISPERIDONE, RISPERIDONE
- \* APOTEX INC.  
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

**APOTEX TECHNOLOGIES**

- \* APOTEX TECHNOLOGIES INC  
PAXIL CR, PAROXETINE HYDROCHLORIDE  
PAXIL, PAROXETINE HYDROCHLORIDE

**APOTHECON**

- \* APOTHECON INC DIV BRISTOL MYERS SQUIBB  
KENALOG-10, TRIAMCINOLONE ACETONIDE  
KENALOG-40, TRIAMCINOLONE ACETONIDE

**APP PHARMS**

- \* APP PHARMACEUTICALS LLC  
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

**APTALIS PHARMA US**

- \* APTALIS PHARMA US INC  
BENTYL, DICYCLOMINE HYDROCHLORIDE

**APTALIS PHARMATECH**

- \* APTALIS PHARMATECH INC  
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

**AQUA PHARMS**

- \* AQUA PHARMACEUTICALS  
CORDRAN SP, FLURANDRENOLIDE  
CORDRAN, FLURANDRENOLIDE  
MONODOX, DOXYCYCLINE  
VERDESO, DESONIDE
- \* AQUA PHARMACEUTICALS LLC  
FLUOROPLEX, FLUOROURACIL  
XOLEGEL, KETOCONAZOLE

**AQUA PHARMS LLC**

- \* AQUA PHARMACEUTICALS LLC  
ACTICLATE, DOXYCYCLINE HYCLATE

**ARBOR PHARMS IRELAND**

- \* ARBOR PHARMACEUTICALS IRELAND LTD  
EDARBI, AZILSARTAN KAMEDOXOMIL  
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL

**ARBOR PHARMS LLC**

- \* ARBOR PHARMACEUTICALS LLC  
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE  
BIDIL, HYDRALAZINE HYDROCHLORIDE  
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE  
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE  
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE  
ERY-TAB, ERYTHROMYCIN  
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE  
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE  
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE  
ERYTHROMYCIN, ERYTHROMYCIN  
GLIADEL, CARMUSTINE  
NYMALIZE, NIMODIPINE  
PCE, ERYTHROMYCIN  
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* ARBOR PHARMACEUTICALS LLC  
 PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE  
 SOTYLIZE, SOTALOL HYDROCHLORIDE

**ARCO PHARMS LLC**

\* ARCO PHARMACEUTICALS LLC  
 THYROSHIELD, POTASSIUM IODIDE (OTC)

**AREVA PHARMS**

\* AREVA PHARMACEUTICALS INC  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

**ARIAD**

\* ARIAD PHARMACEUTICALS INC  
 ICLUSIG, PONATINIB HYDROCHLORIDE

**ASCEND THERAPS US**

\* ASCEND THERAPEUTICS US LLC  
 ESTROGEL, ESTRADIOL

**ASPEN GLOBAL**

\* ASPEN GLOBAL INC  
 MYLERAN, BUSULFAN

**ASPEN GLOBAL INC**

\* ASPEN GLOBAL INC  
 LEUKERAN, CHLORAMBUCIL  
 THIOGUANINE, THIOGUANINE

**ASTELLAS**

\* ASTELLAS PHARMA US INC  
 ADENOCARD, ADENOSINE  
 ADENOSCAN, ADENOSINE  
 AMBISOME, AMPHOTERICIN B  
 ASTAGRAF XL, TACROLIMUS  
 LEXISCAN, REGADENOSON  
 MYCAMINE, MICAFUNGIN SODIUM  
 PROGRAF, TACROLIMUS  
 PROTOPIC, TACROLIMUS  
 VESICARE, SOLIFENACIN SUCCINATE  
 XTANDI, ENZALUTAMIDE

**ASTRAZENECA**

\* ASTRAZENECA LP  
 ENTOCORT EC, BUDESONIDE  
 PULMICORT FLEXHALER, BUDESONIDE  
 SEROQUEL, QUETIAPINE FUMARATE  
 SYMBICORT, BUDESONIDE  
 TENORMIN, ATENOLOL

\* ASTRAZENECA PHARMACEUTICALS LP  
 ATACAND HCT, CANDESARTAN CILEXETIL  
 ATACAND, CANDESARTAN CILEXETIL  
 FASLODEX, FULVESTRANT  
 PLENDIL, FELODIPINE  
 SEROQUEL XR, QUETIAPINE FUMARATE  
 TENORETIC 100, ATENOLOL  
 TENORETIC 50, ATENOLOL  
 ZOMIG, ZOLMITRIPTAN  
 ZOMIG-ZMT, ZOLMITRIPTAN

\* ASTRAZENECA UK LTD  
 ACCOLATE, ZAFIRLUKAST  
 ARIMIDEX, ANASTROZOLE  
 CASODEX, BICALUTAMIDE  
 MERREM, MEROPENEM  
 ZESTORETIC, HYDROCHLOROTHIAZIDE  
 ZESTRIL, LISINOPRIL  
 ZOLADEX, GOSERELIN ACETATE

**ASTRAZENECA AB**

\* ASTRAZENECA AB  
 BYDUREON, EXENATIDE SYNTHETIC  
 BYETTA, EXENATIDE SYNTHETIC  
 FARXIGA, DAPAGLIFLOZIN  
 KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* ASTRAZENECA AB**

ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE  
 SYMLIN, PRAMLINTIDE ACETATE  
 XIGDUO XR, DAPAGLIFLOZIN

**ASTRAZENECA LP****\* ASTRAZENECA LP**

BRILINTA, TICAGRELOR  
 NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

**ASTRAZENECA PHARMS****\* ASTRAZENECA PHARMACEUTICALS LP**

EPANOVA, OMEGA-3-CARBOXYLIC ACIDS  
 MOVANTIK, NALOXEGOL OXALATE  
 NEXIUM IV, ESOMEPRAZOLE SODIUM  
 NEXIUM, ESOMEPRAZOLE MAGNESIUM  
 OLAPARIB, OLAPARIB  
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)  
 PRILOSEC, OMEPRAZOLE  
 PRILOSEC, OMEPRAZOLE MAGNESIUM  
 PULMICORT RESPULES, BUDESONIDE  
 RHINOCORT, BUDESONIDE  
 TOPROL-XL, METOPROLOL SUCCINATE

**ATLAS PHARMS LLC****\* ATLAS PHARMACEUTICALS LLC**

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**ATON****\* ATON PHARMA INC**

CUPRIMINE, PENICILLAMINE  
 EDECRIN, ETHACRYNATE SODIUM  
 EDECRIN, ETHACRYNIC ACID  
 LACRISERT, HYDROXYPROPYL CELLULOSE  
 LODOSYN, CARBIDOPA  
 SYPRINE, TRIENTINE HYDROCHLORIDE  
 TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE  
 TIMOPTIC, TIMOLOL MALEATE

**ATON PHARMA VPNA****\* ATON PHARMA DIV VALEANT PHARMACEUTICALS NORTH AMERICA LLC**

DEMSEER, METYROSINE

**AUROBINDO****\* AUROBINDO PHARMA LTD**

AMOXICILLIN, AMOXICILLIN  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 DIDANOSINE, DIDANOSINE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINOPRIL, LISINOPRIL  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 NEVIRAPINE, NEVIRAPINE  
 ZIDOVUDINE, ZIDOVUDINE

**AUROBINDO PHARM****\* AUROBINDO PHARMA USA INC**

FLUCONAZOLE, FLUCONAZOLE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 GABAPENTIN, GABAPENTIN  
 LEVETIRACETAM, LEVETIRACETAM  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

**AUROBINDO PHARMA****\* AUROBINDO PHARMA**

AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

**\* AUROBINDO PHARMA LTD**

ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AMPICILLIN SODIUM, AMPICILLIN SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

\* AUROBINDO PHARMA LTD  
 ATENOLOL, ATENOLOL  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE  
 CARISOPRODOL, CARISOPRODOL  
 CARVEDILOL, CARVEDILOL  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEFDINIR, CEFDINIR  
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
 CEFPROZIL, CEFPROZIL  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DIDANOSINE, DIDANOSINE  
 FINASTERIDE, FINASTERIDE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
 GLYBURIDE, GLYBURIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 MELOXICAM, MELOXICAM  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM  
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 RIBAVARIN, RIBAVIRIN  
 RIBAVIRIN, RIBAVIRIN  
 RISPERIDONE, RISPERIDONE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SIMVASTATIN, SIMVASTATIN  
 STAVUDINE, STAVUDINE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 TOPIRAMATE, TOPIRAMATE  
 TORSEMIDE, TORSEMIDE  
 TRANDOLAPRIL, TRANDOLAPRIL  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 ZALEPLON, ZALEPLON  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**AUROBINDO PHARMA LTD**

\* AUROBINDO PHARMA LIMITED  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

\* AUROBINDO PHARMA LTD  
 ABACAVIR SULFATE, ABACAVIR SULFATE  
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM  
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\***

- \* AUROBINDO PHARMA LTD  
 AMOXICILLIN, AMOXICILLIN  
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 FAMCICLOVIR, FAMCICLOVIR  
 FELODIPINE, FELODIPINE  
 FINASTERIDE, FINASTERIDE  
 GABAPENTIN, GABAPENTIN  
 GLIMEPIRIDE, GLIMEPIRIDE  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LAMIVUDINE, LAMIVUDINE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MODAFINIL, MODAFINIL  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 OLANZAPINE, OLANZAPINE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXACILLIN SODIUM, OXACILLIN SODIUM  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RAMIPRIL, RAMIPRIL  
 REPAGLINIDE, REPAGLINIDE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VALSARTAN, VALSARTAN
- \* AUROBINDO PHARMA LTD INC  
 CEFPROZIL, CEFPROZIL  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CEPHALEXIN, CEPHALEXIN  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 ZIDOVUDINE, ZIDOVUDINE
- AUROBINDO PHARMA USA**
- \* AUROBINDO PHARMA USA INC  
 ALPRAZOLAM, ALPRAZOLAM  
 NAPROXEN, NAPROXEN
- AUROLIFE PHARMA LLC**
- \* AUROLIFE PHARMA LLC  
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 GLYCOPYRROLATE, GLYCOPYRROLATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* A \*\*****\* AUROLIFE PHARMA LLC**

HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**AUSTARPHARMA LLC****\* AUSTARPHARMA LLC**

ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 METHOCARBAMOL, METHOCARBAMOL  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

**AUXILIUM PHARMS****\* AUXILIUM PHARMACEUTICALS INC**

TESTIM, TESTOSTERONE

**AUXILIUM PHARMS LLC****\* AUXILIUM PHARMACEUTICALS LLC**

DILATRATE-SR, ISOSORBIDE DINITRATE  
 EDEX, ALPROSTADIL  
 ROBAXIN, METHOCARBAMOL  
 ROBAXIN-750, METHOCARBAMOL  
 SEMPREX-D, ACRIVASTINE  
 STRIANT, TESTOSTERONE

**AVACOR PRODS****\* AVACOR PRODUCTS LLC**

MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

**AVANIR PHARMS****\* AVANIR PHARMACEUTICALS INC**

NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

**AVANTHI INC****\* AVANTHI INC**

CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)  
 DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE  
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

**AVEMA PHARMA****\* AVEMA PHARMA SOLUTIONS**

IBUPROFEN, IBUPROFEN (OTC)

**AVENT****\* AVENT INC**

PYTEST KIT, UREA, C-14  
 PYTEST, UREA, C-14

**AVEVA****\* AVEVA DRUG DELIVERY SYSTEMS INC**

CLONIDINE, CLONIDINE  
 FENTANYL-100, FENTANYL  
 FENTANYL-25, FENTANYL  
 FENTANYL-50, FENTANYL  
 FENTANYL-75, FENTANYL  
 NICOTINE, NICOTINE (OTC)

**AVID RADIOPHARMS INC****\* AVID RADIOPHARMACEUTICALS INC**

AMYVID, FLORBETAPIR F-18

**\*\* B \*\*****B BRAUN****\* B BRAUN MEDICAL INC**

ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
 ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL  
 ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL  
 AMINO ACIDS, AMINO ACIDS  
 BALANCED SALT, CALCIUM CHLORIDE  
 BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE  
 CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* B \*\*

## \* B BRAUN MEDICAL INC

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE  
 CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM  
 CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM  
 CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME  
 CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM  
 CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM  
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE  
 FREAMINE HBC 6.9%, AMINO ACIDS  
 FREAMINE III 10%, AMINO ACIDS  
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS  
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS  
 FREAMINE III 8.5%, AMINO ACIDS  
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE  
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE  
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPATAMINE 8%, AMINO ACIDS  
 ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL  
 MANNITOL 10%, MANNITOL  
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL  
 MANNITOL 15%, MANNITOL

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* B \*\*

## \* B BRAUN MEDICAL INC

MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL  
MANNITOL 20%, MANNITOL  
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL  
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL  
MANNITOL 5%, MANNITOL  
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE  
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
NEPHRAMINE 5.4%, AMINO ACIDS  
NUTRILIPID 10%, SOYBEAN OIL  
NUTRILIPID 20%, SOYBEAN OIL  
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC  
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC  
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC  
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC  
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC  
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC  
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC  
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC  
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC  
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC  
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC  
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM  
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC  
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC  
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\*****\* B BRAUN MEDICAL INC**

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PROCALAMINE, AMINO ACIDS  
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL  
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE  
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION  
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 TROPHAMINE 10%, AMINO ACIDS  
 TROPHAMINE, AMINO ACIDS

**BAJAJ MEDICAL LLC****\* BAJAJ MEDICAL LLC**

DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)

**BANNER PHARMACAPS****\* BANNER PHARMACAPS INC**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
 BENZONATATE, BENZONATATE  
 CALCITRIOL, CALCITRIOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 ETHOSUXIMIDE, ETHOSUXIMIDE  
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
 IBUPROFEN, IBUPROFEN (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 MIDOL LIQUID GELS, IBUPROFEN (OTC)  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 NIMODIPINE, NIMODIPINE  
 PARICALCITOL, PARICALCITOL  
 PROGESTERONE, PROGESTERONE  
 VALPROIC ACID, VALPROIC ACID  
 VITAMIN D, ERGOCALCIFEROL  
 ZONISAMIDE, ZONISAMIDE

**BARR****\* BARR LABORATORIES INC**

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
 ARANELLE, ETHINYL ESTRADIOL  
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN  
 BALZIVA-28, ETHINYL ESTRADIOL  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 CAMILA, NORETHINDRONE  
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE  
 CHLORZOXAZONE, CHLORZOXAZONE  
 CLONAZEPAM, CLONAZEPAM  
 CLONIDINE, CLONIDINE  
 DANAZOL, DANAZOL  
 DEMECLOXYCLINE HYDROCHLORIDE, DEMECLOXYCLINE HYDROCHLORIDE  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 DIAZEPAM, DIAZEPAM  
 DIDANOSINE, DIDANOSINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

- \* BARR LABORATORIES INC  
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE  
 DUTASTERIDE, DUTASTERIDE  
 ERRIN, NORETHINDRONE  
 ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE  
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL  
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL  
 ESTROPIPATE, ESTROPIPATE  
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE  
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE  
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
 FLECAINIDE ACETATE, FLECAINIDE ACETATE  
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 HYDROXYUREA, HYDROXYUREA  
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE  
 ISONIAZID, ISONIAZID  
 JUNEL 1.5/30, ETHINYL ESTRADIOL  
 JUNEL 1/20, ETHINYL ESTRADIOL  
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL  
 JUNEL FE 1/20, ETHINYL ESTRADIOL  
 KARIVA, DESOGESTREL  
 KELNOR, ETHINYL ESTRADIOL  
 LEFLUNOMIDE, LEFLUNOMIDE  
 LESSINA-28, ETHINYL ESTRADIOL  
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE  
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE  
 MEGESTROL ACETATE, MEGESTROL ACETATE  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE  
 NIACIN, NIACIN  
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE  
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL  
 NORTREL 1/35-21, ETHINYL ESTRADIOL  
 NORTREL 1/35-28, ETHINYL ESTRADIOL  
 NORTREL 7/7/7, ETHINYL ESTRADIOL  
 ONDANSETRON, ONDANSETRON  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PORTIA-28, ETHINYL ESTRADIOL  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 SPRINTEC, ETHINYL ESTRADIOL  
 TEMOZOLOMIDE, TEMOZOLOMIDE  
 TREXALL, METHOTREXATE SODIUM  
 TRI-LEGEST 21, ETHINYL ESTRADIOL  
 TRI-LEGEST FE, ETHINYL ESTRADIOL  
 TRI-SPRINTEC, ETHINYL ESTRADIOL  
 WARFARIN SODIUM, WARFARIN SODIUM
- \* BARR PHARMACEUTICALS  
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
- BARR LABS DIV TEVA**
- \* BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA  
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM  
 BUDESONIDE, BUDESONIDE  
 OXYBUTYNIN, OXYBUTYNIN
- BARR LABS INC**
- \* BARR LABORATORIES INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* BARR LABORATORIES INC  
 ACITRETIN, ACITRETIN  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 ESTRADIOL, ESTRADIOL  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 NIMODIPINE, NIMODIPINE  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 OLANZAPINE, OLANZAPINE  
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN  
 TRETINOIN, TRETINOIN

**BAUSCH AND LOMB**

\* BAUSCH AND LOMB INC  
 ALWAY, KETOTIFEN FUMARATE (OTC)  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 ALREX, LOTEPIREDNOL ETABONATE  
 BESIVANCE, BESIFLOXACIN HYDROCHLORIDE  
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
 ISTALOL, TIMOLOL MALEATE  
 LATANOPROST, LATANOPROST  
 LOTEMAX, LOTEPIREDNOL ETABONATE  
 MIOCHOL-E, ACETYLCHOLINE CHLORIDE  
 OFLOXACIN, OFLOXACIN  
 OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
 PROLENSA, BROMFENAC SODIUM  
 RETISERT, FLUOCINOLONE ACETONIDE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 VITRASE, HYALURONIDASE  
 ZIRGAN, GANCICLOVIR  
 ZYLET, LOTEPIREDNOL ETABONATE

\* BAUSCH AND LOMB PHARMACEUTICALS INC  
 ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL  
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC  
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
 CROLOM, CROMOLYN SODIUM  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
 DEXASPORIN, DEXAMETHASONE  
 ERYTHROMYCIN, ERYTHROMYCIN  
 FLUNISOLIDE, FLUNISOLIDE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC  
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN  
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE  
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC  
 OFLOXACIN, OFLOXACIN  
 OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE  
 OTICAIR, HYDROCORTISONE  
 PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE  
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM  
 TIMOLOL MALEATE, TIMOLOL MALEATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* BAUSCH AND LOMB PHARMACEUTICALS INC  
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE  
 TOBRAMYCIN, TOBRAMYCIN  
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 TROPICAMIDE, TROPICAMIDE

**BAUSCH AND LOMB INC**

\* BAUSCH AND LOMB INC  
 BEPREVE, BEPOTASTINE BESILATE  
 BROMDAY, BROMFENAC SODIUM  
 LOTEMAX, LOTEPIREDNOL ETABONATE

**BAXTER HLTHCARE**

\* BAXTER HEALTHCARE CORP  
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE  
 ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM  
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM  
 BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS  
 BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE  
 BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE  
 BREVIBLOC, ESMOLOL HYDROCHLORIDE  
 CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE  
 CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM  
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC  
 CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC  
 CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC  
 CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC  
 CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC  
 CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,  
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS  
 CLINOLIPID 20%, OLIVE OIL  
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE  
 CYTOXAN (LYOPHILIZED), CYCLOPHOSPHAMIDE  
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE



## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* B \*\*

## \* BAXTER HEALTHCARE CORP

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,  
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC  
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE  
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
 ETHRANE, ENFLURANE  
 EXTRANEAL, ICODEXTRIN  
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE  
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FORANE, ISOFLURANE  
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN  
 IFEX, IFOSFAMIDE  
 ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE  
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 MESNEX, MESNA  
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM  
 NEXTERONE, AMIODARONE HYDROCHLORIDE  
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN  
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 10% IN WATER, MANNITOL  
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 15% IN WATER, MANNITOL  
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 20% IN WATER, MANNITOL

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* B \*\*

## \* BAXTER HEALTHCARE CORP

OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL  
 OSMITROL 5% IN WATER, MANNITOL  
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM  
 PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE  
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
 PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS  
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 SEVOFLURANE, SEVOFLURANE  
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE  
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION  
 STERILE WATER, STERILE WATER FOR IRRIGATION  
 SUPRANE, DESFLURANE  
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 TIS-U-SOL, MAGNESIUM SULFATE  
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS  
 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS  
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

## \* BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV

PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

**BAXTER HLTHCARE CORP**

## \* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE

PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

- \* BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE  
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

**BAYER**

- \* BAYER HEALTHCARE LLC  
ALEVE, NAPROXEN SODIUM (OTC)  
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)  
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)

**BAYER HEALTHCARE LLC**

- \* BAYER HEALTHCARE LLC  
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)  
CLARITIN HIVES RELIEF, LORATADINE (OTC)  
CLARITIN REDITABS, LORATADINE (OTC)  
CLARITIN, LORATADINE (OTC)  
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)  
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)  
MYCELEX-7, CLOTRIMAZOLE (OTC)  
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)

**BAYER HLTHCARE**

- \* BAYER HEALTHCARE CONSUMER CARE  
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
- \* BAYER HEALTHCARE PHARMACEUTICALS INC  
ADALAT CC, NIFEDIPINE  
ADEMPAS, RIOCIQUAT  
ANGELIQ, DROSPIRENONE  
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE  
AVELOX, MOXIFLOXACIN HYDROCHLORIDE  
BETAPACE, SOTALOL HYDROCHLORIDE  
BEYAZ, DROSPIRENONE  
BILTRICIDE, PRAZIQUANTEL  
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
CIPRO, CIPROFLOXACIN  
CIPRO, CIPROFLOXACIN HYDROCHLORIDE  
CLIMARA PRO, ESTRADIOL  
CLIMARA, ESTRADIOL  
DESONATE, DESONIDE  
DTIC-DOME, DACARBAZINE  
EOVIST, GADOXETATE DISODIUM  
FINACEA, AZELAIC ACID  
GADAVIST, GADOBUTROL  
LEVITRA, VARDENAFIL HYDROCHLORIDE  
MAGNEVIST, GADOPENTETATE DIMEGLUMINE  
MENOSTAR, ESTRADIOL  
MIRENA, LEVONORGESTREL  
NATAZIA, DIENOGEST  
NEXAVAR, SORAFENIB TOSYLATE  
PRECOSE, ACARBOSE  
SAFYRAL, DROSPIRENONE  
SKYLA, LEVONORGESTREL  
STAXYN, VARDENAFIL HYDROCHLORIDE  
STIVARGA, REGORAFENIB  
ULTRAVIST (PHARMACY BULK), IOPROMIDE  
ULTRAVIST 150, IOPROMIDE  
ULTRAVIST 240, IOPROMIDE  
ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE  
ULTRAVIST 300, IOPROMIDE  
ULTRAVIST 370, IOPROMIDE  
XOFIGO, RADIUM RA-223 DICHLORIDE  
YASMIN, DROSPIRENONE  
YAZ, DROSPIRENONE

**BAYSHORE PHARMS LLC**

- \* BAYSHORE PHARMACEUTICALS LLC  
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE  
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\*****BD RX**

\* BD RX INC  
 DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

**BECTON DICKINSON**

\* BECTON DICKINSON AND CO  
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)  
 E-Z SCRUB 201, POVIDONE-IODINE (OTC)  
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)

**BEDFORD**

\* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC  
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM  
 ADENOSINE, ADENOSINE  
 BUMETANIDE, BUMETANIDE  
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE  
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE  
 ENALAPRILAT, ENALAPRILAT  
 ETOMIDATE, ETOMIDATE  
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MILRINONE LACTATE, MILRINONE LACTATE  
 MITOMYCIN, MITOMYCIN  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 RIFAMPIN, RIFAMPIN  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
 VALPROATE SODIUM, VALPROATE SODIUM  
 VECURONIUM BROMIDE, VECURONIUM BROMIDE  
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

**BEDFORD LABS**

\* BEDFORD LABORATORIES  
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE  
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUMAZENIL, FLUMAZENIL  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LORAZEPAM PRESERVATIVE FREE, LORAZEPAM  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

**BELCHER PHARMS**

\* BELCHER PHARMACEUTICALS LLC  
 CEPHALEXIN, CEPHALEXIN  
 DESLORATADINE, DESLORATADINE

**BELCHER PHARMS LLC**

\* BELCHER PHARMACEUTICALS LLC  
 EPINEPHRINE, EPINEPHRINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\*****BEXIMCO USA**

\* BEXIMCO PHARMACEUTICALS USA INC  
CARVEDILOL, CARVEDILOL

**BICON PHARM**

\* BICON PHARMACEUTICAL INC  
FOLIC ACID, FOLIC ACID

**BIO NUCLEONICS**

\* BIO NUCLEONICS INC  
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

**BIO PHARM INC**

\* BIO PHARM INC  
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
RISPERIDONE, RISPERIDONE

**BIOALLIANCE PHARMA**

\* BIOALLIANCE PHARMA  
ORAVIG, MICONAZOLE

**BIOCODEX INC**

\* BIOCODEX INC  
TOTECT, DEXRAZOXANE HYDROCHLORIDE

**BIOCRIST**

\* BIOCRIST PHARMACEUTICALS INC  
RAPIVAB, PERAMIVIR

**BIODELIVERY SCI INTL**

\* BIODELIVERY SCIENCES INTERNATIONAL INC  
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE

**BIOGEN IDEC INC**

\* BIOGEN IDEC INC  
TECFIDERA, DIMETHYL FUMARATE

**BIOKEY**

\* BIOKEY INC  
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
CILOSTAZOL, CILOSTAZOL

**BIOMARIN PHARM**

\* BIOMARIN PHARMACEUTICAL INC  
KUVAN, SAPROPTERIN DIHYDROCHLORIDE

**BIOMEDCL RES FDN**

\* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISIANA  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**BLAIREX**

\* BLAIREX LABORATORIES INC  
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

**BLU CARIBE**

\* BLU CARIBE INC  
GEMFIBROZIL, GEMFIBROZIL  
SIMVASTATIN, SIMVASTATIN

**BLU CARIBE INC**

\* BLU CARIBE INC  
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

**BOEHRINGER INGELHEIM**

\* BOEHRINGER INGELHEIM  
CATAPRES, CLONIDINE HYDROCHLORIDE  
CATAPRES-TTS-1, CLONIDINE  
CATAPRES-TTS-2, CLONIDINE  
CATAPRES-TTS-3, CLONIDINE  
GILOTRIF, AFATINIB DIMALEATE  
MICARDIS HCT, HYDROCHLOROTHIAZIDE  
MICARDIS, TELMISARTAN  
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE  
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)  
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)  
\* BOEHRINGER INGELHEIM PHARMACEUTICALS INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

\* BOEHRINGER INGELHEIM PHARMACEUTICALS INC  
 AGGRENEX, ASPIRIN  
 APTIVUS, TIPRANAVIR  
 ATROVENT HFA, IPRATROPIUM BROMIDE  
 ATROVENT, IPRATROPIUM BROMIDE  
 COMBIVENT RESPIMAT, ALBUTEROL SULFATE  
 COMBIVENT, ALBUTEROL SULFATE  
 FLOMAX, TAMSULOSIN HYDROCHLORIDE  
 JARDIANCE, EMPAGLIFLOZIN  
 JENTADUETO, LINAGLIPTIN  
 MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE  
 MOBIC, MELOXICAM  
 OFEV, NINTEDANIB  
 PERSANTINE, DIPYRIDAMOLE  
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE  
 SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE  
 SPIRIVA, TIOTROPIUM BROMIDE  
 STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE  
 TRADJENTA, LINAGLIPTIN  
 TWYNSTA, AMLODIPINE BESYLATE  
 VIRAMUNE XR, NEVIRAPINE  
 VIRAMUNE, NEVIRAPINE

**BRACCO**

\* BRACCO DIAGNOSTICS INC  
 CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82  
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT  
 CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE  
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE  
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE  
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE  
 ISOVUE-200, IOPAMIDOL  
 ISOVUE-250, IOPAMIDOL  
 ISOVUE-300, IOPAMIDOL  
 ISOVUE-370, IOPAMIDOL  
 ISOVUE-M 200, IOPAMIDOL  
 ISOVUE-M 300, IOPAMIDOL  
 KINEVAC, SINCALIDE  
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES  
 MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT  
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE  
 MULTIHANCE, GADOBENATE DIMEGLUMINE  
 PROHANCE MULTIPACK, GADOTERIDOL  
 PROHANCE, GADOTERIDOL  
 RENOGRAFIN-76, DIATRIZOATE MEGLUMINE  
 SINOGRAFIN, DIATRIZOATE MEGLUMINE

**BRAINTREE**

\* BRAINTREE LABORATORIES INC  
 AXID, NIZATIDINE  
 GOLYTELY, POLYETHYLENE GLYCOL 3350  
 NULYTELY, POLYETHYLENE GLYCOL 3350  
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

**BRAINTREE LABS**

\* BRAINTREE LABORATORIES INC  
 SUCLEAR, MAGNESIUM SULFATE  
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS

**BRECKENRIDGE PHARM**

\* BRECKENRIDGE PHARMACEUTICAL INC  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CILOSTAZOL, CILOSTAZOL  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE  
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL  
 LEVETIRACETAM, LEVETIRACETAM  
 MEFENAMIC ACID, MEFENAMIC ACID  
 MELOXICAM, MELOXICAM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* B \*\***

- \* BRECKENRIDGE PHARMACEUTICAL INC  
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE  
OXCARBAZEPINE, OXCARBAZEPINE  
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

**BRIGHAM WOMENS**

- \* BRIGHAM AND WOMENS HOSP  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**BRIGHAM WOMENS HOSP**

- \* BRIGHAM AND WOMENS HOSP INC  
AMMONIA N 13, AMMONIA N-13

**BRISTOL MYERS SQUIBB**

- \* BRISTOL MYERS SQUIBB  
AZACTAM, AZTREONAM  
BARACLUDE, ENTECAVIR  
GLUCOVANCE, GLYBURIDE  
LYSODREN, MITOTANE  
MEGACE, MEGESTROL ACETATE  
PRAVACHOL, PRAVASTATIN SODIUM
- \* BRISTOL MYERS SQUIBB CO  
AZACTAM IN PLASTIC CONTAINER, AZTREONAM  
DROXIA, HYDROXYUREA  
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE  
HYDREA, HYDROXYUREA  
IXEMPRA KIT, IXABEPILONE  
REYATAZ, ATAZANAVIR SULFATE  
SPRYCEL, DASATINIB  
SUSTIVA, EFAVIRENZ  
VIDEX EC, DIDANOSINE
- \* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE  
ELIQUIS, APIXABAN  
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE  
GLUCOPHAGE, METFORMIN HYDROCHLORIDE  
VIDEX, DIDANOSINE  
ZERIT, STAVUDINE
- \* BRISTOL MYERS SQUIBB PHARMA CO  
COUMADIN, WARFARIN SODIUM

**BRYAN**

- \* BRYAN CORP  
SCLEROSOL, TALC  
TALC, TALC

**\*\* C \*\*****CADENCE PHARMS**

- \* CADENCE PHARMACEUTICALS INC  
OFIRMEV, ACETAMINOPHEN

**CADILA PHARMS LTD**

- \* CADILA PHARMACEUTICALS LTD  
ACYCLOVIR, ACYCLOVIR  
FOLIC ACID, FOLIC ACID  
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
OFLOXACIN, OFLOXACIN

**CADISTA PHARMS**

- \* CADISTA PHARMACEUTICALS INC  
ALENDRONATE SODIUM, ALENDRONATE SODIUM  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
LAMOTRIGINE, LAMOTRIGINE  
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
OXCARBAZEPINE, OXCARBAZEPINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\*****CARACO**

- \* CARACO PHARMACEUTICAL LABORATORIES LTD  
BACLOFEN, BACLOFEN  
FLUMADINE, RIMANTADINE HYDROCHLORIDE  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
SYNALGOS-DC, ASPIRIN

**CARDINAL HEALTH 414**

- \* CARDINAL HEALTH 414 LLC  
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
- \* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES  
AMMONIA N 13, AMMONIA N-13

**CARDINAL HLTH 414**

- \* CARDINAL HEALTH 414  
SODIUM IODIDE I 123, SODIUM IODIDE I-123

**CAREFUSION**

- \* CAREFUSION 213 LLC  
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)  
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

**CARLSBAD**

- \* CARLSBAD TECHNOLOGY INC  
ACYCLOVIR, ACYCLOVIR  
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
FAMOTIDINE, FAMOTIDINE  
GLIMEPIRIDE, GLIMEPIRIDE  
LOVASTATIN, LOVASTATIN  
MELOXICAM, MELOXICAM  
MODAFINIL, MODAFINIL  
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**CAROLINA MEDCL**

- \* CAROLINA MEDICAL PRODUCTS CO  
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE  
ISONIAZID, ISONIAZID  
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE  
SPS, SODIUM POLYSTYRENE SULFONATE  
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

**CATALENT**

- \* CATALENT PHARMA SOLUTIONS LLC  
VALPROIC ACID, VALPROIC ACID

**CEDAR PHARMS**

- \* CEDAR PHARMACEUTICALS LLC  
METHIMAZOLE, METHIMAZOLE  
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

**CELGENE**

- \* CELGENE CORP  
ISTODAX, ROMIDEPSIN  
POMALYST, POMALIDOMIDE  
REVLIMID, LENALIDOMIDE  
THALOMID, THALIDOMIDE  
VIDAZA, AZACITIDINE

**CELGENE CORP**

- \* CELGENE CORP  
OTEZLA, APREMILAST

**CEPHALON**

- \* CEPHALON INC  
ACTIQ, FENTANYL CITRATE  
FENTORA, FENTANYL CITRATE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\*****\* CEPHALON INC**

GABITRIL, TIAGABINE HYDROCHLORIDE  
 NUVIGIL, ARMODAFINIL  
 PROVIGIL, MODAFINIL  
 TREANDA, BENDAMUSTINE HYDROCHLORIDE  
 TRISENOX, ARSENIC TRIOXIDE

**CEREXA**

\* CEREXA INC  
 TEFLARO, CEFTAROLINE FOSAMIL

**CHARTWELL LIFE SCI**

\* CHARTWELL LIFE SCIENCE LLC  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE, DOXYCYCLINE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**CHATTEM**

\* CHATTEM INC  
 SELSUN, SELENIUM SULFIDE  
 UNISOM, DOXYLAMINE SUCCINATE (OTC)

**CHEMISCH FBRK KRSSLR**

\* CHEMISCHE FABRIK KREUSSLER & CO. GMBH  
 ASCLERA, POLIDOCANOL

**CHIESI USA INC**

\* CHIESI USA INC  
 BETHKIS, TOBRAMYCIN  
 CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE  
 CARDENE, NICARDIPINE HYDROCHLORIDE  
 CUROSURF, PORACTANT ALFA  
 ZYFLO CR, ZILEUTON  
 ZYFLO, ZILEUTON

**CHILDRENS HOSP MI**

\* CHILDRENS HOSP MICHIGAN  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**CHIRHOCLIN**

\* CHIRHOCLIN INC  
 CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

**CIPHER PHARMS INC**

\* CIPHER PHARMACEUTICALS INC  
 CONZIP, TRAMADOL HYDROCHLORIDE  
 LIPOFEN, FENOFIBRATE

**CIPLA**

\* CIPLA LTD  
 NEVIRAPINE, NEVIRAPINE  
 RISPERIDONE, RISPERIDONE  
 ZIDOVUDINE, ZIDOVUDINE

**CIPLA LTD**

\* CIPLA LTD  
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
 ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 ANASTROZOLE, ANASTROZOLE  
 CARBOPLATIN, CARBOPLATIN  
 CARVEDILOL, CARVEDILOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CICLOPIROX, CICLOPIROX  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 FAMCICLOVIR, FAMCICLOVIR  
 FINASTERIDE, FINASTERIDE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\*****\* CIPLA LTD**

IRBESARTAN, IRBESARTAN  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 MELOXICAM, MELOXICAM  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 STAVUDINE, STAVUDINE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 TOPIRAMATE, TOPIRAMATE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 ZALEPLON, ZALEPLON  
 ZIDOVUDINE, ZIDOVUDINE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**CITIUS PHARMS**

\* CITIUS PHARMACEUTICALS LLC  
 SUPRENZA, PHENTERMINE HYDROCHLORIDE

**CITRON PHARMA LLC**

\* CITRON PHARMA LLC  
 CORTISPORIN, HYDROCORTISONE  
 THALITONE, CHLORTHALIDONE

**CLARIS LIFESCIENCES**

\* CLARIS LIFESCIENCES LIMITED  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

\* CLARIS LIFESCIENCES LTD  
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
 CIPROFLOXACIN, CIPROFLOXACIN  
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 FUROSEMIDE, FUROSEMIDE  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVOFLOXACIN, LEVOFLOXACIN  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE  
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE

**CLINIGEN HLTHCARE**

\* CLINIGEN HEALTHCARE LTD  
 ETHYOL, AMIFOSTINE  
 FOSCAVIR, FOSCARNET SODIUM

**CLOVER PHARMS**

\* CLOVER PHARMACEUTICALS CORP  
 AMICAR, AMINOCAPROIC ACID

**CNTY LINE PHARMS**

\* COUNTY LINE PHARMACEUTICALS LLC  
 DYNACIN, MINOCYCLINE HYDROCHLORIDE  
 LIDEX, FLUOCINONIDE  
 LOPROX, CICLOPIROX  
 TRANDATE, LABETALOL HYDROCHLORIDE  
 UREX, METHENAMINE HIPPURATE

**COASTAL PHARMS**

\* COASTAL PHARMACEUTICALS  
 BROMFENAC SODIUM, BROMFENAC SODIUM  
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM  
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE  
 NYSTATIN, NYSTATIN  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE AND ASPIRIN, ASPIRIN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**COLGATE**

\* COLGATE ORAL PHARMACEUTICALS INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\***

\* COLGATE ORAL PHARMACEUTICALS INC  
PERIOGARD, CHLORHEXIDINE GLUCONATE

**COLGATE PALMOLIVE**

\* COLGATE PALMOLIVE  
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

**CONCORDIA LABS INC**

\* CONCORDIA LABORATORIES INC  
PHOTOFRIN, PORFIMER SODIUM

**CONCORDIA PHARMS INC**

\* CONCORDIA PHARMACEUTICALS INC  
KAPVAY, CLONIDINE HYDROCHLORIDE  
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE  
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE

**CONTRACT PHARMACAL**

\* CONTRACT PHARMACAL CORP  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CIMETIDINE, CIMETIDINE (OTC)  
FOLIC ACID, FOLIC ACID  
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
IBUPROFEN, IBUPROFEN  
IBUPROFEN, IBUPROFEN (OTC)  
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
PREDNISONE, PREDNISONE  
PROFEN, IBUPROFEN (OTC)  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**CORCEPT THERAP**

\* CORCEPT THERAPEUTICS INC  
KORLYM, MIFEPRISTONE

**CORDEN PHARMA**

\* CORDEN PHARMA LATINA SPA  
GLEOSTINE, LOMUSTINE

**COREPHARMA**

\* COREPHARMA LLC  
ALPRAZOLAM, ALPRAZOLAM  
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE  
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
GLYBURIDE, GLYBURIDE  
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
LEVOCARNITINE, LEVOCARNITINE  
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE  
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
PHENYTOIN, PHENYTOIN  
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE  
POTASSIUM CITRATE, POTASSIUM CITRATE  
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
URSODIOL, URSODIOL

**COVIS INJECTABLES**

\* COVIS INJECTABLES SARL  
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM  
FORTAZ, CEFTAZIDIME  
LANOXIN PEDIATRIC, DIGOXIN  
LANOXIN, DIGOXIN  
ZANTAC, RANITIDINE HYDROCHLORIDE  
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\***

\* COVIS INJECTABLES SARL  
ZINACEF, CEFUROXIME SODIUM

**COVIS PHARMA**

\* COVIS PHARMA SARL  
LANOXIN, DIGOXIN  
PARNATE, TRANYLCPROMINE SULFATE

**COVIS PHARMA SARL**

\* COVIS PHARMA SARL  
BETAPACE AF, SOTALOL HYDROCHLORIDE  
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE  
DUTOPROL, HYDROCHLOROTHIAZIDE  
DYRENIUM, TRIAMTERENE  
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE  
NILANDRON, NILUTAMIDE  
RILUTEK, RILUZOLE  
UROXATRAL, ALFUZOSIN HYDROCHLORIDE

**CPDC**

\* CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**CPPI CV**

\* CP PHARMACEUTICALS INTERNATIONAL CV  
SUTENT, SUNITINIB MALATE

**CRANFORD PHARMS LLC**

\* CRANFORD PHARMACEUTICALS LLC  
INDERAL LA, PROPRANOLOL HYDROCHLORIDE

**CREALTA PHARMS LLC**

\* CREALTA PHARMACEUTICALS LLC  
MIGERGOT, CAFFEINE  
OXANDRIN, OXANDROLONE

**CROWN LABS**

\* CROWN LABORATORIES INC  
ALA-CORT, HYDROCORTISONE  
ALA-SCALP, HYDROCORTISONE  
TRIDERM, TRIAMCINOLONE ACETONIDE

**CSL BEHRING**

\* CSL BEHRING LLC  
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

**CSPC OUYI PHARM CO**

\* CSPC OUYI PHARMACEUTICAL CO LTD  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**CUBIST**

\* CUBIST PHARMACEUTICALS INC  
CUBICIN, DAPTOMYCIN

**CUBIST PHARMS**

\* CUBIST PHARMACEUTICALS INC  
DIFICID, FIDAXOMICIN  
ENTEREG, ALVIMOPAN  
ZERBAXA, CEFTOLOZANE SULFATE

**CUBIST PHARMS INC**

\* CUBIST PHARMACEUTICALS INC  
SIVEXTRO, TEDIZOLID PHOSPHATE

**CUMBERLAND PHARMS**

\* CUMBERLAND PHARMACEUTICALS INC  
ACETADOTE, ACETYLCYSTEINE  
CALDOLOR, IBUPROFEN  
LACTULOSE, LACTULOSE  
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE

**CYPRESS BIOSCIENCE**

\* CYPRESS BIOSCIENCE INC  
SAVELLA, MILNACIPRAN HYDROCHLORIDE

**CYPRESS PHARM**

\* CYPRESS PHARMACEUTICAL INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* C \*\***

\* CYPRESS PHARMACEUTICAL INC  
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 ELIPHOS, CALCIUM ACETATE  
 REZIRA, HYDROCODONE BITARTRATE  
 VITUZ, CHLORPHENIRAMINE MALEATE  
 ZUTRIPRO, CHLORPHENIRAMINE MALEATE

**\*\* D \*\*****DAIICHI**

\* DAIICHI PHARMACEUTICAL CORP  
 FLOXIN OTIC, OFLOXACIN

**DAIICHI SANKYO**

\* DAIICHI SANKYO INC  
 AZOR, AMLODIPINE BESYLATE  
 BENICAR HCT, HYDROCHLOROTHIAZIDE  
 BENICAR, OLMESARTAN MEDOXOMIL  
 EVOXAC, CEVIMELINE HYDROCHLORIDE  
 TRIBENZOR, AMLODIPINE BESYLATE  
 WELCHOL, COLESEVELAM HYDROCHLORIDE

**DANCO LABS LLC**

\* DANCO LABORATORIES LLC  
 MIFEPREX, MIFEPRISTONE

**DARA BIOSCIENCES**

\* DARA BIOSCIENCES INC  
 SOLTAMOX, TAMOXIFEN CITRATE

**DAVA INTL INC**

\* DAVA INTERNATIONAL INC  
 ALPRAZOLAM, ALPRAZOLAM

**DAVA PHARMS INC**

\* DAVA PHARMACEUTICALS INC  
 ACYCLOVIR, ACYCLOVIR  
 AMOXICILLIN, AMOXICILLIN  
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE  
 ATENOLOL, ATENOLOL  
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
 GEMFIBROZIL, GEMFIBROZIL  
 GLYBURIDE (MICRONIZED), GLYBURIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 MORPHINE SULFATE, MORPHINE SULFATE  
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM  
 PROPYLTHIOURACIL, PROPYLTHIOURACIL  
 PYRAZINAMIDE, PYRAZINAMIDE  
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE  
 VOSPIRE ER, ALBUTEROL SULFATE

**DAVIS AND GECK**

\* DAVIS AND GECK DIV AMERICAN CYANAMID CO  
 PRE-OP II, HEXACHLOROPHENE  
 PRE-OP, HEXACHLOROPHENE

**DELCOR ASSET**

\* DELCOR ASSET CORP  
 EVOCLIN, CLINDAMYCIN PHOSPHATE  
 LUXIQ, BETAMETHASONE VALERATE  
 OLUX E, CLOBETASOL PROPIONATE  
 OLUX, CLOBETASOL PROPIONATE  
 VUSION, MICONAZOLE NITRATE  
 ZOVIRAX, ACYCLOVIR

**DELCOR ASSET CORP**

\* DELCOR ASSET CORP  
 ERYGEL, ERYTHROMYCIN  
 EXTINA, KETOCONAZOLE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* D \*\*****DENCO ASSET**

\* DENCO ASSET LLC  
DENAVIR, PENCICLOVIR SODIUM

**DENTSPLY PHARM**

\* DENTSPLY PHARMACEUTICAL INC  
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE  
ORAQIX, LIDOCAINE

**DEPOMED INC**

\* DEPOMED INC  
CAMBIA, DICLOFENAC POTASSIUM  
GRALISE, GABAPENTIN  
LAZANDA, FENTANYL CITRATE  
ZIPSOR, DICLOFENAC POTASSIUM

**DEPROCO**

\* DEPROCO INC  
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE  
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE  
SCANDONEST L, LEVONORDEFIN  
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE  
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

**DEXCEL LTD**

\* DEXCEL LTD  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

**DEXCEL PHARMA**

\* DEXCEL PHARMA TECHNOLOGIES LTD  
OMEPRAZOLE, OMEPRAZOLE (OTC)  
PERIOCHIP, CHLORHEXIDINE GLUCONATE

**DIALYSIS SUPS**

\* DIALYSIS SUPPLIES INC  
NORMOCARB HF 25, MAGNESIUM CHLORIDE  
NORMOCARB HF 35, MAGNESIUM CHLORIDE

**DIGESTIVE CARE INC**

\* DIGESTIVE CARE INC  
PERTZYE, PANCRELIPASE (AMYLASE)

**DISCOVERY LABS**

\* DISCOVERY LABORATORIES INC  
SURFAXIN, LUCINACTANT

**DORADO PHARMA**

\* DORADO PHARMA LLC  
KETOPROFEN, KETOPROFEN

**DORC**

\* DORC INTERNATIONAL BV  
MEMBRANEBLUE, TRYPAN BLUE  
VISIONBLUE, TRYPAN BLUE

**DOUGLAS PHARMS**

\* DOUGLAS PHARMACEUTICALS AMERICA LTD  
MYORISAN, ISOTRETINOIN

**DOW PHARM**

\* DOW PHARMACEUTICAL SCIENCES  
ACANYA, BENZOYL PEROXIDE  
AKNE-MYCIN, ERYTHROMYCIN  
ATRALIN, TRETINOIN  
JUBLIA, EFINACONAZOLE  
NUTRACORT, HYDROCORTISONE  
ONEXTON, BENZOYL PEROXIDE  
OXSORALEN-ULTRA, METHOXSALEN

**DR REDDYS LA**

\* DR REDDYS LABORATORIES LOUISIANA LLC  
IBUPROFEN, IBUPROFEN  
IBUPROFEN, IBUPROFEN (OTC)  
LOPURIN, ALLOPURINOL  
SSD AF, SILVER SULFADIAZINE  
SSD, SILVER SULFADIAZINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* D \*\*****DR REDDYS LABS INC**

\* DR REDDYS LABORATORIES INC  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 AMOXIL, AMOXICILLIN  
 AUGMENTIN '125', AMOXICILLIN  
 AUGMENTIN '200', AMOXICILLIN  
 AUGMENTIN '250', AMOXICILLIN  
 AUGMENTIN '400', AMOXICILLIN  
 AUGMENTIN '500', AMOXICILLIN  
 AUGMENTIN '875', AMOXICILLIN  
 AUGMENTIN ES-600, AMOXICILLIN  
 AUGMENTIN XR, AMOXICILLIN  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 FINASTERIDE, FINASTERIDE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 HABITROL, NICOTINE (OTC)  
 IBUPROFEN, IBUPROFEN  
 IBUPROFEN, IBUPROFEN (OTC)  
 LAROTID, AMOXICILLIN  
 LEVOFLOXACIN, LEVOFLOXACIN  
 MELOXICAM, MELOXICAM  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 SIMVASTATIN, SIMVASTATIN  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**DR REDDYS LABS LTD**

\* DR REDDYS LABORATORIES LIMITED  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

\* DR REDDYS LABORATORIES LTD  
 ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 ANASTROZOLE, ANASTROZOLE  
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
 AZACITIDINE, AZACITIDINE  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL  
 CARVEDILOL, CARVEDILOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DECITABINE, DECITABINE  
 DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE  
 DESLORATADINE, DESLORATADINE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DOCETAXEL, DOCETAXEL  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
 ESZOPICLONE, ESZOPICLONE  
 FAMOTIDINE, FAMOTIDINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* D \*\*****\* DR REDDYS LABORATORIES LTD**

FAMOTIDINE, FAMOTIDINE (OTC)  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE  
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
 FINASTERIDE, FINASTERIDE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GLIMEPIRIDE, GLIMEPIRIDE  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)  
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LAMOTRIGINE, LAMOTRIGINE  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)  
 LATANOPROST, LATANOPROST  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NATEGLINIDE, NATEGLINIDE  
 NIZATIDINE, NIZATIDINE  
 OFLOXACIN, OFLOXACIN  
 OLANZAPINE, OLANZAPINE  
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)  
 OMEPRAZOLE, OMEPRAZOLE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXAPROZIN, OXAPROZIN  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PARICALCITOL, PARICALCITOL  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 RAMIPRIL, RAMIPRIL  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 RISPERIDONE, RISPERIDONE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 SIROLIMUS, SIROLIMUS  
 TACROLIMUS, TACROLIMUS  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 VINORELBINE TARTRATE, VINORELBINE TARTRATE  
 ZAFIRLUKAST, ZAFIRLUKAST  
 ZENATANE, ISOTRETINOIN  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**DR REDDYS LABS SA****\* DR REDDYS LABORATORIES SA**

FENOFIBRATE (MICRONIZED), FENOFIBRATE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* D \*\*****DRAXIMAGE**

- \* DRAXIMAGE INC  
DTPA, TECHNETIUM TC-99M PENTETATE KIT  
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT  
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

**DUCHESNAY**

- \* DUCHESNAY INC  
DICLEGIS, DOXYLAMINE SUCCINATE

**DURAMED PHARMS BARR**

- \* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC  
AVIANE-28, ETHINYL ESTRADIOL  
CRYSELLE, ETHINYL ESTRADIOL  
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL  
DIAMOX, ACETAZOLAMIDE  
ENPRESSE-28, ETHINYL ESTRADIOL  
METHYLPREDNISOLONE, METHYLPREDNISOLONE  
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
VELIVET, DESOGESTREL

**DURAMED RES**

- \* DURAMED RESEARCH INC  
AYGESTIN, NORETHINDRONE ACETATE

**DURATA THERAPS INTL**

- \* DURATA THERAPEUTICS INTERNATIONAL BV  
DALVANCE, DALBAVANCIN HYDROCHLORIDE

**DUSA**

- \* DUSA PHARMACEUTICALS INC  
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**REDDYS**

- \* DOCTOR REDDYS LABORATORIES LTD  
DESLORATADINE, DESLORATADINE  
DIVALPROEX SODIUM, DIVALPROEX SODIUM  
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**\*\* E \*\*****EAGLE PHARMS**

- \* EAGLE PHARMACEUTICALS INC  
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN  
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM  
RYANODEX, DANTROLENE SODIUM

**EASTMAN KODAK**

- \* EASTMAN KODAK CO  
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

**EBEWE PHARMA**

- \* EBEWE PHARMA GES MBH NFG KG  
CARBOPLATIN, CARBOPLATIN  
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
OXALIPLATIN, OXALIPLATIN  
PACLITAXEL, PACLITAXEL

**ECLAT PHARMS LLC**

- \* ECLAT PHARMACEUTICALS LLC  
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE  
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE

**ECOLAB**

- \* ECOLAB INC  
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)  
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

**ECR**

- \* ECR PHARMACEUTICALS  
DEXAMETHASONE, DEXAMETHASONE

**ECR PHARMA**

- \* ECR PHARMA  
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

**EDENBRIDGE PHARMS**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\***

\* EDENBRIDGE PHARMACEUTICALS LLC  
IVERMECTIN, IVERMECTIN

**EDGEMONT PHARMS LLC**

\* EDGEMONT PHARMACEUTICALS LLC  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FORFIVO XL, BUPROPION HYDROCHLORIDE

**EDISON THERAPS LLC**

\* EDISON THERAPEUTICS LLC  
METHERGINE, METHYLERGONOVINE MALEATE

**EI INC**

\* EI INC  
THEROXIDIL, MINOXIDIL (OTC)

**EISAI INC**

\* EISAI INC  
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM  
ACIPHEX, RABEPRAZOLE SODIUM  
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE  
ARICEPT, DONEPEZIL HYDROCHLORIDE  
BANZEL, RUFINAMIDE  
BELVIQ, LORCASERIN HYDROCHLORIDE  
DACOGEN, DECITABINE  
FRAGMIN, DALTEPARIN SODIUM  
FYCOMPA, PERAMPANEL  
HALAVEN, ERIBULIN MESYLATE  
HEXALEN, ALTRETAMINE  
PANRETIN, ALITRETINOIN  
SALAGEN, PILOCARPINE HYDROCHLORIDE  
ZONEGRAN, ZONISAMIDE

**ELAN PHARMA INTL LTD**

\* ELAN PHARMA INTERNATIONAL LTD  
CLINDESSE, CLINDAMYCIN PHOSPHATE  
EVAMIST, ESTRADIOL

**ELI LILLY AND CO**

\* ELI LILLY AND CO  
AXIRON, TESTOSTERONE  
EFFIENT, PRASUGREL HYDROCHLORIDE  
PROZAC, FLUOXETINE HYDROCHLORIDE  
SARAFEM, FLUOXETINE HYDROCHLORIDE

**ELI LILLY CO**

\* ELI LILLY CO  
ADCIRCA, TADALAFIL  
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

**ELITE LABS**

\* ELITE LABORATORIES INC  
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE  
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**ELITE LABS INC**

\* ELITE LABORATORIES INC  
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

**EMCURE PHARMS**

\* EMCURE PHARMACEUTICALS LTD  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

**EMCURE PHARMS INDIA**

\* EMCURE PHARMACEUTICALS LTD INDIA  
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM

**EMCURE PHARMS LTD**

\* EMCURE PHARMACEUTICALS LTD  
ACARBOSE, ACARBOSE  
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
ADENOSINE, ADENOSINE  
AMIKACIN SULFATE, AMIKACIN SULFATE  
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
BICNU, CARMUSTINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\*****\* EMCURE PHARMACEUTICALS LTD**

CIDOFOVIR, CIDOFOVIR  
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
 ETOMIDATE, ETOMIDATE  
 FUROSEMIDE, FUROSEMIDE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE  
 RIFAMPIN, RIFAMPIN  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**EMCURE PHARMS USA****\* EMCURE PHARMACEUTICALS USA INC**

DIFLUNISAL, DIFLUNISAL  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE  
 METHIMAZOLE, METHIMAZOLE  
 NIFEDIPINE, NIFEDIPINE  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**EMCURE USA****\* EMCURE PHARMACEUTICALS USA INC**

BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

**EMD SERONO****\* EMD SERONO INC**

GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA  
 GONAL-F RFF, FOLLITROPIN ALFA/BETA  
 GONAL-F, FOLLITROPIN ALFA/BETA  
 OVIDREL, CHORIOGONADOTROPIN ALFA  
 SAIZEN, SOMATROPIN RECOMBINANT  
 SEROPHENE, CLOMIPHENE CITRATE  
 SEROSTIM, SOMATROPIN RECOMBINANT  
 ZORBTIVE, SOMATROPIN RECOMBINANT

**EMD SERONO INC****\* EMD SERONO INC**

CETROTIDE, CETRORELIX

**EMMAUS MEDCL****\* EMMAUS MEDICAL INC**

NUTRESTORE, GLUTAMINE

**ENDO PHARM****\* ENDO PHARMACEUTICAL SOLUTIONS INC**

SUPPRELIN LA, HISTRELIN ACETATE  
 VALSTAR PRESERVATIVE FREE, VALRUBICIN  
 VANTAS, HISTRELIN ACETATE

**ENDO PHARMS****\* ENDO PHARMACEUTICALS INC**

DELATESTRYL, TESTOSTERONE ENANTHATE  
 FORTESTA, TESTOSTERONE  
 FROVA, FROVATRIPTAN SUCCINATE  
 OPANA ER, OXYMORPHONE HYDROCHLORIDE  
 OPANA, OXYMORPHONE HYDROCHLORIDE  
 PERCODAN, ASPIRIN

**ENDO PHARMS INC****\* ENDO PHARMACEUTICALS INC**

AVEED, TESTOSTERONE UNDECANOATE  
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

**ENDO VENTURES LTD****\* ENDO VENTURES LTD**

NATESTO, TESTOSTERONE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\***

\* ENDO VENTURES LTD IRELAND  
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE

**EPIC PHARMA**

\* EPIC PHARMA INC  
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

\* EPIC PHARMA LLC  
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE  
SULINDAC, SULINDAC  
TRANDOLAPRIL, TRANDOLAPRIL  
URSODIOL, URSODIOL

**EPIC PHARMA INC**

\* EPIC PHARMA INC  
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

**EPIC PHARMA LLC**

\* EPIC PHARMA LLC  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE  
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

**ERGOJECT**

\* ERGOJECT LLC  
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE

**ESSENTIAL ISOTOPES**

\* ESSENTIAL ISOTOPES LLC  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**ETHYPHARM**

\* ETHYPHARM  
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

**EURAND**

\* EURAND AMERICA INC  
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

**EUROHLTH INTL**

\* EUROHEALTH INTERNATIONAL SARL  
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM  
ALPROSTADIL, ALPROSTADIL  
AMIKACIN SULFATE, AMIKACIN SULFATE  
AMRINONE LACTATE, INAMRINONE LACTATE  
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE  
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE  
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM  
AZTREONAM, AZTREONAM  
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE  
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
CAFCIT, CAFFEINE CITRATE  
CARBOPLATIN, CARBOPLATIN  
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE  
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE  
CISPLATIN, CISPLATIN  
CLADRIBINE, CLADRIBINE  
CYCLOSPORINE, CYCLOSPORINE  
CYTARABINE, CYTARABINE  
DACARBAZINE, DACARBAZINE  
DACTINOMYCIN, DACTINOMYCIN  
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE  
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE  
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE  
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE  
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE  
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\***

\* EUROHEALTH INTERNATIONAL SARL  
 DOXYCYCLINE, DOXYCYCLINE HYCLATE  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE  
 ETOPOSIDE, ETOPOSIDE  
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE  
 FLOXURIDINE, FLOXURIDINE  
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE  
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE  
 IFOSFAMIDE, IFOSFAMIDE  
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM  
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM  
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM  
 LEVOCARNITINE, LEVOCARNITINE  
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE  
 MESNA, MESNA  
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 PACLITAXEL, PACLITAXEL  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PENTOSTATIN, PENTOSTATIN  
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE  
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 THIOTEPA, THIOTEPA  
 TORSEMIDE, TORSEMIDE  
 VINBLASTINE SULFATE, VINBLASTINE SULFATE

**EXALENZ BIOSCIENCE**

\* EXALENZ BIOSCIENCE LTD  
 IDKIT:HP, CITRIC ACID

**EXCELLIUM**

\* EXCELLIUM PHARMACEUTICAL INC  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 FOLIC ACID, FOLIC ACID  
 FUROSEMIDE, FUROSEMIDE  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
 LORAZEPAM, LORAZEPAM

**EXELA PHARMA SCIENCE**

\* EXELA PHARMA SCIENCES  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

**EXELA PHARMA SCS LLC**

\* EXELA PHARMA SCIENCES LLC  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE

**EXELIXIS**

\* EXELIXIS INC  
 COMETRIQ, CABOZANTINIB S-MALATE

**FOUGERA**

\* E FOUGERA DIV ALTANA INC  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* E \*\***

\* E FOUGERA DIV ALTANA INC  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
 FLUOCINONIDE, FLUOCINONIDE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 HYDROCORTISONE, HYDROCORTISONE  
 LIDOCAINE, LIDOCAINE  
 NITROGLYCERIN, NITROGLYCERIN  
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN  
 NYSTATIN, NYSTATIN

**LILLY**

\* ELI LILLY AND CO  
 ALIMTA, PEMETREXED DISODIUM  
 CIALIS, TADALAFIL  
 CYMBALTA, DULOXETINE HYDROCHLORIDE  
 EVISTA, RALOXIFENE HYDROCHLORIDE  
 FORTEO, TERIPARATIDE RECOMBINANT HUMAN  
 GEMZAR, GEMCITABINE HYDROCHLORIDE  
 GLUCAGON, GLUCAGON RECOMBINANT  
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT  
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT  
 HUMALOG, INSULIN LISPRO RECOMBINANT  
 HUMATROPE, SOMATROPIN RECOMBINANT  
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)  
 HUMULIN R, INSULIN RECOMBINANT HUMAN  
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE  
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE  
 STRATTERA, ATOMOXETINE HYDROCHLORIDE  
 SYMBYAX, FLUOXETINE HYDROCHLORIDE  
 ZYPREXA ZYDIS, OLANZAPINE  
 ZYPREXA, OLANZAPINE

**\*\* F \*\*****FALCON PHARMS**

\* FALCON PHARMACEUTICALS LTD  
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE  
 MAXITROL, DEXAMETHASONE  
 TOBREX, TOBRAMYCIN  
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

**FAMY CARE LTD**

\* FAMY CARE LTD  
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVONORGESTREL, LEVONORGESTREL (OTC)  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORETHINDRONE, NORETHINDRONE

**FDC LTD**

\* FDC LTD  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 OFLOXACIN, OFLOXACIN  
 TIMOLOL MALEATE, TIMOLOL MALEATE

**FEINSTEIN**

\* FEINSTEIN INSTITUTE MEDICAL RESEARCH  
 AMMONIA N 13, AMMONIA N-13  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**FERA PHARMS**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

\* FERA PHARMACEUTICALS LLC  
 OFLOXACIN, OFLOXACIN  
 TOBRAMYCIN, TOBRAMYCIN

**FERNDALE LABS**

\* FERNDALE LABORATORIES INC  
 HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE

**FERRING**

\* FERRING PHARMACEUTICALS INC  
 ACTHREL, CORTICORELIN OVINE TRIFLUTATE  
 BRAVELLE, UROFOLLITROPIN  
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 ENDOMETRIN, PROGESTERONE  
 FIRMAGON, DEGARELIX ACETATE  
 MENOPUR, MENOTROPINS (FSH  
 MINIRIN, DESMOPRESSIN ACETATE  
 REPRONEX, MENOTROPINS (FSH  
 TEV-TROPIN, SOMATROPIN RECOMBINANT

**FERRING CONTROLLED**

\* FERRING CONTROLLED THERAPEUTICS LTD  
 CERVIDIL, DINOPROSTONE

**FERRING PHARMS AS**

\* FERRING PHARMACEUTICALS AS  
 LYSTEDA, TRANEXAMIC ACID  
 PREPOPIK, CITRIC ACID

**FERRING PHARMS INC**

\* FERRING PHARMACEUTICALS INC  
 DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE  
 DDAVP, DESMOPRESSIN ACETATE

**FOREST LABS**

\* FOREST LABORATORIES INC  
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE  
 CAMPRAL, ACAMPROSATE CALCIUM  
 CELEXA, CITALOPRAM HYDROBROMIDE  
 LEXAPRO, ESCITALOPRAM OXALATE  
 NAMENDA XR, MEMANTINE HYDROCHLORIDE  
 NAMENDA, MEMANTINE HYDROCHLORIDE  
 THYROLAR-0.25, LIOTRIX (T4  
 THYROLAR-0.5, LIOTRIX (T4  
 THYROLAR-1, LIOTRIX (T4  
 THYROLAR-2, LIOTRIX (T4  
 THYROLAR-3, LIOTRIX (T4

**FOREST LABS INC**

\* FOREST LABORATORIES INC  
 BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE  
 BENTYL, DICYCLOMINE HYDROCHLORIDE  
 CANASA, MESALAMINE  
 CARAFATE, SUCRALFATE  
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE  
 LINZESS, LINACLOTIDE  
 NAMZARIC, DONEPEZIL HYDROCHLORIDE  
 PYLERA, BISMUTH SUBCITRATE POTASSIUM  
 RECTIV, NITROGLYCERIN  
 SAPHRIS, ASENAPINE MALEATE  
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE  
 ULTRESA, PANCRELIPASE (AMYLASE  
 URSO 250, URSODIOL  
 URSO FORTE, URSODIOL  
 VIIBRYD, VILAZODONE HYDROCHLORIDE  
 VIOKACE, PANCRELIPASE (AMYLASE  
 ZENPEP, PANCRELIPASE (AMYLASE

**FOREST RES INST INC**

\* FOREST RESEARCH INSTITUTE INC  
 DALIRESP, ROFLUMILAST

**FOUGERA PHARMS**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

\* FOUGERA PHARMACEUTICALS INC  
 ADAPALENE, ADAPALENE  
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE  
 AMCINONIDE, AMCINONIDE  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 C-SOLVE-2, ERYTHROMYCIN  
 CALCIPOTRIENE, CALCIPOTRIENE  
 CICLOPIROX, CICLOPIROX  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CLOTRIMAZOLE, CLOTRIMAZOLE  
 CUTIVATE, FLUTICASONE PROPIONATE  
 DESONIDE, DESONIDE  
 DESOXIMETASONE, DESOXIMETASONE  
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE  
 ECONAZOLE NITRATE, ECONAZOLE NITRATE  
 ERYTHROMYCIN, ERYTHROMYCIN  
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE  
 FLUOCINONIDE, FLUOCINONIDE  
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
 HYDROCORTISONE, HYDROCORTISONE  
 IMIQUIMOD, IMIQUIMOD  
 KETOCONAZOLE, KETOCONAZOLE  
 LIDOCAINE AND PRILOCAINE, LIDOCAINE  
 METRONIDAZOLE, METRONIDAZOLE  
 MOMETASONE FUROATE, MOMETASONE FUROATE  
 MUPIROCIN, MUPIROCIN  
 NYSTATIN, NYSTATIN  
 OXISTAT, OXICONAZOLE NITRATE  
 PAMINE FORTE, METHSCOPOLAMINE BROMIDE  
 PAMINE, METHSCOPOLAMINE BROMIDE  
 PANDEL, HYDROCORTISONE PROBUTATE  
 PREDNICARBATE, PREDNICARBATE  
 SOLARAZE, DICLOFENAC SODIUM  
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM  
 TEMOVATE E, CLOBETASOL PROPIONATE  
 TEMOVATE, CLOBETASOL PROPIONATE  
 TERCONAZOLE, TERCONAZOLE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE  
 ZONALON, DOXEPIIN HYDROCHLORIDE

**FOUGERA PHARMS INC**

\* FOUGERA PHARMACEUTICALS INC  
 FLUOCINONIDE, FLUOCINONIDE  
 TACROLIMUS, TACROLIMUS

**FRESENIUS**

\* FRESENIUS KABI DEUTSCHLAND GMBH  
 INTRALIPID 10%, SOYBEAN OIL  
 INTRALIPID 20%, SOYBEAN OIL  
 INTRALIPID 30%, SOYBEAN OIL

**FRESENIUS KABI**

\* FRESENIUS KABI AUSTRIA GMBH  
 LACTULOSE, LACTULOSE

**FRESENIUS KABI ONCOL**

\* FRESENIUS KABI ONCOLOGY PLC  
 ANASTROZOLE, ANASTROZOLE  
 BICALUTAMIDE, BICALUTAMIDE  
 CARBOPLATIN, CARBOPLATIN  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LETROZOLE, LETROZOLE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

\* FRESENIUS KABI ONCOLOGY PLC  
 OXALIPLATIN, OXALIPLATIN  
 PACLITAXEL, PACLITAXEL

**FRESENIUS KABI USA**

\* FRESENIUS KABI USA LLC  
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM  
 ADENOSINE, ADENOSINE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 ASTRAMORPH PF, MORPHINE SULFATE  
 AZITHROMYCIN, AZITHROMYCIN  
 AZTREONAM, AZTREONAM  
 BACITRACIN, BACITRACIN  
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 CALCITRIOL, CALCITRIOL  
 CARBOPLATIN, CARBOPLATIN  
 CEFOTETAN, CEFOTETAN DISODIUM  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE  
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM  
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC  
 CISPLATIN, CISPLATIN  
 CLADRIBINE, CLADRIBINE  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
 CYTARABINE, CYTARABINE  
 DACARBAZINE, DACARBAZINE  
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE  
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE  
 DIMENHYDRINATE, DIMENHYDRINATE  
 DIPRIVAN, PROPOFOL  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 DOXY 100, DOXYCYCLINE HYCLATE  
 DOXY 200, DOXYCYCLINE HYCLATE  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE  
 ETOPOSIDE, ETOPOSIDE  
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE  
 FLOXURIDINE, FLOXURIDINE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 FLUMAZENIL, FLUMAZENIL  
 FLUOROURACIL, FLUOROURACIL  
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE  
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
 FOLIC ACID, FOLIC ACID  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 FUROSEMIDE, FUROSEMIDE  
 GANCICLOVIR, GANCICLOVIR SODIUM  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

\* FRESSENIUS KABI USA LLC  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE  
 IFOSFAMIDE, IFOSFAMIDE  
 INDOMETHACIN, INDOMETHACIN  
 IOPAMIDOL-250, IOPAMIDOL  
 IOPAMIDOL-300, IOPAMIDOL  
 IOPAMIDOL-370, IOPAMIDOL  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS  
 KANAMYCIN SULFATE, KANAMYCIN SULFATE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM  
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 MANNITOL 25%, MANNITOL  
 MESNA, MESNA  
 METARAMINOL BITARTRATE, METARAMINOL BITARTRATE  
 METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MILRINONE LACTATE, MILRINONE LACTATE  
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
 NAROPIN, ROPIVACAINE HYDROCHLORIDE  
 NEBUPENT, PENTAMIDINE ISETHIONATE  
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE  
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE  
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXALIPLATIN, OXALIPLATIN  
 OXYTOCIN, OXYTOCIN  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PENTAM, PENTAMIDINE ISETHIONATE  
 PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS  
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE  
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE  
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PROGESTERONE, PROGESTERONE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 PROTAMINE SULFATE, PROTAMINE SULFATE  
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE  
 RIFAMPIN, RIFAMPIN  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE  
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE  
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VALPROATE SODIUM, VALPROATE SODIUM  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* F \*\***

\* FRESENIUS KABI USA LLC  
 VIBISONE, CYANOCOBALAMIN  
 VINBLASTINE SULFATE, VINBLASTINE SULFATE  
 VINOELBINE TARTRATE, VINOELBINE TARTRATE  
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE  
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE  
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE

**FRESENIUS MEDCL**

\* FRESENIUS MEDICAL CARE NORTH AMERICA  
 CALCITRIOL, CALCITRIOL  
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM  
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM  
 DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM  
 DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PHOSLO GELCAPS, CALCIUM ACETATE  
 PHOSLYRA, CALCIUM ACETATE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**FSC**

\* FSC LABORATORIES INC  
 PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

**\*\* G \*\*****G AND W LABS**

\* G AND W LABORATORIES INC  
 ACEPHEN, ACETAMINOPHEN (OTC)  
 CICLOPIROX, CICLOPIROX  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
 INDOMETHACIN, INDOMETHACIN  
 METRONIDAZOLE, METRONIDAZOLE  
 MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)  
 MOMETASONE FUROATE, MOMETASONE FUROATE  
 PROCHLORPERAZINE, PROCHLORPERAZINE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE

**G AND W LABS INC**

\* G AND W LABORATORIES INC  
 CALCIPOTRIENE, CALCIPOTRIENE  
 CICLOPIROX, CICLOPIROX  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 FLUOCINONIDE, FLUOCINONIDE  
 METRONIDAZOLE, METRONIDAZOLE  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)

**GALDERMA LABS**

\* GALDERMA LABORATORIES INC  
 CLOBEX, CLOBETASOL PROPIONATE

**GALDERMA LABS LP**

\* GALDERMA LABORATORIES L P  
 CLOBEX, CLOBETASOL PROPIONATE  
 \* GALDERMA LABORATORIES LP

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

\* GALDERMA LABORATORIES LP  
 CAPEX, FLUOCINOLONE ACETONIDE  
 CLOBEX, CLOBETASOL PROPIONATE  
 DESOWEN, DESONIDE  
 DIFFERIN, ADAPALENE  
 EPIDUO, ADAPALENE  
 METROCREAM, METRONIDAZOLE  
 METROGEL, METRONIDAZOLE  
 METROLOTION, METRONIDAZOLE  
 MIRVASO, BRIMONIDINE TARTRATE  
 ORACEA, DOXYCYCLINE  
 PLIAGLIS, LIDOCAINE  
 SOOLANTRA, IVERMECTIN  
 TRI-LUMA, FLUOCINOLONE ACETONIDE  
 VECTICAL, CALCITRIOL

**GALEN (UK)**

\* GALEN LTD  
 DAUNOXOME, DAUNORUBICIN CITRATE

**GALEN SPECIALTY**

\* GALEN SPECIALTY PHARMA US LLC  
 SYNERA, LIDOCAINE

**GALENA BIOPHARMA**

\* GALENA BIOPHARMA  
 ABSTRAL, FENTANYL CITRATE

**GALENA BIOPHARMA INC**

\* GALENA BIOPHARMA INC  
 ZUPLENZ, ONDANSETRON

**GAMBRO RENAL PRODS**

\* GAMBRO RENAL PRODUCTS  
 PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

**GASTROENTERO**

\* GASTROENTERO LOGIC LLC  
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN

**GATE PHARMS**

\* GATE PHARMACEUTICALS  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

**GAVIS PHARMS**

\* GAVIS PHARMACEUTICALS LLC  
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NYSTATIN, NYSTATIN  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 QUINARETIC, HYDROCHLOROTHIAZIDE  
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

**GAVIS PHARMS LLC**

\* GAVIS PHARMACEUTICALS LLC  
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE

**GD SEARLE**

\* GD SEARLE LLC  
 CELEBREX, CELECOXIB  
 DAYPRO, OXAPROZIN

**GD SEARLE LLC**

\* GD SEARLE LLC  
 ALDACTAZIDE, HYDROCHLOROTHIAZIDE  
 ALDACTONE, SPIRONOLACTONE  
 ARTHROTEC, DICLOFENAC SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

\* GD SEARLE LLC  
 CALAN, VERAPAMIL HYDROCHLORIDE  
 COVERA-HS, VERAPAMIL HYDROCHLORIDE  
 CYTOTEC, MISOPROSTOL  
 FLAGYL ER, METRONIDAZOLE  
 FLAGYL, METRONIDAZOLE  
 INSPRA, EPLERENONE  
 LOMOTIL, ATROPINE SULFATE  
 NORPACE CR, DISOPYRAMIDE PHOSPHATE  
 NORPACE, DISOPYRAMIDE PHOSPHATE  
 SYNAREL, NAFARELIN ACETATE

**GE HEALTHCARE**

\* GE HEALTHCARE  
 ADREVIEW, IOBENGUANE SULFATE I-123  
 CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT  
 INDICLOR, INDIUM IN-111 CHLORIDE  
 INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE  
 METASTRON, STRONTIUM CHLORIDE SR-89  
 MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT  
 MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM  
 MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT  
 MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT  
 OMNIPAQUE 140, IOHEXOL  
 OMNIPAQUE 180, IOHEXOL  
 OMNIPAQUE 240, IOHEXOL  
 OMNIPAQUE 300, IOHEXOL  
 OMNIPAQUE 350, IOHEXOL  
 OMNISCAN, GADODIAMIDE  
 OPTISON, ALBUMIN HUMAN  
 TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201  
 VISIPAQUE 270, IODIXANOL  
 VISIPAQUE 320, IODIXANOL  
 VIZAMYL, FLUTEMETAMOL F-18

**GE HLTHCARE INC**

\* GE HEALTHCARE INC  
 DATSCAN, IOFLUPANE I-123

**GEDEON RICHTER USA**

\* GEDEON RICHTER USA INC  
 FINASTERIDE, FINASTERIDE

**GENENTECH**

\* GENENTECH INC  
 ERIVEDGE, VISMODEGIB  
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT  
 NUTROPIN AQ, SOMATROPIN RECOMBINANT  
 NUTROPIN, SOMATROPIN RECOMBINANT

**GENZYME**

\* GENZYME CORP  
 CEREZYME, IMIGLUCERASE  
 CLOLAR, CLOFARABINE  
 MOZOBIL, PLERIXAFOR  
 RENAGEL, SEVELAMER HYDROCHLORIDE  
 RENVELA, SEVELAMER CARBONATE  
 THYROGEN, THYROTROPIN ALFA

**GENZYME CORP**

\* GENZYME CORP  
 CERDELGA, ELIGLUSTAT TARTRATE  
 HECTOROL, DOXERCALCIFEROL  
 KYNAMRO, MIPOMERSEN SODIUM

**GILEAD**

\* GILEAD SCIENCES INC  
 ATRIPLA, EFAVIRENZ  
 CAYSTON, AZTREONAM  
 EMTRIVA, EMTRICITABINE  
 HEPSERA, ADEFOVIR DIPIVOXIL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

\* GILEAD SCIENCES INC  
 LETAIRIS, AMBRISENTAN  
 RANEXA, RANOLAZINE  
 TRUVADA, EMTRICITABINE

**GILEAD SCIENCES INC**

\* GILEAD SCIENCES INC  
 COMPLERA, EMTRICITABINE  
 HARVONI, LEDIPASVIR  
 SOVALDI, SOFOSBUVIR  
 STRIBILD, COBICISTAT  
 TYBOST, COBICISTAT  
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE  
 VISTIDE, CIDOFOVIR  
 VITEKTA, ELVITEGRAVIR  
 ZYDELIG, IDELALISIB

**GLAND PHARMA LTD**

\* GLAND PHARMA LTD  
 ADENOSINE, ADENOSINE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AZITHROMYCIN, AZITHROMYCIN  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MILRINONE LACTATE, MILRINONE LACTATE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**GLAXO GRP ENGLAND**

\* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE  
 INCRUSE ELLIPTA , UMECLIDINIUM BROMIDE

**GLAXO GRP LTD**

\* GLAXO GROUP LTD DBA GLAXOSMITHKLINE  
 ALTABAX, RETAPAMULIN  
 FLOVENT HFA, FLUTICASONE PROPIONATE  
 \* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE  
 ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE  
 ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE  
 ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE  
 ADVAIR HFA, FLUTICASONE PROPIONATE  
 BREO ELLIPTA, FLUTICASONE FUROATE  
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE  
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE  
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE  
 ZANTAC 150, RANITIDINE HYDROCHLORIDE  
 ZANTAC 300, RANITIDINE HYDROCHLORIDE  
 ZANTAC, RANITIDINE HYDROCHLORIDE

**GLAXO WELLCOME**

\* GLAXOSMITHKLINE  
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE

**GLAXOSMITHKLINE**

\* GLAXOSMITHKLINE  
 ABREVA, DOCOSANOL (OTC)  
 ALKERAN, MELPHALAN  
 ALKERAN, MELPHALAN HYDROCHLORIDE  
 AVODART, DUTASTERIDE  
 BACTROBAN, MUPIROCIN  
 BACTROBAN, MUPIROCIN CALCIUM  
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE  
 CEFTIN, CEFUROXIME AXETIL  
 EPIVIR-HBV, LAMIVUDINE  
 FLONASE, FLUTICASONE PROPIONATE  
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE  
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE  
 IMITREX, SUMATRIPTAN  
 IMITREX, SUMATRIPTAN SUCCINATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

- \* GLAXOSMITHKLINE
  - JALYN, DUTASTERIDE
  - MALARONE PEDIATRIC, ATOVAQUONE
  - MALARONE, ATOVAQUONE
  - NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
  - NICORETTE, NICOTINE POLACRILEX (OTC)
  - POTIGA, EZOGABINE
  - PROMACTA, ELTROMBOPAG OLAMINE
  - RELENZA, ZANAMIVIR
  - TAFINLAR, DABRAFENIB MESYLATE
  - TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
  - TIMENTIN, CLAVULANATE POTASSIUM
  - VALTREX, VALACYCLOVIR HYDROCHLORIDE
  - VERAMYST, FLUTICASONE FUROATE
  - VOTRIENT, PAZOPANIB HYDROCHLORIDE
  - WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
  - WELLBUTRIN, BUPROPION HYDROCHLORIDE
  - ZOFRAN ODT, ONDANSETRON
  - ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
  - ZOFRAN, ONDANSETRON HYDROCHLORIDE
  - ZYBAN, BUPROPION HYDROCHLORIDE
- \* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
  - ANORO ELLIPTA, UMECLIDINIUM BROMIDE
  - ARNUITY ELLIPTA, FLUTICASONE FUROATE
- \* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
  - SEREVENT, SALMETEROL XINAFOATE
  - VENTOLIN HFA, ALBUTEROL SULFATE
- \* GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
  - TIMENTIN, CLAVULANATE POTASSIUM

**GLAXOSMITHKLINE CONS**

- \* GLAXOSMITHKLINE CONSUMER HEALTHCARE
  - ALLI, ORLISTAT (OTC)
  - COMMIT, NICOTINE POLACRILEX (OTC)
  - FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
  - NICORETTE, NICOTINE POLACRILEX (OTC)

**GLAXOSMITHKLINE LLC**

- \* GLAXOSMITHKLINE LLC
  - AMERGE, NARATRIPTAN HYDROCHLORIDE
  - DYAZIDE, HYDROCHLOROTHIAZIDE
  - FLOLAN, EPOPROSTENOL SODIUM
  - INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
  - LAMICTAL CD, LAMOTRIGINE
  - LAMICTAL ODT, LAMOTRIGINE
  - LAMICTAL XR, LAMOTRIGINE
  - LAMICTAL, LAMOTRIGINE
  - MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
  - MEPRON, ATOVAQUONE
  - REQUIP XL, ROPINIROLE HYDROCHLORIDE
  - REQUIP, ROPINIROLE HYDROCHLORIDE
  - RHYTMOL SR, PROPAFENONE HYDROCHLORIDE
  - RHYTMOL, PROPAFENONE HYDROCHLORIDE

**GLENMARK GENERICS**

- \* GLENMARK GENERICS INC USA
  - ADAPALENE, ADAPALENE
  - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  - CALCIPOTRIENE, CALCIPOTRIENE
  - IMIQUIMOD, IMIQUIMOD
  - MOMETASONE FUROATE, MOMETASONE FUROATE
  - MUPIROCIN, MUPIROCIN CALCIUM
  - NIZATIDINE, NIZATIDINE
  - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  - ZONISAMIDE, ZONISAMIDE
- \* GLENMARK GENERICS LIMITED
  - BRIELLYN, ETHINYL ESTRADIOL
  - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

- \* GLENMARK GENERICS LIMITED  
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
- \* GLENMARK GENERICS LTD  
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM  
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE  
ALYACEN 1/35, ETHINYL ESTRADIOL  
ALYACEN 7/7/7, ETHINYL ESTRADIOL  
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE  
CARVEDILOL, CARVEDILOL  
CICLOPIROX, CICLOPIROX  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
DESOXIMETASONE, DESOXIMETASONE  
ESZOPICLONE, ESZOPICLONE  
FELODIPINE, FELODIPINE  
FLUCONAZOLE, FLUCONAZOLE  
FLUOCINONIDE, FLUOCINONIDE  
GABAPENTIN, GABAPENTIN  
HEATHER, NORETHINDRONE  
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE  
LAMOTRIGINE, LAMOTRIGINE  
LEVOFLOXACIN, LEVOFLOXACIN  
LITHIUM CARBONATE, LITHIUM CARBONATE  
MARLISSA, ETHINYL ESTRADIOL  
MELOXICAM, MELOXICAM  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE  
MOMETASONE FUROATE, MOMETASONE FUROATE  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
NAPROXEN SODIUM, NAPROXEN SODIUM  
NAPROXEN, NAPROXEN  
NORETHINDRONE, NORETHINDRONE  
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
OMEPRAZOLE, OMEPRAZOLE  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
ONDANSETRON, ONDANSETRON  
OXCARBAZEPINE, OXCARBAZEPINE  
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
RILUZOLE, RILUZOLE  
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
TELMISARTAN, TELMISARTAN  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
THEOPHYLLINE, THEOPHYLLINE  
TOPIRAMATE, TOPIRAMATE  
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL  
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE  
URSODIOL, URSODIOL  
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
VIORELE, DESOGESTREL  
ZOLMITRIPTAN, ZOLMITRIPTAN
- \* GLENMARK GENERICS LTD INDIA  
INDOMETHACIN, INDOMETHACIN  
LITHIUM CARBONATE, LITHIUM CARBONATE  
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

**GLENMARK PHARMS**

- \* GLENMARK PHARMACEUTICALS INC USA  
CICLOPIROX, CICLOPIROX  
CLOTRIMAZOLE, CLOTRIMAZOLE  
MUPIROCIN, MUPIROCIN
- \* GLENMARK PHARMACEUTICALS LTD  
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**GLENMARK PHARMS LTD**

- \* GLENMARK PHARMACEUTICALS LTD



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* G \*\***

\* GLENMARK PHARMACEUTICALS LTD  
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

**GLOBAL ISOTOPES LLC**

\* GLOBAL ISOTOPES LLC DBA ZEVACOR MOLECULAR  
AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**GRANULES INDIA**

\* GRANULES INDIA LTD  
IBUPROFEN, IBUPROFEN (OTC)  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

**GUARDIAN DRUG**

\* GUARDIAN DRUG CO INC  
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

**GUERBET**

\* GUERBET LLC  
DOTAREM, GADOTERATE MEGLUMINE  
HEXABRIX, IOXAGLATE MEGLUMINE  
LIPIODOL, ETHIODIZED OIL  
OXILAN-300, IOXILAN  
OXILAN-350, IOXILAN

**HANFORD GC**

\* GC HANFORD MANUFACTURING CO  
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
AMPICILLIN SODIUM, AMPICILLIN SODIUM  
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

**\*\* H \*\*****HAEMONETICS**

\* HAEMONETICS CORP  
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**HALOCARBON PRODS**

\* HALOCARBON PRODUCTS CORP  
ISOFLURANE, ISOFLURANE  
SEVOFLURANE, SEVOFLURANE

**HALOZYME THERAP**

\* HALOZYME THERAPEUTICS INC  
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

**HAMELN RDS GMBH**

\* HAMELN RDS GMBH  
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

**HANMI PHARM CO LTD**

\* HANMI PHARMACEUTICAL CO LTD  
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM

**HARRIS PHARM**

\* HARRIS PHARMACEUTICAL INC  
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

**HAUPT PHARMA**

\* HAUPT PHARMA INC  
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
NORETHINDRONE, NORETHINDRONE

**HELSINN HLTHCARE**

\* HELSINN HEALTHCARE SA  
AKYNZEO, NETUPITANT  
ALOXI, PALONOSETRON HYDROCHLORIDE

**HERCON PHARM**

\* HERCON PHARMACEUTICAL LLC  
NITROGLYCERIN, NITROGLYCERIN

**HERITAGE PHARMS INC**

\* HERITAGE PHARMACEUTICALS INC  
ACETAZOLAMIDE, ACETAZOLAMIDE  
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE  
CARISOPRODOL AND ASPIRIN, ASPIRIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

\* HERITAGE PHARMACEUTICALS INC  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE, DOXYCYCLINE  
 FELODIPINE, FELODIPINE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
 GLYBURIDE, GLYBURIDE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 LEFLUNOMIDE, LEFLUNOMIDE  
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 NYSTATIN, NYSTATIN  
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE  
 SULINDAC, SULINDAC  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**HETERO LABS LTD III**

\* HETERO LABS LTD UNIT III  
 ABACAVIR SULFATE, ABACAVIR SULFATE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 FINASTERIDE, FINASTERIDE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 METHOCARBAMOL, METHOCARBAMOL  
 NEVIRAPINE, NEVIRAPINE  
 SIMVASTATIN, SIMVASTATIN  
 STAVUDINE, STAVUDINE  
 TORSEMIDE, TORSEMIDE  
 ZIDOVUDINE, ZIDOVUDINE

**HETERO LABS LTD V**

\* HETERO LABS LTD UNIT V  
 ACYCLOVIR, ACYCLOVIR  
 FAMCICLOVIR, FAMCICLOVIR  
 IRBESARTAN, IRBESARTAN  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LAMIVUDINE, LAMIVUDINE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 VALSARTAN, VALSARTAN

**HEYL CHEMISCH**

\* HEYL CHEMISCH PHARMAZEUTISCHE FABRIK  
 RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

**HI TECH PHARMA**

\* HI TECH PHARMACAL CO INC  
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 ACYCLOVIR, ACYCLOVIR  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
 CALCIPOTRIENE, CALCIPOTRIENE  
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE  
 CICLOPIROX, CICLOPIROX  
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
 CORMAX, CLOBETASOL PROPIONATE  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

\* HI TECH PHARMACAL CO INC  
 EMBELINE E, CLOBETASOL PROPIONATE  
 EMBELINE, CLOBETASOL PROPIONATE  
 ERYTHRO-STATIN, ERYTHROMYCIN  
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
 GABAPENTIN, GABAPENTIN  
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 LACTULOSE, LACTULOSE  
 LEVOCARNITINE, LEVOCARNITINE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LIDOCAINE AND PRILOCAINE, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)  
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)  
 NYSTATIN, NYSTATIN  
 OFLOXACIN, OFLOXACIN  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 VOSOL HC, ACETIC ACID, GLACIAL  
 VOSOL, ACETIC ACID, GLACIAL

**HI TECH PHARMA CO**

\* HI TECH PHARMACAL CO INC  
 FLUNISOLIDE, FLUNISOLIDE  
 PREDNISOLONE, PREDNISOLONE

**HI-TECH PHARMA CO**

\* HI-TECH PHARMACAL CO INC  
 FAMOTIDINE, FAMOTIDINE  
 GATIFLOXACIN, GATIFLOXACIN  
 LORAZEPAM, LORAZEPAM  
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

**HI-TECH PHARMACAL**

\* HI-TECH PHARMACAL CO INC  
 BROMFENAC SODIUM, BROMFENAC SODIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE

**HIGH TECH PHARMA**

\* HIGH TECHNOLOGY PHARMACAL CO INC  
 VALPROIC ACID, VALPROIC ACID

**HIKMA**

\* HIKMA FARMACEUTICA LDA  
 CEFOTAXIME, CEFOTAXIME SODIUM  
 \* HIKMA PHARMACEUTICALS  
 AMOXICILLIN, AMOXICILLIN  
 CARVEDILOL, CARVEDILOL  
 CEFACLOR, CEFACLOR  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEPHALEXIN, CEPHALEXIN  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 GABAPENTIN, GABAPENTIN  
 GLYBURIDE (MICRONIZED), GLYBURIDE  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**HIKMA (MAPLE)**

\* HIKMA (MAPLE) LTD  
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

**HIKMA FARMACEUTICA**

\* HIKMA FARMACEUTICA (PORTUGAL) SA

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

- \* HIKMA FARMACEUTICA (PORTUGAL) SA  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE  
 CEFOXITIN, CEFOXITIN SODIUM  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
 CIPROFLOXACIN, CIPROFLOXACIN  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 ENALAPRILAT, ENALAPRILAT  
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUMAZENIL, FLUMAZENIL  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 GRANISTERON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE  
 MILRINONE LACTATE, MILRINONE LACTATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PROGESTERONE, PROGESTERONE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
 VALPROATE SODIUM, VALPROATE SODIUM
- \* HIKMA FARMACEUTICA PORTUGAL LDA  
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
 CEFUROXIME SODIUM, CEFUROXIME SODIUM  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
- \* HIKMA FARMACEUTICA PORTUGAL SA  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 OXYTOCIN, OXYTOCIN  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
- \* HIKMA FARMACEUTICA SA  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
- HIKMA INTL PHARMS**
- \* HIKMA INTERNATIONAL PHARMACEUTICALS LLC  
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN  
 CORTISONE ACETATE, CORTISONE ACETATE  
 DIGOXIN, DIGOXIN  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE  
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINOPRIL, LISINOPRIL  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 METHOCARBAMOL, METHOCARBAMOL  
 NAPROXEN, NAPROXEN
- HIKMA MAPLE**
- \* HIKMA MAPLE LTD  
 ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM  
 ADENOSINE, ADENOSINE  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
 ATIVAN, LORAZEPAM  
 BUMETANIDE, BUMETANIDE  
 CEFOXITIN, CEFOXITIN SODIUM  
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\*****\* HIKMA MAPLE LTD**

DIGOXIN, DIGOXIN  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DOPRAM, DOXAPRAM HYDROCHLORIDE  
 DURAMORPH PF, MORPHINE SULFATE  
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE  
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE  
 FLUMAZENIL, FLUMAZENIL  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 HEPARIN SODIUM, HEPARIN SODIUM  
 INFUMORPH, MORPHINE SULFATE  
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MILRINONE LACTATE, MILRINONE LACTATE  
 MITOMYCIN, MITOMYCIN  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXYTOCIN, OXYTOCIN  
 PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 ROBAXIN, METHOCARBAMOL  
 ROBINUL, GLYCOPYRROLATE  
 SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE  
 SUFENTANIL CITRATE, SUFENTANIL CITRATE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE

**HIKMA PHARM CO LTD**

**\* HIKMA PHARM CO LTD**  
 ARGATROBAN, ARGATROBAN

**HIKMA PHARMS**

**\* HIKMA PHARMACEUTICALS**  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 AMOXICILLIN, AMOXICILLIN  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE  
 GABAPENTIN, GABAPENTIN  
 GEMFIBROZIL, GEMFIBROZIL  
 GLIMEPIRIDE, GLIMEPIRIDE  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
 LAMOTRIGINE, LAMOTRIGINE  
 MODAFINIL, MODAFINIL  
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TOPIRAMATE , TOPIRAMATE

**\* HIKMA PHARMACEUTICALS CO LTD**  
 PARICALCITOL, PARICALCITOL

**\* HIKMA PHARMACEUTICALS LLC**  
 PREDNISONE, PREDNISONE  
 SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX

**HIKMA PHARMS LLC**

**\* HIKMA PHARMACEUTICALS LLC**  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 CAPTOPRIL, CAPTOPRIL  
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE  
 DOXERCALCIFEROL, DOXERCALCIFEROL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

- \* HIKMA PHARMACEUTICALS LLC  
 FOLIC ACID, FOLIC ACID  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
 MITIGARE, COLCHICINE  
 PRIMIDONE, PRIMIDONE  
 ZALEPLON, ZALEPLON
- HILL DERMAC**
- \* HILL DERMACEUTICALS INC  
 DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE  
 DERMOTIC, FLUOCINOLONE ACETONIDE
- HISAMITSU PHARM CO**
- \* HISAMITSU PHARMACEUTICAL CO INC  
 SALONPAS, MENTHOL (OTC)
- HISUN PHARM HANGZHOU**
- \* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
- HOFFMAN LA ROCHE**
- \* HOFFMAN LA ROCHE INC  
 INVIRASE, SAQUINAVIR MESYLATE
- HOFFMANN LA ROCHE**
- \* HOFFMANN LA ROCHE INC  
 ANAPROX DS, NAPROXEN SODIUM  
 ANAPROX, NAPROXEN SODIUM  
 BONIVA, IBANDRONATE SODIUM  
 INVIRASE, SAQUINAVIR MESYLATE  
 ROCEPHIN, CEFTRIAZONE SODIUM  
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE  
 XELODA, CAPECITABINE  
 XENICAL, ORLISTAT  
 ZELBORAF, VEMURAFENIB
- HOPE PHARMS**
- \* HOPE PHARMACEUTICALS  
 NITHIODOTE, SODIUM NITRITE  
 SODIUM NITRITE, SODIUM NITRITE  
 SODIUM THIOSULFATE, SODIUM THIOSULFATE
- HORIZON PHARMA**
- \* HORIZON PHARMA INC  
 DUEXIS, FAMOTIDINE  
 RAYOS, PREDNISONE  
 VIMOVO, ESOMEPRAZOLE MAGNESIUM
- \* HORIZON PHARMA IRELAND LTD  
 PENNSAID, DICLOFENAC SODIUM
- HOSPIRA**
- \* HOSPIRA INC  
 A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE  
 A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE  
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL  
 ACETYLCYSTEINE, ACETYLCYSTEINE  
 ALFENTANIL, ALFENTANIL HYDROCHLORIDE  
 AMIDATE, ETOMIDATE  
 AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID  
 AMINOPHYLLINE, AMINOPHYLLINE  
 AMINOSYN 10% (PH6), AMINO ACIDS  
 AMINOSYN 10%, AMINO ACIDS  
 AMINOSYN 3.5% M, AMINO ACIDS  
 AMINOSYN 3.5%, AMINO ACIDS  
 AMINOSYN 5%, AMINO ACIDS  
 AMINOSYN 7% (PH6), AMINO ACIDS  
 AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN 7%, AMINO ACIDS  
 AMINOSYN 8.5% (PH6), AMINO ACIDS  
 AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* H \*\*

## \* HOSPIRA INC

AMINOSYN 8.5%, AMINO ACIDS  
 AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS  
 AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN II 10%, AMINO ACIDS  
 AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS  
 AMINOSYN II 7%, AMINO ACIDS  
 AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS  
 AMINOSYN II 8.5%, AMINO ACIDS  
 AMINOSYN-HBC 7%, AMINO ACIDS  
 AMINOSYN-HF 8%, AMINO ACIDS  
 AMINOSYN-PF 10%, AMINO ACIDS  
 AMINOSYN-PF 7%, AMINO ACIDS  
 AMINOSYN-RF 5.2%, AMINO ACIDS  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE  
 AQUASOL A, VITAMIN A PALMITATE  
 ARTICAIN HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAIN HYDROCHLORIDE  
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE  
 AZITHROMYCIN, AZITHROMYCIN  
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE  
 BUMETANIDE, BUMETANIDE  
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE  
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE  
 CARBOPLATIN, CARBOPLATIN  
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE  
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE  
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN  
 CIPROFLOXACIN, CIPROFLOXACIN  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CORLOPAM, FENOLDOPAM MESYLATE  
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE  
 CYTARABINE, CYTARABINE  
 DACARBAZINE, DACARBAZINE  
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE  
 DEMEROL, MEPERIDINE HYDROCHLORIDE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 25%, DEXTROSE  
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE  
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE  
 DIAZEPAM, DIAZEPAM  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE  
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE  
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE  
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* H \*\*

## \* HOSPIRA INC

DROPERIDOL, DROPERIDOL  
 ENALAPRILAT, ENALAPRILAT  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE  
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE  
 FENTANYL CITRATE, FENTANYL CITRATE  
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 FOSCARNET SODIUM, FOSCARNET SODIUM  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 FUROSEMIDE, FUROSEMIDE  
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE  
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM  
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 ISOFLURANE, ISOFLURANE  
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE  
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 LEVOPHED, NOREPINEPHRINE BITARTRATE  
 LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE  
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE  
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 LORAZEPAM, LORAZEPAM  
 LTA II KIT, LIDOCAINE HYDROCHLORIDE  
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID  
 M.V.I. ADULT, ASCORBIC ACID  
 M.V.I. PEDIATRIC, ASCORBIC ACID  
 M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID  
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE  
 MAGNESIUM SULFATE, MAGNESIUM SULFATE  
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE  
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL  
 MANNITOL 25%, MANNITOL  
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL  
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 MARCAINE, BUPIVACAINE HYDROCHLORIDE  
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE



## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* H \*\*

## \* HOSPIRA INC

METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
METHOTREXATE SODIUM, METHOTREXATE SODIUM  
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
METOPROLOL TARTRATE, METOPROLOL TARTRATE  
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE  
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE  
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE  
MORPHINE SULFATE, MORPHINE SULFATE  
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE  
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN  
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
PACLITAXEL, PACLITAXEL  
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE  
PHENYTOIN SODIUM, PHENYTOIN SODIUM  
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE  
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE  
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM  
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC  
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC  
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC  
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM  
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC  
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC  
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE  
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE  
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM  
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,  
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE  
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\*****\* HOSPIRA INC**

PROPOFOL, PROPOFOL  
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE  
 QUELICIN, SUCCINYLCHOLINE CHLORIDE  
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE  
 SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS  
 SODIUM BICARBONATE, SODIUM BICARBONATE  
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE  
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE  
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION  
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION  
 SUFENTANIL CITRATE, SUFENTANIL CITRATE  
 TALWIN, PENTAZOCINE LACTATE  
 TAZICEF, CEFTAZIDIME  
 THAM, TROMETHAMINE  
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 VECURONIUM BROMIDE, VECURONIUM BROMIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 VINORELBINE TARTRATE, VINORELBINE TARTRATE  
 VITAMIN K1, PHYTONADIONE  
 ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

**\* HOSPIRA WORLDWIDE, INC**

DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
 NITROPRESS, SODIUM NITROPRUSSIDE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

**HOSPIRA INC****\* HOSPIRA INC**

A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE  
 ADENOSINE, ADENOSINE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE  
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE  
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE  
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM  
 CEFOXITIN, CEFOXITIN SODIUM  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CEFUROXIME SODIUM, CEFUROXIME SODIUM  
 DAPTOMYCIN, DAPTOMYCIN  
 DOCETAXEL, DOCETAXEL  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 IMPENEM AND CILASTATIN, CILASTATIN SODIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 MAXIPIME, CEFEPIME HYDROCHLORIDE  
 MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE  
 MEROPENEM, MEROPENEM  
 MILRINONE LACTATE, MILRINONE LACTATE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NIPENT, PENTOSTATIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* H \*\***

\* HOSPIRA INC  
 OXALIPLATIN, OXALIPLATIN  
 PARICALCITOL, PARICALCITOL  
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
 THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**HOSPIRA WORLDWIDE**

\* HOSPIRA WORLDWIDE PTY  
 OXALIPLATIN, OXALIPLATIN

**HOT SHOTS NM LLC**

\* HOT SHOTS NUCLEAR MEDICINE LLC  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**HOUSTON CYCLOTRON**

\* HOUSTON CYCLOTRON PARTNERS LP  
 AMMONIA N 13, AMMONIA N-13  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**HQ SPCLT PHARMA**

\* HQ SPECIALTY PHARMA CORP  
 CISPLATIN, CISPLATIN  
 TAXOL, PACLITAXEL

**HQ SPECIALITY PHARMA**

\* HQ SPECIALITY PHARMA LLC  
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

**HQ SPECLT PHARMA**

\* HQ SPECIALTY PHARMA  
 VUMON, TENIPOSIDE

**HRA PHARMA**

\* HRA PHARMA LLC  
 METOPIRONE, METYRAPONE

**HYPERION THERAP INC**

\* HYPERION THERAPEUTICS INC  
 RAVICTI, GLYCEROL PHENYL BUTYRATE

**HYPERION THERAPS INC**

\* HYPERION THERAPEUTICS INC  
 BUPHENYL, SODIUM PHENYL BUTYRATE

**ROCHE**

\* HOFFMANN LA ROCHE INC  
 BONIVA, IBANDRONATE SODIUM  
 COPEGUS, RIBAVIRIN  
 FUZEON, ENFUVIRTIDE  
 KLONOPIN, CLONAZEPAM  
 TAMIFLU, OSELTAMIVIR PHOSPHATE  
 VALIUM, DIAZEPAM

**\*\* I \*\*****IDENTI PHARMS INC**

\* IDENTI PHARMACEUTICALS INC  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

**IGI LABS INC**

\* IGI LABORATORIES INC  
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 ECONAZOLE NITRATE, ECONAZOLE NITRATE  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

**IMPAX LABS**

\* IMPAX LABORATORIES INC  
 ACARBOSE, ACARBOSE  
 ALPRAZOLAM, ALPRAZOLAM  
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
 BACLOFEN, BACLOFEN  
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\***

\* IMPAX LABORATORIES INC  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE  
 DANTROLENE SODIUM, DANTROLENE SODIUM  
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE  
 DIGOXIN, DIGOXIN  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 FENOFIBRATE (MICRONIZED), FENOFIBRATE  
 FENOFIBRATE, FENOFIBRATE  
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)  
 LORATADINE, LORATADINE (OTC)  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHYLTESTOSTERONE, METHYLTESTOSTERONE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE  
 OMEPRAZOLE, OMEPRAZOLE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 PENTOXIFYLLINE, PENTOXIFYLLINE  
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE  
 PRIMIDONE, PRIMIDONE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE  
 RILUZOLE, RILUZOLE  
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

**IMPAX LABS INC**

\* IMPAX LABORATORIES INC  
 CABERGOLINE, CABERGOLINE  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE, DOXYCYCLINE  
 LAMOTRIGINE, LAMOTRIGINE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 URSODIOL, URSODIOL

**IMPAX PHARMS**

\* IMPAX PHARMACEUTICALS  
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE  
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE  
 GEMFIBROZIL, GEMFIBROZIL  
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

**INCYTE CORP**

\* INCYTE CORP  
 JAKAFI, RUXOLITINIB PHOSPHATE

**INDICUS PHARMA**

\* INDICUS PHARMA LLC  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 LETROZOLE, LETROZOLE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**INDOCO REMEDIES**

\* INDOCO REMEDIES LTD  
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
 GLIMEPIRIDE, GLIMEPIRIDE

**INJECTALIA**

\* INJECTALIA SRL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\***

\* INJECTALIA SRL  
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**INNOCUTIS HOLDINGS**

\* INNOCUTIS HOLDINGS LLC  
SITAVIG, ACYCLOVIR

**INNOPHARMA LICENSING**

\* INNOPHARMA LICENSING LLC  
ACETYLCYSTEINE, ACETYLCYSTEINE  
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

**INO**

\* INO THERAPEUTICS INC  
INOMAX, NITRIC OXIDE

**INST BIOCHEM**

\* INSTITUT BIOCHEMIQUE SA  
FLECTOR, DICLOFENAC EPOLAMINE

**INST BIOCHIMIQUE**

\* INSTITUTE BIOCHIMIQUE SA (IBSA)  
TIROSINT, LEVOTHYROXINE SODIUM

**INSTITUT BIOCHIMIQUE**

\* INSTITUT BIOCHIMIQUE SA IBSA  
TIROSINT, LEVOTHYROXINE SODIUM

**INSYS THERAP**

\* INSYS THERAPEUTICS INC  
DRONABINOL, DRONABINOL  
SUBSYS, FENTANYL

**INTELLIPHARMACEUTICS**

\* INTELLIPHARMACEUTICS CORP  
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE

**INTERGEL PHARM**

\* INTERGEL PHARMACEUTICAL INC  
NIFEDIPINE, NIFEDIPINE

**INTERMUNE INC**

\* INTERMUNE INC  
ESBRIET, PIRFENIDONE

**INTL MEDICATED**

\* INTERNATIONAL MEDICATED SYSTEMS LTD  
MILRINONE LACTATE, MILRINONE LACTATE

**INTL MEDICATION**

\* INTERNATIONAL MEDICATION SYSTEM  
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE  
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE  
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
MANNITOL 25%, MANNITOL  
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
PHYTONADIONE, PHYTONADIONE

\* INTERNATIONAL MEDICATION SYSTEMS LTD  
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

**INTL MEDICATION SYS**

\* INTERNATIONAL MEDICATION SYSTEMS LTD  
LORAZEPAM, LORAZEPAM

**INVAGEN PHARMS**

\* INVAGEN PHARMACEUTICALS INC  
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
CALCIUM ACETATE, CALCIUM ACETATE  
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
FOLIC ACID, FOLIC ACID  
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
GABAPENTIN, GABAPENTIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\***

\* INVAGEN PHARMACEUTICALS INC  
 GEMFIBROZIL, GEMFIBROZIL  
 GLIMEPIRIDE, GLIMEPIRIDE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 LEVETIRACETAM, LEVETIRACETAM  
 LISINAPRIL, LISINAPRIL  
 MEPROBAMATE, MEPROBAMATE  
 NABUMETONE, NABUMETONE  
 NAPROXEN, NAPROXEN  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE  
 RAMIPRIL, RAMIPRIL  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 TOPIRAMATE, TOPIRAMATE  
 TRANDOLAPRIL, TRANDOLAPRIL  
 WARFARIN SODIUM, WARFARIN SODIUM  
 ZOLMITRIPTAN, ZOLMITRIPTAN  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE  
 ZONISAMIDE, ZONISAMIDE

**INVENTIA HLTHCARE**

\* INVENTIA HEALTHCARE PRIVATE LTD  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**IPCA LABS LTD**

\* IPCA LABORATORIES LTD  
 ALLOPURINOL, ALLOPURINOL  
 ATENOLOL, ATENOLOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE  
 FUROSEMIDE, FUROSEMIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 WARFARIN SODIUM, WARFARIN SODIUM

**IPR**

\* IPR PHARMACEUTICALS INC  
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL  
 ATENOLOL, ATENOLOL  
 CRESTOR, ROSUVASTATIN CALCIUM  
 ZOMIG, ZOLMITRIPTAN

**IPR PHARMS INC**

\* IPR PHARMACEUTICALS INC  
 CAPRELSA, VANDETANIB

**IPSEN INC**

\* IPSEN BIOPHARMACEUTICALS INC  
 INCRELEX, MECASERMIN RECOMBINANT

**IPSEN PHARMA**

\* IPSEN PHARMA BIOTECH SAS  
 SOMATULINE DEPOT, LANREOTIDE ACETATE

**IROKO PHARMS**

\* IROKO PHARMACEUTICALS LLC  
 INDOCIN, INDOMETHACIN

**IROKO PHARMS LLC**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\***

\* IROKO PHARMACEUTICALS LLC  
TIVORBEX, INDOMETHACIN  
ZORVOLEX, DICLOFENAC

**ISO TEX**

\* ISO TEX DIAGNOSTICS INC  
JEANATOPE, ALBUMIN IODINATED I-125 SERUM  
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

**ISOTEX**

\* ISOTEX DIAGNOSTICS  
GLOFIL-125, IOTHALAMATE SODIUM I-125

**ISTITUTO BIO ITA SPA**

\* ISTITUTO BIOCHIMICO ITALIANO SPA  
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
AMPICILLIN SODIUM, AMPICILLIN SODIUM  
NAFCILLIN SODIUM, NAFCILLIN SODIUM  
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM  
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
PIPERACILLIN, PIPERACILLIN SODIUM

**IVAX INTL**

\* IVAX INTERNATIONAL GMBH  
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE  
SYNRIBO, OMACETAXINE MEPESUCCINATE

**IVAX PHARMS**

\* IVAX PHARMACEUTICALS INC  
VALSARTAN, VALSARTAN

**IVAX SUB TEVA PHARMS**

\* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA  
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
BACLOFEN, BACLOFEN  
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
BUMETANIDE, BUMETANIDE  
CABERGOLINE, CABERGOLINE  
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
CIMETIDINE, CIMETIDINE (OTC)  
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
CLOZAPINE, CLOZAPINE  
CYCLOSPORINE, CYCLOSPORINE  
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
DIAZEPAM, DIAZEPAM  
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
FAMOTIDINE, FAMOTIDINE  
FAMOTIDINE, FAMOTIDINE (OTC)  
FLUCONAZOLE, FLUCONAZOLE  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FLUTAMIDE, FLUTAMIDE  
FUROSEMIDE, FUROSEMIDE  
GABAPENTIN, GABAPENTIN  
GLIPIZIDE, GLIPIZIDE  
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE  
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
INDAPAMIDE, INDAPAMIDE  
INDOMETHACIN, INDOMETHACIN  
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LISINOPRIL, LISINOPRIL  
LORAZEPAM, LORAZEPAM  
METHYLDOPA, METHYLDOPA  
MISOPROSTOL, MISOPROSTOL  
NADOLOL, NADOLOL  
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)  
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE  
OXAPROZIN, OXAPROZIN  
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* I \*\***

\* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 SIMVASTATIN, SIMVASTATIN  
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE  
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**\*\* J \*\*****JACOBUS**

\* JACOBUS PHARMACEUTICAL CO  
 DAPSONE, DAPSONE  
 PASER, AMINOSALICYLIC ACID

**JANSSEN BIOTECH**

\* JANSSEN BIOTECH INC  
 ZYTIGA, ABIRATERONE ACETATE

**JANSSEN PHARMS**

\* JANSSEN PHARMACEUTICALS INC  
 AXERT, ALMOTRIPTAN MALATE  
 CONCERTA, METHYLPHENIDATE HYDROCHLORIDE  
 DITROPAN XL, OXYBUTYNIN CHLORIDE  
 DURAGESIC-100, FENTANYL  
 DURAGESIC-12, FENTANYL  
 DURAGESIC-25, FENTANYL  
 DURAGESIC-50, FENTANYL  
 DURAGESIC-75, FENTANYL  
 ELMIRON, PENTOSAN POLYSULFATE SODIUM  
 HALDOL, HALOPERIDOL DECANOATE  
 HALDOL, HALOPERIDOL LACTATE  
 INVEGA SUSTENNA, PALIPERIDONE PALMITATE  
 INVEGA, PALIPERIDONE  
 INVOKAMET, CANAGLIFLOZIN  
 INVOKANA, CANAGLIFLOZIN  
 LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN  
 LEVAQUIN, LEVOFLOXACIN  
 MICRONOR, NORETHINDRONE  
 MODICON 28, ETHINYL ESTRADIOL  
 NIZORAL, KETOCONAZOLE  
 NUCYNTA ER, TAPENTADOL HYDROCHLORIDE  
 NUCYNTA, TAPENTADOL HYDROCHLORIDE  
 ORTHO CYCLEN-28, ETHINYL ESTRADIOL  
 ORTHO EVRA, ETHINYL ESTRADIOL  
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL  
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL  
 ORTHO-CEPT, DESOGESTREL  
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL  
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL  
 PANCREAZE, PANCRELIPASE (AMYLASE  
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE  
 RAZADYNE, GALANTAMINE HYDROBROMIDE  
 RISPERDAL CONSTA, RISPERIDONE  
 RISPERDAL, RISPERIDONE  
 SPORANOX, ITRACONAZOLE  
 TERAZOL 3, TERCONAZOLE  
 TERAZOL 7, TERCONAZOLE  
 TOPAMAX, TOPIRAMATE  
 TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN  
 TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN  
 ULTRACET, ACETAMINOPHEN  
 ULTRAM, TRAMADOL HYDROCHLORIDE  
 XARELTO, RIVAROXABAN

**JANSSEN PRODS**

\* JANSSEN PRODUCTS LP  
 EDURANT, RILPIVIRINE HYDROCHLORIDE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* J \*\***

- \* JANSSEN PRODUCTS LP  
OLYSIO, SIMEPREVIR SODIUM  
PREZISTA, DARUNAVIR ETHANOLATE
- JANSSEN R AND D**
- \* JANSSEN RESEARCH AND DEVELOPMENT LLC  
INTELENCE, ETRAVIRINE  
PARAFON FORTE DSC, CHLORZOXAZONE
- JANSSEN RES AND DEV**
- \* JANSSEN RESEARCH AND DEVELOPMENT LLC  
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
- JANSSEN THERAP**
- \* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP  
SIRTURO, BEDAQUILINE FUMARATE
- JAVELIN PHARMS INC**
- \* JAVELIN PHARMACEUTICALS INC A WHOLLY OWNED SUDSIDIARY OF HOSPIRA INC  
DYLOJECT, DICLOFENAC SODIUM
- JAZZ PHARMS**
- \* JAZZ PHARMACEUTICALS INC  
LUVOX CR, FLUVOXAMINE MALEATE  
XYREM, SODIUM OXYBATE
- JAZZ PHARMS III**
- \* JAZZ PHARMACEUTICALS III INTERNATIONAL LTD  
FAZACLO ODT, CLOZAPINE
- \* JAZZ PHARMACEUTICALS INTERNATIONAL III  
VERSACLOZ, CLOZAPINE
- JAZZ PHARMS INTL**
- \* JAZZ PHARMACEUTICALS INTERNATIONAL LTD  
PRIALT, ZICONOTIDE ACETATE
- JIANGSU HANSOH PHARM**
- \* JIANGSU HANSOH PHARMACEUTICAL CO LTD  
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
VINORELBINE TARTRATE, VINORELBINE TARTRATE
- JIANGSU HENGRUI MED**
- \* JIANGSU HENGRUI MEDICINE CO LTD  
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE  
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
LETROZOLE, LETROZOLE  
OXALIPLATIN, OXALIPLATIN
- JOHNS HOPKINS UNIV**
- \* JOHNS HOPKINS UNIV  
AMMONIA N 13, AMMONIA N-13
- JOHNSON AND JOHNSON**
- \* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES  
MEN'S ROGAINE, MINOXIDIL (OTC)  
ROGAINE (FOR MEN), MINOXIDIL (OTC)  
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)  
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)  
WOMEN'S ROGAINE, MINOXIDIL (OTC)
- \* JOHNSON AND JOHNSON HEALTHCARE PRODUCTS  
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
- \* JOHNSON AND JOHNSON HEALTHCARE PRODUCTS DIV MCNEIL-PPC INC  
NIZORAL A-D, KETOCONAZOLE (OTC)
- JUBILANT CADISTA**
- \* JUBILANT CADISTA PHARMACEUTICALS INC  
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
METHYLPREDNISOLONE, METHYLPREDNISOLONE  
PREDNISONE, PREDNISONE  
PROCOMP, PROCHLORPERAZINE MALEATE  
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
- JUBILANT DRAXIMAGE**
- \* JUBILANT DRAXIMAGE INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* J \*\***

- \* JUBILANT DRAXIMAGE INC
  - AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
  - DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
  - HICON, SODIUM IODIDE I-131
  - PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
  - SODIUM IODIDE I-131, SODIUM IODIDE I-131

**JUBILANT GENERICS**

- \* JUBILANT GENERICS LTD
  - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  - ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
  - LAMOTRIGINE, LAMOTRIGINE
  - OLANZAPINE, OLANZAPINE
  - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  - QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  - RISPERIDONE, RISPERIDONE
  - RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
  - SPIRONOLACTONE, SPIRONOLACTONE
  - VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
  - VALSARTAN, VALSARTAN
  - ZOLMITRIPTAN, ZOLMITRIPTAN

**STEVENS J**

- \* JEROME STEVENS PHARMACEUTICALS INC
  - BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
  - DIGOXIN, DIGOXIN
  - METHOCARBAMOL AND ASPIRIN, ASPIRIN
  - UNITHROID, LEVOTHYROXINE SODIUM \*\*

**\*\* K \*\*****GRIFFEN**

- \* KW GRIFFEN CO
  - BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

**KALEO INC**

- \* KALEO INC
  - EVZIO, NALOXONE HYDROCHLORIDE

**KEN LIFESCIENCE**

- \* KEN LIFESCIENCE
  - PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**KERYX BIOPHARMS**

- \* KERYX BIOPHARMACEUTICALS INC
  - FERRIC CITRATE, FERRIC CITRATE

**KING PHARMS**

- \* KING PHARMACEUTICALS INC
  - ALTACE, RAMIPRIL
  - BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
  - BICILLIN C-R, PENICILLIN G BENZATHINE
  - BICILLIN L-A, PENICILLIN G BENZATHINE
  - CORGARD, NADOLOL
  - CORZIDE, BENDROFLUMETHIAZIDE
  - PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
  - SILVADENE, SILVER SULFADIAZINE
  - SKELAXIN, METAXALONE
  - SYNERCID, DALFOPRISTIN
  - TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
- \* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC SUB KING PHARMACEUTICALS INC
  - TAPAZOLE, METHIMAZOLE
  - TUSSIGON, HOMATROPINE METHYLBROMIDE

**KING PHARMS LLC**

- \* KING PHARMACEUTICALS LLC
  - AVINZA, MORPHINE SULFATE

**KING PHARMS R AND D**

- \* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC
  - CYTOMEL, LIOTHYRONINE SODIUM
  - LEVOXYL, LEVOTHYROXINE SODIUM \*\*

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* K \*\*****KNIGHT THERAPS**

\* KNIGHT THERAPEUTICS USA INC  
IMPAVIDO, MILTEFOSINE

**KOWA CO**

\* KOWA CO LTD  
LIVALO, PITAVASTATIN CALCIUM

**KREITCHMAN PET CTR**

\* KREITCHMAN PET CENTER  
AMMONIA N 13, AMMONIA N-13

**KREMERS URBAN DEV**

\* KREMERS URBAN DEVELOPMENT CO  
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM

**KREMERS URBAN PHARMS**

\* KREMERS URBAN PHARMACEUTICALS INC  
GLYCOLAX, POLYETHYLENE GLYCOL 3350  
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)  
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
MONOKET, ISOSORBIDE MONONITRATE  
OMEPRAZOLE, OMEPRAZOLE

**KRKA TOVARNA ZDRAVIL**

\* KRKA TOVARNA ZDRAVIL DD NOVO MESTO  
LANSOPRAZOLE, LANSOPRAZOLE

**KUDCO IRELAND**

\* KUDCO IRELAND LTD  
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
LETROZOLE, LETROZOLE  
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

**KVK TECH**

\* KVK TECH INC  
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
KALEXATE, SODIUM POLYSTYRENE SULFONATE  
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE  
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**\*\* L \*\*****L PERRIGO CO**

\* L PERRIGO CO  
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

**LAB HRA PHARMA**

\* LABORATOIRE HRA PHARMA  
ELLA, ULIPRISTAL ACETATE

**LANDELA PHARM**

\* LANDELA PHARMACEUTICAL  
ALBUTEROL SULFATE, ALBUTEROL SULFATE  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

**LANNETT**

\* LANNETT CO INC  
ACETAZOLAMIDE, ACETAZOLAMIDE  
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE  
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE  
LANIAZID, ISONIAZID  
LANORINAL, ASPIRIN  
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
PRIMIDONE, PRIMIDONE  
PROBALAN, PROBENECID

\* LANNETT HOLDINGS INC  
BACLOFEN, BACLOFEN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\***

\* LANNETT HOLDINGS INC  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 DANAZOL, DANAZOL  
 DIPYRIDAMOLE, DIPYRIDAMOLE  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE, DOXYCYCLINE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE  
 RIFAMPIN, RIFAMPIN  
 TERBUTALINE SULFATE, TERBUTALINE SULFATE  
 URSODIOL, URSODIOL

**LANNETT HOLDINGS INC**

\* LANNETT HOLDINGS INC  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 CODEINE SULFATE, CODEINE SULFATE  
 DIAZEPAM, DIAZEPAM  
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LETROZOLE, LETROZOLE  
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE  
 METHOCARBAMOL, METHOCARBAMOL  
 MORPHINE SULFATE, MORPHINE SULFATE  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PHENTERMINE RESIN COMPLEX, PHENTERMINE RESIN COMPLEX  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**LANTHEUS MEDCL**

\* LANTHEUS MEDICAL IMAGING INC  
 ABLAVAR, GADOFOSVESET TRISODIUM  
 CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT  
 DEFINITY, PERFLUTREN  
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67  
 NEUROLITE, TECHNETIUM TC-99M BICISATE KIT  
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201  
 XENON XE 133, XENON XE-133

**LANTHEUS MEDICAL**

\* LANTHEUS MEDICAL IMAGING INC  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

**LARKEN LABS**

\* LARKEN LABORATORIES INC  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

**LAVIPHARM LABS**

\* LAVIPHARM LABORATORIES INC  
 FENTANYL-100, FENTANYL  
 FENTANYL-25, FENTANYL  
 FENTANYL-50, FENTANYL  
 FENTANYL-75, FENTANYL

**LEHIGH VALLEY**

\* LEHIGH VALLEY TECHNOLOGIES INC  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**LEK PHARMS**

\* LEK PHARMACEUTICALS D D  
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE

**LEK PHARMS DD**

\* LEK PHARMACEUTICALS DD  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\*****LEO PHARMA AS**

- \* LEO PHARMA AS
  - DOVONEX, CALCIPOTRIENE
  - PICATO, INGENOL MEBUTATE
  - TACLONEX, BETAMETHASONE DIPROPIONATE

**LG LIFE**

- \* LG LIFE SCIENCES LTD
  - VALTROPIN, SOMATROPIN RECOMBINANT

**LG LIFE SCIENCES**

- \* LG LIFE SCIENCES LTD
  - FACTIVE, GEMIFLOXACIN MESYLATE

**LLOYD**

- \* LLOYD INC
  - LEVOTHROID, LEVOTHYROXINE SODIUM \*\*

**LNK**

- \* LNK INTERNATIONAL INC
  - DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
  - IBUPROFEN, IBUPROFEN (OTC)
  - LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

**LOREAL USA**

- \* LOREAL USA PRODUCTS INC
  - ANTHELIOS 20, AVOBENZONE (OTC)
  - ANTHELIOS 40, AVOBENZONE (OTC)
  - ANTHELIOS SX, AVOBENZONE (OTC)
  - CAPITAL SOLEIL 15, AVOBENZONE (OTC)

**LOTUS PHARM CO LTD**

- \* LOTUS PHARMACEUTICAL CO LTD
  - LEVETIRACETAM, LEVETIRACETAM

**LUITPOLD**

- \* LUITPOLD PHARMACEUTICALS INC
  - ACETYLCYSTEINE, ACETYLCYSTEINE
  - ADENOSINE, ADENOSINE
  - AMINOCAPROIC ACID, AMINOCAPROIC ACID
  - AMINOPHYLLINE, AMINOPHYLLINE
  - BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  - BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
  - BROMFENAC SODIUM, BROMFENAC SODIUM
  - BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  - CAFFEINE CITRATE, CAFFEINE CITRATE
  - CALCITRIOL, CALCITRIOL
  - CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
  - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  - CYANOCOBALAMIN, CYANOCOBALAMIN
  - CYCLOSPORINE, CYCLOSPORINE
  - DACTINOMYCIN, DACTINOMYCIN
  - DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
  - DEXFERRUM, IRON DEXTRAN
  - DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
  - DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
  - DROPERIDOL, DROPERIDOL
  - ESTRADIOL VALERATE, ESTRADIOL VALERATE
  - ETOMIDATE, ETOMIDATE
  - FOMEPIZOLE, FOMEPIZOLE
  - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
  - FUROSEMIDE, FUROSEMIDE
  - GANCICLOVIR, GANCICLOVIR SODIUM
  - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  - GLYCOPYRROLATE, GLYCOPYRROLATE
  - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  - HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
  - HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
  - IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
  - INJECTAFER, FERRIC CARBOXYMALTOSIDE
  - LATANOPROST, LATANOPROST
  - LEVETIRACETAM, LEVETIRACETAM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\***

\* LUITPOLD PHARMACEUTICALS INC  
 LEVOCARNITINE, LEVOCARNITINE  
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
 MANNITOL 25%, MANNITOL  
 METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE  
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN  
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 NITROGLYCERIN, NITROGLYCERIN  
 OLANZAPINE, OLANZAPINE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 PROGESTERONE, PROGESTERONE  
 SPRIX, KETOROLAC TROMETHAMINE  
 TORSEMIDE, TORSEMIDE  
 TRANEXAMIC ACID, TRANEXAMIC ACID  
 TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE  
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE  
 VENOFER, IRON SUCROSE  
 ZIDOVUDINE, ZIDOVUDINE

**LUKARE MEDICAL LLC**

\* LUKARE MEDICAL LLC  
 ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

**LUMARA HEALTH INC**

\* LUMARA HEALTH INC  
 MAKENA, HYDROXYPROGESTERONE CAPROATE

**LUNDBECK LLC**

\* LUNDBECK LLC  
 ONFI, CLOBAZAM  
 SABRIL, VIGABATRIN

**LUNDBECK NA LTD**

\* LUNDBECK NA LTD  
 NORTHERA, DROXIDOPA

**LUPIN**

\* LUPIN LTD  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 CARVEDILOL, CARVEDILOL  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEFDINIR, CEFDINIR  
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM  
 CEFPROZIL, CEFPROZIL  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CEPHALEXIN, CEPHALEXIN  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINAPRIL, LISINAPRIL  
 LOVASTATIN, LOVASTATIN  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RAMIPRIL, RAMIPRIL  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SIMVASTATIN, SIMVASTATIN  
 TOPIRAMATE, TOPIRAMATE  
 TRANDOLAPRIL, TRANDOLAPRIL

**LUPIN ATLANTIS**

\* LUPIN ATLANTIS HOLDINGS SA  
 ANTARA (MICRONIZED), FENOFIBRATE

**LUPIN LTD**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\*****\* LUPIN LIMITED**

LEVETIRACETAM, LEVETIRACETAM  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

**\* LUPIN LTD**

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE  
 CELECOXIB, CELECOXIB  
 CIPROFLOXACIN, CIPROFLOXACIN  
 DAYSEE, ETHINYL ESTRADIOL  
 DOXYCYCLINE, DOXYCYCLINE  
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 ENSKYCE, DESOGESTREL  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 ESZOPICLONE, ESZOPICLONE  
 FALLBACK SOLO, LEVONORGESTREL (OTC)  
 FAMOTIDINE, FAMOTIDINE  
 FENOFIBRATE, FENOFIBRATE  
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE  
 GATIFLOXACIN, GATIFLOXACIN  
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 JENCYCLA, NORETHINDRONE  
 KURVELO, ETHINYL ESTRADIOL  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LAMIVUDINE, LAMIVUDINE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LORAZEPAM, LORAZEPAM  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 MEFENAMIC ACID, MEFENAMIC ACID  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 NABUMETONE, NABUMETONE  
 NIACIN, NIACIN  
 NIKKI, DROSPIRENONE  
 NORETHINDRONE, NORETHINDRONE  
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PIRMELLA 1/35, ETHINYL ESTRADIOL  
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL  
 PREGABALIN, PREGABALIN  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 RANOLAZINE, RANOLAZINE  
 RIFABUTIN, RIFABUTIN  
 SUPRAX, CEFIXIME  
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE  
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VALSARTAN, VALSARTAN  
 VYFEMLA, ETHINYL ESTRADIOL  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**LUPIN PHARMS****\* LUPIN PHARMACEUTICALS INC**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 DESLORATADINE, DESLORATADINE  
 MELOXICAM, MELOXICAM  
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* L \*\*****\* LUPIN PHARMACEUTICALS INC**

RIFAMPIN, RIFAMPIN

SUPRAX, CEFIXIME

ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**LYNE****\* LYNE LABORATORIES INC**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE

CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE

CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

DEXAMETHASONE, DEXAMETHASONE

HYDROCORTISONE, HYDROCORTISONE

LEVOCARNITINE, LEVOCARNITINE

TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**PERRIGO****\* L PERRIGO CO**

ACETAMINOPHEN, ACETAMINOPHEN (OTC)

ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)

CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)

CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)

DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)

FAMOTIDINE, FAMOTIDINE (OTC)

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)

IBUPROFEN, IBUPROFEN (OTC)

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)

LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LORATADINE, LORATADINE (OTC)

MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)

MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)

NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

TAB-PROFEN, IBUPROFEN (OTC)

TIOCONAZOLE, TIOCONAZOLE (OTC)

**\*\* M \*\*****MA GENERAL HOSP****\* MASSACHUSETTS GENERAL HOSP**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**MACLEODS PHARMS LTD****\* MACLEODS PHARMACEUTICALS LTD**

AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

FAMCICLOVIR, FAMCICLOVIR

IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

IRBESARTAN, IRBESARTAN

LEVOFLOXACIN, LEVOFLOXACIN

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

MONTELUKAST SODIUM, MONTELUKAST SODIUM

OLANZAPINE, OLANZAPINE

PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE

RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE

SILDENAFIL CITRATE, SILDENAFIL CITRATE

VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**MALLINCKRODT****\* MALLINCKRODT CHEMICAL INC**

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN

METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

METHADOSE, METHADONE HYDROCHLORIDE



## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* M \*\*

## \* MALLINCKRODT INC

ANEXSIA 5/325, ACETAMINOPHEN  
 ANEXSIA 7.5/325, ACETAMINOPHEN  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 FENTANYL CITRATE, FENTANYL CITRATE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE  
 OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE  
 OPTIMARK, GADOVERSETAMIDE  
 OXYCET, ACETAMINOPHEN  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

## \* MALLINCKRODT MEDICAL INC

CONRAY 30, IOTHALAMATE MEGLUMINE  
 CONRAY 43, IOTHALAMATE MEGLUMINE  
 CONRAY, IOTHALAMATE MEGLUMINE  
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE  
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67  
 INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE  
 MD-76R, DIATRIZOATE MEGLUMINE  
 MD-GASTROVIEW, DIATRIZOATE MEGLUMINE  
 OCTROSCAN, INDIUM IN-111 PENTETREOTIDE KIT  
 OPTIRAY 240, IOVERSOL  
 OPTIRAY 300, IOVERSOL  
 OPTIRAY 320, IOVERSOL  
 OPTIRAY 350, IOVERSOL  
 SODIUM IODIDE I 123, SODIUM IODIDE I-123  
 SODIUM IODIDE I 131, SODIUM IODIDE I-131  
 TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT  
 TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
 TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT  
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201  
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR  
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT

**MALLINCKRODT INC**

## \* MALLINCKRODT INC

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 EXALGO, HYDROMORPHONE HYDROCHLORIDE  
 FENTANYL-100, FENTANYL  
 FENTANYL-25, FENTANYL  
 FENTANYL-50, FENTANYL  
 FENTANYL-75, FENTANYL  
 GABLOFEN, BACLOFEN  
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 RESTORIL, TEMAZEPAM  
 ROXICODONE, OXYCODONE HYDROCHLORIDE  
 TOFRANIL, IMIPRAMINE HYDROCHLORIDE  
 TOFRANIL-PM, IMIPRAMINE PAMOATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MALLINCKRODT INC  
XARTEMIS XR, ACETAMINOPHEN

**MALLINCKRODT LLC**

\* MALLINCKRODT LLC  
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE  
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE

**MARATHON PHARMS**

\* MARATHON PHARMACEUTICALS LLC  
PEPCID, FAMOTIDINE  
SECONAL SODIUM, SECOBARBITAL SODIUM

**MARATHON PHARMS LLC**

\* MARATHON PHARMACEUTICALS LLC  
IPIVASK, DESIRUDIN RECOMBINANT

**MARKSANS PHARMA**

\* MARKSANS PHARMA LTD  
GABAPENTIN, GABAPENTIN  
IBUPROFEN, IBUPROFEN  
IBUPROFEN, IBUPROFEN (OTC)  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)  
NAPROXEN, NAPROXEN

**MATAWAN PHARMS**

\* MATAWAN PHARMACEUTICALS LLC  
TRETINOIN, TRETINOIN

**MATRIX LABS LTD**

\* MATRIX LABORATORIES LTD  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
NIFEDIPINE, NIFEDIPINE  
STAVUDINE, STAVUDINE

**MAYER LABS INC**

\* MAYER LABORATORIES INC  
TODAY, NONOXYNOL-9 (OTC)

**MAYNE PHARMA**

\* MAYNE PHARMA INTERNATIONAL PTY LTD  
DORYX, DOXYCYCLINE HYCLATE  
DOXTERIC, DOXYCYCLINE HYCLATE  
ERYC, ERYTHROMYCIN

**MCNEIL**

\* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC  
CHILDREN'S MOTRIN, IBUPROFEN (OTC)  
IBUPROFEN, IBUPROFEN (OTC)  
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)  
IMODIUM MULTI-SYMPOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)  
MOTRIN IB, IBUPROFEN (OTC)  
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)  
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

**MCNEIL CONS**

\* MCNEIL CONSUMER HEALTHCARE  
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)  
CHILDREN'S MOTRIN, IBUPROFEN (OTC)  
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)  
IMODIUM MULTI-SYMPOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)  
IMODIUM, LOPERAMIDE HYDROCHLORIDE  
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)  
PEPCID AC, FAMOTIDINE (OTC)  
PEPCID AC, FAMOTIDINE (OTC)  
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)  
SINE-AID IB, IBUPROFEN (OTC)  
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
TYLENOL, ACETAMINOPHEN (OTC)

**MCNEIL CONSUMER**

\* MCNEIL CONSUMER HEALTHCARE DIV MCNEIL PPC INC  
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MCNEIL CONSUMER HEALTHCARE DIV MCNEIL PPC INC  
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 ZYRTEC, CETIRIZINE HYDROCHLORIDE

**MCPRF**

\* MAYO CLINIC PET RADIOCHEMISTRY FACILITY  
 AMMONIA N 13, AMMONIA N-13  
 CHOLINE C-11, CHOLINE C-11  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**MEDA PHARMS**

\* MEDA PHARMACEUTICALS  
 DYMISTA, AZELASTINE HYDROCHLORIDE  
 EDLUAR, ZOLPIDEM TARTRATE

\* MEDA PHARMACEUTICALS INC  
 ANADROL-50, OXYMETHOLONE  
 ASTELIN, AZELASTINE HYDROCHLORIDE  
 ASTEPRO, AZELASTINE HYDROCHLORIDE  
 AVC, SULFANILAMIDE  
 BUTISOL SODIUM, BUTABARBITAL SODIUM  
 CESAMET, NABILONE  
 COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350  
 COLYTE, POLYETHYLENE GLYCOL 3350  
 CORTIFOAM, HYDROCORTISONE ACETATE  
 DEMADEX, TORSEMIDE  
 DEPEN, PENICILLAMINE  
 DIPENTUM, OLSALAZINE SODIUM  
 ELESTRIN, ESTRADIOL  
 EPIFOAM, HYDROCORTISONE ACETATE  
 FELBATOL, FELBAMATE  
 GASTROCROM, CROMOLYN SODIUM  
 LUFYLLIN, DYPHYLLINE  
 MUSE, ALPROSTADIL  
 OPTIVAR, AZELASTINE HYDROCHLORIDE  
 PROCTOFOAM HC, HYDROCORTISONE ACETATE  
 ROWASA, MESALAMINE  
 SFROWASA, MESALAMINE  
 TRILYTE, POLYETHYLENE GLYCOL 3350

\* MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC  
 SOMA COMPOUND W/ CODEINE, ASPIRIN  
 SOMA COMPOUND, ASPIRIN  
 SOMA, CARISOPRODOL

**MEDA PHARMS INC**

\* MEDA PHARMACEUTICALS INC  
 AEROSPAN HFA, FLUNISOLIDE

**MEDAC PHARMA INC**

\* MEDAC PHARMA INC  
 RASUVO, METHOTREXATE

**MEDEFIL INC**

\* MEDEFIL INC  
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

**MEDICIS**

\* MEDICIS PHARMACEUTICAL CORP  
 ALDARA, IMIQUIMOD  
 AMMONUL, SODIUM BENZOATE  
 CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 ESTRASORB, ESTRADIOL HEMIHYDRATE  
 LOPROX, CICLOPIROX  
 LUZU, LULICONAZOLE  
 MAXAIR, PIRBUTEROL ACETATE  
 METROGEL-VAGINAL, METRONIDAZOLE  
 MINITRAN, NITROGLYCERIN  
 NORFLEX, ORPHENADRINE CITRATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\*****\* MEDICIS PHARMACEUTICAL CORP**

NORGESIC FORTE, ASPIRIN  
 NORGESIC, ASPIRIN  
 SOLODYN, MINOCYCLINE HYDROCHLORIDE  
 SYNACORT, HYDROCORTISONE  
 THEOLAIR, THEOPHYLLINE  
 VANOS, FLUOCINONIDE  
 ZIANA, CLINDAMYCIN PHOSPHATE  
 ZYCLARA, IMIQUIMOD

**MEDICURE**

\* MEDICURE INTERNATIONAL INC  
 AGGRASTAT, TIROFIBAN HYDROCHLORIDE

**MEDIGENE AG**

\* MEDIGENE AG  
 VEREGEN, SINECATECHINS

**MEDIMETRIKS PHARMS**

\* MEDIMETRIKS PHARMACEUTICALS INC  
 LOPROX, CICLOPIROX  
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE  
 SYNALAR, FLUOCINOLONE ACETONIDE

**MEDTECH PRODUCTS**

\* MEDTECH PRODUCTS INC  
 MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)  
 MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MONISTAT 3, MICONAZOLE NITRATE  
 MONISTAT 3, MICONAZOLE NITRATE (OTC)  
 MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 MONISTAT 7, MICONAZOLE NITRATE (OTC)  
 MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
 NIX, PERMETHRIN (OTC)  
 TAGAMET HB, CIMETIDINE (OTC)

**MEDTRONIC NEURO**

\* MEDTRONIC NEUROMODULATION  
 LIORESAL, BACLOFEN

**MERCK**

\* MERCK AND CO INC  
 CANCIDAS, CASPOFUNGIN ACETATE  
 EMEND, APREPITANT  
 FOSAMAX PLUS D, ALENDRONATE SODIUM  
 FOSAMAX, ALENDRONATE SODIUM  
 MAXALT, RIZATRIPTAN BENZOATE  
 MAXALT-MLT, RIZATRIPTAN BENZOATE  
 PRIMAXIN, CILASTATIN SODIUM  
 PROSCAR, FINASTERIDE  
 SINGULAIR, MONTELUKAST SODIUM  
 ZOLINZA, VORINOSTAT

\* MERCK RESEARCH LABORATORIES DIV MERCK CO INC  
 CLINORIL, SULINDAC  
 PRINIVIL, LISINAPRIL  
 PRINZIDE, HYDROCHLOROTHIAZIDE  
 PROPECIA, FINASTERIDE  
 SINGULAIR, MONTELUKAST SODIUM  
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE  
 ZOCOR, SIMVASTATIN

**MERCK AND CO INC**

\* MERCK AND CO INC  
 EMEND, FOSAPREPITANT DIMEGLUMINE  
 FOSAMAX, ALENDRONATE SODIUM

**MERCK SANTE SAS**

\* MERCK SANTE SAS  
 CYANOKIT, HYDROXOCOBALAMIN

**MERCK SHARP DOHME**

\* MERCK SHARP AND DOHME CORP  
 ASMANEX HFA, MOMETASONE FUROATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

- \* MERCK SHARP AND DOHME CORP  
 ASMANEX TWISTHALER, MOMETASONE FUROATE  
 BELSOMRA, SUVOREXANT  
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE  
 CLARINEX D 24 HOUR, DESLORATADINE  
 CLARINEX, DESLORATADINE  
 CLARINEX-D 12 HOUR, DESLORATADINE  
 COZAAR, LOSARTAN POTASSIUM  
 CRIXIVAN, INDINAVIR SULFATE  
 DIPROLENE AF, BETAMETHASONE DIPROPIONATE  
 DIPROLENE, BETAMETHASONE DIPROPIONATE  
 DULERA, FORMOTEROL FUMARATE  
 ELOCON, MOMETASONE FUROATE  
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE  
 HYZAAR, HYDROCHLOROTHIAZIDE  
 INVANZ, ERTAPENEM SODIUM  
 ISENTRESS, RALTEGRAVIR POTASSIUM  
 JANUMET XR, METFORMIN HYDROCHLORIDE  
 JANUMET, METFORMIN HYDROCHLORIDE  
 JANUVIA, SITAGLIPTIN PHOSPHATE  
 LIPTRUZET, ATORVASTATIN CALCIUM  
 LOTRISONE, BETAMETHASONE DIPROPIONATE  
 NASONEX, MOMETASONE FUROATE MONOHYDRATE  
 NITRO-DUR, NITROGLYCERIN  
 NOXAFIL, POSACONAZOLE  
 REBETOL, RIBAVIRIN  
 SINEMET CR, CARBIDOPA  
 SINEMET, CARBIDOPA  
 STROMEKTOL, IVERMECTIN  
 TEMODAR, TEMOZOLOMIDE  
 VICTRELIS, BOCEPREVIR  
 ZONTIVITY, VORAPAXAR SULFATE
- MERIDIAN MEDCL**
- \* MERIDIAN MEDICAL TECHNOLOGIES INC  
 DUODOTE, ATROPINE
- \* MERIDIAN MEDICAL TECHNOLOGIES INC SUB KING PHARMACEUTICALS INC  
 ALSUMA, SUMATRIPTAN SUCCINATE
- MERIDIAN MEDCL TECHN**
- \* MERIDIAN MEDICAL TECHNOLOGIES INC  
 ATROPEN, ATROPINE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
- MERRO PHARM**
- \* MERRO PHARMACEUTICAL CO LTD  
 IBUPROFEN, IBUPROFEN (OTC)
- MERZ PHARMS**
- \* MERZ PHARMACEUTICALS LLC  
 CUVPOSA, GLYCOPYRROLATE  
 NAFTIN, NAFTIFINE HYDROCHLORIDE  
 ONMEL, ITRACONAZOLE
- METHAPHARM**
- \* METHAPHARM INC  
 LEVETIRACETAM, LEVETIRACETAM  
 PROVOCHOLINE, METHACHOLINE CHLORIDE
- MICRO LABS LTD**
- \* MICRO LABS LTD  
 MEFENAMIC ACID, MEFENAMIC ACID  
 NEVIRAPINE, NEVIRAPINE  
 SIMVASTATIN, SIMVASTATIN
- MICRO LABS LTD INDIA**
- \* MICRO LABS LTD INDIA  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 GLIMEPIRIDE, GLIMEPIRIDE  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MICRO LABS LTD INDIA  
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

**MIKAH PHARMA**

\* MIKAH PHARMA LLC  
DANTROLENE SODIUM, DANTROLENE SODIUM  
ISRADIPINE, ISRADIPINE  
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE  
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

**MIKART**

\* MIKART INC  
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
AMINOCAPROIC ACID, AMINOCAPROIC ACID  
AMINOCAPROIC, AMINOCAPROIC ACID  
BENZONATATE, BENZONATATE  
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE  
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
BUTAPAP, ACETAMINOPHEN  
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
CHLORZOXAZONE, CHLORZOXAZONE  
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE  
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE  
ETHOSUXIMIDE, ETHOSUXIMIDE  
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
METHAZOLAMIDE, METHAZOLAMIDE  
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE  
PYRAZINAMIDE, PYRAZINAMIDE  
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

**MILLENNIUM PHARMS**

\* MILLENNIUM PHARMACEUTICALS INC  
VELCADE, BORTEZOMIB

**MIPS CRF**

\* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY  
AMMONIA N 13, AMMONIA N-13

**MIRROR PHARMS**

\* MIRROR PHARMACEUTICALS LLC  
CARISOPRODOL AND ASPIRIN, ASPIRIN  
CARISOPRODOL, CARISOPRODOL  
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
PROBENECID AND COLCHICINE, COLCHICINE

**MISSION PHARMA**

\* MISSION PHARMACAL CO  
BINOSTO, ALENDRONATE SODIUM  
LITHOSTAT, ACETOHYDROXAMIC ACID  
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
TEXACORT, HYDROCORTISONE  
THIOLA, TIOPRONIN  
TINDAMAX, TINIDAZOLE  
UROKIT-K, POTASSIUM CITRATE

**MISSION PHARMACAL CO**

\* MISSION PHARMACAL CO  
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE

**MIST PHARMS LLC**

\* MIST PHARMACEUTICALS LLC  
NITROMIST, NITROGLYCERIN

**MOBERG PHARMA NORTH**

\* MOBERG PHARMA NORTH AMERICA LLC  
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

**MOBIUS THERAP**

\* MOBIUS THERAPEUTICS LLC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MOBIUS THERAPEUTICS LLC  
MITOSOL, MITOMYCIN

**MOLNLYCKE HLTH**

\* MOLNLYCKE HEALTH CARE  
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)  
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

**MONARCH PHARMS**

\* MONARCH PHARMACEUTICALS INC  
CORTISPORIN, BACITRACIN ZINC  
CORTISPORIN, HYDROCORTISONE ACETATE  
CORTISPORIN, HYDROCORTISONE  
MENEST, ESTROGENS, ESTERIFIED  
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE  
NEOSPORIN, GRAMICIDIN  
PEDIOTIC, HYDROCORTISONE  
SEPTRA DS, SULFAMETHOXAZOLE  
SEPTRA, SULFAMETHOXAZOLE  
VIROPTIC, TRIFLURIDINE

**MORTON GROVE**

\* MORTON GROVE PHARMACEUTICALS INC  
LACTULOSE, LACTULOSE

**MORTON GROVE PHARMS**

\* MORTON GROVE PHARMACEUTICALS INC  
GENERLAC, LACTULOSE

**MSD CONSUMER**

\* MSD CONSUMER CARE INC  
ZEGERID OTC, OMEPRAZOLE (OTC)

**MSD INTL**

\* MSD INTERNATIONAL GMBH  
VYTORIN, EZETIMIBE

**MSD INTL GMBH**

\* MSD INTERNATIONAL GMBH  
ZETIA, EZETIMIBE

**MURTY PHARMS**

\* MURTY PHARMACEUTICALS INC  
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
DIPYRIDAMOLE, DIPYRIDAMOLE

**MUSTAFA NEVSAT**

\* MUSTAFA NEVSAT ILAC SANAYII AS  
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE

**MUSTAFA NEVZAT**

\* MUSTAFA NEVZAT ILAC SANAYII AS  
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
VECURONIUM BROMIDE, VECURONIUM BROMIDE

**MUSTAFA NEVZAT ILAC**

\* MUSTAFA NEVZAT ILAC SANAYII AS (MN PHARMACEUTICALS)  
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**MUTUAL PHARM**

\* MUTUAL PHARMACEUTICAL CO INC  
ACETAZOLAMIDE, ACETAZOLAMIDE  
ALBUTEROL SULFATE, ALBUTEROL SULFATE  
ALLOPURINOL, ALLOPURINOL  
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
ATENOLOL AND CHLORTHALIDONE, ATENOLOL  
ATENOLOL, ATENOLOL  
BACTRIM DS, SULFAMETHOXAZOLE  
BACTRIM, SULFAMETHOXAZOLE  
CARISOPRODOL, CARISOPRODOL  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MUTUAL PHARMACEUTICAL CO INC  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 ERGOLOID MESYLATES, ERGOLOID MESYLATES  
 FELODIPINE, FELODIPINE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
 LOVASTATIN, LOVASTATIN  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 METRONIDAZOLE, METRONIDAZOLE  
 MINOXIDIL, MINOXIDIL  
 NYSTATIN, NYSTATIN  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PINDOLOL, PINDOLOL  
 PIROXICAM, PIROXICAM  
 PREDNISON, PREDNISON  
 PRIMIDONE, PRIMIDONE  
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE  
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE  
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 SPIRONOLACTONE, SPIRONOLACTONE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 SULINDAC, SULINDAC  
 TEMAZEPAM, TEMAZEPAM  
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE  
 TOLMETIN SODIUM, TOLMETIN SODIUM  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

**MUTUAL PHARM CO INC**

\* MUTUAL PHARMACEUTICAL CO INC  
 FIBRICOR, FENOFIBRIC ACID  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 QUALAQUIN, QUININE SULFATE

**MUTUAL PHARMA**

\* MUTUAL PHARMACAL CO  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

**MYLAN**

\* MYLAN LABORATORIES INC  
 ACYCLOVIR, ACYCLOVIR  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
 CAPTOPRIL, CAPTOPRIL  
 ETODOLAC, ETODOLAC  
 OLANZAPINE, OLANZAPINE  
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

\* MYLAN PHARMACEUTICALS  
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

\* MYLAN PHARMACEUTICALS INC  
 ACARBOSE, ACARBOSE  
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE  
 ACYCLOVIR, ACYCLOVIR  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
 ALLOPURINOL, ALLOPURINOL  
 ALPRAZOLAM, ALPRAZOLAM  
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE



## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* M \*\*

\* MYLAN PHARMACEUTICALS INC  
 ANASTROZOLE, ANASTROZOLE  
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL  
 ATENOLOL, ATENOLOL  
 AVITA, TRETINOIN  
 AZATHIOPRINE, AZATHIOPRINE  
 AZITHROMYCIN, AZITHROMYCIN  
 BACLOFEN, BACLOFEN  
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BICALUTAMIDE, BICALUTAMIDE  
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE  
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE  
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE  
 BUDESONIDE, BUDESONIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE  
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CARVEDILOL, CARVEDILOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHLOROTHIAZIDE, CHLOROTHIAZIDE  
 CHLORPROPAMIDE, CHLORPROPAMIDE  
 CHLORTHALIDONE, CHLORTHALIDONE  
 CILOSTAZOL, CILOSTAZOL  
 CIMETIDINE, CIMETIDINE  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE  
 CLONAZEPAM, CLONAZEPAM  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM  
 CLORPRES, CHLORTHALIDONE  
 CLOZAPINE, CLOZAPINE  
 CYSTAGON, CYSTEAMINE BITARTRATE  
 DIAZEPAM, DIAZEPAM  
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 DOXYCYCLINE, DOXYCYCLINE  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
 ENALAPRIL MALEATE, ENALAPRIL MALEATE  
 ESTRADIOL, ESTRADIOL  
 ESTROPIPATE, ESTROPIPATE  
 ETIDRONATE DISODIUM, ETIDRONATE DISODIUM  
 ETOPOSIDE, ETOPOSIDE  
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 FAMCICLOVIR, FAMCICLOVIR  
 FAMOTIDINE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 FELODIPINE, FELODIPINE  
 FENOFIBRATE, FENOFIBRATE  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* M \*\*

\* MYLAN PHARMACEUTICALS INC  
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
 FINASTERIDE, FINASTERIDE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
 FLURBIPROFEN, FLURBIPROFEN  
 FLUTAMIDE, FLUTAMIDE  
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 FUROSEMIDE, FUROSEMIDE  
 GABAPENTIN, GABAPENTIN  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GLIMEPIRIDE, GLIMEPIRIDE  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
 GLIPIZIDE, GLIPIZIDE  
 GLYBURIDE (MICRONIZED), GLYBURIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
 HALOPERIDOL, HALOPERIDOL  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 INDAPAMIDE, INDAPAMIDE  
 INDOMETHACIN, INDOMETHACIN  
 KETOCONAZOLE, KETOCONAZOLE  
 KETOPROFEN, KETOPROFEN  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LAMOTRIGINE, LAMOTRIGINE  
 LATANOPROST, LATANOPROST  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM \*\*  
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM  
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINAPRIL, LISINAPRIL  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE  
 LORATADINE, LORATADINE (OTC)  
 LORAZEPAM, LORAZEPAM  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 LOVASTATIN, LOVASTATIN  
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE  
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE  
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM  
 MELOXICAM, MELOXICAM  
 MENTAX, BUTENAFINE HYDROCHLORIDE  
 MERCAPTOPYRINE, MERCAPTOPYRINE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHIMAZOLE, METHIMAZOLE  
 METHOTREXATE SODIUM, METHOTREXATE SODIUM  
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 METHYLDOPA, METHYLDOPA  
 METOLAZONE, METOLAZONE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIRTAZAPINE, MIRTAZAPINE  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE  
 NADOLOL, NADOLOL  
 NAPROXEN, NAPROXEN  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 NIFEDIPINE, NIFEDIPINE  
 NISOLDIPINE, NISOLDIPINE  
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MYLAN PHARMACEUTICALS INC  
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE  
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
 OMEPRAZOLE, OMEPRAZOLE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350  
 PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE, POLYETHYLENE GLYCOL  
 PENTOXIFYLLINE, PENTOXIFYLLINE  
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
 PHENYTEK, PHENYTOIN SODIUM  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PIROXICAM, PIROXICAM  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE  
 PROBENECID, PROBENECID  
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 RISPERIDONE, RISPERIDONE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 SPIRONOLACTONE, SPIRONOLACTONE  
 STAVUDINE, STAVUDINE  
 SULINDAC, SULINDAC  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TACROLIMUS, TACROLIMUS  
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TEMAZEPAM, TEMAZEPAM  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE  
 THIOTHIXENE, THIOTHIXENE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TOLMETIN SODIUM, TOLMETIN SODIUM  
 TOPIRAMATE, TOPIRAMATE  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRANDOLAPRIL, TRANDOLAPRIL  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE  
 URSODIOL, URSODIOL  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 WARFARIN SODIUM, WARFARIN SODIUM  
 ZALEPLON, ZALEPLON  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE  
 ZONISAMIDE, ZONISAMIDE

**MYLAN INSTITUTIONAL**

\* MYLAN INSTITUTIONAL INC

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MYLAN INSTITUTIONAL INC  
SULFAMYLON, MAFENIDE ACETATE

\* MYLAN INSTITUTIONAL LLC  
ALOPRIM, ALLOPURINOL SODIUM  
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
ARGATROBAN, ARGATROBAN  
CARBOPLATIN, CARBOPLATIN  
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM  
CIDOFOVIR, CIDOFOVIR  
COSYNTROPIN, COSYNTROPIN  
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE  
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE  
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE  
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
DURACLON, CLONIDINE HYDROCHLORIDE  
ENLON, EDROPHONIUM CHLORIDE  
ENLON-PLUS, ATROPINE SULFATE  
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE  
FOMEPIZOLE, FOMEPIZOLE  
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE  
ISOSULFAN BLUE, ISOSULFAN BLUE  
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE  
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM  
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE  
MESNA, MESNA  
METHOCARBAMOL, METHOCARBAMOL  
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
PENTOSTATIN, PENTOSTATIN  
RIMSO-50, DIMETHYL SULFOXIDE  
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
SOTRADECOL, SODIUM TETRADECYL SULFATE  
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE  
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE  
TRANEXAMIC ACID, TRANEXAMIC ACID  
ULTIVA, REMIFENTANIL HYDROCHLORIDE

**MYLAN IRELAND LTD**

\* MYLAN IRELAND LTD  
ARIXTRA, FONDAPARINUX SODIUM

**MYLAN LABS**

\* MYLAN LABORATORIES LTD  
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL  
NEVIRAPINE, NEVIRAPINE

**MYLAN LABS LTD**

\* MYLAN LABORATORIES LTD  
VALSARTAN, VALSARTAN

**MYLAN PHARMS INC**

\* MYLAN PHARMACEUTICALS INC  
ABACAVIR SULFATE, ABACAVIR SULFATE  
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM  
ACYCLOVIR, ACYCLOVIR  
ALPRAZOLAM, ALPRAZOLAM  
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE  
AMNESTEEM, ISOTRETINOIN  
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE  
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE  
AVITA, TRETINOIN  
BACLOFEN, BACLOFEN  
CABERGOLINE, CABERGOLINE  
CAPECITABINE, CAPECITABINE

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* M \*\*

\* MYLAN PHARMACEUTICALS INC  
CELECOXIB, CELECOXIB  
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
CILOSTAZOL, CILOSTAZOL  
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
CLONAZEPAM, CLONAZEPAM  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
DESLORATADINE, DESLORATADINE  
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
DIDANOSINE, DIDANOSINE  
DIGOXIN, DIGOXIN  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
DOXYCYCLINE, DOXYCYCLINE  
ENTACAPONE, ENTACAPONE  
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE  
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE  
ESZOPICLONE, ESZOPICLONE  
FENOFIBRATE (MICRONIZED), FENOFIBRATE  
FENOFIBRATE, FENOFIBRATE  
FENOFIBRIC ACID, CHOLINE FENOFIBRATE  
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM  
FINASTERIDE, FINASTERIDE  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE  
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE  
GABAPENTIN, GABAPENTIN  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
IBANDRONATE SODIUM, IBANDRONATE SODIUM  
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE  
INDAPAMIDE, INDAPAMIDE  
INDOMETHACIN, INDOMETHACIN  
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
IRBESARTAN, IRBESARTAN  
ITRACONAZOLE, ITRACONAZOLE  
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
LAMIVUDINE, LAMIVUDINE  
LANSOPRAZOLE, LANSOPRAZOLE  
LEVETIRACETAM, LEVETIRACETAM  
LITHIUM CARBONATE, LITHIUM CARBONATE  
MAXZIDE, HYDROCHLOROTHIAZIDE  
MAXZIDE-25, HYDROCHLOROTHIAZIDE  
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
METHYLCLOTHIAZIDE, METHYLCLOTHIAZIDE  
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE  
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE  
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
MIRTAZAPINE, MIRTAZAPINE  
MODAFINIL, MODAFINIL  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
MORPHINE SULFATE, MORPHINE SULFATE  
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID  
NABUMETONE, NABUMETONE  
NAPROXEN, NAPROXEN  
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
NEVIRAPINE, NEVIRAPINE  
OLANZAPINE, OLANZAPINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

- \* MYLAN PHARMACEUTICALS INC  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PHENYTOIN, PHENYTOIN  
 PINDOLOL, PINDOLOL  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUININE SULFATE, QUININE SULFATE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 RAMIPRIL, RAMIPRIL  
 REPAGLINIDE, REPAGLINIDE  
 RILUZOLE, RILUZOLE  
 RISEDRONATE SODIUM, RISEDRONATE SODIUM  
 RISPERIDONE, RISPERIDONE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 SIMVASTATIN, SIMVASTATIN  
 SUNITINIB MALATE, SUNITINIB MALATE  
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE  
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TELMISARTAN, TELMISARTAN  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TOLAZAMIDE, TOLAZAMIDE  
 TOLBUTAMIDE, TOLBUTAMIDE  
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 TRIAZOLAM, TRIAZOLAM  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 VORICONAZOLE, VORICONAZOLE  
 ZIDOVUDINE, ZIDOVUDINE  
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE  
 ZOLMITRIPTAN, ZOLMITRIPTAN  
 ZONISAMIDE, ZONISAMIDE
- \* MYLAN PHARMACEUTICALS INC.  
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM  
 NIZATIDINE, NIZATIDINE  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

**MYLAN SPECLT**

- \* MYLAN SPECIALTY LP  
 ACCUNEB, ALBUTEROL SULFATE  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 DUONEB, ALBUTEROL SULFATE  
 EPIPEN JR., EPINEPHRINE  
 EPIPEN, EPINEPHRINE  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE  
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE  
 PERFORMIST, FORMOTEROL FUMARATE

**MYLAN TECHNOLOGIES**

- \* MYLAN TECHNOLOGIES  
 XULANE, ETHINYL ESTRADIOL
- \* MYLAN TECHNOLOGIES INC  
 CLONIDINE, CLONIDINE  
 ESTRADIOL, ESTRADIOL  
 FENTANYL-100, FENTANYL  
 FENTANYL-12, FENTANYL  
 FENTANYL-25, FENTANYL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* M \*\***

\* MYLAN TECHNOLOGIES INC  
 FENTANYL-37, FENTANYL  
 FENTANYL-50, FENTANYL  
 FENTANYL-62, FENTANYL  
 FENTANYL-75, FENTANYL  
 FENTANYL-87, FENTANYL  
 NITROGLYCERIN, NITROGLYCERIN

**\*\* N \*\*****NATCO PHARMA**

\* NATCO PHARMA LTD  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

**NATCO PHARMA LTD**

\* NATCO PHARMA LIMITED  
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE

\* NATCO PHARMA LTD  
 ANASTROZOLE, ANASTROZOLE  
 CARISOPRODOL, CARISOPRODOL  
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LETROZOLE, LETROZOLE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

**NAVIDEA BIOPHARMS**

\* NAVIDEA BIOPHARMACEUTICALS INC  
 LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT

**NAVINTA LLC**

\* NAVINTA LLC  
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
 FAMOTIDINE, FAMOTIDINE  
 FOMEPIZOLE, FOMEPIZOLE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE

**NCM USA BRONX LLC**

\* NCM USA BRONX LLC  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**NEOS THERAP INC**

\* NEOS THERAPEUTICS INC  
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

**NEPHRON**

\* NEPHRON CORP  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

\* NEPHRON PHARMACEUTICALS CORP  
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE

**NESHER PHARMS**

\* NESHER PHARMACEUTICALS USA LLC  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
 MICRO-K 10, POTASSIUM CHLORIDE  
 MICRO-K, POTASSIUM CHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**NEW RIVER**

\* NEW RIVER PHARMACEUTICALS INC  
 PROFERDEX, IRON DEXTRAN

**NEXGEN PHARMA**

\* NEXGEN PHARMA INC  
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 CHENODIOL, CHENODIOL

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\*****\* NEXGEN PHARMA INC**

GLYCOPYRROLATE, GLYCOPYRROLATE  
 MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

**NEXGEN PHARMA INC****\* NEXGEN PHARMA INC**

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350

**NEXTWAVE PHARMS****\* NEXTWAVE PHARMACEUTICALS INC**

QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

**NEXUS PHARMS****\* NEXUS PHARMACEUTICALS INC**

CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 LEVOFLOXACIN, LEVOFLOXACIN

**NIAGARA PHARMS****\* NIAGARA PHARMACEUTICALS INC**

PUR-WASH, PURIFIED WATER (OTC)

**NORTEC DEV ASSOC****\* NORTEC DEVELOPMENT ASSOC INC**

PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

**NORTHSTAR HLTHCARE****\* NORTHSTAR HEALTHCARE HOLDINGS LTD**

ALLOPURINOL, ALLOPURINOL  
 ATENOLOL, ATENOLOL  
 BACLOFEN, BACLOFEN  
 GEMFIBROZIL, GEMFIBROZIL  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**NOSTRUM****\* NOSTRUM PHARMACEUTICALS INC**

CARBAMAZEPINE, CARBAMAZEPINE  
 THEOPHYLLINE, THEOPHYLLINE

**NOSTRUM LABS****\* NOSTRUM LABORATORIES INC**

PIROXICAM, PIROXICAM  
 SUCRALFATE, SUCRALFATE

**NOSTRUM PHARMS LLC****\* NOSTRUM PHARMACEUTICALS LLC**

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**NOVA LABS LTD****\* NOVA LABORATORIES LTD**

PURIXAN, MERCAPTOPYRIMIDINE

**NOVADEL****\* NOVADEL PHARMA INC**

ZOLPIDEM, ZOLPIDEM TARTRATE

**NOVARTIS****\* NOVARTIS CONSUMER HEALTH INC**

EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)  
 LAMISIL AT, TERBINAFINE (OTC)  
 LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)  
 LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)  
 PREVACID 24 HR, LANSOPRAZOLE (OTC)  
 THRIVE, NICOTINE POLACRILEX (OTC)  
 TRANSDERM SCOP, SCOPOLAMINE  
 VAGISTAT-1, TIOCONAZOLE (OTC)  
 VOLTAREN, DICLOFENAC SODIUM

**\* NOVARTIS PHARMACEUTICALS CORP**

AFINITOR, EVEROLIMUS  
 AMTURNIDE, ALISKIREN HEMIFUMARATE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\***

\* NOVARTIS PHARMACEUTICALS CORP  
 ARCAPTA NEOHALER, INDACATEROL MALEATE  
 CATAFLAM, DICLOFENAC POTASSIUM  
 CLOZARIL, CLOZAPINE  
 COARTEM, ARTEMETHER  
 DESFERAL, DEFEROXAMINE MESYLATE  
 DIOVAN HCT, HYDROCHLOROTHIAZIDE  
 DIOVAN, VALSARTAN  
 ESTRADERM, ESTRADIOL  
 EXELON, RIVASTIGMINE  
 EXELON, RIVASTIGMINE TARTRATE  
 EXFORGE HCT, AMLODIPINE BESYLATE  
 EXFORGE, AMLODIPINE BESYLATE  
 EXJADE, DEFERASIROX  
 FAMVIR, FAMCICLOVIR  
 FANAPT, ILOPERIDONE  
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 FORADIL, FORMOTEROL FUMARATE  
 GILENYA, FINGOLIMOD  
 GLEVEEC, IMATINIB MESYLATE  
 HYDERGINE, ERGOLOID MESYLATES  
 LAMISIL, TERBINAFFINE HYDROCHLORIDE  
 LAMPRENE, CLOFAZIMINE  
 LESCOL XL, FLUVASTATIN SODIUM  
 LESCOL, FLUVASTATIN SODIUM  
 LOPRESSOR, METOPROLOL TARTRATE  
 LOTREL, AMLODIPINE BESYLATE  
 MYFORTIC, MYCOPHENOLIC ACID  
 NEORAL, CYCLOSPORINE  
 OCUPRESS, CARTEOLOL HYDROCHLORIDE  
 RECLAST, ZOLEDRONIC ACID  
 REGITINE, PHENTOLAMINE MESYLATE  
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE  
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE  
 RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE  
 SANDIMMUNE, CYCLOSPORINE  
 SANDOSTATIN LAR, OCTREOTIDE ACETATE  
 SANDOSTATIN, OCTREOTIDE ACETATE  
 SIGNIFOR, PASIREOTIDE DIASPARTATE  
 STARLIX, NATEGLINIDE  
 TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE  
 TAVIST-1, CLEMASTINE FUMARATE (OTC)  
 TEGRETOL, CARBAMAZEPINE  
 TEGRETOL-XR, CARBAMAZEPINE  
 TEKAMLO, ALISKIREN HEMIFUMARATE  
 TEKTRNA HCT, ALISKIREN HEMIFUMARATE  
 TEKTRNA, ALISKIREN HEMIFUMARATE  
 TOBI PODHALER, TOBRAMYCIN  
 TRILEPTAL, OXCARBAZEPINE  
 TYZEKA, TELBIVUDINE  
 VIVELLE, ESTRADIOL  
 VIVELLE-DOT, ESTRADIOL  
 VOLTAREN, DICLOFENAC SODIUM  
 VOLTAREN-XR, DICLOFENAC SODIUM  
 ZOMETA, ZOLEDRONIC ACID  
 ZORTRESS, EVEROLIMUS

**NOVARTIS PHARM**

\* NOVARTIS PHARMACEUTICAL CORP  
 AFINITOR DISPERZ, EVEROLIMUS

**NOVARTIS PHARMS**

\* NOVARTIS PHARMACEUTICALS CORP  
 FEMARA, LETROZOLE  
 TOBI, TOBRAMYCIN

**NOVARTIS PHARMS CORP**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\***

\* NOVARTIS PHARMACEUTICALS CORP  
SIGNIFOR LAR, PASIREOTIDE PAMOATE  
ZYKADIA, CERITINIB

**NOVAST LABS**

\* NOVAST LABORATORIES CHINA LTD  
NORETHINDRONE, NORETHINDRONE

**NOVAST LABS LTD**

\* NOVAST LABORATORIES LTD  
DASETTA 1/35, ETHINYL ESTRADIOL  
DASETTA 7/7/7, ETHINYL ESTRADIOL  
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL  
ELINEST, ETHINYL ESTRADIOL  
FALMINA, ETHINYL ESTRADIOL  
LARIN 1.5/30, ETHINYL ESTRADIOL  
LARIN 1/20, ETHINYL ESTRADIOL  
LARIN FE 1.5/30, ETHINYL ESTRADIOL  
LARIN FE 1/20, ETHINYL ESTRADIOL  
LEVONEST, ETHINYL ESTRADIOL  
MONO-LINYAH, ETHINYL ESTRADIOL  
NORETHINDRONE, NORETHINDRONE  
PHILITH, ETHINYL ESTRADIOL  
PIMTREA, DESOGESTREL  
SETLAKIN, ETHINYL ESTRADIOL  
TRI-LINYAH, ETHINYL ESTRADIOL  
WEA, ETHINYL ESTRADIOL  
YELA, DROSPIRENONE

**NOVEL LABS INC**

\* NOVEL LABORATORIES INC  
FAMOTIDINE, FAMOTIDINE  
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE  
LEVONORGESTREL, LEVONORGESTREL  
LEVONORGESTREL, LEVONORGESTREL (OTC)  
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE  
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
MISOPROSTOL, MISOPROSTOL  
NITROFURANTOIN, NITROFURANTOIN  
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350  
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL,  
PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE, POLYETHYLENE GLYCOL  
PHENELZINE SULFATE, PHENELZINE SULFATE  
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
TEMAZEPAM, TEMAZEPAM  
TINIDAZOLE, TINIDAZOLE  
TRIMETHOPRIM, TRIMETHOPRIM

**NOVEN**

\* NOVEN PHARMACEUTICALS INC  
MINIVELLE, ESTRADIOL

**NOVEN PHARMS INC**

\* NOVEN PHARMACEUTICALS INC  
COMBIPATCH, ESTRADIOL  
DAYTRANA, METHYLPHENIDATE

**NOVEN THERAP**

\* NOVEN THERAPEUTICS LLC  
BRISDELLE, PAROXETINE MESYLATE  
PEXEVA, PAROXETINE MESYLATE

**NOVEX**

\* NOVEX PHARMA  
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

**NOVO NORDISK**

\* NOVO NORDISK PHARMACEUTICALS INC  
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

**NOVO NORDISK INC**

\* NOVO NORDISK INC  
LEVEMIR FLEXPEN, INSULIN DETEMIR RECOMBINANT  
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* N \*\*****\* NOVO NORDISK INC**

LEVEMIR, INSULIN DETEMIR RECOMBINANT  
 NORDITROPIN FLEXPEN, SOMATROPIN RECOMBINANT  
 NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT  
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)  
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)  
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT  
 NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT  
 NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT  
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT  
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT  
 NOVOLOG, INSULIN ASPART RECOMBINANT  
 PRANDIMET, METFORMIN HYDROCHLORIDE  
 PRANDIN, REPAGLINIDE  
 SAXENDA, LIRAGLUTIDE RECOMBINANT  
 VAGIFEM, ESTRADIOL  
 VICTOZA, LIRAGLUTIDE RECOMBINANT

**NOVOCOL****\* NOVOCOL PHARMACEUTICAL INC**

ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE

**NOVOCOL INC****\* NOVOCOL INC**

LIDOCAINE, LIDOCAINE

**NPS PHARMS INC****\* NPS PHARMACEUTICALS INC**

GATTEX KIT, TEDUGLUTIDE RECOMBINANT

**NU PHARM****\* NU PHARM INC**

DIVALPROEX SODIUM, DIVALPROEX SODIUM

**NUVO PHARM INC****\* NUVO PHARMACEUTICAL INC**

SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

**NUVO RES INC****\* NUVO RESEARCH INC**

PENNSAID, DICLOFENAC SODIUM

**NYCOMED US****\* NYCOMED US INC**

TERCONAZOLE, TERCONAZOLE

**\*\* O \*\*****OAK PHARMS****\* OAK PHARMACEUTICALS INC**

NEMBUTAL SODIUM, PENTOBARBITAL SODIUM  
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE

**OAK PHARMS AKORN****\* OAK PHARMACEUTICALS INC SUB AKORN INC**

COGENTIN, BENZTROPINE MESYLATE  
 DIURIL, CHLOROTHIAZIDE SODIUM

**OAK PHARMS INC****\* OAK PHARMACEUTICALS INC**

ZIOPTAN, TAFLUPROST

**\* OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC**

AZASITE, AZITHROMYCIN  
 BETIMOL, TIMOLOL  
 COSOPT PF, DORZOLAMIDE HYDROCHLORIDE  
 COSOPT, DORZOLAMIDE HYDROCHLORIDE  
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE

**ODYSSEY PHARMS****\* ODYSSEY PHARMACEUTICALS INC**

ANTABUSE, DISULFIRAM  
 NYSTATIN, NYSTATIN  
 SURMONTIL, TRIMIPRAMINE MALEATE  
 URECHOLINE, BETHANECHOL CHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**

\*\* O \*\*

\* ODYSSEY PHARMACEUTICALS INC  
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

**OHM**

\* OHM CORP  
IBUPROFEN, IBUPROFEN (OTC)

**OHM LABS**

\* OHM LABORATORIES INC  
ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)  
IBUPROHM, IBUPROFEN (OTC)  
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

**OHM LABS INC**

\* OHM LABORATORIES INC  
VALSARTAN, VALSARTAN

**OLTA PHARMS**

\* OLTA PHARMACEUTICALS CORP  
LINDANE, LINDANE

**OMAN PHARM PRODUCTS**

\* OMAN PHARMACEUTICAL PRODUCTS CO LLC  
NEOMYCIN SULFATE, NEOMYCIN SULFATE

**OMEROS**

\* OMEROS CORP  
OMIDRIA, KETOROLAC TROMETHAMINE

**ONCO THERAPIES LTD**

\* ONCO THERAPIES LTD  
CARBOPLATIN, CARBOPLATIN  
CISPLATIN, CISPLATIN  
CLADRIBINE, CLADRIBINE  
CYTARABINE, CYTARABINE  
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
FLUOROURACIL, FLUOROURACIL  
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE  
IFOSFAMIDE, IFOSFAMIDE  
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM  
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
OXALIPLATIN, OXALIPLATIN  
PACLITAXEL, PACLITAXEL  
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
VINORELBINE, VINORELBINE

**ONY**

\* ONY INC  
INFASURF PRESERVATIVE FREE, CALFACTANT

**ONYX PHARMS**

\* ONYX PHARMACEUTICALS INC  
KYPROLIS, CARFILZOMIB

**ORAPHARMA**

\* ORAPHARMA INC  
ARESTIN, MINOCYCLINE HYDROCHLORIDE

**ORCHID HLTHCARE**

\* ORCHID HEALTHCARE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
CEFDINIR, CEFDINIR  
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
CEFPROZIL, CEFPROZIL  
CEFUROXIME AXETIL, CEFUROXIME AXETIL  
CEPHALEXIN, CEPHALEXIN  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
DESLORATADINE, DESLORATADINE  
DIVALPROEX SODIUM, DIVALPROEX SODIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**

\*\* O \*\*

## \* ORCHID HEALTHCARE

ESZOPICLONE, ESZOPICLONE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN, LEVOFLOXACIN  
 MODAFINIL, MODAFINIL  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 OLANZAPINE, OLANZAPINE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 ZALEPLON, ZALEPLON

**OREXO AB**

\* OREXO AB  
 ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

**ORGANON USA INC**

\* ORGANON USA INC  
 CYCLESSA, DESOGESTREL  
 DESOGEN, DESOGESTREL  
 FOLLISTIM AQ, FOLLITROPIN ALFA/BETA  
 GANIRELIX ACETATE, GANIRELIX ACETATE  
 IMPLANON, ETNOGESTREL  
 NEXPLANON, ETNOGESTREL  
 NUVARING, ETHINYL ESTRADIOL  
 PREGNYL, GONADOTROPIN, CHORIONIC  
 REMERON SOLTAB, MIRTAZAPINE  
 REMERON, MIRTAZAPINE

**ORIENT PHARMA CO LTD**

\* ORIENT PHARMA CO LTD  
 CARISOPRODOL, CARISOPRODOL

**ORION CORP ORION**

\* ORION CORP ORION PHARMA  
 SPIRONOLACTONE, SPIRONOLACTONE

**ORION PHARMA**

\* ORION PHARMA  
 COMTAN, ENTACAPONE  
 STALEVO 100, CARBIDOPA  
 STALEVO 125, CARBIDOPA  
 STALEVO 150, CARBIDOPA  
 STALEVO 200, CARBIDOPA  
 STALEVO 50, CARBIDOPA  
 STALEVO 75, CARBIDOPA

**ORIT LABS LLC**

\* ORIT LABORATORIES LLC  
 BENZONATATE, BENZONATATE  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 ERGOCALCIFEROL, ERGOCALCIFEROL  
 LEVETIRACETAM, LEVETIRACETAM

**ORPHAN EUROPE**

\* ORPHAN EUROPE  
 CARBAGLU, CARGLUMIC ACID

**OSI PHARMS**

\* OSI PHARMACEUTICALS INC  
 TARCEVA, ERLOTINIB HYDROCHLORIDE

**OSMOTICA PHARM**

\* OSMOTICA PHARMACEUTICAL CORP  
 NIFEDIPINE, NIFEDIPINE  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**OSMOTICA PHARM CORP**

\* OSMOTICA PHARMACEUTICAL CORP

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* O \*\***

\* OSMOTICA PHARMACEUTICAL CORP  
KHEDEZLA, DESVENLAFAXINE

**OTSUKA**

\* OTSUKA PHARMACEUTICAL CO LTD  
ABILIFY, ARIPIPIRAZOLE  
PLETAL, CILOSTAZOL

\* OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC  
ABILIFY, ARIPIPIRAZOLE

**OTSUKA AMERICA PHARM**

\* OTSUKA AMERICA PHARMACEUTICAL INC  
SAMSCA, TOLVAPTAN

**OTSUKA PHARM**

\* OTSUKA PHARMACEUTICAL CO LTD  
BUSULFEX, BUSULFAN

**OTSUKA PHARM CO LTD**

\* OTSUKA PHARMACEUTICAL CO LTD  
ABILIFY MAINTENA KIT, ARIPIPIRAZOLE

**OUTLOOK PHARMS**

\* OUTLOOK PHARMACEUTICALS INC  
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

**\*\* P \*\*****P AND L DEV LLC**

\* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC  
IBUPROFEN, IBUPROFEN (OTC)

**PACIFIC PHARMA**

\* PACIFIC PHARMA  
TIMOLOL MALEATE, TIMOLOL MALEATE

\* PACIFIC PHARMA INC  
TIMOLOL MALEATE, TIMOLOL MALEATE

**PACIRA PHARMS INC**

\* PACIRA PHARMACEUTICALS INC  
DEPOCYT, CYTARABINE  
EXPAREL, BUPIVACAINE

**PACK PHARMS LLC**

\* PACK PHARMACEUTICALS LLC  
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE  
CROMOLYN SODIUM, CROMOLYN SODIUM

**PADDOCK**

\* PADDOCK LABORATORIES INC  
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

**PADDOCK LABS**

\* PADDOCK LABORATORIES INC  
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE

**PADDOCK LLC**

\* PADDOCK LABORATORIES LLC  
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE  
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN  
CALCIUM ACETATE, CALCIUM ACETATE  
CICLOPIROX, CICLOPIROX  
CLINDA-DERM, CLINDAMYCIN PHOSPHATE  
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
CLOTRIMAZOLE, CLOTRIMAZOLE  
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
COLOCORT, HYDROCORTISONE  
COMPRO, PROCHLORPERAZINE  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE  
ERYTHRA-DERM, ERYTHROMYCIN  
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE  
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE  
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE ,  
INDOMETHACIN, INDOMETHACIN  
KIONEX, SODIUM POLYSTYRENE SULFONATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PADDOCK LABORATORIES LLC  
 LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350  
 LORAZEPAM, LORAZEPAM  
 MIDAMOR, AMILORIDE HYDROCHLORIDE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 NYSTOP, NYSTATIN  
 PODOFILOX, PODOFILOX  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350  
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE  
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
 REPAGLINIDE, REPAGLINIDE  
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE  
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

**PALADIN LABS**

\* PALADIN LABS USA INC  
 ANTIZOL, FOMEPIZOLE

**PANACEA BIOTEC LTD**

\* PANACEA BIOTEC LTD  
 TACROLIMUS, TACROLIMUS

**PAR FORM**

\* PAR FORMULATIONS PRIVATE LTD  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 MAFENIDE ACETATE, MAFENIDE ACETATE

**PAR PHARM**

\* PAR PHARMACEUTICAL  
 NABUMETONE, NABUMETONE  
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE  
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

\* PAR PHARMACEUTICAL INC  
 ALPRAZOLAM, ALPRAZOLAM  
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE  
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 CABERGOLINE, CABERGOLINE  
 CALCITONIN-SALMON, CALCITONIN SALMON  
 CAPOTEN, CAPTOPRIL  
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE  
 CHOLESTYRAMINE, CHOLESTYRAMINE  
 CLOMIPHENE CITRATE, CLOMIPHENE CITRATE  
 CLONAZEPAM, CLONAZEPAM  
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
 DEXAMETHASONE, DEXAMETHASONE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
 DOXYCYCLINE, DOXYCYCLINE  
 ESTAZOLAM, ESTAZOLAM  
 FENTANYL CITRATE, FENTANYL CITRATE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLUTAMIDE, FLUTAMIDE  
 GLIPIZIDE, GLIPIZIDE  
 GLYCOPYRROLATE, GLYCOPYRROLATE  
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 HYDROXYUREA, HYDROXYUREA  
 IBUPROFEN, IBUPROFEN (OTC)  
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PAR PHARMACEUTICAL INC  
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
 MEGACE ES, MEGESTROL ACETATE  
 MEGESTROL ACETATE, MEGESTROL ACETATE  
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE  
 METRONIDAZOLE, METRONIDAZOLE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MINOXIDIL, MINOXIDIL  
 NASCOBAL, CYANOCOBALAMIN  
 NATEGLINIDE, NATEGLINIDE  
 NIFEDIPINE, NIFEDIPINE  
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 OLANZAPINE, OLANZAPINE  
 OXANDROLONE, OXANDROLONE  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TORSEMIDE, TORSEMIDE  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 TRANYLCPROMINE SULFATE, TRANYLCPROMINE SULFATE  
 TRAVOPROST, TRAVOPROST  
 URSODIOL, URSODIOL  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**PAR PHARM INC**

\* PAR PHARMACEUTICAL INC  
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE  
 FENTANYL-100, FENTANYL  
 FENTANYL-25, FENTANYL  
 FENTANYL-50, FENTANYL  
 FENTANYL-75, FENTANYL  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**PAR STERILE PRODUCTS**

\* PAR STERILE PRODUCTS LLC  
 ADRENALIN, EPINEPHRINE HYDROCHLORIDE  
 ARGATROBAN, ARGATROBAN  
 BREVITAL SODIUM, METHOHEXITAL SODIUM  
 COLY-MYCIN M, COLISTIMETHATE SODIUM  
 COLY-MYCIN S, COLISTIN SULFATE  
 DANTRIUM, DANTROLENE SODIUM  
 DELESTROGEN, ESTRADIOL VALERATE  
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE  
 ETOMIDATE, ETOMIDATE  
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE  
 KETALAR, KETAMINE HYDROCHLORIDE  
 PITOCIN, OXYTOCIN  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE  
 TRIOSTAT, LIOTHYRONINE SODIUM  
 VASOSTRICT, VASOPRESSIN

**PARAGON BIOTECK**

\* PARAGON BIOTECK INC  
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

**PARAPRO LLC**

\* PARAPRO LLC  
 NATROBA, SPINOSAD

**PARKE DAVIS**

\* PARKE DAVIS DIV WARNER LAMBERT CO  
 CELONTIN, METHSUXIMIDE  
 CEREBYX, FOSPHENYTOIN SODIUM  
 DILANTIN, PHENYTOIN SODIUM



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

- \* PARKE DAVIS DIV WARNER LAMBERT CO  
DILANTIN-125, PHENYTOIN  
NARDIL, PHENELZINE SULFATE  
NEURONTIN, GABAPENTIN  
ZARONTIN, ETHOSUXIMIDE
- \* PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO  
ZARONTIN, ETHOSUXIMIDE

**PERNIX IRELAND LTD**

- \* PERNIX IRELAND LTD  
TREXIMET, NAPROXEN SODIUM

**PERNIX THERAP**

- \* PERNIX THERAPEUTICS LLC  
CEDAX, CEFTIBUTEN DIHYDRATE

**PERNIX THERAPS LLC**

- \* PERNIX THERAPEUTICS LLC  
SILENOR, DOXEPIN HYDROCHLORIDE

**PERRIGO**

- \* PERRIGO CO  
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
CICLOPIROX, CICLOPIROX  
CIMETIDINE, CIMETIDINE (OTC)  
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)  
CLINDETS, CLINDAMYCIN PHOSPHATE  
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
ERYTHROMYCIN, ERYTHROMYCIN  
FAMOTIDINE, FAMOTIDINE  
FAMOTIDINE, FAMOTIDINE (OTC)  
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
IBUPROFEN, IBUPROFEN (OTC)  
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)  
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)  
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)  
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)  
MOMETASONE FUROATE, MOMETASONE FUROATE  
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)  
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
STIE-CORT, HYDROCORTISONE

**PERRIGO CO TENNESSEE**

- \* PERRIGO CO TENNESSEE INC  
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC  
BACITRACIN, BACITRACIN  
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN  
ERYTHROMYCIN, ERYTHROMYCIN  
GENTAMICIN SULFATE, GENTAMICIN SULFATE  
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC  
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE  
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

**PERRIGO ISRAEL**

- \* PERRIGO ISRAEL PHARMACEUTICALS  
FLUOCINONIDE, FLUOCINONIDE
- \* PERRIGO ISRAEL PHARMACEUTICALS LTD  
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
BUTOCONAZOLE NITRATE, BUTOCONAZOLE NITRATE  
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE  
IMIQUIMOD, IMIQUIMOD  
KETOCONAZOLE, KETOCONAZOLE  
MESALAMINE, MESALAMINE  
MINOXIDIL, MINOXIDIL (OTC)

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PERRIGO ISRAEL PHARMACEUTICALS LTD  
 NITROGLYCERIN, NITROGLYCERIN  
 TESTOSTERONE, TESTOSTERONE

**PERRIGO NEW YORK**

\* PERRIGO NEW YORK INC  
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
 AMMONIUM LACTATE, AMMONIUM LACTATE  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CENTANY, MUPIROCIN  
 CICLOPIROX, CICLOPIROX  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 DESONIDE, DESONIDE  
 DESOXIMETASONE, DESOXIMETASONE  
 ECONAZOLE NITRATE, ECONAZOLE NITRATE  
 ERYTHROMYCIN, ERYTHROMYCIN  
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
 GENTAMICIN SULFATE, GENTAMICIN SULFATE  
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE  
 HYDROCORTISONE, HYDROCORTISONE  
 KETOCONAZOLE, KETOCONAZOLE  
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
 MOMETASONE FUROATE, MOMETASONE FUROATE  
 MUPIROCIN, MUPIROCIN  
 NYSTATIN, NYSTATIN  
 PERMETHRIN, PERMETHRIN  
 PERMETHRIN, PERMETHRIN (OTC)  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 SELENIUM SULFIDE, SELENIUM SULFIDE  
 TERCONAZOLE, TERCONAZOLE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**PERRIGO R AND D**

\* PERRIGO R AND D CO  
 CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 DESLORATADINE, DESLORATADINE  
 GUAIFENESIN, GUAIFENESIN (OTC)  
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)  
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)  
 IBUPROFEN, IBUPROFEN  
 IBUPROFEN, IBUPROFEN (OTC)  
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)  
 LEVONORGESTREL, LEVONORGESTREL  
 LEVONORGESTREL, LEVONORGESTREL (OTC)  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)  
 NAPROXEN, NAPROXEN  
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**PERRIGO UK FINCO**

\* PERRIGO UK FINCO LTD PARTNERSHIP  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

**PETNET**

\* PETNET SOLUTIONS INC  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**PF PRISM CV**

\* PF PRISM CV  
 LYRICA, PREGABALIN  
 RAPAMUNE, SIROLIMUS  
 TORISEL, TEMSIROLIMUS

## APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

\*\* P \*\*

## \* PF PRISM CV

TYGACIL, TIGECYCLINE  
 VFEND, VORICONAZOLE  
 XALKORI, CRIZOTINIB  
 XELJANZ, TOFACITINIB CITRATE  
 ZMAX, AZITHROMYCIN

**PFIZER**

## \* PFIZER CENTRAL RESEARCH

DIFLUCAN, FLUCONAZOLE  
 ZITHROMAX, AZITHROMYCIN

## \* PFIZER CHEMICALS DIV PFIZER INC

DIFLUCAN, FLUCONAZOLE  
 ZITHROMAX, AZITHROMYCIN

## \* PFIZER INC

ACOVA, ARGATROBAN  
 ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)  
 ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
 ADVIL COLD AND SINUS, IBUPROFEN (OTC)  
 ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)  
 ADVIL LIQUI-GELS, IBUPROFEN (OTC)  
 ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)  
 ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)  
 ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
 ADVIL, IBUPROFEN (OTC)  
 ALAVERT, LORATADINE (OTC)  
 AXID AR, NIZATIDINE (OTC)  
 CADUET, AMLODIPINE BESYLATE  
 CALAN SR, VERAPAMIL HYDROCHLORIDE  
 CARDURA XL, DOXAZOSIN MESYLATE  
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)  
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)  
 CHILDREN'S ADVIL, IBUPROFEN (OTC)  
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)  
 DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE  
 DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE  
 DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 ELELYSO, TALIGLUCERASE ALFA  
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE  
 GEODON, ZIPRASIDONE HYDROCHLORIDE  
 GEODON, ZIPRASIDONE MESYLATE  
 GLUCOTROL XL, GLIPIZIDE  
 GLUCOTROL, GLIPIZIDE  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPARIN SODIUM, HEPARIN SODIUM  
 INLYTA, AXITINIB  
 JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)  
 LIPITOR, ATORVASTATIN CALCIUM  
 LORATADINE, LORATADINE (OTC)  
 NAVANE, THIOTHIXENE  
 NORVASC, AMLODIPINE BESYLATE  
 PEDIATRIC ADVIL, IBUPROFEN (OTC)  
 PROCARDIA, NIFEDIPINE  
 REVATIO, SILDENAFIL CITRATE  
 SONATA, ZALEPLON  
 TESSALON, BENZONATATE  
 TOVIAZ, FESOTERODINE FUMARATE  
 UNASYN, AMPICILLIN SODIUM  
 ZITHROMAX, AZITHROMYCIN

\* PFIZER LABORATORIES DIV PFIZER INC  
 CARDURA, DOXAZOSIN MESYLATE  
 DIABINESE, CHLORPROPAMIDE  
 FELDENE, PIROXICAM  
 MINIPRESS, PRAZOSIN HYDROCHLORIDE  
 PERMAPEN, PENICILLIN G BENZATHINE  
 PFIZERPEN, PENICILLIN G POTASSIUM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

- \* PFIZER LABORATORIES DIV PFIZER INC  
PROCARDIA XL, NIFEDIPINE  
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE  
UNASYN, AMPICILLIN SODIUM  
VIBRAMYCIN, DOXYCYCLINE  
VIBRAMYCIN, DOXYCYCLINE CALCIUM  
VIBRAMYCIN, DOXYCYCLINE HYCLATE  
VISTARIL, HYDROXYZINE PAMOATE
- \* PFIZER PHARMACEUTICALS INC  
ZOLOFT, SERTRALINE HYDROCHLORIDE
- \* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD  
TIKOSYN, DOFETILIDE

**PFIZER CONS HLTHCARE**

- \* PFIZER CONSUMER HEALTHCARE  
ADVIL, IBUPROFEN SODIUM (OTC)

**PFIZER INC**

- \* PFIZER INC  
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE  
CHANTIX, VARENICLINE TARTRATE  
ELLENC, EPIRUBICIN HYDROCHLORIDE  
GEODON, ZIPRASIDONE HYDROCHLORIDE  
NICOTROL, NICOTINE

**PFIZER IRELAND**

- \* PFIZER IRELAND PHARMACEUTICALS  
RELPAX, ELETRIPTAN HYDROBROMIDE  
VIAGRA, SILDENAFIL CITRATE

**PFIZER LABS**

- \* PFIZER LABS  
DOCETAXEL, DOCETAXEL

**PFIZER PHARMS**

- \* PFIZER PHARMACEUTICALS LTD  
ACCUPRIL, QUINAPRIL HYDROCHLORIDE  
ACCURETIC, HYDROCHLOROTHIAZIDE  
DILANTIN, PHENYTOIN  
LOPID, GEMFIBROZIL  
NEURONTIN, GABAPENTIN  
NITROSTAT, NITROGLYCERIN

**PHARM ASSOC**

- \* PHARMACEUTICAL ASSOC INC  
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
LORAZEPAM, LORAZEPAM  
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
- \* PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS  
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE  
ETHOSUXIMIDE, ETHOSUXIMIDE  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE  
HALOPERIDOL, HALOPERIDOL LACTATE  
LACTULOSE, LACTULOSE  
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE  
PREDNISOLONE, PREDNISOLONE  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE  
VALPROIC ACID, VALPROIC ACID
- \* PHARMACEUTICAL ASSOCIATES INC  
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

**PHARMA-MED INC**

- \* PHARMA-MED INC  
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\*****PHARMACEUTICS**

\* PHARMACEUTICS INTERNATIONAL INC  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**PHARMACHEMIE BV**

\* PHARMACHEMIE BV  
 CARBOPLATIN, CARBOPLATIN  
 CISPLATIN, CISPLATIN  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM  
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

**PHARMACIA AND UPJOHN**

\* PHARMACIA AND UPJOHN  
 XANAX XR, ALPRAZOLAM

\* PHARMACIA AND UPJOHN CO  
 ANSAID, FLURBIPROFEN  
 AROMASIN, EXEMESTANE  
 AZULFIDINE EN-TABS, SULFASALAZINE  
 AZULFIDINE, SULFASALAZINE  
 BACITRACIN, BACITRACIN  
 CAVERJECT IMPULSE, ALPROSTADIL  
 CAVERJECT, ALPROSTADIL  
 CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE  
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 CLEOCIN T, CLINDAMYCIN PHOSPHATE  
 CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE  
 CLEOCIN, CLINDAMYCIN PHOSPHATE  
 COLESTID, COLESTIPOL HYDROCHLORIDE  
 CORTEF, HYDROCORTISONE  
 CORVERT, IBUTILIDE FUMARATE  
 CYKLOKAPRON, TRANEXAMIC ACID  
 DEPO-ESTRADIOL, ESTRADIOL CYPIONATE  
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE  
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE  
 DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE  
 DETROL LA, TOLTERODINE TARTRATE  
 DETROL, TOLTERODINE TARTRATE  
 DIDREX, BENZPHETAMINE HYDROCHLORIDE  
 EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM  
 ESTRING, ESTRADIOL  
 FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE  
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT  
 GENOTROPIN, SOMATROPIN RECOMBINANT  
 GLYNASE, GLYBURIDE  
 GLYSET, MIGLITOL  
 HALCION, TRIAZOLAM  
 HEMABATE, CARBOPROST TROMETHAMINE  
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE  
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE  
 MEDROL, METHYLPREDNISOLONE  
 MYCOBUTIN, RIFABUTIN  
 NICOTROL, NICOTINE  
 OGEN .625, ESTROPIPATE  
 OGEN 1.25, ESTROPIPATE  
 OGEN 2.5, ESTROPIPATE  
 OGEN 5, ESTROPIPATE  
 PREPIDIL, DINOPROSTONE  
 PROSTIN E2, DINOPROSTONE  
 PROSTIN VR PEDIATRIC, ALPROSTADIL  
 PROVERA, MEDROXYPROGESTERONE ACETATE  
 R-GENE 10, ARGININE HYDROCHLORIDE  
 SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE  
 SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE  
 SOMAVERT, PEGVISOMANT  
 XALATAN, LATANOPROST

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PHARMACIA AND UPJOHN CO

XANAX, ALPRAZOLAM  
ZINECARD, DEXRAZOXANE HYDROCHLORIDE  
ZYVOX, LINEZOLID

\* PHARMACIA AND UPJOHN SUB PFIZER INC

DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

**PHARMACYCLICS INC**

\* PHARMACYCLICS INC

IMBRUVICA, IBRUTINIB

**PHARMAFORCE**

\* PHARMAFORCE INC

CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
NANDROLONE DECANOATE, NANDROLONE DECANOATE**PHARMALUCENCE**

\* PHARMALUCENCE INC

AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT  
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT  
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT  
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT  
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT  
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT**PHARMAX**

\* PHARMAX GROUP INC

BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

**PHARMS**

\* PHARMACEUTICALS INTERNATIONAL

ZOLEDRONIC ACID, ZOLEDRONIC ACID

**PHOTOCURE ASA**

\* PHOTOCURE ASA

CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

**PIERRE FABRE**

\* PIERRE FABRE MEDICAMENT

NAVELBINE, VINOURELBINE TARTRATE

**PIERRE FABRE DERMA**

\* PIERRE FABRE DERMATOLOGIE

HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

**PIERREL**

\* PIERREL S.P.A.

ORABLOC, ARTICAINE HYDROCHLORIDE

**PIRAMAL CRITICAL**

\* PIRAMAL CRITICAL CARE INC

ENFLURANE, ENFLURANE  
ISOFLURANE, ISOFLURANE  
SOJOURN, SEVOFLURANE**PIRAMAL ENT**

\* PIRAMAL ENTERPRISES LTD

ISOFLURANE, ISOFLURANE

**PIRAMAL IMAGING**

\* PIRAMAL IMAGING SA

NEURACEQ, FLORBETABEN F-18

**PLIVA**

\* PLIVA INC

AZITHROMYCIN, AZITHROMYCIN  
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
CIMETIDINE, CIMETIDINE  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
METRONIDAZOLE, METRONIDAZOLE  
NAPROXEN, NAPROXEN  
PENTOXIFYLLINE, PENTOXIFYLLINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\*****\* PLIVA INC**

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 THEOPHYLLINE, THEOPHYLLINE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 WARFARIN SODIUM, WARFARIN SODIUM

**PLIVA HRVATSKA DOO****\* PLIVA HRVATSKA DOO**

ADAPALENE, ADAPALENE  
 CARVEDILOL, CARVEDILOL  
 CILOSTAZOL, CILOSTAZOL  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE

**PLIVA LACHEMA****\* PLIVA LACHEMA AS**

CARBOPLATIN, CARBOPLATIN  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

**PLIVA PHARM IND****\* PLIVA PHARMACEUTICAL INDUSTRY INC**

TORSEMIDE, TORSEMIDE

**PLX PHARMA****\* PLX PHARMA INC**

ASPIRIN, ASPIRIN (OTC)

**POHL BOSKAMP****\* POHL BOSKAMP**

NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

**POLYMEDICA****\* POLYMEDICA INDUSTRIES INC**

NEOPAP, ACETAMINOPHEN (OTC)

**POWDER PHARMS****\* POWDER PHARMACEUTICALS INC**

ZINGO, LIDOCAINE HYDROCHLORIDE

**PRAGMA PHARMS LLC****\* PRAGMA PHARMACEUTICALS LLC**

MOXATAG, AMOXICILLIN

**PRECISION DERMAT****\* PRECISION DERMATOLOGY INC**

CLINDAGEL, CLINDAMYCIN PHOSPHATE  
 LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE  
 LOCOID, HYDROCORTISONE BUTYRATE  
 MINOCIN, MINOCYCLINE HYDROCHLORIDE  
 PODOFILOX, PODOFILOX

**PRECISION DOSE****\* PRECISION DOSE INC**

RISPERIDONE, RISPERIDONE

**PRINSTON INC****\* PRINSTON PHARMACEUTICAL INC**

BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 LEVETIRACETAM, LEVETIRACETAM  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINOPRIL, LISINOPRIL  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 METHOCARBAMOL, METHOCARBAMOL  
 NEVIRAPINE, NEVIRAPINE  
 PAROXETINE, PAROXETINE HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\*****PROCTER AND GAMBLE**

- \* PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO  
DIDRONEL, ETIDRONATE DISODIUM

**PROF DSPLS**

- \* PROFESSIONAL DISPOSABLES INC  
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)  
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)  
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

**PROMETHEUS LABS**

- \* PROMETHEUS LABORATORIES INC  
IMURAN, AZATHIOPRINE  
LOTRONEX, ALOSETRON HYDROCHLORIDE  
MERCAPTOPYRINE, MERCAPTOPYRINE  
RIDAURA, AURANOFIN  
ZYLOPRIM, ALLOPURINOL

**PROMIUS PHARMA**

- \* PROMIUS PHARMA LLC  
SECTRAL, ACEBUTOLOL HYDROCHLORIDE  
TENEX, GUANFACINE HYDROCHLORIDE

**PROMIUS PHARMA LLC**

- \* PROMIUS PHARMA LLC  
CLODERM, CLOCORTOLONE PIVALATE

**PROSAM LABS**

- \* PROSAM LABS LLC  
BACLOFEN, BACLOFEN  
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
CARISOPRODOL AND ASPIRIN, ASPIRIN  
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
RIMACTANE, RIFAMPIN  
RISPERIDONE, RISPERIDONE  
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
SIMVASTATIN, SIMVASTATIN  
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

**PROSTRAKAN INC**

- \* PROSTRAKAN INC  
FARESTON, TOREMIFENE CITRATE  
SANCUSO, GRANISETRON

**PROVENSIS**

- \* PROVENSIS LTD  
VARITHENA, POLIDOCANOL

**PROVIDENT PHARM**

- \* PROVIDENT PHARMACEUTICAL INC  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**PULMOFLOW INC**

- \* PULMOFLOW INC  
KITABIS PAK, TOBRAMYCIN

**PULSION MEDCL**

- \* PULSION MEDICAL SYSTEMS AG  
INDOCYANINE GREEN, INDOCYANINE GREEN

**PURACAP PHARM**

- \* PURACAP PHARMACEUTICAL LLC  
MELOXICAM, MELOXICAM

**PURDUE GMP**

- \* PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY  
SEROMYCIN, CYCLOSERINE

**PURDUE PHARM PRODS**

- \* PURDUE PHARMACEUTICAL PRODUCTS LP  
DILAUDID, HYDROMORPHONE HYDROCHLORIDE  
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE

**PURDUE PHARMA**

- \* PURDUE PHARMA PRODUCTS LP  
INTERMEZZO, ZOLPIDEM TARTRATE

**PURDUE PHARMA LP**



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* P \*\***

\* PURDUE PHARMA LP  
 BUTRANS, BUPRENORPHINE  
 HYSINGLA, HYDROCODONE BITARTRATE  
 MS CONTIN, MORPHINE SULFATE  
 OXYCONTIN, OXYCODONE HYDROCHLORIDE

**PUREPAC PHARM**

\* PUREPAC PHARMACEUTICAL CO  
 DIPYRIDAMOLE, DIPYRIDAMOLE

**PVT FORM**

\* PRIVATE FORMULATIONS INC  
 PROPOXYPHENE HYDROCHLORIDE, PROPOXYPHENE HYDROCHLORIDE

**\*\* Q \*\*****QILU PHARM CO LTD**

\* QILU PHARMACEUTICAL CO LTD  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

**QOL MEDCL**

\* QOL MEDICAL LLC  
 ETHAMOLIN, ETHANOLAMINE OLEATE  
 SUCRAID, SACROSIDASE

**QUESTCOR PHARMS**

\* QUESTCOR PHARMACEUTICALS INC  
 H.P. ACTHAR GEL, CORTICOTROPIN

**\*\* R \*\*****RANBAXY**

\* RANBAXY INC  
 ABSORICA, ISOTRETINOIN  
 GLYCOPYRROLATE, GLYCOPYRROLATE

\* RANBAXY LABORATORIES INC  
 EURAX, CROTAMITON  
 EXELDERM, SULCONAZOLE NITRATE  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 HALOG, HALCINONIDE  
 KENALOG, TRIAMCINOLONE ACETONIDE  
 LAC-HYDRIN, AMMONIUM LACTATE  
 RISPERIDONE, RISPERIDONE  
 ULTRAVATE, HALOBETASOL PROPIONATE

\* RANBAXY LABORATORIES LTD  
 ACYCLOVIR, ACYCLOVIR  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 AMOXICILLIN, AMOXICILLIN  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 CARVEDILOL, CARVEDILOL  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CEPHALEXIN, CEPHALEXIN  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DOXYCYCLINE, DOXYCYCLINE  
 FENOFIBRATE, FENOFIBRATE  
 FLECAINIDE ACETATE, FLECAINIDE ACETATE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
 GABAPENTIN, GABAPENTIN  
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* R \*\***

- \* RANBAXY LABORATORIES LTD  
 LORATADINE REDIDOSE, LORATADINE (OTC)  
 LORATADINE, LORATADINE (OTC)  
 LORAZEPAM, LORAZEPAM  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 OXCARBAZEPINE, OXCARBAZEPINE  
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)  
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SIMVASTATIN, SIMVASTATIN  
 SOTRET, ISOTRETINOIN  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TOPIRAMATE, TOPIRAMATE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- \* RANBAXY PHARMACEUTICALS INC  
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 AMOXICILLIN, AMOXICILLIN  
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINOPRIL, LISINOPRIL  
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)  
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 RIOMET, METFORMIN HYDROCHLORIDE  
 SOTRET, ISOTRETINOIN
- RANBAXY LABS LTD**
- \* RANBAXY LABORATORIES LIMITED  
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
- \* RANBAXY LABORATORIES LTD  
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
 FELODIPINE, FELODIPINE  
 FENOFIBRATE, FENOFIBRATE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
- RAPTOR INC**
- \* RAPTOR PHARMACEUTICALS INC  
 PROCYSBI, CYSTEAMINE BITARTRATE
- RARE DIS THERAP**
- \* RARE DISEASE THERAPEUTICS INC  
 CYSTADANE, BETAINE HYDROCHLORIDE
- RECIP**
- \* RECIP AB  
 THYROSAFE, POTASSIUM IODIDE (OTC)
- RECKITT BENCKISER**
- \* RECKITT BENCKISER LLC  
 DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)  
 MUCINEX D, GUAIFENESIN (OTC)  
 MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)  
 MUCINEX, GUAIFENESIN (OTC)
- \* RECKITT BENCKISER PHARMACEUTICALS INC  
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE  
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
- RECORDATI RARE**
- \* RECORDATI RARE DISEASES INC  
 CHEMET, SUCCIMER  
 COSMEGEN, DACTINOMYCIN  
 DESOXYN, METHAMPHETAMINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* R \*\***

\* RECORDATI RARE DISEASES INC  
 INDOCIN, INDOMETHACIN SODIUM  
 MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE  
 NEOPROFEN, IBUPROFEN LYSINE  
 PEGANONE, ETHOTOIN  
 TRANXENE, CLORAZEPATE DIPOTASSIUM

**REMPEX PHARMS INC**

\* REMPEX PHARMACEUTICALS INC  
 MINOCIN, MINOCYCLINE HYDROCHLORIDE

**RENAISSANCE PHARMA**

\* RENAISSANCE PHARMA US HOLDINGS INC  
 ELIMITE, PERMETHRIN

**RHODES PHARMS**

\* RHODES PHARMACEUTICALS LP  
 MORPHINE SULFATE, MORPHINE SULFATE  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 THEOPHYLLINE, THEOPHYLLINE  
 UNIPHYL, THEOPHYLLINE

**RICONPHARMA LLC**

\* RICONPHARMA LLC  
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE

**RISING PHARMS INC**

\* RISING PHARMACEUTICALS INC  
 PARICALCITOL, PARICALCITOL

**ROCHE PALO**

\* ROCHE PALO ALTO LLC  
 CELLCEPT, MYCOPHENOLATE MOFETIL  
 CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE  
 CYTOVENE, GANCICLOVIR SODIUM  
 EC-NAPROSYN, NAPROXEN  
 NAPROSYN, NAPROXEN

**ROCKWELL MEDCL**

\* ROCKWELL MEDICAL TECHNOLOGIES INC  
 CALCITRIOL, CALCITRIOL

**ROMARK**

\* ROMARK LABORATORIES  
 ALINIA, NITAZOXANIDE

**ROSEDALE THERAPEUTIC**

\* ROSEDALE THERAPEUTICS  
 ERGOMAR, ERGOTAMINE TARTRATE

**ROUSES POINT PHARMS**

\* ROUSES POINT PHARMACEUTICALS LLC  
 LEVETIRACETAM, LEVETIRACETAM

**ROXANE**

\* ROXANE LABORATORIES INC  
 ACARBOSE, ACARBOSE  
 ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 ALPRAZOLAM, ALPRAZOLAM  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 ANASTROZOLE, ANASTROZOLE  
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE  
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM  
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE  
 CALCITRIOL, CALCITRIOL  
 CALCIUM ACETATE, CALCIUM ACETATE  
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE  
 CILOSTAZOL, CILOSTAZOL  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 CLOTRIMAZOLE, CLOTRIMAZOLE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* R \*\*****\* ROXANE LABORATORIES INC**

CODEINE SULFATE, CODEINE SULFATE  
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE  
DEXAMETHASONE INTENSOL, DEXAMETHASONE  
DEXAMETHASONE, DEXAMETHASONE  
DIAZEPAM INTENSOL, DIAZEPAM  
DIAZEPAM, DIAZEPAM  
DIGOXIN, DIGOXIN  
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE  
DISULFIRAM, DISULFIRAM  
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
DOXERCALCIFEROL, DOXERCALCIFEROL  
ESZOPICLONE, ESZOPICLONE  
EXEMESTANE, EXEMESTANE  
FAMCICLOVIR, FAMCICLOVIR  
FLECAINIDE ACETATE, FLECAINIDE ACETATE  
FLUCONAZOLE, FLUCONAZOLE  
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
FUROSEMIDE, FUROSEMIDE  
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE  
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE  
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
IRBESARTAN, IRBESARTAN  
LACTULOSE, LACTULOSE  
LETROZOLE, LETROZOLE  
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM  
LEVETIRACETAM, LEVETIRACETAM  
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE  
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE  
LITHIUM CARBONATE, LITHIUM CARBONATE  
LITHIUM CITRATE, LITHIUM CITRATE  
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
LORAZEPAM INTENSOL, LORAZEPAM  
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE  
MEGESTROL ACETATE, MEGESTROL ACETATE  
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
MERCAPTOPYRINE, MERCAPTOPYRINE  
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE  
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
METHOTREXATE SODIUM, METHOTREXATE SODIUM  
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
MONTELUKAST SODIUM, MONTELUKAST SODIUM  
MORPHINE SULFATE, MORPHINE SULFATE  
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
NAPROXEN, NAPROXEN  
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
OXCARBAZEPINE, OXCARBAZEPINE  
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE  
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE  
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE  
PREDNISONE INTENSOL, PREDNISONE  
PREDNISONE, PREDNISONE  
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE  
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* R \*\***

\* ROXANE LABORATORIES INC  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RAMIPRIL, RAMIPRIL  
 RISPERIDONE, RISPERIDONE  
 RITONAVIR, RITONAVIR  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 ROXICET, ACETAMINOPHEN  
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE  
 TINIDAZOLE, TINIDAZOLE  
 TORSEMIDE, TORSEMIDE  
 TRIAZOLAM, TRIAZOLAM  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 ZALEPLON, ZALEPLON  
 ZIDOVUDINE, ZIDOVUDINE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**RUBICON RES PVT LTD**

\* RUBICON RESEARCH PVT LTD  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE

**\*\* S \*\*****SAGE PRODS**

\* SAGE PRODUCTS INC  
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

**SAGENT AGILA**

\* SAGENT AGILA LLC  
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE  
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**SAGENT PHARMS**

\* SAGENT PHARMACEUTICALS INC  
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE  
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE  
 CAFFEINE CITRATE, CAFFEINE CITRATE  
 CALCITRIOL, CALCITRIOL  
 CARBOPLATIN, CARBOPLATIN  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 FLUMAZENIL, FLUMAZENIL  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GLYDO, LIDOCAINE HYDROCHLORIDE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
 HEPARIN SODIUM, HEPARIN SODIUM  
 IBANDRONATE SODIUM, IBANDRONATE SODIUM  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN, LEVOFLOXACIN  
 MESNA, MESNA  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM  
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 OXACILLIN SODIUM, OXACILLIN SODIUM  
 OXYTOCIN, OXYTOCIN  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

**SAGENT STRIDES**

\* SAGENT STRIDES LLC  
 ADENOSINE, ADENOSINE  
 AZITHROMYCIN, AZITHROMYCIN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SAGENT STRIDES LLC  
 BACITRACIN, BACITRACIN  
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**SALIX PHARMS**

\* SALIX PHARMACEUTICALS INC  
 ANUSOL HC, HYDROCORTISONE  
 APRISO, MESALAMINE  
 COLAZAL, BALSALAZIDE DISODIUM  
 DIURIL, CHLOROTHIAZIDE  
 FULYZAQ, CROFELEMER  
 GIAZO, BALSALAZIDE DISODIUM  
 METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE  
 MOVIPREP, ASCORBIC ACID  
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS  
 PEPCID, FAMOTIDINE  
 RELISTOR, METHYLNALTREXONE BROMIDE  
 XIFAXAN, RIFAXIMIN

**SALIX PHARMS INC**

\* SALIX PHARMACEUTICALS INC  
 UCERIS, BUDESONIDE

**SAMSON MEDCL**

\* SAMSON MEDICAL TECHNOLOGIES LLC  
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
 CEFTRIAXONE, CEFTRIAXONE SODIUM

**SANDOZ**

\* SANDOZ  
 DOCETAXEL, DOCETAXEL

\* SANDOZ CANADA INC  
 ANECTINE, SUCCINYLCHOLINE CHLORIDE  
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE  
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE  
 DIGOXIN, DIGOXIN  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE  
 FLUMAZENIL, FLUMAZENIL  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE  
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID  
 INFUVITE PEDIATRIC, ASCORBIC ACID  
 ISONIAZID, ISONIAZID  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE  
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 REGONOL, PYRIDOSTIGMINE BROMIDE  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

\* SANDOZ INC  
 ALPRAZOLAM, ALPRAZOLAM  
 ALTAVERA, ETHINYL ESTRADIOL  
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**

\*\* S \*\*

\* SANDOZ INC  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 AMOXICILLIN, AMOXICILLIN  
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM  
 AMPICILLIN SODIUM, AMPICILLIN SODIUM  
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE  
 ANASTROZOLE, ANASTROZOLE  
 APREPITANT, APREPITANT  
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN  
 ATENOLOL, ATENOLOL  
 AZITHROMYCIN, AZITHROMYCIN  
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BICALUTAMIDE, BICALUTAMIDE  
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE  
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE  
 BUDESONIDE, BUDESONIDE  
 BUMETANIDE, BUMETANIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CAFERGOT, CAFFEINE  
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL  
 CAPTOPRIL, CAPTOPRIL  
 CARISOPRODOL AND ASPIRIN, ASPIRIN  
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN  
 CARVEDILOL, CARVEDILOL  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
 CEFDINIR, CEFDINIR  
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL  
 CEFPROZIL, CEFPROZIL  
 CEFTRIAZONE, CEFTRIAZONE SODIUM  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE  
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE  
 CHOLESTYRAMINE, CHOLESTYRAMINE  
 CILOSTAZOL, CILOSTAZOL  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)  
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE  
 CLONAZEPAM, CLONAZEPAM  
 COSYNTROPIN, COSYNTROPIN  
 CYCLOSPORINE, CYCLOSPORINE  
 DECITABINE, DECITABINE  
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE  
 DESLORATADINE, DESLORATADINE  
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE  
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM  
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 DOXERCALCIFEROL, DOXERCALCIFEROL  
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
 EPLERENONE, EPLERENONE  
 ESTARYLLA, ETHINYL ESTRADIOL  
 ETODOLAC, ETODOLAC  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 FLUOROURACIL, FLUOROURACIL  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\*****\* SANDOZ INC**

FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 FUROSEMIDE, FUROSEMIDE  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GLIPIZIDE, GLIPIZIDE  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
 HALOPERIDOL, HALOPERIDOL  
 HEPARIN SODIUM, HEPARIN SODIUM  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE  
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 INTROVALE, ETHINYL ESTRADIOL  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 IRBESARTAN, IRBESARTAN  
 ISONIAZID, ISONIAZID  
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
 ITRACONAZOLE, ITRACONAZOLE  
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE  
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LISINOPRIL, LISINOPRIL  
 LONOX, ATROPINE SULFATE  
 LORATADINE, LORATADINE (OTC)  
 LORAZEPAM, LORAZEPAM  
 LORYNA, DROSPIRENONE  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 LOVASTATIN, LOVASTATIN  
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE  
 MEROPENEM, MEROPENEM  
 METAXALONE, METAXALONE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METHAZOLAMIDE, METHAZOLAMIDE  
 METHIMAZOLE, METHIMAZOLE  
 METHOCARBAMOL, METHOCARBAMOL  
 METHYLPREDNISOLONE, METHYLPREDNISOLONE  
 METOLAZONE, METOLAZONE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 NABUMETONE, NABUMETONE  
 NADOLOL, NADOLOL  
 NAFCILLIN SODIUM, NAFCILLIN SODIUM  
 NAPROXEN, NAPROXEN  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 NEVIRAPINE, NEVIRAPINE  
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN  
 NIZATIDINE, NIZATIDINE  
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 OMEPRAZOLE, OMEPRAZOLE  
 OMNITROPE, SOMATROPIN RECOMBINANT  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* s \*\***

\* SANDOZ INC  
 OXACILLIN SODIUM, OXACILLIN SODIUM  
 OXALIPLATIN, OXALIPLATIN  
 OXAPROZIN, OXAPROZIN  
 OXAZEPAM, OXAZEPAM  
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM  
 PENICILLIN G SODIUM, PENICILLIN G SODIUM  
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM  
 PERPHENAZINE, PERPHENAZINE  
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUINIDINE SULFATE, QUINIDINE SULFATE  
 RAMIPRIL, RAMIPRIL  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 REPAGLINIDE, REPAGLINIDE  
 RESERPINE, RESERPINE  
 RIBAVIRIN, RIBAVIRIN  
 RIFAMPIN, RIFAMPIN  
 RISPERIDONE, RISPERIDONE  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
 SPIRONOLACTONE, SPIRONOLACTONE  
 SULFADIAZINE, SULFADIAZINE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 SYEDA, DROSPIRENONE  
 TACROLIMUS, TACROLIMUS  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TELMISARTAN, TELMISARTAN  
 TEMAZEPAM, TEMAZEPAM  
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE  
 THIOTHIXENE, THIOTHIXENE  
 TRI-ESTARYLLA, ETHINYL ESTRADIOL  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**SANDOZ CANADA INC**

\* SANDOZ CANADA INC  
 PARICALCITOL, PARICALCITOL

**SANDOZ INC**

\* SANDOZ INC  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM  
 CEFTRIAXONE, CEFTRIAXONE SODIUM  
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE  
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE  
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 OLANZAPINE, OLANZAPINE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SANDOZ INC  
 VORICONAZOLE, VORICONAZOLE  
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**SANOCHEMIA CORP USA**

\* SANOCHEMIA CORP USA  
 SCANLUX-300, IOPAMIDOL  
 SCANLUX-370, IOPAMIDOL

**SANOFI AVENTIS**

\* SANOFI AVENTIS  
 AFREZZA, INSULIN RECOMBINANT HUMAN

**SANOFI AVENTIS US**

\* SANOFI AVENTIS US INC  
 JEVTANA KIT, CABAZITAXEL

\* SANOFI AVENTIS US LLC  
 ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 ALLEGRA, FEXOFENADINE HYDROCHLORIDE  
 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)  
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)  
 AMARYL, GLIMEPIRIDE  
 AMBIEN CR, ZOLPIDEM TARTRATE  
 AMBIEN, ZOLPIDEM TARTRATE  
 ANZEMET, DOLASETRON MESYLATE  
 APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT  
 APIDRA, INSULIN GLULISINE RECOMBINANT  
 ARALEN, CHLOROQUINE PHOSPHATE  
 ARAVA, LEFLUNOMIDE  
 AUBAGIO, TERIFLUNOMIDE  
 AUVI-Q, EPINEPHRINE  
 AVALIDE, HYDROCHLOROTHIAZIDE  
 AVAPRO, IRBESARTAN  
 CANTIL, MEPENZOLATE BROMIDE  
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM  
 CLAFORAN, CEFOTAXIME SODIUM  
 CLOMID, CLOMIPHENE CITRATE  
 DDAVP, DESMOPRESSIN ACETATE  
 DEMEROL, MEPERIDINE HYDROCHLORIDE  
 DIABETA, GLYBURIDE  
 DRISDOL, ERGOCALCIFEROL  
 ELOXATIN, OXALIPLATIN  
 FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX  
 GAVISCON, ALUMINUM HYDROXIDE (OTC)  
 HIPREX, METHENAMINE HIPPURATE  
 KETEK, TELITHROMYCIN  
 LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT  
 LANTUS, INSULIN GLARGINE RECOMBINANT  
 LASIX, FUROSEMIDE  
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
 LOVENOX, ENOXAPARIN SODIUM  
 MULTAQ, DRONEDARONE HYDROCHLORIDE  
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)  
 NICODERM CQ, NICOTINE (OTC)  
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE  
 PHISOHEX, HEXACHLOROPHENE  
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE  
 PLAVIX, CLOPIDOGREL BISULFATE  
 PRIFLTIN, RIFAPENTINE  
 PRIMAQUINE, PRIMAQUINE PHOSPHATE  
 RIFADIN, RIFAMPIN  
 RIFAMATE, ISONIAZID  
 RIFATER, ISONIAZID  
 TAXOTERE, DOCETAXEL

**SANOFI PASTEUR INC**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SANOFI PASTEUR INC  
SKLICE, IVERMECTIN

**SANTARUS INC**

\* SANTARUS INC  
FENOGLIDE, FENOFIBRATE  
GLUMETZA, METFORMIN HYDROCHLORIDE  
UCERIS, BUDESONIDE  
ZEGERID, OMEPRAZOLE

**SANTEN**

\* SANTEN INC  
QUIXIN, LEVOFLOXACIN

**SANTOS BIOTECH**

\* SANTOS BIOTECH INDUSTRIES INC  
ANASTROZOLE, ANASTROZOLE

**SB PHARMCO**

\* SB PHARMCO PUERTO RICO INC  
AVANDAMET, METFORMIN HYDROCHLORIDE  
AVANDARYL, GLIMEPIRIDE  
AVANDIA, ROSIGLITAZONE MALEATE  
COREG CR, CARVEDILOL PHOSPHATE

**SCHERING**

\* SCHERING CORP  
INTEGRILIN, EPTIFIBATIDE  
NOXAFIL, POSACONAZOLE  
REBETOL, RIBAVIRIN

**SCHERING PLOUGH**

\* SCHERING PLOUGH HEALTHCARE PRODUCTS INC  
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)  
CHILDREN'S CLARITIN, LORATADINE (OTC)  
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)  
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)  
CLARITIN REDITABS, LORATADINE (OTC)  
CLARITIN, LORATADINE (OTC)  
CLARITIN-D 24 HOUR, LORATADINE (OTC)  
CLARITIN-D, LORATADINE (OTC)  
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)  
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)  
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)  
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)  
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)  
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)  
SHADE UVAGUARD, AVOBENZONE (OTC)

**SCIECURE PHARMA INC**

\* SCIECURE PHARMA INC  
DORAL, QUAZEPAM

**SCIEGEN PHARMS INC**

\* SCIEGEN PHARMACEUTICALS INC  
CARISOPRODOL, CARISOPRODOL  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
NEVIRAPINE, NEVIRAPINE  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

**SCIOS LLC**

\* SCIOS LLC  
NATRECOR, NESIRITIDE RECOMBINANT

**SEBELA IRELAND LTD**

\* SEBELA IRELAND LTD  
MIACALCIN, CALCITONIN SALMON  
MICORT-HC, HYDROCORTISONE ACETATE  
PRAMOSONE, HYDROCORTISONE ACETATE

**SECAN PHARMS**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SECAN PHARMACEUTICALS INC

AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

**SEPTODONT**

\* SEPTODONT INC

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE  
OCTOCAINE, EPINEPHRINE**SEPTODONT HOLDING**

\* SEPTODONT HOLDING SAS

ORAVERSE, PHENTOLAMINE MESYLATE

**SEPTODONT INC**

\* SEPTODONT INC

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE  
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE**SETON PHARM**

\* SETON PHARMACEUTICAL LLC

PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

**SHASUN CHEMS**

\* SHASUN CHEMICALS AND DRUGS LTD

RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**SHASUN USA**

\* SHASUN USA INC

IBUPROFEN, IBUPROFEN

**SHENZHEN TECHDOW**

\* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD

HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM  
HEPARIN SODIUM, HEPARIN SODIUM**SHERTECH LABS LLC**

\* SHERTECH LABORATORIES LLC

AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18**SHIONOGI INC**

\* SHIONOGI INC

DORIBAX, DORIPENEM  
FURADANTIN, NITROFURANTOIN  
KEFLEX, CEPHALEXIN  
OSPHEA, OSPHEMIFENE  
PONSTEL, MEFENAMIC ACID  
ROBINUL FORTE, GLYCOPYRROLATE  
ROBINUL, GLYCOPYRROLATE  
SULAR, NISOLDIPINE  
ULESFIA, BENZYL ALCOHOL**SHIRE**

\* SHIRE DEVELOPMENT INC

ADDERALL XR 10, AMPHETAMINE ASPARTATE  
ADDERALL XR 15, AMPHETAMINE ASPARTATE  
ADDERALL XR 20, AMPHETAMINE ASPARTATE  
ADDERALL XR 25, AMPHETAMINE ASPARTATE  
ADDERALL XR 30, AMPHETAMINE ASPARTATE  
ADDERALL XR 5, AMPHETAMINE ASPARTATE  
CARBATROL, CARBAMAZEPINE  
INTUNIV, GUANFACINE HYDROCHLORIDE  
LIALDA, MESALAMINE  
PENTASA, MESALAMINE**SHIRE DEV LLC**

\* SHIRE DEVELOPMENT LLC

FOSRENOL, LANTHANUM CARBONATE

**SHIRE DEVELOPMENT**

\* SHIRE DEVELOPMENT INC

VYVANSE, LISDEXAMFETAMINE DIMESYLATE

**SHIRE HUMAN GENETIC**

\* SHIRE HUMAN GENETIC THERAPIES INC

VPRIV, VELAGLUCERASE ALFA

**SHIRE LLC**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\*****\* SHIRE DEVELOPMENT LLC**

AGRYLIN, ANAGRELIDE HYDROCHLORIDE  
 FOSRENOL, LANTHANUM CARBONATE  
 SALURON, HYDROFLUMETHIAZIDE

**SHIRE ORPHAN THERAP****\* SHIRE ORPHAN THERAPIES INC**

FIRAZYR, ICATIBANT ACETATE

**SIGMA TAU****\* SIGMA TAU PHARMACEUTICALS INC**

ABELCET, AMPHOTERICIN B  
 ADAGEN, PEGADEMASE BOVINE  
 CARNITOR SF, LEVOCARNITINE  
 CARNITOR, LEVOCARNITINE  
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE  
 MATULANE, PROCARBAZINE HYDROCHLORIDE

**SIGMAPHARM LABS LLC****\* SIGMAPHARM LABORATORIES LLC**

ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL  
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE  
 DISULFIRAM, DISULFIRAM  
 ERGOCALCIFEROL, ERGOCALCIFEROL  
 FLUCYTOSINE, FLUCYTOSINE  
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
 GRISEOFULVIN, ULTRAMICROSIZED, GRISEOFULVIN, ULTRAMICROSIZED  
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM  
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE  
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

**SILARX****\* SILARX PHARMACEUTICALS INC**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 LEVETIRACETAM, LEVETIRACETAM  
 LORATADINE, LORATADINE (OTC)  
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 THEOPHYLLINE, THEOPHYLLINE

**SILARX PHARMS INC****\* SILARX PHARMACEUTICALS INC**

ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 LAMIVUDINE, LAMIVUDINE  
 RISPERIDONE, RISPERIDONE

**SILVERGATE PHARMS****\* SILVERGATE PHARMACEUTICALS INC**

EPANED KIT, ENALAPRIL MALEATE

**SKINMEDICA****\* SKINMEDICA INC**

VANIQA, EFLORNITHINE HYDROCHLORIDE

**SKYEPHARMA AG****\* SKYEPHARMA AG**

TRIGLIDE, FENOFIBRATE

**SMITHKLINE BEECHAM****\* SMITHKLINE BEECHAM**

LOVAZA, OMEGA-3-ACID ETHYL ESTERS

**\* SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE**

ARRANON, NELARABINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

- \* SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE  
COREG, CARVEDILOL  
TYKERB, LAPATINIB DITOSYLATE
- SOAPCO**
- \* SOAPCO INC  
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
- SOFGEN PHARMS**
- \* SOFGEN PHARMACEUTICALS LLC  
PROGESTERONE, PROGESTERONE
- SOMERSET**
- \* SOMERSET PHARMACEUTICALS INC  
ELDEPRYL, SELEGILINE HYDROCHLORIDE  
EMSAM, SELEGILINE
- SOVEREIGN PHARMS**
- \* SOVEREIGN PHARMACEUTICALS LLC  
OBREDON, GUAIFENESIN
- SPEAR PHARMS**
- \* SPEAR PHARMACEUTICALS INC  
FLUOROURACIL, FLUOROURACIL
- SPEAR PHARMS INC**
- \* SPEAR PHARMACEUTICALS INC  
TRETINOIN, TRETINOIN
- SPECTRUM PHARMS**
- \* SPECTRUM PHARMACEUTICALS INC  
BELEODAQ, BELINOSTAT  
FUSILEV, LEVOLEUCOVORIN CALCIUM
- STAND HOMEOPATH**
- \* STANDARD HOMEOPATHIC CO  
IVY BLOCK, BENTOQUATAM (OTC)
- STASON**
- \* STASON INDUSTRIAL CORP  
ACYCLOVIR, ACYCLOVIR  
CAPTOPRIL, CAPTOPRIL  
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
- STASON PHARMS**
- \* STASON PHARMACEUTICALS INC  
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE  
GLYCOPYRROLATE, GLYCOPYRROLATE
- STERI PHARMA**
- \* STERI PHARMA LLC  
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM  
CEFTRIAZONE, CEFTRIAZONE SODIUM  
CEFUROXIME SODIUM, CEFUROXIME SODIUM
- STI PHARMA LLC**
- \* STI PHARMA LLC  
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE  
DEXAMETHASONE, DEXAMETHASONE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE  
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE  
TRIAFIN-C, CODEINE PHOSPHATE
- STIEFEL**
- \* STIEFEL LABORATORIES INC  
DUAC, BENZOYL PEROXIDE
- STIEFEL GSK**
- \* STIEFEL A GSK CO  
VELTIN, CLINDAMYCIN PHOSPHATE
- STIEFEL LABS INC**
- \* STIEFEL LABORATORIES INC  
FABIOR, TAZAROTENE  
SORIATANE, ACITRETIN  
SORILUX, CALCIPOTRIENE
- STRIDES ARCOLAB LTD**
- \* STRIDES ARCOLAB LTD

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* s \*\*****\* STRIDES ARCOLAB LTD**

AMPICILLIN SODIUM, AMPICILLIN SODIUM  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 CALCITRIOL, CALCITRIOL

**STRIDES PHARMA****\* STRIDES PHARMA GLOBAL PTE LTD**

ACARBOSE, ACARBOSE  
 ERGOCALCIFEROL, ERGOCALCIFEROL  
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE  
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)  
 IMIQUIMOD, IMIQUIMOD  
 MELOXICAM, MELOXICAM  
 METHOXSALEN, METHOXSALEN  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 NEVIRAPINE, NEVIRAPINE  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 TACROLIMUS, TACROLIMUS  
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**SUCAMPO PHARMA LLC****\* SUCAMPO PHARMA AMERICAS LLC**

AMITIZA, LUBIPROSTONE

**SUCAMPO PHARMS****\* SUCAMPO PHARMACEUTICALS INC**

RESCULA, UNOPROSTONE ISOPROPYL

**SUMMERS****\* SUMMERS LABORATORIES INC**

CROTAN, CROTAMITON

**SUN PHARM INDS****\* SUN PHARMACEUTICAL INDUSTRIES LTD**

CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 DESLORATADINE, DESLORATADINE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE  
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 OLANZAPINE, OLANZAPINE  
 ONDANSETRON, ONDANSETRON  
 OXCARBAZEPINE, OXCARBAZEPINE  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE  
 TORSEMIDE, TORSEMIDE

**SUN PHARM INDS (IN)****\* SUN PHARMACEUTICAL INDUSTRIES LTD**

CEPHALEXIN, CEPHALEXIN  
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 ZONISAMIDE, ZONISAMIDE

**SUN PHARM INDS INC****\* SUN PHARMACEUTICAL INDUSTRIES INC**

ALLOPURINOL, ALLOPURINOL  
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 ATENOLOL, ATENOLOL  
 BACLOFEN, BACLOFEN

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SUN PHARMACEUTICAL INDUSTRIES INC  
 BENZONATATE, BENZONATATE  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
 CARVEDILOL, CARVEDILOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLONAZEPAM, CLONAZEPAM  
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
 CLOZAPINE, CLOZAPINE  
 ELIXOPHYLLIN, THEOPHYLLINE  
 ERGOCALCIFEROL, ERGOCALCIFEROL  
 FLURBIPROFEN, FLURBIPROFEN  
 FUROSEMIDE, FUROSEMIDE  
 GEMFIBROZIL, GEMFIBROZIL  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
 GLIPIZIDE, GLIPIZIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 INDOMETHACIN, INDOMETHACIN  
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE  
 LITHIUM CARBONATE, LITHIUM CARBONATE  
 MELOXICAM, MELOXICAM  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METHIMAZOLE, METHIMAZOLE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NIMODIPINE, NIMODIPINE  
 NITROFURANTOIN, NITROFURANTOIN  
 OXAPROZIN, OXAPROZIN  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 REPAGLINIDE, REPAGLINIDE  
 RISPERIDONE, RISPERIDONE  
 THEOCHRON, THEOPHYLLINE  
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 VALPROIC ACID, VALPROIC ACID  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**SUN PHARM INDS LTD**

\* SUN PHARMACEUTICAL INDUSTRIES LTD  
 AZITHROMYCIN, AZITHROMYCIN  
 CARISOPRODOL, CARISOPRODOL  
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 GABAPENTIN, GABAPENTIN



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

- \* SUN PHARMACEUTICAL INDUSTRIES LTD
  - IBANDRONATE SODIUM, IBANDRONATE SODIUM
  - LETROZOLE, LETROZOLE
  - LEVETIRACETAM, LEVETIRACETAM
  - NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
  - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
  - OPCICON ONE-STEP, LEVONORGESTREL (OTC)
  - QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
  - RILUZOLE, RILUZOLE
  - RISPERIDONE, RISPERIDONE
  - TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
  - TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
  - TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
  - VALPROIC ACID, VALPROIC ACID
- \* SUN PHARMACEUTICAL INDUSTRIES LTD.
  - ANASTROZOLE, ANASTROZOLE

**SUN PHARMA GLOBAL**

- \* SUN PHARMA GLOBAL FZE
  - ALENDRONATE SODIUM, ALENDRONATE SODIUM
  - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
  - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  - CAFFEINE CITRATE, CAFFEINE CITRATE
  - CARBIDOPA AND LEVODOPA, CARBIDOPA
  - CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
  - CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  - CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  - CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
  - CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  - DECITABINE, DECITABINE
  - DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
  - DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
  - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
  - DOCEFREZ, DOCETAXEL
  - DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
  - DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  - ENTACAPONE, ENTACAPONE
  - ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
  - ESZOPICLONE, ESZOPICLONE
  - FINASTERIDE, FINASTERIDE
  - GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  - LANSOPRAZOLE, LANSOPRAZOLE
  - LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
  - LEVETIRACETAM, LEVETIRACETAM
  - LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
  - NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
  - NIACIN, NIACIN
  - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
  - OXALIPLATIN, OXALIPLATIN
  - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  - QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  - RISEDRONATE SODIUM, RISEDRONATE SODIUM
  - RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
  - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  - TEMOZOLOMIDE, TEMOZOLOMIDE
  - TOPIRAMATE, TOPIRAMATE
  - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
  - VECURONIUM BROMIDE, VECURONIUM BROMIDE
  - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  - ZOLEDRONIC ACID, ZOLEDRONIC ACID
  - ZOLMITRIPTAN, ZOLMITRIPTAN
- \* SUN PHARMA GLOBAL INC
  - ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
  - ALPRAZOLAM, ALPRAZOLAM
  - AMIFOSTINE, AMIFOSTINE
  - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* S \*\***

\* SUN PHARMA GLOBAL INC  
 BICALUTAMIDE, BICALUTAMIDE  
 CARBOPLATIN, CARBOPLATIN  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

**SUNEVA MEDCL**

\* SUNEVA MEDICAL INC  
 TRETINOIN, TRETINOIN

**SUNOVION**

\* SUNOVION PHARMACEUTICALS INC  
 BROVANA, ARFORMOTEROL TARTRATE  
 XOPENEX HFA, LEVALBUTEROL TARTRATE

**SUNOVION PHARMS INC**

\* SUNOVION PHARMACEUTICALS INC  
 APTIOM, ESLICARBAZEPINE ACETATE  
 LATUDA, LURASIDONE HYDROCHLORIDE  
 LUNESTA, ESZOPICLONE

**SUNSHINE LAKE**

\* SUNSHINE LAKE PHARMA CO LTD  
 ZIDOVUDINE, ZIDOVUDINE

**SUNSTAR AMERICAS**

\* SUNSTAR AMERICAS INC  
 PAROEX, CHLORHEXIDINE GLUCONATE

**SUPERNUS PHARMS**

\* SUPERNUS PHARMACEUTICALS INC  
 OXTELLAR XR, OXCARBAZEPINE  
 TROKENDI XR, TOPIRAMATE

**SUVEN LIFE**

\* SUVEN LIFE SCIENCES LTD  
 MALATHION, MALATHION

**SVADS HOLDINGS SA**

\* SVADS HOLDINGS SA  
 IBUPROFEN, IBUPROFEN (OTC)  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**SVC PHARMA**

\* SVC PHARMA LP  
 DRONABINOL, DRONABINOL

**SWEDISH ORPHAN**

\* SWEDISH ORPHAN BIOVITRUM AB PUBL  
 ORFADIN, NITISINONE

**SYMPLMED PHARMS LLC**

\* SYMPLMED PHARMACEUTICALS LLC  
 ACEON, PERINDOPRIL ERBUMINE

**SYNTHON PHARMS**

\* SYNTHON PHARMACEUTICALS INC  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**\*\* T \*\*****MEDICINES CO**

\* THE MEDICINES CO  
 ANGIOMAX, BIVALIRUDIN  
 CLEVIPREX, CLEVIDIPINE  
 ORBACTIV, ORITAVANCIN DIPHOSPHATE

**RITEDOSE CORP**

\* THE RITEDOSE CORP  
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

**TAKEDA GMBH**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\*****\* TAKEDA GMBH**

ALVESCO, CICLESONIDE  
 OMNARIS, CICLESONIDE  
 ZETONNA, CICLESONIDE

**TAKEDA PHARMS USA****\* TAKEDA PHARMACEUTICALS USA INC**

ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE  
 ACTOPLUS MET, METFORMIN HYDROCHLORIDE  
 ACTOS, PIOGLITAZONE HYDROCHLORIDE  
 BRINTELLIX, VORTIOXETINE HYDROBROMIDE  
 COLCRYS, COLCHICINE  
 CONTRAVE, BUPROPION HYDROCHLORIDE  
 DEXILANT, DEXLANSOPRAZOLE  
 DUETACT, GLIMEPIRIDE  
 KAZANO, ALOGLIPTIN BENZOATE  
 NESINA, ALOGLIPTIN BENZOATE  
 OSENI, ALOGLIPTIN BENZOATE  
 PREVACID, LANSOPRAZOLE  
 PREVPAC, AMOXICILLIN  
 ROZEREM, RAMELTEON  
 ULORIC, FEBUXOSTAT

**TALON THERAP****\* TALON THERAPEUTICS INC**

MARQIBO KIT, VINCRISTINE SULFATE

**TAMARANG****\* TAMARANG SA**

ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

**TARO****\* TARO PHARMACEUTICAL INDUSTRIES LTD**

ACETAZOLAMIDE, ACETAZOLAMIDE  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CARVEDILOL, CARVEDILOL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE  
 DESONIDE, DESONIDE  
 ENALAPRIL MALEATE, ENALAPRIL MALEATE  
 ETODOLAC, ETODOLAC  
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOROURACIL, FLUOROURACIL  
 GABAPENTIN, GABAPENTIN  
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE  
 IMIQUIMOD, IMIQUIMOD  
 KETOCONAZOLE, KETOCONAZOLE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM  
 LORATADINE, LORATADINE (OTC)  
 MELOXICAM, MELOXICAM  
 METRONIDAZOLE, METRONIDAZOLE  
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 OXCARBAZEPINE, OXCARBAZEPINE  
 PHENYTOIN, PHENYTOIN

**\* TARO PHARMACEUTICALS INC**

BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 CLOTRIMAZOLE, CLOTRIMAZOLE  
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)  
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE  
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE  
 FLUOCINONIDE, FLUOCINONIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

- \* TARO PHARMACEUTICALS INC
  - HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
  - MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
  - NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
  - TOPICORT, DESOXIMETASONE
  - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
  - WARFARIN SODIUM, WARFARIN SODIUM
- \* TARO PHARMACEUTICALS USA INC
  - ACETIC ACID, ACETIC ACID, GLACIAL
  - ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
  - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  - AMMONIUM LACTATE, AMMONIUM LACTATE
  - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  - CICLOPIROX, CICLOPIROX
  - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  - CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
  - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  - CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
  - CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  - CLOTRIMAZOLE, CLOTRIMAZOLE
  - DERMABET, BETAMETHASONE VALERATE
  - DESONIDE, DESONIDE
  - DICLOFENAC SODIUM, DICLOFENAC SODIUM
  - DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
  - ECONAZOLE NITRATE, ECONAZOLE NITRATE
  - ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
  - FLO-PRED, PREDNISOLONE ACETATE
  - FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
  - FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
  - FLUOCINONIDE, FLUOCINONIDE
  - FLUOROURACIL, FLUOROURACIL
  - GENTAMICIN SULFATE, GENTAMICIN SULFATE
  - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  - HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
  - HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
  - HYDROCORTISONE, HYDROCORTISONE
  - KETOZOLE, KETOCONAZOLE
  - LIDOCAINE, LIDOCAINE
  - LORATADINE, LORATADINE (OTC)
  - MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
  - MOMETASONE FUROATE, MOMETASONE FUROATE
  - MUPIROCIN, MUPIROCIN
  - NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
  - NYSTATIN, NYSTATIN
  - PHENYTOIN, PHENYTOIN
  - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  - RISPERIDONE, RISPERIDONE
  - SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
  - TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
  - TERCONAZOLE, TERCONAZOLE
  - TERIL, CARBAMAZEPINE
  - TOPICORT, DESOXIMETASONE
  - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
  - TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
  - U-CORT, HYDROCORTISONE ACETATE
- \* TARO PHARMACEUTICALS, INC.
  - HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
  - TOPICORT, DESOXIMETASONE

**TARO PHARM INDS**

- \* TARO PHARMACEUTICAL INDUSTRIES LTD
  - AMCINONIDE, AMCINONIDE
  - CARBAMAZEPINE, CARBAMAZEPINE
  - CICLOPIROX, CICLOPIROX
  - CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

\* TARO PHARMACEUTICAL INDUSTRIES LTD  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
 ETODOLAC, ETODOLAC  
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

**TARO PHARMS IRELAND**

\* TARO PHARMACEUTICALS IRELAND LTD  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE  
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION

**TARO PHARMS NORTH**

\* TARO PHARMACEUTICALS NORTH AMERICA INC  
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)  
 INFANTS' FEVERALL, ACETAMINOPHEN (OTC)  
 OVIDE, MALATHION  
 TOPICORT, DESOXIMETASONE

**TEDOR PHARM**

\* TEDOR PHARMA INC  
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

**TEDOR PHARMA INC**

\* TEDOR PHARMA INC  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

**TEIKOKU PHARMA USA**

\* TEIKOKU PHARMA USA INC  
 LIDODERM, LIDOCAINE

**TEVA**

\* TEVA NEUROSCIENCE INC  
 AZILECT, RASAGILINE MESYLATE

\* TEVA PHARMACEUTICALS USA INC  
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 ACYCLOVIR, ACYCLOVIR  
 ADIPEX-P, PHENTERMINE HYDROCHLORIDE  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 AMOXICILLIN PEDIATRIC, AMOXICILLIN  
 AMOXICILLIN, AMOXICILLIN  
 AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF, AMPHETAMINE  
 ATENOLOL, ATENOLOL  
 AZITHROMYCIN, AZITHROMYCIN  
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
 BETA-VAL, BETAMETHASONE VALERATE  
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
 BICALUTAMIDE, BICALUTAMIDE  
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
 CALCITRIOL, CALCITRIOL  
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL  
 CAPTOPRIL, CAPTOPRIL  
 CARBIDOPA AND LEVODOPA, CARBIDOPA  
 CARVEDILOL, CARVEDILOL  
 CEFACLOR, CEFACLOR  
 CEFPROZIL, CEFPROZIL  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CELECOXIB, CELECOXIB  
 CEPHALEXIN, CEPHALEXIN  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE  
 CILOSTAZOL, CILOSTAZOL  
 CIMETIDINE, CIMETIDINE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE  
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

\* TEVA PHARMACEUTICALS USA INC  
 CLONAZEPAM, CLONAZEPAM  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 CLOTRIMAZOLE, CLOTRIMAZOLE  
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM  
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM  
 DIFLUNISAL, DIFLUNISAL  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE  
 ENALAPRIL MALEATE, ENALAPRIL MALEATE  
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM  
 EPITOL, CARBAMAZEPINE  
 ESTAZOLAM, ESTAZOLAM  
 ESZOPICLONE, ESZOPICLONE  
 ETODOLAC, ETODOLAC  
 FAMOTIDINE, FAMOTIDINE  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 FENOFIBRATE (MICRONIZED), FENOFIBRATE  
 FENOFIBRATE, FENOFIBRATE  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE  
 FINASTERIDE, FINASTERIDE  
 FLUCONAZOLE, FLUCONAZOLE  
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE  
 FLUOCINONIDE, FLUOCINONIDE  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 FLURBIPROFEN, FLURBIPROFEN  
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM  
 GALZIN, ZINC ACETATE  
 GEMFIBROZIL, GEMFIBROZIL  
 GLIMEPIRIDE, GLIMEPIRIDE  
 GLYBURIDE (MICRONIZED), GLYBURIDE  
 GLYBURIDE, GLYBURIDE  
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE  
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 KETOCONAZOLE, KETOCONAZOLE  
 KETOPROFEN, KETOPROFEN  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE  
 LORATADINE, LORATADINE (OTC)  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
 LOVASTATIN, LOVASTATIN  
 MESALAMINE, MESALAMINE  
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MIRTAZAPINE, MIRTAZAPINE  
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE  
 MUPIROCIN, MUPIROCIN  
 NABUMETONE, NABUMETONE  
 NAPROXEN SODIUM, NAPROXEN SODIUM  
 NAPROXEN, NAPROXEN  
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE  
 NEOMYCIN SULFATE, NEOMYCIN SULFATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

\* TEVA PHARMACEUTICALS USA INC  
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
 NYSTATIN, NYSTATIN  
 OFLOXACIN, OFLOXACIN  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON, ONDANSETRON  
 ORAP, PIMOZIDE  
 OXAPROZIN, OXAPROZIN  
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
 PENICILLIN-VK, PENICILLIN V POTASSIUM  
 PIROXICAM, PIROXICAM  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PRELONE, PREDNISOLONE  
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RIBAVIRIN, RIBAVIRIN  
 RISPERIDONE, RISPERIDONE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
 SUCRALFATE, SUCRALFATE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE  
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE  
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
 TOLMETIN SODIUM, TOLMETIN SODIUM  
 TOPIRAMATE, TOPIRAMATE  
 TORSEMIDE, TORSEMIDE  
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
 TRIMETHOPRIM, TRIMETHOPRIM  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**TEVA BRANDED PHARM**

\* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC  
 CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A  
 LOSEASONIQUE, ETHINYL ESTRADIOL  
 NORDETTE-28, ETHINYL ESTRADIOL  
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)  
 PLAN B, LEVONORGESTREL  
 PLAN B, LEVONORGESTREL (OTC)  
 PROAIR HFA, ALBUTEROL SULFATE  
 PROGLYCEM, DIAZOXIDE  
 QNASL, BECLOMETHASONE DIPROPIONATE  
 QUARTETTE, ETHINYL ESTRADIOL  
 QVAR 40, BECLOMETHASONE DIPROPIONATE  
 QVAR 80, BECLOMETHASONE DIPROPIONATE  
 SEASONALE, ETHINYL ESTRADIOL  
 SEASONIQUE, ETHINYL ESTRADIOL  
 ZECURITY, SUMATRIPTAN SUCCINATE

**TEVA PARENTERAL**

\* TEVA PARENTERAL MEDICINES INC  
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

**TEVA PHARMS**

\* TEVA PHARMACEUTICALS USA  
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 ALENDRONATE SODIUM, ALENDRONATE SODIUM  
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\*****\* TEVA PHARMACEUTICALS USA**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
 AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE  
 ANASTROZOLE, ANASTROZOLE  
 AZITHROMYCIN, AZITHROMYCIN  
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE  
 BUDESONIDE, BUDESONIDE  
 CARBAMAZEPINE, CARBAMAZEPINE  
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE  
 CEFDINIR, CEFDINIR  
 CEFPROZIL, CEFPROZIL  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 CROMOLYN SODIUM, CROMOLYN SODIUM  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE  
 DOXEPIH HYDROCHLORIDE, DOXEPIH HYDROCHLORIDE  
 ETHOSUXIMIDE, ETHOSUXIMIDE  
 FAMCICLOVIR, FAMCICLOVIR  
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM  
 GABAPENTIN, GABAPENTIN  
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE  
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 HYDROCORTISONE, HYDROCORTISONE  
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
 IRBESARTAN, IRBESARTAN  
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE  
 LANSOPRAZOLE, LANSOPRAZOLE  
 LEFLUNOMIDE, LEFLUNOMIDE  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE  
 LINEZOLID, LINEZOLID  
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 MEGESTROL ACETATE, MEGESTROL ACETATE  
 MELOXICAM, MELOXICAM  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE  
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 OLANZAPINE, OLANZAPINE  
 OXALIPLATIN, OXALIPLATIN  
 PACLITAXEL, PACLITAXEL  
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE  
 PREGABALIN, PREGABALIN  
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE  
 PROGESTERONE, PROGESTERONE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 QUINIDINE SULFATE, QUINIDINE SULFATE  
 QUININE SULFATE, QUININE SULFATE  
 RAMIPRIL, RAMIPRIL  
 RISEDRONATE SODIUM, RISEDRONATE SODIUM  
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE  
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\*****\* TEVA PHARMACEUTICALS USA**

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE  
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TESTOSTERONE, TESTOSTERONE  
 THEOPHYLLINE, THEOPHYLLINE  
 TRANDOLAPRIL, TRANDOLAPRIL  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
 URSODIOL, URSODIOL  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VANDAZOLE, METRONIDAZOLE  
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE  
 VORICONAZOLE, VORICONAZOLE  
 ZALEPLON, ZALEPLON

**TEVA PHARMS USA****\* TEVA PHARMACEUTICALS USA**

ACITRETIN, ACITRETIN  
 ADENOSINE, ADENOSINE  
 ALPROSTADIL, ALPROSTADIL  
 AMIKACIN SULFATE, AMIKACIN SULFATE  
 ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN  
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE  
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE  
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE  
 CARBOPLATIN, CARBOPLATIN  
 CLARAVIS, ISOTRETINOIN  
 COPAXONE, GLATIRAMER ACETATE  
 CYTOSAR-U, CYTARABINE  
 DACARBAZINE, DACARBAZINE  
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE  
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE  
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 ENALAPRILAT, ENALAPRILAT  
 ENTECAVIR, ENTECAVIR  
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE  
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 ETOPOSIDE, ETOPOSIDE  
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE  
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE  
 FLUOROURACIL, FLUOROURACIL  
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE  
 HALOPERIDOL, HALOPERIDOL LACTATE  
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE  
 IFOSFAMIDE, IFOSFAMIDE  
 IFOSFAMIDE/MESNA KIT, IFOSFAMIDE  
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE  
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN  
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM  
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE  
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE  
 LEVOCARNITINE, LEVOCARNITINE  
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE  
 MESNA, MESNA  
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

- \* TEVA PHARMACEUTICALS USA  
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE  
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE  
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS  
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM  
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE  
 PARICALCITOL, PARICALCITOL  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 PROPOFOL, PROPOFOL  
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE  
 RAMELTEON, RAMELTEON  
 RISEDRONATE SODIUM, RISEDRONATE SODIUM  
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE  
 TOBRAMYCIN, TOBRAMYCIN  
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE  
 VECURONIUM BROMIDE, VECURONIUM BROMIDE  
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE  
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE  
 ZANOSAR, STREPTOZOCIN  
 ZOLMITRIPTAN, ZOLMITRIPTAN
- \* TEVA PHARMACEUTICALS USA INC  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 CAPECITABINE, CAPECITABINE  
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL  
 IMIQUIMOD, IMIQUIMOD  
 METRONIDAZOLE, METRONIDAZOLE  
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 SELFEMRA, FLUOXETINE HYDROCHLORIDE  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
- TEVA PHARMS USA INC**
- \* TEVA PHARMACEUTICALS USA INC  
 ADASUVE, LOXAPINE
- TEVA WOMENS**
- \* TEVA WOMENS HEALTH INC  
 ENJUWIA, ESTROGENS, CONJUGATED SYNTHETIC B  
 PARAGARD T 380A, COPPER  
 REVIA, NALTREXONE HYDROCHLORIDE  
 ZEBETA, BISOPROLOL FUMARATE  
 ZIAC, BISOPROLOL FUMARATE
- THE FEINSTEIN INST**
- \* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH  
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
- THE PHARMA NETWORK**
- \* THE PHARMA NETWORK LLC  
 BENZONATATE, BENZONATATE
- THE PHARMANETWORK**
- \* THE PHARMANETWORK LLC  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
- THEPHARMANETWORK LLC**
- \* THEPHARMANETWORK LLC  
 BENZONATATE, BENZONATATE  
 ISONIAZID, ISONIAZID  
 NIMODIPINE, NIMODIPINE  
 THERMAZENE, SILVER SULFADIAZINE
- THERAKOS**
- \* THERAKOS INC  
 UVADEX, METHOXSALEN
- THERATECHNOLOGIES**
- \* THERATECHNOLOGIES INC  
 EGRIFTA, TESAMORELIN ACETATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\*****THERAVANCE BIOPHARMA**

\* THERAVANCE BIOPHARMA ANTIBIOTICS INC  
VIBATIV, TELAVANCIN HYDROCHLORIDE

**THREE RIVERS PHARMS**

\* THREE RIVERS PHARMACEUTICALS LLC  
RIBASPHERE, RIBAVIRIN  
RIBAVIRIN, RIBAVIRIN

**TOLMAR**

\* TOLMAR INC  
ADAPALENE, ADAPALENE  
ATRIDOX, DOXYCYCLINE HYCLATE  
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE  
CALCIPOTRIENE, CALCIPOTRIENE  
CICLOPIROX, CICLOPIROX  
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
DICLOFENAC SODIUM , DICLOFENAC SODIUM  
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE  
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE  
IMIQUIMOD, IMIQUIMOD  
KETOCONAZOLE, KETOCONAZOLE  
LEVETIRACETAM, LEVETIRACETAM  
LIDOCAINE AND PRILOCAINE, LIDOCAINE  
METRONIDAZOLE, METRONIDAZOLE  
MOMETASONE FUROATE, MOMETASONE FUROATE  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

**TOLMAR THERAP**

\* TOLMAR THERAPEUTICS INC  
ELIGARD, LEUPROLIDE ACETATE

**TORPHARM**

\* TORPHARM INC  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**TORRENT PHARM**

\* TORRENT PHARMA INC  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**TORRENT PHARMS**

\* TORRENT PHARMACEUTICALS LIMITED  
LEVOFLOXACIN, LEVOFLOXACIN

\* TORRENT PHARMACEUTICALS LTD  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
CARBAMAZEPINE, CARBAMAZEPINE  
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
LAMOTRIGINE, LAMOTRIGINE  
LEVETIRACETAM, LEVETIRACETAM  
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
RISPERIDONE, RISPERIDONE  
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
TOPIRAMATE, TOPIRAMATE  
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

\* TORRENT PHARMACEUTICALS LTD.  
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

**TORRENT PHARMS LLC**

\* TORRENT PHARMACEUTICALS LLC  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
OLANZAPINE, OLANZAPINE  
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**TORRENT PHARMS LTD**

\* TORRENT PHARMACEUTICALS LTD

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* T \*\***

\* TORRENT PHARMACEUTICALS LTD  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
 FELODIPINE, FELODIPINE  
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVETIRACETAM, LEVETIRACETAM  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE  
 OLANZAPINE, OLANZAPINE  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE  
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM  
 SILDENAFIL CITRATE, SILDENAFIL CITRATE  
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE  
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TELMISARTAN, TELMISARTAN  
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
 VALSARTAN, VALSARTAN

**TRIS PHARMA INC**

\* TRIS PHARMA INC  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)  
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE  
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE  
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,  
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX  
 IBUPROFEN, IBUPROFEN (OTC)  
 KARBINAL ER, CARBINOXAMINE MALEATE  
 LEVETIRACETAM, LEVETIRACETAM  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 RISPERIDONE, RISPERIDONE  
 THEOPHYLLINE, THEOPHYLLINE

**TRUSTEES UNIV PA**

\* TRUSTEES OF THE UNIV OF PENNSYLVANIA  
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**TRYGG**

\* TRYGG PHARMA INC  
 OMTRYG, OMEGA-3-ACID ETHYL ESTERS

**TWI PHARMS INC**

\* TWI PHARMACEUTICALS INC  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 MEGESTROL ACETATE, MEGESTROL ACETATE  
 NIFEDIPINE, NIFEDIPINE

**\*\* U \*\*****UCB INC**

\* UCB INC  
 KEPPRA XR, LEVETIRACETAM  
 KEPPRA, LEVETIRACETAM  
 METADATE CD, METHYLPHENIDATE HYDROCHLORIDE  
 METADATE ER, METHYLPHENIDATE HYDROCHLORIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 NEUPRO, ROTIGOTINE  
 TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX  
 UNIRETIC, HYDROCHLOROTHIAZIDE  
 UNIVASC, MOEXIPRIL HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* U \*\*****\* UCB INC**

VIMPAT, LACOSAMIDE  
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE  
ZAROXOLYN, METOLAZONE

**UCLA BIOMEDICAL****\* UCLA BIOMEDICAL CYCLOTRON**

AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**UCSF RADIOPHARM****\* UCSF RADIOPHARMACEUTICAL FACILITY**

AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**UIHC PET IMAGING****\* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**UNICHEM****\* UNICHEM LABORATORIES LTD**

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
MELOXICAM, MELOXICAM  
ZALEPLON, ZALEPLON

**UNICHEM LABS LTD****\* UNICHEM LABORATORIES LIMITED**

DIVALPROEX SODIUM, DIVALPROEX SODIUM

**\* UNICHEM LABORATORIES LTD**

AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
LAMOTRIGINE, LAMOTRIGINE  
METRONIDAZOLE, METRONIDAZOLE  
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE  
TOPIRAMATE, TOPIRAMATE

**UNICHEM PHARMS (USA)****\* UNICHEM PHARMACEUTICALS (USA) INC**

BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

**UNIMARK REMEDIES LTD****\* UNIMARK REMEDIES LTD**

MONTELUKAST SODIUM, MONTELUKAST SODIUM

**UNIQUE PHARM LABS****\* UNIQUE PHARMACEUTICAL LABORATORIES**

ATENOLOL, ATENOLOL  
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)  
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
DICLOFENAC SODIUM, DICLOFENAC SODIUM  
FLUCONAZOLE, FLUCONAZOLE  
TINIDAZOLE, TINIDAZOLE

**UNITED BIOMEDCL****\* UNITED BIOMEDICAL INC**

TERBUTALINE SULFATE, TERBUTALINE SULFATE

**UNITED GUARDIAN****\* UNITED GUARDIAN INC**

RENACIDIN, CITRIC ACID

**UNITED THERAP****\* UNITED THERAPEUTICS CORP**

ORENITRAM, TREPROSTINIL DIOLAMINE  
REMODULIN, TREPROSTINIL  
TYVASO, TREPROSTINIL

**UNIV TX MD ANDERSON****\* UNIV TEXAS MD ANDERSON CANCER CENTER**

AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* U \*\***

\* UNIV TEXAS MD ANDERSON CANCER CENTER  
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**UPSHER SMITH**

\* UPSHER SMITH LABORATORIES INC  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
DIVALPROEX SODIUM, DIVALPROEX SODIUM  
FORTICAL, CALCITONIN SALMON RECOMBINANT  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
MORPHINE SULFATE, MORPHINE SULFATE  
NIACOR, NIACIN  
NYSTATIN, NYSTATIN  
ORVATEN, MIDODRINE HYDROCHLORIDE  
OXANDROLONE, OXANDROLONE  
PACERONE, AMIODARONE HYDROCHLORIDE  
PENTOXIL, PENTOXIFYLLINE  
PREVALITE, CHOLESTYRAMINE  
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
QUDEXY XR, TOPIRAMATE  
SORINE, SOTALOL HYDROCHLORIDE  
TOPIRAMATE, TOPIRAMATE  
VOGELXO, TESTOSTERONE  
ZALEPLON, ZALEPLON

**UPSHER SMITH LABS**

\* UPSHER SMITH LABORATORIES INC  
KLOR-CON M10, POTASSIUM CHLORIDE  
KLOR-CON M15, POTASSIUM CHLORIDE  
KLOR-CON M20, POTASSIUM CHLORIDE

**UPSHER-SMITH LABS**

\* UPSHER-SMITH LABORATORIES INC  
KLOR-CON, POTASSIUM CHLORIDE

**US PHARMS HOLDINGS I**

\* US PHARMACEUTICALS HOLDINGS I LLC  
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE  
LOPRESSOR, METOPROLOL TARTRATE  
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE  
LOTENSIN, BENAZEPRIL HYDROCHLORIDE  
PARLODEL, BROMOCRIPTINE MESYLATE

**US WORLDMEDS**

\* US WORLDMEDS LLC  
APOKYN, APOMORPHINE HYDROCHLORIDE  
REVONTO, DANTROLENE SODIUM

**USL PHARMA**

\* USL PHARMA INC  
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
BACLOFEN, BACLOFEN  
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE  
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE  
ESTRADIOL, ESTRADIOL  
FLUOXYMESTERONE, FLUOXYMESTERONE  
JANTOVEN, WARFARIN SODIUM  
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

**USV NORTH AMERICA**

\* USV NORTH AMERICA INC  
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**\*\* V \*\*****VALEANT**

\* VALEANT PHARMACEUTICALS INTERNATIONAL  
ANCOBON, FLUCYTOSINE  
BONTRIL PDM, PHENDIMETRAZINE TARTRATE  
BONTRIL, PHENDIMETRAZINE TARTRATE  
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE  
MIGRANAL, DIHYDROERGOTAMINE MESYLATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\***

\* VALEANT PHARMACEUTICALS INTERNATIONAL  
 MOTOFEN, ATROPINE SULFATE  
 MYSOLINE, PRIMIDONE

**VALEANT BERMUDA**

\* VALEANT INTERNATIONAL BERMUDA  
 APLENZIN, BUPROPION HYDROBROMIDE  
 BENZACLIN, BENZOYL PEROXIDE  
 CARAC, FLUOROURACIL  
 DERMATOP E EMOLLIENT, PREDNICARBATE  
 DERMATOP, PREDNICARBATE  
 ELIDEL, PIMECROLIMUS  
 ISORDIL, ISOSORBIDE DINITRATE  
 KLARON, SULFACETAMIDE SODIUM  
 NORITATE, METRONIDAZOLE  
 PENLAC, CICLOPIROX  
 PENTOXIFYLLINE, PENTOXIFYLLINE  
 RETIN-A, TRETINOIN  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 XENAZINE, TETRABENZAZINE  
 XERESE, ACYCLOVIR  
 ZOVIRAX, ACYCLOVIR

**VALEANT INTL**

\* VALEANT INTERNATIONAL BARBADOS SRL  
 ATIVAN, LORAZEPAM  
 CARDIZEM CD, DILTIAZEM HYDROCHLORIDE  
 CARDIZEM LA, DILTIAZEM HYDROCHLORIDE  
 CARDIZEM, DILTIAZEM HYDROCHLORIDE  
 DICLOFENAC SODIUM, DICLOFENAC SODIUM  
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE  
 FENOFIBRATE, FENOFIBRATE  
 NIFEDIPINE, NIFEDIPINE  
 RENOVA, TRETINOIN  
 RETIN-A MICRO, TRETINOIN  
 RETIN-A, TRETINOIN  
 RETIN-A-MICRO, TRETINOIN  
 TIAZAC, DILTIAZEM HYDROCHLORIDE  
 ULTRAM ER, TRAMADOL HYDROCHLORIDE  
 VASERETIC, ENALAPRIL MALEATE  
 VASOTEC, ENALAPRIL MALEATE  
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE

\* VALEANT INTERNATIONAL SRL  
 BENZAMYCIN, BENZOYL PEROXIDE

**VALEANT LUXEMBOURG**

\* VALEANT PHARMACEUTICALS LUXEMBOURG SARL  
 BENZAMYCIN PAK, BENZOYL PEROXIDE  
 ERTACZO, SERTACONAZOLE NITRATE  
 GRIFULVIN V, GRISEOFULVIN, MICROSIZE  
 TARGRETIN, BEXAROTENE

**VALEANT PHARM INTL**

\* VALEANT PHARMACEUTICALS INTERNATIONAL  
 8-MOP, METHOXSALEN  
 ANDROID 10, METHYLTESTOSTERONE  
 ANDROID 25, METHYLTESTOSTERONE  
 EFUDEX, FLUOROURACIL  
 LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE  
 MESTINON, PYRIDOSTIGMINE BROMIDE  
 OXSORALEN, METHOXSALEN  
 TESTRED, METHYLTESTOSTERONE  
 VIRAZOLE, RIBAVIRIN  
 ZELAPAR, SELEGILINE HYDROCHLORIDE

**VALEANT PHARM NORTH**

\* VALEANT PHARMACEUTICAL NORTH AMERICA LLC  
 MESTINON, PYRIDOSTIGMINE BROMIDE  
 MINITRAN, NITROGLYCERIN

**VALEANT PHARMS**

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\***

\* VALEANT PHARMACEUTICALS NORTH AMERICA  
MEPHYTON, PHYTONADIONE  
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE  
TENSILON, EDROPHONIUM CHLORIDE

**VALEANT PHARMS INC**

\* VALEANT PHARMACEUTICALS INTERNATIONAL INC  
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE  
VISUDYNE, VERTEPORFIN

**VALEANT PHARMS LLC**

\* VALEANT PHARMACEUTICALS NORTH AMERICA LLC  
CAPITAL AND CODEINE, ACETAMINOPHEN  
MACUGEN, PEGAPTANIB SODIUM  
MESTINON, PYRIDOSTIGMINE BROMIDE  
TASMAR, TOLCAPONE  
TIMOPTIC-XE, TIMOLOL MALEATE

**VALEANT PHARMS NORTH**

\* VALEANT PHARMACEUTICALS NORTH AMERICA LLC  
DIASTAT ACUDIAL, DIAZEPAM  
DIASTAT, DIAZEPAM

**VALIDUS PHARMS**

\* VALIDUS PHARMACEUTICALS LLC  
ROCALTROL, CALCITRIOL

**VALIDUS PHARMS INC**

\* VALIDUS PHARMACEUTICALS INC  
EQUETRO, CARBAMAZEPINE  
MARPLAN, ISOCARBOXAZID

**VANDA PHARMS INC**

\* VANDA PHARMACEUTICALS INC  
HETLIOZ, TASIMELTEON

**VANSEN PHARMA**

\* VANSEN PHARMA  
SPECTRACEF, CEFDITOREN PIVOXIL

**VELDANA MEDICAL SA**

\* VELDANA MEDICAL SA  
ECOZA, ECONAZOLE NITRATE

**VEROSCIENCE**

\* VEROSCIENCE LLC  
CYCLOSET, BROMOCRIPTINE MESYLATE

**VERSAPHARM**

\* VERSAPHARM INC  
CICLOPIROX, CICLOPIROX  
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE  
DESOXIMETASONE, DESOXIMETASONE  
ERYTHROMYCIN, ERYTHROMYCIN  
ETHOSUXIMIDE, ETHOSUXIMIDE  
RIFAMPIN, RIFAMPIN

**VERSAPHARM INC**

\* VERSAPHARM INC  
DESOXIMETASONE, DESOXIMETASONE  
RIFAMPIN, RIFAMPIN  
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
\* VERSAPHARM INCORPORATED  
TRANEXAMIC ACID, TRANEXAMIC ACID

**VERTEX PHARMS**

\* VERTEX PHARMACEUTICALS INC  
INCIVEK, TELAPREVIR  
KALYDECO, IVACAFTOR

**VERTICAL PHARMS LLC**

\* VERTICAL PHARMACEUTICALS LLC  
DIVIGEL, ESTRADIOL

**VICURON**

\* VICURON PHARMACEUTICALS INC  
ERAXIS, ANIDULAFUNGIN



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\*****VIFOR FRESENIUS**

\* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE  
VELPHORO, SUCROFERRIC OXYHYDROXIDE

**VIIV HLTHCARE**

\* VIIV HEALTHCARE CO  
COMBIVIR, LAMIVUDINE  
EPIVIR, LAMIVUDINE  
EPZICOM, ABACAVIR SULFATE  
LEXIVA, FOSAMPRENAVIR CALCIUM  
RESCRIPTOR, DELAVIRDINE MESYLATE  
RETROVIR, ZIDOVUDINE  
SELZENTRY, MARAVIROC  
TIVICAY, DOLUTEGRAVIR SODIUM  
TRIUMEQ, ABACAVIR SULFATE  
TRIZIVIR, ABACAVIR SULFATE  
ZIAGEN, ABACAVIR SULFATE

**VINTAGE**

\* VINTAGE PHARMACEUTICALS LLC  
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
ACETIC ACID, ACETIC ACID, GLACIAL  
ALBUTEROL SULFATE, ALBUTEROL SULFATE  
ALPRAZOLAM, ALPRAZOLAM  
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE  
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
DIVALPROEX SODIUM, DIVALPROEX SODIUM  
FOLIC ACID, FOLIC ACID  
GLIMEPIRIDE, GLIMEPIRIDE  
GLYCOPYRROLATE, GLYCOPYRROLATE  
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL  
HYDROCORTISONE, HYDROCORTISONE  
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE  
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
LISINAPRIL, LISINAPRIL  
NYSTATIN, NYSTATIN  
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE  
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
PREDNISOLONE, PREDNISOLONE  
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE  
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE  
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE  
RISPERIDONE, RISPERIDONE  
SPIRONOLACTONE, SPIRONOLACTONE  
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE  
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE  
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
VALPROIC ACID, VALPROIC ACID  
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**VINTAGE PHARMS**

\* VINTAGE PHARMACEUTICALS  
ALPRAZOLAM, ALPRAZOLAM  
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN  
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE  
DISULFIRAM, DISULFIRAM  
GILDAGIA, ETHINYL ESTRADIOL  
GILDESS 24 FE, ETHINYL ESTRADIOL  
GLYCOPYRROLATE, GLYCOPYRROLATE  
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE  
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
LEVETIRACETAM, LEVETIRACETAM  
METHIMAZOLE, METHIMAZOLE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\***

\* VINTAGE PHARMACEUTICALS  
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE  
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE  
 OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

\* VINTAGE PHARMACEUTICALS INC  
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 ALLOPURINOL, ALLOPURINOL  
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE  
 BACLOFEN, BACLOFEN  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN  
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN  
 CARISOPRODOL, CARISOPRODOL  
 CLONAZEPAM, CLONAZEPAM  
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE  
 DEXAMETHASONE, DEXAMETHASONE  
 DIAZEPAM, DIAZEPAM  
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE  
 FUROSEMIDE, FUROSEMIDE  
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE  
 HYDROCORTISONE, HYDROCORTISONE  
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
 IBUPROFEN, IBUPROFEN  
 IBUPROFEN, IBUPROFEN (OTC)  
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE  
 LACTULOSE, LACTULOSE  
 LEVETIRACETAM, LEVETIRACETAM  
 LORAZEPAM, LORAZEPAM  
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE  
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE  
 METHOCARBAMOL, METHOCARBAMOL  
 METHYLPREDNISOLONE, METHYLPREDNISOLONE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 NYSTATIN, NYSTATIN  
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PERPHENAZINE, PERPHENAZINE  
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE  
 PREDNISONE, PREDNISONE  
 PRIMIDONE, PRIMIDONE  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE  
 SULFASALAZINE, SULFASALAZINE  
 TORSEMIDE, TORSEMIDE  
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

**VINTAGE PHARMS LLC**

\* VINTAGE PHARMACEUTICALS LLC  
 CYCLAFEM 1/35, ETHINYL ESTRADIOL  
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL  
 EMOQUETTE, DESOGESTREL  
 FELODIPINE, FELODIPINE  
 GILDESS 1.5/30, ETHINYL ESTRADIOL  
 GILDESS 1/20, ETHINYL ESTRADIOL  
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL  
 GILDESS FE 1/20, ETHINYL ESTRADIOL  
 LETROZOLE, LETROZOLE  
 LEVETIRACETAM, LEVETIRACETAM  
 MEFENAMIC ACID, MEFENAMIC ACID  
 MONTELUKAST SODIUM, MONTELUKAST SODIUM  
 MORPHINE SULFATE, MORPHINE SULFATE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* V \*\***

\* VINTAGE PHARMACEUTICALS LLC  
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL  
 MYZILRA, ETHINYL ESTRADIOL  
 ORSYTHIA, ETHINYL ESTRADIOL  
 PERCOCET, ACETAMINOPHEN  
 PREVIFEM, ETHINYL ESTRADIOL  
 TRI-PREVIFEM, ETHINYL ESTRADIOL

**VIRTUS PHARM**

\* VIRTUS PHARMACEUTICAL INC  
 ACARBOSE, ACARBOSE

**VISTA PHARMS**

\* VISTA PHARMACEUTICALS INC  
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

**VISTAPHARM**

\* VISTAPHARM INC  
 ALBUTEROL SULFATE, ALBUTEROL SULFATE  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN  
 LACTULOSE, LACTULOSE  
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 MORPHINE SULFATE, MORPHINE SULFATE  
 NYSTATIN, NYSTATIN  
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE  
 PHENYTOIN, PHENYTOIN

**VIVIMED LABS**

\* VIVIMED LABS ALATHUR PRIVATE LTD  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

**VIVUS**

\* VIVUS INC  
 QSYMIA, PHENTERMINE HYDROCHLORIDE  
 STENDRA, AVANAFIL

**\*\* W \*\*****WA UNIV SCH MED**

\* WASHINGTON UNIV SCHOOL MEDICINE  
 AMMONIA N 13, AMMONIA N-13

**WARNER CHILCOTT**

\* WARNER CHILCOTT CO LLC  
 LO MINASTRIN FE, ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL  
 \* WARNER CHILCOTT INC  
 LOESTRIN 24 FE, ETHINYL ESTRADIOL  
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL

**WARNER CHILCOTT LLC**

\* WARNER CHILCOTT CO LLC  
 ACTONEL, RISEDRONATE SODIUM  
 ASACOL HD, MESALAMINE  
 ASACOL, MESALAMINE  
 ATELVIA, RISEDRONATE SODIUM  
 CHOLEDYL SA, OXTRIPHYLLINE  
 DELZICOL, MESALAMINE  
 ENABLEX, DARIFENACIN HYDROBROMIDE  
 ESTROSTEP FE, ETHINYL ESTRADIOL  
 FEMCON FE, ETHINYL ESTRADIOL  
 FEMHRT, ETHINYL ESTRADIOL  
 FEMTRACE, ESTRADIOL ACETATE  
 LO LOESTRIN FE, ETHINYL ESTRADIOL  
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL  
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL  
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL  
 MINASTRIN 24 FE, ETHINYL ESTRADIOL  
 OVCON-35, ETHINYL ESTRADIOL  
 SARAFEM, FLUOXETINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\*****WARNER CHILCOTT US**

\* WARNER CHILCOTT US LLC  
ESTRACE, ESTRADIOL

**WARNER IRELAND**

\* WARNER CHILCOTT IRELAND LTD  
FEMRING, ESTRADIOL ACETATE

**WATSON LABS**

\* WATSON LABORATORIES  
FOLIC ACID, FOLIC ACID  
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL  
MICROGESTIN 1/20, ETHINYL ESTRADIOL  
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL  
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL  
NORCO, ACETAMINOPHEN  
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

\* WATSON LABORATORIES INC  
ACARBOSE, ACARBOSE  
AFEDITAB CR, NIFEDIPINE  
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE  
ALBUTEROL SULFATE, ALBUTEROL SULFATE  
ALENDRONATE SODIUM, ALENDRONATE SODIUM  
ALLOPURINOL, ALLOPURINOL  
ALORA, ESTRADIOL  
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
AMOXAPINE, AMOXAPINE  
ATENOLOL AND CHLORTHALIDONE, ATENOLOL  
BACLOFEN, BACLOFEN  
BREVICON 28-DAY, ETHINYL ESTRADIOL  
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
CAPTOPRIL, CAPTOPRIL  
CARISOPRODOL, CARISOPRODOL  
CHLORZOXAZONE, CHLORZOXAZONE  
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE  
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
CLONAZEPAM, CLONAZEPAM  
COL-PROBENECID, COLCHICINE  
CRINONE, PROGESTERONE  
CYCLOSPORINE, CYCLOSPORINE  
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL  
DIAZEPAM, DIAZEPAM  
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE  
DILACOR XR, DILTIAZEM HYDROCHLORIDE  
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE  
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE  
ESTAZOLAM, ESTAZOLAM  
ESTRADIOL, ESTRADIOL  
ESTROPIPATE, ESTROPIPATE  
FENTANYL-100, FENTANYL  
FENTANYL-25, FENTANYL  
FENTANYL-50, FENTANYL  
FENTANYL-75, FENTANYL  
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
GELNIQUE, OXYBUTYNIN CHLORIDE  
GLIPIZIDE, GLIPIZIDE  
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE  
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN  
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE  
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE  
ISRADIPINE, ISRADIPINE  
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\***

\* WATSON LABORATORIES INC  
 LAMOTRIGINE, LAMOTRIGINE  
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 LEVONORGESTREL, LEVONORGESTREL  
 LEVONORGESTREL, LEVONORGESTREL (OTC)  
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL  
 LISINAPRIL, LISINAPRIL  
 LORAZEPAM, LORAZEPAM  
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE  
 MEPROBAMATE, MEPROBAMATE  
 METHOCARBAMOL, METHOCARBAMOL  
 METHYLDOPA, METHYLDOPA  
 METHYLPREDNISOLONE, METHYLPREDNISOLONE  
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
 METOPROLOL TARTRATE, METOPROLOL TARTRATE  
 METRONIDAZOLE, METRONIDAZOLE  
 MICROZIDE, HYDROCHLOROTHIAZIDE  
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE  
 MINOXIDIL, MINOXIDIL  
 MIRTAZAPINE, MIRTAZAPINE  
 NABUMETONE, NABUMETONE  
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE  
 NATEGLINIDE, NATEGLINIDE  
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE  
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)  
 NIZATIDINE, NIZATIDINE  
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL  
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL  
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL  
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL  
 NORINYL 1+50 28-DAY, MESTRANOL  
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE  
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL  
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE  
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN  
 OXYCODONE AND ASPIRIN, ASPIRIN  
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN  
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
 PREDNISOLONE, PREDNISOLONE  
 PREDNISON, PREDNISON  
 PRIMIDONE, PRIMIDONE  
 PROBENECID, PROBENECID  
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
 QUASENSE, ETHINYL ESTRADIOL  
 QUINIDINE SULFATE, QUINIDINE SULFATE  
 RAMIPRIL, RAMIPRIL  
 RAPAFLO, SILODOSIN  
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE  
 SIMVASTATIN, SIMVASTATIN  
 SULFASALAZINE, SULFASALAZINE  
 SULINDAC, SULINDAC  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TELMISARTAN, TELMISARTAN  
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE  
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE  
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE  
 TOPIRAMATE, TOPIRAMATE  
 TRANDOLAPRIL, TRANDOLAPRIL  
 TRELSTAR, TRIPTORELIN PAMOATE  
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL  
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE  
 TRIMETHOPRIM, TRIMETHOPRIM

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\***

- \* WATSON LABORATORIES INC
  - TRIVORA-28, ETHINYL ESTRADIOL
  - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
  - VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
  - ZOVIA 1/35E-28, ETHINYL ESTRADIOL
  - ZOVIA 1/50E-28, ETHINYL ESTRADIOL
- \* WATSON LABS INC
  - LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**WATSON LABS (UTAH)**

- \* WATSON LABORATORIES INC
  - INFED, IRON DEXTRAN
  - NOR-QD, NORETHINDRONE
  - OXYTROL, OXYBUTYNIN
  - PROGESTERONE, PROGESTERONE

**WATSON LABS FLORIDA**

- \* WATSON LABORATORIES INC FLORIDA
  - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**WATSON LABS INC**

- \* WATSON LABORATORIES INC
  - ALBUTEROL SULFATE, ALBUTEROL SULFATE
  - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
  - AMMONIUM LACTATE, AMMONIUM LACTATE
  - BUDESONIDE, BUDESONIDE
  - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  - CLONIDINE, CLONIDINE
  - CORDRAN, FLURANDRENOLIDE
  - CYCLOSPORINE, CYCLOSPORINE
  - DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
  - DICLOFENAC SODIUM, DICLOFENAC SODIUM
  - DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
  - DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
  - EMLA, LIDOCAINE
  - FIORICET W/ CODEINE, ACETAMINOPHEN
  - FIORINAL W/CODEINE, ASPIRIN
  - FIORINAL, ASPIRIN
  - GELNIQUE 3%, OXYBUTYNIN
  - IBANDRONATE SODIUM, IBANDRONATE SODIUM
  - INDOMETHACIN, INDOMETHACIN
  - IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  - IRBESARTAN, IRBESARTAN
  - KADIAN, MORPHINE SULFATE
  - LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
  - LEVOFLOXACIN, LEVOFLOXACIN
  - LEVONORGESTREL, LEVONORGESTREL
  - LEVONORGESTREL, LEVONORGESTREL (OTC)
  - LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
  - LIDOCAINE, LIDOCAINE
  - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  - METRONIDAZOLE, METRONIDAZOLE
  - PREGABALIN, PREGABALIN
  - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  - SILDENAFIL CITRATE, SILDENAFIL CITRATE
  - TRETINOIN, TRETINOIN
  - VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
  - VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  - VALSARTAN, VALSARTAN

**WATSON PHARMS**

- \* WATSON PHARMACEUTICALS
  - TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
  - TENUATE, DIETHYLPROPION HYDROCHLORIDE
- \* WATSON PHARMACEUTICALS INC
  - ACTIGALL, URSODIOL
  - CONDYLOX, PODOFILOX

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\*****WEST WARD PHARM CORP**

\* WEST WARD PHARMACEUTICAL CORP  
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

**WEST-WARD PHARM CORP**

\* WEST-WARD PHARMACEUTICAL CORP  
CEFOTETAN, CEFOTETAN DISODIUM

**WI MEDCL CYCLOTRON**

\* WISCONSIN MEDICAL CYCLOTRON LLC  
AMMONIA N 13, AMMONIA N-13  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**WILSHIRE PHARMS INC**

\* WILSHIRE PHARMACEUTICALS INC  
LAMOTRIGINE, LAMOTRIGINE

**WOCKHARDT**

\* WOCKHARDT AMERICAS INC  
CAPTOPRIL, CAPTOPRIL  
FAMOTIDINE, FAMOTIDINE  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

\* WOCKHARDT EU OPERATIONS (SWISS) AG  
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN  
ACETIC ACID, ACETIC ACID, GLACIAL  
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE  
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
AMOXICILLIN, AMOXICILLIN  
BROMFED-DM, BROMPHENIRAMINE MALEATE  
CARBAMAZEPINE, CARBAMAZEPINE  
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE  
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE  
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE  
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE  
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE  
CROMOLYN SODIUM, CROMOLYN SODIUM  
CYCLOSPORINE, CYCLOSPORINE  
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE  
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE  
ERYTHROMYCIN, ERYTHROMYCIN  
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE  
FLUTICASONONE PROPIONATE, FLUTICASONONE PROPIONATE  
FUROSEMIDE, FUROSEMIDE  
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE  
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE  
LEVETIRACETAM, LEVETIRACETAM  
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE  
LINDANE, LINDANE  
LITHIUM CITRATE, LITHIUM CITRATE  
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)  
LORATADINE, LORATADINE (OTC)  
MEGESTROL ACETATE, MEGESTROL ACETATE  
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE  
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE  
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)  
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)  
NYSTATIN, NYSTATIN  
OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE  
PHENYTOIN, PHENYTOIN  
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE  
PREDNISOLONE, PREDNISOLONE  
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE  
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE  
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE  
SELENIUM SULFIDE, SELENIUM SULFIDE  
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE  
VALPROIC ACID, VALPROIC ACID

\* WOCKHARDT LTD  
ADENOSINE, ADENOSINE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\*****\* WOCKHARDT LTD**

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
 AZITHROMYCIN, AZITHROMYCIN  
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE  
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE  
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM  
 CEFOTAXIME, CEFOTAXIME SODIUM  
 CEFPROZIL, CEFPROZIL  
 CEFTAZIDIME, CEFTAZIDIME  
 CEFTRIAXONE, CEFTRIAXONE SODIUM  
 CEFUROXIME AXETIL, CEFUROXIME AXETIL  
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)  
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE  
 CLARITHROMYCIN, CLARITHROMYCIN  
 DIVALPROEX SODIUM, DIVALPROEX SODIUM  
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
 FAMOTIDINE, FAMOTIDINE (OTC)  
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM  
 FUROSEMIDE, FUROSEMIDE  
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE  
 LEVETIRACETAM, LEVETIRACETAM  
 LEVOFLOXACIN, LEVOFLOXACIN  
 LISINAPRIL, LISINAPRIL  
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE  
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE  
 NIACIN, NIACIN  
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE  
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE  
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)  
 RISPERIDONE, RISPERIDONE  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE  
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE  
 TIMOLOL MALEATE, TIMOLOL MALEATE  
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE  
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE  
 ZONISAMIDE, ZONISAMIDE

**WOCKHARDT EU OPERATN**

**\* WOCKHARDT EU OPERATIONS SWISS AG**  
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN  
 DEXAMETHASONE, DEXAMETHASONE  
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**WOCKHARDT LTD**

**\* WOCKHARDT LTD**  
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE  
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
 ENTACAPONE, ENTACAPONE  
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)  
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)  
 LAMOTRIGINE, LAMOTRIGINE  
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)  
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE



**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* W \*\*****WOCKHARDT USA**

- \* WOCKHARDT USA INC  
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM  
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE  
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE  
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
- \* WOCKHARDT USA LLC  
ENALAPRIL MALEATE, ENALAPRIL MALEATE  
LANSOPRAZOLE, LANSOPRAZOLE  
TOPIRAMATE, TOPIRAMATE

**WRASER PHARMS**

- \* WRASER PHARMACEUTICALS LLC  
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

**WRASER PHARMS LLC**

- \* WRASER PHARMACEUTICALS LLC  
TREZIX, ACETAMINOPHEN

**WUSM CYCLOTRON**

- \* WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY  
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**WYETH PHARMS**

- \* WYETH PHARMACEUTICALS INC SUB PFIZER INC  
LO/OVRAL-28, ETHINYL ESTRADIOL

**WYETH PHARMS INC**

- \* WYETH PHARMACEUTICALS INC  
BOSULIF, BOSUTINIB MONOHYDRATE  
CORDARONE, AMIODARONE HYDROCHLORIDE  
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE  
INDERIDE-40/25, HYDROCHLOROTHIAZIDE  
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE  
PREMARIN, ESTROGENS, CONJUGATED  
PREMPHASE 14/14, ESTROGENS, CONJUGATED  
PREMPRO, ESTROGENS, CONJUGATED  
PRISTIQ, DESVENLAFAXINE SUCCINATE  
PROTONIX IV, PANTOPRAZOLE SODIUM  
PROTONIX, PANTOPRAZOLE SODIUM  
TRECATOR, ETHIONAMIDE  
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM  
ZOSYN, PIPERACILLIN SODIUM

**WYETH PHARMS PFIZER**

- \* WYETH PHARMACEUTICALS INC WHOLLY OWNED SUB PFIZER INC  
DUAVEE, BAZEDOXIFENE ACETATE

**\*\* X \*\*****X GEN PHARMS**

- \* X GEN PHARMACEUTICALS INC  
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM  
AMPHOTERICIN B, AMPHOTERICIN B  
BACIIM, BACITRACIN  
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM  
HYDRO-RX, HYDROCORTISONE  
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE  
LEVETIRACETAM, LEVETIRACETAM  
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM  
NEO-FRADIN, NEOMYCIN SULFATE  
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE  
NEOMYCIN SULFATE, NEOMYCIN SULFATE  
NYSTATIN, NYSTATIN  
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE  
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

**X-GEN PHARMS**

- \* X-GEN PHARMACEUTICALS INC  
PHENYTOIN SODIUM, PHENYTOIN SODIUM  
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* X \*\*****X-GEN PHARMS INC**

\* X-GEN PHARMACEUTICALS INC  
TRANEXAMIC ACID, TRANEXAMIC ACID

**XELLIA PHARMS APS**

\* XELLIA PHARMACEUTICALS APS  
BACITRACIN, BACITRACIN  
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE  
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

**XENOPORT INC**

\* XENOPORT INC  
HORIZANT, GABAPENTIN ENACARBIL

**XSPIRE**

\* XSPIRE LLC  
NALFON, FENOPROFEN CALCIUM

**XTTRIUM**

\* XTTRIUM LABORATORIES INC  
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE  
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

**\*\* Y \*\*****YUNG SHIN PHARM**

\* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD  
CEFACTOR, CEFACOLOR  
CEPHALEXIN, CEPHALEXIN

**\*\* Z \*\*****ZACH SYSTEMS**

\* ZACH SYSTEMS SPA  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE  
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE

**ZAMBON SPA**

\* ZAMBON SPA ITALY  
MONUROL, FOSFOMYCIN TROMETHAMINE

**ZOGENIX INC**

\* ZOGENIX INC  
ZOHYDRO ER, HYDROCODONE BITARTRATE

**ZYDUS HLTHCARE**

\* ZYDUS HEALTHCARE USA LLC  
LANSOPRAZOLE, LANSOPRAZOLE  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**ZYDUS PHARMS USA**

\* ZYDUS PHARMACEUTICALS USA INC  
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE  
ATENOLOL, ATENOLOL  
AZATHIOPRINE, AZATHIOPRINE  
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE  
BENZONATATE, BENZONATATE  
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE  
HALOPERIDOL, HALOPERIDOL  
LAMOTRIGINE, LAMOTRIGINE  
MELOXICAM, MELOXICAM  
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE  
NAPROXEN, NAPROXEN  
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE  
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM  
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE  
RAMIPRIL, RAMIPRIL  
RIBAVIRIN, RIBAVIRIN  
RISPERIDONE, RISPERIDONE  
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE  
SIMVASTATIN, SIMVASTATIN  
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
WARFARIN SODIUM, WARFARIN SODIUM  
ZONISAMIDE, ZONISAMIDE

**APPENDIX B - PRODUCT NAME SORTED BY APPLICANT****\*\* Z \*\*****ZYDUS PHARMS USA INC**

\* ZYDUS PHARMACEUTICALS USA INC  
ACETAZOLAMIDE, ACETAZOLAMIDE  
ACYCLOVIR, ACYCLOVIR  
ALPRAZOLAM, ALPRAZOLAM  
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE  
ANASTROZOLE, ANASTROZOLE  
BICALUTAMIDE, BICALUTAMIDE  
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE  
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE  
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE  
CARVEDILOL, CARVEDILOL  
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE  
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE  
DIPYRIDAMOLE, DIPYRIDAMOLE  
DIVALPROEX SODIUM, DIVALPROEX SODIUM  
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE  
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE  
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE  
ETHOSUXIMIDE, ETHOSUXIMIDE  
ETODOLAC, ETODOLAC  
ETOMIDATE, ETOMIDATE  
FINASTERIDE, FINASTERIDE  
GABAPENTIN, GABAPENTIN  
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE  
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE  
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE  
INDOMETHACIN, INDOMETHACIN  
IRBESARTAN, IRBESARTAN  
LAMOTRIGINE, LAMOTRIGINE  
LEVETIRACETAM, LEVETIRACETAM  
LEVOFLOXACIN, LEVOFLOXACIN  
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE  
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM  
OMEPRAZOLE, OMEPRAZOLE  
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE  
POTASSIUM CITRATE, POTASSIUM CITRATE  
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE  
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE  
RAMIPRIL, RAMIPRIL  
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE  
RISPERIDONE, RISPERIDONE  
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE  
SIROLIMUS, SIROLIMUS  
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE  
TELMISARTAN, TELMISARTAN  
TOPIRAMATE, TOPIRAMATE  
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN  
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE  
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE  
ZOLMITRIPTAN, ZOLMITRIPTAN

**APPENDIX C****UNIFORM TERMS*****DOSAGE FORMS***

AEROSOL	OIL
AEROSOL, FOAM	OIL/DROPS
AEROSOL, METERED	OINTMENT
CAPSULE	OINTMENT, AUGMENTED
CAPSULE, DELAYED REL PELLETS	PASTE
CAPSULE, DELAYED RELEASE	PATCH
CAPSULE, EXTENDED RELEASE	PELLET
CLOTH	POWDER
CONCENTRATE	POWDER, EXTENDED RELEASE
CREAM	POWDER, METERED
CREAM, AUGMENTED	RING
ELIXIR	SHAMPOO
EMULSION	SOLUTION
ENEMA	SOLUTION FOR SLUSH
FILM	SOLUTION, GEL FORMING/DROPS
FILM, EXTENDED RELEASE	SOLUTION, METERED
FOR SOLUTION	SOLUTION/DROPS
FOR SUSPENSION	SPONGE
FOR SUSPENSION, DELAYED RELEASE	SPRAY
FOR SUSPENSION, EXTENDED RELEASE	SPRAY, METERED
GAS	SUPPOSITORY
GEL	SUSPENSION
GEL, AUGMENTED	SUSPENSION, EXTENDED RELEASE
GEL, METERED	SUSPENSION/DROPS
GRANULE	SWAB
GRANULE, DELAYED RELEASE	SYRUP
GUM, CHEWING	SYSTEM
IMPLANT	SYSTEM, EXTENDED RELEASE
INHALANT	TABLET
INJECTABLE	TABLET, CHEWABLE
INJECTABLE, LIPID COMPLEX	TABLET, COATED PARTICLES
INJECTABLE, LIPOSOMAL	TABLET, DELAYED RELEASE
INSERT	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING
INSERT, EXTENDED RELEASE	TABLET, EFFERVESCENT
INTRAUTERINE DEVICE	TABLET, EXTENDED RELEASE
JELLY	TABLET, FOR SUSPENSION
LIQUID	TABLET, ORALLY DISINTEGRATING
LOTION	TAPE
LOTION, AUGMENTED	TROCHE/LOZENGE
LOTION/SHAMPOO	

Note: Terms comprise currently marketed products

**APPENDIX C****UNIFORM TERMS*****ROUTES OF ADMINISTRATION***

BUCCAL	IRRIGATION
DENTAL	IV (INFUSION)
ENDOCERVICAL	N/A
FOR RX COMPOUNDING	NASAL
IMPLANTATION	OPHTHALMIC
INHALATION	ORAL
INJECTION	ORAL-21
INTRA-ANAL	ORAL-28
INTRACRANIAL	OTIC
INTRADERMAL	PERFUSION, CARDIAC
INTRAMUSCULAR	PERIODONTAL
INTRAOCULAR	RECTAL
INTRAPERITONEAL	SPINAL
INTRAPLEURAL	SUBCUTANEOUS
INTRATHECAL	SUBLINGUAL
INTRATRACHEAL	TOPICAL
INTRAUTERINE	TRANSDERMAL
INTRAVENOUS	TRANSMUCOSAL
INTRAVESICAL	URETHRAL
INTRAVITREAL	VAGINAL
IONTOPHORESIS	

Note: Terms comprise currently marketed products

**APPENDIX****UNIFORM TERMS****ABBREVIATIONS**

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
MCI	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SC	SUBCUTANEOUS
SQ CM	SQUARE CENTIMETER
U	UNITS
UCI	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

## PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the Act, those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the Act, and those drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the Act are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name followed by the trade name. Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the Act. It does not prevent the submission or approval of a second 505(b)(1) application except in the case of Orphan Drug exclusivity. Applications qualifying for periods of exclusivity are:

- (1) A new drug application approved after September 24, 1984, for a drug product (including an ester or salt of the active ingredient) of which has never been approved in any other new drug application under Section 505 (b) of the Act. No subsequent ANDA or application described in Section 505(b)(2) of the Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.
- (2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new application or 505(b)(2) application for the drug product with indications or use, this does not preclude the approval of an ANDA or 505(b)(2) application not covered by the exclusivity.
- (3) A supplement to a new drug application for a drug containing a previously approved active ingredient including (any ester or salt of the active ingredient) approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or

sponsored by the applicant. The approval of a subsequent ANDA or 505(b)(2) application for a change approved in the supplement may not be *made effective for three years* from the date of approval of the original supplement.

The Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using FDA Form 3524a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the agency within 30 days of approval on FDA Form 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement". Patent information on unapproved applications or on patents beyond the scope of the Act (i.e., process or manufacturing patents) will not be published. FDA form 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents which include formulation/composition patents; use patents for a particular approved indication or method of using the product; and certain other patents as detailed on FDA Form 3542. This information, as provided by the sponsor on FDA form 3542, will be published as described above.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under section 4(b)(1) of the Q1 Act. A guidance for industry on this subject is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048345.pdf>

Upon approval, patent numbers and expiration dates, in addition to certain other information on appropriate patents claiming drug products that are the subject of approved applications, will be published daily in the [Electronic Orange Book Query](#). The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Electronic Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001	6294540	May 14, 2018	DS DP U-65			
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001	6294540 6641843	May 14, 2018 Feb 04, 2019	DS DP U-65 DP			
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	5905082 5905082*PED 6294540 6294540*PED 6417191 8129385	May 18, 2016 Nov 18, 2016 May 14, 2018 Nov 14, 2018 Mar 28, 2016 Oct 05, 2027	DS DP  DS DP U-1572  DP U-1572 DS DP		NCE	Aug 12, 2018
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	5905082 6294540 6417191	May 18, 2016 May 14, 2018 Mar 28, 2016	DS DP DS DP U-257 DP U-257			
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR</u>						
N 021205 001	5905082 6294540 6417191	May 18, 2016 May 14, 2018 Mar 28, 2016	DS DP U-248 DS DP U-65 DP U-248			
<u>ABARELIX - PLENAXIS</u>						
N 021320 001	5843901 5968895 6180608 6423686 6455499 6699833	Dec 01, 2015 Dec 11, 2016 Dec 11, 2016 Jun 07, 2015 Jun 07, 2015 Dec 11, 2016	DS DP DP DP U-549 DS U-549 DP			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	5604213 5604213 8822438 8822438	Dec 13, 2016 Dec 13, 2016 Aug 24, 2027 Aug 24, 2027	DS DP U-1126 DS DP U-1314 U-1579 U-1580		I-663 NCE	Dec 10, 2015 Apr 28, 2016
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222 6992218	Aug 05, 2017 Jun 06, 2021	DP DP			
<u>ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE)</u>						
N 020802 001	5972916	Jul 14, 2017	U-296			
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	6488962 7976870 8372432 8377453 8394408 8597681 8658631 8668929 8741885	Jun 20, 2020 Jun 01, 2027 Mar 11, 2029 Nov 19, 2029 Mar 11, 2029 Dec 21, 2030 May 16, 2032 Mar 11, 2029 May 16, 2032	DP U-1498 DP U-1499 DP U-1499 DP DP U-1499 DP U-1499		NP	Mar 11, 2017
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8148356 8399445 8653061 8722738	May 21, 2026 Aug 24, 2025 Aug 24, 2025 Apr 06, 2032	DP U-1373 U-1373 U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	5840279 6071498 6681768 6750226 7078412 8051851	Jun 21, 2016 Jun 21, 2016 Aug 07, 2022 Sep 05, 2020 Jul 16, 2020 Apr 22, 2027	DP DP DP DS DP U-1264 DS DP U-1263 DP		NCE	Jul 23, 2017

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001	8592434	Jun 16, 2030	DP U-1460		NP	Apr 12, 2016
	8747896	Jun 03, 2027	DP U-1460			
	8791127	Mar 23, 2027	DP U-1460			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
	6514980	Jan 24, 2019	DP U-1484			
	7223387	May 13, 2023	DP U-1006			
	7223387	May 13, 2023	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
<u>ADAPALENE - ADAPALENE</u>						
A 200298 001					PC	Oct 25, 2014
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	7579377	Feb 23, 2025	U-818			
	7737181	Aug 29, 2024	DP			
	7834060	Mar 12, 2023	U-1078			
	7838558	Mar 12, 2023	DP			
	7868044	Mar 12, 2023	U-1078			
	8703820	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	7998467	May 31, 2028	DP U-1078			
	8435502	Sep 15, 2026	DP U-1078			
	8709392	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	7820186	Nov 23, 2025	DP		NPP	Feb 01, 2016
	7964202	Sep 01, 2024	DP U-1078			
	8071644	Jul 18, 2027	DP U-1078			
	8080537	Jul 18, 2027	U-1078			
	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
	8241649	Dec 23, 2022	DP			
	8445543	Jul 12, 2027	U-1078			
	8809305	Dec 23, 2022	U-1078			
<u>ADEFOVIR DIPIVOXIL - HEPSERA</u>						
N 021449 001	5663159	Sep 02, 2014	DS DP			
	6451340	Jul 23, 2018	DS DP U-470			
<u>ADENOSINE - ADENOSCAN</u>						
N 020059 001	5731296	Mar 24, 2015	U-221			
<u>ADENOSINE - ADENOSCAN</u>						
N 020059 002	5731296	Mar 24, 2015	U-221			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N 020760 001	5763454	Jun 15, 2015	U-282			
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N 020760 002	5763454	Jun 15, 2015	U-282			
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899 001	6723303	Apr 20, 2021	DP		M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROVENTIL-HFA</u>						
N 020503 001	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N 020949 001	6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - ACCUNEB</u>						
N 020949 002	6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6558651	Dec 19, 2016	DP	U-716		
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021	U-716			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	6446627	Dec 18, 2017	DP			
	7105152	Sep 12, 2023	DP			
	7566445	Jun 04, 2017	DP			
	8132712	Sep 07, 2028	DP			
	8834849	Jun 04, 2017	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT</u>						
N 020291 001	5603918	Jun 09, 2015				
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB</u>						
N 020950 001	6632842	Dec 28, 2021	U-532			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	5662271	Sep 02, 2014	DP		NP	Oct 07, 2014
	5964416	Oct 04, 2016	DP			
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	5468743	Apr 20, 2016	DS DP		NCE	Jul 28, 2015
	8664215	Oct 05, 2029		U-1493		
<u>ALCOHOL; CHLORHEXIDINE GLUCONATE - AVAGARD</u>						
N 021074 001	5897031	Jun 21, 2016				
	6090395	Jun 22, 2015	DP			
	6534069	Jun 22, 2015	DP			
	6623744	Jun 23, 2015		U-1008		
	7081246	Aug 03, 2016	DP			
	7566460	Jun 22, 2015	DP	U-1008		
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N 021575 001	5994329	Jul 17, 2018			Y	
	6015801	Jul 17, 2018			Y	
	6225294	Jul 17, 2018			Y	
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N 021762 001	5994329	Jul 17, 2018		U-647	Y	
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>						
N 021287 001	6149940	Aug 22, 2017				
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 001	5559111	Jul 21, 2018	DS DP	U-3		
	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 002	5559111	Jul 21, 2018	DS DP	U-3		
	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	5559111	Jul 21, 2018	DS DP	U-3		
	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	5559111	Jul 21, 2018	DS DP	U-3		
	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	5559111	Jul 21, 2018	DS DP	U-3		
	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	5559111	Jul 21, 2018	DS DP	U-3		
	8613949	Dec 21, 2029	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 001	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 002	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 003	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 004	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 001	5559111	Jul 21, 2018	DS DP U-3			
	8168616	Jul 03, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 002	5559111	Jul 21, 2018	DS DP U-3			
	8168616	Jul 03, 2026	DP			
<u>ALITRETINOIN - PANRETIN</u>						
N 020886 001	5932622	Aug 03, 2016				U-562
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N 021001 001	5565447	May 07, 2015	DS DP U-969			
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N 021001 002	5565447	May 07, 2015	DS DP U-969			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	6150383	Jun 19, 2016		U-1330		
	6211205	Jun 19, 2016		U-1331	NCE	Jan 25, 2018
	6303640	Aug 09, 2016		U-1332		
	6303661	Apr 24, 2017		U-1333		
	6329404	Jun 19, 2016	DP	U-1334		
	6890898	Feb 02, 2019		U-1335		
	7078381	Feb 02, 2019		U-1335		
	7459428	Feb 02, 2019		U-1336		
	7807689	Jun 27, 2028	DS DP	U-1337		
	8173663	Mar 15, 2025		U-1338		
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	6150383	Jun 19, 2016		U-1330		
	6211205	Jun 19, 2016		U-1331	NCE	Jan 25, 2018
	6303640	Aug 09, 2016		U-1332		
	6303661	Apr 24, 2017		U-1333		
	6329404	Jun 19, 2016	DP	U-1334		
	6890898	Feb 02, 2019		U-1335		
	7078381	Feb 02, 2019		U-1335		
	7459428	Feb 02, 2019		U-1336		
	7807689	Jun 27, 2028	DS DP	U-1337		
	8173663	Mar 15, 2025		U-1338		
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6150383	Jun 19, 2016		U-1330		
	6211205	Jun 19, 2016		U-1331	NCE	Jan 25, 2018
	6303640	Aug 09, 2016		U-1332		
	6303661	Apr 24, 2017		U-1333		
	6329404	Jun 19, 2016	DP	U-1334		
	6890898	Feb 02, 2019		U-1335		
	7078381	Feb 02, 2019		U-1335		
	7459428	Feb 02, 2019		U-1336		
	7807689	Jun 27, 2028	DS DP	U-1337		
	8173663	Mar 15, 2025		U-1338		
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8900638	May 24, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8900638	May 24, 2029	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N 021107 001	6284770	Oct 05, 2018	U-405			
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N 021107 002	6284770	Oct 05, 2018	U-405			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 003	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 004	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 001	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 002	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 003	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 004	5741523	Apr 21, 2015				
<u>ALPROSTADIL - MUSE</u>						
N 020700 001	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N 020700 002	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N 020700 003	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N 020700 004	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N 021212 001	5716338	Feb 10, 2015	DP			
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N 021212 002	5716338	Feb 10, 2015	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	5250542	Mar 29, 2016	DS DP U-878		M-128	Oct 18, 2016
	6469030	Nov 29, 2020	U-879			
	8112290	Jul 31, 2030	U-1443			
	8645160	Jun 18, 2029	U-1485			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	5703017	Dec 30, 2014	DS			
	5840722	Nov 24, 2015		U-821		
	5840722	Nov 24, 2015		U-1297		
	7109205	Oct 07, 2015	DS DP			
	7601730	Oct 07, 2015		U-1080		
	8349843	Oct 07, 2015	DS DP			
	RE42462	Jul 29, 2018	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	5703017	Dec 30, 2014	DS			
	5840722	Nov 24, 2015		U-821		
	5840722	Nov 24, 2015		U-1297		
	7109205	Oct 07, 2015	DS DP			
	7601730	Oct 07, 2015		U-1080		
	8349843	Oct 07, 2015	DS DP			
	RE42462	Jul 29, 2018	DS			
<u>AMIFOSTINE - ETHYOL</u>						
N 020221 001	5994409	Dec 08, 2017		U-305		
<u>AMIFOSTINE - ETHYOL</u>						
N 020221 002	5994409	Dec 08, 2017		U-305		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	5954703	Oct 31, 2017				U-289
	6709446	May 01, 2018				U-289
	7723910	Jun 17, 2019				U-289
	8216289	May 01, 2018				U-289
	8758418	May 01, 2018				U-289
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 001	6869939	May 04, 2022				DP
	7635773	Mar 13, 2029				DP
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 002	6869939	May 04, 2022				DP
	7635773	Mar 13, 2029				DP
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 003	6869939	May 04, 2022				DP
	7635773	Mar 13, 2029				DP
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026 001	6828339	Nov 20, 2022				DS
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026 002	6828339	Nov 20, 2022				DS
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026 003	6828339	Nov 20, 2022				DS

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 001	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 002	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 003	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 004	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 005	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 006	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 007	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 008	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 009	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 010	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 011	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 002	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 003	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 004	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 005	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 006	6162802	Dec 19, 2017	DS DP U-185			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 007	6162802	Dec 19, 2017	DS DP U-185			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175	001	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175	002	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175	003	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175	004	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175	005	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	001	6294197	Jun 18, 2017	DP U-3		
		8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	002	6294197	Jun 18, 2017	DP U-3		
		8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	003	6294197	Jun 18, 2017	DP U-3		
		8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	004	6294197	Jun 18, 2017	DP U-3		
		8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	005	6294197	Jun 18, 2017	DP U-3		
		8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100	001	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100	002	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100	003	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100	004	5616599	Apr 25, 2016	DS DP U-3		
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011	001				PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011	002				PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011	004				PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090144	001				PC	Mar 29, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 002	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 003	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 004	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 005	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 001					PC	May 30, 2015
					PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 002					PC	May 30, 2015
					PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 003					PC	May 30, 2015
					PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 004					PC	May 30, 2015
					PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 005					PC	May 30, 2015
					PC	May 30, 2015
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	6544555	Oct 13, 2020	DS DP U-897			
	6669948	Oct 13, 2020	DS DP U-897			
	6723341	Oct 13, 2020	DS DP U-897			
	8299052	May 07, 2027	U-1304			
	8357394	Dec 08, 2026	DP			
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N 050785 001	6746692	Apr 04, 2020	DP			
	6783773	Apr 04, 2020	DP			
	6878386	Apr 04, 2020	U-926			
	7217430	Apr 04, 2020	DP U-926			
	7250176	Apr 04, 2020	U-926			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N 011522 007	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N 011522 008	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N 011522 009	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N 011522 010	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N 011522 011	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N 011522 012	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N 011522 013	6384020	Jul 06, 2020				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N 021303 001	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N 021303 002	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N 021303 003	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N 021303 004	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N 021303 005	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N 021303 006	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHOTERICIN B - ABELCET</u>						
N 050724 001	6406713	Jun 18, 2019	DS			
<u>AMPHOTERICIN B - AMBISOME</u>						
N 050740 001	5874104	Feb 23, 2016		DP	U-922	
	5965156	Oct 12, 2016		DP	U-922	
<u>AMPRENAVIR - AGENERASE</u>						
N 021007 001	5646180	Jul 08, 2014			U-257	
	5723490	Mar 03, 2015			U-257	
	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N 021007 002	5646180	Jul 08, 2014			U-257	
	5723490	Mar 03, 2015			U-257	
	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N 021039 001	5646180	Jul 08, 2014			U-257	
	5723490	Mar 03, 2015			U-257	
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 001	5965525	Feb 17, 2020	DS	DP	U-540	
	6960564	Apr 12, 2021		DP	U-540	
	7709444	Apr 12, 2021		DP	U-540	
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 002	5965525	Feb 17, 2020	DS	DP	U-540	
	6960564	Apr 12, 2021		DP	U-540	
	7709444	Apr 12, 2021		DP	U-540	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1301		I-681	Mar 03, 2017
	6413980	Dec 22, 2019	DS DP U-1302		I-690	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1501		I-691	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1167		NCE	Dec 28, 2017
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1200		I-690	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1323		I-691	Aug 21, 2017
					NCE	Dec 28, 2017
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
<u>APREPITANT - EMEND</u>						
N 021549 001	5719147	Apr 17, 2015	DS DP U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N 021549 002	5719147	Apr 17, 2015	DS DP U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N 021549 003	5719147	Apr 17, 2015	DS DP U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912 001	6040344	Nov 12, 2016	DS			
	6472563	Nov 09, 2021	DS			
	6667344	Jun 22, 2021	DP			
	6720453	Nov 09, 2021	DS			
	6814953	Jun 22, 2021		U-793		
	7145036	Nov 09, 2021	DS			
	7348362	Jun 22, 2021	DP	U-793		
	7462645	Jun 22, 2021		U-793		
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021		U-793		
	7541385	Jun 22, 2021		U-793		
	8110706	Nov 09, 2021	DP			
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N 022434 001	7589106	Sep 26, 2027	DP	U-1163		
	7687516	Sep 26, 2027	DP	U-1164		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 001	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022		U-839	M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 002	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022		U-839	M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 003	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022		U-839	M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022		U-839	M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022		U-839	M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022	U-839		M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-761		M-137	Jun 09, 2017
	6977257	Apr 24, 2022	DS DP			
	7053092	Jan 28, 2022	U-839			
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 002	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022	U-839		M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	<u>ARIPIRAZOLE - ABILIFY</u>					
N 021729 003	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022	U-839		M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 004	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022	U-839		M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 005	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022		U-839	M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-763		I-700	Dec 12, 2017
	7115587	Jul 21, 2024	DS DP U-764		M-137	Jun 09, 2017
	7550445	Jul 21, 2024	DP			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Apr 20, 2015	DS DP U-543		M-150	Dec 05, 2017
	7807680	Oct 19, 2024	DP		NDF	Feb 28, 2016
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Apr 20, 2015	DS DP U-543		M-150	Dec 05, 2017
	7807680	Oct 19, 2024	DP		NDF	Feb 28, 2016
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Apr 20, 2015	DS DP U-1530		M-150	Dec 05, 2017
	7807680	Oct 19, 2024	DP		NDF	Feb 28, 2016
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Apr 20, 2015	DS DP U-1530		M-150	Dec 05, 2017
	7807680	Oct 19, 2024	DP		NDF	Feb 28, 2016
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 001	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 002	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 003	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 004	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 005	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018		U-573		
	6855339	Nov 10, 2018		U-617		
	6861076	Nov 10, 2018		U-617		
	6884439	Nov 10, 2018		U-651		
	6982096	Nov 10, 2018		U-651		
	8273379	Nov 10, 2018		U-1291		
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>						
N 022268 001	5677331	Oct 14, 2014	DP U-977		ODE	Apr 07, 2016
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N 021881 001	7169381	Sep 01, 2024	DS DP			
	7658914	Sep 01, 2024	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020		DP U-326	NCE	Aug 13, 2014
	7741358	Apr 06, 2026	DS DP U-1064			
	8022228	Apr 06, 2026	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020		DP U-326	NCE	Aug 13, 2014
	7741358	Apr 06, 2026	DS DP U-1064			
	8022228	Apr 06, 2026	DS DP			
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	8865187	Mar 23, 2022	DP			
<u>ASPIRIN; DIPYRIDAMOLE - AGGRENOL</u>						
N 020884 001	6015577	Jan 18, 2017		U-302		
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	6087383	Dec 21, 2018	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 001	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 002	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 003	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 004	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 005	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 006	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 007	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 008	5658590	Nov 26, 2016	U-494			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 001	5686104 5969156	Nov 11, 2014 Jul 08, 2016	DP U-213 DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 002	5686104 5969156	Nov 11, 2014 Jul 08, 2016	DP U-213 DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 003	5686104 5969156	Nov 11, 2014 Jul 08, 2016	DP U-213 DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 004	5686104 5969156	Nov 11, 2014 Jul 08, 2016	DP U-213 DS			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5686104 5686104*PED 5969156 5969156*PED RE42461 RE42461*PED	Nov 11, 2014 May 11, 2015 Jul 08, 2016 Jan 08, 2017 Oct 25, 2016 Apr 25, 2017	DP U-1400 DS DS DP U-1400		NC	May 03, 2016
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5686104 5686104*PED 5969156 5969156*PED RE42461 RE42461*PED	Nov 11, 2014 May 11, 2015 Jul 08, 2016 Jan 08, 2017 Oct 25, 2016 Apr 25, 2017	DP U-1400 DS DS DP U-1400		NC	May 03, 2016
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5686104 5686104*PED 5969156 5969156*PED RE42461 RE42461*PED	Nov 11, 2014 May 11, 2015 Jul 08, 2016 Jan 08, 2017 Oct 25, 2016 Apr 25, 2017	DP U-1400 DS DS DP U-1400		NC	May 03, 2016
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5686104 5686104*PED 5969156 5969156*PED RE42461 RE42461*PED	Nov 11, 2014 May 11, 2015 Jul 08, 2016 Jan 08, 2017 Oct 25, 2016 Apr 25, 2017	DP U-1400 DS DS DP U-1400		NC	May 03, 2016
<u>ATOVAQUONE - MEPRON</u>						
N 020500 001	6649659	Jul 10, 2016	DS DP U-69			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935 7501409	Sep 13, 2020 May 05, 2023	DS DP U-155 DP		D-140 NCE	Sep 17, 2017 Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935 7501409	Sep 13, 2020 May 05, 2023	DS DP U-155 DP		D-140 NCE	Sep 17, 2017 Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935 7501409	Sep 13, 2020 May 05, 2023	DS DP U-155 DP		D-140 NCE	Sep 17, 2017 Apr 27, 2017
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524 7141581 8791140	Jun 30, 2020 Jun 30, 2020 Aug 05, 2030	DS DP  DS	 U-1220	 NCE	 Jan 27, 2017
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524 7141581 8791140	Jun 30, 2020 Jun 30, 2020 Aug 05, 2030	DS DP  DS	 U-1220	 NCE	 Jan 27, 2017
<u>AZELAIC ACID - FINACEA</u>						
N 021470 001	6534070	Nov 18, 2018				
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001	8071073 8518919	Jun 04, 2028 Nov 22, 2025	DP  U-1430		M-129 NPP	Aug 30, 2016 Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022371 001	8071073 8518919	Jun 04, 2028 Nov 22, 2025	DP  U-1430			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723 8163723 8163723 8163723 8168620	Aug 29, 2023 Aug 29, 2023 Aug 29, 2023 Aug 29, 2023 Feb 24, 2026	    DP	U-77 U-81 U-644 U-707	NC	May 01, 2015
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	7157584 7572920	May 22, 2025 Jan 07, 2025	DS  DP U-3		NCE	Feb 25, 2016
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	7157584 7572920	May 22, 2025 Jan 07, 2025	DS  DP U-3		NCE	Feb 25, 2016
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	7157584 7572920	May 22, 2025 Jan 07, 2025	DS  DP U-3		NC NCE	Dec 20, 2014 Feb 25, 2016
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	7157584 7572920	May 22, 2025 Jan 07, 2025	DS  DP U-3		NC NCE	Dec 20, 2014 Feb 25, 2016
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050693 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710 002	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050711 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050730 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050733 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050784 001	6268489	Jul 31, 2018	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZITHROMYCIN - ZMAX</u>						
N 050797 001	6068859	May 30, 2017	DP			
	6268489	Jul 31, 2018	DS			
	6984403	Feb 14, 2024	DP U-282			
	7887844	Feb 14, 2024	DP			
<u>AZITHROMYCIN - AZASITE</u>						
N 050810 001	6159458	Nov 04, 2017	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
<u>AZTREONAM - CAYSTON</u>						
N 050814 001	7208141	Dec 20, 2021	DP U-1031		ODE	Feb 22, 2017
	7214364	Dec 20, 2021	DP			
	7427633	Dec 20, 2021	DP U-1031			
	8399496	Dec 20, 2021	DP U-1377			
<u>BACLOFEN - KEMSTRO</u>						
N 021589 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BACLOFEN - KEMSTRO</u>						
N 021589 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N 020610 001	7452872	Aug 24, 2026	U-141			
	7625884	Aug 24, 2026	U-141			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
	8497256	Jun 23, 2031	U-1229			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2017	DS DP U-594		NP	Oct 03, 2016
	6479535	May 06, 2019	DP U-594			
	6479535	May 06, 2019	DP U-904			
	7138392	Apr 04, 2017	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-904			
	8815934	May 06, 2019	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	5683677	Nov 04, 2014	DP		NP	Mar 23, 2015
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 002	5776432	Jul 07, 2015	DP		NP	Mar 23, 2015
	7780038	Jan 24, 2027	DP		NS	Dec 17, 2017
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Oct 02, 2024	DS DP U-1321		NCE	Dec 28, 2017
	8546428	Mar 19, 2029	DS DP U-1321		ODE	Dec 28, 2019
<u>BELINOSTAT - BELEODAQ</u>						
N 206256 001	6888027	Sep 27, 2021	DS DP U-1544		NCE	Jul 03, 2019
	8835501	Oct 27, 2027	DP		ODE	Jul 03, 2021



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP		ODE	Mar 20, 2015
	8436190*PED	Apr 26, 2031			ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS DP U-1402		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP		ODE	Mar 20, 2015
	8436190*PED	Apr 26, 2031			ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS DP U-1402		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	8344006	Sep 23, 2029	DP U-1402		ODE	Mar 20, 2015
	8344006*PED	Mar 23, 2030			ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	8344006	Sep 23, 2029	DP U-1402		ODE	Mar 20, 2015
	8344006*PED	Mar 23, 2030			ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	5733886	Mar 31, 2015	DP U-124			
	5733886	Mar 31, 2015	DP			
	8288434	Aug 05, 2029	DP U-124			
	8663699	Jun 03, 2029	U-124			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	5733886	Mar 31, 2015	DP			
	8288434	Aug 05, 2029	DP U-124			
	8288434	Aug 05, 2029	DP U-134			
	8288434	Aug 05, 2029	DP U-818			
	8288434	Aug 05, 2029	DP U-916			
	8288434	Aug 05, 2029	DP U-921			
	8288434	Aug 05, 2029	DP U-1033			
<u>BENZYL ALCOHOL - ULESFIA</u>						
N 022129 001	5858383	Aug 11, 2017	U-970			
	6139859	Aug 11, 2017	U-970			
	6793931	Jul 11, 2022	DP U-970			
	7294342	May 19, 2024	U-970			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP		NCE	Sep 08, 2014
	8784789	Sep 05, 2024	DP			
	8877168	Jul 30, 2023	DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	5447926	Apr 13, 2016	DS DP U-80			
	6685958	Jun 29, 2021	DP U-80			
	6699492	Mar 31, 2019	DP U-80			
	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
	8604020	Mar 12, 2030	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE</u>						
A 201615 001					PC	Sep 27, 2014
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 021852 001	5763426	Jun 09, 2015	DS DP		NPP	Dec 23, 2017
	6753013	Jan 27, 2020	DP U-88			
	6753013	Jan 27, 2020	DP U-193			
	RE39706	Jun 09, 2015	DS DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-88		I-659	Oct 17, 2015
	6753013	Jan 27, 2020	DP U-193		NPP	Aug 29, 2017
	6787529	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-193			
	RE39706	Jun 09, 2015	DS DP			
<u>BETAMETHASONE VALERATE - LUXIO</u>						
N 020934 001	6126920	Mar 01, 2016		U-484		
	7078058	May 24, 2017	DP			
<u>BEXAROTENE - TARGRETIN</u>						
N 021055 001	5780676	Jul 14, 2015		U-509		
	5962731	Oct 05, 2016		U-475		
<u>BEXAROTENE - TARGRETIN</u>						
N 021056 001	5780676	Jul 14, 2015		U-510		
	5962731	Oct 05, 2016				
<u>BIMATOPROST - LUMIGAN</u>						
N 021275 001	5688819	Aug 19, 2014		U-446		
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	5688819	Aug 19, 2014		U-1081		
	7851504	Jun 13, 2027	DS DP			
	8278353	Mar 16, 2025	DP			
	8299118	Mar 16, 2025		U-1295		
	8309605	Mar 16, 2025		U-1293		
	8309605	Mar 16, 2025		U-1294		
	8338479	Mar 16, 2025	DP	U-1295		
	8524777	Mar 16, 2025		U-1235		
	8586630	Mar 16, 2025		U-1458		
	8772338	Mar 16, 2025	DP	U-1528		
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024		U-939	M-140	Sep 04, 2017
	7388029	Jan 21, 2022		U-938		
	8038988	Aug 25, 2023	DS DP	U-1208		
	8101161	May 25, 2024		U-1217		
	8101161	May 25, 2024		U-1218		
	8263054	Jan 15, 2023		U-1277		
	8541466	Jan 21, 2022		U-1217		
	8632760	Jan 15, 2023		U-1487		
	8758733	Jan 15, 2023		U-1487		
	8906962	Jan 31, 2021		U-1217		
	8926953	Jan 15, 2023		U-1217		
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N 021551 003	7291324	Oct 22, 2022		U-837		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
N 050786 001	6350468	Dec 14, 2018	U-932			
	6350468	Dec 14, 2018	U-956			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N 020873 001	5196404	Dec 15, 2014	DS DP U-1040			
	5196404	Dec 15, 2014	DS DP U-1232			
	7582727	Jul 27, 2028	DP			
	7598343	Jul 27, 2028	DP			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	7772178	Nov 11, 2027	DP U-1128		M-126	Feb 27, 2016
	8119602	Mar 17, 2027	U-1233		NCE	May 13, 2016
	RE43298	Feb 22, 2022	DS DP U-1128		NPP	Feb 13, 2016
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	6083903	Oct 28, 2014	DP U-515		D-142	Oct 08, 2017
	6297217	Oct 28, 2014	U-515		I-695	Oct 08, 2017
	6297217	Oct 28, 2014	U-884		M-139	Aug 08, 2017
	6297217	Oct 28, 2014	U-885		NR	Jan 23, 2015
	6617317	Oct 28, 2014	DS DP		ODE	Jun 20, 2015
	6713446	Jan 25, 2022	DS DP		ODE	Oct 08, 2021
	6747150	Oct 28, 2014	DP			
	6958319	Jan 25, 2022	DS DP			
	7119080	Oct 28, 2014	DP			
<u>BOSENTAN - TRACLEER</u>						
N 021290 001	5292740	Nov 20, 2015				
<u>BOSENTAN - TRACLEER</u>						
N 021290 002	5292740	Nov 20, 2015				
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	6562873	Jul 10, 2021				
	6627210	Jul 18, 2021	DP			
	6641834	Jul 28, 2021	DP			
	6673337	Jul 26, 2021	DP			
<u>BRIMONIDINE TARTRATE - OOLIANA</u>						
N 021764 001	7265117	Aug 19, 2025	DP			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	6562873	Jul 10, 2021	DP			
	6627210	Jul 18, 2021	DP			
	6641834	Jul 28, 2021	DP			
	6673337	Jul 26, 2021	DP			
	8858961	Sep 02, 2023	DP			
	8858961*PED	Mar 02, 2024				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	7439241	Aug 25, 2025	U-1428		NDF	Aug 23, 2016
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
	8859551	May 25, 2024	U-1428			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	6316441	Dec 07, 2019	U-778		NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	7030149	Apr 19, 2022	U-849			
	7320976	Apr 19, 2022	U-849			
	7323463	Jan 19, 2023	DP	Y		
	7642258	Apr 19, 2022	DS DP U-1024			
	8133890	Apr 19, 2022	U-1235			
	8354409	Apr 19, 2022	DP U-1371			
	8748425	Apr 19, 2022	DP U-1524			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-810			
	8927606	Jan 16, 2024	U-1095			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	5679685	Oct 21, 2014	DP			
	5716957	Feb 10, 2015	U-976			
	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - RHINOCORT</u>						
N 020746 001	6291445	Apr 29, 2017		Y		
	6686346	Apr 29, 2017	DP U-557	Y		
	6986904	Apr 29, 2017	DP U-699	Y		
<u>BUDESONIDE - RHINOCORT</u>						
N 020746 002	6291445	Apr 29, 2017				
	6686346	Apr 29, 2017	DP U-557			
	6986904	Apr 29, 2017	DP U-699			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 001	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 002	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 003	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001	5643602	Jul 01, 2014	U-655			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949 001	6027714	Jan 09, 2018	DP U-787			
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949 002	6027714	Jan 09, 2018	DP U-787			
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	8784888	Jun 09, 2020	DP			
	8895064	Sep 07, 2031	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001					NP	Oct 07, 2017
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	5674860	Oct 07, 2014	DP U-1075			
	6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP U-1073			
	7967011	Aug 11, 2021	DP			
	8143239	Jan 29, 2023	DP U-1073			
	8387615	Nov 10, 2024	DP			
	8528545	Oct 16, 2028	DP			
	8575137	Jan 29, 2023	DP U-1073			
	8616196	Apr 07, 2029	DP			
	8875699	Nov 10, 2024	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	5674860	Oct 07, 2014	DP U-1075			
	6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP U-1073			
	7897646	Sep 09, 2018	U-1118			
	7967011	Aug 11, 2021	DP			
	8143239	Jan 29, 2023	DP U-1073			
	8387615	Nov 10, 2024	DP			
	8461211	Sep 09, 2018	U-1118			
	8528545	Oct 16, 2028	DP			
	8575137	Jan 29, 2023	DP U-1073			
	8616196	Apr 07, 2029	DP			
	8875699	Nov 10, 2024	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	8182835	Sep 18, 2018	DP U-1246		NP	Oct 28, 2014
	8834921	Sep 18, 2018	DP U-1587			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	8182835	Sep 18, 2018	DP U-1246		NP	Oct 28, 2014
	8834921	Sep 18, 2018	DP U-1587			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015		U-1072		
	6344211	Dec 18, 2015		U-1556		
	RE41408	Sep 29, 2017		U-1072		
	RE41408	Sep 29, 2017		U-1556		
	RE41489	Sep 29, 2017		U-1072		
	RE41489	Sep 29, 2017		U-1556		
	RE41571	Sep 29, 2017		U-1072		
	RE41571	Sep 29, 2017		U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015		U-1072		
	6344211	Dec 18, 2015		U-1556		
	RE41408	Sep 29, 2017		U-1072		
	RE41408	Sep 29, 2017		U-1556		
	RE41489	Sep 29, 2017		U-1072		
	RE41489	Sep 29, 2017		U-1556		
	RE41571	Sep 29, 2017		U-1072		
	RE41571	Sep 29, 2017		U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015		U-1072		
	6344211	Dec 18, 2015		U-1556		
	RE41408	Sep 29, 2017		U-1072		
	RE41408	Sep 29, 2017		U-1556		
	RE41489	Sep 29, 2017		U-1072		
	RE41489	Sep 29, 2017		U-1556		
	RE41571	Sep 29, 2017		U-1072		
	RE41571	Sep 29, 2017		U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015		U-1072		
	6344211	Dec 18, 2015		U-1556		
	RE41408	Sep 29, 2017		U-1072		
	RE41408	Sep 29, 2017		U-1556		
	RE41489	Sep 29, 2017		U-1072		
	RE41489	Sep 29, 2017		U-1556		
	RE41571	Sep 29, 2017		U-1072		
	RE41571	Sep 29, 2017		U-1556		
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015		U-1072		
	6344211	Dec 18, 2015		U-1556		
	RE41408	Sep 29, 2017		U-1072		
	RE41408	Sep 29, 2017		U-1556		
	RE41489	Sep 29, 2017		U-1072		
	RE41489	Sep 29, 2017		U-1556		
	RE41571	Sep 29, 2017		U-1072		
	RE41571	Sep 29, 2017		U-1556		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026		U-997		
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026		U-997		
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026		U-997		
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515 001	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515 002	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N 022497 001	7674479	Jun 25, 2027	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	7375111	Mar 26, 2025	DP		NC	Sep 10, 2017
	7462626	Jul 20, 2024		U-1583		
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027		U-1584		
	8722085	Nov 08, 2027		U-1585		
	8815889	Jul 20, 2024		U-1586		
<u>BUTOCONAZOLE NITRATE - GYNAZOLE-1</u>						
N 019881 001	5993856	Nov 17, 2017	DP	U-457		
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP		NCE	Jun 17, 2015
	6331635	Mar 26, 2016	DS DP			
	6372780	Mar 26, 2016		U-1067		
	6387946	Mar 26, 2016		U-1067		
	7241907	Dec 10, 2025	DS			
	8927592	Oct 27, 2030		U-1630		
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8877776	Oct 08, 2030	DS DP	U-1617	ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8877776	Oct 08, 2030	DS DP	U-1617	ODE	Nov 29, 2019
<u>CALCIPOTRIENE - DOVONEX</u>						
N 020554 001	5763426	Jun 09, 2015	DS DP			
	RE39706	Jun 09, 2015	DS DP			
<u>CALCIPOTRIENE - DOVONEX</u>						
N 020611 001	5763426	Jun 09, 2015	DS DP			
	RE39706	Jun 09, 2015	DS DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	Sep 27, 2028	DP U-1280		I-657	Sep 27, 2015
	8269128	May 26, 2026	DP U-1280			
<u>CALCITONIN SALMON - MIACALCIN</u>						
N 020313 002	5733569	Mar 31, 2015	U-227			
	5759565	Mar 31, 2015				
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406 001	6440392	Feb 02, 2021	DP U-227			
	RE40812	Feb 02, 2021	DP			
	RE43580	Feb 02, 2021	DP U-227			
<u>CALCITRIOL - CALCIJEX</u>						
N 018874 001	6051567	Aug 02, 2019				
	6265392	Aug 02, 2019				
	6274169	Aug 02, 2019				
<u>CALCITRIOL - CALCIJEX</u>						
N 018874 002	6051567	Aug 02, 2019				
	6265392	Aug 02, 2019				
	6274169	Aug 02, 2019				
<u>CALCIUM ACETATE - PHOSLO</u>						
N 021160 002	6576665	Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6576665	Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	8591938	Feb 23, 2030	DP U-1469			
	8592480	Jul 20, 2027	U-1469			
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
N 020958 001	5989588	Sep 30, 2015	U-349			
	6814978	Aug 26, 2021	DP			
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
N 021823 001	5994329	Jul 17, 2018	U-353			
	6015801	Jul 17, 2018	U-353			
	6165513	Jun 10, 2018	DP			
	6432932	Jul 17, 2018	U-595			
	6465443	Aug 14, 2018	DP			
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N 022193 001	7084130	Nov 29, 2021	DP U-891			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N 021093 001	5721263	Feb 24, 2015	DP U-3			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N 021093 002	5721263	Feb 24, 2015	DP U-3			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N 021093 003	5721263	Feb 24, 2015	DP U-3			
<u>CAPECITABINE - XELODA</u>						
N 020896 001					M-131 PED	Dec 10, 2016 Jun 10, 2017
<u>CAPECITABINE - XELODA</u>						
N 020896 002					M-131 PED	Dec 10, 2016 Jun 10, 2017
<u>CAPSAICIN - OUTENZA</u>						
N 022395 001	6239180	Nov 06, 2016	DP		NCE ODE	Nov 16, 2014 Nov 16, 2016
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 001	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 002	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 003	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 001	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 002	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 003	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024	U-693			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N 021485 001	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N 021485 002	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N 021485 003	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N 021485 004	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N 021485 005	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N 021485 006	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7232818	Apr 14, 2025	DS DP		NCE	Jul 20, 2017
	7417042	Jun 07, 2026	DS DP		ODE	Jul 20, 2019
	7491704	Apr 14, 2025		U-1260		
	7737112	Dec 07, 2027	DP			
	8129346	Dec 25, 2026		U-1260		
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025		U-1260		
	8207297	Apr 14, 2025	DS DP			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001					NCE	Mar 18, 2015
					ODE	Mar 18, 2017
<u>CARVEDILOL - COREG</u>						
N 020297 001	RE40000	Jun 07, 2015	U-233			
<u>CARVEDILOL - COREG</u>						
N 020297 002	RE40000	Jun 07, 2015	U-233			
<u>CARVEDILOL - COREG</u>						
N 020297 003	RE40000	Jun 07, 2015	U-233			
<u>CARVEDILOL - COREG</u>						
N 020297 004	RE40000	Jun 07, 2015	U-233			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 001	6022562	Oct 17, 2015	DP		Y	
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015	U-777			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 002	6022562	Oct 17, 2015	DP		Y	
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015	U-777			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 003	6022562	Oct 17, 2015	DP		Y	
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015	U-777			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 004	6022562	Oct 17, 2015	DP		Y	
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015	U-777			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N 021227 001	5514650	Jan 26, 2015	DP U-607			
	5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N 021227 002	5514650	Jan 26, 2015	DP U-607			
	5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
<u>CEFditoren PIVOXIL - SPECTRACEF</u>						
N 021222 001	5958915	Oct 14, 2016				
<u>CEFditoren PIVOXIL - SPECTRACEF</u>						
N 021222 002	5958915	Oct 14, 2016	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Dec 17, 2018	DS DP U-282		NCE	Oct 29, 2015
	6906055	Dec 15, 2021	DS DP			
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Dec 17, 2018	DS DP U-282		NCE	Oct 29, 2015
	6906055	Dec 15, 2021	DS DP			
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	7129232	Oct 21, 2024	DS DP U-36		NCE	Dec 19, 2019
	8476425	Sep 27, 2032	DS		GAIN	Dec 19, 2024
	8685957	Sep 27, 2032	DS U-36			
	8906898	May 28, 2034	DS DP			
<u>CELECOXIB - CELEBREX</u>						
N 020998 001	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 002	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 003	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 004	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
	7964592	Jan 13, 2027	DS DP			
	8039474	Jun 29, 2030	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8377921	Nov 20, 2027		U-1179		
	8703787	Feb 02, 2032		U-1179		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N 021621 003	6455533	Jul 02, 2018	DP	U-295		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N 021621 004	6455533	Jul 02, 2018	DP	U-295		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N 021621 005	6455533	Jul 02, 2018	DP	U-295		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N 021621 006	6455533	Jul 02, 2018	DP	U-295		
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
N 021150 002	6469009	Jul 13, 2019	DP	U-295		
	6489329	Apr 08, 2016	DP			
	7014867	Jun 10, 2022	DP			
	7226614	Jun 10, 2022		U-295		
<u>CETRORELIX - CETROTIDE</u>						
N 021197 001	6319192	Apr 23, 2019		U-426		
<u>CETRORELIX - CETROTIDE</u>						
N 021197 002	6319192	Apr 23, 2019		U-426		
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N 021669 001	7066916	Feb 17, 2024		U-737		
	7427574	Apr 25, 2026	DP			
	7595021	May 12, 2023	DP	U-1022		
	7717889	Feb 27, 2025	DP	U-1022		
	7935093	Oct 02, 2027	DP	U-1022		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 001	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 002	5690958	Sep 30, 2016	DP			
	6729786	Mar 14, 2023	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP	U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP</u>						
N 020832 003	5538353	Aug 25, 2015	DP			
	5690958	Sep 30, 2016	DP			
	5772346	Apr 22, 2017	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 004	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP	U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 006	5690958	Sep 30, 2016	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003	D468424	Jan 07, 2017				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP SEPP</u>						
N 021555 001	5690958	Sep 30, 2016	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N 021441 001	7863287	Feb 28, 2027	DP			
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N 203155 001					NCE W	Sep 12, 2017 Sep 12, 2017
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224 001	7259186	Jan 07, 2025	DS			
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224 002	7259186	Jan 07, 2025	DS			
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N 021149 001	5767251	Jun 16, 2015				
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N 021149 002	5767251	Jun 16, 2015	DS			
	6706681	Mar 16, 2021	DP			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	5482934	Oct 24, 2017	DS DP U-1002		M-125	Dec 17, 2015
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Aug 25, 2027	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	5482934	Oct 24, 2017	DS DP U-1002		M-125	Dec 17, 2015
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Aug 25, 2027	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	5482934	Oct 24, 2017	DS DP U-557			
	6767901	Oct 21, 2020	DP			
	6939559	Apr 21, 2019	DP			
	7235247	Apr 21, 2019	DP			
	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Aug 25, 2027	U-1357			
<u>CICLOPIROX - LOPROX</u>						
N 020519 001	7018656	Sep 05, 2018	DP			
	7026337	Nov 21, 2016	U-714			
<u>CICLOPIROX - LOPROX</u>						
N 021159 001	7981909	Sep 16, 2017	U-1162			
	8227490	Sep 16, 2017	U-1256			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016		U-559	ODE	Nov 21, 2021
	6211244	Oct 23, 2015	DS DP	U-560		
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP	U-1098		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016			ODE	Nov 21, 2021
	6211244	Oct 23, 2015	DS DP	U-560		
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP	U-1098		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016		U-559	ODE	Nov 21, 2021
	6211244	Oct 23, 2015	DS DP	U-560		
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP	U-1098		
<u>CIPROFLOXACIN - CIPRO</u>						
N 020780 001	5695784	Dec 09, 2014				
<u>CIPROFLOXACIN - CIPRO</u>						
N 020780 002	5695784	Dec 09, 2014				
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N 021744 001	5972389	Sep 19, 2016	DP	U-663		
	6340475	Sep 19, 2016	DP	U-663		
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP	U-663		
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC</u>						
N 020805 001	5843930	Jun 06, 2015		U-646		
	5965549	Jun 06, 2015	DP			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 001	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 002	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
	8846650	Jun 04, 2025	DP	U-1578		
<u>CISAPRIDE MONOHYDRATE - PROPULSID QUICKSOLV</u>						
N 020767 001	5648093	Jul 15, 2014				
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001	8450338	Oct 10, 2028	DP		NP	Jul 16, 2015
	8481083	Oct 10, 2028	DP			
<u>CLARITHROMYCIN - BIAXIN XL</u>						
N 050775 001	6010718	Apr 11, 2017	DP	U-924		
	6551616	Jun 15, 2017		U-924		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N 050767 001	6495157	Jul 20, 2020	DP			
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N 050782 001	6387383	Aug 03, 2020	DP U-818			
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793 001	5993856	Nov 17, 2017	DP U-137			
	6899890	Apr 27, 2023	DP U-137			
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N 050801 001	7141237	Jan 23, 2024	DS DP			
	7374747	Aug 09, 2026	DS DP U-921			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N 050802 001	6387383	Aug 03, 2020	DP U-916			
	RE41134	Feb 24, 2015	DP U-1033			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - VELTIN</u>						
N 050803 001	5690923	Nov 25, 2014	DP			
<u>CLOBAZAM - ONFI</u>						
N 202067 001					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067 002					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067 003					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 203993 001					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - OLUX</u>						
N 021142 001	6126920	Mar 01, 2016	U-484			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021535 001	6106848	Sep 22, 2017				
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021644 001	7316810	Jun 17, 2019	DP			
	7700081	Jan 03, 2022	U-1044			
	8066975	Jun 17, 2019	DP			
	8066976	Jun 17, 2019	DP			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021835 001	5972920	Feb 12, 2018	DP			
	5990100	Mar 24, 2018	DP U-742			
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP U-1410			
<u>CLOFARABINE - CLOLAR</u>						
N 021673 001	5661136	Jan 14, 2018	U-626			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331	003				M-149	Nov 20, 2017
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331	004				M-149	Nov 20, 2017
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839	001	6429210	Jun 10, 2019	DS DP	PED	Nov 06, 2014
		6504030	Jun 10, 2019	DS		
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839	002	6429210	Jun 10, 2019	DS DP	PED	Nov 06, 2014
		6504030	Jun 10, 2019	DS		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	001	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	002	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	003	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	004	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	005	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	006	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>COBICISTAT - TYBOST</u>						
N 203094	001	8148374	Sep 03, 2029	DS DP U-1279	NP	Sep 24, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100	001	5814639	Sep 29, 2015	DS DP	NP	Aug 27, 2015
		5914331	Jul 02, 2017	DS		
		5922695	Jul 25, 2017	DS U-257		
		5935946	Jul 25, 2017	DS DP U-257		
		5977089	Jul 25, 2017	DS DP U-257		
		6043230	Jul 25, 2017	U-257		
		6642245	Nov 04, 2020	U-257		
		6703396	Mar 09, 2021	DS DP		
		7176220	Nov 20, 2023	DS DP U-257		
		7635704	Oct 26, 2026	DS DP U-257		
		8148374	Sep 03, 2029	DS DP U-1279		
		8592397	Jan 13, 2024	DP U-257		
		8633219	Oct 11, 2031	DP U-257		
		8716264	Jan 13, 2024	DP U-257		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	7601758	Feb 10, 2029	U-1007		ODE	Jul 29, 2016
	7619004	Dec 03, 2028	U-1020			
	7820681	Feb 17, 2029	U-1020			
	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Oct 06, 2028	U-1161			
	7981938	Oct 06, 2028	U-1166			
	8093296	Oct 06, 2028	U-1007			
	8093297	Oct 06, 2028	U-1161			
	8093298	Oct 06, 2028	U-1116			
	8097655	Oct 06, 2028	U-1020			
	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021141 001	5693675	Dec 02, 2014				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021176 001	5693675	Dec 02, 2014	DS			
	7229613	Apr 17, 2022		U-851		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 001	5693675	Dec 02, 2014	DS			
	7229613	Apr 17, 2022		U-493		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 002	5693675	Dec 02, 2014	DS			
	7229613	Apr 17, 2022		U-493		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>						
N 021697 001	5723606	Dec 15, 2019	DS DP	U-698		
	5723606	Dec 15, 2019	DS DP	U-868		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER</u>						
N 021697 002	5723606	Dec 15, 2019	DS DP	U-698		
	5723606	Dec 15, 2019	DS DP	U-868		
<u>CORTICOTROPIN - H.P. ACTHAR GEL</u>						
N 008372 008					ODE	Oct 15, 2017
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Mar 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027		U-1179	ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Mar 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027		U-1179	ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	7323195	Jun 07, 2018	DP		NCE	Dec 31, 2017
	7341744	Jun 16, 2018		U-1319		
	8574634	Jan 11, 2018		U-1319		
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Jun 11, 2024	DP	U-817		
	7404489	Mar 12, 2024	DP			
	7879349	Jun 01, 2024	DP	U-1152		
	8003353	Jun 11, 2024		U-817		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023		U-979		
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023		U-1088		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023		U-979		
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023		U-1088		
<u>CYCLOSPORINE - NEORAL</u>						
N 050715 001	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N 050715 002	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N 050715 003	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N 050716 001	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024		U-1479		
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024		U-1483		
	8685930	Aug 27, 2024	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027		U-1399	NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP		ODE	Apr 30, 2020
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027		U-1399	NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP		ODE	Apr 30, 2020
<u>CYSTEAMINE HYDROCHLORIDE - CYSTARAN</u>						
N 200740 001					NP	Oct 02, 2015
					ODE	Oct 02, 2019
<u>CYTARABINE - DEPOCYT</u>						
N 021041 001	5723147	Mar 03, 2015	DP	U-806		
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Feb 18, 2018	DS DP	U-1089	I-682	Apr 04, 2017
	7866474	Aug 31, 2027		DP	I-683	Apr 04, 2017
	7932273	Sep 07, 2025	DS DP		NCE	Oct 19, 2015
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Feb 18, 2018	DS DP	U-1089	I-682	Apr 04, 2017
	7866474	Aug 31, 2027		DP	I-683	Apr 04, 2017
	7932273	Sep 07, 2025	DS DP		NCE	Oct 19, 2015
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP	U-1406	I-678	Jan 08, 2017
	8415345	Jan 20, 2030	DS DP	U-1406	NCE	May 29, 2018
					ODE	May 29, 2020
					ODE	Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP	U-1406	I-678	Jan 08, 2017
	8415345	Jan 20, 2030	DS DP	U-1406	NCE	May 29, 2018
					ODE	May 29, 2020
					ODE	Jan 09, 2021
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	Dec 25, 2023		U-1517	NCE	May 23, 2019
	7115564	Nov 14, 2023	DP		GAIN	May 23, 2024
	7119061	Nov 14, 2023	DP			
	8143212	Nov 14, 2023		U-1517		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018	U-1030		NCE	Jan 22, 2015
	8007826	May 26, 2027	U-1030		ODE	Jan 22, 2017
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
	8663685	Jan 18, 2025	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	7758890	Jul 01, 2025	DP			
	8110225	Dec 24, 2022	DP			
	8604072	Dec 24, 2022	DP			
	8685460	Feb 15, 2023	U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPSONE - ACZONE</u>						
N 021794 001	5863560	Sep 11, 2016	DP			
	6060085	Sep 11, 2016		U-124		
	6620435	Sep 11, 2016	DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 001	6468967	Sep 24, 2019		U-282		
	6852689	Sep 24, 2019		U-282		
	8058238	Nov 28, 2020	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002	6468967	Sep 24, 2019		U-282		
	6852689	Sep 24, 2019		U-282		
	8003673	Sep 04, 2028		U-1180		
	8058238	Nov 28, 2020	DS DP			
	8129342	Nov 28, 2020	DS DP			
	RE39071	Jun 15, 2016	DS DP	U-728		
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N 021513 001	5096890	Mar 13, 2015	DS DP	U-631		
	6106864	Aug 21, 2016	DP	U-630		
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N 021513 002	5096890	Mar 13, 2015	DS DP	U-631		
	6106864	Aug 21, 2016	DP	U-630		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	5843946	Dec 01, 2015	DP U-1209		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-1305		NDF	Dec 16, 2014
	6037157	Jun 26, 2016	U-1209		PED	Jun 16, 2015
	6037157	Jun 26, 2016	U-1305		PED	Aug 01, 2016
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619	001				NCE	Dec 19, 2019
<u>DASATINIB - SPRYCEL</u>						
N 021986	001	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	002	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	003	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	004	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	005	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	006	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DEFERASIROX - EXJADE</u>						
N 021882	001	6465504	Apr 05, 2019	DS DP		I-665 Jan 23, 2016
		6596750	Jun 24, 2017	DS	U-735	
<u>DEFERASIROX - EXJADE</u>						
N 021882	002	6465504	Apr 05, 2019	DS DP		I-665 Jan 23, 2016
		6596750	Jun 24, 2017	DS	U-735	
<u>DEFERASIROX - EXJADE</u>						
N 021882	003	6465504	Apr 05, 2019	DS DP		I-665 Jan 23, 2016
		6596750	Jun 24, 2017	DS	U-735	
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825	001				NCE	Oct 14, 2016
					ODE	Oct 14, 2018

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DELAVIRDINE MESYLATE - RESCRIPTOR</u>						
N 020705 002	6177101	Jun 07, 2019				
<u>DESIRUDIN RECOMBINANT - IPRIVASK</u>						
N 021271 001	5733874	Mar 31, 2015				
<u>DESLORATADINE - CLARINEX</u>						
N 021165 001	6100274	Jul 07, 2019				
	7211582	Dec 30, 2014		U-809		
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014		U-138		
	7405223	Jul 07, 2019		U-886		
<u>DESLORATADINE - CLARINEX</u>						
N 021300 001	6514520	Jun 01, 2018	DP			
	7211582	Dec 30, 2014		U-809		
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014		U-138		
<u>DESLORATADINE - CLARINEX</u>						
N 021312 001	5607697	Jun 07, 2015	DP			
	6100274	Jul 07, 2019	DP			
	7211582	Dec 30, 2014		U-809		
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014		U-138		
	7618649	Dec 19, 2020	DP	U-1017		
<u>DESLORATADINE - CLARINEX</u>						
N 021312 002	5607697	Jun 07, 2015	DP			
	6100274	Jul 07, 2019	DP			
	7211582	Dec 30, 2014		U-809		
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014		U-138		
	7618649	Dec 19, 2020	DP	U-1017		
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N 021313 001	6100274	Jul 07, 2019	DP			
	6709676	Feb 18, 2021	DP	U-707		
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014		U-138		
	7618649	Dec 19, 2020	DP	U-1017		
	8187630	Dec 19, 2020	DP	U-1017		
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>						
N 021605 001	6100274	Jul 07, 2019	DP			
	6979463	Mar 28, 2022	DP			
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014		U-138		
	7618649	Dec 19, 2020	DP	U-1017		
	7820199	Mar 28, 2022	DP			
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N 019955 001	7022340	Apr 30, 2023	DP		Y	
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N 019955 002	7022340	Apr 30, 2023	DP		Y	
<u>DESONIDE - DESONATE</u>						
N 021844 001	6387383	Aug 03, 2020	DS DP U-783			
<u>DESONIDE - VERDESO</u>						
N 021978 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP	U-1412		
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	5990100	Mar 24, 2018	DP	U-1408	NDF	Apr 11, 2016
	8277780	Sep 01, 2028	DP	U-1408		
	8715624	May 26, 2026	DP	U-1408		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Mar 01, 2022	DS U-860		I-675	Feb 14, 2016
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Mar 01, 2022	DS U-860		I-675	Feb 14, 2016
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	6726918	Oct 20, 2020	DP U-1204		I-686	Jun 29, 2017
	6726918	Oct 20, 2020	DP U-1205		ODE	Sep 24, 2017
	6899717	Nov 01, 2023	U-1206			
	7033605	Oct 20, 2020	DP			
	7767223	Nov 28, 2021	DP			
	8034366	Jan 09, 2023	DP U-1204			
	8034366	Jan 09, 2023	DP U-1205			
	8034370	Jan 09, 2023	DP			
	8043628	Oct 20, 2020	DP U-1205			
	8063031	Oct 20, 2020	DP			
	8088407	Oct 20, 2020	DP U-1205			
	8506987	Jan 09, 2023	U-1204			
	8506987	Jan 09, 2023	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020		U-949		
	6939971	Jun 15, 2020		U-950		
	6939971	Jun 15, 2020		U-951		
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026		DP		
	8105626	Sep 27, 2026		DP		
	8173158	Mar 17, 2030		U-949		
	8173158	Mar 17, 2030		U-950		
	8173158	Mar 17, 2030		U-951		
	8461187	Jan 17, 2026		DP		
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023		DP		
	8784885	Oct 15, 2023		DP U-1552		
	8784885	Oct 15, 2023		DP U-1553		
	8784885	Oct 15, 2023		DP U-1554		
	8871273	Jan 11, 2028		DP		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020		U-949		
	6939971	Jun 15, 2020		U-950		
	6939971	Jun 15, 2020		U-951		
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026		DP		
	8105626	Sep 27, 2026		DP		
	8173158	Mar 17, 2030		U-949		
	8173158	Mar 17, 2030		U-950		
	8173158	Mar 17, 2030		U-951		
	8461187	Jan 17, 2026		DP		
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023		DP		
	8722084*PED	Apr 15, 2024				
	8871273	Jan 11, 2028		DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	6716867	Mar 31, 2019		U-1472	M-61	Jun 17, 2016
	6716867*PED	Oct 01, 2019			PED	Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	6716867	Mar 31, 2019		U-1472	M-61	Jun 17, 2016
	6716867*PED	Oct 01, 2019			PED	Dec 17, 2016
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032		U-421		
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	6716867	Mar 31, 2019		U-1472	M-61	Jun 17, 2016
	6716867*PED	Oct 01, 2019			PED	Dec 17, 2016
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032		U-421		
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 001					PC	May 09, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278 001	5908850	Dec 04, 2015		U-422		
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278 002	5908850	Dec 04, 2015		U-422		
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278 003	5908850	Dec 04, 2015		U-422		
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 001	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 002	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 003	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 004	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 005	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 006	5837284	Dec 04, 2015	DP	U-677		
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 007	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 008	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP U-678			
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N 022025 001	6727253	Mar 13, 2020	U-829		ODE	Sep 06, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	7659282	Aug 13, 2026	U-1093			
	8227484	Jul 17, 2023	U-1093			
	RE38115	Jan 26, 2016	DP	Y		
<u>DEXTROMETHORPHAN POLISTIREX - DELSYM</u>						
N 018658 001	5980882	Apr 16, 2017	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8679544	Apr 23, 2030	DP		I-692 NP	Aug 22, 2017 Oct 18, 2016
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8679544	Apr 23, 2030	DP		I-692 NP	Aug 22, 2017 Oct 18, 2016
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	6974595	May 15, 2017	U-436			
	7482377	May 15, 2017	DS DP U-436			
	7759394	Jun 16, 2026	DS DP U-436			
	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6287594	Jan 15, 2019	DP			
	6365180	Jul 15, 2019	DP U-980			
	7662858	Feb 24, 2029	U-1035			
	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
	8110606	Feb 24, 2029	U-980			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
A 202027 001					PC	Nov 23, 2014
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
N 020809 001	5603929	Nov 16, 2014	U-239			
	5653972	Nov 16, 2014	U-239			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8217078	Jul 10, 2029	U-1248			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N 021005 001	5792753	Aug 11, 2015				
	5914322	Aug 11, 2015				
	5985850	Aug 11, 2015	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396	001				NP	Dec 23, 2017
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623	001	8217078	Jul 10, 2029	U-1477	NP	Jan 16, 2017
		8252838	Apr 21, 2028	DP U-1489		
		8546450	Aug 09, 2030	U-1435		
		8546450	Aug 09, 2030	U-1436		
		8563613	Oct 17, 2027	DP U-1488		
		8618164	Jul 10, 2029	U-1477		
		8741956	Jul 10, 2029	U-1435		
		8871809	Oct 17, 2027	U-1614		
<u>DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA</u>						
N 022252	001	6133251	Oct 25, 2016	DP U-1	Y	I-648
		6133251	Oct 25, 2016	DP U-112	Y	
		6133251	Oct 25, 2016	DP U-828	Y	
		6884793	Oct 25, 2016	DP	Y	
		8071577	May 13, 2026	DP U-1		
		8153616	Jan 30, 2028	U-1240		
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212	001	6114319	May 18, 2019	DP	I-653	Jun 13, 2015
		6114319*PED	Nov 18, 2019		M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2015
					PED	Sep 22, 2016
					PED	Dec 13, 2019
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	001	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	002	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	003	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	004	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	005	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	006	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	001	6509376	Oct 29, 2019	DP	NCE	Mar 27, 2018
		7320999	May 18, 2020	U-1384		
		7619001	Apr 01, 2018	U-1384		
		7803840	Apr 01, 2018	U-1385		
		8399514	Feb 07, 2028	U-1384		
		8524773	Apr 01, 2018	U-1384		
		8759393	Oct 29, 2019	DP		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	002	6509376	Oct 29, 2019	DP	NCE	Mar 27, 2018
		7320999	May 18, 2020	U-1384		
		7619001	Apr 01, 2018	U-1384		
		7803840	Apr 01, 2018	U-1385		
		8399514	Feb 07, 2028	U-1384		
		8524773	Apr 01, 2018	U-1384		
		8759393	Oct 29, 2019	DP		



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMYRISTOYL LECITHIN; PERFLEXANE - IMAGENT</u>						
N 021191	001	5695741	Dec 09, 2014	U-458		
		5720938	Feb 24, 2015			
		5798091	Aug 25, 2015	U-458		
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N 021394	001	8263647	May 30, 2022	DP		
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393	001	8883849	Jan 17, 2022	U-1618		
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352	001				NC	Jan 17, 2017
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168	001	6419953	Dec 18, 2018			
		6511678	Dec 18, 2018			
		6528090	Dec 18, 2018	DP		
		6528091	Dec 18, 2018	U-106		
		6713086	Dec 18, 2018	DP U-579		
		6720004	Dec 18, 2018	DP		
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168	002	6511678	Dec 18, 2018			
		6528090	Dec 18, 2018	DP		
		6713086	Dec 18, 2018	DP U-579		
		6720004	Dec 18, 2018	DP		
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	001	6124363	Oct 09, 2018			
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	002	6124363	Oct 09, 2018			
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	003	6124363	Oct 09, 2018			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	001	8129385	Oct 05, 2027	DS DP	NCE	Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N 021720	001	7727548	Jun 23, 2022	DP U-1062		
		7727552	Mar 26, 2018	DP		
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N 021720	002	7727548	Jun 23, 2022	DP U-1062		
		7727552	Mar 26, 2018	DP		
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568	001	8481565	Oct 04, 2026	DP		
<u>DORIPENEM - DORIBAX</u>						
N 022106	001	5317016	Jun 05, 2015	DS DP U-282		
		8247402	Mar 30, 2021	DS DP		
<u>DORIPENEM - DORIBAX</u>						
N 022106	002	5317016	Jun 05, 2015	DS DP U-282		
		8247402	Mar 30, 2021	DS DP		
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N 202667	001				NP	Feb 01, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020		U-620		
	6217909	Jan 09, 2015	DP			
	7915307	Aug 24, 2027		U-620		
	8513299	Apr 14, 2030		U-620		
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020		U-620		
	6217909	Jan 09, 2015	DP			
	7915307	Aug 24, 2027		U-620		
	8513299	Apr 14, 2030		U-620		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 001	6903083	Jul 18, 2021	DS DP		Y	
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 002	6903083	Jul 18, 2021	DS DP		Y	
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	5789395	Aug 30, 2016		U-925	Y	
	5919775	Aug 30, 2016		U-925	Y	
	7211267	Apr 05, 2022		U-925		
	7232572	Apr 05, 2022		U-925		
	7749532	Dec 19, 2027		DP U-1063		
	8206740	Dec 24, 2025		DP U-925		
	8394405	Apr 07, 2024		DP U-925		
	8394406	Apr 07, 2024		DP U-925		
	8470364	Apr 07, 2024		DP U-925		
	8603506	Apr 05, 2022		U-1063		
	8709478	Apr 07, 2024		U-1063		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	6958161	Dec 15, 2022		DP U-918		
	8715724	Feb 03, 2028		DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	6958161	Dec 15, 2022		DP U-918		
	8715724	Feb 03, 2028		DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	6958161	Dec 15, 2022		DP U-918		
	8715724	Feb 03, 2028		DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	6958161	Dec 15, 2022		DP U-918		
	8715724	Feb 03, 2028		DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	6958161	Dec 15, 2022		DP U-918	D-136	Apr 11, 2016
	8715724	Feb 03, 2028		DP	NS	Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876 001	6340695	Jun 21, 2021		DP U-1382		Apr 08, 2016
	7560122	Jan 25, 2019		DP		
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	5223510	Jul 26, 2016		DS DP U-992	NCE	Jul 01, 2014
	5223510	Jul 26, 2016		DS DP U-1261		
	7323493	Jun 19, 2018		DP		
	8318800	Jun 19, 2018		DP		
	8410167	Apr 16, 2029		U-1387		
	8410167	Apr 16, 2029		U-1388		
	8602215	Jun 30, 2031		U-1473		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355 001	8906890	Oct 22, 2031	DP		NS	Mar 01, 2015
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355 002	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N 021098 001	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676 001	5798338	Jul 10, 2015	DP			
	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DP			
	6958326	Dec 20, 2021	DP			
	6987101	Dec 22, 2017		U-758		
	7163931	Dec 20, 2021		U-1		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022		U-1		
	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022		U-1		
	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001	5508276	Jul 18, 2014	DP		M-61	Oct 18, 2015
	6596756	Sep 10, 2019		U-882	NPP	Oct 16, 2017
					NPP	Oct 16, 2017
					PED	Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002	5508276	Jul 18, 2014	DP		M-61	Oct 18, 2015
	6596756	Sep 10, 2019		U-882	NPP	Oct 16, 2017
					NPP	Oct 16, 2017
					PED	Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004	5508276	Jul 18, 2014	DP		M-61	Oct 18, 2015
	6596756	Sep 10, 2019		U-882	NPP	Oct 16, 2017
					NPP	Oct 16, 2017
					PED	Apr 18, 2016
<u>DUTASTERIDE - AVODART</u>						
N 021319 001	5565467	Nov 20, 2015	DS DP			
<u>DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE - JALYN</u>						
N 022460 001	5565467	Nov 20, 2015	DS DP			
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175 001	5993830	Jan 16, 2018	DP	U-1449	NDF	Oct 24, 2016

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 001	5663169	Sep 02, 2014		U-257	NPP	May 02, 2016
	5663169*PED	Mar 02, 2015			PED	Nov 02, 2016
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019		U-248		
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 002	5663169	Sep 02, 2014		U-257		
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019		U-248		
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 003	5663169	Sep 02, 2014		U-257	NPP	May 02, 2016
	5663169*PED	Mar 02, 2015			PED	Nov 02, 2016
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019		U-248		
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 001	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 002	5663169	Sep 02, 2014		U-248	NPP	May 02, 2016
	5663169*PED	Mar 02, 2015			PED	Nov 02, 2016
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5663169*PED	Mar 02, 2015				
	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
	6703396	Mar 09, 2021	DS DP			
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
	8592397	Jan 13, 2024	DP U-750			
	8592397	Jan 13, 2024	DP U-1170			
	8598185	May 01, 2028	DP			
	8716264	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	7214506	Oct 05, 2021	U-281		NCE	Jun 06, 2019
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
<u>EFLORNITHINE HYDROCHLORIDE - VANIQ</u>						
N 021145 001	5648394	Jul 15, 2014	U-334			
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016 001	5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016 002	5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	6916802	Apr 29, 2022	U-1571		NCE	Aug 19, 2019
	7196205	Apr 29, 2022	DS		ODE	Aug 19, 2021
	7615573	Apr 29, 2022	U-1571			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		ODE	Nov 20, 2015
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		ODE	Nov 20, 2015
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		ODE	Nov 20, 2015
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		ODE	Nov 20, 2015
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		ODE	Nov 20, 2015
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMTRICITABINE - EMTRIVA</u>						
N 021500 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	6642245	Nov 04, 2020	U-257			
	6642245	Nov 04, 2020	U-541			
	6703396	Mar 09, 2021	DS DP			
<u>EMTRICITABINE - EMTRIVA</u>						
N 021896 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	5814639	Sep 29, 2015	DS DP		NCE	May 20, 2016
	5914331	Jul 02, 2017	DS		NPP	Dec 13, 2016
	5922695	Jul 25, 2017	DS U-257			
	5935946	Jul 25, 2017	DS DP U-257			
	5977089	Jul 25, 2017	DS DP U-257			
	6043230	Jul 25, 2017	U-257			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8592397	Jan 13, 2024	DP U-257			
	8716264	Jan 13, 2024	DP U-257			
	8841310	Dec 09, 2025	DP U-257			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS DP U-248			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	6043230	Jul 25, 2017	DP U-248			
	6043230	Jul 25, 2017	DP U-541			
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-1259			
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6703396	Mar 09, 2021	DS DP			
	8592397	Jan 13, 2024	DP U-248			
	8592397	Jan 13, 2024	DP U-541			
	8592397	Jan 13, 2024	DP U-1170			
	8716264	Jan 13, 2024	DP U-257			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8568747	Nov 06, 2032	DP			
	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-185			
<u>ENFUVRTIDE - FUZEON</u>						
N 021481 001	6133418	Nov 17, 2014	DS DP			
	6475491	Jun 07, 2015	U-248			
<u>ENTACAPONE - COMTAN</u>						
N 020796 001	6599530	Sep 14, 2018	DP U-219			
<u>ENTECAVIR - ENTECAVIR</u>						
A 202122 001					PC	Feb 21, 2015
<u>ENTECAVIR - ENTECAVIR</u>						
A 202122 002					PC	Feb 21, 2015
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001	5206244	Feb 21, 2015	DS		NPP	Oct 12, 2015
	5206244*PED	Aug 21, 2015			NPP	Mar 20, 2017
					PED	Apr 12, 2016
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002	5206244	Feb 21, 2015	DS		NPP	Oct 12, 2015
	5206244*PED	Aug 21, 2015			NPP	Mar 20, 2017
					PED	Apr 12, 2016
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001	5206244	Feb 21, 2015	DS		NPP	Oct 12, 2015
	5206244*PED	Aug 21, 2015			NPP	Mar 20, 2017
					PED	Apr 12, 2016
					PED	Sep 20, 2017
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	7709517	Aug 13, 2027	DS DP		I-693	Sep 10, 2017
	8183274	May 15, 2026	U-1281		NCE	Aug 31, 2017
	8183274	May 15, 2026	U-1588			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N 020800 001	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N 020800 002	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N 021504 001	6629968	Jun 30, 2020	DS DP			
	6635045	Jun 29, 2021	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPLERENONE - INSPRA</u>						
N 021437 001	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPLERENONE - INSPRA</u>						
N 021437 002	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPLERENONE - INSPRA</u>						
N 021437 003	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N 020738 004	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N 020738 005	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N 020738 006	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N 021268 001	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N 021268 002	5656650	Aug 12, 2014	U-3			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N 020718 001	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N 020718 002	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jun 16, 2019	DS		NCE	Nov 15, 2015
	6469182	Jun 16, 2019		U-1096		
	7470720	Jun 16, 2019	DP			
	8097648	Jan 22, 2021		U-1096		
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP	U-659	I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-1403		
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-1403		
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP	U-659	I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-1403		
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-1403		
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP	U-659	I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-1403		
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-1403		
	RE41065	Nov 08, 2018	DS DP			
<u>ERTAPENEM SODIUM - INVANZ</u>						
N 021337 001	5478820	Nov 21, 2015	DS DP	U-160		
	5952323	May 15, 2017		DP		
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022		DP		
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022		DP		
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2016	DS DP	U-1451	NCE	Nov 08, 2018
	8372431	Apr 17, 2030		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP	U-1451	NCE	Nov 08, 2018
	8372431	Apr 17, 2030		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2016	DS DP	U-1451	NCE	Nov 08, 2018
	8372431	Apr 17, 2030		DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2016	DS DP	U-1451	NCE	Nov 08, 2018
	8372431	Apr 17, 2030		DP		
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N 019386 004	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 019386 005	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 006	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 007	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	5690960	Nov 25, 2014	DP U-373			
	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-770			
	5714504	Feb 03, 2015	DP U-373			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-770			
	5900424	May 04, 2016	DS U-373			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-770			
	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-770			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018		U-1417		
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	5690960	Nov 25, 2014	DP U-373			
	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-770			
	5714504	Feb 03, 2015	DP U-373			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-770			
	5900424	May 04, 2016	DS U-373			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-770			
	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-770			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018		U-1417		
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-773			
	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-773			
	5714504	Feb 03, 2015	DP U-1207			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-773			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-773			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018		U-1417		
	8466175*PED	Nov 25, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 002	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-773			
	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-773			
	5714504	Feb 03, 2015	DP U-1207			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-773			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-773			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 003	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-1207			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 004	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-1207			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 022101 001	5690960	Nov 25, 2014	DP U-858			
	5714504	Feb 03, 2015	DP U-858			
	5900424	May 04, 2016	DS U-858			
	6369085	May 25, 2018	DS DP U-858			
	6428810	Nov 03, 2019	DP U-858			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509		RTO	Mar 28, 2017
	5714504	Feb 03, 2015	DP U-1509			
	5900424	May 04, 2016	DS U-1509			
	6369085	May 25, 2018	DS DP U-1509			
	6428810	Nov 03, 2019	DP U-1509			
	7411070	May 25, 2018	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	5714504	Feb 03, 2015	DP U-1053			
	5900424	May 04, 2016	DS U-1053			
	6369085	May 25, 2018	DS DP U-1053			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
	8557285	May 31, 2022	DP			
	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	5714504	Feb 03, 2015	DP U-1053			
	5900424	May 04, 2016	DS U-1053			
	6369085	May 25, 2018	DS DP U-1053			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
	8557285	May 31, 2022	DP			
	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001	5877192*PED	Nov 27, 2014			D-138	Mar 04, 2017
	6143771	May 27, 2015	DP U-643		I-679	Mar 04, 2017
	6143771	May 27, 2015	DP U-1495			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002	5877192*PED	Nov 27, 2014			D-138	Mar 04, 2017
	6143771	May 27, 2015	DP U-643		I-679	Mar 04, 2017
	6143771	May 27, 2015	DP U-1495			
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 005	5656286	Aug 12, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 006	5656286	Aug 12, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 007	5656286	Aug 12, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 008	5656286	Aug 12, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 009	5656286	Aug 12, 2014	DP			
<u>ESTRADIOL - VAGIFEM</u>						
N 020908 002	5860946	Jul 01, 2017	DP			
	7018992	Sep 17, 2022	U-1023			
<u>ESTRADIOL - MENOSTAR</u>						
N 021674 001	5891868	Nov 21, 2017	DP U-594			
	6692763	Nov 21, 2017	DP U-594			
<u>ESTRADIOL - ELESTRIN</u>						
N 021813 001	7198801	Jun 25, 2022	DP			
	7470433	Aug 03, 2021	DP			
<u>ESTRADIOL - EVAMIST</u>						
N 022014 001	6299900	Feb 19, 2017	DP U-888			
	6299900	Feb 19, 2017	DP U-889			
	6818226	Feb 19, 2017	DP U-888			
	6818226	Feb 19, 2017	DP U-889			
	6923983	Feb 19, 2017	DP U-888			
	6923983	Feb 19, 2017	DP U-889			
	6978945	Jul 31, 2022	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	5656286	Aug 12, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	5656286	Aug 12, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	5656286	Aug 12, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	5656286	Aug 12, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL ACETATE - FEMRING</u>						
N 021367 001	5855906	Dec 19, 2015		U-508		
<u>ESTRADIOL ACETATE - FEMRING</u>						
N 021367 002	5855906	Dec 19, 2015		U-508		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 001	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025		U-904		
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 002	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025		U-904		
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 003	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025		U-904		
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL HEMIHYDRATE - ESTRASORB</u>						
N 021371 001	5629021	Jan 31, 2015	DP			
<u>ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N 021040 001	6747019	Mar 20, 2020		U-311		
	7320970	Mar 30, 2020	DP	U-844		
<u>ESTRADIOL; LEVONORGESTREL - CLIMARA PRO</u>						
N 021258 001	5676968	Oct 14, 2014	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N 020870 001	5656286	Aug 12, 2014				
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N 020870 002	5656286	Aug 12, 2014				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 001	5908638	Jul 26, 2015	DP			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 002	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 003	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 004	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 005	5908638	Jul 26, 2015				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUUIA</u>						
N 021443 001	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUUIA</u>						
N 021443 002	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUUIA</u>						
N 021443 003	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUUIA</u>						
N 021443 004	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUUIA</u>						
N 021443 005	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED; ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPHASE 14/14</u>						
N 020527 002	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 001	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 003	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 004	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 005	5547948	Jan 17, 2015				
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; NORGESTIMATE; NORGESTIMATE; NORGESTIMATE - ORTHO TRI-CYCLEN LO</u>						
N 021241 001	6214815	Jun 09, 2019		U-112		
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N 021840 001	7320969	Jan 30, 2024		U-828		
	7615545	Jun 15, 2023		U-1		
	7855190	Dec 05, 2028		U-1		
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N 022262 001	7615545	Jun 15, 2023		U-1		
	7855190	Dec 05, 2028		U-1		
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING</u>						
N 021187 001	5989581	Apr 08, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT</u>						
N 020946 001	6156742	Dec 05, 2020	U-374			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONALE</u>						
N 021544 001	5898032	Jun 23, 2017	U-1			
	RE39861	Jun 23, 2017	U-828			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL</u>						
N 021864 001	6500814	Sep 03, 2018	U-1			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
	8450299	Oct 07, 2025	U-1			
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>						
N 021180 001	5876746	Nov 20, 2015	DP U-514			
	5972377	Jun 07, 2015	U-514			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE</u>						
N 021490 001	6667050	Apr 06, 2019	DP U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>						
N 021871 001	5552394	Jul 22, 2014	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE</u>						
N 022501 001	5552394	Jul 22, 2014	U-1090			
	7704984	Feb 02, 2029	U-1090			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	5552394	Jul 22, 2014	U-1		NDF	May 08, 2016
	6667050	Apr 06, 2019	DP U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 204426 001	5552394	Jul 22, 2014	U-1			
	6652880	Mar 29, 2020	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654 001	5552394	Jul 22, 2014	U-1			
	6667050	Apr 06, 2019	DP U-1			
	7704984	Feb 02, 2029	U-1			
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190 001					ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	8722037	Sep 28, 2027	DP			
	8888745	Aug 28, 2026	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365		PED	Sep 30, 2014
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365		PED	Sep 30, 2014
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365		PED	Sep 30, 2014
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	5665772	Sep 09, 2019	DS DP		I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-655	Jul 20, 2015
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
	7741338	Dec 06, 2019	DP		ODE	May 05, 2018
	8410131	May 22, 2025	DS DP U-1368		ODE	Apr 26, 2019
	8410131*PED	Nov 22, 2025			PED	Sep 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2014
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2015
	8778962	Feb 18, 2022		U-1541	PED	Apr 29, 2018
	8778962*PED	Aug 18, 2022			PED	Nov 05, 2018
					PED	Oct 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	5665772	Sep 09, 2019	DS DP		I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-655	Jul 20, 2015
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
	7741338	Dec 06, 2019	DP		ODE	May 05, 2018
	8410131	May 22, 2025	DS DP U-1368		ODE	Apr 26, 2019
	8410131*PED	Nov 22, 2025			PED	Sep 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2014
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2015
	8778962	Feb 18, 2022		U-1541	PED	Apr 29, 2018
	8778962*PED	Aug 18, 2022			PED	Nov 05, 2018
					PED	Oct 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	5665772	Sep 09, 2019	DS DP		I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-655	Jul 20, 2015
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
	7741338	Dec 06, 2019	DP		ODE	May 05, 2018
	8410131	May 22, 2025	DS DP U-1368		ODE	Apr 26, 2019
	8410131*PED	Nov 22, 2025			PED	Sep 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2014
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2015
	8778962	Feb 18, 2022		U-1541	PED	Apr 29, 2018
	8778962*PED	Aug 18, 2022			PED	Nov 05, 2018
					PED	Oct 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	5665772	Sep 09, 2019	DS DP		I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-655	Jul 20, 2015
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
	7741338	Dec 06, 2019	DP		ODE	May 05, 2018
	8410131	May 22, 2025	DS DP U-1368		ODE	Apr 26, 2019
	8410131*PED	Nov 22, 2025			PED	Sep 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2014
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2015
	8778962	Feb 18, 2022		U-1541	PED	Apr 29, 2018
	8778962*PED	Aug 18, 2022			PED	Nov 05, 2018
					PED	Oct 26, 2019

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016	DP		PED	Sep 30, 2014
	7297703	Dec 06, 2019	DP		PED	Apr 29, 2018
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022		U-1541		
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016	DP		PED	Sep 30, 2014
	7297703	Dec 06, 2019	DP		PED	Apr 29, 2018
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022		U-1541		
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016	DP		PED	Sep 30, 2014
	7297703	Dec 06, 2019	DP		PED	Apr 29, 2018
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022		U-1541		
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 001	5424286	Dec 01, 2016		U-653	M-111	Oct 19, 2014
	5424286	Dec 01, 2016		U-1108	M-113	Oct 19, 2014
	6858576	Jan 06, 2017		U-656	M-148	Nov 24, 2017
	6858576	Jan 06, 2017		U-1108		
	6872700	Jan 14, 2020		U-654		
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018		U-687		
	6956026	Jan 07, 2018		U-1074		
	6956026	Jan 07, 2018		U-1623		
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018		U-653		
	7741269	Jan 07, 2018		U-1074		
	7741269	Jan 07, 2018		U-1108		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 002	5424286	Dec 01, 2016		U-653	M-111	Oct 19, 2014
	5424286	Dec 01, 2016		U-1108	M-113	Oct 19, 2014
	6858576	Jan 06, 2017		U-656	M-148	Nov 24, 2017
	6858576	Jan 06, 2017		U-1108		
	6872700	Jan 14, 2020		U-654		
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018		U-687		
	6956026	Jan 07, 2018		U-1074		
	6956026	Jan 07, 2018		U-1623		
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018		U-653		
	7741269	Jan 07, 2018		U-1074		
	7741269	Jan 07, 2018		U-1108		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7030106	Jan 25, 2022	DP		M-109	Jan 24, 2015
	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-1173			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 001	RE37721	Oct 25, 2016	DS DP U-473		M-109	Jan 24, 2015
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 002	RE37721	Oct 25, 2016	DS DP U-473		M-109	Jan 24, 2015
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 003	RE37721	Oct 25, 2016	DS DP U-473		M-109	Jan 24, 2015
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 004	RE37721	Oct 25, 2016	DS DP U-473		M-109	Jan 24, 2015
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZOAGABINE - POTIGA</u>						
N 022345 001					NCE	Jun 10, 2016
<u>EZOAGABINE - POTIGA</u>						
N 022345 002					NCE	Jun 10, 2016
<u>EZOAGABINE - POTIGA</u>						
N 022345 003					NCE	Jun 10, 2016
<u>EZOAGABINE - POTIGA</u>						
N 022345 004					NCE	Jun 10, 2016

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363 001	5840763	Sep 01, 2015	U-96		M-112	Feb 09, 2015
	5866581	Oct 04, 2014	U-96			
	5916893	Sep 01, 2015	U-96			
	6124304	Oct 04, 2014	U-96			
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363 002	5840763	Sep 01, 2015	U-96		M-112	Feb 09, 2015
	5866581	Oct 04, 2014	U-96			
	5916893	Sep 01, 2015	U-96			
	6124304	Oct 04, 2014	U-96			
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363 003	5840763	Sep 01, 2015	U-96		M-112	Feb 09, 2015
	5866581	Oct 04, 2014	U-96			
	5916893	Sep 01, 2015	U-96			
	6124304	Oct 04, 2014	U-96			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020325 001	5854267	Dec 29, 2015	U-267			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801 001	5667794	May 02, 2015		Y		
	5854267	Dec 29, 2015	U-267			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801 002	6814978	Aug 26, 2021	DP			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020902 001	5854267	Dec 29, 2015	U-368			
<u>FAMOTIDINE - FLUXID</u>						
N 021712 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE - FLUXID</u>						
N 021712 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519 001	8067033	Jul 18, 2026	DP			
	8067451	Jul 18, 2026	DP	U-1196		
	8309127	Jul 18, 2026	DP			
	8318202	Jul 18, 2026	DP			
	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026		U-1196		
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	5614520	Mar 25, 2019	DS DP	U-954		
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031		U-1346		
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	5614520	Mar 25, 2019	DS DP	U-954		
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031		U-1346		
<u>FENOFIBRATE - TRICOR</u>						
N 021203 001	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
<u>FENOFIBRATE - TRICOR</u>						
N 021203 003	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350 001	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350 002	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - LIPOFEN</u>						
N 021612 001	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - LIPOFEN</u>						
N 021612 002	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - LIPOFEN</u>						
N 021612 003	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - TRICOR</u>						
N 021656 001	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
<u>FENOFIBRATE - TRICOR</u>						
N 021656 002	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 001	7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020	U-1106			
	7863331	Aug 08, 2020	U-1107			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 003	7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020	U-1106			
	7863331	Aug 08, 2020	U-1107			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 004	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418 001	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418 002	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 006	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	6432440	Apr 20, 2018	DP U-1169			
	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	6432440	Apr 20, 2018	DP U-1169			
	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	5697896	Dec 16, 2014	DP			
	5843014	Dec 01, 2015	DP			
	6169920	Jan 02, 2018	DP			
	6171294	Jun 05, 2015	U-736			
	6181963	Nov 02, 2019	DP			
	6195582	Jan 28, 2019	DP U-736			
	6216033	Jun 05, 2015	DP			
	6425892	Jun 05, 2015	U-736			
	6842640	Jun 02, 2015	DP			
	6881208	Apr 19, 2022	U-736			
	6975902	Apr 01, 2024	DP			
	7018370	Jun 05, 2015	U-736			
	7027859	Sep 26, 2014	DP			
	7302293	Jun 05, 2015	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	7754702	Feb 13, 2027	DP U-1432			
	8895612	Jan 08, 2027	DP U-1620			
<u>FERRIC CITRATE - FERRIC CITRATE</u>						
N 205874 001	5753706	Feb 03, 2017	DP U-1577			
	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026	U-1577			
	8299298	Feb 18, 2024	DP			
	8338642	Feb 18, 2024	DS DP U-1577			
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024	U-1577			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	6599498	Jun 30, 2023	DS DP			
	7553479	Mar 08, 2020	DS DP			
	7871597	Mar 08, 2020	DS DP			
	8501158	Mar 08, 2020	U-1422			
	8591864	Mar 08, 2020	DP			
	8926947	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	6858650	Jul 03, 2022	DS U-913			
	7384980	May 11, 2019	DS DP U-913			
	7807715	Jun 07, 2027	DP U-913			
	7855230	May 11, 2019	U-913			
	7985772	May 11, 2019	DS DP U-913			
	8088398	Jun 07, 2027	DP U-913			
	8338478	May 11, 2019	DS DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	6858650	Jul 03, 2022	DS U-913			
	7384980	May 11, 2019	DS DP U-913			
	7807715	Jun 07, 2027	DP U-913			
	7855230	May 11, 2019	U-913			
	7985772	May 11, 2019	DS DP U-913			
	8088398	Jun 07, 2027	DP U-913			
	8338478	May 11, 2019	DS DP U-913			
	8501723	Jun 07, 2027	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY</u>						
A 203330 001					PC	Jun 20, 2015
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES</u>						
A 203330 002					PC	Jun 20, 2015
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N 020625 001	5738872	Feb 28, 2015				
	5855912	Feb 28, 2015				
	5932247	Feb 28, 2015				
	6037353	Mar 14, 2017	U-138			
	6113942	Feb 28, 2015				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 020872 005	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1160			
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 020872 006	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1160			
	6113942	Feb 28, 2015	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N 020872 007	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N 020872 008	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N 020872 009	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N 020872 010	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 021909 002	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1158		
	6037353	Mar 14, 2017		U-1466		
	6723348	Nov 26, 2021	DP	U-1466		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 021909 003	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017				
	6723348	Nov 26, 2021	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N 021963 001	6037353	Mar 14, 2017		U-772		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	6037353	Mar 14, 2017		U-1157		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	6037353	Mar 14, 2017		U-1157		
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N 020786 002	5855912	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1159		
	6039974	Jul 31, 2018	DP			
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N 021704 002	6037353	Mar 14, 2017		U-1159		
	6613357	Dec 25, 2020	DP	U-1159		
	RE39069	May 29, 2018	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7378508	Jul 31, 2027	DS DP		NCE	May 27, 2016
	7863249	Jul 31, 2027	DS DP			
	7906489	Mar 04, 2027		U-319		
	8586551	Apr 12, 2024	DS DP			
	8859510	Jul 31, 2027		U-319		
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001					NCE PED	Dec 17, 2019 Jun 17, 2020
<u>FINASTERIDE - PROSCAR</u>						
N 020180 001	5942519	Oct 23, 2018		U-280		
<u>FINGOLIMOD - GILENYA</u>						
N 022527 001	5604229	Feb 18, 2019	DS	U-1086	M-106	Jul 20, 2014
	6004565	Sep 23, 2017		U-1086	NCE	Sep 21, 2015
	8324283	Mar 29, 2026				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677 001	7807135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N 022273 001	7148207	Dec 20, 2022	DP U-944		ODE	Dec 18, 2015
	7547776	Dec 10, 2018	DS			
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N 021247 001	5776433	Jul 07, 2015	DP		M-128	Aug 28, 2016
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>						
N 021737 001	6217895	Mar 22, 2019	DP U-708			
	6548078	Mar 22, 2019	DP U-708			
<u>FLUOCINOLONE ACETONIDE - ILLUVIEN</u>						
N 201923 001	6217895	Mar 22, 2019	DP U-1597		NP	Sep 26, 2017
	6375972	Apr 26, 2020	DP U-1597			
	6548078	Mar 22, 2019	DP U-1597			
	8252307	Jun 27, 2019	DP			
	8871241	Aug 12, 2027	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
	8247395	Oct 22, 2022	DP			
	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUOCINONIDE - VANOS</u>						
N 021758 001	6765001	Dec 21, 2021	DP			
	7220424	Jan 07, 2023	U-861			
	7794738	Sep 11, 2022	U-1084			
	8232264	Mar 09, 2023	DP			
<u>FLUOROURACIL - CARAC</u>						
N 020985 001	6670335	Jun 02, 2021	DP U-68			
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 001	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 003	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 006	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>						
N 021235 001	5910319	May 29, 2017	U-396			
	5985322	May 29, 2017	U-397			
	RE39030	May 29, 2017	DP U-396			
	RE39030	May 29, 2017	DP U-397			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 001	6960577	Nov 01, 2017	U-962		M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 002	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 003	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 004	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800 7351401 8236282 8691185	Jan 24, 2023 Jan 24, 2023 May 21, 2024 Jan 24, 2023	DS DP U-336 DS DP U-336 DS DP U-336		NCE	Oct 25, 2018
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800 7351401 8236282 8691185	Jan 24, 2023 Jan 24, 2023 May 21, 2024 Jan 24, 2023	DS DP U-336 DS DP U-336 DS DP U-336		NCE	Oct 25, 2018
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	6858596 7101866 7541350 8062264 8147461 8347879 8752543	Aug 03, 2021 Aug 03, 2021 Aug 03, 2021 Apr 05, 2026 Oct 15, 2028 Jul 15, 2028 Apr 05, 2026	DP U-808 DS DP U-808 DP U-988 DP DP DP DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	5873360 7101866 7629335 8113199 8161968 8201556 8534281 8746242	Feb 23, 2016 Aug 03, 2021 Aug 03, 2021 Oct 23, 2027 Feb 05, 2028 Feb 05, 2029 Aug 10, 2029 Oct 11, 2030	DP DS DP U-1559 DP DP DP DP DP		NP	Aug 20, 2017
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	5873360 7101866 7629335 8113199 8161968 8201556 8534281 8746242	Feb 23, 2016 Aug 03, 2021 Aug 03, 2021 Oct 23, 2027 Feb 05, 2028 Feb 05, 2029 Aug 10, 2029 Oct 11, 2030	DP DS DP U-1559 DP DP DP DP DP		NP	Aug 20, 2017



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	5873360	Feb 23, 2016	DP		NP	May 10, 2016
	6537983	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1401			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1401			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Nov 11, 2025	DP U-1424			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1548			
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
N 020833 001	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
N 020833 002	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
N 020833 003	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001	7300669	Oct 20, 2019	DP U-835			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	5658549	Aug 19, 2014	DP U-710			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021		U-581		
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	5658549	Aug 19, 2014	DP U-710			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021		U-581		
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	5658549	Aug 19, 2014	DP U-710			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021		U-581		
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLONASE ALLERGY RELIEF</u>						
N 205434 001					M-147	Jul 23, 2017
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N 021077 001	5873360	Feb 23, 2016	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N 021077	002	5873360	Feb 23, 2016	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N 021077	003	5873360	Feb 23, 2016	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	001	5658549	Aug 19, 2014	DP	U-738	
		5674472	Oct 07, 2014	DP		
		6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6596260	Aug 10, 2014	DP		
		6743413	Jun 01, 2021		U-1591	
		6743413*PED	Dec 01, 2021			
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	002	5658549	Aug 19, 2014	DP	U-738	
		5674472	Oct 07, 2014	DP		
		6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6596260	Aug 10, 2014	DP		
		6743413	Jun 01, 2021		U-1591	
		6743413*PED	Dec 01, 2021			
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	003	5658549	Aug 19, 2014	DP	U-738	
		5674472	Oct 07, 2014	DP		
		6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6596260	Aug 10, 2014	DP		
		6743413	Jun 01, 2021		U-1591	
		6743413*PED	Dec 01, 2021			
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N 021192 001	6242003	Apr 13, 2020				
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033 001	7465462	May 10, 2020	DP U-929			
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033 002	7465462	May 10, 2020	DP U-929			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 001	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 002	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 003	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 004	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 005	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N 020582 001	5767251	Jun 16, 2015				
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N 020582 002	5767251	Jun 16, 2015				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 001	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP	U-567		
	5929028	Jan 14, 2018	DP	U-1366		
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-993		
	7563763	Aug 23, 2019		U-1183		
	7563763	Aug 23, 2019		U-1367		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 002	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP	U-567		
	5929028	Jan 14, 2018	DP	U-1366		
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-993		
	7563763	Aug 23, 2019		U-1183		
	7563763	Aug 23, 2019		U-1367		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 003	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP	U-567		
	5929028	Jan 14, 2018	DP	U-1366		
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-993		
	7563763	Aug 23, 2019		U-1183		
	7563763	Aug 23, 2019		U-1367		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 004	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP	U-567		
	5929028	Jan 14, 2018	DP	U-1366		
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019		U-993		
	7563763	Aug 23, 2019		U-1183		
	7563763	Aug 23, 2019		U-1367		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP	U-1366		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP	U-1366		
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 001	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 002	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 003	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 021765 001	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF</u>						
N 021765 002	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 021765 003	5767251	Jun 16, 2015	DS			
<u>FOMEPIZOLE - ANTIZOL</u>						
N 020696 001	7553863	Jun 30, 2027	DS	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N 020831 001	6488027	Mar 08, 2019				
	6887459	Nov 28, 2020	U-762			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	DP U-813			
	7348362	Jun 22, 2021	DP			
	7462645	Jun 22, 2021	DP U-813			
	8623922	Jun 22, 2021	DP			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	6068832	Aug 27, 2017	DP U-1068			
	7067502	May 21, 2020	DP U-1068			
	7566705	May 21, 2020	DP U-1068			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	6068832	Aug 27, 2017	DP U-1068			
	7067502	May 21, 2020	DP U-1068			
	7566705	May 21, 2020	DP U-1068			
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 021548 001	6436989	Dec 24, 2017	DS DP U-257		NPP	Apr 27, 2015
	6514953	Jul 15, 2019	DS DP U-257		PED	Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 022116 001	6436989	Dec 24, 2017	DS DP U-257		NPP	Apr 27, 2015
					PED	Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001	5691336	Mar 04, 2019	DS DP			
	5716942	Feb 10, 2015	U-850			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002	5691336	Mar 04, 2019	DS DP			
	5716942	Feb 10, 2015	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N 022244 001	6204257	Jul 01, 2022	DS DP U-945			
	6872838	Aug 07, 2018	DS			
<u>FROVATRIPTAN SUCCINATE - FROVA</u>						
N 021006 001	5464864	Nov 07, 2015	U-436			
	5827871	Oct 27, 2015	U-436			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		M-123	Nov 09, 2015
	7456160	Jan 09, 2021	U-596		PED	Nov 17, 2014
	8329680	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>GABAPENTIN - NEURONTIN</u>						
N 020235 001	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020235 002	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020235 003	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020882 001	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020882 002	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 021129 001	6054482	Apr 25, 2017				
	7256216	May 28, 2022	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	6340475	Sep 19, 2016	DP		ODE	Jan 28, 2018
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024		U-1114		
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP	U-1114		
	8252332	Oct 25, 2022	DP	U-1114		
	8333992	Oct 25, 2022	DP	U-1114		
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	6340475	Sep 19, 2016	DP		ODE	Jan 28, 2018
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024		U-1114		
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP	U-1114		
	8252332	Oct 25, 2022	DP	U-1114		
	8333992	Oct 25, 2022	DP	U-1114		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Nov 06, 2022	DS DP		I-652	Jun 06, 2015
	8026279	Nov 10, 2026	DS DP		NCE	Apr 06, 2016
	8048917	Nov 06, 2022	DS DP	U-1247	ODE	Jun 06, 2019
	8114909	Apr 11, 2026		U-1231		
	8686034	Jan 24, 2025		U-1231		
	8686034	Jan 24, 2025		U-1247		
	8795725	Jun 10, 2029	DP	U-1231		
	8795725	Jun 10, 2029	DP	U-1247		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Nov 06, 2022	DS DP		I-652	Jun 06, 2015
	8026279	Nov 10, 2026	DS DP		NCE	Apr 06, 2016
	8048917	Nov 06, 2022	DS DP	U-1247	ODE	Jun 06, 2019
	8114909	Apr 11, 2026		U-1231		
	8686034	Jan 24, 2025		U-1231		
	8686034	Jan 24, 2025		U-1247		
	8795725	Jun 10, 2029	DP	U-1231		
	8795725	Jun 10, 2029	DP	U-1247		
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N 021357 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N 021357 002					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N 021357 003					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N 021357 004					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE MULTIPACK</u>						
N 021358 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE MULTIPACK</u>						
N 021358 002					I-654	Jul 06, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001	5980864	Nov 09, 2016	DS DP U-1119		I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002	5980864	Nov 09, 2016	DS DP U-1119		I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003	5980864	Nov 09, 2016	DS DP U-1119		I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004	5980864	Nov 09, 2016	DS DP U-1119		I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005	5980864	Nov 09, 2016	DS DP U-1119		I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006					I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 001	6676929	May 04, 2020		DP		
	7011815	Feb 01, 2015			U-1112	
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015			U-1112	
	8017105	May 26, 2015	DS			
	8394356	Feb 01, 2015			U-1112	
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 002	6676929	May 04, 2020		DP		
	7011815	Feb 01, 2015			U-1112	
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015			U-1112	
	8017105	May 26, 2015	DS			
	8394356	Feb 01, 2015			U-1112	
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NCE	Mar 20, 2018
<u>GADOTERIDOL - PROHANCE</u>						
N 020131 001	5846519	Dec 08, 2015				
<u>GADOTERIDOL - PROHANCE MULTIPACK</u>						
N 021489 001	5846519	Dec 08, 2015				
<u>GADOXETATE DISODIUM - EOVIIST</u>						
N 022090 001	5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021			U-1239	
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169 001	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017		DP	U-322	
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169 002	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017		DP	U-322	
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169 003	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017		DP	U-322	



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 001	7160559	Dec 20, 2019	DP			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 002	7160559	Dec 20, 2019	DP			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 003	7160559	Dec 20, 2019	DP			
<u>GANCICLOVIR - ZIRGAN</u>						
N 022211 001					ODE	Sep 15, 2016
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057 001	5767082	Jun 16, 2015				
	6653286	Jun 16, 2018	U-1354			
<u>GATIFLOXACIN - ZYMAR</u>						
N 021493 001	5880283	Dec 05, 2015				
	6333045	Aug 20, 2019	DP			
<u>GATIFLOXACIN - ZYMAXID</u>						
N 022548 001	5880283	Dec 05, 2015	DS			
	6333045	Aug 20, 2019	DS DP			
<u>GEFITINIB - IRESSA</u>						
N 021399 001	5770599	May 05, 2017	DS DP U-881			
<u>GEMIFLOXACIN MESYLATE - FACTIVE</u>						
N 021158 001	5633262	Jun 15, 2015				
	5776944	Apr 04, 2017	DS DP			
	5962468	Jun 15, 2015		U-282		
	6262071	Sep 21, 2019		U-513		
	6331550	Sep 21, 2019		U-511		
	6340689	Sep 14, 2019		U-512		
	6455540	Sep 21, 2019		U-511		
	6723734	Mar 20, 2018	DS DP			
	6803376	Sep 21, 2019	DS DP U-608			
	6803376	Sep 21, 2019	DS DP U-609			
<u>GEMTUZUMAB OZOGAMICIN - MYLOTARG</u>						
N 021174 001	5693762	Dec 02, 2014				
	5739116	Apr 14, 2015				
	5767285	Jun 16, 2015				
	5773001	Jun 30, 2015		U-320		
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8232250	Aug 19, 2030	U-441		NP	Jan 28, 2017
	8399413	Aug 19, 2030	U-441			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925 001	6150383	Jun 19, 2016	U-753			
	6211205	Jun 19, 2016	U-753			
	6303640	Aug 09, 2016	U-753			
	6329404	Jun 19, 2016	DP U-753			
	7538125	Jun 19, 2016	DP			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925 002	6150383	Jun 19, 2016	U-753			
	6211205	Jun 19, 2016	U-753			
	6303640	Aug 09, 2016	U-753			
	6329404	Jun 19, 2016	DP U-753			
	7538125	Jun 19, 2016	DP			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001	5741803	Apr 21, 2015	DS DP U-690			
	5741803	Apr 21, 2015	DS DP U-781			
	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002	5741803	Apr 21, 2015	DS DP U-690			
	5741803	Apr 21, 2015	DS DP U-781			
	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	5741803	Apr 21, 2015	DS DP U-690			
	5741803	Apr 21, 2015	DS DP U-781			
	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366	Apr 19, 2020	DS			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 001	RE44459	Mar 26, 2019		U-1431		
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 002	RE44459	Mar 26, 2019		U-1431		
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 003	RE44459	Mar 26, 2019		U-1431		
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 001	6303146	Jul 14, 2019		U-412		
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 002	6303146	Jul 14, 2019		U-412		
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 003	6303146	Jul 14, 2019		U-412		
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032		U-1383	ODE	Feb 01, 2020
	8642012	Sep 22, 2030		U-1383		
<u>GLYCOPYRROLATE - ROBINUL</u>						
N 012827 001	7091236	Apr 24, 2024		U-877	Y	
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N 012827 002	7091236	Apr 24, 2024		U-877	Y	
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N 022571 001	7638552	Aug 20, 2023		U-1076	ODE	Jul 28, 2017
	7816396	Aug 20, 2023		U-1076		
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 019726 001	7118552	Apr 13, 2022		DP		
	7220247	Apr 09, 2022		DP		
	7500964	Feb 26, 2021		DP		
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 020578 001	7118552	Apr 13, 2022		DP		
	7220247	Apr 09, 2022		DP		
	7500964	Feb 26, 2021		DP		
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Oct 22, 2024		DP U-1011		
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239 001	5952340	Sep 14, 2016		U-519		
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239 002	5952340	Sep 14, 2016		U-519		
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239 004	5952340	Sep 14, 2016		U-519		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUAIFENESIN - MUCINEX</u>						
N 021282 001	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN - MUCINEX</u>						
N 021282 002	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-686			
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-686			
	7838032	Apr 28, 2020	DP			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001	5854290	Sep 21, 2015	U-494	Y	D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			PED	May 19, 2018
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002	5854290	Sep 21, 2015	U-494	Y	D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			PED	May 19, 2018
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003	5854290	Sep 21, 2015	U-494	Y	D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			PED	May 19, 2018
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004	5854290	Sep 21, 2015	U-494	Y	D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			PED	May 19, 2018
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	6034267	Mar 08, 2016	U-1087			
	7247655	Mar 08, 2016	DP U-1087			
	7348361	Nov 06, 2020	DP U-1087			
	7530461	Jan 11, 2017	DP U-1087			
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N 022058 001	8062652	Jun 16, 2026	U-1197			
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
N 021859 001	7767429	Sep 23, 2027	DS DP			
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N 020727 001	6465463	Sep 08, 2020	U-71			
	6784177	Sep 08, 2020	U-71			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 001	5994348	Jun 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 002	5994348	Jun 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 003	5994348	Jun 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 004	5994348	Jun 07, 2015	DP			
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 002	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 003	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 005	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 001	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 002	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 001	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 002	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 003	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 004	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 005	6294197	Jun 18, 2017	U-3			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE; IBUPROFEN - VICOPROFEN</u>						
N 020716 001	6348216	Jun 10, 2017				
	6599531	Jun 10, 2017				
<u>HYDROCORTISONE BUTYRATE - LOCOLD</u>						
N 022076 001	7378405	Dec 19, 2026	DP			
	7981877	Jan 23, 2025	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019891 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 002	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 003	6589960	Nov 09, 2020	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 001	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 002	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 003	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 004	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 001	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 002	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 003	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 004	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N 022041 001	5834448	Nov 14, 2016	DP			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N 022041 002	5834448	Nov 14, 2016	DP U-789			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N 021945 001					ODE	Feb 03, 2018
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455 001	6143326	Apr 21, 2017	U-642			
	6294196	Oct 07, 2019	DP			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455 002	6294196	Oct 07, 2019	DP			
	7192938	May 06, 2023	U-798			
	7410957	May 06, 2023	U-887			
	7718634	May 06, 2023	U-642			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021858 001	5662918	Sep 02, 2014	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	7514444	Dec 28, 2026	DS DP		I-680	Feb 12, 2017
	8008309	Dec 28, 2026	DS DP		I-689	Jul 28, 2017
	8476284	Dec 28, 2026		U-1456	NCE	Nov 13, 2018
	8476284	Dec 28, 2026		U-1491	ODE	Nov 13, 2020
	8497277	Dec 28, 2026		U-1456	ODE	Feb 12, 2021
	8497277	Dec 28, 2026		U-1491	ODE	Jul 28, 2021
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026		U-1491		
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031		U-1456		
	8754091	Dec 28, 2026	DP			
<u>IBUPROFEN - MIDOL LIQUID GELS</u>						
N 021472 001	6251426	Jun 25, 2018				
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001	6727286	Nov 27, 2021	DP U-981			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	6727286	Nov 27, 2021	DP U-981			
	8735452	Sep 30, 2029	U-981			
	8871810	Aug 27, 2030	U-1599			
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
	8415337	Mar 02, 2032	DS DP			
<u>IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD</u>						
N 021128 001	6211246	Jun 10, 2019				
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2015	DS DP U-1187		NCE	Aug 25, 2016
					ODE	Aug 25, 2018
<u>ICODEXTRIN - EXTRANEAL</u>						
N 021321 001	6077836	Jun 20, 2017		U-495		
	6248726	Jun 19, 2018		U-495		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8188146	Jan 27, 2020	DS DP		NP	Jul 26, 2015
	8293727	Feb 09, 2030		U-1287		
	8293728	Feb 09, 2030		U-1287		
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030		U-1287		
	8318715	Feb 09, 2030		U-1287		
	8357677	Feb 09, 2030		U-1287		
	8367652	Feb 09, 2030		U-1287		
	8377920	Feb 09, 2030		U-1287		
	8399446	Feb 09, 2030		U-1287		
	8415335	Feb 09, 2030		U-1287		
	8426399	Feb 09, 2030		U-1287		
	8431560	Feb 09, 2030		U-1287		
	8440650	Feb 09, 2030		U-1287		
	8445003	Apr 29, 2030		U-1287		
	8445013	Apr 29, 2030		U-1287		
	8501225	Apr 29, 2030		U-1287		
	8518929	Apr 29, 2030		U-1287		
	8524698	Apr 29, 2030		U-1287		
	8546372	Apr 29, 2030		U-1287		
	8551521	Apr 29, 2030		U-1287		
	8563608	Apr 29, 2030		U-1287		
	8617593	Apr 29, 2030		U-1478		
	8617594	Apr 29, 2030		U-1287		
	8623406	Apr 29, 2030		U-1478		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	RE44599	Jul 21, 2025	U-1558			
	RE44638	Aug 05, 2025	DS DP			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	RE44599	Jul 21, 2025	U-1558			
	RE44638	Aug 05, 2025	DS DP			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	5521184	Jan 04, 2015	DS DP			
	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	5521184	Jan 04, 2015	DS DP U-649			
	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	5521184	Jan 04, 2015	DS DP		I-666	Jan 25, 2016
	6894051	May 23, 2019	DS DP U-649		ODE	Dec 19, 2015
	6958335	Dec 19, 2021	U-791		ODE	Jan 25, 2020
	7544799	Jan 16, 2019	DS DP	Y		
	7544799*PED	Jul 16, 2019				
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	5521184	Jan 04, 2015			I-666	Jan 25, 2016
	6894051	May 23, 2019	DS DP U-649		ODE	Dec 19, 2015
	6958335	Dec 19, 2021	U-791		ODE	Jan 25, 2020
	7544799	Jan 16, 2019	DS DP	Y		
	7544799*PED	Jul 16, 2019				
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMIQUIMOD - ALDARA</u>						
N 020723 001	7696159	Apr 01, 2024	DS U-1047			
	7696159	Apr 01, 2024	DS U-1048			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	8236816	Dec 11, 2029	U-68			
	8299109	Dec 11, 2029	U-68			
	8598196	Aug 18, 2029	U-172			
	8598196	Aug 18, 2029	U-1455			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 002	8222270	Dec 11, 2029	U-68		NS	Jul 15, 2014
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Oct 10, 2020	DS DP U-1168		NCE	Jul 01, 2016
	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 001	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 003	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 005	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 006	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314 001	5753627	May 19, 2015			U-1125	
	5776894	Jul 07, 2015	DS DP			
	6123916	Sep 26, 2017	U-1125			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6432452	Aug 19, 2018	DS	U-68	NCE	Jan 23, 2017
	6844013	Dec 13, 2018	DS DP	U-1221		
	7410656	Aug 19, 2018	DS	U-1222		
	8278292	Feb 20, 2027	DS DP			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026		U-1440		
	8716271	Dec 18, 2026		U-1440		
	8735375	Dec 18, 2026		U-1440		
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6432452	Aug 19, 2018	DS	U-68	NCE	Jan 23, 2017
	6844013	Dec 13, 2018	DS DP	U-1221		
	7410656	Aug 19, 2018	DS	U-1222		
	8278292	Feb 20, 2027	DS DP			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026		U-1440		
	8716271	Dec 18, 2026		U-1440		
	8735375	Dec 18, 2026		U-1440		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N 021172 001	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N 021172 002	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N 021172 003	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 50/50</u>						
N 021810 001	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG</u>						
N 020986 001	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	5693027	Dec 02, 2014	DP			
	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET</u>						
N 020986 004	5866538	Jun 20, 2017	DP			
	RE41956	Jan 21, 2021	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	5618913*PED	Dec 07, 2014				
	5866538	Jun 20, 2017	DP			
	5866538*PED	Dec 20, 2017				
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N 021536 001	5750497	Jun 16, 2019	DS DP U-668		M-115	Apr 06, 2015
	5866538	Jun 20, 2017	DS DP		M-117	May 18, 2015
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DS DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N 021536 003	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DS DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N 021536 004	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DS DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N 021081 001	5656722	Aug 12, 2014	DS DP U-948			
	7476652	Jul 23, 2023	DP			
	7713930	Jun 13, 2023	DP			
	7918833	Sep 23, 2027	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 001	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 002	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG</u>						
N 020563 001					NR	Oct 12, 2015
<u>INSULIN LISPRO RECOMBINANT - HUMALOG PEN</u>						
N 020563 002					NR	Oct 12, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563 003	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868 001	5740794	Apr 21, 2015	DP			
	6257233	May 14, 2019		U-704		
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6685967	Sep 11, 2018	DP			
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868 002	5740794	Apr 21, 2015	DP			
	6257233	May 14, 2019		U-704		
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6685967	Sep 11, 2018	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30</u>						
N 019717 001	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN</u>						
N 019717 002	7291132	Aug 09, 2024	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N</u>						
N 018781	001	7291132	Aug 09, 2024	DP		
<u>ILOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N 022290	001				I-669 ODE	Mar 20, 2016 Sep 19, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454	001	5310912	Feb 25, 2015	DS	NCE	Jan 14, 2016
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527	001	5676930	Oct 14, 2014	DP		
		5683677	Nov 04, 2014	DP		
		6739333	May 26, 2020	DP		
		6983743	May 26, 2020	DP		
<u>IRBESARTAN - AVAPRO</u>						
N 020757	001	6342247	Jun 07, 2015			
<u>IRBESARTAN - AVAPRO</u>						
N 020757	002	6342247	Jun 07, 2015			
<u>IRBESARTAN - AVAPRO</u>						
N 020757	003	6342247	Jun 07, 2015			
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571	001	6403569	Apr 28, 2020	U-449		
		6794370	May 01, 2020	U-606		
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571	002	6403569	Apr 28, 2020	U-449		
		6794370	May 01, 2020	U-606		
<u>IRON DEXTRAN - DEXFERRUM</u>						
N 040024	001	5624668	Sep 29, 2015			
<u>IRON SUCROSE - VENOFER</u>						
N 021135	001				NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N 021135	002				NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N 021135	005				NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	001	7435427	Sep 21, 2021	DP	NP	May 25, 2015
		8367102	Sep 21, 2021	U-1347		
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	002	7435427	Sep 21, 2021	DP	NP	May 25, 2015
		8367102	Sep 21, 2021	U-1347		
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	003	7435427	Sep 21, 2021	DP	NP	May 25, 2015
		8367102	Sep 21, 2021	U-1347		
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	004	7435427	Sep 21, 2021	DP	NP	May 25, 2015
		8367102	Sep 21, 2021	U-1347		
<u>ITRACONAZOLE - SPORANOX</u>						
N 020657	001	5707975	Jan 13, 2015			
		6407079	Jun 18, 2019			
<u>ITRACONAZOLE - SPORANOX</u>						
N 020966	001	6407079	Jun 18, 2019			
<u>ITRACONAZOLE - ONMEL</u>						
N 022484	001	6509038	May 12, 2017	DP	U-1054	
		7081255	May 12, 2017	DP	U-1054	
		8486456	Oct 03, 2028	DP	U-1054	
		8591948	May 12, 2017	DP	U-1054	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	7495103	May 20, 2027	DS DP		NCE	Jan 31, 2017
	8324242	Apr 18, 2027		U-1311	ODE	Jan 31, 2019
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
<u>IVERMECTIN - SKLICE</u>						
N 202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
	8791153	Oct 12, 2027	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001					NP	Dec 19, 2017
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065 001	6670384	Jan 23, 2022	DP U-959		M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-960		PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
	RE41911	Sep 28, 2020	DS DP U-961			
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065 002	6670384	Jan 23, 2022	DP U-959		M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-960		PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
	RE41911	Sep 28, 2020	DS DP U-961			
<u>KETOCONAZOLE - EXTINA</u>						
N 021738 001	7553835	Oct 19, 2018	DP U-245			
	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	7179475	Dec 04, 2018	DP U-792			
	8232276	Nov 24, 2020	DP			
	8735393	Dec 04, 2018	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8008338	May 24, 2027	DS DP U-1181			
	8207215	May 28, 2024	U-1251			
	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024	U-1441			
	8541463*PED	Nov 28, 2024				
	8648107	May 28, 2024	DP			
	8906950	May 28, 2024	U-1626			
<u>KETOROLAC TROMETHAMINE - SPRIX</u>						
N 022382 001	6333044	Dec 25, 2018	DP U-1057			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	7842714	Aug 15, 2029	DS DP			
	8512717	Mar 07, 2028	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	8586633	Jul 30, 2023	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	5654301	Aug 05, 2014	DS DP U-914		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1566		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	5654301	Aug 05, 2014	DS DP U-914		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1566		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	5654301	Aug 05, 2014	DS DP U-914		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1566		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	5654301	Aug 05, 2014	DS DP U-914		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1566		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001	5654301	Aug 05, 2014	DS DP U-911		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1565		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1568		I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	5654301	Aug 05, 2014	DS DP U-914		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1566		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		I-696	Aug 29, 2017
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP U-248			
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	6004968	Mar 20, 2018				
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N 021003 001	5905082	May 18, 2016				
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N 021004 001	6004968	Mar 20, 2018				
<u>LAMIVUDINE; ZIDOVUDINE - COMBIVIR</u>						
N 020857 001	5905082	May 18, 2016	DS DP U-248			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001	5595760	Mar 08, 2020	DP U-831		I-701	Dec 19, 2017
					ODE	Aug 30, 2014
					ODE	Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002	5595760	Mar 08, 2020	DP U-831		I-701	Dec 19, 2017
					ODE	Aug 30, 2014
					ODE	Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003	5595760	Mar 08, 2020	DP U-831		I-701	Dec 19, 2017
					ODE	Aug 30, 2014
					ODE	Dec 16, 2021
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID IV</u>						
N 021566 001	7396841	Aug 17, 2021	DP U-947			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 001	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 002	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 003	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 004	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	6391874	Jul 11, 2017	DS DP U-800			
	6391874	Jul 11, 2017	DS DP U-1429			
	6713485	Sep 29, 2020	DS DP U-800			
	6713485	Sep 29, 2020	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-1429			
	6828320	Jul 11, 2017	U-800			
	6828320	Jul 11, 2017	U-1429			
	7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			
	8821927	Jun 12, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Oct 10, 2019
	8088368	May 12, 2030	DS DP			
	8273341	May 12, 2030	U-1470			
	8334270	Mar 21, 2028	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8822430	May 12, 2030	DS DP U-1470			
	8841278	May 12, 2030	DP U-1470			
	8889159	Mar 26, 2029	DP U-1470			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS DP	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	NS	Jun 05, 2016
	6281230	Jul 24, 2016		U-1212	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 019732 001	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 002	6036976	Dec 13, 2016			M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 005	6036976	Dec 13, 2016			M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 006	6036976	Dec 13, 2016			M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 007	6036976	Dec 13, 2016	DP		NP	Aug 15, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 008	6036976	Dec 13, 2016	DP		NP	Aug 15, 2014

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517	001	6036976				Dec 13, 2016
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517	002	6036976				Dec 13, 2016
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517	003	6036976		DP		Dec 13, 2016
		7429559		DP		Dec 13, 2016
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020708	001	6036976				Dec 13, 2016
<u>LEUPROLIDE ACETATE - VIADUR</u>						
N 021088	001	5728396		U-316		Jan 30, 2017
		5932547				Jun 13, 2017
		5985305				Jan 30, 2017
		6113938				Jul 24, 2018
		6124261				Jun 13, 2017
		6132420				Jan 30, 2017
		6156331				Jan 30, 2017
		6235712				Jun 13, 2017
		6375978				Dec 17, 2018
		6395292				Jan 30, 2017
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343	001	6565874		DP U-801		Oct 28, 2018
		6626870		DP		Mar 27, 2020
		6773714		DP U-801		Oct 28, 2018
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379	001	6565874		DP U-801		Oct 28, 2018
		6626870		DP		Mar 27, 2020
		6773714		DP U-801		Oct 28, 2018
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488	001	6565874		DP U-801		Oct 28, 2018
		6626870		DP		Mar 27, 2020
		6773714		DP U-801		Oct 28, 2018
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731	001	6565874		DP U-621		Oct 28, 2018
		6626870		DP		Mar 27, 2020
		6773714		U-621		Oct 28, 2018
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696	001	6036976		DP		Dec 13, 2016
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696	002	6036976		DP		Dec 13, 2016
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	001	6451289				Mar 21, 2021
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	002	6451289				Mar 21, 2021
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	003	6451289				Mar 21, 2021
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	004	6451289		DP		Mar 21, 2021
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730	001	5836299		DP		Nov 17, 2015
		7256310		DS DP U-636		Oct 08, 2024
		8765153		DP		Dec 08, 2023

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 001	8802142	Jun 07, 2031	DP		NPP	Dec 16, 2014
	8802142*PED	Dec 07, 2031			PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 002	8802142	Jun 07, 2031	DP		NPP	Dec 16, 2014
	8802142*PED	Dec 07, 2031			PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 003	8802142	Jun 07, 2031	DP		NPP	Dec 16, 2014
	8802142*PED	Dec 07, 2031			PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 004	8802142	Jun 07, 2031	DP		NPP	Dec 16, 2014
	8802142*PED	Dec 07, 2031			PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021505 001					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285 001	7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285 002	7858122	Sep 17, 2028	DP			
<u>LEVOPUVIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N 020997 001	5708011	Oct 13, 2014		U-276		
<u>LEVOPUVIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N 020997 002	5708011	Oct 13, 2014		U-276		
<u>LEVOPUVIVACAINE HYDROCHLORIDE - CHIROCAINE</u>						
N 020997 003	5708011	Oct 13, 2014		U-276		
<u>LEVOCARNITINE - CARNITOR</u>						
N 020182 001	6335369	Jan 18, 2021		U-433		
	6429230	Jan 18, 2021		U-433		
	6696493	Jan 18, 2021		U-433		
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N 021721 001	6806256	Feb 26, 2022	DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP		ODE	Mar 07, 2015
					ODE	Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP		ODE	Mar 07, 2015
					ODE	Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP		ODE	Mar 07, 2015
					ODE	Apr 29, 2018
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031		U-839		
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598	Mar 02, 2031		U-839		
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598	Mar 02, 2031		U-839		
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598	Mar 02, 2031		U-839		
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023		U-839		
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	5785053	Dec 05, 2015	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N 021998	001				RTO*	Apr 30, 2016
					RTO**	Apr 30, 2016
<u>LEVONORGESTREL - SKYLA</u>						
N 203159	001	5785053	Dec 05, 2015	DP	NP	Jan 09, 2016
		7252839	Nov 13, 2023	DP		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	001	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	002	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	003	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	004	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	005	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	006	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	007	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	008	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	009	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	010	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	011	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	012	6555581	Feb 15, 2022			
		7067148	Feb 15, 2022	DP		
		7101569	Oct 02, 2023		U-759	



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 002	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 005	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 006	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 007	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 008	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 009	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 010	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 011	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7723390	Mar 14, 2024		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7723390	Mar 14, 2024		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7723390	Mar 14, 2024		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7723390	Mar 14, 2024		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7723390	Mar 14, 2024		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7723390	Mar 14, 2024		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7723390	Mar 14, 2024		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7723390	Mar 14, 2024		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7723390	Mar 14, 2024		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 022121 001	7723390	Mar 14, 2024		DP		
<u>LIDOCAINE - LIDODERM</u>						
N 020612 001	5827529	Oct 27, 2015		U-486		
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	5899880	May 04, 2016		DP		
	6004286	Mar 17, 2017		DP		
	6881200	Jun 11, 2016		DP		
	8540665	Oct 22, 2029		U-1438		
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221 001	8759401	Jul 24, 2026		DP U-1523		
<u>LIDOCAINE; PRILOCAINE - ORAOIX</u>						
N 021451 001	6031007	Apr 01, 2017		DP U-553		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N 021623 001	5658583	Jul 28, 2015	DP			
	5919479	Jul 28, 2015	DP			
	6306431	Jul 28, 2015	DP			
	6465006	Jul 28, 2015	DP			
	6465709	Jul 07, 2020	DP			
	6546281	Jul 28, 2015	DP			
	6780426	Jul 28, 2015	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	5919479	Jul 28, 2015	DP			
	6528086	Sep 28, 2019	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024		U-1278		
	8748573	Jun 20, 2031		U-1515		
	8748573	Jun 20, 2031		U-1516		
	8802628	Jul 24, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024		U-1278		
	8748573	Jun 20, 2031		U-1515		
	8748573	Jun 20, 2031		U-1516		
	8802628	Jul 24, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	6303661	Apr 24, 2017		U-774	M-118	Aug 13, 2015
	6303661	Apr 24, 2017		U-1270	M-121	Aug 13, 2015
	6890898	Feb 02, 2019		U-493	NCE	May 02, 2016
	6890898	Feb 02, 2019		U-1270		
	7078381	Feb 02, 2019		U-493		
	7078381	Feb 02, 2019		U-1270		
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019		U-493		
	7459428	Feb 02, 2019		U-1270		
	8119648	Aug 12, 2023		U-774		
	8119648	Aug 12, 2023		U-1270		
	8178541	Aug 12, 2023		U-775		
	8178541	Aug 12, 2023		U-1244		
	8178541	Aug 12, 2023		U-1245		
	8178541	Aug 12, 2023		U-1270		
	8673927	Aug 23, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8883805	Nov 26, 2025	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	6303661	Apr 24, 2017		U-802	M-146	Jul 30, 2017
	6890898	Feb 02, 2019		U-1039	NC	Jan 30, 2015
	7078381	Feb 02, 2019		U-1039	NCE	May 02, 2016
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019		U-1039		
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP	U-775		
	8673927	Aug 23, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8883805	Nov 26, 2025	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	6303661	Apr 24, 2017		U-802	M-146	Jul 30, 2017
	6890898	Feb 02, 2019		U-1039	NC	Jan 30, 2015
	7078381	Feb 02, 2019		U-1039	NCE	May 02, 2016
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019		U-1039		
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP	U-775		
	8673927	Aug 23, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8883805	Nov 26, 2025	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	6303661	Apr 24, 2017		U-802	M-146	Jul 30, 2017
	6890898	Feb 02, 2019		U-1039	NC	Jan 30, 2015
	7078381	Feb 02, 2019		U-1039	NCE	May 02, 2016
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019		U-1039		
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP	U-775		
	8673927	Aug 23, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8883805	Nov 26, 2025	DP			
<u>LINEZOLID - ZYVOX</u>						
N 021130 001	5688792	Nov 18, 2014	DS	U-319		
	6514529	Mar 15, 2021		DP		
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021130 002	5688792	Nov 18, 2014	DS	U-319		
	6514529	Mar 15, 2021		DP		
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 001	5688792	Nov 18, 2014		U-319		
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021132 001	5688792	Nov 18, 2014	DS	U-319		
	6559305	Jan 29, 2021	DS			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6004297	Jan 28, 2019		DP	M-115	Apr 06, 2015
	6268343	Aug 22, 2022	DS DP	U-968	NCE	Jan 25, 2015
	6458924	Aug 22, 2017	DS DP	U-968		
	7235627	Aug 22, 2017	DS DP			
	8114833	Aug 13, 2025		DP		
	RE41956	Jan 21, 2021		DP		
	RE43834	Jan 28, 2019		DP		
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001					NCE	Jan 25, 2015
					NP	Jan 25, 2017

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Jun 29, 2023	U-727		I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Jun 29, 2023	U-727		I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Jun 29, 2023	U-727		I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Jun 29, 2023	U-842		I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Jun 29, 2023	U-842		I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Jun 29, 2023	U-842		I-645	Jan 31, 2015
	7223735	Jun 29, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 28, 2023	U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678770	Mar 25, 2023	U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP U-842			
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					I-645	Jan 31, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2015	DS U-1317		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS U-1317		ODE	Dec 21, 2019
	6492365	Dec 10, 2019	U-1318			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2015	DS U-1317		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS U-1317		ODE	Dec 21, 2019
	6492365	Dec 10, 2019	U-1318			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2015	DS U-1317		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS U-1317		ODE	Dec 21, 2019
	6492365	Dec 10, 2019	U-1318			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N 020448 001	6814978	Aug 26, 2021	DP			
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMP TOM RELIEF</u>						
N 020606 001	5679376	Oct 21, 2014			Y	
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMP TOM RELIEF</u>						
N 021140 001	6103260	Jul 17, 2017	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021226 001	5648497	Jul 15, 2014				
	5914332	Dec 13, 2015	U-351			
	6037157	Jun 26, 2016	U-346			
	6232333	Nov 07, 2017				
	6284767	Feb 15, 2016	DP U-401			
	6284767	Feb 15, 2016	DP U-688			
	6458818	Nov 07, 2017				
	6521651	Nov 07, 2017	DP			
	6703403	Jun 26, 2016	U-257			
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251 001	5648497	Jul 15, 2014	DS			
	5914332	Dec 13, 2015	DS DP U-351			
	5914332	Dec 13, 2015	DS DP U-895			
	6037157	Jun 26, 2016	U-346			
	6037157	Jun 26, 2016	U-895			
	6284767	Feb 15, 2016	DP U-401			
	6284767	Feb 15, 2016	DP U-895			
	6703403	Jun 26, 2016	U-257			
	6703403	Jun 26, 2016	U-895			
	6911214	Nov 28, 2021	DP U-895			
	8501219	Nov 28, 2021	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	5648497	Jul 15, 2014	DS DP			
	5914332	Dec 13, 2015	DS DP U-688			
	6037157	Jun 26, 2016	U-688			
	6284767	Feb 15, 2016	DP U-688			
	6703403	Jun 26, 2016	U-688			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8268349	Aug 25, 2024	DP			
	8309613	Dec 24, 2024	U-688			
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	5648497	Jul 15, 2014	DS DP			
	5914332	Dec 13, 2015	DS DP U-688			
	6037157	Jun 26, 2016	U-688			
	6284767	Feb 15, 2016	DP U-688			
	6703403	Jun 26, 2016	U-688			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8268349	Aug 25, 2024	DP			
	8309613	Dec 24, 2024	U-688			
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 200738 001					PED	Oct 15, 2014
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP		NDF	Sep 28, 2015
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 001	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 002	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 003	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 004	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 001	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 002	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 003	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 004	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	6716416	May 20, 2022	DP		NDF	Dec 21, 2015
	7052679	Oct 26, 2021	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 28, 2024	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Jul 25, 2022	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	5284858	Jul 14, 2014	DS		I-670	Apr 19, 2016
	6414016	Sep 05, 2020		U-717		
	6414016	Sep 05, 2020		U-1392		
	6583174	Oct 16, 2020	DP			
	6982283	Dec 04, 2022		U-1391		
	7064148	Aug 30, 2022		U-739		
	7064148	Aug 30, 2022		U-1404		
	7417067	Oct 16, 2020	DP			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020		U-1203		
	8071613	Sep 05, 2020		U-1393		
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022		U-1214		
	8097653	Nov 14, 2022		U-1394		
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8389542	Nov 14, 2022	DP	U-1345		
	8389542	Nov 14, 2022	DP	U-1395		
	8748481	Sep 01, 2025		U-1520		
	8779187	Jul 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	5284858	Jul 14, 2014	DS			
	6414016	Sep 05, 2020		U-874		
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022		U-739		
	7064148	Aug 30, 2022		U-873		
	7417067	Oct 16, 2020	DP			
	7795312	Sep 17, 2024		U-1085		
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020		U-1202		
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025		U-1519		
	8779187	Jan 23, 2027	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N 021746 001	5407914	Nov 17, 2014	DS DP	U-1242		
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2016	DS DP	U-540	NCE	Nov 14, 2018
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		D-134	Apr 26, 2015
	8729085	May 26, 2026	DP		I-674	Jun 28, 2016
	8883794	May 26, 2026	DP		NCE	Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		D-134	Apr 26, 2015
	8729085	May 26, 2026	DP		I-674	Jun 28, 2016
	8883794	May 26, 2026	DP		NCE	Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS		D-134	Apr 26, 2015
	8729085	May 26, 2026	DP		I-674	Jun 28, 2016
	8883794	May 26, 2026	DP		NCE	Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS		D-134	Apr 26, 2015
	8729085	May 26, 2026	DP		I-674	Jun 28, 2016
	8883794	May 26, 2026	DP		NCE	Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	5532372	Jul 02, 2018	DS		D-134	Apr 26, 2015
	8729085	May 26, 2026	DP		I-674	Jun 28, 2016
	8883794	May 26, 2026	DP		NCE	Oct 28, 2015
<u>LUTROPIN ALFA - LUVERIS</u>						
N 021322 001	5767251	Jun 16, 2015	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Oct 12, 2022	DS DP		NCE	Oct 18, 2018
	8268847	Apr 18, 2029		U-1446	ODE	Oct 18, 2020
	8367685	Oct 04, 2028	DP U-1445			
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N 021910 001	5945449	Oct 31, 2017	DP U-785			
	7300674	Mar 04, 2023	DP U-785			
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35</u>						
N 021910 002	5945449	Oct 31, 2017	DP U-785			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021850 001	6489346	Jul 16, 2016	DS DP U-588			
	6645988	Jul 16, 2016	DS DP U-588			
	6699885	Jul 16, 2016	U-588			
	7399772	Jul 16, 2016	U-588			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021850 002	6489346	Jul 16, 2016	DS DP U-623			
	6645988	Jul 16, 2016	DS DP U-623			
	6699885	Jul 16, 2016	U-623			
	7399772	Jul 16, 2016	U-623			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N 022456 001	6489346	Jul 16, 2016	DP U-588			
	6489346	Jul 16, 2016	DP U-1021			
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP U-588			
	6699885	Jul 16, 2016	DP U-1021			
	7399772	Jul 16, 2016	DP U-588			
	7399772	Jul 16, 2016	DP U-1021			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N 022456 002	6489346	Jul 16, 2016	DP U-588			
	6489346	Jul 16, 2016	DP U-1021			
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP U-588			
	6699885	Jul 16, 2016	DP U-1021			
	7399772	Jul 16, 2016	DP U-588			
	7399772	Jul 16, 2016	DP U-1021			
<u>MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N 022372 001	6946149	Mar 07, 2023	DP U-837			
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N 203595 001					NC	Jan 18, 2016
<u>MALATHION - OVIDE</u>						
N 018613 001	7560445	Feb 01, 2027	DS DP U-986			
	7977324	Aug 14, 2026	DP			
<u>MANNITOL - ARIDOL KIT</u>						
N 022368 001	5817028	Feb 23, 2015		U-1091		
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001	6586430	Dec 01, 2019	DS DP U-824			
	6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002	6586430	Dec 01, 2019	DS DP U-824			
	6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MECASERMIN RECOMBINANT - INCRELEX</u>						
N 021839 001	5681814	Sep 18, 2017	DP			
	5824642	Jul 08, 2014	U-681			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>						
N 021884	001 5681818	Oct 28, 2014	U-697			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317	001 7838564	Mar 07, 2026	DP		NDF	Aug 23, 2016
	7872050	Jul 08, 2029	U-1427		ODE	Aug 23, 2020
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026	U-1427			
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104</u>						
N 021583	001 6495534	May 15, 2020	DP			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778	001 6592903	Sep 21, 2020	DP			
	7101576	Apr 22, 2024	U-755			
<u>MELOXICAM - MOBIC</u>						
N 021530	001 6184220	Mar 25, 2019	DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487	001 5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487	002 5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021627	001 5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>MENOTROPINS (FSH;LH); MENOTROPINS (FSH;LH) - MENOPUR</u>						
N 021663 001					D-139	Feb 19, 2017

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	001	8809615	Jan 03, 2030	DP		
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	002	8809615	Jan 03, 2030	DP		
<u>MEQUINOL; TRETINOIN - SOLAGE</u>						
N 020922	001	6353029	Aug 24, 2020			
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919	001				ODE	Apr 28, 2021
<u>MESALAMINE - SFROWASA</u>						
N 019618	002	7645801	Jul 24, 2027	DS DP		
<u>MESALAMINE - CANASA</u>						
N 021252	002	8217083	Jun 06, 2028	DP		
		8436051	Jun 06, 2028	DP		
<u>MESALAMINE - ASACOL HD</u>						
N 021830	001	6893662	Nov 15, 2021	DP U-141		
		8580302	Nov 15, 2021	DP		
<u>MESALAMINE - LIALDA</u>						
N 022000	001	6773720	Jun 08, 2020	DP	I-640	Jul 14, 2014
<u>MESALAMINE - APRISO</u>						
N 022301	001	6551620	Apr 20, 2018	DS DP U-907		
		8337886	Apr 20, 2018	DP U-1310		
		8496965	Apr 20, 2018	DP		
		8865688	May 01, 2030	U-1310		
		8911778	Apr 20, 2018	DP U-1310		
<u>MESALAMINE - DELZICOL</u>						
N 204412	001	6649180	Apr 13, 2020	DP		
<u>METAXALONE - SKELAXIN</u>						
N 013217	003	7122566	Feb 06, 2026	U-915		
		7714006	Dec 03, 2021	U-1050		
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202	001	6475521	Mar 19, 2018			
		6660300	Mar 19, 2018	U-542		
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202	004	6475521	Mar 19, 2018			
		6660300	Mar 19, 2018	U-542		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	001	6099859	Mar 20, 2018	DP		
		6495162	Mar 20, 2018	DP		
		6790459	Mar 17, 2021	U-604		
		6866866	Mar 17, 2021	DP		
		7919116	Mar 20, 2018	DP		
		8475841	Mar 20, 2018	U-604		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	002	6099859	Mar 20, 2018	DP		
		6495162	Mar 20, 2018	DP		
		6790459	Mar 17, 2021	U-604		
		6866866	Mar 17, 2021	DP		
		7919116	Mar 20, 2018	DP		
		8475841	Mar 20, 2018	U-604		
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591	001	6890957	Sep 14, 2023	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 001	6340475	Sep 19, 2016	DS DP U-669			
	6488962	Jun 20, 2020	DS DP			
	6635280	Sep 19, 2016	DS DP			
	6723340	Oct 25, 2021	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002	6488962	Jun 20, 2020	DS DP			
	7780987	Mar 23, 2025	DS DP			
	8323692	Mar 23, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	5965584	Jun 19, 2016	DP U-1055		M-116	May 17, 2015
	6166042	Jun 19, 2016	U-679			
	6166043	Jun 19, 2016	U-679			
	6172090	Jun 19, 2016	U-679			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	5965584	Jun 19, 2016	DP U-1055		M-116	May 17, 2015
	6166042	Jun 19, 2016	U-679			
	6166043	Jun 19, 2016	U-679			
	6172090	Jun 19, 2016	U-679			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	5965584	Jun 19, 2016	DP U-973			
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016	U-973			
	6166043	Jun 19, 2016	U-973			
	6172090	Jun 19, 2016	U-973			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	5965584	Jun 19, 2016	DP U-973			
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016	U-973			
	6166043	Jun 19, 2016	U-973			
	6172090	Jun 19, 2016	U-973			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
	8668931	Sep 19, 2023	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 001	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 002	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 003	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 004	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 005	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
	RE44186	Jul 31, 2023	DS DP U-1097		NCE	Jul 31, 2014
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-134	May 24, 2016
					NCE	Jul 31, 2014
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-134	May 24, 2016
					NCE	Jul 31, 2014



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661	Apr 24, 2017				U-802
	6699871	Jul 26, 2022	DS DP			U-802
	6890898	Feb 02, 2019				U-803
	6890898	Feb 02, 2019				U-1036
	6890898	Feb 02, 2019				U-1038
	7078381	Feb 02, 2019				U-803
	7078381	Feb 02, 2019				U-1036
	7078381	Feb 02, 2019				U-1038
	7125873	Jul 26, 2022	DP			U-803
	7125873	Jul 26, 2022	DP			U-1036
	7125873	Jul 26, 2022	DP			U-1038
	7326708	Apr 11, 2026	DS DP			U-802
	7459428	Feb 02, 2019				U-1036
	8414921	Jul 21, 2028	DP			U-1036
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661	Apr 24, 2017				U-802
	6699871	Jul 26, 2022	DS DP			U-802
	6890898	Feb 02, 2019				U-803
	6890898	Feb 02, 2019				U-1036
	6890898	Feb 02, 2019				U-1038
	7078381	Feb 02, 2019				U-803
	7078381	Feb 02, 2019				U-1036
	7078381	Feb 02, 2019				U-1038
	7125873	Jul 26, 2022	DP			U-803
	7125873	Jul 26, 2022	DP			U-1036
	7125873	Jul 26, 2022	DP			U-1038
	7326708	Apr 11, 2026	DS DP			U-802
	7459428	Feb 02, 2019				U-1036
	8414921	Jul 21, 2028	DP			U-1036
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661	Apr 24, 2017				U-1227
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP			U-1227
	6890898	Feb 02, 2019				U-1228
	7078381	Feb 02, 2019				U-1227
	7125873	Jul 26, 2022	DP			U-1227
	7326708	Apr 11, 2026	DS DP			U-1227
	7459428	Feb 02, 2019				U-1227
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661	Apr 24, 2017				U-1227
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP			U-1227
	6890898	Feb 02, 2019				U-1228
	7078381	Feb 02, 2019				U-1227
	7125873	Jul 26, 2022	DP			U-1227
	7326708	Apr 11, 2026	DS DP			U-1227
	7459428	Feb 02, 2019				U-1227
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661	Apr 24, 2017				U-1227
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP			U-1227
	6890898	Feb 02, 2019				U-1228
	7078381	Feb 02, 2019				U-1227
	7125873	Jul 26, 2022	DP			U-1227
	7326708	Apr 11, 2026	DS DP			U-1227
	7459428	Feb 02, 2019				U-1227

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - RASUVO</u>						
N 205776 001	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 002	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 003	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 004	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 005	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 006	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 007	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 008	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 009	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 010	8664231	Jun 01, 2029	U-1442			
<u>METHYL AMINOLEVULINATE HYDROCHLORIDE - METVIXIA</u>						
N 021415 001	6034267	Mar 08, 2016	U-804			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	6559158	Nov 03, 2017	U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	6559158	Nov 03, 2017	U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 001	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 002	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 003	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 004	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 001	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 002	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 003	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 004	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP	U-472		
	6635284	Dec 04, 2015	DP	U-591		
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 001	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 002	7691880	Oct 07, 2024	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP		NDF	Sep 27, 2015
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
	8563033	Feb 15, 2031	DP U-1415			
	8778390	Feb 15, 2031	DP U-1543			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246 001	6413549	Jul 11, 2017	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246 002	6413549	Jul 11, 2017	DP			
<u>METRONIDAZOLE - METROGEL</u>						
N 021789 001	6881726	Feb 21, 2022	DP U-743			
	7348317	Feb 21, 2022	DP U-743			
<u>METRONIDAZOLE - VANDAZOLE</u>						
N 021806 001	7456207	Sep 22, 2024	DP			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001					NP	Mar 24, 2017
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
<u>MICONAZOLE - ORAVIG</u>						
N 022404 001	6916485	Sep 11, 2022	DP U-1051			
	7651698	Sep 11, 2022	U-1051			
	8518442	Sep 11, 2022	DP			
<u>MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N 021308 001	6153635	Nov 28, 2020			Y	
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026 001	8147852	Mar 30, 2028	U-1426			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001					NP	Feb 17, 2015
					ODE	Feb 17, 2019

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 001	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 002	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 003	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 004	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001					NCE ODE	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	6682348	Mar 29, 2022	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 001	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 002	5908838	Feb 19, 2018				
	7541347	Apr 02, 2027				
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 003	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 004	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 005	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
	8722650	Jun 24, 2025				
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
	8722650	Jun 24, 2025				
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	5908838	Feb 19, 2018				
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
	8722650	Jun 24, 2025				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	5908838	Feb 19, 2018				
	7541347	Apr 02, 2027				
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	5908838	Feb 19, 2018				
	7541347	Apr 02, 2027				
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	5908838	Feb 19, 2018				
	7541347	Apr 02, 2027				
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025				
	7919483	Mar 07, 2027				
	8252776	Jun 24, 2025				
	8268804	Jun 24, 2025				
<u>MINOXIDIL - MEN'S ROGAINE</u>						
N 021812 001	6946120	Apr 20, 2019	DP	U-702		
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002					NP	Feb 28, 2017
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	6166197	Dec 26, 2017	DS		NCE	Jan 29, 2018
	6222025	Mar 06, 2015	DS		ODE	Jan 29, 2020
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021		U-1353		
	7511131	Dec 13, 2025	DS			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023		U-913		
	7982049	Nov 04, 2023	DP			
	8835474	Nov 04, 2023		U-1527		
	RE44872	Dec 18, 2023		U-1527		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023		U-913		
	7982049	Nov 04, 2023	DP			
	8835474	Nov 04, 2023		U-1527		
	RE44872	Dec 18, 2023		U-1527		
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MODAFINIL - PROVIGIL</u>						
N 020717 001	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014		U-255		
<u>MODAFINIL - PROVIGIL</u>						
N 020717 002	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014		U-255		
<u>MOMETASONE FUROATE - ELOCON</u>						
N 019625 002					NP	Apr 19, 2016



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067 001	5687710	Nov 18, 2014	DP			
	5829434	Nov 03, 2015	DP			
	6240918	Feb 20, 2017	DP			
	6503537	Mar 17, 2018	DP			
	8173172	Mar 17, 2018	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067 002	5687710	Nov 18, 2014	DP			
	5829434	Nov 03, 2015	DP			
	6240918	Feb 20, 2017	DP			
	6503537	Mar 17, 2018	DP			
	8173172	Mar 17, 2018	DP			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 001	5889015*PED	Jul 27, 2014				
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 002	5889015*PED	Jul 27, 2014				
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N 020762 001	6127353	Oct 03, 2017	DS DP			
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 021409 001	8007830	Oct 24, 2022	DP		NPP	Mar 26, 2015
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	6066339	Nov 25, 2017	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 001	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015		U-584		
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 002	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015		U-584		
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 003	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015		U-584		
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027				
	7682634	Jun 19, 2027				
	7815934	Dec 12, 2027				
	8158156	Jun 19, 2027				
	8685443	Jul 03, 2025				
	8685444	Jul 03, 2025				
	8846104	Jun 19, 2027				
	8877247	Jun 19, 2027				
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027				
	7682634	Jun 19, 2027				
	7815934	Dec 12, 2027				
	8158156	Jun 19, 2027				
	8685443	Jul 03, 2025				
	8685444	Jul 03, 2025				
	8846104	Jun 19, 2027				
	8877247	Jun 19, 2027				
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027				
	7682634	Jun 19, 2027				
	7815934	Dec 12, 2027				
	8158156	Jun 19, 2027				
	8685443	Jul 03, 2025				
	8685444	Jul 03, 2025				
	8846104	Jun 19, 2027				
	8877247	Jun 19, 2027				
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027				
	7682634	Jun 19, 2027				
	7815934	Dec 12, 2027				
	8158156	Jun 19, 2027				
	8685443	Jul 03, 2025				
	8685444	Jul 03, 2025				
	8846104	Jun 19, 2027				
	8877247	Jun 19, 2027				
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027				
	7682634	Jun 19, 2027				
	7815934	Dec 12, 2027				
	8158156	Jun 19, 2027				
	8685443	Jul 03, 2025				
	8685444	Jul 03, 2025				
	8846104	Jun 19, 2027				
	8877247	Jun 19, 2027				
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027				
	7682634	Jun 19, 2027				
	7815934	Dec 12, 2027				
	8158156	Jun 19, 2027				
	8685443	Jul 03, 2025				
	8685444	Jul 03, 2025				
	8846104	Jun 19, 2027				
	8877247	Jun 19, 2027				
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001	5849752	Dec 05, 2016				
	6610327	Oct 29, 2019				
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001	5849752	Dec 05, 2016				
	6548079	Jul 25, 2020				
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOXY</u>						
N 021598 001	6716830	Sep 29, 2019				
	7671070	Sep 29, 2019				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	DP U-709			
	8450311	May 29, 2029	DP			
<u>MUPIROICIN - CENTANY</u>						
N 050788 001	6013657	Jul 08, 2018	DP			
<u>MUPIROICIN CALCIUM - BACTROBAN</u>						
N 050746 001	6025389	Oct 20, 2014	DP U-1122			
<u>MYCOPHENOLATE MOFETIL - CELLCEPT</u>						
N 050759 001	5688529	Nov 18, 2014	DP			
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 001	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 002	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 019599 002					NS	Jan 13, 2015
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	8778365	Jan 31, 2033	DP		NP	Jun 27, 2016
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7662365	Oct 18, 2022	DS DP		NCE	Sep 16, 2019
	7786133	Dec 19, 2027	DP			
	8067431	Dec 16, 2024		U-1185		
	8617530	Oct 18, 2022		U-1185		
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7662365	Oct 18, 2022	DS DP		NCE	Sep 16, 2019
	7786133	Dec 19, 2027	DP			
	8067431	Dec 16, 2024		U-1185		
	8617530	Oct 18, 2022		U-1185		
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NALTREXONE - VIVITROL</u>						
N 021897 001	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6264987	May 19, 2020	DP			
	6331317	Nov 12, 2019	DP			
	6379703	Dec 30, 2018	DP			
	6379704	May 19, 2020	DP			
	6395304	Nov 12, 2019	DP			
	6403114	May 02, 2017	DP			
	6495164	May 25, 2020	DP			
	6495166	Nov 12, 2019	DP			
	6534092	May 19, 2020	DP			
	6537586	Nov 12, 2019	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
	6713090	Nov 12, 2019	DP			
	6939033	Nov 12, 2019	DP			
	7799345	May 25, 2020	DP			
	7919499	Oct 15, 2029			U-1123	
	7919499	Oct 15, 2029			U-1124	
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP		U-867	
	6586458	Aug 14, 2017	DP		U-867	
	7332183	Oct 02, 2025	DP		U-867	
	8022095	Aug 14, 2017	DP		U-867	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NATEGLINIDE - STARLIX</u>						
N 021204 001	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NATEGLINIDE - STARLIX</u>						
N 021204 002	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 002	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 003	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 004	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 005	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NELARABINE - ARRANON</u>						
N 021877 001	5424295	Jun 13, 2017	DS DP			
<u>NEPAFENAC - NEVANAC</u>						
N 021862 001	7834059	Jan 31, 2027	U-1095			
	8071648	Dec 02, 2025	DP			
	8324281	Dec 02, 2025	DP			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	6403609	Jul 17, 2018	DP		NP	Oct 16, 2015
	7947295	Jun 08, 2024	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	5202333	Apr 13, 2015	DS DP U-528		NCE	Oct 10, 2019
	6297375	Feb 22, 2020	DS			
	8623826	Nov 18, 2030	U-528			
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 203411 001					PC	Oct 12, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 205258 001					PC	Oct 12, 2014
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 001	8460704	Mar 12, 2029	U-1409		NPP	Nov 08, 2015
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 002					NPP	Nov 08, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N 020381 001	6080428	May 27, 2017	U-331			
<u>NIACIN - NIASPAN</u>						
N 020381 002	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN</u>						
N 020381 003	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN</u>						
N 020381 004	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>						
N 020381 005	6080428	May 27, 2017	U-331			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 001	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 002	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 003	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 004	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 005	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
<u>NICOTINE - NICODERM CQ</u>						
N 020165 004	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CQ</u>						
N 020165 005	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CQ</u>						
N 020165 006	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICOTROL</u>						
N 020385 001	5656255	Aug 12, 2014				



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 018612	002	8323683				
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 020066	002	8323683		DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	001	8501164		DP		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	002	8501164		DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068	001	7169791		DS DP U-836	ODE	Oct 29, 2014
		8163904		DS DP		
		8293756		DP		
		8389537		DS DP U-1374		
		8415363		DS DP U-1407		
		8501760		DS DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068	002	7169791		DS DP U-836	ODE	Oct 29, 2014
		8163904		DS DP		
		8293756		DP		
		8389537		DS DP U-1374		
		8415363		DS DP U-1407		
		8501760		DS DP		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	001				ODE	May 10, 2020
<u>NINTEDANIB - OFEV</u>						
N 205832	001	6762180		DS DP	NCE	Oct 15, 2019
		7119093		DS DP	ODE	Oct 15, 2021
<u>NINTEDANIB - OFEV</u>						
N 205832	002	6762180		DS DP	NCE	Oct 15, 2019
		7119093		DS DP	ODE	Oct 15, 2021
<u>NISOLDIPINE - SULAR</u>						
N 020356	005	5626874		DP		
<u>NISOLDIPINE - SULAR</u>						
N 020356	006	5626874		DP		
<u>NISOLDIPINE - SULAR</u>						
N 020356	007	5626874		DP		
<u>NISOLDIPINE - SULAR</u>						
N 020356	008	5626874		DP		
<u>NITAZOXANIDE - ALINIA</u>						
N 021497	001	5968961		DP		
		6020353		DS DP		
<u>NITAZOXANIDE - ALINIA</u>						
N 021498	001	5578621		U-525		
		5965590		U-523		
		5968961				
		6020353				
		6117894				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	5732693	Dec 13, 2016	DP U-1230			
	5752504	Dec 13, 2016	DP U-1230			
	6125846	May 16, 2017	DP U-1457			
	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	5732693	Dec 13, 2016	DP U-1230			
	5752504	Dec 13, 2016	DP U-1230			
	6125846	May 16, 2017	DP U-1457			
	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N 018705 002	7872049	Mar 14, 2028	DP U-39			
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 001	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 002	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 003	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROMIST</u>						
N 021780 001	5869082	Apr 16, 2016	DP			
<u>NIZATIDINE - AXID</u>						
N 021494 001	6930119	Jul 17, 2022	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 001	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 002	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 003	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 004	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 005	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008 001	5688530	Nov 18, 2014		U-268		
	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008 002	5688530	Nov 18, 2014		U-268		
	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008 003	5688530	Nov 18, 2014		U-268		
	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 001	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 002	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 003	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 004	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 005	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 006	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 001	6960577	Nov 01, 2017		U-964	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 002	6960577	Nov 01, 2017		U-964	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 003	6960577	Nov 01, 2017		U-964	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 004	6960577	Nov 01, 2017		U-964	NPP	Jul 26, 2016
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173 001	6169084	Sep 30, 2018	DS DP	U-1026		
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173 002	6169084	Sep 30, 2018	DS DP	U-1026		
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173 003	6169084	Sep 30, 2018	DS DP	U-1026		
<u>OLAPARIB - OLAPARIB</u>						
N 206162 001					NCE	Dec 19, 2019
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001	5840757	Nov 24, 2015	DP		NP	Oct 03, 2016

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286 001	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286 003	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286 004	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	5964416	Oct 04, 2016	DP		NCE	Jul 31, 2019
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP U-1547			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1547			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP U-1547			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1547			
	8044046	Nov 10, 2023	U-1547			
<u>OLOPATADINE HYDROCHLORIDE - PATANOL</u>						
N 020688 001	5641805	Jun 06, 2015	U-184			
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545 001	5641805	Jun 06, 2015	U-765	Y		
	5641805*PED	Dec 06, 2015				
	6995186	Nov 12, 2023	DP U-765			
	7402609	Jun 19, 2022	DP			
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	7977376	Feb 02, 2023	DP			
	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	6987103	Jun 28, 2023	U-1300		NCE	Oct 26, 2017
	RE45128	Mar 16, 2019	DS DP U-1576		ODE	Oct 26, 2019
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
N 021654 001	5656667	Apr 10, 2017	DS DP U-822			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2016	DP			
	5948818	May 13, 2016	DP			
	7960370	Feb 07, 2025	DP			
	8383678	Feb 07, 2025	DP U-1511			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810 001	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810 002	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810 003	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC OTC</u>						
N 021229 001	5690960	Nov 25, 2014				
	5753265	Jun 07, 2015				
	5817338	Oct 06, 2015				
	5900424	May 04, 2016				
	6403616	Nov 15, 2019				
	6428810	Nov 03, 2019				
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 001	5690960	Nov 25, 2014		DP U-864		
	5900424	May 04, 2016	DS	U-864		
	6428810	Nov 03, 2019		DP U-864		
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 002	5690960	Nov 25, 2014		DP U-864		
	5900424	May 04, 2016	DS	U-864		
	6428810	Nov 03, 2019		DP U-864		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 16, 2016		U-588		
	6489346	Jul 16, 2016	DS DP	U-588	Y	
	6645988	Jul 16, 2016	DS DP		Y	
	6699885	Jul 16, 2016		U-588	Y	
	6780882	Jul 16, 2016	DS DP			
	7399772	Jul 16, 2016		U-588		
	RE45198	Jul 16, 2016		U-588		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 16, 2016		U-623		
	5840737	Jul 16, 2016		U-624		
	6489346	Jul 16, 2016	DS DP	U-623	Y	
	6489346	Jul 16, 2016	DS DP	U-624	Y	
	6645988	Jul 16, 2016	DS DP		Y	
	6699885	Jul 16, 2016		U-623	Y	
	6699885	Jul 16, 2016		U-624	Y	
	6780882	Jul 16, 2016	DS DP			
	7399772	Jul 16, 2016		U-623		
	7399772	Jul 16, 2016		U-624		
RE45198	Jul 16, 2016		U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 16, 2016		U-588		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 16, 2016		U-623		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281 001	6489346	Jul 15, 2016	DP	U-1025	Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	DP		Y	
	7399772	Jul 15, 2016		U-1025		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	5840737	Jul 16, 2016		U-1025		
	6780882	Jul 16, 2016	DP			
	7399772	Jul 16, 2016		U-1025		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ONDANSETRON - ZOFRAN ODT</u>						
N 020781 001	5955488	Nov 14, 2015				
	6063802	Nov 14, 2015				
<u>ONDANSETRON - ZOFRAN ODT</u>						
N 020781 002	5955488	Nov 14, 2015				
	6063802	Nov 14, 2015				
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	8580830	Nov 23, 2029	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	8580830	Nov 23, 2029	DP			
<u>ONDANSETRON HYDROCHLORIDE - ZOFRAN</u>						
N 020605 001	5854270	Nov 20, 2015	DP U-44			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2015	DS DP U-1569		NCE	Aug 06, 2019
	5998581	Nov 12, 2017	DS		GAIN	Aug 06, 2024
	8420592	Aug 29, 2029	U-1570			
<u>ORLISTAT - XENICAL</u>						
N 020766 001	6004996	Jan 06, 2018				
<u>ORLISTAT - ALLI</u>						
N 021887 001	6004996	Jan 06, 2018	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001	5763483	Dec 27, 2016	DS U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002	5763483	Dec 27, 2016	DS U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003	5763483	Dec 27, 2016	DS U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001	5763483	Dec 27, 2016	DS U-376		NPP	Dec 21, 2015
	5763483	Dec 27, 2016	DS U-1113			
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002	5763483	Dec 27, 2016	DS DP U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8642079	Mar 01, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXALIPLATIN - ELOXATIN</u>						
N 021492 001	5420319	Aug 09, 2016	DS			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021492 002	5420319	Aug 09, 2016	DS			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759 001	5420319 5716988	Aug 09, 2016 Aug 07, 2015	DS DP			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759 002	5420319 5716988	Aug 09, 2016 Aug 07, 2015	DS DP			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759 003	5420319 5716988	Aug 09, 2016 Aug 07, 2015	DS DP			
<u>OXANDROLONE - OXANDRIN</u>						
N 013718 001	5872147 6090799 6576659 6828313	Dec 05, 2017 Jul 18, 2017 Dec 05, 2017 Dec 05, 2017		U-585 U-585 U-585 U-585		
<u>OXANDROLONE - OXANDRIN</u>						
N 013718 002	5872147 6090799 6576659 6828313	Dec 05, 2017 Jul 18, 2017 Dec 05, 2017 Dec 05, 2017		U-585 U-585 U-585 U-585		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014 001	7037525	Feb 12, 2018		U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014 002	7037525	Feb 12, 2018		U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014 003	7037525	Feb 12, 2018		U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021285 001	7037525 8119148	Feb 12, 2018 Dec 19, 2020		U-724 DP U-724		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	7722898 7910131 8617600 8821930	Apr 13, 2027 Apr 13, 2027 Apr 13, 2027 Apr 13, 2027	DP U-1298 DP DP		NDF	Oct 19, 2015
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	7722898 7910131 8617600 8821930	Apr 13, 2027 Apr 13, 2027 Apr 13, 2027 Apr 13, 2027	DP U-1298 DP DP		NDF	Oct 19, 2015
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	7722898 7910131 8617600 8821930	Apr 13, 2027 Apr 13, 2027 Apr 13, 2027 Apr 13, 2027	DP U-1298 DP DP		NDF	Oct 19, 2015
<u>OXYBUTYNIN - OXYTROL</u>						
N 021351 002	5601839 5834010 6743441 7081249 7081250 7081251 7081252 7179483	Apr 26, 2015 Apr 26, 2015 Apr 26, 2020 Apr 26, 2020 Apr 26, 2020 Apr 26, 2020 Apr 26, 2020 Apr 26, 2020		DP U-318 DP U-318 DP U-318 DP U-318 DP U-318 DS DP U-318		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNYNIN - OXYTROL FOR WOMEN</u>						
N 202211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYBUTYNYNIN - GELNIQUE 3%</u>						
N 202513 001	7029694	Apr 26, 2020	DP U-318		NP	Dec 07, 2014
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020	U-318			
<u>OXYBUTYNYNIN CHLORIDE - DITROPAN XL</u>						
N 020897 001	5674895	May 22, 2015				
	5840754	May 22, 2015				
	5912268	May 22, 2015				
	6262115	May 22, 2015	U-393			
<u>OXYBUTYNYNIN CHLORIDE - DITROPAN XL</u>						
N 020897 002	5674895	May 22, 2015				
	5840754	May 22, 2015				
	5912268	May 22, 2015				
	6262115	May 22, 2015	U-393			
<u>OXYBUTYNYNIN CHLORIDE - DITROPAN XL</u>						
N 020897 003	5674895	May 22, 2015				
	5840754	May 22, 2015				
	5912268	May 22, 2015				
	6262115	May 22, 2015	U-393			
<u>OXYBUTYNYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	8241662	Apr 26, 2020	U-318			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP		Y	
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027		U-1556		
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP		Y	
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027		U-1556		
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP		Y	
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027		U-1556		
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP		Y	
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027		U-1556		
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP		Y	
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027		U-1556		
	8894988	Aug 24, 2027	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 001	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 002	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 003	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 004	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 005	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 006	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026		U-1434	I-658	Oct 11, 2015
	7820788	Mar 03, 2024	DP	U-1092	I-676	Sep 06, 2016
	7820788	Mar 03, 2024	DP	U-1290	ODE	Sep 06, 2020
	7820788	Mar 03, 2024	DP	U-1434		
	7923536	Dec 09, 2023		U-1117		
	7923536	Dec 09, 2023		U-1290		
	7923536	Dec 09, 2023		U-1434		
	8034375	Aug 13, 2026		U-1290		
	8138229	Dec 09, 2023	DP	U-1092		
	8138229	Dec 09, 2023	DP	U-1290		
	8138229	Dec 09, 2023	DP	U-1434		
	8268348	Feb 21, 2026		U-1290		
	8314156	Dec 09, 2023		U-1290		
	8314156	Dec 09, 2023		U-1434		
	8853260	Aug 14, 2020	DP			
	RE41884	Aug 14, 2016		U-1117		
	RE41884	Aug 14, 2016		U-1290		
	RE41884	Aug 14, 2016		U-1434		
<u>PALIPERIDONE - INVEGA</u>						
N 021999 001					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 002					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 003					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 004					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 006					PED	Oct 06, 2014

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543		M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543		M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543		M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543		M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543		M-119	Aug 29, 2015
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	5202333	Apr 13, 2015	DS DP U-528		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	5202333	Apr 13, 2015	DS DP U-901		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 022233 001	5202333	Apr 13, 2015	DS DP U-528			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N 022175 001					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N 022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 007	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523	001				NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523	002				NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523	003				NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523	004				NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	004				M-93	Jul 29, 2019
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725	005				M-93	Jul 29, 2019
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	001	7658918	Feb 20, 2028	DP	NCE	Aug 27, 2014
		8221747	Feb 20, 2028	DP		
		8246950	Feb 20, 2028	U-1274		
		8562978	Feb 20, 2028	DP		
		8562979	Feb 20, 2028	DP U-1274		
		8562980	Feb 20, 2028	DP U-1274		
		8562981	Feb 20, 2028	U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	002	7658918	Feb 20, 2028	DP	NCE	Aug 27, 2014
		8221747	Feb 20, 2028	DP		
		8246950	Feb 20, 2028	U-1274		
		8562978	Feb 20, 2028	DP		
		8562979	Feb 20, 2028	DP U-1274		
		8562980	Feb 20, 2028	DP U-1274		
		8562981	Feb 20, 2028	U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	003	7658918	Feb 20, 2028	DP	NCE	Aug 27, 2014
		8221747	Feb 20, 2028	DP		
		8246950	Feb 20, 2028	U-1274		
		8562978	Feb 20, 2028	DP		
		8562979	Feb 20, 2028	DP U-1274		
		8562980	Feb 20, 2028	DP U-1274		
		8562981	Feb 20, 2028	U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	004	7658918	Feb 20, 2028	DP	NCE	Aug 27, 2014
		8221747	Feb 20, 2028	DP		
		8246950	Feb 20, 2028	U-1274		
		8562978	Feb 20, 2028	DP		
		8562979	Feb 20, 2028	DP U-1274		
		8562980	Feb 20, 2028	DP U-1274		
		8562981	Feb 20, 2028	U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	005	8221747	Feb 20, 2028	DP	NCE	Aug 27, 2014
		8562978	Feb 20, 2028	DP		
		8562979	Feb 20, 2028	DP U-1274		
		8562980	Feb 20, 2028	DP U-1274		
		8562981	Feb 20, 2028	U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210	006	8221747	Feb 20, 2028	DP	NCE	Aug 27, 2014
		8562978	Feb 20, 2028	DP		
		8562979	Feb 20, 2028	DP U-1274		
		8562980	Feb 20, 2028	DP U-1274		
		8562981	Feb 20, 2028	U-1274		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222	001				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222	002				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222	003				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N 022542	001				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N 022542	002				NCE	Mar 01, 2017
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 020987	001	5997903		Dec 07, 2016		
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 020987	002	5997903		Dec 07, 2016		
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988	001	6780881		Nov 17, 2021	DP	
		7351723		Nov 17, 2021	DP	
		8754108		Nov 17, 2021	DP	
		8754108*PED		May 17, 2022		
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 022020	001	7544370		Jun 07, 2026	DP	
		7550153		Sep 30, 2024	U-859	
		7553498		Sep 30, 2024	U-859	
		7838027		Sep 30, 2024	DP U-859	
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	001	5597815		Jul 13, 2015	U-1195	
		6136799		Apr 08, 2018		
		6361758		Apr 08, 2018	DP	
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	002	5597815		Jul 13, 2015	U-1195	
		6136799		Apr 08, 2018		
		6361758		Apr 08, 2018	DP	
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	003	5597815		Jul 13, 2015	U-1195	
		5597815*PED		Jan 13, 2016		
		6136799		Apr 08, 2018		
		6136799*PED		Oct 08, 2018		
		6361758		Apr 08, 2018	DP	
		6361758*PED		Oct 08, 2018		
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	001	5597815		Jul 13, 2015	U-1195	
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	002	5597815		Jul 13, 2015	U-1195	
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	003	5597815		Jul 13, 2015	U-1195	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 001	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 002	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 003	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 004	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 005	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020710 001	5811436	Sep 22, 2015				
	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 001	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6172233	Jan 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 002	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6172233	Jan 15, 2018				



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 003	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017			U-286	
	6121291	Mar 17, 2017			U-431	
	6133289	May 19, 2015			U-358	
	6172233	Jan 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 004	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017			U-286	
	6121291	Mar 17, 2017			U-431	
	6133289	May 19, 2015			U-358	
	6172233	Jan 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936 001	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017			U-286	
	6133289	May 19, 2015			U-286	
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP		U-816	
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936 002	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017			U-286	
	6133289	May 19, 2015			U-286	
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP		U-816	
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936 003	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017			U-286	
	6133289	May 19, 2015			U-286	
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP		U-816	
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	5874447	Jun 10, 2017			U-46	
	5874447	Jun 10, 2017			U-286	
	5874447	Jun 10, 2017			U-518	
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	5874447	Jun 10, 2017			U-46	
	5874447	Jun 10, 2017			U-286	
	5874447	Jun 10, 2017			U-518	
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	5874447	Jun 10, 2017			U-46	
	5874447	Jun 10, 2017			U-286	
	5874447	Jun 10, 2017			U-518	
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	5874447	Jun 10, 2017			U-46	
	5874447	Jun 10, 2017			U-286	
	5874447	Jun 10, 2017			U-518	
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	5874447	Jun 10, 2017	DS		NP	Jun 28, 2016
	7598271	Feb 12, 2023	DS			
	8658663	Apr 06, 2029	DS	DP	U-904	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 001	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 002	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 003	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 001	6225284	Jun 28, 2016	DS DP U-1628		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		NP	Dec 15, 2017
	7759308	Oct 25, 2026	DP		ODE	Dec 15, 2021
	8822637	Aug 06, 2023	U-1629			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 002	6225284	Jun 28, 2016	DS DP U-1628		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		NP	Dec 15, 2017
	7759308	Oct 25, 2026	DP		ODE	Dec 15, 2021
	8822637	Aug 06, 2023	U-1629			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 003	6225284	Jun 28, 2016	DS DP U-1628		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		NP	Dec 15, 2017
	7759308	Oct 25, 2026	DP		ODE	Dec 15, 2021
	8822637	Aug 06, 2023	U-1629			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465 001	7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	7262203	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465 002	7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	7262203	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PEGAPTANIB SODIUM - MACUGEN</u>						
N 021756 001	5932462	Aug 03, 2016	DS			
	6011020	Jan 04, 2017	DS			
	6051698	May 19, 2015	DS	U-622		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 001	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS		U-507	
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 002	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS		U-507	
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 003	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS		U-507	
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 004	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS		U-507	
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 005	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS		U-507	
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 001	5344932 7772209 7772209	Jul 24, 2016 Nov 24, 2021 Nov 24, 2021	DS DP	U-1077 U-1296	M-122 PED	Oct 17, 2015 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 002	5344932 7772209	Jul 24, 2016 Nov 24, 2021	DS DP	U-1296	M-122 PED	Oct 17, 2015 Sep 17, 2014
<u>PENCICLOVIR SODIUM - DENAVIR</u>						
N 020629 001	5840763 5866581 5916893 6124304 6469015 6579981	Sep 01, 2015 Oct 04, 2014 Sep 01, 2015 Oct 04, 2014 Oct 22, 2019 Jun 17, 2020		U-501 U-501 U-501 U-501 U-501 U-501		
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	6503745 6562861 8778997	Nov 05, 2019 Dec 17, 2018 May 07, 2027	DS DS		NCE U-1627	Dec 19, 2019
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP DS	U-106	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP DS	U-106	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP DS	U-106	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP DS	U-106	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP DS	U-106	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP DS	U-106	NCE	Oct 22, 2017
<u>PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE - SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS</u>						
N 021084 001	5607979	May 30, 2015				
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	5527521 6033645 8658205 8685441	Feb 22, 2015 Jun 19, 2016 Apr 20, 2019 Jan 13, 2019		DP U-665 DP U-665		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 001	6149938	Jul 23, 2018	DP			
	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 002	6149938	Jul 23, 2018	DP			
	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 003	6149938	Jul 23, 2018	DP U-1243			
	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMLA</u>						
N 022580 001	6071537	Jun 23, 2017		U-1262	NC	Jul 17, 2015
	7056890	Jun 14, 2020	DP	U-1262		
	7553818	Jun 14, 2020		U-1262		
	7659256	Jun 14, 2020	DP	U-1262		
	7674776	Jun 14, 2020	DP	U-1262		
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029		U-1262		
	8895057	Jun 09, 2028		U-1262		
	8895058	Jun 09, 2028	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMLA</u>						
N 022580 002	6071537	Jun 23, 2017		U-1262	NC	Jul 17, 2015
	7056890	Jun 14, 2020	DP	U-1262		
	7553818	Jun 14, 2020		U-1262		
	7659256	Jun 14, 2020	DP	U-1262		
	7674776	Jun 14, 2020	DP	U-1262		
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029		U-1262		
	8895057	Jun 09, 2028		U-1262		
	8895058	Jun 09, 2028	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMLA</u>						
N 022580 003	6071537	Jun 23, 2017		U-1262	NC	Jul 17, 2015
	7056890	Jun 14, 2020	DP	U-1262		
	7553818	Jun 14, 2020		U-1262		
	7659256	Jun 14, 2020	DP	U-1262		
	7674776	Jun 14, 2020	DP	U-1262		
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029		U-1262		
	8895057	Jun 09, 2028		U-1262		
	8895058	Jun 09, 2028	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMLA</u>						
N 022580 004	6071537	Jun 23, 2017		U-1262	NC	Jul 17, 2015
	7056890	Jun 14, 2020	DP	U-1262		
	7553818	Jun 14, 2020		U-1262		
	7659256	Jun 14, 2020	DP	U-1262		
	7674776	Jun 14, 2020	DP	U-1262		
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029		U-1262		
	8895057	Jun 09, 2028		U-1262		
	8895058	Jun 09, 2028	DP			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	6764678	May 11, 2021		U-967		
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			
	7569230	Oct 17, 2023		U-967		
	7575757	Apr 21, 2025	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 001	8859623	Nov 14, 2033		U-1594		
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 002	8859623	Nov 14, 2033		U-1594		
<u>PIMECROLIMUS - ELIDEL</u>						
N 021302 001	5912238	Jun 15, 2016				
	6352998	Oct 26, 2015				
	6423722	Jun 26, 2018				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073 001	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073 002	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073 003	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 001	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 002	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 003	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7566729	Apr 22, 2029		U-1600	NCE	Oct 16, 2019
	7635707	Apr 22, 2029		U-1609	ODE	Oct 15, 2021
	7696326	Dec 18, 2027		U-1601		
	7767225	Sep 22, 2026	DP	U-1602		
	7767700	Dec 18, 2027		U-1601		
	7816383	Jan 08, 2030		U-1603		
	7910610	Jan 08, 2030		U-1604		
	7988994	Sep 22, 2026	DP	U-1602		
	8013002	Jan 08, 2030		U-1603		
	8084475	Jan 08, 2030		U-1605		
	8318780	Jan 08, 2030		U-1606		
	8383150	Sep 22, 2026	DP	U-1607		
	8420674	Dec 18, 2027	DP	U-1608		
	8592462	Apr 22, 2029		U-1609		
	8609701	Apr 22, 2029		U-1610		
	8648098	Jan 08, 2030		U-1611		
	8753679	Sep 22, 2026	DP	U-1602		
	8754109	Jan 08, 2030		U-1612		
	8778947	Aug 30, 2033		U-1613		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5753675	May 19, 2015	DS DP	U-998	NCE	Aug 03, 2014
	5854259	Dec 29, 2015		DP		
	5856336	Dec 25, 2020	DS	U-998		
	6465477	Dec 20, 2016		DP		
	7022713	Feb 19, 2024		U-998		
	8557993	Feb 02, 2024		DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5753675	May 19, 2015	DS DP	U-998	NCE	Aug 03, 2014
	5854259	Dec 29, 2015		DP		
	5856336	Dec 25, 2020	DS	U-998		
	6465477	Dec 20, 2016		DP		
	7022713	Feb 19, 2024		U-998		
	8557993	Feb 02, 2024		DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5753675	May 19, 2015	DS DP	U-998	NCE	Aug 03, 2014
	5854259	Dec 29, 2015		DP		
	5856336	Dec 25, 2020	DS	U-998		
	6465477	Dec 20, 2016		DP		
	7022713	Feb 19, 2024		U-998		
	8557993	Feb 02, 2024	DS DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311 001	6987102	Jul 22, 2023		U-936	ODE	Dec 15, 2015
	7897590	Jul 22, 2023		U-936		
	RE42152	Dec 10, 2018		DP		
<u>POLIDOCANOL - ASCLERA</u>						
N 021201 001					NCE	Mar 30, 2015
<u>POLIDOCANOL - ASCLERA</u>						
N 021201 002					NCE	Mar 30, 2015
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	6572873	May 26, 2020		U-1461		
	6846412	Jul 19, 2022		DP		
	6942165	May 26, 2020		DP		
	7025290	May 26, 2020		DP U-1461		
	7357336	May 26, 2020		U-1461		
	7604185	May 26, 2020	DS DP	U-1462		
	7731986	Nov 17, 2024	DS DP	U-1463		
	7814943	Nov 19, 2027		DP U-1461		
	7842282	May 26, 2020		U-1461		
	7842283	May 26, 2020		DP		
	8122917	Sep 09, 2024		DP		
	8323677	May 26, 2020	DS			
	8734833	May 26, 2020	DS DP			
	RE38919	Oct 14, 2014	DS DP			
	RE40640	Oct 14, 2015	DS DP	U-1462		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5635517	Jul 24, 2016		U-1359	NCE	Feb 08, 2018
	6045501	Aug 28, 2018		U-1361	ODE	Feb 08, 2020
	6315720	Oct 23, 2020		U-1361		
	6316471	Aug 10, 2016	DP	U-1360		
	6476052	Jul 24, 2016	DP	U-1360		
	6561976	Aug 28, 2018		U-1361		
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	6908432	Aug 28, 2018		U-1361		
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024		U-1360		
	8204763	Aug 28, 2018		U-1361		
	8315886	Oct 23, 2020		U-1361		
	8589188	Aug 28, 2018		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-1360		
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5635517	Jul 24, 2016		U-1359	NCE	Feb 08, 2018
	6045501	Aug 28, 2018		U-1361	ODE	Feb 08, 2020
	6315720	Oct 23, 2020		U-1361		
	6316471	Aug 10, 2016	DP	U-1360		
	6476052	Jul 24, 2016	DP	U-1360		
	6561976	Aug 28, 2018		U-1361		
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	6908432	Aug 28, 2018		U-1361		
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024		U-1360		
	8204763	Aug 28, 2018		U-1361		
	8315886	Oct 23, 2020		U-1361		
	8589188	Aug 28, 2018		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-1360		
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5635517	Jul 24, 2016		U-1359	NCE	Feb 08, 2018
	6045501	Aug 28, 2018		U-1361	ODE	Feb 08, 2020
	6315720	Oct 23, 2020		U-1361		
	6316471	Aug 10, 2016	DP	U-1360		
	6476052	Jul 24, 2016	DP	U-1360		
	6561976	Aug 28, 2018		U-1361		
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	6908432	Aug 28, 2018		U-1361		
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024		U-1360		
	8204763	Aug 28, 2018		U-1361		
	8315886	Oct 23, 2020		U-1361		
	8589188	Aug 28, 2018		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-1360		
	8828427	Jun 21, 2031	DS DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016		U-1359	NCE	Feb 08, 2018
	6045501	Aug 28, 2018		U-1361	ODE	Feb 08, 2020
	6315720	Oct 23, 2020		U-1361		
	6316471	Aug 10, 2016	DP	U-1360		
	6476052	Jul 24, 2016	DP	U-1360		
	6561976	Aug 28, 2018		U-1361		
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	6908432	Aug 28, 2018		U-1361		
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024		U-1360		
	8204763	Aug 28, 2018		U-1361		
	8315886	Oct 23, 2020		U-1361		
	8589188	Aug 28, 2018		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-1360		
	8828427	Jun 21, 2031	DS DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
					ODE	Dec 14, 2019
<u>POSACONAZOLE - NOXAFIL</u>						
N 022003 001	5661151	Jul 19, 2019	DS DP	U-760		
	5703079	Aug 26, 2014	DS DP	U-760		
	6958337	Oct 05, 2018	DS DP	U-760		
	8263600	Apr 01, 2022		DP		
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001	5661151	Jul 19, 2019	DS DP	U-1454		
	5703079	Aug 26, 2014	DS DP	U-1454		
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	5661151	Jul 19, 2019	DS DP	U-1454		
	5703079	Aug 26, 2014	DS DP	U-1454		
	8410077	Mar 13, 2029		DP		
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	6028071	Jul 16, 2022	DS DP	U-1004	NCE	Sep 24, 2014
	7622470	May 31, 2025		U-1015	ODE	Sep 24, 2016
	8299078	May 31, 2025		U-1004		
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 002	6028071	Jul 16, 2022	DS DP	U-1004	NCE	Sep 24, 2014
	7622470	May 31, 2025		U-1015	ODE	Sep 24, 2016
	8299078	May 31, 2025		U-1004		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 001	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 002	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 003	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 005	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 006	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 007	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 001	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-639			
	6114304	Sep 05, 2017	U-640			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 002	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-637			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-639			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 003	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-637			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-639			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991		NCE	Jul 10, 2014
	8404703	Jan 02, 2023	U-1381			
	8569325	Jan 02, 2023	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991		NCE	Jul 10, 2014
	8404703	Jan 02, 2023	U-1381			
	8569325	Jan 02, 2023	U-1381			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067 001	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067 002	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE SODIUM PHOSPHATE - PREDNISOLONE SODIUM PHOSPHATE</u>						
A 202179 001					PC	Jun 06, 2015
<u>PREDNISOLONE SODIUM PHOSPHATE - PREDNISOLONE SODIUM PHOSPHATE</u>						
A 202179 002					PC	Jun 06, 2015
<u>PREDNISOLONE SODIUM PHOSPHATE - PREDNISOLONE SODIUM PHOSPHATE</u>						
A 202179 003					PC	Jun 06, 2015
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 001	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 002	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 003	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	6488960	Mar 14, 2020	DP U-1267		M-128	Jul 26, 2015
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	6488960	Mar 14, 2020	DP U-1267		M-128	Jul 26, 2015
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024				
	8394407	Apr 23, 2024	DP U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8168218	Jan 07, 2028	DP U-1269		M-128	Jul 26, 2015
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446 001	6001876	Dec 30, 2018		U-55	Y	I-651 Jun 20, 2015
	6001876	Dec 30, 2018		U-819	Y	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018		U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446 002	6001876	Dec 30, 2018		U-55	Y	I-651 Jun 20, 2015
	6001876	Dec 30, 2018		U-819	Y	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018		U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446 003	6001876	Dec 30, 2018		U-55	Y	I-651 Jun 20, 2015
	6001876	Dec 30, 2018		U-819	Y	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018		U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446 004	6001876	Dec 30, 2018		U-55	Y	I-651 Jun 20, 2015
	6001876	Dec 30, 2018		U-819	Y	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018		U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446 005	6001876	Dec 30, 2018		U-55	Y	I-651 Jun 20, 2015
	6001876	Dec 30, 2018		U-819	Y	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018		U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446 006	6001876	Dec 30, 2018		U-55	Y	I-651 Jun 20, 2015
	6001876	Dec 30, 2018		U-819	Y	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018		U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446 007	6001876	Dec 30, 2018		U-55	Y	I-651 Jun 20, 2015
	6001876	Dec 30, 2018		U-819	Y	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018		U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446 008	6001876	Dec 30, 2018		U-55	Y	I-651 Jun 20, 2015
	6001876	Dec 30, 2018		U-819	Y	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018		U-1250		
<u>PREGABALIN - LYRICA</u>						
N 022488 001	6001876	Dec 30, 2018		U-55	Y	I-651 Jun 20, 2015
	6001876	Dec 30, 2018		U-819	Y	
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018		U-1250		
<u>PROGESTERONE - ENDOMETRIN</u>						
N 022057 001	7300664	Nov 17, 2019		U-856		
	7320800	Nov 17, 2019		U-856		
	7393543	Nov 17, 2019	DP	U-880		
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N 021416 001	5681588	Oct 28, 2014				
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N 021416 002	5681588	Oct 28, 2014				
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>						
N 021416 003	5681588	Oct 28, 2014				
<u>PROPOFOL - DIPRIVAN</u>						
N 019627 002	5714520	Mar 22, 2015				
	5731355	Mar 22, 2015		U-217		
	5731356	Mar 22, 2015		U-218		
	5908869	Mar 22, 2015		U-270		
	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438 001	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438 002	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP ODE	Mar 14, 2017 Mar 14, 2021
<u>QUAZEPAM - DORAL</u>						
N 018708 001	7608616	Jun 03, 2028	U-1012			
<u>QUAZEPAM - DORAL</u>						
N 018708 003	7608616	Jun 03, 2028	U-1012			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 001	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 002	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 003	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 004	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 005	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 001	5684016	Nov 04, 2014	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 002	5684016	Nov 04, 2014	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 003	5684016	Nov 04, 2014	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 004	5684016	Nov 04, 2014	U-210			
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 001					NDF PED	Mar 26, 2016 Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 002					NDF PED	Mar 26, 2016 Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					PC	Sep 24, 2014
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
N 020815 001	6458811	Mar 10, 2017	DS DP U-825		ODE	Sep 13, 2014
	6797719	Mar 10, 2017	DP			
	6894064	Mar 10, 2017	DP U-657			
	8030330	Mar 10, 2017	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022		U-257	NPP	Dec 21, 2014
	7435734	Oct 21, 2022		U-257		
	7435734	Oct 21, 2022		U-900		
	7754731	Mar 11, 2029	DS DP	U-257		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022		U-257	NDF	Dec 21, 2014
	7435734	Oct 21, 2022		U-257		
	7754731	Mar 11, 2029	DS DP	U-257		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022		U-257	NDF	Dec 21, 2014
	7435734	Oct 21, 2022		U-257		
	7754731	Mar 11, 2029	DS DP	U-257		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP		NDF	Dec 20, 2016
	7217713	Oct 21, 2022		U-257		
	7435734	Oct 21, 2022		U-257		
	7754731	Mar 11, 2029	DS DP	U-257		
<u>RAMELTEON - ROZEREM</u>						
N 021782 001	6034239	Jul 22, 2019	DS DP	U-674		
<u>RAMIPRIL - ALTACE</u>						
N 019901 001	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901 002	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901 003	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N 019901 004	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021 001	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021 002	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021 003	7368469	Aug 30, 2020		U-871		
<u>RAMIPRIL - ALTACE</u>						
N 022021 004	7368469	Aug 30, 2020		U-871		
<u>RANOLAZINE - RANEXA</u>						
N 021526 001	6303607	May 27, 2019		U-705		
	6369062	May 27, 2019	DP		Y	
	6479496	May 27, 2019		U-705		
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019		U-705		
	6562826	May 27, 2019		U-705		
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019		U-705		
	6852724	May 27, 2019		U-705		
	6864258	May 27, 2019		U-705		
<u>RANOLAZINE - RANEXA</u>						
N 021526 002	6303607	May 27, 2019		U-705		
	6369062	May 27, 2019	DP			
	6479496	May 27, 2019		U-705		
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019		U-705		
	6562826	May 27, 2019		U-705		
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019		U-705		
	6852724	May 27, 2019		U-705		
	6864258	May 27, 2019		U-705		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 001	5453446	Feb 07, 2017	U-219		I-685	May 29, 2017
	6126968	Sep 18, 2016	DP			
	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002	5453446	Feb 07, 2017	U-219		I-685	May 29, 2017
	6126968	Sep 18, 2016	DP			
	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	6403567	Apr 10, 2022	DS DP U-869			
	6642210	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-116			
	7144872	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-870			
	7183264	Jun 22, 2019	DP U-116			
	7183264	Jun 22, 2019	DP U-869			
	7183264	Jun 22, 2019	DP U-870			
	7582617	Jun 22, 2019	U-1003			
	7655636	Jun 22, 2019	U-869			
	7655637	Jun 22, 2019	DS DP U-869			
	7683037	Jun 22, 2019	U-1042			
	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
	8470801	Jun 22, 2019	U-116			
	8536150	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	7351834	Jan 12, 2020	DS		I-667	Feb 25, 2016
	8637553	Jul 08, 2029	DS DP		NCE	Sep 27, 2017
	8680124	Jul 20, 2028	U-1506		ODE	Feb 25, 2020
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 001	5866591	Sep 10, 2017	DP			
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 002	5866591	Sep 10, 2017	DP			
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 003	5866591	Sep 10, 2017	DP			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIBAVIRIN - VIRAZOLE</u>						
N 018859 001	6150337	Nov 21, 2017	U-400			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBAVIRIN - REBETOL</u>						
N 020903 001	6172046	Sep 21, 2017	U-377			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6524570	Nov 01, 2016	U-499			
	6524570	Nov 01, 2016	U-1013			
<u>RIBAVIRIN - REBETOL</u>						
N 020903 002	6172046	Sep 21, 2017	U-377			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6524570	Nov 01, 2016	U-499			
	6524570	Nov 01, 2016	U-1013			
<u>RIBAVIRIN - COPEGUS</u>						
N 021511 001					NPP	Aug 09, 2014
<u>RIBAVIRIN - REBETOL</u>						
N 021546 001	6172046	Sep 21, 2017	U-521			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-521			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-521			
	6524570	Nov 01, 2016	U-1013			
	6790837	Apr 05, 2023	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029		U-1121		
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS	U-1526		
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	7045620	Jun 19, 2024	DS		ODE	Mar 24, 2017
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029		U-1481		
	8741904	Feb 27, 2026	DS	U-1526		
	8829017	Jul 24, 2029		U-1562		
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP	U-1153		
	7125879	Apr 14, 2023	DS DP	U-1307		
	7638522	Apr 14, 2023	DP			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 001	6165513	Jun 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 002	6165513	Jun 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 003	5994329	Jul 17, 2018		U-353		
	6015801	Jul 17, 2018		U-353		
	6165513	Jun 10, 2018	DP			
	6432932	Jul 17, 2018		U-595		
	6465443	Aug 14, 2018	DP			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 004	6165513	Jun 10, 2018	DP			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 005	6165513	Jun 10, 2018	DP			
	7192938	May 06, 2023		U-353		
	7718634	May 06, 2023		U-662		
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N 022560 001	7645459	Jan 09, 2028	DP	U-662		
	7645460	Jan 09, 2028	DP	U-662		
	8246989	Jan 16, 2026	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 020588 001	5453425	Jul 11, 2014	DP			
	RE39181	Jul 11, 2014	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 001	5688801	Nov 18, 2014		U-543		
	5688801	Nov 18, 2014		U-972		
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 002	5688801	Nov 18, 2014		U-543		
	5688801	Nov 18, 2014		U-972		
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 003	5688801	Nov 18, 2014		U-543		
	5688801	Nov 18, 2014		U-972		
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 004	5688801	Nov 18, 2014		U-543		
	5688801	Nov 18, 2014		U-972		
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 001	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 002	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 003	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 004	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 005	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N 020659 001	5648497	Jul 15, 2014				
	6037157	Jun 26, 2016				
	6703403	Jun 26, 2016	U-564			
<u>RITONAVIR - NORVIR</u>						
N 020680 001	5648497	Jul 15, 2014				
<u>RITONAVIR - NORVIR</u>						
N 020945 001	5648497	Jul 15, 2014				
	6037157	Jun 26, 2016	U-895			
	6232333	Nov 07, 2017				
	6703403	Jun 26, 2016	U-564			
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	5648497	Jul 15, 2014	DS			
	6037157	Jun 26, 2016		U-688		
	6703403	Jun 26, 2016		U-688		
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP	U-688		
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024		U-688		
	8691878*PED	Feb 25, 2025				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Feb 08, 2021	DS DP	U-1301	I-660	Nov 02, 2015
	7157456	Feb 08, 2021	DS DP	U-1302	I-661	Nov 02, 2015
	7585860	Dec 11, 2020	DS	U-1303	I-662	Nov 02, 2015
	7592339	Dec 11, 2020		U-1167	NCE	Jul 01, 2016
	7592339	Dec 11, 2020		U-1200		
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Feb 08, 2021	DS DP	U-1301	I-643	Nov 04, 2014
	7157456	Feb 08, 2021	DS DP	U-1302	I-660	Nov 02, 2015
	7585860	Dec 11, 2020	DS	U-1303	I-661	Nov 02, 2015
	7592339	Dec 11, 2020		U-1167	I-662	Nov 02, 2015
	7592339	Dec 11, 2020		U-1200	NCE	Jul 01, 2016
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Feb 08, 2021	DS DP	U-1301	I-643	Nov 04, 2014
	7157456	Feb 08, 2021	DS DP	U-1302	I-660	Nov 02, 2015
	7585860	Dec 11, 2020	DS	U-1303	I-661	Nov 02, 2015
	7592339	Dec 11, 2020		U-1167	I-662	Nov 02, 2015
	7592339	Dec 11, 2020		U-1200	NCE	Jul 01, 2016
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
<u>RIVASTIGMINE - EXELON</u>						
N 022083 001	6316023	Jan 08, 2019		DP		
	6335031	Jan 08, 2019		DP		
<u>RIVASTIGMINE - EXELON</u>						
N 022083 002	6316023	Jan 08, 2019		DP		
	6335031	Jan 08, 2019		DP		
<u>RIVASTIGMINE - EXELON</u>						
N 022083 005	6316023	Jan 08, 2019		DP	NPP	Jun 27, 2016
	6335031	Jan 08, 2019		DP	NS	Aug 31, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N 020864	001				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N 020864	002				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N 020865	001				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N 020865	002				NPP PED	Dec 16, 2014 Jun 16, 2015
<u>ROFECOXIB - VIOXX</u>						
N 021042	001	5691374 6063811	May 18, 2015 May 06, 2017	U-602		
<u>ROFECOXIB - VIOXX</u>						
N 021042	002	5691374 6063811	May 18, 2015 May 06, 2017	U-602		
<u>ROFECOXIB - VIOXX</u>						
N 021042	003	5691374 6063811	May 18, 2015 May 06, 2017	U-602		
<u>ROFECOXIB - VIOXX</u>						
N 021052	001	5691374 6063811	May 18, 2015 May 06, 2017	U-266		
<u>ROFECOXIB - VIOXX</u>						
N 021052	002	5691374 6063811	May 18, 2015 May 06, 2017	U-266		
<u>ROFLUMILAST - DALIRESP</u>						
N 022522	001	5712298 8431154 8536206 8604064 8618142	Jan 27, 2015 Feb 19, 2023 Mar 08, 2024 Mar 08, 2024 Mar 08, 2024	DS DP U-1115 DP U-1115 U-1115 DP	NCE	Feb 28, 2016
<u>ROMIDEPSIN - ISTODAX</u>						
N 022393	001	7608280 7611724	Aug 22, 2021 Aug 22, 2021	DS DS	NCE ODE ODE	Nov 05, 2014 Nov 05, 2016 Jun 16, 2018
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	001	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	002	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	003	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	004	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	005	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	006	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 001	5670524	Sep 23, 2014	DS DP U-833			
	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 003	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 004	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 005	5670524	Sep 23, 2014	DS DP U-833			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	5741803	Apr 21, 2015	DS DP U-329	Y		
	5741803	Apr 21, 2015	DS DP U-628	Y		
	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	5741803	Apr 21, 2015	DS DP U-329	Y		
	5741803	Apr 21, 2015	DS DP U-628	Y		
	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	5741803	Apr 21, 2015	DS DP U-329	Y		
	5741803	Apr 21, 2015	DS DP U-628	Y		
	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUFINAMIDE - BANZEL</u>						
N 021911 001	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018		DP		
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 002	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018		DP		
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 003	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018		DP		
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 201367 001	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
N 020692 001	5873360	Feb 23, 2016	DP			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			ODE	Dec 13, 2014
	7566714	Nov 17, 2024	U-989		PED	Jun 13, 2015
	7566714*PED	May 17, 2025			PED	Oct 23, 2017
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156	Y		
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 17, 2015				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	7566714	Nov 17, 2024	U-1589			
	7612073	Nov 17, 2024	U-1010			
	8067416	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
<u>SAQUINAVIR - FORTOVASE</u>						
N 020828 001	6008228	Jun 06, 2015				
	6352717	Nov 16, 2019				
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 020628 001					M-61	Nov 30, 2015
					PED	May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 021785 001					M-61	Nov 30, 2015
					PED	May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	7951400	Nov 30, 2028	DP		M-108	Dec 16, 2014
	RE44186	Jul 31, 2023	DS DP U-995		M-134	May 24, 2016
					NCE	Jul 31, 2014
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	7951400	Nov 30, 2028	DP		M-108	Dec 16, 2014
	RE44186	Jul 31, 2023	DS DP U-995		M-134	May 24, 2016
					NCE	Jul 31, 2014
<u>SELEGILINE - EMSAM</u>						
N 021336 001	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE - EMSAM</u>						
N 021336 002	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE - EMSAM</u>						
N 021336 003	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE HYDROCHLORIDE - ZELAPAR</u>						
N 021479 001	5648093	Jul 15, 2014	DP			
	6423342	Mar 01, 2016	DP			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990 001	6727283	Oct 11, 2019	DP U-580			
	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127 001	5667775	Sep 16, 2014	U-246			
	7985418	Oct 27, 2025	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	5667775	Sep 16, 2014	U-246			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	5667775	Sep 16, 2014	U-246			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 020926 001	5667775	Sep 16, 2014	U-246			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179 001	5667775	Sep 16, 2014	U-246			
	6733780	Oct 18, 2020	DP			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179 002	5667775	Sep 16, 2014	U-246			
	6733780	Oct 18, 2020	DP			
<u>SEVOFLURANE - ULTANE</u>						
N 020478 001	5990176	Jan 27, 2017				
	6074668	Jan 09, 2018				
	6288127	Jan 27, 2017				
	6444859	Jan 27, 2017				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 001	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 002	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 003	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
					M-61	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
					M-61	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
					NDF	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILODOSIN - RAPAFLO</u>						
N 022206 001	5387603	Dec 01, 2018	DS DP			
<u>SILODOSIN - RAPAFLO</u>						
N 022206 002	5387603	Dec 01, 2018	DS DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	7671032	May 19, 2025	DS DP		I-697	Nov 05, 2017
	8148399	Sep 05, 2029	DS DP	U-1467	NCE	Nov 22, 2018
	8349869	Jul 28, 2026	DS DP	U-1467		
	8741926	Jul 28, 2026	DS	U-1467		
	8754106	Jul 28, 2026	DS	U-1467		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 001	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 002	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 003	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 004	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 005	6303661	Apr 24, 2017				
	6699871	Jul 26, 2022	DS DP			
	6890898	Feb 02, 2019				
	6890898	Feb 02, 2019				
	6890898	Feb 02, 2019				
	7078381	Feb 02, 2019				
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7326708	Apr 11, 2026	DS DP			
	7459428	Feb 02, 2019				
	8168637	Jun 26, 2022	DP			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 006	6303661	Apr 24, 2017				
	6699871	Jul 26, 2022	DS DP			
	6890898	Feb 02, 2019				
	6890898	Feb 02, 2019				
	6890898	Feb 02, 2019				
	7078381	Feb 02, 2019				
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7326708	Apr 11, 2026	DS DP			
	7459428	Feb 02, 2019				
	8168637	Jun 26, 2022	DP			
<u>SINCALIDE - KINEVAC</u>						
N 017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	5795911	Oct 31, 2020				
	5968973	Apr 10, 2017				
	7858662	Oct 02, 2026	DP			
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676 003					PC	Jul 15, 2014
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001	5989591	Mar 11, 2018	DP			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002	5989591	Mar 11, 2018	DP			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003	5989591	Mar 11, 2018	DP			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004	5989591	Mar 11, 2018	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017			U-774	
	6699871	Jul 26, 2022	DS DP		U-774	
	6890898	Feb 02, 2019			U-775	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-775	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1037	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022			U-775	
	7125873	Jul 26, 2022			U-1036	
	7125873	Jul 26, 2022			U-1037	
	7125873	Jul 26, 2022			U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017			U-774	
	6699871	Jul 26, 2022	DS DP		U-774	
	6890898	Feb 02, 2019			U-775	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-775	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1037	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022			U-775	
	7125873	Jul 26, 2022			U-1036	
	7125873	Jul 26, 2022			U-1037	
	7125873	Jul 26, 2022			U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017			U-774	
	6699871	Jul 26, 2022	DS DP		U-774	
	6890898	Feb 02, 2019			U-775	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-775	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1037	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022			U-775	
	7125873	Jul 26, 2022			U-1036	
	7125873	Jul 26, 2022			U-1037	
	7125873	Jul 26, 2022			U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP		ODE	Jan 14, 2018
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP	U-1419	ODE	Jan 14, 2018
	8568793	Dec 24, 2031	DS DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	6780889	Jul 04, 2020	DP			
	7262219	Jul 04, 2020	DP			
	7668730	Jun 16, 2024		U-1110		
	7765106	Jun 16, 2024		U-1069		
	7765107	Jun 16, 2024		U-1070		
	7851506	Dec 22, 2019		U-1101		
	7851506	Dec 22, 2019		U-1102		
	7895059	Dec 17, 2022		U-1110		
	8263650	Dec 22, 2019	DP	U-1101		
	8263650	Dec 22, 2019	DP	U-1102		
	8324275	Dec 22, 2019		U-1101		
	8324275	Dec 22, 2019		U-1102		
	8457988	Dec 17, 2022		U-1110		
	8589182	Dec 17, 2022		U-1110		
	8731963	Dec 17, 2022		U-1110		
	8772306	Mar 15, 2033		U-1532		
	8859619	Dec 22, 2019	DP			
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N 021892 001	7687075	Jun 22, 2028	DS DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	8496973	Mar 29, 2031	DS DP	U-1419	ODE	Jan 14, 2018
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	7964580	Mar 26, 2029	DS DP	U-1470	NCE	Dec 06, 2018
	8334270	Mar 21, 2028	DS DP	U-1470		
	8580765	Mar 21, 2028	DS DP	U-1470		
	8618076	Dec 11, 2030	DS DP	U-1470		
	8633309	Mar 26, 2029	DS DP	U-1470		
	8889159	Mar 26, 2029	DP	U-1470		
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 001	6017927	Nov 19, 2018	DS DP			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 002	6017927	Nov 19, 2018	DS DP			
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N 019764 002	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N 019764 003	5898030	Apr 27, 2016	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 001	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 002	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 003	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 005	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 008	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 009	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 010	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 011	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 012	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 013	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ</u>						
N 020522 001	5763394	Jun 09, 2015	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ PEN</u>						
N 020522 002	5763394	Jun 09, 2015	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 001	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 002	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 003	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 004	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N 021075 001	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N 021075 002	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N 021075 003	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148 001	5849700	Dec 15, 2015		U-340		
	5849704	Dec 15, 2015				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148 002	5849700	Dec 15, 2015		U-340		
	5849704	Dec 15, 2015				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148 003	5849700	Dec 15, 2015		U-340		
	5849704	Dec 15, 2015				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 004	5849700	Dec 15, 2015			U-340	
	5849704	Dec 15, 2015	DP		U-340	
	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 005	5849700	Dec 15, 2015			U-340	
	5849704	Dec 15, 2015	DP		U-340	
	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 006	5849700	Dec 15, 2015			U-340	
	5849704	Dec 15, 2015	DP		U-340	
	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 007	5849700	Dec 15, 2015			U-340	
	5849704	Dec 15, 2015	DP		U-340	
	6004297	Jan 28, 2019	DP			
	8841252	Dec 26, 2017	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	5849700	Dec 15, 2015			U-1041	
	5849704	Dec 15, 2015	DP		U-1041	
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	5849700	Dec 15, 2015			U-1041	
	5849704	Dec 15, 2015	DP		U-1041	
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	5849700	Dec 15, 2015			U-1041	
	5849704	Dec 15, 2015	DP		U-1041	
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N 021597 004	5898030	Apr 27, 2016	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	7235576	Jan 12, 2020	DS DP		I-677	Nov 22, 2016
	7351834	Jan 12, 2020	DS		ODE	Nov 16, 2014
	7897623	Jan 12, 2020	DP		ODE	Nov 22, 2020
	8124630	Jul 13, 2022			U-1459	
	8618141	Feb 11, 2023			U-1480	
	8877933	Dec 24, 2027	DS DP		U-1624	
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001					ODE	Jul 02, 2016



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jun 22, 2019	DP U-1105		NCE	Jan 18, 2016
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 001	7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 002	7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 003	7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 004	7135465	Feb 18, 2023	DP U-167			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	6174442	Dec 19, 2016	DS U-1468		NP	Nov 27, 2016
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001					NCE	Oct 10, 2019
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	5891086	Jul 27, 2014	DP			
	5957886	Mar 08, 2016	DP			
	6135979	Mar 21, 2017	DP			
	6174304	Dec 13, 2015	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	6681810	Dec 13, 2015	DP			
	7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Aug 10, 2023	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	8287489	Dec 06, 2024	DP			
	8343130	Oct 18, 2022	DP			
	8491524	Nov 21, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N 022377 001	7811254	Aug 26, 2027	DP U-1083			
<u>SUMATRIPTAN SUCCINATE - ZECURITY</u>						
N 202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	8597272	Apr 12, 2027	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>TACROLIMUS - PROTOPIC</u>						
N 050777 001	5665727	Sep 09, 2014		U-919		
<u>TACROLIMUS - PROTOPIC</u>						
N 050777 002	5665727	Sep 09, 2014		U-919		
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-1184			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-1184			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-1184			
	7182958	Apr 26, 2020	DP U-155			
	7182958	Apr 26, 2020	DP U-1184			
<u>TADALAFIL - CIALIS</u>						
N 021368 002	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N 021368 003	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N 021368 004	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-155			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - ADCIRCA</u>						
N 022332 001	5859006	Nov 21, 2017	DS DP U-975		ODE	May 22, 2016
	6821975	Nov 19, 2020	DS DP			
	7182958	Apr 26, 2020	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458 001	8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
	8741620	Feb 24, 2024	DS DP		NPP	Aug 27, 2017
	8790641	Oct 18, 2025		U-1564		
	8790641	Oct 18, 2025		U-1574		
<u>TAMOXIFEN CITRATE - SOLTAMOX</u>						
N 021807 001	6127425	Jun 26, 2018	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 022304 001	6071970	Jun 06, 2017		U-931		
	7994364	Jun 27, 2025	DS DP	U-931		
	RE39593	Aug 05, 2022	DS DP	U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 022304 002	6071970	Jun 06, 2017		U-931		
	7994364	Jun 27, 2025	DS DP	U-931		
	RE39593	Aug 05, 2022	DS DP	U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 022304 003	6071970	Jun 06, 2017		U-931		
	7994364	Jun 27, 2025	DS DP	U-931		
	RE39593	Aug 05, 2022	DS DP	U-931		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794 001	6071970	Jun 06, 2017		U-1289		
	7994364	Jun 27, 2025	DS DP	U-1289		
	RE39593	Aug 05, 2022	DS DP	U-1289		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2017	DS DP	U-1486	NCE	Jan 31, 2019
	8785492	Jan 25, 2033		U-1486	ODE	Jan 31, 2021
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027		U-718	NCE	Jul 07, 2019
	7767657	May 22, 2027		DP		
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	8808716	Feb 24, 2030		DP	NDF	May 11, 2015
<u>TECHNETIUM TC-99M APCITIDE - ACUTECT</u>						
N 020887 001	5645815	Jul 08, 2014				
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N 017858 001					ODE	Aug 13, 2019
<u>TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC</u>						
N 019928 001	6056941	Jul 28, 2019		DP		
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	6409990	May 12, 2020	DS		I-687 NCE ODE	Jun 13, 2017 Mar 13, 2018 Jun 13, 2021
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Feb 23, 2028	DS DP	U-282	NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP	U-282	GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP	U-282		
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Feb 23, 2028	DS DP	U-282	NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP	U-282	GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP	U-282		
<u>TEUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2015	DS DP	U-1320	NCE	Dec 21, 2017
	7056886	Sep 18, 2022		DP U-1320	ODE	Dec 21, 2019
	7847061	Nov 01, 2025		U-1320		
<u>TELAPREVIR - INCIVEK</u>						
N 201917 001	7820671	Feb 25, 2025	DS DP		NCE	May 23, 2016
	8431615	May 30, 2028		U-1398		
	8529882	Aug 31, 2021		U-1398		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
	6858584	Aug 24, 2022	DP		NCE	Sep 11, 2014
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021		U-1005		
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021		U-282		
	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 002	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
	6858584	Aug 24, 2022	DP		NCE	Sep 11, 2014
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021		U-1005		
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021		U-282		
	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELIVUDINE - TYZEKA</u>						
N 022011 001	6395716	Aug 10, 2019		U-782	M-124	Jan 28, 2016
	6444652	Aug 10, 2019		U-782		
	6566344	Aug 10, 2019		U-782		
	6569837	Oct 25, 2020		U-782		
	6569837	Oct 25, 2020		U-999		
	7589079	Sep 11, 2023	DS DP U-999			
	7795238	Aug 10, 2019		U-999		
	7858594	Sep 11, 2023	DS DP U-999			
<u>TELIVUDINE - TYZEKA</u>						
N 022154 001	6395716	Aug 10, 2019		U-999	M-124	Jan 28, 2016
	6444652	Aug 10, 2019		U-999		
	6566344	Aug 10, 2019		U-999		
	6569837	Oct 25, 2020		U-999		
	7795238	Aug 10, 2019		U-999		
	7858594	Sep 11, 2023	DS DP U-999			
<u>TELITHROMYCIN - KETEK</u>						
N 021144 001	5635485	Apr 01, 2018	DS DP U-578			
	D459798	Sep 24, 2015	DP			
<u>TELITHROMYCIN - KETEK</u>						
N 021144 002	5635485	Apr 01, 2018	DS DP U-578			
	D459798	Sep 24, 2015	DP			
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 001					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 002					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 003					PC	Jul 07, 2014
<u>TELMISARTAN - MICARDIS</u>						
N 020850 001	6358986	Jan 10, 2020				
<u>TELMISARTAN - MICARDIS</u>						
N 020850 002	6358986	Jan 10, 2020				
	7998953	Jun 06, 2020		U-1177		
	8003679	Oct 06, 2022		U-1176		
<u>TELMISARTAN - MICARDIS</u>						
N 020850 003	6358986	Jan 10, 2020				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277 001	6987108	Sep 08, 2023	DP			
	7786118	Feb 21, 2023	DP			
	8623868	Feb 21, 2023	DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	5362718	Feb 15, 2019	DS DP	Y	M-61	May 30, 2015
	5362718*PED	Aug 15, 2019			PED	Nov 30, 2014
	8026276	Jan 20, 2026	DP		PED	Nov 30, 2015
	8299116	Jul 25, 2023	DP			
	8455539	Jul 25, 2023	DP			
	8455539*PED	Jan 25, 2024				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
	8791097	May 10, 2032				
	8791097	May 10, 2032			U-1550	
	8791097	May 10, 2032			U-1551	
	RE44768	Feb 15, 2019	DS DP			
	RE44768*PED	Aug 15, 2019				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TERBINAFFINE - LAMISIL</u>						
N 020846 001	5681849	Oct 28, 2014	DP			
<u>TERBINAFFINE - LAMISIL AT</u>						
N 021958 001	5681849	Oct 28, 2014	DP			
<u>TERBINAFFINE HYDROCHLORIDE - LAMISIL AT</u>						
N 021124 001	5681849	Oct 28, 2014				
<u>TERBINAFFINE HYDROCHLORIDE - LAMISIL AT</u>						
N 021124 002	5681849	Oct 28, 2014				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	5679709	Oct 21, 2014	DP U-1285		NCE	Sep 12, 2017
	6794410	Apr 15, 2022	U-1285			
	8802735	Sep 14, 2030	DP			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	5679709	Oct 21, 2014	DP U-1285		NCE	Sep 12, 2017
	6794410	Apr 15, 2022	U-1285			
	8802735	Sep 14, 2030	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 001	6770623	Dec 08, 2018	DP U-597			
	6977077	Aug 19, 2019	U-597			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-790			
	7351414	Aug 19, 2019	U-865			
	7517334	Mar 25, 2025	DP			
	7550434	Dec 08, 2018	DP U-982			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 002	6770623	Dec 08, 2018	DP U-982			
	6977077	Aug 19, 2019	U-982			
	6977077	Aug 19, 2019	U-994			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-983			
	7163684	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-984			
	7351414	Aug 19, 2019	U-994			
	7517334	Mar 25, 2025	DP			
	7550434	Dec 08, 2018	DP U-982			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 001	5861379	May 26, 2020	DS DP U-1100		NCE	Nov 10, 2015
	6020311	May 26, 2015	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 002	5861379	May 26, 2015	DS DP U-1100		NCE	Nov 10, 2015
	6020311	May 26, 2015	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - TESTODERM</u>						
N 019762 001	5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM</u>						
N 019762 002	5840327	Aug 15, 2016				
<u>TESTOSTERONE - ANDRODERM</u>						
N 020489 003					NS	Oct 20, 2014
<u>TESTOSTERONE - ANDRODERM</u>						
N 020489 004					NS	Oct 20, 2014
<u>TESTOSTERONE - TESTODERM TTS</u>						
N 020791 001	6348210	Nov 10, 2019	U-440			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	6503894	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	6503894	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	6503894	Aug 30, 2020	U-490			
<u>TESTOSTERONE - TESTIM</u>						
N 021454 001	7320968	Jan 18, 2025	U-843			
	7608605	Apr 21, 2023	U-1009			
	7608606	Apr 21, 2023	U-1009			
	7608607	Apr 21, 2023	U-1009			
	7608608	Apr 21, 2023	U-1009			
	7608609	Apr 21, 2023	U-1009			
	7608610	Apr 21, 2023	U-1009			
	7935690	Apr 21, 2023	U-1009			
	8063029	Apr 21, 2023	U-843			
	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - FORTESTA</u>						
N 021463 001	6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
<u>TESTOSTERONE - STRIANT</u>						
N 021543 001	6248358	Aug 23, 2019	U-527			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020		U-1103		
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026		U-1103		
	8466138	Oct 12, 2026		U-1103		
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020		U-1103		
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026		U-1103		
	8466138	Oct 12, 2026		U-1103		
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020		U-1103		
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026		U-1103		
	8466138	Oct 12, 2026		U-1103		
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	6299900	Feb 19, 2017		DP U-1103		
	6818226	Feb 19, 2017		DP U-1103		
	6923983	Feb 19, 2017		DP U-1103		
	8071075	Feb 19, 2017		DP U-1103		
	8419307	Feb 26, 2027		U-1386		
	8435944	Jul 05, 2027		U-1390		
	8784878	Jul 13, 2023		DP U-1545		
	8807861	Feb 26, 2027		DP U-1563		
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 202763 001					NP	Feb 14, 2015
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 003					NP	Jan 31, 2016
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	8785426	Feb 11, 2034		DP U-1531	NP	Jun 04, 2017
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	8785426	Feb 11, 2034		DP U-1531	NP	Jun 04, 2017
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	8574622	Feb 04, 2024		DP	NP	May 28, 2017
	8784869	Feb 04, 2024		DP		
	8784882	Feb 04, 2024		DP U-1557		
	8877230	Feb 04, 2024		U-1616		
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027		DP	NP	Mar 05, 2017
	8338395	Feb 27, 2026		U-1500		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TETRABENAZINE - XENAZINE</u>						
N 021894	001				ODE	Aug 15, 2015
<u>TETRABENAZINE - XENAZINE</u>						
N 021894	002				ODE	Aug 15, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023		DP		
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023		DP		
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023		DP		
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-731			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-731			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THYROTROPIN ALFA - THYROGEN</u>						
N 020898 001	5840566	Nov 24, 2015			ODE	Dec 14, 2014

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 001	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 002	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 003	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 004	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 005	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			
	8425934	Apr 17, 2030	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	7879828	Feb 05, 2029	DP			
	8372995	Oct 08, 2030	DP			
	RE40183	Apr 09, 2016	DS DP			
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963 001	6174524	Mar 26, 2019	DP			
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963 002	6174524	Mar 26, 2019	DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6335335	Nov 02, 2018	DP			
	6645963	Nov 16, 2018	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	7070800	Jan 22, 2022	DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7642268	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
	8022082	Jan 19, 2026	DP U-1186			
	RE38912	Oct 11, 2021	DP			
	RE39820	Jan 30, 2018	DS DP U-566			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NP	Sep 24, 2017
	6149054	Dec 16, 2016	DP			
	6176242	May 31, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	RE39820	Jan 30, 2018	DS DP U-1593			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIPRANA VIR - APTIVUS</u>						
N 021814 001	5852195	Jun 22, 2019	DS			
	6147095	Oct 29, 2019		U-670		
	6231887	Jul 27, 2018	DP			
<u>TIPRANA VIR - APTIVUS</u>						
N 022292 001	5852195	Jun 22, 2019	DS			
	6147095	Oct 29, 2019		U-670		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	May 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
<u>TOBRAMYCIN - TOBI</u>						
N 050753 001	5508269	Oct 19, 2014	DP U-909			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	7097827	Apr 16, 2016	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			
	8715623	Dec 19, 2022	DP U-909			
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022		U-1324		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	6956041	Dec 08, 2020	DP		M-135	Feb 21, 2017
	6965027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	7091208	Dec 08, 2020		U-247		
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 001	6630162	Nov 11, 2019	DP U-544			
	6770295	Aug 26, 2019	DP U-544			
	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 002	6630162	Nov 11, 2019	DP U-544			
	6770295	Aug 26, 2019	DP U-544			
	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020	U-978			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020	U-978			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020	U-978			
	8501730	Sep 01, 2026	DS			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 001	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 002	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 003	5998380	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	6503884	Oct 13, 2015	U-598			
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 004	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 005	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 006	5998380	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	6503884	Oct 13, 2015	U-598			
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 001	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7125560	Mar 01, 2019	U-766			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 002	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7125560	Mar 01, 2019	U-766			
	7498311	Oct 13, 2015	U-955			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N 020844 003	5998380	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	6503884	Oct 13, 2015	U-598			
	7018983	Oct 13, 2015	U-723			
	7125560	Mar 01, 2019	U-766			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCANTIN</u>						
N 020671 001	5674872	Oct 07, 2014	U-910			
<u>TOPOTECAN HYDROCHLORIDE - HYCANTIN</u>						
N 020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCANTIN</u>						
N 020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281 001	6339105	Oct 12, 2019	U-435			
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281 002	6339105	Oct 12, 2019	U-435			
<u>TRAMADOL HYDROCHLORIDE - RYBIX ODT</u>						
N 021693 001	6106861	Dec 05, 2017	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 001	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 002	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 003	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 001	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 002	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 003	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8835443	Sep 13, 2025		U-1581	ODE	May 29, 2020
	8835443	Sep 13, 2025		U-1582	ODE	Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8835443	Sep 13, 2025		U-1581	ODE	May 29, 2020
	8835443	Sep 13, 2025		U-1582	ODE	Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8835443	Sep 13, 2025		U-1581	ODE	May 29, 2020
	8835443	Sep 13, 2025		U-1582	ODE	Jan 08, 2021
<u>TRANDOLAPRIL - MAVIK</u>						
N 020528 001	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL - MAVIK</u>						
N 020528 002	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL - MAVIK</u>						
N 020528 003	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 001	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 002	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 003	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 004	5721244	Feb 24, 2015				
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025		U-1182		
	8273795	Mar 04, 2025		U-1182		
	8487005	Mar 04, 2025	DP	U-1182		
	8791160	Mar 04, 2025	DP	U-1182		
	8809394	Mar 04, 2025	DP	U-1182		
<u>TRAVOPROST - TRAVATAN</u>						
N 021257 001	5631287	Dec 22, 2014		U-382		
	5849792	Dec 22, 2014	DP	U-383		
	5889052	Dec 02, 2014	DP	U-383		
	6011062	Dec 22, 2014	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994 001	5889052	Dec 02, 2014	DP U-383			
	8268299	Oct 13, 2029	DP			
	8323630	Sep 20, 2027	DP			
	8388941	Sep 20, 2027	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8722735	Oct 10, 2029	DP		NP	May 15, 2017
	8754123	May 19, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411 001	6607748	Jun 29, 2020	DP			
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411 002	6607748	Jun 29, 2020	DP			
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	5153222	Oct 16, 2014		U-1019	M-145	May 20, 2017
	6521212	Nov 13, 2018		U-1018	ODE	Jul 30, 2016
	6756033	Nov 13, 2018		U-1018		
	6765117	Oct 24, 2017	DS			
	8497393	Dec 15, 2028	DS			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024				
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024				
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024				
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
<u>TRETINOIN - RETIN-A MICRO</u>						
N 020475 001	5955109	Sep 21, 2016	DP	U-134		
<u>TRETINOIN - RETIN-A MICRO</u>						
N 020475 002	5955109	Sep 21, 2016		U-134		
<u>TRETINOIN - RENOVA</u>						
N 021108 001	6531141	Mar 07, 2020				
<u>TRETINOIN - ATRALIN</u>						
N 022070 001	5670547	Sep 23, 2014	DP			
<u>TRIAMCINOLONE ACETONIDE - NASACORT ALLERGY 24 HOUR</u>						
N 020468 002	5976573	Jul 03, 2016	DP			
	6143329	Jul 03, 2016	DP			
	7977045	Jul 03, 2016	DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENC</u>						
N 022048 001	6395294	Jan 13, 2020	DP	U-846		
	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029		U-1257		
	8211880	Mar 10, 2029		U-1258		
<u>TRIMETHOPRIM HYDROCHLORIDE - PRIMSQL</u>						
N 074973 001	5763449	Aug 07, 2016				
	5962461	Aug 07, 2016				

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326 001	6017922	May 18, 2018				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326 002	6017922	May 18, 2018				
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 020715 001	5776885	Jul 07, 2015				
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 021288 001	5776885	Jul 07, 2015	DP			
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	5776885	Jul 07, 2015	DP			
<u>TROGLITAZONE - PRELAY</u>						
N 020719 001	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - PRELAY</u>						
N 020719 002	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - PRELAY</u>						
N 020719 003	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - REZULIN</u>						
N 020720 001	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - REZULIN</u>						
N 020720 002	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - REZULIN</u>						
N 020720 003	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROSPIUM CHLORIDE - SANCTURA XR</u>						
N 022103 001	7410978	Feb 01, 2025	DP			
	7759359	Nov 04, 2024	U-1071			
	7763635	Nov 04, 2024	U-1071			
	7781448	Nov 04, 2024	U-1071			
	7781449	Nov 04, 2024	U-1071			
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N 020759 001	5763454	Jun 15, 2015	U-282			
	6187341	Jan 20, 2019				
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N 020759 002	5763454	Jun 15, 2015	U-282			
	6187341	Jan 20, 2019				
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N 022278 001					ODE	Feb 20, 2016
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8426392	Jun 12, 2030	U-1389		NCE	Aug 13, 2015
	8512745	Feb 14, 2030	DP			
	8735380	Feb 20, 2029	DP			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	5873360	Feb 23, 2016	DP			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	5873360	Feb 23, 2016	DP		NP	Dec 18, 2016
	7439393	Sep 11, 2022	DS DP U-1476			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8309572	Apr 27, 2025	U-1476			
	8511304	Nov 11, 2025	DP U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1476			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214 001	6458836	Jul 09, 2021	U-333			
	6458836	Jul 09, 2021	U-1315			
	6770675	Nov 24, 2018	DP U-1322			
<u>UROFOLLITROPIN - FERTINEX</u>						
N 019415 004	5767067	Jun 16, 2015				
<u>UROFOLLITROPIN - FERTINEX</u>						
N 019415 005	5767067	Jun 16, 2015				
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289 001					D-139	Feb 19, 2017
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N 020487 001	5879706	Jan 19, 2016	DP U-530			
	5879706	Jan 19, 2016	DP U-894			
	6107302	Jan 19, 2016	DS U-530			
	6107302	Jan 19, 2016	DS U-894			
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N 020487 002	5879706	Jan 19, 2016	DP U-530			
	5879706	Jan 19, 2016	DP U-894			
	6107302	Jan 19, 2016	DS U-530			
	6107302	Jan 19, 2016	DS U-894			
<u>VALDECOXIB - BEXTRA</u>						
N 021341 002	5633272	Feb 13, 2015	U-462			
<u>VALDECOXIB - BEXTRA</u>						
N 021341 003	5633272	Feb 13, 2015	U-462			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001	6083953	Mar 29, 2015	DS DP U-384			
	6083953	Mar 29, 2015	DS DP U-854			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	6083953	Mar 29, 2015	DS DP U-384			
	6083953	Mar 29, 2015	DS DP U-854			
	6083953*PED	Sep 29, 2015				
<u>VALSARTAN - VALSARTAN</u>						
A 077492 001					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 002					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 003					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 004					PC	Jan 03, 2015

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VALSARTAN - DIOVAN</u>						
N 021283 001	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 002	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 003	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 004	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	8642608	Feb 06, 2022		U-1490		
	RE42353	Sep 23, 2017	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	8642608	Feb 06, 2022		U-1490		
	RE42353	Sep 23, 2017	DS DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 001	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027		U-1288		
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 002	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027		U-1288		
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 003	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027		U-1288		
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 004	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027		U-1288		
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	6362178	Oct 31, 2018		U-155		
	7696206	Oct 31, 2018		U-155		
	8613950	Dec 23, 2028	DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001	6410550	May 10, 2020	DS DP U-56		M-105	Jul 22, 2014
	6890927	May 06, 2022	DS DP U-56		M-143	Oct 15, 2017
	7265119	Aug 03, 2022	DS DP U-56		M-144	Oct 15, 2017
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002	6410550	May 10, 2020	DS DP U-56		M-105	Jul 22, 2014
	6890927	May 06, 2022	DS DP U-56		M-143	Oct 15, 2017
	7265119	Aug 03, 2022	DS DP U-56		M-144	Oct 15, 2017
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575 001					M-130	Nov 21, 2016
					NCE	Feb 26, 2015
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575 002					M-130	Nov 21, 2016
					NCE	Feb 26, 2015



**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	7504509	Oct 22, 2026	DS DP		NCE	Aug 17, 2016
	7863288	Jun 20, 2029	DS DP		ODE	Aug 17, 2018
	8143271	Jun 21, 2026	DS DP			
	8470818	Aug 02, 2026		U-1418		
	8741920	Jul 27, 2030	DS DP			
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 001	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 002	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 003	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 004	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 001	6403120	Mar 20, 2017			U-535	
	6403120	Mar 20, 2017			U-839	
	6419958	Mar 20, 2017			U-535	
	6419958	Mar 20, 2017			U-839	
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 002	6403120	Mar 20, 2017			U-535	
	6403120	Mar 20, 2017			U-839	
	6419958	Mar 20, 2017			U-535	
	6419958	Mar 20, 2017			U-839	
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 003	6403120	Mar 20, 2017			U-535	
	6403120	Mar 20, 2017			U-839	
	6419958	Mar 20, 2017			U-535	
	6419958	Mar 20, 2017			U-839	
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 004	6403120	Mar 20, 2017			U-535	
	6403120	Mar 20, 2017			U-839	
	6419958	Mar 20, 2017			U-535	
	6419958	Mar 20, 2017			U-839	
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N 020552 001	6096339	Apr 04, 2017			U-365	
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N 020552 002	6096339	Apr 04, 2017			U-365	
<u>VERTEPORFIN - VISUDYNE</u>						
N 021119 001	5707608	Aug 02, 2015				
	5756541	Mar 11, 2016			U-357	
	5770619	Jan 06, 2015			U-357	
	5798349	Aug 25, 2015			U-357	

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VIGABATRIN - SABRIL</u>						
N 020427	001				NCE	Aug 21, 2014
					NPP	Oct 26, 2016
					PED	Feb 21, 2015
					PED	Apr 26, 2017
<u>VIGABATRIN - SABRIL</u>						
N 022006	001				NCE	Aug 21, 2014
					NPP	Oct 26, 2016
					ODE	Aug 21, 2016
					PED	Feb 21, 2015
					PED	Feb 21, 2017
					PED	Apr 26, 2017
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	001	5532241	Sep 29, 2019	DS DP		NCE
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022		U-839	
		8236804	Jun 05, 2022		U-839	
		8673921	Jun 05, 2022	DS DP		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	002	5532241	Sep 29, 2019	DS DP		NCE
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022		U-839	
		8236804	Jun 05, 2022		U-839	
		8673921	Jun 05, 2022	DS DP		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	003	5532241	Sep 29, 2019	DS DP		NCE
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022		U-839	
		8236804	Jun 05, 2022		U-839	
		8673921	Jun 05, 2022	DS DP		
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N 202497	001	6723338	Mar 31, 2020		U-1271	NP
		7247316	Sep 25, 2020	DP		ODE
		7887836	Mar 31, 2020		U-1271	
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388	001	7888364	Nov 11, 2028	DS DP		NCE
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886	001	7235567	Jun 13, 2021	DS DP		NCE
		7304078	Apr 06, 2024	DS DP U-1512		
<u>VORICONAZOLE - VFEND</u>						
N 021266	001	5567817	May 24, 2016	DS DP U-540		
<u>VORICONAZOLE - VFEND</u>						
N 021266	002	5567817	May 24, 2016	DS DP U-540		
<u>VORICONAZOLE - VFEND</u>						
N 021267	001	5567817	May 24, 2016	DS DP U-540		
		6632803	Jun 02, 2018	DP		
<u>VORICONAZOLE - VFEND</u>						
N 021630	001	5567817	May 24, 2016	DS DP U-540		
<u>VORINOSTAT - ZOLINZA</u>						
N 021991	001	7399787	Feb 09, 2025		U-892	
		7456219	Mar 11, 2027	DS		
		7652069	Mar 04, 2023	DP		
		7732490	Mar 04, 2023		U-892	
		7851509	Feb 21, 2024	DP	U-892	
		8067472	Mar 04, 2023		U-892	
		8093295	May 16, 2026	DP		
		8101663	Mar 04, 2023		U-892	
		8450372	Mar 18, 2028		U-892	
		RE38506	Jul 07, 2015	DS DP		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Nov 11, 2030	DS DP			
<u>ZANAMIVIR - RELENZA</u>						
N 021036 001	5648379	Jul 15, 2014		U-274		
	5648379	Jul 15, 2014		U-721		
	5648379	Jul 15, 2014		U-722		
	6294572	Dec 15, 2014	DS DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	5364842	Dec 30, 2016		U-48		
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			
	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	5364842	Dec 30, 2016		U-48		
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			
	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	5364842	Dec 30, 2016		U-48		
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			
	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	5364842	Dec 30, 2016		U-48		
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			
	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 004	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 021483 001	6150366	May 27, 2019	DP	U-719		
	6245766	Dec 18, 2018	U-601			
	7175855	May 18, 2020	DP			
<u>ZIPRASIDONE MESYLATE - GEODON</u>						
N 020919 001	6110918	Mar 26, 2017				
	6232304	Apr 01, 2017				
	6399777	Apr 01, 2017				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223 002	8324189	May 29, 2025	U-53			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223 003	7932241	Feb 05, 2028	DP			
	8324189	May 29, 2025	U-53			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817 001	7932241	Feb 05, 2028	DP			
	8052987	Oct 27, 2023	U-1199			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003	6750237	Nov 28, 2020	DP			
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 004	6750237	Nov 28, 2020	DP			
	7220767	Nov 28, 2020	DP			
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774 001	6514531	Dec 01, 2019	DP			
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774 002	6514531	Dec 01, 2019	DP			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	6761910	Sep 24, 2019	DP	U-674		
	8512747	Sep 24, 2019	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	6761910	Sep 24, 2019	DP	U-674		
	8512747	Sep 24, 2019	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	7632517	Oct 01, 2017	U-70			

**PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328 001	7658945	Apr 15, 2027	DP U-1194		NP	Nov 23, 2014
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328 002	7658945	Apr 15, 2027	DP U-1194		NP	Nov 23, 2014
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

**PATENT AND EXCLUSIVITY TERMS****PATENT & EXCLUSIVITY ABBREVIATIONS**

D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

**EXCLUSIVITY DOSING SCHEDULE**

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M <sup>2</sup> OR 175MG/M <sup>2</sup> INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY DOSING SCHEDULE**

- D-34 EVERY FOUR MONTHS DOSAGE REGIMEN
- D-35 FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
- D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
- D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
- D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
- D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2 TO 1 HOUR BEFORE EATING" TO "... RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
- D-40 ONCE-A-DAY DOSING REGIMEN
- D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
- D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
- D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
- D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
- D-46 NEW DOSING REGIMEN OF 80MG DAILY
- D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
- D-48 ADMINISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL
- D-49 PEDIATRIC DOSING GUIDELINES
- D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
- D-51 OPTIONAL STARTING DOSE OF 40MG/DAY
- D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
- D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
- D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
- D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
- D-56 ADDITION OF POSTPRANDIAL DOSING
- D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
- D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
- D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
- D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
- D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
- D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
- D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
- D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
- D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
- D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
- D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
- D-70 80MG ONCE DAILY DOSING REGIMEN
- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPAON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY DOSING SCHEDULE**

- NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
  - D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
  - D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
  - D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
  - D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
  - D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
  - D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
  - D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
  - D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
  - D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
  - D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
  - D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
  - D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
  - D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
  - D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
  - D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
  - D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
  - D-93 ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
  - D-94 NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD)
  - D-95 BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
  - D-96 ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
  - D-97 PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
  - D-98 DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
  - D-99 ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
  - D-100 750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
  - D-101 ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
  - D-102 NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERGIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
  - D-103 NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
  - D-104 0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
  - D-105 USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
  - D-106 FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
  - D-107 PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
  - D-108 TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
  - D-109 PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE



**PATENT AND EXCLUSIVITY TERMS**

ADB 4 of 67

**EXCLUSIVITY DOSING SCHEDULE**

D-110 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17

D-111 PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION

D-112 PROVIDES FOR PEDIATRIC PUMP USE

D-113 ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN

D-114 NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS

D-115 STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED

D-116 ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULFATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS

D-117 50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER

D-118 TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR

D-119 DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE

D-120 DOSING REGIMEN ADJUSTMENTS

D-121 CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION

D-122 USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

D-123 ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS

D-124 ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS

D-125 EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.

D-126 CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG

D-127 DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE

D-128 SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO

D-129 800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS

D-130 DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN

D-131 EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG

D-132 45MG FOR 6 MONTH ADMINISTRATION

D-133 NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE

D-134 INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY

D-135 UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE

D-136 ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS

D-137 NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS

D-138 80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS

D-139 Additional information added to the Dosing and Administration section of the labeling regarding the administration of Bravelle and Menopur in the same syringe to ovulatory women as part of an ART cycle

D-140 REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY

D-141 DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA

D-142 DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE

D-143 INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG

D-144 LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION

D-145 UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEROSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSION AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSION ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY

I-102 TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER

I-103 PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA

I-104 TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY

I-105 TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY

I-106 TREATMENT OF ACROMEGALY

I-107 VAGINAL CANDIDIASIS

I-108 EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION

I-109 TYPHOID FEVER

I-110 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY

I-111 TREATMENT OF PAGET'S DISEASE OF BONE

I-112 MANAGEMENT OF MODERATE TO SEVERE PAIN

I-113 TREATMENT OF PROSTATITIS

I-114 USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE

I-115 USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK

I-116 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS

I-117 TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE

I-118 PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY

I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY

I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS

I-121 EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS

I-122 PSORIASIS OF THE SCALP

I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER

I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE

I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES

I-126 ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY

I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS

I-128 IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...

I-129 TREATMENT OF ALCOHOL DEPENDENCE

I-130 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS

I-131 PERIPHERAL ARTERIOGRAPHY

I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER

I-133 MANAGEMENT OF CHRONIC STABLE ANGINA

I-134 HEART FAILURE POST MYOCARDIAL INFARCTION

I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA

I-136 IDIOPATHIC CHRONIC URTICARIA

I-137 PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES

I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES

I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN

I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE

I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL

I-142 LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION

I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS

I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS

I-145 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN

I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO <sub>2</sub> ) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCLARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- I-230 IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
- I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
- I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
- I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
- I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
- I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
- I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
- I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
- I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
- I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
- I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
- I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
- I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
- I-245 TREATMENT OF ACUTE SINUSITIS
- I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
- I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
- I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
- I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
- I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER
- I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
- I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
- I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
- I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
- I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
- I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION
- I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
- I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
- I-261 TREATMENT OF SOCIAL ANXIETY DISORDER
- I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
- I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
- I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
- I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
- I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

	PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV



**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTEMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363	ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364	TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366	PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-367	COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES
I-368	USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369	PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371	HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
I-372	NOSOCOMIAL PNEUMONIA
I-373	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-374	SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
I-375	FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
I-376	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
I-377	USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
I-378	RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-379	USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
I-380	TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
I-381	TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
I-382	FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
I-383	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-384	USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

## PATENT AND EXCLUSIVITY TERMS

## EXCLUSIVITY INDICATION

## MELLITUS

- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN  $\geq$  2MCG/ML TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI &
- I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
- I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
- I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION  $\leq$  40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
- I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPANILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
- I-409 ESOPHAGEAL CANDIDIASIS
- I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
- I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
- I-412 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-413 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-414 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-415 SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
- I-416 THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF

**PATENT AND EXCLUSIVITY TERMS**

ADB 15 of 67

**EXCLUSIVITY INDICATION**

- ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
- I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
- I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
- I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
- I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- I-424 MANAGEMENT OF SECONDARY HYPERTHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
- I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
- I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCLARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
- I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
- I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
- I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS
- I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
- I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
- I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
- I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
- I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
- I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
- I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
- I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
- I-454 MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
- I-455 MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
- I-456 TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
- I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
- I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
- I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
- I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
- I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
- I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
- I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
- I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
- I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
- I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
- I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
- I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
- I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN
- I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
- I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
- I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
- I-475 PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
- I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
- I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
- I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
- I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
- I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
- I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
- I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
- I-487 INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
- I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER
- I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
- I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
- I-491 INFLUENZA PROPHYLAXIS
- I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
- I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
- I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
- I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
- I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
- I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
- I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
- I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
- I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
- I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
- I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-508 PREMENSTRUAL DYSPHONIC DISORDER
- I-509 TREATMENT OF IRRATABILITY ASSOCIATED WITH AUTISTIC DISORDER
- I-510 ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP)
- I-511 ADULT MYELOYDYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
- I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
- I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
- I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
- I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
- I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
- I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
- I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
- I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
- I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
- I-524 GENERALIZED ANXIETY DISORDER (GAD)
- I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
- I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
- I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
- I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
- I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER
- I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA
- I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
- I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
- I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER
- I-535 MANAGEMENT OF FIBROMYALGIA
- I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
- I-537 LONG TERM TREATMENT OF PANIC DISORDER
- I-538 SHORT TERM TREATMENT OF PANIC DISORDER
- I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
- I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
- I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
- I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS
- I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
- I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
- I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
- I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
- I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
- I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
- I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSSES
- I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
- I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
- I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
- I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

	BIPOLAR DISORDER, MANIC OR MIXED
I-560	MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
I-561	LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
I-562	MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
I-563	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-564	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-565	USE OF DUTASTERIDE IN COMBINATION WITH TAMUSLOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
I-566	MANAGEMENT OF FIBROMYALGIA
I-567	INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-568	USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQUAMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOID FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
I-593	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
I-594	INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
I-595	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-596	USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-597	MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-598	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
I-599	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
I-600	FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO



**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-601 MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
- I-602 TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
- I-603 GOUT FLARES
- I-604 PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
- I-605 ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
- I-606 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
- I-607 INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
- I-608 REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
- I-610 TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
- I-611 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
- I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
- I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
- I-614 SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
- I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
- I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
- I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
- I-620 FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
- I-621 PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
- I-622 ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
- I-623 TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
- I-624 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
- I-625 PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
- I-626 RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER
- I-627 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
- I-628 MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
- I-629 ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-630 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
- I-631 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
- I-632 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
- I-633 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-634 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
- I-635 ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- I-636 TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
- I-637 USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY INDICATION**

- PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
- I-638 FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
- I-639 TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
- I-640 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- I-641 TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-642 TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-643 REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
- I-644 MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
- I-645 MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
- I-646 SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
- I-647 SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- I-648 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
- I-649 TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
- I-650 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
- I-651 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
- I-652 MANAGEMENT OF POSTHERPETIC NEURALGIA
- I-653 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
- I-654 MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
- I-655 TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
- I-656 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- I-657 PLAQUE PSORIASIS OF THE SCALP
- I-658 FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
- I-659 PLAQUE PSORIASIS OF THE BODY
- I-660 TREATMENT OF DEEP VEIN THROMBOSIS
- I-661 TREATMENT OF PULMONARY EMBOLISM
- I-662 REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
- I-663 IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- I-664 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
- I-665 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L
- I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY
- I-667 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
- I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
- I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%
- I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
- I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA- APPROVED TEST
- I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL

**PATENT AND EXCLUSIVITY TERMS**

ADB 22 of 67

**EXCLUSIVITY INDICATION**

- PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCL. METHICILLIN-SUSCEPTIBLE AND -RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
- I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
- I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE
- I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-679 RISK REDUCTION OF BLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
- I-680 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-681 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
- I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS
- I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED
- I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS
- I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE
- I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY
- I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
- I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE
- I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
- I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
- I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY
- I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.
- I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-REISISTANT PROSTATE CANCER (CRPC)
- I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
- I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA
- I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER
- I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION
- I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
- I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
- I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)
- I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSIONFREE SURVIVAL.

**EXCLUSIVITY MISCELLANEOUS**

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
- M-2 APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
- M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY MISCELLANEOUS**

- M-4 CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN  
CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
- M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
- M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
- M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
- M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
- M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
- M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
- M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- M-12 NEW LANGUAGE FOR PEDIATRIC USE
- M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
- M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION
- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
- M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
- M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
- M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
- M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
- M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST

## PATENT AND EXCLUSIVITY TERMS

## EXCLUSIVITY MISCELLANEOUS

- M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
- M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
- M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
- M-43 INCLUSION OF RESULTS OF STUDY-"PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION
- M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
- M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING - EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
- M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
- M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
- M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
- M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
- M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
- M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
- M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
- M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
- M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
- M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
- M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLSCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
- M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
- M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
- M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
- M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
- M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
- M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
- M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
- M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
- M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
- M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
- M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY MISCELLANEOUS**

- M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
- M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
- M-75 PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITS)
- M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
- M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
- M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
- M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE
- M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
- M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)
- M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES
- M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
- M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
- M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
- M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
- M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
- M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
- M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
- M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
- M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
- M-92 UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION
- M-93 EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
- M-94 INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
- M-95 INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
- M-96 UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
- M-97 LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
- M-98 NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
- M-99 ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
- M-100 INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
- M-101 INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM

## PATENT AND EXCLUSIVITY TERMS

## EXCLUSIVITY MISCELLANEOUS

- M-102 PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
- M-103 SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
- M-104 NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
- M-105 ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
- M-106 INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED,1-MONTH,BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516, ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
- M-107 CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
- M-108 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-109 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-110 LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
- M-111 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
- M-112 LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
- M-113 CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
- M-114 REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
- M-115 LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
- M-116 ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
- M-117 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
- M-118 LABELING CHANGES REGARDING MISSED DOSES
- M-119 CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
- M-120 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
- M-121 LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
- M-122 UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
- M-123 LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
- M-124 LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
- M-125 UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
- M-126 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
- M-127 CLINICAL TRIAL STUDY RESULTS
- M-128 RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
- M-129 ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
- M-130 INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS
- M-131 REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS
- M-132 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY
- M-133 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING
- M-134 ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT
- M-135

**PATENT AND EXCLUSIVITY TERMS****EXCLUSIVITY MISCELLANEOUS**

M-136	ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS
M-137	LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
M-138	INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER
M-139	INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA
M-140	INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION
M-141	REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)
M-142	ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY
M-143	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER
M-144	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE
M-145	ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
M-146	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
M-147	OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES
M-148	LABELING CHANGES BASED ON STUDY H80-EW-GWDM
M-149	INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
M-150	ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE

**PATENT USE**

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION
U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION
U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21	TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22	METHOD OF COMBATING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS



**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF  
U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF  
U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY  
U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY  
U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY  
U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY  
U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN  
U-33 TREATING VIRAL INFECTIONS IN A MAMMAL  
U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL  
U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION  
U-36 METHODS OF TREATING BACTERIAL ILLNESSES  
U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE  
U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA  
U-39 ANGINA PECTORIS  
U-40 METHOD OF TREATMENT OF BURNS  
U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS  
U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER  
U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA  
U-44 RELIEF OF NAUSEA AND VOMITING  
U-45 TREATMENT OF INFLAMMATION AND ANALGESIA  
U-46 TREATMENT OF PANIC DISORDER  
U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE  
U-48 ANALGESIA  
U-49 SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA  
U-50 USE IN TREATING INFLAMMATORY DERMATOSES  
U-51 BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING  
U-52 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION  
U-53 HYPERCALCEMIA OF MALIGNANCY  
U-54 REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS  
U-55 TREATMENT OF PAIN  
U-56 AID TO SMOKING CESSATION  
U-57 OPHTHALMIC USE OF NORFLOXACIN  
U-58 METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES  
U-59 METHOD OF TREATING HYPERCHOLESTEROLEMIA  
U-60 NASAL ADMINISTRATION OF BUTORPHANOL  
U-61 CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD  
U-62 CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY  
U-63 ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE  
U-64 TREATMENT OF VIRAL INFECTIONS  
U-65 METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV  
U-66 TRIPHASIC REGIMEN  
U-67 METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL  
U-68 TREATMENT OF ACTINIC KERATOSIS  
U-69 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS  
U-70 TREATMENT OF TRANSIENT INSOMNIA  
U-71 METHOD OF TREATMENT OF HEART FAILURE  
U-72 TREATMENT OF MIGRAINE  
U-73 METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES  
U-74 METHOD OF PROVIDING HYPNOTIC EFFECT  
U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS  
U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM  
U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS  
U-78 ULCERATIVE COLITIS  
U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD  
U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS  
U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS  
U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE  
U-83 TREATMENT OF SEIZURES

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS  
U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS  
U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY  
U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS  
U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS  
U-89 TREATMENT OR PROPHYLAXIS OF EMESIS  
U-90 TREATMENT OF PYSCHOTIC DISORDERS  
U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS  
U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY  
U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT  
U-94 TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED  
U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS  
U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS  
U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT  
U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL  
U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM  
U-100 METHOD OF TREATING OCULAR INFLAMMATION  
U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED  
U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN  
U-103 TREATMENT OF OCULAR HYPERTENSION  
U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE  
U-105 EMESIS  
U-106 TREATMENT OF EPILEPSY  
U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS  
U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS  
U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE  
U-110 USE AS A RETRIEVABLE PERSSARY  
U-111 DIABETES  
U-112 CONTRACEPTION  
U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE  
U-114 USE FOR INHIBITING BONE RESORPTION  
U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS  
U-116 METHOD OF MYOCARDIAL IMAGING  
U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES  
U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL  
U-119 TREATMENT OF NASAL HYPERSECRETION  
U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES  
U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS  
U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS  
U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS  
U-124 TREATMENT OF ACNE  
U-125 TREATMENT NEUROGENERATIVE DISEASES  
U-126 TREATMENT OF GASTRITIS  
U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE  
U-128 METHOD FOR TREATMENT OF TUMORS  
U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS  
U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS  
U-131 PHOTODAMAGED SKIN  
U-132 INHIBITING HIV PROTEASE  
U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

REDUCED-CALORIE DIET

U-134 TREATMENT OF ACNE VULGARIS

U-135 ANTITUMOR AGENT

U-136 PROCESS FOR WASTE NITROGEN REMOVAL

U-137 METHOD OF TREATING BACTERIAL VAGINOSIS

U-138 TREATMENT OF ALLERGIC RHINITIS

U-139 TREATMENT OF ALLERGIC REACTIONS

U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION

U-141 TREATMENT OF ULCERATIVE COLITIS

U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE

U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING

U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS

U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS

U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS

U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF <sup>13</sup>CO<sub>2</sub>

U-148 DEVICE FOR COLLECTING A BREATH SAMPLE

U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES

U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE

U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD

U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER

U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES

U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER

U-155 TREATMENT OF ERECTILE DYSFUNCTION

U-156 METHOD OF PROVIDING ANESTHESIA

U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY

U-158 ANGINA

U-159 TREATMENT OF INTERSTITIAL CYSTITIS

U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT

U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA

U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS

U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS

U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

U-166 TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER

U-167 METHOD FOR TREATING HIV-1 INFECTION

U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA

U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING

U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT

U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT

U-172 TREATMENT OF GENITAL WARTS

U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES

U-174 USE AS AN ANTIHISTAMINE AGENT

U-175 METHOD OF TREATING MALIGNANT TUMORS

U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES

U-177 FUNGICIDE

U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN

U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT

U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION

U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION  
U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION  
U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS  
U-185 METHOD OF TREATING HYPERTENSION  
U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H.PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT  
U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS  
U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER  
U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE  
U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR  
U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN  
U-192 USE IN TREATING ALLERGIC REACTIONS  
U-193 PSORIASIS  
U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE  
U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON  
U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS  
U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER  
U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA  
U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT  
U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT  
U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT  
U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS  
U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY  
U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA  
U-205 METHOD FOR TREATING HEARTBURN  
U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION  
U-207 USE AS NASAL SPRAY  
U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION  
U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION  
U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE  
U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION  
U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE  
U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA  
U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT  
U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS  
U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE  
U-217 METHOD OF PRODUCING ANESTHESIA  
U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT  
U-219 TREATMENT OF PARKINSON'S DISEASE  
U-220 METHOD OF DIAGNOSIS  
U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION  
U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL  
U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS  
U-224 CONTROLLING INTRAOCULAR PRESSURE  
U-225 METHOD FOR DELIVERY  
U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-227 NASAL ADMINISTRATION  
 U-228 ASTHMA  
 U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)  
 U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS  
 U-231 USE IN PARKINSON'S DISEASE  
 U-232 METHOD OF TREATING MIGRAINE  
 U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE  
 U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS  
 U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN  
 COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE  
 TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE  
 U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY  
 U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE  
 PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS  
 U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF  
 PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES  
 UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....  
 U-239 TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING  
 TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM  
 COMPOUND AND BORIC ACID  
 U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS  
 U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL  
 ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM  
 TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY  
 CONDITIONS  
 U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION  
 U-243 TOPICAL ADMINISTRATION  
 U-244 PLATELET AGGREGATION INHIBITORS  
 U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS  
 U-246 PHOSPHATE BINDING  
 U-247 TREATMENT OF RHEUMATOID ARTHRITIS  
 U-248 TREATMENT OF HIV  
 U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING  
 AEROSOLIZED PARTICLES OF MOMETASONE FUROATE  
 U-250 TREATMENT OF HEPATITIS B INFECTION  
 U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II  
 DIABETES  
 U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE  
 U-253 ORAL TRANSMUCOSAL USE  
 U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN  
 U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH  
 NARCOLEPSY  
 U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV  
 ANTIVIRAL AGENTS  
 U-257 TREATMENT OF HIV INFECTION  
 U-258 TREATMENT OF NEURODEGENERATIVE DISEASES  
 U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE  
 U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR  
 HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR  
 INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION  
 U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING  
 FINASTERIDE  
 U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE  
 U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF  
 BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE  
 MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN  
 U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF  
 BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT  
 THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN  
 U-265 USE AS LAXATIVE  
 U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND  
 SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS;  
 TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS  
 U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING  
 FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE  
 FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-268 ACROMEGALY  
U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS  
U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT  
U-271 METHOD OF TREATING TUMORS  
U-272 METHOD OF TREATING CARCINOMA  
U-273 CUTANEOUS T-CELL LYMPHOMA  
U-274 ZANAMIVIR FOR INHALATION  
U-275 METHOD OF USE OF THE DRUG SUBSTANCE  
U-276 METHOD OF USE OF LEVOBUPIVACAINE  
U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)  
U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT  
U-279 METHOD OF USE OF THE APPROVED PRODUCT  
U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE  
U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS  
U-282 METHOD OF TREATING BACTERIAL INFECTIONS  
U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE  
U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS  
U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA  
U-286 DEPRESSION  
U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS  
U-288 THERAPY OF INFLUENZA  
U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP  
U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)  
U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN  
U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE  
U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID  
U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS  
U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS  
U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY  
U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS  
U-298 METHOD OF COMBATING BACTERIA IN A PATIENT  
U-299 TREATMENT OF ADENOMATOUS POLYPS  
U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA  
U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES  
U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS  
U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS  
U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION  
U-305 METHODS FOR USING THE DRUG PRODUCT  
U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY  
U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA  
U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA  
U-309 TREATING SJOEGREN SYNDROME  
U-310 TREATMENT OF XEROSTOMIA  
U-311 HORMONE REPLACEMENT  
U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER  
U-313 TREATMENT OF CONGESTIVE HEART FAILURE  
U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT

U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER

U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE

U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE

U-319 TREATMENT OF MICROBIAL INFECTIONS

U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA

U-321 REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS

U-322 TREATMENT OF ALZHEIMER'S DEMENTIA

U-323 USE AS A BILE ACID SEQUESTRANT

U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE

U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE

U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER

U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE

U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH

U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-330 TREATMENT OF NAUSEA AND VOMITING

U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM

U-333 METHOD OF TREATING OCULAR HYPERTENSION

U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR

U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS

U-336 DIAGNOSTIC RADIOIMAGING

U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI

U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME

U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN

U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN

U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER

U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER

U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION

U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR

U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION

U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR

U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS

U-348 METHOD OF USE FOR INHIBITING HIV INFECTION

U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION

U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR

U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR

U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR

U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS

U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING

U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.

U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER

U-359 METHOD OF USE OF VISICOL

U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011

U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY

U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS

U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011

U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011

U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION

U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION

U-367 TREATMENT OF CARDIOVASCULAR DISORDERS

U-368 HEARTBURN

U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE

U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS

U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...

U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX

U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C

U-376 TREATMENT OF INFLUENZA

U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS

U-378 METHOD FOR TREATING INCONTINENCE

U-379 METHOD OF TREATING ONYCHROMYCOSIS

U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS

U-381 TREATMENT OF HYPERPHOSPHATEMIA

U-382 METHOD OF STABILIZING PROSTAGLANDIN

U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

U-384 TREATMENT OF CMV RETINITIS

U-385 TREATMENT OF PEPTIC ULCERS

U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA

U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS

U-388 SMOKING CESSATION AID APPLIED TO THE SKIN

U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS

U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)

U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER

U-392 TREATMENT OF PATIENTS FOR INFLAMMATION

U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT

U-394 METHOD OF USE OF ALPHAGAN

U-395 METHOD OF USE OF ALPHAGAN P

U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION

U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA



**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER

U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS

U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS

U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS

U-402 TREATMENT OF ACTINIC KERATOSES

U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES

U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS

U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)

U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL

U-407 METHOD OF TREATING OTOPTHY

U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION

U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE

U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION

U-412 TREATMENT OF TYPE 2 DIABETES

U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS

U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE

U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE

U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE

U-420 METHOD OF TREATMENT OF TYPE II DIABETES

U-421 USE FOR SEDATION

U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER

U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA

U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS

U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION

U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS

U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE

U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS

U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER

U-431 POSTTRAUMATIC STRESS DISORDER

U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE

U-433 USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS

U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

ABOUT 25MG

U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS

U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION

U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE

U-439 TREATMENT OF OBESITY

U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE

U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE

U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG

U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME

U-444 TREATMENT OF MIGRAINE

U-445 USE AS AN ANTIMYCOTIC AGENT

U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA

U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER

U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING

U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER

U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)

U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS

U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN

U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15

U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE

U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN

U-458 METHOD OF USE OF IMAGENT

U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER

U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE

U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE

U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA

U-463 VENOGRAPHY

U-464 PERIPHERAL ARTERIOGRAPHY

U-465 CT IMAGING OF THE HEAD

U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME

U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION

U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS

U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE

U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION

U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS

U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES

U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL

U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN

U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

- ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
- U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
- U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
- U-480 CONTRAST AGENT FOR MRI
- U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
- U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
- U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
- U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
- U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
- U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
- U-489 EXPECTORANT
- U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-491 METHOD OF DELIVERING A DRUG TO THE LUNG
- U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
- U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS
- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL (PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-514 PREVENTION OF OVULATION IN A WOMAN  
U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY  
U-516 METHOD OF TREATING A PSYCHOTIC DISEASE  
U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS  
U-518 OBSESSIVE COMPULSIVE DISORDER  
U-519 POST OPERATIVE NAUSEA AND VOMITING  
U-520 PREMENOPAUSAL OSTEOPOROSIS  
U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C  
U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA  
U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL  
U-524 METHOD OF TREATING DIARRHEA  
U-525 METHOD OF TREATING PARASITIC INFECTIONS  
U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION  
U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE  
U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING  
U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE  
U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES  
U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES  
U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR  
U-533 ERECTILE DYSFUNCTION  
U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA  
U-535 TREATMENT OF SOCIAL ANXIETY DISORDER  
U-536 CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING  
U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE  
U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS  
U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE  
U-540 TREATMENT OF FUNGAL INFECTIONS  
U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1  
U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION  
U-543 TREATMENT OF SCHIZOPHRENIA  
U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.  
U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT  
U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE  
U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER  
U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER  
U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER  
U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA  
U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID  
U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION  
U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS  
U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS  
U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS  
U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING  
U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
- U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDER
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD); ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
- U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
- U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-613 REDUCTION OF SERUM PHOSPHATE
- U-614 TREATMENT OF SEXUAL DYSFUNCTION
- U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
- U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
- U-619 TREATMENT OF MALIGNANT NEOPLASM
- U-620 TREATMENT OF INSOMNIA
- U-621 METHOD OF TREATING CANCER
- U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
- U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
- U-625 ALLERGIC RHINITIS OR NASAL POLYPS
- U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
- U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE

U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN

U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN

U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING

U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR

U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL

U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS

U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS

U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST

U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN

U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE

U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLYCEMIA

U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION

U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE

U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS

U-645 TREATMENT OF ASTHMA

U-646 METHOD OF TREATING OTITIS

U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN

U-649 A METHOD FOR TREATING A TUMOR DISEASE

U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS

U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)

U-652 TREATMENT OF CARDIAC ARRHYTHMIA

U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE

U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4

U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS

U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER

U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN

U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE

U-661 TREATMENT OF SEIZURE DISORDER

U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION

U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

U-666 METHOD OF TREATING ADHD

U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE

U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-669 INDICATION OF TYPE II DIABETES

U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.

U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4

U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER

U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML

U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET

U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS

U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION

U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM

U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER

U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM

U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY

U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE

U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE

U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-685 EXPECTORANT AND COUGH SUPPRESSANT

U-686 EXPECTORANT AND NASAL DECONGESTANT

U-687 REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-689 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-690 TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-691 USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-692 USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

U-693 THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.

U-694 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.

U-695 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-696 TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

U-697 A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY

U-698 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA

U-699 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-700 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-701 TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA

U-702 TOPICAL AEROSOL HAIR REGROWTH TREATMENT

U-703 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB

U-704 METHOD OF ADMINISTERING INSULIN VIA INHALATION

U-705 TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE

U-706 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

U-707 ALLERGIC RHINITIS



**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-708 TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE

U-709 METHOD OF COMBATING BACTERIA IN A PATIENT

U-710 A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549

U-711 ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER

U-712 A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA

U-713 TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE

U-714 TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM

U-715 FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER

U-716 THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

U-717 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-718 TREATMENT OF FUNGAL INFECTIONS

U-719 TREATMENT OF PSYCHOSIS

U-720 TREATMENT OF NEUROLEPTIC DISEASES

U-721 TREATMENT OF INFLUENZA

U-722 PROPHYLAXIS OF INFLUENZA

U-723 PROPHYLACTIC TREATMENT OF MIGRAINE

U-724 METHOD OF TREATING SEIZURES

U-725 ALLERGIC RHINITIS AND URTICARIA

U-726 ALLERGIC RHINITIS

U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

U-728 METHOD FOR TREATING BACTERIAL INFECTION

U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS

U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)

U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE

U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS

U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD

U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE

U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE

U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER

U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMALIAN SUBJECT

U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER

U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.

U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA

U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS

U-745 TREATMENT OR PREVENTION OF EMESIS

U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING

U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER

U-749 METHOD OF CONTRACEPTION

U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS

U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA

U-752 SUNSCREEN

U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES

U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA

U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-757 USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL

U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER

U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE

U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA

U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

U-763 ADMINISTRATION OF ARIPIPIRAZOLE BY INJECTION

U-764 TREATMENT OF SCHIZOPHRENIA

U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS

U-766 TREATMENT OF SEIZURES

U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID

U-769 REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT

U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS

U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA

U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.

U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE

U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA

U-780 A METHOD FOR THE TREATMENT OF CANCER

U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY

U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTENT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE

U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER

U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY

U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS

U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA

U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE

U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING

U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS

U-791 GLEVEEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)

U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS

U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-794 CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE

U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE

U-796 METHOD OF TREATING DEPRESSION

U-797 METHOD OF TREATING ANXIETY

U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID

U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE

U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB

U-801 METHOD OF TREATING CANCER

U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN

U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY

U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES

U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS

U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION

U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA

U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE

U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA

U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-814 TREATMENT OF SCHIZOPHRENIA

U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING

U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER

U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN

U-818 TOPICAL TREATMENT OF ACNE VULGARIS

U-819 MANAGEMENT OF FIBROMYALGIA

U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER

U-821 METHOD OF INHIBITING ENTHOHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.

U-822 USE IN LIPID MANAGEMENT

U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE

U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1

U-825 USE FOR PREVENTION OF BREAST CANCER

U-826 RELIEF OF MODERATE TO SEVERE PAIN

U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES

U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY

U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER

U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE

U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.

U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE

U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION

U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS

U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS

U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE

U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS

U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER

U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS

U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES

U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE

U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY

U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS

U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-853 TREATMENT OR PREVENTION OF EMESIS

U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)

U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION

U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN

U-857 INHIBITION OF TRANSPLANT REJECTION

U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS

U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD

U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION

U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA

U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY

U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIIVE ESOPHAGITIS

U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE

U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES

U-867 TREATMENT OF MIGRAINE

U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA

U-869 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART

U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION

U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH

U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)

U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC  
CANCER, IN COMBINATION WITH GEMCITABINE

U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER

U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR

U-879 A METHOD OF TREATING OR PREVENTING ILEUS

U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY  
PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED  
REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN

U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER

U-882 MANAGEMENT OF FIBROMYALGIA (FM)

U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB

U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR  
THERAPY

U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS,  
SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA

U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN

U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED  
WITH MENOPAUSE)

U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE

U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING  
PERFUSION OF THE EYE

U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA  
(CTCL)

U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION  
OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE

U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER

U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS  
AND CHILDREN TWO YEARS OF AGE AND OLDER

U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS  
PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT

U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH  
SHORT BOWEL SYNDROME

U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS  
WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION

U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA  
(BPH)

U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS

U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE,  
SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE

U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS;  
TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF  
ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS

U-907 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE  
AND OLDER

U-908 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS

U-909 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-910 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR  
SUBSEQUENT CHEMOTHERAPY

U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT  
WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT  
FEASIBLE

U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER  
PROCEDURES

U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE,  
URGENCY, AND FREQUENCY

U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT  
WITH EPILEPSY AGED 17 YEARS AND OLDER

U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER

U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-918 TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-  
RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

U-919 FOR THE TREATMENT OF DERMATITIS

U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS  
INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL  
OCULAR INFECTION EXISTS

U-921 TREATMENT OF ACNE VULGARIS

U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS

U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS

U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA  
OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING  
PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)

U-927 METHOD FOR INCREASING TEAR PRODUCTION

U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI

U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN

U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF  
PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO  
ERADICATE H. PYLORI

U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL  
ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS  
BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE  
HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT  
AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA

U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND  
TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF  
AGE AND OLDER

U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE  
HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT  
AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE  
MYELOMA

U-937 TREATMENT OF PROSTATE CANCER

U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR  
GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR  
GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA

U-941 METHOD TO TREAT OVARIAN CANCER

U-942 METHOD TO TREAT MULTIPLE MYELOMA

U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER

U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION

U-946 TREATMENT OF BREAST CANCER

U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION  
IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL  
GRADES OF EROSIIVE ESOPHAGITIS

U-948 TREATMENT OF DIABETES MELLITUS

U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS

U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS

U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE  
(GERD) FOR 4 WEEKS

U-952 USE AS AN ANALGESIC

U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE  
TREATMENT OF ASYMPTOMATIC HYPERURICEMIA

U-955 PROPHYLACTIC TREATMENT OF MIGRAINE

U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE

U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR  
PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE

U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT  
COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION,  
DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

PT

U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT (DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML

U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT

U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE

U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS

U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS

U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS

U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER

U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)

U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC

U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-969 TREATMENT OF MIGRAINE

U-970 TOPICAL TREATMENT OF LICE INFESTATIONS

U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA

U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE

U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

U-975 TREATMENT OF PULMONARY HYPERTENSION

U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES

U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE

U-978 METHOD OF TREATING HYPONATREMIA

U-979 RELIEF OF MUSCLE SPASM

U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY

U-982 A METHOD OF TREATING OSTEOPOROSIS

U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE

U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE

U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)

U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR

U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS

U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350

U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA

U-990 TREATMENT OF PROTOZOAL INFECTION

U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS

U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION

U-993 METHOD OF TREATING INFERTILITY

U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED

U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN

U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHLORESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA

U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

U-998 ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS

U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS

U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION

U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS

U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW

U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION

U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)

U-1007 METHOD OF TREATING GOUT FLARES

U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION

U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION

U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION

U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B (PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS

U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

U-1019 TREATMENT OF PULMONARY HYPERTENSION

U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES

U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER

U-1022 FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION

U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP

U-1025 TREATING FREQUENT HEARTBURN

U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

U-1027 REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL

U-1028 A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY

U-1029 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

U-1031 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1032 USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS

U-1033 TOPICAL TREATMENT OF ACNE VULGARIS

U-1034 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

U-1035 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1036 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN

U-1037 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST



**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1038 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST

U-1039 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN

U-1040 INHIBITION OF THROMBIN IN A PATIENT

U-1041 TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE

U-1042 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART

U-1043 MANAGEMENT OF MODERATE TO SEVERE PAIN

U-1044 TOPICAL TREATMENT OF SCALP PSORIASIS

U-1045 MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY

U-1046 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY

U-1047 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)

U-1048 WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES

U-1049 PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT

U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS

U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE

U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA

U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS

U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA

U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE

U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA

U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA

U-1067 TREATMENT OF CANCER

U-1068 TREATMENT OF ASTHMA

U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE

U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIDIUM SALT FORMULATION

U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME

U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD

U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT

U-1075 USE FOR THE TREATMENT OF ASTHMA

U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING

U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION

U-1078 TREATMENT OF ACNE

U-1079 REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT

U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1082 INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION  
USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION  
WHERE AN INFECTION OR RISK OF INFECTION EXISTS

U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF  
CLUSTER HEADACHE EPISODES

U-1084 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID  
RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

U-1085 METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL  
DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME

U-1086 TREATMENT OF AUTOIMMUNE DISEASE

U-1087 DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC  
CYSTOSCOPY

U-1088 RELIEF OF MUSCLE SPASM

U-1089 INHIBITION OF THROMBIN

U-1090 LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO  
USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-1091 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER  
WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA

U-1092 TREATMENT OF BREAST CANCER

U-1093 TREATMENT OF PSEUDOBULBAR AFFECT

U-1094 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

U-1095 METHOD OF TREATING OCULAR INFLAMMATION

U-1096 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

U-1097 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2  
DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS  
APPROPRIATE

U-1098 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA

U-1099 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL  
NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA

U-1100 REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY

U-1101 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY

U-1102 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY

U-1103 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A  
DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1104 USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

U-1105 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND  
OLDER

U-1106 TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT

U-1107 TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT

U-1108 TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE

U-1109 TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN  
CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE  
EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-1110 METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN  
A COMPUTER SYSTEM FOR DISTRIBUTION

U-1111 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE  
PAIN

U-1112 METHOD OF MR IMAGING OF A MAMMAL

U-1113 TREATMENT AND PROPHYLAXIS OF INFLUENZA

U-1114 TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING  
NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA

U-1115 TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD  
ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

U-1116 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS

U-1117 TREATMENT OF BREAST CANCER

U-1118 USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING  
CHRONIC BRONCHITIS AND EMPHYSEMA

U-1119 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING

U-1120 TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE  
ADMINISTER ONCE DAILY WITH EVENING MEAL

U-1121 METHOD OF TREATING TRAVELERS' DIARRHEA

U-1122 TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S.  
PYOGENES

U-1123 TREATMENT OF ALCOHOL DEPENDENCE

U-1124 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION

U-1125 METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS

**PATENT AND EXCLUSIVITY TERMS**

ADB 54 of 67

**PATENT USE**

- U-1126 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
- U-1127 TREATMENT OF PATENT DUCTUS ARTERIOSUS
- U-1128 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS ( $\geq 18$  YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
- U-1129 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1130 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1131 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1132 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1133 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1134 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1135 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
- U-1136 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1137 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1138 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1139 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1140 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1141 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1142 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTINO OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1150 TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
- U-1151 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
- U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
- U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
- U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
- U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
- U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATINETS WITH HYPERPHENYLALANINEMIA (HPA)
- U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
- U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
- U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
- U-1163 METHOD OF TREATING THROMBOSIS
- U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
- U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
- U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
- U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
- U-1170 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-1171 REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
- U-1172 TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
- U-1173 TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
- U-1174 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
- U-1175 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
- U-1176 TREATMENT OR PREVENTION OF STROKE
- U-1177 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
- U-1178 RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
- U-1179 TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
- U-1180 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
- U-1181 A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
- U-1182 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
- U-1183 A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
- U-1184 TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
- U-1185 TREATMENT OF OPIOID-INDUCED CONSTIPATION
- U-1186 ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
- U-1187 TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
- U-1188 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
- U-1189 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
- U-1190 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
- U-1191 METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA (INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)
- U-1192 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
- U-1193 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)

U-1194 METHOD FOR TREATING INSOMNIA

U-1195 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA

U-1196 RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS

U-1197 METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

U-1198 RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE

U-1199 TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-1200 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM

U-1201 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS

U-1202 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME

U-1203 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-1204 TREATMENT OF UVEITIS

U-1205 TREATMENT OF MACULAR EDEMA

U-1206 DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX

U-1207 INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIIVE ESOPHAGITIS

U-1208 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-1209 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER

U-1210 USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)

U-1211 USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA

U-1212 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1213 TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER

U-1214 METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1215 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1216 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1217 METHOD OF INCREASING HAIR GROWTH

U-1218 METHOD OF STIMULATING HAIR GROWTH

U-1219 METHOD OF INCREASING THE NUMBER OF HAIRS

U-1220 TREATMENT OF RENAL CELL CARCINOMA

U-1221 TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION

U-1222 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS

U-1223 METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE

U-1224 REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE

U-1225 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS

U-1226 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT

U-1227 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE

U-1228 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN

U-1229 TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS

U-1230 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT

U-1231 TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS

U-1232 USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI. INTENDED FOR USE W/ASPIRIN

U-1233 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

	FOOD
U-1234	FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
U-1235	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1236	USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1237	COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
U-1238	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
U-1239	MAGNETIC RESONANCE IMAGING OF THE LIVER
U-1240	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-1241	MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1242	PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
U-1243	WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
U-1244	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYUREA
U-1245	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
U-1246	SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
U-1247	MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
U-1248	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
U-1249	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
U-1250	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1251	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
U-1252	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
U-1253	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
U-1254	METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
U-1255	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
U-1256	TREATMENT OF SEBORRHEIC DERMATITIS
U-1257	TREATMENT OF OPHTHALMIC DISORDERS
U-1258	VISUALIZATION DURING VITRECTOMY PROCEDURES
U-1259	PROPHYLAXIS OF HIV-1 INFECTION
U-1260	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
U-1261	REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
U-1262	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
U-1263	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
U-1264	TREATMENT OF A RESPIRATORY DISEASE
U-1265	PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1266	METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
U-1267	TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
U-1268	TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
U-1269	TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
U-1270	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
U-1271	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MOR ANTI-LEUKEMIA THERAPIES
U-1272	TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
U-1273	TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

SYSTEM

U-1274 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS

U-1275 TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-1276 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY

U-1277 METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN

U-1278 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS

U-1279 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE

U-1280 USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS

U-1281 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL

U-1282 PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING

U-1283 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA

U-1284 A METHOD OF TREATING A NEOPLASM

U-1285 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS

U-1286 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE

U-1287 METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA

U-1288 TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET

U-1289 MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN

U-1290 TREATMENT OF LUNG CANCER

U-1291 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION

U-1292 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET

U-1293 A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1294 METHOD OF TREATING GLAUCOMA IN A PATIENT

U-1295 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

U-1296 USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION

U-1297 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS

U-1298 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES

U-1299 TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)

U-1300 TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)

U-1301 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

U-1302 TREATMENT OF PULMONARY EMBOLISM (PE)

U-1303 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM

U-1304 USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES

U-1305 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS

U-1306 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

U-1307 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY

U-1308 MULTIPLE MYELOMA

U-1309 BONE METASTASES

U-1310 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

U-1311 METHOD OF TREATING CYSTIC FIBROSIS

U-1312 USE FOR THE TREATMENT OF HYPERGLYCEMIA

U-1313 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-1314 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

U-1315 THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- U-1316 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
- U-1317 TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1318 TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1319 SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
- U-1320 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
- U-1322 METHOD OF REDUCING OCULAR HYPERTENSION
- U-1323 REDUCING THE RISK OF STROKE
- U-1324 MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
- U-1325 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
- U-1326 METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE
- U-1327 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
- U-1328 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
- U-1329 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
- U-1330 METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1331 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1332 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1333 METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
- U-1334 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1335 METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
- U-1336 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN
- U-1337 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
- U-1338 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
- U-1339 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1340 METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1341 METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1342 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1343 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1344 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
- U-1345 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1346 USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE



**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1347 TREATMENT OF A SKIN DISORDER  
 U-1348 TREATMENT OF OSTEOARTHRITIS  
 U-1349 TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS  
 U-1350 TREATMENT OF ANKYLOSING SPONDYLITIS  
 U-1351 TREATMENT OF ACUTE PAIN  
 U-1352 TREATMENT OF PRIMARY DYSMENORRHEA  
 U-1353 ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA  
 U-1354 INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH  
 U-1355 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD  
 U-1356 TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER  
 U-1357 TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD  
 U-1358 TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S.AUREUS  
 U-1359 USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA  
 U-1360 USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA  
 U-1361 USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE  
 U-1362 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET  
 U-1363 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY  
 U-1364 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)  
 U-1365 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT  
 U-1366 TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN  
 U-1367 METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN  
 U-1368 TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB  
 U-1369 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE  
 U-1370 TREATMENT OF DYSpareunia ASSOCIATED WITH MENOPAUSE  
 U-1371 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA  
 U-1372 ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION  
 U-1373 METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS  
 U-1374 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)  
 U-1375 ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS  
 U-1376 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS  
 U-1377 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA  
 U-1378 TREATMENT OF A NITROGEN METABOLISM DISORDER  
 U-1379 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS  
 U-1380 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE  
 U-1381 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS  
 U-1382 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT  
 U-1383 DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER  
 U-1384 METHOD OF TREATING MULTIPLE SCLEROSIS  
 U-1385 METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS

## PATENT AND EXCLUSIVITY TERMS

ADB 61 of 67

## PATENT USE

U-1386 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF  
U-1387 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR  
PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY  
ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS  
U-1388 TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE  
HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH  
MORNING AND EVENING MEALS  
U-1389 ELLA IS AN PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR  
THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR  
SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD  
U-1390 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN  
NEED THEREOF  
U-1391 METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION  
U-1392 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-  
INDUCED CONSTIPATION  
U-1393 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED  
CONSTIPATION  
U-1394 METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION  
THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MICROG+/-  
10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT  
U-1395 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED  
CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE  
AND A PHARMACEUTICALLY SUITABLE EXCIPIENT  
U-1396 TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN  
COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR  
ANASTROZOLE  
U-1397 USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY  
U-1398 METHOD OF TREATING CHRONIC HEPATITIS C  
U-1399 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO  
DIVIDED DOSES  
U-1400 FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS  
FAMILIAL HYPERCHOLESTEROLEMIA  
U-1401 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION  
IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE  
EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS  
U-1402 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)  
AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)  
U-1403 FIRST-LINE TREATMENT OF METASTATIC NON SMAL-CELL LUNG CANCER (NSCLC) WITH EGFR  
EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-  
APPROVED TEST  
U-1404 METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY  
OPENING CIC CHANNELS  
U-1405 THERAPEUTIC TREATMENT OF BONE METASTASES  
U-1406 TREATMENT OF MELANOMA  
U-1407 TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID  
LEUKEMIA (PH + CML)  
U-1408 TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER  
U-1409 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION  
U-1410 TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES  
U-1411 THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT  
OF OPIOID DEPENDENCE  
U-1412 TREATMENT OF ATOPIC DERMATITIS  
U-1413 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE  
DILUENT FOR INJECTION PRIOR TO INFUSION  
U-1414 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)  
U-1415 TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH  
METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS  
1 OR 2  
U-1416 USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-  
LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES  
U-1417 USE FOR TREATMENT OF HELICOBACTER INFECTIONS  
U-1418 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E  
MUTATION AS DETECTED BY AN FDA APPROVED TEST  
U-1419 TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING  
U-1420 METHOD OF ONCE A DAY ADMINISTRATION  
U-1421 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE  
U-1422 METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

- U-1423 AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
- U-1424 LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-1425 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
- U-1426 USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
- U-1427 ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
- U-1428 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
- U-1429 TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
- U-1430 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- U-1431 METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
- U-1432 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
- U-1433 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
- U-1434 TREATMENT OF PANCREATIC CANCER
- U-1435 COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
- U-1436 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
- U-1437 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
- U-1438 ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
- U-1439 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
- U-1440 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
- U-1441 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
- U-1442 SUBCUTANEOUS INJECTION OF METHOTREXATE
- U-1443 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
- U-1444 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE) (25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
- U-1445 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
- U-1446 METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
- U-1447 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
- U-1448 TREATING SEVERE HYPERTRIGLYCERIDEMIA
- U-1449 METHOD OF ALLEVIATING A SKIN CONDITION
- U-1450 TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
- U-1451 APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
- U-1452 METHOD FOR CHRONIC WEIGHT MANAGEMENT
- U-1453 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
- U-1454 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
- U-1455 TREATMENT OF PERIANAL WARTS
- U-1456 TREATMENT OF MANTLE CELL LYMPHOMA
- U-1457 A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM
- U-1458 A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-1459 TREATMENT OF CARCINOMA OF THE THYROID
- U-1460 TREATMENT OF HERPES LABIALIS
- U-1461 A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
- U-1462 A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

- SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE
- U-1463 A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES
- U-1464 TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
- U-1465 USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
- U-1466 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1467 METHOD OF TREATING HEPATITIS C
- U-1468 CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
- U-1469 USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
- U-1470 FOR THE TREATMENT OF HEPATITIS C
- U-1471 A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.
- U-1472 INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
- U-1473 MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
- U-1474 A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT
- U-1475 USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).
- U-1476 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
- U-1477 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE
- U-1478 METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
- U-1479 INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
- U-1480 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
- U-1481 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
- U-1482 DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-1483 INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
- U-1484 COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
- U-1485 TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
- U-1486 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
- U-1487 METHOD OF INCREASING EYELASH GROWTH
- U-1488 USE OF TOPICAL DICLOFENAC FOR TREATING PAIN
- U-1489 USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS
- U-1490 FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
- U-1491 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
- U-1492 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- U-1493 METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
- U-1494 SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
- U-1495 RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.
- U-1496 METHOD TO TREAT HEMANGIOMA.
- U-1497 NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
- U-1498 METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
- U-1499 MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
- U-1500 TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).

**PATENT AND EXCLUSIVITY TERMS**

ADB 64 of 67

**PATENT USE**

U-1501 PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM  
U-1502 PROPHYLAXIS OF PULMONARY EMBOLISM  
U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN  
U-1504 USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4  
U-1505 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS  
U-1506 TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR  
U-1507 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN  
U-1508 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED  
U-1509 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER  
U-1510 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.  
U-1511 TREATMENT OF HYPERTRIGLYCERIDEMIA  
U-1512 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS  
U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS  
U-1514 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL  
U-1515 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.  
U-1516 METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.  
U-1517 TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.  
U-1518 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN  
U-1519 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME  
U-1520 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT  
U-1521 MAINTENANCE TREATMENT OF OPIOID DEPENDENCE  
U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE  
U-1523 METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE  
U-1524 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE  
U-1525 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY  
U-1526 THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE  
U-1527 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY  
U-1528 A METHOD OF LOWERING INTRAOCULAR PRESSURE  
U-1529 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)  
U-1530 USE OF ARIPIRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION  
U-1531 METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE  
U-1532 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.  
U-1533 PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.  
U-1534 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.  
U-1535 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.  
U-1536 ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.  
U-1537 TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.  
U-1538 ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.  
U-1539 PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.  
U-1540 BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.  
U-1541 TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.  
U-1542 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA  
U-1543 TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR

## PATENT AND EXCLUSIVITY TERMS

## PATENT USE

CLAIM 23

U-1544 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).

U-1545 A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE

U-1546 FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.

U-1547 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA

U-1548 FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

U-1549 FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA

U-1550 METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.

U-1551 METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.

U-1552 FOR HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE)

U-1553 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN

U-1554 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)

U-1555 MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.

U-1556 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.

U-1557 A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.

U-1558 FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA

U-1559 INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER

U-1560 A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE

U-1561 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

U-1562 TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)

U-1563 A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.

U-1564 A METHOD OF TREATING GAUCHER'S DISEASE

U-1565 METHOD OF TREATING, AS INTITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARITAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE

U-1566 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-1567 METHOD OF TREATING, AS INTITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARITAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER

U-1568 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE

U-1569 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

U-1570 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE

U-1571 TREATMENT OF GAUCHER DISEASE TYPE 1

U-1572 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.

U-1573 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.

U-1574 A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.

U-1575 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY

U-1576 TREATMENT OF LEUKEMIA

U-1577 CONTROL OF SERUM PHOSPHOROUS LEVELS

U-1578 TREATMENT OF ACUTE OTITIS MEDIA

U-1579 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

U-1580 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY

U-1581 IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1582 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA  
U-1583 FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY  
U-1584 USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS  
U-1585 USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE  
U-1586 FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE  
U-1587 SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.  
U-1588 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).  
U-1589 METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA  
U-1590 KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA  
U-1591 TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER  
U-1592 TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE  
U-1593 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.  
U-1594 DILATION OF THE PUPIL  
U-1595 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS  
U-1596 LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS ≥ 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES  
U-1597 TREATMENT OF DIABETIC MACULAR EDEMA  
U-1598 METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE  
U-1599 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY  
U-1600 DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS  
U-1601 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS  
U-1602 METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION  
U-1603 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE  
U-1604 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2  
U-1605 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER  
U-1606 METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM  
U-1607 METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION  
U-1608 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION  
U-1609 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS  
U-1610 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN USE OF PIRFENIDONE  
U-1611 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER  
U-1612 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER  
U-1613 DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN  
U-1614 USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN  
U-1615 FOR THE TREATMENT OF PATIENTS WITH CCL, FL, OR SLL  
U-1616 NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE  
U-1617 METHOD OF TREATING MEDULLARY THYROID CANCER  
U-1618 A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT  
U-1619 TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)  
U-1620 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.  
U-1621 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.  
U-1622 FOR THE TREATMENT OF POLYCYTHEMIA VERA

**PATENT AND EXCLUSIVITY TERMS****PATENT USE**

U-1623 USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.

U-1624 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.

U-1625 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6

U-1626 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING

U-1627 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS

U-1628 METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION

U-1629 METHOD OF TREATING ACROMEGALY

U-1630 TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL

U-1631 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

U-1632 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1633 USE OF ARIPIRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1634 TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR

U-1635 USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION

U-1636 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.

U-1637 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

U-1638 TREATMENT OF HCV INFECTION USING PARITAPREVIR

U-1639 USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

U-1640 TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

U-1641 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

U-1642 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN